FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sathishkumar, C
   Prabu, P
   Balakumar, M
   Lenin, R
   Prabhu, D
   Anjana, RM
   Mohan, V
   Balasubramanyam, M
AF Sathishkumar, Chandrakumar
   Prabu, Paramasivam
   Balakumar, Mahalingam
   Lenin, Raji
   Prabhu, Durai
   Anjana, Ranjith Mohan
   Mohan, Viswanathan
   Balasubramanyam, Muthuswamy
TI Augmentation of histone deacetylase 3 (<i>HDAC3</i>) epigenetic
   signature at the interface of proinflammation and insulin resistance in
   patients with type 2 diabetes
SO CLINICAL EPIGENETICS
LA English
DT Article
DE HDAC3; Inflammation; Insulin resistance; Type 2 diabetes; Epigenetics;
   Sirt1; Histone modification
ID CHAIN FATTY-ACIDS; METABOLIC SYNDROME; GENE-EXPRESSION; PPAR-GAMMA;
   INHIBITION; SIRT1; COMPLICATIONS; MELLITUS; OBESITY; RATS
AB Background: A role of proinflammation has been implicated in the pathogenesis of diabetes, but the up-stream regulatory signals and molecular signatures are poorly understood. While histone modifications such as changes in histone deacetylase (HDAC) are emerging as novel epigenetic biomarkers, there is lack of studies to demonstrate their clinical relevance in diabetes. Therefore, we investigated the extent of HDAC machinery and inflammatory signals in peripheral blood mononuclear cells (PBMCs) from patients with type 2 diabetes mellitus (T2DM) compared to control subjects.
   Results: HDAC3 activity was significantly (p < 0.05) increased in patients with T2DM compared to control subjects. While subtypes of HDACs were differentially expressed at their transcriptional levels in patients with type 2 diabetes, the most prominent observation is the significantly (p < 0.05) elevated messenger RNA (mRNA) levels of HDAC3. Expression levels of Sirt1 which represents the class III HDAC were decreased significantly in T2DM (p < 0.05). Plasma levels of both TNF-alpha and IL-6 were significantly higher (p < 0.05) in patients with type 2 diabetes compared to control subjects. Among the proinflammatory mediators, the mRNA expression of MCP-1, IL1-beta, NF kappa B, TLR2, and TLR4 were also significantly (p < 0.05) increased in T2DM. Transcriptional levels of DBC1 (deleted in breast cancer 1, which is a negative regulator of HDAC3) were seen significantly reduced in PBMCs from T2DM. Interestingly, HDAC3 activity/HDAC3 mRNA levels positively correlated to proinflammation, poor glycemic control, and insulin resistance.
   Conclusions: Striking message from this study is that while looking for anti-inflammatory strategies and drugs with novel mode of action for T2DM, discovering and designing specific inhibitors targeted to HDAC3 appears promising.
C1 [Balasubramanyam, Muthuswamy] Madras Diabet Res Fdn, Dept Cell & Mol Biol, Madras 600086, Tamil Nadu, India.
   Madras Diabet Res Fdn, Dr Rema Mohan High Throughput Screening HTS Lab, Madras 600086, Tamil Nadu, India.
   Dr Mohans Diabet Specialties Ctr, Madras 600086, Tamil Nadu, India.
C3 Madras Diabetes Research Foundation; Madras Diabetes Research Foundation
RP Balasubramanyam, M (通讯作者)，Madras Diabet Res Fdn, Dept Cell & Mol Biol, Madras 600086, Tamil Nadu, India.
EM balusignal@gmail.com
RI Viswanathan, Mohan/C-2321-2009; Prabu, Paramasivam/V-8323-2018; Rajesh
   Lenin, Raji/AHC-6187-2022; Chandrakumar, Sathishkumar/AAM-3149-2020;
   Prabu, Paramasivam/HPE-3307-2023
OI Chandrakumar, Sathishkumar/0000-0003-2320-050X; Mohan,
   Viswanathan/0000-0001-5038-6210; Prabu, Paramasivam/0000-0002-8626-1601
FU Department of Biotechnology (DBT), Govt. of India; MDRF Intramural
   Research Funding (MIRF); Council of Scientific & Industrial Research
   (CSIR), New Delhi, India
FX This work was supported by grants from the Department of Biotechnology
   (DBT), Govt. of India; MDRF Intramural Research Funding (MIRF); and
   research fellowship assistance from the Council of Scientific &
   Industrial Research (CSIR), New Delhi, India.
CR [Anonymous], 2015, IDF Diabetes Atlas, V7
   Asegaonkar SB, 2011, J DIABETES COMPLICAT, V25, P368, DOI 10.1016/j.jdiacomp.2011.10.001
   Balasubramanyam M, 2011, MOL CELL BIOCHEM, V351, P197, DOI 10.1007/s11010-011-0727-3
   Balasubramanyam M, 2002, ANN NY ACAD SCI, V958, P399
   Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111
   Chen X, 2012, P NATL ACAD SCI USA, V109, P74
   Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270
   Christensen DP, 2011, MOL MED, V17, P378, DOI 10.2119/molmed.2011.00021
   de Kreutzenberg SV, 2010, DIABETES, V59, P1006, DOI 10.2337/db09-1187
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Galmozzi A, 2013, DIABETES, V62, P732, DOI 10.2337/db12-0548
   Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616
   Hartstra AV, 2015, DIABETES CARE, V38, P159, DOI 10.2337/dc14-0769
   Hoeksema MA, 2014, EMBO MOL MED, V6, P1124, DOI 10.15252/emmm.201404170
   Jakobsdottir G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080476
   Jeong Y, 2014, J LEUKOCYTE BIOL, V95, P651, DOI 10.1189/jlb.1013565
   Jia HQ, 2015, P NATL ACAD SCI USA, V112, pE56, DOI 10.1073/pnas.1415195112
   Kaliman P, 2014, PSYCHONEUROENDOCRINO, V40, P96, DOI 10.1016/j.psyneuen.2013.11.004
   Khan S, 2014, CHEM-BIOL INTERACT, V213, P1, DOI 10.1016/j.cbi.2014.02.001
   Kim Y., 2012, ASIA PACIFIC J TOURI, V2012, P1, DOI DOI 10.1016/J.JECP.2012.03.002
   Kotas ME, 2013, ADIPOCYTE, V2, P113, DOI 10.4161/adip.23437
   Larsen L, 2007, DIABETOLOGIA, V50, P779, DOI 10.1007/s00125-006-0562-3
   Lenin R, 2015, J LEUKOCYTE BIOL, V98, P615, DOI 10.1189/jlb.3A1214-609R
   Li DM, 2011, MOL CELL ENDOCRINOL, V344, P69, DOI 10.1016/j.mce.2011.06.028
   Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003
   Lundh M, 2015, DIABETES OBES METAB, V17, P703, DOI 10.1111/dom.12470
   Lundh M, 2012, DIABETOLOGIA, V55, P2421, DOI 10.1007/s00125-012-2615-0
   Ma YD, 2015, INT J CLIN EXP PATHO, V8, P1682
   McGee SL, 2006, CLIN EXP PHARM PHYSL, V33, P365
   McGee-Lawrence ME, 2015, MOL CELL ENDOCRINOL, V410, P42, DOI 10.1016/j.mce.2015.02.001
   Meier BC, 2014, EPIGENOMICS-UK, V6, P209, DOI 10.2217/epi.14.11
   Miller SJ, 2004, MINI-REV MED CHEM, V4, P839, DOI 10.2174/1389557043403288
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mohan Viswanathan, 2010, J Diabetes Sci Technol, V4, P158
   N'Guessan PD, 2009, ARTERIOSCL THROM VAS, V29, P380, DOI 10.1161/ATVBAHA.108.178319
   Nin V, 2014, J BIOL CHEM, V289, P5518, DOI 10.1074/jbc.M113.512913
   Ntanasis-Stathopoulos J, 2013, J MUSCULOSKEL NEURON, V13, P133
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Plaisance V., 2014, J DIABETES RES, V2014, DOI DOI 10.1155/2014/195739
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Raso GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068626
   Remely M, 2014, GENE, V537, P85, DOI 10.1016/j.gene.2013.11.081
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1016/j.febslet.2007.11.057
   Song YS, 2013, DIABETES RES CLIN PR, V101, P341, DOI 10.1016/j.diabres.2013.07.002
   Steliou K, 2012, BIORESEARCH OPEN ACC, V1, P192, DOI 10.1089/biores.2012.0223
   Streja D, 2003, J DIABETES COMPLICAT, V17, P120, DOI 10.1016/S1056-8727(02)00204-0
   Tang JH, 2013, CLIN SCI, V124, P651, DOI 10.1042/CS20120504
   Unnikrishnan R, 2014, DIABETES, V63, P53, DOI 10.2337/db13-1592
   Waldecker M, 2008, J NUTR BIOCHEM, V19, P587, DOI 10.1016/j.jnutbio.2007.08.002
   Wegner M, 2014, DIABETES RES CLIN PR, V105, P164, DOI 10.1016/j.diabres.2014.03.019
   Xiong XJ, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/982380, 10.1155/2013/978398]
   Ye JP, 2013, DIABETES, V62, P685, DOI 10.2337/db12-1354
   Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08
   Yuan H, 2014, ACTA PHYSIOL, V212, P283, DOI 10.1111/apha.12395
   Zeng ZP, 2014, GENE, V533, P427, DOI 10.1016/j.gene.2013.09.123
NR 55
TC 66
Z9 69
U1 0
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD NOV 24
PY 2016
VL 8
AR 125
DI 10.1186/s13148-016-0293-3
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EF7CO
UT WOS:000390487900001
PM 27904654
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Thangavelu, PU
   Krenács, T
   Dray, E
   Duijf, PHG
AF Thangavelu, Pulari U.
   Krenacs, Tibor
   Dray, Eloise
   Duijf, Pascal H. G.
TI In epithelial cancers, aberrant <i>COL17A1</i> promoter methylation
   predicts its misexpression and increased invasion
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Collagen XVII; Epigenetics; Invasion; Prognosis; Breast cancer; Cervical
   cancer
ID SQUAMOUS-CELL CARCINOMA; EXTRACELLULAR-MATRIX; COLLAGEN-XVII; CHROMOSOME
   INSTABILITY; PROTEIN EXPRESSION; DNA METHYLATION; BREAST; SURVIVAL;
   OVEREXPRESSION; IDENTIFICATION
AB Background: Metastasis is a leading cause of death among cancer patients. In the tumor microenvironment, altered levels of extracellular matrix proteins, such as collagens, can facilitate the first steps of cancer cell metastasis, including invasion into surrounding tissue and intravasation into the blood stream. However, the degree of misexpression of collagen genes in tumors remains understudied, even though this knowledge could greatly facilitate the development of cancer treatment options aimed at preventing metastasis.
   Methods: We systematically evaluate the expression of all 44 collagen genes in breast cancer and assess whether their misexpression provides clinical prognostic significance. We use immunohistochemistry on 150 ductal breast cancers and 361 cervical cancers and study DNA methylation in various epithelial cancers.
   Results: In breast cancer, various tests show that COL4A1 and COL4A2 overexpression and COL17A1 (BP180, BPAG2) underexpression provide independent prognostic strength (HR = 1.25, 95% CI = 1.17-1.34, p = 3.03 x 10-10; HR = 1.18, 95% CI = 1.11-1.25, p = 8.11 x 10-10; HR = 0.86, 95% CI = 0.81-0.92, p = 4.57 x 10-6; respectively). Immunohistochemistry on ductal breast cancers confirmed that the COL17A1 protein product, collagen XVII, is underexpressed. This strongly correlates with advanced stage, increased invasion, and postmenopausal status. In contrast, immunohistochemistry on cervical tumors showed that collagen XVII is overexpressed in cervical cancer and this is associated with increased local dissemination. Interestingly, consistent with the opposed direction of misexpression in these cancers, the COL17A1 promoter is hypermethylated in breast cancer and hypomethylated in cervical cancer. We also find that the COL17A1 promoter is hypomethylated in head and neck squamous cell carcinoma, lung squamous cell carcinoma, and lung adenocarcinoma, in all of which collagen XVII overexpression has previously been shown.
   Conclusions: Paradoxically, collagen XVII is underexpressed in breast cancer and overexpressed in cervical and other epithelial cancers. However, the COL17A1 promoter methylation status accurately predicts both the direction of misexpression and the increased invasive nature for five out of five epithelial cancers. This implies that aberrant epigenetic control is a key driver of COL17A1 gene misexpression and tumor cell invasion. These findings have significant clinical implications, suggesting that the COL17A1 promoter methylation status can be used to predict patient outcome. Moreover, epigenetic targeting of COL17A1 could represent a novel strategy to prevent metastasis in patients.
C1 [Thangavelu, Pulari U.; Duijf, Pascal H. G.] Univ Queensland, Diamantina Inst, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.
   [Krenacs, Tibor] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Budapest, Hungary.
   [Krenacs, Tibor] MTA SE Canc Progress Res Grp, Budapest, Hungary.
   [Dray, Eloise] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia.
C3 University of Queensland; Semmelweis University; University of
   Queensland; Queensland University of Technology (QUT)
RP Duijf, PHG (通讯作者)，Univ Queensland, Diamantina Inst, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.
EM p.duijf@uq.edu.au
RI Dray, Eloise/AAD-5147-2021; Duijf, Pascal/E-7110-2012; Dray,
   Eloise/E-3938-2012
OI Duijf, Pascal/0000-0001-8646-9843; Dray, Eloise/0000-0001-6793-9838
FU University of Queensland (UQ) International; UQ Diamantina Institute;
   Career Development Fellowships from the National Breast Cancer
   Foundation; UQ
FX This work was supported by University of Queensland (UQ) International
   and UQ Diamantina Institute scholarships (to PUT), Career Development
   Fellowships from the National Breast Cancer Foundation (to ED, PHGD),
   and grants from UQ Diamantina Institute and UQ (to PHGD). The funding
   bodies were not involved in the design of the study; in the collection,
   analysis, or interpretation of the data; or in writing of the
   manuscript.
CR Amenta PS, 2003, J PATHOL, V199, P298, DOI 10.1002/path.1303
   An JH, 2009, J PROTEOME RES, V8, P2873, DOI 10.1021/pr900020q
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608
   Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001
   Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256
   Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546
   Chu M-L, 2011, ELS
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fábián K, 2014, ANTICANCER RES, V34, P5593
   Fang M, 2014, TUMOR BIOL, V35, P2871, DOI 10.1007/s13277-013-1511-7
   Fischer H, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-17
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Halsted KC, 2008, MODERN PATHOL, V21, P1246, DOI 10.1038/modpathol.2008.129
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hayashi M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-108
   Hiroyasu S, 2016, FASEB J, V30, P2298, DOI 10.1096/fj.201500160R
   Jacków J, 2016, J INVEST DERMATOL, V136, P516, DOI 10.1016/j.jid.2015.10.060
   Järveläinen H, 2009, PHARMACOL REV, V61, P198, DOI 10.1124/pr.109.001289
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krenacs T, 2012, HISTOCHEM CELL BIOL, V138, P653, DOI 10.1007/s00418-012-0981-9
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Löffek S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087263
   Maekawa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066632
   Nakano S, 1999, LAB INVEST, V79, P281
   Network TCGAR, 2014, NATURE, V511, P1
   Oskarsson T, 2013, BREAST, V22, pS66, DOI 10.1016/j.breast.2013.07.012
   Papay J, 2007, APPL IMMUNOHISTO M M, V15, P19, DOI 10.1097/01.pai.0000213143.32030.f5
   Parikka M, 2003, J HISTOCHEM CYTOCHEM, V51, P921, DOI 10.1177/002215540305100707
   Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rizwan A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10002
   Stelkovics E, 2008, APPL IMMUNOHISTO M M, V16, P433, DOI 10.1097/PAI.0b013e318162f8aa
   Tamás L, 2011, PATHOL ONCOL RES, V17, P721, DOI 10.1007/s12253-011-9376-9
   Vaidyanathan S, 2016, ONCOGENE, V35, P5446, DOI 10.1038/onc.2016.94
   Vaidyanathan S, 2016, TARGET ONCOL, V11, P677, DOI 10.1007/s11523-016-0432-y
   Zou X, 2013, J PROTEOMICS, V94, P473, DOI 10.1016/j.jprot.2013.10.020
NR 43
TC 60
Z9 62
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD NOV 18
PY 2016
VL 8
AR 120
DI 10.1186/s13148-016-0290-6
PG 13
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EF7CI
UT WOS:000390487300001
PM 27891193
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU He, JC
   Yao, W
   Wang, JM
   Schemmer, P
   Yang, Y
   Liu, Y
   Qian, YW
   Qi, WP
   Zhang, J
   Shen, Q
   Yang, T
AF He, Jun-chuang
   Yao, Wei
   Wang, Jian-ming
   Schemmer, Peter
   Yang, Yan
   Liu, Yan
   Qian, Ya-wei
   Qi, Wei-peng
   Zhang, Jian
   Shen, Qi
   Yang, Tao
TI <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor
   prognosis and is a potential anti-cancer molecular drug target for HDAC
   inhibitors
SO ONCOTARGET
LA English
DT Article
DE histone deacetylase (HDAC); HDAC inhibitors (HDACIs); microarray;
   transforming acidic coiled-coil-containing protein 3 (TACC3);
   cholangiocarcinoma (CCA)
ID HISTONE DEACETYLASE INHIBITORS; INTRAHEPATIC CHOLANGIOCARCINOMA;
   HEPATOCELLULAR-CARCINOMA; CANCER-TREATMENT; HIGH EXPRESSION;
   BREAST-CANCER; CELL-DEATH; APKC-IOTA; MALIGNANCIES; EPIGENETICS
AB Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expression of HDACs 2, 3, and 8 were up-regulated in CCA tissues and those patients with high expression of HDAC2 and/or HDAC3 had a worse prognosis. In CCA cells, two HDACIs, trichostatin (TSA) and vorinostat (SAHA), suppressed proliferation and induced apoptosis and G2/M cycle arrest. Microarray analysis revealed that TACC3 mRNA was down-regulated in CCA cells treated with TSA. TACC3 was highly expressed in CCA tissues and predicted a poor prognosis in CCA patients. TACC3 knockdown induced G2/M cycle arrest and suppressed the invasion, metastasis, and proliferation of CCA cells, both in vitro and in vivo. TACC3 overexpression reversed the effects of its knockdown. These findings suggest TACC3 may be a useful prognostic biomarker for CCA and is a potential therapeutic target for HDACIs.
C1 [He, Jun-chuang; Yao, Wei; Wang, Jian-ming; Yang, Yan; Liu, Yan; Qian, Ya-wei; Qi, Wei-peng; Zhang, Jian; Shen, Qi; Yang, Tao] Huazhong Univ Sci & Technol, Affiliated Tongji Hosp, Tongji Med Coll, Canc Res Ctr,Dept Biliary & Pancreat Surg, Wuhan 430030, Hubei, Peoples R China.
   [Schemmer, Peter] Univ Heidelberg Hosp, Dept Gen & Transplant Surg, D-69120 Heidelberg, Germany.
C3 Huazhong University of Science & Technology; Ruprecht Karls University
   Heidelberg
RP Wang, JM (通讯作者)，Huazhong Univ Sci & Technol, Affiliated Tongji Hosp, Tongji Med Coll, Canc Res Ctr,Dept Biliary & Pancreat Surg, Wuhan 430030, Hubei, Peoples R China.
EM wjm18jgm@aliyun.com
RI yang, tao/HJP-6478-2023; Yao, Wei/AAI-2185-2019
FU National Natural Science Foundation of China [81172015, 81572417]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81172015 and 81572417 to Professor Jian-ming Wang).
CR Abend A, 2015, PHARMACOL THERAPEUT, V147, P55, DOI 10.1016/j.pharmthera.2014.11.003
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972
   Duvic M, 2016, CANCER TREAT REV, V43, P58, DOI 10.1016/j.ctrv.2015.04.003
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Ha GH, 2015, ONCOGENE, V34, P1667, DOI 10.1038/onc.2014.105
   Ha GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070353
   Ha GH, 2013, TACC3 PROMOTES EPITH, V322, P63
   He P, 2015, INT J CLIN EXP MED, V8, P6510
   Huang ZL, 2015, ONCOTARGET, V6, P6850, DOI 10.18632/oncotarget.3190
   Ilyas SI, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013
   Jiang F, 2016, ONCOL REP, V35, P436, DOI 10.3892/or.2015.4373
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8
   Lee MA, 2004, J CANCER RES CLIN, V130, P346, DOI 10.1007/s00432-003-0534-7
   Ler SY, 2015, ONCOL REP, V34, P2238, DOI 10.3892/or.2015.4263
   Li Q, 2008, HEPATOB PANCREAT DIS, V7, P70
   Ma CQ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.91
   Martin R, 2003, Minerva Chir, V58, P469
   Minamiya Y, 2010, TUMOR BIOL, V31, P533, DOI 10.1007/s13277-010-0066-0
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1
   Nahm JH, 2016, TUMOR BIOL, V37, P393, DOI 10.1007/s13277-015-3810-7
   Nguyen KT, 2009, ANN SURG ONCOL, V16, P3308, DOI 10.1245/s10434-009-0701-4
   Noh EL, 2009, BIOCHEM BIOPH RES CO, V378, P326, DOI 10.1016/j.bbrc.2008.11.057
   Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144
   Patel T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-10
   Patt YZ, 2001, CLIN CANCER RES, V7, P3375
   Peng Lirong, 2011, Handb Exp Pharmacol, V206, P39, DOI 10.1007/978-3-642-21631-2_3
   Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260
   Schneider L, 2008, ONCOGENE, V27, P116, DOI 10.1038/sj.onc.1210628
   Seo J, 2014, J BREAST CANCER, V17, P323, DOI 10.4048/jbc.2014.17.4.323
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shukla V, 2008, MUTAT RES-FUND MOL M, V637, P1, DOI 10.1016/j.mrfmmm.2007.07.012
   Sriraksa R, 2013, ASIAN PAC J CANCER P, V14, P2503, DOI 10.7314/APJCP.2013.14.4.2503
   Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Ulisse S, 2007, ENDOCR-RELAT CANCER, V14, P827, DOI 10.1677/ERC-07-0053
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001
   Wang B, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/374593
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Yang XW, 2001, CANCER RES, V61, P7025
   Yao R, 2012, ONCOGENE, V31, P135, DOI 10.1038/onc.2011.235
   Yim EK, 2009, ONCOL REP, V21, P549, DOI 10.3892/or_00000256
   Yun M, 2015, ONCOL REP, V34, P1397, DOI 10.3892/or.2015.4093
NR 48
TC 28
Z9 30
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2016
VL 7
IS 46
BP 75441
EP 75456
DI 10.18632/oncotarget.12254
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5GF
UT WOS:000389632800079
PM 27705912
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Endo, A
   Ly, T
   Pippa, R
   Bensaddek, D
   Nicolas, A
   Lamond, AI
AF Endo, Akinori
   Ly, Tony
   Pippa, Raffaella
   Bensaddek, Dalila
   Nicolas, Armel
   Lamond, Angus I.
TI The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine
   (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DNA-REPLICATION; BREAST-CANCER; FACTOR-I; MESENCHYMAL TRANSITION;
   ONCOGENE; LINK; FIBROBLASTS; INHERITANCE; METABOLISM; SENESCENCE
AB Tumor invasion into surrounding stromal tissue is a hallmark of high grade, metastatic cancers. Oncogenic transformation of human epithelial cells in culture can be triggered by activation of v-Src kinase, resulting in increased cell motility, invasiveness, and tumorigenicity and provides a valuable model for studying how changes in gene expression cause cancer phenotypes. Here, we show that epithelial cells transformed by activated Src show increased levels of DNA methylation and that the methylation inhibitor 5-azacytidine (5-AzaC) potently blocks the increased cell motility and invasiveness induced by Src activation. A proteomic screen for chromatin regulators acting downstream of activated Src identified the replication-dependent histone chaperone CAF1 as an important factor for Src-mediated increased cell motility and invasion. We show that Src causes a 5-AzaC-sensitive decrease in both mRNA and protein levels of the p150 (CHAF1A) and p60 (CHAF1B), subunits of CAF1. Depletion of CAF1 in untransformed epithelial cells using siRNA was sufficient to recapitulate the increased motility and invasive phenotypes characteristic of transformed cells without activation of Src. Maintaining high levels of CAF1 by exogenous expression suppressed the increased cell motility and invasiveness phenotypes when Src was activated. These data identify a critical role of CAF1 in the dysregulation of cell invasion and motility phenotypes seen in transformed cells and also highlight an important role for epigenetic remodeling through DNA methylation for Src-mediated induction of cancer phenotypes.
C1 [Endo, Akinori; Ly, Tony; Pippa, Raffaella; Bensaddek, Dalila; Nicolas, Armel; Lamond, Angus I.] Univ Dundee, Sch Life Sci, Ctr Gene Regulat & Express, Dow St, Dundee DD1 5EH, Scotland.
C3 University of Dundee
RP Lamond, AI (通讯作者)，Univ Dundee, Sch Life Sci, Ctr Gene Regulat & Express, Dow St, Dundee DD1 5EH, Scotland.
EM a.i.lamond@dundee.ac.uk
RI Lamond, Angus/JFS-7079-2023; Ly, Tony/H-5441-2011; Pippa,
   Raffaella/J-4566-2012
OI Pippa, Raffaella/0000-0002-1028-6511; Ly, Tony/0000-0002-8650-5215
FU Wellcome Trust [073980/Z/03/Z, 105024/Z/14/Z, 098503/E/12/Z,
   BB/K003801/1]; Seventh Framework Programme Grant
   [HEALTH-F4-2010-257082]; Gene Regulation and Expression Strategic Award
   [097945/B/11/Z]; Wellcome Trust [098503/E/12/Z] Funding Source: Wellcome
   Trust
FX This work was supported by Wellcome Trust Grants 073980/Z/03/Z,
   105024/Z/14/Z, 098503/E/12/Z, and BB/K003801/1 (to A. I. L.), Seventh
   Framework Programme Grant HEALTH-F4-2010-257082 (to A. I. L.), and Gene
   Regulation and Expression Strategic Award 097945/B/11/Z. The authors
   declare that they have no conflicts of interest with the contents of
   this article.
CR Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268
   Cheloufi S, 2015, NATURE, V528, P218, DOI 10.1038/nature15749
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Elsberger B, 2014, CRIT REV ONCOL HEMAT, V89, P343, DOI 10.1016/j.critrevonc.2013.12.009
   Exner V, 2006, DEVELOPMENT, V133, P4163, DOI 10.1242/dev.02599
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Hart PC, 2016, ONCOTARGET, V7, P308, DOI 10.18632/oncotarget.5687
   Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100
   Hunter T, 2015, P NATL ACAD SCI USA, V112, P7877, DOI 10.1073/pnas.1508223112
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cb.03.110187.000335
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7
   Kustatscher G, 2014, NAT PROTOC, V9, P2090, DOI 10.1038/nprot.2014.142
   Larance M, 2013, MOL CELL PROTEOMICS, V12, P638, DOI 10.1074/mcp.M112.024547
   Ly T, 2015, ELIFE, V4, DOI 10.7554/eLife.04534
   Ly T, 2014, ELIFE, V3, DOI 10.7554/eLife.01630
   Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506
   OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773
   Petty RD, 2006, J CLIN ONCOL, V24, P1729, DOI 10.1200/JCO.2005.03.3399
   Pippa R., 2016, ONCOTARGET, V5, DOI 10.18632/oncotarget.9840
   Poleshko A, 2010, J BIOL CHEM, V285, P422, DOI 10.1074/jbc.M109.064667
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Ridgway P, 2000, J CELL SCI, V113, P2647
   SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3
   SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399
   SOULE HD, 1990, CANCER RES, V50, P6075
   Staibano S, 2007, HISTOPATHOLOGY, V50, P911, DOI 10.1111/j.1365-2559.2007.02698.x
   Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505
   Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X
   Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4
   WANG E, 1976, P NATL ACAD SCI USA, V73, P4065, DOI 10.1073/pnas.73.11.4065
   Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997
NR 40
TC 9
Z9 12
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 6
PY 2017
VL 292
IS 1
BP 172
EP 184
DI 10.1074/jbc.M116.751024
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EH2DQ
UT WOS:000391578000015
PM 27872192
OA Green Published
DA 2025-01-12
ER

PT J
AU Altamirano, GA
   Ramos, JG
   Gomez, AL
   Luque, EH
   Muñoz-de-Toro, M
   Kass, L
AF Altamirano, Gabriela A.
   Ramos, Jorge G.
   Gomez, Ayelen L.
   Luque, Enrique H.
   Munoz-de-Toro, Monica
   Kass, Laura
TI Perinatal exposure to bisphenol A modifies the transcriptional
   regulation of the β-Casein gene during secretory activation of the rat
   mammary gland
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Bisphenol A; Mammary gland differentiation; beta-Casein; Epigenetic
   modifications; Lactation
ID IN-UTERO EXPOSURE; EPITHELIAL-CELLS; ENDOCRINE DISRUPTORS;
   FUNCTIONAL-DIFFERENTIATION; HISTONE MODIFICATIONS; EXTRACELLULAR-MATRIX;
   DNA METHYLATION; MESSENGER-RNA; BREAST-CANCER; EXPRESSION
AB With the aim to analyze whether bisphenol A (BPA) modifies beta-Casein (beta-Cas) synthesis and transcriptional regulation in perinatally exposed animals, here, pregnant F0 rats were orally exposed to 0, 0.6 or 52 mu g BPA/kg/day from gestation day 9 until weaning. Then, F1 females were bred and mammary glands were obtained on lactation day 2. Perinatal BPA exposure decreased beta-Cas expression without modifying the activation of prolactin receptor. It also decreased the expression of glucocorticoid receptor in BPA52-exposed dams and beta 1 and alpha 6 integrins as well as dystroglycan in both BPA groups. In addition, BPA exposure altered the expression of histone-modifying enzymes and induced histone modifications and DNA methylation in the promoter, enhancer and exon VII of the beta-Cas gene. An impaired crosstalk between the extracellular matrix and lactogenic hormone signaling pathways and epigenetic modifications of the beta-Cas gene could be the molecular mechanisms by which BPA decreased beta-Cas expression. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Altamirano, Gabriela A.; Ramos, Jorge G.; Gomez, Ayelen L.; Luque, Enrique H.; Munoz-de-Toro, Monica; Kass, Laura] Univ Nacl Litoral, Inst Salud & Ambiente Litoral, UNL CONICET, Fac Bioquim & Ciencias Biol, Ciudad Univ,Casilla Correo 242, RA-3000 Santa Fe, Santa Fe, Argentina.
   [Altamirano, Gabriela A.; Munoz-de-Toro, Monica; Kass, Laura] Univ Nacl Litoral, Catedra Patol Humana, Fac Bioquim & Ciencias Biol, Santa Fe, Santa Fe, Argentina.
   [Ramos, Jorge G.] Univ Nacl Litoral, Dept Bioquim Clin & Cuantitat, Fac Bioquim & Ciencias Biol, Santa Fe, Santa Fe, Argentina.
   [Luque, Enrique H.] Univ Nacl Litoral, Catedra Fisiol Humana, Fac Bioquim & Ciencias Biol, Santa Fe, Santa Fe, Argentina.
C3 National University of the Littoral; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); National University of the Littoral;
   National University of the Littoral; National University of the Littoral
RP Kass, L (通讯作者)，Univ Nacl Litoral, Inst Salud & Ambiente Litoral, UNL CONICET, Fac Bioquim & Ciencias Biol, Ciudad Univ,Casilla Correo 242, RA-3000 Santa Fe, Santa Fe, Argentina.
EM lkass@fbcb.uni.edu.ar
RI Luque, Enrique/IXN-4376-2023; Altamirano, Gabriela/AAU-6732-2020
OI Luque, Enrique Hugo/0000-0001-7007-5436
FU Universidad Nacional del Litoral (CAI+D program) [512 01101 00023 LI];
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
   [PIP 112201101 00494]; Agencia Nacional de Promocion Cientifica y
   Tecnologica (ANPCyT, PICT) [1348]
FX This work was supported by grants from: Universidad Nacional del Litoral
   (CAI+D program, 512 01101 00023 LI), the Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET, PIP 112201101 00494),
   and the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT,
   PICT 2014 No 1348). These funding sources had no involvement in the
   study design, the collection, analysis or interpretation of the data,
   the writing of the report, or the decision to submit the article for
   publication.
CR Alcaraz J, 2008, EMBO J, V27, P2829, DOI 10.1038/emboj.2008.206
   Altamirano GA, 2015, MOL CELL ENDOCRINOL, V411, P258, DOI 10.1016/j.mce.2015.05.007
   Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Bosquiazzo VL, 2013, J STEROID BIOCHEM, V138, P1, DOI 10.1016/j.jsbmb.2013.02.011
   Buser AC, 2011, MOL ENDOCRINOL, V25, P955, DOI 10.1210/me.2011-0064
   Cikos S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-113
   Dhimolea E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099800
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495
   Gore AC, 2015, ENDOCR REV, V36, pE1, DOI 10.1210/er.2015-1010
   Groner B, 2002, DOMEST ANIM ENDOCRIN, V23, P25, DOI 10.1016/S0739-7240(02)00142-X
   JOHNSON ML, 1983, J BIOL CHEM, V258, P805
   JONES WK, 1985, J BIOL CHEM, V260, P7042
   Kabotyanski EB, 2006, MOL ENDOCRINOL, V20, P2355, DOI 10.1210/me.2006-0160
   Kabotyanski EB, 2009, J BIOL CHEM, V284, P22815, DOI 10.1074/jbc.M109.032490
   Kass L, 2012, REPROD TOXICOL, V33, P390, DOI 10.1016/j.reprotox.2012.02.002
   Kazi AA, 2007, ENDOCRINOLOGY, V148, P2363, DOI 10.1210/en.2006-1394
   Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Le Beyec J, 2007, EXP CELL RES, V313, P3066, DOI 10.1016/j.yexcr.2007.04.022
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817
   Muschler J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003202
   Osborne G, 2015, REPROD TOXICOL, V54, P148, DOI 10.1016/j.reprotox.2014.07.077
   Qian X, 2014, CRIT REV EUKAR GENE, V24, P357, DOI 10.1615/CritRevEukaryotGeneExpr.2014012215
   Ramos JG, 2003, ENDOCRINOLOGY, V144, P3206, DOI 10.1210/en.2002-0198
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rijnkels M, 2003, GENOMICS, V82, P417, DOI 10.1016/S0888-7543(03)00114-9
   Rijnkels M, 2002, J MAMMARY GLAND BIOL, V7, P327, DOI 10.1023/A:1022808918013
   Rijnkels M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053270
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Rossetti MF, 2015, MOL CELL ENDOCRINOL, V412, P330, DOI 10.1016/j.mce.2015.05.024
   Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5
   STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021
   Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131
   Vigezzi L, 2016, MOL CELL ENDOCRINOL, V426, P33, DOI 10.1016/j.mce.2016.02.010
   Vigezzi L, 2015, REPROD TOXICOL, V52, P83, DOI 10.1016/j.reprotox.2015.01.011
   Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103
   Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1
   Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200
NR 44
TC 25
Z9 25
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 5
PY 2017
VL 439
IS C
BP 407
EP 418
DI 10.1016/j.mce.2016.09.032
PG 12
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA EH3CX
UT WOS:000391647800042
PM 27697584
OA Green Published
DA 2025-01-12
ER

PT J
AU da Motta, LL
   Ledaki, I
   Purshouse, K
   Haider, S
   De Bastiani, MA
   Baban, D
   Morotti, M
   Steers, G
   Wigfield, S
   Bridges, E
   Li, JL
   Knapp, S
   Ebner, D
   Klamt, F
   Harris, AL
   McIntyre, A
AF da Motta, L. L.
   Ledaki, I.
   Purshouse, K.
   Haider, S.
   De Bastiani, M. A.
   Baban, D.
   Morotti, M.
   Steers, G.
   Wigfield, S.
   Bridges, E.
   Li, J-L
   Knapp, S.
   Ebner, D.
   Klamt, F.
   Harris, A. L.
   McIntyre, A.
TI The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and
   downregulates CA9 and angiogenesis in triple negative breast cancer
SO ONCOGENE
LA English
DT Article
ID BROMODOMAIN INHIBITION; EPIGENETIC READERS; ENERGY-METABOLISM; CELL
   METABOLISM; GENE-EXPRESSION; LYSYL OXIDASE; STEM-CELLS; CHIP-SEQ;
   IN-VIVO; C-MYC
AB The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.
C1 [da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J-L; Harris, A. L.; McIntyre, A.] Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Labs, Oxford OX1 2JD, England.
   [da Motta, L. L.; De Bastiani, M. A.; Klamt, F.] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil.
   [da Motta, L. L.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil.
   [Baban, D.] Univ Oxford, Wellcome Trust Ctr Human Genet, High Throughput Genom, Oxford OX1 2JD, England.
   [Li, J-L] Univ Plymouth, Peninsula Schools Med & Dent, Inst Translat & Stratified Med, Plymouth PL4 8AA, Devon, England.
   [Knapp, S.] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford, England.
   [Knapp, S.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Campus Riedberg, Frankfurt, Germany.
   [Knapp, S.] Buchmann Inst Life Sci, Campus Riedberg, Frankfurt, Germany.
   [Ebner, D.] Univ Oxford, TDI, Nuffield Dept Med, Oxford, England.
   [McIntyre, A.] Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England.
C3 University of Oxford; Universidade Federal do Rio Grande do Sul;
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   University of Oxford; Wellcome Centre for Human Genetics; University of
   Plymouth; University of Oxford; Goethe University Frankfurt; University
   of Oxford; University of Nottingham
RP McIntyre, A (通讯作者)，Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England.; Harris, AL (通讯作者)，Univ Oxford, Weatherall Inst Mol Med, Dept Oncol, Mol Oncol Labs, Oxford OX3 9DS, England.
EM aharris.lab@imm.ox.ac.uk; alan.mcintyre@nottingham.ac.uk
RI Knapp, Stefan/AAG-2347-2019; Morotti, Matteo/AAE-8922-2020; De Bastiani,
   Marco/AAO-3798-2020; Motta, Leonardo/C-1551-2015; Harris,
   Adrian/ABA-3343-2020
OI De Bastiani, Marco Antonio/0000-0003-3924-5278; Morotti,
   Matteo/0000-0002-1790-1185; McIntyre, Alan/0000-0002-4791-7292; Harris,
   Adrian/0000-0003-1376-8409; Knapp, Stefan/0000-0001-5995-6494;
   Purshouse, Karin/0000-0003-0942-6342; Ebner, Daniel/0000-0002-6495-7026
FU Cancer Research UK; Breast Cance Research Foundation; Breast Cancer Now;
   Oxford NIHR Biomedical Research Centre; CRUK Oxford Centre; CAPES
   Foundation/Brazil; MRC [G0300648] Funding Source: UKRI
FX This work was funded by grants from Cancer Research UK (ALH), Breast
   Cance Research Foundation (ALH), Breast Cancer Now (AM), Oxford NIHR
   Biomedical Research Centre, and the CRUK Oxford Centre (ALH). Leonardo
   Lisboa da Motta has been awarded a scholarship from the CAPES
   Foundation/Brazil to conduct this study.
CR Alghamdi S, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0278-3
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447
   Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bernardi R, 2014, CELL RES, V24, P904, DOI 10.1038/cr.2014.61
   Bid HK, 2016, MOL CANC THER
   Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Castro MAA, 2009, BIOINFORMATICS, V25, P1468, DOI 10.1093/bioinformatics/btp246
   Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662
   Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492
   Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dubois L, 2011, RADIOTHER ONCOL, V99, P424, DOI 10.1016/j.radonc.2011.05.045
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gieling RG, 2013, J ENZYM INHIB MED CH, V28, P360, DOI 10.3109/14756366.2012.736979
   Gonzales-Cope M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2414-y
   Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006
   Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110
   Halliday GM, 2009, INT J BIOCHEM CELL B, V41, P725, DOI 10.1016/j.biocel.2008.04.026
   Horne GA, 2015, STEM CELLS DEV, V24, P879, DOI 10.1089/scd.2014.0302
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Kümler I, 2014, CANCER TREAT REV, V40, P960, DOI 10.1016/j.ctrv.2014.05.006
   Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261
   McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271
   McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579
   Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126
   Rajagopalan V, 2014, CELL MOL NEUROBIOL, V34, P1059, DOI 10.1007/s10571-014-0083-4
   Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086
   Schödel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Semenza Gregg L, 2016, Biochim Biophys Acta, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036
   Sena JA, 2013, MOL CELL BIOL, V33, P3849, DOI 10.1128/MCB.00731-13
   Sengupta S, 2015, BREAST CANCER RES TR, V150, P265, DOI 10.1007/s10549-015-3319-1
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478
   Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844
   Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613
   Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200
   Wani NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3665
   Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004
   Waschow M., 2012, Nature Methods, V9
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Wu T, 2015, STEM CELL REP, V4, P390, DOI 10.1016/j.stemcr.2015.01.012
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 59
TC 111
Z9 122
U1 0
U2 57
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 5
PY 2017
VL 36
IS 1
BP 122
EP 132
DI 10.1038/onc.2016.184
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EK6XJ
UT WOS:000394069100011
PM 27292261
OA Green Published, hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Wang, ZY
   Li, B
   Zhou, L
   Yu, SB
   Su, ZJ
   Song, JX
   Sun, Q
   Sha, O
   Wang, XM
   Jiang, WQ
   Willert, K
   Wei, L
   Carson, DA
   Lu, DS
AF Wang, Zhongyuan
   Li, Bo
   Zhou, Liang
   Yu, Shubin
   Su, Zijie
   Song, Jiaxing
   Sun, Qi
   Sha, Ou
   Wang, Xiaomei
   Jiang, Wenqi
   Willert, Karl
   Wei, Lei
   Carson, Dennis A.
   Lu, Desheng
TI Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer
   activity in breast cancer cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE prodigiosin; Wnt/beta-catenin signaling; breast cancer; LRP6;
   Dishevelled (DVL)
ID EPIGENETIC INACTIVATION; REGULATES SURVIVIN; BETA-CATENIN; H+-ATPASE;
   EXPRESSION; GENE; ACIDIFICATION; MECHANISM; APOPTOSIS; RECEPTOR
AB Prodigiosin, a natural red pigment produced by numerous bacterial species, has exhibited promising anticancer activity; however, the molecular mechanisms of action of prodigiosin on malignant cells remain unclear. Aberrant activation of the Wnt/beta-catenin signaling cascade is associated with numerous human cancers. In this study, we identified prodigiosin as a potent inhibitor of the Wnt/beta-catenin pathway. Prodigiosin blocked Wnt/beta-catenin signaling by targeting multiple sites of this pathway, including the low-density lipoprotein-receptor-related protein ( LRP) 6, Dishevelled ( DVL), and glycogen synthase kinase-3 beta ( GSK3 beta). In breast cancer MDA-MB-231 and MDA-MB-468 cells, nanomolar concentrations of prodigiosin decreased phosphorylation of LRP6, DVL2, and GSK3 beta and suppressed beta-catenin-stimulated Wnt target gene expression, including expression of cyclin D1. In MDA-MB-231 breast cancer xenografts andMMTV-Wnt1 transgenic mice, administration of prodigiosin slowed tumor progression and reduced the expression of phosphorylated LRP6, phosphorylated and unphosphorylated DVL2, Ser9 phosphorylated GSK3 beta, active beta-catenin, and cyclin D1. Through its ability to inhibit Wnt/a-catenin signaling and reduce cyclin D1 levels, prodigiosin could have therapeutic activity in advanced breast cancers.
C1 [Wang, Zhongyuan; Li, Bo; Zhou, Liang; Yu, Shubin; Su, Zijie; Song, Jiaxing; Sun, Qi; Sha, Ou; Wang, Xiaomei; Jiang, Wenqi; Carson, Dennis A.; Lu, Desheng] Shenzhen Univ, Sch Med, Canc Res Ctr, Dept Pharmacol, Shenzhen 518060, Peoples R China.
   [Li, Bo; Su, Zijie; Song, Jiaxing; Wei, Lei] Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Wuhan 430071, Hubei, Peoples R China.
   [Willert, Karl] Univ Calif San Diego, Dept Cellular & Mol Med, Stem Cell Program, La Jolla, CA 92093 USA.
   [Carson, Dennis A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
C3 Shenzhen University; Wuhan University; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego
RP Carson, DA; Lu, DS (通讯作者)，Shenzhen Univ, Sch Med, Canc Res Ctr, Dept Pharmacol, Shenzhen 518060, Peoples R China.; Carson, DA (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
EM dcarson@ucsd.edu; delu@szu.edu.cn
RI Su, Zijie/JCO-1635-2023; Lu, Deheng/AAK-5216-2020; Zhang,
   Guowei/HJH-0318-2022; bo, li/JNE-6315-2023
OI Lu, Desheng/0000-0002-0314-5649; Su, ZiJie/0000-0002-6437-2925; Bo,
   Li/0000-0002-0684-9852
FU National Nature Science Foundation of China [81372342, 31501143]; Nature
   Science Foundation of Guangdong Province [2014A030310168]; Shenzhen
   Peacock Innovation Team Project [KQTD20140630100658078]; Key Laboratory
   Project of Shenzhen [ZDSY20130329101130496]; Shenzhen Basic Research
   Program [JCYJ20150525092941006, JCYJ20150525092941030]
FX This work was supported by the National Nature Science Foundation of
   China (Grants 81372342 and 31501143), the Nature Science Foundation of
   Guangdong Province (Grant 2014A030310168), the Shenzhen Peacock
   Innovation Team Project (Grant KQTD20140630100658078), the Key
   Laboratory Project of Shenzhen (Grant ZDSY20130329101130496), and the
   Shenzhen Basic Research Program (Grants JCYJ20150525092941006 and
   JCYJ20150525092941030).
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Benhaj K, 2006, ONCOL REP, V15, P701
   Berg G, 2000, J APPL MICROBIOL, V88, P952, DOI 10.1046/j.1365-2672.2000.01064.x
   Castillo-Avila W, 2005, LIFE SCI, V78, P121, DOI 10.1016/j.lfs.2005.04.059
   CASTRO AJ, 1967, NATURE, V213, P903, DOI 10.1038/213903a0
   Chang TM, 2014, INORG CHEM, V53, P7518, DOI 10.1021/ic5008439
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802
   Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Ho TF, 2009, TOXICOL APPL PHARM, V235, P253, DOI 10.1016/j.taap.2008.12.009
   Hong B, 2014, CANCER RES, V74, P1153, DOI 10.1158/0008-5472.CAN-13-0955
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   KATAOKA T, 1995, FEBS LETT, V359, P53, DOI 10.1016/0014-5793(94)01446-8
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Magae J, 1996, J ANTIBIOT, V49, P86, DOI 10.7164/antibiotics.49.86
   Manderville R. A., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P195, DOI 10.2174/1568011013354688
   Milovanovic T, 2004, INT J ONCOL, V25, P1337
   Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x
   Park G, 2003, ORG LETT, V5, P113, DOI 10.1021/ol027165s
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Schimmer AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108694
   Schimmer AD, 2008, CLIN CANCER RES, V14, P8295, DOI 10.1158/1078-0432.CCR-08-0999
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Soto-Cerrato V, 2004, BIOCHEM PHARMACOL, V68, P1345, DOI 10.1016/j.bcp.2004.05.056
   Soto-Cerrato V, 2007, BIOCHEM PHARMACOL, V74, P1340, DOI 10.1016/j.bcp.2007.07.016
   Soto-Cerrato V, 2007, MOL CANCER THER, V6, P362, DOI 10.1158/1535-7163.MCT-06-0266
   Sun-Wada GH, 2015, BBA-BIOENERGETICS, V1847, P1166, DOI 10.1016/j.bbabio.2015.06.010
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   WANG Y, 2013, PLOS ONE, V2013
   Wang YY, 2010, ONCOTARGET, V1, P674, DOI 10.18632/oncotarget.201
   Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110
   Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768
   Williamson NR, 2007, FUTURE MICROBIOL, V2, P605, DOI 10.2217/17460913.2.6.605
   Williamson NR, 2006, NAT REV MICROBIOL, V4, P887, DOI 10.1038/nrmicro1531
   Xiang TX, 2013, J CELL MOL MED, V17, P1236, DOI 10.1111/jcmm.12099
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang T, 2001, CANCER RES, V61, P8664
NR 55
TC 162
Z9 170
U1 4
U2 52
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 15
PY 2016
VL 113
IS 46
BP 13150
EP 13155
DI 10.1073/pnas.1616336113
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ED6MQ
UT WOS:000388970100075
PM 27799526
OA Green Published
DA 2025-01-12
ER

PT J
AU Gaisa, NT
AF Gaisa, N. T.
TI Tumorigenesis from a pathological perspective. Tumor spread and
   epigenetically regulated genes in bladder cancer
SO PATHOLOGE
LA German
DT Article
DE Bladder cancer; Field cancerization; Intraurothelial migration/tumor
   cell seeding; Clonal relationship; DNA methylation
ID ALPHA-TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; BREAST-CANCER;
   INACTIVATION; UROTHELIUM; ITIH5; CARCINOMAS; EXPRESSION; PROGRESSION;
   CLONALITY
AB The article describes the tumorigenesis of bladder cancer from a pathological perspective in three dimensions: morphology, genetics and epigenetics. Field cancerization and tumor cell migration/seeding are the two main hypotheses used for explaining synchronous and metachronous tumors in the urinary tract. By detailed histological mapping of completely embedded cystectomy specimens we found a single tumor focus in nearly 2/3 of the bladders accompanied by surrounding preinvasive carcinoma in situ. We substantiated our findings by studies analyzing TP53 mutations and loss of heterozygosity in various tumor sites. Identical TP53 mutations suggested a clonal relationship of the tumor foci. In situ lineage tracing via cytochrome C oxidase and succinate dehydrogenase enzyme histochemistry and subsequent mitochondrial DNA mutation analysis for definitive evidence of a clonal relationship in bladder tumors remained inconclusive. We found indications for both theories but intraurothelial migration/seeding was more prominent.
   A further mechanism in tumorigenesis is gene inactivation by epigenetic DNA methylation. We analyzed DNA methylation of various genes, which had previously been found by RNA expression analysis to be downregulated in bladder cancer. Most importantly, epigenetically silenced ITIH5 was associated with early relapse in pT1 high grade tumors and functionally showed an enhanced invasive metastatic phenotype in tumor cells, suggesting a putative tumor suppressive role. Thus, epigenetic gene silencing is an additional mechanism of tumorigenesis especially in tumor progression.
C1 [Gaisa, N. T.] Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital
RP Gaisa, NT (通讯作者)，Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM ngaisa@ukaachen.de
OI Gaisa, Nadine/0000-0002-4762-3964
CR Balbás-Martínez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799
   Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x
   Czerniak B, 2016, ANNU REV PATHOL-MECH, V11, P149, DOI 10.1146/annurev-pathol-012513-104703
   Davidson DD, 2006, ANAL QUANT CYTOL, V28, P337
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gaisa NT, 2015, VIRCHOWS ARCH, V466, P423, DOI 10.1007/s00428-015-1726-7
   Gaisa NT, 2011, J PATHOL, V225, P163, DOI 10.1002/path.2945
   Gaisa NT, 2008, HUM PATHOL, V39, P1258, DOI 10.1016/j.humpath.2007.12.017
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   Höglund M, 2007, EUR UROL, V51, P1185, DOI 10.1016/j.eururo.2006.11.025
   Kloten V, 2014, EPIGENETICS-US, V9, P1290, DOI 10.4161/epi.32089
   Leedham SJ, 2008, J PATHOL, V215, P351, DOI 10.1002/path.2379
   Lopez-Beltran A, 2008, J PATHOL, V215, P263, DOI 10.1002/path.2353
   Lu Y, 2011, AM J TRANSL RES, V3, P8
   Novelli M, 2003, P NATL ACAD SCI USA, V100, P3311, DOI 10.1073/pnas.0437825100
   Pita JM, 2009, BRIT J CANCER, V101, P1782, DOI 10.1038/sj.bjc.6605340
   Robert Koch-Institut Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., 2015, GES EP KREBSR DEUTSC
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   Sánchez-Carbayo M, 2012, TUMOR BIOL, V33, P347, DOI 10.1007/s13277-011-0310-2
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760
   SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   TSAI YC, 1995, J UROLOGY, V153, P1697, DOI 10.1016/S0022-5347(01)67507-4
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259
   Zhuo L, 2008, CONNECT TISSUE RES, V49, P311, DOI 10.1080/03008200802325458
   Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200
NR 30
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0172-8113
EI 1432-1963
J9 PATHOLOGE
JI Pathologe
PD NOV
PY 2016
VL 37
SU 2
BP 196
EP 203
DI 10.1007/s00292-016-0207-3
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA EE5GN
UT WOS:000389633700009
PM 27613302
DA 2025-01-12
ER

PT J
AU Bartlett, TE
   Zaikin, A
AF Bartlett, Thomas E.
   Zaikin, Alexey
TI DETECTION OF EPIGENOMIC NETWORK COMMUNITY ONCOMARKERS
SO ANNALS OF APPLIED STATISTICS
LA English
DT Article
DE Computational biology; stochastic networks; community detection;
   epigenomics
ID CPG ISLAND METHYLATION; BREAST; GENOME; PROGRESSION; REGRESSION;
   TRANSCRIPTION; LESIONS; MODELS
AB In this paper we propose network methodology to infer prognostic cancer biomarkers based on the epigenetic pattern DNA methylation. Epigenetic processes such as DNA methylation reflect environmental risk factors, and are increasingly recognised for their fundamental role in diseases such as cancer. DNA methylation is a gene-regulatory pattern, and hence provides a means by which to assess genomic regulatory interactions. Network models are a natural way to represent and analyse groups of such interactions. The utility of network models also increases as the quantity of data and number of variables increase, making them increasingly relevant to large-scale genomic studies. We propose methodology to infer prognostic genomic networks from a DNA methylation-based measure of genomic interaction and association. We then show how to identify prognostic biomarkers from such networks, which we term "network community oncomarkers". We illustrate the power of our proposed methodology in the context of a large publicly available breast cancer dataset.
C1 [Bartlett, Thomas E.] UCL, Dept Stat Sci, 1-19 Torrington Pl, London WC1E 7HB, England.
   [Zaikin, Alexey] UCL, London WC1E 6BT, England.
C3 University of London; University College London; University of London;
   University College London
RP Bartlett, TE (通讯作者)，UCL, Dept Stat Sci, 1-19 Torrington Pl, London WC1E 7HB, England.
EM thomas.bartlett.10@ucl.ac.uk
RI ; Zaikin, Alexey/K-6581-2017
OI Bartlett, Thomas/0000-0003-0831-9713; Zaikin, Alexey/0000-0001-7540-1130
FU EPSRC [EP/M507970/1]; Deanship of Scientifc Research (DSR), King
   Abdulaziz University (KAU), Jeddah [86-130-35-RG]; Russian Foundation
   for Basic Research [14-02-01202, 13-02-00918]; MRC via UCL CoMPLEX
FX Supported in part by EPSRC Grant no. EP/M507970/1 and previously by
   EPSRC and MRC via UCL CoMPLEX. Supported in part by the Deanship of
   Scientifc Research (DSR), King Abdulaziz University (KAU), Jeddah, under
   Grant No. (86-130-35-RG), and from the Russian Foundation for Basic
   Research (14-02-01202, 13-02-00918).
CR Airoldi EM, 2008, J MACH LEARN RES, V9, P1981
   [Anonymous], DETECTION EPIGENOM S
   [Anonymous], PREPRINT
   [Anonymous], JAMA J AM MED ASSOC
   [Anonymous], PREPRINT
   Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Bartlett TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084573
   Bartlett TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068285
   Beguerisse-Díaz M, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0940
   Bhagat R, 2012, CELL ONCOL, V35, P473, DOI 10.1007/s13402-012-0106-4
   Bickel PJ, 2009, P NATL ACAD SCI USA, V106, P21068, DOI 10.1073/pnas.0907096106
   Bonetta L, 2006, NAT METHODS, V3, P141, DOI 10.1038/nmeth0206-141
   Brocks D, 2014, CELL REP, V8, P798, DOI 10.1016/j.celrep.2014.06.053
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Clune J, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2863
   Collins FS, 2007, SCI AM, V296, P50, DOI 10.1038/scientificamerican0307-50
   Cooney CA, 2007, DIS MARKERS, V23, P121, DOI 10.1155/2007/394034
   COX DR, 1972, J R STAT SOC B, V34, P187
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Gao F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054114
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
   HOLLAND PW, 1983, SOC NETWORKS, V5, P109, DOI 10.1016/0378-8733(83)90021-7
   Hotelling H, 1936, BIOMETRIKA, V28, P321, DOI 10.1093/biomet/28.3-4.321
   Jacob L, 2012, ANN APPL STAT, V6, P561, DOI 10.1214/11-AOAS528
   Johnstone IM, 2004, ANN STAT, V32, P1594, DOI 10.1214/009053604000000030
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65
   Kang GH, 2001, CANCER RES, V61, P2847
   Katenka N, 2012, ANN APPL STAT, V6, P1068, DOI 10.1214/12-AOAS550
   Kishida Y, 2012, CARCINOGENESIS, V33, P436, DOI 10.1093/carcin/bgr260
   Lai F, 2014, CELL RES, V24, P263, DOI 10.1038/cr.2014.13
   Latouche P, 2011, ANN APPL STAT, V5, P309, DOI 10.1214/10-AOAS382
   Li CY, 2010, ANN APPL STAT, V4, P1498, DOI 10.1214/10-AOAS332
   Li CH, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0774
   Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039
   Maekawa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066632
   Mardia KV, 2013, J R STAT SOC C-APPL, V62, P487, DOI 10.1111/rssc.12003
   Nandi AK, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0951
   Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284
   Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.066133
   Newman MEJ, 2004, EUR PHYS J B, V38, P321, DOI 10.1140/epjb/e2004-00124-y
   Olhede SC, 2014, P NATL ACAD SCI USA, V111, P14722, DOI 10.1073/pnas.1400374111
   Palla G, 2010, P NATL ACAD SCI USA, V107, P7640, DOI 10.1073/pnas.0912983107
   Peng J, 2010, ANN APPL STAT, V4, P53, DOI 10.1214/09-AOAS271
   Qin T., 2013, P NIPS, P3120
   Reznik E, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0087
   Saavedra S, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0693
   Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Tran TD, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0771
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Venters BJ, 2013, NATURE, V502, P53, DOI 10.1038/nature12535
   Verschuur-Maes AHJ, 2012, BREAST CANCER RES TR, V136, P705, DOI 10.1007/s10549-012-2301-4
   Vu DQ, 2013, ANN APPL STAT, V7, P1010, DOI 10.1214/12-AOAS617
   Wagner A, 2002, GENOME RES, V12, P309, DOI 10.1101/gr.193902
   Wei P, 2010, J R STAT SOC C-APPL, V59, P105, DOI 10.1111/j.1467-9876.2009.00686.x
   Xie W, 2013, CELL, V153, P1134, DOI 10.1016/j.cell.2013.04.022
   Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007
NR 60
TC 3
Z9 3
U1 0
U2 4
PU INST MATHEMATICAL STATISTICS-IMS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 1932-6157
EI 1941-7330
J9 ANN APPL STAT
JI Ann. Appl. Stat.
PD SEP
PY 2016
VL 10
IS 3
BP 1373
EP 1396
DI 10.1214/16-AOAS939
PG 24
WC Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA EE5OL
UT WOS:000389657400013
OA Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Smolkova, B
   Miklikova, S
   Kajabova, VH
   Babelova, A
   El Yamani, N
   Zduriencikova, M
   Fridrichova, I
   Zmetakova, I
   Krivulcik, T
   Kalinkova, L
   Matuskova, M
   Kucerova, L
   Dusinska, M
AF Smolkova, B.
   Miklikova, S.
   Kajabova, V. Horvathova
   Babelova, A.
   El Yamani, N.
   Zduriencikova, M.
   Fridrichova, I.
   Zmetakova, I.
   Krivulcik, T.
   Kalinkova, L.
   Matuskova, M.
   Kucerova, L.
   Dusinska, M.
TI Global and gene specific DNA methylation in breast cancer cells was not
   affected during epithelial-to-mesenchymal transition <i>in vitro</i>
SO NEOPLASMA
LA English
DT Article
DE DNA methylation; mesenchymal stromal cells; epithelial-to-mesenchymal
   transition; gold nanoparticles; breast cancer
ID ADIPOSE-TISSUE; GOLD NANOPARTICLES; STEM-CELLS; PROMOTER METHYLATION;
   TUMOR-GROWTH; EXPRESSION; HISTONE; HYPERMETHYLATION; METASTASIS;
   INDUCTION
AB Epithelial-to-mesenchymal transition (EMT) significantly affects the risk of metastasising in breast cancer. Plasticity and reversibility of EMT suggest that epigenetic mechanisms could be the key drivers of these processes, but little is known about the dynamics of EMT-related epigenetic alterations. We hypothesised that EMT, mediated by autocrine and paracrine signals, will be accompanied by changes in DNA methylation profiles. Therefore, conditioned medium from adipose tissue derived mesenchymal stromal cells was used for induction of EMT in human breast cancer SK-BR-3 cell line. EMT-related morphological alterations and changes in gene expression of EMT-associated markers were assessed. To reverse EMT, 20 nm size gold nanoparticles (AuNPs) synthesized by the citrate reduction method were applied. Finally, DNA methylation of LINE-1 sequences and promoter methylation of TIMP3, ADAM23 and BRMS1 genes were quantitatively evaluated by pyrosequencing. Despite the presence of EMT-associated morphological and gene expression changes in tumour cells, EMT induced by adipose tissue-derived mesenchymal stromal cells had almost no effect on LINE-1 and gene-specific DNA methylation patterns of TIMP3, ADAM23 and BRMS1 genes. Although treatment for 24, 48 or 72 hours with 20 nm AuNPs at a concentration of 3 g/ml slightly decreased gene expression of EMT-associated markers in SK-BR-3 cells, it did not alter global or gene-specific DNA methylation. Our results suggest that changes in DNA methylation are not detectable in vitro in early phases of EMT. Previously published positive findings could represent rather the sustained presence of potent EMT inducing signals or the synergistic effect of various epigenetic mechanisms. Treatthent with AuNPs slightly attenuated EMT, and their therapeutic potential needs to be further investigated.
C1 [Smolkova, B.; Miklikova, S.; Kajabova, V. Horvathova; Babelova, A.; Zduriencikova, M.; Fridrichova, I.; Zmetakova, I.; Krivulcik, T.; Kalinkova, L.; Matuskova, M.; Kucerova, L.] Slovak Acad Sci, Biomed Res Ctr, Canc Res Inst, Bratislava, Slovakia.
   [El Yamani, N.; Dusinska, M.] Norwegian Inst Air Res, Kjeller, Norway.
C3 Slovak Academy of Sciences; NILU
RP Smolkova, B (通讯作者)，Slovak Acad Sci, Biomed Res Ctr, Canc Res Inst, Bratislava, Slovakia.
EM bozena.smolkova@savba.sk
RI Miklikova, Svetlana/F-9775-2018; Dusinska, Maria/LDG-5211-2024;
   Kucerova, Lucia/F-7916-2016; Kalinkova, Lenka/JWA-0263-2024;
   Fridrichova, Ivana/AAF-3485-2019; Babelova, Andrea/E-7768-2018;
   Matuskova, Miroslava/F-6931-2018; el yamani, naouale/ABH-9613-2020;
   Smolkova, Bozena/B-3889-2018; Horvathova Kajabova, Viera/HNQ-4239-2023
OI Kucerova, Lucia/0000-0002-6407-6659; Dusinska,
   Maria/0000-0003-1358-1652; Miklikova, Svetlana/0000-0003-0692-1858; ,
   Kalinkova Lenka/0009-0009-4711-6004; Fridrichova,
   Ivana/0000-0001-7581-1770; Babelova, Andrea/0000-0001-9548-6602;
   Matuskova, Miroslava/0000-0002-0747-9275; el yamani,
   naouale/0000-0001-5456-8230; Smolkova, Bozena/0000-0002-4906-5652;
   Horvathova Kajabova, Viera/0000-0002-7081-0602
FU European Commission [INFRA-2010-1.131, 214547-2, NILU-TAF-279];
   Scientific Grant Agency VEGA [2/0169/14, 2/0120/13, 2/0092/15,
   2/0189/13, NMP.2012.1.3-3, 310584]; Research Council of Norway, project
   NorNANoREG Slovak Research and Development Agency [APVV-0076-10];
   Academy of Finland (AKA) [310584] Funding Source: Academy of Finland
   (AKA)
FX We are grateful to Prof. Andrew Collins for his critical comments and
   English corrections and the staff of NILU Health Effects Laboratory,
   mainly Iren Elisabeth Sturtzel, for their support and excellent
   technical help. This work was supported by the European Commission FP7
   projects QualityNano [INFRA-2010-1.131] Contract no: 214547-2,
   NILU-TAF-279; Scientific Grant Agency VEGA contracts No. 2/0169/14, No.
   2/0120/13, No. 2/0092/15, No. 2/0189/13, NANoREG [NMP.2012.1.3-3],
   Contract no. 310584; Research Council of Norway, project NorNANoREG
   Slovak Research and Development Agency contract No. APVV-0076-10;
   RFL2009, RFL2010 and RFL2013 programs founded by the Slovak Cancer
   Research Foundation.
CR Arvizo RR, 2013, P NATL ACAD SCI USA, V110, P6700, DOI 10.1073/pnas.1214547110
   Arvizo RR, 2011, NANOMED-NANOTECHNOL, V7, P580, DOI 10.1016/j.nano.2011.01.011
   Balansky R, 2013, MUTAT RES-FUND MOL M, V751, P42, DOI 10.1016/j.mrfmmm.2013.08.006
   Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   El-Haibi CP, 2010, J MAMMARY GLAND BIOL, V15, P399, DOI 10.1007/s10911-010-9196-7
   Freese C, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-23
   ISER IC, 2015, MOL NEUROBIOL
   Jin HY, 2010, INT J CANCER, V126, P2102, DOI 10.1002/ijc.24901
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669
   Khamis ZI, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/574025
   Kim J, 2013, CANCER INVEST, V31, P550, DOI 10.3109/07357907.2013.830737
   Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559
   Kucerova L, 2013, NEOPLASMA, V60, P1, DOI 10.4149/neo_2013_001
   Kucerova L, 2007, CANCER RES, V67, P6304, DOI 10.1158/0008-5472.CAN-06-4024
   Kucerova L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-535
   Kumar S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liu FT, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-66
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1
   Mazumder A, 2007, BIOPHYS J, V93, P2209, DOI 10.1529/biophysj.106.102202
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Ng CT, 2011, BIOMATERIALS, V32, P7609, DOI 10.1016/j.biomaterials.2011.06.038
   Nickel A, 2015, TRANSL RES, V165, P126, DOI 10.1016/j.trsl.2014.04.001
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Schweizer R, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/120949
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Smolkova B, 2015, FOOD CHEM TOXICOL, V77, P64, DOI 10.1016/j.fct.2014.12.015
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Sule N, 2008, J BIOMED NANOTECHNOL, V4, P463, DOI 10.1166/jbn.2008.011
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Uboldi C, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-18
   Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18
   van de Wetering M, 2001, CANCER RES, V61, P278
   Xiong XH, 2014, ONCOTARGET, V5, P6453, DOI 10.18632/oncotarget.2203
   Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6
   Zmetakova I, 2013, NEOPLASMA, V60, P635, DOI 10.4149/neo_2013_082
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 49
TC 7
Z9 7
U1 0
U2 7
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2016
VL 63
IS 6
BP 901
EP 910
DI 10.4149/neo_2016_609
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EE9QP
UT WOS:000389961600009
PM 27565328
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Jurkovicova, D
   Magyerkova, M
   Sestakova, Z
   Copakova, L
   Bella, V
   Konecny, M
   Krivjanska, M
   Kulcsar, L
   Chovanec, M
AF Jurkovicova, D.
   Magyerkova, M.
   Sestakova, Z.
   Copakova, L.
   Bella, V.
   Konecny, M.
   Krivjanska, M.
   Kulcsar, L.
   Chovanec, M.
TI Evaluation of expression profiles of microRNAs and two target genes,
   <i>FOXO3a</i> and <i>RUNX2</i>, effectively supports diagnostics and
   therapy predictions in breast cancer
SO NEOPLASMA
LA English
DT Article
DE miRNA; target genes; breast cancer; peripheral blood mononuclear cells;
   BRCA1
ID MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; TRANSCRIPTION FACTORS;
   PROMOTES TUMORIGENESIS; POTENTIAL BIOMARKER; GPER FUNCTION; BRCA1;
   MIR-155; RISK; MUTATIONS
AB Breast cancer (BC) including its progression into bone metastasis is a complex process involving changes in gene expression and function of both, microRNAs (miRNAs) and their target genes. Deregulation of miRNAs has been described as a crucial factor responsible for the initiation and progression of BC, and specific miRNA expression profiles have been found to be associated with particular disease states, histological tumor types, and BRCA1/2 or HER status. BRCA1 tumor suppressor is involved in DNA damage response and repair and epigenetically controls miR-155 expression and its pre-cancerous potential. MiR-155 targets 3'UTR region of multiple components of the pro-oncogenic signaling cascades, including FOXO3a tumor suppressor and RUNX2 transcription factor regulating metastatic potential in BC. We employed qRT-PCR to determine expression level and examine possible regulatory role of selected miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-21, miR-27a and miR-155) and their impact on expression modulation of FOXO3a and RUNX2 in peripheral blood mononuclear cells (PBMCs) in healthy individuals, in women carrying BRCA1 mutations with no disease manifestation, in women carrying BRCA1 mutations after tumor resection and therapy and in women with BC of unknown BRCA1 status in acute stage before tumor resection. Our results showed significant increase of miR-17, miR-19a, miR-21, miR-27, miR-155 and RUNX2 expression in PBMCs in BRCA1 patients and patients in acute stage, while FOXO3a expression was significantly decreased in these patients. MiR-18a and miR-20a expression was not affected. We propose that expressional changes reported in this study could provide significant additive information for early BC diagnosis, disease development prediction and therapy outcome monitoring.
C1 [Jurkovicova, D.; Magyerkova, M.; Krivjanska, M.; Kulcsar, L.; Chovanec, M.] KRD Mol Technol Ltd, Saratovska 26, Bratislava 84201, Slovakia.
   [Jurkovicova, D.; Sestakova, Z.; Chovanec, M.] Slovak Acad Sci, Canc Res Inst, Biomed Res Ctr, Dubravska Cesta 9, Bratislava 84505, Slovakia.
   [Copakova, L.] Natl Canc Inst, Dept Clin Genet, Klenova 1, Bratislava 83310, Slovakia.
   [Bella, V.; Konecny, M.] St Elisabeth Canc Inst, Dept Clin Genet, Heydukova 10, Bratislava 81250, Slovakia.
   [Bella, V.; Konecny, M.] St Elisabeth Canc Inst, Dept Mammol, Heydukova 10, Bratislava 81250, Slovakia.
C3 Slovak Academy of Sciences; National Institute of Oncology (NOU)
RP Jurkovicova, D (通讯作者)，KRD Mol Technol Ltd, Saratovska 26, Bratislava 84201, Slovakia.; Jurkovicova, D (通讯作者)，Slovak Acad Sci, Canc Res Inst, Biomed Res Ctr, Dubravska Cesta 9, Bratislava 84505, Slovakia.
EM dana.j@krdlab.sk
RI Sestakova, Zuzana/KIB-0048-2024; Kulcsár, Ľudovít/ABH-4691-2020;
   Konečný, Michal/HKE-0581-2023; , Miroslav/H-6818-2018
OI Kulcsar, Ludovit/0000-0001-7997-7962; Sestakova,
   Zuzana/0000-0003-3229-0404; , Miroslav/0000-0001-9120-5084; Konecny,
   Michal/0000-0002-8523-3633; Jurkovicova, Dana/0000-0002-7997-6932
FU sources of EU - European fund for regional development through operation
   program of Research and Development [ITMS 26240220074,
   OPVaV-2011/4.2/07-SORO]
FX This work was supported by grant co-sponsored by sources of EU -
   European fund for regional development through operation program of
   Research and Development (project code ITMS 26240220074/call code
   OPVaV-2011/4.2/07-SORO). We would like to greatly acknowledge personnel
   of University Hospital of Medical Faculty, Comenius University and
   National Cancer Institute in Bratislava, Slovakia for their contribution
   and help with patients' samples collection and management.
CR Aguda BD, 2008, P NATL ACAD SCI USA, V105, P19678, DOI 10.1073/pnas.0811166106
   ANANTA JS, 2016, MOL PHARM
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Barnes CJ, 2003, CANCER METAST REV, V22, P301, DOI 10.1023/A:1023726827771
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a
   Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Calvano CMC, 2014, TUMOR BIOL, V35, P7733, DOI 10.1007/s13277-014-2025-7
   Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106
   Chang CW, 2015, ANTICANCER RES, V35, P3969
   Chang S, 2013, TRANSCR-AUSTIN, V4, P24, DOI 10.4161/trns.22600
   Chang SW, 2012, ONCOTARGET, V3, P5, DOI 10.18632/oncotarget.433
   Chen J, 2012, J SURG ONCOL, V106, P260, DOI 10.1002/jso.22153
   Christodoulatos GS, 2014, WORLD J CLIN ONCOL, V5, P71, DOI 10.5306/wjco.v5.i2.71
   Cortez Maria Angelica, 2012, Recent Results Cancer Res, V195, P151, DOI 10.1007/978-3-642-28160-0_13
   Czyzyk-Krzeska MF, 2014, ONCOGENE, V33, P677, DOI 10.1038/onc.2013.26
   Dalamaga M, 2012, MATURITAS, V71, P301, DOI 10.1016/j.maturitas.2011.12.013
   Das K, 2009, EUR J CANCER, V45, P2239, DOI 10.1016/j.ejca.2009.06.021
   de Sanjosé S, 2003, INT J CANCER, V106, P588, DOI 10.1002/ijc.11271
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3
   Duffy MJ, 2006, CLIN CHEM, V52, P345, DOI 10.1373/clinchem.2005.059832
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608
   Ferrari N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100759
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4
   GAO Y, 2016, ONCOTARGET, V7, P23
   Ge YF, 2013, ASIAN PAC J CANCER P, V14, P963, DOI 10.7314/APJCP.2013.14.2.963
   Guo XJ, 2013, CLIN CANCER RES, V19, P4994, DOI 10.1158/1078-0432.CCR-12-3700
   Haffty BG, 2009, ANN ONCOL, V20, P1653, DOI 10.1093/annonc/mdp051
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200
   Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756
   Jurkovicova D, 2015, NEOPLASMA, V62, P949, DOI 10.4149/neo_2015_115
   Jurkovicova D, 2014, NEOPLASMA, V61, P241, DOI 10.4149/neo_2014_032
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Kuhnert F, 2010, BLOOD, V115, P4631, DOI 10.1182/blood-2010-03-276428
   Lappano R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00066
   Li XR, 2010, ENDOCRINOLOGY, V151, P2462, DOI 10.1210/en.2009-1150
   Liu Y, 2015, BREAST CANCER RES TR, V152, P183, DOI 10.1007/s10549-015-3460-x
   Ma J, 2015, LAB INVEST, V95, P1197, DOI 10.1038/labinvest.2015.88
   Machackova E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-140
   Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Mishra S, 2015, CANCER LETT, V369, P67, DOI 10.1016/j.canlet.2015.07.045
   Monsalve M, 2011, CURR DRUG TARGETS, V12, P1322, DOI 10.2174/138945011796150307
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349-7006.2010.01742.x
   Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471
   Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002
   Razzak R, 2016, CURR ONCOL, V23, pE86, DOI 10.3747/co.23.2830
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448
   Rouas R, 2009, EUR J IMMUNOL, V39, P1608, DOI 10.1002/eji.200838509
   Scaling AL, 2014, HORM CANCER-US, V5, P146, DOI 10.1007/s12672-014-0174-1
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Singh A, 2011, CURR DRUG TARGETS, V12, P1311, DOI 10.2174/138945011796150271
   Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997
   Taylor S, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0156-6
   Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Turchinovich A., 2013, Frontiers in Genetics, V4, P119, DOI 10.3389/fgene.2013.00119
   Vimalraj S, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/451248
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Vos S, 2015, ONCOTARGET, V6, P32115, DOI 10.18632/oncotarget.5617
   Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005
   Weber F, 2006, AM J HUM GENET, V78, P961, DOI 10.1086/504090
   Williams C, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.370
   Xiang J, 2010, CURR GENOMICS, V11, P129, DOI 10.2174/138920210790886853
   Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016841
   Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676
   Yang JY, 2011, CURR DRUG TARGETS, V12, P1284, DOI 10.2174/138945011796150299
   Yang ZJ, 2015, TUMOR BIOL, V36, P4565, DOI 10.1007/s13277-015-3101-3
   Yin QY, 2010, J VIROL, V84, P6318, DOI 10.1128/JVI.00635-10
   Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107
   Zhang Zhen-Wu, 2009, Yichuan, V31, P1094, DOI 10.3724/SP.J.1005.2009.01094
   ZHIKE C, BREAST CANC RES TREA, V152, P29
   Zhou SM, 2016, TUMOR BIOL, V37, P6837, DOI 10.1007/s13277-015-4500-1
NR 89
TC 13
Z9 15
U1 0
U2 9
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2016
VL 63
IS 6
BP 941
EP 951
DI 10.4149/neo_2016_613
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EE9QP
UT WOS:000389961600013
PM 27596294
OA Bronze
DA 2025-01-12
ER

PT J
AU Rahmani, E
   Shenhav, L
   Schweiger, R
   Yousefi, P
   Huen, K
   Eskenazi, B
   Eng, C
   Huntsman, S
   Hu, DL
   Galanter, J
   Oh, SS
   Waldenberger, M
   Strauch, K
   Grallert, H
   Meitinger, T
   Gieger, C
   Holland, N
   Burchard, EG
   Zaitlen, N
   Halperin, E
AF Rahmani, Elior
   Shenhav, Liat
   Schweiger, Regev
   Yousefi, Paul
   Huen, Karen
   Eskenazi, Brenda
   Eng, Celeste
   Huntsman, Scott
   Hu, Donglei
   Galanter, Joshua
   Oh, Sam S.
   Waldenberger, Melanie
   Strauch, Konstantin
   Grallert, Harald
   Meitinger, Thomas
   Gieger, Christian
   Holland, Nina
   Burchard, Esteban G.
   Zaitlen, Noah
   Halperin, Eran
TI Genome-wide methylation data mirror ancestry information
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE DNA methylation; Population structure; Ancestry; Epigenetics;
   Epigenome-wide association study (EWAS); Illumina 450K
ID DNA METHYLATION; GENETIC ANCESTRY; BREAST-CANCER; CELL-TYPES;
   ASSOCIATION; ASTHMA; RISK; STRATIFICATION; HETEROGENEITY; NORMALIZATION
AB Background: Genetic data are known to harbor information about human demographics, and genotyping data are commonly used for capturing ancestry information by leveraging genome-wide differences between populations. In contrast, it is not clear to what extent population structure is captured by whole-genome DNA methylation data.
   Results: We demonstrate, using three large-cohort 450K methylation array data sets, that ancestry information signal is mirrored in genome-wide DNA methylation data and that it can be further isolated more effectively by leveraging the correlation structure of CpGs with cis-located SNPs. Based on these insights, we propose a method, EPISTRUCTURE, for the inference of ancestry from methylation data, without the need for genotype data.
   Conclusions: EPISTRUCTURE can be used to infer ancestry information of individuals based on their methylation data in the absence of corresponding genetic data. Although genetic data are often collected in epigenetic studies of large cohorts, these are typically not made publicly available, making the application of EPISTRUCTURE especially useful for anyone working on public data. Implementation of EPISTRUCTURE is available in GLINT, our recently released toolset for DNA methylation analysis at: http://glint-epigenetics.readthedocs.io.
C1 [Rahmani, Elior; Schweiger, Regev] Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel.
   [Shenhav, Liat] Tel Aviv Univ, Dept Stat, Tel Aviv, Israel.
   [Yousefi, Paul; Huen, Karen; Eskenazi, Brenda; Holland, Nina] Univ Calif Berkeley, CERCH, Sch Publ Hlth, Berkeley, CA 94720 USA.
   [Eng, Celeste; Huntsman, Scott; Hu, Donglei; Galanter, Joshua; Oh, Sam S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Galanter, Joshua; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Waldenberger, Melanie; Grallert, Harald; Gieger, Christian] Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
   [Waldenberger, Melanie; Grallert, Harald; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany.
   [Strauch, Konstantin] Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
   [Strauch, Konstantin] Ludwig Maximilians Univ Munchen, Chair Genet Epidemiol, Inst Med Informat Biometry & Epidemiol, Munich, Germany.
   [Grallert, Harald; Gieger, Christian] German Ctr Diabet Res DZD, Neuherberg, Germany.
   [Meitinger, Thomas] Helmholtz Zentrum Munchen, Inst Human Genet, Munich, Germany.
   [Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, Munich, Germany.
   [Halperin, Eran] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA USA.
   [Halperin, Eran] Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, Los Angeles, CA USA.
C3 Tel Aviv University; Tel Aviv University; University of California
   System; University of California Berkeley; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health; Helmholtz Association; Helmholtz-Center Munich - German Research
   Center for Environmental Health; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health; University of
   Munich; Helmholtz Association; Helmholtz-Center Munich - German Research
   Center for Environmental Health; Technical University of Munich;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Rahmani, E (通讯作者)，Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel.; Halperin, E (通讯作者)，Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA USA.; Halperin, E (通讯作者)，Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, Los Angeles, CA USA.
EM elior.rahmani@gmail.com; ehalperin@cs.ucla.edu
RI Gieger, Christian/A-3083-2013; Waldenberger, Melanie/B-5355-2014;
   Rahmani, Elior/AAU-6092-2020; Grallert, Harald/B-3424-2013; Meitinger,
   Thomas/O-1318-2015; Schweiger, Regev/LMP-7468-2024
OI Shenhav, Liat/0000-0003-1708-6050; Meitinger,
   Thomas/0000-0002-8838-8403; Galanter, Joshua/0000-0002-2561-6384; Huen,
   Karen/0000-0003-3604-2096
FU Edmond J. Safra Center for Bioinformatics at Tel-Aviv University; Israel
   Science Foundation [1425/13]; NSF [1331176]; United States-Israel
   Binational Science Foundation [2012304]; Blavatnik Research Foundation;
   Sandler Family Foundation; American Asthma Foundation; Hind
   Distinguished Professorships; NHLBI [K25HL121295]; Helmholtz Zentrum
   Munchen-German Research Center for Environmental Health, Neuherberg,
   Germany; German Federal Ministry of Education and Research (BMBF);
   Federal Ministry of Health (Berlin, Germany); Ministry of Innovation,
   Science, Research and Technology of the state North Rhine-Westphalia
   (Dusseldorf, Germany); Munich Center of Health Sciences (MC Health) as
   part of LMUinnovativ; European Union Seventh Framework Programme (FP7)
   [261433, 603288]; European Union [305280]; Helmholtz-Russia Joint
   Research Group (HRJRG) [310]; German-Israeli Foundation for Scientific
   Research and Development [1094-33.2/2010]; German Center of Diabetes
   Research (DZD); NIH [P01 ES009605, RO1 ES012503, R01 ES 023067, R01
   ES021369]; EPA [RD 82670901, RD 83451301];  [1P60 MD006902]; 
   [1R01HL117004-01];  [R21ES24844-01];  [U54MD009523];  [TRDRP 24RT-0025]
FX This research was partially supported by the Edmond J. Safra Center for
   Bioinformatics at Tel-Aviv University. E.H., E.R. L.S. and R.S. were
   supported in part by the Israel Science Foundation (Grant 1425/13),
   E.H., E.R., and R.S. by NSF Grant 1331176 and United States-Israel
   Binational Science Foundation Grant 2012304. E.R. and L.S. were
   supported by Len Blavatnik and the Blavatnik Research Foundation. C.E.,
   S.H., D.H., J.G., S.O., E.B. were supported by the Sandler Family
   Foundation, the American Asthma Foundation, Hind Distinguished
   Professorships, and by the following research Grants: 1P60 MD006902,
   1R01HL117004-01, R21ES24844-01, U54MD009523, TRDRP 24RT-0025. N.Z. was
   supported in part by an NIH career development award from the NHLBI
   (K25HL121295). KORA was initiated and financed by the Helmholtz Zentrum
   Munchen-German Research Center for Environmental Health, Neuherberg,
   Germany and supported by grants from the German Federal Ministry of
   Education and Research (BMBF), the Federal Ministry of Health (Berlin,
   Germany), the Ministry of Innovation, Science, Research and Technology
   of the state North Rhine-Westphalia (Dusseldorf, Germany), and the
   Munich Center of Health Sciences (MC Health) as part of LMUinnovativ.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The research
   leading to these results has received funding from the European Union
   Seventh Framework Programme (FP7/2007-2013) under Grant Agreements No.
   261433 (BioSHaRe) and No. 603288 (sysVASC) and was supported by the
   European Union's Seventh Framework Programme (FP7-Health-F5-2012) under
   Grant Agreement No. 305280 (MIMOmics), the Helmholtz-Russia Joint
   Research Group (HRJRG) 310, the German-Israeli Foundation for Scientific
   Research and Development (Grant 1094-33.2/2010) and the German Center of
   Diabetes Research (DZD). The CHAMACOS study was supported by the NIH
   Grants P01 ES009605, RO1 ES012503, R01 ES 023067 and R01 ES021369, and
   EPA Grants RD 82670901 and RD 83451301. The contents of this manuscript
   are solely the responsibility of the authors and do not necessarily
   represent the official views of the NIEHS and the EPA.
CR Adams AT, 2014, INFLAMM BOWEL DIS, V20, P1784, DOI 10.1097/MIB.0000000000000179
   Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Banovich NE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004663
   Barfield RT, 2014, GENET EPIDEMIOL, V38, P231, DOI 10.1002/gepi.21789
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5
   Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Elhaik E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4513
   Eskenazi B., 2003, Journal of Children's Health, V1, P3, DOI DOI 10.3109/713610244
   Eskenazi B, 2014, ENVIRON RES, V134, P149, DOI 10.1016/j.envres.2014.07.001
   Fan JB, 2006, METHOD ENZYMOL, V410, P57, DOI 10.1016/S0076-6879(06)10003-8
   Fejerman L, 2008, CANCER RES, V68, P9723, DOI 10.1158/0008-5472.CAN-08-2039
   Fejerman L, 2010, CANCER EPIDEM BIOMAR, V19, P1074, DOI 10.1158/1055-9965.EPI-09-1193
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Galanter J.M., 2016, bioRxiv, P036822, DOI 10.1101/036822
   Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055
   Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050
   Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952
   Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Huen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062565
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   Koestler DC, 2013, EPIGENETICS-US, V8, P816, DOI 10.4161/epi.25430
   Kolz M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000504
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Moen EL, 2013, GENETICS, V194, P987, DOI 10.1534/genetics.113.151381
   Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331
   Pasaniuc B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001371
   Pfeiffer L, 2015, CIRC-CARDIOVASC GENE, V8, P334, DOI 10.1161/CIRCGENETICS.114.000804
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053
   Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pritchard JK, 2000, GENETICS, V155, P945
   Rahmani E, 2016, NAT METHODS, V13, P443, DOI [10.1038/nmeth.3809, 10.1038/NMETH.3809]
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014
   Seow WJ, 2014, ENVIRON MOL MUTAGEN, V55, P449, DOI 10.1002/em.21860
   Singmann P, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0035-3
   Smith AK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-145
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Tibshirani R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tsai HJ, 2005, HUM GENET, V118, P424, DOI 10.1007/s00439-005-0067-z
   Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226
   Yang WY, 2012, NAT GENET, V44, P725, DOI 10.1038/ng.2285
   Yousefi P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2034-y
   Yousefi P, 2015, ENVIRON MOL MUTAGEN, V56, P751, DOI 10.1002/em.21966
   Yousefi P, 2013, EPIGENETICS-US, V8, P1141, DOI 10.4161/epi.26037
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
   Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005
   Zhi D, 2013, EPIGENETICS-US, V8, P802, DOI 10.4161/epi.25501
NR 67
TC 67
Z9 83
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD JAN 3
PY 2017
VL 10
AR 1
DI 10.1186/s13072-016-0108-y
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EI7HT
UT WOS:000392669100001
PM 28149326
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Menendez, JA
   Alarcón, T
AF Menendez, Javier A.
   Alarcon, Tomas
TI Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming
   in Aging and Cancer
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE reprogramming; aging; cancer; senescence; inflammation
ID PLURIPOTENT STEM-CELLS; HUMAN FIBROBLASTS; INNATE IMMUNITY;
   SOMATIC-CELLS; THERAPEUTIC IMPLICATIONS; DIFFERENTIATED CELLS;
   BREAST-CANCER; ASPIRIN USE; IPS CELLS; ACTIVATION
AB The inability of adult tissues to transitorily generate cells with functional stem cell-like properties is a major obstacle to tissue self-repair. Nuclear reprogramming-like phenomena that induce a transient acquisition of epigenetic plasticity and phenotype malleability may constitute a reparative route through which human tissues respond to injury, stress, and disease. However, tissue rejuvenation should involve not only the transient epigenetic reprogramming of differentiated cells, but also the committed re-acquisition of the original or alternative committed cell fate. Chronic or unrestrained epigenetic plasticity would drive aging phenotypes by impairing the repair or the replacement of damaged cells: such uncontrolled phenomena of in vivo reprogramming might also generate cancer-like cellular states. We herein propose that the ability of senescence-associated inflammatory signaling to regulate in vivo reprogramming cycles of tissue repair outlines a threshold model of aging and cancer. The degree of senescence/inflammation-associated deviation from the homeostatic state may delineate a type of thresholding algorithm distinguishing beneficial from deleterious effects of in vivo reprogramming. First, transient activation of NF-kappa B-related innate immunity and senescence-associated inflammatory components (e.g., IL-6) might facilitate reparative cellular reprogramming in response to acute inflammatory events. Second, para-inflammation switches might promote long-lasting but reversible refractoriness to reparative cellular reprogramming. Third, chronic senescence-associated inflammatory signaling might lock cells in highly plastic epigenetic states disabled for reparative differentiation. The consideration of a cellular reprogramming-centered view of epigenetic plasticity as a fundamental element of a tissue's capacity to undergo successful repair, aging degeneration or malignant transformation should provide challenging stochastic insights into the current deterministic genetic paradigm for most chronic diseases, thereby increasing the spectrum of therapeutic approaches for physiological aging and cancer.
C1 [Menendez, Javier A.] Catalan Inst Oncol, Program Canc Therapeut Resistance, Metab & Canc Grp, Girona, Spain.
   [Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.
   [Menendez, Javier A.] METABOSTEM, Barcelona, Spain.
   [Alarcon, Tomas] ICREA, Barcelona, Spain.
   [Alarcon, Tomas] Ctr Recerca Matemat, Computat & Math Biol Res Grp, Barcelona, Spain.
   [Alarcon, Tomas] Univ Autonoma Barcelona, Dept Matemat, Barcelona, Spain.
   [Alarcon, Tomas] Barcelona Grad Sch Math, Barcelona, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI); ICREA; Centre de Recerca Matematica (CRM); Autonomous
   University of Barcelona
RP Menendez, JA (通讯作者)，Catalan Inst Oncol, Program Canc Therapeut Resistance, Metab & Canc Grp, Girona, Spain.; Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.; Menendez, JA (通讯作者)，METABOSTEM, Barcelona, Spain.
EM jmenendez@iconcologia.net
RI Alarcon, Tomas/D-9083-2013; MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI Alarcon, Tomas/0000-0002-8566-3676; MENENDEZ MENENDEZ, JAVIER
   ABEL/0000-0001-8733-4561
FU Ministerio de Ciencia e Innovacion [SAF2016-80639-P]; Plan Nacional de
   I+ D+ I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) [2014 SGR229]; Departament d'Economia i Coneixement, Catalonia,
   Spain; MINECO [MTM2015-71509-C2-1-R, 2014SGR1307, MDM-2014-0445]; AGAUR
   [MTM2015-71509-C2-1-R, 2014SGR1307]; Obra Social La Caixa Foundation on
   Collaborative Mathematics; CERCA Programme of the Generalitat de
   Catalunya; Armangue family (Girona, Catalonia)
FX This work was supported in part by grants from the Ministerio de Ciencia
   e Innovacion (Grant SAF2016-80639-P to JM), Plan Nacional de I+ D+ I,
   Spain and the Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) (Grant 2014 SGR229 to JM), Departament d'Economia i Coneixement,
   Catalonia, Spain. TA acknowledges MINECO and AGAUR for funding under
   grants MTM2015-71509-C2-1-R and 2014SGR1307. TA acknowledges support
   from MINECO for funding awarded to the Barcelona Graduate School of
   Mathematics under the "Maria de Maeztu" programme (grant MDM-2014-0445).
   This work was supported also by a grant of the "Obra Social La Caixa
   Foundation on Collaborative Mathematics awarded to the Centre de Recerca
   Matematica (CRM). The authors have been partially funded by the CERCA
   Programme of the Generalitat de Catalunya. The Metabolism and Cancer
   laboratory is supported by an unrestricted grant from the Armangue
   family (Girona, Catalonia). The authors would like to thank Dr. Kenneth
   McCreath for editorial support.
CR Abad M, 2013, NATURE, V502, P340, DOI 10.1038/nature12586
   Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Aran D, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0995-z
   AUSTGULEN R, 1995, HUM REPROD, V10, P171, DOI 10.1093/humrep/10.1.171
   Avior Y, 2016, NAT REV MOL CELL BIO, V17, P170, DOI 10.1038/nrm.2015.27
   Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005
   Barker N, 2008, COLD SH Q B, V73, P351, DOI 10.1101/sqb.2008.72.003
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6
   Brady JJ, 2013, NAT CELL BIOL, V15, P1244, DOI 10.1038/ncb2835
   Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881
   Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014
   Broz P, 2011, IMMUNOL REV, V243, P174, DOI 10.1111/j.1600-065X.2011.01041.x
   Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183
   Campisi J, 2005, MECH AGEING DEV, V126, P51, DOI 10.1016/j.mad.2004.09.024
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Cantone I, 2013, NAT STRUCT MOL BIOL, V20, P282, DOI 10.1038/nsmb.2489
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chan Andrew T, 2013, Recent Results Cancer Res, V191, P1, DOI 10.1007/978-3-642-30331-9_1
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chang TS, 2015, CLIN CANCER RES, V21, P201, DOI 10.1158/1078-0432.CCR-13-3274
   Chetty R, 2010, J CLIN PATHOL, V63, P488, DOI 10.1136/jcp.2010.076257
   Chiche A, 2017, CELL STEM CELL, V20, P407, DOI 10.1016/j.stem.2016.11.020
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Cooke JP, 2015, CIRCULATION, V132, pE197, DOI 10.1161/CIRCULATIONAHA.115.016792
   Cooke JP, 2014, CURR OPIN GENET DEV, V28, P89, DOI 10.1016/j.gde.2014.11.002
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379
   de Keizer PLJ, 2017, TRENDS MOL MED, V23, P6, DOI 10.1016/j.molmed.2016.11.006
   Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241
   Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012
   Desai TJ, 2013, NATURE, V503, P204, DOI 10.1038/nature12706
   Dimitrov L, 2015, INT J MED SCI, V12, P201, DOI 10.7150/ijms.11047
   Dixit E, 2013, ADV IMMUNOL, V117, P99, DOI 10.1016/B978-0-12-410524-9.00004-9
   Erdogan Ö, 2016, SCI REP-UK, V6, DOI 10.1038/srep24833
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fraser DM, 2014, BRIT J CANCER, V111, P623, DOI 10.1038/bjc.2014.264
   Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254
   Goding CR, 2014, NAT REV CANCER, V14, P568, DOI 10.1038/nrc3781
   Gregg SQ, 2012, HEPATOLOGY, V55, P609, DOI 10.1002/hep.24713
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018
   Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573
   Heo TH, 2016, ONCOTARGET, V7, P15460, DOI 10.18632/oncotarget.7102
   Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110
   Hobbs RM, 2014, CELL STEM CELL, V14, P269, DOI 10.1016/j.stem.2014.02.003
   Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Jessen KR, 2015, DEV CELL, V34, P613, DOI 10.1016/j.devcel.2015.09.005
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Kapetanovic R, 2015, AGEING RES REV, V24, P40, DOI 10.1016/j.arr.2015.02.005
   Kapoor H, 2015, TRANSL RES, V166, P28, DOI 10.1016/j.trsl.2015.01.009
   Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039
   Kim GW, 2015, ARCH PHARM RES, V38, P575, DOI 10.1007/s12272-015-0569-8
   Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012
   Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014
   Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743
   Krishnamurthy S, 2014, STEM CELLS, V32, P2845, DOI 10.1002/stem.1793
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560
   Kurian L, 2013, NAT METHODS, V10, P77, DOI [10.1038/NMETH.2255, 10.1038/nmeth.2255]
   Lasry A, 2015, TRENDS IMMUNOL, V36, P217, DOI 10.1016/j.it.2015.02.009
   Lee J, 2012, CELL, V151, P547, DOI 10.1016/j.cell.2012.09.034
   Letouzé E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018
   Lips Cjm, 2006, Hered Cancer Clin Pract, V4, P169, DOI 10.1186/1897-4287-4-4-169
   Liu GH, 2012, CURR OPIN CELL BIOL, V24, P765, DOI 10.1016/j.ceb.2012.08.014
   Luo M, 2013, STEM CELLS, V31, P1278, DOI 10.1002/stem.1374
   Mahmoudi S, 2016, CELL, V167, P1672, DOI 10.1016/j.cell.2016.11.050
   Marión RM, 2017, STEM CELL REP, V8, P460, DOI 10.1016/j.stemcr.2017.01.001
   Mauer J, 2015, TRENDS IMMUNOL, V36, P92, DOI 10.1016/j.it.2014.12.008
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Menendez JA, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1160854
   Menendez JA, 2016, STEM CELL REP, V6, P273, DOI 10.1016/j.stemcr.2015.12.012
   Menendez Javier A, 2014, Oncoscience, V1, P803
   Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262
   Montgomery RR, 2015, J LEUKOCYTE BIOL, V98, P937, DOI 10.1189/jlb.5MR0315-104R
   Mosteiro L, 2016, SCIENCE, V354, DOI 10.1126/science.aaf4445
   Muñoz-Espín D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Muñoz-Espín D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   O'Neill LAJ, 2012, CELL, V151, P471, DOI 10.1016/j.cell.2012.10.006
   Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052
   Ohnishi K, 2014, BIOCHEM BIOPH RES CO, V455, P10, DOI 10.1016/j.bbrc.2014.07.020
   Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106
   Park TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042838
   Pasque V, 2010, COLD SH Q B, V75, P189, DOI 10.1101/sqb.2010.75.002
   Pasque V, 2011, TRENDS GENET, V27, P516, DOI 10.1016/j.tig.2011.08.002
   Pietras EM, 2016, NAT CELL BIOL, V18, P607, DOI 10.1038/ncb3346
   Popov S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056328
   Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005
   Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587
   Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541
   Rincon M, 2012, TRENDS IMMUNOL, V33, P571, DOI 10.1016/j.it.2012.07.003
   Ritschka B, 2017, GENE DEV, V31, P172, DOI 10.1101/gad.290635.116
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1
   Roy S, 2013, P NATL ACAD SCI USA, V110, P4598, DOI 10.1073/pnas.1218682110
   Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002
   Sanges D, 2013, CELL REP, V4, P271, DOI 10.1016/j.celrep.2013.06.015
   Sayed N, 2015, CIRCULATION, V131, P300, DOI 10.1161/CIRCULATIONAHA.113.007394
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886
   Soria-Valles C, 2017, MECH AGEING DEV, V165, P10, DOI 10.1016/j.mad.2016.10.004
   Soria-Valles C, 2015, CELL CYCLE, V14, P3345, DOI 10.1080/15384101.2015.1093443
   Soria-Valles C, 2015, NAT CELL BIOL, V17, P1004, DOI 10.1038/ncb3207
   Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764
   Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041
   Streicher SA, 2014, CANCER EPIDEM BIOMAR, V23, P1254, DOI 10.1158/1055-9965.EPI-13-1284
   Sugimoto K, 2011, TRENDS CELL BIOL, V21, P212, DOI 10.1016/j.tcb.2010.12.004
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777
   Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Terlizzi M, 2014, PHARMACOL THERAPEUT, V143, P24, DOI 10.1016/j.pharmthera.2014.02.002
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785
   Toubai T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00539
   Tung PY, 2015, ONCOGENE, V34, P2288, DOI 10.1038/onc.2014.172
   van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581
   Vega ME, 2014, CELL CYCLE, V13, P3857, DOI 10.4161/15384101.2014.972875
   Wang DH, 2016, ADV EXP MED BIOL, V908, P183, DOI 10.1007/978-3-319-41388-4_10
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299
   Yang CS, 2011, STEM CELLS, V29, P1528, DOI 10.1002/stem.717
   Yang M, 2013, CANCER CELL, V23, P709, DOI 10.1016/j.ccr.2013.05.015
   Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190
   Zhong HH, 2016, CANCER RES, V76, P480, DOI 10.1158/0008-5472.CAN-15-0883
   Zhou JB, 2015, ONCOTARGET, V6, P5490, DOI 10.18632/oncotarget.3545
   Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
   ZOLTI M, 1991, FERTIL STERIL, V56, P265
NR 144
TC 21
Z9 22
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PY 2017
VL 5
AR 49
DI 10.3389/fcell.2017.00049
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA VH8AQ
UT WOS:000455238900049
PM 28529938
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Notarte, KI
   Nakao, Y
   Yaguchi, T
   Bungihan, M
   Suganuma, K
   dela Cruz, TE
AF Notarte, K., I
   Nakao, Y.
   Yaguchi, T.
   Bungihan, M.
   Suganuma, K.
   dela Cruz, T. E.
TI Trypanocidal activity, cytotoxicity and histone modifications induced by
   malformin A<sub>1</sub> isolated from the marine-derived fungus
   <i>Aspergillus tubingensis</i> IFM 63452
SO MYCOSPHERE
LA English
DT Article
DE bioactivities; epigenetics; fungal natural products; marine fungi
ID TRYPANOSOMA-CONGOLENSE; BREAST-CANCER; DISEASE; CHEMOTHERAPY;
   METABOLITES; CELLS; H4
AB Malformin A(1), a cyclic pentapeptide, was isolated from the marine-derived fungus Aspergillus tubingensis IFM 63452. The identity of the compound was established based on TOFMS and H-1 NMR data. Malformin A(1) exhibited trypanocidal activity against Trypanosoma congolense (IC50: 15.08 ng/mL). Interestingly, the compound was selective for T. congolense rendering a selectivity index value that ranged from 3.33 to 4.67. It also demonstrated cytotoxicity against HeLa (IC50: 50.15 ng/mL) and P388 (IC50: 70.38 ng/mL) cell lines. To further identify the possible mechanism of its cytotoxic effect, immunofluorescence staining was conducted to follow the epigenetic changes induced by the compound in the amino acid lysine of histone H3 and H4 in HeLa. The compound induced repressive levels of H3K27me3, H3K27ac and H4K5ac, and enhanced levels of H3K9me2, H3K9me3 and H4K16ac supporting the compound's chemotherapeutic potential.
C1 [Notarte, K., I; dela Cruz, T. E.] Univ Santo Tomas, Res Ctr Nat & Appl Sci, Grad Sch, Manila, Philippines.
   [Notarte, K., I] Univ Santo Tomas, Res Ctr Nat & Appl Sci, Senior High Sch, Manila, Philippines.
   [Notarte, K., I; dela Cruz, T. E.] Univ Santo Tomas, Res Ctr Nat & Appl Sci, Fungal Biodivers Ecogen & Systemat Grp, Manila, Philippines.
   [Nakao, Y.] Waseda Univ, Sch Adv Sci & Engn, Biol Chem Lab, Tokyo, Japan.
   [Yaguchi, T.] Chiba Univ, Med Mycol Res Ctr, Chiba, Japan.
   [Bungihan, M.] St Marys Univ, Sch Arts & Sci, Nueva Vizcaya, Philippines.
   [Suganuma, K.] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido, Japan.
C3 University of Santo Tomas; University of Santo Tomas; University of
   Santo Tomas; Waseda University; Chiba University; Obihiro University of
   Agriculture & Veterinary Medicine
RP Notarte, KI (通讯作者)，Univ Santo Tomas, Res Ctr Nat & Appl Sci, Grad Sch, Manila, Philippines.; Notarte, KI (通讯作者)，Univ Santo Tomas, Res Ctr Nat & Appl Sci, Senior High Sch, Manila, Philippines.; Notarte, KI (通讯作者)，Univ Santo Tomas, Res Ctr Nat & Appl Sci, Fungal Biodivers Ecogen & Systemat Grp, Manila, Philippines.
EM kinotarte@gmail.com
RI dela Cruz, Thomas/L-6929-2019; Bungihan, Melfei/ADH-4121-2022; Notarte,
   Kin Israel/Q-9050-2019
OI dela Cruz, Thomas Edison E./0000-0002-5505-3498; Bungihan,
   Melfei/0000-0002-8122-8087; Notarte, Kin Israel/0000-0002-6055-0886
FU Department of Science and Technology - Science Education Institute;
   Grants-in-Aid for Scientific Research [16K18793] Funding Source: KAKEN
FX A warm gratitude is given to the Chemical Biology Laboratory of the
   School of Advanced Science and Engineering, Waseda University, Tokyo,
   Japan for the research internship of one of the authors (KIRN). The
   authors acknowledge the technical help given by Dr. Daisuke Arai, the
   research grant provided by the Department of Science and Technology -
   Science Education Institute, and the facility support provided by the
   Research Center for the Natural and Applied Sciences of the University
   of Santo Tomas.
CR Afewerk Y, 2000, ACTA TROP, V76, P231, DOI 10.1016/S0001-706X(00)00108-X
   Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022
   De Silva DD, 2013, FUNGAL DIVERS, V62, P1, DOI 10.1007/s13225-013-0265-2
   De Silva DD, 2012, FUNGAL DIVERS, V55, P1, DOI 10.1007/s13225-012-0151-3
   dela Cruz TE, 2006, MYCOL PROG, V5, P108, DOI 10.1007/s11557-006-0504-y
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106
   GLASS NL, 1995, APPL ENVIRON MICROB, V61, P1323, DOI 10.1128/AEM.61.4.1323-1330.1995
   Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07
   JONES EBG, 1995, CAN J BOT, V73, pS790, DOI 10.1139/b95-324
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   KIM KW, 1993, BIOSCI BIOTECH BIOCH, V57, P240, DOI 10.1271/bbb.57.240
   Kimura H, 2008, CELL STRUCT FUNCT, V33, P61, DOI 10.1247/csf.07035
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klinch MA, 2002, IDENTIFICATION COMMO
   Koch A, 2005, J ETHNOPHARMACOL, V101, P95, DOI 10.1016/j.jep.2005.03.011
   Kohlmeyer J., 1979, Marine Mycology
   Kojima Y, 2009, J ANTIBIOT, V62, P681, DOI 10.1038/ja.2009.100
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006
   Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Raper K.B., 1977, The genus Aspergillus, V3rd
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Roche Joelle, 2013, Cancers (Basel), V5, P334, DOI 10.3390/cancers5020334
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Solis MJL, 2010, BOT MAR, V53, P587, DOI 10.1515/BOT.2010.071
   Suffness M., 1990, Methods in Plant Biochemistry, V6
   Suganuma K, 2014, J VET MED SCI, V76, P1437, DOI 10.1292/jvms.14-0273
   Tan QW, 2015, INT J MOL SCI, V16, P5750, DOI 10.3390/ijms16035750
   Tempone AG, 2005, PHYTOMEDICINE, V12, P382, DOI 10.1016/j.phymed.2003.10.007
   Urbina JA, 2002, CURR PHARM DESIGN, V8, P287, DOI 10.2174/1381612023396177
   Zhan JX, 2007, PHYTOCHEMISTRY, V68, P368, DOI 10.1016/j.phytochem.2006.09.038
NR 35
TC 16
Z9 19
U1 1
U2 15
PU MYCOSPHERE PRESS
PI GUIYANG
PA GUIZHOU KEY LAB AGRIC BIOTECH, GUIZHOU ACAD AGRIC SCI, GUIYANG, 00000,
   PEOPLES R CHINA
SN 2077-7000
J9 MYCOSPHERE
JI Mycosphere
PY 2017
VL 8
IS 1
BP 111
EP 120
DI 10.5943/mycosphere/8/1/10
PG 10
WC Mycology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mycology
GA EN6LW
UT WOS:000396116500010
OA gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Dewi, DL
   Mohapatra, SR
   Cabañes, SB
   Adam, I
   Patterson, LFS
   Berdel, B
   Kahloon, M
   Thümann, L
   Loth, S
   Heilmann, K
   Weichenhan, D
   Mücke, O
   Heiland, I
   Wimberger, P
   Kuhlmann, JD
   Kellner, KH
   Schott, S
   Plass, C
   Platten, M
   Gerhäuser, C
   Trump, S
   Opitz, CA
AF Dewi, Dyah L.
   Mohapatra, Soumya R.
   Cabanes, Saioa Blanco
   Adam, Isabell
   Patterson, Luis F. Somarribas
   Berdel, Bianca
   Kahloon, Masroor
   Thuemann, Loreen
   Loth, Stefanie
   Heilmann, Katharina
   Weichenhan, Dieter
   Muecke, Oliver
   Heiland, Ines
   Wimberger, Pauline
   Kuhlmann, Jan Dominik
   Kellner, Karl-Heinz
   Schott, Sarah
   Plass, Christoph
   Platten, Michael
   Gerhaeuser, Clarissa
   Trump, Saskia
   Opitz, Christiane A.
TI Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter
   hypermethylation in ER-positive breast cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE DNA methylation; epigenetics; estrogen receptor; immunosuppression;
   indoleamine-2,3dioxygenase; tryptophan metabolism
ID TUMORAL IMMUNE RESISTANCE; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN
   DEGRADATION; GENOME BROWSER; INHIBITION; IDO; MECHANISM; ESTROGEN;
   METASTASIS; METABOLISM
AB Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer. As the response of breast cancer to immune checkpoint inhibitors may be limited, a better understanding of the expression of additional targetable immunomodulatory pathways is of importance. We therefore investigated the regulation of IDO1 expression in different breast cancer subtypes. We identified estrogen receptor a (ER) as a negative regulator of IDO1 expression. Serum kynurenine levels as well as tumoral IDO1 expression were lower in patients with ER-positive than ER-negative tumors and an inverse relationship between IDO1 and estrogen receptor mRNA was observed across 14 breast cancer data sets. Analysis of whole genome bisulfite sequencing, 450k, MassARRAY and pyrosequencing data revealed that the IDO1 promoter is hypermethylated in ER-positive compared with ER-negative breast cancer. Reduced induction of IDO1 was also observed in human ER-positive breast cancer cell lines. IDO1 induction was enhanced upon DNA demethylation in ER-positive but not in ER-negative cells and methylation of an IDO1 promoter construct reduced IDO1 expression, suggesting that enhanced methylation of the IDO1 promoter suppresses IDO1 in ER-positive breast cancer. The association of ER overexpression with epigenetic downregulation of IDO1 appears to be a particular feature of breast cancer as IDO1 was not suppressed by IDO1 promoter hypermethylation in the presence of high ER expression in cervical or endometrial cancer.
C1 [Dewi, Dyah L.; Mohapatra, Soumya R.; Cabanes, Saioa Blanco; Adam, Isabell; Patterson, Luis F. Somarribas; Berdel, Bianca; Kahloon, Masroor; Opitz, Christiane A.] German Canc Res Ctr, Brain Canc Metab Grp, INF 280, Heidelberg, Germany.
   [Thuemann, Loreen; Loth, Stefanie; Trump, Saskia] UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Leipzig, Germany.
   [Heilmann, Katharina; Weichenhan, Dieter; Muecke, Oliver; Plass, Christoph; Gerhaeuser, Clarissa] German Canc Res Ctr, Epigen & Canc Risk Factors, Heidelberg, Germany.
   [Heiland, Ines] UiT Arctic Univ Norway, Dept Arctic & Marine Biol, Tromso, Norway.
   [Wimberger, Pauline; Kuhlmann, Jan Dominik] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dept Gynecol & Obstet, Dresden, Germany.
   [Wimberger, Pauline; Kuhlmann, Jan Dominik] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany.
   [Wimberger, Pauline; Kuhlmann, Jan Dominik] German Canc Consortium DKTK, Dresden, Germany.
   [Wimberger, Pauline; Kuhlmann, Jan Dominik] German Canc Res Ctr, Heidelberg, Germany.
   [Kellner, Karl-Heinz] Neuroimmun GmbH, Karlsruhe, Germany.
   [Schott, Sarah] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.
   [Platten, Michael; Opitz, Christiane A.] Univ Heidelberg Hosp, Neurol Clin, Heidelberg, Germany.
   [Platten, Michael; Opitz, Christiane A.] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany.
   [Platten, Michael] German Canc Res Ctr, Clin Cooperat Unit, Neuroimmunol & Brain Tumor Immunol, Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; Helmholtz Center for Environmental Research (UFZ);
   Helmholtz Association; German Cancer Research Center (DKFZ); UiT The
   Arctic University of Tromso; Technische Universitat Dresden; Helmholtz
   Association; German Cancer Research Center (DKFZ); Ruprecht Karls
   University Heidelberg; Helmholtz Association; German Cancer Research
   Center (DKFZ); Helmholtz Association; German Cancer Research Center
   (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ);
   Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ)
RP Opitz, CA (通讯作者)，German Canc Res Ctr, Brain Canc Metab Grp, INF 280, Heidelberg, Germany.; Opitz, CA (通讯作者)，Univ Heidelberg Hosp, Neurol Clin, Heidelberg, Germany.; Opitz, CA (通讯作者)，Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany.
EM c.opitz@dkfz.de
RI Dewi, Dyah Laksmi/GOP-2412-2022; Opitz, Christiane/I-9507-2012; Trump,
   Saskia/ABG-5182-2021; Thürmann, Loreen/AAD-4716-2022; Platten,
   Michael/F-2902-2013; Heiland, Ines/B-9212-2014; Schott,
   Sarah/D-5242-2018
OI Somarribas Patterson, Luis Felipe/0000-0002-8919-6024; Kahloon, Masroor
   Ahmad/0000-0003-4766-4149; Platten, Michael/0000-0002-4746-887X; Opitz,
   Christiane/0000-0001-5575-9821; Heiland, Ines/0000-0002-9124-5112;
   Gerhauser, Clarissa/0000-0002-5792-3901; Dewi, Dyah
   Laksmi/0000-0001-7937-4221; Schott, Sarah/0000-0002-1714-1147; Trump,
   Saskia/0000-0002-9894-1807; Mohapatra, Soumya/0000-0002-4350-6410;
   Thurmann, Loreen/0000-0003-1109-1924
FU BMBF [01ZX1402]; Otto Bayer Fellowship; Helmholtz Initiative on
   Personalized Medicine; University of Costa Rica (UCR); Costa Rica's
   Ministry of Science, Technology and Telecommunications (MICITT);
   Helmholtz International Graduate School for Cancer Research Fellowship
FX This work was supported by grants from the BMBF e:Med initiative
   (GlioPATH, 01ZX1402) to SL, ST and CAO and an Otto Bayer Fellowship to
   DLD. ST was supported by the Helmholtz Initiative on Personalized
   Medicine (iMed). LFSP is supported by scholarships from the University
   of Costa Rica (UCR) and Costa Rica's Ministry of Science, Technology and
   Telecommunications (MICITT). SRM and KH are supported by a Helmholtz
   International Graduate School for Cancer Research Fellowship.
CR Balachandran VP, 2011, NAT MED, V17, P1094, DOI 10.1038/nm.2438
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247
   Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005
   Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652
   D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066
   Larrain MTI, 2014, TUMOR BIOL, V35, P6511, DOI 10.1007/s13277-014-1859-3
   Jacquemier J, 2012, INT J CANCER, V130, P96, DOI 10.1002/ijc.25979
   Juhász C, 2012, NUCL MED BIOL, V39, P926, DOI 10.1016/j.nucmedbio.2012.01.010
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Litzenburger UM, 2014, ONCOTARGET, V5, P1038, DOI 10.18632/oncotarget.1637
   Lyon Debra E, 2011, BMC Res Notes, V4, P156, DOI 10.1186/1756-0500-4-156
   Miyan M, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0983-9
   Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196
   Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002
   Opitz CA, 2007, CELL MOL LIFE SCI, V64, P2542, DOI 10.1007/s00018-007-7140-9
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pilotte L, 2012, P NATL ACAD SCI USA, V109, P2497, DOI 10.1073/pnas.1113873109
   Pitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001
   ROSE DP, 1967, CLIN CHIM ACTA, V18, P221, DOI 10.1016/0009-8981(67)90161-1
   Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Smith C, 2012, CANCER DISCOV, V2, P722, DOI 10.1158/2159-8290.CD-12-0014
   Soliman H, 2013, CANCER IMMUNOL IMMUN, V62, P829, DOI 10.1007/s00262-013-1393-y
   Srijaipracharoen S, 2010, ASIAN PAC J CANCER P, V11, P215
   Stavrum AK, 2013, J BIOL CHEM, V288, P34555, DOI 10.1074/jbc.M113.474908
   Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08
   Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9
   Théate I, 2015, CANCER IMMUNOL RES, V3, P161, DOI 10.1158/2326-6066.CIR-14-0137
   Trump S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28616
   Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934
   Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27048, 10.4161/21624011.2014.957994]
   Vigneron N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1003012
   Xue ZT, 2012, MOL IMMUNOL, V51, P101, DOI 10.1016/j.molimm.2012.01.006
   Yuan HY, 2012, ONCOTARGET, V3, P345
NR 42
TC 27
Z9 29
U1 1
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2017
VL 6
IS 2
AR e1274477
DI 10.1080/2162402X.2016.1274477
PG 12
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA EQ3QG
UT WOS:000397987000028
PM 28344890
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gaál, Z
   Oláh, É
   Rejto, L
   Bálint, BL
   Csernoch, L
AF Gaal, Zsuzsanna
   Olah, Eva
   Rejto, Laszlo
   Balint, Balint Laszlo
   Csernoch, Laszlo
TI Expression Levels of Warburg-Effect Related microRNAs Correlate with
   each Other and that of Histone Deacetylase Enzymes in Adult
   Hematological Malignancies with Emphasis on Acute Myeloid Leukemia
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Acute myeloid leukemia; Warburg-effect; microRNA; oncomiR; Anti-oncomiR;
   Histone deacetylase
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER CELLS; LYSINE ACETYLATION;
   TUMOR-SUPPRESSOR; METABOLISM; HEMATOPOIESIS; EPIGENETICS; GROWTH; SIRT6
AB Disruption of epigenetic regulation and characteristic metabolic alterations (known as the Warburg-effect) are well-known hallmarks of cancer. In our study we investigated the expression levels of microRNAs and histone deacetylase enzymes via RT-qPCR in bone marrow specimens of adult patients suffering from hematological malignancies (total cohort n = 40), especially acute myeloid leukemia (n = 27). The levels of the three examined Warburg-effect related microRNAs (miR-378*, miR-23b, miR-26a) positively correlated with each other and the oncogenic miR-155 and miR-125b, while negatively with the level of the tumorsuppressor miR-124. Significant relationships have been confirmed between the levels of SIRT6, HDAC4 and the microRNAs listed above. In NPM1-mutated AML (n = 6), the level of miR-125b was significantly lower than in the group of AML patients not carrying this mutation (n = 13) (p < 0.05). In M5 FAB type of AML (n = 5), the level of miR-124 was significantly higher compared to the M2 group (n = 7) (p < 0.05). In two cases of FAB M5 AML, the levels of SIRT6 and miR-26a increased during the first 4 weeks of treatment. In the total cohort, white blood cell count at the time of the diagnosis significantly correlated with the levels of HDAC4, SIRT6, miR-124 and miR-26a. Our results suggest that Warburg-effect related microRNAs may have important role in the pathogenesis of leukemia, and the potential oncogenic property of HDAC4 and SIRT6 cannot be excluded in hematological malignancies. Elevated level of miR-125b can contribute to adverse prognosis of AML without NPM1 mutation. The prevailment of the tumorsuppressor property of miR-124 may depend on the accompanying genetic alterations.
C1 [Gaal, Zsuzsanna; Csernoch, Laszlo] Univ Debrecen, Dept Physiol, Nagyerdei Krt 98 POB 22, H-4012 Debrecen, Hungary.
   [Olah, Eva] Univ Debrecen, Inst Pediat, Nagyerdei Krt 98 POB 32,PO 4012, Debrecen, Hungary.
   [Rejto, Laszlo] Univ Debrecen, Inst Internal Med, Nagyerdei Krt 98 POB 20, H-4012 Debrecen, Hungary.
   [Balint, Balint Laszlo] Univ Debrecen, Dept Biochem & Mol Biol, Genom Med & Bioinformat Core Facil, Nagyerdei Krt 98 POB 6, H-4012 Debrecen, Hungary.
C3 University of Debrecen; University of Debrecen; University of Debrecen;
   University of Debrecen
RP Csernoch, L (通讯作者)，Univ Debrecen, Dept Physiol, Nagyerdei Krt 98 POB 22, H-4012 Debrecen, Hungary.
EM gaal.zsuzsanna@med.unideb.hu; eolah@dote.hu; lrejto@med.unideb.hu;
   balintblaszlo@gmail.com; csl@edu.unideb.hu
RI Balint, Balint/A-3853-2010
OI Balint, Balint/0000-0002-6163-7190; Csernoch, Laszlo/0000-0002-2446-1456
FU [TAMOP-4.1.2. E-13/1/KONV-2013-0010];  [TAMOP 4.2.4. A/2-11-1-2012-0001]
FX TAMOP-4.1.2. E-13/1/KONV-2013-0010, TAMOP 4.2.4. A/2-11-1-2012-0001
CR Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025
   Brait M, 2011, TOXICOL MECH METHOD, V21, P275, DOI 10.3109/15376516.2011.562671
   Busch S, 2015, J IMMUNOL, V194, P1646, DOI 10.4049/jimmunol.1402163
   Chen B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-443
   Chen L, 2014, INT J MOL SCI, V15, P11435, DOI 10.3390/ijms150711435
   Cheng JJ, 2013, CELL REP, V5, P471, DOI 10.1016/j.celrep.2013.08.050
   Czimmerer Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055168
   Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002
   Etchegaray JP, 2015, NAT CELL BIOL, V17, P545, DOI 10.1038/ncb3147
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Havelange V, 2010, AM J HEMATOL, V85, P935, DOI 10.1002/ajh.21863
   Hirsch P, 2015, LEUKEMIA LYMPHOMA, V56, P147, DOI 10.3109/10428194.2014.913288
   Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45
   Jiang WJ, 2015, LEUKEMIA LYMPHOMA, V56, P460, DOI 10.3109/10428194.2014.924115
   Khalaj M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00361
   Li HJ, 2014, ASIAN PAC J CANCER P, V15, P7015, DOI 10.7314/APJCP.2014.15.17.7015
   Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014
   Marcucci G, 2011, BLOOD, V117, P1121, DOI 10.1182/blood-2010-09-191312
   Nakajima H, 2014, CANCER SCI, V105, P1093, DOI 10.1111/cas.12484
   Schotte D, 2011, HAEMATOL-HEMATOL J, V96, P703, DOI 10.3324/haematol.2010.026138
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Shan CL, 2014, MOL CELL, V55, P552, DOI 10.1016/j.molcel.2014.06.020
   Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040
   Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689
   Zhong L, 2010, TRANSCR-AUSTIN, V1, P17, DOI 10.4161/trns.1.1.12143
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
   Zhou JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019798
   Zhu YD, 2012, MED ONCOL, V29, P2323, DOI 10.1007/s12032-011-0140-5
NR 31
TC 7
Z9 9
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JAN
PY 2017
VL 23
IS 1
BP 207
EP 216
DI 10.1007/s12253-016-0151-9
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EI2HN
UT WOS:000392307600027
PM 27864740
DA 2025-01-12
ER

PT J
AU Napoli, S
   Piccinelli, V
   Mapelli, SN
   Pisignano, G
   Catapano, CV
AF Napoli, Sara
   Piccinelli, Valentina
   Mapelli, Sarah N.
   Pisignano, Giuseppina
   Catapano, Carlo V.
TI Natural antisense transcripts drive a regulatory cascade controlling
   c-MYC transcription
SO RNA BIOLOGY
LA English
DT Article
DE c-MYC; epigenetics; long noncoding RNA; natural antisense transcripts;
   small RNAs; transcriptional regulation
ID MOUSE OOCYTES; EPIGENETIC REGULATION; GENE-EXPRESSION; READ ALIGNMENT;
   NONCODING RNAS; BREAST-CANCER; HUMAN-CELLS; WEB SERVER; BIOGENESIS;
   SIRNAS
AB Cis-natural antisense transcripts (cis-NATs) are long noncoding RNAs transcribed from the opposite strand and overlapping coding and noncoding genes on the sense strand. cis-NATs are widely present in the human genome and can be involved in multiple mechanisms of gene regulation. Here, we describe the presence of cis-NATs in the 3' distal region of the c-MYC locus and investigate their impact on transcriptional regulation of this key oncogene in human cancers. We found that cis-NATs are produced as consequence of the activation of cryptic transcription initiation sites in the 3' distal region downstream of the c-MYC 3'UTR. The process is tightly regulated and leads to the formation of two main transcripts, NAT6531 and NAT6558, which differ in their ability to fold into stem-loop secondary structures. NAT6531 acts as a substrate for DICER and as a source of small RNAs capable of modulating c-MYC transcription. This complex system, based on the interplay between cis-NATs and NAT-derived small RNAs, may represent an important layer of epigenetic regulation of the expression of c-MYC and other genes in human cells.
C1 [Napoli, Sara; Piccinelli, Valentina; Mapelli, Sarah N.; Pisignano, Giuseppina; Catapano, Carlo V.] USI, IOR, Tumor Biol & Expt Therapeut Program, Bellinzona, Switzerland.
   [Catapano, Carlo V.] Univ Lausanne, Fac Biol & Med, Dept Oncol, Lausanne, Switzerland.
C3 Institute of Oncology Research (IOR); Universita della Svizzera
   Italiana; University of Lausanne
RP Catapano, CV (通讯作者)，IOR, Via Vela 6, CH-6500 Bellinzona, Switzerland.
EM carlo.catapano@ior.iosi.ch
RI Pisignano, Giuseppina/LEL-7430-2024; mapelli, sarah/AAC-6093-2022
OI Catapano, Carlo V./0000-0002-7079-557X; Pisignano,
   Giuseppina/0000-0001-7476-3447
FU Swiss National Science Foundation [310030-153099]; Ticino Foundation for
   Cancer Research; Virginia Boeger Foundation; Fidinam; Ceresio
   Foundation; Novartis Foundation; Ticino Foundation for Cancer Research
   (Mario Luvini fellowship); Swiss National Science Foundation (SNF)
   [310030_153099] Funding Source: Swiss National Science Foundation (SNF)
FX This work was funded by grants from the Swiss National Science
   Foundation (Grant no. 310030-153099), Ticino Foundation for Cancer
   Research, Virginia Boeger Foundation, Fidinam and Ceresio Foundation to
   CVC. SN and GP were supported by fellowships from the Novartis
   Foundation and Ticino Foundation for Cancer Research (Mario Luvini
   fellowship), respectively.
CR Albino D, 2012, CANCER RES, V72, P2889, DOI 10.1158/0008-5472.CAN-12-0212
   Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07
   Carlile M, 2009, NUCLEIC ACIDS RES, V37, P2274, DOI 10.1093/nar/gkp088
   Chen JJ, 2005, TRENDS GENET, V21, P326, DOI 10.1016/j.tig.2005.04.006
   Conley AB, 2012, NUCLEIC ACIDS RES, V40, P1438, DOI 10.1093/nar/gkr1010
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017
   Faghihi MA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r56
   Flemr M, 2013, CELL, V155, P807, DOI 10.1016/j.cell.2013.10.001
   Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013
   He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Jin H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-6
   Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009
   Kim SW, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1235
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32
   Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li KG, 2010, ONCOTARGET, V1, P447, DOI 10.18632/oncotarget.178
   Li N, 2015, P NATL ACAD SCI USA, V112, P4357, DOI 10.1073/pnas.1406130112
   Ling KH, 2016, GENOMICS, V107, P88, DOI 10.1016/j.ygeno.2016.01.006
   Ma XX, 2014, RNA BIOL, V11, P373, DOI 10.4161/rna.28725
   Mandal AK, 2013, NUCLEIC ACIDS RES, V41, P2121, DOI 10.1093/nar/gks1457
   Maute RL, 2013, P NATL ACAD SCI USA, V110, P1404, DOI 10.1073/pnas.1206761110
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Morrissy AS, 2011, GENOME RES, V21, P1203, DOI 10.1101/gr.113431.110
   Napoli S, 2009, EMBO J, V28, P1708, DOI 10.1038/emboj.2009.139
   Nicolas E, 2007, NAT STRUCT MOL BIOL, V14, P372, DOI 10.1038/nsmb1239
   Pall GS, 2008, NAT PROTOC, V3, P1077, DOI 10.1038/nprot.2008.67
   Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594
   Pisignano G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15622
   Raina M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00171
   Rennie W, 2014, NUCLEIC ACIDS RES, V42, pW114, DOI 10.1093/nar/gku376
   Rybak-Wolf A, 2014, CELL, V159, P1153, DOI 10.1016/j.cell.2014.10.040
   Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253
   Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507
   Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904
   Topisirovic I, 2009, EMBO J, V28, P1087, DOI 10.1038/emboj.2009.53
   Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200
   Várallyay E, 2008, NAT PROTOC, V3, P190, DOI 10.1038/nprot.2007.528
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908
   Werner A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-19
   Werner MS, 2015, CELL REP, V12, P1089, DOI 10.1016/j.celrep.2015.07.033
   Wight M, 2013, ESSAYS BIOCHEM, V54, P91, DOI [10.1042/BSE0540091, 10.1042/bse0540091]
   Yan K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010132
   Yang JS, 2011, MOL CELL, V43, P892, DOI 10.1016/j.molcel.2011.07.024
   Yu R, 2014, MOL CELL, V53, P262, DOI 10.1016/j.molcel.2013.11.014
   Yuan CH, 2015, DNA RES, V22, P233, DOI 10.1093/dnares/dsv008
   Zamudio JR, 2014, CELL, V156, P920, DOI 10.1016/j.cell.2014.01.041
   Zhang XM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r20
   Zong X, 2016, NUCL ACIDS RES
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 55
TC 13
Z9 13
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PY 2017
VL 14
IS 12
BP 1742
EP 1755
DI 10.1080/15476286.2017.1356564
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FT6VH
UT WOS:000423291400017
PM 28805496
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Tekpli, X
   Skaug, V
   Bæra, R
   Phillips, DH
   Haugen, A
   Mollerup, S
AF Tekpli, Xavier
   Skaug, Vidar
   Baera, Rita
   Phillips, David H.
   Haugen, Aage
   Mollerup, Steen
TI Estrogen receptor expression and gene promoter methylation in non-small
   cell lung cancer - a short report
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Estrogen receptor; Lung cancer; Gene expression; DNA methylation; DNA
   adducts
ID BRONCHIAL EPITHELIAL-CELLS; ABERRANT DNA METHYLATION; CIGARETTE-SMOKING;
   PROSTATE-CANCER; BREAST-CANCER; PROGESTERONE-RECEPTORS; SIGNALING
   PATHWAYS; OVARIAN-CARCINOMA; CPG ISLAND; BETA
AB In the past, anomalous estrogen receptor (ER) regulation has been associated with various lung pathologies, but so far its involvement in lung cancer initiation and/or progression has remained unclear. Here, we aimed at assessing in vivo and in vitro ER expression and its possible epigenetic regulation in non-small cell lung cancer (NSCLC) samples and their corresponding normal tissues and cells.
   ER alpha and ER beta gene expression levels were assessed using real time quantitative PCR (RT-qPCR), whereas ER alpha and ER beta gene promoter methylation levels were assessed using DNA bisulfite conversion followed by pyrosequencing. We included NSCLC (n = 87) and adjacent histologically normal lung tissue samples from lung cancer patients (n = 184), primary normal bronchial epithelial-derived cell cultures (n = 11), immortalized bronchial epithelial-derived cell lines (n = 3) and NSCLC derived cell lines (n = 9).
   Using RT-qPCR we found significantly lower ER alpha and ER beta expression levels in the NSCLC tissue samples compared to their normal adjacent tissue samples. These lower ER expression levels were confirmed in vitro using primary normal bronchial epithelial-derived cell cultures, immortalized bronchial epithelial-derived cell lines and NSCLC-derived cell lines. By using this latter panel of cells, we found that ER gene promoter hypermethylation was associated with decreased ER expression. In addition we found that in tumor and normal lung tissues, smoking was associated with decreased ER expression and that normal lung tissues with a low ER beta expression level exhibited increased smoking-related DNA adducts.
   Taken together, our results indicate that decreased ER expression mediated by DNA methylation may play a role in NSCLC development.
C1 [Tekpli, Xavier; Skaug, Vidar; Baera, Rita; Haugen, Aage; Mollerup, Steen] Natl Inst Occupat Hlth, Sect Toxicol & Biol Working Environm, Dept Biol & Chem Working Environm, POB 8149,Gydas Vei 8, N-0033 Oslo, Norway.
   [Tekpli, Xavier] Oslo Univ Hosp, Inst Canc Res, Dept Genet, Oslo, Norway.
   [Phillips, David H.] Kings Coll London, MRC PHE Ctr Environm & Hlth, Analyt & Environm Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.
C3 University of Oslo; University of London; King's College London
RP Tekpli, X (通讯作者)，Natl Inst Occupat Hlth, Sect Toxicol & Biol Working Environm, Dept Biol & Chem Working Environm, POB 8149,Gydas Vei 8, N-0033 Oslo, Norway.; Tekpli, X (通讯作者)，Oslo Univ Hosp, Inst Canc Res, Dept Genet, Oslo, Norway.
EM xavier.tekpli@medisin.uio.no
RI Tekpli, Xavier/O-2614-2019
OI Tekpli, Xavier/0000-0003-4042-8290; Phillips, David/0000-0001-8509-3485
FU Norwegian Cancer Society
FX This study was supported by grants from the Norwegian Cancer Society. We
   are grateful to Mrs. Tove Andreassen and Mrs. Elin Einarsdottir Thorner
   for excellent technical assistance. The authors gratefully acknowledge
   collaboration of Dr. Lodve Stangeland, Haukeland University Hospital,
   Bergen, for recruiting the lung cancer patients and collecting the
   tissue specimens.
CR Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533
   Belinsky SA, 2002, CARCINOGENESIS, V23, P335, DOI 10.1093/carcin/23.2.335
   Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018
   Cincin ZB, 2015, CELL ONCOL, V38, P195, DOI 10.1007/s13402-015-0222-z
   Di Nunno L, 2000, ARCH PATHOL LAB MED, V124, P1467
   Early G., 2005, LANCET, V365
   Ellem SJ, 2007, NAT REV CANCER, V7, P621, DOI 10.1038/nrc2174
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fasco MJ, 2002, MOL CELL ENDOCRINOL, V188, P125, DOI 10.1016/S0303-7207(01)00750-X
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Issa JPJ, 1996, CANCER RES, V56, P973
   Kawai H, 2005, CLIN CANCER RES, V11, P5084, DOI 10.1158/1078-0432.CCR-05-0200
   Kennelly R, 2008, LANCET ONCOL, V9, P385, DOI 10.1016/S1470-2045(08)70100-1
   Kerr A, 2008, ADV EXP MED BIOL, V617, P377, DOI 10.1007/978-0-387-69080-3_36
   Kirn V, 2014, J CANCER RES CLIN, V140, P1681, DOI 10.1007/s00432-014-1729-9
   Koren A, 2015, CELL ONCOL, V38, P387, DOI 10.1007/s13402-015-0238-4
   LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633
   Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Márquez-Garbán DC, 2007, STEROIDS, V72, P135, DOI 10.1016/j.steroids.2006.11.019
   Mishra S, 2015, ONCOTARGET, V6, P44388, DOI 10.18632/oncotarget.6317
   Mollerup S, 2002, LUNG CANCER, V37, P153, DOI 10.1016/S0169-5002(02)00039-9
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Niikawa H, 2008, CLIN CANCER RES, V14, P4417, DOI 10.1158/1078-0432.CCR-07-1950
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Oie HK, 1996, J CELL BIOCHEM, P24
   Olivo-Marston SE, 2010, CARCINOGENESIS, V31, P1778, DOI 10.1093/carcin/bgq156
   PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0
   Prodromaki E, 2015, CELL ONCOL, V38, P307, DOI 10.1007/s13402-015-0231-y
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Raso MG, 2009, CLIN CANCER RES, V15, P5359, DOI 10.1158/1078-0432.CCR-09-0033
   Schwartz AG, 2005, CLIN CANCER RES, V11, P7280, DOI 10.1158/1078-0432.CCR-05-0498
   Stabile LP, 2011, CLIN CANCER RES, V17, P154, DOI 10.1158/1078-0432.CCR-10-0992
   Stabile LP, 2002, CANCER RES, V62, P2141
   Suzuki F, 2008, CANCER SCI, V99, P2365, DOI 10.1111/j.1349-7006.2008.00988.x
   Tekpli X, 2012, INT J CANCER, V131, P1509, DOI 10.1002/ijc.27421
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   Traynor AM, 2009, LUNG CANCER, V64, P51, DOI 10.1016/j.lungcan.2008.07.002
   WU AH, 1985, JNCI-J NATL CANCER I, V74, P747
   Yu XF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-29
   Zeng C, 2015, CELL ONCOL, V38, P319, DOI 10.1007/s13402-015-0225-9
   Zhang X, 2007, ONCOGENE, V26, P7346, DOI 10.1038/sj.onc.1210537
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zhao XZ, 2015, ONCOTARGETS THER, V8, P2849, DOI 10.2147/OTT.S90085
NR 44
TC 8
Z9 9
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2016
VL 39
IS 6
BP 583
EP 589
DI 10.1007/s13402-016-0295-3
PG 7
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA ED6SB
UT WOS:000388985200008
PM 27572263
DA 2025-01-12
ER

PT J
AU Grandin, M
   Mathot, P
   Devailly, G
   Bidet, Y
   Ghantous, A
   Fayrot, C
   Gibert, B
   Gadot, N
   Puisieux, I
   Herceg, Z
   Delcros, JG
   Bernet, A
   Mehlen, P
   Dante, R
AF Grandin, Melodie
   Mathot, Pauline
   Devailly, Guillaume
   Bidet, Yannick
   Ghantous, Akram
   Fayrot, Clementine
   Gibert, Benjamin
   Gadot, Nicolas
   Puisieux, Isabelle
   Herceg, Zdenko
   Delcros, Jean-Guy
   Bernet, Agnes
   Mehlen, Patrick
   Dante, Robert
TI Inhibition of DNA methylation promotes breast tumor sensitivity to
   netrin-1 interference
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; breast cancer; decitabine; dependence receptor; DNA
   methylation
ID CELL LUNG-CANCER; MAMMARY EPITHELIAL-CELLS; DCC GENE-PRODUCT; EPIGENETIC
   THERAPY; INDUCED APOPTOSIS; SURVIVAL FACTOR; DAP-KINASE; RECEPTOR;
   DEATH; TRANSFORMATION
AB In a number of human cancers, NTN1 upregulation inhibits apoptosis induced by its so-called dependence receptors DCC and UNC5H, thus promoting tumor progression. In other cancers however, the selective inhibition of this dependence receptor death pathway relies on the silencing of pro-apoptotic effector proteins. We show here that a substantial fraction of human breast tumors exhibits simultaneous DNA methylation-dependent loss of expression of NTN1 and of DAPK1, a serine threonine kinase known to transduce the netrin-1 dependence receptor pro-apoptotic pathway. The inhibition of DNA methylation by drugs such as decitabine restores the expression of both NTN1 and DAPK1 in netrin-1-low cancer cells. Furthermore, a combination of decitabine with NTN1 silencing strategies or with an anti-netrin-1 neutralizing antibody potentiates tumor cell death and efficiently blocks tumor growth in different animal models. Thus, combining DNA methylation inhibitors with netrin-1 neutralizing agents may be a valuable strategy for combating cancer.
C1 [Grandin, Melodie; Mathot, Pauline; Devailly, Guillaume; Fayrot, Clementine; Gibert, Benjamin; Delcros, Jean-Guy; Bernet, Agnes; Mehlen, Patrick; Dante, Robert] Uriversite Lyon, Ctr Leon Berard, Canc & Dev Lab,CRCL,INSERM U1052,CNRS UMR5286, Dependence Receptors,Equipe Labellisee La Ligue,L, Lyon, France.
   [Bidet, Yannick] Ctr Jean Perrin, Lab Oncol Mol, Clermont Ferrand, France.
   [Ghantous, Akram; Herceg, Zdenko] IARC, Epigenet Grp, Lyon, France.
   [Gadot, Nicolas] Univ Lyor, Hop Edouard Herriot, Hosp Civils Lyon, Endocrine Differentiat Lab,CRCL,Anat Pathol, Lyon, France.
   [Puisieux, Isabelle] UCBL, CLB, Targeting Tumor & Its Immure Environm Lab CRCL, INSERM U1052,CNRS UMR5286, Lyon, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Universite Claude Bernard Lyon 1;
   UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie
   (CRCL); Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Centre Jean Perrin; World Health Organization;
   International Agency for Research on Cancer (IARC); UNICANCER; Centre
   Leon Berard; Centre de Recherche en cancerologie (CRCL); CHU Lyon;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB)
RP Mehlen, P; Dante, R (通讯作者)，Uriversite Lyon, Ctr Leon Berard, Canc & Dev Lab,CRCL,INSERM U1052,CNRS UMR5286, Dependence Receptors,Equipe Labellisee La Ligue,L, Lyon, France.
EM patrick.mehlen@lyon.unicancer.fr; robert.dante@lyon.unicancer.fr
RI Herceg, Zdenko/JOZ-6188-2023; GHANTOUS, Akram/C-1689-2017; Bidet,
   Yannick/O-5753-2019; Devailly, Guillaume/S-3998-2019; Bernet,
   Agnes/GSN-2702-2022; delcros, jean-guy/N-5813-2017
OI Bidet, Yannick/0000-0002-9624-8195; GIBERT,
   Benjamin/0000-0002-5295-3124; Devailly, Guillaume/0000-0001-8878-9357;
   Grandin, Melodie/0000-0001-6784-9496; delcros,
   jean-guy/0000-0002-9593-4046
FU CNRS; University of Lyon; Centre Leon Berard; Ligue Contre le Cancer;
   INCA; ANR; ERC; EC FP7 Hermione-2man; Fondation Bettencourt; LabEx
   DEVweCAN
FX We are grateful to Drs. A Puisieux and AP Morel for the HMLER cells and
   to Sandrine Viala for her nice and efficient work. We thank Dr B.
   Manship for editing of this manuscript and helpful discussions. This
   work was supported by institutional grants from the CNRS, the University
   of Lyon, the Centre Leon Berard, the Ligue Contre le Cancer, the INCA,
   the ANR, the ERC, the EC FP7 Hermione-2man and from the Fondation
   Bettencourt. MG was supported by a fellowship grant from the LabEx
   DEVweCAN.
CR Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009
   Beygo J, 2013, HUM MOL GENET, V22, P544, DOI 10.1093/hmg/dds465
   Bongo JB, 2014, J CARDIOL, V63, P95, DOI 10.1016/j.jjcc.2013.10.006
   Cirulli V, 2007, NAT REV MOL CELL BIO, V8, P296, DOI 10.1038/nrm2142
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299
   Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491
   Devailly G, 2015, NUCLEIC ACIDS RES, V43, P5838, DOI 10.1093/nar/gkv508
   Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105
   Grandin M, 2016, CANCER CELL, V29, P173, DOI 10.1016/j.ccell.2016.01.001
   Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021
   Harter PN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092311
   HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174
   Kilinc D, 2012, DNA CELL BIOL, V31, P826, DOI 10.1089/dna.2011.1431
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Krimpenfort P, 2012, NATURE, V482, P538, DOI 10.1038/nature10790
   Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584
   Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715
   Lund P, 2011, MOL CANCER THER, V10, P1611, DOI 10.1158/1535-7163.MCT-11-0140
   Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441
   Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1
   Mian OY, 2011, MOL CANCER RES, V9, P1152, DOI 10.1158/1541-7786.MCR-11-0252
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Paradisi A, 2013, EMBO MOL MED, V5, P1821, DOI 10.1002/emmm.201302654
   Pulling LC, 2009, CARCINOGENESIS, V30, P2023, DOI 10.1093/carcin/bgp276
   Qi Q, 2015, P NATL ACAD SCI USA, V112, P7255, DOI 10.1073/pnas.1505917112
   Ramkhelawon B, 2014, NAT MED, V20, P377, DOI 10.1038/nm.3467
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Rodríguez-Paredes M, 2011, CANCER DISCOV, V1, P557, DOI 10.1158/2159-8290.CD-11-0271
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang XM, 2004, MOL CANCER RES, V2, P685
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Walker JA, 2004, GENOMICS, V83, P518, DOI 10.1016/j.ygeno.2003.09.003
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Zhu YY, 2013, J CLIN INVEST, V123, P2935, DOI 10.1172/JCI65988
NR 45
TC 22
Z9 24
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD AUG
PY 2016
VL 8
IS 8
BP 863
EP 877
DI 10.15252/emmm.201505945
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DW4SO
UT WOS:000383633500004
PM 27378792
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Tomita, Y
   Lee, MJ
   Lee, S
   Tomita, S
   Chumsri, S
   Cruickshank, S
   Ordentlich, P
   Trepel, JB
AF Tomita, Yusuke
   Lee, Min-Jung
   Lee, Sunmin
   Tomita, Saori
   Chumsri, Saranya
   Cruickshank, Scott
   Ordentlich, Peter
   Trepel, Jane B.
TI The interplay of epigenetic therapy and immunity in locally recurrent or
   metastatic estrogen receptor-positive breast cancer: Correlative
   analysis of ENCORE 301, a randomized, placebo-controlled phase II trial
   of exemestane with or without entinostat
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Breast cancer; entinostat; exemestane; histone deacetylase inhibitors;
   HLA-DR; immune checkpoint receptor; immune subsets; monocyte;
   myeloid-derived suppressor cell; regulatory T cell
ID HISTONE DEACETYLASE INHIBITORS; THYMIC EPITHELIAL TUMORS; MHC CLASS-I;
   SUPPRESSOR-CELLS; CHECKPOINT BLOCKADE; HDAC INHIBITORS; OPEN-LABEL;
   CD40; ACTIVATION; EXPRESSION
AB Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall survival among patients who received entinostat. We investigated the impact of entinostat on immune subsets with CD40, HLA-DR, and immune checkpoint receptor expression analyses in 34 patient blood samples from ENCORE 301. We found that entinostat significantly decreased granulocytic and monocytic MDSCs at cycle 1 day 15. MDSC CD40 was significantly downregulated by entinostat. A significant increase in HLA-DR expression on CD14(+) monocytes by entinostat was observed. Entinostat did not impact T-cell subsets or T-cell immune checkpoint receptor expression. Our findings suggest that a significant interplay between this epigenetic regimen and host immune homeostatic mechanisms may impact therapeutic outcome.
C1 [Tomita, Yusuke; Lee, Min-Jung; Lee, Sunmin; Tomita, Saori; Trepel, Jane B.] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Chumsri, Saranya] Mayo Clin, Jacksonville, FL 32224 USA.
   [Cruickshank, Scott; Ordentlich, Peter] Syndax Pharmaceut Inc, Waltham, MA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Mayo Clinic
RP Trepel, JB (通讯作者)，NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM trepel@helix.nih.gov
RI Kim, Tae-Hee/AAN-9079-2021
FU Intramural Research Program, Center for Cancer Research, National Cancer
   Institute, National Institutes of Health; Syndax Pharmaceuticals
FX This work was supported by the Intramural Research Program, Center for
   Cancer Research, National Cancer Institute, National Institutes of
   Health and by research funding and clinical trial support from Syndax
   Pharmaceuticals.
CR Akimova T, 2010, CLIN IMMUNOL, V136, P348, DOI 10.1016/j.clim.2010.04.018
   Bridle BW, 2013, MOL THER, V21, P887, DOI 10.1038/mt.2012.265
   Carter CA, 2016, ANN ONCOL, V27, P693, DOI 10.1093/annonc/mdw008
   Chang YC, 2008, BLOOD, V111, P5054, DOI 10.1182/blood-2007-12-130609
   Cronin K, 2013, HUM VACC IMMUNOTHER, V9, P784, DOI 10.4161/hv.23085
   Damuzzo V, 2015, CYTOM PART B-CLIN CY, V88, P77, DOI [10.1002/cyto.b.21206, 10.1002/cytob.21206]
   de Zoeten EF, 2011, MOL CELL BIOL, V31, P2066, DOI 10.1128/MCB.05155-11
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Doñas C, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/679804
   Draghiciu O, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.954829
   Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5
   Fakhrejahani F, 2015, CURR OPIN UROL, V25, P586, DOI 10.1097/MOU.0000000000000213
   Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626
   Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467
   Gustafson MP, 2015, CLIN CANCER RES, V21, P4224, DOI 10.1158/1078-0432.CCR-15-0260
   Huang JP, 2012, BLOOD, V120, P3030, DOI 10.1182/blood-2012-05-427799
   Kim JW, 2015, CURR OPIN ONCOL, V27, P191, DOI 10.1097/CCO.0000000000000177
   Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111
   Kroesen M, 2014, ONCOTARGET, V5, P6558, DOI 10.18632/oncotarget.2289
   Laborde RR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00147
   Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901
   Lucas JL, 2009, CELL IMMUNOL, V257, P97, DOI 10.1016/j.cellimm.2009.03.004
   Madan RA, 2016, BJU INT, V118, P590, DOI 10.1111/bju.13412
   Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017
   Manning J, 2008, IMMUNOLOGY, V123, P218, DOI 10.1111/j.1365-2567.2007.02689.x
   Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226
   Pan PY, 2010, CANCER RES, V70, P99, DOI 10.1158/0008-5472.CAN-09-1882
   Poschke I, 2012, CLIN IMMUNOL, V144, P250, DOI 10.1016/j.clim.2012.06.003
   Rajan A, 2014, LANCET ONCOL, V15, P191, DOI 10.1016/S1470-2045(13)70596-5
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Shen L, 2012, ONCOIMMUNOLOGY, V1, P948, DOI 10.4161/onci.20306
   Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815
   Solito S, 2014, ANN NY ACAD SCI, V1319, P47, DOI 10.1111/nyas.12469
   Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Thomas A, 2015, LANCET ONCOL, V16, P177, DOI 10.1016/S1470-2045(14)71181-7
   Thomas A, 2014, CLIN CANCER RES, V20, P5392, DOI 10.1158/1078-0432.CCR-14-0968
   Toh B, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001162
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Vonderheide RH, 2007, CLIN CANCER RES, V13, P1083, DOI 10.1158/1078-0432.CCR-06-1893
   Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883
   West AC, 2013, CANCER RES, V73, P7265, DOI 10.1158/0008-5472.CAN-13-0890
   Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96
   Woods DM, 2013, MELANOMA RES, V23, P341, DOI 10.1097/CMR.0b013e328364c0ed
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
   Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505
   Zhang Z, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.996470
   Zhang ZY, 2012, PROSTATE, V72, P90, DOI 10.1002/pros.21410
NR 50
TC 59
Z9 61
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2016
VL 5
IS 11
AR e1219008
DI 10.1080/2162402X.2016.1219008
PG 12
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA ED8UG
UT WOS:000389145800004
PM 27999738
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, JF
   Iwanowycz, S
   Yu, F
   Jia, XM
   Leng, SL
   Wang, YZ
   Li, W
   Huang, S
   Ai, W
   Fan, DP
AF Wang, Junfeng
   Iwanowycz, Stephen
   Yu, Fang
   Jia, Xuemei
   Leng, Shuilong
   Wang, Yuzhen
   Li, Wei
   Huang, Shiang
   Ai, Walden
   Fan, Daping
TI microRNA-155 deficiency impairs dendritic cell function in breast cancer
SO OncoImmunology
LA English
DT Article
DE Breast cancer; CCR7; dendritic cell; epigenetic modulation;
   Immunotherapy; microRNA-155; tumor microenvironment
ID BALANCING IMMUNITY; SUPPRESSOR-CELLS; GENE-EXPRESSION; PROTECTIVE ROLE;
   TUMOR-CELLS; IN-VIVO; MIR-155; IMMUNOTHERAPY; TOLERANCE; DIFFERENTIATION
AB In antitumor immunity, dendritic cells (DCs) capture, process, and present tumor antigens to T cells, initiating a tumoricidal response. However, DCs are often dysfunctional due to their exposure to the tumor microenvironment (TME), leading to tumor escape from immune surveillance. Here, a vital role of microRNA-155 (miR-155) in regulating the function of DCs in breast cancer is reported. Host miR-155 deficiency enhanced breast cancer growth in mice, accompanied by reduced DCs in the tumors and draining lymph nodes. miR-155 deficiency in DCs impaired their maturation, migration ability, cytokine production, and the ability to activate T cells. We demonstrate that miR-155 regulates DC migration through epigenetic modulation of CCR7 expression. Moreover, IL-6 and IL-10, two cytokines abundant in the TME, are found to impair DC maturation by suppressing miR-155 expression. Furthermore, animal studies show that a lack of miR-155 diminishes the effectiveness of DC-based immunotherapy for breast cancer. In conclusion, these findings suggest that miR-155 is a master regulator of DC function in breast cancer, including maturation, cytokine secretion, migration toward lymph nodes, and activation of T-cells. These results suggest that boosting the expression of a single microRNA, miR-155, may significantly improve the efficacy of DC-based immunotherapies for breast cancer.
C1 [Wang, Junfeng; Huang, Shiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Stem Cell Res & Applicat, Wuhan 430022, Peoples R China.
   [Wang, Junfeng; Iwanowycz, Stephen; Yu, Fang; Jia, Xuemei; Leng, Shuilong; Wang, Yuzhen; Li, Wei; Fan, Daping] Univ South Carolina, Sch Med, Dept Cell Biol & Anat, 6439 Garners Ferry Rd, Columbia, SC 29208 USA.
   [Ai, Walden] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA.
C3 Huazhong University of Science & Technology; University of South
   Carolina System; University of South Carolina Columbia; University of
   South Carolina System; University of South Carolina Columbia
RP Huang, S (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Stem Cell Res & Applicat, Wuhan 430022, Peoples R China.; Fan, DP (通讯作者)，Univ South Carolina, Sch Med, Dept Cell Biol & Anat, 6439 Garners Ferry Rd, Columbia, SC 29208 USA.
EM sa2huang@hotmail.com; daping.fan@uscmed.sc.edu
RI wang, wei/JYP-7819-2024; Yu, Fang/C-2933-2014; Wang,
   Junfeng/AAJ-3248-2020
FU NIH [R01HL116626, AT003961-8455]; National Natural Science Foundation of
   China [3097112]
FX This work was supported by NIH R01HL116626 and AT003961-8455 (to DF),
   and National Natural Science Foundation of China 3097112 (to SH).
CR Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417
   Bolisetty MT, 2009, J VIROL, V83, P12009, DOI 10.1128/JVI.01182-09
   CASEY AE, 1951, P SOC EXP BIOL MED, V77, P358
   Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432
   de Vries IJM, 2003, CANCER RES, V63, P12
   Del Vecchio M, 2007, CLIN CANCER RES, V13, P4677, DOI 10.1158/1078-0432.CCR-07-0776
   Dhodapkar MV, 2008, CELL DEATH DIFFER, V15, P39, DOI 10.1038/sj.cdd.4402247
   Dunand-Sauthier I, 2014, J IMMUNOL, V193, P1690, DOI 10.4049/jimmunol.1301913
   Dunand-Sauthier I, 2011, BLOOD, V117, P4490, DOI 10.1182/blood-2010-09-308064
   Escobar TM, 2014, IMMUNITY, V40, P865, DOI 10.1016/j.immuni.2014.03.014
   Förster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297
   Gambari R, 2011, BIOCHEM PHARMACOL, V82, P1416, DOI 10.1016/j.bcp.2011.08.007
   Gasparini P, 2014, P NATL ACAD SCI USA, V111, P4536, DOI 10.1073/pnas.1402604111
   Henry CJ, 2008, J IMMUNOL, V181, P8576, DOI 10.4049/jimmunol.181.12.8576
   Holmstrom K, 2010, HUM IMMUNOL, V71, P67, DOI 10.1016/j.humimm.2009.10.001
   Incio J, 2016, CLIN CANCER RES, V22, P2993, DOI 10.1158/1078-0432.CCR-15-1839
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Ji Y, 2015, P NATL ACAD SCI USA, V112, P476, DOI 10.1073/pnas.1422916112
   Jia XM, 2014, BREAST CANCER RES TR, V148, P291, DOI 10.1007/s10549-014-3164-7
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825
   Landeira D, 2010, NAT CELL BIOL, V12, P618, DOI 10.1038/ncb2065
   Liao XH, 2012, CELL METAB, V15, P545, DOI 10.1016/j.cmet.2012.01.022
   Lind EF, 2015, J IMMUNOL, V195, P4632, DOI 10.4049/jimmunol.1302941
   Lu CM, 2011, BLOOD, V117, P4293, DOI 10.1182/blood-2010-12-322503
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x
   Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Moran TP, 2014, J IMMUNOL, V193, P4904, DOI 10.4049/jimmunol.1401104
   Nachat-Kappes R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051525
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258
   Park SJ, 2004, J IMMUNOL, V173, P3844, DOI 10.4049/jimmunol.173.6.3844
   Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x
   Radford KJ, 2014, CURR OPIN IMMUNOL, V27, P26, DOI 10.1016/j.coi.2014.01.005
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422
   Steinbrink K, 1999, BLOOD, V93, P1634, DOI 10.1182/blood.V93.5.1634.405k11_1634_1642
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009
   Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100
   Wang JF, 2015, INT J CANCER, V136, pE602, DOI 10.1002/ijc.29151
   Xu H, 2012, FRONT MED, V5, P323
   Yu F, 2013, MOL CANCER RES, V11, P923, DOI 10.1158/1541-7786.MCR-12-0686
   Zhang MZ, 2013, J CONTROL RELEASE, V168, P251, DOI 10.1016/j.jconrel.2013.03.020
   Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647
NR 50
TC 32
Z9 35
U1 2
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2016
VL 5
IS 11
AR e1232223
DI 10.1080/2162402X.2016.1232223
PG 14
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA ED8UG
UT WOS:000389145800008
PM 27999745
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Aristizabal-Pachon, AF
   Satie-Takahashi, C
AF Aristizabal-Pachon, Andres Felipe
   Satie-Takahashi, Catarina
TI Effect of genetics, epigenetics and variations in the transcriptional
   expression of cadherin-E in breast cancer susceptibility
SO BIOMEDICA
LA Spanish
DT Article
DE Breast neoplasms/genetics; cadherins; polymerase chain reaction;
   restriction fragment length polymorphism; reverse transcriptase
   polymerase chain reaction
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; DNA METHYLATION PROFILES;
   CELL-ADHESION; PROMOTER POLYMORPHISM; CDH1 GENE; RISK; HYPERMETHYLATION;
   ASSOCIATION; MUTATIONS
AB Introduction: Cadherin-E (CDH1) is an important regulator of epithelial-mesenchymal transition, invasion and metastasis in many carcinomas. However, germinal epimutations and mutations effect in breast cancer susceptibility is not clear.
   Objective: To evaluate rs334558 polymorphism, promoter methylation status and CDH1 expression profile in breast cancer patients.
   Materials and methods: We collected peripheral blood samples from 102 breast cancer patients and 102 healthy subjects. The identification of rs334558 polymorphism was performed using PCR-RFLP, while methylation-specific PCR (MSP) and methylation-sensitive high-resolution melting (MS-HRM) were used to explore CDH1 methylation status; finally, CDH1 transcriptional expression profile was evaluated using RT-qPCR.
   Results: We found no association between rs334558 polymorphism and breast cancer. Aberrant promoter methylation profile was found in breast cancer patients and it was related with early cancer stages. CDH1 down-regulation was significantly associated with metastasis and promoter methylation.
   Conclusion: CDH1 alterations were associated with invasion and metastasis in breast cancer. Our results offer further evidence of CDH1 relevance in breast cancer development and progression.
C1 [Aristizabal-Pachon, Andres Felipe; Satie-Takahashi, Catarina] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
   [Satie-Takahashi, Catarina] Univ Sao Paulo, Fac Filosofia Ciencias & Letras Ribeirao Preto, Dept Biol, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Aristizabal-Pachon, AF (通讯作者)，Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM sagipe07@gmail.com
RI Aristizabal-Pachon, Andres Felipe/J-3046-2015
OI Aristizabal-Pachon, Andres Felipe/0000-0003-3004-4867
CR [Anonymous], EST 2014 INC CANC BR
   Aristizabal-Pachon AF, 2015, COMPLEXO DEGRADACAO, P25
   Aristizabal-Pachon Andres Felipe, 2015, Asian Pac J Cancer Prev, V16, P7277
   Asiaf A, 2014, ASIAN PAC J CANCER P, V15, P6397, DOI 10.7314/APJCP.2014.15.15.6397
   Beeghly-Fadiel A, 2010, BREAST CANCER RES TR, V121, P445, DOI 10.1007/s10549-009-0579-7
   Boonstra JJ, 2011, J GASTROINTEST SURG, V15, P48, DOI 10.1007/s11605-010-1358-9
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Brito Claudia, 2009, Rev. Saúde Pública, V43, P481, DOI 10.1590/S0034-89102009000300012
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Chien MH, 2012, HEAD NECK-J SCI SPEC, V34, P405, DOI 10.1002/hed.21746
   Aristizábal-Pachón AF, 2015, J EGYPT NATL CANCER, V27, P217, DOI 10.1016/j.jnci.2015.09.003
   GUMBINER BM, 1993, J CELL SCI, P155
   Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790
   Lei HX, 2002, INT J CANCER, V98, P199, DOI 10.1002/ijc.10176
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Shan K, 2007, REPRODUCTION, V134, P373, DOI 10.1530/REP-07-0104
   Shin Y, 2004, CARCINOGENESIS, V25, P895, DOI 10.1093/carcin/bgh073
   Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220
   Tahara T, 2011, VIRCHOWS ARCH, V458, P205, DOI 10.1007/s00428-010-1038-x
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tempfer CB, 2009, HUM REPROD UPDATE, V15, P97, DOI 10.1093/humupd/dmn040
   Tipirisetti NR, 2013, GENET TEST MOL BIOMA, V17, P494, DOI 10.1089/gtmb.2012.0485
   Tudoran O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102764
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Yamada H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-63
   Yu JC, 2006, J BIOMED SCI, V13, P419, DOI 10.1007/s11373-006-9069-7
   Yuan YL, 2012, ASIAN PAC J CANCER P, V13, P5149, DOI 10.7314/APJCP.2012.13.10.5149
   Zmetakova I, 2013, NEOPLASMA, V60, P635, DOI 10.4149/neo_2013_082
   Zou XP, 2009, WORLD J GASTROENTERO, V15, P5340, DOI 10.3748/wjg.15.5340
NR 34
TC 4
Z9 4
U1 0
U2 20
PU INST NACIONAL SALUD
PI BOGOTA D C
PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C,
   00000, COLOMBIA
SN 0120-4157
J9 BIOMEDICA
JI Biomedica
PD DEC
PY 2016
VL 36
IS 4
BP 593
EP 602
DI 10.7705/biomedica.v36i4.3135
PG 10
WC Tropical Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Tropical Medicine
GA ED1XK
UT WOS:000388638000013
PM 27992986
OA gold
DA 2025-01-12
ER

PT J
AU Quemener, C
   Baud, J
   Boye, K
   Dubrac, A
   Billottet, C
   Soulet, F
   Darlot, F
   Dumartin, L
   Sire, M
   Grepin, R
   Daubon, T
   Rayne, F
   Wodrich, H
   Couvelard, A
   Pineau, R
   Schilling, M
   Castronovo, V
   Sue, SC
   Clarke, K
   Lomri, A
   Khatib, AM
   Hagedorn, M
   Prats, H
   Bikfalvi, A
AF Quemener, Cathy
   Baud, Jessica
   Boye, Kevin
   Dubrac, Alexandre
   Billottet, Clotilde
   Soulet, Fabienne
   Darlot, Florence
   Dumartin, Laurent
   Sire, Marie
   Grepin, Renaud
   Daubon, Thomas
   Rayne, Fabienne
   Wodrich, Harald
   Couvelard, Anne
   Pineau, Raphael
   Schilling, Martin
   Castronovo, Vincent
   Sue, Shih-Che
   Clarke, Kim
   Lomri, Abderrahim
   Khatib, Abdel-Majid
   Hagedorn, Martin
   Prats, Herve
   Bikfalvi, Andreas
TI Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion
   of Pancreatic Cancer
SO CANCER RESEARCH
LA English
DT Article
ID PLATELET-FACTOR-4 VARIANT; BREAST-CANCER; TUMOR PROGRESSION; EXPRESSION;
   GROWTH; INHIBITION; DIVERGENCE; DIAGNOSIS; MELANOMA
AB The CXCL4 paralog CXCL4L1 is a less studied chemokine that has been suggested to exert an antiangiogenic function. However, CXCL4L1 is also expressed in patient tumors, tumor cell lines, and murine xenografts, prompting amore detailed analysis of its role in cancer pathogenesis. We used genetic and antibody-based approaches to attenuate CXCL4L1 in models of pancreatic ductal adenocarcinoma (PDAC). Mechanisms of expression were assessed in cell coculture experiments, murine, and avian xeno-transplants, including through an evaluation of CpG methylation and mutation of critical CpG residues. CXCL4L1 gene expression was increased greatly in primary and metastatic PDAC. We found that myofibroblasts triggered cues in the tumor microenvironment, which led to induction of CXCL4L1 in tumor cells. CXCL4L1 expression was also controlled by epigenetic modifications at critical CpG islands, which were mapped. CXCL4L1 inhibited angiogenesis but also affected tumor development more directly, depending on the tumor cell type. In vivo administration of an mAb against CXCL4L1 demonstrated a blockade in the growth of tumors positive for CXCR3, a critical receptor for CXCL4 ligands. Our findings define a protumorigenic role in PDAC development for endogenous CXCL4L1, which is independent of its antiangiogenic function. (C) 2016 AACR.
C1 [Quemener, Cathy; Baud, Jessica; Boye, Kevin; Dubrac, Alexandre; Billottet, Clotilde; Soulet, Fabienne; Darlot, Florence; Dumartin, Laurent; Sire, Marie; Grepin, Renaud; Daubon, Thomas; Pineau, Raphael; Lomri, Abderrahim; Khatib, Abdel-Majid; Hagedorn, Martin; Bikfalvi, Andreas] INSERM, U1029, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
   [Quemener, Cathy; Baud, Jessica; Boye, Kevin; Dubrac, Alexandre; Billottet, Clotilde; Soulet, Fabienne; Darlot, Florence; Dumartin, Laurent; Sire, Marie; Grepin, Renaud; Daubon, Thomas; Rayne, Fabienne; Wodrich, Harald; Pineau, Raphael; Lomri, Abderrahim; Khatib, Abdel-Majid; Hagedorn, Martin; Bikfalvi, Andreas] Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
   [Dubrac, Alexandre; Prats, Herve] INSERM, U1037, Toulouse, France.
   [Rayne, Fabienne; Wodrich, Harald] CNRS UMR 5234, Pessac, France.
   [Couvelard, Anne] Hop Bichat Claude Bernard, Dept Pathol, Paris, France.
   [Schilling, Martin] Univ Homburg Saar, Dept Visceral Surg, Homburg, Germany.
   [Castronovo, Vincent] Univ Liege, Dept Pathol, Liege, Belgium.
   [Sue, Shih-Che] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan.
   [Clarke, Kim] Univ Liverpool, Dept Integrat Biol, Liverpool, Merseyside, England.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS);
   CNRS - National Institute for Biology (INSB); Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Bichat-Claude Bernard - APHP; University of Liege; National Tsing Hua
   University; University of Liverpool
RP Bikfalvi, A (通讯作者)，INSERM, U1029, Allee Geoffroy St Hilaire, F-33615 Pessac, France.; Bikfalvi, A (通讯作者)，Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
EM andreas.bikfalvi@u-bordeaux.fr
RI Hagedorn, Martin/B-4272-2008; Prats, Hervé/M-4495-2014; Billottet,
   Clotilde/JLL-5864-2023; Dubrac, Alexandre/AAQ-9515-2021; KHATIB,
   Abdel-Majid/A-9948-2015; Wodrich, Harald/P-1777-2019
OI KHATIB, Abdel-Majid/0000-0001-6957-0384; Anne,
   Couvelard/0000-0002-6316-1210; Boye, Kevin/0000-0002-5749-959X;
   Fabienne, Rayne/0000-0003-0713-1137; Wodrich,
   Harald/0000-0002-4764-1708; Hagedorn, Martin/0000-0002-0960-5116;
   dubrac, alexandre/0000-0002-3829-2577; Lomri,
   Abderrahim/0000-0001-9847-026X; Prats, Herve/0000-0002-4861-2167
FU Agence Nationale de la Recherche; Association de la Recherche sur le
   Cancer; Ligue Nationale contre Cancer; Institut National du Cancer
   (INCA); ANR; INCA; Ministere de la Recherche and Fondation pour la
   Recherche Meedicale
FX This work was supported by grants from Agence Nationale de la Recherche,
   the Association de la Recherche sur le Cancer, the Ligue Nationale
   contre Cancer (A. Bikfalvi), Institut National du Cancer (INCA; to A.
   Bikfalvi and H. Prats), and ANR (M. Hagedorn). This work was also
   supported by a PhD fellowship from INCA (A. Dubrac) and the Ministere de
   la Recherche and Fondation pour la Recherche Meedicale (K. Boye and L.
   Dumartin).
CR Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Billottet C, 2013, BBA-REV CANCER, V1836, P287, DOI 10.1016/j.bbcan.2013.08.002
   Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804
   Clarke K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005325
   Cook N, 2008, METHOD ENZYMOL, V439, P73, DOI 10.1016/S0076-6879(07)00406-5
   Dubrac A, 2010, BLOOD, V116, P4703, DOI 10.1182/blood-2010-03-274852
   Dumartin L, 2010, GASTROENTEROLOGY, V138, P1595, DOI 10.1053/j.gastro.2009.12.061
   Furuya M, 2012, CANCER BIOL THER, V13, P671, DOI 10.4161/cbt.20084
   Giuliani N, 2006, HAEMATOLOGICA, V91, P1489
   Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012
   Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102
   Hashimoto K, 2009, ARTHRITIS RHEUM-US, V60, P3303, DOI 10.1002/art.24882
   Hedrich HJ, 2012, LABORATORY MOUSE, P1
   Hellebrekers DMEI, 2006, CANCER RES, V66, P10770, DOI 10.1158/0008-5472.CAN-06-1609
   Ishikawa M, 2005, CANCER SCI, V96, P387, DOI 10.1111/j.1349-7006.2005.00064.x
   Karin N, 2016, J LEUKOCYTE BIOL, V99, P857, DOI 10.1189/jlb.2MR0915-441R
   Kuo JH, 2013, J BIOL CHEM, V288, P13522, DOI 10.1074/jbc.M113.455329
   Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897
   Lasagni L, 2007, BLOOD, V109, P4127, DOI 10.1182/blood-2006-10-052035
   Liu ZQ, 2014, N AM J MED SCI, V6, P160, DOI 10.4103/1947-2714.128482
   Pakneshan P, 2005, CARCINOGENESIS, V26, P557, DOI 10.1093/carcin/bgi009
   Platonova N, 2013, BLOOD, V121, P1229, DOI 10.1182/blood-2012-08-450502
   Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813
   Seo J, 2009, BIOCHEM BIOPH RES CO, V382, P519, DOI 10.1016/j.bbrc.2009.03.049
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Struyf S, 2004, CIRC RES, V95, P855, DOI 10.1161/01.RES.0000146674.38319.07
   Struyf S, 2007, CANCER RES, V67, P5940, DOI 10.1158/0008-5472.CAN-06-4682
   Struyf S, 2011, BLOOD, V117, P480, DOI 10.1182/blood-2009-11-253591
   Van Raemdonck K, 2015, CYTOKINE GROWTH F R, V26, P311, DOI 10.1016/j.cytogfr.2014.11.009
   Van Raemdonck K, 2014, ONCOTARGET, V5, P10916
   Vandercappellen J, 2007, J LEUKOCYTE BIOL, V82, P1519, DOI 10.1189/jlb.0407206
   Vandercappellen J, 2010, MOL CANCER RES, V8, P322, DOI 10.1158/1541-7786.MCR-09-0176
   Verbeke H, 2010, HUM PATHOL, V41, P990, DOI 10.1016/j.humpath.2009.09.021
NR 36
TC 30
Z9 32
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2016
VL 76
IS 22
BP 6507
EP 6519
DI 10.1158/0008-5472.CAN-15-2864
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED3IF
UT WOS:000388742100010
PM 27634764
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Uehiro, N
   Sato, F
   Pu, F
   Tanaka, S
   Kawashima, M
   Kawaguchi, K
   Sugimoto, M
   Saji, S
   Toi, M
AF Uehiro, Natsue
   Sato, Fumiaki
   Pu, Fengling
   Tanaka, Sunao
   Kawashima, Masahiro
   Kawaguchi, Kosuke
   Sugimoto, Masahiro
   Saji, Shigehira
   Toi, Masakazu
TI Circulating cell-free DNA-based epigenetic assay can detect early breast
   cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Circulating DNA; Breast cancer; Epigenetics; DNA methylation; Early
   detection
ID FATE DETERMINATION FACTOR; TUMOR DNA; PLASMA DNA; PROMOTER
   HYPERMETHYLATION; SCREENING MAMMOGRAPHY; ABERRANT METHYLATION; FACTOR
   DACH1; GENE; SENSITIVITY; BIOMARKERS
AB Background: Circulating cell-free DNA (cfDNA) has recently been recognized as a resource for biomarkers of cancer progression, treatment response, and drug resistance. However, few have demonstrated the usefulness of cfDNA for early detection of cancer. Although aberrant DNA methylation in cfDNA has been reported for more than a decade, its diagnostic accuracy remains unsatisfactory for cancer screening. Thus, the aim of the present study was to develop a highly sensitive cfDNA-based system for detection of primary breast cancer (BC) using epigenetic biomarkers and digital PCR technology.
   Methods: Array-based genome-wide DNA methylation analysis was performed using 56 microdissected breast tissue specimens, 34 cell lines, and 29 blood samples from healthy volunteers (HVs). Epigenetic markers for BC detection were selected, and a droplet digital methylation-specific PCR (ddMSP) panel with the selected markers was established. The detection model was constructed by support vector machine and evaluated using cfDNA samples.
   Results: The methylation array analysis identified 12 novel epigenetic markers (JAK3, RASGRF1, CPXM1, SHF, DNM3, CAV2, HOXA10, B3GNT5, ST3GAL6, DACH1, P2RX3, and chr8: 23572595) for detecting BC. We also selected four internal control markers (CREM, GLYATL3, ELMOD3, and KLF9) that were identified as infrequently altered genes using a public database. A ddMSP panel using these 16 markers was developed and detection models were constructed with a training dataset containing cfDNA samples from 80 HVs and 87 cancer patients. The best detection model adopted four methylation markers (RASGRF1, CPXM1, HOXA10, and DACH1) and two parameters (cfDNA concentration and the mean of 12 methylation markers), and, and was validated in an independent dataset of 53 HVs and 58 BC patients. The area under the receiver operating characteristic curve for cancer-normal discrimination was 0.916 and 0.876 in the training and validation dataset, respectively. The sensitivity and the specificity of the model was 0.862 (stages 0-I 0.846, IIA 0.862, IIB-III 0.818, metastatic BC 0.935) and 0.827, respectively.
   Conclusion: Our epigenetic-marker-based system distinguished BC patients from HVs with high accuracy. As detection of early BC using this system was comparable with that of mammography screening, this system would be beneficial as an optional method of screening for BC.
C1 [Uehiro, Natsue; Sato, Fumiaki; Tanaka, Sunao; Kawashima, Masahiro; Kawaguchi, Kosuke; Toi, Masakazu] Kyoto Univ, Grad Sch Med, Dept Breast Surg, Kyoto, Japan.
   [Pu, Fengling; Saji, Shigehira] Kyoto Univ, Grad Sch Med, Dept Target Therapy Oncol, Kyoto, Japan.
   [Sugimoto, Masahiro] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
   [Saji, Shigehira] Fukushima Med Univ, Dept Med Oncol, Fukushima, Japan.
C3 Kyoto University; Kyoto University; Keio University; Fukushima Medical
   University
RP Sato, F (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Breast Surg, Kyoto, Japan.
EM fsatoh@kuhp.kyoto-u.ac.jp
RI Sugimoto, Masahiro/B-7391-2014; Kawaguchi, Kosuke/AAS-9011-2020
OI Kawaguchi, Kosuke/0000-0002-3161-7981; Sugimoto,
   Masahiro/0000-0003-3316-2543
FU Project for Development of Innovative Research on Cancer Therapeutics
   (P-DIRECT)/Ministry of Education, Culture, Sports, Science and
   Technology of Japan; Princess Takamatsu Cancer Research Fund;
   Grants-in-Aid for Scientific Research [16H05400] Funding Source: KAKEN
FX This research was funded by the Project for Development of Innovative
   Research on Cancer Therapeutics (P-DIRECT)/Ministry of Education,
   Culture, Sports, Science and Technology of Japan and was partly
   supported by the Princess Takamatsu Cancer Research Fund.
CR Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Calvo F, 2011, NAT CELL BIOL, V13, P819, DOI 10.1038/ncb2271
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang EJ, 2004, FEBS LETT, V564, P166, DOI 10.1016/S0014-5793(04)00338-2
   Chen K, 2013, ONCOTARGET, V4, P923, DOI 10.18632/oncotarget.1094
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   del Carmen MG, 2007, AM J ROENTGENOL, V188, P1147, DOI 10.2214/AJR.06.0619
   Duffy MJ, 2010, CLIN CHIM ACTA, V411, P1869, DOI 10.1016/j.cca.2010.08.039
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   Fu YJ, 2016, MED SCI MONITOR, V22, P3154, DOI 10.12659/MSM.896563
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Graham LJ, 2014, J CANCER, V5, P58, DOI 10.7150/jca.7047
   Hofvind S, 2012, BRIT J RADIOL, V85, pE1226, DOI 10.1259/bjr/15168178
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Jacobsen KK, 2015, INT J CANCER, V137, P2198, DOI 10.1002/ijc.29593
   Jahr S, 2001, CANCER RES, V61, P1659
   Kerlikowske K, 2013, JAMA INTERN MED, V173, P807, DOI 10.1001/jamainternmed.2013.307
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee K, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0351-1
   Martínez-Galán J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59
   Marttila S, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1381-z
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Ohuchi N, 2016, LANCET, V387, P341, DOI 10.1016/S0140-6736(15)00774-6
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054
   Perkins G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047020
   Popov VM, 2009, CANCER RES, V69, P5752, DOI 10.1158/0008-5472.CAN-08-3992
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Sharma G, 2012, TUMOR BIOL, V33, P1837, DOI 10.1007/s13277-012-0443-y
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 2002, CLIN CANCER RES, V8, P3761
   Suzuki A, 2008, CANCER SCI, V99, P2264, DOI 10.1111/j.1349-7006.2008.00926.x
   Takamaru H, 2012, CANCER PREV RES, V5, P1203, DOI 10.1158/1940-6207.CAPR-12-0056
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wessely Frank, 2012, Frontiers in Genetics, V3, P161, DOI 10.3389/fgene.2012.00161
   Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105
   Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06
   Wu KM, 2014, CANCER RES, V74, P829, DOI 10.1158/0008-5472.CAN-13-2466
   Wu KM, 2011, J BIOL CHEM, V286, P2132, DOI 10.1074/jbc.M110.148395
   Yan WJ, 2013, EPIGENETICS-US, V8, P1373, DOI 10.4161/epi.26781
   Zhao F, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.3
   Zhong Xiao Yan, 2007, Archives of Gynecology and Obstetrics, V276, P327, DOI 10.1007/s00404-007-0345-1
   Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587
NR 52
TC 83
Z9 98
U1 0
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD DEC 19
PY 2016
VL 18
AR 129
DI 10.1186/s13058-016-0788-z
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EH1DN
UT WOS:000391503900001
PM 27993161
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sticca, T
   Caberg, JH
   Wenric, S
   Poulet, C
   Herens, C
   Jamar, M
   Josse, C
   El Guendi, S
   Max, S
   Beguin, Y
   Gothot, A
   Caers, J
   Bours, V
AF Sticca, Tiberio
   Caberg, Jean-Hubert
   Wenric, Stephane
   Poulet, Christophe
   Herens, Christian
   Jamar, Mauricette
   Josse, Claire
   El Guendi, Sonia
   Max, Stephanie
   Beguin, Yves
   Gothot, Andre
   Caers, Jo
   Bours, Vincent
TI Genomic studies of multiple myeloma reveal an association between X
   chromosome alterations and genomic profile complexity
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID BREAST-CANCER; INSTABILITY; EXPRESSION; HETEROZYGOSITY
AB The genomic profile of multiple myeloma (MM) has prognostic value by dividing patients into a good prognosis hyperdiploid group and a bad prognosis nonhyperdiploid group with a higher incidence of IGH translocations. This classification, however, is inadequate and many other parameters like mutations, epigenetic modifications, and genomic heterogeneity may influence the prognosis. We performed a genomic study by array-based comparative genomic hybridization on a cohort of 162 patients to evaluate the frequency of genomic gains and losses. We identified a high frequency of X chromosome alterations leading to partial Xq duplication, often associated with inactive X (Xi) deletion in female patients. This partial X duplication could be a cytogenetic marker of aneuploidy as it is correlated with a high number of chromosomal breakages. Patient with high level of chromosomal breakage had reduced survival regardless the region implicated. A higher transcriptional level was shown for genes with potential implication in cancer and located in this altered region. Among these genes, IKBKG and IRAK1 are members of the NFKB pathway which plays an important role in MM and is a target for specific treatments. (c) 2016 Wiley Periodicals, Inc.
C1 [Sticca, Tiberio; Wenric, Stephane; Poulet, Christophe; Josse, Claire; El Guendi, Sonia; Bours, Vincent] Univ Liege, Lab Human Genet, GIGA Res, Liege, Belgium.
   [Caberg, Jean-Hubert; Herens, Christian; Jamar, Mauricette; Bours, Vincent] Univ Hosp CHU, Dept Human Genet, Liege, Belgium.
   [Max, Stephanie; Gothot, Andre] Univ Hosp CHU, Dept Hematol & Immuno Hematol, Liege, Belgium.
   [Beguin, Yves; Caers, Jo] Univ Liege, Hematol Lab, GIGA Res, Liege, Belgium.
   [Beguin, Yves; Caers, Jo] Univ Hosp CHU, Dept Clin Hematol, Liege, Belgium.
C3 University of Liege; University of Liege; University of Liege;
   University of Liege; University of Liege
RP Bours, V (通讯作者)，CHU Sart Tilman, Dept Human Genet, Univ Hosp CHU, Ave Hop 1, B-4000 Liege, Belgium.
EM vbours@ulg.ac.be
RI Josse, Claire/AAQ-9398-2020; Wenric, Stephane/AAA-9599-2019; Poulet,
   Christophe/L-5430-2013
OI Poulet, Christophe/0000-0003-4055-5441; Wenric,
   Stephane/0000-0001-5625-2133; Josse, Claire/0000-0003-0315-3718; Caers,
   Jo/0000-0002-3175-1195
FU National Fund for Scientific Research (PDR); National Fund for
   Scientific Research (Televie); National Fund for Scientific Research
   (FRIA); Centre-Anti-Cancereux (ULg, Liege); Fond d'Investissementa la
   recherche Scientifique (CHU, Liege); Region Wallonne; University of
   Liege (Fonds speciaux pour la recherche)
FX Supported by: National Fund for Scientific Research (PDR, Televie, and
   FRIA); Centre-Anti-Cancereux (ULg, Liege); Fond d'Investissementa la
   recherche Scientifique (CHU, Liege); Region Wallonne; and University of
   Liege (Fonds speciaux pour la recherche).
CR Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426
   Aigelsreiter A, 2012, HUM PATHOL, V43, P1012, DOI 10.1016/j.humpath.2011.08.009
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997
   Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032
   Cagnetta A, 2015, BIOMED RES INT, V2015, P1
   Chaligné R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Chung JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052461
   de Carvalho F, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/257695
   Gronseth CM, 2015, CANCER-AM CANCER SOC, V121, P2900, DOI 10.1002/cncr.29475
   Herrero AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121581
   Jäger N, 2013, CELL, V155, P567, DOI 10.1016/j.cell.2013.09.042
   Kang J, 2015, PLOS ONE, V10
   Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood-2012-01-405985
   Krem MM, 2015, BRIT J HAEMATOL, V171, P13, DOI 10.1111/bjh.13507
   Kumar S, 2012, BLOOD, V119, P2100, DOI 10.1182/blood-2011-11-390658
   Lose F, 2008, JNCI-J NATL CANCER I, V100, DOI 10.1093/jnci/djn345
   Munshi NC, 2011, CLIN CANCER RES, V17, P1234, DOI 10.1158/1078-0432.CCR-10-1843
   Przybytkowski E, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-579
   Rashid NU, 2014, BLOOD, V124, P3110, DOI 10.1182/blood-2014-04-569327
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Sankaranarayanan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121396
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Smadja NV, 2001, BLOOD, V98, P2229, DOI 10.1182/blood.V98.7.2229
   Sun ZF, 2015, EPIGENOMICS-UK, V7, P1099, DOI 10.2217/epi.15.43
   Vitre BD, 2012, CURR OPIN CELL BIOL, V24, P809, DOI 10.1016/j.ceb.2012.10.006
   Walker BA, 2006, CLIN LYMPHOMA MYELOM, V7, P186, DOI 10.3816/CLM.2006.n.057
   Wang HM, 2011, CELL BIOCHEM BIOPHYS, V61, P355, DOI 10.1007/s12013-011-9218-0
   Wee ZN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9746
   Zeng ZM, 2012, EXP CELL RES, V318, P1759, DOI 10.1016/j.yexcr.2012.04.021
NR 31
TC 2
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD JAN
PY 2017
VL 56
IS 1
BP 18
EP 27
DI 10.1002/gcc.22397
PG 10
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EC0FS
UT WOS:000387774400003
PM 27454822
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Zou, F
   Li, JZ
   Jie, XH
   Peng, X
   Fan, RQ
   Wang, MM
   Wang, JJ
   Liu, ZQ
   Li, H
   Deng, H
   Yang, XH
   Luo, DY
AF Zou, Fan
   Li, Jizhu
   Jie, Xiaohua
   Peng, Xiong
   Fan, Ruiqi
   Wang, Mengmeng
   Wang, Jiangjie
   Liu, Zhuoqi
   Li, Hua
   Deng, Huan
   Yang, Xiaohong
   Luo, Daya
TI Rs3842530 Polymorphism in MicroRNA-205 Host Gene in Lung and Breast
   Cancer Patients
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Breast Neoplasms; Male; Lung Neoplasms; MicroRNAs; Polymorphism; Single
   Nucleotide
ID DOWN-REGULATION; BLADDER-CANCER; EXPRESSION; MIR-205; RISK; CARCINOMA;
   GENOMICS; INVASION
AB Background: The expression of miR-205 is closely related to the occurrence, development, and prognosis of lung cancer and breast cancer. However, studies show that it plays opposite roles in different tumor types. Because the expression and regulation of miR-205 are primarily confined to epigenetic areas, whether genetic variation of miR-205 is related to the occurrence or to the development of tumors has not been reported. The aim of this study was to screen genetic variation of miR-205 gene and to investigate its association with the risk and development of lung and breast cancer.
   Material/Methods: Genomic DNA was extracted from cultured tumor cell lines and formalin-fixed and paraffin-embedded lung and breast tissue samples. Bisulfite Clone Sequencing (BCS) and qRT-PCR were employed to detect the DNA methylation status and gene expression of the miR-205 gene, respectively. Genetic variation of miR-205 and miR-205HG were genotyped with PCR-sequencing method. Immunohistochemical analysis for ER, PR, and HER2 was performed on breast tissue samples.
   Results: A polymorphism, rs3842530, located downstream of the miR-205 gene and in the fourth exon of the miR-205 host gene (miR-205HG), was screened. rs3842530 had no correlation with the risk of breast cancer, but was associated with the risk of lung cancer (P<0.05).
   Conclusions: These results indicate that the functional association of rs3842530 in miR-205HG and lung cancer might provide a possible explanation for the tissue-dependent function of miR-205 in different tumors.
C1 [Zou, Fan; Li, Jizhu; Jie, Xiaohua; Peng, Xiong] Nanchang Univ, Sch Med, Clin Med Coll 2, Nanchang, Jiangxi, Peoples R China.
   [Fan, Ruiqi; Wang, Jiangjie; Liu, Zhuoqi; Yang, Xiaohong; Luo, Daya] Nanchang Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Nanchang, Jiangxi, Peoples R China.
   [Wang, Mengmeng; Deng, Huan] Nanchang Univ, Affiliated Hosp 4, Dept Pathol, Nanchang, Jiangxi, Peoples R China.
   [Li, Hua] Nanchang Univ, Dept Biochem & Mol Biol, Med Expt Teaching Ctr, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Yang, XH; Luo, DY (通讯作者)，Nanchang Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Nanchang, Jiangxi, Peoples R China.
EM xiaohongyang2007@163.com; luodaya@ncu.edu.cn
FU National Natural Science Foundation of China [81160248, 81360313];
   Natural Science Foundation of Jiangxi Province [20142BAB215051];
   Scientific Research Foundation of Jiangxi Provincial Education
   Department [GJJ150216]; Nanchang University Training Programs for
   Innovation and Entrepreneurship [2015207]; Nanchang University
   Innovation Credits and Research Training Projects [20140584]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81160248 and 81360313), the Natural
   Science Foundation of Jiangxi Province (Grant No. 20142BAB215051), the
   Scientific Research Foundation of Jiangxi Provincial Education
   Department (Grant No. GJJ150216), the Nanchang University Training
   Programs for Innovation and Entrepreneurship (Grant No. 2015207), and
   the Nanchang University Innovation Credits and Research Training
   Projects (Grant No. 20140584)
CR Aguirre-Gamboa R, 2014, BIOINFORMATICS, V30, P1630, DOI 10.1093/bioinformatics/btu087
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Brunese L, 2013, MED SCI MONITOR, V19, P95, DOI 1
   Bulut G, 2016, ASIAN PAC J CANCER P, V16, P8203
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chacon-Cortes D, 2015, TUMOR BIOL, V36, P5369, DOI 10.1007/s13277-015-3200-1
   Fassina A, 2011, CHEST, V140, P1305, DOI 10.1378/chest.11-0708
   Flego Veljko, 2013, Med Sci Monit, V19, P846, DOI 10.12659/MSM.889554
   Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Goswami Chirayu Pankaj, 2012, J Clin Bioinforma, V2, P23, DOI 10.1186/2043-9113-2-23
   Guan HY, 2013, J CLIN ENDOCR METAB, V98, pE1334, DOI 10.1210/jc.2013-1053
   Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065
   Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091
   Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134
   Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   McAuley AK, 2015, DIABETES VASC DIS RE, V12, P133, DOI 10.1177/1479164114560160
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Qin AY, 2013, EUR J CELL BIOL, V92, P54, DOI 10.1016/j.ejcb.2012.11.002
   Sobin LH, 2011, TNM CLASSIFICATION M
   Sun X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.269
   Truscott M, 2011, GENE DEV, V25, P1820, DOI 10.1101/gad.16947411
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Wu HL, 2009, EXPERT OPIN THER TAR, V13, P1439, DOI 10.1517/14728220903338777
   Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
   Xie H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046990
   Xu T, 2008, CARCINOGENESIS, V29, P2126, DOI 10.1093/carcin/bgn195
   Yang HS, 2008, CANCER RES, V68, P2530, DOI 10.1158/0008-5472.CAN-07-5991
   Ye YQ, 2008, CANCER PREV RES, V1, P460, DOI 10.1158/1940-6207.CAPR-08-0135
NR 30
TC 7
Z9 8
U1 0
U2 5
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD NOV 25
PY 2016
VL 22
BP 4555
EP 4564
AR 901042
DI 10.12659/MSM.901042
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ED0BG
UT WOS:000388507400001
PM 27885248
OA Green Published
DA 2025-01-12
ER

PT J
AU Bernhart, SH
   Kretzmer, H
   Holdt, LM
   Jühling, F
   Ammerpohl, O
   Bergmann, AK
   Northoff, BH
   Doose, G
   Siebert, R
   Stadler, PF
   Hoffmann, S
AF Bernhart, Stephan H.
   Kretzmer, Helene
   Holdt, Lesca M.
   Juehling, Frank
   Ammerpohl, Ole
   Bergmann, Anke K.
   Northoff, Bernd H.
   Doose, Gero
   Siebert, Reiner
   Stadler, Peter F.
   Hoffmann, Steve
TI Changes of bivalent chromatin coincide with increased expression of
   developmental genes in cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RNA-POLYMERASE-II; GENOME-WIDE; DNA HYPERMETHYLATION; METHYLOME
   ANALYSIS; CELL SIGNATURE; BREAST-CANCER; METHYLATION; BIOMARKERS;
   HOXB13; MARKS
AB Bivalent (poised or paused) chromatin comprises activating and repressing histone modifications at the same location. This combination of epigenetic marks at promoter or enhancer regions keeps genes expressed at low levels but poised for rapid activation. Typically, DNA at bivalent promoters is only lowly methylated in normal cells, but frequently shows elevated methylation levels in cancer samples. Here, we developed a universal classifier built from chromatin data that can identify cancer samples solely from hypermethylation of bivalent chromatin. Tested on over 7,000 DNA methylation data sets from several cancer types, it reaches an AUC of 0.92. Although higher levels of DNA methylation are often associated with transcriptional silencing, counter-intuitive positive statistical dependencies between DNA methylation and expression levels have been recently reported for two cancer types. Here, we re-analyze combined expression and DNA methylation data sets, comprising over 5,000 samples, and demonstrate that the conjunction of hypermethylation of bivalent chromatin and up-regulation of the corresponding genes is a general phenomenon in cancer. This up-regulation affects many developmental genes and transcription factors, including dozens of homeobox genes and other genes implicated in cancer. Thus, we reason that the disturbance of bivalent chromatin may be intimately linked to tumorigenesis.
C1 [Bernhart, Stephan H.; Kretzmer, Helene; Juehling, Frank; Doose, Gero; Stadler, Peter F.; Hoffmann, Steve] Univ Leipzig, Chair Bioinformat, D-04107 Leipzig, Germany.
   [Bernhart, Stephan H.; Kretzmer, Helene; Juehling, Frank; Doose, Gero; Stadler, Peter F.; Hoffmann, Steve] Univ Leipzig, Interdisciplinary Ctr Bioinformat, Transcriptome Bioinformat Grp, D-04107 Leipzig, Germany.
   [Holdt, Lesca M.; Northoff, Bernd H.] Ludwig Maximilians Univ Munchen, Inst Lab Med, D-81377 Munich, Germany.
   [Juehling, Frank] INSERM, Inst Rech Malad Virales & Hepat U1110, F-67000 Strasbourg, France.
   [Juehling, Frank] Univ Strasbourg, F-67000 Strasbourg, France.
   [Ammerpohl, Ole; Bergmann, Anke K.; Siebert, Reiner] Univ Kiel, D-24105 Kiel, Germany.
   [Ammerpohl, Ole; Bergmann, Anke K.; Siebert, Reiner] Univ Hosp Schleswig Holstein, Inst Human Genet, Campus Kiel, D-24105 Kiel, Germany.
   [Bergmann, Anke K.] Christian Albrechts Univ Kiel, Kiel, Germany.
   [Bergmann, Anke K.] Univ Hosp Schleswig Holstein, Dept Pediat, Campus Kiel, Kiel, Germany.
   [Siebert, Reiner] Univ Ulm, Ulm, Germany.
   [Siebert, Reiner] Univ Ulm, Inst Human Genet, Med Ctr, D-89081 Ulm, Germany.
   [Stadler, Peter F.; Hoffmann, Steve] Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04107 Leipzig, Germany.
   [Stadler, Peter F.] Univ Vienna, Dept Theoret Chem, A-1090 Vienna, Austria.
   [Stadler, Peter F.] Max Planck Inst Math Sci, D-04103 Leipzig, Germany.
   [Stadler, Peter F.] Santa Fe Inst, Santa Fe, NM 87501 USA.
C3 Leipzig University; Leipzig University; University of Munich;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universites de Strasbourg Etablissements Associes; Universite
   de Strasbourg; University of Kiel; University of Kiel; Schleswig
   Holstein University Hospital; University of Kiel; University of Kiel;
   Schleswig Holstein University Hospital; Ulm University; Ulm University;
   Leipzig University; University of Vienna; Max Planck Society; The Santa
   Fe Institute
RP Hoffmann, S (通讯作者)，Univ Leipzig, Chair Bioinformat, D-04107 Leipzig, Germany.; Hoffmann, S (通讯作者)，Univ Leipzig, Interdisciplinary Ctr Bioinformat, Transcriptome Bioinformat Grp, D-04107 Leipzig, Germany.; Hoffmann, S (通讯作者)，Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04107 Leipzig, Germany.
EM steve@bioinf.uni-leipzig.de
RI Bergmann, Anke/AAT-2509-2020; Siebert, Reiner/A-8049-2010; Kretzmer,
   Helene/GSJ-2664-2022; Hoffmann, Steve/E-1438-2013; Ammerpohl,
   Ole/G-2691-2010; Stadler, Peter F./L-7857-2015
OI Northoff, Bernd/0000-0002-7333-3231; Bergmann, Anke
   Katharina/0000-0002-1367-2725; , Stephan/0000-0002-5928-9449; Stadler,
   Peter F./0000-0002-5016-5191; Kretzmer, Helene/0000-0002-0723-4980
FU HTCR; German BMBF [031 6065A, 01KU1002A-J, 01KU1505-C G]; European Union
   [HEALTH-F5-2011-282510]; LIFE (Leipzig Research Center for Civilization
   Diseases), Leipzig University; European Union; European Regional
   Development Fund (ERDF); European Social Fund (ESF); Free State of
   Saxony; French National Research Agency [LABEX ANR-10-LAB-28_HepSYS];
   German Research Foundation (DFG); Universitat Leipzig
FX We thank Bernhard Radlwimmer for helpful discussion, Wolfgang Wilfert
   for technical assistance and the ICGC MMML-Seq and BLUEPRINT consortia.
   We acknowledge the support of the non profit foundation HTCR, which
   holds human tissue on trust, making it broadly available for research on
   an ethical and legal basis. This research was supported by the German
   BMBF (PTJ grant HNPCCSys 031 6065A, ICGC MMML-Seq 01KU1002A-J, and
   ICGC-Data Mining 01KU1505-C & G) the European Union in the framework of
   the BLUEPRINT Project (HEALTH-F5-2011-282510) and LIFE (Leipzig Research
   Center for Civilization Diseases), Leipzig University. LIFE is funded by
   the European Union, by the European Regional Development Fund (ERDF),
   the European Social Fund (ESF) and by the Free State of Saxony within
   the excellence initiative. This work has been published under the
   framework of the LABEX ANR-10-LAB-28_HepSYS and benefits from a funding
   from the state managed by the French National Research Agency as part of
   the Investments for the future program. We acknowledge support from the
   German Research Foundation (DFG) and Universitat Leipzig within the
   program of Open Access Publishing.
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Adams D, 2012, NAT BIOTECHNOL, V30, P224, DOI 10.1038/nbt.2153
   [Anonymous], NUCLEIC ACIDS RES
   [Anonymous], THE NEW ENGLAND JOUR
   Ballings M., 2013, AUC THRESHOLD INDEPE
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bartlett TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068285
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Charlton J, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0136-4
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Das C, 2012, BBA-GENE REGUL MECH, V1819, P332, DOI 10.1016/j.bbagrm.2011.08.001
   Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Gaertner B, 2012, CELL REP, V2, P1670, DOI 10.1016/j.celrep.2012.11.024
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gottschling S, 2012, LUNG CANCER, V75, P45, DOI 10.1016/j.lungcan.2011.05.020
   Hahn MA, 2014, CANCER RES, V74, P3617, DOI 10.1158/0008-5472.CAN-13-3147
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Holdt LM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003588
   Hon G, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000201
   Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987
   Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986
   Jerevall PL, 2008, BREAST CANCER RES TR, V107, P225, DOI 10.1007/s10549-007-9541-8
   Jin BL, 2012, CELL REP, V2, P1411, DOI 10.1016/j.celrep.2012.10.017
   Kent WJ, 2010, BIOINFORMATICS, V26, P2204, DOI 10.1093/bioinformatics/btq351
   Klapper W, 2008, BLOOD, V112, P1374, DOI 10.1182/blood-2008-01-136465
   Klapper W, 2012, BLOOD, V119, P1882, DOI 10.1182/blood-2011-10-388470
   Kretzmer H, 2015, NAT GENET, V47, P1316, DOI 10.1038/ng.3413
   Kron K, 2012, CLIN CANCER RES, V18, P2896, DOI 10.1158/1078-0432.CCR-11-2901
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Lee ST, 2015, NUCLEIC ACIDS RES, V43, P2590, DOI 10.1093/nar/gkv103
   Lesch BJ, 2013, P NATL ACAD SCI USA, V110, P16061, DOI 10.1073/pnas.1315204110
   Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008
   Margaritis T, 2008, CELL, V133, P581, DOI 10.1016/j.cell.2008.04.027
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Muratani M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5361
   Nejman D, 2014, CANCER RES, V74, P1475, DOI 10.1158/0008-5472.CAN-13-3042
   Nevedomskaya E, 2014, GENOM DATA, V2, P195, DOI 10.1016/j.gdata.2014.06.023
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   Rosolowski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076287
   Scaffidi P, 2010, COLD SH Q B, V75, P251, DOI 10.1101/sqb.2010.75.007
   Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Song IS, 2009, CANCER RES, V69, P3131, DOI 10.1158/0008-5472.CAN-08-2240
   Suvà ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008
   Teschendorff AE, 2015, JAMA ONCOL, V1, P476, DOI 10.1001/jamaoncol.2015.1053
   Thasler Wolfgang E., 2003, Cell and Tissue Banking, V4, P49, DOI 10.1023/A:1026392429112
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Voigt P, 2012, CELL, V151, P181, DOI 10.1016/j.cell.2012.09.002
   Wang Z, 2007, CLIN CANCER RES, V13, P6327, DOI 10.1158/1078-0432.CCR-07-0310
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yu K, 2014, BIOCHEM BIOPH RES CO, V444, P1, DOI 10.1016/j.bbrc.2013.12.125
   Zerbino DR, 2014, BIOINFORMATICS, V30, P1008, DOI 10.1093/bioinformatics/btt737
   Zhang NQ, 2015, BIOINFORMATICS, V31, P3401, DOI 10.1093/bioinformatics/btv370
NR 71
TC 76
Z9 89
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 23
PY 2016
VL 6
AR 37393
DI 10.1038/srep37393
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EC7UD
UT WOS:000388344900001
PM 27876760
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sahni, JM
   Gayle, SS
   Bonk, KLW
   Vite, LC
   Yori, JL
   Webb, B
   Ramos, EK
   Seachrist, DD
   Landis, MD
   Chang, JC
   Bradner, JE
   Keri, RA
AF Sahni, Jennifer M.
   Gayle, Sylvia S.
   Bonk, Kristen L. Weber
   Vite, Leslie Cuellar
   Yori, Jennifer L.
   Webb, Bryan
   Ramos, Erika K.
   Seachrist, Darcie D.
   Landis, Melissa D.
   Chang, Jenny C.
   Bradner, James E.
   Keri, Ruth A.
TI Bromodomain and Extraterminal Protein Inhibition Blocks Growth of
   Triple-negative Breast Cancers through the Suppression of Aurora Kinases
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE anticancer drug; apoptosis; breast cancer; bromodomain-containing
   protein 4 (BRD4); cellular senescence; inhibition mechanism; Aurora
   kinase
ID SELECTIVE-INHIBITION; GENE-EXPRESSION; CELLS; SUBTYPES; PROGRESSION;
   RESISTANCE; TUMORS; MODELS; BRD4; OVEREXPRESSION
AB Bromodomain and extraterminal (BET) proteins are epigenetic readers that recognize acetylated histones and mark areas of the genome for transcription. BRD4, a BET family member protein, has been implicated in a number of types of cancer, and BET protein inhibitors (BETi) are efficacious in many preclinical cancer models. However, the drivers of response to BETi vary depending on tumor type, and little is known regarding the target genes conveying BETi activity in triple-negative breast cancer (TNBC). Here, we show that BETi repress growth of multiple in vitro and in vivo models of TNBC by inducing two terminal responses: apoptosis and senescence. Unlike in other cancers, response to BETi in TNBC is not dependent upon suppression of MYC. Instead, both end points are preceded by the appearance of polyploid cells caused by the suppression of Aurora kinases A and B (AURKA/B), which are critical mediators of mitosis. In addition, AURKA/B inhibitors phenocopy the effects of BETi. These results indicate that Aurora kinases play an important role in the growth suppressive activity of BETi in TNBC. Elucidating the mechanism of response to BETi in TNBC should 1) facilitate the prediction of how distinct TNBC tumors will respond to BETi and 2) inform the rational design of drug combination therapies.
C1 [Sahni, Jennifer M.; Gayle, Sylvia S.; Bonk, Kristen L. Weber; Vite, Leslie Cuellar; Yori, Jennifer L.; Webb, Bryan; Ramos, Erika K.; Seachrist, Darcie D.; Keri, Ruth A.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Keri, Ruth A.] Case Western Reserve Univ, Dept Genet & Genome Sci & Gen Med Sci Oncol, Cleveland, OH 44106 USA.
   [Landis, Melissa D.; Chang, Jenny C.] Houston Methodist Hosp, Methodist Canc Ctr, Houston, TX 77030 USA.
   [Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Bradner, James E.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; Houston Methodist;
   Harvard University; Dana-Farber Cancer Institute; Novartis; Novartis USA
RP Keri, RA (通讯作者)，Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.; Keri, RA (通讯作者)，Case Western Reserve Univ, Dept Genet & Genome Sci & Gen Med Sci Oncol, Cleveland, OH 44106 USA.
EM keri@case.edu
RI Keri, Ruth/ABF-2209-2021
OI Keri, Ruth/0000-0002-1640-3088; Cuellar-Vite,
   Leslie/0000-0002-9906-1334; Sahni, Jennifer/0000-0002-2735-1789
FU National Institutes of Health [P30043703, T32CA059366, R25GM075207,
   T32GM008056, RO1CA154384, RO1CA206505]
FX This work was supported by National Institutes of Health Grants
   P30043703 (to the Core Facilities of the Case Comprehensive Cancer
   Center), T32CA059366 (to J.M.S. and S. S. G.), R25GM075207 (to L. C. V.
   and E. K. R.), T32GM008056 (to L. C. V.), RO1CA154384 (to R. A. K.), and
   RO1CA206505 (to R. A. K.). The authors declare that they have no
   conflicts of interest with the contents of this article. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299
   Bolanos-Garcia VM, 2005, INT J BIOCHEM CELL B, V37, P1572, DOI 10.1016/j.biocel.2005.02.021
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091
   Dreier MR, 2009, EXP CELL RES, V315, P1085, DOI 10.1016/j.yexcr.2009.02.008
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353
   Görgün G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106
   Kimura M, 2004, BIOCHEM BIOPH RES CO, V316, P930, DOI 10.1016/j.bbrc.2004.01.178
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062
   Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483
   Montañez-Wiscovich ME, 2009, ONCOGENE, V28, P3608, DOI 10.1038/onc.2009.221
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Sadaie M, 2015, MOL BIOL CELL, V26, P2971, DOI 10.1091/mbc.E15-01-0003
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Tatsuka M, 1998, CANCER RES, V58, P4811
   Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242
   Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111
   Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005
   Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979
   Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200
   Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546
   You JX, 2009, MOL CELL BIOL, V29, P5094, DOI 10.1128/MCB.00299-09
   Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081
NR 44
TC 45
Z9 56
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 4
PY 2016
VL 291
IS 45
BP 23756
EP 23768
DI 10.1074/jbc.M116.738666
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EC1RH
UT WOS:000387884400035
PM 27650498
OA Green Published
DA 2025-01-12
ER

PT J
AU Levine, AJ
   Puzio-Kuter, AM
   Chan, CS
   Hainaut, P
AF Levine, Arnold J.
   Puzio-Kuter, Anna M.
   Chan, Chang S.
   Hainaut, Pierre
TI The Role of the p53 Protein in Stem-Cell Biology and Epigenetic
   Regulation
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID IN-VITRO EXPANSION; BREAST-CANCER; PROSPECTIVE IDENTIFICATION;
   PROGENITOR CELLS; DNA METHYLATION; SELF-RENEWAL; EVOLUTION; APOPTOSIS;
   P63; PLURIPOTENCY
AB The p53 protein plays a passive and an active role in stem cells. The transcriptional activities of p53 for cell-cycle arrest and DNA repair are largely turned off in stem cells, but there is some indication that long-term stem-cell viability may require other p53-regulated functions. When p53 is activated in stem cells, it stops cell division and promotes the commitment to a differentiation pathway and the formation of progenitor cells. In the absence of any p53 activity, stem-cell replication continues and mistakes in the normal epigenetic pathway occur at a higher probability. In the presence of a functionally active p53 protein, epigenetic stability is enforced and stem-cell replication is regulated by commitment to differentiation. Over a lifetime of an organism, stem-cell clones compete in a tissue niche for Darwinian replicative advantages and in doing so accumulate mutations that permit stem-cell replication. Mutations in the p53 gene give stem cells this advantage, increase the clonal stem-cell population, and lower the age at which cancers can occur. Li-Fraumeni patients that inherit p53 mutations develop tumors in a tissue-type-specific fashion at younger ages. Throughout the life of a Li-Fraumeni patient, the tumor types that arise occur in tissues where stem cells are active and cell division is most rapid. Thus, p53 mutations that are inherited or occur during developmental life act in stem cells of the mesenchymal and epithelial lineages, whereas p53 mutations that occur in progenitor or differentiated (somatic) cells later in life function in tissues of endodermal origins, indicating that p53 may function differently in different developmental lineages.
C1 [Levine, Arnold J.; Puzio-Kuter, Anna M.; Chan, Chang S.] Inst Adv Study, Princeton, NJ 08340 USA.
   [Levine, Arnold J.; Puzio-Kuter, Anna M.; Chan, Chang S.] Rutgers Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   [Hainaut, Pierre] Grenoble Inst Res Canc, Grenoble, France.
C3 Institute for Advanced Study - USA; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey
RP Levine, AJ (通讯作者)，Inst Adv Study, Princeton, NJ 08340 USA.; Levine, AJ (通讯作者)，Rutgers Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
EM alevine@ias.edu
RI Hainaut, Pierre/B-6018-2012
OI Hainaut, Pierre/0000-0002-1303-1610
FU NCI NIH HHS [P01 CA087497] Funding Source: Medline
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ariffin H, 2014, P NATL ACAD SCI USA, V111, P15497, DOI 10.1073/pnas.1417322111
   ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7
   Bao XC, 2015, CELL RES, V25, P80, DOI 10.1038/cr.2014.165
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816
   Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Bondar T, 2010, CELL STEM CELL, V6, P309, DOI 10.1016/j.stem.2010.03.002
   Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4
   Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114
   Dumay A, 2013, INT J CANCER, V132, P1227, DOI 10.1002/ijc.27767
   Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016
   Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004
   Gregorieff Alex, 2015, Curr Protoc Stem Cell Biol, V34, DOI 10.1002/9780470151808.sc02f01s34
   GURDON JB, 1973, BRIT MED BULL, V29, P259, DOI 10.1093/oxfordjournals.bmb.a071017
   Haoudi A, 2004, J BIOMED BIOTECHNOL, P185, DOI 10.1155/S1110724304403131
   Harris Chris R, 2010, Genes Cancer, V1, P115, DOI 10.1177/1947601909360812
   HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375
   Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050
   Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204
   Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826
   Itzkovitz S, 2012, NAT CELL BIOL, V14, P106, DOI 10.1038/ncb2384
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531
   Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017
   Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036
   KLEINSMITH LJ, 1964, CANCER RES, V24, P1544
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020
   Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290
   LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026
   LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235
   Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804
   Marión RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   Markert EK, 2011, P NATL ACAD SCI USA, V108, P21276, DOI 10.1073/pnas.1117029108
   Marusyk A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000324
   Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108
   Muller AJ, 2000, P NATL ACAD SCI USA, V97, P8421, DOI 10.1073/pnas.140208197
   Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175
   Noutsopoulos D, 2010, CELL RES, V20, P553, DOI 10.1038/cr.2010.48
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004
   Pankow S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000782
   Pearson BJ, 2010, DEVELOPMENT, V137, P213, DOI 10.1242/dev.044297
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Puzio-Kuter AM, 2009, NAT BIOTECHNOL, V27, P914, DOI 10.1038/nbt1009-914
   Raj N, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026047
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Schuijers J, 2012, EMBO J, V31, P2685, DOI 10.1038/emboj.2012.149
   Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539
   Smeenk L, 2008, NUCLEIC ACIDS RES, V36, P3639, DOI 10.1093/nar/gkn232
   STEVENS LC, 1974, DEV BIOL, V37, P369, DOI 10.1016/0012-1606(74)90155-9
   Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301
   Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337
   Sun W, 1999, CANCER RES, V59, P6118
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tinat J, 2009, J CLIN ONCOL, V27, pE108, DOI 10.1200/JCO.2009.22.7967
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Tozluoglu M, 2008, NUCLEIC ACIDS RES, V36, P5033, DOI 10.1093/nar/gkn481
   Trkova M, 2002, J HUM GENET, V47, P381, DOI 10.1007/s100380200055
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Turner N, 2013, CANCER TREAT REV, V39, P541, DOI 10.1016/j.ctrv.2012.12.001
   Ungewitter E, 2010, GENE DEV, V24, P2408, DOI 10.1101/gad.1987810
   Vigano MA, 2006, EMBO J, V25, P5105, DOI 10.1038/sj.emboj.7601375
   Watkins-Chow DE, 2008, GENOME RES, V18, P60, DOI 10.1101/gr.6927808
   Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023
   Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968
   Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108
   Yi L, 2014, ONCOTARGET, V5, P8924, DOI 10.18632/oncotarget.2441
   Yi L, 2012, CANCER RES, V72, P5635, DOI 10.1158/0008-5472.CAN-12-1451
   Yun MH, 2013, P NATL ACAD SCI USA, V110, P17392, DOI 10.1073/pnas.1310519110
NR 92
TC 32
Z9 36
U1 0
U2 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD SEP
PY 2016
VL 6
IS 9
AR a026153
DI 10.1101/cshperspect.a026153
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EC7KQ
UT WOS:000388317500005
PM 27352800
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Han, YJ
   Zhang, J
   Zheng, YL
   Huo, DZ
   Olopade, OI
AF Han, Yoo-Jeong
   Zhang, Jing
   Zheng, Yonglan
   Huo, Dezheng
   Olopade, Olufunmilayo I.
TI Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; AFRICAN ANCESTRY; RISK;
   WOMEN; METHYLATION; VARIANTS
AB Genome wide association studies (GWAS) have identified low penetrance and high frequency single nucleotide polymorphisms (SNPs) that contribute to genetic susceptibility of breast cancer. The SNPs at 16q12, close to the TOX3 and CASC16 genes, represent one of the susceptibility loci identified by GWAS, showing strong evidence for breast cancer association across various populations. To examine molecular mechanisms of TOX3 regulation in breast cancer, we investigated both genetic and epigenetic factors using cell lines and datasets derived from primary breast tumors available through The Cancer Genome Atlas (TCGA). TOX3 expression is highly up-regulated in luminal subtype tumors compared to normal breast tissues or basal-like tumors. Expression quantitative trait loci (eQTL) analyses revealed significant associations of rs3803662 and rs4784227 genotypes with TOX3 expression in breast tumors. Bisulfite sequencing of four CpG islands in the TOX3 promoter showed a clear difference between luminal and basal-like cancer cell lines. 5-Aza-2'-deoxy-cytidine treatment of a basal-like cancer cell line increased expression of TOX3. TCGA dataset verified significantly lower levels of methylation of the promoter in luminal breast tumors with an inverse correlation between methylation and expression of TOX3. Methylation QTL (mQTL) analyses showed a weak or no correlation of rs3803662 or rs4784227 with TOX3 promoter methylation in breast tumors, indicating an independent relationship between the genetic and epigenetic events. These data suggest a complex system of TOX3 regulation in breast tumors, driven by germline variants and somatic epigenetic modifications in a subtype specific manner.
C1 [Han, Yoo-Jeong; Zhang, Jing; Zheng, Yonglan; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, Ctr Clin Canc Genet & Global Hlth, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Han, Yoo-Jeong; Zhang, Jing; Zheng, Yonglan; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, Sect Hematol & Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Huo, Dezheng] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago
RP Han, YJ; Olopade, OI (通讯作者)，Univ Chicago, Dept Med, Ctr Clin Canc Genet & Global Hlth, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Han, YJ; Olopade, OI (通讯作者)，Univ Chicago, Dept Med, Sect Hematol & Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM yjhan@medicine.bsd.uchicago.edu; folopade@medicine.bsd.uchicago.edu
RI Zheng, Yonglan/O-4112-2019
OI Zheng, Yonglan/0000-0001-6597-7072
FU NIH [R01 CM 42996-01]; NIH Specialized Program of Research Excellence in
   Breast Cancer [P50 CA125183]; Breast Cancer Research Foundation; Ralph
   and Marion Falk Medical Research Trust
FX This work was supported by NIH R01 CM 42996-01 (OIO), NIH Specialized
   Program of Research Excellence in Breast Cancer P50 CA125183 (OIO),
   Breast Cancer Research Foundation (YH and OIO), and the Ralph and Marion
   Falk Medical Research Trust (OIO). OIO is American Cancer Society
   Clinical Research Professor.The authors thank Dr. Charles M. Perou
   (University of North Carolina, Chapel Hill, NC) for generously providing
   the University of North Carolina dataset and Dr. Albert C. Yeh
   (University of Chicago) for critically reviewing the manuscript. We also
   thank Dr. Tatyana Grushko and Ms. Maria Gomez for assistance with FISH
   experiments and data interpretation, and Ms. Mariann Coyle for
   assistance with the cell culturing. This work was supported by NIH R01
   CA142996-01 (OIO), NIH Specialized Program of Research Excellence in
   Breast Cancer P50 CA125183 (OIO), Breast Cancer Research Foundation (YH
   and OIO), and the Ralph and Marion Falk Medical Research Trust (OIO).
   OK) is American Cancer Society Clinical Research Professor.
CR Baumgartner A, 2006, J HISTOCHEM CYTOCHEM, V54, P1363, DOI 10.1369/jhc.6A6974.2006
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Chen F, 2011, HUM MOL GENET, V20, P4491, DOI 10.1093/hmg/ddr367
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Dittmer S, 2011, J CELL SCI, V124, P252, DOI 10.1242/jcs.068759
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Gudmundsdottir ET, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-621
   Han W, 2011, CANCER EPIDEM BIOMAR, V20, P793, DOI 10.1158/1055-9965.EPI-10-1282
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Huo DZ, 2012, CARCINOGENESIS, V33, P835, DOI 10.1093/carcin/bgs093
   Jones JO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074102
   Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034
   Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054
   Long JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001002
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Millis RM, 2011, CURR HYPERTENS REP, V13, P21, DOI 10.1007/s11906-010-0173-8
   O'Flaherty E, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-13
   Riaz M, 2012, BREAST CANCER RES TR, V133, P843, DOI 10.1007/s10549-011-1663-3
   Ruiz-Narváez EA, 2010, CANCER EPIDEM BIOMAR, V19, P1320, DOI 10.1158/1055-9965.EPI-09-1250
   Shan JX, 2013, CANCER RES, V73, P2840, DOI 10.1158/0008-5472.CAN-12-4313
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339
   Vo AT, 2012, OBSTET GYNECOL INT, V2012, DOI [10.1156/2012/6022720, DOI 10.1156/2012/6022720]
   Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Zheng YL, 2013, CARCINOGENESIS, V34, P1520, DOI 10.1093/carcin/bgt090
NR 28
TC 21
Z9 24
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 2
PY 2016
VL 11
IS 11
AR e0165559
DI 10.1371/journal.pone.0165559
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EA6DJ
UT WOS:000386715500037
PM 27806084
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Su, CH
   Lin, IH
   Tzeng, TY
   Hsieh, WT
   Hsu, MT
AF Su, Chia-Hsin
   Lin, I-Hsuan
   Tzeng, Tsai-Yu
   Hsieh, Wen-Ting
   Hsu, Ming-Ta
TI Regulation of <i>IL</i>-<i>20</i> Expression by Estradiol through
   KMT2B-Mediated Epigenetic Modification
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; BREAST-CANCER; ESTROGEN-RECEPTOR; TGF-BETA; T-CELLS; ALPHA;
   GENE; MLL; ACTIVATION; CYTOKINES
AB Cytokines are low molecular weight regulatory proteins, or glycoproteins, with both tumorpromoting and inhibitory effects on breast cancer growth. Different cytokines play important roles in breast cancer initiation and progression. Here, we show that of the 39 interleukin (IL) genes, IL-20 is the only gene over-expressed in MCF-7 cells treated with estradiol (E2) and that induction of IL-20 expression by estrogen was epigenetically regulated. Methylation of histone H3K4 in the IL-20 promoter was shown to occur via the specific recruitment of KMT2B by estrogen receptor alpha (ER alpha), but not by other members of the mixed-lineage leukemia (MLL) family of histone methyltransferases. Depletion of KMT2B, or IL-20, disrupts estrogen signaling, attenuates cell proliferation, reduces colony formation, and results in cell cycle arrest. Furthermore, we demonstrated that KMT2B-mediated epigenetic modification also affected the expression of several ER alpha target genes. IL-20 and KMT2B expression were also associated with ER alpha-positive breast cancer tissues. We have revealed an important role for KMT2B in the epigenetic transcriptional regulation of cytokine IL-20, and other ER alpha-responsive genes, in breast cancer cells. Inhibition of IL-20 and KMT2B may have therapeutic benefits in ER alpha-positive breast cancer.
C1 [Su, Chia-Hsin; Hsieh, Wen-Ting; Hsu, Ming-Ta] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Sch Life Sci, Taipei 11221, Taiwan.
   [Lin, I-Hsuan] Taipei Med Univ, Ctr Translat Med, Taipei, Taiwan.
   [Tzeng, Tsai-Yu] Natl Yang Ming Univ, Univ Syst Taiwan, VYM Genome Res Ctr, Taipei 11221, Taiwan.
   [Hsu, Ming-Ta] Chien Tien Hsu Canc Res Fdn, Taipei 11221, Taiwan.
C3 National Yang Ming Chiao Tung University; Taipei Medical University;
   National Yang Ming Chiao Tung University
RP Hsu, MT (通讯作者)，Natl Yang Ming Univ, Inst Biochem & Mol Biol, Sch Life Sci, Taipei 11221, Taiwan.; Hsu, MT (通讯作者)，Chien Tien Hsu Canc Res Fdn, Taipei 11221, Taiwan.
EM mth@ym.edu.tw
RI Lin, I-Hsuan/N-6501-2013
OI Lin, I-Hsuan/0000-0002-6207-1299; Tzeng, Tsai-Yu/0000-0001-7334-6270;
   Hsieh, Wen-Ting/0000-0003-3201-7547
FU Ministry of Education, Aim for the Top University Plan
FX This work was supported by a grant from the Ministry of Education, Aim
   for the Top University Plan. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Blot E, 2003, BRIT J CANCER, V88, P1207, DOI 10.1038/sj.bjc.6600872
   Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648
   Chen YY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/294320
   Cho YA, 2013, CANCER RES TREAT, V45, P210, DOI 10.4143/crt.2013.45.3.210
   Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282
   Esquivel-Velázquez M, 2015, J INTERF CYTOK RES, V35, P1, DOI 10.1089/jir.2014.0026
   Ferrari F, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-446
   Gaughan L, 2013, NUCLEIC ACIDS RES, V41, P6892, DOI 10.1093/nar/gkt469
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Hsu YH, 2012, J IMMUNOL, V188, P1981, DOI 10.4049/jimmunol.1102843
   Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735
   KOBAYASHI Y, 1993, BLOOD, V82, P3220
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4
   Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002
   Nicolini A, 2006, BIOMED PHARMACOTHER, V60, P548, DOI 10.1016/j.biopha.2006.07.086
   PRIGOGINA EL, 1986, HUM GENET, V73, P137, DOI 10.1007/BF00291604
   Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783
   Reed JR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2246
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rivas MA, 2008, EXP CELL RES, V314, P509, DOI 10.1016/j.yexcr.2007.10.005
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Schraets D, 2003, ONCOGENE, V22, P3655, DOI 10.1038/sj.onc.1206438
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438
   Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042
   Su CH, 2014, NUCLEIC ACIDS RES, V42, P3073, DOI 10.1093/nar/gkt1341
   Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284
   Tan G, 2016, BIOINFORMATICS, V32, P1555, DOI 10.1093/bioinformatics/btw024
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Vega VB, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r82
   Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298
   Wang PF, 2009, MOL CELL BIOL, V29, P6074, DOI 10.1128/MCB.00924-09
   Yang J, 2014, HISTOCHEM CELL BIOL, V142, P401, DOI 10.1007/s00418-014-1222-1
   Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459
NR 47
TC 17
Z9 19
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 2
PY 2016
VL 11
IS 11
AR e0166090
DI 10.1371/journal.pone.0166090
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EA6DJ
UT WOS:000386715500082
PM 27806114
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Faghihloo, E
   Araei, Y
   Mohammadi, M
   Mirzaei, H
   Mohammadi, HR
   Mokhtari-Azad, T
AF Faghihloo, E.
   Araei, Y.
   Mohammadi, M.
   Mirzaei, H.
   Mohammadi, H. R.
   Mokhtari-Azad, T.
TI The effect of oxamflatin on the E-cadherin expression in gastric cancer
   cell line
SO CANCER GENE THERAPY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; HDAC INHIBITOR; OVARIAN-CANCER; VALPROIC
   ACID; BREAST-CANCER; MECHANISMS; APOPTOSIS; MIGRATION; COMPOUND
AB Gastric cancer is among the leading causes of cancer-related death, and the symptoms are commonly characterized in advanced stages. Histone acetylation is among the most important epigenetic alterations occurring during cancer development. In addition, reduced E-cadherin, expression is a major contributor in the process of tumor cell invasion and metastasis. Oxamflatin is a histone deacetylase inhibitor that has been suggested as a promising anti-tumor agent;, yet its effect on the viability and invasion of gastric tumor cells is unclear. We aimed to assess the impact of oxamflatin on the viability of gastric tumor cells and expression of E-cadherin :as a marker of tumor invasion Susceptibility. In this study; MKN-45 cells were treated with 1, 2.5 and 5 mM oxamflatin and followed by MTT assay after 24-48 h of incubation. To determine E-cadherin expression in treated cells, total RNA was extracted and reverse transcribed to complementary DNA, followed by quantitative real-time PCR. MTT results showed that the viability of MKN-45 cells declines with increasing concentrations of oxamflatin. The results of quantitative real-time PCR showed increased expression of E-cadherin following treatment with oxamflatin at the concentration of 2.5 mM compared with 1 mM. The present results showed that Oxamflatin can induce E-cadherin expression and also reduce cell viability in the MKN-45 cell line. On the basis of these findings, oxamflatin can be further considered for the prevention of tumor metastasis.
C1 [Faghihloo, E.] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran.
   [Araei, Y.] Islamic Azad Univ, Pharmaceut Sci Branch, Tehran, Iran.
   [Mohammadi, M.] Lorestan Univ Med Sci, Hepatitis Res Ctr, Khorramabad, Iran.
   [Mohammadi, M.] Lorestan Univ Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Khorramabad, Iran.
   [Mirzaei, H.] Mashhad Univ Med Sci, Fac Med, Dept Med Biotechnol, Mashhad, Iran.
   [Mohammadi, H. R.] Shiraz Univ Med Sci, Sch Pharm, Dept Toxicol & Pharmacol, Shiraz, Iran.
   [Mokhtari-Azad, T.] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Islamic Azad University;
   Lorestan University of Medical Sciences; Lorestan University of Medical
   Sciences; Mashhad University of Medical Sciences; Shiraz University of
   Medical Science; Tehran University of Medical Sciences
RP Mokhtari-Azad, T (通讯作者)，Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran.
EM mokhtari@sina.tums.ac.ir
RI faghihloo, Ebrahim/AAW-9102-2021; mirzaei, hamed/X-2374-2018; Mohammadi,
   Mohsen/M-2468-2017
OI mirzaei, hamed/0000-0002-9399-8281; Mohammadi,
   Hamidreza/0000-0002-6467-523X; Mohammadi, Mohsen/0000-0002-1580-6539
CR Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Feng S, 2016, CANCER, V6, P7
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187
   Kaufmann M, 2003, J CLIN ONCOL, V21, P2600, DOI 10.1200/JCO.2003.01.136
   Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564
   Komatsu N, 2006, ONCOL REP, V15, P187
   Mirzaei H, 2016, J CANCER RES THER, V12, P498, DOI 10.4103/0973-1482.153661
   Moghimi-Dehkordi B, 2008, ASIAN PAC J CANCER P, V9, P317
   Moody TW, 2010, LUNG CANCER, V68, P154, DOI 10.1016/j.lungcan.2009.06.012
   Peart MJ, 2003, CANCER RES, V63, P4460
   RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0
   Salarini R, 2015, CURR CANC DRUG TARGE
   Sonoda H, 1996, ONCOGENE, V13, P143
   Takai N, 2005, ONCOL REP, V14, P1287
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97
   Wang YL, 2016, CURR MOL MED, V16, P232, DOI 10.2174/1566524016666160225151408
   Yazdizadeh Bahareh, 2005, Asian Pac J Cancer Prev, V6, P130
   Zhang L, 2011, PHARMAZIE, V66, P614, DOI 10.1691/ph.2011.1506
   Zhu JS, 2005, WORLD J GASTROENTERO, V11, P7536, DOI 10.3748/wjg.v11.i47.7536
NR 21
TC 23
Z9 25
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD NOV
PY 2016
VL 23
IS 11
BP 396
EP 399
DI 10.1038/cgt.2016.52
PG 4
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA EC3YT
UT WOS:000388063700005
PM 27767089
OA Bronze
DA 2025-01-12
ER

PT J
AU Bulus, AD
   Asci, A
   Erkekoglu, P
   Balci, A
   Andiran, N
   Koçer-Gümüsel, B
AF Bulus, Ayse Derya
   Asci, Ali
   Erkekoglu, Pinar
   Balci, Aylin
   Andiran, Nesibe
   Kocer-Gumusel, Belma
TI The evaluation of possible role of endocrine disruptors in central and
   peripheral precocious puberty
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article
DE Bisphenol A; central precocios puberty; endocrine disrupting chemical;
   peripheral precocious puberty; phthalate
ID NUTRITION EXAMINATION SURVEY; BREAST-CANCER CELLS; BISPHENOL-A; URINARY
   LEVELS; PHTHALATE METABOLITES; NATIONAL-HEALTH; HUMAN EXPOSURE; HUMAN
   PLASMA; ASSOCIATION; POPULATION
AB Exposure to environmental chemicals can affect genetic and epigenetic molecular pathways and may cause altered growth and development. Among those exposures, endocrine-disrupting chemicals (EDCs) are of particular concern as humans are abundantly exposed to these chemicals by various means in every period of life. Several well-known environmental chemicals, including phthalates and bisphenol A (BPA), are classified as EDCs. These EDCs are suggested to play roles in early onset of puberty in girls. The aim of this study is to determine plasma phthalate (di(2-ethylhexyl) phthalate [ DEHP] and its main metabolite mono(2-ethylhexyl) phthalate [ MEHP]) and urinary BPA levels in girls with idiopathic central precocious puberty (CPP) and peripheral precocious puberty (PPP). This study was performed on newly diagnosed idiopathic central precocious puberty (CPP) patients (n = 42) and peripheral precocious puberty (PPP) (n = 42) patients, who were admitted to Kecioren, Training and Research Hospital, Clinic of Pediatric Endocrinology between August 2012 and -July 2013. Nonobese healthy girls (n = 50) were used as the control group. Urinary BPA levels were not statistically different in control, PPP and CPP groups (medians 10.91, 10.63 and 10.15 mu g/g creatinine, respectively; p > 0.05). Plasma DEHP levels were significantly higher in PPP group when compared to control. Plasma MEHP levels were not significantly different in control and PPP groups (p > 0.05). However, in CPP group, both plasma DEHP and MEHP levels were significantly higher than control and PPP groups. This study showed that phthalates might play a role in the occurence of CPP in girls.
C1 [Bulus, Ayse Derya; Andiran, Nesibe] Kecioren Training & Res Hosp, Pediat Endocrinol Clin, Minist Hlth, Ankara, Turkey.
   [Asci, Ali; Erkekoglu, Pinar; Balci, Aylin; Kocer-Gumusel, Belma] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Toxicol, Ankara, Turkey.
   [Andiran, Nesibe] Yildirim Beyazit Univ, Div Endocrinol, Dept Pediat, Ankara, Turkey.
C3 Ankara Kecioren Training & Research Hospital; Ministry of Health -
   Turkey; Hacettepe University; Ankara Yildirim Beyazit University
RP Koçer-Gümüsel, B (通讯作者)，Hacettepe Univ, Fac Pharm, Dept Pharmaceut Toxicol, Ankara, Turkey.
EM belmagumusel@yahoo.com
RI balci ozyurt, aylin/HKE-3259-2023; Gumusel, Belma/AAH-1102-2021; Aşcı,
   Ali/CAH-0242-2022
OI Balci Ozyurt, Aylin/0000-0002-0060-271X; Kocer Gumusel,
   Belma/0000-0003-4311-2291; Asci, Ali/0000-0003-2866-0935
CR Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491
   Atta I, 2015, JCPSP-J COLL PHYSICI, V25, P124, DOI 02.2015/JCPSP.124128
   Braun JM, 2011, CURR OPIN PEDIATR, V23, P233, DOI 10.1097/MOP.0b013e3283445675
   Braun JM, 2013, CURR OPIN PEDIATR, V25, P247, DOI 10.1097/MOP.0b013e32835e1eb6
   BRIDGES NA, 1994, ARCH DIS CHILD, V70, P116, DOI 10.1136/adc.70.2.116
   Calafat AM, 2011, ENVIRON HEALTH PERSP, V119, P50, DOI 10.1289/ehp.1002316
   Caserta D, 2008, HUM REPROD UPDATE, V14, P59, DOI 10.1093/humupd/dmm025
   Clark K, 2003, HDB ENV CHEM, P22
   Colón I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999
   Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002
   Dickerson SM, 2012, CONTEMP ENDOCRINOL S, P49, DOI 10.1007/978-1-60761-561-3_3
   Durmaz E, 2014, J CLIN RES PEDIATR E, V6, P16, DOI 10.4274/Jcrpe.1220
   Erkekoglu P, 2014, ENVIRON TOXICOL, V29, P98, DOI 10.1002/tox.20776
   Erkekoglu P, 2011, DRUG CHEM TOXICOL, V34, P379, DOI 10.3109/01480545.2010.547499
   Erkekoglu P, 2010, TOXICOL APPL PHARM, V248, P52, DOI 10.1016/j.taap.2010.07.016
   Erkekoglu P, 2010, FREE RADICAL BIO MED, V49, P559, DOI 10.1016/j.freeradbiomed.2010.04.038
   Hauser R, 2005, OCCUP ENVIRON MED, V62, DOI 10.1136/oem.2004.017590
   Johnson GE, 2008, MUTAT RES-GEN TOX EN, V651, P56, DOI 10.1016/j.mrgentox.2007.10.019
   Katchy A, 2014, TOXICOL SCI, V138, P21, DOI 10.1093/toxsci/kft271
   Kato K, 2004, ENVIRON HEALTH PERSP, V112, P327, DOI 10.1289/ehp.6663
   Keizer-Schrama SMPFD, 2001, HUM REPROD UPDATE, V7, P287
   Kim EJ, 2014, SCI TOTAL ENVIRON, V470, P1401, DOI 10.1016/j.scitotenv.2013.07.040
   Lebrethon MC, 2000, CURR OPIN PEDIATR, V12, P394, DOI 10.1097/00008480-200008000-00020
   Lee SH, 2014, REPROD TOXICOL, V44, P1, DOI 10.1016/j.reprotox.2013.03.008
   Lomenick JP, 2010, J PEDIATR-US, V156, P221, DOI 10.1016/j.jpeds.2009.09.047
   Massart F, 2006, Minerva Pediatr, V58, P247
   Mouritsen A, 2010, INT J ANDROL, V33, P346, DOI 10.1111/j.1365-2605.2010.01051.x
   OGATA M, 1988, INT ARCH OCC ENV HEA, V61, P131, DOI 10.1007/BF00381617
   Paris I, 2003, ANAL LETT, V36, P2649, DOI 10.1081/AL-120024639
   Park MJ, 2006, KOR J PEDIAT, V46, P610
   Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526
   Qiao L, 2010, WEI SHENG YAN JIU, V39, P208
   Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI 10.4161/cbt.18942
   Saravanabhavan G, 2013, INT J HYG ENVIR HEAL, V216, P652, DOI 10.1016/j.ijheh.2012.12.009
   Sathyanarayana S, 2008, PEDIATRICS, V121, pE260, DOI 10.1542/peds.2006-3766
   Sengupta S, 2013, BRIT J PHARMACOL, V169, P167, DOI 10.1111/bph.12122
   Shelby MD, 2006, NTP CERHR MON, V18, pvii
   Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723
   Teilmann G, 2005, PEDIATRICS, V116, P1323, DOI 10.1542/peds.2005-0012
   Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   Vandenberg Laura N., 2013, Reviews on Environmental Health, V28, P37, DOI 10.1515/reveh-2012-0034
   Wilkinson CF, 1999, REGUL TOXICOL PHARM, V30, P140, DOI 10.1006/rtph.1999.1338
   Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690
   Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0
   Yum T, 2013, J ENVIRON SCI HEAL A, V48, P912, DOI 10.1080/10934529.2013.762734
NR 46
TC 40
Z9 47
U1 0
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1537-6516
EI 1537-6524
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD SEP
PY 2016
VL 26
IS 7
BP 493
EP 500
DI 10.3109/15376516.2016.1158894
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA EC2CU
UT WOS:000387918000001
PM 27451808
DA 2025-01-12
ER

PT J
AU Liu, YH
   Wilson, D
   Leach, RJ
   Chen, YD
AF Liu, Yuanhang
   Wilson, Desiree
   Leach, Robin J.
   Chen, Yidong
TI MBDDiff: an R package designed specifically for processing MBDcap-seq
   datasets
SO BMC GENOMICS
LA English
DT Article
DE MBDCap-seq; DNA methylation; Differentially methylation; Differential
   methylated regions; MBDDiff; XBSeq
ID DIFFERENTIAL EXPRESSION ANALYSIS; PROSTATE-CANCER; SEQUENCING DATA;
   BASIC CONCEPTS; DNA; EPIGENETICS
AB Background: Since its initial discovery in 1975, DNA methylation has been intensively studied and shown to be involved in various biological processes, such as development, aging and tumor progression. Many experimental techniques have been developed to measure the level of DNA methylation. Methyl-CpG binding domain-based capture followed by high-throughput sequencing (MBDCap-seq) is a widely used method for characterizing DNA methylation patterns in a genome-wide manner. However, current methods for processing MBDCap-seq datasets does not take into account of the region-specific genomic characteristics that might have an impact on the measurements of the amount of methylated DNA (signal) and background fluctuation (noise). Thus, specific software needs to be developed for MBDCap-seq experiments.
   Results: A new differential methylation quantification algorithm for MBDCap-seq, MBDDiff, was implemented. To evaluate the performance of the MBDDiff algorithm, a set of simulated signal based on negative binomial and Poisson distribution with parameters estimated from real MBDCap-seq datasets accompanied with different background noises were generated, and then performed against a set of commonly used algorithms for MBDCap-seq data analysis in terms of area under the ROC curve (AUC), number of false discoveries and statistical power. In addition, we also demonstrated the effective of MBDDiff algorithm to a set of in-house prostate cancer samples, endometrial cancer samples published earlier, and a set of public-domain triple negative breast cancer samples to identify potential factors that contribute to cancer development and recurrence.
   Conclusions: In this paper we developed an algorithm, MBDDiff, designed specifically for datasets derived from MBDCap-seq. MBDDiff contains three modules: quality assessment of datasets and quantification of DNA methylation; determination of differential methylation of promoter regions; and visualization functionalities. Simulation results suggest that MBDDiff performs better compared to MEDIPS and DESeq in terms of AUC and the number of false discoveries at different levels of background noise. MBDDiff outperforms MEDIPS with increased backgrounds noise, but comparable performance when noise level is lower. By applying MBDDiff to several MBDCap-seq datasets, we were able to identify potential targets that contribute to the corresponding biological processes. Taken together, MBDDiff provides user an accurate differential methylation analysis for data generated by MBDCap-seq, especially under noisy conditions.
C1 [Liu, Yuanhang; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Liu, Yuanhang; Wilson, Desiree; Leach, Robin J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Leach, Robin J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
   [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; University of Texas System;
   University of Texas Health Science Center at San Antonio
RP Chen, YD (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.; Chen, YD (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
EM Cheny8@uthscsa.edu
OI Liu, Yuanhang/0000-0002-0147-8394; Leach, Robin/0000-0002-3201-5579
FU Genome Sequencing Facility of the Greehey Children's Cancer Research
   Institute, UTHSCSA; National Institutes of Health Cancer Center Shared
   Resources [NIH-NCI P30CA54174]; NIGMS [R01GM113245]
FX This research was supported in part by the Genome Sequencing Facility of
   the Greehey Children's Cancer Research Institute, UTHSCSA, which
   provided MBDCap-seq service. Fundings for this research were provided
   partially by the National Institutes of Health Cancer Center Shared
   Resources (NIH-NCI P30CA54174) to YC and NIGMS (R01GM113245) to YC and
   YL.
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   [Anonymous], BMC BIOINFORMATI S12
   Baccarelli A, 2010, CIRC-CARDIOVASC GENE, V3, P567, DOI 10.1161/CIRCGENETICS.110.958744
   Bera TK, 2004, P NATL ACAD SCI USA, V101, P3059, DOI 10.1073/pnas.0308746101
   Chen HIH, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S7-S14
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Gentilini D, 2013, AGE, V35, P1961, DOI 10.1007/s11357-012-9463-1
   Gu F, 2013, PLOS ONE, V8
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inbar-Feigenberg M, 2013, FERTIL STERIL, V99, P607, DOI 10.1016/j.fertnstert.2013.01.117
   Johnson NL, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471715816
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]
   Li N, 2010, METHODS, V52, P203, DOI 10.1016/j.ymeth.2010.04.009
   Lienhard M, 2014, BIOINFORMATICS, V30, P284, DOI 10.1093/bioinformatics/btt650
   Morrissey C, 2008, CLIN EXP METASTAS, V25, P377, DOI 10.1007/s10585-007-9116-4
   Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Taiwo O, 2012, NAT PROTOC, V7, P617, DOI 10.1038/nprot.2012.012
NR 23
TC 3
Z9 3
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 18
PY 2016
VL 17
SU 4
AR 432
DI 10.1186/s12864-016-2794-z
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DW4OX
UT WOS:000383623900003
PM 27556923
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ozbayer, C
   Degirmenci, I
   Ustuner, D
   Ak, G
   Saydam, F
   Colak, E
   Gunes, HV
   Metintas, M
AF Ozbayer, Cansu
   Degirmenci, Irfan
   Ustuner, Derya
   Ak, Guntulu
   Saydam, Faruk
   Colak, Ertugrul
   Gunes, Hasan Veysi
   Metintas, Muzaffer
TI miRSNPs of miR1274 and miR3202 Genes that Target MeCP2 and DNMT3b Are
   Associated with Lung Cancer Risk: A Study Conducted on MassARRAY
   Genotyping
SO JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY
LA English
DT Article
DE lung cancer; DNA methylation; DNA methyltransferases; MassARRAY;
   methyl-binding proteins; miRSNP
ID SQUAMOUS-CELL CARCINOMA; CPG-BINDING-PROTEINS; DNA METHYLATION;
   TUMOR-SUPPRESSOR; BREAST-CANCER; MICRORNA EXPRESSION; EPIGENETIC
   INACTIVATION; COLORECTAL-CANCER; SATELLITE REGIONS; PROSTATE-CANCER
AB Genetic variants of miRNAs that target DNMTs and MBDs involved in DNA methylation were scanned with current databases, and 35 miRSNPs in 22 miRNA genes were identified. The aim of the study was to determine the association between these variants of miRNA genes and lung cancer (LC). DNA samples were isolated from blood samples and genotyped using a Sequenom MassARRAY System. An association between the rs188912830 gene variant of miR3202 that targets the MeCP2 protein and LC was indicated in both subtypes. The presence of the C-allele in patients with LC and its subtypes was significantly lower, and the absence of the C-allele was determined to increase the risk of LC by 7,429-times compared to the presence (p=0,010). The rs318039 gene variant of miR1274 that targets DNMT3b was found to be associated with LC subtypes. When allele distributions were compared, the numbers of individuals with the C-allele were significantly lower in the NSCLC and SCLC groups. No significant associations were found for the rs72563729 variant of the miR200b gene that targets DNMT3a or for the rs145416750 variant of the miR513c gene that targets TRDMT1. The other 33 variants were found to be ancestral genotypes. Consequently, rs188912830 and rs318039 variations were associated with LC subtypes. Importantly, this study is the first to indicate the functional characterisation of miRSNPs of genes that target DNA methylation.
C1 [Ozbayer, Cansu] Dumlupinar Univ, Sch Hlth Sci, TR-43000 Kutahya, Turkey.
   [Degirmenci, Irfan; Gunes, Hasan Veysi] Eskisehir Osmangazi Univ, Dept Med Biol, Eskisehir, Turkey.
   [Ustuner, Derya] Eskisehir Osmangazi Univ, Vocat Sch Hlth Serv, Eskisehir, Turkey.
   [Ak, Guntulu; Metintas, Muzaffer] Eskisehir Osmangazi Univ, Dept Pulm Dis, Eskisehir, Turkey.
   [Saydam, Faruk] Recep Tayyip Erdogan Univ, Fac Med, Dept Med Biol & Genet, Rize, Turkey.
   [Colak, Ertugrul] Eskisehir Osmangazi Univ, Fac Med, Dept Biostat, Eskisehir, Turkey.
C3 Dumlupinar University; Eskisehir Osmangazi University; Eskisehir
   Osmangazi University; Eskisehir Osmangazi University; Recep Tayyip
   Erdogan University; Eskisehir Osmangazi University
RP Ozbayer, C (通讯作者)，Dumlupinar Univ, Sch Hlth Sci, TR-43000 Kutahya, Turkey.
EM c.ozbayer@gmail.com
RI Degirmenci, Irfan/AAG-6619-2020; Metintas, Muzaffer/JWA-4269-2024;
   Çolak, Ertuğrul/AAG-2140-2020; Ak, Guntulu/AFP-3587-2022; Ozbayer,
   Cansu/F-6442-2015
OI Ozbayer, Cansu/0000-0002-1120-1874
FU Research Foundation of Eskisehir Osmangazi University, Turkey
   [201241020]
FX This study was supported by grant 201241020 from the Research Foundation
   of Eskisehir Osmangazi University, Turkey.
CR Bader S, 2003, ONCOGENE, V22, P3506, DOI 10.1038/sj.onc.1206574
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Buechner J, 2011, BRIT J CANCER, V105, P296, DOI 10.1038/bjc.2011.220
   Campayo M, 2013, EUR RESPIR J, V41, P1172, DOI 10.1183/09031936.00048712
   Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339
   Chen MF, 2012, CANCER-AM CANCER SOC, V118, P4074, DOI 10.1002/cncr.26736
   Chung GE, 2010, ONCOL REP, V23, P113, DOI 10.3892/or_00000612
   Cui FM, 2013, J TOXICOL ENV HEAL A, V76, P107, DOI 10.1080/15287394.2013.738176
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Janssen EAM, 2010, MODERN PATHOL, V23, P1567, DOI 10.1038/modpathol.2010.177
   Jiang LL, 2013, CANCER INVEST, V31, P538, DOI 10.3109/07357907.2013.820314
   Jiang LL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-318
   Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2
   Khan AP, 2010, MOL CELL PROTEOMICS, V9, P298, DOI 10.1074/mcp.M900159-MCP200
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lehmann TP, 2013, ONCOL LETT, V5, P569, DOI 10.3892/ol.2012.1040
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Leng S, 2011, INT J MOL EPIDEMIOL, V2, P145
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Li J, 2013, CANCER LETT, V329, P84, DOI 10.1016/j.canlet.2012.10.019
   Li LG, 2014, MATH PROBL ENG, V2014, DOI 10.1155/2014/181050
   Li Y, 2013, BIOCHEM BIOPH RES CO, V440, P604, DOI 10.1016/j.bbrc.2013.09.111
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Lin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069230
   Liu CX, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-661
   Liu ZS, 2008, CANCER LETT, V268, P158, DOI 10.1016/j.canlet.2008.03.034
   Luleyap UH, 2008, MOLEKULER GENETIGIN, P438
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   Metintas S, 2012, INT J ENVIRON HEAL R, V22, P468, DOI 10.1080/09603123.2011.654330
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Mishra PJ, 2008, CELL CYCLE, V7, P853, DOI 10.4161/cc.7.7.5666
   Novik K. L., 2002, Current Issues in Molecular Biology, V4, P111
   Parry Lee, 2011, Genes Cancer, V2, P618, DOI 10.1177/1947601911418499
   Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5
   Peterlongo P, 2011, J MED GENET, V48, P703, DOI 10.1136/jmedgenet-2011-100103
   Ronchetti D, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-37
   Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Shen HB, 2002, CANCER RES, V62, P4992
   Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tang MQ, 2009, CURR GENOMICS, V10, P336, DOI 10.2174/138920209788920994
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Wu N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016264
   Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542
   Xia HP, 2009, BIOCHEM BIOPH RES CO, V380, P205, DOI 10.1016/j.bbrc.2008.12.169
   Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048
   Yu XF, 2011, WORLD J GASTROENTERO, V17, P4711, DOI 10.3748/wjg.v17.i42.4711
   Zhang JG, 2011, J THORAC ONCOL, V6, P671, DOI 10.1097/JTO.0b013e318208eb35
   Zhao GL, 2013, SCI WORLD J, DOI 10.1155/2013/726963
   Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x
   Zhou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063142
NR 62
TC 0
Z9 0
U1 1
U2 15
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0731-8898
EI 2162-6537
J9 J ENVIRON PATHOL TOX
JI J. Environ. Pathol. Toxicol. Oncol.
PY 2016
VL 35
IS 3
BP 222
EP 235
DI 10.1615/JEnvironPatholToxicolOncol.2016016320
PG 14
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA EC0MA
UT WOS:000387794000003
DA 2025-01-12
ER

PT J
AU Si, XX
   Zang, RC
   Zhang, EB
   Liu, Y
   Shi, X
   Zhang, ES
   Shao, LP
   Li, AD
   Yang, N
   Han, X
   Pan, BJ
   Zhang, ZH
   Sun, L
   Sun, YJ
AF Si, Xinxin
   Zang, Ruochen
   Zhang, Erbao
   Liu, Yue
   Shi, Xiao
   Zhang, Ershao
   Shao, Lipei
   Li, Andi
   Yang, Nan
   Han, Xiao
   Pan, Beijing
   Zhang, Zhihong
   Sun, Luan
   Sun, Yujie
TI LncRNA H19 confers chemoresistance in ERα-positive breast cancer through
   epigenetic silencing of the pro-apoptotic gene BIK
SO ONCOTARGET
LA English
DT Article
DE breast cancer; chemoresistance; lncRNA H19; apoptosis; estrogen receptor
ID LONG NONCODING RNAS; GASTRIC-CANCER; MESENCHYMAL TRANSITION;
   CELL-PROLIFERATION; BH3-ONLY PROTEIN; POOR-PROGNOSIS; RESISTANCE;
   EXPRESSION; ESTROGEN; PACLITAXEL
AB Breast cancer is a common malignancy in women. Acquisition of drug resistance is one of the main obstacles encountered in breast cancer therapy. Long non-coding RNA (lncRNA) has been demonstrated to play vital roles in both development and tumorigenesis. However, the relationship between lncRNAs and the development of chemoresistance is not well established. In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ER alpha-positive breast cancer cells, but not in ER alpha-negative breast cancer cells. LncRNA H19 attenuated cell apoptosis in response to PTX treatment by inhibiting transcription of pro-apoptotic genes BIK and NOXA. H19 was further confirmed to suppress the promoter activity of BIK by recruiting EZH2 and by trimethylating the histone H3 at lysine 27. Interestingly, our data showed that lncRNA H19 was one of the downstream target molecules of ER alpha. Altered ERa expression may therefore change H19 levels to modulate the apoptosis response to chemotherapy in breast cancer cells. Our data suggest that the ER alpha-H19-BIK signaling axis plays an important role in promoting chemoresistance.
C1 [Si, Xinxin; Zang, Ruochen; Liu, Yue; Shi, Xiao; Zhang, Ershao; Shao, Lipei; Li, Andi; Yang, Nan; Han, Xiao; Sun, Luan; Sun, Yujie] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Collaborat Innovat Ctr Canc Med, Nanjing, Jiangsu, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Si, Xinxin; Zang, Ruochen; Liu, Yue; Shi, Xiao; Zhang, Ershao; Shao, Lipei; Li, Andi; Sun, Luan; Sun, Yujie] Nanjing Med Univ, Dept Cell Biol, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Erbao; Yang, Nan; Han, Xiao] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China.
   [Pan, Beijing; Zhang, Zhihong] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University; Nanjing Medical University;
   Nanjing Medical University
RP Sun, L; Sun, YJ (通讯作者)，Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.; Sun, YJ (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Collaborat Innovat Ctr Canc Med, Nanjing, Jiangsu, Peoples R China.; Sun, YJ (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.; Sun, L; Sun, YJ (通讯作者)，Nanjing Med Univ, Dept Cell Biol, Nanjing, Jiangsu, Peoples R China.
EM carolsun133@hotmail.com; yujiesun@njmu.edu.cn
RI 韩, 晓/GXV-2361-2022; Yang, Nan/KVY-0759-2024; Sun, Yujie/HHZ-7619-2022;
   SHAO, LIPEI/IYJ-5311-2023; li, andi/GQH-7343-2022; Zang,
   Ruochen/GWQ-6991-2022
OI Si, Xinxin/0000-0003-0393-4223; Shao, Lipei/0000-0003-3009-7096; Zang,
   Ruochen/0000-0002-8496-7862
FU National Natural Science Foundation of China [81172091, 81301897]; Open
   Foundation of State Key Laboratory of Pharmaceutical Biotechnology of
   Nanjing University; College Postgraduates Innovative Research Plan of
   Jiangsu Province [CXZZ13_0561]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No.81172091), National Natural Science
   Foundation of China (Grant No.81301897), the Open Foundation of State
   Key Laboratory of Pharmaceutical Biotechnology of Nanjing University,
   and the College Postgraduates Innovative Research Plan of Jiangsu
   Province (Grant No.CXZZ13_0561).
CR [Anonymous], ONCOTARGET, DOI 10.18632/oncotarget.8063
   [Anonymous], ONCOTARGET
   [Anonymous], ONCOGENE
   Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031
   Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037
   Chen JS, 2016, NEOPLASMA, V63, P223, DOI 10.4149/207_150821N454
   Davidovich C, 2015, RNA, V21, P2007, DOI 10.1261/rna.053918.115
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170
   Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592
   Giovarelli M, 2014, P NATL ACAD SCI USA, V111, pE5023, DOI 10.1073/pnas.1415098111
   Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701
   Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101
   Keniry A, 2012, NAT CELL BIOL, V14, P659, DOI 10.1038/ncb2521
   Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460
   Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229
   Li WB, 2015, DRUG METAB REV, V47, P191, DOI 10.3109/03602532.2015.1007012
   Liang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20121
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575
   Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150
   Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885
   Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   Plaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209
   Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864
   Shi JF, 2014, INT J BIOCHEM CELL B, V53, P35, DOI 10.1016/j.biocel.2014.04.016
   Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782
   Sui M, 2011, CURR MED CHEM, V18, P4674, DOI 10.2174/092986711797379348
   Sui M, 2007, CANCER RES, V67, P5337, DOI 10.1158/0008-5472.CAN-06-4582
   Sun H, 2015, ONCOL REP, V33, P3045, DOI 10.3892/or.2015.3899
   Tabuchi Y, 2009, INT J ONCOL, V34, P313, DOI 10.3892/ijo_00000153
   Tsang WP, 2007, ONCOGENE, V26, P4877, DOI 10.1038/sj.onc.1210266
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang LJ, 2015, CELL RES, V25, P335, DOI 10.1038/cr.2015.21
   Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001
   Wongtrakoongate P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005615
   Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x
   Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002
   Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266
   Zhang EB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0914-7
   Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221
NR 44
TC 127
Z9 135
U1 0
U2 24
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 6
PY 2016
VL 7
IS 49
BP 81452
EP 81462
DI 10.18632/oncotarget.13263
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE8LO
UT WOS:000389877500108
PM 27845892
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Yang, W
   Bang, H
   Jang, K
   Kyung, M
   Choi, JK
AF Yang, Woojin
   Bang, Hyoeun
   Jang, Kiwon
   Sung, Min Kyung
   Choi, Jung Kyoon
TI Predicting the recurrence of noncoding regulatory mutations in cancer
SO BMC BIOINFORMATICS
LA English
DT Article
ID CHROMATIN ORGANIZATION; GENES; DNA; INTERACTOME; NETWORK; DISEASE;
   GENOMES; LANDSCAPES; ELEMENTS; CELLS
AB Background: One of the greatest challenges in cancer genomics is to distinguish driver mutations from passenger mutations. Whereas recurrence is a hallmark of driver mutations, it is difficult to observe recurring noncoding mutations owing to a limited amount of whole-genome sequenced samples. Hence, it is required to develop a method to predict potentially recurrent mutations.
   Results: In this work, we developed a random forest classifier that predicts regulatory mutations that may recur based on the features of the mutations repeatedly appearing in a given cohort. With breast cancer as a model, we profiled 35 quantitative features describing genetic and epigenetic signals at the mutation site, transcription factors whose binding motif was disrupted by the mutation, and genes targeted by long-range chromatin interactions. A true set of mutations for machine learning was generated by interrogating publicly available pan-cancer genomes based on our statistical model of mutation recurrence. The performance of our random forest classifier was evaluated by cross validations. The variable importance of each feature in the classification of mutations was investigated. Our statistical recurrence model for the random forest classifier showed an area under the curve (AUC) of similar to 0.78 in predicting recurrent mutations. Chromatin accessibility at the mutation sites, the distance from the mutations to known cancer risk loci, and the role of the target genes in the regulatory or protein interaction network were among the most important variables.
   Conclusions: Our methods enable to characterize recurrent regulatory mutations using a limited number of whole-genome samples, and based on the characterization, to predict potential driver mutations whose recurrence is not found in the given samples but likely to be observed with additional samples.
C1 [Yang, Woojin; Bang, Hyoeun; Jang, Kiwon; Sung, Min Kyung; Choi, Jung Kyoon] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST)
RP Choi, JK (通讯作者)，Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea.
EM jungkyoon@kaist.ac.kr
RI Choi, Jung/C-2070-2011
OI Sung, Minkyung/0000-0001-6573-2622; Jang, Kiwon/0000-0002-3789-5667
FU Ministry of Health and Welfare through Korea Health Industry Development
   Institute [HI13C2143]; KAIST Future Systems Healthcare Project; Ministry
   of Science, ICT and Future Planning [2016M3C9A4921712]; CHUNG Moon Soul
   Centre of KAIST; KAIST Institute for the BioCentury
FX This work was supported by the Ministry of Health and Welfare funded
   through the Korea Health Industry Development Institute [HI13C2143], by
   the KAIST Future Systems Healthcare Project, and by the Ministry of
   Science, ICT and Future Planning [2016M3C9A4921712]. Research facilities
   were supported by the CHUNG Moon Soul Centre of KAIST and the KAIST
   Institute for the BioCentury.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], NATURE, DOI DOI 10.1038/NATURE10386
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Das J, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-92
   de Laat W, 2013, NATURE, V502, P499, DOI 10.1038/nature12753
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Hansen RS, 2010, P NATL ACAD SCI USA, V107, P139, DOI 10.1073/pnas.0912402107
   He B, 2014, P NATL ACAD SCI USA, V111, pE2191, DOI 10.1073/pnas.1320308111
   Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Kim K, 2015, NUCLEIC ACIDS RES, V43, P5716, DOI 10.1093/nar/gkv532
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lee I, 2011, GENOME RES, V21, P1109, DOI 10.1101/gr.118992.110
   Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Melton C, 2015, NAT GENET, V47, P710, DOI 10.1038/ng.3332
   Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221
   Rolland T, 2014, CELL, V159, P1212, DOI 10.1016/j.cell.2014.10.050
   Schuster-Böckler B, 2012, NATURE, V488, P504, DOI 10.1038/nature11273
   Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005
   Svetlichnyy D, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004590
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Woo YH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1982
   Yu HY, 2011, NAT METHODS, V8, P478, DOI [10.1038/NMETH.1597, 10.1038/nmeth.1597]
NR 27
TC 9
Z9 9
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 3
PY 2016
VL 17
AR 492
DI 10.1186/s12859-016-1385-y
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA EE1YS
UT WOS:000389380800001
PM 27912731
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lin, SC
   Chou, YT
   Jiang, SS
   Chang, JL
   Chung, CH
   Kao, YR
   Chang, IS
   Wu, CW
AF Lin, Sheng-Chieh
   Chou, Yu-Ting
   Jiang, Shih Sheng
   Chang, Junn-Liang
   Chung, Chih-Hung
   Kao, Yu-Rung
   Chang, I-Shou
   Wu, Cheng-Wen
TI Epigenetic Switch between <i>SOX2</i> and <i>SOX9</i> Regulates Cancer
   Cell Plasticity
SO CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LUNG ADENOCARCINOMA;
   ADHESION MOLECULE; MULTIPLE ROLES; BREAST-CANCER; CYCLIN-A; EXPRESSION;
   DIFFERENTIATION; CARCINOMA
AB Cell differentiation within stem cell lineages can check proliferative potential, but nodal pathways that can limit tumor growth are obscure. Here, we report that lung cancer cell populations generate phenotypic and oncogenic plasticity via a switch between differentiation programs controlled by SOX2 and SOX9, thus altering proliferative and invasive capabilities. In lung cancer cells, SOX2 bound the EPCAM promoter to induce EpCAM-p21(Cip1)-cyclin A2 signaling, encouraging cell proliferation as well as barrier properties. In contrast, SOX9 bound the SLUG promoter to induce SLUG-mediated cell invasion with a spindle-like phenotype. Pharmacologic inhibition of HDAC elevated a SOX9-positive cell population from SOX2-positive cells, whereas ectopic expression of SOX2 inhibited SOX9 with increased H3K9me2 levels on the SOX9promoter. In clinical specimens, the expression of SOX2 and SOX9 correlated negatively and positively with lung tumor grade, respectively. Our findings identify SOX2 and SOX9 as nodal epigenetic regulators in determining cancer cell plasticity and metastatic progression. (C) 2016 AACR.
C1 [Lin, Sheng-Chieh; Chou, Yu-Ting; Wu, Cheng-Wen] Natl Tsing Hua Univ, Inst Biotechnol, Coll Life Sci, Hsinchu, Taiwan.
   [Jiang, Shih Sheng; Chang, I-Shou] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan.
   [Chang, Junn-Liang] Taoyuan Armed Forces Gen Hosp, Dept Pathol & Lab Med, Taoyuan, Taiwan.
   [Chang, Junn-Liang] Ming Chuan Univ, Dept Biomed Engn, Taoyuan, Taiwan.
   [Chung, Chih-Hung; Kao, Yu-Rung; Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.
   [Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan.
C3 National Tsing Hua University; National Health Research Institutes -
   Taiwan; Ming Chuan University; Academia Sinica - Taiwan; National Yang
   Ming Chiao Tung University; National Yang Ming Chiao Tung University;
   National Yang Ming Chiao Tung University
RP Wu, CW (通讯作者)，Natl Yang Ming Univ, 155,Sec 2,Linong St, Taipei 11221, Taiwan.; Chou, YT (通讯作者)，Natl Tsing Hua Univ, 101,Sec 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.
EM ytchou@life.nthu.edu.tw; cwwu@ym.edu.tw
RI Wen-shiang, Chen/B-4794-2009; Chang, I-Shou/D-2084-2010; Jiang,
   Shih/J-9671-2019
OI Chou, Yu-Ting/0000-0001-9274-8603
CR Adam RC, 2015, NATURE, V521, P366, DOI 10.1038/nature14289
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305
   BOYER B, 1993, APMIS, V101, P257, DOI 10.1111/j.1699-0463.1993.tb00109.x
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Chao Y, 1998, CANCER RES, V58, P985
   Chen HM, 2003, ORAL ONCOL, V39, P476, DOI 10.1016/S1368-8375(03)00007-1
   Chen X, 2008, COLD SH Q B, V73, P203, DOI 10.1101/sqb.2008.73.026
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   Chou YT, 2012, CELL DEATH DIFFER, V19, P2015, DOI 10.1038/cdd.2012.91
   Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518
   Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638
   Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837
   Cox JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015486
   Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977
   Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9
   Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063
   González B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Hotta A, 2009, NAT METHODS, V6, P370, DOI [10.1038/NMETH.1325, 10.1038/nmeth.1325]
   Huang HP, 2011, J BIOL CHEM, V286, P33520, DOI 10.1074/jbc.M111.256164
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138
   Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151
   Kimura O, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/172913
   Lim SY, 2013, STEM CELL TRANSL MED, V2, P715, DOI 10.5966/sctm.2012-0161
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022
   Ng VY, 2010, STEM CELLS, V28, P29, DOI 10.1002/stem.221
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629
   Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110
   Sakai D, 2006, DEVELOPMENT, V133, P1323, DOI 10.1242/dev.02297
   Shen CI, 2014, CELL TRANSPLANT, V23, P1031, DOI [10.3727/096368913X666403, 10.3727/096368913x666403]
   Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Shiwarski DJ, 2014, CLIN CANCER RES, V20, P4673, DOI 10.1158/1078-0432.CCR-14-0363
   Sholl LM, 2010, APPL IMMUNOHISTO M M, V18, P55, DOI 10.1097/PAI.0b013e3181b16b88
   Tompkins DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008248
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Yamamizu K, 2014, DEVELOPMENT, V141, P4254, DOI 10.1242/dev.115436
NR 46
TC 47
Z9 50
U1 2
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2016
VL 76
IS 23
BP 7036
EP 7048
DI 10.1158/0008-5472.CAN-15-3178
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EE2SX
UT WOS:000389435800027
PM 27758880
OA Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Segedi, M
   Anderson, LN
   Espin-Garcia, O
   Borgida, A
   Bianco, T
   Cheng, DX
   Chen, Z
   Patel, D
   Brown, MC
   Xu, W
   Reisman, D
   Gallinger, S
   Cotterchio, M
   Hung, R
   Liu, G
   Cleary, SP
AF Segedi, Maja
   Anderson, Laura N.
   Espin-Garcia, Osvaldo
   Borgida, Ayelet
   Bianco, Teresa
   Cheng, Dangxiao
   Chen, Zhuo
   Patel, Devalben
   Brown, M. Catherine
   Xu, Wei
   Reisman, David
   Gallinger, Steven
   Cotterchio, Michelle
   Hung, Rayjean
   Liu, Geoffrey
   Cleary, Sean P.
TI <i>BRM</i> polymorphisms, pancreatic cancer risk and survival
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
ID SWI/SNF COMPLEX; LUNG-CANCER; CELL CARCINOMA; BREAST-CANCER; EXPRESSION;
   ASSOCIATION; PROLIFERATION; FAMILIES; HISTORY; BRCA1
AB Variant alleles of two promoter polymorphisms in the BRM gene (BRM-741, BRM-1321), create MEF2D transcription binding sites that lead to epigenetic silencing of BRM, the key catalytic component of the SWI/SNF chromatin remodeling complex. BRM suppression can be reversed pharmacologically.(1) Our group and others have reported associations with lung, head and neck, hepatocellular cancer risk,(1-3) and with lung and esophageal cancer prognosis (ASCO 2013; abstract 11057 & 4077). Herein, we assessed risk and survival associations with pancreatic cancer. A provincial population-based case-control study was conducted with 623 histologically confirmed pancreatic adenocarcinoma cases and 1,192 age/gender distribution-matched controls.(4) Survival of cases was obtained through the Ontario Cancer Registry. Logistic and Cox proportional hazard regression models were fitted, adjusting for relevant covariates. Median age was 65 y; 52% were male; Stage I (8%), II (55%), III (14%), IV (23%); 53% after curative resection, 79% after chemotherapy; and 83% had died. In the risk analysis, adjusted odds ratios (aOR) were 1.01 (95% CI: 0.1-2.0) and 0.96 (95% CI: 0.7-1.3) for the homozygotes of BRM-741 and BRM-1321, respectively; aOR of double-homozygotes was 1.11 (95% CI: 0.80-1.53), compared to the double-wildtype. For the survival analysis, adjusted hazard ratios (aHR) were 2.19 (95% CI: 1.9-2.5) for BRM-741 and 1.94 (95% CI: 1.7-2.2) for BRM-1321, per unit increase in variant alleles. Compared with the double-wildtype, aHR for carrying no, one, and two double-homozygotes were 2.14 (95% CI: 1.6-2.8), 4.17 (95% CI: 3.0-5.7), 8.03 (95% CI: 5.7-11.4), respectively. In conclusion, two functional promoter BRM polymorphisms were not associated with pancreatic adenocarcinoma risk, but are strongly associated with survival.
   What's new? The putative tumor suppressor gene BRM is inactivated in about 20% of solid tumor types, with its silencing occurring through epigenetic alterations of two variants in the promoter region. In this study, the influence of those variants on risk and survival in cancer was explored in more than 620 patients with pancreatic adenocarcinoma. Analyses show that the two polymorphisms, BRM-741 and BRM-1321, are significantly associated with worse survival but not with increased risk of developing pancreatic cancer. The findings are of potential therapeutic importance, as BRM silencing is pharmacologically reversible.
C1 [Segedi, Maja] Univ British Columbia, Dept Surg, Vancouver, BC, Canada.
   [Segedi, Maja; Espin-Garcia, Osvaldo; Borgida, Ayelet; Bianco, Teresa; Cheng, Dangxiao; Chen, Zhuo; Patel, Devalben; Brown, M. Catherine; Xu, Wei; Gallinger, Steven; Liu, Geoffrey; Cleary, Sean P.] Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Anderson, Laura N.; Borgida, Ayelet; Bianco, Teresa; Gallinger, Steven; Hung, Rayjean; Cleary, Sean P.] Mt Sinai Hospital, Lunenfeld Res Inst, Toronto, ON, Canada.
   [Reisman, David] Univ Florida, Med Oncol, Gainesville, FL USA.
   [Cotterchio, Michelle] Canc Care Ontario, Prevent & Canc Control, Toronto, ON, Canada.
C3 University of British Columbia; University of Toronto; University Health
   Network Toronto; Princess Margaret Cancer Centre; University of Toronto;
   Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute;
   Baycrest; State University System of Florida; University of Florida;
   Cancer Care Ontario
RP Liu, G (通讯作者)，610 Univ Ave,7-124, Toronto, ON M5P 2H7, Canada.
EM Geoffrey.Liu@uhn.ca
RI Liu, Geoffrey/N-4421-2016; Espin-Garcia, Osvaldo/IYJ-5501-2023; Hung,
   Rayjean/A-7439-2013; Anderson, Laura/K-4707-2019; Gallinger,
   Steven/E-4575-2013; Cleary, Sean/F-6810-2013; xu, wei/HHD-2891-2022
OI Liu, Geoffrey/0000-0002-2603-7296; Espin-Garcia,
   Osvaldo/0000-0003-2052-2626; Cotterchio, Michelle/0000-0003-2862-7895;
   Anderson, Laura N./0000-0002-6106-5073; Cleary, Sean/0000-0002-5274-9983
CR Anderson LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066768
   Anderson LN, 2009, CANCER CAUSE CONTROL, V20, P825, DOI 10.1007/s10552-009-9303-5
   [Anonymous], 2005, NAT CLIN PRACT ONCOL, V2, P416
   Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Bradbury PA, 2008, CANCER EPIDEM BIOMAR, V17, P204, DOI 10.1158/1055-9965.EPI-07-0470
   Cotterchio M, 2000, Chronic Dis Can, V21, P81
   Cotterchio M, 2014, CANCER EPIDEM BIOMAR, V23, P469, DOI 10.1158/1055-9965.EPI-13-0965
   Cui YF, 2012, ENDOCR-RELAT CANCER, V19, pF9, DOI 10.1530/ERC-12-0105
   Edge S., 2010, AJCC CANC STAGING HD, V19, P718
   Endo M, 2013, LIVER INT, V33, P105, DOI 10.1111/liv.12005
   Gao XR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055169
   Ghadirian P, 2002, INT J CANCER, V97, P807, DOI 10.1002/ijc.10123
   Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228
   Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514
   Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80
   Halliday GM, 2012, EXP DERMATOL, V21, P599, DOI 10.1111/j.1600-0625.2012.01522.x
   Hassan MM, 2007, AM J GASTROENTEROL, V102, P2696, DOI 10.1111/j.1572-0241.2007.01510.x
   Hemminki K, 2003, INT J CANCER, V103, P525, DOI 10.1002/ijc.10863
   Iqbal J, 2012, BRIT J CANCER, V107, P2005, DOI 10.1038/bjc.2012.483
   Jacobs EJ, 2009, CANCER CAUSE CONTROL, V20, P1261, DOI 10.1007/s10552-009-9339-6
   Kahali B, 2014, ONCOTARGET, V5, P3316, DOI 10.18632/oncotarget.1945
   Kastrinos F, 2009, JAMA-J AM MED ASSOC, V302, P1790, DOI 10.1001/jama.2009.1529
   Klein AP, 2004, CANCER RES, V64, P2634, DOI 10.1158/0008-5472.CAN-03-3823
   Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2
   Li L, 2014, HUM PATHOL, V45, P2247, DOI 10.1016/j.humpath.2014.06.027
   Little J, 2009, EUR J CLIN INVEST, V39, P247, DOI 10.1111/j.1365-2362.2009.02125.x
   Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81
   Maisonneuve P, 2010, DIGEST DIS, V28, P645, DOI 10.1159/000320068
   Matsubara D, 2013, CANCER SCI, V104, P266, DOI 10.1111/cas.12065
   Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091
   Mehrotra A, 2014, ARCH BIOCHEM BIOPHYS, V563, P125, DOI 10.1016/j.abb.2014.07.004
   Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331
   Numata M, 2013, INT J ONCOL, V42, P403, DOI 10.3892/ijo.2012.1723
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Skulte KA, 2014, EPIGENOMICS-UK, V6, P397, DOI 10.2217/epi.14.37
   Society AC, 2013, CANC FACTS FIG 2013
   Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U
   Wang JR, 2013, CARCINOGENESIS, V34, P1012, DOI 10.1093/carcin/bgt008
   Wong KM, 2014, CANCER MED-US, V3, P426, DOI 10.1002/cam4.201
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Xia QY, 2014, HISTOPATHOLOGY, V64, P847, DOI 10.1111/his.12334
NR 43
TC 13
Z9 13
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2016
VL 139
IS 11
BP 2474
EP 2481
DI 10.1002/ijc.30369
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DX8NQ
UT WOS:000384646200010
PM 27487558
OA Bronze
DA 2025-01-12
ER

PT J
AU Banerjee, P
   Surendran, H
   Chowdhury, DR
   Prabhakar, K
   Pal, R
AF Banerjee, Poulomi
   Surendran, Harshini
   Chowdhury, Debabani Roy
   Prabhakar, Karthik
   Pal, Rajarshi
TI Metformin mediated reversal of epithelial to mesenchymal transition is
   triggered by epigenetic changes in E-cadherin promoter
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE Epithelial-mesenchymal transition; Metformin; Diabetes; ERK; AMPK;
   E-cadherin; Methylation
ID ACTIVATED PROTEIN-KINASE; BREAST-CANCER; IN-VIVO; DNA METHYLATION;
   TGF-BETA; CELLS; METASTASIS; EXPRESSION; CARCINOMA; INVASION
AB Epithelial-mesenchymal transition (EMT) is one of the key biological phenomena behind cancer and metastasis. Clinical studies suggest that patients undergoing metformin therapy are less predisposed to cancer but the underlying mechanism is far from clear. Given that metformin also acts as TGF-beta inhibitor, we sought to explore whether and how metformin could modulate EMT in a cancer like microenvironment. Our data using human cell lines revealed that metformin induced a distinct change from stromal-shaped mesenchymal cells to cuboidal-shaped epithelial cells with upregulation of epithelial markers and mitigation of their invasive property. One of the key regulatory pathways, which intersect tumorigenesis and metformin activity, is AMPK. We demonstrated that metformin attenuates ERK signaling by activating AMPK pathway leading to suppression of Snail and Slug resulting in upregulation of crucial tumor suppressor gene E-cadherin. ChIP assay confirmed insufficient binding of repressors like Slug to the E-cadherin promoter. Further, our data revealed reduction in HDAC activity prompting hypomethylation of E-cadherin promoter thus reflecting an epigenetic modification. To expand the translational significance of the study we verified these findings in diabetic patients undergoing metformin treatment. To our knowledge this is the first report representing an inverse relationship of AMPK and ERK signaling axis in promoting mesenchymal to epithelial transition (MET) via reexpression of E-cadherin upon metformin treatment thus rationalizing lower incidence of cancer in metforminadministered patients.
   Metformin promotes reversal of the epithelial-mesenchymal transition.
   Metformin attenuates ERK signaling by activating AMP kinase.
   Metformin induces hypomethylation of the E-cadherin gene promoter.
   Epigenetic modification of the E-cadherin promoter was observed in leukocytes from diabetic subjects.
   These findings provide a potential basis for decreased cancer incidence in metformin-treated subjects.
C1 [Banerjee, Poulomi; Surendran, Harshini; Pal, Rajarshi] Manipal Univ, Sch Regenerat Med, Bangalore 560065, Karnataka, India.
   [Prabhakar, Karthik] Manipal Hosp, Dept Endocrinol & Diabet, Bangalore 560017, Karnataka, India.
   [Chowdhury, Debabani Roy] Ctr Cellular & Mol Biol, Funct Genom & Gene Silencing Grp, Hyderabad 500007, Andhra Pradesh, India.
C3 Manipal Academy of Higher Education (MAHE); Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Centre for Cellular &
   Molecular Biology (CCMB)
RP Pal, R (通讯作者)，Manipal Univ, Sch Regenerat Med, Bangalore 560065, Karnataka, India.
EM rajarshi.pal@manipal.edu
OI , Harshini/0009-0007-8114-4987; banerjee, poulomi/0000-0002-0987-6442;
   Pal, Rajarshi/0000-0001-6334-4562
FU Manipal University, Manipal
FX The authors would like to thank Dr. Antonio Garcia de Herreros,
   IMIM-Hospital del Mar, Barcelona, Spain; Dr. James Nelson, Stanford
   University, CA, USA and Dr. K. Satyamoorthy, Manipal University,
   Manipal, India for providing the plasmids. We gratefully thank the
   support extended by Manipal University, Manipal for the required
   facilities and intramural funding for carrying out the present study.
CR Austin P, 2013, MOL CANCER RES, V11, P530, DOI 10.1158/1541-7786.MCR-12-0385
   Banerjee P, 2016, STEM CELLS, V34, P334, DOI 10.1002/stem.2245
   Banerjee P, 2015, EXP DERMATOL, V24, P391, DOI 10.1111/exd.12671
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Carpenter PM, 2002, AM J CLIN PATHOL, V118, P887, DOI 10.1092/4XKDDK4A2R4GBRK7
   Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Chen CL, 2003, EUR J CANCER, V39, P517, DOI 10.1016/S0959-8049(02)00175-2
   Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162
   Cufí S, 2010, CELL CYCLE, V9, P4461, DOI 10.4161/cc.9.22.14048
   Das S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-94
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8
   Han WG, 2006, ANAL BIOCHEM, V355, P50, DOI 10.1016/j.ab.2006.05.010
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Howard EW, 2008, MINI-REV MED CHEM, V8, P496, DOI 10.2174/138955708784223521
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kim HS, 2012, BIOCHEM PHARMACOL, V83, P385, DOI 10.1016/j.bcp.2011.11.008
   Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200
   Kim MJ, 2010, J BIOL CHEM, V285, P14617, DOI 10.1074/jbc.M109.085456
   Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138
   Lee JH, 2013, AM J PHYSIOL-RENAL, V304, pF686, DOI 10.1152/ajprenal.00148.2012
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Lin YC, 2014, J CELL SCI, V127, P85, DOI 10.1242/jcs.132779
   Luo QQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-517
   Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324
   Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Plews RL, 2015, J CLIN ENDOCR METAB, V100, pE748, DOI 10.1210/jc.2014-1777
   Quinn BJ, 2013, TRENDS ENDOCRIN MET, V24, P469, DOI 10.1016/j.tem.2013.05.004
   Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Sarkar S, 2011, ANTICANCER RES, V31, P2723
   Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503
   Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874
   Sheng W, 2006, MOL BIOL CELL, V17, P2009, DOI 10.1091/mbc.E05-10-0951
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
NR 38
TC 37
Z9 38
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD DEC
PY 2016
VL 94
IS 12
BP 1397
EP 1409
DI 10.1007/s00109-016-1455-7
PG 13
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA EF0QD
UT WOS:000390029900009
PM 27534967
DA 2025-01-12
ER

PT J
AU Zhang, YY
   Huang, SH
   Zhou, HR
   Chen, CJ
   Tian, LH
   Shen, JZ
AF Zhang, Yuan-Yuan
   Huang, Si-Han
   Zhou, Hua-Rong
   Chen, Cong-Jie
   Tian, Li-Hong
   Shen, Jian-Zhen
TI Role of HOTAIR in the diagnosis and prognosis of acute leukemia
SO ONCOLOGY REPORTS
LA English
DT Article
DE long non-coding RNA; HOTAIR; acute leukemia; epigenetics
ID NONCODING RNA HOTAIR; AGGRESSIVE BREAST-CANCER; ACUTE MYELOID-LEUKEMIA;
   GROUP PROTEIN EZH2; DNA METHYLTRANSFERASES; POOR-PROGNOSIS; LSD1;
   MAINTENANCE; METHYLATION; MARKER
AB HOX antisense intergenic RNA (HOTAIR), a long non-coding RNA, plays an important role in the development of many types of cancers. Its function in acute leukemia (AL), however, has not been examined. The present study investigated the role of HOTAIR and its downstream genes in AL, and determined whether it could act as a molecular marker for prediction of leukemia development and prognosis. Real-time quantitative PCR was used to examine the expression of each gene in the HOTAIR signaling pathway in AL patients. The relationship between expression of HOTAIR and downstream genes and AL prognosis was analyzed. Expression of HOTAIR in patients with acute monocytic leukemia (M5) was increased as compared to controls (P<0.05). Compared to patients with low HOTAIR expression, overall survival and event-free survival of patients with high HOTAIR expression was significantly reduced. In addition, the expression of downstream genes in the HOTAIR signaling pathway including EZH2, LSD1, DNMT3A and DNMT3B was significantly increased in AL patients, and showed a significant positive correlation with high expression of HOTAIR (P<0.05). In conclusion, HOTAIR was closely related with a poor prognosis in AL patients. It may be involved in the development of leukemia by mediating methylation of DNA and histones.
C1 [Zhang, Yuan-Yuan; Huang, Si-Han; Zhou, Hua-Rong; Chen, Cong-Jie; Tian, Li-Hong; Shen, Jian-Zhen] Fujian Med Univ, Union Hosp, Fujian Prov Key Lab Hematol, Fujian Inst Hematol, 29 Xin Quan Rd, Fuzhou 350001, Fujian, Peoples R China.
C3 Fujian Medical University
RP Shen, JZ (通讯作者)，Fujian Med Univ, Union Hosp, Fujian Prov Key Lab Hematol, Fujian Inst Hematol, 29 Xin Quan Rd, Fuzhou 350001, Fujian, Peoples R China.
EM doctorsjz@163.com
RI zhang, yuanyuan/GYA-4428-2022
FU National Natural Science Foundation of China [81370629, 81300428]; Major
   Research of Fujian Medical University [09-ZD021]; Science and Technology
   Department of Fujian Province [2011Y4002]; Education Department of
   Fujian Province [JA10129]; National and Fujian Provincial Key Clinical
   Specialty Discipline Construction Program (China)
FX The present study was supported by the National Natural Science
   Foundation of China (nos. 81370629 and 81300428), the Major Research of
   Fujian Medical University (09-ZD021), the Science and Technology
   Department of Fujian Province (2011Y4002), the Education Department of
   Fujian Province (JA10129), and the National and Fujian Provincial Key
   Clinical Specialty Discipline Construction Program (China).
CR [Anonymous], CHINA CANC
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Chalei V, 2014, ELIFE, V3, DOI 10.7554/eLife.04530
   Chédin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999
   Chen C, 2011, CANCER INVEST, V29, P548, DOI 10.3109/07357907.2011.597810
   Chen T, 2006, CURR TOP MICROBIOL, V301, P179
   Chisholm KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047998
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Döhner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Haemmerle M, 2015, INT J MOL SCI, V16, P1395, DOI 10.3390/ijms16011395
   Hao SF, 2015, INT J CLIN EXP PATHO, V8, P7223
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547
   Lee DH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001224
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li XL, 2014, MUTAT RES-REV MUTAT, V762, P1, DOI 10.1016/j.mrrev.2014.04.002
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Margot JB, 2001, J CELL BIOCHEM, V83, P373, DOI 10.1002/jcb.1236
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Muto Tomoya, 2015, Rinsho Ketsueki, V56, P2287, DOI 10.11406/rinketsu.56.2287
   Nakagawa T, 2013, BIOCHEM BIOPH RES CO, V436, P319, DOI 10.1016/j.bbrc.2013.05.101
   Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092
   Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Robaina MC, 2015, EXP MOL PATHOL, V98, P200, DOI 10.1016/j.yexmp.2015.03.006
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wu SH, 2015, ONCOL LETT, V10, P2410, DOI 10.3892/ol.2015.3552
   Wu ZH, 2014, ONCOL REP, V32, P395, DOI 10.3892/or.2014.3186
   Ye P, 2015, REJUV RES, V18, P332, DOI 10.1089/rej.2014.1642
   Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
   Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35
NR 51
TC 47
Z9 57
U1 1
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2016
VL 36
IS 6
BP 3113
EP 3122
DI 10.3892/or.2016.5147
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED2DG
UT WOS:000388653200004
PM 27748863
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Savas, P
   Teo, ZL
   Lefevre, C
   Flensburg, C
   Caramia, F
   Alsop, K
   Mansour, M
   Francis, PA
   Thorne, HA
   Silva, MJ
   Kanu, N
   Dietzen, M
   Rowan, A
   Kschischo, M
   Fox, S
   Bowtell, DD
   Dawson, SJ
   Speed, TP
   Swanton, C
   Loi, S
AF Savas, Peter
   Teo, Zhi Ling
   Lefevre, Christophe
   Flensburg, Christoffer
   Caramia, Franco
   Alsop, Kathryn
   Mansour, Mariam
   Francis, Prudence A.
   Thorne, Heather A.
   Silva, Maria Joao
   Kanu, Nnennaya
   Dietzen, Michelle
   Rowan, Andrew
   Kschischo, Maik
   Fox, Stephen
   Bowtell, David D.
   Dawson, Sarah-Jane
   Speed, Terence P.
   Swanton, Charles
   Loi, Sherene
TI The Subclonal Architecture of Metastatic Breast Cancer: Results from a
   Prospective Community-Based Rapid Autopsy Program "CASCADE"
SO PLOS MEDICINE
LA English
DT Article
ID COPY-NUMBER; MUTATIONAL PROCESSES; DOMAIN MUTATIONS; EVOLUTION; MODEL;
   DNA; HETEROGENEITY; NORMALIZATION; HISTORY
AB Background
   Understanding the cancer genome is seen as a key step in improving outcomes for cancer patients. Genomic assays are emerging as a possible avenue to personalised medicine in breast cancer. However, evolution of the cancer genome during the natural history of breast cancer is largely unknown, as is the profile of disease at death. We sought to study in detail these aspects of advanced breast cancers that have resulted in lethal disease.
   Methods and Findings
   Three patients with oestrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and one patient with triple negative breast cancer underwent rapid autopsy as part of an institutional prospective community-based rapid autopsy program (CASCADE). Cases represented a range of management problems in breast cancer, including late relapse after early stage disease, de novo metastatic disease, discordant disease response, and disease refractory to treatment. Between 5 and 12 metastatic sites were collected at autopsy together with available primary tumours and longitudinal metastatic biopsies taken during life. Samples underwent paired tumour-normal whole exome sequencing and single nucleotide polymorphism (SNP) arrays. Subclonal architectures were inferred by jointly analysing all samples from each patient. Mutations were validated using high depth amplicon sequencing.
   Between cases, there were significant differences in mutational burden, driver mutations, mutational processes, and copy number variation. Within each case, we found dramatic heterogeneity in subclonal structure from primary to metastatic disease and between metastatic sites, such that no single lesion captured the breadth of disease. Metastatic cross-seeding was found in each case, and treatment drove subclonal diversification. Subclones displayed parallel evolution of treatment resistance in some cases and apparent augmentation of key oncogenic drivers as an alternative resistance mechanism. We also observed the role of mutational processes in subclonal evolution.
   Limitations of this study include the potential for bias introduced by joint analysis of formalin-fixed archival specimens with fresh specimens and the difficulties in resolving subclones with whole exome sequencing. Other alterations that could define subclones such as structural variants or epigenetic modifications were not assessed.
   Conclusions
   This study highlights various mechanisms that shape the genome of metastatic breast cancer and the value of studying advanced disease in detail. Treatment drives significant genomic heterogeneity in breast cancers which has implications for disease monitoring and treatment selection in the personalised medicine paradigm.
C1 [Savas, Peter; Teo, Zhi Ling; Caramia, Franco; Mansour, Mariam; Silva, Maria Joao] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia.
   [Lefevre, Christophe; Flensburg, Christoffer] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
   [Lefevre, Christophe; Flensburg, Christoffer] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia.
   [Alsop, Kathryn; Thorne, Heather A.; Bowtell, David D.] Peter MacCallum Canc Ctr, Div Res, Canc Genom Program, Melbourne, Vic, Australia.
   [Francis, Prudence A.; Dawson, Sarah-Jane; Loi, Sherene] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia.
   [Thorne, Heather A.] Peter MacCallum Canc Ctr, Div Res, kConFab, Melbourne, Vic, Australia.
   [Kanu, Nnennaya; Dietzen, Michelle; Swanton, Charles] UCL Canc Inst, CRUK Lung Canc Ctr Excellence, London, England.
   [Rowan, Andrew; Swanton, Charles] Francis Crick Inst, London, England.
   [Kschischo, Maik] Univ Appl Sci Koblenz, Dept Math & Technol, RheinAhrCampus Remagen, Remagen, Germany.
   [Fox, Stephen] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia.
   [Bowtell, David D.; Dawson, Sarah-Jane; Loi, Sherene] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.
   [Speed, Terence P.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic, Australia.
   [Speed, Terence P.] Univ Melbourne, Dept Math & Stat, Parkville, Vic, Australia.
C3 Peter Maccallum Cancer Center; Walter & Eliza Hall Institute; University
   of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer
   Center; Peter Maccallum Cancer Center; University of London; University
   College London; Francis Crick Institute; Peter Maccallum Cancer Center;
   University of Melbourne; Peter Maccallum Cancer Center; Walter & Eliza
   Hall Institute; University of Melbourne
RP Loi, S (通讯作者)，Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia.; Loi, S (通讯作者)，Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.
EM sherene.loi@petermac.org
RI Kschischo, Maik/AFR-1691-2022; Speed, Terence/B-8085-2009; Loi,
   Sherene/ITT-3863-2023; Dawson, Sarah-Jane/LOR-8459-2024; Swanton,
   Charles/AEY-0113-2022; Loi, Sherene/H-1979-2016; Fox,
   Stephen/G-9719-2016; Bowtell, David/H-1007-2016; Francis,
   Prudence/J-4003-2012
OI Silva, Maria Joao/0000-0003-0803-6561; lefevre,
   christophe/0000-0002-2876-0648; Dawson, Sarah-Jane/0000-0002-8276-0374;
   Loi, Sherene/0000-0001-6137-9171; Thorne, Heather/0000-0003-3610-2511;
   Fox, Stephen/0000-0002-7648-8896; Swanton, Charles/0000-0002-4299-3018;
   Teo, Zhi Ling/0000-0002-0748-0858; Savas, Peter/0000-0001-5999-428X;
   Bowtell, David/0000-0001-9089-7525; Alsop, Kathryn/0000-0002-4107-3041;
   Francis, Prudence/0000-0002-7207-9286
FU National Breast Cancer Foundation of Australia; Breast Cancer Research
   Foundation (BCRF), New York; UK Medical Research Council grant (UKMRC)
   [MR/FC001169/1]; Francis Crick Institute; Cancer Research UK [FC001169];
   UKMRC [FC001169]; Wellcome Trust [FC001169]; National Health and Medical
   Research Council of Australia (NHMRC); NBCF; Cancer Therapeutics CRC;
   NHMRC; Cancer Australia; National Institutes of Health; Cancer Council
   of Queensland; Cancer Council of New South Wales; Cancer Council of
   Victoria; Cancer Council of Tasmania; Cancer Council of South Australia;
   Cancer Foundation of Western Australia; Victorian Cancer Agency; NHMRC
   Program Grant [1054618]; Cancer Research UK (TRACERx); Cancer Research
   UK Lung Cancer Centre of Excellence; Stand Up 2 Cancer (SU2C); Rosetrees
   Trust; NovoNordisk Foundation [16584]; Prostate Cancer Foundation; BCRF;
   European Research Council; National Institute for Health Research;
   University College London Hospitals Biomedical Research Centre; Cancer
   Research UK University College London Experimental Cancer Medicine
   Centre; John Colebatch Cancer Council of Victoria Clinical Fellowship;
   MRC [G0701935] Funding Source: UKRI
FX This work was supported by the National Breast Cancer Foundation (NBCF,
   http://nbcf.org.au/) of Australia, the Breast Cancer Research Foundation
   (BCRF, https://www.bcrfcure.org/), New York, a UK Medical Research
   Council grant (UKMRC, MR/FC001169/1), and the Francis Crick Institute
   (https://www.crick.ac.uk/), which receives its core funding from Cancer
   Research UK (FC001169, http://www.cancerresearchuk.org/), the UKMRC
   (FC001169, http://www.mrc.ac.uk/), and the Wellcome Trust (FC001169,
   https://wellcome.ac.uk/). PS is supported by National Health and Medical
   Research Council of Australia (NHMRC, https://www.nhmrc.gov.au), NBCF,
   and Cancer Therapeutics CRC (https://www.cancercrc.com/) post-graduate
   scholarships. The kConFab Clinical Follow-Up Study is supported by the
   NHMRC, NBCF, Cancer Australia (https://canceraustralia.gov.au/), and the
   National Institutes of Health (https://www.nih.gov/). kConFab is
   supported by NBCF, previously the NHMRC, the Cancer Councils of
   Queensland (https://cancerqld.org.au/), New South Wales
   (http://www.cancercouncil.com.au/), Victoria
   (http://www.cancervic.org.au/), Tasmania (http://www.cancertas.org.au/),
   and South Australia (https://www.cancersa.org.au/), and the Cancer
   Foundation of Western Australia (https://www.cancerwa.asn.au/). SJD is
   supported by a NBCF and Victorian Cancer Agency
   (http://www.victoriancanceragency.org.au/) Fellowship. TPS is supported
   by a NHMRC Program Grant (1054618). CS is the Royal Society Napier
   Research Professor and is funded by Cancer Research UK (TRACERx), the
   Cancer Research UK Lung Cancer Centre of Excellence
   (http://www.cruklungcentre.org/), Stand Up 2 Cancer (SU2C,
   http://www.standup2cancer.org/), the Rosetrees Trust
   (http://www.rosetreestrust.co.uk/), NovoNordisk Foundation (ID 16584,
   http://novonordiskfonden.dk/), the Prostate Cancer Foundation
   (https://www.pcf.org), BCRF, and the European Research Council (THESEUS,
   https://erc.europa.eu/). Support was provided to CS by the National
   Institute for Health Research (http://www.nihr.ac.uk/), the University
   College London Hospitals Biomedical Research Centre
   (http://www.uclhospitals.brc.nihr.ac.uk/), and the Cancer Research UK
   University College London Experimental Cancer Medicine Centre
   (http://www.ctc.ucl.ac.uk/). SL is supported by the John Colebatch
   Cancer Council of Victoria Clinical Fellowship
   (http://www.cancervic.org.au/) and the NHMRC. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Alsop K, 2016, NAT BIOTECHNOL, V34, P1010, DOI 10.1038/nbt.3674
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   [Anonymous], SIGN MUT PROC HUM CA
   Auwera G A., 2013, Curr. Protoc. Bioinforma., V43, DOI 10.1002/0471250953.2013. 43.issue-1
   Bengtsson H, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-245
   Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391
   Chen GB, 2012, NATURE, V482, P246, DOI 10.1038/nature10795
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952
   El-Kebir M, 2016, CELL SYST, V3, P43, DOI 10.1016/j.cels.2016.07.004
   Erdmann J, 2016, NAT MED, V22, P963, DOI 10.1038/nm0916-963
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061
   Fumagalli D, 2016, ANN ONCOL, V27, P1860, DOI 10.1093/annonc/mdw286
   Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Griffith M, 2015, CELL SYST, V1, P210, DOI 10.1016/j.cels.2015.08.015
   Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347
   Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012
   Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605
   Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948
   Kawate H, 2002, J BIOL CHEM, V277, P36304, DOI 10.1074/jbc.M204956200
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604
   Légaré S, 2015, CANCER RES, V75, P4351, DOI 10.1158/0008-5472.CAN-14-3475
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Miller ML, 2015, CELL SYST, V1, P197, DOI 10.1016/j.cels.2015.08.014
   Morrissy AS, 2016, NATURE, V529, P351, DOI 10.1038/nature16478
   Murtaza M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9760
   Niknafs N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004416
   Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823
   Olshen AB, 2011, BIOINFORMATICS, V27, P2038, DOI 10.1093/bioinformatics/btr329
   Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410
   Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4
   Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]
   Sanchez-Garcia F, 2014, CELL, V159, P1461, DOI 10.1016/j.cell.2014.10.048
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520
   Staaf J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-409
   Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513
   Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Xin JW, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0953-9
   Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886
   Yau C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r92
   Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394
NR 58
TC 107
Z9 114
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD DEC
PY 2016
VL 13
IS 12
AR e1002204
DI 10.1371/journal.pmed.1002204
PG 25
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EI0DJ
UT WOS:000392142400015
PM 28027312
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Rhie, SK
   Guo, Y
   Tak, YG
   Yao, LJ
   Shen, H
   Coetzee, GA
   Laird, PW
   Farnham, PJ
AF Rhie, Suhn Kyong
   Guo, Yu
   Tak, Yu Gyoung
   Yao, Lijing
   Shen, Hui
   Coetzee, Gerhard A.
   Laird, Peter W.
   Farnham, Peggy J.
TI Identification of activated enhancers and linked transcription factors
   in breast, prostate, and kidney tumors by tracing enhancer networks
   using epigenetic traits
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE DNA methylation; Epigenetics; Enhancer; Transcription factor; Networks
ID DNA METHYLATION; REGULATORY ELEMENTS; EXPRESSION; GENOME; DYNAMICS;
   BINDING; FOXA1; HOXC6
AB Background: Although technological advances now allow increased tumor profiling, a detailed understanding of the mechanisms leading to the development of different cancers remains elusive. Our approach toward understanding the molecular events that lead to cancer is to characterize changes in transcriptional regulatory networks between normal and tumor tissue. Because enhancer activity is thought to be critical in regulating cell fate decisions, we have focused our studies on distal regulatory elements and transcription factors that bind to these elements.
   Results: Using DNA methylation data, we identified more than 25,000 enhancers that are differentially activated in breast, prostate, and kidney tumor tissues, as compared to normal tissues. We then developed an analytical approach called Tracing Enhancer Networks using Epigenetic Traits that correlates DNA methylation levels at enhancers with gene expression to identify more than 800,000 genome-wide links from enhancers to genes and from genes to enhancers. We found more than 1200 transcription factors to be involved in these tumor-specific enhancer networks. We further characterized several transcription factors linked to a large number of enhancers in each tumor type, including GATA3 in non-basal breast tumors, HOXC6 and DLX1 in prostate tumors, and ZNF395 in kidney tumors. We showed that HOXC6 and DLX1 are associated with different clusters of prostate tumor-specific enhancers and confer distinct transcriptomic changes upon knockdown in C42B prostate cancer cells. We also discovered de novo motifs enriched in enhancers linked to ZNF395 in kidney tumors.
   Conclusions: Our studies characterized tumor-specific enhancers and revealed key transcription factors involved in enhancer networks for specific tumor types and subgroups. Our findings, which include a large set of identified enhancers and transcription factors linked to those enhancers in breast, prostate, and kidney cancers, will facilitate understanding of enhancer networks and mechanisms leading to the development of these cancers.
C1 [Rhie, Suhn Kyong; Guo, Yu; Tak, Yu Gyoung; Yao, Lijing; Farnham, Peggy J.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, 1450 Biggy St,NRT G511B, Los Angeles, CA 90089 USA.
   [Rhie, Suhn Kyong; Guo, Yu; Tak, Yu Gyoung; Yao, Lijing; Farnham, Peggy J.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511B, Los Angeles, CA 90089 USA.
   [Shen, Hui; Coetzee, Gerhard A.; Laird, Peter W.] Van Andel Res Inst, Grand Rapids, MI 49503 USA.
C3 University of Southern California; University of Southern California;
   Van Andel Institute
RP Farnham, PJ (通讯作者)，Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, 1450 Biggy St,NRT G511B, Los Angeles, CA 90089 USA.; Farnham, PJ (通讯作者)，Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511B, Los Angeles, CA 90089 USA.
EM peggy.farnham@med.usc.edu
RI Yao, Lijing/N-2954-2017; Coetzee, Gerhard/AAG-8439-2019; Skanderup,
   Anders/K-1081-2013; LAIRD, PETER W/G-8683-2012
OI Rhie, Suhn/0000-0002-5522-5296; Shen, Hui/0000-0001-9767-4084; LAIRD,
   PETER W/0000-0001-9117-3641
FU NIH [R01CA136924, R01CA190182]
FX This work was supported by the following grants from the NIH:
   R01CA136924 and R01CA190182.
CR Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Alexa A., 2010, R Package Version 2.16.0
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115
   Blattler A, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0469-0
   Brawley OW, 2009, CA-CANCER J CLIN, V59, P264, DOI 10.3322/caac.20026
   Chiang YT, 2014, ASIAN J ANDROL, V16, P545, DOI 10.4103/1008-682X.122875
   Dalgin GS, 2007, CANCER INFORM, V3, P65
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ecker JR, 2012, NATURE, V489, P52, DOI 10.1038/489052a
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001
   Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Hamid ARAH, 2015, PROSTATE, V75, P1868, DOI 10.1002/pros.23065
   Haq R, 2011, J CLIN ONCOL, V29, P3474, DOI 10.1200/JCO.2010.32.6223
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Herwartz C, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/804264
   Jin FL, 2013, NATURE, V503, P290, DOI 10.1038/nature12644
   Jordanovski D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074911
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Leyten GHJM, 2015, CLIN CANCER RES, V21, P3061, DOI 10.1158/1078-0432.CCR-14-3334
   Meyer CA, 2014, NAT REV GENET, V15, P709, DOI 10.1038/nrg3788
   Racioppi L, 2013, TRENDS MOL MED, V19, P83, DOI 10.1016/j.molmed.2012.12.004
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906
   Rhie SK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-331
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taberlay PC, 2014, GENOME RES, V24, P1421, DOI 10.1101/gr.163485.113
   Tak YG, 2016, NUCLEIC ACIDS RES, V44, P4123, DOI 10.1093/nar/gkv1530
   Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024
   Xiong Z, 2014, BIOMED RES INT, V2014
   Yao LJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0668-3
NR 39
TC 45
Z9 51
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD NOV 9
PY 2016
VL 9
AR 50
DI 10.1186/s13072-016-0102-4
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EB7XL
UT WOS:000387604300001
PM 27833659
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Siddiqui, S
   Akhter, N
   Deo, SVS
   Shukla, NK
   Husain, SA
AF Siddiqui, Sarah
   Akhter, Naseem
   Deo, S. V. S.
   Shukla, N. K.
   Husain, Syed Akhtar
TI A study on promoter methylation of <i>PTEN</i> in sporadic breast cancer
   patients from North India
SO BREAST CANCER
LA English
DT Article
DE Breast cancer; PTEN; Promoter methylation; Protein expression
ID TUMOR-SUPPRESSOR GENE; MICROSATELLITE INSTABILITY; MUTATION ANALYSIS;
   CELL-SURVIVAL; PTEN/MMAC1; INACTIVATION; PROGRESSION; EXPRESSION;
   PATHWAY; 10Q23
AB Epigenetic silencing of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) through DNA methylation has been implicated in the pathogenesis of breast cancer. Present study investigates the contribution of PTEN promoter methylation and its associated protein expression in sporadic breast cancer patients from North India.
   A total of 360 paired breast carcinoma and adjacent normal tissue samples from 180 sporadic breast cancer patients were included in the present study and examined for PTEN promoter methylation status by methylation-specific polymerase chain reaction. Immunohistochemistry method was used for determining PTEN protein expression. Molecular findings were statistically correlated with various clinicopathological parameters to identify associations of clinical relevance.
   Presence of PTEN promoter methylation (39.44 %) significantly correlated with its expression downregulation (45.56 %) in breast tumors (P = 0.0001). Furthermore, their interaction with various clinical parameters was evidenced in stratified analysis. Correlation of PTEN promoter methylation with histologically more malignant grade and PTEN expression loss with triple negative tumor status remained significant even after Bonferroni correction (P < 0.003).
   Results implicate promoter methylation to be a mechanism partially responsible for PTEN silencing in sporadic breast cancer for North Indian women. Besides, methylation and expression loss of PTEN exhibited promising potential as candidate biomarkers of risk assessment in subcategorized breast tumors with critical pathologic parameters.
C1 [Siddiqui, Sarah; Akhter, Naseem; Husain, Syed Akhtar] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
   [Deo, S. V. S.; Shukla, N. K.] All India Inst Med Sci, Dept Surg Oncol, New Delhi 110029, India.
C3 Jamia Millia Islamia; All India Institute of Medical Sciences (AIIMS)
   New Delhi
RP Husain, SA (通讯作者)，Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
EM akhtarhusain2000@yahoo.com
RI Shukla, Neeraj/ABD-4938-2020; Deo, Salil/AHE-2796-2022; Akhter,
   Naseem/ABF-4588-2021
OI Akhter, Naseem/0000-0003-2011-0955
FU Council of Scientific and Industrial Research (CSIR), Delhi, India
FX The authors thank all the patients who participated in this study and
   acknowledge the efforts and contribution of doctors, nurses, and
   hospital administration staff of AIIMS and all the support staff of
   Jamia Millia Islamia who made this study possible. Financial support for
   the production of the manuscript was provided by Council of Scientific
   and Industrial Research (CSIR), Delhi, India.
CR [Anonymous], 2009, LANCET, V374, P1567, DOI 10.1016/S0140-6736(09)61930-9
   [Anonymous], BREAST DIS
   Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100
   Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940
   Chen ST, 1999, BREAST CANCER RES TR, V55, P85, DOI 10.1023/A:1006142919428
   Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762
   Dean SJR, 2014, AM J CLIN PATHOL, V141, P323, DOI 10.1309/AJCPR11DEAYPTUSL
   Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Khurana, 2014, CLIN OVARIAN OTHER G, V7, P33, DOI [10.1016/j.cogc.2014.12.002, DOI 10.1016/J.COGC.2014.12.002]
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Marty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204
   Nandakumar A, 2010, INDIA J SURG ONCOL, V1, P8, DOI 10.1007/s13193-010-0004-z
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Rhei E, 1997, CANCER RES, V57, P3657
   Rizvi MMA, 2011, J CANCER RES CLIN, V137, P1255, DOI 10.1007/s00432-011-0994-0
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Shi W, 2003, INT J CANCER, V104, P195, DOI 10.1002/ijc.10909
   Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.0.CO;2-P
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199
   Takiar R, 2008, ASIAN PAC J CANCER P, V9, P777
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Weng LP, 1999, CANCER RES, V59, P5808
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331
   Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4
NR 40
TC 10
Z9 11
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1340-6868
EI 1880-4233
J9 BREAST CANCER-TOKYO
JI Breast Cancer
PD NOV
PY 2016
VL 23
IS 6
BP 922
EP 931
DI 10.1007/s12282-015-0665-0
PG 10
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA EB2UP
UT WOS:000387218400015
PM 26754093
DA 2025-01-12
ER

PT J
AU Zhang, F
   Ren, CY
   Zhao, HQ
   Yang, L
   Su, F
   Zhou, MM
   Han, JW
   Sobie, EA
   Walsh, MJ
AF Zhang, Fan
   Ren, Chunyan
   Zhao, Hengqiang
   Yang, Lei
   Su, Fei
   Zhou, Ming-Ming
   Han, Junwei
   Sobie, Eric A.
   Walsh, Martin J.
TI Identification of novel prognostic indicators for triple-negative breast
   cancer patients through integrative analysis of cancer genomics data and
   protein interactome data
SO ONCOTARGET
LA English
DT Article
DE triple-negative breast cancer; landmark for cancer prognosis; GTPase;
   ubiquitination; oxidative damage
ID MOLECULAR PORTRAITS; OPEN-LABEL; GENE; EXPRESSION; SELECTION; RAB6;
   COMBINATION; TMF/ARA160; PREDICTION; BIOMARKERS
AB Triple negative breast cancers (TNBCs) are highly heterogeneous and aggressive without targeted treatment. Here, we aim to systematically dissect TNBCs from a prognosis point of view by building a subnetwork atlas for TNBC prognosis through integrating multi-dimensional cancer genomics data from The Cancer Genome Atlas (TCGA) project and the interactome data from three different interaction networks. The subnetworks are represented as the protein-protein interaction modules perturbed by multiple genetic and epigenetic interacting mechanisms contributing to patient survival. Predictive power of these subnetwork-derived prognostic models is evaluated using Monte Carlo cross-validation and the concordance index (C-index). We uncover subnetwork biomarkers of low oncogenic GTPase activity, low ubiquitin/proteasome degradation, effective protection from oxidative damage, and tightly immune response are linked to better prognosis. Such a systematic approach to integrate massive amount of cancer genomics data into clinical practice for TNBC prognosis can effectively dissect the molecular mechanisms underlying TNBC patient outcomes and provide potential opportunities to optimize treatment and develop therapeutics.
C1 [Zhang, Fan; Zhao, Hengqiang; Yang, Lei; Su, Fei; Han, Junwei] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150086, Peoples R China.
   [Ren, Chunyan; Zhou, Ming-Ming; Sobie, Eric A.; Walsh, Martin J.] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA.
C3 Harbin Medical University; Icahn School of Medicine at Mount Sinai
RP Han, JW (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150086, Peoples R China.; Sobie, EA; Walsh, MJ (通讯作者)，Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA.
EM hanjunwei1981@163.com; eric.sobie@mssm.edu; martin.walsh@mssm.edu
RI Zhao, Hengqiang/HTO-8796-2023; REN, CHUNYAN/F-1880-2017; Han,
   Junwei/T-9849-2018
OI REN, CHUNYAN/0000-0002-3913-2479; Han, Junwei/0000-0002-3276-0819
FU National Natural Science Foundation of China [31401127, 31200998]
FX This research was supported by National Natural Science Foundation of
   China [31401127 to J.H. and 31200998 to F.Z].
CR Abrham G, 2009, INT J CANCER, V125, P43, DOI 10.1002/ijc.24277
   Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bianchini G., 2016, Nature reviews Clinical oncology
   Cai YF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005643
   Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Cheng L, 2016, SCI REP-UK, V6, DOI 10.1038/srep30024
   Chou KC, 2015, MED CHEM, V11, P218, DOI 10.2174/1573406411666141229162834
   Chou KC, 2011, J THEOR BIOL, V273, P236, DOI 10.1016/j.jtbi.2010.12.024
   Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772
   Das J, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-92
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Desmedt C, 2011, J CLIN ONCOL, V29, P1578, DOI 10.1200/JCO.2010.31.2231
   ERLANDSSON R, 1990, ONCOGENE, V5, P1207
   Fridmann-Sirkis Y, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-18
   Fujino T, 2000, BBA-PROTEIN STRUCT M, V1478, P102, DOI 10.1016/S0167-4838(00)00004-2
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Gonzalez-Angulo AM, 2014, ANN ONCOL, V25, P1122, DOI 10.1093/annonc/mdu124
   Hadari YR, 2000, J CELL SCI, V113, P2385
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Itoh M, 2014, BREAST CANCER RES TR, V143, P403, DOI 10.1007/s10549-013-2763-z
   Jang M, 2012, CANCER RES, V72, P4214, DOI 10.1158/0008-5472.CAN-12-1110
   Khurana E, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002886
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lal S, 2008, CANCER SCI, V99, P2045, DOI 10.1111/j.1349-7006.2008.00903.x
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168
   Liedtke C, 2015, CURR OPIN OBSTET GYN, V27, P77, DOI 10.1097/GCO.0000000000000137
   Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237
   NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X
   Opdam FJM, 2000, J CELL SCI, V113, P2725
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405
   Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570
   Sabatier R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027656
   Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep27842
   Sun J, 2014, MOL BIOSYST, V10, P2074, DOI 10.1039/c3mb70608g
   Tibshirani R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Vandin F, 2012, BIOCOMPUT-PAC SYM, P55
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Weathington NM, 2014, J CLIN INVEST, V124, P6, DOI 10.1172/JCI71602
   Yamane J, 2007, EXP CELL RES, V313, P3472, DOI 10.1016/j.yexcr.2007.07.010
   Yoo HM, 2014, MOL CELL, V56, P261, DOI 10.1016/j.molcel.2014.08.007
   Yu HY, 2011, NAT METHODS, V8, P478, DOI [10.1038/NMETH.1597, 10.1038/nmeth.1597]
   Yuan Y, 2014, NAT BIOTECHNOL, V32, P644, DOI 10.1038/nbt.2940
   Zhang F, 2016, BRIEFINGS BIOINFORMA
   Zhang M, 2015, CELL DEATH DIFFER, V22, P1922, DOI 10.1038/cdd.2015.51
   Zhou M, 2016, SCI REP-UK, V6, DOI 10.1038/srep31038
   Zhou M, 2015, MOL BIOSYST, V11, P760, DOI 10.1039/c4mb00511b
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 56
TC 12
Z9 13
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 1
PY 2016
VL 7
IS 44
BP 71620
EP 71634
DI 10.18632/oncotarget.12287
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5VQ
UT WOS:000387449100045
PM 27690302
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Xiang, TX
   Fan, YC
   Li, CH
   Li, LL
   Ying, Y
   Mu, JH
   Peng, WY
   Feng, YX
   Oberst, M
   Kelly, K
   Ren, GS
   Tao, Q
AF Xiang, Tingxiu
   Fan, Yichao
   Li, Chunhong
   Li, Lili
   Ying, Ying
   Mu, Junhao
   Peng, Weiyan
   Feng, Yixiao
   Oberst, Michael
   Kelly, Kathleen
   Ren, Guosheng
   Tao, Qian
TI DACT2 silencing by promoter CpG methylation disrupts its regulation of
   epithelial-to-mesenchymal transition and cytoskeleton reorganization in
   breast cancer cells
SO ONCOTARGET
LA English
DT Article
DE DACT2; tumor suppressor; methylation; EMT; breast cancer
ID CANDIDATE TUMOR-SUPPRESSOR; BETA-CATENIN; LUNG-CANCER;
   HEPATOCELLULAR-CARCINOMA; GENE; EXPRESSION; WNT; ANTAGONIST; DAPPER2;
   MICE
AB Wnt signaling plays an important role in breast carcinogenesis. DAPPER2 (DACT2) functions as an inhibitor of canonical Wnt signaling and plays distinct roles in different cell contexts, with its role in breast tumorigenesis unclear. We investigated DACT2 expression in breast cancer cell lines and primary tumors, as well as its functions and molecular mechanisms. Results showed that DACT2 expression was silenced in 9/9 of cell lines. Promoter CpG methylation of DACT2 was detected in 89% (8/9) of cell lines, as well as in 73% (107/147) of primary tumors, but only in 20% (1/5) of surgical margin tissues and in none of normal breast tissues. Demethylation of BT549 and T47D cell lines with 5-aza-2'-deoxycytidine restored DACT2 expression along with promoter demethylation, suggesting that its downregulation in breast cancer is dependent on promoter methylation. Furthermore, ectopic expression of DACT2 induced breast cell apoptosis in vitro, and further inhibited breast tumor cell proliferation, migration and EMT, through antagonizing Wnt/beta-catenin and Akt/GSK-3 signaling. Thus, these results demonstrate that DACT2 functions as a tumor suppressor for breast cancer but was frequently disrupted epigenetically in this cancer.
C1 [Xiang, Tingxiu; Mu, Junhao; Peng, Weiyan; Feng, Yixiao; Ren, Guosheng; Tao, Qian] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.
   [Fan, Yichao; Li, Lili; Ying, Ying; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
   [Fan, Yichao; Li, Lili; Ying, Ying; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Fan, Yichao; Li, Lili; Ying, Ying; Tao, Qian] CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
   [Li, Chunhong] Suining Sichuan Ctr Hosp, Oncol Dept, Chengdu, Sichuan, Peoples R China.
   [Oberst, Michael; Kelly, Kathleen] NCI, Signal Transduct Sect, NIH, Bethesda, MD 20892 USA.
C3 Chongqing Medical University; Chinese University of Hong Kong; Chinese
   University of Hong Kong; CUHK Shenzhen Research Institute; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Ren, GS; Tao, Q (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
EM rgs726@163.com; qtao@cuhk.edu.hk
RI Xiang, Tingxiu/E-6157-2016; Tao, Qian/T-4743-2018; Li, Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889
FU National Natural Science Foundation of China [31420103915, 81372238,
   81572327]; VC special fund from The Chinese University of Hong Kong
FX This study was supported by National Natural Science Foundation of China
   (#31420103915, #81372238, #81572327) and VC special fund from The
   Chinese University of Hong Kong.
CR Astolfi A, 2010, LAB INVEST, V90, P1285, DOI 10.1038/labinvest.2010.110
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5
   Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917
   Gao S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-57
   Hou J, 2013, CANCER PREV RES, V6, P791, DOI 10.1158/1940-6207.CAPR-12-0352
   Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Katoh M, 2003, INT J ONCOL, V22, P907
   Kettunen P, 2010, GENE EXPR PATTERNS, V10, P140, DOI 10.1016/j.gep.2010.02.002
   Kim EY, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-26
   Lee WC, 2010, AM J PHYSIOL-RENAL, V299, pF740, DOI 10.1152/ajprenal.00148.2010
   Li X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054868
   Meng FW, 2008, J CELL SCI, V121, P2904, DOI 10.1242/jcs.032417
   Najafov A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037013
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Noviello C, 1996, CLIN CANCER RES, V2, P1601
   Su Y, 2007, FASEB J, V21, P682, DOI 10.1096/fj.06-6246com
   Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520
   Xiang TX, 2013, J CELL MOL MED, V17, P1236, DOI 10.1111/jcmm.12099
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Xiang TX, 2011, CHIN J CANC
   Yang ZQ, 2010, MOL CARCINOGEN, V49, P508, DOI 10.1002/mc.20622
   Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569
NR 36
TC 25
Z9 29
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 25
PY 2016
VL 7
IS 43
BP 70924
EP 70935
DI 10.18632/oncotarget.12341
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5VI
UT WOS:000387448300139
PM 27708215
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Yu, P
   Guo, YW
   Yusufu, M
   Liu, ZM
   Wang, S
   Yin, XJ
   Peng, GL
   Wang, LQ
   Zhao, XW
   Guo, H
   Huang, T
   Liu, CP
AF Yu, Pan
   Guo, Yawen
   Yusufu, Maimaiti
   Liu, Zeming
   Wang, Shan
   Yin, Xingjie
   Peng, Gongling
   Wang, Longqiang
   Zhao, Xiangwang
   Guo, Hui
   Huang, Tao
   Liu, Chunping
TI Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter
   methylation in breast cancer cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE EZH2; methylation; RASSF2A; tumor suppressor
ID TUMOR-SUPPRESSOR GENE; GROUP PROTEIN EZH2; HISTONE METHYLATION;
   EPIGENETIC THERAPY; COLORECTAL-CANCER; DNA METHYLATION;
   HYPERMETHYLATION; METHYLTRANSFERASE; EFFECTOR; INVASION
AB EZH2, the catalytic subunit of polycomb repressor complex 2, has oncogenic properties, whereas RASSF2A, a Ras association domain family protein, has a tumor suppressor role in many types of human cancer. However, the interrelationship between these two genes remains unclear. Here, we showed that the downregulation of EZH2 reduces CpG island methylation of the RASSF2A promoter, thereby leading to increased RASSF2A expression. Our findings also showed that knockdown of EZH2 increased RASSF2A expression in the human breast cancer cell line MCF-7 in cooperation with DNMT1. This was similar to the effect of 5-Aza-CdR, a DNA methylation inhibitor that reactivates tumor suppressor genes and activated RASSF2A expression in our study. The EZH2 inhibitor DZNep markedly suppressed the proliferation, migration, and invasion of MCF-7 cells treated with ADR and TAM. EZH2 inhibits the expression of tumor suppressor gene RASSF2A via promoter hypermethylation. Thus, it plays an important role in tumorigenesis and is a potential therapeutic target for the treatment of breast cancer.
C1 [Yu, Pan; Guo, Yawen; Yusufu, Maimaiti; Liu, Zeming; Wang, Shan; Yin, Xingjie; Zhao, Xiangwang; Guo, Hui; Huang, Tao; Liu, Chunping] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan 430022, Peoples R China.
   [Peng, Gongling; Wang, Longqiang] Wuhan Cent Hosp, Dept Thyroid & Breast Surg, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Liu, CP (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan 430022, Peoples R China.
EM lcp191@163.com
RI Wang, Liang-Jen/AAR-1089-2020
OI Liu, Zeming/0000-0001-6132-4701
FU National Natural Science Foundation of China [81550009]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant number: 81550009).
CR Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051
   Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496
   Gordon Marilyn, 2011, Small GTPases, V2, P148
   Guerrero-Setas D, 2013, MODERN PATHOL, V26, P1111, DOI 10.1038/modpathol.2013.32
   Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Liao XY, 2008, INT J CANCER, V123, P296, DOI 10.1002/ijc.23494
   Mezzanotte JJ, 2014, EPIGENETICS-US, V9, P1496, DOI 10.4161/15592294.2014.983361
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Momparler RL, 2015, EXPERT OPIN INV DRUG, V24, P1031, DOI 10.1517/13543784.2015.1051220
   Momparler RL, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-19
   Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051
   Natsume A, 2013, CANCER RES, V73, P4559, DOI 10.1158/0008-5472.CAN-13-0109
   Ning XH, 2015, CANCER LETT, V359, P198, DOI 10.1016/j.canlet.2015.01.005
   Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540
   Park HW, 2007, INT J CANCER, V120, P7, DOI 10.1002/ijc.22276
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Richter AM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00021
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Unland R, 2015, ANTI-CANCER DRUG, V26, P301, DOI 10.1097/CAD.0000000000000181
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Völkel P, 2007, BIOCHIMIE, V89, P1, DOI 10.1016/j.biochi.2006.07.009
   Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200
   Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081
   Xiao X, 2014, TUMOR BIOL, V35, P3755, DOI 10.1007/s13277-013-1497-1
   Yan HC, 2013, ONCOL LETT, V6, P845, DOI 10.3892/ol.2013.1438
   Ye XN, 2016, LEUKEMIA LYMPHOMA, V57, P1311, DOI 10.3109/10428194.2015.1091931
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 34
TC 8
Z9 12
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD OCT
PY 2016
VL 40
IS 10
BP 1062
EP 1070
DI 10.1002/cbin.10646
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EB4GD
UT WOS:000387327500005
PM 27436059
OA hybrid
DA 2025-01-12
ER

PT J
AU Yao, ZX
   Sherif, ZA
AF Yao, Zhixing
   Sherif, Zaki A.
TI The effect of epigenetic silencing and TP53 mutation on the expression
   of DLL4 in human cancer stem disorder
SO ONCOTARGET
LA English
DT Article
DE p53; DLL4; Notch; epigenetics; angiogenesis
ID NOTCH SIGNALING PATHWAY; LIGAND 4 DLL4; BREAST-CANCER; TUMOR-GROWTH;
   CELL FATE; VEGF; ANGIOGENESIS; P53; DEACETYLASE; METASTASIS
AB The Li-Fraumeni Syndrome (LFS), a genetically rare heterogeneous cancer syndrome, is characterized primarily by a germline p53 (TP53) gene mutation. We recently discovered a balanced reciprocal chromosomal translocation t(11; 15) (q23;q15) in the non-cancerous skin fibroblasts of a bilateral breast cancer patient in LFS family. This prompted us to investigate the breakpoint region of the translocation, which uncovered a gene that encodes a Notch ligand, DLL4, (locus at 15q15.1), a key target in tumor vasculature. We analyzed DLL4 gene expression and protein level in LFS non-cancerous skin fibroblast cell lines and non-LFS cancer cell lines. DLL4 is abrogated in all the LFS cells and drastically down-regulated in breast (MCF7) and brain (IMR32) cancer cells and tumor tissue samples. However, DNA methylation studies revealed that DLL4 promoter is silenced only in MCF7 but not in LFS cells. We further investigated the regulation of DLL4 gene expression by ChIP assays, which demonstrated that p53 binds to DLL4 promoter through its association with CTCF, a chromosomal networking protein CCCTC binding factor. This implies a possible karyotype-phenotype correlation with respect to DLL4 in LFS and breast cancer initiation and progression. The drastic reduction or absence in the expression of DLL4 in LFS as well as breast and brain cancer cells is significant and supports the concept that this ligand may also play a role in cancer immune-surveillance; and its resuscitation in the tumor microenvironment may stimulate T-cell immunity and suppress tumor growth. Therefore, DLL4 may provide a strong platform as an immuno-therapeutic target in LFS and cancer patients.
C1 [Yao, Zhixing; Sherif, Zaki A.] Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA.
C3 Howard University
RP Sherif, ZA (通讯作者)，Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA.
EM zaki.sherif@howard.edu
RI Sherif, Zaki/AAC-9991-2019
FU National Cancer Institute; National Institutes of Health
   [1U01CA185188-01A1]; National Institute on Minority Health and Health
   Disparities of the National Institutes of Health [U54MD008149,
   G12MD007597]; Howard University Bridge Fund Pilot Study (BFPSP)
FX We would like to acknowledge research support from the National Cancer
   Institute and National Institutes of Health under award number
   1U01CA185188-01A1. This research was also supported, in part, by the
   National Institute on Minority Health and Health Disparities of the
   National Institutes of Health under award number U54MD008149. A partial
   support was also provided by Howard University Bridge Fund Pilot Study
   (BFPSP). This project was also supported (in part) by the National
   Institute on Minority Health and Health Disparities of the National
   Institutes of Health under Award Number G12MD007597. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Cancer Institute or the
   National Institutes of Health.
CR [Anonymous], 2011, GENES CANC
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Canalis E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0200-y
   Cognat E, 2014, STROKE, V45, P842, DOI 10.1161/STROKEAHA.113.003339
   Dziewulska D, 2008, J CLIN NEUROSCI, V15, P535, DOI 10.1016/j.jocn.2007.06.022
   El Kaffas A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093888
   Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260
   Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010
   Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940
   Grego-Bessa J, 2004, CELL CYCLE, V3, P718
   Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917
   He H, 2011, CHINESE MED J-PEKING, V124, P118, DOI 10.3760/cma.j.issn.0366-6999.2011.01.022
   Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978-1-4614-0899-4_14
   Huang YH, 2011, CANCER RES, V71, P6122, DOI 10.1158/0008-5472.CAN-10-4366
   Jakobsson L, 2009, BIOCHEM SOC T, V37, P1233, DOI 10.1042/BST0371233
   Jin Y, 2014, BIOCHEM SOC T, V42, P1576, DOI 10.1042/BST20140231
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jubb AM, 2009, BRIT J CANCER, V101, P1749, DOI 10.1038/sj.bjc.6605368
   Kangsamaksin T, 2015, CANCER DISCOV, V5, P182, DOI 10.1158/2159-8290.CD-14-0650
   Kelleher FC, 2006, ACTA ONCOL, V45, P375, DOI 10.1080/02841860600602946
   Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Kulic I, 2015, J EXP MED, V212, P37, DOI 10.1084/jem.20121192
   Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074
   Liu SX, 2015, HIPPOCAMPUS, V25, P670, DOI 10.1002/hipo.22402
   Maillard I, 2005, ANNU REV IMMUNOL, V23, P945, DOI 10.1146/annurev.immunol.23.021704.115747
   Masciari S, 2012, BREAST CANCER RES TR, V133, P1125, DOI 10.1007/s10549-012-1993-9
   Merkenschlager M, 2013, CELL, V152, P1285, DOI 10.1016/j.cell.2013.02.029
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Qiu XX, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000057
   Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004
   Schneider BP, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2250
   Sherif Z., 2015, ADV TECHNIQUES BIOL, V2015, P1
   Sherif ZA, 2006, CANCER GENET CYTOGEN, V168, P50, DOI 10.1016/j.cancergencyto.2005.12.009
   Shutter JR, 2000, GENE DEV, V14, P1313
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Tada M, 2012, FEBS J, V279, P2096, DOI 10.1111/j.1742-4658.2012.08595.x
   van den Akker NMS, 2012, DIFFERENTIATION, V84, DOI 10.1016/j.diff.2012.04.002
   Wang HC, 2014, CLIN CHIM ACTA, V436, P243, DOI 10.1016/j.cca.2014.06.005
   Xiao M, 2014, HUM PATHOL, V45, P2302, DOI 10.1016/j.humpath.2014.04.025
   Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751
   Zanotti S, 2013, EUR J ENDOCRINOL, V168, pR95, DOI 10.1530/EJE-13-0115
NR 46
TC 8
Z9 8
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 27
PY 2016
VL 7
IS 39
BP 62976
EP 62988
DI 10.18632/oncotarget.11316
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2DN
UT WOS:000387167800014
PM 27542210
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Llorca-Cardeñosa, MJ
   Fleitas, T
   Ibarrola-Villava, M
   Peña-Chilet, M
   Mongort, C
   Martinez-Ciarpaglini, C
   Navarro, L
   Gambardella, V
   Castillo, J
   Roselló, S
   Navarro, S
   Ribas, G
   Cervantes, A
AF Jessica Llorca-Cardenosa, Marta
   Fleitas, Tania
   Ibarrola-Villava, Maider
   Pena-Chilet, Maria
   Mongort, Cristina
   Martinez-Ciarpaglini, Carolina
   Navarro, Lara
   Gambardella, Valentina
   Castillo, Josefa
   Rosello, Susana
   Navarro, Samuel
   Ribas, Gloria
   Cervantes, Andres
TI Epigenetic changes in localized gastric cancer: the role of RUNX3 in
   tumor progression and the immune microenvironment
SO ONCOTARGET
LA English
DT Article
DE RUNX3; ARID1A; gastric cancer; gene methylation; immune microenvironment
ID REMODELING GENE ARID1A; BREAST-CANCER; METHYLATION; EXPRESSION;
   INFECTION
AB Gastric cancer (GC) pathogenesis involves genetic, epigenetic and environmental factors. Epigenetic alterations, such as DNA methylation are considered pivotal in the inactivation of tumor-related genes. We assessed a methylation panel of 5 genes to study their association to GC progression and microsatellite instability (MSI), and studied the role of RUNX3 in GC pathogenesis and the tumor immune microenvironment.
   The methylation status of 47 promoter-CpG islands was studied through MALDI-TOF mass spectrometry analysis in 35 Microsatellite stable (MSS) GC, 26 MSI, and 18 cancer-free samples (CFS), and 6 MSS GC and 4 MSI GC cell lines. We also studied RUNX3 expression by immunohistochemistry (IHC) in 40 samples, and validated differences in methylation levels between tumor, normal, and immune tissue in 14 additional samples.
   Unsupervised hierarchical clustering of methylation levels revealed no distinct subgroups between MSI and MSS samples or cell lines. CFSs clustered together showing higher levels of RUNX3 methylation compared to GC samples. RUNX3 showed protein silencing in cancer and normal mucosa, compared to inflammatory peritumoural infiltrate in almost all cases, showing a non-lymphocytic predominant pattern and being correlated with epigenetic silencing.
   Our results show aberrant promoter's methylation in APC, CDH1, CDKN2A, MLH1 and RUNX3 associated with GC, as well as a non-lymphocytic predominant infiltrate with high expression of RUNX3. Deep study of RUNX3 inflammation signaling could help in understanding inflammation and immune activation in the tumor microenvironment.
C1 [Jessica Llorca-Cardenosa, Marta; Fleitas, Tania; Ibarrola-Villava, Maider; Pena-Chilet, Maria; Gambardella, Valentina; Castillo, Josefa; Rosello, Susana; Ribas, Gloria; Cervantes, Andres] Univ Valencia, Biomed Res Inst INCLIVA, Med Oncol, Valencia, Spain.
   [Mongort, Cristina; Martinez-Ciarpaglini, Carolina; Navarro, Lara; Navarro, Samuel] Univ Valencia, Biomed Res Inst INCLIVA, Dept Pathol, Valencia, Spain.
C3 University of Valencia; University of Valencia
RP Ribas, G; Cervantes, A (通讯作者)，Univ Valencia, Biomed Res Inst INCLIVA, Med Oncol, Valencia, Spain.
EM gribas@incliva.es; andres.cervantes@uv.es
RI Navarro, Samuel/AAD-2021-2020; Navarro, Lara/AAJ-5884-2020;
   Ribas-Despuig, Gloria/M-6190-2017; Pena-Chilet, Maria/A-8387-2015;
   Rosello Keranen, Susana/E-7734-2015; Ribas, Gloria/K-3379-2013;
   Cervantes, Andres/J-8713-2013
OI Martinez Ciarpaglini, Carolina/0000-0002-8797-2114; Pena-Chilet,
   Maria/0000-0002-6445-9617; Castillo Aliaga, Josefa/0000-0002-4092-0085;
   Gambardella, Valentina/0000-0001-6081-8830; Mongort,
   Cristina/0009-0009-7921-7862; Fleitas-Kanonnikoff,
   Tania/0000-0002-2789-9082; Rosello Keranen, Susana/0000-0003-3915-4130;
   Bowcock, Anne/0000-0001-8691-9090; Ribas, Gloria/0000-0001-6883-4130;
   Cervantes, Andres/0000-0003-3806-3691; Ibarrola-Villava,
   Maider/0000-0003-0946-8075
FU Generalitat Valenciana [2015/005, Prometeo/2013/005]; Ministerio de
   Salud Carlos III [PI13/00606, PI12/02767, CM13/00193, CD15/00153,
   CPII14-00013]; FEDER; European Society of Medical Oncology (ESMO
   translational research fellowship)
FX This study was supported by grants from the Generalitat Valenciana
   (Prometeo 2015/005), Ministerio de Salud Carlos III (PI13/00606 and
   PI12/02767), and FEDER. TF is funded by a Rio Hortega grant
   (CM13/00193), MI-V is funded on a Sara Borrell contract (CD15/00153),
   and GR is funded on a Miquel Servet II contract (CPII14-00013) all from
   the Ministerio de Salud Carlos III; MJL-C is funded on a Prometeo
   contract (Prometeo/2013/005) from the Generalitat Valenciana; VG is
   funded by a translational research stay grant from the European Society
   of Medical Oncology (ESMO translational research fellowship 2014).
CR Bang YJ, 2010, LANCET, V376, P1302
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Cervantes A, 2013, CANC TREAT REV
   Chang MS, 2006, CLIN CANCER RES, V12, P2995, DOI 10.1158/1078-0432.CCR-05-1601
   Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Cristescu R, 2015, NAT MED
   Fallone CA, 1997, HELICOBACTER
   Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92
   Gajewski TF, 2013, INNATE ADAPTIVE IMMU, V14
   Ibarrola-Villava M, 2015, ONCOTARGET, V6, P26935, DOI 10.18632/oncotarget.4775
   Inada R, 2015, WORLD J GASTROENTERO, V21, P2159, DOI 10.3748/wjg.v21.i7.2159
   Jo P, CPG ISLAND METHYLATO, P564
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Kurklu B, 2015, ONCOGENE, V34, P2856, DOI 10.1038/onc.2014.233
   Lee KH, 2013, FREQUENT PROMOTER ME, V3774, P3765
   Liu J-B, 2012, WORLD J GASTROENTERO
   Loh M, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-55
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
   Lotem J, 2015, RUNX3 INTERFACE IMMU
   Niccolai E, 2015, WORLD J GASTROENTERO, V21, P5778, DOI 10.3748/wjg.v21.i19.5778
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Sciences M, 1999, CPG ISLAND METHYLATO, V96, P8681
   Shigeyasu K, 2015, CANCER, P1
   Sun SHDHY, 2011, PATHOBIOLOGIC IMPLIC, P447
   Toyota M, 1999, ADV BRIEF ABERRANT M, P5438
   Virchow R, 1881, Br Med J, V2, P198
   Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170
   Wang DD, 2012, PLOS ONE
   Wang K, 2011, NAT GENET
   Wu RC, 2014, CANCER BIOL THER, V15, P655, DOI 10.4161/cbt.28411
   Yagi K, 2010, COLORECTAL CANC, P21
   Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398
   Yao DM, 2012, CLIN CHIM ACTA, V413, P787, DOI 10.1016/j.cca.2012.01.013
   Zhang YW, 2013, WORLD J GASTROENTERO, V19, P1778, DOI 10.3748/wjg.v19.i11.1778
   Zhao C, 2012, PROMOTER METHYLATION, P1271
   Zong L, 2014, PLOS ONE
NR 39
TC 11
Z9 12
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 27
PY 2016
VL 7
IS 39
BP 63424
EP 63436
DI 10.18632/oncotarget.11520
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2DN
UT WOS:000387167800047
PM 27566570
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Deng, JY
   Zhang, JH
   Wang, CY
   Wei, Q
   Zhou, DZ
   Zhao, KL
AF Deng Jiaying
   Zhang Junhua
   Wang Chunyu
   Wei Qing
   Zhou Daizhan
   Zhao Kuaile
TI Methylation and expression of PTPN22 in esophageal squamous cell
   carcinoma
SO ONCOTARGET
LA English
DT Article
DE PTPN22; ESCC; methylation; expression; prognosis
ID NEGATIVE BREAST-CANCER; PROMOTER METHYLATION; DNA METHYLATION; ABERRANT
   METHYLATION; METASTASIS; GENE; EPIGENETICS; PROGRESSION; LANDSCAPE;
   PROGNOSIS
AB Esophageal squamous cell carcinoma (ESCC) is a fatal disease contributed by both genetic and epigenetic factors. The epigenetic alteration of protein tyrosine phosphatase non-receptor type 22 (PTPN22) and its clinical significance in ESCC were still not yet clarified. A quantitative methylation study of PTPN22 and its expression were conducted in 121 and 31 paired tumor and adjacent normal tissue (ANT), respectively. Moreover, the association between PTPN22 methylation and clinicopathological parameters was evaluated. We found that the methylation level of PTPN22 was significantly elevated in tumor tissues (66.3%) relative to ANT (62.1%) (p=0.005). The methylation level of non-smoking ANT (59.1%) was significant lower than smoking ESCC tissue (65.8%) (p=0.03); similarly, the methylation levels in ANT with no lymph node invasion (57.6%) were significant lower than tumor tissues with lymph node invasion (67.5%) (p=0.001). PTPN22 expression in ESCC was lower than normal tissues, however the difference was not statistically significant (p=0.55). Lower expression was more frequently occurred in N1-3 and III stage patients, while higher expression was more likely to occur in N-0 and I-II stage patients. Lower expression of PTPN22 was associated with poor overall survival (p=0.04). Taken together, PTPN22 was hypermethylationed in ESCC. Hypermethylation was associated with lymph node invasion. The PTPN22 expression may act as a prognostic biomarker to identify patients at risk of high grade.
C1 [Deng Jiaying; Zhang Junhua; Wang Chunyu; Zhao Kuaile] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China.
   [Deng Jiaying; Zhang Junhua; Wang Chunyu; Zhao Kuaile] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Wei Qing] Tongji Univ, Peoples Hosp 10, Dept Pathol, Shanghai 200072, Peoples R China.
   [Zhou Daizhan] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Ctr, Shanghai 200030, Peoples R China.
C3 Fudan University; Fudan University; Tongji University; Shanghai Jiao
   Tong University
RP Zhao, KL (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China.; Zhao, KL (通讯作者)，Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Zhou, DZ (通讯作者)，Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Ctr, Shanghai 200030, Peoples R China.
EM zhoudaizhan@163.com; kuaile_z@sina.com
RI Wei, Qing/G-5523-2014; Wang, Chunyu/HPC-0200-2023; Zhang,
   Junhua/V-2129-2018; Zhou, Dingzi/HZI-7813-2023
FU National Natural Science Foundation of China Research [21172043];
   National Natural Science Foundation of China (Beijing, PR China)
   [31200954]; China Postdoctoral Science Foundation (Beijing, PR China)
   [2012M510110, 2013T60440]
FX This study was financially supported by the National Natural Science
   Foundation of China Research (grant number 21172043), the National
   Natural Science Foundation of China (31200954 Beijing, PR China) and the
   China Postdoctoral Science Foundation Funded Project (2012M510110,
   2013T60440 Beijing, PR China).
CR Beleford D, 2010, CLIN CANCER RES, V16, P398, DOI 10.1158/1078-0432.CCR-09-1677
   Castelo-Branco P, 2013, LANCET ONCOL, V14, P534, DOI 10.1016/S1470-2045(13)70110-4
   Dai W, 2011, CLIN CANCER RES, V17, P4052, DOI 10.1158/1078-0432.CCR-10-3021
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dong ZM, 2012, AM J MED SCI, V343, P375, DOI 10.1097/MAJ.0b013e3182253430
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076
   Guo W, 2014, CANCER-AM CANCER SOC, V120, P2412, DOI 10.1002/cncr.28764
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hu CY, 2014, CLIN CANCER RES, V20, P4349, DOI 10.1158/1078-0432.CCR-14-0494
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [DOI 10.3322/caac.20115, DOI 10.3322/CAAC.21492, DOI 10.3322/CANJCLIN.49.1.33]
   Jia Y, 2012, EPIGENOMICS-UK, V4, P135, DOI [10.2217/EPI.12.11, 10.2217/epi.12.11]
   Jiang HL, 2016, CANCER RES, V76, P952, DOI 10.1158/0008-5472.CAN-15-1630
   Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877
   Kalari S, 2013, ONCOGENE, V32, P3559, DOI 10.1038/onc.2012.362
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Kumari A, 2009, ANN SURG ONCOL, V16, P1051, DOI 10.1245/s10434-009-0333-8
   Lee HS, 2015, ONCOL LETT, V9, P1691, DOI 10.3892/ol.2015.2917
   Lewandowska J, 2011, MUTAGENESIS, V26, P475, DOI 10.1093/mutage/ger019
   Li RN, 2014, J SURG ONCOL, V109, P623, DOI 10.1002/jso.23522
   Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935
   Luo ZG, 2014, J INT MED RES, V42, P35, DOI 10.1177/0300060513504705
   Negro R, 2012, BLOOD, V119, P6278, DOI 10.1182/blood-2012-01-403162
   Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279
   Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang JD, 2013, DIS ESOPHAGUS, V26, P737, DOI 10.1111/dote.12021
   Wu YX, 2016, ONCOTARGETS THER, V9, P279, DOI 10.2147/OTT.S97899
   Yang JY, 2011, LUNG CANCER, V74, P305, DOI 10.1016/j.lungcan.2011.03.002
   Zhang J, 2015, ONCOGENE, V34, P3283, DOI 10.1038/onc.2014.259
NR 30
TC 6
Z9 6
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 27
PY 2016
VL 7
IS 39
BP 64043
EP 64052
DI 10.18632/oncotarget.11581
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2DN
UT WOS:000387167800097
PM 27613842
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Pan, MR
   Hsu, MC
   Luo, CW
   Chen, LT
   Shan, YS
   Hung, WC
AF Pan, Mei-Ren
   Hsu, Ming-Chuan
   Luo, Chi-Wen
   Chen, Li-Tzong
   Shan, Yan-Shen
   Hung, Wen-Chun
TI The histone methyltransferase G9a as a therapeutic target to override
   gemcitabine resistance in pancreatic cancer
SO ONCOTARGET
LA English
DT Article
DE lysine demethylase; drug resistance; interleukin-8; pancreatic stellate
   cell
ID EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; BREAST-CANCER; RIBONUCLEOTIDE
   REDUCTASE; INTERLEUKIN-8 EXPRESSION; ADENOCARCINOMA CELLS; EPIGENETIC
   DRUGS; TRANSCRIPTION; METHYLATION; METASTASIS; REPRESSION
AB Gemcitabine (GEM) resistance is a critical issue for pancreatic cancer treatment. The involvement of epigenetic modification in GEM resistance is still unclear. We established a GEM-resistant subline PANC-1-R from the parental PANC-1 pancreatic cancer cells and found the elevation of various chromatin-modifying enzymes including G9a in GEM-resistant cells. Ectopic expression of G9a in PANC-1 cells increased GEM resistance while inactivation of G9a in PANC-1-R cells reduced it. Challenge of PANC-1 cells with GEM increased the expression of sternness markers including CD133, nestin and Lgr5 and promoted sphere forming activity suggesting chemotherapy enriched cancer cells with stem-like properties. Inhibition of G9a in PANC-1-R cells reduced sternness and invasiveness and sensitized the cells to GEM. We revealed interleukin-8 (IL-8) is a downstream effector of G9a to increase GEM resistance. G9a-overexpressing PANC-1-R cells exhibited autocrine IL-8/CXCR1/2 stimulation to increase GEM resistance which could be decreased by anti-IL-8 antibody and G9a inhibitor. IL-8 released by cancer cells also activated pancreatic stellate cell (PSC) to increase GEM resistance. In orthotopic animal model, GEM could not suppress tumor growth of PANC-1-R cells and eventually promoted tumor metastasis. Combination with G9a inhibitor and GEM reduced tumor growth, metastasis, IL-8 expression and PSC activation in animals. Finally, we showed that overexpression of G9a correlated with poor survival and early recurrence in pancreatic cancer patients. Collectively, our results suggest G9a is a therapeutic target to override GEM resistance in the treatment of pancreatic cancer.
C1 [Pan, Mei-Ren] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.
   [Pan, Mei-Ren] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan.
   [Hsu, Ming-Chuan; Chen, Li-Tzong; Hung, Wen-Chun] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan.
   [Luo, Chi-Wen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol, Kaohsiung 807, Taiwan.
   [Chen, Li-Tzong] Natl Cheng Kung Univ Hosp, Div Hematol Oncol, Dept Internal Med, Tainan 704, Taiwan.
   [Shan, Yan-Shen] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 704, Taiwan.
   [Shan, Yan-Shen] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 704, Taiwan.
   [Hung, Wen-Chun] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 704, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; National
   Health Research Institutes - Taiwan; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital; National Cheng Kung University;
   National Cheng Kung University Hospital; National Cheng Kung University;
   National Cheng Kung University; National Cheng Kung University Hospital;
   National Cheng Kung University
RP Hung, WC (通讯作者)，Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan.; Hung, WC (通讯作者)，Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 704, Taiwan.
EM hung1228@nhri.org.tw
RI Hsu, MC/AAE-5310-2020; Luo, Chi-Wen/V-4112-2019; Hung,
   Wen-Chun/F-4846-2011
OI Luo, Chi-Wen/0000-0001-6852-575X
FU Ministry of Science and Technology of Republic of China
   [102-2320-B-037-035, 103-2314-B-037 -075, 103-2321-B-400 -021];
   Kaohsiung Medical University Research Foundation [KMU-Q103003]
FX We thank Dr. Jieh-Yuan Liou for providing PANC-1-R cell line and Ms.
   Wen-Yu Pan for establishing the Miapaca-2-R cell line. This study was
   supported by the grant 102-2320-B-037-035, 103-2314-B-037 -075,
   103-2321-B-400 -021 from Ministry of Science and Technology of Republic
   of China and KMU-Q103003 from the Kaohsiung Medical University Research
   Foundation. Taiwan Ministry of Health and Welfare
   (MOHW105-TDU-B-212-134005) and Health and welfare surcharge of tobacco
   products.
CR Ammerpohl O, 2007, BRIT J CANCER, V96, P73, DOI 10.1038/sj.bjc.6603511
   Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X
   Bernhard W, 2011, FEBS LETT, V585, P3549, DOI 10.1016/j.febslet.2011.10.018
   Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Chang CC, 2015, CANCER RES, V75, P2375, DOI 10.1158/0008-5472.CAN-14-3076
   Chen LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05911
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Gallipoli P, 2015, THER ADV HEMATOL, V6, P103, DOI 10.1177/2040620715577614
   Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203
   Goan YG, 1999, CANCER RES, V59, P4204
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189
   Jiao F, 2014, INT J ONCOL, V45, P1523, DOI 10.3892/ijo.2014.2568
   Lai YS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.37
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159
   Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023
   Mani E, 2014, EUR J GYNAECOL ONCOL, V35, P140
   Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639
   Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018
   Moore PS, 2004, BBA-MOL CELL RES, V1693, P167, DOI 10.1016/j.bbamcr.2004.07.001
   Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390
   Nakano Y, 2007, BRIT J CANCER, V96, P457, DOI 10.1038/sj.bjc.6603559
   Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267
   Ohhashi S, 2008, ANTICANCER RES, V28, P2205
   Pan MR, 2008, J BIOL CHEM, V283, P11155, DOI 10.1074/jbc.M710038200
   Pan MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18709
   Pan MR, 2001, FEBS LETT, V508, P365, DOI 10.1016/S0014-5793(01)03118-0
   Qin L, 2014, MOL PHARMACOL, V86, P561, DOI 10.1124/mol.114.092544
   Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528
   Shi Q, 2000, J INTERF CYTOK RES, V20, P1023, DOI 10.1089/10799900050198471
   Shi Q, 1999, CLIN CANCER RES, V5, P3711
   Shinde R, 2015, J IMMUNOL, V195, P2374, DOI 10.4049/jimmunol.1402854
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Sidler C, 2014, AGING-US, V6, P564, DOI 10.18632/aging.100679
   Spratlin J, 2004, CLIN CANCER RES, V10, P6956, DOI 10.1158/1078-0432.CCR-04-0224
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Tan AC, 2009, MOL ONCOL, V3, P425, DOI 10.1016/j.molonc.2009.03.004
   Tao H, 2014, MOL CELL BIOCHEM, V394, P23, DOI 10.1007/s11010-014-2077-4
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
NR 42
TC 43
Z9 46
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 20
PY 2016
VL 7
IS 38
BP 61136
EP 61151
DI 10.18632/oncotarget.11256
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2CN
UT WOS:000387164700026
PM 27531902
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Hassan, HE
   Keita, JA
   Narayan, L
   Brady, SM
   Frederick, R
   Carlson, S
   Glass, KC
   Natesan, S
   Buttolph, T
   Fandy, TE
AF Hassan, Hazem E.
   Keita, Jean-Arnaud
   Narayan, Lawrence
   Brady, Sean M.
   Frederick, Richard
   Carlson, Samuel
   Glass, Karen C.
   Natesan, Senthil
   Buttolph, Thomm
   Fandy, Tamer E.
TI The combination of dimethoxycurcumin with DNA methylation inhibitor
   enhances gene re-expression of promoter-methylated genes and antagonizes
   their cytotoxic effect
SO EPIGENETICS
LA English
DT Article
DE Dimethoxycurcumin; DNA methylation; decitabine; DNA pyrosequencing;
   histone acetylation; histone methylation; leukemia
ID BREAST-CANCER CELLS; HISTONE DEACETYLASES; EPIGENETIC CHANGES; CURCUMIN
   ANALOG; LEUKEMIA-CELLS; EXPRESSION; THERAPY; CHROMATIN; PROTEIN;
   DEMETHYLATION
AB Curcumin and its analogs exhibited antileukemic activity either as single agent or in combination therapy. Dimethoxycurcumin (DMC) is a more metabolically stable curcumin analog that was shown to induce the expression of promoter-methylated genes without reversing DNA methylation. Accordingly, co-treatment with DMC and DNA methyltransferase (DNMT) inhibitors could hypothetically enhance the re-expression of promoter-methylated tumor suppressor genes. In this study, we investigated the cytotoxic effects and epigenetic changes associated with the combination of DMC and the DNMT inhibitor decitabine (DAC) in primary leukemia samples and cell lines. The combination demonstrated antagonistic cytotoxic effects and was minimally cytotoxic to primary leukemia cells. The combination did not affect the metabolic stability of DMC. Although the combination enhanced the downregulation of nuclear DNMT proteins, the hypomethylating activity of the combination was not increased significantly compared to DAC alone. On the other hand, the combination significantly increased H3K27 acetylation (H3K27Ac) compared to the single agents near the promoter region of promoter-methylated genes. Furthermore, sequential chromatin immunoprecipitation (ChIP) and DNA pyrosequencing of the chromatin-enriched H3K27Ac did not show any significant decrease in DNA methylation compared to other regions. Consequently, the enhanced induction of promoter-methylated genes by the combination compared to DAC alone is mediated by a mechanism that involves increased histone acetylation and not through potentiation of the DNA hypomethylating activity of DAC. Collectively, our results provide the mechanistic basis for further characterization of this combination in leukemia animal models and early phase clinical trials.
C1 [Hassan, Hazem E.] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Hassan, Hazem E.] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt.
   [Keita, Jean-Arnaud; Narayan, Lawrence; Brady, Sean M.; Frederick, Richard; Carlson, Samuel; Glass, Karen C.; Fandy, Tamer E.] Albany Coll Pharm Vermont Campus, Dept Pharmaceut Sci, Colchester, VT USA.
   [Natesan, Senthil] Washington State Univ, Dept Expt & Syst Pharmacol, Spokane, WA USA.
   [Buttolph, Thomm] Univ Vermont, Dept Neurol Sci, Burlington, VT USA.
C3 University System of Maryland; University of Maryland Baltimore;
   Egyptian Knowledge Bank (EKB); Helwan University; Washington State
   University; University of Vermont
RP Fandy, TE (通讯作者)，Albany Coll Pharm, 261 Mt View Dr, Colchester, VT 05446 USA.
EM tamer.fandy@acphs.edu
RI Glass, Karen/AAV-1076-2021; Natesan, Senthil/E-5354-2011
OI Natesan, Senthil/0000-0001-5347-6940; Carlson,
   Samuel/0000-0001-9881-4210; Glass, Karen/0000-0002-2761-733X
FU Scholarship of Discovery Intramural Research Grant Program (SDIRGP) from
   Albany College of Pharmacy; University of Maryland intramural research
   grant; NIH from the COBRE Program of the National Center for Research
   Resources [5 P30 RR032135]; NIH from the National Institute of General
   Medical Sciences [8 P30 GM 103498]
FX This work was supported by the Scholarship of Discovery Intramural
   Research Grant Program (SDIRGP) from Albany College of Pharmacy to TEF
   and University of Maryland intramural research grant to HH. The work was
   also supported by NIH Grant Numbers 5 P30 RR032135 from the COBRE
   Program of the National Center for Research Resources and 8 P30 GM
   103498 from the National Institute of General Medical Sciences. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of NIH.
CR Aggarwal BB, 2013, MOL NUTR FOOD RES, V57, P1529, DOI 10.1002/mnfr.201200838
   Al-Ali HK, 2014, J GERIATR ONCOL, V5, P89, DOI 10.1016/j.jgo.2013.08.004
   [Anonymous], 2013, BRIT J PHARMACOL, DOI DOI 10.1111/BPH.12131
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Chen CQ, 2013, CARCINOGENESIS, V34, P1442, DOI 10.1093/carcin/bgt070
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Dubovsky JA, 2007, PROSTATE, V67, P1781, DOI 10.1002/pros.20665
   Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547
   Fandy TE, 2009, CURR MED CHEM, V16, P2075, DOI 10.2174/092986709788612738
   Fu N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000216
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Hassan HE, 2015, PHARM RES-DORDR, V32, P863, DOI 10.1007/s11095-014-1502-4
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kihslinger JE, 2007, LEUKEMIA LYMPHOMA, V48, P1676, DOI 10.1080/10428190701493910
   Kotecha R, 2016, ONCOTARGET, V7, P52517, DOI 10.18632/oncotarget.9593
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Parashar G, 2016, CLIN EXP MED, V16, P471, DOI 10.1007/s10238-015-0366-1
   Pesakhov S, 2016, ONCOTARGET, V7, P31847, DOI 10.18632/oncotarget.7240
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Qin T, 2007, CLIN CANCER RES, V13, P4225, DOI 10.1158/1078-0432.CCR-06-2762
   Quintás-Cardama A, 2010, NAT REV CLIN ONCOL, V7, P433, DOI 10.1038/nrclinonc.2010.87
   Raynal NJM, 2012, CANCER RES, V72, P1170, DOI 10.1158/0008-5472.CAN-11-3248
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Schermelleh L, 2005, NAT METHODS, V2, P751, DOI 10.1038/NMETH794
   Shu LM, 2011, AAPS J, V13, P606, DOI 10.1208/s12248-011-9300-y
   Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7
   Tamvakopoulos C, 2007, CLIN CANCER RES, V13, P1269, DOI 10.1158/1078-0432.CCR-06-1839
   Taverna S, 2015, ONCOTARGET, V6, P21918, DOI 10.18632/oncotarget.4204
   Tie F, 2009, DEVELOPMENT, V136, P3131, DOI 10.1242/dev.037127
   Tsimberidou AM, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0065-5
   Vendetti FP, 2013, EXPERT OPIN BIOL TH, V13, P1273, DOI 10.1517/14712598.2013.819337
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   WEBER J, 1994, CANCER RES, V54, P1766
   Weng QY, 2016, TUMOR BIOL, V37, P9959, DOI 10.1007/s13277-016-4861-0
   Wu LX, 2015, CLIN CANCER RES, V21, P833, DOI 10.1158/1078-0432.CCR-13-3317
   Yang XW, 2000, CANCER RES, V60, P6890
   Yu JH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055934, 10.1371/journal.pone.0057564]
   Zhang TY, 2015, EMBO REP, V16, P1467, DOI 10.15252/embr.201540945
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 45
TC 12
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2016
VL 11
IS 10
BP 740
EP 749
DI 10.1080/15592294.2016.1226452
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EB3UM
UT WOS:000387293900004
PM 27588609
OA Green Published, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Montenegro, MF
   Sánchez-del-Campo, L
   González-Guerrero, R
   Martínez-Barba, E
   Piñero-Madrona, A
   Cabezas-Herrera, J
   Rodríguez-López, JN
AF Montenegro, M. F.
   Sanchez-del-Campo, L.
   Gonzalez-Guerrero, R.
   Martinez-Barba, E.
   Pinero-Madrona, A.
   Cabezas-Herrera, J.
   Rodriguez-Lopez, J. N.
TI Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer
   cells and serves as an early-stage biomarker for predicting metastasis
SO ONCOGENE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LYSINE METHYLATION;
   ESTROGEN-RECEPTOR; DNA METHYLATION; E2F1; METHYLTRANSFERASE; EXPRESSION;
   LSD1; REPRESSION
AB During the course of cancer progression, neoplastic cells undergo dynamic and reversible transitions between multiple phenotypic states, and this plasticity is enabled by underlying shifts in epigenetic regulation. Our results identified a negative feedback loop in which SET9 controls DNA methyltransferase-1 protein stability, which represses the transcriptional activity of the SET9 promoter in coordination with Snail. The modulation of SET9 expression in breast cancer cells revealed a connection with E2F1 and the silencing of SET9 was sufficient to complete an epigenetic program that favored epithelial-mesenchymal transition and the generation of cancer stem cells, indicating that SET9 plays a role in modulating breast cancer metastasis. SET9 expression levels were significantly higher in samples from patients with pathological complete remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a tumor suppressor in breast cancer and that its expression may serve as a prognostic marker for malignancy.
C1 [Montenegro, M. F.; Gonzalez-Guerrero, R.; Rodriguez-Lopez, J. N.] Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain.
   [Sanchez-del-Campo, L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England.
   [Martinez-Barba, E.] Univ Hosp Virgen Arrixaca, IMIB, Dept Pathol, Murcia, Spain.
   [Pinero-Madrona, A.] Univ Hosp Virgen Arrixaca, IMIB, Dept Surg, Murcia, Spain.
   [Cabezas-Herrera, J.] Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain.
C3 University of Murcia; Ludwig Institute for Cancer Research; University
   of Oxford; Hospital Clinico Universitario Virgen de la Arrixaca;
   Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico
   Universitario Virgen de la Arrixaca
RP Rodríguez-López, JN (通讯作者)，Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain.; Cabezas-Herrera, J (通讯作者)，Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain.
EM juan.cabezas@carm.es; neptuno@um.es
RI Piñero-Madrona, Antonio/AAB-5138-2022; Neptuno, Jose/F-5012-2016;
   CABEZAS-HERRERA, JUAN/J-9434-2015; Montenegro, Maria/AAF-2695-2021; del
   Campo, Luis/R-1308-2018
OI Cabezas-Herrera, Juan/0000-0001-9053-5380; Sanchez del Campo,
   Luis/0000-0002-9537-7761; Pinero-Madrona, Antonio/0000-0002-7718-8318;
   Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Gonzalez Guerrero,
   Rebeca/0000-0003-1006-7658; Montenegro, Maria
   Fernanda/0000-0002-0064-0484
FU Ministerio de Economia y Competitividad (MINECO); Fondos (FEDER)
   [SAF2013-48375-C2-1-R]; Fundacion Seneca, Region de Murcia (FS-RM)
   [15230/PI/10, 19304/PI/14]; Ludwig Institute for Cancer Research; FAECC
FX This work was supported by grants from Ministerio de Economia y
   Competitividad (MINECO; Co-financing with Fondos FEDER)
   (SAF2013-48375-C2-1-R) to JNR-L and Fundacion Seneca, Region de Murcia
   (FS-RM) (15230/PI/10 and 19304/PI/14) to JNR-L, JC-H, and AP-M. JC-H is
   contracted by the FFIS. MFM is contracted by Fundacion de la Asociacion
   Espanola contra el Cancer (FAECC). LS-d-C is supported by the Ludwig
   Institute for Cancer Research and FAECC.
CR Alla V, 2010, JNCI-J NATL CANCER I, V102, P127, DOI 10.1093/jnci/djp458
   Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111
   Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196
   Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang HW, 2014, MOLECULES, V19, P3149, DOI 10.3390/molecules19033149
   Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872
   Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575
   Engelmann D, 2010, CELL MOL LIFE SCI, V67, P931, DOI 10.1007/s00018-009-0222-0
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Geng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054959
   Gupta A, 2003, CANCER, V97, P2341, DOI 10.1002/cncr.11332
   Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y
   Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147
   Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Laine A, 2014, CLIN CANCER RES, V20, P3644, DOI 10.1158/1078-0432.CCR-13-1942
   Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Mukherjee D, 2013, AM J CANCER RES, V3, P46
   Muñoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Nakshatri H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2559
   Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202
   Pützer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009
   Pyle AD, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-235
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Sáez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009
   Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863
   Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tao DY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0412-y
   Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782
   Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914
   Yui S, 2005, CANCER SCI, V96, P560, DOI 10.1111/j.1349-7006.2005.00097.x
NR 55
TC 32
Z9 35
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 24
PY 2016
VL 35
IS 47
BP 6143
EP 6152
DI 10.1038/onc.2016.154
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA ED0CE
UT WOS:000388509800010
PM 27132511
OA Bronze
DA 2025-01-12
ER

PT J
AU Saad, A
   Bijian, K
   Qiu, DH
   da Silva, SD
   Marques, M
   Chang, CH
   Nassour, H
   Ramotar, D
   Damaraju, S
   Mackey, J
   Bismar, T
   Witcher, M
   Alaoui-Jamali, MA
AF Saad, Amine
   Bijian, Krikor
   Qiu, Dinghong
   da Silva, Sabrina Daniela
   Marques, Maud
   Chang, Chia-Hao
   Nassour, Hassan
   Ramotar, Dindial
   Damaraju, Sambasivarao
   Mackey, John
   Bismar, Tarek
   Witcher, Michael
   Alaoui-Jamali, Moulay A.
TI Insights into a novel nuclear function for Fascin in the regulation of
   the amino-acid transporter SLC3A2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HISTONE METHYLTRANSFERASE COMPLEX; NEGATIVE BREAST-CANCER; ACTIN-RELATED
   PROTEINS; TRANSCRIPTION FACTORS; STATISTICAL-MODEL; BINDING PROTEIN;
   LOCALIZATION; GENE; RNA; PHOSPHORYLATION
AB Fascin 1 (FSCN1) is a cytoskeleton-associated protein recognized to function primarily in the regulation of cytoskeleton structure and formation of plasma membrane protrusions. Here we report a novel nuclear function for Fascin 1. Biochemical studies and genome wide localization using ChIP-seq identified phosphorylated Fascin 1 (pFascin) in complexes associated with transcription and that it co-localizes with histone H3 Lys4 trimethylation (H3K4me3) on chromatin. Gene expression profiling identified genes affected by Fascin 1 including SLC3A2, a gene encoding for a plasma membrane transporter that regulates intracellular amino acid levels. RbBP5, a subunit of the H3K4 histone methyltransferase (HMT) complex was found to interact with Fascin 1 supporting its role in H3K4me3 establishment at target genes. Moreover, we show that changes to SLC3A2 levels affect amino acid-mediated mTORC1 activation. These results reveal that Fascin 1 has a yet undiscovered nuclear function as an epigenetic modulator of genes essential for amino acid metabolism.
C1 [Saad, Amine; Bijian, Krikor; Qiu, Dinghong; da Silva, Sabrina Daniela; Marques, Maud; Chang, Chia-Hao; Witcher, Michael; Alaoui-Jamali, Moulay A.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Med, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
   [Saad, Amine; Bijian, Krikor; Qiu, Dinghong; da Silva, Sabrina Daniela; Marques, Maud; Chang, Chia-Hao; Witcher, Michael; Alaoui-Jamali, Moulay A.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Oncol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
   [Saad, Amine; Bijian, Krikor; Qiu, Dinghong; da Silva, Sabrina Daniela; Marques, Maud; Chang, Chia-Hao; Witcher, Michael; Alaoui-Jamali, Moulay A.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Pharmacol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
   [Saad, Amine; Bijian, Krikor; Qiu, Dinghong; da Silva, Sabrina Daniela; Marques, Maud; Chang, Chia-Hao; Witcher, Michael; Alaoui-Jamali, Moulay A.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Therapeut, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
   [Saad, Amine; Bijian, Krikor; Qiu, Dinghong; da Silva, Sabrina Daniela; Marques, Maud; Chang, Chia-Hao; Witcher, Michael; Alaoui-Jamali, Moulay A.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
   [da Silva, Sabrina Daniela; Alaoui-Jamali, Moulay A.] McGill Univ, Otolaryngol Head & Neck Surg, Fac Med, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.
   [Nassour, Hassan; Ramotar, Dindial] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Immunol & Oncol, Montreal, PQ H1T 2M4, Canada.
   [Damaraju, Sambasivarao] Univ Alberta, Cross Canc Inst, Dept Lab Med, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.
   [Damaraju, Sambasivarao] Univ Alberta, Cross Canc Inst, Dept Pathol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.
   [Mackey, John] Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.
   [Bismar, Tarek] Univ Calgary, Southern Alberta Canc Inst, Dept Pathol & Lab Med, Calgary, AB, Canada.
   [Bismar, Tarek] Univ Calgary, Southern Alberta Canc Inst, Dept Oncol, Calgary, AB, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University; Lady Davis Institute; McGill University; McGill University;
   Universite de Montreal; University of Alberta; University of Alberta;
   University of Alberta; University of Calgary; University of Calgary
RP Alaoui-Jamali, MA (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Med, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.; Alaoui-Jamali, MA (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Oncol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.; Alaoui-Jamali, MA (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Pharmacol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.; Alaoui-Jamali, MA (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Therapeut, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.; Alaoui-Jamali, MA (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.; Alaoui-Jamali, MA (通讯作者)，McGill Univ, Otolaryngol Head & Neck Surg, Fac Med, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.
EM moulay.alaoui-jamali@mcgill.ca
RI Bismar, Tarek/ABH-6129-2020; Wurzba, Sabrina/ABF-5002-2020
OI Wurzba, Sabrina/0000-0002-3742-2819
FU Quebec Breast Cancer Foundation; Canadian Institutes of Health Research
FX This study was supported by the Quebec Breast Cancer Foundation and in
   part by the Canadian Institutes of Health Research. We would also like
   to thank Dr. Jessica N Nichol for the critical feedback of this
   manuscript.
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Cantor JM, 2012, J CELL SCI, V125, P1373, DOI 10.1242/jcs.096040
   Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978
   Darnel AD, 2009, CLIN CANCER RES, V15, P1376, DOI 10.1158/1078-0432.CCR-08-1789
   de la Ballina LR, 2016, J BIOL CHEM, V291, P9700, DOI 10.1074/jbc.M115.704254
   De Luca P, 2011, MOL CANCER RES, V9, P1078, DOI 10.1158/1541-7786.MCR-11-0155
   del Amo EM, 2008, EUR J PHARM SCI, V35, P161, DOI 10.1016/j.ejps.2008.06.015
   Desideri E., 2015, GLUTAMINE ADDICTION, P99
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Dion V, 2010, CURR OPIN CELL BIOL, V22, P383, DOI 10.1016/j.ceb.2010.02.006
   Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010
   Esnakula AK, 2014, J CLIN PATHOL, V67, P153, DOI 10.1136/jclinpath-2013-201698
   Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510
   Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206
   Grande MA, 1997, J CELL SCI, V110, P1781
   Groen CM, 2015, MOL BIOL CELL, V26, P1901, DOI 10.1091/mbc.E14-09-1384
   Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Henderson NC, 2004, J BIOL CHEM, V279, P54731, DOI 10.1074/jbc.M408700200
   Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895
   Hu W, 2000, CLIN EXP METASTAS, V18, P83, DOI 10.1023/A:1026596609969
   Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191
   Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4
   Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O
   Jawhari AU, 2003, AM J PATHOL, V162, P69, DOI 10.1016/S0002-9440(10)63799-6
   Jayo A, 2016, DEV CELL, V38, P371, DOI 10.1016/j.devcel.2016.07.021
   Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472
   Justin N, 2010, CURR OPIN STRUC BIOL, V20, P730, DOI 10.1016/j.sbi.2010.09.012
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kelpsch DJ, 2016, MOL BIOL CELL, V27, P2965, DOI 10.1091/mbc.E15-09-0634
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Lee JH, 2008, MOL CELL BIOL, V28, P609, DOI 10.1128/MCB.01356-07
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Matsumura F, 2013, J IMMUNOL, V191, P6156, DOI 10.4049/jimmunol.1300498
   Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406
   Milkereit R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8250
   Nakae K, 2000, J ANTIBIOT, V53, P1130, DOI 10.7164/antibiotics.53.1130
   Nardozzi JD, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-32
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Obrdlik A, 2008, MOL CELL BIOL, V28, P6342, DOI 10.1128/MCB.00766-08
   Ono S, 1997, J BIOL CHEM, V272, P2527
   Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725
   Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229
   Perez-Lluch S, 2011, NUCLEIC ACIDS RES, V39, P4628, DOI 10.1093/nar/gkq1322
   Pilipuk GP, 2003, J BIOL CHEM, V278, P35668, DOI 10.1074/jbc.M305182200
   Pochini L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00061
   Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8
   Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027
   Van Impe K, 2003, J BIOL CHEM, V278, P17945, DOI 10.1074/jbc.M209946200
   van Nuland R, 2013, MOL CELL BIOL, V33, P2067, DOI 10.1128/MCB.01742-12
   Winder SJ, 2005, J CELL SCI, V118, P651, DOI 10.1242/jcs.01670
   Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08
   Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191
   Xie JJ, 2005, BIOCHEM BIOPH RES CO, V337, P355, DOI 10.1016/j.bbrc.2005.09.055
   Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
   Yoder BJ, 2005, CLIN CANCER RES, V11, P186
   Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x
NR 66
TC 24
Z9 28
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 7
PY 2016
VL 6
AR 36699
DI 10.1038/srep36699
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EB0XX
UT WOS:000387071200001
PM 27819326
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Raju, I
   Kaushal, GP
   Haun, RS
AF Raju, Ilangovan
   Kaushal, Gur P.
   Haun, Randy S.
TI Epigenetic regulation of <i>KLK7</i> gene expression in pancreatic and
   cervical cancer cells
SO BIOLOGICAL CHEMISTRY
LA English
DT Article
DE chromatin; epigenetics; KLK7; pancreatic cancer; transcription;
   trichostatin A
ID HISTONE DEACETYLASE INHIBITOR; NF-KAPPA-B; CORNEUM CHYMOTRYPTIC ENZYME;
   HUMAN TISSUE KALLIKREINS; PROMOTER ACTIVITY; BREAST-CANCER; DUCTAL
   ADENOCARCINOMA; TRANSCRIPTION FACTOR; SP1 SITE; METHYLATION
AB Kallikrein-related peptidase 7 (KLK7) is a serine protease encoded within the kallikrein gene cluster located on human chromosome region 19q13.3-13.4. KLK7 is overexpressed in human pancreatic ductal adenocarcinomas (PDACs), but not in normal pancreas. Examination of KLK7 mRNA levels in pancreatic cancer cell lines revealed that it is readily detected in MIA PaCa-2 and PK-1 cells, but not in Panc-1 cells. Treatment of Panc-1 cells with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) significantly induced KLK7 mRNA expression. Similarly, KLK7 is highly expressed in cervical cancer cells, but its expression in the human cervical cancer cell line HeLa is only detected following TSA treatment. Promoter deletion analysis revealed that the proximal -238 promoter region, containing a putative Sp1-binding site, was sufficient for TSA activation of luciferase reporter activity, which was abrogated by the disruption of the Sp1-binding sequence. Consistent with the notion that TSA induced KLK7 expression via Sp1, co-expression of Sp1 with the KLK7-promoter/luciferase construct produced a significant increase in reporter activity. Chromatin immunoprecipitation (ChIP) analysis revealed enriched Sp1 occupancy on the KLK7 promoter following TSA treatment. Similarly, ChIP analysis showed the histone active mark, H3K4Me3, in the KLK7 promoter region was significantly increased after exposure to TSA.
C1 [Raju, Ilangovan; Kaushal, Gur P.; Haun, Randy S.] Cent Arkansas Vet Healthcare Syst, 4300 West 7th St, Little Rock, AR 72205 USA.
   [Raju, Ilangovan; Haun, Randy S.] Univ Arkansas Med Sci, Dept Pharmaceut Sci, 4301 W Markham St,753, Little Rock, AR 72205 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System; University of Arkansas
   System; University of Arkansas Medical Sciences
RP Haun, RS (通讯作者)，Cent Arkansas Vet Healthcare Syst, 4300 West 7th St, Little Rock, AR 72205 USA.; Haun, RS (通讯作者)，Univ Arkansas Med Sci, Dept Pharmaceut Sci, 4301 W Markham St,753, Little Rock, AR 72205 USA.
EM HaunRandyS@uams.edu
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
   Office of Research and Development, Biomedical Laboratory Research and
   Development, VA Merit Award [0113X000828]
FX We thank Dr. Chou-Zen Giam for the kind gift of the E-selectin-Luc
   reporter plasmid. This work was supported by the U.S. Department of
   Veterans Affairs, Veterans Health Administration, Office of Research and
   Development, Biomedical Laboratory Research and Development, VA Merit
   Award 0113X000828 (RSH).
CR Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Borgoño CA, 2004, MOL CANCER RES, V2, P257
   Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262
   Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660
   Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931
   Debela M, 2006, J BIOL CHEM, V281, P25678, DOI 10.1074/jbc.M602372200
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   Gan L, 2000, GENE, V257, P119, DOI 10.1016/S0378-1119(00)00382-6
   Gao CZ, 2006, FEBS LETT, V580, P5096, DOI 10.1016/j.febslet.2006.08.038
   Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200
   Iakovlev V, 2012, CANCER EPIDEM BIOMAR, V21, P1135, DOI 10.1158/1055-9965.EPI-11-1079
   Ishii S, 2008, P NATL ACAD SCI USA, V105, P4179, DOI 10.1073/pnas.0710140105
   Johnson SK, 2007, CANCER, V109, P1811, DOI 10.1002/cncr.22606
   Kim SY, 2003, J VIROL, V77, P3394, DOI 10.1128/JVI.77.6.3394-3401.2003
   KOBARI M, 1986, TOHOKU J EXP MED, V150, P231, DOI 10.1620/tjem.150.231
   Lee C, 2013, BIOTECHNIQUES, V54, P141, DOI 10.2144/000113999
   Lee H, 2006, MOL CELL BIOL, V26, P5259, DOI 10.1128/MCB.01971-05
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pampalakis G, 2006, BIOL CHEM, V387, P773, DOI 10.1515/BC.2006.097
   Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0
   Philip S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004040
   Planque C, 2005, BIOCHEM BIOPH RES CO, V329, P1260, DOI 10.1016/j.bbrc.2005.02.100
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Pufahl L, 2012, J CELL MOL MED, V16, P1461, DOI 10.1111/j.1582-4934.2011.01420.x
   Ramani VC, 2008, BIOCHEM BIOPH RES CO, V369, P1169, DOI 10.1016/j.bbrc.2008.03.021
   Ramani VC, 2011, BBA-MOL CELL RES, V1813, P1525, DOI 10.1016/j.bbamcr.2011.05.007
   Ramani VC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-373
   Ramani VC, 2008, PANCREAS, V37, P399, DOI 10.1097/MPA.0b013e31817f76f7
   Rückert F, 2008, BRIT J CANCER, V99, P1484, DOI 10.1038/sj.bjc.6604717
   Santin AD, 2004, GYNECOL ONCOL, V94, P283, DOI 10.1016/j.ygyno.2004.05.023
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Sowa Y, 1999, CANCER RES, V59, P4266
   Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967
   Talieri M, 2004, THROMB HAEMOSTASIS, V91, P180, DOI 10.1160/TH03-05-0261
   Tamir A, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0109-z
   Tanimoto H, 1999, CANCER, V86, P2074, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2074::AID-CNCR27>3.0.CO;2-3
   Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200
   Walker F, 2014, BIOL CHEM, V395, P1075, DOI 10.1515/hsz-2014-0142
   Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817
   Wang WX, 1999, CLIN CANCER RES, V5, P119
   Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.3.CO;2-X
   Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184
   Zhang Y, 2006, MOL CELL BIOL, V26, P6748, DOI 10.1128/MCB.00560-06
   Zhao SJ, 2003, CANCER RES, V63, P2624
NR 56
TC 14
Z9 14
U1 0
U2 9
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
EI 1437-4315
J9 BIOL CHEM
JI Biol. Chem.
PD NOV
PY 2016
VL 397
IS 11
BP 1135
EP 1146
DI 10.1515/hsz-2015-0307
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EA4AQ
UT WOS:000386551200004
PM 27279059
DA 2025-01-12
ER

PT J
AU Adriaens, ME
   Prickaerts, P
   Chan-Seng-Yue, M
   van den Beucken, T
   Dahlmans, VEH
   Eijssen, LM
   Beck, T
   Wouters, BG
   Voncken, JW
   Evelo, CTA
AF Adriaens, Michiel E.
   Prickaerts, Peggy
   Chan-Seng-Yue, Michelle
   van den Beucken, Twan
   Dahlmans, Vivian E. H.
   Eijssen, Lars M.
   Beck, Timothy
   Wouters, Bradly G.
   Voncken, Jan Willem
   Evelo, Chris T. A.
TI Quantitative analysis of ChIP-seq data uncovers dynamic and sustained
   H3K4me3 and H3K27me3 modulation in cancer cells under hypoxia
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE Epigenomics; Transcriptomics; Data normalization; ChIP-sequencing;
   H3K4me3; H3K27me3; Hypoxia; MCF7
ID CHROMATIN STATE; R-PACKAGE; NORMALIZATION; GENERATION; BINDING; STEM;
   PLURIPOTENT; EPIGENOMICS; PROFILES; GENES
AB Background: A comprehensive assessment of the epigenetic dynamics in cancer cells is the key to understanding the molecular mechanisms underlying cancer and to improving cancer diagnostics, prognostics and treatment. By combining genome-wide ChIP-seq epigenomics and microarray transcriptomics, we studied the effects of oxygen deprivation and subsequent reoxygenation on histone 3 trimethylation of lysine 4 (H3K4me3) and lysine 27 (H3K27me3) in a breast cancer cell line, serving as a model for abnormal oxygenation in solid tumors. A priori, epigenetic markings and gene expression levels not only are expected to vary greatly between hypoxic and normoxic conditions, but also display a large degree of heterogeneity across the cell population. Where traditionally ChIP-seq data are often treated as dichotomous data, the model and experiment here necessitate a quantitative, data-driven analysis of both datasets.
   Results: We first identified genomic regions with sustained epigenetic markings, which provided a sample-specific reference enabling quantitative ChIP-seq data analysis. Sustained H3K27me3 marking was located around centromeres and intergenic regions, while sustained H3K4me3 marking is associated with genes involved in RNA binding, translation and protein transport and localization. Dynamic marking with both H3K4me3 and H3K27me3 (hypoxia-induced bivalency) was found in CpG-rich regions at loci encoding factors that control developmental processes, congruent with observations in embryonic stem cells.
   Conclusions: In silico-identified epigenetically sustained and dynamic genomic regions were confirmed through ChIP-PCR in vitro, and obtained results are corroborated by published data and current insights regarding epigenetic regulation.
C1 [Adriaens, Michiel E.] Maastricht Univ, Maastricht Ctr Syst Biol MaCSBio, Maastricht, Netherlands.
   [Adriaens, Michiel E.; Eijssen, Lars M.; Evelo, Chris T. A.] Maastricht Univ, Dept Bioinformat BiGCaT, Maastricht, Netherlands.
   [Prickaerts, Peggy; Dahlmans, Vivian E. H.; Voncken, Jan Willem] Maastricht Univ, Dept Mol Genet, Maastricht, Netherlands.
   [Chan-Seng-Yue, Michelle; Beck, Timothy] Univ Hlth Network, Dept Informat, Toronto, ON, Canada.
   [Chan-Seng-Yue, Michelle; Beck, Timothy] Univ Hlth Network, Dept Bio Comp, Toronto, ON, Canada.
   [van den Beucken, Twan; Wouters, Bradly G.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [van den Beucken, Twan; Wouters, Bradly G.] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON, Canada.
   [van den Beucken, Twan; Wouters, Bradly G.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
   [van den Beucken, Twan; Wouters, Bradly G.] Maastricht Univ, Maastricht Radiat Oncol MaastRO Lab, Maastricht, Netherlands.
   [Chan-Seng-Yue, Michelle] Hosp Sick Children, Ctr Heart, Biobank, Toronto, ON, Canada.
   [Beck, Timothy] Human Longev Inc, San Diego, CA USA.
C3 Maastricht University; Maastricht University; Maastricht University;
   University of Toronto; University Health Network Toronto; University of
   Toronto; University Health Network Toronto; University of Toronto;
   University Health Network Toronto; Princess Margaret Cancer Centre;
   University of Toronto; University Health Network Toronto; University of
   Toronto; Maastricht University; University of Toronto; Hospital for Sick
   Children (SickKids)
RP Adriaens, ME (通讯作者)，Maastricht Univ, Maastricht Ctr Syst Biol MaCSBio, Maastricht, Netherlands.; Adriaens, ME (通讯作者)，Maastricht Univ, Dept Bioinformat BiGCaT, Maastricht, Netherlands.
EM michiel.adriaens@maastrichtuniversity.nl
RI Prickaerts, Peggy/K-7562-2012; Evelo, Chris/D-2914-2009; Wouters,
   Bradly/T-1525-2017
OI van den Beucken, Twan/0000-0002-2233-7558; Chan-Seng-Yue,
   Michelle/0000-0003-3773-9354; Evelo, Chris/0000-0002-5301-3142; Wouters,
   Bradly/0000-0002-8187-592X; Adriaens, Michiel/0000-0002-4472-7119
FU Dutch Science Organization (ZonMW-NWO): VIDI grant [016.046.362];
   University Limburg (tUL); Dutch Province of Limburg; Maastricht
   University BOS; Ontario Institute for Cancer Research (PanCuRx
   Translational Research Initiative) - Government of Ontario (Ministry of
   Research, Innovation and Science)
FX These studies received financial support from the Dutch Science
   Organization (ZonMW-NWO): VIDI grant 016.046.362 (JWV); transnational
   University Limburg (tUL) grant (JWV/BGW); the Dutch Province of Limburg
   (MEA); Maastricht University BOS-funding (CTAE). This study was
   conducted with the support of the Ontario Institute for Cancer Research
   (PanCuRx Translational Research Initiative) through funding provided by
   the Government of Ontario (Ministry of Research, Innovation and
   Science). None of the funding sources had any role in study design, data
   collection, analysis and interpretation, writing of the manuscript or
   the decision to submit the manuscript for publication.
CR Angelini C, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0579-z
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bonhoure N, 2014, GENOME RES, V24, P1157, DOI 10.1101/gr.168260.113
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Chen KF, 2016, MOL CELL BIOL, V36, P662, DOI 10.1128/MCB.00970-14
   Cheung MS, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr425
   Day DS, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-6-r69
   De Gobbi M, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-9
   Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305
   Fullwood MJ, 2009, GENOME RES, V19, P521, DOI 10.1101/gr.074906.107
   Grossmann S, 2007, BIOINFORMATICS, V23, P3024, DOI 10.1093/bioinformatics/btm440
   Huang WC, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr592
   Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508
   Klein HU, 2014, BIOINFORMATICS, V30, P1154, DOI 10.1093/bioinformatics/btu003
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Liang K, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-199
   Liu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11275
   Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399
   Malone BM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025260
   Mardis ER, 2007, NAT METHODS, V4, P613, DOI 10.1038/nmeth0807-613
   Mercier E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016432
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Muiño JM, 2011, PLANT METHODS, V7, DOI 10.1186/1746-4811-7-11
   Nix DA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-523
   Orlando DA, 2014, CELL REP, V9, P1163, DOI 10.1016/j.celrep.2014.10.018
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Pelz CR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-520
   Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004
   Prickaerts P, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0086-0
   Rosenfeld JA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-143
   Rozowsky J, 2009, NAT BIOTECHNOL, V27, P66, DOI 10.1038/nbt.1518
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887
   Scacheri PC, 2006, METHOD ENZYMOL, V411, P270, DOI 10.1016/S0076-6879(06)11014-9
   Simó-Riudalbas L, 2014, HUM GENET, V133, P713, DOI 10.1007/s00439-013-1373-5
   Taslim C, 2011, BIOINFORMATICS, V27, P1569, DOI 10.1093/bioinformatics/btr165
   Voncken JW, 1999, J CELL SCI, V112, P4627
   Wu DY, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00169
   Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683
   Young MD, 2011, NUCLEIC ACIDS RES, V39, P7415, DOI 10.1093/nar/gkr416
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 46
TC 18
Z9 21
U1 1
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD NOV 1
PY 2016
VL 9
AR 48
DI 10.1186/s13072-016-0090-4
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EA9KL
UT WOS:000386962500001
PM 27822313
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lee, JJ
   Kim, M
   Kim, HP
AF Lee, Jong-Joo
   Kim, Mikyoung
   Kim, Hyoung-Pyo
TI Epigenetic regulation of long noncoding RNA UCA1 by SATB1 in breast
   cancer
SO BMB REPORTS
LA English
DT Article
DE Breast cancer; Epigenetic regulation; Histone methylation; SATB1; UCA1
ID CHROMATIN ORGANIZER SATB1; CARCINOMA-ASSOCIATED 1; CELL-GROWTH;
   BINDING-PROTEIN; TUMOR GROWTH; ARCHITECTURE; HALLMARKS; TARGET; GENES
AB Special AT-rich sequence binding protein 1 (SATB1) is a nuclear matrix-associated DNA-binding protein that functions as a chromatin organizer. SATB1 is highly expressed in aggressive breast cancer cells and promotes growth and metastasis by reprograming gene expression. Through genome-wide cross-examination of gene expression and histone methylation, we identified SATB1 target genes for which expression is associated with altered epigenetic marks. Among the identified genes, long noncoding RNA urothelial carcinoma-associated 1 (UCA1) was upregulated by SATB1 depletion. Upregulation of UCA1 coincided with increased H3K4 trimethylation (H3K4me3) levels and decreased H3K27 trimethylation (H3K27me3) levels. Our study showed that SATB1 binds to the upstream region of UCA1 in vivo, and that its promoter activity increases with SATB1 depletion. Furthermore, simultaneous depletion of SATB1 and UCA1 potentiated suppression of tumor growth and cell survival. Thus, SATB1 repressed the expression of oncogenic UCA1, suppressing growth and survival of breast cancer cells.
C1 [Lee, Jong-Joo; Kim, Mikyoung; Kim, Hyoung-Pyo] Yonsei Univ, Coll Med, Inst Trop Med, Dept Environm Med Biol, Seoul 03722, South Korea.
   [Lee, Jong-Joo; Kim, Hyoung-Pyo] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kim, HP (通讯作者)，Yonsei Univ, Coll Med, Inst Trop Med, Dept Environm Med Biol, Seoul 03722, South Korea.; Kim, HP (通讯作者)，Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 03722, South Korea.
EM kimhp@yuhs.ac
RI Kim, Dong-Hyun/AAH-3043-2020
OI Kim, Hyoung-Pyo/0000-0003-1441-8822
FU National R&D Program for Cancer Control; Ministry for Health, Welfare
   and Family Affairs, Korea [1120370]; National Research Foundation (NRF)
   of Korea grant (MEST) [NRF-2011-0030086, 2012M3A9B4028272,
   2016R1A2B4014183]
FX This work was supported by a grant from the National R&D Program for
   Cancer Control, Ministry for Health, Welfare and Family Affairs, Korea
   (1120370 to H.-P. Kim), and a National Research Foundation (NRF) of
   Korea grant (MEST; NRF-2011-0030086, 2012M3A9B4028272, and
   2016R1A2B4014183 to H.-P. Kim).
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Burute M, 2012, IMMUNOL CELL BIOL, V90, P852, DOI 10.1038/icb.2012.28
   Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146
   DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115
   Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009
   Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516
   Kumar PP, 2014, ELIFE, V3, DOI 10.7554/eLife.02805
   Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008
   Rosenbloom KR, 2012, NUCLEIC ACIDS RES, V40, pD912, DOI 10.1093/nar/gkr1012
   Tuo YL, 2015, EUR REV MED PHARMACO, V19, P3403
   Wang F, 2008, FEBS LETT, V582, P1919, DOI 10.1016/j.febslet.2008.05.012
   Wang Z, 2012, NUCLEIC ACIDS RES, V40, P4193, DOI 10.1093/nar/gkr1284
   Wu W, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059016, 10.1371/journal.pone.0059749]
   Xue M, 2016, J CANCER RES CLIN, V142, P1407, DOI 10.1007/s00432-015-2042-y
   Xue M, 2014, TUMOR BIOL, V35, P6901, DOI 10.1007/s13277-014-1925-x
   Xue M, 2014, ONCOL REP, V31, P1993, DOI 10.3892/or.2014.3092
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
NR 25
TC 32
Z9 32
U1 0
U2 4
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD OCT 31
PY 2016
VL 49
IS 10
BP 578
EP 583
DI 10.5483/BMBRep.2016.49.10.156
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EA4HC
UT WOS:000386570900010
PM 27697109
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Yu-Rice, Y
   Jin, Y
   Han, B
   Qu, Y
   Johnson, J
   Watanabe, T
   Cheng, L
   Deng, N
   Tanaka, H
   Gao, B
   Liu, Z
   Sun, Z
   Bose, S
   Giuliano, A
   Cui, X
AF Yu-Rice, Y.
   Jin, Y.
   Han, B.
   Qu, Y.
   Johnson, J.
   Watanabe, T.
   Cheng, L.
   Deng, N.
   Tanaka, H.
   Gao, B.
   Liu, Z.
   Sun, Z.
   Bose, S.
   Giuliano, A. E.
   Cui, X.
TI FOXC1 is involved in ERa silencing by counteracting GATA3 binding and is
   implicated in endocrine resistance
SO ONCOGENE
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION PATTERNS; BREAST-CANCER CELLS;
   TRANSCRIPTIONAL REGULATION; FORKHEAD DOMAIN; POOR-PROGNOSIS; TAMOXIFEN;
   PROTEIN; FOXA1; OVEREXPRESSION
AB Estrogen receptor-alpha (ER alpha) mediates the essential biological function of estrogen in breast development and tumorigenesis. Multiple mechanisms, including pioneer factors, coregulators and epigenetic modifications have been identified as regulators of ER alpha signaling in breast cancer. However, previous studies of ER alpha regulation have focused on luminal and HER2-positive subtypes rather than basal-like breast cancer (BLBC), in which ER alpha is underexpressed. In addition, mechanisms that account for the decrease or loss of ER expression in recurrent tumors after endocrine therapy remain elusive. Here, we demonstrate a novel FOXC1-driven mechanism that suppresses ERa expression in breast cancer. We find that FOXC1 competes with GATA-binding protein 3 (GATA3) for the same binding regions in the cis-regulatory elements upstream of the ER alpha gene and thereby downregulates ER alpha expression and consequently its transcriptional activity. The forkhead domain of FOXC1 is essential for the competition with GATA3 for DNA binding. Counteracting the action of GATA3 at the ER alpha promoter region, overexpression of FOXC1 hinders recruitment of RNA polymerase II and increases histone H3K9 trimethylation at ER alpha promoters. Importantly, ectopic FOXC1 expression in luminal breast cancer cells reduces sensitivity to estrogen and tamoxifen. Furthermore, in breast cancer patients with ER-positive primary tumors who received adjuvant tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors. Our findings highlight a clinically relevant mechanism that contributes to the low or absent ER alpha expression in BLBC. This study suggests a new paradigm to study ER alpha regulation during breast cancer progression and indicates a role of FOXC1 in the modulation of cellular response to endocrine treatment.
C1 [Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Tanaka, H.; Gao, B.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.
   [Cheng, L.; Sun, Z.] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China.
   [Deng, N.; Liu, Z.] Cedars Sinai Med Ctr, Dept Surg, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA.
   [Bose, S.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Pathol, Los Angeles, CA 90048 USA.
C3 Cedars Sinai Medical Center; Chongqing Medical University; Cedars Sinai
   Medical Center; Cedars Sinai Medical Center
RP Cui, X (通讯作者)，Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.
EM Xiaojiang.Cui@cshs.org
OI Tanaka, Hisashi/0000-0001-9223-4186; Johnson,
   Jeffrey/0000-0003-2912-443X
FU National Institutes of Health [CA151610]; Avon Foundation for Women
   [02-2014-063]; David Salomon Translational Breast Cancer Research Fund;
   Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Margie and
   Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund;
   Fashion Footwear Charitable Foundation of New York, Inc.
FX We thank Dr Julia Gee for discussion about antiestrogen experiments.
   This work was supported by the National Institutes of Health (CA151610),
   the Avon Foundation for Women (02-2014-063) and David Salomon
   Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick
   Discovery Fund in Cellular Therapy to Xiaojiang Cui, the Fashion
   Footwear Charitable Foundation of New York, Inc., associates for Breast
   and Prostate Cancer Studies, the Margie and Robert E. Petersen
   Foundation, and the Linda and Jim Lippman Research Fund to Armando
   Giuliano.
CR Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Bartkuhn M, 2008, BBA-MOL CELL RES, V1783, P2161, DOI 10.1016/j.bbamcr.2008.07.011
   Becker M, 2005, MOL CANCER THER, V4, P151
   Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299
   Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200
   Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326
   Bulger M, 2010, DEV BIOL, V339, P250, DOI 10.1016/j.ydbio.2009.11.035
   Caizzi L, 2014, P NATL ACAD SCI USA, V111, P4892, DOI 10.1073/pnas.1315445111
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Gaughan L, 2013, NUCLEIC ACIDS RES, V41, P6892, DOI 10.1093/nar/gkt469
   Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004
   Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Manavathi B, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00034
   Marconett CN, 2010, MOL BIOL CELL, V21, P1166, DOI 10.1091/mbc.E09-08-0689
   Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010
   Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858
   Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200
   Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948
   Oyama M, 2011, J BIOL CHEM, V286, P818, DOI 10.1074/jbc.M110.156877
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x
   Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje
   PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Saleem RA, 2004, NUCLEIC ACIDS RES, V32, P4182, DOI 10.1093/nar/gkh742
   Saleem RA, 2003, HUM MOL GENET, V12, P2993, DOI 10.1093/hmg/ddg324
   Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X
   Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025
   Shenker NS, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1335-5
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sparano JA, 2010, SURG ONCOL CLIN N AM, V19, P581, DOI 10.1016/j.soc.2010.03.008
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277-012-0629-3
   Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029
   Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347
   Ye Q, 2015, AM J CANCER RES, V5, P1519
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
NR 49
TC 29
Z9 36
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 13
PY 2016
VL 35
IS 41
BP 5400
EP 5411
DI 10.1038/onc.2016.78
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EA5QU
UT WOS:000386677800006
PM 27041579
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Liu, HD
   Li, W
   Yu, XF
   Gao, F
   Duan, Z
   Ma, XL
   Tan, SM
   Yuan, YC
   Liu, LJ
   Wang, J
   Zhou, XM
   Yang, YF
AF Liu, Haidan
   Li, Wei
   Yu, Xinfang
   Gao, Feng
   Duan, Zhi
   Ma, Xiaolong
   Tan, Shiming
   Yuan, Yunchang
   Liu, Lijun
   Wang, Jian
   Zhou, Xinmin
   Yang, Yifeng
TI EZH2-mediated <i>Puma</i> gene repression regulates non-small cell lung
   cancer cell proliferation and cisplatin-induced apoptosis
SO ONCOTARGET
LA English
DT Article
DE polycomb repressive complex 2; EZH2; PUMA; non-small cell lung cancer;
   cisplatin
ID GROUP PROTEIN EZH2; ZESTE HOMOLOG 2; NF-KAPPA-B; BCL-X-L;
   METHYLTRANSFERASE EZH2; SELECTIVE-INHIBITION; PROSTATE-CANCER;
   BREAST-CANCER; P53 STATUS; E-CADHERIN
AB Polycomb group (PcG) proteins are highly conserved epigenetic effectors that maintain the silenced state of genes. EZH2 is the catalytic core and one of the most important components of the polycomb repressive complex 2 (PRC2). In non-small cell lung cancer (NSCLC) cells and primary lung tumors, we found that PRC2 components, including EZH2, are overexpressed. High levels of EZH2 protein were associated with worse overall survival rate in NSCLC patients. RNA interference mediated attenuation of EZH2 expression blunted the malignant phenotype in this setting, exerting inhibitory effects on cell proliferation, anchorage-independent growth, and tumor development in a xenograft mouse model. Unexpectedly, we discovered that, in the suppression of EZH2, p53 upregulated modulator of apoptosis (PUMA) expression was concomitantly induced. This is achieved through EZH2 directly binds to the Puma promoter thus epigenetic repression of PUMA expression. Furthermore, cisplatin-induced apoptosis of EZH2-knocking down NSCLC cells was elevated as a consequence of increased PUMA expression. Our work reveals a novel epigenetic regulatory mechanism controlling PUMA expression and suggests that EZH2 offers a candidate molecular target for NSCLC therapy and EZH2-regulated PUMA induction would synergistically increase the sensitivity to platinum agents in non-small cell lung cancers.
C1 [Liu, Haidan; Liu, Lijun; Wang, Jian; Yang, Yifeng] Cent S Univ, Xiangya Hosp 2, Clin Ctr Gene Diag & Therapy, Changsha, Hunan, Peoples R China.
   [Liu, Haidan; Ma, Xiaolong; Zhou, Xinmin; Yang, Yifeng] Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha, Hunan, Peoples R China.
   [Yuan, Yunchang] Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha, Hunan, Peoples R China.
   [Li, Wei] Cent S Univ, Xiangya Hosp 3, Dept Radiol, Changsha, Hunan, Peoples R China.
   [Yu, Xinfang] Cent S Univ, Hunan Canc Hosp, Changsha, Hunan, Peoples R China.
   [Yu, Xinfang] Cent S Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.
   [Gao, Feng] Cent S Univ, Xiangya Hosp 3, Dept Ultrasonog, Changsha, Hunan, Peoples R China.
   [Tan, Shiming] Cent S Univ, Xiangya Hosp 3, Dept Hemopathol, Changsha, Hunan, Peoples R China.
   [Duan, Zhi] Albert Einstein Coll Med, Bronx, NY 10467 USA.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Central
   South University; Central South University; Central South University;
   Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University
RP Yang, YF (通讯作者)，Cent S Univ, Xiangya Hosp 2, Clin Ctr Gene Diag & Therapy, Changsha, Hunan, Peoples R China.; Zhou, XM; Yang, YF (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha, Hunan, Peoples R China.
EM mark037100@163.com; yyf627@163.com
RI Ma, Xiaolong/ABC-9088-2021; Yang, Yifeng/HLH-7494-2023
FU National Natural Science Foundation of China [81401548, 81572280,
   81502121]; Health and Family Planning Commission of Hunan Province
   [B2016125]; Science and Technology Department of Hunan province
   [2011TT2017]
FX This work was supported by National Natural Science Foundation of China
   (No. 81401548, No. 81572280 and No. 81502121), Research Project of
   Health and Family Planning Commission of Hunan Province (B2016125) and
   Research Project of Science and Technology Department of Hunan province
   (2011TT2017).
CR Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Cheng HY, 2013, CARCINOGENESIS, V34, P739, DOI 10.1093/carcin/bgs393
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Deb G, 2014, MOL CANCER RES, V12, P639, DOI 10.1158/1541-7786.MCR-13-0546
   Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Gélinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205
   Gomes NP, 2010, GENE DEV, V24, P1022, DOI 10.1101/gad.1881010
   Hai J, 2012, CLIN CANCER RES, V18, P1914, DOI 10.1158/1078-0432.CCR-11-2893
   Han T, 2016, ONCOTARGET, V7, P11194, DOI 10.18632/oncotarget.7156
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Holubec H, 2005, J HISTOCHEM CYTOCHEM, V53, P229, DOI 10.1369/jhc.4A6386.2005
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Keilhack H, 2015, EPIGENOMICS-UK, V7, P337, DOI 10.2217/epi.15.14
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913
   Li Y, 2003, CANCER RES, V63, P1527
   Liu HD, 2014, CANCER PREV RES, V7, P74, DOI 10.1158/1940-6207.CAPR-13-0133
   Liu HD, 2013, J BIOL CHEM, V288, P25924, DOI 10.1074/jbc.M113.464669
   Liu HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032624
   Luo WR, 2012, INT J CANCER, V131, P1863, DOI 10.1002/ijc.27467
   Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150
   Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110
   Qiao YB, 2015, J BIOL CHEM, V290, P2508, DOI 10.1074/jbc.M114.603761
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51
   Wang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19239
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353
   Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429
   Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45
   Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6
   Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200
   Zhang YJ, 2009, MOL BIOL CELL, V20, P3077, DOI 10.1091/mbc.E08-11-1109
NR 63
TC 39
Z9 41
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2016
VL 7
IS 35
BP 56338
EP 56354
DI 10.18632/oncotarget.10841
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EA8TL
UT WOS:000386911600032
PM 27472460
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Mao, SQ
   Fan, R
   Gu, TL
   Zhong, QL
   Gong, ML
   Dong, CZ
   Hao, LM
   Zhang, LN
AF Mao, Shuqi
   Fan, Rui
   Gu, Tianlun
   Zhong, Qilong
   Gong, Minli
   Dong, Changzheng
   Hao, Linmei
   Zhang, Lina
TI Hypermethylation of <i>SCNN1A</i> gene-body increases the risk of
   essential hypertension
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Epigenetic; DNA methylation; SCNN1A gene; essential hypertension
ID GENOME-WIDE ANALYSIS; DNA METHYLATION ANALYSIS; BREAST-CANCER PATIENTS;
   ABERRANT METHYLATION; PANCREATIC-ISLETS; PERIPHERAL-BLOOD; EXPRESSION;
   PRESSURE; PROMOTER; TRANSCRIPTION
AB The goal of this study was to investigate the contribution of nonvoltage-gated 1 alpha subunit (SCNN1A) gene-body methylation of essential hypertension (EH), and to explore whether the methylation level could be altered by antihypertensive therapy. Our study performed methylation analysis of peripheral blood DNA using bisulphite pyrosequencing technology among 60 non-EH controls, 60 incident EH cases and 60 prevalent EH cases. Our results reported that the incident cases had a higher SCNN1A methylation level than the non-EH controls (16.15 +/- 4.51 versus 13.66 +/- 4.08. P=0.041), and prevalent cases (16.15 +/- 4.51 versus 13.77 +/- 3.90, P=0.002). Logistic regression analysis results showed that SCNN1A hypermethylation was the risk factor of EH in incident cases compared with non-EH (OR=1.157, P=0.01), and in incident cases compared with prevalent cases (OR= 1.149, P=0.013). The SCNN1A methylation level was found to be positively correlated with age in non-EH (r=0.343, P=0.007). Significantly higher methylation level was identified in female than male in non-EH (t=3.878, P=2.71x10(-4)). Receiver operating characteristic (ROC) curve analysis revealed that 10.833% methylation level is an appropriate cut-off value for the SCNN1A gene-body methylation to predict the onset of EH between non-EH and incident cases (area under curve: 0.638, P<0.009, 95% CI: 0.539-0.736). In conclusion, our study indicated hypermethylation of SCNN1A gene-body was associated with the risk of EH, SCNN1A gene-body methylation has an important diagnostic value to EH, and SCNN/A gene-body methylation level could be modified by age, gender and antihypertensive therapy.
C1 [Mao, Shuqi; Fan, Rui; Gu, Tianlun; Dong, Changzheng; Zhang, Lina] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Dept Prevent Med, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China.
   [Zhong, Qilong; Gong, Minli; Hao, Linmei] Seventh Hosp Ningbo, Clin Lab, Ningbo 315211, Zhejiang, Peoples R China.
   [Fan, Rui] Lihuili Eastern Hosp, Ningbo Med Ctr, Dept Med Qual, Ningbo, Zhejiang, Peoples R China.
C3 Ningbo University
RP Dong, CZ; Zhang, LN (通讯作者)，Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Dept Prevent Med, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China.; Hao, LM (通讯作者)，Seventh Hosp Ningbo, Clin Lab, Ningbo 315211, Zhejiang, Peoples R China.
EM dongchangzheng@nbu.edu.cn; hlm3043@21cn.com; zhanglina@nbu.edu.cn
RI zhao, haiping/I-1306-2014; Mao, Shuqi/IQR-8069-2023
OI Mao, Shuqi/0000-0003-0672-8126
FU Zhejiang Province Social development Research Project [2016033178]; K.C.
   Wong Magna Fund in Ningbo University; Ningbo Social Development Research
   Project [2014C50051]; Ningbo Medical Science and Technology Plan Project
   [2013A39]; Outstanding (Postgraduate) Dissertation Growth Foundation of
   Ningbo University [py2014015]; Scientific Research Innovation Foundation
   of Ningbo University [G16097, G15-070]
FX Our research was supported by Zhejiang Province Social development
   Research Project (2016033178), K.C. Wong Magna Fund in Ningbo
   University, Ningbo Social Development Research Project (2014C50051),
   Ningbo Medical Science and Technology Plan Project (2013A39),
   Outstanding (Postgraduate) Dissertation Growth Foundation of Ningbo
   University (py2014015), the Scientific Research Innovation Foundation of
   Ningbo University (G16097), and the Scientific Research Innovation
   Foundation of Ningbo University (G15-070).
CR Aavik E, 2015, EUR HEART J, V36, P993, DOI 10.1093/eurheartj/ehu437
   Adeyemo A, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000564
   Alisch RS, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-18
   Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Baker SE, 2012, MED SCI SPORT EXER, V44, P2315, DOI 10.1249/MSS.0b013e318266ebc3
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Binder A, 2007, CURR OPIN CARDIOL, V22, P176, DOI 10.1097/HCO.0b013e3280d357f9
   Bogdarina I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009237
   Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767
   Bubien JK, 2010, J BIOL CHEM, V285, P23527, DOI 10.1074/jbc.R109.025049
   Cho HM, 2011, AM J HYPERTENS, V24, P1286, DOI 10.1038/ajh.2011.136
   Cho YS, 2009, NAT GENET, V41, P527, DOI 10.1038/ng.357
   Christensen BM, 2010, J AM SOC NEPHROL, V21, P1942, DOI 10.1681/ASN.2009101077
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Cotton AM, 2011, HUM GENET, V130, P187, DOI 10.1007/s00439-011-1007-8
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3
   Fan R, 2015, MOL MED REP, V12, P2390, DOI 10.3892/mmr.2015.3631
   Fan SC, 2009, BIOCHEM BIOPH RES CO, V383, P421, DOI 10.1016/j.bbrc.2009.04.023
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Flis S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092305
   Friso S, 2008, ATHEROSCLEROSIS, V199, P323, DOI 10.1016/j.atherosclerosis.2007.11.029
   Grodzicki T, 1998, AM J HYPERTENS, V11, P425, DOI 10.1016/S0895-7061(97)00500-1
   Hall E, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0522-z
   Han K, 2013, GENES GENOM, V35, P265, DOI 10.1007/s13258-013-0095-3
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Khattar RS, 2001, CIRCULATION, V104, P783, DOI 10.1161/hc3201.094227
   Kim YH, 2015, GENES GENOM, V37, P479, DOI 10.1007/s13258-015-0277-2
   Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384
   Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32
   Martinez-Glez V, 2007, NEOPLASMA, V54, P123
   Mirza S, 2012, ANN SURG ONCOL, V19, P3107, DOI 10.1245/s10434-012-2323-5
   Morita S, 2012, INT J MOL SCI, V13, P8259, DOI 10.3390/ijms13078259
   Movassagh M, 2011, CIRCULATION, V124, P2411, DOI 10.1161/CIRCULATIONAHA.111.040071
   Rice T, 2000, CIRCULATION, V102, P1956, DOI 10.1161/01.CIR.102.16.1956
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Schild L, 2010, BBA-MOL BASIS DIS, V1802, P1159, DOI 10.1016/j.bbadis.2010.06.014
   Schmieder R E, 1986, Cardiol Clin, V4, P57
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Talens RP, 2012, INT J EPIDEMIOL, V41, P106, DOI 10.1093/ije/dyr153
   Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503
   Wang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065676
   XU L, 2014, BIOMED RES INT, V2014, DOI [DOI 10.1155/2014/151723, 10.1155/2014/151723., DOI 10.1155/2014/15172324696842]
   Zhang L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052384, 10.1371/journal.pone.0066569]
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 48
TC 9
Z9 9
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 8
BP 8047
EP 8056
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EA5IR
UT WOS:000386653400029
DA 2025-01-12
ER

PT J
AU Lv, ZD
   Song, YH
   Yang, DX
   Dong, Q
   Mao, Y
   Jin, LY
   Liu, D
   Fu, GM
   Li, FN
   Song, Z
   Kong, B
   Wang, HB
AF Lv, Zhi-Dong
   Song, Yu-Hua
   Yang, Dong-Xia
   Dong, Qian
   Mao, Yan
   Jin, Li-Ying
   Liu, Dong
   Fu, Guang-Ming
   Li, Fu-Nian
   Song, Zhen
   Kong, Bin
   Wang, Hai-Bo
TI Down-regulation of CXCL12 by hypermethylation induces cell
   proliferation, growth and invasion in triple-negative breast cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Triple-negative breast cancer; CXCL12; DNA mehtylation; cell
   proliferation; cell invasion
ID DNA METHYLATION; METASTASIS; ACTIVATION; EXPRESSION; TUMOR; PROGNOSIS
AB We previously reported that CXCL12 was reduced in breast cancer, and its expression was associated with clinicopathological factors and prognosis. However, the epigenetic regulation and molecular functions of CXCL12 in Triple-negative breast cancer (TNBC) remain unknown. In this study, CXCL12 expression levels and methylation status of its promoter region in TNBC cell lines and TNBC tissues (n = 105) as well as normal breast tissues (n = 105) were assessed by RTq-PCR and methylation analysis, respectively. The cellular functions of CXCL12 on TNBC cell proliferation, growth and invasion were investigated in vivo and in vitro. Our data revealed that CXCL12 was frequently silenced by promoter hypermethylation in both tested TNBC cell lines and primary TNBC, and correlation analysis between methylation status and clinicopathological parameters found that TNBC methylation was significantly correlated with lymph node status and TNM stage, while no significant correlation was found in other parameters. In addition, demethylation treatment resulted in re-expression of CXCL12 in TNBC cell lines, and cellular function experiments revealed that restoration of CXCL12 inhibited MDA-MB-231 cell proliferation and suppressed cell invasion. Furthermore, animal studies revealed that nude mice injected with the Lentivirus-CXCL12 cell lines featured a lighter weight than the control cells. These data suggest that CXCL12 may function as a tumor suppressor gene, which is down-regulated through promoter hypermethylation in TNBC development.
C1 [Lv, Zhi-Dong; Song, Yu-Hua; Yang, Dong-Xia; Mao, Yan; Liu, Dong; Li, Fu-Nian; Song, Zhen; Kong, Bin; Wang, Hai-Bo] Qingdao Univ, Affiliated Hosp, Ctr Diag & Treatment Breast Dis, Qingdao 266003, Shandong, Peoples R China.
   [Dong, Qian] Qingdao Univ, Affiliated Hosp, Dept Pediat Surg, Qingdao, Peoples R China.
   [Jin, Li-Ying] Qingdao Univ, Affiliated Hosp, Cerebrovasc Dis Res Inst, Qingdao, Peoples R China.
   [Fu, Guang-Ming] Qingdao Univ, Affiliated Hosp, Dept Pathol, Qingdao, Peoples R China.
C3 Qingdao University; Qingdao University; Qingdao University; Qingdao
   University
RP Wang, HB (通讯作者)，Qingdao Univ, Affiliated Hosp, Ctr Diag & Treatment Breast Dis, Qingdao 266003, Shandong, Peoples R China.
EM qingyiwhb@126.com
RI wang, jiaqi/JSL-7112-2023; fu, fu/KCJ-8833-2024
FU National Natural Science Foundation of China [81302290]
FX This study was supported by National Natural Science Foundation of China
   (No. 81302290).
CR Anders HJ, 2014, TRENDS MOL MED, V20, P154, DOI 10.1016/j.molmed.2013.12.002
   Burnett JP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15821
   Chen HY, 2015, J CANCER, V6, P740, DOI 10.7150/jca.11691
   Chiba F, 2014, INT J ONCOL, V44, P177, DOI 10.3892/ijo.2013.2180
   Duda DG, 2014, CLIN CANCER RES, V17, P2074
   Grogg A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1897-2
   Gunzer M, 2007, Ernst Schering Found Symp Proc, P97
   Itakura M, 2013, BRIT J CANCER, V109, P1100, DOI 10.1038/bjc.2013.440
   Lim JB, 2015, CYTOKINE, V73, P16, DOI 10.1016/j.cyto.2015.01.010
   Liu J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0817-z
   Liu Y, 2014, INT J EXP PATHOL, V95, P153, DOI 10.1111/iep.12065
   Lv ZD, 2014, INT J CLIN EXP PATHO, V7, P6671
   Perez-Janices N, 2015, ONCOTARGET, V6, P23944, DOI 10.18632/oncotarget.4062
   Shenoy N, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0180-y
   Sui P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0809-z
   Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959
   Suzuki M, 2015, INT J ONCOL, V47, P791, DOI 10.3892/ijo.2015.3046
   Tamamis P, 2014, J CHEM INF MODEL, V54, P1174, DOI 10.1021/ci500069y
   Tsai MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep13574
   Uto-Konomi A, 2013, BIOCHEM BIOPH RES CO, V431, P772, DOI 10.1016/j.bbrc.2013.01.032
   Wang H, 2014, ONCOL LETT, V7, P1581, DOI 10.3892/ol.2014.1926
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x
   Williamson JS, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0111-3
   Zhao DX, 2014, CELL IMMUNOL, V289, P155, DOI 10.1016/j.cellimm.2014.03.020
   Zhi Y, 2012, DIGEST DIS SCI, V57, P650, DOI 10.1007/s10620-011-1922-5
NR 25
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 8
BP 8190
EP 8198
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EA5IR
UT WOS:000386653400044
DA 2025-01-12
ER

PT J
AU Cui, W
   Dai, XP
   Marcho, C
   Han, ZB
   Zhang, K
   Tremblay, KD
   Mager, J
AF Cui, Wei
   Dai, Xiangpeng
   Marcho, Chelsea
   Han, Zhengbin
   Zhang, Kun
   Tremblay, Kimberly D.
   Mager, Jesse
TI Towards Functional Annotation of the Preimplantation Transcriptome: An
   RNAi Screen in Mammalian Embryos
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DOUBLE-STRANDED-RNA; CELL FATE; ZYGOTIC TRANSITION; BREAST-CANCER; MOUSE
   OOCYTES; DYNAMICS; REVEALS; INTERFERENCE; EXPRESSION; SPECIFICATION
AB With readily available transcriptome-wide data, understanding the role of each expressed gene is an essential next step. Although RNAi technologies allow for genome-wide screens in cell culture, these approaches cannot replace strategies for discovery in the embryo. Here we present, for the first time, a knockdown screen in mouse preimplantation embryos. Early mammalian development encompasses dynamic cellular, molecular and epigenetic events that are largely conserved from mouse to man. We assayed 712 genes for requirements during preimplantation. We identified 59 genes required for successful development or outgrowth and implantation. We have characterized each phenotype and revealed cellular, molecular, and lineage specific defects following knockdown of transcript. Induced network analyses demonstrate this as a valid approach to identify networks of genes that play important roles during preimplantation. Our approach provides a robust and efficient strategy towards identification of novel phenotypes during mouse preimplantation and facilitates functional annotation of the mammalian transcriptome.
C1 [Cui, Wei; Marcho, Chelsea; Han, Zhengbin; Tremblay, Kimberly D.; Mager, Jesse] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.
   [Dai, Xiangpeng] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
   [Han, Zhengbin] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Peoples R China.
   [Zhang, Kun] Zhejiang Univ, Coll Anim Sci, Inst Anim Genet & Reprod, Lab Mammalian Mol Embryol, Hangzhou 310058, Zhejiang, Peoples R China.
C3 University of Massachusetts System; University of Massachusetts Amherst;
   Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center; Harbin Institute of Technology; Zhejiang University
RP Mager, J (通讯作者)，Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.
EM jmager@vasci.umass.edu
RI Zhang, Kun/GNP-6238-2022; Marcho, Chelsea/N-8230-2019; Cui,
   Wei/F-2192-2016
OI mager, jesse/0000-0002-4123-0633; Tremblay,
   Kimberly/0000-0002-3059-9910; Marcho, Chelsea/0000-0003-0932-7416;
   Zhang, Kun/0000-0002-2324-9381; Cui, Wei/0000-0001-7281-3471
FU March of Dimes Research Grant [6-FY11-367]; NIH [R21HD078942]; Lalor
   Foundation
FX This work was funded in part by March of Dimes Research Grant
   #6-FY11-367 and NIH R21HD078942 to J.M. W.C. was supported by Lalor
   Foundation postdoctoral fellowship.
CR Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003
   Armant DR, 2005, DEV BIOL, V280, P260, DOI 10.1016/j.ydbio.2005.02.009
   Arnold SJ, 2009, NAT REV MOL CELL BIO, V10, P91, DOI 10.1038/nrm2618
   Barry G, 2013, EXP APPL ACAROL, V59, P319, DOI 10.1007/s10493-012-9598-x
   Bermejo JL, 2013, INT J CANCER, V133, P362, DOI 10.1002/ijc.28040
   Bruinsma CF, 2016, HUM MOL GENET, V25, P1, DOI 10.1093/hmg/ddv436
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   Burton A, 2014, NAT REV MOL CELL BIO, V15, P722, DOI 10.1038/nrm3885
   Cockburn K, 2010, J CLIN INVEST, V120, P995, DOI 10.1172/JCI41229
   Cox BJ, 2010, GENOME RES, V20, P1154, DOI 10.1101/gr.105106.110
   Cui W, 2016, MOL REPROD DEV, V83, P124, DOI 10.1002/mrd.22600
   Cui W, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.113.108266
   Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905
   David G, 2008, P NATL ACAD SCI USA, V105, P4168, DOI 10.1073/pnas.0710285105
   Daxinger L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r96
   Dietrich JE, 2015, EMBO REP, V16, P1005, DOI 10.15252/embr.201540162
   Eppig JT, 2015, NUCLEIC ACIDS RES, V43, pD726, DOI 10.1093/nar/gku967
   Fleming TP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1000, DOI 10.2741/Fleming
   Flicek P, 2013, NUCLEIC ACIDS RES, V41, pD48, DOI 10.1093/nar/gks1236
   Fong B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-2
   Gérard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828
   Guérin P, 2001, HUM REPROD UPDATE, V7, P175, DOI 10.1093/humupd/7.2.175
   Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534-5807(03)00373-3
   Hutten S, 2014, J CELL SCI, V127, P1065, DOI 10.1242/jcs.141788
   Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
   Kim J, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005970
   Kipp AP, 2012, BBA-GEN SUBJECTS, V1820, P1588, DOI 10.1016/j.bbagen.2012.05.016
   Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047
   LATHAM KE, 1991, MOL REPROD DEV, V30, P182, DOI 10.1002/mrd.1080300303
   Li L, 2013, MOL ASPECTS MED, V34, P919, DOI 10.1016/j.mam.2013.01.003
   Li Q, 2011, BIOL REPROD, V84, P1111, DOI 10.1095/biolreprod.110.089557
   Ma P, 2016, CELL DEATH DIFFER, V23, P1119, DOI 10.1038/cdd.2016.31
   Marcho C, 2015, REPRODUCTION, V150, pR109, DOI 10.1530/REP-15-0180
   Marikawa Y, 2009, MOL REPROD DEV, V76, P1019, DOI 10.1002/mrd.21057
   Martello G, 2013, EMBO J, V32, P2561, DOI 10.1038/emboj.2013.177
   Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850
   Maserati M, 2014, ZYGOTE, V22, P331, DOI 10.1017/S0967199412000561
   Maserati M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022516
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3
   Nestorov P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14347
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9
   Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040
   Okamoto Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19134
   Paul S, 2014, MOL REPROD DEV, V81, P171, DOI 10.1002/mrd.22219
   Petrinovic MM, 2013, P NATL ACAD SCI USA, V110, P1083, DOI 10.1073/pnas.1214255110
   Pfender S, 2015, NATURE, V524, P239, DOI 10.1038/nature14568
   Qin JW, 2005, BIOL REPROD, V73, P434, DOI 10.1095/biolreprod.105.040030
   Qin JW, 2005, MOL REPROD DEV, V70, P455, DOI 10.1002/mrd.20225
   Sánchez F, 2012, BBA-MOL BASIS DIS, V1822, P1896, DOI 10.1016/j.bbadis.2012.05.013
   Schultz RM, 2002, HUM REPROD UPDATE, V8, P323, DOI 10.1093/humupd/8.4.323
   Sengoku K, 2001, MOL REPROD DEV, V58, P262, DOI 10.1002/1098-2795(200103)58:3<262::AID-MRD3>3.0.CO;2-8
   SPINDLE AI, 1973, THE JOURNAL OF EXPER, V186, P305, DOI DOI 10.1002/JEZ.1401860308
   Stein P, 2005, DEV BIOL, V286, P464, DOI 10.1016/j.ydbio.2005.08.015
   Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801
   Sun YH, 2015, INT J CLIN EXP PATHO, V8, P9081
   Svoboda P, 2000, DEVELOPMENT, V127, P4147
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100
   Wang HM, 2014, CELL RES, V24, P1067, DOI 10.1038/cr.2014.99
   Wang JD, 2013, PEST MANAG SCI, V69, P781, DOI 10.1002/ps.3432
   Wang QT, 2004, DEV CELL, V6, P133, DOI 10.1016/S1534-5807(03)00404-0
   Weng TT, 2014, AM J RESP CRIT CARE, V190, P1402, DOI 10.1164/rccm.201404-0744OC
   Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016
   Wilson RC, 2013, ANNU REV BIOPHYS, V42, P217, DOI 10.1146/annurev-biophys-083012-130404
   Wu GM, 2010, DEVELOPMENT, V137, P4159, DOI 10.1242/dev.056630
   Wu WL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh010
   Xenopoulos Panagiotis, 2012, Results Probl Cell Differ, V55, P185, DOI 10.1007/978-3-642-30406-4_10
   Yan LY, 2013, NAT STRUCT MOL BIOL, V20, P1131, DOI 10.1038/nsmb.2660
   You FM, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-253
   YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0
   Yu SY, 2011, BLOOD, V117, P2166, DOI 10.1182/blood-2010-09-306563
   Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018
   Zernicka-Goetz M, 2009, NAT REV GENET, V10, P467, DOI 10.1038/nrg2564
   Zhang K, 2013, DEV BIOL, V383, P15, DOI 10.1016/j.ydbio.2013.09.005
   Zhang K, 2013, DEV BIOL, V373, P359, DOI 10.1016/j.ydbio.2012.10.026
   Zhou LQ, 2015, TRENDS CELL BIOL, V25, P82, DOI 10.1016/j.tcb.2014.09.006
NR 76
TC 26
Z9 31
U1 0
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 21
PY 2016
VL 6
AR 37396
DI 10.1038/srep37396
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EC5RW
UT WOS:000388194900001
PM 27869233
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mair, B
   Konopka, T
   Kerzendorfer, C
   Sleiman, K
   Salic, S
   Serra, V
   Muellner, MK
   Theodorou, V
   Nijman, SMB
AF Mair, Barbara
   Konopka, Tomasz
   Kerzendorfer, Claudia
   Sleiman, Katia
   Salic, Sejla
   Serra, Violeta
   Muellner, Markus K.
   Theodorou, Vasiliki
   Nijman, Sebastian M. B.
TI Gain- and Loss-of-Function Mutations in the Breast Cancer Gene
   <i>GATA3</i> Result in Differential Drug Sensitivity
SO PLOS GENETICS
LA English
DT Article
ID G9A HISTONE METHYLTRANSFERASE; LUMINAL CELL FATE; SOMATIC MUTATIONS;
   MUTANT P53; NUCLEAR-LOCALIZATION; MOLECULAR PORTRAITS;
   ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; EXPRESSION DATA
AB Patterns of somatic mutations in cancer genes provide information about their functional role in tumourigenesis, and thus indicate their potential for therapeutic exploitation. Yet, the classical distinction between oncogene and tumour suppressor may not always apply. For instance, TP53 has been simultaneously associated with tumour suppressing and promoting activities. Here, we uncover a similar phenomenon for GATA3, a frequently mutated, yet poorly understood, breast cancer gene. We identify two functional classes of frameshift mutations that are associated with distinct expression profiles in tumours, differential disease-free patient survival and gain-and loss-of-function activities in a cell line model. Furthermore, we find an estrogen receptor-independent synthetic lethal interaction between a GATA3 frameshift mutant with an extended C-terminus and the histone methyltransferases G9A and GLP, indicating perturbed epigenetic regulation. Our findings reveal important insights into mutant GATA3 function and breast cancer, provide the first potential therapeutic strategy and suggest that dual tumour suppressive and oncogenic activities are more widespread than previously appreciated.
C1 [Mair, Barbara; Kerzendorfer, Claudia; Sleiman, Katia; Muellner, Markus K.; Nijman, Sebastian M. B.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.
   [Mair, Barbara; Konopka, Tomasz; Salic, Sejla; Nijman, Sebastian M. B.] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford, England.
   [Mair, Barbara; Konopka, Tomasz; Salic, Sejla; Nijman, Sebastian M. B.] Univ Oxford, Target Discovery Inst, Nuffield Dept Clin Med, Oxford, England.
   [Serra, Violeta] Vali dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain.
   [Theodorou, Vasiliki] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Crete, Greece.
   [Muellner, Markus K.] PhoreMost Ltd, Babraham Sci Pk, Cambridge, England.
C3 Austrian Academy of Sciences; CeMM Research Center for Molecular
   Medicine of the Austrian Academy of Sciences; Ludwig Institute for
   Cancer Research; University of Oxford; University of Oxford; Foundation
   for Research & Technology - Hellas (FORTH); UK Research & Innovation
   (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC);
   Babraham Institute
RP Nijman, SMB (通讯作者)，Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.; Nijman, SMB (通讯作者)，Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford, England.; Nijman, SMB (通讯作者)，Univ Oxford, Target Discovery Inst, Nuffield Dept Clin Med, Oxford, England.
EM sebastian.nijman@ludwig.ox.ac.uk
RI Theodorou, Vasiliki/H-1576-2016; Muellner, Markus/HNS-3544-2023; Serra,
   Violeta/AAG-8328-2019
OI Konopka, Tomasz/0000-0003-3042-4712; Theodorou,
   Vasiliki/0000-0003-1614-700X; Nijman, Sebastian/0000-0003-0464-6661;
   Mair, Barbara/0000-0001-6982-2529; Serra, Violeta/0000-0001-6620-1065
FU European Research Council under the European Union [311166]; DOC
   fellowship of the Austrian Academy of Sciences; FERO Foundation;
   Wellcome Trust [090532/Z/09/Z]; MRC [G0900747 91070]; European Research
   Council (ERC) [311166] Funding Source: European Research Council (ERC)
FX The research leading to these results has received funding from the
   European Research Council under the European Union's Seventh Framework
   Programme (FP7/2007-2013)/ERC grant agreement no. [311166]. BM was
   supported by a DOC fellowship of the Austrian Academy of Sciences. The
   PDX model generation was supported by a "GHD-pink" research support via
   the FERO Foundation to VS. The High-Throughput Genomics Group at the
   Wellcome Trust Centre for Human Genetics is funded by Wellcome Trust
   grant reference 090532/Z/09/Z and MRC Hub grant G0900747 91070. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adomas AB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-278
   Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bates DL, 2008, J MOL BIOL, V381, P1292, DOI 10.1016/j.jmb.2008.06.072
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Busch M, 2014, HUM MOL GENET, V23, P3958, DOI 10.1093/hmg/ddu111
   Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560
   Chen TH, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2727-x
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943
   Chu IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061125
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111
   Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Du F, 2015, MED RES REV, V35, P1300, DOI 10.1002/med.21362
   Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   Gaynor KU, 2013, HORM CANCER-US, V4, P123, DOI 10.1007/s12672-013-0138-x
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hoch RV, 1999, INT J CANCER, V84, P122
   Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488
   Jiang YZ, 2014, CANCER-AM CANCER SOC, V120, P1329, DOI 10.1002/cncr.28566
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347
   KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
   Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lee J, 2014, NUCLEIC ACIDS RES, V42, P6839, DOI 10.1093/nar/gku360
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu JJ, 2016, CANCER LETT, V376, P104, DOI 10.1016/j.canlet.2016.03.038
   Liu SJ, 2014, CANCER RES, V74, P641, DOI 10.1158/0008-5472.CAN-13-2319
   Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Nehrt NL, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S4-S9
   Nguyen AHT, 2013, HUM MOL GENET, V22, P2400, DOI 10.1093/hmg/ddt088
   Nijman SMB, 2015, NAT CHEM BIOL, V11, P942, DOI 10.1038/nchembio.1963
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Ping Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep27545
   Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040
   Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Tindemans I, 2014, IMMUNITY, V41, P191, DOI 10.1016/j.immuni.2014.06.006
   Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531
   Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
   Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251
NR 88
TC 36
Z9 42
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD SEP
PY 2016
VL 12
IS 9
AR e1006279
DI 10.1371/journal.pgen.1006279
PG 26
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DZ7TF
UT WOS:000386069000015
PM 27588951
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Andrieu, G
   Tran, AH
   Strissel, KJ
   Denis, GV
AF Andrieu, Guillaume
   Tran, Anna H.
   Strissel, Katherine J.
   Denis, Gerald V.
TI BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1
   Signaling
SO CANCER RESEARCH
LA English
DT Article
ID BET BROMODOMAIN INHIBITION; NOTCH LIGAND; T-CELLS; THERAPEUTIC TARGET;
   COLORECTAL-CANCER; DENDRITIC CELLS; INFLAMMATION; CHROMATIN; PROTEIN;
   KINASE
AB The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers. However, it remains unclear howindividual family members participate in cancer progression and small molecule inhibitors such as JQ1 can target functionally independent BET proteins. Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-negative breast cancer migration and invasion. BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling. BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion. BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation. Moreover, in patients, BRD4 and Jagged1 expression positively correlated with the presence of distant metastases. These results identify a BRD4/Jagged1/Notch1 signaling pathway that is critical for dissemination of triple-negative breast cancer. (C) 2016 AACR.
C1 [Andrieu, Guillaume; Tran, Anna H.; Strissel, Katherine J.; Denis, Gerald V.] Boston Univ, Sch Med, Ctr Canc, Boston, MA 02118 USA.
   [Denis, Gerald V.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Denis, GV (通讯作者)，Boston Univ, Sch Med, 72 East Concord St,Room K520, Boston, MA 02118 USA.
EM gdenis@bu.edu
OI Denis, Gerald/0000-0001-9886-0401; Andrieu,
   Guillaume/0000-0003-0289-4952
FU NIH [U01CA182898]
FX This work was supported by a grant from the NIH (U01CA182898) to G.V.
   Denis.
CR Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838
   Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Bugeon L, 2008, J IMMUNOL, V181, P8189, DOI 10.4049/jimmunol.181.12.8189
   Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111
   Chen HF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5697
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Dai Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.137
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u
   Denis GV, 2000, CELL GROWTH DIFFER, V11, P417
   Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261
   Dey A, 2009, MOL BIOL CELL, V20, P4899, DOI 10.1091/mbc.E09-05-0380
   Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055
   Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126
   Gopisetty A, 2013, J IMMUNOL, V190, P5516, DOI 10.4049/jimmunol.1202298
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guo N, 2000, J CELL SCI, V113, P3085
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   High FA, 2008, P NATL ACAD SCI USA, V105, P1955, DOI 10.1073/pnas.0709663105
   Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928
   Kim MH, 2013, J CLIN INVEST, V123, P3211, DOI 10.1172/JCI65521
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Li D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00254
   Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846
   Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Motz GT, 2013, IMMUNITY, V39, P61, DOI 10.1016/j.immuni.2013.07.005
   Nadeem A, 2015, PHARMACOL RES, V99, P248, DOI 10.1016/j.phrs.2015.06.001
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Vigouroux S, 2003, J VIROL, V77, P10872, DOI 10.1128/JVI.77.20.10872-10880.2003
   Wang F, 2013, VITAM HORM, V91, P49, DOI 10.1016/B978-0-12-407766-9.00003-1
   Wang FN, 2010, BIOCHEM J, V425, P71, DOI 10.1042/BJ20090928
   Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200
   Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299
   Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048
   Yvon ES, 2003, BLOOD, V102, P3815, DOI 10.1182/blood-2002-12-3826
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 50
TC 104
Z9 119
U1 0
U2 28
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2016
VL 76
IS 22
BP 6555
EP 6567
DI 10.1158/0008-5472.CAN-16-0559
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED3IF
UT WOS:000388742100014
PM 27651315
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Cotarelo, CL
   Schad, A
   Kirkpatrick, CJ
   Sleeman, JP
   Springer, E
   Schmidt, M
   Thaler, S
AF Cotarelo, Cristina L.
   Schad, Arno
   Kirkpatrick, Charles James
   Sleeman, Jonathan P.
   Springer, Erik
   Schmidt, Marcus
   Thaler, Sonja
TI Detection of cellular senescence within human invasive breast carcinomas
   distinguishes different breast tumor subtypes
SO ONCOTARGET
LA English
DT Article
DE cellular senescence; breast cancer subtypes; breast cancer pathology
ID GENE-EXPRESSION; DNA-DAMAGE; CANCER; P53; CELLS; OVEREXPRESSION;
   TUMORIGENESIS; SURVEILLANCE; RESTORATION; HALLMARKS
AB Oncogene-induced senescence is thought to act as a barrier to tumorigenesis by arresting cells at risk of malignant transformation. Nevertheless, numerous findings suggest that senescent cells may conversely promote tumor progression through the development of the senescence-associated secretome they produce. It is likely that the composition and the physiological consequences mediated by the senescence secretome are dependent on the oncogenes that trigger the senescence program. Breast cancer represents a heterogenous disease that can be divided into breast cancer subtypes due to different subsets of genetic and epigenetic abnormalities. As tumor initiation and progression of these breast cancer subtypes is triggered by diverse oncogenic stimuli, differences in the senescence secretomes within breast tumors might be responsible for tumor initiation, progression, metastasis and therapeutic response. Many studies have addressed the role of senescence as a barrier to tumor progression using murine xenograft models. However, few investigations have been performed to elucidate the degree to which senescent tumor cells are present within untreated human tumors, and if present, whether these senescent tumor cells may play a role in disease progression. In the present study we analysed the appearance of senescent cells within invasive breast cancers. Detection of cellular senescence by the use of SA beta-galactosidase (SA beta-gal) staining within invasive breast carcinoms from 129 untreated patients revealed differences in the amount of SA beta-gal+tumor cells between breast cancer subtypes. The highest percentages of SA beta-gal+tumor cells were found in HER2-positive and luminal A breast carcinomas whereas triple negative tumors showed either little or no positivity.
C1 [Cotarelo, Cristina L.; Schad, Arno; Kirkpatrick, Charles James; Springer, Erik] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Pathol, Mainz, Germany.
   [Sleeman, Jonathan P.; Thaler, Sonja] Heidelberg Univ, Med Fac Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Mannheim, Germany.
   [Sleeman, Jonathan P.] KIT Campus Nord, Inst Toxicol & Genet, Karlsruhe, Germany.
   [Schmidt, Marcus] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Obstet & Gynecol, Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Ruprecht Karls University
   Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology;
   Johannes Gutenberg University of Mainz
RP Thaler, S (通讯作者)，Heidelberg Univ, Med Fac Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Mannheim, Germany.
EM Sonja.Thaler@medma.uni-heidelberg.de
RI Thaler, Sonja/AAC-4784-2020; Schmidt, Marcus/H-3383-2013; Sleeman,
   Jonathan/H-2515-2013
OI Kirkpatrick, Charles James/0000-0002-0088-418X; Sleeman,
   Jonathan/0000-0003-1718-7687
FU Deutsche Forschungsgemeinschaft (DFG) [TH1523/1-2, TH1523/2-2]
FX Financial support was obtained from the Deutsche Forschungsgemeinschaft
   (DFG grant TH1523/1-2 and TH1523/2-2 to S. Thaler).
CR Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Bavik C, 2006, CANCER RES, V66, P794, DOI 10.1158/0008-5472.CAN-05-1716
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918
   Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Coppé JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Angelini PD, 2013, CANCER RES, V73, P450, DOI 10.1158/0008-5472.CAN-12-2301
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884
   Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herschkowitz JI, BREAST CANC RES, V10, pR75
   Hoenicke L, 2012, CARCINOGENESIS, V33, P1123, DOI 10.1093/carcin/bgs124
   Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599
   Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560
   Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
   Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275
   Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shah PP, 2013, GENE DEV, V27, P1787, DOI 10.1101/gad.223834.113
   Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518
   Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111
   te Poele RH, 2002, CANCER RES, V62, P1876
   Untch M, 2013, BREAST CARE, V8, P221, DOI 10.1159/000351692
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541
   Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289
   Walerych D, 2012, CARCINOGENESIS, V33, P2007, DOI 10.1093/carcin/bgs232
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008-5472.CAN-06-1594
NR 44
TC 17
Z9 18
U1 2
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2016
VL 7
IS 46
BP 74846
EP 74859
DI 10.18632/oncotarget.12432
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5GF
UT WOS:000389632800033
PM 27713152
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Rizzo, F
   Rinaldi, A
   Marchese, G
   Coviello, E
   Sellitto, A
   Cordella, A
   Giurato, G
   Nassa, G
   Ravo, M
   Tarallo, R
   Milanesi, L
   Destro, A
   Torzilli, G
   Roncalli, M
   Di Tommaso, L
   Weisz, A
AF Rizzo, Francesca
   Rinaldi, Antonio
   Marchese, Giovanna
   Coviello, Elena
   Sellitto, Assunta
   Cordella, Angela
   Giurato, Giorgio
   Nassa, Giovanni
   Ravo, Maria
   Tarallo, Roberta
   Milanesi, Luciano
   Destro, Anna
   Torzilli, Guido
   Roncalli, Massimo
   Di Tommaso, Luca
   Weisz, Alessandro
TI Specific patterns of PIWI-interacting small noncoding RNA expression in
   dysplastic liver nodules and hepatocellular carcinoma
SO ONCOTARGET
LA English
DT Article
DE hepatocarcinogenesis; hepatocellular carcinoma; piRNAs; small non-coding
   RNA; smallRNA-seq
ID SIGNALING PATHWAYS; MESSENGER-RNAS; BREAST-CANCER; PIRNAS; CELLS;
   IDENTIFICATION; REGENERATION; BIOGENESIS; CARCINOGENESIS; METASTASIS
AB Hepatocellular carcinoma ( HCC) is the result of a stepwise process, often beginning with development within a cirrhotic liver of premalignant lesions, morphologically characterized by low-( LGDN) and high-grade ( HGDN) dysplastic nodules. PIWI-interacting RNAs ( piRNAs) are small noncoding RNAs ( sncRNAs), 23-35 nucleotide-long, exerting epigenetic and post-transcriptional regulation of gene expression. Recently the PIWI-piRNA pathway, best characterized in germline cells, has been identified also in somatic tissues, including stem and cancer cells, where it influences key cellular processes.
   Small RNA sequencing was applied to search for liver piRNAs and to profile their expression patterns in cirrhotic nodules ( CNs), LGDN, HGDN, early HCC and progressed HCC ( pHCC), analyzing 55 samples ( 14 CN, 9 LGDN, 6 HGDN, 6 eHCC and 20 pHCC) from 17 patients, aiming at identifying possible relationships between these sncRNAs and liver carcinogenesis. We identified a 125 piRNA expression signature that characterize HCC from matched CNs, correlating also to microvascular invasion in HCC. Functional analysis of the predicted RNA targets of deregulated piRNAs indicates that these can target key signaling pathways involved in hepatocarcinogenesis and HCC progression, thereby affecting their activity. Interestingly, 24 piRNAs showed specific expression patterns in dysplastic nodules, respect to cirrhotic liver and/ or pHCC.
   The results demonstrate that the PIWI-piRNA pathway is active in human liver, where it represents a new player in the molecular events that characterize hepatocarcinogenesis, from early stages to pHCC. Furthermore, they suggest that piRNAs might be new disease biomarkers, useful for differential diagnosis of dysplastic and neoplastic liver lesions.
C1 [Rizzo, Francesca; Rinaldi, Antonio; Coviello, Elena; Sellitto, Assunta; Giurato, Giorgio; Nassa, Giovanni; Ravo, Maria; Tarallo, Roberta; Weisz, Alessandro] Univ Salerno, Lab Mol Med & Genom, Dept Med Surg & Dent Schola Med Salernitana, Baronissi, SA, Italy.
   [Marchese, Giovanna; Giurato, Giorgio; Nassa, Giovanni] Univ Salerno, Genomix4life, Baronissi, SA, Italy.
   [Cordella, Angela] Fdn IRCCS SDN, Naples, Italy.
   [Milanesi, Luciano] CNR, Inst Biomed Technol, Milan, Italy.
   [Destro, Anna; Roncalli, Massimo; Di Tommaso, Luca] Humanitas Clin & Res Ctr, Pathol Unit, Rozzano Milan, Italy.
   [Torzilli, Guido; Roncalli, Massimo; Di Tommaso, Luca] Humanitas Univ, Dept Biomed Sci, Rozzano Milan, Italy.
   [Torzilli, Guido] Humanitas Clin & Res Ctr, Hepatobiliary & Gen Surg, Rozzano Milan, Italy.
C3 University of Salerno; University of Salerno; IRCCS Istituto di Ricerca
   Diagnostica e Nucleare (SDN); Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Tecnologie Biomediche (ITB-CNR); Humanitas University
RP Weisz, A (通讯作者)，Univ Salerno, Lab Mol Med & Genom, Dept Med Surg & Dent Schola Med Salernitana, Baronissi, SA, Italy.
EM aweisz@unisa.it
RI Milanesi, Luciano/AAE-7230-2019; Nassa, Giovanni/AAB-2059-2022;
   Sellitto, Assunta/AEL-1404-2022; Rinaldi, Antonio/KEH-6587-2024;
   Giurato, Giorgio/K-3859-2018; Tarallo, Roberta/C-2600-2014; TORZILLI,
   GUIDO/AAC-8149-2019; di tommaso, luca/ACI-7061-2022; Roncalli,
   Massimo/HJZ-1838-2023; DESTRO, ANNARITA/HII-7324-2022; Weisz,
   Alessandro/A-1317-2014; Rizzo, Francesca/K-3057-2016
OI SELLITTO, Assunta/0000-0002-6555-2362; Marchese,
   Giovanna/0000-0002-9594-0729; Cordella, Angela/0000-0001-9784-7010;
   Ravo, Maria/0000-0003-1003-2922; Rinaldi, Antonio/0000-0001-8854-6048;
   Milanesi, Luciano/0000-0002-1201-3939; Giurato,
   Giorgio/0000-0002-0538-8978; Tarallo, Roberta/0000-0001-9668-3632;
   TORZILLI, GUIDO/0000-0001-5798-5021; di tommaso,
   luca/0000-0002-9013-4728; Roncalli, Massimo/0000-0002-7901-8910; DESTRO,
   ANNARITA/0000-0001-5388-0353; Weisz, Alessandro/0000-0003-0455-2083;
   Rizzo, Francesca/0000-0003-1783-5015
FU MIUR [PRIN 2010LC747T, FIRB RBFR12W5V5_003]; AIRC [IG-17426, IG-15437];
   CNR; University of Salerno [FARB 2014, 2015]; University of Milano
   [Unimi-FD-BIOMETRA-2014]; Genomix4Life Srl
FX Work supported by: MIUR (Grants: PRIN 2010LC747T and FIRB
   RBFR12W5V5_003), AIRC (Grants: IG-17426 and IG-15437), CNR (Flagship
   Projects Epigen and InterOmics), University of Salerno (Grants: FARB
   2014 and 2015), University of Milano (Grant: Unimi-FD-BIOMETRA-2014) and
   Genomix4Life Srl.
CR Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004
   Coban Z, 2012, J CELL BIOCHEM, V113, P2179, DOI 10.1002/jcb.24104
   Di Tommaso L, 2013, BEST PRACT RES CL GA, V27, P269, DOI 10.1016/j.bpg.2013.03.015
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Ghidini M, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00036
   Giurato G, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-362
   Gou LT, 2014, CELL RES, V24, P680, DOI 10.1038/cr.2014.41
   Han BW, 2014, CURR BIOL, V24, pR730, DOI 10.1016/j.cub.2014.07.037
   Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476
   Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131
   Houwing S, 2007, CELL, V129, P69, DOI 10.1016/j.cell.2007.03.026
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Ishizu H, 2015, CELL REP, V12, P429, DOI 10.1016/j.celrep.2015.06.035
   Jiang JX, 2011, CELL BIOCHEM BIOPHYS, V61, P53, DOI 10.1007/s12013-011-9160-1
   Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193
   Lakshmi SS, 2008, NUCLEIC ACIDS RES, V36, pD173, DOI 10.1093/nar/gkm696
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Law PTY, 2013, J HEPATOL, V58, P1165, DOI 10.1016/j.jhep.2013.01.032
   Li YP, 2015, MOL MED, V21, P381, DOI 10.2119/molmed.2014.00203
   Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677
   Lu YL, 2010, BMB REP, V43, P635, DOI 10.3858/BMBRep.2010.43.9.635
   Macaulay IC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004126
   Martinez VD, 2016, GASTRIC CANCER, V19, P660, DOI 10.1007/s10120-015-0487-y
   Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423
   Mei YP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8316
   Moeini A, 2012, LIVER CANCER, V1, P83, DOI 10.1159/000342405
   Müller S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0358-5
   Nault JC, 2014, HEPATOLOGY, V60, P1983, DOI 10.1002/hep.27372
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ravo M, 2015, ONCOTARGET, V6, P4677, DOI 10.18632/oncotarget.2911
   Reuter M, 2011, NATURE, V480, P264, DOI 10.1038/nature10672
   Rizzo F, 2014, HEPATOLOGY, V60, P798, DOI 10.1002/hep.27267
   Rouget C, 2010, NATURE, V467, P1128, DOI 10.1038/nature09465
   SAKAMOTO M, 1991, HUM PATHOL, V22, P172, DOI 10.1016/0046-8177(91)90039-R
   Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0
   Shi JH, 2014, WORLD J GASTROENTERO, V20, P16167, DOI 10.3748/wjg.v20.i43.16167
   Siomi MC, 2011, NAT REV MOL CELL BIO, V12, P246, DOI 10.1038/nrm3089
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
   Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711
   Thomson T, 2009, ANNU REV CELL DEV BI, V25, P355, DOI 10.1146/annurev.cellbio.24.110707.175327
   Tornillo L, 2002, LAB INVEST, V82, P547, DOI 10.1038/labinvest.3780449
   Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333
   Weick EM, 2014, DEVELOPMENT, V141, P3458, DOI 10.1242/dev.094037
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Xie YJ, 2015, MOL MED REP, V11, P1455, DOI 10.3892/mmr.2014.2847
   Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135
   Zhang P, 2015, CELL RES, V25, P193, DOI [10.1038/cr.2015.14, 10.1038/cr.2015.4]
   Zhang Y, 2011, BIOINFORMATICS, V27, P771, DOI 10.1093/bioinformatics/btr016
   Zhao YM, 2012, CANCER-AM CANCER SOC, V118, P2708, DOI 10.1002/cncr.26524
   2009, HEPATOLOGY, V49, P658, DOI DOI 10.1002/HEP.22709
NR 54
TC 52
Z9 55
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 23
PY 2016
VL 7
IS 34
BP 54650
EP 54661
DI 10.18632/oncotarget.10567
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9DY
UT WOS:000385435000046
PM 27429044
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kong, HK
   Park, SJ
   Kim, YS
   Kim, KM
   Lee, HW
   Kang, HG
   Woo, YM
   Park, EY
   Ko, JY
   Suzuki, H
   Chun, KH
   Song, E
   Jang, KY
   Park, JH
AF Kong, Hyun Kyung
   Park, Sae Jeong
   Kim, Ye Sol
   Kim, Kyoung Min
   Lee, Hyun-Woo
   Kang, Hyeok-Gu
   Woo, Yu Mi
   Park, Eun Young
   Ko, Je Yeong
   Suzuki, Hiromu
   Chun, Kyung-Hee
   Song, Erwei
   Jang, Kyu Yun
   Park, Jong Hoon
TI Epigenetic activation of LY6K predicts the presence of metastasis and
   poor prognosis in breast carcinoma
SO ONCOTARGET
LA English
DT Article
DE breast cancer; LY6K; metastasis; DNA methylation; histone modification
ID CPG ISLAND SHORES; CANCER GENOMICS; LY-6K GENE; STEM-CELLS; METHYLATION;
   HYPERMETHYLATION; EXPRESSION; PROMOTER; TUMORS
AB The role of lymphocyte antigen 6 complex, locus K (LY6K) in breast cancer has been studied, whereas the epigenetic control of LY6K transcription is not fully understood. Here, we report that breast cancer patients with increased LY6K expression had shorter disease-free and overall survival than the patients with low levels of LY6K by multivariate analysis. LY6K also was upregulated in breast cancer patients with distant metastases than those without distant metastases, downregulating E-cadherin expression. Furthermore, xenograft tumor volumes from LY6K knockdown nude mice were reduced than those of mice treated with control lentivirus. Interestingly, LY6K has a CpG island (CGI) around the transcription start site and non-CGI in its promoter, called a CGI shore. LY6K expression was inversely correlated with methylation in not only CGI but CGI shore, which are associated with histone modifications. Additionally, LY6K methylation was increased by the PAX3 transcription factor due to the SNP242 mutation in LY6K CGI shore. Taken together, breast cancer risk and metastasis were significantly associated with not only LY6K expression, but also methylation of CGI shore which induced by SNP242 mutation. Our results suggest that an understanding epigenetic mechanism of the LY6K gene may be useful to diagnose carcinogenic risk and predict outcomes of patients with metastatic breast cancer.
C1 [Kong, Hyun Kyung; Park, Sae Jeong; Kim, Ye Sol; Woo, Yu Mi; Park, Eun Young; Ko, Je Yeong; Park, Jong Hoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.
   [Kim, Kyoung Min; Jang, Kyu Yun] Chonbuk Natl Univ, Sch Med, Dept Pathol, Res Inst Clin Med, Jeonju, South Korea.
   [Kim, Kyoung Min; Jang, Kyu Yun] Res Inst Endocrine Sci, Jeonju, South Korea.
   [Lee, Hyun-Woo; Kang, Hyeok-Gu; Chun, Kyung-Hee] Yonsei Univ, Dept Biochem & Mol Biol, Coll Med, Seoul, South Korea.
   [Lee, Hyun-Woo] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea.
   [Kang, Hyeok-Gu; Chun, Kyung-Hee] Yonsei Univ, Brain Korea PLUS Project Med Sci 21, Coll Med, Seoul, South Korea.
   [Suzuki, Hiromu] Sapporo Med Univ, Dept Mol Biol, Sapporo, Hokkaido, Japan.
   [Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China.
C3 Sookmyung Women's University; Jeonbuk National University; Yonsei
   University; Yonsei University Health System; Yonsei University; Yonsei
   University; Yonsei University Health System; Sapporo Medical University;
   Sun Yat Sen University
RP Park, JH (通讯作者)，Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.; Jang, KY (通讯作者)，Chonbuk Natl Univ, Sch Med, Dept Pathol, Res Inst Clin Med, Jeonju, South Korea.; Jang, KY (通讯作者)，Res Inst Endocrine Sci, Jeonju, South Korea.; Song, E (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China.
EM songerwei02@yahoo.com.cn; kyjang@chonbuk.ac.kr; parkjh@sookmyung.ac.kr
RI Kim, Yesol/ABI-1909-2020
OI Chun, Kyung-Hee/0000-0002-9867-7321; Kim, Yesol/0009-0001-7665-9472
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2016R1A2A1A05005295, 2016R1A 5A1011974, 2013R1A1A2059379]
FX This study was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIP) (2016R1A2A1A05005295,
   2016R1A 5A1011974, and Research fellow 2013R1A1A2059379).
CR Britton Kelly M, 2011, Cancers (Basel), V3, P2106, DOI 10.3390/cancers3022106
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Choi SH, 2009, INT J ONCOL, V35, P601, DOI 10.3892/ijo_00000371
   Dalen AGD, 2003, INT J CANCER, V103, P768, DOI 10.1002/ijc.10903
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gustavson MD, 2009, APPL IMMUNOHISTO M M, V17, P329, DOI 10.1097/PAI.0b013e318195ecaa
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Hsieh MJ, 2006, BIOCHEM BIOPH RES CO, V349, P573, DOI 10.1016/j.bbrc.2006.08.064
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ishikawa N, 2007, CANCER RES, V67, P11601, DOI 10.1158/0008-5472.CAN-07-3243
   Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270
   Lee JW, 2006, ONCOL REP, V16, P1211
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017
   Matsuda R, 2011, BRIT J CANCER, V104, P376, DOI 10.1038/sj.bjc.6605990
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Parrella P, 2010, BREAST CARE, V5, P66, DOI 10.1159/000309138
   Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Suda T, 2007, CANC SCI
   Yamamoto N, 2012, BREAST CANCER RES TR, V132, P165, DOI 10.1007/s10549-011-1575-2
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Zhang B, 2012, BIOMARKERS, V17, P372, DOI 10.3109/1354750X.2012.680609
NR 32
TC 12
Z9 16
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 23
PY 2016
VL 7
IS 34
BP 55677
EP 55689
DI 10.18632/oncotarget.10972
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9DY
UT WOS:000385435000122
PM 27494879
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Yao, L
   Chi, YY
   Hu, X
   Li, S
   Qiao, F
   Wu, J
   Shao, ZM
AF Yao, Ling
   Chi, Yayun
   Hu, Xin
   Li, Shan
   Qiao, Feng
   Wu, Jong
   Shao, Zhi-Ming
TI Elevated expression of RNA methyltransferase BCDIN3D predicts poor
   prognosis in breast cancer
SO ONCOTARGET
LA English
DT Article
DE BCDIN3D; breast cancer; TNBC
ID EPIGENETICS
AB Background: BCDIN3D is a member of the Bin3 methyl-transferase family that targets the 5' mono-phosphate of nucleic acids. Although BCDIN3D has been shown to increase tumorigenic phenotypes and invasiveness in MDA-MB-231 cells, its the clinical implications in breast cancer remain unclear. Methods: We screened for BCDIN3D using tissue microarrays constructed from 250 patients who were histologically confirmed to have invasive ductal breast carcinoma at the Fudan University Shanghai Cancer Center. Results: The survival analysis by Kaplan-Meier and Cox regression showed that BCDIN3D expression level served as a prognostic factor for disease-free survival (P = 0.042). The prognostic value of BCDIN3D was most significant in triplenegative breast cancer (TNBC) patients (P = 0.007). Conclusions: BCDIN3D might serve as an important prognostic factor for TNBC patients.
C1 [Yao, Ling; Chi, Yayun; Hu, Xin; Li, Shan; Qiao, Feng; Wu, Jong; Shao, Zhi-Ming] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr & Canc Inst, Shanghai, Peoples R China.
   [Wu, Jong; Shao, Zhi-Ming] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
   [Wu, Jong; Shao, Zhi-Ming] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Wu, J; Shao, ZM (通讯作者)，Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr & Canc Inst, Shanghai, Peoples R China.; Wu, J; Shao, ZM (通讯作者)，Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Wu, J; Shao, ZM (通讯作者)，Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.
EM wujiong1122@vip.sina.com; shaozmyl@126.com
RI Hu, Xin/JEP-4891-2023; Zhang, Lanjing/GZB-0260-2022; Wu,
   Jiong/LFT-4903-2024
FU National Natural Science Foundation of China [81202082]
FX This research was supported by grants from the National Natural Science
   Foundation of China (81202082). These funding agencies had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bastien RRL, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-44
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   FRANKEL AD, 1981, J MOL BIOL, V146, P611, DOI 10.1016/0022-2836(81)90049-8
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   He CA, 2010, NAT CHEM BIOL, V6, P863, DOI 10.1038/nchembio.482
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Kanwal R, 2010, J APPL PHYSIOL, V109, P598, DOI 10.1152/japplphysiol.00066.2010
   Liu N., 2014, Transl Res
   Loenen WAM, 2006, BIOCHEM SOC T, V34, P330, DOI 10.1042/BST0340330
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Sibbritt T, 2013, WIRES RNA, V4, P397, DOI 10.1002/wrna.1166
   Virani S, 2012, ILAR J, V53, P359, DOI 10.1093/ilar.53.3-4.359
   Xhemalce B, 2013, BRIEF FUNCT GENOMICS, V12, P244, DOI 10.1093/bfgp/els064
   Xhemalce B, 2012, CELL, V151, P278, DOI 10.1016/j.cell.2012.08.041
NR 18
TC 17
Z9 19
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 16
PY 2016
VL 7
IS 33
BP 53895
EP 53902
DI 10.18632/oncotarget.9656
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9DG
UT WOS:000385433000095
PM 27259993
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Li, M
   Li, X
   Zhuang, Y
   Wang, Y
   Burow, ME
   Collins-Burow, B
   Xue, M
   Song, CJ
   Shan, B
AF Li, Miao
   Li, Xi
   Zhuang, Yan
   Wang, Yan
   Burow, Matthew E.
   Collins-Burow, Bridgette
   Xue, Min
   Song, Chengjie
   Shan, Bin
TI Induction of HOXA9 expression in three-dimensional organotypic culture
   of the Claudin-low breast cancer cells
SO ONCOTARGET
LA English
DT Article
DE breast cancer; extracellular matrix; three-dimensional organotypic
   culture; gene expression; homeobox gene
ID NONCODING RNA HOTAIR; TO-MESENCHYMAL TRANSITION; LUNG ADENOCARCINOMA
   CELLS; GENE-EXPRESSION; THERAPEUTIC TARGET; I COLLAGEN; METHYLATION;
   METASTASIS; INHIBITION; SUBTYPES
AB The gene expression signatures of the molecular intrinsic subtypes of breast cancer are regulated by epigenetic mechanisms such as methylation of CpG islands in gene promoters. Epigenetic codes can be regulated by the tumor microenvironment. The Claudin-low subtype is associated with triple-negative invasive ductal carcinomas in patients. Herein we explored epigenetic regulation of gene expression in the Claudin-low breast cancer cells by extracellular matrix (ECM), a key component of the tumor microenvironment. We modeled attachment to ECM using laminin rich ECM three-dimensional organotypic culture (lrECM 3D). In 2D and lrECM 3D cultures we examined expression of the homeobox (HOX) genes that epigenetically regulated in development and cancer. We demonstrated induction of the selected HOX genes in lrECM 3D culture of the Claudin-low breast cancer cells MDA-MB-231 and Hs578T. In particular activation of HOXA9 expression in lrECM 3D culture required binding of bromodomain containing 4 to the HOXA9 promoter and involved CpG hypomethylation. Our findings warrant further investigation of the ECM-regulated epigenetic coding of gene expression in the Claudin-low breast cancer.
C1 [Li, Miao] China Med Univ, Dept Microbiol & Parasitol, Coll Basic Med Sci, Shenyang, Peoples R China.
   [Li, Xi] Peoples Hosp Liaoning Prov, Dept Sports Med & Joint Surg, Shenyang, Peoples R China.
   [Zhuang, Yan; Burow, Matthew E.; Collins-Burow, Bridgette] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
   [Wang, Yan] Zunyi Med Coll, Dept Biol Engn, Zhuhai Campus, Zhuhai, Peoples R China.
   [Xue, Min; Song, Chengjie] Xuzhou Med Coll, Dept Physiol, Xuzhou, Peoples R China.
   [Shan, Bin] Washington State Univ, Elson S Floyd Coll Med, Dept Biomed Sci, Spokane, WA 99202 USA.
C3 China Medical University; Tulane University; Zunyi Medical University;
   Xuzhou Medical University; Washington State University
RP Li, M (通讯作者)，China Med Univ, Dept Microbiol & Parasitol, Coll Basic Med Sci, Shenyang, Peoples R China.; Shan, B (通讯作者)，Washington State Univ, Elson S Floyd Coll Med, Dept Biomed Sci, Spokane, WA 99202 USA.
EM sendtolm@126.com; bin.shan@wsu.edu
RI Burow, Matthew/D-6351-2013
FU Washington State University Startup Fund; National Nature Science
   Foundation of China [81401334]; Education Departmental Natural Science
   Research Funds of Jiangsu Provincial Higher School of China
   [12KJB310018]
FX This work is supported by Washington State University Startup Fund
   awarded to BS and Grant No. 81401334 from the National Nature Science
   Foundation of China awarded to XL. MX and CS are supported by the
   Education Departmental Natural Science Research Funds of Jiangsu
   Provincial Higher School of China (12KJB310018). We are grateful to Dr.
   James Bradner for providing JQ1.
CR Amatangelo MD, 2013, CELL CYCLE, V12, P2113, DOI 10.4161/cc.25163
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   Friedland JC, 2007, J CELL SCI, V120, P3700, DOI 10.1242/jcs.03484
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lelièvre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y
   Li C, 2012, GENE, V511, P143, DOI 10.1016/j.gene.2012.09.093
   Li C, 2011, MOL CARCINOGEN, V50, P563, DOI 10.1002/mc.20742
   Li DD, 2013, AM J PATHOL, V182, P64, DOI 10.1016/j.ajpath.2012.08.042
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Licchesi Julien D. F., 2009, V507, P305, DOI 10.1007/978-1-59745-522-0_22
   Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497
   Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-16
   Nguyen HT, 2012, ONCOL REP, V28, P117, DOI 10.3892/or.2012.1764
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shan B, 2005, J BIOL CHEM, V280, P1103, DOI 10.1074/jbc.M406293200
   Shan B, 2005, EXP CELL RES, V305, P10, DOI 10.1016/j.yexcr.2004.09.033
   Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200
   Shan B, 2007, J MOL CELL CARDIOL, V42, P517, DOI 10.1016/j.yjmcc.2006.08.004
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Soshnikova N, 2009, EPIGENETICS-US, V4, P537, DOI 10.4161/epi.4.8.10132
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Teoh-Fitzgerald ML, 2014, ONCOGENE, V33, P358, DOI 10.1038/onc.2012.582
   Vizirianakis IS, 2001, ARCH BIOCHEM BIOPHYS, V385, P108, DOI 10.1006/abbi.2000.2134
   Yotsumoto F, 2013, MOL CANCER RES, V11, P506, DOI 10.1158/1541-7786.MCR-12-0428
   Zhuang Y, 2015, MOL CARCINOGEN, V54, P1656, DOI 10.1002/mc.22237
   Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35
   Zhuang Y, 2010, BIOCHEM BIOPH RES CO, V392, P608, DOI 10.1016/j.bbrc.2010.01.091
   Ziober BL, 1999, CELL GROWTH DIFFER, V10, P479
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 54
TC 10
Z9 13
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 9
PY 2016
VL 7
IS 32
BP 51503
EP 51514
DI 10.18632/oncotarget.10491
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9CC
UT WOS:000385429100059
PM 27409175
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Shen, KK
   Lu, FF
   Xie, JL
   Wu, MF
   Cai, B
   Liu, YR
   Zhang, H
   Tan, HS
   Pan, YY
   Xu, HX
AF Shen, Kaikai
   Lu, Fangfang
   Xie, Jianling
   Wu, Minfeng
   Cai, Bo
   Liu, Yurong
   Zhang, Hong
   Tan, Hongsheng
   Pan, Yingyi
   Xu, Hongxi
TI Cambogin exerts anti-proliferative and pro-apoptotic effects on breast
   adenocarcinoma through the induction of NADPH oxidase 1 and the
   alteration of mitochondrial morphology and dynamics
SO ONCOTARGET
LA English
DT Article
DE breast cancer; cambogin; reactive oxygen species; NADPH oxidase 1;
   thioredoxin-1/ASK1 complex
ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; SIGNAL-REGULATING KINASE-1; REACTIVE
   OXYGEN; CANCER-CELLS; EPIGENETIC REGULATION; OXIDATIVE STRESS; NOX
   FAMILY; DEATH; THIOREDOXIN; PATHWAY
AB Cambogin, a bioactive polycyclic polyprenylated acylphoroglucinol (PPAP) derived from the Garcinia genus, possesses proapoptotic effect in medulloblastoma and breast cancer cells. We have previously demonstrated that the proapoptotic effect of cambogin is driven by the production of reactive oxygen species (ROS). Here we have shown that the inhibitory effect of cambogin on cell proliferation is associated with the loss of mitochondrial transmembrane potential (Delta psi(m)) and mitochondrial fragmentation. Cambogin also promotes the mutual complex formation of the membrane-bound subunit p22(phox) of NADPH oxidase 1 (NOX1), as well as the phosphorylation of the cytosolic subunit p47(phox), subsequently enhancing membrane-bound NOX1 activity, which leads to increases in intracellular and mitochondrial levels of O-2(center dot-) and H2O2. Pharmacological inhibition of NOX1 using apocynin (pan-NOX inhibitor), ML171 (NOX1 inhibitor) or siRNA against NOX1 prevents the increases in O-2(center dot-) and H2O2 levels and the anti-proliferative effect of cambogin. Antioxidants, including SOD (superoxide dismutase), CAT (catalase) and EUK-8, are also able to restore cell viability in the presence of cambogin. Besides, cambogin increases the dissociation of thioredoxin-1 (Trx1) from ASK1, switching the inactive form of ASK1 to the active kinase, subsequently leads to the phosphorylation of JNK/SAPK, which is abolished upon ML171 treatment. The proapoptotic effect of cambogin in breast cancer cells is also aggravated upon knocking down Trx1 in MCF-7 cells. Taken in conjunction, these data indicate that the anti-proliferative and pro-apoptotic effect of cambogin is mediated via inducing NOX1-dependent ROS production and the dissociation of ASK1 and Trx1.
C1 [Shen, Kaikai; Lu, Fangfang; Wu, Minfeng; Cai, Bo; Liu, Yurong; Zhang, Hong; Tan, Hongsheng; Pan, Yingyi; Xu, Hongxi] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
   [Xu, Hongxi] Shanghai Univ TCM, Guanghua Integrat Med Hosp, Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 201203, Peoples R China.
   [Zhang, Hong; Tan, Hongsheng; Xu, Hongxi] Shanghai Coll TCM New Drug Discovery, Engn Res Ctr, Shanghai 201203, Peoples R China.
   [Xie, Jianling] South Australian Hlth & Med Res Inst, Nutr & Metab, North Terrace, Adelaide, SA 5000, Australia.
   [Xie, Jianling] Univ Southampton, Ctr Biol Sci, Life Sci Bldg, Southampton SO17 1BJ, Hants, England.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; South Australian Health & Medical
   Research Institute (SAHMRI); University of Southampton
RP Pan, YY; Xu, HX (通讯作者)，Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.; Xu, HX (通讯作者)，Shanghai Univ TCM, Guanghua Integrat Med Hosp, Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 201203, Peoples R China.; Xu, HX (通讯作者)，Shanghai Coll TCM New Drug Discovery, Engn Res Ctr, Shanghai 201203, Peoples R China.
EM pyy16@126.com; xuhongxi88@gmail.com
RI YINGYI, PAN/LBH-9957-2024; tan, Hongsheng/AAD-5830-2020; Zhang,
   Hong/AAD-5927-2020; Liu, Yurong/AFQ-1753-2022; Shen,
   Kaikai/AAD-9970-2019; Xu, Hongxi/AAC-2799-2020; Xie,
   Jianling/N-1877-2014
OI Xie, Jianling/0000-0002-0588-8016; Tan, Hongsheng/0000-0003-0921-5481;
   Xu, Hongxi/0000-0001-6238-4511
FU Foundation of Shanghai University of Traditional Chinese Medicine
   [2012JW05]; National Natural Science Foundation of China [81303266,
   81303188]; Natural Science and Technology Foundation for Distinguished
   Young Scholars of Shanghai [13ZR1462000]; Chen Guang Foundation of
   Shanghai Ministry of Education [13CG46]; 085 special project for the
   Priority Academic Program Development of Shanghai Higher Education
   Institutions [ZYX-CXYJ-012]
FX This work was supported financially by the Foundation of Shanghai
   University of Traditional Chinese Medicine (2012JW05 to K. Shen),
   National Natural Science Foundation of China (81303266 to K. Shen;
   81303188 to H. Zhang), Natural Science and Technology Foundation for
   Distinguished Young Scholars of Shanghai (13ZR1462000 to K. Shen), Chen
   Guang Foundation of Shanghai Ministry of Education (13CG46 to K. Shen),
   and 085 special project for the Priority Academic Program Development of
   Shanghai Higher Education Institutions (ZYX-CXYJ-012 to H. Xu).
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Akita M, 2014, INT J ONCOL, V45, P1901, DOI 10.3892/ijo.2014.2608
   Al Ghouleh I, 2013, CARDIOVASC RES, V97, P134, DOI 10.1093/cvr/cvs295
   Alexandre J, 2007, CANCER RES, V67, P3512, DOI 10.1158/0008-5472.CAN-06-3914
   Aon MA, 2006, BBA-MOL BASIS DIS, V1762, P232, DOI 10.1016/j.bbadis.2005.06.008
   Aon MA, 2004, P NATL ACAD SCI USA, V101, P4447, DOI 10.1073/pnas.0307156101
   Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4
   Bonner MY, 2012, CELL MOL LIFE SCI, V69, P2435, DOI 10.1007/s00018-012-1017-2
   Bossis G, 2014, CELL REP, V7, P1815, DOI 10.1016/j.celrep.2014.05.016
   Chen JM, 2004, CLIN CANCER RES, V10, P7703, DOI 10.1158/1078-0432.CCR-04-1130
   Chen Y, 2006, FEBS LETT, V580, P6596, DOI 10.1016/j.febslet.2006.11.007
   Cheng AC, 2010, FOOD FUNCT, V1, P301, DOI 10.1039/c0fo00134a
   Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200
   Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X
   Garrido-Urbani S, 2014, M S-MED SCI, V30, P415, DOI 10.1051/medsci/20143004016
   Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200
   Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200
   Haldar S, 1997, CANCER RES, V57, P229
   Han QB, 2009, CURR MED CHEM, V16, P3775, DOI 10.2174/092986709789104993
   Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122
   Hsieh CJ, 2014, FREE RADICAL BIO MED, V67, P159, DOI 10.1016/j.freeradbiomed.2013.10.004
   Jiang SG, 2011, PLANTA MED, V77, P1005, DOI 10.1055/s-0030-1270732
   Jo GH, 2014, INT J ONCOL, V45, P1497, DOI 10.3892/ijo.2014.2536
   Kan WLT, 2013, INT J CANCER, V132, P707, DOI 10.1002/ijc.27694
   Kello M, 2014, MOLECULES, V19, P10877, DOI 10.3390/molecules190810877
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Liochev SI, 1999, IUBMB LIFE, V48, P157, DOI 10.1080/713803492
   Liu H., 2006, CHINESE OVERSEAS VOL, V1, P1, DOI DOI 10.1016/J.JCP.2005.10.016.MR2215655
   Lu J, 2012, ANTIOXID REDOX SIGN, V17, P1738, DOI 10.1089/ars.2012.4650
   MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550
   Mishra P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.992217
   Miyano K, 2007, BIOCHIMIE, V89, P1133, DOI 10.1016/j.biochi.2007.05.003
   Mohankumar K, 2014, CHEM-BIOL INTERACT, V210, P51, DOI 10.1016/j.cbi.2013.12.006
   Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003
   Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012
   Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421
   Saito J, 2007, BIOCHEM J, V405, P591, DOI 10.1042/BJ20070231
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Sarosiek KA, 2013, TRENDS CELL BIOL, V23, P612, DOI 10.1016/j.tcb.2013.08.003
   Sart S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/105135
   Shen KK, 2015, MOL CANCER THER, V14, P1738, DOI 10.1158/1535-7163.MCT-14-1048
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021
   Surakasula A, 2014, J RES PHARM PRACT, V3, P12, DOI 10.4103/2279-042X.132704
   Thomadaki H, 2006, BIOL CHEM, V387, P1081, DOI 10.1515/BC.2006.133
   Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080
   Tochhawng L, 2013, MITOCHONDRION, V13, P246, DOI 10.1016/j.mito.2012.08.002
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Wang M, 2007, INT J BIOCHEM CELL B, V39, P2076, DOI 10.1016/j.biocel.2007.05.022
   Wang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10293
   Weaver JR, 2015, DIABETOLOGIA, V58, P113, DOI 10.1007/s00125-014-3398-2
   Zhang H, 2014, J NAT PROD, V77, P1700, DOI 10.1021/np5003498
   Zhang X, 2015, FREE RADICAL BIO MED, V89, P192, DOI 10.1016/j.freeradbiomed.2015.07.010
   Zschauer TC, 2011, ARTERIOSCL THROM VAS, V31, P650, DOI 10.1161/ATVBAHA.110.218982
NR 60
TC 22
Z9 25
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 50596
EP 50611
DI 10.18632/oncotarget.10585
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000135
PM 27418140
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Xu, ZY
   Shen, J
   Wang, MH
   Yi, T
   Yu, YY
   Zhu, YX
   Chen, B
   Chen, JP
   Li, LF
   Li, MX
   Zuo, J
   Jiang, H
   Zhou, DX
   Luan, JJ
   Xiao, ZG
AF Xu, Zhenyu
   Shen, Jing
   Wang, Maggie Haitian
   Yi, Tao
   Yu, Yangyang
   Zhu, Yinxin
   Chen, Bo
   Chen, Jianping
   Li, Longfei
   Li, Minxing
   Zuo, Jian
   Jiang, Hui
   Zhou, Dexi
   Luan, Jiajie
   Xiao, Zhangang
TI Comprehensive molecular profiling of the B7 family of immune-regulatory
   ligands in breast cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE B7 family; breast cancer; cancer immunotherapy; CD28 family; check point
ID T-CELL; B7-H3 EXPRESSION; RECEPTOR; IMMUNOTHERAPY; MEMBER; PROGRESSION;
   SURVIVAL; CTLA-4; HHLA2; BTLA
AB The B7 gene family has crucial roles in the regulation of adaptive cellular immunity. In cancer, deregulation of co-inhibitory B7 molecules is associated with reduced antitumor immunity and cancer immune evasion. FDA approval of cancer immunotherapy antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1)-both ligands of the B7 family-demonstrate the impact of these checkpoint regulators in cancer. Using data from cBioPortal, we performed comprehensive molecular profiling of the 10 currently known B7 family proteins in 105 different cancers. B7 family members were amplified in breast cancer: with B7 mRNA levels upregulated in a cohort of 1,098 patients with all types of breast cancer and in 82 patients with triple-negative breast cancer. Promoter methylation analysis indicated an epigenetic basis for deregulation of certain B7 family genes in breast cancer. Moreover, patients with B7-H6 genomic alterations had significantly worse overall survival, and certain clinical attributes were associated with B7-H6 expression, which indicates that B7-H6 may be a potential target for breast cancer immunotherapy. Finally, using network analysis (based on data from cBioportal), we identified BTLA, MARCH8, PLSCR1 and SMAD3 as potentially involved in T cell signaling under regulation of B7 family proteins.
C1 [Xu, Zhenyu; Zuo, Jian; Jiang, Hui; Zhou, Dexi; Luan, Jiajie] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.
   [Shen, Jing; Li, Longfei; Li, Minxing; Xiao, Zhangang] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Mol Pharmacol Lab, Luzhou, Sichuan, Peoples R China.
   [Wang, Maggie Haitian] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China.
   [Yi, Tao] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Yu, Yangyang] Shenzhen Univ, Hlth Sci Ctr, Dept Physiol, Ctr Diabet Obes & Metab, Shenzhen, Guangdong, Peoples R China.
   [Zhu, Yinxin] Soochow Univ, Affiliated Hosp 3, Dept Gastroenterol, Changzhou, Peoples R China.
   [Chen, Bo] Kunming Med Univ, Expt Ctr Med Sci Res, Kunming, Yunnan, Peoples R China.
   [Chen, Jianping] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Breast & Thyroid Surg, Wuhu, Anhui, Peoples R China.
C3 Wannan Medical College; Southwest Medical University; Chinese University
   of Hong Kong; Hong Kong Baptist University; Shenzhen University; Soochow
   University - China; Kunming Medical University; Wannan Medical College
RP Luan, JJ (通讯作者)，Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.; Xiao, ZG (通讯作者)，Southwest Med Univ, Sch Pharm, Dept Pharmacol, Mol Pharmacol Lab, Luzhou, Sichuan, Peoples R China.
EM luanjiajie757@163.com; xzg555898@hotmail.com
RI 周, 德喜/ABF-6374-2020; , yitao/N-6724-2013; Jiajie, Luan/AAM-2206-2021;
   Li, Longfei/W-1440-2019; Wang, Maggie Haitian/F-5954-2017
OI Zuo, Jian/0000-0003-4940-9408; YI, Tao/0000-0002-4089-3611; Wang, Maggie
   Haitian/0000-0003-1223-4595
FU National Natural Science Foundation of China [81503093]; University
   Natural Science Research Project of Anhui Province [KJ2016A732]; Talent
   Scientific Research Foundation of Yijishan Affiliated Hospital of Wannan
   Medical College [YR201504]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (Grant No. 81503093), the University Natural Science
   Research Project of Anhui Province (Grant No. KJ2016A732) and the Talent
   Scientific Research Foundation of Yijishan Affiliated Hospital of Wannan
   Medical College (Grant No. YR201504).
CR [Anonymous], 2015, Pharmacotherapy, V35, P1205, DOI 10.1002/phar.1679
   Assal A, 2015, IMMUNOTHERAPY-UK, V7, P1169, DOI 10.2217/imt.15.78
   Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681
   Brustmann H, 2015, INT J GYNECOL PATHOL, V34, P187, DOI 10.1097/PGP.0000000000000116
   Byers JT, 2015, ANN SURG ONCOL, V22, pS1574, DOI 10.1245/s10434-014-4293-2
   Ceeraz S, 2013, TRENDS IMMUNOL, V34, P556, DOI 10.1016/j.it.2013.07.003
   Chen LJ, 2015, AM J TRANSL RES, V7, P2646
   Chen XJ, 2014, PATHOL ONCOL RES, V20, P203, DOI 10.1007/s12253-013-9686-1
   Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003
   Dong Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/156432
   Fusi A, 2015, LANCET ONCOL, V16, P1285, DOI 10.1016/S1470-2045(15)00307-1
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Greaves P, 2013, BLOOD, V121, P734, DOI 10.1182/blood-2012-10-385591
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Huang CL, 2016, ONCOL REP, V35, P2183, DOI 10.3892/or.2016.4607
   Janakiram M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1026534
   Janakiram M, 2015, CLIN CANCER RES, V21, P2359, DOI 10.1158/1078-0432.CCR-14-1495
   Jeon H, 2014, CELL REP, V9, P1089, DOI 10.1016/j.celrep.2014.09.053
   Jin YJ, 2015, INT J CLIN EXP PATHO, V8, P13987
   Jung Keunok, 2013, Immune Netw, V13, P184, DOI 10.4110/in.2013.13.5.184
   Kaifu T, 2011, CELL MOL LIFE SCI, V68, P3531, DOI 10.1007/s00018-011-0802-7
   Kopf M, 2000, J EXP MED, V192, P53, DOI 10.1084/jem.192.1.53
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Leung Joanne, 2014, Immune Netw, V14, P265, DOI 10.4110/in.2014.14.6.265
   Mao YX, 2015, ONCOTARGET, V6, P3452, DOI 10.18632/oncotarget.3097
   Mulder Nicola J, 2002, Brief Bioinform, V3, P225
   Pesce S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1001224
   Podojil JR, 2013, BIODRUGS, V27, P1, DOI 10.1007/s40259-012-0001-6
   Ramsay AG, 2013, BRIT J HAEMATOL, V162, P313, DOI 10.1111/bjh.12380
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   Safaei HR, 2016, TUMOR BIOL, V37, P7583, DOI 10.1007/s13277-015-4652-z
   SALEH S, 1990, EUR J CLIN PHARMACOL, V39, P169, DOI 10.1007/BF00280053
   Schlecker E, 2014, CANCER RES, V74, P3429, DOI 10.1158/0008-5472.CAN-13-3017
   Seliger B, 2012, CANCER IMMUNOL IMMUN, V61, P1327, DOI 10.1007/s00262-012-1293-6
   Seliger B, 2008, TRENDS MOL MED, V14, P550, DOI 10.1016/j.molmed.2008.09.010
   Semeraro M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2327
   Shang YJ, 2012, INFLAMMATION, V35, P1102, DOI 10.1007/s10753-011-9417-2
   Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3
   Sperling AI, 2001, CLIN IMMUNOL, V100, P261, DOI 10.1006/clim.2001.5084
   Sun J, 2014, ONCOTARGETS THER, V7, P1979, DOI 10.2147/OTT.S63424
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Wang L, 2011, J EXP MED, V208, P577, DOI 10.1084/jem.20100619
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
   Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944
   Wilcox RA, 2012, EUR J HAEMATOL, V88, P465, DOI 10.1111/j.1600-0609.2012.01766.x
   Xiao YP, 2015, CLIN CANCER RES, V21, P2201, DOI 10.1158/1078-0432.CCR-14-2658
   Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013
   Zhang XQ, 2014, INT J CLIN EXP PATHO, V7, P6936
   Zhao RH, 2013, P NATL ACAD SCI USA, V110, P9879, DOI 10.1073/pnas.1303524110
   Zhou Y, 2015, INT J CLIN EXP PATHO, V8, P9428
   Zhu YW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3043
NR 52
TC 35
Z9 36
U1 1
U2 29
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2016
VL 5
IS 8
AR e1207841
DI 10.1080/2162402X.2016.1207841
PG 10
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA DZ0IW
UT WOS:000385522800020
PM 27622076
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Keinan-Boker, L
   Goldbourt, U
AF Keinan-Boker, Lital
   Goldbourt, Uri
TI Cancer incidence in Holocaust male survivorsAn Israeli cohort study
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cancer incidence; cohort; Holocaust; Israel; males
ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-WAR-II; HEART-DISEASE MORTALITY;
   1944-1945 DUTCH FAMINE; BREAST-CANCER; COLORECTAL-CANCER; NETHERLANDS
   COHORT; ENERGY RESTRICTION; FOLLOW-UP; RISK
AB Previous studies, often using proxy exposure assessment and not controlling for individual risk factors, suggested higher cancer risk in Holocaust survivors. We have used individual-level data from a male cohort of Israeli civil servants recruited in 1963 to investigate cancer incidence in Holocaust survivors, controlling for potential confounders. The analysis included 4,669 Europe-born subjects; 689 exposed=E (immigrated to Israel after 1939 and reported of being in Nazi camps during World War II); 2,307 potentially exposed=PE (immigrated to Israel after 1939 and reported of not being in Nazi camps); and 1,673 non-exposed=NE (immigrated to Israel prior to 1939). Vital status and cancer incidence in the cohort were determined based on national registries. Socioeconomic level, health behaviors and cancer incidence were compared between the groups and Cox proportional hazards regression models adjusting for potential confounders assessed hazard risk ratios for cancer by exposure status. All-cause mortality was studied as a competing risk. In total, 241, 682, and 522 cancer cases were diagnosed in the E, PE, and NE, respectively. Compared with the NE, all-site cancer incidence was higher in the E (HR=1.13, 95%CI 0.97-1.32) but not in the PE. All-cause mortality competed with all-site invasive cancer incidence in the E group (HR=1.18, 95%CI 1.02-1.38). Colorectal and lung cancer seemed to be positively though non-significantly associated with the exposure while prostate cancer was not. Male Holocaust survivors may be at a weakly increased risk for all-site, colorectal and lung cancer. The role of age at exposure and residual confounding should be further investigated.
   What's new? Prolonged exposure to extreme physical and emotional stress may cause permanent changes in gene expression. These epigenetic changes may then increase the risk of chronic diseases later in life. In this study of Israeli Holocaust survivors, the authors found that people in this cohort may have an increased risk of cancer. Because individualized exposure data were available with long follow up, the study was designed to adjust for individual risk factors such as smoking and obesity. Further questions, such as the impact of age at exposure, would be worth investigating.
C1 [Keinan-Boker, Lital] Israel Minist Hlth, Israel Ctr Dis Control, Ramat Gan, Israel.
   [Keinan-Boker, Lital] Univ Haifa, Sch Publ Hlth, Haifa, Israel.
   [Goldbourt, Uri] Tel Aviv Univ, Sch Publ Hlth, Sackler Fac Med, Tel Aviv, Israel.
   [Goldbourt, Uri] Sheba Med Ctr, Neufeld Cardiac Res Inst, Ramat Gan, Israel.
C3 University of Haifa; Tel Aviv University; Sackler Faculty of Medicine;
   Chaim Sheba Medical Center
RP Keinan-Boker, L (通讯作者)，Sheba Med Ctr, Israel Minist Hlth, Gertner Inst, Israel Ctr Dis Control, IL-52621 Ramat Gan, Israel.
EM lital.keinan2@moh.health.gov.il
OI Keinan-Boker, Lital/0000-0002-8092-0717
CR [Anonymous], USITC PUBL
   Bedmonson D, 2013, AM HEART J, V166, P806
   Bishop KS, 2015, NUTRIENTS, V7, P922, DOI 10.3390/nu7020922
   Boekelheide K, 2012, ENVIRON HEALTH PERSP, V120, P1353, DOI 10.1289/ehp.1204934
   Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf
   Brunello N, 2001, NEUROPSYCHOBIOLOGY, V43, P150, DOI 10.1159/000054884
   Denaro N, 2014, J CANC THERAPEUT RES, V3
   Dirx MJM, 2001, AM J EPIDEMIOL, V154, P530, DOI 10.1093/aje/154.6.530
   Dirx MJM, 2003, CANCER-AM CANCER SOC, V97, P46, DOI 10.1002/cncr.11052
   Dirx MJM, 1999, CANCER CAUSE CONTROL, V10, P189, DOI 10.1023/A:1008821524297
   Eaton C B, 1995, Arch Fam Med, V4, P323, DOI 10.1001/archfami.4.4.323
   Elias SG, 2004, JNCI-J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087
   Elias SG, 2005, CANCER EPIDEM BIOMAR, V14, P1981, DOI 10.1158/1055-9965.EPI-04-0839
   Fentiman IS, 2007, INT J CLIN PRACT, V61, P937, DOI 10.1111/j.1742-1241.2007.01288.x
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fu SS, 2007, NICOTINE TOB RES, V9, P1071, DOI 10.1080/14622200701488418
   GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862
   GROEN JJ, 1968, ISRAEL J MED SCI, V4, P177
   Hughes LAE, 2010, INT J EPIDEMIOL, V39, P1333, DOI 10.1093/ije/dyq062
   Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951
   Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184
   Keinan-Boker L, 2009, JNCI-J NATL CANCER I, V101, P1489, DOI 10.1093/jnci/djp327
   Kogevinas M., 1997, Social Inequalities and Cancer
   Kohn R, 2014, SOC PSYCH PSYCH EPID, V49, P703, DOI 10.1007/s00127-013-0805-9
   Koupil I, 2009, INT J CANCER, V124, P1416, DOI 10.1002/ijc.24093
   Landau R, 2000, J TRAUMA STRESS, V13, P473, DOI 10.1023/A:1007737425260
   Merletti F, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-S1-S7
   Michels KB, 2003, J WOMEN HEALTH GEN-B, V12, P157, DOI 10.1089/154099903321576556
   Nilsen TIL, 2001, BRIT J CANCER, V85, P959, DOI [10.1038/sj.bjc.6691946, 10.1054/bjoc.2001.1946]
   Panagioti M, 2009, CLIN PSYCHOL REV, V29, P471, DOI 10.1016/j.cpr.2009.05.001
   Rosbahm TE, 2002, BRIT J CANCER, V86, P362
   Rosenbaum S, 2015, METABOLISM, V64, P926, DOI [10.1016/j.metabol.2015.01.016, 10.1016/j.metabol.2015.04.009]
   Saffery R, 2014, ACTA OBSTET GYN SCAN, V93, P1090, DOI 10.1111/aogs.12431
   Sagi-Schwartz A, 2003, AM J PSYCHIAT, V160, P1086, DOI 10.1176/appi.ajp.160.6.1086
   Sharon A, 2009, BRIT J PSYCHIAT, V195, P331, DOI 10.1192/bjp.bp.108.058784
   Simons CCJM, 2014, CANCER EPIDEM BIOMAR, V23, P1852, DOI 10.1158/1055-9965.EPI-13-1285
   Svensson E, 2005, CANCER CAUSE CONTROL, V16, P215, DOI 10.1007/s10552-004-3073-x
   Svensson E, 2002, EUR J CANCER PREV, V11, P489, DOI 10.1097/00008469-200210000-00012
   Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882
   Uauy R, 2005, J NUTR, V135, p2934S, DOI 10.1093/jn/135.12.2934S
   VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197
   Vin-Raviv N, 2014, INT PSYCHOGERIATR, V26, P499, DOI 10.1017/S1041610213002081
   Ziegler JL, 2009, FRONT BIOSCI-LANDMRK, V14, P3455, DOI 10.2741/3464
NR 43
TC 6
Z9 6
U1 0
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2016
VL 139
IS 11
BP 2426
EP 2435
DI 10.1002/ijc.30378
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DX8NQ
UT WOS:000384646200005
PM 27509441
OA Bronze
DA 2025-01-12
ER

PT J
AU Srinivas, C
   Swathi, V
   Priyanka, C
   Devi, TA
   Reddy, BVS
   Ramaiah, MJ
   Bhadra, U
   Bhadra, MP
AF Srinivas, Chatla
   Swathi, V.
   Priyanka, C.
   Devi, T. Anjana
   Reddy, B. V. Subba
   Ramaiah, M. Janaki
   Bhadra, Utpal
   Bhadra, Manika Pal
TI Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the
   expression of microRNAs in hepatocellular carcinoma
SO APOPTOSIS
LA English
DT Article
DE SAHA; HDAC; Histones; microRNA; Hepatocellular carcinoma
ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID;
   SIGNALING TRANSDUCTION; EPIGENETIC REGULATION; MOLECULAR-MECHANISMS;
   BREAST-CANCER; LUNG-CANCER; HEPATITIS-B; CELLS; VORINOSTAT
AB In eukaryotes, transcriptional regulation occurs via chromatin remodeling, mainly through post translational modifications of histones that package DNA into structural units. Histone deacetylases (HDACs) are enzymes that play important role in various biological processes by repressing gene expression. Suberoylanilide hydroxamic acid (SAHA) is a known HDAC inhibitor that showed significant anti cancer activity by relieving gene silencing against hematologic and solid tumors. We have designed and synthesized a series of SAHA analogs C1-C4 and performed biological studies to elucidate its anti-cancer effects. It is observed that SAHA analogs significantly inhibited cell proliferation and induced apoptosis in hepatocellular carcinoma (HCC) cell lines HepG2 and SK-HEP-1. These analogs also showed non-toxic activity towards primary human hepatocytes, which describes its tumor specificity. SAHA analogs exhibited strong HDAC inhibition, which is 2-3 fold higher compared to SAHA. Moreover, these molecules induced hyper acetylation of histone H3 at various positions on the lysine residue. Further, it is observed that SAHA analogs are strong inducers of apoptosis, as they regulated the expression of various proteins involved in both extrinsic and intrinsic pathways. Interestingly, SAHA analogs induced upregulation of tumor suppressor miRNAs by activating its biogenesis pathway. Further, it is confirmed by microRNA (miRNA) prediction tools that these miRNAs are capable of targeting various anti-apoptotic genes. Based on these findings we conclude that SAHA analogs could be strong HDAC inhibitors with promising apoptosis inducing nature in HCC.
C1 [Srinivas, Chatla; Swathi, V.; Priyanka, C.; Devi, T. Anjana; Bhadra, Manika Pal] CSIR Indian Inst Chem Technol, Ctr Chem Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.
   [Swathi, V.; Reddy, B. V. Subba] CSIR Indian Inst Chem Technol, Ctr Semiochem, Hyderabad, Andhra Pradesh, India.
   [Ramaiah, M. Janaki] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, India.
   [Bhadra, Utpal] CSIR Ctr Cellular & Mol Biol, Funct Genom & Gene Silencing Grp, Hyderabad, Andhra Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Indian Institute of Chemical Technology (IICT); Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical
   Technology (IICT); Shanmugha Arts, Science, Technology & Research
   Academy (SASTRA); Council of Scientific & Industrial Research (CSIR) -
   India; CSIR - Centre for Cellular & Molecular Biology (CCMB)
RP Bhadra, MP (通讯作者)，CSIR Indian Inst Chem Technol, Ctr Chem Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.
EM chatlas10@gmail.com; swathireddychem19@gmail.com;
   priyankacilamkoti@gmail.com; anjana@iict.res.in; basireddy@iict.res.in;
   janaki7777@gmail.com; utpal@ccmb.res.in; manika@iict.res.in
RI RAMAIAH, JANAKI/AAL-9074-2020; Reddy, Basireddy/H-9619-2013; Devi,
   Anjana/AAG-1930-2020; Chatla, Srinivas/AAA-9299-2020
OI Ramaiah, Janaki/0000-0003-1814-2819; Chatla,
   Srinivas/0000-0002-8509-8494
FU CSIR 12th FYP project-SMILE [CSC-0111]; CSIR
FX The entire work was supported by CSIR 12th FYP project-SMILE (CSC-0111).
   CS and VS thank CSIR for their fellowship. All the authors thank P.
   Devender for maintaining the cell culture facility.
CR Al-Yacoub N, 2012, J INVEST DERMATOL, V132, P2263, DOI 10.1038/jid.2012.125
   Bandi N, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-55
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bi Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040169
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Darvas K, 2010, INT J CANCER, V127, P1384, DOI 10.1002/ijc.25170
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Deshpande R, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/686074
   Di Bisceglie AM, 2009, HEPATOLOGY, V49, pS56, DOI 10.1002/hep.22962
   Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Fan HT, 2012, EPIGENETICS-US, V7, P1379, DOI 10.4161/epi.22609
   Ferenci P, 2010, J CLIN GASTROENTEROL, V44, P239, DOI 10.1097/MCG.0b013e3181d46ef2
   Fomer A, 2014, NAT REV CLIN ONCOL, V11, P525, DOI 10.1038/nrclinonc.2014.122
   Gish RG, 2006, CLIN GASTROENTEROL H, V4, P252, DOI 10.1016/j.cgh.2006.01.001
   Gish Robert G, 2013, Gastroenterol Hepatol (N Y), V9, P1
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Jazirehi AR, 2013, AM J CLIN EXP IMMUNO, V2, P55
   Kang MR, 2009, BIOCHEM PHARMACOL, V78, P486, DOI 10.1016/j.bcp.2009.05.010
   Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Krammer PH, 2007, ADV CANCER RES, V97, P111, DOI 10.1016/S0065-230X(06)97005-5
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Li M, 2009, WORLD J SURG, V33, P667, DOI 10.1007/s00268-008-9836-x
   Li ZC, 2012, INT J BIOL SCI, V8, P394, DOI 10.7150/ijbs.3882
   Liu K, 2015, MED SCI MONIT BASIC, V21, P15, DOI 10.12659/MSMBR.893327
   Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Mack GS, 2010, NAT BIOTECHNOL, V28, P1259, DOI 10.1038/nbt.1724
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Napso T, 2014, INT J ONCOL, V44, P1971, DOI 10.3892/ijo.2014.2386
   Nishioka C, 2008, LEUKEMIA RES, V32, P1382, DOI 10.1016/j.leukres.2008.02.018
   Reed JC, 2008, BLOOD, V111, P3322, DOI 10.1182/blood-2007-09-078162
   Rosato RR, 2003, MOL CANCER THER, V2, P1273
   Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274
   Schrump DS, 2009, CLIN CANCER RES, V15, P3947, DOI 10.1158/1078-0432.CCR-08-2787
   Seeff LB, 2006, ONCOGENE, V25, P3771, DOI 10.1038/sj.onc.1209560
   Shan G, 2008, NAT BIOTECHNOL, V26, P933, DOI 10.1038/nbt.1481
   Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31
   Smith KT, 2009, INT J BIOCHEM CELL B, V41, P21, DOI 10.1016/j.biocel.2008.09.008
   Srinivas C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142006
   Stamatopoulos B, 2010, HAEMATOL-HEMATOL J, V95, P1136, DOI 10.3324/haematol.2009.013847
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Sun C, 2008, BIOCHEM PHARMACOL, V76, P120, DOI 10.1016/j.bcp.2008.04.004
   Vilarinho Silvia, 2015, Curr Treat Options Gastroenterol, V13, P219, DOI 10.1007/s11938-015-0049-8
   Walczak Henning, 2008, V414, P221
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wiech NL, 2009, CURR TOP MED CHEM, V9, P257, DOI 10.2174/156802609788085241
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Wozniak MB, 2010, HAEMATOL-HEMATOL J, V95, P613, DOI 10.3324/haematol.2009.013870
   Xiao ZG, 2014, CANCER RES, V74, P6236, DOI 10.1158/0008-5472.CAN-14-0855
   Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yi B, 2013, CANCER PREV RES, V6, P401, DOI 10.1158/1940-6207.CAPR-13-0032
   Zhu AX, 2013, J CLIN ONCOL, V31, P406, DOI 10.1200/JCO.2012.46.1897
NR 60
TC 23
Z9 25
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD NOV
PY 2016
VL 21
IS 11
BP 1249
EP 1264
DI 10.1007/s10495-016-1278-6
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DY5QM
UT WOS:000385156400005
PM 27502208
DA 2025-01-12
ER

PT J
AU Wong, EM
   Joo, JE
   McLean, CA
   Baglietto, L
   English, DR
   Severi, G
   Wu, HC
   Terry, MB
   Hopper, JL
   Milne, RL
   Giles, GG
   Southey, MC
AF Wong, Ee Ming
   Joo, JiHoon E.
   McLean, Catriona A.
   Baglietto, Laura
   English, Dallas R.
   Severi, Gianluca
   Wu, Hui-Chen
   Terry, Mary Beth
   Hopper, John L.
   Milne, Roger L.
   Giles, Graham G.
   Southey, Melissa C.
TI Analysis of the breast cancer methylome using formalin-fixed
   paraffin-embedded tumour
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; FFPE; Methylome
ID DNA METHYLATION; TISSUE; RASSF1A; ARRAY
AB Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffin-embedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour tissues and compared the DNA methylation in corresponding adjacent non-tumour ductal epithelium (ADJ(NT)). These studies are technically challenging due to the spectrum of breast cancer pathologies, the variable suitability of DNA extracted from FFPE material and the difficulties in identifying ADJ(NT). We assessed the suitability of FFPE breast cancer material for genome-wide DNA methylation assessment of tumour and ADJ(NT).
   Twenty-one archival breast tumour tissues with paired ADJ(NT) obtained from separate blocks and at least 2 cm from the tumour were sourced from The Melbourne Collaborative Cohort Study (MCCS). DNA was prepared from macrodissected tissue samples and assessed for genome-wide methylation using the Infinium HumanMethylation450 Beadchip (HM450K) array.
   The 1000 most differentially methylated probes between tumour and ADJ(NT) in this FFPE-derived dataset differentiated tumour and ADJ(NT) in The Cancer Genome Atlas Network data (TCGA; derived from high molecular weight DNA using the same HM450K array).
   Large-scale studies of genome-wide DNA methylation using FFPE breast cancer specimens offer the opportunity to further refine the pathological classification of tumours, to include subtypes that are underrepresented in the TCGA data and provide the capacity to further explore intra-tumoural heterogeneity.
C1 [Wong, Ee Ming; Joo, JiHoon E.; Southey, Melissa C.] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic 3010, Australia.
   [McLean, Catriona A.] Alfred Hosp, Alfred Hlth, Anat Pathol, Melbourne, Vic 3181, Australia.
   [Baglietto, Laura; Severi, Gianluca] Univ Paris 11, Univ Paris Saclay, UVSQ, CESP,INSERM, Villejuif, France.
   [Baglietto, Laura; Severi, Gianluca] Gustave Roussy, F-94805 Villejuif, France.
   [Baglietto, Laura; English, Dallas R.; Severi, Gianluca; Milne, Roger L.; Giles, Graham G.; Southey, Melissa C.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
   [Baglietto, Laura; English, Dallas R.; Severi, Gianluca; Hopper, John L.; Milne, Roger L.; Giles, Graham G.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia.
   [Severi, Gianluca] Human Genet Fdn, HuGeF, I-10126 Turin, Italy.
   [Wu, Hui-Chen] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA.
   [Terry, Mary Beth] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
C3 University of Melbourne; Florey Institute of Neuroscience & Mental
   Health; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Paris Saclay; UNICANCER; Gustave Roussy; Cancer
   Council Victoria; University of Melbourne; Columbia University; Columbia
   University
RP Southey, MC (通讯作者)，Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic 3010, Australia.; Southey, MC (通讯作者)，Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
EM msouthey@unimelb.edu.au
RI Baglietto, Laura/AAB-9051-2019; Southey, Melissa/CAA-7064-2022; Giles,
   Graham/LCD-5671-2024; English, Dallas/AAH-5005-2019; Wu,
   Lisa/JPA-4139-2023; Severi, Gianluca/H-3774-2018
OI Terry, Mary Beth/0000-0002-4106-5033; Wong, Ee Ming/0000-0002-7288-7865;
   English, Dallas/0000-0001-7828-8188; Southey,
   Melissa/0000-0002-6313-9005; McLean, Catriona/0000-0002-0302-5727;
   Baglietto, Laura/0000-0002-8193-7529; Severi,
   Gianluca/0000-0001-7157-419X
FU National Health and Medical Research Council (NHMRC) [APP1011618,
   APP1026892]; Victorian Breast Cancer Research Consortium; Dyason
   Fellowship
FX This work was further supported by the National Health and Medical
   Research Council (NHMRC; APP1011618 and APP1026892) and The Victorian
   Breast Cancer Research Consortium. MCS is a NHMRC Senior Research Fellow
   and JLH is a NHMRC Senior Principal Research Fellow. EMW is a recipient
   of the Dyason Fellowship.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   [Anonymous], 2011, EXPERT REV MOL DIAGN, V11, P470
   [Anonymous], WHO CLASSIFICATION T
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279
   Chung W, 2011, CANCER EPIDEM BIOMAR, V20, P1483, DOI 10.1158/1055-9965.EPI-11-0067
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joo JE, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-23
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Li ZB, 2015, BREAST CANCER RES TR, V149, P767, DOI 10.1007/s10549-015-3276-8
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6
   Rauscher GH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1777-9
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Slater AA, 2013, EPIGENETICS-US, V8, P252, DOI 10.4161/epi.23817
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Volodko N, 2016, CANCERS, V8, DOI 10.3390/cancers8060055
   Wong Ee Ming, 2015, BMC Res Notes, V8, P543, DOI 10.1186/s13104-015-1487-z
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
NR 26
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV
PY 2016
VL 160
IS 1
BP 173
EP 180
DI 10.1007/s10549-016-3971-0
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DY5WU
UT WOS:000385175900017
PM 27604360
DA 2025-01-12
ER

PT J
AU Messier, TL
   Boyd, JR
   Gordon, JAR
   Stein, JL
   Lian, JB
   Stein, GS
AF Messier, Terri L.
   Boyd, Joseph R.
   Gordon, Jonathan A. R.
   Stein, Janet L.
   Lian, Jane B.
   Stein, Gary S.
TI Oncofetal Epigenetic Bivalency in Breast Cancer Cells: H3K4 and H3K27
   Tri-Methylation as a Biomarker for Phenotypic Plasticity
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; STATE; IDENTIFICATION; HETEROGENEITY; INITIATION;
   EPIGENOME; GENES; LINES
AB Alterations in the epigenetic landscape are fundamental drivers of aberrant gene expression that contribute to cancer progression and pathology. Understanding specific modes of epigenetic regulation can be used to identify novel biomarkers or targets for therapeutic intervention to clinically treat solid tumors and leukemias. The bivalent marking of gene promoters by H3K4me3 and H3K27me3 is a primary mechanism to poise genes for expression in pluripotent embryonic stem cells (ESC). In this study we interrogated three well-established mammary cell lines to model epigenetic programming observed among breast cancer subtypes. Evidence is provided for a distinct bivalent signature, activating and repressive histone marks co-residing at the same gene promoter, in the MCF7 (ESR/PGR+) luminal breast cancer cell line. We identified a subset of genes, enriched for developmental pathways that regulate cellular phenotype and signaling, and partially recapitulate the bivalent character observed in ESC. We validated the biological relevance of this "oncofetal epigenetic" signature using data from ESR/PGR+ tumor samples from breast cancer patients. This signature of oncofetal epigenetic control is an informative biomarker and may provide novel therapeutic targets, selective for both recurring and treatment-resistant cancers. (C) 2016 Wiley Periodicals, Inc.
C1 Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   Univ Vermont, Coll Med, Ctr Canc, Burlington, VT USA.
C3 University of Vermont; University of Vermont
RP Stein, GS (通讯作者)，Univ Vermont, Coll Med, 149 Beaumont Ave,HSRF 326, Burlington, VT 05405 USA.
EM gary.stein@uvm.edu
FU Pfizer Investigator-Initiated Research Award [WS2049100]; NIH
   [R37DE012528, P01 CA 082834]
FX Contract grant sponsor: Pfizer Investigator-Initiated Research
   Award;Contract grant number: WS2049100.Contract grant sponsor:
   NIH;Contract grant numbers: R37DE012528, P01 CA 082834.
CR Agarwal P, 2016, ONCOTARGET, DOI 10.18632/oncotarget.6843
   [Anonymous], ONCOTARGET
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Bapat SA, 2014, EPIGENETICS, V5, P716
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Coradini D, 2014, CHIN J CANCER, V33, DOI 10.5732/cjc.013.10040
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P35, DOI 10.1007/978-1-61779-612-8_3
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Grandy RA, 2016, MOL CELL BIOL, V36, P615, DOI 10.1128/MCB.00877-15
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704
   Lu Y, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0049-1
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Romano P, 2009, NUCLEIC ACIDS RES, V37, pD925, DOI 10.1093/nar/gkn730
   Sehl ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135797
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Stricker SH, 2014, EPIGENETICS-US, V9, P798, DOI 10.4161/epi.28600
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takeshima H, 2015, CARCINOGENESIS, V36, P192, DOI 10.1093/carcin/bgu238
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Wang X, 2014, ONCOL REP, V31, P1975, DOI 10.3892/or.2014.3112
   Xu SLY, 2014, METHODS MOL BIOL, V1150, P97, DOI 10.1007/978-1-4939-0512-6_5
NR 37
TC 21
Z9 25
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2016
VL 231
IS 11
BP 2474
EP 2481
DI 10.1002/jcp.25359
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA DY3TU
UT WOS:000385018400022
PM 26916849
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kim, JY
   Park, K
   Jung, HH
   Lee, E
   Cho, EY
   Lee, KH
   Bae, SY
   Lee, SK
   Kim, SW
   Lee, JE
   Nam, SJ
   Ahn, JS
   Im, YH
   Park, YH
AF Kim, Ji-Yeon
   Park, Kyunghee
   Jung, Hae Hyun
   Lee, Eunjin
   Cho, Eun Yoon
   Lee, Kwang Hee
   Bae, Soo Youn
   Lee, Se Kyung
   Kim, Seok Won
   Lee, Jeong Eon
   Nam, Seok Jin
   Ahn, Jin Seok
   Im, Young-Hyuck
   Park, Yeon Hee
TI Association between Mutation and Expression of <i>TP53</i> as a
   Potential Prognostic Marker of Triple-Negative Breast Cancer
SO CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Tumor suppressor protein p53; Triple-negative breast neoplasms;
   Prognosis; AmpliSeq; nCounter mRNA expression assay;
   Immunohistochemistry
ID P53 TUMOR-SUPPRESSOR; EPIGENETIC REGULATION; MOUSE MODEL; GENE;
   CHEMOTHERAPY; SIGNATURE; SURVIVAL; GROWTH; GAIN
AB Purpose
   TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
   Materials and Methods
   We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
   Results
   Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36 +/- 132.73 vs. 339.61 +/- 143.21 vs. 99.53 +/- 99.57, respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patients with a TP53 missense mutation (5-year distant recurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
   Conclusion
   Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.
C1 [Kim, Ji-Yeon; Ahn, Jin Seok; Park, Yeon Hee] Sungkyunkwan Univ, Sch Med, Dept Med, Div Hematol Oncol, Seoul, South Korea.
   [Park, Kyunghee; Lee, Eunjin] Sungkyunkwan Univ, Sch Med, Samsung Genome Inst, Seoul, South Korea.
   [Jung, Hae Hyun; Im, Young-Hyuck; Park, Yeon Hee] Sungkyunkwan Univ, Sch Med, Biomed Res Inst, Seoul, South Korea.
   [Cho, Eun Yoon] Sungkyunkwan Univ, Sch Med, Canc Compan Diagnost, Innovat Canc Med Inst, Seoul, South Korea.
   [Lee, Kwang Hee] Thermo Fisher Sci Corp, Life Sci Solut Grp, Seoul, South Korea.
   [Bae, Soo Youn; Lee, Se Kyung; Kim, Seok Won; Lee, Jeong Eon; Nam, Seok Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung; Sungkyunkwan University (SKKU);
   Samsung Medical Center; Sungkyunkwan University (SKKU); Sungkyunkwan
   University (SKKU); Thermo Fisher Scientific; Sungkyunkwan University
   (SKKU); Samsung Medical Center
RP Im, YH; Park, YH (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM imyh00@skku.edu; yhparkhmo@skku.edu
RI Lee, sujeong/KUD-4735-2024; Park, KyungHo/JPL-5809-2023; Lee,
   Sang/AAG-2448-2019
FU Samsung Biomedical Research Institute [SBRI GL1-B2-251-1-2]
FX This research was funded by the Samsung Biomedical Research Institute
   (SBRI GL1-B2-251-1-2).
CR Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540
   COLES C, 1992, CANCER RES, V52, P5291
   Eikesdal HP, 2014, ACTA ONCOL, V53, P1347, DOI 10.3109/0284186X.2014.922215
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   Hong D, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat003
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   MAZARS R, 1992, CANCER RES, V52, P3918
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Park YH, 2015, INT J CANCER, V136, P1976, DOI 10.1002/ijc.29233
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Saldaña-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   SIDRANSKY D, 1992, CANCER RES, V52, P2984
   Sigal A, 2000, CANCER RES, V60, P6788
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405
   Végran F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055103
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251
NR 28
TC 52
Z9 58
U1 0
U2 11
PU KOREAN CANCER ASSOCIATION
PI SEOUL
PA RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 110-999,
   SOUTH KOREA
SN 1598-2998
EI 2005-9256
J9 CANCER RES TREAT
JI Cancer Res. Treat.
PD OCT
PY 2016
VL 48
IS 4
BP 1338
EP 1350
DI 10.4143/crt.2015.430
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DY6JS
UT WOS:000385212800019
PM 26910472
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ruan, PF
   Shen, J
   Santella, RM
   Zhou, SG
   Wang, S
AF Ruan, Peifeng
   Shen, Jing
   Santella, Regina M.
   Zhou, Shuigeng
   Wang, Shuang
TI NEpiC: a network-assisted algorithm for epigenetic studies using mean
   and variance combined signals
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DNA METHYLATION SIGNATURES; GENOME-WIDE ASSOCIATION; BREAST-CANCER;
   TUMOR-SUPPRESSOR; GENES; EXPRESSION; IDENTIFICATION; PROTEIN; LIVER;
   RISK
AB DNA methylation plays an important role in many biological processes. Existing epigenome-wide association studies (EWAS) have successfully identified aberrantly methylated genes in many diseases and disorders with most studies focusing on analysing methylation sites one at a time. Incorporating prior biological information such as biological networks has been proven to be powerful in identifying disease-associated genes in both gene expression studies and genome-wide association studies (GWAS) but has been under studied in EWAS. Although recent studies have noticed that there are differences in methylation variation in different groups, only a few existing methods consider variance signals in DNA methylation studies. Here, we present a network-assisted algorithm, NEpiC, that combines both mean and variance signals in searching for differentially methylated sub-networks using the protein-protein interaction (PPI) network. In simulation studies, we demonstrate the power gain from using both the prior biological information and variance signals compared to using either of the two or neither information. Applications to several DNA methylation datasets from the Cancer Genome Atlas (TCGA) project and DNA methylation data on hepatocellular carcinoma (HCC) from the Columbia University Medical Center (CUMC) suggest that the proposed NEpiC algorithm identifies more cancer-related genes and generates better replication results.
C1 [Ruan, Peifeng; Zhou, Shuigeng] Fudan Univ, Sch Comp Sci, Shanghai 200433, Peoples R China.
   [Ruan, Peifeng; Zhou, Shuigeng] Fudan Univ, Shanghai Key Lab Intelligent Informat Proc, Shanghai 200433, Peoples R China.
   [Shen, Jing; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Wang, Shuang] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA.
C3 Fudan University; Fudan University; Columbia University; Columbia
   University
RP Wang, S (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA.
EM sw2206@columbia.edu
RI Ruan, Peifeng/AAV-6152-2020
OI Ruan, Peifeng/0000-0002-1364-7992
FU National Natural Science Foundation of China [61272380]; National
   Institutes of Health [R01ES05116, P30ES009089]; Department of
   Biostatistics, Columbia University
FX National Natural Science Foundation of China [61272380 to P.R. and
   S.Z.]; National Institutes of Health [R01ES05116 and P30ES009089 to
   S.J., R.S. and S.W.]. Funding for open access charge: Departmental fund
   from Department of Biostatistics, Columbia University.
CR Ammerpohl O, 2012, INT J CANCER, V130, P1319, DOI 10.1002/ijc.26136
   Baranzini SE, 2009, HUM MOL GENET, V18, P2078, DOI 10.1093/hmg/ddp120
   Birts CN, 2011, BIOL CELL, V103, P1, DOI 10.1042/BC20100067
   Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177
   Chen M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001353
   Chen Y, 2014, GENET EPIDEMIOL, V38, P42, DOI 10.1002/gepi.21774
   Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570
   Dunwell T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-44
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749
   House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169
   Jia PL, 2011, BIOINFORMATICS, V27, P95, DOI 10.1093/bioinformatics/btq615
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Keita M, 2013, GYNECOL ONCOL, V128, P356, DOI 10.1016/j.ygyno.2012.11.036
   Kittaka N, 2008, EUR J CANCER, V44, P885, DOI 10.1016/j.ejca.2008.02.019
   Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249
   Landi D, 2012, CANCER-AM CANCER SOC, V118, P4670, DOI 10.1002/cncr.27435
   Leclerc D, 2013, CANCER PREV RES, V6, P1171, DOI 10.1158/1940-6207.CAPR-13-0198
   Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933
   Lee HS, 2009, CLIN CANCER RES, V15, P812, DOI 10.1158/1078-0432.CCR-08-0266
   Liu S, 2013, CURR CANCER THER REV, V9, P137, DOI 10.2174/15733947113099990001
   Luedi PP, 2007, GENOME RES, V17, P1723, DOI 10.1101/gr.6584707
   Mayol G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048401
   Morgan WA, 1939, BIOMETRIKA, V31, P13, DOI 10.1093/biomet/31.1-2.13
   Ongenaert M, 2008, NUCLEIC ACIDS RES, V36, pD842, DOI 10.1093/nar/gkm788
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Pitman EJG, 1939, BIOMETRIKA, V31, P9, DOI 10.1093/biomet/31.1-2.9
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Rossin EJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001273
   Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Saitta C, 2015, LIVER INT, V35, P2311, DOI 10.1111/liv.12807
   Salyer SA, 2013, BBA-MOL BASIS DIS, V1832, P1734, DOI 10.1016/j.bbadis.2013.04.023
   Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699
   Shen J, 2013, EPIGENETICS-US, V8, P34, DOI 10.4161/epi.23062
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6
   Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761
   Sun H, 2013, STAT MED, V32, P2127, DOI 10.1002/sim.5694
   Sun H, 2012, BIOINFORMATICS, V28, P1368, DOI 10.1093/bioinformatics/bts145
   Tam CW, 2006, ENDOCRINOLOGY, V147, P5023, DOI 10.1210/en.2006-0207
   Tao MH, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12431
   Tao R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019862
   Teschendorff AE, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003709
   Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170
   Than BLN, 2014, ONCOGENE, V33, P3861, DOI 10.1038/onc.2013.350
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Wang K, 2007, AM J HUM GENET, V81, P1278, DOI 10.1086/522374
   West J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01630
   Wong IHN, 1999, CANCER RES, V59, P71
   Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/NMETH.1282, 10.1038/nmeth.1282]
   Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yeh KT, 2011, EPIGENETICS-US, V6, P727, DOI 10.4161/epi.6.6.15856
   Zender L, 2010, J HEPATOL, V52, P921, DOI 10.1016/j.jhep.2009.12.034
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhang HH, 2013, INT J CLIN EXP PATHO, V6, P1734
   Zhang N., 2015, BIOINFORMATICS
NR 64
TC 13
Z9 15
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD SEP 19
PY 2016
VL 44
IS 16
AR e134
DI 10.1093/nar/gkw546
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DX9BC
UT WOS:000384687000004
PM 27302130
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Wendling, CA
AF Wendling, C. -A.
TI Adverse childhood experiences, breast cancer, and psychotherapy
SO PSYCHO-ONCOLOGIE
LA English
DT Article
DE Breast cancer; Trauma; Psychotherapy; Epigenetics; Psychoneuroimmunology
ID STRESS; BRAIN
AB This study is based on 14 women's breast cancer autobiographies that mention adverse childhood experiences. Recent research has established that early trauma tends to be associated with long-lasting physiological deregulations such as an overactive fight-or-flight response and a weakened immune competence. Stress hormones, such as cortisol, play a crucial role in tumor genesis, therefore, a relationship between adverse childhood events and breast cancer can be hypothesized. However, successful psychotherapy combining a somatic technique and a talking cure can reverse the harmful effects of early adverse experiences through the epigenetic route.
C1 [Wendling, C. -A.] Univ Strasbourg, Pole LANSAD, 4 Rue Blaise Pascal, F-67081 Strasbourg, France.
   [Wendling, C. -A.] Univ Paris 07, Ctr Rech Psychanal Med & Soc, 5 Rue Thomas Mann, F-75013 Paris, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Universite Paris Cite
RP Wendling, CA (通讯作者)，Univ Strasbourg, Pole LANSAD, 4 Rue Blaise Pascal, F-67081 Strasbourg, France.; Wendling, CA (通讯作者)，Univ Paris 07, Ctr Rech Psychanal Med & Soc, 5 Rue Thomas Mann, F-75013 Paris, France.
EM cathyannewendling@gmail.com
CR Accad E, 2001, THE WOUNDED BREAST
   [Anonymous], 2009, BRAIN EMOTIONAL SYST
   [Anonymous], THE PLACEBO RESPONSE
   [Anonymous], SAUVE TOI LOLA
   [Anonymous], 2003, Affect Regulation and the Repair of the Self
   [Anonymous], 2010, IMPACT EARLY LIFE TR
   Antoni MH, 2013, BRAIN BEHAV IMMUN, V30, pS88, DOI 10.1016/j.bbi.2012.05.009
   Baker GK, 2008, CANC IS A BITCH
   Barasch MI, 1995, THE HEALING PATH
   Bondar AB, 2005, MESSAGES HEART LEARN
   Brown DW, 2009, AM J PREV MED, V37, P389, DOI 10.1016/j.amepre.2009.06.021
   Brunet C, 2005, VIE VAUT MILLE MAUX
   Chartier MJ, 2007, AM J EPIDEMIOL, V165, P1031, DOI 10.1093/aje/kwk113
   Cromer KR, 2006, J TRAUMA STRESS, V19, P967, DOI 10.1002/jts.20168
   Doidge N., 2007, The brain that changes itself: Stories of the personal triumph from the frontiers of brain science
   Dong M, 2003, ARCH INTERN MED, V163, P1949, DOI 10.1001/archinte.163.16.1949
   Fagundes CP, 2013, BRAIN BEHAV IMMUN, V27, P8, DOI 10.1016/j.bbi.2012.06.014
   Feinstein D, 2010, REV GEN PSYCHOL, V14, P283, DOI 10.1037/a0021252
   Ford J.D., 2010, IMPACT EARLY LIFE TR
   Fosha D., 2009, The healing power of emotion: Affective neuroscience, development, and clinical practice
   Gerhardt S., 2004, WHY LOVE MATTERS AFF
   Gonzalez Pardo H, 2013, PSICOTHEMA, V25, P3
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Joseph B., 1996, My Healing From Breast Cancer
   Justice B., 1988, Who gets sick
   Kahane DeborahH., 1995, No Less A Woman: Femininity, Sexuality Breast Cancer
   Kandel E., 2005, PSYCHIAT PSYCHOANALY
   Kelly-Irving M, 2013, INT J PUBLIC HEALTH, V58, P3, DOI 10.1007/s00038-012-0370-0
   LaPrairie JL., 2010, The Impact of Early Life Trauma on Health and Disease. The Hidden Epidemic
   Lewis CE, 1994, PSYCHONEUROIMMUNOLOL
   Mate G., 2003, BODY SAYS NO UNDERST
   Mathews HL, 2011, BRAIN BEHAV IMMUN, V25, P830, DOI 10.1016/j.bbi.2010.12.002
   McDonald PG, 2013, BRAIN BEHAV IMMUN, V30, pS1, DOI 10.1016/j.bbi.2013.01.003
   McDougall J, 2000, J ANAL PSYCHOL, V45, P45, DOI 10.1111/1465-5922.00135
   Miller G, 2009, ANNU REV PSYCHOL, V60, P501, DOI 10.1146/annurev.psych.60.110707.163551
   Ogden P., 2009, The healing power of emotion: Perspectives from affective neuroscience and clinical practice
   Ornish D, 2008, LANCET ONCOL, V9, P1048, DOI 10.1016/S1470-2045(08)70234-1
   Pettason A, 2008, I AM NOT MY BREAST C
   Pressman SD, 2005, PSYCHOL BULL, V131, P925, DOI 10.1037/0033-2909.131.6.925
   Robles TF, 2011, SOC PERSONAL PSYCHOL, V5, P518, DOI 10.1111/j.1751-9004.2011.00368.x
   Rodriguez T, 2013, SCI AM MIND, V24, P17
   Rubert F, 2006, VIE EST SIMPLEMENT
   Siegel D., 2009, The Healing Power of Emotion: Affective Neuroscience, Development Clinical Practice
   Stankiewicz AM, 2013, BRAIN RES BULL, V98, P76, DOI 10.1016/j.brainresbull.2013.07.003
   Tabet S, 2010, LES PATIENTES
   Tart C., 1997, Body mind spirit: Exploring the parapsychology of spirituality
   Teicher M.H., 2010, The impact of early life trauma on health and disease: The hidden epidemic
   Thayer JF, 2005, PSYCHONEUROENDOCRINO, V30, P1050, DOI 10.1016/j.psyneuen.2005.04.014
   Tronick E., 2009, The Healing Power of Emotion. Affective Neuroscience, Development
   Unternaehrer E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.77
   Vaillant M, 2008, ANN SINGULIERE AVEC
   Yehuda R, 2009, J TRAUMA STRESS, V22, P427, DOI 10.1002/jts.20448
NR 52
TC 2
Z9 2
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1778-3798
EI 1778-381X
J9 PSYCHO-ONCOLOGIE
JI Psycho-Oncologie
PD SEP
PY 2016
VL 10
IS 3
BP 221
EP 226
DI 10.1007/s11839-016-0588-9
PG 6
WC Oncology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Psychology
GA DY6EH
UT WOS:000385198700011
DA 2025-01-12
ER

PT J
AU Niu, NF
   Liu, TZ
   Cairns, J
   Ly, RC
   Tan, XL
   Deng, M
   Fridley, BL
   Kalari, KR
   Abo, RP
   Jenkins, G
   Batzler, A
   Carlson, EE
   Barman, P
   Moran, S
   Heyn, H
   Esteller, M
   Wang, LW
AF Niu, Nifang
   Liu, Tongzheng
   Cairns, Junmei
   Ly, Reynold C.
   Tan, Xianglin
   Deng, Min
   Fridley, Brooke L.
   Kalari, Krishna R.
   Abo, Ryan P.
   Jenkins, Gregory
   Batzler, Anthony
   Carlson, Erin E.
   Barman, Poulami
   Moran, Sebastian
   Heyn, Holger
   Esteller, Manel
   Wang, Liewei
TI Metformin pharmacogenomics: a genome-wide association study to identify
   genetic and epigenetic biomarkers involved in metformin anticancer
   response using human lymphoblastoid cell lines
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID CATION TRANSPORTER 1; TOXIN EXTRUSION 1; BREAST-CANCER; VARIANTS;
   MULTIDRUG; CHIP; PHARMACOKINETICS; METABOLISM; BIGUANIDES; PREVENTION
AB Metformin is currently considered as a promising anticancer agent in addition to its anti-diabetic effect. To better individualize metformin therapy and explore novel molecular mechanisms in cancer treatment, we conducted a pharmacogenomic study using 266 lymphoblastoid cell lines (LCLs). Metformin cytotoxicity assay was performed using the MTS assay. Genome-wide association (GWA) analyses were performed in LCLs using 1.3 million SNPs, 485k DNA methylation probes, 54k mRNA expression probe sets, and metformin cytotoxicity (IC50s). Top candidate genes were functionally validated using siRNA screening, followed by MTS assay in breast cancer cell lines. Further study of one top candidate, STUB1, was performed to elucidate the mechanisms by which STUB1 might contribute to metformin action. GWA analyses in LCLs identified 198 mRNA expression probe sets, 12 SNP loci, and 5 DNA methylation loci associated with metformin IC50 with P-values <10(-4) or <10(-5). Integrated SNP/methylation loci-expression-IC50 analyses found 3 SNP loci or 5 DNA methylation loci associated with metformin IC50 through trans-regulation of expression of 11 or 26 genes with P-value <10(-4). Functional validation of top 61 candidate genes in 4 IPA networks indicated down regulation of 14 genes significantly altered metformin sensitivity in two breast cancer cell lines. Mechanistic studies revealed that the E3 ubiquitin ligase, STUB1, could influence metformin response by facilitating proteasome-mediated degradation of cyclin A. GWAS using a genomic data-enriched LCL model system, together with functional and mechanistic studies using cancer cell lines, help us to identify novel genetic and epigenetic biomarkers involved in metformin anticancer response.
C1 [Niu, Nifang; Cairns, Junmei; Ly, Reynold C.; Wang, Liewei] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN USA.
   [Liu, Tongzheng; Deng, Min] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Div Oncol, Rochester, MN USA.
   [Tan, Xianglin] UMDNJ, Canc Inst New Jersey, New Brunswick, NJ USA.
   [Fridley, Brooke L.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
   [Kalari, Krishna R.; Jenkins, Gregory; Batzler, Anthony; Carlson, Erin E.; Barman, Poulami] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Biostat & Informat, Rochester, MN USA.
   [Abo, Ryan P.] MIT, Dept Biol, Cambridge, MA USA.
   [Moran, Sebastian; Heyn, Holger; Esteller, Manel] L Hosp Llobregat, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain.
C3 Mayo Clinic; Mayo Clinic; Rutgers University System; Rutgers University
   New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers
   Cancer Institute of New Jersey; University of Kansas; University of
   Kansas Medical Center; Mayo Clinic; Massachusetts Institute of
   Technology (MIT); Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); University of Barcelona; ICREA
RP Wang, LW (通讯作者)，Mayo Clin, Div Clin Pharmacol, Dept Mol Pharmacol & Expt Therapeut, 200 First St SW, Rochester, MN 55905 USA.
EM wang.liewei@mayo.edu
RI Barman, Poulami/ABG-1426-2020; Esteller, Manel/L-5956-2014; Moran,
   Sebastian/G-5293-2013
OI Deng, Min/0000-0003-1987-9775; Kalari, Krishna/0000-0001-8944-8378; Ly,
   Reynold/0000-0002-3016-6859; Esteller, Manel/0000-0003-4490-6093; Heyn,
   Holger/0000-0002-3276-1889; Moran, Sebastian/0000-0003-4192-8983
FU NIH [R01CA196648, R01 CA138461, U19 GM61388, R01 CA80127, R01 CA84354,
   R01 CA105857]; ICREA Funding Source: Custom
FX This work was supported by NIH grants R01CA196648, R01 CA138461, U19
   GM61388 (The Pharmacogenomics Research Network); R01 CA80127, R01
   CA84354 and R01 CA105857.
CR Ahlin G, 2011, PHARMACOGENOMICS J, V11, P400, DOI 10.1038/tpj.2010.54
   Aldea M, 2014, TUMOR BIOL, V35, P5101, DOI 10.1007/s13277-014-1676-8
   Becker ML, 2009, PHARMACOGENOMICS J, V9, P242, DOI 10.1038/tpj.2009.15
   Becker MSL, 2009, DIABETES, V58, P745, DOI 10.2337/db08-1028
   Becker ML, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/686315
   Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782
   Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x
   Cai XB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133349
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Chen LG, 2010, PHARMACOGENET GENOM, V20, P687, DOI 10.1097/FPC.0b013e32833fe789
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Chen Y, 2009, PHARMACOGENOMICS J, V9, P127, DOI 10.1038/tpj.2008.19
   Chlebowski RT, 2012, J CLIN ONCOL, V30, P2844, DOI 10.1200/JCO.2011.39.7505
   Christensen MMH, 2011, PHARMACOGENET GENOM, V21, P837, DOI 10.1097/FPC.0b013e32834c0010
   Deng XS, 2012, CELL CYCLE, V11, P367, DOI 10.4161/cc.11.2.18813
   Gaude H, 2012, ONCOGENE, V31, P1582, DOI 10.1038/onc.2011.342
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Gong L, 2012, PHARMACOGENET GENOM, V22, P820, DOI 10.1097/FPC.0b013e3283559b22
   Goswami S, 2014, CLIN PHARMACOL THER, V96, P370, DOI 10.1038/clpt.2014.109
   Hadad SM, 2015, BREAST CANCER RES TR, V150, P149, DOI 10.1007/s10549-015-3307-5
   Hatoum D, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/548436
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Jablonski KA, 2010, DIABETES, V59, P2672, DOI 10.2337/db10-0543
   Jiang Jing, 2013, Frontiers in Genetics, V4, P166, DOI 10.3389/fgene.2013.00166
   Joerger M, 2015, PROSTATE CANCER P D, V18, P167, DOI 10.1038/pcan.2015.8
   Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3
   Li L, 2008, CANCER RES, V68, P7050, DOI 10.1158/0008-5472.CAN-08-0405
   Liang XM, 2015, MOL PHARMACEUT, V12, P4301, DOI 10.1021/acs.molpharmaceut.5b00501
   Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814
   Liu TZ, 2014, MOL CELL, V56, P681, DOI 10.1016/j.molcel.2014.10.007
   Luo KT, 2012, EMBO J, V31, P3008, DOI 10.1038/emboj.2012.158
   McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2
   McDonough H, 2009, J BIOL CHEM, V284, P20649, DOI 10.1074/jbc.M109.011767
   Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948
   Motohashi H, 2013, AAPS J, V15, P581, DOI 10.1208/s12248-013-9465-7
   Nestor CE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0576-y
   Niu NF, 2010, GENOME RES, V20, P1482, DOI 10.1101/gr.107672.110
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Pollak M, 2014, NAT MED, V20, P591, DOI 10.1038/nm.3596
   Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232
   Pollak MN, 2012, CANCER DISCOV, V2, P778, DOI 10.1158/2159-8290.CD-12-0263
   Reitman ML, 2007, J CLIN INVEST, V117, P1226, DOI 10.1172/JCI32133
   Rodriguez-Lirio A, 2015, Leuk Res Treatment, V2015, P516460, DOI 10.1155/2015/516460
   Schisler JC, 2013, J CLIN INVEST, V123, P3588, DOI 10.1172/JCI69080
   Semiz S, 2013, BIOCHEM MEDICA, V23, P154, DOI 10.11613/BM.2013.020
   Smith MA, 2013, CLIN CANCER RES, V19, P2828, DOI 10.1158/1078-0432.CCR-13-0043
   Song IS, 2008, CLIN PHARMACOL THER, V84, P559, DOI 10.1038/clpt.2008.61
   Song IS, 2008, XENOBIOTICA, V38, P1252, DOI [10.1080/00498250802130039, 10.1080/00498250802130039 ]
   Suryadinata R, 2010, BIOSCIENCE REP, V30, P243, DOI 10.1042/BSR20090171
   van Leeuwen N, 2012, DIABETOLOGIA, V55, P1971, DOI 10.1007/s00125-012-2537-x
   Wang LW, 2014, DIABETES, V63, P2609, DOI 10.2337/db14-0609
   Williams CC, 2013, J HEALTH CARE POOR U, V24, P93, DOI 10.1353/hpu.2013.0044
   Yang K, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-32
   Zhou KX, 2014, LANCET DIABETES ENDO, V2, P481, DOI 10.1016/S2213-8587(14)70050-6
   Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735
NR 57
TC 15
Z9 18
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2016
VL 25
IS 21
BP 4819
EP 4834
DI 10.1093/hmg/ddw301
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EP0FC
UT WOS:000397061300016
PM 28173075
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU ter Brugge, P
   Kristel, P
   van der Burg, E
   Boon, U
   de Maaker, M
   Lips, E
   Mulder, L
   de Ruiter, J
   Moutinho, C
   Gevensleben, H
   Marangoni, E
   Majewski, I
   Józwiak, K
   Kloosterman, W
   van Roosmalen, M
   Duran, K
   Hogervorst, F
   Turner, N
   Esteller, M
   Cuppen, E
   Wesseling, J
   Jonkers, J
AF ter Brugge, Petra
   Kristel, Petra
   van der Burg, Eline
   Boon, Ute
   de Maaker, Michiel
   Lips, Esther
   Mulder, Lennart
   de Ruiter, Julian
   Moutinho, Catia
   Gevensleben, Heidrun
   Marangoni, Elisabetta
   Majewski, Ian
   Jozwiak, Katarzyna
   Kloosterman, Wigard
   van Roosmalen, Markus
   Duran, Karen
   Hogervorst, Frans
   Turner, Nick
   Esteller, Manel
   Cuppen, Edwin
   Wesseling, Jelle
   Jonkers, Jos
TI Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of
   BRCA1-Deficient Breast Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID MAMMARY-TUMORS; POLY(ADP-RIBOSE) POLYMERASE; CHEMOTHERAPY RESISTANCE;
   PREDICTS SENSITIVITY; CISPLATIN RESISTANCE; BRCA1; METHYLATION;
   MUTATIONS; PROMOTER; CELLS
AB Background: Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in patient-derived xenograft (PDX) models of BRCA1-mutated and BRCA1-methylated triple-negative breast cancer.
   Methods: A cohort of 75 mice carrying BRCA1-deficient breast PDX tumors was treated with cisplatin, melphalan, nimustine, or olaparib, and treatment sensitivity was determined. In tumors that acquired therapy resistance, BRCA1 expression was investigated using quantitative real-time polymerase chain reaction and immunoblotting. Next-generation sequencing, methylation-specific multiplex ligation-dependent probe amplification (MLPA) and Target Locus Amplification (TLA)-based sequencing were used to determine mechanisms of BRCA1 re-expression in therapy-resistant tumors.
   Results: BRCA1 protein was not detected in therapy-sensitive tumors but was found in 31 out of 42 resistant cases. Apart from previously described mechanisms involving BRCA1-intragenic deletions and loss of BRCA1 promoter hypermethylation, a novel resistance mechanism was identified in four out of seven BRCA1-methylated PDX tumors that re-expressed BRCA1 but retained BRCA1 promoter hypermethylation. In these tumors, we found de novo gene fusions that placed BRCA1 under the transcriptional control of a heterologous promoter, resulting in re-expression of BRCA1 and acquisition of therapy resistance.
   Conclusions: In addition to previously described clinically relevant resistance mechanisms in BRCA1-deficient tumors, we describe a novel resistance mechanism in BRCA1-methylated PDX tumors involving de novo rearrangements at the BRCA1 locus, demonstrating that BRCA1-methylated breast cancers may acquire therapy resistance via both epigenetic and genetic mechanisms.
C1 [ter Brugge, Petra; Kristel, Petra; van der Burg, Eline; Boon, Ute; de Maaker, Michiel; Lips, Esther; Mulder, Lennart; de Ruiter, Julian; Wesseling, Jelle; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
   [ter Brugge, Petra; Kristel, Petra; van der Burg, Eline; Boon, Ute; de Maaker, Michiel; Lips, Esther; Mulder, Lennart; de Ruiter, Julian; Wesseling, Jelle; Jonkers, Jos] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Majewski, Ian] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.
   [Jozwiak, Katarzyna] Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Hogervorst, Frans] Netherlands Canc Inst, Family Canc Clin, Amsterdam, Netherlands.
   [Hogervorst, Frans] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands.
   [Moutinho, Catia; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.
   [Gevensleben, Heidrun; Turner, Nick] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England.
   [Marangoni, Elisabetta] Inst Curie, Translat Res Dept, Lab Preclin Investigat, Paris, France.
   [Kloosterman, Wigard; van Roosmalen, Markus; Duran, Karen; Cuppen, Edwin] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain.
   [Gevensleben, Heidrun] Univ Hosp Bonn, Inst Pathol, Bonn, Germany.
   [Majewski, Ian] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
C3 Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands
   Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer
   Institute; Netherlands Cancer Institute; Institut d'Investigacio
   Biomedica de Bellvitge (IDIBELL); University of London; Institute of
   Cancer Research - UK; Royal Marsden NHS Foundation Trust; UNICANCER;
   Universite PSL; Institut Curie; Utrecht University; Utrecht University
   Medical Center; University of Barcelona; ICREA; University of Bonn;
   Walter & Eliza Hall Institute
RP Wesseling, J; Jonkers, J (通讯作者)，Netherlands Canc Inst, Div Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.; Wesseling, J; Jonkers, J (通讯作者)，Netherlands Canc Inst, Canc Genom Ctr Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM j.wesseling@nki.nl; j.jonkers@nki.nl
RI Jonkers, Jos/AAG-3246-2019; Moutinho, Cátia/ABS-8506-2022; Marangoni,
   Elisabetta/GSO-3945-2022; Esteller, Manel/L-5956-2014; Cuppen,
   Edwin/H-2389-2016
OI Marangoni, Elisabetta/0000-0002-3337-6448; Moutinho,
   Catia/0000-0003-3885-0847; Majewski, Ian/0000-0002-6087-635X; Mulder,
   Lennart/0000-0001-8844-1481; Jonkers, Jos/0000-0002-9264-9792; Esteller,
   Manel/0000-0003-4490-6093; Cuppen, Edwin/0000-0002-0400-9542; Wesseling,
   Jelle/0000-0002-8940-2676; Jozwiak, Katarzyna/0000-0002-9614-6586
FU Dutch Cancer Society [NKI 2011-5197, EMCR 2014-7048]; Netherlands
   Organization for Scientific Research (NWO-NGI Zenith) [93512009];
   Eurocan Platform network of excellence - EU Seventh Framework Programme;
   CombatCancer synergy project - European Research Council; Cancer
   Genomics Netherlands gravitation programme; Cancer Systems Biology
   Center (CSBC) - NWO; Netherlands Organization for Scientific Research
   (NWO-ZonMW Vici) [91814643]; ICREA Funding Source: Custom
FX This research was supported by grants from the Dutch Cancer Society (NKI
   2011-5197 and EMCR 2014-7048); the Netherlands Organization for
   Scientific Research (NWO-NGI Zenith 93512009 and NWO-ZonMW Vici
   91814643); the Eurocan Platform network of excellence, funded by the EU
   Seventh Framework Programme; the CombatCancer synergy project, funded by
   the European Research Council; and the Cancer Genomics Netherlands
   gravitation programme and Cancer Systems Biology Center (CSBC), funded
   by the NWO.
CR Alli Elizabeth, 2011, BMC Pharmacology, V11, P7, DOI 10.1186/1471-2210-11-7
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537
   Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9
   Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019
   Cai FF, 2014, TUMOR BIOL, V35, P3839, DOI 10.1007/s13277-013-1508-2
   de Vree PJP, 2014, NAT BIOTECHNOL, V32, P1019, DOI 10.1038/nbt.2959
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027
   Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4
   Gupta A, 2009, FUTURE MED CHEM, V1, P1125, DOI [10.4155/fmc.09.84, 10.4155/FMC.09.84]
   Hay T, 2009, CANCER RES, V69, P3850, DOI 10.1158/0008-5472.CAN-08-2388
   Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049
   Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755
   Lord CJ, 2006, CLIN CANCER RES, V12, P4463, DOI 10.1158/1078-0432.CCR-06-1269
   Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078
   Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Sato K, 2005, ANTICANCER RES, V25, P4021
   Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Wang YQ, 2010, CANCER SCI, V101, P1618, DOI 10.1111/j.1349-7006.2010.01568.x
   Wang YR, 2010, MOL CELL PROBE, V24, P15, DOI 10.1016/j.mcp.2009.08.001
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
   Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081
NR 44
TC 151
Z9 159
U1 0
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD NOV
PY 2016
VL 108
IS 11
AR djw148
DI 10.1093/jnci/djw148
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EK4LD
UT WOS:000393897300010
PM 27381626
DA 2025-01-12
ER

PT J
AU Gonzalez-Guerrico, AM
   Espinoza, I
   Schroeder, B
   Park, CH
   Mohan, KVPC
   Khurana, A
   Corominas-Faja, B
   Cuyàs, E
   Alarcón, T
   Kleer, C
   Menendez, JA
   Lupu, R
AF Gonzalez-Guerrico, Anatilde M.
   Espinoza, Ingrid
   Schroeder, Barbara
   Park, Cheol Hong
   Mohan, Chandra K. V. P.
   Khurana, Ashwani
   Corominas-Faja, Bruna
   Cuyas, Elisabet
   Alarcon, Tomas
   Kleer, Celina
   Menendez, Javier A.
   Lupu, Ruth
TI Suppression of endogenous lipogenesis induces reversion of the malignant
   phenotype and normalized differentiation in breast cancer
SO ONCOTARGET
LA English
DT Article
DE fatty acid synthase; lipogenesis; cancer; tumor reversion; phenotype
ID FATTY-ACID SYNTHASE; EPITHELIAL-MESENCHYMAL TRANSITION; RECIPROCAL
   INTERACTIONS; 3-DIMENSIONAL CULTURE; EPIGENETIC LANDSCAPE; TISSUE
   ARCHITECTURE; METABOLIC-CONTROL; TUMOR-GROWTH; CELL-LINES; IN-VIVO
AB The correction of specific signaling defects can reverse the oncogenic phenotype of tumor cells by acting in a dominant manner over the cancer genome. Unfortunately, there have been very few successful attempts at identifying the primary cues that could redirect malignant tissues to a normal phenotype. Here we show that suppression of the lipogenic enzyme fatty acid synthase (FASN) leads to stable reversion of the malignant phenotype and normalizes differentiation in a model of breast cancer (BC) progression. FASN knockdown dramatically reduced tumorigenicity of BC cells and restored tissue architecture, which was reminiscent of normal ductal-like structures in the mammary gland. Loss of FASN signaling was sufficient to direct tumors to a reversed phenotype that was near normal when considering the development of polarized growth-arrested acinar-like structure similar to those formed by nonmalignant breast cells in a 3D reconstituted basement membrane in vitro. This process, in vivo, resulted in a low proliferation index, mesenchymal-epithelial transition, and shut-off of the angiogenic switch in FASN-depleted BC cells orthotopically implanted into mammary fat pads. The role of FASN as a negative regulator of correct breast tissue architecture and terminal epithelial cell differentiation was dominant over the malignant phenotype of tumor cells possessing multiple cancer-driving genetic lesions as it remained stable during the course of serial in vivo passage of orthotopic tumor-derived cells. Transient knockdown of FASN suppressed hallmark structural and cytosolic/secretive proteins (vimentin, N-cadherin, fibronectin) in a model of EMT-induced cancer stem cells (CSC). Indirect pharmacological inhibition of FASN promoted a phenotypic switch from basal-to luminal-like tumorsphere architectures with reduced intrasphere heterogeneity. The fact that sole correction of exacerbated lipogenesis can stably reprogram cancer cells back to normal-like tissue architectures might open a new avenue to chronically restrain BC progression by using FASN-based differentiation therapies.
C1 [Gonzalez-Guerrico, Anatilde M.; Schroeder, Barbara; Park, Cheol Hong; Mohan, Chandra K. V. P.; Khurana, Ashwani; Lupu, Ruth] Mayo Clin, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Espinoza, Ingrid] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA.
   [Espinoza, Ingrid] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.
   [Corominas-Faja, Bruna; Cuyas, Elisabet; Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, ProCURE Program Canc Therapeut Resistance, Girona, Catalonia, Spain.
   [Corominas-Faja, Bruna; Cuyas, Elisabet; Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.
   [Alarcon, Tomas] CRM, Computat & Math Biol Res Grp, Barcelona, Spain.
   [Alarcon, Tomas] UAB, Dept Matemat, Barcelona, Spain.
   [Alarcon, Tomas] ICREA Inst Catalana Estudis & Recerca Avancats, Barcelona, Spain.
   [Alarcon, Tomas] Barcelona Grad Sch Math BGSMath, Barcelona, Spain.
   [Kleer, Celina] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
   [Lupu, Ruth] Mayo Clin, Ctr Canc, Rochester, MN 55905 USA.
C3 Mayo Clinic; University of Mississippi Medical Center; University of
   Mississippi; University of Mississippi; University of Mississippi
   Medical Center; Institut Catala d'Oncologia; Universitat de Girona;
   Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio
   Biomedica de Girona (IDIBGI); Centre de Recerca Matematica (CRM);
   Autonomous University of Barcelona; ICREA; University of Michigan
   System; University of Michigan; Mayo Clinic
RP Lupu, R (通讯作者)，Mayo Clin, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA.; Menendez, JA (通讯作者)，Catalan Inst Oncol, Metab & Canc Grp, ProCURE Program Canc Therapeut Resistance, Girona, Catalonia, Spain.; Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.; Lupu, R (通讯作者)，Mayo Clin, Ctr Canc, Rochester, MN 55905 USA.
EM jmenendez@idibgi.org; lupu.ruth@mayo.edu
RI venkatapoorna, chandra/L-2428-2016; Cuyas, Elisabet/G-8582-2018;
   MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016; Alarcon, Tomas/D-9083-2013
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561; Cuyas,
   Elisabet/0000-0001-5353-440X; Alarcon, Tomas/0000-0002-8566-3676
FU National Institute of Health/National Cancer Institute [R01-CA116623];
   Ministerio de Ciencia e Innovacion [SAF2012-38914]; Plan Nacional de
   I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) [2014 SGR229]; Departament d'Economia I Coneixement, Catalonia,
   Spain; "Sara Borrell" post-doctoral contract (Ministerio de Sanidad y
   Consumo, Fondo de Investigacion Sanitaria -FIS-, Spain) [CD15/00033];
   National Cancer Institute [R01CA125577] Funding Source: NIH RePORTER;
   ICREA Funding Source: Custom
FX We are greatly indebted to Prof. Robert A. Weinberg (Whitehead Institute
   for Biomedical Research, Cambridge, MA, USA) for providing the
   HMLER<SUP>shCntrol</SUP> and HMLER<SUP>shEcad</SUP> cells used in this
   work. Work in the corresponding authors' labs was supported by the
   National Institute of Health/National Cancer Institute award
   R01-CA116623 to Ruth Lupu and by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2012-38914), Plan Nacional de I+D+I, Spain and the
   Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014
   SGR229), Departament d'Economia I Coneixement, Catalonia, Spain to
   Javier A. Menendez. Elisabet Cuyas is the recipient of a "Sara Borrell"
   post-doctoral contract (CD15/00033, Ministerio de Sanidad y Consumo,
   Fondo de Investigacion Sanitaria -FIS-, Spain).
CR Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358
   Beliveau A, 2010, GENE DEV, V24, P2800, DOI 10.1101/gad.1990410
   Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Bissell MJ, 1999, CANCER RES, V59, p1757S
   Chen A, 2009, CANCER RES, V69, P6721, DOI 10.1158/0008-5472.CAN-08-4069
   Choi Y, 2013, HUM PATHOL, V44, P2581, DOI 10.1016/j.humpath.2013.07.003
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Cufí S, 2013, FOOD CHEM TOXICOL, V60, P360, DOI 10.1016/j.fct.2013.07.063
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   DEGOS L, 1992, Current Opinion in Oncology, V4, P45, DOI 10.1097/00001622-199202000-00007
   Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]
   Goding CR, 2014, NAT REV CANCER, V14, P568, DOI 10.1038/nrc3781
   Griss T, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002309
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Huang Sui, 2006, Breast Dis, V26, P27
   Huang S, 2013, CANCER METAST REV, V32, P423, DOI 10.1007/s10555-013-9435-7
   Huang S, 2012, BIOESSAYS, V34, P149, DOI 10.1002/bies.201100031
   Huang S, 2009, SEMIN CELL DEV BIOL, V20, P869, DOI 10.1016/j.semcdb.2009.07.003
   Itoh M, 2007, CANCER RES, V67, P4759, DOI 10.1158/0008-5472.CAN-06-4246
   Kam Yoonseok, 2009, BMC Res Notes, V2, P130, DOI 10.1186/1756-0500-2-130
   Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491
   Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689
   Krause S, 2008, TISSUE ENG PT C-METH, V14, P261, DOI 10.1089/ten.tec.2008.0030
   Krause S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-263
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673
   Lelièvre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711
   Li QL, 2014, J BIOL CHEM, V289, P1303, DOI 10.1074/jbc.M113.502278
   Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8
   Lotem J, 2006, ONCOGENE, V25, P7663, DOI 10.1038/sj.onc.1209816
   Loubière C, 2015, ONCOTARGET, V6, P15652, DOI 10.18632/oncotarget.3404
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928
   Maguire S, 2014 NCRI CANC C
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15
   Menendez JA, 2015, CELL CYCLE, V14, P3801, DOI 10.1080/15384101.2015.1022697
   Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262
   Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479
   Menendez JA, 2010, BBA-MOL CELL BIOL L, V1801, P381, DOI 10.1016/j.bbalip.2009.09.005
   Menendez JA, 2009, CLIN CHEM, V55, P425, DOI 10.1373/clinchem.2008.115352
   Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030
   Nair V, 2013, CARCINOGENESIS, V34, P2870, DOI 10.1093/carcin/bgt231
   Nowak D, 2009, BLOOD, V113, P3655, DOI 10.1182/blood-2009-01-198911
   Pandey PR, 2012, RECENT PAT ANTI-CANC, V7, P185
   Peng XJ, 2004, INT J ONCOL, V25, P961
   Petersen OW, 2001, BREAST CANCER RES, V3, P213
   Petersen OW, 1998, ADV CANCER RES, V75, P135, DOI 10.1016/S0065-230X(08)60741-1
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503
   Sell S, 2005, STEM CELL REV, V1, P197, DOI 10.1385/SCR:1:3:197
   Shekhar MPV, 2013, ONCOTARGET, V4, P231, DOI 10.18632/oncotarget.818
   Smart CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064388
   Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022
   Vazquez-Martin A, 2008, CELL PROLIFERAT, V41, P59, DOI 10.1111/j.1365-2184.2007.00498.x
   Vazquez-Martin A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02560
   Vazquez-Martin A, 2013, CELL CYCLE, V12, P207, DOI 10.4161/cc.23352
   Wahdan-Alaswad RS, 2014, HORM CANCER-US, V5, P374, DOI 10.1007/s12672-014-0188-8
   Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821
   Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   Zaytseva YY, 2014, CARCINOGENESIS, V35, P1341, DOI 10.1093/carcin/bgu042
   Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057
   Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439
NR 73
TC 33
Z9 36
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 1
PY 2016
VL 7
IS 44
BP 71151
EP 71168
DI 10.18632/oncotarget.9463
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5VQ
UT WOS:000387449100008
PM 27223424
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Xu, X
   Lv, YG
   Yan, CY
   Yi, J
   Ling, R
AF Xu, Xin
   Lv, Yong-gang
   Yan, Chang-you
   Yi, Jun
   Ling, Rui
TI Enforced expression of hsa-miR-125a-3p in breast cancer cells
   potentiates docetaxel sensitivity via modulation of BRCA1 signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Breast cancer; miRNAs; Chemoresistance; BRCA1; Docetaxel
ID NF-KAPPA-B; PROSTATE-CANCER; UP-REGULATION; LUNG-CANCER; RESISTANCE;
   MICRORNAS; GENE; ACTIVATION; INHIBITOR; CISPLATIN
AB Epigenetic gene inactivation by microRNAs (miRNAs) plays a key role in malignant transformation, prevention of apoptosis, drug resistance and metastasis. It has been shown that miR-125a is down regulated in HER2-amplified and HER2-overexpressing breast cancers (BCa), and this miRNA is believed to serve as an important tumor suppressor. miR-125a has two mature forms: hsa-miR-125a-3p and hsa-miR-125a-5p. However, the functional details of these miRNAs in BCa, particularly during pathogenesis of drug resistance, remain largely unexplored. Herein, we reported that hsa-miR-125a-3p expression was significantly reduced in chemoresistant BCa tissues and in experimentally established chemoresistant BCa cells. hsa-miR-125a-3p knockdown promoted cell proliferation and compromised docetaxel (Dox)-induced cell death, whereas overexpression of hsa-miR-125a-3p attenuated Dox chemoresistance in BCa cells. From a mechanistic standpoint, hsa-miR-125a-3p directly targeted 3'-untranslated regions (3'-UTRs) of breast cancer early onset gene 1 (BRCA1) and inhibits its protein expression via translational repression mechanism. In addition, suppression of BRCA1 expression by siRNA treatment effectively improved hsa-miR-125a-3p deficiency-triggered chemoresistance in BCa cells. Collectively, these findings suggest that hsa-miR-125a-3p may function as a tumor suppressor by regulating the BRCA1 signaling, and reintroduction of hsa-miR-125a-3p analogs could be a potential adjunct therapy for advanced/chemoresistant BCa. (C) 2016 Published by Elsevier Inc.
C1 [Xu, Xin; Lv, Yong-gang; Yi, Jun; Ling, Rui] Fourth Mil Med Univ, Xijing Hosp, Dept Thyroid Gland & Breast Vasc Surg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
   [Yan, Chang-you] Xian Hlth Management Serv Ctr, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Military Medical University
RP Yi, J; Ling, R (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Thyroid Gland & Breast Vasc Surg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM yijun1720@163.com; lingrui0105@163.com
CR Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003
   Borgan E, 2011, MOL ONCOL, V5, P564, DOI 10.1016/j.molonc.2011.08.004
   Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196
   Czerwinska Patrycja, 2015, Contemp Oncol (Pozn), V19, pA7, DOI 10.5114/wo.2014.47126
   Ding J, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.122333
   Dong YS, 2016, CELL DEATH DIFFER, V23, P787, DOI 10.1038/cdd.2015.139
   Fan Z, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.21
   Feng WN, 2015, INT J CLIN EXP PATHO, V8, P12869
   Ferroudj S., 2016, HEPATOL RES
   Harte MT, 2014, ONCOGENE, V33, P713, DOI 10.1038/onc.2013.10
   Jiang LL, 2013, CANCER INVEST, V31, P538, DOI 10.3109/07357907.2013.820314
   Jiang LL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-318
   Kopczynska E, 2015, WSPOLCZESNA ONKOL, V19, P423, DOI 10.5114/wo.2015.56648
   Li W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.223
   Li W, 2015, TOXICOL APPL PHARM, V285, P98, DOI 10.1016/j.taap.2015.04.001
   Li W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021082
   Liang Y, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.112235
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Min WL, 2014, MED SCI MONIT BASIC, V20, P97, DOI 10.12659/MSMBR.891246
   Ning P, 2016, ENDOCR-RELAT CANCER, V23, P595, DOI 10.1530/ERC-16-0126
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Reid LJ, 2008, P NATL ACAD SCI USA, V105, P20876, DOI 10.1073/pnas.0811203106
   Riquelme I, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030424
   Scata KA, 2007, ADV EXP MED BIOL, V608, P70
   Singh R, 2013, CANCER BIOL THER, V14, P201, DOI 10.4161/cbt.23296
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   Wang J, 2015, DRUG DEVELOP RES, V76, P368, DOI 10.1002/ddr.21275
   Yu L, 2013, FEBS LETT, V587, P2542, DOI 10.1016/j.febslet.2013.06.029
   Zhang C, 2014, BBA-GENE REGUL MECH, V1839, P1170, DOI 10.1016/j.bbagrm.2014.08.006
   Zhang JX, 2016, BIOCHEM BIOPH RES CO, V478, P337, DOI 10.1016/j.bbrc.2016.07.054
   Zhang S, 2013, REPRODUCTION, V145, P177, DOI 10.1530/REP-12-0336
   Zhang S, 2012, J BIOL CHEM, V287, P40471, DOI 10.1074/jbc.M112.383802
   Zhang XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153194
   Zhou DH, 2014, NUTR CANCER, V66, P636, DOI 10.1080/01635581.2014.894101
NR 34
TC 44
Z9 46
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 28
PY 2016
VL 479
IS 4
BP 893
EP 900
DI 10.1016/j.bbrc.2016.09.087
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EB2NY
UT WOS:000387200300045
PM 27693788
DA 2025-01-12
ER

PT J
AU Choubey, SK
   Mariadasse, R
   Rajendran, S
   Jeyaraman, J
AF Choubey, Sanjay K.
   Mariadasse, Richard
   Rajendran, Santhosh
   Jeyaraman, Jeyakanthan
TI Identification of novel histone deacetylase 1 inhibitors by combined
   pharmacophore modeling, 3D-QSAR analysis, <i>in silico</i> screening and
   Density Functional Theory (DFT) approaches
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Pharmacophore; 3D-QSAR; DFT; MM/GBSA; Molecular docking
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; EXPRESSION; TRANSCRIPTION;
   CARCINOMA; HDACS; BETA
AB Overexpression of HDAC1, a member of Class I histone deacetylase is reported to be implicated in breast cancer. Epigenetic alteration in carcinogenesis has been the thrust of research for few decades. Increased deacetylation leads to accelerated cell proliferation, cell migration, angiogenesis and invasion. HDAC1 is pronounced as the potential drug target towards the treatment of breast cancer. In this study, the biochemical potential of 6-aminonicotinamide derivatives was rationalized. Five point pharmacophore model with one hydrogen-bond acceptor (A3), two hydrogen-bond donors (D5, D6), one ring (R12) and one hydrophobic group (H8) was developed using 6-aminonicotinamide derivatives. The pharmacophore hypothesis yielded a 3D-QSAR model with correlation-coefficient (r(2) = 0.977, q(2) = 0.801) and it was externally validated with (r(2)pred = 0.929, r(2)cv = 0.850 and r(2)m = 0:856) which reveals the statistical significance of the model having high predictive power. The model was then employed as 3D search query for virtual screening against compound libraries (Zinc, Maybridge, Enamine, Asinex, Toslab, Life-Chem and Specs) in order to identify novel scaffolds which can be experimentally validated to design future drug molecule. Density Functional Theory (DFT) at B3LYP/6-31G* level was employed to explore the electronic features of the ligands involved in charge transfer reaction during receptor ligand interaction. Binding free energy (Delta G(bind)) calculation was done using MM/GBSA which defines the affinity of ligands towards the receptor. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Choubey, Sanjay K.; Mariadasse, Richard; Rajendran, Santhosh; Jeyaraman, Jeyakanthan] Alagappa Univ, Dept Bioinformat, Struct Biol & Biocomp Lab, Karaikkudi 630004, Tamil Nadu, India.
C3 Alagappa University
RP Jeyaraman, J (通讯作者)，Alagappa Univ, Dept Bioinformat, Struct Biol & Biocomp Lab, Karaikkudi 630004, Tamil Nadu, India.
EM jjkanthan@gmail.com
RI Mariadasse, Richard/GWC-4667-2022
OI Mariadasse, Richard/0000-0002-3041-6993; , Santhosh
   Rajendran/0009-0000-2207-3663
FU DBT, DST, UGC; DBT [BT/PR4524/BID/7/3888/2012]
FX JJ thanks DBT, DST, UGC for financial assistance and SKC gratefully
   thanks DBT (BT/PR4524/BID/7/3888/2012) for financial support and also
   acknowledges UGC-innovation scheme for providing computational facility.
CR [Anonymous], 2015, SCHROD REL 2015 1 PR
   [Anonymous], 2015, CONFGEN VERS 3 1
   [Anonymous], 2015, SMALL
   [Anonymous], 2015, GLID VERS 6 6
   [Anonymous], 2015, SCHROD REL 2015 1 LI
   [Anonymous], 2015, JAG VERS 8 7
   [Anonymous], SCHROD REL 2015 1 MA
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Christopher L., 2007, BIOORG MED CHEM LETT, V5, P5300
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dixon Steven L., 2006, COMPUTER AIDED MOL D, V20, P647
   Duong V, 2006, ONCOGENE, V25, P1799, DOI 10.1038/sj.onc.1209102
   Eom M, 2012, KOREAN J PATHOL, V46, P311, DOI 10.4132/KoreanJPathol.2012.46.4.311
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243
   Huang XJ, 2001, J BIOL CHEM, V276, P12497, DOI 10.1074/jbc.C100034200
   Jang E.R., 2004, ONCOGENE, V4, P23
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kang HJ, 2014, CANCER RES, V74, P1484, DOI 10.1158/0008-5472.CAN-13-2020
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Madeira M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-425
   Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031
   Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020
   Park YJ, 2011, PROG DRUG RES, V67, P25, DOI 10.1007/978-3-7643-8989-5_2
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295
   Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Waldmann T, 2013, CURR OPIN CELL BIOL, V25, P184, DOI 10.1016/j.ceb.2013.01.001
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
NR 34
TC 15
Z9 15
U1 0
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-2860
EI 1872-8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD DEC 5
PY 2016
VL 1125
BP 391
EP 404
DI 10.1016/j.molstruc.2016.06.082
PG 14
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DY0KG
UT WOS:000384785100044
DA 2025-01-12
ER

PT J
AU Feng, JX
   Xu, GY
   Liu, JW
   Zhang, N
   Li, LL
   Ji, JF
   Zhang, JC
   Zhang, L
   Wang, GN
   Wang, XL
   Tan, J
   Huang, BQ
   Lu, J
   Zhang, Y
AF Feng, Jingxin
   Xu, Guiying
   Liu, Jiwei
   Zhang, Na
   Li, Lili
   Ji, Jiafei
   Zhang, Jianchao
   Zhang, Lian
   Wang, Guannan
   Wang, Xiuli
   Tan, Jiang
   Huang, Baiqu
   Lu, Jun
   Zhang, Yu
TI Phosphorylation of LSD1 at Ser112 is crucial for its function in
   induction of EMT and metastasis in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE LSD1; Phosphorylation; EMT; Breast cancer; Metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; EPIGENETIC MODIFICATION CONTRIBUTES;
   HISTONE DEMETHYLASE LSD1; CHROMATIN IMMUNOPRECIPITATION; PROTEIN;
   PROLIFERATION; PROGRESSION; EXPRESSION; REPRESSION; CROSSTALK
AB LSD1 is overexpressed in various cancers including breast cancer, but its functional roles in tumourigenesis are not fully understood. This study aims at revealing the role of LSD1 in breast cancer development. In addition, it has been reported that phosphorylation of the Serine 112 residue of LSD1 by PKC alpha is crucial for its function in gene regulation. We also explored whether this phosphorylation affects LSD1's role in breast cancer development.
   This study includes LSD1 IHC data generated with tissue microarrays of 163 cases of breast cancer samples and 72 normal tissues. In vitro, role of LSD1, LSD1 S112D mutant (a phosphorylation simulation) and LSD1 S112A mutant (an unphosphorylation simulation) in induction of EMT is evaluated. Mechanismly, we checked the role of LSD1 and its mutant on E-cadherin promoter histone modifications. We also investigated the role of LSD1 and its mutants in metastasis with a nude mice model.
   We found LSD1 is expressed at a higher level in breast cancer tissues compared with that in normal tissues, and LSD1 expression is closely linked to breast cancer metastasis. LSD1 potentiates EMT in breast epithelia cells by repressing E-cadherin expression through demethylating H3K4me at gene's promoter, during which phosphorylation of LSD1 Ser112 is crucial for its binding and demethylation activity. In vivo, knockdown of LSD1 impairs the metastatic ability of MDA-MB-231 breast cancer cells in nude mice. Ectopic overexpression of either LSD1 or LSD1 S112D mutant (a phosphorylation simulation) facilitates metastasis, whereas the LSD1 S112A mutant (an unphosphorylation simulation) fails to affect the metastasis.
   Data presented in this report indicate that LSD1 is able to induce EMT and to promote metastasis in breast cancer, and phosphorylation at LSD1 Ser112 is crucial for these functions.
C1 [Feng, Jingxin; Liu, Jiwei; Zhang, Na; Wang, Xiuli; Tan, Jiang; Zhang, Yu] Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.
   [Xu, Guiying] Tumor Hosp Jilin Prov, Breast Surg, Changchun 130000, Peoples R China.
   [Li, Lili] Tianjin Med Univ Canc Inst & Hosp, Dept Bone & Soft Tissue Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300202, Peoples R China.
   [Ji, Jiafei; Huang, Baiqu; Lu, Jun] Northeast Normal Univ, Key Lab Mol Epigenet, MOE, Changchun 130024, Peoples R China.
   [Zhang, Jianchao] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Biotechnol, Shenzhen Key Lab Mol Biol Neural Dev, Shenzhen 518055, Guangdong, Peoples R China.
   [Zhang, Lian] Jilin Univ, Dept Pathol, Hosp 2, Changchun 130041, Peoples R China.
   [Wang, Guannan] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun 130117, Peoples R China.
C3 Northeast Normal University - China; Tianjin Medical University;
   Northeast Normal University - China; Chinese Academy of Sciences;
   Shenzhen Institute of Advanced Technology, CAS; Jilin University;
   Northeast Normal University - China
RP Zhang, Y (通讯作者)，Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.
EM zhangy288@nenu.edu.cn
RI Zhang, Na/KQU-7102-2024; Feng, Jingxin/KEI-4101-2024
OI Li, Lili/0000-0002-6095-3853; Feng, Jing-Xin/0000-0003-0677-2792
FU National Natural Science Foundation of China [31570718, 31571478,
   31571317, 31371294, 31271442, 31401105]; Jilin Scientific and
   Technological Development Program [20140520003JH, 20160101157JC];
   "Program for Introducing Talents to Universities'' [B07017]
FX We thank Dr. Huang Wei from the School of Mathematics and Statistics of
   Northeast Normal University for kindly providing statistical analysis
   guidance. This work was supported by the grants from the National
   Natural Science Foundation of China (Grant Numbers 31570718, 31571478,
   31571317, 31371294, 31271442 and 31401105) and from Jilin Scientific and
   Technological Development Program (Grant Numbers 20140520003JH and
   20160101157JC). We also acknowledge the support from the "Program for
   Introducing Talents to Universities'' (B07017) in assistance of
   international cooperation.
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bennani-Baiti IM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3249
   Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932
   Chen M, 2016, MOL BIOL CELL, V27, P1358, DOI 10.1091/mbc.E15-10-0738
   Chen Y, 2006, P NATL ACAD SCI USA, V103, P13956, DOI 10.1073/pnas.0606381103
   Coover RA, 2016, ORG BIOMOL CHEM, V14, P4576, DOI 10.1039/c6ob00529b
   Derr RS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-604
   Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harmeyer KM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1347
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li LL, 2015, INT J CANCER, V136, P1285, DOI 10.1002/ijc.29110
   Li YX, 2016, ONCOL REP, V35, P3586, DOI 10.3892/or.2016.4729
   Liang Q, 2013, SCI REP-UK, V3, DOI 10.1038/srep02932
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Luo HC, 2016, CELL REP, V15, P2665, DOI 10.1016/j.celrep.2016.05.050
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Ma L, 2016, CANCER MED-US, V5, P684, DOI 10.1002/cam4.623
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Metzger E, 2016, NAT STRUCT MOL BIOL, V23, P132, DOI 10.1038/nsmb.3153
   Nagasawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118002
   Nam HJ, 2014, MOL CELL, V53, P791, DOI 10.1016/j.molcel.2014.01.028
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Stazi G, 2016, EXPERT OPIN THER PAT, V26, P565, DOI 10.1517/13543776.2016.1165209
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Venne AS, 2014, PROTEOMICS, V14, P513, DOI 10.1002/pmic.201300344
   Vianello P, 2016, J MED CHEM, V59, P1501, DOI 10.1021/acs.jmedchem.5b01209
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang M, 2015, BIOCHEM BIOPH RES CO, V467, P310, DOI 10.1016/j.bbrc.2015.09.164
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Yang WH, 2016, NAT IMMUNOL, V17, P613, DOI 10.1038/ni.3468
   Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
   Ying HQ, 2014, CELL RES, V24, P1282, DOI 10.1038/cr.2014.103
   Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045
   Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x
NR 48
TC 53
Z9 60
U1 1
U2 37
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2016
VL 159
IS 3
BP 443
EP 456
DI 10.1007/s10549-016-3959-9
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW4KY
UT WOS:000383613100005
PM 27572339
DA 2025-01-12
ER

PT J
AU Fischer, C
   Mamillapalli, R
   Goetz, LG
   Jorgenson, E
   Ilagan, Y
   Taylor, HS
AF Fischer, Catha
   Mamillapalli, Ramanaiah
   Goetz, Laura G.
   Jorgenson, Elisa
   Ilagan, Ysabel
   Taylor, Hugh S.
TI Bisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine
   Dysregulation in the Mouse Mammary Gland: A Potential Mechanism
   Programming Breast Cancer Risk
SO HORMONES & CANCER
LA English
DT Article
ID ESTROGEN-RECEPTOR-BETA; ENDOCRINE-DISRUPTING COMPOUNDS; GENE-EXPRESSION;
   EPIGENETIC MECHANISM; WIDESPREAD EXPOSURE; PRENATAL EXPOSURE; ER-BETA;
   TISSUE; ESTRADIOL; ALTERS
AB Bisphenol-A (BPA) is a ubiquitous estrogen-like endocrine disrupting compound (EDC). BPA exposure in utero has been linked to breast cancer and abnormal mammary gland development in mice. The recent rise in incidence of human breast cancer and decreased age of first detection suggests a possible environmental etiology. We hypothesized that developmental programming of carcinogenesis may involve an aberrant immune response. Both innate and adaptive immunity play a role in tumor suppression through cytolytic CD8, NK, and Th1 T-cells. We hypothesized that BPA exposure in utero would lead to dysregulation of both innate and adaptive immunity in the mammary gland. CD1 mice were exposed to BPA in utero during gestation (days 9-21) via osmotic minipump. At 6 weeks, the female offspring were ovariectomized and estradiol was given at 8 weeks. RNA and protein were extracted from the posterior mammary glands, and the mRNA and protein levels were measured by PCR array, qRT-PCR, and western blot. In mouse mammary tissue, BPA exposure in utero significantly decreased the expression of members of the chemokine CXC family (Cxcl2, Cxcl4, Cxcl14, and Ccl20), interleukin 1 (Il1) gene family (Il1 beta and Il1rn), interleukin 2 gene family (Il7 receptor), and interferon gene family (interferon regulatory factor 9 (Irf9), as well as immune response gene 1 (Irg1). Additionally, BPA exposure in utero decreased Esr1 receptor gene expression and increased Esr2 receptor gene expression. In utero exposure of BPA resulted in significant changes to inflammatory modulators within mammary tissue. We suggest that dysregulation of inflammatory cytokines, both pro-inflammatory and anti-inflammatory, leads to a microenvironment that may promote disordered cell growth through inhibition of the immune response that targets cancer cells.
C1 [Fischer, Catha; Mamillapalli, Ramanaiah; Goetz, Laura G.; Jorgenson, Elisa; Ilagan, Ysabel; Taylor, Hugh S.] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,POB 208063, New Haven, CT 06510 USA.
   [Taylor, Hugh S.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Mamillapalli, R (通讯作者)，Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,POB 208063, New Haven, CT 06510 USA.
EM ramana.mamillapalli@yale.edu
RI Goetz, Teddy/AED-8183-2022; Mamillapalli, Ramanaiah/K-6357-2019
OI Mamillapalli, Ramanaiah/0000-0002-4022-8910; Goetz,
   Teddy/0000-0002-1138-6602; Jorgensen, Elisa/0000-0002-6405-867X
FU NIH [RO1 HD076422]
FX This work was supported by NIH Grant RO1 HD076422.
CR Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052
   Aldad TS, 2011, FERTIL STERIL, V96, P175, DOI 10.1016/j.fertnstert.2011.04.010
   Armstrong CM, 2013, ENDOCR-RELAT CANCER, V20, P515, DOI 10.1530/ERC-12-0308
   Ashworth JJ, 2008, CLIN GENET, V73, P55, DOI 10.1111/j.1399-0004.2007.00927.x
   Asztalos S, 2010, CANCER PREV RES, V3, P301, DOI 10.1158/1940-6207.CAPR-09-0069
   Baek JM, 2015, INT J SURG, V14, P17, DOI 10.1016/j.ijsu.2014.10.007
   Balfe P, 2004, EJSO, V30, P469, DOI 10.1016/j.ejso.2004.02.010
   BARR AJ, 1999, CRC METH SIG TRANS, P227
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Biondo C, 2014, INFECT IMMUN, V82, P4508, DOI 10.1128/IAI.02104-14
   Block K, 2000, FASEB J, V14, P1101, DOI 10.1096/fasebj.14.9.1101
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   Calhoun KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085894
   Chapalamadugu KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089096
   Chen HZ, 2014, J NEUROSCI, V34, P11897, DOI 10.1523/JNEUROSCI.1545-14.2014
   Chen Y, 2011, CANCER BIOL THER, V11, P497, DOI 10.4161/cbt.11.5.14667
   Cipelli R, 2014, REPRODUCTION, V147, P419, DOI 10.1530/REP-13-0423
   Corbel T, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.112.106369
   Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067
   De Coster S, 2012, J ENVIRON PUBLIC HEA, V2012, DOI 10.1155/2012/713696
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282
   Ehrlich S, 2014, JAMA-J AM MED ASSOC, V311, P859, DOI 10.1001/jama.2013.283735
   Elsworth JD, 2013, NEUROTOXICOLOGY, V35, P113, DOI 10.1016/j.neuro.2013.01.001
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Gerona RR, 2013, ENVIRON SCI TECHNOL, V47, P12477, DOI 10.1021/es402764d
   Hall CJ, 2013, CELL METAB, V18, P265, DOI 10.1016/j.cmet.2013.06.018
   Hijazi A, 2015, FASEB J, V29, P4968, DOI 10.1096/fj.15-270942
   Horstman KA, 2012, BIRTH DEFECTS RES B, V95, P318, DOI 10.1002/bdrb.21020
   Hu YF, 1998, INT J ONCOL, V12, P1225
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Kim JH, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-30
   Ko KP, 2013, AM J CLIN NUTR, V98, P1493, DOI 10.3945/ajcn.112.057760
   Kozai TDY, 2014, BIOMATERIALS, V35, P9620, DOI 10.1016/j.biomaterials.2014.08.006
   Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855
   Lamartiniere CA, 2011, HORM MOL BIOL CLIN I, V5, P45, DOI 10.1515/HMBCI.2010.075
   Li XT, 2014, PHYTOTHER RES, V28, P1553, DOI 10.1002/ptr.5167
   Liao CY, 2011, ENVIRON SCI TECHNOL, V45, P9372, DOI 10.1021/es202507f
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Melzer D, 2011, ENVIRON HEALTH PERSP, V119, P1788, DOI 10.1289/ehp.1103809
   Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110
   Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738
   Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002
   Nahar MS, 2014, ENVIRON MOL MUTAGEN, V55, P184, DOI 10.1002/em.21823
   Nishikawa M, 2010, ENVIRON HEALTH PERSP, V118, P1196, DOI 10.1289/ehp.0901575
   Normanton M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106673
   Owen JL, 2011, CELL IMMUNOL, V270, P172, DOI 10.1016/j.cellimm.2011.05.004
   Paulose T, 2015, REPROD TOXICOL, V54, P58, DOI 10.1016/j.reprotox.2014.09.012
   Peretz J, 2014, ENVIRON HEALTH PERSP, V122, P775, DOI 10.1289/ehp.1307728
   Polanczyk M, 2004, AM J PATHOL, V164, P1915, DOI 10.1016/S0002-9440(10)63752-2
   Poola I, 2005, CLIN CANCER RES, V11, P7579, DOI 10.1158/1078-0432.CCR-05-0728
   Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526
   Ribeiro Daniel, 2013, Adv Biol Regul, V53, P211, DOI 10.1016/j.jbior.2012.10.005
   Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804
   Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008
   Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002
   Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5
   Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005
   Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109
   Ubertini V, 2015, ONCOGENE, V34, P2493, DOI 10.1038/onc.2014.191
   Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561
   Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716
   Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015
   Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902
   Wang PX, 2015, J HEPATOL, V62, P111, DOI 10.1016/j.jhep.2014.08.022
   Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159
   Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195
   Yakimchuk K, 2013, MOL CELL ENDOCRINOL, V375, P121, DOI 10.1016/j.mce.2013.05.016
NR 77
TC 34
Z9 38
U1 0
U2 24
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1868-8497
EI 1868-8500
J9 HORM CANCER-US
JI Horm. Cancer
PD AUG
PY 2016
VL 7
IS 4
BP 241
EP 251
DI 10.1007/s12672-016-0254-5
PG 11
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA DY0FX
UT WOS:000384773800004
PM 26911702
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Gherardini, L
   Sharma, A
   Capobianco, E
   Cinti, C
AF Gherardini, Lisa
   Sharma, Ankush
   Capobianco, Enrico
   Cinti, Caterina
TI Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Epigenetic memory; cancer epigenomics; cancer therapy; epi-drugs;
   precision medicine; translational medicine
ID HISTONE DEACETYLASE INHIBITORS; DNA METHYLTRANSFERASE; NONCODING RNAS;
   EMBRYONIC STEM; EPIGENETIC REGULATION; HDAC INHIBITOR; BREAST-CANCER;
   CELL-LINES; TRANSCRIPTION; GENOME
AB Recent pan-cancer studies have shown the importance of coupling DNA methylation patterns with transcriptome profiles to reveal tumor subgroups with clinically relevant distinct characteristics. While the coupling patterns remain in most cases matter for further study and/or interpretation, it is emerging that all associations between epigenetic changes and specific cancer histotypes can facilitate the development of novel epidrugs. In particular, together with chemotherapy and chemoprevention of cancer, these epidrugs will target specific enzymes involved in the complex regulation of gene expression. This perspective surveys recent cancer epigenetic findings on target drugs and therapeutic strategies, and focuses on the epigenetic modifications that can reverse a stable differentiated state of adult cell towards neoplastic phenotypes. The relevance of such developments may thus pave the way for patient's customized personalized therapies.
C1 [Gherardini, Lisa; Cinti, Caterina] CNR, Inst Clin Physiol, Expt Oncol Unit, Siena, Italy.
   [Sharma, Ankush; Capobianco, Enrico] IFC CNR, LISM, Pisa, Italy.
   [Capobianco, Enrico] Univ Miami, CCS, Miami, FL 33154 USA.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Fisiologia Clinica (IFC-CNR); University of Miami
RP Capobianco, E (通讯作者)，Univ Miami, CCS, Miami, FL 33154 USA.
EM ecapobianco@med.miami.edu
RI ; Sharma, Ankush/E-2821-2012; gherardini, lisa/HCI-2927-2022
OI Cinti, Caterina/0000-0001-8049-0369; Sharma, Ankush/0000-0002-1399-7503;
   gherardini, lisa/0000-0002-7003-4295
FU Italian National Council of Research; Istituto Toscano Tumori (ITT)
FX The authors thank Dr. C. Trimarchi for helpful discussions. This work is
   supported by the Italian National Council of Research and by the
   Istituto Toscano Tumori (ITT).
CR Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bu QG, 2014, CANCER BIOL THER, V15, P951, DOI 10.4161/cbt.28931
   Caudron-Herger M, 2012, CURR OPIN GENET DEV, V22, P179, DOI 10.1016/j.gde.2011.12.005
   Caudron-Herger M, 2011, NUCLEUS-PHILA, V2, P410, DOI 10.4161/nucl.2.5.17736
   Cheedipudi S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00019
   Chun P, 2015, ARCH PHARM RES, V38, P933, DOI 10.1007/s12272-015-0571-1
   Cinti C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017132
   Coral S, 2013, CANCER IMMUNOL IMMUN, V62, P605, DOI 10.1007/s00262-012-1365-7
   Cramer SA, 2015, EXPERT OPIN DRUG DEL, V12, P1501, DOI 10.1517/17425247.2015.1021678
   Ehrlich M, 2013, ADV EXP MED BIOL, V754, P31, DOI 10.1007/978-1-4419-9967-2_2
   El Baroudi M, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-S1-S8
   Ellinger J, 2015, EXPERT REV MOL DIAGN, V15, P505, DOI 10.1586/14737159.2015.1019477
   Falahi F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00022
   Foltz G, 2009, ONCOGENE, V28, P2667, DOI 10.1038/onc.2009.122
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Fujita T, 2015, METHODS MOL BIOL, V1288, P43, DOI 10.1007/978-1-4939-2474-5_4
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Gandhi NS, 2014, J CONTROL RELEASE, V194, P238, DOI 10.1016/j.jconrel.2014.09.001
   Guil S, 2012, NAT STRUCT MOL BIOL, V19, P1068, DOI 10.1038/nsmb.2428
   Halley-Stott RP, 2013, BRIEF FUNCT GENOMICS, V12, P164, DOI 10.1093/bfgp/elt011
   Hu Z, 2015, J CLIN INVEST, V125, P425, DOI 10.1172/JCI78206
   Huang YC, 2015, ONCOTARGET, V6, P18590, DOI 10.18632/oncotarget.4068
   Jurkowski TP, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0044-x
   Kasap C, 2014, NAT CHEM BIOL, V10, P626, DOI 10.1038/nchembio.1551
   Khan Dilshad H., 2012, Advances in Biological Regulation, V52, P377, DOI 10.1016/j.jbior.2012.04.003
   Kim HS, 2015, J KOREAN MED SCI, V30, P1375, DOI 10.3346/jkms.2015.30.10.1375
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   Kuang YT, 2015, MOL ONCOL, V9, P1799, DOI 10.1016/j.molonc.2015.06.002
   Lai F, 2014, CURR OPIN GENET DEV, V25, P38, DOI 10.1016/j.gde.2013.11.017
   Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410
   Lauffer BEL, 2013, J BIOL CHEM, V288, P26926, DOI 10.1074/jbc.M113.490706
   Lee JYC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00081
   Li SY, 2015, J CONTROL RELEASE, V205, P7, DOI 10.1016/j.jconrel.2014.11.011
   Liao J, 2015, NAT GENET, V47, P469, DOI 10.1038/ng.3258
   Liu SJ, 2012, ADV DRUG DELIVER REV, V64, P1532, DOI 10.1016/j.addr.2012.08.004
   Maddalo D, 2014, NATURE, V516, P423, DOI 10.1038/nature13902
   Maeder ML, 2013, NAT METHODS, V10, P977, DOI [10.1038/nmeth.2598, 10.1038/NMETH.2598]
   Malecová B, 2010, CURR OPIN MOL THER, V12, P214
   Medina-Franco JL, 2013, MOL DIVERS, V17, P337, DOI 10.1007/s11030-013-9428-z
   Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088
   Mora A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00059
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Naldi I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098101
   Orom UA, 2011, TRENDS GENET, V27, P433, DOI 10.1016/j.tig.2011.06.009
   Pan DN, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002761
   Peedicayil J, 2012, CURR CLIN PHARMACOL, V7, P333, DOI 10.2174/157488412803305858
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Swierczynski S, 2015, EXPERT OPIN BIOL TH, V15, P651, DOI 10.1517/14712598.2015.1025047
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thomas X, 2012, EXPERT OPIN DRUG DIS, V7, P1039, DOI 10.1517/17460441.2012.722618
   Valdés-Mora F, 2015, ONCOGENE, V34, P1609, DOI 10.1038/onc.2014.111
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Vesci L, 2015, ONCOTARGET, V6, P5735, DOI 10.18632/oncotarget.3240
   Waldrip ZJ, 2014, EPIGENETICS-US, V9, P1207, DOI 10.4161/epi.29919
   Wen WS, 2016, INT J CANCER, V138, P1328, DOI 10.1002/ijc.29626
   Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6
   Wu FL, 2015, CANCER LETT, V363, P7, DOI 10.1016/j.canlet.2015.01.006
   Xiao A, 2013, NUCLEIC ACIDS RES, V41, pD415, DOI 10.1093/nar/gks1144
   Xu DZ, 2009, CELL CYCLE, V8, P3688, DOI 10.4161/cc.8.22.9908
   Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589
   Yao Yixin, 2014, Gene Technol, V3, P114
   Yoo J, 2012, ADV PROTEIN CHEM STR, V87, P219, DOI 10.1016/B978-0-12-398312-1.00008-1
   Youngson NA, 2008, ANNU REV GENOM HUM G, V9, P233, DOI 10.1146/annurev.genom.9.081307.164445
NR 69
TC 11
Z9 11
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2016
VL 17
IS 10
BP 856
EP 865
DI 10.2174/1381612822666160527154757
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DX9NU
UT WOS:000384723200002
PM 27229488
DA 2025-01-12
ER

PT J
AU Freeman, JR
   Chu, S
   Hsu, T
   Huang, YT
AF Freeman, Joshua R.
   Chu, Su
   Hsu, Thomas
   Huang, Yen-Tsung
TI Epigenome-wide association study of smoking and DNA methylation in
   non-small cell lung neoplasms
SO ONCOTARGET
LA English
DT Article
DE epigenetics; DNA methylation; non-small cell lung cancer; smoking
ID CIGARETTE-SMOKING; CANCER-EPIDEMIOLOGY; BREAST-CANCER; GENES; RISK;
   EXPRESSION; PATTERNS; PATHWAY; PROTEIN; TAZ
AB Tobacco smoke is a well-established lung cancer carcinogen. We hypothesize that epigenetic processes underlie carcinogenesis. The objective of this study is to examine the effects of smoke exposure on DNA methylation to search for novel susceptibility loci. We obtained epigenome-wide DNA methylation data from lung adenocarcinoma (LUAD) and lung squamous cell (LUSC) tissues in The Cancer Genome Atlas (TCGA). We performed a two-stage discovery (n = 326) and validation (n = 185) analysis to investigate the association of epigenetic DNA methylation level with cigarette smoking pack-years. We also externally validated our findings in an independent dataset. Linear model with least square estimator and spline regression were performed to examine the association between DNA methylation and smoking. We identified five CpG sites highly associated with pack-years of cigarette smoking. Smoking was negatively associated with methylation levels in cg25771041 (WWTR1, p = 3.6 x 10(-9)), cg16200496 (NFIX, p = 3.4 x 10(-12)), cg22515201 (PLA2G6, p = 1.0 x 10(-9)) and cg24823993 (NHP2L1, p = 5.1 x 10(-8)) and positively associated with the methylation level in cg11875268 (SMUG1, p = 4.3 x 10(-8)). The CpG-smoking association was stronger in LUSC than LUAD. Of the five loci, smoking explained the most variation in cg16200496 (R-2 = 0.098 [both types] and 0.144 [LUSC]). We identified 5 novel CpG candidates that demonstrate differential methylation patterns associated with smoke exposure in lung neoplasms.
C1 [Freeman, Joshua R.; Chu, Su; Huang, Yen-Tsung] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
   [Freeman, Joshua R.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA 01003 USA.
   [Hsu, Thomas] Brown Univ, Dept Med, Providence, RI 02912 USA.
   [Huang, Yen-Tsung] Brown Univ, Dept Biostat, Providence, RI 02912 USA.
   [Huang, Yen-Tsung] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan.
C3 Brown University; University of Massachusetts System; University of
   Massachusetts Amherst; Brown University; Brown University; Academia
   Sinica - Taiwan
RP Huang, YT (通讯作者)，Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.; Huang, YT (通讯作者)，Brown Univ, Dept Biostat, Providence, RI 02912 USA.; Huang, YT (通讯作者)，Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan.
EM Yen-Tsung_Huang@brown.edu
RI Huang, Yen-Tsung/AAQ-3919-2021
OI Freeman, Joshua/0000-0001-7483-7848; Huang,
   Yen-Tsung/0000-0001-7657-0040
FU Brown Junior Faculty Research Awards in Genetics and Population Studies
FX The work is supported by the Brown Junior Faculty Research Awards in
   Genetics and Population Studies (to J.R.F., S.C., T.H. and Y.T.H.). We
   also would like to thank the editor and the four anonymous referees for
   their thoughtful comments and suggestions.
CR Abdel-Fatah TMA, 2013, BREAST CANCER RES TR, V142, P515, DOI 10.1007/s10549-013-2769-6
   [Anonymous], ENV HLTH PERSP
   [Anonymous], TUMOUR BIOL
   [Anonymous], DIABETOLOGIA
   [Anonymous], SVA SURROGATE VARIAB
   [Anonymous], 2015, Tobacco
   [Anonymous], SARCOIDOSIS VASC DIF
   [Anonymous], EPIGENOMICS
   [Anonymous], PREV TOB US GLOB HLT
   [Anonymous], CURR PHARM DES
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Besingi W, 2014, HUM MOL GENET, V23, P2290, DOI 10.1093/hmg/ddt621
   Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8
   Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001
   Deslee G, 2010, AM J RESP CELL MOL, V43, P576, DOI 10.1165/rcmb.2009-0221OC
   Dogan MV, 2016, PSYCHONEUROENDOCRINO, V66, P176, DOI 10.1016/j.psyneuen.2016.01.018
   Ezzati M, 2005, INT J CANCER, V116, P963, DOI 10.1002/ijc.21100
   Falvella FS, 2009, INT J CANCER, V124, P2880, DOI 10.1002/ijc.24302
   Fasanelli F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10192
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Hata T, 2004, INT J ONCOL, V24, P513
   Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
   Hecht SS, 2016, ACCOUNTS CHEM RES, V49, P106, DOI 10.1021/acs.accounts.5b00472
   Hicks C, 2013, CANCER INFORM, V12, P155, DOI 10.4137/CIN.S11831
   Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004
   Hosgood HD, 2008, CARCINOGENESIS, V29, P1938, DOI 10.1093/carcin/bgn178
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029
   Huang RY, 2015, EBIOMEDICINE, V2, P1677, DOI 10.1016/j.ebiom.2015.09.031
   Huang YT, 2011, P NATL ACAD SCI USA, V108, P16345, DOI 10.1073/pnas.1102769108
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987
   Jin YT, 2016, CANCER INVEST, V34, P173, DOI 10.3109/07357907.2016.1156689
   Khan RJ, 2015, TOB INDUC DIS, V13, DOI 10.1186/s12971-015-0041-z
   Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082
   Leduc N, 2016, J THORAC ONCOL, V11, P769, DOI 10.1016/j.jtho.2016.01.019
   Liu M, 2015, AM J TRANSL RES, V7, P2026
   Mao Y, 2015, BIOMED PHARMACOTHER, V76, P82, DOI 10.1016/j.biopha.2015.10.005
   MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   NEBL G, 1995, CELL MOL BIOL RES, V41, P85
   Noguchi S, 2014, CLIN CANCER RES, V20, P4660, DOI 10.1158/1078-0432.CCR-13-3328
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Pasmant E, 2011, MOL MED, V17, P79, DOI 10.2119/molmed.2010.00079
   Ray BK, 2013, CANCER RES, V73, P736, DOI 10.1158/0008-5472.CAN-12-2601
   Saito H, 1996, CYTOGENET CELL GENET, V72, P191, DOI 10.1159/000134186
   Schultz A, 2006, MOL CELL BIOL, V26, P5146, DOI 10.1128/MCB.02374-05
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Strimmer K, 2008, BIOINFORMATICS, V24, P1461, DOI 10.1093/bioinformatics/btn209
   Sun YV, 2013, HUM GENET, V132, P1027, DOI 10.1007/s00439-013-1311-6
   Sweasy JB, 2006, CELL CYCLE, V5, P250, DOI 10.4161/cc.5.3.2414
   Teschendorff AE, 2015, JAMA ONCOL, V1, P476, DOI 10.1001/jamaoncol.2015.1053
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   van Osch FHM, 2016, J UROLOGY, V195, P872, DOI 10.1016/j.juro.2015.10.139
   Villalba M, 2016, ONCOTARGET, V7, P22752, DOI 10.18632/oncotarget.8045
   Vineis P, 2007, CANCER EPIDEM BIOMAR, V16, P1954, DOI 10.1158/1055-9965.EPI-07-0457
   Wang Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0184-4
   White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981
   Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b
   Zaghlool SB, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0040-6
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
NR 61
TC 24
Z9 26
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 25
PY 2016
VL 7
IS 43
BP 69579
EP 69591
DI 10.18632/oncotarget.11831
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5VI
UT WOS:000387448300037
PM 27602958
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Grampp, S
   Platt, JL
   Lauer, V
   Salama, R
   Kranz, F
   Neumann, VK
   Wach, S
   Stöhr, C
   Hartmann, A
   Eckardt, KU
   Ratcliffe, PJ
   Mole, DR
   Schödel, J
AF Grampp, Steffen
   Platt, James L.
   Lauer, Victoria
   Salama, Rafik
   Kranz, Franziska
   Neumann, Viviana K.
   Wach, Sven
   Stoehr, Christine
   Hartmann, Arndt
   Eckardt, Kai-Uwe
   Ratcliffe, Peter J.
   Mole, David R.
   Schoedel, Johannes
TI Genetic variation at the 8q24.21 renal cancer susceptibility locus
   affects HIF binding to a MYC enhancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; C-MYC; COLORECTAL-CANCER; CELL
   CARCINOMA; CHROMOSOME 8Q24; COMMON VARIANT; BREAST-CANCER; SNP
   RS6983267; RISK
AB Clear cell renal cell carcinoma (ccRCC) is characterized by loss of function of the von Hippel-Lindau tumour suppressor (VHL) and unrestrained activation of hypoxia-inducible transcription factors (HIFs). Genetic and epigenetic determinants have an impact on HIF pathways. A recent genome-wide association study on renal cancer susceptibility identified single-nucleotide polymorphisms (SNPs) in an intergenic region located between the oncogenes MYC and PVT1. Here using assays of chromatin conformation, allele-specific chromatin immunoprecipitation and genome editing, we show that HIF binding to this regulatory element is necessary to trans-activate MYC and PVT1 expression specifically in cells of renal tubular origins. Moreover, we demonstrate that the risk-associated polymorphisms increase chromatin accessibility and activity as well as HIF binding to the enhancer. These findings provide further evidence that genetic variation at HIF-binding sites modulates the oncogenic transcriptional output of the VHL-HIF axis and provide a functional explanation for the disease-associated effects of SNPs in ccRCC.
C1 [Grampp, Steffen; Lauer, Victoria; Kranz, Franziska; Neumann, Viviana K.; Eckardt, Kai-Uwe; Schoedel, Johannes] Univ Klinikum Erlangen, Dept Hypertens & Nephrol, Ulmenweg 18, D-91054 Erlangen, Germany.
   [Grampp, Steffen; Lauer, Victoria; Kranz, Franziska; Neumann, Viviana K.; Eckardt, Kai-Uwe; Schoedel, Johannes] Univ Erlangen Nurnberg, Ulmenweg 18, D-91054 Erlangen, Germany.
   [Platt, James L.; Salama, Rafik; Ratcliffe, Peter J.; Mole, David R.] Univ Oxford, Nuffield Dept Med, Henry Wellcome Bldg Mol Physiol,Roosevelt Dr, Oxford OX3 7BN, England.
   [Kranz, Franziska] Univ Erlangen Nurnberg, Dept Comp Sci 9, Cauerstr 11, D-91058 Erlangen, Germany.
   [Wach, Sven] Univ Klinikum Erlangen, Dept Urol, Krankenhausstr 12, D-91054 Erlangen, Germany.
   [Wach, Sven] Univ Erlangen Nurnberg, Krankenhausstr 12, D-91054 Erlangen, Germany.
   [Stoehr, Christine; Hartmann, Arndt] Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.
   [Stoehr, Christine; Hartmann, Arndt] Univ Erlangen Nurnberg, Krankenhausstr 8-10, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Oxford; University of Erlangen Nuremberg; University of
   Erlangen Nuremberg; University of Erlangen Nuremberg; University of
   Erlangen Nuremberg; University of Erlangen Nuremberg
RP Schödel, J (通讯作者)，Univ Klinikum Erlangen, Dept Hypertens & Nephrol, Ulmenweg 18, D-91054 Erlangen, Germany.; Schödel, J (通讯作者)，Univ Erlangen Nurnberg, Ulmenweg 18, D-91054 Erlangen, Germany.
EM johannes.schoedel@uk-erlangen.de
RI Stöhr, Christine/N-6637-2018
OI Stoehr, Christine/0000-0001-7501-4886; Salama,
   Rafik/0000-0001-5549-7796; Kranz, Franziska/0000-0002-2715-9586;
   Schodel, Johannes/0000-0002-3587-8839; Mole, David/0000-0002-0984-300X;
   Ratcliffe, Peter/0000-0002-2853-806X
FU German Research Foundation [SCHO 1598/1]; Wilhelm Sander-Stiftung
   [2014.168.1]; Interdisciplinary Centre for Clinical Research [TPJ31];
   ELAN Fonds at the University of Erlangen-Nurnberg; Center of Kidney and
   Blood Pressure Research Regensburg-Erlangen-Nuremberg (REN); Cancer
   Research UK [A416016]; Wellcome Trust [088182/Z/09/Z, 078333/Z/05/Z,
   WT091857MA]; Ludwig Institute for Cancer Research; Higher Education
   Funding Council for England; Deanship of Scientific Research (DSR), King
   Abdulaziz University, Ministry of High Education for Saudi Arabia; Else
   Kroner-Fresenius Exzellenzstipendium [2014_EKES.11]; National Institutes
   of Health Research (NIHR) [RP-2015-06-004] Funding Source: National
   Institutes of Health Research (NIHR); Wellcome Trust [088182/Z/09/Z,
   078333/Z/05/Z] Funding Source: Wellcome Trust
FX This work was funded by the German Research Foundation (SCHO 1598/1),
   the Wilhelm Sander-Stiftung (2014.168.1), the Interdisciplinary Centre
   for Clinical Research (TPJ31) and the ELAN Fonds at the University of
   Erlangen-Nurnberg, the Center of Kidney and Blood Pressure Research
   Regensburg-Erlangen-Nuremberg (REN), the Ludwig Institute for Cancer
   Research, Cancer Research UK (A416016), the Wellcome Trust
   (088182/Z/09/Z, 078333/Z/05/Z, WT091857MA), the Higher Education Funding
   Council for England, and the Deanship of Scientific Research (DSR), King
   Abdulaziz University, Ministry of High Education for Saudi Arabia. J.S.
   is a recipient of an Else Kroner-Fresenius Exzellenzstipendium
   (2014_EKES.11). We thank B. Teschemacher, S. Pallfy and R. Jung for
   excellent technical assistance. We thank the Core Unit for Next
   Generation Sequencing at the University of Erlangen-Nurnberg. HKC-8
   cells were provided by L. Racusen, 786-O cells re-expressing pVHL were a
   gift from W.G. Kaelin Jr. RCC L1 and RCC L34 cells were provided by M.S.
   Wiesener. RCC4 cells were a gift from C.H. Buys. We thank C. Warnecke
   for providing cell lines. We thank M. Saleem and P. Mundel for the
   podocyte cell line, M. Goppelt-Struebe together with colleagues from the
   Department of Urology, University Erlangen-Nurnberg, for help with
   generating the primary tubular cell cultures and colleagues from the
   Department of Cardiology, University Erlangen-Nurnberg, for providing
   HUVECs.
CR Al Olama AA, 2009, NAT GENET, V41, P1058, DOI 10.1038/ng.452
   Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808
   [Anonymous], 2013, NATURE
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642
   Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Davies JOJ, 2016, NAT METHODS, V13, P74, DOI [10.1038/NMETH.3664, 10.1038/nmeth.3664]
   Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200
   Enciso-Mora V, 2010, NAT GENET, V42, P1126, DOI 10.1038/ng.696
   Farsijani NM, 2016, J CLIN INVEST, V126, P1425, DOI 10.1172/JCI74997
   Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016
   Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999
   Gudmundsson J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3776
   Gudmundsson J, 2012, NAT GENET, V44, P1326, DOI 10.1038/ng.2437
   Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448
   Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015
   Han SS, 2012, HUM MOL GENET, V21, P1190, DOI 10.1093/hmg/ddr551
   Henrion MYR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122589
   Jasinski-Bergner S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008805
   Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502
   Kiemeney LA, 2008, NAT GENET, V40, P1307, DOI 10.1038/ng.229
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917
   Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Platt J. L., 2016, EMBO REP
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Purdue MP, 2011, NAT GENET, V43, P60, DOI 10.1038/ng.723
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Salama R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134645
   Schödel J, 2012, NAT GENET, V44, P420, DOI 10.1038/ng.2204
   Schödel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029
   Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
   Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110
   Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09
   Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106
   Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022
   Yeager M, 2009, NAT GENET, V41, P1055, DOI 10.1038/ng.444
   Zheng SL, 2007, JNCI-J NATL CANCER I, V99, P1525, DOI 10.1093/jnci/djm169
NR 56
TC 68
Z9 76
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 24
PY 2016
VL 7
AR 13183
DI 10.1038/ncomms13183
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DZ5QO
UT WOS:000385916800001
PM 27774982
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Gregoire, JM
   Fleury, L
   Salazar-Cardozo, C
   Alby, F
   Masson, V
   Arimondo, PB
   Ausseil, F
AF Gregoire, Jean-Marc
   Fleury, Laurence
   Salazar-Cardozo, Clara
   Alby, Frederic
   Masson, Veronique
   Arimondo, Paola Barbara
   Ausseil, Frederic
TI Identification of epigenetic factors regulating the mesenchyme to
   epithelium transition by RNA interference screening in breast cancer
   cells
SO BMC CANCER
LA English
DT Article
DE Epithelium; Mesenchyme; Transition; RNAi; Screening; DOT1L; KAT5/Tip60
ID DNA-DAMAGE RESPONSE; E-CADHERIN; MIR-200 FAMILY; STEM-CELLS; SUPPRESSOR
   GENE; SELF-RENEWAL; BETA-CATENIN; TUMOR-CELLS; CHROMATIN; METASTASIS
AB Background: In breast cancer, the epithelial to mesenchyme transition (EMT) is associated to tumour dissemination, drug resistance and high relapse risks. It is partly controlled by epigenetic modifications such as histone acetylation and methylation. The identification of genes involved in these reversible modifications represents an interesting therapeutic strategy to fight metastatic disease by inducing mesenchymal cell differentiation to an epithelial phenotype.
   Methods: We designed a siRNA library based on chromatin modification-related to functional domains and screened it in the mesenchymal breast cancer cell line MDA-MB-231. The mesenchyme to epithelium transition (MET) activation was studied by following human E-CADHERIN (E-CAD) induction, a specific MET marker, and cell morphology. Candidate genes were validated by studying the expression of several differential marker genes and their impact on cell migration.
   Results: The screen led to the identification of 70 gene candidates among which some are described to be, directly or indirectly, involved in EMT like ZEB1, G9a, SMAD5 and SMARCD3. We also identified the DOT1L as involved in EMT regulation in MDA-MB-231. Moreover, for the first time, KAT5 gene was linked to the maintenance of the mesenchymal phenotype.
   Conclusions: A multi-parametric RNAi screening approach was developed to identify new EMT regulators such as KAT5 in the triple negative breast cancer cell line MDA-MB-231.
C1 [Gregoire, Jean-Marc; Fleury, Laurence; Salazar-Cardozo, Clara; Alby, Frederic; Masson, Veronique; Arimondo, Paola Barbara; Ausseil, Frederic] CNRS, Unite Serv & Rech, Pierre Fabre ETaC 3388, CRDPF, 3 Ave H Curien,BP 13652, F-31035 Toulouse 01, France.
C3 Centre National de la Recherche Scientifique (CNRS)
RP Ausseil, F (通讯作者)，CNRS, Unite Serv & Rech, Pierre Fabre ETaC 3388, CRDPF, 3 Ave H Curien,BP 13652, F-31035 Toulouse 01, France.
EM frederic.ausseil@pierre-fabre.com
RI Arimondo, Paola/R-9095-2017
FU Institut de Recherche Pierre Fabre; Centre national de la Recherche
   Scientifique
FX This work was funded by the Institut de Recherche Pierre Fabre and the
   Centre national de la Recherche Scientifique.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359
   Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540
   Boutros M, 2008, NAT REV GENET, V9, P554, DOI 10.1038/nrg2364
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Cerone MA, 2011, CANCER RES, V71, P3328, DOI 10.1158/0008-5472.CAN-10-2734
   Chung NJ, 2008, J BIOMOL SCREEN, V13, P149, DOI 10.1177/1087057107312035
   D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628
   Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Fazzio TG, 2008, CELL CYCLE, V7, P3302, DOI 10.4161/cc.7.21.6928
   Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5
   Huang H, 2007, J CANCER RES CLIN, V133, P761, DOI 10.1007/s00432-007-0221-1
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355
   Jordan NV, 2013, MOL CELL BIOL, V33, P3011, DOI 10.1128/MCB.01443-12
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010
   Lall S, 2007, NAT STRUCT MOL BIOL, V14, P1110, DOI 10.1038/nsmb1107-1110
   Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lu MY, 2014, CANCER RES, V74, P4574, DOI 10.1158/0008-5472.CAN-13-3367
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152
   Nickel A, 2015, TRANSL RES, V165, P126, DOI 10.1016/j.trsl.2014.04.001
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221
   Pu SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014122
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007
   Stec E, 2012, J BIOMOL SCREEN, V17, P1316, DOI 10.1177/1087057112453071
   Sun MN, 2012, J MOL CELL BIOL, V4, P304, DOI 10.1093/jmcb/mjs048
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Thiery JP, 2013, CANCER CELL, V23, P272, DOI 10.1016/j.ccr.2013.03.004
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Zhang L, 2014, ONCOTARGET, V5, P10665, DOI 10.18632/oncotarget.2496
   Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013
NR 56
TC 15
Z9 17
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 31
PY 2016
VL 16
AR 700
DI 10.1186/s12885-016-2683-5
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DX3OE
UT WOS:000384281600001
PM 27581651
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Theodoraki, MN
   Lorenz, KJ
   Schneider, J
   Thierauf, JC
   Spagnoli, G
   Schuler, PJ
   Hoffmann, TK
   Laban, S
AF Theodoraki, Marie-Nicole
   Lorenz, Kai J.
   Schneider, Juliane
   Thierauf, Julia C.
   Spagnoli, Giulio
   Schuler, Patrick J.
   Hoffmann, Thomas K.
   Laban, Simon
TI Influence of Photodynamic Therapy on the Expression of Cancer/Testis
   Antigens in Squamous Cell Carcinoma of the Head and Neck
SO ANTICANCER RESEARCH
LA English
DT Article
DE Head and neck squamous cell carcinoma (HNSCC); cancer/testis antigen;
   MAGE; NY-ESO-1; photodynamic therapy
ID CANCER-TESTIS ANTIGENS; BREAST-CANCER; MAGE-A; GENES; MELANOMA;
   NY-ESO-1; IMMUNOTHERAPY; GAMETOGENESIS; LYMPHOCYTES; METHYLATION
AB Background: Photodynamic therapy (PDT) represents a palliative treatment resulting in induction of inflammatory reactions with importance for the development of an antitumor immunity. Cancer/testis antigens (CTAs) have been associated with poor prognosis in different types of cancer, including head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Tumor tissue samples before and after PDT were evaluated for the expression of four different CTAs by immunohistochemistry. Expression intensity and subcellular expression pattern were assessed. Results: Before PDT, expression of any CTA was detectable in 91%. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). Conclusion: This study investigated the impact of PDT on CTA expression in HNSCC, detecting modified expression patterns after PDT. These changes may have been caused by immunological pressure or epigenetic regulation of CTA expression.
C1 [Theodoraki, Marie-Nicole; Thierauf, Julia C.; Schuler, Patrick J.; Hoffmann, Thomas K.; Laban, Simon] Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Ulm, Germany.
   [Lorenz, Kai J.] Hosp German Armed Forces, Dept Otorhinolaryngol, Ulm, Germany.
   [Schneider, Juliane] Hosp German Armed Forces, Dept Pathol, Ulm, Germany.
   [Spagnoli, Giulio] Univ Basel Hosp, Dept Biomed, Basel, Switzerland.
C3 Ulm University; University of Basel
RP Theodoraki, MN (通讯作者)，Univ Ulm, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Frauensteige 12, D-89070 Ulm, Germany.
EM nicole.theodoraki@uniklinik-ulm.de
RI Laban, Simon/AAH-4577-2019; Schuler, Patrick/AEN-1595-2022; Hoffmann,
   Thomas/HPE-6581-2023; Theodoraki, Marie-Nicole/AAR-7548-2020
OI Schuler, Patrick/0000-0002-1065-8709; Theodoraki,
   Marie-Nicole/0000-0002-5491-1593; Laban, Simon/0000-0001-6732-7137
CR Ademuyiwa FO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038783
   Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673
   [Anonymous], 2011, PHOTOCH PHOTOBIO SCI, DOI DOI 10.1039/c0pp00354a
   Atanackovic D, 2006, CANCER BIOL THER, V5, P1218, DOI 10.4161/cbt.5.9.3174
   Bart J, 2002, LANCET ONCOL, V3, P357, DOI 10.1016/S1470-2045(02)00776-3
   Cappell KM, 2012, MOL CELL BIOL, V32, P4131, DOI 10.1128/MCB.00686-12
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Clauditz TS, 2013, J ORAL PATHOL MED, V42, P125, DOI 10.1111/j.1600-0714.2012.01178.x
   Cuffel C, 2011, INT J CANCER, V128, P2625, DOI 10.1002/ijc.25607
   Demyanenko SV, 2014, BBA-GEN SUBJECTS, V1840, P262, DOI 10.1016/j.bbagen.2013.09.014
   DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677
   Figueiredo DLA, 2011, HEAD NECK-J SCI SPEC, V33, P702, DOI 10.1002/hed.21522
   Fiszer D, 1998, AM J REPROD IMMUNOL, V40, P172
   Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097
   Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001
   Gjerstorff MF, 2015, ONCOTARGET, V6, P15772, DOI 10.18632/oncotarget.4694
   Jungbluth Achim A, 2007, Cancer Immun, V7, P15
   Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4
   Karbach J, 2014, CANCER IMMUNOL RES, V2, P404, DOI 10.1158/2326-6066.CIR-13-0200
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Koltun M, 2014, PHOTODIAGN PHOTODYN, V11, P546, DOI 10.1016/j.pdpdt.2014.08.004
   Laban S, 2014, INT J CANCER, V135, P1142, DOI 10.1002/ijc.28752
   Lee HJ, 2015, ONCOLOGY-BASEL, V89, P337, DOI 10.1159/000439535
   Minner S, 2011, HUM PATHOL, V42, P1946, DOI 10.1016/j.humpath.2011.02.017
   Mroz P, 2013, CANCER RES, V73, P6462, DOI 10.1158/0008-5472.CAN-11-2572
   Nardiello T, 2011, CLIN CANCER RES, V17, P4309, DOI 10.1158/1078-0432.CCR-10-1820
   Nowis D, 2005, ACTA BIOCHIM POL, V52, P339
   Ogata K, 2011, ANN SURG ONCOL, V18, P1195, DOI 10.1245/s10434-010-1399-z
   Old L J, 2001, Cancer Immun, V1, P1
   Por E, 2010, J BIOL CHEM, V285, P14475, DOI 10.1074/jbc.M109.084400
   Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910
   Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5
   Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174
   Simon R, 2010, METHODS MOL BIOL, V664, P113, DOI 10.1007/978-1-60761-806-5_12
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Thong PSP, 2007, LANCET ONCOL, V8, P950, DOI 10.1016/S1470-2045(07)70318-2
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Vermorken JB, 2010, ANN ONCOL, V21, P252, DOI 10.1093/annonc/mdq453
   Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
   Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028
   von Boehmer Lotta, 2013, Cancer Immun, V13, P12
   Wang M, 2015, INT J CLIN EXP PATHO, V8, P3513
   Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215
   Zhang W, 2015, EPIGENETICS-US, V10, P736, DOI 10.1080/15592294.2015.1062206
NR 46
TC 4
Z9 5
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD AUG
PY 2016
VL 36
IS 8
BP 3973
EP 3982
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW9QW
UT WOS:000383997800025
PM 27466502
DA 2025-01-12
ER

PT J
AU Abramczyk, H
   Surmacki, J
   Kopec, M
   Olejnik, AK
   Kaufman-Szymczyk, A
   Fabianowska-Majewska, K
AF Abramczyk, Halina
   Surmacki, Jakub
   Kopec, Monika
   Olejnik, Alicja Klaudia
   Kaufman-Szymczyk, Agnieszka
   Fabianowska-Majewska, Krystyna
TI Epigenetic changes in cancer by Raman imaging, fluorescence imaging, AFM
   and scanning near-field optical microscopy (SNOM). Acetylation in normal
   and human cancer breast cells MCF10A, MCF7 and MDA-MB-231
SO ANALYST
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; LIPID DROPLETS; DNA METHYLATION;
   IN-VIVO; PHASE-TRANSITIONS; UNIFIED VIEW; OLEIC-ACID; SPECTROSCOPY;
   MICROSPECTROSCOPY; SPECTRA
AB This paper examines epigenetic changes in breast cancer by Raman imaging, fluorescence imaging, AFM and SNOM and discusses how they contribute to different aspects of tumourigenesis in malignant human breast epithelial cell lines MCF7 and MDA-MB-231 compared with non-malignant MCF10A cell lines. The paper focuses on information that can be extracted from Raman microscopy and Raman imaging for the biological material of nucleoli contained within the cell nucleus and lipid droplets within the cell cytoplasm. The biochemical composition of the nuclei and lipid droplets in the non-malignant and malignant human breast epithelial cell lines has been monitored. The potential of Raman microspectroscopy to monitor acetylation processes and a prognostic value of Raman biomarkers in breast cancer have been discussed.
C1 [Abramczyk, Halina; Surmacki, Jakub; Kopec, Monika] Lodz Univ Technol, Lab Laser Mol Spect, Inst Appl Radiat Chem, Lodz, Poland.
   [Olejnik, Alicja Klaudia] Lodz Univ Technol, Inst Appl Radiat Chem, Lodz, Poland.
   [Kaufman-Szymczyk, Agnieszka; Fabianowska-Majewska, Krystyna] Med Univ, Dept Biomed Chem, Lodz, Poland.
C3 Lodz University of Technology; Lodz University of Technology
RP Abramczyk, H (通讯作者)，Lodz Univ Technol, Lab Laser Mol Spect, Inst Appl Radiat Chem, Lodz, Poland.
EM abramczy@mitr.p.lodz.pl
RI Kaufman-Szymczyk, Agnieszka/S-9624-2016; Olejnik, Alicja/AAE-1327-2019;
   Olejnik, Alicja/R-5241-2018; Surmacki, Jakub/N-1140-2016
OI Abramczyk, Halina/0000-0002-7222-3583; Olejnik,
   Alicja/0000-0001-7397-009X; Surmacki, Jakub/0000-0001-6654-0286;
   Kaufman-Szymczyk, Agnieszka/0000-0001-6014-7280; Kopec,
   Monika/0000-0001-5412-0399
FU National Science Center of Poland [UMO 2012/07/B/ST4/01588]
FX This work was supported by the National Science Center of Poland (grant
   UMO 2012/07/B/ST4/01588).
CR Abramczyk H, 2009, J MOL STRUCT, V924, P175, DOI 10.1016/j.molstruc.2008.12.055
   Abramczyk H, 2015, ANALYST, V140, P2224, DOI 10.1039/c4an01875c
   Abramczyk H, 2014, ANALYST, V139, P5547, DOI 10.1039/c4an00966e
   Abramczyk H, 2013, CHEM REV, V113, P5766, DOI 10.1021/cr300147r
   Abramczyk H, 2013, J PHYS CHEM C, V117, P4999, DOI 10.1021/jp305891p
   Abramczyk H, 2012, PROG BIOPHYS MOL BIO, V108, P74, DOI 10.1016/j.pbiomolbio.2011.10.004
   Abramczyk H, 2011, J MOL LIQ, V164, P123, DOI 10.1016/j.molliq.2011.04.021
   Abramczyk Halina., 2011, Journal of Biophysical Chemistry, V2, P158
   Almond LM, 2014, GASTROINTEST ENDOSC, V79, P37, DOI 10.1016/j.gie.2013.05.028
   ASH EA, 1972, NATURE, V237, P510, DOI 10.1038/237510a0
   Au WC, 2008, GENETICS, V179, P263, DOI 10.1534/genetics.108.088518
   Bailo E, 2008, CHEM SOC REV, V37, P921, DOI 10.1039/b705967c
   Beller M, 2010, FEBS LETT, V584, P2176, DOI 10.1016/j.febslet.2010.03.022
   Bertram John S., 2000, Molecular Aspects of Medicine, V21, P167, DOI 10.1016/S0098-2997(00)00007-8
   Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Brewster VL, 2011, ANAL CHEM, V83, P6074, DOI 10.1021/ac2012009
   Brozek-Pluska B, 2015, ANALYST, V140, P2134, DOI 10.1039/c4an01877j
   Brozek-Pluska B, 2015, ANALYST, V140, P2107, DOI 10.1039/c4an01394h
   Brozek-Pluska B, 2012, ANALYST, V137, P3773, DOI 10.1039/c2an16179f
   Brozek-Pluska B, 2012, TECHNOL CANCER RES T, V11, P317, DOI 10.7785/tcrt.2012.500280
   Brozek-Pluska B, 2011, J MED CHEM, V54, P3386, DOI 10.1021/jm200180f
   Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x
   Cermelli S, 2006, CURR BIOL, V16, P1783, DOI 10.1016/j.cub.2006.07.062
   Cheng JX, 2007, APPL SPECTROSC, V61, p197A, DOI 10.1366/000370207781746044
   Chowdary MVP, 2006, BIOPOLYMERS, V83, P556, DOI 10.1002/bip.20586
   Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   Dieing T., 2011, SPRINGER SERIES OPTI, P1
   Diem M, 2012, SPECTROSC-INT J, V27, P463, DOI 10.1155/2012/848360
   DURIG U, 1986, J APPL PHYS, V59, P3318, DOI 10.1063/1.336848
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Erickson KL, 2010, PROSTAG LEUKOTR ESS, V82, P237, DOI 10.1016/j.plefa.2010.02.019
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2005, EMBO REP, V6, P624, DOI 10.1038/sj.embor.7400456
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feng SY, 2011, SCI CHINA LIFE SCI, V54, P828, DOI 10.1007/s11427-011-4212-8
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gniadecka M, 1998, J INVEST DERMATOL, V110, P393, DOI 10.1046/j.1523-1747.1998.00146.x
   GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965
   Guo Y, 2008, NATURE, V453, P657, DOI 10.1038/nature06928
   Haka AS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3247154
   Hedegaard M, 2010, ANAL CHEM, V82, P2797, DOI 10.1021/ac902717d
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herranz Michel, 2007, Methods Mol Biol, V361, P25
   Hofmann UG, 1997, J STRUCT BIOL, V119, P84, DOI 10.1006/jsbi.1997.3868
   Huang NY, 2011, OPT EXPRESS, V19, P22892, DOI 10.1364/OE.19.022892
   Huang Y., 2011, BREAST CANCER RES, V13, P1
   Jarvis RM, 2007, ANALYST, V132, P1053, DOI 10.1039/b702944f
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim M, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1922329
   Kline NJ, 1997, J RAMAN SPECTROSC, V28, P119, DOI 10.1002/(SICI)1097-4555(199702)28:2/3<119::AID-JRS73>3.0.CO;2-3
   Kohlwein SD, 2013, GENETICS, V193, P1, DOI 10.1534/genetics.112.143362
   Koljenovic S, 2005, ANAL CHEM, V77, P7958, DOI 10.1021/ac0512599
   Krafft C, 2005, SPECTROCHIM ACTA A, V61, P1529, DOI 10.1016/j.saa.2004.11.017
   Laska J, 2005, POLYMER, V46, P1485, DOI 10.1016/j.polymer.2004.12.008
   Li QS, 2008, BIOCHEM BIOPH RES CO, V374, P609, DOI 10.1016/j.bbrc.2008.07.078
   Li ZH, 2014, CURR BIOL, V24, P1485, DOI 10.1016/j.cub.2014.05.022
   Lin-Vien D., 1991, The Handbook of infrared and raman characteristic frequencies of organic molecules, P1, DOI 10.1016/B978-0-08-057116-4.50027-4
   Liu R, 2011, TRAC-TREND ANAL CHEM, V30, P1462, DOI 10.1016/j.trac.2011.06.011
   Lombardi JR, 2009, ACCOUNTS CHEM RES, V42, P734, DOI 10.1021/ar800249y
   Luo X. G., 2011, HISTONE MODIFICATION, P321
   Maes EM, 2001, J AM CHEM SOC, V123, P11664, DOI 10.1021/ja0031927
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Mallidis C, 2014, HUM REPROD UPDATE, V20, P403, DOI 10.1093/humupd/dmt055
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nafie LA, 2010, J RAMAN SPECTROSC, V41, P1566, DOI 10.1002/jrs.2859
   Nazlin KH, 1999, J AGR FOOD CHEM, V47, P924
   Notingher I, 2006, EXPERT REV MED DEVIC, V3, P215, DOI 10.1586/17434440.3.2.215
   Olson MOJ., 2015, NUCL STRUCTURE FUNCT, P1
   Ortiz C, 2006, ANAL BIOCHEM, V353, P157, DOI 10.1016/j.ab.2006.03.025
   Parker F. S., 1983, APPL RAMAN RESONANCE
   Rehman IU, 2013, SER MED PHYS BIOMED, P1
   Reue K, 2011, J LIPID RES, V52, P1865, DOI 10.1194/jlr.E020602
   Robert B, 2009, PHOTOSYNTH RES, V101, P147, DOI 10.1007/s11120-009-9440-4
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Rotsch C, 1999, P NATL ACAD SCI USA, V96, P921, DOI 10.1073/pnas.96.3.921
   Rygula A, 2013, J RAMAN SPECTROSC, V44, P1061, DOI 10.1002/jrs.4335
   Saar BG, 2010, SCIENCE, V330, P1368, DOI 10.1126/science.1197236
   Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x
   Schütz CA, 2014, INT J NANOMED, V9, P3481, DOI 10.2147/IJN.S65082
   Shetty G, 2006, BRIT J CANCER, V94, P1460, DOI 10.1038/sj.bjc.6603102
   Singh RK, 2010, CELL CYCLE, V9, P4236, DOI 10.4161/cc.9.20.13636
   SNYDER RG, 1978, SPECTROCHIM ACTA A, V34, P395, DOI 10.1016/0584-8539(78)80167-6
   Soldatova AV, 2010, J AM CHEM SOC, V132, P4614, DOI 10.1021/ja906233m
   SPIKER RC, 1975, BIOCHIM BIOPHYS ACTA, V388, P361, DOI 10.1016/0005-2760(75)90095-8
   SPIRO TG, 1995, METHODS ENZYMOL, V246, P416
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Sundararajan N, 2006, ANAL CHEM, V78, P3543, DOI 10.1021/ac051525i
   Surmacki J, 2015, ANALYST, V140, P2121, DOI 10.1039/c4an01876a
   Surmacki J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-48
   Talari ACS, 2015, APPL SPECTROSC REV, V50, P46, DOI 10.1080/05704928.2014.923902
   Thiam AR, 2013, NAT REV MOL CELL BIO, V14, P775, DOI 10.1038/nrm3699
   Tuma R, 2005, J RAMAN SPECTROSC, V36, P307, DOI 10.1002/jrs.1323
   VERMA SP, 1977, BIOCHIM BIOPHYS ACTA, V486, P217, DOI 10.1016/0005-2760(77)90018-2
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640
   Wise B.M., PLS TOOLBOX VERSION
   Yu YQ, 2007, J PHYS CHEM C, V111, P8971, DOI 10.1021/jp0675781
   Zhang DL, 2014, ACCOUNTS CHEM RES, V47, P2282, DOI 10.1021/ar400331q
   Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110
NR 113
TC 36
Z9 39
U1 0
U2 58
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2016
VL 141
IS 19
BP 5646
EP 5658
DI 10.1039/c6an00859c
PG 13
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DX3XD
UT WOS:000384309800020
PM 27460599
DA 2025-01-12
ER

PT J
AU Cauchi, JP
   Camilleri, L
   Scerri, C
AF Cauchi, John Paul
   Camilleri, Liberato
   Scerri, Christian
TI Environmental and lifestyle risk factors of breast cancer in Malta-a
   retrospective case-control study
SO EPMA JOURNAL
LA English
DT Article
DE Breast cancer; Environment; Lifestyle; Environmental health; Targeted
   prevention; Predictive medicine
ID EPIGENETIC MECHANISMS; ALCOHOL-CONSUMPTION; EXPOSURE; METAANALYSIS;
   PREVENTION; PREDICTION; OBESITY; FIBER; FAT
AB Aim and Background: Environmental exposures are known to play a role in the development of cancer, including breast cancer. There are known associations of breast cancer with environmental factors such as sunlight exposure, diet and exercise and alcohol consumption as well as physiological factors. This study examines the prevalence of risk factors for breast cancer related to dietary intake, environment and lifestyle in the female population of Malta. Malta has had little research in this area, and therefore an exploratory study was carried out.
   Methods: A retrospective case-control design was applied. Two hundred cases and 403 controls were included. Both cases and controls were subjects without a known family history for breast cancer. Controls were age-matched to cases in an age-decade category roughly at a 2: 1 ratio. Interviews were carried out face-to-face using a questionnaire designed by Maltese and Sicilian researchers, encompassing various factors including diet, lifestyle, physiological factors and medical history. Breast cancer risk was then analysed using both univariate and multivariate analyses. For factors having a metric scale, the Mann-Whitney test was used to compare mean scores, while for categorical factors, the chi-square test was used to compare percentages between the case and control groups. Statistical modelling was carried out using binary logistic regression to relate the likelihood of breast cancer to over 50 risk/protective factors analysed collectively.
   Results: Univariate analysis showed around 20 parameters of interest, 14 of which were statistically significant at a 0.05 level of significance. Logistic regression analysis identified 11 predictors of interest that were statistically significant. Tomato, coffee and canned meat consumption were associated with lower likelihood of breast cancer (OR = 0.988, 0.901, 0.892, respectively), whereas beans and cabbage consumption and low sodium salt were positively associated with breast cancer (OR = 1.045, 1.834, 1.028, respectively). Premenopausal status was associated with a lower risk of breast cancer compared to postmenopausal status (OR = 0.067). Not having experienced myocardial infarction was associated with lower odds of breast cancer (OR = 0.331). Increased height was also found to have a strong association with risk of breast cancer, with the odds of having breast cancer increasing for every centimetre increase in height (OR = 1.048). In terms of quantity, odds of having breast cancer were lower in those exposed to sunlight (OR = 0.891). The odds of having breast cancer were also lower in those not using the oral contraceptive pill (OR = 0.454).
   Conclusions: Various factors in this exploratory study were found to be associated with development of breast cancer. While causal conclusions cannot be made, tomato consumption is of particular interest, as these results corroborate findings found in other studies. A negative association of breast cancer with sunlight exposure and oral contraceptive pill use corroborates findings in other studies. Other associations with dietary intake can be explained by dietary changes. More robust studies in this area, including possible longitudinal studies, are warranted.
C1 [Cauchi, John Paul] Univ Malta, Dept Physiol & Biochem, Room 111, Msida 2080, Msd, Malta.
   [Camilleri, Liberato] Univ Malta, Fac Sci, Stat & Operat Res, Room 509,Maths & Phys Bldg, Msida, Malta.
   [Scerri, Christian] Univ Malta, Fac Med & Surg, Physiol & Biochem, Biomed Sci Bldg, Msida, Malta.
C3 University of Malta; University of Malta; University of Malta
RP Cauchi, JP (通讯作者)，Univ Malta, Dept Physiol & Biochem, Room 111, Msida 2080, Msd, Malta.
EM john.cauchi@gmail.com
RI Scerri, Christian/D-3077-2012
OI Scerri, Christian/0000-0002-6499-234X; Cauchi, John
   Paul/0000-0001-8983-8499
FU IMaGenX; EU
FX The funding for this research was obtained as part of IMaGenX - and
   Italia-Malta co-financed EU project Operational Programme 2007-2013.
CR [Anonymous], 2013, Fisheries of the United States: 2012, P1
   [Anonymous], 2012, Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012
   [Anonymous], CRIT REV FOOD SCI NU
   Aune D, 2012, ANN ONCOL, V23, P1394, DOI 10.1093/annonc/mdr589
   Bakker MF, 2016, AM J CLIN NUTR, V103, P454, DOI 10.3945/ajcn.114.101659
   Banerjee HN, 2009, BIOMARK MED, V3, P397, DOI 10.2217/BMM.09.26
   Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596
   Blackadar CB, 2016, WORLD J CLIN ONCOL, V7, P54, DOI 10.5306/wjco.v7.i1.54
   Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006
   Brown N, 2012, AM J HUM BIOL, V24, P158, DOI 10.1002/ajhb.22212
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Cabanes A, 2011, BREAST CANCER RES TR, V129, P135, DOI 10.1007/s10549-011-1414-5
   Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
   Chia KS, 2005, INT J CANCER, V113, P302, DOI 10.1002/ijc.20561
   Chik F, 2012, ADV EXP MED BIOL, V720, P91, DOI 10.1007/978-1-4614-0254-1_8
   Coronado GD, 2011, SALUD PUBLICA MEXICO, V53, P440
   Guindalini RSC, 2016, CANCER-AM CANCER SOC, V122, P1913, DOI 10.1002/cncr.29972
   Dalmas M., 2007, CANC BURDEN RESIDENT
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Debald M, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-22
   Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260
   Ekenga CC, 2014, CANCER RES, V74, P3076, DOI 10.1158/0008-5472.CAN-13-2430
   Engel LS, 2014, ENVIRON HEALTH PERSP, V122, P165, DOI 10.1289/ehp.1206274
   Fenga C, 2016, BIOMED REP, V4, P282, DOI 10.3892/br.2016.575
   Giovannucci E, 2002, EXP BIOL MED, V227, P852, DOI 10.1177/153537020222701003
   Golubnitschaja O, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-6
   Harvey PW, 2003, J APPL TOXICOL, V23, P285, DOI 10.1002/jat.946
   Harvie M, 2003, Obes Rev, V4, P157, DOI 10.1046/j.1467-789X.2003.00108.x
   Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262
   HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561
   HSIEH C, 1994, EUR J CANCER, V30A, P969, DOI 10.1016/0959-8049(94)90125-2
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lajous M, 2008, AM J CLIN NUTR, V87, P1384, DOI 10.1093/ajcn/87.5.1384
   Ligibel JA, 2013, AM SOC CLIN ONCOL ED, V2013, P52, DOI DOI 10.1200/EDB00K_
   Ligibel J, 2011, ONCOLOGY-NY, V25, P994
   Mattisson I, 2004, BRIT J CANCER, V90, P122, DOI 10.1038/sj.bjc.6601516
   Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538
   Oyesanmi Olu, 2010, Evid Rep Technol Assess (Full Rep), P1
   Pizot C, 2016, EUR J CANCER, V52, P138, DOI 10.1016/j.ejca.2015.10.063
   Randall LM, 2016, GYNECOL ONCOL, V141, P10, DOI 10.1016/j.ygyno.2016.03.007
   Rivero J, 2016, TOXICOL LETT, V246, P42, DOI 10.1016/j.toxlet.2016.02.003
   Sieri S, 2008, AM J CLIN NUTR, V88, P1304, DOI 10.3945/ajcn.2008.26090
   Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143
   Stephenson GD, 2003, NUTR CANCER, V45, P1, DOI 10.1207/S15327914NC4501_1
   Trinh T, 2015, BRIT J CANCER, V113, P159, DOI 10.1038/bjc.2015.185
   Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668
   Weihrauch MR, 2004, ANN ONCOL, V15, P1460, DOI 10.1093/annonc/mdh256
   Wu SH, 2013, J BREAST CANCER, V16, P171, DOI 10.4048/jbc.2013.16.2.171
   Wu XY, 2015, ONCOL RES, V22, P129, DOI 10.3727/096504015X14267282610894
   Yu XF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-96
NR 50
TC 20
Z9 21
U1 2
U2 28
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1878-5077
EI 1878-5085
J9 EPMA J
JI EPMA J.
PD SEP 20
PY 2016
VL 7
AR 20
DI 10.1186/s13167-016-0069-z
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA DW3KF
UT WOS:000383539800001
PM 27679672
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lynch, SM
   O'Neill, KM
   McKenna, MM
   Walsh, CP
   McKenna, DJ
AF Lynch, Seodhna M.
   O'Neill, Karla M.
   McKenna, Michael M.
   Walsh, Colum P.
   McKenna, Declan J.
TI Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer
SO PROSTATE
LA English
DT Article
DE microRNA; miR-200c; miR-141; prostate cancer; DNA methylation
ID DNA METHYLATION; MESENCHYMAL TRANSITION; BREAST-CANCER; CELLS;
   MICRORNAS; SOY; HYPERMETHYLATION; FAMILY; EPIGENETICS; EXPRESSION
AB BACKGROUND. In prostate cancer (PCa), abnormal expression of several microRNAs (miRNAs) has been previously reported. Increasing evidence shows that aberrant epigenetic regulation of miRNAs is a contributing factor to their altered expression in cancer. In this study, we investigate whether expression of miR-200c and miR-141 in PCa is related to the DNA methylation status of their promoter.
   METHODS. PCR analysis of miR-200c and miR-141, and CpG methylation analysis of their common promoter, was performed in PCa cell-lines and in archived prostate biopsy specimens. The biological significance of miR-200c and miR-141 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets DNMT3A and TET1/TET3 was investigated. The effect on promoter methylation status in cells treated with demethylating agents was also examined.
   RESULTS. miR-200c and miR-141 are both highly elevated in LNCaP, 22RV1, and DU145 cells, but significantly reduced in PC3 cells. This correlates inversely with the methylation status of the miR-200c/miR-141 promoter, which is unmethylated in LNCaP, 22RV1, and DU145 cells, but hypermethylated in PC3. In PC3 cells, miR-200c and miR-141 expression is subsequently elevated by treatment with the demethylating drug decitabine (5-aza-2'deoxycytidine) and by knockdown of DNA methyltransferase 1 (DNMT1), suggesting their expression is regulated by methylation. Expression of miR-200c and miR-141 in prostate biopsy tissue was inversely correlated with methylation in promoter CpG sites closest to the miR-200c/miR-141 loci. In vitro, over-expression of miR-200c in PC3 cells inhibited growth and clonogenic potential, as well as inducing apoptosis. Expression of the genes DNMT3A and TET1/TET3 were down-regulated by miR-200c and miR-141 respectively. Finally, treatment with the soy isoflavone genistein caused demethylation of the promoter CpG sites closest to the miR-200c/miR-141 loci resulting in increased miR-200c expression.
   CONCLUSIONS. Our findings provide evidence that miR-200c and miR-141 are under epigenetic regulation in PCa cells. We propose that profiling their expression and methylation status may have potential as a novel biomarker or focus of therapeutic intervention in the diagnosis and prognosis of PCa. (C) 2016 Wiley Periodicals, Inc.
C1 [Lynch, Seodhna M.; O'Neill, Karla M.; Walsh, Colum P.; McKenna, Declan J.] Univ Ulster, Biomed Sci Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland.
   [O'Neill, Karla M.] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [McKenna, Michael M.] Altnagelvin Hosp, Western Hlth & Social Care Trust, Dept Cellular Pathol, Derry, North Ireland.
C3 Ulster University; Queens University Belfast
RP McKenna, DJ (通讯作者)，Univ Ulster, Biomed Sci Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland.
EM dj.mckenna@ulster.ac.uk
RI Walsh, Colum/ABD-7013-2020
OI McKenna, Declan/0000-0002-3492-8136; Lynch, Seodhna/0000-0002-5738-1129
FU Western Health and Social Care Trust; Department of Employment and
   Learning, Northern Ireland; Medical Research Council [MR/J007773/1]; MRC
   [MR/J007773/1] Funding Source: UKRI
FX Grant sponsor: Western Health and Social Care Trust; Grant sponsor:
   Department of Employment and Learning, Northern Ireland; Grant sponsor:
   Medical Research Council; Grant number: MR/J007773/1.
CR Adjakly M, 2013, ANTICANCER RES, V33, P39
   Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   Cheng HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069239
   Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070372
   Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058929
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Estey EH, 2013, LEUKEMIA, V27, P1803, DOI 10.1038/leu.2013.173
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Feng Wang XZ, 2014, CANC LETT, V344, P166
   Gandellini P, 2010, DISCOV MED, V9, P212
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Heneghan HM, 2010, CURR OPIN PHARMACOL, V10, P543, DOI 10.1016/j.coph.2010.05.010
   Hu X, 2014, CELL STEM CELL, V14, P512, DOI 10.1016/j.stem.2014.01.001
   Irwin RE, 2014, GENOMICS, V104, P383, DOI 10.1016/j.ygeno.2014.08.013
   Jerónimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Kozaki K, 2012, CANCER SCI, V103, P837, DOI 10.1111/j.1349-7006.2012.02236.x
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Lillycrop KA, 2012, BEST PRACT RES CL EN, V26, P667, DOI 10.1016/j.beem.2012.03.009
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x
   Meiers I, 2007, PATHOLOGY, V39, P299, DOI 10.1080/00313020701329906
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572
   Parasramka MA, 2012, MOL CARCINOGEN, V51, P213, DOI 10.1002/mc.20822
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011
   Ross SA, 2011, ADV NUTR, V2, P472, DOI 10.3945/an.111.001206
   Selth LA, 2013, BRIT J CANCER, V109, P641, DOI 10.1038/bjc.2013.369
   Tang HL, 2013, CLIN CANCER RES, V19, P5602, DOI 10.1158/1078-0432.CCR-13-1326
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574
   Vardi A, 2010, IN VIVO, V24, P393
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Watahiki A, 2013, INT J MOL SCI, V14, P7757, DOI 10.3390/ijms14047757
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Zorn CS, 2007, CLIN CANCER RES, V13, P2136, DOI 10.1158/1078-0432.CCR-06-2381
NR 43
TC 55
Z9 59
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD SEP 15
PY 2016
VL 76
IS 13
BP 1146
EP 1159
DI 10.1002/pros.23201
PG 14
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA DW2MO
UT WOS:000383476700002
PM 27198154
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Krishnan, NM
   Dhas, K
   Nair, J
   Palve, V
   Bagwan, J
   Siddappa, G
   Suresh, A
   Kekatpure, VD
   Kuriakose, MA
   Panda, B
AF Krishnan, Neeraja M.
   Dhas, Kunal
   Nair, Jayalakshmi
   Palve, Vinayak
   Bagwan, Jamir
   Siddappa, Gangotri
   Suresh, Amritha
   Kekatpure, Vikram D.
   Kuriakose, Moni Abraham
   Panda, Binay
TI A Minimal DNA Methylation Signature in Oral Tongue Squamous Cell
   Carcinoma Links Altered Methylation with Tumor Attributes
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID MICRORNA-B-10 PROMOTES MIGRATION; GASTRIC-CANCER; GENOMIC
   CHARACTERIZATION; OVARIAN-CANCER; BREAST-CANCER; RANDOM FOREST;
   EXPRESSION; HEAD; EPIGENETICS; SUPPRESSOR
AB Oral tongue squamous cell carcinomas (OTSCC) are a homogenous group of aggressive tumors in the head and neck region that spread early to lymph nodes and have a higher incidence of regional failure. In addition, there is a rising incidence of oral tongue cancer in younger populations. Studies on functional DNA methylation changes linked with altered gene expression are critical for understanding the mechanisms underlying tumor development and metastasis. Such studies also provide important insight into biomarkers linked with viral infection, tumor metastasis, and patient survival in OTSCC. Therefore, we performed genome-wide methylation analysis of tumors (N = 52) and correlated altered methylation with differential gene expression. The minimal tumor-specific DNA 5-methylcytosine signature identified genes near 16 different differentially methylated regions, which were validated using genomic data from The Cancer Genome Atlas cohort. In our cohort, hypermethylation of MIR10B was significantly associated with the differential expression of its target genes NR4A3 and BCL2L11 (P = 0.0125 and P = 0.014, respectively), which was inversely correlated with disease-free survival (P = 9E - 15 and P = 2E - 15, respectively) in patients. Finally, differential methylation in FUT3, TRIM5, TSPAN7, MAP3K8, RPS6KA2, SLC9A9, and NPAS3 genes was found to be predictive of certain clinical and epidemiologic parameters. (C) 2016 AACR.
C1 [Krishnan, Neeraja M.; Dhas, Kunal; Nair, Jayalakshmi; Palve, Vinayak; Bagwan, Jamir; Panda, Binay] Ganit Labs, BioIT Ctr, Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India.
   [Siddappa, Gangotri; Suresh, Amritha; Kuriakose, Moni Abraham] Mazumdar Shaw Ctr Translat Res, Integrated Head & Neck Oncol Program, Bangalore, Karnataka, India.
   [Kekatpure, Vikram D.; Kuriakose, Moni Abraham] Mazumdar Shaw Med Ctr, Head & Neck Oncol, Bangalore, Karnataka, India.
   [Panda, Binay] Strand Life Sci, Bangalore, Karnataka, India.
RP Panda, B (通讯作者)，Ganit Labs, Inst Bioinformat & Appl Biotechnol, Biotech Pk,Elect City Phase 1, Bangalore 560100, Karnataka, India.
EM binay@ganitlabs.in
RI Krishnan, Neeraja/LMO-5114-2024
OI Palve, Vinayak/0000-0002-8221-5018; Kuriakose, Moni/0000-0003-4229-752X
FU Department of Electronics and Information Technology, Government of
   India [18(4)/2010-E-Infra]; Department of IT, BT and ST, Government of
   Karnataka, India [3451-00-090-2-22]
FX Research presented in this article is funded by the Department of
   Electronics and Information Technology, Government of India [ref nr.:
   18(4)/2010-E-Infra., 31-03-2010] and the Department of IT, BT and ST,
   Government of Karnataka, India (ref nr.: 3451-00-090-2-22).
CR Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beggs Andrew D, 2015, Oncoscience, V2, P508
   Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Boulesteix AL, 2015, BRIEF BIOINFORM, V16, P338, DOI 10.1093/bib/bbu012
   Boulesteix AL, 2012, WIRES DATA MIN KNOWL, V2, P493, DOI 10.1002/widm.1072
   Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305
   Breiman L., 2001, MACH LEARN, V45, P5, DOI DOI 10.1023/A:1010933404324
   CARR BI, 1984, CARCINOGENESIS, V5, P1583, DOI 10.1093/carcin/5.12.1583
   Cheong CM, 2015, EXP CELL RES, V332, P24, DOI 10.1016/j.yexcr.2015.01.006
   Chow Maggie L., 2012, Frontiers in Genetics, V3, P11, DOI 10.3389/fgene.2012.00011
   Clark AM, 2004, GENE CHROMOSOME CANC, V41, P99, DOI 10.1002/gcc.20069
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   DENDA A, 1985, CARCINOGENESIS, V6, P145, DOI 10.1093/carcin/6.1.145
   Deutsch AJA, 2012, ANTI-CANCER AGENT ME, V12, P1001
   Diaz-Uriarte R, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-328
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Fakhry C, 2014, J CLIN ONCOL, V32, P3365, DOI 10.1200/JCO.2014.55.1937
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fortin JP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0503-2
   Gasche JA, 2012, FUTURE ONCOL, V8, P1407, DOI [10.2217/FON.12.138, 10.2217/fon.12.138]
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004
   Ignatov T, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-51
   Ignatov T, 2013, CANCER INVEST, V31, P309, DOI 10.3109/07357907.2013.789901
   Jeong JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016205
   Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Krishnan Neeraja, 2015, F1000Res, V4, P1215, DOI 10.12688/f1000research.7302.1
   Krishnan NM, 2015, BIORXIV, DOI http://dx.doi.org/10.1101/033829
   KURIAKOSE M, 1992, ORAL ONCOL, V28B, P113, DOI 10.1016/0964-1955(92)90038-3
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Lechner M, 2013, GENOME MED, V5, DOI 10.1186/gm419
   Li Z, 2015, GASTRIC CANCER, V18, P43, DOI 10.1007/s10120-014-0340-8
   Lin CH, 2001, CANCER RES, V61, P4238
   Llewellyn CD, 2001, ORAL ONCOL, V37, P401, DOI 10.1016/S1368-8375(00)00135-4
   Lu YC, 2012, CANCER PREV RES, V5, P665, DOI 10.1158/1940-6207.CAPR-11-0358
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Maegawa S, 2014, GENOME RES, V24, P580, DOI 10.1101/gr.157529.113
   Maitra A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3873
   Mascolo M, 2012, INT J MOL SCI, V13, P2331, DOI 10.3390/ijms13022331
   Milosevic N, 2013, NEOPLASIA, V15, P1354, DOI 10.1593/neo.131660
   Mishra A, 2014, ASIAN PAC J CANCER P, V15, P537, DOI 10.7314/APJCP.2014.15.2.537
   Moreira F, 2011, AM J PATHOL, V179, P462, DOI 10.1016/j.ajpath.2011.03.044
   Pathak KA, 2006, ORAL ONCOL, V42, P837, DOI 10.1016/j.oraloncology.2005.12.002
   Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Pogribny IP, 2014, CANCER LETT, V342, P223, DOI 10.1016/j.canlet.2012.01.038
   Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Serpa J, 2006, CANCER LETT, V242, P191, DOI 10.1016/j.canlet.2005.11.009
   Severino P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-533
   Shaw RJ, 2013, ANN SURG ONCOL, V20, P2796, DOI 10.1245/s10434-012-2713-8
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877
   Tibshirani R, 1997, J AM STAT ASSOC, V92, P13
   Tunca B, 2013, J CANCER RES CLIN, V139, P691, DOI 10.1007/s00432-013-1372-x
   Uekusa S, 2014, INT J ONCOL, V44, P1669, DOI 10.3892/ijo.2014.2340
   Wang YY, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0673-8
   Wilson GA, 2013, EPIGENETICS-US, V8, P953, DOI 10.4161/epi.25614
   Yeh KT, 2003, ONCOL REP, V10, P659
NR 68
TC 37
Z9 37
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD SEP
PY 2016
VL 14
IS 9
BP 805
EP 819
DI 10.1158/1541-7786.MCR-15-0395
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DW0UY
UT WOS:000383359700005
PM 27288358
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Mastaglio, F
   Bedair, K
   Papaemmanuil, E
   Groves, MJ
   Hyslop, A
   Keenan, N
   Hothersall, EJ
   Campbell, PJ
   Bowen, DT
   Tauro, S
AF Mastaglio, Francesca
   Bedair, Khaled
   Papaemmanuil, Elli
   Groves, Michael J.
   Hyslop, Ann
   Keenan, Norene
   Hothersall, Eleanor J.
   Campbell, Peter J.
   Bowen, David T.
   Tauro, Sudhir
TI Impact of socioeconomic status on disease phenotype, genomic landscape
   and outcomes in myelodysplastic syndromes
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE Socioeconomic status; myelodysplastic syndromes; International
   Prognostic Scoring System; outcomes; healthcare; genomic
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER; MYELOID-LEUKEMIA;
   DIAGNOSIS; SURVIVAL; CLASSIFICATION; DEPRIVATION; MUTATIONS; PROGNOSIS;
   BRITAIN
AB Genetic and epigenetic alterations contribute to the biological and clinical characteristics of myelodysplastic syndromes (MDS), but a role for socioeconomic environment remains unclear. Here, socioeconomic status (SES) for 283 MDS patients was estimated using the Scottish Index of Multiple Deprivation tool. Indices were assigned to quintile categorical indicators ranked from SES1 (lowest) to SES5 (highest). Clinicopathological features and outcomes between SES quintiles containing 15%, 20%, 19%, 30% and 16% of patients were compared. Prognostic scores identified lower-risk MDS in 82% of patients, with higher-risk disease in 18%. SES quintiles did not associate with age, gender, cytogenetics, International Prognostic scores or, in sub-analysis (n = 95), driver mutations. The odds ratio of a diagnosis of refractory anaemia was greater than other MDS sub-types in SES5 (OR 1.9, P = 0.024). Most patients (91%) exclusively received supportive care. SES did not associate with leukaemic transformation or cause of death. Cox regression models confirmed male gender (P < 0.05), disease- risk (P < 0.0001) and age (P < 0.01) as independent predictors of leukaemia-free survival, with leukaemic transformation an additional determinant of overall survival (P = 0.07). Thus, if access to healthcare is equitable, SES does not determine disease biology or survival in MDS patients receiving supportive treatment; additional studies are required to determine whether outcomes following disease-modifying therapies are influenced by SES.
C1 [Mastaglio, Francesca; Groves, Michael J.; Tauro, Sudhir] Univ Dundee, Ninewells Hosp & Med Sch, Dundee Canc Ctr, Dundee DD1 9SY, Scotland.
   [Bedair, Khaled; Hothersall, Eleanor J.] Univ Dundee, Div Populat Hlth Sci, Dundee, Scotland.
   [Bedair, Khaled] Univ Dundee, Ninewells Hosp & Med Sch, Photobiol Unit, Dept Dermatol, Dundee, Scotland.
   [Papaemmanuil, Elli; Campbell, Peter J.] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England.
   [Hyslop, Ann; Keenan, Norene; Tauro, Sudhir] Univ Dundee, Ninewells Hosp & Med Sch, Dept Haematol, Dundee, Scotland.
   [Bowen, David T.] St Jamess Inst Oncol, Leeds, W Yorkshire, England.
   [Papaemmanuil, Elli] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
C3 University of Dundee; University of Dundee; University of Dundee;
   Wellcome Trust Sanger Institute; University of Dundee; Saint James's
   University Hospital; Memorial Sloan Kettering Cancer Center
RP Tauro, S (通讯作者)，Univ Dundee, Ninewells Hosp & Med Sch, Dundee Canc Ctr, Dundee DD1 9SY, Scotland.
EM s.tauro@dundee.ac.uk
RI Hothersall, Eleanor/AGI-1122-2022
OI Hothersall-Davies, Eleanor/0000-0002-9956-4863
FU Tayside Leukaemia Research Endowment Fund
FX We acknowledge support from the Tayside Leukaemia Research Endowment
   Fund to set up the Tayside MDS Registry.
CR Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540
   BARKER DJP, 1981, BMJ-BRIT MED J, V283, P398, DOI 10.1136/bmj.283.6288.398
   Bejar R, 2014, BLOOD, V124, P2793, DOI 10.1182/blood-2014-04-522136
   BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb02771.x
   Bowen DT, 2013, BEST PRACT RES CL HA, V26, P319, DOI 10.1016/j.beha.2013.09.002
   CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162
   Dayyani F, 2010, CANCER-AM CANCER SOC, V116, P2174, DOI 10.1002/cncr.24984
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Durairaj S, 2013, BRIT J HAEMATOL, V161, P280, DOI 10.1111/bjh.12204
   England JT, 2013, LEUKEMIA RES, V37, P1495, DOI 10.1016/j.leukres.2013.08.021
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Garcia-Manero G, 2014, AM J HEMATOL, V89, P97, DOI 10.1002/ajh.23642
   Gomez N, 2015, AM J PUBLIC HEALTH, V105, P538, DOI 10.2105/AJPH.2014.302261
   Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079
   Itzykson R, 2014, LEUKEMIA, V28, P497, DOI 10.1038/leu.2013.343
   Itzykson R, 2013, BEST PRACT RES CL HA, V26, P355, DOI 10.1016/j.beha.2014.01.001
   Kolahdooz F, 2014, LANCET ONCOL, V15, pE504, DOI 10.1016/S1470-2045(14)70508-X
   Kristinsson SY, 2009, J CLIN ONCOL, V27, P2073, DOI 10.1200/JCO.2008.18.2006
   Kroll ME, 2012, BRIT J CANCER, V106, P1556, DOI 10.1038/bjc.2012.102
   Lightfoot TJ, 2012, EUR J CANCER, V48, P263, DOI 10.1016/j.ejca.2011.10.007
   Lv L, 2011, AM J HEMATOL, V86, P163, DOI 10.1002/ajh.21941
   Lyratzopoulos G, 2012, BRIT J CANCER, V106, P1068, DOI 10.1038/bjc.2012.30
   Malcovati L, 2013, BLOOD, V122, P2943, DOI 10.1182/blood-2013-03-492884
   Mukherjee D, 2014, J PATHOL, V232, P289, DOI 10.1002/path.4299
   Munro AJ, 2005, LANCET ONCOL, V6, P912, DOI 10.1016/S1470-2045(05)70436-8
   Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139
   Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886
   Platzbecker U, 2015, LEUKEMIA, V29, P1447, DOI 10.1038/leu.2015.92
   Ramsay SE, 2015, J EPIDEMIOL COMMUN H, V69, P1224, DOI 10.1136/jech-2015-205542
   Roberts MC, 2015, AM J PUBLIC HEALTH, V105, pE4, DOI 10.2105/AJPH.2014.302490
   Rutherford MJ, 2013, INT J CANCER, V133, P2192, DOI 10.1002/ijc.28221
   Schiffer Charles A, 2006, Hematology Am Soc Hematol Educ Program, P205
   Starks AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057361
   Stringhini S, 2015, INT J EPIDEMIOL, V44, P1320, DOI 10.1093/ije/dyv060
   Stringhini S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001479
   Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199
   WALBURG HE, 1968, INT J CANCER, V3, P150, DOI 10.1002/ijc.2910030118
   Wang R, 2009, CANCER CAUSE CONTROL, V20, P1369, DOI 10.1007/s10552-009-9362-7
NR 38
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUL
PY 2016
VL 174
IS 2
BP 227
EP 234
DI 10.1111/bjh.14042
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA DW6PP
UT WOS:000383773700005
PM 27098194
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Paolillo, C
   Londin, E
   Fortina, P
AF Paolillo, Carmela
   Londin, Eric
   Fortina, Paolo
TI Next generation sequencing in cancer: opportunities and challenges for
   precision cancer medicine
SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
LA English
DT Article
DE Cancer genomics; circulating cancer cells; formalin-fixed
   paraffin-embedded; precision oncology
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; POLYMERASE MOLECULES;
   PROSTATE-CANCER; PLASMA DNA; MUTATIONS; GENOMICS; SURVIVAL;
   QUANTIFICATION; HETEROGENEITY
AB Over the past decade, testing the genes of patients and their specific cancer types has become standardized practice in medical oncology since somatic mutations, changes in gene expression and epigenetic modifications are all hallmarks of cancer. However, while cancer genetic assessment has been limited to single biomarkers to guide the use of therapies, improvements in nucleic acid sequencing technologies and implementation of different genome analysis tools have enabled clinicians to detect these genomic alterations and identify functional and disease-associated genomic variants. Next-generation sequencing (NGS) technologies have provided clues about therapeutic targets and genomic markers for novel clinical applications when standard therapy has failed. While Sanger sequencing, an accurate and sensitive approach, allows for the identification of potential novel variants, it is however limited by the single amplicon being interrogated. Similarly, quantitative and qualitative profiling of gene expression changes also represents a challenge for the cancer field. Both RT-PCR and microarrays are efficient approaches, but are limited to the genes present on the array or being assayed. This leaves vast swaths of the transcriptome, including non-coding RNAs and other features, unexplored. With the advent of the ability to collect and analyze genomic sequence data in a timely fashion and at an ever-decreasing cost, many of these limitations have been overcome and are being incorporated into cancer research and diagnostics giving patients and clinicians new hope for targeted and personalized treatment. Below we highlight the various applications of next-generation sequencing in precision cancer medicine.
C1 [Paolillo, Carmela; Fortina, Paolo] Sidney Kimmel Med Coll, Dept Canc Biol, Philadelphia, PA USA.
   [Londin, Eric] Thomas Jefferson Univ, Computat Med Ctr, Philadelphia, PA 19107 USA.
C3 Thomas Jefferson University; Thomas Jefferson University
RP Fortina, P (通讯作者)，Thomas Jefferson Univ, Canc Genom & Bioinformat Lab, Sidney Kimmel Canc Ctr, Bluemle Life Sci Bldg 1009, Philadelphia, PA 19107 USA.
EM paolo.fortina@jefferson.edu
RI Fortina, Paolo/ABE-8350-2020; Paolillo, Carmela/AAK-2578-2020
OI Fortina, Paolo/0000-0002-5898-2081; Paolillo,
   Carmela/0000-0003-2677-5747; Londin, Eric/0000-0003-4331-6366
FU Kimmel Cancer Center (Philadelphia, PA); Celsee Diagnostics Research
   Grant
FX This work was supported in part by the Kimmel Cancer Center
   (Philadelphia, PA to PF). CP is supported by a Celsee Diagnostics
   Research Grant.
CR Aarthy R, 2015, MOL DIAGN THER, V19, P339, DOI 10.1007/s40291-015-0167-y
   Aggarwal C, 2013, ANN ONCOL, V24, P420, DOI 10.1093/annonc/mds336
   Ashton PM, 2015, NAT BIOTECHNOL, V33, P296, DOI 10.1038/nbt.3103
   Ashworth T. R., 1869, Aust. J. Med, V14, P146
   Belic J, 2015, CLIN CHEM, V61, P838, DOI 10.1373/clinchem.2014.234286
   Bodi K, 2013, J Biomol Tech, V24, P73, DOI 10.7171/jbt.13-2402-002
   Carr TH, 2016, NAT REV CANCER, V16, P319, DOI 10.1038/nrc.2016.35
   Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Damodaran Senthilkumar, 2015, Am Soc Clin Oncol Educ Book, pe175, DOI 10.14694/EdBook_AM.2015.35.e175
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872
   Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986
   Fernandez SV, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0445-3
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015
   Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403
   Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73
   Guttery DS, 2015, CLIN CHEM, V61, P974, DOI 10.1373/clinchem.2015.238717
   Hagemann IS, 2013, CANCER GENET-NY, V206, P420, DOI 10.1016/j.cancergen.2013.11.003
   Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427
   Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140
   Jahr S, 2001, CANCER RES, V61, P1659
   Janku F, 2014, THER ADV MED ONCOL, V6, P43, DOI 10.1177/1758834013517414
   Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108
   Koboldt DC, 2013, CELL, V155, P27, DOI 10.1016/j.cell.2013.09.006
   Korlach J, 2008, P NATL ACAD SCI USA, V105, P1176, DOI 10.1073/pnas.0710982105
   Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892
   Luthra R, 2015, CANCERS, V7, P2023, DOI 10.3390/cancers7040874
   Maggi E, 2015, MUTAT RES-FUND MOL M, V782, P44, DOI 10.1016/j.mrfmmm.2015.10.005
   Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419
   Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177
   Metzker ML, 2005, GENOME RES, V15, P1767, DOI 10.1101/gr.3770505
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Nadauld L, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.e17641
   Paolillo C, 38 ANN SABCS 2015 SA
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Robson ME, 2015, J CLIN ONCOL, V33, P3660, DOI 10.1200/JCO.2015.63.0996
   Roeder I, 2008, BLOOD, V112, P4874, DOI 10.1182/blood-2008-05-155374
   Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242
   Roychowdhury S, 2014, ANNU REV GENOM HUM G, V15, P395, DOI 10.1146/annurev-genom-090413-025552
   Schneider GF, 2012, NAT BIOTECHNOL, V30, P326, DOI 10.1038/nbt.2181
   Schroeder C, 2015, BREAST CANCER RES TR, V152, P129, DOI 10.1007/s10549-015-3429-9
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Singh RR, 2014, BRIT J CANCER, V111, P2014, DOI 10.1038/bjc.2014.518
   Sukhai MA, 2016, GENET MED, V18, P128, DOI 10.1038/gim.2015.47
   Susswein LR, 2016, GENET MED, V18, P823, DOI 10.1038/gim.2015.166
   Westbrook CJ, 2015, HUM IMMUNOL, V76, P891, DOI 10.1016/j.humimm.2015.03.022
   Xuan JK, 2013, CANCER LETT, V340, P284, DOI 10.1016/j.canlet.2012.11.025
NR 48
TC 15
Z9 18
U1 1
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0036-5513
EI 1502-7686
J9 SCAND J CLIN LAB INV
JI Scand. J. Clin. Lab. Invest.
PY 2016
VL 76
SU 245
SI SI
BP S84
EP S91
DI 10.1080/00365513.2016.1210331
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DV7IS
UT WOS:000383110200019
PM 27542004
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Joo, MK
   Park, JJ
   Chun, HJ
AF Joo, Moon Kyung
   Park, Jong-Jae
   Chun, Hoon Jai
TI Impact of homeobox genes in gastrointestinal cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Homeobox genes; HOX genes; Caudal-related homeobox transcription factor
   2; Gastrointestinal cancers; HOXB7
ID SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; GASTRIC
   INTESTINAL METAPLASIA; COLON-CANCER; HOX GENES; COLORECTAL-CANCER;
   TUMOR-SUPPRESSOR; HOMEODOMAIN PROTEIN; BREAST-CANCER; PROMOTER
   HYPERMETHYLATION
AB Homeobox genes, including HOX and non-HOX genes, have been identified to be expressed aberrantly in solid tumors. In gastrointestinal (GI) cancers, most studies have focused on the function of non-HOX genes including caudal-related homeobox transcription factor 1 (CDX1) and CDX2. CDX2 is a crucial factor in the development of pre-cancerous lesions such as Barrett's esophagus or intestinal metaplasia in the stomach, and its tumor suppressive role has been investigated in colorectal cancers. Recently, several HOX genes were reported to have specific roles in GI cancers; for example, HOXA13 in esophageal squamous cell cancer and HOXB7 in stomach and colorectal cancers. HOXD10 is upregulated in colorectal cancer while it is silenced epigenetically in gastric cancer. Thus, it is essential to examine the differential expression pattern of various homeobox genes in specific tumor types or cell lineages, and understand their underlying mechanisms. In this review, we summarize the available research on homeobox genes and present their potential value for the prediction of prognosis in GI cancers.
C1 [Joo, Moon Kyung; Park, Jong-Jae] Korea Univ, Div Gastroenterol, Dept Internal Med, Coll Med,Guro Hosp, Seoul 08308, South Korea.
   [Chun, Hoon Jai] Korea Univ, Inst Digest Dis & Nutr, Div Gastroenterol & Hepatol, Coll Med,Dept Internal Med, 126-1,Anam Dong 5 Ga, Seoul 02841, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Chun, HJ (通讯作者)，Korea Univ, Inst Digest Dis & Nutr, Div Gastroenterol & Hepatol, Coll Med,Dept Internal Med, 126-1,Anam Dong 5 Ga, Seoul 02841, South Korea.
EM drchunhj@chol.com
OI Joo, Moon Kyung/0000-0001-6050-3695
FU Korean College of Helicobacter and Upper Gastrointestinal Research
   Foundation Grant; Korea University Grant [K1512661]
FX Supported by the Korean College of Helicobacter and Upper
   Gastrointestinal Research Foundation Grant; and a Korea University
   Grant, No. K1512661.
CR Baba Y, 2009, CLIN CANCER RES, V15, P4665, DOI 10.1158/1078-0432.CCR-09-0401
   Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4
   Bhatlekar S, 2014, STEM CELLS DEV, V23, P167, DOI 10.1089/scd.2013.0039
   Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465
   Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7
   Cai JQ, 2016, TUMOR BIOL, V37, P1641, DOI 10.1007/s13277-015-3948-3
   Care A, 1996, MOL CELL BIOL, V16, P4842
   Chen KN, 2005, CLIN CANCER RES, V11, P1044
   Coskun M, 2014, CARCINOGENESIS, V35, P1185, DOI 10.1093/carcin/bgu037
   di Pietro M, 2012, P NATL ACAD SCI USA, V109, P9077, DOI 10.1073/pnas.1116933109
   Ebert MPA, 2006, GASTROENTEROLOGY, V131, P1418, DOI 10.1053/j.gastro.2006.08.034
   Errico MC, 2013, INT J CANCER, V133, P879, DOI 10.1002/ijc.28097
   Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597
   Fang S, 2016, LAB INVEST, V96, P60, DOI 10.1038/labinvest.2015.123
   Gu ZD, 2009, CANCER RES, V69, P4969, DOI 10.1158/0008-5472.CAN-08-4546
   Guo JB, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0393-x
   Guo M, 2007, INT J CANCER, V121, P1219, DOI 10.1002/ijc.22828
   Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200
   Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143
   Han Y, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0564-1
   Haria Dhwani, 2013, Cancer Hallm, V1, P67
   Hinkel I, 2012, GASTROENTEROLOGY, V142, P875, DOI 10.1053/j.gastro.2011.12.037
   Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598
   Hong CS, 2015, BIOCHEM J, V472, P393, DOI 10.1042/BJ20150213
   How C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067846
   Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108
   Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112
   Joo MK, 2016, J GASTROEN HEPATOL, V31, P1717, DOI 10.1111/jgh.13330
   Jung C, 2005, BRIT J CANCER, V92, P2233, DOI 10.1038/sj.bjc.6602631
   Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330
   Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614
   Kanai M, 2010, ONCOL REP, V23, P843, DOI 10.3892/or_00000706
   Knösel T, 2012, INT J COLORECTAL DIS, V27, P1391, DOI 10.1007/s00384-012-1460-4
   Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533
   Liu Q, 2007, MODERN PATHOL, V20, P1286, DOI 10.1038/modpathol.3800968
   Liu S, 2015, CANCER RES, V75, P709, DOI 10.1158/0008-5472.CAN-14-3100
   Liu T, 2007, CARCINOGENESIS, V28, P488, DOI 10.1093/carcin/bgl176
   Lord RVN, 2005, SURGERY, V138, P924, DOI 10.1016/j.surg.2005.05.007
   Lu MH, 2012, CLIN CANCER RES, V18, P6416, DOI 10.1158/1078-0432.CCR-12-0832
   Lv J, 2012, MED ONCOL, V29, P151, DOI 10.1007/s12032-010-9816-5
   Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770
   Ma J, 2008, CARCINOGENESIS, V29, P1327, DOI 10.1093/carcin/bgn112
   Ma JA, 2010, CARCINOGENESIS, V31, P1552, DOI 10.1093/carcin/bgq140
   Ma RL, 2014, ONCOL REP, V31, P2157, DOI 10.3892/or.2014.3088
   Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482
   Olsen J, 2016, EXP MOL PATHOL, V100, P59, DOI 10.1016/j.yexmp.2015.11.009
   Park KJ, 2017, GASTRIC CANCER, V20, P104, DOI 10.1007/s10120-015-0592-y
   Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020
   Platais C, 2016, J ORAL PATHOL MED, V45, P239, DOI 10.1111/jop.12388
   Rad A, 2016, TUMOR BIOL, V37, P1715, DOI 10.1007/s13277-015-3780-9
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rawat VPS, 2012, BLOOD, V120, P519, DOI 10.1182/blood-2012-02-385898
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Sakai H, 2004, GUT, V53, P323, DOI 10.1136/gut.2003.026609
   Sanz-Pamplona R, 2011, CLIN CANCER RES, V17, P7303, DOI 10.1158/1078-0432.CCR-11-1570
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shen LY, 2011, CANCER LETT, V312, P18, DOI 10.1016/j.canlet.2011.07.020
   Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902
   Souza RF, 2008, AM J PHYSIOL-GASTR L, V295, pG211, DOI 10.1152/ajpgi.90250.2008
   Sue S, 2016, J GASTROENTEROL, V51, P949, DOI 10.1007/s00535-016-1176-2
   Takahashi O, 2007, ONCOL REP, V17, P753
   Vaninetti N, 2009, MOL CARCINOGEN, V48, P965, DOI 10.1002/mc.20549
   Wang LJ, 2012, MOL MED, V18, P389, DOI 10.2119/molmed.2011.00172
   Wang Z, 2007, CLIN CANCER RES, V13, P6327, DOI 10.1158/1078-0432.CCR-07-0310
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Xiao FM, 2014, EUR J CANCER, V50, P1541, DOI 10.1016/j.ejca.2014.01.024
   Xie X, 2013, BIOMARKERS, V18, P297, DOI 10.3109/1354750X.2013.773380
   Yan LH, 2014, WORLD J GASTROENTERO, V20, P3960, DOI 10.3748/wjg.v20.i14.3960
   Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304
NR 69
TC 46
Z9 51
U1 1
U2 26
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD OCT 7
PY 2016
VL 22
IS 37
BP 8247
EP 8256
DI 10.3748/wjg.v22.i37.8247
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DX9BT
UT WOS:000384689000001
PM 27729732
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Koh, HB
   Scruggs, AM
   Huang, SK
AF Koh, Hailey B.
   Scruggs, Anne M.
   Huang, Steven K.
TI Transforming Growth Factor-1 Increases DNA Methyltransferase 1 and 3a
   Expression through Distinct Post-transcriptional Mechanisms in Lung
   Fibroblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Akt PKB; DNA methylation; DNA methyltransferase; fibroblast; glycogen
   synthase kinase 3 (GSK-3); mammalian target of rapamycin (mTOR);
   transforming growth factor beta (TGF-B); ubiquitylation
   (ubiquitination); DNMT1; DNMT3a
ID INDUCED PULMONARY-FIBROSIS; FOCAL ADHESION KINASE; ZINC-FINGER PROTEINS;
   BETA TGF-BETA; PROSTAGLANDIN E-2; MYOFIBROBLAST DIFFERENTIATION;
   TUMOR-SUPPRESSOR; DNMT1 STABILITY; BREAST-CANCER; T-CELLS
AB DNA methylation is a fundamental epigenetic mark that plays a critical role in differentiation and is mediated by the actions of DNA methyltransferases (DNMTs). TGF-1 is one of the most potent inducers of fibroblast differentiation, and although many of its actions on fibroblasts are well described, the ability of TGF-1 to modulate DNA methylation in mesenchymal cells is less clear. Here, we examine the ability of TGF-1 to modulate the expression of various DNMTs in primary lung fibroblasts (CCL210). TGF-1 increased the protein expression, but not RNA levels, of both DNMT1 and DNMT3a. The increases in DNMT1 and DNMT3a were dependent on TGF-1 activation of focal adhesion kinase and PI3K/Akt. Activation of mammalian target of rapamycin complex 1 by Akt resulted in increased protein translation of DNMT3a. In contrast, the increase in DNMT1 by TGF-1 was not dependent on new protein synthesis and instead was due to decreased protein degradation. TGF-1 treatment led to the phosphorylation and inactivation of glycogen synthase kinase-3, which resulted in inhibition of DNMT1 ubiquitination and proteosomal degradation. The phosphorylation and inactivation of glycogen synthase kinase-3 was dependent on mammalian target of rapamycin complex 1. These results demonstrate that TGF-1 increases expression of DNMT1 and DNMT3a through different post-transcriptional mechanisms. Because DNA methylation is critical to many processes including development and differentiation, for which TGF-1 is known to be crucial, the ability of TGF-1 to increase expression of both DNMT1 and DNMT3a demonstrates a novel means by which TGF-1 may regulate DNA methylation in these cells.
C1 [Koh, Hailey B.; Scruggs, Anne M.; Huang, Steven K.] Univ Michigan, Div Pulm & Crit Care Med, Sch Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Huang, SK (通讯作者)，6301 MSRB IIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM stehuang@umich.edu
FU NHLBI, National Institutes of Health [HL119289, HL127203]; National
   Heart Lung and Blood Institute [R01HL127203] Funding Source: NIH
   RePORTER; National Institute of Environmental Health Sciences
   [P30ES017885] Funding Source: NIH RePORTER
FX This work was funded by Grants HL119289 and HL127203 from the NHLBI,
   National Institutes of Health (to S. K. H.). The authors declare that
   they have no conflicts of interest with the contents of this article.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Aschner Y, 2016, AM J RESP CELL MOL, V54, P647, DOI 10.1165/rcmb.2015-0391TR
   Azizi M, 2014, CANCER BIOL THER, V15, P419, DOI 10.4161/cbt.27630
   Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC
   Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BORDER WA, 1994, NEW ENGL J MED, V331, P1286
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001
   Chen TL, 2013, INHAL TOXICOL, V25, P525, DOI 10.3109/08958378.2013.809393
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050
   Domingo-Gonzalez R, 2015, AM J PHYSIOL-LUNG C, V308, pL86, DOI 10.1152/ajplung.00283.2014
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Estève PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Garrison G, 2013, AM J RESP CELL MOL, V48, P550, DOI 10.1165/rcmb.2012-0262OC
   Gorelik G, 2007, J IMMUNOL, V179, P5553, DOI 10.4049/jimmunol.179.8.5553
   Harding P, 2006, KIDNEY INT, V69, P1578, DOI 10.1038/sj.ki.5000323
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hodge David R., 2007, Cancer Genomics & Proteomics, V4, P387
   Horowitz JC, 2007, CELL SIGNAL, V19, P761, DOI 10.1016/j.cellsig.2006.10.001
   Huang S, 2007, AM J PHYSIOL-LUNG C, V292, pL405, DOI 10.1152/ajplung.00232.2006
   Huang SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107055
   Huang SK, 2012, FASEB J, V26, P3703, DOI 10.1096/fj.11-203323
   Huang SK, 2010, AM J PATHOL, V177, P2245, DOI 10.2353/ajpath.2010.100446
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002
   Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Keerthisingam CB, 2001, AM J PATHOL, V158, P1411, DOI 10.1016/S0002-9440(10)64092-8
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x
   Lang UE, 2013, ONCOGENE, V32, P4557, DOI 10.1038/onc.2012.457
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Li CR, 2013, J BIOL CHEM, V288, P19127, DOI 10.1074/jbc.M113.453357
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li M, 2011, J CLIN INVEST, V121, P277, DOI 10.1172/JCI42090
   Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011
   Li YP, 2010, EXP GERONTOL, V45, P312, DOI 10.1016/j.exger.2009.12.008
   Lin RK, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-46
   Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161
   Lin RK, 2010, J CLIN INVEST, V120, P521, DOI 10.1172/JCI40706
   Martin M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-435
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Neveu WA, 2015, AM J PHYSIOL-CELL PH, V309, pC616, DOI 10.1152/ajpcell.00086.2015
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pan XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060335
   Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11
   QUDDUS J, 1993, J CLIN INVEST, V92, P38, DOI 10.1172/JCI116576
   Rabinovich EI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033770
   Sanders YY, 2012, AM J RESP CRIT CARE, V186, P525, DOI 10.1164/rccm.201201-0077OC
   Shamma A, 2013, MOL CELL BIOL, V33, P3113, DOI 10.1128/MCB.01597-12
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Soltani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039736
   Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014
   SZYF M, 1991, J BIOL CHEM, V266, P10027
   Tabish AM, 2015, METHODS MOL BIOL, V1315, P201, DOI 10.1007/978-1-4939-2715-9_15
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Thomas PE, 2007, AM J PHYSIOL-LUNG C, V293, pL417, DOI 10.1152/ajplung.00489.2006
   Wang HZ, 2011, J IMMUNOL, V186, P5217, DOI 10.4049/jimmunol.1002513
   Wettlaufer SH, 2016, AM J RESP CELL MOL, V54, P114, DOI 10.1165/rcmb.2014-0468OC
   Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200
   Zhang Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025168
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 70
TC 21
Z9 25
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 9
PY 2016
VL 291
IS 37
BP 19287
EP 19298
DI 10.1074/jbc.M116.723080
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DV9EL
UT WOS:000383242800010
PM 27405758
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Sharma, S
   Xing, F
   Liu, Y
   Wu, KR
   Said, N
   Pochampally, R
   Shiozawa, Y
   Lin, HK
   Balaji, KC
   Watabe, K
AF Sharma, Sambad
   Xing, Fei
   Liu, Yin
   Wu, Kerui
   Said, Neveen
   Pochampally, Radhika
   Shiozawa, Yusuke
   Lin, Hui-Kuan
   Balaji, K. C.
   Watabe, Kounosuke
TI Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic
   Dormancy of Prostate Cancer in Bone
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE DNA demethylation; prostate cancer; stromal cell; tumor cell biology;
   tumor microenvironment; BMP7; bone metastasis; dormancy; SPARC
ID BREAST-CANCER; TUMOR-GROWTH; MORPHOGENETIC PROTEIN-7; RADICAL
   PROSTATECTOMY; PROGNOSTIC VALUE; DEFICIENT MICE; CELL DORMANCY;
   IN-VITRO; EXPRESSION; PROGRESSION
AB Prostate cancer is known to frequently recur in bone; however, how dormant cells switch its phenotype leading to recurrent tumor remains poorly understood. We have isolated two syngeneic cell lines (indolent and aggressive) through in vivo selection by implanting PC3mm stem-like cells into tibial bones. We found that indolent cells retained the dormant phenotype, whereas aggressive cells grew rapidly in bone in vivo, and the growth rates of both cells in culture were similar, suggesting a role of the tumor microenvironment in the regulation of dormancy and recurrence. Indolent cells were found to secrete a high level of secreted protein acidic and rich in cysteine (SPARC), which significantly stimulated the expression of BMP7 in bone marrow stromal cells. The secreted BMP7 then kept cancer cells in a dormant state by inducing senescence, reducing stemness, and activating dormancy-associated p38 MAPK signaling and p21 expression in cancer cells. Importantly, we found that SPARC was epigenetically silenced in aggressive cells by promoter methylation, but 5-azacytidine treatment reactivated the expression. Furthermore, high SPARC promoter methylation negatively correlated with disease-free survival of prostate cancer patients. We also found that the COX2 inhibitor NS398 down-regulated DNMTs and increased expression of SPARC, which led to tumor growth suppression in bone in vivo. These findings suggest that SPARC plays a key role in maintaining the dormancy of prostate cancer cells in the bone microenvironment.
C1 [Sharma, Sambad; Xing, Fei; Liu, Yin; Wu, Kerui; Shiozawa, Yusuke; Lin, Hui-Kuan; Watabe, Kounosuke] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.
   [Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.
   [Balaji, K. C.] Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.
   [Pochampally, Radhika] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.
   [Pochampally, Radhika] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest
   University; Wake Forest Baptist Medical Center; Wake Forest University;
   Wake Forest Baptist Medical Center; University of Mississippi Medical
   Center; University of Mississippi; University of Mississippi; University
   of Mississippi Medical Center
RP Watabe, K (通讯作者)，Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.
EM kwatabe@wakehealth.edu
RI Said, Neveen/K-1563-2019
OI Wu, Kerui/0000-0002-5504-8875
FU Comprehensive Cancer Center of Wake Forest University NCI, National
   Institutes of Health [P30CA012197]
FX We thank Dr. Aya Kobayashi for help with the initial work of isolation
   and characterization of the clones. The Flow Cytometry Shared Resources,
   Cell and Viral Vector Core Lab are supported by the Comprehensive Cancer
   Center of Wake Forest University NCI, National Institutes of Health
   Grant (P30CA012197).
CR Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863
   Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
   Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Almog N, 2010, CANCER LETT, V294, P139, DOI 10.1016/j.canlet.2010.03.004
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Brekken Rolf A., 2001, Matrix Biology, V19, P816
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330
   Chéry L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480
   Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357
   De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200
   Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039
   DeRosa CA, 2012, PROSTATE CANCER P D, V15, P150, DOI 10.1038/pcan.2011.61
   Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585
   Ferrario A, 2005, CANCER RES, V65, P9473, DOI 10.1158/0008-5472.CAN-05-1659
   Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091
   Golembieski WA, 2008, GLIA, V56, P1061, DOI 10.1002/glia.20679
   Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008-5472.CAN-05-2012
   Horwich A, 2013, ANN ONCOL, V24, P106, DOI 10.1093/annonc/mdt208
   Jacob K, 1999, CANCER RES, V59, P4453
   Jones MK, 1999, NAT MED, V5, P1418
   Kapinas K, 2012, MATRIX BIOL, V31, P299, DOI 10.1016/j.matbio.2012.03.002
   Kim IY, 2004, CANCER RES, V64, P7355, DOI 10.1158/0008-5472.CAN-04-0154
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807
   Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059
   Kwabi-Addo B, 2010, CLIN CANCER RES, V16, P3539, DOI 10.1158/1078-0432.CCR-09-3342
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Leyton PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076947
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Marcelino J, 2001, P NATL ACAD SCI USA, V98, P11353, DOI 10.1073/pnas.201367598
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   McCabe NP, 2011, NEOPLASIA, V13, P31, DOI 10.1593/neo.10998
   Mohler JL, 2013, J NATL COMPR CANC NE, V11, P1471, DOI 10.6004/jnccn.2013.0174
   Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078-0432.CCR-08-1754
   MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071
   Nagai MA, 2011, BREAST CANCER RES TR, V126, P1, DOI 10.1007/s10549-010-0867-2
   Nagaraju GP, 2014, CARCINOGENESIS, V35, P967, DOI 10.1093/carcin/bgu072
   Nishikawa M, 2004, J AM COLL SURGEONS, V199, P428, DOI 10.1016/j.jamcollsurg.2004.05.265
   OSSOWSKI L, 1987, J CELL PHYSIOL, V133, P288, DOI 10.1002/jcp.1041330212
   Pan MR, 2008, EXP BIOL MED, V233, P456, DOI 10.3181/0709-RM-257
   Podgorski I, 2009, AM J PATHOL, V175, P1255, DOI 10.2353/ajpath.2009.080906
   Podhajcer OL, 2008, CANCER METAST REV, V27, P523, DOI 10.1007/s10555-008-9135-x
   Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2
   Said N, 2009, ONCOGENE, V28, P3487, DOI 10.1038/onc.2009.205
   Said N, 2013, J CLIN INVEST, V123, P751, DOI 10.1172/JCI64782
   Said NA, 2008, NEOPLASIA, V10, P1092, DOI 10.1593/neo.08672
   Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092
   Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157
   Tai IT, 2008, DRUG RESIST UPDATE, V11, P231, DOI 10.1016/j.drup.2008.08.005
   Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4
   Thomas R, 2000, CLIN CANCER RES, V6, P1140
   Weckermann D, 2001, J UROLOGY, V166, P699, DOI 10.1016/S0022-5347(05)66046-6
   Welsh JB, 2001, CANCER RES, V61, P5974
   Wong SY, 2008, CLIN EXP METASTAS, V25, P109, DOI 10.1007/s10585-007-9126-2
   Wong SY, 2007, P NATL ACAD SCI USA, V104, P12784, DOI 10.1073/pnas.0705499104
   Ye L, 2007, J UROLOGY, V178, P1086, DOI 10.1016/j.juro.2007.05.003
   Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4
   Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888
   Zhang JL, 2014, ONCOL REP, V31, P2312, DOI 10.3892/or.2014.3118
   Zietman AL, 2010, J CLIN ONCOL, V28, P1106, DOI 10.1200/JCO.2009.25.8475
NR 68
TC 82
Z9 88
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 9
PY 2016
VL 291
IS 37
BP 19351
EP 19363
DI 10.1074/jbc.M116.737379
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DV9EL
UT WOS:000383242800015
PM 27422817
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Jain, K
   Warmack, RA
   Debler, EW
   Hadjikyriacou, A
   Stavropoulos, P
   Clarke, SG
AF Jain, Kanishk
   Warmack, Rebeccah A.
   Debler, Erik W.
   Hadjikyriacou, Andrea
   Stavropoulos, Peter
   Clarke, Steven G.
TI Protein Arginine Methyltransferase Product Specificity Is Mediated by
   Distinct Active-site Architectures
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE enzyme catalysis; epigenetics; histone methylation; post-translational
   modification (PTM); protein methylation; PRMT; PRMT product specificity;
   methyltransferase; protein arginine methylation
ID SYMMETRIC DIMETHYLATION; POSTTRANSLATIONAL MODIFICATIONS; EPIGENETIC
   REGULATION; TRYPANOSOMA-BRUCEI; BREAST-CANCER; HISTONE H4; 7 PRMT7;
   METHYLATION; EXPRESSION; BIOLOGY
AB In the family of protein arginine methyltransferases (PRMTs) that predominantly generate either asymmetric or symmetric dimethylarginine (SDMA), PRMT7 is unique in producing solely monomethylarginine (MMA) products. The type of methylation on histones and other proteins dictates changes in gene expression, and numerous studies have linked altered profiles of methyl marks with disease phenotypes. Given the importance of specific inhibitor development, it is crucial to understand the mechanisms by which PRMT product specificity is conferred. We have focused our attention on active-site residues of PRMT7 from the protozoan Trypanosoma brucei. We have designed 26 single and double mutations in the active site, including residues in the Glu-Xaa(8)-Glu (double E) loop and the Met-Gln-Trp sequence of the canonical Thr-His-Trp (THW) loop known to interact with the methyl-accepting substrate arginine. Analysis of the reaction products by high resolution cation exchange chromatography combined with the knowledge of PRMT crystal structures suggests a model where the size of two distinct subregions in the active site determines PRMT7 product specificity. A dual mutation of Glu-181 to Asp in the double E loop and Gln-329 to Ala in the canonical THW loop enables the enzyme to produce SDMA. Consistent with our model, the mutation of Cys-431 to His in the THW loop of human PRMT9 shifts its product specificity from SDMA toward MMA. Together with previous results, these findings provide a structural basis and a general model for product specificity in PRMTs, which will be useful for the rational design of specific PRMT inhibitors.
C1 [Jain, Kanishk; Warmack, Rebeccah A.; Hadjikyriacou, Andrea; Clarke, Steven G.] Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr East, Los Angeles, CA 90095 USA.
   [Jain, Kanishk; Warmack, Rebeccah A.; Hadjikyriacou, Andrea; Clarke, Steven G.] Univ Calif Los Angeles, Inst Mol Biol, 607 Charles E Young Dr East, Los Angeles, CA 90095 USA.
   [Debler, Erik W.; Stavropoulos, Peter] Rockefeller Univ, Cell Biol Lab, New York, NY 10065 USA.
   [Stavropoulos, Peter] Rockefeller Univ, Lab Lymphocyte Biol, New York, NY 10065 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Rockefeller University; Rockefeller University
RP Clarke, SG (通讯作者)，Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr East, Los Angeles, CA 90095 USA.; Clarke, SG (通讯作者)，Univ Calif Los Angeles, Inst Mol Biol, 607 Charles E Young Dr East, Los Angeles, CA 90095 USA.
EM clarke@mbi.ucla.edu
RI Debler, Erik/D-1794-2013
OI Debler, Erik/0000-0002-2587-2150; Jain, Kanishk/0000-0001-8039-0464;
   Clarke, Steven/0000-0002-7303-6632
FU National Institutes of Health [GM026020]; Ruth L. Kirschstein National
   Service Award [GM007185];  [DRG-1977-08]
FX This work was supported by National Institutes of Health Grant GM026020
   (to S. G. C.) and Ruth L. Kirschstein National Service Award GM007185
   (to K. J., R. A. W., and A. H.). The authors declare that they have no
   conflicts of interest with the contents of this article. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.Frey
   Fellow of the Damon Runyon Cancer Research Foundation supported by Grant
   DRG-1977-08.
CR Baldwin RM, 2015, ONCOTARGET, V6, P3013, DOI 10.18632/oncotarget.3072
   Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Cura V, 2014, ACTA CRYSTALLOGR D, V70, P2401, DOI 10.1107/S1399004714014278
   Debler EW, 2016, P NATL ACAD SCI USA, V113, P2068, DOI 10.1073/pnas.1525783113
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Dhar S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01311
   Feng Y, 2013, J BIOL CHEM, V288, P37010, DOI 10.1074/jbc.M113.525345
   Feng Y, 2011, BIOCHEMISTRY-US, V50, P7033, DOI 10.1021/bi200456u
   Ferreira TR, 2014, MOL MICROBIOL, V94, P1085, DOI 10.1111/mmi.12819
   Fisk JC, 2009, J BIOL CHEM, V284, P11590, DOI 10.1074/jbc.M807279200
   Fuhrmann J, 2016, ACS CHEM BIOL, V11, P654, DOI 10.1021/acschembio.5b00942
   Fuhrmann J, 2015, CHEM REV, V115, P5413, DOI 10.1021/acs.chemrev.5b00003
   Gayatri S, 2014, BBA-GENE REGUL MECH, V1839, P702, DOI 10.1016/j.bbagrm.2014.02.015
   GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0
   Gui SY, 2014, J BIOL CHEM, V289, P9320, DOI 10.1074/jbc.M113.535278
   Hadjikyriacou A, 2015, J BIOL CHEM, V290, P16723, DOI 10.1074/jbc.M115.659433
   Hasegawa M, 2014, FEBS LETT, V588, P1942, DOI 10.1016/j.febslet.2014.03.053
   Hu H, 2016, EXPERT OPIN INV DRUG, V25, P335, DOI 10.1517/13543784.2016.1144747
   Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905
   Karkhanis V, 2012, J BIOL CHEM, V287, P29801, DOI 10.1074/jbc.M112.378281
   Lott K, 2014, MICROBIOLOGYOPEN, V3, P595, DOI 10.1002/mbo3.191
   Martens-Lobenhoffer J, 2016, ANAL BIOCHEM, V493, P14, DOI 10.1016/j.ab.2015.10.001
   Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209
   Morales Y, 2016, ARCH BIOCHEM BIOPHYS, V590, P138, DOI 10.1016/j.abb.2015.11.030
   Schapira M, 2016, CURR OPIN CHEM BIOL, V33, P81, DOI 10.1016/j.cbpa.2016.05.030
   Schapira M, 2014, MEDCHEMCOMM, V5, P1779, DOI 10.1039/c4md00269e
   Suárez-Calvet M, 2016, ACTA NEUROPATHOL, V131, P587, DOI 10.1007/s00401-016-1544-2
   Sun LT, 2011, P NATL ACAD SCI USA, V108, P20538, DOI 10.1073/pnas.1106946108
   Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308
   Walsh G, 2006, NAT BIOTECHNOL, V24, P1241, DOI 10.1038/nbt1252
   Wang CY, 2014, STRUCTURE, V22, P756, DOI 10.1016/j.str.2014.03.003
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Wang M, 2013, BIOCHEMISTRY-US, V52, P5430, DOI 10.1021/bi4005123
   Wang YC, 2014, CELL RES, V24, P143, DOI 10.1038/cr.2013.151
   Yang YZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7428
   Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
   Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6
   Zurita-Lopez CI, 2012, J BIOL CHEM, V287, P7859, DOI 10.1074/jbc.M111.336271
NR 40
TC 35
Z9 42
U1 1
U2 23
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 26
PY 2016
VL 291
IS 35
BP 18299
EP 18308
DI 10.1074/jbc.M116.740399
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DV9EC
UT WOS:000383241800022
PM 27387499
OA Green Published
DA 2025-01-12
ER

PT J
AU Li, YY
   Buckhaults, P
   Cui, XQ
   Tollefsbol, TO
AF Li, Yuanyuan
   Buckhaults, Phillip
   Cui, Xiangqin
   Tollefsbol, Trygve O.
TI Combinatorial epigenetic mechanisms and efficacy of early breast cancer
   inhibition by nutritive botanicals
SO EPIGENOMICS
LA English
DT Article
DE breast tumorigenesis; broccoli sprouts; EGCG; epigenetic; green tea;
   polyphenols; sulforaphane
ID BIOACTIVE DIETARY-COMPONENTS; GREEN TEA POLYPHENOL; ALPHA ER-ALPHA;
   CELL-LINES; DNA METHYLATION; GENE; THERAPY; SULFORAPHANE; PROGRESSION;
   EXPRESSION
AB Aim: Aberrant epigenetic events are important contributors to the pathogenesis of different types of cancers and dietary botanicals with epigenetic properties can influence early cancer development leading to cancer prevention effects. We sought to investigate potential combinatorial effects of bioactive dietary components including green tea polyphenols (GTPs) and broccoli sprouts (BSp) on neutralizing epigenetic aberrations during breast tumorigenesis. Materials & methods: The combinatorial effects were evaluated in a breast cancer transformation cellular system and breast cancer mouse xenografts. Results & conclusion: Combined treatment with epigallocatechin-3-gallate in GTPs and sulforaphane in BSp resulted in a synergistic inhibition of breast cancer cellular growth. Further studies revealed this combination led to genome-wide epigenetic alterations. Combinatorial diets significantly inhibited tumor growth in breast cancer mouse xenografts. Collectively, these studies indicate that combined GTPs and BSp are highly effective in inhibiting early breast cancer development by, at least in part, regulating epigenetic mechanisms.
C1 [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Buckhaults, Phillip] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.
   [Cui, Xiangqin] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of South Carolina System; University of South Carolina
   Columbia; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Li, YY (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.; Li, YY (通讯作者)，Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Li, YY (通讯作者)，Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
EM lyy@uab.edu
FU National Cancer Institute [R01 CA178441, R03 CA176766]; American
   Institute for Cancer Research [316184]
FX This work was supported by grants from the National Cancer Institute
   (R01 CA178441; R03 CA176766) and the American Institute for Cancer
   Research (316184). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Barbouti A, 2003, CANCER RES, V63, P1202
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Cammas L, 2007, DEV DYNAM, V236, P2899, DOI 10.1002/dvdy.21312
   CDC, 1999 2012 CANC INC M
   Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100
   Chen CY, 2011, J CELL MOL MED, V15, P14, DOI 10.1111/j.1582-4934.2010.01219.x
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   DeAngelis JT, 2011, J PROTEOME RES, V10, P447, DOI 10.1021/pr100533k
   Du HY, 2009, PROTEIN PEPTIDE LETT, V16, P486, DOI 10.2174/092986609788167824
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fang MZ, 2003, CANCER RES, V63, P7563
   Gordon JAR, 2011, CELLS TISSUES ORGANS, V194, P146, DOI 10.1159/000324790
   Guo SQ, 2005, J NUTR, V135, p2978S, DOI 10.1093/jn/135.12.2978S
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hanlon N, 2008, BRIT J NUTR, V99, P559, DOI 10.1017/S0007114507824093
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hays A, 2013, PHARM RES-DORDR, V30, P2260, DOI 10.1007/s11095-012-0962-7
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jäkel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411
   Jezierska A, 2006, MED SCI MONITOR, V12, pBR245
   Jiang M, 2009, FEBS LETT, V583, P2171, DOI 10.1016/j.febslet.2009.06.010
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054369
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Liang J, 2011, MOL CELL BIOL, V31, P2577, DOI 10.1128/MCB.05103-11
   Luft F, 2010, J MOL MED-JMM, V88, P1, DOI 10.1007/s00109-009-0570-0
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mitchell NE, 2013, EPIGENOMICS-UK, V5, P155, DOI [10.2217/EPI.13.6, 10.2217/epi.13.6]
   Montagna C, 2003, CANCER RES, V63, P2179
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Reubi JC, 1997, CANCER RES, V57, P1377
   Rodriguez V, 2007, GENE CHROMOSOME CANC, V46, P694, DOI 10.1002/gcc.20454
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Stevens VL, 2006, CANCER EPIDEM BIOMAR, V15, P1226, DOI 10.1158/1055-9965.EPI-05-0930
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Thakur VS, 2012, CURR PHARM BIOTECHNO, V13, P191
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Utsugi T, 1996, CANCER RES, V56, P2809
   Wang XH, 2011, ANN MED, V43, P347, DOI 10.3109/07853890.2011.573806
   Warren JD, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-133
   Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 59
TC 29
Z9 37
U1 2
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD AUG
PY 2016
VL 8
IS 8
BP 1019
EP 1037
DI 10.2217/epi-2016-0024
PG 19
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DU5JE
UT WOS:000382247200004
PM 27478970
OA Green Submitted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Strbenac, D
   Mann, GJ
   Yang, JYH
   Ormerod, JT
AF Strbenac, Dario
   Mann, Graham J.
   Yang, Jean Y. H.
   Ormerod, John T.
TI Differential distribution improves gene selection stability and has
   competitive classification performance for patient survival
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EXPRESSION ANALYSIS; BREAST-CANCER; VARIABILITY; CLASSIFIERS;
   PREDICTION; PROGNOSIS; RISK; METHYLATION; DISCOVERY; PROFILES
AB A consistent difference in average expression level, often referred to as differential expression (DE), has long been used to identify genes useful for classification. However, recent cancer studies have shown that when transcription factors or epigenetic signals become deregulated, a change in expression variability (DV) of target genes is frequently observed. This suggests that assessing the importance of genes by either differential expression or variability alone potentially misses sets of important biomarkers that could lead to improved predictions and treatments. Here, we describe a new approach for assessing the importance of genes based on differential distribution (DD), which combines information from differential expression and differential variability into a unified metric. We show that feature ranking and selection stability based on DD can perform two to three times better than DE or DV alone, and that DD yields equivalent error rates to DE and DV. Finally, assessing genes via differential distribution produces a complementary set of selected genes to DE and DV, potentially opening up new categories of biomarkers.
C1 [Strbenac, Dario; Yang, Jean Y. H.; Ormerod, John T.] Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia.
   [Mann, Graham J.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2060, Australia.
   [Mann, Graham J.] Univ Sydney, Ctr Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Ormerod, John T.] Univ Melbourne, ARC Ctr Excellence Math & Stat Frontiers, Parkville, Vic 3010, Australia.
C3 University of Sydney; University of Sydney; Melanoma Institute
   Australia; University of Sydney; Westmead Institute for Medical
   Research; University of Melbourne
RP Ormerod, JT (通讯作者)，Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia.; Ormerod, JT (通讯作者)，Univ Melbourne, ARC Ctr Excellence Math & Stat Frontiers, Parkville, Vic 3010, Australia.
EM john.ormerod@sydney.edu.au
RI Mann, Graham/G-4758-2014; Yang, Jean/D-2920-2015
OI Mann, Graham/0000-0003-1301-405X; Yang, Jean/0000-0002-5271-2603
FU Australian Government Department of Education and Training Australian
   Postgraduate Award; Australian Research Council DECRA Fellowship
   [DE130101670]; National Health and Medical Research Council of Australia
   Program [633004]; Australian Research Council Discovery [DP130100488];
   Cancer Institute New South Wales Translational Program [10TPG/1/02];
   Australian Research Council [DE130101670] Funding Source: Australian
   Research Council
FX Australian Government Department of Education and Training Australian
   Postgraduate Award (to D.S.); Australian Research Council DECRA
   Fellowship [DE130101670 to J.T.O.]; National Health and Medical Research
   Council of Australia Program [633004 to G.M.]; Australian Research
   Council Discovery [DP130100488 to J.Y.H.Y. and G.M.]; Cancer Institute
   New South Wales Translational Program [10TPG/1/02 to G.M.]. Funding for
   open access charge: Australian Research Council Discovery [DP130100488].
CR [Anonymous], 2013, Biological Knowledge Discovery Handbook, DOI DOI 10.1002/9781118617151.CH14
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Bar HY, 2014, J AM STAT ASSOC, V109, P537, DOI 10.1080/01621459.2014.884502
   Cun YP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-69
   Domany E, 2014, CANCER RES, V74, P4612, DOI 10.1158/0008-5472.CAN-13-3338
   Eschrich S, 2005, J CLIN ONCOL, V23, P3526, DOI 10.1200/JCO.2005.00.695
   Ferté C, 2013, CLIN CANCER RES, V19, P4315, DOI 10.1158/1078-0432.CCR-12-3937
   Ganzfried BF, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat013
   Ghosh AK, 2006, TECHNOMETRICS, V48, P120, DOI 10.1198/004017005000000391
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gunther EC, 2003, P NATL ACAD SCI USA, V100, P9608, DOI 10.1073/pnas.1632587100
   Haraksingh RR, 2013, J MOL BIOL, V425, P3970, DOI 10.1016/j.jmb.2013.07.015
   Ho JWK, 2008, BIOINFORMATICS, V24, pI390, DOI 10.1093/bioinformatics/btn142
   Hulse AM, 2013, GENETICS, V193, P95, DOI 10.1534/genetics.112.146779
   Jayawardana K, 2015, INT J CANCER, V136, P863, DOI 10.1002/ijc.29047
   Kim Y, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S2-S4
   Li L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-93
   Li XJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007013
   Lin WJ, 2013, BRIEF BIOINFORM, V14, P13, DOI 10.1093/bib/bbs006
   Lisowska KM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00006
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203
   Mostafavi S, 2014, J IMMUNOL, V193, P4485, DOI 10.4049/jimmunol.1401280
   Phipson B, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0465-4
   Rappaport N, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat018
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   ROUSSEEUW PJ, 1993, J AM STAT ASSOC, V88, P1273, DOI 10.2307/2291267
   Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871
   Strbenac D, 2015, BIOINFORMATICS, V31, P1851, DOI 10.1093/bioinformatics/btv066
   Takahashi M, 2010, SCHIZOPHR RES, V119, P210, DOI 10.1016/j.schres.2009.12.024
   Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170
   Tian L, 2011, BIOSTATISTICS, V12, P68, DOI 10.1093/biostatistics/kxq047
   Tofigh A, 2014, CELL REP, V9, P129, DOI 10.1016/j.celrep.2014.08.073
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Witten DM, 2011, ANN APPL STAT, V5, P2493, DOI 10.1214/11-AOAS493
NR 36
TC 14
Z9 14
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 27
PY 2016
VL 44
IS 13
AR e119
DI 10.1093/nar/gkw444
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DV5VR
UT WOS:000382999300004
PM 27190235
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Chen, HY
   Lin, LT
   Wang, ML
   Lee, SH
   Tsai, ML
   Tsai, CC
   Liu, WH
   Chen, TC
   Yang, YP
   Lee, YY
   Chang, YL
   Huang, PI
   Chen, YW
   Lo, WL
   Chiou, SH
   Chen, MT
AF Chen, Hsiao-Yun
   Lin, Liang-Ting
   Wang, Mong-Lien
   Lee, Shu-Hsien
   Tsai, Ming-Long
   Tsai, Chi-Chang
   Liu, Wei-Hsiu
   Chen, Tzu-Chien
   Yang, Yi-Ping
   Lee, Yi-Yen
   Chang, Yuh-Lih
   Huang, Pin-I
   Chen, Yi-Wei
   Lo, Wen-Liang
   Chiou, Shih-Hwa
   Chen, Ming-Teh
TI Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy
   and chemoresistance in glioblastoma
SO ONCOTARGET
LA English
DT Article
DE Musashi-1; apoptosis; IL-6; chemoresistance; GBM
ID RNA-BINDING PROTEIN; CELL MARKER MUSASHI-1; CANCER STEM-CELLS;
   NF-KAPPA-B; EPIGENETIC REGULATION; INTERLEUKIN-6 IL-6; PI3K/AKT PATHWAY;
   GENE-EXPRESSION; BREAST-CANCER; GLIOMA-CELLS
AB Glioblastoma multiform (GBM) is one of the most lethal human malignant brain tumors with high risks of recurrence and poor treatment outcomes. The RNA-binding protein Musashi-1 (MSI1) is a marker of neural stem/progenitor cells. Recent study showed that high expression level of MSI1 positively correlates with advanced grade of GBM, where MSI1 increases the growth of GBM. Herein, we explore the roles of MSI1 as well as the underlying mechanisms in the regulation of drug resistance and tumorigenesis of GBM cells. Our results demonstrated that overexpression of MSI1 effectively protected GBM cells from drug-induced apoptosis through down-regulating pro-apoptotic genes; whereas inhibition of AKT withdrew the MSI1-induced antiapoptosis and cell survival. We further showed that MSI1 robustly promoted the secretion of the pro-inflammatory cytokine IL-6, which was governed by AKT activity. Autonomously, the secreted IL-6 enhanced AKT activity in an autocrine/paracrine manner, forming a positive feedback regulatory loop with the MSI1-AKT pathway. Our results conclusively demonstrated a novel drug resistance mechanism in GBM cells that MSI1 inhibits drug-induced apoptosis through AKT/IL6 regulatory circuit. MSI1 regulates both cellular signaling and tumor-microenvironmental cytokine secretion to create an intra-and intercellular niche for GBM to survive from chemo-drug attack.
C1 [Chen, Hsiao-Yun; Tsai, Ming-Long; Yang, Yi-Ping; Lee, Yi-Yen; Huang, Pin-I; Chen, Yi-Wei; Lo, Wen-Liang; Chiou, Shih-Hwa; Chen, Ming-Teh] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Inst Clin Med, Taipei, Taiwan.
   [Lin, Liang-Ting; Wang, Mong-Lien; Lee, Shu-Hsien; Tsai, Chi-Chang; Chang, Yuh-Lih; Chiou, Shih-Hwa] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Inst Pharmacol, Taipei, Taiwan.
   [Chiou, Shih-Hwa; Chen, Ming-Teh] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Sch Med, Taipei, Taiwan.
   [Liu, Wei-Hsiu; Yang, Yi-Ping] Taipei Vet Gen Hosp, Grad Inst Med Sci, Dept Neurol Surg, Natl Def Med Ctr, Taipei, Taiwan.
   [Chen, Tzu-Chien; Chang, Yuh-Lih; Chiou, Shih-Hwa] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
   [Huang, Pin-I; Chen, Yi-Wei] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan.
   [Lo, Wen-Liang] Taipei Vet Gen Hosp, Div Oral & Maxillofacial Surg, Dept Stomatol, Taipei, Taiwan.
   [Lee, Yi-Yen; Chen, Ming-Teh] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; National Yang Ming Chiao Tung University; Taipei Veterans
   General Hospital; National Yang Ming Chiao Tung University; Taipei
   Veterans General Hospital; Taipei Veterans General Hospital; National
   Defense Medical Center; Taipei Veterans General Hospital; Taipei
   Veterans General Hospital; Taipei Veterans General Hospital; Taipei
   Veterans General Hospital
RP Chiou, SH; Chen, MT (通讯作者)，Natl Yang Ming Univ, Taipei Vet Gen Hosp, Inst Clin Med, Taipei, Taiwan.; Chiou, SH (通讯作者)，Natl Yang Ming Univ, Taipei Vet Gen Hosp, Inst Pharmacol, Taipei, Taiwan.; Chiou, SH; Chen, MT (通讯作者)，Natl Yang Ming Univ, Taipei Vet Gen Hosp, Sch Med, Taipei, Taiwan.; Chiou, SH (通讯作者)，Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.; Chen, MT (通讯作者)，Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
EM shchiou@vghtpe.gov.tw; mtchen@vghtpe.gov.tw
RI Chen, Chung-Hsuan/F-7940-2012; Chen, Jiming/AAA-3575-2020; Chen,
   Yi/JBR-7728-2023; chen, yuling/JMQ-4121-2023; Lin,
   Liang-Ting/AAF-4073-2020
OI Lin, Liang-Ting/0000-0003-2715-9567
FU NSC MOST [MOST 105-2633-B-009-003, MOST 104-2321-B-010-010, MOST
   1053-3011-B-010-001]; Taipei Veterans General Hospital [E99-101];
   Department of Health Cancer Center Research of Excellence
   [DOH101-TD-C-111-007]; Yen-Tjing-Ling Medical Foundation [CI-102/103];
   Ministry of Health and Welfare [MOHW105-TDU-B-211-133017,
   MOHW105-TDU-B211-134003]; NRPB Human iPSC Alliance-Core Service
   [MOST104-2325-B-001-010]; Genomic Center Project; National Yang-Ming
   University (Ministry of Education, Aim for the Top University Plan),
   Taiwan
FX This stuck, was funded by the NSC & MOST (MOST 105-2633-B-009-003, MOST
   104-2321-B-010-010, MOST 1053-3011-B-010-001), Taipei Veterans General
   Hospital (Stem Cell Project E99-101), The Department of Health Cancer
   Center Research of Excellence (DOH101-TD-C-111-007), Yen-Tjing-Ling
   Medical Foundation (CI-102/103), Ministry of Health and Welfare
   (MOHW105-TDU-B-211-133017, MOHW105-TDU-B211-134003), NRPB Human iPSC
   Alliance-Core Service (MOST104-2325-B-001-010), and The Genomic Center
   Project and Cancer Center Project of National Yang-Ming University
   (Ministry of Education, Aim for the Top University Plan), Taiwan.
CR Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006
   Bharadwaj U, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-106
   Bobryshev YV, 2010, DIS ESOPHAGUS, V23, P580, DOI 10.1111/j.1442-2050.2010.01061.x
   Chalaris A, 2007, BLOOD, V110, P1748, DOI 10.1182/blood-2007-01-067918
   Chen KL, 2015, LIVER INT, V35, P986, DOI 10.1111/liv.12458
   Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200
   Chen ZH, 2014, MOL CELL BIOCHEM, V385, P169, DOI 10.1007/s11010-013-1825-1
   Chiou GY, 2013, MOL CELL, V52, P693, DOI 10.1016/j.molcel.2013.11.009
   Cho HY, 2014, CELL IMMUNOL, V289, P27, DOI 10.1016/j.cellimm.2014.03.003
   Chou CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066268
   Cui L, 2012, CANCER BIOL THER, V13, P496, DOI 10.4161/cbt.19592
   Cui YP, 2015, MOL MED REP, V12, P7027, DOI 10.3892/mmr.2015.4236
   Dahlrot RH, 2013, J NEURO-ONCOL, V115, P453, DOI 10.1007/s11060-013-1246-8
   Denysenko T, 2010, CELL BIOCHEM FUNCT, V28, P343, DOI 10.1002/cbf.1666
   Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562
   Gallay N, 2009, LEUKEMIA, V23, P1029, DOI 10.1038/leu.2008.395
   Götte M, 2008, J PATHOL, V215, P317, DOI 10.1002/path.2364
   Hafizi S, 2005, FASEB J, V19, P971, DOI 10.1096/fj.04-2532fje
   Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312
   Hirota Y, 1999, MECH DEVELOP, V87, P93, DOI 10.1016/S0925-4773(99)00143-4
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Jourdan M, 2005, EUR CYTOKINE NETW, V16, P57
   Jourdan M, 2009, BRIT J HAEMATOL, V145, P45, DOI 10.1111/j.1365-2141.2008.07562.x
   Jung AS, 2011, CELL CYCLE, V10, P1838, DOI 10.4161/cc.10.11.15776
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Kawashima T, 2000, DEV GENES EVOL, V210, P162, DOI 10.1007/s004270050024
   Khor TO, 2004, CANCER LETT, V210, P139, DOI 10.1016/j.canlet.2004.01.017
   Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354
   Kim BH, 2008, ACTA PHARMACOL SIN, V29, P113, DOI 10.1111/j.1745-7254.2008.00725.x
   Kim MO, 2009, J CELL PHYSIOL, V219, P752, DOI 10.1002/jcp.21721
   Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014
   Kurihara Y, 1997, GENE, V186, P21, DOI 10.1016/S0378-1119(96)00673-7
   Lázár-Molnár E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614
   Leibovich-Rivkin T, 2013, NEOPLASIA, V15, P1330, DOI 10.1593/neo.131688
   Lin LT, 2013, MOL IMAGING BIOL, V15, P262, DOI 10.1007/s11307-012-0591-x
   Liu NL, 2015, FEBS LETT, V589, P897, DOI 10.1016/j.febslet.2015.02.026
   Liu QL, 2010, J NEURO-ONCOL, V100, P165, DOI 10.1007/s11060-010-0158-0
   Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P547, DOI 10.1007/s00401-007-0278-6
   McCubrey JA, 2008, ADV ENZYME REGUL, V48, P113, DOI 10.1016/j.advenzreg.2008.02.006
   McFarland BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078728
   Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648
   Muto J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033431
   Nagata T, 1999, J MOL BIOL, V287, P315, DOI 10.1006/jmbi.1999.2596
   Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007
   Okano H, 2002, J CELL SCI, V115, P1355
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015
   Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097
   Sanchez-Diaz PC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-280
   Sano M, 2000, BIOCHEM BIOPH RES CO, V269, P798, DOI 10.1006/bbrc.2000.2364
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Stupp Roger, 2005, Curr Neurol Neurosci Rep, V5, P198, DOI 10.1007/s11910-005-0047-7
   Sureban SM, 2008, GASTROENTEROLOGY, V134, P1448, DOI 10.1053/j.gastro.2008.02.057
   Tang CH, 2007, J IMMUNOL, V179, P1292, DOI 10.4049/jimmunol.179.2.1292
   Tchirkov A, 2007, BRIT J CANCER, V96, P474, DOI 10.1038/sj.bjc.6603586
   Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132
   Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878
   Wang Q, 2013, ANAT REC, V296, P1154, DOI 10.1002/ar.22723
   Wegiel B, 2008, INT J CANCER, V122, P1521, DOI 10.1002/ijc.23261
   Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455
   Yoda A, 2000, GENES CELLS, V5, P885, DOI 10.1046/j.1365-2443.2000.00378.x
   Yu ZY, 2015, ONCOTARGET, V6, P32930, DOI 10.18632/oncotarget.5405
   Zacharaki EI, CLASSIFICATION BRAIN, V62, P1609
   Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630
   Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200
NR 68
TC 46
Z9 49
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 5
PY 2016
VL 7
IS 27
BP 42485
EP 42501
DI 10.18632/oncotarget.9890
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DS7DI
UT WOS:000380942600120
PM 27285760
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Luzhna, L
   Kovalchuk, O
AF Luzhna, Lidia
   Kovalchuk, Olga
TI Mammary gland and radiation: Knowns and unknowns
SO CELL CYCLE
LA English
DT Article
DE breast cancer; epigenetics; gene expression; ionizing radiation; mammary
   gland; microRNA
ID LOW-DOSE RADIATION; BREAST-CANCER; IONIZING-RADIATION; APOPTOSIS; CELLS;
   FLUOROSCOPY; ACTIVATION; EXPOSURE; HORMESIS; MIR-34A
AB Effective breast cancer management and decreasing breast cancer fatalities is contingent upon reliable diagnostic procedures and treatment modalities, including those based on ionizing radiation. On the one hand, ionizing radiation is widely used for cancer diagnostics and therapy, on the other hand it is genotoxic cancer-causing agent. Here we discuss recent studies on the effects of low (diagnostic) and high (treatment) doses of ionizing radiation on healthy breast cells, breast cancer cells, and cancer cells resistant to common drug therapies.
C1 [Luzhna, Lidia; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, 4401 Univ Dr, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
CR BLACK DM, 1994, EUR J CANCER, V30A, P1957, DOI 10.1016/0959-8049(94)00386-J
   BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Boutis K, 2014, J EMERG MED, V47, P36, DOI 10.1016/j.jemermed.2014.01.030
   Calabrese EJ, 2003, ANNU REV PHARMACOL, V43, P175, DOI 10.1146/annurev.pharmtox.43.100901.140223
   Chandna S, 2002, RADIAT RES, V157, P516, DOI 10.1667/0033-7587(2002)157[0516:LDRHIH]2.0.CO;2
   Cherubini R, 2015, RADIAT PROT DOSIM, V166, P137, DOI 10.1093/rpd/ncv294
   Das S, 2015, J CLIN DIAGN RES, V9, pXC05
   Feinendegen LE, 2005, BRIT J RADIOL, V78, P3, DOI 10.1259/bjr/63353075
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hitchins MP, 2010, ADV GENET, V70, P201, DOI [10.1016/S0065-2660(10)70008-0, 10.1016/B978-0-12-380866-0.60008-3]
   Howe GR, 1996, RADIAT RES, V145, P694, DOI 10.2307/3579360
   Luzhna Lidia, 2015, Genes Cancer, V6, P71
   Luzhna Lidia, 2014, Oncoscience, V1, P751
   Luzhna L, 2015, ONCOTARGET, V6, P1678, DOI 10.18632/oncotarget.3188
   Morgan WF, 2013, RADIAT RES, V179, P501, DOI 10.1667/RR3306.1
   Mullenders L, 2009, NAT REV CANCER, V9, P596, DOI 10.1038/nrc2677
   Nowosielska EM, 2005, NUKLEONIKA, V50, pS21
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Russo J, 2000, J Natl Cancer Inst Monogr, P17
   Schüler E, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-29
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
NR 23
TC 2
Z9 2
U1 1
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2016
VL 15
IS 15
BP 1975
EP 1976
DI 10.1080/15384101.2016.1170262
PG 2
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DU5DR
UT WOS:000382232900011
PM 27392129
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Lo, PK
   Zhang, YS
   Wolfson, B
   Gernapudi, R
   Yao, Y
   Duru, N
   Zhou, Q
AF Lo, Pang-Kuo
   Zhang, Yongshu
   Wolfson, Benjamin
   Gernapudi, Ramkishore
   Yao, Yuan
   Duru, Nadire
   Zhou, Qun
TI Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis
   contributes to breast tumorigenesis
SO ONCOTARGET
LA English
DT Article
DE BRCA1; NEAT1; miR-129; WNT4; breast cancer stem cells
ID CARCINOMA IN-SITU; MAMMARY EPITHELIAL-CELLS; BASAL-LIKE PHENOTYPE;
   CANCER STEM-CELLS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; MUTATION
   CARRIERS; GLAND DEVELOPMENT; PROSTATE-CANCER; TUMORS
AB Dysregulation of long non-codng RNA (lncRNA) expression has been found to contribute to tumorigenesis. However, the roles of lncRNAs in BRCA1-related breast cancer remain largely unknown. In this study, we delineate the role of the novel BRCA1/lncRNA NEAT1 signaling axis in breast tumorigenesis. BRCA1 inhibits NEAT1 expression potentially through binding to its genomic binding site upstream of the NEAT1 gene. BRCA1 deficiency in human normal/cancerous breast cells and mouse mammary glands leads to NEAT1 overexpression. Our studies show that NEAT1 upregulation resulting from BRCA1 deficiency stimulates in vitro and in vivo breast tumorigenicity. We have further identified molecular mediators downstream of the BRCA1/NEAT1 axis. NEAT1 epigenetically silences miR-129-5p expression by promoting the DNA methylation of the CpG island in the miR-129 gene. Silencing of miR-129-5p expression by NEAT1 results in upregulation of WNT4 expression, a target of miR-129-5p, which leads to activation of oncogenic WNT signaling. Our functional studies indicate that this NEAT1/miR-129-5p/WNT4 axis contributes to the tumorigenic effects of BRCA1 deficiency. Finally our in silico expression correlation analysis suggests the existence of the BRCA1/NEAT1/miR-129-5p axis in breast cancer. Our findings, taken together, suggest that the dysregulation of the BRCA1/NEAT1/miR-129-5p/WNT4 signaling axis is involved in promoting breast tumorigenesis.
C1 [Lo, Pang-Kuo; Zhang, Yongshu; Wolfson, Benjamin; Gernapudi, Ramkishore; Yao, Yuan; Duru, Nadire; Zhou, Qun] Univ Maryland, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Zhou, Q (通讯作者)，Univ Maryland, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA.
EM qzhou@som.umaryland.edu
RI yao, yuan/AHB-5578-2022
OI Wolfson, Benjamin/0000-0001-5074-3193
FU ACS; NIH/NCI [CA163820A1, CA157779A1]
FX This work was supported by Grants from the ACS and NIH/NCI R01
   (CA163820A1 and CA157779A1).
CR Adriaens C, 2016, NAT MED, V22, P861, DOI 10.1038/nm.4135
   Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358
   Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929
   Bryan BB, 2006, MODERN PATHOL, V19, P617, DOI 10.1038/modpathol.3800570
   Buckley NE, 2012, STEM CELL REV REP, V8, P982, DOI 10.1007/s12015-012-9354-y
   Burga LN, 2009, CANCER RES, V69, P1273, DOI 10.1158/0008-5472.CAN-08-2954
   Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Cooper DR, 2014, GENES-BASEL, V5, P1050, DOI 10.3390/genes5041050
   Deng K, ACTA BIOCH IN PRESS
   Dimitrov SD, 2013, GENE DEV, V27, P2274, DOI 10.1101/gad.225045.113
   Duru N, 2016, ONCOTARGET, DOI 10.18632/oncotarget.10203
   Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Gorski JJ, 2011, NUCLEIC ACIDS RES, V39, P9536, DOI 10.1093/nar/gkr679
   Gu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.537
   Guo S, 2015, INT J CLIN EXP PATHO, V8, P5395
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Jensen Mette Munk, 2008, BMC Med Imaging, V8, P16, DOI 10.1186/1471-2342-8-16
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Leal JA, 2013, CANCER LETT, V338, P174, DOI 10.1016/j.canlet.2012.04.020
   Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226
   Li QL, 2014, J BIOL CHEM, V289, P1303, DOI 10.1074/jbc.M113.502278
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872
   Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0
   Pandey PR, 2013, ONCOGENE, V32, P5111, DOI 10.1038/onc.2012.519
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Pronina IV, 2016, GENE, V576, P483, DOI 10.1016/j.gene.2015.10.059
   Rajaram RD, 2015, EMBO J, V34, P641, DOI 10.15252/embj.201490434
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Rodríguez-Pinilla SM, 2007, J CLIN PATHOL, V60, P1006, DOI 10.1136/jcp.2006.042143
   Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837
   Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286
   Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522
   Sharma V, 2015, EMBO REP, V16, P1520, DOI 10.15252/embr.201540437
   Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Standaert L, 2014, RNA, V20, P1844, DOI 10.1261/rna.047332.114
   Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]
   Thike AA, 2013, J CLIN PATHOL, V66, P665, DOI 10.1136/jclinpath-2012-201428
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95
   Wu Q, 2014, ONCOTARGET, V5, P11552, DOI 10.18632/oncotarget.2594
   Xu J, 2007, ONCOGENE, V26, P2925, DOI 10.1038/sj.onc.1210088
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Zhang HX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10201
   Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932
   Zhang YS, 2012, J BIOL CHEM, V287, P41514, DOI 10.1074/jbc.M112.404871
   Zhen L, 2015, TUMOUR BIOL
NR 76
TC 79
Z9 87
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 4
PY 2016
VL 7
IS 40
BP 65067
EP 65089
DI 10.18632/oncotarget.11364
PG 23
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB3QQ
UT WOS:000387281000043
PM 27556296
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kong, SY
   Kim, KS
   Kim, J
   Kim, MK
   Lee, KH
   Lee, JY
   Oh, N
   Park, JI
   Park, JH
   Heo, SH
   Shim, SH
   Lee, DR
   Kim, KP
   Park, KS
AF Kong, Sun-Young
   Kim, Kwang-Soo
   Kim, Jiewan
   Kim, Min Kyeong
   Lee, Ki Hong
   Lee, Je-Yong
   Oh, Nuri
   Park, Ji-In
   Park, Ji-Hoon
   Heo, Sun-Hee
   Shim, Sung Han
   Lee, Dong Ryul
   Kim, Keun Pil
   Park, Kyung-Soon
TI The ELK3-GATA3 axis orchestrates invasion and metastasis of breast
   cancer cells <i>in vitro</i> and <i>in vivo</i>
SO ONCOTARGET
LA English
DT Article
DE ELK3; GATA3; metastasis; migration; invasion
ID EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; TRANSCRIPTION FACTOR;
   TUMOR-METASTASIS; FACTOR NET; EXPRESSION; GATA3; GROWTH; LINES
AB Triple-negative breast cancer is a highly aggressive tumor subtype that lacks effective therapeutic targets. Here, we show that ELK3 is overexpressed in a subset of breast cancers, in particular basal-like and normal-like/claudin-low cell lines. Suppression of ELK3 in MDA-MB-231 cells led to transdifferentiation from an invasive mesenchymal phenotype to a non-invasive epithelial phenotype both in vitro and in vivo. Suppression of ELK3 resulted in extensive changes in genome expression profiles. Among these, GATA3, a master suppressor of metastasis, was epigenetically activated. Also, suppression of GATA3 led to the restoration of migration and invasion. These results suggest that the ELK3-GATA3 axis is a major pathway that promotes metastasis of MDA-MB-231 cells.
C1 [Kim, Kwang-Soo; Kim, Jiewan; Lee, Je-Yong; Oh, Nuri; Park, Ji-In; Park, Ji-Hoon; Shim, Sung Han; Lee, Dong Ryul; Park, Kyung-Soon] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul, South Korea.
   [Kong, Sun-Young; Kim, Min Kyeong; Lee, Ki Hong] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Syst Canc Sci, Goyang Si, Gyeonggi Do, South Korea.
   [Kong, Sun-Young] Natl Canc Ctr, Res Inst, Translat Epidemiol Branch, Goyang Si, Gyeonggi Do, South Korea.
   [Kong, Sun-Young] Natl Canc Ctr, Hosp, Ctr Diagnost Oncol, Dept Lab Med, Goyang Si, Gyeonggi Do, South Korea.
   [Heo, Sun-Hee] Univ Ulsan, Biomed Res Ctr, Asan Inst Sci, Coll Med, Ulsan, South Korea.
   [Heo, Sun-Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Ulsan, South Korea.
   [Kim, Keun Pil] Chung Ang Univ, Dept Life Sci, Seoul, South Korea.
C3 Pochon Cha University; National Cancer Center - Korea (NCC); National
   Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC);
   University of Ulsan; University of Ulsan; Asan Medical Center; Chung Ang
   University
RP Park, KS (通讯作者)，CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul, South Korea.
EM kspark@cha.ac.kr
RI Kong, Sun-Young/ABB-7914-2021; H, sunny/AAR-5101-2020
FU Korea Science and Engineering Foundation of the Korean government (MOST)
   [2012M3A9C6050367]; Priority Research Centers Program through National
   Research Foundation of Korea (NRF) - Ministry of Education, Science, and
   Technology [2015R1A2A2A01003498, 2015M3A9C6028961]; National Cancer
   Center Grant [NCC-1210101]
FX This work was supported by the Korea Science and Engineering Foundation
   of the Korean government (MOST) (2012M3A9C6050367), and by the Priority
   Research Centers Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education, Science, and Technology
   (2015R1A2A2A01003498, 2015M3A9C6028961). This work was also supported by
   a National Cancer Center Grant (NCC-1210101).
CR Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139
   Calvo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078097
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Chu IM, 2012, ONCOGENE, V31, P2017, DOI 10.1038/onc.2011.382
   Chu IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061125
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003
   Ducret C, 1999, MOL CELL BIOL, V19, P7076
   Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126
   GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502
   Heo SH, 2015, GENE EXPRESSION, V16, P197, DOI 10.3727/105221615X14399878166276
   Humphries MJ, 2001, MOL BIOTECHNOL, V18, P57, DOI 10.1385/MB:18:1:57
   Li BW, 2008, TOHOKU J EXP MED, V216, P139, DOI 10.1620/tjem.216.139
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Robertson ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113050
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011
   Sloan KA, 2009, CARCINOGENESIS, V30, P1433, DOI 10.1093/carcin/bgp129
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   Yang H, 2015, ELIFE, V4, DOI 10.7554/eLife.10870
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503
NR 31
TC 30
Z9 31
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 4
PY 2016
VL 7
IS 40
BP 65137
EP 65146
DI 10.18632/oncotarget.11427
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB3QQ
UT WOS:000387281000047
PM 27556500
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Lo, PK
   Lee, JS
   Liang, XH
   Sukumar, S
AF Lo, Pang-Kuo
   Lee, Ji Shin
   Liang, Xiaohui
   Sukumar, Saraswati
TI The dual role of FOXF2 in regulation of DNA replication and the
   epithelial-mesenchymal transition in breast cancer progression
SO CELLULAR SIGNALLING
LA English
DT Article
DE FOXF2; DNA methylation; Epithelial-to-mesenchymal transition;
   Basal-like/triple-negative breast cancer; Luminal breast cancer;
   HER2-positive breast cancer
ID BOX TRANSCRIPTION FACTORS; GENE FOXF1; CELL-LINES; EXPRESSION; SUBTYPES;
   BASAL; LUNG; REREPLICATION; PATHWAY; F1
AB Dysregulation of Forkhead-box (FOX) transcription factors is linked to cancers of numerous tissue types. Here, we report that FOXF2 is frequently silenced in luminal-type and HER2-positive breast cancers, but is overexpressed in basal-like breast cancers; thus, FOXF2 appears to play distinct roles in different breast cancer subtypes. Inactivation of FOXF2 in luminal-type and HER2-positive breast cancers is attributable to epigenetic silencing. Silencing of FOXF2 is associated with poor prognosis in luminal-type breast cancer. Ectopic expression of FOXF2 in luminal and HER2-positive breast cancer cells suppresses their tumorigenic properties in vitro and in vivo via inhibition of the CDK2-RB-E2F cascade. The in vivo function of FOXF2 is to maintain the stringency of DNA replication, and its loss triggers dysregulation of DNA replication, which in turn activates the p53 checkpoint pathway. Besides its role in cell cycle regulation, FOXF2 is functionally required for mobility and epithelial-to-mesenchymal transition (EMT) of normal breast epithelial cells. In basal-like breast cancer cells, the cell cycle function of FOXF2 is impaired. However, the EMT function of FOXF2 is still required for mobility, invasiveness and anchorage-independent growth of basal-like breast cancer cells. Our gene expression profiling studies demonstrate that FOXF2 regulates the expression of genes implicated in cell cycle and EMT regulation. Moreover, FOXF2 is highly co-expressed with basal- and metastasis-related genes in breast cancer. These findings suggest that FOXF2 has a dual role in breast tumorigenesis and functions as either a tumor suppressor or an oncogene depending on the breast tumor subtype. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1,Room 143, Baltimore, MD 21231 USA.
   [Lee, Ji Shin] Chonnam Natl Univ, Sch Med, Dept Pathol, Gwangju, South Korea.
   [Lee, Ji Shin] Res Inst, Gwangju, South Korea.
   [Liang, Xiaohui] Wuhan Univ, Sch Publ Hlth, Wuhan, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins Medicine; Chonnam National
   University; Wuhan University
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1,Room 143, Baltimore, MD 21231 USA.; Lo, PK (通讯作者)，Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.
EM PLo@som.umaryland.edu; saras@jhmi.edu
FU National Institutes of Health [SPORE-1 P50 CA088843-08]; Department of
   Defense [W81XWH-04-1-0595]
FX The work was supported by the National Institutes of Health [grant
   number: SPORE-1 P50 CA088843-08] and the Department of Defense [grant
   number: Center of Excellence-W81XWH-04-1-0595] to SS. We thank Dr. W.
   Kaelin, Dana-Farber Cancer Institute at Boston, for kindly providing the
   promoter-reporter plasmid of DNA polymerase a gene and E2F1 expression
   plasmids (wild-type and E132 mutant); and Dr. P. Carlsson, Goteborg
   University, Sweden, for kindly providing reporter plasmids pApo-Luc and
   p4XFREAC-Luc.
CR Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493
   Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518
   Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663
   Cai J, 2015, CANCER LETT, V367, P129, DOI 10.1016/j.canlet.2015.07.001
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488
   Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005
   ELSTON CW, 1990, HISTOPATHOLOGY, V16, P109
   FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JOP.777003, 10.5858/134.6.907, 10.1200/JCO.2009.25.6529]
   Hellqvist M, 1996, J BIOL CHEM, V271, P4482
   Hilmarsdottir B, 2014, GENES-BASEL, V5, P804, DOI 10.3390/genes5030804
   Hirata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055502
   Hook SS, 2007, CURR OPIN CELL BIOL, V19, P663, DOI 10.1016/j.ceb.2007.10.007
   Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614
   Jackson Brian C., 2010, Human Genomics, V4, P345
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008-5472.CAN-10-2993
   Kong PZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061591
   Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2012, CELL SIGNAL, V24, P316, DOI 10.1016/j.cellsig.2011.09.017
   Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576
   Mahlapuu M, 2001, DEVELOPMENT, V128, P2397
   Mahlapuu M, 2001, DEVELOPMENT, V128, P155
   Malin D, 2007, MOL CELL BIOL, V27, P2486, DOI 10.1128/MCB.01736-06
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677
   Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Saito RA, 2010, CANCER RES, V70, P2644, DOI 10.1158/0008-5472.CAN-09-3644
   Schneider DJ, 2012, FASEB J, V26, P503, DOI 10.1096/fj.11-186098
   SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544
   Shao JW, 2015, FEBS OPEN BIO, V5, P893, DOI 10.1016/j.fob.2015.10.009
   Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008-5472.CAN-06-0452
   Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tian HP, 2015, J BIOL CHEM, V290, P19173, DOI 10.1074/jbc.M114.636126
   van der Heul-Nieuwenhuijsen L, 2009, PROSTATE, V69, P1538, DOI 10.1002/pros.20996
   Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6
   Wang QS, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0531-1
   Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166
   Xu JY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005769
   Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012
   Zhang Y, 2015, ONCOL REP, V33, P2592, DOI 10.3892/or.2015.3833
   Zheng YZ, 2015, MOL CLIN ONCOL, V3, P713, DOI 10.3892/mco.2015.511
   Zhu H, 2016, LIFE SCI, V144, P194, DOI 10.1016/j.lfs.2015.12.001
   Zhu H, 2014, ONCOL REP, V32, P1327, DOI 10.3892/or.2014.3357
NR 62
TC 28
Z9 32
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2016
VL 28
IS 10
BP 1502
EP 1519
DI 10.1016/j.cellsig.2016.06.021
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DU6UW
UT WOS:000382351100007
PM 27377963
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Parisi, C
   Mastoraki, S
   Markou, A
   Strati, A
   Chimonidou, M
   Georgoulias, V
   Lianidou, ES
AF Parisi, C.
   Mastoraki, S.
   Markou, A.
   Strati, A.
   Chimonidou, M.
   Georgoulias, V.
   Lianidou, E. S.
TI Development and validation of a multiplex methylation specific
   PCR-coupled liquid bead array for liquid biopsy analysis
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Liquid biopsy; Circulating tumor cells; Circulating tumor DNA; DNA
   methylation; Methylation specific PCR; Breast cancer
ID CIRCULATING TUMOR-CELLS; PROVIDES PROGNOSTIC INFORMATION; SOX17 PROMOTER
   METHYLATION; BREAST-CANCER; DNA METHYLATION; MOLECULAR CHARACTERIZATION;
   METASTASIS SUPPRESSOR; IMPRINT METHYLATION; CANDIDATE GENES; EXPRESSION
AB Background: Liquid biopsy is based on minimally invasive blood tests and has the potential to characterize the evolution of a solid tumor in real time, by extracting molecular information from circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Epigenetic silencing of tumor and metastasis suppressor genes plays a key role in survival and metastatic potential of cancer cells. Our group was the first to show the presence of epigenetic alterations in CTCs.
   Methods: We present the development and analytical validation of a highly specific and sensitive Multiplex Methylation Specific PCR-coupled liquid bead array (MMSPA) for the simultaneous detection of the methylation status of three tumor and metastasis suppressor genes (CST6, SOX17 and BRMS1) in liquid biopsy material (CTCs, corresponding ctDNA) and paired primary breast tumors.
   Results: In the EpCAM-positive CFCs fraction we observed methylation of: a) CST6, in 11/30(37%) and 11/30(37%), b) BRMS1 in 8/30(27%) and 11/30(37%) c) SOX17 in 8/30(27%) and 13/30(43%) early breast cancer patients and patients with verified metastasis respectively. In ctDNA we observed methylation of: a) CST6, in 5/30(17%) and 10/31(32%), b) BRMS1 in 8/30 (27%) and 8/31 (26%) c) SOX17 in 5/30(17%) and 13/31(42%) early breast cancer patients and patients with verified metastasis respectively.
   Conclusions: Our results indicate a high cancerous load at the epigenetic level in EpCAM-positive CFCs fractions and corresponding ctDNA in breast cancer. The main principle of the developed methodology has the potential to be extended in a large number of gene-targets and be applied in many types of cancer. (C) 2016 Published by Elsevier B.V.
C1 [Parisi, C.; Mastoraki, S.; Markou, A.; Strati, A.; Chimonidou, M.; Lianidou, E. S.] Univ Athens, Dept Chem, Analyt Chem Lab, Anal Circulating Tumor Cells Lab, Athens 15771, Greece.
   [Georgoulias, V.] Univ Crete, Dept Med Oncol, Iraklion 71110, Crete, Greece.
C3 National & Kapodistrian University of Athens; University of Crete
RP Lianidou, ES (通讯作者)，Univ Athens, Dept Chem, Analyt Chem Lab, Anal Circulating Tumor Cells Lab, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
RI Strati, Areti/AIE-5421-2022; Markou, Athina/AAY-7110-2020
OI Mastoraki, Sofia/0000-0001-8140-6106; Lianidou, Evi/0000-0002-7796-5914;
   Markou, Athina/0000-0001-7760-9701; Parisi, Cleo/0000-0002-2907-4025
FU European Union Seventh Framework Programme for the Innovative Medicine
   Initiative [115749]; "Onco-Seed diagnostics" grant, under Sinergasia
   program; European Regional Development Fund; National Resources (General
   Secretariat of Research and Technology in Greece) [09SigmagammaN-11-902]
FX This work was supported by the European Union Seventh Framework
   Programme (FP7/2007-2013) for the Innovative Medicine Initiative [grant
   agreement no 115749] and partly by "Onco-Seed diagnostics" grant, under
   the Sinergasia 2009 program that was co-funded by the European Regional
   Development Fund and National Resources (General Secretariat of Research
   and Technology in Greece), Project code: Onco-Seed diagnostics (grant
   agreement no 09 Sigma gamma N-11-902).
CR Alix-Panabières C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820
   Balgkouranidou I, 2014, BRIT J CANCER, V110, P2054, DOI 10.1038/bjc.2014.104
   Balgkouranidou I, 2013, CLIN CHEM LAB MED, V51, P1505, DOI 10.1515/cclm-2012-0320
   Beck BH, 2010, EUR J CANCER, V46, P1283, DOI 10.1016/j.ejca.2010.02.023
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Du YC, 2009, GASTROENTEROLOGY, V137, P1346, DOI 10.1053/j.gastro.2009.06.041
   Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023
   Fu DY, 2010, BREAST CANCER RES TR, V119, P601, DOI 10.1007/s10549-009-0339-8
   Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hiura H, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-8
   Ignatiadis M, 2014, ANN ONCOL, V25, P2304, DOI 10.1093/annonc/mdu480
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanwal R, 2015, METHODS MOL BIOL, V1238, P3, DOI 10.1007/978-1-4939-1804-1_1
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LEON SA, 1977, CANCER RES, V37, P646
   Li ZB, 2015, BREAST CANCER RES TR, V149, P767, DOI 10.1007/s10549-015-3276-8
   Lianidou ES, 2014, CLIN CHEM, V60, P1249, DOI 10.1373/clinchem.2014.230144
   Lianidou ES, 2014, CRIT REV CL LAB SCI, V51, P160, DOI 10.3109/10408363.2014.896316
   Markou A, 2011, CLIN CHEM, V57, P421, DOI 10.1373/clinchem.2010.154328
   Marzese DM, 2013, EXPERT REV MOL DIAGN, V13, P827, DOI 10.1586/14737159.2013.845088
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192
   Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030
   Pavlidis P, 2003, BIOINFORMATICS, V19, P295, DOI 10.1093/bioinformatics/19.2.295
   Pixberg CF, 2015, GENES-BASEL, V6, P1053, DOI 10.3390/genes6041053
   Potter NT, 2014, CLIN CHEM, V60, P1183, DOI 10.1373/clinchem.2013.221044
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Sato A, 2011, FERTIL STERIL, V95, P129, DOI 10.1016/j.fertnstert.2010.06.076
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117
   Snellenberg S, 2012, VIROLOGY, V422, P357, DOI 10.1016/j.virol.2011.11.006
   Spruijt CG, 2014, NAT STRUCT MOL BIOL, V21, P949, DOI 10.1038/nsmb.2910
   Vorkas PA, 2010, J MOL DIAGN, V12, P697, DOI 10.2353/jmoldx.2010.100008
   Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369
NR 42
TC 10
Z9 10
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD OCT 1
PY 2016
VL 461
BP 156
EP 164
DI 10.1016/j.cca.2016.08.003
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA DW8ZM
UT WOS:000383944000026
PM 27510924
DA 2025-01-12
ER

PT J
AU Li, YX
   Seto, E
AF Li, Yixuan
   Seto, Edward
TI HDACs and HDAC Inhibitors in Cancer Development and Therapy
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; HUMAN BREAST-CANCER;
   EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCELLULAR-CARCINOMA; ACUTE
   MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; DNA-DAMAGE RESPONSE; PHASE-I;
   POOR-PROGNOSIS; BIOLOGICAL EVALUATION
AB Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied post-translational histone modification, is controlled by the opposing activities of histone acetyl-transferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.
C1 [Li, Yixuan; Seto, Edward] George Washington Univ, Ctr Canc, Dept Biochem & Mol Med, Washington, DC 20037 USA.
C3 George Washington University
RP Seto, E (通讯作者)，George Washington Univ, Ctr Canc, Dept Biochem & Mol Med, Washington, DC 20037 USA.
EM seto@gwu.edu
RI li, yixuan/P-5376-2016
OI Li, Yixuan/0000-0002-3550-8192
FU National Institutes of Health (NIH) [R01CA169210, R01CA187040]
FX This work is supported in part by National Institutes of Health (NIH)
   Grants R01CA169210 and R01CA187040 to E.S.
CR Adams H, 2010, EXPERT OPIN THER TAR, V14, P577, DOI 10.1517/14728221003796609
   Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060
   Ahn MY, 2015, ONCOL REP, V33, P1899, DOI 10.3892/or.2015.3776
   Ahrens TD, 2015, EPIGENETICS-US, V10, P431, DOI 10.1080/15592294.2015.1039216
   Aldana-Masangkay GI, 2011, LEUKEMIA LYMPHOMA, V52, P1544, DOI 10.3109/10428194.2011.570821
   Amengual JE, 2015, CLIN CANCER RES, V21, P4663, DOI 10.1158/1078-0432.CCR-14-3068
   Bajbouj K, 2012, J NEURO-ONCOL, V107, P503, DOI 10.1007/s11060-011-0791-2
   Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9
   Banerji U, 2012, CLIN CANCER RES, V18, P2687, DOI 10.1158/1078-0432.CCR-11-3165
   Bangert A, 2012, ONCOGENE, V31, P4677, DOI 10.1038/onc.2011.614
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Beagle BR, 2015, ONCOTARGET, V6, P2088, DOI 10.18632/oncotarget.2992
   Bergman JA, 2012, J MED CHEM, V55, P9891, DOI 10.1021/jm301098e
   Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022
   Bilen MA, 2015, CANCER CHEMOTH PHARM, V75, P869, DOI 10.1007/s00280-015-2695-x
   Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910
   Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313
   Brunetto AT, 2013, CLIN CANCER RES, V19, P5494, DOI 10.1158/1078-0432.CCR-13-0735
   Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v
   Buurman R, 2012, GASTROENTEROLOGY, V143, P811, DOI 10.1053/j.gastro.2012.05.033
   Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612
   Cai X, 2010, J MED CHEM, V53, P2000, DOI 10.1021/jm901453q
   Cao K, 2015, ONCOGENE, V34, P5960, DOI 10.1038/onc.2015.46
   Cha TL, 2009, CLIN CANCER RES, V15, P840, DOI 10.1158/1078-0432.CCR-08-1918
   Chen IC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-254
   Chen SY, 2015, CELL CYCLE, V14, P2520, DOI 10.1080/15384101.2015.1055426
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Choy E, 2015, CANCER-AM CANCER SOC, V121, P1223, DOI 10.1002/cncr.29175
   Christiansen AJ, 2011, P NATL ACAD SCI USA, V108, P4141, DOI 10.1073/pnas.1011037108
   Chun P, 2015, ARCH PHARM RES, V38, P933, DOI 10.1007/s12272-015-0571-1
   Colarossi L, 2014, PROTEOM CLIN APPL, V8, P924, DOI 10.1002/prca.201400058
   Conrad E, 2016, CELL DEATH DIFFER, V23, P110, DOI 10.1038/cdd.2015.75
   Conti C, 2010, CANCER RES, V70, P4470, DOI 10.1158/0008-5472.CAN-09-3028
   de Cremoux P, 2015, BREAST CANCER RES TR, V149, P81, DOI 10.1007/s10549-014-3233-y
   Dong LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-53
   Dong M, 2012, CANCER CHEMOTH PHARM, V69, P1413, DOI 10.1007/s00280-012-1847-5
   Dowling DP, 2008, BIOCHEMISTRY-US, V47, P13554, DOI 10.1021/bi801610c
   Duan WW, 2015, BIOORGAN MED CHEM, V23, P4481, DOI 10.1016/j.bmc.2015.06.015
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Ecker J, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0201-7
   Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Fan J, 2014, TUMOR BIOL, V35, P11523, DOI 10.1007/s13277-014-2358-2
   Feng GW, 2014, EUR REV MED PHARMACO, V18, P811
   Feng LF, 2013, J MOL MED, V91, P49, DOI 10.1007/s00109-012-0932-x
   Fischer C, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-4
   Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119
   Fleming CL, 2014, J MED CHEM, V57, P1132, DOI 10.1021/jm401945k
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020
   Frye R, 2012, CLIN J ONCOL NURS, V16, P195, DOI 10.1188/12.CJON.195-204
   Furumai R, 2002, CANCER RES, V62, P4916
   Galli M, 2010, ANN HEMATOL, V89, P185, DOI 10.1007/s00277-009-0793-8
   Galloway TJ, 2015, CLIN CANCER RES, V21, P1566, DOI 10.1158/1078-0432.CCR-14-2820
   Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055
   Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007
   Gruhn B, 2013, LEUKEMIA RES, V37, P1200, DOI 10.1016/j.leukres.2013.07.016
   Gryder BE, 2013, J MED CHEM, V56, P5782, DOI 10.1021/jm400467w
   Guerrant W, 2013, BIOORG MED CHEM LETT, V23, P3283, DOI 10.1016/j.bmcl.2013.03.108
   Guha M, 2015, NAT REV DRUG DISCOV, V14, P226, DOI 10.1038/nrd4583
   Gupta M, 2012, LEUKEMIA, V26, P1356, DOI 10.1038/leu.2011.340
   Guzman ML, 2014, MOL CANCER THER, V13, P1979, DOI 10.1158/1535-7163.MCT-13-0963
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Halsall JA, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0021-9
   Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Huang WJ, 2012, CHEMMEDCHEM, V7, P1815, DOI 10.1002/cmdc.201200300
   Huang ZM, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0111-1
   Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674
   Hui KF, 2014, INT J CANCER, V135, P2950, DOI 10.1002/ijc.28924
   Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280-000000000-00000
   Ishikawa S, 2014, INT J CANCER, V135, P2528, DOI 10.1002/ijc.28672
   Jazirehi AR, 2014, J IMMUNOL, V192, P3981, DOI 10.4049/jimmunol.1302532
   Jin ZL, 2014, INT J CLIN EXP PATHO, V7, P5872
   Juengel E, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-152
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Jung KH, 2012, J CELL BIOCHEM, V113, P2167, DOI 10.1002/jcb.24090
   Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049
   Kaliszczak M, 2013, BRIT J CANCER, V108, P342, DOI 10.1038/bjc.2012.576
   Kaluza D, 2013, ARTERIOSCL THROM VAS, V33, P533, DOI 10.1161/ATVBAHA.112.300415
   Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298
   Kang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.422
   Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065
   Karthik S, 2014, BIOMED PHARMACOTHER, V68, P327, DOI 10.1016/j.biopha.2014.01.002
   Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Kikuchi S, 2015, LEUKEMIA, V29, P1918, DOI 10.1038/leu.2015.83
   Kim JK, 2013, MOL CANCER RES, V11, P62, DOI 10.1158/1541-7786.MCR-12-0332
   Knipstein J, 2011, EXPERT OPIN INV DRUG, V20, P1455, DOI 10.1517/13543784.2011.613822
   Koeneke E, 2015, CELLS-BASEL, V4, P135, DOI 10.3390/cells4020135
   Kong HS, 2012, PHARM RES-DORDR, V29, P3373, DOI 10.1007/s11095-012-0832-3
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Koprinarova M, 2011, DNA REPAIR, V10, P970, DOI 10.1016/j.dnarep.2011.07.003
   Kotian S, 2011, J BIOL CHEM, V286, P7722, DOI 10.1074/jbc.C110.194233
   Kraker AJ, 2003, MOL CANCER THER, V2, P401
   KrennHrubec K, 2007, BIOORG MED CHEM LETT, V17, P2874, DOI 10.1016/j.bmcl.2007.02.064
   Lachenmayer A, 2012, J HEPATOL, V56, P1343, DOI 10.1016/j.jhep.2012.01.009
   Lamblin M, 2010, BIOORGAN MED CHEM, V18, P4119, DOI 10.1016/j.bmc.2010.03.078
   Lee H, 2004, MOL CELL BIOL, V24, P765, DOI 10.1128/MCB.24.2.765-773.2004
   Lee HY, 2014, J MED CHEM, V57, P4009, DOI 10.1021/jm401899x
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee JY, 2010, J CELL BIOL, V189, P671, DOI 10.1083/jcb.201001039
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Lee JH, 2013, P NATL ACAD SCI USA, V110, P15704, DOI 10.1073/pnas.1313893110
   Lee SH, 2014, INT J MED SCI, V11, P994, DOI 10.7150/ijms.8522
   Li DW, 2014, PROTEIN CELL, V5, P214, DOI 10.1007/s13238-013-0010-3
   Li S, 2015, TUMOR BIOL, V36, P9661, DOI 10.1007/s13277-015-3747-x
   Li YX, 2015, MOL CELL BIOL, V35, P3547, DOI 10.1128/MCB.00400-15
   Li Y, 2006, GENE DEV, V20, P2566, DOI 10.1101/gad.1455006
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067
   Liao W, 2013, AM J CANCER RES, V3, P374
   Liffers K, 2016, TARGET ONCOL, V11, P29, DOI 10.1007/s11523-015-0372-y
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Lin YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123935
   Liu KP, 2013, BIOCHEM BIOPH RES CO, V441, P970, DOI 10.1016/j.bbrc.2013.11.007
   Lobera M, 2013, NAT CHEM BIOL, V9, P319, DOI [10.1038/NCHEMBIO.1223, 10.1038/nchembio.1223]
   Locatelli SL, 2014, LEUKEMIA, V28, P1861, DOI 10.1038/leu.2014.81
   Lopez G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133302
   Luna Augustin, 2013, Genome Integr, V4, P6, DOI 10.1186/2041-9414-4-6
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Lv Z, 2016, MOL CARCINOGEN, V55, P1024, DOI 10.1002/mc.22345
   Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a
   Malvaez M, 2013, P NATL ACAD SCI USA, V110, P2647, DOI 10.1073/pnas.1213364110
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723
   Marek L, 2013, J MED CHEM, V56, P427, DOI 10.1021/jm301254q
   Marquard L, 2008, HISTOPATHOLOGY, V53, P267, DOI [10.1111/j.1365-2559.2008.03109.x, 10.1111/j.0309-0167.2008.03109.x]
   Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x
   Matsuba S, 2014, J PHARMACOL EXP THER, V351, P510, DOI 10.1124/jpet.114.217315
   McDermott J, 2014, DRUG TODAY, V50, P337, DOI 10.1358/dot.2014.50.5.2138703
   McGraw AL, 2013, AM J HEALTH-SYST PH, V70, P1115, DOI 10.2146/ajhp120163
   Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396
   Methot JL, 2008, BIOORG MED CHEM LETT, V18, P973, DOI 10.1016/j.bmcl.2007.12.031
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395
   Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899
   Min SK, 2012, KOREAN J PATHOL, V46, P142, DOI 10.4132/KoreanJPathol.2012.46.2.142
   Minami J, 2014, LEUKEMIA, V28, P680, DOI 10.1038/leu.2013.231
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Minamiya Y, 2010, TUMOR BIOL, V31, P533, DOI 10.1007/s13277-010-0066-0
   Mishima Y, 2015, BRIT J HAEMATOL, V169, P423, DOI 10.1111/bjh.13315
   Mithraprabhu S, 2014, EPIGENETICS-US, V9, P1511, DOI 10.4161/15592294.2014.983367
   Moffat D, 2010, J MED CHEM, V53, P8663, DOI 10.1021/jm101177s
   Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x
   Moresi V, 2012, P NATL ACAD SCI USA, V109, P1649, DOI 10.1073/pnas.1121159109
   Morschhauser F, 2015, INVEST NEW DRUG, V33, P423, DOI 10.1007/s10637-015-0206-x
   Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Murakami T, 2008, J INVEST DERMATOL, V128, P1506, DOI 10.1038/sj.jid.5701216
   Nakashima H, 2015, J BIOL CHEM, V290, P1485, DOI 10.1074/jbc.M114.593871
   Newbold A, 2013, MOL CANCER THER, V12, P2709, DOI 10.1158/1535-7163.MCT-13-0626
   Niegisch G, 2013, UROL ONCOL-SEMIN ORI, V31, P1770, DOI 10.1016/j.urolonc.2012.06.015
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684
   Olsen CA, 2012, ACS MED CHEM LETT, V3, P749, DOI 10.1021/ml300162r
   Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Ouaïssi M, 2008, ANN SURG ONCOL, V15, P2318, DOI 10.1245/s10434-008-9940-z
   Ouaïssi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108520
   Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13
   Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582
   Park J, 2015, EPIGENOMICS-UK, V7, P641, DOI [10.2217/epi.15.16, 10.2217/EPI.15.16]
   Pauer LR, 2004, CANCER INVEST, V22, P886, DOI 10.1081/CNV-200039852
   Peng LR, 2015, J BIOL CHEM, V290, P8904, DOI 10.1074/jbc.M114.612796
   Poyet C, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-10
   Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102
   Qian CG, 2012, CLIN CANCER RES, V18, P4104, DOI 10.1158/1078-0432.CCR-12-0055
   Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0
   Radhakrishnan R, 2015, J BIOL CHEM, V290, P22795, DOI 10.1074/jbc.M114.612945
   Raha P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0533-z
   Ray A, 2013, J BIOL CHEM, V288, P27232, DOI 10.1074/jbc.M113.481184
   Reid T, 2004, LUNG CANCER, V45, P381, DOI 10.1016/j.lungcan.2004.03.002
   Rettig I, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.24
   Rhodes LV, 2014, BREAST CANCER RES TR, V145, P593, DOI 10.1007/s10549-014-2979-6
   Richardson PG, 2015, EXPERT REV ANTICANC, V15, P737, DOI 10.1586/14737140.2015.1047770
   Riley JS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.481
   Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773
   Saijo K, 2015, CANCER SCI, V106, P208, DOI 10.1111/cas.12585
   Saijo K, 2012, CANCER SCI, V103, P1994, DOI 10.1111/cas.12002
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365
   Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988
   Schölz C, 2015, NAT BIOTECHNOL, V33, P415, DOI 10.1038/nbt.3130
   Schroeder FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071323
   Schüler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Seo HW, 2009, FEBS LETT, V583, P55, DOI 10.1016/j.febslet.2008.11.044
   Seo J, 2014, J BREAST CANCER, V17, P323, DOI 10.4048/jbc.2014.17.4.323
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shi WY, 2014, J NEURO-ONCOL, V118, P313, DOI 10.1007/s11060-014-1433-2
   Shi Y, 2015, ANN ONCOL, V26, P1766, DOI 10.1093/annonc/mdv237
   Shi Y, 2015, ONCOL REP, V34, P399, DOI 10.3892/or.2015.3986
   Shimizu T, 2014, CLIN CANCER RES, V20, P5032, DOI 10.1158/1078-0432.CCR-14-0570
   Shukla S, 2015, CANCER PREV RES, V8, P552, DOI 10.1158/1940-6207.CAPR-14-0286
   Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019
   Sodji QH, 2015, EUR J MED CHEM, V96, P340, DOI 10.1016/j.ejmech.2015.04.014
   Son CH, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-49
   Song CL, 2013, J BIOL CHEM, V288, P28021, DOI 10.1074/jbc.M113.498758
   Sonnemann J, 2014, BRIT J CANCER, V110, P656, DOI 10.1038/bjc.2013.742
   Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152
   Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111
   Stypula-Cyrus Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064600
   Sudo T, 2011, ONCOL REP, V26, P777, DOI 10.3892/or.2011.1361
   Sun LD, 2015, EMBO REP, V16, P689, DOI 10.15252/embr.201439792
   Suzuki T, 2014, CHEMMEDCHEM, V9, P657, DOI 10.1002/cmdc.201300414
   Suzuki T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068669
   Suzuki T, 2012, J MED CHEM, V55, P9562, DOI 10.1021/jm300837y
   Takasaka N, 2014, J IMMUNOL, V192, P958, DOI 10.4049/jimmunol.1302341
   Tang C, 2015, J MED CHEM, V58, P4550, DOI 10.1021/acs.jmedchem.5b00099
   Taylor BS, 2011, CANCER DISCOV, V1, P587, DOI 10.1158/2159-8290.CD-11-0181
   Thurn KT, 2013, MOL CANCER THER, V12, P2078, DOI 10.1158/1535-7163.MCT-12-1242
   Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018
   Tomosugi M, 2012, CANCER SCI, V103, P2139, DOI 10.1111/cas.12012
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002
   Turtoi A, 2012, ANGIOGENESIS, V15, P543, DOI 10.1007/s10456-012-9279-8
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485
   Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Venugopal B, 2013, CLIN CANCER RES, V19, P4262, DOI 10.1158/1078-0432.CCR-13-0312
   Venza I, 2013, PIGM CELL MELANOMA R, V26, P193, DOI 10.1111/pcmr.12049
   Vidal-Laliena M, 2013, J BIOL CHEM, V288, P21096, DOI 10.1074/jbc.M113.458323
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Wang G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049104
   Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577
   Wang LH, 2015, ONCOTARGET, V6, P9740, DOI 10.18632/oncotarget.3149
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Wang RH, 2014, INT J BIOL SCI, V10, P1193, DOI 10.7150/ijbs.11066
   Webster BR, 2013, J CELL SCI, V126, P4843, DOI 10.1242/jcs.131300
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Wells CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068915
   West AC, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27414
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   West AC, 2013, CANCER RES, V73, P7265, DOI 10.1158/0008-5472.CAN-13-0890
   Wilmott JS, 2015, MODERN PATHOL, V28, P884, DOI 10.1038/modpathol.2015.34
   Xiao W, 2014, J CELL MOL MED, V18, P646, DOI 10.1111/jcmm.12212
   Xie T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0047577, 10.1371/journal.pone.0042001]
   Xue K, 2015, J CANC RES CLIN ONCO
   Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310
   Yang FC, 2013, J BIOL CHEM, V288, P6227, DOI 10.1074/jbc.M112.431239
   Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025
   Younes A, 2011, LANCET ONCOL, V12, P1222, DOI 10.1016/S1470-2045(11)70265-0
   Zhang J, 2014, CELL MOL LIFE SCI, V71, P3885, DOI 10.1007/s00018-014-1656-6
   Zhang LS, 2015, ONCOTARGET, V6, P9073, DOI 10.18632/oncotarget.3268
   Zhang M, 2014, MOL CELL, V55, P31, DOI 10.1016/j.molcel.2014.04.028
   Zhang X, 2015, EUR J MED CHEM, V95, P127, DOI 10.1016/j.ejmech.2015.03.035
   Zhang X, 2013, MOLECULES, V18, P6491, DOI 10.3390/molecules18066491
   Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhao J, 2016, HEPATOLOGY, V63, P668, DOI 10.1002/hep.27853
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
   Zhou XG, 2014, NEOPLASIA, V16, P1028, DOI 10.1016/j.neo.2014.09.012
   Zhou ZW, 2015, DRUG DES DEV THER, V9, P1511, DOI 10.2147/DDDT.S75976
   Zibelman M, 2015, INVEST NEW DRUG, V33, P1040, DOI 10.1007/s10637-015-0261-3
   Zorzi AP, 2013, PEDIATR BLOOD CANCER, V60, P1868, DOI 10.1002/pbc.24694
   Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09
   Zwergel C, 2015, EXPERT OPIN DRUG DIS, V10, P599, DOI 10.1517/17460441.2015.1038236
NR 268
TC 808
Z9 893
U1 16
U2 181
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD OCT
PY 2016
VL 6
IS 10
AR a026831
DI 10.1101/cshperspect.a026831
PG 34
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EC7LA
UT WOS:000388318800005
PM 27599530
OA Green Published, Green Accepted, Bronze
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Cui, J
   Duan, B
   Zhao, XY
   Chen, Y
   Sun, SX
   Deng, WJ
   Zhang, YJ
   Du, J
   Chen, YC
   Gu, L
AF Cui, Jie
   Duan, Biao
   Zhao, Xuyang
   Chen, Yan
   Sun, Shixun
   Deng, Wenjie
   Zhang, Yujie
   Du, Jun
   Chen, Yongchang
   Gu, Luo
TI MBD3 mediates epigenetic regulation on <i>EPAS1</i> promoter in cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE EPAS1; MBD3; Cancer; Methylation
ID RENAL-CELL CARCINOMA; DNA DEMETHYLATION; STEM-CELLS; HYPOXIA; BINDING;
   HIF2-ALPHA; PROTEINS; METHYLATION; EXPRESSION; ROLES
AB Hypoxia-inducible factor 2 alpha (HIF2 alpha) plays critical roles in cancer progression. Although the mechanisms of HIF2 alpha translation and degradation have been well studied, the mechanism for HIF2 alpha regulation at transcriptional level is still not fully understood. Here, we present evidence that DNA methylation in promoter contributes to transcription of EPAS1 coding HIF2 alpha. Methylated CpG binding protein 3 (MBD3) contributes to the intricate regulatory mechanism. We showed that MBD3 bound to the EPAS1 promoter in breast cancer cells and amplified EPAS1 transcription through demethylating CpG located around transcriptional start site in MDA-MB-468 cells. This enabled MDA-MB-468 cells to activate HIF2 alpha-mediated angiogenesis. However, in 7860 cells, the demethylation function of MBD3 on EPAS1 was not observed because of the poor methylated-CpG promoter. Nevertheless, depletion of MBD3 induced by shRNA decreased EPAS1 transcription and therefore decreased HIF2 alpha-mediated cellular response in both MDA-MB-468 and 7860 cancer cells. These results indicated that the endogenous MBD3 was involved in regulating the transcription and therefore the transcriptional activities of HIF2 alpha, suggesting that MBD3 may be a potential therapeutic target of tumor.
C1 [Cui, Jie; Chen, Yan; Gu, Luo] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 211166, Jiangsu, Peoples R China.
   [Cui, Jie] Xuzhou Med Univ, Dept Physiol, Xuzhou 221004, Jiangsu, Peoples R China.
   [Duan, Biao; Zhao, Xuyang; Sun, Shixun; Deng, Wenjie; Zhang, Yujie; Du, Jun; Gu, Luo] Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China.
   [Gu, Luo] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, 101 Longmindadao Rd, Nanjing 211166, Jiangsu, Peoples R China.
   [Chen, Yongchang] Univ Jiangsu, Dept Physiol, Zhenjiang 212013, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Xuzhou Medical University; Nanjing Medical
   University; Nanjing Medical University; Jiangsu University
RP Gu, L (通讯作者)，Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 211166, Jiangsu, Peoples R China.; Gu, L (通讯作者)，Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China.; Gu, L (通讯作者)，Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, 101 Longmindadao Rd, Nanjing 211166, Jiangsu, Peoples R China.
EM lgu@njmu.edu.cn
RI Cui, Jie/ABB-3831-2020
FU National Natural Science Foundation of China [81372319, 81201614];
   Natural Science Foundation of Jiangsu province [BK2012839]; Postdoctoral
   Science Foundation of China [2012 T50511]; High-Level Talents in Six
   Industries of Jiangsu Province [JY-020]; College Graduates Research and
   Innovation Program of Jiangsu Province [JX22013315]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD)
FX This work was supported by grant from the National Natural Science
   Foundation of China (No. 81372319) to Luo Gu; the National Natural
   Science Foundation of China (No. 81201614), the Natural Science
   Foundation of Jiangsu province (No. BK2012839), the Postdoctoral Science
   Foundation of China (No. 2012 T50511), and the High-Level Talents in Six
   Industries of Jiangsu Province (No. JY-020) to Jun Du; a grant from the
   College Graduates Research and Innovation Program of Jiangsu Province
   (No. JX22013315) to Jie Cui; and a Project Funded by the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD).
CR Aranda E, 2009, BIOL RES, V42, P377, DOI /S0716-97602009000300012
   Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106
   Brown SE, 2008, GENE, V420, P99, DOI 10.1016/j.gene.2008.05.009
   Brown SE, 2007, MOL CELL BIOL, V27, P4938, DOI 10.1128/MCB.01880-06
   Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705
   Cramer JM, 2014, J BIOL CHEM, V289, P1294, DOI 10.1074/jbc.M113.512236
   Crook JM, 2006, NAT CELL BIOL, V8, P212, DOI 10.1038/ncb0306-212
   Cui Y, 2015, NUCLEIC ACIDS RES, V43, P3046, DOI 10.1093/nar/gkv098
   Cui Y, 2013, EPIGENETICS-US, V8, P1089, DOI 10.4161/epi.25958
   De Miguel MP, 2015, CURR MOL MED, V15, P343
   Devailly DVG, 2014, ONCOTARGET, V5, DOI 10.18632/oncotarget.1681
   Dudás J, 2014, TUMOR BIOL, V35, P7807, DOI 10.1007/s13277-014-2001-2
   Fatrai S, 2011, BLOOD, V117, P3320, DOI 10.1182/blood-2010-08-303669
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Günther K, 2013, NUCLEIC ACIDS RES, V41, P3010, DOI 10.1093/nar/gkt035
   Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Iurlaro M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r119
   Joshi S, 2014, MOL CANCER RES, V12, P1520, DOI 10.1158/1541-7786.MCR-13-0682
   Kim WY, 2009, J CLIN INVEST, V119, P3182, DOI 10.1172/JCI38443C1
   Lachance G, 2014, P NATL ACAD SCI USA, V111, P7783, DOI 10.1073/pnas.1322909111
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018
   Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010
   Micucci C, 2015, BRIT J CANCER, V113, P1178, DOI 10.1038/bjc.2015.338
   Mohlin S, 2015, CANCER RES, V75, P4617, DOI 10.1158/0008-5472.CAN-15-0708
   Moniz S, 2015, J CELL SCI, V128, P3082, DOI 10.1242/jcs.168864
   Pal A, 2010, J CELL MOL MED, V14, P2646, DOI 10.1111/j.1582-4934.2009.00792.x
   Pastor WA, 2013, NAT REV MOL CELL BIO, V14, P341, DOI 10.1038/nrm3589
   Peng L, 2016, J CELL SCI, V129, P1059, DOI 10.1242/jcs.179044
   Purdue MP, 2011, NAT GENET, V43, P60, DOI 10.1038/ng.723
   Putra AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134496
   Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587
   Raspaglio G, 2014, GENE, V542, P173, DOI 10.1016/j.gene.2014.03.037
   Rawluszko-Wieczorek AA, 2014, MOL CANCER RES, V12, P1112, DOI 10.1158/1541-7786.MCR-14-0054
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   Shahrzad S, 2007, EPIGENETICS-US, V2, P119, DOI 10.4161/epi.2.2.4613
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   Srinivasan S, 2015, ANGIOGENESIS, V18, P449, DOI 10.1007/s10456-015-9468-3
   Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410
   van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203
   Vogler M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069128
   Yildirim O, 2011, CELL, V147, P1498, DOI 10.1016/j.cell.2011.11.054
   Yoo S, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004898
   Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001
NR 45
TC 22
Z9 23
U1 0
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2016
VL 37
IS 10
BP 13455
EP 13467
DI 10.1007/s13277-016-5237-1
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EB7AZ
UT WOS:000387538700048
PM 27465550
DA 2025-01-12
ER

PT J
AU Deb, P
   Bhan, A
   Hussain, I
   Ansari, KI
   Bobzean, SA
   Pandita, TK
   Perrotti, LI
   Mandal, SS
AF Deb, Paromita
   Bhan, Arunoday
   Hussain, Imran
   Ansari, Khairul I.
   Bobzean, Samara A.
   Pandita, Tej K.
   Perrotti, Linda I.
   Mandal, Subhrangsu S.
TI Endocrine disrupting chemical, bisphenol-A, induces breast cancer
   associated gene HOXB9 expression <i>in vitro</i> and <i>in vivo</i>
SO GENE
LA English
DT Article
DE HOXB9; Gene expression; Estrogen signaling; Bisphenol-A; Endocrine
   disruption; Epigenetics
ID ESTROGEN-RECEPTOR-ALPHA; TO-MESENCHYMAL TRANSITION; MLL HISTONE
   METHYLASES; MAMMARY-GLAND; TRANSFORMING GROWTH-FACTOR-BETA-1; CRITICAL
   ROLES; TUMOR-GROWTH; CELL-CYCLE; EXPOSURE; ESTRADIOL
AB HOXB9 is a homeobox-containing gene that plays a key role in mammary gland development and is associated with breast and other types of cancer. Here, we demonstrate that HOXB9 expression is transcriptionally regulated by estradiol (E2), in vitro and in vivo. We also demonstrate that the endocrine disrupting chemical bisphenol-A (BPA) induces HOXB9 expresion in cultured human breast cancer cells (MCF7) as well as in vivo in the mammary glands of ovariectomized (OVX) rats. Luciferase assay showed that estrogen-response-elements (EREs) in the HOXB9 promoter are required for BPA-induced expression. Estrogen-receptors (ERs) and ER-co-regulators such as MLL-histone methylase (MLL3), histone acetylases, CBP/P300, bind to the HOXB9 promoter EREs in the presence of BPA, modify chromatin (histone methylation and acetylation) and lead to gene activation. In summary, our results demonstrate that BPA exposure, like estradiol, increases HOXB9 expression in breast cells both in vitro and in vivo through a mechanism that involves increased recruitment of transcription and chromatin modification factors. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Deb, Paromita; Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Mandal, Subhrangsu S.] Univ Texas Arlington, Epigenet Res Lab, Dept Chem & Biochem, Arlington, TX 76019 USA.
   [Bobzean, Samara A.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.
   [Pandita, Tej K.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Arlington; University of
   Texas System; University of Texas Arlington; Houston Methodist
RP Mandal, SS (通讯作者)，Univ Texas Arlington, Epigenet Res Lab, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI bhan, arunoday/F-1066-2011; Pandita, Tej/AAM-9188-2020; Ansari,
   Khairul/C-9791-2011
OI Perrotti, Linda/0000-0002-6297-2572; Mandal,
   Subhrangsu/0000-0001-8495-9881; Hussain, Imran/0000-0003-1563-7656
FU NIH [1R15 ES019129-01];  [RO1 CA129537];  [RO1GM109768];  [RO1CA154320]
FX We thank all the Mandal lab members for helpful discussions. Research in
   Mandal laboratory is supported by grant from NIH (1R15 ES019129-01) and
   Pandita laboratory is supported by RO1 CA129537, RO1GM109768 and
   RO1CA154320.
CR Abdel-Rahman WM, 2012, ASIAN PAC J CANCER P, V13, P5937, DOI 10.7314/APJCP.2012.13.12.5937
   Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352
   Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006
   Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t
   Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x
   Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x
   Ansari KI, 2009, J INORG BIOCHEM, V103, P818, DOI 10.1016/j.jinorgbio.2009.02.004
   Ansari KI, 2009, FRONT BIOSCI-LANDMRK, V14, P3483, DOI 10.2741/3466
   Bannister AJ, 2004, METHOD ENZYMOL, V376, P269
   Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i
   Bobzean SAM, 2014, BRAIN RES BULL, V103, P49, DOI 10.1016/j.brainresbull.2014.02.002
   BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Bulynko YA, 2011, BIOCHEMISTRY-US, V50, P313, DOI 10.1021/bi101762x
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen BS, 2004, BIOCHEMISTRY-US, V43, P12741, DOI 10.1021/bi048993r
   Chen F, 1997, DEV BIOL, V181, P186, DOI 10.1006/dbio.1996.8440
   Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541
   Chiba N, 2012, P NATL ACAD SCI USA, V109, P2760, DOI 10.1073/pnas.1018867108
   Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v
   Darda L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122285
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959
   Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012
   Fang LP, 2014, BIOCHEM BIOPH RES CO, V446, P272, DOI 10.1016/j.bbrc.2014.02.095
   Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   Fucic A., 2012, ENV HLTH, V11
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07
   Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Hueber SD, 2008, BIOESSAYS, V30, P965, DOI 10.1002/bies.20823
   Hussain I, 2015, BBA-GENE REGUL MECH, V1849, P697, DOI 10.1016/j.bbagrm.2015.02.003
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Jiang SM, 2006, MOL ENDOCRINOL, V20, P311, DOI 10.1210/me.2005-0100
   Lappin Terence R J, 2006, Ulster Med J, V75, P23
   Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856
   Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103
   Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455
   MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633
   Maeda K, 2005, INT J CANCER, V114, P436, DOI 10.1002/ijc.20706
   Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346
   Mandal SS, 2010, FASEB J, V24
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81
   Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369
   Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888
   Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999
   Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200
   Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI 10.4161/cbt.18942
   Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Seki H, 2012, ANN SURG ONCOL, V19, P1831, DOI 10.1245/s10434-012-2295-5
   Sengupta S, 2013, BRIT J PHARMACOL, V169, P167, DOI 10.1111/bph.12122
   Sha L, 2015, CLIN EXP MED, V15, P55, DOI 10.1007/s10238-014-0276-7
   Shibata H, 1997, RECENT PROG HORM RES, V52, P141
   Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x
   Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024
   Tomioka N, 2010, CANCER GENET CYTOGEN, V201, P6, DOI 10.1016/j.cancergencyto.2010.04.017
   Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014
   YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0
   Zhan J, 2015, HISTOPATHOLOGY, V66, P955, DOI 10.1111/his.12585
NR 83
TC 52
Z9 61
U1 0
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD SEP 30
PY 2016
VL 590
IS 2
BP 234
EP 243
DI 10.1016/j.gene.2016.05.009
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DT9SN
UT WOS:000381842700006
PM 27182052
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Dong, TH
   Zhang, MY
   Dong, Y
   Herman, JG
   van Engeland, M
   Zhong, GL
   Guo, MZ
AF Dong, Tenghui
   Zhang, Meiying
   Dong, Yan
   Herman, James G.
   van Engeland, Manon
   Zhong, Guanglin
   Guo, Mingzhou
TI Methylation of <i>RASSF10</i> Promotes Cell Proliferation and Serves as
   a Docetaxel Resistant Marker in Human Breast Cancer
SO DISCOVERY MEDICINE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; EPIGENETIC INACTIVATION; MALIGNANT-MELANOMA;
   COLORECTAL-CANCER; GASTRIC-CANCER; FREQUENT; HYPERMETHYLATION;
   HETEROZYGOSITY; METASTASIS; MECHANISMS
AB Breast cancer is a leading cause of death among females worldwide. However, the mechanisms of breast cancer remain largely unclear. RASSF10 is frequently methylated in certain types of human cancers. To understand the mechanism of RASSF10 in breast cancer, samples of breast cancer cell lines, primary cancer, breast tissue adjacent to cancer, and normal breast tissue were investigated in this study. Methylation specific PCR (MSP), flow cytometry, western blot, and siRNA knockdown assay were used. Complete methylation was found in MCF7, MDA-MB-435, and MDA-MB-468 cells, partial methylation was found in ZR75-1 cells, and unmethylation was revealed in SKBR3 cells. Loss of RASSF10 expression was found in MCF7, MDA-MB-435, and MDA-MB-468 cells, and high expression of RASSF10 was found in ZR75-1 and SKBR3 cells. The expression of RASSF10 was induced by 5-aza-2'-deoxycytidine (5-Aza) in MCF7, MDA-MB435, and MDA-MB-468 cells. RASSF10 methylation was found in 77.8% (49/63) of primary breast cancer and 17.8% (8/45) of adjacent tissue samples. No methylation was found in normal breast tissue samples. Restoration of RASSF10 expression inhibited cell proliferation and induced G2/M phase arrest in MCF7 and MDA-MB-468 cells. RASSF10 sensitized these cells to docetaxel. RASSF10 induced apoptosis and activated P53 signaling in breast cancer cells. In conclusion, RASSF10 is frequently methylated in human breast cancer and infrequently in adjacent tissue samples. RASSF10 methylation may serve as an early detective marker. The expression of RASSF10 is regulated by promoter region methylation. Since restoration of RASSF10 expression sensitized breast cancer cells to docetaxel, RASSF10 methylation is a potential docetaxel resistant marker. RASSF10 suppresses breast cancer growth by activating P53 signaling.
C1 [Dong, Tenghui; Zhang, Meiying; Dong, Yan; Guo, Mingzhou] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
   [Zhang, Meiying] Nankai Univ, Coll Med, Tianjin 300071, Peoples R China.
   [Herman, James G.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA.
   [van Engeland, Manon] Maastricht Univ, Med Ctr, Dept Pathol, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands.
   [Zhong, Guanglin] Chinese Peoples Liberat Army Gen Hosp, Dept Internal Med, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Nankai University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Maastricht University; Chinese People's Liberation Army
   General Hospital
RP Guo, MZ (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
EM guanglin1963@aliyun.com
RI van Engeland, Manon/A-7479-2009; Wang, Haitao/GYV-1262-2022
FU National Basic Research Program (973 Program) [2012CB934002,
   2015CB553904, 2010CB912802]; National Key Scientific Instrument Special
   Program of China [2011YQ03013405]; National High-Tech R&D Program (863
   Program) [SS2012AA020314, SS2012AA020821, SS2012AA020303]; National
   Science Foundation of China [81121004, 81071953, 81161120432, 81490753]
FX This work was supported by grants from the National Basic Research
   Program (973 Program No. 2012CB934002, 2015CB553904, 2010CB912802),
   National Key Scientific Instrument Special Program of China (Grant No.
   2011YQ03013405), National High-Tech R&D Program (863 Program No.
   SS2012AA020314, SS2012AA020821, SS2012AA020303), and National Science
   Foundation of China (Grant No. 81121004, 81071953, 81161120432,
   81490753).
CR Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155
   Altinok A, 2007, ADV DRUG DELIVER REV, V59, P1036, DOI 10.1016/j.addr.2006.09.022
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Armand JP, 2003, B CANCER, V90, P1067
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Bernardini M, 2005, NEOPLASIA, V7, P603, DOI 10.1593/neo.04760
   CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y
   Cao BP, 2013, DISCOV MED, V16, P137
   Chen JX, 2004, GENE, V340, P61, DOI 10.1016/j.gene.2004.05.028
   Dansranjavin T, 2012, PROSTATE, V72, P1550, DOI 10.1002/pros.22510
   Djos A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-40
   Esteller M, 2001, CANCER RES, V61, P3225
   Guo J, 2014, ONCOTARGET
   Guo J, 2015, ONCOTARGET, V6, P4202, DOI 10.18632/oncotarget.2866
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   Guo MZ, 2015, DISCOV MED, V19, P151
   Guo MZ, 2014, DISCOV MED, V17, P67
   Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42
   Hill VK, 2011, ONCOGENE, V30, P978, DOI 10.1038/onc.2010.471
   Jia Y, 2014, EPIGENETICS, V5, P743
   Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073
   Kang S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-136
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Katase N, 2008, ONCOL RES, V17, P273, DOI 10.3727/096504008786991594
   Kudo T, 2012, CANCER RES, V72, P2901, DOI 10.1158/0008-5472.CAN-12-0572
   Lu D, 2014, DISCOV MED, V17, P169
   Miller BJ, 2003, AM J HUM GENET, V73, P748, DOI 10.1086/378522
   Murray S, 2012, CANCER TREAT REV, V38, P890, DOI 10.1016/j.ctrv.2012.02.011
   Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230
   Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4
   Tirkkonen M, 1999, GENE CHROMOSOME CANC, V24, P56, DOI 10.1002/(SICI)1098-2264(199901)24:1<56::AID-GCC8>3.0.CO;2-X
   Tirkkonen M, 1997, CANCER RES, V57, P1222
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033
   Yan WJ, 2014, J CELL MOL MED, V18, P2499, DOI 10.1111/jcmm.12325
   Yan WJ, 2013, EPIGENETICS-US, V8, P1373, DOI 10.4161/epi.26781
   Zhang DS, 2014, DRUG DES DEV THER, V8, P279, DOI 10.2147/DDDT.S56801
   Zhang Xiao-Mei, 2010, Front Med China, V4, P378, DOI 10.1007/s11684-010-0230-3
NR 45
TC 6
Z9 6
U1 0
U2 3
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD NOV
PY 2015
VL 20
IS 111
BP 261
EP 271
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CY3MH
UT WOS:000366313400001
PM 26645898
DA 2025-01-12
ER

PT J
AU Simiele, F
   Recchiuti, A
   Patruno, S
   Plebani, R
   Pierdomenico, AM
   Codagnone, M
   Romano, M
AF Simiele, Felice
   Recchiuti, Antonio
   Patruno, Sara
   Plebani, Roberto
   Pierdomenico, Anna Maria
   Codagnone, Marilina
   Romano, Mario
TI Epigenetic regulation of the formyl peptide receptor 2 gene
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE Chromatin; Histones; G protein-coupled receptors; Inflammation; Lipoxins
ID LIPOXIN A(4) RECEPTOR; ACUTE INFLAMMATORY RESPONSES; ARACHIDONIC-ACID;
   HUMAN-LEUKOCYTES; OVARIAN-CANCER; SEVERE ASTHMA; HOST-DEFENSE;
   EXPRESSION; PATHWAYS; ASPIRIN
AB Lipoxin (LX) A4, a main stop signal of inflammation, exerts potent bioactions by activating a specific G protein-coupled receptor, termed formyl peptide receptor 2 and recently renamed ALX/FPR2. Knowledge of the regulatory mechanisms that drive ALX/FPR2 gene expression is key for the development of innovative anti-inflammatory pharmacology. Here, we examined chromatin patterns of the ALX/FPR2 gene. We report that in MDA-MB231 breast cancer cells, the ALX/FPR2 gene undergoes epigenetic silencing characterized by low acetylation at lysine 27 and trimethylation at lysine 4, associated with high methylation at lysine 27 of histone 3. This pattern, which is consistent with transcriptionally inaccessible chromatin leading to low ALX/FPR2 mRNA and protein expression, is reversed in polymorphonuclear leukocytes that express high ADC/FPR2 levels. Activation of p300 histone acetyltransferase and inhibition of DNA methyltransferase restored chromatin accessibility and significantly increased ALX/FPR2 mRNA transcription and protein levels in MDA-MB231 cells, as well as in pulmonary artery endothelial cells. In both cells types, changes in the histone acetylation/methylation status enhanced ALX/FPR2 signaling in response to LXA(4). Collectively, these results uncover unappreciated epigenetic regulation of ALX/FPR2 expression that can be exploited for innovative approaches to inflammatory disorders. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Simiele, Felice; Recchiuti, Antonio; Patruno, Sara; Plebani, Roberto; Codagnone, Marilina; Romano, Mario] G DAnnunzio Univ Chieti Pescara, Dept Med Oral & Biotechnol Sci, Via Luigi Polacchi 11-13, I-66100 Chieti, Italy.
   [Pierdomenico, Anna Maria] G DAnnunzio Univ Chieti Pescara, Dept Med & Aging Sci, Via Luigi Polacchi 11-13, I-66100 Chieti, Italy.
   [Simiele, Felice; Recchiuti, Antonio; Patruno, Sara; Plebani, Roberto; Pierdomenico, Anna Maria; Codagnone, Marilina; Romano, Mario] G DAnnunzio Univ Chieti Pescara, Ctr Aging Sci & Translat Med CeSI MeT, Via Luigi Polacchi 11-13, I-66100 Chieti, Italy.
C3 G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of
   Chieti-Pescara; G d'Annunzio University of Chieti-Pescara
RP Romano, M (通讯作者)，CeSI MeT, Via Luigi Polacchi 11-13, I-66013 Chieti, Italy.
EM mromano@unich.it
RI Recchiuti, Antonio/K-7670-2016; Plebani, Roberto/LKL-1958-2024; Romano,
   Mario/I-7986-2012; Patruno, Sara/P-7868-2018
OI ROMANO, Mario/0000-0001-8512-1458; Patruno, Sara/0000-0002-8425-7844
FU Italian Ministry of Education, University and Research [PRIN
   2010YK7Z5K_002]
FX This work was supported in part by a grant from the Italian Ministry of
   Education, University and Research to M.R. (PRIN 2010YK7Z5K_002).
CR Baker N, 2009, J IMMUNOL, V182, P3819, DOI 10.4049/jimmunol.0803175
   Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200
   Bonnans C, 2006, AM J PATHOL, V168, P1064, DOI 10.2353/ajpath.2006.051056
   Cattaneo F, 2013, INT J MOL SCI, V14, P7193, DOI 10.3390/ijms14047193
   CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475
   Coffelt SB, 2009, MOL CANCER RES, V7, P907, DOI 10.1158/1541-7786.MCR-08-0326
   Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com
   Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526
   FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253
   Gastardelo TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111317
   Khau T, 2011, FASEB J, V25, P483, DOI 10.1096/fj.09-154096
   Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028
   Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107
   Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108
   Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC
   Li BZ, 2011, CELL RES, V21, P1172, DOI 10.1038/cr.2011.92
   Liu Y, 2013, CANCER RES, V73, P550, DOI 10.1158/0008-5472.CAN-12-2290
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x
   Meng F, 2013, BRIT J CANCER, V108, P579, DOI 10.1038/bjc.2013.10
   Moniri MR, 2015, CYTOTECHNOLOGY, V67, P379, DOI 10.1007/s10616-014-9692-5
   Montero-Melendez T, 2013, CELL DEATH DIFFER, V20, P567, DOI 10.1038/cdd.2012.154
   Morris T, 2010, P NATL ACAD SCI USA, V107, P8842, DOI 10.1073/pnas.1000373107
   Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477
   Pasini A, 2015, DRUGS, V75, P1757, DOI 10.1007/s40265-015-0461-3
   Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786
   Pierdomenico AM, 2015, J BIOL CHEM, V290, P3592, DOI 10.1074/jbc.M114.592352
   Planagumà A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC
   Rasool M, 2015, BMC MED GENOMICS, V8, DOI 10.1186/1755-8794-8-S1-S5
   Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev
   SERHAN CN, 1984, BIOCHEM BIOPH RES CO, V118, P943, DOI 10.1016/0006-291X(84)91486-4
   SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335
   Simiele F, 2012, FASEB J, V26, P1323, DOI 10.1096/fj.11-198069
   Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578
NR 34
TC 14
Z9 17
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 0006-3002
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD OCT
PY 2016
VL 1859
IS 10
BP 1252
EP 1258
DI 10.1016/j.bbagrm.2016.07.007
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DU7UC
UT WOS:000382419100002
PM 27424221
DA 2025-01-12
ER

PT J
AU Warchal, SJ
   Dawson, JC
   Carragher, NO
AF Warchal, Scott J.
   Dawson, John C.
   Carragher, Neil O.
TI Development of the Theta Comparative Cell Scoring Method to Quantify
   Diverse Phenotypic Responses Between Distinct Cell Types
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
ID CANCER; ASSAY; HETEROGENEITY; MODELS
AB In this article, we have developed novel data visualization tools and a Theta comparative cell scoring (TCCS) method, which supports high-throughput in vitro pharmacogenomic studies across diverse cellular phenotypes measured by multiparametric high-content analysis. The TCCS method provides a univariate descriptor of divergent compound-induced phenotypic responses between distinct cell types, which can be used for correlation with genetic, epigenetic, and proteomic datasets to support the identification of biomarkers and further elucidate drug mechanism-of-action. Application of these methods to compound profiling across high-content assays incorporating well-characterized cells representing known molecular subtypes of disease supports the development of personalized healthcare strategies without prior knowledge of a drug target. We present proof-of-principle data quantifying distinct phenotypic response between eight breast cancer cells representing four disease subclasses. Application of the TCCS method together with new advances in next-generation sequencing, induced pluripotent stem cell technology, gene editing, and high-content phenotypic screening are well placed to advance the identification of predictive biomarkers and personalized medicine approaches across a broader range of disease types and therapeutic classes.
C1 [Warchal, Scott J.; Dawson, John C.; Carragher, Neil O.] Univ Edinburgh, Canc Res UK Edinburgh Ctr, Inst Genet & Mol Med, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland.
C3 University of Edinburgh
RP Carragher, NO (通讯作者)，Univ Edinburgh, Canc Res UK Edinburgh Ctr, Inst Genet & Mol Med, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland.
EM n.carragher@ed.ac.uk
RI Dawson, John/HDM-6702-2022
OI Warchal, Scott/0000-0003-1743-2160; Carragher, Neil/0000-0001-5541-9747;
   Dawson, John/0000-0001-5713-1026
FU Cancer Research UK Edinburgh Centre studentship award; Research Councils
   UK (RCUK) fellowship award
FX Cancer Research UK Edinburgh Centre studentship award to S.J.W. and
   Research Councils UK (RCUK) fellowship award to N.O.C.
CR Akbani R, 2014, MOL CELL PROTEOMICS, V13, P1625, DOI 10.1074/mcp.O113.034918
   Aronson SJ, 2015, NATURE, V526, P336, DOI 10.1038/nature15816
   Biankin AV, 2015, NATURE, V526, P361, DOI 10.1038/nature15819
   Bickle M, 2010, ANAL BIOANAL CHEM, V398, P219, DOI 10.1007/s00216-010-3788-3
   Caie PD, 2010, MOL CANCER THER, V9, P1913, DOI 10.1158/1535-7163.MCT-09-1148
   Cardnell RJ, 2013, CLIN CANCER RES, V19, P6322, DOI 10.1158/1078-0432.CCR-13-1975
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100
   Day F, 2015, TARGET ONCOL, V10, P99, DOI 10.1007/s11523-014-0319-8
   Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581
   Fliri AF, 2005, J MED CHEM, V48, P6918, DOI 10.1021/jm050494g
   Fliri AF, 2005, P NATL ACAD SCI USA, V102, P261, DOI 10.1073/pnas.0407790101
   Gustafsdottir SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080999
   Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Koboldt DC, 2013, CELL, V155, P27, DOI 10.1016/j.cell.2013.09.006
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kümmel A, 2012, J BIOMOL SCREEN, V17, P843, DOI 10.1177/1087057112439324
   Kümmel A, 2010, J BIOMOL SCREEN, V15, P95, DOI 10.1177/1087057109351311
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Lee J, 2013, CURR OPIN CHEM BIOL, V17, P118, DOI 10.1016/j.cbpa.2012.12.022
   Lee JA, 2013, J BIOMOL SCREEN, V18, P1143, DOI 10.1177/1087057113506118
   Ljosa V, 2013, J BIOMOL SCREEN, V18, P1321, DOI 10.1177/1087057113503553
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Perlman ZE, 2004, SCIENCE, V306, P1194, DOI 10.1126/science.1100709
   Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI 10.1038/NCHEMBIO.1986
   Reisen F, 2015, ASSAY DRUG DEV TECHN, V13, P415, DOI 10.1089/adt.2015.656
   Reisen F, 2013, J BIOMOL SCREEN, V18, P1284, DOI 10.1177/1087057113501390
   Rix U, 2009, NAT CHEM BIOL, V5, P616, DOI 10.1038/nchembio.216
   Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Singh S, 2014, J BIOMOL SCREEN, V19, P640, DOI 10.1177/1087057114528537
   Smith K, 2014, J BIOMOL SCREEN, V19, P685, DOI 10.1177/1087057114527313
   Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598
   Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736
   Swinney DC, 2013, J BIOMOL SCREEN, V18, P1186, DOI 10.1177/1087057113501199
   Tanaka M, 2005, PLOS BIOL, V3, P764, DOI 10.1371/journal.pbio.0030128
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 40
TC 13
Z9 14
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD SEP
PY 2016
VL 14
IS 7
SI SI
BP 395
EP 406
DI 10.1089/adt.2016.730
PG 12
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DU6JI
UT WOS:000382320400004
PM 27552144
OA Green Submitted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Terracina, KP
   Graham, LJ
   Payne, KK
   Manjili, MH
   Baek, A
   Damle, SR
   Bear, HD
AF Terracina, Krista P.
   Graham, Laura J.
   Payne, Kyle K.
   Manjili, Masoud H.
   Baek, Annabel
   Damle, Sheela R.
   Bear, Harry D.
TI DNA methyltransferase inhibition increases efficacy of adoptive cellular
   immunotherapy of murine breast cancer
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE T lymphocytes; Immunotherapy; Decitabine; Epigenetic; Myeloid derived
   suppressor cells
ID ANTITUMOR IMMUNE-RESPONSES; REGULATORY T-CELLS; SUPPRESSOR-CELLS;
   MAMMARY-CARCINOMA; LYMPHOCYTES; THERAPY; ANTIGEN; INDUCTION; AUGMENTS;
   CYCLOPHOSPHAMIDE
AB Adoptive T cell immunotherapy is a promising approach to cancer treatment that currently has limited clinical applications. DNA methyltransferase inhibitors (DNAMTi) have known potential to affect the immune system through multiple mechanisms that could enhance the cytotoxic T cell responses, including: upregulation of tumor antigen expression, increased MHC class I expression, and blunting of myeloid derived suppressor cells (MDSCs) expansion. In this study, we have investigated the effect of combining the DNAMTi, decitabine, with adoptive T cell immunotherapy in the murine 4T1 mammary carcinoma model. We found that expression of neu, MHC class I molecules, and several murine cancer testis antigens (CTA) was increased by decitabine treatment of 4T1 cells in vitro. Decitabine also increased expression of multiple CTA in two human breast cancer cell lines. Decitabine-treated 4T1 cells stimulated greater IFN-gamma release from tumor-sensitized lymphocytes, implying increased immunogenicity. Expansion of CD11b + Gr1 + MDSC in 4T1 tumor-bearing mice was significantly diminished by decitabine treatment. Decitabine treatment improved the efficacy of adoptive T cell immunotherapy in mice with established 4T1 tumors, with greater inhibition of tumor growth and an increased cure rate. Decitabine may have a role in combination with existing and emerging immunotherapies for breast cancer.
C1 [Terracina, Krista P.; Graham, Laura J.; Bear, Harry D.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA 23284 USA.
   [Manjili, Masoud H.; Damle, Sheela R.; Bear, Harry D.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
   [Terracina, Krista P.; Graham, Laura J.; Manjili, Masoud H.; Baek, Annabel; Damle, Sheela R.; Bear, Harry D.] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, West Hosp 7-402,1200 East Broad St,POB 980011, Richmond, VA 23298 USA.
   [Payne, Kyle K.] Wistar Inst Anat & Biol, Tumor Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University; The Wistar Institute
RP Bear, HD (通讯作者)，Virginia Commonwealth Univ, Dept Surg, Richmond, VA 23284 USA.; Bear, HD (通讯作者)，Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA.; Bear, HD (通讯作者)，Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, West Hosp 7-402,1200 East Broad St,POB 980011, Richmond, VA 23298 USA.
EM hdbear@vcu.edu
RI Payne, Kyle/AAL-6614-2020
OI Baek, Annabel/0000-0002-3111-409X; Terracina,
   Krista/0000-0002-5761-9037; Payne, Kyle/0000-0002-6531-9835
FU National Institutes of Health [P30CA16059, T32CA085159]; National Cancer
   Institute [F30CA192836-01A1]
FX The Flow Cytometry Shared Resource Core was supported in part by Grant
   P30CA16059 from the National Institutes of Health to the Massey Cancer
   Center. Dr. Terracina was supported by a training grant from the
   National Institutes of Health (T32CA085159). Ms. Damle was supported by
   a fellowship grant from the National Cancer Institute (F30CA192836-01A1)
CR Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545
   Ascierto ML, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-145
   Bernhard H, 2008, CANCER IMMUNOL IMMUN, V57, P271, DOI 10.1007/s00262-007-0355-7
   Besser MJ, 2010, CLIN CANCER RES, V16, P2646, DOI 10.1158/1078-0432.CCR-10-0041
   Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284
   Cha E, 2010, BREAST CANCER RES TR, V122, P359, DOI 10.1007/s10549-009-0573-0
   Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670
   Cruz CR, 2011, CLIN CANCER RES, V17, P7058, DOI 10.1158/1078-0432.CCR-11-1873
   Daurkin I, 2010, CANCER IMMUNOL IMMUN, V59, P697, DOI 10.1007/s00262-009-0786-4
   Domschke C, 2013, CANCER IMMUNOL IMMUN, V62, P1053, DOI 10.1007/s00262-013-1414-x
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181
   Gibb DR, 2011, J IMMUNOL, V186, P4244, DOI 10.4049/jimmunol.1003318
   Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020
   Héninger E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00029
   Ho WY, 2002, J CLIN INVEST, V110, P1415, DOI 10.1172/JCI200217214
   Howlader N., 2013, SEER CANC STAT REV
   Ikezawa Y, 2005, J DERMATOL SCI, V39, P105, DOI 10.1016/j.jdermsci.2005.02.002
   Itzhaki O, 2011, J IMMUNOTHER, V34, P212, DOI 10.1097/CJI.0b013e318209c94c
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Karpf AR, 2006, EPIGENETICS-US, V1, P116, DOI 10.4161/epi.1.3.2988
   Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111
   Kmieciak M, 2007, EUR J IMMUNOL, V37, P675, DOI 10.1002/eji.200636639
   Kmieciak M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-35
   Krishnadas DK, 2014, TUMOR BIOL, V35, P5753, DOI 10.1007/s13277-014-1764-9
   Lampen MH, 2011, CURR OPIN IMMUNOL, V23, P293, DOI 10.1016/j.coi.2010.12.005
   Le HK, 2009, INT IMMUNOPHARMACOL, V9, P900, DOI 10.1016/j.intimp.2009.03.015
   Meier J, 2013, BIOL BLOOD MARROW TR, V19, P366, DOI 10.1016/j.bbmt.2012.12.004
   Miller CHT, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-54
   Morales JK, 2009, CANCER IMMUNOL IMMUN, V58, P941, DOI 10.1007/s00262-008-0609-z
   Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126
   Payne KK, 2013, BREAST CANCER RES TR, V142, P45, DOI 10.1007/s10549-013-2733-5
   Raval RR, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-14
   Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191
   Saleem SJ, 2012, J IMMUNOL, V189, P511, DOI 10.4049/jimmunol.1200647
   Símová J, 2011, BRIT J CANCER, V105, P1533, DOI 10.1038/bjc.2011.428
   Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4
   Toor AA, 2012, BRIT J HAEMATOL, V158, P700, DOI 10.1111/j.1365-2141.2012.09225.x
   Triozzi PL, 2012, CANCER IMMUNOL IMMUN, V61, P1441, DOI 10.1007/s00262-012-1204-x
   Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269
   Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449
   Zhang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057114
NR 43
TC 37
Z9 45
U1 0
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD SEP
PY 2016
VL 65
IS 9
BP 1061
EP 1073
DI 10.1007/s00262-016-1868-8
PG 13
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA DU2HM
UT WOS:000382031800004
PM 27416831
OA Green Accepted
DA 2025-01-12
ER

PT J
AU O'Brien, KM
   Shi, M
   Sandler, DP
   Taylor, JA
   Zaykin, DV
   Keller, J
   Wise, AS
   Weinberg, CR
AF O'Brien, Katie M.
   Shi, Min
   Sandler, Dale P.
   Taylor, Jack A.
   Zaykin, Dmitri V.
   Keller, Jean
   Wise, Alison S.
   Weinberg, Clarice R.
TI A family-based, genome-wide association study of young-onset breast
   cancer: inherited variants and maternally mediated effects
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID FALSE DISCOVERY RATE; BIRTH-WEIGHT; SUSCEPTIBILITY; RISK; REPLICATION;
   PARENTS; GENES; BRCA1; LOCI; AGE
AB Young-onset breast cancer shows certain phenotypic and etiologic differences from older-onset breast cancer and may be influenced by some distinct genetic variants. Few genetic studies of breast cancer have targeted young women and no studies have examined whether maternal variants influence disease in their adult daughters through prenatal effects. We conducted a family-based, genome-wide association study of young-onset breast cancer (age at diagnosis o50 years). A total of 602 188 single-nucleotide polymorphisms (SNPs) were genotyped for 1279 non-Hispanic white cases and their parents or sisters. We used likelihood-based log-linear models to test for transmission asymmetry within families and for maternally mediated genetic effects. Three autosomal SNPs (rs28373882, P=2.8 x 10(-7); rs879162, P=9.2 x 10(-7); rs12606061, P=9.1 x 10(-7)) were associated with risk of young-onset breast cancer at a false-discovery rate below 0.20. None of these loci has been previously linked with young-onset or overall breast cancer risk, and their functional roles are unknown. There was no evidence of maternally mediated, X-linked, or mitochondrial genetic effects, and no notable findings within cancer subcategories defined by menopausal status, estrogen receptor status, or by tumor invasiveness. Further investigations are needed to explore other potential genetic, epigenetic, or epistatic mechanisms and to confirm the association between these three novel loci and youngonset breast cancer.
C1 [O'Brien, Katie M.; Shi, Min; Zaykin, Dmitri V.; Wise, Alison S.; Weinberg, Clarice R.] NIEHS, Biostat & Computat Biol Branch, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
   [Sandler, Dale P.; Taylor, Jack A.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
   [Keller, Jean] Westat Corp, Durham, NC USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS); Westat
RP Weinberg, CR (通讯作者)，NIEHS, Biostat & Computat Biol Branch, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM weinber2@niehs.nih.gov
RI Sandler, Dale/E-5110-2019; taylor, jack/C-7154-2019; Christina E.
   Weinberg, née/AAV-1839-2020; Shi, Min/GXM-3977-2022; O'Brien,
   Katie/G-8579-2014; Zaykin, Dmitri/C-3752-2019
OI taylor, jack/0000-0001-5303-6398; Weinberg, Clarice/0000-0002-7713-8556;
   O'Brien, Katie/0000-0002-1931-1349; Zaykin, Dmitri/0000-0002-9444-2859
FU Intramural Research Program of the NIH; National Institute of
   Environmental Health Sciences [Z01-ES044005, Z01-ES102245]; Susan G
   Komen for the Cure [FAS0703856]
FX This work was supported by the Intramural Research Program of the NIH,
   the National Institute of Environmental Health Sciences (project
   Z01-ES044005 to DPS and project Z01-ES102245 to CRW) and Susan G Komen
   for the Cure (grant FAS0703856 to CRW). We thank the Center for
   Inherited Disease Research, the Genetics Coordinating Center at the
   University of Washington (Cecelia Laurie, Quenna Wong, Sarah Nelson, and
   Cathy Laurie), and Jing Dong and Lauren Wilson from NIEHS for reviewing
   earlier drafts of this paper.
CR Ahsan H, 2014, CANCER EPIDEM BIOMAR, V23, P658, DOI 10.1158/1055-9965.EPI-13-0340
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471
   Anderson WF, 2007, CANCER CAUSE CONTROL, V18, P1187, DOI 10.1007/s10552-007-9057-x
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561
   Han MR, 2015, BREAST CANCER-TOKYO, V22, P544, DOI 10.1007/s12282-014-0518-2
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Kibriya MG, 2009, BREAST CANCER RES TR, V114, P463, DOI 10.1007/s10549-008-0039-9
   Kim HC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3158
   Li JM, 2011, BREAST CANCER RES TR, V126, P717, DOI 10.1007/s10549-010-1172-9
   Long JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001002
   Mellemkjær L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004
   Möller S, 2016, CANCER EPIDEM BIOMAR, V25, P145, DOI 10.1158/1055-9965.EPI-15-0913
   OBrien KM, 2014, AM J EPIDEMIOL, V179, P382, DOI 10.1093/aje/kwt258
   Panagiotou OA, 2012, INT J EPIDEMIOL, V41, P273, DOI 10.1093/ije/dyr178
   Shi M, 2013, INT J EPIDEMIOL, V42, P298, DOI 10.1093/ije/dys212
   Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Tung N, 2015, CANCER-AM CANCER SOC, V121, P25, DOI 10.1002/cncr.29010
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   Udler MS, 2010, HUM MOL GENET, V19, P2507, DOI 10.1093/hmg/ddq122
   Wei H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051758
   Weinberg CR, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004174
   Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802
   Weinberg CR, 1999, AM J HUM GENET, V64, P1186, DOI 10.1086/302337
   Whittemore AS, 2004, CANCER EPIDEM BIOMAR, V13, P2078
   Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893
   Wise AS, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00015
   Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7
   Yekutieli D, 1999, J STAT PLAN INFER, V82, P171, DOI 10.1016/S0378-3758(99)00041-5
NR 42
TC 8
Z9 10
U1 0
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP
PY 2016
VL 24
IS 9
BP 1316
EP 1323
DI 10.1038/ejhg.2016.11
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DU6FV
UT WOS:000382310600013
PM 26883092
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Sotolongo, A
   Mónica, FZ
   Kots, A
   Xiao, HJ
   Liu, J
   Seto, E
   Bian, K
   Murad, F
AF Sotolongo, Alex
   Monica, Fabiola Zakia
   Kots, Alex
   Xiao, Haijie
   Liu, Jun
   Seto, Edward
   Bian, Ka
   Murad, Ferid
TI Epigenetic regulation of soluble guanylate cyclase (sGC) 1 in breast
   cancer cells
SO FASEB JOURNAL
LA English
DT Article
DE histone acetyltransferase; histone deacetylase; inhibitors
ID HISTONE DEACETYLASE INHIBITORS; NITRIC-OXIDE SYNTHASE; MESENCHYMAL
   TRANSITION; PROTEIN ACETYLATION; TRICHOSTATIN-A; EXPRESSION; GENE;
   DIFFERENTIATION; STIMULATION; REPRESSION
AB Soluble guanylate cyclase (sGC) is a heterodimer composed of and subunits. The loss of sGC1 has been implicated in several vascular and nonvascular diseases. Our analysis showed that higher levels of sGC1 in breast cancer tissues are correlated with greater survival probability than lower sGC1 levels. However, there is no information on sGC regulation by epigenetic mechanisms. We examined the role of histone deacetylase (HDAC) inhibitors in regulating sGC1 and -1 expression in human breast cancer MDA-MB-231 and MDA-MB-468 cell lines. The class I HDAC inhibitors increased the expression of sGC1 more than sGC1. Transient overexpression of HDAC3, but not HDAC1 or HDAC2, significantly reduced sGC1 mRNA. Chromatin immunoprecipitation assay confirmed an enhanced binding of HDAC3 to the sGC1 proximal promoter, which could be reversed by panobinostat (LBH-589) treatment. Mutations at the CCAAT binding sequence, a major element regulating sGC1 expression, markedly reduced the efficacy of LBH-589 in augmenting sGC1 promoter activity. LBH-589 markedly enhanced the binding of nuclear transcription factor Y, subunit , to the sGC1 promoter (CCAAT binding sequence). In summary, HDAC3 is an endogenous antagonist of sGC1 expression. Inhibition of HDAC3 with targeted therapy could benefit treatment of the diseases associated with sGC1 down-regulation and/or deficiency such as cancer and several vascular-related diseases.Sotolongo, A., Monica, F. Z., Kots, A., Xiao, H., Liu, J., Seto, E., Bian, K., Murad, F. Epigenetic regulation of soluble guanylate cyclase (sGC) 1 in breast cancer cells.
C1 [Sotolongo, Alex; Monica, Fabiola Zakia; Kots, Alex; Xiao, Haijie; Liu, Jun; Seto, Edward; Bian, Ka; Murad, Ferid] George Washington Univ, Dept Biochem & Mol Med, Washington, DC USA.
   [Seto, Edward] George Washington Univ, Ctr Canc, Washington, DC USA.
   [Monica, Fabiola Zakia] Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, Campinas, SP, Brazil.
C3 George Washington University; George Washington University; Universidade
   Estadual de Campinas
RP Bian, K (通讯作者)，George Washington Univ, Sch Med, Dept Biochem & Mol Med, 2300 Eye St NW, Washington, DC 20037 USA.
EM bcmkxb@gwu.edu
RI Kots, Alexander/AAF-5404-2020; Monica, Fabiola/B-4191-2013
OI Monica, Fabiola/0000-0002-8449-6677; Kots, Alexander/0000-0002-5278-5888
FU SAo Paulo Research Foundation (FAPESP) [2013/02246-7]; Coordination for
   the Improvement of Higher Education Personnel Foundation (CAPES) [BEX
   6718-14]; State University of Campinas (UNICAMP); George Washington
   University; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [13/02246-7] Funding Source: FAPESP; Swedish Research Council
   [2013-02246] Funding Source: Swedish Research Council
FX F.Z.M. acknowledges the SAo Paulo Research Foundation (FAPESP;
   2013/02246-7), the Coordination for the Improvement of Higher Education
   Personnel Foundation (CAPES; BEX 6718-14), the State University of
   Campinas (UNICAMP), and George Washington University for research
   support. The authors thank Kleber Fertrin (University of Campinas) for
   valuable discussion of the experimental methods and results. Author
   contributions: A. Sotolongo and H. Xiao performed the experiments and
   analyzed the data; F. Z. Monica analyzed the data and wrote the
   manuscript; A. Kots analyzed the data; J. Liu perfomed the experiments;
   E. Seto supported the experiments and corrected the manuscript; K. Bian
   designed the experiments, analyzed the data and wrote the manuscript;
   and F. Murad conceived and supported the experiments, contributed
   reagents, sourced materials, provided analysis tools, and wrote the
   paper.
CR Alexandre EC, 2014, J PHARMACOL EXP THER, V349, P2, DOI 10.1124/jpet.113.211029
   Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6
   Bian K, 2014, NITRIC OXIDE-BIOL CH, V43, P3, DOI 10.1016/j.niox.2014.08.006
   Bian K, 2012, IUBMB LIFE, V64, P676, DOI 10.1002/iub.1057
   Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006
   Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444
   Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214
   Campanero MR, 2008, ONCOGENE, V27, P1263, DOI 10.1038/sj.onc.1210735
   Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200
   Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200
   Glaser KB, 2004, BIOCHEM BIOPH RES CO, V325, P683, DOI 10.1016/j.bbrc.2004.10.082
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Kang JH, 2008, J CELL BIOCHEM, V104, P1192, DOI 10.1002/jcb.21697
   KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23
   Kourea Helen P, 2014, Curr Mol Pharmacol, V7, P4
   Leiria LO, 2014, J UROLOGY, V191, P539, DOI 10.1016/j.juro.2013.09.020
   Li Y, 2015, ONCOTARGET, V6, P4345, DOI 10.18632/oncotarget.2999
   Lin JE, 2010, GASTROENTEROLOGY, V138, P241, DOI 10.1053/j.gastro.2009.08.064
   Marro ML, 2008, J BIOL CHEM, V283, P20027, DOI 10.1074/jbc.M801223200
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Monica F, 2014, OA BIOCH, V2, P3
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Mujoo K, 2010, NITRIC OXIDE-BIOL CH, V22, P43, DOI 10.1016/j.niox.2009.11.007
   MURAD F, 1988, COLD SPRING HARB SYM, V53, P1005, DOI 10.1101/SQB.1988.053.01.115
   Nakane M, 1994, Adv Pharmacol, V26, P7, DOI 10.1016/S1054-3589(08)60048-4
   Nielsen TO, 2015, CLIN CANCER RES, V21, P1779, DOI 10.1158/1078-0432.CCR-14-2552
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Peng Lirong, 2011, Handb Exp Pharmacol, V206, P39, DOI 10.1007/978-3-642-21631-2_3
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916
   RIBEIRO MO, 1992, HYPERTENSION, V20, P298, DOI 10.1161/01.HYP.20.3.298
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179
   Shailubhai K, 2000, CANCER RES, V60, P5151
   Sharina IG, 2003, P NATL ACAD SCI USA, V100, P11523, DOI 10.1073/pnas.1934338100
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Silva FH, 2014, J SEX MED, V11, P2661, DOI 10.1111/jsm.12682
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Weissmann N, 2014, AM J RESP CRIT CARE, V189, P1359, DOI 10.1164/rccm.201311-2037OC
   Wen HC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125518
   Wilson C, 2014, CANCER EPIDEM BIOMAR, V23, P2328, DOI 10.1158/1055-9965.EPI-14-0440
   Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
   Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113
   Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004
   Zhu HF, 2011, MOL PHARMACOL, V80, P1076, DOI 10.1124/mol.111.073585
   Zuzga DS, 2012, INT J CANCER, V130, P2539, DOI 10.1002/ijc.26257
NR 55
TC 13
Z9 13
U1 1
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2016
VL 30
IS 9
BP 3171
EP 3180
DI 10.1096/fj.201600339R
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA DV3JD
UT WOS:000382816300017
PM 27279362
DA 2025-01-12
ER

PT J
AU Jorgensen, EM
   Alderman, MH
   Taylor, HS
AF Jorgensen, Elisa M.
   Alderman, Myles H., III
   Taylor, Hugh S.
TI Preferential epigenetic programming of estrogen response after <i>in
   utero</i> xenoestrogen (bisphenol-A) exposure
SO FASEB JOURNAL
LA English
DT Article
DE endocrine disruptor; methylation; ER binding; uterus
ID ENDOCRINE DISRUPTORS; REPRODUCTIVE HEALTH; GENE-EXPRESSION;
   MAMMARY-GLAND; RECEPTOR; MECHANISM; ALTERS; TARGET; ALPHA
AB Bisphenol-A (BPA) is an environmentally ubiquitous estrogen-like endocrine-disrupting compound. Exposure to BPA in utero has been linked to female reproductive disorders, including endometrial hyperplasia and breast cancer. Estrogens are an etiological factor in many of these conditions. We sought to determine whether in utero exposure to BPA altered the global CpG methylation pattern of the uterine genome, subsequent gene expression, and estrogen response. Pregnant mice were exposed to an environmentally relevant dose of BPA or DMSO control. Uterine DNA and RNA were examined by using methylated DNA immunoprecipitation methylation microarray, expression microarray, and quantitative PCR. In utero BPA exposure altered the global CpG methylation profile of the uterine genome and subsequent gene expression. The effect on gene expression was not apparent until sexual maturation, which suggested that estrogen response was the primary alteration. Indeed, prenatal BPA exposure preferentially altered adult estrogen-responsive gene expression. Changes in estrogen response were accompanied by altered methylation that preferentially affected estrogen receptor- (ER)-binding genes. The majority of genes that demonstrated both altered expression and ER binding had decreased methylation. BPA selectively altered the normal developmental programming of estrogen-responsive genes via modification of the genes that bind ER. Gene-environment interactions driven by early life xenoestrogen exposure likely contributes to increased risk of estrogen-related disease in adults.Jorgensen, E. M., Alderman, M. H., III, Taylor, H. S. Preferential epigenetic programming of estrogen response after in utero xenoestrogen (bisphenol-A) exposure.
C1 [Jorgensen, Elisa M.; Alderman, Myles H., III; Taylor, Hugh S.] Yale Univ, Sch Med, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.
C3 Yale University
RP Taylor, HS (通讯作者)，Yale Univ, Sch Med, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.
EM hugh.taylor@yale.edu
OI Jorgensen, Elisa/0000-0002-6405-867X; Alderman III,
   Myles/0000-0001-8515-1462
FU U.S. National Institutes of Health (NIH) Eunice Kennedy Shriver National
   Institute of Child Health and Human Development [R01-HD076422]; NIH
   National Institute of Environmental Health Sciences [R01-ES010610]
FX The authors thank Aiping Lin (Department of Biostatistics, Yale
   University) and Xiaoqing Yu (Department of Public Health, Yale
   University) for assistance with data analysis. This work was supported
   by U.S. National Institutes of Health (NIH) Eunice Kennedy Shriver
   National Institute of Child Health and Human Development Grant
   R01-HD076422; and NIH National Institute of Environmental Health
   Sciences Grant R01-ES010610. Author contributions: E. M. Jorgensen, M.
   H. Alderman, and H. S. Taylor designed the research, analyzed data, and
   wrote the paper. E. M. Jorgensen and M. H. Alderman performed the
   research. The authors declare no conflicts of interest.
CR Adewale HB, 2009, BIOL REPROD, V81, P690, DOI 10.1095/biolreprod.109.078261
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071
   COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890
   Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067
   Delmas AL, 2011, CARCINOGENESIS, V32, P1625, DOI 10.1093/carcin/bgr193
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P404, DOI 10.1056/NEJM197108122850711
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53
   Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311
   Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773
   Holder AM, 2013, BREAST CANCER RES TR, V137, P319, DOI 10.1007/s10549-012-2354-4
   Howdeshell KL, 1999, NATURE, V401, P763, DOI 10.1038/44517
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Lakind JS, 2008, J EXPO SCI ENV EPID, V18, P608, DOI 10.1038/jes.2008.20
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Mileva G, 2014, INT J ENV RES PUB HE, V11, P7537, DOI 10.3390/ijerph110707537
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045
   Peretz J, 2014, ENVIRON HEALTH PERSP, V122, P775, DOI 10.1289/ehp.1307728
   Peruzzi D, 2009, CLIN CANCER RES, V15, P4104, DOI 10.1158/1078-0432.CCR-08-3226
   Rackow BW, 2008, FERTIL STERIL, V89, P1234, DOI [10.1016/j.fertnstert.2007.04.060, 10.1016/j.fertnstert.2007.12.030]
   Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Seisenberger S, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0330
   Sheehan DM, 2000, P SOC EXP BIOL MED, V224, P57, DOI 10.1046/j.1525-1373.2000.22401.x
   Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050
   Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5
   Yu NF, 2008, CURR MED CHEM, V15, P1350, DOI 10.2174/092986708784567653
NR 37
TC 48
Z9 52
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2016
VL 30
IS 9
BP 3194
EP 3201
DI 10.1096/fj.201500089R
PG 8
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA DV3JD
UT WOS:000382816300019
PM 27312807
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Xu, YM
   Li, X
   Wang, HT
   Xie, PM
   Yan, X
   Bai, Y
   Zhang, TG
AF Xu, Yanmei
   Li, Xia
   Wang, Hongtao
   Xie, Pengmu
   Yan, Xun
   Bai, Yu
   Zhang, Tingguo
TI Hypermethylation of <i>CDH13, DKK3</i> and <i>FOXL2</i> promoters and
   the expression of EZH2 in ovary granulosa cell tumors
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE granulosa cell tumors; DNA methylation; histone modifications; tumor
   suppressor gene; clinicopathological features
ID HUMAN HEPATOCELLULAR-CARCINOMA; H-CADHERIN CDH13; DNA-METHYLATION;
   ABERRANT METHYLATION; NONSMALL CELL; BREAST-CANCER; LUNG-CANCER;
   CLINICAL CHARACTERISTICS; PROGNOSTIC-SIGNIFICANCE; MUTATIONAL ANALYSIS
AB Aberrant epigenetic modification is associated with the development and progression of cancer. Hypermethylation of tumor suppressor gene promoters and cooperative histone modification have been considered to be the primary mechanisms of epigenetic modification. Ovary granulosa cell tumors (GCTs) are relatively rare, accounting for similar to 3% of all ovarian malignancies. The present study assessed hyper-methylation of the cadherin 13 (CDH13), dickkopf WNT signaling pathway inhibitor 3 (DKK3) and forkhead box L2 (FOXL2) promoters in 30 GCT tissues and 30 healthy control tissues using methylation-specific polymerase chain reaction analysis. The data showed that the frequencies of CDH13, DKK3 and FOXL2 promoter methylation were significantly higher in the GCT tissues, compared with the healthy control tissues (86.67, vs. 23.33%; 80, vs. 26.67% and 66.67, vs. 20%, respectively; P<0.001). Immunostaining of enhancer of zeste homolog 2 (EZH2), a histone H3K27 methyltransferase, showed that the EZH2 protein was expressed in 11 of the 30 GCT tissue samples, whereas no EZH2 protein was expressed in the 30 healthy control tissues (P<0.01). These data suggested that hypermethylation of the CDH13, DKK3 and FOXL2 gene promoters, and overexpression of the EZH2 protein were involved in the development of GCT.
C1 [Xu, Yanmei; Zhang, Tingguo] Shandong Univ, Inst Pathol & Pathophysiol, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
   [Xu, Yanmei; Xie, Pengmu; Yan, Xun; Bai, Yu] Shandong Shanxian Cent Hosp, Dept Pathol, Heze 274300, Shandong, Peoples R China.
   [Li, Xia] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Hongtao] Tianjin Med Univ Canc Inst & Hosp, Dept Gynecol & Obster, Natl Clin Res Canc, Tianjin 300060, Peoples R China.
C3 Shandong University; Air Force Military Medical University; Tianjin
   Medical University
RP Zhang, TG (通讯作者)，Shandong Univ, Inst Pathol & Pathophysiol, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM xymhky@126.com
CR Abudukadeer A, 2012, INT J MOL SCI, V13, P8353, DOI 10.3390/ijms13078353
   Amente S, 2011, AM J CANCER RES, V1, P413
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chen HY, 2015, AM J CANCER RES, V5, P180
   D'Angelo E, 2011, MODERN PATHOL, V24, P1360, DOI 10.1038/modpathol.2011.95
   Dhillon VS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-33
   Dhillon VS, 2004, CLIN CANCER RES, V10, P5537, DOI 10.1158/1078-0432.CCR-04-0228
   Dhillon VS, 2004, BRIT J CANCER, V90, P874, DOI 10.1038/sj.bjc.6601567
   FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
   Gomes A, 2014, REV PORT PNEUMOL, V20, P20, DOI 10.1016/j.rppneu.2013.07.003
   Hashem IAT, 2015, INFORM SYST, V47, P98, DOI 10.1016/j.is.2014.07.006
   Hayashi T, 2012, J CANCER RES CLIN, V138, P799, DOI 10.1007/s00432-012-1158-6
   Hibi K, 2005, DIS COLON RECTUM, V48, P1282, DOI 10.1007/s10350-004-0947-7
   Hoffmann MJ, 2007, CANCER BIOL THER, V6, P1403, DOI 10.4161/cbt.6.9.4542
   Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145
   Kang WS, 2013, J CANCER RES CLIN, V139, P97, DOI 10.1007/s00432-012-1262-7
   Kawakami M, 1999, INT J ONCOL, V15, P715
   Kim JS, 2005, CANCER, V104, P1825, DOI 10.1002/cncr.21409
   Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147
   Kontic M, 2012, CLIN LUNG CANCER, V13, P297, DOI 10.1016/j.cllc.2011.11.003
   Lee YK, 2008, INT J GYNECOL CANCER, V18, P642, DOI 10.1111/j.1525-1438.2007.01065.x
   Liang LB, 2015, TUMOR BIOL, V36, P1245, DOI 10.1007/s13277-014-2750-y
   Lin YL, 2014, MED SCI MONITOR, V20, P1572, DOI 10.12659/MSM.892130
   Ling QX, 2014, AM J CANCER RES, V4, P508
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Nishida N, 2012, HEPATOLOGY, V56, P994, DOI 10.1002/hep.25706
   Oseto K, 2014, J OBSTET GYNAECOL RE, V40, P1197, DOI 10.1111/jog.12324
   Ottolenghi C, 2005, HUM MOL GENET, V14, P2053, DOI 10.1093/hmg/ddi210
   Putku M, 2015, HUM GENET, V134, P291, DOI 10.1007/s00439-014-1521-6
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com
   Rosario R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046270
   Rush Margaret, 2009, Epigenetics, V4, P404
   Schmidt D, 2004, DEVELOPMENT, V131, P933, DOI 10.1242/dev.00969
   Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007
   Sun HD, 2012, GYNECOL ONCOL, V124, P244, DOI 10.1016/j.ygyno.2011.10.015
   Tao LL, 2015, CANCER BIOTHER RADIO, V30, P100, DOI 10.1089/cbr.2014.1797
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2002, CANCER RES, V62, P3382
   Tran S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076642
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Voorham QJM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-603
   Wang JJ, 2013, BIOCHEM BIOPH RES CO, V433, P470, DOI 10.1016/j.bbrc.2013.03.037
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Xue RL, 2014, ONCOTARGETS THER, V7, P1987, DOI 10.2147/OTT.S67355
   Yin DT, 2013, ENDOCR-RELAT CANCER, V20, P507, DOI 10.1530/ERC-13-0053
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
   Zhai X, 2014, ASIAN PAC J CANCER P, V15, P4925, DOI 10.7314/APJCP.2014.15.12.4925
   Zhao YX, 2013, ONCOL LETT, V5, P1211, DOI 10.3892/ol.2013.1161
   Zhong Yun-Hua, 2015, Asian Pac J Cancer Prev, V16, P1139
   Zhou Xiao-yu, 2010, Zhonghua Zhong Liu Za Zhi, V32, P328
NR 59
TC 14
Z9 14
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2016
VL 14
IS 3
BP 2739
EP 2745
DI 10.3892/mmr.2016.5521
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DU8EF
UT WOS:000382445400113
PM 27431680
OA Bronze
DA 2025-01-12
ER

PT J
AU Chen, JP
   Wang, FR
   Xu, JF
   He, ZX
   Lu, YH
   Wang, ZW
AF Chen, Jinpeng
   Wang, Feiran
   Xu, Junfei
   He, Zhixian
   Lu, Yuhua
   Wang, Zhiwei
TI The role of PAQR3 gene promoter hypermethylation in breast cancer and
   prognosis
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast cancer; PAQR3; methylation; prognosis
ID TUMOR-SUPPRESSOR; GOLGI-APPARATUS; CELL CARCINOMA; RKTG; EPIGENOMICS;
   PLAYS; RAF
AB PAQR3 is a tumor suppressor in breast cancer and its expression regulation mechanism has not been well elucidated. In this study, we found that PAQR3 expression was downregulated in breast cancer tissues, and the downregulation of PAQR3 expression was found to be significantly associated with aberrant methylation of the gene promoter. Methylation-specific PCR showed that hypermethylation of the PAQR3 gene was observed in 71.8% of the breast cancers, whereas it was found in only 28.2% of the corresponding non-tumor tissues. Moreover, we found that the PAQR3 promoter methylation status was related to lymph node metastasis (P=0.01). In addition, overexpression of PAQR3 inhibited breast cancer cell invasion and growth. Furthermore, PAQR3 expression was restored in MCF-7 cells after treatment with the demethylating agent, 5-aza-2-deoxy-cytidine, and the effect of demethylation induced invasion and proliferation suppression of MCF-7 cells. Collectively, our results suggested that the aberrant methylation of PAQR3 underlies its downregulation in breast cancer and our data indicated that epigenetic silencing of PAQR3 gene expression by promoter hypermethylation may play an important role in breast cancer.
C1 [Chen, Jinpeng; Wang, Feiran; Xu, Junfei; He, Zhixian; Lu, Yuhua; Wang, Zhiwei] Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University
RP Wang, ZW (通讯作者)，Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
EM youyi701@163.com
RI WANG, JIAXUAN/JMP-8599-2023; Chen, Jinpeng/AAG-4624-2021
FU Jiangsu Postdoctoral Science Foundation [1402202C]
FX This study was supported by the grants from the Jiangsu Postdoctoral
   Science Foundation (grant no. 1402202C).
CR Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fan FJ, 2008, CARCINOGENESIS, V29, P1157, DOI 10.1093/carcin/bgn119
   Fenaux Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS36, DOI 10.1038/ncponc0351
   Feng L, 2007, P NATL ACAD SCI USA, V104, P14348, DOI 10.1073/pnas.0701298104
   Hinestrosa MC, 2007, NAT REV CANCER, V7, P309, DOI 10.1038/nrc2113
   Jiang YH, 2011, CANCER RES, V71, P2959, DOI 10.1158/0008-5472.CAN-10-4077
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Li ZH, 2015, ONCOTARGET, V6, P12357, DOI 10.18632/oncotarget.3657
   Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168
   Liu CC, 2015, BIOCHEM J, V467, P415, DOI 10.1042/BJ20141392
   Liu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083083
   Luo X, 2008, BIOCHEM J, V414, P399, DOI 10.1042/BJ20080948
   Ma ZQ, 2015, TUMOR BIOL, V36, P3319, DOI 10.1007/s13277-014-2964-z
   Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2
   Wang LD, 2013, ENDOCRINOLOGY, V154, P4525, DOI 10.1210/en.2013-1633
   Wang X, 2013, DIABETES, V62, P444, DOI 10.2337/db12-0244
   Wang X, 2012, CARCINOGENESIS, V33, P2228, DOI 10.1093/carcin/bgs245
   Wu HG, 2014, ONCOL REP, V32, P2687, DOI 10.3892/or.2014.3532
   Wu Q, 2016, TUMOR BIOL, V37, P561, DOI 10.1007/s13277-015-3770-y
   Xie XD, 2008, CARCINOGENESIS, V29, P1632, DOI 10.1093/carcin/bgn139
   Yu X, 2015, AM J CANCER RES, V5, P2562
   Zhang Y, 2010, ONCOGENE, V29, P5404, DOI 10.1038/onc.2010.270
NR 23
TC 15
Z9 15
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD SEP
PY 2016
VL 36
IS 3
BP 1612
EP 1618
DI 10.3892/or.2016.4951
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU8ET
UT WOS:000382446800050
PM 27461225
OA Bronze
DA 2025-01-12
ER

PT J
AU Yu, LD
   Ham, K
   Gao, XH
   Castro, L
   Yan, YT
   Kissling, GE
   Tucker, CJ
   Flagler, N
   Dong, R
   Archer, TK
   Dixon, D
AF Yu, Linda
   Ham, Kyle
   Gao, Xiaohua
   Castro, Lysandra
   Yan, Yitang
   Kissling, Grace E.
   Tucker, Charles J.
   Flagler, Norris
   Dong, Ray
   Archer, Trevor K.
   Dixon, Darlene
TI Epigenetic regulation of transcription factor promoter regions by
   low-dose genistein through mitogen-activated protein kinase and
   mitogen-and-stress activated kinase 1 nongenomic signaling
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Epigenetic; Histone H3; Leiomyoma; MAPK(p44/42); MSK1
ID HISTONE H3 PHOSPHORYLATION; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER
   CELLS; HUMAN UTERINE LEIOMYOMAS; MATCHED MYOMETRIUM; GROWTH-FACTORS;
   ER-ALPHA; PATHWAY; CHROMATIN; TRANSDUCTION
AB Background: The phytoestrogen, genistein at low doses nongenomically activates mitogen-activated protein kinase p44/42 (MAPK(p44/42)) via estrogen receptor alpha (ER alpha) leading to proliferation of human uterine leiomyoma cells. In this study, we evaluated if MAPK(p44/42) could activate downstream effectors such as mitogen-and stress-activated protein kinase 1 (MSK1), which could then epigenetically modify histone H3 by phosphorylation following a low dose (1 mu g/ml) of genistein.
   Results: Using hormone-responsive immortalized human uterine leiomyoma (ht-UtLM) cells, we found that genistein activated MAPK(p44/42) and MSK1, and also increased phosphorylation of histone H3 at serine10 (H3S10ph) in ht-UtLM cells. Colocalization of phosphorylated MSK1 and H3S10ph was evident by confocal microscopy in ht-UtLM cells (r = 0.8533). Phosphorylation of both MSK1 and H3S10ph was abrogated by PD98059 (PD), a MEK1 kinase inhibitor, thereby supporting genistein's activation of MSK1 and Histone H3 was downstream of MAPK(p44/42). In proliferative (estrogenic) phase human uterine fibroid tissues, phosphorylated MSK1 and H3S10ph showed increased immunoexpression compared to normal myometrial tissues, similar to results observed in in vitro studies following low-dose genistein administration. Real-time RT-PCR arrays showed induction of growth-related transcription factor genes, EGR1, Elk1, ID1, and MYB (cMyb) with confirmation by western blot, downstream of MAPK in response to low-dose genistein in ht-UtLM cells. Additionally, genistein induced associations of promoter regions of the above transcription factors with H3S10ph as evidenced by Chromatin Immunoprecipitation (ChIP) assays, which were inhibited by PD. Therefore, genistein epigenetically modified histone H3 by phosphorylation of serine 10, which was regulated by MSK1 and MAPK activation.
   Conclusion: Histone H3 phosphorylation possibly represents a mechanism whereby increased transcriptional activation occurs following low-dose genistein exposure.
C1 [Yu, Linda; Ham, Kyle; Gao, Xiaohua; Castro, Lysandra; Yan, Yitang; Dong, Ray; Dixon, Darlene] NIEHS, Mol Pathogenesis Grp, Toxicol Program NTP Lab, Div NTP DNTP,NIH,US Dept Hlth & Human Serv HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Kissling, Grace E.] NIEHS, Biostat & Computat Biol Branch, DIR, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Tucker, Charles J.] NIEHS, Signal Transduct Lab, DIR, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Flagler, Norris] NIEHS, Cellular & Mol Pathol Branch, DNTP, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Archer, Trevor K.] NIEHS, Chromatin & Gene Express Grp, Epigenet & Stem Cell Biol Lab, DIR,NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS); National Institutes of Health (NIH) - USA; NIH National
   Institute of Environmental Health Sciences (NIEHS); National Institutes
   of Health (NIH) - USA; NIH National Institute of Environmental Health
   Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH
   National Institute of Environmental Health Sciences (NIEHS)
RP Dixon, D (通讯作者)，NIEHS, Mol Pathogenesis Grp, Toxicol Program NTP Lab, Div NTP DNTP,NIH,US Dept Hlth & Human Serv HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
EM dixon@niehs.nih.gov
RI Tucker, Charles/JZT-3183-2024
OI Tucker, Charles Jeffrey Jeff CJ Tucker/0009-0005-4329-7910; Archer,
   Trevor K/0000-0001-7651-3644
FU Intramural Research Program of the NIH; NIEHS; DNTP
FX The authors kindly thank Drs. Wei Qu and Kyathanahalli Janardhan for
   their critical review of this manuscript. The authors would also like to
   thank Alicia B. Moore for her excellent assistance with formatting the
   manuscript. This research was supported by the Intramural Research
   Program of the NIH, NIEHS and DNTP.
CR [Anonymous], 1998, Practical Nonparametric Statistics
   Arthur JSC, 2008, FRONT BIOSCI-LANDMRK, V13, P5866, DOI 10.2741/3122
   Bulun SE, 2013, NEW ENGL J MED, V369, P1344, DOI 10.1056/NEJMra1209993
   Cardozo ER, 2012, AM J OBSTET GYNECOL, V206, DOI [10.1016/j.ajog.2011.12.002, 10.1016/j.ajog.2012.08.020]
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E
   Choi EJ, 2013, MOL MED REP, V7, P781, DOI 10.3892/mmr.2013.1283
   Ciarmela P, 2011, HUM REPROD UPDATE, V17, P772, DOI 10.1093/humupd/dmr031
   Conover W.J., 1999, Practical Nonparametric Statistics, Vthird
   DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876
   Di X, 2008, HUM REPROD, V23, P1873, DOI 10.1093/humrep/den087
   Dixon D, 2000, ENVIRON HEALTH PERSP, V108, P795, DOI 10.2307/3454309
   Dong ZG, 2006, MOL CARCINOGEN, V45, P416, DOI 10.1002/mc.20220
   Drayer SM, 2015, INT J GYNECOL OBSTET, V131, P117, DOI 10.1016/j.ijgo.2015.04.051
   Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030
   Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121
   Espino PS, 2006, CANCER RES, V66, P4610, DOI 10.1158/0008-5472.CAN-05-4251
   Espino PS, 2009, INT J CANCER, V124, P562, DOI 10.1002/ijc.23959
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   He SH, 2008, J CELL BIOCHEM, V104, P2004, DOI 10.1002/jcb.21485
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Hermon TL, 2008, VIRCHOWS ARCH, V453, P557, DOI 10.1007/s00428-008-0679-5
   Hong SH, 2010, PLACENTA, V31, P240, DOI 10.1016/j.placenta.2009.11.015
   Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158/0008-5472.CAN-07-6597
   Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007
   Lipovka Y, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160017
   Maw MK, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-430
   Moore AB, 2007, HUM REPROD, V22, P2623, DOI 10.1093/humrep/dem185
   Moutsatsou Paraskevi, 2007, Hormones (Athens), V6, P173
   Pagel JI, 2011, INDIAN J BIOCHEM BIO, V48, P226
   Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003
   Petroff BK, 2006, APPL IMMUNOHISTO M M, V14, P360, DOI 10.1097/00129039-200609000-00017
   Pollack AZ, 2015, ENVIRON RES, V137, P101, DOI 10.1016/j.envres.2014.06.028
   Seo HS, 2006, BREAST CANCER RES TR, V99, P121, DOI 10.1007/s10549-006-9191-2
   Sokal RR., 2012, Biometry, V4
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Vicent GP, 2008, J STEROID BIOCHEM, V109, P344, DOI 10.1016/j.jsbmb.2008.03.015
   Vitale DC, 2013, EUR J DRUG METAB PH, V33, P885
   Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036
   Yu LD, 2008, MOL MED, V14, P264, DOI 10.2119/2007-00101.Yu
   Yu Linda, 2012, J Signal Transduct, V2012, P204236, DOI 10.1155/2012/204236
   Zhang HM, 2008, NUCLEIC ACIDS RES, V36, P2594, DOI 10.1093/nar/gkn099
   Zhou Y, 2011, FRONT BIOSCI-LANDMRK, V16, P1109, DOI 10.2741/3738
NR 44
TC 12
Z9 12
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD AUG 31
PY 2016
VL 14
AR 18
DI 10.1186/s12964-016-0141-2
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DV3IV
UT WOS:000382815400001
PM 27582276
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kuo, LT
   Lu, HY
   Lee, CC
   Tsai, JC
   Lai, HS
   Tseng, HM
   Kuo, MF
   Tu, YK
AF Kuo, Lu-Ting
   Lu, Hsueh-Yi
   Lee, Chien-Chang
   Tsai, Jui-Chang
   Lai, Hong-Shiee
   Tseng, Ham-Min
   Kuo, Meng-Fai
   Tu, Yong-Kwang
TI Multiplexed methylation profiles of tumor suppressor genes and clinical
   outcome in oligodendroglial tumors
SO CANCER MEDICINE
LA English
DT Article
DE ESR1; IGSF4; methylation; multiplex ligation-dependent probe
   amplification assay; oligodendroglioma
ID DNA METHYLATION; MS-MLPA; PROMOTER METHYLATION; EXPRESSION ANALYSIS;
   COLORECTAL-CANCER; POOR-PROGNOSIS; BREAST-CANCER; LUNG-CANCER; CPG
   ISLANDS; HYPERMETHYLATION
AB Aberrant methylation has been associated with transcriptional inactivation of tumor-related genes in a wide spectrum of human neoplasms. The influence of DNA methylation in oligodendroglial tumors is not fully understood. Genomic DNA was isolated from 61 oligodendroglial tumors for analysis of methylation using methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA). We correlated methylation status with clinicopathological findings and outcome. The genes found to be most frequently methylated in oligodendroglial tumors were RASSF1A (80.3%), CASP8 (70.5%), and CDKN2A (52.5%). Kaplan-Meier survival curve analysis demonstrated longer duration of progression-free survival in patients with 19q loss, aged less than 38years, and with a proliferative index of less than 5%. Methylation of the ESR1 promoter is significantly associated with shorter duration of overall survival and progression-free survival, and that methylation of IGSF4 and RASSF1A is significantly associated with shorter duration of progression-free survival. However, none of the methylation status of ESR1, IGSF4, and RASSF1A was of prognostic value for survival in a multivariate Cox model. A number of novel and interesting epigenetic alterations were identified in this study. The findings highlight the importance of methylation profiles in oligodendroglial tumors and their possible involvement in tumorigenesis.
C1 [Kuo, Lu-Ting; Tsai, Jui-Chang; Tseng, Ham-Min; Kuo, Meng-Fai; Tu, Yong-Kwang] Natl Taiwan Univ Hosp, Div Neurosurg, Dept Surg, Taipei 100, Taiwan.
   [Lu, Hsueh-Yi] Natl Yunlin Univ Sci & Technol, Dept Ind Engn & Management, Touliu 640, Yunlin, Taiwan.
   [Lee, Chien-Chang] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Emergency Med, Touliu 640, Yunlin, Taiwan.
   [Lai, Hong-Shiee] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Yunlin University Science & Technology; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University Hospital
RP Kuo, LT (通讯作者)，Natl Taiwan Univ Hosp, Div Neurosurg, 1 Jen Ai Rd Sect 1, Taipei 100, Taiwan.
EM kuoluting@gmail.com
RI liu, xingsheng/AAI-2278-2019; Kuo, Lu-Ting/AAU-3205-2021; Lee,
   Chien-Chang/HHM-5986-2022
OI KUO, MENG-FAI/0000-0002-1803-2719; Lai, Hong-Shiee/0000-0002-7958-2183;
   Kuo, Lu-Ting/0000-0002-1405-8700; Tu, Yong-kwang/0000-0003-2113-1176;
   LEE, CHIEN-CHANG/0000-0002-1243-2463; TSAI,
   JUI-CHANG/0000-0003-2723-6841
FU National Taiwan University Hospital [NTUH95A18, NTUH96N018]; National
   Science Council [98-2314-B-002-045-MY2]
FX This study was supported by grants from National Taiwan University
   Hospital (NTUH95A18, NTUH96N018) (L. Kuo) and the National Science
   Council (98-2314-B-002-045-MY2) (L. Kuo).
CR Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7
   Bello MJ, 2004, ACTA NEUROPATHOL, V108, P413, DOI 10.1007/s00401-004-0911-6
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Buhmeida A, 2011, ANTICANCER RES, V31, P2975
   Castro M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-86
   Coons SW, 1997, NEUROSURGERY, V41, P878, DOI 10.1097/00006123-199710000-00021
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   Darling J L, 1991, Br J Neurosurg, V5, P438
   Dehais C, 2006, CANCER-AM CANCER SOC, V107, P1891, DOI 10.1002/cncr.22211
   Fallon KB, 2004, J NEUROPATH EXP NEUR, V63, P314, DOI 10.1093/jnen/63.4.314
   Franco-Hernandez C, 2007, INT J ONCOL, V30, P209
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Gumy-Pause F, 2012, GENE CHROMOSOME CANC, V51, P174, DOI 10.1002/gcc.20941
   HEEGAARD S, 1995, CANCER, V76, P1809, DOI 10.1002/1097-0142(19951115)76:10<1809::AID-CNCR2820761020>3.0.CO;2-I
   Huang ZH, 2011, EXP MOL PATHOL, V91, P702, DOI 10.1016/j.yexmp.2011.08.004
   Issa JPJ, 1997, LEUKEMIA, V11, pS7
   Jeuken JW, 2007, LAB INVEST, V87, P1055, DOI 10.1038/labinvest.3700664
   Kaina B, 2002, INT J CLIN PHARM TH, V40, P354
   Kikuchi S, 2006, CANCER-AM CANCER SOC, V106, P1751, DOI 10.1002/cncr.21800
   Kuo LT, 2009, INT J CANCER, V124, P2872, DOI 10.1002/ijc.24303
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Lee JY, 2011, CHILD NERV SYST, V27, P1877, DOI 10.1007/s00381-011-1525-7
   Livide G, 2012, PATHOL ONCOL RES, V18, P703, DOI 10.1007/s12253-012-9498-8
   McLendon RE, 2005, CANCER, V104, P1693, DOI 10.1002/cncr.21362
   Mitchell SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-54
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Peters I, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-49
   Sardi I, 2009, ONCOL REP, V22, P773, DOI 10.3892/or_00000499
   SCHMIDT EE, 1994, CANCER RES, V54, P6321
   Schwarzenbach H, 2011, J CANCER RES CLIN, V137, P811, DOI 10.1007/s00432-010-0941-5
   Simon M, 2006, ONCOL REP, V16, P127
   Stephen Josena K, 2011, Cancers (Basel), V3, P1732, DOI 10.3390/cancers3021732
   Stephen JK, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0005-3
   Uhlmann K, 2003, INT J CANCER, V106, P52, DOI 10.1002/ijc.11175
   Wolter M, 2001, J NEUROPATH EXP NEUR, V60, P1170, DOI 10.1093/jnen/60.12.1170
NR 39
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD AUG
PY 2016
VL 5
IS 8
BP 1830
EP 1839
DI 10.1002/cam4.762
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DS6XM
UT WOS:000380926600012
PM 27367901
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Liu, SL
   Sui, YF
   Lin, MZ
AF Liu, S. -L.
   Sui, Y. -F.
   Lin, M. -Z.
TI MiR-375 is epigenetically downregulated due to promoter methylation and
   modulates multi-drug resistance in breast cancer cells via targeting
   YBX1
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE MiR-375; Methylation; MDR; YBX1; Breast cancer
ID PACLITAXEL RESISTANCE; CHEMORESISTANCE; YB-1; HYPERMETHYLATION;
   SIGNATURES; EMT
AB OBJECTIVE: In this study, we firstly verified how miR-375 is downregulated in breast cancer cells with multi-drug resistance (MDR) and further investigated the regulative effect of miR-375 on Ybx1 expression.
   MATERIALS AND METHODS: MiR-375 expression and promoter methylation status were studied by retrieving data in NCBI GEO Datasets, qRT-PCR and Methylation-Specific PCR (MSP) assay. Drug sensitivity of the cancer cells was assessed using MTT assay. The binding between miR-375 and YBX1 gene was predicted using Targetscan 7.1 and verified using western blot and dual luciferase assay.
   RESULTS: MiR-375 is significantly downregulated in both MCF-7/ADM and MCF-7/PTX cells than in MCF-7 cells. MCF-7/ADM and MCF-7/PTX cells had significantly higher level of promoter methylation than MCF-7 cells. 5-AZA-dC treatment significantly reduced the methylation in MCF-7/ADM and MCF-7/PTX cells and increased miR-375 expression. MiR-375 can directly target 3'UTR of YBX1 and thereby decrease its expression in MCF-7/ADM and MCF-7/PTX cells. Both miR-375 overexpression and YBX1 knockdown significantly decreased P-gp expression and increased chemosensitivity of the cancer cells.
   CONCLUSIONS: MiR-375 is downregulated in MCF-7/ADM and MCF-7/PTX cells, and its down-regulation is a result of promoter methylation. MiR-375 can directly target 3'UTR of YBX1 and thereby decrease its expression, which might be an important mechanism of MDR in breast cancer cells.
C1 [Liu, S. -L.] Peoples Hosp Changle, Clin Lab, Weifang, Shandong, Peoples R China.
   [Sui, Y. -F.; Lin, M. -Z.] Dongying Hekou Peoples Hosp, Clin Lab, Dongying, Shandong, Peoples R China.
   Weifang Peoples Hosp, Dept Breast Surg, Weifang, Shandong, Peoples R China.
RP Lin, MZ (通讯作者)，Dongying Hekou Peoples Hosp, Clin Lab, Dongying, Shandong, Peoples R China.
EM mingzhenlin1@outlook.com
CR [Anonymous], BIOCH RES INT
   [Anonymous], ONCOTARGET
   Bagasra O, 2004, J MOL HISTOL, V35, P545
   Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007
   Cui FY, 2016, ONCOL REP, V36, P487, DOI 10.3892/or.2016.4834
   Davies AH, 2015, ONCOTARGET, V6, P20570, DOI 10.18632/oncotarget.4135
   Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056
   Guay D, 2008, INT J BIOCHEM CELL B, V40, P2492, DOI 10.1016/j.biocel.2008.04.011
   He DX, 2014, FEBS J, V281, P4718, DOI 10.1111/febs.13012
   Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010
   Huang JX, 2005, INT J ONCOL, V26, P607
   Kang Y, 2013, JNCI-J NATL CANCER I, V105, P1485, DOI 10.1093/jnci/djt210
   Kerb R, 2001, PHARMACOGENOMICS, V2, P51, DOI 10.1517/14622416.2.1.51
   Lasham A, 2016, INT J CANCER, V139, P1157, DOI 10.1002/ijc.30137
   Li B, 2013, EUR REV MED PHARMACO, V17, P1191
   Li L, 2016, EUR REV MED PHARMACO, V20, P2004
   Lu L, 2012, EUR REV MED PHARMACO, V16, P1271
   Lu YJ, 2016, INFLAMMATION, V39, P10, DOI [10.1007/s10753-015-0217-y, 10.1155/2016/3961903]
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Ren GB, 2016, EUR REV MED PHARMACO, V20, P657
   Shen Y, 2013, BRIT J CANCER, V109, P92, DOI 10.1038/bjc.2013.308
   Shen YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109299
   Sun EH, 2014, EUR REV MED PHARMACO, V18, P2783
   Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076
   Traverso N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/972913
   Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128
   Ye XM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-134
   Zhu XL, 2013, ACTA BIOCH BIOPH SIN, V45, P80, DOI 10.1093/abbs/gms099
NR 29
TC 32
Z9 34
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD AUG
PY 2016
VL 20
IS 15
BP 3223
EP 3229
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DU8KF
UT WOS:000382461300013
PM 27466996
DA 2025-01-12
ER

PT J
AU Zhang, JL
   Zhu, XB
   Li, YH
   Zhu, LY
   Li, SM
   Zheng, GY
   Ren, Q
   Xiao, YH
   Feng, FM
AF Zhang, Jinling
   Zhu, Xuebin
   Li, Yuhong
   Zhu, Lingyan
   Li, Shiming
   Zheng, Guoying
   Ren, Qi
   Xiao, Yonghong
   Feng, Fumin
TI Correlation of CpG Island Methylation of the Cytochrome P450 2E1/2D6
   Genes with Liver Injury Induced by Anti-Tuberculosis Drugs: A Nested
   Case-Control Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE tuberculosis; anti-TB drug-induced liver injury; methylation; cytochrome
   P450 2E1; cytochrome P450 2D6; case-control study
ID DNA METHYLATION; BREAST-CANCER; LUNG-CANCER; LOW-DOSAGE; POLYMORPHISMS;
   SUSCEPTIBILITY; POPULATION; METABOLISM; PROMOTER; ENZYMES
AB This study investigated the role of CpG island methylation of the CYP2E1 and CYP2D6 genes in liver injury induced by anti-TB drugs from an epigenetic perspective in a Chinese cohort. A 1:1 matched nested case-control study design was applied. Pulmonary tuberculosis (TB) patients, who underwent standard anti-TB therapy and developed liver injury were defined as cases, while those who did not develop liver injury were defined as control. The two groups were matched in terms of sex, treatment regimen, and age. In 114 pairs of cases, CpG island methylation levels of the CYP2E1 and CYP2D6 genes in plasma cell-free DNA were found to be significantly correlated with the occurrence of anti-TB drug-induced liver injury (ADLI), with odds ratio (OR) values of 2.429 and 3.500, respectively (p < 0.01). Moreover, through multivariate logistic regression analysis, CpG island methylation of the CYP2E1 and CYP2D6 genes in plasma cell-free DNA were found to be significantly correlated with the occurrence of ADLI, with adjusted OR values of 4.390 (95% confidence interval (CI):1.982-9.724) and 9.193 (95% CI:3.624-25.888), respectively (p < 0.001). These results suggest that aberrantly elevated methylation of CpG islands of the CYP2E1 and CYP2D6 genes in plasma cell-free DNA may increase the risk of ADLI in Chinese TB patients.
C1 [Zhang, Jinling; Zhu, Xuebin; Li, Yuhong; Zhu, Lingyan; Zheng, Guoying; Ren, Qi; Xiao, Yonghong; Feng, Fumin] North China Univ Sci & Technol, Sch Publ Hlth, Hebei Prov Key Lab Occupat Hlth & Safety Coal Ind, 57 Jianshe Rd, Tangshan 063000, Peoples R China.
   [Li, Shiming] Tangshan TB Hosp, Dept Clin Labs, Tangshan 063000, Peoples R China.
C3 North China University of Science & Technology
RP Feng, FM (通讯作者)，North China Univ Sci & Technol, Sch Publ Hlth, Hebei Prov Key Lab Occupat Hlth & Safety Coal Ind, 57 Jianshe Rd, Tangshan 063000, Peoples R China.
EM xiaoyao_1986@126.com; zxb5060408412@sina.com; 15133912746@163.com;
   erheyan@163.com; lsm2268909good@163.com; zhengying0918@aliyun.com;
   qren0819@hotmail.com; kycxyh@tom.com; fm_feng@sina.com
RI weng, xin/HNQ-8347-2023; Xiao, Yonghong/AAF-3743-2020
OI Feng, Fumin/0000-0001-6506-2235
FU National Natural Science Foundation of China [81041096]
FX This study was supported by National Natural Science Foundation of China
   (No.: 81041096). We are grateful to the staffs in Clinical Laboratories
   Department at Tangshan Tuberculosis Hospital, for their support with the
   samples collection. And we thank all the TB patients participating in
   this study.
CR Anker P, 2001, CLIN CHIM ACTA, V313, P143, DOI 10.1016/S0009-8981(01)00666-0
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Castillejos-López MD, 2008, REV INVEST CLIN, V60, P47
   Chang H, 2008, EXP MOL PATHOL, V85, P96, DOI 10.1016/j.yexmp.2008.07.001
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Fukino K, 2008, J TOXICOL SCI, V33, P187, DOI 10.2131/jts.33.187
   Gao Y, 1999, MUTAT RES-GEN TOX EN, V444, P441, DOI 10.1016/S1383-5718(99)00092-3
   Huang YS, 2003, HEPATOLOGY, V37, P924, DOI 10.1053/jhep.2003.50144
   Kim SJ, 2010, J MOL MED, V88, P1123, DOI 10.1007/s00109-010-0652-z
   Kovalenko VM, 2007, TOXICOL APPL PHARM, V225, P293, DOI 10.1016/j.taap.2007.08.011
   Le Marchand L, 1998, CANCER RES, V58, P4858
   Lopez-Serra L, 2008, BRIT J CANCER, V98, P1881, DOI 10.1038/sj.bjc.6604374
   Marez D, 1997, PHARMACOGENETICS, V7, P193, DOI 10.1097/00008571-199706000-00004
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Padjen K, 2005, MOL CELL BIOL, V25, P4782, DOI 10.1128/MCB.25.11.4782-4791.2005
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Truong PK, 2014, ASIAN PAC J CANCER P, V15, P9607, DOI 10.7314/APJCP.2014.15.22.9607
   Qi L, 2012, TOHOKU J EXP MED, V228, P43, DOI 10.1620/tjem.228.43
   Rendic S, 2015, CHEM RES TOXICOL, V28, P38, DOI 10.1021/tx500444e
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Saeed HM, 2013, ASIAN PAC J CANCER P, V14, P3761, DOI 10.7314/APJCP.2013.14.6.3761
   Schlesselman James J., 1982, CASE CONTROL STUDIES, P144
   Schutz C, 2012, SAMJ S AFR MED J, V102, P506, DOI 10.7196/SAMJ.5650
   Shanmugam Muthu K, 2013, Subcell Biochem, V61, P627, DOI 10.1007/978-94-007-4525-4_27
   Shen LH, 2013, ENVIRON TOXICOL PHAR, V36, P149, DOI 10.1016/j.etap.2013.03.016
   Shukla D, 2013, BIOMED PAP, V157, P304, DOI 10.5507/bp.2013.028
   Snykers S, 2009, J HEPATOL, V51, P187, DOI 10.1016/j.jhep.2009.03.009
   Sun F, 2008, INT J TUBERC LUNG D, V12, P994
   Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x
   Turesky RJ, 2011, CHEM RES TOXICOL, V24, P1169, DOI 10.1021/tx200135s
   Vaissière T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833
   Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC
   Yimer G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027810
   Zhang B, 2011, ENVIRON TOXICOL PHAR, V32, P486, DOI 10.1016/j.etap.2011.07.001
   Zhou SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483
NR 35
TC 14
Z9 18
U1 0
U2 11
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2016
VL 13
IS 8
AR 776
DI 10.3390/ijerph13080776
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DU8KV
UT WOS:000382462900031
PM 27490558
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, XM
   Li, C
   Wang, D
   Chen, Q
   Li, CL
   Li, HJ
AF Zhang, Xuemei
   Li, Chuan
   Wang, Da
   Chen, Qu
   Li, Chang-Long
   Li, Hong-Jiang
TI Aberrant methylation of <i>ATG2B</i>, <i>ATG4D</i>, <i>ATG9A</i> and
   <i>ATG9B</i> CpG island promoter is associated with decreased mRNA
   expression in sporadic breast carcinoma
SO GENE
LA English
DT Article
DE Autophagy-related gene; Breast cancer; Gene expression; Methylation;
   Clinicopathological revalance
ID DUAL ROLES; AUTOPHAGY; COMPLEX; CANCER; SURVIVAL; PROTEIN; GENE
AB Epigenetic modifications are critical determinants in tumor initiation and progression. This study aims to detect the promoter methylation status and the mRNA expression levels of ATG2B, ATG4D, ATG9A and ATG9B, and then to explore their relationship in invasive ductal carcinomas (IDCs) and matched normal tissues (MNTs) of the breast. Methylation was observed as follows: 61.0% in ATG2B, 46.8% in ATG4D, 56.4% in ATG9A, and 74.0% in ATG9B of IDCs. Meanwhile, their mRNA expression levels of the IDCs was lower than that of the MNTs (P < 0.001, P = 0.019, P < 0.001 and P < 0.001, respectively). Methylated IDCs of ATG2B, ATG9A, ATG9B and unmethylated ATG4D, ATG9B showed significantly lower expression values compared to the MNTs (P = 0.003, P < 0.001, P < 0.001, P = 0.014 and P = 0.002, respectively). The methylations of ATG2B and ATG9B were related to their lower expression levels in IDCs (P = 0.017 and P = 0.023). Moreover, ATG2B methylation was positively associated with the grade (P = 0.024) and TNM stage (P = 0.015); Methylation of ATG4D and ATG9A was positively correlated to lymph node involvement (P = 0.012 and P = 0.018), while methylation of ATG9B appeared susceptible to CK5/6 positive status and deteriorated TNM stages (P = 0.003 and P = 0.012). Moreover, the decreased expression of ATG2B was related to the ER and PR status (P = 0.004 and P = 0.003). The ER, HER-2 and lymph node metastasis status are the determinants to reducing the expression of ATG4D, ATG9A and ATG9B (P = 0.026, P = 0.010 and P = 0.011, respectively). This study highlights the transcriptional inactivation mechanisms of ATG2B, ATG4D, ATG9A and ATG9B promoter methylation status and the possible origin of autophagy signal pathway repression in IDCs. (C) 2016 Published by Elsevier B.V.
C1 [Zhang, Xuemei; Li, Chuan; Wang, Da; Chen, Qu; Li, Chang-Long] Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu, Sichuan, Peoples R China.
   [Li, Hong-Jiang] Sichuan Univ, West China Hosp, Dept Thyroid & Breast Surg, Chengdu, Sichuan Provinc, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, CL (通讯作者)，Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu, Sichuan, Peoples R China.; Li, HJ (通讯作者)，Sichuan Univ, West China Hosp, Dept Thyroid & Breast Surg, Chengdu, Sichuan Provinc, Peoples R China.
EM changlongli@scu.edu.cn; lihongjiang@sohu.com
RI Hongjiang, Li/AAV-3060-2021
FU National Natural Science Foundation of China [0040105401080]
FX This study is supported by grants from National Natural Science
   Foundation of China (grant No. 0040105401080). We also thank the editor
   and anonymous reviewers for their helpful and constructive comments for
   improving the manuscript.
CR Aine M, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0144-4
   Au KY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146770
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307
   Füllgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   He CC, 2008, MOL BIOL CELL, V19, P5506, DOI 10.1091/mbc.E08-05-0544
   Itakura E, 2012, J CELL SCI, V125, P1488, DOI 10.1242/jcs.094110
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kojima T, 2015, REPROD BIOL, V15, P131, DOI 10.1016/j.repbio.2015.05.001
   Kusama Y, 2009, APOPTOSIS, V14, P1165, DOI 10.1007/s10495-009-0390-2
   Kyöstilä K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005169
   Li M, 2011, J BIOL CHEM, V286, P7327, DOI 10.1074/jbc.M110.199059
   Morani F, 2014, ENDOCR-RELAT CANCER, V21, pR13, DOI 10.1530/ERC-13-0271
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Obara K, 2008, J BIOL CHEM, V283, P23972, DOI 10.1074/jbc.M803180200
   Orsi A, 2012, MOL BIOL CELL, V23, P1860, DOI 10.1091/mbc.E11-09-0746
   Romanyuk D, 2011, ACTA BIOCHIM POL, V58, P365
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Sui XB, 2015, CANCER LETT, V360, P106, DOI 10.1016/j.canlet.2015.02.009
   Takahashi Y, 2012, BREAST CANCER-TOKYO, V19, P242, DOI 10.1007/s12282-011-0272-7
   Tamura H, 2010, J HISTOCHEM CYTOCHEM, V58, P443, DOI 10.1369/jhc.2010.955690
   Tang JY, 2013, VIRCHOWS ARCH, V463, P737, DOI 10.1007/s00428-013-1482-5
   Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Yu ZQ, 2012, AUTOPHAGY, V8, P883, DOI 10.4161/auto.19652
   Zavodszky E, 2013, FEBS LETT, V587, P1988, DOI 10.1016/j.febslet.2013.04.025
NR 32
TC 32
Z9 34
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD SEP 30
PY 2016
VL 590
IS 2
BP 285
EP 292
DI 10.1016/j.gene.2016.05.036
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DT9SN
UT WOS:000381842700012
PM 27265029
DA 2025-01-12
ER

PT J
AU Mao, X
   Gauche, C
   Coughtrie, MWH
   Bui, C
   Gulberti, S
   Merhi-Soussi, F
   Ramalanjaona, N
   Bertin-Jung, I
   Diot, A
   Dumas, D
   Caires, ND
   Thompson, AM
   Bourdon, JC
   Ouzzine, M
   Fournel-Gigleux, S
AF Mao, X.
   Gauche, C.
   Coughtrie, M. W. H.
   Bui, C.
   Gulberti, S.
   Merhi-Soussi, F.
   Ramalanjaona, N.
   Bertin-Jung, I.
   Diot, A.
   Dumas, D.
   Caires, N. De Freitas
   Thompson, A. M.
   Bourdon, J-C
   Ouzzine, M.
   Fournel-Gigleux, S.
TI The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor
   regulator and a prognostic marker in breast cancer
SO ONCOGENE
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; EXPRESSION; RECEPTOR; CELLS; PROTEOGLYCANS;
   METHYLATION; MAMMARY; HYPERMETHYLATION; BIOSYNTHESIS; SPECIFICITY
AB Heparan sulfate (HS) proteoglycan chains are key components of the breast tumor microenvironment that critically influence the behavior of cancer cells. It is established that abnormal synthesis and processing of HS play a prominent role in tumorigenesis, albeit mechanisms remain mostly obscure. HS function is mainly controlled by sulfotransferases, and here we report a novel cellular and pathophysiological significance for the 3-O-sulfotransferase 3-OST3A (HS3ST3A), catalyzing the final maturation step of HS, in breast cancer. We show that 3-OST3A is epigenetically repressed in all breast cancer cell lines of a panel representative of distinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloan-kettering breast cancer (SKBR3) cells. Epigenetic mechanisms involved both DNA methylation and histone modifications, producing different repressive chromatin environments depending on the cell molecular signature. Gain and loss of function experiments by cDNA and siRNA transfection revealed profound effects of 3-OST3A expression on cell behavior including apoptosis, proliferation, response to trastuzumab in vitro and tumor growth in xenografted mice. 3-OST3A exerted dual activities acting as tumor-suppressor in lumA-michigan cancer foundation (MCF)-7 and triple negative-MD Anderson (MDA) metastatic breast (MB)-231 cells, or as an oncogenic factor in HER2+-SKBR3 cells. Mechanistically, fluorescence-resonance energy transfer-fluorescence-lifetime imaging microscopy experiments indicated that the effects of 3-OST3A in MCF-7 cells were mediated by altered interactions between HS and fibroblast growth factor-7 (FGF-7). Further, this interplay between HS and FGF-7 modulated downstream ERK, AKT and p38 cascades, suggesting that altering 3-O-sulfation affects FGFR2IIIb-mediated signaling. Corroborating our cellular data, a clinical study conducted in a cohort of breast cancer patients uncovered that, in HER2+ patients, high level expression of 3-OST3A in tumors was associated with reduced relapse-free survival. Our findings define 3-OST3A as a novel regulator of breast cancer pathogenicity, displaying tumor-suppressive or oncogenic activities in a cell-and tumor-dependent context, and demonstrate the clinical value of the HS-O-sulfotransferase 3-OST3A as a prognostic marker in HER2+ patients.
C1 [Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine IMoPA, CNRS, UMR 7365, MolCelTEG Team, Vandoeuvre Les Nancy, France.
   [Mao, X.; Gauche, C.; Bui, C.; Gulberti, S.; Merhi-Soussi, F.; Ramalanjaona, N.; Bertin-Jung, I.; Dumas, D.; Ouzzine, M.; Fournel-Gigleux, S.] Univ Lorraine, Fac Med, Glycofluo Platform, Biopole, Campus Biol Sante, Vandoeuvre Les Nancy, France.
   [Mao, X.] Luxembourg Inst Hlth, Lab Expt Canc Res, Luxembourg, Luxembourg.
   [Coughtrie, M. W. H.; Diot, A.; Bourdon, J-C] Univ Dundee, Med Res Inst, Div Canc Res, Dundee, Scotland.
   [Coughtrie, M. W. H.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.
   [Dumas, D.] PTIBC IBISA Nancy, Cellular & Tissular Core Imaging Facil, Vandoeuvre Les Nancy, France.
   [Caires, N. De Freitas] INSERM, U1019E11, Lille, France.
   [Thompson, A. M.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute
   for Engineering & Systems Sciences (INSIS); Universite de Lorraine;
   Universite de Lorraine; Luxembourg Institute of Health; University of
   Dundee; University of British Columbia; Institut National de la Sante et
   de la Recherche Medicale (Inserm); University of Texas System; UTMD
   Anderson Cancer Center
RP Fournel-Gigleux, S (通讯作者)，Univ Lorraine, Univ Lorraine IMoPA, MolCelTEG Team, UMR 7365,CNRS,Biopole,Fac Med, Campus Biol Sante,CS 50184, F-54505 Vandoeuvre Les Nancy, Lorraine, France.
EM sylvie.fournel-gigleux@univ-lorraine.fr
RI Fournel-Gigleux, Sylvie/F-5862-2013; Ouzzine, Mohamed/G-4368-2013;
   Dumas, Dominique/A-5633-2012; Coughtrie, Michael/C-3855-2009; Bourdon,
   jean-christophe/A-4439-2008
OI Coughtrie, Michael/0000-0003-1989-1416; GULBERTI,
   Sandrine/0000-0002-9378-4697; OUZZINE, Mohamed/0000-0003-0058-4950;
   dominique, Dumas/0000-0002-2786-9633; Bourdon,
   jean-christophe/0000-0003-4623-9386
FU Agence Nationale de la Recherche (ANR-GAG Network) [ANR-08-PCVI-0023];
   Royal Society; Region Lorraine; Lorraine University; International
   Associated Laboratory (SFGEN); Cancer Research UK (CRUK); NHS Tayside
   through the Chief Scientist Office; Agence Nationale de la Recherche
   (ANR Meca-GT) [ANR-13-BSV8-0011-01]; NHS Tayside through Health Sciences
   Scotland; Breast Cancer Campaign; Agence Nationale de la Recherche (ANR)
   [ANR-13-BSV8-0011, ANR-08-PCVI-0023] Funding Source: Agence Nationale de
   la Recherche (ANR)
FX Dr Philippe Lassalle (INSERM U1019E11, Campus Institut Pasteur de Lille,
   Lille, France) is gratefully acknowledged for support with the xenograft
   experiments and for helpful discussion. Matthieu Chabel and Anne Robert
   are acknowledged for excellent technical assistance and Xiaomeng Pang is
   acknowledged for performing methylation analysis. This work was
   supported by Agence Nationale de la Recherche (ANR-GAG Network
   ANR-08-PCVI-0023 and ANR Meca-GT ANR-13-BSV8-0011-01), a Royal Society
   International Joint grant (to MWHC and SF-G), grants from Region
   Lorraine and Lorraine University to SF-G and to NR, and was carried out
   under auspices of the International Associated Laboratory (SFGEN) funded
   between CNRS-UL (SF-G) and University of Dundee (J-CB and MWHC). Tayside
   Tissue Bank is supported by Breast Cancer Campaign, Cancer Research UK
   (CRUK) and by NHS Tayside through the Chief Scientist Office and Health
   Sciences Scotland (formerly the Scottish Academic Health Science
   Collaboration, AHSC).
CR Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811
   Breton C, 2012, CURR OPIN STRUC BIOL, V22, P540, DOI 10.1016/j.sbi.2012.06.007
   Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862
   Bui C, 2010, FASEB J, V24, P436, DOI 10.1096/fj.09-136291
   Cha JY, 2008, MOL CANCER RES, V6, P435, DOI 10.1158/1541-7786.MCR-07-0187
   Cha JYY, 2009, J BIOL CHEM, V284, P6227, DOI 10.1074/jbc.M803998200
   Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085
   DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876
   Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669
   Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362
   FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200
   Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hwang JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079634
   Jacquemier J, 1998, J PATHOL, V186, P269, DOI 10.1002/(SICI)1096-9896(1998110)186:3<269::AID-PATH187>3.0.CO;2-G
   Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001
   Kitsberg DI, 1996, ONCOGENE, V13, P2507
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239
   Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002
   Löfgren L, 2007, ANTICANCER RES, V27, P3045
   Luo YD, 2006, J BIOL CHEM, V281, P21052, DOI 10.1074/jbc.M601559200
   Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73
   Mehta M, 2010, ANTICANCER RES, V30, P4883
   Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146
   Nieto L, 2013, CHEMBIOCHEM, V14, P1732, DOI 10.1002/cbic.201300313
   Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200
   Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292
   Purdie CA, 2010, HISTOPATHOLOGY, V56, P702, DOI 10.1111/j.1365-2559.2010.03533.x
   Raman Karthik, 2010, Curr Chem Biol, V4, P20
   Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842
   Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Song K, 2011, CANCER BIOL THER, V12, P388, DOI 10.4161/cbt.12.5.15957
   Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300
   Thacker BE, 2014, MATRIX BIOL, V35, P60, DOI 10.1016/j.matbio.2013.12.001
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960
   Xu RY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.398826
   Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u
   Zang XP, 2004, CLIN EXP METASTAS, V21, P437, DOI 10.1007/s10585-004-2051-8
NR 48
TC 22
Z9 23
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD SEP 22
PY 2016
VL 35
IS 38
BP 5043
EP 5055
DI 10.1038/onc.2016.44
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DW9GT
UT WOS:000383965300008
PM 27041583
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, Q
   Trevino, LS
   Wong, RLY
   Medvedovic, M
   Chen, J
   Ho, SM
   Shen, JJ
   Foulds, CE
   Coarfa, C
   O'Malley, BW
   Shilatifard, A
   Walker, CL
AF Wang, Quan
   Trevino, Lindsey S.
   Wong, Rebecca Lee Yean
   Medvedovic, Mario
   Chen, Jing
   Ho, Shuk-mei
   Shen, Jianjun
   Foulds, Charles E.
   Coarfa, Cristian
   O'Malley, Bert W.
   Shilatifard, Ali
   Walker, Cheryl L.
TI Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental
   Exposures to Prostate Cancer Risk
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID RAT VENTRAL PROSTATE; CYSTATIN-RELATED PROTEIN; BINDING-PROTEIN; HISTONE
   H3; BISPHENOL-A; NEONATAL EXPOSURE; GENE-EXPRESSION; BREAST-CANCER;
   LIPOPHILIN-B; HUMAN GENOME
AB Tissue and organ development is a time of exquisite sensitivity to environmental exposures, which can reprogram developing tissues to increase susceptibility to adult diseases, including cancer. In the developing prostate, even brief exposure to endocrine-disrupting chemicals (EDCs) can increase risk for developing cancer in adulthood, with disruption of the epigenome thought to play a key role in this developmental reprogramming. We find that EDC-induced nongenomic phosphoinositide 3-kinase; (PI3K) signaling engages the histone methyltransferase mixed-lineage leukemia 1 (MLL1), responsible for the histone H3 lysine 4 trimethylation (H3K4me3) active epigenetic mark, to increase cleavage and formation of active MLL1 dimers. In the developing prostate, EDC-induced MLL1 activation increased H3K4me3 at genes associated with prostate cancer, with increased H3K4me3 and elevated basal and hormone-induced expression of reprogrammed genes persisting into adulthood. These data identify a mechanism for MLL1 activation that is vulnerable to disruption by environmental exposures, and link MLL1 activation by EDCs to developmental reprogramming of genes involved in prostate cancer.
C1 [Wang, Quan; Trevino, Lindsey S.; Wong, Rebecca Lee Yean; Walker, Cheryl L.] Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, 2121 West Holcombe Blvd, Houston, TX 77030 USA.
   [Foulds, Charles E.; Coarfa, Cristian; O'Malley, Bert W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Medvedovic, Mario; Chen, Jing; Ho, Shuk-mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA.
   [Medvedovic, Mario; Chen, Jing; Ho, Shuk-mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA.
   [Shen, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX 78957 USA.
   [Shilatifard, Ali] Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Baylor College of Medicine; University System
   of Ohio; University of Cincinnati; University System of Ohio; University
   of Cincinnati; University of Texas System; UTMD Anderson Cancer Center;
   Northwestern University; Feinberg School of Medicine
RP Walker, CL (通讯作者)，Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, 2121 West Holcombe Blvd, Houston, TX 77030 USA.
EM cwalker@ibt.tamhsc.edu
RI Qin, Jun/A-1148-2010; Chen, Jing/A-7928-2013
OI Chen, Jing/0000-0002-6227-7393; Foulds, Charles/0000-0003-4908-1473
FU National Institute of Environmental Health Sciences Grants [RC2ES018789,
   P30ES023512, ES023206, U01 ES026719]; Cancer Prevention Research
   Institute of Texas (CPRIT) Grant [RP120855]; Welch Foundation (Houston,
   TX) [BE-0023]; CPRIT Core Facility Support Award [RP120348, RP120092];
   Baylor College of Medicine Advanced Technology Core Bioinformatics Core;
   National Cancer Institute Shared Resources Award [P30CA125123]
FX This work was supported by National Institute of Environmental Health
   Sciences Grants RC2ES018789, P30ES023512, ES023206 and U01 ES026719; the
   Cancer Prevention Research Institute of Texas (CPRIT) Grant RP120855;
   and the Welch Foundation Grant BE-0023 (Houston, TX) (to C.L.W.). This
   study also made use of the MD Anderson Science Park Next Generation
   Sequencing Core, supported by the CPRIT Core Facility Support Award
   RP120348, and the Baylor College of Medicine Advanced Technology Core
   Bioinformatics Core, supported by the CPRIT Core Facility Support Award
   RP120092 and a National Cancer Institute Shared Resources Award
   P30CA125123.
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138
   BOSLAND MC, 1995, CARCINOGENESIS, V16, P1311, DOI 10.1093/carcin/16.6.1311
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Carter D, 2003, CLIN CANCER RES, V9, P749
   Culleton J, 2007, INT J CANCER, V120, P1087, DOI 10.1002/ijc.22471
   D'Aloisio AA, 2010, ENVIRON HEALTH PERSP, V118, P375, DOI 10.1289/ehp.0901423
   Devos A, 1997, MOL ENDOCRINOL, V11, P1033, DOI 10.1210/me.11.8.1033
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   FLUCHTER SH, 1989, PROSTATE, V14, P27, DOI 10.1002/pros.2990140105
   Gore AC, 2015, ENDOCR REV, V36, pE1, DOI 10.1210/er.2015-1010
   Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Ho SM, 2015, ENDOCRINOLOGY, V156, P3984, DOI 10.1210/en.2015-1067
   Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X
   Jackson Brian C., 2011, Human Genomics, V5, P691
   Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877
   Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200
   Lamb JC, 2014, REGUL TOXICOL PHARM, V69, P22, DOI 10.1016/j.yrtph.2014.02.002
   Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034
   LEA OA, 1979, J BIOL CHEM, V254, P6196
   Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li YP, 2011, DIABETES CARE, V34, P1014, DOI 10.2337/dc10-2039
   Lilja H, 2007, J CLIN ONCOL, V25, P431, DOI 10.1200/JCO.2006.06.9351
   Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507
   Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350
   Mahabir S, 2012, CANCER CAUSE CONTROL, V23, P983, DOI 10.1007/s10552-012-9962-5
   Matsushima A, 2010, ENVIRON HEALTH PERSP, V118, P1267, DOI 10.1289/ehp.0901819
   MILLS JS, 1987, NUCLEIC ACIDS RES, V15, P7709, DOI 10.1093/nar/15.19.7709
   Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3
   Oram S, 2006, PROSTATE, V66, P768, DOI 10.1002/pros.20395
   PARKER M, 1982, NATURE, V298, P92, DOI 10.1038/298092a0
   Pavlopoulou A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013781
   Prins GS, 2014, ENDOCRINOLOGY, V155, P805, DOI 10.1210/en.2013-1955
   Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009
   Rochester JR, 2013, REPROD TOXICOL, V42, P132, DOI 10.1016/j.reprotox.2013.08.008
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455
   Taguchi Yasuto, 2004, Nucl Recept, V2, P5, DOI 10.1186/1478-1336-2-5
   Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308
   Tosoian J, 2010, THESCIENTIFICWORLDJO, V10, P1919, DOI 10.1100/tsw.2010.182
   Treviño LS, 2015, PROG BIOPHYS MOL BIO, V118, P8, DOI 10.1016/j.pbiomolbio.2015.02.013
   Vanaken H, 1996, MOL CELL ENDOCRINOL, V121, P197, DOI 10.1016/0303-7207(96)03866-X
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056
   Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220
   Wise LA, 2005, OBSTET GYNECOL, V105, P167, DOI 10.1097/01.AOG.0000147839.74848.7c
   Wong RLY, 2015, EPIGENETICS-US, V10, P127, DOI 10.1080/15592294.2015.1009768
   Wong RLY, 2013, CLIN CANCER RES, V19, P3732, DOI 10.1158/1078-0432.CCR-13-0021
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Zhang P, 2015, GENE DEV, V29, P123, DOI 10.1101/gad.254870.114
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 62
TC 53
Z9 59
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD AUG
PY 2016
VL 30
IS 8
BP 856
EP 871
DI 10.1210/me.2015-1310
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA DU0ZB
UT WOS:000381932700005
PM 27219490
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Imamura, T
   Komatsu, S
   Ichikawa, D
   Kawaguchi, T
   Miyamae, M
   Okajima, W
   Ohashi, T
   Arita, T
   Konishi, H
   Shiozaki, A
   Morimura, R
   Ikoma, H
   Okamoto, K
   Otsuji, E
AF Imamura, Taisuke
   Komatsu, Shuhei
   Ichikawa, Daisuke
   Kawaguchi, Tsutomu
   Miyamae, Mahito
   Okajima, Wataru
   Ohashi, Takuma
   Arita, Tomohiro
   Konishi, Hirotaka
   Shiozaki, Atsushi
   Morimura, Ryo
   Ikoma, Hisashi
   Okamoto, Kazuma
   Otsuji, Eigo
TI Liquid biopsy in patients with pancreatic cancer: Circulating tumor
   cells and cell-free nucleic acids
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Pancreatic cancer; Biomarker; Liquid biopsy; Circulating tumor cells;
   Cell-free nucleic acids
ID METASTATIC BREAST-CANCER; ANTIGEN MESSENGER-RNA; K-RAS MUTATIONS; LONG
   NONCODING RNAS; PERIPHERAL-BLOOD; PLASMA DNA; RT-PCR;
   ACQUIRED-RESISTANCE; CLINICAL UTILITY; POOR-PROGNOSIS
AB Despite recent advances in surgical techniques and perioperative management, the prognosis of pancreatic cancer (PCa) remains extremely poor. To provide optimal treatment for each patient with Pca, superior biomarkers are urgently needed in all phases of management from early detection to staging, treatment monitoring, and prognosis. In the blood of patients with cancer, circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs), such as DNA, mRNA, and noncoding RNA have been recognized. In the recent years, their presence in the blood has encouraged researchers to investigate their potential use as novel blood biomarkers, and numerous studies have demonstrated their potential clinical utility as a biomarker for certain types of cancer. This concept, called "liquid biopsy" has been focused on as a less invasive, alternative approach to cancer tissue biopsy for obtaining genetic and epigenetic aberrations that contribute to oncogenesis and cancer progression. In this article, we review the available literature on CTCs and cfNAs in patients with cancer, particularly focusing on PCa, and discuss future perspectives in this field.
C1 [Imamura, Taisuke; Komatsu, Shuhei; Ichikawa, Daisuke; Kawaguchi, Tsutomu; Miyamae, Mahito; Okajima, Wataru; Ohashi, Takuma; Arita, Tomohiro; Konishi, Hirotaka; Shiozaki, Atsushi; Morimura, Ryo; Ikoma, Hisashi; Okamoto, Kazuma; Otsuji, Eigo] Kyoto Prefectural Univ Med, Div Digest Surg, Dept Surg, Kyoto 6028566, Japan.
C3 Kyoto Prefectural University of Medicine
RP Komatsu, S (通讯作者)，Kyoto Prefectural Univ Med, Div Digest Surg, Dept Surg, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.
EM skomatsu@koto.kpu-m.ac.jp
RI Arita, Tomohiro/AAQ-1339-2021
OI Arita, Tomohiro/0000-0001-7127-6504
FU Grants-in-Aid for Scientific Research [15K19906] Funding Source: KAKEN
CR Abue M, 2015, INT J ONCOL, V46, P539, DOI 10.3892/ijo.2014.2743
   Ali S, 2011, AM J TRANSL RES, V3, P28
   Alix-Panabières C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Ashworth T.R., 1869, Aust Med J, V14, P146
   Balic M, 2012, EXPERT REV MOL DIAGN, V12, P303, DOI [10.1586/ERM.12.12, 10.1586/erm.12.12]
   Baraniskin A, 2013, INT J CANCER, V132, pE48, DOI 10.1002/ijc.27791
   Bidard FC, 2013, ANN ONCOL, V24, P2057, DOI 10.1093/annonc/mdt176
   Bissolati M, 2015, TUMOR BIOL, V36, P991, DOI 10.1007/s13277-014-2716-0
   Bobek V, 2014, WORLD J GASTROENTERO, V20, P17163, DOI 10.3748/wjg.v20.i45.17163
   CACHIA PG, 1994, LEUKEMIA, V8, P677
   Carlsen AL, 2013, PANCREAS, V42, P1107, DOI 10.1097/MPA.0b013e318296bb34
   Castells A, 1999, J CLIN ONCOL, V17, P578, DOI 10.1200/JCO.1999.17.2.578
   Catenacci DVT, 2015, GASTROENTEROLOGY, V149, P1794, DOI 10.1053/j.gastro.2015.08.050
   Cauley CE, 2015, J AM COLL SURGEONS, V221, P699, DOI 10.1016/j.jamcollsurg.2015.05.014
   Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014
   Chausovsky G, 1999, CANCER, V86, P2398, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2398::AID-CNCR30>3.0.CO;2-5
   Chen H, 2010, EJSO-EUR J SURG ONC, V36, P657, DOI 10.1016/j.ejso.2010.05.014
   Chen QL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0225-z
   Chen XQ, 2000, CLIN CANCER RES, V6, P3823
   Clarke LE, 2003, INT J ONCOL, V22, P425
   Cooper CL, 2013, PATHOLOGY, V45, P286, DOI 10.1097/PAT.0b013e32835f2205
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Danila DC, 2007, CLIN CANCER RES, V13, P7053, DOI 10.1158/1078-0432.CCR-07-1506
   Dasi F, 2006, ANN NY ACAD SCI, V1075, P204, DOI 10.1196/annals.1368.028
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   de Albuquerque A, 2012, ONCOLOGY-BASEL, V82, P3, DOI 10.1159/000335479
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Earl J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1779-7
   Erbes T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1190-4
   FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773
   Funaki NO, 1998, CLIN CANCER RES, V4, P855
   Funaki NO, 1996, LIFE SCI, V59, P2187, DOI 10.1016/S0024-3205(96)00576-0
   Ganepola GAP, 2014, WORLD J GASTRO ONCOL, V6, P22, DOI 10.4251/wjgo.v6.i1.22
   Gao L, 2014, CLIN LAB, V60, P73, DOI 10.7754/Clin.Lab.2013.121210
   Garcia V, 2006, CLIN CANCER RES, V12, P2095, DOI 10.1158/1078-0432.CCR-05-1644
   Giacona MB, 1998, PANCREAS, V17, P89, DOI 10.1097/00006676-199807000-00012
   Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178
   Hayes DF, 2006, CLIN CANCER RES, V12, P4218, DOI 10.1158/1078-0432.CCR-05-2821
   Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82
   Ho AS, 2010, TRANSL ONCOL, V3, P109, DOI 10.1593/tlo.09256
   Hoffmann K, 2007, WORLD J GASTROENTERO, V13, P257, DOI 10.3748/wjg.v13.i2.257
   Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964
   Huang C, 2015, MINERVA MED, V106, P143
   Ishizone S, 2006, CANCER SCI, V97, P119, DOI 10.1111/j.1349-7006.2006.00148.x
   Iwanicki-Caron I, 2013, AM J GASTROENTEROL, V108, P152, DOI 10.1038/ajg.2012.367
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kamande JW, 2013, ANAL CHEM, V85, P9092, DOI 10.1021/ac401720k
   Kang CY, 2014, J GASTROINTEST SURG, V18, P7, DOI 10.1007/s11605-013-2326-y
   Kawaguchi T, 2013, BRIT J CANCER, V108, P361, DOI 10.1038/bjc.2012.546
   Khoja L, 2012, BRIT J CANCER, V106, P508, DOI 10.1038/bjc.2011.545
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kinugasa H, 2015, CANCER-AM CANCER SOC, V121, P2271, DOI 10.1002/cncr.29364
   Kojima M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118220
   Komatsu S, 2015, EXPERT OPIN BIOL TH, V15, P773, DOI 10.1517/14712598.2015.1029914
   Kong XY, 2011, DIGEST DIS SCI, V56, P602, DOI 10.1007/s10620-010-1285-3
   Kopreski MS, 1999, CLIN CANCER RES, V5, P1961
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Kulemann B, 2015, PANCREAS, V44, P547, DOI 10.1097/MPA.0000000000000324
   Kurihara T, 2008, J HEPATO-BILIARY-PAN, V15, P189, DOI 10.1007/s00534-007-1250-5
   LaConti JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020687
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E
   LEON SA, 1977, CANCER RES, V37, P646
   Li AG, 2013, CLIN CANCER RES, V19, P3600, DOI 10.1158/1078-0432.CCR-12-3092
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Li J, 2014, PANCREATOLOGY, V14, P385, DOI 10.1016/j.pan.2014.07.013
   Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893
   Liu JQ, 2012, INT J CANCER, V131, P683, DOI 10.1002/ijc.26422
   Liu R, 2012, CLIN CHEM, V58, P610, DOI 10.1373/clinchem.2011.172767
   Lo KW, 1999, CLIN CHEM, V45, P1292
   Lu XX, 2013, CELL TISSUE RES, V354, P891, DOI 10.1007/s00441-013-1711-x
   Lukyanchuk VV, 2003, ANTICANCER RES, V23, P2711
   Lustberg MB, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3622
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3
   Madhavan B, 2015, INT J CANCER, V136, P2616, DOI 10.1002/ijc.29324
   Magistrelli P, 2008, PANCREAS, V37, P101, DOI 10.1097/MPA.0b013e31815e72bc
   Maire F, 2002, BRIT J CANCER, V87, P551, DOI 10.1038/sj.bjc.6600475
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   Marchese R, 2004, BRIT J CANCER, V90, P2243, DOI 10.1038/sj.bjc.6601854
   Mataki Y, 2004, CLIN CANCER RES, V10, P3807, DOI 10.1158/1078-0432.CCR-03-0130
   Melnikov AA, 2009, J SURG ONCOL, V99, P119, DOI 10.1002/jso.21208
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Miyamae M, 2015, BRIT J CANCER, V113, P1467, DOI 10.1038/bjc.2015.366
   Miyazono F, 1999, AM J SURG, V177, P475, DOI 10.1016/S0002-9610(99)00086-0
   Modali SD, 2015, MOL ENDOCRINOL, V29, P224, DOI 10.1210/me.2014-1304
   Morimura R, 2011, BRIT J CANCER, V105, P1733, DOI 10.1038/bjc.2011.453
   Moriyama H, 2002, INT J ONCOL, V21, P949
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   O'Flaherty JD, 2012, LUNG CANCER, V76, P19, DOI 10.1016/j.lungcan.2011.10.018
   Ozaka M, 2012, CANCER CHEMOTH PHARM, V69, P1197, DOI 10.1007/s00280-012-1822-1
   Pang EJ, 2015, TUMOR BIOL, V36, P2403, DOI 10.1007/s13277-014-2850-8
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Peng W, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0346-4
   Permuth-Wey J, 2015, CANCER PREV RES, V8, P826, DOI 10.1158/1940-6207.CAPR-15-0094
   Que RS, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-219
   REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308
   Rhim AD, 2014, GASTROENTEROLOGY, V146, P647, DOI 10.1053/j.gastro.2013.12.007
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695
   Sastre J, 2008, ANN ONCOL, V19, P935, DOI 10.1093/annonc/mdm583
   Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557
   Sausen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8686
   Schultz NA, 2014, JAMA-J AM MED ASSOC, V311, P392, DOI 10.1001/jama.2013.284664
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078-0432.CCR-06-2701
   SHAPIRO B, 1983, CANCER-AM CANCER SOC, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S
   Sheng WA, 2014, LAB CHIP, V14, P89, DOI 10.1039/c3lc51017d
   Silva JM, 2002, GUT, V50, P530, DOI 10.1136/gut.50.4.530
   Silva JM, 2001, CLIN CANCER RES, V7, P2821
   Singh N, 2015, CANCER INVEST, V33, P78, DOI 10.3109/07357907.2014.1001894
   Slater EP, 2014, TRANSL ONCOL, V7, P464, DOI 10.1016/j.tranon.2014.05.007
   SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773
   Soeth E, 2005, J CANCER RES CLIN, V131, P669, DOI 10.1007/s00432-005-0008-1
   SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67
   Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236
   Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107
   Sultana A, 2008, BRIT J CANCER, V99, P6, DOI 10.1038/sj.bjc.6604436
   Sun YW, 2014, BRIT J CANCER, V111, P2131, DOI 10.1038/bjc.2014.520
   Szymanski M, 2005, BBA-REV CANCER, V1756, P65, DOI 10.1016/j.bbcan.2005.07.005
   TADA M, 1991, GASTROENTEROLOGY, V100, P233, DOI 10.1016/0016-5085(91)90606-L
   Tahira AC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-141
   Takai E, 2015, SCI REP-UK, V5, DOI 10.1038/srep18425
   Theodor L, 1999, DIGEST DIS SCI, V44, P2014, DOI 10.1023/A:1026618317716
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Uchikura K, 2002, ANN SURG ONCOL, V9, P364, DOI 10.1245/aso.2002.9.4.364
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van de Stolpe A, 2011, CANCER RES, V71, P5955, DOI 10.1158/0008-5472.CAN-11-1254
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   VASIOUKHIN V, 1994, BRIT J HAEMATOL, V86, P774, DOI 10.1111/j.1365-2141.1994.tb04828.x
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Wang J, 2009, CANCER PREV RES, V2, P807, DOI 10.1158/1940-6207.CAPR-09-0094
   Wang P, 2013, MOL ONCOL, V7, P334, DOI 10.1016/j.molonc.2012.10.011
   Wang WS, 2013, CANCER PREV RES, V6, P331, DOI 10.1158/1940-6207.CAPR-12-0307
   Wang YX, 2015, ONCOTARGET, V6, P35684, DOI 10.18632/oncotarget.5533
   Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Wong SCC, 2004, CLIN CANCER RES, V10, P1613, DOI 10.1158/1078-0432.CCR-1168-3
   Wu J, 2014, ASIAN PAC J CANCER P, V15, P10647, DOI 10.7314/APJCP.2014.15.24.10647
   Xu JW, 2016, ANN SURG, V263, P1173, DOI 10.1097/SLA.0000000000001345
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yamada T, 1998, CLIN CANCER RES, V4, P1527
   Z'graggen K, 2001, SURGERY, V129, P537, DOI 10.1067/msy.2001.113819
   Zambon CF, 2000, CLIN CHIM ACTA, V302, P35, DOI 10.1016/S0009-8981(00)00351-X
   Závesky L, 2015, PATHOL ONCOL RES, V21, P1027, DOI 10.1007/s12253-015-9914-y
   Zhang JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121920
   Zhang YJ, 2015, INT J CANCER, V136, P1228, DOI 10.1002/ijc.29070
   Zhang YL, 2005, WORLD J GASTROENTERO, V11, P1023, DOI 10.3748/wjg.v11.i7.1023
   Zhao CY, 2013, ONCOL REP, V30, P276, DOI 10.3892/or.2013.2420
   Zhou JH, 2011, J SURG RES, V171, P631, DOI 10.1016/j.jss.2010.05.007
   Zill OA, 2015, CANCER DISCOV, V5, P1040, DOI 10.1158/2159-8290.CD-15-0274
NR 155
TC 50
Z9 58
U1 0
U2 18
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 7
PY 2016
VL 22
IS 25
BP 5627
EP 5641
DI 10.3748/wjg.v22.i25.5627
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DS4PV
UT WOS:000380763900002
PM 27433079
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lubecka, K
   Kurzava, L
   Flower, K
   Buvala, H
   Zhang, H
   Teegarden, D
   Camarillo, I
   Suderman, M
   Kuang, SH
   Andrisani, O
   Flanagan, JM
   Stefanska, B
AF Lubecka, Katarzyna
   Kurzava, Lucinda
   Flower, Kirsty
   Buvala, Hannah
   Zhang, Hao
   Teegarden, Dorothy
   Camarillo, Ignacio
   Suderman, Matthew
   Kuang, Shihuan
   Andrisani, Ourania
   Flanagan, James M.
   Stefanska, Barbara
TI Stilbenoids remodel the DNA methylation patterns in breast cancer cells
   and inhibit oncogenic NOTCH signaling through epigenetic regulation of
   MAML2 transcriptional activity
SO CARCINOGENESIS
LA English
DT Article
ID ADENOSINE-ANALOGS; GENE-EXPRESSION; ADIPOSE-TISSUE; RETINOIC ACID;
   HYPOMETHYLATION; LIVER; GROWTH; RESVERATROL; ACTIVATION; MIGRATION
AB We established the role for epigenetics in regulation of NOTCH signaling in breast cancer. This may constitute a common mechanism of activation of oncogenic signals. Our study provides support for epigenetic-targeting strategies in anticancer approaches.DNA hypomethylation was previously implicated in cancer progression and metastasis. The purpose of this study was to examine whether stilbenoids, resveratrol and pterostilbene thought to exert anticancer effects, target genes with oncogenic function for de novo methylation and silencing, leading to inactivation of related signaling pathways. Following Illumina 450K, genome-wide DNA methylation analysis reveals that stilbenoids alter DNA methylation patterns in breast cancer cells. On average, 75% of differentially methylated genes have increased methylation, and these genes are enriched for oncogenic functions, including NOTCH signaling pathway. MAML2, a coactivator of NOTCH targets, is methylated at the enhancer region and transcriptionally silenced in response to stilbenoids, possibly explaining the downregulation of NOTCH target genes. The increased DNA methylation at MAML2 enhancer coincides with increased occupancy of repressive histone marks and decrease in activating marks. This condensed chromatin structure is associated with binding of DNMT3B and decreased occupancy of OCT1 transcription factor at MAML2 enhancer, suggesting a role of DNMT3B in increasing methylation of MAML2 after stilbenoid treatment. Our results deliver a novel insight into epigenetic regulation of oncogenic signals in cancer and provide support for epigenetic-targeting strategies as an effective anticancer approach.
C1 [Lubecka, Katarzyna; Kurzava, Lucinda; Buvala, Hannah; Teegarden, Dorothy; Stefanska, Barbara] Purdue Univ, Dept Nutr Sci, 201 S Univ St,Hansen Bldg,Room 109, W Lafayette, IN 47907 USA.
   [Flower, Kirsty; Flanagan, James M.] Imperial Coll London, Dept Surg & Canc, Epigenet Unit, London, England.
   [Zhang, Hao; Andrisani, Ourania] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Teegarden, Dorothy; Camarillo, Ignacio; Kuang, Shihuan; Andrisani, Ourania; Stefanska, Barbara] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.
   [Camarillo, Ignacio] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.
   [Suderman, Matthew] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Suderman, Matthew] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
   [Kuang, Shihuan] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Imperial College London;
   Purdue University System; Purdue University; Purdue University System;
   Purdue University; Purdue University System; Purdue University;
   University of Bristol; University of Bristol; Purdue University System;
   Purdue University
RP Stefanska, B (通讯作者)，Purdue Univ, Dept Nutr Sci, 201 S Univ St,Hansen Bldg,Room 109, W Lafayette, IN 47907 USA.
EM bstefanska@purdue.edu
RI Stefańska, Barbara/ABD-1161-2021; Zheng, Yiming/AFQ-9684-2022; Lubecka,
   Katarzyna/S-9731-2016
OI Lubecka-Gajewska, Katarzyna/0000-0002-4250-0922; Andrisani,
   Ourania/0000-0002-6230-0303; Flanagan, James/0000-0003-4955-1383; Kuang,
   Shihuan/0000-0001-9180-3180; Suderman, Matthew/0000-0002-2715-9930
FU Indiana Clinical and Translational Sciences Institute; National
   Institutes of Health, National Center for Advancing Translational
   Sciences, Clinical and Translational Sciences Award [UL1TR001108];
   Women's Global Health Institute (WGHI MEER); USDA National Institute of
   Food and Agriculture (Hatch project) [1005656]; Purdue University Center
   for Cancer Research Undergraduate Research Program; Breast Cancer Now;
   Cancer Research UK [A13086]; National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Imperial College Healthcare
   NHS Trust and Imperial College London; NIFA [1005656, 812223] Funding
   Source: Federal RePORTER
FX Indiana Clinical and Translational Sciences Institute funded, in part by
   grant number UL1TR001108 from the National Institutes of Health,
   National Center for Advancing Translational Sciences, Clinical and
   Translational Sciences Award; the Women's Global Health Institute (WGHI
   MEER); USDA National Institute of Food and Agriculture (Hatch project
   1005656); and the Purdue University Center for Cancer Research
   Undergraduate Research Program granted to B.S. J.M.F. and K.J.F. were
   funded by Breast Cancer Now and acknowledge funding support from Cancer
   Research UK (A13086) and the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Imperial College Healthcare
   NHS Trust and Imperial College London.
CR [Anonymous], BR J PHARM
   [Anonymous], CLIN CANC RES
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bolós V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3447
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Brown SE, 2008, GENE, V420, P99, DOI 10.1016/j.gene.2008.05.009
   Cappell KM, 2012, MOL CELL BIOL, V32, P4131, DOI 10.1128/MCB.00686-12
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cheishvili D, 2015, ONCOTARGET, V6, P33253, DOI 10.18632/oncotarget.5291
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2
   DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110
   Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880
   Gracia A, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0411-9
   Hatada I, 2006, ONCOGENE, V25, P3059, DOI 10.1038/sj.onc.1209331
   Hon GC, 2009, HUM MOL GENET, V18, pR195, DOI 10.1093/hmg/ddp409
   Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110
   Ilhan A, 2011, HUM PATHOL, V42, P641, DOI 10.1016/j.humpath.2010.10.004
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Lacey JV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-84
   Li YJ, 2015, TUMOR BIOL, V36, P9941, DOI 10.1007/s13277-015-3766-7
   Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200
   Lou XD, 2014, ARCH IMMUNOL THER EX, V62, P329, DOI 10.1007/s00005-014-0271-4
   Ly D, 2013, INT J CANCER, V132, P1918, DOI 10.1002/ijc.27841
   Mas VR, 2007, TRANSPLANTATION, V84, P1262, DOI 10.1097/01.tp.0000287596.91520.1a
   Mayol G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048401
   Nakazawa Y, 2011, CANCER RES, V71, P1146, DOI 10.1158/0008-5472.CAN-10-2695
   Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Peng Guang-Hua, 2013, Methods Mol Biol, V935, P311, DOI 10.1007/978-1-62703-080-9_22
   Primiani CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110972
   Sengelaub CA, 2016, EMBO J, V35, P62, DOI 10.15252/embj.201591973
   Shao CB, 2011, CLIN CANCER RES, V17, P4320, DOI 10.1158/1078-0432.CCR-10-2992
   Sharma AK, 2008, J BIOL CHEM, V283, P32860, DOI 10.1074/jbc.M804916200
   Siegel R. L., 2015, CA-CANCER J CLIN, V65, P5
   Starska K, 2015, TUMOR BIOL, V36, P2309, DOI 10.1007/s13277-014-2838-4
   Stefanska B, 2013, CARCINOGENESIS, V34, P2738, DOI 10.1093/carcin/bgt273
   Stefanska B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068439
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Suman S, 2013, BRIT J CANCER, V109, P2587, DOI 10.1038/bjc.2013.642
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Wilhelm-Benartzi CS, 2013, BRIT J CANCER, V109, P1394, DOI 10.1038/bjc.2013.496
   Wysocka M, 2014, J INVEST DERMATOL, V134, P229, DOI 10.1038/jid.2013.279
   Xia SS, 2014, ONCOL LETT, V7, P1889, DOI 10.3892/ol.2014.2023
   Zhang Peng, 2014, Genes Cancer, V5, P154
NR 53
TC 83
Z9 86
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2016
VL 37
IS 7
BP 656
EP 668
DI 10.1093/carcin/bgw048
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DT0XJ
UT WOS:000381206000002
PM 27207652
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Gurard-Levin, ZA
   Wilson, LOW
   Pancaldi, V
   Postel-Vinay, S
   Sousa, FG
   Reyes, C
   Marangoni, E
   Gentien, D
   Valencia, A
   Pommier, Y
   Cottu, P
   Almouzni, G
AF Gurard-Levin, Zachary A.
   Wilson, Laurence O. W.
   Pancaldi, Vera
   Postel-Vinay, Sophie
   Sousa, Fabricio G.
   Reyes, Cecile
   Marangoni, Elisabetta
   Gentien, David
   Valencia, Alfonso
   Pommier, Yves
   Cottu, Paul
   Almouzni, Genevieve
TI Chromatin Regulators as a Guide for Cancer Treatment Choice
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID BREAST-CANCER; GENE-EXPRESSION; INDUCTION CHEMOTHERAPY; CLASSIFICATION;
   CENTROMERES; RESISTANCE; CHAPERONES; EPIGENETICS; RECURRENCE; SELECTION
AB The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio-and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators-factors involved in the establishment and maintenance of functional chromatin domains-can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with doc-etaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel highresponders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. (C) 2016 AACR.
C1 [Gurard-Levin, Zachary A.; Wilson, Laurence O. W.; Almouzni, Genevieve] PSL Res Univ, CNRS, Inst Curie, UMR3664,Equipe Labellisee Ligue Canc, Paris, France.
   [Gurard-Levin, Zachary A.; Wilson, Laurence O. W.; Almouzni, Genevieve] Univ Paris 06, Sorbonne Univ, CNRS, UMR3664, Paris, France.
   [Pancaldi, Vera; Valencia, Alfonso] Care of Fernandez M, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.
   [Postel-Vinay, Sophie] Gustave Roussy, DITEP Dept Innovat Therapeut & Essais Precoces, Villejuif, France.
   [Postel-Vinay, Sophie] Gustave Roussy, Inserm Unit U981, Villejuif, France.
   [Postel-Vinay, Sophie] Univ Paris 11, Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France.
   [Sousa, Fabricio G.; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Sousa, Fabricio G.; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Reyes, Cecile; Marangoni, Elisabetta; Gentien, David] PSL Res Univ, Inst Curie, Translat Res Dept, Genom Platform, Paris, France.
   [Cottu, Paul] Inst Curie, Med Oncol, Paris, France.
C3 UNICANCER; Universite PSL; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Sorbonne Universite; Centro
   Nacional de Investigaciones Oncologicas (CNIO); UNICANCER; Gustave
   Roussy; Universite Paris Saclay; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Universite Paris
   Saclay; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); UNICANCER; Universite PSL; Institut Curie;
   UNICANCER; Universite PSL; Institut Curie
RP Almouzni, G (通讯作者)，PSL Res Univ, CNRS, Inst Curie, UMR3664,Equipe Labellisee Ligue Canc, Paris, France.; Almouzni, G (通讯作者)，Univ Paris 06, Sorbonne Univ, CNRS, UMR3664, Paris, France.; Gurard-Levin, ZA (通讯作者)，Inst Curie, 26 Rue Ulm, F-75005 Paris, France.
EM zachary.gurard-levin@curie.fr; genevieve.almouzni@curie.fr
RI Cottu, Paul/ABC-8595-2020; Pommier, Yves/L-2169-2016; Valencia,
   Alfonso/AAN-9230-2020; Pancaldi, Vera/I-2555-2015; Marangoni,
   Elisabetta/GSO-3945-2022; Gentien, David/O-9356-2019; Wilson,
   Laurence/B-4362-2019; Almouzni, Genevieve/ABG-1029-2021; Sousa,
   Fabricio/O-8878-2015; valencia, alfonso/I-3127-2015
OI Sousa, Fabricio/0000-0003-0444-754X; valencia,
   alfonso/0000-0002-8937-6789; Marangoni, Elisabetta/0000-0002-3337-6448;
   Pancaldi, Vera/0000-0002-7433-624X; Almouzni,
   Genevieve/0000-0001-5570-0723
FU la Ligue Nationale contre le Cancer (Equipe labellisee Ligue); European
   Commission Network of Excellence EpiGeneSys [HEALTH-F4-2010-257082]; ERC
   [2009AdG_20090506, 678563]; European Commission [FP7_HEALTH-2010-259743,
   ANR-11-LABX-0044_DEEP, ANR-10-IDEX-0001-02 PSL, ANR-12-BSV5-0022-02,
   ANR-14-CE16-0009, ANR-14-CE100013]; Aviesan ITMO cancer project
   "Epigenomics of breast cancer; Grant "INCa-DGOS-4654" [SIRIC11-002];
   FEBS fellowship; NIH Intramural Program, Center for Cancer Research [Z01
   BC 006150];  [ANR10-IDEX-0001-02 PSL];  [ANR-11-LBX-0044]; European
   Research Council (ERC) [678563] Funding Source: European Research
   Council (ERC)
FX G. Almouzni's team is supported by la Ligue Nationale contre le Cancer
   (Equipe labellisee Ligue), the European Commission Network of Excellence
   EpiGeneSys [HEALTH-F4-2010-257082; an EpiGeneSys small call award to
   Z.A. Gurard-Levin and V. Pancaldi (2014)] ERC Advanced Grant
   2009AdG_20090506 "Eccentric," ERC Proof of Concept No 678563 "EPOCH28"
   to G. Almouzni, the European Commission large-scale integrating project
   FP7_HEALTH-2010-259743 "MODHEP," ANR-11-LABX-0044_DEEP and
   ANR-10-IDEX-0001-02 PSL, ANR "CHAPINHIB" ANR-12-BSV5-0022-02, ANR
   "Epicure" ANR-14-CE16-0009, ANR "CELLECTCHIP" ANR-14-CE100013, and
   Aviesan ITMO cancer project "Epigenomics of breast cancer." Acquisition
   of the Nanostring platform was initiated and supported by
   ANR10-IDEX-0001-02 PSL, ANR-11-LBX-0044, and Grant "INCa-DGOS-4654"
   SIRIC11-002. V. Pancaldi is supported by a FEBS fellowship. Y. Pommier
   and F.G. Sousa were supported by the NIH Intramural Program, Center for
   Cancer Research (Z01 BC 006150).
CR Abascal F, 2013, MOL BIOL EVOL, V30, P1853, DOI 10.1093/molbev/mst086
   Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915
   Allan Rhys S, 2012, Nature, V487, P249, DOI 10.1038/nature11173
   Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799
   Bonneau C, 2015, ANTICANCER RES, V35, P5179
   Bourgo RJ, 2009, MOL BIOL CELL, V20, P3192, DOI 10.1091/mbc.E08-12-1224
   Boyarchuk E, 2014, J CELL SCI, V127, P3347, DOI 10.1242/jcs.148189
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Brownlee PM, 2015, DNA REPAIR, V32, P127, DOI 10.1016/j.dnarep.2015.04.023
   Brumbaugh CD, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-479
   CHEVALLIER B, 1993, AM J CLIN ONCOL-CANC, V16, P223, DOI 10.1097/00000421-199306000-00006
   Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286
   Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6
   Corpet A, 2011, EMBO J, V30, P480, DOI 10.1038/emboj.2010.335
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   de Oca RM, 2015, MOL ONCOL, V9, P657, DOI 10.1016/j.molonc.2014.11.002
   Díaz-Uriarte R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-3
   Fernández-Delgado M, 2014, J MACH LEARN RES, V15, P3133
   Filipescu D, 2014, ANNU REV CELL DEV BI, V30, P615, DOI 10.1146/annurev-cellbio-100913-013311
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Giovinazzi S, 2012, ONCOGENE, V31, P13, DOI 10.1038/onc.2011.211
   Gurard-Levin ZA, 2014, ANNU REV BIOCHEM, V83, P487, DOI 10.1146/annurev-biochem-060713-035536
   Gyorffy B, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0514-2
   Helmer RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080461
   Husain A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10549
   Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968
   Lacoste N, 2014, MOL CELL, V53, P631, DOI 10.1016/j.molcel.2014.01.018
   Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078
   Marchionni L, 2008, ANN INTERN MED, V148, P358, DOI 10.7326/0003-4819-148-5-200803040-00208
   Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445
   Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Patani N, 2013, INT J CANCER, V133, P1, DOI 10.1002/ijc.27997
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Riddick G, 2011, BIOINFORMATICS, V27, P220, DOI 10.1093/bioinformatics/btq628
   RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288
   Romanelli A, 2012, MOL CANCER THER, V11, P2693, DOI 10.1158/1535-7163.MCT-12-0441-T
   Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344
   SATALOFF DM, 1995, J AM COLL SURGEONS, V180, P297
   Shah MA, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-29
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Skulte KA, 2014, EPIGENOMICS-UK, V6, P397, DOI 10.2217/epi.14.37
   Song L, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-5
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sousa FG, 2015, DNA REPAIR, V28, P107, DOI 10.1016/j.dnarep.2015.01.011
   Sullivan LL, 2011, CHROMOSOME RES, V19, P457, DOI 10.1007/s10577-011-9208-5
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798
   Venneti S, 2013, BRAIN PATHOL, V23, P217, DOI 10.1111/bpa.12022
   Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6
   Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125
   Wijdeven RH, 2015, CANCER RES, V75, P4176, DOI 10.1158/0008-5472.CAN-15-0380
   Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
NR 58
TC 13
Z9 14
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2016
VL 15
IS 7
BP 1768
EP 1777
DI 10.1158/1535-7163.MCT-15-1008
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DS9FC
UT WOS:000381087200032
PM 27196757
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Mustafi, SB
   Chakraborty, PK
   Naz, S
   Dwivedi, SKD
   Street, M
   Basak, R
   Yang, D
   Ding, K
   Mukherjee, P
   Bhattacharya, R
AF Mustafi, Soumyajit Banerjee
   Chakraborty, Prabir Kumar
   Naz, Sarwat
   Dwivedi, Shailendra Kumar Dhar
   Street, Mark
   Basak, Rumki
   Yang, Da
   Ding, Kai
   Mukherjee, Priyabrata
   Bhattacharya, Resham
TI MDR1 mediated chemoresistance: BMI1 and TIP60 in action
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE BMI1; MDR; TIP60; Chemoresistance
ID DRUG-RESISTANCE; BREAST-CANCER; HISTONE ACETYLTRANSFERASE;
   MULTIDRUG-RESISTANCE; EPIGENETIC REGULATION; CISPLATIN RESISTANCE;
   PLATINUM COMPOUNDS; GENE-EXPRESSION; BETA-CATENIN; PROTEIN
AB Chemotherapy-induced emergence of drug resistant cells is frequently observed and is exemplified by the expression of family of drug resistance proteins including, multidrug resistance protein 1 (MDR1). However, a concise mechanism for chemotherapy-induced MDR1 expression is unclear. Mechanistically, mutational selection, epigenetic alteration, activation of the Wnt pathway or impaired p53 function have been implicated. The present study describes that the surviving fraction of cisplatin resistant cells co-upregulate MDR1, BMI1 and acetyl transferase activity of TIP60. Using complementary gain and loss of function approaches, we demonstrate that the expression of MDR1 is positively regulated by BMI1, a stem-cell factor classically known as a transcriptional repressor. Our study establishes a functional interaction between TIP60 and BMI-1 resulting in upregulation of MDR1 expression. Chromatin immunoprecipitation (ChIP) assays further establish that the proximal MDR1 promoter responds to cisplatin in a BMI1 dependent manner. BMIl interacts with a cluster of E-box elements on the MDR1 promoter and recruits TIP60 resulting in acetylation of histone H2A and H3. Collectively, our data establish a hitherto unknown liaison among MDR1, BMIl and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. In conclusion, our results advocate utilizing anti-BMI1 strategies to alleviate acquired resistance to chemotherapy. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Mustafi, Soumyajit Banerjee; Chakraborty, Prabir Kumar; Naz, Sarwat; Dwivedi, Shailendra Kumar Dhar; Street, Mark; Basak, Rumki; Mukherjee, Priyabrata; Bhattacharya, Resham] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA.
   [Mustafi, Soumyajit Banerjee; Naz, Sarwat; Dwivedi, Shailendra Kumar Dhar; Street, Mark; Basak, Rumki; Bhattacharya, Resham] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73190 USA.
   [Chakraborty, Prabir Kumar; Mukherjee, Priyabrata] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA.
   [Bhattacharya, Resham] Univ Oklahoma, Coll Med, Dept Cell Biol, Oklahoma City, OK 73190 USA.
   [Yang, Da] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA USA.
   [Yang, Da] Univ Pittsburgh, Inst Canc, Womens Canc Res Ctr, Pittsburgh, PA USA.
   [Yang, Da] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA USA.
   [Ding, Kai] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Oklahoma System;
   University of Oklahoma Health Sciences Center
RP Bhattacharya, R (通讯作者)，OUHSC, Peggy & Charles Stephenson Canc Ctr, 975 NE 10th St,BRC 1409B, Oklahoma City, OK 73104 USA.
RI Dwivedi, Shailendra/Q-2204-2019; Naz, Sarwat/J-2794-2019; Yang,
   Da/I-9054-2012
OI Yang, Da/0000-0002-8336-9457
FU National Institutes of Health (NIH) [CA 157481, HL120585]
FX This study was supported by the National Institutes of Health (NIH) CA
   157481 (RB) and HL120585 (PM); the funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009
   Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
   Ahmed N, 2014, MOL ASPECTS MED, V39, P110, DOI 10.1016/j.mam.2013.06.002
   Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750
   Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0
   Berek J S, 2000, Gynecol Obstet Fertil, V28, P576
   Bhattacharya R, 2015, GENES DIS, V2, P225, DOI 10.1016/j.gendis.2015.04.001
   Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552
   Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5
   Brown R, 2014, NAT REV CANCER, V14, P747, DOI 10.1038/nrc3819
   Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009
   Coffey K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045539
   Crea F, 2011, INT J CANCER, V128, P1946, DOI 10.1002/ijc.25522
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X
   Duan ZF, 2004, MOL CANCER THER, V3, P833
   Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287
   Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0
   Gatti L, 2015, DRUG RESIST UPDATE, V20, P1, DOI 10.1016/j.drup.2015.04.001
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342
   HAMAGUCHI K, 1993, CANCER RES, V53, P5225
   Henrique R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-898
   Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-74
   Hernández-Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Johnson RA, 2005, J BIOL CHEM, V280, P13213, DOI 10.1074/jbc.M414646200
   Katayama K., 2014, SPE/AAPG/SEG Pore Pressure Workshop, V2014, P1, DOI [10.1155/2014/476974, DOI 10.1155/2014/476974]
   Kim MY, 2007, MOL CELL BIOL, V27, P6506, DOI 10.1128/MCB.01515-06
   Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644
   Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200
   Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Manzo F, 2009, EXPERT OPIN THER PAT, V19, P761, DOI 10.1517/13543770902895727
   Mechetner E, 1998, CLIN CANCER RES, V4, P389
   Miyamoto N, 2008, J BIOL CHEM, V283, P18218, DOI 10.1074/jbc.M802332200
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Mustafi SB, 2014, ANTIOXID REDOX SIGN, V20, P2891, DOI 10.1089/ars.2013.5340
   Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800
   PASTAN I, 1987, NEW ENGL J MED, V316, P1388
   Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410
   Pisco AO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3467
   Qin L, 2008, BIOCHEM BIOPH RES CO, V371, P531, DOI 10.1016/j.bbrc.2008.04.117
   ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sharma D, 2004, CANCER BIOL THER, V3, P549, DOI 10.4161/cbt.3.6.1041
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029
   Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931
   Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982
   Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102
   Sustácková G, 2012, J CELL PHYSIOL, V227, P1838, DOI 10.1002/jcp.22912
   Toth M, 2012, CANCER SCI, V103, P659, DOI 10.1111/j.1349-7006.2012.02215.x
   Trock BJ, 1997, J NATL CANCER I, V89, P917, DOI 10.1093/jnci/89.13.917
   Vadlapatla RK, 2013, CURR PHARM DESIGN, V19, P7126, DOI 10.2174/13816128113199990493
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Wang BS, 2006, MOL PHARMACOL, V70, P267, DOI 10.1124/mol.105.019810
   Wang EF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017918
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Xia ZX, 2015, CURR CANCER DRUG TAR, V15, P519, DOI 10.2174/1568009615666150506093643
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yu TX, 2012, J BIOL CHEM, V287, P3760, DOI 10.1074/jbc.M111.316349
NR 76
TC 22
Z9 22
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 1876-4320
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD AUG
PY 2016
VL 1859
IS 8
BP 983
EP 993
DI 10.1016/j.bbagrm.2016.06.062
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DT0HE
UT WOS:000381163600004
PM 27295567
DA 2025-01-12
ER

PT J
AU Movassaghian, S
   Xie, YR
   Hildebrandt, C
   Rosati, R
   Li, Y
   Kim, NH
   Conti, DS
   da Rocha, SRP
   Yang, ZQ
   Merkel, OM
AF Movassaghian, Sara
   Xie, Yuran
   Hildebrandt, Claudia
   Rosati, Rayna
   Li, Ying
   Kim, Na Hyung
   Conti, Denise S.
   da Rocha, Sandro R. P.
   Yang, Zeng-Quan
   Merkel, Olivia M.
TI Post-Transcriptional Regulation of the GASC1 Oncogene with Active
   Tumor-Targeted siRNA-Nanoparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE nanoparticle; siRNA; polyethylenimine (PEI); transferrin; transferrin
   receptor; GASC1; artificial virus; targeting; breast cancer; oncogene;
   targeted therapy
ID NEGATIVE BREAST-CANCER; GENE DELIVERY; IN-VIVO; TRANSFECTION EFFICIENCY;
   NONVIRAL VECTOR; THERAPY; CELLS; POLYETHYLENIMINE; RECEPTOR; EPIGENETICS
AB Basal-like breast cancer (BLBC) accounts for the most aggressive types of breast cancer, marked by high rates of relapse and poor prognoses and with no effective clinical therapy yet. Therefore, investigation of new targets and treatment strategies is more than necessary. Here, we identified a receptor that can be targeted in BLBC for efficient and specific siRNA mediated gene knockdown of therapeutically relevant genes such as the histone demethylase GASC1, which is involved in multiple signaling pathways leading to tumorigenesis. Breast cancer and healthy breast cell lines were compared regarding transferrin receptor (TfR) expression via flow cytometry and transferrin binding assays. Nanobioconjugates made of low molecular weight polyethylenimine (LMW-PEI) and transferrin (Tf) were synthesized to contain a bioreducible disulfide bond. siRNA complexation was characterized by condensation assays and dynamic light scattering. Cytotoxicity, transfection efficiency, and the targeting specificity of the conjugates were investigated in TfR positive and negative healthy breast and breast cancer cell lines by flow cytometry, confocal microscopy, RT-PCR, and Western blot. Breast cancer cell lines revealed a significantly higher TfR expression than healthy breast cells. The conjugates efficiently condensed siRNA into particles with 45 nm size at low polymer concentrations, showed no apparent toxicity on different breast cancer cell lines, and had significantly greater transfection and gene knockdown activity on mRNA and protein levels than PEI/siRNA leading to targeted and therapeutic growth inhibition post GASC1 knockdown. The synthesized nanobioconjugates improved the efficiency of gene transfer and targeting specificity in transferrin receptor positive cells but not in cells with basal receptor expression. Therefore, these materials in combination with our newly identified siRNA sequences are promising candidates for therapeutic targeting of hard-to-treat BLBC and are currently further investigated regarding in vivo targeting efficacy and biocompatibility.
C1 [Movassaghian, Sara; Xie, Yuran; Hildebrandt, Claudia; Rosati, Rayna; Li, Ying; Kim, Na Hyung; Merkel, Olivia M.] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 259 Mack Ave, Detroit, MI 48201 USA.
   [Movassaghian, Sara; Rosati, Rayna; Yang, Zeng-Quan; Merkel, Olivia M.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA.
   [Hildebrandt, Claudia] Univ Kiel, Dept Pharmaceut & Biopharmaceut, D-24118 Kiel, Germany.
   [Conti, Denise S.] Wayne State Univ, Coll Engn, Dept Chem Engn & Mat Sci, Detroit, MI 48202 USA.
   [da Rocha, Sandro R. P.] Virginia Commonwealth Univ, Coll Pharm, Dept Pharmaceut, Richmond, VA 23298 USA.
   [da Rocha, Sandro R. P.] Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA.
   [Merkel, Olivia M.] Univ Munich, Dept Pharm Pharmaceut Technol & Biopharmaceut, D-80539 Munich, Germany.
   [Conti, Denise S.] FDA, CDER, Off Gener Drugs, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
C3 Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne
   State University; University of Kiel; Wayne State University; Virginia
   Commonwealth University; Virginia Commonwealth University; University of
   Munich; US Food & Drug Administration (FDA)
RP Merkel, OM (通讯作者)，Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 259 Mack Ave, Detroit, MI 48201 USA.
EM olivia.merkel@wayne.edu
RI da Rocha, Sandro/F-6890-2014; Kim, Nan/T-8627-2019; Conti,
   Denise/H-1756-2012; Merkel, Olivia/A-9772-2010
OI Merkel, Olivia/0000-0002-4151-3916
FU Karmanos Cancer Institute-SRIG grant; Angelika Burger Fellowship grant;
   National Institutes of Health [R21CA175244-01A1]; Department of Defense
   (DoD) Prostate Cancer Program [PC121737, PC130259]; NIH Center Grant
   [P30CA22453]
FX This work was supported by the Karmanos Cancer Institute-SRIG grant and
   Angelika Burger Fellowship grant awarded to O.M.M. and Z.-Q.Y. and
   partially supported by grants from the National Institutes of Health
   R21CA175244-01A1 (to Z.-Q.Y.) and the Department of Defense (DoD)
   Prostate Cancer Program PC121737 and PC130259 (to Z.-Q.Y.). The NIH
   Center Grant P30CA22453 supporting the Wayne State Microscopy, Imaging
   and Cytometry Resources (MICR) is gratefully acknowledged. We thank Dr.
   Stephen P. Ethier for providing human SUM breast cancer cell lines and
   acknowledge Barani Govindarajan and Dr. Yuanyuan Jiang for technical
   support.
CR Akhtar MJ, 2014, CLIN CHIM ACTA, V436, P78, DOI 10.1016/j.cca.2014.05.004
   Ardana A, 2015, J CHEM TECHNOL BIOT, V90, P1196, DOI 10.1002/jctb.4508
   Behr JP, 1997, CHIMIA, V51, P34
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Camp ER, 2013, CANCER GENE THER, V20, P222, DOI 10.1038/cgt.2013.9
   Crich SG, 2015, NANOSCALE, V7, P6527, DOI 10.1039/c5nr00352k
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   DeCarlo D, 2012, EUR J MED CHEM, V56, P179, DOI 10.1016/j.ejmech.2012.08.010
   Deng ZJ, 2013, ACS NANO, V7, P9571, DOI 10.1021/nn4047925
   Elsayed M, 2014, BIOMACROMOLECULES, V15, P1299, DOI 10.1021/bm401849d
   Essex S, 2015, GENE THER, V22, P257, DOI 10.1038/gt.2014.97
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Germershaus O, 2008, BIOCONJUGATE CHEM, V19, P244, DOI 10.1021/bc700311n
   Gopal V, 2011, BIOCONJUGATE CHEM, V22, P2244, DOI 10.1021/bc2002874
   Habashy HO, 2010, BREAST CANCER RES TR, V119, P283, DOI 10.1007/s10549-009-0345-x
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   Höbel S, 2013, WIRES NANOMED NANOBI, V5, P484, DOI 10.1002/wnan.1228
   Holowatyj A, 2013, CURR CANCER THER REV, V9, P78, DOI 10.2174/1573394711309010007
   Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351
   Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382
   Li ZH, 2012, ACCOUNTS CHEM RES, V45, P1122, DOI 10.1021/ar200253u
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Martinez-Fong D, 1999, MOL BRAIN RES, V69, P249, DOI 10.1016/S0169-328X(99)00114-X
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Mayle KM, 2012, BBA-GEN SUBJECTS, V1820, P264, DOI 10.1016/j.bbagen.2011.09.009
   Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592
   Merdan T, 2003, BIOCONJUGATE CHEM, V14, P989, DOI 10.1021/bc0340767
   Merkel OM, 2011, BIOMATERIALS, V32, P4936, DOI 10.1016/j.biomaterials.2011.03.035
   Merkel OM, 2009, BIOCONJUGATE CHEM, V20, P1270, DOI 10.1021/bc9001695
   Moffatt S, 2006, GENE THER, V13, P761, DOI 10.1038/sj.gt.3302721
   Movassaghian S., 2015, Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies, P433
   Navarro G., 2013, PHARM NANOTECHNOL, V1, P165, DOI DOI 10.2174/22117385113019990003
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/WHE.11.5, 10.2217/whe.11.5]
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437
   Sartor CI, 1997, CANCER RES, V57, P978
   Shastry M, 2013, CURR OPIN OBSTET GYN, V25, P40, DOI 10.1097/GCO.0b013e32835c1633
   Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123
   Shen H, 2012, CANCER GENE THER, V19, P367, DOI 10.1038/cgt.2012.22
   Shim MS, 2010, FEBS J, V277, P4814, DOI 10.1111/j.1742-4658.2010.07904.x
   Taranejoo S, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.42096
   Tortorella S, 2014, J MEMBRANE BIOL, V247, P291, DOI 10.1007/s00232-014-9637-0
   van der Meel R, 2013, ADV DRUG DELIVER REV, V65, P1284, DOI 10.1016/j.addr.2013.08.012
   Waldmann T, 2013, CURR OPIN CELL BIOL, V25, P184, DOI 10.1016/j.ceb.2013.01.001
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021
   Xie YR, 2016, J CONTROL RELEASE, V229, P120, DOI 10.1016/j.jconrel.2016.03.029
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Ye Q, 2015, AM J CANCER RES, V5, P1519
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhao F, 2013, BIOMACROMOLECULES, V14, P476, DOI 10.1021/bm301718f
   Zuckerman JE, 2015, NUCLEIC ACID THER, V25, P53, DOI 10.1089/nat.2014.0505
NR 54
TC 4
Z9 4
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD AUG
PY 2016
VL 13
IS 8
BP 2605
EP 2621
DI 10.1021/acs.molpharmaceut.5b00948
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DS6AT
UT WOS:000380864800002
PM 27223606
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Cockburn, JG
   Hallett, RM
   Gillgrass, AE
   Dias, KN
   Whelan, T
   Levine, MN
   Hassell, JA
   Bane, A
AF Cockburn, Jessica G.
   Hallett, Robin M.
   Gillgrass, Amy E.
   Dias, Kay N.
   Whelan, T.
   Levine, M. N.
   Hassell, John A.
   Bane, Anita
TI The effects of lymph node status on predicting outcome in
   ER+/HER2-tamoxifen treated breast cancer patients using gene signatures
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Lymph node status; Gene signature; Estrogen receptor;
   Prognosis; Oncotype DX; Prosigna
ID ADJUVANT CHEMOTHERAPY; ENDOCRINE THERAPY; STEM-CELL; EXPRESSION;
   RECURRENCE; RISK; METASTASIS; EPIGENETICS; CONCORDANCE; PROGNOSIS
AB Background: Lymph node (LN) status is the most important prognostic variable used to guide ER positive (+) breast cancer treatment. While a positive nodal status is traditionally associated with a poor prognosis, a subset of these patients respond well to treatment and achieve long-term survival. Several gene signatures have been established as a means of predicting outcome of breast cancer patients, but the development and indication for use of these assays varies. Here we compare the capacity of two approved gene signatures and a third novel signature to predict outcome in distinct LN negative (-) and LN+ populations. We also examine biological differences between tumours associated with LN- and LN+ disease.
   Methods: Gene expression data from publically available data sets was used to compare the ability of Oncotype DX and Prosigna to predict Distant Metastasis Free Survival (DMFS) using an in silico platform. A novel gene signature (Ellen) was developed by including patients with both LN- and LN+ disease and using Prediction Analysis of Microarrays (PAM) software. Gene Set Enrichment Analysis (GSEA) was used to determine biological pathways associated with patient outcome in both LN- and LN+ tumors.
   Results: The Oncotype DX gene signature, which only used LN- patients during development, significantly predicted outcome in LN- patients, but not LN+ patients. The Prosigna gene signature, which included both LN- and LN+ patients during development, predicted outcome in both LN- and LN+ patient groups. Ellen was also able to predict outcome in both LN- and LN+ patient groups. GSEA suggested that epigenetic modification may be related to poor outcome in LN- disease, whereas immune response may be related to good outcome in LN+ disease.
   Conclusions: We demonstrate the importance of incorporating lymph node status during the development of prognostic gene signatures. Ellen may be a useful tool to predict outcome of patients regardless of lymph node status, or for those with unknown lymph node status. Finally we present candidate biological processes, unique to LN- and LN+ disease, that may indicate risk of relapse.
C1 [Cockburn, Jessica G.; Gillgrass, Amy E.; Dias, Kay N.; Whelan, T.; Levine, M. N.; Bane, Anita] Juravinski Hosp & Canc Ctr, Dept Oncol, Hamilton, ON, Canada.
   [Hallett, Robin M.; Hassell, John A.] McMaster Univ, Ctr Funct Genom, Dept Biochem & Biomed Sci, Hamilton, ON, Canada.
   [Bane, Anita] Juravinski Hosp & Canc Ctr, Dept Pathol, Hamilton, ON, Canada.
C3 McMaster University; McMaster University; McMaster University
RP Bane, A (通讯作者)，Juravinski Hosp & Canc Ctr, Dept Oncol, Hamilton, ON, Canada.; Bane, A (通讯作者)，Juravinski Hosp & Canc Ctr, Dept Pathol, Hamilton, ON, Canada.
EM bane@hhsc.ca
RI Cockburn, Jessica/AAR-8937-2021; Whelan, Timothy/D-3185-2017
OI Cockburn, Jessica/0000-0001-6308-0923; Gillgrass,
   Amy/0000-0002-6257-4013; Whelan, Timothy/0000-0001-9844-2023
FU Canadian Breast Cancer Foundation
FX Funding for this project was provided by an operating grant (AB, JH) and
   fellowship (JGC, AEG) from the Canadian Breast Cancer Foundation.
CR Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6
   [Anonymous], BREAST
   [Anonymous], 2014, Cell research
   [Anonymous], SURG MAN EARL STAG I
   [Anonymous], GENE SET ENRICHMENT
   [Anonymous], CA CANC J CLIN
   [Anonymous], PRACT GUID ONC
   [Anonymous], BREAST CANC RES TREA
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Blohmer J U, 2013, J Med Econ, V16, P30, DOI 10.3111/13696998.2012.722572
   Capulli M, 2012, J BONE MINER RES, V27, P2387, DOI 10.1002/jbmr.1686
   Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X
   Dvorkin-Gheva A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103514
   Elloumi F, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-54
   Englert NA, 2011, J STEROID BIOCHEM, V123, P140, DOI 10.1016/j.jsbmb.2010.12.010
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Filipits M, 2011, CLIN CANCER RES, V17, P6012, DOI 10.1158/1078-0432.CCR-11-0926
   Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673
   Gyorffy B, 2012, BREAST CANCER RES TR, V132, P1025, DOI 10.1007/s10549-011-1676-y
   Gyorffy B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005645
   Habel LA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1412
   Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227
   Hallett RM, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-120
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Holt S, 2013, BRIT J CANCER, V108, P2250, DOI 10.1038/bjc.2013.207
   Hsu DS, 2010, CANCER INVEST, V28, P765, DOI 10.3109/07357900903095755
   Huynh KT, 2012, CLIN EXP METASTAS, V29, P747, DOI 10.1007/s10585-012-9491-3
   Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334
   Joh JE, 2011, ONCOLOGIST, V16, P1520, DOI 10.1634/theoncologist.2011-0045
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059
   Miller CP, 2014, CANCER IMMUNOL RES, V2, P301, DOI 10.1158/2326-6066.CIR-13-0189
   Mirisola V, 2009, EUR J CANCER, V45, P2579, DOI 10.1016/j.ejca.2009.06.026
   Muss HB, 2005, JAMA-J AM MED ASSOC, V293, P1073, DOI 10.1001/jama.293.9.1073
   Oh E, 2012, BREAST CANCER RES TR, V132, P499, DOI 10.1007/s10549-011-1626-8
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2012, ANN ONCOL, V23, P2866, DOI 10.1093/annonc/mds080
   Singh SK, 2003, CANCER RES, V63, P5821
   Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273
   The Gene Ontology Consortium, 2014, Nucleic Acids Res, V43, pD1049
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Ursaru M, 2015, MED-SURG J, V119, P374
   Van den Eynden GG, 2007, CLIN EXP METASTAS, V24, P13, DOI 10.1007/s10585-006-9049-3
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
NR 55
TC 9
Z9 10
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 28
PY 2016
VL 16
AR 555
DI 10.1186/s12885-016-2501-0
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DT0VK
UT WOS:000381200900003
PM 27469239
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Zhou, WC
   Tian, M
   Hu, JJ
   Li, LH
   He, Y
AF Zhou, Wence
   Tian, Ming
   Hu, Jinjing
   Li, Lihong
   He, Yong
TI SFRP5 as a prognostic biomarker for patients with pancreatic ductal
   adenocarcinoma
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE SFRP5; PDAC; prognosis; biomarker
ID FREQUENT EPIGENETIC INACTIVATION; SIGNALING PATHWAYS; WNT ANTAGONIST;
   BREAST-CANCER; METHYLATION; EXPRESSION; MARKERS; GENES
AB Secreted frizzled-related protein 5 (SFRP5) is a member of the SFRP family and plays an important role in Wnt (wingless-type) signaling pathway. Aberrant expression of SFRP5 has recently been reported in several human cancers, but studies on human pancreatic ductal adenocarcinoma (PDAC) are lacking. Therefore, the aim of this study was to measure the expression of SFRP5 in pancreatic cancer patients and its correlation with prognosis. Semiquantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and Western blotting (WB) were used to explore the expression of SFRP5 in human PDAC tissues. Using immunohistochemistry to determine the expression of SFRP5 in 71 patients with PDAC. The results of qRT-PCR and WB showed that the expression of SFRP5 was lower in PDAC tissues than that of precancerous tissues. The expression of SFRP5 was correlated with distant metastasis (absent vs. present; P<0.001), TNM Stage (I-II vs. III-IV; P=0.008), first symptom (pain vs. others; P=0.023). Low expression of SFRP5 in PDAC was a poor prognostic factor for human PDAC. In conclusion, our data suggest that low expression of SFRP5 severs as a prognostic biomarker for PDAC therapy.
C1 [Zhou, Wence; Tian, Ming; Hu, Jinjing; Li, Lihong; He, Yong] Lanzhou Univ, Hosp 1, Dept Gen Surg 2, Lanzhou 730000, Peoples R China.
C3 Lanzhou University
RP Zhou, WC; Tian, M (通讯作者)，Lanzhou Univ, Hosp 1, Dept Gen Surg 2, Lanzhou 730000, Peoples R China.
EM zhouwc129@163.com; tianm13@lzu.edu.cn
RI Tian, Ming/AAH-7102-2020
OI Ye, Cheng/0000-0001-9180-6648
FU Central University Fundamental Research Funds for Lanzhou University
   [lzujbky-2012-163/167]; Gansu provincial Natural Science Foundation
   [1208RJZA219]
FX This research was supported by the Central University Fundamental
   Research Funds for Lanzhou University (No. lzujbky-2012-163/167) and
   Gansu provincial Natural Science Foundation (No. 1208RJZA219).
CR Ardengh J C, 2003, HPB (Oxford), V5, P226, DOI 10.1080/13651820310001342
   Bilimoria KY, 2007, CANCER-AM CANCER SOC, V110, P738, DOI 10.1002/cncr.22852
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Fesinmeyer MD, 2005, CANCER EPIDEM BIOMAR, V14, P1766, DOI 10.1158/1055-9965.EPI-05-0120
   Goggins M, 2005, J CLIN ONCOL, V23, P4524, DOI 10.1200/JCO.2005.19.711
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kuhlmann KFD, 2007, CANCER EPIDEM BIOMAR, V16, P886, DOI 10.1158/1055-9965.EPI-06-0779
   Lamerz R, 1999, ANN ONCOL, V10, P145, DOI 10.1023/A:1008386130283
   Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   PASANEN PA, 1994, J CANCER RES CLIN, V120, P494, DOI 10.1007/BF01191804
   Qi J, 2006, WORLD J GASTROENTERO, V12, P7113, DOI 10.3748/wjg.v12.i44.7113
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   SHAHANGIAN S, 1989, CLIN CHEM, V35, P405
   Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083
   Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Yang ZY, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-26
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103
NR 23
TC 0
Z9 1
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 3
BP 3442
EP 3447
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DO2FA
UT WOS:000377594100077
DA 2025-01-12
ER

PT J
AU Jiang, YC
   Qiu, Y
   Minn, AJ
   Zhang, NR
AF Jiang, Yuchao
   Qiu, Yu
   Minn, Andy J.
   Zhang, Nancy R.
TI Assessing intratumor heterogeneity and tracking longitudinal and spatial
   clonal evolutionary history by next-generation sequencing
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE intratumor heterogeneity; cancer evolution; clonal deconvolution; cancer
   genomics; phylogeny inference
ID BREAST-CANCER METASTASIS; COPY NUMBER; SNP ARRAY; INFERENCE; POPULATION;
   FRAMEWORK; TUMORS; GENES
AB Cancer is a disease driven by evolutionary selection on somatic genetic and epigenetic alterations. Here, we propose Canopy, a method for inferring the evolutionary phylogeny of a tumor using both somatic copy number alterations and single-nucleotide alterations from one or more samples derived from a single patient. Canopy is applied to bulk sequencing datasets of both longitudinal and spatial experimental designs and to a transplantable metastasis model derived from human cancer cell line MDA-MB-231. Canopy successfully identifies cell populations and infers phylogenies that are in concordance with existing knowledge and ground truth. Through simulations, we explore the effects of key parameters on deconvolution accuracy and compare against existing methods. Canopy is an open-source R package available at https://cran.r-project.org/web/packages/Canopy/.
C1 [Jiang, Yuchao] Univ Penn, Perelman Sch Med, Genom & Computat Biol Grad Program, Philadelphia, PA 19104 USA.
   [Jiang, Yuchao; Zhang, Nancy R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
   [Qiu, Yu; Minn, Andy J.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Qiu, Yu; Minn, Andy J.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
   [Qiu, Yu; Minn, Andy J.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Qiu, Yu; Minn, Andy J.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; University of Pennsylvania; University of Pennsylvania;
   University of Pennsylvania
RP Zhang, NR (通讯作者)，Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
EM nzh@wharton.upenn.edu
OI Jiang, Yuchao/0000-0001-6905-6377; Minn, Andy/0000-0003-1418-0906
FU NIH [R01-HG006137]
FX This work was supported by NIH Grant R01-HG006137 (to N.R.Z.).
CR Andor N, 2014, BIOINFORMATICS, V30, P50, DOI 10.1093/bioinformatics/btt622
   Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230
   Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Chen H, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1252
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Deshwar AG, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0602-8
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952
   El-Kebir M, 2016, CELL SYST, V3, P43, DOI 10.1016/j.cels.2016.07.004
   Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   GUSFIELD D, 1991, NETWORKS, V21, P19, DOI 10.1002/net.3230210104
   Ha G, 2014, GENOME RES, V24, P1881, DOI 10.1101/gr.180281.114
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987
   Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562
   Jiao W, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-35
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   KIMURA M, 1969, GENETICS, V61, P893
   Li B, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0473-4
   Lönnstedt IM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0470-7
   Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Niknafs N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004416
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Oesper L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r80
   Popic V, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0647-8
   Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]
   Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214
   Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Yuan K, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0592-6
   Zare H, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003703
NR 42
TC 140
Z9 165
U1 0
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 13
PY 2016
VL 113
IS 37
BP E5528
EP E5537
DI 10.1073/pnas.1522203113
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DV7BW
UT WOS:000383092000020
PM 27573852
OA Green Published
DA 2025-01-12
ER

PT J
AU Li, XN
   Wu, YM
   Liu, AH
   Tang, X
AF Li, Xiunan
   Wu, Yumei
   Liu, Aihui
   Tang, Xin
TI MiR-27b is epigenetically downregulated in tamoxifen resistant breast
   cancer cells due to promoter methylation and regulates tamoxifen
   sensitivity by targeting HMGB3
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MiR-27b; Promoter methylation; Tamoxifen; HMGB3
ID UP-REGULATION; CONTRIBUTES; MICRORNAS; APOPTOSIS; PROTEINS; GROWTH;
   SRC-3; DNA
AB MiR-27b downregulation is significantly associated with tamoxifen resistance in breast cancer cells. However, how it is downregulated in tamoxifen resistant (TamR) breast cancer cells and its downstream regulation were not clear. By performing MSP assay and QRT-PCR analysis with the use of 5-AZA-dC, a DNA methyltransferase inhibitor, we observed that TamR MCF-7 cells had significantly higher levels of methylation in the miR-27b promoter region than tamoxifen sensitive MCF-7 (TamS) cells and demethylation restored miR-27b expression. Re-expression of miR-27b sensitized TamR MCF-7 cells to tamoxifen, inhibited invasion and reversed epithelial-mesenchymal transition (EMT)-like properties. By using bioinformatics analysis and following dual luciferase and western blot analysis, this study confirmed a direct regulation of miR-27b on HMGB3 expression by binding to the 3'UTR. In addition, this study also found that silencing of HMGB3 indeed partially phenocopied the effects of miR-27b in reducing tamoxifen resistance and cell invasion and in reversing EMT-like properties. Therefore, we infer that HMGB3 is a functional target of miR-27b in modulation of tamoxifen resistance and EMT. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Li, Xiunan; Wu, Yumei; Liu, Aihui; Tang, Xin] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Breast Surg, Beijing 100006, Peoples R China.
C3 Capital Medical University
RP Wu, YM (通讯作者)，Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Gynecol Oncol, 17 Qihelou St, Beijing 100006, Peoples R China.
EM yumeiwu1@163.com
FU Beijing Natural Science Foundation [7142055]
FX This study was supported by Beijing Natural Science Foundation
   (7142055).
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6
   Bai JX, 2013, ENDOCRINOLOGY, V154, P635, DOI 10.1210/en.2012-1607
   Chen XD, 2014, TUMOR BIOL, V35, P11081, DOI 10.1007/s13277-014-2405-z
   Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z
   Chu JJ, 2015, ONCOTARGET, V6, P31944, DOI 10.18632/oncotarget.5128
   Elgamal OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076402
   Gojis O, 2010, NAT REV CLIN ONCOL, V7, P83, DOI 10.1038/nrclinonc.2009.219
   He DX, 2014, FEBS J, V281, P4718, DOI 10.1111/febs.13012
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Lü MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep08735
   Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334
   Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353
   Pincini A, 2013, CELL CYCLE, V12, P2409, DOI 10.4161/cc.25415
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Shang YL, 2016, ONCOTARGET, V7, P538, DOI 10.18632/oncotarget.6374
   Shao CB, 2009, EPIGENETICS-US, V4, P165, DOI 10.4161/epi.4.3.8277
   Shen R, 2015, AM J TRANSL RES, V7, P2115
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Takahashi RU, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8318
   Traverso N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/972913
   Ujihira T, 2015, SCI REP-UK, V5, DOI 10.1038/srep07641
   Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128
   Ward A, 2014, J PATHOL, V233, P368, DOI 10.1002/path.4363
   Xue M, 2014, ONCOL REP, V31, P1993, DOI 10.3892/or.2014.3092
   Yang BR, 2016, TUMOR BIOL, V37, P1771, DOI 10.1007/s13277-015-3951-8
   Ye J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060687
   Ye XM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-134
NR 29
TC 50
Z9 56
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 2
PY 2016
VL 477
IS 4
BP 768
EP 773
DI 10.1016/j.bbrc.2016.06.133
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DS7ND
UT WOS:000380969300039
PM 27363334
DA 2025-01-12
ER

PT J
AU Nguyen, T
   Shively, JE
AF Nguyen, Tung
   Shively, John E.
TI Induction of Lumen Formation in a Three-dimensional Model of Mammary
   Morphogenesis by Transcriptional Regulator ID4 <i>ROLE OF CaMK2D IN THE
   EPIGENETIC REGULATION OF ID4 GENE EXPRESSION</i>
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CELL ADHESION MOLECULE; DIFFERENTIATION 4 ID4; BILIARY GLYCOPROTEIN
   CD66A; BREAST-CANCER CELLS; NF-KAPPA-B; PROSTATE-CANCER; CYTOPLASMIC
   DOMAIN; DOWN-REGULATION; HISTONE DEACETYLASE-4; MALIGNANT BREAST
AB Concomitant loss of lumen formation and cell adhesion protein-CEACAM1 is a hallmark feature of breast cancer. In a three-dimensional culture model, transfection of CEACAM1 into MCF7 breast cells can restore lumen formation by an unknown mechanism. ID4, a transcriptional regulator lacking a DNA binding domain, is highly up-regulated in CEACAM1-transfected MCF7 cells, and when down-regulated with RNAi, abrogates lumen formation. Conversely, when MCF7 cells, which fail to form lumena in a three-dimensional culture, are transfected with ID4, lumen formation is restored, demonstrating that ID4 may substitute for CEACAM1. After showing the ID4 promoter is hypermethylated in MCF7 cells but hypomethylated in MCF/CEACAM1 cells, ID4 expression was induced in MCF7 cells by agents affecting chromatin remodeling and methylation. Mechanistically, CaMK2D was up-regulated in CEACAM1-transfected cells, effecting phosphorylation of HDAC4 and its sequestration in the cytoplasm by the adaptor protein 14-3-3. CaMK2D also phosphorylates CEACAM1 on its cytoplasmic domain and mutation of these phosphorylation sites abrogates lumen formation. Thus, CEACAM1 is able to maintain the active transcription of ID4 by an epigenetic mechanism involving HDAC4 and CaMK2D, and the same kinase enables lumen formation by CEACAM1. Because ID4 can replace CEACAM1 in parental MCF7 cells, it must act downstream from CEACAM1 by inhibiting the activity of other transcription factors that would otherwise prevent lumen formation. This overall mechanism may be operative in other cancers, such as colon and prostate, where the down-regulation of CEACAM1 is observed.
C1 [Nguyen, Tung; Shively, John E.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunol, Duarte, CA 91010 USA.
C3 City of Hope; Beckman Research Institute of City of Hope
RP Shively, JE (通讯作者)，1450 E Duarte Rd, Duarte, CA 91010 USA.
EM jshively@coh.org
FU National Institutes of Health [CA84202]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant CA84202. The authors declare that they have no conflicts of
   interest with the contents of this article. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Anderson ME, 2009, J CLIN INVEST, V119, P1082, DOI 10.1172/JCI39262
   Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438
   Beauchemin N, 2013, CANCER METAST REV, V32, P643, DOI 10.1007/s10555-013-9444-6
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200
   Chen CJ, 2010, EXP CELL RES, V316, P638, DOI 10.1016/j.yexcr.2009.11.001
   Chinaranagari S, 2014, ONCOTARGET, V5, P7172, DOI 10.18632/oncotarget.2262
   Culver C, 2010, MOL CELL BIOL, V30, P4901, DOI 10.1128/MCB.00409-10
   Federman N, 2014, J PHYSIOL-PARIS, V108, P278, DOI 10.1016/j.jphysparis.2014.06.003
   Gray CBB, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00015
   Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139
   Hoffman L, 2013, BIOCHEMISTRY-US, V52, P1198, DOI 10.1021/bi3016586
   Huang J, 1998, ANTICANCER RES, V18, P3203
   Huang J, 1999, J CELL SCI, V112, P4193
   Itahana Y, 2003, CANCER RES, V63, P7098
   Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002
   Jin L, 2008, EXP BIOL MED, V233, P849, DOI 10.3181/0712-RM-352
   Junankar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7548
   Killoran RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123934
   Kim NS, 2006, MOL CELL BIOL, V26, P1002, DOI 10.1128/MCB.26.3.1002-1013.2006
   Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81
   Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199
   Kuzontkoski PM, 2010, ONCOGENE, V29, P3793, DOI 10.1038/onc.2010.147
   Li CL, 2011, BIOCHEM BIOPH RES CO, V409, P125, DOI 10.1016/j.bbrc.2011.04.128
   Li Y, 2013, EXP CELL RES, V319, P1061, DOI 10.1016/j.yexcr.2013.02.020
   Little GH, 2007, J BIOL CHEM, V282, P7219, DOI 10.1074/jbc.M604281200
   Liu QA, 2011, ANN DIAGN PATHOL, V15, P30, DOI 10.1016/j.anndiagpath.2010.07.010
   Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999
   Marley PD, 1996, BIOCHEM BIOPH RES CO, V221, P15, DOI 10.1006/bbrc.1996.0536
   Müller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200
   Nishino TG, 2008, BIOCHEM BIOPH RES CO, V377, P852, DOI 10.1016/j.bbrc.2008.10.079
   Patel D, 2015, BBA-REV CANCER, V1855, P92, DOI 10.1016/j.bbcan.2014.12.002
   Patel D, 2014, MOL ENDOCRINOL, V28, P1239, DOI 10.1210/me.2014-1100
   Pradeep CR, 2012, ONCOGENE, V31, P907, DOI 10.1038/onc.2011.279
   Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200
   Sharma P, 2015, BIOCHIMIE, V112, P139, DOI 10.1016/j.biochi.2015.03.006
   Toko H, 2010, CIRCULATION, V122, P891, DOI 10.1161/CIRCULATIONAHA.109.935296
   Tokuzawa Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001019
   Nguyen T, 2014, J BIOL CHEM, V289, P2934, DOI 10.1074/jbc.M113.496992
   Tzortzopoulos A, 2004, BIOCHEMISTRY-US, V43, P6270, DOI 10.1021/bi035449u
   Wang JL, 2011, CHINESE J PHYSIOL, V54, P332, DOI 10.4077/CJP.2011.AMM087
   Weng CY, 2016, J BIOL CHEM, V291, P16777, DOI 10.1074/jbc.M115.710152
   Woodcock JM, 2015, ONCOTARGET, V6, P14522, DOI 10.18632/oncotarget.3995
   Yang CC, 2015, ACTA BIOCH BIOPH SIN, V47, P788, DOI 10.1093/abbs/gmv075
   Yokoyama S, 2007, ONCOGENE, V26, P7637, DOI 10.1038/sj.onc.1210577
   Zhang T, 2007, J BIOL CHEM, V282, P35078, DOI 10.1074/jbc.M707083200
   Zhao H, 2010, PROSTATE CANCER P D, V13, P252, DOI 10.1038/pcan.2010.9
NR 50
TC 6
Z9 6
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 5
PY 2016
VL 291
IS 32
BP 16766
EP 16776
DI 10.1074/jbc.M115.710160
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DS5MQ
UT WOS:000380826700033
PM 27302061
OA Green Published
DA 2025-01-12
ER

PT J
AU Crismale-Gann, C
   Stires, H
   Katz, TA
   Cohick, WS
AF Crismale-Gann, Catina
   Stires, Hillary
   Katz, Tiffany A.
   Cohick, Wendie S.
TI Tumor Phenotype and Gene Expression During Early Mammary Tumor
   Development in Offspring Exposed to Alcohol In Utero
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Mammary Tumor; Alcohol Exposure In Utero; Insulin-Like Growth Factor;
   Tumor Phenotype; Hormone Receptors
ID GROWTH-FACTOR-II; HUMAN-BREAST-CANCER; MESSENGER-RNA EXPRESSION;
   PROGESTERONE-RECEPTOR; IGF-II; WILMS-TUMOR; RATS; ESTROGEN; ORIGINS;
   ETHANOL
AB BackgroundAlcohol exposure in utero increases susceptibility to carcinogen-induced mammary tumorigenesis in adult offspring and causes tumors with a more malignant phenotype. This study was conducted to identify changes early in tumor development that might lead to this outcome.
   MethodsPregnant Sprague-Dawley rats were fed a liquid diet containing 6.7% ethanol (alcohol), an isocaloric liquid diet without alcohol (pair-fed), or rat chow adlibitum (ad lib) from gestation day 7 until parturition. At birth, female progeny were cross-fostered to control dams. Pups were weaned at postnatal day (PND) 21 and fed rat chow adlibitum for the remainder of the experiment. Female offspring were administered N-nitroso-N-methylurea (NMU; 50mg/kg body weight) on PND 50. Mammary glands were palpated weekly, and offspring were euthanized at 16weeks post-NMU injection.
   ResultsAt 16weeks post-NMU, tumor multiplicity was greater in alcohol-exposed offspring compared with control groups. Estrogen receptor- (ER) mRNA expression was decreased in tumors from alcohol-exposed offspring, and these animals developed more ER-negative tumors relative to the pair-fed group. Alcohol-exposed offspring also tended to develop more progesterone receptor (PR)-positive tumors. All tumors were HER2-negative. PR positivity was associated with higher Ki67 expression, suggesting that PR-positive tumors were more proliferative. Tumors from alcohol-exposed animals exhibited increased mRNA expression of the insulin-like growth factor (IGF) family members IGF-II and IGFBP-5. IGF-II and DNA methyltransferase mRNA tended to be greater in the normal contralateral mammary glands of these animals.
   ConclusionsThese data indicate that alcohol exposure in utero may shift NMU-induced tumor development toward a more aggressive phenotype and that alterations in IGF-II expression may contribute to these changes. Additional studies should be aimed at epigenetic mechanisms that underlie IGF-II expression to further delineate how this gene is altered in mammary glands of adults exposed to alcohol in utero.
C1 [Crismale-Gann, Catina; Stires, Hillary; Katz, Tiffany A.; Cohick, Wendie S.] Rutgers State Univ, Dept Anim Sci, 59 Dudley Rd, New Brunswick, NJ 08901 USA.
C3 Rutgers University System; Rutgers University New Brunswick
RP Cohick, WS (通讯作者)，Rutgers State Univ, Dept Anim Sci, 59 Dudley Rd, New Brunswick, NJ 08901 USA.
EM cohick@aesop.rutgers.edu
OI Andrews, Hillary/0000-0002-0177-2024
FU National Institutes of Health [F31CA132620]; Charles and Johanna Busch
   Memorial Fund; NJ Agricultural Experiment Station (Rutgers University);
   NIH [P30 ES005022]
FX The authors would like to thank Dr. Kenneth Reuhl for performing
   histopathological classification of the tumors. This work was supported
   by a grant from the National Institutes of Health (F31CA132620 to TAK),
   the Charles and Johanna Busch Memorial Fund and the NJ Agricultural
   Experiment Station (Rutgers University to WSC), and by NIH P30 ES005022
   to Rutgers University. The authors have declared that no competing
   interests exist.
CR Abel E, 1979, NEUROBEHAV TOXICOL, V1, P145
   Agostini-Dreyer A, 2015, ENDOCRINOLOGY, V156, P4141, DOI 10.1210/en.2015-1215
   Akkiprik M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2116
   Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   Calhoun BC, 2015, SEMIN DIAGN PATHOL, V32, P362, DOI 10.1053/j.semdp.2015.02.011
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cui HM, 2001, CANCER RES, V61, P4947
   CULLEN KJ, 1991, CANCER RES, V51, P4978
   Dyer JS, 2011, SEMIN REPROD MED, V29, P266, DOI 10.1055/s-0031-1275521
   Feeley LP, 2014, MODERN PATHOL, V27, P554, DOI 10.1038/modpathol.2013.153
   Fenton SE, 2015, J CLIN ENDOCR METAB, V100, P3245, DOI 10.1210/jc.2015-2848
   Hakkak R, 2000, CANCER EPIDEM BIOMAR, V9, P113
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   HASLAM SZ, 1979, BIOCHEM J, V182, P127, DOI 10.1042/bj1820127
   Hilakivi-Clarke L, 2004, BRIT J CANCER, V90, P2225, DOI 10.1038/sj.bjc.6601793
   Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002
   KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891
   Knutson TP, 2014, PHARMACOL THERAPEUT, V142, P114, DOI 10.1016/j.pharmthera.2013.11.010
   Lan N, 2009, ALCOHOL CLIN EXP RES, V33, P1075, DOI 10.1111/j.1530-0277.2009.00929.x
   Li XQ, 2007, CANCER SCI, V98, P1592, DOI 10.1111/j.1349-7006.2007.00565.x
   LIEBER CS, 1989, ALCOHOL ALCOHOLISM, V24, P197
   LOCHRY EA, 1980, J STUD ALCOHOL, V41, P1031, DOI 10.15288/jsa.1980.41.1031
   Ma ZK, 2015, INT J MOL SCI, V16, P7655, DOI 10.3390/ijms16047655
   MANNI A, 1982, CANCER RES, V42, P3492
   McCampbell AS, 2008, LAB INVEST, V88, P615, DOI 10.1038/labinvest.2008.29
   MILLER MW, 1992, BRAIN RES, V595, P17, DOI 10.1016/0006-8993(92)91447-M
   Nayak RB, 2008, INDIAN PEDIATR, V45, P977
   Obr AE, 2012, MOL CELL ENDOCRINOL, V357, P4, DOI 10.1016/j.mce.2011.10.030
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367
   OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701
   PAIK S, 1992, BREAST CANCER RES TR, V22, P31, DOI 10.1007/BF01833331
   Perks CM, 1999, J CELL BIOCHEM, V75, P652, DOI 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0
   Polanco Tiffany A., 2011, Hormones & Cancer, V2, P239, DOI 10.1007/s12672-011-0074-6
   Polanco TA, 2010, ALCOHOL CLIN EXP RES, V34, P1879, DOI 10.1111/j.1530-0277.2010.01276.x
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Roy RN, 2000, CANCER LETT, V153, P67, DOI 10.1016/S0304-3835(00)00347-5
   Simmen FA, 2011, EUR J CANCER PREV, V20, P539, DOI 10.1097/CEJ.0b013e328348fc21
   SINGER C, 1995, CANCER RES, V55, P2448
   Soares-Maia R, 2013, J ENVIRON PATHOL TOX, V32, P157, DOI 10.1615/JEnvironPatholToxicolOncol.2013007541
   Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x
   Soto AM, 2015, NAT REV ENDOCRINOL, V11, P507, DOI 10.1038/nrendo.2015.125
   Tang P, 2009, DIAGN MOL PATHOL, V18, P125, DOI 10.1097/PDM.0b013e31818d107b
   Thordarson G, 2001, CARCINOGENESIS, V22, P2039, DOI 10.1093/carcin/22.12.2039
   van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562
   Wadhwa PD, 2009, SEMIN REPROD MED, V27, P358, DOI 10.1055/s-0029-1237424
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   YEE D, 1988, CANCER RES, V48, P6691
NR 49
TC 2
Z9 3
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD AUG
PY 2016
VL 40
IS 8
BP 1679
EP 1690
DI 10.1111/acer.13139
PG 12
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse
GA DS4CP
UT WOS:000380729300012
PM 27373230
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Dominguez, D
   Tsai, YH
   Gomez, N
   Jha, DK
   Davis, I
   Wang, ZF
AF Dominguez, Daniel
   Tsai, Yi-Hsuan
   Gomez, Nicholas
   Jha, Deepak Kumar
   Davis, Ian
   Wang, Zefeng
TI A high-resolution transcriptome map of cell cycle reveals novel
   connections between periodic genes and cancer
SO CELL RESEARCH
LA English
DT Article
DE cell cycle; periodic transcriptome; epigenetic regulation; mitotic trait
ID BREAST-CANCER; REGULATED GENES; NONCODING RNAS; HUMAN GENOME;
   EXPRESSION; FOXM1; IDENTIFICATION; CTCF; SIGNATURES; LANDSCAPE
AB Progression through the cell cycle is largely dependent on waves of periodic gene expression, and the regulatory networks for these transcriptome dynamics have emerged as critical points of vulnerability in various aspects of tumor biology. Through RNA-sequencing of human cells during two continuous cell cycles (>2.3 billion paired reads), we identified over 1 000 mRNAs, non-coding RNAs and pseudogenes with periodic expression. Periodic transcripts are enriched in functions related to DNA metabolism, mitosis, and DNA damage response, indicating these genes likely represent putative cell cycle regulators. Using our set of periodic genes, we developed a new approach termed "mitotic trait" that can classify primary tumors and normal tissues by their transcriptome similarity to different cell cycle stages. By analyzing >4 000 tumor samples in The Cancer Genome Atlas (TCGA) and other expression data sets, we found that mitotic trait significantly correlates with genetic alterations, tumor subtype and, notably, patient survival. We further defined a core set of 67 genes with robust periodic expression in multiple cell types. Proteins encoded by these genes function as major hubs of protein-protein interaction and are mostly required for cell cycle progression. The core genes also have unique chromatin features including increased levels of CTCF/RAD21 binding and H3K36me3. Loss of these features in uterine and kidney cancers is associated with altered expression of the core 67 genes. Our study suggests new chromatin-associated mechanisms for periodic gene regulation and offers a predictor of cancer patient outcomes.
C1 [Dominguez, Daniel; Tsai, Yi-Hsuan; Wang, Zefeng] Univ North Carolina Chapel Hill, Dept Pharmacol, Chapel Hill, NC 27514 USA.
   [Dominguez, Daniel; Gomez, Nicholas; Davis, Ian; Wang, Zefeng] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA.
   [Tsai, Yi-Hsuan] Univ North Carolina Chapel Hill, Program Bioinformat & Computat Biol, Chapel Hill, NC USA.
   [Gomez, Nicholas] Univ North Carolina Chapel Hill, Curriculum Genet & Mol Biol, Chapel Hill, NC USA.
   [Jha, Deepak Kumar] Univ North Carolina Chapel Hill, Dept Biochem & Biophys, Chapel Hill, NC USA.
   [Davis, Ian] Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC USA.
   [Davis, Ian] Univ North Carolina Chapel Hill, Dept Pediat, Chapel Hill, NC USA.
   [Davis, Ian] Univ North Carolina Chapel Hill, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
   [Wang, Zefeng] Chinese Acad Sci, CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina School of Medicine; University of North Carolina
   School of Medicine; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina School of Medicine;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Chinese Academy of
   Sciences; Max Planck Society
RP Wang, ZF (通讯作者)，Univ North Carolina Chapel Hill, Dept Pharmacol, Chapel Hill, NC 27514 USA.; Wang, ZF (通讯作者)，Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA.; Wang, ZF (通讯作者)，Chinese Acad Sci, CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China.
EM wangzefeng@picb.ac.cn
RI yijing, zhang/HNC-0874-2023; Jha, Deepak/AAK-2279-2020
OI Jha, Deepak/0000-0002-6657-5662; Wang, Zefeng/0000-0002-6605-3637
FU NIH [R01CA158283]; Jefferson-Pilot fellowship
FX We thank Dr Jan Prins and Darshan Singh for suggestions in analyzing
   RNA-seq data. We thank Drs William Marzluff, Jean Cook, Michael Emanuele
   and Mauro Calabrese for reading this manuscript and providing comments.
   We thank Peter Sudmant for his assistance and advice with permutation
   analysis and helpful comments on this manuscript. This work is supported
   by an NIH grant (R01CA158283) and Jefferson-Pilot fellowship to ZW.
CR Bähler J, 2005, ANNU REV GENET, V39, P69, DOI 10.1146/annurev.genet.39.110304.095808
   Bar-Joseph Z, 2008, P NATL ACAD SCI USA, V105, P955, DOI 10.1073/pnas.0704723105
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472
   Chibon F, 2013, EUR J CANCER, V49, P2000, DOI 10.1016/j.ejca.2013.02.021
   Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Dominguez D, 2016, ELIFE, V5, DOI 10.7554/eLife.10288
   Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967
   Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gonzalez-Perez A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r106
   Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264
   Grant GD, 2012, MOL BIOL CELL, V23, P3079, DOI 10.1091/mbc.E11-02-0170
   Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r24
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857
   Heidari N, 2014, GENOME RES, V24, P1905, DOI 10.1101/gr.176586.114
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Holwerda SJB, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0369
   Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848
   Inghirami G, 2005, CELL CYCLE, V4, P1131, DOI 10.4161/cc.4.9.1985
   Johnson DG, 1998, FRONT BIOSCI, V3, pd447
   Kittler R, 2007, NAT CELL BIOL, V9, P1401, DOI 10.1038/ncb1659
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kontzoglou K, 2013, ONCOLOGY-BASEL, V84, P219, DOI 10.1159/000346475
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Lehr HA, 2013, MODERN PATHOL, V26, P336, DOI 10.1038/modpathol.2012.140
   Mihály Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y
   Mukherji M, 2006, P NATL ACAD SCI USA, V103, P14819, DOI 10.1073/pnas.0604320103
   Nekrasov M, 2012, NAT STRUCT MOL BIOL, V19, P1076, DOI 10.1038/nsmb.2424
   Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rubio ED, 2008, P NATL ACAD SCI USA, V105, P8309, DOI 10.1073/pnas.0801273105
   Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111
   Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113
   Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113
   Smith E, 2014, NAT STRUCT MOL BIOL, V21, P210, DOI 10.1038/nsmb.2784
   Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273
   Thomas AA, 2014, JAMA NEUROL, V71, P1437, DOI 10.1001/jamaneurol.2014.1701
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368
   Uchida F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-321
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Xie D, 2013, CELL, V155, P713, DOI 10.1016/j.cell.2013.09.043
   Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024
   Zaidi SK, 2014, CANCER RES, V74, P420, DOI 10.1158/0008-5472.CAN-13-2837
NR 58
TC 68
Z9 80
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD AUG
PY 2016
VL 26
IS 8
BP 946
EP 962
DI 10.1038/cr.2016.84
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DS6WN
UT WOS:000380923900011
PM 27364684
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Chung, CY
   Sun, Z
   Mullokandov, G
   Bosch, A
   Qadeer, ZA
   Cihan, E
   Rapp, Z
   Parsons, R
   Aguirre-Ghiso, JA
   Farias, EF
   Brown, BD
   Gaspar-Maia, A
   Bernstein, E
AF Chung, Chi-Yeh
   Sun, Zhen
   Mullokandov, Gavriel
   Bosch, Almudena
   Qadeer, Zulekha A.
   Cihan, Esma
   Rapp, Zachary
   Parsons, Ramon
   Aguirre-Ghiso, Julio A.
   Farias, Eduardo F.
   Brown, Brian D.
   Gaspar-Maia, Alexandre
   Bernstein, Emily
TI Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis
SO CELL REPORTS
LA English
DT Article
ID HUMAN BREAST-CANCER; POLYCOMB GROUP PROTEIN; STEM-CELLS; GLAND
   DEVELOPMENT; GENE-EXPRESSION; CHEMICAL PROBE; NOTCH; TUMORS;
   HETEROGENEITY; RESISTANCE
AB Chromatin-mediated processes influence the development and progression of breast cancer. Using murine mammary carcinoma-derived tumorspheres as a functional readout for an aggressive breast cancer phenotype, we performed a loss-of-function screen targeting 60 epigenetic regulators. We identified the Polycomb protein Cbx8 as a key regulator of mammary carcinoma both in vitro and in vivo. Accordingly, Cbx8 is overexpressed in human breast cancer and correlates with poor survival. Our genomic analyses revealed that Cbx8 positively regulates Notch signaling by maintaining H3K4me3 levels on Notch-network gene promoters. Ectopic expression of Notch1 partially rescues tumorsphere formation in Cbx8-depleted cells. We find that Cbx8 associates with non-PRC1 complexes containing the H3K4 methyltransferase complex component WDR5, which together regulate Notch gene expression. Thus, our study implicates a key non-canonical role for Cbx8 in promoting breast tumorigenesis.
C1 [Chung, Chi-Yeh; Sun, Zhen; Qadeer, Zulekha A.; Cihan, Esma; Rapp, Zachary; Parsons, Ramon; Gaspar-Maia, Alexandre; Bernstein, Emily] Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Chung, Chi-Yeh; Mullokandov, Gavriel; Brown, Brian D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Sun, Zhen] Icahn Sch Med Mt Sinai, Dept Dev & Regenerat Biol, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Bosch, Almudena] Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Chung, Chi-Yeh; Sun, Zhen; Mullokandov, Gavriel; Qadeer, Zulekha A.; Parsons, Ramon; Aguirre-Ghiso, Julio A.; Brown, Brian D.; Bernstein, Emily] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Aguirre-Ghiso, Julio A.; Farias, Eduardo F.] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, One Gustave L Levy Pl, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn
   School of Medicine at Mount Sinai
RP Gaspar-Maia, A; Bernstein, E (通讯作者)，Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl, New York, NY 10029 USA.; Bernstein, E (通讯作者)，Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, One Gustave L Levy Pl, New York, NY 10029 USA.
EM alexandre.maia@mssm.edu; emily.bernstein@mssm.edu
RI Parsons, Ramon/KFT-2922-2024; Brown, Brian D./JOZ-4915-2023;
   AguirreGhiso, Julio/KXR-3097-2024; Gaspar-Maia, Alexandre/AAY-5416-2020;
   Sun, Zhen/J-8845-2019
OI Qadeer, Zulekha/0000-0002-1335-660X; Karlovich,
   Esma/0000-0003-1030-2101; Gaspar-Maia, Alexandre/0000-0001-8528-5575;
   Sun, Zhen/0000-0001-9515-1925; Parsons, Ramon/0000-0002-6656-3514
FU Office of Research Infrastructure of the NIH [S10OD018522]; Department
   of Defense Breast Cancer Research Program [BC100975]; New York Stem Cell
   Foundation-Druckenmiller fellowship; NCI [T32 T32CA078207-11]; Helmsley
   Trust Award; NIH Pathfinder Award [DP2DK083052-01]; Juvenile Diabetes
   Research Foundation award [JDRF-17-2010-770, R01 CA82783, R01CA184016];
   Samuel Waxman Cancer Research Foundation Tumor Dormancy Program award;
   JJR Foundation; Mary Kay Foundation
FX The authors thank M. Mahajan, O. Jabado, and H. Shah from the ISMMS
   Genomics Core Facility, members of the E.B. lab, S. Aaronson lab, I.
   Aifantis lab, G. Peters lab, F. Hof lab, G. de Haan lab, D.
   Placantonakis lab, J. Wang lab, S. Frye lab, and I. Lemischka lab, M.
   Walsh, V. Gouon-Evans, J. Jin, W. Guo, N. Bansal, and M.S. Sosa for
   advice, reagents, and technical support. This work was supported by the
   Office of Research Infrastructure of the NIH (award number S10OD018522),
   the Department of Defense Breast Cancer Research Program award BC100975,
   a New York Stem Cell Foundation-Druckenmiller fellowship to A.G.-M., NCI
   T32 T32CA078207-11 to Z.A.Q., a Helmsley Trust Award to G.M., an NIH
   Pathfinder Award (DP2DK083052-01) and Juvenile Diabetes Research
   Foundation award (JDRF-17-2010-770) to B.D.B., R01 CA82783 and
   R01CA184016 to R.P., a Samuel Waxman Cancer Research Foundation Tumor
   Dormancy Program award to J.A.A.-G., E.F.F., and E.B., and The JJR and
   Mary Kay Foundations award to E.B.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553
   Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006
   Bosch A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3247
   Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001
   Campbell RM, 2014, J CLIN INVEST, V124, P64, DOI 10.1172/JCI71605
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Creppe C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004851
   D'Angelo RC, 2015, MOL CANCER THER, V14, P779, DOI 10.1158/1535-7163.MCT-14-0228
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133
   Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002
   Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582
   Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036
   Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077
   Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Kurpios NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058151
   Li G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080970
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110
   Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006
   O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23
   Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18
   Ren CY, 2015, CHEM BIOL, V22, P161, DOI 10.1016/j.chembiol.2014.11.021
   Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Simhadri C, 2014, J MED CHEM, V57, P2874, DOI 10.1021/jm401487x
   Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018
   Stuckey JI, 2016, NAT CHEM BIOL, V12, P180, DOI 10.1038/nchembio.2007
   Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008
   Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029
   Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Whitcomb SJ, 2007, TRENDS GENET, V23, P494, DOI 10.1016/j.tig.2007.08.006
   Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009
   Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017
NR 56
TC 72
Z9 93
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUL 12
PY 2016
VL 16
IS 2
BP 472
EP 486
DI 10.1016/j.celrep.2016.06.002
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DS0CG
UT WOS:000380262300018
PM 27346354
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Yao, CJ
   Chow, JM
   Yang, CM
   Kuo, HC
   Chang, CL
   Lee, HL
   Lai, IC
   Chuang, SE
   Lai, GM
AF Yao, Chih-Jung
   Chow, Jyh-Ming
   Yang, Chia-Ming
   Kuo, Hui-Ching
   Chang, Chia-Lun
   Lee, Hsin-Lun
   Lai, I-Chun
   Chuang, Shuang-En
   Lai, Gi-Ming
TI Chinese Herbal Mixture, Tien-Hsien Liquid, Induces G2/M Cycle Arrest and
   Radiosensitivity in MCF-7 Human Breast Cancer Cells through Mechanisms
   Involving DNMT1 and Rad51 Downregulation
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID DNA METHYLTRANSFERASE-1; EPIGENETIC REGULATION; EXPRESSION; THERAPY;
   DYSREGULATION; INHIBITION; RESISTANCE; MAMMARY; GROWTH; REPAIR
AB The Chinese herbal mixture, Tien-Hsien Liquid (THL), has been proven to suppress the growth and invasiveness of cancer cells and is currently regarded as a complementary medicine for the treatment of cancer. Our previous study using acute promyelocytic leukemia cells uncovered its effect on the downregulation of DNA methyltransferase 1 (DNMT1) which is often overexpressed in cancer cells resulting in the repression of tumor suppressors via hypermethylation. Herein, we explored the effects of THL in MCF-7 breast cancer cells that also demonstrate elevated DNMT1. The results show that THL dose-dependently downregulated DNMT1 accompanied by the induction of tumor suppressors such as p21 and p15. THL arrested cell cycle in G2/M phase and decreased the protein levels of cyclin A, cyclin B1, phospho-pRb, and AKT. DNMT1 inhibition was previously reported to exert a radiosensitizing effect in cancer cells through the repression of DNA repair. We found that THL enhanced radiation-induced clonogenic cell death in MCF-7 cells and decreased the level of DNA double-strand break repair protein, Rad51. Our observations may be the result of DNMT1 downregulation. Due to the fact that DNMT1 inhibition is now a mainstream strategy for anticancer therapy, further clinical trials of THL to confirm its clinical efficacy are warranted.
C1 [Yao, Chih-Jung; Lai, Gi-Ming] Taipei Med Univ, Comprehens Canc Ctr, Taipei 11031, Taiwan.
   [Yao, Chih-Jung; Kuo, Hui-Ching; Lai, Gi-Ming] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11696, Taiwan.
   [Yao, Chih-Jung; Chow, Jyh-Ming; Lai, Gi-Ming] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.
   [Chow, Jyh-Ming; Chang, Chia-Lun; Lai, Gi-Ming] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Hematol & Med Oncol, Taipei 11696, Taiwan.
   [Yang, Chia-Ming] Formosa Canc Fdn, Taipei 10597, Taiwan.
   [Lee, Hsin-Lun] Taipei Med Univ, Acad Sinica, PhD Program Translat Med, Taipei 11031, Taiwan.
   [Lai, I-Chun] Taipei Vet Gen Hosp, Dept Oncol, Div Radiat Oncol, Taipei 11217, Taiwan.
   [Chuang, Shuang-En; Lai, Gi-Ming] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Township 35053, Miaoli County, Taiwan.
C3 Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei
   Medical University; Taipei Medical University; Taipei Municipal WanFang
   Hospital; Taipei Medical University; Taipei Medical University; Academia
   Sinica - Taiwan; Taipei Veterans General Hospital; National Health
   Research Institutes - Taiwan
RP Lai, GM (通讯作者)，Taipei Med Univ, Comprehens Canc Ctr, Taipei 11031, Taiwan.; Lai, GM (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11696, Taiwan.; Lai, GM (通讯作者)，Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.; Lai, GM (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Hematol & Med Oncol, Taipei 11696, Taiwan.; Lai, GM (通讯作者)，Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Township 35053, Miaoli County, Taiwan.
EM gminlai@nhri.org.tw
FU National Health Research Institutes [CA-104-PP-35]; Wan Fang Hospital,
   Taipei Medical University [98TMU-WFH-02-2]; Health and Welfare Surcharge
   of tobacco products, Taiwan [MOHW104-TDU-B-212-124-001]
FX The authors would like to thank Feida Union Pharmaceutical Manufactory
   for providing THL. This work was supported by National Health Research
   Institutes (Grant CA-104-PP-35), Wan Fang Hospital, Taipei Medical
   University (98TMU-WFH-02-2), and Health and Welfare Surcharge of tobacco
   products, Taiwan (MOHW104-TDU-B-212-124-001).
CR Agoston AT, 2007, AM J PATHOL, V170, P1585, DOI 10.2353/ajpath.2007.060779
   Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Chia JS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-175
   Choi DS, 2014, STEM CELLS, V32, P2309, DOI 10.1002/stem.1746
   CHOY H, 1993, CANCER, V71, P3774, DOI 10.1002/1097-0142(19930601)71:11<3774::AID-CNCR2820711147>3.0.CO;2-0
   Clemens DL, 2003, HEPATOLOGY, V38, P385, DOI 10.1053/jhep.2003.50332
   Du LQ, 2011, MED ONCOL, V28, P1481, DOI 10.1007/s12032-010-9605-1
   Hine CM, 2012, MOL THER, V20, P347, DOI 10.1038/mt.2011.215
   Hsieh WT, 2006, FOOD CHEM TOXICOL, V44, P974, DOI 10.1016/j.fct.2005.11.013
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401
   Kuo WH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/803239
   Lai T.-Y., 2011, EVID-BASED COMPL ALT, V2011
   Leigh A. B., INTEGRATIVE IN PRESS
   Li SY, 2015, J CONTROL RELEASE, V205, P7, DOI 10.1016/j.jconrel.2014.11.011
   Maacke H, 2000, INT J CANCER, V88, P907, DOI 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4
   Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312
   McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158
   Menschikowski M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1937-y
   Nogueira A, 2010, CANCER CHEMOTH PHARM, V66, P501, DOI 10.1007/s00280-009-1187-2
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Pellerito C, 2015, J INORG BIOCHEM, V150, P18, DOI 10.1016/j.jinorgbio.2015.06.001
   Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x
   Saini KS, 2013, CANCER TREAT REV, V39, P935, DOI 10.1016/j.ctrv.2013.03.009
   Singh V, 2013, CURR CANCER DRUG TAR, V13, P379, DOI 10.2174/15680096113139990077
   SKEHAN P, 1990, JNCI-J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Sun A, 2005, J ALTERN COMPLEM MED, V11, P245, DOI 10.1089/acm.2005.11.245
   Sun A, 2004, AM J CHINESE MED, V32, P221, DOI 10.1142/S0192415X04001886
   Tang HL, 2014, MOL CANCER THER, V13, P3185, DOI 10.1158/1535-7163.MCT-14-0243
   Thummuri D, 2015, LIFE SCI, V130, P73, DOI 10.1016/j.lfs.2015.03.016
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   Wang J, 2012, INT J MOL MED, V30, P1166, DOI 10.3892/ijmm.2012.1095
   Yao CJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/617085
   Yu JH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055934, 10.1371/journal.pone.0057564]
   Yu ZJ, 2015, MOL CARCINOGEN, V54, P707, DOI 10.1002/mc.22133
   Zielske SP, 2015, J CELL BIOCHEM, V116, P212, DOI 10.1002/jcb.24959
NR 41
TC 4
Z9 4
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2016
VL 2016
AR 3251046
DI 10.1155/2016/3251046
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA DS3TD
UT WOS:000380704700001
PM 27525019
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Singh, B
   Kinne, HE
   Milligan, RD
   Washburn, LJ
   Olsen, M
   Lucci, A
AF Singh, Balraj
   Kinne, Hannah E.
   Milligan, Ryan D.
   Washburn, Laura J.
   Olsen, Mark
   Lucci, Anthony
TI Important Role of FTO in the Survival of Rare Panresistant
   Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe
   Metabolic Challenge
SO PLOS ONE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; CLONAL EVOLUTION; OBESITY GENE;
   METASTASIS; RISK; ENCODES; IMPACT; TUMOR
AB We have previously shown that only 0.01% cells survive a metabolic challenge involving lack of glutamine in culture medium of SUM149 triple-negative Inflammatory Breast Cancer cell line. These cells, designated as SUM149-MA for metabolic adaptability, are resistant to chemotherapeutic drugs, and they efficiently metastasize to multiple organs in nude mice. We hypothesized that obesity-related molecular networks, which normally help in cellular and organismal survival under metabolic challenges, may help in the survival of MA cells. The fat mass and obesity-associated protein FTO is overexpressed in MA cells. Obesity-associated cis-acting elements in non-coding region of FTO regulate the expression of IRX3 gene, thus activating obesity networks. Here we found that IRX3 protein is significantly overexpressed in MA cells (5 to 6-fold) as compared to the parental SUM149 cell line, supporting our hypothesis. We also obtained evidence that additional key regulators of energy balance such as ARID5B, IRX5, and CUX1 P200 repressor could potentially help progenitor-like TNBC cells survive in glutamine-free medium. MO-I-500, a pharmacological inhibitor of FTO, significantly (> 90%) inhibited survival and/or colony formation of SUM149-MA cells as compared to untreated cells or those treated with a control compound MO-I-100. Curiously, MO-I-500 treatment also led to decreased levels of FTO and IRX3 proteins in the SUM149 cells initially surviving in glutamine-free medium as compared to MO-I-100 treatment. Interestingly, MO-I-500 treatment had a relatively little effect on cell growth of either the SUM149 or SUM149-MA cell line when added to a complete medium containing glutamine that does not pose a metabolic challenge. Importantly, once selected and cultured in glutamine-free medium, SUM149-MA cells were no longer affected by MO-I-500 even in Gln-free medium. We conclude that panresistant MA cells contain interconnected molecular networks that govern developmental status and energy balance, and genetic and epigenetic alterations that are selected during cancer evolution.
C1 [Singh, Balraj; Kinne, Hannah E.; Milligan, Ryan D.; Washburn, Laura J.; Lucci, Anthony] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA.
   [Singh, Balraj; Kinne, Hannah E.; Milligan, Ryan D.; Washburn, Laura J.; Lucci, Anthony] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA.
   [Olsen, Mark] Midwestern Univ, Coll Pharm Glendale, Dept Pharmaceut Sci, Glendale, AZ USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Midwestern University;
   Midwestern University - College of Pharmacy - Glendale
RP Lucci, A (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA.; Lucci, A (通讯作者)，Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA.
EM alucci@mdanderson.org
OI Lucci, Anthony/0000-0003-4039-174X
FU State of Texas Rare and Aggressive Breast Cancer Research Program Grant;
   Breast Cancer Metastasis Research Program at MD Anderson Cancer Center;
   National Institutes of Health [CA16672]
FX This study was supported by a State of Texas Rare and Aggressive Breast
   Cancer Research Program Grant, Breast Cancer Metastasis Research Program
   at MD Anderson Cancer Center, and CA16672 (Core) from the National
   Institutes of Health. Sponsors or funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Barnabas N, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/872743
   Bellefroid EJ, 1998, EMBO J, V17, P191, DOI 10.1093/emboj/17.1.191
   Berulava T, 2013, EUR J HUM GENET, V21, P317, DOI 10.1038/ejhg.2012.168
   Chao HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051719
   Claussnitzer M, 2015, NEW ENGL J MED, V373, P895, DOI 10.1056/NEJMoa1502214
   Hernández-Caballero ME, 2015, MOL BIOL REP, V42, P699, DOI 10.1007/s11033-014-3817-y
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848
   Fredriksson R, 2008, ENDOCRINOLOGY, V149, P2062, DOI 10.1210/en.2007-1457
   Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561
   Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710
   Gulati P, 2013, P NATL ACAD SCI USA, V110, P2557, DOI 10.1073/pnas.1222796110
   Jacobsson JA, 2012, OBES REV, V13, P1096, DOI 10.1111/j.1467-789X.2012.01025.x
   Jain R, 2013, J MAMMARY GLAND BIOL, V18, P257, DOI 10.1007/s10911-013-9307-3
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Masuda H, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3579
   McKnight SL, 2010, SCIENCE, V330, P1338, DOI 10.1126/science.1199908
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Peters U, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003171
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154
   Singh B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109487
   Singh B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036510
   Singh B, 2010, CLIN EXP METASTAS, V27, P233, DOI 10.1007/s10585-010-9321-4
   Smemo S, 2014, NATURE, V507, P371, DOI 10.1038/nature13138
   Stratigopoulos G, 2011, J BIOL CHEM, V286, P2155, DOI 10.1074/jbc.M110.188482
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Tiwari A, 2012, DOMEST ANIM ENDOCRIN, V42, P1, DOI 10.1016/j.domaniend.2011.08.001
   Van Laere SJ, 2013, CLIN CANCER RES, V19, P4685, DOI 10.1158/1078-0432.CCR-12-2549
   Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600
   Yamakawa T, 2010, BIOCHEM BIOPH RES CO, V391, P277, DOI 10.1016/j.bbrc.2009.11.049
   Zheng GQ, 2014, ACS CHEM NEUROSCI, V5, P658, DOI 10.1021/cn500042t
NR 32
TC 100
Z9 104
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 8
PY 2016
VL 11
IS 7
AR e0159072
DI 10.1371/journal.pone.0159072
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DR6IK
UT WOS:000380005400207
PM 27390851
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Campoy, EM
   Laurito, SR
   Branham, MT
   Urrutia, G
   Mathison, A
   Gago, F
   Orozco, J
   Urrutia, R
   Mayorga, LS
   Roqué, M
AF Campoy, Emanuel M.
   Laurito, Sergio R.
   Branham, Maria T.
   Urrutia, Guillermo
   Mathison, Angela
   Gago, Francisco
   Orozco, Javier
   Urrutia, Raul
   Mayorga, Luis S.
   Roque, Maria
TI Asymmetric Cancer Hallmarks in Breast Tumors on Different Sides of the
   Body
SO PLOS ONE
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; METHYLATION PROFILE; LATERALITY; ASSOCIATION;
   SURVIVAL
AB During the last decades it has been established that breast cancer arises through the accumulation of genetic and epigenetic alterations in different cancer related genes. These alterations confer the tumor oncogenic abilities, which can be resumed as cancer hallmarks (CH). The purpose of this study was to establish the methylation profile of CpG sites located in cancer genes in breast tumors so as to infer their potential impact on 6 CH: i.e. sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, induction of angiogenesis, genome instability and invasion and metastasis. For 51 breast carcinomas, MS-MLPA derived-methylation profiles of 81 CpG sites were converted into 6 CH profiles. CH profiles distribution was tested by different statistical methods and correlated with clinical-pathological data. Unsupervised Hierarchical Cluster Analysis revealed that CH profiles segregate in two main groups (bootstrapping 90-100%), which correlate with breast laterality (p = 0.05). For validating these observations, gene expression data was obtained by RealTime-PCR in a different cohort of 25 tumors and converted into CH profiles. This analyses confirmed the same clustering and a tendency of association with breast laterality (p = 0.15). In silico analyses on gene expression data from TCGA Breast dataset from left and right breast tumors showed that they differed significantly when data was previously converted into CH profiles (p = 0.033). We show here for the first time, that breast carcinomas arising on different sides of the body present differential cancer traits inferred from methylation and expression profiles. Our results indicate that by converting methylation or expression profiles in terms of Cancer Hallmarks, it would allow to uncover veiled associations with clinical features. These results contribute with a new finding to the better understanding of breast tumor behavior, and can moreover serve as proof of principle for other bilateral cancers like lung, testes or kidney.
C1 [Campoy, Emanuel M.; Laurito, Sergio R.; Branham, Maria T.; Urrutia, Guillermo; Mayorga, Luis S.; Roque, Maria] IHEM CONICET, Mendoza, Argentina.
   [Campoy, Emanuel M.; Gago, Francisco; Orozco, Javier; Mayorga, Luis S.] Natl Univ Cuyo, Fac Med Sci, Mendoza, Argentina.
   [Laurito, Sergio R.; Roque, Maria] Natl Univ Cuyo, Fac Exact Sci, Mendoza, Argentina.
   [Mathison, Angela; Urrutia, Raul] Mayo Clin, Epigenet & Chromatin Dynam Lab, Div Gastroenterol & Hepatol, GI Res Unit,Epigen Translat Program,Ctr Individua, Rochester, MN USA.
   [Gago, Francisco; Orozco, Javier] Gineco Mamario Inst, Mendoza, Argentina.
   [Gago, Francisco; Orozco, Javier] Italian Hosp Mendoza, Mendoza, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza; Mayo
   Clinic
RP Roqué, M (通讯作者)，IHEM CONICET, Mendoza, Argentina.; Roqué, M (通讯作者)，Natl Univ Cuyo, Fac Exact Sci, Mendoza, Argentina.
EM mroque@mendoza-conicet.gob.ar
OI Campoy, Emanuel/0000-0003-0521-6073; Mathison,
   Angela/0000-0002-6763-2710; Mayorga, Luis S/0000-0002-5995-0671; Roque,
   Maria/0000-0002-9564-1032
FU Argentine National Institute of Cancer from Argentina; Scientific and
   Technical Secretary (SECTyP) of the National University of Cuyo,
   Argentina; Argentine National Institute of Cancer (INC); American
   Society of Biochemist and Molecular Biology; National Institute of
   Diabetes and Digestive and Kidney Diseases [R01DK052913] Funding Source:
   NIH RePORTER
FX This work has been in part supported by a Grant from the Argentine
   National Institute of Cancer from Argentina and from the Scientific and
   Technical Secretary (SECTyP) of the National University of Cuyo,
   Argentina (MR received the funding). This work has been in part
   supported by a Grant from the Argentine National Institute of Cancer
   (INC) and from the Scientific and Technical Secretary (SECTyP) of the
   National University of Cuyo, Argentina. EC obtained a fellowship from
   the American Society of Biochemist and Molecular Biology to perform the
   gene expression assays.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Borisenkov MF, 2001, SURVIVAL HUMAN BREAS, V27, P631
   Branham MT, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.17
   Brim H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020216
   Cappello F, 2001, J ANAT, V199, P617, DOI 10.1017/S002187820100841X
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8
   Dammann R, 2001, CANCER RES, V61, P3105
   Dane S, 2008, LYMPHOLOGY, V41, P75
   de Blacam C, 2011, IRISH J MED SCI, V180, P727, DOI 10.1007/s11845-011-0713-5
   Delahunt B, 1994, RENAL CELL CARCINOMA, P300
   Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261
   Fatima N, 2013, ASIAN PAC J CANCER P, V14, P43, DOI 10.7314/APJCP.2013.14.1.43
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Garfinkel L, 1969, APPRAISAL LEFT RIGHT, V1
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HARTVEIT F, 1984, ONCOLOGY-BASEL, V41, P149, DOI 10.1159/000225812
   HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448
   Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Maunakea AK, 2010, CIRC RES, V107, P327, DOI 10.1161/CIRCRESAHA.110.222463
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Onibokun O, 2015, BREAST J, V21, P213, DOI 10.1111/tbj.12385
   Perkins CI, 2004, CANCER CAUSE CONTROL, V15, P637, DOI 10.1023/B:CACO.0000036171.44162.5f
   Robichaux JP, 2015, ONCOGENE, V34, P2003, DOI 10.1038/onc.2014.149
   Roychoudhuri R, 2006, CANCER CAUSE CONTROL, V17, P655, DOI 10.1007/s10552-005-0615-9
   Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
   Sodir NM, 2011, ONCOTARGET, V2, P1307
   STONE JM, 1991, BRIT J CANCER, V64, P132, DOI 10.1038/bjc.1991.256
   Twelves D, 2013, BREAST CANCER RES TR, V139, P341, DOI 10.1007/s10549-013-2544-8
   Veltmaat JM, 2013, J MAMMARY GLAND BIOL, V18, P179, DOI 10.1007/s10911-013-9287-3
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Waterland RA, 2009, EPIGENETICS-US, V4, P523, DOI 10.4161/epi.4.8.10155
   Wilting J, 2011, CURR MED CHEM, V18, P5519, DOI 10.2174/092986711798347252
NR 38
TC 7
Z9 7
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2016
VL 11
IS 7
AR e0157416
DI 10.1371/journal.pone.0157416
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DR3NH
UT WOS:000379809400013
PM 27383829
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ghosh, S
   Taylor, A
   Chin, M
   Huang, HR
   Conery, AR
   Mertz, JA
   Salmeron, A
   Dakle, PJ
   Mele, D
   Cote, A
   Jayaram, H
   Setser, JW
   Poy, F
   Hatzivassiliou, G
   DeAlmeida-Nagata, D
   Sandy, P
   Hatton, C
   Romero, FA
   Chiang, E
   Reimer, T
   Crawford, T
   Pardo, E
   Watson, VG
   Tsui, V
   Cochran, AG
   Zawadzke, L
   Harmange, JC
   Audia, JE
   Bryant, BM
   Cummings, RT
   Magnuson, SR
   Grogan, JL
   Bellon, SF
   Albrecht, BK
   Sims, RJ
   Lora, JM
AF Ghosh, Srimoyee
   Taylor, Alexander
   Chin, Melissa
   Huang, Hon-Ren
   Conery, Andrew R.
   Mertz, Jennifer A.
   Salmeron, Andres
   Dakle, Pranal J.
   Mele, Deanna
   Cote, Alexandre
   Jayaram, Hari
   Setser, Jeremy W.
   Poy, Florence
   Hatzivassiliou, Georgia
   DeAlmeida-Nagata, Denise
   Sandy, Peter
   Hatton, Charlie
   Romero, F. Anthony
   Chiang, Eugene
   Reimer, Thornik
   Crawford, Terry
   Pardo, Eneida
   Watson, Venita G.
   Tsui, Vickie
   Cochran, Andrea G.
   Zawadzke, Laura
   Harmange, Jean-Christophe
   Audia, James E.
   Bryant, Barbara M.
   Cummings, Richard T.
   Magnuson, Steven R.
   Grogan, Jane L.
   Bellon, Steve F.
   Albrecht, Brian K.
   Sims, Robert J., III
   Lora, Jose M.
TI Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CANCER-IMMUNOTHERAPY; IMMUNE-RESPONSES; BREAST-CANCER; P300; CHROMATIN;
   FOXP3; ACETYLTRANSFERASES; LYMPHOCYTES; ACTIVATION; CBP/P300
AB Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control. Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription. Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain: acetylated histone interactions with chemical probes serves as a powerful means for understanding biological processes regulated by these chromatin adaptors. Here we describe the discovery and characterization of potent and selective small molecule inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays. We use these tools to demonstrate a critical role for CREBBP/EP300 bromodomains in regulatory T cell biology. Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, our data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small molecule-based approach for cancer immunotherapy.
C1 [Ghosh, Srimoyee; Taylor, Alexander; Chin, Melissa; Huang, Hon-Ren; Conery, Andrew R.; Mertz, Jennifer A.; Salmeron, Andres; Dakle, Pranal J.; Mele, Deanna; Cote, Alexandre; Jayaram, Hari; Setser, Jeremy W.; Poy, Florence; Sandy, Peter; Hatton, Charlie; Pardo, Eneida; Watson, Venita G.; Zawadzke, Laura; Harmange, Jean-Christophe; Audia, James E.; Bryant, Barbara M.; Cummings, Richard T.; Bellon, Steve F.; Albrecht, Brian K.; Sims, Robert J., III; Lora, Jose M.] Constellat Pharmaceut Inc, 215 First St, Cambridge, MA 02142 USA.
   [Hatzivassiliou, Georgia; DeAlmeida-Nagata, Denise; Romero, F. Anthony; Chiang, Eugene; Reimer, Thornik; Crawford, Terry; Tsui, Vickie; Cochran, Andrea G.; Magnuson, Steven R.; Grogan, Jane L.] Genentech Inc, San Francisco, CA 94080 USA.
   [Chin, Melissa] Editas Med Inc, Cambridge, MA USA.
   [Huang, Hon-Ren] Intellia Therapeut, Cambridge, MA USA.
   [Salmeron, Andres] Potenza Therapeut, Cambridge, MA USA.
   [Dakle, Pranal J.; Mele, Deanna] AstraZeneca, Waltham, MA USA.
   [Sandy, Peter] Evelo Therapeut, Cambridge, MA USA.
   [Zawadzke, Laura] EMD Serono, Billerica, MA USA.
   [Harmange, Jean-Christophe] Third Rock Ventures, Boston, MA USA.
C3 Roche Holding; Genentech; AstraZeneca
RP Sims, RJ; Lora, JM (通讯作者)，Constellat Pharmaceut Inc, 215 First St, Cambridge, MA 02142 USA.
EM robert.sims@constellationpharma.com; jose.lora@constellationpharma.com
RI ; Romero, F. Anthony/S-8530-2018
OI Bryant, Barbara/0000-0003-2707-1186; CONERY, ANDREW/0000-0003-3638-7633;
   Audia, James/0000-0003-2501-8138; Romero, F.
   Anthony/0000-0001-7917-1459; Cochran, Andrea/0000-0001-6469-795X;
   Hatton, Charlie/0000-0001-9903-4291
CR Anderson AC, 2014, CANCER IMMUNOL RES, V2, P393, DOI 10.1158/2326-6066.CIR-14-0039
   Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Cai GF, 2008, NAT IMMUNOL, V9, P176, DOI 10.1038/ni1554
   Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x
   Chen JH, 2011, EPIGENETICS-US, V6, P957, DOI 10.4161/epi.6.8.16065
   Chen JH, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12224
   Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471
   Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282
   Conery AR, 2016, ELIFE, V5, DOI [10.7554/eLife.10483, 10.7554/eLife.19432]
   Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202
   deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216
   Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   Goodman RH, 2000, GENE DEV, V14, P1553
   Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010
   Huang H.-R., 2014, Patent No. [WO2014144303A1, 2014144303]
   Jain N, 2010, P NATL ACAD SCI USA, V107, P1524, DOI 10.1073/pnas.0910341107
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318
   Josling GA, 2012, GENES-BASEL, V3, P320, DOI 10.3390/genes3020320
   Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Liu YJ, 2014, MOL CELL BIOL, V34, P3993, DOI 10.1128/MCB.00919-14
   Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286
   Manning ET, 2001, MOL CELL BIOL, V21, P3876, DOI 10.1128/MCB.21.12.3876-3887.2001
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992
   Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005
   Picaud S., 2015, CANC RES, V75, P5106
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rothbart SB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00489
   Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Savage PA, 2013, TRENDS IMMUNOL, V34, P33, DOI 10.1016/j.it.2012.08.005
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110
   Taylor A. M., 2016, ACS MED CHE IN PRESS
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118
   West NR, 2013, BRIT J CANCER, V108, P155, DOI 10.1038/bjc.2012.524
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
   Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742
NR 46
TC 61
Z9 71
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 17
PY 2016
VL 291
IS 25
BP 13014
EP 13027
DI 10.1074/jbc.M115.708560
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DR2YT
UT WOS:000379770500011
PM 27056325
OA Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Zhang, HK
   Qi, J
   Reyes, JM
   Li, L
   Rao, PK
   Li, FG
   Lin, CY
   Perry, JA
   Lawlor, MA
   Federation, A
   De Raedt, T
   Li, YY
   Liu, Y
   Duarte, MA
   Zhang, YX
   Herter-Sprie, GS
   Kikuchi, E
   Carretero, J
   Perou, CM
   Reibel, JB
   Paulk, J
   Bronson, RT
   Watanabe, H
   Brainson, CF
   Kim, CF
   Hammerman, PS
   Brown, M
   Cichowski, K
   Long, H
   Bradner, JE
   Wong, KK
AF Zhang, Haikuo
   Qi, Jun
   Reyes, Jaime M.
   Li, Lewyn
   Rao, Prakash K.
   Li, Fugen
   Lin, Charles Y.
   Perry, Jennifer A.
   Lawlor, Matthew A.
   Federation, Alexander
   De Raedt, Thomas
   Li, Yvonne Y.
   Liu, Yan
   Duarte, Melissa A.
   Zhang, Yanxi
   Herter-Sprie, Grit S.
   Kikuchi, Eiki
   Carretero, Julian
   Perou, Charles M.
   Reibel, Jacob B.
   Paulk, Joshiawa
   Bronson, Roderick T.
   Watanabe, Hideo
   Brainson, Christine Fillmore
   Kim, Carla F.
   Hammerman, Peter S.
   Brown, Myles
   Cichowski, Karen
   Long, Henry
   Bradner, James E.
   Wong, Kwok-Kin
TI Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in
   Lung Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID GROUP PROTEIN EZH2; ZESTE HOMOLOG 2; SELECTIVE-INHIBITION; HISTONE
   METHYLTRANSFERASE; BREAST-CANCER; EXPRESSION; ENHANCER; MUTATIONS; GENE;
   CELLS
AB As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS - and EGFR - mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression. To target EZH2-dependent cancers, we developed a potent open-source EZH2 inhibitor, JQEZ5, that promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a subset of lung cancer.
   SIGNIFICANCE: EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity. Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer. (C) 2016 AACR.
C1 [Zhang, Haikuo; Qi, Jun; Reyes, Jaime M.; Lin, Charles Y.; Perry, Jennifer A.; Lawlor, Matthew A.; Federation, Alexander; Li, Yvonne Y.; Liu, Yan; Zhang, Yanxi; Herter-Sprie, Grit S.; Kikuchi, Eiki; Reibel, Jacob B.; Paulk, Joshiawa; Watanabe, Hideo; Hammerman, Peter S.; Bradner, James E.; Wong, Kwok-Kin] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
   [Zhang, Haikuo; Qi, Jun; De Raedt, Thomas; Li, Yvonne Y.; Liu, Yan; Zhang, Yanxi; Herter-Sprie, Grit S.; Kikuchi, Eiki; Reibel, Jacob B.; Watanabe, Hideo; Hammerman, Peter S.; Brown, Myles; Cichowski, Karen; Bradner, James E.; Wong, Kwok-Kin] Harvard Med Sch, Dept Med, Boston, MA USA.
   [Li, Lewyn; Rao, Prakash K.; Li, Fugen; Duarte, Melissa A.; Brown, Myles; Long, Henry] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
   [De Raedt, Thomas; Cichowski, Karen] Brigham & Womens Hosp, Dept Med, Genet Div, 75 Francis St, Boston, MA 02115 USA.
   [Carretero, Julian] Univ Valencia, Dept Physiol, Burjassot, Spain.
   [Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Bronson, Roderick T.] Harvard Med Sch, Dept Microbiol & Immunol, Div Immunol, Boston, MA USA.
   [Brainson, Christine Fillmore; Kim, Carla F.] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA.
   [Brainson, Christine Fillmore; Kim, Carla F.] Harvard Stem Cell Inst, Cambridge, MA USA.
   [Brainson, Christine Fillmore; Kim, Carla F.] Harvard Med Sch, Dept Genet, Boston, MA USA.
   [Wong, Kwok-Kin] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Dana-Farber Cancer Institute; Harvard University; Brigham &
   Women's Hospital; University of Valencia; University of North Carolina;
   University of North Carolina Chapel Hill; Harvard University; Harvard
   Medical School; Harvard University; Boston Children's Hospital; Harvard
   University; Harvard University; Harvard Medical School; Harvard
   University; Dana-Farber Cancer Institute
RP Wong, KK (通讯作者)，Harvard Med Sch, Belfer Inst Appl Canc Sci, Dana Farber Canc Inst, Ctr Thorac Oncol, 450 Brookline Ave,LC 4115, Boston, MA 02215 USA.; Bradner, JE (通讯作者)，Harvard Med Sch, Dana Farber Canc Inst, 450 Brookline Ave,LC 2210, Boston, MA 02215 USA.
EM james_bradner@dfci.harvard.edu; kwong1@partners.org
RI Brown, Myles/B-6906-2008; Li, Yvonne/M-2459-2019; Brainson,
   Christine/AAG-4688-2020; Kikuchi, Eiki/M-9688-2014; Carretero,
   Julian/N-5214-2014; Wong, Kwok-Kin/ADH-7803-2022; De Raedt,
   Thomas/AAC-3172-2021; Perou, Charles/H-9934-2014
OI Brainson, Christine/0000-0002-0854-5043; wong, kwok
   kin/0000-0001-6323-235X; Federation, Alexander/0000-0002-7771-1148;
   Perou, Charles/0000-0001-9827-2247; Lawlor, Matthew/0000-0003-0700-5763;
   Paulk, Joshiawa/0000-0002-6134-1840; Reyes, Jaime/0000-0001-7895-2472
FU Deutsche Forschungsgemeinschaft [HE 6897/1-1]; NIH/NCI [1R01CA195740-01,
   P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10,
   5R01CA166480-04]; Gross-Loh Family Fund for Lung Cancer Research at
   Dana-Farber Cancer Institute; Susan Spooner Family Lung Cancer Research
   Fund at Dana-Farber Cancer Institute; Burroughs-Wellcome Fund; William
   Lawrence and Blanche Hughes Foundation; Leukemia and Lymphoma Society
   SCOR grant
FX G.S. Herter-Sprie was supported by the Deutsche Forschungsgemeinschaft
   (HE 6897/1-1). K.-K. Wong and C.M. Perou are supported by NIH/NCI
   1R01CA195740-01. K.-K. Wong is also supported by NIH/NCI P01CA120964,
   5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, and 5R01CA166480-04
   grants and the Gross-Loh Family Fund for Lung Cancer Research and Susan
   Spooner Family Lung Cancer Research Fund at Dana-Farber Cancer
   Institute. J.E. Bradner is supported by the Burroughs-Wellcome Fund, the
   William Lawrence and Blanche Hughes Foundation, and a Leukemia and
   Lymphoma Society SCOR grant.
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Britson JS, 2009, BIOCHEM BIOPH RES CO, V390, P849, DOI 10.1016/j.bbrc.2009.10.061
   Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Chen BF, 2014, EPIGENETICS-US, V9, P669, DOI 10.4161/epi.28324
   Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775
   Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135
   DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Hamidi T, 2015, EPIGENOMICS-UK, V7, P247, DOI [10.2217/epi.14.80, 10.2217/EPI.14.80]
   Herrera-Merchan A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1623
   Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Horiuchi KY, 2013, ASSAY DRUG DEV TECHN, V11, P227, DOI 10.1089/adt.2012.480
   Hwang JS, 2015, TUMOR BIOL, V36, P8819, DOI 10.1007/s13277-015-3629-2
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kalinic M, 2014, J COMPUT AID MOL DES, V28, P1109, DOI 10.1007/s10822-014-9788-1
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Lv YJ, 2012, ONCOL REP, V28, P147, DOI 10.3892/or.2012.1787
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suzuki M, 2014, ONCOL LETT, V8, P1025, DOI 10.3892/ol.2014.2234
   Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535
   Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115
   Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 53
TC 98
Z9 106
U1 0
U2 26
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD SEP
PY 2016
VL 6
IS 9
BP 1006
EP 1021
DI 10.1158/2159-8290.CD-16-0164
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW0TT
UT WOS:000383356400025
PM 27312177
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Morera, L
   Roatsch, M
   Fürst, MCD
   Hoffmann, I
   Senger, J
   Hau, M
   Franz, H
   Schüle, R
   Heinrich, MR
   Jung, M
AF Morera, Ludovica
   Roatsch, Martin
   Fuerst, Michael C. D.
   Hoffmann, Inga
   Senger, Johanna
   Hau, Mirjam
   Franz, Henriette
   Schuele, Roland
   Heinrich, Markus R.
   Jung, Manfred
TI 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as
   Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A
SO CHEMMEDCHEM
LA English
DT Article
DE epigenetics; histone demethylase; inhibitors; medicinal chemistry;
   radical reactions
ID SELECTIVE-INHIBITION; CANCER-THERAPY; BREAST-CANCER; AMINO-ACIDS;
   JMJD2A; DEACETYLASE; METHYLATION; RECEPTOR; POTENT; CELLS
AB Overexpression of the histone lysine demethylase KDM4A, which regulates H3K9 and H3K36 methylation states, has been related to the pathology of several human cancers. We found that a previously reported hydroxamate-based histone deacetylase (HDAC) inhibitor (SW55) was also able to weakly inhibit this demethylase with an IC50 value of 25.4m. Herein we report the synthesis and biochemical evaluations, with two orthogonal invitro assays, of a series of derivatives of this lead structure. With extensive chemical modifications on the lead structure, also by exploiting the versatility of the radical arylation with aryldiazonium salts, we were able to increase the potency of the derivatives against KDM4A to the low-micromolar range and, more importantly, to obtain demethylase selectivity with respect to HDACs. Cell-permeable derivatives clearly showed a demethylase-inhibition-dependent antiproliferative effect against HL-60 human promyelocytic leukemia cells.
C1 [Morera, Ludovica; Roatsch, Martin; Hoffmann, Inga; Senger, Johanna; Hau, Mirjam; Jung, Manfred] Univ Freiburg, Inst Pharmaceut Sci, Albertstr 25, D-79104 Freiburg, Germany.
   [Fuerst, Michael C. D.; Heinrich, Markus R.] Univ Erlangen Nurnberg, Dept Chem & Pharm, Schuhstr 19, D-91052 Erlangen, Germany.
   [Franz, Henriette; Schuele, Roland] Univ Med Ctr Freiburg, Cent Clin Res, Breisacher Str 66, D-79106 Freiburg, Germany.
   [Franz, Henriette] Univ Freiburg, Inst Anat & Cell Biol, Albertstr 17, D-79104 Freiburg, Germany.
C3 University of Freiburg; University of Erlangen Nuremberg; University of
   Freiburg; University of Freiburg
RP Jung, M (通讯作者)，Univ Freiburg, Inst Pharmaceut Sci, Albertstr 25, D-79104 Freiburg, Germany.
EM manfred.jung@pharmazie.uni-freiburg.de
RI Heinrich, Michael/HSC-5705-2023; Schüle, Rebecca/B-5763-2019; Jung,
   Manfred/Q-8029-2016; Roatsch, Martin/I-3676-2012
OI Franz, Henriette/0000-0001-9358-7442; Jung, Manfred/0000-0002-6361-7716;
   Roatsch, Martin/0000-0002-9274-1433; Heinrich,
   Markus/0000-0001-7113-2025
FU Studienstiftung des deutschen Volkes; Collaborative Research Center CRC
   [992]; European Research Council (ERC) [322844]; Deutsche
   Forschungsgemeinschaft [CRC 850, CRC 746, Schu688/12-1, Ju 295/13-1];
   COST action [CM1406]
FX We thank Karin Schmidtkunz (University of Freiburg) for assistance with
   cell culture experiments, and Juliane Mietz and Marina Auth for their
   help with compound synthesis. M. R. and M.C.D.F. are grateful for
   support through doctoral scholarships from the Studienstiftung des
   deutschen Volkes. JMJ demethylase work was funded by the Collaborative
   Research Center CRC 992 MEDEP "Medical Epigenetics" (Project A04 to M.
   J. and Project B01 to R.S.). R.S. was further supported by grants from
   the European Research Council (ERC AdGrant 322844) and the Deutsche
   Forschungsgemeinschaft (CRC 850, CRC 746, and Schu688/12-1). HDAC
   research in the Jung group is funded by the Deutsche
   Forschungsgemeinschaft (Ju 295/13-1). We thank the COST action CM1406
   (Epigenetic Chemical Biology EPICHEMBIO) for support. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR ANDERSON GW, 1960, J AM CHEM SOC, V82, P3359, DOI 10.1021/ja01498a032
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bavetsias V, 2016, J MED CHEM, V59, P1388, DOI 10.1021/acs.jmedchem.5b01635
   Berry WL, 2012, INT J ONCOL, V41, P1701, DOI 10.3892/ijo.2012.1618
   Bowman WR, 2007, CHEM SOC REV, V36, P1803, DOI 10.1039/b605183a
   Burdick DJ, 2003, BIOORG MED CHEM LETT, V13, P1015, DOI 10.1016/S0960-894X(03)00084-2
   Cheng JJ, 2014, BIOORG MED CHEM LETT, V24, P4768, DOI 10.1016/j.bmcl.2014.06.080
   Chu CH, 2014, J MED CHEM, V57, P5975, DOI 10.1021/jm500249n
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273
   Fehler SK, 2012, TETRAHEDRON LETT, V53, P2189, DOI 10.1016/j.tetlet.2012.02.070
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Hackanson B, 2012, LEUKEMIA RES, V36, P1055, DOI 10.1016/j.leukres.2012.02.026
   Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655
   Heltweg B, 2005, METHODS, V36, P332, DOI 10.1016/j.ymeth.2005.03.003
   Hoffmann I, 2012, MOL ONCOL, V6, P683, DOI 10.1016/j.molonc.2012.07.004
   Itoh Y, 2015, ACS MED CHEM LETT, V6, P665, DOI 10.1021/acsmedchemlett.5b00083
   Karytinos A, 2009, J BIOL CHEM, V284, P17775, DOI 10.1074/jbc.M109.003087
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kogure M, 2013, CANCER LETT, V336, P76, DOI 10.1016/j.canlet.2013.04.009
   Kralj A, 2014, CHEMMEDCHEM, V9, P151, DOI 10.1002/cmdc.201300369
   Liu K, 2015, PHARMACOL THERAPEUT, V151, P121, DOI 10.1016/j.pharmthera.2015.04.001
   Liu YX, 2013, GUT, V62, P571, DOI 10.1136/gutjnl-2011-301059
   Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046
   Luo XL, 2011, J AM CHEM SOC, V133, P9451, DOI 10.1021/ja201597b
   McAllister TE, 2016, J MED CHEM, V59, P1308, DOI 10.1021/acs.jmedchem.5b01758
   McGrath J, 2015, PHARMACOL THERAPEUT, V150, P1, DOI 10.1016/j.pharmthera.2015.01.002
   Morera L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0223-4
   NAGAO Y, 1988, CHEM PHARM BULL, V36, P495
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Pratsch G, 2012, TOP CURR CHEM, V320, P33, DOI 10.1007/128_2011_127
   Pratsch G, 2011, ORG BIOMOL CHEM, V9, P3746, DOI 10.1039/c1ob05292f
   Roatsch M, 2016, FUTURE MED CHEM, V8, P1553, DOI 10.4155/fmc.15.188
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s
   Rotili D, 2014, J MED CHEM, V57, P42, DOI 10.1021/jm4012802
   Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976
   Rüger N, 2015, CHEMMEDCHEM, V10, P1875, DOI 10.1002/cmdc.201500335
   Sekirnik R, 2009, CHEM COMMUN, P6376, DOI 10.1039/b916357c
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C
   Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179
   Studer A., 2001, Radicals in Organic Synthesis, V2, P44
   Suzuki T, 2013, J MED CHEM, V56, P7222, DOI 10.1021/jm400624b
   TAKEDA K, 1994, SYNTHESIS-STUTTGART, P1063
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Vaillard S. E., 2012, ENCY RADICALS CHEM, V2
   Vaillard SE, 2009, MODERN ARYLATION METHODS, P475, DOI 10.1002/9783527627325.ch13
   Valenzuela-Fernández A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Van Rechem C, 2015, CANCER DISCOV, V5, P245, DOI 10.1158/2159-8290.CD-14-1159
   Wegener D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8
   Wetzel A., 2008, ANGEW CHEM, V120, P9270
   Wetzel A, 2008, ANGEW CHEM INT EDIT, V47, P9130, DOI 10.1002/anie.200803785
   Wetzel A, 2010, CHEM-EUR J, V16, P2547, DOI 10.1002/chem.200902927
   Wittich S, 2002, J MED CHEM, V45, P3296, DOI 10.1021/jm0208119
   Woon E. C. Y., 2012, ANGEW CHEM, V124, P1663
   Woon ECY, 2012, ANGEW CHEM INT EDIT, V51, P1631, DOI 10.1002/anie.201107833
   Xu WH, 2015, BIOL CHEM, V396, P929, DOI 10.1515/hsz-2014-0284
   Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Zhang X, 2013, BIOORGAN MED CHEM, V21, P6981, DOI 10.1016/j.bmc.2013.09.023
NR 64
TC 17
Z9 17
U1 0
U2 16
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD SEP
PY 2016
VL 11
IS 18
BP 2063
EP 2083
DI 10.1002/cmdc.201600218
PG 21
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DW5NX
UT WOS:000383693800011
PM 27505861
DA 2025-01-12
ER

PT J
AU Yu, SM
   Kim, SJ
AF Yu, Seon-Mi
   Kim, Song Ja
TI 5-Azacytidine regulates matrix metalloproteinase-9 expression, and the
   migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase
   and ERK1/2 pathways
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE 5-azacytidine; matrix metalloproteinase-9; migration; invasion; HT1080
   human fibrosarcoma cells
ID CANCER STEM-CELLS; MATRIX METALLOPROTEINASES; IV COLLAGENASE; TISSUE
   INHIBITORS; EPITHELIAL-CELLS; DNA METHYLATION; GENE-EXPRESSION;
   BREAST-CANCER; MUSCLE-CELLS; TUMOR
AB Abnormal methylation of promoter CpG islands is one of the hallmarks of cancer cells, and is catalyzed by DNA methyltransferases. 5-azacytidine (5-aza C), a methyl-transferase inhibitor, can cause demethylation of promoter regions of diverse genes. Epigenetic processes contribute to the regulation of matrix metalloproteinase (MMP) expression. However, little is known about the mechanisms and effects of 5-aza C on the invasive and migratory capacities of human fibrosarcoma HT1080 cells. In the present study, we found that 5-aza C induces MMP-9 activity, as determined by zymography. HT1080 cell proliferation was determined following 5-aza C administration by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle was examined by flow cytometry. 5-aza C treatment inhibited cell proliferation without affecting cell viability. Furthermore, 5-aza C significantly promoted migration and invasion of HT1080 cells. 5-aza C treatment enhanced phosphorylation of extracellular signal-regulated kinase (ERK) and phosphoinositide (PI)3-kinase/Akt, and their inhibitors blocked MMP-9 activity induction, and cellular invasion and migration. Together, these findings suggest that promoter methylation may be one of the mechanisms modulating MMP-9 levels in HT1080 cells, and that 5-aza C-induced MMP-9 production is associated with the activation of ERK and PI3-kinase/Akt signaling pathways.
C1 [Yu, Seon-Mi; Kim, Song Ja] Kongju Natl Univ, Dept Biol Sci, Coll Nat Sci, Gongju 32588, South Korea.
C3 Kongju National University
RP Kim, SJ (通讯作者)，Kongju Natl Univ, Dept Biol Sci, Daehakro 56, Gongju 32588, South Korea.
EM ksj85@kongju.ac.kr
FU National Research Foundation of Korea (NRF) grants - Korea government
   (MSIP) [2015R1C1A2A01055015, 2014R1A1A3049653]; Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea
   [A120960-1201-0000300]
FX The present was supported by the National Research Foundation of Korea
   (NRF) grants funded by the Korea government (MSIP) (nos.
   2015R1C1A2A01055015 and 2014R1A1A3049653) and the Korean Health
   Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
   (A120960-1201-0000300).
CR Alexander VM, 2010, INT J CLIN EXP MED, V3, P95
   Avgustinova A, 2016, CURR OPIN GENET DEV, V36, P8, DOI 10.1016/j.gde.2016.01.003
   Bernal T, 2013, EXP HEMATOL, V41, P172, DOI 10.1016/j.exphem.2012.10.005
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chia-Lan T, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0119-1
   CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0
   Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082
   Ito M, 2014, BREAST CANCER RES TR, V144, P59, DOI 10.1007/s10549-014-2859-0
   Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04-0929
   Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024-3205(03)00434-X
   Liang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992
   Liu ZJ, 2014, ONCOL REP, V32, P659, DOI 10.3892/or.2014.3244
   Lu Y, 2004, INVEST OPHTH VIS SCI, V45, P2998, DOI 10.1167/iovs.04-0051
   LYONS JG, 1993, J BIOL CHEM, V268, P19143
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Offersen BV, 2007, LUNG CANCER, V56, P43, DOI 10.1016/j.lungcan.2006.11.018
   Qiu XN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012994
   Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066
   Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.0.CO;2-4
   Rodriguez J, 2006, CANCER RES, V66, P8462, DOI 10.1158/0008-5472.CAN-06-0293
   Saika S, 2004, INVEST OPHTH VIS SCI, V45, P100, DOI 10.1167/iovs.03-0700
   SATO H, 1993, ONCOGENE, V8, P395
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   SNYDER RD, 1989, MUTAT RES, V226, P185, DOI 10.1016/0165-7992(89)90018-3
   Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364
   STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252
   Wang D, 2014, ONCOTARGET, V5, P10803, DOI 10.18632/oncotarget.2506
   WATANABE H, 1993, J CELL SCI, V104, P991
   Wu Y, 2006, ONCOL REP, V16, P625
   Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455
   Yu SM, 2015, INT J ONCOL, V47, P1469, DOI 10.3892/ijo.2015.3110
   Yu SM, 2013, EXP CELL RES, V319, P2822, DOI 10.1016/j.yexcr.2013.08.026
   Zhang ZM, 2015, AUTOIMMUN REV, V14, P854, DOI 10.1016/j.autrev.2015.05.008
NR 40
TC 11
Z9 12
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD SEP
PY 2016
VL 49
IS 3
BP 1241
EP 1247
DI 10.3892/ijo.2016.3612
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU8EY
UT WOS:000382447300040
PM 27573026
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhou, J
   Luo, J
   Wu, K
   Yun, EJ
   Kapur, P
   Pong, RC
   Du, Y
   Wang, B
   Authement, C
   Hernandez, E
   Yang, J
   Xiao, G
   Cha, TL
   Wu, HC
   Wu, D
   Margulis, V
   Lotan, Y
   Brugarolas, J
   He, D
   Hsieh, JT
AF Zhou, J.
   Luo, J.
   Wu, K.
   Yun, E-j
   Kapur, P.
   Pong, R-C
   Du, Y.
   Wang, B.
   Authement, C.
   Hernandez, E.
   Yang, J.
   Xiao, G.
   Cha, T-L
   Wu, H-C
   Wu, D.
   Margulis, V.
   Lotan, Y.
   Brugarolas, J.
   He, D.
   Hsieh, J-T
TI Loss of DAB2IP in RCC cells enhances their growth and resistance to
   mTOR-targeted therapies
SO ONCOGENE
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER;
   BREAST-CANCER; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA;
   RENAL-CARCINOMA; DOWN-REGULATION; ACTIVATION; EXPRESSION
AB Targeted therapies using small-molecule inhibitors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develop drug resistance and eventually succumb to disease. Currently, understanding of mechanisms leading to SMIs resistance and any identifiable predictive marker(s) are still lacking. We discovered that DAB2IP, a novel Ras-GTPase-activating protein, was frequently epigenetically silenced in RCC, and DAB2IP loss was correlated with the overall survival of RCC patients. Loss of DAB2IP in RCC cells enhances their sensitivities to growth factor stimulation and resistances to SMI (such as mammalian target of rapamycin (mTOR) inhibitors). Mechanistically, loss of DAB2IP results in the activation of extracellular signal-regulated kinase/RSK1 and phosphoinositide-3 kinase/mTOR pathway, which synergizes the induction of hypoxia-inducible factor (HIF)-2 alpha expression. Consequently, elevated HIF-2 alpha suppresses p21/WAF1 expression that is associated with resistance to mTOR inhibitors. Thus combinatorial targeting both pathways resulted in a synergistic tumor inhibition. DAB2IP appears to be a new prognostic/predictive marker for mRCC patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.
C1 [Zhou, J.; Wu, K.; Du, Y.; Wang, B.; Wu, D.; He, D.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China.
   [Zhou, J.; Yun, E-j; Pong, R-C; Authement, C.; Hernandez, E.; Margulis, V.; Lotan, Y.; Hsieh, J-T] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA.
   [Luo, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Guangdong, Peoples R China.
   [Kapur, P.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA.
   [Yang, J.; Xiao, G.] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
   [Cha, T-L] Triserv Gen Hosp, Div Urol, Dept Surg, Natl Def Med Ctr, Taipei, Taiwan.
   [Wu, H-C] China Med Univ Hosp, Dept Urol, Taichung, Taiwan.
   [Brugarolas, J.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
C3 Xi'an Jiaotong University; University of Texas System; University of
   Texas Southwestern Medical Center Dallas; Sun Yat Sen University;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; National Defense Medical Center;
   Tri-Service General Hospital; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP He, D (通讯作者)，Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China.; Hsieh, JT (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA.
EM hedl@mail.xjtu.edu.cn; jt.hsieh@utsouthwestern.edu
RI Lotan, Yair/ABD-9149-2022
OI Zhou, Jiancheng/0000-0001-8533-0903
FU National Natural Science Foundation of China [NSFC 81202014];
   Fundamental Research Funds for the Central Universities in China;
   Endowment for Research in Urologic Oncology
FX We thank John Santoyo for editorial assistance. This work was supported
   in part by Jean H and John T Walter, Jr, Endowment for Research in
   Urologic Oncology (to J-TH), the National Natural Science Foundation of
   China (NSFC 81202014 to KW) and the Fundamental Research Funds for the
   Central Universities in China (to KW).
CR Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105
   [Anonymous], 2013, NATURE
   Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185
   Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200
   Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Das F, 2010, FEBS LETT, V584, P4268, DOI 10.1016/j.febslet.2010.09.010
   Di Lorenzo G, 2009, EUR UROL, V56, P959, DOI 10.1016/j.eururo.2009.09.002
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965
   Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09
   Kroeger N, 2014, EUR UROL, V65, P1086, DOI 10.1016/j.eururo.2013.07.031
   Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302
   Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108
   Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629
   Omeir RL, 2011, COMPARATIVE MED, V61, P243
   Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319
   Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323
   Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012
   Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2
   Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200
   RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6
   Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699
   Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626
   Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343
   Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166
   Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143
   Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399
   Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
   Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200
   Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954
   Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200
   Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x
NR 50
TC 29
Z9 31
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD SEP 1
PY 2016
VL 35
IS 35
BP 4663
EP 4674
DI 10.1038/onc.2016.4
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DU6PE
UT WOS:000382336300012
PM 26876207
DA 2025-01-12
ER

PT J
AU Choi, HJ
   Jang, S
   Ryu, JE
   Lee, HJ
   Lee, HB
   Ahn, WS
   Kim, HJ
   Lee, HJ
   Lee, HJ
   Gong, GY
   Son, WC
AF Choi, Hyun-Ji
   Jang, Sungwoong
   Ryu, Jae-Eun
   Lee, Hyo-Ju
   Lee, Han-Byul
   Ahn, Woo-Sung
   Kim, Hye-Jin
   Lee, Hyo-Jin
   Lee, Hee Jin
   Gong, Gyung-Yub
   Son, Woo-Chan
TI Significance of EZH2 expression in canine mammary tumors
SO BMC VETERINARY RESEARCH
LA English
DT Article
DE Dog; Canine mammary tumor; EZH2; Comparative oncology
ID BREAST-CANCER; ANIMAL-MODEL; PROLIFERATION; TRANSLATION; CARCINOMA;
   TAMOXIFEN; PROSTATE; ENHANCER; PROMOTES; MARKER
AB Background: Current studies report that aberrations in epigenetic regulators or chromatin modifications are related to tumor development and maintenance. EZH2 (Enhancer of zeste homolog 2) is one of the catalytic subunits of Polycomb repressive complex 2, a crucial epigenetic regulator. EZH2 has a master regulatory function in such processes as cell proliferation, stem cell differentiation, and early embryogenesis. In humans, EZH2 is linked to oncogenic function in several carcinomas, including breast cancer, and dysregulation of EZH2 has been particularly associated with loss of differentiation and the development of poorly differentiated breast cancer. In our present study, we were interested in determining whether EZH2 is increased in canine mammary tumors, which show similarities to human breast cancer.
   Results: Investigation of the expression of EZH2 in canine mammary tumors revealed that EZH2 protein was overexpressed in canine mammary carcinomas, as in human breast cancer. In addition, the immunohistochemical expression level of EZH2 was associated with the degree of malignancy in canine mammary carcinoma. This is the first report to describe EZH2 expression in canine mammary tumors.
   Conclusions: Because the expression of EZH2 was similar in canine mammary carcinoma and human breast cancer, spontaneous canine mammary tumors may be a suitable model for studying EZH2 and treatment development.
C1 [Choi, Hyun-Ji; Jang, Sungwoong; Ryu, Jae-Eun; Lee, Hyo-Ju; Lee, Han-Byul; Ahn, Woo-Sung; Son, Woo-Chan] Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.
   [Choi, Hyun-Ji; Jang, Sungwoong; Ryu, Jae-Eun; Lee, Hyo-Ju; Lee, Han-Byul; Kim, Hye-Jin; Lee, Hyo-Jin; Lee, Hee Jin; Gong, Gyung-Yub; Son, Woo-Chan] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olympic Ro 43-gil, Seoul 138736, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center
RP Son, WC (通讯作者)，Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.; Son, WC (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olympic Ro 43-gil, Seoul 138736, South Korea.
EM wcson@amc.seoul.kr
RI lee, hyoju/M-1792-2017
OI , an-useong/0000-0002-5074-9381
FU Korean Health Technology Research and Development Project, Ministry of
   Health and Welfare, Republic of Korea [HI10C2014, HI06C0868]
FX This study was supported by grants from the Korean Health Technology
   Research and Development Project, Ministry of Health and Welfare,
   Republic of Korea (grant numbers: HI10C2014 and HI06C0868).
CR [Anonymous], 2020, TUMORS DOMESTIC ANIM
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Borge KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126371
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Cook N, 2012, DRUG DISCOV TODAY, V17, P253, DOI 10.1016/j.drudis.2012.02.003
   Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kung AL, 2007, ADV CANCER RES, V96, P191, DOI 10.1016/S0065-230X(06)96007-2
   Kuntz K, 2014, EUR J CANCER, V50, P92, DOI 10.1016/S0959-8049(14)70403-4
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Li LY, 2014, BIOMEDICINE-TAIWAN, V4, DOI 10.7603/s40681-014-0001-6
   MACEWEN EG, 1990, CANCER METAST REV, V9, P125, DOI 10.1007/BF00046339
   Moe L, 2001, J REP FER S, P439
   Moore H. E., 2013, THESIS
   Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273
   Pinho SS, 2012, TRANSL RES, V159, P165, DOI 10.1016/j.trsl.2011.11.005
   Queiroga FL, 2011, IN VIVO, V25, P455
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Ranieri G, 2013, CRIT REV ONCOL HEMAT, V88, P187, DOI 10.1016/j.critrevonc.2013.03.005
   Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Roh S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-299
   Salas Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127381
   STRANDBERG JD, 1974, AM J PATHOL, V75, P225
   Sun F, 2009, MOL CANCER THER, V8, P3191, DOI 10.1158/1535-7163.MCT-09-0479
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vinothini G, 2009, ONCOL RES, V18, P193, DOI 10.3727/096504009X12596189659042
   Volkel P, 2015, AM J TRANSL RES, V7, P175
   Wang H, 2012, UROL ONCOL-SEMIN ORI, V30, P428, DOI 10.1016/j.urolonc.2010.09.005
   Xiao YT, 2011, INT J BIOCHEM CELL B, V43, P474, DOI 10.1016/j.biocel.2011.01.005
   Xu BW, 2015, EXP HEMATOL, V43, P698, DOI 10.1016/j.exphem.2015.05.001
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Zhang JX, 2015, CANCER LETT, V356, P929, DOI 10.1016/j.canlet.2014.11.003
NR 36
TC 7
Z9 7
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746-6148
J9 BMC VET RES
JI BMC Vet. Res.
PD AUG 9
PY 2016
VL 12
AR 164
DI 10.1186/s12917-016-0789-2
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA DT3DE
UT WOS:000381359900001
PM 27502594
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhao, X
   Liu, XL
   Wang, GJ
   Wen, X
   Zhang, XY
   Hoffman, AR
   Li, W
   Hu, JF
   Cui, JW
AF Zhao, Xin
   Liu, Xiaoliang
   Wang, Guanjun
   Wen, Xue
   Zhang, Xiaoying
   Hoffman, Andrew R.
   Li, Wei
   Hu, Ji-Fan
   Cui, Jiuwei
TI Loss of insulin-like growth factor II imprinting is a hallmark
   associated with enhanced chemo/radiotherapy resistance in cancer stem
   cells
SO ONCOTARGET
LA English
DT Article
DE cancer stem cells; epigenetics; genomic imprinting; IGF2;
   intrachromosomal looping
ID LONG NONCODING RNA; COLORECTAL-CANCER; IGF2; GENE; PROMOTER; SURVIVAL;
   RECEPTOR; TUMORS; MODEL; IDENTIFICATION
AB Insulin-like growth factor II (IGF2) is maternally imprinted in most tissues, but the epigenetic regulation of the gene in cancer stem cells (CSCs) has not been defined. To study the epigenetic mechanisms underlying self-renewal, we isolated CSCs and non-CSCs from colon cancer (HT29, HRT18, HCT116), hepatoma (Hep3B), breast cancer (MCF7) and prostate cancer (ASPC) cell lines. In HT29 and HRT18 cells that show loss of IGF2 imprinting (LOI), IGF2 was biallelically expressed in the isolated CSCs. Surprisingly, we also found loss of IGF2 imprinting in CSCs derived from cell lines HCT116 and ASPC that overall demonstrate maintenance of IGF2 imprinting. Using chromatin conformation capture (3C), we found that intrachromosomal looping between the IGF2 promoters and the imprinting control region (ICR) was abrogated in CSCs, in parallel with loss of IGF2 imprinting in these CSCs. Loss of imprinting led to increased IGF2 expression in CSCs, which have a higher rate of colony formation and greater resistance to chemotherapy and radiotherapy in vitro. These studies demonstrate that IGF2 LOI is a common feature in CSCs, even when the stem cells are derived from a cell line in which the general population of cells maintain IGF2 imprinting. This finding suggests that aberrant IGF2 imprinting may be an intrinsic epigenetic control mechanism that enhances stemness, self-renewal and chemo/radiotherapy resistance in cancer stem cells.
C1 [Zhao, Xin; Liu, Xiaoliang; Wang, Guanjun; Wen, Xue; Zhang, Xiaoying; Li, Wei; Hu, Ji-Fan; Cui, Jiuwei] Jilin Univ, Hosp 1, Ctr Canc, Changchun 130021, Jilin, Peoples R China.
   [Hoffman, Andrew R.; Hu, Ji-Fan] Stanford Univ, Sch Med, Palo Alto Vet Inst Res, Palo Alto, CA 94304 USA.
C3 Jilin University; Stanford University
RP Li, W; Hu, JF; Cui, JW (通讯作者)，Jilin Univ, Hosp 1, Ctr Canc, Changchun 130021, Jilin, Peoples R China.; Hu, JF (通讯作者)，Stanford Univ, Sch Med, Palo Alto Vet Inst Res, Palo Alto, CA 94304 USA.
EM jdyylw@163.com; jifan@stanford.edu; cuijiuwei@vip.qq.com
RI 张, 晓颖/ABD-9142-2021; Hu, Jifan/Q-3003-2019
OI HU, Jifan/0000-0002-2174-0361; Hoffman, Andrew/0000-0002-0145-1917
FU California Institute of Regenerative Medicine (CIRM) [RT2-01942]; Jilin
   International Collaboration Grant [20120720]; National Natural Science
   Foundation of China [81272294, 31430021, 81071920, 81372835]; Jilin
   Science and Technique Program grant [11GG003]; Development and Reform
   Commission Fund of Jilin Province [2014N147]; Provincial Science Fund of
   Jilin Provincial Department of Science and Technology [20140414014GH,
   20150101176]; Norman Bethune Program of Jilin University [2012202];
   Natural Science Foundation for Young Scientists of Jilin Province, China
   [20140520035JH]; "13th Five-Year" science and technology research of the
   Education Department of Jilin Province, China [2016-483]; Health and
   Family Planning Commission for Young Scientists of Jilin Province, China
   [2015Q008]; VA Merit-Review grant
FX This work was supported by California Institute of Regenerative Medicine
   (CIRM) grant (RT2-01942), Jilin International Collaboration Grant
   (20120720), the National Natural Science Foundation of China grant
   (81272294, 31430021) to J.F.H.; the National Natural Science Foundation
   of China grant (81071920, 81372835) and Jilin Science and Technique
   Program grant (11GG003), Development and Reform Commission Fund of Jilin
   Province (2014N147), Provincial Science Fund of Jilin Provincial
   Department of Science and Technology (20140414014GH, 20150101176), and
   Norman Bethune Program of Jilin University (2012202). to J.C., Natural
   Science Foundation for Young Scientists of Jilin Province, China
   (20140520035JH) to L.X.L.; "13th Five-Year" science and technology
   research of the Education Department of Jilin Province, China (2016-483)
   to Z.X.; Health and Family Planning Commission for Young Scientists of
   Jilin Province, China (2015Q008) to L.X.L.; and the VA Merit-Review
   grant to A.R.H.
CR Bao Bin, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1425s61
   Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320
   Bodzin AS, 2012, J CELL PHYSIOL, V227, P2947, DOI 10.1002/jcp.23041
   Chapuis N, 2010, HAEMATOL-HEMATOL J, V95, P415, DOI 10.3324/haematol.2009.010785
   Chen HL, 2006, EMBO J, V25, P5329, DOI 10.1038/sj.emboj.7601399
   Church DN, 2012, ONCOGENE, V31, P3635, DOI 10.1038/onc.2011.526
   Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7
   Fan XL, 2011, INT J COLORECTAL DIS, V26, P1279, DOI 10.1007/s00384-011-1248-y
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Heidegger I, 2011, CANCER BIOL THER, V11, P701, DOI 10.4161/cbt.11.8.14689
   Hofmann WK, 2002, EXP HEMATOL, V30, P318, DOI 10.1016/S0301-472X(01)00797-4
   Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79
   Lai CY, 2012, CANCER RES, V72, P5111, DOI 10.1158/0008-5472.CAN-12-0624
   Leick MB, 2012, AM J STEM CELLS, V1, P59
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li S, 2014, INT J ONCOL, V44, P1806, DOI 10.3892/ijo.2014.2362
   Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08
   Li T, 2014, HUM MOL GENET, V23, P117, DOI 10.1093/hmg/ddt405
   Liao WT, 2014, AM J STEM CELLS, V3, P46
   Nie ZL, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-86
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94
   Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328
   Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490
   Puglisi MA, 2009, EUR REV MED PHARMACO, V13, P55
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Schneider M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-96
   Schulenburg A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0113-9
   Seccareccia E, 2012, GROWTH HORM IGF RES, V22, P193, DOI 10.1016/j.ghir.2012.09.003
   Shah MM, 2014, GYNECOL ONCOL, V132, P483, DOI 10.1016/j.ygyno.2013.12.001
   Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104
   Sun JN, 2014, NUCLEIC ACIDS RES, V42, P9588, DOI 10.1093/nar/gku549
   Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Vu TH, 2010, HUM MOL GENET, V19, P901, DOI 10.1093/hmg/ddp558
   Wang H, 2014, INT J CANCER, V135, P2783, DOI 10.1002/ijc.28922
   Wang J, 2014, CELL BIOCHEM BIOPHYS, V69, P389, DOI 10.1007/s12013-014-9844-4
   Wang L, 2014, MOL MED REP, V9, P2117, DOI 10.3892/mmr.2014.2063
   Xu C, 2013, CANCER RES, V73, P3181, DOI 10.1158/0008-5472.CAN-12-4403
   Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   Yao XM, 2003, CLIN CANCER RES, V9, P2719
   Zhang SH, 2014, INT J CANCER, V134, P1583, DOI 10.1002/ijc.28487
   Zou GM, 2010, ANTI-CANCER AGENT ME, V10, P172, DOI 10.2174/187152010790909263
NR 52
TC 24
Z9 26
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 9
PY 2016
VL 7
IS 32
BP 51349
EP 51364
DI 10.18632/oncotarget.9784
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9CC
UT WOS:000385429100047
PM 27275535
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Tang, H
   Wu, YF
   Liu, M
   Qin, YR
   Wang, HY
   Wang, LL
   Li, SM
   Zhu, H
   He, Z
   Luo, JP
   Wang, HY
   Wang, QM
   Luo, SX
AF Tang, Hong
   Wu, Yufeng
   Liu, Ming
   Qin, Yanru
   Wang, Haiying
   Wang, Lili
   Li, Shaomei
   Zhu, Hui
   He, Zheng
   Luo, Junpeng
   Wang, Hongyan
   Wang, Qiming
   Luo, Suxia
TI SEMA3B improves the survival of patients with esophageal squamous cell
   carcinoma by upregulating p53 and p21
SO ONCOLOGY REPORTS
LA English
DT Article
DE esophageal squamous cell carcinoma; SEMA3B; p21; p53; Akt
ID TUMOR-SUPPRESSOR GENE; SEMAPHORIN 3B; CHROMOSOME 3P21.3; BREAST-CANCER;
   PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; SIGNALING PATHWAY;
   ALLELE LOSS; LUNG; EXPRESSION
AB As one of the most common malignancies, esophageal squamous cell carcinoma (ESCC) is ranked as the sixth leading cause of cancer-related death worldwide. In our previous study, by employing cDNA microarray analysis, semaphorin 3B (SEMA3B) was found to be significantly downregulated in ESCC. In the present study, SEMA3B down regulation at the mRNA level was found in 34 of 60 primary ESCCs (56.7%) and in 6 of 9 ESCC cell lines (66.7%) by transcription-polymerase chain reaction (RT-PCR). Moreover, immunohistochemical (IHC) staining of SEMA3B in a tissue microarray further indicated that downregulated expression of SEMA3B protein was found in 125 of 222 (56.3%) ESCC cases and downregulation of SEMA3B protein was significantly correlated with lymph node metastasis (P=0.000), advanced clinicopathological stage (P=0.001) and poor disease-specific survival (P=0.017) of ESCC patients. In addition, functional studies demonstrated that the SEMA3B gene could suppress the tumorigenic ability of ESCC cells and cell motility. Furthermore, it was found that by upregulating p53 and p21 expression and inhibiting Akt (Ser473) phosphorylation, SEMA3B could induce cell cycle arrest at G1/S phase. Taken together, our results suggest that SEMA3B may be an important tumor-suppressor gene in the malignant progression of ESCC, as well as a valuable prognostic marker for ESCC patients.
C1 [Tang, Hong; Wu, Yufeng; Wang, Haiying; Wang, Lili; Li, Shaomei; Zhu, Hui; He, Zheng; Luo, Junpeng; Wang, Hongyan; Wang, Qiming; Luo, Suxia] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China.
   [Qin, Yanru] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Oncol, Zhengzhou 450052, Henan, Peoples R China.
   [Liu, Ming] Univ Hong Kong, Dept Clin Oncol, L10-56, Hong Kong, Hong Kong, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; University of Hong Kong
RP Wang, QM; Luo, SX (通讯作者)，Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China.
EM qimingwang1006@163.com; luosxrm@163.com
RI WANG, JINGYI/GSJ-1241-2022; Wang, Sophia/GQZ-3301-2022; junpeng,
   Luo/G-1462-2010; wang, lili/HDL-7210-2022; Li, Tingting/HKE-0812-2023;
   shi, zhensheng/GXN-3967-2022
OI /0000-0002-9253-9841; Wu, Yufeng/0000-0003-0510-0388
CR BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601
   Chen RP, 2014, ONCOL REP, V31, P1211, DOI 10.3892/or.2014.2972
   Daigo Y, 1999, CANCER RES, V59, P1966
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411
   Nguyen H, 2011, MOL CANCER RES, V9, P1479, DOI 10.1158/1541-7786.MCR-11-0213
   Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041
   Janku F, 2010, NAT REV CLIN ONCOL, V7, P401, DOI 10.1038/nrclinonc.2010.64
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Ji L, 2002, CANCER RES, V62, P2715
   Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701
   Kuroki T, 2003, CANCER RES, V63, P3352
   Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020
   Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/jhc.10706, 10.1002/ijc.10706]
   Loginov VI, 2009, MOL BIOL+, V43, P1014, DOI 10.1134/S0026893309060156
   Loginov VI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123369
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   OGASAWARA S, 1995, CANCER RES, V55, P891
   Oliveira CS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-630
   Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
   Qin Yan-Ru, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P80
   Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155
   Reungwetwattana T, 2012, CLIN LUNG CANCER, V13, P252, DOI 10.1016/j.cllc.2011.09.004
   Rolny C, 2008, J EXP MED, V205, P1155, DOI 10.1084/jem.20072509
   Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760
   Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C
   Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759
   Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Tunuguntla R, 2003, GYNECOL ONCOL, V89, P453, DOI 10.1016/S0090-8258(03)00077-5
   Wang K, 2013, ONCOL REP, V29, P1175, DOI 10.3892/or.2012.2213
   Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823
   Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514
   Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
   Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6
NR 47
TC 18
Z9 20
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2016
VL 36
IS 2
BP 900
EP 908
DI 10.3892/or.2016.4901
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DQ5ME
UT WOS:000379248700036
PM 27349960
OA hybrid
DA 2025-01-12
ER

PT J
AU Park, UH
   Kang, MR
   Kim, EJ
   Kwon, YS
   Hur, W
   Yoon, SK
   Song, BJ
   Park, JH
   Hwang, JT
   Jeong, JC
   Um, SJ
AF Park, U-H
   Kang, M-R
   Kim, E-J
   Kwon, Y-S
   Hur, W.
   Yoon, S. K.
   Song, B-J
   Park, J. H.
   Hwang, J-T
   Jeong, J-C
   Um, S-J
TI ASXL2 promotes proliferation of breast cancer cells by linking ERα to
   histone methylation
SO ONCOGENE
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; H3K27 DEMETHYLASES; HISTOLOGIC
   GRADE; LSD1; TRANSCRIPTION; COACTIVATOR; MECHANISMS; CARCINOGENESIS;
   EPIGENETICS
AB Estrogen receptor alpha (ER alpha) has a pivotal role in breast carcinogenesis by associating with various cellular factors. Selective expression of additional sex comb-like 2 (ASXL2) in ER alpha-positive breast cancer cells prompted us to investigate its role in chromatin modification required for ERa activation and breast carcinogenesis. Here, we observed that ASXL2 interacts with ligand E2-bound ERa and mediates ERa activation. Chromatin immunoprecipitation-sequencing analysis supports a positive role of ASXL2 at ERa target gene promoters. ASXL2 forms a complex with histone methylation modifiers including LSD1, UTX and MLL2, which all are recruited to the E2-responsive genes via ASXL2 and regulate methylations at histone H3 lysine 4, 9 and 27. The preferential binding of the PHD finger of ASXL2 to the dimethylated H3 lysine 4 may account for its requirement for ERa activation. On ASXL2 depletion, the proliferative potential of MCF7 cells and tumor size of xenograft mice decreased. Together with our finding on the higher ASXL2 expression in ERa-positive patients, we propose that ASXL2 could be a novel prognostic marker in breast cancer.
C1 [Park, U-H; Kwon, Y-S; Um, S-J] Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea.
   [Kang, M-R] Korea Res Inst Biosci & Biotechnol, Bioevaluat Ctr, Ochang, Cheongwon, South Korea.
   [Kim, E-J] Dankook Univ, Dept Mol Biol, Gyeonggi Do, South Korea.
   [Hur, W.; Yoon, S. K.] Catholic Univ, Liver Res Ctr, Seoul, South Korea.
   [Hur, W.; Yoon, S. K.] Catholic Univ, Coll Med, WHO Collaborating Ctr Viral Hepatitis, Seoul, South Korea.
   [Song, B-J] Catholic Univ, Coll Med, Seoul St Marys Hosp, Breast Ctr,Dept Surg, Seoul, South Korea.
   [Park, J. H.; Hwang, J-T] Korea Food Res Inst, Songnam, Gyeonggi Do, South Korea.
   [Jeong, J-C] Dongguk Univ, Coll Oriental Med, Dept Biochem Mol Biol & Internal Med, Kyungpook, South Korea.
C3 Sejong University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB); Dankook University; Catholic University of Korea;
   Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital; Korea Food Research Institute (KFRI); Dongguk
   University
RP Um, SJ (通讯作者)，Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea.
EM umsj@sejong.ac.kr
RI Kim, Kyoungmi/AEP-3965-2022
FU National R&D program for Cancer Control [1120210]; Korea Food Research
   Institute; Basic Science Research Program through NRF grant, Republic of
   Korea [2014R1A2A1A11052685]
FX This study was supported in part by a grant of the National R&D program
   for Cancer Control (1120210), a grant from the Korea Food Research
   Institute, and a grant of the Basic Science Research Program through NRF
   grant (2014R1A2A1A11052685), Republic of Korea.
CR Akhavantabasi S, 2010, MAMM GENOME, V21, P388, DOI 10.1007/s00335-010-9268-4
   Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Aravind L, 2012, CELL CYCLE, V11, P119, DOI 10.4161/cc.11.1.18475
   Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014
   Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Farber CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002038
   Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522
   Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X
   Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Katoh M, 2013, BRIT J CANCER, V109, P299, DOI 10.1038/bjc.2013.281
   Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830
   Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Lai HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073983
   Lai HL, 2012, J MOL CELL CARDIOL, V53, P734, DOI 10.1016/j.yjmcc.2012.08.014
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102
   Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Park UH, 2011, J BIOL CHEM, V286, P1354, DOI 10.1074/jbc.M110.177816
   Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c
   Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13
   Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Stratmann A, 2012, MOL CELL ENDOCRINOL, V348, P12, DOI 10.1016/j.mce.2011.09.028
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
NR 52
TC 37
Z9 41
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL 14
PY 2016
VL 35
IS 28
BP 3742
EP 3752
DI 10.1038/onc.2015.443
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DR0UQ
UT WOS:000379622800012
PM 26640146
DA 2025-01-12
ER

PT J
AU Yu, C
   Wang, J
AF Yu, Chong
   Wang, Jin
TI A Physical Mechanism and Global Quantification of Breast Cancer
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; P53; LANDSCAPE; PATHWAY; BRCA1; ROBUSTNESS; CELLS; HER2
AB Initiation and progression of cancer depend on many factors. Those on the genetic level are often considered crucial. To gain insight into the physical mechanisms of breast cancer, we construct a gene regulatory network (GRN) which reflects both genetic and environmental aspects of breast cancer. The construction of the GRN is based on available experimental data. Three basins of attraction, representing the normal, premalignant and cancer states respectively, were found on the phenotypic landscape. The progression of breast cancer can be seen as switching transitions between different state basins. We quantified the stabilities and kinetic paths of the three state basins to uncover the biological process of breast cancer formation. The gene expression levels at each state were obtained, which can be tested directly in experiments. Furthermore, by performing global sensitivity analysis on the landscape topography, six key genes (HER2, MDM2, TP53, BRCA1, ATM, CDK2) and four regulations (HER2aTP53, CDK2aBRCA1, ATM -> MDM2, TP53 -> ATM) were identified as being critical for breast cancer. Interestingly, HER2 and MDM2 are the most popular targets for treating breast cancer. BRCA1 and TP53 are the most important oncogene of breast cancer and tumor suppressor gene, respectively. This further validates the feasibility of our model and the reliability of our prediction results. The regulation ATM -> MDM2 has been extensive studied on DNA damage but not on breast cancer. We notice the importance of ATM -> MDM2 on breast cancer. Previous studies of breast cancer have often focused on individual genes and the anti-cancer drugs are mainly used to target the individual genes. Our results show that the network-based strategy is more effective on treating breast cancer. The landscape approach serves as a new strategy for analyzing breast cancer on both the genetic and epigenetic levels and can help on designing network based medicine for breast cancer.
C1 [Yu, Chong; Wang, Jin] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.
   [Wang, Jin] Jilin Univ, Coll Phys, Changchun 130012, Jilin, Peoples R China.
   [Wang, Jin] SUNY Stony Brook, Dept Chem Phys & Appl Math, Stony Brook, NY 11794 USA.
C3 Chinese Academy of Sciences; Changchun Institute of Applied Chemistry,
   CAS; Jilin University; State University of New York (SUNY) System; Stony
   Brook University
RP Wang, J (通讯作者)，Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.; Wang, J (通讯作者)，Jilin Univ, Coll Phys, Changchun 130012, Jilin, Peoples R China.; Wang, J (通讯作者)，SUNY Stony Brook, Dept Chem Phys & Appl Math, Stony Brook, NY 11794 USA.
EM jin.wang.1@stonybrook.edu
OI Yu, Chong/0000-0003-1289-8578
FU Natural Science Foundation of China (NSFC) [91430217]
FX This work is supported by Natural Science Foundation of China (NSFC
   Grant No. 91430217).
CR Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005
   Amar D, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002955
   [Anonymous], 2010, Introduction to cancer biology, V2nd
   [Anonymous], 2012, MORTALITY STAT
   Ao P, 2008, MED HYPOTHESES, V70, P678, DOI 10.1016/j.mehy.2007.03.043
   Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625
   Brekman A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3130
   Burga LN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2850
   Chen GC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003666
   Chou WW, 2009, J CELL BIOCHEM, V107, P408, DOI 10.1002/jcb.22137
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002
   Deisenroth Chad, 2011, Genes Cancer, V2, P392, DOI 10.1177/1947601911409737
   Flobak A, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004426
   Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2
   Garner E, 2007, CANCER RES, V67, P7631, DOI 10.1158/0008-5472.CAN-07-0334
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Huang S, 2009, SEMIN CELL DEV BIOL, V20, P869, DOI 10.1016/j.semcdb.2009.07.003
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973
   Li CH, 2015, CANCER RES, V75, P2607, DOI 10.1158/0008-5472.CAN-15-0079
   Li CH, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0774
   Li CH, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003165
   Lin WY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068578
   Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26
   Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379
   Molina MA, 2001, CANCER RES, V61, P4744
   Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699
   Papanikolaou V, 2009, INT J ONCOL, V35, P1141, DOI 10.3892/ijo_00000430
   Parikh AP, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003713
   PIERCE GB, 1971, CANCER RES, V31, P127
   Reznik E, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004176
   Sasai M, 2003, P NATL ACAD SCI USA, V100, P2374, DOI 10.1073/pnas.2627987100
   Scata KA, 2007, ADV EXP MED BIOL, V608, P70
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Storey KB, 2004, BIOL REV, V79, P207, DOI 10.1017/S1464793103006195
   Walerych D, 2012, CARCINOGENESIS, V33, P2007, DOI 10.1093/carcin/bgs232
   Wang H, 2001, CLIN CANCER RES, V7, P3613
   Wang J, 2008, P NATL ACAD SCI USA, V105, P12271, DOI 10.1073/pnas.0800579105
   Wang J, 2011, P NATL ACAD SCI USA, V108, P8257, DOI 10.1073/pnas.1017017108
   Wang J, 2010, P NATL ACAD SCI USA, V107, P8195, DOI 10.1073/pnas.0910331107
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527
NR 44
TC 14
Z9 15
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2016
VL 11
IS 7
AR e0157422
DI 10.1371/journal.pone.0157422
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ9CP
UT WOS:000379508300009
PM 27410227
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, YH
   Liss, AL
   Chung, E
   Pierce, LJ
   Kleer, CG
AF Zhang, Yanhong
   Liss, Adam L.
   Chung, Eugene
   Pierce, Lori J.
   Kleer, Celina G.
TI Stromal cells in phyllodes tumors of the breast are enriched for EZH2
   and stem cell marker expression
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE EZH2; ALDH1; Phyllodes tumors; Breast cancer; Stromal cells; Stem cell
ID IMMUNOHISTOCHEMICAL EXPRESSION; CYSTOSARCOMA-PHYLLODES; HISTOLOGIC
   FEATURES; PROTEIN EZH2; POLYCOMB; CANCER; GRADE; RHABDOMYOSARCOMA;
   PROGRESSION; METASTASIS
AB Phyllodes tumors (PTs) of the breast are fibroepithelial neoplasms with stromal hypercellularity, which is the basis for their classification as benign, borderline, and malignant. The histologic diagnosis of PTs is often difficult, and the pathological features may not always predict clinical behavior. The pathobiology of PT remains poorly understood. Enhancer of Zeste 2 (EZH2) epigenetically regulates cell-type identity, cellular differentiation, and breast cancer stem cells. EZH2 exerts oncogenic functions in breast cancer and is associated with metastasis. We hypothesized that in PTs, EZH2 and the stem cell marker ALDH1 may be expressed in stromal cells and may be associated with their degree of differentiation. Forty PTs were histologically characterized at our institution following the World Health Organization criteria. We investigated the expression of EZH2 and ALDH1 by immunohistochemistry and recorded as percentage of positive epithelial and stromal cells. EZH2 was positive when over 10 % of cells exhibited nuclear staining; ALDH1 was positive when over 5 % of cells had cytoplasmic staining. Of the 40 PTs, 24 (60 %) were histologically benign, 8 (20 %) borderline, and 8 (20 %) malignant. Stromal EZH2 was significantly associated with the diagnosis of malignant PT, as it was detected in 1 of 24 (4 %) benign, 3 of 8 (37.5 %) borderline, and 5 of 8 (62.5 %) malignant tumors. Stromal EZH2 was significantly associated with stromal overgrowth (p = 0.01), atypia (p = 0.01), hypercellularity (p = 0.01), and mitoses (p = 0.02), all features of malignant PT. Stromal EZH2 and ALDH1 were significantly associated with grade of PT (p = 0.01 and p < 0.05 respectively). In conclusion, EZH2 and ALDH1 expression in the stroma of PT may mark malignant progression and may be helpful to distinguish histologically benign from borderline and malignant tumors in challenging cases. Our study also suggests that PTs contain mesenchymal stem cells, shedding light into the pathogenesis of these tumors.
C1 [Zhang, Yanhong] Univ Calif Davis, Dept Pathol, Sacramento, CA 95817 USA.
   [Liss, Adam L.; Chung, Eugene; Pierce, Lori J.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
   [Kleer, Celina G.] Univ Michigan, Dept Pathol, Comprehens Canc Ctr 4217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Pierce, Lori J.; Kleer, Celina G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
C3 University of California System; University of California Davis;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Kleer, CG (通讯作者)，Univ Michigan, Dept Pathol, Comprehens Canc Ctr 4217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.; Kleer, CG (通讯作者)，Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
EM kleer@umich.edu
FU NIH [R01 CA107469, CA125577]; National Institutes of Health through the
   University of Michigan's Cancer Center Support Grant [5 P30 CA46592];
   National Cancer Institute [R01CA107469, R01CA125577, P30CA046592]
   Funding Source: NIH RePORTER
FX This work was supported by NIH Grants R01 CA107469 and CA125577, and the
   National Institutes of Health through the University of Michigan's
   Cancer Center Support Grant (5 P30 CA46592).
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   August DA, 2000, SURG ONCOL, V9, P49, DOI 10.1016/S0960-7404(00)00022-0
   Barth RJ, 1999, BREAST CANCER RES TR, V57, P291, DOI 10.1023/A:1006260225618
   Belkacémi Y, 2008, INT J RADIAT ONCOL, V70, P492, DOI 10.1016/j.ijrobp.2007.06.059
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039
   Chen WH, 2005, J SURG ONCOL, V91, P185, DOI 10.1002/jso.20334
   Ciarapica R, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-63
   Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   GRIMES MM, 1992, MODERN PATHOL, V5, P232
   Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008
   Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585
   Karim RZ, 2009, BREAST, V18, P165, DOI 10.1016/j.breast.2009.03.001
   Karim RZ, 2010, HISTOPATHOLOGY, V56, P868, DOI 10.1111/j.1365-2559.2010.03562.x
   Khosravi-Shahi P, 2011, SURG ONCOL, V20, pE143, DOI 10.1016/j.suronc.2011.04.007
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kleer CG, 2001, MODERN PATHOL, V14, P185, DOI 10.1038/modpathol.3880282
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Kwon JE, 2012, TUMOR BIOL, V33, P787, DOI 10.1007/s13277-011-0296-9
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
   Lenhard MS, 2008, EUR J OBSTET GYN R B, V138, P217, DOI 10.1016/j.ejogrb.2007.08.002
   Lin JJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3631
   Mitus J, 2014, BREAST J, V20, P639, DOI 10.1111/tbj.12333
   Noronha Y, 2011, INT J SURG PATHOL, V19, P152, DOI 10.1177/1066896910382009
   Pezner RD, 2008, INT J RADIAT ONCOL, V71, P710, DOI 10.1016/j.ijrobp.2007.10.051
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Rosen P, 1993, ATLAS TUMOR PATHOLOG, V7
   Sawyer EJ, 2002, J PATHOL, V196, P437, DOI 10.1002/path.1067
   Sawyer EJ, 2000, AM J PATHOL, V156, P1093, DOI 10.1016/S0002-9440(10)64977-2
   Tan PH, 2005, MODERN PATHOL, V18, P1527, DOI 10.1038/modpathol.3800488
   Tan PH, 2012, J CLIN PATHOL, V65, P69, DOI 10.1136/jclinpath-2011-200368
   Tan WJ, 2014, HISTOPATHOLOGY, V64, P807, DOI 10.1111/his.12329
   Tse GMK, 2009, BREAST CANCER RES TR, V114, P441, DOI 10.1007/s10549-008-0030-5
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
NR 42
TC 9
Z9 10
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2016
VL 158
IS 1
BP 21
EP 28
DI 10.1007/s10549-016-3853-5
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DQ8XE
UT WOS:000379494200003
PM 27290698
DA 2025-01-12
ER

PT J
AU Zhang, N
   Huang, Y
   Wu, FB
   Zhao, YB
   Li, X
   Shen, PF
   Yang, L
   Luo, Y
   Yang, L
   He, G
AF Zhang, Nan
   Huang, Yan
   Wu, Fengbo
   Zhao, Yinbo
   Li, Xiang
   Shen, Pengfei
   Yang, Lu
   Luo, Yan
   Yang, Li
   He, Gu
TI Codelivery of a miR-124 Mimic and Obatoclax by Cholesterol-Penetratin
   Micelles Simultaneously Induces Apoptosis and Inhibits Autophagic Flux
   in Breast Cancer in Vitro and in Vivo
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE penetratin; miR-124; obatoclax; apoptosis; autophagic flux; breast
   cancer
ID HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; CO-DELIVERY;
   CHOLANGIOCARCINOMA CELLS; EPIGENETIC REGULATION; GX15-070 OBATOCLAX;
   DOWN-REGULATION; PHASE-I; MICRORNA-124; TUMOR
AB Penetratin is a classical cell-penetrating peptide with the potential to assist in the transmembrane delivery of proteins or drugs. However, the synthesis and application of cholesterol-penetratin (Chol-P) conjugates as nonviral delivery systems for microRNAs or drugs have not previously been reported. In this study, the amphiphilic Chol-P was shown to self-assemble into micelles and efficiently deliver miR-124 and obatoclax. The codelivered miR-124-M-Oba had a homogeneous particle size and a positive zeta potential. Treatment with miR-124 mincreased cytotoxicity, and cell proliferation, was promoted by miR-124 inhibitor-loaded micelles in MCF-7 human breast cancer cells. Moreover, the inhibitory effects on cell proliferation, colony formation, and cell migration were increased in the miR-124-M-Oba group compared to the miR-124-M group. miR-124-M-Oba induced higher levels of mitochondrial apoptosis via Bax and caspase-9 activation. In addition, we found that the cationic Chol-P and miR-124-M could potently induce autophagy, and miR-124 was degraded in the corresponding autophagolysosomes. The obatoclax encapsulated in miR-124-M-Oba could inhibit the degradation of miR-124 and p62 in autophagolysosomes, which consequently maintained the concentration of miR-124 in breast cancer cells. Furthermore, miR-124-M-Oba potently inhibited tumor growth in subcutaneous xenograft breast cancer models. In summary, the miR-124-M-Oba prepared in this work showed improved apoptosis induction and autophagic flux inhibitory effects in MCF-7 cells, and miR-124-M-Oba may have potential applications in breast cancer therapy.
C1 [Li, Xiang; He, Gu] Sichuan Univ, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, West China Hosp,Dept Pharm,West China Med Sch, Chengdu 610041, Peoples R China.
   Sichuan Univ, West China Med Sch, Dept Urol, West China Hosp, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, X; He, G (通讯作者)，Sichuan Univ, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, West China Hosp,Dept Pharm,West China Med Sch, Chengdu 610041, Peoples R China.
EM hegu@scu.edu.cn; xiangli.87@scu.edu.cn
RI He, Gu/G-5446-2015
OI Zeng, Hong/0000-0003-0097-1977; He, Gu/0000-0002-1536-8882
FU National Natural Science Foundation of China [81273471]; Fundamental
   Research Funds for the Central Universities; Distinguished Young
   Scholars of Sichuan University [2015SCU04A13]
FX We are grateful for financial support from the National Natural Science
   Foundation of China (81273471), the Fundamental Research Funds for the
   Central Universities, and Distinguished Young Scholars of Sichuan
   University (2015SCU04A13).
CR [Anonymous], CANC BIOL THER
   Babu A, 2014, MOL PHARMACEUT, V11, P2720, DOI 10.1021/mp500259e
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45
   Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208
   Chen CK, 2014, NANOSCALE, V6, P1567, DOI 10.1039/c3nr04804g
   Chen SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128472
   Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294
   Chiappini C, 2015, NAT MATER, V14, P532, DOI [10.1038/nmat4249, 10.1038/NMAT4249]
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   de Greñu BD, 2011, CHEM-EUR J, V17, P14074, DOI 10.1002/chem.201101547
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1
   Feng TB, 2015, TUMOR BIOL, V36, P5987, DOI 10.1007/s13277-015-3275-8
   Gandhi NS, 2014, J CONTROL RELEASE, V194, P238, DOI 10.1016/j.jconrel.2014.09.001
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Han ZB, 2013, CELL PHYSIOL BIOCHEM, V31, P823, DOI 10.1159/000350100
   He ZY, 2014, INT J PHARMACEUT, V469, P168, DOI 10.1016/j.ijpharm.2014.04.056
   He ZY, 2013, J CONTROL RELEASE, V172, P679, DOI 10.1016/j.jconrel.2013.10.015
   He ZY, 2013, J BIOMED NANOTECHNOL, V9, P833, DOI 10.1166/jbn.2013.1587
   Heidari N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.53
   Huang SB, 2009, CLIN CANCER RES, V15, P150, DOI 10.1158/1078-0432.CCR-08-1575
   Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038
   Hwang JJ, 2010, CLIN CANCER RES, V16, P4038, DOI 10.1158/1078-0432.CCR-10-0822
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919
   Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lan SH, 2014, AUTOPHAGY, V10, P1687, DOI 10.4161/auto.29959
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075
   Lee HK, 2013, ONCOTARGET, V4, P346, DOI 10.18632/oncotarget.868
   Lee Y, 2013, BONE, V56, P383, DOI 10.1016/j.bone.2013.07.007
   Li B, 2013, COLLOID POLYM SCI, V291, P1319, DOI 10.1007/s00396-012-2861-1
   Li CG, 2009, J MOL CELL BIOL, V1, P37, DOI 10.1093/jmcb/mjp002
   Li HM, 2015, ADV FUNCT MATER, V25, P7457, DOI 10.1002/adfm.201503115
   Li J, 2015, ONCOTARGET, V6, P26177, DOI 10.18632/oncotarget.4614
   Li LS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-163
   Li WT, 2014, TUMOR BIOL, V35, P10897, DOI 10.1007/s13277-014-2402-2
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Liu JJ, 2015, NANOSCALE, V7, P3614, DOI 10.1039/c5nr00072f
   Liu YY, 2014, NANOSCALE, V6, P4325, DOI 10.1039/c3nr06599e
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309
   McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86
   Mott JL, 2008, MOL CANCER THER, V7, P2339, DOI 10.1158/1535-7163.MCT-08-0285
   Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192
   Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104
   Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006
   Pérez-Galán P, 2008, LEUKEMIA, V22, P1712, DOI 10.1038/leu.2008.175
   Pierson J, 2008, J NEURO-ONCOL, V90, P1, DOI 10.1007/s11060-008-9624-3
   Qian XM, 2014, BIOMATERIALS, V35, P2322, DOI 10.1016/j.biomaterials.2013.11.039
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Roberts R, 2013, AUTOPHAGY, V9, P667, DOI 10.4161/auto.23877
   Schimmer AD, 2008, CLIN CANCER RES, V14, P8295, DOI 10.1158/1078-0432.CCR-08-0999
   Shi SJ, 2014, J CONTROL RELEASE, V194, P228, DOI 10.1016/j.jconrel.2014.09.005
   Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951
   Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100
   Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang DR, 2014, CIRC RES, V114, P67, DOI 10.1161/CIRCRESAHA.114.301633
   Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598
   Wang S, 2014, NANOSCALE, V6, P7635, DOI 10.1039/c4nr00843j
   Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318
   Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8
   Wu XZ, 2014, ANTIMICROB AGENTS CH, V58, P5342, DOI 10.1128/AAC.02823-14
   Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-276
   Yang CL, 2015, MOL PHARMACEUT, V12, P2167, DOI 10.1021/acs.molpharmaceut.5b00155
   Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020
   Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323
   Zeng B, 2012, FEBS LETT, V586, P3271, DOI 10.1016/j.febslet.2012.06.049
   Zhang JK, 2014, MACROMOL CHEM PHYS, V215, P163, DOI 10.1002/macp.201300551
   Zhang Y, 2014, PEPTIDES, V58, P83, DOI 10.1016/j.peptides.2014.06.008
   Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015
   Zhao YB, 2014, INT J MOL SCI, V15, P17565, DOI 10.3390/ijms151017565
   Zou DF, 2014, NEURAL REGEN RES, V9, P1241, DOI 10.4103/1673-5374.135333
NR 85
TC 22
Z9 23
U1 0
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
EI 1543-8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2016
VL 13
IS 7
BP 2466
EP 2483
DI 10.1021/acs.molpharmaceut.6b00211
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DQ8JB
UT WOS:000379455800032
PM 27266580
DA 2025-01-12
ER

PT J
AU Martín-Sánchez, E
   Pernaut-Leza, E
   Mendaza, S
   Cordoba, A
   Vicente-Garcia, F
   Monreal-Santesteban, I
   Vizcaino, JP
   De Cerio, MJD
   Perez-Janices, N
   Blanco-Luquin, I
   Escors, D
   Ulazia-Garmendia, A
   Guerrero-Setas, D
AF Martin-Sanchez, E.
   Pernaut-Leza, E.
   Mendaza, S.
   Cordoba, A.
   Vicente-Garcia, F.
   Monreal-Santesteban, I.
   Perez Vizcaino, J.
   Diaz De Cerio, M. J.
   Perez-Janices, N.
   Blanco-Luquin, I.
   Escors, D.
   Ulazia-Garmendia, A.
   Guerrero-Setas, D.
TI Gene promoter hypermethylation is found in sentinel lymph nodes of
   breast cancer patients, in samples identified as positive by one-step
   nucleic acid amplification of cytokeratin 19 mRNA
SO VIRCHOWS ARCHIV
LA English
DT Article
DE Breast cancer; DNA methylation; EPB41L3; OSNA; RASSF1; RASSF2; SLN;
   TSLC-1; TSP-1
ID TUMOR-SUPPRESSOR GENES; AXILLARY DISSECTION; RASSF2 HYPERMETHYLATION;
   METHYLATION ANALYSIS; MOLECULAR METHOD; DNA METHYLATION; METASTASIS;
   EXPERIENCE; BIOPSY; WOMEN
AB We analysed the promoter methylation status of five genes, involved in adhesion (EPB41L3, TSLC-1), apoptosis (RASSF1, RASSF2) or angiogenesis (TSP-1), in intraoperative sentinel lymph node (SLN) biopsy samples from patients with breast cancer, that had been processed by the one-step nucleic acid amplification (OSNA) technique. SLN resection is performed to estimate the risk of tumour cells in the clinically negative axilla, to avoid unnecessary axillary lymph node dissection. OSNA is currently one of the eligible molecular methods for detecting tumour cells in SLNs. It is based on the quantitative evaluation of cytokeratin 19 mRNA which allows distinguishing between macrometastasis, micrometastasis and isolated tumour cells, on the basis of the quantity of tumour cells present. There have been no prior studies on the question whether or not samples processed by OSNA can be used for further molecular studies, including epigenetic abnormalities which are some of the most important molecular alterations in breast cancer. Genomic DNA was extracted from samples obtained from 50 patients diagnosed with primary breast cancer. The content of tumour cells in SLNs was evaluated by OSNA, and the promoter methylation status of the selected genes was analysed by methylation-specific PCR. All were found to be hypermethylated to a variable degree, and RASSF1 hypermethylation was significantly associated with macrometastasis, micrometastasis and isolated tumour cells (p = 0.002). We show that samples used for OSNA are suitable for molecular studies, including gene promoter methylation. These samples provide a new source of material for the identification of additional biomarkers.
C1 [Martin-Sanchez, E.; Pernaut-Leza, E.; Mendaza, S.; Cordoba, A.; Vicente-Garcia, F.; Monreal-Santesteban, I.; Perez-Janices, N.; Ulazia-Garmendia, A.; Guerrero-Setas, D.] Inst Invest Sanitarias Navarra IdiSNA, Canc Epigenet Grp, Navarrabiomed Biomed Res Ctr, Navarra, Spain.
   [Cordoba, A.; Diaz De Cerio, M. J.; Guerrero-Setas, D.] Complejo Hosp Navarra, Dept Pathol, Navarra Hlth Serv, Navarra, Spain.
   [Vicente-Garcia, F.] Complejo Hosp Navarra, Dept Surg, Navarra Hlth Serv, Navarra, Spain.
   [Perez Vizcaino, J.] Complejo Hosp Navarra, Dept Hematol, Navarra Hlth Serv, Navarra, Spain.
   [Blanco-Luquin, I.; Escors, D.] Inst Invest Sanitarias Navarra IdiSNA, Canc Immunomodulat Grp, Navarrabiomed Biomed Res Ctr, Navarra, Spain.
C3 Navarrabiomed; Servicio Navarro de Salud - Osasunbidea; Servicio Navarro
   de Salud - Osasunbidea; Servicio Navarro de Salud - Osasunbidea;
   Navarrabiomed
RP Guerrero-Setas, D (通讯作者)，Inst Invest Sanitarias Navarra IdiSNA, Canc Epigenet Grp, Navarrabiomed Biomed Res Ctr, Navarra, Spain.; Guerrero-Setas, D (通讯作者)，Complejo Hosp Navarra, Dept Pathol, Navarra Hlth Serv, Navarra, Spain.
EM dguerres@navarra.es
RI Escors, David/C-1549-2008; Martín-Sánchez, Esperanza/M-7578-2015;
   Luquin, Idoia/AAA-9134-2019
OI Martin-Sanchez, Esperanza/0000-0002-8155-9185; Blanco,
   Idoia/0000-0003-2917-586X; Monreal Santesteban,
   inaki/0000-0002-0158-3565
FU Department of Health from the Government of Navarra [70/09]
FX This work was funded by a competitive research grant from the Department
   of Health from the Government of Navarra (70/09).
CR Agostini M, 2012, CANCER BIOMARK, V11, P89, DOI 10.3233/CBM-2012-0263
   Ahmed SS, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201771
   Babar M, 2014, EJSO-EUR J SURG ONC, V40, P282, DOI 10.1016/j.ejso.2013.10.030
   Bakkum-Gamez JN, 2015, GYNECOL ONCOL, V137, P14, DOI 10.1016/j.ygyno.2015.01.552
   Barault L, 2015, ANN ONCOL, V26, P1994, DOI 10.1093/annonc/mdv272
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Bernet L, 2011, HISTOPATHOLOGY, V58, P863, DOI 10.1111/j.1365-2559.2011.03836.x
   Blanco-Luquin I, 2015, PATHOL INT, V65, P476, DOI 10.1111/pin.12332
   Boers A, 2014, BRIT J CANCER, V111, P1095, DOI 10.1038/bjc.2014.392
   Brambilla T, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00037
   Breslin TM, 2000, J CLIN ONCOL, V18, P3480, DOI 10.1200/JCO.2000.18.20.3480
   Cavalli LR, 2003, CANCER GENET CYTOGEN, V146, P33, DOI 10.1016/S0165-4608(03)00123-7
   Chen KM, 2015, JAMA OTOLARYNGOL, V141, P257, DOI 10.1001/jamaoto.2014.3393
   Cserni G, 2012, J CLIN PATHOL, V65, P193, DOI 10.1136/jclinpath-2011-200301
   de Boer M, 2010, JNCI-J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008
   Edge SB., 2010, AJCC Cancer Staging Manual. 7th
   Ellis, 2003, INT AGENCY RES CANC, V5, P13
   Elston C W, 2002, Histopathology, V41, P154
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Guerrero D, 2008, BJU INT, V102, P747, DOI 10.1111/j.1464-410X.2008.07603.x
   Guerrero D, 2011, INT J CANCER, V128, P2853, DOI 10.1002/ijc.25629
   Guerrero-Setas D, 2013, HISTOPATHOLOGY, V63, P659, DOI 10.1111/his.12204
   Guerrero-Setas D, 2013, MODERN PATHOL, V26, P1111, DOI 10.1038/modpathol.2013.32
   Hagrass HA, 2014, MOL BIOL REP, V41, P57, DOI 10.1007/s11033-013-2837-3
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hubers AJ, 2014, LUNG CANCER, V84, P127, DOI 10.1016/j.lungcan.2014.01.019
   Illyes I, 2014, VIRCHOWS ARCH, V465, P15, DOI 10.1007/s00428-014-1579-5
   Inda MDM, 2007, NEUROPATHOLOGY, V27, P341, DOI 10.1111/j.1440-1789.2007.00788.x
   Jara-Lazaro AR, 2014, J CLIN PATHOL, V67, P1032, DOI 10.1136/jclinpath-2014-202361
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Layeeque R, 2004, ANN SURG, V239, P841, DOI 10.1097/01.sla.0000128304.13522.00
   Lee BB, 2009, CLIN CANCER RES, V15, P6185, DOI 10.1158/1078-0432.CCR-09-0111
   Liu CY, 2014, BIOMED REP, V2, P525, DOI 10.3892/br.2014.268
   Majchrzak-Celinska A, 2015, TUMOR BIOL, V36, P3831, DOI 10.1007/s13277-014-3025-3
   Merlo DF, 2012, BREAST CANCER RES TR, V134, P363, DOI 10.1007/s10549-012-2031-7
   Nagasaka T, 2009, JNCI-J NATL CANCER I, V101, P1244, DOI 10.1093/jnci/djp265
   Perez-Janices N, 2015, ONCOTARGET, V6, P23944, DOI 10.18632/oncotarget.4062
   Perez-Janices N, 2015, ONCOTARGET, V6, P368, DOI 10.18632/oncotarget.2745
   Piñero A, 2013, CLIN TRANSL ONCOL, V15, P117, DOI 10.1007/s12094-012-0887-y
   Ram R, 2014, INT J BREAST CANCER, V2014, DOI 10.1155/2014/513780
   Reintgen Douglas, 2000, Breast J, V6, P299, DOI 10.1046/j.1524-4741.2000.20057.x
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Schem C, 2009, VIRCHOWS ARCH, V454, P203, DOI 10.1007/s00428-008-0703-9
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Snook KL, 2011, BRIT J SURG, V98, P527, DOI 10.1002/bjs.7347
   Snowsill T, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI [10.3310/hta18580, 10.3310/hta19020]
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Takahashi Y, 2012, BREAST CANCER-TOKYO, V19, P242, DOI 10.1007/s12282-011-0272-7
   Tsujimoto M, 2007, CLIN CANCER RES, V13, P4807, DOI 10.1158/1078-0432.CCR-06-2512
   Laia BV, 2011, DIAGN MOL PATHOL, V20, P18, DOI 10.1097/PDM.0b013e3181eb9b30
   Veronesi U, 1999, JNCI-J NATL CANCER I, V91, P368, DOI 10.1093/jnci/91.4.368
   Veronesi U, 2001, EUR J CANCER, V37, P454, DOI 10.1016/S0959-8049(00)00410-X
   Vilardell F, 2012, VIRCHOWS ARCH, V460, P569, DOI 10.1007/s00428-012-1241-z
   Watabe K, 2003, HISTOL HISTOPATHOL, V18, P1321, DOI 10.14670/HH-18.1321
   Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108
   Wong J, 2015, J CLIN PATHOL, V68, P536, DOI 10.1136/jclinpath-2014-202799
   Wu YY, 2015, METHODS MOL BIOL, V1238, P425, DOI 10.1007/978-1-4939-1804-1_23
   Wu Y, 2014, ASIAN PAC J CANCER P, V15, P1171, DOI 10.7314/APJCP.2014.15.3.1171
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450
   Youlden DR, 2012, CANCER EPIDEMIOL, V36, P237, DOI 10.1016/j.canep.2012.02.007
NR 69
TC 11
Z9 11
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD JUL
PY 2016
VL 469
IS 1
BP 51
EP 59
DI 10.1007/s00428-016-1941-x
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DQ5SG
UT WOS:000379264700007
PM 27097811
DA 2025-01-12
ER

PT J
AU Gao, W
   Li, JZH
   Chen, SQ
   Chu, CY
   Chan, JYW
   Wong, TS
AF Gao, Wei
   Li, John Zeng-Hong
   Chen, Si-Qi
   Chu, Chiao-Yun
   Chan, Jimmy Yu-Wai
   Wong, Thian-Sze
TI Decreased brain-expressed X-linked 4 (BEX4) expression promotes growth
   of oral squamous cell carcinoma
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Oral cancer; Squamous cell carcinoma; Brain-expressed X-linked family;
   BEX4; Tumor growth; S100A family
ID ACUTE MYELOID-LEUKEMIA; EPIGENETIC REGULATION; MALIGNANT GLIOMA;
   BREAST-CANCER; APOPTOSIS; GENE; INHIBITION; PSORIASIN; FAMILY; CYCLE
AB Background: Brain-expressed X-linked (BEX) 4 is a member of BEX family. The functional role of BEX4 in oral squamous cell carcinoma (OSCC) remains unknown.
   Methods: Expression level of BEX family members (BEX1-5) in OSCC tissues and the paired normal epithelial were examined. Functions of epigenetic changes (DNA methylation and histone modifications) on BEX4 suppression in OSCC were examined by zebularine and trichostatin A (TSA) treatment on OSCC cell lines. Lentivector containing full-length BEX4 was used to generate OSCC cell lines with stable BEX4 expression. Effects of BEX4 expression on OSCC proliferation were monitored with xCELLigence RTCA real-time cell analyzer. BEX4-overexpressing CAL27 was implanted into nude mice to evaluate the effects on tumor growth in vivo. The signaling pathways regulated by BEX4 in OSCC was explored using human whole-transcript expression microarray.
   Results: Among the 5 BEX family members, BEX1 and BEX4 showed significant down-regulation in OSCC (P < 0.001). BEX3, in comparison, was overexpressed in the primary tumor. BEX4 expression in OSCC cell lines was re-activated after zebularine and TSA treatment. High BEX4 expression could suppress proliferation of OSCC in vitro. Subcutaneous tumor volume of BEX4-overexpressing CAL27 was remarkably reduced in nude mice. Microarray experiment showed that S100A family members (S100A7, S100A7A, S100A8, S100A9 & S100A12) might be the downstream targets of BEX4 in OSCC.
   Conclusions: BEX4 functions as tumor suppressor by inhibiting proliferation and growth of oral cancer. Decreased BEX4 contributes to the increased proliferative propensity of OSCC.
C1 [Gao, Wei; Li, John Zeng-Hong; Chen, Si-Qi; Chu, Chiao-Yun; Chan, Jimmy Yu-Wai; Wong, Thian-Sze] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Li, John Zeng-Hong] First Peoples Hosp Foshan, Dept Otolaryngol, Foshan, Guangdong, Peoples R China.
C3 University of Hong Kong
RP Wong, TS (通讯作者)，Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
EM thainsze@gmail.com
RI Wong, Thian/C-4447-2009
OI gao, wei/0000-0002-7426-1874; Wong, Thian Sze/0000-0002-8245-4019
FU Seed Funding for Basic Research, the University of Hong Kong; University
   of Hong Kong
FX The study was support by Seed Funding for Basic Research, the University
   of Hong Kong.
CR Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
   Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0
   Chen HY, 2014, AM J CANCER RES, V4, P89
   Chen LH, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0138-5
   Farshadpour F, 2007, ORAL DIS, V13, P239, DOI 10.1111/j.1601-0825.2006.01274.x
   Fernandez EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117206
   Fischer C, 2007, LEUKEMIA, V21, P374, DOI 10.1038/sj.leu.2404493
   Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453
   Funk S, 2015, INT J CANCER, V136, P2037, DOI 10.1002/ijc.29262
   Hattinger E, 2013, CURR OPIN PHARMACOL, V13, P588, DOI 10.1016/j.coph.2013.04.007
   Hu ZD, 2015, J BIOL CHEM, V290, P25756, DOI 10.1074/jbc.M115.665208
   Jerjes W, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-9
   Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841
   Kesting MR, 2009, ORAL ONCOL, V45, P731, DOI 10.1016/j.oraloncology.2008.11.012
   Khammanivong A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069395
   Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173
   Li JC, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0211-0
   Liu XL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-96
   Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200
   Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394
   Naderi A, 2010, INT J CANCER, V126, P1596, DOI 10.1002/ijc.24866
   Noguchi M, 2002, ORAL SURG ORAL MED O, V93, P682, DOI 10.1067/moe.2002.122341
   Röhrs S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-86
   Saintigny P, 2011, CANCER PREV RES, V4, P218, DOI 10.1158/1940-6207.CAPR-10-0155
   Vilar M, 2006, EMBO J, V25, P1219, DOI 10.1038/sj.emboj.7601017
   Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Xiao Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091782
   Zhang LQ, 2008, BIOCHEM GENET, V46, P293, DOI 10.1007/s10528-008-9148-8
   Zhou G, 2008, ONCOGENE, V27, P3527, DOI 10.1038/sj.onc.1211015
   Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9
   Zhou XP, 2012, BIOCHEM BIOPH RES CO, V427, P574, DOI 10.1016/j.bbrc.2012.09.100
NR 32
TC 16
Z9 17
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD JUN 13
PY 2016
VL 35
AR 92
DI 10.1186/s13046-016-0355-6
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DQ9TE
UT WOS:000379551400001
PM 27297407
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Jia, W
   Du, JZ
   Hu, DN
   Dong, YL
   Cu, XB
   Liang, WH
   Jiang, JF
   Tao, L
   Pan, XL
   Zhang, WJ
   Pang, LJ
   Li, F
AF Jia, Wei
   Du, Jinze
   Hu, Danni
   Dong, Yuling
   Cu, Xiaobin
   Liang, Weihua
   Jiang, Jinfang
   Tao, Lin
   Pan, Xiaolin
   Zhang, Wenjie
   Pang, Lijuan
   Li, Feng
TI Association between hypermethylation of the <i>SFRP1</i> promoter and
   cervical cancer in Han and Uyghur patients from Xinjiang
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE SFRP1; cervical cancer; Uyghur; Han; methylation; HPV
ID CANONICAL WNT PATHWAY; EPIGENETIC INACTIVATION; CELL-PROLIFERATION;
   SIGNALING PATHWAY; BREAST-CANCER; METHYLATION; GENE; ACTIVATION;
   CARCINOMA; TRANSFORMATION
AB Purpose: DNA methylation is an early and frequent molecular change in the progression from precancerous lesions to invasive cancer. Silencing of the secreted frizzled-related protein 1 (SFRP1) gene through hypermethylation may be an important factor in the development of cervical cancer because SFRP1 functions as a negative regulator of Wnt signaling that is commonly activated in human cancers. Methods: The methylation of 23 CpG sites in the SFRP1 promoter was detected by MALDI-TOF mass spectrometry. In addition, polymerase chain reaction (PCR) was performed to detect infections with human papillomavirus 16 (HPV16) and determine the correlation between SFRP1 methylation and HPV infection. Results: Methylation of the SFRP1 CpG 2.3, 4, and 17 sites in cervical cancer samples from Uyghur patients was significantly higher than in samples from cervical intraepithelial neoplasia types 2 and 3 (CIN 2/3) (P = 0.003, 0.006, 0.006, respectively). The mean methylation levels of CpG 1, 7, 9.10, 12.13, 14.15, 18, and 25 were significantly increased in cervical cancer from Han patients compared with the CIN2/3 group (P = 0.003, 0.003, 0.001, 0.001, 0.001, 0.000, 0.001, respectively). HPV16 infection had no significant effect on the methylation of SFRP1 in cervical cancer tissue from Uyghur or Han patients (P > 0.05). Conclusion: Our study demonstrated that hypermethylation of different CpG sites of the SFRP1 gene, occurring during the evolution of CIN 2/3 to cervical cancer, was associated with cervical carcinogenesis in both Uyghur and Han patients, but that there were differences between these groups suggesting ethnic differences in genetic susceptibility to cervical cancer.
C1 [Jia, Wei; Du, Jinze; Hu, Danni; Dong, Yuling; Cu, Xiaobin; Liang, Weihua; Jiang, Jinfang; Tao, Lin; Pan, Xiaolin; Zhang, Wenjie; Pang, Lijuan; Li, Feng] Shihezi Univ Sch Med, Affiliated Hosp Immunol 1, Dept Pathol, Shihezi, Xinjiang, Peoples R China.
   [Jia, Wei; Du, Jinze; Hu, Danni; Dong, Yuling; Cu, Xiaobin; Liang, Weihua; Jiang, Jinfang; Tao, Lin; Pan, Xiaolin; Zhang, Wenjie; Pang, Lijuan; Li, Feng] Shihezi Univ Sch Med, Affiliated Hosp Immunol 1, Key Labs Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China.
   [Jia, Wei; Cu, Xiaobin; Liang, Weihua; Jiang, Jinfang; Tao, Lin; Pan, Xiaolin; Pang, Lijuan; Li, Feng] Shihezi Univ Sch Med, Affiliated Hosp Immunol 1, Dept Pathol, Shihezi, Xinjiang, Peoples R China.
   [Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China.
   [Hu, Danni] First Peoples Hosp Changde City, Dept Pathol, Changde, Hunan, Peoples R China.
C3 Shihezi University; Shihezi University; Shihezi University; Capital
   Medical University
RP Li, F (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China.; Pang, LJ (通讯作者)，Shihezi Univ Sch Med, Dept Pathol, 59 North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.
EM ocean123456@163.com; lifeng7855@126.com
RI Lin, Tao/KRO-9146-2024; Zhang, Wenjie/O-5336-2014
FU Preeminent Youth Foundation of Shihezi University School of Medicine
   [2013ZRKXYQ-YD18]
FX This work was supported by the Preeminent Youth Foundation of Shihezi
   University School of Medicine (No. 2013ZRKXYQ-YD18). The funding
   agencies had no role in the design, execution, or analysis of the data
   from this study, or the decision to submit this paper for publication.
CR Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   BRINTON LA, 1987, JNCI-J NATL CANCER I, V79, P23
   Camilli TC, 2010, BIOCHEM PHARMACOL, V80, P702, DOI 10.1016/j.bcp.2010.03.002
   Chen YC, 2014, INT J PUBLIC ADM DIG, V1, P1, DOI 10.4018/ijpada.2014010101
   Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004
   Cohen Y, 2003, CLIN CANCER RES, V9, P2981
   Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20
   Dehan P, 2009, EXPERT REV MOL DIAGN, V9, P651, DOI [10.1586/erm.09.53, 10.1586/ERM.09.53]
   Esteller M, 2001, CANCER RES, V61, P3225
   Garland SM, 2008, VACCINE, V26, pM89, DOI 10.1016/j.vaccine.2008.06.020
   Guenin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042704
   Hall S, 1996, GYNECOL ONCOL, V62, P353, DOI 10.1006/gyno.1996.0248
   Hellberg D, 2005, ANTICANCER RES, V25, P3041
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jiang GX, 2010, DIGEST DIS SCI, V55, P2838, DOI 10.1007/s10620-009-1099-3
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kuzmin I, 2003, CANCER RES, V63, P1888
   Lichtig H, 2010, VIROLOGY, V396, P47, DOI 10.1016/j.virol.2009.10.011
   Lin YW, 2009, J CANCER RES CLIN, V135, P1665, DOI 10.1007/s00432-009-0613-5
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Murata H, 2004, LAB INVEST, V84, P1050, DOI 10.1038/labinvest.3700118
   Rampias T, 2010, MOL CANCER RES, V8, P433, DOI 10.1158/1541-7786.MCR-09-0345
   Salehi R, 2012, Adv Biomed Res, V1, P87, DOI 10.4103/2277-9175.105169
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Sova P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI 10.1158/1055-9965.EPI-05-0323
   Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Üren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012
   Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Ziegler RG, 2002, J NUTR, V132, p2345S, DOI 10.1093/jn/132.8.2345S
   zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046
NR 45
TC 1
Z9 1
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 6
BP 6597
EP +
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DQ8VD
UT WOS:000379488600101
DA 2025-01-12
ER

PT J
AU Vojta, A
   Samarzija, I
   Bockor, L
   Zoldos, V
AF Vojta, Aleksandar
   Samarzija, Ivana
   Bockor, Luka
   Zoldos, Vlatka
TI Glyco-genes change expression in cancer through aberrant methylation
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE DNA methylation; Gene expression; Cancer; Epigenetics; Protein
   glycosylation
ID CELL-ADHESION; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; PROTEIN
   GLYCOSYLATION; COLORECTAL-CANCER; O-GLYCANS; MEMBRANE-PROTEINS;
   CERVICAL-CANCER; N-GLYCOSYLATION; IN-SITU
AB Background: Most eukaryotic proteins are modified by covalent addition of glycan molecules that considerably influence their function. Aberrant glycosylation is profoundly involved in malignant transformation, tumor progression and metastasis. Some glycan structures are tumor-specific and reflect disturbed glycan biosynthesis pathways.
   Methods: We analyzed DNA methylation and expression of 86 glyco-genes in melanoma, hepatocellular, breast and cervical cancers using data from publicly available databases. We also analyzed methylation datasets without the available matching expression data for glyco-genes in lung cancer, and progression of melanoma into lymph node and brain metastases.
   Results: Ten glyco-genes (GALNT3, GALNT6, GALNT7, GALNT14, MGAT3, MAN1A1, MAN1C1, ST3GAL2, ST6GAL1, ST8S1A3) showing changes in both methylation and expression in the same type of cancer belong to GaINAc transferases, GlcNAc transferases, mannosidases and sialyltransferases, which is in line with changes in glycan structures already reported in the same type of tumors. Some of those genes were additionally identified as potentially valuable for disease prognosis. The MGAT5B gene, so far identified as specifically expressed in brain, emerged as a novel candidate gene that is epigenetically dysregulated in different cancers other than brain cancer. We also report for the first time aberrant expression of the GALNT and MAN genes in cancer by aberrant promoter methylation.
   Conclusions: Aberrant expression of glyco-genes due to aberrant promoter methylation could be a way leading to characteristic glycosylation profiles commonly described in cancer.
   General significance: Methylation status in promoters of candidate glyco-genes might serve as prognostic markers for specific tumors and point to potential novel targets for epigenetic drugs. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Vojta, Aleksandar; Samarzija, Ivana; Bockor, Luka; Zoldos, Vlatka] Univ Zagreb, Fac Sci, Dept Biol, Div Mol Biol, Horvatovac 102a, HR-10000 Zagreb, Croatia.
C3 University of Zagreb
RP Zoldos, V (通讯作者)，Univ Zagreb, Fac Sci, Dept Biol, Div Mol Biol, Horvatovac 102a, HR-10000 Zagreb, Croatia.
EM vzoldos@biol.pmf.hr
RI Bočkor, Luka/IZP-9117-2023; Vojta, Aleksandar/S-2086-2017; Samarzija,
   Ivana/ABI-3186-2022
OI Bockor, Luka/0000-0002-2096-0944
FU European Commission [315997]; Croatian national science foundation
   (HRZZ) project EpiGlycolgG (Epigenetic regulation of IgG glycosylation)
   [3361]
FX This project was supported by the European Commission (FP7) Projects
   RegPot Integra-Life, Grant Agreement no. 315997, and Croatian national
   science foundation (HRZZ) project EpiGlycolgG (Epigenetic regulation of
   IgG glycosylation; Grant Agreement no. 3361).
CR Abbott KL, 2006, EXP CELL RES, V312, P2837, DOI 10.1016/j.yexcr.2006.05.022
   [Anonymous], 2012, TRANSF GLYC ROADM FU
   [Anonymous], MOL CARCINOG
   Antony P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-901
   Anugraham M, 2014, MOL CELL PROTEOMICS, V13, P2213, DOI 10.1074/mcp.M113.037085
   Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8
   Arnold JN, 2011, J PROTEOME RES, V10, P1755, DOI 10.1021/pr101034t
   Bartling B, 2011, CANCER BIOMARK, V10, P145, DOI 10.3233/CBM-2012-0239
   Berois N, 2013, CLIN CHEM, V59, P225, DOI 10.1373/clinchem.2012.192328
   Blomme B, 2009, J HEPATOL, V50, P592, DOI 10.1016/j.jhep.2008.12.010
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Brockhausen I, 2006, EMBO REP, V7, P599, DOI 10.1038/sj.embor.7400705
   Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124
   Chen YC, 2014, INT J CANCER, V135, P117, DOI 10.1002/ijc.28658
   Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208
   de Leoz MLA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002717
   DENNIS J, 1982, NATURE, V300, P274, DOI 10.1038/300274a0
   Drake PM, 2010, CLIN CHEM, V56, P223, DOI 10.1373/clinchem.2009.136333
   Durand G, 2000, CLIN CHEM, V46, P795
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Farkas SA, 2013, EPIGENETICS-US, V8, P1213, DOI 10.4161/epi.26346
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Granovsky M, 2000, NAT MED, V6, P306
   He LZ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1309
   Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364
   Horvat T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054672
   Horvat T, 2012, BBA-GEN SUBJECTS, V1820, P1412, DOI 10.1016/j.bbagen.2011.12.007
   Horvat T, 2011, CLIN EPIGENETICS, V2, P425, DOI 10.1007/s13148-011-0039-1
   Julien S, 2005, BREAST CANCER RES TR, V90, P77, DOI 10.1007/s10549-004-3137-3
   Kagan BL, 2003, CANCER RES, V63, P1696
   Kawamura YI, 2008, GASTROENTEROLOGY, V135, P142, DOI 10.1053/j.gastro.2008.03.031
   Kim YS, 2012, J BIOL CHEM, V287, P32467, DOI 10.1074/jbc.M112.370064
   Knezevic A, 2010, GLYCOBIOLOGY, V20, P959, DOI 10.1093/glycob/cwq051
   Koslowski M, 2009, J BIOL CHEM, V284, P28607, DOI 10.1074/jbc.M109.031120
   Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190
   Kroes RA, 2010, P NATL ACAD SCI USA, V107, P12646, DOI 10.1073/pnas.0909862107
   LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808
   Lauc G, 2014, BBA-GEN SUBJECTS, V1840, P65, DOI 10.1016/j.bbagen.2013.08.017
   Lauc G, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001256
   Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3
   Lee JK, 2012, J BIOL CHEM, V287, P28526, DOI 10.1074/jbc.M112.367565
   Li DQ, 2008, J IMMUNOL, V180, P3158, DOI 10.4049/jimmunol.180.5.3158
   Li X, 2012, GLYCOBIOLOGY, V22, P602, DOI 10.1093/glycob/cwr179
   Liu TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107941
   Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108
   Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417
   Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420
   Maverakis E, 2015, J AUTOIMMUN, V57, P1, DOI 10.1016/j.jaut.2014.12.002
   Mehta A, 2012, CANCER EPIDEM BIOMAR, V21, P925, DOI 10.1158/1055-9965.EPI-11-1183
   Mitoma J, 2007, NAT IMMUNOL, V8, P409, DOI 10.1038/ni1442
   Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18
   Moremen KW, 2012, NAT REV MOL CELL BIO, V13, P448, DOI 10.1038/nrm3383
   Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200
   Ni IBP, 2010, PATHOL RES PRACT, V206, P223, DOI 10.1016/j.prp.2009.11.006
   Ninomiya T, 1996, J HEPATOL, V25, P445, DOI 10.1016/S0168-8278(96)80203-0
   Pangeni RP, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0089-x
   Park CY, 2015, BIOINFORMATICS, V31, P1093, DOI 10.1093/bioinformatics/btu786
   Park JH, 2010, CANCER RES, V70, P2759, DOI 10.1158/0008-5472.CAN-09-3911
   Peng RQ, 2012, J BIOL CHEM, V287, P14301, DOI 10.1074/jbc.M111.337642
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Pinho SS, 2013, BBA-GEN SUBJECTS, V1830, P2690, DOI 10.1016/j.bbagen.2012.10.021
   Pinho SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033191
   Potapenko IO, 2010, MOL ONCOL, V4, P98, DOI 10.1016/j.molonc.2009.12.001
   R Core Team, 2014, R LANG ENV STAT COMP
   Rho JH, 2014, PROTEOMES, V2, DOI 10.3390/proteomes2010001
   Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Saldova R, 2011, EPIGENETICS-US, V6, P1362, DOI 10.4161/epi.6.11.17977
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
   Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577
   Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003
   Sethi MK, 2014, J PROTEOME RES, V13, P277, DOI 10.1021/pr400861m
   Shen J, 2013, EPIGENETICS-US, V8, P34, DOI 10.4161/epi.23062
   Shi JX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4365
   Shimodaira K, 1997, CANCER RES, V57, P5201
   Stone EL, 2009, MOL CELL BIOL, V29, P3770, DOI 10.1128/MCB.00204-09
   Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438
   Suzuki O, 2002, INT J ONCOL, V20, P1005
   Suzuki O, 2015, INT J ONCOL, V46, P973, DOI 10.3892/ijo.2015.2818
   Takamaru H, 2012, CANCER PREV RES, V5, P1203, DOI 10.1158/1940-6207.CAPR-12-0056
   Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200
   Tellez CS, 2007, J INVEST DERMATOL, V127, P387, DOI 10.1038/sj.jid.5700539
   Tsuboi S, 2012, TRENDS MOL MED, V18, P224, DOI 10.1016/j.molmed.2012.02.001
   Tuupanen S, 2014, BRIT J CANCER, V111, P1657, DOI 10.1038/bjc.2014.429
   Vasseur JA, 2012, GLYCOBIOLOGY, V22, P1684, DOI 10.1093/glycob/cws108
   Vojta A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/954060
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Wang P.H., 2005, J CANC MOL, V1, P73
   Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815
   Wang ZQ, 2014, ONCOTARGET, V5, P544, DOI 10.18632/oncotarget.1652
   Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344
   Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033
   Zang Shizhu, 2014, Genomics Proteomics & Bioinformatics, V12, P276, DOI 10.1016/j.gpb.2014.09.004
   Zhou XF, 2011, CLIN INVEST MED, V34, pE155
NR 96
TC 42
Z9 49
U1 0
U2 37
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD AUG
PY 2016
VL 1860
IS 8
SI SI
BP 1776
EP 1785
DI 10.1016/j.bbagen.2016.01.002
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DQ5WB
UT WOS:000379274800019
PM 26794090
DA 2025-01-12
ER

PT J
AU Stottrup, C
   Tsang, T
   Chin, YR
AF Stottrup, Casey
   Tsang, Tiffany
   Chin, Y. Rebecca
TI Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in
   Breast Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; PI3K INHIBITORS; SOLID
   TUMORS; KINASE; RECEPTOR; THERAPY; PATHWAY; CELLS; AMPLIFICATION
AB Acquired resistance to molecular targeted therapy represents a major challenge for the effective treatment of cancer. Hyperactivation of the PI3K/AKT pathway is frequently observed in virtually all human malignancies, and numerous PI3K and AKT inhibitors are currently under clinical evaluation. However, mechanisms of acquired resistance to AKT inhibitors have yet to be described. Here, we use a breast cancer preclinical model to identify resistance mechanisms to a small molecule allosteric AKT inhibitor, MK2206. Using a step-wise and chronic high-dose exposure, breast cancer cell lines harboring oncogenic PI3K resistant to MK2206 were established. Using this model, we reveal that AKT3 expression is markedly upregulated in AKT inhibitor-resistant cells. Induction of AKT3 is regulated epigenetically by the bromodomain and extra terminal domain proteins. Importantly, knockdown of AKT3, but not AKT1 or AKT2, in resistant cells restores sensitivity to MK2206. AKT inhibitor-resistant cells also display an epithelial to mesenchymal transition phenotype as assessed by alterations in the levels of E-Cadherin, N-Cadherin, and vimentin, as well as enhanced invasiveness of tumor spheroids. Notably, the invasive morphology of resistant spheroids is diminished upon AKT3 depletion. We also show that resistance to MK2206 is reversible because upon drug removal resistant cells regain sensitivity to AKT inhibition, accompanied by reexpression of epithelial markers and reduction of AKT3 expression, implying that epigenetic reprogramming contributes to acquisition of resistance. These findings provide a rationale for developing therapeutics targeting AKT3 to circumvent acquired resistance in breast cancer. (C) 2016 AACR.
C1 [Stottrup, Casey; Tsang, Tiffany; Chin, Y. Rebecca] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,E CLS 633A,3 Blackfan Circle, Boston, MA 02115 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School
RP Chin, YR (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,E CLS 633A,3 Blackfan Circle, Boston, MA 02115 USA.
EM rchin1@bidmc.harvard.edu
OI CHIN, Yuet Ming Rebecca/0000-0001-8976-3466; Tsang,
   Tiffany/0000-0002-2324-4978
FU NIH National Cancer Institute [R00CA157945]; V Foundation for Cancer
   Research; Pfizer CTI
FX This study was supported in part by a grant from the NIH National Cancer
   Institute (Y.R. Chin and C. Stottrup; R00CA157945), a grant from the V
   Foundation for Cancer Research (Y.R. Chin), and a sponsored research
   grant from Pfizer CTI (Y.R. Chin and T. Tsang).
CR Arboleda MJ, 2003, CANCER RES, V63, P196
   Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286
   Blake JF, 2012, J MED CHEM, V55, P8110, DOI 10.1021/jm301024w
   Brown Kristin K, 2015, F1000Prime Rep, V7, P13, DOI 10.12703/P7-13
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chin YR, 2014, CANCER DISCOV, V4, P942, DOI 10.1158/2159-8290.CD-13-0873
   Chin YR, 2014, CANCER RES, V74, P964, DOI 10.1158/0008-5472.CAN-13-2175
   Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287
   Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Ercan D, 2012, CANCER DISCOV, V2, P934, DOI 10.1158/2159-8290.CD-12-0103
   Frederick BA, 2007, MOL CANCER THER, V6, P1683, DOI 10.1158/1535-7163.MCT-07-0138
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Grabinski N, 2014, CELL SIGNAL, V26, P1021, DOI 10.1016/j.cellsig.2014.01.018
   Han J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000684
   Heredia NJ, 2013, METHODS, V59, pS20, DOI 10.1016/j.ymeth.2012.09.012
   Hofmann I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044146
   Hudis C, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3577
   Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465
   Huw LY, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.46
   Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108
   KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985
   Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/FON.12.86, 10.2217/fon.12.86]
   Landis J, 2014, J BIOL CHEM, V289, P18603, DOI 10.1074/jbc.M114.564070
   Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072
   Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402
   Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782
   Matà R, 2016, ONCOTARGET, V7, P7683, DOI 10.18632/oncotarget.6524
   Moore DA, 2015, J MOL DIAGN, V17, P616, DOI 10.1016/j.jmoldx.2015.05.001
   Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695
   Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783
   Ringel MD, 2001, CANCER RES, V61, P6105
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Saura C, 2014, CLIN CANCER RES, V20, P1935, DOI 10.1158/1078-0432.CCR-13-1070
   Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626
   Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343
   Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tao JJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005125
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860
   Turner KM, 2015, P NATL ACAD SCI USA, V112, P3421, DOI 10.1073/pnas.1414573112
   Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Yan YB, 2013, CLIN CANCER RES, V19, P6976, DOI 10.1158/1078-0432.CCR-13-0978
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
   Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033
   Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474
NR 53
TC 48
Z9 54
U1 3
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG 1
PY 2016
VL 15
IS 8
BP 1964
EP 1974
DI 10.1158/1535-7163.MCT-15-0748
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DV6MI
UT WOS:000383049800018
PM 27297869
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Bednarek, K
   Kiwerska, K
   Szaumkessel, M
   Bodnar, M
   Kostrzewska-Poczekaj, M
   Marszalek, A
   Janiszewska, J
   Bartochowska, A
   Jackowska, J
   Wierzbicka, M
   Grenman, R
   Szyfter, K
   Giefing, M
   Jarmuz-Szymczak, M
AF Bednarek, K.
   Kiwerska, K.
   Szaumkessel, M.
   Bodnar, M.
   Kostrzewska-Poczekaj, M.
   Marszalek, A.
   Janiszewska, J.
   Bartochowska, A.
   Jackowska, J.
   Wierzbicka, M.
   Grenman, R.
   Szyfter, K.
   Giefing, M.
   Jarmuz-Szymczak, M.
TI Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma
SO TUMOR BIOLOGY
LA English
DT Article
DE CDK1; Overexpression; Gene methylation; microRNA; Western blot;
   Immunohistochemistry
ID GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; KINASE 1 CDK1;
   TRANSCRIPTION FACTOR; TUMOR PROGRESSION; NECK-CANCER; EXPRESSION; CYCLE;
   GENE; HEAD
AB In this study, we analyzed the expression profile of four genes (CCNA2, CCNB1, CCNB2, and CDK1) in laryngeal squamous cell carcinoma (LSCC) cell lines and tumor samples. With the application of microarray platform, we have shown the overexpression of these genes in all analyzed LSCC samples in comparison to non-cancer controls from head and neck region. We have selected CDK1 for further analysis, due to its leading role in cell cycle regulation. It is a member of the Ser/Thr protein kinase family of proven oncogenic properties. The results obtained for CDK1 were further confirmed with the application of reverse transcription quantitative polymerase chain reaction (RT-qPCR) technique, Western blot, and immunohistochemistry (IHC). The observed upregulation of CDK1 in laryngeal squamous cell carcinoma has encouraged us to analyze for genetic mechanisms that can be responsible this phenomenon. Therefore, with the application of array-CGH, sequencing analysis and two methods for epigenetic regulation analysis (DNA methylation and miRNA expression), we tried to identify such potential mechanisms. Our attempts to identify the molecular mechanisms responsible for observed changes failed as we did not observe significant alterations neither in the DNA sequence nor in the gene copy number that could underline CDK1 upregulation. Similarly, the pyrosequencing and miRNA expression analyses did not reveal any differences in methylation level and miRNA expression, respectively; thus, these mechanisms probably do not contribute to elevation of CDK1 expression in LSCC. However, our results suggest that alteration of CDK1 expression on both mRNA and protein level probably appears on the very early step of carcinogenesis.
C1 [Bednarek, K.; Kiwerska, K.; Szaumkessel, M.; Kostrzewska-Poczekaj, M.; Janiszewska, J.; Giefing, M.; Jarmuz-Szymczak, M.] PAS, Inst Human Genet, Dept Canc Genet, Poznan, Poland.
   [Bodnar, M.; Marszalek, A.] Nicolaus Copernicus Univ, Coll Med, Dept Clin Pathomorphol, Bydgoszcz, Poland.
   [Marszalek, A.] Greater Poland Canc Ctr, Dept Oncol Pathol, Poznan, Poland.
   [Bartochowska, A.; Jackowska, J.; Wierzbicka, M.; Giefing, M.] Univ Med Sci, Dept Otolaryngol & Laryngol Oncol, Poznan, Poland.
   [Grenman, R.] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland.
   [Grenman, R.] Turku Univ Hosp, Dept Med Biochem, Turku, Finland.
   [Grenman, R.] Univ Turku, Turku, Finland.
   [Szyfter, K.] Univ Med Sci, Dept Audiol & Phoniatry, Poznan, Poland.
   [Jarmuz-Szymczak, M.] Univ Med Sci, Dept Hematol, Poznan, Poland.
C3 Polish Academy of Sciences; Institute of Human Genetics of the Polish
   Academy of Sciences; Nicolaus Copernicus University; Wielkopolskie
   Centrum Onkologii; University of Turku; University of Turku; University
   of Turku
RP Jarmuz-Szymczak, M (通讯作者)，PAS, Inst Human Genet, Dept Canc Genet, Poznan, Poland.; Jarmuz-Szymczak, M (通讯作者)，Univ Med Sci, Dept Hematol, Poznan, Poland.
EM maljar@man.poznan.pl
RI Giefing, Maciej/D-2568-2009; Bednarek, Kinga/HGF-0045-2022; Bodnar,
   Magdalena/D-6131-2014
OI Giefing, Maciej/0000-0002-4760-8246; Bednarek,
   Kinga/0000-0003-0135-4663; Jarmuz-Szymczak,
   Malgorzata/0000-0003-0437-5806; Kiwerska, Katarzyna/0000-0002-2319-0201;
   Bartochowska, Anna/0000-0001-7862-1411; Bodnar,
   Magdalena/0000-0003-3748-1058; Kostrzewska-Poczekaj,
   Magdalena/0000-0001-8099-3839; Jackowska, Joanna/0000-0002-5189-5823;
   Wierzbicka, Malgorzata/0000-0003-0006-6352; Janiszewska,
   Joanna/0000-0002-1765-0152; Szyfter, Krzysztof/0000-0003-2631-6399
FU National Science Centre [N N403 153140, NN401195839]; European Union
FX This work was funded by the National Science Centre, number N N403
   153140, NN401195839 and Scholarship support for Ph.D. students
   specializing in majors strategic for Wielkopolska's development for year
   2011/2012, Sub-measure 8.2.2 Human Capital Operational Programme,
   co-financed by European Union under the European Social Fund
CR Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725
   Bodnar M, 2015, J ORAL PATHOL MED, V44, P437, DOI 10.1111/jop.12270
   Bodnar M, 2014, ADV MED SCI-POLAND, V59, P206, DOI 10.1016/j.advms.2014.03.005
   Bodnar M, 2013, J ORAL PATHOL MED, V42, P267, DOI 10.1111/jop.12000
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burduk PK, 2015, HEAD NECK-J SCI SPEC, V37, P418, DOI 10.1002/hed.23618
   Chae SW, 2011, YONSEI MED J, V52, P445, DOI 10.3349/ymj.2011.52.3.445
   Chang JT, 2005, INT J CANCER, V114, P942, DOI 10.1002/ijc.20663
   Chen S, 2015, CANCER LETT, V362, P122, DOI 10.1016/j.canlet.2015.03.029
   Chen X, 2015, MED ORAL PATOL ORAL, V20, pE7, DOI 10.4317/medoral.19841
   Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83
   Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109
   Enserink JM, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-11
   Ford HL, 1999, J CELL BIOCHEM, P166
   Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022
   Giefing M, 2008, CANCER GENET CYTOGEN, V184, P38, DOI 10.1016/j.cancergencyto.2008.03.004
   Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840
   Glover A. R., 2015, ONCOTARGET
   Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606
   Jarmuz M, 2005, CANCER GENET CYTOGEN, V160, P82, DOI 10.1016/j.cancergencyto.2004.12.006
   Jarmuz M, 2002, EUR ARCH OTO-RHINO-L, V259, P269, DOI 10.1007/s00405-002-0450-5
   Jarmuz-Szymczak M, 2013, MOL BIOL REP, V40, P4161, DOI 10.1007/s11033-013-2496-4
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kang J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-32
   Karatas OF, 2014, HEAD NECK
   Kostrzewska-Poczekaj M, 2010, CANCER BIOMARK, V8, P11, DOI 10.3233/DMA-2011-0814
   Landry BD, 2014, EMBO J, V33, P1044, DOI 10.1002/embj.201386877
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Lian M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084854
   Linton A, 2014, BRIT J CANCER, V110, P510, DOI 10.1038/bjc.2013.731
   Liu P, 2008, ONCOGENE, V27, P4733, DOI 10.1038/onc.2008.104
   Liu Y, 2014, J CONTROL RELEASE, V192, P114, DOI 10.1016/j.jconrel.2014.07.001
   Malinen M, 2013, MOL CELL ENDOCRINOL, V365, P270, DOI 10.1016/j.mce.2012.10.028
   Maurya SS, 2015, ENVIRON MOL MUTAGEN, V56, P313, DOI 10.1002/em.21920
   MEEKER TC, 1987, ONCOGENE RES, V1, P87
   Nair Jayalakshmi, 2015, Genes Cancer, V6, P328
   NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x
   Pezzuto F, 2015, ONCOLOGY-BASEL, V89, P125, DOI 10.1159/000381717
   REMMELE W, 1987, PATHOLOGE, V8, P138
   RIKIMARU K, 1992, HEAD NECK-J SCI SPEC, V14, P8, DOI 10.1002/hed.2880140103
   Santamaría D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046
   Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170
   Sung WW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-951
   Szaumkessel M, 2011, INT J ONCOL, V39, P505, DOI 10.3892/ijo.2011.1039
   Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552
   Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248
   van Oijen MGCT, 2000, CANCER EPIDEM BIOMAR, V9, P249
   Xi QH, 2015, TUMOR BIOL, V36, P4939, DOI 10.1007/s13277-015-3141-8
   Yang JQ, 2014, INT J CLIN EXP PATHO, V7, P4295
   Zhao J, 2013, ONCOL REP, V30, P253, DOI 10.3892/or.2013.2426
NR 52
TC 32
Z9 34
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2016
VL 37
IS 8
BP 11115
EP 11126
DI 10.1007/s13277-016-4991-4
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DV1HW
UT WOS:000382672900112
PM 26912061
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhao, N
   Li, SW
   Wang, RZ
   Xiao, MH
   Meng, Y
   Zeng, CX
   Fang, JH
   Yang, JE
   Zhuang, SM
AF Zhao, Na
   Li, Siwen
   Wang, Ruizhi
   Xiao, Manhuan
   Meng, Yu
   Zeng, Chunxian
   Fang, Jian-Hong
   Yang, Jine
   Zhuang, Shi-Mei
TI Expression of microRNA-195 is transactivated by Sp1 but inhibited by
   histone deacetylase 3 in hepatocellular carcinoma cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE miR-195; Non-coding RNA; Sp1; HDAC3; Hepatocellular carcinoma
ID BREAST-CANCER; PROLIFERATION; PROGNOSIS; TARGET; RECRUITMENT;
   REPRESSION; REVEALS; MIR-195; ALPHA; HDAC2
AB MiR-195 expression is frequently reduced in various cancers, but its underlying mechanisms remain unknown. To explore whether abnormal transcription contributed to miR-195 downregulation in hepatocellular carcinoma (HCC), we characterized the -2165-bp site upstream of mature miR-195 as transcription start site and the -2.4 to -2.0-kb fragment as the promoter of miR-195 gene. Subsequent investigation showed that deletion of the predicted Sp1 binding site decreased the miR-195 promoter activity; Sp1 silencing significantly reduced the miR-195 promoter activity and the endogenous miR-195 level; Sp1 directly interacted with the miR-195 promoter in vitro and in vivo. These data suggest Sp1 as a transactivator for miR-195 transcription. Interestingly, miR-195 expression was also subjected to epigenetic regulation. Histone deacetylase 3 (HDAC3) could anchor to the miR-195 promoter via interacting with Sp1 and consequently repress the Sp1-mediated miR-195 transactivation by deacetylating histone in HCC cells. Consistently, substantial increase of HDAC3 protein was detected in human HCC tissues and HDAC3 upregulation was significantly correlated with miR-195 downregulation, suggesting that HDAC3 elevation may represent an important cause for miR-195 reduction in HCC. Our findings uncover the mechanisms underlying the transcriptional regulation and expression deregulation of miR-195 in HCC cells and provide new insight into microRNA biogenesis in cancer cells. (C) 2016 Published by Elsevier B.V.
C1 [Zhao, Na; Li, Siwen; Wang, Ruizhi; Xiao, Manhuan; Meng, Yu; Zeng, Chunxian; Fang, Jian-Hong; Yang, Jine; Zhuang, Shi-Mei] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn,Minist Educ, State Key Lab Biocontrol,Innovat Ctr Cell Signali, Guangzhou 510275, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Yang, JE; Zhuang, SM (通讯作者)，Sun Yat Sen Univ, Sch Life Sci, Xin Gang Xi Rd 135, Guangzhou 510275, Guangdong, Peoples R China.
EM zhaonaxiaojie@126.com; lisiwen128@163.com; 08wangrz@gmail.com;
   moira_xiao@foxmail.com; mengyu294689775@Gmail.com; zcx1114@163.com;
   van641@163.com; lssyje@mail.sysu.edu.cn; zhuangshimei@163.com
RI Fang, Jian-hong/HCH-6747-2022; Li, Siwen/HOH-0658-2023; 睿智,
   王/JCO-1988-2023
OI Fang, Jianhong/0000-0002-7723-5348; Zhao, Na/0000-0002-8161-3380;
   Zhuang, Shi-Mei/0000-0002-2512-3942; Yang, Jin-E/0000-0002-7511-1042
FU Ministry of Health of China [2012ZX10002011]; National Natural Science
   Foundation of China [91440205, 81402421]; Natural Science Foundation of
   Guangdong Province [2014A030311031]
FX This work was supported by Ministry of Health of China [2012ZX10002011];
   National Natural Science Foundation of China [91440205, 81402421]; and
   Natural Science Foundation of Guangdong Province (2014A030311031).
CR Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627
   Buurman R, 2012, GASTROENTEROLOGY, V143, P811, DOI 10.1053/j.gastro.2012.05.033
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Cho JH, 2015, J BIOL CHEM, V290, P10555, DOI 10.1074/jbc.M114.624361
   Deng HX, 2013, GENE, V518, P351, DOI 10.1016/j.gene.2012.12.103
   Ding J, 2013, HEPATOLOGY, V58, P654, DOI 10.1002/hep.26378
   Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Fu MG, 2013, FEBS LETT, V587, P3471, DOI 10.1016/j.febslet.2013.08.036
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hsieh TH, 2015, MOL THER, V23, P656, DOI 10.1038/mt.2014.247
   JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370
   Jia DS, 2011, HEPATOLOGY, V54, P1227, DOI 10.1002/hep.24495
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Liu M, 2014, PROTEIN CELL, V5, P673, DOI 10.1007/s13238-014-0065-9
   Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Mladenova V, 2009, BIOTECHNOL BIOTEC EQ, V23, P1044, DOI 10.1080/13102818.2009.10817609
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Suzuki A, 2010, J BIOL CHEM, V285, P13444, DOI 10.1074/jbc.M109.062430
   Tropberger P, 2013, NAT STRUCT MOL BIOL, V20, P657, DOI 10.1038/nsmb.2581
   Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919
   Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489
   Zhang QQ, 2012, NEURO-ONCOLOGY, V14, P278, DOI 10.1093/neuonc/nor216
   Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
NR 38
TC 30
Z9 34
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 1876-4320
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD JUL
PY 2016
VL 1859
IS 7
BP 933
EP 942
DI 10.1016/j.bbagrm.2016.05.006
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DQ1KI
UT WOS:000378959500011
PM 27179445
DA 2025-01-12
ER

PT J
AU Dagdemir, A
   Judes, G
   Lebert, A
   Echegut, M
   Karsli-Ceppioglu, S
   Rifaï, K
   Daures, M
   Ngollo, M
   Dubois, L
   Penault-Llorca, F
   Bignon, YJ
   Bernard-Gallon, D
AF Dagdemir, Aslihan
   Judes, Gaelle
   Lebert, Andre
   Echegut, Maureen
   Karsli-Ceppioglu, Seher
   Rifai, Khaldoun
   Daures, Marine
   Ngollo, Marjolaine
   Dubois, Lucas
   Penault-Llorca, Frederique
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique
TI Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and
   Mesenchymal-like Breast Cancer Subtype Cells
SO CANCER GENOMICS & PROTEOMICS
LA English
DT Article
DE Breast cancer cell lines; histone methyl transferase inhibitor; histone
   deacetylase inhibitor
ID SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; BRCA2
   PROMOTER; RECEPTOR; ESTROGEN; P300; GENE; TRIMETHYLATION; COACTIVATORS;
   METHYLATION
AB Background/Aim: Numerous studies have shown that breast cancer and epigenetic mechanisms have a very powerful interactive relation. The MCF7 cell line, representative of luminal subtype and the MDA-MB 231 cell line representative of mesenchymal-like subtype were treated respectively with a Histone Methyl Transferase Inhibitors (HMTi), 3-Deazaneplanocin hydrochloride (DZNep), two histone deacetylase inhibitors (HDACi), sodium butyrate (NaBu), and suberoylanilide hydroxamic acid (SAHA) for 48 h. Materials and Methods: Chromatin immunoprecipitation (ChIP) was used to observe HDACis (SAHA and NaBu) and HMTi (DZNep) impact on histones and more specifically on H3K27me3, H3K9ac and H3K4ac marks with Q-PCR analysis of BRCA1, SRC3 and P300 genes. Furthermore, the HDACi and HMTi effects on mRNA and protein expression of BRCA1, SRC3 and P300 genes were checked. In addition, statistical analyses were used. Results: In the MCF7 luminal subtype with positive ER, H3k4ac was significantly increased on BRCA1 with SAHA. On the contrary, in the MDA-MB 231 breast cancer cell line, representative of mesenchymal-like subtype with negative estrogen receptor, HDACis had no effect. Also, DZNEP decreased significantly H3K27me3 on BRCA1 in MDA-MB 231. Besides, on SRC3, a significant increase for H3K4ac was obtained in MCF7 treated with SAHA. And DZNEP had no effect in MCF7. Also, in MDA-MB 231 treated with DZNEP, H3K27me3 significantly decreased on SRC3 while H3K4ac was significantly increased in MDA-MB-231 treated with SAHA or NaBu for P300. Conclusion: Luminal and mesenchymal-like breast cancer subtype cell lines seemed to act differently to HDACis (SAHA and NaBu) or HMTi (DZNEP) treatments.
C1 [Dagdemir, Aslihan; Judes, Gaelle; Echegut, Maureen; Karsli-Ceppioglu, Seher; Rifai, Khaldoun; Daures, Marine; Ngollo, Marjolaine; Dubois, Lucas; Bignon, Yves-Jean; Bernard-Gallon, Dominique] CBRV, Ctr Jean Perrin, Dept Oncogenet, Clermont Ferrand, France.
   [Dagdemir, Aslihan; Judes, Gaelle; Echegut, Maureen; Karsli-Ceppioglu, Seher; Rifai, Khaldoun; Daures, Marine; Ngollo, Marjolaine; Dubois, Lucas; Penault-Llorca, Frederique; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Univ Auvergne, EA ERTICA 4677, Clermont Ferrand, France.
   [Lebert, Andre] Univ Blaise Pascal, Inst Pascal UMR CNRS UBP 6602, Aubiere, France.
   [Karsli-Ceppioglu, Seher] Marmara Univ, Fac Pharm, Dept Toxicol, Istanbul, Turkey.
   [Penault-Llorca, Frederique] Ctr Jean Perrin, Dept Biopathol, Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA);
   Universite Clermont Auvergne (UCA); Centre National de la Recherche
   Scientifique (CNRS); Marmara University; UNICANCER; Centre Jean Perrin
RP Bernard-Gallon, D (通讯作者)，CBRV, Ctr Jean Perrin, Dept Oncogenet, EA 4677, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.
EM dominique.gallon-bernard@clermont.unicancer.fr
RI Karsli-Ceppioglu, Seher/JED-4667-2023; Bernard-Gallon,
   Dominique/L-6079-2015
OI Bernard-Gallon, Dominique/0000-0003-2931-5340
FU Scientific and Technology Research Council of Turkey [TUBITAK-2219];
   Hariri Foundation (Beyrouth, Liban); La Ligue Contre Le Cancer (Comite
   du Puy de Dome); Protema Saglik Hizm A.S (Istanbul, Turkey)
FX Aslihan Dagdemir was supported by Protema Saglik Hizm A.S (Istanbul,
   Turkey). Seher Karsli-Ceppioglu was supported by the Scientific and
   Technology Research Council of Turkey (TUBITAK-2219) project grants.
   Khaldoun RIFAI was supported by Hariri Foundation (Beyrouth, Liban).
   This work was supported by La Ligue Contre Le Cancer (Comite du Puy de
   Dome).
CR [Anonymous], AGROCOLAE STAT PROCE
   [Anonymous], MULTCOMP SIMULTANEOU
   [Anonymous], CANC LETT
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Bosviel R, 2012, OMICS, V16, P707, DOI 10.1089/omi.2012.0060
   Bosviel R, 2011, CLIN CHIM ACTA, V412, P1472, DOI 10.1016/j.cca.2011.04.027
   CAILLEAU R, 1974, CANCER RES, V34, P801
   Campàs-Moya C, 2009, DRUG TODAY, V45, P787, DOI 10.1358/dot.2009.45.11.1437052
   CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7
   Dagdemir A, 2013, EPIGENOMICS-UK, V5, P51, DOI [10.2217/epi.12.74, 10.2217/EPI.12.74]
   Daures M, 2016, OMICS, V20, P123, DOI 10.1089/omi.2015.0113
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853
   Fermento ME, 2014, EXP MOL PATHOL, V97, P411, DOI 10.1016/j.yexmp.2014.09.019
   Gojis O, 2010, NAT REV CLIN ONCOL, V7, P83, DOI 10.1038/nrclinonc.2009.219
   Heiberger R.M., 2013, HH: Statistical analysis and data display: Heiberger and Holland. R package version 2.3-37
   Hsieh C.L., 2016, LIFE SCI
   Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Judes G, 2015, EPIGENOMICS-UK, V7, P1351, DOI 10.2217/epi.15.76
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Kurebayashi J, 2000, CLIN CANCER RES, V6, P512
   Li LP, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-014-0030-5
   Madak-Erdogan Z, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.28
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994
   Nohara Kazunari, 2007, Kobe J Med Sci, V53, P265
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353
   Raats M. M., 1992, Food Quality and Preference, V3, P89, DOI 10.1016/0950-3293(91)90028-D
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Vissac-Sabatier C, 2003, NUTR CANCER, V45, P247, DOI 10.1207/S15327914NC4502_15
   Wang L, 2014, INT J BIOL SCI, V10, P563, DOI 10.7150/ijbs.8579
   Wang ZT, 2016, CELL SIGNAL, V28, P506, DOI 10.1016/j.cellsig.2016.02.006
   Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930
   York B, 2010, J BIOL CHEM, V285, P38743, DOI 10.1074/jbc.R110.193367
NR 42
TC 12
Z9 13
U1 1
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 1109-6535
EI 1790-6245
J9 CANCER GENOM PROTEOM
JI Cancer Genomics Proteomics
PD JUL-AUG
PY 2016
VL 13
IS 4
BP 291
EP 303
PG 13
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DQ5NR
UT WOS:000379252600005
PM 27365379
DA 2025-01-12
ER

PT J
AU Xu, L
   Liu, HY
   Yu, J
   Wang, ZY
   Zhu, Q
   Li, ZP
   Zhong, Q
   Zhang, SY
   Qu, MQ
   Lan, Q
AF Xu, Liang
   Liu, Hongyuan
   Yu, Ju
   Wang, Zhongyong
   Zhu, Qing
   Li, Zongping
   Zhong, Qi
   Zhang, Shuyu
   Qu, Mingqi
   Lan, Qing
TI Methylation-induced silencing of maspin contributes to the proliferation
   of human glioma cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE maspin; glioma; DNA methylation; proliferation
ID BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR RECEPTOR; PROMOTER
   METHYLATION; PROSTATE-CANCER; EPITHELIAL-CELLS; EPIGENETIC REGULATION;
   GENE-EXPRESSION; CARCINOMA-CELLS; DOWN-REGULATION; P53
AB Maspin, a member of the serpin superfamily of serine protease inhibitors, has been reported to be involved in cancer initiation and progression. However, the expression of maspin and its expression regulation in glioma remain unknown. In the present study, we aimed to investigate the function of maspin in glioma cells and its regulatory mechanism. We found that the expression of maspin was silenced in glioma cells and tissues. Although maspin had no effect on the migration and invasion of human glioma cells in vitro, overexpression of maspin inhibited cell growth in U87 cells. We showed that the methylase inhibitor 5-Aza-2'-deoxycytidine induced the expression of maspin in glioma cell lines. Furthermore, both U87 and U251 cells showed hypermethylation in the maspin promoter. In addition, bisulphite sequencing analysis indicated that 16 CpG sites in the promoter were completely methylated in glioma cells and cancerous tissues, while CpG dinucleotides in the maspin promoter were unmethylated in normal brain tissues. Our data suggest that methylation-induced silencing of maspin contributes to the proliferation of human glioma cells, and maspin may be a potential therapeutic target in glioma.
C1 [Xu, Liang; Yu, Ju; Wang, Zhongyong; Zhu, Qing; Lan, Qing] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, 1055 Sanxiang Rd, Suzhou 215004, Jiangsu, Peoples R China.
   [Liu, Hongyuan; Li, Zongping; Zhong, Qi] Mianyang Cent Hosp, Dept Neurosurg, Mianyang 621000, Sichuan, Peoples R China.
   [Zhang, Shuyu] Soochow Univ, Sch Radiat Med & Protect, Coll Med, Suzhou 215123, Jiangsu, Peoples R China.
   [Zhang, Shuyu] Soochow Univ, Jiangsu Prov Key Lab Radiat Med & Protect, Coll Med, Suzhou 215123, Jiangsu, Peoples R China.
   [Qu, Mingqi] Henan Prov Peoples Hosp, Dept Neurosurg, 7 Weiwu Rd, Zhengzhou 450000, Henan, Peoples R China.
C3 Soochow University - China; Soochow University - China; Soochow
   University - China; Zhengzhou University
RP Lan, Q (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, 1055 Sanxiang Rd, Suzhou 215004, Jiangsu, Peoples R China.; Qu, MQ (通讯作者)，Henan Prov Peoples Hosp, Dept Neurosurg, 7 Weiwu Rd, Zhengzhou 450000, Henan, Peoples R China.
EM qmq123@163.com; szlq0008@163.com
FU National Natural Science Foundation of China [81072058]; Natural Science
   Foundation of Jiangsu Province [BK2010230]; Foundation Program of Suzhou
   Science and Technology Project [SYSD2014092]; Research and Innovation
   Project for College Graduates of Jiangsu Province [2014-1263];
   Foundation of Young Member of the Second Affiliated Hospital of Soochow
   University [SDFEYQN1409]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81072058), the Natural Science Foundation of
   Jiangsu Province (BK2010230), the Foundation Program of Suzhou Science
   and Technology Project (SYSD2014092), Research and Innovation Project
   for College Graduates of Jiangsu Province (2014-1263), and the
   Foundation of Young Member of the Second Affiliated Hospital of Soochow
   University (SDFEYQN1409).
CR [Anonymous], 2007, ACTA NEUROPATHOL, DOI DOI 10.1007/s00401-007-0243-4
   Bailey CM, 2005, J BIOL CHEM, V280, P34210, DOI 10.1074/jbc.M503523200
   Bernardo M Margarida, 2011, Genes Cancer, V2, P1009, DOI 10.1177/1947601912440170
   Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200
   Bodenstine TM, 2012, CANCER METAST REV, V31, P529, DOI 10.1007/s10555-012-9361-0
   Burgess DJ, 2012, NAT REV CANCER, V12, P448, DOI 10.1038/nrc3300
   Cahill N, 2013, EPIGENETICS-US, V8, P138, DOI 10.4161/epi.23439
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039
   Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324
   Dzinic SH, 2014, ONCOTARGET, V5, P11225, DOI 10.18632/oncotarget.2615
   Eitel JA, 2009, CELL CYCLE, V8, P896, DOI 10.4161/cc.8.6.7899
   Endsley MP, 2011, J BIOL CHEM, V286, P24599, DOI 10.1074/jbc.M111.235788
   Huse JT, 2013, ANNU REV MED, V64, P59, DOI 10.1146/annurev-med-100711-143028
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jiang RQ, 2010, INT J CANCER, V126, P1263, DOI 10.1002/ijc.24854
   Kaplun A, 2012, CRIT REV EUKAR GENE, V22, P249, DOI 10.1615/CritRevEukarGeneExpr.v22.i3.80
   Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005
   Li XH, 2006, CANCER RES, V66, P9323, DOI 10.1158/0008-5472.CAN-06-1578
   Li XH, 2011, MOL CANCER RES, V9, P733, DOI 10.1158/1541-7786.MCR-10-0505
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Machowska M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-142
   Machtens S, 2001, INT J CANCER, V95, P337, DOI 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1
   McKenzie S, 2008, ONCOGENE, V27, P7171, DOI 10.1038/onc.2008.321
   Mueller S, 2012, NEURO-ONCOLOGY, V14, P1146, DOI 10.1093/neuonc/nos140
   Prasad CP, 2010, CHEM-BIOL INTERACT, V183, P455, DOI 10.1016/j.cbi.2009.11.019
   Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Sarkar S, 2013, EPIGENOMICS-UK, V5, P87, DOI [10.2217/EPI.12.68, 10.2217/epi.12.68]
   Secord AA, 2011, GYNECOL ONCOL, V123, P314, DOI 10.1016/j.ygyno.2011.08.003
   Sharma G, 2011, TUMOR BIOL, V32, P23, DOI 10.1007/s13277-010-0087-8
   Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034
   Stark AM, 2010, NEUROL RES, V32, P303, DOI 10.1179/016164109X12518779082192
   Sulaiman L, 2013, EPIGENETICS-US, V8, P646, DOI 10.4161/epi.24823
   Toillon RA, 2007, MOL CELL PROTEOMICS, V6, P1239, DOI 10.1074/mcp.M600477-MCP200
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Xie RF, 2013, ONCOL REP, V29, P177, DOI 10.3892/or.2012.2102
   Yin SP, 2006, CANCER RES, V66, P4173, DOI 10.1158/0008-5472.CAN-05-3514
   Yoshizawa K, 2011, ONCOL REP, V26, P1555, DOI 10.3892/or.2011.1419
   Zhang M, 2009, CELL CYCLE, V8, P1112, DOI 10.4161/cc.8.8.8506
   Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105
   Zhang WG, 2002, INT J ONCOL, V20, P1145
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 43
TC 5
Z9 8
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2016
VL 36
IS 1
BP 57
EP 64
DI 10.3892/or.2016.4783
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DP7EJ
UT WOS:000378661700007
PM 27177016
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Ali, A
   Ullah, F
   Ali, IS
   Faraz, A
   Khan, M
   Shah, STA
   Ali, N
   Saeed, M
AF Ali, Arshad
   Ullah, Farman
   Ali, Irum Sabir
   Faraz, Ahmad
   Khan, Mumtaz
   Shah, Syed Tahir Ali
   Ali, Nawab
   Saeed, Muhammad
TI Aberrant Promoter Methylation at CpG Cytosines Induce the Upregulation
   of the <i>E2F5</i> Gene in Breast Cancer
SO JOURNAL OF BREAST CANCER
LA English
DT Article
DE Breast neoplasms; E2F5 transcription factor; Methylation; Promoter
ID TUMOR-SUPPRESSOR GENES; MARKERS; FAMILY; EXPRESSION; CARCINOMA; AGE
AB The promoter methylation status of cell cycle regulatory genes plays a crucial role in the regulation of the eukaryotic cell cycle. CpG cytosines are actively subjected to methylation during tumorigenesis, resulting in gain/loss of function. E2F5 gene has growth repressive activities; various studies suggest its involvement in tumorigenesis. This study aims to investigate the epigenetic regulation of E2F5 in breast cancer to better understand tumor biology. Methods: The promoter methylation status of 50 breast tumor tissues and adjacent normal control tissues was analyzed. mRNA expression was determined using SYBR green quantitative polymerase chain reaction (PCR), and methylation-specific PCR was performed for bisulfite-modified genomic DNA using E2F5-specific primers to assess promoter methylation. Data was statistically analyzed. Results: Significant (p<0.001) upregulation was observed in E2F5 expression among tumor tissues, relative to the control group. These samples were hypo-methylated at the E2F5 promoter region in the tumor tissues, compared to the control. Change in the methyl-ation status (Delta meth) was significantly lower (p=0.022) in the tumor samples, indicating possible involvement in tumorigenesis. Patients at the postmenopausal stage showed higher methylation (75%) than those at the premenopausal stage (23.1%). Interestingly, methylation levels gradually increased from the early to the advanced stages of the disease (p<0.001), which suggests a putative role of E2F5 methylation in disease progression that can significantly modulate tumor biology at more advanced stage and at postmenopausal age (Pearson's r= 0.99 and 0.86, respectively). Among tissues with different histological status, methylation frequency was higher in invasive lobular carcinoma (80.0%), followed by invasive ductal carcinoma (46.7%) and ductal carcinoma in situ (20.0%). Conclusion: Methylation is an important epigenetic factor that might be involved in the upregulation of E2F5 gene in tumor tissues,
C1 [Ali, Arshad; Ullah, Farman; Saeed, Muhammad] COMSATS Inst Informat Technol CIIT, Dept Biosci, Canc Genet & Epigenet Lab, Pk Rd, Islamabad 44000, Pakistan.
   [Ali, Arshad; Ullah, Farman; Ali, Nawab] Kohat Univ Sci & Technol, Dept Biotechnol & Genet Engn, Kohat, Pakistan.
   [Ali, Irum Sabir; Faraz, Ahmad; Khan, Mumtaz] Lady Reading Hosp, Post Grad Med Inst, Dept Surg Unit C, Peshawar, Pakistan.
   [Shah, Syed Tahir Ali] Div Headquarter Hosp, Dept Surg, Kohat, Pakistan.
C3 COMSATS University Islamabad (CUI); Kohat University of Science &
   Technology
RP Saeed, M (通讯作者)，COMSATS Inst Informat Technol CIIT, Dept Biosci, Canc Genet & Epigenet Lab, Pk Rd, Islamabad 44000, Pakistan.
EM muhammad.saeed@comsats.edu.pk
RI /I-1343-2018; Ali, Arshad/X-5071-2019
OI Ali, Dr. Arshad/0000-0002-4076-6620
FU PGMI; Lady Reading Hospital, Peshawar
FX The authors specially acknowledge and are thankful to all the
   participants as well as the supporting staff at PGMI; Lady Reading
   Hospital, Peshawar. We express our gratitude to the members of the
   Cancer Genetics & Epigenetics Laboratory, Biosciences (CIIT), Islamabad,
   Pakistan, for their kind cooperation and provision of the research
   platform.
CR Almén MS, 2014, GENE, V548, P61, DOI 10.1016/j.gene.2014.07.009
   Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481
   Aziz Z., 2004, JPMA Journal of the Pakistan Medical Association, V54, P448
   Baxter E, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-45
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Colozza M, 2005, ANN ONCOL, V16, P1723, DOI 10.1093/annonc/mdi352
   Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Eymin B, 2010, CELL ADHES MIGR, V4, P114, DOI 10.4161/cam.4.1.10977
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fuchs B, 2001, GENE, V278, P245, DOI 10.1016/S0378-1119(01)00731-4
   HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Kim TM, 2008, INT J CANCER, V123, P2808, DOI 10.1002/ijc.23901
   Kothandaraman Narasimhan, 2010, BMC Cancer, V10, P64, DOI 10.1186/1471-2407-10-64
   Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5
   Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878
   Lee JTY., 2011, J BIOMATERIALS NANOB, V2, P41, DOI [10.4236/jbnb.2011.21006, DOI 10.4236/JBNB.2011.21006]
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Ng JMK, 2015, INT J MOL SCI, V16, P2472, DOI 10.3390/ijms16022472
   Ozdemir F, 2012, EXP THER MED, V4, P1092, DOI 10.3892/etm.2012.715
   Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G
   Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Strauss WM., 2001, CURR PROTOC MOL BIOL
   Ullah F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134687
   Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471
   Yu HP, 2011, MOL CARCINOGEN, V50, P697, DOI 10.1002/mc.20806
NR 30
TC 5
Z9 5
U1 0
U2 2
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD JUN
PY 2016
VL 19
IS 2
BP 133
EP 141
DI 10.4048/jbc.2016.19.2.133
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DQ1PN
UT WOS:000378973000004
PM 27382388
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Ishibashi, K
   Kumai, T
   Ohkuri, T
   Kosaka, A
   Nagato, T
   Hirata, Y
   Ohara, K
   Oikawa, K
   Aoki, N
   Akiyama, N
   Sado, M
   Kitada, M
   Harabuchi, Y
   Celis, E
   Kobayashi, H
AF Ishibashi, Kei
   Kumai, Takumi
   Ohkuri, Takayuki
   Kosaka, Akemi
   Nagato, Toshihiro
   Hirata, Yui
   Ohara, Kenzo
   Oikawa, Kensuke
   Aoki, Naoko
   Akiyama, Naoko
   Sado, Masatoshi
   Kitada, Masahiro
   Harabuchi, Yasuaki
   Celis, Esteban
   Kobayashi, Hiroya
TI Epigenetic modification augments the immunogenicity of human leukocyte
   antigen G serving as a tumor antigen for T cell-based immunotherapy
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Human leukocyte antigen G; immune escape; immunotherapy; peptide
   vaccine; 5-aza-2 '-deoxycytidine
ID HLA-G EXPRESSION; G UP-REGULATION; MHC CLASS-II; LUNG-CANCER; G GENE;
   BREAST-CANCER; CARCINOMA; RECEPTOR; MOLECULES; 5-AZA-2'-DEOXYCYTIDINE
AB Tumor immune escape has been a major problem for developing effective immunotherapy. The human leukocyte antigen G (HLA-G) is a non-classical MHC class I molecule whose primary function is to protect the fetus from the mother's immune system. While HLA-G is hardly found in normal adult tissues, various tumor cells are known to express it, aiding their escape from the immune system. Thus, HLA-G is an attractive immunotherapy target. CD4(+) helper T lymphocytes (HTLs) play an important role in the immune reaction against tumors by assisting in the generation and persistence of CD8(+) cytotoxic T lymphocytes (CTLs) or by displaying direct antitumor effects. We report here that HLA-G expression in breast cancer significantly correlates with a poor prognosis. Also, we describe that the MHC class II-binding peptide HLA-G(26-40) was effective in eliciting tumor-reactive CD4(+) T cell responses. Furthermore, treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine increased HLA-G expression in tumors and subsequently enhanced recognition by HLA-G(26-40)-specific HTLs. These findings predict that a combination immunotherapy targeting HLA-G together with a DNA methyltransferase inhibitor could be useful against some cancers.
C1 [Ishibashi, Kei; Kumai, Takumi; Ohkuri, Takayuki; Kosaka, Akemi; Hirata, Yui; Ohara, Kenzo; Oikawa, Kensuke; Aoki, Naoko; Kobayashi, Hiroya] Asahikawa Med Univ, Dept Pathol, Asahikawa, Hokkaido, Japan.
   [Ishibashi, Kei; Kitada, Masahiro] Asahikawa Med Univ Hosp, Resp & Breast Ctr, Asahikawa, Hokkaido, Japan.
   [Kumai, Takumi; Nagato, Toshihiro; Hirata, Yui; Ohara, Kenzo; Harabuchi, Yasuaki] Asahikawa Med Univ, Dept Otolaryngol Head & Neck Surg, Asahikawa, Hokkaido, Japan.
   [Kumai, Takumi; Celis, Esteban] Augusta Univ, Ctr Canc, Canc Immunol Inflammat & Tolerance Program, Augusta, GA USA.
   [Akiyama, Naoko; Sado, Masatoshi] Asahikawa Med Univ Hosp, Dept Surg Pathol, Asahikawa, Hokkaido, Japan.
C3 Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical
   College; University System of Georgia; Augusta University; Asahikawa
   Medical College
RP Kumai, T; Ohkuri, T (通讯作者)，Asahikawa Med Univ, Dept Pathol, Asahikawa, Hokkaido, Japan.; Kumai, T (通讯作者)，Asahikawa Med Univ, Dept Otolaryngol Head & Neck Surg, Asahikawa, Hokkaido, Japan.; Kumai, T (通讯作者)，Augusta Univ, Ctr Canc, Canc Immunol Inflammat & Tolerance Program, Augusta, GA USA.
EM t-kumai@asahikawa-med.ac.jp; ohkurit@asahikawa-med.ac.jp
RI kumai, takumi/JAX-8625-2023; Ohkuri, Takayuki/AHE-0329-2022
OI Ohkuri, Takayuki/0000-0002-6889-7809
FU JSPS KAKENHI Grant [24791735]; National Cancer Institute of the National
   Institutes of Health [R01CA136828, R01CA157303]; Augusta University
   Cancer Center; Georgia Research Alliance; Grants-in-Aid for Scientific
   Research [24791735] Funding Source: KAKEN
FX This work was supported by grants from JSPS KAKENHI Grant Number
   24791735, the National Cancer Institute of the National Institutes of
   Health, R01CA136828 and R01CA157303, and by start-up funds from Augusta
   University Cancer Center and the Georgia Research Alliance.
CR Andersen MH, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.983770
   Bahri R, 2006, J IMMUNOL, V176, P1331, DOI 10.4049/jimmunol.176.3.1331
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
   Bukur J, 2003, CANCER RES, V63, P4107
   Chen BG, 2013, HUM IMMUNOL, V74, P286, DOI 10.1016/j.humimm.2012.12.005
   Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962
   Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x
   Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4
   de Kruijf EM, 2010, J IMMUNOL, V185, P7452, DOI 10.4049/jimmunol.1002629
   El-Chennawi F, 2004, EGYP J IMMUNOL EGYP, V12, P57
   Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208
   Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872
   He X, 2010, ANN SURG ONCOL, V17, P1459, DOI 10.1245/s10434-009-0891-9
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Ibrahim EC, 2001, CANCER RES, V61, P6838
   Kapasi K, 2000, IMMUNOLOGY, V101, P191, DOI 10.1046/j.1365-2567.2000.00109.x
   Ketroussi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022776
   Kleinberg L, 2006, VIRCHOWS ARCH, V449, P31, DOI 10.1007/s00428-005-0144-7
   Kobayashi H, 2000, CANCER RES, V60, P5228
   Komohara Y, 2007, ONCOL REP, V18, P1463
   Kumai T, 2013, BRIT J CANCER, V109, P2155, DOI 10.1038/bjc.2013.577
   Kumai T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976077
   Lich JD, 2000, J EXP MED, V191, P1513, DOI 10.1084/jem.191.9.1513
   Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398
   MCMASTER MT, 1995, J IMMUNOL, V154, P3771
   Monti P, 2004, J IMMUNOL, V172, P7341, DOI 10.4049/jimmunol.172.12.7341
   Moreau P, 2003, P NATL ACAD SCI USA, V100, P1191, DOI 10.1073/pnas.0337539100
   Mouillot G, 2005, INT J CANCER, V113, P928, DOI 10.1002/ijc.20682
   Munir S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23991
   Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730
   Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126
   Ogino T, 2003, CLIN CANCER RES, V9, P4043
   ONNO M, 1994, HUM IMMUNOL, V41, P79, DOI 10.1016/0198-8859(94)90089-2
   PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209
   Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200
   Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318
   Poláková K, 2009, LEUKEMIA RES, V33, P518, DOI 10.1016/j.leukres.2008.08.003
   Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093
   Riteau B, 2001, INT IMMUNOL, V13, P193, DOI 10.1093/intimm/13.2.193
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Torres MI, 2004, INT IMMUNOL, V16, P579, DOI 10.1093/intimm/dxh061
   Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7
   Wastowski IJ, 2013, AM J PATHOL, V182, P540, DOI 10.1016/j.ajpath.2012.10.021
   Yie SM, 2007, LUNG CANCER, V58, P267, DOI 10.1016/j.lungcan.2007.06.011
   Yie SM, 2007, ANN SURG ONCOL, V14, P2721, DOI 10.1245/s10434-007-9464-y
   Zhou JH, 2006, LIFE SCI, V78, P2643, DOI 10.1016/j.lfs.2005.10.039
NR 48
TC 31
Z9 33
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2016
VL 5
IS 6
AR e1169356
DI 10.1080/2162402X.2016.1169356
PG 10
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA DQ4GS
UT WOS:000379162700045
PM 27471649
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Nelson, DM
   Jaber-Hijazi, F
   Cole, JJ
   Robertson, NA
   Pawlikowski, JS
   Norris, KT
   Criscione, SW
   Pchelintsev, NA
   Piscitello, D
   Stong, N
   Rai, TS
   McBryan, T
   Otte, GL
   Nixon, C
   Clark, W
   Riethman, H
   Wu, H
   Schotta, G
   Garcia, BA
   Neretti, N
   Baird, DM
   Berger, SL
   Adams, PD
AF Nelson, David M.
   Jaber-Hijazi, Farah
   Cole, John J.
   Robertson, Neil A.
   Pawlikowski, Jeffrey S.
   Norris, Kevin T.
   Criscione, Steven W.
   Pchelintsev, Nikolay A.
   Piscitello, Desiree
   Stong, Nicholas
   Rai, Taranjit Singh
   McBryan, Tony
   Otte, Gabriel L.
   Nixon, Colin
   Clark, William
   Riethman, Harold
   Wu, Hong
   Schotta, Gunnar
   Garcia, Benjamin A.
   Neretti, Nicola
   Baird, Duncan M.
   Berger, Shelley L.
   Adams, Peter D.
TI Mapping H4K20me3 onto the chromatin landscape of senescent cells
   indicates a function in control of cell senescence and tumor suppression
   through preservation of genetic and epigenetic stability
SO GENOME BIOLOGY
LA English
DT Article
DE Cell senescence; Chromatin; Tumor suppression; SUV420H2/H4K20me3
ID ONCOGENE-INDUCED SENESCENCE; H4 LYSINE-20 TRIMETHYLATION; DNA-DAMAGE
   RESPONSE; HISTONE H4; HETEROCHROMATIN FOCI; BREAST-CANCER; IN-VIVO;
   NUCLEAR LAMINA; PROTEINS; GENOME
AB Background: Histone modification H4K20me3 and its methyltransferase SUV420H2 have been implicated in suppression of tumorigenesis. The underlying mechanism is unclear, although H4K20me3 abundance increases during cellular senescence, a stable proliferation arrest and tumor suppressor process, triggered by diverse molecular cues, including activated oncogenes. Here, we investigate the function of H4K20me3 in senescence and tumor suppression.
   Results: Using immunofluorescence and ChIP-seq we determine the distribution of H4K20me3 in proliferating and senescent human cells. Altered H4K20me3 in senescence is coupled to H4K16ac and DNA methylation changes in senescence. In senescent cells, H4K20me3 is especially enriched at DNA sequences contained within specialized domains of senescence-associated heterochromatin foci (SAHF), as well as specific families of non-genic and genic repeats. Altered H4K20me3 does not correlate strongly with changes in gene expression between proliferating and senescent cells; however, in senescent cells, but not proliferating cells, H4K20me3 enrichment at gene bodies correlates inversely with gene expression, reflecting de novo accumulation of H4K20me3 at repressed genes in senescent cells, including at genes also repressed in proliferating cells. Although elevated SUV420H2 upregulates H4K20me3, this does not accelerate senescence of primary human cells. However, elevated SUV420H2/H4K20me3 reinforces oncogene-induced senescence-associated proliferation arrest and slows tumorigenesis in vivo.
   Conclusions: These results corroborate a role for chromatin in underpinning the senescence phenotype but do not support a major role for H4K20me3 in initiation of senescence. Rather, we speculate that H4K20me3 plays a role in heterochromatinization and stabilization of the epigenome and genome of pre-malignant, oncogene-expressing senescent cells, thereby suppressing epigenetic and genetic instability and contributing to long-term senescence-mediated tumor suppression.
C1 [Nelson, David M.; Jaber-Hijazi, Farah; Cole, John J.; Robertson, Neil A.; Pawlikowski, Jeffrey S.; Pchelintsev, Nikolay A.; Piscitello, Desiree; Rai, Taranjit Singh; McBryan, Tony; Adams, Peter D.] Univ Glasgow, Inst Canc Sci, Glasgow G61 1BD, Lanark, Scotland.
   [Nelson, David M.; Jaber-Hijazi, Farah; Cole, John J.; Robertson, Neil A.; Pawlikowski, Jeffrey S.; Pchelintsev, Nikolay A.; Piscitello, Desiree; Rai, Taranjit Singh; McBryan, Tony; Nixon, Colin; Clark, William; Adams, Peter D.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
   [Norris, Kevin T.; Baird, Duncan M.] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff CF14 4XN, S Glam, Wales.
   [Criscione, Steven W.; Neretti, Nicola] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02903 USA.
   [Stong, Nicholas; Riethman, Harold] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
   [Rai, Taranjit Singh] Univ West Scotland, Inst Biomed & Environm Hlth Res, Paisley PA1 2BE, Renfrew, Scotland.
   [Otte, Gabriel L.; Berger, Shelley L.] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Epigenet Program, Philadelphia, PA 19104 USA.
   [Wu, Hong] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   [Schotta, Gunnar] Univ Munich, Planegg Martinsried, Germany.
   [Schotta, Gunnar] Munich Ctr Integrated Prot Sci CiPSM, Biomed Ctr, Planegg Martinsried, Germany.
   [Garcia, Benjamin A.] Univ Penn, Perelman Sch Med, Dept Biochem & Biophys, Epigenet Program, Philadelphia, PA 19104 USA.
C3 University of Glasgow; Beatson Institute; Cardiff University; Brown
   University; The Wistar Institute; University of West Scotland;
   University of Pennsylvania; Fox Chase Cancer Center; University of
   Munich; University of Munich; University of Pennsylvania
RP Adams, PD (通讯作者)，Univ Glasgow, Inst Canc Sci, Glasgow G61 1BD, Lanark, Scotland.; Adams, PD (通讯作者)，Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
EM p.adams@beatson.gla.ac.uk
RI Stong, Nicholas/ABB-7516-2021; Singh, Taranjit/ABE-8233-2020; Baird,
   Duncan/C-9671-2011; Rai, Taranjit Singh/A-3659-2012
OI Robertson, Neil/0000-0002-9509-1157; Schotta,
   Gunnar/0000-0003-4940-6135; Jaber-Hijazi, Farah/0000-0001-6094-751X;
   Stong, Nicholas/0000-0002-0678-637X; Berger,
   Shelley/0000-0001-5398-4400; Pawlikowski, Jeff/0000-0001-6641-1038;
   Adams, Peter/0000-0002-0684-1770; Piscitello,
   Desiree/0000-0002-2510-4717; Neretti, Nicola/0000-0002-9552-1663; Rai,
   Taranjit Singh/0000-0002-7276-7492; Baird, Duncan/0000-0001-8408-5467
FU CRUK core grant; NRSA F31 Diversity award; NIH [R21HG007205,
   R21CA177395, T32 GM007601, GM110174, CA196539, K25 AG028753, K25
   AG028753-03S1, R56 AG050582-01]; NIA [F31AG050365, PO1 AG031862];
   Deutsche Forschungsgemeinschaft [SFB1064 TP11]; Cancer Research UK
   [C17199/A13490, C17199/A18246]; Wales Cancer Research Centre; CRUK
   [C10652/A16566]
FX Mouse experiments were part funded by a CRUK core grant to BICR. NS was
   supported by a predoctoral NRSA F31 Diversity award and the HR lab by
   NIH grants R21HG007205 and R21CA177395. SWC was supported by NIA
   F31AG050365 and NIH T32 GM007601. Work in the lab of GS was supported by
   Deutsche Forschungsgemeinschaft SFB1064 TP11. Work in the lab of BAG was
   supported by NIH GM110174 and CA196539. Work in the lab of NN was
   supported in part by NIH K25 AG028753, K25 AG028753-03S1 and R56
   AG050582-01. Work in the lab of DMB was funded by Cancer Research UK
   (C17199/A13490 and C17199/A18246) and the Wales Cancer Research Centre.
   Work in the lab of SLB was supported by NIA PO1 AG031862. Work in the
   lab of PDA was supported by NIA PO1 AG031862 and CRUK C10652/A16566.
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081
   Benhamed M, 2012, NAT CELL BIOL, V14, P266, DOI 10.1038/ncb2443
   Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032
   Blahnik KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017121
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x
   Cecco M, 2013, AGING CELL, V12, P247, DOI 10.1111/acel.12047
   Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010
   Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918
   Chicas A, 2012, P NATL ACAD SCI USA, V109, P8971, DOI 10.1073/pnas.1119836109
   Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a
   Cosme-Blanco W, 2007, EMBO REP, V8, P497, DOI 10.1038/sj.embor.7400937
   Cruickshanks HA, 2013, NAT CELL BIOL, V15, P1495, DOI 10.1038/ncb2879
   Cruickshanks HA, 2011, CURR OPIN GENET DEV, V21, P100, DOI 10.1016/j.gde.2010.10.007
   De Cecco M, 2013, AGING-US, V5, P867, DOI 10.18632/aging.100621
   di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118
   Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327
   Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548
   Evertts AG, 2013, MOL BIOL CELL, V24, P3025, DOI 10.1091/mbc.E12-07-0529
   Evertts AG, 2013, J BIOL CHEM, V288, P12142, DOI 10.1074/jbc.M112.428318
   Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026
   Ferbeyre G, 2000, GENE DEV, V14, P2015
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884
   Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005
   Giordano J, 2007, PLOS COMPUT BIOL, V3, P1321, DOI 10.1371/journal.pcbi.0030137
   Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283
   Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947
   Hahn M, 2013, GENE DEV, V27, P859, DOI 10.1101/gad.210377.112
   Hansen RS, 2010, P NATL ACAD SCI USA, V107, P139, DOI 10.1073/pnas.0912402107
   Harlow E, 1988, ANTIBODIES LAB MANUA
   Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144
   Hori T, 2014, DEV CELL, V29, P740, DOI 10.1016/j.devcel.2014.05.001
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ivanov A, 2013, J CELL BIOL, V202, P129, DOI 10.1083/jcb.201212110
   Jeyapalan JC, 2007, MECH AGEING DEV, V128, P36, DOI 10.1016/j.mad.2006.11.008
   Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238
   Kreiling JA, 2011, AGING CELL, V10, P292, DOI 10.1111/j.1474-9726.2010.00666.x
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuerbitz SJ, 1999, CELL GROWTH DIFFER, V10, P27
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020
   Marión RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025680
   Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545
   Martin N, 2013, EMBO J, V32, P982, DOI 10.1038/emboj.2013.37
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052
   Nicetto D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003188
   O'Sullivan RJ, 2010, NAT STRUCT MOL BIOL, V17, P1218, DOI 10.1038/nsmb.1897
   PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6
   Pérez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773
   Phalke S, 2009, NAT GENET, V41, P696, DOI 10.1038/ng.360
   Plazas-Mayorca MD, 2009, J PROTEOME RES, V8, P5367, DOI 10.1021/pr900777e
   Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rai TS, 2014, GENE DEV, V28, P2712, DOI 10.1101/gad.247528.114
   RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Sadaie M, 2013, GENE DEV, V27, P1800, DOI 10.1101/gad.217281.113
   Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113
   Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095
   Shah PP, 2013, GENE DEV, V27, P1787, DOI 10.1101/gad.223834.113
   Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Van Meter M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6011
   Vijg J, 2013, ANNU REV PHYSIOL, V75, P645, DOI 10.1146/annurev-physiol-030212-183715
   Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Ye XF, 2007, MOL CELL BIOL, V27, P2452, DOI 10.1128/MCB.01592-06
   Yokoyama Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3681
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019
   Zhang RG, 2007, MOL CELL BIOL, V27, P2343, DOI 10.1128/MCB.02019-06
NR 90
TC 71
Z9 83
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD JUL 25
PY 2016
VL 17
AR 158
DI 10.1186/s13059-016-1017-x
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DR8LL
UT WOS:000380149300001
PM 27457071
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wang, JJ
   Duan, ZJ
   Nugent, Z
   Zou, JX
   Borowsky, AD
   Zhang, YH
   Tepper, CG
   Li, JJ
   Fiehn, O
   Xu, JZ
   Kung, HJ
   Murphy, LC
   Chen, HW
AF Wang, Junjian
   Duan, Zhijian
   Nugent, Zoann
   Zou, June X.
   Borowsky, Alexander D.
   Zhang, Yanhong
   Tepper, Clifford G.
   Li, Jian Jian
   Fiehn, Oliver
   Xu, Jianzhen
   Kung, Hsing-Jien
   Murphy, Leigh C.
   Chen, Hong-Wu
TI Reprogramming metabolism by histone methyltransferase NSD2 drives
   endocrine resistance via coordinated activation of pentose phosphate
   pathway enzymes
SO CANCER LETTERS
LA English
DT Article
DE Histone methyltransferase; NSD2; Tamoxifen resistance; Pentose phosphate
   pathway; Metabolism
ID GENE-EXPRESSION; BREAST-TUMORS; CELL-GROWTH; SURVIVAL; TIGAR;
   PROLIFERATION; CONTRIBUTES; REPRESSION; INHIBITION; VARIANT
AB Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose 6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Wang, Junjian; Duan, Zhijian; Zou, June X.; Tepper, Clifford G.; Kung, Hsing-Jien; Chen, Hong-Wu] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA.
   [Nugent, Zoann; Murphy, Leigh C.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada.
   [Borowsky, Alexander D.; Zhang, Yanhong] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA.
   [Li, Jian Jian] Univ Calif Davis, Dept Radiat Oncol, Sch Med, Sacramento, CA 95817 USA.
   [Fiehn, Oliver] Univ Calif Davis, UC Davis Genome Ctr Metabol, Davis, CA 95616 USA.
   [Xu, Jianzhen] Shantou Univ, Coll Med, Dept Bioinformat, Shantou, Peoples R China.
   [Kung, Hsing-Jien; Chen, Hong-Wu] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of Manitoba; University of California System; University of
   California Davis; University of California System; University of
   California Davis; University of California System; University of
   California Davis; Shantou University; University of California System;
   University of California Davis
RP Chen, HW (通讯作者)，Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA.; Chen, HW (通讯作者)，Univ Calif Davis, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA.
EM hwzchen@ucdavis.edu
RI Li, Zi-Jian/IWM-1489-2023; Wang, Junjian/S-5574-2019; Fiehn,
   Oliver/AFO-9881-2022; Zou, June/LDF-4772-2024; Kung,
   Hsing-Jien/C-7651-2013; Borowsky, Alexander/S-5404-2017; Xu,
   Jianzhen/G-2456-2011
OI Wang, Junjian/0000-0002-5328-2908; Li, Jian Jian/0000-0003-3694-9675;
   Xu, Jianzhen/0000-0002-0697-9075
FU NIH [DK060019, CA206222, CA150197]; National Natural Science Foundation
   of China [81373655]; Natural Science Foundation of Guangdong Province,
   China [2013B021800226]; Manitoba Breast Tumor Bank, Canadian Tumor
   Repository Network - CancerCare Manitoba Foundation (CCMF); Canadian
   Institutes of Health Research (CIHR) [PRG80155]; CDMRP [893261,
   CA150197] Funding Source: Federal RePORTER
FX We thank Dr. Robert Clarke for providing the cells. This work was
   supported in part by grants from the NIH DK060019 and CA206222 to
   H.-W.C., and CA150197 to H.-J.K, and by grants from the National Natural
   Science Foundation of China (No. 81373655) and the Natural Science
   Foundation of Guangdong Province, China (No. 2013B021800226) to J.W.
   This study was also supported by the Manitoba Breast Tumor Bank, a
   member of the Canadian Tumor Repository Network which was funded in part
   by the CancerCare Manitoba Foundation (CCMF) and the Canadian Institutes
   of Health Research (CIHR, PRG80155).
CR Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803
   Brunner N, 1997, CANCER RES, V57, P3486
   Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833
   Cheung EC, 2016, GENE DEV, V30, P52, DOI 10.1101/gad.271130.115
   Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001
   Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Düvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Gallo M, 2015, CANCER CELL, V28, P715, DOI 10.1016/j.ccell.2015.10.005
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172
   Jin K, 2015, CANCER DISCOV, V5, P944, DOI 10.1158/2159-8290.CD-15-0090
   Jo A, 2015, LEUKEMIA, V29, P1076, DOI 10.1038/leu.2015.5
   Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199
   Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674
   Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122
   Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349
   Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707
   Meissen JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046770
   Nin DS, 2014, MOL CANCER THER, V13, P2572, DOI 10.1158/1535-7163.MCT-14-0019
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Pinheiro I, 2012, CELL, V150, P948, DOI 10.1016/j.cell.2012.06.048
   Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566
   Razandi M, 2013, ONCOGENE, V32, P3274, DOI 10.1038/onc.2012.335
   Riganti C, 2012, FREE RADICAL BIO MED, V53, P421, DOI 10.1016/j.freeradbiomed.2012.05.006
   Shrivastav A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3660
   Snell L, 2006, METH MOLEC MED, V120, P3
   VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12
   Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110
   Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459
NR 43
TC 68
Z9 73
U1 1
U2 37
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD AUG 10
PY 2016
VL 378
IS 2
BP 69
EP 79
DI 10.1016/j.canlet.2016.05.004
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DP4DP
UT WOS:000378446700001
PM 27164560
OA Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Xiong, XF
   Zhang, JL
   Liang, WG
   Cao, WJ
   Qin, SN
   Dai, LB
   Ye, DP
   Liu, ZH
AF Xiong, Xifeng
   Zhang, Jinli
   Liang, Weiguo
   Cao, Wenjuan
   Qin, Shengnan
   Dai, Libing
   Ye, Dongping
   Liu, Zhihe
TI Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in
   osteosarcoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE osteosarcoma; enhancer of zeste homolog 2; fuse binding protein 1; c-Myc
ID FAR UPSTREAM ELEMENT; HEPATITIS-C VIRUS; CANCER-CELLS; TUMOR-SUPPRESSOR;
   HISTONE METHYLTRANSFERASE; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER;
   BREAST-CANCER; MYC; OVEREXPRESSION
AB Osteosarcoma is the primary cancer of leaf tissue and is regarded as a differentiation disease caused by genetic and epigenetic changes which interrupt the osteoblast differentiation from mesenchymal stem cells. Because of its high malignancy degree and rapid development, the morbidity and mortality are high. The enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of polycomb repressive complex 2 (PRC2) and has been demonstrated to be involved in a variety of biological processes, such as cell proliferation and program cell death. EZH2 impairs gene expression by catalyzing the tri-methylation of histone H3 lysine 27 (H3K27me3) which controls gene transcription epigenetically. It is reported that EZH2 expression is higher in osteosarcoma than in osteoblastoma and the highest expression of EZH2 is found in osteosarcoma with metastasis. In the past few years, several potent inhibitors of EZH2 have been discovered, and GSK343 is one of them. In this study, we found that GSK343 inhibited osteosarcoma cell viability, restrained cell cycle transition and promoted programmed cell death. GSK343 not only inhibited the expression of EZH2 and its target, c-Myc and H3K27me3, but it also inhibited fuse binding protein 1 (FBP1) expression, another c-Myc regulator. Furthermore, we found that FBP1 physically interacts with EZH2. Based on these results, we believe that GSK343 is a potential molecule for osteosarcoma clinical treatment. Other than the inhibition on EZH2-c-Myc signal pathway, we postulate that the inhibition on FBP1-c-Myc signal pathway is another potential underlying mechanism with which GSK343 inhibits osteosarcoma cell viability.
C1 [Xiong, Xifeng; Zhang, Jinli; Liang, Weiguo; Cao, Wenjuan; Qin, Shengnan; Dai, Libing; Ye, Dongping; Liu, Zhihe] Jinan Univ, Guangzhou Inst Traumat Surg, Guangzhou Red Cross Hosp, Coll Med, 396 Tongfu Zhong Rd, Guangzhou 510220, Guangdong, Peoples R China.
C3 Jinan University
RP Liu, ZH (通讯作者)，Jinan Univ, Guangzhou Inst Traumat Surg, Guangzhou Red Cross Hosp, Coll Med, 396 Tongfu Zhong Rd, Guangzhou 510220, Guangdong, Peoples R China.
EM zliu0731@163.com
RI Xiong, Xifeng/JCN-5469-2023
OI Qin, Shengnan/0000-0003-1307-0481
FU National Natural Science Foundation of China [81272222]; Medical and
   Health Science and Technology Project of Guangzhou [20161A010019]
FX This study was supported by the National Natural Science Foundation of
   China (nos. 81272222, to Z.L.) and Medical and Health Science and
   Technology Project of Guangzhou (no. 20161A010019, to X.X.). The authors
   would like to thank Siyu Liu from Rutgers, the State University of New
   Jersey, USA for her help in manuscript writing. Flow cytometry work was
   supported by Guangdong Provincial Key Laboratory of Malignant Tumor
   Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun
   Yat-Sen University.
CR Amatangelo MD, 2013, CELL CYCLE, V12, P2113, DOI 10.4161/cc.25163
   Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje
   Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226
   Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chien HL, 2011, J VIROL, V85, P4698, DOI 10.1128/JVI.01950-10
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Dixit U, 2015, J VIROL, V89, P7905, DOI 10.1128/JVI.00729-15
   Dixit U, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-925
   DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465
   Ferraro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115276
   Kaur M, 2013, CANCER RES, V73, P695, DOI 10.1158/0008-5472.CAN-12-2522
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Kuser-Abali G, 2014, EPIGENETICS-US, V9, P634, DOI 10.4161/epi.27957
   Li K, 2013, CHINESE MED J-PEKING, V126, P82, DOI 10.3760/cma.j.issn.0366-6999.20122477
   Liu TP, 2015, ANTI-CANCER DRUG, V26, P139, DOI 10.1097/CAD.0000000000000166
   Lv YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12999
   Malz M, 2009, HEPATOLOGY, V50, P1130, DOI 10.1002/hep.23051
   Matsushita K, 2006, CANCER RES, V66, P1409, DOI 10.1158/0008-5472.CAN-04-4459
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Popovic R, 2012, CANCER DISCOV, V2, P405, DOI 10.1158/2159-8290.CD-12-0076
   Rabenhorst U, 2009, HEPATOLOGY, V50, P1121, DOI 10.1002/hep.23098
   Radulovic V, 2013, LEUKEMIA, V27, P523, DOI 10.1038/leu.2012.368
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Zhang J, 2013, ONCOGENE, V32, P2907, DOI 10.1038/onc.2012.350
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
   Zhang ZB, 2008, J VIROL, V82, P5761, DOI 10.1128/JVI.00064-08
   Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94
   Zubaidah RM, 2008, PROTEOMICS, V8, P5086, DOI 10.1002/pmic.200800322
NR 42
TC 25
Z9 27
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2016
VL 49
IS 2
BP 623
EP 628
DI 10.3892/ijo.2016.3541
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DP1QD
UT WOS:000378263600019
PM 27278257
OA Bronze
DA 2025-01-12
ER

PT J
AU Cisneros-Soberanis, F
   Andonegui, MA
   Herrera, LA
AF Cisneros-Soberanis, Fernanda
   Andonegui, Marco A.
   Herrera, Luis A.
TI <i>miR</i>-<i>125b</i>-<i>1</i> is repressed by histone modifications in
   breast cancer cell lines
SO SPRINGERPLUS
LA English
DT Article
DE Epigenetics; Gene promoter; Histone modifications; DNA methylation
ID MICRORNAS; TRIMETHYLATION; SUPPRESSION; RESISTANCE; EXPRESSION;
   H3K27ME3; CONFERS
AB Purpose: Downregulation of miR-125b-1 is associated with poor prognosis in breast cancer patients. In this work we investigated the effect of histone modifications on the regulation of this gene promoter.
   Methods and results: We evaluated the enrichment of two histone modifications involved in gene repression, H3K9me3 and H3K27me3, on the miR-125b-1 promoter in two breast cancer cell lines, MCF7 (luminal A subtype) and MDA-MB-231 (triple-negative subtype), compared to the non-transformed breast cell line MCF10A. H3K27me3 and H3K9me3 were enriched in MCF7 and MDA-MB-231 cells, respectively. Next, we used an EZH2 inhibitor to examine the reactivation of miR-125b-1 in MCF7 cells and evaluated the transcriptional levels of pri-miR-125b-1 and mature miR-125b by qRT-PCR. pri-miRNA and mature miRNA transcripts were both increased after treatment of MCF7 cells with the EZH2 inhibitor, whereas no effect on miR-125b-1 expression levels was observed in MDA-MB-231 and MCF10A cells. We subsequently evaluated the effect of miR-125b-1 reactivation on the expression and protein levels of BAK1, a target of miR-125b. We observed 60 and 70 % decreases in the expression and protein levels of BAK1, respectively, compared to cells that were not treated with the EZH2 inhibitor. We over-expressed KDM4B/JMJD2B to reactivate this miRNA, resulting in a three-fold increase in miR-125b expression compared with the same cell line without KDM4B/JMJD2B over-expression.
   Conclusion: The miR-125b-1 is repressed by different epigenetic mechanisms depending on the breast cancer subtype and that miR-125b-1 reactivation specifically eliminates the effect of repressive histone modifications on the expression of an pro-apoptotic target.
C1 [Cisneros-Soberanis, Fernanda; Andonegui, Marco A.; Herrera, Luis A.] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol, Unidad Invest Biomed Canc, Ave San Fernando 22, Mexico City 14080, DF, Mexico.
C3 Instituto Nacional de Cancerologia (INCAN); Universidad Nacional
   Autonoma de Mexico
RP Herrera, LA (通讯作者)，Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol, Unidad Invest Biomed Canc, Ave San Fernando 22, Mexico City 14080, DF, Mexico.
EM herreram@biomedicas.unam.mx
RI Herrera, Luis/GOV-3311-2022
OI Cisneros-Soberanis, Fernanda/0000-0003-1120-1695
FU Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica,
   UNAM [IN208815]
FX FCS was a fellow of the Programa de Doctorado en Ciencias Biomedicas,
   Universidad Nacional Autonoma de Mexico (UNAM). This work was partially
   supported by the Programa de Apoyo a Proyectos de Investigacion e
   Innovacion Tecnologica, UNAM, Grant Number IN208815.
CR Banzhaf-Strathmann J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-30
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chien CH, 2011, NUCLEIC ACIDS RES, V39, P9345, DOI 10.1093/nar/gkr604
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Jene-Sanz A, 2013, MOL CELL BIOL, V33, P3951, DOI 10.1128/MCB.00426-13
   Kim J, 2012, ILAR J, V53, P232, DOI 10.1093/ilar.53.3-4.232
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Soto-Reyes E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-40
   Vilquin P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0515-1
   Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.292
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
NR 19
TC 20
Z9 20
U1 0
U2 11
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-1801
J9 SPRINGERPLUS
JI SpringerPlus
PD JUL 2
PY 2016
VL 5
AR 959
DI 10.1186/s40064-016-2475-z
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ0YP
UT WOS:000378928000005
PM 27386402
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gale, M
   Sayegh, J
   Cao, J
   Norcia, M
   Gareiss, P
   Hoyer, D
   Merkel, JS
   Yan, Q
AF Gale, Molly
   Sayegh, Joyce
   Cao, Jian
   Norcia, Michael
   Gareiss, Peter
   Hoyer, Denton
   Merkel, Jane S.
   Yan, Qin
TI Screen-identified selective inhibitor of lysine demethylase 5A blocks
   cancer cell growth and drug resistance
SO ONCOTARGET
LA English
DT Article
DE histone demethylase inhibitor; KDM5A; anti-cancer drug; drug resistance;
   epigenetics
ID HISTONE DEMETHYLASE; BREAST-CANCER; RBP2; BINDING; DOMAIN; FAMILY;
   KDM5A; TUMORIGENESIS; METASTASIS; DISCOVERY
AB Lysine demethylase 5A (KDM5A/RBP2/JARID1A) is a histone lysine demethylase that is overexpressed in several human cancers including lung, gastric, breast and liver cancers. It plays key roles in important cancer processes including tumorigenesis, metastasis, and drug tolerance, making it a potential cancer therapeutic target. Chemical tools to analyze KDM5A demethylase activity are extremely limited as available inhibitors are not specific for KDM5A. Here, we characterized KDM5A using a homogeneous luminescence-based assay and conducted a screen of about 9,000 small molecules for inhibitors. From this screen, we identified several 3-thio-1,2,4-triazole compounds that inhibited KDM5A with low mu M in vitro IC50 values. Importantly, these compounds showed great specificity and did not inhibit its close homologue KDM5B (PLU1/JARID1B) or the related H3K27 demethylases KDM6A (UTX) and KDM6B (JMJD3). One compound, named YUKA1, was able to increase H3K4me3 levels in human cells and selectively inhibit the proliferation of cancer cells whose growth depends on KDM5A. As KDM5A was shown to mediate drug tolerance, we investigated the ability of YUKA1 to prevent drug tolerance in EGFR-mutant lung cancer cells treated with gefitinib and HER2+ breast cancer cells treated with trastuzumab. Remarkably, this compound hindered the emergence of drug-tolerant cells, highlighting the critical role of KDM5A demethylase activity in drug resistance. The small molecules presented here are excellent tool compounds for further study of KDM5A's demethylase activity and its contributions to cancer.
C1 [Gale, Molly; Sayegh, Joyce; Cao, Jian; Yan, Qin] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
   [Norcia, Michael; Gareiss, Peter; Hoyer, Denton; Merkel, Jane S.] Yale Univ, Yale Ctr Mol Discovery, West Haven, CT USA.
   [Sayegh, Joyce] Azusa Pacific Univ, Dept Biol & Chem, Azusa, CA USA.
C3 Yale University; Yale University; Azusa Pacific University
RP Yan, Q (通讯作者)，Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
EM qin.yan@yale.edu
RI Cao, Jian/K-2440-2014; Yan, Qin/E-8893-2012
OI Yan, Qin/0000-0003-4077-453X; Gareiss, Peter/0009-0009-6738-2414; Cao,
   Jian/0000-0003-3424-6802
FU Yale Center for Molecular Discovery; American Cancer Society Research
   Scholar Grant [RSG-13-384-01-DMC]; Department of Defense Breast Cancer
   Research Program [W81XWH-14-1-0308]; National Cancer Institute [R21
   CA187862, CA191548, P30 CA16359]; NSF [DGE-1122492]
FX This work was supported in part by a pilot grant from the Yale Center
   for Molecular Discovery, American Cancer Society Research Scholar Grant
   RSG-13-384-01-DMC, Department of Defense Breast Cancer Research Program
   W81XWH-14-1-0308, National Cancer Institute grants R21 CA187862 and
   CA191548 (all to Q.Y.), by National Cancer Institute grant P30 CA16359
   (to Yale Comprehensive Cancer Center) and by NSF Graduate Research
   Fellowship DGE-1122492 (to M.G.).
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063
   Bavetsias V, 2016, J MED CHEM, V59, P1388, DOI 10.1021/acs.jmedchem.5b01635
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383
   Cao J, 2014, CELL REP, V6, P868, DOI 10.1016/j.celrep.2014.02.004
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   FATTAEY AR, 1993, ONCOGENE, V8, P3149
   Gale M, 2015, EPIGENOMICS-UK, V7, P57, DOI [10.2217/EPI.14.63, 10.2217/epi.14.63]
   Guzmán C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Horton JR, 2016, J BIOL CHEM, V291, P2631, DOI 10.1074/jbc.M115.698449
   Hou JL, 2012, AM J TRANSL RES, V4, P247
   Itoh Y, 2015, ACS MED CHEM LETT, V6, P665, DOI 10.1021/acsmedchemlett.5b00083
   Jiping Zeng, 2013, J Cell Biochem, V114, P2666, DOI 10.1002/jcb.24613
   Kawamura A, 2010, ANAL BIOCHEM, V404, P86, DOI 10.1016/j.ab.2010.04.030
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Liang XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069784
   Liefke R, 2010, GENE DEV, V24, P590, DOI 10.1101/gad.563210
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Outchkourov NS, 2013, CELL REP, V3, P1071, DOI 10.1016/j.celrep.2013.02.030
   Rasmussen PB, 2014, EPIGENOMICS-UK, V6, P277, DOI [10.2217/epi.14.14, 10.2217/EPI.14.14]
   Sakurai M, 2010, MOL BIOSYST, V6, P357, DOI 10.1039/b912993f
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w
   Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Wang SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084735
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
NR 37
TC 64
Z9 74
U1 0
U2 23
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 28
PY 2016
VL 7
IS 26
BP 39931
EP 39944
DI 10.18632/oncotarget.9539
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DP6NV
UT WOS:000378614700076
PM 27224921
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU LaBarge, MA
   Mora-Blanco, EL
   Samson, S
   Miyano, M
AF LaBarge, Mark A.
   Mora-Blanco, E. Lorena
   Samson, Susan
   Miyano, Masaru
TI Breast Cancer beyond the Age of Mutation
SO GERONTOLOGY
LA English
DT Article
DE Breast cancer; Aging; Microenvironment; Epigenetics
ID MAMMARY EPITHELIAL-CELLS; SOMATIC MUTATIONS; GENE-EXPRESSION;
   COLORECTAL-CANCER; TUMOR-CELLS; STEM-CELLS; RISK; MICROENVIRONMENT;
   METHYLATION; GENOME
AB Age is the greatest risk factor for breast cancer, but the reasons underlying this association are unclear. While there is undeniably a genetic component to all cancers, the accumulation of mutations with age is insufficient to explain the age-dependent increase in breast cancer incidence. In this viewpoint, we propose a multilevel framework to better understand the respective roles played by somatic mutation, microenvironment, and epigenetics making women more susceptible to breast cancer with age. The process of aging is associated with gradual breast tissue changes that not only corrupt the tumor-suppressive activity of normal tissue but also impose age-specific epigenetic changes that alter gene expression, thus reinforcing cellular phenotypes that are associated with a continuum of age-related tissue micro-environments. The evidence discussed here suggests that while the riddle of whether epigenetics drives microenvironmental changes, or whether changes in the microenvironment alter heritable cellular memory has not been solved, a path has been cleared enabling functional analysis leading to the prediction of key nodes in the network that link the microenvironment with the epigenome. The hypothesis that the accumulation of somatic mutations with age drives the age-related increase in breast cancer incidence, if correct, has a somewhat nihilistic conclusion, namely that cancers will be impossible to avoid. Alternatively, if microenvironment-driven epigenetic changes are the key to explaining susceptibility to age-related breast cancers, then there is hope that primary prevention is possible because epigenomes are relatively malleable. (C) 2015 The Author(s) Published by S. Karger AG, Basel
C1 [LaBarge, Mark A.; Mora-Blanco, E. Lorena; Miyano, Masaru] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.
   [Samson, Susan] Univ Calif San Francisco, Breast Oncol Program, BSAC, San Francisco, CA 94143 USA.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   San Francisco
RP LaBarge, MA (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Natl Lab, 1 Cyclotron Rd,MS977, Berkeley, CA 94720 USA.
EM MALabarge@lbl.gov
RI LaBarge, Mark/E-2621-2013
OI LaBarge, Mark/0000-0003-2405-4719
FU National Institutes of Aging [NIA R01AG040081]; California Breast Cancer
   Research Program; Anita Tarr Turk Fund for Breast Cancer Research
   [20IB-0109]; Era of Hope Scholar Award from Congressionally Directed
   Medical Research Program's Breast Cancer Research Program [BC141351]
FX We are grateful for the generous support received from the National
   Institutes of Aging (NIA R01AG040081), the California Breast Cancer
   Research Program and Anita Tarr Turk Fund for Breast Cancer Research
   (20IB-0109), and the Era of Hope Scholar Award (BC141351) from the
   Congressionally Directed Medical Research Program's Breast Cancer
   Research Program.
CR Anderson WF, 2014, J NATL CANC I, V106
   ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1
   Bapat SA, 2010, EPIGENETICS-US, V5, P716, DOI 10.4161/epi.5.8.13014
   Baysan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094045
   Bissell M J, 1981, Int Rev Cytol, V70, P27, DOI 10.1016/S0074-7696(08)61130-4
   Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   BRANDA RF, 1993, MUTAT RES, V285, P267, DOI 10.1016/0027-5107(93)90115-V
   Buettner VL, 1999, ENVIRON MOL MUTAGEN, V33, P320, DOI 10.1002/(SICI)1098-2280(1999)33:4<320::AID-EM9>3.0.CO;2-S
   Campisi J, 2009, AGING CELL, V8, P221, DOI 10.1111/j.1474-9726.2009.00475.x
   Chanson L, 2011, P NATL ACAD SCI USA, V108, P3264, DOI 10.1073/pnas.1019556108
   Chen JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129895
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI [10.2217/epi.09.25, 10.2217/EPI.09.25]
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   DesRochers TM, 2012, EPIGENETICS-US, V7, P34, DOI 10.4161/epi.7.1.18546
   Dollé MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403
   Dollé MET, 2002, NUCLEIC ACIDS RES, V30, P545, DOI 10.1093/nar/30.2.545
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   Esserman LJ, 2011, BREAST CANCER RES TR, V129, P607, DOI 10.1007/s10549-011-1564-5
   Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005
   Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456
   Garbe JC, 2012, CANCER RES, V72, P3687, DOI 10.1158/0008-5472.CAN-12-0157
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Haakensen VD, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-77
   Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697
   HOWEEDY AA, 1990, LAB INVEST, V63, P798
   Issa JPJ, 2011, CANCER PREV RES, V4, P6, DOI 10.1158/1940-6207.CAPR-10-0348
   Jackson HW, 2015, NAT CELL BIOL, V17, P217, DOI 10.1038/ncb3118
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jenkins EO, 2014, ONCOLOGIST, V19, P1076, DOI 10.1634/theoncologist.2014-0184
   Jie G, 2007, INT J CLIN PRACT, V61, P1523, DOI 10.1111/j.1742-1241.2006.01033.x
   Khokha R., 2011, Cold Spring Harb Perspect Biol, V3
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   LaBarge MA, 2009, INTEGR BIOL-UK, V1, P70, DOI 10.1039/b816472j
   Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Martinson HA, 2013, EXP CELL RES, V319, P1671, DOI 10.1016/j.yexcr.2013.04.018
   McGowan PO, 2010, NEUROBIOL DIS, V39, P66, DOI 10.1016/j.nbd.2009.12.026
   McGowan PO, 2008, BRAIN RES, V1237, P12, DOI 10.1016/j.brainres.2008.07.074
   Milanese TR, 2006, J NATL CANCER I, V98, P1600, DOI 10.1093/jnci/djj439
   MOOLGAVKAR SH, 1988, RISK ANAL, V8, P383, DOI 10.1111/j.1539-6924.1988.tb00502.x
   Oyer JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004832
   Pelissier FA, 2014, CELL REP, V7, P1926, DOI 10.1016/j.celrep.2014.05.021
   Phelan CM, 2014, BRIT J CANCER, V110, P530, DOI 10.1038/bjc.2013.741
   PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Rodwell GEJ, 2004, PLOS BIOL, V2, P2191, DOI 10.1371/journal.pbio.0020427
   Sloan EK, 2009, AM J PATHOL, V174, P2035, DOI 10.2353/ajpath.2009.080924
   Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168
   Sotgia F, 2009, AM J PATHOL, V174, P746, DOI 10.2353/ajpath.2009.080658
   Sputova Klara, 2013, Genome Integr, V4, P4, DOI 10.1186/2041-9414-4-4
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112
   Tomasetti C, 2013, P NATL ACAD SCI USA, V110, P1999, DOI 10.1073/pnas.1221068110
   Vijg J, 2014, CURR OPIN GENET DEV, V26, P141, DOI 10.1016/j.gde.2014.04.002
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Well D, 2007, SEMIN NUCL MED, V37, P173, DOI 10.1053/j.semnuclmed.2007.01.004
   Yau C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1765
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
NR 63
TC 36
Z9 40
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PY 2016
VL 62
IS 4
BP 434
EP 442
DI 10.1159/000441030
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DP1NY
UT WOS:000378257900008
PM 26539838
OA Green Published, Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Liu, SL
   Zhang, XJ
   Zhao, KB
AF Liu, Shenglin
   Zhang, Xuejun
   Zhao, Kebin
TI Methylation-specific electrochemical biosensing strategy for highly
   sensitive and quantitative analysis of promoter methylation of
   tumor-suppressor gene in real sample
SO JOURNAL OF ELECTROANALYTICAL CHEMISTRY
LA English
DT Article
DE Electrochemical biosensor; DNA methylation; Tumor suppressor gene; High
   sensitivity; Practicability
ID SURFACE-PLASMON RESONANCE; WNT ANTAGONIST GENES; DNA METHYLATION;
   BREAST-CANCER; METHYLTRANSFERASE ACTIVITY; PCR ASSAY; HYPERMETHYLATION;
   AMPLIFICATION; INACTIVATION; EPIGENETICS
AB A handy and practical methylation-specific electrochemical biosensing strategy was developed by integrating bisulfite conversion and PCR amplification with high efficient electrochemical biosensor. The dual signal amplification of PCR and enzyme-catalyzed electrochemical sensing resulted in higher sensitivity of the proposed method. The primers for PCR and capture probes for amplicons binding were specifically designed to distinguish different CpG islands in the promoter regions of target gene, which further enhanced the specificity. The designed method showed very high sensitivity and specificity for DNA methylation analysis and was able to respond to about 8 copies of methylated promotor of secreted frizzled-related protein 2 (SFRP2) gene in 10,000 times of unmethylated genomic DNA. Moreover, the established biosensor was successfully verified for quantitative detection of SFRP2 promotor methylation in breast primary tumor tissues and subtlemonitor of SFRP2 promotor methylation status changes in real sample with the demethylating agent treatment This proposed strategy presented a simple and pragmatic platform toward high sensitive and quantitative detection promoter methylation of tumor-suppressor gene for early diagnosis and prognostic assessment of cancer, as well as monitoring response to therapeutic agents. (C) 2016 Published by Elsevier B.V.
C1 [Liu, Shenglin; Zhang, Xuejun] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China.
   [Liu, Shenglin] Xiqing Hosp Tianjin, Dept Lab Med, Tianjin 300380, Peoples R China.
   [Zhao, Kebin] Shanxi Med Univ, Hosp 1, Dept Lab Med, Taiyuan 030001, Peoples R China.
C3 Tianjin Medical University; Shanxi Medical University
RP Zhao, KB (通讯作者)，Shanxi Med Univ, Hosp 1, Dept Lab Med, Taiyuan 030001, Peoples R China.
EM sxzhaokebin@126.com
FU National Science Foundation of China [31240036, 31370891]; Natural
   Science Foundation of Tianjin [13JCZDJC30000]
FX This work was supported by the National Science Foundation of China
   (31240036, 31370891) and the Natural Science Foundation of Tianjin
   (13JCZDJC30000).
CR Bailey VJ, 2009, GENOME RES, V19, P1455, DOI 10.1101/gr.088831.108
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Capel E, 2007, ONCOGENE, V26, P7596, DOI 10.1038/sj.onc.1210581
   Chan KCA, 2008, CLIN CHEM, V54, P1528, DOI 10.1373/clinchem.2008.104653
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Geng Y, 2014, BIOSENS BIOELECTRON, V61, P593, DOI 10.1016/j.bios.2014.06.010
   Gore SD, 2006, BLOOD, V108, p156A, DOI 10.1182/blood.V108.11.517.517
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu J, 2012, BIOSENS BIOELECTRON, V31, P451, DOI 10.1016/j.bios.2011.11.014
   Jenkins GJS, 2002, BRIT J SURG, V89, P8, DOI 10.1046/j.0007-1323.2001.01968.x
   Kim SE, 2014, BIOSENS BIOELECTRON, V58, P333, DOI 10.1016/j.bios.2014.02.064
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li XM, 2015, ANALYST, V140, P6230, DOI 10.1039/c5an01015b
   Li Y, 2012, BIOSENS BIOELECTRON, V38, P407, DOI 10.1016/j.bios.2012.05.002
   Mikeska T, 2014, GENES-BASEL, V5, P821, DOI 10.3390/genes5030821
   Pan SY, 2010, BIOSENS BIOELECTRON, V26, P850, DOI 10.1016/j.bios.2010.08.007
   Reddy P, 2014, J IMMUNOL METHODS, V408, P114, DOI 10.1016/j.jim.2014.05.012
   Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Suter JD, 2010, BIOSENS BIOELECTRON, V26, P1016, DOI 10.1016/j.bios.2010.08.050
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   von Kanel T, 2010, CLIN CHEM, V56, P1098, DOI 10.1373/clinchem.2009.142828
   Wang H, 2013, ANN HEMATOL, V92, P199, DOI 10.1007/s00277-012-1595-y
   Xue Q, 2015, BIOSENS BIOELECTRON, V66, P547, DOI 10.1016/j.bios.2014.12.017
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Zhang HQ, 2007, ANALYST, V132, P724, DOI 10.1039/b704256f
   Zhou YL, 2014, ANAL CHIM ACTA, V840, P28, DOI 10.1016/j.aca.2014.06.020
NR 33
TC 15
Z9 16
U1 1
U2 50
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1572-6657
EI 1873-2569
J9 J ELECTROANAL CHEM
JI J. Electroanal. Chem.
PD JUL 15
PY 2016
VL 773
BP 63
EP 68
DI 10.1016/j.jelechem.2016.03.001
PG 6
WC Chemistry, Analytical; Electrochemistry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Electrochemistry
GA DP4JY
UT WOS:000378463400009
OA Bronze
DA 2025-01-12
ER

PT J
AU Krishnan, P
   Ghosh, S
   Graham, K
   Mackey, JR
   Kovalchuk, O
   Damaraju, S
AF Krishnan, Preethi
   Ghosh, Sunita
   Graham, Kathryn
   Mackey, John R.
   Kovalchuk, Olga
   Damaraju, Sambasivarao
TI Piwi-interacting RNAs and PIWI genes as novel prognostic markers for
   breast cancer
SO ONCOTARGET
LA English
DT Article
DE piRNA; PIWI; breast cancer; prognostic marker; TCGA
ID GASTRIC-CANCER; STEM-CELLS; EXPRESSION PATTERNS; MICRORNA SIGNATURE;
   PIRNAS; IDENTIFICATION; TRANSCRIPTOMES; BIOGENESIS
AB Piwi-interacting RNAs (piRNAs), whose role in germline maintenance has been established, are now also being classified as post-transcriptional regulators of gene expression in somatic cells. PIWI proteins, central to piRNA biogenesis, have been identified as genetic and epigenetic regulators of gene expression. piRNAs/PIWIs have emerged as potential biomarkers for cancer but their relevance to breast cancer has not been comprehensively studied. piRNAs and mRNAs were profiled from normal and breast tumor tissues using next generation sequencing and Agilent platforms, respectively. Gene targets for differentially expressed piRNAs were identified from mRNA expression dataset. piRNAs and PIWI genes were independently assessed for their prognostic significance (outcomes: Overall Survival, OS and Recurrence Free Survival, RFS). We discovered eight piRNAs as novel independent prognostic markers and their association with OS was confirmed in an external dataset (The Cancer Genome Atlas). Further, PIWIL3 and PIWIL4 genes showed prognostic relevance. 306 gene targets exhibited reciprocal relationship with piRNA expression. Cancer cell pathways such as apoptosis and cell signaling were the key Gene Ontology terms associated with the regulated gene targets. Overall, we have captured the entire cascade of events in a dysregulated piRNA pathway and have identified novel markers for breast cancer prognostication.
C1 [Krishnan, Preethi; Damaraju, Sambasivarao] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
   [Ghosh, Sunita; Graham, Kathryn; Mackey, John R.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
   [Ghosh, Sunita; Graham, Kathryn; Mackey, John R.; Damaraju, Sambasivarao] Cross Canc Inst, Alberta Hlth Serv, Edmonton, AB T6G 1Z2, Canada.
   [Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Alberta; University of Alberta; University of Alberta;
   Alberta Health Services (AHS); University of Lethbridge
RP Damaraju, S (通讯作者)，Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.; Damaraju, S (通讯作者)，Cross Canc Inst, Alberta Hlth Serv, Edmonton, AB T6G 1Z2, Canada.
EM sdamaraj@ualberta.ca
RI Krishnan, Preethi/AAY-2604-2020; Ghosh, Sunita/ITU-0007-2023
OI Ghosh, Sunita/0000-0002-9763-5058
FU CBCF - Prairies/NWT Chapter
FX Funding was generously provided by CBCF - Prairies/NWT Chapter to SD.
CR Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916
   Bastani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082144
   Brower-Toland B, 2007, GENE DEV, V21, P2300, DOI 10.1101/gad.1564307
   Busch J, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0180-3
   Chan M, 2013, CLIN CANCER RES, V19, P4477, DOI 10.1158/1078-0432.CCR-12-3401
   Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004
   Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715
   Cui L, 2011, CLIN BIOCHEM, V44, P1050, DOI 10.1016/j.clinbiochem.2011.06.004
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dobbin KK, 2008, CLIN CANCER RES, V14, P108, DOI 10.1158/1078-0432.CCR-07-0443
   Dobbin KK, 2007, BIOSTATISTICS, V8, P101, DOI 10.1093/biostatistics/kxj036
   Enright AJ, 2004, GENOME BIOL, V5
   Gasparini P, 2014, ONCOTARGET, V5, P1174, DOI 10.18632/oncotarget.1682
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Greither T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-272
   Grivna ST, 2006, GENE DEV, V20, P1709, DOI 10.1101/gad.1434406
   Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476
   Houwing S, 2007, CELL, V129, P69, DOI 10.1016/j.cell.2007.03.026
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Iliev R, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S91295
   Iwasaki YW, 2015, ANNU REV BIOCHEM, V84, P405, DOI 10.1146/annurev-biochem-060614-034258
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Krishnan P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1899-0
   Lakshmi SS, 2008, NUCLEIC ACIDS RES, V36, pD173, DOI 10.1093/nar/gkm696
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lau NC, 2006, SCIENCE, V313, P363, DOI 10.1126/science.1130164
   Li L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-38
   Liu N, 2014, INT J CANCER, V134, P1359, DOI 10.1002/ijc.28468
   Martin M., 2011, EMBNET J, V17
   Martinez VD, 2016, GASTRIC CANCER, V19, P660, DOI 10.1007/s10120-015-0487-y
   Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Moyano M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0133-5
   Ng KW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0491-9
   Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9
   Peng L, 2015, TUMOR BIOL, P1
   Sarot E, 2004, GENETICS, V166, P1313, DOI 10.1534/genetics.166.3.1313
   Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0
   Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426
   Su YY, 2012, INT IMMUNOPHARMACOL, V13, P468, DOI 10.1016/j.intimp.2012.05.016
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
   Watanabe T, 2014, MOL CELL, V56, P18, DOI 10.1016/j.molcel.2014.09.012
   Yang X, 2015, INT J CLIN EXP MED, V8, P13353
   Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008
NR 46
TC 65
Z9 70
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 21
PY 2016
VL 7
IS 25
BP 37944
EP 37956
DI 10.18632/oncotarget.9272
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DP1CW
UT WOS:000378229100042
PM 27177224
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, Q
   Madany, P
   Dobson, JR
   Schnabl, JM
   Sharma, S
   Smith, TC
   van Wijnen, AJ
   Stein, JL
   Lian, JB
   Stein, GS
   Muthuswami, R
   Imbalzano, AN
   Nickerson, JA
AF Wu, Qiong
   Madany, Pasil
   Dobson, Jason R.
   Schnabl, Jake M.
   Sharma, Soni
   Smith, Tara C.
   van Wijnen, Andre J.
   Stein, Janet L.
   Lian, Jane B.
   Stein, Gary S.
   Muthuswami, Rohini
   Imbalzano, Anthony N.
   Nickerson, Jeffrey A.
TI The BRG1 chromatin remodeling enzyme links cancer cell metabolism and
   proliferation
SO ONCOTARGET
LA English
DT Article
DE breast cancer; metabolism; lipogenesis; gene regulation; BRG1
ID FATTY-ACID SYNTHASE; ATP-CITRATE LYASE; MAMMALIAN SWI/SNF COMPLEXES;
   COA-CARBOXYLASE-ALPHA; THERAPEUTIC TARGET; ANTITUMOR-ACTIVITY;
   MOLECULAR-CLONING; EPITHELIAL-CELLS; LUNG-CANCER; EXPRESSION
AB Cancer cells reprogram cellular metabolism to meet the demands of growth. Identification of the regulatory machinery that regulates cancer-specific metabolic changes may open new avenues for anti-cancer therapeutics. The epigenetic regulator BRG1 is a catalytic ATPase for some mammalian SWI/SNF chromatin remodeling enzymes. BRG1 is a well-characterized tumor suppressor in some human cancers, but is frequently overexpressed without mutation in other cancers, including breast cancer. Here we demonstrate that BRG1 upregulates de novo lipogenesis and that this is crucial for cancer cell proliferation. Knockdown of BRG1 attenuates lipid synthesis by impairing the transcription of enzymes catalyzing fatty acid and lipid synthesis. Remarkably, exogenous addition of palmitate, the key intermediate in fatty acid synthesis, rescued the cancer cell proliferation defect caused by BRG1 knockdown. Our work suggests that targeting BRG1 to reduce lipid metabolism and, thereby, to reduce proliferation, has promise for epigenetic therapy in triple negative breast cancer.
C1 [Wu, Qiong; Madany, Pasil; Dobson, Jason R.; Schnabl, Jake M.; Smith, Tara C.; Imbalzano, Anthony N.; Nickerson, Jeffrey A.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA 01655 USA.
   [Sharma, Soni; Muthuswami, Rohini] Jawaharlal Nehru Univ, Sch Life Sci, Delhi, India.
   [van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
   [Stein, Janet L.; Lian, Jane B.; Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Stein, Janet L.; Lian, Jane B.; Stein, Gary S.] Univ Vermont, Coll Med, Vermont Canc Ctr Basic & Translat Res, Burlington, VT USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Jawaharlal Nehru University, New Delhi; Mayo Clinic;
   University of Vermont; University of Vermont
RP Imbalzano, AN; Nickerson, JA (通讯作者)，Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA 01655 USA.
EM anthony.imbalzano@umassmed.edu; jeffrey.nickerson@umassmed.edu
RI Muthuswami, Rohini/Q-9841-2019; van Wijnen, Andre/AAG-3578-2019
OI SHARMA, SONI/0000-0003-3617-4179; van Wijnen, Andre
   J./0000-0002-4458-0946; Muthuswami, Rohini/0000-0002-0559-9484; Dobson,
   Jason/0000-0002-2306-2250
FU NIH [P01 CA82834, R01 EB014869, R21 CA185926]
FX This work was supported by NIH grants P01 CA82834, R01 EB014869, and R21
   CA185926.
CR Abramson HN, 2011, J MED CHEM, V54, P5615, DOI 10.1021/jm2005805
   Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345
   Chajès V, 2006, CANCER RES, V66, P5287, DOI 10.1158/0008-5472.CAN-05-1489
   Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000
   de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dutta P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049822
   ELSHOURBAGY NA, 1992, EUR J BIOCHEM, V204, P491, DOI 10.1111/j.1432-1033.1992.tb16659.x
   Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122
   Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]
   Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032
   Gabrielson EW, 2001, CLIN CANCER RES, V7, P153
   GHOSH B, 1995, MOL CELL BIOCHEM, V151, P77, DOI 10.1007/BF01076899
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200
   HALVORSON DL, 1984, LIPIDS, V19, P851, DOI 10.1007/BF02534514
   Han GS, 2010, J BIOL CHEM, V285, P14628, DOI 10.1074/jbc.M110.117747
   Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008
   Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111
   IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0
   Imbalzano Anthony N, 2013, Commun Integr Biol, V6, pe25153, DOI 10.4161/cib.25153
   Imbalzano KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055628
   JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Jubierre L, 2016, ONCOGENE
   Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628
   Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071
   Khwairakpam AD, 2015, CURR DRUG TARGETS, V16, P156, DOI 10.2174/1389450115666141224125117
   Krammer J, 2011, INT J MED SCI, V8, P599, DOI 10.7150/ijms.8.599
   Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673
   KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379
   Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897
   KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0
   Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017
   Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022
   Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007
   Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235
   Mukherjee A, 2012, J BIOL CHEM, V287, P24990, DOI 10.1074/jbc.M112.340083
   Muthuswami R, 2000, BIOCHEMISTRY-US, V39, P4358, DOI 10.1021/bi992503r
   Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008-5472.CAN-12-4593
   Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961
   Rudolph MC, 2003, J MAMMARY GLAND BIOL, V8, P287, DOI 10.1023/B:JOMG.0000010030.73983.57
   Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280
   Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004
   Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638
   Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119
   Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113
   Sturmey RG, 2009, REPROD DOMEST ANIM, V44, P50, DOI 10.1111/j.1439-0531.2009.01402.x
   Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521
   Vazquez-Martin A, 2008, CELL PROLIFERAT, V41, P59, DOI 10.1111/j.1365-2184.2007.00498.x
   Verhoeven G, 2002, Verh K Acad Geneeskd Belg, V64, P189
   Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212
   Wang C, 2015, EXPERT REV ANTICANC, V15, P667, DOI 10.1586/14737140.2015.1038246
   Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117
   Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733
   Watanabe T, 2011, BRIT J CANCER, V104, P146, DOI 10.1038/sj.bjc.6606018
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Wu Q, 2016, ONCOTARGET, V7, P27158, DOI 10.18632/oncotarget.8384
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112
   Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439
NR 71
TC 49
Z9 58
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 21
PY 2016
VL 7
IS 25
BP 38270
EP 38281
DI 10.18632/oncotarget.9505
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DP1CW
UT WOS:000378229100068
PM 27223259
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Acevedo, M
   Vernier, M
   Mignacca, L
   Lessard, F
   Huot, G
   Moiseeva, O
   Bourdeau, V
   Ferbeyre, G
AF Acevedo, Mariana
   Vernier, Mathieu
   Mignacca, Lian
   Lessard, Frederic
   Huot, Genevieve
   Moiseeva, Olga
   Bourdeau, Veronique
   Ferbeyre, Gerardo
TI A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from
   PML-induced Senescence
SO CANCER RESEARCH
LA English
DT Article
ID DNA-DAMAGE RESPONSE; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; PREMATURE
   SENESCENCE; HETEROCHROMATIN FORMATION; CPG METHYLATION; BREAST-CANCER;
   ONCOGENIC RAS; CYCLE ARREST; ACTIVATION
AB Promyelocytic leukemia (PML) plays a tumor suppressive role by inducing cellular senescence in response to oncogenic stress. However, tumor cell lines fail to engage in complete senescence upon PML activation. In this study, we investigated the mechanisms underlying resistance to PML-induced senescence. Here, we report that activation of the cyclin-dependent kinases CDK4 and CDK6 are essential and sufficient to impair senescence induced by PML expression. Disrupting CDK function by RNA interference or pharmacological inhibition restored senescence in tumor cells and diminished their tumorigenic potential in mouse xenograft models. Complete senescence correlated with an increase in autophagy, repression of E2F target genes, and an gene expression signature of blocked DNA methylation. Accordingly, treatment of tumor cells with inhibitors of DNA methylation reversed resistance to PML-induced senescence. Further, CDK inhibition with palbociclib promoted autophagy-dependent degradation of the DNA methyltransferase DNMT1. Lastly, we found that CDK4 interacted with and phosphorylated DNMT1 in vitro, suggesting that CDK activity is required for its stabilization. Taken together, our findings highlight a potentially valuable feature of CDK4/6 inhibitors as epigenetic modulators to facilitate activation of senescence programs in tumor cells. (C)2016 AACR.
C1 [Acevedo, Mariana; Vernier, Mathieu; Mignacca, Lian; Lessard, Frederic; Huot, Genevieve; Moiseeva, Olga; Bourdeau, Veronique; Ferbeyre, Gerardo] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal
RP Ferbeyre, G (通讯作者)，Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada.; Bourdeau, V (通讯作者)，Univ Montreal, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.
EM veronique.bourdeau@umontreal.ca; g.ferbeyre@umontreal.ca
RI Ferbeyre, Gerardo/A-1569-2010; Moiseeva, Olga/Q-4848-2016
OI Vernier, Mathieu/0000-0001-9356-7353; Lessard,
   Frederic/0000-0002-1724-7267
FU CIHR [RN196161-300726]
FX This work was funded by grant CIHR RN196161-300726.
CR Ablain J, 2014, NAT MED, V20, P167, DOI 10.1038/nm.3441
   Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005
   Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003
   Burton DGA, 2014, CELL MOL LIFE SCI, V71, P4373, DOI 10.1007/s00018-014-1691-3
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Chanudet E, 2010, LEUKEMIA, V24, P483, DOI 10.1038/leu.2009.234
   Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200
   Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023
   Coit P, 2013, J AUTOIMMUN, V43, P78, DOI 10.1016/j.jaut.2013.04.003
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Cruickshanks HA, 2013, NAT CELL BIOL, V15, P1495, DOI 10.1038/ncb2879
   Deschênes-Simard X, 2013, GENE DEV, V27, P900, DOI 10.1101/gad.203984.112
   Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170
   Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548
   Dubovsky JA, 2007, PROSTATE, V67, P1781, DOI 10.1002/pros.20665
   Ferbeyre G, 2000, GENE DEV, V14, P2015
   Ferbeyre G, 2002, LEUKEMIA, V16, P1918, DOI 10.1038/sj.leu.2402722
   Fry DW, 2004, MOL CANCER THER, V3, P1427
   Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Lavoie G, 2011, BIOCHEM BIOPH RES CO, V409, P187, DOI 10.1016/j.bbrc.2011.04.115
   Law ME, 2015, MOL PHARMACOL, V88, P846, DOI 10.1124/mol.115.099325
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Lin ZW, 2012, DIGEST DIS SCI, V57, P3145, DOI 10.1007/s10620-012-2288-z
   Lu F, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-12
   Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018
   Moiseeva O, 2006, MOL BIOL CELL, V17, P1583, DOI 10.1091/mbc.E05-09-0858
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052
   Patel Nikul, 2012, Sarcoma, V2012, P498472, DOI 10.1155/2012/498472
   Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127
   Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Sherman MY, 2011, AGING CELL, V10, P949, DOI 10.1111/j.1474-9726.2011.00736.x
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Talluri S, 2014, CELL CYCLE, V13, P641, DOI 10.4161/cc.27527
   Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341
   Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809
   Vernier M, 2014, CELL CYCLE, V13, P696, DOI 10.4161/cc.28090
   Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111
   Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464
   Wiesmann F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2319
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
NR 51
TC 47
Z9 50
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2016
VL 76
IS 11
BP 3252
EP 3264
DI 10.1158/0008-5472.CAN-15-2347
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DO8UV
UT WOS:000378060900016
PM 27206849
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Stratikopoulos, EE
   Parsons, RE
AF Stratikopoulos, Elias E.
   Parsons, Ramon E.
TI Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors
   to the Rescue
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SELECTIVE-INHIBITION; TUMOR-SUPPRESSOR; BREAST-CANCER; KINASE;
   BROMODOMAIN; MUTATIONS; PTEN; GENE; P110-BETA; ACTIVATION
AB The PI3K signaling pathway is a complex and tightly regulated network that is critical for many physiologic processes, such as cell growth, proliferation, metabolism, and survival. Aberrant activation of this pathway can occur through mutation of almost any of its major nodes and has been implicated in a number of human diseases, including cancer. The high frequency of mutations in this pathway in multiple types of cancer has led to the development of small-molecule inhibitors of PI3K, several of which are currently in clinical trials. However, several feedback mechanisms either within the PI3K pathway or in compensatory pathways can render tumor cells resistant to therapy. Recently, targeting proteins of the bromodomain and extraterminal (BET) family of epigenetic readers of histone acetylation has been shown to effectively block adaptive signaling response of cancer cells to inhibitors of the PI3K pathway, which at least in some cases can restore sensitivity. BET inhibitors also enforce blockade of the MAPK, JAK/STAT, and ER pathways, suggesting they may be a rational combinatorial partner for divergent oncogenic signals that are subject to homeostatic regulation. Here, we review the PI3K pathway as a target for cancer therapy and discuss the potential use of BET inhibition to enhance the clinical efficacy of PI3K inhibitors. (C) 2016 AACR.
C1 [Stratikopoulos, Elias E.; Parsons, Ramon E.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Parsons, RE (通讯作者)，Mt Sinai Sch Med, 1 Gustave Levy Pl, New York, NY 10029 USA.
EM ramon.parsons@mssm.edu
RI Parsons, Ramon/KFT-2922-2024
OI Parsons, Ramon/0000-0002-6656-3514
FU NCI of the NIH [R01CA129432]; Stand Up To Cancer Dream Team
   Translational Research Grant [SU2C-AACR-DT0209]
FX R.E. Parsons is supported by the NCI of the NIH under award number
   R01CA129432 and a Stand Up To Cancer Dream Team Translational Research
   Grant (SU2C-AACR-DT0209). Stand Up To Cancer is a program of the
   Entertainment Industry Foundation. Research grants are administered by
   the American Association for Cancer Research, the scientific partner of
   SU2C.
CR Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561
   Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chen LJ, 2015, ACS MED CHEM LETT, V6, P764, DOI 10.1021/acsmedchemlett.5b00084
   Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471
   Clément S, 2001, NATURE, V409, P92, DOI 10.1038/35051094
   Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007
   Dittmann A, 2014, ACS CHEM BIOL, V9, P495, DOI 10.1021/cb400789e
   Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096
   Ember SWJ, 2014, ACS CHEM BIOL, V9, P1160, DOI 10.1021/cb500072z
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226
   Garrett JT, 2013, CANCER RES, V73, P6013, DOI 10.1158/0008-5472.CAN-13-1191
   Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108
   Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023
   Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006
   Gonzalez-Angulo AM, 2013, J CLIN ONCOL, V31
   Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583
   Hao YJ, 2013, CANCER CELL, V23, P583, DOI 10.1016/j.ccr.2013.03.021
   Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799
   Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016
   Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091
   Jing Y, 2016, ONCOTARGET, V7, P2545, DOI 10.18632/oncotarget.6309
   Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91
   Juric D, 2013, P EUR CANC C 2013 20
   Juric D, 2013, CANC RES S, V73
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948
   Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336
   Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liu SH, 2014, MOL CANCER THER, V13, P1194, DOI 10.1158/1535-7163.MCT-13-0341
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Martin MP, 2013, ACS CHEM BIOL, V8, P2360, DOI 10.1021/cb4003283
   Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343
   Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394
   Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pazarentzos E, 2016, ONCOGENE, V35, P1198, DOI 10.1038/onc.2015.173
   Philp AJ, 2001, CANCER RES, V61, P7426
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008
   Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037
   Tao JJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005125
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860
   Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112
   Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020
   Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105
   WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611
   Wong C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.396
NR 67
TC 34
Z9 41
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2016
VL 22
IS 11
BP 2605
EP 2610
DI 10.1158/1078-0432.CCR-15-2389
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DP2RN
UT WOS:000378338200003
PM 27250929
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Ben-Zaken, S
   Meckel, Y
   Nemet, D
   Dror, N
   Eliakim, A
AF Ben-Zaken, Sigal
   Meckel, Yoav
   Nemet, Dan
   Dror, Nitzan
   Eliakim, Alon
TI Polymorphism of the IGF-I System and Sports Performance
SO PEDIATRIC ENDOCRINOLOGY REVIEWS PER
LA English
DT Article
DE IGF; IGF receptor; Myostatin; Single nucleotide polymorphism; Sport
ID GROWTH-FACTOR-I; INDUCED CARDIAC-HYPERTROPHY; LEFT-VENTRICULAR MASS;
   BREAST-CANCER RISK; MYOSTATIN GENE; MYOFIBER HYPERTROPHY; ATHLETIC
   PERFORMANCE; MUSCLE HYPERTROPHY; NEGATIVE REGULATOR; BODY-COMPOSITION
AB The potential use genetic polymorphism, and in particularly polymorphism of hormone genes, as a tool to predict athletic performance is currently very challenging. Recent studies suggest that single nucleotide polymorphisms in IGF-I and myostatin may be beneficial for endurance and short distance running, and may even be associated with elite performance. Polymorphism in IGF-I receptor may differentiate between the two edges of the endurance-power athletic performance running spectrum suggesting beneficial effects for endurance and prevent from success in power events. In contrast, and despite similar metabolic demands, the myostatin-IGF-I-IGF-IR system seems not to play an important role in swimming excellence. This suggests that combining different sport disciplines for sports genetic research purposes should be done with extreme caution. Finally, since any phenotype reflects a complex relationship between genes, environment, epigenetic factors, and the interactions between them, consulting the young athlete regarding future success cannot be based solely on genetic polymorphism.
C1 [Ben-Zaken, Sigal; Meckel, Yoav] Zinman Coll Phys Educ & Sports Sci, Wingate Inst, Genet & Mol Biol Lab, Netanya, IL USA.
   [Nemet, Dan; Dror, Nitzan; Eliakim, Alon] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Child Hlth & Sports Ctr,Pediat Dept, Tel Aviv, IL USA.
RP Eliakim, A (通讯作者)，Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Dept Pediat, IL-69978 Tel Aviv, Israel.
EM eliakim.alon@clalit.org.il
RI Dror, Nitzan/HDO-5240-2022; Ben-Zaken, Sigal/ABG-8545-2021
CR Amthor H, 2002, DEV BIOL, V251, P241, DOI 10.1006/dbio.2002.0812
   Bamman MM, 2007, J APPL PHYSIOL, V102, P2232, DOI 10.1152/japplphysiol.00024.2007
   Ben-Zaken S, 2015, GROWTH HORM IGF RES, V25, P196, DOI 10.1016/j.ghir.2015.04.001
   Ben-Zaken S, 2015, J SCI MED SPORT, V18, P323, DOI 10.1016/j.jsams.2014.03.007
   Ben-Zaken S, 2013, GROWTH HORM IGF RES, V23, P175, DOI 10.1016/j.ghir.2013.06.005
   Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154
   Canzian F, 2006, BRIT J CANCER, V94, P299, DOI 10.1038/sj.bjc.6602936
   Chagnon YC, 2001, J APPL PHYSIOL, V90, P1777, DOI 10.1152/jappl.2001.90.5.1777
   Clemmons DR, 2009, TRENDS ENDOCRIN MET, V20, P349, DOI 10.1016/j.tem.2009.04.002
   COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109
   Cooper David N, 2010, Hum Genomics, V4, P284
   Corsi AM, 2002, J AM GERIATR SOC, V50, P1463, DOI 10.1046/j.1532-5415.2002.50376.x
   Eliakim A, 2010, MED SPORT SCI, V55, P128, DOI 10.1159/000321977
   Fedoruk MN, 2008, SCAND J MED SCI SPOR, V18, P123, DOI 10.1111/j.1600-0838.2007.00759.x
   Ferrell RE, 1999, GENOMICS, V62, P203, DOI 10.1006/geno.1999.5984
   Gonçalves CEB, 2012, INT J SPORT PHYSIOL, V7, P390, DOI 10.1123/ijspp.7.4.390
   González E, 2003, J PHYSIOL-LONDON, V552, P833, DOI 10.1113/jphysiol.2003.048165
   González-Freire M, 2010, AGE, V32, P405, DOI 10.1007/s11357-010-9139-7
   Greig CA, 2006, GROWTH HORM IGF RES, V16, P373, DOI 10.1016/j.ghir.2006.09.005
   Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71
   Gronek P, 2014, ACTA BIOCHIM POL, V61, P245
   Horio T, 2010, J HUM HYPERTENS, V24, P320, DOI 10.1038/jhh.2009.73
   Huuskonen A, 2011, MED SCI SPORT EXER, V43, P2368, DOI 10.1249/MSS.0b013e3182220179
   Ikeda H, 2009, J MOL CELL CARDIOL, V47, P664, DOI 10.1016/j.yjmcc.2009.08.028
   Ivey FM, 2000, J GERONTOL A-BIOL, V55, pM641, DOI 10.1093/gerona/55.11.M641
   JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228
   Karlowatz RJ, 2011, BRIT J SPORT MED, V45, P36, DOI 10.1136/bjsm.2008.050567
   Kim J, 2008, MOL ENDOCRINOL, V22, P2531, DOI 10.1210/me.2008-0265
   Kostek MA, 2009, MED SCI SPORT EXER, V41, P1063, DOI 10.1249/MSS.0b013e3181930337
   Kostek MC, 2010, EUR J APPL PHYSIOL, V110, P315, DOI 10.1007/s00421-010-1500-0
   Kostek MC, 2005, J APPL PHYSIOL, V98, P2147, DOI 10.1152/japplphysiol.00817.2004
   KrychGarsztka K, 2011, HUM MOV, V12, DOI [DOI 10.2478/V10038-011-0021-Y, 10.2478/v10038-011-0021-y]
   Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205
   Lee C, 2000, J PEDIATR ENDOCR MET, V13, P621, DOI 10.1515/JPEM.2000.13.6.621
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Li X, 2014, J SPORT SCI, V32, P883, DOI 10.1080/02640414.2013.865252
   Li ZB, 2008, J BIOL CHEM, V283, P19371, DOI 10.1074/jbc.M802585200
   LORD SR, 1994, J AM GERIATR SOC, V42, P1110, DOI 10.1111/j.1532-5415.1994.tb06218.x
   Lynch NA, 1999, J APPL PHYSIOL, V86, P188, DOI 10.1152/jappl.1999.86.1.188
   Maglischo EW., 2003, Swimming fastest
   McLeod TCV, 2011, J ATHL TRAINING, V46, P206, DOI 10.4085/1062-6050-46.2.206
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457
   Morissette MR, 2009, AM J PHYSIOL-CELL PH, V297, pC1124, DOI 10.1152/ajpcell.00043.2009
   Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079
   Nemet D, 2010, MED SPORT SCI, V55, P141, DOI 10.1159/000321978
   Nishi M, 2002, BIOCHEM BIOPH RES CO, V293, P247, DOI 10.1016/S0006-291X(02)00209-7
   Palles C, 2008, HUM MOL GENET, V17, P1457, DOI 10.1093/hmg/ddn034
   Patel AV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002578
   Philippou A., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P208
   POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609
   Rantanen T, 1997, J AM GERIATR SOC, V45, P1439, DOI 10.1111/j.1532-5415.1997.tb03193.x
   REED RL, 1991, J AM GERIATR SOC, V39, P555, DOI 10.1111/j.1532-5415.1991.tb03592.x
   Ríos R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001
   Santiago C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016323
   Scheinowitz M, 2003, GROWTH HORM IGF RES, V13, P19, DOI 10.1016/S1096-6374(02)00137-5
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Seibert MJ, 2001, J AM GERIATR SOC, V49, P1093, DOI 10.1046/j.1532-5415.2001.49214.x
   Sood S, 2012, EUR J APPL PHYSIOL, V112, P743, DOI 10.1007/s00421-011-2028-7
   STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486
   Sun G, 1999, INT J OBESITY, V23, P929, DOI 10.1038/sj.ijo.0801021
   Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200
   ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x
NR 63
TC 1
Z9 1
U1 0
U2 11
PU MEDICAL MEDIA
PI NETANYA
PA PO BOX 8214, NETANYA, 4250543, ISRAEL
SN 1565-4753
J9 PEDIATR ENDOCR REV P
JI Pediatr. Endocrinol. Rev. PER
PD JUN
PY 2016
VL 13
IS 4
BP 741
EP 748
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA DP4KF
UT WOS:000378464100006
PM 27464417
DA 2025-01-12
ER

PT J
AU Lin, FM
   Kumar, S
   Ren, J
   Karami, S
   Bahnassy, S
   Li, Y
   Zheng, XF
   Wang, J
   Bawa-Khalfe, T
AF Lin, Feng-Ming
   Kumar, Santosh
   Ren, Jing
   Karami, Samaneh
   Bahnassy, Shaymaa
   Li, Yue
   Zheng, Xiaofeng
   Wang, Jing
   Bawa-Khalfe, Tasneem
TI SUMOylation of HP1α supports association with ncRNA to define
   responsiveness of breast cancer cells to chemotherapy
SO ONCOTARGET
LA English
DT Article
DE SUMO; SENP7; HP1 alpha; ncRNA; Rad51C
ID PERICENTRIC HETEROCHROMATIN; PROSTATE-CANCER; RNA-BINDING; PROTEIN;
   GENE; TRANSCRIPTION; EXPRESSION; HP1(HS-ALPHA); SUPPRESSION; RECRUITMENT
AB Epigenetic reprogramming allows cancer cells to bypass normal checkpoints and potentiate aberrant proliferation. Several chromatin regulators are subject to reversible SUMO-modification but little is known about how SUMOylation of chromatin-remodelers modulates the cancer epigenome. Recently, we demonstrated that SUMO-protease SENP7L is upregulated in aggressive BCa and maintains hypoSUMOylated heterochromatin protein 1-alpha (HP1 alpha). Canonical models define HP1 alpha as a "reader" of repressive H3K9m3 marks that supports constitutive heterochromatin. It is unclear how SUMOylation affects HP1 alpha function in BCa cells. This report shows HP1 alpha SUMO-dynamics are closely regulated in a complex with SENP7L and SUMO-E3 Polycomb-2 (PC2/CBX4). This complex accumulates at H3K9m3 sites, hypoSUMOylates HP1 alpha and PC2, and reduces PC2's SUMO-E3 activity. HyperSUMO conditions cause complex dissociation, SUMOylation of PC2 and HP1 alpha, and recruitment of SUMOylated HP1 alpha to multiple DNA-repair genes including Rad51C. SUMOylated HP1 alpha's enrichment at euchromatin requires chromatin-bound non-coding RNA (ncRNA), reduces Rad51C protein, and increases DNA-breaks in BCa cells. Hence, HP1 alpha SUMOylation and consistently low SENP7L increase efficacy of DNA-damaging chemotherapeutic agents. BCa patients on chemotherapy that express low SENP7L exhibit greater survival rates than patients with high SENP7L. Collectively, these studies suggest that SUMOylated HP1 alpha is a critical epigenetic-regulator of DNA-repair in BCa that could define chemotherapy responsiveness.
C1 [Lin, Feng-Ming] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA.
   [Kumar, Santosh; Ren, Jing; Karami, Samaneh; Bahnassy, Shaymaa; Bawa-Khalfe, Tasneem] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA.
   [Li, Yue] Univ Texas Houston, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX USA.
   [Zheng, Xiaofeng; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Houston System; University of Houston; University of Texas System;
   University of Texas Health Science Center Houston; University of Texas
   System; UTMD Anderson Cancer Center
RP Bawa-Khalfe, T (通讯作者)，Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA.
EM tbawa-khalfe@uh.edu
RI Bahnassy, Shaymaa/E-8130-2012
OI Bahnassy, Shaymaa/0000-0001-9882-4195; Karami,
   Samaneh/0000-0003-3174-5147
FU Center for Cancer Epigenetics at UT MD Anderson Cancer Center
FX This work was supported in part by the Innovative Pilot Award to TBK
   from the Center for Cancer Epigenetics at UT MD Anderson Cancer Center.
CR Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   Bawa-Khalfe T, 2007, J BIOL CHEM, V282, P37341, DOI 10.1074/jbc.M706978200
   Bawa-Khalfe T, 2012, P NATL ACAD SCI USA, V109, P17466, DOI 10.1073/pnas.1209378109
   Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748
   Bawa-Khalfe T, 2010, SUBCELL BIOCHEM, V54, P170, DOI 10.1007/978-1-4419-6676-6_14
   Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006
   Blume SW, 2003, J CELL BIOCHEM, V88, P165, DOI 10.1002/jcb.10326
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561
   Cheng JK, 2006, NEOPLASIA, V8, P667, DOI 10.1593/neo.06445
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   Deng Z, 2009, MOL CELL, V35, P403, DOI 10.1016/j.molcel.2009.06.025
   Eilebrecht Sebastian, 2010, BMC Res Notes, V3, P146, DOI 10.1186/1756-0500-3-146
   Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Garvin AJ, 2013, EMBO REP, V14, P975, DOI 10.1038/embor.2013.141
   Hayashi MT, 2009, NAT CELL BIOL, V11, P357, DOI 10.1038/ncb1845
   Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810
   Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682
   Kumar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067009
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Maison C, 2012, NAT STRUCT MOL BIOL, V19, P458, DOI 10.1038/nsmb.2244
   Maison C, 2011, NAT GENET, V43, P220, DOI 10.1038/ng.765
   Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519
   Merrill JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008794
   Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Panteleeva I, 2007, EMBO J, V26, P3616, DOI 10.1038/sj.emboj.7601789
   Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108
   Romeo K, 2015, CELL REPORTS
   Sampl S, 2012, TRANSL ONCOL, V5, P56, DOI 10.1593/tlo.11202
   Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241
   Stehmeier P, 2009, MOL CELL, V33, P400, DOI 10.1016/j.molcel.2009.01.013
   Tomikawa J, 2011, J BIOL CHEM, V286, P34788, DOI 10.1074/jbc.M111.275750
   Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145
   Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054
   Yang SH, 2010, MOL CELL BIOL, V30, P2193, DOI 10.1128/MCB.01510-09
   Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6
NR 41
TC 12
Z9 15
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 24
PY 2016
VL 7
IS 21
BP 30336
EP 30349
DI 10.18632/oncotarget.8733
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4IZ
UT WOS:000377746600038
PM 27107417
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Bouwmeester, MC
   Ruiter, S
   Lommelaars, T
   Sippel, J
   Hodemaekers, HM
   van den Brandhof, EJ
   Pennings, JLA
   Kamstra, JH
   Jelinek, J
   Issa, JPJ
   Legler, J
   van der Ven, LTM
AF Bouwmeester, Manon C.
   Ruiter, Sander
   Lommelaars, Tobias
   Sippel, Josefine
   Hodemaekers, Hennie M.
   van den Brandhof, Evert-Jan
   Pennings, Jeroen L. A.
   Kamstra, Jorke H.
   Jelinek, Jaroslav
   Issa, Jean-Pierre J.
   Legler, Juliette
   van der Ven, Leo T. M.
TI Zebrafish embryos as a screen for DNA methylation modifications after
   compound exposure
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Epigenetics; DNA methylation; Environmental contaminant exposure;
   Screening; Zebrafish embryo
ID BRAIN AROMATASE GENE; DANIO-RERIO EMBRYOS; BISPHENOL-A; ENVIRONMENTAL
   EXPOSURE; PROMOTER METHYLATION; HEALTH OUTCOMES; BREAST-CANCER;
   END-POINTS; EXPRESSION; EPIGENETICS
AB Modified epigenetic programming early in life is proposed to underlie the development of an adverse adult phenotype, known as the Developmental Origins of Health and Disease (DOHaD) concept. Several environmental contaminants have been implicated as modifying factors of the developing epigenome. This underlines the need to investigate this newly recognized toxicological risk and systematically screen for the epigenome modifying potential of compounds. In this study, we examined the applicability of the zebrafish embryo as a screening model for DNA methylation modifications. Embryos were exposed from 0 to 72 h post fertilization (hpf) to bisphenol-A (BPA), diethylstilbestrol, 17 alpha-ethynylestradiol, nickel, cadmium, tributyltin, arsenite, perfluoroctanoic acid, valproic acid, flusilazole, 5-azacytidine (5AC) in subtoxic concentrations. Both global and site-specific methylation was examined. Global methylation was only affected by 5AC. Genome wide locus-specific analysis was performed for BPA exposed embryos using Digital Restriction Enzyme Analysis of Methylation (DREAM), which showed minimal wide scale effects on the genome, whereas potential informative markers were not confirmed by pyrosequencing. Site-specific methylation was examined in the promoter regions of three selected genes vasa, vtg1 and cyp19a2, of which vasa (ddx4) was the most responsive. This analysis distinguished estrogenic compounds from metals by direction and sensitivity of the effect compared to embryotoxicity. In conclusion, the zebrafish embryo is a potential screening tool to examine DNA methylation modifications after xenobiotic exposure. The next step is to examine the adult phenotype of exposed embryos and to analyze molecular mechanisms that potentially link epigenetic effects and altered phenotypes, to support the DOHaD hypothesis. (C) 2015 Elsevier Inc All rights reserved.
C1 [Bouwmeester, Manon C.; Ruiter, Sander; Lommelaars, Tobias; Sippel, Josefine; Hodemaekers, Hennie M.; Pennings, Jeroen L. A.; van der Ven, Leo T. M.] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, POB 1, NL-3720 BA Bilthoven, Netherlands.
   [van den Brandhof, Evert-Jan] Natl Inst Publ Hlth & Environm RIVM, Ctr Environm Qual, POB 1, NL-3720 BA Bilthoven, Netherlands.
   [Kamstra, Jorke H.; Legler, Juliette] Vrije Univ Amsterdam, Inst Environm Studies IVM, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.
   [Jelinek, Jaroslav; Issa, Jean-Pierre J.] Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19122 USA.
   [Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
C3 Netherlands National Institute for Public Health & the Environment;
   Netherlands National Institute for Public Health & the Environment;
   Vrije Universiteit Amsterdam; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; University of Texas System; UTMD
   Anderson Cancer Center
RP van der Ven, LTM (通讯作者)，Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM leo.van.der.ven@rivm.nl
RI Jelinek, Jaroslav/O-6876-2019; Ruiter, Sander/LJM-5334-2024; Legler,
   Juliette/N-3393-2013; Kamstra, Jorke/K-9533-2013; Jelinek,
   Jaroslav/D-2282-2012
OI Issa, Jean-Pierre/0000-0003-2258-5030; Legler,
   Juliette/0000-0001-6321-1567; Kamstra, Jorke/0000-0001-7984-0229;
   Pennings, Jeroen L.A./0000-0002-9188-6358; Jelinek,
   Jaroslav/0000-0002-2533-0220
FU RIVM strategic research program [S/340007]; NWO [ASPASIA/864.09.005,
   VIDI/864.09.005]
FX This study has been performed by order and for the account of The
   Netherlands Food and Consumer Product Safety Authority (NVWA), and we
   thank Dr. Jacqueline JM Castenmiller (NVWA) for her active support. The
   study was further supported by the RIVM strategic research program,
   project S/340007. JK and JL were supported by NWO ASPASIA/864.09.005 and
   VIDI/864.09.005. We wish to acknowledge Hans Cremers, Wilmer Wamsteeker
   and Kevin van Dal (RIVM) for the technical support. We thank Wilma
   Steegenga and Carolien Lute of the Department Agrotechnology and Food
   Sciences of Wageningen University for using the pyrosequencing
   facilities.
CR Arita A, 2009, METALLOMICS, V1, P222, DOI 10.1039/b903049b
   Bailey Kathryn A, 2014, Curr Environ Health Rep, V1, P22
   Bakulski KM, 2012, CURR ALZHEIMER RES, V9, P563
   Chow WS, 2013, J APPL TOXICOL, V33, P670, DOI 10.1002/jat.2723
   Contractor RG, 2004, J TOXICOL ENV HEAL A, V67, P1, DOI 10.1080/15287390490253633
   Diotel N, 2010, FRONT NEUROENDOCRIN, V31, P172, DOI 10.1016/j.yfrne.2010.01.003
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang XF, 2013, ENVIRON TOXICOL PHAR, V36, P40, DOI 10.1016/j.etap.2013.02.014
   Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444
   FRIEDMAN S, 1979, BIOCHEM BIOPH RES CO, V89, P1328, DOI 10.1016/0006-291X(79)92154-5
   Gluckman PD, 2004, PEDIATR RES, V56, P311, DOI 10.1203/01.PDR.0000135998.08025.FB
   Gorelick DA, 2014, ENVIRON HEALTH PERSP, V122, P356, DOI 10.1289/ehp.1307329
   Greally JM, 2013, ALTEX-ALTERN ANIM EX, V30, P445, DOI 10.14573/altex.2013.4.445
   Hao RX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079020
   Hermsen SAB, 2011, TOXICOL IN VITRO, V25, P745, DOI 10.1016/j.tiv.2011.01.005
   Ho SM, 2012, ILAR J, V53, P289, DOI 10.1093/ilar.53.3-4.289
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005
   Jelinek J, 2012, EPIGENETICS-US, V7, P1368, DOI 10.4161/epi.22552
   Ji WD, 2008, CARCINOGENESIS, V29, P1267, DOI 10.1093/carcin/bgn012
   Jiang L, 2013, CELL, V153, P773, DOI 10.1016/j.cell.2013.04.041
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kamstra J.H., 2014, ENV SCI POLLUT RES I
   Kamstra JH, 2015, ZEBRAFISH, V12, P230, DOI 10.1089/zeb.2014.1033
   Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Le Page Y, 2008, MOL REPROD DEV, V75, P1549, DOI 10.1002/mrd.20892
   Li D, 2009, AQUAT TOXICOL, V91, P229, DOI 10.1016/j.aquatox.2008.11.007
   Li MY, 2013, BIOCHIMIE, V95, P850, DOI 10.1016/j.biochi.2012.12.003
   Li X, 2011, J STEROID BIOCHEM, V127, P9, DOI 10.1016/j.jsbmb.2011.03.012
   Li Y, 2014, ENVIRON HEALTH PERSP, V122, P262, DOI 10.1289/ehp.1307351
   Lindeman LC, 2010, INT J DEV BIOL, V54, P803, DOI 10.1387/ijdb.103081ll
   MacKay AB, 2007, GENOME, V50, P778, DOI 10.1139/G07-055
   Marsit CJ, 2015, J EXP BIOL, V218, P71, DOI 10.1242/jeb.106971
   Menuet A, 2005, J COMP NEUROL, V485, P304, DOI 10.1002/cne.20497
   Mhanni AA, 2004, DEV GENES EVOL, V214, P412, DOI 10.1007/s00427-004-0418-0
   Mitsui N, 2007, COMP BIOCHEM PHYS C, V146, P581, DOI 10.1016/j.cbpc.2007.07.004
   Nagasawa K, 2013, MOL REPROD DEV, V80, P118, DOI 10.1002/mrd.22142
   Newman MR, 2012, EPIGENETICS-US, V7, P92, DOI 10.4161/epi.7.1.18815
   OECD, 2002, OECD SER TEST ASS
   Olsvik PA, 2014, COMP BIOCHEM PHYS C, V165, P17, DOI 10.1016/j.cbpc.2014.05.004
   Potok ME, 2013, CELL, V153, P759, DOI 10.1016/j.cell.2013.04.030
   Quinlivan EP, 2008, ANAL BIOCHEM, V373, P383, DOI 10.1016/j.ab.2007.09.031
   Rasoulpour RJ, 2011, TOXICOL MECH METHOD, V21, P298, DOI 10.3109/15376516.2011.557883
   Reed CE, 2013, BIRTH DEFECTS RES C, V99, P134, DOI 10.1002/bdrc.21035
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Schmidt K, 2004, J EXP ZOOL PART B, V302B, P446, DOI 10.1002/jez.b.21010
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Slob W, 2002, TOXICOL SCI, V66, P298, DOI 10.1093/toxsci/66.2.298
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Strömqvist M, 2010, AQUAT TOXICOL, V98, P275, DOI 10.1016/j.aquatox.2010.02.023
   Sun H, 2013, GENES-BASEL, V4, P583, DOI 10.3390/genes4040583
   Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4
   Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4
   Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308
   Tian MP, 2012, TOXICOLOGY, V296, P48, DOI 10.1016/j.tox.2012.03.003
   Tung EWY, 2010, TOXICOL APPL PHARM, V248, P201, DOI 10.1016/j.taap.2010.08.001
   Urvalek AM, 2014, J BIOL CHEM, V289, P19519, DOI 10.1074/jbc.M114.556555
   Vaiserman A, 2014, AGING DIS, V5, P419, DOI 10.14336/AD.2014.0500419
   van Esterik JCJ, 2015, TOXICOL LETT, V232, P293, DOI 10.1016/j.toxlet.2014.10.021
   van Esterik JCJ, 2014, TOXICOLOGY, V321, P40, DOI 10.1016/j.tox.2014.04.001
   Wang B, 2012, CURR MED CHEM, V19, P2611, DOI 10.2174/092986712800492913
   Wang GY, 2013, J ADOLESCENT HEALTH, V52, pS14, DOI 10.1016/j.jadohealth.2012.04.019
   Wang H, 2005, GENE, V356, P91, DOI 10.1016/j.gene.2005.03.041
   Woldemichael BT, 2014, PROG MOL BIOL TRANSL, V122, P305, DOI 10.1016/B978-0-12-420170-5.00011-8
   World Health Organization, 2014, Noncommunicable diseases (NCD) country profiles: South Africa
   Xu N, 2014, MOL ENDOCRINOL, V28, P1329, DOI 10.1210/me.2014-1042
   Zelic R, 2015, PROSTATE CANCER P D, V18, P1, DOI 10.1038/pcan.2014.45
   Zhong LQ, 2014, AQUAT TOXICOL, V149, P1, DOI 10.1016/j.aquatox.2014.01.022
NR 71
TC 50
Z9 57
U1 1
U2 54
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JAN 15
PY 2016
VL 291
BP 84
EP 96
DI 10.1016/j.taap.2015.12.012
PG 13
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA DO9IO
UT WOS:000378100100009
PM 26712470
DA 2025-01-12
ER

PT J
AU Lu, YJ
   Liu, YQ
   Liao, SY
   Tu, WL
   Shen, Y
   Yan, YL
   Tao, DC
   Lu, YL
   Ma, YX
   Yang, Y
   Zhang, SZ
AF Lu, Yongjie
   Liu, Yunqiang
   Liao, Shunyao
   Tu, Wenling
   Shen, Ying
   Yan, Yuanlong
   Tao, Dachang
   Lu, Yilu
   Ma, Yongxin
   Yang, Yuan
   Zhang, Sizhong
TI Epigenetic modifications promote the expression of the orphan nuclear
   receptor NR0B1 in human lung adenocarcinoma cells
SO ONCOTARGET
LA English
DT Article
DE NR0B1; lung adenocarcinoma; DNA methylation; histone modifications; cell
   self-renewal
ID EMBRYONIC STEM-CELLS; TRANSCRIPTIONAL COACTIVATOR CBP; HISTONE LYSINE
   METHYLATION; BREAST-CANCER; DNA HYPOMETHYLATION; PROGNOSTIC-FACTOR;
   PROSTATE-CANCER; DAX1; ESTROGEN; BETA
AB The ectopic activation of NR0B1 is involved in the development of some cancers. However, the regulatory mechanisms controlling NR0B1 expression are not well understood. Therefore, the epigenetic modifications promoting NR0B1 activation were examined in this study. NR0B1 protein was detected in cancerous tissues of more than 50% of human lung adenocarcinoma (ADCA) cases and tended to be expressed in low-differentiated cancerous tissues obtained from males. Nevertheless, NR0B1 activation in ADCA has not previously been correlated with DNA demethylation. NR0B1 expression was not detected in 293T cells, although it contains a hypomethylated NR0B1 promoter. Treating 293T cells with a histone deacetylase inhibitor increased acetylated histone H4 binding to the NR0B1 promoter and activated NR0B1 expression. In contrast, treatment with histone methylase inhibitors decreased the methylation of histones H3K9 and H3K27 and slightly induced NR0B1 transcription. Furthermore, the level of acetyl-histone H4 binding to the NR0B1 promoter increased, whereas the occupancy of H3K27me3 was lower in cancerous tissues than in non-cancerous tissues. Similar histone occupancies were confirmed in a comparison of cancerous tissues with strong, moderate and negative NR0B1 expression. In conclusion, this study shows that CpG methylation within the NR0B1 promoter is not involved in the in vivo regulation of NR0B1 expression, whereas the hyperacetylation of histone H4 and the unmethylation of histones H3K9 and H3K27, and their binding to the NR0B1 promoter results in decondensed euchromatin for NR0B1 activation.
C1 [Lu, Yongjie; Liu, Yunqiang; Tu, Wenling; Shen, Ying; Yan, Yuanlong; Tao, Dachang; Lu, Yilu; Ma, Yongxin; Yang, Yuan; Zhang, Sizhong] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Genet, Chengdu, Sichuan Provinc, Peoples R China.
   [Lu, Yongjie; Liu, Yunqiang; Tu, Wenling; Shen, Ying; Yan, Yuanlong; Tao, Dachang; Lu, Yilu; Ma, Yongxin; Yang, Yuan; Zhang, Sizhong] Sichuan Univ, West China Med Sch, West China Hosp, Div Human Morbid Genom,State Key Lab Biotherapy, Chengdu, Sichuan Provinc, Peoples R China.
   [Liao, Shunyao] Sichuan Acad Med Sci, Ctr Diabet, Chengdu, Sichuan Provinc, Peoples R China.
   [Liao, Shunyao] Sichuan Acad Med Sci, Inst Transplantat, Chengdu, Sichuan Provinc, Peoples R China.
   [Liao, Shunyao] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu, Sichuan Provinc, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan Provincial People's
   Hospital; Sichuan Provincial People's Hospital; University of Electronic
   Science & Technology of China; Sichuan Provincial People's Hospital
RP Liu, YQ (通讯作者)，Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Genet, Chengdu, Sichuan Provinc, Peoples R China.; Liu, YQ (通讯作者)，Sichuan Univ, West China Med Sch, West China Hosp, Div Human Morbid Genom,State Key Lab Biotherapy, Chengdu, Sichuan Provinc, Peoples R China.
EM yq_liu@scu.edu.cn
RI ma, yongxin/KHT-7878-2024; Liao, Shunyao/M-4123-2018; shen,
   ying/HHS-5635-2022
OI yang, yuan/0000-0002-9206-0312; Liu, Yunqiang/0000-0001-7691-7630
FU National Natural Science Foundation of China [81370748, 81471430]
FX This work was supported by research grants from the National Natural
   Science Foundation of China (81370748 and 81471430).
CR Abd-Elaziz M, 2003, CANCER SCI, V94, P980, DOI 10.1111/j.1349-7006.2003.tb01388.x
   Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Fujii S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09146
   Guo W, 2014, ONCOTARGET, V5, P9349, DOI 10.18632/oncotarget.2430
   Honda S, 2015, P NATL ACAD SCI USA, V112, pE3816, DOI 10.1073/pnas.1510077112
   Hoyle C, 2002, MOL ENDOCRINOL, V16, P747, DOI 10.1210/me.16.4.747
   Ishibashi H, 2005, CANCER RES, V65, P6450, DOI 10.1158/0008-5472.CAN-04-3087
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x
   Jiang HL, 2014, CELL PHYSIOL BIOCHEM, V34, P734, DOI 10.1159/000363038
   Kelly VR, 2011, MOL CELL ENDOCRINOL, V332, P116, DOI 10.1016/j.mce.2010.10.003
   Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039
   Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lanzino M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.235
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Martins RST, 2013, GENE, V530, P66, DOI 10.1016/j.gene.2013.07.052
   Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nakamura Y, 2009, ENDOCR J, V56, P39, DOI 10.1507/endocrj.K08E-177
   Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140
   Nandy SB, 2015, FUTURE ONCOL, V11, P983, DOI [10.2217/fon.14.301, 10.2217/FON.14.301]
   Niakan KK, 2006, MOL GENET METAB, V88, P261, DOI 10.1016/j.ymgme.2005.12.010
   Niakan KK, 2005, MOL GENET METAB, V86, P70, DOI 10.1016/j.ymgme.2005.07.019
   Oda T, 2009, AM J PATHOL, V175, P1235, DOI 10.2353/ajpath.2009.090010
   Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Plotnikov AN, 2014, STRUCTURE, V22, P353, DOI 10.1016/j.str.2013.10.021
   Qin Y, 2015, ONCOTARGET, V6, P27130, DOI 10.18632/oncotarget.4825
   Rao M, 2011, CANCER RES, V71, P4192, DOI 10.1158/0008-5472.CAN-10-2442
   Ren X, 2015, J STEROID BIOCHEM, V150, P54, DOI 10.1016/j.jsbmb.2015.03.010
   Saito S, 2005, CANCER SCI, V96, P645, DOI 10.1111/j.1349-7006.2005.00101.x
   Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200
   Stabile LP, 2002, CANCER RES, V62, P2141
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sun C, 2008, BIOCHEM BIOPH RES CO, V372, P91, DOI 10.1016/j.bbrc.2008.04.154
   Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tang ZP, 2016, MOL ONCOL, V10, P317, DOI 10.1016/j.molonc.2015.10.015
   Uranishi K, 2013, MOL CELL BIOL, V33, P2056, DOI 10.1128/MCB.01520-12
   Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673
   Wan JH, 2015, NUCLEIC ACIDS RES, V43, P3591, DOI 10.1093/nar/gkv238
   Zhang H, 2011, ANTICANCER RES, V31, P443
   Zhang JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6042
NR 45
TC 8
Z9 8
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 12
PY 2016
VL 7
IS 28
BP 43162
EP 43176
DI 10.18632/oncotarget.9012
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8QU
UT WOS:000385395700025
PM 27281610
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, LH
   Hsu, WL
   Tseng, YJ
   Liu, DW
   Weng, CF
AF Chen, Li-Hsuen
   Hsu, Wen-Lin
   Tseng, Yen-Ju
   Liu, Dai-Wei
   Weng, Ching-Feng
TI Involvement of DNMT 3B promotes epithelial-mesenchymal transition and
   gene expression profile of invasive head and neck squamous cell
   carcinomas cell lines
SO BMC CANCER
LA English
DT Article
DE Head and neck cancer; Invasion; EMT; DNMT; miR-29b
ID TUMOR-SUPPRESSOR GENE; DE-NOVO METHYLATION; TENASCIN-C; TGF-BETA;
   CANCER-CELLS; DNA METHYLTRANSFERASES; BREAST-CANCER;
   HUMAN-PAPILLOMAVIRUS; PROTEIN EXPRESSION; PROLINE OXIDASE
AB Background: The 5-year overall survival rates for head and neck cancer (HNC) relies on distant metastasis. Importantly, the epithelial-mesenchymal transition (EMT) is believed to be an initial step of metastasis. However, the relationship of epigenetic with EMT formation is still unexplored in HNC. This study focuses on invasive subclones of HNC cell lines through the simulation of invasion in vitro; and underlying mechanisms were analyzed including DNA methylation and gene expression profile.
   Methods: Invasive subclones of NHC cell lines were successfully obtained using transwell coated with Matrixgel. Cells invaded through 8 mu m pore several times were subcultured and examined with EMT features including morphology, EMT marker genes expression, and invasive ability. Moreover, compared the profile of genes expression in parental and invasive cells was analyzed using mRNA expression array.
   Results: DNA methyltransferase 3B (DNMT 3B) was upregulated in invasive subclones and might control the 5' region of E-cadherin (E-cad) methylation and further inhibited E-cad protein expression. Interference of DNMT 3B by siRNA or miRNA 29b could reduce EMT and cell invasion. Expression array analysis revealed the most possible involved pathways in cell invasion including arginine and proline metabolism, TGF-beta, and focal adhesion.
   Conclusions: DNMT 3B might control EMT by DNA methylation manner in invasive HNC cell lines. Moreover, miR-29b mimic downregulated DNMT 3B and inhibited EMT and cell invasion indicated the role of therapeutic agent for invasive HNC. Genes identified from array data and new molecules are involved in metastasis of HNC need further validation.
C1 [Chen, Li-Hsuen; Tseng, Yen-Ju; Weng, Ching-Feng] Natl Dong Hwa Univ, Dept Life Sci, Hualien, Taiwan.
   [Chen, Li-Hsuen; Tseng, Yen-Ju; Weng, Ching-Feng] Natl Dong Hwa Univ, Inst Biotechnol, Hualien, Taiwan.
   [Hsu, Wen-Lin; Tseng, Yen-Ju; Liu, Dai-Wei] Buddhist Tzu Chi Gen Hosp, Dept Radiat Oncol, Hualien, Taiwan.
   [Hsu, Wen-Lin; Liu, Dai-Wei] Tzu Chi Univ, Sch Med, Hualien, Taiwan.
C3 National Dong Hwa University; National Dong Hwa University; Buddhist Tzu
   Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University
RP Weng, CF (通讯作者)，Natl Dong Hwa Univ, Dept Life Sci, Hualien, Taiwan.; Weng, CF (通讯作者)，Natl Dong Hwa Univ, Inst Biotechnol, Hualien, Taiwan.; Liu, DW (通讯作者)，Buddhist Tzu Chi Gen Hosp, Dept Radiat Oncol, Hualien, Taiwan.
EM dwliu5177@yahoo.com.tw; cfweng@mail.ndhu.edu.tw
OI Weng, Ching-Feng/0000-0002-9747-8697
FU Buddhist Tzu Chi General Hospital [TCRD 100-28, TCRD 101-18]
FX This work was supported by grants from the Buddhist Tzu Chi General
   Hospital (TCRD 100-28 & TCRD 101-18).
CR Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854
   BOYER B, 1993, APMIS, V101, P257, DOI 10.1111/j.1699-0463.1993.tb00109.x
   Brambert PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117310
   Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chang HW, 2002, CANCER, V94, P386, DOI 10.1002/cncr.10211
   Chang KT, 2009, J STRUCT BIOL, V167, P200, DOI 10.1016/j.jsb.2009.06.005
   Chen L, 2015, MED IMAGE ANAL, V23, P1, DOI 10.1016/j.media.2015.03.004
   Chen SY, 2014, ARCH BIOCHEM BIOPHYS, V555, P1, DOI 10.1016/j.abb.2014.05.004
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837
   Cortez MA, 2010, GENE CHROMOSOME CANC, V49, P981, DOI 10.1002/gcc.20808
   Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V
   De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Flavin R, 2009, INT J GYNECOL CANCER, V19, P641, DOI 10.1111/IGC.0b013e3181a48cf9
   Freedman ND, 2007, BRIT J CANCER, V96, P1469, DOI 10.1038/sj.bjc.6603713
   Gandini S, 2008, INT J CANCER, V122, P155, DOI 10.1002/ijc.23033
   Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006
   GRINNELL F, 1981, J INVEST DERMATOL, V76, P181, DOI 10.1111/1523-1747.ep12525694
   Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4
   Hameed R, 2015, CANC CELL MICROENVIR, V2, pe847
   Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367
   Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179
   Hashimoto Y, 2007, MOL BIOL CELL, V18, P4591, DOI 10.1091/mbc.E07-02-0157
   Hay ED, 1995, ACTA ANAT, V154, P8
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V85, P1
   Ibarra N, 2005, BIOCHEM SOC T, V33, P1243, DOI 10.1042/BST0331243
   Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105
   Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714
   Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jinnin M, 2004, ONCOGENE, V23, P1656, DOI 10.1038/sj.onc.1207064
   Junghans D, 2005, CURR OPIN CELL BIOL, V17, P446, DOI 10.1016/j.ceb.2005.08.008
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2
   Kim SK, 1996, CANCER RES, V56, P2519
   Kinoshita T, 2013, BRIT J CANCER, V109, P2636, DOI 10.1038/bjc.2013.607
   Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B
   Li H, 2011, J BIOL CHEM, V286, P21500, DOI 10.1074/jbc.M110.207951
   Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006
   Lin TS, 2005, CANCER LETT, V226, P77, DOI 10.1016/j.canlet.2004.12.031
   Lingen MW, 2011, ORAL DIS, V17, P7, DOI 10.1111/j.1601-0825.2011.01789.x
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   Liu W, 2010, ONCOGENE, V29, P4914, DOI 10.1038/onc.2010.237
   Liu W, 2012, BIOFACTORS, V38, P398, DOI 10.1002/biof.1036
   Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Melo SA, 2013, NAT CELL BIOL, V15, P139, DOI 10.1038/ncb2684
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x
   Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017
   Ostler K, 2007, ONCOGENE, V26, P5553, DOI 10.1038/sj.onc.1210351
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Park J, 2014, ONCOGENE, V33, P1649, DOI 10.1038/onc.2013.118
   Phang JM, 2008, PPAR RES, V2008, DOI 10.1155/2008/542694
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rothschild SI, 2012, ONCOGENE, V31, P4221, DOI 10.1038/onc.2011.578
   Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013
   Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0
NR 87
TC 40
Z9 40
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 8
PY 2016
VL 16
AR 431
DI 10.1186/s12885-016-2468-x
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DR4XJ
UT WOS:000379906500001
PM 27391030
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pefani, DE
   Pankova, D
   Abraham, AG
   Grawenda, AM
   Vlahov, N
   Scrace, S
   Neill, EO
AF Pefani, Dafni-Eleftheria
   Pankova, Daniela
   Abraham, Aswin G.
   Grawenda, Anna M.
   Vlahov, Nikola
   Scrace, Simon
   Neill, Eric O'
TI TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2
   Nuclear Translocation
SO MOLECULAR CELL
LA English
DT Article
ID BREAST-CANCER CELLS; DNA METHYLATION; EXPRESSION LEVELS; DEPENDENT
   MANNER; GROWTH; YAP; TUMORIGENESIS; ACTIVATION; CARCINOMA; INVASION
AB Epigenetic inactivation of the Hippo pathway scaffold RASSF1A is associated with poor prognosis in a wide range of sporadic human cancers. Loss of expression reduces tumor suppressor activity and promotes genomic instability, but how this pleiotropic biomarker is regulated at the protein level is unknown. Here we show that TGF-beta is the physiological signal that stimulates RASSF1A degradation by the ubiquitin-proteasome pathway. In response to TGF-beta, RASSF1A is recruited to TGF-beta receptor I and targeted for degradation by the co-recruited E3 ubiquitin ligase ITCH. RASSF1A degradation is necessary to permit Hippo pathway effector YAP1 association with SMADs and subsequent nuclear translocation of receptor-activated SMAD2. We find that RASSF1A expression regulates TGF-beta-induced YAP1/SMAD2 interaction and leads to SMAD2 cytoplasmic retention and inefficient transcription of TGF-beta targets genes. Moreover, RASSF1A limits TGF-beta induced invasion, offering a new framework on how RASSF1A affects YAP1 transcriptional output and elicits its tumor-suppressive function.
C1 [Pefani, Dafni-Eleftheria; Pankova, Daniela; Abraham, Aswin G.; Grawenda, Anna M.; Vlahov, Nikola; Scrace, Simon; Neill, Eric O'] Univ Oxford, CRUK MRC Inst Radiat Oncol, Oxford OX3 7DQ, England.
   [Pefani, Dafni-Eleftheria; Pankova, Daniela; Abraham, Aswin G.; Grawenda, Anna M.; Vlahov, Nikola; Scrace, Simon; Neill, Eric O'] Univ Oxford, Dept Oncol, Oxford OX3 7DQ, England.
C3 University of Oxford; University of Oxford
RP Neill, EO (通讯作者)，Univ Oxford, CRUK MRC Inst Radiat Oncol, Oxford OX3 7DQ, England.; Neill, EO (通讯作者)，Univ Oxford, Dept Oncol, Oxford OX3 7DQ, England.
EM eric.oneill@oncology.ox.ac.uk
OI Abraham, Aswin George/0000-0003-0024-3339
FU Cancer Research UK [A19277]
FX The authors would like to thank Pamela Rabbits and Andy Ryan for
   providing cell lines; Annie Angers, Jeff Wrana, and Alex Bullock for
   providing constructs; and Maria Laura Tognoli for useful comments on the
   manuscript. This work was funded by Cancer Research UK A19277.
CR Ahn EY, 2013, MOL CANCER RES, V11, P748, DOI 10.1158/1541-7786.MCR-12-0665
   Alarcón C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035
   Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021
   Bhaskaran N, 2008, PROTEOMICS, V8, P4507, DOI 10.1002/pmic.200700960
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Bilgrami SM, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-178
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696
   Colón-González F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001
   David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009
   Dubois F, 2016, CANCER RES, V76, P1627, DOI 10.1158/0008-5472.CAN-15-1008
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07
   Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653
   Grawenda AM, 2015, BRIT J CANCER, V113, P372, DOI 10.1038/bjc.2015.221
   Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040
   Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115
   Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494
   Korah R, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-87
   Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079
   Lee MG, 2016, CANCER RES, V76, P1847, DOI 10.1158/0008-5472.CAN-15-1752
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369
   Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Pastuszak-Lewandoska D, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0230-6
   Pefani DE, 2016, FEBS J, V283, P1392, DOI 10.1111/febs.13604
   Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035
   Salah Z, 2011, CANCER RES, V71, P2010, DOI 10.1158/0008-5472.CAN-10-3516
   Schmierer B, 2008, P NATL ACAD SCI USA, V105, P6608, DOI 10.1073/pnas.0710134105
   Song MS, 2008, ONCOGENE, V27, P3176, DOI 10.1038/sj.onc.1210971
   Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200
   Suryaraja R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.91
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   van der Weyden L, 2012, CANCER RES, V72, P3817, DOI 10.1158/0008-5472.CAN-11-3343
   van Eijk KR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-636
   Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748
   Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012
   Vlahov N, 2015, CURR BIOL, V25, P3019, DOI 10.1016/j.cub.2015.09.072
   WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092
   Xie SP, 2005, AM J PHYSIOL-LUNG C, V288, pL68, DOI 10.1152/ajplung.00156.2004
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5
   Yee KS, 2012, CANCER RES, V72, P2206, DOI 10.1158/0008-5472.CAN-11-2906
   Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
NR 47
TC 113
Z9 126
U1 1
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JUL 7
PY 2016
VL 63
IS 1
BP 156
EP 166
DI 10.1016/j.molcel.2016.05.012
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DT6UC
UT WOS:000381618700016
PM 27292796
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Aghagolzadeh, P
   Radpour, R
AF Aghagolzadeh, Parisa
   Radpour, Ramin
TI New trends in molecular and cellular biomarker discovery for colorectal
   cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Colorectal cancer; Biomarkers; Cancer diagnosis; Cancer therapy;
   Predictive marker; Prognostic marker
ID ISLAND METHYLATOR PHENOTYPE; GENE-EXPRESSION PATTERNS; CIRCULATING
   MUTANT-DNA; ABERRANT CRYPT FOCI; MICROSATELLITE INSTABILITY;
   BREAST-CANCER; TELOMERE LENGTH; PROMOTER HYPERMETHYLATION; SOMATIC
   MUTATION; FECAL DNA
AB Colorectal cancer (CRC) is the third leading cause of cancer death worldwide, which is consequence of multistep tumorigenesis of several genetic and epigenetic events. Since CRC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches, selection of appropriate therapeutic strategies and efficient follow-up programs are essential to reduce CRC mortalities. Biomarker discovery for CRC based on the personalized genotype and clinical information could facilitate the classification of patients with certain types and stages of cancer to tailor preventive and therapeutic approaches. These cancer-related biomarkers should be highly sensitive and specific in a wide range of specimen(s) (including tumor tissues, patients' fluids or stool). Reliable biomarkers which enable the early detection of CRC, can improve early diagnosis, prognosis, treatment response prediction, and recurrence risk. Advances in our understanding of the natural history of CRC have led to the development of different CRC associated molecular and cellular biomarkers. This review highlights the new trends and approaches in CRC biomarker discovery, which could be potentially used for early diagnosis, development of new therapeutic approaches and follow-up of patients.
C1 [Aghagolzadeh, Parisa; Radpour, Ramin] Univ Hosp Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Radpour, R (通讯作者)，Univ Hosp Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.
EM ramin.radpour@dkf.unibe.ch
RI Radpour, PD Dr. Ramin/J-4949-2014
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833; Aghagolzadeh, Dr.
   Parisa/0000-0002-1519-5790
CR Akagi Y, 2013, MOL CLIN ONCOL, V1, P582, DOI 10.3892/mco.2013.116
   [Anonymous], 2014, JAMA, V312, P2566, DOI 10.1001/jama.2014.15746
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Becker C, 2005, CELL CYCLE, V4, P217
   Berger F, 2013, THERANOSTICS, V3, P932, DOI 10.7150/thno.7445
   Béroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187
   Bisoffi M, 2006, INT J CANCER, V119, P2255, DOI 10.1002/ijc.22120
   BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0
   Böckelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Coppedè F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Craven B, 2015, INFLAMM BOWEL DIS, V21, P485, DOI 10.1097/MIB.0000000000000303
   Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   de la Chapelle A, 2009, INT J CANCER, V125, P1492, DOI 10.1002/ijc.24491
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Dhaliwal A, 2015, WORLD J GASTRO ONCOL, V7, P178, DOI 10.4251/wjgo.v7.i10.178
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Diehl F, 2008, GASTROENTEROLOGY, V135, P489, DOI 10.1053/j.gastro.2008.05.039
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Duffy MJ, 2015, BIOMARK MED, V9, P337, DOI 10.2217/bmm.15.3
   Ebos JML, 2008, CANCER RES, V68, P521, DOI 10.1158/0008-5472.CAN-07-3217
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2000, CANCER RES, V60, P4366
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fransén K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049
   Frattini M, 2006, ANN NY ACAD SCI, V1075, P185, DOI 10.1196/annals.1368.025
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Gerger A, 2011, CANCER J, V17, P134, DOI 10.1097/PPO.0b013e318212db3c
   Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160
   Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798
   González-González M, 2013, CANCER GENOM PROTEOM, V10, P19
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Haghighi MM, 2014, GENET TEST MOL BIOMA, V18, P236, DOI 10.1089/gtmb.2013.0436
   Haghighi MM, 2009, INT J COLORECTAL DIS, V24, P885, DOI 10.1007/s00384-009-0731-1
   Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018
   Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275
   HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7
   HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0
   Hawk ET, 2002, SURG CLIN N AM, V82, P905, DOI 10.1016/S0039-6109(02)00046-4
   Heaphy CM, 2007, CLIN CANCER RES, V13, P7037, DOI 10.1158/1078-0432.CCR-07-0432
   Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031
   Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007
   Hundt S, 2007, CANCER EPIDEM BIOMAR, V16, P1935, DOI 10.1158/1055-9965.EPI-06-0994
   Huynh C, 2011, ONCOGENE, V30, P1481, DOI 10.1038/onc.2010.523
   Itzkowitz SH, 2002, GASTROENTEROL CLIN N, V31, P1133, DOI 10.1016/S0889-8553(02)00047-X
   Kane MF, 1997, CANCER RES, V57, P808
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kim MS, 2011, J CELL BIOL, V195, P815, DOI 10.1083/jcb.201106131
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243
   Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278
   KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011
   Lazarev I, 2014, IN VIVO, V28, P349
   Lee HS, 2013, TRANSL ONCOL, V6, P290, DOI 10.1593/tlo.13118
   Lefebure B, 2010, ANN SURG, V251, P275, DOI 10.1097/SLA.0b013e3181c35c87
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x
   Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100
   Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2
   Li Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep07097
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Liu GH, 2013, TUMOR BIOL, V34, P2175, DOI 10.1007/s13277-013-0753-8
   Liu H, 2013, INT J COLORECTAL DIS, V28, P697, DOI 10.1007/s00384-013-1674-0
   Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma WH, 2015, ONCOTARGET, V6, P15984, DOI 10.18632/oncotarget.3762
   Ma YL, 2012, GUT, V61, P1447, DOI 10.1136/gutjnl-2011-301122
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9
   Meeker AK, 2004, AM J PATHOL, V164, P925, DOI 10.1016/S0002-9440(10)63180-X
   Mehta RS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju016
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Monzo M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000145
   Muraki K, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00135
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565
   O'Sullivan J, 2006, CANCER EPIDEM BIOMAR, V15, P573, DOI 10.1158/1055-9965.EPI-05-0542
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Osborn NK, 2005, GASTROENTEROLOGY, V128, P192, DOI 10.1053/j.gastro.2004.10.041
   Otori K, 1998, CANCER, V83, P896, DOI 10.1002/(SICI)1097-0142(19980901)83:5<896::AID-CNCR14>3.0.CO;2-Q
   Perilli L, 2014, ONCOTARGET, V5, P6611, DOI 10.18632/oncotarget.2245
   Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6
   Pu XX, 2010, J GASTROEN HEPATOL, V25, P1674, DOI 10.1111/j.1440-1746.2010.06417.x
   Qi J, 2006, WORLD J GASTROENTERO, V12, P7113, DOI 10.3748/wjg.v12.i44.7113
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027355
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Radpour R, 2009, GENET TEST MOL BIOMA, V13, P565, DOI 10.1089/gtmb.2009.0060
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237
   Raynaud CM, 2008, ANN ONCOL, V19, P1875, DOI 10.1093/annonc/mdn405
   Rial NS, 2012, EXPERT REV GASTROENT, V6, P507, DOI [10.1586/EGH.12.23, 10.1586/egh.12.23]
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Santini D, 2008, ONCOLOGIST, V13, P1270, DOI 10.1634/theoncologist.2008-0181
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Schwarzenbach H, 2008, ANN NY ACAD SCI, V1137, P190, DOI 10.1196/annals.1448.025
   Sinicrope FA, 2015, CLIN CANCER RES, V21, P5294, DOI 10.1158/1078-0432.CCR-15-0527
   Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73
   Suzuki H, 2014, BIOCHEM BIOPH RES CO, V455, P35, DOI 10.1016/j.bbrc.2014.07.007
   Takagi S, 1999, CANCER, V86, P1431, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1431::AID-CNCR7>3.0.CO;2-R
   Tan SH, 2007, ONCOL REP, V18, P1225
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Tsai HL, 2015, INT J CLIN EXP PATHO, V8, P1900
   Utting M, 2002, CLIN CANCER RES, V8, P35
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186
   Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weissmann-Brenner A, 2012, INT J ONCOL, V40, P2097, DOI 10.3892/ijo.2012.1403
   Whiffin N, 2014, HUM MOL GENET, V23, P4729, DOI 10.1093/hmg/ddu177
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592
   Wu WY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-30
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Zhang AJ, 2004, ONCOGENE, V23, P7441, DOI 10.1038/sj.onc.1207527
   Zhou B, 2014, CANCER CAUSE CONTROL, V25, P1397, DOI 10.1007/s10552-014-0445-8
   Zou HZ, 2009, GASTROENTEROLOGY, V136, P459, DOI 10.1053/j.gastro.2008.10.023
NR 138
TC 59
Z9 63
U1 0
U2 12
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 7
PY 2016
VL 22
IS 25
BP 5678
EP 5693
DI 10.3748/wjg.v22.i25.5678
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DS4PV
UT WOS:000380763900006
PM 27433083
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Chen, Q
   Zheng, PS
   Yang, WT
AF Chen, Qian
   Zheng, Peng-Sheng
   Yang, Wen-Ting
TI EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin
   signaling-dependent cell expansion in cervical carcinoma
SO ONCOTARGET
LA English
DT Article
DE EZH2; cervical cancer; proliferation; Wnt/beta-catenin signaling; GSK3
   beta and TP53
ID ZESTE HOMOLOG 2; GROUP PROTEIN EZH2; BREAST-CANCER; DEVELOPMENTAL
   REGULATORS; INCREASED EXPRESSION; COLORECTAL-CANCER; SOMATIC MUTATIONS;
   DOWN-REGULATION; POLYCOMB; ENHANCER
AB Enhancer of zeste homolog 2 (EZH2), a catalytic core component of the Polycomb repressive complex 2 (PRC2), stimulates the silencing of target genes through histone H3 lysine 27 trimethylation (H3K27me3). Recent findings have indicated EZH2 is involved in the development and progression of various human cancers. However, the exact mechanism of EZH2 in the promotion of cervical cancer is largely unknown. Here, we show that EZH2 expression gradually increases during the progression of cervical cancer. We identified a significant positive correlation between EZH2 expression and cell proliferation in vitro and tumor formation in vivo by the up-regulation or down regulation of EZH2 using CRISPR-Cas9-mediated gene editing technology and shRNA in HeLa and SiHa cells. Further investigation indicated that EZH2 protein significantly accelerated the cell cycle transition from the G0/G1 to S phase. TOP/FOP-Flash reporter assay revealed that EZH2 significantly activated Wnt/beta-catenin signaling and the target genes of Wnt/beta-catenin pathway were up-regulated, including p-catenin, cyclin D1, and c-myc. Moreover, dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays confirmed that EZH2 inhibited the expression of glycogen synthase kinase-3 beta (GSK-3 beta) and TP53 through physically interacting with motifs in the promoters of the GSK-3 beta and TP53 genes. Additionally, blockage of the Wnt/beta-catenin pathway resulted in significant inhibition of cell proliferation, and activation of the Wnt/beta-catenin pathway resulted in significant enhancement of cell proliferation, as induced by EZH2. Taken together, our data demonstrate that EZH2 promotes cell proliferation and tumor formation in cervical cancer through activating the Wnt/beta-catenin pathway by epigenetic silencing via GSK-3 beta and TP53.
C1 [Chen, Qian; Zheng, Peng-Sheng; Yang, Wen-Ting] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China.
   [Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian, Peoples R China.
C3 Xi'an Jiaotong University
RP Zheng, PS; Yang, WT (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China.; Zheng, PS (通讯作者)，Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian, Peoples R China.
EM zpsheng@mail.xjtu.edu.cn; 04203031@stu.xjtu.edu.cn
RI Zheng, Pengsheng/F-7821-2013
FU National Natural Science Foundation of China [81472728]; National
   natural science foundation [81302278]
FX This Work was supported by a grant awarded to Prof. Peng-Sheng Zheng
   from the National Natural Science Foundation of China (No. 81472728) and
   a Young grant (No. 81302278) from the National natural science
   foundation to Wen-Ting Yang.
CR Andersson E, 2010, DEV DYNAM, V239, P237, DOI 10.1002/dvdy.22101
   [Anonymous], J PATHOL
   Bai J, 2014, CELL PROLIFERAT, V47, P211, DOI 10.1111/cpr.12103
   Barsotti AM, 2015, ONCOTARGET, V6, P2928, DOI 10.18632/oncotarget.2758
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen SQ, 2014, INT J GYNECOL CANCER, V24, P1653, DOI 10.1097/IGC.0000000000000273
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Ding MY, 2015, CLIN EXP PHARMACOL P, V42, P458, DOI 10.1111/1440-1681.12382
   Duffy DJ, 2014, MOL CANCER THER, V13, P454, DOI 10.1158/1535-7163.MCT-13-0560-T
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feng H, 2015, J HEPATOL, V62, P1100, DOI 10.1016/j.jhep.2014.11.040
   Fornaro L, 2012, ANN ONCOL, V23, P1370, DOI 10.1093/annonc/mds031
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jiang FZ, 2015, ONCOTARGET, V6, P44660, DOI 10.18632/oncotarget.6350
   Jin MF, 2015, ONCOL LETT, V10, P857, DOI 10.3892/ol.2015.3319
   Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Li Y, 2010, AM J HUM GENET, V86, P696, DOI 10.1016/j.ajhg.2010.03.004
   Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu X, 2014, ONCOTARGET, V5, P10870, DOI 10.18632/oncotarget.2539
   Liu Xiao-dong, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P1029
   Liu YY, 2014, INT J GYNECOL PATHOL, V33, P218, DOI 10.1097/PGP.0b013e31829c6574
   Lu H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.293
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Moore HM, 2013, BREAST CANCER RES TR, V138, P741, DOI 10.1007/s10549-013-2498-x
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Perez-Plasencia Carlos, 2008, Int Arch Med, V1, P10, DOI 10.1186/1755-7682-1-10
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sing A, 2009, CELL, V138, P885, DOI 10.1016/j.cell.2009.08.020
   Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Tiffen JC, 2015, ONCOTARGET, V6, P27023, DOI 10.18632/oncotarget.4809
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tseng RC, 2008, ONCOGENE, V27, P4488, DOI 10.1038/onc.2008.83
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wang HL, 2015, MOL MED REP, V12, P2503, DOI 10.3892/mmr.2015.3745
   Wang LW, 2003, CLIN CANCER RES, V9, P6371
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yuan JB, 2012, ASIAN PAC J CANCER P, V13, P6197, DOI 10.7314/APJCP.2012.13.12.6197
NR 61
TC 44
Z9 49
U1 0
U2 22
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 14
PY 2016
VL 7
IS 24
BP 36115
EP 36129
DI 10.18632/oncotarget.8741
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4MJ
UT WOS:000377756800049
PM 27092879
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Jia, LY
   Liu, W
   Cao, B
   Li, HL
   Yin, CG
AF Jia, Liyan
   Liu, Wei
   Cao, Bo
   Li, Hongli
   Yin, Chonggao
TI MiR-507 inhibits the migration and invasion of human breast-cancer cells
   through Flt-1 suppression
SO ONCOTARGET
LA English
DT Article
DE miR-507; Flt-1; molecular mechanism; invasion; PlGF-1
ID EPIGENETIC MECHANISMS; ACTIN POLYMERIZATION; METASTASIS; MICRORNAS;
   TARGET; PHOSPHORYLATION; MOTILITY; GROWTH; GLIOMA; EGF
AB Vascular endothelial growth factor receptor-1/fms-related tyrosine kinase-1 (VEGFR-1/Flt-1) is a tyrosine kinase receptor that binds placental growth factor (PlGF). Flt-1 is also highly expressed in breast-cancer tissues and breast-cancer cell lines. However, the molecular mechanism by which Flt-1 promotes breast-cancer invasion and metastasis by binding to PlGF-1 is unclear. In this study, we discovered that PlGF-1 and Flt-1 played a key role in the migration and invasion of breast cancer. Flt-1 promoted the migration and chemotaxis of breast-cancer cells by binding to PlGF-1. In addition, Flt-1 was confirmed to be a direct target gene of miR-507. miR-507 up-regulation inhibited the invasion and metastasis of breast-cancer cells in vitro and in vivo. Flt-1 overexpression rescued the invasion partially caused by the ectopic expression of miR-507. miR-507 expression in breast-cancer tissues and cell lines was lower than that in adjacent non-neoplastic tissues and normal cells. Clinical analysis indicated that miR-507 was negatively correlated with tumor differentiation, lymphatic metastasis, and the expression of Flt-1 in breast cancer. Furthermore, we showed that miR-507 down-regulation was due to the hypermethylation of its promotor region. Our results indicated that miR-507 represented potential therapeutic targets in breast cancer by modulating Flt-1.
C1 [Jia, Liyan; Liu, Wei; Cao, Bo] Weifang Med Univ, Affiliated Hosp, Weifang 261053, Peoples R China.
   [Li, Hongli] Weifang Med Univ, Med Res Ctr, Weifang 261053, Peoples R China.
   [Yin, Chonggao] Weifang Med Univ, Coll Nursing, Weifang 261053, Peoples R China.
C3 Shandong Second Medical University; Shandong Second Medical University;
   Shandong Second Medical University
RP Li, HL (通讯作者)，Weifang Med Univ, Med Res Ctr, Weifang 261053, Peoples R China.; Yin, CG (通讯作者)，Weifang Med Univ, Coll Nursing, Weifang 261053, Peoples R China.
EM wfyxylihongli@163.com; ycglihongli@163.com
RI Cao, Bo/D-1983-2017; LI, Hongli/JMQ-9352-2023
FU National Scientific Foundation of China [81402389]; Foundation of
   Shandong Educational Committee [J12LK03, J13LK03]
FX This work was supported by National Scientific Foundation of China
   (81402389), Foundation of Shandong Educational Committee (J12LK03 and
   J13LK03).
CR Chen WY, 2015, J NEURO-ONCOL, V125, P43, DOI 10.1007/s11060-015-1887-x
   Dong Q, 2012, J BIOL CHEM, V287, P41720, DOI 10.1074/jbc.M112.405415
   Durante M, 2010, RADIAT RES, V174, P20, DOI 10.1667/RR2063.1
   Fan C., 2016, ONCOTARGET
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200
   Guo H, 2009, J NEUROCHEM, V109, P203, DOI 10.1111/j.1471-4159.2009.05946.x
   He Y, 2013, MOL BIOL CELL, V24, P3369, DOI 10.1091/mbc.E13-07-0405
   Kaufman-Szymczyk A, 2015, INT J MOL SCI, V16, P29732, DOI 10.3390/ijms161226195
   Kedmi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005866
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Linos E, 2008, JNCI-J NATL CANCER I, V100, P1352, DOI 10.1093/jnci/djn305
   Liu K, 2015, INT J ONCOL, V46, P2526, DOI 10.3892/ijo.2015.2949
   Mukherjee D, 2013, AM J CANCER RES, V3, P46
   Ning Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065217
   Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X
   Prattichizzo F, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0090-4
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Shi L, 2014, BRIT J CANCER, V111, P2316, DOI 10.1038/bjc.2014.580
   Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017
   Sun L, 2016, MOL CARCINOGEN, V55, P40, DOI 10.1002/mc.22256
   Taylor AP, 2010, BRIT J CANCER, V103, P82, DOI 10.1038/sj.bjc.6605746
   Van Impe K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3585
   Wang F, 2015, INT J MOL MED, V35, P1395, DOI 10.3892/ijmm.2015.2123
   Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246
   Yamamoto S, 2014, MOL CANCER RES, V12, P58, DOI 10.1158/1541-7786.MCR-13-0246-T
   Yin CG, 2013, BREAST CANCER RES TR, V142, P297, DOI 10.1007/s10549-013-2737-1
NR 27
TC 22
Z9 25
U1 1
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 14
PY 2016
VL 7
IS 24
BP 36743
EP 36754
DI 10.18632/oncotarget.9163
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4MJ
UT WOS:000377756800098
PM 27167339
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Gao, D
   Herman, JG
   Guo, MZ
AF Gao, Dan
   Herman, James G.
   Guo, Mingzhou
TI The clinical value of aberrant epigenetic changes of DNA damage repair
   genes in human cancer
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; DNA damage repair; MGMT; synthetic lethality; PARP
   inhibitor
ID SQUAMOUS-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; SPORADIC
   BREAST-CANCER; NONPOLYPOSIS COLORECTAL-CANCER; MGMT PROMOTER
   METHYLATION; PERIPHERAL-BLOOD DNA; MISMATCH-REPAIR; OVARIAN-CANCER;
   MICROSATELLITE INSTABILITY; LUNG-CANCER
AB The stability and integrity of the human genome are maintained by the DNA damage repair (DDR) system. Unrepaired DNA damage is a major source of potentially mutagenic lesions that drive carcinogenesis. In addition to gene mutation, DNA methylation occurs more frequently in DDR genes in human cancer. Thus, DNA methylation may play more important roles in DNA damage repair genes to drive carcinogenesis. Aberrant methylation patterns in DNA damage repair genes may serve as predictive, diagnostic, prognostic and chemosensitive markers of human cancer. MGMT methylation is a marker for poor prognosis in human glioma, while, MGMT methylation is a sensitive marker of glioma cells to alkylating agents. Aberrant epigenetic changes in DNA damage repair genes may serve as therapeutic targets. Treatment of MLH1-methylated colon cancer cell lines with the demethylating agent 5'-aza-2'-deoxycytidine induces the expression of MLH1 and sensitizes cancer cells to 5-fluorouracil. Synthetic lethality is a more exciting approach in patients with DDR defects. PARP inhibitors are the most effective anticancer reagents in BRCA-deficient cancer cells.
C1 [Gao, Dan; Guo, Mingzhou] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
   [Gao, Dan] Nankai Univ, Coll Med, Tianjin 300071, Peoples R China.
   [Herman, James G.] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA USA.
C3 Chinese People's Liberation Army General Hospital; Nankai University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Guo, MZ (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
EM mzguo@hotmail.com
RI Wang, Haitao/GYV-1262-2022
FU National Basic Research Program of China (973 Program) [2012CB934002,
   2015CB553904]; National High-tech R&D Program of China (863 Program)
   [SS2012AA020314, SS2012AA020821, SS2012AA020303]; National Key
   Scientific instrument Special Programme of China [2011YQ03013405];
   National Science Foundation of China [81490753]
FX This work was supported by the following grants: National Basic Research
   Program of China (973 Program No. 2012CB934002, 2015CB553904); National
   High-tech R&D Program of China (863 Program No. SS2012AA020314,
   SS2012AA020821, SS2012AA020303); National Key Scientific instrument
   Special Programme of China (Grant No. 2011YQ03013405); National Science
   Foundation of China (Grant No. 81490753).
CR Abbotts R, 2014, CANCER MANAG RES, V6, P77, DOI 10.2147/CMAR.S50497
   Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082
   Al-Kaabi A, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/260549
   Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087
   Auerkari EI, 2006, ORAL ONCOL, V42, P5, DOI 10.1016/j.oraloncology.2005.03.016
   Banzai C, 2014, INT J CLIN ONCOL, V19, P127, DOI 10.1007/s10147-013-0530-0
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bogush T. A., 2015, Antibiotiki i Khimioterapiya, V60, P42
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1
   Cao SL, 2015, CLIN RES HEPATOL GAS, V39, P198, DOI 10.1016/j.clinre.2014.09.003
   da Silva FCC, 2009, SAO PAULO MED J, V127, P46, DOI 10.1590/S1516-31802009000100010
   Casse C, 2003, MUTAT RES-FUND MOL M, V528, P19, DOI 10.1016/S0027-5107(03)00078-2
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chen BS, 2011, CANCER LETT, V309, P37, DOI 10.1016/j.canlet.2011.05.013
   Chen HY, 2010, INT J CANCER, V126, P1944, DOI 10.1002/ijc.24772
   Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066
   Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096
   Cramer-Morales K, 2013, BLOOD, V122, P1293, DOI 10.1182/blood-2013-05-501072
   Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399
   D'Andrea AD, 2010, NEW ENGL J MED, V362, P1909, DOI 10.1056/NEJMra0809889
   D'Andrea AD, 2003, CELL CYCLE, V2, P290, DOI 10.4161/cc.2.4.413
   Das M, 2015, TUMOR BIOL, V36, P1627, DOI 10.1007/s13277-014-2762-7
   de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453
   Derks S, 2014, CANCER METAST REV, V33, P161, DOI 10.1007/s10555-013-9462-4
   Dhillon KK, 2011, CANCER SCI, V102, P663, DOI 10.1111/j.1349-7006.2010.01840.x
   Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2004, ONCOGENE, V23, P1, DOI 10.1038/sj.onc.1207316
   Esteller M, 2000, CANCER RES, V60, P2368
   Esteller M, 2002, J NATL CANCER I, V94, P26
   Fang F, 2014, CLIN CANCER RES, V20, P6504, DOI 10.1158/1078-0432.CCR-14-1553
   Leal MF, 2007, WORLD J GASTROENTERO, V13, P2568, DOI 10.3748/wjg.v13.i18.2568
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Fleischer T, 2014, INT J CANCER, V134, P2615, DOI 10.1002/ijc.28606
   Fortini P, 2003, MUTAT RES-FUND MOL M, V531, P127, DOI 10.1016/j.mrfmmm.2003.07.004
   Fujita H, 2007, ONCOL REP, V18, P1129
   Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3
   Ghosh A, 2012, ANN SURG ONCOL, V19, pS528, DOI 10.1245/s10434-011-1991-x
   Glasspool RM, 2014, BRIT J CANCER, V110, P1923, DOI 10.1038/bjc.2014.116
   González-Ramírez I, 2011, ORAL ONCOL, V47, P22, DOI 10.1016/j.oraloncology.2010.10.002
   Guan HX, 2008, CANCER-AM CANCER SOC, V113, P247, DOI 10.1002/cncr.23548
   Guo He, 2014, Zhonghua Yi Xue Za Zhi, V94, P2193
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   Guo MZ, 2014, DISCOV MED, V17, P67
   Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Harada H, 2013, CANCER-AM CANCER SOC, V119, P792, DOI 10.1002/cncr.27754
   Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475
   Haydon AMM, 2002, LANCET ONCOL, V3, P83, DOI 10.1016/S1470-2045(02)00649-6
   Hegi ME, 2009, CLIN CANCER RES, V15, P5026, DOI 10.1158/1078-0432.CCR-08-1169
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hess CJ, 2008, CELL ONCOL, V30, P299, DOI 10.3233/CLO-2008-0426
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Heyn H, 2013, EXPERT REV MOL DIAGN, V13, P473, DOI [10.1586/ERM.13.36, 10.1586/erm.13.36]
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Hofstetter B, 2010, INT J RADIAT ONCOL, V76, P1512, DOI 10.1016/j.ijrobp.2009.10.037
   House MG, 2003, SURGERY, V134, P902, DOI 10.1016/S0039-6060(03)00412-4
   Howard JH, 2009, CANCER BIOL THER, V8, P94, DOI 10.4161/cbt.8.1.7469
   Hühn D, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13837
   Inno A, 2014, WORLD J CLIN CASES, V2, P835, DOI 10.12998/wjcc.v2.i12.835
   Jacinto FV, 2007, DNA REPAIR, V6, P1155, DOI 10.1016/j.dnarep.2007.03.013
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Kane MF, 1997, CANCER RES, V57, P808
   KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110
   Kim DS, 2009, LUNG CANCER, V65, P247, DOI 10.1016/j.lungcan.2009.03.011
   Kim HG, 2010, J SURG ONCOL, V101, P28, DOI 10.1002/jso.21432
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Kobayashi H, 2013, ONCOL REP, V30, P1019, DOI 10.3892/or.2013.2541
   Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195
   Ksiaa F, 2009, CLIN CHIM ACTA, V404, P128, DOI 10.1016/j.cca.2009.03.044
   Laskar RS, 2015, TUMOR BIOL, V36, P4661, DOI 10.1007/s13277-015-3114-y
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee EJ, 2006, EUR J CANCER, V42, P972, DOI 10.1016/j.ejca.2006.01.021
   Lee JH, 2008, INT J CANCER, V122, P1573, DOI 10.1002/ijc.23166
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Levine AJ, 2012, CANCER PREV RES, V5, P328, DOI 10.1158/1940-6207.CAPR-11-0419
   Li GM, 1999, ONCOL RES, V11, P393
   Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115
   Li JF, 2013, ANTIOXID REDOX SIGN, V18, P2429, DOI 10.1089/ars.2012.5107
   Li W, 2014, ASIAN PAC J CANCER P, V15, P5233, DOI 10.7314/APJCP.2014.15.13.5233
   Li YZ, 2015, GASTRIC CANCER, V18, P280, DOI 10.1007/s10120-014-0370-2
   Liu LM, 2015, BIO-MED MATER ENG, V26, pS2217, DOI 10.3233/BME-151527
   Liu YP, 2013, ONCOL LETT, V5, P935, DOI 10.3892/ol.2012.1096
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
   Maldonado L, 2014, J UROLOGY, V192, P1542, DOI 10.1016/j.juro.2014.04.082
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238
   Martin SA, 2010, CLIN CANCER RES, V16, P5107, DOI 10.1158/1078-0432.CCR-10-0821
   Martin SA, 2009, EMBO MOL MED, V1, P323, DOI 10.1002/emmm.200900040
   Matsushita M, 2005, ONCOL REP, V14, P191
   McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390
   Minniti G, 2014, J NEURO-ONCOL, V118, P377, DOI 10.1007/s11060-014-1443-0
   Mitsuno M, 2007, J GASTROENTEROL, V42, P866, DOI 10.1007/s00535-007-2113-1
   Moon YW, 1998, MUTAT RES-FUND MOL M, V421, P191, DOI 10.1016/S0027-5107(98)00165-1
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683
   Nagasaka T, 2010, CANCER RES, V70, P3098, DOI 10.1158/0008-5472.CAN-09-3290
   Neamatzadeh H, 2015, J RES MED SCI, V20, P284
   Neumann AS, 2005, MOL CARCINOGEN, V42, P65, DOI 10.1002/mc.20069
   Olopade OI, 2003, CANCER CELL, V3, P417, DOI 10.1016/S1535-6108(03)00111-9
   Peng B, 2006, EPIGENETICS-US, V1, P138, DOI 10.4161/epi.1.3.2938
   Pengt B, 2005, J BIOL CHEM, V280, P4182, DOI 10.1074/jbc.M412566200
   Pierini S, 2014, HEAD NECK-J SCI SPEC, V36, P1103, DOI 10.1002/hed.23413
   Plumb JA, 2000, CANCER RES, V60, P6039
   Plummer R, 2010, CLIN CANCER RES, V16, P4527, DOI 10.1158/1078-0432.CCR-10-0984
   Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3
   Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904
   Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512
   Rabik CA, 2006, CANCER TREAT REV, V32, P261, DOI 10.1016/j.ctrv.2006.03.004
   Rebbeck TR, 2015, JAMA-J AM MED ASSOC, V313, P1347, DOI 10.1001/jama.2014.5985
   Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443
   Rivera AL, 2010, NEURO-ONCOLOGY, V12, P116, DOI 10.1093/neuonc/nop020
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222
   Sabatino MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-259
   Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002
   Schärer OD, 2005, CHEMBIOCHEM, V6, P27, DOI 10.1002/cbic.200400287
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Shilpa V, 2014, GENOMICS, V104, P257, DOI 10.1016/j.ygeno.2014.08.016
   Sinicrope FA, 2012, CLIN CANCER RES, V18, P1506, DOI 10.1158/1078-0432.CCR-11-1469
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Su YY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0784-4
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Sweasy JB, 2006, CELL CYCLE, V5, P250, DOI 10.4161/cc.5.3.2414
   Tawfik HM, 2011, AM J OTOLARYNG, V32, P528, DOI 10.1016/j.amjoto.2010.11.005
   Tong SY, 2010, ACTA OBSTET GYN SCAN, V89, P629, DOI 10.3109/00016341003678443
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Toyooka S, 2008, NEW ENGL J MED, V358, P2513, DOI 10.1056/NEJMc080835
   Toyota M, 2010, ADV GENET, V70, P309, DOI [10.1016/S0065-2660(10)70011-0, 10.1016/B978-0-12-380866-0.60011-3]
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   van der Heijden MS, 2003, CANCER RES, V63, P2585
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Vogelsang M, 2014, J CANCER RES CLIN, V140, P1825, DOI 10.1007/s00432-014-1736-x
   Wang HW, 2010, LIFE SCI, V86, P185, DOI 10.1016/j.lfs.2009.11.023
   Wang L, 1997, INT J CANCER, V71, P719, DOI 10.1002/(SICI)1097-0215(19970529)71:5<719::AID-IJC5>3.0.CO;2-U
   Wang L, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-173
   Wang P, 2010, J DIGEST DIS, V11, P343, DOI 10.1111/j.1751-2980.2010.00459.x
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Wang YC, 2003, J CLIN INVEST, V111, P887, DOI 10.1172/JCI200315475
   Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588
   Wu YH, 2007, ONCOGENE, V26, P4761, DOI 10.1038/sj.onc.1210284
   Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5
   Yamamoto H, 2015, ARCH TOXICOL, V89, P899, DOI 10.1007/s00204-015-1474-0
   Yan WJ, 2016, EPIGENOMICS-UK, V8, P119, DOI 10.2217/epi.15.84
   Yang J, 2010, J UROLOGY, V184, P336, DOI 10.1016/j.juro.2010.03.044
   Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Yun Tianyang, 2015, Genes Cancer, V6, P38
   Zhang L, 2003, CARCINOGENESIS, V24, P1039, DOI 10.1093/carcin/bgg062
   Zhao H, 2015, CURR PROTEIN PEPT SC, V16, P316, DOI 10.2174/138920371604150429154840
   Zhou JD, 2015, AM J CANCER RES, V5, P1786
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775
NR 169
TC 70
Z9 73
U1 0
U2 17
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 14
PY 2016
VL 7
IS 24
BP 37331
EP 37346
DI 10.18632/oncotarget.7949
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4MJ
UT WOS:000377756800142
PM 26967246
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Pimson, C
   Ekalaksananan, T
   Pientong, C
   Promthet, S
   Putthanachote, N
   Suwanrungruang, K
   Wiangnon, S
AF Pimson, Charinya
   Ekalaksananan, Tipaya
   Pientong, Chamsai
   Promthet, Supannee
   Putthanachote, Nuntiput
   Suwanrungruang, Krittika
   Wiangnon, Surapon
TI Aberrant methylation of <i>PCDH10</i> and <i>RASSFIA</i> genes in blood
   samples for non-invasive diagnosis and prognostic assessment of gastric
   cancer
SO PEERJ
LA English
DT Article
DE Gastric cancer; PCDH10; RASSFIA methylation; Survival;
   Clinicopathological factors
ID CIRCULATING TUMOR-CELLS; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   EPIGENETIC INACTIVATION; PERIPHERAL-BLOOD; BREAST-CANCER; BIOMARKER;
   SURVIVAL; ASSOCIATION; SERUM
AB Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising candidates for non-invasive diagnosis. Transcriptional inactivation of tumor suppressor genes, like PCDH10 and RASSFIA, by methylation is associated with progression of gastric cancer, and such methylation can therefore be utilized as a bionlarker.
   Methods. The present research was conducted to evaluate DNA methylation in these two genes using blood samples of gastric cancer cases. Clinicopathological data were also analyzed and cumulative survival rates generated for comparison.
   Results. High frequencies of PCDH10 and RASSFIA methylations in the gastric cancer group were noted (94.1% and 83.2%, respectively, as compared to 2.97% and 5.45% in 202 matched controls). Most patients (53.4%) were in severe stage of the disease, with a median survival time of 8.4 months after diagnosis. Likewise, the patients with of 7 metastases, or RASSFIA and PCDH10 methylation, had median survival times of 7.3, 7.8 and 8.4 months, respectively. A Kaplan-Meier analysis showed that cumuiative survival was significantly lower in those cases positive for methylation of RASSFIA than in their negative counterparts. Similarly, whereas almost 100% of patients positive for PCDH10 methylation had died after five years, none of the negative cases died over this Period. Notably, the methylations of RASSFIA and PCDH10 were found to be higher in the late-stage patients land were also significantly correlated with metastasis and histology.
   Conclusions. PCDH10 and RASSFIA methylations in blood samples can serve as potential non-invasive diagnostic indicators in blood for gastric cancer. In addition to RASSFIA methylation, tumor stage proved to be a major prognostic factor in terms of survival rates.
C1 [Pimson, Charinya] Khon Kaen Univ, Grad Sch, Biomed Sci Programme, Khon Kaen, Thailand.
   [Ekalaksananan, Tipaya; Pientong, Chamsai] Khon Kaen Univ, Dept Microbiol, Fac Med, Khon Kaen, Thailand.
   [Ekalaksananan, Tipaya; Pientong, Chamsai] Khon Kaen Univ, HPV & EBV, Khon Kaen, Thailand.
   [Ekalaksananan, Tipaya; Pientong, Chamsai] Khon Kaen Univ, Carcinogenesis Res Grp, Khon Kaen, Thailand.
   [Promthet, Supannee; Putthanachote, Nuntiput] Khon Kaen Univ, Fac Publ Hlth, Dept Epidemiol, Khon Kaen, Thailand.
   [Suwanrungruang, Krittika] Khon Kaen Univ, Fac Med, Srinagarind Hosp, Canc Unit, Khon Kaen, Thailand.
   [Wiangnon, Surapon] Khon Kaen Univ, Dept Pediat, Fac Med, Khon Kaen, Thailand.
C3 Khon Kaen University; Khon Kaen University; Khon Kaen University; Khon
   Kaen University; Khon Kaen University; Khon Kaen University; Khon Kaen
   University
RP Ekalaksananan, T (通讯作者)，Khon Kaen Univ, Dept Microbiol, Fac Med, Khon Kaen, Thailand.; Ekalaksananan, T (通讯作者)，Khon Kaen Univ, HPV & EBV, Khon Kaen, Thailand.; Ekalaksananan, T (通讯作者)，Khon Kaen Univ, Carcinogenesis Res Grp, Khon Kaen, Thailand.
EM tipeka@kku.ac.th
FU HPV & EBV and Carcinogenesis Research Group; Faculty of Medicine, Khon
   Kaen University, Thailand [IN58334]
FX This work was supported by financial grants from the HPV & EBV and
   Carcinogenesis Research Group, and the Faculty of Medicine, Khon Kaen
   University, Thailand (Grant number IN58334). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Almeida PR, 2010, J CLIN PATHOL, V63, P635, DOI 10.1136/jcp.2010.076026
   Balgkouranidou I, 2015, MUTAT RES-FUND MOL M, V778, P46, DOI 10.1016/j.mrfmmm.2015.05.002
   Byun DS, 2001, CANCER RES, V61, P7034
   Choi KS, 2015, BRIT J CANCER, V112, P608, DOI 10.1038/bjc.2014.608
   Coumans FAW, 2012, CLIN CANCER RES, V18, P5711, DOI 10.1158/1078-0432.CCR-12-1585
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Deng JY, 2014, J AM COLL SURGEONS, V219, P904, DOI 10.1016/j.jamcollsurg.2014.06.014
   Esposito A, 2014, CANCER TREAT REV, V40, P648, DOI 10.1016/j.ctrv.2013.10.003
   Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029
   Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637
   Grawenda AM, 2015, BRIT J CANCER, V113, P372, DOI 10.1038/bjc.2015.221
   Hamashima C, 2015, WORLD J GASTROENTERO, V21, P2460, DOI 10.3748/wjg.v21.i8.2460
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Huang H, 2015, WORLD J GASTROENTERO, V21, P1865, DOI 10.3748/wjg.v21.i6.1865
   Hung ECW, 2009, J CLIN PATHOL, V62, P308, DOI 10.1136/jcp.2007.048470
   Ignatiadis M, 2014, ANN ONCOL, V25, P2304, DOI 10.1093/annonc/mdu480
   Jin ZL, 2015, ONCOL LETT, V9, P1502, DOI 10.3892/ol.2015.2959
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Joo MK, 2015, MOL MED REP, V11, P3039, DOI 10.3892/mmr.2014.3055
   Jung KW, 2013, CANCER RES TREAT, V45, P162, DOI 10.4143/crt.2013.45.3.162
   Kim JH, 2015, ANN SURG TREAT RES, V89, P81, DOI 10.4174/astr.2015.89.2.81
   Kohler C, 2011, ANTICANCER RES, V31, P2623
   Kwon HC, 2012, WORLD J GASTROENTERO, V18, P4744, DOI 10.3748/wjg.v18.i34.4744
   Levenson VV, 2010, EXPERT REV MOL DIAGN, V10, P481, DOI 10.1586/ERM.10.17
   Li L, 2012, J EPIDEMIOL, V22, P384, DOI 10.2188/jea.JE20120003
   Li ZS, 2012, BBA-MOL CELL RES, V1823, P298, DOI 10.1016/j.bbamcr.2011.11.011
   Lin LL, 2012, J PROTEOMICS, V75, P3081, DOI 10.1016/j.jprot.2012.03.046
   Liu JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04143
   Madic J, 2015, INT J CANCER, V136, P2158, DOI 10.1002/ijc.29265
   Miki K, 2003, AM J GASTROENTEROL, V98, P735, DOI 10.1016/S0002-9270(03)00128-X
   Miki K, 2011, P JPN ACAD B-PHYS, V87, P405, DOI 10.2183/pjab.87.405
   Otani K, 2013, EXPERT REV MOL DIAGN, V13, P445, DOI [10.1586/ERM.13.32, 10.1586/erm.13.32]
   Pasechnikov V, 2014, WORLD J GASTROENTERO, V20, P13842, DOI 10.3748/wjg.v20.i38.13842
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557
   Sayres LC, 2011, OBSTET GYNECOL SURV, V66, P431, DOI 10.1097/OGX.0b013e31822dfbe2
   Shanmuganathan R, 2013, J MOL DIAGN, V15, P17, DOI 10.1016/j.jmoldx.2012.06.007
   Shi DT, 2014, TUMOR BIOL, V35, P943, DOI 10.1007/s13277-013-1123-2
   Tahara T, 2015, EPIGENOMICS-UK, V7, P475, DOI 10.2217/epi.15.4
   Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074
   Wani K, 2016, METHODS MOL BIOL, V1392, P177, DOI 10.1007/978-1-4939-3360-0_16
   Warton K, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00013
   Yamashita K, 2007, ANTICANCER RES, V27, P4381
   Ye M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-120
   Yu B, 2010, NEOPLASMA, V57, P247, DOI 10.4149/neo_2010_03_247
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
NR 47
TC 36
Z9 40
U1 0
U2 12
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUN 9
PY 2016
VL 4
AR e2112
DI 10.7717/peerj.2112
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DO8IP
UT WOS:000378027200007
PM 27330867
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wu, Q
   Sharma, S
   Cui, H
   LeBlanc, SE
   Zhang, H
   Muthuswami, R
   Nickerson, JA
   Imbalzano, AN
AF Wu, Qiong
   Sharma, Soni
   Cui, Hang
   LeBlanc, Scott E.
   Zhang, Hong
   Muthuswami, Rohini
   Nickerson, Jeffrey A.
   Imbalzano, Anthony N.
TI Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of
   chemotherapy drugs in breast cancer cells
SO ONCOTARGET
LA English
DT Article
DE epigenetics; BRG1; SWI/SNF; breast cancer; drug transporters
ID MULTIDRUG-RESISTANCE PROTEINS; SWI/SNF COMPLEX; TRANSCRIPTIONAL
   ACTIVATION; CONFERS RESISTANCE; TRANSPORTER GENES; ABC TRANSPORTERS;
   SWI2/SNF2 FAMILY; MOLECULAR-BASIS; EXPRESSION; PROLIFERATION
AB Brahma related gene product 1 (BRG1) is an ATPase that drives the catalytic activity of a subset of the mammalian SWI/SNF chromatin remodeling enzymes. BRG1 is overexpressed in most human breast cancer tumors without evidence of mutation and is required for breast cancer cell proliferation. We demonstrate that knockdown of BRG1 sensitized triple negative breast cancer cells to chemotherapeutic drugs used to treat breast cancer. An inhibitor of the BRG1 bromodomain had no effect on breast cancer cell viability, but an inhibitory molecule that targets the BRG1 ATPase activity recapitulated the increased drug efficacy observed in the presence of BRG1 knockdown. We further demonstrate that inhibition of BRG1 ATPase activity blocks the induction of ABC transporter genes by these chemotherapeutic drugs and that BRG1 binds to ABC transporter gene promoters. This inhibition increased intracellular concentrations of the drugs, providing a likely mechanism for the increased chemosensitivity. Since ABC transporters and their induction by chemotherapy drugs are a major cause of chemoresistance and treatment failure, these results support the idea that targeting the enzymatic activity of BRG1 would be an effective adjuvant therapy for breast cancer.
C1 [Wu, Qiong; Cui, Hang; LeBlanc, Scott E.; Zhang, Hong; Nickerson, Jeffrey A.; Imbalzano, Anthony N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA.
   [Sharma, Soni; Muthuswami, Rohini] Jawaharlal Nehru Univ, Sch Life Sci, Delhi, India.
   [Cui, Hang] Abace Biotech Co Ltd, BDA, Yi Zhuang Biomed Pk, Beijing, Peoples R China.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Jawaharlal Nehru University, New Delhi
RP Nickerson, JA; Imbalzano, AN (通讯作者)，Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA.
EM jeffrey.nickerson@umassmed.edu; anthony.imbalzano@umassmed.edu
RI Cui, Hang/ITW-2452-2023; Muthuswami, Rohini/Q-9841-2019
OI Muthuswami, Rohini/0000-0002-0559-9484; SHARMA, SONI/0000-0003-3617-4179
FU NIH [P01 CA82834, R21 CA185926, R01 EB014869]
FX This work was supported by NIH grants P01 CA82834, R21 CA185926, and R01
   EB014869.
CR Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772
   Barbieri I, 2013, BRIEF FUNCT GENOMICS, V12, P219, DOI 10.1093/bfgp/elt007
   Barinaga M, 1997, SCIENCE, V278, P1036, DOI 10.1126/science.278.5340.1036
   Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845
   Cai SF, 2015, MOL CELL, V60, P561, DOI 10.1016/j.molcel.2015.10.042
   CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7
   CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346
   Cui YH, 1999, MOL PHARMACOL, V55, P929
   CUTTS JH, 1960, CANCER RES, V20, P1023
   de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005
   de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Dreyer G, 2013, BREAST, V22, P761, DOI 10.1016/j.breast.2013.01.009
   Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402
   Dutta P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049822
   Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008
   Fedorov O, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500723
   Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122
   Fish PV, 2012, J MED CHEM, V55, P9831, DOI 10.1021/jm3010515
   Folmer Y, 2007, CANCER GENE THER, V14, P875, DOI 10.1038/sj.cgt.7701082
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   GILMAN A, 1946, SCIENCE, V103, P409, DOI 10.1126/science.103.2675.409
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gottesman MM, 2006, FEBS LETT, V580, P998, DOI 10.1016/j.febslet.2005.12.060
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200
   Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018
   HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
   Hlavác V, 2013, PHARMACOGENOMICS, V14, P515, DOI [10.2217/PGS.13.26, 10.2217/pgs.13.26]
   Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911
   Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Horn PJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD1019, DOI 10.2741/Horn
   Imbalzano KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055628
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Keppler D, 2011, HANDB EXP PHARMACOL, V201, P299, DOI 10.1007/978-3-642-14541-4_8
   KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X
   Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/FON.12.86, 10.2217/fon.12.86]
   Li Yong Tsuey, 2012, Int J Nanomedicine, V7, P2473, DOI 10.2147/IJN.S30500
   Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x
   Litviakov NV, 2013, CANCER CHEMOTH PHARM, V71, P153, DOI 10.1007/s00280-012-1992-x
   Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017
   Livasy Chad A, 2009, Surg Pathol Clin, V2, P247, DOI 10.1016/j.path.2009.02.005
   LOTHSTEIN L, 1989, J BIOL CHEM, V264, P16054
   Marquez SB, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00372
   Meng XN, 2015, PHARMACOGENOMICS, V16, P23, DOI [10.2217/pgs.14.159, 10.2217/PGS.14.159]
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minegaki T, 2013, ONCOL LETT, V5, P427, DOI 10.3892/ol.2012.1014
   Moitra K, 2011, BIOL CHEM, V392, P29, DOI 10.1515/BC.2011.006
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x
   Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618
   Muthuswami R, 2000, BIOCHEMISTRY-US, V39, P4358, DOI 10.1021/bi992503r
   Nabholtz JM, 2001, SEMIN ONCOL, V28, P1
   Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121
   Nies AT, 2014, WILEY SER DRUG DISC, P161
   Nigam SK, 2015, NAT REV DRUG DISCOV, V14, P29, DOI 10.1038/nrd4461
   Oakman C, 2010, BREAST, V19, P312, DOI 10.1016/j.breast.2010.03.026
   Oguri T, 2007, MOL CANCER THER, V6, P122, DOI 10.1158/1535-7163.MCT-06-0529
   Oike T, 2014, J RADIAT RES, V55, P613, DOI 10.1093/jrr/rrt227
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Persidis A, 1999, NAT BIOTECHNOL, V17, P94, DOI 10.1038/5289
   Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003
   Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961
   Ruff P, 2009, CANCER CHEMOTH PHARM, V64, P763, DOI 10.1007/s00280-009-0925-9
   Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638
   Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113
   Slot AJ, 2011, ESSAYS BIOCHEM, V50, P179, DOI [10.1042/BSE0500179, 10.1042/bse0500179]
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sprouse AA, 2014, ANTICANCER RES, V34, P5363
   Subhani S, 2015, BIOMED PHARMACOTHER, V71, P37, DOI 10.1016/j.biopha.2015.02.009
   Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521
   Surowiak P, 2006, CLIN CANCER RES, V12, P7149, DOI 10.1158/1078-0432.CCR-06-0564
   Szakács G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Trotter KW, 2008, MOL CELL BIOL, V28, P1413, DOI 10.1128/MCB.01301-07
   Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004
   UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004
   Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798
   Vtorushin S. V., 2014, Experimental Oncology, V36, P144
   Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Watanabe T, 2011, BRIT J CANCER, V104, P146, DOI 10.1038/sj.bjc.6606018
   Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Xu JW, 2011, INT J ONCOL, V39, P1501, DOI 10.3892/ijo.2011.1143
   Yao Jie, 2005, Zhonghua Zhongliu Zazhi, V27, P721
   Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2
   Zhou J, 2008, WORLD J GASTROENTERO, V14, P925, DOI 10.3748/wjg.14.925
NR 99
TC 40
Z9 45
U1 1
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2016
VL 7
IS 19
BP 27158
EP 27175
DI 10.18632/oncotarget.8384
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4HF
UT WOS:000377741700018
PM 27029062
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Cai, FF
   Chen, S
   Wang, MH
   Lin, XY
   Zhang, L
   Zhang, JX
   Wang, LX
   Yang, J
   Ding, JH
   Pan, X
   Shao, ZM
   Biskup, E
AF Cai, Feng-Feng
   Chen, Su
   Wang, Ming-Hong
   Lin, Xiao-Yan
   Zhang, Lian
   Zhang, Jia-Xin
   Wang, Lian-Xin
   Yang, Jun
   Ding, Jin-Hua
   Pan, Xin
   Shao, Zhi-Ming
   Biskup, Ewelina
TI Pyrosequencing quantified methylation level of BRCA1 promoter as
   prognostic factor for survival in breast cancer patient
SO ONCOTARGET
LA English
DT Article
DE breast cancer; BRCA1; methylation; pyrosequencing; prognosis
ID DNA-METHYLATION; SPORADIC BREAST; EPIGENETIC THERAPY; HYPERMETHYLATION;
   EXPRESSION; MORTALITY; PROTEINS; ROLES; WOMEN; SERUM
AB BRCA1 promoter methylation is an essential epigenetic transcriptional silencing mechanism, related to breast cancer (BC) occurrence and progression. We quantified the methylation level of BRCA1 promoter and evaluated its significance as prognostic and predictive factor. BRCA1 promoter methylation level was quantified by pyrosequencing in surgical cancerous and adjacent normal specimens from 154 BC patients. A follow up of 98 months was conducted to assess the correlation between BRCA1-methylation level vs. overall survival (OS) and disease free survival (DFS). The mean methylation level in BC tissues was significantly higher (mean 32.6%; median 31.9%) than in adjacent normal samples (mean 16.2%; median 13.0%) (P < 0.0001). Tumor stage (R = 0.6165, P < 0.0001) and size (R = 0.7328, P < 0.0001) were significantly correlated with the methylation level. Patients with unmethylated BRCA1 had a better OS and DFS compared to the methylated group (each P < 0.0001). BRCA1 promoter methylation level has a statistically significance on survival in BC patients (HazR = 1.465, P = 0.000) and is an independent prognostic factor for OS in BC patients (HazR = 2.042, P = 0.000). Patients with ductal type, HER2 negative, lymph node negative stage 1 + 2 tumors had a better OS and DFS. Classification of grades and molecular subtypes did not show any prognostic significance. Pyrosequencing is a precise and efficient method to quantify BRCA1 promoter methylation level, with a high potential for future clinical implication, as it identifies subgroups of patients with poorer prognosis.
C1 [Cai, Feng-Feng; Lin, Xiao-Yan; Zhang, Lian] Tongji Univ, Sch Med, Yangpu Hosp, Dept Breast Surg, Shanghai 200092, Peoples R China.
   [Chen, Su] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Forens Sci, Dept Mol & Cellular Biol, Xian 710049, Shaanxi, Peoples R China.
   [Wang, Ming-Hong] Tongji Univ, Sch Med, Yangpu Hosp, Dept Gen Practice, Shanghai 200092, Peoples R China.
   [Zhang, Jia-Xin] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200433, Peoples R China.
   [Wang, Lian-Xin; Yang, Jun] Qidong Hosp, Dept Gen Surg, Qidong, Jiangsu, Peoples R China.
   [Ding, Jin-Hua] Lihuili Eastern Hosp, Dept Thyroid & Breast Surg, Ningbo Med Ctr, Ningbo, Zhejiang, Peoples R China.
   [Pan, Xin] Tongji Univ, Yangpu Hosp, Sch Med, Cent Lab, Shanghai 200092, Peoples R China.
   [Shao, Zhi-Ming] Fudan Univ, Dept Oncol, Shanghai Med Coll, Dept Breast Surg,Key Lab Breast Canc Shanghai,Sha, Shanghai 200433, Peoples R China.
   [Biskup, Ewelina] Univ Basel Hosp, Dept Oncol, CH-4031 Basel, Switzerland.
C3 Tongji University; Xi'an Jiaotong University; Tongji University; Fudan
   University; Tongji University; Fudan University; University of Basel
RP Cai, FF (通讯作者)，Tongji Univ, Sch Med, Yangpu Hosp, Dept Breast Surg, Shanghai 200092, Peoples R China.; Pan, X (通讯作者)，Tongji Univ, Yangpu Hosp, Sch Med, Cent Lab, Shanghai 200092, Peoples R China.; Shao, ZM (通讯作者)，Fudan Univ, Dept Oncol, Shanghai Med Coll, Dept Breast Surg,Key Lab Breast Canc Shanghai,Sha, Shanghai 200433, Peoples R China.
EM caifengfeng@medmail.com.cn; xinpanpx@163.com; zhimingshao@yahoo.com
OI Biskup, Ewelina/0000-0002-9871-927X
FU National Key Basic Research Program of China [2013CB531601]; National
   Natural Science Foundation of China [30972633]; Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry [2015-311]; Shanghai Health and Family Planning Commission
   Project [20134298]; Shanghai Health and Family Planning Commission Fund
   [2014118]; Shanghai Yangpu District Science and Technology Commission
   Project; Shanghai Yangpu District Health and Family Planning Commission
   Project; Shanghai Yangpu District Health and Family Planning Commission
   Fund
FX This work was supported by the National Key Basic Research Program of
   China Grants (2013CB531601), the National Natural Science Foundation of
   China Grants (30972633), the Scientific Research Foundation for the
   Returned Overseas Chinese Scholars, State Education Ministry (2015-311),
   the Shanghai Health and Family Planning Commission Project (20134298),
   the Shanghai Health and Family Planning Commission Fund for Qing Nian Yi
   Shi Training Project (2014118), the Shanghai Yangpu District Science and
   Technology Commission Project (2016-2017), the Shanghai Yangpu District
   Health and Family Planning Commission Project (2016-2017), and the
   Shanghai Yangpu District Health and Family Planning Commission Fund for
   Bai Yi Deng Gao Training Project (2014-2016). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], BIOTECHNIQUES
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bayraktar S, 2011, BREAST CANCER RES TR, V130, P145, DOI 10.1007/s10549-011-1711-z
   Cai FF, 2011, INT J MOL SCI, V12, P4465, DOI 10.3390/ijms12074465
   Cai FF, 2014, TUMOR BIOL, V35, P3839, DOI 10.1007/s13277-013-1508-2
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Dejeux Emelyne, 2009, V507, P189, DOI 10.1007/978-1-59745-522-0_15
   Duncan JA, 1998, J CLIN PATHOL-MOL PA, V51, P237, DOI 10.1136/mp.51.5.237
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Hall MJ, 2009, CANCER-AM CANCER SOC, V115, P2222, DOI 10.1002/cncr.24200
   Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100
   Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256
   Iwagami S, 2012, ANN SURG ONCOL, V19, P2726, DOI 10.1245/s10434-011-2176-3
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lin XY, 2013, TUMOR BIOL, V34, P3239, DOI 10.1007/s13277-013-0895-8
   Manoranjan B, 2014, CANCER GENOMICS: FROM BENCH TO PERSONALIZED MEDICINE, P321, DOI 10.1016/B978-0-12-396967-5.00019-0
   Marsh Sharon, 2007, V373, P15
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Pace LE, 2014, JAMA-J AM MED ASSOC, V311, P1327, DOI 10.1001/jama.2014.1398
   Rius M, 2012, ONCOGENE, V31, P4257, DOI 10.1038/onc.2011.601
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ruscito I, 2014, EUR J CANCER, V50, P2090, DOI 10.1016/j.ejca.2014.05.001
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   van den Bergh RCN, 2009, CANCER-AM CANCER SOC, V115, P3868, DOI 10.1002/cncr.24446
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 46
TC 10
Z9 11
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2016
VL 7
IS 19
BP 27499
EP 27510
DI 10.18632/oncotarget.8355
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4HF
UT WOS:000377741700046
PM 27027444
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, S
   Sun, KX
   Liu, BL
   Zong, ZH
   Zhao, Y
AF Chen, Shuo
   Sun, Kai-Xuan
   Liu, Bo-Liang
   Zong, Zhi-Hong
   Zhao, Yang
TI The role of glycogen synthase kinase-3β (GSK-3β) in endometrial
   carcinoma: A carcinogenesis, progression, prognosis, and target therapy
   marker
SO ONCOTARGET
LA English
DT Article
DE endometrial carcinoma; GSK-3 beta; microRNA-129; AZD 1080; tumorigenesis
   and progression
ID HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; EPIGENETIC REGULATION;
   GASTRIC-CANCER; TUMOR INVASION; CELL-DEATH; MICRORNAS; METASTASIS;
   OVEREXPRESSION; PROLIFERATION
AB Purpose: Glycogen synthase kinase-3 beta (GSK-3 beta) is a serine/threonine kinase involved in cancer development. Herein, we demonstrated the role of GSK-3 beta in endometrial cancer (EC) and identified new therapeutic targets.
   Results: GSK-3 beta was overexpressed in EC tissues, and was positively correlated with International Federation of Gynecology and Obstetrics (FIGO) staging, dedifferentiation, and myometrial infiltration depth. Besides, GSK-3 beta overexpression predicted lower cumulative and relapse-free survival rate. si-GSK-3 beta transfection suppressed cell proliferation, migration, invasion, and promoted cell apoptosis through downregulating NF-kB, Cyclin D1 and MMP9 expression whereas upregulating P21 expression. Bioinformatic predictions and dual-luciferase reporter assays showed that GSK-3 beta was a possible target of miR-129. MiR-129 transfection reduced GSK-3 beta expression, and exhibited the same trend as si-GSK-3 beta transfection in cell function experiments. The nude mouse xenograft assay showed that miR-129 overexpression may suppress tumor growth through downregulating GSK-3 beta expression. Further studies showed that AZD1080, a GSK-3 beta inhibitor, could also inhibit EC cell proliferation, migration and invasion, while induced cell apoptosis through modulating relevant genes downstream of GSK-3 beta signaling.
   Experimental Design: GSK-3 beta expression was determined in EC tissue and normal endometrial tissues by immunohistochemistry. After GSK-3 beta down-regulation by si-GSK-3 beta, microRNA-129 mimic transfection or GSK-3 beta inhibitor exposure, EC cell phenotypes and related molecules were examined.
   Conclusions: Our results demonstrate for the first time that GSK-3 beta may be a novel and important therapeutic target for the treatment of endometrial carcinoma. GSK-3 beta inhibitor AZD1080 may be an effective drug for treating endometrial carcinoma.
C1 [Chen, Shuo; Sun, Kai-Xuan; Liu, Bo-Liang; Zhao, Yang] China Med Univ, Dept Gynecol, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
   [Zong, Zhi-Hong] China Med Univ, Dept Biochem & Mol Biol, Coll Basic Med, Shenyang 100013, Peoples R China.
C3 China Medical University; China Medical University
RP Zhao, Y (通讯作者)，China Med Univ, Dept Gynecol, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
EM yida.zhaoyang@163.com
RI Chen, Shuo/ADR-6229-2022
OI Chen, Shuo/0000-0002-5122-3656; Zhao, Yang/0000-0003-3226-8127
FU Natural Scientific Foundation of China [81202049, 81472440, 81472502];
   Liaoning Science and Technology Grant [L2013021077]
FX This work was supported by the Natural Scientific Foundation of China
   (Nos. 81202049; 81472440; 81472502), and Liaoning Science and Technology
   Grant (L2013021077).
CR Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o
   Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8
   Aoki D, 2014, J OBSTET GYNAECOL RE, V40, P338, DOI 10.1111/jog.12360
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543
   Chen S, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0496-4
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Gao XJ, 2013, CELL BIOL INT, V37, P768, DOI 10.1002/cbin.10095
   Georgievska B, 2013, J NEUROCHEM, V125, P446, DOI 10.1111/jnc.12203
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075
   Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057
   Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Ouyang Q, 2016, NEURO-ONCOLOGY, V18, P216, DOI 10.1093/neuonc/nov114
   Qiao GL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105624
   Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121
   Shi GM, 2010, HEPATOLOGY, V52, P183, DOI 10.1002/hep.23661
   Shimura T, 2011, J RADIAT RES, V52, P539, DOI 10.1269/jrr.11098
   Takahashi-Yanaga F, 2013, BIOCHEM PHARMACOL, V86, P191, DOI 10.1016/j.bcp.2013.04.022
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Ushijima K, 2009, J GYNECOL ONCOL, V20, P67, DOI 10.3802/jgo.2009.20.2.67
   Xiao YY, 2015, J CELL MOL MED, V19, P2172, DOI 10.1111/jcmm.12597
   Yohn NL, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-19
   Yoshino Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13249
   Zeng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091231
   Zhai J, 2015, BIOCHEM BIOPH RES CO, V464, P161, DOI 10.1016/j.bbrc.2015.06.108
   Zhang JP, 2015, THERANOSTICS, V5, P733, DOI 10.7150/thno.10305
NR 34
TC 23
Z9 24
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2016
VL 7
IS 19
BP 27538
EP 27551
DI 10.18632/oncotarget.8485
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4HF
UT WOS:000377741700049
PM 27050373
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Spans, L
   Van den Broeck, T
   Smeets, E
   Prekovic, S
   Thienpont, B
   Lambrechts, D
   Karnes, RJ
   Erho, N
   Alshalalfa, M
   Davicioni, E
   Helsen, C
   Gevaert, T
   Tosco, L
   Haustermans, K
   Lerut, E
   Joniau, S
   Claessens, F
AF Spans, Lien
   Van den Broeck, Thomas
   Smeets, Elien
   Prekovic, Stefan
   Thienpont, Bernard
   Lambrechts, Diether
   Karnes, R. Jeffrey
   Erho, Nicholas
   Alshalalfa, Mohammed
   Davicioni, Elai
   Helsen, Christine
   Gevaert, Thomas
   Tosco, Lorenzo
   Haustermans, Karin
   Lerut, Evelyne
   Joniau, Steven
   Claessens, Frank
CA PEARL Consortium
TI Genomic and epigenomic analysis of high-risk prostate cancer reveals
   changes in hydroxymethylation and TET1
SO ONCOTARGET
LA English
DT Article
DE high-risk prostate cancer; genomics; TET1; epigenetics; DNA
   hydroxymethylation
ID SOMATIC POINT MUTATIONS; CELL POLARITY; 5-HYDROXYMETHYLCYTOSINE CONTENT;
   TRANSCRIPTIONAL REGULATION; RADICAL PROSTATECTOMY; SEQUENCING DATA;
   BREAST-CANCER; DNA; 5-METHYLCYTOSINE; GENE
AB The clinical heterogeneity of prostate cancer (PCa) makes it difficult to identify those patients that could benefit from more aggressive treatments. As a contribution to a better understanding of the genomic changes in the primary tumor that are associated with the development of high-risk disease, we performed exome sequencing and copy number determination of a clinically homogeneous cohort of 47 high-risk PCas. We confirmed recurrent mutations in SPOP, PTEN and TP53 among the 850 point mutations we detected. In seven cases, we discovered genomic aberrations in the TET1 (Ten-Eleven Translocation 1) gene which encodes a DNA hydroxymethylase than can modify methylated cytosines in genomic DNA and thus is linked with gene expression changes. TET1 protein levels were reduced in tumor versus non-tumor prostate tissue in 39 of 40 cases. The clinical relevance of changes in TET1 levels was demonstrated in an independent PCa cohort, in which low TET1 mRNA levels were significantly associated with worse metastases-free survival. We also demonstrate a strong reduction in hydroxymethylated DNA in tumor tissue in 27 of 41 cases. Furthermore, we report the first exploratory (h) MeDIP-Seq analyses of eight high-risk PCa samples. This reveals a large heterogeneity in hydroxymethylation changes in tumor versus non-tumor genomes which can be linked with cell polarity.
C1 [Spans, Lien; Van den Broeck, Thomas; Smeets, Elien; Prekovic, Stefan; Helsen, Christine; Claessens, Frank] Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Campus Gasthuisberg, Leuven, Belgium.
   [Spans, Lien] Univ Leuven, Dept Human Genet, Lab Genet Malignant Disorders, Campus Gasthuisberg, Leuven, Belgium.
   [Van den Broeck, Thomas; Tosco, Lorenzo; Joniau, Steven] Univ Hosp Leuven, Dept Urol, Campus Gasthuisberg, Leuven, Belgium.
   [Thienpont, Bernard; Lambrechts, Diether] VIB, Vesalius Res Ctr, Leuven, Belgium.
   [Thienpont, Bernard; Lambrechts, Diether] Univ Leuven, Dept Oncol, Lab Translat Genet, Campus Gasthuisberg, Leuven, Belgium.
   [Karnes, R. Jeffrey] Mayo Clin, Dept Urol, Rochester, MN USA.
   [Erho, Nicholas; Alshalalfa, Mohammed; Davicioni, Elai] GenomeDx Biosci Inc, Res & Dev, Vancouver, BC, Canada.
   [Gevaert, Thomas] Univ Leuven, Dept Dev & Regenerat, Organ Syst, Campus Gasthuisberg, Leuven, Belgium.
   [Haustermans, Karin] Univ Leuven, Dept Oncol, Lab Expt Radiotherapy, Campus Gasthuisberg, Leuven, Belgium.
   [Lerut, Evelyne] Univ Hosp Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium.
C3 KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; Flanders
   Institute for Biotechnology (VIB); KU Leuven; Mayo Clinic; GenomeDx
   Biosciences; KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven
RP Claessens, F (通讯作者)，Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Campus Gasthuisberg, Leuven, Belgium.
EM Frank.Claessens@kuleuven.be
RI Haustermans, Karin/AAB-5912-2021; Helsen, Christine/IQU-7720-2023;
   Thienpont, Bernard/JBR-9581-2023; Lambrechts, Diether/AAJ-3167-2020;
   Smeets, Elien/JJC-6956-2023; Claessens, Frank/M-8565-2016; joniau,
   steven/K-7655-2013
OI Claessens, Frank/0000-0002-8676-7709; Helsen,
   Christine/0000-0003-1048-2798; Prekovic, Stefan/0000-0002-7051-9321;
   Haustermans, Karin/0000-0003-0364-682X; Thienpont,
   Bernard/0000-0002-8772-6845; Van den Broeck, Thomas/0000-0002-7237-7160;
   Lambrechts, Diether/0000-0002-3429-302X; joniau,
   steven/0000-0003-3195-9890
FU FWO-Vlaanderen [G.0684.12N]; Belgian federal government [KPC_29_023]; KU
   Leuven [OT/11/081, GOA/15/017]; University Hospitals Leuven ('Klinisch
   Onderzoeksfonds' - KOF)
FX This work was supported by research grants from the FWO-Vlaanderen
   (G.0684.12N), from the Belgian federal government (National Cancer Plan
   KPC_29_023), from the KU Leuven (OT/11/081 and GOA/15/017) and from the
   University Hospitals Leuven ('Klinisch Onderzoeksfonds' - KOF). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104
   Boormans JL, 2013, INT J CANCER, V133, P335, DOI 10.1002/ijc.28025
   Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080
   Cadet J, 2014, MUTAT RES-GEN TOX EN, V764, P18, DOI 10.1016/j.mrgentox.2013.09.001
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969
   Delatte B, 2014, EMBO J, V33, P1198, DOI 10.15252/embj.201488290
   Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052
   Dhiman VK, 2015, ONCOTARGET, V6, P42575, DOI 10.18632/oncotarget.6471
   Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855
   Feng JH, 2015, INT J CLIN EXP MED, V8, P203
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Goering Wolfgang, 2012, Methods Mol Biol, V863, P47, DOI 10.1007/978-1-61779-612-8_4
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Herrmann JL, 2011, CANCER LETT, V306, P1, DOI 10.1016/j.canlet.2011.01.014
   HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017
   Klein EA, 2014, EUROPEAN UROLOGY
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Larson DE, 2012, BIOINFORMATICS, V28, P311, DOI 10.1093/bioinformatics/btr665
   Leake R, 2000, J CLIN PATHOL, V53, P634, DOI 10.1136/jcp.53.8.634
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0070-0
   Lindberg J, 2013, EUR UROL, V63, P702, DOI 10.1016/j.eururo.2012.11.053
   Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Müller U, 2014, NUCLEIC ACIDS RES, V42, P8592, DOI 10.1093/nar/gku552
   Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020
   Neri F, 2015, ONCOGENE, V34, P4168, DOI 10.1038/onc.2014.356
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Piccolo SR, 2012, GENOMICS, V100, P337, DOI 10.1016/j.ygeno.2012.08.003
   Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81
   Ren SC, 2013, J UROLOGY, V190, P2278, DOI 10.1016/j.juro.2013.07.001
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.05.001, 10.1016/j.cell.2015.06.053]
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Shen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065598
   Sugimoto M, 2008, J CELL BIOL, V183, P19, DOI 10.1083/jcb.200803133
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takai H, 2014, CELL REP, V9, P48, DOI 10.1016/j.celrep.2014.08.071
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Wang DJ, 2015, ONCOTARGET, V6, P41045, DOI 10.18632/oncotarget.5728
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 57
TC 29
Z9 33
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 26
PY 2016
VL 7
IS 17
BP 24326
EP 24338
DI 10.18632/oncotarget.8220
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO3UB
UT WOS:000377706200102
PM 27014907
OA Green Accepted, gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Estal, RM
   Suela, SP
   Jiménez, ID
   Gonzalez, CA
   Rojas, CE
   García-Casado, Z
   Guerrero, JAL
   Fita, MJJ
   Heras, ABS
   Huerta, AS
   Bertrán, AS
   González, IC
   García, ML
   Simó, GP
   González, EB
   Gilabert, PB
AF Murria Estal, Rosa
   Palanca Suela, Sarai
   de Juan Jimenez, Inmaculada
   Alenda Gonzalez, Cristina
   Egoavil Rojas, Cecilia
   Garcia-Casado, Zaida
   Lopez Guerrero, Jose Antonio
   Juan Fita, Maria Jose
   Sanchez Heras, Ana Beatriz
   Segura Huerta, Angel
   Santaballa Bertran, Ana
   Chirivella Gonzalez, Isabel
   Llop Garcia, Marta
   Perez Simo, Gema
   Barragan Gonzalez, Eva
   Bolufer Gilabert, Pascual
TI Relationship of immunohistochemistry, copy number aberrations and
   epigenetic disorders with BRCAness pattern in hereditary and sporadic
   breast cancer
SO FAMILIAL CANCER
LA English
DT Article
DE BRCAness; Copy number aberrations; Promoter methylation; microRNA
   expression; Immunohistochemical markers
ID DEPENDENT PROBE AMPLIFICATION; NEOADJUVANT CHEMOTHERAPY; MYC;
   METHYLATION; PROMOTER; BRCA2; CARCINOMAS; TUMORS; CLASSIFICATION;
   SENSITIVITY
AB The study aims to identify the relevance of immunohistochemistry (IHC), copy number aberrations (CNA) and epigenetic disorders in BRCAness breast cancers (BCs). We studied 95 paraffin included BCs, of which 41 carried BRCA1/BRCA2 germline mutations and 54 were non hereditary (BRCAX/Sporadic). Samples were assessed for BRCA1ness and CNAs by Multiplex Ligation-dependent Probe Amplification (MLPA); promoter methylation (PM) was assessed by methylation-specific-MLPA and the expression of miR-4417, miR-423-3p, miR-590-5p and miR-187-3p by quantitative RT-PCR. IHC markers Ki67, ER, PR, HER2, CK5/6, EGFR and CK18 were detected with specific primary antibodies (DAKO, Denmark). BRCAness association with covariates was performed using multivariate binary logistic regression (stepwise backwards Wald option). BRCA1/2 mutational status (p = 0.027), large tumor size (p = 0.041) and advanced histological grade (p = 0.017) among clinic-pathological variables; ER (p < 0.001) among IHC markers; MYC (p < 0.001) among CNA; APC (p = 0.065), ATM (p = 0.014) and RASSF1 (p = 0.044) among PM; and miR-590-5p (p = 0.001), miR-4417 (p = 0.019) and miR-423 (p = 0.013) among microRNA expression, were the selected parameters significantly related with the BRCAness status. The logistic regression performed with all these parameters selected ER? as linked with the lack of BRCAness (p = 0.001) and MYC CNA, APC PM and miR-590-5p expression with BRCAness (p = 0.014, 0.045 and 0.007, respectively). In conclusion, the parameters ER expression, APC PM, MYC CNA and miR-590-5p expression, allowed detection of most BRCAness BCs. The identification of BRCAness can help establish a personalized medicine addressed to predict the response to specific treatments.
C1 [Murria Estal, Rosa; Palanca Suela, Sarai; de Juan Jimenez, Inmaculada; Llop Garcia, Marta; Perez Simo, Gema; Barragan Gonzalez, Eva; Bolufer Gilabert, Pascual] Univ Hosp La Fe, Serv Clin Anal, Mol Biol Lab, Torre A 4a Planta, Valencia 46026, Spain.
   [Alenda Gonzalez, Cristina; Egoavil Rojas, Cecilia] Univ Gen Hosp, Dept Pathol, Alicante, Spain.
   [Garcia-Casado, Zaida; Lopez Guerrero, Jose Antonio] IVO, Mol Biol Lab, Valencia, Spain.
   [Juan Fita, Maria Jose] IVO, Dept Oncol, Valencia, Spain.
   [Sanchez Heras, Ana Beatriz] Elche Hosp, Genet Counseling Unit, Alicante, Spain.
   [Segura Huerta, Angel] Univ Hosp La Fe, Genet Counseling Unit, Valencia, Spain.
   [Santaballa Bertran, Ana] Univ Hosp La Fe, Dept Oncol, Valencia, Spain.
   [Chirivella Gonzalez, Isabel] Clin Univ Hosp, Genet Counseling Unit, Valencia, Spain.
C3 General University Hospital of Alicante; Instituto Valenciano De
   Oncologia; Instituto Valenciano De Oncologia
RP Gilabert, PB (通讯作者)，Univ Hosp La Fe, Serv Clin Anal, Mol Biol Lab, Torre A 4a Planta, Valencia 46026, Spain.
EM bolufer_pas@gva.es
RI Gonzalez, Cesar/O-2100-2013; Lopez-Guerrero, Jose Antonio/Z-2413-2019;
   Garcia-Casado, Zaida/Z-2125-2019; Egoavil, Cecilia/X-5134-2018;
   Sanchez-Heras, Ana Beatriz/KSP-5768-2024
OI Murria, Rosa/0000-0003-4647-6066; GARCIA-CASADO,
   ZAIDA/0000-0001-6592-6099; Egoavil, Cecilia/0000-0003-0166-4901;
   Sanchez-Heras, Ana Beatriz/0000-0003-1742-5374
FU Carlos III Health Institute [PI10/00347]
FX We would like to thank to the Carlos III Health Institute for having
   granted the Project PI10/00347. We also would like to thank to the
   Health Research Institute La Fe for having granted Rosa Murria Estal
   which made possible her participation in the study. We should thank the
   effort to perform this work to the pathologists Ana Garcia Martinez
   (University Hospital La Fe) and Francisco Javier Segui Ivanez
   (University Hospital of Alicante), to the laboratory technician
   Estefania Rojas Calvente (University Hospital of Alicante), to David
   Hervas statistician of the Health Research Institute La Fe and to Jacobo
   Martinez Santamaria, Mercedes Goicoechea Saez and Dolores Salas Trejo
   (General department of public health, Conselleria de Sanitat,
   Generalitat Valenciana). Finally we would like to acknowledge the
   patients enrolled in this study and the Biobank of the General
   University Hospital of Alicante and the biobank for the biomedical
   research and public health of the Comunidad Valenciana (IBSP-CV) as part
   of the Valenciana Biobank Network (RVB) and the National Biobank.
CR Akashi-Tanaka S, 2015, CLIN BREAST CANCER, V15, P80, DOI 10.1016/j.clbc.2014.08.003
   Alles MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004710
   Ben Gacem R, 2012, CANCER EPIDEMIOL, V36, P190, DOI 10.1016/j.canep.2011.09.001
   Bunyan DJ, 2004, BRIT J CANCER, V91, P1155, DOI 10.1038/sj.bjc.6602121
   Chalasani P, 2013, ONCOLOGIST, V18, P909, DOI 10.1634/theoncologist.2013-0039
   Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   de Juan I, 2009, BREAST CANCER RES TR, V115, P405, DOI 10.1007/s10549-008-0073-7
   Cardeñosa EE, 2008, MED CLIN-BARCELONA, V130, P121, DOI 10.1157/13115767
   GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325
   Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512
   Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z
   Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Lips EH, 2011, ANN ONCOL, V22, P870, DOI 10.1093/annonc/mdq468
   Lips EH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3049
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Palacios J, 2008, PATHOBIOLOGY, V75, P85, DOI 10.1159/000123846
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Schouten PC, 2015, MOL ONCOL, V9, P1274, DOI 10.1016/j.molonc.2015.03.002
   Stein RA, 2006, ENDOCR-RELAT CANCER, V13, pS25, DOI 10.1677/erc.1.01292
   Tibshirani R. J., 2009, STAT APPL GENET MOL, V8, P1, DOI DOI 10.2202/1544-6115.1438
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Wessels LFA, 2002, CANCER RES, V62, P7110
   Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 36
TC 11
Z9 12
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1389-9600
EI 1573-7292
J9 FAM CANCER
JI Fam. Cancer
PD APR
PY 2016
VL 15
IS 2
BP 193
EP 200
DI 10.1007/s10689-015-9864-2
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DO6LS
UT WOS:000377895600005
PM 26723934
DA 2025-01-12
ER

PT J
AU Zondervan, KT
   Rahmioglu, N
   Morris, AP
   Nyholt, DR
   Montgomery, GW
   Becker, CM
   Missmer, SA
AF Zondervan, Krina T.
   Rahmioglu, Nilufer
   Morris, Andrew P.
   Nyholt, Dale R.
   Montgomery, Grant W.
   Becker, Christian M.
   Missmer, Stacey A.
TI Beyond Endometriosis Genome-Wide Association Study: From Genomics to
   Phenomics to the Patient
SO SEMINARS IN REPRODUCTIVE MEDICINE
LA English
DT Article
DE endometriosis; genes; genome-wide association study; epigenetic;
   phenotype; EPHect
ID PHENOTYPE DATA-COLLECTION; QUALITY-OF-LIFE; GENETIC RISK; SUSCEPTIBILITY
   LOCI; SEQUENCE VARIATION; BREAST-CANCER; DISEASE STAGE; EXPRESSION;
   VARIANTS; METAANALYSIS
AB Endometriosis is a heritable, complex chronic inflammatory disease, for which much of the causal pathogenic mechanism remains unknown. Genome-wide association studies (GWAS) to date have identified 12 single nucleotide polymorphisms at 10 independent genetic loci associated with endometriosis. Most of these were more strongly associated with revised American Fertility Society stage III/IV, rather than stage III. The loci are almost all located in intergenic regions that are known to play a role in the regulation of expression of target genes yet to be identified. To identify the target genes and pathways perturbed by the implicated variants, studies are required involving functional genomic annotation of the surrounding chromosomal regions, in terms of transcription factor binding, epigenetic modification (e.g., DNA methylation and histone modification) sites, as well as their correlation with RNA transcription. These studies need to be conducted in tissue types relevant to endometriosis in particular, endometrium. In addition, to allow biologically and clinically relevant interpretation of molecular profiling data, they need to be combined and correlated with detailed, systematically collected phenotypic information (surgical and clinical). The WERF Endometriosis Phenome and Biobanking Harmonisation Project is a global standardization initiative that has produced consensus data and sample collection protocols for endometriosis research. These now pave the way for collaborative studies integrating phenomic with genomic data, to identify informative subtypes of endometriosis that will enhance understanding of the pathogenic mechanisms of the disease and discovery of novel, targeted treatments.
C1 [Zondervan, Krina T.; Becker, Christian M.] Univ Oxford, Endometriosis Care Ctr, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Zondervan, Krina T.; Rahmioglu, Nilufer; Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England.
   [Nyholt, Dale R.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Montgomery, Grant W.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [Missmer, Stacey A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Missmer, Stacey A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA USA.
   [Missmer, Stacey A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA.
C3 University of Oxford; University of Oxford; Wellcome Centre for Human
   Genetics; University of Liverpool; Queensland University of Technology
   (QUT); QIMR Berghofer Medical Research Institute; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Brigham &
   Women's Hospital; Harvard Medical School; Harvard University; Harvard
   Medical School; Brigham & Women's Hospital
RP Zondervan, KT (通讯作者)，Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Level 3, Oxford OX3 9DU, England.
EM krina.zondervan@obs-gyn.ox.ac.uk
RI rahmioglu, nilufer/AAO-5653-2020; Nyholt, Dale/J-3174-2017; Montgomery,
   Grant/B-7148-2008; Zondervan, Krina/M-1143-2013
OI Nyholt, Dale/0000-0001-7159-3040; Montgomery, Grant/0000-0002-4140-8139;
   RAHMIOGLU, NILUFER/0000-0002-5169-8571; Zondervan,
   Krina/0000-0002-0275-9905
FU MRC [MR/K011480/1]; NHMRC [339446, 619667]; Wellcome Trust [WT098017];
   MRC [MR/K011480/1] Funding Source: UKRI
FX N.R. was supported by an MRC grant (MR/K011480/1). A.P. M. is a Wellcome
   Trust Senior Fellow in Basic Biomedical Science (WT098017). G.W.M. is
   supported by the NHMRC Fellowships Scheme (339446, 619667).
CR Adachi S, 2010, J HUM GENET, V55, P816, DOI 10.1038/jhg.2010.118
   Adamson GD, 2010, J ENDOMETR PELVIC PA, V2, P3, DOI 10.1177/228402651000200102
   Albertsen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058257
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   [Anonymous], 1985, Fertil Steril, V43, P351
   [Anonymous], 2015, Nature, DOI DOI 10.1038/NATURE15393
   Barrett JC, 2015, NAT REV GENET, V16, P561, DOI 10.1038/nrg3998
   Barrier BF, 2010, CLIN OBSTET GYNECOL, V53, P397, DOI 10.1097/GRF.0b013e3181db7c33
   Becker CM, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.709
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Borowski A, 2006, CANCER IMMUNOL IMMUN, V55, P363, DOI 10.1007/s00262-005-0017-6
   Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Canis M, 1997, FERTIL STERIL, V67, P817
   Chadwick LH, 2012, EPIGENOMICS-UK, V4, P317, DOI [10.2217/EPI.12.18, 10.2217/epi.12.18]
   Chardin P, 2006, NAT REV MOL CELL BIO, V7, P54, DOI 10.1038/nrm1788
   Chevillard G, 2011, CELL MOL LIFE SCI, V68, P3337, DOI 10.1007/s00018-011-0747-x
   Degner JF, 2012, NATURE, V482, P390, DOI 10.1038/nature10808
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   Fassbender A, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.1209
   Ferreira MAR, 2009, AM J HUM GENET, V85, P745, DOI 10.1016/j.ajhg.2009.10.005
   Gaetje R, 2007, FERTIL STERIL, V87, P651, DOI 10.1016/j.fertnstert.2006.07.1533
   GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Goumenou AG, 2000, INT J MOL MED, V6, P667
   Grundberg E, 2013, AM J HUM GENET, V93, P876, DOI 10.1016/j.ajhg.2013.10.004
   Grundberg E, 2012, NAT GENET, V44, P1084, DOI 10.1038/ng.2394
   Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761
   Guida M, 2009, EUR J GYNAECOL ONCOL, V30, P267
   HALME J, 1984, OBSTET GYNECOL, V64, P151
   Heid IM, 2010, NAT GENET, V42, P949, DOI 10.1038/ng.685
   Houle D, 2010, NAT REV GENET, V11, P855, DOI 10.1038/nrg2897
   Ibrahim-Verbaas CA, 2014, STROKE, V45, P403, DOI 10.1161/STROKEAHA.113.003044
   Jarinova O, 2009, ARTERIOSCL THROM VAS, V29, P1671, DOI 10.1161/ATVBAHA.109.189522
   Jostins L, 2011, HUM MOL GENET, V20, pR182, DOI 10.1093/hmg/ddr378
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee SH, 2013, HUM MOL GENET, V22, P832, DOI 10.1093/hmg/dds491
   Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lou XY, 2013, OMICS, V17, P510, DOI 10.1089/omi.2013.0058
   Lower KM, 2013, HUM MUTAT, V34, P1140, DOI 10.1002/humu.22343
   Lu Y, 2015, HUM MOL GENET, V24, P5955, DOI 10.1093/hmg/ddv306
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   Martini M, 2002, INT J CANCER, V102, P398, DOI 10.1002/ijc.10715
   Mathur SP, 2000, AM J REPROD IMMUNOL, V44, P89, DOI 10.1111/j.8755-8920.2000.440204.x
   Matsuzaki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061690
   Matsuzaki S, 2010, J CLIN ENDOCR METAB, V95, P3437, DOI 10.1210/jc.2009-2713
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036
   Miao RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074409
   Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242
   Min JL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002505
   Missmer SA, 2004, OBSTET GYNECOL, V104, P965, DOI 10.1097/01.AOG.0000142714.54857.f8
   Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275
   Missmer SA, 2003, OBSTET GYN CLIN N AM, V30, P3
   Morris AP, 2011, GENET EPIDEMIOL, V35, P809, DOI 10.1002/gepi.20630
   Nnoaham KE, 2011, FERTIL STERIL, V96, P366, DOI 10.1016/j.fertnstert.2011.05.090
   Nyholt DR, 2012, NAT GENET, V44, P1355, DOI 10.1038/ng.2445
   Painter JN, 2011, NAT GENET, V43, P51, DOI 10.1038/ng.731
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004
   Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-320
   Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4
   Rahmioglu N, 2015, WOMENS HEALTH, V11, P577, DOI 10.2217/whe.15.41
   Rahmioglu N, 2015, HUM MOL GENET, V24, P1185, DOI 10.1093/hmg/ddu516
   Rahmioglu N, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.1208
   Rahmioglu N, 2014, HUM REPROD UPDATE, V20, P702, DOI 10.1093/humupd/dmu015
   Rahmioglu N, 2012, CURR OBSTET GYNECOL, V1, P124, DOI 10.1007/s13669-012-0016-5
   Ren Y, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003778
   Rogers PAW, 2013, REPROD SCI, V20, P483, DOI 10.1177/1933719113477495
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Saha R, 2015, FERTIL STERIL, V104, P947, DOI 10.1016/j.fertnstert.2015.06.035
   Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X
   Sapkota Y, 2015, MOL HUM REPROD, V21, P594, DOI 10.1093/molehr/gav021
   Sapkota Y, 2015, HUM REPROD, V30, P239, DOI 10.1093/humrep/deu267
   Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073
   SIMPSON JL, 1980, AM J OBSTET GYNECOL, V137, P327, DOI 10.1016/0002-9378(80)90917-5
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Smemo S, 2014, NATURE, V507, P371, DOI 10.1038/nature13138
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Tamaresis JS, 2014, ENDOCRINOLOGY, V155, P4986, DOI 10.1210/en.2014-1490
   Tamimi RM, 2012, BREAST CANCER RES TR, V131, P159, DOI 10.1007/s10549-011-1702-0
   Taylor HS, 1999, HUM REPROD, V14, P1328, DOI 10.1093/humrep/14.5.1328
   Treloar SA, 1999, FERTIL STERIL, V71, P701, DOI 10.1016/S0015-0282(98)00540-8
   Treloar SA, 2005, AM J HUM GENET, V77, P365, DOI 10.1086/432960
   Tulac S, 2003, J CLIN ENDOCR METAB, V88, P3860, DOI 10.1210/jc.2003-030494
   Uno S, 2010, NAT GENET, V42, P707, DOI 10.1038/ng.612
   Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068
   Vercellini P, 1996, FERTIL STERIL, V65, P299, DOI 10.1016/S0015-0282(16)58089-3
   Vercellini P, 2011, HUM REPROD, V26, P3, DOI 10.1093/humrep/deq302
   Vitonis AF, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.1244
   Wang YY, 2010, ONCOTARGET, V1, P674, DOI 10.18632/oncotarget.201
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wu Y, 2005, AM J OBSTET GYNECOL, V193, P371, DOI 10.1016/j.ajog.2005.01.034
   Yarwood A, 2015, ANN RHEUM DIS, V74, P170, DOI 10.1136/annrheumdis-2013-204133
   Zondervan KT, 2007, HUM REPROD, V22, P717, DOI 10.1093/humrep/del446
   Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270
   Zondervan KT, 2002, HUM REPROD, V17, P1415, DOI 10.1093/humrep/17.6.1415
NR 103
TC 54
Z9 61
U1 0
U2 10
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1526-8004
EI 1526-4564
J9 SEMIN REPROD MED
JI Semin. Reprod. Med.
PD JUL
PY 2016
VL 34
IS 4
BP 242
EP 254
DI 10.1055/s-0036-1585408
PG 13
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA DT5SJ
UT WOS:000381542600009
PM 27513026
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Yoshida, K
   Nagasaka, T
   Umeda, Y
   Tanaka, T
   Kimura, K
   Taniguchi, F
   Fuji, T
   Shigeyasu, K
   Mori, Y
   Yanai, H
   Yagi, T
   Goel, A
   Fujiwara, T
AF Yoshida, Kazuhiro
   Nagasaka, Takeshi
   Umeda, Yuzo
   Tanaka, Takehiro
   Kimura, Keisuke
   Taniguchi, Fumitaka
   Fuji, Tomokazu
   Shigeyasu, Kunitoshi
   Mori, Yoshiko
   Yanai, Hiroyuki
   Yagi, Takahito
   Goel, Ajay
   Fujiwara, Toshiyoshi
TI Expansion of epigenetic alterations in <i>EFEMP1</i> promoter predicts
   malignant formation in pancreatobiliary intraductal papillary mucinous
   neoplasms
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Mucinous neoplasms; Methylation; Epigenetics; EFEMP1; Invasive
   carcinoma; Dysplasia
ID COLORECTAL TUMORIGENESIS; DUCTAL ADENOCARCINOMA; UPDATED EXPERIENCE;
   SURGICAL RESECTION; GNAS MUTATIONS; BREAST-CANCER; LUNG-CANCER; K-RAS;
   PANCREAS; METHYLATION
AB Although limited understanding exists for the presence of specific genetic mutations and aberrantly methylated genes in pancreatobiliary intraductal papillary mucinous neoplasms (IPMNs), the fundamental understanding of the dynamics of methylation expansion across CpG dinucleotides in specific gene promoters during carcinogenesis remains unexplored. Expansion of DNA methylation in some gene promoter regions, such as EFEMP1, one of the fibulin family, with tumor progression has been reported in several malignancies. We hypothesized that DNA hypermethylation in EFEMP1 promoter would expand with the tumor grade of IPMN.
   A sample of 65 IPMNs and 30 normal pancreatic tissues was analyzed. IPMNs were divided into the following three subsets according to pathological findings: 31 with low-grade dysplasia (low grade), 11 with high-grade dysplasia (high grade), and 23 with associated invasive carcinoma (invasive Ca). Mutations in the KRAS or GNAS genes were analyzed by Sanger sequencing, and methylation status of two discrete regions within the EFEMP1 promoter, namely region 1 and region 2, was analyzed by bisulfite sequencing and fluorescent high-sensitive assay for bisulfite DNA (Hi-SA). Expression status of EFEMP1 was investigated by immunohistochemistry (IHC).
   KRAS mutations were detected in 39, 55, and 70 % of low-grade, high-grade, and invasive Ca, respectively. GNAS mutations were observed in 32, 55, and 22 % of low-grade, high-grade, and invasive Ca, respectively. The methylation of individual regions (region 1 or 2) in the EFEMP1 promoter was observed in 84, 91, and 87 % of low-grade, high-grade, and invasive Ca, respectively. However, simultaneous methylation of both regions (extensive methylation) was exclusively detected in 35 % of invasive Ca (p = 0.001) and five of eight IPMNs (63 %) with extensive methylation, whereas 20 of 57 (35.1 %) tumors of unmethylation or partial methylation of the EFEMP1 promoter region showed weak staining EFEMP1 in extracellular matrix (p = 0.422). In addition, extensive EFEMP1 methylation was particularly present in malignant tumors without GNAS mutations and associated with disease-free survival of patients with IPMNs (p < 0.0001).
   Extensive methylation of the EFEMP1 gene promoter can discriminate invasive from benign IPMNs with superior accuracy owing to their stepwise accumulation of tumor progression.
C1 [Yoshida, Kazuhiro; Nagasaka, Takeshi; Umeda, Yuzo; Kimura, Keisuke; Taniguchi, Fumitaka; Fuji, Tomokazu; Shigeyasu, Kunitoshi; Mori, Yoshiko; Yagi, Takahito; Fujiwara, Toshiyoshi] Okayama Univ, Dept Surg Gastroenterol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.
   [Tanaka, Takehiro; Yanai, Hiroyuki] Okayama Univ, Dept Pathol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Okayama 7008558, Japan.
   [Goel, Ajay] Baylor Univ, Ctr Gastrointestinal Canc Res, Ctr Epigenet Canc Prevent & Canc Genom, Baylor Res Inst, Dallas, TX 75246 USA.
   [Goel, Ajay] Baylor Univ, Charles Sammons Canc Ctr A, Dallas, TX 75246 USA.
C3 Okayama University; Okayama University; Baylor Scott & White Health;
   Baylor University; Baylor University Medical Center; Baylor University;
   Baylor University Medical Center
RP Nagasaka, T (通讯作者)，Okayama Univ, Dept Surg Gastroenterol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.
EM takeshin@cc.okayama-u.ac.jp
RI Goel, Ajay/ADO-9623-2022; Yanai, Hiroyuki/B-2191-2011
OI Goel, Ajay/0000-0003-1396-6341; Yoshida, Kazuhiro/0000-0002-0244-3855;
   Yanai, Hiroyuki/0000-0002-9989-5144; Nagasaka,
   Takeshi/0000-0002-4236-350X
FU KAKENHI [20590572, 25860409, 26462016, 15H03034]; Grants-in-Aid for
   Scientific Research [20590572, 26462016, 15H03034, 25860409] Funding
   Source: KAKEN
FX This study was funded by KAKENHI (20590572, 25860409, 26462016, and
   15H03034).
CR Adsay NV, 2002, J GASTROINTEST SURG, V6, P656, DOI 10.1016/S1091-255X(02)00057-4
   Adsay NV., 2010, WHO CLASSIFICATION T, P304
   Amato E, 2014, J PATHOL, V233, P217, DOI 10.1002/path.4344
   Chadwick B, 2009, APPL IMMUNOHISTO M M, V17, P31, DOI 10.1097/PAI.0b013e31817c02c6
   Chari ST, 2002, GASTROENTEROLOGY, V123, P1500, DOI 10.1053/gast.2002.36552
   Chaumeil J, 2012, CURR OPIN IMMUNOL, V24, P153, DOI 10.1016/j.coi.2012.01.003
   Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023
   Cooper CL, 2013, PATHOLOGY, V45, P286, DOI 10.1097/PAT.0b013e32835f2205
   Dal Molin M, 2013, ANN SURG ONCOL, V20, P3802, DOI 10.1245/s10434-013-3096-1
   Das KK, 2014, GUT, V63, P1627, DOI 10.1136/gutjnl-2013-306219
   Farrell JJ, 2002, GASTROINTEST ENDOSC, V55, P701, DOI 10.1067/mge.2002.123641
   Fritz S, 2009, ANN SURG, V249, P440, DOI 10.1097/SLA.0b013e31819a6e16
   Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161
   Kanda M, 2013, CLIN GASTROENTEROL H, V11, P719, DOI 10.1016/j.cgh.2012.11.016
   Kim SC, 2008, J HEPATO-BILIARY-PAN, V15, P183, DOI 10.1007/s00534-007-1231-8
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875
   Maire F, 2002, GUT, V51, P717, DOI 10.1136/gut.51.5.717
   Matthaei H, 2012, ANN SURG, V255, P326, DOI 10.1097/SLA.0b013e3182378a18
   Mino-Kenudson M, 2011, GUT, V60, P1712, DOI 10.1136/gut.2010.232272
   Mohri D, 2012, J GASTROENTEROL, V47, P203, DOI 10.1007/s00535-011-0482-y
   Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398
   Nagasaka T, 2009, JNCI-J NATL CANCER I, V101, P1244, DOI 10.1093/jnci/djp265
   Nomoto S, 2010, ANN SURG ONCOL, V17, P923, DOI 10.1245/s10434-009-0790-0
   Parmigiani G, 2009, GENOMICS, V93, P17, DOI 10.1016/j.ygeno.2008.07.005
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Raimondo M, 2002, AM J GASTROENTEROL, V97, P2553
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rui W, 2010, LUNG CANCER, V69, P239, DOI 10.1016/j.lungcan.2009.10.009
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Salvia R, 2004, ANN SURG, V239, P678, DOI 10.1097/01.sla.0000124386.54496.15
   Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P280, DOI 10.1007/s00534-005-1056-2
   Schmidt D, 2012, CELL, V148, P335, DOI 10.1016/j.cell.2011.11.058
   Schoedel KE, 2006, DIAGN CYTOPATHOL, V34, P605, DOI 10.1002/dc.20511
   Schönleben F, 2008, LANGENBECK ARCH SURG, V393, P289, DOI 10.1007/s00423-008-0285-7
   Schönleben F, 2007, CANCER LETT, V249, P242, DOI 10.1016/j.canlet.2006.09.007
   SESSA F, 1994, VIRCHOWS ARCH, V425, P357
   Sohn TA, 2004, ANN SURG, V239, P788, DOI 10.1097/01.sla.0000128306.90650.aa
   Takeda M, 2011, ACTA MED OKAYAMA, V65, P169
   Tanaka M, 2012, PANCREATOLOGY, V12, P183, DOI 10.1016/j.pan.2012.04.004
   Wang Z, 2012, PATHOL ONCOL RES, V18, P263, DOI 10.1007/s12253-011-9437-0
   Wasif N, 2010, CANCER-AM CANCER SOC, V116, P3369, DOI 10.1002/cncr.25070
   Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108
   Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543
   Yang TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067458
   Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015
   Zhu XJ, 2014, MOL MED REP, V9, P2283, DOI 10.3892/mmr.2014.2135
NR 47
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD JUL
PY 2016
VL 142
IS 7
BP 1557
EP 1569
DI 10.1007/s00432-016-2164-x
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DN9VS
UT WOS:000377429400016
PM 27095449
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Medina-Aguilar, R
   Pérez-Plasencia, C
   Marchat, LA
   Gariglio, P
   Mena, JG
   Cuevas, SR
   Ruíz-García, E
   Astudillo-de la Vega, H
   Juárez, JH
   Flores-Pérez, A
   López-Camarillo, C
AF Medina-Aguilar, Rubiceli
   Perez-Plasencia, Carlos
   Marchat, Laurence A.
   Gariglio, Patricio
   Garcia Mena, Jaime
   Rodriguez Cuevas, Sergio
   Ruiz-Garcia, Erika
   Astudillo-de la Vega, Horacio
   Hernandez Juarez, Jennifer
   Flores-Perez, Ali
   Lopez-Camarillo, Cesar
TI Methylation Landscape of Human Breast Cancer Cells in Response to
   Dietary Compound Resveratrol
SO PLOS ONE
LA English
DT Article
ID PTEN/AKT PATHWAY; GENE-EXPRESSION; DNA METHYLATION; TUMOR-CELLS; CYCLIN
   B1; PREVENTION; HEXOKINASE; CARCINOMA; APOPTOSIS
AB Aberrant DNA methylation is a frequent epigenetic alteration in cancer cells that has emerged as a pivotal mechanism for tumorigenesis. Accordingly, novel therapies targeting the epigenome are being explored with the aim to restore normal DNA methylation patterns on oncogenes and tumor suppressor genes. A limited number of studies indicate that dietary compound resveratrol modulates DNA methylation of several cancer-related genes; however a complete view of changes in methylome by resveratrol has not been reported yet. In this study we performed a genome-wide survey of DNA methylation signatures in triple negative breast cancer cells exposed to resveratrol. Our data showed that resveratrol treatment for 24 h and 48 h decreased gene promoter hypermethylation and increased DNA hypomethylation. Of 2476 hypermethylated genes in control cells, 1,459 and 1,547 were differentially hypomethylated after 24 h and 48 h, respectively. Remarkably, resveratrol did not induce widespread non-specific DNA hyper- or hypomethylation as changes in methylation were found in only 12.5% of 27,728 CpG loci. Moreover, resveratrol restores the hypomethylated and hypermethylated status of key tumor suppressor genes and oncogenes, respectively. Importantly, the integrative analysis of methylome and transcriptome profiles in response to resveratrol showed that methylation alterations were concordant with changes in mRNA expression. Our findings reveal for the first time the impact of resveratrol on the methylome of breast cancer cells and identify novel potential targets for epigenetic therapy. We propose that resveratrol may be considered as a dietary epidrug as it may exert its anti-tumor activities by modifying the methylation status of cancer-related genes which deserves further in vivo characterization.
C1 [Medina-Aguilar, Rubiceli; Gariglio, Patricio; Garcia Mena, Jaime; Hernandez Juarez, Jennifer] CINVESTAV IPN, Dept Genet & Biol Mol, Mexico City, DF, Mexico.
   [Perez-Plasencia, Carlos] FES Iztacala UNAM, Unidad Biomed, Lab Genom Func, Tlalnepantla, Estado De Mexic, Mexico.
   [Marchat, Laurence A.] Inst Politecn Nacl, Escuela Nacl Med & Homeopatia, Programa Biomed Mol & Red Biotecnol, Mexico City, DF, Mexico.
   [Rodriguez Cuevas, Sergio] FUCAM, Inst Enfermedades Mama, Mexico City, DF, Mexico.
   [Ruiz-Garcia, Erika] Inst Nacl Cancerol, Lab Med Translac, Mexico City, DF, Mexico.
   [Astudillo-de la Vega, Horacio] Hosp Oncol, Ctr Med Siglo 21, Lab Invest Canc & Terapia Celular, Mexico City, DF, Mexico.
   [Flores-Perez, Ali; Lopez-Camarillo, Cesar] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, Mexico City, DF, Mexico.
C3 CINVESTAV - Centro de Investigacion y de Estudios Avanzados del
   Instituto Politecnico Nacional; Universidad Nacional Autonoma de Mexico;
   Instituto Politecnico Nacional - Mexico; Instituto Nacional de
   Cancerologia (INCAN)
RP López-Camarillo, C (通讯作者)，Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, Mexico City, DF, Mexico.
EM genomicas@yahoo.com.mx
RI Perez-Plasencia, Carlos/P-2372-2019; Lopez-Camarillo, Cesar/I-1946-2019;
   Marchat, Laurence/S-8418-2018; Garcia-Mena, Jaime/B-1625-2008
OI Ruiz-Garcia, Erika/0000-0002-0446-123X; Lopez-Camarillo,
   Cesar/0000-0002-9417-2609; Ali, Flores-Perez/0000-0001-9141-9234;
   Marchat, Laurence/0000-0003-1615-8614; Garcia-Mena,
   Jaime/0000-0002-0595-3711; Perez-Plasencia, Carlos/0000-0002-8593-8211
FU CONACYT SALUD [233370, 222335]; CONACYT fellowship; Universidad Autonoma
   de la Ciudad de Mexico (UACM)
FX The authors acknowledge CONACYT SALUD for support of this work (233370
   and 222335 grants). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. Rubiceli Medina was supported by a CONACYT fellowship. The
   authors also thank Universidad Autonoma de la Ciudad de Mexico (UACM)
   for support. We thanks to Universidad Autonoma de la Ciudad de Mexico
   (UACM) for support. Rubiceli Medina was supported by CONACYT fellowship.
CR Adriaens ME, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-42
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Brait M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044951
   BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699
   Chae SW, 2011, YONSEI MED J, V52, P445, DOI 10.3349/ymj.2011.52.3.445
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Colin D, 2011, CANCER PREV RES, V4, P1095, DOI 10.1158/1940-6207.CAPR-10-0274
   Dai WQ, 2015, ONCOTARGET, V6, P13703, DOI 10.18632/oncotarget.3800
   Dhar S, 2015, BBA-MOL CELL RES, V1853, P265, DOI 10.1016/j.bbamcr.2014.11.004
   Dickinson RE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027792
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fanale D, 2013, BREAST CANCER RES TR, V140, P505, DOI 10.1007/s10549-013-2649-0
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637
   Gao Z, 2011, BIOCHEM BIOPH RES CO, V407, P271, DOI 10.1016/j.bbrc.2011.02.008
   Huang V, 2012, NUCLEIC ACIDS RES, V40, P1695, DOI 10.1093/nar/gkr934
   Li D, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-26
   Lin CY, 2013, J FUNCT FOODS, V5, P790, DOI 10.1016/j.jff.2013.01.025
   Link A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057709
   Medina A, 2016, ONCOLOGY REPORTS
   Minatani N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144862
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Ou YW, 2013, CANCER BIOL THER, V14, P45, DOI 10.4161/cbt.22627
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Pfister S, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm094
   Phuah NH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/804510
   Ross SA, 2008, NUTR REV, V66, pS1, DOI 10.1111/j.1753-4887.2008.00055.x
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Thakur VS, 2014, AAPS J, V16, P151, DOI 10.1208/s12248-013-9548-5
   Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263
   Udali S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0077-1
   Whitlock NC, 2012, NUTR CANCER, V64, P493, DOI 10.1080/01635581.2012.667862
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Zhang B, 2009, BLOOD, V114, P4300, DOI 10.1182/blood-2008-12-193326
NR 38
TC 48
Z9 52
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2016
VL 11
IS 6
AR e0157866
DI 10.1371/journal.pone.0157866
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ0AM
UT WOS:000378859400022
PM 27355345
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Fontelles, CC
   Carney, E
   Clarke, J
   Nguyen, NM
   Yin, C
   Jin, L
   Cruz, MI
   Ong, TP
   Hilakivi-Clarke, L
   de Assis, S
AF Fontelles, Camile Castilho
   Carney, Elissa
   Clarke, Johan
   Nguyen, Nguyen M.
   Yin, Chao
   Jin, Lu
   Cruz, M. Idalia
   Ong, Thomas Prates
   Hilakivi-Clarke, Leena
   de Assis, Sonia
TI Paternal overweight is associated with increased breast cancer risk in
   daughters in a mouse model
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCIBLE FACTOR 1-ALPHA; BIRTH-WEIGHT; EPIGENETIC INHERITANCE; SPERM
   RNAS; HIGH-FAT; EXPRESSION; DIET; AGE; PREGNANCY; HYPOXIA
AB While many studies have shown that maternal weight and nutrition in pregnancy affects offspring's breast cancer risk, no studies have investigated the impact of paternal body weight on daughters' risk of this disease. Here, we show that diet-induced paternal overweight around the time of conception can epigenetically reprogram father's germ-line and modulate their daughters' birth weight and likelihood of developing breast cancer, using a mouse model. Increased body weight was associated with changes in the miRNA expression profile in paternal sperm. Daughters of overweight fathers had higher rates of carcinogen-induced mammary tumors which were associated with delayed mammary gland development and alterations in mammary miRNA expression. The hypoxia signaling pathway, targeted by miRNAs down-regulated in daughters of overweight fathers, was activated in their mammary tissues and tumors. This study provides evidence that paternal peri-conceptional body weight may affect daughters' mammary development and breast cancer risk and warrants further studies in other animal models and humans.
C1 [Fontelles, Camile Castilho; Carney, Elissa; Clarke, Johan; Nguyen, Nguyen M.; Yin, Chao; Jin, Lu; Cruz, M. Idalia; Hilakivi-Clarke, Leena; de Assis, Sonia] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA.
   [Fontelles, Camile Castilho; Ong, Thomas Prates] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Food & Expt Nutr, Sao Paulo, SP, Brazil.
   [Fontelles, Camile Castilho; Ong, Thomas Prates] Food Res Ctr, Sao Paulo, SP, Brazil.
C3 Georgetown University; Universidade de Sao Paulo
RP de Assis, S (通讯作者)，Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA.
EM deassiss@georgetown.edu
RI Ong, Thomas/N-1272-2019; Assis, Sonia/N-8274-2013; Castilho Fontelles,
   Camile/J-3722-2016
OI Castilho Fontelles, Camile/0000-0001-9018-5122; Ong,
   Thomas/0000-0002-7709-1866; de Assis, Sonia/0000-0001-5053-0614
FU American Cancer Society; Prevent Cancer Foundation [299045]; National
   Institutes of Health [1P30-CA51008]; Brazilian National Council for
   Scientific and Technological Development (CNPq) [153478/2012-8]
FX We thank the following Lombardi Cancer Center Shared Resources (SR) for
   their assistance: Animal Model SR, Histopathology & Tissue SR and
   Genomics & Epigenomics SR. This study was supported by the American
   Cancer Society (pilot grant to S.D.A.), the Prevent Cancer Foundation
   (Research grant # 299045 to S.D.A.) and National Institutes of Health
   (1P30-CA51008). C.C.F. was supported by a scholarship from the Brazilian
   National Council for Scientific and Technological Development (CNPq;
   153478/2012-8).
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Apostoli AJ, 2014, INT J CANCER, V134, P1055, DOI 10.1002/ijc.28432
   Bentovim L, 2012, DEVELOPMENT, V139, P4473, DOI 10.1242/dev.083881
   Burton NO, 2011, P NATL ACAD SCI USA, V108, P19683, DOI 10.1073/pnas.1113310108
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   Chen Q, 2016, SCIENCE, V351, P397, DOI 10.1126/science.aad7977
   Choi JY, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-143
   de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936
   de Assis Sonia, 2010, J Vis Exp, DOI 10.3791/2260
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   de Assis S, 2011, CANCER PREV RES, V4, P1436, DOI 10.1158/1940-6207.CAPR-10-0346
   Donkin I, 2016, CELL METAB, V23, P369, DOI 10.1016/j.cmet.2015.11.004
   Gapp K, 2014, NAT NEUROSCI, V17, P667, DOI 10.1038/nn.3695
   Goodrich R, 2007, ARCH ANDROLOGY, V53, P161, DOI 10.1080/01485010701216526
   Grandjean V, 2015, SCI REP-UK, V5, DOI 10.1038/srep18193
   Grenier L, 2010, BIOL REPROD, V83, P195, DOI 10.1095/biolreprod.109.083345
   Griffiths LJ, 2007, INT J EPIDEMIOL, V36, P104, DOI 10.1093/ije/dyl210
   Gu SG, 2012, NAT GENET, V44, P157, DOI 10.1038/ng.1039
   Hermo L, 2010, MICROSC RES TECHNIQ, V73, P243, DOI 10.1002/jemt.20783
   Hilakivi-Clarke L, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3649
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Hosken DJ, 2014, TRENDS ECOL EVOL, V29, P451, DOI 10.1016/j.tree.2014.05.006
   Hudson TS, 2012, CARCINOGENESIS, V33, P1225, DOI 10.1093/carcin/bgs129
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Ji BT, 1997, J NATL CANCER I, V89, P238, DOI 10.1093/jnci/89.3.238
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832
   Kawano M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044542
   Kohler Betsy A, 2015, J Natl Cancer Inst, V107, pdjv048, DOI 10.1093/jnci/djv048
   Lambrot R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3889
   Liu WM, 2012, P NATL ACAD SCI USA, V109, P490, DOI 10.1073/pnas.1110368109
   Marczylo EL, 2012, EPIGENETICS-US, V7, P432, DOI 10.4161/epi.19794
   Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x
   Messerschmidt DM, 2014, GENE DEV, V28, P812, DOI 10.1101/gad.234294.113
   Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841
   Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491
   Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850
   Pasquier J, 2015, J ONCOL, V2015, DOI 10.1155/2015/792182
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Rando OJ, 2012, CELL, V151, P702, DOI 10.1016/j.cell.2012.10.020
   Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rodgers AB, 2015, P NATL ACAD SCI USA, V112, P13699, DOI 10.1073/pnas.1508347112
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   Sendler E, 2013, NUCLEIC ACIDS RES, V41, P4104, DOI 10.1093/nar/gkt132
   Sharma U, 2016, SCIENCE, V351, P391, DOI 10.1126/science.aad6780
   Soubry A, 2015, INT J OBESITY, V39, P650, DOI 10.1038/ijo.2013.193
   Soubry A, 2015, PROG BIOPHYS MOL BIO, V118, P79, DOI 10.1016/j.pbiomolbio.2015.02.008
   Soubry A, 2014, BIOESSAYS, V36, P359, DOI 10.1002/bies.201300113
   Soubry A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-29
   Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4
   Teras LR, 2015, AM J EPIDEMIOL, V182, P41, DOI 10.1093/aje/kwu487
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang W, 2014, CLIN CHIM ACTA, V428, P32, DOI 10.1016/j.cca.2013.10.018
   Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007
   Weiss-Salz I, 2007, EUR J CANCER PREV, V16, P549, DOI 10.1097/CEJ.0b013e328032783f
   Ye LY, 2014, PANCREATOLOGY, V14, P391, DOI 10.1016/j.pan.2014.06.008
   Yu ZR, 2012, J MAMMARY GLAND BIOL, V17, P59, DOI 10.1007/s10911-012-9246-4
NR 65
TC 24
Z9 25
U1 0
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 24
PY 2016
VL 6
DI 10.1038/srep28602
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DP7BS
UT WOS:000378654600001
PM 27339599
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Yoshihama, S
   Roszik, J
   Downs, I
   Meissner, TB
   Vijayan, S
   Chapuy, B
   Sidiq, T
   Shipp, MA
   Lizee, GA
   Kobayashi, KS
AF Yoshihama, Sayuri
   Roszik, Jason
   Downs, Isaac
   Meissner, Torsten B.
   Vijayan, Saptha
   Chapuy, Bjoern
   Sidiq, Tabasum
   Shipp, Margaret A.
   Lizee, Gregory A.
   Kobayashi, Koichi S.
TI NLRC5/MHC class I transactivator is a target for immune evasion in
   cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE MHC class I; CITA; cancer; immune evasion; NLRC5
ID MHC CLASS-I; HLA CLASS-I; NUCLEOTIDE-BINDING DOMAIN; GENE-EXPRESSION;
   BREAST-CANCER; CELLS; RESPONSES; ANTIGEN; TUMORS; CARCINOGENESIS
AB Cancer cells develop under immune surveillance, thus necessitating immune escape for successful growth. Loss of MHC class I expression provides a key immune evasion strategy in many cancers, although the molecular mechanisms remain elusive. MHC class I transactivator (CITA), known as "NLRC5" [NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5], has recently been identified as a critical transcriptional coactivator of MHC class I gene expression. Here we show that the MHC class I transactivation pathway mediated by CITA/NLRC5 constitutes a target for cancer immune evasion. In all the 21 tumor types we examined, NLRC5 expression was highly correlated with the expression of MHC class I, with cytotoxic T-cell markers, and with genes in the MHC class I antigen-presentation pathway, including LMP2/LMP7, TAP1, and beta 2-microglobulin. Epigenetic and genetic alterations in cancers, including promoter methylation, copy number loss, and somatic mutations, were most prevalent in NLRC5 among all MHC class I-related genes and were associated with the impaired expression of components of the MHC class I pathway. Strikingly, NLRC5 expression was significantly associated with the activation of CD8(+) cytotoxic T cells and patient survival in multiple cancer types. Thus, NLRC5 constitutes a novel prognostic biomarker and potential therapeutic target of cancers.
C1 [Yoshihama, Sayuri; Downs, Isaac; Vijayan, Saptha; Sidiq, Tabasum; Kobayashi, Koichi S.] Texas A&M Hlth Sci Ctr, Dept Microbial Pathogenesis & Immunol, College Stn, TX 77843 USA.
   [Yoshihama, Sayuri] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba 2608670, Japan.
   [Roszik, Jason; Lizee, Gregory A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77054 USA.
   [Meissner, Torsten B.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Lizee, Gregory A.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Chiba University; University of Texas System;
   UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Dana-Farber Cancer Institute; University
   of Texas System; UTMD Anderson Cancer Center
RP Kobayashi, KS (通讯作者)，Texas A&M Hlth Sci Ctr, Dept Microbial Pathogenesis & Immunol, College Stn, TX 77843 USA.
EM kobayashi@medicine.tamhsc.edu
RI Vijayan, Saptha/AAA-1727-2019
OI Vijayan, Saptha/0000-0002-2194-9843; Kobayashi,
   Koichi/0000-0003-2930-0114; Roszik, Janos/0000-0002-4561-6170; Lizee,
   Gregory/0000-0003-4449-7461; Chapuy, Bjoern/0000-0002-6485-8773
FU NIH [R01DK074738]; Broad Foundation [IBD-0328]; National Multiple
   Sclerosis Society [PP1779]; Texas A&M Clinical Science and Translational
   Research Institute, Texas A&M Genomics Grant Program; Center for
   Translational Environmental and Health Research; Sumitomo Life Welfare
   and Culture Foundation
FX This work was supported by NIH Grant R01DK074738, Broad Foundation Grant
   IBD-0328, and National Multiple Sclerosis Society Grant PP1779 (to
   K.S.K.), by the Texas A&M Clinical Science and Translational Research
   Institute, Texas A&M Genomics Grant Program, and the Center for
   Translational Environmental and Health Research (K.S.K.). S.Y. is the
   recipient of a fellowship from the Sumitomo Life Welfare and Culture
   Foundation.
CR Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215
   Biswas A, 2012, J IMMUNOL, V189, P516, DOI 10.4049/jimmunol.1200064
   Campoli M, 2008, ONCOGENE, V27, P5869, DOI 10.1038/onc.2008.273
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Dietrich Jorg, 2011, Expert Rev Clin Pharmacol, V4, P233, DOI 10.1586/ecp.11.1
   Djajadiningrat RS, 2015, J UROLOGY, V193, P1245, DOI 10.1016/j.juro.2014.11.057
   Dubois LG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00418
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270
   Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9
   Hanagiri T, 2013, ANTICANCER RES, V33, P2123
   Inoue M, 2012, ONCOIMMUNOLOGY, V1, P1104, DOI 10.4161/onci.21056
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kobayashi KS, 2012, NAT REV IMMUNOL, V12, P813, DOI 10.1038/nri3339
   Kuenzel S, 2010, J IMMUNOL, V184, P1990, DOI 10.4049/jimmunol.0900557
   Lampen MH, 2011, CURR OPIN IMMUNOL, V23, P293, DOI 10.1016/j.coi.2010.12.005
   Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692
   Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91
   Ludigs K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005088
   Meissner TB, 2012, MICROBES INFECT, V14, P477, DOI 10.1016/j.micinf.2011.12.007
   Meissner TB, 2012, J IMMUNOL, V188, P4951, DOI 10.4049/jimmunol.1103160
   Meissner TB, 2012, BIOCHEM BIOPH RES CO, V418, P786, DOI 10.1016/j.bbrc.2012.01.104
   Meissner TB, 2010, P NATL ACAD SCI USA, V107, P13794, DOI 10.1073/pnas.1008684107
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004
   Pollack BP, 2011, CLIN CANCER RES, V17, P4400, DOI 10.1158/1078-0432.CCR-10-3283
   Robbins GR, 2012, J BIOL CHEM, V287, P24294, DOI 10.1074/jbc.M112.364604
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Staehli F, 2012, J IMMUNOL, V188, P3820, DOI 10.4049/jimmunol.1102671
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040
   Sun QF, 2011, J THORAC CARDIOV SUR, V141, P808, DOI 10.1016/j.jtcvs.2010.04.031
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tong YZ, 2012, CELL RES, V22, P822, DOI 10.1038/cr.2012.53
   Vermeulen CFW, 2005, HUM IMMUNOL, V66, P1167, DOI 10.1016/j.humimm.2005.10.011
   Yao Y, 2012, CELL RES, V22, P836, DOI 10.1038/cr.2012.56
NR 43
TC 207
Z9 226
U1 4
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 24
PY 2016
VL 113
IS 21
BP 5999
EP 6004
DI 10.1073/pnas.1602069113
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN0UD
UT WOS:000376779900068
PM 27162338
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Bell, JSK
   Kagey, JD
   Barwick, BG
   Dwivedi, B
   McCabe, MT
   Kowalski, J
   Vertino, PM
AF Bell, Joshua S. K.
   Kagey, Jacob D.
   Barwick, Benjamin G.
   Dwivedi, Bhakti
   McCabe, Michael T.
   Kowalski, Jeanne
   Vertino, Paula M.
TI Factors affecting the persistence of drug-induced reprogramming of the
   cancer methylome
SO EPIGENETICS
LA English
DT Article
DE Cancer; chromatin; DNA methylation; epigenetic therapy; 5-aza-2 '
   deoxycytidine
ID CPG ISLAND PROMOTERS; RNA-POLYMERASE-II; R-LOOP FORMATION; DNA
   METHYLATION; DEMETHYLATING AGENTS; GENE-EXPRESSION; OVARIAN-CANCER;
   METHYLTRANSFERASE SETD2; EPIGENETIC THERAPY; MYELOID-LEUKEMIA
AB Aberrant DNA methylation is a critical feature of cancer. Epigenetic therapy seeks to reverse these changes to restore normal gene expression. DNA demethylating agents, including 5-aza-2'-deoxycytidine (DAC), are currently used to treat certain leukemias, and can sensitize solid tumors to chemotherapy and immunotherapy. However, it has been difficult to pin the clinical efficacy of these agents to specific demethylation events, and the factors that contribute to the durability of response remain largely unknown. Here we examined the genome-wide kinetics of DAC-induced DNA demethylation and subsequent remethylation after drug withdrawal in breast cancer cells. We find that CpGs differ in both their susceptibility to demethylation and propensity for remethylation after drug removal. DAC-induced demethylation was most apparent at CpGs with higher initial methylation levels and further from CpG islands. Once demethylated, such sites exhibited varied remethylation potentials. The most rapidly remethylating CpGs regained >75% of their starting methylation within a month of drug withdrawal. These sites had higher pretreatment methylation levels, were enriched in gene bodies, marked by H3K36me3, and tended to be methylated in normal breast cells. In contrast, a more resistant class of CpG sites failed to regain even 20% of their initial methylation after 3 months. These sites had lower pretreatment methylation levels, were within or near CpG islands, marked by H3K79me2 or H3K4me2/3, and were overrepresented in sites that become aberrantly hypermethylated in breast cancers. Thus, whereas DAC-induced demethylation affects both endogenous and aberrantly methylated sites, tumor-specific hypermethylation is more slowly regained, even as normal methylation promptly recovers. Taken together, these data suggest that the durability of DAC response is linked to its selective ability to stably reset at least a portion of the cancer methylome.
C1 [Bell, Joshua S. K.; Kagey, Jacob D.; Barwick, Benjamin G.] Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA.
   [Dwivedi, Bhakti; Kowalski, Jeanne; Vertino, Paula M.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [McCabe, Michael T.; Vertino, Paula M.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Kowalski, Jeanne] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University; Emory University
RP Vertino, PM (通讯作者)，Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Vertino, PM (通讯作者)，Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
RI Barwick, Benjamin/O-5185-2019
OI Dwivedi, Bhakti/0000-0002-9029-3737; Kowalski,
   Jeanne/0000-0003-3458-3024; Barwick, Benjamin/0000-0001-9810-3566;
   Kagey, Jacob/0000-0002-6994-1795
FU Winship Biostatistics and Bioinformatics Shared Resource of Emory
   University; Winship Cancer Center Support [P30 CA0138292]
FX This research project was supported in part by the Winship Biostatistics
   and Bioinformatics Shared Resource of Emory University and the Winship
   Cancer Center Support grant P30 CA0138292.
CR Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736
   Barfield RT, 2012, BIOINFORMATICS, V28, P1280, DOI 10.1093/bioinformatics/bts124
   Baubec T, 2015, NATURE, V520, P243, DOI 10.1038/nature14176
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Blattler A, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0469-0
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472
   Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433
   Duncan CG, 2012, GENOME RES, V22, P2339, DOI 10.1101/gr.132738.111
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547
   Follo MY, 2011, LEUKEMIA, V25, P271, DOI 10.1038/leu.2010.266
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Ginno PA, 2013, GENOME RES, V23, P1590, DOI 10.1101/gr.158436.113
   Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jonkers I, 2014, ELIFE, V3, DOI 10.7554/eLife.02407
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kalac M, 2011, BLOOD, V118, P5506, DOI 10.1182/blood-2011-02-336891
   Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004
   Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740
   Kellner WA, 2015, GENOME RES, V25, P1600, DOI 10.1101/gr.189068.114
   Koch F, 2011, TRANSCR-AUSTIN, V2, P263, DOI 10.4161/trns.2.6.18747
   KOHONEN T, 1990, P IEEE, V78, P1464, DOI 10.1109/5.58325
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Liu XL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2562
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739
   Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126
   Patel K, 2010, NUCLEIC ACIDS RES, V38, P4313, DOI 10.1093/nar/gkq187
   Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shen LL, 2010, J CLIN ONCOL, V28, P605, DOI 10.1200/JCO.2009.23.4781
   Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Treppendahl MB, 2014, J CLIN INVEST, V124, P47, DOI 10.1172/JCI69737
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Veloso A, 2014, GENOME RES, V24, P896, DOI 10.1101/gr.171405.113
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Zheng WH, 2012, J AM CHEM SOC, V134, P18004, DOI 10.1021/ja307060p
NR 60
TC 6
Z9 10
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2016
VL 11
IS 4
BP 273
EP 287
DI 10.1080/15592294.2016.1158364
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DN7RC
UT WOS:000377274000003
PM 27082926
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU O'Sullivan, DE
   Johnson, KC
   Skinner, L
   Koestler, DC
   Christensen, BC
AF O'Sullivan, Dylan E.
   Johnson, Kevin C.
   Skinner, Lucy
   Koestler, Devin C.
   Christensen, Brock C.
TI Epigenetic and genetic burden measures are associated with tumor
   characteristics in invasive breast carcinoma
SO EPIGENETICS
LA English
DT Article
DE Breast cancer; DNA methylation; deregulation; dysregulation; epigenome;
   TCGA
ID DNA METHYLATION; CANCER; CLASSIFICATION; TISSUE
AB The development and progression of invasive breast cancer is characterized by alterations to the genome and epigenome. However, the relationship between breast tumor characteristics, disease subtypes, and patient outcomes with the cumulative burden of these molecular alterations are not well characterized. We determined the average departure of tumor DNA methylation from adjacent normal breast DNA methylation using Illumina 450K methylation data from 700 invasive breast tumors and 90 adjacent normal breast tissues in The Cancer Genome Atlas. From this we generated a novel summary measure of altered DNA methylation, the DNA methylation dysregulation index (MDI), and examined the relation of MDI with tumor characteristics and summary measures that quantify cumulative burden of genetic mutation and copy number alterations. Our analysis revealed that MDI was significantly associated with tumor stage (P = 0.017). Across invasive breast tumor subtypes we observed significant differences in genome-wide DNA MDIs (P = 4.9E-09) and in a fraction of the genome with copy number alterations (FGA) (P = 4.6E-03). Results from a linear regression adjusted for subject age, tumor stage, and estimated tumor purity indicated a positive significant association of MDI with both MCB and FGA (P = 0.036 and P < 2.2E-16). A recursively partitioned mixture model of all 3 somatic alteration burden measures resulted in classes of tumors whose epigenetic and genetic burden profile were associated with the PAM50 subtype and mutations in TP53, PIK3CA, and CDH1. Together, our work presents a novel framework for characterizing the epigenetic burden and adds to the understanding of the aggregate impact of epigenetic and genetic alterations in breast cancer.
C1 [O'Sullivan, Dylan E.; Johnson, Kevin C.; Skinner, Lucy; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Epidemiol, Hanover, NH USA.
   [O'Sullivan, Dylan E.; Johnson, Kevin C.; Skinner, Lucy; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
   [Koestler, Devin C.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
   [Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH USA.
C3 Dartmouth College; Dartmouth College; University of Kansas; University
   of Kansas Medical Center; Dartmouth College
RP Johnson, KC (通讯作者)，Geisel Sch Med Dartmouth, Dept Epidemiol, Hanover, NH USA.; Johnson, KC (通讯作者)，Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
EM Kevin.C.johnson.GR@Dartmouth.edu
RI Christensen, Brock/B-8460-2009; Koestler, Devin/D-7902-2015
OI Koestler, Devin/0000-0002-0598-0146
FU National Institutes of Health [P20GM104416/8189]
FX This work was supported by the National Institutes of Health (grant
   numbers P20GM104416/8189 to [BCC]).
CR Birkbak NJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080023
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Houseman EA, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0527-y
   Houseman EA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-365
   Houseman EA, 2014, CANCER INFORM, V13, P53, DOI 10.4137/CIN.S13980
   Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Roy DM, 2014, PROTEIN CELL, V5, P265, DOI 10.1007/s13238-014-0031-6
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21332
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758
   van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang Z, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0699-9
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
NR 29
TC 12
Z9 14
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2016
VL 11
IS 5
BP 344
EP 353
DI 10.1080/15592294.2016.1168673
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DN7RJ
UT WOS:000377274700003
PM 27070496
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Sun, RR
   Shen, J
   Gao, Y
   Zhou, YB
   Yu, ZJ
   Hornicek, F
   Kan, QC
   Duan, ZF
AF Sun, Ranran
   Shen, Jacson
   Gao, Yan
   Zhou, Yubing
   Yu, Zujiang
   Hornicek, Francis
   Kan, Quancheng
   Duan, Zhenfeng
TI Overexpression of EZH2 is associated with the poor prognosis in
   osteosarcoma and function analysis indicates a therapeutic potential
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma; EZH2; tissue microarray; proliferation; apoptosis
ID TUMOR-CELL PROLIFERATION; CANCER STEM-CELLS; BREAST-CANCER; HISTONE H3;
   EXPRESSION; GENE; PROGRESSION; INHIBITOR; PROSTATE; INVASION
AB Osteosarcoma is a primary malignant bone tumor that has a poor prognosis due to local recurrence, metastasis, and chemotherapy resistance. Therefore, there is an urgent need to develop novel potential therapeutic targets for osteosarcoma. Enhancer of zeste homologue 2 (EZH2) is a member of the polycomb group of proteins, which has important functions in epigenetic silencing and cell cycle regulation. Overexpression of EZH2 has been found in several malignancies, however, its expression and the role of EZH2 in osteosarcoma is largely unknown. In this study, we examined EZH2 expression by immunohistochemistry in a large series of osteosarcoma tissues in association with tumor characteristics and patient outcomes. EZH2 expression was also analyzed in a microarray dataset of osteosarcoma. Results showed that higher expression of EZH2 was significantly associated with more aggressive tumor behavior and poor patient outcomes of osteosarcoma. We subsequently investigated the functional and therapeutic relevance of EZH2 as a target in osteosarcoma. Immunohistochemical analysis indicated that EZH2 expression was significantly associated with more aggressive tumor behavior and poorer patient outcomes of osteosarcoma. EZH2 silencing by siRNA inhibited osteosarcoma cell growth, proliferation, migration, and invasion. Moreover, suppression of EZH2 attenuated cancer stem cell functions. Similar results were observed in osteosarcoma cells treated with EZH2 specific inhibitor 3-deazaneplanocin A (DZNep), which exhausted cellular levels of EZH2. These results suggest that EZH2 is critical for the growth and metastasis of osteosarcoma, and an epigenetic therapy that pharmacologically targets EZH2 via specific inhibitors may constitute a novel approach to the treatment of osteosarcoma.
C1 [Sun, Ranran; Zhou, Yubing; Yu, Zujiang; Kan, Quancheng; Duan, Zhenfeng] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Henan, Peoples R China.
   [Sun, Ranran; Shen, Jacson; Gao, Yan; Hornicek, Francis; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
C3 Zhengzhou University; Harvard University; Massachusetts General Hospital
RP Kan, QC; Duan, ZF (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Henan, Peoples R China.; Duan, ZF (通讯作者)，Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
EM qckan19632012@163.com; zduan@mgh.harvard.edu
OI Hornicek, Francis/0000-0002-6916-8042
FU Joint Research Fund devoted to clinical pharmacy and precision medicine;
   National Natural Science Foundation of China [81402266, 81372875];
   Gattegno fund; Kenneth Stanton Fund; Wechsler fund; 5451 project of
   Health Science and Technology of Henan Province, China
FX This work was supported by a Joint Research Fund devoted to clinical
   pharmacy and precision medicine (Z.D and Q.K). Support has also been
   provided by the National Natural Science Foundation of China (No.:
   81402266 and 81372875), the Gattegno and Wechsler funds, and the Kenneth
   Stanton Fund. Dr. Sun is supported by the 5451 project of Health Science
   and Technology of Henan Province, China.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Bjornland K, 2005, J SURG RES, V127, P151, DOI 10.1016/j.jss.2004.12.016
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078-0432.CCR-10-2047
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Chen HM, 1996, GENOMICS, V38, P30, DOI 10.1006/geno.1996.0588
   Chen YC, 2010, CANCER LETT, V297, P109, DOI 10.1016/j.canlet.2010.05.003
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Gao Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11365
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hayden A, 2011, BREAST CANCER RES TR, V127, P109, DOI 10.1007/s10549-010-0982-0
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431
   Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304
   Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112
   Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Li H, 2012, CANCER PREV RES, V5, P484, DOI 10.1158/1940-6207.CAPR-11-0414
   Liu B, 2011, ACTA ONCOL, V50, P1142, DOI 10.3109/0284186X.2011.584553
   Lv YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12999
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mu ZM, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-70
   Osaka E, 2014, J ORTHOP RES, V32, P1075, DOI 10.1002/jor.22632
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585-011-9384-x
   Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Simon R, 2007, CANCER INFORM, V3, P11
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Zhang LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075851
   Zhou WY, 2014, DISCOV MED, V17, P301
NR 43
TC 51
Z9 55
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 21
PY 2016
VL 7
IS 25
BP 38333
EP 38346
DI 10.18632/oncotarget.9518
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DP1CW
UT WOS:000378229100073
PM 27223261
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chen, XH
   Hu, HY
   He, L
   Yu, XY
   Liu, XY
   Zhong, R
   Shu, MG
AF Chen, Xiaohua
   Hu, Hanyang
   He, Lin
   Yu, Xueyuan
   Liu, Xiangyu
   Zhong, Rong
   Shu, Maoguo
TI A novel subtype classification and risk of breast cancer by histone
   modification profiling
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Histone modification; Bivalent chromatin; Subtype classification; Breast
   cancer
ID GENE; TRANSCRIPTION; PROGRESSION; PLASTICITY; SURVIVAL; OVARIAN; MEMORY;
   SOX4; RACE
AB Breast cancer has been classified into several intrinsic molecular subtypes on the basis of genetic and epigenetic factors. However, knowledge about histone modifications that contribute to the classification and development of biologically distinct breast cancer subtypes remains limited. Here we compared the genome-wide binding patterns of H3K4me3 and H3K27me3 between human mammary epithelial cells and three breast cancer cell lines representing the luminal, HER2, and basal subtypes. We characterized thousands of unique binding events as well as bivalent chromatin signatures unique to each cancer subtype, which were involved in different epigenetic regulation programs and signaling pathways in breast cancer progression. Genes linked to the unique histone mark features exhibited subtype-specific expression patterns, both in cancer cell lines and primary tumors, some of which were confirmed by qPCR in our primary cancer samples. Finally, histone mark-based gene classifiers were significantly correlated with relapse-free survival outcomes in patients. In summary, we have provided a valuable resource for the identification of novel biomarkers of subtype classification and clinical prognosis evaluation in breast cancers.
C1 [Chen, Xiaohua; He, Lin; Yu, Xueyuan; Liu, Xiangyu; Shu, Maoguo] Xi An Jiao Tong Univ, Dept Plast Aesthet & Craniofacial Surg, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Chen, Xiaohua] PLA, Dept Lab Med, Hosp 161, Wuhan 430010, Peoples R China.
   [Chen, Xiaohua; Hu, Hanyang] Wuhan Univ, Sch Basic Med Sci, Wuhan 430071, Peoples R China.
   [Shu, Maoguo] Forth Mil Med Univ, Xijing Hosp, Dept Plast Surg, Xian 710032, Peoples R China.
   [Zhong, Rong] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Dept Epidemiol & Biostat, Wuhan 430030, Peoples R China.
   [Zhong, Rong] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth, Wuhan 430030, Peoples R China.
C3 Xi'an Jiaotong University; Wuhan University; Air Force Military Medical
   University; Huazhong University of Science & Technology; Huazhong
   University of Science & Technology
RP Shu, MG (通讯作者)，Xi An Jiao Tong Univ, Dept Plast Aesthet & Craniofacial Surg, Affiliated Hosp 1, Xian 710061, Peoples R China.; Shu, MG (通讯作者)，Forth Mil Med Univ, Xijing Hosp, Dept Plast Surg, Xian 710032, Peoples R China.
EM shumaoguo@163.com
RI Liu, Xiangyu/JVZ-3534-2024; Zhong, Rong/Q-1813-2019
OI Hu, Hanyang/0000-0002-5867-3668
FU National Natural Science Foundation of China [81372077]
FX We thank the respective authors for their contributions to generate the
   sequencing data, as well as all the people who participated in this
   study and helped us successfully complete the research. This work was
   supported by the National Natural Science Foundation of China (Grant No.
   81372077).
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bapat SA, 2010, EPIGENETICS-US, V5, P716, DOI 10.4161/epi.5.8.13014
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chaligné R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Marjanovic ND, 2013, CELL CYCLE, V12, P2713, DOI 10.4161/cc.26075
   Markou A, 2014, CLIN CHEM, V60, P197, DOI 10.1373/clinchem.2013.210542
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092
   O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466
   Peng F, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.4
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454
   Su Y, 2015, CELL REP, V11, P1549, DOI 10.1016/j.celrep.2015.05.011
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
NR 40
TC 22
Z9 27
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2016
VL 157
IS 2
BP 267
EP 279
DI 10.1007/s10549-016-3826-8
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM7ZU
UT WOS:000376580900007
PM 27178334
DA 2025-01-12
ER

PT J
AU Vázquez-Martínez, ER
   Camacho-Arroyo, I
   Zarain-Herzberg, A
   Rodríguez, MC
   Mendoza-Garcés, L
   Ostrosky-Wegman, P
   Cerbón, M
AF Ricardo Vazquez-Martinez, Edgar
   Camacho-Arroyo, Ignacio
   Zarain-Herzberg, Angel
   Carmen Rodriguez, Maria
   Mendoza-Garces, Luciano
   Ostrosky-Wegman, Patricia
   Cerbon, Marco
TI Estradiol differentially induces progesterone receptor isoforms
   expression through alternative promoter regulation in a mouse embryonic
   hypothalamic cell line
SO ENDOCRINE
LA English
DT Article
DE Progesterone receptor isoforms; Estradiol; Epigenetic marks;
   Transcription factors; Hypothalamus; Histone acetylation
ID BREAST-CANCER CELLS; ELEMENT HALF-SITE; ESTROGEN-RECEPTOR; DNA
   METHYLATION; RAT-BRAIN; GENE-EXPRESSION; SEXUAL-DIFFERENTIATION; HISTONE
   ACETYLATION; HUMAN GENOME; ALPHA
AB Progesterone receptor (PR) presents two main isoforms (PR-A and PR-B) that are regulated by two specific promoters and transcribed from alternative transcriptional start sites. The molecular regulation of PR isoforms expression in embryonic hypothalamus is poorly understood. The aim of the present study was to assess estradiol regulation of PR isoforms in a mouse embryonic hypothalamic cell line (mHypoE-N42), as well as the transcriptional status of their promoters. MHypoE-N42 cells were treated with estradiol for 6 and 12 h. Then, Western blot, real-time quantitative reverse transcription polymerase chain reaction, and chromatin and DNA immunoprecipitation experiments were performed. PR-B expression was transiently induced by estradiol after 6 h of treatment in an estrogen receptor alpha (ER alpha)-dependent manner. This induction was associated with an increase in ER alpha phosphorylation (serine 118) and its recruitment to PR-B promoter. After 12 h of estradiol exposure, a downregulation of this PR isoform was associated with a decrease of specific protein 1, histone 3 lysine 4 trimethylation, and RNA polymerase II occupancy on PR-B promoter, without changes in DNA methylation and hydroxymethylation. In contrast, there were no estradiol-dependent changes in PR-A expression that could be related with the epigenetic marks or the transcription factors evaluated. We demonstrate that PR isoforms are differentially regulated by estradiol and that the induction of PR-B expression is associated to specific transcription factors interactions and epigenetic changes in its promoter in embryonic hypothalamic cells.
C1 [Ricardo Vazquez-Martinez, Edgar; Camacho-Arroyo, Ignacio; Cerbon, Marco] Univ Nacl Autonoma Mexico, Unidad Invest Reprod Humana, Inst Nacl Perinatol, Fac Quim, Ciudad Univ,Av Univ 3000, Mexico City 04510, DF, Mexico.
   [Zarain-Herzberg, Angel] Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City, DF, Mexico.
   [Carmen Rodriguez, Maria] SSA, Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico.
   [Mendoza-Garces, Luciano] SSA, Inst Nacl Geriatria, Cuernavaca, DF, Mexico.
   [Ostrosky-Wegman, Patricia] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Med Genom & Toxicol Ambiental, Mexico City, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma
   de Mexico; Instituto Nacional de Salud Publica; Universidad Nacional
   Autonoma de Mexico
RP Cerbón, M (通讯作者)，Univ Nacl Autonoma Mexico, Unidad Invest Reprod Humana, Inst Nacl Perinatol, Fac Quim, Ciudad Univ,Av Univ 3000, Mexico City 04510, DF, Mexico.
EM mcerbon85@yahoo.com.mx
RI Camacho-Arroyo, Ignacio/AAM-4654-2021
OI VAZQUEZ-MARTINEZ, EDGAR RICARDO/0000-0001-7151-2976; Mendoza-Garces,
   Luciano/0000-0002-0646-7088
FU Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica
   (PAPIIT) [IN210412, IA202814]; Programa de Apoyo a la Investigacion para
   Estudiantes de Posgrado (PAIP) from the Universidad Nacional Autonoma de
   Mexico (UNAM, Mexico) [5000-9108, 5000-9141]; CONACYT [CVU 288806]
FX We acknowledge the technical support of Lucia Flores Peredo
   (Departamento de Bioquimica, Facultad de Medicina, Universidad Nacional
   Autonoma de Mexico, Mexico) regarding ChIP technique and Patricia
   Mendoza-Lorenzo (Division Academica de Ciencias Basicas, Unidad
   Chontalpa, Universidad Juarez Autonoma de Tabasco, Mexico) for her
   assistance in real-time PCR experiments. This work was supported by the
   Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica
   (PAPIIT) No. IN210412 and IA202814, and Programa de Apoyo a la
   Investigacion para Estudiantes de Posgrado (PAIP) No. 5000-9108 and
   5000-9141, from the Universidad Nacional Autonoma de Mexico (UNAM,
   Mexico). E.R.V-M. is recipient of a Ph.D. scholarship from CONACYT (CVU
   288806).
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Camacho-Arroyo I, 2003, COMP BIOCHEM PHYS A, V136, P447, DOI 10.1016/S1095-6433(03)00204-6
   Camacho-Arroyo I, 1998, NEUROREPORT, V9, P3993, DOI 10.1097/00001756-199812210-00001
   Camacho-Arroyo I, 2007, COMP BIOCHEM PHYS A, V146, P644, DOI 10.1016/j.cbpa.2006.04.023
   Chai SY, 2012, MOL HUM REPROD, V18, P401, DOI 10.1093/molehr/gas012
   Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9
   Dalvi PS, 2011, AM J PHYSIOL-REG I, V300, pR1030, DOI 10.1152/ajpregu.00649.2010
   Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281
   Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P3928, DOI 10.1210/en.140.9.3928
   Fleury L, 2008, ONCOGENE, V27, P4075, DOI 10.1038/onc.2008.41
   Gagnidze K, 2013, J NEUROENDOCRINOL, V25, P939, DOI 10.1111/jne.12085
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Gavin DP, 2013, NEUROPHARMACOLOGY, V75, P233, DOI 10.1016/j.neuropharm.2013.07.036
   Gonzales KL, 2012, J NEUROENDOCRINOL, V24, P285, DOI 10.1111/j.1365-2826.2011.02232.x
   Gonzales KL, 2008, ENDOCRINOLOGY, V149, P4615, DOI 10.1210/en.2008-0511
   González-Arenas A, 2012, BBA-MOL CELL RES, V1823, P379, DOI 10.1016/j.bbamcr.2011.11.004
   Guerra-Araiza C, 2000, LIFE SCI, V66, P1743, DOI 10.1016/S0024-3205(00)00497-5
   Guerra-Araiza C, 2002, BRAIN RES BULL, V59, P105, DOI 10.1016/S0361-9230(02)00845-6
   HAGIHARA K, 1994, BIOCHEM BIOPH RES CO, V205, P1093, DOI 10.1006/bbrc.1994.2778
   Hansberg-Pastor V, 2013, STEROIDS, V78, P500, DOI 10.1016/j.steroids.2013.02.010
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Khan S, 2007, J MOL ENDOCRINOL, V39, P289, DOI 10.1677/JME-07-0043
   KRAUS WL, 1993, MOL ENDOCRINOL, V7, P1603, DOI 10.1210/me.7.12.1603
   Kuo John, 2010, Biol Sex Differ, V1, P7, DOI 10.1186/2042-6410-1-7
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee BY, 2012, NUCLEIC ACIDS RES, V40, P2481, DOI 10.1093/nar/gkr1115
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li X, 2014, REPROD SCI, V21, P898, DOI 10.1177/1933719113518982
   Mendoza-Garcés L, 2013, BRAIN RES, V1535, P71, DOI 10.1016/j.brainres.2013.08.042
   Mendoza-Garcés L, 2010, NEUROREPORT, V21, P513, DOI 10.1097/WNR.0b013e3283390440
   Meyer JL, 2014, INT J MOL MED, V33, P897, DOI 10.3892/ijmm.2014.1637
   Nestor CE, 2014, METHODS MOL BIOL, V1094, P259, DOI 10.1007/978-1-62703-706-8_20
   OMALLEY BW, 1970, P NATL ACAD SCI USA, V67, P501
   Pathiraja TN, 2011, CLIN CANCER RES, V17, P4177, DOI 10.1158/1078-0432.CCR-10-2950
   Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369
   Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008
   Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972
   Quadros PS, 2008, ENDOCRINOLOGY, V149, P3054, DOI 10.1210/en.2007-1133
   Quadros PS, 2007, J COMP NEUROL, V504, P42, DOI 10.1002/cne.21427
   Quadros PS, 2002, ENDOCRINOLOGY, V143, P3727, DOI 10.1210/en.2002-211438
   Vázquez-Martínez ER, 2014, MOL CELL ENDOCRINOL, V392, P115, DOI 10.1016/j.mce.2014.05.011
   Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200
   Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X
   Schwarz JM, 2010, ENDOCRINOLOGY, V151, P4871, DOI 10.1210/en.2010-0142
   Stratmann A, 2011, FEBS J, V278, P1458, DOI 10.1111/j.1742-4658.2011.08058.x
   Tang MY, 2002, MOL CELL ENDOCRINOL, V192, P45, DOI 10.1016/S0303-7207(02)00111-9
   VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244
   Wagner CK, 1998, ENDOCRINOLOGY, V139, P3658, DOI 10.1210/en.139.8.3658
   White MM, 2007, J MOL ENDOCRINOL, V38, P35, DOI 10.1677/jme.1.02058
   Won J.K., 2012, MOL ENDOCRINOL, V26, P955, DOI DOI 10.1210/ME.2012-1066
   Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003
   Yang HC, 2014, NUCLEIC ACIDS RES, V42, P13573, DOI 10.1093/nar/gku1145
   Yilmaz MB, 2011, J MOL ENDOCRINOL, V47, P69, DOI 10.1530/JME-10-0149
NR 56
TC 7
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD JUN
PY 2016
VL 52
IS 3
BP 618
EP 631
DI 10.1007/s12020-015-0825-1
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA DM9ER
UT WOS:000376668100024
PM 26676302
DA 2025-01-12
ER

PT J
AU Wang, Q
   Ma, S
   Song, N
   Li, X
   Liu, L
   Yang, SD
   Ding, X
   Shan, L
   Zhou, X
   Su, DX
   Wang, Y
   Zhang, Q
   Liu, XH
   Yu, N
   Zhang, K
   Shang, YF
   Yao, Z
   Shi, L
AF Wang, Qian
   Ma, Shuai
   Song, Nan
   Li, Xin
   Liu, Ling
   Yang, Shangda
   Ding, Xiang
   Shan, Lin
   Zhou, Xing
   Su, Dongxue
   Wang, Yue
   Zhang, Qi
   Liu, Xinhua
   Yu, Na
   Zhang, Kai
   Shang, Yongfeng
   Yao, Zhi
   Shi, Lei
TI Stabilization of histone demethylase PHF8 by USP7 promotes breast
   carcinogenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID LINKED MENTAL-RETARDATION; CLEFT LIP/CLEFT PALATE; DNA-DAMAGE;
   CELL-PROLIFERATION; P53-MDM2 PATHWAY; STRUCTURAL BASIS; RECRUITS USP7;
   CANCER CELLS; COMPLEX; REPAIR
AB The histone demethylase PHF8 has been implicated in multiple pathological disorders, including X-linked mental retardation and tumorigenesis. However, it is not clear how the abundance and function of PHF8 are regulated. Here, we report that PHF8 physically associates with the deubiquitinase USP7. Specifically, we demonstrated that USP7 promotes deubiquitination and stabilization of PHF8, leading to the upregulation of a group of genes, including cyclin A2, that are critical for cell growth and proliferation. The USP7-encoding gene was also transcriptionally regulated by PHF8, via positive feedback. USP7 was overexpressed in breast carcinomas, and the level of expression positively correlated with expression of PHF8 and cyclin A2 and with the histological grade of breast cancer. We showed that USP7 promotes breast carcinogenesis by stabilizing PHF8 and upregulating cyclin A2 and that the interaction between USP7 and PHF8 is augmented during DNA damage. Moreover, USP7-promoted PHF8 stabilization conferred cellular resistance to genotoxic insults and was required for the recruitment of BLM and KU70, which are both essential for DNA double-strand break repair. Our study mechanistically links USP7 to epigenetic regulation and DNA repair. Moreover, these data support the pursuit of USP7 and PHF8 as potential targets for breast cancer intervention, especially in combination with chemo-or radiotherapies.
C1 [Wang, Qian; Ma, Shuai; Song, Nan; Li, Xin; Liu, Ling; Yang, Shangda; Shan, Lin; Zhou, Xing; Su, Dongxue; Wang, Yue; Zhang, Qi; Liu, Xinhua; Yu, Na; Zhang, Kai; Shang, Yongfeng; Yao, Zhi; Shi, Lei] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Tianjin, Peoples R China.
   [Wang, Qian; Yao, Zhi] Tianjin Med Univ, Tianjin Key Lab Cellular & Mol Immunol, Dept Immunol,Sch Basic Med Sci, Key Lab Immune Microenvironm & Dis,Minist Educ, Tianjin, Peoples R China.
   [Ding, Xiang] Chinese Acad Sci, Inst Biophys, Lab Prote, Beijing 100080, Peoples R China.
   [Shang, Yongfeng] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Biochem & Mol Biol, Minist Educ,Sch Basic Med Sci,Hlth Sci Ctr, Beijing 100871, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Chinese Academy
   of Sciences; Institute of Biophysics, CAS; Peking University
RP Shi, L (通讯作者)，Tianjin Med Univ, Dept Biochem & Mol Biol, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.; Yao, Z (通讯作者)，Tianjin Med Univ, Dept Immunol, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
EM yaozhi@tmu.edu.cn; shilei@tmu.edu.cn
RI zhang, kai/H-4237-2018; Wang, Xin/JCE-2009-2023
OI Zhang, Kai/0000-0003-2800-0531
FU National Natural Science Foundation of China [81272284, 91219102,
   81572882, 91219201, 81530073, 81130048]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81272284 and 91219102 to L. Shi, 81572882 to Z.
   Yao, and 91219201, 81530073, and 81130048 to Y. Shang). We thank Xingzhi
   Xu (Capital Normal University, Beijing, China) and Bin Peng (Capital
   Normal University, Beijing, China) for providing help on the UV-laser
   micropoint experiment. We thank Tao Sun (Nankai University, Tianjin,
   China) for providing help on the IHC experiment.
CR Abidi FE, 2007, CLIN GENET, V72, P19, DOI 10.1111/j.1399-0004.2007.00817.x
   Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Birks EJ, 2008, CARDIOVASC RES, V79, P472, DOI 10.1093/cvr/cvn083
   Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Chen W, 2004, CANCER RES, V64, P3949, DOI 10.1158/0008-5472.CAN-03-3906
   Daubeuf S, 2009, BLOOD, V113, P3264, DOI 10.1182/blood-2008-07-168203
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Entezam A, 2009, NUCLEIC ACIDS RES, V37, P6371, DOI 10.1093/nar/gkp666
   Epping MT, 2011, NAT CELL BIOL, V13, P102, DOI 10.1038/ncb2142
   Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519
   Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400
   Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211
   Fortschegger K, 2010, MOL CELL BIOL, V30, P3286, DOI 10.1128/MCB.01520-09
   Giovinazzi S, 2013, CELL DEATH DIFFER, V20, P721, DOI 10.1038/cdd.2012.169
   Gopinathan L, 2014, CANCER RES, V74, P3870, DOI 10.1158/0008-5472.CAN-13-3440
   Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Hao H, 2015, MOL CELL, V59, P956, DOI 10.1016/j.molcel.2015.07.033
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027
   Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38
   Jenkins EC, 2012, AM J MED GENET A, V158A, P1060, DOI 10.1002/ajmg.a.35275
   Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002
   Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731
   Laumonnier F, 2005, J MED GENET, V42, P780, DOI 10.1136/jmg.2004.029439
   Lecona E, 2015, MOL CELL BIOL, V35, P1157, DOI 10.1128/MCB.01197-14
   Lee C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123865
   Lee HR, 2011, NAT STRUCT MOL BIOL, V18, P1336, DOI 10.1038/nsmb.2142
   Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Li X, 2014, P NATL ACAD SCI USA, V111, P7096, DOI 10.1073/pnas.1324036111
   Lim HJ, 2013, MOL CELL BIOL, V33, P4166, DOI 10.1128/MCB.00689-13
   Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024
   Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272
   Ma Q, 2015, ONCOTARGETS THER, V8, P1979, DOI 10.2147/OTT.S85443
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024
   Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633
   Polo SE, 2012, MOL CELL, V45, P505, DOI 10.1016/j.molcel.2011.12.035
   Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261
   Qiu JH, 2010, CELL RES, V20, P908, DOI 10.1038/cr.2010.81
   Reverdy C, 2012, CHEM BIOL, V19, P467, DOI 10.1016/j.chembiol.2012.02.007
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Sarkari F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000624
   Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2
   Schwertman P, 2012, NAT GENET, V44, P598, DOI 10.1038/ng.2230
   Shen YZ, 2014, BIOCHEM BIOPH RES CO, V451, P119, DOI 10.1016/j.bbrc.2014.07.076
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013
   Suganuma T, 2010, CELL RES, V20, P861, DOI 10.1038/cr.2010.110
   Sun XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077353
   Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248
   Ummat A, 2012, NAT STRUCT MOL BIOL, V19, P628, DOI 10.1038/nsmb.2295
   van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013
   van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018
   Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Yang F, 2015, J BIOL CHEM, V290, P6507, DOI 10.1074/jbc.M114.620369
   Zhu GC, 2015, EPIGENOMICS-UK, V7, P143, DOI [10.2217/EPI.14.82, 10.2217/epi.14.82]
   Zhu QZ, 2015, CELL CYCLE, V14, P1413, DOI 10.1080/15384101.2015.1007785
NR 64
TC 158
Z9 172
U1 2
U2 55
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2016
VL 126
IS 6
BP 2205
EP 2220
DI 10.1172/JCI85747
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DN4IF
UT WOS:000377027500018
PM 27183383
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Menschikowski, M
   Hagelgans, A
   Nacke, B
   Jandeck, C
   Mareninova, OA
   Asatryan, L
   Siegert, G
AF Menschikowski, Mario
   Hagelgans, Albert
   Nacke, Brit
   Jandeck, Carsten
   Mareninova, Olga A.
   Asatryan, Liana
   Siegert, Gabriele
TI Epigenetic control of group V phospholipase A<sub>2</sub> expression in
   human malignant cells
SO TUMOR BIOLOGY
LA English
DT Article
DE Group V sPLA2; Leukaemia; Solid cancer cells; DNA methylation
ID HUMAN NEUTROPHILS; DNA METHYLATION; GENE-EXPRESSION; EMERGING ROLES;
   CANCER; ENZYMES; MECHANISMS; INDUCTION; PATHWAYS; DISEASE
AB Secreted phospholipases A(2) (sPLA(2)) are suggested to play an important role in inflammation and tumorigenesis. Different mechanisms of epigenetic regulation are involved in the control of group IIA, III and X sPLA(2)s expression in cancer cells, but group V sPLA(2) (GV-PLA(2)) in this respect has not been studied. Here, we demonstrate the role of epigenetic mechanisms in regulation of GV-PLA(2) expression in different cell lines originating from leukaemia and solid cancers. In blood leukocytes from leukaemic patients, levels of GV-PLA(2) transcripts were significantly lower in comparison to those from healthy individuals. Similarly, in DU-145 and PC-3 prostate and CAL-51 and MCF-7 mammary cancer cell lines, levels of GV-PLA(2) transcripts were significantly lower in relation to those found in normal epithelial cells of prostate or mammary. By sequencing and methylation-specific high-resolution melting (MS-HRM) analyses of bisulphite-modified DNA, distinct CpG sites in the GV-PLA(2) promoter region were identified that were differentially methylated in cancer cells in comparison to normal epithelial and endothelial cells. Spearman rank order analysis revealed a significant negative correlation between the methylation degree and the cellular expression of GV-PLA(2) (r = -0.697; p = 0.01). The effects of demethylating agent (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) on GV-PLA(2) transcription in the analysed cells confirmed the importance of DNA methylation and histone modification in the regulation of the GV-PLA(2) gene expression in leukaemic, prostate and mammary cancer cell lines. The exposure of tumour cells to human recombinant GV-PLA(2) resulted in a reduced colony forming activity of MCF-7, HepG2 and PC-3 cells, but not of DU-145 cells suggesting a cell-type-dependent effect of GV-PLA(2) on cell growth. In conclusion, our results suggest that epigenetic mechanisms such as DNA methylation and histone modification play an important role in downregulation of GV-PLA(2) expression in cancer cells.
C1 [Menschikowski, Mario; Hagelgans, Albert; Nacke, Brit; Jandeck, Carsten; Siegert, Gabriele] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
   [Mareninova, Olga A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Mareninova, Olga A.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Asatryan, Liana] USC Sch Pharm, Titus Family Dept Clin Pharm, Los Angeles, CA USA.
C3 Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System; University of California
   System; University of California Los Angeles; University of Southern
   California
RP Menschikowski, M (通讯作者)，Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
EM Mario.Menschikowski@uniklinikum-dresden.de
OI Mareninova, Olga A./0000-0003-0881-4079
CR Balestrieri B, 2006, BBA-MOL CELL BIOL L, V1761, P1280, DOI 10.1016/j.bbalip.2006.07.008
   BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1
   Bernard D, 2014, BBA-REV CANCER, V1846, P40, DOI 10.1016/j.bbcan.2014.03.003
   Boilard E, 2010, EMBO MOL MED, V2, P172, DOI 10.1002/emmm.201000072
   Brglez V, 2014, BIOCHIMIE, V107, P114, DOI 10.1016/j.biochi.2014.09.023
   Brglez V, 2014, BIOCHEM BIOPH RES CO, V445, P230, DOI 10.1016/j.bbrc.2014.01.182
   CHEN J, 1994, J BIOL CHEM, V269, P2365
   Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200
   DENNIS EA, 1992, ADV EXP MED BIOL, V318, P35
   Douet V, 2007, BIOCHEM BIOPH RES CO, V354, P66, DOI 10.1016/j.bbrc.2006.12.151
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Fiancette R, 2009, LEUKEMIA, V23, P1196, DOI 10.1038/leu.2009.36
   Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517
   Gorovetz M, 2006, GYNECOL ONCOL, V103, P831, DOI 10.1016/j.ygyno.2006.06.042
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Henderson WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056172
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Ito M, 2004, J GASTROEN HEPATOL, V19, P1140, DOI 10.1111/j.1440-1746.2004.03435.x
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200
   Lacroux C, 2012, J VIROL, V86, P2056, DOI 10.1128/JVI.06532-11
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Martín R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-154
   Masuda S, 2005, BBA-MOL CELL BIOL L, V1736, P200, DOI 10.1016/j.bbalip.2005.08.014
   McCurdy R., 2008, Gene Ther. Mol. Biol, V12, P15
   Menschikowski M, 2006, PROSTAG OTH LIPID M, V79, P1, DOI 10.1016/j.prostaglandins.2005.10.005
   Menschikowski M, 2008, NEOPLASIA, V10, P1195, DOI 10.1593/neo.08640
   Menschikowski M, 2008, NEOPLASIA, V10, P279, DOI 10.1593/neo.07965
   Menschikowski M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-576
   Miki Y, 2007, ANTICANCER RES, V27, P1493
   Mounier CM, 2008, BRIT J CANCER, V98, P587, DOI 10.1038/sj.bjc.6604184
   Munoz Nilda M, 2012, Pulm Circ, V2, P182, DOI 10.4103/2045-8932.97604
   Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435
   Murakami M, 2015, J LIPID RES, V56, P1248, DOI 10.1194/jlr.R058123
   Murakami M, 2013, BIOCHIMIE, V95, P43, DOI 10.1016/j.biochi.2012.09.007
   Pucer A, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-111
   Quach ND, 2014, BIOCHEM PHARMACOL, V90, P338, DOI 10.1016/j.bcp.2014.05.022
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rosengren B, 2006, ARTERIOSCL THROM VAS, V26, P1579, DOI 10.1161/01.ATV.0000221231.56617.67
   Rosenson Robert S, 2009, Curr Cardiol Rep, V11, P445
   Rubio JM, 2015, J IMMUNOL, V194, P3327, DOI 10.4049/jimmunol.1401026
   Scott KF, 2010, BIOCHIMIE, V92, P601, DOI 10.1016/j.biochi.2010.03.019
   Sonoki K, 2012, J CARDIOVASC PHARM, V60, P367, DOI 10.1097/FJC.0b013e3182646ccc
   Surrel F, 2009, MOL PHARMACOL, V76, P778, DOI 10.1124/mol.108.053371
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   Xue ML, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4473
   Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050
NR 47
TC 9
Z9 9
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2016
VL 37
IS 6
BP 8097
EP 8105
DI 10.1007/s13277-015-4670-x
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM6LT
UT WOS:000376464700109
PM 26715269
DA 2025-01-12
ER

PT J
AU Jia, ZM
   Ai, X
   Teng, JF
   Wang, YP
   Wang, BJ
   Zhang, X
AF Jia, Zhuo-min
   Ai, Xing
   Teng, Jing-fei
   Wang, Yun-peng
   Wang, Bao-jun
   Zhang, Xu
TI p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4
   acetylation to regulate bladder cancer cell proliferation
SO TUMOR BIOLOGY
LA English
DT Article
DE CK2; HDAC2 phosphorylation; KLF4 acetylation; Notch-1; p21
ID KRUPPEL-LIKE FACTOR-4; EPIGENETIC ALTERATIONS; TUMOR-SUPPRESSOR;
   DOWN-REGULATION; STEM-CELLS; LINE RKO; EXPRESSION; TRANSCRIPTION; GENE;
   P21(WAF1/CIP1)
AB Kruppel-like factor 4 (KLF4) is a transcription factor involved in both tumor suppression and oncogenesis as a transcriptional activator or repressor in a context-dependent manner. KLF4 acts as a regulator of p53 depending on p21 status in breast cancer. However, the mechanisms underlying the distinct role of KLF4 remain poorly understood. Here, we revealed that p21 depletion converted KLF4 from a cell cycle inhibitor to a promoter of bladder cancer cell proliferation. Additionally, KLF4 was acetylated in a p21-dependent manner to inhibit bladder cancer cell growth as a tumor suppressor. However, deacetylated KLF4 functioned as an oncogene promoting bladder cancer cell proliferation. Mechanistically, p21 and CK2 interaction, but not CK2 alone, enhanced HDAC2 phosphorylation and restricted KLF4 deacetylation and subsequent tumor promotion. Furthermore, we observed that KLF4 was acetylated by CBP/p300 and that overexpression of CBP resulted in KLF4 acetylation and tumor suppression even in p21-depleted bladder cancer cells. Moreover, we discovered that Notch-1 knockdown-induced KLF4 is acetylated form of KLF4, which may mediate Notch-1 function in bladder cancer cell proliferation. Our data demonstrate that KLF4 acts as a tumor suppressor or oncogene to activate or repress target gene transcription depending on its acetylation status, which is regulated by p21 and CK2 interaction-mediated HDAC2 phosphorylation. Targeting KLF4 at the post-transcriptional levels may provide novel insight for bladder cancer therapy.
C1 [Jia, Zhuo-min; Wang, Yun-peng; Wang, Bao-jun; Zhang, Xu] Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Clin Div Surg, Beijing 100853, Peoples R China.
   [Jia, Zhuo-min; Ai, Xing; Teng, Jing-fei] Mil Gen Hosp Beijing PLA, Dept Urol, Beijing 100700, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Zhang, X (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Clin Div Surg, Beijing 100853, Peoples R China.; Ai, X (通讯作者)，Mil Gen Hosp Beijing PLA, Dept Urol, Beijing 100700, Peoples R China.
EM aixing0007@163.com; zhangxu_2016@sina.com
RI zhang, xu/GYE-3558-2022
FU Military General Hospital of Beijing PLA Innovation Cultivation Fund
   [2015-LC-13]
FX This project was supported by "Military General Hospital of Beijing PLA
   Innovation Cultivation Fund 2015-LC-13."
CR Adenuga D, 2010, ARCH BIOCHEM BIOPHYS, V498, P62, DOI 10.1016/j.abb.2010.04.002
   Ai X, 2014, ONCOL REP, V32, P1459, DOI 10.3892/or.2014.3350
   An J, 2011, FASEB J, V25, P3634, DOI 10.1096/fj.11-186924
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667
   Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413
   Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645
   Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6
   Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200
   Foster KW, 1999, CELL GROWTH DIFFER, V10, P423
   Foster KW, 2000, CANCER RES, V60, P6488
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Gotz C, 1996, ONCOGENE, V13, P391
   Habuchi T, 2005, UROLOGY, V66, P64, DOI 10.1016/j.urology.2005.08.065
   Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978-1-4614-0899-4_14
   Huang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.433
   Junttila TT, 2003, CLIN CANCER RES, V9, P5346
   Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
   Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217
   Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176
   Lesch HP, 2011, GENE THER, V18, P531, DOI 10.1038/gt.2010.162
   Meng F, 2009, BIOCHEM BIOPH RES CO, V387, P13, DOI 10.1016/j.bbrc.2009.05.112
   Muto S, 2000, CANCER RES, V60, P4021
   Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1
   Ortega CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115609
   Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Segré CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848
   Tien YT., 2015, Vet J
   Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200
   Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9
   Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414
   Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619
   Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318
   Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090
   Yao K, 2014, STEM CELL RES, V12, P139, DOI 10.1016/j.scr.2013.10.005
   Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200
   Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591
   Yusuf I, 2008, INT IMMUNOL, V20, P671, DOI 10.1093/intimm/dxn024
   Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200
   Zhang XH, 2012, ARTERIOSCL THROM VAS, V32, P1015, DOI 10.1161/ATVBAHA.111.244962
   Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067
   Zheng B, 2011, CELL RES, V21, P1487, DOI 10.1038/cr.2011.34
NR 43
TC 20
Z9 25
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2016
VL 37
IS 6
BP 8293
EP 8304
DI 10.1007/s13277-015-4618-1
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM6LT
UT WOS:000376464700129
PM 26729194
DA 2025-01-12
ER

PT J
AU Knothe, C
   Shiratori, H
   Resch, E
   Ultsch, A
   Geisslinger, G
   Doehring, A
   Lötsch, J
AF Knothe, Claudia
   Shiratori, Hiromi
   Resch, Eduard
   Ultsch, Alfred
   Geisslinger, Gerd
   Doehring, Alexandra
   Loetsch, Joern
TI Disagreement between two common biomarkers of global DNA methylation
SO CLINICAL EPIGENETICS
LA English
DT Article
ID S-ADENOSYL METHIONINE; PERIPHERAL-BLOOD; METHYLTRANSFERASE INHIBITORS;
   MATERNAL-CARE; BREAST-CANCER; EXPRESSION; DISEASE; EPIGENETICS;
   STATISTICS; RESPONSES
AB Background: The quantification of global DNA methylation has been established in epigenetic screening. As more practicable alternatives to the HPLC-based gold standard, the methylation analysis of CpG islands in repeatable elements (LINE-1) and the luminometric methylation assay (LUMA) of overall 5-methylcytosine content in "CCGG" recognition sites are most widely used. Both methods are applied as virtually equivalent, despite the hints that their results only partly agree. This triggered the present agreement assessments.
   Results: Three different human cell types (cultured MCF7 and SHSY5Y cell lines treated with different chemical modulators of DNA methylation and whole blood drawn from pain patients and healthy volunteers) were submitted to the global DNA methylation assays employing LINE-1 or LUMA-based pyrosequencing measurements. The agreement between the two bioassays was assessed using generally accepted approaches to the statistics for laboratory method comparison studies. Although global DNA methylation levels measured by the two methods correlated, five different lines of statistical evidence consistently rejected the assumption of complete agreement. Specifically, a bias was observed between the two methods. In addition, both the magnitude and direction of bias were tissue-dependent. Interassay differences could be grouped based on Bayesian statistics, and these groups allowed in turn to re-identify the originating tissue.
   Conclusions: Although providing partly correlated measurements of DNA methylation, interchangeability of the quantitative results obtained with LINE-1 and LUMA was jeopardized by a consistent bias between the results. Moreover, the present analyses strongly indicate a tissue specificity of the differences between the two methods.
C1 [Knothe, Claudia; Geisslinger, Gerd; Doehring, Alexandra; Loetsch, Joern] Goethe Univ Frankfurt, Inst Clin Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
   [Shiratori, Hiromi; Resch, Eduard; Geisslinger, Gerd; Loetsch, Joern] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
   [Ultsch, Alfred] Univ Marburg, DataBion Res Grp, Hans Meerwein Str, D-35032 Marburg, Germany.
C3 Goethe University Frankfurt; Fraunhofer Gesellschaft; Philipps
   University Marburg
RP Lötsch, J (通讯作者)，Goethe Univ Frankfurt, Inst Clin Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.; Lötsch, J (通讯作者)，Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM j.loetsch@em.uni-frankfurt.de
OI Resch, Eduard/0000-0002-7685-6388; Lotsch, Jorn/0000-0002-5818-6958
FU Else Kroner-Fresenius Foundation (EKFS); Research Training Group
   Translational Research Innovation-Pharma (TRIP); Landesoffensive zur
   Entwicklung wissenschaftlich-okonomischer Exzellenz (LOEWE);
   LOEWE-Zentrum fur Translationale Medizin und Pharmakologie; European
   Union [602919]
FX The work has been supported by the Else Kroner-Fresenius Foundation
   (EKFS), Research Training Group Translational Research Innovation-Pharma
   (TRIP, GG, JL), and the Landesoffensive zur Entwicklung
   wissenschaftlich-okonomischer Exzellenz (LOEWE), LOEWE-Zentrum fur
   Translationale Medizin und Pharmakologie (GG, JL). Additional support of
   the analytical environment was gained from the European Union Seventh
   Framework Programme (FP7/2007-2013) under grant agreement no. 602919
   ("GLORIA", JL,) The funders had no role in the method design, data
   selection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akers SN, 2014, GYNECOL ONCOL, V132, P462, DOI 10.1016/j.ygyno.2013.12.024
   Andreotti G, 2014, EPIGENETICS-US, V9, P404, DOI 10.4161/epi.27386
   [Anonymous], 1995, INTRO BOOTSTRAP
   Aporntewan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017934
   Arhondakis S, 2004, GENE, V325, P165, DOI 10.1016/j.gene.2003.10.009
   Babic Bozovic I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127423
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bland JM, 2003, ULTRASOUND OBST GYN, V22, P85, DOI 10.1002/uog.122
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Boeckmann A.J., 1994, NONMEM Users Guide
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Breimann L, 1993, CLASSIFICATION REGRE
   Brown TA, 2016, NANOTOXICOLOGY, V10, P453, DOI 10.3109/17435390.2015.1078852
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Craig JM, 2011, EPIGENETICS: A REFERENCE MANUAL, P1
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Delgado-Cruzata L, 2014, EPIGENETICS-US, V9, P1504, DOI 10.4161/15592294.2014.983364
   Di Francesco A, 2015, BRAIN BEHAV IMMUN, V45, P139, DOI 10.1016/j.bbi.2014.11.002
   Ding R, 2016, MUTAT RES-GEN TOX EN, V796, P46, DOI 10.1016/j.mrgentox.2015.12.002
   Diorio J, 2007, J PSYCHIATR NEUROSCI, V32, P275
   Doehring A, 2013, PAIN, V154, P15, DOI 10.1016/j.pain.2012.06.011
   Doehring A, 2009, CLIN J PAIN, V25, P781, DOI 10.1097/AJP.0b013e3181b43e12
   Doehring A, 2009, PHARMACOGENET GENOM, V19, P407, DOI 10.1097/FPC.0b013e328320a3fd
   Duda R.O., 2006, Pattern Classification
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Eller CD, 2007, GENE, V390, P153, DOI 10.1016/j.gene.2006.09.018
   Fahy J, 2012, EXPERT OPIN THER PAT, V22, P1427, DOI 10.1517/13543776.2012.729579
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Federico C, 2000, CHROMOSOME RES, V8, P737, DOI 10.1023/A:1026797522102
   Florea AM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/486072
   Ham MS, 2013, MOL CLIN ONCOL, V1, P373, DOI 10.3892/mco.2012.53
   Hill T., 2007, Statistics methods and applications
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   Houseman E Andres, 2015, Curr Environ Health Rep, V2, P145, DOI 10.1007/s40572-015-0050-3
   Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189
   Ivanov M, 2014, TRENDS PHARMACOL SCI, V35, P384, DOI 10.1016/j.tips.2014.05.004
   Jabbari K, 1998, GENE, V224, P123, DOI 10.1016/S0378-1119(98)00474-0
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kamakura M, 2011, NATURE, V473, P478, DOI 10.1038/nature10093
   Kampstra P., 2008, J STAT SOFTW, V28
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1
   Keller M, 2014, DIABETOLOGIA, V57, P2374, DOI 10.1007/s00125-014-3356-z
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Knothe C, 2015, EPIGENOMICS
   Lisanti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079044
   Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659
   Lötsch J, 2013, TRENDS MOL MED, V19, P742, DOI 10.1016/j.molmed.2013.08.006
   Lötsch J, 2010, INFLAMM RES, V59, P989, DOI 10.1007/s00011-010-0215-3
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Magari RT, 2002, BIOPHARM-APPL T BIO, V15, P28
   Martín-Núñez GM, 2014, EPIGENETICS-US, V9, P1322, DOI 10.4161/15592294.2014.969617
   Marques-Rocha JL, 2016, EPIGENETICS-US, V11, P49, DOI 10.1080/15592294.2015.1135286
   McCullough LE, 2016, BREAST CANC RES TREA
   McGrayne S. B., 2011, Ghosh notes that the use of "concentration camp"at the mid-century would not necessarily
   Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161
   Mohsen K, 2006, EPIGENETICS, V1, P46
   MOMPARLER RL, 1984, LEUKEMIA RES, V8, P1043, DOI 10.1016/0145-2126(84)90059-6
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Ohka F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023332
   Ou XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041143
   Pavlícek A, 2001, GENE, V276, P39, DOI 10.1016/S0378-1119(01)00645-X
   Penzkofer T, 2005, NUCLEIC ACIDS RES, V33, pD498, DOI 10.1093/nar/gki044
   Rasoulpour RJ, 2011, TOXICOL MECH METHOD, V21, P298, DOI 10.3109/15376516.2011.557883
   Sasai N, 2009, INT J DEV BIOL, V53, P323, DOI 10.1387/ijdb.082652ns
   SMIRNOV N, 1948, ANN MATH STAT, V19, P279, DOI 10.1214/aoms/1177730256
   SMITH SS, 1991, MOL CARCINOGEN, V4, P91, DOI 10.1002/mc.2940040202
   Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Striebel W., 2002, THERAPIE CHRONISCHER
   TWYCROSS R, 2007, PALLIATIVE CARE FORM, P269
   Ultsch A., 2003, INNOVATIONS CLASSIFI
   Ultsch A, 2015, INT J MOL SCI, V16, P25897, DOI 10.3390/ijms161025897
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   WIGLER MH, 1981, CELL, V24, P285, DOI 10.1016/0092-8674(81)90317-2
   WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269
   Williams G, 2011, USE R, P3, DOI 10.1007/978-1-4419-9890-3
   Wojdacz Tomasz K, 2008, BMC Res Notes, V1, P54, DOI 10.1186/1756-0500-1-54
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yafune A, 1999, STAT MED, V18, P581, DOI 10.1002/(SICI)1097-0258(19990315)18:5<581::AID-SIM47>3.3.CO;2-T
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhang XN, 2014, COMP BIOCHEM PHYS C, V160, P54, DOI 10.1016/j.cbpc.2013.11.008
   Zheng PF, 2015, J INT MED RES, V43, P758, DOI 10.1177/0300060515591062
NR 92
TC 12
Z9 13
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAY 23
PY 2016
VL 8
AR 60
DI 10.1186/s13148-016-0227-0
PG 17
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DN1WR
UT WOS:000376856600001
PM 27222668
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Bediaga, NG
   Beristain, E
   Calvo, B
   Viguri, MA
   Gutierrez-Corres, B
   Rezola, R
   Ruiz-Diaz, I
   Guerra, I
   de Pancorbo, MM
AF Bediaga, Naiara G.
   Beristain, Elena
   Calvo, Borja
   Viguri, Maria A.
   Gutierrez-Corres, Borja
   Rezola, Ricardo
   Ruiz-Diaz, Irune
   Guerra, Isabel
   de Pancorbo, Marian M.
TI Luminal B breast cancer subtype displays a dicotomic epigenetic pattern
SO SPRINGERPLUS
LA English
DT Article
DE Epigenetic; Methylation; Breast cancer; Luminal subtypes
ID DNA METHYLATION
AB Luminal B breast tumors have aggressive clinical and biological features, and constitute the most heterogeneous molecular subtype, both clinically and molecularly. Unfortunately, the immunohistochemistry correlate of the luminal B subtype remains still imprecise, and it has now become of paramount importance to define a classification scheme capable of segregating luminal tumors into clinically meaningful subgroups that may be used clinically to guide patient management. With the aim of unraveling the DNA methylation profiles of the luminal subtypes currently being most used in the clinical setting, we have quantified the DNA methylation level of 27,578 CpG sites in 17 luminal B (ER+, Ki67 >= 20 % or PgR < 20 % and HER2-), 8 luminal A (ER+ and Ki67 > 20 %) and 4 luminal B-HER2+ (ER+ and HER2+) breast cancer samples by using the Illumina Infinium methylation microarray approach. Unsupervised hierarchical clustering revealed that DNA methylation stratifies luminal B samples in two categories with differing epigenetic and clinical features. One subgroup of luminal B samples showed a methylator phenotype and clustered with the lumB-HER tumors, while the other showed less methylated events, clustered with the luminal A. A 3 CpG marker panel capable of discriminating methylator versus non-methylator luminal B samples was identified and further validated in an independent cohort of patients. Our results provide evidence that DNA methylation and, more specifically, a panel of 3 CpG markers, enables the stratification of luminal B samples in two categories with differing epigenetic and clinical features and support the utilization of this panel for therapeutic stratification of patients with luminal breast cancer.
C1 [Bediaga, Naiara G.; de Pancorbo, Marian M.] Univ Basque Country, UPV EHU, Lascaray Res Ctr, BIOMICs Res Grp, Avda Miguel Unamuno 3, Vitoria 01006, Spain.
   [Beristain, Elena] OSI Araba Univ Hosp, BioAraba Natl Hlth Inst, Mol Epi Genet Lab, Vitoria 01006, Spain.
   [Calvo, Borja] Univ Basque Country, UPV EHU, Intelligent Syst Grp, Donostia San Sebastian, Basque Country, Spain.
   [Viguri, Maria A.; Gutierrez-Corres, Borja; Guerra, Isabel] OSI Araba Univ Hosp, Serv Anat Pathol, Vitoria 01009, Spain.
   [Rezola, Ricardo] Serv Anat Pathol, Onkol, Paseo Dr Begiristain 121, Donostia San Sebastian 20014, Gipuzkoa, Spain.
   [Ruiz-Diaz, Irune] Hosp Univ Donostia, Serv Anat Pathol, Paseo Dr Begiristain 121, Donostia San Sebastian 20014, Gipuzkoa, Spain.
C3 University of Basque Country; University Hospital of Araba; University
   of Basque Country; University Hospital of Araba
RP de Pancorbo, MM (通讯作者)，Univ Basque Country, UPV EHU, Lascaray Res Ctr, BIOMICs Res Grp, Avda Miguel Unamuno 3, Vitoria 01006, Spain.
EM marian.mdepancorbo@ehu.eus
RI Bediaga, Naiara/AAD-6062-2020; Calvo, Borja/AAB-2278-2019
OI G. Bediaga, Naiara/0000-0002-7363-0068; M. de Pancorbo,
   Marian/0000-0002-8081-0702; MARTINEZ DE PANCORBO, MARIA DE LOS
   ANGELES/0000-0002-7408-6068
FU Departamento de Sanidad del Gobierno Vasco [CGL2008-01131]; Departamento
   de Ciencia y Tecnologia del Gobierno Vasco [S-PE08UN45, PE09BF02];
   Basque Government (Departamento de Educacion, Universidades e
   Investigacion); Spanish Ministry of Science and Innovation
   [PTA2009-2147]
FX This work was supported by Grants from Project CGL2008-01131
   (Departamento de Sanidad del Gobierno Vasco), S-PE08UN45 and PE09BF02
   (Departamento de Ciencia y Tecnologia del Gobierno Vasco). N.G.B. had a
   postdoctoral fellowship from the Basque Government (Departamento de
   Educacion, Universidades e Investigacion). E.B. had a grant from the
   Spanish Ministry of Science and Innovation (PTA2009-2147).
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Cornen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081843
   Creighton CJ, 2012, BIOL-TARGETS THER, V6, P289, DOI 10.2147/BTT.S29923
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Li YS, 2014, HUM MOL GENET, V23, P5378, DOI 10.1093/hmg/ddu256
   Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679
   Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y
   Pogue-Geile KL, 2013, JNCI-J NATL CANCER I, V105, P1782, DOI 10.1093/jnci/djt321
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
NR 23
TC 14
Z9 14
U1 0
U2 14
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-1801
J9 SPRINGERPLUS
JI SpringerPlus
PD MAY 14
PY 2016
VL 5
AR 623
DI 10.1186/s40064-016-2235-0
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DM6HW
UT WOS:000376453300004
PM 27330889
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kala, R
   Tollefsbol, TO
AF Kala, Rishabh
   Tollefsbol, Trygve O.
TI A Novel Combinatorial Epigenetic Therapy Using Resveratrol and
   Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in
   ERα-Negative Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; REACTIVATION; ACTIVATION; PROMOTER;
   SIRT1; HYPERMETHYLATION; METHYLATION; SENSITIVITY; MECHANISMS; COMPLEXES
AB Breast cancer is the second most common cancer and a leading cause of cancer death in women. Specifically, estrogen receptor-alpha (ER alpha)-negative breast cancers are clinically more aggressive and normally do not respond to conventional hormone-directed therapies such as tamoxifen. Although epigenetic-based therapies such as 5-aza-2'-deoxycytidine and/or trichostatin A as DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, respectively, can regulate the expression of ER alpha, this can often lead to a number of side effects. Plant-based dietary compounds such as resveratrol and pterostilbene in novel combinatorial therapy provides new avenues to target these side effects and provide similar results with a higher level of safety. Here, we report that combinatorial resveratrol and pterostilbene leads to the reactivation of ER alpha expression in ER alpha-negative breast cancer cells in a time-dependent manner. Chromatin immunoprecipitation analysis of the ER alpha promoter in each cell type revealed an increase in enrichment of acetyl-H3, acetyl-H3lysine9 (H3K9) and acetyl-H4 active chromatin markers in the ER alpha promoter region after combinatorial treatment. This treatment also resulted in a significant change in HDAC and histone acetyl transferase (HAT) enzyme activity in these cells after 3 days of treatments. The combination resulted in a significant decrease in DNMT enzyme activity and 5-methylcytosine levels in MDA-MB-157 breast cancer cells. Moreover, reactivation of ER alpha expression by resveratrol combined with pterostilbene was found to sensitize ERa-dependent response to 17 beta-estradiol (E2)-mediated cellular proliferation and antagonist 4-hydroxytamoxifen (4-OHT)-mediated inhibition of cellular proliferation in ER alpha-negative breast cancer cells. E2 and 4-OHT further affected the ER alpha-responsive downstream progesterone receptor (PGR) gene in ER alpha reactivated MDA-MB-157 cells. Collectively, our findings provide a new and safer way of restoring ERa expression by regulating epigenetic mechanisms with the use of phyto-chemicals in combinatorial therapy. This combination can further provide effective treatment options for hormonal refractory breast cancer with available anti-hormonal therapy.
C1 [Kala, Rishabh; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, 1530 3rd Ave South, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, 1802 6th Ave South, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, 1675 Univ Blvd, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, 1825 Univ Blvd, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, 1530 3rd Ave South, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Ctr Comprehens Canc, 1802 6th Ave South, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Nutr Obes Res Ctr, 1675 Univ Blvd, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Diabet Ctr, 1825 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI Kala, Rishabh/AAR-1625-2020
FU NCI [ROI CA178441]; American Institute for Cancer Research [316184]
FX This work was supported in part by grants from the NCI (ROI CA178441)
   and the American Institute for Cancer Research (316184).
CR Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Gracia A, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0411-9
   Kala R, 2012, J NUTR FOOD SCI S, VS5
   Kala R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1693-z
   Kong SY, 2011, J BIOL CHEM, V286, P16967, DOI 10.1074/jbc.M111.218206
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Saldanha SN, 2014, EXP CELL RES, V324, P40, DOI 10.1016/j.yexcr.2014.01.024
   Saxena Neeraj K, 2010, Mol Cell Pharmacol, V2, P191
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Wang L, 2012, MOL MED REP, V6, P904, DOI 10.3892/mmr.2012.1001
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 26
TC 68
Z9 73
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2016
VL 11
IS 5
AR e0155057
DI 10.1371/journal.pone.0155057
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DM7YQ
UT WOS:000376576700036
PM 27159275
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Meseure, D
   Vacher, S
   Lallemand, F
   Alsibai, KD
   Hatem, R
   Chemlali, W
   Nicolas, A
   De Koning, L
   Pasmant, E
   Callens, C
   Lidereau, R
   Morillon, A
   Bieche, I
AF Meseure, Didier
   Vacher, Sophie
   Lallemand, Francois
   Alsibai, Kinan Drak
   Hatem, Rana
   Chemlali, Walid
   Nicolas, Andre
   De Koning, Leanne
   Pasmant, Eric
   Callens, Celine
   Lidereau, Rosette
   Morillon, Antonin
   Bieche, Ivan
TI Prognostic value of a newly identified <i>MALAT1</i> alternatively
   spliced transcript in breast cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE MALAT1; alternatively spliced transcript; breast cancer; prognostic
   value; signalling pathways
ID LONG NONCODING RNA; CELL LUNG-CANCER; METASTASIS; PROLIFERATION;
   INHIBITION; PATHWAY; EXPRESSION; PROMOTES; REVEALS; ALPHA
AB Background: Epigenetic deregulation is considered as a new hallmark of cancer. The long non-coding RNA MALAT1 has been implicated in several cancers; however, its role in breast cancer is still little known.
   Methods: We used RT-PCR, in situ hybridisation, and RPPA methods to quantify (i) the full-length (FL) and an alternatively spliced variant (Dsv) of MALAT1, and (ii) a panel of transcripts and proteins involved in MALAT1 pathways, in a large series of breast tumours from patients with known clinical/ pathological status and long-term outcome.
   Results: MALAT1 was overexpressed in 14% (63/446) of the breast tumours. MALAT1-overexpressed tumour epithelial cells showed marked diffuse nuclear signals and numerous huge nuclear speckles. Screening of the dbEST database led to the identification of Dsv-MALAT1, a major alternatively spliced MALAT1 transcript, with a very different expression pattern compared with FL-MALAT1. This alternative Dsv-MALAT1 transcript was mainly underexpressed (18.8%) in our breast tumour series. Multivariate analysis showed that alternative Dsv-MALAT1 transcript is an independent prognostic factor. Dsv-MALAT1 expression was associated with alterations of the pre-mRNAs alternative splicing machinery, and of the Drosha-DGCR8 complex required for non-coding RNA biogenesis. Alternative Dsv-MALAT1 transcript expression was associated to YAP protein status and with an activation of the PI3K-AKT pathway.
   Conclusions: Our results reveal a complex expression pattern of various MALAT1 transcript variants in breast tumours, and suggest that this pattern of expressions should be taken into account to evaluate MALAT1 as predictive biomarker and therapeutic target.
C1 [Meseure, Didier; Vacher, Sophie; Lallemand, Francois; Hatem, Rana; Chemlali, Walid; Callens, Celine; Lidereau, Rosette; Bieche, Ivan] Inst Curie, Unit Pharmacogenet, Dept Genet, 26 Rue Ulm, F-75248 Paris, France.
   [Meseure, Didier; Alsibai, Kinan Drak; Nicolas, Andre] Inst Curie, Dept Pathol, Platform Investigat Pathol, 26 Rue Ulm, F-75248 Paris, France.
   [De Koning, Leanne] Inst Curie, Dept Translat Res, 26 Rue Ulm, F-75248 Paris, France.
   [Pasmant, Eric; Bieche, Ivan] Paris Descartes Univ, Sorbonne Paris Cite, Fac Pharmaceut & Biol Sci, EA7331, F-75006 Paris, France.
   [Morillon, Antonin] Inst Curie, CNRS UMR 3244, 26 Rue Ulm, F-75248 Paris, France.
C3 UNICANCER; Universite PSL; Institut Curie; UNICANCER; Universite PSL;
   Institut Curie; UNICANCER; Universite PSL; Institut Curie; Universite
   Paris Cite; Universite PSL; UNICANCER; Institut Curie; Centre National
   de la Recherche Scientifique (CNRS); Sorbonne Universite; CNRS -
   National Institute for Biology (INSB)
RP Bieche, I (通讯作者)，Inst Curie, Unit Pharmacogenet, Dept Genet, 26 Rue Ulm, F-75248 Paris, France.; Bieche, I (通讯作者)，Paris Descartes Univ, Sorbonne Paris Cite, Fac Pharmaceut & Biol Sci, EA7331, F-75006 Paris, France.
EM ivan.bieche@curie.fr
RI Alsibai, Kinan/ABD-5521-2020; Bieche, Ivan/O-7399-2017; Pasmant,
   Eric/O-7249-2017; Morillon, Antonin/M-4751-2017
OI VACHER, Sophie/0000-0002-0042-6023; Meseure, Didier/0000-0001-6730-6686;
   Bieche, Ivan/0000-0002-2430-5429; Drak Alsibai,
   Kinan/0000-0001-5975-2627; Pasmant, Eric/0000-0002-1881-8762; Morillon,
   Antonin/0000-0002-0575-5264
FU Comite departemental des Hauts-de-Seine de la Ligue Nationale Contre le
   Cancer; Association pour la recherche en cancerologie de Saint-Cloud
   (ARCS);  [INCa-DGOS-4654]
FX We thank the staff of Institut Curie-Hospital Rene Huguenin for their
   assistance in specimen collection and patient care. We thank Aurelie
   Barbet, Floriane Bard and Caroline Lecerf for performing RPPA
   experiments. The RPPA platform is supported by Canceropole
   Ile-de-France. This work was supported by the Comite departemental des
   Hauts-de-Seine de la Ligue Nationale Contre le Cancer, the Association
   pour la recherche en cancerologie de Saint-Cloud (ARCS), and by Grant
   INCa-DGOS-4654.
CR Bièche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917
   Bièche I, 1999, CLIN CHEM, V45, P1148
   Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Gibb EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025915
   Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163
   Guo FJ, 2010, ACTA BIOCH BIOPH SIN, V42, P224, DOI 10.1093/abbs/gmq008
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109-013-1028-y
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Han YH, 2013, FEBS LETT, V587, P3875, DOI 10.1016/j.febslet.2013.10.023
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hu LW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0123-z
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Lai MC, 2012, MED ONCOL, V29, P1810, DOI 10.1007/s12032-011-0004-z
   Macias S, 2012, NAT STRUCT MOL BIOL, V19, P760, DOI 10.1038/nsmb.2344
   Mathews J, 2013, EXP MOL PATHOL, V95, P319, DOI 10.1016/j.yexmp.2013.09.006
   Miyagawa R, 2012, RNA, V18, P738, DOI 10.1261/rna.028639.111
   Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Troncale S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038686
   Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022
   Weinmann L, 2009, CELL, V136, P496, DOI 10.1016/j.cell.2008.12.023
   Wu XS, 2014, CANCER BIOL THER, V15, P806, DOI 10.4161/cbt.28584
   Xu SP, 2015, INT J CLIN EXP PATHO, V8, P4881
   Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhang J, 2015, INT J CLIN EXP MED, V8, P5499
NR 34
TC 74
Z9 77
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUN 14
PY 2016
VL 114
IS 12
BP 1395
EP 1404
DI 10.1038/bjc.2016.123
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DO8WZ
UT WOS:000378067500024
PM 27172249
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Serra, A
   Gallart-Palau, X
   See-Toh, RSE
   Hemu, X
   Tam, JP
   Sze, SK
AF Serra, Aida
   Gallart-Palau, Xavier
   See-Toh, Rachel Su-En
   Hemu, Xinya
   Tam, James P.
   Sze, Siu Kwan
TI Commercial processed soy-based food product contains glycated and
   glycoxidated lunasin proteoforms
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BREAST-CANCER RISK; ELECTRON-CAPTURE DISSOCIATION; END-PRODUCTS;
   TOP-DOWN; MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATION; PROTEIN
   IDENTIFICATION; SOYBEAN PRODUCTS; DIETARY SOY; PEPTIDES
AB Nutraceuticals have been proposed to exert positive effects on human health and confer protection against many chronic diseases. A major bioactive component of soy-based foods is lunasin peptide, which has potential to exert a major impact on the health of human consumers worldwide, but the biochemical features of dietary lunasin still remain poorly characterized. In this study, lunasin was purified from a soy-based food product via strong anion exchange solid phase extraction and then subjected to top-down mass spectrometry analysis that revealed in detail the molecular diversity of lunasin in processed soybean foods. We detected multiple glycated proteoforms together with potentially toxic advanced glycation end products (AGEs) derived from lunasin. In both cases, modification sites were Lys24 and Lys29 located at the helical region that shows structural homology with a conserved region of chromatin-binding proteins. The identified post-translational modifications may have an important repercussion on lunasin epigenetic regulatory capacity. Taking together, our results demonstrate the importance of proper chemical characterization of commercial processed food products to assess their impact on consumer's health and risk of chronic diseases.
C1 [Serra, Aida; Gallart-Palau, Xavier; See-Toh, Rachel Su-En; Hemu, Xinya; Tam, James P.; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
C3 Nanyang Technological University
RP Sze, SK (通讯作者)，Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
EM sksze@ntu.edu.sg
RI Serra, Aida/L-6850-2016; Gallart-Palau, Xavier/L-6566-2016; Hemu,
   Xinya/KEI-3842-2024; Sze, Siu Kwan/AAO-3342-2020; Tam, James
   P/A-2176-2011
OI Sze, Siu Kwan/0000-0002-5652-1687; Tam, James P/0000-0003-4433-198X
FU NTU iFood [S006]; Singapore Ministry of Education [RGT15/13]; NTU-NHG
   Ageing Research Grant [ARG/14017]
FX This work is in part supported by grants from the NTU iFood (grant #:
   S006), the Singapore Ministry of Education (Tier 1: RGT15/13) and
   NTU-NHG Ageing Research Grant (ARG/14017). We thank Vincent for his
   collaboration on this study during his Undergraduate Research Experience
   on CAmpus (URECA).
CR Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042
   [Anonymous], 2005, NUTRACEUTICAL PROTEI
   Ansari NA, 2013, AGING DIS, V4, P50
   BALDWIN JE, 1993, TETRAHEDRON LETT, V34, P5645, DOI 10.1016/S0040-4039(00)73905-0
   Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001
   BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527
   Cavazos A, 2012, J FOOD SCI, V77, pC539, DOI 10.1111/j.1750-3841.2012.02676.x
   Chang HC, 2014, CANCER IMMUNOL IMMUN, V63, P283, DOI 10.1007/s00262-013-1513-8
   Chen GJ, 2015, FOOD CHEM, V168, P190, DOI 10.1016/j.foodchem.2014.06.081
   Cho YA, 2010, EUR J CLIN NUTR, V64, P924, DOI 10.1038/ejcn.2010.95
   De Mejia EG, 2004, J AGR FOOD CHEM, V52, P5882, DOI 10.1021/jf0496752
   Delgado-Andrade C, 2012, AMINO ACIDS, V43, P595, DOI 10.1007/s00726-011-1107-8
   Dia VP, 2009, FOOD CHEM, V114, P108, DOI 10.1016/j.foodchem.2008.09.023
   Galvez AF, 1999, NAT BIOTECHNOL, V17, P495, DOI 10.1038/8676
   Gault J, 2014, PROTEOMICS, V14, P1141, DOI 10.1002/pmic.201300394
   Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679
   Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Guner H, 2014, J AM SOC MASS SPECTR, V25, P464, DOI 10.1007/s13361-013-0789-4
   Han X, 2011, J PROTEOME RES, V10, P2930, DOI 10.1021/pr200153k
   He J, 2005, ANN INTERN MED, V143, P1, DOI 10.7326/0003-4819-143-1-200507050-00004
   Hernández-Ledesma B, 2008, PERSPECT MED CHEM, V2, P75
   Hirose K, 2005, BRIT J CANCER, V93, P15, DOI 10.1038/sj.bjc.6602659
   Horn DM, 2000, P NATL ACAD SCI USA, V97, P10313, DOI 10.1073/pnas.97.19.10313
   Jeong HJ, 2007, J AGR FOOD CHEM, V55, P632, DOI 10.1021/jf062405u
   Joubran Y, 2013, FOOD CHEM, V141, P3796, DOI 10.1016/j.foodchem.2013.06.096
   Kelleher NL, 1998, PROTEIN SCI, V7, P1796, DOI 10.1002/pro.5560070815
   Kelleher NL, 1999, J AM CHEM SOC, V121, P806, DOI 10.1021/ja973655h
   Key TJ, 1999, BRIT J CANCER, V81, P1248, DOI 10.1038/sj.bjc.6690837
   Kim K, 2013, THROMB RES, V131, P254, DOI 10.1016/j.thromres.2013.01.002
   Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474
   Kyle S, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-28
   LeDuc RD, 2004, NUCLEIC ACIDS RES, V32, pW340, DOI 10.1093/nar/gkh447
   Lele DS, 2015, EUR J MED CHEM, V92, P637, DOI 10.1016/j.ejmech.2015.01.032
   Lin RY, 2003, ATHEROSCLEROSIS, V168, P213, DOI 10.1016/S0021-9150(03)00050-9
   Liu JB, 2015, FOOD CHEM, V175, P258, DOI 10.1016/j.foodchem.2014.11.142
   Lukens JR, 2014, NATURE, V516, P246, DOI 10.1038/nature13788
   Maier H., 2014, J. Diabetes Res. Clin. Metab., V3, P2, DOI [10.7243/2050-0866-3-2, DOI 10.7243/2050-0866-3-2]
   Malaguti M, 2014, INT J MOL SCI, V15, P21120, DOI 10.3390/ijms151121120
   Martínez-González MA, 2002, EUR J NUTR, V41, P153, DOI 10.1007/s00394-002-0370-6
   Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264
   Mudgett MB, 1997, PLANT PHYSIOL, V115, P1481, DOI 10.1104/pp.115.4.1481
   Nielsen ML, 2005, MOL CELL PROTEOMICS, V4, P835, DOI 10.1074/mcp.T400022-MCP200
   OBRIEN J, 1989, CRIT REV FOOD SCI, V28, P211, DOI 10.1080/10408398909527499
   ODANI S, 1987, J BIOL CHEM, V262, P10502
   Park JH, 2005, J AGR FOOD CHEM, V53, P7686, DOI 10.1021/jf0506481
   Perrone L, 2015, J ALZHEIMERS DIS, V45, P965, DOI 10.3233/JAD-140720
   Sala-Vila A, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0583-y
   Seber LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035409
   Seo J, 2004, J BIOCHEM MOL BIOL, V37, P35
   Serra A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23005
   SHAHIDI F, 1992, CRIT REV FOOD SCI, V32, P67, DOI 10.1080/10408399209527581
   Sun CL, 2002, CANCER EPIDEM BIOMAR, V11, P1674
   Swiatecka D, 2010, J SCI FOOD AGR, V90, P1837, DOI 10.1002/jsfa.4022
   Sze SK, 2003, ANAL CHEM, V75, P1599, DOI 10.1021/ac020446t
   Sze SK, 2002, P NATL ACAD SCI USA, V99, P1774, DOI 10.1073/pnas.251691898
   Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118652
   Taylor SW, 2000, J BIOL CHEM, V275, P38417, DOI 10.1074/jbc.M006762200
   Traverso N, 2004, J GERONTOL A-BIOL, V59, P890, DOI 10.1093/gerona/59.9.B890
   Trock BJ, 2006, JNCI-J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102
   Uribarri J, 2006, CLIN J AM SOC NEPHRO, V1, P1293, DOI 10.2215/CJN.01270406
   Uribarri J, 2010, J AM DIET ASSOC, V110, P911, DOI 10.1016/j.jada.2010.03.018
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wang WY, 2008, J AOAC INT, V91, P936
   Wei P, 2012, ASIAN PAC J TROP MED, V5, P243, DOI 10.1016/S1995-7645(12)60033-9
   Xue J, 2011, STRUCTURE, V19, P722, DOI 10.1016/j.str.2011.02.013
   YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263
   Zhang CX, 2010, CANCER SCI, V101, P501, DOI 10.1111/j.1349-7006.2009.01376.x
   Zheng F, 2002, DIABETES-METAB RES, V18, P224, DOI 10.1002/dmrr.283
   Zubarev RA, 2004, CURR OPIN BIOTECH, V15, P12, DOI 10.1016/j.copbio.2003.12.002
   Zubarev RA, 2000, ANAL CHEM, V72, P563, DOI 10.1021/ac990811p
NR 71
TC 19
Z9 19
U1 0
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 18
PY 2016
VL 6
AR 26106
DI 10.1038/srep26106
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DM0UF
UT WOS:000376060600001
PM 27189269
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Butts, B
   Gary, RA
   Dunbar, SB
   Butler, J
AF Butts, Brittany
   Gary, Rebecca A.
   Dunbar, Sandra B.
   Butler, Javed
TI Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase
   Recruitment Domain and Outcomes in Heart Failure
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; epigenetic; inflammation
ID NLRP3 INFLAMMASOME ACTIVATION; ACUTE MYOCARDIAL-INFARCTION; 6-MINUTE
   WALK TEST; DNA METHYLATION; BREAST-CANCER; PROMOTER METHYLATION;
   ABERRANT METHYLATION; PROSTATE-CANCER; GENE PROMOTER; ASC GENE
AB Background: Heart failure (HF) is associated with inflammation characterized by the formation of the inflammasome, which triggers maturation of inflammatory cytokines. Apoptosis-associated speck-like protein with a caspase recruitment domain (ASC), a vital component of the inflammasome, is controlled through epigenetic modification, which may be a candidate pathway for worsening HF. This study examined the inflammasome pathway in HF and the relationships between ASC CpG methylation and outcomes in HF.
   Methods and Results: Stored samples from 155 HF outpatients (ejection fraction 29.9 +/- 14.9%) were analyzed for percentage methylation of 7 CpG sites in the intron region preceding exon 1 of the ASC gene. ASC methylation was inversely related to ASC mRNA (r = -0.33; P <.001) and protein (r = -0.464; P <.001). ASC methylation had a positive linear relationship with ejection fraction (r = 0.85; P <.001), quality of life (r = 0.83; P <.001), and 6-minute walk test (r = 0.59; P =.023) and a negative linear relationship with depression (r = -0.81; P <.001) and anxiety (r = -0.75; P <.001). Higher ASC methylation was associated with a lower risk for clinical events (hazard ratio [HR] 0.16; P =.025), whereas higher protein (HR = 1.78; P =.045) and mRNA expression (HR = 1.18; P =.05) were associated with a greater risk.
   Conclusions: Increased methylation of CpG sites in the intron region of ASC is associated with improved outcomes in HF. The associated decrease in ASC expression implicates this inflammatory mediator as a possible driver of HF outcomes and may represent a therapeutic target.
C1 [Butts, Brittany; Gary, Rebecca A.; Dunbar, Sandra B.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA.
   [Butler, Javed] SUNY Stony Brook, Div Cardiol, Stony Brook, NY 11794 USA.
C3 Emory University; State University of New York (SUNY) System; Stony
   Brook University
RP Butler, J (通讯作者)，SUNY Stony Brook, Div Cardiol, Hlth Sci Ctr, T-16,Room 080, Stony Brook, NY 11794 USA.
EM javed.butler@stonybrookmedicine.edu
RI Butler, Javed/AEW-5002-2022
OI Butts, Brittany/0000-0002-4862-7086
FU PHS Grant from the Clinical and Translational Science Award Program,
   National Institutes of Health, National Center for Advancing
   Translational Sciences [UL1TR000454]; National Institutes of Health
   National Institute of Nursing Research grant [T32NR012715,
   1F31NR015180-01]
FX Supported in part by PHS Grant UL1TR000454 from the Clinical and
   Translational Science Award Program, National Institutes of Health,
   National Center for Advancing Translational Sciences. B. Butts was
   funded in part by the National Institutes of Health National Institute
   of Nursing Research grant numbers T32NR012715 (PI S. Dunbar) and
   1F31NR015180-01 (PI B. Butts).
CR Abbate A, 2013, EXP PHYSIOL, V98, P385, DOI 10.1113/expphysiol.2012.069021
   Abbate A, 2010, AM J CARDIOL, V105, P1371, DOI 10.1016/j.amjcard.2009.12.059
   Argos M, 2015, ENVIRON HEALTH PERSP, V123, P64, DOI 10.1289/ehp.1307884
   Arslan S, 2007, TEX HEART I J, V34, P166
   Bigford GE, 2013, ASN NEURO, V5, P243, DOI 10.1042/AN20130021
   BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702
   Bracey NA, 2013, EXP PHYSIOL, V98, P462, DOI 10.1113/expphysiol.2012.068338
   Butts B, 2015, J CARD FAIL, V21, P586, DOI 10.1016/j.cardfail.2015.04.014
   Chang YQ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1549
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Collard RL, 2006, PROSTATE, V66, P687, DOI 10.1002/pros.20371
   Conway KE, 2000, CANCER RES, V60, P6236
   Damaschke NA, 2013, PROSTATE, V73, P1721, DOI 10.1002/pros.22716
   Delgado-Cruzata L, 2015, J NUTR, V145, P783, DOI 10.3945/jn.114.202853
   Dharmarajan K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h411
   Fan CN, 2014, NUTR HOSP, V30, P42, DOI 10.3305/nh.2014.30.1.7521
   Fyhrquist F, 2013, NAT REV CARDIOL, V10, P274, DOI 10.1038/nrcardio.2013.30
   Glezeva N, 2014, HEART FAIL REV, V19, P681, DOI 10.1007/s10741-013-9405-8
   Granata S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122272
   Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3
   Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44
   Hoque R, 2015, AM J PHYSIOL-GASTR L, V308, pG643, DOI 10.1152/ajpgi.00388.2014
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Horsburgh S, 2015, EXERC IMMUNOL REV, V21, P26
   Kapoor-Vazirani P, 2011, MOL CELL BIOL, V31, P1594, DOI 10.1128/MCB.00524-10
   Kawaguchi M, 2011, CIRCULATION, V123, P594, DOI 10.1161/CIRCULATIONAHA.110.982777
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lebel-Binay S, 2000, EUR CYTOKINE NETW, V11, P15
   Lee S, 2015, AM J RESP CELL MOL B, DOI [10.1165/remb.2015-0231TR, DOI 10.1165/REMB.2015-0231TR]
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Ling C, 2014, DRUG DISCOV TODAY, V19, P1015, DOI 10.1016/j.drudis.2014.03.006
   McClay JL, 2014, HUM MOL GENET, V23, P1175, DOI 10.1093/hmg/ddt511
   Mezzaroma E, 2011, P NATL ACAD SCI USA, V108, P19725, DOI 10.1073/pnas.1108586108
   Nakajima K, 2010, INT J SPORTS MED, V31, P671, DOI 10.1055/s-0029-1246140
   Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2
   Ottini L, 2015, MUTAT RES-GEN TOX EN, V779, P57, DOI 10.1016/j.mrgentox.2015.01.006
   Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007
   Rang Franka J, 2014, Biology (Basel), V3, P403, DOI 10.3390/biology3020403
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Salloum FN, 2009, CARDIOVASC DRUG THER, V23, P129, DOI 10.1007/s10557-008-6154-3
   Sarkar A, 2006, J IMMUNOL, V176, P4979, DOI 10.4049/jimmunol.176.8.4979
   Scharf AND, 2011, FEBS LETT, V585, P2001, DOI 10.1016/j.febslet.2010.11.029
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720
   Takahashi M, 2014, INT HEART J, V55, P101, DOI 10.1536/ihj.13-388
   Takumi S, 2015, J APPL TOXICOL, V35, P1550, DOI 10.1002/jat.3117
   Taniguchi S, 2007, SEMIN IMMUNOPATHOL, V29, P231, DOI 10.1007/s00281-007-0082-3
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025
NR 55
TC 21
Z9 22
U1 0
U2 5
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
EI 1532-8414
J9 J CARD FAIL
JI J. Card. Fail.
PD MAY
PY 2016
VL 22
IS 5
BP 340
EP 346
DI 10.1016/j.cardfail.2015.12.004
PG 7
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA DL8KL
UT WOS:000375890800004
PM 26700661
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Hsieh, CL
   Ma, HP
   Su, CM
   Chang, YJ
   Hung, WY
   Ho, YS
   Huang, WJ
   Lin, RK
AF Hsieh, Chang-Lin
   Ma, Hon-Ping
   Su, Chih-Ming
   Chang, Yu-Jia
   Hung, Wan-Yu
   Ho, Yuan-Soon
   Huang, Wei-Jan
   Lin, Ruo-Kai
TI Alterations in histone deacetylase 8 lead to cell migration and poor
   prognosis in breast cancer
SO LIFE SCIENCES
LA English
DT Article
DE Breast cancer; HDAC8; DNA methylation; Cell migration; TCGA; IPA;
   PCI-34051; Tamoxifen
ID PROSTATE-CANCER; GENE-EXPRESSION; TUMOR-CELLS; IN-VITRO; PROTEIN;
   METASTASIS; P53; HYPOMETHYLATION; EPIGENETICS; INVASION
AB Aims: Alterations in histone proteins can lead to breast tumorigenesis. Selective histone deacetylase 8 (HDAC8) inhibitors with fewer adverse effects have been developed. A more comprehensive study of alterations and its mechanisms in HDAC8 is required. In this study, we investigated mechanisms of dysregulation of HDAC8 expression and its biological role and pathways in breast cancer.
   Main methods: Alterations in HDAC8 were analyzed in Taiwanese breast cancer patients; and in tissue samples from The Cancer Genome Atlas (TCGA) data set that were derived from Western countries. Knockdown by si-HDAC8, treatment with the HDAC8-specific inhibitor PCI-34051, SRB assays, wound healing, Transwell migration assays, Illumina BeadArray (TM) arrays and Ingenuity Pathway Analysis (IPA) were performed in breast cancer cells.
   Key findings: HDAC8 mRNA expression was upregulated in paired breast cancer tissue from Taiwanese patients and in paired breast cancer tissues from the TCGA data set. Hypomethylation of promoter regions was significantly correlated with HDAC8 mRNA overexpression in 588 breast cancer patients from the TCGA data set and was associated with poor prognosis in early-stage breast cancer. HDAC8 mRNA overexpression was associated with late stages and tumor progression. Wound healing and Transwell migration assays revealed that knockdown by si-HDAC8 or PCI-34051 treatment significantly inhibited breast cancer cell migration. Knockdown by si-HDAC8, Illumina BeadArray (TM) arrays and IPA found that ID3 and PTP4A2 pathways were regulated by HDAC8 in cancer cell migration.
   Significance: Hypomethylation of the HDAC8 promoter is correlated with HDAC8 overexpression and breast cancer progression and is a potential prognosis marker and drug target. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hsieh, Chang-Lin] Taipei Med Univ, Profess Master Program Pharmaceut & Biotechnol, Taipei 110, Taiwan.
   [Ma, Hon-Ping] Shuang Ho Hosp, Emergency Dept, New Taipei 235, Taiwan.
   [Su, Chih-Ming; Chang, Yu-Jia] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   [Hung, Wan-Yu; Lin, Ruo-Kai] Taipei Med Univ, Master Program Clin Pharmacogen & Pharmacoprote, Taipei 110, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ, Ctr Comprehens Canc, Grad Inst Biomed Technol, Taipei 110, Taiwan.
   [Huang, Wei-Jan; Lin, Ruo-Kai] Taipei Med Univ, Grad Inst Pharmacognosy, PhD Program Clin Drug Discovery Bot Herbs, Taipei 110, Taiwan.
   [Ma, Hon-Ping] Taipei Med Univ, Sch Med, Dept Emergency Med, Taipei 110, Taiwan.
   [Su, Chih-Ming] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Taipei 235, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Medical University; Taipei Medical University; Taipei
   Medical University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; Shuang Ho Hospital
RP Lin, RK (通讯作者)，Taipei Med Univ, Grad Inst Pharmacognosy, Master Program Clin Pharmacogen & Pharmacoprote, PhD Program Clin Drug Discovery Bot Herbs, 250 Wu Hsing St, Taipei 110, Taiwan.
EM linruokai@tmu.edu.tw
RI Huang, JianJang/A-1743-2012; Su, ChihMing/KOD-8182-2024
FU Taipei Medical University-Shuang Ho Hospital [100TMU-SHH-01-4]; Ministry
   of Science and Technology [NSC 101-2320-B-038-026-MY3,
   MOST104-2320-B-038-051-MY3]; Health and welfare surcharge of tobacco
   products (Republic of China) [MOHW105-TDU-B-212-134001]
FX This work was supported in part by grants 100TMU-SHH-01-4 from Taipei
   Medical University-Shuang Ho Hospital and NSC 101-2320-B-038-026-MY3 and
   MOST104-2320-B-038-051-MY3 from the Ministry of Science and Technology
   and MOHW105-TDU-B-212-134001 from Health and welfare surcharge of
   tobacco products (Republic of China).
CR Ademuyiwa FO, 2011, CANCER RES, V71, P640, DOI 10.1158/0008-5472.CAN-10-3021
   Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9
   Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199
   Burnum KE, 2012, ENDOCRINOLOGY, V153, P4568, DOI 10.1210/en.2012-1335
   Chakrabarti A, 2015, TRENDS PHARMACOL SCI, V36, P481, DOI 10.1016/j.tips.2015.04.013
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Dai M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3441
   Daoud SS, 2003, CANCER RES, V63, P2782
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019
   Espinosa AV, 2009, CLIN EXP METASTAS, V26, P517, DOI 10.1007/s10585-009-9251-1
   Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2
   Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080
   Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104
   Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041
   Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025
   Koeneke E, 2015, CELLS-BASEL, V4, P135, DOI 10.3390/cells4020135
   Lee H, 2006, MOL CELL BIOL, V26, P5259, DOI 10.1128/MCB.01971-05
   Lee JY, 2009, BBA-GEN SUBJECTS, V1790, P1673, DOI 10.1016/j.bbagen.2009.08.005
   Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108
   Lopez G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133302
   Majumdar S, 2011, CURR GENOMICS, V12, P486, DOI 10.2174/138920211797904061
   Micelli C, 2015, DRUG DISCOV TODAY, V20, P718, DOI 10.1016/j.drudis.2015.01.007
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Noh EH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048315
   Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290
   Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5
   Wen GY, 2011, CANCER LETT, V308, P23, DOI 10.1016/j.canlet.2011.04.010
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wilson JW, 2001, CANCER RES, V61, P8803
   Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81
   Yang SW, 2013, J NEUROSCI, V33, P12728, DOI 10.1523/JNEUROSCI.0698-13.2013
   Ye XC, 2012, PROSTATE, V72, P291, DOI 10.1002/pros.21431
NR 39
TC 32
Z9 36
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD APR 15
PY 2016
VL 151
BP 7
EP 14
DI 10.1016/j.lfs.2016.02.092
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DL6DK
UT WOS:000375728400002
PM 26926079
DA 2025-01-12
ER

PT J
AU Lapierre, M
   Linares, A
   Dalvai, M
   Duraffourd, C
   Bonnet, S
   Boulahtouf, A
   Rodriguez, C
   Jalaguier, S
   Assou, S
   Orsetti, B
   Balaguer, P
   Maudelonde, T
   Blache, P
   Bystricky, K
   Boulle, N
   Cavaillès, V
AF Lapierre, Marion
   Linares, Aurelien
   Dalvai, Mathieu
   Duraffourd, Celine
   Bonnet, Sandrine
   Boulahtouf, Abdelhay
   Rodriguez, Carmen
   Jalaguier, Stephan
   Assou, Said
   Orsetti, Beatrice
   Balaguer, Patrick
   Maudelonde, Thierry
   Blache, Philippe
   Bystricky, Kerstin
   Boulle, Nathalie
   Cavailles, Vincent
TI Histone deacetylase 9 regulates breast cancer cell proliferation and the
   response to histone deacetylase inhibitors
SO ONCOTARGET
LA English
DT Article
DE breast cancer; histone deacetylase; HDAC9; HDAC inhibitors; SOX9
ID GENE-EXPRESSION; ESTROGEN-RECEPTOR; STEM-CELLS; SOX9; HDAC9;
   TRANSCRIPTION; ACETYLATION; MECHANISMS; PREDICTOR; PATHWAY
AB Histone lysine acetylation is an epigenetic mark regulated by histone acetyltransferases and histone deacetylases (HDAC) which plays an important role in tumorigenesis. In this study, we observed a strong overexpression of class IIa HDAC9, at the mRNA and protein levels, in the most aggressive human breast cancer cell lines (i.e. in basal breast cancer cells vs luminal ones or in malignant vs begnin MCF10A breast epithelial cell lines). HDAC9 overexpression was associated with higher rates of gene transcription and increased epigenetic marks on the HDAC9 promoter. Ectopic expression of HDAC9 in MCF7 luminal breast cancer cells led to an increase in cell proliferation and to a decrease in apoptosis. These effects were associated with a deregulated expression of several genes controlled by HDAC inhibitors such as CDKN1A, BAX and TNFRSF10A. Inversely, knock-down of HDAC9 expression in MDA-MB436 basal breast cancer cells reduced cell proliferation. Moreover, high HDAC9 expression decreased the efficacy of HDAC inhibitors to reduce cell proliferation and to regulate CDKN1A gene expression. Interestingly, the gene encoding the transcription factor SOX9 was identified by a global transcriptomic approach as an HDAC9 target gene. In stably transfected MCF7 cells, SOX9 silencing significantly decreased HDAC9 mitogenic activity. Finally, in a large panel of breast cancer biopsies, HDAC9 expression was significantly increased in tumors of the basal subtype, correlated with SOX9 expression and associated with poor prognosis. Altogether, these results indicate that HDAC9 is a key factor involved in mammary carcinogenesis and in the response to HDAC inhibitors.
C1 [Lapierre, Marion; Linares, Aurelien; Bonnet, Sandrine; Boulahtouf, Abdelhay; Rodriguez, Carmen; Jalaguier, Stephan; Orsetti, Beatrice; Balaguer, Patrick; Blache, Philippe; Boulle, Nathalie; Cavailles, Vincent] Inst Rech Cancerol Montpellier, Montpellier, France.
   [Lapierre, Marion; Linares, Aurelien; Bonnet, Sandrine; Boulahtouf, Abdelhay; Rodriguez, Carmen; Jalaguier, Stephan; Orsetti, Beatrice; Balaguer, Patrick; Blache, Philippe; Boulle, Nathalie; Cavailles, Vincent] INSERM, U1194, Montpellier, France.
   [Lapierre, Marion; Linares, Aurelien; Bonnet, Sandrine; Boulahtouf, Abdelhay; Rodriguez, Carmen; Jalaguier, Stephan; Assou, Said; Orsetti, Beatrice; Balaguer, Patrick; Blache, Philippe; Boulle, Nathalie; Cavailles, Vincent] Univ Montpellier, F-34059 Montpellier, France.
   [Lapierre, Marion; Linares, Aurelien; Bonnet, Sandrine; Boulahtouf, Abdelhay; Rodriguez, Carmen; Jalaguier, Stephan; Orsetti, Beatrice; Balaguer, Patrick; Blache, Philippe; Boulle, Nathalie; Cavailles, Vincent] Inst Canc Montpellier, Montpellier, France.
   [Dalvai, Mathieu; Bystricky, Kerstin] Univ Toulouse, UPS, Lab Biol Mol Eucaryote, Toulouse, France.
   [Dalvai, Mathieu; Bystricky, Kerstin] CNRS, UMR5099, Toulouse, France.
   [Duraffourd, Celine; Maudelonde, Thierry; Boulle, Nathalie] CHU Arnaud Villeneuve, Biol Cellulaire Lab, Montpellier, France.
   [Assou, Said] INSERM, Inst Regenerat Med & Biotherapy, U1183, Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; Universite de
   Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du
   Cancer Montpellier / Val d'Aurelle (ICM); Universite de Toulouse;
   Universite Toulouse III - Paul Sabatier; Centre National de la Recherche
   Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III -
   Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS
   - National Institute for Biology (INSB); Universite de Montpellier; CHU
   de Montpellier; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Montpellier
RP Cavaillès, V (通讯作者)，Inst Rech Cancerol Montpellier, Montpellier, France.; Cavaillès, V (通讯作者)，INSERM, U1194, Montpellier, France.; Cavaillès, V (通讯作者)，Univ Montpellier, F-34059 Montpellier, France.; Cavaillès, V (通讯作者)，Inst Canc Montpellier, Montpellier, France.
EM vincent.cavailles@inserm.fr
RI Balaguer, Patrick/I-2973-2016; Bystricky, Kerstin/AAA-3003-2020;
   Cavailles, Vincent/Y-5379-2019; Jalaguier, Stéphan/AAC-1847-2020;
   Rodríguez, Carmen/R-9541-2019; Lapierre, Marion/M-4964-2016; Bystricky,
   Kerstin/B-8670-2009
OI assou, said/0000-0001-6448-7995; Lapierre, Marion/0000-0002-4708-805X;
   blache, philippe/0000-0002-4085-2465; Cavailles,
   Vincent/0000-0002-7160-3074; Bystricky, Kerstin/0000-0001-6717-3721;
   Jalaguier, Stephan/0000-0002-0149-3738
FU INCa [2011-054]; Institut National de la Sante et de la Recherche
   Medicale; University of Montpellier; Ligue Nationale contre le Cancer;
   Association pour la Recherche sur le Cancer
FX This work was supported by the INCa (2011-054), the "Institut National
   de la Sante et de la Recherche Medicale'', the University of
   Montpellier, the "Ligue Nationale contre le Cancer'', the "Association
   pour la Recherche sur le Cancer''.
CR Beaumont T, 2011, Nurs Stand, V25, P49
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489
   Carrasco E, 2014, EUR J CLIN INVEST, V44, P678, DOI 10.1111/eci.12276
   Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086
   Chakravarty G, 2011, CANCER BIOL THER, V11, P71, DOI 10.4161/cbt.11.1.13952
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Clocchiatti A, 2013, FASEB J, V27, P942, DOI 10.1096/fj.12-209346
   de Zoeten EF, 2010, GASTROENTEROLOGY, V138, P583, DOI 10.1053/j.gastro.2009.10.037
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Filipits M, 2011, CLIN CANCER RES, V17, P6012, DOI 10.1158/1078-0432.CCR-11-0926
   Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jézéquel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107
   Kuo WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045831
   Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1
   Linares A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/856985
   Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041
   Méjat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395
   MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   New M, 2013, CELL DEATH DIFFER, V20, P1306, DOI 10.1038/cdd.2013.47
   Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200
   Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rodriguez AL, 2004, J MED CHEM, V47, P600, DOI 10.1021/jm030404c
   Slingerland M, 2014, ANTI-CANCER DRUG, V25, P140, DOI 10.1097/CAD.0000000000000040
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08
   van Rooij E, 2010, CIRC RES, V106, P155, DOI 10.1161/CIRCRESAHA.109.207084
   Wang HY, 2013, J BIOL CHEM, V288, P6478, DOI 10.1074/jbc.M112.419184
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yuan ZG, 2010, J BIOL CHEM, V285, P39329, DOI 10.1074/jbc.M110.179333
   Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9
   Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498
   Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098
NR 48
TC 47
Z9 53
U1 1
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 12
PY 2016
VL 7
IS 15
BP 19693
EP 19708
DI 10.18632/oncotarget.7564
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL7ES
UT WOS:000375804000047
PM 26930713
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Pucci, S
   Zonetti, MJ
   Fisco, T
   Polidoro, C
   Bocchinfuso, G
   Palleschi, A
   Novelli, G
   Spagnoli, LG
   Mazzarelli, P
AF Pucci, Sabina
   Zonetti, Maria Jose
   Fisco, Tommaso
   Polidoro, Chiara
   Bocchinfuso, Gianfranco
   Palleschi, Antonio
   Novelli, Giuseppe
   Spagnoli, Luigi G.
   Mazzarelli, Paola
TI Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target
   in human breast cancer
SO ONCOTARGET
LA English
DT Article
DE breast cancer; carnitine palmitoyl transferase-1A; HDAC inhibitor; tumor
   metabolism; tumor specific target
ID HISTONE DEACETYLASE INHIBITORS; PALMITOYLTRANSFERASE-I; SWISS-MODEL;
   MACROMOLECULAR STRUCTURES; CELL-SURVIVAL; COLON-CANCER; PHASE-I;
   PROTEIN; GROWTH; ACID
AB Transcriptional mechanisms epigenetically-regulated in tumoral tissues point out new targets for anti-cancer therapies. Carnitine palmitoyl transferase I (CPT1) is the rate-limiting enzyme in the transport of long-chain fatty acids for beta-oxidation. Here we identified the tumor specific nuclear CPT1A as a product of the transcript variant 2, that doesn't retain the classical transferase activity and is strongly involved in the epigenetic regulation of cancer pro-survival, cell death escaping and tumor invasion pathways. The knockdown of CPT1A variant 2 by small interfering RNAs (siRNAs), was sufficient to induce apoptosis in MCF-7, SK-BR3 and MDA-MB-231 breast cancer cells. The cell death triggered by CPT1A silencing correlated with reduction of HDAC activity and histone hyperacetylation. Docking experiments and molecular dynamics simulations confirmed an high binding affinity of the variant 2 for HDAC1. The CPT1A silenced cells showed an up-regulated transcription of pro-apoptotic genes (BAD, CASP9, COL18A1) and down-modulation of invasion and metastasis related-genes (TIMP-1, PDGF-A, SERPINB2). These findings provide evidence of the CPT1 variant 2 involvement in breast cancer survival, cell death escape and invasion. Thus, we propose nuclear CPT1A as a striking tumor specific target for anticancer therapeutics, more selective and effective as compared with the well-known HDAC inhibitors.
C1 [Pucci, Sabina; Zonetti, Maria Jose; Fisco, Tommaso; Polidoro, Chiara; Novelli, Giuseppe; Spagnoli, Luigi G.; Mazzarelli, Paola] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.
   [Bocchinfuso, Gianfranco; Palleschi, Antonio] Univ Roma Tor Vergata, Dept Chem Sci & Technol, Rome, Italy.
C3 University of Rome Tor Vergata; University of Rome Tor Vergata
RP Pucci, S; Spagnoli, LG (通讯作者)，Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.
EM sabina.pucci@uniroma2.it; spagnoli@alleanzacontroilcancro.it
RI Novelli, Giuseppe/A-5195-2013; Bocchinfuso, Gianfranco/E-9014-2011
OI Novelli, Giuseppe/0000-0002-7781-602X; Bocchinfuso,
   Gianfranco/0000-0002-5556-7691; Spagnoli, Luigi
   Giusto/0000-0002-0684-5501; Fisco, Tommaso/0000-0002-6687-3264
FU Alleanza contro il cancro (ACC) - National Institute of Health -
   Programma Straordinario di Ricerca Oncologica
FX This work was supported in part by Alleanza contro il cancro (ACC) -
   National Institute of Health (ISS) Art. 3 DM21 July 2006 - Programma
   Straordinario di Ricerca Oncologica 2006.
CR Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3
   Bocchinfuso G, 2007, PROTEINS, V66, P963, DOI 10.1002/prot.21050
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984
   Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304
   Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Davis T, 2000, CLIN CANCER RES, V6, P4334
   Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Feng WW, 2007, INT J CANCER, V120, P1664, DOI 10.1002/ijc.22474
   Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929
   Lopez Rodas G, 1993, FEBS LETT, V317, P175
   López-Viñas E, 2007, J BIOL CHEM, V282, P18212, DOI 10.1074/jbc.M700885200
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Martinelli S, 2008, HUM MOL GENET, V17, P2018, DOI 10.1093/hmg/ddn099
   Mazzarelli P, 2007, CANCER BIOL THER, V6, P1606, DOI 10.4161/cbt.6.10.4742
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Palleschi A, 2006, INT J PHARMACEUT, V322, P13, DOI 10.1016/j.ijpharm.2006.05.029
   Pieper U, 2009, NUCLEIC ACIDS RES, V37, pD347, DOI 10.1093/nar/gkn791
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Sierra AY, 2008, J BIOL CHEM, V283, P6878, DOI 10.1074/jbc.M707965200
   Sieuwerts AM, 2007, CLIN CHEM, V53, P1280, DOI 10.1373/clinchem.2006.082800
   Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925
   Tonnetti L, 2008, CANCER RES, V68, P5648, DOI 10.1158/0008-5472.CAN-07-5850
   Vajda S, 2009, CURR OPIN STRUC BIOL, V19, P164, DOI 10.1016/j.sbi.2009.02.008
   Van Gunsteren W.F., 1996, The GROMOS96 Manual and User Guide
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   WEIS BC, 1994, J BIOL CHEM, V269, P18712
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
NR 39
TC 64
Z9 73
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 12
PY 2016
VL 7
IS 15
BP 19982
EP 19996
DI 10.18632/oncotarget.6964
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL7ES
UT WOS:000375804000068
PM 26799588
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Li, TT
   Kong, ANT
   Ma, ZQ
   Liu, HY
   Liu, PH
   Xiao, Y
   Jiang, XH
   Wang, L
AF Li, Tingting
   Kong, Ah-Ng Tony
   Ma, Zhiqiang
   Liu, Haiyan
   Liu, Pinghua
   Xiao, Yu
   Jiang, Xuehua
   Wang, Ling
TI Protein arginine methyltransferase 1 may be involved in pregnane x
   receptor-activated overexpression of multidrug resistance 1 gene during
   acquired multidrug resistant
SO ONCOTARGET
LA English
DT Article
DE multidrug resistance; p-glycoprotein; protein arginine methyl
   transferase 1; pregnane x receptor
ID BREAST-CANCER CELLS; P-GLYCOPROTEIN; DRUG-RESISTANCE; IN-VIVO;
   SALVIANOLIC ACID; HISTONE H4; EPIGENETIC REGULATION;
   CALCIUM-ANTAGONISTS; CYTOCHROME-P450 3A4; EPITHELIAL-CELLS
AB Purpose: Pregnane x receptor (PXR) - activated overexpression of the multidrug resistance 1 (MDR1) gene is an important way for tumor cells to acquire drug resistance. However, the detailed mechanism still remains unclear. In the present study, we aimed to investigate whether protein arginine methyl transferase 1(PRMT1) is involved in PXR - activated overexpression of MDR1 during acquired multidrug resistant.
   Experimental Design: Arginine methyltransferase inhibitor 1 (AMI-1) was used to pharmacologically block PRMT1 in resistant breast cancer cells (MCF7/adr). The mRNA and protein levels of MDR1 were detected by real-time PCR and western blotting analysis. Immunofluorescence microscopy and co-immunoprecipitation were used to investigate the physical interaction between PXR and PRMT1. Then, 136 candidate compounds were screened for PRMT1 inhibitors. Lastly, luciferase reporter gene and nude mice bearing resistant breast cancer xenografts were adopted to investigate the anti-tumor effect of PRMT1 inhibitors when combined with adriamycin.
   Results: AMI-1 significantly suppressed the expression of MDR1 in MCF7/adr cells and increased cells sensitivity of MCF7/adr to adriamycin. Physical interaction between PRMT1 and PXR exists in MCF7/adr cells, which could be disrupted by AMI-1. Those results suggest that PRMT1 may be involved in PXR-activated overexpression of MDR1 in resistant breast cancer cells, and AMI-1 may suppress MDR1 by disrupting the interaction between PRMT1 and PXR. Then, five compounds including rutin, isoquercitrin, salvianolic acid A, naproxen, and felodipline were identified to be PRMT1 inhibitors. Finally, those PRMT1 inhibitors were observed to significantly decrease MDR1 promoter activity in vitro and enhance the antitumor effect of adriamycin in nude mice that bearing resistant breast cancer xenografts.
   Conclusions: PRMT1 may be an important co-activator of PXR in activating MDR1 gene during acquired resistance, and PRMT1 inhibitor combined with chemotherapy drugs may be a new strategy for overcoming tumor MDR.
C1 [Li, Tingting; Jiang, Xuehua; Wang, Ling] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Tingting; Ma, Zhiqiang; Liu, Haiyan; Liu, Pinghua] Peoples Hosp Xishuangbanna Dai Autonomous Prefect, Jinghong 666100, Yunnan, Peoples R China.
   [Kong, Ah-Ng Tony] Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Kong, Ah-Ng Tony] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.
   [Xiao, Yu] Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, State Drug Clin Trial Agcy, Chengdu 610065, Sichuan, Peoples R China.
C3 Sichuan University; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University System; Rutgers University New Brunswick;
   Sichuan Provincial People's Hospital
RP Wang, L (通讯作者)，Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
EM rebeccawang312@gmail.com
RI Ma, qiang/HZK-3874-2023; Kong, Ah-Ng/AAX-2828-2020; Li,
   Tingting/HKE-0812-2023
CR Abdallah HM, 2015, J ADV RES, V6, P45, DOI 10.1016/j.jare.2014.11.008
   CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632
   Chen YH, 2009, EXP EYE RES, V89, P1028, DOI 10.1016/j.exer.2009.09.004
   Cheng DH, 2004, J BIOL CHEM, V279, P23892, DOI 10.1074/jbc.M401853200
   Dagher Z, 2012, FOOD CHEM TOXICOL, V50, P4109, DOI 10.1016/j.fct.2012.08.013
   Durmus S, 2015, ADV CANCER RES, V125, P1, DOI 10.1016/bs.acr.2014.10.001
   Feng Y, 2009, BIOCHEM BIOPH RES CO, V379, P567, DOI 10.1016/j.bbrc.2008.12.119
   Golfakhrabadi F, 2015, J ARTHROPOD-BORNE DI, V9, P104
   Gupta A, 2008, DRUG METAB DISPOS, V36, P1172, DOI 10.1124/dmd.107.018689
   Harmsen S, 2013, EUR J PHARM SCI, V48, P644, DOI 10.1016/j.ejps.2012.12.019
   Harmsen S, 2009, CANCER CHEMOTH PHARM, V64, P35, DOI 10.1007/s00280-008-0842-3
   Harmsen S, 2010, CANCER CHEMOTH PHARM, V66, P765, DOI 10.1007/s00280-009-1221-4
   HOLLT V, 1992, BIOCHEM PHARMACOL, V43, P2601, DOI 10.1016/0006-2952(92)90149-D
   Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905
   Klepsch F, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002036
   Kovalev A. A., 2013, Experimental Oncology, V35, P287
   Li X, 2014, TOXICOL APPL PHARM, V275, P163, DOI 10.1016/j.taap.2013.12.015
   Lim YP, 2007, PHARMACOGENET GENOM, V17, P369, DOI 10.1097/FPC.0b013e32803e40d7
   Liu HM, 2013, XENOBIOTICA, V43, P1018, DOI 10.3109/00498254.2013.791003
   Mani S, 2005, CLIN CANCER RES, V11, P6359, DOI 10.1158/1078-0432.CCR-05-0252
   Mensah-Osman EJ, 2007, CANCER-AM CANCER SOC, V109, P957, DOI 10.1002/cncr.22479
   MULLER C, 1995, J CELL PHYSIOL, V163, P538, DOI 10.1002/jcp.1041630314
   Murayama N, 2014, CHEM RES TOXICOL, V27, P304, DOI 10.1021/tx4004374
   Nabekura T, 2010, TOXINS, V2, P1207, DOI 10.3390/toxins2061207
   Navaratnarajah P, 2012, BIOCHEMISTRY-US, V51, P19, DOI 10.1021/bi2011674
   Ofer M, 2006, EUR J PHARM SCI, V29, P251, DOI 10.1016/j.ejps.2006.06.010
   Okura T, 2010, BIOL PHARM BULL, V33, P255, DOI 10.1248/bpb.33.255
   Orlova R. V., 2015, Voprosy Onkologii (St. Petersburg), V61, P244
   Peng XX, 2012, CHIN J CANCER, V31, P110, DOI 10.5732/cjc.011.10327
   Pluchino KM, 2012, DRUG RESIST UPDATE, V15, P98, DOI 10.1016/j.drup.2012.03.002
   Pondugula SR, 2015, TOXICOL LETT, V232, P580, DOI 10.1016/j.toxlet.2014.12.015
   Qiao EQ, 2014, ONCOL LETT, V7, P1191, DOI 10.3892/ol.2014.1817
   Rizzo G, 2005, MOL PHARMACOL, V68, P551, DOI 10.1124/mol.105.012104
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b
   Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Sun QZ, 2012, J IMMUNOL, V188, P3506, DOI 10.4049/jimmunol.1102635
   Takara K, 2012, MOL MED REP, V5, P603, DOI 10.3892/mmr.2011.734
   Tian YA, 2013, DRUG METAB REV, V45, P166, DOI 10.3109/03602532.2012.756012
   Wagner S, 2006, J BIOL CHEM, V281, P27242, DOI 10.1074/jbc.M605172200
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Wang T, 2011, NEUROCHEM RES, V36, P103, DOI 10.1007/s11064-010-0270-8
   Wang X, 2015, ANTI-CANCER DRUG, V26, P210, DOI 10.1097/CAD.0000000000000184
   Wang YM, 2013, TOXICOL APPL PHARM, V272, P96, DOI 10.1016/j.taap.2013.05.014
   Wooderchak WL, 2008, BIOCHEMISTRY-US, V47, P9456, DOI 10.1021/bi800984s
   Xie Y., 2011, TRANSCRIPATIONAL REG
   Xie Y, 2009, J BIOL CHEM, V284, P9199, DOI 10.1074/jbc.M806193200
   Xu XM, 2013, TOXICOL APPL PHARM, V273, P68, DOI 10.1016/j.taap.2013.08.021
   Zrieki A, 2008, PHARM RES-DORDR, V25, P1991, DOI 10.1007/s11095-008-9596-1
NR 50
TC 15
Z9 16
U1 0
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 12
PY 2016
VL 7
IS 15
BP 20236
EP 20248
DI 10.18632/oncotarget.7752
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL7ES
UT WOS:000375804000086
PM 26934120
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Si, XX
   Liu, Y
   Lv, JH
   Ding, HJ
   Zhang, XA
   Shao, LP
   Yang, N
   Cheng, H
   Sun, L
   Zhu, DL
   Yang, Y
   Li, AD
   Han, X
   Sun, YJ
AF Si, Xinxin
   Liu, Yue
   Lv, Jinghuan
   Ding, Haijian
   Zhang, Xin A.
   Shao, Lipei
   Yang, Nan
   Cheng, He
   Sun, Luan
   Zhu, Dongliang
   Yang, Yin
   Li, Andi
   Han, Xiao
   Sun, Yujie
TI ERα propelled aberrant global DNA hypermethylation by activating the
   DNMT1 gene to enhance anticancer drug resistance in human breast cancer
   cells
SO ONCOTARGET
LA English
DT Article
DE ER alpha; DNMT1; DNMT3b; global DNA hypermethylation; breast cancer
   chemoresistance
ID ESTROGEN-RECEPTOR GENE; EXPRESSION; METHYLATION; PACLITAXEL;
   HYPOMETHYLATION; CONTRIBUTES; EPIGENETICS; PHENOTYPE; KINASE
AB Drug-induced aberrant DNA methylation is the first identified epigenetic marker involved in chemotherapy resistance. Understanding how the aberrant DNA methylation is acquired would impact cancer treatment in theory and practice. In this study we systematically investigated whether and how ER alpha propelled aberrant global DNA hypermethylation in the context of breast cancer drug resistance. Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ER alpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells. In support of these observations, estrogen enhanced multi-drug resistance of breast cancer cells by up-regulation of DNMT1 and DNMT3b genes. Nevertheless, the aberrant global DNA hypermethylation was dominantly induced by ER alpha-activated-DNMT1, since DNMT1 over-expression significantly increased global DNA methylation and DNMT1 knockdown reversed the ER alpha-induced global DNA methylation. Altering DNMT3b expression had no detectable effect on global DNA methylation. Consistently, the expression level of DNMT1 was positively correlated with ER alpha in 78 breast cancer tissue samples shown by our immunohistochemistry (IHC) analysis and negatively correlated with relapse-free survival (RFS) and distance metastasis-free survival (DMFS) of ER alpha-positive breast cancer patients. This study provides a new perspective for understanding the mechanism underlying drug-resistance-facilitating aberrant DNA methylation in breast cancer and other estrogen dependent tumors.
C1 [Si, Xinxin; Liu, Yue; Ding, Haijian; Shao, Lipei; Yang, Nan; Cheng, He; Sun, Luan; Yang, Yin; Li, Andi; Han, Xiao; Sun, Yujie] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Xin A.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA.
   [Zhang, Xin A.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA.
   [Si, Xinxin; Liu, Yue; Ding, Haijian; Shao, Lipei; Cheng, He; Sun, Luan; Zhu, Dongliang; Yang, Yin; Li, Andi; Sun, Yujie] Nanjing Med Univ, Dept Cell Biol, Nanjing, Jiangsu, Peoples R China.
   [Lv, Jinghuan] Nanjing Med Univ, Suzhou Hosp, Municipal Hosp, Dept Pathol, Suzhou, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; Nanjing Medical University; Nanjing Medical
   University
RP Sun, YJ (通讯作者)，Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.; Sun, YJ (通讯作者)，Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China.; Sun, YJ (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.; Sun, YJ (通讯作者)，Nanjing Med Univ, Dept Cell Biol, Nanjing, Jiangsu, Peoples R China.
EM yujiesun@njmu.edu.cn
RI SHAO, LIPEI/IYJ-5311-2023; Sun, Yujie/HHZ-7619-2022; 韩, 晓/GXV-2361-2022;
   Yang, Nan/KVY-0759-2024; Hu, Ying/GQZ-8100-2022; li, andi/GQH-7343-2022
OI Si, Xinxin/0000-0003-0393-4223; Shao, Lipei/0000-0003-3009-7096
FU National Natural Science Foundation of China [81172091, 81301897]; Open
   Foundation of State Key Laboratory of Pharmaceutical Biotechnology of
   Nanjing University; College Postgraduates Innovative Research Plan of
   Jiangsu Province [CXZZ13_0561]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No.81172091), National Natural Science
   Foundation of China (Grant No.81301897), the Open Foundation of State
   Key Laboratory of Pharmaceutical Biotechnology of Nanjing University and
   the College Postgraduates Innovative Research Plan of Jiangsu Province
   (Grant No.CXZZ13_0561).
CR Barone I, 2010, CLIN CANCER RES, V16, P2702, DOI 10.1158/1078-0432.CCR-09-1753
   Cardoso F, 2012, ANN ONCOL, V23, P11, DOI 10.1093/annonc/mds232
   Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427
   Chen GG, 2008, MED RES REV, V28, P954, DOI 10.1002/med.20131
   Colleoni M, 2009, BREAST CANCER RES TR, V116, P359, DOI 10.1007/s10549-008-0223-y
   Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   FALETTE NS, 1990, CANCER RES, V50, P3974
   Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Gampenrieder SP, 2013, J ONCOL, V2013, DOI 10.1155/2013/732047
   Ghoshal K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010338
   Gravina GL, 2011, ENDOCRINOLOGY, V152, P4550, DOI 10.1210/en.2011-1056
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607
   Lai JC, 2009, ANTICANCER RES, V29, P2535
   Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708
   Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526
   Marques M, 2013, NUCLEIC ACIDS RES, V41, P8094, DOI 10.1093/nar/gkt595
   NYCE J, 1989, CANCER RES, V49, P5829
   NYCE J, 1993, P NATL ACAD SCI USA, V90, P2960, DOI 10.1073/pnas.90.7.2960
   Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Plaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209
   Pruthi S, 2007, MAYO CLIN PROC, V82, P1131, DOI 10.4065/82.9.1131
   Regan MM, 2005, BREAST, V14, P582, DOI 10.1016/j.breast.2005.08.021
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Saito K, 2010, CLIN CANCER RES, V16, P2418, DOI 10.1158/1078-0432.CCR-09-2819
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shi JF, 2014, INT J BIOCHEM CELL B, V53, P35, DOI 10.1016/j.biocel.2014.04.016
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Sui M, 2007, CANCER RES, V67, P5337, DOI 10.1158/0008-5472.CAN-06-4582
   Vincent ZL, 2011, FERTIL STERIL, V95, P1522, DOI 10.1016/j.fertnstert.2010.09.030
   Voso MT, 2004, BLOOD, V103, P698, DOI 10.1182/blood-2003-07-2249
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Yamagata Y, 2009, HUM REPROD, V24, P1126, DOI 10.1093/humrep/dep015
   Yang XJ, 2012, BIOCHEM BIOPH RES CO, V420, P570, DOI 10.1016/j.bbrc.2012.03.035
   Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13
   Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088
   Zhu DL, 2012, MED ONCOL, V29, P3207, DOI 10.1007/s12032-012-0239-3
NR 44
TC 17
Z9 19
U1 2
U2 25
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 12
PY 2016
VL 7
IS 15
BP 20966
EP 20980
DI 10.18632/oncotarget.8038
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL7ES
UT WOS:000375804000141
PM 26980709
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Wu, JJ
   Li, X
   Xu, YQ
   Yang, T
   Yang, QY
   Yang, CF
   Jiang, YG
AF Wu, Jianjun
   Li, Xun
   Xu, Yiqin
   Yang, Ti
   Yang, Qiaoyuan
   Yang, Chengfeng
   Jiang, Yiguo
TI Identification of a long non-coding RNA NR_026689 associated with lung
   carcinogenesis induced by NNK
SO ONCOTARGET
LA English
DT Article
DE lncRNA; NR_026689; lung carcinogenesis; NNK
ID PROSTATE-CANCER; GASTRIC-CANCER; BREAST-CANCER; IN-VIVO; EXPRESSION;
   BIOMARKERS; METASTASIS; CARCINOMA; SMOKE; TUMORIGENESIS
AB Long non-coding RNAs (lncRNA) are thought to be important epigenetic regulators involved in the development of a variety of cancers. Alterations in lncRNA expression are associated with exposure to chemical carcinogens. However, it is still unclear whether lncRNA expression during lung carcinogenesis is induced by chemical carcinogens. In this study, using NNK-induced rat lung cancer model established by our previous study, we determined the lncRNA expression profiles, and an alteration in lncRNA expression was observed in lung cancer tissues and blood in the NNK treatment group. Using quantitative reverse-transcription PCR (qRT-PCR), five differentially expressed lncRNAs were further detected and validated. We identified a novel lncRNA, NR_026689, which showed increased expression in lung cancer tissues induced by NNK and the alteration of lncRNA NR_026689 was specifically observed in lung tissue. The level of NR_026689 was determined and significantly increased in rat whole blood at the 10th and 20th week after NNK treatment to evaluate it as a potential early marker for lung cancer. Together, these findings suggest that lncRNA NR_026689 may be a potential early biomarker for lung cancer and is associated with lung carcinogenesis induced by NNK.
C1 [Wu, Jianjun; Li, Xun; Xu, Yiqin; Yang, Ti; Yang, Qiaoyuan; Jiang, Yiguo] Guangzhou Med Univ, Inst Chem Carcinogenesis, State Key Lab Resp Dis, Guangzhou 511436, Guangdong, Peoples R China.
   [Yang, Chengfeng] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [Yang, Chengfeng] Michigan State Univ, Ctr Integrat Toxicol, E Lansing, MI 48824 USA.
C3 State Key Laboratory of Respiratory Disease; Guangzhou Medical
   University; Michigan State University; Michigan State University
RP Jiang, YG (通讯作者)，Guangzhou Med Univ, Inst Chem Carcinogenesis, State Key Lab Resp Dis, Guangzhou 511436, Guangdong, Peoples R China.
EM jiangyiguo@vip.163.com
RI Yang, Yuanhe/D-1448-2011; FENG, YING/KWU-9364-2024
OI Yang, Chengfeng/0000-0002-2196-6854; Jiang, Yiguo/0000-0002-9499-2594
FU National Natural Science Foundation of China [81172633, 21277036,
   81473000]; Research Fund for the Doctoral Program of Higher Education of
   China [20114423110002]; Guangdong Natural Science Foundation
   [2014A030311017]; University Talent Program of Guangdong [2013-164];
   University Major Program of Guangdong [2014SZD48]
FX This work was supported by the National Natural Science Foundation of
   China (81172633 to J.Y., 21277036 to J.Y., 81473000 to W.J.), the
   Research Fund for the Doctoral Program of Higher Education of China
   (20114423110002 to J.Y.), the Guangdong Natural Science Foundation
   (2014A030311017 to J.Y.), the University Talent Program of Guangdong
   (2013-164 to J.Y.), the University Major Program of Guangdong
   (2014SZD48).
CR Akopyan G, 2006, INT J ONCOL, V29, P745
   [Anonymous], TUMOUR BIOL
   Bai WL, 2014, EXP MOL PATHOL, V96, P354, DOI 10.1016/j.yexmp.2014.02.016
   Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Crea F, 2014, ONCOTARGET, V5, P764, DOI 10.18632/oncotarget.1769
   Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192
   DeOcesano-Pereira C, 2014, NUCLEIC ACIDS RES, V42, P8343, DOI 10.1093/nar/gku561
   Dong L, 2015, INT J CANCER, V137, P1128, DOI 10.1002/ijc.29484
   Eissmann M, 2012, RNA BIOL, V9, P1076, DOI 10.4161/rna.21089
   Gao LY, 2013, TOXICOL LETT, V223, P205, DOI 10.1016/j.toxlet.2013.09.015
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021
   Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194
   Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686
   IARC (International Agency for Research on Cancer), 2007, IARC MON EV CARC RIS, V89, P457
   Koh W, 2014, P NATL ACAD SCI USA, V111, P7361, DOI 10.1073/pnas.1405528111
   Lempiäinen H, 2013, TOXICOL SCI, V131, P375, DOI 10.1093/toxsci/kfs303
   Li JG, 2014, GUT, V63, P1700, DOI 10.1136/gutjnl-2013-305806
   Lin XX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0042-4
   Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200
   Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014
   Parkinson DR, 2012, CLIN CANCER RES, V18, P619, DOI 10.1158/1078-0432.CCR-11-2017
   Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1
   Recio L, 2013, TOXICOL SCI, V135, P369, DOI 10.1093/toxsci/kft153
   Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292
   Rossi MN, 2014, INT J CELL BIOL, V2014, DOI DOI 10.1155/2014/473857
   Sax SN, 2013, LANCET ONCOL, V14, pE439, DOI 10.1016/S1470-2045(13)70438-8
   Shen XK, 2015, ONCOTARGET, V6, P21730, DOI 10.18632/oncotarget.4419
   Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silva JM, 2010, GENOMICS, V95, P355, DOI 10.1016/j.ygeno.2010.02.009
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621
   Tang JW, 2015, ONCOTARGET, V6, P4505, DOI 10.18632/oncotarget.2934
   Thai P, 2013, AM J RESP CELL MOL, V49, P204, DOI 10.1165/rcmb.2013-0159RC
   Tong YS, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-3
   Wen Jing, 2011, Chin J Cancer, V30, P551, DOI 10.5732/cjc.011.10059
   Wu JJ, 2013, TOXICOL APPL PHARM, V267, P238, DOI 10.1016/j.taap.2013.01.002
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013
   Yang QY, 2014, TOXICOL LETT, V229, P430, DOI 10.1016/j.toxlet.2014.07.004
NR 42
TC 16
Z9 17
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 22
PY 2016
VL 7
IS 12
BP 14486
EP 14498
DI 10.18632/oncotarget.7475
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5OT
UT WOS:000375687200091
PM 26908441
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chang, YC
   Lin, CW
   Yu, CC
   Wang, BY
   Huang, YH
   Hsieh, YC
   Kuo, YL
   Chang, WW
AF Chang, Yu-Chao
   Lin, Cheng-Wei
   Yu, Cheng-Chia
   Wang, Bing-Yen
   Huang, Yu-Hao
   Hsieh, Yang-Chih
   Kuo, Yu-Liang
   Chang, Wen-Wei
TI Resveratrol suppresses myofibroblast activity of human buccal mucosal
   fibroblasts through the epigenetic inhibition of ZEB1 expression
SO ONCOTARGET
LA English
DT Article
DE resveratrol; oral submucous fibrosis; ZEB1; EZH2; H3K27me3
ID ORAL SUBMUCOUS FIBROSIS; EPITHELIAL-MESENCHYMAL TRANSITION; TIME
   QUANTITATIVE PCR; GENE-EXPRESSION; RENAL FIBROSIS; BREAST-CANCER;
   PATHWAY; TRANSDIFFERENTIATION; VALIDATION; CARCINOMA
AB Oral submucous fibrosis (OSF) is a precancerous condition of the oral mucosa without specific therapeutic drugs. We previously demonstrated that the zinc finger E-box binding homeobox 1 (ZEB1) plays a pathogenic role in the induction of the myofibroblast activity of buccal mucosal fibroblasts (BMFs) and contributes to the pathogenesis of OSF. Resveratrol is a natural polyphenolic flavonoid with anti-fibrosis activity in various tissues and has the capability to inhibit ZEB1 in oral cancer cells. We examined the effect of resveratrol on the myofibroblast activity of human primary fibrotic BMFs (fBMFs) derived from OSF tissues. With the collagen contraction assay, resveratrol displayed anti-myofibroblast activity in three fBMF lines. Resveratrol also inhibited the expression of fibrogenic genes at the mRNA and protein levels in a doseand time-dependent manner. The downregulation of ZEB1 in fBMFs by resveratrol was mediated by epigenetic mechanisms, such as the upregulated expression of miR-200c and the enhancer of zeste homolog 2 (EZH2), as well as the trimethylated lysine 27 of histone H3 (H3K27me3). Resveratrol also increased the binding of H3K27me3 to the ZEB1 promoter. The knockdown of EZH2 in fBMFs caused the upregulation of ZEB1 and suppressed the inhibitory effect of resveratrol. Furthermore, the reversed expression pattern between EZH2 and ZEB1 was observed in 6/8 OSF tissues with twofold upregulation of ZEB1 expression compared with the adjacent normal mucosa. In conclusion, our data suggest that resveratrol epigenetically inhibits ZEB1 expression to suppress the myofibroblast activity of fBMFs and may serve as a dietary supplement for OSF patients.
C1 [Chang, Yu-Chao; Yu, Cheng-Chia] Chung Shan Med Univ, Sch Dent, Taichung, Taiwan.
   [Chang, Yu-Chao; Yu, Cheng-Chia] Chung Shan Med Univ Hosp, Dept Dent, Taichung 40201, Taiwan.
   [Lin, Cheng-Wei; Huang, Yu-Hao; Hsieh, Yang-Chih; Chang, Wen-Wei] Chung Shan Med Univ, Sch Biomed Sci, Coll Med Sci & Technol, Taichung, Taiwan.
   [Yu, Cheng-Chia] Chung Shan Med Univ, Inst Oral Sci, Taichung, Taiwan.
   [Wang, Bing-Yen] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
   [Wang, Bing-Yen] ChangHua Christian Hosp, Dept Surg, Div Throac Surg, Changhua, ChangHua County, Taiwan.
   [Wang, Bing-Yen] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Kuo, Yu-Liang] Chung Shan Med Univ, Sch Med Imaging & Radiol Sci, Taichung, Taiwan.
   [Kuo, Yu-Liang] Chung Shan Med Univ Hosp, Dept Med Imaging, Taichung 40201, Taiwan.
   [Chang, Wen-Wei] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 40201, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Chung Shan Medical University; Chung Shan
   Medical University; Chung Shan Medical University; Changhua Christian
   Hospital; National Yang Ming Chiao Tung University; Chung Shan Medical
   University; Chung Shan Medical University; Chung Shan Medical University
   Hospital; Chung Shan Medical University; Chung Shan Medical University
   Hospital
RP Chang, WW (通讯作者)，Chung Shan Med Univ, Sch Biomed Sci, Coll Med Sci & Technol, Taichung, Taiwan.; Chang, WW (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung 40201, Taiwan.
EM changww@csmu.edu.tw
RI Chang, Wen-Wei/C-1611-2013
OI Chang, Wen-Wei/0000-0003-2283-1377
FU Ministry of Science and Technology of Taiwan [NSC
   100-2632-B-040-001-MY3, MOST 103-2314-B-040-015-MY3]
FX This work was supported by the Ministry of Science and Technology of
   Taiwan (grant No. NSC 100-2632-B-040-001-MY3 and MOST
   103-2314-B-040-015-MY3).
CR Avon Sylvie Louise, 2004, J Can Dent Assoc, V70, P244
   Ayakannu T, 2015, MOL HUM REPROD, V21, P723, DOI 10.1093/molehr/gav033
   Bai YH, 2014, BIOCHEM PHARMACOL, V92, P484, DOI 10.1016/j.bcp.2014.09.002
   Bo S, 2013, CURR MED CHEM, V20, P1323, DOI 10.2174/0929867311320100009
   Borriello A, 2014, CANCER TREAT RES, V159, P167, DOI 10.1007/978-3-642-38007-5_10
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Carey MF, 2009, COLD SPRING HARBOR P, V2009
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chang YC, 2002, ORAL ONCOL, V38, P195, DOI 10.1016/S1368-8375(01)00045-8
   Chang YC, 2014, J CELL MOL MED, V18, P698, DOI 10.1111/jcmm.12219
   Conte E, 2015, HISTOL HISTOPATHOL, V30, P523, DOI 10.14670/HH-30.523
   Di Pascoli M, 2013, J HEPATOL, V58, P904, DOI 10.1016/j.jhep.2012.12.012
   Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004
   Gupta Soma, 2004, Indian J Clin Biochem, V19, P138, DOI 10.1007/BF02872409
   Haque MF, 1998, CYTOKINE, V10, P713, DOI 10.1006/cyto.1997.0342
   Haque MF, 2000, J ORAL PATHOL MED, V29, P123, DOI 10.1034/j.1600-0714.2000.290304.x
   Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hu FW, 2012, MOL NUTR FOOD RES, V56, P1247, DOI 10.1002/mnfr.201200150
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Krämer M, 2013, ANN RHEUM DIS, V72, P614, DOI 10.1136/annrheumdis-2012-201615
   Kuno A, 2015, ANN NY ACAD SCI
   Li C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101455
   Li JH, 2010, AM J PATHOL, V177, P1065, DOI 10.2353/ajpath.2010.090923
   Li L, 2014, FOOD CHEM TOXICOL, V63, P166, DOI 10.1016/j.fct.2013.08.036
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107
   Mohelnikova-Duchonova B, 2012, DIS MARKERS, V32, P203, DOI [10.1155/2012/582107, 10.3233/DMA-2011-0875]
   Novelle MG, 2015, AGEING RES REV, V21, P1, DOI 10.1016/j.arr.2015.01.002
   PINDBORG JJ, 1966, ORAL SURG ORAL MED O, V22, P764, DOI 10.1016/0030-4220(66)90367-7
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Singh CK, 2015, ANN N Y ACAD SCI
   St John SE, 2013, BIOORGAN MED CHEM, V21, P6022, DOI 10.1016/j.bmc.2013.07.037
   Tao K, 2015, INFLAMMATION, V38, P1273, DOI 10.1007/s10753-014-0097-6
   Tilakaratne WM, 2006, ORAL ONCOL, V42, P561, DOI 10.1016/j.oraloncology.2005.08.005
   VANWYK CW, 1990, J ORAL PATHOL MED, V19, P182
   Wang YY, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-99
   Wei J, 2015, ARTHRITIS RHEUMATOL, V67, P1323, DOI 10.1002/art.39061
   Xao YT, 2015, PEDIATR RES, V77, P310, DOI 10.1038/pr.2014.181
   Xiong MX, 2012, AM J PHYSIOL-RENAL, V302, pF369, DOI 10.1152/ajprenal.00268.2011
   Yang SF, 2007, ORAL DIS, V13, P234, DOI 10.1111/j.1601-0825.2006.01272.x
   Yang SJ, 2014, METABOLISM, V63, P693, DOI 10.1016/j.metabol.2014.02.003
   Yang ZH, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-31
   Yu CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055122
   Yu HP, 2008, SHOCK, V30, P324, DOI 10.1097/SHK.0b013e318164f013
   Zhou Y, 2016, MOL CELL BIOCHEM, V411, P143, DOI 10.1007/s11010-015-2576-y
NR 47
TC 26
Z9 29
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 15
PY 2016
VL 7
IS 11
BP 12137
EP 12149
DI 10.18632/oncotarget.7763
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5LW
UT WOS:000375679600031
PM 26934322
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ciechomska, M
   O'Reilly, S
   Przyborski, S
   Oakley, F
   Bogunia-Kubik, K
   van Laar, JM
AF Ciechomska, Marzena
   O'Reilly, Steven
   Przyborski, Stefan
   Oakley, Fiona
   Bogunia-Kubik, Katarzyna
   van Laar, Jacob M.
TI Histone Demethylation and Toll-like Receptor 8-Dependent Cross-Talk in
   Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic
   Sclerosis Via Fra-2
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID HEPATIC STELLATE CELLS; PULMONARY-HYPERTENSION; EXTRACELLULAR-MATRIX;
   TISSUE INHIBITOR; BREAST-CANCER; FIBROSIS; TRANSCRIPTION; SKIN;
   METALLOPROTEINASES-1; INTERLEUKIN-6
AB Objective. To investigate whether epigenetic changes can modulate monocytes to produce tissue inhibitor of metalloproteinases 1 (TIMP-1) via Fra-2 (an activator protein 1 [AP-1] family member), a novel downstream mediator that promotes fibrogenesis.
   Methods. AP-1 transcription factors and TIMP-1 expression were measured in monocytes from systemic sclerosis (SSc) patients and healthy controls. Involvement of Fra-2 in the regulation of TIMP-1 following treatment with Toll-like receptor 8 (TLR-8) agonist was investigated using a luciferase activity assay and chromatin immunoprecipita-tion (ChIP) analysis. Expression of TIMP-1 and Fra-2 was determined in response to TLR-8 treatment and to different histone modifications, including 3'-deazaneplanocin (DZNep) and apicidin. Fibroblasts from healthy controls were cocultured with DZNep plus TLR-8-treated healthy controlmonocytes.
   Results. Up-regulation of Fra-2 was detected in bleomycin-challenged mice and in skin biopsy samples from SSc patients. Enhanced expression of Fra-2 and TIMP-1 was correlated in SScmonocytes (P=0.021). The expression of Fra-1 was significantly reduced (P=0.037) in SSc monocytes. Inhibiting AP-1 activity reduced TIMP-1 production in TLR-8-stimulatedmonocytes from healthy controls and SSc patients. ChIP experiments revealed binding of Fra-2 to the TIMP-1 promoter. Stimulation with DZNep plus TLR-8 enhanced Fra-2 and TIMP-1 expression in healthy control monocytes, whereas TLR8 plus apicidin repressed Fra-2 and TIMP-1 expression. Finally, healthy control monocytes treated with DZNep plus TLR-8 induced strong production ofa-smoothmuscle actin in dermal fibroblasts, which was inhibited by TIMP-1-blocking antibody.
   Conclusion. These data demonstrate a novel role of histone demethylation induced by DZNep on Fra-2-mediated TIMP-1 production by monocytes in the presence of TLR-8 agonist. This consequently orchestrates the transdifferentiation of fibroblasts, a key event in the pathogenesis of SSc.
C1 [Ciechomska, Marzena; O'Reilly, Steven; Oakley, Fiona; van Laar, Jacob M.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Ciechomska, Marzena] Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Ciechomska, Marzena] Natl Inst Geriatr Rheumatol & Rehabil, Warsaw, Poland.
   [O'Reilly, Steven; Przyborski, Stefan] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
   [Bogunia-Kubik, Katarzyna] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Bogunia-Kubik, Katarzyna] Wroclaw Med Univ, Wroclaw, Poland.
   [van Laar, Jacob M.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
C3 Newcastle University - UK; Polish Academy of Sciences; Hirszfeld
   Institute of Immunology & Experimental Therapy of the Polish Academy of
   Sciences; National Institute of Geriatrics, Rheumatology &
   Rehabilitation; Durham University; Polish Academy of Sciences; Hirszfeld
   Institute of Immunology & Experimental Therapy of the Polish Academy of
   Sciences; Wroclaw Medical University; Utrecht University; Utrecht
   University Medical Center
RP Ciechomska, M (通讯作者)，Newcastle Univ, Musculoskeletal Res Grp, 4th Floor Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE4 2HH, Tyne & Wear, England.
EM m.m.ciechomska@gmail.com
RI O'Reilly, Steven/AAX-7038-2020
OI O'Reilly, Steven/0000-0001-7483-740X; Ciechomska,
   Marzena/0000-0002-0961-6130; Bogunia-Kubik,
   Katarzyna/0000-0001-9744-0376; Oakley, Fiona/0000-0001-8692-1836
FU NIHR Newcastle Biomedical Research Centre at Newcastle Hospitals
   Foundation Trust; JGW Patterson Foundation; European Union Structural
   Funds; Wroclaw Centre of Biotechnology (Leading National Research Centre
   [KNOW] program); Foundation for Polish Science (Homing Plus grant)
   [2013-8/4]; Eli Lilly; Pfizer; MSD; Roche; NIHR Newcastle Biomedical
   Research Centre at Newcastle University
FX Supported by the NIHR Newcastle Biomedical Research Centre based at
   Newcastle Hospitals Foundation Trust and Newcastle University, the JGW
   Patterson Foundation, the Foundation for Polish Science (Homing Plus
   grant/2013-8/4), and the European Union Structural Funds. Cost of
   publication was supported by the Wroclaw Centre of Biotechnology
   (Leading National Research Centre [KNOW] program for the years
   2014-2018).Dr. van Laar has received consulting fees, speaking fees,
   and/or honoraria from Eli Lilly, Pfizer, MSD, and Roche (less than
   $10,000 each).
CR Avouac J, 2012, ARTHRITIS RHEUM-US, V64, P1642, DOI 10.1002/art.33501
   Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333
   Beyer C, 2010, ARTHRITIS RHEUM-US, V62, P2831, DOI 10.1002/art.27647
   Binai N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033508
   Ciechomska M, 2014, GENES IMMUN, V15, P433, DOI 10.1038/gene.2014.44
   Ciechomska M, 2013, ANN RHEUM DIS, V72, P1382, DOI 10.1136/annrheumdis-2012-201958
   Gibbons MA, 2011, AM J RESP CRIT CARE, V184, P569, DOI 10.1164/rccm.201010-1719OC
   Girard N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098176
   Hemmatazad H, 2009, ARTHRITIS RHEUM-US, V60, P1519, DOI 10.1002/art.24494
   Higashi-Kuwata N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3066
   Huber LC, 2007, ARTHRITIS RHEUM, V56, P2755, DOI 10.1002/art.22759
   Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414
   Kireva T, 2011, HEPATOLOGY, V53, P1259, DOI 10.1002/hep.24175
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Krämer M, 2013, ANN RHEUM DIS, V72, P614, DOI 10.1136/annrheumdis-2012-201615
   LEROY EC, 1988, J RHEUMATOL, V15, P202
   Li M, 2011, J IMMUNOL, V187, P2711, DOI 10.4049/jimmunol.1100479
   Lovelock JD, 2005, AM J PHYSIOL-HEART C, V288, pH461, DOI 10.1152/ajpheart.00402.2004
   Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002
   Maurer B, 2012, ANN RHEUM DIS, V71, P1382, DOI 10.1136/annrheumdis-2011-200940
   NORMAND J, 1995, IN VITRO CELL DEV-AN, V31, P447
   O'Reilly S, 2012, CYTOKINE GROWTH F R, V23, P99, DOI 10.1016/j.cytogfr.2012.04.003
   Rajasekaran S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041611
   Reich N, 2010, ARTHRITIS RHEUM-US, V62, P280, DOI 10.1002/art.25056
   Ren Ying, 2012, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V28, P232
   Seki E, 2009, HEPATOLOGY, V50, P185, DOI 10.1002/hep.22952
   Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200
   Song T, 2015, ONCOTARGET, V6, P12061, DOI 10.18632/oncotarget.3616
   Strange G, 2009, INT J RHEUM DIS, V12, P192, DOI 10.1111/j.1756-185X.2009.01410.x
   Takada Y, 2011, ONCOGENE, V30, P3821, DOI 10.1038/onc.2011.101
   Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139
   Williams SM, 2014, J MOL CELL CARDIOL, V67, P112, DOI 10.1016/j.yjmcc.2013.12.013
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 33
TC 41
Z9 44
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUN
PY 2016
VL 68
IS 6
BP 1493
EP 1504
DI 10.1002/art.39602
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA DW2TB
UT WOS:000383493600023
PM 26814616
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pathania, R
   Ramachandran, S
   Mariappan, G
   Thakur, P
   Shi, HD
   Choi, JH
   Manicassamy, S
   Kolhe, R
   Prasad, PD
   Sharma, S
   Lokeshwar, BL
   Ganapathy, V
   Thangaraju, M
AF Pathania, Rajneesh
   Ramachandran, Sabarish
   Mariappan, Gurusamy
   Thakur, Priyanka
   Shi, Huidong
   Choi, Jeong-Hyeon
   Manicassamy, Santhakumar
   Kolhe, Ravindra
   Prasad, Puttur D.
   Sharma, Suash
   Lokeshwar, Bal L.
   Ganapathy, Vadivel
   Thangaraju, Muthusamy
TI Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer
   Stem-like Cells and Attenuates Mammary Tumor Growth
SO CANCER RESEARCH
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; DNA METHYLATION; HOMOLOGOUS
   RECOMBINATION; MICROTUBULE ATTACHMENT; TRASTUZUMAB HERCEPTIN;
   THERAPEUTIC TARGETS; GENE-EXPRESSION; KINETOCHORE; RESISTANCE
AB Recently, impressive technical advancements have been made in the isolation and validation of mammary stem cells and cancer stem cells (CSC), but the signaling pathways that regulate stem cell self-renewal are largely unknown. Furthermore, CSCs are believed to contribute to chemo- and radio-resistance. In this study, we used the MMTV-Neu-Tg mouse mammary tumor model to identify potential new strategies for eliminating CSCs. We found that both luminal progenitor and basal stem cells are susceptible to genetic and epigenetic modifications, which facilitate oncogenic transformation and tumorigenic potential. A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. RNA-seq analysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin modifiers blocks growth-promoting signaling molecules such as RAD51AP1 and SPC25, which play key roles in DNA damage repair and kinetochore assembly. Moreover, RAD51AP1 and SPC25 were significantly overexpressed in human breast tumor tissues and were associated with reduced overall patient survival. In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer. (C)2016 AACR.
C1 [Pathania, Rajneesh; Mariappan, Gurusamy; Thakur, Priyanka; Shi, Huidong; Prasad, Puttur D.; Thangaraju, Muthusamy] Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd,CN-1161, Augusta, GA 30912 USA.
   [Ramachandran, Sabarish] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.
   [Shi, Huidong; Choi, Jeong-Hyeon; Manicassamy, Santhakumar; Kolhe, Ravindra; Prasad, Puttur D.; Sharma, Suash; Lokeshwar, Bal L.; Thangaraju, Muthusamy] Augusta Univ, Med Coll Georgia, CRU Canc Ctr, Augusta, GA 30912 USA.
   [Choi, Jeong-Hyeon] Augusta Univ, Med Coll Georgia, Dept Biostat, Augusta, GA 30912 USA.
   [Manicassamy, Santhakumar] Augusta Univ, Med Coll Georgia, Immunotherapy Ctr, Augusta, GA 30912 USA.
   [Kolhe, Ravindra; Sharma, Suash] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.
   [Lokeshwar, Bal L.] Augusta Univ, Med Coll Georgia, Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA.
   [Lokeshwar, Bal L.] Augusta Univ, Med Coll Georgia, Dept Med & Surg, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; Texas Tech University
   System; Texas Tech University Health Science Center; University System
   of Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); University System of Georgia; Augusta University
RP Thangaraju, M (通讯作者)，Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd,CN-1161, Augusta, GA 30912 USA.
EM mthangaraju@gru.edu
RI Sharma, Atul/ISS-2723-2023; Ramachandran, Sabarish/K-8146-2016;
   Lokeshwar, Bal/O-3196-2019; MARIAPPAN, GURUSAMY/E-6361-2019; Pathania,
   Rajneesh/H-9985-2016
OI KOLHE, RAVINDRA/0000-0002-8283-2403; MARIAPPAN,
   GURUSAMY/0000-0002-0790-5545; Shi, Huidong/0000-0003-1137-3390;
   Pathania, Rajneesh/0000-0003-0099-3682
FU NIH [5R01CA131402, 5R01CA15677-07]; Department of Defense [BC074289];
   Augusta University; Department of Biotechnology (DBT), India
FX This work was supported by grants from the NIH 5R01CA131402 (M.
   Thangaraju) and 5R01CA15677-07 (B.L. Lokeshwar), Department of Defense
   (BC074289), and Augusta University Intramural Pilot Study grant,
   Start-up and Bridge funds. G. Mariappan is a fellow of Department of
   Biotechnology (DBT), India sponsored overseas fellowship program.
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Brower V, 2011, NATURE, V471, pS12, DOI 10.1038/471S12a
   Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029
   Curtis SJ, 2010, CELL STEM CELL, V7, P127, DOI 10.1016/j.stem.2010.05.021
   Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957
   DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852
   Dunlop MH, 2012, J BIOL CHEM, V287, P12343, DOI 10.1074/jbc.C112.352161
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Helleday T, 2010, CARCINOGENESIS, V31, P955, DOI 10.1093/carcin/bgq064
   Henson SE, 2006, MUTAT RES-FUND MOL M, V601, P113, DOI 10.1016/j.mrfmmm.2006.06.016
   Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]
   MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327
   Martin-Castillo B, 2013, CELL CYCLE, V12, P225, DOI 10.4161/cc.23274
   McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058
   MILLER FR, 1983, INVAS METAST, V3, P22
   Oliveras-Ferraros C, 2010, INT J ONCOL, V37, P669, DOI 10.3892/ijo_00000716
   Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Schoch C, 2005, GENE CHROMOSOME CANC, V43, P227, DOI 10.1002/gcc.20193
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Song Li-Jie, 2015, Asian Pac J Cancer Prev, V16, P3667
   Sun SC, 2010, CELL CYCLE, V9, P4552, DOI 10.4161/cc.9.22.13815
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Wiese C, 2007, MOL CELL, V28, P482, DOI 10.1016/j.molcel.2007.08.027
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yuen KWY, 2005, CURR OPIN CELL BIOL, V17, P576, DOI 10.1016/j.ceb.2005.09.012
   Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012
NR 47
TC 124
Z9 139
U1 3
U2 36
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2016
VL 76
IS 11
BP 3224
EP 3235
DI 10.1158/0008-5472.CAN-15-2249
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DO8UV
UT WOS:000378060900014
PM 27197203
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Caiado, F
   Silva-Santos, B
   Norell, H
AF Caiado, Francisco
   Silva-Santos, Bruno
   Norell, Hakan
TI Intra-tumour heterogeneity - going beyond genetics
SO FEBS JOURNAL
LA English
DT Article
DE cancer mutation; cancer stem cells; clonal evolution; leukaemia
   initiating cells; lineage tracing; next-generation sequencing;
   non-genetic variability; population dynamics; single-cell
   transcriptomics; sub-clone
ID ACUTE MYELOID-LEUKEMIA; B-16 MELANOMA VARIANTS; CLONAL EVOLUTION; DNA
   METHYLATION; IN-VITRO; BREAST-CANCER; RNA-SEQ; CELLS; EXPRESSION;
   MUTATIONS
AB Cancer patients die primarily due to disease recurrence after transient treatment responses. The emergence of therapy-resistant escape variants is fuelled by intra-tumour heterogeneity, underpinned by interference and Darwinian evolution among continuously developing sub-clones in the mutating tumour. Novel cancer cell variants build upon the pre-existing genetic landscape and tumour heterogeneity is often ascribed largely to genetic variability. While mutations are required for cancer development and studies of genetic evolution of tumours have improved our understanding of cancer biology, genetics only represents one dimension of the fitness of each cancer cell. Beyond the mutations, several non-genetic factors also add significant variability, resulting in a complex and highly dynamic tumour cell population that can drive disease under almost any condition. This viewpoint article summarizes the genetic basis of intra-tumour heterogeneity, before dissecting four major interdependent non-genetic factors we think critically contribute to the overall variability of tumour cells in all types of cancer: epigenetic regulation, cellular differentiation hierarchies, gene expression stochasticity and tumour microenvironment. We finally present the relevant technological approaches to address the combined contribution of both genetic and non-genetic factors to intra-tumour heterogeneity, focusing on genomic profiling, cellular lineage tracing and single-cell RNA sequencing technologies. This strategy will ultimately allow dissection of the full range and depth of intra-tumour heterogeneity. We thus believe that understanding how cancer genetics synergize with the emerging non-genetic factors will be key for development of therapies able to tackle tumour escape and thereby improve cancer patient survival.
C1 [Caiado, Francisco; Silva-Santos, Bruno; Norell, Hakan] Univ Lisbon, Fac Med, Inst Med Mol, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal.
C3 Universidade de Lisboa; Instituto Superior de Ciencias da Saude Egas
   Moniz
RP Silva-Santos, B; Norell, H (通讯作者)，Univ Lisbon, Fac Med, Inst Med Mol, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal.
EM bssantos@medicina.ulisboa.pt; hnorell@medicina.ulisboa.pt
RI Caiado, Francisco/LQJ-7413-2024
OI Caiado, Francisco/0000-0003-4096-4448; Norell,
   Haakan/0000-0001-5232-7660; Silva-Santos, Bruno/0000-0003-4141-9302
FU Associacao Portuguesa Contra a Leucemia (APCL-SEMAPA); Fundacao para a
   Ciencia e Tecnologia (FCT) [SFRH/BPD/91344/2012, SFRH/BCC/105888/2014,
   SFRH/BPD/112968/2015]; FCT [EXPL/BIM-ONC/1656/2013]; Fundação para a
   Ciência e a Tecnologia [SFRH/BPD/91344/2012, SFRH/BCC/105888/2014,
   SFRH/BPD/112968/2015, EXPL/BIM-ONC/1656/2013] Funding Source: FCT
FX Our work was funded by Associacao Portuguesa Contra a Leucemia
   (APCL-SEMAPA 2014 to HN) and Fundacao para a Ciencia e Tecnologia (FCT)
   through individual fellowships (SFRH/BPD/91344/2012 to FC;
   SFRH/BCC/105888/2014 and SFRH/BPD/112968/2015 to HN) and a FCT research
   grant (EXPL/BIM-ONC/1656/2013 to HN).
CR Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923
   Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650
   Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984
   Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446
   BARRANCO SC, 1972, CANCER RES, V32, P2733
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beerman I, 2015, CELL STEM CELL, V16, P613, DOI 10.1016/j.stem.2015.05.009
   Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841
   Blundell JR, 2014, GENOMICS, V104, P417, DOI 10.1016/j.ygeno.2014.09.005
   Bochtler T, 2013, J CLIN ONCOL, V31, P3898, DOI 10.1200/JCO.2013.50.7921
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Brocks D, 2014, CELL REP, V8, P798, DOI 10.1016/j.celrep.2014.06.053
   Brown TM, 2006, AM J PUBLIC HEALTH, V96, P2104, DOI 10.2105/AJPH.2005.078436
   Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460
   Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025
   Chibon F, 2013, EUR J CANCER, V49, P2000, DOI 10.1016/j.ejca.2013.02.021
   Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105
   Cohen AA, 2008, SCIENCE, V322, P1511, DOI 10.1126/science.1160165
   DANIELSON KG, 1980, CANCER RES, V40, P1812
   Desai MM, 2007, GENETICS, V176, P1759, DOI 10.1534/genetics.106.067678
   Desai MM, 2013, GENETICS, V193, P565, DOI 10.1534/genetics.112.147157
   DEXTER DL, 1978, CANCER RES, V38, P3174
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Ding L, 2013, CANCER LETT, V340, P212, DOI 10.1016/j.canlet.2012.12.028
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Flynn DFB, 2011, ECOLOGY, V92, P1573, DOI 10.1890/10-1245.1
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gerstung M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6901
   GRAY JM, 1964, JNCI-J NATL CANCER I, V32, P1201, DOI 10.1093/jnci/32.6.1201
   Greaves M, 2013, EVOL APPL, V6, P102, DOI 10.1111/eva.12017
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Grün D, 2015, CELL, V163, P799, DOI 10.1016/j.cell.2015.10.039
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Herron MD, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001490
   Hughes AEO, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004462
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Junker JP, 2015, MOL CELL, V58, P563, DOI 10.1016/j.molcel.2015.05.019
   Kleppe M, 2014, NAT MED, V20, P342, DOI 10.1038/nm.3522
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670
   Kvitek DJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003972
   Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395
   Landau DA, 2014, CANCER CELL, V26, P813, DOI 10.1016/j.ccell.2014.10.012
   Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019
   Lang GI, 2013, NATURE, V500, P571, DOI 10.1038/nature12344
   Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557
   Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485
   Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293
   Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088
   MAKINO S, 1953, JNCI-J NATL CANCER I, V13, P1213
   Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768
   Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556
   Mazor T, 2015, CANCER CELL, V28, P307, DOI 10.1016/j.ccell.2015.07.012
   MITELMAN F, 1972, SCIENCE, V176, P1340, DOI 10.1126/science.176.4041.1340
   Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917
   Munsky B, 2012, SCIENCE, V336, P183, DOI 10.1126/science.1216379
   Naik SH, 2014, EXP HEMATOL, V42, P598, DOI 10.1016/j.exphem.2014.05.003
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109
   Nguyen LV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6871
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Oakes CC, 2014, CANCER DISCOV, V4, P348, DOI 10.1158/2159-8290.CD-13-0349
   Paguirigan AL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0763
   Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257
   PERTSCHUK LP, 1978, CANCER-AM CANCER SOC, V41, P907, DOI 10.1002/1097-0142(197803)41:3<907::AID-CNCR2820410318>3.0.CO;2-V
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Polyak K, 2014, NAT MED, V20, P344, DOI 10.1038/nm.3518
   Porter SN, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r75
   POSTE G, 1980, CANCER RES, V40, P1636
   Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781
   RAZ A, 1980, CANCER RES, V40, P1645
   Schmitt MW, 2012, P NATL ACAD SCI USA, V109, P14508, DOI 10.1073/pnas.1208715109
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   SHAPIRO JR, 1981, CANCER RES, V41, P2349
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111
   Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110
   True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Van Loo P, 2014, CURR OPIN GENET DEV, V24, P82, DOI 10.1016/j.gde.2013.12.004
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wu AR, 2014, NAT METHODS, V11, P41, DOI 10.1038/nmeth.2694
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
NR 90
TC 60
Z9 72
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD JUN
PY 2016
VL 283
IS 12
BP 2245
EP 2258
DI 10.1111/febs.13705
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DT2NN
UT WOS:000381317100004
PM 26945550
OA Bronze
DA 2025-01-12
ER

PT J
AU Yari, K
   Payandeh, M
   Rahimi, Z
AF Yari, Kheirollah
   Payandeh, Mehrdad
   Rahimi, Zohreh
TI Association of the hypermethylation status of <i>PTEN</i> tumor
   suppressor gene with the risk of breast cancer among Kurdish population
   from Western Iran
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; PTEN; Methylation; Epigenetic; Methylation-specific PCR;
   Iranian population
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; SPORADIC BREAST
AB Breast cancer is the most common cancer with high morbidity and mortality among women worldwide. Aberrant hypermethylation in promoter regions of the tumor suppressor genes such as PTEN gene is a key event in the progression and development of breast cancer. The aim of the present study was to evaluate an association between PTEN gene methylation status with the risk of breast cancer in an Iranian population. We studied 255 individuals, including 103 patients with breast cancer, 102 first-degree female relatives of patients (mother, sister, or daughter of patients), and 50 healthy individuals as a control group. Genomic DNA was extracted from peripheral blood leukocytes, and the PTEN promoter methylation status was detected using methylation-specific PCR (MSP) method with specific methylated and unmethylated primers. In some samples, direct DNA sequencing was used to confirm the results obtained by the MSP method. The frequency of PTEN-methylated (MM) genotype was 6 % in the healthy control group, 23.3 % in relatives of patients, and 41.7 % in patients (chi (2) = 24.62, p < 0.001). There were significant differences in the frequency of PTEN-methylated genotype between healthy control compared to that in patients (chi (2) = 15.1, p < 0.001) and also compared to that in relatives of patients (chi (2) = 6.9, p = 0.009). In the presence of PTEN MM genotype, there was a 3.1-fold susceptibility to breast cancer compared to the UU genotype (p < 0.001). Also, in the presence of PTEN M allele, the risk of breast cancer was 2.71-fold compared to the presence of U allele (p < 0.001). Our findings indicated increased frequency of hypermethylation of PTEN promoter in the studied patients and their relatives that could be considered as one of the epigenetic factors affecting the risk of breast cancer in Iranians.
C1 [Yari, Kheirollah; Rahimi, Zohreh] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran.
   [Payandeh, Mehrdad] Kermanshah Univ Med Sci, Dept Hematol & Med Oncol, Kermanshah, Iran.
   [Rahimi, Zohreh] Kermanshah Univ Med Sci, Dept Clin Biochem, Kermanshah, Iran.
C3 Kermanshah University of Medical Sciences; Kermanshah University of
   Medical Sciences; Kermanshah University of Medical Sciences
RP Rahimi, Z (通讯作者)，Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran.; Rahimi, Z (通讯作者)，Kermanshah Univ Med Sci, Dept Clin Biochem, Kermanshah, Iran.
EM zrahimi@kums.ac.ir
RI Rahimi, Zohreh/M-9180-2017; Yari, Kheirollah/AAC-8969-2021; Yari,
   Khierollah/M-4283-2017; Payandeh, Mehrdad/N-1029-2017
OI Yari, Khierollah/0000-0002-8592-7651; Rahimi,
   Zohreh/0000-0001-7589-3307; Payandeh, Mehrdad/0000-0003-0074-7166
FU Kermanshah University of Medical Sciences, Office of the Vice Chancellor
   for Research, Kermanshah, Iran [92396]
FX This work was performed in partial fulfillment of the requirements for
   PhD by Research of Mr. Kheirolah Yari, Kermanshah University of Medical
   Sciences, Kermanshah, Iran and was financially supported by a grant
   (grant number 92396) from the Kermanshah University of Medical Sciences,
   Office of the Vice Chancellor for Research, Kermanshah, Iran.
CR Alipour M, 2013, IRAN J CANCER PREV, V6, P59
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gheibi A, 2012, Adv Biomed Res, V1, P80, DOI 10.4103/2277-9175.102990
   Hashemi M, 2013, MOL MED REP, V7, P342, DOI 10.3892/mmr.2012.1174
   Izadi P, 2014, MOL BIOL REP, V41, P7607, DOI 10.1007/s11033-014-3650-3
   Izadi P, 2012, CELL J, V14, P102
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Khakpour G, 2015, TUMOR BIOL, V36, P4905, DOI 10.1007/s13277-015-3567-z
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Licchesi JD, 2009, METHYLATION SPECIFIC, P305
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Mojaver Mahboobeh, 2015, Adv Biomed Res, V4, P136, DOI 10.4103/2277-9175.161532
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Pirouzpanah S, 2015, J MOL MED, V93, P917, DOI 10.1007/s00109-015-1268-0
   Pirouzpanah S, 2010, CANCER CAUSE CONTROL, V21, P2101, DOI 10.1007/s10552-010-9629-z
   Rahimi Z, 2014, ASIAN PAC J CANCER P, V16, P1175
   Rahimi Zohreh, 2015, Asian Pac J Cancer Prev, V16, P1175
   Sadeq V, 2011, MED ONCOL, V28, P420, DOI 10.1007/s12032-010-9473-8
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Sun Z, 2015, TUMOR BIOL, V36, P1
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Yari K, 2014, ASIAN PAC J CANCER P, V15, P6199, DOI 10.7314/APJCP.2014.15.15.6199
   Yin L, 2013, ANAL PTEN METHYLATIO
   Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331
NR 28
TC 26
Z9 26
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2016
VL 37
IS 6
BP 8145
EP 8152
DI 10.1007/s13277-015-4731-1
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM6LT
UT WOS:000376464700114
PM 26715274
DA 2025-01-12
ER

PT J
AU Rossi, EL
   de Angel, RE
   Bowers, LW
   Khatib, SA
   Smith, LA
   Van Buren, E
   Bhardwaj, P
   Giri, D
   Estecio, MR
   Troester, MA
   Hair, BY
   Kirk, EL
   Gong, T
   Shen, JJ
   Dannenberg, AJ
   Hursting, SD
AF Rossi, Emily L.
   de Angel, Rebecca E.
   Bowers, Laura W.
   Khatib, Subreen A.
   Smith, Laura A.
   Van Buren, Eric
   Bhardwaj, Priya
   Giri, Dilip
   Estecio, Marcos R.
   Troester, Melissa A.
   Hair, Brionna Y.
   Kirk, Erin L.
   Gong, Ting
   Shen, Jianjun
   Dannenberg, Andrew J.
   Hursting, Stephen D.
TI Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary
   Tumor Growth Persist in Formerly Obese Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID BODY-MASS INDEX; BREAST-CANCER; BARIATRIC SURGERY; DNA METHYLATION;
   CALORIE RESTRICTION; WEIGHT-LOSS; EXPRESSION; MORTALITY; EZH2;
   RESISTANCE
AB Using a murine model of basal-like breast cancer, we tested the hypothesis that chronic obesity, an established breast cancer risk and progression factor in women, induces mammary gland epigenetic reprogramming and increases mammary tumor growth. Moreover, we assessed whether the obesity-induced epigenetic and protumor effects are reversed by weight normalization. Ovariectomized female C57BL/6 mice were fed a control diet or diet-induced obesity (DIO) regimen for 17 weeks, resulting in a normal weight or obese phenotype, respectively. Mice on the DIO regimen were then randomized to continue the DIO diet or were switched to the control diet, resulting in formerly obese (FOb) mice with weights comparable with control mice. At week 24, all mice were orthotopically injected with MMTV-Wnt-1 mouse mammary tumor cells. Mean tumor volume, serum IL6 levels, expression of proinflammatory genes in the mammary fat pad, and mammary DNA methylation profiles were similar in DIO and FOb mice and higher than in controls. Many of the genes found to have obesity-associated hypermethylation in mice were also found to be hypermethylated in the normal breast tissue of obese versus nonobese human subjects, and nearly all of these concordant genes remained hypermethylated after significant weight loss in the FOb mice. Our findings suggest that weight normalization may not be sufficient to reverse the effects of chronic obesity on epigenetic reprogramming and inflammatory signals in the microenvironment that are associated with breast cancer progression. (C) 2016 AACR.
C1 [Rossi, Emily L.; Bowers, Laura W.; Khatib, Subreen A.; Smith, Laura A.; Hursting, Stephen D.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA.
   [de Angel, Rebecca E.; Hursting, Stephen D.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.
   [Van Buren, Eric] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Bhardwaj, Priya; Dannenberg, Andrew J.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
   [Giri, Dilip] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.
   [Estecio, Marcos R.; Gong, Ting; Shen, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA.
   [Troester, Melissa A.; Hair, Brionna Y.; Kirk, Erin L.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of Texas System; University of Texas Austin; University of
   North Carolina; University of North Carolina Chapel Hill; Cornell
   University; Weill Cornell Medicine; Memorial Sloan Kettering Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center;
   University of North Carolina; University of North Carolina Chapel Hill
RP Hursting, SD (通讯作者)，Univ N Carolina, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
EM hursting@email.unc.edu
RI Bhardwaj, Priya/CAJ-2736-2022
OI Estecio, Marcos/0000-0002-6874-7413; Rossi, Emily/0000-0002-2312-4239;
   Bhardwaj, Priya/0000-0001-8740-0143
FU Breast Cancer Research Foundation; MD Anderson Science Park NGS Core -
   CPRIT Core Facility Support Grant [RP120348]; NCI [R25CA057726];
   Outstanding Investigator Grant from the NCI [R35CA197627]
FX The animal study reported here was funded by a grant to S.D. Hursting
   from the Breast Cancer Research Foundation. The mouse methylation
   analysis was funded by a pilot grant from the MD Anderson Science Park
   NGS Core, supported by CPRIT Core Facility Support Grant RP120348.
   Fellowships to E.L. Rossi and L.W. Bowers were supported by a grant from
   the NCI (R25CA057726). S.D. Hursting is supported by an Outstanding
   Investigator Grant from the NCI (R35CA197627).
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barres R, 2013, CELL REP, V3, P1020, DOI 10.1016/j.celrep.2013.03.018
   Bhardwaj P, 2013, CANCER PREV RES, V6, P282, DOI 10.1158/1940-6207.CAPR-12-0467
   Borengasser SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084209
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Chen XL, 2010, BREAST CANCER RES TR, V122, P823, DOI 10.1007/s10549-009-0708-3
   Christou NV, 2008, SURG OBES RELAT DIS, V4, P691, DOI 10.1016/j.soard.2008.08.025
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   De Angel RE, 2013, CANCER BIOL THER, V14, P357, DOI 10.4161/cbt.23623
   De Angel RE, 2013, MOL CARCINOGEN, V52, P446, DOI 10.1002/mc.21878
   Fabian CJ, 2013, BREAST CANCER RES TR, V142, P119, DOI 10.1007/s10549-013-2730-8
   Furet JP, 2010, DIABETES, V59, P3049, DOI 10.2337/db10-0253
   Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Hair BY, 2015, BREAST CANCER RES TR, V151, P453, DOI 10.1007/s10549-015-3401-8
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Hursting SD, 2012, CANCER PREV RES, V5, P1260, DOI 10.1158/1940-6207.CAPR-12-0140
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lashinger LM, 2014, J NUTR, V144, P109, DOI 10.3945/jn.113.178533
   Milagro FI, 2011, FASEB J, V25, P1378, DOI 10.1096/fj.10-170365
   Nogueira LM, 2012, CANCER MED-US, V1, P275, DOI 10.1002/cam4.23
   Nogueira LM, 2012, ENDOCR-RELAT CANCER, V19, P57, DOI 10.1530/ERC-11-0213
   Núñez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195
   Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE
   Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059
   Sinicrope FA, 2011, J CLIN ONCOL, V29, P4, DOI 10.1200/JCO.2010.32.1752
   Sjöström L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
   Sundaram S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00175
   Svirshchevskaya EV, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-176
   Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37
   Whiteman MK, 2005, CANCER EPIDEM BIOMAR, V14, P2009, DOI 10.1158/1055-9965.EPI-05-0106
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 33
TC 42
Z9 51
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAY
PY 2016
VL 9
IS 5
BP 339
EP 348
DI 10.1158/1940-6207.CAPR-15-0348
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DL7VR
UT WOS:000375848700002
PM 26869351
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Shin, E
   Lee, Y
   Koo, JS
AF Shin, Eunah
   Lee, YuKyung
   Koo, Ja Seung
TI Differential expression of the epigenetic methylation-related protein
   DNMT1 by breast cancer molecular subtype and stromal histology
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Breast cancer; DNA methylation; DNMT1
ID DNA METHYLTRANSFERASE 1; CARCINOGENESIS; TARGET
AB Background: We assessed the expression of methylation-related proteins 5-meC, DNMT1, and ISL-1 in breast cancer and evaluated their relationship to clinicopathological factors.
   Methods: Immunohistochemical staining for ER, PR, HER-2, Ki-67, 5-meC, DNMT1, and ISL-1 were performed on 348 breast cancer samples in tissue microarray. Samples were subgrouped into luminal A, luminal B, HER-2, or triple-negative breast cancer (TNBC) according to immunohistochemical staining for ER, PR, HER-2, and Ki-67. The tumor stroma was histologically subtyped into desmoplastic, sclerotic, normal-like, or inflammatory type.
   Results: Tumor expression of DNMT1 differed by molecular subtype: it was higher in TNBC and lower in luminal A (p < 0.001) samples. DNMT1 expression was also related to higher histologic grade, ER negativity, PR negativity, and higher Ki-67 LI (p < 0.001). In western blot, protein expressions of DNMT1 and ISL-1 were higher in TNBC and relatively lower in the remaining subtypes. High tumor expression of DNMT1 was associated with shorter OS in univariate analysis (p = 0.041). DNMT1 and 5-meC were differentially expressed by stromal phenotype: 5-meC was higher in normal-like type and lower in sclerotic type (p = 0.049); DNMT1 was higher in inflammatory and lower in sclerotic type (p < 0.001).
   Conclusions: Tumor expression of DNMT1 in breast cancer differed by molecular subtype and stromal histological type. DNMT1 was highly expressed in TNBC and in breast cancer with inflammatory stromal type.
C1 [Shin, Eunah] CHA Univ, CHA Gangnam Med Ctr, Dept Pathol, Seoul, South Korea.
   [Lee, YuKyung; Koo, Ja Seung] Yonsei Univ, Coll Med, Dept Pathol, 50 Yonsei Ro, Seoul 120752, South Korea.
C3 Pochon Cha University; Yonsei University; Yonsei University Health
   System
RP Koo, JS (通讯作者)，Yonsei Univ, Coll Med, Dept Pathol, 50 Yonsei Ro, Seoul 120752, South Korea.
EM kjs1976@yuhs.ac
RI Kim, Sun Jung/AAM-7334-2020
OI Shin, Eunah/0000-0001-5961-3563; koo, ja seung/0000-0003-4546-4709
FU Grant from the National R&D Program for Cancer Control, Ministry of
   Health and Welfare, Republic of Korea [1420080]; Basic Science Research
   Program through the National Research Foundation of Korea (NRF) -
   Ministry of Science, ICT and Future Planning [2015R1A1A1A05001209]
FX This study was supported by a Grant from the National R&D Program for
   Cancer Control, Ministry of Health and Welfare, Republic of Korea
   (1420080). This research was supported by Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT and Future Planning (2015R1A1A1A05001209).
CR Amato RJ, 2012, CANCER INVEST, V30, P415, DOI 10.3109/07357907.2012.675381
   Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Hodge David R., 2007, Cancer Genomics & Proteomics, V4, P387
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kovacsovics-Bankowskil M, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0038-9
   Li M, 2014, CHINESE J CANCER RES, V26, P371, DOI 10.3978/j.issn.1000-9604.2014.08.03
   Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024
   Östman A, 2014, SEMIN CANCER BIOL, V25, P1, DOI 10.1016/j.semcancer.2014.02.004
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rodriguez-Canales J, 2007, J PATHOL, V211, P410, DOI 10.1002/path.2133
   Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Thottassery JV, 2014, CANCER CHEMOTH PHARM, V74, P291, DOI 10.1007/s00280-014-2503-z
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Wu CT, 2011, CANCER-AM CANCER SOC, V117, P5221, DOI 10.1002/cncr.26150
   Xu HY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-330
   Yu ZJ, 2015, MOL CARCINOGEN, V54, P707, DOI 10.1002/mc.22133
   Zhang JJ, 2012, CLIN TRANSL ONCOL, V14, P116, DOI 10.1007/s12094-012-0770-x
   Zhao HF, 2015, ONCOL LETT, V9, P2307, DOI 10.3892/ol.2015.3038
NR 24
TC 39
Z9 42
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD APR 12
PY 2016
VL 14
AR 87
DI 10.1186/s12967-016-0840-x
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DJ9EM
UT WOS:000374516800001
PM 27071379
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Stephen, HM
   Khoury, RJ
   Majmudar, PR
   Blaylock, T
   Hawkins, K
   Salama, MS
   Scott, MD
   Cosminsky, B
   Utreja, NK
   Britt, J
   Conway, RE
AF Stephen, H. M.
   Khoury, R. J.
   Majmudar, P. R.
   Blaylock, T.
   Hawkins, K.
   Salama, M. S.
   Scott, M. D.
   Cosminsky, B.
   Utreja, N. K.
   Britt, J.
   Conway, R. E.
TI Epigenetic suppression of neprilysin regulates breast cancer invasion
SO ONCOGENESIS
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ABERRANT DNA METHYLATION;
   ENDOTHELIN-B-RECEPTOR; CD10 EXPRESSION; COLORECTAL-CANCER; STROMAL CD10;
   CARCINOMA; PROMOTER; CELLS; GENE
AB In women, invasive breast cancer is the second most common cancer and the second cause of cancer-related death. Therefore, identifying novel regulators of breast cancer invasion could lead to additional biomarkers and therapeutic targets. Neprilysin, a cell-surface enzyme that cleaves and inactivates a number of substrates including endothelin-1 (ET1), has been implicated in breast cancer, but whether neprilysin promotes or inhibits breast cancer cell progression and metastasis is unclear. Here, we asked whether neprilysin expression predicts and functionally regulates breast cancer cell invasion. RT-PCR and flow cytometry analysis of MDA-MB-231 and MCF-7 breast cancer cell lines revealed decreased neprilysin expression compared with normal epithelial cells. Expression was also suppressed in invasive ductal carcinoma (IDC) compared with normal tissue. In addition, in vitro invasion assays demonstrated that neprilysin overexpression decreased breast cancer cell invasion, whereas neprilysin suppression augmented invasion. Furthermore, inhibiting neprilysin in MCF-7 breast cancer cells increased ET1 levels significantly, whereas overexpressing neprilysin decreased extracellular-signal related kinase (ERK) activation, indicating that neprilysin negatively regulates ET1-induced activation of mitogen-activated protein kinase (MAPK) signaling. To determine whether neprilysin was epigenetically suppressed in breast cancer, we performed bisulfite conversion analysis of breast cancer cells and clinical tumor samples. We found that the neprilysin promoter was hypermethylated in breast cancer; chemical reversal of methylation in MDA-MB-231 cells reactivated neprilysin expression and inhibited cancer cell invasion. Analysis of cancer databases revealed that neprilysin methylation significantly associates with survival in stage I IDC and estrogen receptor-negative breast cancer subtypes. These results demonstrate that neprilysin negatively regulates the ET axis in breast cancer, and epigenetic suppression of neprilysin in invasive breast cancer cells enables invasion. Together, this implicates neprilysin as an important regulator of breast cancer invasion and clarifies its utility as a potential biomarker for invasive breast cancer.
C1 [Stephen, H. M.; Khoury, R. J.; Majmudar, P. R.; Blaylock, T.; Hawkins, K.; Salama, M. S.; Scott, M. D.; Cosminsky, B.; Utreja, N. K.; Britt, J.; Conway, R. E.] Lipscomb Univ, Dept Biol, Coll Liberal Arts & Sci, 1 Univ Pk Dr, Nashville, TN USA.
C3 Lipscomb University
RP Conway, RE (通讯作者)，Lipscomb Univ, Dept Biol, Coll Liberal Arts & Sci, 1 Univ Pk Dr, Nashville, TN USA.
EM beth.conway@lipscomb.edu
OI Majmudar, Parth/0000-0002-8442-0859
FU Langford-Yates Research Fellowship; Gallaher Research Endowment;
   Lipscomb University College of Liberal Arts and Sciences and Department
   of Biology; National Cancer Institute
FX We wish to acknowledge the Lipscomb University College of Liberal Arts
   and Sciences and Department of Biology, along with the Langford-Yates
   Research Fellowship and the Gallaher Research Endowment for financially
   supporting this research. We also thank the Lipscomb University College
   of Pharmacy Bioanalytical Core Lab, along with Ms Amber Bradley, for
   training and assisting the authors' use of flow cytometry in this study.
   We are grateful to Amanda D Williams for her technical assistance to and
   general support of all authors in the laboratory. We thank Christina
   Brannan and the Vanderbilt University Medical Center Shared Pathology
   Resource Lab for their technical assistance on western blots and
   immunohistochemistry, respectively. We also acknowledge the Cooperative
   Human Tissue Network, which is funded by the National Cancer Institute,
   for providing the tumor samples.
CR Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Conway RE, 2013, ANGIOGENESIS, V16, P847, DOI 10.1007/s10456-013-9360-y
   Esteban F, 2006, CANCER METAST REV, V25, P137, DOI 10.1007/s10555-006-8161-9
   Fujita S, 2010, INT J COLORECTAL DIS, V25, P681, DOI 10.1007/s00384-010-0913-x
   Fukusumi T, 2014, BRIT J CANCER, V111, P506, DOI 10.1038/bjc.2014.289
   GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035
   Garcia-Manero G, 2003, CANCER, V97, P695, DOI 10.1002/cncr.11090
   Goodman OB, 2006, J BIOL CHEM, V281, P33597, DOI 10.1074/jbc.M602490200
   GREAVES M F, 1975, British Journal of Cancer, V32, P280, DOI 10.1038/bjc.1975.218
   Grimshaw MJ, 2004, CANCER RES, V64, P2461, DOI 10.1158/0008-5472.CAN-03-1069
   Ha NH, 2011, CANCER RES, V71, P7259, DOI 10.1158/0008-5472.CAN-11-1143
   Hagemann T, 2005, DNA CELL BIOL, V24, P766, DOI 10.1089/dna.2005.24.766
   Horiguchi A, 2008, PROSTATE CANCER P D, V11, P79, DOI 10.1038/sj.pcan.4500984
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Ikawa Y, 2010, J PEDIAT HEMATOL ONC, V32, P4, DOI 10.1097/MPH.0b013e3181c29c3c
   Ikenaga N, 2010, GASTROENTEROLOGY, V139, P1041, DOI 10.1053/j.gastro.2010.05.084
   Iwaya K, 2002, VIRCHOWS ARCH, V440, P589, DOI 10.1007/s00428-002-0639-4
   Jang TJ, 2013, KOREAN J PATHOL, V47, P340, DOI 10.4132/KoreanJPathol.2013.47.4.340
   JOHNSON AR, 1984, PEPTIDES, V5, P789, DOI 10.1016/0196-9781(84)90023-8
   Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258
   Kajiyama H, 2005, CLIN CANCER RES, V11, P1798, DOI 10.1158/1078-0432.CCR-04-2395
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Kuniyasu H, 2010, GUT, V59, P348, DOI 10.1136/gut.2009.178376
   LEBIEN TW, 1989, BLOOD, V73, P625
   Leithner K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-40
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Makretsov NA, 2007, MODERN PATHOL, V20, P84, DOI 10.1038/modpathol.3800713
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   Omran OM, 2012, J ENVIRON PATHOL TOX, V31, P203, DOI 10.1615/JEnvironPatholToxicolOncol.v31.i3.20
   Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050
   Premkumar VG, 2008, BRIT J NUTR, V100, P1179, DOI 10.1017/S0007114508968276
   Puri V, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/437957
   Rosanò L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546
   San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200
   Sasaki T, 2014, J SURG RES, V192, P390, DOI 10.1016/j.jss.2014.05.071
   Seiler R, 2012, HUM PATHOL, V43, P269, DOI 10.1016/j.humpath.2011.04.030
   SHIPP MA, 1991, BLOOD, V78, P1834
   Smollich M, 2008, BREAST CANCER RES TR, V108, P175, DOI 10.1007/s10549-007-9589-5
   Smollich M, 2007, BREAST CANCER RES TR, V106, P361, DOI 10.1007/s10549-007-9516-9
   Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536
   Taghizadeh-Kermani A, 2014, IRAN J CANCER PREV, V7, P17
   Tamkus D, 2013, ISRN ONCOL, V2013
   Taylor KH, 2006, LEUKEMIA, V20, P1910, DOI 10.1038/sj.leu.2404353
   Vo TND, 2015, BREAST CANCER-TOKYO, V22, P117, DOI 10.1007/s12282-013-0459-1
   Toussaint J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012100
   Usmani BA, 2000, CLIN CANCER RES, V6, P1664
   VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150
   Witkiewicz AK, 2010, CANCER BIOL THER, V10, P391, DOI 10.4161/cbt.10.4.12449
   Wülfing P, 2004, ONCOL REP, V11, P791
   Wülfing P, 2003, CLIN CANCER RES, V9, P4125
   Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239
   Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.654926
NR 53
TC 16
Z9 17
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD MAR
PY 2016
VL 5
AR e207
DI 10.1038/oncsis.2016.16
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DJ8OB
UT WOS:000374470500002
PM 26950599
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Soriano, A
   París-Coderch, L
   Jubierre, L
   Martínez, A
   Zhou, XY
   Piskareva, O
   Bray, I
   Vidal, I
   Almazán-Moga, A
   Molist, C
   Roma, J
   Bayascas, JR
   Casanovas, O
   Stallings, RL
   de Toledo, JS
   Gallego, S
   Segura, MF
AF Soriano, Aroa
   Paris-Coderch, Laia
   Jubierre, Luz
   Martinez, Alba
   Zhou, Xiangyu
   Piskareva, Olga
   Bray, Isabella
   Vidal, Isaac
   Almazan-Moga, Ana
   Molist, Carla
   Roma, Josep
   Bayascas, Jose R.
   Casanovas, Oriol
   Stallings, Raymond L.
   Sanchez de Toledo, Jose
   Gallego, Soledad
   Segura, Miguel F.
TI MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by
   targeting cell cycle, survival and vascular permeability genes
SO ONCOTARGET
LA English
DT Article
DE microRNA; neuroblastoma; epigenetic therapy; vascular permeability
ID HIGH-RISK NEUROBLASTOMA; CHEMOTHERAPY-INDUCED APOPTOSIS; CHECKPOINT
   KINASE 1; BREAST-CANCER; MULTIDRUG-RESISTANCE; TUMOR-SUPPRESSOR;
   DRUG-RESISTANCE; P53 FUNCTION; EXPRESSION; MIR-497
AB Despite multimodal therapies, a high percentage of high-risk neuroblastoma (NB) become refractory to current treatments, most of which interfere with cell cycle and DNA synthesis or function, activating the DNA damage response (DDR). In cancer, this process is frequently altered by deregulated expression or function of several genes which contribute to multidrug resistance (MDR). MicroRNAs are outstanding candidates for therapy since a single microRNA can modulate the expression of multiple genes of the same or different pathways, thus hindering the development of resistance mechanisms by the tumor. We found several genes implicated in the MDR to be overexpressed in high-risk NB which could be targeted by microRNAs simultaneously. Our functional screening identified several of those microRNAs that reduced proliferation of chemoresistant NB cell lines, the best of which was miR-497. Low expression of miR-497 correlated with poor patient outcome. The overexpression of miR-497 reduced the proliferation of multiple chemoresistant NB cell lines and induced apoptosis in MYCN-amplified cell lines. Moreover, the conditional expression of miR-497 in NB xenografts reduced tumor growth and inhibited vascular permeabilization. MiR-497 targets multiple genes related to the DDR, cell cycle, survival and angiogenesis, which renders this molecule a promising candidate for NB therapy.
C1 [Soriano, Aroa; Paris-Coderch, Laia; Jubierre, Luz; Vidal, Isaac; Almazan-Moga, Ana; Molist, Carla; Roma, Josep; Sanchez de Toledo, Jose; Gallego, Soledad; Segura, Miguel F.] Vall dHebron Res Inst VHIR UAB, Lab Translat Res Child & Adolescent Canc, Barcelona, Spain.
   [Martinez, Alba; Casanovas, Oriol] Catalan Inst Oncol IDIBELL, Tumor Angiogenesis Grp, Barcelona, Spain.
   [Zhou, Xiangyu; Bayascas, Jose R.] Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain.
   [Zhou, Xiangyu; Bayascas, Jose R.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain.
   [Piskareva, Olga; Bray, Isabella; Stallings, Raymond L.] Royal Coll Surgeons Ireland, Mol & Cellular Therapeut, Dublin 2, Ireland.
   [Piskareva, Olga; Bray, Isabella; Stallings, Raymond L.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Institut Catala d'Oncologia;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Autonomous
   University of Barcelona; Autonomous University of Barcelona; Royal
   College of Surgeons - Ireland; National Children's Research Centre
   (NCRC); Trinity College Dublin; Our Ladys Children Hospital Crumlin
RP Soriano, A; Segura, MF (通讯作者)，Vall dHebron Res Inst VHIR UAB, Lab Translat Res Child & Adolescent Canc, Barcelona, Spain.
EM aroa.soriano@vhir.org; miguel.segura@vhir.org
RI Bray, Isabella/D-6179-2012; Gallego, Soledad/ABI-1334-2020; Segura,
   Miguel/J-4749-2013; Stallings, Raymond/A-7213-2008; Soriano,
   Aroa/J-9105-2016; Casanovas, Oriol/L-5210-2014; Bayascas, Jose
   R/C-9450-2011; Gallego, Soledad/KFB-5062-2024
OI Vidal, Isaac/0000-0002-8904-5955; Soriano, Aroa/0000-0001-9659-1471;
   Casanovas, Oriol/0000-0002-4298-3995; Segura, Miguel
   F./0000-0003-0916-3618; Bayascas, Jose R/0000-0002-6096-2151; Roma,
   Josep/0000-0001-7692-6123; Paris Coderch, Laia/0000-0003-2145-5752;
   Gallego, Soledad/0000-0002-4712-9624; Piskareva,
   Olga/0000-0003-4466-0441; Jubierre Zapater, Luz/0000-0001-9934-1590
FU Instituto de Salud Carlos III [CP11/00052, PI14/00561, RD12/0036/0016,
   PI14/00647]; European Regional Development Fund (ERDF); Asociacion
   Espanola Contra el Cancer-Junta de Barcelona; European Commission;
   Children's Medical and Research Foundation
FX This work was supported by Instituto de Salud Carlos III (CP11/00052,
   PI14/00561, RD12/0036/0016 and PI14/00647) co-financed by the European
   Regional Development Fund (ERDF), Asociacion Espanola Contra el
   Cancer-Junta de Barcelona and European Commission's Framework Programme
   7 through the Marie Curie Career Integration Grants. RLS was a recipient
   of a grant from the Children's Medical and Research Foundation.
CR Ackermann S, 2011, CLIN CANCER RES, V17, P731, DOI 10.1158/1078-0432.CCR-10-1129
   Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825
   Althoff K, 2013, INT J CANCER, V133, P1064, DOI 10.1002/ijc.28091
   Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200
   Azzi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00211
   Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850
   Carr J, 2006, CANCER RES, V66, P2138
   CASTLE VP, 1993, AM J PATHOL, V143, P1543
   Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108
   Creevey L, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-23
   Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311
   Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278
   DOLE MG, 1995, CANCER RES, V55, P2576
   Eggert A, 2000, CLIN CANCER RES, V6, P1900
   Flavin RJ, 2009, MODERN PATHOL, V22, P197, DOI 10.1038/modpathol.2008.135
   Furuta M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060155
   Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048
   GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128
   GOTTESMAN MM, 1993, CANCER RES, V53, P747
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214
   Ho R, 2002, CANCER RES, V62, P6462
   Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315
   Irwin MS, 2015, PEDIATR CLIN N AM, V62, P225, DOI 10.1016/j.pcl.2014.09.015
   Itesako T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084311
   Jaboin J, 2002, CANCER RES, V62, P6756
   Janas MM, 2012, EMBO J, V31, P2446, DOI 10.1038/emboj.2012.119
   Keshelava N, 2001, CANCER RES, V61, P6185
   Keshelava N, 1998, CANCER RES, V58, P5396
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020
   LASORELLA A, 1995, CANCER RES, V55, P4711
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Li WD, 2014, BIOCHEM BIOPH RES CO, V449, P235, DOI 10.1016/j.bbrc.2014.05.011
   Liby TA, 2012, INT J CANCER, V130, P532, DOI 10.1002/ijc.26010
   Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo M, 2013, SURGERY, V153, P836, DOI 10.1016/j.surg.2012.12.004
   Luo QF, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-95
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577
   Marshall GM, 2014, NAT REV CANCER, V14, P277, DOI 10.1038/nrc3679
   Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601
   Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429
   Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405
   Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201
   Özata DM, 2011, ENDOCR-RELAT CANCER, V18, P643, DOI 10.1530/ERC-11-0082
   Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470-2045(08)70069-X
   Qiu YY, 2014, TUMOR BIOL, V35, P2599, DOI 10.1007/s13277-013-1342-6
   Russell MR, 2013, CANCER RES, V73, P776, DOI 10.1158/0008-5472.CAN-12-2669
   Scala S, 1996, CANCER RES, V56, P3737
   Segerström L, 2006, PEDIATR RES, V60, P576, DOI 10.1203/01.pdr.0000242494.94000.52
   Shen L, 2012, EXP THER MED, V3, P475, DOI 10.3892/etm.2011.428
   Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399
   Stallings RL, 2010, EXPERT OPIN THER TAR, V14, P951, DOI 10.1517/14728222.2010.510136
   Toker Alex, 2014, Advances in Biological Regulation, V55, P28, DOI 10.1016/j.jbior.2014.04.001
   Troppan K, 2015, INT J MOL SCI, V16, P18077, DOI 10.3390/ijms160818077
   Turner KM, 2015, P NATL ACAD SCI USA, V112, P3421, DOI 10.1073/pnas.1414573112
   Tweddle DA, 2001, CANCER RES, V61, P8
   Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094
   Wang L, 2013, ASIAN PAC J CANCER P, V14, P3499, DOI 10.7314/APJCP.2013.14.6.3499
   Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618
   Wang SH, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-172
   Wang W, 2014, BIOCHEM BIOPH RES CO, V449, P432, DOI 10.1016/j.bbrc.2014.05.053
   Xie Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0844-4
   Xu H, 2011, INT J CANCER, V129, P1953, DOI 10.1002/ijc.25842
   Xu JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092847
   Xu SH, 2015, ONCOTARGET, V6, P26457, DOI 10.18632/oncotarget.4762
   Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345
   Yadav S, 2011, J BIOL CHEM, V286, P37347, DOI 10.1074/jbc.M111.235531
   Yang CH, 2013, INT J CANCER, V132, P116, DOI 10.1002/ijc.27657
   Zage PE, 2008, PEDIATR BLOOD CANCER, V51, P747, DOI 10.1002/pbc.21713
   Zhao WY, 2013, BIOCHEM BIOPH RES CO, V435, P466, DOI 10.1016/j.bbrc.2013.05.010
   Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998
NR 80
TC 27
Z9 32
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 23
PY 2016
VL 7
IS 8
BP 9271
EP 9287
DI 10.18632/oncotarget.7005
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL4OW
UT WOS:000375618100062
PM 26824183
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Nishioka, C
   Ikezoe, T
   Yang, J
   Yokoyama, A
AF Nishioka, Chie
   Ikezoe, Takayuki
   Yang, Jing
   Yokoyama, Akihito
TI BCR/ABL increases EZH2 levels which regulates XIAP expression via
   miRNA-219 in chronic myeloid leukemia cells
SO LEUKEMIA RESEARCH
LA English
DT Article
DE EZH2; BCR/ABL; XIAP; miR-219
ID TUMOR-SUPPRESSOR MICRORNAS; DOWN-REGULATION; BREAST-CANCER; APOPTOSIS;
   ACTIVATION; GROWTH; DIFFERENTIATION; PROTEINS; GENE; TRANSFORMATION
AB In this study, we showed that the levels of EZH2 in bone marrow mononuclear cells (BMMNCs) isolated from individuals with chronic myeloid leukemia (CML) (n = 12) were significantly greater than those in BMMNCs isolated from healthy volunteers (n = 6) as well as individuals with Philadelphia chromosome-negative myeloproliferative neoplasms. Lentiviral transduction of the BCR/ABL gene in Ba/F3 cells increased EZH2 levels in parallel with phosphorylation of STAT5. Notably, chromatin immunoprecipitation assays showed that STAT5A bound to a promoter region of the EZH2 gene, resulting in an increase in the transcriptional activity of EZH2 in leukemia cells. Importantly, downregulation of EZH2 by short hairpin RNAs (shRNAs) inhibited the expression of XIAP and increased the miR-219 levels associated with a decrease in hypermethylation of miR-219-1 CpG islands. Moreover, overexpression of miR-219 decreased the levels of XIAP in CML cells. Since the 3'-untranslated region (3'-UTR) of XIAP contains miR219-5p-complementary binding site, miR-219 might modulate the expression of XIAP through binding of miR-219 on the 3'-UTR of XIAP.
   Taken together, BCR/ABL positively regulates the expression of EZH2 via STAT5 signaling. EZH2 modulates epigenetic changes at DNA methylated regions encoding miR-219 and downregulates the level of miR-219, resulting in upregulation of XIAP. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Nishioka, Chie; Ikezoe, Takayuki; Yang, Jing; Yokoyama, Akihito] Kochi Univ, Kochi Med Sch, Dept Hematol & Resp Med, Nankoku, Kochi 7838505, Japan.
C3 Kochi University
RP Ikezoe, T (通讯作者)，Kochi Univ, Dept Hematol & Resp Med, Oko Cho, Nankoku, Kochi 7838505, Japan.
EM ikezoet@kochi-u.ac.jp
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen DL, 2015, ONCOTARGET, V6, P10868, DOI 10.18632/oncotarget.3451
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479
   Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fava C, 2015, EXPERT OPIN EMERG DR, V20, P183, DOI 10.1517/14728214.2015.1031217
   Ferraro A, 2013, INT J BIOCHEM CELL B, V45, P243, DOI 10.1016/j.biocel.2012.10.009
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908
   Hibino S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.17
   Hochhaus A, 2015, ANN HEMATOL, V94, pS133, DOI 10.1007/s00277-015-2323-1
   Hua WF, 2010, EUR J PHARMACOL, V637, P16, DOI 10.1016/j.ejphar.2010.03.051
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Konuma T, 2010, DEV GROWTH DIFFER, V52, P505, DOI 10.1111/j.1440-169X.2010.01191.x
   KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lee J, 2012, J CANCER RES CLIN, V138, P2095, DOI 10.1007/s00432-012-1292-1
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lima RT, 2006, J CHEMOTHERAPY, V18, P98, DOI 10.1179/joc.2006.18.1.98
   Liu J, 2013, CELL PHYSIOL BIOCHEM, V32, P1213, DOI 10.1159/000354520
   Liu S, 2013, FEBS LETT, V587, P2247, DOI 10.1016/j.febslet.2013.05.054
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390
   Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   MIYAGI T, 1993, INT J CANCER, V53, P457, DOI 10.1002/ijc.2910530318
   Momeny M, 2010, MED ONCOL, V27, P833, DOI 10.1007/s12032-009-9294-9
   Moore MAS, 2007, EXP HEMATOL, V35, P105, DOI 10.1016/j.exphem.2007.01.018
   Nishioka C, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.33
   Nishioka C, 2014, CANCER SCI, V105, P297, DOI 10.1111/cas.12339
   O'Shea JJ, 2011, NAT REV IMMUNOL, V11, P239, DOI 10.1038/nri2958
   Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968
   Schepers H, 2007, BLOOD, V110, P2880, DOI 10.1182/blood-2006-08-039073
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726
   Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151
   Tam WF, 2013, CANCER RES, V73, P373, DOI 10.1158/0008-5472.CAN-12-0255
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Volpe G, 2009, CANCER LETT, V274, P1, DOI 10.1016/j.canlet.2008.06.003
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhang RJ, 2012, ONCOL REP, V28, P2278, DOI 10.3892/or.2012.2033
NR 48
TC 20
Z9 21
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD JUN
PY 2016
VL 45
BP 24
EP 32
DI 10.1016/j.leukres.2016.03.012
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA DJ6RM
UT WOS:000374340600004
PM 27070757
DA 2025-01-12
ER

PT J
AU Mullins, CS
   Hühns, M
   Krohn, M
   Peters, S
   Cheynet, V
   Oriol, G
   Guillotte, M
   Ducrot, S
   Mallet, F
   Linnebacher, M
AF Mullins, Christina S.
   Huehns, Maja
   Krohn, Mathias
   Peters, Sven
   Cheynet, Valerie
   Oriol, Guy
   Guillotte, Michele
   Ducrot, Sandrine
   Mallet, Francois
   Linnebacher, Michael
TI Generation, Characterization and Application of Antibodies Directed
   against HERV-H Gag Protein in Colorectal Samples
SO PLOS ONE
LA English
DT Article
ID HUMAN-ENDOGENOUS-RETROVIRUS; BREAST-CANCER; EXPRESSION; CELLS;
   INFECTION; SEQUENCE; ELEMENTS; IDENTIFICATION; LYMPHOMA; FAMILY
AB Introduction
   A substantial part of the human genome originates from transposable elements, remnants of ancient retroviral infections. Roughly 8% of the human genome consists of about 400,000 LTR elements including human endogenous retrovirus (HERV) sequences. Mainly, the interplay between epigenetic and post-transcriptional mechanisms is thought to silence HERV expression in most physiological contexts. Interestingly, aberrant reactivation of several HERV-H loci appears specific to colorectal carcinoma (CRC).
   Results
   The expression of HERV-H Gag proteins (Gag-H) was assessed using novel monoclonal mouse anti Gag-H antibodies. In a flow cytometry screen four antibody clones were tested on a panel of primary CRC cell lines and the most well performing ones were subsequently validated in western blot analysis. Finally, Gag-H protein expression was analyzed by immune histology on cell line cytospins and on clinical samples. There, we found a heterogeneous staining pattern with no background staining of endothelial, stromal and infiltrating immune cells but diffuse staining of the cytoplasm for positive tumor and normal crypt cells of the colonic epithelium.
   Conclusion
   Taken together, the Gag-H antibody clone(s) present a valuable tool for staining of cells with colonic origin and thus form the basis for future more detailed investigations. The observed Gag-H protein staining in colonic epithelium crypt cells demands profound analyses of a potential role for Gag-H in the normal physiology of the human gut.
C1 [Mullins, Christina S.; Krohn, Mathias; Peters, Sven; Linnebacher, Michael] Univ Med Rostock, Dept Gen Surg Mol Oncol & Immunotherapy, Schillingallee 69, D-18057 Rostock, Germany.
   [Huehns, Maja] Univ Med Rostock, Inst Pathol, Strempelstr 14, D-18055 Rostock, Germany.
   [Cheynet, Valerie; Oriol, Guy; Mallet, Francois] Ctr Hosp Lyon Sud, Canc Biomarkers Res Grp, Joint Unit Hosp Civils Lyon, Batiment 3F, F-69495 Lyon, France.
   [Guillotte, Michele] BioMerieux, Global R&D Immunoassay, Marcy Letoile, France.
   [Ducrot, Sandrine] BioMerieux, Raw Mat Dept, R&D Immunoassay, Marcy Letoile, France.
   [Mallet, Francois] Univ Lyon 1, EA Pathophysiol Injury Induced Immunosuppress, Hosp Civils Lyon, BioMerieux,Hop Edouard Herriot, 5 Pl Arsonval, F-69437 Lyon 3, France.
C3 University of Rostock; University of Rostock; bioMerieux; CHU Lyon;
   bioMerieux; bioMerieux; Universite Claude Bernard Lyon 1; bioMerieux;
   CHU Lyon
RP Linnebacher, M (通讯作者)，Univ Med Rostock, Dept Gen Surg Mol Oncol & Immunotherapy, Schillingallee 69, D-18057 Rostock, Germany.
EM michael.linnebacher@med.uni-rostock.de
RI Mullins, Christina/ABG-4821-2021; Mallet, Francois/G-4812-2014;
   Linnebacher, Michael/AAT-3763-2021
OI Linnebacher, Christina/0000-0003-2296-2027; ORIOL,
   guy/0009-0009-4309-1217; MALLET, Francois/0000-0002-1331-096X
FU Deutsche Krebshilfe; bioMerieux SA; German Cancer Aid (DKH e.V.)
   [110943]; Academy of Finland (AKA) [110943] Funding Source: Academy of
   Finland (AKA)
FX Deutsche Krebshilfe, http://www.krebshilfe.de, funded CSM with a PostDoc
   scholarship. This work was supported by bioMerieux SA in the form of
   salaries for authors [VC, GO, MG, SD and FM]. CSM received a "Mildred
   Scheel PostDoc Stipendium" from the German Cancer Aid (DKH e.V.
   #110943). The funder provided support, but did not have any additional
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The specific roles of these
   authors are articulated in the 'author contributions' section.
CR Ahn K, 2009, MOL CELLS, V28, P99, DOI 10.1007/s10059-009-0107-y
   Alves Pedro M S, 2008, Cancer Immun, V8, P11
   Belshaw R, 2005, MOL BIOL EVOL, V22, P814, DOI 10.1093/molbev/msi088
   Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000
   Bock M, 2000, CURR OPIN GENET DEV, V10, P651, DOI 10.1016/S0959-437X(00)00138-6
   Brudek T, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-104
   Chiang CY, 2005, VIRUS RES, V108, P139, DOI 10.1016/j.virusres.2004.08.022
   Contreras-Galindo R, 2008, J VIROL, V82, P9329, DOI 10.1128/JVI.00646-08
   Contreras-Galindo R, 2007, AIDS RES HUM RETROV, V23, P116, DOI 10.1089/aid.2006.0117
   Feng WJN, 2007, INT J CANCER, V120, P81, DOI 10.1002/ijc.22256
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Gimenez J, 2010, NUCLEIC ACIDS RES, V38, P2229, DOI 10.1093/nar/gkp1214
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kraus B, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-21
   Kudo-Saito C, 2014, CANCER RES, V74, P1361, DOI 10.1158/0008-5472.CAN-13-1349
   Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Liang QY, 2009, BIOCHEM BIOPH RES CO, V382, P468, DOI 10.1016/j.bbrc.2009.03.058
   Maldonado JO, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00302
   Maletzki C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143194
   Maletzki C, 2015, WORLD J GASTROENTERO, V21, P164, DOI 10.3748/wjg.v21.i1.164
   Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485
   Mallet F, 2004, P NATL ACAD SCI USA, V101, P1731, DOI 10.1073/pnas.0305763101
   Miyamoto M, 1991, Med J Osaka Univ, V40, P5
   Mullins CS, 2012, WORLD J GASTROENTERO, V18, P6027, DOI 10.3748/wjg.v18.i42.6027
   Mullins CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071070
   Mullins CS, 2014, J CANC SCI THER, V6. 6, P177, DOI [10.4172/1948-5956.1000269, DOI 10.4172/1948-5956.1000269]
   Ostwald C, 2009, INT J ONCOL, V35, P321, DOI 10.3892/ijo_00000343
   Perot P, ONCOTARGET IN PRESS
   Pérot P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040194
   Sacha JB, 2012, J IMMUNOL, V189, P1467, DOI 10.4049/jimmunol.1200079
   Schiavetti F, 2002, CANCER RES, V62, P5510
   Stake MS, 2013, VIRUSES-BASEL, V5, P2767, DOI 10.3390/v5112767
   Wang DZ, 2013, ANNU REV MED, V64, P131, DOI 10.1146/annurev-med-112211-154330
   Wang-Johanning F, 2003, CANCER-AM CANCER SOC, V98, P187, DOI 10.1002/cncr.11451
   Wang-Johanning F, 2008, CANCER RES, V68, P5869, DOI 10.1158/0008-5472.CAN-07-6838
   Wentzensen N, 2007, INT J CANCER, V121, P1417, DOI 10.1002/ijc.22826
NR 37
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2016
VL 11
IS 4
AR e0153349
DI 10.1371/journal.pone.0153349
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DK5QZ
UT WOS:000374976200023
PM 27119520
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Zinzalla, G
AF Zinzalla, Giovanna
TI A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF
   Chromatin Remodelling Complex
SO CHEMBIOCHEM
LA English
DT Article
DE cancer; epigenetics; SWI/SNF complexes; transcription factors
ID PROTEIN-PROTEIN INTERACTION; C-MYC; LEUKEMIA MAINTENANCE; SYNTHETIC
   LETHAL; BAF COMPLEXES; LUNG-CANCER; MUTANT P53; MECHANISMS; SUBUNIT;
   TARGET
AB Mutations in subunits of the SWI/SNF chromatin remodelling complex are found in 20% of human cancers. At face value, this would appear to indicate that this multiprotein complex is a potent tumour suppressor. However, it has recently emerged that some mutations in the SWI/SNF complex can have a gain-of-function effect and that in other tumours, such as pancreatic cancer, leukaemia, and breast cancer, the wild-type complex is used to drive cancer. Thus, paradoxically, this "tumour suppressor" has become an attractive target for developing anticancer agents. The SWI/SNF complex makes several protein-protein interactions both within the complex and with a wide range of transcription factors, and targeting these protein-protein interactions is emerging as the best approach to modulating the activity of the complex selectively.
C1 [Zinzalla, Giovanna] Karolinska Inst, Microbiol Tumour & Cell Biol MTC, Tomtebodavagen 23A, S-17165 Stockholm, Sweden.
   [Zinzalla, Giovanna] Karolinska Inst, Sci Life Lab, Tomtebodavagen 23A, S-17165 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Zinzalla, G (通讯作者)，Karolinska Inst, Microbiol Tumour & Cell Biol MTC, Tomtebodavagen 23A, S-17165 Stockholm, Sweden.; Zinzalla, G (通讯作者)，Karolinska Inst, Sci Life Lab, Tomtebodavagen 23A, S-17165 Stockholm, Sweden.
EM giovanna.zinzalla@ki.se
RI Zinzalla, Giovanna/AEP-7607-2022
OI Zinzalla, Dr Giovanna/0000-0002-1130-4865
CR Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495
   Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811
   Clark P. G., 2015, ANGEW CHEM, V127, P6315, DOI DOI 10.1002/ANGE.201501394
   Clark PGK, 2015, ANGEW CHEM INT EDIT, V54, P6217, DOI 10.1002/anie.201501394
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32
   Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018
   Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480
   Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111
   Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251
   Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036
   Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X
   Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968
   Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]
   Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129
   Komiya Y, 2014, BIOCHEM BIOPH RES CO, V444, P382, DOI 10.1016/j.bbrc.2014.01.064
   Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019
   Li GH, 2015, FEBS LETT, V589, P2893, DOI 10.1016/j.febslet.2015.04.023
   Li XS, 2010, MOL CELL BIOL, V30, P1673, DOI 10.1128/MCB.00540-09
   Liu Y., 2015, SEMIN CANCER BIOL, DOI [10.1016/j.sem-cancer.2015.09.014, DOI 10.1016/J.SEM-CANCER.2015.09.014]
   Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Narlikar GJ, 2013, CELL, V154, P490, DOI 10.1016/j.cell.2013.07.011
   Nieddu E, 2005, FASEB J, V19, P632, DOI 10.1096/fj.04-2369fje
   Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200
   Pfister NT, 2015, GENE DEV, V29, P1298, DOI 10.1101/gad.263202.115
   Puri PL, 2012, GENE DEV, V26, P2673, DOI 10.1101/gad.207415.112
   Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X
   Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799
   Sammak S, 2015, PROG BIOPHYS MOL BIO, V119, P41, DOI 10.1016/j.pbiomolbio.2015.06.004
   Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284
   Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113
   Sodir NM, 2011, ONCOTARGET, V2, P1307
   Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260
   Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112
   Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808
   Tartey S, 2014, EMBO J, V33, P2332, DOI 10.15252/embj.201488447
   Theodoulou NH, 2016, J MED CHEM, V59, P1425, DOI 10.1021/acs.jmedchem.5b00256
   Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798
   Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007
   Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Yu BX, 2013, ACS CHEM BIOL, V8, P524, DOI 10.1021/cb300564v
   Zhao YJ, 2015, J MED CHEM, V58, P1038, DOI 10.1021/jm501092z
NR 46
TC 17
Z9 20
U1 0
U2 11
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
PD APR 15
PY 2016
VL 17
IS 8
SI SI
BP 677
EP 682
DI 10.1002/cbic.201500565
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DK7RX
UT WOS:000375124500004
PM 26684344
DA 2025-01-12
ER

PT J
AU Drummond, ML
   Prehoda, KE
AF Drummond, Michael L.
   Prehoda, Kenneth E.
TI Molecular Control of Atypical Protein Kinase C: Tipping the Balance
   between Self-Renewal and Differentiation
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE differentiation; protein kinase; cell proliferation
ID ASYMMETRIC CELL-DIVISION; CANCER STEM-CELLS; APICAL-BASAL POLARITY;
   BETA-CATENIN; DROSOPHILA NEUROBLASTS; EPITHELIAL POLARITY; APICOBASAL
   POLARITY; TARGETING CANCER; BREAST-CANCER; PAR COMPLEX
AB Complex organisms are faced with the challenge of generating and maintaining diverse cell types, ranging from simple epithelia to neurons and motile immune cells [1-3]. To meet this challenge, a complex set of regulatory pathways controls nearly every aspect of cell growth and function, including genetic and epigenetic programming, cytoskeleton dynamics, and protein trafficking. The far reach of cell fate specification pathways makes it particularly catastrophic when they malfunction, both during development and for tissue homeostasis in adult organisms. Furthermore, the therapeutic promise of stem cells derives from their ability to deftly navigate the multitude of pathways that control cell fate [4]. How the molecular components making up these pathways function to specify cell fate is beginning to become clear. Work from diverse systems suggests that the atypical Protein Kinase C (aPKC) is a key regulator of cell fate decisions in metazoans [5-7]. Here, we examine some of the diverse physiological outcomes of aPKC's function in differentiation, along with the molecular pathways that control aPKC and those that are responsive to changes in its catalytic activity. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Drummond, Michael L.; Prehoda, Kenneth E.] Univ Oregon, Inst Mol Biol, Dept Chem & Biochem, 1229 Univ Oregon, Eugene, OR 97403 USA.
C3 University of Oregon
RP Prehoda, KE (通讯作者)，Univ Oregon, Inst Mol Biol, Dept Chem & Biochem, 1229 Univ Oregon, Eugene, OR 97403 USA.
EM prehoda@uoregon.edu
RI Drummond, Michael/KWT-6187-2024
OI Prehoda, Ken/0000-0003-4214-6158
FU NIH [R01 GM068032]
FX We would like to thank the members of the Prehoda lab for their helpful
   discussions and critical reading of this manuscript. This work was
   supported by NIH grant R01 GM068032 (K.E.P).
CR Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796
   Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Archibald A, 2015, MOL BIOL CELL, V26, P3578, DOI 10.1091/mbc.E15-05-0265
   Atwood SX, 2007, J CELL SCI, V120, P3200, DOI 10.1242/jcs.014902
   Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002
   Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Bailey MJ, 2015, DEV CELL, V35, P199, DOI 10.1016/j.devcel.2015.09.016
   Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766
   Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721
   Bassères DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942
   Bayraktar OA, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-26
   Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038
   Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486
   Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Bunker BD, 2015, ELIFE, V4, DOI 10.7554/eLife.03189
   Cameron AJM, 2009, NAT STRUCT MOL BIOL, V16, P624, DOI 10.1038/nsmb.1606
   Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632
   Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059
   Chang KC, 2010, DEV CELL, V19, P778, DOI 10.1016/j.devcel.2010.10.007
   Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27
   Choi WS, 2013, MOL BIOL CELL, V24, P945, DOI 10.1091/mbc.E12-10-0736
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139
   Colosimo PF, 2010, DEV DYNAM, V239, P115, DOI 10.1002/dvdy.21963
   Dard N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007117
   Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977
   Dong W, 2015, J CELL BIOL, V211, P273, DOI 10.1083/jcb.201503067
   Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120
   Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110
   Goh LH, 2013, DEV BIOL, V381, P353, DOI 10.1016/j.ydbio.2013.06.031
   Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007
   Goulas S, 2012, CELL STEM CELL, V11, P529, DOI 10.1016/j.stem.2012.06.017
   Graybill C, 2012, J BIOL CHEM, V287, P21003, DOI 10.1074/jbc.M112.360495
   Guyer RA, 2015, J BIOL CHEM, V290, P8457, DOI 10.1074/jbc.M114.621011
   Harris RE, 2011, DEV CELL, V20, P72, DOI 10.1016/j.devcel.2010.11.019
   Hirano Y, 2004, J BIOL CHEM, V279, P31883, DOI 10.1074/jbc.M403092200
   Homem CCF, 2012, DEVELOPMENT, V139, P4297, DOI 10.1242/dev.080515
   Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119
   Insolera R, 2011, DEV NEUROBIOL, V71, P483, DOI 10.1002/dneu.20867
   Ivey RA, 2014, J BIOL CHEM, V289, P25021, DOI 10.1074/jbc.M114.565671
   Jiang HQ, 2011, EXP CELL RES, V317, P2780, DOI 10.1016/j.yexcr.2011.07.020
   Jiang K, 2014, P NATL ACAD SCI USA, V111, pE4842, DOI 10.1073/pnas.1417147111
   Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008
   KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0
   Kohwi M, 2013, NAT REV NEUROSCI, V14, P823, DOI 10.1038/nrn3618
   Komori H, 2014, DEVELOPMENT, V141, P51, DOI 10.1242/dev.099382
   Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1
   Lai SL, 2014, ELIFE, V3, DOI 10.7554/eLife.03363
   Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200
   Lange C, 2010, CELL CYCLE, V9, P1893, DOI 10.4161/cc.9.10.11598
   Lange C, 2009, CELL STEM CELL, V5, P320, DOI 10.1016/j.stem.2009.05.026
   Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406
   Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299
   Leonard TA, 2011, CELL, V144, P55, DOI 10.1016/j.cell.2010.12.013
   Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Lopez-Garcia LA, 2011, CHEM BIOL, V18, P1463, DOI 10.1016/j.chembiol.2011.08.010
   Lu M. S., 1843, MOL PATHWAYS REGULAT
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244
   Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009
   Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079
   Niessen MT, 2013, J CELL BIOL, V202, P887, DOI 10.1083/jcb.201307001
   Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200
   Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567
   Paul A, 2014, CELL DEATH DIFFER, V21, P1469, DOI 10.1038/cdd.2014.62
   Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550
   Prehoda KE, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001388
   Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079
   Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847
   Rubin AI, 2005, NEW ENGL J MED, V353, P2262, DOI 10.1056/NEJMra044151
   Sabherwal N, 2014, DEV CELL, V31, P559, DOI 10.1016/j.devcel.2014.10.023
   Sabherwal N, 2009, DEVELOPMENT, V136, P2767, DOI 10.1242/dev.034454
   Saiz N, 2013, DEVELOPMENT, V140, P4311, DOI 10.1242/dev.093922
   Saiz N, 2013, REPRODUCTION, V145, pR65, DOI 10.1530/REP-12-0381
   Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86
   Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7
   Siddiquee KAZ, 2008, CELL RES, V18, P254, DOI 10.1038/cr.2008.18
   Speicher S, 2008, CURR BIOL, V18, P831, DOI 10.1016/j.cub.2008.04.072
   Standaert M. L., 2001, BIOCHEMISTRY MOSC, V40, P249
   Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075
   Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898
   Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033
   Tobias I. S., 2015, BIOCH J
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Vorhagen S, 2014, EXP CELL RES, V328, P296, DOI 10.1016/j.yexcr.2014.08.008
   Wang C., 2012, STRUCTURE, V1993, P791
   Wang GH, 2009, J BIOL CHEM, V284, P14469, DOI 10.1074/jbc.M808909200
   Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
NR 98
TC 25
Z9 30
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 10
PY 2016
VL 428
IS 7
SI SI
BP 1455
EP 1464
DI 10.1016/j.jmb.2016.03.003
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DK4VL
UT WOS:000374918300005
PM 26992354
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kawaguchi, K
   Kinameri, A
   Suzuki, S
   Senga, S
   Ke, YQ
   Fujii, H
AF Kawaguchi, Koichiro
   Kinameri, Ayumi
   Suzuki, Shunsuke
   Senga, Shogo
   Ke, Youqiang
   Fujii, Hiroshi
TI The cancer-promoting gene fatty acid-binding protein 5 (<i>FABP5</i>) is
   epigenetically regulated during human prostate carcinogenesis
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE DNA methylation; epigenetics; fatty-acid-binding proteins (FABPs);
   FABP5; metastasis; prostate cancer
ID DNA METHYLTRANSFERASES; TRANSCRIPTION FACTORS; GEL-ELECTROPHORESIS;
   CELL-PROLIFERATION; MOLECULAR-CLONING; MESSENGER-RNA; FACTOR FAMILY;
   C-MYC; EXPRESSION; METHYLATION
AB FABPs (fatty-acid-binding proteins) are a family of low-molecular-mass intracellular lipid-binding proteins consisting of ten isoforms. FABPs are involved in binding and storing hydrophobic ligands such as long-chain fatty acids, as well as transporting these ligands to the appropriate compartments in the cell. FABP5 is overexpressed in multiple types of tumours. Furthermore, up-regulation of FABP5 is strongly associated with poor survival in triple-negative breast cancer. However, the mechanisms underlying the specific up-regulation of the FABP5 gene in these cancers remain poorly characterized. In the present study, we determined that FABP5 has a typical CpG island around its promoter region. The DNA methylation status of the CpG island in the FABP5 promoter of benign prostate cells (PNT2), prostate cancer cells (PC-3, DU-145, 22Rv1 and LNCaP) and human normal or tumour tissue was assessed by bisulfite sequencing analysis, and then confirmed by COBRA (combined bisulfite restriction analysis) and qAMP (quantitative analysis of DNA methylation using real-time PCR). These results demonstrated that overexpression of FABP5 in prostate cancer cells can be attributed to hypomethylation of the CpG island in its promoter region, along with up-regulation of the direct trans-acting factors Sp1 (specificity protein 1) and c-Myc. Together, these mechanisms result in the transcriptional activation of FABP5 expression during human prostate carcinogenesis. Importantly, silencing of Sp1, c-Myc or FABP5 expression led to a significant decrease in cell proliferation, indicating that up-regulation of FABP5 expression by Sp1 and c-Myc is critical for the proliferation of prostate cancer cells.
C1 [Kawaguchi, Koichiro; Fujii, Hiroshi] Shinshu Univ, Interdisciplinary Grad Sch Sci & Technol, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Nagano 3994598, Japan.
   [Kinameri, Ayumi; Suzuki, Shunsuke; Senga, Shogo] Shinshu Univ, Fac Agr, Dept Biosci & Biotechnol, Inst Biomed Sci,Interdisciplinary Cluster Cutting, Nagano 3994598, Japan.
   [Ke, Youqiang] Univ Liverpool, Dept Mol & Clin Canc Med, Mol Pathol Lab, 5-6th Floor,Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
   [Fujii, Hiroshi] Shinshu Univ, Inst Biomed Sci, Dept Interdisciplinary Genome Sci & Cell Metab, Interdisciplinary Cluster Cutting Edge Res, Nagano 3994598, Japan.
C3 Shinshu University; Shinshu University; University of Liverpool; Shinshu
   University
RP Fujii, H (通讯作者)，Shinshu Univ, Interdisciplinary Grad Sch Sci & Technol, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Nagano 3994598, Japan.; Fujii, H (通讯作者)，Shinshu Univ, Inst Biomed Sci, Dept Interdisciplinary Genome Sci & Cell Metab, Interdisciplinary Cluster Cutting Edge Res, Nagano 3994598, Japan.
EM hfujii@shinshu-u.ac.jp
OI Senga, Shogo/0009-0006-8355-5416; Suzuki, Shunsuke/0000-0002-5716-8838
FU Uehara Memorial Foundation; Chinomori Foundation; Shinshu University;
   Integration Research for Agriculture and Interdisciplinary Fields; 
   [22570112]; MRC [MC_PC_14110] Funding Source: UKRI
FX This study was supported in part by a research grant from Grant-in-Aid
   for Scientific Research (C) [grant number 22570112]. This work was also
   supported in part by the Uehara Memorial Foundation, the Chinomori
   Foundation, Shinshu University, and Integration Research for Agriculture
   and Interdisciplinary Fields.
CR Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008-5472.CAN-2506-2
   Adamson J, 2003, ONCOGENE, V22, P2739, DOI 10.1038/sj.onc.1206341
   Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490
   Bao Zhengzheng, 2013, Genes Cancer, V4, P297, DOI 10.1177/1947601913499155
   Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Blattler A, 2013, J BIOL CHEM, V288, P34287, DOI 10.1074/jbc.R113.512517
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen R, 2011, J INT MED RES, V39, P533, DOI 10.1177/147323001103900222
   Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003
   Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889
   Daniel FI, 2011, CANCER-AM CANCER SOC, V117, P677, DOI 10.1002/cncr.25482
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   DeLeon M, 1996, J NEUROSCI RES, V44, P283
   Fang LY, 2010, J ORAL PATHOL MED, V39, P342, DOI 10.1111/j.1600-0714.2009.00836.x
   Fernandez AF, 2012, TRENDS GENET, V28, P474, DOI 10.1016/j.tig.2012.05.006
   Foster CS, 1999, BJU INT, V83, P171
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujii K, 2005, PROTEOMICS, V5, P1411, DOI 10.1002/pmic.200401004
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Guo MM, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0542-7
   Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jaworski C, 1996, BIOCHEM J, V320, P49, DOI 10.1042/bj3200049
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jeong CY, 2012, ONCOL REP, V28, P1283, DOI 10.3892/or.2012.1922
   Jing C, 2000, CANCER RES, V60, P2390
   Jing C, 2001, CANCER RES, V61, P4357
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021
   Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327
   Knoepfler PS, 2008, CELL STEM CELL, V2, P18, DOI 10.1016/j.stem.2007.12.004
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Kovar JL, 2006, AM J PATHOL, V169, P1415, DOI 10.2353/ajpath.2006.060324
   KRIEG P, 1993, J BIOL CHEM, V268, P17362
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Liang P, 2003, NAT REV CANCER, V3, P869, DOI 10.1038/nrc1214
   Liu RZ, 2011, AM J PATHOL, V178, P997, DOI 10.1016/j.ajpath.2010.11.075
   Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879
   MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641
   Marinescu VD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-79
   Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297
   Massoner P, 2014, BRIT J CANCER, V111, P955, DOI 10.1038/bjc.2014.366
   Morgan EA, 2008, INT J ONCOL, V32, P767
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   Münz M, 2005, CANCER LETT, V225, P151, DOI 10.1016/j.canlet.2004.11.048
   Münz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Oakes CC, 2006, EPIGENETICS-US, V1, P146, DOI 10.4161/epi.1.3.3392
   Powell CA, 2015, ONCOTARGET, V6, P6373, DOI 10.18632/oncotarget.3442
   Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006
   SIEGENTHALER G, 1993, BIOCHEM BIOPH RES CO, V190, P482, DOI 10.1006/bbrc.1993.1073
   Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H
   Smathers Rebecca L., 2011, Human Genomics, V5, P170
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Storch J, 2010, J BIOL CHEM, V285, P32679, DOI 10.1074/jbc.R110.135210
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935
   Watanabe R, 1997, J DERMATOL SCI, V16, P17, DOI 10.1016/S0923-1811(97)00615-4
   WATANABE R, 1994, BIOCHEM BIOPH RES CO, V200, P253, DOI 10.1006/bbrc.1994.1442
   WEN Y, 1995, GENE, V158, P269, DOI 10.1016/0378-1119(95)00168-6
   Wu XY, 2014, AM J CLIN EXP UROL, V2, P111
   Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100
   Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010
NR 72
TC 51
Z9 64
U1 0
U2 21
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD FEB 15
PY 2016
VL 473
BP 449
EP 461
DI 10.1042/BJ20150926
PN 4
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DK2ZR
UT WOS:000374785000009
PM 26614767
DA 2025-01-12
ER

PT J
AU Yang, X
   Li, M
   Tang, Y
   Wang, YL
   Threadgill, MD
   Han, JY
   Han, X
   Chen, L
   Chen, H
   Hu, WP
   Lin, X
AF Yang, Xi
   Li, Ming
   Tang, Yi
   Wang, Ya-Lan
   Threadgill, Michael D.
   Han, Jia-Yue
   Han, Xu
   Chen, Liang
   Chen, Huan
   Hu, Wen-Ping
   Lin, Xiao
TI ART1 induces aberrant methylation of uPA promoter: a preliminary study
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ART1; DNMT1; methylation; metastasis; invasion
ID MONO-ADP-RIBOSYLATION; DNA METHYLATION; BREAST-CANCER; PROSTATE-CANCER;
   DEMETHYLATION; EXPRESSION; GROWTH; 5-AZA-2'-DEOXYCYTIDINE;
   HYPOMETHYLATION; INHIBITION
AB Colorectal carcinoma remains one of the most prevalent cancers with high morbidity and mortality. Arginine ADP-ribosyltransferase 1 (ART1) is one of the major mono-ADP-ribose transferases and has been shown to be involved importantly in many biological processes. DNA methylation is an important epigenetic mechanism in tumorgenesis. However, the influence of ART1 on DNA methylation contributing to this function in colorectal carcinoma cells remains unclear. The expression and activity of DNA methyltransferase 1 (DNMT1) was detected by western blotting. The binding between ART1 and DNMT1 was assessed by co-immunoprecipitation. The methylation status of uPA gene was determined by bisulfite sequencing PCR. DNMT1 expression and activity were increased as ART1 was silenced, and decreased as ART1 was over-expressed in CT26 colorectal carcinoma cells. The expression of DNMT1 decreased and uPA increased, respectively, following the treatment with 5-aza-2'deoxycytidine in GFP-shART1 group. Invasion and metastasis were enhanced in GFP-shART1 group treated with 5-aza-dC. Similar regulation of expression of DNMT1 and uPA were confirmed in Balb/c mice. This study revealed that silencing of ART1 induced hypermethylation of uPA gene and over-expression causes hypomethylation. It probably relates to the feedback mechanism of NF-kappa B to PARP1 thus mediating the expression and activity of DNMT1. The relationship between ART1 and DNA methylation might offer a new therapeutic target for the improved treatment of this major cancer.
C1 [Yang, Xi; Li, Ming; Tang, Yi; Wang, Ya-Lan; Lin, Xiao] Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
   [Han, Jia-Yue; Han, Xu; Chen, Liang; Chen, Huan; Hu, Wen-Ping] Chongqing Med Univ, Clin Med Coll, Chongqing 400016, Peoples R China.
   [Threadgill, Michael D.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Bath
RP Wang, YL (通讯作者)，Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM wangyalan074@126.com
RI Threadgill, Michael/C-3925-2009; Hu, Wenping/K-7348-2015
FU Ministry of Education Specialized Research Fund for the Doctoral Program
   of Higher Education [20105503110009]; Basic and Advanced Research
   Program of Chongqing [20140106]; Science and Technology Project of the
   Education Commission of Chongqing [KJ110-322]; National High Technology
   Research and Development Program of China [2012AA02A201]; college
   students' scientific research and innovation experimental program of
   Chongqing Medical university [201319]; college students' innovation and
   training program of Chongqing [201310631020]
FX This research was supported by grants from the Ministry of Education
   Specialized Research Fund for the Doctoral Program of Higher Education
   (Grant No. 20105503110009), the Basic and Advanced Research Program of
   Chongqing (Grant No. 20140106), the Science and Technology Project of
   the Education Commission of Chongqing (Grant No. KJ110-322) and the
   National High Technology Research and Development Program of China (No.
   2012AA02A201), the college students' scientific research and innovation
   experimental program of Chongqing Medical university (Grant No. 201319)
   and the college students' innovation and training program of Chongqing
   (Grant No. 201310631020).
CR Barbara KD, 2003, ANN NY ACAD SCI, V983, P28
   BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   Caiafa P, 2009, FASEB J, V23, P672, DOI 10.1096/fj.08-123265
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Castagnini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041417
   Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hua D, 2011, EXP MOL PATHOL, V91, P455, DOI 10.1016/j.yexmp.2011.05.001
   Hwang YS, 2006, MOL CARCINOGEN, V45, P518, DOI 10.1002/mc.20183
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kandenwein JA, 2011, J NEURO-ONCOL, V103, P533, DOI 10.1007/s11060-010-0411-6
   Kisseljova NP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P743, DOI 10.1007/s10541-005-0179-z
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Kuang J, 2014, ONCOL REP, V31, P2335, DOI 10.3892/or.2014.3100
   Lan J, 2010, ACTA BIOCH BIOPH SIN, V42, P243, DOI 10.1093/abbs/gmq015
   Lantry LE, 1999, CARCINOGENESIS, V20, P343, DOI 10.1093/carcin/20.2.343
   [黎明 LI Ming], 2008, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V30, P237
   Meng Huan X, 2011, Cancers (Basel), V3, P1798, DOI 10.3390/cancers3021798
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Pakneshan P, 2005, CARCINOGENESIS, V26, P557, DOI 10.1093/carcin/bgi009
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Pan J, 2012, CANCER GENE THER, V19, P715, DOI 10.1038/cgt.2012.48
   Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463
   Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393
   Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Scarpa ES, 2013, FEBS J, V280, P3551, DOI 10.1111/febs.12290
   Shota T, 2008, ANTICANCER RES, V28, P3593
   Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940
   [宋光林 Song Guanglin], 2013, [肿瘤, Tumor], V33, P490
   Tang Y, 2013, INT J MOL MED, V32, P130, DOI 10.3892/ijmm.2013.1370
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Xiao M, 2013, CELL PHYSIOL BIOCHEM, V32, P1587, DOI 10.1159/000356595
   [徐剑侠 Xu Jianxia], 2012, [肿瘤, Tumor], V32, P949
   Yang L, 2009, PHARM CLIN RES, V4, P17
   Yau L, 2003, EUR J BIOCHEM, V270, P101, DOI 10.1046/j.1432-1033.2003.03366.x
NR 43
TC 0
Z9 0
U1 0
U2 10
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 4
BP 4269
EP 4282
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DL1RL
UT WOS:000375409600015
DA 2025-01-12
ER

PT J
AU Kostka, G
   Urbanek-Olejnik, K
   Liszewska, M
   Winczura, A
AF Kostka, Grazyna
   Urbanek-Olejnik, Katarzyna
   Liszewska, Monika
   Winczura, Alicja
TI The effect of acute dichlorodiphenyltrichloroethane exposure on
   hypermethylation status and down-regulation of <i>p53</i> and
   <i>p16<SUP>INK4a</SUP></i> genes in rat liver
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE dichlorodiphenyltrichloroethane; genes expression; DNA methylation; DNA
   methyltransferase 1; DNA synthesis
ID CONSTITUTIVE ACTIVE/ANDROSTANE RECEPTOR; ALTERED DNA METHYLATION; EARLY
   HEPATIC-CHANGES; NUCLEAR RECEPTOR; HEPATOCELLULAR-CARCINOMA; EPIGENETIC
   EVENTS; PROMOTER REGION; BREAST-CANCER; DDT; REPLICATION
AB The aim of the study was to investigate the early effect of acute dichlorodiphenyltrichloroethane (DDT) exposure on the methylation status of the promoter region of two tumor suppressor genes: p53 and p16(INK4a) (p16) in rat liver. We analyzed their transcript and protein expression profiles concurrently with the examination of transcriptional and protein expression levels of DNA (cytosine-5)-methyltransferase 1 (Dnmt1). Male Wistar rats were treated with a single dose of DDT (57 mg kg(-1) of body weight) and the methylation status of p53 and p16 genes was examined after 24 h using methylation-sensitive restriction analysisMSRA. The obtained results indicate that DDT induced alternations in methylation of the promoter region in both p53 and p16 genes. In all the tested samples, the promoter CpG islands of p53 (-261, -179, and -450) were methylated within 100% as compared to control samples (0%). The methylation status of the p16 promoter (-11 and +77) was also altered due to exposure to DDT. Methylated cytosines were detectable in 75% of the tested DNA samples. The Real-time PCR and western blot analyses showed a decrease in mRNA and protein levels of p53, respectively, which was related to the increase in DNA synthesis. These relationships were also observed for mRNA and protein expressions of p16, although to a slighter extent. We also showed that hypermethylation in the promoter region of both tumor suppressor genes was consistent with an increased Dnmt1 mRNA level, and this relationship was further confirmed at the protein level of DNMT1. Concluding, our data suggests that epigenetically mediated changes in gene expression may play an important role in the mechanism of DDT toxicity, including carcinogenic action. (c) 2014 Wiley Periodicals, Inc. Environ Toxicol 31: 584-592, 2016.
C1 [Kostka, Grazyna; Urbanek-Olejnik, Katarzyna; Liszewska, Monika] Natl Inst Hyg, Natl Inst Publ Hlth, Dept Toxicol & Risk Assessment, Chocimska 24, PL-00791 Warsaw, Poland.
   [Winczura, Alicja] Polish Acad Sci, Inst Biochem & Biophys, Dept Mol Biol, Pawinskiego 5a, Warsaw, Poland.
C3 National Institute of Public Health (NIPH); National Institute of
   Hygiene (NIH); Polish Academy of Sciences; Institute of Biochemistry &
   Biophysics - Polish Academy of Sciences
RP Urbanek-Olejnik, K (通讯作者)，Natl Inst Hyg, Natl Inst Publ Hlth, Dept Toxicol & Risk Assessment, Chocimska 24, PL-00791 Warsaw, Poland.
EM kolejnik@pzh.gov.pl
FU Polish Grant [P05D 028 26, NN404 123438]
FX Contract grant sponsor: Polish Grant. Contract grant number: P05D 028
   26, NN404 123438
CR [Anonymous], 1991, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, V53, P179, DOI DOI 10.7705/BIOMEDICA.V25I3.1358,335-345
   Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Baccarelli A, 2010, CIRC-CARDIOVASC GENE, V3, P567, DOI 10.1161/CIRCGENETICS.110.958744
   Bachman AN, 2006, TOXICOL SCI, V91, P393, DOI 10.1093/toxsci/kfj155
   Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Bouwman H, 2011, ENVIRON HEALTH PERSP, V119, P744, DOI 10.1289/ehp.1002127
   Canales-Aguirre A, 2011, INT J ENV RES PUB HE, V8, P540, DOI 10.3390/ijerph8020540
   Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030
   Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58
   Essers J, 2005, MOL CELL BIOL, V25, P9350, DOI 10.1128/MCB.25.21.9350-9359.2005
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Frigo DE, 2004, CARCINOGENESIS, V25, P249, DOI 10.1093/carcin/bgh009
   Goodman JI, 2002, ANNU REV PHARMACOL, V42, P501, DOI 10.1146/annurev.pharmtox.42.092001.141143
   Harada T, 2003, TOXICOL PATHOL, V31, P87, DOI 10.1080/01926230390173941
   Hashimoto H, 2009, EPIGENETICS-US, V4, P8, DOI 10.4161/epi.4.1.7370
   Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001
   Hou LF, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-25
   Huang WD, 2005, MOL ENDOCRINOL, V19, P1646, DOI 10.1210/me.2004-0520
   Jeltsch A, 2006, CURR TOP MICROBIOL, V301, P203
   Kazantseva YA, 2013, TOXICOL APPL PHARM, V271, P137, DOI 10.1016/j.taap.2013.05.008
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   KOSTKA G, 1994, J APPL TOXICOL, V14, P337, DOI 10.1002/jat.2550140504
   Kostka G, 2000, TOXICOLOGY, V142, P135, DOI 10.1016/S0300-483X(99)00164-X
   Kostka G, 2007, TOXICOLOGY, V239, P127, DOI 10.1016/j.tox.2007.07.003
   Kutanzi KR, 2010, MUTAT RES-FUND MOL M, V694, P1, DOI 10.1016/j.mrfmmm.2010.07.006
   Lafon-Hughes L, 2008, MUTAT RES-REV MUTAT, V658, P191, DOI 10.1016/j.mrrev.2008.01.008
   Liu WB, 2009, TOXICOL LETT, V189, P5, DOI 10.1016/j.toxlet.2009.04.022
   McGlynn KA, 2006, JNCI-J NATL CANCER I, V98, P1005, DOI 10.1093/jnci/djj266
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Mrema EJ, 2013, TOXICOLOGY, V307, P74, DOI 10.1016/j.tox.2012.11.015
   Nagayama Junya, 2003, Fukuoka Acta Medica, V94, P166
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Pérez-Maldonado IN, 2005, ENVIRON RES, V98, P177, DOI 10.1016/j.envres.2004.11.001
   Persson EC, 2012, INT J CANCER, V131, P2078, DOI 10.1002/ijc.27459
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phillips JM, 2007, TOXICOL SCI, V96, P72, DOI 10.1093/toxsci/kfl188
   Pogribny I. P., 2010, Experimental Oncology, V32, P132
   Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0
   Rogan WJ, 2005, LANCET, V366, P763, DOI 10.1016/S0140-6736(05)67182-6
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shutoh Y, 2009, J TOXICOL SCI, V34, P469, DOI 10.2131/jts.34.469
   Spada F, 2006, ADV ENZYME REGUL, V46, P224, DOI 10.1016/j.advenzreg.2006.01.011
   Takeshita K, 2011, P NATL ACAD SCI USA, V108, P9055, DOI 10.1073/pnas.1019629108
   Tebourbi O, 2010, ENVIRON TOXICOL PHAR, V29, P271, DOI 10.1016/j.etap.2010.03.002
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   WHO (World Health Organization), 2010, ENV HLTH CRIT, V241
   Yamamoto Y, 2004, CANCER RES, V64, P7197, DOI 10.1158/0008-5472.CAN-04-1459
   Yáñez L, 2004, ENVIRON RES, V94, P18, DOI 10.1016/S0013-9351(03)00047-1
   Zhang X, 2012, ENVIRON MOL MUTAGEN, V53, P542, DOI 10.1002/em.21718
NR 54
TC 5
Z9 7
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-4081
EI 1522-7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD MAY
PY 2016
VL 31
IS 5
BP 584
EP 592
DI 10.1002/tox.22071
PG 9
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA DJ6OM
UT WOS:000374332800008
PM 25410620
DA 2025-01-12
ER

PT J
AU He, DX
   Gu, F
   Gao, F
   Hao, JJ
   Gong, DS
   Gu, XT
   Mao, AQ
   Jin, J
   Fu, L
   Ma, X
AF He, Dong-Xu
   Gu, Feng
   Gao, Fei
   Hao, Jun-jun
   Gong, Desheng
   Gu, Xiao-Ting
   Mao, Ai-Qin
   Jin, Jian
   Fu, Li
   Ma, Xin
TI Genome-wide profiles of methylation, microRNAs, and gene expression in
   chemoresistant breast cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; NEOADJUVANT CHEMOTHERAPY;
   MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; OVARIAN-CANCER; STEM-CELLS;
   SURVIVAL; METASTASIS; BIOMARKER; CYTOSCAPE
AB Cancer chemoresistance is regulated by complex genetic and epigenetic networks. In this study, the features of gene expression, methylation, and microRNA (miRNA) expression were investigated with high-throughput sequencing in human breast cancer MCF-7 cells resistant to adriamycin (MCF-7/ADM) and paclitaxel (MCF-7/PTX). We found that: (1) both of the chemoresistant cell lines had similar, massive changes in gene expression, methylation, and miRNA expression versus chemosensitive controls. (2) Pairwise integration of the data highlighted sets of genes that were regulated by either methylation or miRNAs, and sets of miRNAs whose expression was controlled by DNA methylation in chemoresistant cells. (3) By combining the three sets of high-throughput data, we obtained a list of genes whose expression was regulated by both methylation and miRNAs in chemoresistant cells; (4) Expression of these genes was then validated in clinical breast cancer samples to generate a 17-gene signature that showed good predictive and prognostic power in triple-negative breast cancer patients receiving anthracycline-taxane-based neoadjuvant chemotherapy. In conclusion, our results have generated a new workflow for the integrated analysis of the effects of miRNAs and methylation on gene expression during the development of chemoresistance.
C1 [He, Dong-Xu] Jiangnan Univ, Natl Engn Lab Cereal Fermentat Technol, Wuxi 214122, Peoples R China.
   [Gu, Feng; Fu, Li] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin 300060, Peoples R China.
   [Gu, Feng; Fu, Li] Tianjin Med Univ, Canc Inst & Hosp, Res Lab, State Key Lab Breast Canc Res, Tianjin 300060, Peoples R China.
   [Gao, Fei; Gong, Desheng] Chinese Acad Agr Sci, Agr Genomes Inst Shenzhen, Shenzhen 518120, Peoples R China.
   [Hao, Jun-jun] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China.
   [Gu, Xiao-Ting; Mao, Ai-Qin; Jin, Jian; Ma, Xin] Jiangnan Univ, Sch Pharmaceut Sci, Dept Cellular & Mol Pharmacol, Wuxi 214122, Peoples R China.
C3 Jiangnan University; Tianjin Medical University; Tianjin Medical
   University; Chinese Academy of Agricultural Sciences; Agriculture
   Genomes Institute at Shenzhen, CAAS; Chinese Academy of Sciences;
   Kunming Institute of Zoology, CAS; Jiangnan University
RP Fu, L (通讯作者)，Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin 300060, Peoples R China.; Fu, L (通讯作者)，Tianjin Med Univ, Canc Inst & Hosp, Res Lab, State Key Lab Breast Canc Res, Tianjin 300060, Peoples R China.; Jin, J; Ma, X (通讯作者)，Jiangnan Univ, Sch Pharmaceut Sci, Dept Cellular & Mol Pharmacol, Wuxi 214122, Peoples R China.
EM jinjian31@163.com; fulijyb@hotmail.com; maxin@jiangnan.edu.cn
RI Ma, Xin/G-1297-2013
FU China National Natural Science Foundation [81572940, 91439131, 31200126,
   31550006, 81272358]; Natural Science Foundation for Distinguished Young
   Scholars of Jiangsu Province [BK20140004]; Program for New Century
   Excellent Talents in University of The Ministry of Education of China
   [NCET-12-0880]; National High Technology Research and Development
   Program (863 Program) of China [SQ2015AA020948]; Fundamental Research
   Funds for the Central Universities [JUSRP51311A, JUSRP51519]
FX This work was supported by the China National Natural Science Foundation
   81572940 and 91439131 to Xin Ma; 31200126 and 31550006 to Dong-Xu He;
   81272358 to Feng Gu; the Natural Science Foundation for Distinguished
   Young Scholars of Jiangsu Province (BK20140004 to Xin Ma); the Program
   for New Century Excellent Talents in University of The Ministry of
   Education of China (NCET-12-0880) to Xin Ma; the National High
   Technology Research and Development Program (863 Program) of China
   (SQ2015AA020948) to Xin Ma; Fundamental Research Funds for the Central
   Universities (JUSRP51311A and JUSRP51519) to Xin Ma and Jin Jian. We
   thank Dr. IC Bruce for reading the manuscript.
CR Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795
   BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311
   Bishop C. M., 2003, NATO SCI SERIES
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Cha JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5952
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chatr-aryamontri A, 2015, NUCLEIC ACIDS RES, V43, pD470, DOI 10.1093/nar/gku1204
   Chen DH, 2013, CANCER RES, V73, P5821, DOI 10.1158/0008-5472.CAN-13-1080
   Chuthapisith S, 2007, INT J ONCOL, V30, P1545
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Dunn LL, 2006, CARCINOGENESIS, V27, P2157, DOI 10.1093/carcin/bgl045
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036
   Goda K, 2009, CURR CANCER DRUG TAR, V9, P281, DOI 10.2174/156800909788166493
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108
   He DX, 2014, FEBS J, V281, P4718, DOI 10.1111/febs.13012
   He DX, 2014, MOL PHARMACOL, V86, P536, DOI 10.1124/mol.114.092759
   Horak CE, 2013, CLIN CANCER RES, V19, P1587, DOI 10.1158/1078-0432.CCR-12-1359
   Horak P, 2014, SCI REP-UK, V4, DOI 10.1038/srep03739
   Jiang L, 2014, FEBS LETT, V588, P2009, DOI 10.1016/j.febslet.2014.04.024
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Lee SH, 2003, AM J SURG, V186, P348, DOI 10.1016/S0002-9610(03)00271-X
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma X, 2012, P NATL ACAD SCI USA, V109, P16282, DOI 10.1073/pnas.1202989109
   Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562
   Nabholtz JMA, 2002, SEMIN ONCOL, V29, P28, DOI 10.1053/sonc.2002.34262
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Rathnagiriswaran S, 2010, INT J ONCOL, V36, P607, DOI 10.3892/ijo_00000536
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shats I, 2011, CANCER RES, V71, P1772, DOI 10.1158/0008-5472.CAN-10-1735
   Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457
   Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Traverso N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/972913
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Turner N, 2013, CANCER TREAT REV, V39, P541, DOI 10.1016/j.ctrv.2012.12.001
   Vié N, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-14
   Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Xiang TX, 2013, J CELL MOL MED, V17, P1236, DOI 10.1111/jcmm.12099
   Yamasaki T, 2013, J UROLOGY, V190, P1059, DOI 10.1016/j.juro.2013.02.089
   Zelcer N, 2001, J BIOL CHEM, V276, P46400, DOI 10.1074/jbc.M107041200
   Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611
NR 55
TC 38
Z9 39
U1 0
U2 28
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 20
PY 2016
VL 6
AR 24706
DI 10.1038/srep24706
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DJ7FT
UT WOS:000374378000002
PM 27094684
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Aprelikova, O
   Chen, K
   El Touny, LH
   Brignatz-Guittard, C
   Han, J
   Qiu, TH
   Yang, HH
   Lee, MP
   Zhu, M
   Green, JE
AF Aprelikova, Olga
   Chen, Kenny
   El Touny, Lara H.
   Brignatz-Guittard, Constance
   Han, Justin
   Qiu, Tinghu
   Yang, Howard H.
   Lee, Maxwell P.
   Zhu, Min
   Green, Jeffrey E.
TI The epigenetic modifier JMJD6 is amplified in mammary tumors and
   cooperates with c-Myc to enhance cellular transformation, tumor
   progression, and metastasis
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Mammary cancer; Myc; JMJD6; Copy number variants; Epigenetics; Tumor
   progression
ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN BREAST-CANCER; TRANSCRIPTIONAL
   PAUSE RELEASE; TAG TRANSGENIC MICE; PROTEIN 6 JMJD6; VEGF-RECEPTOR 1;
   GENE-EXPRESSION; ARGININE METHYLATION; INDUCED APOPTOSIS; KI-RAS
AB Background: Oncogene overexpression in primary cells often triggers the induction of a cellular safeguard response promoting senescence or apoptosis. Secondary cooperating genetic events are generally required for oncogene-induced tumorigenesis to overcome these biologic obstacles. We employed comparative genomic hybridization for eight genetically engineered mouse models of mammary cancer to identify loci that might harbor genes that enhance oncogene-induced tumorigenesis.
   Results: Unlike many other mammary tumor models, the MMTV-Myc tumors displayed few copy number variants except for amplification of distal mouse chromosome 11 in 80 % of the tumors (syntenic to human 17q23-qter often amplified in human breast cancer). Analyses of candidate genes located in this region identified JMJD6 as an epigenetic regulatory gene that cooperates with Myc to enhance tumorigenesis. It suppresses Myc-induced apoptosis under varying stress conditions through inhibition of p19ARF messenger RNA (mRNA) and protein, leading to reduced levels of p53. JMJD6 binds to the p19ARF promoter and exerts its inhibitory function through demethylation of H4R3me2a. JMJD6 overexpression in MMTV-Myc cell lines increases tumor burden, induces EMT, and greatly enhances tumor metastasis. Importantly, we demonstrate that co-expression of high levels of JMJD6 and Myc is associated with poor prognosis for human ER+ breast cancer patients.
   Conclusions: A novel epigenetic mechanism has been identified for how JMJD6 cooperates with Myc during oncogenic transformation. Combined high expression of Myc and JMJD6 confers a more aggressive phenotype in mouse and human tumors. Given the pleiotropic pro-tumorigenic activities of JMJD6, it may be useful as a prognostic factor and a therapeutic target for Myc-driven mammary tumorigenesis.
C1 [Aprelikova, Olga; Chen, Kenny; El Touny, Lara H.; Brignatz-Guittard, Constance; Han, Justin; Qiu, Tinghu; Yang, Howard H.; Lee, Maxwell P.; Zhu, Min; Green, Jeffrey E.] NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 4054,37 Convent Dr, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Aprelikova, O (通讯作者)，NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 4054,37 Convent Dr, Bethesda, MD 20892 USA.
EM apreliko@mail.nih.gov
RI Lee, Ju-Seog/X-1786-2018
OI Chen, Kenny/0000-0002-1939-9213
FU Intramural Research Program of the NIH; CCR; NCI
FX This work was supported by the Intramural Research Program of the NIH,
   CCR, and NCI. We would like to thank Dr. Evan and Dr. Lazebnik for
   pBabe-MycER (TM) puro and hygro plasmids, Dr. Desai for pLV-JMJD6 and
   LacZ plasmids, Dr. Johnson for pBabe-p19ARF plasmid, Dr. Liu for
   depositing data into Gene Expression Omnibus, and members of Green lab
   for helpful discussions. We are grateful to Dr. Kent Hunter for critical
   reading of the manuscript. We would also like to thank the Array Core
   Facility of the National Cancer Institute for performing array CGH
   analysis.
CR ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8
   Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746
   Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106
   Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466
   Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108
   Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801
   Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691
   Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200
   Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658
   Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892
   EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T
   Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   Heim A, 2014, NUCLEIC ACIDS RES, V42, P7833, DOI 10.1093/nar/gku488
   Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346
   HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755
   Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312
   Inaki K, 2014, GENOME RES, V24, P1559, DOI 10.1101/gr.164871.113
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Lee YF, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3200
   Li XG, 2010, BLOOD, V115, P2028, DOI 10.1182/blood-2009-07-236059
   Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686
   Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491
   Liu ML, 2001, ONCOGENE, V20, P2044, DOI 10.1038/sj.onc.1204280
   Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456
   Liu W, 2013, CELL, V155, P1581, DOI 10.1016/j.cell.2013.10.056
   McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804
   Montagna C, 2003, CANCER RES, V63, P2179
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261
   Poulard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126181
   Poulard C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087982
   Qi JW, 2013, P NATL ACAD SCI USA, V110, P13863, DOI 10.1073/pnas.1304529110
   Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10
   Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shiio Y, 2006, J BIOL CHEM, V281, P2750, DOI 10.1074/jbc.M509349200
   SHIU RP, 1993, CLIN CHEM, V39, P353
   Silva GO, 2015, BREAST CANCER RES TR, V152, P347, DOI 10.1007/s10549-015-3476-2
   Somiari SB, 2004, CANCER GENET CYTOGEN, V155, P108, DOI 10.1016/j.cancergencyto.2004.02.023
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5
   Toffoli S, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0466-y
   Unoki M, 2013, J BIOL CHEM, V288, P6053, DOI 10.1074/jbc.M112.433284
   Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313
   Wang F, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001819
   Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636
   Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.3.CO;2-V
   Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865
   Wysocka J, 2006, FRONT BIOSCI-LANDMRK, V11, P344, DOI 10.2741/1802
   Xu XJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-396
   Yang YZ, 2010, MOL CELL, V40, P1016, DOI 10.1016/j.molcel.2010.11.024
   Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099
   Zhang J, 2013, TUMOR BIOL, V34, P2397, DOI 10.1007/s13277-013-0789-9
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zheng YB, 2010, J BIOL CHEM, V285, P35654, DOI 10.1074/jbc.M110.128959
   Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 69
TC 52
Z9 61
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD APR 14
PY 2016
VL 8
AR 38
DI 10.1186/s13148-016-0205-6
PG 16
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DK1KW
UT WOS:000374672100001
PM 27081402
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wang, K
   Yang, FQ
   Men, XJ
   Li, GQ
   Sun, CT
AF Wang, Kai
   Yang, Fuqian
   Men, Xiaojuan
   Li, Guoqiang
   Sun, Chuntao
TI MiR-138 suppresses EMT through degradation KDM6B in breast carcinoma
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE miR-138; EMT; KDM6B; breast cancer
ID LYSINE 27 TRIMETHYLATION; SMALL RNAS; MICRORNAS; EXPRESSION; BIOGENESIS;
   SIGNATURE; PROMOTES
AB Breast carcinoma has become the fifth mortality rate in world and the most common cancer in women. MicroRNA is a group of non-coding small RNA which approximal 20-24 nt length, it binding target gene 3'-UTR, thereby degradation its target gene mRNA. Now, more and more microRNA was found participate tumor development. Here, we demonstrate that miR-138 was down-regulated in breast carcinoma samples as well as breast cancer cell lines, and the decreased miR-138 was correlated with Lymph Node Metastasis and TNM stage poor prognosis. Furthermore, we found over-expression of miR-138 could inhibit breast cancer cell proliferation and metastasis. Most important was we uncovered the mechanism of MiR-138 in suppresson of Epithelial-to-mesenchymal transition (EMT) and breast cancer cells invasion. Through degradation of KDM6B, therefore down-regulating KDM6B, and inhibited H3K27me3 demethylation, miR-138 could thereby inhibit EMT. In conclusion, we provide a novel epigenetic mechanism regulating tumor cell invasion and EMT, and provide a new biomarker for breast diagnosis and prognosis.
C1 [Wang, Kai; Yang, Fuqian; Men, Xiaojuan] Weifang City Peoples Hosp, Breast Surg, Weifang 261041, Shandong, Peoples R China.
   [Sun, Chuntao] Weifang City Peoples Hosp, Dept Intervent Radiol, Weifang 261041, Shandong, Peoples R China.
   [Li, Guoqiang] Shengli Oilfield Cent Hosp, Dongying 257034, Shandong, Peoples R China.
RP Sun, CT (通讯作者)，Weifang City Peoples Hosp, Dept Intervent Radiol, Weifang 261041, Shandong, Peoples R China.
EM sunchuntao1980@163.com
RI Wang, Kai/IWD-8760-2023
OI Wang, Kai/0000-0002-6170-4744
FU Wu Jieping medical foundation [320.6750.13237]
FX Wu Jieping medical foundation: (project number: 320.6750.13237).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Behm-Ansmant I, 2006, COLD SPRING HARB SYM, V71, P523, DOI 10.1101/sqb.2006.71.013
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014
   Díaz VM, 2014, CELL ADHES MIGR, V8, P418, DOI 10.4161/19336918.2014.969998
   Giovannetti E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049145
   Han LP, 2015, TUMOUR BIOL
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Kim VN, 2005, MOL CELLS, V19, P1
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Liu XW, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-57
   Muñoz-Rodríguez JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124340
   Pan HW, 2013, CURR PHARM DESIGN, V19, P1273
   Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Shen J, 2013, CANCER LETT, V329, P125, DOI 10.1016/j.canlet.2012.11.001
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang B, 2015, J DERMATOL SCI, V78, P161, DOI 10.1016/j.jdermsci.2015.02.019
   Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110
   Xi Jianzhong Jeff, 2013, Cancer Treat Res, V158, P119, DOI 10.1007/978-3-642-31659-3_5
   Yang T, 2015, TUMOR BIOL, V36, P8185, DOI 10.1007/s13277-015-3498-8
   Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121
NR 27
TC 0
Z9 0
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 2
BP 4719
EP 4728
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DK1EL
UT WOS:000374655200529
DA 2025-01-12
ER

PT J
AU Lin, MX
   Shi, CM
   Lin, XY
   Pan, J
   Shen, SF
   Xu, ZB
   Chen, Q
AF Lin, Mengxin
   Shi, Chunmei
   Lin, Xiaoyan
   Pan, Jie
   Shen, Songfei
   Xu, Zongbin
   Chen, Qiang
TI sMicroRNA-1290 inhibits cells proliferation and migration by targeting
   <i>FOXA1</i> in gastric cancer cells
SO GENE
LA English
DT Article
DE Gastric cancer; miR-1290; Proliferation; Migration; Apoptosis; FOXA1
ID BREAST-CANCER; EXPRESSION
AB Background/Aims: Gastric cancer is the third leading cause of cancer-related deaths in the world with high mortality rate due to the lack of markers in early detection and effective therapies. MicroRNAs (miRNAs), a critical part of epigenetic regulations in tumor, have been shown to be closely related to the initiation, development, invasion, metastasis and prognosis of gastric cancer. The present study aims to investigate the expression of miR-1290 in gastric tumor cells and to elucidate the target gene of miR-1290 in SGC-7901 gastric cancer cells.
   Methodology: The fluorescence in situ hybridization, real time PCR and Western blot were used to investigate the expression of miR-1290 in gastric tumor cells and clinical gastric tumor samples. The effect of miR-1290 expression on gastric tumor cells was studied using Synthetic miR-1290 inhibitor transfection, in vitro wound healing assay and flow cytometry analysis. Bioinformatics and Luciferase reporter assay were used to predict and validate the target gene of miR-1290.
   Results: Our results revealed that miR-1290 was highly expressed in SGC-7901 gastric cancer cells as well as in clinical gastric cancer samples, which was correlated with clinical stages, depth of invasion and lymph node metastasis. Synthetic miR-1290 inhibitor transfection significantly inhibited the proliferation and migration of SGC-7901 cells. Bioinformatics analysis and luciferase reporter assay suggested that miR-1290 functioned in gastric cancer cells by targeting FOXA1 gene.
   Conclusion: miR-1290 promotes gastric tumor cells proliferation and metastasis through FOXA1, which could be used as a marker for diagnosis and a target for therapeutic intervention. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Lin, Mengxin; Shi, Chunmei; Lin, Xiaoyan; Shen, Songfei; Chen, Qiang] Fujian Med Univ, Union Hosp, Dept Oncol, Fuzhou 350001, Fujian Province, Peoples R China.
   [Pan, Jie; Xu, Zongbin] Fujian Med Univ, Union Hosp, Dept Gen Surg, Fuzhou 350001, Fujian Province, Peoples R China.
C3 Fujian Medical University; Fujian Medical University
RP Chen, Q (通讯作者)，Fujian Med Univ, Union Hosp, 29 Xinquan Rd, Fuzhou 350001, Fujian Province, Peoples R China.
EM qiang_c@yeah.net
RI chen, qiang/GWZ-7308-2022
FU  [2013YZ0002]
FX This work was supported by Gene profiling of gastric cancer and its
   potential in individualized diagnosis and treatment (grant number:
   2013YZ0002).
CR Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327
   [Anonymous], 2015, UROL ONCOL
   Belian E, 2010, ANTICANCER RES, V30, P629
   Biffi R, 2011, EJSO-EUR J SURG ONC, V37, P305, DOI 10.1016/j.ejso.2011.01.013
   Catalano V, 2009, CRIT REV ONCOL HEMAT, V71, P127, DOI 10.1016/j.critrevonc.2009.01.004
   Chen L, 2014, SCI REP-UK, V4, DOI 10.1038/srep03819
   Duan L, 2014, MOL BIOSYST, V10, P2775, DOI 10.1039/c4mb00338a
   Endo Y, 2013, ENDOCR-RELAT CANCER, V20, P91, DOI 10.1530/ERC-12-0207
   Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Jain RK, 2011, HISTOPATHOLOGY, V58, P766, DOI 10.1111/j.1365-2559.2011.03796.x
   Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11
   Li M, 2015, WORLD J GASTROENTERO, V21, P3245, DOI 10.3748/wjg.v21.i11.3245
   Nobutake Y., 2009, CLIN CANCER RES, V15, P4009
   Okamura K, 2007, CELL, V130, P89, DOI 10.1016/j.cell.2007.06.028
   Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106
   Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979
   WHO, 2014, STOM CANC EST INC MO
   Wu J, 2013, CANCER LETT, V329, P155, DOI 10.1016/j.canlet.2012.10.038
   Yelamanchili SV, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.498
   Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040797
   Zhu Y., 2012, PLOS ONE, V7, P20
NR 23
TC 39
Z9 43
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 15
PY 2016
VL 582
IS 2
BP 137
EP 142
DI 10.1016/j.gene.2016.02.001
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DH4MY
UT WOS:000372761300005
PM 26851540
DA 2025-01-12
ER

PT J
AU Merino, VF
   Nguyen, N
   Jin, K
   Sadik, H
   Cho, SW
   Korangath, P
   Han, LF
   Foster, YMN
   Zhou, XC
   Zhang, Z
   Connolly, RM
   Stearns, V
   Ali, SZ
   Adams, C
   Chen, Q
   Pan, DJ
   Huso, DL
   Ordentlich, P
   Brodie, A
   Sukumar, S
AF Merino, Vanessa F.
   Nguyen, Nguyen
   Jin, Kideok
   Sadik, Helen
   Cho, Soonweng
   Korangath, Preethi
   Han, Liangfeng
   Foster, Yolanda M. N.
   Zhou, Xian C.
   Zhang, Zhe
   Connolly, Roisin M.
   Stearns, Vered
   Ali, Syed Z.
   Adams, Christina
   Chen, Qian
   Pan, Duojia
   Huso, David L.
   Ordentlich, Peter
   Brodie, Angela
   Sukumar, Saraswati
TI Combined Treatment with Epigenetic, Differentiating, and
   Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in
   Triple-Negative Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID RECEPTORS; STEM-CELLS;
   CARCINOMA-CELLS; PHASE-I; GENE-EXPRESSION; SOLID TUMORS; IDENTIFICATION;
   INFLAMMATION; REACTIVATION
AB Efforts to induce the differentiation of cancer stem cells through treatment with all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silencing of the retinoic acid receptor (RAR)-beta. The histone deacetylase inhibitor entinostat is emerging as a promising antitumor agent when added to the standard-of-care treatment for breast cancer. However, the combination of epigenetic, cellular differentiation, and chemotherapeutic approaches against triple-negative breast cancer (TNBC) has not been investigated. In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-beta expression. Entinostat and doxorubicin treatment inhibited topoisomerase II-beta (TopoII-beta) and relieved TopoII-beta-mediated transcriptional silencing of RAR-beta. Notably, EAD was the most effective combination in inducing differentiation of breast tumor-initiating cells in vivo. Furthermore, gene expression analysis revealed that the epithelium-specific ETS transcription factor-1 (ESE-1 or ELF3), known to regulate proliferation and differentiation, enhanced cell differentiation in response to EAD triple therapy. Finally, we demonstrate that patient-derived metastatic cells also responded to treatment with EAD. Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC.
C1 [Merino, Vanessa F.; Nguyen, Nguyen; Jin, Kideok; Sadik, Helen; Cho, Soonweng; Korangath, Preethi; Han, Liangfeng; Foster, Yolanda M. N.; Zhou, Xian C.; Zhang, Zhe; Connolly, Roisin M.; Stearns, Vered; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Ali, Syed Z.; Adams, Christina] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA.
   [Chen, Qian; Pan, Duojia] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   [Huso, David L.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
   [Ordentlich, Peter] Syndax Pharmaceut, Dept Translat Med, Waltham, MA USA.
   [Brodie, Angela] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; University System of Maryland;
   University of Maryland Baltimore
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, 1650 Orleans St,CRB1 Room 143, Baltimore, MD 21231 USA.
EM vmerino1@jhmi.edu
OI Cho, Soonweng/0000-0002-1637-2875; Korangath,
   Preethi/0000-0002-6623-493X
FU NCI NIH HHS [P30 CA006973] Funding Source: Medline; NIGMS NIH HHS [T32
   GM008752] Funding Source: Medline
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bhat-Nakshatri P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02530
   Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405
   Chen MC, 2011, HEPATOLOGY, V53, P148, DOI 10.1002/hep.23964
   Chen YH, 2006, CANCER RES, V66, P8749, DOI 10.1158/0008-5472.CAN-06-0581
   Cheong HS, 2010, BMB REP, V43, P830, DOI 10.5483/BMBRep.2010.43.12.830
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Connolly RM, 2013, CLIN CANCER RES, V19, P1651, DOI 10.1158/1078-0432.CCR-12-3175
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Davis SL, 2014, THER ADV MED ONCOL, V6, P88, DOI 10.1177/1758834013519843
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761
   Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643
   Kim MS, 2003, CANCER RES, V63, P7291
   Kumar S, 2011, CELL, V147, P1422, DOI 10.1016/j.cell.2011.11.034
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liu T, 2005, BRIT J CANCER, V93, P310, DOI 10.1038/sj.bjc.6602700
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McNamara S, 2008, MOL CELL BIOL, V28, P2066, DOI 10.1128/MCB.01576-07
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   Nacht M, 1999, CANCER RES, V59, P5464
   Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186
   Papi A, 2012, CELL DEATH DIFFER, V19, P1208, DOI 10.1038/cdd.2011.207
   Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wu J, 2008, CELL RES, V18, P649, DOI 10.1038/cr.2008.57
NR 36
TC 36
Z9 39
U1 2
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2016
VL 76
IS 7
BP 2013
EP 2024
DI 10.1158/0008-5472.CAN-15-1619
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DJ4IW
UT WOS:000374169600035
PM 26787836
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Bakshi, A
   Herke, SW
   Batzer, MA
   Kim, J
AF Bakshi, Arundhati
   Herke, Scott W.
   Batzer, Mark A.
   Kim, Joomyeong
TI DNA methylation variation of human-specific Alu repeats
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; epigenetic biomarkers; epigenomes; retrotransposons;
   SINE
ID BIQ ANALYZER; RETROTRANSPOSONS; EXPRESSION; ELEMENTS; CELLS; GENE;
   HYPOMETHYLATION; SUBFAMILIES; LANDSCAPE; PROMOTER
AB DNA methylation is the major repression mechanism for human retrotransposons, such as the Alu family. Here, we have determined the methylation levels associated with 5238 loci belonging to 2 Alu subfamilies, AluYa5 and AluYb8, using high-throughput targeted repeat element bisulfite sequencing (HT-TREBS). The results indicate that approximate to 90% of loci are repressed by high methylation levels. Of the remaining loci, many of the hypomethylated elements are found near gene promoters and show high levels of DNA methylation variation. We have characterized this variation in the context of tumorigenesis and interindividual differences. Comparison of a primary breast tumor and its matched normal tissue revealed early DNA methylation changes in approximate to 1% of AluYb8 elements in response to tumorigenesis. Simultaneously, AluYa5/Yb8 elements proximal to promoters also showed differences in methylation of up to one order of magnitude, even between normal individuals. Overall, the current study demonstrates that early loss of methylation occurs during tumorigenesis in a subset of young Alu elements, suggesting their potential clinical relevance. However, approaches such as deep-bisulfite-sequencing of individual loci using HT-TREBS are required to distinguish clinically relevant loci from the background observed for AluYa5/Yb8 elements in general with regard to high levels of interindividual variation in DNA methylation.
C1 [Bakshi, Arundhati; Herke, Scott W.; Batzer, Mark A.; Kim, Joomyeong] Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.
C3 Louisiana State University System; Louisiana State University
RP Kim, J (通讯作者)，Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.
EM jkim@lsu.edu
FU National Institutes of Health [R01 GM066225, R01 GM097074, R01 GM59290]
FX We would like to thank Dr. Muhammad Ekram for initial help in library
   construction and bioinformatics. We also thank Jerilyn Walker, Dr. Hana
   Kim, B. Pinithi Perera, Corey Bretz and Terri Cain for their careful
   reading and discussion of the manuscript. This research was supported by
   the National Institutes of Health R01 GM066225 (J.K.), R01 GM097074
   (J.K.) and R01 GM59290 (M.A.B.).
CR Akers SN, 2014, GYNECOL ONCOL, V132, P462, DOI 10.1016/j.ygyno.2013.12.024
   Bae JM, 2012, INT J CANCER, V131, P1323, DOI 10.1002/ijc.27369
   Bakshi A, 2015, GENOM DATA, V3, P87, DOI 10.1016/j.gdata.2014.11.013
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Bennett EA, 2008, GENOME RES, V18, P1875, DOI 10.1101/gr.081737.108
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Blomquist TM, 2013, GENE REGUL SYST BIO, V7, P125, DOI 10.4137/GRSB.S11879
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bollati V, 2009, CARCINOGENESIS, V30, P1330, DOI 10.1093/carcin/bgp149
   Carroll ML, 2001, J MOL BIOL, V311, P17, DOI 10.1006/jmbi.2001.4847
   CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750
   Cordaux R, 2004, TRENDS GENET, V20, P464, DOI 10.1016/j.tig.2004.07.012
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   Crawford EL, 2007, CARCINOGENESIS, V28, P2552, DOI 10.1093/carcin/bgm214
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236
   Dewannieux M, 2005, GENOMICS, V86, P378, DOI 10.1016/j.ygeno.2005.05.009
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ekram MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101683
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Han KD, 2005, GENOME RES, V15, P655, DOI 10.1101/gr.3492605
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523
   Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Khakpour G, 2015, TUMOR BIOL, V36, P4905, DOI 10.1007/s13277-015-3567-z
   KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106290
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087
   Lutsik P, 2011, NUCLEIC ACIDS RES, V39, pW551, DOI 10.1093/nar/gkr312
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245
   Molaro A, 2011, CELL, V146, P1028, DOI 10.1016/j.cell.2011.08.016
   Park SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100429
   Peixoto A, 2013, J HUM GENET, V58, P78, DOI 10.1038/jhg.2012.137
   Rhee YY, 2015, VIRCHOWS ARCH, V466, P675, DOI 10.1007/s00428-015-1749-0
   Rodriguez J, 2008, NUCLEIC ACIDS RES, V36, P770, DOI 10.1093/nar/gkm1105
   Roy-Engel AM, 2002, GENOME RES, V12, P1333, DOI 10.1101/gr.384802
   RUBIN CM, 1994, NUCLEIC ACIDS RES, V22, P5121, DOI 10.1093/nar/22.23.5121
   SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613
   SHEN MR, 1991, J MOL EVOL, V33, P311
   Teugels E, 2005, HUM MUTAT, V26, DOI 10.1002/humu.9366
   Ueki T, 2009, CANCER RES, V69, P8752, DOI 10.1158/0008-5472.CAN-09-1809
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Xie HH, 2009, NUCLEIC ACIDS RES, V37, P4331, DOI 10.1093/nar/gkp393
   Xing J, 2004, J MOL BIOL, V344, P675, DOI 10.1016/j.jmb.2004.09.058
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 54
TC 28
Z9 34
U1 1
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2016
VL 11
IS 2
BP 163
EP 173
DI 10.1080/15592294.2015.1130518
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DJ0WP
UT WOS:000373925400007
PM 26890526
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Jiang, F
   Li, Y
   Mu, J
   Hu, CY
   Zhou, M
   Wang, XX
   Si, L
   Ning, SL
   Li, Z
AF Jiang, Fei
   Li, Yuan
   Mu, Juan
   Hu, Chunyan
   Zhou, Ming
   Wang, Xingxing
   Si, Lu
   Ning, Shilong
   Li, Zhong
TI Glabridin inhibits cancer stem cell-like properties of human breast
   cancer cells: An epigenetic regulation of miR-148a/SMAd2 signaling
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE cancer stem cell-like properties; glabridin; transforming growth factor
   beta-SMADs signal pathway; microRNA-148a; epigenetic regulation
ID EPITHELIAL-MESENCHYMAL TRANSITION; LICORICE ROOT; TUMOR-GROWTH;
   METASTASIS; ANGIOGENESIS; EXPRESSION; ISOFLAVAN; RECEPTOR; MARKERS; MICE
AB In breast cancer, the cancer stem cells (CSCs) are thought to be the main cause of metastasis and recurrence. Targeting of CSCs or cancer cells with stem cell-like properties has become a new approach for the treatment of breast cancer. Glabridin (GLA), a phytochemical from the root of Glycyrrhiza glabra, exhibited effective antitumor properties in various human cancer cells. However, the roles of GLA in the regulation of CSC-like properties and the underlying molecular mechanisms remain unclear. Here, we reported that GLA attenuated the CSC-like properties through microRNA-148a (miR-148a)/transforming growth factor beta (TGF)-SMAD2 signal pathway in vitro and in vivo. In MDA-MB-231 and Hs-578T breast cancer cell lines, GLA enhanced the expression of miR-148a through DNA demethylation. By targeting of the SMAD2-3-UTR, miR-148a blocked the expression/activation of SMAD2, and in turn, restored the epithelial characteristics, adhesive abilities, and CSC-like properties. Furthermore, in mouse xenograft models, we also confirmed that GLA attenuated the tumor growth, mesenchymal characteristics, and CSCs-like properties via demethylation-activated miR-148a. Our findings suggested a potential treatment strategy to reduce the CSCs-like properties, and therefore enhance the effectiveness of breast cancer therapy. (c) 2015 Wiley Periodicals, Inc.
C1 [Jiang, Fei; Li, Yuan; Mu, Juan; Hu, Chunyan; Zhou, Ming; Wang, Xingxing; Si, Lu; Ning, Shilong; Li, Zhong] Nanjing Med Univ, Minist Educ, Sch Publ Hlth, Key Lab Modern Toxicol,Dept Nutr & Food Hyg, Nanjing 211166, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Li, Z (通讯作者)，Nanjing Med Univ, Minist Educ, Sch Publ Hlth, Key Lab Modern Toxicol,Dept Nutr & Food Hyg, Nanjing 211166, Jiangsu, Peoples R China.
RI xu, zhipeng/M-7708-2019; Zhou, Ming/AAL-3456-2020
FU National Natural Science Foundation of China [81171987, 81402667];
   Doctoral Program of Higher Education of China [20133234110007]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 81171987; 81402667; Grant sponsor: Doctoral Program of Higher
   Education of China; Grant number: 20133234110007
CR Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333
   Atkinson RL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3471
   Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782
   Bambang IF, 2013, ONCOGENE, V32, P1240, DOI 10.1038/onc.2012.149
   Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Bueno L, 2008, EUR J CANCER, V44, P142, DOI 10.1016/j.ejca.2007.10.008
   Cohen MM, 2003, AM J MED GENET A, V116A, P1, DOI 10.1002/ajmg.a.10750
   Dontu G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2130
   Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a
   Fukai T, 2003, FITOTERAPIA, V74, P624, DOI 10.1016/S0367-326X(03)00164-3
   Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709
   Hsu YL, 2011, MOL NUTR FOOD RES, V55, P318, DOI 10.1002/mnfr.201000148
   Jiang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096698
   Jiang RR, 2013, ARCH TOXICOL, V87, P991, DOI 10.1007/s00204-012-0933-0
   Kang JS, 2005, J PHARMACOL EXP THER, V312, P1187, DOI 10.1124/jpet.104.077107
   Kwon HS, 2008, CLIN EXP IMMUNOL, V151, P165, DOI 10.1111/j.1365-2249.2007.03539.x
   Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815
   Nabekura T, 2008, CANCER CHEMOTH PHARM, V62, P867, DOI 10.1007/s00280-007-0676-4
   Takagi S, 2008, J BIOL CHEM, V283, P9674, DOI 10.1074/jbc.M709382200
   Tamir S, 2000, CANCER RES, V60, P5704
   Tsai YM, 2011, INTEGR CANCER THER, V10, P341, DOI 10.1177/1534735410384860
   Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96
   Wicha MS, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1990
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Yan H, 2014, MOL CARCINOGEN, V53, P960, DOI 10.1002/mc.22064
   Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5
   Yu XQ, 2008, LIFE SCI, V82, P68, DOI 10.1016/j.lfs.2007.10.019
   Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28
   Zhong ZJ, 2010, CLIN CANCER RES, V16, P1191, DOI 10.1158/1078-0432.CCR-09-1634
NR 32
TC 66
Z9 69
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAY
PY 2016
VL 55
IS 5
BP 929
EP 940
DI 10.1002/mc.22333
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA DJ3IA
UT WOS:000374096800042
PM 25980823
DA 2025-01-12
ER

PT J
AU Griseri, P
   Garrone, O
   Lo Sardo, A
   Monteverde, M
   Rusmini, M
   Tonissi, F
   Merlano, M
   Bruzzi, P
   Lo Nigro, C
   Ceccherini, I
AF Griseri, Paola
   Garrone, Ornella
   Lo Sardo, Alessandra
   Monteverde, Martino
   Rusmini, Marta
   Tonissi, Federica
   Merlano, Marco
   Bruzzi, Paolo
   Lo Nigro, Cristiana
   Ceccherini, Isabella
TI Genetic and epigenetic factors affect RET gene expression in breast
   cancer cell lines and influence survival in patients
SO ONCOTARGET
LA English
DT Article
DE RET gene; breast cancer; single nucleotide polymorphism; gene
   expression; resistance to hormonal therapy
ID HIRSCHSPRUNG-DISEASE; ENDOCRINE RESISTANCE; ALPHA; COMMON;
   PROTOONCOGENE; ANTIESTROGEN; INHIBITION; COMBINATION; MODULATION;
   ACTIVATION
AB Germline and somatic mutations play a crucial role in breast cancer (BC), driving the initiation, progression, response to therapy and outcome of the disease. Hormonal therapy is limited to patients with tumors expressing steroid hormone receptors, such as estrogen receptor (ER), nevertheless resistance often limits its success.
   The RET gene is known to be involved in neurocristopathies such as Hirschsprung disease and Multiple Endocrine Neoplasia type 2, in the presence of loss-of-function and gain-of-function mutations, respectively. More recently, RET over-expression has emerged as a new player in ER-positive (ER+) BC, and as a potential target to enhance sensitivity and avoid resistance to tamoxifen therapy.
   Therefore, targeting the RET pathway may lead to new therapies in ER+ BC. To this end, we have investigated the molecular mechanisms which underlie RET overexpression and its possible modulation in two BC cell lines, MCF7 and T47D, showing different RET expression levels. Moreover, we have carried out a pilot association study in 93 ER+ BC patients. Consistent with the adverse role of RET overexpression in BC, increased overall survival was observed in carriers of the variant allele of SNP rs2435357, a RET polymorphism already known to be associated with reduced RET expression.
C1 [Griseri, Paola; Lo Sardo, Alessandra; Rusmini, Marta; Ceccherini, Isabella] IRCCS Giannina Gaslini Inst, UOC Med Genet, Genoa, Italy.
   [Garrone, Ornella; Merlano, Marco] S Croce & Carle Teaching Hosp, Dept Oncol, Unit Med Oncol, Cuneo, Italy.
   [Monteverde, Martino; Tonissi, Federica; Lo Nigro, Cristiana] S Croce & Carle Teaching Hosp, Dept Oncol, Lab Canc Genet & Translat Oncol, Cuneo, Italy.
   [Bruzzi, Paolo] IRCCS AUO San Martino IST, Clin Epidemiol, Genoa, Italy.
C3 University of Genoa; IRCCS Istituto Giannina Gaslini; University of
   Genoa; IRCCS AOU San Martino IST
RP Ceccherini, I (通讯作者)，IRCCS Giannina Gaslini Inst, UOC Med Genet, Genoa, Italy.
EM isa.c@unige.it
RI griseri, paola/AAJ-4823-2020; Garrone, Ornella/HHS-9402-2022; Bruzzi,
   Paolo/AAU-3363-2021; merlano, marco/HHS-9397-2022; rusmini,
   marta/K-7042-2016; Ceccherini, Isabella/P-8195-2014
OI rusmini, marta/0000-0002-3109-413X; Bruzzi, Paolo/0000-0002-7874-2077;
   Garrone, Ornella/0000-0001-7359-5410; Lo Nigro,
   Cristiana/0000-0002-3615-2431; Ceccherini, Isabella/0000-0001-8732-1955
FU Fondazione Umberto Veronesi; Italian Association for Cancer Research
   [GI-13217]; Italian Ministry of Health ("Cinque per mille"); Italian
   Ministry of Health ("Ricerca Corrente")
FX We would like to thank Luca Boni (Istituto Toscano Tumori, ITT) for his
   assistance and suggestions with statistical matters during the revision.
   This work has been performed thanks to the following supports: Young
   Investigator Fellowship awarded by the Fondazione Umberto Veronesi to
   PG, Italian Association for Cancer Research (GI-13217 to IC), Italian
   Ministry of Health ("Cinque per mille" and "Ricerca Corrente" to the
   Gaslini Institute).
CR Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754
   Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721
   Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010
   Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005
   Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102
   Borun P, 2012, HERED CANCER CLIN PR, V10, DOI 10.1186/1897-4287-10-14
   Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100
   Brufsky AM, 2014, AM J CLIN ONCOL-CANC, V37, P404, DOI 10.1097/COC.0000000000000086
   Byler S, 2014, ANTICANCER RES, V34, P1071
   de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001
   Emison ES, 2010, AM J HUM GENET, V87, P60, DOI 10.1016/j.ajhg.2010.06.007
   Emison ES, 2005, NATURE, V434, P857, DOI 10.1038/nature03467
   Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fiorito E, 2013, CHROMOSOMA, V122, P1, DOI 10.1007/s00412-012-0392-7
   Gattelli A, 2013, EMBO MOL MED, V5, P1335, DOI 10.1002/emmm.201302625
   Goncalves R, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0460-4
   Grice EA, 2005, HUM MOL GENET, V14, P3837, DOI 10.1093/hmg/ddi408
   Griseri P, 2005, HUM MUTAT, V25, P189, DOI 10.1002/humu.20135
   Griseri P, 2003, GUT, V52, P1154, DOI 10.1136/gut.52.8.1154
   Griseri P, 2007, HUM MUTAT, V28, P168, DOI 10.1002/humu.20397
   Griseri P, 2011, HUM MOL GENET, V20, P4556, DOI 10.1093/hmg/ddr390
   Hickey JG, 2009, GENE CHROMOSOME CANC, V48, P429, DOI 10.1002/gcc.20653
   Huang B, 2014, MOL CELL ENDOCRINOL, P26
   Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiang Q, 2015, AM J HUM GENET, V96, P581, DOI 10.1016/j.ajhg.2015.02.014
   Jordan VC, 2014, ENDOCR-RELAT CANCER, V21, pR235, DOI 10.1530/ERC-14-0092
   Kang J, 2010, ONCOGENE, V29, P3228, DOI 10.1038/onc.2010.71
   Lantieri F, 2006, ANN HUM GENET, V70, P12, DOI 10.1111/j.1529-8817.2005.00196.x
   Livi L, 2006, BREAST J, V12, P353, DOI 10.1111/j.1075-122X.2006.00275.x
   Maxwell JE, 2014, CANCER-AM CANCER SOC, V120, P3287, DOI 10.1002/cncr.28858
   Milani A, 2014, WORLD J CLIN ONCOL, V5, P990, DOI 10.5306/wjco.v5.i5.990
   Morandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265
   Morandi A, 2011, TRENDS MOL MED, V17, P149, DOI 10.1016/j.molmed.2010.12.007
   Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Patel A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002734
   Plaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209
   Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018
   Rusmini M, 2014, J CELL PHYSIOL, V229, P2027, DOI 10.1002/jcp.24660
   Rusmini M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059066
   Scott RP, 2005, J BIOL CHEM, V280, P13442, DOI 10.1074/jbc.M500507200
   Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030
   Shiovitz S, 2015, ANN ONCOL, V26, P1291, DOI 10.1093/annonc/mdv022
   Spanheimer PM, 2014, CLIN CANCER RES, V20, P2115, DOI 10.1158/1078-0432.CCR-13-2221
   Spanheimer PM, 2013, ANN SURG ONCOL, V20, P2204, DOI 10.1245/s10434-012-2570-5
   Stine ZE, 2011, HUM MOL GENET, V20, P3746, DOI 10.1093/hmg/ddr291
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Tao Z, 2014, CELL BIOCH BIOPHYS, P28
   Thomas S, 2009, CANCER LETT, V280, P184, DOI 10.1016/j.canlet.2008.12.026
   Tozlu S, 2006, ENDOCR-RELAT CANCER, V13, P1109, DOI 10.1677/erc.1.01120
   Travaglini L, 2009, INT J BIOCHEM CELL B, V41, P225, DOI 10.1016/j.biocel.2008.08.019
   van der Groep P, 2011, CELL ONCOL, V34, P71, DOI 10.1007/s13402-011-0010-3
   Veiga-Fernandes H, 2007, NATURE, V446, P547, DOI 10.1038/nature05597
   Wang CY, 2012, BREAST CANCER RES TR, V133, P487, DOI 10.1007/s10549-011-1775-9
   Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539
   Yang XW, 2001, CANCER RES, V61, P7025
   Yi X, 2008, BIOCHEM PHARMACOL, V75, P1697, DOI 10.1016/j.bcp.2007.10.035
NR 59
TC 24
Z9 26
U1 1
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 3
PY 2016
VL 7
IS 18
BP 26465
EP 26479
DI 10.18632/oncotarget.8417
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO3ZW
UT WOS:000377722300117
PM 27034161
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Rasmussen, RD
   Gajjar, MK
   Jensen, KE
   Hamerlik, P
AF Rasmussen, Rikke D.
   Gajjar, Madhavsai K.
   Jensen, Kamilla E.
   Hamerlik, Petra
TI Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Glioblastoma; Genotoxic stress; DNA repair; SAHA; Olaparib
ID SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITORS;
   BREAST-CANCER CELLS; HUMAN GLIOMA-CELLS; DNA-DAMAGE; POLY(ADP-RIBOSE)
   POLYMERASE; INDIVIDUAL CELLS; OVARIAN-CANCER; STEM-CELLS; IN-VITRO
AB Recent clinical trials have demonstrated that targeting chromatin remodeling factors is as a promising strategy for the treatment of glioblastoma (GBM). We and others have shown constitutive activation of DNA damage response (DDR) pathways in gliomas and suggested that targeting the DDR may improve the currently grim prognosis for patients. Based on our previous findings that inhibition of poly(ADP-ribose) polymerase (PARP) increases radio sensitivity of the notoriously radio-resistant GBM cells, we hypothesized that epigenetic down-regulation of the DDR responses and induction of oxidative stress via HDAC inhibition would contribute to more efficient targeting of this deadly disease. Our data show that SAHA, an HDAC class I + II inhibitor, in combination with olaparib (PARP inhibitor): i) enhanced inhibition of GBM cell survival, ii) induced apoptosis, and iii) impaired cell cycle progression. These results provide a pre-clinical rationale for combined administration of SAHA and olaparib, which are already individually in clinical trials. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Rasmussen, Rikke D.; Gajjar, Madhavsai K.; Jensen, Kamilla E.; Hamerlik, Petra] Danish Canc Soc, Res Ctr, Brain Tumor Biol Grp, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Hamerlik, Petra] Copenhagen Univ Hosp, Finsen Ctr, Dept Radiat Biol, DK-2100 Copenhagen, Denmark.
C3 Danish Cancer Society; University of Copenhagen
RP Hamerlik, P (通讯作者)，Danish Canc Soc, Res Ctr, Brain Tumor Biol Grp, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
EM pkn@cancer.dk
RI Bartek, Jiri/G-5870-2014; Hamerlik, Petra/G-7398-2016
OI Hamerlik, Petra/0000-0002-5856-0161
FU Danish Cancer Society Research Center; Dansk Kraeftforsknings Fond
   [53236016]
FX This work was supported by the Danish Cancer Society Research Center and
   Dansk Kraeftforsknings Fond (53236016). We would like to thank our
   postdoctoral fellow Marina Cihova for assistance with Traffic Light
   Reporter System, Dr. Monica Venere (Ohio State University, USA) for
   proofreading the manuscript and Ib Jarle Christensen (Copenhagen
   University Hospital, Denmark) with the statistical analysis of our data.
CR Auffinger B, 2015, EXPERT REV NEUROTHER, V15, P741, DOI 10.1586/14737175.2015.1051968
   Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249
   Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x
   Certo MT, 2011, NAT METHODS, V8, P671, DOI [10.1038/NMETH.1648, 10.1038/nmeth.1648]
   Chamberlain MC, 2011, J NEURO-ONCOL, V101, P319, DOI 10.1007/s11060-010-0251-4
   Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009
   Cornago M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.412
   Dungey FA, 2008, INT J RADIAT ONCOL, V72, P1188, DOI 10.1016/j.ijrobp.2008.07.031
   Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201
   Eyüpoglu IY, 2005, J NEUROCHEM, V93, P992, DOI 10.1111/j.1471-4159.2005.03098.x
   Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694
   Gräff J, 2012, NATURE, V483, P222, DOI 10.1038/nature10849
   Groth A, 2007, SCIENCE, V318, P1928, DOI 10.1126/science.1148992
   Ha K, 2014, ONCOTARGET, V5, P5637, DOI 10.18632/oncotarget.2154
   Hanson JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069964
   Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100
   Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165
   Jain S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-24
   Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208
   Komatsu N, 2006, ONCOL REP, V15, P187
   Konstantinopoulos PA, 2014, GYNECOL ONCOL, V133, P599, DOI 10.1016/j.ygyno.2014.03.007
   Krajewska M, 2015, ONCOGENE, V34, P3474, DOI 10.1038/onc.2014.276
   Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545
   Lucio-Eterovic AK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-243
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L
   Park JH, 2008, BIOCHEM BIOPH RES CO, V368, P318, DOI 10.1016/j.bbrc.2008.01.056
   Petruccelli LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020987
   Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659
   Rigakos G, 2012, ONCOLOGIST, V17, P956, DOI 10.1634/theoncologist.2012-0028
   Rivera M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.75
   Singh MM, 2015, NEURO-ONCOLOGY, V17, P1463, DOI 10.1093/neuonc/nov041
   Singh MM, 2011, NEURO-ONCOLOGY, V13, P894, DOI 10.1093/neuonc/nor049
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tanaka S, 2013, NAT REV CLIN ONCOL, V10, P14, DOI 10.1038/nrclinonc.2012.204
   Tu WZ, 2013, FEBS LETT, V587, P3437, DOI 10.1016/j.febslet.2013.08.028
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Venere M, 2014, CELL DEATH DIFFER, V21, P258, DOI 10.1038/cdd.2013.136
   Wu JX, 2010, PROTEIN CELL, V1, P117, DOI 10.1007/s13238-010-0010-5
   Xu JH, 2011, J NEURO-ONCOL, V105, P241, DOI 10.1007/s11060-011-0604-7
   Yin D, 2007, CLIN CANCER RES, V13, P1045, DOI 10.1158/1078-0432.CCR-06-1261
NR 44
TC 56
Z9 62
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD MAY
PY 2016
VL 10
IS 5
BP 751
EP 763
DI 10.1016/j.molonc.2015.12.014
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DN8EA
UT WOS:000377310800009
PM 26794465
OA Green Published
DA 2025-01-12
ER

PT J
AU Tang, XF
   Tang, JJ
   Liu, X
   Zeng, L
   Cheng, C
   Lu, YQ
   Li, LP
   Qin, SL
   Sang, Y
   Deng, LM
   Lv, XB
AF Tang, Xiaofeng
   Tang, Jianjun
   Liu, Xia
   Zeng, Lei
   Cheng, Chun
   Lu, Yanqin
   Li, Liping
   Qin, Shu-Lan
   Sang, Yi
   Deng, Liang-Ming
   Lv, Xiao-Bin
TI Downregulation of miR-129-2 by promoter hypermethylation regulates
   breast cancer cell proliferation and apoptosis
SO ONCOLOGY REPORTS
LA English
DT Article
DE miR-129-2; methylation; BCL2L2; breast cancer; apoptosis; proliferation
ID MICRORNA EXPRESSION PROFILE; MESENCHYMAL TRANSITION; EPIGENETIC
   REGULATION; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; DNA METHYLATION; BIRC6;
   METASTASIS; STATISTICS; MIGRATION
AB Aberrant expression of the miR-129 family has been found in several types of cancer, yet its expression and potential biologic role in breast cancer remain largely unknown. In the present study, we found that miR-129-2 was consistently downregulated in the breast cancer specimens and cell lines. Overexpression of miR-129-2-3p markedly suppressed breast cancer cell proliferation and induced its apoptosis. In addition, a luciferase reporter assay revealed that miR-129-2-3p suppressed BCL2L2 expression. Furthermore, BCL2L2 was able to reverse miR-129-2-3p-mediated cell apoptosis, indicating that BCL2L2 plays a crucial role in mediating the tumor-suppressive role of miR-129-2-3p. Moreover, bisulfite DNA sequencing PCR (BSP) analysis identified that promoter hypermethylation was responsible for the downregulation of miR-129-2 in breast cancer. Collectively, our findings indicate that miR-129-2 is downregulated in breast cancer cells by promoter hypermethylation. Moreover, downregulation of miR-129-2 results in BCL2L2 overexpression and disease progression in breast cancer patients.
C1 [Tang, Xiaofeng; Cheng, Chun; Lu, Yanqin; Li, Liping; Qin, Shu-Lan; Sang, Yi; Lv, Xiao-Bin] Nanchang Univ, Affiliated Hosp 3, Ctr Lab, Nanchang Key Lab Canc Pathogenesis & Translat Res, Nanchang 330008, Jiangxi, Peoples R China.
   [Tang, Jianjun] Jiangxi Canc Hosp, Dept Gastroenterol, Nanchang 330029, Jiangxi, Peoples R China.
   [Zeng, Lei] Jiangxi Canc Hosp, Dept Radiat Oncol, Nanchang 330029, Jiangxi, Peoples R China.
   [Liu, Xia] Guangzhou Med Univ, Guangzhou Municipal Peoples Hosp 1, Dept Oncol, Guangzhou 510180, Guangdong, Peoples R China.
   [Deng, Liang-Ming] Gaoming Heshui Hosp, Dept Med, Foshan 528500, Guangdong, Peoples R China.
C3 Nanchang University; Guangzhou Medical University
RP Lv, XB (通讯作者)，Nanchang Univ, Affiliated Hosp 3, Ctr Lab, Nanchang Key Lab Canc Pathogenesis & Translat Res, Nanchang 330008, Jiangxi, Peoples R China.; Deng, LM (通讯作者)，Gaoming Heshui Hosp, Dept Med, Foshan 528500, Guangdong, Peoples R China.
EM 2806119774@qq.com; promab2006@126.com
RI Lv, Xiao-Bin/T-7607-2019; Li, LiPing/HKE-9058-2023; tang,
   xiaofeng/JUF-8623-2023
OI Sang, Yi/0000-0001-6534-0741
FU Natural Science Foundation of China [81560452, 81102023, 81560403]
FX The present study was supported by grants from the Natural Science
   Foundation of China (81560452 and 81102023 to X.B.L.; 81560403 to J.T.).
CR Bedi U, 2014, ONCOTARGET, V5, P2016, DOI 10.18632/oncotarget.1875
   Chen QW, 2014, ONCOL REP, V31, P523, DOI 10.3892/or.2013.2913
   Cui L, 2013, CANCER-AM CANCER SOC, V119, P1618, DOI 10.1002/cncr.27903
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Diao YR, 2014, J BIOL CHEM, V289, P529, DOI 10.1074/jbc.M113.494716
   Dong YH, 2014, ONCOL LETT, V8, P963, DOI 10.3892/ol.2014.2301
   Dossing KBV, 2015, GENES-BASEL, V6, P1, DOI 10.3390/genes6010001
   Duan LJ, 2014, FEBS LETT, V588, P1644, DOI 10.1016/j.febslet.2014.03.002
   Gong C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6406
   He Y, 2014, LIVER INT, V34, P646, DOI 10.1111/liv.12367
   Hu TT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125281
   Huang ZM, 2009, J DIGEST DIS, V10, P188, DOI 10.1111/j.1751-2980.2009.00384.x
   Kang M, 2013, INT J MOL MED, V32, P51, DOI 10.3892/ijmm.2013.1384
   Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179
   Li HP, 2014, ONCOTARGET, V5, P7610, DOI 10.18632/oncotarget.2282
   Li MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077829
   Lu CY, 2013, GENE CHROMOSOME CANC, V52, P636, DOI 10.1002/gcc.22059
   Lu KP, 2015, ONCOL REP, V34, P995, DOI 10.3892/or.2015.4025
   Luk SUI, 2014, ONCOTARGET, V5, P6896, DOI 10.18632/oncotarget.2229
   Lv XB, 2015, ONCOTARGET, V6, P36370, DOI 10.18632/oncotarget.5639
   Lv XB, 2014, CELL BIOL INT, V38, P435, DOI 10.1002/cbin.10225
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Salilew-Wondim D, 2010, REPROD FERT DEVELOP, V22, P564, DOI 10.1071/RD09112
   Sang Yi, 2015, Asian Pac J Cancer Prev, V16, P1197
   Tan GS, 2015, ONCOTARGET, V6, P8676, DOI 10.18632/oncotarget.3254
   Tang WQ, 2015, INT J CANCER, V136, pE475, DOI 10.1002/ijc.29194
   Tian Xiang-Yang, 2015, Asian Pac J Cancer Prev, V16, P6129
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wu Q, 2014, ONCOTARGET, V5, P11552, DOI 10.18632/oncotarget.2594
   Xiao YY, 2015, J CELL MOL MED, V19, P2172, DOI 10.1111/jcmm.12597
   Yang Y, 2015, MOL CELL BIOCHEM, V404, P229, DOI 10.1007/s11010-015-2382-6
   Yim RL, 2014, ONCOTARGET, V5, P9770, DOI 10.18632/oncotarget.2390
   Yu FY, 2012, J BIOL CHEM, V287, P465, DOI 10.1074/jbc.M111.280768
NR 33
TC 44
Z9 46
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2016
VL 35
IS 5
BP 2963
EP 2969
DI 10.3892/or.2016.4647
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DJ3AS
UT WOS:000374077700053
PM 26935022
OA Bronze
DA 2025-01-12
ER

PT J
AU Tan, WW
   Allred, JB
   Moreno-Aspitia, A
   Northfelt, DW
   Ingle, JN
   Goetz, MP
   Perez, EA
AF Tan, Winston W.
   Allred, Jacob B.
   Moreno-Aspitia, Alvaro
   Northfelt, Donald W.
   Ingle, James N.
   Goetz, Matthew P.
   Perez, Edith A.
TI Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal
   Metastatic Breast Cancer Patients
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Aromatase refractory; Endocrine resistant breast cancer; Histone
   deacetylase inhibitors; Phase I study
ID HISTONE DEACETYLASE INHIBITOR; ESTROGEN-RECEPTOR-ALPHA; CELLS;
   EXPRESSION; RECURRENT; THERAPY; ER
AB Epigenetic changes are important in cancer pathogenesis. In a phase I study of histone deacetylase inhibitor, we tested panobinostat combined with letrozole for safety and efficacy in patients with metastatic breast cancer. Our results have shown this combination is safe. The recommended dose for the phase II study was panobinostat 20 mg orally 3 times each week and oral letrozole 2.5 mg daily.
   Introduction: Histone deacetylase inhibitors have been found to restore sensitivity to the estrogen receptor in endocrine-resistant and triple-negative breast cancer cell lines. We decided to test panobinostat, a pan-histone deacetylase inhibitor, because of preclinical data, combined with letrozole in a phase I study. Patients and Methods: We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors. Dose level 1 was panobinostat 20 mg orally 3 times weekly with oral letrozole 2.5 mg daily. Dose level 2 was panobinostat 30 mg orally 3 times weekly, with the same dose of letrozole. Results: A total of 12 patients (6 at each dose level) were enrolled, and 43 cycles of treatment were given. Of the 6 patients at dose level 1, 1 experienced dose-limiting toxicity (20-mg dose level; an increase in creatinine). At the 30-mg dose level, 3 of 6 patients experienced dose-limiting toxicity, 1 each of grade 3 thrombocytopenia with bleeding, grade 4 thrombocytopenia, and grade 3 diarrhea. The maximum tolerated dose was 20 mg. Of the 12 patients, 2 experienced a partial response, and 5 had stable disease. The most common severe adverse event was thrombocytopenia, occurring in 4 of 12 patients. Conclusion: The recommended phase II starting dose is panobinostat 20 mg orally 3 times weekly (eg, Monday, Wednesday, Friday) and oral letrozole 2.5 mg daily. This dose should be escalated to 30 mg orally 3 times weekly if no grade 3 toxicity has developed, because the partial responses occurred in patients receiving the 30-mg dose. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tan, Winston W.; Moreno-Aspitia, Alvaro; Perez, Edith A.] Mayo Clin, Dept Hematol Oncol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
   [Allred, Jacob B.] Mayo Clin, Dept Biostat, Rochester, MN USA.
   [Northfelt, Donald W.] Mayo Clin, Dept Med Oncol, Scottsdale, AZ USA.
   [Ingle, James N.; Goetz, Matthew P.] Mayo Clin, Dept Med Oncol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic
RP Tan, WW (通讯作者)，Mayo Clin, Dept Hematol Oncol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM tan.winston@mayo.edu
RI Perez, Edith/ACA-8756-2022
OI Harrington, Jon/0000-0003-1293-5201
FU Novartis
FX W.W. Tan is the primary investigator for the North Central Cancer
   Treatment Group N093B phase I/II study of panobinostat (LBH589) and
   letrozole in patients with triple negative metastatic breast cancer
   (ClinicalTrials.gov identifier, NCT01105312). The present study was
   sponsored by Novartis.
CR Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kubo M, 2013, BREAST CANCER RES TR, V137, P93, DOI 10.1007/s10549-012-2332-x
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Sabnis GJ, 2009, CANC RES S, V69
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Yang XW, 2000, CANCER RES, V60, P6890
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 13
TC 39
Z9 46
U1 1
U2 7
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD APR
PY 2016
VL 16
IS 2
BP 82
EP 86
DI 10.1016/j.clbc.2015.11.003
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DI8LS
UT WOS:000373753100002
PM 26774555
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Paul, MR
   Levitt, NP
   Moore, DE
   Watson, PM
   Wilson, RC
   Denlinger, CE
   Watson, DK
   Anderson, PE
AF Paul, Matt R.
   Levitt, Nicholas P.
   Moore, David E.
   Watson, Patricia M.
   Wilson, Robert C.
   Denlinger, Chadrick E.
   Watson, Dennis K.
   Anderson, Paul E.
TI Multivariate models from RNA-Seq SNVs yield candidate molecular targets
   for biomarker discovery: SNV-DA
SO BMC GENOMICS
LA English
DT Article
DE Multivariate models; SNV; Biomarker discovery; sPLS-DA; ER; TNBC; NSCLC;
   ERPAHS
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; CELL LUNG-CANCER; BREAST-CANCER; HIGH
   EXPRESSION; DOWN-REGULATION; TUMOR-CELLS; PPAR-GAMMA; E-CADHERIN; GENE;
   RECEPTOR
AB Background: It has recently been shown that significant and accurate single nucleotide variants (SNVs) can be reliably called from RNA-Seq data. These may provide another source of features for multivariate predictive modeling of disease phenotype for the prioritization of candidate biomarkers. The continuous nature of SNV allele fraction features allows the concurrent investigation of several genomic phenomena, including allele specific expression, clonal expansion and/or deletion, and copy number variation.
   Results: The proposed software pipeline and package, SNV Discriminant Analysis (SNV-DA), was applied on two RNA-Seq datasets with varying sample sizes sequenced at different depths: a dataset containing primary tumors from twenty patients with different disease outcomes in lung adenocarcinoma and a larger dataset of primary tumors representing two major breast cancer subtypes, estrogen receptor positive and triple negative. Predictive models were generated using the machine learning algorithm, sparse projections to latent structures discriminant analysis. Training sets composed of RNA-Seq SNV features limited to genomic regions of origin (e.g. exonic or intronic) and/or RNA-editing sites were shown to produce models with accurate predictive performances, were discriminant towards true label groupings, and were able to produce SNV rankings significantly different from than univariate tests. Furthermore, the utility of the proposed methodology is supported by its comparable performance to traditional models as well as the enrichment of selected SNVs located in genes previously associated with cancer and genes showing allele-specific expression. As proof of concept, we highlight the discovery of a previously unannotated intergenic locus that is associated with epigenetic regulatory marks in cancer and whose significant allele-specific expression is correlated with ER+ status; hereafter named ER+ associated hotspot (ERPAHS).
   Conclusion: The use of models from RNA-Seq SNVs to identify and prioritize candidate molecular targets for biomarker discovery is supported by the ability of the proposed method to produce significantly accurate predictive models that are discriminant towards true label groupings. Importantly, the proposed methodology allows investigation of mutations outside of exonic regions and identification of interesting expressed loci not included in traditional gene annotations. An implementation of the proposed methodology is provided that allows the user to specify SNV filtering criteria and cross-validation design during model creation and evaluation.
C1 [Paul, Matt R.; Levitt, Nicholas P.; Moore, David E.; Anderson, Paul E.] Coll Charleston, Dept Comp Sci, 66 George St, Charleston, SC 29401 USA.
   [Watson, Patricia M.; Wilson, Robert C.; Watson, Dennis K.] Med Univ S Carolina, Hollings Canc Ctr, 165 Canon St, Charleston, SC 29425 USA.
   [Wilson, Robert C.; Denlinger, Chadrick E.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol, 165 Canon St, Charleston, SC 29425 USA.
   [Denlinger, Chadrick E.] Med Univ S Carolina, Dept Surg, 165 Canon St, Charleston, SC 29425 USA.
   [Paul, Matt R.] Univ Penn, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.
C3 College of Charleston; Medical University of South Carolina; Medical
   University of South Carolina; Medical University of South Carolina;
   University of Pennsylvania
RP Paul, MR (通讯作者)，Coll Charleston, Dept Comp Sci, 66 George St, Charleston, SC 29401 USA.; Paul, MR (通讯作者)，Univ Penn, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.
EM mattpaul@mail.med.upenn.edu
FU Genomics Shared Resource, Hollings Cancer Center, Medical University of
   South Carolina; Hollings Cancer Center, Medical University of South
   Carolina Support Grant [P30 CA 138313]; Genomics and Computational
   Biology graduate group at the University of Pennsylvania
FX We acknowledge support from the Genomics Shared Resource, Hollings
   Cancer Center, Medical University of South Carolina. This shared
   resource is supported in part by the Hollings Cancer Center, Medical
   University of South Carolina Support Grant (P30 CA 138313). We also
   acknowledge support from the Genomics and Computational Biology graduate
   group at the University of Pennsylvania as well as the lab of Dr. Lewis
   Chodosh.
CR Abravanel DL, 2015, J CLIN INVEST, V125, P2484, DOI 10.1172/JCI74883
   Anderson P, 2014, COMP INT BIOINF COMP, P20141
   Andres SA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-326
   [Anonymous], 2014, IARC NONSERIAL PUBLI
   Ansari D, 2015, J CANCER RES CLIN, V141, P369, DOI 10.1007/s00432-014-1817-x
   Autelitano F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110316
   Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661
   Barlin JN, 2013, GYNECOL ONCOL, V128, P512, DOI 10.1016/j.ygyno.2012.11.018
   Basu S, 2008, COMP TRIPLE NEGATIVE, V112, p[5, 995]
   Blumenthal RD, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-2
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Bruzzoni-Giovanelli H, 2015, ONCOTARGET, V6, P36269, DOI 10.18632/oncotarget.5915
   Butrym A, 2012, LEUKEMIA RES, V36, P876, DOI 10.1016/j.leukres.2012.01.017
   Bylesjö M, 2006, J CHEMOMETR, V20, P341, DOI 10.1002/cem.1006
   Cantara S, 2012, J CLIN ENDOCR METAB, V97, P4253, DOI 10.1210/jc.2012-2360
   Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253
   Cao LQ, 2015, CANCER LETT, V359, P127, DOI 10.1016/j.canlet.2015.01.004
   Chakravarti A, 2001, NATURE, V409, P822, DOI 10.1038/35057281
   Chang SH, 2012, MOL THER, V20, P2052, DOI 10.1038/mt.2012.125
   Chen XJ, 2015, AM J CANCER RES, V5, P2808
   Cheng YSL, 2014, CLIN ORAL INVEST, V18, P985, DOI 10.1007/s00784-013-1041-0
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Dadlchah E, 2013, ARCH IRAN MED, V16, P463, DOI 013168/AIm.006
   Deng Y, 2012, MOL CARCINOGEN, V51, P500, DOI 10.1002/mc.20813
   Driver KE, 2008, CARCINOGENESIS, V29, P333, DOI 10.1093/carcin/bgm284
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Furrukh Muhammad, 2013, Sultan Qaboos Univ Med J, V13, P202
   George NI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125224
   Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664
   Hiramoto-Yamaki N, 2010, J CELL BIOL, V190, P461, DOI 10.1083/jcb.201005141
   Hsu YM, 2007, J CELL PHYSIOL, V210, P626, DOI 10.1002/jcp.20859
   Igci YZ, 2011, ENDOCR PATHOL, V22, P86, DOI 10.1007/s12022-011-9157-8
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Jima DD, 2010, BLOOD, V116, pE118, DOI 10.1182/blood-2010-05-285403
   Jing J, 2009, EUR J CELL BIOL, V88, P325, DOI 10.1016/j.ejcb.2009.02.186
   Johansson HJ, 2015, CLIN PROTEOM, V12, DOI 10.1186/s12014-015-9080-y
   Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630
   Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x
   Jung YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137204
   Kalari KR, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00012
   Karp CM, 2007, ONCOGENE, V26, P1780, DOI 10.1038/sj.onc.1209980
   Kawakami M, 2013, CANCER SCI, V104, P1447, DOI 10.1111/cas.12250
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202. Article published online before March 2002
   Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333
   Kundu A, 2013, CELL BIOCHEM BIOPHYS, V65, P13, DOI 10.1007/s12013-012-9398-2
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lin J, 2016, WORLD NEUROSURG, V85, P42, DOI 10.1016/j.wneu.2015.07.068
   Listgarten J, 2004, CLIN CANCER RES, V10, P2725, DOI 10.1158/1078-0432.CCR-1115-03
   Liu BY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0877-8
   Liu XC, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0878-7
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marquez-Medina D, 2015, FUTURE ONCOL, V11, P2525, DOI 10.2217/fon.15.183
   Mayba O, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0405-3
   McAvoy S, 2007, CYTOGENET GENOME RES, V118, P260, DOI 10.1159/000108309
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Milioli HH, 2015, CANCER GENOM PROTEOM, V12, P89
   Misra SK, 2015, CHEM COMMUN, V51, P16710, DOI 10.1039/c5cc07709e
   Naba A, 2014, ELIFE, V3, DOI 10.7554/eLife.01308
   Okumura AJ, 2006, J BIOL CHEM, V281, P4495, DOI 10.1074/jbc.M509715200
   Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080
   Piskol R, 2013, AM J HUM GENET, V93, P641, DOI 10.1016/j.ajhg.2013.08.008
   Prakash A, 2014, DNA REPAIR, V14, P17, DOI 10.1016/j.dnarep.2013.12.003
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ramaswami G, 2014, NUCLEIC ACIDS RES, V42, pD109, DOI 10.1093/nar/gkt996
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Robertson FM, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-497
   Romanska HM, 2015, BRIT J CANCER, V113, P1350, DOI 10.1038/bjc.2015.344
   Royds JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026737
   Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993
   Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
   Tanaka K, 2006, DNA SEQUENCE, V17, P242, DOI 10.1080/10425170600805433
   Vainio P, 2013, ONCOTARGET, V5, P742
   Van Dyke AL, 2009, J CANCER EPIDEMIOL, V2009, DOI 10.1155/2009/242151
   Varley KE, 2014, BREAST CANCER RES TR, V146, P287, DOI 10.1007/s10549-014-3019-2
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
   Wu YP, 2015, ONCOTARGET, V6, P32890, DOI 10.18632/oncotarget.5335
   Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806
   Xu LM, 2013, EXP THER MED, V5, P742, DOI 10.3892/etm.2013.911
   Yoshida T, 2010, CANCER INFORM, V9, P147
   Zawadzka AM, 2014, MOL CELL PROTEOMICS, V13, P1034, DOI 10.1074/mcp.M113.035485
   Zeng M, 2014, MOL BIOL CELL, V25, P3954, DOI 10.1091/mbc.E14-01-0004
   Zhang P, 2012, MOL BIOL REP, V39, P1471, DOI 10.1007/s11033-011-0884-1
   Zienolddiny S, 2012, LUNG CANCER-TARGETS, V3, P1, DOI 10.2147/LCTT.S13256
   Zinrajh D, 2014, ONCOL LETT, V7, P2175, DOI 10.3892/ol.2014.2035
NR 89
TC 6
Z9 6
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAR 31
PY 2016
VL 17
AR 263
DI 10.1186/s12864-016-2542-4
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DI5RP
UT WOS:000373557200001
PM 27029813
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pheiffer, C
   Erasmus, RT
   Kengne, AP
   Matsha, TE
AF Pheiffer, Carmen
   Erasmus, Rajiv T.
   Kengne, Andre P.
   Matsha, Tandi E.
TI Differential DNA methylation of microRNAs within promoters, intergenic
   and intragenic regions of type 2 diabetic, pre-diabetic and non-diabetic
   individuals
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE DNA methylation; MicroRNAs; Type 2 diabetes; Pre-diabetes; Promoters;
   Intragenic regions; Intragenic regions
ID EPIGENETIC DYSREGULATION; SUSCEPTIBILITY LOCI; METHYLOME ANALYSIS;
   PANCREATIC-ISLETS; BREAST-CANCER; EXPRESSION; CELLS; RISK;
   COMPLICATIONS; ASSOCIATION
AB Objective: Accumulating evidence supports the role of epigenetic modifications, and in particular DNA methylation and non-coding RNAs in the pathophysiology of type 2 diabetes. Alterations inmethylation patterns within promoter regions are linked with aberrant transcription and pathological gene expression; however the role of methylation within non-promoter regions is not yet fully elucidated.
   Design and methods: We performed whole genome methylated DNA immunoprecipitation sequencing (MeDIP-Seq) in peripheral-blood-derived DNA from age-gender-body mass index (BMI)-ethnicity matched type 2 diabetic, pre-diabetic and non-diabetic individuals.
   Results: The density of methylation normalized to the average length of the promoter, intergenic and intragenic regions and to CpG count was 3.17, 9.80 and 0.09 for the promoter, intergenic and intragenic regions, respectively. Methylation within these regions varied according to glucose tolerance status and was associated with hypermethylation rather than hypomethylation. MicroRNA-DNA methylation peaks accounted for 4.8% of the total number of peaks detected. Differential DNA methylation of these microRNA peaks was observed during dysglycemia, with the promoter, intergenic and intragenic regions accounting for 2%, 95% and 3% respectively, of the differentially methylated microRNA peaks.
   Conclusion: Genome-wide DNA methylation varied according to glucose tolerance. Methylation within non-promoter regions accounted for the majority of differentially methylated peaks identified, thus highlighting the importance of DNA methylation within these non-promoter regions in the pathogenesis of type 2 diabetes. This study suggests that DNA methylation within intergenic regions is a mechanism regulating microRNAs, another increasingly important epigenetic factor, during type 2 diabetes. (C) 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Pheiffer, Carmen] South African Med Res Council, Biomed Res & Innovat Platform, POB 19070, ZA-7505 Cape Town, South Africa.
   [Erasmus, Rajiv T.] Natl Hlth Lab Serv, Fac Med & Hlth Sci, Div Chem Pathol, Cape Town, South Africa.
   [Erasmus, Rajiv T.] Univ Stellenbosch, Cape Town, South Africa.
   [Erasmus, Rajiv T.; Kengne, Andre P.] South African Med Res Council, Noncommunicable Dis Res Unit, ZA-7505 Cape Town, South Africa.
   [Kengne, Andre P.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Matsha, Tandi E.] Cape Peninsula Univ Technol, Fac Hlth & Wellness Sci, Dept Biomed Sci, ZA-7530 Cape Town, South Africa.
C3 South African Medical Research Council; Stellenbosch University; South
   African Medical Research Council; University of Cape Town; Cape
   Peninsula University of Technology
RP Pheiffer, C (通讯作者)，South African Med Res Council, Biomed Res & Innovat Platform, POB 19070, ZA-7505 Cape Town, South Africa.; Matsha, TE (通讯作者)，Cape Peninsula Univ Technol, Fac Hlth & Wellness Sci, Biomed Sci, POB 1906, ZA-7530 Cape Town, South Africa.
EM carmen.pheiffer@mrc.ac.za; matshat@cput.ac.za
RI Kengne, Andre/ABB-3696-2020
OI Kengne, Andre Pascal/0000-0002-5183-131X; Matsha,
   Tandi/0000-0001-5251-030X; Pheiffer, Carmen/0000-0002-0707-1552
FU South African Medical Research Council (MRC); National Treasury under
   its Economic Competitiveness and Support Package
   [MRC-RFA-UFSP-01-2013/VMH Study]; National Research Foundation of South
   Africa [87838]
FX This work was supported by the South African Medical Research Council
   (MRC) with funds from National Treasury under its Economic
   Competitiveness and Support Package (MRC-RFA-UFSP-01-2013/VMH Study),
   and partly by the National Research Foundation of South Africa for the
   grant, Unique Grant No. 87838.
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803
   [Anonymous], 2014, IDF Diabetes Atlas, V6th
   Baroukh N, 2007, J BIOL CHEM, V282, P19575, DOI 10.1074/jbc.M611841200
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chen P, 2014, ASIAN PAC J CANCER P, V15, P9185, DOI 10.7314/APJCP.2014.15.21.9185
   Clark C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050233
   Dayeh TA, 2013, DIABETOLOGIA, V56, P1036, DOI 10.1007/s00125-012-2815-7
   Dayeh T, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004160
   del Rosario MC, 2014, METABOLISM, V63, P654, DOI 10.1016/j.metabol.2014.01.007
   Down TA, 2008, NAT BIOTECHNOL, V26, P779, DOI 10.1038/nbt1414
   Du B, 2010, FEBS LETT, V584, P811, DOI 10.1016/j.febslet.2009.12.053
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345
   Fernandez-Valverde SL, 2011, DIABETES, V60, P1825, DOI 10.2337/db11-0171
   He XX, 2015, MOL BIOSYST, V11, P532, DOI 10.1039/c4mb00563e
   Heard-Costa NL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000539
   Kong L, 2011, ACTA DIABETOL, V48, P61, DOI 10.1007/s00592-010-0226-0
   Ku CS, 2011, J MED GENET, V48, P721, DOI 10.1136/jmedgenet-2011-100242
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Li YS, 2015, SCI REP-UK, V5, DOI 10.1038/srep08790
   Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003
   Lovis P, 2008, DIABETES, V57, P2728, DOI 10.2337/db07-1252
   Matsha TE, 2012, CARDIOVASC J AFR, V23, P5, DOI 10.5830/CVJA-2010-087
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948
   Milagro FI, 2013, MOL ASPECTS MED, V34, P782, DOI 10.1016/j.mam.2012.06.010
   Morita S, 2012, INT J MOL SCI, V13, P8259, DOI 10.3390/ijms13078259
   Philibert Robert A., 2012, Frontiers in Genetics, V3, P54, DOI 10.3389/fgene.2012.00054
   Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200
   Rönn T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003572
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Tang LL, 2014, GENE, V547, P329, DOI 10.1016/j.gene.2014.06.062
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Treangen TJ, 2012, NAT REV GENET, V13, P36, DOI 10.1038/nrg3117
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609
   Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503
   Yuan W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6719
   Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 41
TC 25
Z9 27
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD APR
PY 2016
VL 49
IS 6
BP 433
EP 438
DI 10.1016/j.clinbiochem.2015.11.021
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA DI0TI
UT WOS:000373209700003
PM 26656639
DA 2025-01-12
ER

PT J
AU Kristiansen, S
   Nielsen, D
   Sölétormos, G
AF Kristiansen, Soren
   Nielsen, Dorte
   Soletormos, Gyorgy
TI Detection and monitoring of hypermethylated <i>RASSF1A</i> in serum from
   patients with metastatic breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DNA methylation; Epigenetics; Monitoring; Metastatic breast cancer;
   RASSF1A
ID PROMOTER HYPERMETHYLATION; METHYLATED DNA; TUMOR-MARKERS; CPG ISLAND;
   BLOOD; BISULFITE; GENES; CYTOSINE; ORIGIN; CELLS
AB Background: Circulating hypermethylated RASSF1A could be a novel and potential useful marker for monitoring patients with metastatic breast cancer. Technical obstacles include fragmentation of the circulating DNA, fluctuations in the concentration, low concentrations of circulating tumor DNA, and different locations of methylation in the RASSF1A gene among patients. One common method for detection of hypermethylated genes is sodium bisulfite conversion of non-methylated cytosine to uracil, followed by detection with PCR. However, the method relies on full conversion of all non-methylated cytosines, cause strand breaks, and loss of DNA. Alternatively, methylation-sensitive restriction enzymes have been used to digest genomic DNA, as well as sodium bisulfite-treated DNA. By flanking different regions of the RASSF1A with different PCR primer pairs, we analyzed for methylated genomic regions resistant to cleavage by the methylation-sensitive restriction enzymes HpaII and BstUI. The goal was to find region(s) in RASSF1A with high sensitivity and specificity that could be used for monitoring.
   Results: The serum was spiked with non-human control DNA. By tracing the spiking control, the isolation procedure of the rare circulating tumor DNA was initially optimized. By analysis of production of PCR amplicons from HpaII-or BstUI-treated DNA isolated from 24 patients with metastatic breast cancer, we located four regions resulting in sensitivities from 63 to 83 %. When examining samples from 24 control subjects, these four regions gave a specificity of 100 %. Among these four regions, the primer pair with the highest PCR efficacy was selected to monitor the RASSF1A concentration in 31 collected serum samples. The spiked DNA was then used to calculate the tumor RASSF1A concentrations independent of fluctuations in circulating non-tumor DNA. As a proof of principle, there was concordance in the kinetics of the RASSF1A and the serological cancer biomarkers CA 15-3, CEA, and TPA.
   Conclusions: Methylation-sensitive restriction enzymes may be a useful methodological approach for monitoring circulating hypermethylated RASSF1A among patients with metastatic breast cancer.
C1 [Kristiansen, Soren; Soletormos, Gyorgy] Univ Copenhagen, Nordsjaellands Hosp Hillerod, Dept Clin Biochem, Dyrehavevej 29, DK-3400 Hillerod, Denmark.
   [Nielsen, Dorte] Univ Copenhagen, Herlev Hosp, Dept Oncol, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Kristiansen, S (通讯作者)，Univ Copenhagen, Nordsjaellands Hosp Hillerod, Dept Clin Biochem, Dyrehavevej 29, DK-3400 Hillerod, Denmark.
EM skri0117@regionh.dk
OI Kristiansen, Soren/0000-0003-1851-5363; Nielsen, Dorte
   Lisbet/0000-0002-8766-8729
FU Nordsjaellands Hospital, Hillerod; Foundation of Maren and Jens
   Thestrup; Foundation of Olga Bryde Nielsen
FX Soren Kristiansen received research grants from the Nordsjaellands
   Hospital, Hillerod, the Foundation of Maren and Jens Thestrup, and the
   Foundation of Olga Bryde Nielsen.
CR ANKER P, 1975, CANCER RES, V35, P2375
   [Anonymous], NCCN CLIN PRACT GUID
   Dammann R, 2001, CANCER RES, V61, P3105
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2007, BRIT J CANCER, V96, P26
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   FRASER CG, 1990, CLIN CHEM, V36, P1625
   Genereux DP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn691
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   HAYATSU H, 1970, BIOCHEMISTRY-US, V9, P2858, DOI 10.1021/bi00816a016
   Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679
   Jahr S, 2001, CANCER RES, V61, P1659
   Kristiansen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/986024
   Kristiansen S, 2014, CRIT REV CL LAB SCI, V51, P149, DOI 10.3109/10408363.2014.893279
   Kristiansen S, 2013, INT J BIOL MARKER, V28, P141, DOI [10.5301/JBM.5000009, 10.5301/jbm.5000009]
   Matuschek C, 2010, EUR J MED RES, V15, P277
   Moelans CB, 2014, MODERN PATHOL, V27, P869, DOI 10.1038/modpathol.2013.207
   Nielsen D, 2000, CANCER CHEMOTH PHARM, V46, P459, DOI 10.1007/s002800000178
   Ruiz-García L, 2010, METHODS MOL BIOL, V631, P63, DOI 10.1007/978-1-60761-646-7_7
   Soletormos G, 1996, CLIN CHEM, V42, P564
   Sölétormos G, 2001, DAN MED BULL, V48, P229
   SUZUKI T, 1994, NUCLEIC ACIDS RES, V22, P4997, DOI 10.1093/nar/22.23.4997
   Tan SH, 2007, ONCOL REP, V18, P1225
   Tanaka K, 2007, BIOORG MED CHEM LETT, V17, P1912, DOI 10.1016/j.bmcl.2007.01.040
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022
   WHO, 1979, HDB REP RES CANC TRE
   Yan PS, 2003, CANCER RES, V63, P6178
   Yasasever V, 1997, CLIN BIOCHEM, V30, P53, DOI 10.1016/S0009-9120(96)00133-6
NR 29
TC 12
Z9 12
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD APR 1
PY 2016
VL 8
AR 35
DI 10.1186/s13148-016-0199-0
PG 9
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DI1NH
UT WOS:000373262300001
PM 27042241
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhao, QY
   Lei, PJ
   Zhang, XR
   Zheng, JY
   Wang, HY
   Zhao, J
   Li, YM
   Ye, M
   Li, LY
   Wei, G
   Wu, M
AF Zhao, Quan-Yi
   Lei, Pin-Ji
   Zhang, Xiaoran
   Zheng, Jun-Yi
   Wang, Hui-Yi
   Zhao, Jiao
   Li, Yi-Ming
   Ye, Mei
   Li, Lianyun
   Wei, Gang
   Wu, Min
TI Global histone modification profiling reveals the epigenomic dynamics
   during malignant transformation in a four-stage breast cancer model
SO CLINICAL EPIGENETICS
LA English
DT Article
DE H3K9 methylation; Epigenomics; Breast cancer transformation; KDM3A;
   Transcription regulation
ID SOMATIC MUTATIONS; GENES; EPIGENETICS; EZH2; SETD2; CELLS;
   IDENTIFICATION; REPRESSION; DISCOVERY; PATTERNS
AB Background: Epigenetic regulation has emerged to be the critical steps for tumorigenesis and metastasis. Multiple histone methyltransferase and demethylase have been implicated as tumor suppressors or oncogenes recently. But the key epigenomic events in cancer cell transformation still remain poorly understood.
   Methods: A breast cancer transformation model was established via stably expressing three oncogenes in primary breast epithelial cells. Chromatin immunoprecipitation followed by the next-generation sequencing of histone methylations was performed to determine epigenetic events during transformation. Western blot, quantitative RT-PCR, and immunostaining were used to determine gene expression in cells and tissues.
   Results: Histones H3K9me2 and me3, two repressive marks of transcription, decrease in in vitro breast cancer cell model and in vivo clinical tissues. A survey of enzymes related with H3K9 methylation indicated that KDM3A/JMJD1A, a demethylase for H3K9me1 and me2, gradually increases during cancer transformation and is elevated in patient tissues. KDM3A/JMJD1A deficiency impairs the growth of tumors in nude mice and transformed cell lines. Genome-wide ChIP-seq analysis reveals that the boundaries of decreased H3K9me2 large organized chromatin K9 modifications (LOCKs) are enriched with cancer-related genes, such as MYC and PAX3. Further studies show that KDM3A/JMJD1A directly binds to these oncogenes and regulates their transcription by removing H3K9me2 mark.
   Conclusions: Our study demonstrates reduction of histones H3K9 me2 and me3, and elevation of KDM3A/JMJD1A as important events for breast cancer, and illustrates the dynamic epigenomic mechanisms during breast cancer transformation.
C1 [Zhao, Quan-Yi; Lei, Pin-Ji; Zheng, Jun-Yi; Wang, Hui-Yi; Li, Lianyun; Wu, Min] Wuhan Univ, Coll Life Sci, Dept Biochem & Mol Biol, Wuhan 430072, Hubei, Peoples R China.
   [Zhao, Jiao; Li, Yi-Ming; Ye, Mei] Wuhan Univ, Zhongnan Hosp, Dept Geriatr, Div Gastroenterol, Wuhan 430072, Hubei, Peoples R China.
   [Zhang, Xiaoran; Wei, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
C3 Wuhan University; Wuhan University; Max Planck Society; Chinese Academy
   of Sciences
RP Wu, M (通讯作者)，Wuhan Univ, Coll Life Sci, Dept Biochem & Mol Biol, Wuhan 430072, Hubei, Peoples R China.; Wei, G (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
EM weigang77@gmail.com; wumin@whu.edu.cn
RI Lei, Pin-Ji/AAX-1878-2021; Wu, Min/AAE-5066-2021; WEI,
   GANG/AGL-1853-2022; Li, Yiming/ADL-5470-2022; YE, Mei/V-2483-2019
OI Li, Lianyun/0000-0003-4194-3059; Lei, Pin-Ji/0000-0003-2539-5179; Zhao,
   Quanyi/0000-0001-9849-4528
FU National Basic Research Program of China (973 Program) [2011CB504206,
   2012CB518700]; National Natural Science Foundation of China [31470771,
   91019013, 31221061, 31370866, 31200653]
FX We thank Dr. Man Mohan (Shanghai Jiao Tong University, China), Dr.
   Hong-Bing Shu (Wuhan University, China), and Dr. Wei Xie (Tsinghua
   University, China) for discussion and revision of the manuscript. This
   work was supported by grants from the National Basic Research Program of
   China (973 Program, 2011CB504206 and 2012CB518700) and the National
   Natural Science Foundation of China to Min Wu (31470771 and 91019013)
   and Lianyun Li (31221061, 31200653, and 31370866).
CR Béguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482
   Chen L, 2014, BRIT J CANCER, V110, P1014, DOI 10.1038/bjc.2013.808
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Danielsson F, 2013, P NATL ACAD SCI USA, V110, P6853, DOI 10.1073/pnas.1216436110
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Herz HM, 2013, TRENDS BIOCHEM SCI, V38, P621, DOI 10.1016/j.tibs.2013.09.004
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ibragimova I, 2013, EPIGENETICS-US, V8, P486, DOI 10.4161/epi.24552
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
   Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu YL, 2014, PHARMACOL THERAPEUT, V143, P275, DOI 10.1016/j.pharmthera.2014.03.007
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236
   Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026
   Putiri EL, 2014, ONCOTARGET, V5, P6338, DOI 10.18632/oncotarget.2215
   Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298
   Wang X, 2012, J CELL SCI, V125, P4058, DOI 10.1242/jcs.103531
   Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539
   Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Young LC, 2013, BIOCHEM CELL BIOL, V91, P369, DOI 10.1139/bcb-2012-0054
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhao QY, 2012, SPRINGERPLUS, V1, DOI 10.1186/2193-1801-1-65
   Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894
NR 47
TC 60
Z9 71
U1 0
U2 28
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAR 31
PY 2016
VL 8
AR 34
DI 10.1186/s13148-016-0201-x
PG 15
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DI1NA
UT WOS:000373261600001
PM 27034728
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhou, L
   Zhong, Y
   Yang, FH
   Li, ZB
   Zhou, J
   Liu, XH
   Li, M
   Hu, F
AF Zhou, Lin
   Zhong, Yan
   Yang, Fang-hui
   Li, Zi-bo
   Zhou, Jiang
   Liu, Xie-hong
   Li, Min
   Hu, Fang
TI Kaiso represses the expression of glucocorticoid receptor via a
   methylation-dependent mechanism and attenuates the anti-apoptotic
   activity of glucocorticoids in breast cancer cells
SO BMB REPORTS
LA English
DT Article
DE Breast cancer; Epigenetics; Glucocorticoid receptor; Kaiso
ID EPITHELIAL-CELLS; BINDING-PROTEIN; TRANSCRIPTION; GENES; PROTECTION;
   INDUCTION; ACTIVATOR; PROMOTER; CATENIN; ALPHA
AB Kaiso is a Pox Virus and Zinc Finger (POZ-ZF) transcription factor with bi-modal DNA-binding specificity. Here, we demonstrated that Kaiso expression is inversely correlated with glucocorticoid receptor (GR) expression in breast carcinomas. Knockdown of Kaiso increased GR expression, while overexpression of Kaiso inhibited GR expression in breast cancer cells. Furthermore, Kaiso repressed GR proximal promoter-reporter activity in a dose-dependent manner. Remarkably, ChIP experiments demonstrated that endogenous Kaiso was associated with the GR promoter sequence in a methylation-dependent manner. Since glucocorticoids inhibit chemotherapy-induced apoptosis and have been widely used as a co-treatment of patients with breast cancer, we assessed the role of Kasio in GR-mediated anti-apoptotic effects. We found that overexpression of Kaiso attenuated the anti-apoptotic effects of glucocorticoids in breast cancer cells. Our findings suggest that GR is a putative target gene of Kaiso and suggest Kaiso to be a potential therapeutic target in GC-combination chemotherapy in breast cancer.
C1 [Zhou, Lin; Yang, Fang-hui; Li, Zi-bo; Zhou, Jiang; Liu, Xie-hong; Li, Min] Changsha Med Univ, Clin Med Lab, Dept Clin Biochem, Changsha 410219, Hunan, Peoples R China.
   [Zhou, Lin] Changsha Med Univ, Inst Neurosci, Dept Anat Histol & Embryol, Changsha 410219, Hunan, Peoples R China.
   [Zhong, Yan] Cent S Univ, Xiangya Hosp 2, Dept Gynaecol & Obstet, Changsha 410011, Hunan, Peoples R China.
   [Hu, Fang] Cent S Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Changsha 410011, Hunan, Peoples R China.
C3 Changsha Medical University; Changsha Medical University; Central South
   University; Central South University
RP Hu, F (通讯作者)，Cent S Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Changsha 410011, Hunan, Peoples R China.
EM hufanghf@yeah.net
RI LI, MIN/U-3131-2018; Zibo, Li/AGI-3194-2022
OI Zhou, Lin/0009-0001-9740-1980
FU Outstanding Youth Research Foundation of Education Bureau of Hunan
   Province, China [2011B017]; National Natural Science Foundation of China
   [81300503]
FX This study was supported by the Outstanding Youth Research Foundation of
   Education Bureau of Hunan Province, China (No. 2011B017) and the
   National Natural Science Foundation of China (Grant No. 81300503).
CR Chebotaev D, 2007, ONCOGENE, V26, P3060, DOI 10.1038/sj.onc.1210108
   Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421
   Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398
   Daniel JM, 1999, MOL CELL BIOL, V19, P3614
   Donaldson NS, 2010, EXP CELL RES, V316, P1692, DOI 10.1016/j.yexcr.2010.03.011
   Jones J, 2014, CLIN EXP METASTAS, V31, P497, DOI 10.1007/s10585-014-9644-7
   Karmakar S, 2013, J BIOL CHEM, V288, P24020, DOI 10.1074/jbc.M113.473819
   Kay P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024839
   Lind GE, 2006, CELL ONCOL, V28, P259
   Ling J, 2012, CANCER LETT, V322, P119, DOI 10.1016/j.canlet.2012.02.033
   Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344
   Machuca C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-9
   Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200
   Nesset KA, 2014, EPIGENETICS-US, V9, P851, DOI 10.4161/epi.28484
   Rodova M, 2004, MOL CELL BIOL, V24, P7188, DOI 10.1128/MCB.24.16.7188-7196.2004
   Ruzov A, 2004, DEVELOPMENT, V131, P6185, DOI 10.1242/dev.01549
   Schorr K, 2000, CANCER RES, V60, P5950
   Turner JD, 2010, BIOCHEM PHARMACOL, V80, P1860, DOI 10.1016/j.bcp.2010.06.037
   Vermeulen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037864
   Vilasco M, 2011, BREAST CANCER RES TR, V130, P1, DOI 10.1007/s10549-011-1689-6
   Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546
   Yemelyanov A, 2007, ONCOGENE, V26, P1885, DOI 10.1038/sj.onc.1209991
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
NR 23
TC 5
Z9 5
U1 0
U2 11
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD MAR
PY 2016
VL 49
IS 3
BP 167
EP 172
DI 10.5483/BMBRep.2016.49.3.151
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DH8QH
UT WOS:000373059900006
PM 26424557
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU He, BK
   Chen, Z
AF He, Baokun
   Chen, Zheng
TI Molecular Targets for Small-Molecule Modulators of Circadian Clocks
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Circadian clock; drug metabolism; metabolic syndrome; molecular target;
   nuclear receptor; small-molecule modulator
ID AMELIORATES AUTOIMMUNE ARTHRITIS; REV-ERB; GENE-EXPRESSION;
   TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; NUCLEAR RECEPTORS; CHEMICAL
   BIOLOGY; BREAST-CANCER; RHYTHMS; PERIOD
AB Background: Circadian clocks are endogenous timing systems that regulate various aspects of mammalian metabolism, physiology and behavior. Traditional chronotherapy refers to the administration of drugs in a defined circadian time window to achieve optimal pharmacokinetic and therapeutic efficacies. In recent years, substantial efforts have been dedicated to developing novel small-molecule modulators of circadian clocks.
   Methods: Here, we review the recent progress in the identification of molecular targets of small-molecule clock modulators and their efficacies in clock-related disorders. Specifically, we examine the clock components and regulatory factors as possible molecular targets of small molecules, and we review several key clock-related disorders as promising venues for testing the preventive/therapeutic efficacies of these small molecules. Finally, we also discuss circadian regulation of drug metabolism.
   Results: Small molecules can modulate the period, phase and/or amplitude of the circadian cycle. Core clock proteins, nuclear hormone receptors, and clock-related kinases and other epigenetic regulators are promising molecular targets for small molecules. Through these targets small molecules exert protective effects against clock-related disorders including the metabolic syndrome, immune disorders, sleep disorders and cancer. Small molecules can also modulate circadian drug metabolism and response to existing therapeutics.
   Conclusion: Small-molecule clock modulators target clock components or diverse cellular pathways that functionally impinge upon the clock. Target identification of new small-molecule modulators will deepen our understanding of key regulatory nodes in the circadian network. Studies of clock modulators will facilitate their therapeutic applications, alone or in combination, for clock-related diseases.
C1 [He, Baokun; Chen, Zheng] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St,MSB 6-200, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College Medical Hospital; University
   of Texas System; University of Texas Health Science Center Houston
RP Chen, Z (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St,MSB 6-200, Houston, TX 77030 USA.
EM Zheng.chen.1@uth.tmc.edu
FU Robert A. Welch Foundation [AU-1731]; American Heart Association
   [11SDG7600045]; NIH/NIA [R01 AG045828]; American Heart Association (AHA)
   [11SDG7600045] Funding Source: American Heart Association (AHA)
FX We thank Seung-Hee (Sally) Yoo for critical reading. This work was in
   part supported by the Robert A. Welch Foundation (AU-1731), American
   Heart Association (11SDG7600045), and NIH/NIA (R01 AG045828) to Z.C.
CR Antoch Marina P, 2013, Handb Exp Pharmacol, P289, DOI 10.1007/978-3-642-25950-0_12
   Arendt J, 2010, OCCUP MED-OXFORD, V60, P10, DOI 10.1093/occmed/kqp162
   Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050
   Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006
   Baek SY, 2014, ACTA PHARMACOL SIN, V35, P1177, DOI 10.1038/aps.2014.58
   Barclay JL, 2013, AM J PHYSIOL-ENDOC M, V304, pE1053, DOI 10.1152/ajpendo.00512.2012
   Barnea M, 2012, BBA-MOL BASIS DIS, V1822, P1796, DOI 10.1016/j.bbadis.2012.08.005
   Bass J, 2012, NATURE, V491, P348, DOI 10.1038/nature11704
   Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633
   Bellet MM, 2013, P NATL ACAD SCI USA, V110, P3333, DOI 10.1073/pnas.1214266110
   Canaple L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052
   Caton PW, 2011, DIABETES OBES METAB, V13, P1097, DOI 10.1111/j.1463-1326.2011.01466.x
   Chen Z, 2013, CELL MOL LIFE SCI, V70, P2985, DOI 10.1007/s00018-012-1207-y
   Chen Z, 2012, P NATL ACAD SCI USA, V109, P101, DOI 10.1073/pnas.1118034108
   Chun SK, 2014, ACS CHEM BIOL, V9, P703, DOI 10.1021/cb400752k
   De Mei C, 2015, ONCOGENE, V34, P2597, DOI 10.1038/onc.2014.203
   Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Gachon F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015
   Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106
   Gerhart-Hines Z, 2015, DIABETES OBES METAB, V17, P12, DOI 10.1111/dom.12510
   Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109
   Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102
   Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022
   Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019
   Hirota T, 2012, SCIENCE, V337, P1094, DOI 10.1126/science.1223710
   Hirota T, 2009, CHEM BIOL, V16, P921, DOI 10.1016/j.chembiol.2009.09.002
   Hirota T, 2008, P NATL ACAD SCI USA, V105, P20746, DOI 10.1073/pnas.0811410106
   Hu Y, 2011, ONCOTARGET, V2, P1279
   Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978
   Isojima Y, 2009, P NATL ACAD SCI USA, V106, P15744, DOI 10.1073/pnas.0908733106
   Iwata K, 2011, BIOL PHARM BULL, V34, P1765
   Jeong K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12801
   Jetten Anton M, 2013, Front Endocrinol (Lausanne), V4, P1, DOI 10.3389/fendo.2013.00001
   Jia YJ, 2013, CANCER EPIDEMIOL, V37, P197, DOI 10.1016/j.canep.2013.01.005
   Jones CR, 2013, EXP NEUROL, V243, P28, DOI 10.1016/j.expneurol.2012.07.012
   Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007
   Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Kojima S, 2011, J CELL SCI, V124, P311, DOI 10.1242/jcs.065771
   Kon N, 2008, NAT CELL BIOL, V10, P1463, DOI 10.1038/ncb1806
   Kondoh D, 2014, BIOL PHARM BULL, V37, P1422, DOI 10.1248/bpb.b14-00229
   Kosir R, 2013, IUBMB LIFE, V65, P487, DOI 10.1002/iub.1160
   Kumar N, 2011, ACS CHEM BIOL, V6, P218, DOI 10.1021/cb1002762
   Kwak Y, 2013, J BIOL CHEM, V288, P36878, DOI 10.1074/jbc.M113.494856
   Lamia KA, 2009, SCIENCE, V326, P437, DOI 10.1126/science.1172156
   Lee JW, 2015, CHEMMEDCHEM, V10, P1489, DOI 10.1002/cmdc.201500260
   Lee JW, 2011, ANGEW CHEM INT EDIT, V50, P10608, DOI 10.1002/anie.201103915
   Lee J, 2015, INT IMMUNOPHARMACOL, V26, P103, DOI 10.1016/j.intimp.2015.03.017
   Lee Y, 2011, J BIOL CHEM, V286, P7033, DOI 10.1074/jbc.M110.207217
   Levi F, 2007, ANNU REV PHARMACOL, V47, P593, DOI 10.1146/annurev.pharmtox.47.120505.105208
   Liu AC, 2007, NAT CHEM BIOL, V3, P630, DOI 10.1038/nchembio.2007.37
   Maier B, 2009, GENE DEV, V23, P708, DOI 10.1101/gad.512209
   Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253
   McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9
   Meng QJ, 2010, P NATL ACAD SCI USA, V107, P15240, DOI 10.1073/pnas.1005101107
   Nakahata Y, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-5
   Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002
   Nakamura TJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE1025, DOI 10.1152/ajpendo.90392.2008
   Nohara K, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00035
   Onishi Y, 2012, NUCLEIC ACIDS RES, V40, P9482, DOI 10.1093/nar/gks779
   Onishi Y, 2012, BIOSCIENCE REP, V32, P45, DOI 10.1042/BSR20110002
   Oshima T, 2015, ANGEW CHEM INT EDIT, V54, P7193, DOI 10.1002/anie.201502942
   Parsons MJ, 2015, INT J OBESITY, V39, P842, DOI 10.1038/ijo.2014.201
   Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270
   Quiroz JA, 2004, MOL INTERV, V4, P259, DOI 10.1124/mi.4.5.6
   Reischl S, 2011, FEBS LETT, V585, P1393, DOI 10.1016/j.febslet.2011.02.038
   Sahar S, 2012, TRENDS ENDOCRIN MET, V23, P1, DOI 10.1016/j.tem.2011.10.005
   Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018
   Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106
   Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386
   Shi SQ, 2013, CURR BIOL, V23, P372, DOI 10.1016/j.cub.2013.01.048
   Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030
   Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075
   Stearns AT, 2008, J PHARMACOL SCI, V108, P144, DOI 10.1254/jphs.08100SC
   Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430
   Trump RP, 2013, J MED CHEM, V56, P4729, DOI 10.1021/jm400458q
   Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750
   Um JH, 2007, J BIOL CHEM, V282, P20794, DOI 10.1074/jbc.C700070200
   Wallach T, 2015, FEBS LETT, V589, P1530, DOI 10.1016/j.febslet.2015.04.059
   Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415
   Wang NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009
   Wang YJ, 2015, BIOCHEM PHARMACOL, V96, P315, DOI 10.1016/j.bcp.2015.06.010
   Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d
   Xu T, 2011, J BIOL CHEM, V286, P22707, DOI 10.1074/jbc.C111.250407
   Yagita K, 2009, ACTA HISTOCHEM CYTOC, V42, P89, DOI 10.1267/ahc.09015
   Yang X, 2007, COLD SPRING HARB SYM, V72, P387, DOI 10.1101/sqb.2007.72.058
   Yu WJ, 2006, J CELL SCI, V119, P4793, DOI 10.1242/jcs.03174
   Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111
   Zhang YKJ, 2009, DRUG METAB DISPOS, V37, P106, DOI 10.1124/dmd.108.024174
NR 90
TC 35
Z9 41
U1 2
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2002
EI 1875-5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PY 2016
VL 17
IS 5
BP 503
EP 512
DI 10.2174/1389200217666160111124439
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DH9NP
UT WOS:000373123200007
PM 26750111
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Markozashvili, D
   Pichugin, A
   Barat, A
   Camara-Clayette, V
   Vasilyeva, NV
   Lelievre, H
   Kraus-Berthier, L
   Depil, S
   Ribrag, V
   Vassetzky, Y
AF Markozashvili, Diana
   Pichugin, Andrei
   Barat, Ana
   Camara-Clayette, Valerie
   Vasilyeva, Natalia V.
   Lelievre, Helene
   Kraus-Berthier, Laurence
   Depil, Stephane
   Ribrag, Vincent
   Vassetzky, Yegor
TI Histone deacetylase inhibitor abexinostat affects chromatin organization
   and gene transcription in normal B cells and in mantle cell lymphoma
SO GENE
LA English
DT Article
DE Transcription; Cancer; Lymphoma; HDACi; Epigenetics
ID GLUTATHIONE-S-TRANSFERASE; EXPRESSION PROFILES; GSTP1 EXPRESSION;
   CANCER-CELLS; COLON-CANCER; NUCLEAR REORGANIZATION; CERVICAL-CANCER; CD5
   EXPRESSION; BREAST-CANCER; ATM GENE
AB Mantle cell lymphoma (MCL) is a rare lymphoma caused by the t(11:14) juxtaposing the cyclin D1 (CCND1) locus on chromosome 11 and the immunoglobulin heavy chain (IgH) locus on chromosome 14. Several new treatments are proposed for MCL, including histone deacetylase inhibitors (HDACi). We have studied gene expression and chromatin organization in the translocated 11q13 locus in MCL cells as compared to lymphoblastoid cell lines as well as the effect of HDACi abexinostat on chromatin organization and gene expression in the 11q13 locus. We have identified a cluster of genes overexpressed in the translocation region on chromosome 11 in MCL cells. Abexinostat provokes a genome-wide disaggregation of heterochromatin. The genes upregulated after the t(11:14) translocation react to the HDACi treatment by increasing their expression, but their gene promoters do not show significant alterations in H3K9Ac and H3K9me2 levels in abexinostat-treated cells. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Markozashvili, Diana; Pichugin, Andrei; Barat, Ana; Vassetzky, Yegor] Univ Paris 11, CNRS, UMR 8126, Inst Cancerol Gustave Roussy, F-94805 Villejuif, France.
   [Markozashvili, Diana; Pichugin, Andrei; Barat, Ana; Vassetzky, Yegor] LIA 1066 Lab Francorusse Rech Oncol, F-94805 Villejuif, France.
   [Pichugin, Andrei] Peter Great St Petersburg Polytech Univ, St Petersburg, Russia.
   [Camara-Clayette, Valerie; Ribrag, Vincent] Inst Cancerol Gustave Roussy, F-94805 Villejuif, France.
   [Vasilyeva, Natalia V.] Mechnikov North Western State Med Univ, Kashkin Res Inst Med Mycol, Moscow, Russia.
   [Lelievre, Helene; Kraus-Berthier, Laurence; Depil, Stephane] IRIS, 50 Rue Carnot, F-92284 Suresnes, France.
   [Vassetzky, Yegor] Koltzov Inst Dev Biol, Moscow, Russia.
C3 Universite Paris Saclay; UNICANCER; Gustave Roussy; Centre National de
   la Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Peter the Great St. Petersburg Polytechnic University;
   UNICANCER; Gustave Roussy; North-Western State Medical University named
   after I.I. Mechnikov; Servier; Institut de Recherches Internationales
   Servier; Russian Academy of Sciences; Koltzov Institute of Developmental
   Biology of the Russian Academy of Sciences
RP Vassetzky, Y (通讯作者)，Univ Paris 11, CNRS, UMR 8126, Inst Cancerol Gustave Roussy, F-94805 Villejuif, France.
EM vassetzky@igr.fr
RI VASILYEVA, NATALIA/P-1132-2014; Markozashvili, Diana/E-1126-2018;
   PICHUGIN, Andrey/Q-1759-2016; Vassetzky, Yegor/C-6447-2008
OI Vasilyeva, Natalya/0000-0003-3693-5468; PICHUGIN,
   Andrey/0000-0003-3810-1977; Vassetzky, Yegor/0000-0003-3101-7043;
   Vasil'eva, Natalia V./0000-0002-6951-6596
FU Laboratoires Servier [PHA78454 014]
FX This research was supported by a study grant PHA78454 014 from the
   Laboratoires Servier. We thank Ms. Shirmone Botha for critical reading
   of the manuscript.
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Allinne J, 2014, BLOOD, V123, P2044, DOI 10.1182/blood-2013-06-510511
   Alonso-Ramirez R, 2010, ARTHRITIS, DOI 10.1155/2010/130646
   Arai T, 2008, EJSO-EUR J SURG ONC, V34, P734, DOI 10.1016/j.ejso.2007.07.008
   Bennaceur-Griscelli A, 2004, CLIN CANCER RES, V10, P3029, DOI 10.1158/1078-0432.CCR-03-0554
   Bhalla S, 2009, CLIN CANCER RES, V15, P3354, DOI 10.1158/1078-0432.CCR-08-2365
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Borhani N., 2014, CLIN OVARIAN GYNECOL, V7, P18, DOI [10.1016/j.cogc.2014.12.004, DOI 10.1016/J.COGC.2014.12.004]
   Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238
   Camara-Clayette V, 2012, EXPERT REV ANTICANC, V12, P1205, DOI [10.1586/ERA.12.99, 10.1586/era.12.99]
   Cekartova M, 2015, EXP CELL RES, V331, P1, DOI 10.1016/j.yexcr.2014.11.016
   Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104
   Chen DW, 2013, TUMOR BIOL, V34, P1553, DOI 10.1007/s13277-013-0685-3
   Chen GD, 2012, J INVEST DERMATOL, V132, P2632, DOI 10.1038/jid.2012.193
   CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x
   Chevillard-Briet M, 2014, HUM MOL GENET, V23, P2120, DOI 10.1093/hmg/ddt604
   Covington KR, 2014, CANCER METAST REV, V33, P921, DOI 10.1007/s10555-014-9518-0
   Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063
   Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937
   Daibata M, 2004, INT J CANCER, V108, P845, DOI 10.1002/ijc.11647
   Dasmahapatra G, 2011, MOL CANCER THER, V10, P1686, DOI 10.1158/1535-7163.MCT-10-1108
   Escoda-Ferran C, 2014, FEBS LETT, V588, P2805, DOI 10.1016/j.febslet.2014.05.064
   Fiancette R, 2010, LEUKEMIA RES, V34, P1043, DOI 10.1016/j.leukres.2009.11.017
   Freier K, 2003, CANCER RES, V63, P1179
   Greiner TC, 2006, P NATL ACAD SCI USA, V103, P2352, DOI 10.1073/pnas.0510441103
   Halsall J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033453
   Harewood L, 2010, GENOME RES, V20, P554, DOI 10.1101/gr.103622.109
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   HISHIMA T, 1994, AM J PATHOL, V145, P268
   Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5
   Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jaffe E. S., 2001, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
   Ji Yuxin, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P359
   Jiang L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-20
   Kang JU, 2012, INT J MOL MED, V29, P81, DOI 10.3892/ijmm.2011.811
   Kaplan D, 2001, P NATL ACAD SCI USA, V98, P13850, DOI 10.1073/pnas.241509398
   Katz SG, 2014, BLOOD, V123, P884, DOI 10.1182/blood-2013-04-499079
   Kawamata N, 2007, BLOOD, V110, P2667, DOI 10.1182/blood-2005-11-026344
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Knævelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768
   Li M, 2015, HUM PATHOL, V46, P707, DOI 10.1016/j.humpath.2015.01.009
   Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3
   Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483
   Liu Z, 2002, AM J CLIN PATHOL, V118, P216
   Morschhauser F., 2015, INVESTIG NEW DRUGS
   Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090
   Nicol JW, 2009, BIOINFORMATICS, V25, P2730, DOI 10.1093/bioinformatics/btp472
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Rafique S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0719-9
   Razin SV, 2004, CRIT REV EUKAR GENE, V14, P79, DOI 10.1615/CritRevEukaryotGeneExpr.v14.50
   RIMOKH R, 1994, BLOOD, V83, P3689
   Rybárová S, 2014, ACTA HISTOCHEM, V116, P1390, DOI 10.1016/j.acthis.2014.09.002
   Sakuraba K, 2011, ANTICANCER RES, V31, P77
   Sastry KSR, 2014, CELL DEATH DIFFER, V21, P1936, DOI 10.1038/cdd.2014.140
   Schmidt C, 2008, HEMATOL ONCOL CLIN N, V22, P953, DOI 10.1016/j.hoc.2008.07.001
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Solovei I, 2002, FISH PRACTICAL APPRO
   Stilgenbauer S, 2000, ANN ONCOL, V11, P127, DOI 10.1023/A:1008315003377
   Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Van Den Broeck A, 2012, CARCINOGENESIS, V33, P320, DOI 10.1093/carcin/bgr292
   Vazquez-Ortiz G, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-68
   Wang JH, 2005, J BIOL CHEM, V280, P12766, DOI 10.1074/jbc.M412446200
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wlodarska I, 2008, BLOOD, V111, P5683, DOI 10.1182/blood-2007-10-118794
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Zhai C, 2014, ONCOGENE, V33, P484, DOI 10.1038/onc.2012.604
   Zhou CF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-102
   ZUKERBERG LR, 1993, AM J CLIN PATHOL, V100, P373, DOI 10.1093/ajcp/100.4.373
NR 71
TC 9
Z9 10
U1 0
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD APR 12
PY 2016
VL 580
IS 2
BP 134
EP 143
DI 10.1016/j.gene.2016.01.017
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DE8KO
UT WOS:000370885100007
PM 26774800
DA 2025-01-12
ER

PT J
AU Sun, HP
   Li, K
   Shen, SQ
AF Sun, Huapeng
   Li, Kun
   Shen, Shiqiang
TI A study of the role of Notch1 and JAG1 gene methylation in development
   of breast cancer
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Notch1; JAG1; Methylation of DNA; Breast cancer; Intraductal
   proliferative lesions of lacteal gland; MassARRAY
ID DNA METHYLATION; SIGNALING MOLECULES; TUMOR; EPIGENETICS; EXPRESSION;
   SERUM; MECHANISM; LEVEL; POOR
AB This study is to explore the roles of gene methylation of Notch1 and JAG1 in development of invasive ductal carcinoma of breast. Quantitative analysis the DNA methylation levels of Notch1 and JAG1 gene by the MassARRAY method in invasive ductal carcinoma of breast (IDC; n = 89), atypical ductal hyperplasia of breast (ADH; n = 11), and ordinary ductal hyperplasia of breast (UDH; n = 20). The expressions of JAG1 and Notch1 protein in four breast tissues were detected by immunohistochemistry SP method. (1) Positive expression rates of Notch1 protein in IDC and DCIS were 88.7 % (79/89) and 70.0 % (14/20), respectively, which were significantly higher than the levels in ADH (36.0 %, 4/11) and UDH (25.0 %, 5/20; P< 0.05). Notch1 protein expression was significant positively correlated with lymph node metastasis, pathological grades, and TNM stages of IDC. (2) Positive expression rates of JAG1 protein in IDC and DCIS were 89.9 % (80/89) and 75.0 % (15/20), respectively, which were significantly higher than those of ADH (45.0 %, 5/11) and UDH (30.0 %, 6/20; P< 0.05). JAG1 protein expression was significant positive correlation with lymph node metastasis, pathological grades and TNM stages of IDC. There is an overall hypomethylation alteration of Notch1 and JAG gene in IDC, with corresponding over-expression of Notch1 and JAG1 protein. This inverse correlation shows that the alteration of protein expression results from hypomethylation oncogene Notch1 and JAG1, and this change may play an important role in occurrence and progression of breast cancer.
C1 [Sun, Huapeng; Shen, Shiqiang] Wuhan Univ, Dept Gen Surg, Renmin Hosp, Wuhan 430071, Hubei Province, Peoples R China.
   [Li, Kun] Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan 430071, Hubei Province, Peoples R China.
C3 Wuhan University; Wuhan University
RP Shen, SQ (通讯作者)，Wuhan Univ, Dept Gen Surg, Renmin Hosp, Wuhan 430071, Hubei Province, Peoples R China.
EM 1459195529@qq.com
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   [Anonymous], LUNG CANC
   [Anonymous], PLOS ONE
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Dominguez M, 2014, SEMIN CELL DEV BIOL, V28, P78, DOI 10.1016/j.semcdb.2014.04.012
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fujita N, 2014, ONCOL LETT, V8, P397, DOI 10.3892/ol.2014.2068
   Fukushige S, 2013, TOHOKU J EXP MED, V229, P173, DOI 10.1620/tjem.229.173
   Gautrey HE, 2014, FASEB J, V28, P3261, DOI 10.1096/fj.13-246173
   Haller F, 2014, ENDOCR-RELAT CANCER, V21, P567, DOI 10.1530/ERC-14-0254
   Han JX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2875
   Hao L, 2010, ONCOGENE, V29, P201, DOI 10.1038/onc.2009.323
   Heyn H, 2014, CELL REP, V7, P331, DOI 10.1016/j.celrep.2014.03.016
   Itoh H, 2014, SCI TOTAL ENVIRON, V490, P603, DOI 10.1016/j.scitotenv.2014.05.035
   Jiao F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092190
   Jonusiene V, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0438-y
   Koch U, 2010, CURR TOP DEV BIOL, V92, P411, DOI 10.1016/S0070-2153(10)92013-9
   Mitsuhashi Y, 2012, HISTOPATHOLOGY, V60, P826, DOI 10.1111/j.1365-2559.2011.04158.x
   Parr C, 2004, INT J MOL MED, V14, P779
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Sharma G, 2010, CLIN BIOCHEM, V43, P373, DOI 10.1016/j.clinbiochem.2009.10.009
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Tokarz Paulina, 2013, Postepy Biochem, V59, P267
   Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x
NR 27
TC 13
Z9 17
U1 0
U2 19
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD APR
PY 2016
VL 33
IS 4
AR 35
DI 10.1007/s12032-016-0750-z
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DG7KK
UT WOS:000372263000006
PM 26971121
DA 2025-01-12
ER

PT J
AU Efimova, EV
   Takahashi, S
   Shamsi, NA
   Wu, D
   Labay, E
   Ulanovskaya, OA
   Weichselbaum, RR
   Kozmin, SA
   Kron, SJ
AF Efimova, Elena V.
   Takahashi, Satoe
   Shamsi, Noumaan A.
   Wu, Ding
   Labay, Edwardine
   Ulanovskaya, Olesya A.
   Weichselbaum, Ralph R.
   Kozmin, Sergey A.
   Kron, Stephen J.
TI Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID DAMAGE RESPONSE; O-GLCNAC; ONCOMETABOLITE 2-HYDROXYGLUTARATE; CELLULAR
   SENESCENCE; EMERGING ROLES; CHROMATIN; 53BP1; CELLS; BREAK; INHIBITOR
AB Conventional wisdom ascribes metabolic reprogramming in cancer to meeting increased demands for intermediates to support rapid proliferation. Prior models have proposed benefits toward cell survival, immortality, and stress resistance, although the recent discovery of oncometabolites has shifted attention to chromatin targets affecting gene expression. To explore further effects of cancer metabolism and epigenetic deregulation, DNA repair kinetics were examined in cells treated with metabolic intermediates, oncometabolites, and/or metabolic inhibitors by tracking resolution of double-strand breaks (DSB) in irradiated MCF7 breast cancer cells. Disrupting cancer metabolism revealed roles for both glycolysis and glutaminolysis in promoting DSB repair and preventing accelerated senescence after irradiation. Targeting pathways common to glycolysis and glutaminolysis uncovered opposing effects of the hexosamine biosynthetic pathway (HBP) and tricarboxylic acid (TCA) cycle. Treating cells with the HBP metabolite N-acetylglucosamine (GlcNAc) or augmenting protein O-GlcNAcylation with small molecules or RNAi targeting O-GlcNAcase each enhanced DSB repair, while targeting O-GlcNAc transfer-ase reversed GlcNAc's effects. Opposing the HBP, TCA metabolites including alpha-ketoglutarate blocked DSB resolution. Strikingly, DNA repair could be restored by the oncometabolite 2-hydroxyglutarate (2-HG). Targeting downstream effectors of histone methylation and demethylation implicated the PRC1/2 polycomb complexes as the ultimate targets for metabolic regulation, reflecting known roles for Polycomb group proteins in nonhomologous end-joining DSB repair. Our findings that epigenetic effects of cancer metabolic reprogramming may promote DNA repair provide a molecular mechanism by which deregulation of metabolism may not only support cell growth but also maintain cell immortality, drive therapeutic resistance, and promote genomic instability. (C) 2015 AACR.
C1 [Efimova, Elena V.; Takahashi, Satoe; Wu, Ding; Kron, Stephen J.] Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.
   [Efimova, Elena V.; Takahashi, Satoe; Wu, Ding; Labay, Edwardine; Weichselbaum, Ralph R.; Kron, Stephen J.] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA.
   [Shamsi, Noumaan A.; Ulanovskaya, Olesya A.; Kozmin, Sergey A.] Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.
   [Labay, Edwardine; Weichselbaum, Ralph R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University of Chicago
RP Kron, SJ (通讯作者)，Univ Chicago, Gordon Ctr Integrat Sci, 929 East 57th St,GCIS W522A, Chicago, IL 60637 USA.
EM skron@uchicago.edu
OI Kron, Stephen/0000-0003-1518-2436
FU NIH [R01s CA164492, CA176843, CA164492-S1]; Grant Achatz and the Alinea
   team; Susan G. Komen Postdoctoral Fellowship [KG101224];  [P50
   GM086145];  [Ludwig Center for Metastasis Research]
FX This work was generously supported by NIH R01s CA164492 and CA176843,
   metabolomics supplement CA164492-S1, and a grant from Grant Achatz and
   the Alinea team (to S.J. Kron), by a Susan G. Komen Postdoctoral
   Fellowship KG101224 (to S. Takahashi), by P50 GM086145 (to S.A. Kozmin),
   and by funds from the Ludwig Center for Metastasis Research (to R.R.
   Weichselbaum).
CR Azad A, 2014, INT J RADIAT ONCOL, V88, P385, DOI 10.1016/j.ijrobp.2013.10.043
   Badeaux AI, 2013, NAT REV MOL CELL BIO, V14, P211, DOI 10.1038/nrm3545
   Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080
   Buchakjian MR, 2010, NAT REV MOL CELL BIO, V11, P715, DOI 10.1038/nrm2972
   Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345
   Castoreno AB, 2011, ACS CHEM BIOL, V6, P86, DOI 10.1021/cb1002976
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Delatte B, 2014, EMBO J, V33, P1198, DOI 10.15252/embj.201488290
   di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501
   Efimova EV, 2010, CANCER RES, V70, P6277, DOI 10.1158/0008-5472.CAN-09-4224
   Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318
   Frezza C, 2009, SEMIN CANCER BIOL, V19, P4, DOI 10.1016/j.semcancer.2008.11.008
   Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296
   Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145
   Gieni RS, 2011, CELL CYCLE, V10, P883, DOI 10.4161/cc.10.6.14907
   Goodarzi AA, 2012, MUTAT RES-FUND MOL M, V736, P39, DOI 10.1016/j.mrfmmm.2011.05.017
   Guppy M, 2002, BIOCHEM J, V364, P309, DOI 10.1042/bj3640309
   Gut P, 2013, NATURE, V502, P489, DOI 10.1038/nature12752
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanover JA, 2012, NAT REV MOL CELL BIO, V13, P312, DOI 10.1038/nrm3334
   Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hunt CR, 2013, RADIAT RES, V179, P383, DOI 10.1667/RR3308.2
   Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   Ismail IH, 2013, J BIOL CHEM, V288, P26944, DOI 10.1074/jbc.M113.461699
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154
   Kondoh H, 2005, CANCER RES, V65, P177
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310
   Labay Edwardine, 2011, Int J High Throughput Screen, V2, P1
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Lehár J, 2008, NAT CHEM BIOL, V4, P674, DOI 10.1038/nchembio.120
   Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040
   Liu Jinping, 2013, Frontiers in Genetics, V4, P182, DOI 10.3389/fgene.2013.00182
   Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   Love DC, 2010, SEMIN CELL DEV BIOL, V21, P646, DOI 10.1016/j.semcdb.2010.05.001
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Nandi A, 2006, ANAL CHEM, V78, P452, DOI 10.1021/ac051207j
   Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719
   Rossetto D, 2010, CLIN CANCER RES, V16, P4543, DOI 10.1158/1078-0432.CCR-10-0513
   Smeenk G, 2013, ANNU REV BIOCHEM, V82, P55, DOI 10.1146/annurev-biochem-061809-174504
   Ulanovskaya OA, 2011, CHEM BIOL, V18, P222, DOI 10.1016/j.chembiol.2010.12.015
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019
   Zachara NE, 2011, AMINO ACIDS, V40, P793, DOI 10.1007/s00726-010-0695-z
   Zimmerman M, 2014, TRENDS CELL BIOL, V24, P108, DOI 10.1016/j.tcb.2013.09.003
NR 66
TC 44
Z9 47
U1 1
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD FEB
PY 2016
VL 14
IS 2
BP 173
EP 184
DI 10.1158/1541-7786.MCR-15-0263
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DG3XI
UT WOS:000372003900004
PM 26538285
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Shan, M
   Yin, HZ
   Li, JN
   Li, XB
   Wang, D
   Su, YH
   Niu, M
   Zhong, ZB
   Wang, J
   Zhang, XY
   Kang, WL
   Pang, D
AF Shan, Ming
   Yin, Huizi
   Li, Junnan
   Li, Xiaobo
   Wang, Dong
   Su, Yonghui
   Niu, Ming
   Zhong, Zhenbin
   Wang, Ji
   Zhang, Xianyu
   Kang, Wenli
   Pang, Da
TI Detection of aberrant methylation of a six-gene panel in serum DNA for
   diagnosis of breast cancer
SO ONCOTARGET
LA English
DT Article
DE breast cancer; DNA methylation; diagnosis; MethyLight
ID GENE PROMOTER HYPERMETHYLATION; PLASMA DNA; MICROSATELLITE ALTERATIONS;
   NUCLEIC-ACIDS; DENSITY; MARKERS; RISK; BIOMARKERS; PATTERNS; SUBTYPES
AB Detection of breast cancer at an early stage is the key for successful treatment and improvement of outcome. However the limitations of mammography are well recognized, especially for those women with premenopausal breast cancer. Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we examined the promoter methylation of six genes (SFN, P16, hMLH1, HOXD13, PCDHGB7 and RASSF1a) in circulating free DNA (cfDNA) extracted from serum. We used a high-throughput DNA methylation assay (MethyLight) to examine serum from 749 cases including breast cancer patients, patients with benign breast diseases and healthy women. The six-gene methylation panel test achieved 79.6% and 82.4% sensitivity with a specificity of 72.4% and 78.1% in diagnosis of breast cancer when compared with healthy and benign disease controls, respectively. Moreover, the methylation panel positive group showed significant differences in the following independent variables: (a) involvement of family history of tumors; (b) a low proliferative index, ki-67; (c) high ratios in luminal subtypes. Additionally the panel also complemented some breast cancer cases which were neglected by mammography or ultrasound. These data suggest that epigenetic markers in serum have potential for diagnosis of breast cancer.
C1 [Shan, Ming; Yin, Huizi; Su, Yonghui; Niu, Ming; Zhong, Zhenbin; Wang, Ji; Zhang, Xianyu; Pang, Da] Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Canc Surg, Harbin, Peoples R China.
   [Shan, Ming; Pang, Da] Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin, Peoples R China.
   [Li, Junnan] Harbin Med Univ, Dept Epidemiol & Biostat, Harbin, Peoples R China.
   [Li, Xiaobo] Harbin Med Univ, Dept Pathol, Harbin, Peoples R China.
   [Wang, Dong] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
   [Kang, Wenli] Gen Hosp Heilongjiang Prov Land Reclamat Headquar, Dept Oncol, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University; Harbin Medical University
RP Pang, D (通讯作者)，Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Canc Surg, Harbin, Peoples R China.; Pang, D (通讯作者)，Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin, Peoples R China.
EM pangda@ems.hrbmu.edu.cn
RI Liu, Zhe/KEJ-5299-2024; Li, J/JXL-5833-2024
FU Affiliated Tumor Hospital of Harbin Medical University [JJZ2010-04]; 'Wu
   Liande' funding of Harbin Medical University [WLD-QN1118]; National
   Natural Science Fund [81172498]; Special Fund of Translational Medical
   Research between China and Russia [CR201402]; Heilongjiang Province
   Science Fund [QC2015113]
FX This study was supported by the funding of the Affiliated Tumor Hospital
   of Harbin Medical University (JJZ2010-04), the 'Wu Liande' funding of
   Harbin Medical University (WLD-QN1118), the National Natural Science
   Fund (81172498), the Special Fund of Translational Medical Research
   between China and Russia (CR201402) and the Heilongjiang Province
   Science Fund (QC2015113).
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Boyd NF, 2007, NEW ENGL J MED, V356, P227, DOI 10.1056/NEJMoa062790
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Goessl C, 1998, CANCER RES, V58, P4728
   Gonzalez R, 2000, ANN ONCOL, V11, P1097, DOI 10.1023/A:1008305412635
   Hibi K, 1998, CANCER RES, V58, P1405
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Holst CR, 2003, CANCER RES, V63, P1596
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hugh J, 2009, J CLIN ONCOL, V27, P1168, DOI 10.1200/JCO.2008.18.1024
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kagan Jacob, 2007, Cancer Res, V67, P4545, DOI 10.1158/0008-5472.CAN-06-2888
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   LEON SA, 1977, CANCER RES, V37, P646
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mandelson MT, 2000, J NATL CANCER I, V92, P1081, DOI 10.1093/jnci/92.13.1081
   McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034
   Müller HM, 2003, CANCER RES, V63, P7641
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Nothacker M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-335
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Sergeant G, 2008, J SURG RES, V150, P144, DOI 10.1016/j.jss.2008.02.012
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Soong R, 1996, HUM PATHOL, V27, P1050, DOI 10.1016/S0046-8177(96)90282-8
   Suijkerbuijk KPM, 2011, ANN ONCOL, V22, P24, DOI 10.1093/annonc/mdq305
   Teh W, 1998, EUR J CANCER, V34, P449, DOI 10.1016/S0959-8049(97)10066-1
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291
   Wittenberger T, 2014, EPIGENOMICS-UK, V6, P311, DOI [10.2217/EPI.14.20, 10.2217/epi.14.20]
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
NR 45
TC 78
Z9 88
U1 2
U2 19
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 5
PY 2016
VL 7
IS 14
BP 18485
EP 18494
DI 10.18632/oncotarget.7608
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5TE
UT WOS:000375699000094
PM 26918343
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Montenegro, MF
   González-Guerrero, R
   Sánchez-del-Campo, L
   Piñero-Madrona, A
   Cabezas-Herrera, J
   Rodríguez-López, JN
AF Montenegro, M. F.
   Gonzalez-Guerrero, R.
   Sanchez-del-Campo, L.
   Pinero-Madrona, A.
   Cabezas-Herrera, J.
   Rodriguez-Lopez, J. N.
TI Targeting the epigenetics of the DNA damage response in breast cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INITIATING CELLS; STEM-CELLS;
   IONIZING-RADIATION; ESTROGEN-RECEPTOR; CYCLE ARREST; BRCA1; DEATH;
   53BP1; METHYLATION
AB Cancer is as much an epigenetic disease as it is a genetic disease, and epigenetic alterations in cancer often serve as potent surrogates for genetic mutations. Because the epigenetic factors involved in the DNA damage response are regulated by multiple elements, therapies to target specific components of the epigenetic machinery can be inefficient. In contrast, therapies aimed at inhibiting the methionine cycle can indirectly inhibit both DNA and protein methylation, and the wide variety of genes and pathways that are affected by these methylations make this global strategy very attractive. In the present study, we propose an adjuvant therapy that targets the epigenetics of the DNA damage response in breast cancer cells and that results in efficient apoptosis and a reduction in distant metastases in vivo. We observed that a combined therapy designed to uncouple adenosine metabolism using dipyridamole in the presence of a new synthetic antifolate, 3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin, simultaneously and efficiently blocked both the folic cycle and the methionine cycle in breast cancer cells and sensitized these cells to radiotherapy. The treatment impeded the recruitment of 53BP1 and BRCA1 to the chromatin regions flanking DNA double-strand breaks and thereby avoided the DNA damage responses in breast cancer cells that were exposed to ionizing radiation. In addition, this hypomethylating therapy was also efficient in reducing the self-renewal capability of breast cancer-initiating cells and induced reversion of mesenchymal phenotypes in breast cancer cells.
C1 [Montenegro, M. F.; Gonzalez-Guerrero, R.; Rodriguez-Lopez, J. N.] Univ Murcia, Sch Biol, Dept Biochem & Mol Biol A, E-30100 Murcia, Spain.
   [Sanchez-del-Campo, L.] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford OX3 7DQ, England.
   [Pinero-Madrona, A.] Univ Hosp Virgen de la Arrixaca, Inst Murciano Invest Biosanitaria, Dept Surg, Murcia 30120, Spain.
   [Cabezas-Herrera, J.] Univ Hosp Virgen de la Arrixaca, Inst Murciano Invest Biosanitaria, Translat Canc Res Grp, Murcia 30120, Spain.
C3 University of Murcia; University of Oxford; Ludwig Institute for Cancer
   Research; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital
   Clinico Universitario Virgen de la Arrixaca
RP Rodríguez-López, JN (通讯作者)，Univ Murcia, Sch Biol, Dept Biochem & Mol Biol A, E-30100 Murcia, Spain.
EM neptuno@um.es
RI Neptuno, Jose/F-5012-2016; Montenegro, Maria/AAF-2695-2021;
   CABEZAS-HERRERA, JUAN/J-9434-2015; del Campo, Luis/R-1308-2018;
   Piñero-Madrona, Antonio/AAB-5138-2022
OI Pinero-Madrona, Antonio/0000-0002-7718-8318; Gonzalez Guerrero,
   Rebeca/0000-0003-1006-7658; Sanchez del Campo, Luis/0000-0002-9537-7761;
   Montenegro, Maria Fernanda/0000-0002-0064-0484; Cabezas-Herrera,
   Juan/0000-0001-9053-5380; Rodriguez-Lopez, Jose
   Neptuno/0000-0001-6863-1173
FU Ministerio de Economia y Competitividad (MINECO); Fondos FEDER
   [SAF2013-48375-C2-1-R]; Fundacion Seneca; Region de Murcia (FS-RM)
   [19304/PI/14]; Ludwig Institute for Cancer Research; FAECC
FX This work was supported by grants from the Ministerio de Economia y
   Competitividad (MINECO; Co-financing with Fondos FEDER)
   (SAF2013-48375-C2-1-R) to JNR-L, and the Fundacion Seneca, the Region de
   Murcia (FS-RM; 19304/PI/14) to JNR-L, JC-H and AP-M. JC-H is contracted
   by the FFIS. MFM is contracted by Fundacion de la Asociacion Espanola
   contra el Cancer (FAECC). LS-d-C is supported by the Ludwig Institute
   for Cancer Research and the FAECC.
CR Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535-7163.MCT-05-0400
   Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274
   Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X
   Coene ED, 2005, MOL BIOL CELL, V16, P997, DOI 10.1091/mbc.e04-10-0895
   Croke M, 2013, CELL CYCLE, V12, P3629, DOI 10.4161/cc.26582
   Guendel I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011379
   Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y
   Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   Jänicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659
   Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Karimi-Busheri F, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2583
   Kim BC, 2010, ONCOL REP, V24, P395, DOI 10.3892/or_00000872
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lagadec C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2479
   Lee YH, 2011, GENE DEV, V25, P176, DOI 10.1101/gad.1975811
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Liang K, 2003, MOL CANCER THER, V2, P1113
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mannello F, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-169
   Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605
   Montenegro MF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-539
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Okunieff P, 2009, CLIN CANCER RES, V15, P5663, DOI 10.1158/1078-0432.CCR-09-0357
   Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658
   Piao L, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.002
   Rodríguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200
   Sáez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009
   Sáez-Ayala M, 2011, CHEMMEDCHEM, V6, P440, DOI 10.1002/cmdc.201000482
   Sánchez-del-Campo L, 2008, INT J CANCER, V123, P2446, DOI 10.1002/ijc.23813
   Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063
   Suman S, 2012, CYTOTECHNOLOGY, V64, P9, DOI 10.1007/s10616-011-9395-0
   Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556
   Venere M, 2014, CELL DEATH DIFFER, V21, P258, DOI 10.1038/cdd.2013.136
   Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50
   Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897
   You Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.443
   Yun J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00163
NR 41
TC 20
Z9 20
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR
PY 2016
VL 7
AR e2180
DI 10.1038/cddis.2016.85
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DK9UR
UT WOS:000375277600007
PM 27054335
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Evans, IC
   Barnes, JL
   Garner, IM
   Pearce, DR
   Maher, TM
   Xu, SW
   Renzoni, EA
   Wells, AU
   Denton, CP
   Laurent, GJ
   Abraham, DJ
   McAnulty, RJ
AF Evans, Iona C.
   Barnes, Josephine L.
   Garner, Ian M.
   Pearce, David R.
   Maher, Toby M.
   Xu, Shiwen
   Renzoni, Elisabetta A.
   Wells, Athol U.
   Denton, Christopher P.
   Laurent, Geoffrey J.
   Abraham, David J.
   McAnulty, Robin J.
TI Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in
   pulmonary fibrosis
SO CLINICAL SCIENCE
LA English
DT Article
DE cyclooxygenase-2; DNA methylation; fibroblast; idiopathic pulmonary
   fibrosis; prostaglandin E-2; systemic sclerosis
ID LUNG FIBROBLASTS; DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT
   METHYLATION; BREAST-CANCER; BLEOMYCIN; GENE; EXPRESSION; MICE;
   PROLIFERATION
AB Fibroblasts derived from the lungs of patients with idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc) produce low levels of prostaglandin (PG) E-2, due to a limited capacity to up-regulate cyclooxygenase-2 (COX-2). This deficiency contributes functionally to the fibroproliferative state, however the mechanisms responsible are incompletely understood. In the present study, we examined whether the reduced level of COX-2 mRNA expression observed in fibrotic lung fibroblasts is regulated epigenetically. The DNA methylation inhibitor, 5-aza-2'-deoxycytidine (5AZA) restored COX-2 mRNA expression by fibrotic lung fibroblasts dose dependently. Functionally, this resulted in normalization of fibroblast phenotype in terms of PGE(2) production, collagen mRNA expression and sensitivity to apoptosis. COX-2 methylation assessed by bisulfite sequencing and methylation microarrays was not different in fibrotic fibroblasts compared with controls. However, further analysis of the methylation array data identified a transcriptional regulator, chromosome 8 open reading frame 4 (thyroid cancer protein 1, TC-1) (c8orf4), which is hypermethylated and down-regulated in fibrotic fibroblasts compared with controls. siRNA knockdown of c8orf4 in control fibroblasts down-regulated COX-2 and PGE(2) production generating a phenotype similar to that observed in fibrotic lung fibroblasts. Chromatin immunoprecipitation demonstrated that c8orf4 regulates COX-2 expression in lung fibroblasts through binding of the proximal promoter. We conclude that the decreased capacity of fibrotic lung fibroblasts to up-regulate COX-2 expression and COX-2-derived PGE(2) synthesis is due to an indirect epigenetic mechanism involving hypermethylation of the transcriptional regulator, c8orf4.
C1 [Evans, Iona C.; Barnes, Josephine L.; Garner, Ian M.; Pearce, David R.; Maher, Toby M.; McAnulty, Robin J.] UCL, UCL Resp Ctr Inflammat & Tissue Repair, Rayne Bldg, London WC1E 6JF, England.
   [Maher, Toby M.; Renzoni, Elisabetta A.; Wells, Athol U.] Royal Brompton Hosp, NIHR Biomed Res Unit, Sydney St, London SW3 6NP, England.
   [Maher, Toby M.; Renzoni, Elisabetta A.; Wells, Athol U.] Royal Brompton Hosp, Interstitial Lung Dis Unit, Sydney St, London SW3 6NP, England.
   [Xu, Shiwen; Denton, Christopher P.; Abraham, David J.] UCL, Ctr Rheumatol & Connect Tissue Dis, Royal Free Campus, London NW3 2PF, England.
   [Laurent, Geoffrey J.] Univ Western Australia, Harry Perkins Inst Med Res, Sch Med & Pharmacol, Ctr Cell Therapy & Regenerat Med, Crawley, WA 6009, Australia.
C3 University of London; University College London; Royal Brompton
   Hospital; Royal Brompton Hospital; University of London; University
   College London; University of Western Australia; Harry Perkins Institute
   of Medical Research
RP McAnulty, RJ (通讯作者)，UCL, UCL Resp Ctr Inflammat & Tissue Repair, Rayne Bldg, London WC1E 6JF, England.
EM r.mcanulty@ucl.ac.uk
RI Maher, Toby/AAM-1618-2020; Abraham, David/AGI-5959-2022; McAnulty,
   Robin/C-2502-2008
OI McAnulty, Robin/0000-0003-1936-4245; Evans, Iona/0000-0002-0225-3154;
   Renzoni, Elisabetta/0000-0002-1118-797X; Maher,
   Toby/0000-0001-7192-9149; Barnes, Josephine/0000-0001-9938-3176; Pearce,
   David/0000-0001-8443-2924
FU Wellcome Trust [071124]; Arthritis Research Campaign [18312]; Medical
   Research Council [G1000440]; MRC [G1000440] Funding Source: UKRI
FX This work was supported by The Wellcome Trust [ grant number 071124];
   the Arthritis Research Campaign [ grant number 18312]; and the Medical
   Research Council [ grant number G1000440].
CR Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bonner JC, 2002, AM J PATHOL, V161, P459, DOI 10.1016/S0002-9440(10)64202-2
   BOROK Z, 1991, AM REV RESPIR DIS, V144, P1080, DOI 10.1164/ajrccm/144.5.1080
   Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427
   Charbeneau RP, 2003, AM J PHYSIOL-LUNG C, V284, pL1103, DOI 10.1152/ajplung.00350.2002
   Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642
   Chung YL, 2004, MOL CANCER THER, V3, P317
   Cisneros J, 2012, AM J PHYSIOL-LUNG C, V303, pL295, DOI 10.1152/ajplung.00332.2011
   Coward WR, 2014, FASEB J, V28, P3183, DOI 10.1096/fj.13-241760
   Coward WR, 2009, MOL CELL BIOL, V29, P4325, DOI 10.1128/MCB.01776-08
   Dakhlallah D, 2013, AM J RESP CRIT CARE, V187, P397, DOI 10.1164/rccm.201205-0888OC
   Dees C, 2014, ANN RHEUM DIS, V73, P1232, DOI 10.1136/annrheumdis-2012-203194
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Friedman JB, 2004, INT J CANCER, V111, P72, DOI 10.1002/ijc.20235
   Fujita M, 2003, AM J RESP CELL MOL, V29, P669, DOI 10.1165/rcmb.2002-0046OC
   Glenisson W, 2007, BBA-MOL CELL RES, V1773, P1572, DOI 10.1016/j.bbamcr.2007.05.016
   Gribbin J, 2006, THORAX, V61, P980, DOI 10.1136/thx.2006.062836
   Hodges RJ, 2004, AM J PATHOL, V165, P1663, DOI 10.1016/S0002-9440(10)63423-2
   Huang SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107055
   Huang SK, 2010, AM J PATHOL, V177, P2245, DOI 10.2353/ajpath.2010.100446
   Hur K, 2003, BIOCHEM BIOPH RES CO, V310, P844, DOI 10.1016/j.bbrc.2003.09.095
   Imai N, 2007, STEM CELLS, V25, P2469, DOI 10.1634/stemcells.2007-0049
   Keerthisingam CB, 2001, AM J PATHOL, V158, P1411, DOI 10.1016/S0002-9440(10)64092-8
   Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612
   Kim J, 2009, J IMMUNOL, V183, P3996, DOI 10.4049/jimmunol.0900956
   Kim Y, 2006, FEBS LETT, V580, P3519, DOI 10.1016/j.febslet.2006.05.036
   Maher TM, 2007, EUR RESPIR J, V30, P835, DOI 10.1183/09031936.00069307
   Maher TM, 2010, AM J RESP CRIT CARE, V182, P73, DOI 10.1164/rccm.200905-0674OC
   Marchand-Adam S, 2003, AM J RESP CRIT CARE, V168, P1156, DOI 10.1164/rccm.200212-1514OC
   McAnulty RJ, 2007, INT J BIOCHEM CELL B, V39, P666, DOI 10.1016/j.biocel.2006.11.005
   Moore BB, 2000, J IMMUNOL, V165, P4032, DOI 10.4049/jimmunol.165.7.4032
   Moore BB, 2005, J IMMUNOL, V174, P5644, DOI 10.4049/jimmunol.174.9.5644
   Moore BB, 2003, AM J PHYSIOL-LUNG C, V284, pL342, DOI 10.1152/ajplung.00168.2002
   Moore BB, 2001, J IMMUNOL, V167, P4368, DOI 10.4049/jimmunol.167.8.4368
   Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050
   Rabinovich EI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033770
   Reinhardt A. K., 2005, RESP RES, V2005, P6
   Rosenbloom J, 2013, BBA-MOL BASIS DIS, V1832, P1088, DOI 10.1016/j.bbadis.2012.12.007
   Sanders YY, 2008, AM J RESP CELL MOL, V39, P610, DOI 10.1165/rcmb.2007-0322OC
   Sanders YY, 2012, AM J RESP CRIT CARE, V186, P525, DOI 10.1164/rccm.201201-0077OC
   Song SH, 2001, CANCER RES, V61, P4628
   Sunde M, 2004, CANCER RES, V64, P2766, DOI 10.1158/0008-5472.CAN-03-2093
   Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139
   Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866
   Yang ZQ, 2007, INT J CANCER, V121, P1265, DOI 10.1002/ijc.22831
NR 48
TC 60
Z9 63
U1 0
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD APR 1
PY 2016
VL 130
IS 8
BP 575
EP 586
DI 10.1042/CS20150697
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DN4KO
UT WOS:000377035400003
PM 26744410
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Wu, JC
   Lai, CS
   Lee, PS
   Ho, CT
   Liou, WS
   Wang, YJ
   Pan, MH
AF Wu, Jia-Ching
   Lai, Ching-Shu
   Lee, Pei-Sheng
   Ho, Chi-Tang
   Liou, Wen-Shiung
   Wang, Ying-Jan
   Pan, Min-Hsiung
TI Anti-cancer efficacy of dietary polyphenols is mediated through
   epigenetic modifications
SO CURRENT OPINION IN FOOD SCIENCE
LA English
DT Article
ID GREEN TEA POLYPHENOLS; CELL-CYCLE ARREST; BREAST-CANCER; DNA
   METHYLTRANSFERASES; PANCREATIC-CANCER; UP-REGULATION; CURCUMIN;
   APOPTOSIS; METHYLATION; INHIBITION
AB Accumulating studies in tumorigenesis indicate that dysregulated gene expression caused by genetic and epigenetic changes lead to the formation of human cancers, and most dysregulated or dysfunctional genes are associated with cell proliferation, programmed cell death (PCD), metastasis, and, in part, tumor suppressor genes (TSGs) or oncogenes. Epigenetic modifications are important regulatory mechanisms that are induced by chemical treatment or environmental changes. Recently, studies have considered the effects of epigenetic modifications on tumorigenesis and disease. Over the past few decades, dietary polyphenols have become a focus of investigation because of their bioactive function in cancer prevention and treatment. In this review article, we summarize the current research on the anti-cancer effects of polyphenols and provide useful information to help promote polyphenol application in cancer research.
C1 [Wu, Jia-Ching; Wang, Ying-Jan] Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Coll Med, Tainan 704, Taiwan.
   [Lai, Ching-Shu] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung 811, Taiwan.
   [Wu, Jia-Ching; Lee, Pei-Sheng; Pan, Min-Hsiung] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA.
   [Liou, Wen-Shiung] Kaohsiung Vet Gen Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.
   [Wang, Ying-Jan] Asia Univ, Dept Biomed Informat, Taichung, Taiwan.
   [Wang, Ying-Jan; Pan, Min-Hsiung] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan.
   [Pan, Min-Hsiung] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
C3 National Cheng Kung University; National Kaohsiung University of Science
   & Technology; National Taiwan University; Rutgers University System;
   Rutgers University New Brunswick; Kaohsiung Veterans General Hospital;
   Asia University Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; Asia University Taiwan
RP Wang, YJ (通讯作者)，Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Coll Med, Tainan 704, Taiwan.; Pan, MH (通讯作者)，Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.; Wang, YJ (通讯作者)，Asia Univ, Dept Biomed Informat, Taichung, Taiwan.; Wang, YJ; Pan, MH (通讯作者)，China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan.; Pan, MH (通讯作者)，Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
EM yjwang@mail.ncku.edu.tw; mhpan@ntu.edu.tw
RI Wang, Ying-Jan/JGD-2274-2023; Ho, Chi-Tang/B-5629-2012; Pan,
   Min-Hsiung/AAT-8865-2021
OI Pan, Min-Hsiung/0000-0002-5188-7030; Lee, Pei-Sheng/0009-0001-9223-5944
FU National Taiwan University [NTU-104R7777]; Ministry of Science and
   Technology [101-2628-B-022-001-MY4, 102-2628-B-002-053-MY3]
FX This study was supported by the National Taiwan University NTU-104R7777;
   Ministry of Science and Technology 101-2628-B-022-001-MY4,
   102-2628-B-002-053-MY3.
CR [Anonymous], 2015, MATH PROBL ENG
   Appari M, 2014, INT J ONCOL, V45, P1391, DOI 10.3892/ijo.2014.2539
   Busch C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0095-z
   Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070372
   Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058929
   Deb G, 2015, MOL CARCINOGEN, V54, P485, DOI 10.1002/mc.22121
   Guo H, 2015, TUMOUR BIOL
   Henning SM, 2013, EPIGENOMICS-UK, V5, P729, DOI 10.2217/epi.13.57
   Hirata H, 2013, BRIT J CANCER, V108, P2070, DOI 10.1038/bjc.2013.173
   Khan MA, 2015, ONCOL REP, V33, P1976, DOI 10.3892/or.2015.3802
   Kronski E, 2014, MOL ONCOL, V8, P581, DOI 10.1016/j.molonc.2014.01.005
   Li HX, 2013, MOL CELL BIOCHEM, V382, P137, DOI 10.1007/s11010-013-1728-1
   Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236
   Li YJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080475, 10.1371/journal.pone.0070390]
   Ma J, 2014, TOXICOL LETT, V231, P82, DOI 10.1016/j.toxlet.2014.09.014
   Mallucci L, 2014, DRUG DISCOV TODAY, V19, P383, DOI 10.1016/j.drudis.2013.11.018
   Ng EKO, 2014, TUMOR BIOL, V35, P2591, DOI 10.1007/s13277-013-1341-7
   Prasad Ram, 2015, Genes Cancer, V6, P49
   Ren XQ, 2015, MOL CELL PROTEOMICS, V14, P316, DOI 10.1074/mcp.M114.041905
   Saud SM, 2014, CARCINOGENESIS, V35, P2778, DOI 10.1093/carcin/bgu209
   Serman L, 2014, BOSNIAN J BASIC MED, V14, P191, DOI 10.17305/bjbms.2014.4.205
   Sharma V, 2015, FOLIA BIOL-PRAGUE, V61, P81
   Shimizu Shigeomi, 2015, Nihon Rinsho, V73, P1302
   Shukla S, 2013, CURR CANCER THER REV, V9, P97, DOI 10.2174/15733947113099990002
   Shukla S, 2014, CANCER LETT, V355, P9, DOI 10.1016/j.canlet.2014.09.017
   Sinha S, 2015, MOL CELL ENDOCRINOL, V406, P102, DOI 10.1016/j.mce.2015.02.020
   Sopjani M, 2015, CURR MOL MED, V15, P27, DOI 10.2174/1566524015666150114111258
   Thakur VS, 2012, CARCINOGENESIS, V33, P377, DOI 10.1093/carcin/bgr277
   Toden S, 2015, CANCER PREV RES, V8, P431, DOI 10.1158/1940-6207.CAPR-14-0354
   Wang SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134110
   Wu DS, 2013, ONCOL REP, V30, P2969, DOI 10.3892/or.2013.2734
   Wu J. C., 2015, MOL NUTR FOOD RES
   Yang SF, 2015, ONCOTARGET, V6, P2736, DOI 10.18632/oncotarget.3088
   Yang YQ, 2012, HISTOL HISTOPATHOL, V27, P217, DOI 10.14670/HH-27.217
   Ye MX, 2015, CANCER LETT, V357, P196, DOI 10.1016/j.canlet.2014.11.028
   Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74
   Zheng JJ, 2014, FEBS J, V281, P88, DOI 10.1111/febs.12574
NR 37
TC 17
Z9 19
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-7993
EI 2214-8000
J9 CURR OPIN FOOD SCI
JI Curr. Opin. Food Sci.
PD APR
PY 2016
VL 8
BP 1
EP 7
DI 10.1016/j.cofs.2016.01.009
PG 7
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA EL5JE
UT WOS:000394656600003
DA 2025-01-12
ER

PT J
AU Zink, LM
   Hake, SB
AF Zink, Lisa-Maria
   Hake, Sandra B.
TI Histone variants: nuclear function and disease
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID CENTROMERE PROTEIN-A; PANCREATIC NEUROENDOCRINE TUMORS; BREAST-CANCER;
   CENP-A; H2A VARIANTS; CELLULAR PROLIFERATION; MAMMALIAN DEVELOPMENT;
   EPIGENETIC REGULATOR; MACROH2A1 ISOFORMS; DRIVER MUTATIONS
AB Histone variants have emerged as important contributors to the regulation of chromatin structure and therefore of almost all DNA-based processes. Hence, these specialized proteins play important roles in transcriptional regulation, cell cycle progression, DNA repair, chromatin stability, chromosome segregation and apoptosis. Due to their evident biological significance, it is not surprising that mutations or the deregulation of their expression levels can have severe implications for cellular functions that ultimately might contribute to or even drive disease development, most notably cancer. Besides the histones themselves, their respective chaperone/remodeling complexes needed for precise variant chromatin deposition, are consequently frequent targets in neoplasms and diverse diseases. In this review, we briefly summarize current understanding on the function of human/mammalian histone variants and their regulatory networks and highlight their roles in cancer development.
C1 [Zink, Lisa-Maria; Hake, Sandra B.] Ludwig Maximilians Univ Munchen, Dept Mol Biol, Biomed Ctr, Grosshadener Str 9, D-82152 Planegg Martinsried, Germany.
   [Hake, Sandra B.] Ctr Integrated Prot Sci Munich, Butenandtstr 5-13, D-81377 Munich, Germany.
   [Hake, Sandra B.] Univ Munich, Biomed Ctr Munich, Mol Biol, Grosshaderner Str 9,Bldg N-B, D-82152 Planegg Martinsried, Germany.
C3 University of Munich; University of Munich; University of Munich
RP Zink, LM; Hake, SB (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Mol Biol, Biomed Ctr, Grosshadener Str 9, D-82152 Planegg Martinsried, Germany.; Hake, SB (通讯作者)，Ctr Integrated Prot Sci Munich, Butenandtstr 5-13, D-81377 Munich, Germany.; Hake, SB (通讯作者)，Univ Munich, Biomed Ctr Munich, Mol Biol, Grosshaderner Str 9,Bldg N-B, D-82152 Planegg Martinsried, Germany.
EM lisa-maria.zink@med.uni-muenchen.de; sandra.hake@med.uni-muenchen.de
OI Zink, Lisa-Maria/0000-0003-4181-2761
FU Deutsche Forschungsgemeinschaft (DFG) [CRC1064]; CIPSM
FX We thank Marcus Buschbeck for critical reading of the manuscript. This
   work was supported by the Deutsche Forschungsgemeinschaft (DFG; CRC1064,
   project A10) and CIPSM to SBH. We apologize to those authors whose work
   we could not cite due to space limitations.
CR Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X
   Athwal RK, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-2
   Baptista T, 2013, ONCOTARGET, V4, P1673, DOI 10.18632/oncotarget.1237
   Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Billon P, 2012, BBA-GENE REGUL MECH, V1819, P290, DOI 10.1016/j.bbagrm.2011.10.004
   Bönisch C, 2008, EXPERT REV PROTEOMIC, V5, P105, DOI 10.1586/14789450.5.1.105
   Bönisch C, 2012, NUCLEIC ACIDS RES, V40, P10719, DOI 10.1093/nar/gks865
   Bönisch C, 2012, NUCLEIC ACIDS RES, V40, P5951, DOI 10.1093/nar/gks267
   Buschbeck M, 2010, EPIGENETICS-US, V5, P118, DOI 10.4161/epi.5.2.11076
   Buschbeck M, 2009, NAT STRUCT MOL BIOL, V16, P1074, DOI 10.1038/nsmb.1665
   Chen HS, 2015, MOL CELL, V59, P719, DOI 10.1016/j.molcel.2015.07.011
   Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275
   Creppe C, 2012, MOL CELL BIOL, V32, P1442, DOI 10.1128/MCB.06323-11
   Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390
   de Tayrac M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073332
   Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0
   Duarte LF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6210
   Dunleavy EM, 2009, CELL, V137, P485, DOI 10.1016/j.cell.2009.02.040
   Eirín-López JM, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-31
   Elsässer SJ, 2015, NATURE, V522, P240, DOI 10.1038/nature14345
   Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3
   Feng J, 2015, HUM PATHOL, V46, P1626, DOI 10.1016/j.humpath.2015.07.002
   Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039
   Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110
   Gibbons RJ, 2003, NAT GENET, V34, P446, DOI 10.1038/ng1213
   Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003
   Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148
   Hu Y, 2011, P NATL ACAD SCI USA, V108, P17141, DOI 10.1073/pnas.1104409108
   Hu Z, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2487
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Iouzalen N, 1996, NUCLEIC ACIDS RES, V24, P3947, DOI 10.1093/nar/24.20.3947
   Jang CW, 2015, GENE DEV, V29, P1377, DOI 10.1101/gad.264150.115
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590
   Kato T, 2007, CANCER RES, V67, P8544, DOI 10.1158/0008-5472.CAN-07-1307
   Kim K, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-34
   Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   Lacoste N, 2014, MOL CELL, V53, P631, DOI 10.1016/j.molcel.2014.01.018
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Liu XW, 1996, MOL CELL BIOL, V16, P4305
   Mao Z, 2014, CELL RES, V24, P389, DOI 10.1038/cr.2014.30
   Marinoni I, 2014, GASTROENTEROLOGY, V146, P453, DOI 10.1053/j.gastro.2013.10.020
   Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850
   McGovern SL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3181
   Mendiburo MJ, 2011, SCIENCE, V334, P686, DOI 10.1126/science.1206880
   Mishra PK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002303
   Monteiro FL, 2014, ONCOTARGET, V5, P3428, DOI 10.18632/oncotarget.2007
   Nashun B, 2015, MOL CELL, V60, P611, DOI 10.1016/j.molcel.2015.10.010
   Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11
   Obri A, 2014, NATURE, V505, P648, DOI 10.1038/nature12922
   Papamichos-Chronakis M, 2011, CELL, V144, P200, DOI 10.1016/j.cell.2010.12.021
   Pehrson JR, 2014, MOL CELL BIOL, V34, P4523, DOI 10.1128/MCB.00794-14
   Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899
   Posavec M, 2013, CELL MOL LIFE SCI, V70, P1509, DOI 10.1007/s00018-013-1294-4
   Qiu JJ, 2013, TUMOR BIOL, V34, P2971, DOI 10.1007/s13277-013-0860-6
   Rai TS, 2014, GENE DEV, V28, P2712, DOI 10.1101/gad.247528.114
   Rasmussen TP, 1999, NUCLEIC ACIDS RES, V27, P3685, DOI 10.1093/nar/27.18.3685
   Ratnakumar K, 2012, GENE DEV, V26, P433, DOI 10.1101/gad.179416.111
   Ricketts MD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8711
   Roberts C, 2002, MOL CELL BIOL, V22, P2318, DOI 10.1128/MCB.22.7.2318-2328.2002
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26
   Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027
   Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465
   Svotelis A, 2009, BIOCHEM CELL BIOL, V87, P179, DOI 10.1139/O08-138
   Valente V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062200
   VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593
   Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009
   Voon HPJ, 2015, CELL REP, V11, P405, DOI 10.1016/j.celrep.2015.03.036
   Wu Q, 2012, LUNG CANCER, V77, P407, DOI 10.1016/j.lungcan.2012.04.007
NR 71
TC 47
Z9 62
U1 0
U2 15
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
EI 1879-0380
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD APR
PY 2016
VL 37
BP 82
EP 89
DI 10.1016/j.gde.2015.12.002
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA DO8WX
UT WOS:000378067300012
PM 26826795
DA 2025-01-12
ER

PT J
AU Puttipanyalears, C
   Kitkumthorn, N
   Buranapraditkun, S
   Keelawat, S
   Mutirangura, A
AF Puttipanyalears, Charoenchai
   Kitkumthorn, Nakarin
   Buranapraditkun, Supranee
   Keelawat, Somboon
   Mutirangura, Apiwat
TI Breast cancer upregulating genes in stromal cells by LINE-1
   hypermethylation and micrometastatic detection
SO EPIGENOMICS
LA English
DT Article
DE breast cancer; LINE-1 hypermethylation; tumor supporting tissue
ID METHYLATION PATTERNS; TGF-BETA; FIBROBLASTS; CARCINOMA; PROLIFERATION;
   SIGNATURES
AB Changes in the methylation level of genes containing LINE-1 alter host gene regulation. Aim: This study demonstrates that paracrine signaling of breast cancer influences the epigenetic regulation of stromal cells. Methods: We proved in vitro and in vivo breast cancer promoted LINE-1 methylation exists exclusively in female stromal cells. Results: Genes containing LINE-1 of breast cancer stromal cells were upregulated. Furthermore, one of the genes, MUC-1, was demonstrated to have expression in plasma cells from the lymph nodes of patients with lymph node metastasis or micrometastasis. Conclusion: Breast cancer sends a paracrine signal to stroma cells causing LINE-1 epigenetic regulation. Moreover, the regulated genes in stroma cells are potential biomarkers for detecting breast cancer micrometastasis.
C1 [Puttipanyalears, Charoenchai] Chulalongkorn Univ, Fac Grad Sch, Interdept Program BioMed Sci, Bangkok, Thailand.
   [Puttipanyalears, Charoenchai; Mutirangura, Apiwat] Chulalongkorn Univ, Fac Med, Dept Anat, Ctr Excellence Mol Genet Canc & Human Dis, Bangkok 10330, Thailand.
   [Kitkumthorn, Nakarin] Mahidol Univ, Fac Dent, Dept Oral Biol, Bangkok 10700, Thailand.
   [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Dept Med, Div Allergy & Clin Immunol, Bangkok 10330, Thailand.
   [Keelawat, Somboon] Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Mahidol University;
   Chulalongkorn University; Chulalongkorn University
RP Mutirangura, A (通讯作者)，Chulalongkorn Univ, Fac Med, Dept Anat, Ctr Excellence Mol Genet Canc & Human Dis, Bangkok 10330, Thailand.
EM mapiwat@chula.ac.th
RI Keelawat, Somboon/AAH-8616-2020
OI Keelawat, Somboon/0000-0002-4180-7914
FU National Science and Technology Development Agency (NSTDA), Thailand;
   Thailand Research Fund [RSA5580013]; Royal Golden Jubilee PhD Program
   [PHD/0053/2549]; Anantara Siam Bangkok Hotel Care for Cancer Fun Run;
   Thai Red Cross Society; Chulalongkorn University
FX This study was financially supported by a Research Chair Grant 2011 from
   the National Science and Technology Development Agency (NSTDA), Thailand
   grant number RSA5580013 from the Thailand Research Fund, The Royal
   Golden Jubilee PhD Program (grant number PHD/0053/2549) and the Anantara
   Siam Bangkok Hotel Care for Cancer 2016 Fun Run in coordination with the
   Thai Red Cross Society and Chulalongkorn University. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Aporntewan C, 2011, ASIAN BIOMED, V5, P257, DOI 10.5372/1905-7415.0502.034
   Aporntewan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017934
   AYDINER A, 1994, ACTA ONCOL, V33, P181, DOI 10.3109/02841869409098402
   Baba Y, 2014, CLIN CANCER RES, V1, P1
   Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Gaeta CM, 2013, Q J NUCL MED MOL IM, V57, P352
   Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785
   HELLMAN S, 1994, J CLIN ONCOL, V12, P2229, DOI 10.1200/JCO.1994.12.10.2229
   Hugo HJ, 2012, CANCER MICROENVIRON, V5, P83, DOI 10.1007/s12307-012-0098-7
   Jotzu C, 2010, ANAL CELL PATHOL, V33, P61, DOI [10.1155/2010/695162, 10.3233/ACP-CLO-2010-0535]
   Kaer K, 2013, GENE, V518, P231, DOI 10.1016/j.gene.2013.01.008
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Khowutthitham S, 2012, GENES GENOM, V34, P517, DOI 10.1007/s13258-012-0058-0
   Kitkumthorn N, 2012, ASIAN PAC J CANCER P, V13, P4469, DOI 10.7314/APJCP.2012.13.9.4469
   Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8
   Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107
   Lee HS, 2015, ONCOL LETT, V9, P1691, DOI 10.3892/ol.2015.2917
   Man YG, 2004, EXP CELL RES, V301, P103, DOI 10.1016/j.yexcr.2004.08.037
   MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8
   Patchsung M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037009
   Pedraza V, 2010, CANCER-AM CANCER SOC, V116, P486, DOI 10.1002/cncr.24805
   Phokaew C, 2008, NUCLEIC ACIDS RES, V36, P5704, DOI 10.1093/nar/gkn571
   ROSEN PP, 1989, J CLIN ONCOL, V7, P1239, DOI 10.1200/JCO.1989.7.9.1239
   Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949
   Shao ZM, 2000, ONCOGENE, V19, P4337, DOI 10.1038/sj.onc.1203785
   Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
   Thierry T, 2000, NUCLEIC ACIDS RES, V28, P411
   Wanichnopparat W, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-205
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129
NR 33
TC 17
Z9 17
U1 0
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD APR
PY 2016
VL 8
IS 4
BP 475
EP 486
DI 10.2217/epi-2015-0007
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DJ4OR
UT WOS:000374186500004
PM 27035076
DA 2025-01-12
ER

PT J
AU Gerashchenko, BI
   Salmina, K
   Eglitis, J
   Huna, A
   Grjunberga, V
   Erenpreisa, J
AF Gerashchenko, B. I.
   Salmina, K.
   Eglitis, J.
   Huna, A.
   Grjunberga, V.
   Erenpreisa, J.
TI Disentangling the aneuploidy and senescence paradoxes: a study of
   triploid breast cancers non-responsive to neoadjuvant therapy
SO HISTOCHEMISTRY AND CELL BIOLOGY
LA English
DT Article
DE Breast cancer; Triple-negative; Triploidy; Resistance; Self-renewal;
   Senescence
ID EMBRYONAL CARCINOMA-CELLS; DNA-DAMAGE RESPONSE; TUMOR-CELLS; CHROMOSOMAL
   INSTABILITY; PROGNOSTIC-SIGNIFICANCE; REVERSIBLE POLYPLOIDY;
   SELF-RENEWAL; EXPRESSION; RESISTANCE; KARYOTYPE
AB Aneuploid cells should have a reduced proliferation rate due to difficulty in proceeding through mitosis. However, contrary to this, high aneuploidy is associated with aggressive tumour growth and poor survival prognosis, in particular in triploid breast cancer. A further paradox revolves around the observation that, while cell senescence should inhibit proliferation, the senescence marker p16INK4a correlates with poor treatment outcome in patients with a very aggressive triple-negative breast carcinoma (TNBC). In this study, we aim to pour light on the possible relationship of these conundrums with polyploidy of tumour cells. We performed detailed analysis of DNA histogram profiles in diagnostic core biopsies of 30 cases of operable breast cancer and found that near triploidy in TNBC and other forms correlated with weak or no response to neoadjuvant chemotherapy (NAC) as scored by Miller-Payne index. Polyploid cells in operation samples from tumours that were non-responsive to NAC treatment were Ki67 and CD44 positive. In addition, polyploid cells were positive for markers of embryonic stemness (OCT4, SOX2, NANOG) and senescence (p16INK4a). The relationship patterns between p16INK4a and NANOG were heterogeneous, with predominantly mutually exclusive expression but also synergistic and intermediate variants in the same samples. We conclude that the aneuploidy and senescence paradoxes can be explained by the mutual platform of polyploidy, conferring genomic and epigenetic instability as a survival advantage. Such cells are able to bypass aneuploidy restrictions of conventional mitosis and overcome the barrier of senescence by a shift to self-renewal, resulting in progression of cancer.
C1 [Gerashchenko, B. I.; Salmina, K.; Huna, A.; Erenpreisa, J.] Latvian Biomed Res & Study Ctr, Ratsupites 1, LV-1067 Riga, Latvia.
   [Gerashchenko, B. I.] Natl Acad Sci Ukraine, RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, UA-03022 Kiev, Ukraine.
   [Eglitis, J.; Grjunberga, V.] Univ Latvia, Fac Med, LV-1586 Riga, Latvia.
C3 Latvian Biomedical Research & Study Centre; National Academy of Sciences
   Ukraine; Kavetsky Institute of Experimental Pathology, Oncology &
   Radiobiology of NASU; University of Latvia
RP Erenpreisa, J (通讯作者)，Latvian Biomed Res & Study Ctr, Ratsupites 1, LV-1067 Riga, Latvia.
EM katrina@biomed.lu.lv
OI Huna, Anda/0000-0003-2030-8865
FU Latvian Scientific Council [ESF
   2013/0023/1DP/1.1.1.2.0/13/APIA/VIAA/037, 341/2012]; LOreal Latvian
   fellowship "For Women in Science"; Latvian National Commission for
   UNESCO; Latvian Academy of Sciences
FX We are thankful to the medical nurse Aija Karklina for clinical
   management of the project, Dr. Ingrida Shlosberga, for preparing biopsy
   smears for DNA cytometry, and MsC biol. Elina Zandberga for sharing some
   primary cultures of operation material. Dr. Jamie Honeychurch is
   acknowledged for editing the manuscript and Jekabs Krigerts for
   preparation of illustrations for the manuscript. ESF
   2013/0023/1DP/1.1.1.2.0/13/APIA/VIAA/037, Grant 341/2012 of the Latvian
   Scientific Council were the sources of funding. AH received fellowship:
   The LOreal Latvian fellowship "For Women in Science" with the support of
   the Latvian National Commission for UNESCO and the Latvian Academy of
   Sciences.
CR Abou-Bakr AA, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.317
   Achuthan S, 2011, J BIOL CHEM, V286, P37813, DOI 10.1074/jbc.M110.200675
   Arima Y, 2012, INT J CANCER, V130, P2568, DOI 10.1002/ijc.26271
   AUER GU, 1980, ANAL QUANT CYTOL, V2, P161
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Chitikova ZV, 2014, CELL CYCLE, V13, P1424, DOI 10.4161/cc.28402
   Dang D, 2013, BREAST CANCER MANAG, V2, P537, DOI 10.2217/BMT.13.59
   Dayal JHS, 2013, BRIT J CANCER, V108, P873, DOI 10.1038/bjc.2013.42
   Di Leo A, 2015, BREAST, V24, P321, DOI 10.1016/j.breast.2015.03.001
   Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295
   Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739
   ERENPREISA J, 1979, HISTOCHEMISTRY, V60, P321, DOI 10.1007/BF00500660
   Erenpreisa Jekaterina, 2015, Oncoscience, V2, P3
   Erenpreisa J, 2011, CELL BIOL INT, V35, P687, DOI 10.1042/CBI20100762
   FALLENIUS AG, 1988, CANCER-AM CANCER SOC, V62, P331, DOI 10.1002/1097-0142(19880715)62:2<331::AID-CNCR2820620218>3.0.CO;2-8
   Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011
   Gerashchenko B. I., 2014, Experimental Oncology, V36, P219
   Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7
   Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123
   Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642
   Heng HH, 2016, DEBATING CANCER: THE PARADOX IN CANCER RESEARCH, P230
   Ho CC, 2010, ONCOTARGET, V1, P583
   Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Huna A, 2015, CELL CYCLE, V14, P2969, DOI 10.1080/15384101.2015.1056948
   Huna Anda, 2011, J Aging Res, V2011, P103253, DOI 10.4061/2011/103253
   Ivanov A, 2003, J CELL SCI, V116, P4095, DOI 10.1242/jcs.00740
   Jackson TR, 2013, CELL CYCLE, V12, P430, DOI 10.4161/cc.23285
   Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058
   Lamb R, 2014, ONCOTARGET, V5, P7833, DOI 10.18632/oncotarget.2312
   Leibowitz ML, 2015, ANNU REV GENET, V49, P183, DOI 10.1146/annurev-genet-120213-092228
   Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mosieniak G, 2010, CURR PHARM DESIGN, V16, P734, DOI 10.2174/138161210790883714
   Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1
   Palla AR, 2014, ONCOGENE, V33, P2513, DOI 10.1038/onc.2013.196
   Pisco AO, 2015, BRIT J CANCER, V112, P1725, DOI 10.1038/bjc.2015.146
   Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030
   Schulze S, 2011, CELL ONCOL, V34, P199, DOI 10.1007/s13402-011-0013-0
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003
   Sherman MY, 2011, AGING CELL, V10, P949, DOI 10.1111/j.1474-9726.2011.00736.x
   Staarmann J, 2015, FOLIA HISTOCHEM CYTO, V53, P11, DOI 10.5603/FHC.a2015.0001
   Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663
   Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106
   Teixeira M.T., 1995, CANC CYTOGENETICS, P493
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0
   Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002
   Wu P. C., 2012, Experimental Oncology, V34, P298
   Zhang D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/432652
   Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96
   Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825
NR 55
TC 32
Z9 33
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0948-6143
EI 1432-119X
J9 HISTOCHEM CELL BIOL
JI Histochem. Cell Biol.
PD APR
PY 2016
VL 145
IS 4
BP 497
EP 508
DI 10.1007/s00418-016-1415-x
PG 12
WC Cell Biology; Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Microscopy
GA FH6OF
UT WOS:000411295900001
PM 26860864
DA 2025-01-12
ER

PT J
AU Varier, RA
   Pau, ECD
   van der Groep, P
   Lindeboom, RGH
   Matarese, F
   Mensinga, A
   Smits, AH
   Edupuganti, RR
   Baltissen, MP
   Jansen, PWTC
   ter Hoeve, N
   van Weely, DR
   Poser, I
   van Diest, PJ
   Stunnenberg, HG
   Vermeulen, M
AF Varier, Radhika A.
   Pau, Enrique Carrillo de Santa
   van der Groep, Petra
   Lindeboom, Rik G. H.
   Matarese, Filomena
   Mensinga, Anneloes
   Smits, Arne H.
   Edupuganti, Raghu Ram
   Baltissen, Marijke P.
   Jansen, Pascal W. T. C.
   ter Hoeve, Natalie
   van Weely, Danny R.
   Poser, Ina
   van Diest, Paul J.
   Stunnenberg, Hendrik G.
   Vermeulen, Michiel
TI Recruitment of the Mammalian Histone-modifying EMSY Complex to Target
   Genes Is Regulated by ZNF131
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CHROMATIN MODIFICATIONS; BREAST-CANCER; MARKS
AB Recent work from others and us revealed interactions between the Sin3/HDAC complex, the H3K4me3 demethylase KDM5A, GATAD1, and EMSY. Here, we characterize the EMSY/KDM5A/SIN3B complex in detail by quantitative interaction proteomics and ChIP-sequencing. We identify a novel substoichiometric interactor of the complex, transcription factor ZNF131, which recruits EMSY to a large number of active, H3K4me3 marked promoters. Interestingly, using an EMSY knock-out line and subsequent rescue experiments, we show that EMSY is in most cases positively correlated with transcriptional activity of its target genes and stimulates cell proliferation. Finally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner. Taken together, these data open venues for exploring the possibility that sporadic breast cancer patients with EMSY amplification might benefit from epigenetic combination therapy targeting both the KDM5A demethylase and histone deacetylases.
C1 [Varier, Radhika A.; Mensinga, Anneloes; Smits, Arne H.; Jansen, Pascal W. T. C.; van Weely, Danny R.; Vermeulen, Michiel] Univ Med Ctr Utrecht, Dept Mol Canc Res, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.
   [Pau, Enrique Carrillo de Santa; Lindeboom, Rik G. H.; Matarese, Filomena; Smits, Arne H.; Edupuganti, Raghu Ram; Baltissen, Marijke P.; Jansen, Pascal W. T. C.; Stunnenberg, Hendrik G.; Vermeulen, Michiel] Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl Zuid 30, NL-6525 GA Nijmegen, Netherlands.
   [van der Groep, Petra; ter Hoeve, Natalie; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
   [Poser, Ina] Max Planck Inst Mol Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.
   [Varier, Radhika A.] Francis Crick Inst, Cell Fate & Gene Regulat Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.
   [Pau, Enrique Carrillo de Santa] BBVA Fdn, CNIO Canc Cell Biol Programme, Spanish Natl Canc Res Ctr CNIO, Epithelial Carcinogenesis Grp, Madrid, Spain.
   [Mensinga, Anneloes] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University Medical Center; Max Planck Society;
   Francis Crick Institute; Centro Nacional de Investigaciones Oncologicas
   (CNIO); Utrecht University; Utrecht University Medical Center
RP Vermeulen, M (通讯作者)，Univ Med Ctr Utrecht, Dept Mol Canc Res, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.; Vermeulen, M (通讯作者)，Radboud Inst Mol Life Sci, Dept Mol Biol, Geert Grootepl Zuid 30, NL-6525 GA Nijmegen, Netherlands.
EM m.vermeulen@ncmls.ru.nl
RI Stunnenberg, Hendrik/D-6875-2012; Edupuganti, Venkata/AAG-6486-2019;
   Lindeboom, Rik/IST-3118-2023; de Santa Pau, Enrique/AAV-7544-2021;
   Vermeulen, Michiel/C-8883-2013
OI Varier, Radhika/0000-0003-1302-3159; Edupuganti, Raghu
   Ram/0000-0001-9414-2672; Lindeboom, Rik/0000-0002-3660-504X; CARRILLO DE
   SANTA PAU, ENRIQUE/0000-0002-2310-2267; Smits, Arne
   H/0000-0001-5011-0898; Vermeulen, Michiel/0000-0003-0836-6894
FU Dutch Cancer Society [UU2009-4488]; Netherlands Organization for
   Scientific Research (NWO-VIDI) [864.09.003]; Netherlands Organization
   for Scientific Research (NWO Gravitation program CGC.nl)
FX This work was supported by Grant UU2009-4488 from the Dutch Cancer
   Society (to K. W. F.) and by grants from the Netherlands Organization
   for Scientific Research (NWO-VIDI, project number 864.09.003 and the NWO
   Gravitation program CGC.nl). The authors declare that they have no
   conflicts of interest with the contents of this article.
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Chikina MD, 2012, BIOINFORMATICS, V28, P607, DOI 10.1093/bioinformatics/bts009
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   Donaldson NS, 2010, EXP CELL RES, V316, P1692, DOI 10.1016/j.yexcr.2010.03.011
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006
   McDonel P, 2009, INT J BIOCHEM CELL B, V41, P108, DOI 10.1016/j.biocel.2008.07.022
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Moshkin YM, 2009, MOL CELL, V35, P782, DOI 10.1016/j.molcel.2009.07.020
   Poser I, 2008, NAT METHODS, V5, P409, DOI 10.1038/NMETH.1199
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Reynolds N, 2013, DEVELOPMENT, V140, P505, DOI 10.1242/dev.083105
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Smits AH, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks941
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   VANDIEST PJ, 1992, HUM PATHOL, V23, P876, DOI 10.1016/0046-8177(92)90398-M
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Viré E, 2014, MOL CELL, V53, P806, DOI 10.1016/j.molcel.2014.01.029
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 29
TC 32
Z9 38
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 1
PY 2016
VL 291
IS 14
BP 7313
EP 7324
DI 10.1074/jbc.M115.701227
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DW2BJ
UT WOS:000383447600009
PM 26841866
OA Green Published
DA 2025-01-12
ER

PT J
AU Schemionek, M
   Herrmann, O
   Reher, MM
   Chatain, N
   Schubert, C
   Costa, IG
   Hänzelmann, S
   Gusmao, EG
   Kintsler, S
   Braunschweig, T
   Hamilton, A
   Helgason, GV
   Copland, M
   Schwab, A
   Müller-Tidow, C
   Li, S
   Holyoake, TL
   Brümmendorf, TH
   Koschmieder, S
AF Schemionek, M.
   Herrmann, O.
   Reher, M. M.
   Chatain, N.
   Schubert, C.
   Costa, I. G.
   Haenzelmann, S.
   Gusmao, E. G.
   Kintsler, S.
   Braunschweig, T.
   Hamilton, A.
   Helgason, G. V.
   Copland, M.
   Schwab, A.
   Mueller-Tidow, C.
   Li, S.
   Holyoake, T. L.
   Bruemmendorf, T. H.
   Koschmieder, S.
TI Mtss1 is a critical epigenetically regulated tumor suppressor in CML
SO LEUKEMIA
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; SQUAMOUS-CELL
   CARCINOMA; MISSING-IN-METASTASIS; BCR-ABL ACTIVITY; STEM-CELLS;
   BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION;
   DOWN-REGULATION
AB Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr-Abl mice and in patients with CML at diagnosis, and Mtss1 was restored when patients achieved complete remission. Forced expression of Mtss1 decreased clonogenic capacity and motility of murine myeloid progenitor cells and reduced tumor growth. Viral transduction of Mtss1 into lineage-depleted SCLtTA/Bcr-Abl bone marrow cells decreased leukemic cell burden in recipients, and leukemogenesis was reduced upon injection of Mtss1-overexpressing murine myeloid 32D cells. Tyrosine kinase inhibitor (TKI) therapy and reversion of Bcr-Abl expression increased Mtss1 expression but failed to restore it to control levels. CML patient samples revealed higher DNA methylation of specific Mtss1 promoter CpG sites that contain binding sites for Kaiso and Rest transcription factors. In summary, we identified a novel tumor suppressor in CML stem cells that is downregulated by both Bcr-Abl kinase-dependent and -independent mechanisms. Restored Mtss1 expression markedly inhibits primitive leukemic cell biology in vivo, providing a therapeutic rationale for the Bcr-Abl-Mtss1 axis to target TKI-resistant CML stem cells in patients.
C1 [Schemionek, M.; Herrmann, O.; Reher, M. M.; Chatain, N.; Schubert, C.; Bruemmendorf, T. H.; Koschmieder, S.] Rhein Westfal TH Aachen, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Fac Med, Aachen, Germany.
   [Costa, I. G.; Haenzelmann, S.; Gusmao, E. G.] Rhein Westfal TH Aachen, Inst Biomed Engn, IZKF Res Grp Bioinformat, Aachen, Germany.
   [Kintsler, S.; Braunschweig, T.] Rhein Westfal TH Aachen, Inst Pathol, Fac Med, Aachen, Germany.
   [Hamilton, A.] London Res Inst Canc Res UK, Haematopoiet Stem Cell Lab, London, England.
   [Helgason, G. V.; Copland, M.; Holyoake, T. L.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.
   [Schwab, A.] Univ Munster, Inst Physiol 2, D-48149 Munster, Germany.
   [Mueller-Tidow, C.] Univ Halle, Dept Hematol & Oncol, Halle, Germany.
   [Li, S.] Univ Massachusetts, Sch Med, Worcester, MA USA.
C3 RWTH Aachen University; RWTH Aachen University; RWTH Aachen University;
   University of London; Institute of Cancer Research - UK; University of
   Glasgow; University of Munster; Martin Luther University Halle
   Wittenberg; University of Massachusetts System; University of
   Massachusetts Worcester
RP Schemionek, M (通讯作者)，Rhein Westfal TH Aachen, Univ Klinikum, Med Klin Hamatol Onkol Hamostaseol & SCT 4, Pauwelsstr 30, D-52074 Aachen, Germany.
EM mschemionek@ukaachen.de
RI Holyoake, Tessa/M-3668-2015; Gusmao, Eduardo/O-3435-2019; Schemionek,
   Mirle/HKN-2406-2023; Costa, Ivan/D-5335-2014; Muller-Tidow,
   Carsten/O-7207-2018; Gesteira Costa Filho, Ivan/B-5737-2008;
   Braunschweig, Till/AAO-5725-2020; Gusmao, Eduardo/J-9673-2016
OI Helgason, G Vignir/0000-0003-1616-132X; Muller-Tidow,
   Carsten/0000-0002-7166-5232; Copland, Mhairi/0000-0002-7655-016X;
   Koschmieder, Steffen/0000-0002-1011-8171; Hanzelmann,
   Sonja/0000-0003-4953-0101; Gesteira Costa Filho,
   Ivan/0000-0003-2890-8697; Braunschweig, Till/0000-0001-9166-2912;
   Schemionek, Mirle/0000-0002-5947-3529; Gusmao,
   Eduardo/0000-0001-7461-1443
FU Medical Faculty, RWTH Aachen University [Start-691306-46/13]; German
   Research Foundation (DFG) [KO 2155/2-2]; German Jose Carreras Leukemia
   Foundation (DJCLS) [10/23]; Cancer Research UK (CRUK) programme
   [C11074/A11008]; MRC [G0600782] Funding Source: UKRI
FX The authors thank Kristina Feldberg for excellent technical assistance.
   MS has received grant funding by the Medical Faculty, RWTH Aachen
   University (Start-691306-46/13). SK has received grant funding by the
   German Research Foundation (DFG KO 2155/2-2) and by the German Jose
   Carreras Leukemia Foundation (DJCLS grant 10/23). TH has received grant
   funding by the Cancer Research UK (CRUK) programme (C11074/A11008).
CR Benita Y, 2010, BLOOD, V115, P5376, DOI 10.1182/blood-2010-01-263855
   Bolton-Gillespie E, 2013, BLOOD, V121, P4175, DOI 10.1182/blood-2012-11-466938
   Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804
   Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274
   Cao M, 2012, BIOCHEM J, V446, P469, DOI 10.1042/BJ20120329
   Chaudhary F, 2015, BIOCHEM J, V465, P89, DOI 10.1042/BJ20140573
   Chen YY, 2011, BLOOD, V118, P390, DOI 10.1182/blood-2010-11-316760
   Cofre J, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-28
   Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721
   DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902
   Dieterich P, 2008, P NATL ACAD SCI USA, V105, P459, DOI 10.1073/pnas.0707603105
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Elling C, 2011, BLOOD, V117, P2935, DOI 10.1182/blood-2010-05-286757
   Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411
   Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732
   Hamilton A, 2006, LEUKEMIA, V20, P1035, DOI 10.1038/sj.leu.2404189
   Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   Hu XL, 2011, CANCER RES, V71, P2882, DOI 10.1158/0008-5472.CAN-10-2493
   Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304
   Isaksson HS, 2014, ONCOTARGET, V5, P4040, DOI 10.18632/oncotarget.1938
   Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497
   Jongen-Lavrencic M, 2005, LEUKEMIA, V19, P373, DOI 10.1038/sj.leu.2403626
   Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543
   Kayser G, 2015, BRIT J CANCER, V112, P866, DOI 10.1038/bjc.2015.2
   Kedmi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005866
   Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x
   Korhonen J, 2009, BIOINFORMATICS, V25, P3181, DOI 10.1093/bioinformatics/btp554
   Krause DS, 2014, BLOOD, V123, P1361, DOI 10.1182/blood-2013-11-538694
   Kuck D, 2010, MOL CANCER THER, V9, P3015, DOI 10.1158/1535-7163.MCT-10-0609
   Kumari A, 2012, BLOOD, V119, P530, DOI 10.1182/blood-2010-08-303495
   Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005
   Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65
   Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059
   Li YH, 2014, ONCOL REP, V31, P2438, DOI 10.3892/or.2014.3098
   Makishima H, 2011, BLOOD, V117, pE198, DOI 10.1182/blood-2010-06-292433
   Mali RS, 2011, CANCER CELL, V20, P357, DOI 10.1016/j.ccr.2011.07.016
   Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997
   Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465
   Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951
   Oki Y, 2007, CANCER, V109, P899, DOI 10.1002/cncr.22470
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Schemionek M, 2012, LEUKEMIA, V26, P1030, DOI 10.1038/leu.2011.366
   Schemionek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125783
   Schemionek M, 2010, BLOOD, V115, P3185, DOI 10.1182/blood-2009-04-215376
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Tabe Y, 2012, LEUKEMIA, V26, P883, DOI 10.1038/leu.2011.291
   Thomas EK, 2008, LEUKEMIA, V22, P898, DOI 10.1038/leu.2008.71
   Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106
   Wang J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-227
   Wilczynski B, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-82
   Wu WY, 2014, MOL CELL BIOCHEM, V388, P249, DOI 10.1007/s11010-013-1916-z
   Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
   Yu D, 2012, ONCOGENE, V31, P3561, DOI 10.1038/onc.2011.509
   Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890
   Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350
   Zhong JT, 2013, ONCOTARGET, V4, P2339, DOI 10.18632/oncotarget.1446
NR 63
TC 31
Z9 32
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2016
VL 30
IS 4
BP 823
EP 832
DI 10.1038/leu.2015.329
PG 10
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA DJ3RK
UT WOS:000374123100008
PM 26621336
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Jiang, X
   Hu, C
   Arnovitz, S
   Bugno, J
   Yu, M
   Zuo, ZX
   Chen, P
   Huang, H
   Ulrich, B
   Gurbuxani, S
   Weng, HY
   Strong, J
   Wang, YG
   Li, YY
   Salat, J
   Li, SL
   Elkahloun, AG
   Yang, Y
   Neilly, MB
   Larson, RA
   Le Beau, MM
   Herold, T
   Bohlander, SK
   Liu, PP
   Zhang, JW
   Li, ZJ
   He, C
   Jin, J
   Hong, S
   Chen, JJ
AF Jiang, Xi
   Hu, Chao
   Arnovitz, Stephen
   Bugno, Jason
   Yu, Miao
   Zuo, Zhixiang
   Chen, Ping
   Huang, Hao
   Ulrich, Bryan
   Gurbuxani, Sandeep
   Weng, Hengyou
   Strong, Jennifer
   Wang, Yungui
   Li, Yuanyuan
   Salat, Justin
   Li, Shenglai
   Elkahloun, Abdel G.
   Yang, Yang
   Neilly, Mary Beth
   Larson, Richard A.
   Le Beau, Michelle M.
   Herold, Tobias
   Bohlander, Stefan K.
   Liu, Paul P.
   Zhang, Jiwang
   Li, Zejuan
   He, Chuan
   Jin, Jie
   Hong, Seungpyo
   Chen, Jianjun
TI miR-22 has a potent anti-tumour role with therapeutic potential in acute
   myeloid leukaemia
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CELL SELF-RENEWAL; TUMOR-SUPPRESSOR; DELETED REGION; STEM-CELLS; MLL;
   TARGETS; GENE; DIFFERENTIATION; TET2; IDENTIFICATION
AB MicroRNAs are subject to precise regulation and have key roles in tumorigenesis. In contrast to the oncogenic role of miR-22 reported in myelodysplastic syndrome (MDS) and breast cancer, here we show that miR-22 is an essential anti-tumour gatekeeper in de novo acute myeloid leukaemia (AML) where it is significantly downregulated. Forced expression of miR-22 significantly suppresses leukaemic cell viability and growth in vitro, and substantially inhibits leukaemia development and maintenance in vivo. Mechanistically, miR-22 targets multiple oncogenes, including CRTC1, FLT3 and MYCBP, and thus represses the CREB and MYC pathways. The downregulation of miR-22 in AML is caused by TET1/GFI1/EZH2/SIN3A-mediated epigenetic repression and/or DNA copy-number loss. Furthermore, nanoparticles carrying miR-22 oligos significantly inhibit leukaemia progression in vivo. Together, our study uncovers a TET1/GFI1/EZH2/SIN3A/miR-22/CREB-MYC signalling circuit and thereby provides insights into epigenetic/genetic mechanisms underlying the pathogenesis of AML, and also highlights the clinical potential of miR-22-based AML therapy.
C1 [Jiang, Xi; Hu, Chao; Zuo, Zhixiang; Weng, Hengyou; Strong, Jennifer; Wang, Yungui; Chen, Jianjun] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH 45219 USA.
   [Jiang, Xi; Hu, Chao; Arnovitz, Stephen; Zuo, Zhixiang; Chen, Ping; Huang, Hao; Ulrich, Bryan; Weng, Hengyou; Wang, Yungui; Li, Yuanyuan; Salat, Justin; Li, Shenglai; Neilly, Mary Beth; Larson, Richard A.; Le Beau, Michelle M.; Li, Zejuan; Chen, Jianjun] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA.
   [Hu, Chao; Wang, Yungui; Jin, Jie] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
   [Bugno, Jason; Yang, Yang; Hong, Seungpyo] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA.
   [Yu, Miao; He, Chuan] Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.
   [Yu, Miao; He, Chuan] Univ Chicago, Howard Hughes Med Inst, Inst Biophys Dynam, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Zuo, Zhixiang] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   [Gurbuxani, Sandeep] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Elkahloun, Abdel G.; Liu, Paul P.] NHGRI, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
   [Herold, Tobias] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany.
   [Bohlander, Stefan K.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1142, New Zealand.
   [Zhang, Jiwang] Loyola Univ, Med Ctr, Inst Oncol, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Li, Zejuan] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Hong, Seungpyo] Yonsei Univ, Integrated Sci & Engn Div, Underwood Int Coll, Inchon 406840, South Korea.
C3 University System of Ohio; University of Cincinnati; University of
   Chicago; Zhejiang University; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital; University
   of Chicago; University of Chicago; Howard Hughes Medical Institute; Sun
   Yat Sen University; State Key Lab Oncology South China; University of
   Chicago; National Institutes of Health (NIH) - USA; NIH National Human
   Genome Research Institute (NHGRI); University of Munich; University of
   Auckland; Loyola University Chicago; University of Chicago; Yonsei
   University
RP Chen, JJ (通讯作者)，Univ Cincinnati, Dept Canc Biol, Cincinnati, OH 45219 USA.; Chen, JJ (通讯作者)，Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA.
EM chen3jj@ucmail.uc.edu
RI Jin, Jie/JAX-2131-2023; He, Chuan/HZJ-6319-2023; Larson,
   Richard/AAE-7223-2019; Zhang, Jiwang/AAG-2706-2021; Hong,
   Seungpyo/HCI-9922-2022; chen, JJ/HGB-6029-2022; li,
   yuanyuan/GZA-4435-2022; Sun, Hao/T-5576-2019; Zuo, Zhixiang/M-4441-2016;
   Herold, Tobias/AAD-1072-2019; Li, Shenglai/Z-3558-2019
OI Zuo, Zhixiang/0000-0002-2492-2689; Larson, Richard/0000-0001-9168-3203;
   Herold, Tobias/0000-0002-9615-9432; Li, Shenglai/0000-0002-1227-4338;
   HUANG, HAO/0000-0002-6687-6967; Chen, Jianjun/0000-0003-3749-2902
FU Leukemia & Lymphoma Society (LLS) Translational Research Grant; National
   Institutes of Health (NIH) R01 Grant [CA178454, CA182528, CA127277];
   American Cancer Society (ACS) Research Scholar grant; University of
   Chicago Committee on Cancer Biology (CCB) Fellowship Program; LLS
   Special Fellowship; Gabrielle's Angel Foundation for Cancer Research;
   Intramural Research Program of National Human Genome Research Institute,
   NIH
FX Special thanks to the late Dr Janet Rowley for her long-term support. We
   also thank Drs Pier P. Pandolfi, Sheena Josselyn, Dong-Er Zhang, Scott
   Armstrong, Michael Cleary, James Mulloy, Robert Slany, Lin He and
   Michael Thirman for providing mouse models, retroviral constructs or
   cell lines, and the German AMLCG study group for AML microarray data.
   This work was supported by Leukemia & Lymphoma Society (LLS)
   Translational Research Grant (J.C.), the National Institutes of Health
   (NIH) R01 Grants CA178454, CA182528 and CA127277 (J.C.), American Cancer
   Society (ACS) Research Scholar grant (J.C.), The University of Chicago
   Committee on Cancer Biology (CCB) Fellowship Program (X.J.), LLS Special
   Fellowship (Z.L.), Gabrielle's Angel Foundation for Cancer Research
   (J.C., Z.L., X.J. and H.H.) and Intramural Research Program of National
   Human Genome Research Institute, NIH (A.G.E. and P.P.L.). C.H. is an
   investigator of the Howard Hughes Medical Institute.
CR Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039
   Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5
   Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603
   Bar N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010859
   Cartron Pierre-Francois, 2013, Genes Cancer, V4, P235, DOI 10.1177/1947601913489020
   Chattopadhyay P, 1997, ONCOGENE, V15, P871, DOI 10.1038/sj.onc.1201238
   Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765
   Cheng JC, 2008, BLOOD, V111, P1182, DOI 10.1182/blood-blood-2007-04-083600
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   DRACH J, 1993, CANCER RES, V53, P2100
   Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100
   Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8
   Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519
   Graubert T, 2011, HEMATOL-AM SOC HEMAT, P543, DOI 10.1182/asheducation-2011.1.543
   Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13
   Grimwade D, 2011, HEMATOL ONCOL CLIN N, V25, P1135, DOI 10.1016/j.hoc.2011.09.018
   Gurha P, 2012, CIRCULATION, V125, P2751, DOI 10.1161/CIRCULATIONAHA.111.044354
   Haferlach C, 2012, GENE CHROMOSOME CANC, V51, P328, DOI 10.1002/gcc.21918
   He CJ, 2012, NUCLEIC ACIDS RES, V40, P4002, DOI 10.1093/nar/gkr1312
   Hu X, 2014, CELL STEM CELL, V14, P512, DOI 10.1016/j.stem.2014.01.001
   Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110
   Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Jacoby MA, 2012, EXPERT REV MOL DIAGN, V12, P253, DOI [10.1586/erm.12.18, 10.1586/ERM.12.18]
   Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028
   Jiang X, 2009, P NATL ACAD SCI USA, V106, P10183, DOI 10.1073/pnas.0812105106
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Konishi H, 2003, ONCOGENE, V22, P1892, DOI 10.1038/sj.onc.1206304
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105
   Li ZJ, 2013, J CLIN ONCOL, V31, P1172, DOI 10.1200/JCO.2012.44.3184
   Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Modi DA, 2014, NANOSCALE, V6, P2812, DOI 10.1039/c3nr05042d
   Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001
   Ninomiya S, 2012, CYTOGENET GENOME RES, V136, P246, DOI 10.1159/000337297
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Parkin B, 2010, BLOOD, V116, P4958, DOI 10.1182/blood-2010-01-266999
   Parkin B, 2010, CLIN CANCER RES, V16, P4135, DOI 10.1158/1078-0432.CCR-09-2639
   Pigazzi M, 2013, HAEMATOLOGICA, V98, P602, DOI 10.3324/haematol.2012.070664
   Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114
   Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Sandoval S, 2009, ADV HEMATOL, V2009
   Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973
   Schwäble J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood-2004-03-0940
   Sekeres MJ, 2012, J NEUROSCI, V32, P17857, DOI 10.1523/JNEUROSCI.1419-12.2012
   Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004
   Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003
   Takahashi S, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-13
   Thambyrajah R, 2016, NAT CELL BIOL, V18, P21, DOI 10.1038/ncb3276
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907
   Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Wu Xi, 2014, Advances in Biological Regulation, V54, P214, DOI 10.1016/j.jbior.2013.09.004
   Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158
   Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241
   Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044
   Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443
   Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004
   Zeisig Bernd B, 2012, Cancer Cell, V22, P698, DOI 10.1016/j.ccr.2012.10.017
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 70
TC 113
Z9 124
U1 0
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2016
VL 7
AR 11452
DI 10.1038/ncomms11452
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DK4NU
UT WOS:000374896000001
PM 27116251
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Gong, C
   Yao, S
   Gomes, AR
   Man, EPS
   Lee, HJ
   Gong, G
   Chang, S
   Kim, SB
   Fujino, K
   Kim, SW
   Park, SK
   Lee, JW
   Lee, MH
   Khoo, US
   Lam, EWF
AF Gong, C.
   Yao, S.
   Gomes, A. R.
   Man, E. P. S.
   Lee, H. J.
   Gong, G.
   Chang, S.
   Kim, S-B
   Fujino, K.
   Kim, S-W
   Park, S. K.
   Lee, J. W.
   Lee, M. H.
   Khoo, U. S.
   Lam, E. W-F
CA KOHBRA Study Grp
TI BRCA1 positively regulates <i>FOXO3</i> expression by restricting
   <i>FOXO3</i> gene methylation and epigenetic silencing through targeting
   EZH2 in breast cancer
SO ONCOGENESIS
LA English
DT Article
ID PROMOTES TUMORIGENESIS; PROTEINS; INHIBITION; SURVIVIN; CELLS;
   LOCALIZATION; ACTIVATION
AB BRCA1 mutation or depletion correlates with basal-like phenotype and poor prognosis in breast cancer but the underlying reason remains elusive. RNA and protein analysis of a panel of breast cancer cell lines revealed that BRCA1 deficiency is associated with downregulation of the expression of the pleiotropic tumour suppressor FOXO3. Knockdown of BRCA1 by small interfering RNA (siRNA) resulted in downregulation of FOXO3 expression in the BRCA1-competent MCF-7, whereas expression of BRCA1 restored FOXO3 expression in BRCA1-defective HCC70 and MDA-MB-468 cells, suggesting a role of BRCA1 in the control of FOXO3 expression. Treatment of HCC70 and MDA-MB-468 cells with either the DNA methylation inhibitor 5-aza-2'-deoxycitydine, the N-methyltransferase enhancer of zeste homologue 2 (EZH2) inhibitor GSK126 or EZH2 siRNA induced FOXO3 mRNA and protein expression, but had no effect on the BRCA1-competent MCF-7 cells. Chromatin immunoprecipitation (ChIP) analysis demonstrated that BRCA1, EZH2, DNMT1/3a/b and histone H3 lysine 27 trimethylation (H3K27me3) are recruited to the endogenous FOXO3 promoter, further advocating that these proteins interact to modulate FOXO3 methylation and expression. In addition, ChIP results also revealed that BRCA1 depletion promoted the recruitment of the DNA methyltransferases DNMT1/3a/3b and the enrichment of the EZH2-mediated transcriptional repressive epigenetic marks H3K27me3 on the FOXO3 promoter. Methylated DNA immunoprecipitation assays also confirmed increased CpG methylation of the FOXO3 gene on BRCA1 depletion. Analysis of the global gene methylation profiles of a cohort of 33 familial breast tumours revealed that FOXO3 promoter methylation is significantly associated with BRCA1 mutation. Furthermore, immunohistochemistry further suggested that FOXO3 expression was significantly associated with BRCA1 status in EZH2-positive breast cancer. Consistently, high FOXO3 and EZH2 mRNA levels were significantly associated with good and poor prognosis in breast cancer, respectively. Together, these data suggest that BRCA1 can prevent and reverse FOXO3 suppression via inhibiting EZH2 and, consequently, its ability to recruit the transcriptional repressive H3K27me3 histone marks and the DNA methylases DNMT1/3a/3b, to induce DNA methylation and gene silencing on the FOXO3 promoter.
C1 [Gong, C.; Yao, S.; Gomes, A. R.; Fujino, K.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.
   [Gong, C.; Man, E. P. S.; Khoo, U. S.] Univ Hong Kong, Dept Pathol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Lee, H. J.; Gong, G.] Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, Seoul, South Korea.
   [Chang, S.] Univ Ulsan, Coll Med, Dept Biomed Sci, Asan Med Ctr, Seoul, South Korea.
   [Kim, S-B] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
   [Kim, S-W] Daerim St Marys Hosp, Dept Surg, Seoul, South Korea.
   [Park, S. K.] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
   [Lee, J. W.] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Surg, Seoul, South Korea.
   [Lee, M. H.] Soonchunhyang Univ, Coll Med, Soonchunhyang Univ Hosp, Dept Surg, Seoul, South Korea.
C3 Imperial College London; University of Hong Kong; University of Ulsan;
   University of Ulsan; University of Ulsan; Catholic University of Korea;
   Seoul National University (SNU); University of Ulsan; Asan Medical
   Center; Soonchunhyang University; Soonchunhyang University Hospital
RP Lam, EWF (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.; Khoo, US (通讯作者)，Univ Hong Kong, Dept Pathol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
EM uskhoo@pathology.hku.hk; eric.lam@imperial.ac.uk
RI Khoo, Ui/K-2041-2019; Kim, Sung-Bae/JXL-8219-2024; lee,
   Jong/AAM-9747-2021; Lee, Hwi-Won/HLH-1635-2023; Kim,
   Sun-Whe/J-2741-2012; Lee, Jin-Ho/AEE-5544-2022; Lam, Eric/AAW-8566-2020;
   Khoo, Ui Soon/C-4293-2009
OI Lam, Eric/0000-0003-1274-3576; Chang, Suhwan/0000-0002-0282-0120; Khoo,
   Ui Soon/0000-0003-2200-7505
FU Breast Cancer Campaign; Cancer Research UK; Joint Imperial College
   London; University of Hong Kong; MRC [MR/N012097/1] Funding Source: UKRI
FX This work is funded by grants from Breast Cancer Campaign and Cancer
   Research UK. CG is a recipient of the Joint Imperial College London and
   University of Hong Kong studentship.
CR Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Buckley NE, 2013, NUCLEIC ACIDS RES, V41, P8601, DOI 10.1093/nar/gkt626
   Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200
   de Moraes GN, 2016, CURR DRUG TARGETS, V17, P164, DOI 10.2174/1389450115666141122211549
   Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000
   Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Gao SB, 2014, J HEPATOL, V61, P832, DOI 10.1016/j.jhep.2014.05.015
   Gomes AR, 2013, CHIN J CANCER, V32, P365, DOI 10.5732/cjc.012.10277
   Gong C, 2015, ONCOGENE, V34, P5012, DOI 10.1038/onc.2014.421
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Habashy HO, 2011, BREAST CANCER RES TR, V129, P11, DOI 10.1007/s10549-010-1161-z
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Hill SJ, 2014, MOL CELL BIOL, V34, P3828, DOI 10.1128/MCB.01646-13
   Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Hu T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05810
   Janatova M, 2005, HUM MUTAT, V25, P319, DOI 10.1002/humu.9308
   Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756
   Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368
   Kennedy SM, 2003, BRIT J CANCER, V88, P1077, DOI 10.1038/sj.bjc.6600776
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539
   Lee JM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju089
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mori S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088891
   Narod Steven, 2004, Hered Cancer Clin Pract, V2, P5, DOI 10.1186/1897-4287-2-1-5
   Promkan M, 2009, INT J CANCER, V125, P2820, DOI 10.1002/ijc.24684
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Somasundaram K, 2003, J CELL BIOCHEM, V88, P1084, DOI 10.1002/jcb.10469
   Thépot S, 2011, CELL CYCLE, V10, P2323, DOI 10.4161/cc.10.14.16399
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009
   Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676
   Yang YC, 2014, J THORAC ONCOL, V9, P1305, DOI 10.1097/JTO.0000000000000240
   Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872
NR 46
TC 29
Z9 31
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD APR
PY 2016
VL 5
AR e214
DI 10.1038/oncsis.2016.23
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DK9UW
UT WOS:000375278100003
PM 27043660
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Joo, MK
   Park, JJ
   SoonYoo, H
   Lee, BJ
   Chun, HJ
   Lee, SW
   Bak, YT
AF Joo, Moon Kyung
   Park, Jong-Jae
   SoonYoo, Hyo
   Lee, Beom Jae
   Chun, Hoon Jai
   Lee, Sang Woo
   Bak, Young-Tae
TI Epigenetic regulation and anti-tumorigenic effects of SH2-containing
   protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells
SO TUMOR BIOLOGY
LA English
DT Article
DE SHP1; Methylation; JAK2; STAT3
ID COLORECTAL-CANCER; DNA METHYLTRANSFERASE; MULTIPLE-MYELOMA; STAT3
   ACTIVATION; BREAST-CANCER; METHYLATION; INHIBITION; PATHWAY; INDUCTION;
   CARCINOMA
AB SH2-containing protein tyrosine phosphatase 1 (SHP1) is an important negative regulator in cytokine-mediated signal transduction and cell cycling. Recent studies have demonstrated that SHP1 promoter methylation is frequently observed in gastric adenocarcinoma tissues. In this in vitro study, we attempted to reveal promoter hypermethylation and to investigate effects of SHP1 in gastric carcinoma cell lines. We observed that both gene and protein expression of SHP1 were negative in 8 of 10 gastric cancer cell lines (SNU-1, SNU-5, SNU-16, SNU-638, SNU-719, MKN-28, MKN-45, AGS). Methylation-specific PCR (MSP) showed a methylation-specific band only in the 10 gastric cancer lines. Bisulfite pyrosequencing in AGS, MKN-28, and SNU-719 cells indicated that methylation frequency was as high as 94.4, 92.6, and 94.5 %, respectively, in the three cell lines. Treatment of SNU-719, MKN-28, and AGS cells with 5-Aza-2'-deoxycytidine (5-Aza-dc) led to re-expression of SHP1 in these cells. Introduction of exogenous SHP1 in SNU-719 and MKN-28 cells by transient transfection substantially downregulated protein expression of constitutive phosphor-Janus kinase 2 (JAK2) (tyrosine 1007/1008) and phosphor-signal transducers and activators of transcription 3 (STAT3) (tyrosine 705), which in turn decreased expression of STAT3 target genes including those encoding cyclin D1, MMP-9, VEGF-1, and survivin. Induction of SHP1 significantly inhibited cell proliferation, migration and invasion in SNU-719 and MKN-28 cells. Taken together, epigenetic silencing of SHP1 is frequently caused by promoter hypermethylation in gastric carcinoma cells. Overexpression of SHP1 downregulates the JAK2/STAT3 pathway to modulate various target genes and inhibit cell proliferation, migration, and invasion in gastric cancer cells.
C1 [Joo, Moon Kyung; Park, Jong-Jae; SoonYoo, Hyo; Lee, Beom Jae; Bak, Young-Tae] Korea Univ, Guro Hosp, Coll Med, Dept Internal Med,Div Gastroenterol, 148 Gurodong Ro, Seoul 152703, South Korea.
   [Chun, Hoon Jai] Korea Univ, Anam Hosp, Coll Med, Dept Internal Med,Div Gastroenterol, 73 Inchon Ro, Seoul 136705, South Korea.
   [Lee, Sang Woo] Korea Univ, Ansan Hosp, Coll Med, Dept Internal Med,Div Gastroenterol, 123 Jeokgeum Ro, Ansan 425707, Gyeonggi Do, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine); Korea University;
   Korea University Medicine (KU Medicine)
RP Park, JJ (通讯作者)，Korea Univ, Guro Hosp, Coll Med, Dept Internal Med,Div Gastroenterol, 148 Gurodong Ro, Seoul 152703, South Korea.
EM gi7pjj@korea.ac.kr
RI Kim, Jeong/AAO-6927-2021
OI Joo, Moon Kyung/0000-0001-6050-3695
FU Korea University Research and Business Foundation, Medical Center Branch
   [R1211041]
FX The study was supported by a grant to JJP from the Korea University
   Research and Business Foundation, Medical Center Branch
   (http://research.kumc.ac.kr) (R1211041).
CR Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522
   Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570
   Chen J, 2012, MOL CANCER THER, V11, P277, DOI 10.1158/1535-7163.MCT-11-0648
   Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007
   Deng JY, 2013, TUMOR BIOL, V34, P2791, DOI 10.1007/s13277-013-0837-5
   Douziech N, 1999, ENDOCRINOLOGY, V140, P765, DOI 10.1210/en.140.2.765
   Giraud AS, 2012, EXPERT OPIN THER TAR, V16, P889, DOI 10.1517/14728222.2012.709238
   Gu XQ, 2013, INT J MED SCI, V10, P870, DOI 10.7150/ijms.5727
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Han YJ, 2006, BLOOD, V108, P2796, DOI 10.1182/blood-2006-04-017434
   Hsu KW, 2012, CARCINOGENESIS, V33, P1459, DOI 10.1093/carcin/bgs165
   Huang Z, 2011, NAT COMMUN, V2, DOI [10.1038/ncomms1465, 10.1038/ncomms1545]
   Jackson CB, 2009, J GASTROEN HEPATOL, V24, P505, DOI 10.1111/j.1440-1746.2009.05822.x
   Jiménez DJ, 2012, WORLD J MICROB BIOT, V28, P361, DOI 10.1007/s11274-011-0828-x
   Jia YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054774
   Kang GH, 2001, CANCER RES, V61, P2847
   Kim MJ, 2013, CANCER LETT, V335, P145, DOI 10.1016/j.canlet.2013.02.010
   Koyama M, 2003, LAB INVEST, V83, P1849, DOI 10.1097/01.LAB.0000106503.65258.2B
   Ksiaa F, 2009, CLIN CHIM ACTA, V404, P128, DOI 10.1016/j.cca.2009.03.044
   Lee JH, 2014, CANCER LETT, V345, P140, DOI 10.1016/j.canlet.2013.12.008
   Lee S, 2012, INT J ONCOL, V40, P889, DOI 10.3892/ijo.2011.1245
   López-Ruiz P, 2011, ANTI-CANCER AGENT ME, V11, P89, DOI 10.2174/187152011794941154
   McTavish N, 2007, CELL DEATH DIFFER, V14, P1700, DOI 10.1038/sj.cdd.4402172
   Oka T, 2002, CANCER RES, V62, P6390
   Park E, 2012, INT J ONCOL, V40, P1259, DOI 10.3892/ijo.2011.1290
   PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123
   Rhee YH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-28
   Rivera MN, 2009, P NATL ACAD SCI USA, V106, P8338, DOI 10.1073/pnas.0811349106
   Ruchusatsawat K, 2006, J MOL MED, V84, P175, DOI 10.1007/s00109-005-0020-6
   Sandur SK, 2010, MOL CANCER RES, V8, P107, DOI 10.1158/1541-7786.MCR-09-0257
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Souma Y, 2012, INT J CANCER, V131, P1287, DOI 10.1002/ijc.27350
   Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640
   Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682
   Wang ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075788
   Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1
   Xiong H, 2012, MOL CARCINOGEN, V51, P174, DOI 10.1002/mc.20777
   Xiong H, 2009, J CELL MOL MED, V13, P3668, DOI 10.1111/j.1582-4934.2009.00661.x
   Yang XW, 2001, CANCER RES, V61, P7025
   Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.3.CO;2-W
   Zapata PD, 2002, J CLIN ENDOCR METAB, V87, P915, DOI 10.1210/jc.87.2.915
   Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223
NR 42
TC 16
Z9 16
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2016
VL 37
IS 4
BP 4603
EP 4612
DI 10.1007/s13277-015-4228-y
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DK4QS
UT WOS:000374904500041
PM 26508024
DA 2025-01-12
ER

PT J
AU Liu, YB
   Dong, ZM
   Liang, J
   Guo, YL
   Guo, X
   Shen, SP
   Kuang, G
   Guo, W
AF Liu, Yibing
   Dong, Zhiming
   Liang, Jia
   Guo, Yanli
   Guo, Xin
   Shen, Supeng
   Kuang, Gang
   Guo, Wei
TI Methylation-mediated repression of potential tumor suppressor miR-203a
   and miR-203b contributes to esophageal squamous cell carcinoma
   development
SO TUMOR BIOLOGY
LA English
DT Article
DE miR-203a; miR-203b; Esophageal squamous cell carcinoma; Expression;
   Methylation
ID DOWN-REGULATION; HEPATOCELLULAR-CARCINOMA; OVARIAN-CANCER;
   BREAST-CANCER; INVASION; PROLIFERATION; MICRORNA-203; EXPRESSION;
   PROGRESSION; MIGRATION
AB MiRNAs regulate gene expression and play pivotal roles in biological processes. MiRNAs can be inactivated by epigenetic mechanisms, such as DNA hypermethylation of CpG sites within CpG islands. Here, we investigated the role and methylation status of miR-203a and miR-203b in esophageal cancer cell lines and primary esophageal squamous cell carcinoma (ESCC) tumors and further elucidate the role of both miRNAs in the prognosis of ESCC. The present study revealed a strong downregulation of miR-203a and miR-203b in esophageal cancer cell lines and primary ESCC samples. Treatment of esophageal cancer cells with demethylating agent 5-Aza-dC led to increased miR-203a and miR-203b expression, confirming the epigenetic regulation of both miRNAs. The inhibition of proliferation and invasiveness in esophageal cancer cells after treated with 5-Aza-dC or transfected with miR-203a or miR-203b mimics, suggesting the tumor suppressor role of both miRNAs in esophageal cancer. Furthermore, the critical CpG sites of miR-203a and miR-203b were found to be located in proximal promoter region, and the proximal promoter hypermethylation of both miRNAs was found to influence transcriptional activity. Downregulation and hypermethylation of miR-203a and miR-203b were associated with TNM stage, pathological differentiation, and lymph node metastasis. ESCC patients in stages III and IV, with reduced expression of miR-203a or hypermethylation of miR-203a or miR-203b, demonstrated poor patient survival. In summary, our results suggest that miR-203a and miR-203b may function as tumor-suppressive miRNAs that are inactivated through proximal promoter hypermethylation and miR-203a expression and methylation may be useful prognostic marker in ESCC patients.
C1 [Liu, Yibing] Hebei Med Univ, Hosp 4, Dept Internal Med Oncol, Shijiazhuang, Hebei, Peoples R China.
   [Dong, Zhiming; Liang, Jia; Guo, Yanli; Guo, Xin; Shen, Supeng; Kuang, Gang; Guo, Wei] Hebei Med Univ, Hosp 4, Hebei Canc Inst, Pathol Lab, Jiankang Rd 12, Shijiazhuang 050011, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Guo, W (通讯作者)，Hebei Med Univ, Hosp 4, Hebei Canc Inst, Pathol Lab, Jiankang Rd 12, Shijiazhuang 050011, Hebei, Peoples R China.
EM guowei7303@163.com
RI Guo, Xinqi/O-3643-2018
FU National Natural Science Foundation [81472335]
FX We thank the patients for taking part in this study. This research was
   supported by the National Natural Science Foundation (no. 81472335).
CR Botezatu A, 2011, MOL MED REP, V4, P121, DOI 10.3892/mmr.2010.394
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chang X, 2015, BIOCHEM BIOPH RES CO, V456, P361, DOI 10.1016/j.bbrc.2014.11.087
   Chen HY, 2012, MED ONCOL, V29, P1859, DOI 10.1007/s12032-011-0031-9
   Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171
   Chen ZG, 2014, MOL MED REP, V9, P503, DOI 10.3892/mmr.2013.1814
   Chim CS, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-197
   Chim CS, 2011, J CELL MOL MED, V15, P2760, DOI 10.1111/j.1582-4934.2011.01274.x
   Diao YR, 2014, J BIOL CHEM, V289, P529, DOI 10.1074/jbc.M113.494716
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Guohong Zhang, 2010, PLoS One, V5, pe9668, DOI 10.1371/journal.pone.0009668
   He JG, 2013, J SURG ONCOL, V108, P121, DOI 10.1002/jso.23315
   Hezova R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0280-6
   Huang YW, 2014, GYNECOL ONCOL, V133, P340, DOI 10.1016/j.ygyno.2014.02.009
   Ikenaga N, 2010, ANN SURG ONCOL, V17, P3120, DOI 10.1245/s10434-010-1188-8
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Jamali Z, 2015, ORAL ONCOL, V51, P321, DOI 10.1016/j.oraloncology.2015.01.008
   Joyce CE, 2011, HUM MOL GENET, V20, P4025, DOI 10.1093/hmg/ddr331
   Lee SA, 2015, J BIOSCI BIOENG
   Li ZW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116170
   Liao HZ, 2015, ONCOTARGET, V6, P8914, DOI 10.18632/oncotarget.3563
   Liu YR, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0214-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117035
   Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006
   Nagaraja V, 2014, J GASTROINTEST ONCOL, V5, P67, DOI 10.3978/j.issn.2078-6891.2013.054
   Okumura T, 2014, INT J ONCOL, V44, P1923, DOI 10.3892/ijo.2014.2365
   Oom AL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/959461
   Qu Y, 2013, INT J CANCER, V133, P544, DOI 10.1002/ijc.28056
   Ralfkiaer U, 2011, BLOOD, V118, P5891, DOI 10.1182/blood-2011-06-358382
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005
   Taipaleenmäki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026
   Takeshita N, 2012, INT J ONCOL, V41, P1653, DOI 10.3892/ijo.2012.1614
   Tang GD, 2015, MOL MED REP, V11, P2838, DOI 10.3892/mmr.2014.3101
   Tian LL, 2014, TUMOR BIOL, V35, P5953, DOI 10.1007/s13277-014-1790-7
   Wang C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-58
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105570
   Wang SS, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0681-x
   Xu MX, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0255-7
   Xue JY, 2014, WORLD J CLIN ONCOL, V5, P730, DOI 10.5306/wjco.v5.i4.730
   Yan B, 2013, J EXP BIOL, V216, P447, DOI 10.1242/jeb.076315
   Yantiss RK, 2009, AM J SURG PATHOL, V33, P572, DOI 10.1097/PAS.0b013e31818afd6b
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zhang F, 2014, CANCER LETT, V342, P121, DOI 10.1016/j.canlet.2013.08.037
   Zhang K, 2015, J CELL PHYSIOL, V230, P903, DOI 10.1002/jcp.24821
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhou M, 2014, CELL IMMUNOL, V292, P65, DOI 10.1016/j.cellimm.2014.09.004
   Zhou XY, 2014, ONCOTARGET, V5, P11631, DOI 10.18632/oncotarget.2600
NR 50
TC 32
Z9 34
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2016
VL 37
IS 4
BP 5621
EP 5632
DI 10.1007/s13277-015-4432-9
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DK4QS
UT WOS:000374904500146
PM 26577858
DA 2025-01-12
ER

PT J
AU Kamdar, SN
   Ho, LT
   Kron, KJ
   Isserlin, R
   van der Kwast, T
   Zlotta, AR
   Fleshner, NE
   Bader, G
   Bapat, B
AF Kamdar, Shivani N.
   Ho, Linh T.
   Kron, Ken J.
   Isserlin, Ruth
   van der Kwast, Theodorus
   Zlotta, Alexandre R.
   Fleshner, Neil E.
   Bader, Gary
   Bapat, Bharati
TI Dynamic interplay between locus-specific DNA methylation and
   hydroxymethylation regulates distinct biological pathways in prostate
   carcinogenesis
SO CLINICAL EPIGENETICS
LA English
DT Article
DE 5-Hydroxymethylcytosine; 5-Methylcytosine; Whole-genome; Prostate
   cancer; Cell lines; Integrative analysis
ID CPG ISLAND HYPERMETHYLATION; HUMAN CANCERS; 5-HYDROXYMETHYLCYTOSINE
   CONTENT; BREAST-CANCER; HETEROGENEITY; GENES; MUTATIONS; IDH1;
   PERSPECTIVES; EXPRESSION
AB Background: Despite the significant global loss of DNA hydroxymethylation marks in prostate cancer tissues, the locus-specific role of hydroxymethylation in prostate tumorigenesis is unknown. We characterized hydroxymethylation and methylation marks by performing whole-genome next-generation sequencing in representative normal and prostate cancer-derived cell lines in order to determine functional pathways and key genes regulated by these epigenomic modifications in cancer.
   Results: Our cell line model shows disruption of hydroxymethylation distribution in cancer, with global loss and highly specific gain in promoter and CpG island regions. Significantly, we observed locus-specific retention of hydroxymethylation marks in specific intronic and intergenic regions which may play a novel role in the regulation of gene expression in critical functional pathways, such as BARD1 signaling and steroid hormone receptor signaling in cancer. We confirm a modest correlation of hydroxymethylation with expression in intragenic regions in prostate cancer, while identifying an original role for intergenic hydroxymethylation in differentially expressed regulatory pathways in cancer. We also demonstrate a successful strategy for the identification and validation of key candidate genes from differentially regulated biological pathways in prostate cancer.
   Conclusions: Our results indicate a distinct function for aberrant hydroxymethylation within each genomic feature in cancer, suggesting a specific and complex role for the deregulation of hydroxymethylation in tumorigenesis, similar to methylation. Subsequently, our characterization of key cellular pathways exhibiting dynamic enrichment patterns for methylation and hydroxymethylation marks may allow us to identify differentially epigenetically modified target genes implicated in prostate cancer tumorigenesis.
C1 [Kamdar, Shivani N.; Ho, Linh T.; Kron, Ken J.; van der Kwast, Theodorus; Bapat, Bharati] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Kamdar, Shivani N.; Bapat, Bharati] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
   [Isserlin, Ruth; Bader, Gary] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada.
   [van der Kwast, Theodorus] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada.
   [Zlotta, Alexandre R.] Univ Toronto, Univ Hlth Network, Div Urol, Dept Surg & Surg Oncol, Toronto, ON, Canada.
   [Fleshner, Neil E.] Univ Hlth Network, Div Urol, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto;
   University of Toronto; University Health Network Toronto; University of
   Toronto; University Health Network Toronto; University of Toronto;
   University Health Network Toronto
RP Bapat, B (通讯作者)，Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Bapat, B (通讯作者)，Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
EM bapat@lunenfeld.ca
RI Zlotta, Alexandre/K-8285-2015; Van der Kwast, Theodorus/JFA-1932-2023;
   Bapat, Bharati/B-5839-2014; Bader, Gary/C-1176-2009
OI Van der Kwast, Theodorus/0000-0001-8640-5786; Bader,
   Gary/0000-0003-0185-8861
FU Bill and Kathleen Troost Innovation Grant of the Canadian Cancer Society
   [701456]; University of Toronto (UofT) Fellowship; Q.C. Scholarship
   (UofT); OSOTF Studentship at Mount Sinai Hospital (MSH); Paul Starita
   Graduate Student Fellowship (UofT); Research Training Centre (RTC)
   Travel Award at MSH; Laboratory Medicine and Pathobiology (LMP) Travel
   Award at U of T; Ontario Graduate Scholarship (OGS)-Faculty of Medicine
   at University of Toronto (UofT); Scace Graduate Fellowship in Prostate
   Cancer Research (UofT); George Sidney Brett Memorial Fund (UofT); Frank
   Fletcher Memorial Fund (UofT)
FX The authors would like to acknowledge the support from the Bill and
   Kathleen Troost Innovation Grant of the Canadian Cancer Society (Grant
   #701456), to BB, TvdK, and NF. LTH is funded by the University of
   Toronto (UofT) Fellowship, Lorne F. Lambier, Q.C. Scholarship (UofT),
   OSOTF Studentship at Mount Sinai Hospital (MSH), Paul Starita Graduate
   Student Fellowship (UofT), Research Training Centre (RTC) Travel Award
   at MSH, and the Laboratory Medicine and Pathobiology (LMP) Travel Award
   at U of T. SNK is funded by the Ontario Graduate Scholarship
   (OGS)-Faculty of Medicine at University of Toronto (UofT), Scace
   Graduate Fellowship in Prostate Cancer Research (UofT), George Sidney
   Brett Memorial Fund (UofT), Research Training Centre (RTC) Travel Award
   at MSH, and the Frank Fletcher Memorial Fund (UofT).
CR Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500
   [Anonymous], 2011, DiffBind
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bangma CH, 2007, WORLD J UROL, V25, P3, DOI 10.1007/s00345-007-0145-z
   Bhattacharyya S, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt601
   Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014
   Brocks D, 2014, CELL REP, V8, P798, DOI 10.1016/j.celrep.2014.06.053
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017
   Fraser M, 2015, UROL ONCOL-SEMIN ORI, V33, P85, DOI 10.1016/j.urolonc.2013.10.020
   Goessl C, 2000, CANCER RES, V60, P5941
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Haley H, 2013, P NATL ACAD SCI USA, V111, P11139
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Khare T, 2012, NAT STRUCT MOL BIOL, V19, P1037, DOI 10.1038/nsmb.2372
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lercher L, 2014, CHEM COMMUN, V50, P1794, DOI 10.1039/c3cc48151d
   Li WW, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/870726
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Luboldt HJ, 2001, EUR UROL, V39, P131, DOI 10.1159/000052427
   Mariani Christopher J, 2013, Cancers (Basel), V5, P786, DOI 10.3390/cancers5030786
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Michalakis S, 2014, INVEST OPHTH VIS SCI, V55
   Nestor CE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0576-y
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Park SW, 2009, APMIS, V117, P880, DOI 10.1111/j.1600-0463.2009.02550.x
   Rampal R, 2014, CELL REP, V9, P1841, DOI 10.1016/j.celrep.2014.11.004
   Rhee SY, 2008, NAT REV GENET, V9, P509, DOI 10.1038/nrg2363
   Ruijter ET, 1996, J PATHOL, V180, P295
   Sérandour AA, 2012, NUCLEIC ACIDS RES, V40, P8255, DOI 10.1093/nar/gks595
   Shang B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.244
   Shukla A, 2015, GENE, V564, P109, DOI 10.1016/j.gene.2015.03.075
   Spiciarich D, 2014, FASEB J, V28
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247
   Stroud H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r54
   Sun WJ, 2014, GENOMICS, V104, P347, DOI 10.1016/j.ygeno.2014.08.021
   Takayama K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9219
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Ura K, 2006, CLIN CANCER RES, V12, P6611, DOI 10.1158/1078-0432.CCR-06-0783
   Uribe-Lewis S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0605-5
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Vasanthakumar A, 2015, CANCER GENET-NY, V208, P167, DOI 10.1016/j.cancergen.2015.02.009
   Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773
   Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhang YJ, 2009, CANCER LETT, V275, P277, DOI 10.1016/j.canlet.2008.10.042
   Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237
NR 59
TC 20
Z9 25
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAR 15
PY 2016
VL 8
AR 32
DI 10.1186/s13148-016-0195-4
PG 17
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA DG3KJ
UT WOS:000371967900001
PM 26981160
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU El Tayebi, HM
   Abdelaziz, AI
AF El Tayebi, Hend Mohamed
   Abdelaziz, Ahmed Ihab
TI Epigenetic regulation of insulin-like growth factor axis in
   hepatocellular carcinoma
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Insulin-like growth factors; Insulin-like
   growth factor receptors; Epigenetics; microRNAs
ID FACTOR-II RECEPTOR; FACTOR-BINDING PROTEIN-3; FACTOR TYPE-2 RECEPTOR;
   BREAST-CANCER CELLS; IGF-II; MESSENGER-RNA; SIGNALING PATHWAYS;
   CPG-ISLANDS; GENE; EXPRESSION
AB The insulin-like growth factor (IGF) signaling pathway is an important pathway in the process of hepatocarcinogenesis, and the IGF network is clearly dysregulated in many cancers and developmental abnormalities. In hepatocellular carcinoma (HCC), only a minority of patients are eligible for curative treatments, such as tumor resection or liver transplant. Unfortunately, there is a high recurrence of HCC after surgical tumor removal. Recent research efforts have focused on targeting IGF axis members in an attempt to find therapeutic options for many health problems. In this review, we shed lights on the regulation of members of the IGF axis, mainly by microRNAs in HCC. MicroRNAs in HCC attempt to halt the aberrant expression of the IGF network, and a single microRNA can have multiple downstream targets in one or more signaling pathways. Targeting microRNAs is a relatively new approach for identifying an efficient radical cure for HCC.
C1 [El Tayebi, Hend Mohamed; Abdelaziz, Ahmed Ihab] German Univ Cairo, Fac Pharm & Biotechnol, Dept Pharmacol & Toxicol, Mol Pathol Res Grp, Cairo 11835, Egypt.
C3 Egyptian Knowledge Bank (EKB); German University in Cairo
RP Abdelaziz, AI (通讯作者)，German Univ Cairo, Fac Pharm & Biotechnol, Dept Pharmacol & Toxicol, Mol Pathol Res Grp, Cairo 11835, Egypt.
EM ahmed.ihab.abdelaziz@gmail.com
RI El Tayebi, Hend M./ABG-7392-2020
OI Abdelaziz, Ahmed/0000-0002-3367-2247
CR Aleem E, 2011, TOXICOL PATHOL, V39, P524, DOI 10.1177/0192623310396905
   Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029
   [Anonymous], RECENT PROG HORM RES
   Assal RA, 2015, DESPITE REPRESSING I
   Assal RA, 2015, MOL MED REP, V12, P645, DOI 10.3892/mmr.2015.3382
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O
   BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Bassiouni AA, 2015, J HEPATOL, V62, pS495, DOI 10.1016/S0168-8278(15)30690-5
   Basu S, 2014, NUCLEIC ACIDS RES, V42, P7170, DOI 10.1093/nar/gku346
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023
   Coutinho-Camillo CM, 2003, DIAGN MOL PATHOL, V12, P57, DOI 10.1097/00019606-200303000-00008
   Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914
   DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68
   delPeso L, 1997, SCIENCE, V278, P687
   DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447
   DESOUZA AT, 1995, ONCOGENE, V10, P1725
   deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167
   El Tayebi HM, 2013, BIOCHEM BIOPH RES CO, V434, P421, DOI 10.1016/j.bbrc.2013.04.003
   El Tayebi HM, 2012, FEBS LETT, V586, P3309, DOI 10.1016/j.febslet.2012.06.054
   El Tayebi HM, 2012, J HEPATOL, V56, pS112, DOI 10.1016/S0168-8278(12)60281-5
   El Tayebi HM, 2011, BIOMARKERS, V16, P346, DOI 10.3109/1354750X.2011.573095
   El Tayebi HM, 2015, ONCOL LETT, V10, P3206, DOI 10.3892/ol.2015.3725
   El Tayebi HM, 2014, MIR 155 INDUCES MTOR
   Espelund U, 2005, EUR J ENDOCRINOL, V153, P861, DOI 10.1530/eje.1.02028
   Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726
   Fernández-Rodriguez CM, 2001, DIGEST DIS SCI, V46, P1313, DOI 10.1023/A:1010631800505
   Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387
   Gary-Bobo M, 2007, CURR MED CHEM, V14, P2945, DOI 10.2174/092986707782794005
   Habashy DA, 2013, MICRORNA 17 5P PROMO
   He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641
   Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200
   Hung TC, 2014, INT J PHOTOENERGY, V2014, DOI 10.1155/2014/239137
   Huynh H, 2002, CELL GROWTH DIFFER, V13, P115
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459
   Jia CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027008
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Kaseb AO, 2011, J CLIN ONCOL, V29, P3892, DOI 10.1200/JCO.2011.36.0636
   Killian JK, 1999, MAMM GENOME, V10, P74, DOI 10.1007/s003359900947
   Kim WY, 2011, ENDOCRINOLOGY, V152, P2164, DOI 10.1210/en.2010-0693
   Krassas GE, 2003, J CLIN ENDOCR METAB, V88, P132, DOI 10.1210/jc.2002-021349
   LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3
   Law PTY, 2012, CARCINOGENESIS, V33, P1134, DOI 10.1093/carcin/bgs130
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lelbach A., 2005, ACTA PHYSIOLOGICA HUNGARICA, V92, P97, DOI 10.1556/APhysiol.92.2005.2.1
   Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li D, 2011, J BIOL CHEM, V286, P36677, DOI 10.1074/jbc.M111.270561
   Lin SL, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/26818
   Lund P, 2004, CANCER LETT, V206, P85, DOI 10.1016/j.canlet.2003.10.018
   Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102
   Mazziotti G, 2002, CANCER, V95, P2539, DOI 10.1002/cncr.11002
   Mills JJ, 1998, ONCOGENE, V16, P2797, DOI 10.1038/sj.onc.1201801
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019
   MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0
   MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   O'Gorman DB, 1999, CANCER RES, V59, P5692
   OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408
   OH YM, 1993, J BIOL CHEM, V268, P14964
   OKA Y, 1985, J BIOL CHEM, V260, P9435
   Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203
   Poirier K, 2003, J PATHOL, V201, P473, DOI 10.1002/path.1477
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609
   Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801
   Richardson AE, 2011, GROWTH FACTORS, V29, P82, DOI 10.3109/08977194.2011.565003
   Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280
   Rosenfeld R G, 1990, Recent Prog Horm Res, V46, P99
   Roth R A, 1994, Growth Regul, V4 Suppl 1, P31
   Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001
   Scharf JG, 2001, J CLIN PATHOL-MOL PA, V54, P138, DOI 10.1136/mp.54.3.138
   SCHIRMACHER P, 1992, CANCER RES, V52, P2549
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x
   Su WW, 2010, J CLIN LAB ANAL, V24, P195, DOI 10.1002/jcla.20320
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tabano S, 2010, EPIGENETICS-US, V5, P313, DOI 10.4161/epi.5.4.11637
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tanaka S, 1996, CANCER RES, V56, P3391
   Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456
   Vorwerk P, 2003, LEUKEMIA RES, V27, P807, DOI 10.1016/S0145-2126(03)00014-6
   Waly A, 2013, J HEPATOL, V58, pS448, DOI 10.1016/S0168-8278(13)61098-3
   Waly AA, 2014, EASL HCC SUMM HEP
   Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Wollmann H, 2012, CURR OPIN PLANT BIOL, V15, P63, DOI 10.1016/j.pbi.2011.10.001
   Wu J, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-30
   XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542
   Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   Yaseen MA, 2001, REPRODUCTION, V122, P601, DOI 10.1530/rep.0.1220601
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875
   Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065
NR 107
TC 13
Z9 13
U1 0
U2 10
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAR 7
PY 2016
VL 22
IS 9
BP 2668
EP 2677
DI 10.3748/wjg.v22.i9.2668
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DG0ZH
UT WOS:000371794300003
PM 26973407
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Kim, SE
   Hinoue, T
   Kim, MS
   Sohn, KJ
   Cho, RC
   Weisenberger, DJ
   Laird, PW
   Kim, YI
AF Kim, Sung-Eun
   Hinoue, Toshinori
   Kim, Michael S.
   Sohn, Kyoung-Jin
   Cho, Robert C.
   Weisenberger, Daniel J.
   Laird, Peter W.
   Kim, Young-In
TI Effects of folylpolyglutamate synthase modulation on global and
   gene-specific DNA methylation and gene expression in human colon and
   breast cancer cells
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Folate; Folylpolyglutamate synthase (FPGS); DNA methylation; Gene
   expression; Colon cancer; Breast cancer
ID GAMMA-GLUTAMATE SYNTHETASE; THYMIDYLATE SYNTHASE; IN-VITRO;
   5-FLUOROURACIL RESISTANCE; BIOCHEMICAL MODULATION; COLORECTAL-CANCER;
   THYMIDINE KINASE; FOLATE; CHEMOSENSITIVITY; CARCINOMA
AB Folylpolyglutamate synthase (FPGS) plays a critical role in intracellular folate homeostasis. FPGS-induced polyglutamylated folates are better substrates for several enzymes involved in the generation of S-adenosylmethionine, the primary methyl group donor, and hence FPGS modulation may affect DNA methylation. DNA methylation is an important epigenetic determinant in gene expression and aberrant DNA methylation is mechanistically linked cancer development. We investigated whether FPGS modulation would affect global and gene-specific promoter DNA methylation with consequent functional effects on gene expression profiles in HCT116 colon and MDA-MB-435 breast cancer cells. Although FPGS modulation altered global DNA methylation and DNA methyltransferases (DNMT) activity, the effects of FPGS modulation on global DNA methylation and DNMT activity could not be solely explained by intracellular folate concentrations and content of long-chain folylpolyglutamates, and it may be cell-specific. FPGS modulation influenced differential gene expression and promoter cytosine-guanine dinucleotide sequences (CpG) DNA methylation involved in cellular development, cell cycle, cell death and molecular transport. Some of the altered gene expression was associated with promoter CpG DNA methylation changes. In both the FPGS-overexpressed HCT116 and MDA-MB-435 cell lines, we identified several differentially expressed genes involved in folate biosynthesis and one-carbon metabolism, which might in part have contributed to the observed increased efficacy of 5-fluorouracil in response to FPGS overexpression. Our data suggest that FPGS modulation affects global and promoter CpG DNA methylation and expression of several genes involved in important biological pathways. The potential role of FPGS modulation in DNA methylation and its associated downstream functional effects warrants further studies. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Kim, Sung-Eun; Cho, Robert C.; Kim, Young-In] Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 1A8, Canada.
   [Kim, Sung-Eun; Kim, Michael S.; Kim, Young-In] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1T8, Canada.
   [Hinoue, Toshinori] Van Andel Res Inst, Ctr Epigenet, Grand Rapids, MI 49503 USA.
   [Sohn, Kyoung-Jin; Kim, Young-In] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.
   [Weisenberger, Daniel J.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90089 USA.
   [Weisenberger, Daniel J.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
   [Kim, Young-In] St Michaels Hosp, Div Gastroenterol, Toronto, ON M5B 1W8, Canada.
C3 University of Toronto; University of Toronto; Saint Michaels Hospital
   Toronto; Van Andel Institute; University of Toronto; University of
   Southern California; University of Southern California; University of
   Toronto; Saint Michaels Hospital Toronto
RP Kim, SE (通讯作者)，St Michaels Hosp, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1T8, Canada.
EM sungeun.kim@alum.utoronto.ca
RI Kim, Kyu/F-6596-2010; Weisenberger, Daniel/AAA-8314-2020; LAIRD, PETER
   W/G-8683-2012
OI LAIRD, PETER W/0000-0001-9117-3641
FU Canadian Institutes of Health Research [14126]
FX Funding was provided by the Canadian Institutes of Health Research
   (Grant Number 14126 to YIK).
CR Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Cheradame S, 1997, EUR J CANCER, V33, P950, DOI 10.1016/S0959-8049(97)00028-2
   Cho RC, 2007, MOL CANCER THER, V6, P2909, DOI 10.1158/1535-7163.MCT-07-0449
   Fan CW, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-254
   Fanciullino R, 2006, ANTI-CANCER DRUG, V17, P463, DOI 10.1097/01.cad.0000198914.83195.61
   Gál P, 2002, IMMUNOBIOLOGY, V205, P383, DOI 10.1078/0171-2985-00140
   Golubovskaya V, 2015, J CANCER RES CLIN, V141, P1613, DOI 10.1007/s00432-015-1924-3
   Hagmann W, 2009, PANCREATOLOGY, V9, P136, DOI 10.1159/000178884
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Houshdaran S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009359
   Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677
   KIM JS, 1993, J BIOL CHEM, V268, P21680
   Kim SE, 2015, GENES NUTR, V10, DOI [10.1007/s12263-014-0444-0, 10.1007/s12263-015-0475-1]
   Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703
   Kim YI, 2007, MOL NUTR FOOD RES, V51, P267, DOI 10.1002/mnfr.200600191
   Koch M, 2011, BREAST CANCER RES TR, V128, P337, DOI 10.1007/s10549-010-1085-7
   Kubota T, 2005, METH MOLEC MED, V111, P257
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Lantermann A, 2002, INT J COLORECTAL DIS, V17, P238, DOI 10.1007/s00384-001-0382-3
   Lawrence SA, 2014, J BIOL CHEM, V289, P29386, DOI 10.1074/jbc.M114.593244
   Li En, 2000, P351
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Look KY, 1997, ANTICANCER RES, V17, P2353
   Ly A, 2012, ANTIOXID REDOX SIGN, V17, P302, DOI 10.1089/ars.2012.4554
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686
   Moran RG, 1999, SEMIN ONCOL, V26, P24
   Oguri T, 2005, LUNG CANCER, V49, P345, DOI 10.1016/j.lungcan.2005.05.003
   Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18
   ROMANINI A, 1991, CANCER RES, V51, P789
   SHANE B, 1989, VITAM HORM, V45, P263
   Shane B., 2010, Folate in Health and Disease, V2nd, P1
   Sima A, 2009, BBA-GEN SUBJECTS, V1790, P1660, DOI 10.1016/j.bbagen.2009.09.004
   Sohn KJ, 2004, GUT, V53, P1825, DOI 10.1136/gut.2004.042713
   Streit M, 2002, CANCER RES, V62, P2004
   Tsujie M, 2007, ANTICANCER RES, V27, P2241
   van der Wilt CL, 2001, CANCER RES, V61, P3675
   Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503
   WANG FS, 1993, CANCER RES, V53, P3677
   Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970
   Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   Yoshinare K, 2003, CANCER SCI, V94, P633, DOI 10.1111/j.1349-7006.2003.tb01495.x
   Zhang Jun-hua, 2005, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V23, P6
   Zhou HR, 2013, PLANT CELL, V25, P2545, DOI 10.1105/tpc.113.114678
NR 48
TC 8
Z9 8
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD MAR
PY 2016
VL 29
BP 27
EP 35
DI 10.1016/j.jnutbio.2015.10.019
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA DF9AR
UT WOS:000371653100004
PM 26895662
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Govindarajah, V
   Leung, YK
   Ying, J
   Gear, R
   Bornschein, RL
   Medvedovic, M
   Ho, SM
AF Govindarajah, Vinothini
   Leung, Yuet-Kin
   Ying, Jun
   Gear, Robin
   Bornschein, Robert L.
   Medvedovic, Mario
   Ho, Shuk-Mei
TI <i>In utero</i> exposure of rats to high-fat diets perturbs gene
   expression profiles and cancer susceptibility of prepubertal mammary
   glands
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Breast cancer; Epigenetics; Developmental origin of health and disease;
   DNA methylation; DNA methyl transferases; Methylated DNA binding domain
ID BREAST-CANCER; MATERNAL DIET; RISK; DIFFERENTIATION; PREGNANCY; PROTEIN;
   METAANALYSIS; METHYLATION; INHIBITION; PATTERN
AB Human studies suggest that high-fat diets (HEDs) increase the risk of breast cancer. The 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis rat model is commonly used to evaluate the effects of lifestyle factors such as HFD on mammary tumor risk. Past studies focused primarily on the effects of continuous maternal exposure on the risk of offspring at the end of puberty (PND50). We assessed the effects of prenatal HFD exposure on cancer susceptibility in prepubertal mammary glands and identified key gene networks associated with such disruption. During pregnancy, dams were fed AIN-93G-based diets with isocaloric high olive oil, butterfat or safflower oil. The control group received AIN-93G. Female offspring were treated with DMBA on PND21. However, a significant increase in tumor volume and a trend of shortened tumor latency were observed in rats with HFD exposure against the controls (P=.048 and P=.067, respectively). Large-volume tumors harbored carcinoma in situ. Transcriptome profiling identified 43 differentially expressed genes in the mammary glands of the HFBUTTER group as compared with control. Rapid hormone signaling was the most dysregulated pathway. The diet also induced aberrant expression of Dnmt3a, Mbd1 and Mbd3, consistent with potential epigenetic disruption. Collectively, these findings provide the first evidence supporting susceptibility of prepubertal mammary glands to DMBA-induced tumorigenesis that can be modulated by dietary fat that involves aberrant gene expression and likely epigenetic dysregulation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Govindarajah, Vinothini; Leung, Yuet-Kin; Ying, Jun; Bornschein, Robert L.; Medvedovic, Mario; Ho, Shuk-Mei] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA.
   [Leung, Yuet-Kin; Ho, Shuk-Mei] Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA.
   [Leung, Yuet-Kin; Ho, Shuk-Mei] Cincinnati Canc Ctr, Cincinnati, OH USA.
   [Gear, Robin] Univ Cincinnati, Med Ctr, Dept Pharmacol & Cell Biophys Pharmacol, Cincinnati, OH 45267 USA.
   [Ho, Shuk-Mei] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati; University System of Ohio; University
   of Cincinnati; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Cincinnati VA Medical Center
RP Ho, SM (通讯作者)，Univ Cincinnati, Dept Environm Hlth, Div Environm Genet & Mol Toxicol, Coll Med,Med Ctr, Room 128,Kettering Complex,160 Panzeca Way, Cincinnati, OH 45267 USA.
EM shuk-mei.ho@uc.edu
RI Leung, Ricky/H-5958-2019
OI Leung, Yuet-kin/0000-0003-2063-277X
FU NIH [ES020988, ES019480, ES006096, BX000675, HL111638, HL127624];
   University of Cincinnati Medical Center; VA [547613, 1I01BX000675-01A2]
   Funding Source: Federal RePORTER
FX We thank Dr. Mei Yan for pathology support and Ms. Nancy K. Voynow for
   her professional editing of this manuscript. This work was supported by
   NIH grants ES020988, ES019480 and ES006096 to SMH; grant ES006096 to
   SMH, MM, YKL and VA; grant BX000675 to SMH; and grants HL111638 and
   HL127624 to MM, and an internal funding source from the University of
   Cincinnati Medical Center.
CR Aagaard-Tillery KM, 2008, J MOL ENDOCRINOL, V41, P91, DOI 10.1677/JME-08-0025
   Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506
   Abbas T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012914
   Akhavan-Niaki H, 2013, CELL BIOCHEM BIOPHYS, V67, P501, DOI 10.1007/s12013-013-9555-2
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Andrade FD, 2015, CHEM-BIOL INTERACT, V239, P118, DOI 10.1016/j.cbi.2015.06.035
   Andrade FD, 2014, J NUTR BIOCHEM, V25, P613, DOI 10.1016/j.jnutbio.2014.02.002
   Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019
   Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9
   Bonte D, 2008, NEOPLASIA, V10, P920, DOI 10.1593/neo.08216
   Borengasser SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084209
   Boyd NF, 2003, BRIT J CANCER, V89, P1672, DOI 10.1038/sj.bjc.6601314
   BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479
   de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   Dmitriev AA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/735292
   FREEDMAN LS, 1990, CANCER RES, V50, P5710
   Gordon RR, 2010, CLIN EXP METASTAS, V27, P279, DOI 10.1007/s10585-010-9326-z
   Heffelfinger SC, 2004, LAB INVEST, V84, P989, DOI 10.1038/labinvest.3700128
   Heffelfinger SC, 2003, LAB INVEST, V83, P1001, DOI 10.1097/01.LAB.0000075641.27128.67
   Hilakivi-Clarke L, 2002, CLIN CANCER RES, V8, P3601
   Hilakivi-Clarke L, 1999, NUTRITION, V15, P392, DOI 10.1016/S0899-9007(99)00029-5
   HilakiviClarke L, 1996, JNCI-J NATL CANCER I, V88, P1821, DOI 10.1093/jnci/88.24.1821
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]
   Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603
   Kuppuswamy U, 2014, ALGORITHM MOL BIOL, V9, DOI 10.1186/1748-7188-9-10
   Kushi L, 2002, AM J MED, V113, P63, DOI 10.1016/S0002-9343(01)00994-9
   La Merrill M, DIETARY FAT ALTERS P
   LaRocca J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024432
   Lo CY, 2009, INT J CANCER, V125, P767, DOI 10.1002/ijc.24464
   Lonne GK, 2010, MOL CANCER, V14, P9
   Mansouri M, 2014, BIOCHIMIE, V99, P71, DOI 10.1016/j.biochi.2013.11.010
   Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737
   Martin LJ, 2011, CANCER RES, V71, P123, DOI 10.1158/0008-5472.CAN-10-1436
   Masuyama H, 2012, ENDOCRINOLOGY, V153, P2823, DOI 10.1210/en.2011-2161
   Medvedovic M, 2009, PHYSIOL GENOMICS, V38, P80, DOI 10.1152/physiolgenomics.00007.2009
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Meric-Bernstam F, 2014, MOL CANCER THER, V13, P1382, DOI 10.1158/1535-7163.MCT-13-0482
   OGAWA M, 1991, RES COMMUN CHEM PATH, V74, P241
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629
   Prentice RL, 2009, AM J EPIDEMIOL, V169, P977, DOI 10.1093/aje/kwp008
   Reddy KB, 2007, INT J ONCOL, V30, P971
   Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9
   ROSE DP, 1991, JNCI-J NATL CANCER I, V83, P1491, DOI 10.1093/jnci/83.20.1491
   Ross JS, 2015, ARCH PATHOL LAB MED, V139, P642, DOI 10.5858/arpa.2014-0200-OA
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   RUSSO J, 1980, CANCER RES, V40, P2677
   RUSSO J, 1987, LAB INVEST, V57, P112
   Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758
   Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592
   Shimano N, 2007, IN VIVO, V21, P983
   Skinner MK, 2008, REPROD TOXICOL, V25, P2, DOI 10.1016/j.reprotox.2007.09.001
   Skinner MK, 2011, BIRTH DEFECTS RES C, V93, P51, DOI 10.1002/bdrc.20199
   Strakovsky RS, 2011, J PHYSIOL-LONDON, V589, P2707, DOI 10.1113/jphysiol.2010.203950
   Suter MA, 2012, FASEB J, V26, P5106, DOI 10.1096/fj.12-212878
   Tang WY, 2012, ENDOCRINOLOGY, V153, P42, DOI 10.1210/en.2011-1308
   Tinker LF, 2007, J AM DIET ASSOC, V107, P1155, DOI 10.1016/j.jada.2007.04.010
   Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631
   Turner LB, 2011, AM J HUM BIOL, V23, P601, DOI 10.1002/ajhb.21176
   Vasan N, 2014, ONCOLOGIST, V19, P453, DOI 10.1634/theoncologist.2013-0377
   Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802
   Wang Q, 2013, ENVIRON HEALTH PERSP, V121, P1334, DOI 10.1289/ehp.1307297
   Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439
   WELSCH CW, 1992, CANCER RES, V52, pS2040
   WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037
   WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6
   Williams YN, 2006, ONCOGENE, V25, P1446, DOI 10.1038/sj.onc.1209192
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
   Zheng SS, 2012, EPIGENETICS-US, V7, P183, DOI 10.4161/epi.7.2.18972
   Zhu ZJ, 2011, CANCER PREV RES, V4, P1675, DOI 10.1158/1940-6207.CAPR-11-0175
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 77
TC 23
Z9 25
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD MAR
PY 2016
VL 29
BP 73
EP 82
DI 10.1016/j.jnutbio.2015.11.003
PG 10
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA DF9AR
UT WOS:000371653100009
PM 26895667
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Noberini, R
   Uggetti, A
   Pruneri, G
   Minucci, S
   Bonaldi, T
AF Noberini, Roberta
   Uggetti, Andrea
   Pruneri, Giancarlo
   Minucci, Saverio
   Bonaldi, Tiziana
TI Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile
   Histone Post-translational Modification Patterns in Patient Samples
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID PARAFFIN-EMBEDDED TISSUE; PHOSPHOPROTEOME ANALYSIS; PROTEOMIC ANALYSIS;
   SUPER-SILAC; IN-VIVO; CHROMATIN; METHYLATION; QUANTIFICATION; DYNAMICS;
   SUBTYPES
AB Histone post-translational modifications (hPTMs) generate a complex combinatorial code that has been implicated with various pathologies, including cancer. Dissecting such a code in physiological and diseased states may be exploited for epigenetic biomarker discovery, but hPTM analysis in clinical samples has been hindered by technical limitations. Here, we developed a method (PAThology tissue analysis of Histones by Mass Spectrometry - PAT-H-MS) that allows to perform a comprehensive, unbiased and quantitative MS-analysis of hPTM patterns on formalin-fixed paraffin-embedded (FFPE) samples. In pairwise comparisons, histone extracted from formalin-fixed paraffin-embedded tissues showed patterns similar to fresh frozen samples for 24 differentially modified peptides from histone H3. In addition, when coupled with a histone-focused version of the super-SILAC approach, this method allows the accurate quantification of modification changes among breast cancer patient samples. As an initial application of the PAThology tissue analysis of Histones by Mass Spectrometry method, we analyzed breast cancer samples, revealing significant changes in histone H3 methylation patterns among Luminal A-like and Triple Negative disease subtypes. These results pave the way for retrospective epigenetic studies that combine the power of MS-based hPTM analysis with the extensive clinical information associated with formalin-fixed paraffin-embedded archives.
C1 [Noberini, Roberta] IIT SEMM, Ist Italiano Tecnol, Ctr Genom Sci, Via Adamello 16, I-20139 Milan, Italy.
   [Uggetti, Andrea; Pruneri, Giancarlo] European Inst Oncol, Dept Pathol, Biobank Translat Med Unit, Via Ripamonti 435, I-20141 Milan, Italy.
   [Pruneri, Giancarlo] Univ Milan, Sch Med, I-20122 Milan, Italy.
   [Minucci, Saverio; Bonaldi, Tiziana] European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
   [Minucci, Saverio] European Inst Oncol, Drug Dev Program, Via Adamello 16, I-20139 Milan, Italy.
   [Minucci, Saverio] Univ Milan, Dept Biosci, I-20133 Milan, Italy.
C3 Istituto Italiano di Tecnologia - IIT; IRCCS European Institute of
   Oncology (IEO); University of Milan; IRCCS European Institute of
   Oncology (IEO); IRCCS European Institute of Oncology (IEO); University
   of Milan
RP Bonaldi, T (通讯作者)，European Inst Oncol, Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
EM tiziana.bonaldi@ieo.eu
RI Noberini, Roberta/AAP-4527-2020; Minucci, Saverio/J-9669-2012; Pruneri,
   Giancarlo/AAC-7767-2022; Bonaldi, Tiziana/K-5075-2016
OI Minucci, Saverio/0000-0001-5678-536X; Pruneri,
   Giancarlo/0000-0002-7963-7172; Noberini, Roberta/0000-0002-7267-1079;
   Bonaldi, Tiziana/0000-0003-3556-1265
FU Giovanni Armenise-Harvard Foundation Career Development Program; Italian
   Association for Cancer Research (AIRC); Italian Ministry of Health;
   Epigen flagship project grant
FX T.B. research is supported by grants from the Giovanni Armenise-Harvard
   Foundation Career Development Program, the Italian Association for
   Cancer Research (AIRC), the Italian Ministry of Health and the Epigen
   flagship project grant. We declare no conflict of interest.
CR Amatori S, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-18
   Boersema PJ, 2013, MOL CELL PROTEOMICS, V12, P158, DOI 10.1074/mcp.M112.023614
   Bonaldi T, 2004, METHOD ENZYMOL, V377, P111
   Bremang M, 2013, MOL BIOSYST, V9, P2231, DOI 10.1039/c3mb00009e
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cuomo A, 2011, AMINO ACIDS, V41, P387, DOI 10.1007/s00726-010-0668-2
   Fanelli M, 2010, P NATL ACAD SCI USA, V107, P21535, DOI 10.1073/pnas.1007647107
   Fowler CB, 2013, EXPERT REV PROTEOMIC, V10, P389, DOI 10.1586/14789450.2013.820531
   Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jung HR, 2010, MOL CELL PROTEOMICS, V9, P838, DOI 10.1074/mcp.M900489-MCP200
   Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089
   Monetti M, 2011, NAT METHODS, V8, P655, DOI [10.1038/NMETH.1647, 10.1038/nmeth.1647]
   Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026
   Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715
   Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200
   Ostasiewicz P, 2010, J PROTEOME RES, V9, P3688, DOI 10.1021/pr100234w
   Palmer-Toy DE, 2005, J PROTEOME RES, V4, P2404, DOI 10.1021/pr050208p
   Pan C, 2008, PROTEOMICS, V8, P4534, DOI 10.1002/pmic.200800105
   Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Soldi M, 2014, PROTEOMICS, V14, P2212, DOI 10.1002/pmic.201400075
   Soldi M, 2013, INT J MOL SCI, V14, P5402, DOI 10.3390/ijms14035402
   Tian Y, 2009, J PROTEOME RES, V8, P1657, DOI 10.1021/pr800952h
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wakabayashi M, 2014, J PROTEOME RES, V13, P915, DOI 10.1021/pr400960r
   Zhang Y, 2015, PROTEOMICS, V15, P2568, DOI 10.1002/pmic.201400454
NR 33
TC 37
Z9 39
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAR
PY 2016
VL 15
IS 3
SI SI
BP 866
EP 877
DI 10.1074/mcp.M115.054510
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DG2KB
UT WOS:000371894700010
PM 26463340
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhang, X
   Peng, DN
   Xi, YX
   Yuan, C
   Sagum, CA
   Klein, BJ
   Tanaka, K
   Wen, H
   Kutateladze, TG
   Li, W
   Bedford, MT
   Shi, XB
AF Zhang, Xi
   Peng, Danni
   Xi, Yuanxin
   Yuan, Chao
   Sagum, Cari A.
   Klein, Brianna J.
   Tanaka, Kaori
   Wen, Hong
   Kutateladze, Tatiana G.
   Li, Wei
   Bedford, Mark T.
   Shi, Xiaobing
TI G9a-mediated methylation of ERα links the PHF20/MOF histone
   acetyltransferase complex to hormonal gene expression
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; METHYLTRANSFERASE G9A; LYSINE METHYLATION;
   BREAST-CANCER; HINGE-REGION; AROMATASE INHIBITOR; NUCLEAR RECEPTORS;
   EFFECTOR PROTEIN; K303R MUTATION; COACTIVATOR
AB The euchromatin histone methyltransferase 2 (also known as G9a) methylates histone H3K9 to repress gene expression, but it also acts as a coactivator for some nuclear receptors. The molecular mechanisms underlying this activation remain elusive. Here we show that G9a functions as a coactivator of the endogenous oestrogen receptor alpha (ER alpha) in breast cancer cells in a histone methylation-independent manner. G9a dimethylates ER alpha at K235 both in vitro and in cells. Dimethylation of ER alpha K235 is recognized by the Tudor domain of PHF20, which recruits the MOF histone acetyltransferase (HAT) complex to ER alpha target gene promoters to deposit histone H4K16 acetylation promoting active transcription. Together, our data suggest the molecular mechanism by which G9a functions as an ER alpha coactivator. Along with the PHF20/MOF complex, G9a links the crosstalk between ER alpha methylation and histone acetylation that governs the epigenetic regulation of hormonal gene expression.
C1 [Zhang, Xi; Peng, Danni; Yuan, Chao; Sagum, Cari A.; Tanaka, Kaori; Wen, Hong; Bedford, Mark T.; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA.
   [Zhang, Xi; Peng, Danni; Yuan, Chao; Sagum, Cari A.; Tanaka, Kaori; Wen, Hong; Bedford, Mark T.; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA.
   [Xi, Yuanxin; Li, Wei] Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Klein, Brianna J.; Kutateladze, Tatiana G.] Univ Colorado, Dept Pharmacol, Sch Med, Aurora, CO 80045 USA.
   [Bedford, Mark T.; Shi, Xiaobing] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Texas System; University of Texas Health Science
   Center Houston
RP Shi, XB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA.; Shi, XB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA.; Shi, XB (通讯作者)，Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
EM xbshi@mdanderson.org
RI Li, Wei/AFW-2599-2022; Xing, Puyuan/GMX-3723-2022
OI Wen, Hong/0000-0001-8739-4572; Shi, Xiaobing/0000-0001-5242-8189;
   Kutateladze, Tatiana/0000-0001-7375-6990
FU American Cancer Society [RSG-13-290-01-TBE, CPRIT RP110471, RP140323,
   G1719]; Jeanne F. Shelby Scholarship Fund; CPRIT [RP110471, RP150292];
   NIH [HG007538, DK062248, GM101664]
FX We thank M. Barton, J. Tyler, M. Lee, T. Jenuwein and Y. Tanaka for
   reagents. We thank Dr Briana Dennehey and Joseph Munch for comments and
   editing the manuscript. We thank the MD Anderson Sequencing and
   Microarray Facility and the Science Park Next-Generation Sequencing
   Facility (CPRIT RP120348) for Solexa sequencing and the Protein Array
   and Analysis Core (RP130432) for the protein domain array work. This
   work was supported by grants to X.S. (American Cancer Society
   RSG-13-290-01-TBE, CPRIT RP110471, RP140323, Welch G1719 and the Jeanne
   F. Shelby Scholarship Fund), W.L. (CPRIT RP110471, RP150292 and NIH
   HG007538), M.T.B. (CPRIT RP110471 and NIH DK062248) and T.G.K. (NIH
   GM101664). X.Z. is a MDACC Center for Cancer Epigenetics Postdoctoral
   Scholar. B.J.K. is an American Heart Association Postdoctoral Fellow.
   W.L. is a Duncan Scholar. X.S. is an R. Lee Clark Fellow.
CR Abbasi S, 2013, INT J CLIN EXP MED, V6, P39
   Akué-Gédu R, 2009, J MED CHEM, V52, P6369, DOI 10.1021/jm901018f
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Badeaux AI, 2012, J BIOL CHEM, V287, P429, DOI 10.1074/jbc.M111.271163
   Barone I, 2010, ONCOGENE, V29, P2404, DOI 10.1038/onc.2009.520
   Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194
   Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449
   Bittencourt D, 2012, P NATL ACAD SCI USA, V109, P19673, DOI 10.1073/pnas.1211803109
   Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981
   Chen DS, 1999, MOL CELL BIOL, V19, P1002
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Conway K, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1731
   Cui GF, 2012, NAT STRUCT MOL BIOL, V19, P916, DOI 10.1038/nsmb.2353
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Espejo Alexsandra, 2004, Methods Mol Biol, V264, P173
   Fuqua SAW, 2000, CANCER RES, V60, P4026
   Herynk MH, 2009, ONCOGENE, V28, P3177, DOI 10.1038/onc.2009.174
   Herynk MH, 2007, CLIN CANCER RES, V13, P3235, DOI 10.1158/1078-0432.CCR-06-2608
   Howe EA, 2011, BIOINFORMATICS, V27, P3209, DOI 10.1093/bioinformatics/btr490
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jeong KW, 2012, MOL ENDOCRINOL, V26, P955, DOI 10.1210/me.2012-1066
   Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153
   Kachirskaia I, 2008, J BIOL CHEM, V283, P34660, DOI 10.1074/jbc.M806020200
   Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625
   Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531
   Klein BJ, 2014, CELL REP, V6, P325, DOI 10.1016/j.celrep.2013.12.021
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016
   Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200
   Lee JS, 2011, P NATL ACAD SCI USA, V108, P13510, DOI 10.1073/pnas.1106106108
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Leutz A, 2011, TRANSCR-AUSTIN, V2, P3, DOI 10.4161/trns.2.1.13510
   Ling BMT, 2012, P NATL ACAD SCI USA, V109, P841, DOI 10.1073/pnas.1111628109
   Liu F, 2010, J MED CHEM, V53, P5844, DOI 10.1021/jm100478y
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Moore KE, 2013, MOL CELL, V50, P444, DOI 10.1016/j.molcel.2013.03.005
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200
   Purcell DJ, 2011, J BIOL CHEM, V286, P41963, DOI 10.1074/jbc.M111.298463
   Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88
   Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607
   Regnard C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001327
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612
   Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200
   Tebbit CL, 2004, GENE CHROMOSOME CANC, V40, P51, DOI 10.1002/gcc.20017
   Tokunaga E, 2004, BREAST CANCER RES TR, V84, P289, DOI 10.1023/B:BREA.0000019963.67754.93
   Tong Q, 2015, STRUCTURE, V23, P312, DOI 10.1016/j.str.2014.11.013
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200
   Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543
   West L. E, J BIOL CHEM, V285
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5
   Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y
   Zhang T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3062
   Zhang X, 2013, P NATL ACAD SCI USA, V110, P17284, DOI 10.1073/pnas.1307959110
   Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100
NR 74
TC 27
Z9 34
U1 0
U2 40
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10810
DI 10.1038/ncomms10810
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG0EJ
UT WOS:000371736200001
PM 26960573
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, GZ
   Gao, YC
   Zheng, LJ
   Ma, DN
   Wei, M
   Zhang, ZL
AF Li, Guang-Zhen
   Gao, Yan-Chao
   Zheng, Li-Jie
   Ma, De-Ning
   Wei, Meng
   Zhang, Zong-Li
TI Downgraded expression of SEMA3B indicates an unfavorable prognosis in
   patients of resectable hepatocellular carcinoma
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; SEMA3B; biomarker; prognosis; invasion;
   migration
ID ENDOTHELIAL GROWTH-FACTOR; EPIGENETIC INACTIVATION; MICROVESSEL DENSITY;
   BREAST-CANCER; SEMAPHORIN 3B; ALLELE LOSS; INHIBITION; 3P21.3; LUNG;
   APOPTOSIS
AB Background: The SEMA3B protein plays an important role in suppressing tumor development as an angiogenesis inhibitor, which might be a predictable bio-marker for prognosis in hepatocellular carcinoma as our hypothesis. Methods: In this study, we have demonstrated the expression of semaphorin3B (SEMA3B) and microvascular density (MVD) in hepatocellular carcinoma (HCC) tissues. Results: We found that about 42.9% cells are SEMA3B-positive, which is significant lower compared with that of in normal liver and paraneoplastic tissues (78.6%, 85.7%, respectively). We observed that MVD in SEMA3B-positive HCC tumor tissues were lower than that of SEMA3B-negative (P<0.05). Our clinical data prospective study demonstrated that the lower expression of SEMA3B was closely related to the tumor nodular number, tumor size, capsulation and CLIP score (P<0.05) accordingly. As of rate of recurrence and metastasis, the patients in SEMA3B-positive group were significantly lower than that of the SEMA3B-negative group, also SEMA3B-positive group comes with the higher survival rate as well (P<0.05). Take them all together, we summarized that SEMA3B protein acts as an inhibitor though inhibiting angiogenesis, migration, and invasion during the process of human hepatocellular carcinoma. The downgraded expression level of SEMA3B closely associated with tumor progression and prognosis. Conclusion: SEMA3B could be an independent predictor of prognosis and a possible novel target of anti-angiogenic therapy for patients with HCC.
C1 [Li, Guang-Zhen; Gao, Yan-Chao; Ma, De-Ning; Wei, Meng; Zhang, Zong-Li] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China.
   [Li, Guang-Zhen] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Gao, Yan-Chao] Liaocheng Peoples Hosp, Dept Hepatobiliary Surg, Liaocheng, Shandong, Peoples R China.
   [Zheng, Li-Jie] Shandong Univ, Qilu Hosp, Dept Gen Surg, Qingdao, Shandong, Peoples R China.
C3 Shandong University; Huazhong University of Science & Technology;
   Shandong University
RP Zhang, ZL (通讯作者)，Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China.
EM 13708933969@163.com
CR Bachelder RE, 2001, CANCER RES, V61, P5736
   Bachelder RE, 2003, CANCER RES, V63, P5230
   Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001
   Beuten J, 2009, J UROLOGY, V182, P1614, DOI 10.1016/j.juro.2009.06.016
   Braga E. A., 2003, Molekulyarnaya Biologiya (Moscow), V37, P194
   Cai GL, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0030-y, 10.1186/S40659-015-0030-Y]
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Chebib I, 2007, BIOMARK INSIGHTS, V2, P59
   Döme B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302
   Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033
   Green TD, 2012, J LEUKOCYTE BIOL, V92, P633, DOI 10.1189/jlb.1211604
   Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200
   Halbersztadt Alicja, 2006, Ginekol Pol, V77, P63
   Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041
   Joseph D, 2010, MOL CANCER THER, V9, P499, DOI 10.1158/1535-7163.MCT-09-0664
   Kigel B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003287
   Manghisi G, 1998, HEPATOLOGY, V28, P751
   Masood R, 2003, INT J CANCER, V104, P603, DOI 10.1002/ijc.10996
   Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233
   Nair PN, 2007, CANCER GENET CYTOGEN, V174, P100, DOI 10.1016/j.cancergencyto.2006.11.017
   Nasarre P, 2003, NEOPLASIA, V5, P83, DOI 10.1016/S1476-5586(03)80020-9
   Neufeld G, 2007, ADV EXP MED BIOL, V600, P118
   Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211
   Patel S, 2011, CLIN BIOCHEM, V44, P869, DOI 10.1016/j.clinbiochem.2011.04.019
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Pronina I V, 2009, Mol Biol (Mosk), V43, P439
   PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1
   Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019
   Sabag AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042912
   Schindl M, 2001, FERTIL STERIL, V75, P131, DOI 10.1016/S0015-0282(00)01642-3
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Shirvan A, 2000, MOL BRAIN RES, V83, P81, DOI 10.1016/S0169-328X(00)00198-4
   Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x
   Takahashi T, 1997, J NEUROSCI, V17, P9183
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408
   Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074
   Yin Q, 2007, INT J EXP PATHOL, V88, P415, DOI 10.1111/j.1365-2613.2007.00545.x
   Zhang L, 2012, MOL BIOL REP, V39, P5085, DOI 10.1007/s11033-011-1304-2
   Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831
NR 44
TC 1
Z9 1
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 2
BP 841
EP 853
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DG1EU
UT WOS:000371809200039
DA 2025-01-12
ER

PT J
AU Krishnaveni, D
   Bhayal, AC
   Shravan, KP
   Jyothy, A
   Pratibha, N
   Venkateshwari, A
AF Krishnaveni, D.
   Bhayal, A. C.
   Shravan, K. P.
   Jyothy, A.
   Pratibha, N.
   Venkateshwari, A.
TI Heterozygosity of stromelysin-1 (rs3025058) promoter polymorphism is
   associated with gastric cancer
SO INDIAN JOURNAL OF CANCER
LA English
DT Article
DE Gastric cancer; matrix metalloprotienases; matrix metalloprotienases-3;
   polymorphism; risk factors rs3025058; stromelysin-1
ID MATRIX METALLOPROTEINASES; BREAST-CANCER; GENE; SUSCEPTIBILITY;
   EPIDEMIOLOGY; EXPRESSION; RISK; MMP3
AB BACKGROUND: Gastric cancer (GC) is the third most common cancer in India and is mediated by multiple genetic, epigenetic and environmental risk factors. A single nucleotide polymorphism rs3025058 at - 1171 of the stromelysin-1 (matrix metalloproteinase [MMP]-3) promoter is resulting due to insertion/deletion of adenine thought to have an impact on increasing the risk for tumor formation. AIM: This study is aimed to understand the role of stromelysin-1 rs3025058 (-1171, 5A/6A) promoter polymorphism in the etiology of GC in Indian population. MATERIALS AND METHODS: Genomic DNA was isolated from blood samples of the GC patients and controls. The genotyping of stromelysin-1 rs3025058 (-1171, 5A/6A) promoter polymorphism was carried out by amplification refractory mutation system-polymerase chain reaction method followed by agarose gel electrophoresis. RESULTS: The frequency of 5A/5A, 5A/6A, and 6A/6A genotypes in GC patients were 7.69%, 76.92%, and 15.38%, while in controls were 5.31%, 86.73%, and7.96%, respectively. There was a significant difference in the distribution of 5A/6A genotype in patients compared to the controls (P < 0.05). CONCLUSION: This study showed an increased frequency of heterozygotes for stromelysin-1 rs3025058 and thought to be involved in the etiology of GC.
C1 [Krishnaveni, D.; Bhayal, A. C.; Jyothy, A.; Venkateshwari, A.] Inst Genet, Dept Cell Biol, Hyderabad, Andhra Pradesh, India.
   [Krishnaveni, D.; Bhayal, A. C.; Jyothy, A.; Venkateshwari, A.] Hosp Genet Dis, Hyderabad, Andhra Pradesh, India.
   [Pratibha, N.] Osmania Univ, Dept Genet, Hyderabad 500007, Andhra Pradesh, India.
   [Shravan, K. P.] Gandhi Hosp, Dept Gastroenterol, Secunderabad, Andhra Pradesh, India.
C3 Osmania University
RP Venkateshwari, A (通讯作者)，Inst Genet, Dept Cell Biol, Hyderabad, Andhra Pradesh, India.
EM venkateshwari@yahoo.com
RI Devulapalli, Dr Krishnaveni/KBB-1404-2024
OI Devulapalli, Dr Krishnaveni/0000-0001-5810-5073
CR Alberts SR, 2003, ANN ONCOL, V14, P31, DOI 10.1093/annonc/mdg726
   Borghaei RC, 2004, BIOCHEM BIOPH RES CO, V316, P182, DOI 10.1016/j.bbrc.2004.02.030
   Ghilardi G, 2002, CLIN CANCER RES, V8, P3820
   Krishnaveni D, 2012, INDIAN J CLIN BIOCHE, V27, P259, DOI 10.1007/s12291-012-0210-2
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lei HX, 2002, CLIN CHEM, V48, P798
   Letra A, 2007, ARCH ORAL BIOL, V52, P954, DOI 10.1016/j.archoralbio.2007.04.005
   Medley TL, 2003, CIRC RES, V92, P1254, DOI 10.1161/01.RES.0000076891.24317.CA
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Neugut AI, 1996, SEMIN ONCOL, V23, P281
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Schwartz GK, 1996, SEMIN ONCOL, V23, P316
   SPURR N K, 1988, Genomics, V2, P119, DOI 10.1016/0888-7543(88)90093-6
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Sumathi B, 2009, SINGAP MED J, V50, P147
   Sung NY, 2007, BRIT J CANCER, V97, P700, DOI 10.1038/sj.bjc.6603893
   Terashima M, 1999, CIRCULATION, V99, P2717, DOI 10.1161/01.CIR.99.21.2717
   VAIRA D, 1988, J CLIN PATHOL, V41, P812, DOI 10.1136/jcp.41.3.355-b
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wiencke K, 2004, J HEPATOL, V41, P209, DOI 10.1016/j.jhep.2004.04.024
   Yang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087562
   YE S, 1995, BRIT HEART J, V73, P209
   Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5
NR 23
TC 7
Z9 7
U1 0
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0019-509X
EI 1998-4774
J9 INDIAN J CANCER
JI Indian J. Cancer
PD APR-JUN
PY 2015
VL 52
IS 2
BP 251
EP U121
DI 10.4103/0019-509X.175806
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DE9OW
UT WOS:000370968600040
PM 26853425
DA 2025-01-12
ER

PT J
AU Duvall-Noelle, N
   Karwandyar, A
   Richmond, A
   Raman, D
AF Duvall-Noelle, N.
   Karwandyar, A.
   Richmond, A.
   Raman, D.
TI LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex
SO ONCOGENE
LA English
DT Article
ID METASTATIC BREAST-CANCER; E-CADHERIN REPRESSION; CHEMOKINE RECEPTORS;
   TUMOR-GROWTH; CELLS; SNAIL; EXPRESSION; LOCALIZATION; CARCINOMA; CXCR4
AB Nuclear LASP-1 (LIM and SH3 protein-1) has a direct correlation with overall survival of breast cancer patients. In this study, immunohistochemical analysis of a human breast TMA showed that LASP-1 is absent in normal human breast epithelium but the expression increases with malignancy and is highly nuclear in aggressive breast cancer. We investigated whether the chemokines and growth factors present in the tumor microenvironment could trigger nuclear translocation of LASP-1. Treatment of human breast cancer cells with CXCL12, EGF and HRG, and HMEC-CXCR2 cells with CXCL8 facilitated nuclear shuttling of LASP-1. Data from the biochemical analysis of the nuclear and cytosolic fractions further confirmed the nuclear translocation of LASP-1 upon chemokine and growth factor treatment. CXCL12-dependent nuclear import of LASP-1 could be blocked by CXCR4 antagonist, AMD-3100. Knock down of LASP-1 resulted in alterations in gene expression leading to an increased level of cell-junction and extracellular matrix proteins and an altered cytokine secretory profile. Three-dimensional cultures of human breast cancer cells on Matrigel revealed an altered colony growth, morphology and arborization pattern in LASP-1 knockdown cells. Functional analysis of the LASP-1 knockdown cells revealed increased adhesion to collagen IV and decreased invasion through the Matrigel. Proteomic analysis of immunoprecipitates of LASP-1 and subsequent validation approaches revealed that LASP-1 associated with the epigenetic machinery especially UHRF1, DNMT1, G9a and the transcription factor Snail1. Interestingly, LASP-1 associated with UHRF1, G9a, Snail1 and di- and tri-methylated histoneH3 in a CXCL12-dependent manner based on immunoprecipitation and proximity ligation assays. LASP-1 also directly bound to Snail1 which may stabilize Snail1. Thus, nuclear LASP-1 appears to functionally serve as a hub for the epigenetic machinery.
C1 [Duvall-Noelle, N.; Karwandyar, A.; Richmond, A.; Raman, D.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA.
   [Richmond, A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
C3 Vanderbilt University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Tennessee Valley Healthcare System
RP Raman, D (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA.
EM dayanidhi.raman@vanderbilt.edu
RI Richmond, Ann/A-3048-2014
FU Department of Defense, IDEA grant [W81XWH-11-1-0413]; VICTR award -
   Vanderbilt Clinical and Translational Science Award (CTSA) grant from
   NCRR/NIH [UL1 TR000445]; NIH [CA-34590]; VA Merit Award; Career
   Scientist Award from the Tennessee Valley Healthcare System; Department
   of Veterans Affairs; Ingram Professorship
FX This work was supported by the Department of Defense, IDEA grant
   W81XWH-11-1-0413 (to DR), VICTR award, supported in part by Vanderbilt
   Clinical and Translational Science Award (CTSA) grant, UL1 TR000445 from
   NCRR/NIH (to DR), NIH grants CA-34590 (to AR), VA Merit Award (to AR),
   Career Scientist Award (to AR) from the Tennessee Valley Healthcare
   System and the Department of Veterans Affairs and Ingram Professorship
   (to AR).
CR Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   Cipriano R, 2014, ONCOGENE, V33, P3298, DOI 10.1038/onc.2013.293
   Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Frietsch JJ, 2010, BRIT J CANCER, V102, P1645, DOI 10.1038/sj.bjc.6605685
   Fulton AM, 2009, CURR ONCOL REP, V11, P125, DOI 10.1007/s11912-009-0019-1
   Goldberg-Bittman L, 2004, IMMUNOL LETT, V92, P171, DOI 10.1016/j.imlet.2003.10.020
   Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016
   Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198
   Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115
   Li HY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2680
   Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335
   Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045
   Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021
   Mihlan S, 2013, ONCOGENE, V32, P2107, DOI 10.1038/onc.2012.216
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Neel NF, 2008, THESIS
   Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997
   Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318
   Orth MF, 2015, ONCOTARGET, V6, P26, DOI 10.18632/oncotarget.3083
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Raman D, 2009, METHOD ENZYMOL, V460, P297
   Raman D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010050
   Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579
   Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709
   Wikman H, 2014, ONCOTARGET, V5, P3076, DOI 10.18632/oncotarget.1832
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128
NR 39
TC 37
Z9 41
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 3
PY 2016
VL 35
IS 9
BP 1122
EP 1133
DI 10.1038/onc.2015.166
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DF4WH
UT WOS:000371351700006
PM 25982273
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wang, HJ
   Song, CH
   Ding, YL
   Pan, XK
   Ge, Z
   Tan, BH
   Gowda, C
   Sachdev, M
   Muthusami, S
   Ouyang, HS
   Lai, LX
   Francis, OL
   Morris, CL
   Abdel-Azim, H
   Dorsam, G
   Xiang, MX
   Payne, KJ
   Dovat, S
AF Wang, Haijun
   Song, Chunhua
   Ding, Yali
   Pan, Xiaokang
   Ge, Zheng
   Tan, Bi-Hua
   Gowda, Chandrika
   Sachdev, Mansi
   Muthusami, Sunil
   Ouyang, Hongsheng
   Lai, Liangxue
   Francis, Olivia L.
   Morris, Christopher L.
   Abdel-Azim, Hisham
   Dorsam, Glenn
   Xiang, Meixian
   Payne, Kimberly J.
   Dovat, Sinisa
TI Transcriptional Regulation of <i>JARID1B/KDM5B</i> Histone Demethylase
   by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in
   B-cell Acute Lymphoblastic Leukemia
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE hematopoiesis; lymphocyte; signal transduction; transcription
   regulation; transcription repressor; tumor suppressor gene; ck2; ikzf1
ID ACUTE MYELOID-LEUKEMIA; DNA-BINDING PROTEINS; GENOME-WIDE ANALYSIS;
   MYELOPROLIFERATIVE NEOPLASMS; CENTROMERIC HETEROCHROMATIN;
   NUCLEAR-PROTEIN; BREAST-CANCER; ACTIVE GENES; EXPRESSION; INHIBITORS
AB Impaired function of the Ikaros (IKZF1) protein is associated with the development of high-risk B-cell precursor acute lymphoblastic leukemia (B-ALL). The mechanisms of Ikaros tumor suppressor activity in leukemia are unknown. Ikaros binds to the upstream regulatory elements of its target genes and regulates their transcription via chromatin remodeling. Here, we report that Ikaros represses transcription of the histone H3K4 demethylase, JARID1B (KDM5B). Transcriptional repression of JARID1B is associated with increased global levels of H3K4 trimethylation. Ikaros-mediated repression of JARID1B is dependent on the activity of the histone deacetylase, HDAC1, which binds to the upstream regulatory element of JARID1B in complex with Ikaros. In leukemia, JARID1B is overexpressed, and its inhibition results in cellular growth arrest. Ikaros-mediated repression of JARID1B in leukemia is impaired by pro-oncogenic casein kinase 2 (CK2). Inhibition of CK2 results in increased binding of the Ikaros-HDAC1 complex to the promoter of JARID1B, with increased formation of trimethylated histone H3 lysine 27 and decreased histone H3 Lys-9 acetylation. In cases of high-risk B-ALL that carry deletion of one Ikaros (IKZF1) allele, targeted inhibition of CK2 restores Ikaros binding to the JARID1B promoter and repression of JARID1B. In summary, the presented data suggest a mechanism through which Ikaros and HDAC1 regulate the epigenetic signature in leukemia: via regulation of JARID1B transcription. The presented data identify JARID1B as a novel therapeutic target in B-ALL and provide a rationale for the use of CK2 inhibitors in the treatment of high-risk B-ALL.
C1 [Wang, Haijun; Ouyang, Hongsheng; Lai, Liangxue] Xinxiang Med Univ, Dept Pathol, Xinxiang 453003, Henan, Peoples R China.
   [Wang, Haijun; Song, Chunhua; Ding, Yali; Pan, Xiaokang; Ge, Zheng; Tan, Bi-Hua; Gowda, Chandrika; Sachdev, Mansi; Muthusami, Sunil; Dovat, Sinisa] Penn State Univ, Coll Med, Hershey, PA 17033 USA.
   [Francis, Olivia L.; Morris, Christopher L.; Payne, Kimberly J.] Loma Linda Univ, Loma Linda, CA 92350 USA.
   [Abdel-Azim, Hisham] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90027 USA.
   [Dorsam, Glenn] N Dakota State Univ, Fargo, ND 58108 USA.
   [Xiang, Meixian] South Cent Univ Nationalities, Coll Pharm, Wuhan 430074, Peoples R China.
C3 Xinxiang Medical University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health;
   Loma Linda University; Children's Hospital Los Angeles; University of
   Southern California; North Dakota State University Fargo; South Central
   Minzu University
RP Dovat, S (通讯作者)，Penn State Univ, Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Hershey, PA 17033 USA.
EM sdovat@hmc.psu.edu
RI Ding, Yali/AAD-1895-2019; Payne, Kimberly/AAS-6814-2020; Dorsam,
   Glenn/GYD-8815-2022; Wang, Haijun/A-7691-2016; song, chunhua/K-7882-2016
OI Muthusami, Sunil/0000-0003-0497-6142; Wang, Haijun/0000-0001-6058-0121;
   song, chunhua/0000-0002-4081-2543; Dovat, Sinisa/0000-0003-3906-6165;
   Payne, Kimberly/0000-0002-7025-5821
FU National Institutes of Health (NIH) [R01 HL095120]; St. Baldrick's
   Foundation; Hyundai Hope on Wheels Scholar Grant Award; Four Diamonds
   Fund of the Pennsylvania State University College of Medicine; John
   Wawrynovic Leukemia Research Scholar Endowment; NIH [R21CA162259,
   1R15AI101968-01A1]; Hyundai Hope on Wheels Grant; Department of
   Pathology and Human Anatomy; Department of Basic Sciences; Center for
   Health Disparities and Molecular Medicine (NIH) at Loma Linda University
   School of Medicine [P20MD006988]; Natural Science Foundation of China
   [31200264]; Natural Science Foundation of Hubei Province [2015BCA268];
   Natural Science Foundation of Wuhan City [2015070404010201,
   2014070404010210]
FX This work was supported by National Institutes of Health (NIH) Grant R01
   HL095120, a St. Baldrick's Foundation Career Development Award, a
   Hyundai Hope on Wheels Scholar Grant Award, the Four Diamonds Fund of
   the Pennsylvania State University College of Medicine, and the John
   Wawrynovic Leukemia Research Scholar Endowment (to S. D.). This work was
   also supported by NIH grant R21CA162259, a St. Baldrick's Foundation
   Research Grant, a Hyundai Hope on Wheels Grant (to K. J. P.), the
   Department of Pathology and Human Anatomy, the Department of Basic
   Sciences (Grant to Promote Collaborative and Translational Research to
   K. J. P. and C. L. M.), and the Center for Health Disparities and
   Molecular Medicine (NIH Grant P20MD006988) at Loma Linda University
   School of Medicine. This work was supported in part by NIH Grant
   1R15AI101968-01A1 (to G. P. D.) and by Natural Science Foundation of
   China Grant 31200264, Natural Science Foundation of Hubei Province Grant
   2015BCA268, and "Chenguang Planning" from Natural Science Foundation of
   Wuhan City Grants 2015070404010201 and 2014070404010210 (to M. X.). The
   authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Battistutta R, 2011, BIOCHEMISTRY-US, V50, P8478, DOI 10.1021/bi2008382
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383
   Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9
   Cellot S, 2013, BLOOD, V122, P1545, DOI 10.1182/blood-2013-04-496281
   Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502
   Dovat S, 2011, MOL CELL BIOCHEM, V356, P201, DOI 10.1007/s11010-011-0964-5
   ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982
   Ferreirós-Vidal I, 2013, BLOOD, V121, P1769, DOI 10.1182/blood-2012-08-450114
   Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001
   GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3
   GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790
   Gómez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004
   Gurel Z, 2008, J BIOL CHEM, V283, P8291, DOI 10.1074/jbc.M707906200
   Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732
   Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Jäger R, 2010, LEUKEMIA, V24, P1290, DOI 10.1038/leu.2010.99
   Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505
   Kathrein KL, 2005, MOL CELL BIOL, V25, P1645, DOI 10.1128/MCB.25.5.1645-1654.2005
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5
   Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602
   Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200
   Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090
   Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200
   Li ZJ, 2012, PEDIATR BLOOD CANCER, V59, P69, DOI 10.1002/pbc.23406
   LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229
   Madsen B, 2002, MECH DEVELOP, V119, pS239, DOI 10.1016/S0925-4773(03)00123-0
   Mai A, 2008, BIOORG MED CHEM LETT, V18, P2530, DOI 10.1016/j.bmcl.2008.03.055
   Gomes AM, 2014, HAEMATOLOGICA, V99, P1062, DOI 10.3324/haematol.2013.096438
   MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292
   Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253
   Pagano MA, 2008, BIOCHEM J, V415, P353, DOI 10.1042/BJ20080309
   Popescu M, 2009, J BIOL CHEM, V284, P13869, DOI 10.1074/jbc.M900209200
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Ronni T, 2007, J BIOL CHEM, V282, P2538, DOI 10.1074/jbc.M605627200
   Rudant J, 2013, LEUKEMIA, V27, P746, DOI 10.1038/leu.2012.244
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893
   Song CH, 2015, BLOOD, V126, P1813, DOI 10.1182/blood-2015-06-651505
   Stewart MH, 2015, BLOOD, V125, P2075, DOI 10.1182/blood-2014-08-596734
   Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351
   Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680
   Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69
   Theocharides APA, 2015, LEUKEMIA, V29, P177, DOI 10.1038/leu.2014.150
   Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350
   Zhang JW, 2012, NAT IMMUNOL, V13, P86, DOI 10.1038/ni.2150
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
NR 61
TC 45
Z9 53
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 19
PY 2016
VL 291
IS 8
BP 4004
EP 4018
DI 10.1074/jbc.M115.679332
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DF4RQ
UT WOS:000371338400027
PM 26655717
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Wang, YJ
   Alla, V
   Goody, D
   Gupta, SK
   Spitschak, A
   Wolkenhauer, O
   Pützer, BM
   Engelmann, D
AF Wang, Yajie
   Alla, Vijay
   Goody, Deborah
   Gupta, Shailendra K.
   Spitschak, Alf
   Wolkenhauer, Olaf
   Puetzer, Brigitte M.
   Engelmann, David
TI Epigenetic factor EPC1 is a master regulator of DNA damage response by
   interacting with E2F1 to silence death and activate metastasis-related
   gene signatures
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID POLYCOMB GROUP PROTEIN; HISTONE METHYLTRANSFERASE ACTIVITY;
   PROSTATE-CANCER; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION;
   ACETYLTRANSFERASE COMPLEX; DIFFERENTIAL REGULATION; FOXM1 EXPRESSION;
   FAMILY-MEMBERS; UP-REGULATION
AB Transcription factor E2F1 is a key regulator of cell proliferation and apoptosis. Recently, it has been shown that aberrant E2F1 expression often detectable in advanced cancers contributes essentially to cancer cell propagation and characterizes the aggressive potential of a tumor. Conceptually, this requires a subset of malignant cells capable of evading apoptotic death through anticancer drugs. The molecular mechanism by which the pro-apoptotic activity of E2F1 is antagonized is widely unclear. Here we report a novel function for EPC1 (enhancer of polycomb homolog 1) in DNA damage protection. Depletion of EPC1 potentiates E2F1-mediated apoptosis in response to genotoxic treatment and abolishes tumor cell motility. We found that E2F1 directly binds to the EPC1 promoter and EPC1 vice versa physically interacts with bifunctional E2F1 to modulate its transcriptional activity in a target gene-specific manner. Remarkably, nuclear-colocalized EPC1 activates E2F1 to upregulate the expression of anti-apoptotic survival genes such as BCL-2 or Survivin/BIRC5 and inhibits death-inducing targets. The uncovered cooperativity between EPC1 and E2F1 triggers a metastasis-related gene signature in advanced cancers that predicts poor patient survival. These findings unveil a novel oncogenic function of EPC1 for inducing the switch into tumor progression-relevant gene expression that may help to set novel therapies.
C1 [Wang, Yajie; Alla, Vijay; Goody, Deborah; Spitschak, Alf; Puetzer, Brigitte M.; Engelmann, David] Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, D-18055 Rostock, Germany.
   [Gupta, Shailendra K.; Wolkenhauer, Olaf] Univ Rostock, Dept Syst Biol & Bioinformat, D-18055 Rostock, Germany.
C3 University of Rostock; University of Rostock
RP Pützer, BM (通讯作者)，Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, D-18055 Rostock, Germany.
RI Gupta, Shailendra/F-9108-2010
OI Gupta, Shailendra/0000-0002-3470-3260
FU German Cancer Aid, Dr Mildred Scheel Stiftung [109801]; German Federal
   Ministry of Education and Research (BMBF) as part of the eBio:SysMet
   project [0316171]
FX German Cancer Aid, Dr Mildred Scheel Stiftung [109801 to B. M. P. and D.
   E.]; German Federal Ministry of Education and Research (BMBF) as part of
   the eBio:SysMet project [0316171 to B. M. P.]. Funding for open access
   charge: German Cancer Aid, Dr Mildred Scheel Stiftung [109801 to B. M.
   P. and D. E.]; German Federal Ministry of Education and Research (BMBF)
   as part of the eBio:SysMet project [0316171 to B. M. P.].
CR Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476
   Alla V, 2010, JNCI-J NATL CANCER I, V102, P127, DOI 10.1093/jnci/djp458
   Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540
   Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Cavalli G, 2012, SCIENCE, V338, P1430, DOI 10.1126/science.1232332
   Cecchini MJ, 2011, BIOCHEM J, V434, P297, DOI 10.1042/BJ20101210
   Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389
   de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559
   Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004
   Engelmann D, 2013, J MOL CELL BIOL, V5, P391, DOI 10.1093/jmcb/mjt035
   Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575
   Engelmann D, 2010, DRUG RESIST UPDATE, V13, P119, DOI 10.1016/j.drup.2010.06.001
   Engelmann D, 2010, CELL MOL LIFE SCI, V67, P931, DOI 10.1007/s00018-009-0222-0
   Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576
   Gulzar ZG, 2013, ONCOGENE, V32, P70, DOI 10.1038/onc.2012.27
   Hallstrom TC, 2006, GENE DEV, V20, P613, DOI 10.1101/gad.1345006
   Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100
   HAYES PH, 1984, P NATL ACAD SCI-BIOL, V81, P545, DOI 10.1073/pnas.81.2.545
   Huang X, 2014, LEUKEMIA, V28, P1081, DOI 10.1038/leu.2013.316
   Ji JY, 2012, G3-GENES GENOM GENET, V2, P1651, DOI 10.1534/g3.112.004333
   Ji W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013442
   Johnson JL, 2012, CANCER RES, V72, P516, DOI 10.1158/0008-5472.CAN-11-2647
   Jost CA, 1996, VIROLOGY, V220, P78, DOI 10.1006/viro.1996.0288
   Joung H, 2012, ATHEROSCLEROSIS, V222, P84, DOI 10.1016/j.atherosclerosis.2012.02.015
   Kee HJ, 2012, CELL DEATH DIFFER, V19, P121, DOI 10.1038/cdd.2011.72
   Kee HJ, 2007, J BIOL CHEM, V282, P7700, DOI 10.1074/jbc.M611198200
   Kim HE, 2010, PIGM CELL MELANOMA R, V23, P845, DOI 10.1111/j.1755-148X.2010.00753.x
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Kim JR, 2009, J BIOL CHEM, V284, P16308, DOI 10.1074/jbc.M807725200
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knoll S, 2014, EMBO REP, V15, P1315, DOI 10.15252/embr.201439392
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977
   Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231
   Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941
   Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007
   Li L, 2003, PROTEINS, V53, P693, DOI 10.1002/prot.10460
   Li ZL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-276
   Lin WC, 2001, GENE DEV, V15, P1833
   Lorenzen S, 2007, PROTEINS, V68, P187, DOI 10.1002/prot.21442
   Meier C, 2014, J PATHOL, V234, P351, DOI 10.1002/path.4400
   Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485
   Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005
   Nagel S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-151
   Nakahata S, 2009, GENE CHROMOSOME CANC, V48, P768, DOI 10.1002/gcc.20681
   Nara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056954
   Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119
   Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699
   Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0
   Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998
   Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003
   Pützer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009
   Racek T, 2008, J BIOL CHEM, V283, P34305, DOI 10.1074/jbc.M803925200
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   SATO T, 1985, DEV BIOL, V110, P53, DOI 10.1016/0012-1606(85)90063-6
   Sawa M, 2005, INT J HEMATOL, V82, P42, DOI 10.1532/IJH97.05013
   Shackney SE, 2014, CANCER INFORM, V13, P89, DOI 10.4137/CIN.S14062
   Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239
   Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859
   Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002
   Stankunas K, 1998, DEVELOPMENT, V125, P4055
   Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617
   Su YR, 2010, CANCER RES, V70, P9207, DOI 10.1158/0008-5472.CAN-10-1743
   Su YC, 2012, BBA-GEN SUBJECTS, V1820, P1744, DOI 10.1016/j.bbagen.2012.07.009
   Tang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035435
   Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004
   Thomas S, 2011, CANCER RES, V71, P832, DOI 10.1158/0008-5472.CAN-10-0730
   Van Den Broeck A, 2012, CARCINOGENESIS, V33, P320, DOI 10.1093/carcin/bgr292
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vékony H, 2008, J CLIN PATHOL, V61, P744, DOI 10.1136/jcp.2007.054262
   Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321
   von Eyss B, 2012, EMBO J, V31, P972, DOI 10.1038/emboj.2011.451
   Wang CG, 2007, J BIOL CHEM, V282, P29902, DOI 10.1074/jbc.M704757200
   Wang S, 1999, MOL CELL BIOL, V19, P7447
   Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yang XL, 2014, ONCOTARGETS THER, V7, P1033, DOI 10.2147/OTT.S63145
   Yoon SO, 2006, CANCER RES, V66, P6288, DOI 10.1158/0008-5472.CAN-06-0826
   Zhang Y, 2007, PROTEINS, V69, P108, DOI 10.1002/prot.21702
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
NR 91
TC 31
Z9 34
U1 1
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN 8
PY 2016
VL 44
IS 1
BP 117
EP 133
DI 10.1093/nar/gkv885
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DF3RM
UT WOS:000371264000018
PM 26350215
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Xu, F
   Zhang, YJ
   Li, L
   Zhang, YJ
   Han, JC
   Yu, YY
   Mat, CN
AF Xu, Feng
   Zhang, Ya-Jun
   Li, Li
   Zhang, Yi-Jie
   Han, Ji-Chang
   Yu, Yan-Yan
   Mat, Chao -Nan
TI microRNA-214 inhibits the proliferation of non-small cell lung cancer
   via the suppression of IRS1
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Non-small cell lung cancer; miR-214; insulin receptor substrate 1;
   proliferation
ID HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; NSCLC CELLS; GROWTH; INVASION;
   MIR-214; MIGRATION; RISK
AB Accumulating evidences have proved that microRNAs (miRNAs) act as critical epigenetic regulators in tumor carcinogenesis. However, the biological function of miR-214 in non-small cell lung cancer (NSCLC) remains unclear. In this study, we found that the expression level of miR-214 was down-regulated in NSCLC tissues and cell lines. Overexpression of miR-214 inhibited cell proliferation and induced cell apoptosis and cell cycle arrest in A549 cells. Insulin receptor substrate 1 (IRS1) was identified as a direct target of miR-214 in NSCLC cells, and its protein level was negatively regulated by miR-214. Inhibition of IRS1 showed a similar effect with miR-214 overexpression. Furthermore, IRS1 inversely correlated with miR-214 in NSCLC tissues. Therefore, those data reported in this manuscript suggested that miR-214 functions as a candidate tumor suppressor in NSCLC by directly targeting IRS1. miR-214 may therefore be useful as a potential therapeutic target for NSCLC patients.
C1 [Xu, Feng; Zhang, Ya-Jun; Zhang, Yi-Jie; Han, Ji-Chang; Mat, Chao -Nan] Henan Univ, Huaihe Hosp, Deparement Respirat, Kaifeng 475000, Henan Province, Peoples R China.
   [Xu, Feng] Henan Univ, Huaihe Hosp, Deparement Ultrasound Diag, Kaifeng 475000, Henan Province, Peoples R China.
   [Li, Li] Henan Univ, Inst Nursing, Tokyo Ave & Rd Intersect, Kaifeng 475000, Henan Province, Peoples R China.
C3 Henan University; Henan University; Henan University
RP Li, L (通讯作者)，Henan Univ, Inst Nursing, Tokyo Ave & Rd Intersect, Kaifeng 475000, Henan Province, Peoples R China.
EM yiiezhang76@sina.com
RI Xu, Feng/L-8097-2019; Zhang, Y J/HLG-1022-2023
FU Education Department of Henan Province [14A320082]
FX This work was supported by grants from Education Department of Henan
   Province (No. 14A320082).
CR Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2
   Cheng ZS, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.51
   Dong XQ, 2012, CANCER EPIDEMIOL, V36, P206, DOI 10.1016/j.canep.2011.05.013
   Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070
   Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P1236, DOI 10.6004/jnccn.2012.0130
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jiang J, 2014, TUMOR BIOL, V35, P10019, DOI 10.1007/s13277-014-2294-1
   Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Peng RQ, 2012, J BIOL CHEM, V287, P14301, DOI 10.1074/jbc.M111.337642
   Porter HA, 2013, CANCER LETT, V338, P239, DOI 10.1016/j.canlet.2013.03.030
   Su WJ, 2015, PROSTATE, V75, P855, DOI 10.1002/pros.22968
   Wang JW, 2014, FEBS J, V281, P1355, DOI 10.1111/febs.12659
   Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039
   Wang YL, 2014, BIOCHEM BIOPH RES CO, V446, P1255, DOI 10.1016/j.bbrc.2014.03.107
   Wu L, 2015, ONCOL REP, V34, P2797, DOI 10.3892/or.2015.4251
   Xiang J, 2015, INT J CLIN EXP PATHO, V8, P9147
   Xu XY, 2015, FEBS LETT, V589, P407, DOI 10.1016/j.febslet.2014.12.027
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Zhang XJ, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-46
   Zhou J, 2013, BIOCHEM BIOPH RES CO, V433, P207, DOI 10.1016/j.bbrc.2013.02.084
NR 23
TC 1
Z9 1
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 1
BP 22
EP 29
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DF4XG
UT WOS:000371354200003
DA 2025-01-12
ER

PT J
AU Pisanic, TR
   Athamanolap, P
   Poh, W
   Chen, C
   Hulbert, A
   Brock, MV
   Herman, JG
   Wang, TH
AF Pisanic, Thomas R., II
   Athamanolap, Pornpat
   Poh, Weijie
   Chen, Chen
   Hulbert, Alicia
   Brock, Malcolm V.
   Herman, James G.
   Wang, Tza-Huei
TI DREAMing: a simple and ultrasensitive method for assessing intratumor
   epigenetic heterogeneity directly from liquid biopsies
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CANCER STEM-CELLS; DNA METHYLATION; TUMOR HETEROGENEITY; CPG ISLAND;
   PROMOTER METHYLATION; NUCLEIC-ACIDS; BREAST-CANCER; RESOLUTION; PCR;
   HYPERMETHYLATION
AB Many cancers comprise heterogeneous populations of cells at primary and metastatic sites throughout the body. The presence or emergence of distinct subclones with drug-resistant genetic and epigenetic phenotypes within these populations can greatly complicate therapeutic intervention. Liquid biopsies of peripheral blood from cancer patients have been suggested as an ideal means of sampling intratumor genetic and epigenetic heterogeneity for diagnostics, monitoring and therapeutic guidance. However, current molecular diagnostic and sequencing methods are not well suited to the routine assessment of epigenetic heterogeneity in difficult samples such as liquid biopsies that contain intrinsically low fractional concentrations of circulating tumor DNA (ctDNA) and rare epigenetic subclonal populations. Here we report an alternative approach, deemed DREAMing (Discrimination of Rare EpiAlleles by Melt), which uses semi-limiting dilution and precise melt curve analysis to distinguish and enumerate individual copies of epiallelic species at single-CpG-site resolution in fractions as low as 0.005%, providing facile and inexpensive ultrasensitive assessment of locus-specific epigenetic heterogeneity directly from liquid biopsies. The technique is demonstrated here for the evaluation of epigenetic heterogeneity at p14ARF and BRCA1 gene-promoter loci in liquid biopsies obtained from patients in association with non-small cell lung cancer (NSCLC) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN), respectively.
C1 [Pisanic, Thomas R., II; Wang, Tza-Huei] Johns Hopkins Inst NanoBioTechnol, Baltimore, MD 21218 USA.
   [Athamanolap, Pornpat; Wang, Tza-Huei] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.
   [Poh, Weijie; Chen, Chen; Hulbert, Alicia; Brock, Malcolm V.; Herman, James G.; Wang, Tza-Huei] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Program, Baltimore, MD 21287 USA.
   [Chen, Chen] Cent S Univ, Dept Thorac Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Wang, Tza-Huei] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Medicine; Central South University; Johns Hopkins University
RP Herman, JG (通讯作者)，Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Program, Baltimore, MD 21287 USA.
EM hermanj3@upmc.edu; thwang@jhu.edu
RI chen, chen/M-6561-2017; Wang, Tza-Huei/A-3337-2010; Hulbert,
   Alicia/AAP-5714-2021; Pisanic, Thomas/E-5793-2015
OI Chen, Chen/0000-0003-4569-6032; Poh, Weijie/0000-0002-9700-3237;
   Pisanic, Thomas/0000-0001-5796-0836; Athamanolap,
   Pornpat/0000-0001-6124-4955; Wang, Tza-Huei/0000-0002-3540-9354;
   Hulbert, Alicia/0000-0002-1196-1953
FU National Institutes of Health [R01CA155305, R21CA186809, U54CA151838];
   Royal Thai Government fellowship
FX National Institutes of Health [R01CA155305, R21CA186809 and
   U54CA151838]. Funding for open access charge: National Institutes of
   Health. Pornpat Athamanolap was supported by the Royal Thai Government
   fellowship. The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bailey VJ, 2010, CLIN CHEM, V56, P1022, DOI 10.1373/clinchem.2009.140244
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Blake RD, 1998, NUCLEIC ACIDS RES, V26, P3323, DOI 10.1093/nar/26.14.3323
   Brown R, 2014, NAT REV CANCER, V14, P747, DOI 10.1038/nrc3819
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Candiloro ILM, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-7
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Dwight Z, 2011, BIOINFORMATICS, V27, P1019, DOI 10.1093/bioinformatics/btr065
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Esteller M, 2000, CANCER RES, V60, P129
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fischer JR, 2007, LUNG CANCER, V56, P115, DOI 10.1016/j.lungcan.2006.11.016
   Genereux DP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn691
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Holmes EE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093933
   Hsu HS, 2004, CLIN CANCER RES, V10, P4734, DOI 10.1158/1078-0432.CCR-03-0704
   Ilie M, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.11
   Keeley B, 2013, CLIN CHIM ACTA, V425, P169, DOI 10.1016/j.cca.2013.07.023
   Korbie DJ, 2008, NAT PROTOC, V3, P1452, DOI 10.1038/nprot.2008.133
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442
   Landau D.A., CANC CELL, V26, P813
   Lo YMD, 2007, NAT REV GENET, V8, P71, DOI 10.1038/nrg1982
   Lo YMD, 1999, CANCER RES, V59, P3899
   Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mao F, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-76
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32
   Moelans CB, 2014, MODERN PATHOL, V27, P869, DOI 10.1038/modpathol.2013.207
   Nabilsi NH, 2014, GENOME RES, V24, P329, DOI 10.1101/gr.161737.113
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Oakes CC, 2014, CANCER DISCOV, V4, P348, DOI 10.1158/2159-8290.CD-13-0349
   Poh W, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.3525.3525
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Saito K, 2013, MOL CANCER THER, V12, P1616, DOI 10.1158/1535-7163.MCT-12-1239
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shipony Z, 2014, NATURE, V513, P115, DOI 10.1038/nature13458
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Turner NC, 2012, LANCET ONCOL, V13, pE178, DOI 10.1016/S1470-2045(11)70335-7
   Tusnády GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012
   Varley KE, 2009, NUCLEIC ACIDS RES, V37, P4603, DOI 10.1093/nar/gkp457
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang Q, 2015, GENE CHROMOSOME CANC, V54, P110, DOI 10.1002/gcc.22224
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
NR 66
TC 46
Z9 50
U1 1
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC 15
PY 2015
VL 43
IS 22
AR e154
DI 10.1093/nar/gkv795
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DF3IN
UT WOS:000371237600006
PM 26304549
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Yu, XQ
   Sun, SY
AF Yu, Xiaoqing
   Sun, Shuying
TI HMM-DM: identifying differentially methylated regions using a hidden
   Markov model
SO STATISTICAL APPLICATIONS IN GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE bisulfite sequencing; cancer; differential methylation; hidden Markov
   model
ID DNA METHYLATION; METHYLOME ANALYSIS; ACCURATE; PLURIPOTENT; PIPELINE;
   ALIGNER; PACKAGE; READS; LOCI; RRBS
AB DNA methylation is an epigenetic modification involved in organism development and cellular differentiation. Identifying differential methylations can help to study genomic regions associated with diseases. Differential methylation studies on single-CG resolution have become possible with the bisulfite sequencing (BS) technology. However, there is still a lack of efficient statistical methods for identifying differentially methylated (DM) regions in BS data. We have developed a new approach named HMM-DM to detect DM regions between two biological conditions using BS data. This new approach first uses a hidden Markov model (HMM) to identify DM CG sites accounting for spatial correlation across CG sites and variation across samples, and then summarizes identified sites into regions. We demonstrate through a simulation study that our approach has a superior performance compared to BSmooth. We also illustrate the application of HMM-DM using a real breast cancer dataset.
C1 [Yu, Xiaoqing] Yale Univ, Dept Biostat, New Haven, CT 06511 USA.
   [Sun, Shuying] Texas State Univ, Dept Math, San Marcos, TX 78666 USA.
C3 Yale University; Texas State University System; Texas State University
   San Marcos
RP Yu, XQ (通讯作者)，Yale Univ, Dept Biostat, New Haven, CT 06511 USA.
EM yuxq1120@gmail.com
RI Yu, Xiaoqing/E-2388-2013
FU Dr. Shuying Sun's start-up funds by Texas State University; Research
   Enhancement Program by Texas State University
FX This work was supported by Dr. Shuying Sun's start-up funds and the
   Research Enhancement Program provided by Texas State University.
CR Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   [Anonymous], GITHUB REPOSITORY
   [Anonymous], STAT APPL G IN PRESS
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Campagna D, 2013, BIOINFORMATICS, V29, P268, DOI 10.1093/bioinformatics/bts675
   Chen PY, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-203
   Dolzhenko E, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-215
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Feng H, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku154
   GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414
   Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R83, 10.1186/gb-2012-13-10-r83]
   Harris EY, 2010, BIOINFORMATICS, V26, P572, DOI 10.1093/bioinformatics/btp706
   Hebestreit K, 2013, BIOINFORMATICS, V29, P1647, DOI 10.1093/bioinformatics/btt263
   Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238
   Jayanth N, 2011, J PHYS CHEM B, V115, P6234, DOI 10.1021/jp200185k
   Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/nmeth.1828, 10.1038/NMETH.1828]
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Li S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S5-S10
   Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Neal RM, 2003, ANN STAT, V31, P705, DOI 10.1214/aos/1056562461
   Park Y, 2014, BIOINFORMATICS, V30, P2414, DOI 10.1093/bioinformatics/btu339
   Robinson MD, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00324
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Saito Y, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gkt1373
   Song Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081148
   Stockwell PA, 2014, BIOINFORMATICS, V30, P1814, DOI 10.1093/bioinformatics/btu126
   Strathdee G, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004222
   Sun DQ, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r38
   Sun SY, 2016, STAT APPL GENET MOL, V15, P55, DOI 10.1515/sagmb-2015-0076
   Sun ZF, 2012, BIOINFORMATICS, V28, P2180, DOI 10.1093/bioinformatics/bts337
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Wang HQ, 2011, BIOINFORMATICS, V27, P225, DOI 10.1093/bioinformatics/btq650
   Warden CD, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt242
   Wei SH, 2003, ANN NY ACAD SCI, V983, P243, DOI 10.1111/j.1749-6632.2003.tb05979.x
   Xi YP, 2009, BMC BIOINFORMATICS, V10, DOI [10.1186/1471-2105-10-S1-S58, 10.1186/1471-2105-10-232]
   Xi YX, 2012, BIOINFORMATICS, V28, P430, DOI 10.1093/bioinformatics/btr668
   Xu HY, 2013, GENET EPIDEMIOL, V37, P377, DOI 10.1002/gepi.21726
NR 43
TC 23
Z9 29
U1 0
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 2194-6302
EI 1544-6115
J9 STAT APPL GENET MOL
JI Stat. Appl. Genet. Mol. Biol.
PD MAR
PY 2016
VL 15
IS 1
BP 69
EP 81
DI 10.1515/sagmb-2015-0077
PG 13
WC Biochemistry & Molecular Biology; Mathematical & Computational Biology;
   Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology;
   Mathematics
GA DE9QB
UT WOS:000370971800005
PM 26887041
DA 2025-01-12
ER

PT J
AU Holm, K
   Staaf, J
   Lauss, M
   Aine, M
   Lindgren, D
   Bendahl, PO
   Vallon-Christersson, J
   Barkardottir, RB
   Höglund, M
   Borg, A
   Jönsson, G
   Ringnér, M
AF Holm, Karolina
   Staaf, Johan
   Lauss, Martin
   Aine, Mattias
   Lindgren, David
   Bendahl, Par-Ola
   Vallon-Christersson, Johan
   Barkardottir, Rosa Bjork
   Hoglund, Mattias
   Borg, Ake
   Jonsson, Goran
   Ringner, Markus
TI An integrated genomics analysis of epigenetic subtypes in human breast
   tumors links DNA methylation patterns to chromatin states in normal
   mammary cells
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Breast cancer; DNA methylation; Histone modification; Gene expression;
   Copy number alteration; Mutation; BRCA1; BRCA2; ENCODE; The Cancer
   Genome Atlas
ID GENE-EXPRESSION; COPY NUMBER; MOLECULAR PORTRAITS; PROFILING REVEALS;
   CANCER; HYPERMETHYLATION; SIGNATURE; HYPOMETHYLATION; MUTATIONS;
   FEATURES
AB Background: Aberrant DNA methylation is frequently observed in breast cancer. However, the relationship between methylation patterns and the heterogeneity of breast cancer has not been comprehensively characterized.
   Methods: Whole-genome DNA methylation analysis using Illumina Infinium HumanMethylation450 BeadChip arrays was performed on 188 human breast tumors. Unsupervised bootstrap consensus clustering was performed to identify DNA methylation epigenetic subgroups (epitypes). The Cancer Genome Atlas data, including methylation profiles of 669 human breast tumors, was used for validation. The identified epitypes were characterized by integration with publicly available genome-wide data, including gene expression levels, DNA copy numbers, whole-exome sequencing data, and chromatin states.
   Results: We identified seven breast cancer epitypes. One epitype was distinctly associated with basal-like tumors and with BRCA1 mutations, one epitype contained a subset of ERBB2-amplified tumors characterized by multiple additional amplifications and the most complex genomes, and one epitype displayed a methylation profile similar to normal epithelial cells. Luminal tumors were stratified into the remaining four epitypes, with differences in promoter hypermethylation, global hypomethylation, proliferative rates, and genomic instability. Specific hyper- and hypomethylation across the basal-like epitype was rare. However, we observed that the candidate genomic instability drivers BRCA1 and HORMAD1 displayed aberrant methylation linked to gene expression levels in some basal-like tumors. Hypomethylation in luminal tumors was associated with DNA repeats and subtelomeric regions. We observed two dominant patterns of aberrant methylation in breast cancer. One pattern, constitutively methylated in both basal-like and luminal breast cancer, was linked to genes with promoters in a Polycomb-repressed state in normal epithelial cells and displayed no correlation with gene expression levels. The second pattern correlated with gene expression levels and was associated with methylation in luminal tumors and genes with active promoters in normal epithelial cells.
   Conclusions: Our results suggest that hypermethylation patterns across basal-like breast cancer may have limited influence on tumor progression and instead reflect the repressed chromatin state of the tissue of origin. On the contrary, hypermethylation patterns specific to luminal breast cancer influence gene expression, may contribute to tumor progression, and may present an actionable epigenetic alteration in a subset of luminal breast cancers.
C1 [Holm, Karolina; Staaf, Johan; Lauss, Martin; Aine, Mattias; Bendahl, Par-Ola; Vallon-Christersson, Johan; Hoglund, Mattias; Borg, Ake; Jonsson, Goran; Ringner, Markus] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden.
   [Holm, Karolina; Staaf, Johan; Vallon-Christersson, Johan; Borg, Ake; Jonsson, Goran; Ringner, Markus] Lund Univ, CREATE Hlth Ctr Translat Canc Res, Lund, Sweden.
   [Lindgren, David] Lund Univ, Dept Lab Med Lund, Div Translat Canc Res, Lund, Sweden.
   [Barkardottir, Rosa Bjork] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland.
C3 Lund University; Lund University; Lund University; Landspitali National
   University Hospital
RP Ringnér, M (通讯作者)，Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden.; Ringnér, M (通讯作者)，Lund Univ, CREATE Hlth Ctr Translat Canc Res, Lund, Sweden.
EM markus.ringner@med.lu.se
RI Ringnér, Markus/G-3641-2011; Aine, Mattias/AAU-7281-2020
OI Aine, Mattias/0000-0002-0851-5952; Vallon-Christersson,
   Johan/0000-0002-2195-0385; Ringner, Markus/0000-0001-5469-8940; Staaf,
   Johan/0000-0001-5254-5115
FU Swedish Cancer Society; Swedish Research Council
FX The present study was supported by the Swedish Cancer Society and the
   Swedish Research Council.
CR Aine M, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0144-4
   Ali HR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0431-1
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104
   Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fredlund E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3236
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jönsson G, 2012, CANCER RES, V72, P4028, DOI 10.1158/0008-5472.CAN-12-0097
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Karlsson A, 2014, CLIN CANCER RES, V20, P6127, DOI 10.1158/1078-0432.CCR-14-1087
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442
   Lauss M, 2013, CANCER INFORM, V12, P193, DOI 10.4137/CIN.S12862
   Lauss M, 2012, EPIGENETICS-US, V7, P858, DOI 10.4161/epi.20837
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lusa L, 2007, JNCI-J NATL CANCER I, V99, P1715, DOI 10.1093/jnci/djm216
   Naeem H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-51
   Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Paquet ER, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju357
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Planck M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078614
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Prat A, 2014, BREAST CANCER RES TR, V147, P185, DOI 10.1007/s10549-014-3056-x
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Russnes HG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000611
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2010, LANCET ONCOL, V11, P719, DOI 10.1016/S1470-2045(10)70174-1
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092
   Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
NR 61
TC 60
Z9 72
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD FEB 29
PY 2016
VL 18
AR 27
DI 10.1186/s13058-016-0685-5
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DE9IX
UT WOS:000370951300001
PM 26923702
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hasegawa, M
   Takahashi, H
   Rajabi, H
   Alam, M
   Suzuki, Y
   Yin, L
   Tagde, A
   Maeda, T
   Hiraki, M
   Sukhatme, VP
   Kufe, D
AF Hasegawa, Masanori
   Takahashi, Hidekazu
   Rajabi, Hasan
   Alam, Maroof
   Suzuki, Yozo
   Yin, Li
   Tagde, Ashujit
   Maeda, Takahiro
   Hiraki, Masayuki
   Sukhatme, Vikas P.
   Kufe, Donald
TI Functional interactions of the cystine/glutamate antiporter, CD44v and
   MUC1-C oncoprotein in triple-negative breast cancer cells
SO ONCOTARGET
LA English
DT Article
DE xCT; MUC1-C; CD44v; epigenetics; ferroptosis
ID GLUTATHIONE SYNTHESIS; ACTIVATION; EXPRESSION; TARGET; OVEREXPRESSION;
   GLUTAMINE; X(C)(-); PROTEIN
AB The xCT light chain of the cystine/glutamate transporter (system X-C(-)) is of importance for the survival of triple-negative breast cancer (TNBC) cells. The MUC1-C transmembrane oncoprotein is aberrantly overexpressed in TNBC and, like xCT, has been linked to maintaining glutathione (GSH) levels and redox balance. However, there is no known interaction between MUC1-C and xCT. Here we show that silencing MUC1-C is associated with decreases in xCT expression in TNBC cells. The results demonstrate that MUC1-C forms a complex with xCT and the CD44 variant (CD44v), which interacts with xCT and thereby controls GSH levels. MUC1-C binds directly with CD44v and in turn promotes stability of xCT in the cell membrane. The interaction between MUC1-C and xCT is further supported by the demonstration that targeting xCT with silencing or the inhibitor sulfasalazine suppresses MUC1 gene transcription by increasing histone and DNA methylation on the MUC1 promoter. In terms of the functional significance of the MUC1-C/xCT interaction, we show that MUC1-C protects against treatment with erastin, an inhibitor of X C -and inducer of ferroptosis, a form of non-apoptotic cell death. These findings indicate that targeting this novel MUC1-C/ xCT pathway could represent a potential therapeutic approach for promoting TNBC cell death.
C1 [Hasegawa, Masanori; Takahashi, Hidekazu; Rajabi, Hasan; Alam, Maroof; Suzuki, Yozo; Yin, Li; Tagde, Ashujit; Maeda, Takahiro; Hiraki, Masayuki; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
   [Sukhatme, Vikas P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [Takahashi, Hidekazu] Osaka Univ, Dept Gastrointestinal Surg, Grad Sch Med, Suita, Osaka, Japan.
   [Suzuki, Yozo] Osaka Police Hosp, Dept Surg Gastroenterol, Osaka, Osaka, Japan.
C3 Harvard University; Harvard Medical School; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School; Beth Israel
   Deaconess Medical Center; Osaka University; Osaka Police Hospital
RP Kufe, D (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM donald_kufe@dfci.harvard.edu
RI Sukhatme, Vikas/W-2776-2019; Tagde, Ashujit/M-9497-2014
OI Hasegawa, Masanori/0000-0002-4354-6105; Hiraki,
   Masayuki/0000-0001-6445-7390
FU National Cancer Institute of the National Institutes of Health
   [CA097098, CA166480]; Lung Cancer Research Foundation
FX Research reported in this paper was supported by the National Cancer
   Institute of the National Institutes of Health under award numbers
   CA097098 and CA166480, and by the Lung Cancer Research Foundation.
CR Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661
   Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426
   Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523
   Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848
   Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158
   Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4
   Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589
   Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000
   Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600
   Hitchler MJ, 2009, FREE RADICAL BIO MED, V47, P115, DOI 10.1016/j.freeradbiomed.2009.04.010
   Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Jin CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039432
   Joshi MD, 2009, MOL CANCER THER, V8, P3056, DOI 10.1158/1535-7163.MCT-09-0646
   Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391
   Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513
   Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015
   Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391
   Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366
   Lu HQ, 2015, P NATL ACAD SCI USA, V112, pE4600, DOI 10.1073/pnas.1513433112
   Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638
   Narang VS, 2007, CHEMOTHERAPY, V53, P210, DOI 10.1159/000100812
   Okuno S, 2003, BRIT J CANCER, V88, P951, DOI 10.1038/sj.bjc.6600786
   Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070
   Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308
   Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156
   Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050
   Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854
   Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311
   Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031
   Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200
   Siroy A, 2013, HUM PATHOL, V44, P2159, DOI 10.1016/j.humpath.2013.04.010
   Tagde A, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.45
   Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442
   TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8
   Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020
   Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018
   Yamada N, 2008, CANCER RES, V68, P2708, DOI 10.1158/0008-5472.CAN-07-6844
   Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048
NR 43
TC 143
Z9 166
U1 2
U2 41
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 15
PY 2016
VL 7
IS 11
BP 11756
EP 11769
DI 10.18632/oncotarget.7598
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5LW
UT WOS:000375679600003
PM 26930718
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Prattichizzo, F
   Giuliani, A
   Recchioni, R
   Bonafè, M
   Marcheselli, F
   De Carolis, S
   Campanati, A
   Giuliodori, K
   Rippo, MR
   Brugè, F
   Tiano, L
   Micucci, C
   Ceriello, A
   Offidani, A
   Procopio, AD
   Olivieri, F
AF Prattichizzo, Francesco
   Giuliani, Angelica
   Recchioni, Rina
   Bonafe, Massimiliano
   Marcheselli, Fiorella
   De Carolis, Sabrina
   Campanati, Anna
   Giuliodori, Katia
   Rippo, Maria Rita
   Bruge, Francesca
   Tiano, Luca
   Micucci, Carla
   Ceriello, Antonio
   Offidani, Annamaria
   Procopio, Antonio Domenico
   Olivieri, Fabiola
TI Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in
   endothelial cells and in circulating angiogenic cells
SO ONCOTARGET
LA English
DT Article
DE miR-146a-5p; miR-126-3p; SASP; HUVEC; replicative senescence; Gerotarget
ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ONCOGENE-INDUCED SENESCENCE;
   ACTIVATED PROTEIN-KINASE; DNA-DAMAGE RESPONSE; CELLULAR SENESCENCE;
   DISEASE; AGE; PSORIASIS; SKIN
AB Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence-and SASP-associated markers (interleukin [IL]-6, senescence associated-beta-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs' secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy.
   TNF-alpha blockade associated with adalimumab induced significant reduction in released IL-6 and significant increase in eNOS and miR-126-3p expression levels in long-term HUVEC cultures.
   A significant reduction in miR-146a-5p expression levels both in long-term HUVEC cultures and in CACs isolated from psoriasis patients was also evident. Interestingly, conditioned medium from senescent HUVECs treated with adalimumab was less consistent than medium from untreated cells in inducing migration-and mammosphere-promoting effects on MCF-7 cells.
   Our findings suggest that adalimumab can induce epigenetic modifications in cells undergoing senescence, thus contributing to the attenuation of SASP tumor-promoting effects.
C1 [Prattichizzo, Francesco; Giuliani, Angelica; Rippo, Maria Rita; Micucci, Carla; Procopio, Antonio Domenico; Olivieri, Fabiola] Univ Politecn Marche, DISCLIMO, Dept Clin & Mol Sci, Ancona, Italy.
   [Prattichizzo, Francesco; Ceriello, Antonio] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [Prattichizzo, Francesco; Ceriello, Antonio] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain.
   [Prattichizzo, Francesco; Ceriello, Antonio] IRCCS MultiMed, Sesto San Giovanni, MI, Italy.
   [Recchioni, Rina; Marcheselli, Fiorella; Procopio, Antonio Domenico; Olivieri, Fabiola] Natl Inst INRCA IRCCS, Ctr Clin Pathol & Innovat Therapy, Ancona, Italy.
   [Bonafe, Massimiliano; De Carolis, Sabrina] Univ Bologna, Dept Expt Diagnost & Specialty Med, DIMES, Bologna, Italy.
   [Campanati, Anna; Giuliodori, Katia; Offidani, Annamaria] Univ Politecn Marche, Dermatol Clin, Dept Clin & Mol Med, Ancona, Italy.
   [Bruge, Francesca; Tiano, Luca] Univ Politecn Marche, Dept Clin & Dent Sci, DISCO, Ancona, Italy.
C3 Marche Polytechnic University; University of Barcelona; Hospital Clinic
   de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERDEM; IRCCS Multimedica; University of Bologna; Marche Polytechnic
   University; Marche Polytechnic University
RP Campanati, A (通讯作者)，Univ Politecn Marche, Dermatol Clin, Dept Clin & Mol Med, Ancona, Italy.
EM anna.campanati@gmail.com
RI Procopio, Antonio/AAB-2451-2021; Giuliani, Angelica/AAB-9024-2019;
   Marcheselli, Fiorella/AAB-4170-2021; Recchioni, Rina/ABH-7802-2020;
   Bonafe, Massimiliano/K-5416-2016; Campanati, Anna/AAD-9584-2022;
   Ceriello, Antonio/J-9575-2016; Tiano, Luca/ABC-2341-2020; Prattichizzo,
   Francesco/J-3046-2018; Olivieri, Fabiola/K-6465-2016
OI Tiano, Luca/0000-0002-7519-7106; Recchioni, Rina/0000-0002-7596-3077;
   Marcheselli, Fiorella/0000-0003-1188-1651; Prattichizzo,
   Francesco/0000-0002-2959-2658; Ceriello, Antonio/0000-0001-8122-3203;
   Olivieri, Fabiola/0000-0002-9606-1144; Giuliani,
   Angelica/0000-0002-8477-8519; RIPPO, Maria Rita/0000-0003-3024-3495;
   Procopio, Antonio/0000-0001-6897-8724; DE CAROLIS,
   SABRINA/0000-0001-5785-2624
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Avgerinou G, 2011, INT J CARDIOL, V151, P382, DOI 10.1016/j.ijcard.2011.06.112
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Balistreri CR, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-24
   Brezinski EA, 2014, CURR PHARM DESIGN, V20, P513, DOI 10.2174/138161282004140213123852
   Campanati A, 2013, EUR J INFLAMM, V11, P489, DOI 10.1177/1721727X1301100218
   Campanati A, 2009, INT J IMMUNOPATH PH, V22, P371, DOI 10.1177/039463200902200214
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Carracedo J, 2012, MECH AGEING DEV, V133, P647, DOI 10.1016/j.mad.2012.09.002
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   De Simone C, 2013, EXPERT OPIN BIOL TH, V13, P1673, DOI 10.1517/14712598.2013.848194
   den Broeder A, 2002, J RHEUMATOL, V29, P2288
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Donato AJ, 2008, AGING CELL, V7, P805, DOI 10.1111/j.1474-9726.2008.00438.x
   Ferrand M, 2015, AGING-US, V7, P986, DOI 10.18632/aging.100845
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   HENSELER T, 1995, J AM ACAD DERMATOL, V32, P982, DOI 10.1016/0190-9622(95)91336-X
   Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520
   Hugh J, 2014, J AM ACAD DERMATOL, V70, P168, DOI 10.1016/j.jaad.2013.09.020
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448
   Koziel R, 2014, AGING CELL, V13, P1038, DOI 10.1111/acel.12266
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Laberge RM, 2012, AGING CELL, V11, P569, DOI 10.1111/j.1474-9726.2012.00818.x
   Lim H, 2015, BIOCH PHARM
   Longo VD, 2015, AGING CELL, V14, P497, DOI 10.1111/acel.12338
   Maggio M, 2006, J GERONTOL A-BIOL, V61, P575, DOI 10.1093/gerona/61.6.575
   Matsushita H, 2001, CIRC RES, V89, P793, DOI 10.1161/hh2101.098443
   McCarthy DA, 2013, J BIOL CHEM, V288, P32149, DOI 10.1074/jbc.M113.493841
   Nelson DM, 2014, AGE, V36, P1049, DOI 10.1007/s11357-014-9637-0
   Newgard CB, 2013, J CLIN INVEST, V123, P946, DOI 10.1172/JCI68833
   Oglesby IK, 2010, J IMMUNOL, V184, P1702, DOI 10.4049/jimmunol.0902669
   Olivieri F, 2014, AGING-US, V6, P771, DOI 10.18632/aging.100693
   Olivieri F, 2013, FREE RADICAL BIO MED, V63, P410, DOI 10.1016/j.freeradbiomed.2013.05.033
   Papi A, 2014, J CELL PHYSIOL, V229, P1595, DOI 10.1002/jcp.24601
   Papi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054968
   Prattichizzo F, 2015, CURR DRUG TARGETS
   Purcell M, 2014, CELL CYCLE, V13, P3927, DOI 10.4161/15384101.2014.973327
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Stepanova M, 2015, ONCOTARGET, V6, P1414, DOI 10.18632/oncotarget.2725
   Steyers CM, 2014, INT J MOL SCI, V15, P11324, DOI 10.3390/ijms150711324
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Veitonmäki N, 2003, FASEB J, V17, P764, DOI 10.1096/fj.02-0599-fje
   Waaijer MEC, 2012, AGING CELL, V11, P722, DOI 10.1111/j.1474-9726.2012.00837.x
   Wu ZS, 2015, AGING-US, V7, P70, DOI 10.18632/aging.100722
   Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010
   Zacarias-Fluck MF, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv020
   Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143
   Zhang HR, 2009, CLIN SCI, V116, P219, DOI 10.1042/CS20080196
   Zhang YM, 2009, FASEB J, V23, P1358, DOI 10.1096/fj.08-110296
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 55
TC 69
Z9 72
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 15
PY 2016
VL 7
IS 11
BP 11945
EP 11958
DI 10.18632/oncotarget.7858
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5LW
UT WOS:000375679600017
PM 26943583
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Noh, H
   Park, J
   Shim, M
   Lee, Y
AF Noh, Hyunggyun
   Park, Joonwoo
   Shim, Myeongguk
   Lee, YoungJoo
TI Trichostatin A enhances estrogen receptor-alpha repression in MCF-7
   breast cancer cells under hypoxia
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Estrogen receptor; Hypoxia; Trichostatin A; Breast cancer
ID HISTONE DEACETYLASE INHIBITOR; ER-ALPHA; DOWN-REGULATION; TRANSCRIPTION;
   REACTIVATION; DEGRADATION; ACTIVATION; RESISTANCE; TAMOXIFEN; THERAPY
AB Estrogen receptor (ER) is a crucial determinant of resistance to endocrine therapy, which may change during the progression of breast cancer. We previously showed that hypoxia induces ESR1 gene repression and ER alpha protein degradation via proteasome-mediated pathway in breast cancer cells. HDAC plays important roles in the regulation of histone and non-histone protein post-translational modification. HDAC inhibitors can induce epigenetic changes and have therapeutic potential for targeting various cancers. Trichostatin A exerts potent antitumor activities against breast cancer cells in vitro and in vivo. In this report, we show that TSA augments ESR1 gene repression at the transcriptional level and down regulates Ma protein expression under hypoxic conditions through a proteasome-mediated pathway. TSA-induced estrogen response element-driven reporter activity in the absence of estrogen was synergistically enhanced under hypoxia; however, TSA inhibited cell proliferation under both normoxia and hypoxia. Our data show that the hypoxia-induced repression of ESR1 and degradation of ER alpha are enhanced by concomitant treatment with TSA. These findings expand our understanding of hormone responsiveness in the tumor microenvironment; however, additional in-depth studies are required to elucidate the detailed mechanisms of TSA-induced ER alpha regulation under hypoxia. (C) 2016 Published by Elsevier Inc.
C1 [Noh, Hyunggyun; Park, Joonwoo; Shim, Myeongguk; Lee, YoungJoo] Sejong Univ, Dept Integrated Biosci & Biotechnol, Coll Life Sci, Seoul 143747, South Korea.
C3 Sejong University
RP Lee, Y (通讯作者)，Sejong Univ, Dept Integrated Biosci & Biotechnol, Coll Life Sci, Seoul 143747, South Korea.
EM yjlee@sejong.ac.kr
OI Lee, YoungJoo/0000-0001-7835-1546
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science and Technology
   [2015M3C8A6A06014500, 2015R1A2A2A04003620]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2015M3C8A6A06014500;
   2015R1A2A2A04003620) to YJL.
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   Cho J, 2006, J STEROID BIOCHEM, V100, P18, DOI 10.1016/j.jsbmb.2006.03.002
   Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162
   de Cremoux P, 2015, BREAST CANCER RES TR, V149, P81, DOI 10.1007/s10549-014-3233-y
   Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104
   Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354
   Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037
   Han JY, 2015, J GINSENG RES, V39, P105, DOI 10.1016/j.jgr.2014.09.001
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728
   Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x
   Lee YJ, 1998, MOL CELL ENDOCRINOL, V137, P85, DOI 10.1016/S0303-7207(97)00235-9
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Liu JB, 2015, BIOCHEM BIOPH RES CO, V467, P242, DOI 10.1016/j.bbrc.2015.09.182
   Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2
   Lu HQ, 2015, P NATL ACAD SCI USA, V112, pE4600, DOI 10.1073/pnas.1513433112
   Margueron R, 2004, J MOL ENDOCRINOL, V32, P583, DOI 10.1677/jme.0.0320583
   Nechuta S., 2015, INT J CANC IN PRESS
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Ryu K, 2011, BIOCHEM BIOPH RES CO, V407, P831, DOI 10.1016/j.bbrc.2011.03.119
   Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339
   Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Tu ZZ, 2012, MOL CELL BIOCHEM, V366, P111, DOI 10.1007/s11010-012-1288-9
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yan G, 2013, MOL CARCINOGEN, V52, P404, DOI 10.1002/mc.21875
   Yang XW, 2000, CANCER RES, V60, P6890
   Yi X, 2008, BIOCHEM PHARMACOL, V75, P1697, DOI 10.1016/j.bcp.2007.10.035
NR 34
TC 7
Z9 8
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 12
PY 2016
VL 470
IS 3
BP 748
EP 752
DI 10.1016/j.bbrc.2016.01.022
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DE2OR
UT WOS:000370467100043
PM 26768368
DA 2025-01-12
ER

PT J
AU Messier, TL
   Gordon, JAR
   Boyd, JR
   Tye, CE
   Browne, G
   Stein, JL
   Lian, JB
   Stein, GS
AF Messier, Terri L.
   Gordon, Jonathan A. R.
   Boyd, Joseph R.
   Tye, Coralee E.
   Browne, Gillian
   Stein, Janet L.
   Lian, Jane B.
   Stein, Gary S.
TI Histone H3 lysine 4 acetylation and methylation dynamics define breast
   cancer subtypes
SO ONCOTARGET
LA English
DT Article
DE epigenetics; breast cancer; estrogen receptor pathway; EMT pathway;
   histone H3K4 modifications
ID CELL-LINE VARIANT; MESENCHYMAL TRANSITION; PROMOTES METASTASIS;
   STEM-CELLS; TRANSCRIPTION; IDENTIFICATION; GENERATION; INHIBITORS;
   MODELS; ALPHA
AB The onset and progression of breast cancer are linked to genetic and epigenetic changes that alter the normal programming of cells. Epigenetic modifications of DNA and histones contribute to chromatin structure that result in the activation or repression of gene expression. Several epigenetic pathways have been shown to be highly deregulated in cancer cells. Targeting specific histone modifications represents a viable strategy to prevent oncogenic transformation, tumor growth or metastasis. Methylation of histone H3 lysine 4 has been extensively studied and shown to mark genes for expression; however this residue can also be acetylated and the specific function of this alteration is less well known. To define the relative roles of histone H3 methylation (H3K4me3) and acetylation (H3K4ac) in breast cancer, we determined genomic regions enriched for both marks in normal-like (MCF10A), transformed (MCF7) and metastatic (MDA-MB-231) cells using a genome-wide ChIP-Seq approach. Our data revealed a genome-wide gain of H3K4ac associated with both early and late breast cancer cell phenotypes, while gain of H3K4me3 was predominantly associated with late stage cancer cells. Enrichment of H3K4ac was over-represented at promoters of genes associated with cancer-related phenotypic traits, such as estrogen response and epithelial-to-mesenchymal transition pathways. Our findings highlight an important role for H3K4ac in predicting epigenetic changes associated with early stages of transformation. In addition, our data provide a valuable resource for understanding epigenetic signatures that correlate with known breast cancer-associated oncogenic pathways.
C1 [Messier, Terri L.; Gordon, Jonathan A. R.; Boyd, Joseph R.; Tye, Coralee E.; Browne, Gillian; Stein, Janet L.; Lian, Jane B.; Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Messier, Terri L.; Gordon, Jonathan A. R.; Boyd, Joseph R.; Tye, Coralee E.; Browne, Gillian; Stein, Janet L.; Lian, Jane B.; Stein, Gary S.] Univ Vermont, Coll Med, Ctr Canc, Burlington, VT 05405 USA.
C3 University of Vermont; University of Vermont
RP Stein, GS (通讯作者)，Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.; Stein, GS (通讯作者)，Univ Vermont, Coll Med, Ctr Canc, Burlington, VT 05405 USA.
EM gary.stein@uvm.edu
OI Tye, Coralee/0000-0002-3349-1833
FU Pfizer Investigator-Initiated Research (IIR) Award [WS2049100]; National
   Institutes of Health/National Cancer Institute [P01 CA082834]
FX All authors are supported by a Pfizer Investigator-Initiated Research
   (IIR) Award WS2049100, and a National Institutes of Health/National
   Cancer Institute P01 CA082834.
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   [Anonymous], ASN00022011AA
   Blankenberg D, 2010, BIOINFORMATICS, V26, P1783, DOI 10.1093/bioinformatics/btq281
   Bonnay F, 2014, EMBO J, V33, P2349, DOI 10.15252/embj.201488456
   Chaligné R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114
   Chand AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031593
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Damaskos C, 2015, ANTICANCER RES, V35, P3129
   Deschênes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Duan Q, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.11
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   Garcia BA, 2007, J BIOL CHEM, V282, P7641, DOI 10.1074/jbc.M607900200
   Ghosh MG, 2000, CANCER RES, V60, P6367
   Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926
   Gozgit JM, 2006, MOL CANCER RES, V4, P905, DOI 10.1158/1541-7786.MCR-06-0147
   Guillemette B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001354
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kent WJ, 2010, BIOINFORMATICS, V26, P2204, DOI 10.1093/bioinformatics/btq351
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66
   Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021
   Li QH, 2011, ANN APPL STAT, V5, P1752, DOI 10.1214/11-AOAS466
   Lin BY, 2015, ONCOTARGET, V6, P5369, DOI 10.18632/oncotarget.3030
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin M, 2011, EMBnet J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.1089/cmb.2017.0096, 10.14806/ej.17.1.200]
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Ordóñez NG, 2013, ADV ANAT PATHOL, V20, P352, DOI 10.1097/PAP.0b013e3182a28a68
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
   Salz T, 2015, MOL CANCER RES, V13, P461, DOI 10.1158/1541-7786.MCR-14-0389
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun XJ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00108
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r52
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
NR 53
TC 79
Z9 96
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 2
PY 2016
VL 7
IS 5
BP 5094
EP 5109
DI 10.18632/oncotarget.6922
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5HD
UT WOS:000369952800002
PM 26783963
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Ghoshal, A
   Goswami, U
   Sahoo, AK
   Chattopadhyay, A
   Ghosh, SS
AF Ghoshal, Archita
   Goswami, Upashi
   Sahoo, Amaresh Kumar
   Chattopadhyay, Arun
   Ghosh, Siddhartha Sankar
TI Targeting Wnt Canonical Signaling by Recombinant sFRP1 Bound Luminescent
   Au-Nanocluster Embedded Nanoparticles in Cancer Theranostics
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE nanoparticle; gold nanocluster; secreted frizzled-related protein 1
   (sFRP1); Wnt signaling pathway; cancer cotherapy
ID FLUORESCENT GOLD NANOCLUSTERS; METASTATIC BREAST-CANCER; INVASIVE
   BLADDER-CANCER; PHASE-III TRIAL; RADIATION-THERAPY; DRUG-DELIVERY;
   ANTAGONIST SFRP1; HYDROGEL NANOCARRIER; ONCOLOGY-GROUP; GENE-THERAPY
AB Secreted frizzled-related protein 1 (SFRP1) is a natural blocker of the Wnt signaling pathway in normal adult cells but is epigenetically silenced in cancer cells leading to aberrant proliferation. In this study, we have reported novel composite nanoparticles fabricated with gold nanocluster embedded chitosan and alginate, bound to bacterially expressed human recombinant sFRP1. The Wnt pathway, which is upregulated in cancer, has been specifically targeted with the nanoparticles to achieve an antiproliferative effect on cancer cells, as evident from reduced levels of downstream molecules, namely, beta-catenin, cyclin D1, and survivin. The nanoparticles enabled sustained release of sFRP1 outside the cells, where it is functional. Moreover, remarkable luminescence properties of gold nanoclusters were exploited for binding, imaging, and tracking studies. Co-therapy of sFRP1-loaded nanoparticles with the drug cisplatin targeted two independent pathways to induce apoptosis, as documented by flow cytometry based assays. Overall, this nanosystem is promising for tracking, and targeting cancer signaling with therapeutic protein.
C1 [Ghoshal, Archita; Ghosh, Siddhartha Sankar] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
   [Goswami, Upashi; Sahoo, Amaresh Kumar; Chattopadhyay, Arun; Ghosh, Siddhartha Sankar] Indian Inst Technol Guwahati, Ctr Nanotechnol, Gauhati 781039, Assam, India.
   [Chattopadhyay, Arun] Indian Inst Technol Guwahati, Dept Chem, Gauhati 781039, Assam, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Guwahati; Indian
   Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati
RP Ghosh, SS (通讯作者)，Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
EM sghosh@iitg.ernet.in
RI Sahoo, Amaresh/HCI-0398-2022; Goswami, Upashi/ABA-6099-2021
OI Sahoo, Amaresh/0000-0002-9014-3317; Ghoshal, Archita/0000-0002-9210-3140
FU Department of Biotechnology; Department of Electronics and Information
   Technology, Government of India [5(9)/2012-NANO (Vol. II)]
FX We acknowledge the Department of Biotechnology and the Department of
   Electronics and Information Technology (No. 5(9)/2012-NANO (Vol. II)),
   Government of India for financial support. We also acknowledge the help
   of Central Instruments Facility (CIF) and the Centre for Nanotechnology,
   IIT Guwahati, as well as GE Healthcare.
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Banerjee S, 2013, RSC ADV, V3, P14123, DOI 10.1039/c3ra23181j
   Bardhan R, 2011, ACCOUNTS CHEM RES, V44, P936, DOI 10.1021/ar200023x
   Bian PP, 2013, NANOSCALE, V5, P6161, DOI 10.1039/c3nr01282d
   Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Chacon JA, 2015, CLIN CANCER RES, V21, P611, DOI 10.1158/1078-0432.CCR-14-1934
   Chen AM, 2009, SMALL, V5, P2673, DOI 10.1002/smll.200900621
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Ghosh R, 2015, ACS APPL MATER INTER, V7, P209, DOI 10.1021/am505799q
   Ghoshal A, 2015, APPL BIOCHEM BIOTECH, V175, P2087, DOI 10.1007/s12010-014-1354-8
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e
   Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784
   James ND, 2012, NEW ENGL J MED, V366, P1477, DOI 10.1056/NEJMoa1106106
   Ju SM, 2014, EUR REV MED PHARMACO, V18, P1135
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd, P54, DOI DOI 10.1007/978-0-387-46312-4
   Le Guével X, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/27/275103
   Leamon CP, 2004, ADV DRUG DELIVER REV, V56, P1127, DOI 10.1016/j.addr.2004.01.008
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lin CAJ, 2009, ACS NANO, V3, P395, DOI 10.1021/nn800632j
   Liu C, 2015, BIOMED REP, V3, P123, DOI 10.3892/br.2014.388
   Ma LL, 2009, ACS NANO, V3, P2686, DOI 10.1021/nn900440e
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   MATHE G, 1969, LANCET, V1, P697, DOI 10.1016/S0140-6736(69)92648-8
   Miles D, 2002, ONCOLOGIST, V7, P13
   Moore DH, 2012, GYNECOL ONCOL, V124, P529, DOI 10.1016/j.ygyno.2011.11.003
   O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annonc/mdh097
   Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606
   Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561
   RAMU A, 1984, CANCER RES, V44, P4392
   RemunanLopez C, 1997, J CONTROL RELEASE, V44, P215, DOI 10.1016/S0168-3659(96)01525-8
   Retnakumari A, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/5/055103
   Richardson TP, 2001, CRIT REV EUKAR GENE, V11, P47
   Ricketts CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085621
   Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019
   Sahoo AK, 2014, ACS APPL MATER INTER, V6, P712, DOI 10.1021/am4051266
   Shiang YC, 2012, J MATER CHEM, V22, P12972, DOI 10.1039/c2jm30563a
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Singh AK, 2012, INT J NANOMED, V7, P2739, DOI 10.2147/IJN.S28357
   Solal-Céligny P, 1998, J CLIN ONCOL, V16, P2332, DOI 10.1200/JCO.1998.16.7.2332
   SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749
   Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Tian DH, 2012, LANGMUIR, V28, P3945, DOI 10.1021/la204380a
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Vernejoul F, 2006, MOL THER, V14, P758, DOI 10.1016/j.ymthe.2006.07.010
   Wang CS, 2011, ANGEW CHEM INT EDIT, V50, P11644, DOI 10.1002/anie.201105573
   Wu X, 2010, NANOSCALE, V2, P2244, DOI 10.1039/c0nr00359j
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Zhang AL, 2012, J COLLOID INTERF SCI, V372, P239, DOI 10.1016/j.jcis.2012.01.005
   Zhang X.-D., 2014, ADV HEALTHC MATER, V3, P152
   Zhen ZP, 2013, ACS NANO, V7, P4830, DOI 10.1021/nn305791q
NR 59
TC 21
Z9 21
U1 4
U2 56
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373-9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD DEC
PY 2015
VL 1
IS 12
BP 1256
EP 1266
DI 10.1021/acsbiomaterials.5b00305
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA DE5MO
UT WOS:000370675300009
PM 33429673
DA 2025-01-12
ER

PT J
AU Han, T
   Jiao, F
   Hu, H
   Yuan, CC
   Wang, L
   Jin, ZL
   Song, WF
   Wang, LW
AF Han, Ting
   Jiao, Feng
   Hu, Hai
   Yuan, Cuncun
   Wang, Lei
   Jin, Zi-Liang
   Song, Wei-feng
   Wang, Li-Wei
TI EZH2 promotes cell migration and invasion but not alters cell
   proliferation by suppressing E-cadherin, partly through association with
   MALAT-1 in pancreatic cancer
SO ONCOTARGET
LA English
DT Article
DE pancreatic cancer; enhancer of zeste homolog 2; metastasis associated
   lung adenocarcinoma transcript 1; long non-coding RNA; cell migration
ID GROUP PROTEIN EZH2; MESENCHYMAL TRANSITION; EPIGENETIC REGULATION;
   BLADDER-CANCER; BREAST-CANCER; EXPRESSION; PROSTATE; METASTASIS;
   REPRESSION; GENE
AB Enhancer of zeste homolog 2 (EZH2) is an essential component of the polycomb repressive complex 2 (PRC2), which is required for epigenetic silencing of target genes, including those affecting cancer progression. Its role in pancreatic cancer remains to be clarified; therefore, we investigated the effects of aberrantly expressed EZH2 on pancreatic cancer. We found that EZH2 expression is up-regulated in pancreatic cancer tissues and positively correlated with lymph node metastasis and advanced clinical stage in pancreatic cancer patients. EZH2 knockdown in pancreatic cancer cell lines inhibited cell migration and invasion, but did not alter cell proliferation. Silencing of EZH2 also increased E-cadherin expression in vitro, and E-cadherin expression was inversely correlated with EZH2 expression in pancreatic cancer tissue samples. Patients with high EZH2 and low E-cadherin expression had the worst prognosis. RIP and ChIP assays suggest that EZH2 is recruited to the E-cadherin promoter by the long non-coding RNA, MALAT-1 (metastasis associated in lung adenocarcinoma transcript 1), where it represses E-cadherin expression. Our results show that EZH2-based therapies may be an option for the treatment of pancreatic cancer.
C1 [Han, Ting; Jiao, Feng; Hu, Hai; Song, Wei-feng; Wang, Li-Wei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Med Oncol, Shanghai 201620, Peoples R China.
   [Han, Ting; Jiao, Feng; Hu, Hai; Song, Wei-feng; Wang, Li-Wei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Pancreat Canc Ctr, Shanghai 201620, Peoples R China.
   [Han, Ting; Jiao, Feng; Wang, Lei; Jin, Zi-Liang; Wang, Li-Wei] Shanghai Key Lab Pancreat Dis, Shanghai 201620, Peoples R China.
   [Yuan, Cuncun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Pathol, Shanghai 201620, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Jiao, F; Wang, LW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Med Oncol, Shanghai 201620, Peoples R China.; Jiao, F; Wang, LW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Pancreat Canc Ctr, Shanghai 201620, Peoples R China.; Jiao, F; Wang, LW (通讯作者)，Shanghai Key Lab Pancreat Dis, Shanghai 201620, Peoples R China.
EM jiao_f@outlook.com; yzwlw@hotmail.com
RI 韩, 挺/JJD-2015-2023
FU National Natural Science Foundation of China [81502017, 81502018,
   81572315, 81171887, 91229117]; Program of Shanghai Subject Chief
   Scientist [12XD1404200]; Shanghai International Science and Technology
   Cooperation Project [12410709000]; Shanghai Science and Technology
   Committee [11DZ1922002]; Shanghai Hospital Development Center
   [SHDC12014128]; National Key Clinical Discipline-Oncology; Songjiang
   Liandong Program [0702N14002]
FX This study was supported in part by the National Natural Science
   Foundation of China (grant NO. 81502017, 81502018, 81572315, 81171887
   and 91229117), by Program of Shanghai Subject Chief Scientist (grant NO.
   12XD1404200), by Shanghai International Science and Technology
   Cooperation Project (grant NO. 12410709000), by Shanghai Science and
   Technology Committee (grant NO. 11DZ1922002), by Research Grant from
   Shanghai Hospital Development Center (SHDC12014128), by National Key
   Clinical Discipline-Oncology, and by Songjiang Liandong
   Program(0702N14002).
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   [Anonymous], STEM CELLS
   [Anonymous], NATURE
   [Anonymous], RES VET SCI
   [Anonymous], BJU INT
   [Anonymous], PLOS ONE
   [Anonymous], FASEB J
   [Anonymous], CELL CYCLE
   [Anonymous], CANC LETT
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Beuran M, 2015, PANCREATOLOGY, V15, P217, DOI 10.1016/j.pan.2015.02.011
   Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chen S, 2014, ONCOTARGET, V5, P10421, DOI 10.18632/oncotarget.2126
   Chen X, 2015, SCI REP-UK, V5, DOI 10.1038/srep08293
   Ferraro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115276
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3
   Graziano F, 2004, CLIN CANCER RES, V10, P2784, DOI 10.1158/1078-0432.CCR-03-0320
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931
   Jiao F, 2015, INT J MOL SCI, V16, P6677, DOI 10.3390/ijms16046677
   Jiao F, 2014, ONCOL REP, V32, P2485, DOI 10.3892/or.2014.3518
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Luo WR, 2012, INT J CANCER, V131, P1863, DOI 10.1002/ijc.27467
   Mallen-St Clair J, 2012, GENE DEV, V26, P439, DOI 10.1101/gad.181800.111
   Momparler RL, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-19
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256
   Takayama K, 2015, ONCOTARGET, V6, P2263, DOI 10.18632/oncotarget.2949
   Teven CM, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/201371
   Tie F, 2001, DEVELOPMENT, V128, P275
   Tripathi SK, 2014, IMMUNOL REV, V261, P62, DOI 10.1111/imr.12204
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang C, 2013, MOL CARCINOGEN, V52, P229, DOI 10.1002/mc.21848
   Wang HF, 2014, GENET MOL RES, V13, P9939, DOI 10.4238/2014.November.27.23
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wu YS, 2015, INT J ONCOL, V46, P2586, DOI 10.3892/ijo.2015.2976
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099763
   Zhang JS, 2012, CELL MOL LIFE SCI, V69, P2161, DOI 10.1007/s00018-012-0920-x
NR 49
TC 73
Z9 80
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 8
PY 2016
VL 7
IS 10
BP 11194
EP 11207
DI 10.18632/oncotarget.7156
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5LK
UT WOS:000375678300036
PM 26848980
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Pattabiraman, DR
   Bierie, B
   Kober, KI
   Thiru, P
   Krall, JA
   Zill, C
   Reinhardt, F
   Tam, WL
   Weinberg, RA
AF Pattabiraman, Diwakar R.
   Bierie, Brian
   Kober, Katharina Isabelle
   Thiru, Prathapan
   Krall, Jordan A.
   Zill, Christina
   Reinhardt, Ferenc
   Tam, Wai Leong
   Weinberg, Robert A.
TI Activation of PKA leads to mesenchymal-to-epithelial transition and loss
   of tumor-initiating ability
SO SCIENCE
LA English
DT Article
ID DEPENDENT PROTEIN-KINASE; BREAST-CANCER CELLS; CYCLIC-AMP; STEM-CELLS;
   SIGNALING AXIS; EXPRESSION; GROWTH; PHOSPHORYLATION; MECHANISMS;
   REPRESSION
AB The epithelial-to-mesenchymal transition enables carcinoma cells to acquire malignancy-associated traits and the properties of tumor-initiating cells (TICs). TICs have emerged in recent years as important targets for cancer therapy, owing to their ability to drive clinical relapse and enable metastasis. Here, we propose a strategy to eliminate mesenchymal TICs by inducing their conversion to more epithelial counterparts that have lost tumor-initiating ability. We report that increases in intracellular levels of the second messenger, adenosine 3', 5'-monophosphate, and the subsequent activation of protein kinase A (PKA) induce a mesenchymal-to-epithelial transition (MET) in mesenchymal human mammary epithelial cells. PKA activation triggers epigenetic reprogramming of TICs by the histone demethylase PHF2, which promotes their differentiation and loss of tumor-initiating ability. This study provides proof-of-principle for inducing an MET as differentiation therapy for TICs and uncovers a role for PKA in enforcing and maintaining the epithelial state.
C1 [Pattabiraman, Diwakar R.; Bierie, Brian; Kober, Katharina Isabelle; Thiru, Prathapan; Krall, Jordan A.; Zill, Christina; Reinhardt, Ferenc; Tam, Wai Leong; Weinberg, Robert A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
   [Tam, Wai Leong] Genome Inst Singapore, 60 Biopolis St, Singapore, Singapore.
   [Tam, Wai Leong] Canc Sci Inst Singapore, 14 Med Dr, Singapore, Singapore.
   [Weinberg, Robert A.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Weinberg, Robert A.] MIT, Ludwig Ctr Mol Oncol, Cambridge, MA 02142 USA.
C3 Massachusetts Institute of Technology (MIT); Whitehead Institute; Agency
   for Science Technology & Research (A*STAR); A*STAR - Genome Institute of
   Singapore (GIS); Massachusetts Institute of Technology (MIT);
   Massachusetts Institute of Technology (MIT)
RP Weinberg, RA (通讯作者)，Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.; Weinberg, RA (通讯作者)，MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Weinberg, RA (通讯作者)，MIT, Ludwig Ctr Mol Oncol, Cambridge, MA 02142 USA.
EM weinberg@wi.mit.edu
RI Tam, Wai/P-1497-2019; Pattabiraman, Diwakar/AAE-6338-2020
OI Kober, Katharina Isabelle/0000-0002-8076-3379; Tam, Wai
   Leong/0000-0003-2365-5264; Pattabiraman, Diwakar/0000-0002-2418-6458
FU C. J. Martin Overseas Biomedical Fellowship from the National Health and
   Medical Research Council of Australia [NHMRC APP1071853]; National
   Research Foundation, Singapore [NRF-NRFF2015-04]; National Medical
   Research Council, Singapore [NMRC/TCR/007-NCC/2013]; Ludwig Center for
   Molecular Oncology at MIT; Breast Cancer Research Foundation; Samuel
   Waxman Cancer Research Foundation; NIH [R01-CA078461]
FX We thank the Keck Microscopy Facility, Metabolite Profiling Core
   Facility, Genome Technology Core, Bioinformatics and Research Computing
   Core, and Proteomics Core Facility at the Whitehead Institute; the Koch
   Institute Swanson Biotechnology Center (SBC), specifically the Histology
   Facility and the High-Throughput Screening Facility; J. Benson (SBC) for
   providing the compound library; D. Bachovchin (Broad Institute) for
   assistance with automation; and T. DiCesare for assistance with
   scientific illustration. We thank A. Dongre, S. Iyer, and J. Frose for
   technical assistance; all members of the Weinberg laboratory for helpful
   discussions; and A. Lambert, K. Krishnan, and S. Rajavasireddy for
   critical reading of the manuscript. D.R.P is supported by a C. J. Martin
   Overseas Biomedical Fellowship from the National Health and Medical
   Research Council of Australia (NHMRC APP1071853). W.L.T. is supported by
   the National Research Foundation, Singapore (NRF-NRFF2015-04); and
   National Medical Research Council, Singapore (NMRC/TCR/007-NCC/2013).
   This research was supported by the Ludwig Center for Molecular Oncology
   at MIT (R.A.W.), Breast Cancer Research Foundation (R.A.W.), Samuel
   Waxman Cancer Research Foundation (R.A.W.) and NIH R01-CA078461
   (R.A.W.). R.A.W. is an American Cancer Society and D.K. Ludwig
   Foundation Cancer Research Professor. R.A.W. is a shareholder in and the
   chairman of the Scientific Advisory Board of Verastem, Inc., a company
   focused on developing drugs to treat cancer by the targeted killing of
   cancer stem cells. The Whitehead Institute and the authors (R.A.W.,
   D.R.P., B.B., and W.L.T.) have filed a patent application
   (PCT/US2015/028239) that covers methods of differentiating cancer stem
   cells through the induction of a MET and the use of these methods for
   treating cancer. RNA-Seq and ChIP-Seq data from this study have been
   deposited at GEO under accession number GSE74883.
CR Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Amieux PS, 2002, J BIOL CHEM, V277, P27294, DOI 10.1074/jbc.M200302200
   Anastassiou D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-529
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228
   Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911
   Broillet MC, 1999, ANN NY ACAD SCI, V868, P730, DOI 10.1111/j.1749-6632.1999.tb11352.x
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016466
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Ellenrieder V, 2001, CANCER RES, V61, P4222
   Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874
   GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5
   GREEN H, 1978, CELL, V15, P801, DOI 10.1016/0092-8674(78)90265-9
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8
   Hublitz P, 2009, INT J DEV BIOL, V53, P335, DOI 10.1387/ijdb.082717ph
   Iglesias-Bartolome R, 2015, NAT CELL BIOL, V17, P793, DOI 10.1038/ncb3164
   Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Linnemann JR, 2015, DEVELOPMENT, V142, P3239, DOI 10.1242/dev.123554
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   MEYER RB, 1974, LIFE SCI, V14, P1019, DOI 10.1016/0024-3205(74)90228-8
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nadella KS, 2008, CANCER RES, V68, P2671, DOI 10.1158/0008-5472.CAN-07-6002
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Propper DJ, 1999, CLIN CANCER RES, V5, P1682
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Saunders MP, 1997, J CLIN ENDOCR METAB, V82, P4044, DOI 10.1210/jc.82.12.4044
   Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l
   Shaikh D, 2012, CELL SIGNAL, V24, P2396, DOI 10.1016/j.cellsig.2012.08.007
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200
   Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479
   Singh R, 2014, CELL SIGNAL, V26, P1604, DOI 10.1016/j.cellsig.2014.03.028
   SOMMERS CL, 1990, CANCER RES, V50, P67
   SOULE HD, 1990, CANCER RES, V50, P6075
   Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005
   Taskén K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003
   Taylor SS, 2012, NAT REV MOL CELL BIO, V13, P646, DOI 10.1038/nrm3432
   TAYLORPAPADIMITRIOU J, 1980, J CELL PHYSIOL, V102, P317, DOI 10.1002/jcp.1041020306
   Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 60
TC 255
Z9 300
U1 0
U2 83
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 4
PY 2016
VL 351
IS 6277
BP 1042
EP +
DI 10.1126/science.aad3680
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF8HE
UT WOS:000371597500033
PM 26941323
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kavlashvili, T
   Jia, YC
   Dai, DH
   Meng, XB
   Thiel, KW
   Leslie, KK
   Yang, SJ
AF Kavlashvili, Tamar
   Jia, Yichen
   Dai, Donghai
   Meng, Xiangbing
   Thiel, Kristina W.
   Leslie, Kimberly K.
   Yang, Shujie
TI Inverse Relationship between Progesterone Receptor and Myc in
   Endometrial Cancer
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; EXPRESSION; ESTROGEN; RESPONSIVENESS; MECHANISMS;
   INHIBITORS; PROMOTERS; CARCINOMA; CELLS; WOMEN
AB Endometrial cancer, the most common gynecologic malignancy, is a hormonally-regulated disease. Response to progestin therapy positively correlates with hormone receptor expression, in particular progesterone receptor (PR). However, many advanced tumors lose PR expression. We recently reported that the efficacy of progestin therapy can be significantly enhanced by combining progestin with epigenetic modulators, which we term "molecularly enhanced progestin therapy." What remained unclear was the mechanism of action and if estrogen receptor alpha (ER alpha), the principle inducer of PR, is necessary to restore functional expression of PR via molecularly enhanced progestin therapy. Therefore, we modeled advanced endometrial tumors that have lost both ER alpha and PR expression by generating ER alpha-null endometrial cancer cell lines. CRISPR-Cas9 technology was used to delete ER alpha at the genomic level. Our data demonstrate that treatment with a histone deacetylase inhibitor (HDACi) was sufficient to restore functional PR expression, even in cells devoid of ER alpha. Our studies also revealed that HDACi treatment results in marked downregulation of the oncogene Myc. We established that PR is a negative transcriptional regulator of Myc in endometrial cancer in the presence or absence of ER alpha, which is in contrast to studies in breast cancer cells. First, estrogen stimulation augmented PR expression and decreased Myc in endometrial cancer cell lines. Second, progesterone increased PR activity yet blunted Myc mRNA and protein expression. Finally, overexpression of PR by adenoviral transduction in ER alpha-null endometrial cancer cells significantly decreased expression of Myc and Myc-regulated genes. Analysis of the Cancer Genome Atlas (TCGA) database of endometrial tumors identified an inverse correlation between PR and Myc mRNA levels, with a corresponding inverse correlation between PR and Myc downstream transcriptional targets SRD5A1, CDK2 and CCNB1. Together, these data reveal a previously unanticipated inverse relationship between the tumor suppressor PR and the oncogene Myc in endometrial cancer.
C1 [Kavlashvili, Tamar; Jia, Yichen; Dai, Donghai; Meng, Xiangbing; Thiel, Kristina W.; Leslie, Kimberly K.; Yang, Shujie] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.
   [Meng, Xiangbing; Leslie, Kimberly K.; Yang, Shujie] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
   [Jia, Yichen] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
C3 University of Iowa; University of Iowa; University of Washington;
   University of Washington Seattle
RP Yang, SJ (通讯作者)，Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.; Yang, SJ (通讯作者)，Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
EM Shujie-yang@uiowa.edu
OI meng, xiangbing/0000-0002-9612-6438; Thiel,
   Kristina/0000-0001-8295-864X; Jia, Yichen/0000-0002-9127-5610; Yang,
   Shujie/0000-0003-1753-3068; Kavlashvili, Tamar/0000-0003-3827-8975;
   Leslie, Kimberly/0000-0002-2704-8990; Dai, Donghai/0000-0002-9670-7822
FU American Cancer Society Institutional Research Grant; NIH [R01CA99908,
   R01CA184101]; Department of Obstetrics and Gynecology Research
   Development Fund
FX This work was supported by the American Cancer Society Institutional
   Research Grant (SY), and the NIH R01CA99908 and R01CA184101 (KKL), the
   Department of Obstetrics and Gynecology Research Development Fund (KKL).
   The funders did not play a role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], COLD SPRING HARB PER
   [Anonymous], 2015, CANC FACTS FIG
   [Anonymous], COLD SPRING HARB PER
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Diep CH, 2015, J MOL ENDOCRINOL, V54, pR31, DOI 10.1530/JME-14-0252
   DUBIK D, 1987, CANCER RES, V47, P6517
   Giulianelli S, 2012, CANCER RES, V72, P2416, DOI 10.1158/0008-5472.CAN-11-3290
   Hunter DJ, 2010, CANCER EPIDEM BIOMAR, V19, P2496, DOI 10.1158/1055-9965.EPI-10-0747
   Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489
   Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1
   Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057
   Li CI, 2012, CANCER RES, V72, P2028, DOI 10.1158/0008-5472.CAN-11-4064
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McEwan MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049160
   Moore MR, 1997, J STEROID BIOCHEM, V62, P243, DOI 10.1016/S0960-0760(97)00036-8
   Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x
   Prystowsky MB, 2009, J PATHOL, V218, P467, DOI 10.1002/path.2554
   Raeder MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054873
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Singh M, 2007, GYNECOL ONCOL, V106, P325, DOI 10.1016/j.ygyno.2007.03.042
   Tansey WP, 2014, NEW J SCI, V2014, P27, DOI DOI 10.1155/2014/757534
   Wargon V, 2015, INT J CANCER, V136, P2680, DOI 10.1002/ijc.29304
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yang S, 2013, CURR PHARM DES
   Yang SJ, 2014, ONCOTARGET, V5, P9783, DOI 10.18632/oncotarget.2392
   Yang SJ, 2011, DISCOV MED, V12, P205
   Yang S, 2011, TRENDS ENDOCRIN MET, V22, P145, DOI 10.1016/j.tem.2011.01.005
NR 27
TC 34
Z9 36
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2016
VL 11
IS 2
AR e0148912
DI 10.1371/journal.pone.0148912
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DD6MN
UT WOS:000370038400103
PM 26859414
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Xiao, HW
   Wang, LMM
   Luo, Y
   Lai, XY
   Li, CH
   Shi, JM
   Tan, YM
   Fu, S
   Wang, YB
   Zhu, N
   He, JS
   Zheng, WY
   Yu, XH
   Cai, Z
   Huang, H
AF Xiao, Haowen
   Wang, Li-Mengmeng
   Luo, Yi
   Lai, Xiaoyu
   Li, Caihua
   Shi, Jimin
   Tan, Yamin
   Fu, Shan
   Wang, Yebo
   Zhu, Ni
   He, Jingsong
   Zheng, Weiyan
   Yu, Xiaohong
   Cai, Zhen
   Huang, He
TI Mutations in epigenetic regulators are involved in acute lymphoblastic
   leukemia relapse following allogeneic hematopoietic stem cell
   transplantation
SO ONCOTARGET
LA English
DT Article
DE acute lymphoblastic leukemia; relapse; allogeneic hematopoietic stem
   cell transplantation; mutation; epigenetic regulators
ID HUMAN BREAST-CANCER; GENETIC ALTERATIONS; GENOMIC ANALYSIS; SETD2;
   CHILDHOOD; REVEALS; REMISSION; EVOLUTION; ADULTS
AB Although steady improvements to chemotherapeutic treatments has helped cure 80% of childhood acute lymphoblastic leukemia (ALL) cases, chemotherapy has proven to be less effective in treating the majority of adult patients, leaving allogeneic hematopoietic stem cell transplantation (allo-HSCT) as the primary adult treatment option. Nevertheless relapse are the leading cause of death following allo-HSCT. The genetic pathogenesis of relapse following allo-HSCT in Philadelphia chromosome-negative ALL (Ph- ALL) remains unexplored. We performed longitudinal whole-exome sequencing analysis in three adult patients with Ph- B-cell ALL (Ph- B-ALL) on samples collected from diagnosis to relapse after allo-HSCT. Based on these data, we performed target gene sequencing on 23 selected genes in 58 adult patients undergoing alloHSCT with Ph- B-ALL. Our results revealed a significant enrichment of mutations in epigenetic regulators from relapsed samples, with recurrent somatic mutations in SETD2, CREBBP, KDM6A and NR3C1. The relapsed samples were also enriched in signaling factor mutations, including KRAS, PTPN21, MYC and USP54. Furthermore, we are the first to reveal the clonal evolution patterns during leukemia relapse after alloHSCT. Cells present in relapsed specimens were genetically related to the diagnosed tumor, these cells therefore arose from either an existing subclone that was not eradicated by allo-HSCT therapy, or from the same progenitor that acquired new mutations. In some cases, however, it is possible that leukemia recurrence following allo-HSCT could result from a secondary malignancy with a distinct set of mutations. We identified novel genetic causes of leukemia relapse after allo-HSCT using the largest generated data set to date from adult patients with Ph- B-ALL.
C1 [Xiao, Haowen; Wang, Li-Mengmeng; Luo, Yi; Lai, Xiaoyu; Shi, Jimin; Tan, Yamin; Fu, Shan; Wang, Yebo; Zhu, Ni; He, Jingsong; Zheng, Weiyan; Yu, Xiaohong; Cai, Zhen; Huang, He] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Xiao, Haowen] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Hematol, Guangzhou Liuhuaqiao Hosp, Guangzhou, Guangdong, Peoples R China.
   [Li, Caihua] Genesky Biotechnol Inc, Ctr Genet & Genom Anal, Shanghai, Peoples R China.
C3 Zhejiang University; Southern Theater Command General Hospital
RP Huang, H (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
EM hehuangyu@126.com
RI Wang, Yebo/JXY-7023-2024; Wang, Hailong/C-2641-2011; zhang,
   ying/HJB-1230-2022; Lai, Xiao-Yu/HJZ-0331-2023
FU National Natural Science Foundation of China [81230014, 81170501,
   81470309, 81100387]; Science Technology Department of Zhejiang Province
   [2012C13021-1]; National High Technology Research and Development
   Program of China [2012AA020905]
FX This work was supported by grants from the Key Project of the National
   Natural Science Foundation of China (81230014), the National Natural
   Science Foundation of China (81170501) and the Major Technology Program
   (Key Social Development) of the Science Technology Department of
   Zhejiang Province (2012C13021-1), all awarded to Prof. He Huang. This
   work was also supported by grants from the National High Technology
   Research and Development Program of China (2012AA020905) awarded to Dr.
   Yi Luo, as well as by the National Natural Science Foundation of China
   grant (81470309, 81100387) awarded to Dr. Haowen Xiao.
CR Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290
   [Anonymous], MOL CANC RES
   [Anonymous], 2011, CURRENT USE OUTCOME
   [Anonymous], 2013, NATURE, V499, P43
   Bishop MR, 2008, BONE MARROW TRANSPL, V41, P635, DOI 10.1038/sj.bmt.1705952
   Byun S, 2013, CLIN CANC RES
   Cairo MS, 2010, BIOL BLOOD MARROW TR, V16, P709, DOI 10.1016/j.bbmt.2010.03.002
   Carlucci A, 2010, J BIOL CHEM, V285, P39260, DOI 10.1074/jbc.M110.174706
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Driessen EMC, 2013, HAEMATOLOGICA, V98, P937, DOI 10.3324/haematol.2012.067983
   Harrison CJ, 2011, CLIN LAB MED, V31, P631, DOI 10.1016/j.cll.2011.08.016
   Hogan LE, 2011, BLOOD, V118, P5218, DOI 10.1182/blood-2011-04-345595
   Korff S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-329
   Kuiper RP, 2007, LEUKEMIA, V21, P1258, DOI 10.1038/sj.leu.2404691
   Laport GG, 2008, BLOOD, V112, P903, DOI 10.1182/blood-2008-03-143115
   Liu JN, 2012, EXP HEMATOL, V40, P487, DOI 10.1016/j.exphem.2012.01.017
   Makki MS, 2013, EXP CELL RES, V319, P612, DOI 10.1016/j.yexcr.2012.12.021
   Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469
   Marks DI, 2008, BLOOD, V112, P426, DOI 10.1182/blood-2007-12-128918
   Mullighan CG, 2009, LEUKEMIA, V23, P1209, DOI 10.1038/leu.2009.18
   Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266
   Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866
   Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   Mullighan CG, 2011, BEST PRACT RES CL HA, V24, P489, DOI 10.1016/j.beha.2011.09.004
   Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727
   Mullighan CG, 2011, CLIN CANCER RES, V17, P396, DOI 10.1158/1078-0432.CCR-10-1203
   Newbold RF, 2010, ANTICANCER RES, V30, P3309
   Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2
   Shieh A, 2013, BLOOD, V121, P4884, DOI 10.1182/blood-2012-05-432252
   Tang P, 2013, LEUKEMIA, V27, P1210, DOI 10.1038/leu.2012.316
   Tarpey PS, 2009, NAT GENET, V41, P535, DOI 10.1038/ng.367
   Thieme S, 2013, BLOOD, V121, P2462, DOI 10.1182/blood-2012-08-452003
   Tomblyn MB, 2009, J CLIN ONCOL, V27, P3634, DOI 10.1200/JCO.2008.20.2960
   Yanada M, 2006, CANCER-AM CANCER SOC, V106, P2657, DOI 10.1002/cncr.21932
   Yang JJ, 2008, BLOOD, V112, P4178, DOI 10.1182/blood-2008-06-165027
   Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894
NR 36
TC 27
Z9 32
U1 0
U2 20
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 19
PY 2016
VL 7
IS 3
BP 2696
EP 2708
DI 10.18632/oncotarget.6259
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GV
UT WOS:000369951800041
PM 26527318
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, B
   Bae, H
   Lee, H
   Lee, S
   Park, JC
   Kim, KR
   Kim, SJ
AF Kim, Byungtak
   Bae, Hansol
   Lee, Hyunkyung
   Lee, Seungyeon
   Park, Jeong Chan
   Kim, Kye Ryung
   Kim, Sun Jung
TI Proton Beams Inhibit Proliferation of Breast Cancer Cells by Altering
   DNA Methylation Status
SO JOURNAL OF CANCER
LA English
DT Article
DE Alu; breast cancer; epigenetics; LINE1; methylation; proton beam
ID RADIATION-THERAPY; GASTRIC CARCINOMAS; ESOPHAGEAL CANCER; IRRADIATION;
   HYPOMETHYLATION; ASSOCIATION; EXPRESSION; TRIAL
AB Proton beam therapy has been gaining popularity in the management of a wide spectrum of cancers. However, little is known about the effect of proton beams on epigenetic alterations. In this study, the effects of proton beams on DNA methylation were evaluated in the breast cell lines MCF-10A and MCF-7. Pyrosequencing analysis of the long interspersed element 1 (LINE1) gene indicated that a few specific CpG sites were induced to be hypermethylated by proton beam treatment from 64.5 to 76.5% and from 57.7 to 60.0% (p < 0.05) in MCF-10A and MCF-7, respectively. Genome-wide methylation analysis identified "Developmental Disorder, Hereditary Disorder, Metabolic Disease" as the top network in the MCF-7 cell line. The proliferation rate significantly decreased in proton beam-treated cells, as judged by colony formation and cell proliferation assay. Upon treatment with the proton beam, expression of selected genes (MDH2, STYXL1, CPE, FAM91A1, and GPR37) was significantly changed in accordance with the changes of methylation level. Taken together, the findings demonstrate that proton beam-induced physiological changes of cancer cells via methylation modification assists in establishing the epigenetic basis of proton beam therapy for cancer.
C1 [Kim, Byungtak; Bae, Hansol; Lee, Hyunkyung; Lee, Seungyeon; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
   [Park, Jeong Chan; Kim, Kye Ryung] Korea Atom Energy Res Inst, Korea Multipurpose Accelerator Complex, Gyeongju, South Korea.
C3 Dongguk University; Korea Atomic Energy Research Institute (KAERI)
RP Kim, SJ (通讯作者)，Dongguk Univ, Dept Life Sci, Goyang 10326, South Korea.
EM sun-jungk@dongguk.edu
RI kim, sun/T-1013-2019; Bae, Hansol/AGH-4590-2022
FU National Research Foundation of Korea (NRF) [2014M2B2A4030844,
   2012R1A1A2040830]
FX This work was supported by National Research Foundation of Korea (NRF)
   grants 2014M2B2A4030844 and NRF-2012R1A1A2040830.
CR Bae JH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1229-6
   Baran I, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/498914
   Barchitta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109478
   Bush DA, 2014, INT J RADIAT ONCOL, V90, P501, DOI [10.1016/j.ijrobp.2014.05.130, 10.1016/j.ijrobp.2014.05.1308]
   Calugaru V, 2014, INT J RADIAT ONCOL, V90, P36, DOI 10.1016/j.ijrobp.2014.05.018
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Esposito G, 2006, RADIAT PROT DOSIM, V122, P166, DOI 10.1093/rpd/ncl389
   Foussard H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012257
   Ha BG, 2015, INT J ONCOL, V46, P2621, DOI 10.3892/ijo.2015.2942
   Halvorsen AR, 2014, INT J CANCER, V135, P2085, DOI 10.1002/ijc.28862
   Hou J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123316
   Ishikawa H, 2015, ANTICANCER RES, V35, P1757
   Jeong EG, 2007, APMIS, V115, P900, DOI 10.1111/j.1600-0463.2007.apm_706.x
   Kedracka-Krok S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084621
   Kim B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097818
   KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x
   Kuban DA, 2011, INT J RADIAT ONCOL, V79, P1310, DOI 10.1016/j.ijrobp.2010.01.006
   Kumar A, 2011, INT J RADIAT BIOL, V87, P1086, DOI 10.3109/09553002.2011.605417
   Li LR, 2013, PATHOL ONCOL RES, V19, P195, DOI 10.1007/s12253-012-9569-x
   Lima F, 2014, ENVIRON MOL MUTAGEN, V55, P266, DOI 10.1002/em.21832
   Lukens JN, 2015, CURR OPIN ONCOL, V27, P165, DOI 10.1097/CCO.0000000000000181
   Muroi H, 2015, INT SURG, V100, P180, DOI 10.9738/INTSURG-D-13-00188.1
   Ogata T, 2005, CANCER RES, V65, P113
   Park SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129931
   Rana S, 2014, J MED PHYS, V39, P212, DOI 10.4103/0971-6203.144483
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Romanowska-Dixon B, 2013, ACTA BIOCHIM POL, V60, P307
   Sawada J, 2012, CANCER CELL, V22, P235, DOI 10.1016/j.ccr.2012.06.013
   Schübeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192
   Soes Signe, 2014, Oncoscience, V1, P367
   Tahara T, 2010, INT J MOL MED, V25, P471, DOI 10.3892/ijmm_00000367
   Wang Jingzi, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P228
   Woloszynska-Read A, 2008, CLIN CANCER RES, V14, P3283, DOI 10.1158/1078-0432.CCR-07-5279
   Xiang SY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-44
   Zhang XC, 2013, J THORAC ONCOL, V8, P1484, DOI 10.1097/JTO.0b013e3182a5fdcb
   Zietman AL, 2010, J CLIN ONCOL, V28, P1106, DOI 10.1200/JCO.2009.25.8475
NR 37
TC 10
Z9 12
U1 0
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2016
VL 7
IS 3
BP 344
EP 352
DI 10.7150/jca.13396
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DD8LP
UT WOS:000370178400015
PM 26918048
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Luo, XJ
   Yang, LF
   Xiao, LB
   Xia, XF
   Dong, X
   Zhong, JF
   Liu, Y
   Li, NM
   Chen, L
   Li, HD
   Li, W
   Liu, WB
   Yu, XF
   Chen, HY
   Tang, M
   Weng, XX
   Yi, W
   Bode, A
   Dong, ZG
   Liu, JK
   Cao, Y
AF Luo, Xiangjian
   Yang, Lifang
   Xiao, Lanbo
   Xia, Xiaofeng
   Dong, Xin
   Zhong, Juanfang
   Liu, Ying
   Li, Namei
   Chen, Ling
   Li, Hongde
   Li, Wei
   Liu, Wenbin
   Yu, Xinfang
   Chen, Hanyong
   Tang, Min
   Weng, Xinxian
   Yi, Wei
   Bode, Ann
   Dong, Zigang
   Liu, Jikai
   Cao, Ya
TI Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell
   metastasis
SO ONCOTARGET
LA English
DT Article
DE grifolin; ERK1/2; DNMT1; metastasis
ID ANTITUMOR NATURAL-PRODUCT; NASOPHARYNGEAL CARCINOMA-CELLS; MUSHROOM
   ALBATRELLUS-CONFLUENS; SIGNAL-REGULATED KINASE; BREAST-CANCER; PROMOTER
   HYPERMETHYLATION; MOLECULAR TARGETS; DNA METHYLATION; IN-VITRO;
   INHIBITORS
AB Grifolin, a secondary metabolite isolated from the fresh fruiting bodies of the mushroom Albatrellus confluens, has been reported by us and others to display potent antitumor effects. However, the molecular target of grifolin has not been identified and the underlying mechanism of action is not fully understood. Here, we report that the ERK1/2 protein kinases are direct molecular targets of grifolin. Molecular modeling, affinity chromatography and fluorescence quenching analyses showed that grifolin directly binds to ERK1/2. And in vitro and ex vivo kinase assay data further demonstrated that grifolin inhibited the kinase activities of ERK1/2. We found that grifolin suppressed adhesion, migration and invasion of high-metastatic cancer cells. The inhibitory effect of grifolin against tumor metastasis was further confirmed in a metastatic mouse model. We found that grifolin decreased phosphorylation of Elk1 at Ser383, and the protein as well as the mRNA level of DNMT1 was also down-regulated. By luciferase reporter and ChIP assay analyses, we confirmed that grifolin inhibited the transcription activity of Elk1 as well as its binding to the dnmt1 promoter region. Moreover, we report that significant increases in the mRNA levels of Timp2 and pten were induced by grifolin. Thus, our data suggest that grifolin exerts its anti-tumor activity by epigenetic reactivation of metastasis inhibitory-related genes through ERK1/2-Elk1-DNMT1 signaling. Grifolin may represent a promising therapeutic lead compound for intervention of cancer metastasis, and it may also be useful as an ERK1/2 kinase inhibitor as well as an epigenetic agent to further our understanding of DNMT1 function.
C1 [Luo, Xiangjian; Yang, Lifang; Xiao, Lanbo; Dong, Xin; Zhong, Juanfang; Liu, Ying; Li, Namei; Chen, Ling; Li, Hongde; Li, Wei; Liu, Wenbin; Yu, Xinfang; Tang, Min; Weng, Xinxian; Yi, Wei; Cao, Ya] Cent S Univ, Canc Res Inst, Key Lab, Chinese Minist Educ,Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China.
   [Luo, Xiangjian; Yang, Lifang; Cao, Ya] Cent S Univ, Xiangya Hosp, Mol Imaging Ctr, Changsha 410078, Hunan, Peoples R China.
   [Xia, Xiaofeng] Houston Methodist Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA.
   [Chen, Hanyong; Bode, Ann; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.
   [Liu, Jikai] Chinese Acad Sci, State Key Lab Phytochem & Plant Resource West Chi, Kunming Inst Bot, Kunming 650204, Yunnan, Peoples R China.
C3 Central South University; Central South University; Houston Methodist;
   University of Minnesota System; Chinese Academy of Sciences; Kunming
   Institute of Botany, CAS
RP Luo, XJ (通讯作者)，Cent S Univ, Canc Res Inst, Key Lab, Chinese Minist Educ,Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China.
EM luocsu@hotmail.com; jkliu@mail.kib.ac.cn; ycao98@vip.sina.com
RI wang, wei/JYP-7819-2024; Liu, Wenbin/GVU-0680-2022; Dong,
   Xin/IZQ-2213-2023; Ling, Jie/JJF-9995-2023; Tang, Min/KOC-3090-2024
FU National Natural Science Foundation of China [81573014, 81372393,
   81430064]; National key basic research and development program
   [2011CB504300]
FX This work was supported by grant from the National Natural Science
   Foundation of China (81573014,81372393,81430064) and National key basic
   research and development program (2011CB504300).
CR [Anonymous], SCHROD SUIT
   Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f
   CHEN ZP, 1994, J BIOL CHEM, V269, P25770
   COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231
   Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372
   Gao Y, 2015, CURR MED CHEM
   Giannelli G, 2007, CURR PHARM DESIGN, V13, P3301, DOI 10.2174/138161207782360609
   Han S, 2015, MOL BIOL REP, V42, P35, DOI 10.1007/s11033-014-3737-x
   Hara T, 2009, N-S ARCH PHARMACOL, V380, P247, DOI 10.1007/s00210-009-0425-9
   Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070
   HIRATA Y, 1950, J BIOL CHEM, V184, P135
   Horio Takeshi, 2006, Nihon Rinsho, V64 Suppl 6, P171
   Jin S, 2007, APOPTOSIS, V12, P1317, DOI 10.1007/s10495-007-0062-z
   Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107
   Khan MA, 2015, ONCOL REP, V33, P1976, DOI 10.3892/or.2015.3802
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Li JB, 2014, ONCOL REP, V31, P2206, DOI 10.3892/or.2014.3061
   Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160
   Liu S., 2008, EXPT STUDY EGCG INHI, P123
   Liu XT, 2010, PLANTA MED, V76, P182, DOI 10.1055/s-0029-1186001
   Luo DQ, 2005, Z NATURFORSCH C, V60, P50
   Luo XJ, 2011, EUR J PHARMACOL, V670, P427, DOI 10.1016/j.ejphar.2011.08.026
   Luo XJ, 2011, EUR J CANCER, V47, P316, DOI 10.1016/j.ejca.2010.09.021
   Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039
   Mondal S, 2012, ANTI-CANCER AGENT ME, V12, P49, DOI 10.2174/187152012798764697
   Montiel-Duarte C, 2008, LEUKEMIA RES, V32, P709, DOI 10.1016/j.leukres.2007.09.005
   Pan QF, 2014, DIS ESOPHAGUS, V27, P396, DOI 10.1111/dote.12106
   Pavese JM, 2010, CANCER METAST REV, V29, P465, DOI 10.1007/s10555-010-9238-z
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Quang DN, 2006, BIOORGAN MED CHEM, V14, P164, DOI 10.1016/j.bmc.2005.08.005
   Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Sahin M, 2010, CANCER METAST REV, V29, P655, DOI 10.1007/s10555-010-9253-0
   Song J, 2009, CHEM BIODIVERS, V6, P1435, DOI 10.1002/cbdv.200800217
   Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007
   Sulzmaier FJ, 2013, CANCER RES, V73, P6099, DOI 10.1158/0008-5472.CAN-13-1087
   Thomas X, 2012, EXPERT OPIN DRUG DIS, V7, P1039, DOI 10.1517/17460441.2012.722618
   Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660
   Weng CJ, 2012, CANCER METAST REV, V31, P323, DOI 10.1007/s10555-012-9347-y
   Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yang G, 2014, CANCER PREV RES, V7, P1056, DOI 10.1158/1940-6207.CAPR-14-0141
   Yang XY, 2005, CELL ONCOL, V27, P215
   Ye M, 2005, FEBS LETT, V579, P3437, DOI 10.1016/j.febslet.2005.05.013
   Ye M, 2007, CANCER LETT, V258, P199, DOI 10.1016/j.canlet.2007.09.001
   Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218
   Zaidman BZ, 2005, APPL MICROBIOL BIOT, V67, P453, DOI 10.1007/s00253-004-1787-z
NR 49
TC 28
Z9 30
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 15
PY 2015
VL 6
IS 40
BP 42704
EP 42716
DI 10.18632/oncotarget.5678
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD4QP
UT WOS:000369907900025
PM 26516701
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Song, MA
   Brasky, TM
   Marian, C
   Weng, DY
   Taslim, C
   Dumitrescu, RG
   Llanos, AA
   Freudenheim, JL
   Shields, PG
AF Song, Min-Ae
   Brasky, Theodore M.
   Marian, Catalin
   Weng, Daniel Y.
   Taslim, Cenny
   Dumitrescu, Ramona G.
   Llanos, Adana A.
   Freudenheim, Jo L.
   Shields, Peter G.
TI Racial differences in genome-wide methylation profiling and gene
   expression in breast tissues from healthy women
SO EPIGENETICS
LA English
DT Article
DE breast; disparity; genome-wide DNA methylation; gene expression; race
ID ONE-CARBON METABOLISM; DNA METHYLATION; TUMOR-SUPPRESSOR; PROMOTER
   METHYLATION; ELONGATION; SIGNATURES; CHROMATIN; PATTERNS; OPCML; ARRAY
AB Breast cancer is more common in European Americans (EAs) than in African Americans (AAs) but mortality from breast cancer is higher among AAs. While there are racial differences in DNA methylation and gene expression in breast tumors, little is known whether such racial differences exist in breast tissues of healthy women. Genome-wide DNA methylation and gene expression profiling was performed in histologically normal breast tissues of healthy women. Linear regression models were used to identify differentially-methylated CpG sites (CpGs) between EAs (n = 61) and AAs (n = 22). Correlations for methylation and expression were assessed. Biological functions of the differentially-methylated genes were assigned using the Ingenuity Pathway Analysis. Among 485 differentially-methylated CpGs by race, 203 were hypermethylated in EAs, and 282 were hypermethylated in AAs. Promoter-related differentially-methylated CpGs were more frequently hypermethylated in EAs (52%) than AAs (27%) while gene body and intergenic CpGs were more frequently hypermethylated in AAs. The differentially-methylated CpGs were enriched for cancer-associated genes with roles in cell death and survival, cellular development, and cell-to-cell signaling. In a separate analysis for correlation in EAs and AAs, different patterns of correlation were found between EAs and AAs. The correlated genes showed different biological networks between EAs and AAs; networks were connected by Ubiquitin C. To our knowledge, this is the first comprehensive genome-wide study to identify differences in methylation and gene expression between EAs and AAs in breast tissues from healthy women. These findings may provide further insights regarding the contribution of epigenetic differences to racial disparities in breast cancer.
C1 [Song, Min-Ae; Brasky, Theodore M.; Marian, Catalin; Weng, Daniel Y.; Taslim, Cenny; Shields, Peter G.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Song, Min-Ae; Brasky, Theodore M.; Marian, Catalin; Weng, Daniel Y.; Taslim, Cenny; Shields, Peter G.] James Canc Hosp, Columbus, OH USA.
   [Marian, Catalin] Victor Babes Univ Med & Pharm, Biochem & Pharmacol Dept, Timisoara 300041, Romania.
   [Dumitrescu, Ramona G.] Distilled Spirits Council US, Washington, DC USA.
   [Llanos, Adana A.] Rutgers Sch Publ Hlth, Dept Epidemiol, New Brunswick, NJ 08903 USA.
   [Llanos, Adana A.] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   [Freudenheim, Jo L.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University; James Cancer Hospital & Solove Research Institute; Victor
   Babes University of Medicine & Pharmacy, Timisoara; Rutgers University
   System; Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences; Rutgers Cancer
   Institute of New Jersey; State University of New York (SUNY) System;
   University at Buffalo, SUNY
RP Shields, PG (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
EM Peter.Shields@OSUMC.edu
RI Shields, Peter/I-1644-2012; Marian, Catalin/KHU-8477-2024; Llanos,
   Adana/J-8695-2019; Song, Min-Ae/AAF-9672-2021; Marian,
   Catalin/P-2885-2019
OI Freudenheim, Jo/0000-0002-9301-0499; Marian, Catalin/0000-0002-7749-1384
FU  [DOD BC022346]
FX This work was supported by a grant, DOD BC022346. We thank the Genomics
   Core Facility at Roswell Park Cancer Institute (Buffalo, NY) and Nucleic
   Acid Shared Resource at The Ohio State University (Columbus, OH) for
   performing Illumina HumanMethylation450 Beadchip and GeneChip (R) Human
   Transcriptome Array 2.0, respectively.
CR Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101
   Adkins RM, 2011, BIRTH DEFECTS RES A, V91, P728, DOI 10.1002/bdra.20770
   Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599
   [Anonymous], ADV BIOSCI BIOTECHNO
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bock C, 2007, PLOS COMPUT BIOL, V3, P1055, DOI 10.1371/journal.pcbi.0030110
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Conway K, 2015, CANCER EPIDEM BIOMAR, V24, P921, DOI 10.1158/1055-9965.EPI-14-1228
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   D'Orazi G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-63
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Howlin J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2087
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kornblihtt AR, 2006, NAT STRUCT MOL BIOL, V13, P5, DOI 10.1038/nsmb0106-5
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Llanos AA, 2015, CARCINOGENESIS, V36, P60, DOI 10.1093/carcin/bgu219
   Llanos AA, 2013, BREAST CANCER RES TR, V138, P571, DOI 10.1007/s10549-013-2452-y
   Llanos AAM, 2015, EPIGENETICS-US, V10, P727, DOI 10.1080/15592294.2015.1062205
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Mahajan K, 2015, ONCOGENE, V34, P4162, DOI 10.1038/onc.2014.350
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371
   Pirone JR, 2012, CANCER EPIDEM BIOMAR, V21, P1735, DOI 10.1158/1055-9965.EPI-12-0451
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576
   Rotunno M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3689
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Sun XZ, 2013, CLIN CANCER RES, V19, P4972, DOI 10.1158/1078-0432.CCR-13-0029
   Sun XZ, 2012, BREAST CANCER RES TR, V131, P1003, DOI 10.1007/s10549-011-1789-3
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tao MH, 2011, ALCOHOL, V45, P689, DOI 10.1016/j.alcohol.2010.11.006
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37
   Wang S, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-219
   Xiang Y, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S5-S4
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
NR 44
TC 41
Z9 44
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC 2
PY 2015
VL 10
IS 12
BP 1177
EP 1187
DI 10.1080/15592294.2015.1121362
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DD4EG
UT WOS:000369874700009
PM 26680018
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Jia, LY
   Shanmugam, MK
   Sethi, G
   Bishayee, A
AF Jia, Lee Yueh
   Shanmugam, Muthu K.
   Sethi, Gautam
   Bishayee, Anupam
TI Potential role of targeted therapies in the treatment of triple-negative
   breast cancer
SO ANTI-CANCER DRUGS
LA English
DT Article
DE angiogenesis; chemotherapy; targeted therapies; triple-negative breast
   cancer
ID BEVACIZUMAB-CONTAINING THERAPY; ANDROGEN RECEPTOR EXPRESSION; HISTONE
   DEACETYLASES HDACS; GROWTH-FACTOR RECEPTORS; RANDOMIZED PHASE-II;
   NEOADJUVANT CHEMOTHERAPY; EPIGENETIC REGULATION; KINASE INHIBITORS;
   CELLS; PHENOTYPE
AB Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10-20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application.
C1 [Jia, Lee Yueh; Shanmugam, Muthu K.; Sethi, Gautam] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore.
   [Sethi, Gautam] Curtin Univ, Sch Biomed Sci, CHIRI Biosci Res Precinct, Perth, WA 6845, Australia.
   [Bishayee, Anupam] Larkin Hlth Sci Inst, Coll Pharm, Dept Pharmaceut Sci, Miami, FL USA.
C3 National University of Singapore; Curtin University
RP Sethi, G (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore.
EM phcgs@nus.edu.sg
RI Bishayee, Anupam/G-4290-2012; Sethi, Gautam/F-2372-2011
OI Bishayee, Anupam/0000-0001-9159-960X; Sethi, Gautam/0000-0002-8677-8475
FU NUHS Bench-to-Bedside grant
FX This work was supported by an NUHS Bench-to-Bedside grant to G.S.
CR Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004
   Agrawal Laila Saied, 2014, Clin Adv Hematol Oncol, V12, P654
   Ahmed MAH, 2012, BREAST CANCER RES TR, V133, P979, DOI 10.1007/s10549-011-1865-8
   Anders C, 2014, BREAST CANCER RES TR, V146, P557, DOI 10.1007/s10549-014-3039-y
   André F, 2013, CLIN CANCER RES, V19, P3693, DOI 10.1158/1078-0432.CCR-13-0190
   [Anonymous], IARC LAT WORLD CANC
   [Anonymous], AM SOC CLIN ONC ANN
   [Anonymous], 2012 ASCO ANN M 1 5
   Bahhnassy A, 2015, MOL MED REP, V12, P851, DOI 10.3892/mmr.2015.3560
   Bansal N, 2015, ONCOTARGET, V6, P34087, DOI 10.18632/oncotarget.6048
   Bartholomeusz C, 2015, MOL CANC THER
   Barton VN, 2015, MOL CANCER THER, V14, P769, DOI 10.1158/1535-7163.MCT-14-0926
   Baselga J, 2013, J CLIN ONCOL, V31, P2586, DOI 10.1200/JCO.2012.46.2408
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Blanchard Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095663
   Bostrom Pia, 2009, BMC Res Notes, V2, P140, DOI 10.1186/1756-0500-2-140
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Britton KM, 2012, CANCER LETT, V323, P97, DOI 10.1016/j.canlet.2012.03.041
   Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699
   Brufsky A, 2012, BREAST CANCER RES TR, V133, P1067, DOI 10.1007/s10549-012-2008-6
   Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019
   Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579
   Cetin I, 2014, ASIAN PAC J CANCER P, V15, P2427, DOI 10.7314/APJCP.2014.15.6.2427
   Chokunonga E, 2013, INT J CANCER, V133, P721, DOI 10.1002/ijc.28063
   Chuang HC, 2012, BREAST CANCER RES TR, V134, P649, DOI 10.1007/s10549-012-2106-5
   Collina F, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/158682
   Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54
   Datta A, 2014, ONCOTARGET, V5, P5920, DOI 10.18632/oncotarget.1874
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001
   Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9
   Feng M, 2014, J CLIN INVEST, V124, P5291, DOI 10.1172/JCI76711
   Feng SC, 2015, HISTOL HISTOPATHOL, V30, P13, DOI 10.14670/HH-30.13
   Foekens JA, 2001, CANCER RES, V61, P5407
   Geng SQ, 2014, CANCER LETT, V349, P1, DOI 10.1016/j.canlet.2014.03.036
   Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Gholami S, 2014, BREAST CANCER RES TR, V148, P489, DOI 10.1007/s10549-014-3180-7
   Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3
   Gutteridge E, 2010, INT J CANCER, V126, P1806, DOI 10.1002/ijc.24884
   Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149
   Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005
   Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024
   Jung SY, 2015, ONCOL REP, V34, P2731, DOI 10.3892/or.2015.4249
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Kim YS, 2014, J BREAST CANCER, V17, P121, DOI 10.4048/jbc.2014.17.2.121
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liang HY, 2010, IDRUGS, V13, P646
   Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85
   Mancini P, 2014, CANCERS, V6, P2187, DOI 10.3390/cancers6042187
   Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799
   McGhan LJ, 2014, ANN SURG ONCOL, V21, P361, DOI 10.1245/s10434-013-3260-7
   Mehta R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065113
   Miles DW, 2013, BRIT J CANCER, V108, P1052, DOI 10.1038/bjc.2013.69
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006
   O'Shaughnessy J, 2014, J CLIN ONCOL, V32, P3840, DOI 10.1200/JCO.2014.55.2984
   Oakman C, 2011, EUR J CANCER, V47, pS370, DOI 10.1016/S0959-8049(11)70207-6
   Papa A, 2015, EXPERT OPIN THER TAR, V19, P55, DOI 10.1517/14728222.2014.970176
   Petrelli F, 2014, BREAST CANCER RES TR, V144, P223, DOI 10.1007/s10549-014-2876-z
   Petrelli F, 2012, LUNG CANCER, V78, P8, DOI 10.1016/j.lungcan.2012.06.009
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Schmadeka R, 2014, AM J CLIN PATHOL, V141, P462, DOI 10.1309/AJCPQN8GZ8SILKGN
   Shanle EK, 2013, MOL ENDOCRINOL, V27, P1762, DOI 10.1210/me.2013-1164
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Smart E, 2013, HORM MOL BIOL CLIN I, V16, P117, DOI 10.1515/hmbci-2013-0042
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Thike AA, 2014, MODERN PATHOL, V27, P352, DOI 10.1038/modpathol.2013.145
   Thummuri D, 2015, LIFE SCI, V130, P73, DOI 10.1016/j.lfs.2015.03.016
   Tomao F, 2015, ONCOTARGETS THER, V8, P177, DOI 10.2147/OTT.S67673
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324
   Viale G, 2009, BREAST CANCER RES TR, V116, P317, DOI 10.1007/s10549-008-0206-z
   von Minckwitz G, 2012, ANN ONCOL, V23, P35, DOI 10.1093/annonc/mds193
   von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595
   Wabinga H, 2011, IARC Sci Publ, P243
   Wang XZ, 2015, ONCOL REP, V33, P526, DOI 10.3892/or.2014.3665
   Wu MQ, 2013, ASIAN PAC J CANCER P, V14, P287, DOI 10.7314/APJCP.2013.14.1.287
   Yan Y, 2013, ANN ONCOL, V24, P1986, DOI 10.1093/annonc/mdt132
   Yi YW, 2013, J CELL MOL MED, V17, P648, DOI 10.1111/jcmm.12046
   Zhao P, 2011, CANCER SCI, V102, P1107, DOI 10.1111/j.1349-7006.2011.01894.x
NR 93
TC 58
Z9 60
U1 0
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4973
EI 1473-5741
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD MAR
PY 2016
VL 27
IS 3
BP 147
EP 155
DI 10.1097/CAD.0000000000000328
PG 9
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA DI5CI
UT WOS:000373515300001
PM 26682525
DA 2025-01-12
ER

PT J
AU Yang, QW
   Nair, S
   Laknaur, A
   Ismail, N
   Diamond, MP
   Al-Hendy, A
AF Yang, Qiwei
   Nair, Sangeeta
   Laknaur, Archana
   Ismail, Nahed
   Diamond, Michael P.
   Al-Hendy, Ayman
TI The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene
   Expression in Human Uterine Fibroids
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE BRCA1; DNA damage repair; EZH2; fibroid; H3K27me3; RAD51
ID HISTONE METHYLTRANSFERASE EZH2; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER;
   HOMOLOGOUS RECOMBINATION; MUTATION CARRIERS; SKIN-CANCER; BISPHENOL-A;
   METHYLATION; LEIOMYOMA; BRCA1
AB Uterine fibroids are benign, smooth muscle tumors that occur in approximately 70%-80% of women by age 50 yr. The cellular and molecular mechanism(s) by which uterine fibroids (UFs) develop are not fully understood. Accumulating evidence demonstrates that several genetic abnormalities, including deletions, rearrangements, translocations, as well as mutations, have been found in UFs. These genetic anomalies suggest that low DNA damage repair capacity may be involved in UF formation. The objective of this study was to determine whether expression levels of DNA damage repair-related genes were altered, and how they were regulated in the pathogenesis of UFs. Expression levels of DNA repair-related genes RAD51 and BRCA1 were deregulated in fibroid tissues as compared to adjacent myometrial tissues. Expression levels of chromatin protein enhancer of zeste homolog 2 (EZH2) were higher in a subset of fibroids as compared to adjacent myometrial tissues by both immunohistochemistry and Western blot analysis. Treatment with an inhibitor of EZH2 markedly increased expression levels of RAD51 and BRCA1 in fibroid cells and inhibited cell proliferation paired with cell cycle arrest. Restoring the expression of RAD51 and BRCA1 by treatment with EZH2 inhibitor was dependent on reducing the enrichment of trimethylation of histone 3 lysine 27 epigenetic mark in their promoter regions. This study reveals the important role of EZH2-regulated DNA damage-repair genes via histone methylation in fibroid biology, and may provide novel therapeutic targets for the medical treatment of women with symptomatic UFs.
C1 [Yang, Qiwei; Nair, Sangeeta; Laknaur, Archana; Diamond, Michael P.; Al-Hendy, Ayman] Augusta Univ, Med Coll Georgia, Dept Obstet & Gynecol, Div Translat Res, Augusta, GA 30912 USA.
   [Ismail, Nahed] Univ Pittsburgh, Dept Pathol, Clin Microbiol Div, Pittsburgh, PA USA.
C3 University System of Georgia; Augusta University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Yang, QW (通讯作者)，Augusta Univ, Med Coll Georgia, Dept Obstet & Gynecol, Div Translat Res, Augusta, GA 30912 USA.
EM qyang@gru.edu
RI Yang, Qiwei/AAI-7414-2021; Al-hendy, Ayman/J-9324-2019
OI , Qiwei Yang/0000-0001-7131-8946
FU Augusta University Startup package; National Institutes of Health grant
   [HD04622811]; Augusta University intramural Grants Program
FX This work was supported in part by an Augusta University Startup
   package, the National Institutes of Health grant HD04622811 to A.A., and
   the Augusta University intramural Grants Program to Q.Y.
CR Akinyemi B O, 2004, Niger J Med, V13, P318
   Al-Hendy A, 2006, HUM REPROD UPDATE, V12, P385, DOI 10.1093/humupd/dml015
   [Anonymous], 2010, J NANOMATERIALS
   [Anonymous], 2014, INT J DIFF EQS, DOI DOI 10.1074/JBC.M114.550012
   Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226
   Avan A, 2012, MOL CANCER THER, V11, P1735, DOI 10.1158/1535-7163.MCT-12-0037
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bae WK, 2015, MOL CARCINOGEN, V54, P1172, DOI 10.1002/mc.22188
   Benard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108265
   Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6
   Bernier J, 2015, BREAST, V24, P100, DOI 10.1016/j.breast.2014.12.003
   Bertsch E, 2014, MODERN PATHOL, V27, P1144, DOI 10.1038/modpathol.2013.243
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Bulun SE, 2013, NEW ENGL J MED, V369, P1344, DOI 10.1056/NEJMra1209993
   Burns KA, 2012, ARCH TOXICOL, V86, P1491, DOI 10.1007/s00204-012-0868-5
   Cao W, 2011, CANCER PREV RES, V4, P1816, DOI 10.1158/1940-6207.CAPR-11-0130
   Carcangiu ML, 2006, AM J SURG PATHOL, V30, P1222, DOI 10.1097/01.pas.0000202161.80739.ac
   Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen JJ, 1999, CANCER RES, V59, p1752S
   Chen YH, 2012, AM J TRANSL RES, V4, P364
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Cousineau I, 2005, CANCER RES, V65, P11384, DOI 10.1158/0008-5472.CAN-05-2156
   El-Shennawy GA, 2011, ARCH GYNECOL OBSTET, V283, P1313, DOI 10.1007/s00404-010-1550-x
   Fischer C, 2010, GYNECOL ENDOCRINOL, V26, P4, DOI 10.3109/09513590903159573
   Fuller S, 2008, BREAST J, V14, P603, DOI 10.1111/j.1524-4741.2008.00661.x
   Girard N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098176
   Halder SK, 2015, MOL GENET GENOMICS, V290, P505, DOI 10.1007/s00438-014-0938-x
   Halder SK, 2013, HUM REPROD, V28, P2407, DOI 10.1093/humrep/det265
   Heinonen HR, 2014, FERTIL STERIL, V102, P1137, DOI 10.1016/j.fertnstert.2014.06.040
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Hilário SG, 2009, FERTIL STERIL, V91, P240, DOI 10.1016/j.fertnstert.2007.11.006
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Hunter DS, 2002, CANCER RES, V62, P3766
   Ingraham SE, 2006, MUTAT RES-FUND MOL M, V602, P43, DOI 10.1016/j.mrfmmm.2006.07.007
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Konno Y, 2014, ONCOTARGET, V5, P6049, DOI 10.18632/oncotarget.2157
   Lee EH, 2010, BREAST CANCER RES TR, V122, P11, DOI 10.1007/s10549-010-0859-2
   Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095
   LI TC, 1988, FERTIL STERIL, V50, P52
   Li Y, 2012, ENVIRON HEALTH PERSP, V120, P1029, DOI 10.1289/ehp.1104689
   Lu YX, 2013, J BIOL CHEM, V288, P23554, DOI 10.1074/jbc.M113.482497
   Magwood AC, 2013, DNA REPAIR, V12, P1122, DOI 10.1016/j.dnarep.2013.10.006
   Majewski IJ, 2008, PLOS BIOL, V6, P796, DOI 10.1371/journal.pbio.0060093
   Matta JL, 2003, J AM ACAD DERMATOL, V49, P433, DOI 10.1067/S0190-9622(03)00918-6
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mittal P, 2015, J CLIN INVEST, V125, P3280, DOI 10.1172/JCI81534
   Müller J, 2009, CURR OPIN GENET DEV, V19, P150, DOI 10.1016/j.gde.2009.03.001
   NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9
   Ostrup O, 2014, BBA-GENE REGUL MECH, V1839, P1307, DOI 10.1016/j.bbagrm.2014.09.013
   Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530
   Ramos JM, 2004, CANCER-AM CANCER SOC, V100, P1352, DOI 10.1002/cncr.20135
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Rieker RJ, 2013, PATHOLOGY, V45, P388, DOI 10.1097/PAT.0b013e328360bf97
   Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Shozu M, 2003, FERTIL STERIL, V79, P628, DOI 10.1016/S0015-0282(02)04761-1
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Subramanyam S, 2013, NUCLEIC ACIDS RES, V41, P9020, DOI 10.1093/nar/gkt691
   Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vikhliaeva E M, 2001, Vopr Onkol, V47, P200
   Villanova FE, 2006, STEROIDS, V71, P960, DOI 10.1016/j.steroids.2006.07.005
   Ward A, 2015, CANCER TREAT REV, V41, P35, DOI 10.1016/j.ctrv.2014.10.006
   Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Yang Q, 2013, CELL PROLIFERAT, V46, P654, DOI 10.1111/cpr.12076
   Yang QW, 2016, REPROD SCI, V23, P163, DOI 10.1177/1933719115584449
   Yang QW, 2012, AM J PHYSIOL-LUNG C, V303, pL1001, DOI 10.1152/ajplung.00092.2012
   Yang QW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-286
   Yang QW, 2004, CANCER RES, V64, P4531, DOI 10.1158/0008-5472.CAN-04-0956
   Yang QW, 2003, CANCER RES, V63, P6299
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yuan RQ, 1999, PROSTATE, V40, P37
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zhang KL, 2014, ONCOL REP, V32, P2143, DOI 10.3892/or.2014.3459
   Zhao YY, 2007, MOL HUM REPROD, V13, P343, DOI 10.1093/molehr/gam007
NR 86
TC 33
Z9 37
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD MAR 1
PY 2016
VL 94
IS 3
AR 69
DI 10.1095/biolreprod.115.134924
PG 15
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA FA0GW
UT WOS:000405110600011
PM 26888970
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Richter, AM
   Walesch, SK
   Dammann, RH
AF Richter, Antje M.
   Walesch, Sara K.
   Dammann, Reinhard H.
TI Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its
   Growth Inhibitory Function in Breast Cancer
SO CANCERS
LA English
DT Article
DE breast cancer; tumour suppressor; DNA methylation; epigenetics; RASSF
ID EPIGENETIC INACTIVATION; GASTRIC-CANCER; FAMILY; HYPERMETHYLATION;
   PATTERNS; FREQUENT; MODELS; 3P21.3; LOCUS
AB Breast cancer is the most common cancer in women, with 1.7 million new cases each year. As early diagnosis and prognosis are crucial factors in cancer treatment, we investigated potential DNA methylation biomarkers of the tumour suppressor family Ras-association domain family (RASSF). Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby promotes cancer development and progression. In this study we analysed the tumour suppressors RASSF1A and RASSF10. Our study shows that RASSF10 is expressed in normal breast but inactivated by methylation in breast cancer. We observed a significant inactivating promoter methylation of RASSF10 in primary breast tumours. RASSF10 is inactivated in 63% of primary breast cancer samples but only 4% of normal control breast tissue is methylated (p < 0.005). RASSF1A also shows high promoter methylation levels in breast cancer of 56% vs. 8% of normal tissue (p < 0.005). Interestingly more than 80% of breast cancer samples harboured a hypermethylation of RASSF10 and/or RASSF1A promoter. Matching samples exhibited a strong tumour specific promoter methylation of RASSF10 in comparison to the normal control breast tissue. Demethylation treatment of breast cancer cell lines MCF7 and T47D reversed RASSF10 promoter hypermethylation and re-established RASSF10 expression. In addition, we could show the growth inhibitory potential of RASSF10 in breast cancer cell lines MCF7 and T47D upon exogenous expression of RASSF10 by colony formation. We could further show, that RASSF10 induced apoptotic changes in MCF7 and T47D cells, which was verified by a significant increase in the apoptotic sub G1 fraction by 50% using flow cytometry for MCF7 cells. In summary, our study shows the breast tumour specific inactivation of RASSF10 and RASSF1A due to DNA methylation of their CpG island promoters. Furthermore RASSF10 was characterised by the ability to block growth of breast cancer cell lines by apoptosis induction.
C1 [Richter, Antje M.; Walesch, Sara K.; Dammann, Reinhard H.] Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
C3 Justus Liebig University Giessen
RP Richter, AM (通讯作者)，Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
EM antje.m.richter@gen.bio.uni-giessen.de;
   sara.walesch@gen.bio.uni-giessen.de;
   reinhard.dammann@gen.bio.uni-giessen.de
CR Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844
   Engel C, 2015, BREAST CARE, V10, P7, DOI 10.1159/000376600
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Haag Tanja, 2014, Genes Cancer, V5, P365
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380
   Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42
   Hill VK, 2011, ONCOGENE, V30, P978, DOI 10.1038/onc.2010.471
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Li ZH, 2014, ONCOL REP, V31, P1661, DOI 10.3892/or.2014.3039
   Nounou MI, 2015, BREAST CANCER-BASIC, V9, P17, DOI 10.4137/BCBCR.S29420
   Paska AV, 2015, BIOCHEM MEDICA, V25, P161, DOI 10.11613/BM.2015.017
   Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8
   Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18
   Richter AM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00021
   Richter Antje M, 2013, Cancers (Basel), V5, P1566, DOI 10.3390/cancers5041566
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056
   Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007
   Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318
   Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
NR 27
TC 21
Z9 21
U1 0
U2 3
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2016
VL 8
IS 3
AR 26
DI 10.3390/cancers8030026
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO7QP
UT WOS:000396885500001
PM 26927176
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Macrì, S
   Simula, L
   Pellarin, I
   Pegoraro, S
   Onorati, M
   Sgarra, R
   Manfioletti, G
   Vignali, R
AF Macri, Simone
   Simula, Luca
   Pellarin, Ilenia
   Pegoraro, Silvia
   Onorati, Marco
   Sgarra, Riccardo
   Manfioletti, Guidalberto
   Vignali, Robert
TI Hmga2 is required for neural crest cell specification in <i>Xenopus</i>
   <i>laevis</i>
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE HMGA2; Neural crest; Xenopus; Epithelial-mesenchymal transition; Breast
   cancer
ID MOBILITY GROUP A2; NF-KAPPA-B; MESENCHYMAL TRANSITION; STEM-CELLS;
   EPIGENETIC REGULATION; SIGNALING PATHWAYS; DISINTEGRIN ADAM12;
   SELF-RENEWAL; EXPRESSION; GENE
AB HMGA proteins are small nuclear proteins that bind DNA by conserved AT-hook motifs, modify chromatin architecture and assist in gene expression. Two HMGAs (HMGA1 and HMGA2), encoded by distinct genes, exist in mammals and are highly expressed during embryogenesis or reactivated in tumour progression. We here addressed the in vivo role of Xenopus hmga2 in the neural crest cells (NCCs). We show that hmga2 is required for normal NCC specification and development. hmga2 knockdown leads to severe disruption of major skeletal derivatives of anterior NCCs. We show that, within the NCC genetic network, hmga2 acts downstream of msx1, and is required for msxl, pax3 and snail2 activities, thus participating at different levels of the network. Because of hmga2 early effects in NCC specification, the subsequent epithelial-mesenchymal transition (EMT) and migration of NCCs towards the branchial pouches are also compromised. Strictly paralleling results on embryos, interfering with Hmga2 in a breast cancer cell model for EMT leads to molecular effects largely consistent with those observed on NCCs. These data indicate that Hmga2 is recruited in key molecular events that are shared by both NCCs and tumour cells. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Macri, Simone; Simula, Luca; Onorati, Marco; Vignali, Robert] Univ Pisa, Dipartimento Biol, Unita Biol Cellulare & Sviluppo, SS12 Abetone & Brennero 4, I-56127 Pisa, Italy.
   [Pellarin, Ilenia; Pegoraro, Silvia; Sgarra, Riccardo; Manfioletti, Guidalberto] Univ Trieste, Dipartimento Sci Vita, Via Giorgieri 5, I-34127 Trieste, Italy.
   [Macri, Simone] Univ Helsinki, Bioctr, Inst Biotechnol, Viikinkaari 1 POB 65, FI-00014 Helsinki, Finland.
   [Simula, Luca] Univ Roma Tor Vergata, Dept Biol, IRCCS, Fdn Santa Lucia, I-00173 Rome, Italy.
   [Pellarin, Ilenia] Ctr Riferimento Oncol, Natl Canc Inst, Dept Translat Res, Div Expt Oncol 2, I-33081 Aviano, Italy.
   [Onorati, Marco] Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St,SHM C338, New Haven, CT USA.
C3 University of Pisa; University of Trieste; University of Helsinki;
   University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Aviano (CRO);
   Yale University
RP Vignali, R (通讯作者)，Univ Pisa, Dipartimento Biol, Unita Biol Cellulare & Sviluppo, SS12 Abetone & Brennero 4, I-56127 Pisa, Italy.
EM robert.vignali@unipi.it
RI Pellarin, Ilenia/AAY-2238-2020; Simula, Luca/H-1933-2018; Macri,
   Simone/AAD-1489-2021; Onorati, Marco/K-3919-2018; Pegoraro,
   Silvia/G-9217-2018
OI Pellarin, Ilenia/0000-0002-1041-1722; Simula, Luca/0000-0002-6440-1810;
   Macri, Simone/0000-0001-7436-258X; Onorati, Marco/0000-0001-8517-930X;
   Pegoraro, Silvia/0000-0002-1819-7417; MANFIOLETTI,
   GUIDALBERTO/0000-0001-7913-2601
FU MIUR; AIRC [IG 12024]; ITT grant
FX We thank Michela Ori and Federico Cremisi for comments; Massimiliano
   Andreazzoli, Eric Bellefroid, Daniel Kessler, Anne-Helene Monsoro-Burq,
   Michela Ori, Jean-Paul Saint-Jeannet, for reagents; DonateIla De
   Matienzo, Marzia Fabbri and Davide Martini for technical assistance;
   Salvatore Di Maria for frog care. Supported by MIUR 2007, 2009 to R.V.
   and G.M., AIRC IG 12024 to G.M. and ITT 2008 grant to R.V.
CR Albrechtsen R, 2013, J CELL SCI, V126, P4707, DOI 10.1242/jcs.129510
   Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458
   Alfandari D, 2001, CURR BIOL, V11, P918, DOI 10.1016/S0960-9822(01)00263-9
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Aoki Y, 2003, DEV BIOL, V259, P19, DOI 10.1016/S0012-1606(03)00161-1
   Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238
   Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733
   Bang AG, 1999, DEV BIOL, V212, P366, DOI 10.1006/dbio.1999.9319
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Battista S, 1999, CANCER RES, V59, P4793
   Benini F, 2006, BIOCHEM BIOPH RES CO, V351, P392, DOI 10.1016/j.bbrc.2006.10.074
   BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611
   Chau KY, 2000, J NEUROSCI, V20, P7317
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   Chien C.S., 2015, CANCER RES, V2215
   Chiou GY, 2013, MOL CELL, V52, P693, DOI 10.1016/j.molcel.2013.11.009
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005
   Cousin H, 2012, DEV BIOL, V368, P335, DOI 10.1016/j.ydbio.2012.05.036
   de Crozé N, 2011, P NATL ACAD SCI USA, V108, P155, DOI 10.1073/pnas.1010740107
   Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428
   Fedele M, 2006, CELL CYCLE, V5, P2045, DOI 10.4161/cc.5.18.3211
   Fedele M, 2010, BBA-GENE REGUL MECH, V1799, P48, DOI 10.1016/j.bbagrm.2009.11.007
   Federico A, 2014, BIOL OPEN, V3, P372, DOI 10.1242/bio.20146759
   Ferronha T, 2013, J NEUROSCI, V33, P2773, DOI 10.1523/JNEUROSCI.4511-12.2013
   Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271
   Grammer TC, 2000, DEV BIOL, V228, P197, DOI 10.1006/dbio.2000.9945
   Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573
   Hardcastle Z, 2000, CURR BIOL, V10, P1511, DOI 10.1016/S0960-9822(00)00825-3
   HARLAND RM, 1991, METHOD CELL BIOL, V36, P685
   Harrer M, 2004, J CELL SCI, V117, P3459, DOI 10.1242/jcs.01160
   Harrison M, 2004, DEV DYNAM, V231, P214, DOI 10.1002/dvdy.20113
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Heller N, 1997, MECH DEVELOP, V69, P83, DOI 10.1016/S0925-4773(97)00158-5
   Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E
   Hock R, 2006, EUR J CELL BIOL, V85, P519, DOI 10.1016/j.ejcb.2006.02.010
   HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0
   Hu N, 2014, DEV BIOL, V396, P159, DOI 10.1016/j.ydbio.2014.09.034
   Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012
   Kuriyama S, 2008, PHILOS T R SOC B, V363, P1349, DOI 10.1098/rstb.2007.2252
   LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609
   Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005
   Le Douarin N., 1999, The Neural Crest, P445
   Li H, 2013, BREAST CANCER RES TR, V139, P691, DOI 10.1007/s10549-013-2602-2
   Li H, 2012, BREAST CANCER RES TR, V135, P759, DOI 10.1007/s10549-012-2220-4
   Li ZZ, 2012, DEV CELL, V23, P1176, DOI 10.1016/j.devcel.2012.10.019
   Luo T, 2003, P NATL ACAD SCI USA, V100, P532, DOI 10.1073/pnas.0237226100
   Lupo G, 2002, DEVELOPMENT, V129, P5421, DOI 10.1242/dev.00095
   Macrì S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069866
   Mao XG, 2013, ONCOTARGET, V4, P1050, DOI 10.18632/oncotarget.1131
   MAYOR R, 1995, DEVELOPMENT, V121, P767
   Mayor R, 2013, DEVELOPMENT, V140, P2247, DOI 10.1242/dev.091751
   Milet C, 2012, DEV BIOL, V366, P22, DOI 10.1016/j.ydbio.2012.01.013
   Mizuseki K, 1998, DEVELOPMENT, V125, P579
   Monsoro-Burq AH, 2005, DEV CELL, V8, P167, DOI 10.1016/j.devcel.2004.12.017
   Monzen K, 2008, NAT CELL BIOL, V10, P567, DOI 10.1038/ncb1719
   Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848
   NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2
   Nichane M, 2008, DEV BIOL, V322, P355, DOI 10.1016/j.ydbio.2008.08.003
   Nieuwkoop PD., 1967, Normal Table of Xenopus Laevis (Daudin)
   Nikitina N, 2009, CURR TOP DEV BIOL, V86, P1, DOI 10.1016/S0070-2153(09)01001-1
   Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017
   Ochoa SD, 2012, DEV BIOL, V361, P313, DOI 10.1016/j.ydbio.2011.10.034
   PAPALOPULU N, 1993, DEVELOPMENT, V117, P961
   Parameswaran S, 2014, DEVELOPMENT, V141, P4087, DOI 10.1242/dev.107326
   Pasqualetti M, 2000, DEVELOPMENT, V127, P5367
   Pegoraro S, 2015, ONCOTARGET, V6, P19087, DOI 10.18632/oncotarget.4236
   Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8
   Reisoli E, 2010, DEVELOPMENT, V137, P2927, DOI 10.1242/dev.041079
   Rizzi C, 2013, HUM PATHOL, V44, P122, DOI 10.1016/j.humpath.2012.05.001
   Sgarra R, 2004, FEBS LETT, V574, P1, DOI 10.1016/j.febslet.2004.08.013
   Sgarra R, 2010, BBA-GENE REGUL MECH, V1799, P37, DOI 10.1016/j.bbagrm.2009.08.009
   Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699
   Spokony RF, 2002, DEVELOPMENT, V129, P421
   Strobl-Mazzulla PH, 2012, J CELL BIOL, V198, P999, DOI 10.1083/jcb.201203098
   Strobl-Mazzulla PH, 2010, DEV CELL, V19, P460, DOI 10.1016/j.devcel.2010.08.009
   Stuhlmiller TJ, 2012, CELL MOL LIFE SCI, V69, P3715, DOI 10.1007/s00018-012-0991-8
   Suzuki A, 1997, DEVELOPMENT, V124, P3037
   Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876
   Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293
   Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385
   THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P
   Theveneau E, 2012, DEV BIOL, V366, P34, DOI 10.1016/j.ydbio.2011.12.041
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Van Grunsven LA, 2006, DEV DYNAM, V235, P1491, DOI 10.1002/dvdy.20727
   Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523
   Wu JJ, 2011, CANCER RES, V71, P349, DOI 10.1158/0008-5472.CAN-10-2550
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yu KR, 2015, CELL REP, V10, P441, DOI 10.1016/j.celrep.2014.12.038
   Zaidi MR, 2006, CANCER RES, V66, P7453, DOI 10.1158/0008-5472.CAN-06-0931
   Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
NR 96
TC 18
Z9 20
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0012-1606
EI 1095-564X
J9 DEV BIOL
JI Dev. Biol.
PD MAR 1
PY 2016
VL 411
IS 1
BP 25
EP 37
DI 10.1016/j.ydbio.2016.01.014
PG 13
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA DF6CY
UT WOS:000371444600003
PM 26806704
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Guy, MS
   Qamar, L
   Behbakht, K
   Post, MD
   Sheeder, J
   Sartorius, CA
   Spillman, MA
AF Guy, Michael S.
   Qamar, Lubna
   Behbakht, Kian
   Post, Miriam D.
   Sheeder, Jeanelle
   Sartorius, Carol A.
   Spillman, Monique A.
TI Progestin treatment decreases CD133+cancer stem cell populations in
   endometrial cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Endometrial cancer; Cancer stem cells; Hormonal treatment; Progestin;
   Progesterone
ID MEDROXYPROGESTERONE ACETATE; EPIGENETIC REGULATION; BREAST-CANCER;
   IDENTIFICATION; CARCINOMA; WOMEN; CD133; TUMORIGENICITY; GROWTH; AGE
AB Objectives. Endometrial cancer is a hormonally responsive malignancy. Response to progestins is associated with estrogen receptor (ER) and progesterone receptor (PR) status. CD133 is a marker of endometrial cancer stem cells. We postulated that CD133 + cells express ER and PR and that progestin therapy differentially regulates CD133 + cells.
   Methods. The Ishikawa (ER/PR positive) and KLE (ER/PR negative) cell lines were examined for the presence of CD133 populations. Cell lines were treated with 30.4 mu M medroxyprogesterone 17-acetate (MPA) for 6 days. After treatment, cell counts, apoptosis assays and CD133 + populations were examined. In a clinical project, we identified 12 endometrial cancer patients who were treated with progestin drugs at our institution. Using immunohistochemistry, CD133, ER, PR, and androgen receptor (AR) expression was scored and evaluated for change over time on serial biopsies.
   Results. CD133 + populations were identified in Ishikawa and KLE cell lines. MPA treatment resulted in a significant reduction in the percentage of live cells (Ishikawa, P = 0.036; KLE, P = 0.0002), significant increase in apoptosis (Ishikawa, P = 0.01; KLE, P = 0.0006) and significant decrease in CD133 + populations (Ishikawa, P < 0.0001; KLE, P = 0.0001). ER, PR, AR and CD133 were present in 96.4%, 96.4%, 89.3% and 100% of patient samples respectively. Paralleling the in vitro results, CD133 expression decreased in patients who had histologic response to progestin treatment.
   Conclusion. CD133 + populations decreased after treatment with MPA in an in vitro model and in patients responding to treatment with progestins. Progestin treatment differentially decreases CD133 + cells. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Guy, Michael S.] Univ Cincinnati, Dept Obstet & Gynecol, Div Gynecol Oncol, Sch Med, Cincinnati, OH 45219 USA.
   [Qamar, Lubna; Behbakht, Kian; Sheeder, Jeanelle] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Aurora, CO 80045 USA.
   [Post, Miriam D.; Sartorius, Carol A.] Univ Colorado Denver Sch Med, Dept Pathol, Aurora, CO 80045 USA.
   [Spillman, Monique A.] Baylor Univ, Med Ctr, Texas Oncol, Charles A Sammons Canc Ctr, Dallas, TX 75246 USA.
   [Guy, Michael S.] 337 Oak Forest Dr, Dayton, OH 45419 USA.
C3 University System of Ohio; University of Cincinnati; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; Baylor University Medical Center; Texas Oncology; Baylor
   University
RP Guy, MS (通讯作者)，Univ Cincinnati, Dept Obstet & Gynecol, Div Gynecol Oncol, Sch Med, Cincinnati, OH 45219 USA.
EM michael.s.guy@gmail.com
RI Guy, Michael/AAB-9231-2020; Sheeder, Jeanelle/D-4960-2013
OI Guy, Michael/0000-0001-6752-8959; Sheeder, Jeanelle/0000-0002-4463-3569
FU Academic Enrichment Fund
FX This study was supported by the Academic Enrichment Fund administered by
   the Department of Obstetrics and Gynecology at the University of
   Colorado School of Medicine. We thank Dr. Twila Jackson, PhD for
   generously providing the Ishikawa and KLE cell lines and Dr. Britta
   Jacobsen, PhD (Univ of Colorado School of Medicine and Anschutz Medical
   Campus) for the LNCaP cell line.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Apparao KBC, 2002, BIOL REPROD, V66, P297, DOI 10.1095/biolreprod66.2.297
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Decruze SB, 2007, INT J GYNECOL CANCER, V17, P964, DOI 10.1111/j.1525-1438.2007.00897.x
   Duska LR, 2001, GYNECOL ONCOL, V83, P388, DOI 10.1006/gyno.2001.6434
   Friel AM, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-147
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   GITSCH G, 1995, OBSTET GYNECOL, V85, P504, DOI 10.1016/0029-7844(95)00001-8
   Hackenberg R, 1996, J STEROID BIOCHEM, V56, P113, DOI 10.1016/0960-0760(95)00228-6
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017
   Kryczek I, 2012, INT J CANCER, V130, P29, DOI 10.1002/ijc.25967
   Lee NK, 2007, OBSTET GYNECOL, V109, P655, DOI 10.1097/01.AOG.0000255980.88205.15
   Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10
   Li LK, 2001, CANCER RES, V61, P4386
   Luo LJ, 2011, EXP MOL PATHOL, V91, P596, DOI 10.1016/j.yexmp.2011.06.005
   Moe BT, 2009, ANTICANCER RES, V29, P1047
   Nakamura M, 2010, HUM PATHOL, V41, P1516, DOI 10.1016/j.humpath.2010.05.006
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rutella S, 2009, CLIN CANCER RES, V15, P4299, DOI 10.1158/1078-0432.CCR-08-1883
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Singh M, 2007, GYNECOL ONCOL, V106, P325, DOI 10.1016/j.ygyno.2007.03.042
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Steffensen KD, 2011, J ONCOL, V2011, DOI 10.1155/2011/620523
   Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736
   Tran BN, 2000, AM J CLIN ONCOL-CANC, V23, P476, DOI 10.1097/00000421-200010000-00009
   Ushijima K, 2007, J CLIN ONCOL, V25, P2798, DOI 10.1200/JCO.2006.08.8344
   von Gruenigen VE, 2005, AM J OBSTET GYNECOL, V193, P1369, DOI 10.1016/j.ajog.2005.03.038
NR 33
TC 12
Z9 14
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 2016
VL 140
IS 3
BP 518
EP 526
DI 10.1016/j.ygyno.2015.12.022
PG 9
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA DF5DT
UT WOS:000371372700024
PM 26731726
DA 2025-01-12
ER

PT J
AU Palma, CD
   Grassi, ML
   Thomé, CH
   Ferreira, GA
   Albuquerque, D
   Pinto, MT
   Melo, FUF
   Kashima, S
   Covas, DT
   Pitteri, SJ
   Faça, VM
AF Palma, Camila de Souza
   Grassi, Mariana Lopes
   Thome, Carolina Hassibe
   Ferreira, Germano Aguiar
   Albuquerque, Daniele
   Pinto, Mariana Tomazini
   Ferreira Melo, Fernanda Ursoli
   Kashima, Simone
   Covas, Dimas Tadeu
   Pitteri, Sharon J.
   Faca, Vitor M.
TI Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals
   Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID TRANSCRIPTIONAL REPRESSOR SNAIL; STATISTICAL-MODEL; MESSENGER-RNA;
   PROGRESSION; EXPRESSION; RECRUITMENT; METASTASIS; INDUCTION; MIGRATION;
   NETWORKS
AB Epithelial to mesenchymal transition (EMT)(1) occurs naturally during embryogenesis, tissue repair, cancer progression, and metastasis. EMT induces cellular and microenvironmental changes resulting in loss of epithelial and acquisition of mesenchymal phenotypes, which promotes cellular invasive and migratory capabilities. EMT can be triggered by extracellular factors, including TGF-, HGF, and EGF. Overexpression of transcription factors, such as SNAIL, SLUG, ZEB1/2, and TWIST1, also induces EMT and is correlated to cancer aggressiveness. Here, the breast adenocarcinoma cell line MCF7 was transduced with SNAIL to identify specific mechanisms controlled by this transcription factor during EMT. Overexpression of SNAIL led to EMT, which was thoroughly validated by molecular, morphological, and functional experiments. Subcellular proteome enrichment followed by GEL-LC-MS/MS was performed to provide extensive protein fractionation and in-depth proteomic analysis. Quantitative analysis relied on a SILAC strategy, using the invasive breast cancer cell line MDA-MB-231 as a reference for quantitation. Subsets of proteins enriched in each subcellular compartment led to a complementary list of 4289 proteins identified with high confidence. A subset of differentially expressed proteins was validated by Western blot, including regulation in specific cellular compartments, potentially caused by protein translocation. Protein network analysis highlighted complexes involved in cell cycle control and epigenetic regulation. Flow cytometry analysis indicated that SNAIL overexpression led to cell cycle arrest in G(0)/G(1) phases. Furthermore, down-regulation of HDAC1 was observed, supporting the involvement of epigenetic processes in SNAIL-induced EMT. When HDAC1 activity was inhibited, MCF7 not only apparently initiated EMT but also up-regulated SNAIL, indicating the cross-talk between these two proteins. Both HDAC1 inhibition and SNAIL overexpression activated the AKT pathway. These molecular mechanisms appear to be essential to EMT and therefore for cancer metastasis. Specific control of such epigenetic processes might then represent effective approaches for clinical management of metastatic cancer.
C1 [Palma, Camila de Souza; Grassi, Mariana Lopes; Thome, Carolina Hassibe; Albuquerque, Daniele; Faca, Vitor M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Av Bandeirantes,3900 Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Palma, Camila de Souza; Grassi, Mariana Lopes; Thome, Carolina Hassibe; Ferreira, Germano Aguiar; Pinto, Mariana Tomazini; Ferreira Melo, Fernanda Ursoli; Kashima, Simone; Covas, Dimas Tadeu; Faca, Vitor M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto Blood Ctr, Cell Based Therapy Ctr, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Pitteri, Sharon J.] Stanford Univ, Sch Med, Canary Ctr Stanford Canc Early Detect, Dept Radiol, Stanford, CA 94305 USA.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Stanford
   University
RP Faça, VM (通讯作者)，Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Av Bandeirantes,3900 Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
EM vitor.faca@fmrp.usp.br
RI Covas, Dimas/AAL-8499-2021; Ferreira, Germano/M-4789-2014; Faça,
   Vitor/A-3989-2013; Covas, Dimas/C-5431-2013; Palma, Camila/A-8206-2017;
   Pinto, Mariana/B-6129-2017; Kashima, Simone/G-4876-2012
OI FACA, VITOR MARCEL/0000-0003-3205-7944; Covas,
   Dimas/0000-0002-7364-2595; Pitteri, Sharon/0000-0002-3119-873X; Palma,
   Camila/0000-0002-4868-8540; Pinto, Mariana/0000-0002-5176-7776; Ursoli,
   Fernanda/0000-0002-8499-000X; Ferreira, Germano/0000-0002-3149-3077;
   Kashima, Simone/0000-0002-1487-0141
FU FAPESP Young Scientist Grant [2011/09740-1]; CNPq; Center for Cell-based
   Therapy-CTC-CEPID; FAPESP Grant [2013/08135-2]; CISBi-NAP; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [11/09740-1] Funding
   Source: FAPESP
FX This work was supported in part by FAPESP Young Scientist Grant
   2011/09740-1, CNPq, Center for Cell-based Therapy-CTC-CEPID, FAPESP
   Grant 2013/08135-2, and CISBi-NAP.
CR Adam RM, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-30
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181
   Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514
   Dreger M, 2003, EUR J BIOCHEM, V270, P589, DOI 10.1046/j.1432-1033.2003.03426.x
   Faca V, 2006, J PROTEOME RES, V5, P2009, DOI 10.1021/pr060102+
   Faca VM, 2008, PLOS MED, V5, P953, DOI 10.1371/journal.pmed.0050123
   Francí C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519
   Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446
   Gong C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6406
   Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013
   Guo SC, 2005, CANCER RES, V65, P3011, DOI 10.1158/0008-5472.CAN-04-3624
   Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006
   Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034
   Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kiesslich T, 2013, MOL CLIN ONCOL, V1, P3, DOI 10.3892/mco.2012.28
   Kurozumi A, 2016, CANCER SCI, V107, P84, DOI 10.1111/cas.12842
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lakshmaiah KC, 2014, J CANCER RES THER, V10, P469, DOI 10.4103/0973-1482.137937
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lindsey S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00358
   MacLean B, 2006, BIOINFORMATICS, V22, P2830, DOI 10.1093/bioinformatics/btl379
   Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Naber HPH, 2013, BIOCHEM BIOPH RES CO, V435, P58, DOI 10.1016/j.bbrc.2013.04.037
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rauch A, 2006, J PROTEOME RES, V5, P112, DOI 10.1021/pr0503533
   Salton M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023882
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Sugimachi K, 2003, CLIN CANCER RES, V9, P2657
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Thomé CH, 2012, MOL CELL PROTEOMICS, V11, P1898, DOI 10.1074/mcp.M112.019661
   Uhlén M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200
   Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104
   Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248
   Vetter G, 2009, BIOCHEM BIOPH RES CO, V385, P485, DOI 10.1016/j.bbrc.2009.05.025
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wang SC, 2005, ANN NY ACAD SCI, V1059, P11, DOI 10.1196/annals.1339.002
   Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813
   Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005
   Zhang L, 2015, MOL MED REP, V12, P7869, DOI 10.3892/mmr.2015.4443
   Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 57
TC 38
Z9 42
U1 0
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAR
PY 2016
VL 15
IS 3
SI SI
BP 906
EP 917
DI 10.1074/mcp.M115.052910
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DG2KB
UT WOS:000371894700013
PM 26764010
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Weigel, C
   Veldwijk, MR
   Oakes, CC
   Seibold, P
   Slynko, A
   Liesenfeld, DB
   Rabionet, M
   Hanke, SA
   Wenz, F
   Sperk, E
   Benner, A
   Rösli, C
   Sandhoff, R
   Assenov, Y
   Plass, C
   Herskind, C
   Chang-Claude, J
   Schmezer, P
   Popanda, O
AF Weigel, Christoph
   Veldwijk, Marlon R.
   Oakes, Christopher C.
   Seibold, Petra
   Slynko, Alla
   Liesenfeld, David B.
   Rabionet, Mariona
   Hanke, Sabrina A.
   Wenz, Frederik
   Sperk, Elena
   Benner, Axel
   Roesli, Christoph
   Sandhoff, Roger
   Assenov, Yassen
   Plass, Christoph
   Herskind, Carsten
   Chang-Claude, Jenny
   Schmezer, Peter
   Popanda, Odilia
TI Epigenetic regulation of diacylglycerol kinase alpha promotes
   radiation-induced fibrosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GROWTH-FACTOR-BETA; DNA METHYLATION; GENE-EXPRESSION; INTRAOPERATIVE
   RADIOTHERAPY; HEPATOCELLULAR-CARCINOMA; FIBROBLAST ACTIVATION;
   PULMONARY-FIBROSIS; HIGH-THROUGHPUT; LUNG FIBROSIS; X-RAYS
AB Radiotherapy is a fundamental part of cancer treatment but its use is limited by the onset of late adverse effects in the normal tissue, especially radiation-induced fibrosis. Since the molecular causes for fibrosis are largely unknown, we analyse if epigenetic regulation might explain inter-individual differences in fibrosis risk. DNA methylation profiling of dermal fibroblasts obtained from breast cancer patients prior to irradiation identifies differences associated with fibrosis. One region is characterized as a differentially methylated enhancer of diacylglycerol kinase alpha (DGKA). Decreased DNA methylation at this enhancer enables recruitment of the profibrotic transcription factor early growth response 1 (EGR1) and facilitates radiation-induced DGKA transcription in cells from patients later developing fibrosis. Conversely, inhibition of DGKA has pronounced effects on diacylglycerol-mediated lipid homeostasis and reduces profibrotic fibroblast activation. Collectively, DGKA is an epigenetically deregulated kinase involved in radiation response and may serve as a marker and therapeutic target for personalized radiotherapy.
C1 [Weigel, Christoph; Oakes, Christopher C.; Assenov, Yassen; Plass, Christoph; Schmezer, Peter; Popanda, Odilia] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Veldwijk, Marlon R.; Wenz, Frederik; Sperk, Elena; Herskind, Carsten] Heidelberg Univ, Dept Radiat Oncol, Univ Med Mannheim, Med Fac Mannheim, D-68167 Mannheim, Germany.
   [Seibold, Petra; Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.
   [Slynko, Alla; Benner, Axel] German Canc Res Ctr, Div Biostat, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.
   [Liesenfeld, David B.] German Canc Res Ctr, Div Prevent Oncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Rabionet, Mariona; Sandhoff, Roger] German Canc Res Ctr, Lipid Pathobiochem Grp, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Hanke, Sabrina A.; Roesli, Christoph] German Canc Res Ctr, Div Stem Cells & Canc, Jr Res Grp Biomarker Discovery, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Hanke, Sabrina A.; Roesli, Christoph] HI STEM gGmbH, Biomarker Discovery, D-69120 Heidelberg, Germany.
   [Sandhoff, Roger] Tech Univ Appl Sci Mannheim, Instrumental Analyt & Bioanalyt, D-68163 Mannheim, Germany.
   [Assenov, Yassen] German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg Mannheim, D-69120 Heidelberg, Germany.
   [Oakes, Christopher C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Helmholtz Association; German Cancer Research Center
   (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ);
   Helmholtz Association; German Cancer Research Center (DKFZ); German
   Centre for Cardiovascular Research; University System of Ohio; Ohio
   State University
RP Popanda, O (通讯作者)，German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM o.popanda@dkfz.de
RI Weigel, Christoph/KRO-5697-2024; Popanda, Odilia/P-6917-2019; Roesli,
   Christoph/B-9527-2018; Oakes, Christopher/H-7288-2014; Sperk,
   Elena/KHD-6997-2024; Herskind, Carsten/J-2457-2019; Benner,
   Axel/ABE-2980-2020
OI Sperk, Elena/0000-0002-8771-8124; Weigel, Christoph/0009-0005-0862-4883;
   Herskind, Carsten/0000-0001-6554-5907
FU Deutsche Krebshilfe grant [109394]; Helmholtz International Graduate
   School for Cancer Research; EURATOM under the ESTRO GENEPI project
   [FIR1-CT-2002-00213, FI6R-036437]
FX We would like to thank Clarissa Gerhauser for help with HPLC analysis,
   Anders Lindroth and Dieter Weichenhan for helpful discussions, Philipp
   Mallm and Karsten Rippe for their great support with ChIP- and
   RNA-sequencing. Reinhard Gliniorz, Oliver Mucke and Peter Waas are
   acknowledged for their excellent technical assistance and Ursula Eilber
   for her support summarizing patient data. Miriam Bierbaum, Nicole Guerth
   and Anne Kirchner are gratefully acknowledged for cell culture work in
   connection with establishing and retrieving fibroblast cultures. This
   work was funded by the Deutsche Krebshilfe grant nr. 109394. C.W. was
   supported by the Helmholtz International Graduate School for Cancer
   Research. Fibroblast cultures were established with support from EURATOM
   under the ESTRO GENEPI project contract numbers FIR1-CT-2002-00213 and
   FI6R-036437.
CR ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   [Anonymous], 1995, Int J Radiat Oncol Biol Phys, V31, P1049
   Avouac J, 2012, ARTHRITIS RHEUM-US, V64, P1642, DOI 10.1002/art.33501
   Barnett GC, 2009, NAT REV CANCER, V9, P134, DOI 10.1038/nrc2587
   Baumann M, 2003, RADIOTHER ONCOL, V69, P121, DOI 10.1016/j.radonc.2003.08.006
   Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135
   Bhattacharyya S, 2013, J PATHOL, V229, P286, DOI 10.1002/path.4131
   Bhattacharyya S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023082
   Blank E, 2010, ANN SURG ONCOL, V17, pS352, DOI [10.1245/s10434-010-1265-z, 10.1245/s10434-010-1257-z]
   Castelino FV, 2012, CURR OPIN RHEUMATOL, V24, P649, DOI 10.1097/BOR.0b013e328356d9f6
   Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036
   Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200
   Chianale F, 2010, P NATL ACAD SCI USA, V107, P4182, DOI 10.1073/pnas.0908326107
   Chu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068943
   de la Fuente A, 2004, BIOINFORMATICS, V20, P3565, DOI 10.1093/bioinformatics/bth445
   Dominguez CL, 2013, CANCER DISCOV, V3, P782, DOI 10.1158/2159-8290.CD-12-0215
   Dorling L, 2016, CLIN CANCER RES, V22, P1413, DOI 10.1158/1078-0432.CCR-15-1080
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Efron B, 2001, J AM STAT ASSOC, V96, P1151, DOI 10.1198/016214501753382129
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Gan L, 2011, BIOCHEM BIOPH RES CO, V409, P7, DOI 10.1016/j.bbrc.2011.04.084
   Hagège H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243
   HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156
   Heinloth AN, 2003, MOL CARCINOGEN, V37, P65, DOI 10.1002/mc.10122
   Herskind C, 1996, RADIAT RES, V145, P299, DOI 10.2307/3578985
   Herskind C, 2005, RADIAT RES, V163, P208, DOI 10.1667/RR3292
   Iyoda T, 2012, J BIOL CHEM, V287, P22635, DOI 10.1074/jbc.M111.335695
   Kai M, 2009, FEBS LETT, V583, P3265, DOI 10.1016/j.febslet.2009.09.017
   Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609
   Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Liu Q, 2013, INT J RADIAT ONCOL, V85, P1127, DOI 10.1016/j.ijrobp.2012.08.005
   Luzina IG, 2006, AM J RESP CELL MOL, V35, P298, DOI 10.1165/rcmb.2006-0033OC
   Mann DA, 2014, HEPATOLOGY, V60, P1418, DOI 10.1002/hep.27131
   MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194
   Mérida I, 2008, BIOCHEM J, V409, P1, DOI 10.1042/BJ20071040
   Milne SB, 2008, BIOCHEMISTRY-US, V47, P9372, DOI 10.1021/bi800492c
   Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871
   Olenchock BA, 2006, NAT IMMUNOL, V7, P1174, DOI 10.1038/ni1400
   Opgen-Rhein R, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-37
   Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rabionet M, 2013, J LIPID RES, V54, P3312, DOI 10.1194/jlr.M040097
   Rainero E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097144
   Sato M, 2013, PHARMACOLOGY, V92, P99, DOI 10.1159/000351849
   Shulga YV, 2011, CHEM REV, V111, P6186, DOI 10.1021/cr1004106
   Sperk E, 2012, BREAST CANCER RES TR, V135, P253, DOI 10.1007/s10549-012-2168-4
   Sun SR, 2014, AM J NEPHROL, V39, P436, DOI 10.1159/000362249
   Sunaga H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3563
   Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685
   Takeishi K, 2012, J HEPATOL, V57, P77, DOI 10.1016/j.jhep.2012.02.026
   Tang N, 2014, J CELL MOL MED, V18, P156, DOI 10.1111/jcmm.12178
   TEERLINK T, 1989, CLIN CHIM ACTA, V183, P309, DOI 10.1016/0009-8981(89)90365-3
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Thannickal VJ, 2014, J CLIN INVEST, V124, P4673, DOI 10.1172/JCI74368
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Vanhille L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7905
   Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37
   Weigel C, 2015, ONCOGENE, V34, P2145, DOI 10.1038/onc.2014.145
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Williams JM, 2007, J AM SOC NEPHROL, V18, P1112, DOI 10.1681/ASN.2006090973
   Yang JI, 2010, AM J PHYSIOL-GASTR L, V298, pG126, DOI 10.1152/ajpgi.00299.2009
   Yarnold J, 2010, RADIOTHER ONCOL, V97, P149, DOI 10.1016/j.radonc.2010.09.002
   Zeisberg EM, 2013, J PATHOL, V229, P264, DOI 10.1002/path.4120
   Zeybel M, 2012, NAT MED, V18, P1369, DOI 10.1038/nm.2893
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 67
TC 44
Z9 50
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10893
DI 10.1038/ncomms10893
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG4CN
UT WOS:000372018200001
PM 26964756
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lakisic, G
   Lebreton, A
   Pourpre, R
   Wendling, O
   Libertini, E
   Radford, EJ
   Le Guillou, M
   Champy, MF
   Wattenhofer-Donzé, M
   Soubigou, G
   Ait-Si-Ali, S
   Feunteun, J
   Sorg, T
   Coppée, JY
   Ferguson-Smith, AC
   Cossart, P
   Bierne, H
AF Lakisic, Goran
   Lebreton, Alice
   Pourpre, Renaud
   Wendling, Olivia
   Libertini, Emanuele
   Radford, Elizabeth J.
   Le Guillou, Morwenna
   Champy, Marie-France
   Wattenhofer-Donze, Marie
   Soubigou, Guillaume
   Ait-Si-Ali, Slimane
   Feunteun, Jean
   Sorg, Tania
   Coppee, Jean-Yves
   Ferguson-Smith, Anne C.
   Cossart, Pascale
   Bierne, Helene
TI Role of the BAHD1 Chromatin-Repressive Complex in Placental Development
   and Regulation of Steroid Metabolism
SO PLOS GENETICS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE; DNA METHYLATION;
   TRANSCRIPTIONAL REPRESSION; GLYCOGEN CELLS; BREAST-CANCER; SANT DOMAIN;
   PROMOTER; PROTEIN; NURD
AB BAHD1 is a vertebrate protein that promotes heterochromatin formation and gene repression in association with several epigenetic regulators. However, its physiological roles remain unknown. Here, we demonstrate that ablation of the Bahd1 gene results in hypocholesterolemia, hypoglycemia and decreased body fat in mice. It also causes placental growth restriction with a drop of trophoblast glycogen cells, a reduction of fetal weight and a high neonatal mortality rate. By intersecting transcriptome data from murine Bahd1 knockout ( KO) placentas at stages E16.5 and E18.5 of gestation, Bahd1-KO embryonic fibroblasts, and human cells stably expressing BAHD1, we also show that changes in BAHD1 levels alter expression of steroid/lipid metabolism genes. Biochemical analysis of the BAHD1associated multiprotein complex identifies MIER proteins as novel partners of BAHD1 and suggests that BAHD1-MIER interaction forms a hub for histone deacetylases and methyltransferases, chromatin readers and transcription factors. We further show that overexpression of BAHD1 leads to an increase of MIER1 enrichment on the inactive X chromosome ( Xi). In addition, BAHD1 and MIER1/3 repress expression of the steroid hormone receptor genes ESR1 and PGR, both playing important roles in placental development and energy metabolism. Moreover, modulation of BAHD1 expression in HEK293 cells triggers epigenetic changes at the ESR1 locus. Together, these results identify BAHD1 as a core component of a chromatin-repressive complex regulating placental morphogenesis and body fat storage and suggest that its dysfunction may contribute to several human diseases.
C1 [Lakisic, Goran; Pourpre, Renaud; Bierne, Helene] Univ Paris Saclay, Equipe Microbiol Cellulaire & Epigenet, AgroParisTech, Micalis Inst, Jouy En Josas, France.
   [Lebreton, Alice; Cossart, Pascale] Inst Pasteur, Unite Interact Bacteries Cellules, Paris, France.
   [Lebreton, Alice; Cossart, Pascale] INSERM, U604, Paris, France.
   [Lebreton, Alice; Cossart, Pascale] INRA, USC2020, Paris, France.
   [Wendling, Olivia; Champy, Marie-France; Wattenhofer-Donze, Marie; Sorg, Tania] Univ Strasbourg, INSERM, CNRS, ICS MCI,PHENOMIN,UMR7104,U964, Illkirch Graffenstaden, France.
   [Libertini, Emanuele; Soubigou, Guillaume; Coppee, Jean-Yves] Inst Pasteur, Dept Genomes & Genet, Plateforme Transcriptome & Epigenome, Paris, France.
   [Radford, Elizabeth J.; Ferguson-Smith, Anne C.] Univ Cambridge, Dept Genet, Downing St, Cambridge CB2 3EH, England.
   [Radford, Elizabeth J.] NHS Fdn Trust, Cambridge Univ Hosp, Cambridge, England.
   [Le Guillou, Morwenna; Feunteun, Jean] Univ Paris Saclay, Stabilite Genet & Oncogenese, CNRS, UMR8200, Villejuif, France.
   [Ait-Si-Ali, Slimane] Univ Paris Diderot Paris 7, CNRS, UMR7216, Paris, France.
   [Lebreton, Alice] PSL Res Univ, IBENS, CNRS,ARN, Ecole Normale Super Equipe Infection & Devenir, Paris, France.
C3 Universite Paris Saclay; AgroParisTech; Pasteur Network; Universite
   Paris Cite; Institut Pasteur Paris; Institut National de la Sante et de
   la Recherche Medicale (Inserm); INRAE; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Pasteur Network; Universite Paris Cite; Institut Pasteur Paris;
   University of Cambridge; University of Cambridge; Oxford University
   Hospitals NHS Foundation Trust; Universite Paris Saclay; Centre National
   de la Recherche Scientifique (CNRS); CNRS - National Institute for
   Biology (INSB); Centre National de la Recherche Scientifique (CNRS);
   CNRS - National Institute for Biology (INSB); Universite Paris Cite;
   Centre National de la Recherche Scientifique (CNRS); Universite PSL;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Bierne, H (通讯作者)，Univ Paris Saclay, Equipe Microbiol Cellulaire & Epigenet, AgroParisTech, Micalis Inst, Jouy En Josas, France.
EM helene.bierne@jouy.inra.fr
RI Feunteun, Jean/AAZ-1267-2020; Ferguson-Smith, Anne/G-7534-2011; Cossart,
   Pascale/HLH-1874-2023; Lebreton, Alice/M-8764-2015; Feunteun,
   Jean/IAR-5595-2023
OI Wattenhofer-Donze, Marie/0000-0002-6092-274X; Lebreton,
   Alice/0000-0002-6643-902X; Ferguson-Smith, Anne/0000-0002-7608-5894;
   Feunteun, Jean/0000-0003-1212-9189; AIT-SI-ALI,
   Slimane/0000-0001-8211-9256; Radford, Elizabeth/0000-0002-7829-5422;
   LAKISIC, Goran/0000-0002-0079-5072; Bierne, Helene/0000-0002-0525-0848
FU French National Research Agency [ANR 11-BSV3-0003 EPILIS]; French Ligue
   Nationale Contre le Cancer (comite regional d'lle-de-France) [LNCC
   RS10/75-76, LNCC 131/12]; Institut National de la Recherche Agronomique
   (AO blanc MICA); Advanced Grant from the European Research Council
   (BacCellEpi) [670823]; iXcore Fundation for Research; Agence Nationale
   de la Recherche (ANR) [ANR-11-BSV3-0003] Funding Source: Agence
   Nationale de la Recherche (ANR); MRC [MR/J001597/1] Funding Source: UKRI
FX This work was supported by grants from the French National Research
   Agency (ANR 11-BSV3-0003 EPILIS, to HB, SASA and JYC), the French Ligue
   Nationale Contre le Cancer (comite regional d'lle-de-France, LNCC
   RS10/75-76 and LNCC 131/12, to HB) and the Institut National de la
   Recherche Agronomique (AO blanc MICA 2011, to HB), as well as an
   Advanced Grant from the European Research Council (project number
   670823, BacCellEpi, to PC) and an award from the iXcore Fundation for
   Research (to HB). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albrecht ED, 2010, INT J DEV BIOL, V54, P397, DOI 10.1387/ijdb.082758ea
   Armache KJ, 2011, SCIENCE, V334, P977, DOI 10.1126/science.1210915
   Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Barak Y, 2008, PPAR RES, V2008, DOI 10.1155/2008/142082
   Bierne H, 2009, P NATL ACAD SCI USA, V106, P13826, DOI 10.1073/pnas.0901259106
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bukovsky Antonin, 2003, Reprod Biol Endocrinol, V1, P36, DOI 10.1186/1477-7827-1-36
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Clements JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032499
   Coan PM, 2006, DEV DYNAM, V235, P3280, DOI 10.1002/dvdy.20981
   Coan PM, 2005, PLACENTA, V26, pS10, DOI 10.1016/j.placenta.2004.12.009
   Ding J, 2015, DIABETES
   Ding ZH, 2004, J BIOL CHEM, V279, P28009, DOI 10.1074/jbc.M403793200
   Ding ZH, 2003, MOL CELL BIOL, V23, P250, DOI 10.1128/MCB.23.1.250-258.2003
   Dynon K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045956
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Escamilla-Del-Arenal M, 2013, MOL CELL BIOL, V33, P5005, DOI 10.1128/MCB.00866-13
   Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017
   Fujimoto J, 2005, J STEROID BIOCHEM, V94, P67, DOI 10.1016/j.jsbmb.2004.12.030
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Gambino YP, 2012, BBA-MOL CELL RES, V1823, P900, DOI 10.1016/j.bbamcr.2012.01.015
   Haig D, 2014, HEREDITY, V113, P96, DOI 10.1038/hdy.2013.97
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200
   Jain N, 2003, BIOINFORMATICS, V19, P1945, DOI 10.1093/bioinformatics/btg264
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kelly RDW, 2013, BIOCHEM SOC T, V41, P741, DOI 10.1042/BST20130010
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006
   Lebreton A, 2014, MBIO, V5, DOI 10.1128/mBio.00775-13
   Lebreton A, 2011, SCIENCE, V331, P1319, DOI 10.1126/science.1200120
   Lefebvre L, 2012, REPROD BIOMED ONLINE, V25, P44, DOI 10.1016/j.rbmo.2012.03.019
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200
   Li SN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084046
   Libertin E, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00339
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Maltepe E, 2005, DEVELOPMENT, V132, P3393, DOI 10.1242/dev.01923
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532
   McCarthy PL, 2008, BRIT J CANCER, V99, P639, DOI 10.1038/sj.bjc.6604518
   McDonel P, 2009, INT J BIOCHEM CELL B, V41, P108, DOI 10.1016/j.biocel.2008.07.022
   Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020
   Natale DRC, 2006, METH MOLEC MED, V121, P275
   Nie GY, 2006, BIOL REPROD, V74, P366, DOI 10.1095/biolreprod.105.047324
   Pérez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114
   Plaster N, 2007, DEV DYNAM, V236, P1891, DOI 10.1002/dvdy.21196
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012
   Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09
   Salazar J, 2007, CLIN CHEM LAB MED, V45, P615, DOI 10.1515/CCLM.2007.131
   Simmons DG, 2008, DEVELOPMENT, V135, P2083, DOI 10.1242/dev.020099
   Singh H, 2010, PLACENTA, V31, P1085, DOI 10.1016/j.placenta.2010.10.003
   Sober S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13336
   Tesser RB, 2010, HISTOCHEM CELL BIOL, V134, P83, DOI 10.1007/s00418-010-0714-x
   van Greevenbroek MMJ, 2014, CURR OPIN LIPIDOL, V25, P176, DOI 10.1097/MOL.0000000000000068
   Wang L, 2008, EMBO REP, V9, P555, DOI 10.1038/embor.2008.67
   Weimann M, 2013, NAT METHODS, V10, P339, DOI [10.1038/NMETH.2397, 10.1038/nmeth.2397]
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Williamson CM., 2013, Mouse Imprinting Data and References
   Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3
   Yang N, 2013, CRIT REV BIOCHEM MOL, V48, P211, DOI 10.3109/10409238.2012.742035
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 70
TC 27
Z9 31
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2016
VL 12
IS 3
AR e1005898
DI 10.1371/journal.pgen.1005898
PG 26
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DI1PV
UT WOS:000373268900016
PM 26938916
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Bamodu, OA
   Huang, WC
   Lee, WH
   Wu, A
   Wang, LS
   Hsiao, M
   Yeh, CT
   Chao, TY
AF Bamodu, Oluwaseun Adebayo
   Huang, Wen-Chien
   Lee, Wei-Hwa
   Wu, Alexander
   Wang, Liang Shun
   Hsiao, Michael
   Yeh, Chi-Tai
   Chao, Tsu-Yi
TI Aberrant KDM5B expression promotes aggressive breast cancer through
   MALAT1 overexpression and downregulation of hsa-miR-448
SO BMC CANCER
LA English
DT Article
DE hsa-miR-448; KDM5B; MALAT1; Histone demethylase; Long non-coding RNA;
   microRNA; Triple negative breast cancer; Epigenetics; Anticancer target
ID LONG NONCODING RNA; CELL-PROLIFERATION; PROTEIN; GROWTH; METASTASIS;
   COMPLEXES; MIGRATION; INVASION; PLU-1
AB Background: Triple negative breast cancers (TNBC) possess cell dedifferentiation characteristics, carry out activities connate to those of cancer stem cells (CSCs) and are associated with increased metastasis, as well as, poor clinical prognosis. The regulatory mechanism of this highly malignant phenotype is still poorly characterized. Accruing evidence support the role of non-coding RNAs (ncRNAs) as potent regulators of CSC and metastatic gene expression, with their dysregulation implicated in tumorigenesis and disease progression.
   Methods: In this study, we investigated TNBC metastasis, metastasis-associated genes and potential inhibitory mechanisms using bioinformatics, tissue microarray analyses, immunoblotting, polymerase chain reaction, loss and gain of gene function assays and comparative analyses of data obtained.
   Results: Compared with other breast cancer types, the highly metastatic MDA-MB-231 cells concurrently exhibited increased expression levels of Lysine-specific demethylase 5B protein (KDM5B) and long non-coding RNA (lncRNA), MALAT1, suggesting their functional association. KDM5B-silencing in the TNBC cells correlated with the upregulation of hsa-miR-448 and led to suppression of MALAT1 expression with decreased migration, invasion and clonogenic capacity in vitro, as well as, poor survival in vivo. This projects MALAT1 as a mediator of KDM5B oncogenic potential and highlights the critical role of this microRNA, lncRNA and histone demethylase in cancer cell motility and metastatic colonization. Increased expression of KDM5B correlating with disease progression and poor clinical outcome in breast cancer was reversed by hsa-miR-448.
   Conclusions: Our findings demonstrate the critical role of KDM5B and its negative regulator hsa-miR-448 in TNBC metastasis and progression. Hsa-miR-448 disrupting KDM5B-MALAT1 signalling axis and associated activities in TNBC cells, projects it as a putative therapeutic factor for selective eradication of TNBC cells.
C1 [Bamodu, Oluwaseun Adebayo; Wang, Liang Shun; Yeh, Chi-Tai; Chao, Tsu-Yi] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei City, Taiwan.
   [Bamodu, Oluwaseun Adebayo; Wang, Liang Shun; Yeh, Chi-Tai; Chao, Tsu-Yi] Taipei Med Univ, Shuang Ho Hosp, Dept Med Res & Educ, New Taipei City, Taiwan.
   [Huang, Wen-Chien] Mackay Mem Hosp, Dept Thorac Surg, Taipei 10449, Taiwan.
   [Lee, Wei-Hwa] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan.
   [Wu, Alexander] Taipei Med Univ, Grad Inst Translat Med, Taipei City, Taiwan.
   [Wu, Alexander] Acad Sinica, PhD Program Translat Med, Taipei 115, Taiwan.
   [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Chao, Tsu-Yi] Triserv Gen Hosp, Taipei City, Taiwan.
C3 Taipei Medical University; Mackay Memorial Hospital; Taipei Medical
   University; Shuang Ho Hospital; Academia Sinica - Taiwan; Academia
   Sinica - Taiwan; Tri-Service General Hospital
RP Yeh, CT (通讯作者)，Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei City, Taiwan.; Yeh, CT (通讯作者)，Taipei Med Univ, Shuang Ho Hosp, Dept Med Res & Educ, New Taipei City, Taiwan.
EM ctyeh@s.tmu.edu.tw
RI Cheng, Ann-Lii/ACM-0936-2022; Hsiao, Michael/U-6238-2019; Huang,
   Chi-Chang/A-3280-2013; Bamodu, Oluwaseun Adebayo/B-9784-2018
OI Bamodu, Oluwaseun Adebayo/0000-0001-8229-0408; Hsiao,
   Michael/0000-0001-8529-9213
FU National Science Council of Taiwan [MOST103-2325-B-038-002]; Taipei
   Medical University-Shuang Ho Hospital [100TMU-SHH-07, 101TMU-SHH-04]
FX This work was supported by the National Science Council of Taiwan grant
   to Tsu-Yi Chao (MOST103-2325-B-038-002) and grants from Taipei Medical
   University-Shuang Ho Hospital (100TMU-SHH-07 and 101TMU-SHH-04) to
   Chi-Tai Yeh. The authors thank Fang-Ting Kuo (Flow Cytometry Core
   Facility Center, Taipei Medical University-Shuang Ho Hospital) for her
   assistance with the flow cytometry, molecular and cell-based assays.
CR Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Bellucci M, 2011, NAT METHODS, V8, P444, DOI 10.1038/nmeth.1611
   Berrada N, 2010, ANN ONCOL, V21, P30, DOI 10.1093/annonc/mdq279
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Braun JE, 2011, MOL CELL, V44, P120, DOI 10.1016/j.molcel.2011.09.007
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Carper Miranda B, 2014, Genes Cancer, V5, P420
   Chen CYA, 2011, WIRES RNA, V2, P167, DOI 10.1002/wrna.40
   Chiu W-T, 2011, CANC RES
   Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Dai B, 2014, BIOCHEM BIOPH RES CO, V454, P221, DOI 10.1016/j.bbrc.2014.10.078
   Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128-08
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Hüttenhofer A, 2005, TRENDS GENET, V21, P289, DOI 10.1016/j.tig.2005.03.007
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiao F, 2014, ONCOL REP, V7, P8
   Jiao F, 2014, ONCOL REP, V32, P2485, DOI 10.3892/or.2014.3518
   Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755
   Kanematsu S, 2011, ONCOL REP, V26, P603, DOI 10.3892/or.2011.1311
   Kantara C, 2015, LAB INVEST, V95, P100, DOI 10.1038/labinvest.2014.133
   Kleffel S, 2013, ADV EXP MED BIOL, V734, P145, DOI 10.1007/978-1-4614-1445-2_8
   Li L, 2009, P NATL ACAD SCI USA, V106, P12956, DOI 10.1073/pnas.0906005106
   Liu XH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-348
   McMullin RP, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3625
   Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841
   Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489
   Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266
   Olopade OI, 2008, CLIN CANCER RES, V14, P7988, DOI 10.1158/1078-0432.CCR-08-1211
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Price C, 2014, GENES DIS, V1, P53, DOI 10.1016/j.gendis.2014.06.004
   Rothschild Sacha I, 2014, Mol Cell Ther, V2, P7
   Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976
   Rytelewski M, 2014, MOL ONCOL, V8, P1429, DOI 10.1016/j.molonc.2014.05.017
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Wang ZR, 2015, AM J CANCER RES, V5, P87
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 49
TC 103
Z9 119
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 25
PY 2016
VL 16
AR 160
DI 10.1186/s12885-016-2108-5
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DF9FR
UT WOS:000371666900006
PM 26917489
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhang, HT
   Zeng, LF
   He, QY
   Tao, WA
   Zha, ZG
   Hu, CD
AF Zhang, Huan-Tian
   Zeng, Ling-Fei
   He, Qing-Yu
   Tao, W. Andy
   Zha, Zhen-Gang
   Hu, Chang-Deng
TI The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal
   degradation of PRMT5
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE CHIP; E3 ubiquitin ligase; PRMT5; Ubiquitination; Chaperone; Prostate
   cancer
ID ARGININE METHYLTRANSFERASE 5; PHASE-II TRIAL; TUMOR-SUPPRESSOR;
   NEUROENDOCRINE DIFFERENTIATION; PROTEIN-DEGRADATION; BREAST-CANCER;
   CELL-GROWTH; CHAPERONE; METHYLATION; EXPRESSION
AB Protein arginine methyltransferase 5 (PRMT5) is an important member of the protein arginine methyltransferase family that regulates many cellular processes through epigenetic control of target gene expression. Because of its overexpression in a number of human cancers and its essential role in cell proliferation, transformation, and cell cycle progression, PRMT5 has been recently proposed to function as an oncoprotein in cancer cells. However, how its expression is regulated in cancer cells remains largely unknown. We have previously demonstrated that the transcription of PRMT5 can be negatively regulated by the PKC/c-Fos signaling pathway through modulating the transcription factor NF-Y in prostate cancer cells. In the present study, we demonstrated that PRMT5 undergoes polyubiquitination, possibly through multiple lysine residues. We also identified carboxyl terminus of heat shock cognate 70-interacting protein (CHIP), an important chaperone-dependent E3 ubiquitin ligase that couples protein folding/refolding to protein degradation, as an interacting protein of PRMT5 via mass spectrometry. Their interaction was further verified by co-immuoprecipitation, GST pull-down, and bimolecular fluorescence complementation (BiFC) assay. In addition, we provided evidence that the CHIP/chaperone system is essential for the negative regulation of PRMT5 expression via K48-linked ubiquitin-dependent proteasomal degradation. Given that down-regulation of CHIP and overexpression of PRMT5 have been observed in several human cancers, our finding suggests that down-regulation of CHIP may be one of the mechanisms underlying PRMT5 overexpression in these cancers. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Huan-Tian; Zha, Zhen-Gang; Hu, Chang-Deng] Jinan Univ, Inst Orthoped Dis, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
   [Zhang, Huan-Tian; Zha, Zhen-Gang; Hu, Chang-Deng] Jinan Univ, Dept Orthoped, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
   [Zhang, Huan-Tian; Zeng, Ling-Fei; Tao, W. Andy; Hu, Chang-Deng] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.
   [Zhang, Huan-Tian; Zeng, Ling-Fei; Tao, W. Andy; Hu, Chang-Deng] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.
   [Zeng, Ling-Fei; Tao, W. Andy] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.
   [He, Qing-Yu] Jinan Univ, Key Lab Funct Prot Res, Guangdong Higher Educ Inst, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Jinan University; Purdue University System; Purdue
   University; Purdue University System; Purdue University; Purdue
   University System; Purdue University; Jinan University
RP Zha, ZG (通讯作者)，Jinan Univ, Inst Orthoped Dis, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.; Hu, CD (通讯作者)，Jinan Univ, Dept Orthoped, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
EM zhzgg@vip.163.com; hu1@purdue.edu
RI Tao, Andy/N-1290-2019; He, Qing-Yu/H-7078-2014
OI He, Qing-Yu/0000-0003-0503-9492
FU China Scholarship Council; Jinan University; Institute of Orthopedic
   Diseases of Jinan University; U.S. Army Medical Research Acquisition
   Activity, Prostate Cancer Research Program [PC11190, PC120512]; Purdue
   University Center for Cancer Research Small Grants; NCI CCSG [CA23168]
FX We thank members of the Hu lab for helpful suggestions and discussions.
   Huan-Tian Zhang was supported by a scholarship from China Scholarship
   Council and a graduate fellowship from Jinan University and Institute of
   Orthopedic Diseases of Jinan University for his study in the Hu lab at
   Purdue University. This study was partially supported by grants from
   U.S. Army Medical Research Acquisition Activity, Prostate Cancer
   Research Program (PC11190 and PC120512), and Purdue University Center
   for Cancer Research Small Grants. DNA sequencing was conducted in the
   Purdue University Center for Cancer Research Genomic Core Facility
   supported by NCI CCSG CA23168 to Purdue University Center for Cancer
   Research.
CR ALI SA, 1995, BIOTECHNIQUES, V18, P746
   Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452
   Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200
   Chen ZB, 2015, INT J MOL SCI, V16, P4560, DOI 10.3390/ijms16034560
   Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014
   Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17
   Choi JY, 2007, MOL CELL NEUROSCI, V34, P69, DOI 10.1016/j.mcn.2006.10.002
   Cook C, 2012, HUM MOL GENET, V21, P2936, DOI 10.1093/hmg/dds125
   Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008-5472.CAN-08-2229
   Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001
   Gu ZP, 2012, BIOCHEM J, V446, P235, DOI 10.1042/BJ20120768
   Höhfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206
   Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3
   Jan CI, 2011, J PATHOL, V225, P424, DOI 10.1002/path.2921
   Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802
   Jiang BJ, 2015, J BIOL CHEM, V290, P11704, DOI 10.1074/jbc.M114.635086
   Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200
   Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839
   Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001
   Kim JM, 2005, CLIN CANCER RES, V11, P473
   Kirkin V, 2011, CURR OPIN GENET DEV, V21, P21, DOI 10.1016/j.gde.2010.10.004
   Kodama Y, 2012, BIOTECHNIQUES, V53, P285, DOI [10.2144/000113943, 10.2144/0000113943]
   Kodama Y, 2010, BIOTECHNIQUES, V49, P793, DOI 10.2144/000113519
   Koh CM, 2015, NATURE, V523, P96, DOI 10.1038/nature14351
   Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577
   Maloney A, 2007, CANCER RES, V67, P3239, DOI 10.1158/0008-5472.CAN-06-2968
   McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2
   Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072
   Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1
   Pacey S, 2012, INVEST NEW DRUG, V30, P341, DOI 10.1007/s10637-010-9493-4
   Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004
   Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794
   Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144
   Paul I, 2015, INT J BIOCHEM CELL B, V58, P37, DOI 10.1016/j.biocel.2014.10.027
   Paul I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/918183
   Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531
   Powers MA, 2011, CANCER RES, V71, P5579, DOI 10.1158/0008-5472.CAN-11-0458
   Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6
   Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561
   Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043
   Sharp SY, 2007, MOL CANCER THER, V6, P1198, DOI 10.1158/1535-7163.MCT-07-0149
   Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9
   Suarez CD, 2014, AM J CANCER RES, V4, P850
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Tripathi V, 2007, J BIOL CHEM, V282, P28441, DOI 10.1074/jbc.M703698200
   Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08
   Wang PC, 2013, P NATL ACAD SCI USA, V110, P11205, DOI 10.1073/pnas.1308974110
   Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522
   Wang TX, 2014, ONCOTARGET, V5, P1969, DOI 10.18632/oncotarget.1890
   Wang YM, 2014, CARCINOGENESIS, V35, P983, DOI 10.1093/carcin/bgt393
   Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110
   Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885
   Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899
   Yamaguchi H, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00015
   Yang YL, 2009, CANCER SCI, V100, P24, DOI 10.1111/j.1349-7006.2008.01013.x
   Yerlikaya A, 2013, RECENT PAT ANTI-CANC, V8, P298, DOI 10.2174/1574891X113089990033
   Zhang HT, 2014, BBA-GENE REGUL MECH, V1839, P1330, DOI 10.1016/j.bbagrm.2014.09.015
   Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023
   Zhou MJ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0093-6
NR 61
TC 57
Z9 64
U1 1
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 1879-2596
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD FEB
PY 2016
VL 1863
IS 2
BP 335
EP 346
DI 10.1016/j.bbamcr.2015.12.001
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DC1CT
UT WOS:000368955100017
PM 26658161
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Poumpouridou, N
   Acha-Sagredo, A
   Goutas, N
   Vlachodimitropoulos, D
   Chatziioannidou, I
   Lianidou, E
   Liloglou, T
   Kroupis, C
AF Poumpouridou, Nikoleta
   Acha-Sagredo, Amelia
   Goutas, Nikolaos
   Vlachodimitropoulos, Dimitrios
   Chatziioannidou, Ioanna
   Lianidou, Evi
   Liloglou, Triantafyllos
   Kroupis, Christos
TI Development and validation of molecular methodologies to assess
   <i>PALB2</i> expression in sporadic breast cancer
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE PALB2; DNA methylation; Pyrosequencing; RT-qPCR; mRNA expression; Breast
   cancer
ID DNA METHYLATION BIOMARKERS; POLYMERASE-CHAIN-REACTION; SUSCEPTIBILITY
   GENE; OVARIAN-CANCER; PROMOTER HYPERMETHYLATION; STRONG CANDIDATE;
   FAMILY-HISTORY; MESSENGER-RNA; RT-PCR; BRCA1
AB Objectives: Recent reports have included PALB2 (Partner and localizer of BRCA2) in the growing list of hereditary cancer genes. PALB2 mutations confer a moderate breast cancer risk in heterozygotes and Fanconi anemia in biallelic mutation carriers. PALB2 protein co-localizes with BRCA2 and BRCA1 in nuclear structures and enables error-free homologous recombination repair of double-stranded DNA breaks. This important contribution could be severely diminished if affected by epigenetic mechanisms such as promoter CpG island methylation. The aim of our study was to develop molecular methodologies in order to assess accurately PALB2 expression in breast cancer tissues.
   Design and methods: DNA and RNA were extracted from 91 sporadic fresh-frozen breast tissues with known histopathological data. DNA was subjected to sodium bisulfite conversion reaction and the CpG island of the PALB2 promoter was analyzed by pyrosequencing. RNA was converted to cDNA and analyzed by a newly developed and validated RT-qPCR assay based on a hydrolysis probe (TaqMan) in the Light Cycler.
   Results: PALB2 promoter was not methylated in any of the samples tested. 87 out of 91 (95.6%) primary tumors were positive for PALB2 expression, as checked at the mRNA level. When levels of PALB2 mRNA were compared to histopathological data (tumor size, grade, lymph node involvement, metastasis, hormone receptors and HER2 overexpression), no significant statistical correlation was found.
   Conclusions: DNA methylation is an unlike mechanism for PALB2 transcriptional regulation. PALB2 mRNA expression does not seem be a promising prognostic biomarker for sporadic breast cancer. (C) 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Poumpouridou, Nikoleta; Chatziioannidou, Ioanna] Univ Athens, Sch Med, Attikon Univ Gen Hosp, Dept Clin Biochem, Haidari 12462, Greece.
   [Acha-Sagredo, Amelia; Liloglou, Triantafyllos] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L3 9TA, Merseyside, England.
   [Goutas, Nikolaos; Vlachodimitropoulos, Dimitrios] Univ Athens, Sch Med, Evgenidio Hosp, Anat Pathol Lab, Athens 15128, Greece.
   [Lianidou, Evi; Kroupis, Christos] Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
C3 University Hospital Attikon; National & Kapodistrian University of
   Athens; University of Liverpool; National & Kapodistrian University of
   Athens; Athens Medical School; National & Kapodistrian University of
   Athens
RP Kroupis, C (通讯作者)，Univ Athens, Sch Med, Attikon Univ Gen Hosp, 1 Rimini St, Haidari 12462, Greece.
EM ckroupis@med.uoa.gr
RI Liloglou, Triantafillos/KTI-2202-2024; Acha-Sagredo,
   Amelia/AAE-5699-2020; Kroupis, Christos/K-2725-2013
OI Acha-Sagredo, Amelia/0000-0001-8265-8604; Kroupis,
   Christos/0000-0002-5876-2599; Lianidou, Evi/0000-0002-7796-5914;
   Vlachodimitropoulos, Dimitris/0000-0002-8720-9960; Liloglou,
   Triantafillos/0000-0003-0460-1404
FU European Social fund [NSRF HRAKLEITOS 70/3/10973]
FX This work was supported from Grant NSRF HRAKLEITOS 70/3/10973 from the
   European Social fund 2007-2013.
CR Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Buisson R, 2013, M S-MED SCI, V29, P301, DOI 10.1051/medsci/2013293017
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958
   Couch FJ, 2015, J CLIN ONCOL, V33, P304, DOI 10.1200/JCO.2014.57.1414
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Hellebrand H, 2011, HUM MUTAT, V32, pE2176, DOI 10.1002/humu.21478
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Janatova M, 2013, CANCER EPIDEM BIOMAR, V22, P2323, DOI 10.1158/1055-9965.EPI-13-0745-T
   Kroupis C, 2005, CLIN BIOCHEM, V38, P50, DOI 10.1016/j.clinbiochem.2004.09.012
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Livingston DM, 2009, SCIENCE, V324, P602, DOI 10.1126/science.1174839
   Markopoulou S, 2012, CLIN CHEM LAB MED, V50, P1723, DOI 10.1515/cclm-2012-0124
   Melichar B, 2012, CLIN CHEM LAB MED, V50, P1699, DOI 10.1515/cclm-2012-0495
   Mikeska T, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-26
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126
   Pavlidou A, 2014, CLIN BREAST CANCER, V14, P122, DOI 10.1016/j.clbc.2013.10.012
   Potapova A, 2008, CANCER RES, V68, P998, DOI 10.1158/0008-5472.CAN-07-2418
   Poumpouridou N, 2012, CLIN CHEM LAB MED, V50, P423, DOI 10.1515/cclm-2011-0840
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Southey MC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2796
   Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106
   Tischkowitz M, 2007, P NATL ACAD SCI USA, V104, P6788, DOI 10.1073/pnas.0701724104
   Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022
NR 37
TC 5
Z9 5
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD FEB
PY 2016
VL 49
IS 3
BP 253
EP 259
DI 10.1016/j.clinbiochem.2015.10.009
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA DC3XN
UT WOS:000369153100011
PM 26526077
DA 2025-01-12
ER

PT J
AU Ward, AK
   Mellor, P
   Smith, SE
   Kendall, S
   Just, NA
   Vizeacoumar, FS
   Sarker, S
   Phillips, Z
   Alvi, R
   Saxena, A
   Vizeacoumar, FJ
   Carlsen, SA
   Anderson, DH
AF Ward, Alison K.
   Mellor, Paul
   Smith, Shari E.
   Kendall, Stephanie
   Just, Natasha A.
   Vizeacoumar, Frederick S.
   Sarker, Sabuj
   Phillips, Zoe
   Alvi, Riaz
   Saxena, Anurag
   Vizeacoumar, Franco J.
   Carlsen, Svein A.
   Anderson, Deborah H.
TI Epigenetic silencing of CREB3L1 by DNA methylation is associated with
   high-grade metastatic breast cancers with poor prognosis and is
   prevalent in triple negative breast cancers
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Prognostic marker; Triple negative breast cancer; CREB3L1; DNA
   methylation; Unfolded protein response
ID UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR; TRICHOSTATIN-A; OASIS;
   LONG; GENE; ACTIVATION; MECHANISMS; RESISTANCE; EXPRESSION
AB Background: CREB3L1 (cAMP-responsive element-binding protein 3-like protein 1), a member of the unfolded protein response, has recently been identified as a metastasis suppressor in both breast and bladder cancer.
   Methods: Quantitative real time PCR (qPCR) and immunoblotting were used to determine the impact of histone deacetylation and DNA methylation inhibitors on CREB3L1 expression in breast cancer cell lines. Breast cancer cell lines and tumor samples were analyzed similarly, and CREB3L1 gene methylation was determined using sodium bisulfite conversion and DNA sequencing. Immunohistochemistry was used to determine nuclear versus cytoplasmic CREB3L1 protein. Large breast cancer database analyses were carried out to examine relationships between CREB3L1 gene methylation and mRNA expression in addition to CREB3L1 mRNA expression and prognosis.
   Results: This study demonstrates that the low CREB3L1 expression previously seen in highly metastatic breast cancer cell lines is caused in part by epigenetic silencing. Treatment of several highly metastatic breast cancer cell lines that had low CREB3L1 expression with DNA methyltransferase and histone deacetylase inhibitors induced expression of CREB3L1, both mRNA and protein. In human breast tumors, CREB3L1 mRNA expression was upregulated in low and medium-grade tumors, most frequently of the luminal and HER2 amplified subtypes. In contrast, CREB3L1 expression was repressed in high-grade tumors, and its loss was most frequently associated with triple negative breast cancers (TNBCs). Importantly, bioinformatics analyses of tumor databases support these findings, with methylation of the CREB3L1 gene associated with TNBCs, and strongly negatively correlated with CREB3L1 mRNA expression. Decreased CREB3L1 mRNA expression was associated with increased tumor grade and reduced progression-free survival. An immunohistochemistry analysis revealed that low-grade breast tumors frequently had nuclear CREB3L1 protein, in contrast to the high-grade breast tumors in which CREB3L1 was cytoplasmic, suggesting that differential localization may also regulate CREB3L1 effectiveness in metastasis suppression.
   Conclusions: Our data further strengthens the role for CREB3L1 as a metastasis suppressor in breast cancer and demonstrates that epigenetic silencing is a major regulator of the loss of CREB3L1 expression. We also highlight that CREB3L1 expression is frequently altered in many cancer types suggesting that it could have a broader role in cancer progression and metastasis.
C1 [Ward, Alison K.; Mellor, Paul; Smith, Shari E.; Kendall, Stephanie; Just, Natasha A.; Vizeacoumar, Frederick S.; Vizeacoumar, Franco J.; Anderson, Deborah H.] Univ Saskatchewan, Canc Res Grp, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
   [Sarker, Sabuj; Phillips, Zoe; Alvi, Riaz] Saskatchewan Canc Agcy, Epidemiol & Performance Measurement, 4-2105 8th St, Saskatoon, SK S7H 0T8, Canada.
   [Saxena, Anurag] Royal Univ Hosp, Dept Pathol & Lab Med, 2841-103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.
   [Vizeacoumar, Franco J.; Carlsen, Svein A.; Anderson, Deborah H.] Saskatchewan Canc Agcy, Canc Res, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
C3 University of Saskatchewan; University of Saskatchewan; University of
   Saskatchewan; University of Saskatchewan
RP Anderson, DH (通讯作者)，Univ Saskatchewan, Canc Res Grp, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.; Anderson, DH (通讯作者)，Saskatchewan Canc Agcy, Canc Res, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
EM deborah.anderson@saskcancer.ca
RI Vizeacoumar, Franco/GLS-7161-2022
OI Vizeacoumar, Frederick Sagayaraj/0000-0002-4676-2911
FU Saskatchewan Cancer Agency; Saskatchewan Health Research Foundation;
   Canadian Institutes of Health Research [MOP-137154]
FX We thank J. Rideout for technical assistance. We are grateful to the
   Manitoba Tumor Bank for supplying the patient samples, and to the
   patients for providing them. AKW was supported by a postdoctoral
   fellowship from the Saskatchewan Cancer Agency. PM and SES were each
   supported by a postdoctoral fellowship from the Saskatchewan Health
   Research Foundation. The Saskatchewan Cancer Agency and the Canadian
   Institutes of Health Research (MOP-137154) provided funding for the
   project.
CR Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-8
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780
   Barbashina V, 2013, HUM PATHOL, V44, P1577, DOI 10.1016/j.humpath.2013.01.003
   Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777
   Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153
   Brisotto G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1646-6
   Canada BCSo, 2015, TYP BREAST CANC
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119
   Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479
   Denard B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129233
   Denard B, 2012, ELIFE, V1, DOI 10.7554/eLife.00090
   Denard B, 2011, CELL HOST MICROBE, V10, P65, DOI 10.1016/j.chom.2011.06.006
   Diab SG, 1999, J CLIN ONCOL, V17, P1442, DOI 10.1200/JCO.1999.17.5.1442
   Doma MK, 2007, CELL, V131, P660, DOI 10.1016/j.cell.2007.10.041
   Dong DZ, 2005, CANCER RES, V65, P5785, DOI 10.1158/0008-5472.CAN-05-0754
   Dufey E, 2014, AM J PHYSIOL-CELL PH, V307, pC582, DOI 10.1152/ajpcell.00258.2014
   Elston C W, 2002, Histopathology, V41, P154
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gencheva M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-79
   Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Honma Y, 1999, MOL BRAIN RES, V69, P93, DOI 10.1016/S0169-328X(99)00102-3
   Huang JT, 2015, CLIN CHEM, V61, P290, DOI 10.1373/clinchem.2014.230227
   Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kobayashi H, 2012, METHODS MOL BIOL, V825, P223, DOI 10.1007/978-1-61779-436-0_17
   Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213
   Kondo S, 2012, CELL DEATH DIFFER, V19, P1939, DOI 10.1038/cdd.2012.77
   Li Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep07097
   Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Mazaika E, 2014, CURR PROTOC HUM GENE, V82
   Mellor P, 2013, MOL CELL BIOL, V33, P4985, DOI 10.1128/MCB.00959-13
   Morimoto M, 2015, PEDIATR RES, V78, P609, DOI 10.1038/pr.2015.156
   Murakami T, 2006, J NEUROCHEM, V96, P1090, DOI 10.1111/j.1471-4159.2005.03596.x
   Newsham IF, 1998, AM J PATHOL, V153, P5, DOI 10.1016/S0002-9440(10)65538-1
   Notte A, 2015, INT J BIOCHEM CELL B, V62, P1, DOI 10.1016/j.biocel.2015.02.010
   Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204
   Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055
   Pérez-Ortín JE, 2012, BBA-GENE REGUL MECH, V1819, P604, DOI 10.1016/j.bbagrm.2011.12.002
   PW, 2012, PW SPEARM RANK CORR
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Roller C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00010
   Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606
   Rose M, 2014, EPIGENETICS-US, V9, P1626, DOI 10.4161/15592294.2014.988052
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Scriven P, 2007, J MOL MED, V85, P331, DOI 10.1007/s00109-006-0150-5
   Sekhavat A, 2007, BIOCHEM CELL BIOL, V85, P751, DOI 10.1139/O07-145
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   So A, 2009, CANCER METAST REV, V28, P219, DOI 10.1007/s10555-008-9180-5
   Society AC, 2015, TYP BREAST CANC
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Toikkanen S, 1997, BRIT J CANCER, V76, P1234, DOI 10.1038/bjc.1997.540
   Tozlu S, 2006, ENDOCR-RELAT CANCER, V13, P1109, DOI 10.1677/erc.1.01120
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131
   Wasif N, 2010, ANN SURG ONCOL, V17, P1862, DOI 10.1245/s10434-010-0953-z
   Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200
NR 63
TC 47
Z9 50
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD JAN 25
PY 2016
VL 18
AR 12
DI 10.1186/s13058-016-0672-x
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DC0CE
UT WOS:000368883700001
PM 26810754
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kosumi, K
   Baba, Y
   Sakamoto, A
   Ishimoto, T
   Harada, K
   Nakamura, K
   Kurashige, J
   Hiyoshi, Y
   Iwatsuki, M
   Iwagami, S
   Sakamoto, Y
   Miyamoto, Y
   Yoshida, N
   Oki, E
   Watanabe, M
   Hino, S
   Nakao, M
   Baba, H
AF Kosumi, Keisuke
   Baba, Yoshifumi
   Sakamoto, Akihisa
   Ishimoto, Takatsugu
   Harada, Kazuto
   Nakamura, Kenichi
   Kurashige, Junji
   Hiyoshi, Yukiharu
   Iwatsuki, Masaaki
   Iwagami, Shiro
   Sakamoto, Yasuo
   Miyamoto, Yuji
   Yoshida, Naoya
   Oki, Eiji
   Watanabe, Masayuki
   Hino, Shinjiro
   Nakao, Mitsuyoshi
   Baba, Hideo
TI Lysine-specific demethylase-1 contributes to malignant behavior by
   regulation of invasive activity and metabolic shift in esophageal cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE lysine-specific demethylase-1; Warburg effect; esophageal cancer;
   metabolic shift; invasive activity
ID SQUAMOUS-CELL CARCINOMA; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER;
   GENE-EXPRESSION; BREAST-CANCER; 1 LSD1; INHIBITORS; PHOSPHORYLATION;
   METASTASIS; RECURRENCE
AB Lysine-specific demethylase-1 (LSD1) removes the methyl groups from mono-and di-methylated lysine 4 of histone H3. Previous studies have linked LSD1 to malignancy in several human tumors, and LSD1 is considered to epigenetically regulate the energy metabolism genes in adipocytes and hepatocellular carcinoma. This study investigates the function of LSD1 in the invasive activity and the metabolism of esophageal cancer cells. We investigated whether LSD1 immunohistochemical expression levels are related to clinical and pathological features, including the maximum standard uptake value in fluorodeoxyglucose positron emission tomography assay. The influence of LSD1 on cell proliferation, invasion and glucose uptake was evaluated in vitro by using specific small interfering RNA for LSD1, and an LSD1 inhibitor. We also evaluated two major energy pathways (glycolytic pathway and mitochondrial respiration) by measuring the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) with an extracellular flux analyzer. High LSD1 immunohistochemical expression was significantly associated with high tumor stage, lymphovascular invasion, poor prognosis, and high maximum standard uptake value in esophageal cancer patients. In the in vitro analysis, LSD1 knockdown significantly suppressed the invasive activity and glucose uptake of cancerous cells, reduced their ECAR and increased their OCR and OCR/ECAR. LSD1 may contribute to malignant behavior by regulating the invasive activity and metabolism, activating the glycolytic pathway and inhibiting the mitochondrial respiration of esophageal cancer cells. The results support LSD1 as a potential therapeutic target.
C1 [Kosumi, Keisuke; Baba, Yoshifumi; Ishimoto, Takatsugu; Harada, Kazuto; Nakamura, Kenichi; Kurashige, Junji; Hiyoshi, Yukiharu; Iwatsuki, Masaaki; Iwagami, Shiro; Sakamoto, Yasuo; Miyamoto, Yuji; Yoshida, Naoya; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto, Japan.
   [Sakamoto, Akihisa; Hino, Shinjiro; Nakao, Mitsuyoshi] Kumamoto Univ, Dept Med Cell Biol, Inst Mol Embryol & Genet, Kumamoto, Japan.
   [Oki, Eiji] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan.
   [Watanabe, Masayuki] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan.
C3 Kumamoto University; Kumamoto University; Kyushu University; Japanese
   Foundation for Cancer Research
RP Baba, H (通讯作者)，Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM hdobaba@kumamoto-u.ac.jp
RI Oki, Eiji/AFO-6423-2022; Ishimoto, Takatsugu/AAP-1356-2020
OI Miyamoto, Yuji/0000-0003-3948-5044
FU Japan Society for the Promotion of Science (JSPS) [26713042];
   Grants-in-Aid for Scientific Research [26713042, 15K10122, 25430178,
   15K15068, 15H04707] Funding Source: KAKEN
FX Grant sponsor: Grant-in-Aid for Scientific Research from the Japan
   Society for the Promotion of Science (JSPS); Grant number: 26713042
CR Allum WH, 2009, J CLIN ONCOL, V27, P5062, DOI 10.1200/JCO.2009.22.2083
   Bando H, 2005, CLIN CANCER RES, V11, P5784, DOI 10.1158/1078-0432.CCR-05-0149
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Ding J, 2013, DIGEST DIS SCI, V58, P1581, DOI 10.1007/s10620-012-2552-2
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739
   Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119
   Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805
   Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Hino S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1755
   Hiyoshi Y, 2009, CLIN CANCER RES, V15, P1915, DOI 10.1158/1078-0432.CCR-08-2545
   Huang ZB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075007, 10.1371/journal.pone.0070077]
   Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Karashima R, 2015, SURG TODAY, V45, P471, DOI 10.1007/s00595-014-0965-6
   Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237
   Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839
   Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299
   Okabe H, 2011, ANN SURG ONCOL, V18, P1175, DOI 10.1245/s10434-010-1391-7
   Ouyang HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062192
   Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013
   Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1
   Rizk NP, 2010, ANN SURG, V251, P46, DOI 10.1097/SLA.0b013e3181b2f6ee
   Sakamoto A, 2015, CANCER RES, V75, P1445, DOI 10.1158/0008-5472.CAN-14-1560
   Sawayama H, 2014, ANN SURG ONCOL, V21, P1756, DOI 10.1245/s10434-013-3371-1
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Schreurs LMA, 2014, ANN SURG ONCOL, V21, P3751, DOI 10.1245/s10434-014-3848-6
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Singh MM, 2011, NEURO-ONCOLOGY, V13, P894, DOI 10.1093/neuonc/nor049
   Sohda M, 2010, ANN SURG ONCOL, V17, P3181, DOI 10.1245/s10434-010-1177-y
   Thallinger CMR, 2011, J CLIN ONCOL, V29, P4709, DOI 10.1200/JCO.2011.36.7599
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   WICK AN, 1957, J BIOL CHEM, V224, P963
   Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480
   Yao F, 2013, TUMOR BIOL, V34, P25, DOI 10.1007/s13277-012-0506-0
   Yasuda T, 2012, ANN SURG ONCOL, V19, P652, DOI 10.1245/s10434-011-1928-4
   Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018
   Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x
   Zhao ZK, 2012, WORLD J GASTROENTERO, V18, P6651, DOI 10.3748/wjg.v18.i45.6651
NR 50
TC 25
Z9 27
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 15
PY 2016
VL 138
IS 2
BP 428
EP 439
DI 10.1002/ijc.29714
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DC4AF
UT WOS:000369161200018
PM 26240060
OA Bronze
DA 2025-01-12
ER

PT J
AU Kato, Y
   Egusa, C
   Maeda, T
   Tsuboi, R
AF Kato, Yukihiko
   Egusa, Chizu
   Maeda, Tatsuo
   Tsuboi, Ryoji
TI Combination of retinoid and histone deacetylase inhibitor produced an
   anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor
   suppressor gene, retinoic acid receptorβ2, via histone acetylation
SO JOURNAL OF DERMATOLOGICAL SCIENCE
LA English
DT Article
DE Retinoic acid receptor; Cutaneous T cell lymphoma; Histone acetylation;
   DNA methylation
ID BREAST-CANCER; LUNG-CANCER; DIFFERENTIAL EXPRESSION; DNA METHYLATION;
   DOWN-REGULATION; UP-REGULATION; BETA GENE; GROWTH; PROMOTER;
   INACTIVATION
AB Background: Retinoids exert anti-proliferative, differentiative, and apoptosis-inducing effects through their receptors. Retinoic acid receptor (RAR) beta 2 behaves as a tumor suppressor gene, and its expression is suppressible by DNA methylation in many malignancies.
   Objective: We aimed to determine whether combining a retinoid, Am 80, with a histone deacetylase inhibitor, MS-275, could suppress tumor growth in a RAR beta 2-negative human cutaneous T cell lymphoma (CTCL) cell lines and freshly isolated primary CTCL cells, and to elucidate the epigenetic mechanism behind the phenomena.
   Methods: SeAx cells were implanted subcutaneously in NOD-SCID mice which were randomly divided into four groups and treated with either Am80, MS-275 by oral gavage (five days/week), or a combination of the two agents. Cell proliferation assay, methylation-specific PCR, flow cytometric analysis of cell cycle and apoptosis and chromatin immunoprecipitation assay were employed.
   Results: Quantitative PCR analysis revealed that RAR beta 2 gene expression was restored only by this combination rather than by either of the agents singly. Restored retinoid sensitivity was observed in combining retinoid with a histone deacetylase inhibitor significantly inhibited cell growth in vitro, suppressed subcutaneously transplanted tumor growth, and prolonged survival of tumor-bearing mice in vivo by more strongly inducing apoptosis and p21 expression in CTCL cells than either agent alone. In the combination treatment, the histone H4 acetylation level at lysine 12 and 16 in the promoter region increased after restoration of RAR beta 2 expression although the DNA methylation of RAR beta 2 remained unchanged.
   Conclusion: This is the first report of histone acetylation as the primary event in the restoration of RAR beta 2. Inducible RAR beta 2 expression may serve as a reliable predictor for tumor response in patients undergoing 'epigenetic & differentiation' therapy. (C) 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Kato, Yukihiko; Egusa, Chizu; Maeda, Tatsuo; Tsuboi, Ryoji] Tokyo Med Univ, Dept Dermatol, Tokyo 1600023, Japan.
   [Kato, Yukihiko] Tokyo Metropolitan Tama Med Ctr, Dept Dermatol, Fuchu, Tokyo 1838524, Japan.
C3 Tokyo Medical University
RP Kato, Y (通讯作者)，Tokyo Med Univ, Dept Dermatol, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.
EM y-kato@tokyo-med.ac.jp
FU Private University Strategic Research Based Support Project Epigenetics:
   A research project aimed at a general cancer cure using epigenetic
   targets [S0801020]; Japan Society for the Promotion of Science [24 591
   636]; Clinical Research Fund of the Tokyo Metropolitan Government
   [H25050201, H26050101]
FX This research was partially funded by the Private University Strategic
   Research Based Support Project Epigenetics: A research project aimed at
   a general cancer cure using epigenetic targets. (S0801020), Grant-in-Aid
   for Scientific Research (C) by Japan Society for the Promotion of
   Science (24 591 636) and the Clinical Research Fund of the Tokyo
   Metropolitan Government (H25050201 and H26050101).
CR Alexander J.M., 2014, NEUROSCIENCE
   Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Arulogun SO, 2008, BLOOD, V112, P3082, DOI 10.1182/blood-2008-05-154609
   Botchkarev VA, 2012, J INVEST DERMATOL, V132, P2505, DOI 10.1038/jid.2012.182
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x
   Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199
   Dummer R, 2012, LEUKEMIA LYMPHOMA, V53, P1501, DOI 10.3109/10428194.2012.656625
   Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614
   Gao T., 2013, PLOS ONE, V2950
   Hoffman AD, 1996, CLIN CANCER RES, V2, P1077
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   HU L, 1991, CANCER RES, V51, P3972
   Lee MO, 2000, BIOCHEM PHARMACOL, V59, P485, DOI 10.1016/S0006-2952(99)00355-X
   Lee SM, 2010, CANCER GENET CYTOGEN, V197, P39, DOI 10.1016/j.cancergencyto.2009.10.008
   Lippman SM, 1997, CANCER CHEMOTHER BIO, V17, P349
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164
   Moison C, 2013, FASEB J, V27, P1468, DOI 10.1096/fj.12-210971
   Muratake H, 2013, CHEM PHARM BULL, V61, P846, DOI 10.1248/cpb.c13-00356
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Park SH, 2011, CANCER LETT, V310, P232, DOI 10.1016/j.canlet.2011.07.009
   Ponomaryova AA, 2011, EUR J CANCER PREV, V20, P453, DOI 10.1097/CEJ.0b013e3283498eb4
   Qian DZ, 2007, PROSTATE, V67, P1182, DOI 10.1002/pros.20611
   Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540
   Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Wang XF, 2005, CLIN CANCER RES, V11, P3535, DOI 10.1158/1078-0432.CCR-04-1092
   Wang YM, 2003, CLIN CANCER RES, V9, P5257
   Wang ZB, 2009, CURR OPIN GENET DEV, V19, P127, DOI 10.1016/j.gde.2009.02.001
   Whittaker SJ, 2003, BRIT J DERMATOL, V149, P1095, DOI 10.1111/j.1365-2133.2003.05698.x
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624
   Xu XC, 1997, CANCER RES, V57, P4992
   XU XC, 1994, CANCER RES, V54, P3580
NR 42
TC 9
Z9 10
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0923-1811
EI 1873-569X
J9 J DERMATOL SCI
JI J. Dermatol. Sci.
PD JAN
PY 2016
VL 81
IS 1
BP 17
EP 25
DI 10.1016/j.jdermsci.2015.10.016
PG 9
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA DB4GH
UT WOS:000368471000003
PM 26596218
DA 2025-01-12
ER

PT J
AU Denis, H
   Van Grembergen, O
   Delatte, B
   Dedeurwaerder, S
   Putmans, P
   Calonne, E
   Rothé, F
   Sotiriou, C
   Fuks, F
   Deplus, R
AF Denis, Helene
   Van Grembergen, Olivier
   Delatte, Benjamin
   Dedeurwaerder, Sarah
   Putmans, Pascale
   Calonne, Emilie
   Rothe, Francoise
   Sotiriou, Christos
   Fuks, Francois
   Deplus, Rachel
TI MicroRNAs regulate KDM5 histone demethylases in breast cancer cells
SO MOLECULAR BIOSYSTEMS
LA English
DT Article
ID EPIGENETIC REGULATION; TUMOR INVASION; GASTRIC-CANCER; MAMMARY-GLAND;
   STEM-CELLS; PROLIFERATION; GENE; EXPRESSION; METASTASIS; PLU-1
AB MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Alteration of miRNA levels is common in tumors and contributes to the pathogenesis of human malignancies. In the present study we examined the role played by miR-137 in breast tumorigenesis. We found miR-137 levels to be lower in breast cancer cells than in their non-tumorigenic counterparts and observed reduced proliferation and migration of breast cancer cells overexpressing miR-137. We further identified KDM5B, a histone demethylase known to be involved in breast cancer tumorigenesis, as a target of miR-137. As the involvement of histone demethylases in cancer is still poorly understood and as the role of miRNAs in controlling epigenetic mechanisms in cancer is emerging, we broadened our study to the whole KDM5 histone demethylase family to see if the genes coding for these epigenetic enzymes might be regulated by miRNAs in cancer cells. We discovered that KDM5C is overexpressed in breast cancer cells, providing evidence that miR-138 regulates its expression. We found miR-138 overexpression to affect breast cancer cell proliferation. Altogether, our findings suggest that miRNAs may regulate KDM5 histone demethylase levels in breast cancer and thereby control breast cancer cell proliferation and migration.
C1 [Denis, Helene; Van Grembergen, Olivier; Delatte, Benjamin; Dedeurwaerder, Sarah; Putmans, Pascale; Calonne, Emilie; Fuks, Francois; Deplus, Rachel] Univ Libre Bruxelles, Fac Med, Lab Canc Epigenet, Brussels, Belgium.
   [Rothe, Francoise; Sotiriou, Christos] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre
   de Bruxelles
RP Deplus, R (通讯作者)，Univ Libre Bruxelles, Fac Med, Lab Canc Epigenet, Brussels, Belgium.
EM rdeplus@ulb.ac.be
RI Deplus, Rachel/LPP-7920-2024; Fuks, Francois/HJY-8201-2023; Delatte,
   Benjamin/AAE-9276-2020
OI Delatte, Benjamin/0000-0002-6798-0600
FU Belgian Fonds National de la Recherche Scientifique; Brussels Region;
   Televie; Innoviris/Brubreast grant; Interuniversity Attraction Poles
   [IUAP P6/28]; Fonds National de la Recherche Scientifique; Plan National
   Cancer; IAP [P7/03]; Belgian Foundation against Cancer; Action de
   Recherche Concertee; Belgian ARC
FX H. D. was supported by the Belgian Fonds National de la Recherche
   Scientifique and the Brussels Region, O. V. G. by the Televie, S. D. by
   the Televie and the Innoviris/Brubreast grant and R. D. by the
   Interuniversity Attraction Poles [IUAP P6/28] and the Televie. B. D. is
   a Research Fellow from the Fonds National de la Recherche Scientifique.
   F. F. is a Professor of the "Universite Libre de Bruxelles''. This work
   was funded by grants from the Fonds National de la Recherche
   Scientifique and Televie, the "Plan National Cancer'', the IAP P7/03, by
   the Brussels Region, by the Belgian Foundation against Cancer and by the
   "Action de Recherche Concertee''. Funding for open access charge:
   Belgian ARC.
CR Amente S, 2015, ONCOTARGET, V6, P14572, DOI 10.18632/oncotarget.3990
   Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912
   Bilynskyj B. T., 2010, Experimental Oncology, V32, P190
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Derfoul A, 2011, CARCINOGENESIS, V32, P1607, DOI 10.1093/carcin/bgr184
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kang N, 2015, LUNG CANCER, V89, P99, DOI 10.1016/j.lungcan.2015.05.011
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Le Quesne J, 2010, MOL ONCOL, V4, P230, DOI 10.1016/j.molonc.2010.04.009
   Lim S, 2010, INT J CANCER, V127, P1991, DOI 10.1002/ijc.25538
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Liu M, 2011, INT J CANCER, V128, P1269, DOI 10.1002/ijc.25452
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martin-Manso G, 2011, ARCH BIOCHEM BIOPHYS, V509, P147, DOI 10.1016/j.abb.2011.03.004
   Mestdagh P, 2010, MOL CELL, V40, P762, DOI 10.1016/j.molcel.2010.11.038
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Steponaitiene R, 2016, MOL CARCINOGEN, V55, P376, DOI 10.1002/mc.22287
   Sun GQ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1532
   Suzuki T, 2013, CANCER SCI, V104, P795, DOI 10.1111/cas.12169
   Tarantino C, 2010, FASEB J, V24, P3255, DOI 10.1096/fj.09-152207
   van Zutven LJCM, 2006, GENE CHROMOSOME CANC, V45, P437, DOI 10.1002/gcc.20308
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wang ZR, 2015, AM J CANCER RES, V5, P87
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
   Zou MR, 2014, J BIOL CHEM, V289, P17620, DOI 10.1074/jbc.M114.570853
NR 55
TC 32
Z9 36
U1 0
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742-206X
EI 1742-2051
J9 MOL BIOSYST
JI Mol. Biosyst.
PY 2016
VL 12
IS 2
BP 404
EP 413
DI 10.1039/c5mb00513b
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DB9TD
UT WOS:000368858900010
PM 26621457
DA 2025-01-12
ER

PT J
AU Choi, SY
   Chen, ZM
   Tang, LH
   Fang, YZ
   Shin, SJ
   Panarelli, NC
   Chen, YT
   Li, Y
   Jiang, XJ
   Du, YCN
AF Choi, Soyoung
   Chen, Zhengming
   Tang, Laura H.
   Fang, Yuanzhang
   Shin, Sandra J.
   Panarelli, Nicole C.
   Chen, Yao-Tseng
   Li, Yi
   Jiang, Xuejun
   Du, Yi-Chieh Nancy
TI Bcl-xL promotes metastasis independent of its anti-apoptotic activity
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BREAST-CANCER CELLS; MOUSE MODEL; FAMILY; BCL-X(L); EXPRESSION; GENE;
   CARCINOMAS; PROTEINS; BAX; OVEREXPRESSION
AB Bcl-xL suppresses mitochondria-mediated apoptosis and is frequently overexpressed in cancer to promote cancer cell survival. Bcl-xL also promotes metastasis. However, it is unclear whether this metastatic function is dependent on its anti-apoptotic activity in the mitochondria. Here we demonstrate that Bcl-xL promotes metastasis independent of its anti-apoptotic activity. We show that apoptosis-defective Bcl-xL mutants and an engineered Bcl-xL targeted to the nucleus promote epithelial-mesenchymal transition, migration, invasion and stemness in pancreatic neuroendocrine tumour (panNET) and breast cancer cell lines. However, Bcl-xL proteins targeted to the mitochondria or outside of the nucleus do not have these functions. We confirm our findings in spontaneous and xenograft mouse models. Furthermore, Bcl-xL exerts metastatic function through epigenetic modification of the TGF beta promoter to increase TGF beta signalling. Consistent with these findings, we detect nuclear Bcl-xL in human metastatic panNETs. Taken together, the metastatic function of Bcl-xL is independent of its anti-apoptotic activity and its residence in the mitochondria.
C1 [Choi, Soyoung; Shin, Sandra J.; Panarelli, Nicole C.; Chen, Yao-Tseng; Du, Yi-Chieh Nancy] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Chen, Zhengming] Weill Cornell Med, Div Biostat & Epidemiol, Dept Healthcare Policy & Res, New York, NY 10065 USA.
   [Tang, Laura H.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
   [Fang, Yuanzhang; Li, Yi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Jiang, Xuejun] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Memorial Sloan Kettering Cancer Center; Baylor College
   of Medicine; Memorial Sloan Kettering Cancer Center
RP Du, YCN (通讯作者)，Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
EM nad2012@med.cornell.edu
RI Fang, Yuanzhang/H-3047-2019; Li, Yilin/JCD-8027-2023; Li, Yi/A-7635-2009
OI Fang, Yuanzhang/0000-0002-6985-9388; Li, Yi/0000-0002-9976-518X; Chen,
   Zhengming/0000-0001-9437-6452
FU DOD [W81XWH-13-1-0331]; NIH [1R21CA173348-01A1, 1R01GM113013, 1R01
   CA166413, UL1TR000457, 1R01CA124820]; Cycle for Survival
FX We thank Bu Jung Kim, Samantha Li, Sharon Pang, Leigh Selesner,
   Stephanie Azzopardi, Megan Wong and Christina Cherny in the Du
   laboratory for technical assistance; Harold Varmus, Jane Lyons and Aihao
   Ding for critical reading of the manuscript; Danny Huang for mouse
   database design and schematic; Diane L. Reidy and David S. Klimtra for
   the assistance on the research using human cancer samples; The
   Translational Research Program, especially Rob Kim, Bing He and Yifang
   Liu; Prashant Monian, Matthew Van Brocklin, Chris Harris, Joan Massague,
   Eileen White, Inna Serganova, Ronald Blasberg, David Andrews and
   Jae-Hyuck Shim for reagents; Ching-Hwa Sung and Juan Mendez for
   protocols; Mark Rubin, Timothy Hla and Ethel Cesarman for equipment and
   encouragement; Steven Merlin and Jason McCormick for cell sorting and
   training on flow cytometry; Sylvain Galvani for training on confocal
   microscope; Katia Manova-Todorova and Sho Fujisawa for imaging analysis;
   and the Weill Cornell Research Animal Resource Center. This work is
   partially supported by DOD grant W81XWH-13-1-0331 (to S.C. and
   Y.-C.N.D.), NIH grants 1R21CA173348-01A1 (to X.J. and Y.-C.N.D.),
   1R01GM113013 (to X.J.), 1R01 CA166413 (to X.J.), UL1TR000457 (to Z.C.)
   and 1R01CA124820 (to Y.L.) and a Cycle for Survival grant (to X.J.).
CR BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615
   Davids MS, 2012, J CLIN ONCOL, V30, P3127, DOI 10.1200/JCO.2011.37.0981
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Du YCN, 2007, PLOS BIOL, V5, P2255, DOI 10.1371/journal.pbio.0050276
   Du YCN, 2011, P NATL ACAD SCI USA, V108, P16753, DOI 10.1073/pnas.1114022108
   Du YCN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006932
   España L, 2004, BREAST CANCER RES TR, V87, P33, DOI 10.1023/B:BREA.0000041579.51902.89
   EVERS BM, 1991, GASTROENTEROLOGY, V101, P303, DOI 10.1016/0016-5085(91)90004-5
   Fernández Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009
   Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208
   Hager JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004455
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardwick JM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008722
   Ho JN, 2010, CANCER SCI, V101, P1417, DOI 10.1111/j.1349-7006.2010.01552.x
   Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Keitel U, 2014, ONCOTARGET, V5, P11778, DOI 10.18632/oncotarget.2634
   Koehler BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076446
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2
   Loftus SK, 2001, DNA RES, V8, P221, DOI 10.1093/dnares/8.5.221
   Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Méndez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000
   Michels Judith, 2013, Int J Cell Biol, V2013, P705294, DOI 10.1155/2013/705294
   Olopade OI, 1997, CANCER J SCI AM, V3, P230
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400
   Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18
   Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5
   Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941
   Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281
   Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090
   Sánchez-Ceja SG, 2006, LUNG CANCER, V54, P163, DOI 10.1016/j.lungcan.2006.07.012
   Schulze-Bergkamen H, 2008, WORLD J GASTROENTERO, V14, P3829, DOI 10.3748/wjg.14.3829
   SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834
   Sharma J, 2005, PANCREAS, V30, P337, DOI 10.1097/01.mpa.0000160282.64451.f1
   Soini Y, 1999, CLIN CANCER RES, V5, P3508
   Tang LH, 2012, CLIN CANCER RES, V18, P4612, DOI 10.1158/1078-0432.CCR-11-3264
   Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516
   Walensky LD, 2012, J CLIN ONCOL, V30, P554, DOI 10.1200/JCO.2011.37.9339
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Weiler M, 2006, CELL DEATH DIFFER, V13, P1156, DOI 10.1038/sj.cdd.4401786
   Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36
   Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002
   Yasmin R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/201703
   YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
NR 57
TC 64
Z9 71
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2016
VL 7
AR 10384
DI 10.1038/ncomms10384
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DC2AI
UT WOS:000369019200003
PM 26785948
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Goozee, KG
   Shah, TM
   Sohrabi, HR
   Rainey-Smith, SR
   Brown, B
   Verdile, G
   Martins, RN
AF Goozee, K. G.
   Shah, T. M.
   Sohrabi, H. R.
   Rainey-Smith, S. R.
   Brown, B.
   Verdile, G.
   Martins, R. N.
TI Examining the potential clinical value of curcumin in the prevention and
   diagnosis of Alzheimer's disease
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Curcumin; Alzheimer's disease; Amyloid; Retinal imaging
ID AMYLOID-BETA-PEPTIDE; BLOOD-BRAIN-BARRIER; SALIVARY ALPHA-AMYLASE;
   BREAST-CANCER CELLS; KAPPA-B ACTIVATION; IN-VITRO; EPIGENETIC
   MECHANISMS; MOUSE MODEL; NEURODEGENERATIVE DISORDERS; NEUROFIBRILLARY
   TANGLES
AB Curcumin derived from turmeric is well documented for its anti-carcinogenic, antioxidant and anti-inflammatory properties. Recent studies show that curcumin also possesses neuroprotective and cognitive-enhancing properties that may help delay or prevent neurodegenerative diseases, including Alzheimer's disease (AD). Currently, clinical diagnosis of AD is onerous, and it is primarily based on the exclusion of other causes of dementia. In addition, phase III clinical trials of potential treatments have mostly failed, leaving disease-modifying interventions elusive. AD can be characterised neuropathologically by the deposition of extracellular amyloid (A) plaques and intracellular accumulation of tau-containing neurofibrillary tangles. Disruptions in A metabolism/clearance contribute to AD pathogenesis. In vitro studies have shown that A metabolism is altered by curcumin, and animal studies report that curcumin may influence brain function and the development of dementia, because of its antioxidant and anti-inflammatory properties, as well as its ability to influence A metabolism. However, clinical studies of curcumin have revealed limited effects to date, most likely because of curcumin's relatively low solubility and bioavailability, and because of selection of cohorts with diagnosed AD, in whom there is already major neuropathology. However, the fresh approach of targeting early AD pathology (by treating healthy, pre-clinical and mild cognitive impairment-stage cohorts) combined with new curcumin formulations that increase bioavailability is renewing optimism concerning curcumin-based therapy. The aim of this paper is to review the current evidence supporting an association between curcumin and modulation of AD pathology, including in vitro and in vivo studies. We also review the use of curcumin in emerging retinal imaging technology, as a fluorochrome for AD diagnostics.
C1 [Goozee, K. G.; Martins, R. N.] McCusker KARVIAH Res Ctr, Sydney, NSW 2154, Australia.
   [Goozee, K. G.; Shah, T. M.; Sohrabi, H. R.; Rainey-Smith, S. R.; Brown, B.; Verdile, G.; Martins, R. N.] Edith Cowan Univ, Ctr Excellence Alzheimers Dis Res & Care, Sch Med Sci, Joondalup, WA 6027, Australia.
   [Shah, T. M.; Sohrabi, H. R.; Rainey-Smith, S. R.; Brown, B.; Verdile, G.; Martins, R. N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA 6009, Australia.
   [Goozee, K. G.; Verdile, G.; Martins, R. N.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Crawley, WA 6009, Australia.
   [Verdile, G.] Curtin Univ, Curtin Hlth Innovat Res Inst Biosci, Sch Biomed Sci, Bentley, WA 6102, Australia.
C3 Edith Cowan University; Hollywood Private Hospital; University of
   Western Australia; University of Western Australia; Curtin University
RP Martins, RN (通讯作者)，McCusker KARVIAH Res Ctr, Sydney, NSW 2154, Australia.; Martins, RN (通讯作者)，Edith Cowan Univ, Ctr Excellence Alzheimers Dis Res & Care, Sch Med Sci, Joondalup, WA 6027, Australia.; Martins, RN (通讯作者)，Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA 6009, Australia.; Martins, RN (通讯作者)，Univ Western Australia, Sch Psychiat & Clin Neurosci, Crawley, WA 6009, Australia.
EM ralph.n.martins@gmail.com
RI ; Sohrabi, Hamid Reza/D-2744-2013; Brown, Belinda/D-1709-2016
OI Martins, Ralph/0000-0002-4828-9363; Verdile,
   Giuseppe/0000-0003-2475-0124; Sohrabi, Hamid Reza/0000-0001-8017-8682;
   Rainey-Smith, Stephanie/0000-0001-7328-9624; Goozee,
   Kathryn/0000-0002-3573-1554; Brown, Belinda/0000-0001-7927-2540; Shah,
   Tejal/0000-0002-3069-3835
FU McCusker Alzheimer's Research Foundation; Anglican Retirement Villages
   (ARV); Foundation for Aged Care; ARV; Co-operative Research Centre for
   Mental Health; Edith Cowan University; Pfizer; Takeda; Curtin University
   Senior Research Fellowship [CRF140196]; NHMRC [APP1045507]
FX The authors gratefully acknowledge the combined support of the McCusker
   Alzheimer's Research Foundation and the Anglican Retirement Villages
   (ARV).K. G. G. is supported by a grant through the Foundation for Aged
   Care, ARV, and a scholarship from the Co-operative Research Centre for
   Mental Health. R. N. M., T. M. S., H. R. S., S. R. R.-S., B. B. and G. V
   are supported by the Edith Cowan University and the McCusker Alzheimer's
   Research Foundation. H. R. S. has received renumeration from Pfizer and
   Takeda. R. N. M. is the founder and chief scientific officer of the
   biotech company, Alzhyme. G. V. is supported by the Curtin University
   Senior Research Fellowship (CRF140196) and the NHMRC (APP1045507).4
CR Agrawal DK, 2010, MED RES REV, V30, P818, DOI 10.1002/med.20188
   Ahmed T, 2010, NEUROSCIENCE, V169, P1296, DOI 10.1016/j.neuroscience.2010.05.078
   Ahmed T, 2009, PHARMACOL BIOCHEM BE, V91, P554, DOI 10.1016/j.pbb.2008.09.010
   Ammon HP, 1991, PLATA MED, V57, P107
   Anand P, 2010, BIOCHEM PHARMACOL, V79, P330, DOI 10.1016/j.bcp.2009.09.003
   Ansari R, 2014, J CLIN NEUROL, V10, P281, DOI 10.3988/jcn.2014.10.4.281
   Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591
   Ataie A, 2010, J MED FOOD, V13, P821, DOI 10.1089/jmf.2009.1278
   Balazs R, 2011, NEUROBIOL AGING, V32, P1181, DOI 10.1016/j.neurobiolaging.2011.02.024
   Banerjee R, 2014, SPECTROCHIM ACTA A, V117, P798, DOI 10.1016/j.saa.2013.09.064
   Basnet P, 2011, MOLECULES, V16, P4567, DOI 10.3390/molecules16064567
   Bates KA, 2009, MOL PSYCHIATR, V14, P469, DOI 10.1038/mp.2008.96
   Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c
   Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455
   Belkacemi A, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002055
   Belviranli M, 2013, BIOGERONTOLOGY, V14, P187, DOI 10.1007/s10522-013-9422-y
   Benny M, 2006, BIOAV BIOC BCM 95
   Bieschke J, 2012, NAT CHEM BIOL, V8, P93, DOI 10.1038/nchembio.719
   Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337
   Bulteau AL, 2006, ANTIOXID REDOX SIGN, V8, P136, DOI 10.1089/ars.2006.8.136
   Caesar I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031424
   Cash DM, 2013, NEUROLOGY, V81, P1425, DOI 10.1212/WNL.0b013e3182a841c6
   Chandra V, 2001, NEUROLOGY, V57, P985, DOI 10.1212/WNL.57.6.985
   Chatterton RT, 1996, CLIN PHYSIOL, V16, P433, DOI 10.1111/j.1475-097X.1996.tb00731.x
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Cheng KK, 2015, BIOMATERIALS, V44, P155, DOI 10.1016/j.biomaterials.2014.12.005
   Cheng KK, 2013, AAPS J, V15, P324, DOI 10.1208/s12248-012-9444-4
   Chételat G, 2012, NEUROLOGY, V78, P477, DOI 10.1212/WNL.0b013e318246d67a
   Chételat G, 2011, BRAIN, V134, P798, DOI 10.1093/brain/awq383
   Chiu SS, 2011, ANTICANCER RES, V31, P907
   Chouliaras L, 2010, PROG NEUROBIOL, V90, P498, DOI 10.1016/j.pneurobio.2010.01.002
   Cole GM, 2007, ADV EXP MED BIOL, V595, P197
   Commandeur JNM, 1996, XENOBIOTICA, V26, P667, DOI 10.3109/00498259609046741
   Cox KHM, 2015, J PSYCHOPHARMACOL, V29, P642, DOI 10.1177/0269881114552744
   Daniilidou M, 2011, CURR MED CHEM, V18, P1751, DOI 10.2174/092986711795496872
   Davinelli S, 2014, J NUTR HEALTH AGING, V18, P800, DOI [10.1007/s12603-014-0520-6, 10.1007/s12603-014-0552-y]
   DiSilvestro RA, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-79
   Dong SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031211
   Du LP, 2012, NUTR CANCER, V64, P1228, DOI 10.1080/01635581.2012.717682
   Faller P, 2012, CHEM-EUR J, V18, P15910, DOI 10.1002/chem.201202697
   Fenech M, 2010, ALZHEIMERS DEMENT, V6, pS70
   Feng D, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-40
   Ferreira ST, 2011, NEUROBIOL LEARN MEM, V96, P529, DOI 10.1016/j.nlm.2011.08.003
   Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304
   Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104
   Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com
   Foster JK, 2009, MOL PSYCHIATR, V14, P239, DOI 10.1038/mp.2008.115
   Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1
   Friedman L, 2009, ANTI-CANCER DRUG, V20, P444, DOI 10.1097/CAD.0b013e32832afc04
   Frost S, 2010, J ALZHEIMERS DIS, V22, P1, DOI 10.3233/JAD-2010-100819
   Frost Shaun., 2014, Alzheimer's Dementia: The Journal of the Alzheimer's Association, V10, P234, DOI [10.1016/j.jalz.2014.04.341, DOI 10.1016/J.JALZ.2014.04, 10.1016/j.jalz.2014.04]
   Fu Z, 2014, BIOCHEMISTRY-US, V53, P7893, DOI 10.1021/bi500910b
   Fux R, 2005, AM J PHYSIOL-RENAL, V289, pF786, DOI 10.1152/ajprenal.00465.2004
   GALLACHER DV, 1983, INT REV PHYSIOL, V28, P1
   Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824
   Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x
   Gauthier S, 2013, ALZHEIMERS DEMENT, V9, P326, DOI 10.1016/j.jalz.2011.11.005
   Gerenu G, 2015, ACS CHEM NEUROSCI, V6, P1393, DOI 10.1021/acschemneuro.5b00082
   Ghalebani L, 2012, BIOCHEM BIOPH RES CO, V421, P554, DOI 10.1016/j.bbrc.2012.04.043
   Ghoneim AI, 2002, PHARMACOL RES, V46, P273, DOI 10.1016/S1043-6618(02)00123-8
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Gupta SC, 2013, BIOFACTORS, V39, P2, DOI 10.1002/biof.1079
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hamaguchi T, 2010, CNS NEUROSCI THER, V16, P285, DOI 10.1111/j.1755-5949.2010.00147.x
   Hanai H, 2009, CURR PHARM DESIGN, V15, P2087, DOI 10.2174/138161209788489177
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hishikawa Nozomi, 2012, Ayu, V33, P499, DOI 10.4103/0974-8520.110524
   Huang HC, 2012, NEUROCHEM RES, V37, P1584, DOI 10.1007/s11064-012-0754-9
   Huang HC, 2009, J ALZHEIMERS DIS, V16, P15, DOI 10.3233/JAD-2009-0960
   Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855
   Ireson C, 2001, CANCER RES, V61, P1058
   Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967
   Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036
   Jackson JK, 2006, INFLAMM RES, V55, P168, DOI 10.1007/s00011-006-0067-z
   Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945
   Jayaraj RL, 2014, CHEM-BIOL INTERACT, V220, P149, DOI 10.1016/j.cbi.2014.06.022
   Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028
   Jiaranaikulwanitch J, 2012, MOLECULES, V17, P8312, DOI 10.3390/molecules17078312
   Joe B, 1997, MOL CELL BIOCHEM, V169, P125, DOI 10.1023/A:1006877928703
   Johnson E., 2007, INT J BIOSTAT, V3
   Kayabasi U, 2014, INT J OPHTHALMOL CLI, V3, P1
   Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S
   Khan MA, 2015, PHARMACEUTICS, V7, P43, DOI 10.3390/pharmaceutics7020043
   Kim DC, 2012, BMB REP, V45, P221, DOI 10.5483/BMBRep.2012.45.4.221
   Kim DSHL, 2001, NEUROSCI LETT, V303, P57, DOI 10.1016/S0304-3940(01)01677-9
   Kim M, 2010, NUTR RES PRACT, V4, P191, DOI 10.4162/nrp.2010.4.3.191
   Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200
   Kochi A, 2015, CURR ALZHEIMER RES, V12, P415
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044
   Krishnaswamy S, 2009, CRIT REV CL LAB SCI, V46, P282, DOI 10.3109/10408360903335821
   Kumar TP, 2011, MOL CELL ENDOCRINOL, V331, P1, DOI 10.1016/j.mce.2010.07.004
   Kurd SK, 2008, J AM ACAD DERMATOL, V58, P625, DOI 10.1016/j.jaad.2007.12.035
   Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121
   Li Y, 2009, J NEUROCHEM, V110, P61
   Li YJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080475, 10.1371/journal.pone.0070390]
   Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001
   Lim TG, 2014, CANCER PREV RES, V7, P466, DOI 10.1158/1940-6207.CAPR-13-0387
   Lin RZ, 2008, NEUROSCI LETT, V440, P344, DOI 10.1016/j.neulet.2008.05.070
   Liu DW, 2013, J BREAST CANCER, V16, P133, DOI 10.4048/jbc.2013.16.2.133
   Liu HY, 2010, NEUROSCI LETT, V485, P83, DOI 10.1016/j.neulet.2010.08.035
   Liu YB, 2008, J NEUROCHEM, V105, P1336, DOI 10.1111/j.1471-4159.2008.05236.x
   Lopresti AL, 2014, J AFFECT DISORDERS, V167, P368, DOI 10.1016/j.jad.2014.06.001
   Ma QL, 2009, J NEUROSCI, V29, P9078, DOI 10.1523/JNEUROSCI.1071-09.2009
   Maher P, 2010, NEUROBIOL AGING, V31, P706, DOI 10.1016/j.neurobiolaging.2008.05.020
   Majeed M., 1996, Turmeric and the healing curcuminoids: Their amazing antioxidant properties and protective powers
   Manczak M, 2010, J ALZHEIMERS DIS, V20, pS609, DOI 10.3233/JAD-2010-100564
   MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x
   Masoumi A, 2009, J ALZHEIMERS DIS, V17, P703, DOI 10.3233/JAD-2009-1080
   MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x
   Mastroeni D, 2011, NEUROBIOL AGING, V32, P1161, DOI 10.1016/j.neurobiolaging.2010.08.017
   Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8
   McClure R, 2015, J ALZHEIMERS DIS, V44, P283, DOI 10.3233/JAD-140798
   McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
   Merina B, 2006, SPICE INDIA, V2, P11
   Milobedzka J, 1910, BER DTSCH CHEM GES, V43, P2163, DOI 10.1002/cber.191004302168
   Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972-2327.40220
   Mithu VS, 2014, J BIOL CHEM, V289, P11122, DOI 10.1074/jbc.M113.519447
   Mizwicki MT, 2012, J ALZHEIMERS DIS, V29, P51, DOI 10.3233/JAD-2012-110560
   Mohorko N, 2010, J NEUROPATH EXP NEUR, V69, P405, DOI 10.1097/NEN.0b013e3181d709eb
   Mutsuga M, 2012, J VET MED SCI, V74, P51, DOI 10.1292/jvms.11-0307
   Ng TP, 2006, AM J EPIDEMIOL, V164, P898, DOI 10.1093/aje/kwj267
   O'Malley TT, 2014, BIOCHEM J, V461, P413, DOI 10.1042/BJ20140219
   Ohno M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00022
   Oliva CA, 2013, AGEING RES REV, V12, P786, DOI 10.1016/j.arr.2013.03.006
   Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025
   Orhan IE, 2013, CURR NEUROPHARMACOL, V11, P379, DOI 10.2174/1570159X11311040003
   Pan CJ, 2006, J CONTROL RELEASE, V116, P42, DOI 10.1016/j.jconrel.2006.08.023
   Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5
   Park SY, 2008, FOOD CHEM TOXICOL, V46, P2881, DOI 10.1016/j.fct.2008.05.030
   Parr C, 2015, FASEB J, V29, P623, DOI 10.1096/fj.14-253211
   Patil R, 2015, MACROMOL BIOSCI, V15, P1212, DOI 10.1002/mabi.201500062
   Peschel D, 2007, J NUTR BIOCHEM, V18, P113, DOI 10.1016/j.jnutbio.2006.03.007
   Pescosolido N, 2014, PLANTA MED, V80, P249, DOI 10.1055/s-0033-1351074
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   Prince M., 2009, Alzheimer's disease international: World Alzheimer's report 2009
   Purro SA, 2012, J NEUROSCI, V32, P3492, DOI 10.1523/JNEUROSCI.4562-11.2012
   Qu TY, 2000, NEUROBIOL AGING, V21, P647, DOI 10.1016/S0197-4580(00)00167-6
   Rachmawati H, 2015, DRUG DEV IND PHARM, V41, P560, DOI 10.3109/03639045.2014.884127
   Rajasekar N, 2013, EUR J PHARMACOL, V715, P381, DOI 10.1016/j.ejphar.2013.04.033
   Re F, 2012, NANOMED-NANOTECHNOL, V8, pS51, DOI 10.1016/j.nano.2012.05.007
   Reddy PH, 2012, BBA-MOL BASIS DIS, V1822, P639, DOI 10.1016/j.bbadis.2011.10.011
   Refolo LM, 2000, NEUROBIOL DIS, V7, P690, DOI 10.1006/nbdi.2000.0366
   Reinke AA, 2007, CHEM BIOL DRUG DES, V70, P206, DOI 10.1111/j.1747-0285.2007.00557.x
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Ringman John M., 2005, Current Alzheimer Research, V2, P131, DOI 10.2174/1567205053585882
   Ringman JM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt146
   Ryu EK, 2006, J MED CHEM, V49, P6111, DOI 10.1021/jm0607193
   Sathya M, 2012, CLIN CHIM ACTA, V414, P171, DOI 10.1016/j.cca.2012.08.013
   Sezgin Z, 2014, NEUROCHEM INT, V78, P105, DOI 10.1016/j.neuint.2014.09.012
   Shahani K, 2010, CANCER RES, V70, P4443, DOI 10.1158/0008-5472.CAN-09-4362
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Shaji S, 2005, BRIT J PSYCHIAT, V186, P136, DOI 10.1192/bjp.186.2.136
   Sharma RA, 2007, ADV EXP MED BIOL, V595, P453
   Shi XL, 2015, NEUROSCI LETT, V594, P105, DOI 10.1016/j.neulet.2015.03.045
   Shimmyo Y, 2008, NEUROREPORT, V19, P1329, DOI 10.1097/WNR.0b013e32830b8ae1
   Soni K. B., 1992, Indian Journal of Physiology and Pharmacology, V36, P273
   Soudamini K. K., 1992, Indian Journal of Physiology and Pharmacology, V36, P239
   SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x
   STOCKERT JC, 1989, Z NATURFORSCH C, V44, P327
   Teiten MH, 2013, MOL NUTR FOOD RES, V57, P1619, DOI 10.1002/mnfr.201300201
   Thangapazham RL, 2007, ADV EXP MED BIOL, V595, P343
   Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042
   Tiwari V, 2013, NEUROSCIENCE, V244, P147, DOI 10.1016/j.neuroscience.2013.03.042
   Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030
   Tsui KH, 2008, J ANDROL, V29, P661, DOI 10.2164/jandrol.108.004911
   Tu YS, 2014, EXP THER MED, V8, P260, DOI 10.3892/etm.2014.1717
   Valera E, 2013, J NEUROSCI, V33, P10512, DOI 10.1523/JNEUROSCI.5183-12.2013
   van Stegeren A, 2006, PSYCHONEUROENDOCRINO, V31, P137, DOI 10.1016/j.psyneuen.2005.05.012
   Vickland V., 2012, MODELLING IMPACT INT
   Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9
   Villemagne VL, 2013, J ALZHEIMERS DIS, V33, pS349, DOI 10.3233/JAD-2012-129034
   Walsh DM, 2012, PROG MOL BIOL TRANSL, V107, P101, DOI 10.1016/B978-0-12-385883-2.00012-6
   Wan WB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/301575
   Wang F, 2006, J FLUORESC, V16, P53, DOI 10.1007/s10895-005-0025-0
   Wang X, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-88
   Wang YF, 2013, J MOL NEUROSCI, V51, P344, DOI 10.1007/s12031-013-9989-4
   Wang YJ, 2009, NEUROTOX RES, V15, P3, DOI 10.1007/s12640-009-9000-x
   Xiao ZJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0101251, 10.1371/journal.pone.0107072]
   Xu YX, 1998, HEMATOPATHOL MOL HEM, V11, P49
   Yanagisawa D, 2015, NEUROBIOL AGING, V36, P201, DOI 10.1016/j.neurobiolaging.2014.07.041
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Zambón D, 2010, AM J MED, V123, P267, DOI 10.1016/j.amjmed.2009.08.015
   Zhang C, 2010, J BIOL CHEM, V285, P28472, DOI 10.1074/jbc.M110.133520
   Zhang L, 2006, J ALZHEIMERS DIS, V10, P1
   Zhang X, 2011, EUR J PHARM SCI, V42, P540, DOI 10.1016/j.ejps.2011.02.009
   ZHAO BL, 1989, CELL BIOPHYS, V14, P175, DOI 10.1007/BF02797132
   Zhao J, 2012, BBA-BIOMEMBRANES, V1818, P3121, DOI 10.1016/j.bbamem.2012.08.012
   Zhou HY, 2011, CURR DRUG TARGETS, V12, P332, DOI 10.2174/138945011794815356
   Zona C, 2011, J LABELLED COMPD RAD, V54, P629, DOI 10.1002/jlcr.1907
NR 191
TC 166
Z9 175
U1 1
U2 136
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD FEB 14
PY 2016
VL 115
IS 3
BP 449
EP 465
DI 10.1017/S0007114515004687
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DH2RF
UT WOS:000372633100009
PM 26652155
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Sciamanna, I
   De Luca, C
   Spadafora, C
AF Sciamanna, Ilaria
   De Luca, Chiara
   Spadafora, Corrado
TI The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the
   Genesis, Progression, and Therapy of Cancer
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE LINE-1 retrotransposons; reverse transcriptase; tumorigenesis;
   differentiation therapy; cancer heterogeneity; epigenetics
ID SOMATIC L1 RETROTRANSPOSITION; DEPENDENT DNA-POLYMERASE; TRANSPOSABLE
   ELEMENTS; NONCODING RNA; CELL-PROLIFERATION; EXPRESSION;
   DIFFERENTIATION; PSEUDOGENES; RETROELEMENTS; LANDSCAPE
AB In higher eukaryotic genomes, Long Interspersed Nuclear Element 1 (LINE-1) retrotransposons represent a large family of repeated genomic elements. They transpose using a reverse transcriptase (RT), which they encode as part of the ORF2p product. RT inhibition in cancer cells, either via RNA interference-dependent silencing of active LINE-1 elements, or using RT inhibitory drugs, reduces cancer cell proliferation, promotes their differentiation and antagonizes tumor progression in animal models. Indeed, the non-nucleoside RT inhibitor efavirenz has recently been tested in a phase II clinical trial with metastatic prostate cancer patients. An in-depth analysis of ORF2p in a mouse model of breast cancer showed ORF2p to be precociously expressed in precancerous lesions and highly abundant in advanced cancer stages, while being barely detectable in normal breast tissue, providing a rationale for the finding that RT-expressing tumors are therapeutically sensitive to RT inhibitors. We summarize mechanistic and gene profiling studies indicating that abundant LINE-1-derived RT can "sequester" RNA substrates for reverse transcription in tumor cells, entailing the formation of RNA:DNA hybrid molecules and impairing the overall production of regulatory miRNAs, with a global impact on the cell transcriptome. Based on these data, LINE-1-ORF2 encoded RT has a tumor-promoting potential that is exerted at an epigenetic level. We propose a model whereby LINE1-RT drives a previously unrecognized global regulatory process, the deregulation of which drives cell transformation and tumorigenesis with possible implications for cancer cell heterogeneity.
C1 [Sciamanna, Ilaria; De Luca, Chiara] Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Spadafora, Corrado] Natl Resarch Council Italy, Inst Translat Pharmacol, Rome, Italy.
C3 Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Farmacologia Traslazionale (IFT-CNR)
RP Spadafora, C (通讯作者)，Natl Resarch Council Italy, Inst Translat Pharmacol, Rome, Italy.
EM cspadaf@tin.it
OI Spadafora, Corrado/0000-0002-5743-3224; Sciamanna,
   Ilaria/0000-0002-5629-6184; De Luca, Chiara/0000-0002-3249-2594
FU Italian Ministry of Health [15ONC/8]
FX Work in our laboratory was supported by the Italian Ministry of Health
   grant n. 15ONC/8 "Endogenous Reverse Transcriptase as a tumor marker and
   causative agent of tumor onset and progression:" to CS.
CR Aalto AP, 2012, CURR OPIN CELL BIOL, V24, P333, DOI 10.1016/j.ceb.2012.03.006
   Aschacher T, 2016, ONCOGENE, V35, P94, DOI 10.1038/onc.2015.65
   Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486
   BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0
   Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802
   Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119
   Belancio VP, 2010, SEMIN CANCER BIOL, V20, P200, DOI 10.1016/j.semcancer.2010.06.001
   Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423
   Böhne A, 2008, CHROMOSOME RES, V16, P203, DOI 10.1007/s10577-007-1202-6
   Borchert Glen M, 2011, Mob Genet Elements, V1, P8
   Bourque G, 2009, CURR OPIN GENET DEV, V19, P607, DOI 10.1016/j.gde.2009.10.013
   Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100
   Callinan P, 2006, GENOME DYN, V1, P104, DOI 10.1159/000092503
   Chen L, 2012, BREAST CANCER RES TR, V136, P129, DOI 10.1007/s10549-012-2246-7
   Chen L, 2012, EPIGENETICS-US, V7, P758, DOI 10.4161/epi.20706
   Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248
   Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18
   Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958
   Dela Cruz F, 2012, ONCOTARGET, V3, P559
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Doucet AJ, 2015, MOL BIOL EVOL, V32, P1815, DOI 10.1093/molbev/msv062
   Doucet-O'Hare TT, 2015, P NATL ACAD SCI USA, V112, pE4894, DOI 10.1073/pnas.1502474112
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Ewing AD, 2015, GENOME RES, V25, P1536, DOI 10.1101/gr.196238.115
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Feschotte C, 2008, NAT REV GENET, V9, P397, DOI 10.1038/nrg2337
   Garcia-Perez JL, 2007, HUM MOL GENET, V16, P1569, DOI 10.1093/hmg/ddm105
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107
   Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022
   Gualtieri A, 2013, ONCOTARGET, V4, P1882, DOI 10.18632/oncotarget.1188
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hagan Christy R, 2002, Am J Pharmacogenomics, V2, P25, DOI 10.2165/00129785-200202010-00003
   Hanahan D, 2014, LANCET, V383, P558, DOI 10.1016/S0140-6736(13)62226-6
   Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006
   Hecht M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130277
   Herschhorn A, 2010, CELL MOL LIFE SCI, V67, P2717, DOI 10.1007/s00018-010-0346-2
   Houédé N, 2014, ONCOLOGIST, V19, P1227, DOI 10.1634/theoncologist.2014-0345
   Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   KACAR Y, 1992, DNA CELL BIOL, V11, P781, DOI 10.1089/dna.1992.11.781
   Kaer K, 2013, GENE, V518, P231, DOI 10.1016/j.gene.2013.01.008
   Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909
   Kapusta A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003470
   Kelley D, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r107
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Kulpa DA, 2006, NAT STRUCT MOL BIOL, V13, P655, DOI 10.1038/nsmb1107
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367
   Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077
   Lehnert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004456
   Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2
   Levin HL, 2011, NAT REV GENET, V12, P615, DOI 10.1038/nrg3030
   Li LC, 2014, EPIGENETICS-US, V9, P45, DOI 10.4161/epi.26830
   Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8
   Lowe CB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043128
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma YL, 2010, J CELL MOL MED, V14, P2697, DOI 10.1111/j.1582-4934.2010.01191.x
   Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045
   Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   MIKI Y, 1992, CANCER RES, V52, P643
   Miousse IR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/131547
   MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0
   Muñoz-López M, 2010, CURR GENOMICS, V11, P115, DOI 10.2174/138920210790886871
   Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714
   Natoli C, 2011, BBA-REV CANCER, V1816, P13, DOI 10.1016/j.bbcan.2011.02.002
   Nelson AC, 2013, DEVELOPMENT, V140, P1385, DOI 10.1242/dev.084459
   Nishihara H, 2006, GENOME RES, V16, P864, DOI 10.1101/gr.5255506
   Ohms S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00338
   Ohms S, 2014, ONCOTARGET, V5, P4103, DOI 10.18632/oncotarget.1822
   OHNO S, 1972, BROOKHAVEN SYM BIOL, P366
   Oliver KR, 2011, MOBILE DNA-UK, V2, DOI 10.1186/1759-8753-2-8
   ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0
   Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214
   Ostertag EM, 2003, AM J HUM GENET, V73, P1444, DOI 10.1086/380207
   Patnala R, 2014, BREAST CANCER RES TR, V143, P239, DOI 10.1007/s10549-013-2812-7
   Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594
   Perreault J, 2005, NUCLEIC ACIDS RES, V33, P2032, DOI 10.1093/nar/gki504
   Piatek MJ, 2014, BIOCHEM SOC T, V42, P1174, DOI 10.1042/BST20140068
   Pink RC, 2011, RNA, V17, P792, DOI 10.1261/rna.2658311
   Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349
   Rebollo R, 2012, ANNU REV GENET, V46, P21, DOI 10.1146/annurev-genet-110711-155621
   Rodic N, 2015, NAT MED, V21, P1060, DOI 10.1038/nm.3919
   Rodic N, 2014, AM J PATHOL, V184, P1280, DOI 10.1016/j.ajpath.2014.01.007
   Rodic N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003402
   Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562
   Sciamanna I, 2014, ONCOTARGET, V5, P8039, DOI 10.18632/oncotarget.2504
   Sciamanna I, 2011, GENES-BASEL, V2, P360, DOI 10.3390/genes2020360
   Sciamanna I, 2013, ONCOTARGET, V4, P2271, DOI 10.18632/oncotarget.1403
   Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032
   Sinibaldi-Vallebona Paola, 2011, Cancers (Basel), V3, P1141, DOI 10.3390/cancers3011141
   Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072
   Solyom S, 2012, GENOME RES, V22, P2328, DOI 10.1101/gr.145235.112
   Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214
   Spadafora C, 2008, HUM REPROD, V23, P735, DOI 10.1093/humrep/dem425
   Spadafora C, 2015, ANN NY ACAD SCI, V1341, P164, DOI 10.1111/nyas.12637
   Stella GM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-12
   Suh N, 2010, CURR BIOL, V20, P271, DOI 10.1016/j.cub.2009.12.044
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Temin H M, 1971, J Natl Cancer Inst, V46, P3
   TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0
   Terasaki N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074629
   ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x
   van den Hurk JAJM, 2007, HUM MOL GENET, V16, P1587, DOI 10.1093/hmg/ddm108
   Vitullo P, 2012, MOL REPROD DEV, V79, P118, DOI 10.1002/mrd.22003
   WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0
   Watanabe T, 2011, SCIENCE, V332, P848, DOI 10.1126/science.1203919
   Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001
   Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007
   Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
NR 118
TC 37
Z9 43
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD FEB 11
PY 2016
VL 4
AR 6
DI 10.3389/fchem.2016.00006
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DI2ZU
UT WOS:000373368700001
PM 26904537
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yuan, LW
   Yamashita, H
   Seto, Y
AF Yuan, Lian-Wen
   Yamashita, Hiroharu
   Seto, Yasuyuki
TI Glucose metabolism in gastric cancer: The cutting-edge
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Glucose metabolism; Warburg effect; Metabolomics; Gastric cancer;
   Biomarker; Therapy
ID POSITRON-EMISSION-TOMOGRAPHY; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA;
   NUCLEAR-MAGNETIC-RESONANCE; GROWTH-FACTOR RECEPTOR; BODY-MASS INDEX;
   PYRUVATE-KINASE; F-18-FDG PET/CT; BREAST-CANCER; FACTOR-I;
   MICROSATELLITE INSTABILITY
AB Glucose metabolism in gastric cancer cells differs from that of normal epithelial cells. Upregulated aerobic glycolysis (Warburg effect) in gastric cancer meeting the demands of cell proliferation is associated with genetic mutations, epigenetic modification and proteomic alteration. Understanding the mechanisms of aerobic glycolysis may contribute to our knowledge of gastric carcinogenesis. Metabolomic studies offer novel, convenient and practical tools in the search for new biomarkers for early detection, diagnosis, prognosis, and chemosensitivity prediction of gastric cancer. Interfering with the process of glycolysis in cancer cells may provide a new and promising therapeutic strategy for gastric cancer. In this article, we present a brief review of recent studies of glucose metabolism in gastric cancer, with primary focus on the clinical applications of new biomarkers and their potential therapeutic role in gastric cancer.
C1 [Yuan, Lian-Wen] Ctr South Univ, Xiangya Hosp 2, Dept Geriatr Surg, 932 South Lushan Rd, Changsha 410011, Hunan, Peoples R China.
   [Yuan, Lian-Wen; Yamashita, Hiroharu; Seto, Yasuyuki] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Tokyo 1138655, Japan.
C3 Central South University; University of Tokyo
RP Yuan, LW (通讯作者)，Ctr South Univ, Xiangya Hosp 2, Dept Geriatr Surg, 932 South Lushan Rd, Changsha 410011, Hunan, Peoples R China.
EM yuanlianwen1971@aliyun.com
RI Yamashita, Hiroharu/E-7058-2011
OI Yamashita, Hiroharu/0000-0002-9468-3716
FU China Scholarship Council [[2014] 3012]; Grants-in-Aid for Scientific
   Research [15H04806, 24108007] Funding Source: KAKEN
FX Supported by The China Scholarship Council, No. [2014] 3012.
CR Abbassi-Ghadi N, 2013, EUR J CANCER, V49, P3625, DOI 10.1016/j.ejca.2013.07.004
   Abnet CC, 2008, EUR J CANCER, V44, P465, DOI 10.1016/j.ejca.2007.12.009
   Alakus H, 2010, NUCL MED COMMUN, V31, P532, DOI 10.1097/MNM.0b013e32833823ac
   Allen BG, 2013, CLIN CANCER RES, V19, P3905, DOI 10.1158/1078-0432.CCR-12-0287
   An JY, 2011, J GASTRIC CANCER, V11, P1, DOI 10.5230/jgc.2011.11.1.1
   An JY, 2013, WORLD J GASTROENTERO, V19, P9410, DOI 10.3748/wjg.v19.i48.9410
   Arakaki AK, 2008, NATURE, V456, P443, DOI 10.1038/456443c
   Augustin R, 2010, IUBMB LIFE, V62, P315, DOI 10.1002/iub.315
   Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4
   BASSALYK LS, 1987, NEOPLASMA, V34, P319
   Bayet-Robert M, 2010, MAGN RESON MED, V63, P1172, DOI 10.1002/mrm.22303
   Bhattacharya B, 2014, BRIT J PHARMACOL, V171, P3255, DOI 10.1111/bph.12668
   Buller CL, 2008, AM J PHYSIOL-CELL PH, V295, pC836, DOI 10.1152/ajpcell.00554.2007
   Cai Z, 2010, MOL CELL PROTEOMICS, V9, P2617, DOI 10.1074/mcp.M110.000661
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Cayvarli H, 2014, MOL IMAGING RADIONUC, V23, P76, DOI 10.4274/mirt.83803
   Chan DC, 2007, ANN SURG ONCOL, V14, P84, DOI 10.1245/s10434-006-9091-z
   Chen J, 2012, ONCOL REP, V27, P523, DOI 10.3892/or.2011.1524
   Chen JL, 2014, ELECTROPHORESIS, V35, P1032, DOI 10.1002/elps.201300243
   Chen JL, 2010, WORLD J GASTROENTERO, V16, P5874, DOI 10.3748/wjg.v16.i46.5874
   Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040965
   Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150
   Chung HW, 2013, GASTRIC CANCER, V16, P185, DOI 10.1007/s10120-012-0165-2
   Coupe NA, 2014, ANN NUCL MED, V28, P128, DOI 10.1007/s12149-013-0791-8
   D'Ugo D, 2009, LANCET ONCOL, V10, P191, DOI 10.1016/S1470-2045(09)70021-X
   Dasu A, 2003, PHYS MED BIOL, V48, P2829, DOI 10.1088/0031-9155/48/17/307
   DICHIRO G, 1982, NEUROLOGY, V32, P1323, DOI 10.1212/WNL.32.12.1323
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Eigenbrodt E, 1997, ANTICANCER RES, V17, P3153
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ganapathy-Kanniappan S, 2009, ANTICANCER RES, V29, P4909
   Geschwind Jean-Francois, 2004, Expert Rev Anticancer Ther, V4, P449, DOI 10.1586/14737140.4.3.449
   Goerres GW, 2005, EUR J NUCL MED MOL I, V32, P153, DOI 10.1007/s00259-004-1633-7
   GRAHAM EM, 1992, DEV OPHTHALMOL, V23, P106
   Granchi C, 2014, BIOORG MED CHEM LETT, V24, P4915, DOI 10.1016/j.bmcl.2014.09.041
   Gryko M, 2014, POL J PATHOL, V65, P135, DOI 10.5114/PJP.2014.42678
   Gu HW, 2011, ANAL CHIM ACTA, V686, P57, DOI 10.1016/j.aca.2010.11.040
   Ngo H, 2015, MOL BIOL REP, V42, P825, DOI 10.1007/s11033-014-3764-7
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herrmann K, 2007, J NUCL MED, V48, P1945, DOI 10.2967/jnumed.107.044867
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   Holmes E, 2008, CELL, V134, P714, DOI 10.1016/j.cell.2008.08.026
   Hori S, 2011, LUNG CANCER, V74, P284, DOI 10.1016/j.lungcan.2011.02.008
   Hu JD, 2011, WORLD J GASTROENTERO, V17, P727, DOI 10.3748/wjg.v17.i6.727
   Hur H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098581
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687
   Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001
   Ikeda A, 2012, BIOMED CHROMATOGR, V26, P548, DOI 10.1002/bmc.1671
   Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481
   Jung J, 2014, ANN SURG ONCOL, V21, pS736, DOI 10.1245/s10434-014-3886-0
   Kim EY, 2011, EUR J RADIOL, V79, P183, DOI 10.1016/j.ejrad.2010.02.005
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim K, 2009, MOL CELL PROTEOMICS, V8, P558, DOI 10.1074/mcp.M800165-MCP200
   Kim KB, 2010, J TOXICOL ENV HEAL A, V73, P1420, DOI 10.1080/15287394.2010.511545
   Krause BJ, 2010, EUR J NUCL MED MOL I, V37, P1861, DOI 10.1007/s00259-010-1493-2
   Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5
   Kubo Makoto, 2005, Gastric Cancer, V8, P39, DOI 10.1007/s10120-004-0304-5
   Kwon H, 2015, ARCH PHARM RES, V38, P372, DOI 10.1007/s12272-015-0552-4
   Kwon OH, 2012, BIOCHEM BIOPH RES CO, V423, P38, DOI 10.1016/j.bbrc.2012.05.063
   Lee JW, 2012, EUR J NUCL MED MOL I, V39, P1425, DOI 10.1007/s00259-012-2164-2
   Leung WK, 2008, LANCET ONCOL, V9, P279, DOI 10.1016/S1470-2045(08)70072-X
   Li HM, 2015, ONCOL LETT, V9, P143, DOI 10.3892/ol.2014.2687
   Li H, 2011, CANCER-AM CANCER SOC, V117, P3135, DOI 10.1002/cncr.25893
   Lim JY, 2012, WORLD J GASTROENTERO, V18, P4037, DOI 10.3748/wjg.v18.i30.4037
   Lin LL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1230-0
   Lin LL, 2012, J PROTEOMICS, V75, P3081, DOI 10.1016/j.jprot.2012.03.046
   Lin S, 2014, WORLD J GASTROENTERO, V20, P1107, DOI 10.3748/wjg.v20.i4.1107
   Lin ZX, 2008, INT J RADIAT ONCOL, V70, P1219, DOI 10.1016/j.ijrobp.2007.09.050
   Liu JF, 2010, WORLD J GASTROENTERO, V16, P4986, DOI 10.3748/wjg.v16.i39.4986
   Liu P, 2005, WORLD J GASTROENTERO, V11, P4904, DOI 10.3748/wjg.v11.i31.4904
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Lutz MP, 2012, EUR J CANCER, V48, P2941, DOI 10.1016/j.ejca.2012.07.029
   Ma J, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3628
   Ma QM, 2013, EUR J RADIOL, V82, pE302, DOI 10.1016/j.ejrad.2013.01.021
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7
   Malkowski B, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/696423
   Manerba M, 2015, EUR J PHARM SCI, V74, P95, DOI 10.1016/j.ejps.2015.04.022
   Marimuthu Sathiya P, 2011, J Carcinog, V10, P30, DOI 10.4103/1477-3163.90481
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006
   Min Y, 2005, GUT, V54, P591, DOI 10.1136/gut.2004.048926
   Mochiki E, 2004, WORLD J SURG, V28, P247, DOI 10.1007/s00268-003-7191-5
   Morvan D, 2007, CANCER RES, V67, P2150, DOI 10.1158/0008-5472.CAN-06-2346
   Ngo DC, 2015, MOL BIOL REP, V42, P819, DOI 10.1007/s11033-015-3857-y
   Ott K, 2008, CLIN CANCER RES, V14, P2012, DOI 10.1158/1078-0432.CCR-07-0934
   Otto C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-122
   Ozcan S, 2014, CANCER PREV RES, V7, P226, DOI 10.1158/1940-6207.CAPR-13-0235
   Pak KH, 2011, J SURG ONCOL, V104, P566, DOI 10.1002/jso.21997
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126
   Qiu MZ, 2011, TUMOR BIOL, V32, P159, DOI 10.1007/s13277-010-0109-6
   Qiu YP, 2010, J PROTEOME RES, V9, P1627, DOI 10.1021/pr901081y
   Rho M, 2007, ANTICANCER RES, V27, P251
   Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019
   Ruiz-Lozano P, 1999, CELL GROWTH DIFFER, V10, P295
   Sasada S, 2013, ONCOL REP, V29, P925, DOI 10.3892/or.2012.2182
   Sheu SM, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0096-9
   Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337
   Shimada Y, 2013, CLIN NUCL MED, V38, pE417, DOI 10.1097/RLU.0b013e318279f0d9
   Smolková K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003
   Song H, 2012, BRAZ J MED BIOL RES, V45, P78, DOI 10.1590/S0100-879X2011007500158
   Song H, 2011, ONCOL REP, V26, P431, DOI 10.3892/or.2011.1302
   Tae CH, 2015, ASIA-PAC J CLIN ONCO, V11, P34, DOI 10.1111/ajco.12294
   Takebayashi R, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-34
   Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4
   Wahdan-Alaswad R, 2013, CELL CYCLE, V12, P3759, DOI 10.4161/cc.26641
   Wang CS, 2006, ANN CLIN LAB SCI, V36, P23
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang HB, 2011, PATHOL RES PRACT, V207, P169, DOI 10.1016/j.prp.2010.12.009
   Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9
   Wang LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067542
   Wang X, 2010, INT J CANCER, V127, P2841, DOI 10.1002/ijc.25294
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Watanabe M, 2010, MOL CANCER RES, V8, P1547, DOI 10.1158/1541-7786.MCR-10-0011
   Watanabe Y, 2013, INT J HEMATOL, V97, P43, DOI 10.1007/s12185-012-1225-4
   Wu HL, 2014, CELL SIGNAL, V26, P2397, DOI 10.1016/j.cellsig.2014.07.024
   Wu H, 2010, ANAL BIOANAL CHEM, V396, P1385, DOI 10.1007/s00216-009-3317-4
   Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18
   Yamada A, 2006, ANN NUCL MED, V20, P597, DOI 10.1007/BF02984657
   Yamagata H, 2005, DIABETES CARE, V28, P789, DOI 10.2337/diacare.28.4.789
   Yamashita K, 2011, SURG TODAY, V41, P24, DOI 10.1007/s00595-010-4370-5
   Yang P, 2009, EUR J CANCER, V45, P2867, DOI 10.1016/j.ejca.2009.04.019
   Yin LN, 2013, CELL BIOCHEM BIOPHYS, V67, P1033, DOI 10.1007/s12013-013-9601-0
   Younes M, 1995, ANTICANCER RES, V15, P2895
   Younes M, 1997, CANCER-AM CANCER SOC, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7
   Younes M, 2001, ANTICANCER RES, V21, P575
   Yu LZ, 2011, J GASTROEN HEPATOL, V26, P1290, DOI 10.1111/j.1440-1746.2011.06724.x
   Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI [10.1517/14728222.12.5.589, 10.1517/14728222.12.5.589 ]
   Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50
   Zhang Y, 2013, CHINESE MED J-PEKING, V126, P1930, DOI 10.3760/cmaj.issn.0366-6999.20111240
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhou M, 2013, NUCL MED COMMUN, V34, P694, DOI 10.1097/MNM.0b013e328361663a
   Zhu ZH, 2008, J NUCL MED TECHNOL, V36, P25, DOI 10.2967/jnmt.107.044081
NR 139
TC 89
Z9 96
U1 3
U2 49
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 14
PY 2016
VL 22
IS 6
BP 2046
EP 2059
DI 10.3748/wjg.v22.i6.2046
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DB5MX
UT WOS:000368559400010
PM 26877609
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Gao, YY
   Zhao, YP
   Zhang, JC
   Lu, Y
   Liu, X
   Geng, PY
   Huang, BQ
   Zhang, Y
   Lu, J
AF Gao, Yanyan
   Zhao, Yaping
   Zhang, Juechao
   Lu, Yang
   Liu, Xin
   Geng, Pengyu
   Huang, Baiqu
   Zhang, Yu
   Lu, Jun
TI The dual function of PRMT1 in modulating epithelial-mesenchymal
   transition and cellular senescence in breast cancer cells through
   regulation of ZEB1
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN ARGININE-METHYLTRANSFERASE; HISTONE H4; IN-VIVO; METHYLATION;
   INACTIVATION; CONTRIBUTES; SUPPRESSION; CHECKPOINT; RESISTANCE;
   INDUCTION
AB Although the involvement of protein arginine methyltransferase 1 (PRMT1) in tumorigenesis has been reported, its roles in breast cancer progression and metastasis has not been elucidated. Here we identified PRMT1 as a key regulator of the epithelial-mesenchymal transition (EMT) in breast cancer. We showed that the EMT program induced by PRMT1 endowed the human mammary epithelial cells with cancer stem cell properties. Moreover, PRMT1 promoted the migratory and invasive behaviors in breast cancer cells. We also demonstrated that abrogation of PRMT1 expression in breast cancer cells abated metastasis in vivo in mouse model. In addition, knockdown of PRMT1 arrested cell growth in G1 tetraploidy and induced cellular senescence. Mechanistically, PRMT1 impacted EMT process and cellular senescence by mediating the asymmetric dimethylation of arginine 3 of histone H4 (H4R3me2as) at the ZEB1 promoter to activate its transcription, indicating the essential roles of this epigenetic control both in EMT and in senescence. Thus, we unraveled a dual function of PRMT1 in modulation of both EMT and senescence via regulating ZEB1. This finding points to the potent value of PRMT1 as a dual therapeutic target for preventing metastasis and for inhibiting cancer cell growth in malignant breast cancer patients.
C1 [Gao, Yanyan; Zhang, Juechao; Huang, Baiqu; Zhang, Yu] NE Normal Univ, Inst Genet & Cytol, Changchun 130024, Peoples R China.
   [Zhao, Yaping; Lu, Yang; Liu, Xin; Geng, Pengyu; Lu, Jun] NE Normal Univ, Minist Educ, Key Lab Mol Epigenet, Changchun 130021, Peoples R China.
C3 Northeast Normal University - China; Northeast Normal University - China
RP Zhang, Y (通讯作者)，NE Normal Univ, Inst Genet & Cytol, Changchun 130024, Peoples R China.; Lu, J (通讯作者)，NE Normal Univ, Minist Educ, Key Lab Mol Epigenet, Changchun 130021, Peoples R China.
EM Zhangy288@nenu.edu.cn; luj809@nenu.edu.cn
FU National Natural Science Foundation of China [31571478, 31570718,
   31571317, 31371294]; Programme for Introducing Talents to Universities
   [B07017]; Fundamental Research Funds for the Central Universities
   [10QNJJ014]
FX This work was sported by the grants from the National Natural Science
   Foundation of China (Grant numbers 31571478, 31570718, 31571317, and
   31371294), the Programme for Introducing Talents to Universities
   (B07017) and the Fundamental Research Funds for the Central Universities
   (10QNJJ014).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Avasarala S, 2015, J BIOL CHEM, V290, P13479, DOI 10.1074/jbc.M114.636050
   Baldwin R Mitchell, 2014, World J Biol Chem, V5, P115, DOI 10.4331/wjbc.v5.i2.115
   Baldwin RM, 2012, CELL CYCLE, V11, P4597, DOI 10.4161/cc.22871
   Baygi ME, 2010, CELL BIOL TOXICOL, V26, P553, DOI 10.1007/s10565-010-9163-5
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805
   Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250
   Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642
   Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9
   Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200
   Guo AL, 2014, MOL CELL PROTEOMICS, V13, P372, DOI 10.1074/mcp.O113.027870
   Hay ED, 1995, ACTA ANAT, V154, P8
   Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Li LL, 2015, INT J CANCER, V136, P1285, DOI 10.1002/ijc.29110
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411
   Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172
   Mathioudaki K, 2008, BRIT J CANCER, V99, P2094, DOI 10.1038/sj.bjc.6604807
   Mathioudaki K, 2011, TUMOR BIOL, V32, P575, DOI 10.1007/s13277-010-0153-2
   Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Scorilas A, 2000, BIOCHEM BIOPH RES CO, V278, P349, DOI 10.1006/bbrc.2000.3807
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086
   Smit MA, 2010, AGING-US, V2, P735, DOI 10.18632/aging.100209
   STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723
   Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8
   Xu J, 2013, MOL CELL, V51, P5, DOI 10.1016/j.molcel.2013.05.004
   Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
   Yu ZB, 2009, MOL CELL BIOL, V29, P2982, DOI 10.1128/MCB.00042-09
   Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045
   Zhang Y, 2013, FEBS J, V280, P4625, DOI 10.1111/febs.12435
NR 53
TC 90
Z9 107
U1 2
U2 33
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 27
PY 2016
VL 6
AR 19874
DI 10.1038/srep19874
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB7BP
UT WOS:000368669700002
PM 26813495
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Artacho-Cordón, F
   Ríos-Arrabal, S
   Olivares-Urbano, MA
   Storch, K
   Dickreuter, E
   Muñoz-Gámez, JA
   León, J
   Calvente, I
   Torné, P
   Salinas, MD
   Cordes, N
   Núñez, MI
AF Artacho-Cordon, Francisco
   Rios-Arrabal, Sandra
   Auxiliadora Olivares-Urbano, Maria
   Storch, Katja
   Dickreuter, Ellen
   Antonio Munoz-Gamez, Jose
   Leon, Josefa
   Calvente, Irene
   Torne, Pablo
   del Mar Salinas, Maria
   Cordes, Nils
   Isabel Nunez, Maria
TI Valproic acid modulates radiation-enhanced matrix metalloproteinase
   activity and invasion of breast cancer cells
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article
DE Matrix metalloproteinases; ionizing radiation; breast cancer; tumour
   microenvironment; histone deacetylases; invasion; epigenetic regulation
ID HISTONE DEACETYLASE INHIBITORS; IONIZING-RADIATION; HDAC INHIBITOR;
   TISSUE INHIBITOR; MICROENVIRONMENT; VORINOSTAT; EXPRESSION;
   PHOSPHORYLATION; TUMORIGENESIS; MALIGNANCIES
AB Purpose: To evaluate matrix metalloproteinase (MMP) activity and invasion after ionizing radiation (IR) exposure and to determine whether MMP could be epigenetically modulated by histone deacetylase (HDAC) inhibition.Material and methods: Two human breast cancer cell lines (MDA-MB-231 and MCF-7) were cultured in monolayer (2D) and in laminin-rich extracellular matrix (3D). Invasion capability, collagenolytic and gelatinolytic activity, MMP and TIMP protein and mRNA expression and clonogenic survival were analyzed after IR exposure, with and without a HDAC inhibition treatment [1.5mM valproic acid (VA) or 1M trichostatin-A (TSA)].Results: IR exposure resulted in cell line-dependent stimulation of invasion capacity. In contrast to MCF-7 cells, irradiated MDA-MB-231 showed significantly enhanced mRNA expression of mmp-1, mmp-3 and mmp-13 and of their regulators timp-1 and timp-2 relative to unirradiated controls. This translated into increased collagenolytic and gelatinolytic activity and could be reduced after valproic acid (VA) treatment. Additionally, VA also mitigated IR-enhanced mmp and timp mRNA expression as well as IR-increased invasion capability. Finally, our data confirm the radiosensitizing effect of VA.Conclusion: These results suggest that IR cell line-dependently induces upregulation of MMP mRNA expression, which appears to be mechanistically linked to a higher invasion capability that is modifiable by HDAC inhibition.
C1 [Artacho-Cordon, Francisco; Rios-Arrabal, Sandra; Auxiliadora Olivares-Urbano, Maria; Calvente, Irene; del Mar Salinas, Maria; Isabel Nunez, Maria] Univ Granada, Dept Radiol & Phys Med, Granada 18012, Spain.
   [Artacho-Cordon, Francisco; Rios-Arrabal, Sandra; Antonio Munoz-Gamez, Jose; Leon, Josefa; Calvente, Irene; Isabel Nunez, Maria] Univ Granada, Univ Hosp Granada, Biosan Inst Granada ibs GRANADA, Granada 18012, Spain.
   [Rios-Arrabal, Sandra; Isabel Nunez, Maria] Univ Granada, Inst Biopathol & Regenerat Med IBIMER, Granada 18012, Spain.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Tech Univ Dresden, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, D-01062 Dresden, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, D-01062 Dresden, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Radiat Oncol, D-01062 Dresden, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] German Canc Consortium DKTK, Dresden, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] German Canc Res Ctr, Heidelberg, Germany.
   [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, D-01314 Dresden, Germany.
   [Antonio Munoz-Gamez, Jose; Leon, Josefa] CIBER Hepat & Digest Dis CIBEREHD, Barcelona, Spain.
   [Torne, Pablo] San Cecilio Univ Hosp, Gen Surg Management Unit, Granada, Spain.
C3 University of Granada; University of Granada; University of Granada;
   Technische Universitat Dresden; Technische Universitat Dresden; Carl
   Gustav Carus University Hospital; Helmholtz Association;
   Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat
   Dresden; Carl Gustav Carus University Hospital; Helmholtz Association;
   German Cancer Research Center (DKFZ); Helmholtz Association; German
   Cancer Research Center (DKFZ); Helmholtz Association; Helmholtz-Zentrum
   Dresden-Rossendorf (HZDR); CIBER - Centro de Investigacion Biomedica en
   Red; CIBEREHD; Hospital Universitario San Cecilio
RP Núñez, MI (通讯作者)，Univ Granada, Dept Radiol & Med Fis, Av Madrid S-N, Granada 18012, Spain.
EM isabeln@ugr.es
RI Núñez, María/L-9924-2014; Leon, Pepi/K-8972-2014; Artacho-Cordon,
   Francisco/A-3166-2015
OI Artacho-Cordon, Francisco/0000-0003-3850-6173; Cordes,
   Nils/0000-0001-5684-629X; Asensio/0000-0003-1376-0941
FU Fondo de Investigacion Sanitaria [PI080728]; Andalusian Council of
   Health [PI0730-2013]; Spanish Ministry of Science and Education
   [FPU12/02524]; Fundacion Benefica San Francisco Javier y Santa Candida,
   University of Granada; San Cecilio University Hospital, Granada;
   Bundesministerium fur Bildung und Forschung (BMBF) [03ZIK041]; Saxon
   Ministry of Science and Arts; EFRE Europaische Fonds fur regionale
   Entwicklung, Europa fordert Sachsen [100066308]
FX This study was supported by the Fondo de Investigacion Sanitaria
   (PI080728) and the Andalusian Council of Health (PI0730-2013) to M. I.
   Nunez. A grant from the Spanish Ministry of Science and Education to F.
   Artacho-Cordon (FPU12/02524) greatly aided this work. S. Rios-Arrabal is
   supported by the Fundacion Benefica San Francisco Javier y Santa
   Candida, University of Granada. This research was also funded by the San
   Cecilio University Hospital, Granada. Nils Cordes received grants from
   the Bundesministerium fur Bildung und Forschung (BMBF Contract 03ZIK041
   to N.C.) and the Saxon Ministry of Science and Arts and the EFRE
   Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen
   (100066308).
CR Artacho-Cordón A, 2012, CANCER BIOL THER, V13, P14, DOI 10.4161/cbt.13.1.18869
   Artacho-Cordón F, 2012, SURG ONCOL, V21, pE143, DOI 10.1016/j.suronc.2012.06.001
   Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254
   Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735
   Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018
   Bouchard G, 2013, BRIT J CANCER, V109, P1829, DOI 10.1038/bjc.2013.502
   Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   De Schutter H, 2009, ANTI-CANCER AGENT ME, V9, P99, DOI 10.2174/187152009787047707
   Debeb BG, 2010, INT J RADIAT ONCOL, V76, P889, DOI 10.1016/j.ijrobp.2009.09.052
   Duenas-Gonzalez A, 2008, CANCER TREAT REV, V34, P206, DOI 10.1016/j.ctrv.2007.11.003
   Eck SM, 2009, J AUTOIMMUN, V33, P214, DOI 10.1016/j.jaut.2009.09.011
   Eke I, 2011, RADIOTHER ONCOL, V99, P271, DOI 10.1016/j.radonc.2011.06.007
   Fujita M, 2011, CANCER SCI, V102, P792, DOI 10.1111/j.1349-7006.2011.01852.x
   Furmanova-Hollenstein P, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-105
   Groselj B, 2013, BRIT J CANCER, V108, P748, DOI 10.1038/bjc.2013.21
   Hehlgans S, 2013, RADIOTHER ONCOL, V109, P126, DOI 10.1016/j.radonc.2013.08.023
   Kawano T, 2010, INT J ONCOL, V37, P787, DOI 10.3892/ijo_00000728
   Köhrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188
   Lemay R, 2011, INT J RADIAT BIOL, V87, P472, DOI 10.3109/09553002.2011.542541
   Li T, 2011, CANCER GENE THER, V18, P617, DOI 10.1038/cgt.2011.29
   Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056
   Mitmaker EJ, 2011, SURGERY, V149, P504, DOI 10.1016/j.surg.2010.10.007
   Moncharmont C, 2014, CRIT REV ONCOL HEMAT, V92, P133, DOI 10.1016/j.critrevonc.2014.05.006
   Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088
   Munshi A, 2006, MOL CANCER THER, V5, P1967, DOI 10.1158/1535-7163.MCT-06-0022
   Nakopoulou L, 2003, BREAST CANCER RES TR, V77, P145, DOI 10.1023/A:1021371028777
   Nambiar DK, 2015, BIOCHEM BIOPH RES CO, V456, P262, DOI 10.1016/j.bbrc.2014.11.069
   Neri A, 2012, HUM PATHOL, V43, P1184, DOI 10.1016/j.humpath.2011.09.018
   Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011
   Noë V, 2001, J CELL SCI, V114, P111
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Palmieri D, 2009, CLIN CANCER RES, V15, P6148, DOI 10.1158/1078-0432.CCR-09-1039
   Paquette B, 2011, BRIT J CANCER, V105, P534, DOI 10.1038/bjc.2011.260
   Park S, 2011, WATER RESOUR MANAG, V25, P1, DOI 10.1007/s11269-010-9684-y
   Ríos-Arrabal S, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-404
   Schneider U, 2011, GENES-BASEL, V2, P1033, DOI 10.3390/genes2041033
   Schrohl AS, 2003, MOL CELL PROTEOMICS, V2, P164, DOI 10.1074/mcp.M300019-MCP200
   Sendon-Lago J, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0505-8
   Shabason JE, 2011, J CELL MOL MED, V15, P2735, DOI 10.1111/j.1582-4934.2011.01296.x
   Shiao SL, 2010, J MAMMARY GLAND BIOL, V15, P411, DOI 10.1007/s10911-010-9194-9
   Shoji M, 2012, INT J ONCOL, V40, P2140, DOI 10.3892/ijo.2012.1416
   Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang F, 2013, CLIN INVEST MED, V36, pE87, DOI 10.25011/cim.v36i2.19571
   Yu J, 2012, EUR J GYNAECOL ONCOL, V33, P285
   Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200
   Zhong HM, 2013, INT IMMUNOPHARMACOL, V17, P329, DOI 10.1016/j.intimp.2013.06.027
   Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097
NR 49
TC 9
Z9 9
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD DEC 2
PY 2015
VL 91
IS 12
BP 946
EP 956
DI 10.3109/09553002.2015.1087067
PG 11
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA DB4YK
UT WOS:000368519400004
PM 26490761
DA 2025-01-12
ER

PT J
AU Jiang, CJ
   Li, YS
   Zhao, Z
   Lu, JP
   Chen, H
   Ding, N
   Wang, GJ
   Xu, J
   Li, X
AF Jiang, Chunjie
   Li, Yongsheng
   Zhao, Zheng
   Lu, Jianping
   Chen, Hong
   Ding, Na
   Wang, Guangjuan
   Xu, Juan
   Li, Xia
TI Identifying and functionally characterizing tissue-specific and
   ubiquitously expressed human lncRNAs
SO ONCOTARGET
LA English
DT Article
DE ubiquitously expressed lncRNAs; tissue-specific lncRNAs; genomic
   structure; epigenetic regulation; functional prediction
ID LONG NONCODING RNAS; PROSTATE-SPECIFIC GENE; HUMAN GENOME;
   CELL-DIFFERENTIATION; BREAST-CANCER; SEQ DATA; REVEALS; ANNOTATION;
   EVOLUTION; TRANSCRIPTOMICS
AB Recent advances in transcriptome sequencing have made it possible to distinguish ubiquitously expressed long non-coding RNAs (UE lncRNAs) from tissue-specific lncRNAs (TS lncRNAs), thereby providing clues to their cellular functions. Here, we assembled and functionally characterized a consensus lncRNA transcriptome by curating hundreds of RNA-seq datasets across normal human tissues from 16 independent studies. In total, 1,184 UE and 2,583 TS lncRNAs were identified. These different lncRNA populations had several distinct features. Specifically, UE lncRNAs were associated with genomic compaction and highly conserved exons and promoter regions. We found that UE lncRNAs are regulated at the transcriptional level (with especially strong regulation of enhancers) and are associated with epigenetic modifications and post-transcriptional regulation. Based on these observations we propose a novel way to predict the functions of UE and TS lncRNAs through analysis of their genomic location and similarities in epigenetic modifications. Our characterization of UE and TS lncRNAs may provide a foundation for lncRNA genomics and the delineation of complex disease mechanisms.
C1 [Jiang, Chunjie; Li, Yongsheng; Zhao, Zheng; Lu, Jianping; Chen, Hong; Ding, Na; Wang, Guangjuan; Xu, Juan; Li, Xia] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
C3 Harbin Medical University
RP Xu, J; Li, X (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
EM xujuanbiocc@ems.hrbmu.edu.cn; lixia@hrbmu.edu.cn
RI Jiang, Chunjie/AAU-1775-2020; 陆, 建平/HPB-6780-2023; li, xia/HHZ-7468-2022
OI Xu, Juan/0000-0002-3709-4165; Li, Yongsheng/0000-0003-1914-0727; Chen,
   Hong/0000-0001-8054-7417; Jiang, Chunjie/0000-0002-3033-092X
FU National High Technology Research and Development Program of China [863
   Program] [2014AA021102]; National Program on Key Basic Research Project
   [973 Program] [2014CB910504]; National Natural Science Foundation of
   China [91439117, 61473106, 61203264, 31571331, 61502126]; China
   Postdoctoral Science Foundation [2014T70364, 2015M571436, LBH-Z14134];
   Natural Science Foundation of Heilongjiang Province [QC2015020];
   WeihanYu Youth Science Fund Project of Harbin Medical University; Harbin
   Special Funds of Innovative Talents on Science and Technology Research
   Project [RC2015QN003080]
FX This work was supported by the National High Technology Research and
   Development Program of China [863 Program, Grant No. 2014AA021102], the
   National Program on Key Basic Research Project [973 Program, Grant No.
   2014CB910504], the National Natural Science Foundation of China [Grant
   Nos. 91439117, 61473106, 61203264, 31571331 and 61502126], the China
   Postdoctoral Science Foundation [Grant Nos. 2014T70364, 2015M571436 and
   LBH-Z14134], Natural Science Foundation of Heilongjiang Province [Grant
   No. QC2015020], WeihanYu Youth Science Fund Project of Harbin Medical
   University, Harbin Special Funds of Innovative Talents on Science and
   Technology Research Project [Grant No. RC2015QN003080].
CR Amin V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7370
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Castillo-Davis CI, 2002, NAT GENET, V31, P415, DOI 10.1038/ng940
   Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Di Gesualdo F, 2014, ONCOTARGET, V5, P10976, DOI 10.18632/oncotarget.2770
   Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Goodrich JA, 2006, NAT REV MOL CELL BIO, V7, P612, DOI 10.1038/nrm1946
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hsu CW, 2008, PROTEOMICS, V8, P1975, DOI 10.1002/pmic.200701004
   Ke J, 2015, ONCOTARGET, V6, P21934, DOI 10.18632/oncotarget.4290
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liao Q, 2011, NUCLEIC ACIDS RES, V39, P3864, DOI 10.1093/nar/gkq1348
   Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604
   Makarova JA, 2005, GENE, V363, P51, DOI 10.1016/j.gene.2005.08.010
   Malek E, 2014, ONCOTARGET, V5, P8027, DOI 10.18632/oncotarget.2469
   Mercer TR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-14
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Morán I, 2012, CELL METAB, V16, P435, DOI 10.1016/j.cmet.2012.08.010
   Mudge JM, 2013, GENOME RES, V23, P1961, DOI 10.1101/gr.161315.113
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Pandey GK, 2015, ONCOTARGET, V6, P18265, DOI 10.18632/oncotarget.4251
   Pennacchio LA, 2013, NAT REV GENET, V14, P288, DOI 10.1038/nrg3458
   Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Quek XC, 2015, NUCLEIC ACIDS RES, V43, pD168, DOI 10.1093/nar/gku988
   Ramsköld D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000598
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sanbonmatsu K., 2015, BIOCH BIOPHYS ACTA
   Shen XK, 2015, ONCOTARGET, V6, P21730, DOI 10.18632/oncotarget.4419
   Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005
   Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454
   TIEDGE H, 1993, J NEUROSCI, V13, P2382, DOI 10.1523/JNEUROSCI.13-06-02382.1993
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303
   Washietl S, 2014, GENOME RES, V24, P616, DOI 10.1101/gr.165035.113
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060
   Yin YF, 2015, CELL STEM CELL, V16, P504, DOI 10.1016/j.stem.2015.03.007
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Zabidi MA, 2015, NATURE, V518, P556, DOI 10.1038/nature13994
   Zaidi SK, 2010, MOL CELL BIOL, V30, P4758, DOI 10.1128/MCB.00646-10
NR 59
TC 94
Z9 101
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 9
PY 2016
VL 7
IS 6
BP 7120
EP 7133
DI 10.18632/oncotarget.6859
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DM1RE
UT WOS:000376123100055
PM 26760768
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Choi, SK
   Hong, SH
   Kim, HS
   Shin, CY
   Nam, SW
   Choi, WS
   Han, JW
   You, JS
AF Choi, Sung Kyung
   Hong, Seong Hwi
   Kim, Hyuk Soon
   Shin, Chan Young
   Nam, Suk Woo
   Choi, Wahn Soo
   Han, Jeung-Whan
   You, Jueng Soo
TI JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the
   bidirectional MYC-AP4 axis via multiple mechanisms
SO ONCOLOGY REPORTS
LA English
DT Article
DE epigenetic reader BRD4; JQ1; MYC; AP4; breast cancer
ID ACUTE MYELOID-LEUKEMIA; C-MYC; SUPER-ENHANCERS; SELECTIVE-INHIBITION;
   SMALL MOLECULES; BREAST-CANCER; AP4; TRANSFORMATION; BROMODOMAINS;
   RESISTANCE
AB Bromodomain and extra-terminal domain (BET) family proteins are representative epigenetic modulators that read acetylated lysine residues and transfer cellular signals. Recently, the BET protein inhibitor JQ1 was developed and has been extensively studied in many cancer cell types. We demonstrated that JQ1 effectively suppressed the MYC-AP4 axis and induced antitumorigenic effects by targeting a bidirectional positive loop between MYC and AP4 which was first proposed in the present study. MYC and AP4 are the direct targets of BRD4, as demonstrated by chromatin immunoprecipitation (ChIP) assay and BRD4 loss-of-function experiments. Although inhibition of the MYC/MAC dimer suppressed AP4, the efficacy of suppression was not as effective as BRD4 inhibition. Notably, AP4 loss-of-function studies demonstrated that AP4 is a major critical target of JQ1 and that MYC is a novel downstream target of AP4, as demonstrated by AP4 binding to the MYC promoter. Taken together, our results suggest that the epigenetic reader BRD4 is a key mediator of the activated MYC-AP4 axis, which supports the possibility that targeting BET protein is a novel therapeutic strategy for MYC-AP4 axis-activated cancers.
C1 [Choi, Sung Kyung; Hong, Seong Hwi; Kim, Hyuk Soon; Shin, Chan Young; Choi, Wahn Soo; You, Jueng Soo] Konkuk Univ, Sch Med, Seoul 143701, South Korea.
   [Nam, Suk Woo] Catholic Univ, Coll Med, Funct RNom Res Ctr, Seoul 137701, South Korea.
   [Han, Jeung-Whan] Sungkyunkwan Univ, Sch Pharm, Res Ctr Epigenome Regulat, Suwon 440746, South Korea.
   [Shin, Chan Young; Choi, Wahn Soo; You, Jueng Soo] Konkuk Univ, Med Ctr, Seoul 143701, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Catholic University
   of Korea; Sungkyunkwan University (SKKU); Konkuk University; Konkuk
   University Medical Center
RP You, JS (通讯作者)，Konkuk Univ, Sch Med, Dept Biochem, 120 Neungdong Ro, Seoul 143701, South Korea.
EM jsyou@kku.ac.kr
RI Kim, Hyuk Soon/IQW-9348-2023; Choi, Hayoung/AAI-8638-2020
OI Kim, Hyuk Soon/0000-0002-0566-0142
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future Planning
   [2013R1A1A1057575]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT and Future Planning (2013R1A1A1057575).
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256
   Bihani T, 2015, ONCOTARGET, V6, P2407, DOI 10.18632/oncotarget.2964
   Chou C, 2014, NAT IMMUNOL, V15, P884, DOI 10.1038/ni.2943
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gong H, 2014, MOL MED REP, V10, P336, DOI 10.3892/mmr.2014.2209
   Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019
   Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124
   Jackstadt R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.282
   Jackstadt R, 2014, ONCOTARGET, V5, P7316, DOI 10.18632/oncotarget.2348
   Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812
   Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949
   Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Mo H, 2006, P NATL ACAD SCI USA, V103, P6344, DOI 10.1073/pnas.0601418103
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   You JS, 2014, ARCH PHARM RES, V37, P1367, DOI 10.1007/s12272-014-0455-9
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 28
TC 21
Z9 24
U1 1
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD FEB
PY 2016
VL 35
IS 2
BP 1186
EP 1194
DI 10.3892/or.2015.4410
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DA8IZ
UT WOS:000368049600070
PM 26573731
OA Bronze
DA 2025-01-12
ER

PT J
AU Qadi, AA
   Taberlay, PC
   Phillips, JL
   Young, A
   West, AC
   Brettingham-Moore, KH
   Dickinson, JL
   Holloway, AF
AF Qadi, Abeer A.
   Taberlay, Phillippa C.
   Phillips, Jessica L.
   Young, Arabella
   West, Alison C.
   Brettingham-Moore, Kate H.
   Dickinson, Joanne L.
   Holloway, Adele F.
TI The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE LIFR; RUNX1; GENE REGULATION
ID MESENCHYMAL STROMAL CELLS; CORE-BINDING-FACTOR; GM-CSF PROMOTER;
   BREAST-CANCER; INTERLEUKIN-6 FAMILY; EXPRESSION; CYTOKINES;
   IDENTIFICATION; HEMATOPOIESIS; GP130
AB Activation of cytokine signaling via the leukemia inhibitory factor receptor (LIFR) plays an integral role in hematopoiesis, osteogenesis, and placental development, along with mediating neurotrophic mechanisms. However, the regulatory control of the LIFR gene has remained largely unexplored. Here, we characterize the LIFR gene as a novel target of the RUNX1 transcription factor. The RUNX1 transcription factor is an essential regulator of hematopoiesis and is a frequent target of point mutations and chromosomal alterations in leukemia. RUNX1 regulates hematopoiesis through its control of genes important for hematopoietic cell growth, proliferation, and differentiation, including a number of cytokines and cytokine receptors. LIFR is regulated by two alternate promoters: a placental-specific and a ubiquitously active general promoter. We show that both of these promoters are regulated by RUNX1. However, in myeloid cells LIFR expression is driven solely by the general LIFR promoter with our data indicating that the placental promoter is epigenetically silenced in these cells. While RUNX1 activates the LIFR general promoter, the oncogenic RUNX1-ETO fusion protein generated by the t(8; 21) translocation commonly associated with acute myeloid leukemia represses promoter activity. The data presented here establish LIFR as a transcriptional target of RUNX1 and suggest that disruption of RUNX1 activity in myeloid cells may result in altered LIFR signaling in these cells. (C) 2015 Wiley Periodicals, Inc.
C1 [Qadi, Abeer A.; Phillips, Jessica L.; Young, Arabella; West, Alison C.; Dickinson, Joanne L.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7000, Australia.
   [Taberlay, Phillippa C.] Garvan Inst Med Res, Genom & Epigenet Div, Darlinghurst, NSW 2010, Australia.
   [Brettingham-Moore, Kate H.; Holloway, Adele F.] Univ Tasmania, Sch Med, Hobart, Tas 7000, Australia.
C3 University of Tasmania; Menzies Institute for Medical Research; Garvan
   Institute of Medical Research; University of Tasmania
RP Holloway, AF (通讯作者)，Univ Tasmania, Sch Med, Private Bag 34, Hobart, Tas 7000, Australia.
EM A.F.Holloway@utas.edu.au
RI Dickinson, Joanne/J-7728-2014; Brettingham-Moore, Kate/N-7500-2017;
   Taberlay, Phillippa/C-9616-2010
OI Brettingham-Moore, Kate/0000-0002-4304-4586; Taberlay,
   Phillippa/0000-0002-5298-8730; Qadi, Abeer/0000-0002-2688-708X;
   Dickinson, Joanne/0000-0003-4621-1703; Holloway,
   Adele/0000-0003-2213-1717; Young, Arabella/0000-0002-6845-9753
FU The David Collins Leukaemia Foundation [H0017943, H0018719]
FX Grant sponsor: The David Collins Leukaemia Foundation; Grant numbers:
   H0017943, H0018719.
CR ASOU H, 1991, BLOOD, V77, P2031
   Bee T, 2009, BLOOD CELL MOL DIS, V43, P35, DOI 10.1016/j.bcmd.2009.03.011
   Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474
   Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777
   Brettingham-Moore KH, 2008, NUCLEIC ACIDS RES, V36, P2639, DOI 10.1093/nar/gkn117
   Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#
   Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940
   Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328
   Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917
   Deverman BE, 2012, J NEUROSCI, V32, P2100, DOI 10.1523/JNEUROSCI.3803-11.2012
   DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247
   Dimitriadis E, 2010, PLACENTA, V31, pS99, DOI 10.1016/j.placenta.2009.12.027
   ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0
   Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250
   FURLEY AJ, 1986, BLOOD, V68, P1101
   GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6
   GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x
   Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20
   Janes KA, 2011, CELL CYCLE, V10, P3461, DOI 10.4161/cc.10.20.18029
   KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243
   KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683
   Kuphal S, 2013, EXP MOL PATHOL, V95, P156, DOI 10.1016/j.yexmp.2013.06.012
   Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670
   LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321
   Mathieu ME, 2012, STEM CELL REV REP, V8, P1, DOI 10.1007/s12015-011-9261-7
   Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014
   Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5
   MEYERS S, 1995, MOL CELL BIOL, V15, P1974
   Nakashima K, 1998, SEMIN HEMATOL, V35, P210
   Oakford PC, 2010, LEUKEMIA RES, V34, P1203, DOI 10.1016/j.leukres.2010.03.029
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Ottersbach K, 2010, INT J DEV BIOL, V54, P1099, DOI 10.1387/ijdb.093057ko
   PATTILLO RA, 1972, J CLIN ENDOCR METAB, V34, P59, DOI 10.1210/jcem-34-1-59
   Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727
   Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855
   Schraml E, 2008, GERONTOLOGY, V54, P312, DOI 10.1159/000161736
   Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Taylor DS, 1996, J BIOL CHEM, V271, P14020, DOI 10.1074/jbc.271.24.14020
   Uchida H, 1997, J IMMUNOL, V158, P2251
   VERFAILLIE C, 1991, BLOOD, V77, P263
   Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957
   Wang ZY, 1998, J BIOL CHEM, V273, P26069, DOI 10.1074/jbc.273.40.26069
   WARE CB, 1995, DEVELOPMENT, V121, P1283
   WETZLER M, 1994, CANCER RES, V54, P1837
   Wu M, 2013, CYTOKINE, V62, P334, DOI 10.1016/j.cyto.2013.03.002
   Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407
   ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085
NR 48
TC 7
Z9 7
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2016
VL 117
IS 1
BP 49
EP 58
DI 10.1002/jcb.25246
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DB0WX
UT WOS:000368229800005
PM 26060100
DA 2025-01-12
ER

PT J
AU McCullough, LE
   Chen, J
   Cho, YH
   Khankari, NK
   Bradshaw, PT
   White, AJ
   Garbowski, G
   Teitelbaum, SL
   Terry, MB
   Neugut, AI
   Hibshoosh, H
   Santella, RM
   Gammon, MD
AF McCullough, Lauren E.
   Chen, Jia
   Cho, Yoon Hee
   Khankari, Nikhil K.
   Bradshaw, Patrick T.
   White, Alexandra J.
   Garbowski, Gail
   Teitelbaum, Susan L.
   Terry, Mary Beth
   Neugut, Alfred I.
   Hibshoosh, Hanina
   Santella, Regina M.
   Gammon, Marilie D.
TI DNA methylation modifies the association between obesity and survival
   after breast cancer diagnosis
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Body mass index; Epigenetics; Methylation; Breast cancer; Survival
ID CPG ISLAND HYPERMETHYLATION; PROMOTER HYPERMETHYLATION; LINE-1
   METHYLATION; POOR-PROGNOSIS; LONG-ISLAND; GENE; TUMOR; HYPOMETHYLATION;
   CELL; SERUM
AB Mechanisms underlying the poor breast cancer prognosis among obese women are unresolved. DNA methylation levels are linked to obesity and to breast cancer survival. We hypothesized that obesity may work in conjunction with the epigenome to alter prognosis. Using a population-based sample of women diagnosed with first primary breast cancer, we examined modification of the obesity-mortality association by DNA methylation. In-person interviews were conducted approximately 3 months after diagnosis. Weight and height were assessed [to estimate body mass index (BMI)], and blood samples collected. Promoter methylation of 13 breast cancer-related genes was assessed in archived tumor by methylation-specific PCR and Methyl Light. Global methylation in white blood cell DNA was assessed by analysis of long interspersed elements-1 (LINE-1) and with the luminometric methylation assay (LUMA). Vital status among 1308 patients (with any methylation biomarker and complete BMI assessment) was determined after approximately 15 years of follow-up (N = 194/441 deaths due to breast cancer-specific/all-cause mortality). We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) using two-sided p values of 0.05. Breast cancer-specific mortality was higher among obese (BMI a parts per thousand yen 30) patients with promoter methylation in APC (HR = 2.47; 95 % CI = 1.43-4.27) and TWIST1 (HR = 4.25; 95 % CI = 1.43-12.70) in breast cancer tissue. Estimates were similar, but less pronounced, for all-cause mortality. Increased all-cause (HR = 1.81; 95 % CI = 1.19-2.74) and breast cancer-specific (HR = 2.61; 95 % CI = 1.45-4.69) mortality was observed among obese patients with the lowest LUMA levels. The poor breast cancer prognosis associated with obesity may depend on methylation profiles, which warrants further investigation.
C1 [McCullough, Lauren E.; Gammon, Marilie D.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Chen, Jia; Teitelbaum, Susan L.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA.
   [Chen, Jia] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
   [Chen, Jia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
   [Cho, Yoon Hee; Garbowski, Gail; Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Khankari, Nikhil K.] Vanderbilt Univ, Div Epidemiol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Bradshaw, Patrick T.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.
   [White, Alexandra J.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
   [Terry, Mary Beth; Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY 10032 USA.
   [Hibshoosh, Hanina] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia
   University; Vanderbilt University; University of California System;
   University of California Berkeley; National Institutes of Health (NIH) -
   USA; NIH National Institute of Environmental Health Sciences (NIEHS);
   Columbia University; Columbia University; Columbia University
RP McCullough, LE (通讯作者)，Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM lauren.mccullough@emory.edu
RI Cho, Yoon/AAN-6560-2021; Bradshaw, Patrick/AAJ-7529-2021; White,
   Alexandra/D-9687-2019
OI White, Alexandra/0000-0003-2455-2945; Cho, Yoon Hee/0000-0002-4290-7140;
   Terry, Mary Beth/0000-0002-4106-5033
FU National Cancer Institute [R25CA057726, UO1CA/ES66572, R01CA66572,
   R01CA109753, 3R01CA109753-04S1]; National Institutes of Environmental
   Health and Sciences [P30ES009089, P30ES10126]; Department of Defense
   [BC972772]
FX This work was supported in part by Grants from the National Cancer
   Institute (R25CA057726, UO1CA/ES66572, R01CA66572, R01CA109753,
   3R01CA109753-04S1); the National Institutes of Environmental Health and
   Sciences (P30ES009089, P30ES10126); and the Department of Defense
   (BC972772).
CR Allison PD., 2010, SURVIVAL ANAL USING
   Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257
   [Anonymous], 1989, Applied Logistic Regression
   [Anonymous], 2014, Breast cancer
   [Anonymous], 2014, CANC TREATM SURV FAC
   [Anonymous], 2002, Logistic regression
   Baba Y, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-125
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bradshaw PT, 2012, EPIDEMIOLOGY, V23, P320, DOI 10.1097/EDE.0b013e31824596a1
   Cairns BJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-7
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Clarke CA, 2012, JNCI-J NATL CANCER I, V104, P1094, DOI 10.1093/jnci/djs264
   Cleveland RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1803, DOI 10.1158/1055-9965.EPI-06-0889
   Cleveland RJ, 2012, EUR J CANCER PREV, V21, P46, DOI 10.1097/CEJ.0b013e3283498dd4
   Cole SR, 2002, INT J EPIDEMIOL, V31, P163, DOI 10.1093/ije/31.1.163
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   CREESE I, 1975, LIFE SCI, V17, P993, DOI 10.1016/0024-3205(75)90454-3
   Deneberg S, 2010, LEUKEMIA, V24, P932, DOI 10.1038/leu.2010.41
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, CANCER RES, V60, P5021
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   Gammon MD, 2004, ARCH ENVIRON HEALTH, V59, P640, DOI 10.1080/00039890409602948
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Gyorffy B, 2016, INT J CANCER, V138, P87, DOI 10.1002/ijc.29684
   Incidence Rates by Race/Ethnicity, 2015, REP C TRAUM BRAIN IN
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1
   Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022
   Khankari NK, 2015, CANCER-AM CANCER SOC, V121, P2244, DOI 10.1002/cncr.29329
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Klein C, 2005, P AM ASS CANC RES, V46
   Ligibel J, 2011, ONCOLOGY-NY, V25, P994
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loi S, 2005, CANCER EPIDEM BIOMAR, V14, P1686, DOI 10.1158/1055-9965.EPI-05-0042
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Protani M, 2010, BREAST CANCER RES TR, V123, P627, DOI 10.1007/s10549-010-0990-0
   Rockwood LD, 2004, MUTAT RES-FUND MOL M, V548, P117, DOI 10.1016/j.mrfmmm.2004.01.005
   Saito K, 2010, CLIN CANCER RES, V16, P2418, DOI 10.1158/1078-0432.CCR-09-2819
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Snedeker S M, 1996, Prog Clin Biol Res, V394, P211
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304
   van Bemmel D, 2012, CANCER EPIDEM BIOMAR, V21, P1143, DOI 10.1158/1055-9965.EPI-11-1030
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V134, P1103, DOI 10.1007/s10549-012-2038-0
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
NR 56
TC 16
Z9 18
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2016
VL 156
IS 1
BP 183
EP 194
DI 10.1007/s10549-016-3724-0
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DG7IU
UT WOS:000372258800019
PM 26945992
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Avgustinova, A
   Benitah, SA
AF Avgustinova, Alexandra
   Aznar Benitah, Salvador
TI The epigenetics of tumour initiation: cancer stem cells and their
   chromatin
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN REPRESSION; BREAST-CANCER;
   EZH2; PLASTICITY; IDENTIFICATION; TRANSCRIPTION; DEMETHYLASES;
   ORGANIZATION; EQUILIBRIUM
AB Cancer stem cells (CSCs) have been identified in various tumours and are defined by their potential to initiate tumours upon transplantation, self-renew and reconstitute tumour heterogeneity. Modifications of the epigenome can favour tumour initiation by affecting genome integrity, DNA repair and tumour cell plasticity. Importantly, an in-depth understanding of the epigenomic alterations underlying neoplastic transformation may open new avenues for chromatin-targeted cancer treatment, as these epigenetic changes could be inherently more amenable to inhibition and reversal than hardwired genomic alterations. Here we discuss how CSC function is affected by chromatin state and epigenomic instability.
C1 [Avgustinova, Alexandra; Aznar Benitah, Salvador] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain.
   [Aznar Benitah, Salvador] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.
C3 Barcelona Institute of Science & Technology; Institute for Research in
   Biomedicine - IRB Barcelona; ICREA
RP Benitah, SA (通讯作者)，Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain.; Benitah, SA (通讯作者)，Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.
EM salvador.aznar-benitah@irbbarcelona.org
RI Avgustinova, Alexandra/ABE-7886-2020; Aznar Benitah,
   Salvador/F-4761-2016
OI Avgustinova, Alexandra/0000-0001-6016-2931; Aznar Benitah,
   Salvador/0000-0002-9059-5049
FU European Research Council (ERC); Worldwide Cancer Research Foundation;
   Foundation La Marato; Spanish Ministry of Economy and Development;
   Foundation Vencer el Cancer ('Beat Cancer'); Government of Cataluna;
   Foundation Botin; Institute for Research in Biomedicine (IRB-Barcelona);
   COFUND Marie Curie EU Action Fellowship; ICREA Funding Source: Custom
FX Research in the lab of S.A.B. is supported by the European Research
   Council (ERC), the Worldwide Cancer Research Foundation, the Foundation
   La Marato, the Spanish Ministry of Economy and Development, the
   Foundation Vencer el Cancer ('Beat Cancer'), the Government of Cataluna
   (SGR and Mario Salvia grants), the Foundation Botin, and the Institute
   for Research in Biomedicine (IRB-Barcelona). A. A. is funded by a COFUND
   Marie Curie EU Action Fellowship. We thank Veronica Raker for editing
   the manuscript.
CR Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chen JK, 2013, NAT GENET, V45, P34, DOI 10.1038/ng.2491
   Christophorou MA, 2014, NATURE, V507, P104, DOI 10.1038/nature12942
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Greaves M, 2015, CANCER DISCOV, V5, P806, DOI 10.1158/2159-8290.CD-15-0439
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736
   He KJ, 2011, MOL CANCER THER, V10, P938, DOI 10.1158/1535-7163.MCT-10-1120
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Kakarougkas A, 2014, MOL CELL, V55, P723, DOI 10.1016/j.molcel.2014.06.028
   Kalousi A, 2015, CELL REP, V11, P149, DOI 10.1016/j.celrep.2015.03.005
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Kouzarides T, 2007, CELL, V128, P802, DOI 10.1016/j.cell.2007.02.018
   Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006
   Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Lin BY, 2015, ONCOTARGET, V6, P5369, DOI 10.18632/oncotarget.3030
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Morgan MA, 2015, GENE DEV, V29, P238, DOI 10.1101/gad.255182.114
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221
   Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222
   Rinaldi L, 2015, FEBS J, V282, P1589, DOI 10.1111/febs.12946
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rompolas P, 2012, NATURE, V487, P496, DOI 10.1038/nature11218
   Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032
   Schuster-Böckler B, 2012, NATURE, V488, P504, DOI 10.1038/nature11273
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Seton-Rogers S, 2014, NAT REV CANCER, V14, P7
   Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Shukla S, 2014, BBA-GEN SUBJECTS, V1840, P3494, DOI 10.1016/j.bbagen.2014.09.017
   Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Tetteh PW, 2015, TRENDS CELL BIOL, V25, P100, DOI 10.1016/j.tcb.2014.09.003
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Trowbridge JJ, 2012, GENE DEV, V26, P344, DOI 10.1101/gad.184341.111
   van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581
   Vissers JHA, 2012, J CELL SCI, V125, P3939, DOI 10.1242/jcs.107375
   Wang ZW, 2013, J CELL PHYSIOL, V228, P556, DOI 10.1002/jcp.24162
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938
   Yamazaki J, 2013, EPIGENETICS-US, V8, P92, DOI 10.4161/epi.23243
   Yanger K, 2014, CELL STEM CELL, V15, P340, DOI 10.1016/j.stem.2014.06.003
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yu CC, 2011, J ONCOL, V2011, DOI 10.1155/2011/609259
NR 76
TC 49
Z9 52
U1 0
U2 20
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
EI 1879-0380
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD FEB
PY 2016
VL 36
BP 8
EP 15
DI 10.1016/j.gde.2016.01.003
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA DM4AO
UT WOS:000376288100003
PM 26874045
DA 2025-01-12
ER

PT J
AU Sepulveda, JL
   Gutierrez-Pajares, JL
   Luna, A
   Yao, Y
   Tobias, JW
   Thomas, S
   Woo, Y
   Giorgi, F
   Komissarova, EV
   Califano, A
   Wang, TC
   Sepulveda, AR
AF Sepulveda, Jorge L.
   Gutierrez-Pajares, Jorge L.
   Luna, Aesis
   Yao, Yuan
   Tobias, John W.
   Thomas, Steven
   Woo, Yanghee
   Giorgi, Federico
   Komissarova, Elena V.
   Califano, Andrea
   Wang, Timothy C.
   Sepulveda, Antonia R.
TI High-definition CpG methylation of novel genes in gastric carcinogenesis
   identified by next-generation sequencing
SO MODERN PATHOLOGY
LA English
DT Article
ID DNA METHYLATION; MICROSATELLITE INSTABILITY; HELICOBACTER-PYLORI;
   INTESTINAL METAPLASIA; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; CANCER; EXPRESSION; PHENOTYPE; CHFR
AB Gastric cancers are the most frequent gastric malignancy and usually arise in the sequence of Helicobacter pylori-associated chronic gastritis. CpG methylation is a central mechanism of epigenetic gene regulation affecting cancer-related genes, and occurs early in gastric carcinogenesis. DNA samples from non-metaplastic gastric mucosa with variable levels of gastritis (non-metaplastic mucosa), intestinal metaplasia, or gastric cancer were screened with methylation arrays for CpG methylation of cancer-related genes and 30 gene targets were further characterized by high-definition bisulfite next-generation sequencing. In addition, data from The Cancer Genome Atlas were analyzed for correlation of methylation with gene expression. Overall, 13 genes had significantly increased CpG methylation in gastric cancer vs non-metaplastic mucosa (BRINP1, CDH11, CHFR, EPHA5, EPHA7, FGF2, FLI1, GALR1, HS3ST2, PDGFRA, SEZ6L, SGCE, and SNRPN). Further, most of these genes had corresponding reduced expression levels in gastric cancer compared with intestinal metaplasia, including novel hypermethylated genes in gastric cancer (FLI1, GALR1, SGCE, and SNRPN), suggesting that they may regulate neoplastic transformation from non-malignant intestinal metaplasia to cancer. Our data suggest a tumor-suppressor role for FLI1 in gastric cancer, consistent with recently reported data in breast cancer. For the genes with strongest methylation/expression correlation, namely FLI1, the expression was lowest in microsatellite-unstable tumors compared with other gastric cancer molecular subtypes. Importantly, reduced expression of hypermethylated BRINP1 and SGCE was significantly associated with favorable survival in gastric cancer. In summary, we report novel methylation gene targets that may have functional roles in discrete stages of gastric carcinogenesis and may serve as biomarkers for diagnosis and prognosis of gastric cancer.
C1 [Sepulveda, Jorge L.; Gutierrez-Pajares, Jorge L.; Luna, Aesis; Thomas, Steven; Sepulveda, Antonia R.] Columbia Univ, Dept Pathol & Cell Biol, 630W 168th St,VC-14 RM 212, New York, NY 10032 USA.
   [Yao, Yuan] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
   [Tobias, John W.] Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA.
   [Woo, Yanghee] Columbia Univ, Dept Surg, New York, NY USA.
   [Giorgi, Federico; Komissarova, Elena V.; Califano, Andrea] Columbia Univ, Dept Syst Biol, New York, NY USA.
   [Wang, Timothy C.] Columbia Univ, Dept Med, Div Gastroenterol, New York, NY USA.
C3 Columbia University; University of Pennsylvania; University of
   Pennsylvania; Columbia University; Columbia University; Columbia
   University
RP Sepulveda, AR (通讯作者)，Columbia Univ, Dept Pathol & Cell Biol, 630W 168th St,VC-14 RM 212, New York, NY 10032 USA.
EM as4400@columbia.edu
RI wang, tim/JXM-8048-2024; Gutierrez-Pajares, Jorge/ABF-2634-2021;
   Califano, Andrea/F-7239-2012; Giorgi, Federico/AAD-5797-2020
OI Gutierrez-Pajares, Jorge L./0000-0002-3573-0754; Wang,
   Timothy/0000-0001-5730-3019; Woo, Yanghee/0000-0002-6676-0593; Thomas,
   Steven/0000-0002-2626-6291; Komissarova, Elena V./0000-0001-6848-0635;
   Luna, Aesis/0000-0001-7942-8541; Giorgi, Federico/0000-0002-7325-9908;
   Califano, Andrea/0000-0003-4742-3679
FU Department of Pathology and Cell Biology, Columbia University; Herbert
   Irving Comprehensive Cancer Center
FX Next-generation bisulfite sequencing was performed by the Molecular
   Cytogenetics & Epigenetics Shared Resource of the Herbert Irving
   Comprehensive Cancer Center. This study was funded by the Department of
   Pathology and Cell Biology, Columbia University and by a pilot award
   from the Herbert Irving Comprehensive Cancer Center.
CR Abedin MJ, 2014, CIRC RES, V114, P1690, DOI 10.1161/CIRCRESAHA.1134303145
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   [Anonymous], TRIM GAL
   [Anonymous], WHAT AR KEY STAT STO
   [Anonymous], 2012, GLOBOCAN 2012 EST CA
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Beetz C, 2005, ONCOL REP, V13, P335
   Benetatos L, 2010, LEUKEMIA RES, V34, P148, DOI 10.1016/j.leukres.2009.06.019
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Chan AOO, 2006, GUT, V55, P463, DOI 10.1136/gut.2005.077776
   Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Fu Z, 2009, J CLIN INVEST, V119, P2714, DOI 10.1172/JCI37405
   Gologan A, 2005, CLIN LAB MED, V25, P197, DOI 10.1016/j.cll.2004.12.002
   Gronbaek K, 2008, MODERN PATHOL, V21, P632, DOI 10.1038/modpathol.2008.27
   Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165
   Han HS, 2010, ONCOL LETT, V1, P555, DOI 10.3892/ol_00000098
   Herrera V, 2009, CLIN MICROBIOL INFEC, V15, P971, DOI 10.1111/j.1469-0691.2009.03031.x
   Herrero R, 2014, JAMA-J AM MED ASSOC, V312, P1197, DOI 10.1001/jama.2014.10498
   Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Kawano H, 2004, MOL BRAIN RES, V125, P60, DOI 10.1016/j.molbrainres.2004.04.001
   Kim SY, 2015, INT J CANCER, V137, P819, DOI 10.1002/ijc.29449
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Leung WK, 2000, AM J PATHOL, V156, P537, DOI 10.1016/S0002-9440(10)64758-X
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin PC, 2015, ANN SURG ONCOL, V22, pS1419, DOI 10.1245/s10434-014-4277-2
   Loh M, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-55
   Misawa K, 2008, CLIN CANCER RES, V14, P7604, DOI 10.1158/1078-0432.CCR-07-4673
   Motani K, 2010, CANCER SCI, V101, P1822, DOI 10.1111/j.1349-7006.2010.01610.x
   Murphy G, 2015, CLIN GASTROENTEROL H, V13, P2282, DOI 10.1016/j.cgh.2015.05.040
   Oki E, 2009, WORLD J GASTROENTERO, V15, P2520, DOI 10.3748/wjg.15.2520
   Ortega P, 2010, INT J ONCOL, V36, P1209, DOI 10.3892/ijo_00000604
   Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   R Core Team, LANG ENV STAT COMP
   Satoh A, 2003, CANCER RES, V63, P8606
   Scheiber MN, 2014, NEOPLASIA, V16, P801, DOI 10.1016/j.neo.2014.08.007
   Sepulveda AR, 2010, GASTROENTEROLOGY, V138, P1836, DOI 10.1053/j.gastro.2009.12.042
   Sepulveda Antonia R, 2009, J Mol Diagn, V11, P266, DOI 10.2353/jmoldx.2009.080125
   Sepulveda AR, 2002, GASTROENTEROL CLIN N, V31, P517, DOI 10.1016/S0889-8553(02)00012-2
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Taniguchi S, 2007, SEMIN IMMUNOPATHOL, V29, P231, DOI 10.1007/s00281-007-0082-3
   To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Wang JD, 2007, HUM PATHOL, V38, P1649, DOI 10.1016/j.humpath.2007.01.030
   Wang MM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0907-6
   Yao Y, 2004, LAB INVEST, V84, P915, DOI 10.1038/labinvest.3700117
   Yoshida K, 2006, ANTICANCER RES, V26, P49
NR 56
TC 44
Z9 47
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2016
VL 29
IS 2
BP 182
EP 193
DI 10.1038/modpathol.2015.144
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DC3JL
UT WOS:000369115500010
PM 26769141
OA Bronze
DA 2025-01-12
ER

PT J
AU Lin, AF
   Li, CL
   Xing, Z
   Hu, QS
   Liang, K
   Han, L
   Wang, C
   Hawke, DH
   Wang, SY
   Zhang, YY
   Wei, YK
   Ma, GL
   Park, PK
   Zhou, JW
   Zhou, Y
   Hu, ZB
   Zhou, YB
   Marks, JR
   Liang, H
   Hung, MC
   Lin, CR
   Yang, LQ
AF Lin, Aifu
   Li, Chunlai
   Xing, Zhen
   Hu, Qingsong
   Liang, Ke
   Han, Leng
   Wang, Cheng
   Hawke, David H.
   Wang, Shouyu
   Zhang, Yanyan
   Wei, Yongkun
   Ma, Guolin
   Park, Peter K.
   Zhou, Jianwei
   Zhou, Yan
   Hu, Zhibin
   Zhou, Yubin
   Marks, Jeffery R.
   Liang, Han
   Hung, Mien-Chie
   Lin, Chunru
   Yang, Liuqing
TI The <i>LINK</i>-<i>A</i> lncRNA activates normoxic HIF1α signalling in
   triple-negative breast cancer
SO NATURE CELL BIOLOGY
LA English
DT Article
ID LONG NONCODING RNAS; TYROSINE KINASE; TUMOR-GROWTH; EPIGENETIC
   REGULATION; BINDING SITES; HYPOXIA; PROMOTES; PROTEIN; HIF-1; TARGET
AB Although long non-coding RNAs (lncRNAs) predominately reside in the nucleus and exert their functions in many biological processes, their potential involvement in cytoplasmic signal transduction remains unexplored. Here, we identify a cytoplasmic lncRNA, LINK-A (long intergenic non-coding RNA for kinase activation), which mediates HB-EGF-triggered, EGFR:GPNMB heterodimer-dependent HIF1 alpha phosphorylation at Tyr 565 and Ser 797 by BRK and LRRK2, respectively. These events cause HIF1 alpha stabilization, HIF1 alpha-p300 interaction, and activation of HIF1 alpha transcriptional programs under normoxic conditions. Mechanistically, LINK-A facilitates the recruitment of BRK to the EGFR:GPNMB complex and BRK kinase activation. The BRK-dependent HIF1 alpha Tyr 565 phosphorylation interferes with Pro 564 hydroxylation, leading to normoxic HIF1 alpha stabilization. Both LINK-A expression and LINK-A-dependent signalling pathway activation correlate with triple-negative breast cancer (TNBC), promoting breast cancer glycolysis reprogramming and tumorigenesis. Our findings illustrate the magnitude and diversity of cytoplasmic lncRNAs in signal transduction and highlight the important roles of lncRNAs in cancer.
C1 [Lin, Aifu; Li, Chunlai; Xing, Zhen; Hu, Qingsong; Liang, Ke; Wang, Shouyu; Zhang, Yanyan; Wei, Yongkun; Park, Peter K.; Hung, Mien-Chie; Lin, Chunru; Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Han, Leng] Univ Texas Hlth Sci Ctr Houston, McGroven Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Wang, Cheng; Hu, Zhibin] Nanjing Med Univ, Dept Epidemiol & Biostat, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Cheng; Hu, Zhibin] Nanjing Med Univ, Sch Publ Hlth, Minist Educ MOE, Nanjing 210029, Jiangsu, Peoples R China.
   [Hawke, David H.; Liang, Han] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Ma, Guolin; Zhou, Yubin] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.
   [Zhou, Jianwei] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhou, Yan] Yixing Peoples Hosp, Dept Oncol, 75 Zhenguan Rd, Yixing 214200, Peoples R China.
   [Marks, Jeffery R.] Duke Univ, Sch Med, Div Surg Sci, Dept Surg, Durham, NC 27710 USA.
   [Liang, Han] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Hung, Mien-Chie; Lin, Chunru; Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung 404, Taiwan.
   [Hung, Mien-Chie] China Med Univ, Grad Inst Canc Biol, Taichung 404, Taiwan.
   [Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston; Nanjing
   Medical University; Nanjing Medical University; University of Texas
   System; UTMD Anderson Cancer Center; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center;
   University of Texas System; University of Texas Health Science Center
   Houston; Nanjing Medical University; Duke University; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; China Medical University Taiwan; China
   Medical University Taiwan; University of Texas System; UTMD Anderson
   Cancer Center
RP Lin, CR; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Lin, CR; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
EM clin2@mdanderson.org; lyang7@mdanderson.org
RI Zhou, Yubin/D-4748-2011; Yang, Liuqing/HQY-8902-2023; Han,
   Leng/HCH-3491-2022; Chen, Wei/GZK-7348-2022; Li, Chunlai/AAI-8839-2021;
   Zhou, Jianwei/JPW-9256-2023; Hung, Mien-Chie/ABD-5911-2021; Ma,
   Guolin/D-2504-2018; Zhang, Yanyan/P-9931-2018
OI Ma, Guolin/0000-0001-5460-3446; Hung, Mien-Chie/0000-0003-4317-4740;
   ZHOU, YUBIN/0000-0001-7962-0517; Liang, Ke/0009-0002-2078-989X; Li,
   Chunlai/0000-0003-1897-9889; Hawke, David/0000-0002-6102-7843; Han,
   Leng/0000-0002-7380-2640; Zhang, Yanyan/0000-0002-6037-5918
FU NIH [R00DK094981, R00CA166527]; UT Startup grant; UT STARS grant; CPRIT
   award [R1218]
FX We thank S. Kopetz for providing cetuximab and J. Chen for providing
   SFB-tagged expression vector. We thank D. Aten for assistance with
   figure presentation. This work was supported by the NIH R00 award
   (R00DK094981), UT Startup and UT STARS grants to C.Lin, and the NIH R00
   award (R00CA166527), CPRIT award (R1218), UT Startup and UT STARS grants
   to L.Y.
CR Agalliu I, 2015, JAMA NEUROL, V72, P58, DOI 10.1001/jamaneurol.2014.1973
   Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009
   Anderson TMR, 2013, CANCER RES, V73, P5810, DOI 10.1158/0008-5472.CAN-13-0523
   Andrews SJ, 2014, NAT REV GENET, V15, P193, DOI 10.1038/nrg3520
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998
   Brauer PM, 2010, BBA-REV CANCER, V1806, P66, DOI 10.1016/j.bbcan.2010.02.003
   Bubb KL, 2006, GENETICS, V173, P2165, DOI 10.1534/genetics.106.055715
   Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508
   Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031
   Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233
   Ciesla J, 2006, ACTA BIOCHIM POL, V53, P11
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Han L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4963
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956
   Knowles HJ, 2006, CANCER RES, V66, P2600, DOI 10.1158/0008-5472.CAN-05-2351
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kuschel A, 2012, J CELL PHYSIOL, V227, P514, DOI 10.1002/jcp.22798
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8
   Martin I, 2014, CELL, V157, P472, DOI 10.1016/j.cell.2014.01.064
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Miah S, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.11
   Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440
   Morlando M, 2014, CHEMMEDCHEM, V9, P505, DOI 10.1002/cmdc.201300569
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Orom UA, 2010, COLD SH Q B, V75, P325, DOI 10.1101/sqb.2010.75.058
   Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611
   Ruiz-Orera J, 2014, ELIFE, V3, DOI 10.7554/eLife.03523
   Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001
   Schödel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Schwab LP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3087
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com
   Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049
   Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324
   Vance KW, 2014, TRENDS GENET, V30, P348, DOI 10.1016/j.tig.2014.06.001
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Wang XT, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003756
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013
   Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451
   Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024
   Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010
NR 61
TC 433
Z9 473
U1 7
U2 174
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD FEB
PY 2016
VL 18
IS 2
BP 213
EP +
DI 10.1038/ncb3295
PG 27
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DC3NZ
UT WOS:000369127300010
PM 26751287
OA Green Accepted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Jha, AK
   Sharma, V
   Nikbakht, M
   Jain, V
   Sehgal, A
   Capalash, N
   Kaur, J
AF Jha, A. K.
   Sharma, V.
   Nikbakht, M.
   Jain, V.
   Sehgal, A.
   Capalash, N.
   Kaur, J.
TI A comparative analysis of methylation status of tumor suppressor genes
   in paired biopsy and serum samples from cervical cancer patients among
   north indian population
SO RUSSIAN JOURNAL OF GENETICS
LA English
DT Article
DE promoter hypermethylation; p16; RAR beta 2; biomarkers
ID HYPERMETHYLATION-ASSOCIATED INACTIVATION; DEPENDENT KINASE INHIBITOR;
   BREAST-CANCER; PROMOTER HYPERMETHYLATION; DNA METHYLATION; QUANTITATIVE
   DETECTION; MULTIPLE GENES; CPG ISLAND; P53; CARCINOGENESIS
AB Tumor-specific genetic or epigenetic alterations have been detected in serum DNA in case of various types of cancers. In breast cancer, the detection of tumor suppressor gene hypermethylation has been reported in several body fluids. Promoter hypermethylation of some genes like MYOD1, CALCA, hTERT, etc. has also been detected in serum samples from cervical cancer. The present study is the first report on the comparison of promoter hypermethylation of tumor suppressor genes like p14, p15, p16, p21, p27, p57, p53, p73, RAR beta 2, FHIT, DAPK, STAT1, and RB1 genes in paired biopsy and serum samples from cervical cancer patients among north Indian population. This is also the first report on the hypermethylation of these genes in serum samples from cervical cancer patients among north Indian population. According to the results of the present study, promoter hypermethylation of these genes can also be detected in serum samples of cervical cancer patients. The sensitivity of detection of promoter hypermethylalion in serum samples of cervical cancer patients as compared to paired biopsy samples was found to be around 83.3%. It was observed that promoter hypermethylation was mainly observed in the serum samples in the higher stages and very rarely in the lower stages. The present study clearly showed that serum of patients with cervical cancer can also be used to study methylated genes as biomarkers.
C1 [Jha, A. K.; Sharma, V.; Nikbakht, M.; Capalash, N.; Kaur, J.] Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.
   [Jain, V.] Mohan Dai Oswal Canc Treatment & Res Fdn, Dept Gynaecol, Ludhiana, Punjab, India.
   [Jha, A. K.] IMS Engn Coll, Dept Biotechnol, Ghaziabad 201009, India.
   [Sehgal, A.] Govt Med Coll & Hosp, Dept Gynaecol, Chandigarh, India.
C3 Panjab University
RP Jha, AK (通讯作者)，Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.; Jha, AK (通讯作者)，IMS Engn Coll, Dept Biotechnol, Ghaziabad 201009, India.
EM jagsekhon@yahoo.com
RI Kaur, Jagdeep/C-4155-2015; nikbakht, mohsen/O-9391-2016
OI Kaur, Jagdeep/0000-0002-2252-2489; Capalash, Neena/0000-0002-0197-8428;
   nikbakht, mohsen/0000-0001-6621-5424
FU CSIR (Council of Scientific and Industrial Research), India
FX The authors acknowledge the financial assistance provided by CSIR
   (Council of Scientific and Industrial Research), India to AKJ. We also
   acknowledge the help provided by Ruchi Aggarwal for helping in arranging
   the reference section.
CR Aggarwal R., 2015, BIOCH MOSCO IN PRESS
   Anker P, 2002, CLIN CHEM, V48, P1210
   [Anonymous], 2004, CANC RES
   Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003
   Chim CS, 2006, J CLIN PATHOL, V59, P921, DOI 10.1136/jcp.2005.035089
   Chim CS, 2005, LEUKEMIA, V19, P2352, DOI 10.1038/sj.leu.2403904
   Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, CANCER RES, V60, P129
   Go JH, 2003, MODERN PATHOL, V16, P752, DOI 10.1097/01.MP.0000081728.21368.85
   Herman JG, 1996, CANCER RES, V56, P722
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jha A. K., 2014, European Journal of Medicinal Plants, V4, P503
   Jha AK, 2010, FOLIA BIOL-PRAGUE, V56, P195
   Jha A.K., 2011, J MED MED SCI, V2, P696
   Jha AK, 2012, MOL BIOL REP, V39, P9145, DOI 10.1007/s11033-012-1787-5
   Jha AK, 2012, ONCOL LETT, V3, P1331, DOI 10.3892/ol.2012.655
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kim JS, 2004, J CLIN ONCOL, V22, P3443, DOI 10.1200/JCO.2004.11.135
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Müller HM, 2003, CANCER RES, V63, P7641
   Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Shao ZM, 2002, ANTI-CANCER DRUG, V13, P353, DOI 10.1097/00001813-200204000-00003
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Siu LLP, 2002, AM J PATHOL, V160, P59
   Trejo-Becerril C, 2003, INT J CANCER, V104, P663, DOI 10.1002/ijc.11003
   Virmani AK, 2001, CLIN CANCER RES, V7, P584
   Widschwendter A, 2004, CLIN CANCER RES, V10, P565, DOI 10.1158/1078-0432.CCR-0825-03
   Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020
   Yeh KT, 2003, ONCOL REP, V10, P659
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 34
TC 9
Z9 11
U1 0
U2 8
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1022-7954
EI 1608-3369
J9 RUSS J GENET+
JI Russ. J. Genet.
PD FEB
PY 2016
VL 52
IS 2
BP 226
EP 230
DI 10.1134/S1022795416010075
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DI3CU
UT WOS:000373376600014
PM 27215041
DA 2025-01-12
ER

PT J
AU Kagan, SH
AF Kagan, Sarah H.
TI THE FUTURE OF GERO-ONCOLOGY NURSING
SO SEMINARS IN ONCOLOGY NURSING
LA English
DT Article
DE older adult; older people; geriatric oncology; gero-oncology nursing
ID AGING-IN-PLACE; GERIATRIC ASSESSMENT; HEALTH-CARE; CANCER SURVIVORSHIP;
   BREAST-CANCER; AGE; FRAILTY; NURSES; MULTIMORBIDITY; EPIGENETICS
AB OBJECTIVES: To project the future of gero-oncology nursing as a distinct specialty, framed between analysis of current challenges and explication of prospective solutions.
   DATA SOURCES: Peer-reviewed literature, policy directives, web-based resources, and author expertise.
   CONCLUSION: Oncology nursing faces several challenges in meeting the needs of older people living with cancer. Realigning cancer nursing education, practice, and research to match demographic and epidemiological realities mandates redesign. Viewing geriatric oncology as an optional sub-specialty limits oncology nursing, where older people represent the majority of oncology patients and cancer survivors. The future of gero-oncology nursing lies in transforming oncology nursing itself.
C1 [Kagan, Sarah H.] Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Kagan, SH (通讯作者)，Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM skagan@nursing.upenn.edu
CR Adams KB, 2011, AGEING SOC, V31, P683, DOI 10.1017/S0144686X10001091
   [Anonymous], 2013, DELIVERING HIGH QUAL
   [Anonymous], CANC SERV COM AG LEA
   [Anonymous], 2008, Retooling for an aging America: Building the Healthcare Workforce
   [Anonymous], 2014, BMJ
   [Anonymous], JONAS KOVNERS HLTH C
   [Anonymous], 2008, CANC CARE WHOLE PATI
   [Anonymous], COMMUNITY ONCOL
   Bellury L, 2012, CANCER-AM CANCER SOC, V118, P6171, DOI 10.1002/cncr.27656
   Bellury LM, 2011, EUR J ONCOL NURS, V15, P233, DOI 10.1016/j.ejon.2011.03.008
   Berman A, 2005, J PROF NURS, V21, P268, DOI 10.1016/j.profnurs.2005.07.005
   Best M, 2015, PALLIAT SUPPORT CARE, V13, P1335, DOI 10.1017/S1478951514001217
   Bond SM, 2016, SEMIN ONCOL NURS, V32, P3, DOI 10.1016/j.soncn.2015.11.002
   Boswell SS, 2012, EDUC GERONTOL, V38, P465, DOI 10.1080/03601277.2011.559864
   Bousfield C, 2010, EDUC GERONTOL, V36, P451, DOI 10.1080/03601270903324362
   Bravell ME, 2011, ARCH GERONTOL GERIAT, V53, P40, DOI 10.1016/j.archger.2010.06.011
   Bridges J, 2016, SEMIN ONCOL NURS, V32, P16, DOI 10.1016/j.soncn.2015.11.003
   Burhenn PS, 2016, SEMIN ONCOL NURS, V32, P24, DOI 10.1016/j.soncn.2015.11.004
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Capezuti E, 2012, J CLIN NURS, V21, P3117, DOI 10.1111/j.1365-2702.2012.04259.x
   Clark AE, 2013, NURS CLIN N AM, V48, P649, DOI 10.1016/j.cnur.2013.08.004
   Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9
   Clegg A, 2011, CLIN MED, V11, P72, DOI 10.7861/clinmedicine.11-1-72
   Coffey Alice, 2015, Nurs Older People, V27, P33, DOI 10.7748/nop.27.1.33.e648
   Cohen JE, 2003, SCIENCE, V302, P1172, DOI 10.1126/science.1088665
   Coulmas F, 2007, ROUTL CONTEMP JPN SE, V16, P1
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   de Moor JS, 2013, CANCER EPIDEM BIOMAR, V22, P561, DOI 10.1158/1055-9965.EPI-12-1356
   Decoster L, 2013, J GERIATR ONCOL, V4, P235, DOI 10.1016/j.jgo.2013.04.010
   Fawcett J, 1984, Image J Nurs Sch, V16, P84
   Fried TR, 2011, ARCH INTERN MED, V171, P75, DOI 10.1001/archinternmed.2010.318
   Gilje F, 2007, J PROF NURS, V23, P21, DOI 10.1016/j.profnurs.2006.12.001
   Gilligan AM, 2014, AM J PHARM EDUC, V78, DOI 10.5688/ajpe78110
   Golden AG, 2015, ACAD MED, V90, P1236, DOI 10.1097/ACM.0000000000000822
   Gosney M, 2009, CLIN ONCOL-UK, V21, P86, DOI 10.1016/j.clon.2008.11.005
   Greenfield EA, 2012, GERONTOLOGIST, V52, P1, DOI 10.1093/geront/gnr108
   Huang AR, 2011, CAN GERIATR J, V14, P100, DOI [10.5770/cgj.v14i4.8, 10.57700/cgj.v14i4.8]
   Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kagan SH, 2015, J NURS MANAGE, V23, P644, DOI 10.1111/jonm.12191
   Kagan SH, 2015, CANCER NURS, V38, P330, DOI 10.1097/NCC.0000000000000270
   Kagan SH, 2014, CANCER NURS, V37, P478, DOI 10.1097/NCC.0000000000000199
   Kagan SH, 2014, CANCER NURS, V37, P236, DOI 10.1097/NCC.0000000000000134
   Kagan Sarah H, 2008, Semin Oncol Nurs, V24, P246, DOI 10.1016/j.soncn.2008.08.004
   Kenis C, 2014, J GERIATR ONCOL, V5, P431, DOI 10.1016/j.jgo.2014.06.043
   Litwin H, 2011, GERONTOLOGIST, V51, P379, DOI 10.1093/geront/gnq094
   Lockhart JS, 2013, J NURS EDUC, V52, P383, DOI 10.3928/01484834-20130529-01
   Luciani A, 2004, SEMIN ONCOL, V31, P264, DOI 10.1053/j.seminoncol.2003.12.035
   Lynch MP, 2016, SEMIN ONCOL NURS, V32, P44, DOI 10.1016/j.soncn.2015.11.006
   Lyon D, 2014, BIOL RES NURS, V16, P160, DOI 10.1177/1099800413483545
   Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003
   McCormack B, 2004, J CLIN NURS, V13, P31, DOI 10.1111/j.1365-2702.2004.00924.x
   McCormack B, 2006, J ADV NURS, V56, P472, DOI 10.1111/j.1365-2648.2006.04042.x
   McNeil C, 2013, JNCI-J NATL CANCER I, V105, P585, DOI 10.1093/jnci/djt104
   Mezey M, 2002, J GERONTOL A-BIOL, V57, pM438, DOI 10.1093/gerona/57.7.M438
   Mezey M, 2008, J AM GERIATR SOC, V56, P1724, DOI 10.1111/j.1532-5415.2008.01857.x
   Mezey M, 2007, GERIATR NURS, V28, P9, DOI 10.1016/j.gerinurse.2007.10.013
   Millon-Underwood Sandra, 2008, Semin Oncol Nurs, V24, P279, DOI 10.1016/j.soncn.2008.08.008
   Mintzer DM, 2013, J CLIN ONCOL, V31, P393, DOI 10.1200/JCO.2012.47.0088
   Morgan B, 2016, SEMIN ONCOL NURS, V32, P33, DOI 10.1016/j.soncn.2015.11.005
   Olshansky SJ, 2009, MILBANK Q, V87, P842, DOI 10.1111/j.1468-0009.2009.00581.x
   Palos GR, 2013, CLIN J ONCOL NURS, V17, P88, DOI 10.1188/13.CJON.88-90
   Patterson SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub2
   Puts MTE, 2014, ANN ONCOL, V25, P307, DOI 10.1093/annonc/mdt386
   Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620
   Reeves S, 2013, J INTERPROF CARE, V27, P441, DOI 10.3109/13561820.2013.846033
   Rodin MB, 2007, J CLIN ONCOL, V25, P1936, DOI 10.1200/JCO.2006.10.2954
   Rowland JH, 2014, J CLIN ONCOL, V32, P2662, DOI 10.1200/JCO.2014.55.8361
   Rozanova J, 2016, AGEING SOC, V36, P17, DOI 10.1017/S0144686X14000907
   Salive ME, 2013, EPIDEMIOL REV, V35, P75, DOI 10.1093/epirev/mxs009
   Scharlach A, 2012, GERONTOLOGIST, V52, P418, DOI 10.1093/geront/gnr083
   SECCOMBE K, 1991, GERONTOLOGIST, V31, P527, DOI 10.1093/geront/31.4.527
   Simonds VW, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120205
   Skeath P, 2013, QUAL HEALTH RES, V23, P1155, DOI 10.1177/1049732313499074
   Smith BD, 2009, J CLIN ONCOL, V27, P2758, DOI 10.1200/JCO.2008.20.8983
   Solberg LB, 2015, J AM GERIATR SOC, V63, P997, DOI 10.1111/jgs.13394
   Stichler JF, 2013, HERD-HEALTH ENV RES, V6, P7, DOI 10.1177/193758671300600202
   Thibault GE, 2013, HEALTH AFFAIR, V32, P1928, DOI 10.1377/hlthaff.2013.0827
   Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265
   Trajkovski S, 2013, J ADV NURS, V69, P1224, DOI 10.1111/jan.12086
   Van Cleave JH, 2016, SEMIN ONCOL NURS, V32, P55, DOI 10.1016/j.soncn.2015.11.007
   Vorderstrasse Allison A, 2014, Semin Oncol Nurs, V30, P130, DOI 10.1016/j.soncn.2014.03.007
   Voyer P, 2010, GERIATR NURS, V31, P105, DOI 10.1016/j.gerinurse.2009.12.001
   Weicht B, 2013, J AGING STUD, V27, P188, DOI 10.1016/j.jaging.2013.03.001
   WHO, 2007, Global Age-Friendly Cities: A Guide
   Wiles JL, 2012, GERONTOLOGIST, V52, P357, DOI 10.1093/geront/gnr098
   Yancik R, 2005, CANCER J, V11, P437, DOI 10.1097/00130404-200511000-00002
NR 87
TC 14
Z9 15
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-2081
EI 1878-3449
J9 SEMIN ONCOL NURS
JI Semin. Oncol. Nurs.
PD FEB
PY 2016
VL 32
IS 1
BP 65
EP 76
DI 10.1016/j.soncn.2015.11.008
PG 12
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA FR0XR
UT WOS:000418788400008
PM 26830269
DA 2025-01-12
ER

PT J
AU Zhao, HJ
   Leppert, JT
   Peehl, DM
AF Zhao, Hongjuan
   Leppert, John T.
   Peehl, Donna M.
TI A Protective Role for Androgen Receptor in Clear Cell Renal Cell
   Carcinoma Based on Mining TCGA Data
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; CIRCADIAN REGULATION; GENE-EXPRESSION; KIDNEY; THERAPY;
   PATHWAY; PROTEIN; TUMORS
AB Androgen receptor (AR) is expressed in normal murine and human kidneys of both genders, but its physiologic role is uncertain. Several studies showed loss of AR in renal cell carcinoma (RCC) in conjunction with increasing clinical stage and pathological grade, but others found that higher AR expression correlated with worse outcomes. Limited functional studies with renal cell lines suggested tumor-promoting activity of AR. In this study, we queried transcriptomic, proteomic, epigenetic and survival data from The Cancer Genome Atlas (TCGA) to evaluate AR expression and its association with overall survival in three subtypes of RCC (clear cell [ccRCC], papillary [pRCC], and chromophobe [chRCC]). We found that although there was no significant difference in AR mRNA expression in ccRCC of males vs. females, AR protein expression in ccRCC was significantly higher in male compared to female patients. More importantly, higher expression of AR at both transcript and protein levels was associated with improved overall survival in both genders with ccRCC, but did not predict survival of either gender with pRCC or chRCC. Genes whose transcript levels were associated with AR mRNA levels significantly overlapped between ccRCC and pRCC, but not with chRCC, suggesting a similar transcriptional program mediated by AR in ccRCC and pRCC. Ingenuity pathway analysis also identified overlapping pathways and upstream regulators enriched in AR-associated genes in ccRCC and pRCC. Hypermethylation of CpG sites located in the promoter and first exon of AR was associated with loss of AR expression and poor overall survival. Our findings support a tumor suppressor role for AR in both genders that might be exploited to decrease the incidence or progression of ccRCC.
C1 [Zhao, Hongjuan; Leppert, John T.; Peehl, Donna M.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.
   [Leppert, John T.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System
RP Peehl, DM (通讯作者)，Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.
EM dpeehl@stanford.edu
OI Leppert, John/0000-0001-9980-3863
FU Department of Urology at Stanford University
FX The authors thank the Department of Urology at Stanford University for
   funding. The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anderson JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139267
   Barton VN, 2015, MOL CANCER THER, V14, P769, DOI 10.1158/1535-7163.MCT-14-0926
   Bonny O, 2013, CURR OPIN NEPHROL HY, V22, P439, DOI 10.1097/MNH.0b013e32836213b8
   Brown DF, 1998, MODERN PATHOL, V11, P55
   BULLOCK LP, 1974, ENDOCRINOLOGY, V94, P746, DOI 10.1210/endo-94-3-746
   CATTERALL JF, 1986, RECENT PROG HORM RES, V42, P71
   Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46
   Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014
   Furutani T, 2002, BIOCHEM BIOPH RES CO, V294, P779, DOI 10.1016/S0006-291X(02)00564-8
   Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327
   Ha YS, 2015, J UROLOGY, V194, P1441, DOI 10.1016/j.juro.2015.03.078
   Harries LW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-315
   He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681
   Huang R, 2015, MOL CANCER THER, V14, P1066, DOI 10.1158/1535-7163.MCT-14-0620
   King SC, 2014, J UROLOGY, V191, P1665, DOI 10.1016/j.juro.2013.12.046
   Langner C, 2004, J UROLOGY, V171, P611, DOI 10.1097/01.ju.0000108040.14303.c2
   Linehan WM, 2014, NAT REV UROL, V11, P614, DOI 10.1038/nrurol.2014.262
   Liu Q, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0117-z
   Mazzoccoli G, 2014, TUMOR BIOL, V35, P1, DOI 10.1007/s13277-013-1076-5
   Naderi A, 2015, EXP CELL RES, V331, P239, DOI 10.1016/j.yexcr.2014.10.002
   Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159
   Noh SJ, 2013, PATHOLOGY, V45, P574, DOI 10.1097/PAT.0b013e3283652c7a
   Okazaki H, 2014, CANCER RES, V74, P543, DOI 10.1158/0008-5472.CAN-12-3241
   PAPAC RJ, 1993, EUR J CANCER, V29A, P997, DOI 10.1016/S0959-8049(05)80209-6
   Pihlajamaa P, 2014, EMBO J, V33, P312, DOI 10.1002/embj.201385895
   Quinkler M, 2005, HYPERTENSION, V46, P787, DOI 10.1161/01.HYP.0000184362.61744.c1
   Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029
   Stone L, 2014, NAT REV UROL, V11, P425, DOI 10.1038/nrurol.2014.159
   Stow LR, 2011, J AM SOC NEPHROL, V22, P598, DOI 10.1681/ASN.2010080803
   Thong AE, 2014, UROL ONCOL, V32, P43, DOI DOI 10.1016/J.UR0L0NC.2013.05.008
   Tobert CM, 2013, UROL ONCOL-SEMIN ORI, V31, P1316, DOI 10.1016/j.urolonc.2011.12.014
   Tokonami N, 2014, J AM SOC NEPHROL, V25, P1430, DOI 10.1681/ASN.2013060641
   Williams EM, 2015, INT UROL NEPHROL, V47, P81, DOI 10.1007/s11255-014-0834-7
   Wuerzner G, 2014, NEPHROL DIAL TRANSPL, V29, P1475, DOI 10.1093/ndt/gft525
   Zhu G, 2014, UROLOGY, V83, P510
NR 35
TC 41
Z9 45
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2016
VL 11
IS 1
AR e0146505
DI 10.1371/journal.pone.0146505
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DC9GD
UT WOS:000369528200015
PM 26814892
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Sakamoto, T
   Kobayashi, S
   Yamada, D
   Nagano, H
   Tomokuni, A
   Tomimaru, Y
   Noda, T
   Gotoh, K
   Asaoka, T
   Wada, H
   Kawamoto, K
   Marubashi, S
   Eguchi, H
   Doki, Y
   Mori, M
AF Sakamoto, Takuya
   Kobayashi, Shogo
   Yamada, Daisaku
   Nagano, Hiroaki
   Tomokuni, Akira
   Tomimaru, Yoshito
   Noda, Takehiro
   Gotoh, Kunihito
   Asaoka, Tadafumi
   Wada, Hiroshi
   Kawamoto, Koichi
   Marubashi, Shigeru
   Eguchi, Hidetoshi
   Doki, Yuichiro
   Mori, Masaki
TI A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal
   Transition and Attenuates Chemoresistance in Biliary Tract Cancer
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; PANCREATIC-CANCER; BREAST-CANCER; TGF-BETA;
   MOLECULAR-MECHANISMS; CURATIVE RESECTION; FEEDBACK LOOP; CELL-LINES;
   PHASE-II; CHOLANGIOCARCINOMA
AB Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-beta 1). The EMT is reversible; therefore, it is conceivable that it could be related to some epigenetic changes. We focused on histone deacetylase (HDAC) inhibitors as regulators of TGF-beta 1 signaling, and investigated their effect on EMT and chemoresistance. We employed four BTC cell lines (MzChA-1, gemcitabine-resistant MzChA-1, TFK-1, and gemcitabine-resistant TFK-1) and used vorinostat as the HDAC inhibitor. The relative mRNA expression of an epithelial marker (CDH1) and mesenchymal markers (CDH2, vimentin, SNAI1) were measured by qRT-PCR to evaluate factors associated with EMT. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to evaluate the chemoresistance of each cell line. In addition, NOD/SCID mice were used to evaluate the effect of vorinostat in vivo. In the parent MzChA-1 and TFK-1 cell lines, TGF-beta 1 induced EMT and chemoresistance; while vorinostat inhibited the EMT and chemoresistance induced by TGF-beta 1. In gemcitabine-resistant cell lines that highly expressed TGF-beta 1, vorinostat inhibited EMT and attenuated chemoresistance. We showed that vorinostat inhibits nuclear translocation of SMAD4 which is a signaling factor of TGF-beta 1, and this is one of the mechanisms by which vorinostat regulates EMT. We also showed that vorinostat attenuates the binding affinity of SMAD4 to the CDH1-related transcription factors SNAI1, SNAI2, ZEB1, ZEB2, and TWIST. Furthermore, combination therapy with vorinostat and gemcitabine improved survival time in the mice xenografted with gemcitabine resistant MzChA-1 cells. In conclusion, vorinostat regulated TGF-beta 1-induced EMT and chemoresistance through inhibition of SMAD4 nuclear translocation.
C1 [Sakamoto, Takuya; Kobayashi, Shogo; Yamada, Daisaku; Nagano, Hiroaki; Tomokuni, Akira; Tomimaru, Yoshito; Noda, Takehiro; Gotoh, Kunihito; Asaoka, Tadafumi; Wada, Hiroshi; Kawamoto, Koichi; Marubashi, Shigeru; Eguchi, Hidetoshi; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan.
   [Kobayashi, Shogo] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Higashinari Ku, Osaka, Osaka 5378511, Japan.
C3 Osaka University; Osaka Medical Center for Cancer & Cardiovascular
   Diseases
RP Eguchi, H (通讯作者)，Osaka Univ, Grad Sch Med, Dept Surg, Yamadaoka 2-2 E2, Suita, Osaka 5650871, Japan.
EM heguchi@gesurg.med.osaka-u.ac.jp
RI Tomimaru, Yoshito/IQS-7856-2023; Sakamoto, Takuya/K-9973-2015; Mori,
   Masaki/AGA-2440-2022
FU JSPS [24592024, 26861069]; Grants-in-Aid for Scientific Research
   [24592024, 26861069] Funding Source: KAKEN
FX This work was supported by Grant-in-Aid for Scientific Research of JSPS
   ((C) 24592024), and Grand-in-Aid for Young Scientists of JSPS ((B)
   26861069).
CR Abaza MSI, 2014, INT J MOL MED, V34, P513, DOI 10.3892/ijmm.2014.1795
   Bellucci L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054102
   Cassier PA, 2014, ANN ONCOL, V25, P1074, DOI 10.1093/annonc/mdu045
   Chanmee T, 2014, J BIOL CHEM, V289, P26038, DOI 10.1074/jbc.M114.564120
   Chung CL, 2012, AM J RESP CELL MOL, V46, P437, DOI 10.1165/rcmb.2011-0118OC
   Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082
   DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545
   Fakih MG, 2012, CANCER CHEMOTH PHARM, V69, P743, DOI 10.1007/s00280-011-1762-1
   Farrell J, 2014, J PROTEOME RES, V13, P2874, DOI 10.1021/pr5000285
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926
   Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4
   Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002
   Jang JY, 2005, ANN SURG, V241, P77, DOI 10.1097/01.sla.0000150166.94732.88
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kaimori A, 2010, HEPATOLOGY, V52, P1033, DOI 10.1002/hep.23765
   Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273
   Kim HJ, 2014, SURG TODAY, V44, P1879, DOI 10.1007/s00595-014-0846-z
   KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7
   Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010
   Kobayashi S, 2011, J SURG ONCOL, V104, P499, DOI 10.1002/jso.21971
   Krug LM, 2015, LANCET ONCOL, V16, P447, DOI 10.1016/S1470-2045(15)70056-2
   Kurahara H, 2012, J SURG ONCOL, V105, P655, DOI 10.1002/jso.23020
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13
   Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Murakami S, 2014, SURG TODAY, V44, P1847, DOI 10.1007/s00595-013-0825-9
   MURAKAMI T, 1987, HEPATOLOGY, V7, P551, DOI 10.1002/hep.1840070322
   Nakashima S, 2015, CANCER SCI, V106, P584, DOI 10.1111/cas.12652
   Ngamphaiboon N, 2015, INVEST NEW DRUG, V33, P225, DOI 10.1007/s10637-014-0174-6
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Nitta T, 2014, BRIT J CANCER, V111, P1363, DOI 10.1038/bjc.2014.415
   Ogunwobi OO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063765
   Ramaswamy B, 2012, BREAST CANCER RES TR, V132, P1063, DOI 10.1007/s10549-011-1928-x
   Reguart N, 2014, LUNG CANCER, V84, P161, DOI 10.1016/j.lungcan.2014.02.011
   Rodrigues MF, 2015, J CELL BIOCHEM, V116, P797, DOI 10.1002/jcb.25036
   Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   SHIMIZU Y, 1992, INT J CANCER, V52, P252, DOI 10.1002/ijc.2910520217
   Sui XB, 2015, CANCER LETT, V360, P106, DOI 10.1016/j.canlet.2015.02.009
   Sun SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091610
   Talbot Lindsay J, 2012, Int J Biochem Mol Biol, V3, P117
   Tu YF, 2014, BREAST CANCER RES TR, V146, P145, DOI 10.1007/s10549-014-3008-5
   Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Yamada D, 2013, EUR J CANCER, V49, P1725, DOI 10.1016/j.ejca.2012.12.002
   Yamada D, 2012, ANN SURG ONCOL, V19, pS355, DOI 10.1245/s10434-011-1797-x
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
NR 50
TC 50
Z9 53
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 4
PY 2016
VL 11
IS 1
AR e0145985
DI 10.1371/journal.pone.0145985
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DA3FF
UT WOS:000367681500043
PM 26726879
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Hu, Q
   Chen, J
   Zhang, J
   Xu, CW
   Yang, S
   Jiang, H
AF Hu, Qi
   Chen, Jing
   Zhang, Jing
   Xu, Changwu
   Yang, Shuo
   Jiang, Hong
TI IOX1, a JMJD2A inhibitor, suppresses the proliferation and migration of
   vascular smooth muscle cells induced by angiotensin II by regulating the
   expression of cell cycle-related proteins
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Jumonji domain-containing 2A; histone methylation; vascular smooth
   muscle cells; angiotensin II; cell cycle; cyclin D1; p21
ID HISTONE DEMETHYLASE; BREAST-CANCER; ACTIVATION; ATHEROSCLEROSIS; GENE;
   METHYLATION; TRANSITION; REPRESSION; PHENOTYPE; BINDING
AB The epigenetic modification of vascular smooth muscle cell (VSMC) phenotypic switching, proliferation, migration, apoptosis and extracellular matrix synthesis is known to occur in atherosclerosis. The aim of the present study was to investigate the effects of IOX1, a Jumonji domain-containing 2A (JMJD2A) inhibitor, on regulation of the cell cycle in angiotensin II (Ang II)-stimulated VSMCs and to elucidate the possible mechanisms involved. The proliferation and migration of the Ang II-stimulated VSMCs in the presence or absence of IOX1 were evaluated in vitro. Flow cytometric analysis was used to determine the effects of IOX1 on cell cycle progression. RT-qPCR and western blot analysis were carried out to measure the expression levels of cell cycle-related genes. The trimethylation of histone H3 lysine 9 (H3K9me3) at the promoters of these genes was detected by chromatin immunoprecipitation (ChIP) assay. We confirmed that the JMJD2A levels were increased, whereas the H3K9me3 levels were decreased in the Ang II-stimulated VSMCs. The inhibition of JMJD2A by IOX1 suppressed the Ang II-induced cell proliferation, migration and cell cycle progression by inhibiting cyclin D1 expression and increasing p21 expression. The underlying mechanisms were related to the restoration of the H3K9me3 levels at the promoters of these genes. In conclusion, the findings of our study indicate that IOX1 exerts its anti-proliferative and anti-migratory effects by regulating the expression of the cell cycle-related proteins, cyclin D1 and p21.
C1 [Hu, Qi; Chen, Jing; Xu, Changwu; Yang, Shuo; Jiang, Hong] Wuhan Univ, Renmin Hosp, Dept Cardiol, Cardiovasc Res Inst, Wuhan 430060, Hubei, Peoples R China.
   [Zhang, Jing] China Three Gorges Univ, Dept Cardiol, Coll Clin Med Sci 1, Yichang 443000, Hubei, Peoples R China.
C3 Wuhan University; China Three Gorges University
RP Jiang, H (通讯作者)，Wuhan Univ, Renmin Hosp, Dept Cardiol, Cardiovasc Res Inst, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM chenjing821111@163.com; pyh_hongj@163.com
RI Zhang, Jinwei/Q-7959-2019; Hu, Qi/GOV-6201-2022
FU National Natural Science Foundation of the People's Republic of China
   [81170195, 81200156]; Fundamental Research Funds for the Central
   Universities [20120141120079]
FX This study was supported by grants from the National Natural Science
   Foundation of the People's Republic of China grants (nos. 81170195 and
   81200156) and the Fundamental Research Funds for the Central
   Universities (no. 20120141120079). We would like to thank Professor
   Yanhong Tang, Professor Xi Wang, Dr Teng Wang and Dr Ping Hu from the
   Renmin Hospital of Wuhan University for their excellent technical
   assistance.
CR Berry WL, 2012, INT J ONCOL, V41, P1701, DOI 10.3892/ijo.2012.1618
   Chen D, 2014, BBA-MOL CELL RES, V1843, P454, DOI 10.1016/j.bbamcr.2013.11.024
   Chen ZZ, 2007, P NATL ACAD SCI USA, V104, P10818, DOI 10.1073/pnas.0704525104
   Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884
   Doran AC, 2008, ARTERIOSCL THROM VAS, V28, P812, DOI 10.1161/ATVBAHA.107.159327
   Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758
   Kim JE, 2010, KOREAN J PHYSIOL PHA, V14, P299, DOI 10.4196/kjpp.2010.14.5.299
   Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8
   Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131
   Kogure M, 2013, CANCER LETT, V336, P76, DOI 10.1016/j.canlet.2013.04.009
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lockman K, 2007, CIRC RES, V101, pE115, DOI 10.1161/CIRCRESAHA.107.164178
   Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006
   Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032
   Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812
   Schiller R, 2014, CHEMMEDCHEM, V9, P566, DOI 10.1002/cmdc.201300428
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643
   Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179
   Tsaousi A, 2011, CIRC RES, V108, P427, DOI 10.1161/CIRCRESAHA.110.233999
   Villeneuve LM, 2008, P NATL ACAD SCI USA, V105, P9047, DOI 10.1073/pnas.0803623105
   Weiss D, 2001, AM J CARDIOL, V87, p25C
   Weng XY, 2014, BIOCHEM BIOPH RES CO, V447, P263, DOI 10.1016/j.bbrc.2014.03.140
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Zhang DZ, 2005, MOL CELL BIOL, V25, P6404, DOI 10.1128/MCB.25.15.6404-6414.2005
   Zhang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087561
NR 30
TC 22
Z9 30
U1 2
U2 29
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2016
VL 37
IS 1
BP 189
EP 196
DI 10.3892/ijmm.2015.2393
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DA5UB
UT WOS:000367867000023
PM 26530537
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhong, ZB
   Shan, M
   Wang, J
   Liu, T
   Xia, BS
   Niu, M
   Ren, YL
   Pang, D
AF Zhong, Zhenbin
   Shan, Ming
   Wang, Ji
   Liu, Tong
   Xia, Bingshu
   Niu, Ming
   Ren, Yanlv
   Pang, Da
TI <i>HOXD13</i> methylation status is a prognostic indicator in breast
   cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE HOXD13; breast cancer; DNA methylation; epigenetics; prognosis
ID DNA METHYLATION; CPG-ISLANDS; EXPRESSION; GENE; THERAPY; PATTERNS;
   FREQUENT; COMPLEX; HOXA5
AB Homeobox protein Hox-D13 is encoded by HOXD13 gene which is frequently methylated in cancer and has been recognized as a tumor suppressor in pancreatic cancer. In this study, we examined HOXD13 mRNA expression in 40 pairs of breast cancers and corresponding normal breast tissues. Bisulfite sequencing of HOXD13 promoter was performed in 6 pairs of breast tumors and corresponding normal breast tissues to examine the potential HOXD13 CpG methylated sites. HOXD13 DNA methylation frequency analysis was performed using MethyLight in 196 pairs of breast cancers and corresponding normal breast samples. DNA methylation status and clinicopathological features were investigated. Kaplan-Meier survival analysis and Cox proportional hazards models were utilized to assess the effect of methylation status on overall survival. We found that 60% (24/40) of breast cancers showed low HOXD13 mRNA expression when compared with corresponding normal breast tissue. The predicted CpG island was located in the -1325 bp to +675 bp region. Next, the -332 bp site in HOXD13 gene promoter was further examined and in 57.7% (113/196) samples methylation was detected at this site. HOXD13 methylation was correlated with larger tumor size (P = 0.004), but not with other clinico-pathological parameters. In addition, patients with methylated -HOXD13 promoter had worse overall survival (OS) (P = 0.005). Based on our results we conclude that HOXD13 methylation is a common event in primary breast cancer and is associated with poor survival of breast cancer patients. HOXD13 methylation could therefore potentially be used as a prognostic factor for breast cancer.
C1 [Zhong, Zhenbin; Shan, Ming; Wang, Ji; Liu, Tong; Xia, Bingshu; Niu, Ming; Ren, Yanlv; Pang, Da] Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, Harbin 150081, Peoples R China.
   [Pang, Da] Heilongjiang Acad Med Sci, Harbin, Peoples R China.
C3 Harbin Medical University
RP Pang, D (通讯作者)，Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, 150 Haping Rd, Harbin 150081, Peoples R China.
EM renyanlu@hotmail.com; pangda@ems.hrbmu.edu.cn
RI Shan, Ming/K-8967-2019
OI LIU, TONG/0000-0001-9234-1328
FU National Natural Science Fund [81172498]; fund of The Affiliated Tumor
   Hospital of Harbin Medical University [JJZ2010-04]; Harbin Medical
   University [WLD-QN1118]; Special Fund of Translational Medical Research
   between China [CR201402]; Special Fund of Translational Medical Research
   between Russia [CR201402]
FX This project was supported by grants from the National Natural Science
   Fund (81172498), the fund of The Affiliated Tumor Hospital of Harbin
   Medical University (JJZ2010-04), the 'Wu Lian-de' funding of Harbin
   Medical University (WLD-QN1118) and the Special Fund of Translational
   Medical Research between China and Russia (CR201402).
CR [Anonymous], 2007, J CLIN ONCOL, DOI DOI 10.1200/JCO.2006.09.2775
   Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320
   Cantile M, 2009, INT J CANCER, V125, P1532, DOI 10.1002/ijc.24438
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Goodman FR, 2003, LANCET, V362, P651, DOI 10.1016/S0140-6736(03)14187-6
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JOP.777003, 10.5858/134.6.907, 10.1200/JCO.2009.25.6529]
   Henderson GS, 2006, CELL ONCOL, V28, P305
   Huang YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-245
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jung SY, 2010, BREAST CANCER RES TR, V120, P627, DOI 10.1007/s10549-010-0780-8
   LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0
   Li SY, 2015, J CONTROL RELEASE, V205, P7, DOI 10.1016/j.jconrel.2014.11.011
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Makiyama K, 2005, ONCOL REP, V13, P673
   Knaul FM, 2008, REPROD HEALTH MATTER, V16, P113, DOI 10.1016/S0968-8080(08)32414-8
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548
   Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269
   Sakata M, 2009, ANTICANCER RES, V29, P2231
   Shinawi T, 2013, EPIGENETICS-US, V8, P149, DOI 10.4161/epi.23398
   Shu Y, 2011, WORLD J GASTROENTERO, V17, P3407, DOI 10.3748/wjg.v17.i29.3407
   Svingen T, 2003, CANCER BIOL THER, V2, P518, DOI 10.4161/cbt.2.5.441
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006
NR 36
TC 17
Z9 17
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 9
BP 10716
EP U5335
PG 53
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DA4ZX
UT WOS:000367812800098
PM 26617782
DA 2025-01-12
ER

PT J
AU Zhao, EH
   Ding, J
   Xia, YF
   Liu, ML
   Ye, BW
   Choi, JH
   Yan, CH
   Dong, Z
   Huang, S
   Zha, YH
   Yang, LQ
   Cui, HJ
   Ding, HF
AF Zhao, Erhu
   Ding, Jane
   Xia, Yingfeng
   Liu, Mengling
   Ye, Bingwei
   Choi, Jeong-Hyeon
   Yan, Chunhong
   Dong, Zheng
   Huang, Shuang
   Zha, Yunhong
   Yang, Liqun
   Cui, Hongjuan
   Ding, Han-Fei
TI KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid
   Metabolism
SO CELL REPORTS
LA English
DT Article
ID HISTONE LYSINE METHYLATION; PYRUVATE-KINASE M2; BREAST-CANCER; NEURONAL
   DIFFERENTIATION; METHYLTRANSFERASE G9A; CELL-PROLIFERATION; SYNTHESIS
   PATHWAY; SERINE SYNTHESIS; AMPLIFIED GENES; GLYCINE
AB The histone lysine demethylase KDM4C is often over-expressed in cancers primarily through gene amplification. The molecular mechanisms of KDM4C action in tumorigenesis are not well defined. Here, we report that KDM4C transcriptionally activates amino acid biosynthesis and transport, leading to a significant increase in intracellular amino acid levels. Examination of the serine-glycine synthesis pathway reveals that KDM4C epigenetically activates the pathway genes under steady-state and serine deprivation conditions by removing the repressive histone modification H3 lysine 9 (H3K9) trimethylation. This action of KDM4C requires ATF4, a transcriptional master regulator of amino acid metabolism and stress responses. KDM4C activates ATF4 transcription and interacts with ATF4 to target serine pathway genes for transcriptional activation. We further present evidence for KDM4C in transcriptional coordination of amino acid metabolism and cell proliferation. These findings suggest a molecular mechanism linking KDM4C-mediated H3K9 demethylation and ATF4-mediated transactivation in reprogramming amino acid metabolism for cancer cell proliferation.
C1 [Zhao, Erhu; Yang, Liqun; Cui, Hongjuan] Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400715, Peoples R China.
   [Zhao, Erhu; Ding, Jane; Xia, Yingfeng; Liu, Mengling; Ye, Bingwei; Choi, Jeong-Hyeon; Yan, Chunhong; Ding, Han-Fei] Georgia Regents Univ, Med Coll Georgia, Canc Ctr, Augusta, GA 30912 USA.
   [Choi, Jeong-Hyeon] Georgia Regents Univ, Med Coll Georgia, Dept Biostat & Epidemiol, Augusta, GA 30912 USA.
   [Yan, Chunhong; Ding, Han-Fei] Georgia Regents Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.
   [Dong, Zheng] Georgia Regents Univ, Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA.
   [Ding, Han-Fei] Georgia Regents Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.
   [Huang, Shuang] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.
   [Xia, Yingfeng; Liu, Mengling; Zha, Yunhong] Three Gorges Univ, Coll Med, Hosp Yichang 1, Insititute Translat Neurosci, Yichang 443000, Peoples R China.
   [Xia, Yingfeng; Liu, Mengling; Zha, Yunhong] Three Gorges Univ, Coll Med, Hosp Yichang 1, Dept Neurol, Yichang 443000, Peoples R China.
C3 Southwest University - China; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; University System of Georgia; Augusta University;
   State University System of Florida; University of Florida; China Three
   Gorges University; China Three Gorges University
RP Cui, HJ (通讯作者)，Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400715, Peoples R China.; Ding, HF (通讯作者)，Georgia Regents Univ, Med Coll Georgia, Canc Ctr, Augusta, GA 30912 USA.; Ding, HF (通讯作者)，Georgia Regents Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.; Ding, HF (通讯作者)，Georgia Regents Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.
EM hcui@swu.edu.cn; hding@gru.edu
RI Ye, Bingwei/AAH-1139-2021; Xia, Yingfeng/H-8473-2015
OI Huang, Shuang/0000-0002-9674-2249; Yan, Chunhong/0000-0002-3974-7991;
   Xia, Yingfeng/0000-0001-6545-6680; Ding, Han-Fei/0000-0001-5702-3439
FU National Basic Research Program of China [2012CB114603]; NIH [R01
   CA190429]; US Department of Defense [W81XWH-12-1-0613]; National Natural
   Science Foundation of China [81201981]
FX We thank Dr. Nabieh Ayoub of the Israel Institute of Technology for
   providing pEGFP-KDM4C-wt and pEGFP-KDM4C-S198M, and Drs. LesleyAnn
   Hawthorn, Sam Chang, and Eiko Kitamura of the Georgia Regents University
   Cancer Center Genomics Core for assistance in microarray gene expression
   profiling. The work was supported by a grant from the National Basic
   Research Program of China (2012CB114603 to H.C.), grants from the NIH
   (R01 CA190429 to H.-F.D.) and US Department of Defense (W81XWH-12-1-0613
   to H.-F.D.), and a grant from the National Natural Science Foundation of
   China (81201981 to Y.Z.).
CR Adams CM, 2007, J BIOL CHEM, V282, P16744, DOI 10.1074/jbc.M610510200
   Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004
   Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   DeBerardinis RJ, 2011, CELL METAB, V14, P285, DOI 10.1016/j.cmet.2011.08.004
   Dey S, 2010, J BIOL CHEM, V285, P33165, DOI 10.1074/jbc.M110.167213
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925
   Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236
   Gregory BL, 2014, GENOME RES, V24, P52, DOI 10.1101/gr.156141.113
   Gut P, 2013, NATURE, V502, P489, DOI 10.1038/nature12752
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405
   Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Kalhan SC, 2012, J BIOL CHEM, V287, P19786, DOI 10.1074/jbc.R112.357194
   Katada S, 2012, CELL, V148, P24, DOI 10.1016/j.cell.2012.01.001
   Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008
   Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414
   Kim TD, 2014, AM J TRANSL RES, V6, P236
   Kupershmit I, 2014, NUCLEIC ACIDS RES, V42, P6168, DOI 10.1093/nar/gku253
   Labbé RM, 2014, AM J TRANSL RES, V6, P1
   Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557
   Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743
   Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013
   Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556
   Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706
   Seo J, 2009, DIABETES, V58, P2565, DOI 10.2337/db09-0335
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teperino R, 2010, CELL METAB, V12, P321, DOI 10.1016/j.cmet.2010.09.004
   Terndrup M, 2014, MOL CELL BIOL, V34, P1031, DOI 10.1128/MCB.00864-13
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702
   Wang XW, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-830
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109
NR 58
TC 112
Z9 126
U1 0
U2 34
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JAN 26
PY 2016
VL 14
IS 3
BP 506
EP 519
DI 10.1016/j.celrep.2015.12.053
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DB7NF
UT WOS:000368701600012
PM 26774480
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Jiang, T
   Wang, Y
   Zhou, F
   Gao, GH
   Ren, SX
   Zhou, CC
AF Jiang, Tao
   Wang, Yan
   Zhou, Fei
   Gao, Guanghui
   Ren, Shengxiang
   Zhou, Caicun
TI Prognostic value of high EZH2 expression in patients with different
   types of cancer: a systematic review with meta-analysis
SO ONCOTARGET
LA English
DT Article
DE enhancer of zeste homologue 2; cancer; prognosis; systematic review;
   meta-analysis
ID ZESTE HOMOLOG 2; GROUP PROTEIN EZH2; BREAST-CANCER; TUMOR PROGRESSION;
   PHARMACOLOGICAL DISRUPTION; HISTONE METHYLTRANSFERASE; THERAPEUTIC
   TARGET; CELL-PROLIFERATION; POOR-PROGNOSIS; CARCINOMA
AB Enhancer of zeste homologue 2 (EZH2) is a potential independent mechanism for epigenetic silencing of tumor suppressor genes in cancer. We conducted an electronic search on PubMed, EMBASE, Web of Science, and Cochrane library to perform this up-to-date meta-analysis. Fifty-one studies with a total of 9444 patients were included. The prevalence of high EZH2 expression was 0.54 (95% CI: 0.47-0.61). High EZH2 expression was significantly associated with poorer prognosis [overall survival: HR 1.54 (95% CI: 1.30-1.78), P < 0.000; disease free survival: HR 1.35 (95% CI: 1.001.71), P < 0.000]. In breast cancer, high EZH2 expression correlated with histological types [OR: 1.53 (95CI: 1.13-2.06); P < 0.006], histological grade [OR: 1.62 (95CI: 1.35-1.95); P < 0.000], estrogen receptor (ER) negativity [OR: 2.05 (95CI: 1.67-2.52); P < 0.000], progesterone receptor (PgR) negativity [OR: 1.42 (95CI: 1.03-1.96); P = 0.034], HER-2 positivity [OR: 1.35 (95CI: 1.08-1.69); P = 0.009], and high p53 expression [OR: 1.66 (95CI: 1.07-2.59); P = 0.024]. These results suggest that high EZH2 expression may be a promising prognostic factor to different cancers. High EZH2 expression tends to correlate with pathological types, histological grade, ER negativity, PgR negativity, HER-2 positivity and p53 high expression in breast cancer.
C1 [Jiang, Tao; Wang, Yan; Zhou, Fei; Gao, Guanghui; Ren, Shengxiang; Zhou, Caicun] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol,Thorac Canc Inst, Shanghai 200433, Peoples R China.
C3 Tongji University
RP Zhou, CC (通讯作者)，Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol,Thorac Canc Inst, Shanghai 200433, Peoples R China.
EM caicunzhou_dr@163.com
FU National Natural Science Foundation of China [81172101]; key project of
   the Science and Technology Commission of Shanghai Municipality
   [11JC1411301]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81172101) and the key project of the Science
   and Technology Commission of Shanghai Municipality (No. 11JC1411301).
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   [Anonymous], MOL CARCINOG
   Athanassiadou AM, 2011, ACTA CYTOL, V55, P180, DOI 10.1159/000320790
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Benard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108265
   Cao W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052984
   Cao W, 2012, CANCER-AM CANCER SOC, V118, P2858, DOI 10.1002/cncr.26575
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Chen SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125480
   Chen XH, 2013, INT J ONCOL, V43, P1467, DOI 10.3892/ijo.2013.2062
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   De Brot M, 2012, PATHOLOGY, V44, P303, DOI 10.1097/PAT.0b013e3283534bcb
   Dong M, 2014, ONCOL REP, V32, P1101, DOI 10.3892/or.2014.3322
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Geng J, 2015, CANCER LETT, V359, P275, DOI 10.1016/j.canlet.2015.01.031
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Ha SY, 2012, PATHOL RES PRACT, V208, P462, DOI 10.1016/j.prp.2012.05.012
   He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031
   He LJ, 2012, ASIAN PAC J CANCER P, V13, P3173, DOI 10.7314/APJCP.2012.13.7.3173
   Hinz S, 2008, J CANCER RES CLIN, V134, P331, DOI 10.1007/s00432-007-0288-8
   Hinz S, 2009, J UROLOGY, V182, P2920, DOI 10.1016/j.juro.2009.08.014
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Jene-Sanz A, 2013, MOL CELL BIOL, V33, P3951, DOI 10.1128/MCB.00426-13
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knudsen ES, 2013, CELL CYCLE, V12, P2042, DOI 10.4161/cc.25065
   Lee H, 2012, HUM PATHOL, V43, P1704, DOI 10.1016/j.humpath.2011.12.019
   Li K, 2013, CHINESE MED J-PEKING, V126, P82, DOI 10.3760/cma.j.issn.0366-6999.20122477
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503
   Liu DC, 2011, PATHOL RES PRACT, V207, P472, DOI 10.1016/j.prp.2011.05.010
   Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081484
   Liu YL, 2015, J CANCER RES CLIN, V141, P661, DOI 10.1007/s00432-014-1854-5
   Liu YY, 2014, INT J GYNECOL PATHOL, V33, P218, DOI 10.1097/PGP.0b013e31829c6574
   Lv YJ, 2012, ONCOL REP, V28, P147, DOI 10.3892/or.2012.1787
   Meng XJ, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-188
   Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Panousis D, 2013, J BUON, V18, P879
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Roh S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-299
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Wan LY, 2013, CLIN TRANSL ONCOL, V15, P132, DOI 10.1007/s12094-012-0897-9
   Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421
   Wu ZY, 2013, J NEUROL SCI, V335, P191, DOI 10.1016/j.jns.2013.09.030
   Xu CH, 2014, LUNG CANCER, V86, P268, DOI 10.1016/j.lungcan.2014.09.010
   Zhang JX, 2015, CANCER LETT, V356, P929, DOI 10.1016/j.canlet.2014.11.003
   Zhang YD, 2014, TECHNOLOGIES, V2, DOI 10.3390/technologies2040164
NR 62
TC 56
Z9 63
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 4584
EP 4597
DI 10.18632/oncotarget.6612
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400070
PM 26683709
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Buchegger, K
   Ili, C
   Riquelme, I
   Letelier, P
   Corvalán, AH
   Brebi, P
   Huang, THM
   Roa, JC
AF Buchegger, Kurt
   Ili, Carmen
   Riquelme, Ismael
   Letelier, Pablo
   Corvalan, Alejandro H.
   Brebi, Priscilla
   Huang, Tim Hui-Ming
   Carlos Roa, Juan
TI <i>Reprimo</i> as a modulator of cell migration and invasion in the
   MDA-MB-231 breast cancer cell line
SO BIOLOGICAL RESEARCH
LA English
DT Article
DE Reprimo; MDA-MB-231; Migration; Invasion
ID CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENES; ABERRANT
   METHYLATION; PROMOTER METHYLATION; POTENTIAL BIOMARKER; IDENTIFICATION;
   EXPRESSION; PROGNOSIS; DIAGNOSIS; P16
AB Background: Reprimo (RPRM), a highly glycosylated protein, is a new downstream effector of p53-induced cell cycle arrest at the G2/M checkpoint, and a putative tumor suppressor gene frequently silenced via methylation of its promoter region in several malignances. The aim of this study was to characterize the epigenetic inactivation and its biological function in BC cell lines.
   Methods: The correlation between RPRM methylation and loss of mRNA expression was assessed in six breast cancer cell lines by methylation specific PCR (MSP), 5'-Aza-2'-deoxycytidine treatment and RT-PCR assays. MDA-MB-231 cells were chosen to investigate the phenotypic effect of RPRM in cell proliferation, cell cycle, cell death, cell migration and invasion.
   Results: In the cancer methylome system (CMS) (web-based system for visualizing and analyzing genome-wide methylation data of human cancers), the CpG island region of RPRM (1.1 kb) was hypermethylated in breast cancer compared to normal breast tissue; more interesting still was that ER alpha(+) tumors showed higher methylation intensity than ER alpha(-). Downregulation of RPRM mRNA by methylation was confirmed in MDA-MB-231 and BT-20 cell lines. In addition, overexpression of RPRM in MDA-MB-231 cells resulted in decreased rates of cell migration, wound healing and invasion in vitro. However, RPRM overexpression did not alter cell viability, phosphatidylserine (PS) translocation or G2/M cell cycle transition.
   Conclusion: Taken together, these data suggest that RPRM is involved in decreased cell migration and invasion in vitro, acting as a potential tumor suppressor gene in the MDA-MB-231 cell line.
C1 [Buchegger, Kurt; Ili, Carmen; Riquelme, Ismael; Brebi, Priscilla] Univ La Frontera, Dept Pathol, Mol Pathol Lab BIOREN CEGIN, Sch Med, Temuco, Chile.
   [Letelier, Pablo] Univ Catolica Temuco, Sch Hlth Sci, Temuco, Chile.
   [Corvalan, Alejandro H.] Pontificia Univ Catolica Chile, Ctr Translat Res Oncol CITO, Alameda 340, Santiago, Chile.
   [Corvalan, Alejandro H.] Pontificia Univ Catolica Chile, Dept Hematol & Oncol, Alameda 340, Santiago, Chile.
   [Huang, Tim Hui-Ming] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, STRF, Room 225,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Carlos Roa, Juan] Pontificia Univ Catolica Chile, Dept Pathol, Adv Ctr Chron Dis ACCDiS CITO, Sch Med, Alameda 340, Santiago, Chile.
C3 Universidad de La Frontera; Universidad Catolica de Temuco; Pontificia
   Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; Pontificia Universidad Catolica de Chile
RP Roa, JC (通讯作者)，Pontificia Univ Catolica Chile, Dept Pathol, Adv Ctr Chron Dis ACCDiS CITO, Sch Med, Alameda 340, Santiago, Chile.
EM jcroas@gmail.com
RI Ili, Carmen/X-4070-2019; Buchegger, Kurt/AAH-4678-2021; Roa,
   Juan/K-4749-2014; Riquelme, Ismael/H-9391-2016
OI Roa, Juan Carlos/0000-0001-8313-8774; Brebi,
   Priscilla/0000-0002-3896-146X; Buchegger, Kurt/0000-0002-3872-2522;
   Riquelme, Ismael/0000-0002-9545-3971; Letelier,
   Pablo/0000-0001-9803-9752; Ili, Carmen/0000-0002-4009-4406; Corvalan,
   Alejandro/0000-0001-5492-3853
FU Chilean government scholarship grant: CONICYT [21100814, 24121558];
   Chilean government scholarship grant: Becas Chile grant [75130093];
   Chilean government scholarship grant: Project CORFO-CEGIN [09CN14-5960];
   Project FONDECYT [3130630]
FX We thank so much PhD. Tim Hui-Ming Huang and his research team for their
   help into this work. This works was supported through Chilean government
   scholarship grants such as: CONICYT Scholarship No 21100814, CONICYT
   support scholarship for doctoral thesis work No 24121558, Becas Chile
   grant of internship No 75130093, Project CORFO-CEGIN 09CN14-5960 and
   C.I. supported by Project FONDECYT Post-Doctoral No 3130630.
CR [Anonymous], 2013, GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base
   Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522
   Brebi P, 2014, BIOMARKERS, V19, P181, DOI 10.3109/1354750X.2013.867535
   Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056
   Ellinger J, 2008, PROSTATE, V68, P42, DOI 10.1002/pros.20651
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Hamilton JP, 2006, CLIN CANCER RES, V12, P6637, DOI 10.1158/1078-0432.CCR-06-1781
   Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P701, DOI 10.1016/j.cgh.2006.03.007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Kramer N, 2013, MUTAT RES-REV MUTAT, V752, P10, DOI 10.1016/j.mrrev.2012.08.001
   Li LY, 2010, J CANCER, V1, P126
   Luo J, 2011, DIAGN CYTOPATHOL, V39, P752, DOI 10.1002/dc.21461
   Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09
   Moon HS, 2003, INT J GYNECOL CANCER, V13, P640, DOI 10.1046/j.1525-1438.2003.13396.x
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200
   Ooki A, 2013, MOL CANCER RES, V11, P1362, DOI 10.1158/1541-7786.MCR-13-0091
   Piao Z, 2001, GENE CHROMOSOME CANC, V30, P113, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.3.CO;2-Y
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Saavedra K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125834
   Sato N, 2003, CANCER RES, V63, P3735
   Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P286, DOI 10.1007/s00534-005-1057-1
   Sato N, 2006, CANCER-AM CANCER SOC, V107, P251, DOI 10.1002/cncr.21977
   Schneider BG, 2010, INT J CANCER, V127, P2588, DOI 10.1002/ijc.25274
   Song YM, 2008, CARCINOGENESIS, V29, P307, DOI 10.1093/carcin/bgm269
   Wong TS, 2005, INT J CANCER, V117, P697, DOI 10.1002/ijc.21208
   Xu M, 2012, ENDOCRINOLOGY, V153, P2963, DOI 10.1210/en.2011-2021
   Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437
NR 31
TC 14
Z9 15
U1 0
U2 27
PU SOC BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0716-9760
EI 0717-6287
J9 BIOL RES
JI Biol. Res.
PD JAN 22
PY 2016
VL 49
AR 5
DI 10.1186/s40659-016-0066-7
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA DC0FC
UT WOS:000368891600001
PM 26796959
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Vad-Nielsen, J
   Jakobsen, KR
   Daugaard, TF
   Thomsen, R
   Brügmann, A
   Sorensen, BS
   Nielsen, AL
AF Vad-Nielsen, Johan
   Jakobsen, Kristine Raaby
   Daugaard, Tina Fuglsang
   Thomsen, Rune
   Brugmann, Anja
   Sorensen, Boe Sandahl
   Nielsen, Anders Lade
TI Regulatory dissection of the <i>CBX5</i> and <i>hnRNPA1</i>
   bi-directional promoter in human breast cancer cells reveals novel
   transcript variants differentially associated with HP1α down-regulation
   in metastatic cells
SO BMC CANCER
LA English
DT Article
DE Metastasis; Heterochromatin; Cell invasion; Epigenetics; Transcriptional
   regulation
ID HETEROCHROMATIN-ASSOCIATED PROTEIN; CHROME SHADOW DOMAIN; HISTONE H3;
   MESSENGER-RNA; ALTERNATIVE POLYADENYLATION; CHROMOSOMAL-PROTEIN; GENE
   ORGANIZATION; HP1 PROTEINS; BINDING; EXPRESSION
AB Background: The three members of the human heterochromatin protein 1 (HP1) family of proteins, HP1 alpha, HP1 beta, and HP gamma, are involved in chromatin packing and epigenetic gene regulation. HP1 alpha is encoded from the CBX5 gene and is a suppressor of metastasis. CBX5 is down-regulated at the transcriptional and protein level in metastatic compared to non-metastatic breast cancer. CBX5 shares a bi-directional promoter structure with the hnRNPA1 gene. But whereas CBX5 expression is down-regulated in metastatic cells, hnRNAP1 expression is constant. Here, we address the regulation of CBX5 in human breast cancer.
   Methods: Transient transfection and transposon mediated integration of dual-reporter mini-genes containing the bi-directional hnRNPA1 and CBX5 promoter was performed to investigate transcriptional regulation in breast cancer cell lines. Bioinformatics and functional analysis were performed to characterize transcriptional events specifically regulating CBX5 expression. TSA treatment and Chromatin Immunoprecipitation (ChIP) were performed to investigate the chromatin structure along CBX5 in breast cancer cells. Finally, expression of hnRNPA1 and CBX5 mRNA isoforms were measured by quantitative reverse transcriptase PCR (qRT-PCR) in breast cancer tissue samples.
   Results: We demonstrate that an hnRNPA1 and CBX5 bi-directional core promoter fragment does not comprise intrinsic capacity for specific CBX5 down-regulation in metastatic cells. Characterization of transcriptional events in the 20 kb CBX5 intron 1 revealed existence of several novel CBX5 transcripts. Two of these encode consensus HP1 alpha protein but used autonomous promoters in intron 1 by which HP1 alpha expression could be de-coupled from the bi-directional promoter. In addition, another CBX5 transcriptional isoform, STET, was discovered. This transcript includes CBX5 exon 1 and part of intron 1 sequences but lacks inclusion of HP1 alpha encoding exons. Inverse correlation between STET and HP1 alpha coding CBX5 mRNA expression was observed in breast cancer cell lines and tissue samples from breast cancer patients.
   Conclusion: We find that HP1 alpha is down-regulated in a mechanism involving CBX5 promoter downstream sequences and that regulation through alternative polyadenylation and splicing generates a transcript, STET, with potential importance in carcinogenesis.
C1 [Vad-Nielsen, Johan; Jakobsen, Kristine Raaby; Daugaard, Tina Fuglsang; Thomsen, Rune; Nielsen, Anders Lade] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.
   [Jakobsen, Kristine Raaby; Sorensen, Boe Sandahl] Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus, Denmark.
   [Brugmann, Anja] Aalborg Univ Hosp, Dept Pathol, Aalborg, Denmark.
C3 Aarhus University; Aarhus University; Aalborg University; Aalborg
   University Hospital
RP Nielsen, AL (通讯作者)，Aarhus Univ, Dept Biomed, Bartholin Bldg, DK-8000 Aarhus C, Denmark.
EM aln@biomed.au.dk
RI Gammelgaard, Kristine/AAW-1794-2021; Nielsen, Anders Lade/Q-9604-2016
OI Sorensen, Boe/0000-0002-9472-8099; Nielsen, Anders
   Lade/0000-0003-4372-9961; Brugmann, Anja/0000-0002-1951-3186; Jakobsen,
   Kristine Raaby/0000-0002-5334-7767; Daugaard, Tina
   Fuglsang/0000-0003-0320-3076; Thomsen, Rune/0000-0002-9969-6567
FU Lundbeck Foundation; Familien Hede Nielsens Fond; Direktor Jacob Madsen
   & Hustru Olga Madsens Fond; Fabrikant Einar Willumsens Mindelegat; Marie
   og Borge Kroghs Fond; Fonden til Laegevidenskabens Fremme
FX This work was supported by The Lundbeck Foundation, Familien Hede
   Nielsens Fond, Direktor Jacob Madsen & Hustru Olga Madsens Fond,
   Fabrikant Einar Willumsens Mindelegat, Marie og Borge Kroghs Fond, and
   Fonden til Laegevidenskabens Fremme. We thank Toke Elbaek Linnet and
   Dennis Bruun Christensen for the scientific contribution to the hereby
   presented results.
CR AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168
   Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4
   Alló M, 2009, NAT STRUCT MOL BIOL, V16, P717, DOI 10.1038/nsmb.1620
   Ameyar-Zazoua M, 2012, NAT STRUCT MOL BIOL, V19, P998, DOI 10.1038/nsmb.2373
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Antoniou MN, 2013, HUM GENE THER, V24, P363, DOI 10.1089/hum.2013.062
   Bekenstein U, 2013, MOL CELL NEUROSCI, V56, P436, DOI 10.1016/j.mcn.2012.12.002
   Berglund P, 2006, CELL CYCLE, V5, P606, DOI 10.4161/cc.5.6.2569
   Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587
   Brugmann A, 2014, ADV BREAST CANC RES, V3, P22
   Cheng B, 2012, MOL CELL, V45, P38, DOI 10.1016/j.molcel.2011.10.022
   Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X
   Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200
   Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   Debies MT, 2001, J MAMMARY GLAND BIOL, V6, P441, DOI 10.1023/A:1014739131690
   EISSENBERG JC, 1992, GENETICS, V131, P345
   EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923
   Elkon R, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-7-r59
   Hoque M, 2013, NAT METHODS, V10, P133, DOI [10.1038/NMETH.2288, 10.1038/nmeth.2288]
   JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862
   Jang SM, 2014, EMBO REP, V15, P686, DOI 10.15252/embr.201338356
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127
   Koyanagi KO, 2005, GENE, V353, P169, DOI 10.1016/j.gene.2005.04.027
   Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lavigne M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000769
   Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1
   LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x
   Li YY, 2006, PLOS COMPUT BIOL, V2, P687, DOI 10.1371/journal.pcbi.0020074
   Lin JM, 2007, GENOME RES, V17, P818, DOI 10.1101/gr.5623407
   Luo WT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003613
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194
   Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Nojima T, 2013, CELL REP, V3, P1080, DOI 10.1016/j.celrep.2013.03.012
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Norwood LE, 2004, BREAST CANCER RES, V336, P37
   Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075
   Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200
   Palimaru I, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-464
   PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263
   Richart AN, 2012, J BIOL CHEM, V287, P18730, DOI 10.1074/jbc.M111.337204
   SAUNDERS WS, 1993, J CELL SCI, V104, P573
   Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316
   Shi YS, 2012, RNA, V18, P2105, DOI 10.1261/rna.035899.112
   SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789
   Thliveris AT, 2012, G3-GENES GENOM GENET, V2, P569, DOI 10.1534/g3.112.002436
   Thomsen R, 2011, MOL CARCINOGEN, V50, P601, DOI 10.1002/mc.20755
   Thomsen Rune, 2010, J Bioinform Comput Biol, V8, P885, DOI 10.1142/S0219720010004963
   Tian B, 2007, GENOME RES, V17, P156, DOI 10.1101/gr.5532707
   Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804
   Vad-Nielsen J, 2015, CANCER BIOL THER, V16, P189, DOI 10.1080/15384047.2014.1001277
   Wakano C, 2012, BBA-GENE REGUL MECH, V1819, P688, DOI 10.1016/j.bbagrm.2012.02.006
   Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4
   Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102
   Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8
   Yang MQ, 2007, PLOS COMPUT BIOL, V3, P733, DOI 10.1371/journal.pcbi.0030072
   Yang MQ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S6-S9
   Yang MQ, 2008, BMC GENOMICS S2, V9, pS3
   Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983
   Zhou ZL, 2010, BIOCHEM BIOPH RES CO, V398, P565, DOI 10.1016/j.bbrc.2010.06.119
   Zhou ZL, 2010, MOL BIOL REP, V37, P2407, DOI 10.1007/s11033-009-9751-8
   Zhou ZJ, 2009, MOL BIOL REP, V36, P7, DOI 10.1007/s11033-007-9145-8
NR 70
TC 12
Z9 14
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 20
PY 2016
VL 16
AR 32
DI 10.1186/s12885-016-2059-x
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DB3CC
UT WOS:000368386600001
PM 26791953
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ramachandran, K
   Speer, C
   Nathanson, L
   Claros, M
   Singal, R
AF Ramachandran, Kavitha
   Speer, Carl
   Nathanson, Lubov
   Claros, Martha
   Singal, Rakesh
TI Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Epigenetics; prostate cancer; DNA methylation; drug resistance
ID CELL-CYCLE REGULATION; DOWN-REGULATION; BREAST-CANCER; DOCETAXEL;
   PREDNISONE; HYPERMETHYLATION; MITOXANTRONE; APOPTOSIS; GENES;
   OVEREXPRESSION
AB Background/Aim: Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. However, the median time to progression on cabazitaxel is 2.8 months. We aimed to determine whether DNA methylation plays a role in cabazitaxel resistance. Materials and Methods: DU145 cells, resistant to docetaxel and cabaxitaxel (DU145 10DRCR), were generated from cells resistant to 10 nM docetaxel (DU145 10DR). The effect of pre-treatment with 5-azacytidine was determined with regards to cabazitaxel sensitivity. Gene expression profiling was carried-out on DU145 10DR, DU145 10DRCR and DU145 10DRCR treated with 5-azacytidine. Results: Pre-treatment of cells with 5-azacytidine resulted in enhanced sensitivity to cabazitaxel. Gene expression profiling identified a subset of genes that may be regulated by DNA methylation. Conclusion: Our results indicate that DNA methylation of pro-apoptotic and cell-cycle regulatory genes may contribute to cabazitaxel resistance and pre-treatment with 5-azacytidine may restore sensitivity to cabazitaxel in prostate cancer cells.
C1 [Ramachandran, Kavitha; Claros, Martha; Singal, Rakesh] Univ Miami, Sylvester Canc Ctr, Miami, FL USA.
   [Speer, Carl; Nathanson, Lubov] Nova SE Univ, Miami, FL USA.
C3 University of Miami; Nova Southeastern University
RP Singal, R (通讯作者)，1550 NW 10th Ave PAP 219 M877, Miami, FL 33136 USA.
EM rsingal@med.miami.edu
RI Nathanson, Lubov/ABC-2642-2021
OI Nathanson, Lubov/0000-0003-1038-9083
FU Sanofi-Aventis
FX This work was funded by a grant from Sanofi-Aventis to RS.
CR Dai W, 2011, CLIN CANCER RES, V17, P4052, DOI 10.1158/1078-0432.CCR-10-3021
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
   De Larco JE, 2003, P NATL ACAD SCI USA, V100, P13988, DOI 10.1073/pnas.2335921100
   Diaz-Moralli S, 2013, PHARMACOL THERAPEUT, V138, P255, DOI 10.1016/j.pharmthera.2013.01.011
   Gordian E, 2009, ANTICANCER RES, V29, P3207
   Huang XG, 2012, BLOOD, V120, P1095, DOI 10.1182/blood-2012-03-415984
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito K, 2014, ONCOGENE, V33, P1862, DOI 10.1038/onc.2013.130
   Khor GH, 2013, INT J MED SCI, V10, P1727, DOI 10.7150/ijms.6884
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Marín-Aguilera M, 2012, MOL CANCER THER, V11, P329, DOI 10.1158/1535-7163.MCT-11-0289
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007
   Ramachandran K, 2011, ANTICANCER RES, V31, P3757
   Ramachandran K, 2009, CANCER RES, V69, P1527, DOI 10.1158/0008-5472.CAN-08-3609
   Reis IM, 2015, BRIT J CANCER, V113, P460, DOI 10.1038/bjc.2015.240
   Shin SH, 2013, AM J PATHOL, V182, P1275, DOI 10.1016/j.ajpath.2013.01.004
   Siegel R. L., 2015, Cancer statistics
   Singal R, 2015, CLIN GENITOURIN CANC, V13, P22, DOI 10.1016/j.clgc.2014.07.008
   Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174
   Wallingford JB, 2005, DEVELOPMENT, V132, P4421, DOI 10.1242/dev.02068
   Yu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029450
   Zhu YJ, 2013, MOL CELL BIOCHEM, V374, P113, DOI 10.1007/s11010-012-1510-9
NR 26
TC 27
Z9 27
U1 0
U2 10
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2016
VL 36
IS 1
BP 161
EP 168
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ9XD
UT WOS:000367450000020
PM 26722040
DA 2025-01-12
ER

PT J
AU Dallol, A
   Buhmeida, A
   Merdad, A
   Al-Maghrabi, J
   Gari, MA
   Abu-Elmagd, MM
   Elaimi, A
   Assidi, M
   Chaudhary, AG
   Abuzenadah, AM
   Nedjadi, T
   Ermiah, E
   Alkhayyat, SS
   Al-Qahtani, MH
AF Dallol, Ashraf
   Buhmeida, Abdelbaset
   Merdad, Adnan
   Al-Maghrabi, Jaudah
   Gari, Mamdooh A.
   Abu-Elmagd, Muhammad M.
   Elaimi, Aisha
   Assidi, Mourad
   Chaudhary, Adeel G.
   Abuzenadah, Adel M.
   Nedjadi, Taoufik
   Ermiah, Eramah
   Alkhayyat, Shadi S.
   Al-Qahtani, Mohammed H.
TI Frequent methylation of the KLOTHO gene and overexpression of the FGFR4
   receptor in invasive ductal carcinoma of the breast
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; Methylation; KLOTHO; FGFR4; FGF19
ID TUMOR-SUPPRESSOR; GASTRIC-CANCER; EXPRESSION; PROGNOSIS; PATHWAYS
AB Invasive ductal carcinoma of the breast is the most common cancer affecting women worldwide. The marked heterogeneity of breast cancer is matched only with the heterogeneity in its associated or causative factors. Breast cancer in Saudi Arabia is apparently an early onset with many of the affected females diagnosed before they reach the age of 50 years. One possible rationale underlying this observation is that consanguinity, which is widely spread in the Saudi community, is causing the accumulation of yet undetermined cancer susceptibility mutations. Another factor could be the accumulation of epigenetic aberrations caused by the shift toward a Western-like lifestyle in the past two decades. In order to shed some light into the molecular mechanisms underlying breast cancer in the Saudi community, we identified KLOTHO (KL) as a tumor-specific methylated gene using genome-wide methylation analysis of primary breast tumors utilizing the MBD-seq approach. KL methylation was frequent as it was detected in 55.3 % of breast cancer cases from Saudi Arabia (n = 179) using MethyLight assay. Furthermore, KL is downregulated in breast tumors with its expression induced following treatment with 5-azacytidine. The involvement of KL in breast cancer led us to investigate its relationship in the context of breast cancer, with one of the protagonists of its function, fibroblast growth factor receptor 4 (FGFR4). Overexpression of FGFR4 in breast cancer is frequent in our cohort and this overexpression is associated with poor overall survival. Interestingly, FGFR4 expression is higher in the absence of KL methylation and lower when KL is methylated and presumably silenced, which is suggestive of an intricate relationship between the two factors. In conclusion, our findings further implicate "metabolic" genes or pathways in breast cancer that are disrupted by epigenetic mechanisms and could provide new avenues for understanding this disease in a new context.
C1 [Dallol, Ashraf; Buhmeida, Abdelbaset; Gari, Mamdooh A.; Abu-Elmagd, Muhammad M.; Assidi, Mourad; Chaudhary, Adeel G.; Abuzenadah, Adel M.; Al-Qahtani, Mohammed H.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah 21589, Saudi Arabia.
   [Dallol, Ashraf; Elaimi, Aisha; Abuzenadah, Adel M.] King Abdulaziz Univ, KACST Technol Innovat Ctr Personalized Med, Jeddah 21589, Saudi Arabia.
   [Merdad, Adnan] King Abdulaziz Univ, Dept Surg, Fac Med, Jeddah 21589, Saudi Arabia.
   [Al-Maghrabi, Jaudah] King Abdulaziz Univ, Dept Pathol, Fac Med, Jeddah 21589, Saudi Arabia.
   [Gari, Mamdooh A.; Elaimi, Aisha; Chaudhary, Adeel G.; Abuzenadah, Adel M.; Al-Qahtani, Mohammed H.] King Abdulaziz Univ, Fac Appl Med Sci, Jeddah 21589, Saudi Arabia.
   [Nedjadi, Taoufik] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia.
   [Ermiah, Eramah] Natl Canc Inst, Dept Oncol, Sabratha, Libya.
   [Abu-Elmagd, Muhammad M.] Menia Univ, Dept Zool, Fac Sci, Al Minya, Egypt.
   [Alkhayyat, Shadi S.] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia.
C3 King Abdulaziz University; King Abdulaziz University; King Abdulaziz
   University; King Abdulaziz University; King Abdulaziz University; King
   Abdulaziz University; Egyptian Knowledge Bank (EKB); Minia University;
   King Abdulaziz University; King Abdulaziz University Hospital - Jeddah
RP Dallol, A (通讯作者)，King Abdulaziz Univ, Ctr Excellence Genom Med Res, POB 80216, Jeddah 21589, Saudi Arabia.
EM adallol@kau.edu.sa
RI Al-Maghrabi, Jaudah/L-4367-2013; Buhmeida, Abdelbaset/H-9481-2012;
   Nedjadi, Taoufik/H-9709-2012; Elaimi, Aisha/AAY-8795-2020; Abu-Elmagd,
   Muhammad/O-4978-2019; Al-Qahtani, Mohammed/AAZ-1729-2020; Abu-Elmagd,
   Muhammad/C-3657-2011; Dallol, Ashraf/H-8661-2012; ASSIDI,
   Mourad/A-6152-2013
OI Abu-Elmagd, Muhammad/0000-0002-4979-701X; AL-MAGHRABI,
   JAUDAH/0000-0002-0812-9592; Dallol, Ashraf/0000-0002-8803-228X; ASSIDI,
   Mourad/0000-0003-2750-1764; Buhmeida, Abdelbaset/0000-0002-0248-8025
FU Ministry of Education and King Abdulaziz City for Science and Technology
   (KACST) [ARP-29-292]
FX The authors would like thank the Ministry of Education and King
   Abdulaziz City for Science and Technology (KACST) for their financial
   support to this research project (ARP-29-292).
CR Abu-Elmagd M, 2001, DEV BIOL, V237, P258, DOI 10.1006/dbio.2001.0378
   Buhmeida A, 2014, TUMOR BIOL, V35, P2817, DOI 10.1007/s13277-013-1374-y
   Chen CD, 2015, J MOL NEUROSCI, V55, P76, DOI 10.1007/s12031-014-0336-1
   Dallol A, 2011, METHODS MOL BIOL, V724, P191, DOI 10.1007/978-1-61779-055-3_13
   Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2
   Kuro-O M, 2008, BIOL CHEM, V389, P233, DOI 10.1515/BC.2008.028
   Kuro-O M, 2012, CURR OPIN NEPHROL HY, V21, P362, DOI 10.1097/MNH.0b013e32835422ad
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109
   Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718
   Luo YD, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-21
   Marmé F, 2010, ANN ONCOL, V21, P1636, DOI 10.1093/annonc/mdq017
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Masuda H, 2005, MECH AGEING DEV, V126, P1274, DOI 10.1016/j.mad.2005.07.007
   Mehmood A, 2011, TUMOR REGISTRY ANN R
   Merdad A, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S1-S3
   Najjar H, 2010, INT J SURG, V8, P448, DOI 10.1016/j.ijsu.2010.05.012
   Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Ravikumar P, 2014, AM J PHYSIOL-LUNG C, V307, pL566, DOI 10.1152/ajplung.00306.2013
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4
   Salmon-Divon M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-415
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023
   Xu B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-84
   Xu YC, 2015, ENDOCR REV, V36, P174, DOI 10.1210/er.2013-1079
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 30
TC 24
Z9 24
U1 0
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9677
EP 9683
DI 10.1007/s13277-015-3733-3
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ8DC
UT WOS:000367329300063
PM 26152288
DA 2025-01-12
ER

PT J
AU Singhal, SK
   Usmani, N
   Michiels, S
   Metzger-Filho, O
   Saini, KS
   Kovalchuk, O
   Parliament, M
AF Singhal, Sandeep K.
   Usmani, Nawaid
   Michiels, Stefan
   Metzger-Filho, Otto
   Saini, Kamal S.
   Kovalchuk, Olga
   Parliament, Matthew
TI Towards understanding the breast cancer epigenome: a comparison of
   genome-wide DNA methylation and gene expression data
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; breast cancer; epigenetics; expression; microarray
ID 5-HYDROXYMETHYLCYTOSINE; 5-METHYLCYTOSINE; CPG; CLASSIFICATION;
   NORMALIZATION; EPIGENETICS; METHYLOME; MECHANISM; PROFILES; SUBTYPES
AB Until recently, an elevated disease risk has been ascribed to a genetic predisposition, however, exciting progress over the past years has discovered alternate elements of inheritance that involve epigenetic regulation. Epigenetic changes are heritably stable alterations that include DNA methylation, histone modifications and RNA-mediated silencing. Aberrant DNA methylation is a common molecular basis for a number of important human diseases, including breast cancer. Changes in DNA methylation profoundly affect global gene expression patterns. What is emerging is a more dynamic and complex association between DNA methylation and gene expression than previously believed. Although many tools have already been developed for analyzing genome-wide gene expression data, tools for analyzing genome-wide DNA methylation have not yet reached the same level of refinement.
   Here we provide an in-depth analysis of DNA methylation in parallel with gene expression data characteristics and describe the particularities of low-level and high-level analyses of DNA methylation data. Low-level analysis refers to pre-processing of methylation data (i.e. normalization, transformation and filtering), whereas high-level analysis is focused on illustrating the application of the widely used class comparison, class prediction and class discovery methods to DNA methylation data. Furthermore, we investigate the influence of DNA methylation on gene expression by measuring the correlation between the degree of CpG methylation and the level of expression and to explore the pattern of methylation as a function of the promoter region.
C1 [Singhal, Sandeep K.; Usmani, Nawaid; Parliament, Matthew] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada.
   [Michiels, Stefan] Inst Gustave Roussy, Serv Biostat & Epidemiol, Villejuif, France.
   [Michiels, Stefan] Univ Paris 11, INSERM, CESP, U1018, Villejuif, France.
   [Metzger-Filho, Otto] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
   [Saini, Kamal S.] Quantum Hlth Analyt SPRL, Liege, Belgium.
   [Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
   [Kovalchuk, Olga] Canada Canc & Aging Res Labs Ltd, Lethbridge, AB, Canada.
C3 University of Alberta; UNICANCER; Gustave Roussy; Universite Paris
   Saclay; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Harvard University; Harvard Medical School; Dana-Farber Cancer
   Institute; University of Lethbridge
RP Parliament, M (通讯作者)，Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada.; Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.; Kovalchuk, O (通讯作者)，Canada Canc & Aging Res Labs Ltd, Lethbridge, AB, Canada.
EM olga.kovalchuk@uleth.ca; matthew.parliament@albertahealthservices.ca
RI Saini, Kamal S./ABD-5499-2021; Michiels, Stefan/L-1516-2013
OI Saini, Kamal S./0000-0001-6301-3309; Michiels,
   Stefan/0000-0002-6963-2968
CR Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080
   Archer KJ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-60
   Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bibikova M, 2010, WIRES SYST BIOL MED, V2, P210, DOI 10.1002/wsbm.35
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bibikova Marina, 2009, V507, P149, DOI 10.1007/978-1-59745-522-0_12
   BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   BORISOV N.M., 2014, Oncotarget
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Dabney AR, 2005, BIOINFORMATICS, V21, P4148, DOI 10.1093/bioinformatics/bti681
   Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dedeurwaerder S., 2011, EMBO molecular medicine, P1
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Delongchamp RR, 2002, ADJUSTING CDNA ARRAY
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Hahn MA, 2015, METHODS MOL BIOL, V1238, P273, DOI 10.1007/978-1-4939-1804-1_14
   Heller G, 2015, ONCOTARGET, V6, P394, DOI 10.18632/oncotarget.2697
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Houseman EA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-365
   Hsueh HM, 2013, GENE, V518, P179, DOI 10.1016/j.gene.2012.11.034
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Carmona FJ, 2011, CANCER BIOMARK, V9, P101, DOI 10.3233/CBM-2011-0184
   Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Ko M, 2015, IMMUNOL REV, V263, P6, DOI 10.1111/imr.12239
   Koestler DC, 2013, STAT APPL GENET MOL, V12, P225, DOI 10.1515/sagmb-2012-0068
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kroeze LI, 2015, BBA-REV CANCER, V1855, P144, DOI 10.1016/j.bbcan.2015.01.001
   Lai J, 2014, ONCOTARGET, V5, P6909, DOI 10.18632/oncotarget.2230
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lezhnina K, 2014, ONCOTARGET, V5, P9022, DOI 10.18632/oncotarget.2493
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993
   Pogribny IP, 2013, CANCER LETT, V334, P39, DOI 10.1016/j.canlet.2012.09.010
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Renner M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r137
   Risso D, 2009, BIOINFORMATICS, V25, P2685, DOI 10.1093/bioinformatics/btp443
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280
   Shames DS, 2007, CURR MOL MED, V7, P85, DOI 10.2174/156652407779940413
   Siegmund KD, 2004, BIOINFORMATICS, V20, P1896, DOI 10.1093/bioinformatics/bth176
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   van de Wiel MA, 2007, BIOINFORMATICS, V23, P892, DOI 10.1093/bioinformatics/btm030
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Wang XM, 2010, J CELL BIOCHEM, V109, P818, DOI 10.1002/jcb.22461
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wei Hu, 2010, Journal of Biomedical Science & Engineering, V3, P59, DOI 10.4236/jbise.2010.31009
   Weidman JR, 2007, CANCER J, V13, P9, DOI 10.1097/PPO.0b013e31803c71f2
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Yu B, 2015, ONCOTARGET, V6, P3627, DOI 10.18632/oncotarget.2875
   Zhang WW, 2015, GENOME BIOL, V16, DOI [10.1186/s13059-015-0694-1, 10.1186/s13059-015-0581-9]
NR 77
TC 16
Z9 19
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 19
PY 2016
VL 7
IS 3
BP 3002
EP 3017
DI 10.18632/oncotarget.6503
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GV
UT WOS:000369951800062
PM 26657508
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ozturk, S
   Papageorgis, P
   Wong, CK
   Lambert, AW
   Abdolmaleky, HM
   Thiagalingam, A
   Cohen, HT
   Thiagalingam, S
AF Ozturk, Sait
   Papageorgis, Panagiotis
   Wong, Chen Khuan
   Lambert, Arthur W.
   Abdolmaleky, Hamid M.
   Thiagalingam, Arunthathi
   Cohen, Herbert T.
   Thiagalingam, Sam
TI SDPR functions as a metastasis suppressor in breast cancer by promoting
   apoptosis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE metastasis; breast cancer; SDPR; epigenetics; metastasis suppressor
ID TUMOR-METASTASIS; EXPRESSION; GENES; PROGRESSION; LANDSCAPE; INSIGHTS;
   PATHWAY; NM23-H1; FAMILY; KIDNEY
AB Metastatic dissemination of breast cancer cells represents a significant clinical obstacle to curative therapy. The loss of function of metastasis suppressor genes is a major rate-limiting step in breast cancer progression that prevents the formation of new colonies at distal sites. However, the discovery of new metastasis suppressor genes in breast cancer using genomic efforts has been slow, potentially due to their primary regulation by epigenetic mechanisms. Here, we report the use of model cell lines with the same genetic lineage for the identification of a novel metastasis suppressor gene, serum deprivation response (SDPR), localized to 2q32-33, a region reported to be associated with significant loss of heterozygosity in breast cancer. In silico metaanalysis of publicly available gene expression datasets suggests that the loss of expression of SDPR correlates with significantly reduced distant-metastasis-free and relapse-free survival of breast cancer patients who underwent therapy. Furthermore, we found that stable SDPR overexpression in highly metastatic breast cancer model cell lines inhibited prosurvival pathways, shifted the balance of Bcl-2 family proteins in favor of apoptosis, and decreased migration and intravasation/extravasation potential, with a corresponding drastic suppression of metastatic nodule formation in the lungs of NOD/SCID mice. Moreover, SDPR expression is silenced by promoter DNA methylation, and as such it exemplifies epigenetic regulation of metastatic breast cancer progression. These observations highlight SDPR as a potential prognostic biomarker and a target for future therapeutic applications.
C1 [Ozturk, Sait; Cohen, Herbert T.; Thiagalingam, Sam] Boston Univ, Sch Med, Cell & Mol Biol Grad Program, Boston, MA 02118 USA.
   [Ozturk, Sait; Lambert, Arthur W.; Cohen, Herbert T.; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Med, Mol & Translat Med Grad Program, Boston, MA 02118 USA.
   [Ozturk, Sait; Papageorgis, Panagiotis; Wong, Chen Khuan; Lambert, Arthur W.; Abdolmaleky, Hamid M.; Thiagalingam, Arunthathi; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Med, Biomed Genet Sect, Boston, MA 02118 USA.
   [Ozturk, Sait; Papageorgis, Panagiotis; Wong, Chen Khuan; Lambert, Arthur W.; Abdolmaleky, Hamid M.; Thiagalingam, Arunthathi; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Med, Ctr Canc, Boston, MA 02118 USA.
   [Papageorgis, Panagiotis; Wong, Chen Khuan; Thiagalingam, Sam] Boston Univ, Sch Med, Genet & Genom Grad Program, Boston, MA 02118 USA.
   [Cohen, Herbert T.; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
C3 Boston University; Boston University; Boston University; Boston
   University; Boston University; Boston University
RP Thiagalingam, S (通讯作者)，Boston Univ, Sch Med, Cell & Mol Biol Grad Program, Boston, MA 02118 USA.
EM samthia@bu.edu
RI Papageorgis, Panagiotis/J-5711-2019
OI Papageorgis, Panagiotis/0000-0002-7595-5616; Wong, Chen
   Khuan/0000-0001-9811-3334; Mostafavi Abdolmaleky,
   Hamid/0000-0002-8872-5174
FU Susan G. Komen for the Cure [KG081435]; NIH [CA165707]; Research
   Promotion Foundation of Cyprus [DIDAKTOR 0609/24]; Department of
   Defense, Breast Cancer Research Program [W81XWH-11-1-0060]; Boston
   University Genome Science Institute; IVIS/Metabolic Phenotyping
   Core/Medicine; BU Flow Cytometry Core; Boston University Clinical and
   Translational Science Institute (NIH CTSA Award) [UL1-TR000157]
FX This work was supported by grants from Susan G. Komen for the Cure
   (KG081435) and the NIH (CA165707) (to S.T.), Research Promotion
   Foundation of Cyprus (DIDAKTOR 0609/24) (to P.P.), and Department of
   Defense, Breast Cancer Research Program (W81XWH-11-1-0060) (to A.W.L.).
   We also acknowledge a seed grant from the Boston University Genome
   Science Institute, and support from the IVIS/Metabolic Phenotyping
   Core/Medicine, BU Flow Cytometry Core, and the core facilities at Boston
   University Clinical and Translational Science Institute (NIH CTSA Award
   UL1-TR000157). We thank Drs. Bert Vogelstein and Jian Yu (Sidney Kimmel
   Comprehensive Cancer Center at Johns Hopkins), Steven Santner (Karmanos
   Cancer Institute), Joan Massague (Memorial Sloan Kettering Cancer
   Center), and Ramon Parsons (Icahn School of Medicine at Mount Sinai) for
   generously providing reagents and cell lines. We also thank Drs. David
   C. Seldin, Gerald V. Denis, and M. Isabel Dominguez for their valuable
   suggestions for the research project. Our thanks also go to Dr. Deniz
   Civril (Georgetown University) for her help with data analysis.
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Bandyopadhyay S, 2004, ONCOGENE, V23, P5675, DOI 10.1038/sj.onc.1207734
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000
   Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940
   Friedrich K, 2008, CELL ONCOL, V30, P39
   Gianazza E, 2012, J PROTEOMICS, V76, P125, DOI 10.1016/j.jprot.2012.07.032
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Gustincich S, 1999, GENOMICS, V57, P120, DOI 10.1006/geno.1998.5733
   Guzmán C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887
   Hartsough MT, 2001, CANCER RES, V61, P2320
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   LEONE A, 1993, ONCOGENE, V8, P2325
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x
   Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207
   Ozturk S, 2015, SYSTEMS BIOL CANC, P282
   Papageorgis P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0607-y
   Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594
   Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218
   Swanton C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2807
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Uhlén M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200
   Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
NR 36
TC 56
Z9 61
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 19
PY 2016
VL 113
IS 3
BP 638
EP 643
DI 10.1073/pnas.1514663113
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB4BX
UT WOS:000368458800054
PM 26739564
OA Green Published
DA 2025-01-12
ER

PT J
AU Phan, NLC
   Trinh, NV
   Pham, PV
AF Nhan Lu-Chinh Phan
   Ngu Van Trinh
   Phuc Van Pham
TI Low concentrations of 5-aza-2′-deoxycytidine induce breast cancer stem
   cell differentiation by triggering tumor suppressor gene expression
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE breast cancer; breast cancer stem cells; differentiation; epigenetics;
   5-aza-2 '-deoxycytidine
ID CD44 SPLICE VARIANTS; SIDE POPULATION; P53/P21(WAF1/CIP1) PATHWAY;
   DRUG-RESISTANCE; CERVICAL-CANCER; CARCINOMA-CELLS; SELF-RENEWAL; CYCLE
   ARREST; COLON-CANCER; LUNG-CANCER
AB Background: Breast cancer stem cells (BCSCs) are considered the cause of tumor growth, multidrug resistance, metastasis, and recurrence. Therefore, differentiation therapy to reduce self-renewal of BCSCs is a promising approach. We have examined the effects of 5-aza-2 '-deoxycytidine (DAC) on BCSC differentiation.
   Materials and methods: BCSCs were treated with a range of DAC concentrations from 0.625 to 100 mu M. The differentiation status of DAC-treated BCSCs was graded by changes in cell proliferation, CD44(+)CD24(-) phenotype, expression of tumor suppressor genes, including BRCA1, BRCA2, p15, p16, p53, and PTEN, and antitumor drug resistance.
   Results: DAC treatment caused significant BCSC differentiation. BCSCs showed a 15%-23% reduction in proliferation capacity, 3.0%-21.3% decrease in the expression of BCSC marker CD44(+)/CD24(-), activation of p53 expression, and increased p15, p16, BRCA1, and BRCA2 expression. Concentrations of DAC ranging from 0.625 to 40 mu M efficiently induce cell cycle arrest in S-phase. ABCG2, highly expressed in BCSCs, also decreased with DAC exposure. Of particular note, drug-sensitivity of BCSCs to doxorubicin, verapamil, and tamoxifen also increased 1.5-, 2.0-, and 3.7-fold, respectively, after pretreatment with DAC.
   Conclusion: DAC reduced breast cancer cell survival and induced differentiation through reexpression of tumor suppressor genes. These results indicate the potential of DAC in targeting specific chemotherapy-resistant cells within a tumor.
C1 [Nhan Lu-Chinh Phan; Ngu Van Trinh; Phuc Van Pham] Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam.
C3 Vietnam National University Ho Chi Minh City (VNUHCM) System; VNU-HCM
   University of Science (VNUHCM-US)
RP Pham, PV (通讯作者)，Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, 227 Nguyen Van Cu,Dist 5, Ho Chi Minh City, Vietnam.
EM pvphuc@hcmuns.edu.vn
RI ; Trinh, Van Ngu/GRY-7486-2022; PHAM, VAN PHUC/L-6131-2013
OI Phan Lu-Chinh, Nhan/0000-0002-7029-1232; Trinh, Van
   Ngu/0000-0002-5958-8975; PHAM, VAN PHUC/0000-0001-7254-0717
FU Ministry of Science and Technology, Vietnam [DTDL.2011-T/30]
FX This study was funded by Ministry of Science and Technology under grant
   No. DTDL.2011-T/30, Vietnam.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Amatori S, 2009, LUNG CANCER, V66, P184, DOI 10.1016/j.lungcan.2009.01.015
   Askari M, 2013, MOL BIOL REP, V40, P4921, DOI 10.1007/s11033-013-2592-5
   Chen BY, 2007, BIOCHEM BIOPH RES CO, V357, P1084, DOI 10.1016/j.bbrc.2007.04.091
   Christgen M, 2007, MOL CELL BIOCHEM, V306, P201, DOI 10.1007/s11010-007-9570-y
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Debeb BG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-180
   Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005
   Durmus S, 2015, PHARM RES-DORDR, V32, P37, DOI 10.1007/s11095-014-1442-z
   Farinha NJ, 2004, ANTICANCER RES, V24, P75
   Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Gomez-Cabrero A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073607
   Guo Y, 2006, LEUKEMIA, V20, P115, DOI 10.1038/sj.leu.2404019
   Han Xin-Ai, 2013, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V21, P356, DOI 10.7534/j.issn.1009-2137.2013.02.020
   Han Xu, 2013, Zhonghua Zhong Liu Za Zhi, V35, P17, DOI 10.3760/cma.j.issn.0253-3766.2013.01.004
   HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0
   Herman JG, 1996, CANCER RES, V56, P722
   HERRLICH P, 1995, EUR J CANCER, V31A, P1110, DOI 10.1016/0959-8049(95)00252-E
   Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   JONAS SK, 1995, ONCOL REP, V2, P1103
   Kainz C, 1996, INT J CANCER, V69, P170
   KAN M, 1995, JPN J CANCER RES, V86, P847, DOI 10.1111/j.1349-7006.1995.tb03095.x
   Kang HF, 2013, ONCOTARGETS THER, V6, P411, DOI 10.2147/OTT.S43744
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491
   Lee JJ, 2012, KOREAN J PATHOL, V46, P554
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Lemaire M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-128
   Liu SV, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00135
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Lu Y, 2012, J CANCER, V3, P333, DOI 10.7150/jca.4046
   Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096
   MATSUMURA Y, 1995, J PATHOL, V177, P11, DOI 10.1002/path.1711770104
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Momparler RL, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00188
   Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030
   Naldi I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098101
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592
   Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39
   Pham PV, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-209
   Phuc PV, 2011, ONCOTARGETS THER, V4, P71, DOI 10.2147/OTT.S21431
   Van Pham P, 2012, ONCOTARGETS THER, V5, P77, DOI 10.2147/OTT.S30609
   PINTO A, 1984, BLOOD, V64, P922
   Prabhakaran P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00134
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   Roy R, 2010, BREAST CANC RES S1, V12
   Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002
   Schnekenburger M, 2011, BIOCHEM PHARMACOL, V81, P364, DOI 10.1016/j.bcp.2010.10.013
   Sharma A, 2012, MOL CANCER THER, V11, P77, DOI 10.1158/1535-7163.MCT-11-0508
   Shi CJ, 2010, CANCER BIOL THER, V10, P1183, DOI 10.4161/cbt.10.11.13664
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Song DY, 2014, EXP THER MED, V7, P1071, DOI 10.3892/etm.2014.1571
   Sophos NA, 2003, CHEM-BIOL INTERACT, V143, P5, DOI 10.1016/S0009-2797(02)00163-1
   Su J, 2011, ARCH MED RES, V42, P15, DOI 10.1016/j.arcmed.2011.01.007
   Takehara M, 2011, BIOCHEM PHARMACOL, V81, P1124, DOI 10.1016/j.bcp.2011.02.012
   Tanaka H, 2009, ANTICANCER RES, V29, P2147
   Uchida N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104022
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wongtrakoongate P, 2014, BRIT J CANCER, V110, P2131, DOI 10.1038/bjc.2014.128
   Xiong HH, 2009, J HUAZHONG U SCI-MED, V29, P498, DOI 10.1007/s11596-009-0421-9
   Yao TT, 2013, GENET MOL RES, V12, P312, DOI 10.4238/2013.February.4.5
   Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031
   Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940
   Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331
   Zheng ZX, 2012, FASEB J, V26, P449, DOI 10.1096/fj.11-190025
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
   Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868
NR 74
TC 15
Z9 17
U1 0
U2 13
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2016
VL 9
DI 10.2147/OTT.S96291
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CZ5JL
UT WOS:000367138600001
PM 26730203
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Romagnolo, DF
   Papoutsis, AJ
   Laukaitis, C
   Selmin, OI
AF Romagnolo, Donato F.
   Papoutsis, Andreas J.
   Laukaitis, Christina
   Selmin, Ornella I.
TI Constitutive expression of AhR and <i>BRCA-1</i> promoter CpG
   hypermethylation as biomarkers of ERα-negative breast tumorigenesis
SO BMC CANCER
LA English
DT Article
DE BRCA-1; AhR; CpG methylation; Epigenetics; SAhRMs; ER alpha; Breast
   cancer
ID ARYL-HYDROCARBON RECEPTOR; INDUCED MAMMARY-TUMORS; SPORADIC BREAST;
   ESTROGEN-RECEPTOR; GENE-EXPRESSION; OVARIAN-CANCER; PROTEIN EXPRESSION;
   MESSENGER-RNA; MCF-7 CELLS; METHYLATION
AB Background: Only 5-10 % of breast cancer cases is linked to germline mutations in the BRCA-1 gene and occurs early in life. Conversely, sporadic breast tumors, which represent 90-95 % of breast malignancies, have lower BRCA-1 expression, but not mutated BRCA-1 gene, and tend to occur later in life in combination with other genetic alterations and/or environmental exposures. The latter may include environmental and dietary factors that activate the aromatic hydrocarbon receptor (AhR). Therefore, understanding if changes in expression and/or activation of the AhR are associated with somatic inactivation of the BRCA-1 gene may provide clues for breast cancer therapy.
   Methods: We evaluated Brca-1 CpG promoter methylation and expression in mammary tumors induced in Sprague-Dawley rats with the AhR agonist and mammary carcinogen 7,12-dimethyl-benzo(a) anthracene (DMBA). Also, we tested in human estrogen receptor (ER) a-negative sporadic UACC-3199 and ER alpha-positive MCF-7 breast cancer cells carrying respectively, hyper-and hypomethylated BRCA-1 gene, if the treatment with the AhR antagonist alpha-naphthoflavone (alpha NF) modulated BRCA-1 and ER alpha expression. Finally, we examined the association between expression of AhR and BRCA-1 promoter CpG methylation in human triple-negative (TNBC), luminal-A (LUM-A), LUM-B, and epidermal growth factor receptor-2 (HER-2)-positive breast tumor samples.
   Results: Mammary tumors induced with DMBA had reduced BRCA-1 and ERa expression; higher Brca-1 promoter CpG methylation; increased expression of Ahr and its downstream target Cyp1b1; and higher proliferation markers Ccnd1 (cyclin D1) and Cdk4. In human UACC-3199 cells, low BRCA-1 was paralleled by constitutive high AhR expression; the treatment with alpha NF rescued BRCA-1 and ER alpha, while enhancing preferential expression of CYP1A1 compared to CYP1B1. Conversely, in MCF-7 cells, alpha NF antagonized estradiol-dependent activation of BRCA-1 without effects on expression of ER alpha. TNBC exhibited increased basal AhR and BRCA-1 promoter CpG methylation compared to LUM-A, LUM-B, and HER-2-positive breast tumors.
   Conclusions: Constitutive AhR expression coupled to BRCA-1 promoter CpG hypermethylation may be predictive markers of ER alpha-negative breast tumor development. Regimens based on selected AhR modulators (SAhRMs) may be useful for therapy against ERa-negative tumors, and possibly, TNBC with increased AhR and hypermethylated BRCA-1 gene.
C1 [Romagnolo, Donato F.; Papoutsis, Andreas J.; Laukaitis, Christina; Selmin, Ornella I.] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
   [Romagnolo, Donato F.; Laukaitis, Christina; Selmin, Ornella I.] Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA.
   [Laukaitis, Christina] Univ Arizona, Coll Med, Dept Med, Tucson, AZ 85724 USA.
C3 University of Arizona; University of Arizona; University of Arizona
RP Romagnolo, DF (通讯作者)，Univ Arizona, Dept Nutr Sci, 303 Shantz Bldg, Tucson, AZ 85721 USA.
EM donato@u.arizona.edu
RI Selmin, Ornella/ABC-8971-2020; Laukaitis, Christina/AAL-5865-2021
OI Laukaitis, Christina/0000-0003-1466-7941
FU Arizona Biomedical Research Commission [QSR14082995]; US Department of
   Defense Breast Cancer Program [BC134119]
FX We acknowledge the technical assistance of Jamie Borg in tissue
   collection and analysis. This work was supported by grants from the
   Arizona Biomedical Research Commission (QSR14082995) and the US
   Department of Defense Breast Cancer Program (BC134119). Frozen tissue
   samples were provided by the UACC Cancer Biorepository (PI: S.
   Chambers), a part of the University of Arizona Cancer Center's Tissue
   Acquisition and Cellular/Molecular Analysis Shared Resource (TACMASR),
   NIH CA023074.
CR Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545
   Angus WGR, 1999, CARCINOGENESIS, V20, P947, DOI 10.1093/carcin/20.6.947
   [Anonymous], 2015, CANC FACTS FIG 2015
   Bal A, 2012, VIRCHOWS ARCH, V461, P305, DOI 10.1007/s00428-012-1286-z
   Barhoover MA, 2010, MOL PHARMACOL, V77, P195, DOI 10.1124/mol.109.059675
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935
   Berchuck A, 1998, CLIN CANCER RES, V4, P2433
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525
   Ciolino HP, 2002, INT J ONCOL, V21, P385
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Dobrovic A, 1997, CANCER RES, V57, P3347
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061
   Ghadirian P, 2009, BREAST CANCER RES TR, V117, P417, DOI 10.1007/s10549-008-0292-y
   Gorski JJ, 2009, CLIN CANCER RES, V15, P1514, DOI 10.1158/1078-0432.CCR-08-0640
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207
   Jacot W, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-523
   Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95
   Jeffy BD, 1999, MOL CARCINOGEN, V26, P100, DOI 10.1002/(SICI)1098-2744(199910)26:2<100::AID-MC5>3.0.CO;2-1
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Jeffy BD, 2002, ENVIRON MOL MUTAGEN, V39, P235, DOI 10.1002/em.10051
   Jeffy BD, 2002, CANCER RES, V62, P113
   Jeffy BD, 2000, NEOPLASIA, V2, P460, DOI 10.1038/sj.neo.7900104
   Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004
   Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535
   Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Locke WJ, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0086-0
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MCKAY JA, 1995, FEBS LETT, V374, P270, DOI 10.1016/0014-5793(95)01126-Y
   Mense SM, 2009, CARCINOGENESIS, V30, P1202, DOI 10.1093/carcin/bgp093
   MERCHANT M, 1993, TOXICOL APPL PHARM, V120, P179, DOI 10.1006/taap.1993.1101
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Murray GI, 1997, CANCER RES, V57, P3026
   Papoutsis AJ, 2015, MOL CARCINOGEN, V54, P261, DOI 10.1002/mc.22095
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Romagnolo APG, 2015, ANTI-CANCER AGENT ME, V15, P4
   Romagnolo DF, 2014, ADV NUTR, V5, P373, DOI 10.3945/an.114.005868
   Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074
   Safe S, 1999, Expert Opin Investig Drugs, V8, P1385, DOI 10.1517/13543784.8.9.1385
   SANTOSTEFANO M, 1993, MOL PHARMACOL, V43, P200
   Sappok A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-8
   Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145
   Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H
   Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670
   Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Yang XH, 2008, J CELL BIOCHEM, V104, P402, DOI 10.1002/jcb.21630
   Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249
   Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322
NR 73
TC 25
Z9 29
U1 0
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 29
PY 2015
VL 15
AR 1026
DI 10.1186/s12885-015-2044-9
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ7YC
UT WOS:000367315600009
PM 26715507
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Menendez, JA
AF Menendez, Javier A.
TI Metabolic control of cancer cell stemness: Lessons from iPS cells
SO CELL CYCLE
LA English
DT Article
DE cancer stem cells; epigenetic landscapes; metabolism; reprogramming;
   stemness; Waddington
ID ATPASE INHIBITORY FACTOR-1; STRESS DEFENSE-MECHANISMS; BREAST-CANCER;
   ENERGY-METABOLISM; SOMATIC-CELLS; GLUCOSE-METABOLISM; ONCOMETABOLITE
   2-HYDROXYGLUTARATE; MITOCHONDRIAL REGULATION; COLORECTAL-CANCER;
   DRUG-RESISTANCE
AB The Nobel prized discovery of nuclear reprogramming is swiftly providing mechanistic evidence of a role for metabolism in the generation of cancer stem cells (CSC). Traditionally, the metabolic demands of tumors have been viewed as drivers of the genetic programming detected in cancer tissues. Beyond the energetic requirements of specific cancer cell states, it is increasingly recognized that metabolism per se controls epi-transcriptional networks to dictate cancer cell fate, i.e., metabolism can define CSC. Here I review the CSC-related metabolic features found in induced pluripotent stem (iPS) cells to provide an easily understandable framework in which the infrastructure and functioning of cellular metabolism might control the efficiency and kinetics of reprogramming in the re-routing of non-CSC to CSC-like cellular states. I suggest exploring how metabolism-dependent regulation of epigenetics can play a role in directing CSC states beyond conventional energetic demands of stage-specific cancer cell states, opening a new dimension of cancer in which the physiological state of CSC might be governed not only by cell-autonomous cues but also by local micro-environmental and systemic metabolo-epigenetic interactions. Forthcoming studies should decipher how specific metabolites integrate and mediate the overlap between the CSC-intrinsic micro-epigenetics and the upstream local and systemic macro-epigenetics," thus paving the way for targeted epigenetic regulation of CSCs through metabolic modulation including "smart foods" or systemic "metabolic nichotherapies."
C1 [Menendez, Javier A.] Catalan Inst Oncol, Translat Res Lab, Metab & Canc Grp, Girona, Spain.
   [Menendez, Javier A.] Girona Biomed Res Inst, Mol Oncol Grp, Girona, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI)
RP Menendez, JA (通讯作者)，Catalan Inst Oncol, Translat Res Lab, Metab & Canc Grp, Girona, Spain.
EM jmenendez@iconcologia.net
RI MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561
FU Ministerio de Ciencia e Innovacion [SAF2012-38914]; Plan Nacional de
   ICDCI, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR), Departament d'Economia I Coneixement, Catalonia, Spain [2014
   SGR229]
FX This work was supported by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2012-38914), Plan Nacional de ICDCI, Spain and the
   Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014
   SGR229), Departament d'Economia I Coneixement, Catalonia, Spain to
   Javier A. Menendez.
CR Aldea M, 2011, CANCER LETT, V311, P210, DOI 10.1016/j.canlet.2011.07.022
   [Anonymous], 2014, STEM CELL ENERGETICS, V15, P679
   [Anonymous], 1957, The strategy of the genes, DOI DOI 10.4324/9781315765471
   Apostolou E, 2013, NATURE, V502, P462, DOI 10.1038/nature12749
   Armstrong L, 2010, STEM CELLS, V28, P661, DOI 10.1002/stem.307
   Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034
   Boivin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014558
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bukowiecki R, 2014, GERONTOLOGY, V60, P174, DOI 10.1159/000355050
   Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312
   Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405
   Chen CT, 2012, BBA-GEN SUBJECTS, V1820, P571, DOI 10.1016/j.bbagen.2011.09.013
   Chen T, AGING CELL, V10, P908
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Corominas-Faja B, 2013, CELL CYCLE, V12, P3109, DOI 10.4161/cc.26173
   Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403
   Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y
   Cufí S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Cuyàs E, 2014, ONCOTARGET, V5, P3970, DOI 10.18632/oncotarget.2147
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   Del Barco S, 2011, ONCOTARGET, V2, P896, DOI 10.18632/oncotarget.387
   DeLaBarre B, 2014, CHEM BIOL, V21, P1143, DOI 10.1016/j.chembiol.2014.08.007
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Easley CA, 2010, CELL REPROGRAM, V12, P263, DOI 10.1089/cell.2010.0011
   Folmes CDL, 2013, CELL CYCLE, V12, P2355, DOI 10.4161/cc.25509
   Folmes CDL, 2013, J CARDIOVASC TRANSL, V6, P10, DOI 10.1007/s12265-012-9431-2
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Folmes CDL, 2012, ANN NY ACAD SCI, V1254, P82, DOI 10.1111/j.1749-6632.2012.06487.x
   Folmes CDL, 2011, BIOMARK MED, V5, P715, DOI [10.2217/BMM.11.87, 10.2217/bmm.11.87]
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   Formentini L, 2012, MOL CELL, V45, P731, DOI 10.1016/j.molcel.2012.01.008
   Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254
   Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145
   Goding CR, 2014, NAT REV CANCER, V14, P568, DOI 10.1038/nrc3781
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008
   He J, 2012, STEM CELLS DEV, V21, P2630, DOI 10.1089/scd.2012.0015
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Huang S, 2012, BIOESSAYS, V34, P149, DOI 10.1002/bies.201100031
   Huang S, 2011, PHILOS T R SOC B, V366, P2247, DOI 10.1098/rstb.2011.0008
   Huang S, 2009, SEMIN CELL DEV BIOL, V20, P869, DOI 10.1016/j.semcdb.2009.07.003
   Huang S, 2009, BIOESSAYS, V31, P546, DOI 10.1002/bies.200800189
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772
   Janzer A, 2014, P NATL ACAD SCI USA, V111, P10574, DOI 10.1073/pnas.1409844111
   Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068
   Kawamura T, 2014, BIOCHEM J, V463, P53, DOI 10.1042/BJ20140669
   Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37
   Kobayashi CI, 2012, J CELL PHYSIOL, V227, P421, DOI 10.1002/jcp.22764
   Krell D, 2013, FUTURE ONCOL, V9, P1923, DOI [10.2217/fon.13.143, 10.2217/FON.13.143]
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Li G, 2013, CURR MOL MED, V13, P459
   Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131
   Liu WB, 2013, BIOCHEM BIOPH RES CO, V431, P767, DOI 10.1016/j.bbrc.2012.12.148
   Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557
   Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014
   Louie SM, 2013, BBA-MOL CELL BIOL L, V1831, P1566, DOI 10.1016/j.bbalip.2013.07.008
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655
   Mathonnet M, 2014, WORLD J GASTROENTERO, V20, P4189, DOI 10.3748/wjg.v20.i15.4189
   Menendez JA, 2015, ONCOSCIENCE, V1, P803
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262
   Menendez JA, 2014, ADV EXP MED BIOL, V824, P117, DOI 10.1007/978-3-319-07320-0_10
   Menendez JA, 2014, CELL CYCLE, V13, P699, DOI 10.4161/cc.28079
   Menendez JA, 2014, CELL CYCLE, V13, P358, DOI 10.4161/cc.27770
   Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479
   Menendez JA, 2011, CELL CYCLE, V10, P3658, DOI 10.4161/cc.10.21.18128
   Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638
   Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005
   Osawa T, 2013, CELL CYCLE, V12, P2519, DOI 10.4161/cc.25729
   Pandey PR, 2013, ONCOGENE, V32, P5111, DOI 10.1038/onc.2012.519
   Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6
   Pani G, 2010, CANCER METAST REV, V29, P351, DOI 10.1007/s10555-010-9225-4
   Panopoulos AD, 2012, CELL RES, V22, P168, DOI 10.1038/cr.2011.177
   Pei SS, 2013, J BIOL CHEM, V288, P33542, DOI 10.1074/jbc.M113.511170
   Perales-Clemente E, 2014, ANTIOXID REDOX SIGN, V21, P1648, DOI 10.1089/ars.2014.6000
   Philip B, 2013, CARCINOGENESIS, V34, P1699, DOI 10.1093/carcin/bgt209
   Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232
   Prigione A, 2015, CELL MOL LIFE SCI
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552
   Prigione A, 2011, STEM CELLS, V29, P1338, DOI 10.1002/stem.683
   Prigione A, 2010, INT J DEV BIOL, V54, P1729, DOI 10.1387/ijdb.103198ap
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404
   Riggs JW, 2013, STEM CELLS DEV, V22, P37, DOI 10.1089/scd.2012.0375
   Saha SK, 2014, NATURE, V513, P110, DOI 10.1038/nature13441
   Sánchez-Aragó M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.9
   Sánchez-Aragó M, 2013, EMBO REP, V14, P638, DOI 10.1038/embor.2013.72
   Sánchez-Aragó M, 2013, ANTIOXID REDOX SIGN, V19, P285, DOI 10.1089/ars.2012.4883
   Sánchez-Aragó M, 2012, CELL CYCLE, V11, P2963, DOI 10.4161/cc.21387
   Sánchez-Aragó M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012
   Sánchez-Cenizo L, 2010, J BIOL CHEM, V285, P25308, DOI 10.1074/jbc.M110.146480
   Saretzki G, 2008, STEM CELLS, V26, P455, DOI 10.1634/stemcells.2007-0628
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schieber MS, 2013, CANCER CELL, V23, P265, DOI 10.1016/j.ccr.2013.02.021
   Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652
   Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529
   Shiraki N, 2014, CELL METAB, V19, P780, DOI 10.1016/j.cmet.2014.03.017
   Shyh-Chang N, 2013, DEVELOPMENT, V140, P2535, DOI 10.1242/dev.091777
   Shyh-Chang N, 2011, EMBO J, V30, P4851, DOI 10.1038/emboj.2011.436
   Son MJ, 2013, INT J BIOCHEM CELL B, V45, P2512, DOI 10.1016/j.biocel.2013.07.023
   Son MJ, 2013, STEM CELLS, V31, P1121, DOI 10.1002/stem.1368
   Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024
   Teicher BA, 2012, CLIN CANCER RES, V18, P5537, DOI 10.1158/1078-0432.CCR-12-2587
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Teslaa T, 2015, EMBO J, V34, P138, DOI 10.15252/embj.201490446
   Tomasson MH, 2009, J CELL BIOCHEM, V106, P745, DOI 10.1002/jcb.22050
   Tung P-Y, 2014, ONCOGENE, P2014
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
   Vazquez-Martin A, 2013, CELL CYCLE, V12, P3471, DOI 10.4161/cc.26692
   Vazquez-Martin A, 2013, CELL CYCLE, V12, P207, DOI 10.4161/cc.23352
   Vazquez-Martin A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00964
   Vazquez-Martin A, 2012, CELL CYCLE, V11, P974, DOI 10.4161/cc.11.5.19450
   Wang J, 2009, SCIENCE, V325, P435, DOI 10.1126/science.1173288
   Wang S, 2013, CELL STEM CELL, V13, P617, DOI 10.1016/j.stem.2013.10.005
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watson J, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120144
   Willers IM, 2011, BBA-BIOENERGETICS, V1807, P543, DOI 10.1016/j.bbabio.2010.10.016
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Xu XL, 2013, CELL METAB, V18, P325, DOI 10.1016/j.cmet.2013.06.005
   Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364
   Yang M, 2013, J CLIN INVEST, V123, P3652, DOI 10.1172/JCI67228
   Yoo MH, 2008, MOL CELLS, V26, P514
   Zhang J, 2012, CELL STEM CELL, V11, P589, DOI 10.1016/j.stem.2012.10.005
   Zhang J, 2011, EMBO J, V30, P4860, DOI 10.1038/emboj.2011.401
   Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
   Zviran A, 2014, GENOME BIOL, V15, DOI 10.1186/gb4167
NR 145
TC 32
Z9 33
U1 0
U2 29
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD DEC 17
PY 2015
VL 14
IS 24
BP 3801
EP 3811
DI 10.1080/15384101.2015.1022697
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CZ4HD
UT WOS:000367063200012
PM 25738999
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Santarelli, L
   Staffolani, S
   Strafella, E
   Nocchi, L
   Manzella, N
   Grossi, P
   Bracci, M
   Pignotti, E
   Alleva, R
   Borghi, B
   Pompili, C
   Sabbatini, A
   Rubini, C
   Zuccatosta, L
   Bichisecchi, E
   Valentino, M
   Horwood, K
   Comar, M
   Bovenzi, M
   Dong, LF
   Neuzil, J
   Amati, M
   Tomasetti, M
AF Santarelli, Lory
   Staffolani, Sara
   Strafella, Elisabetta
   Nocchi, Linda
   Manzella, Nicola
   Grossi, Paola
   Bracci, Massimo
   Pignotti, Elettra
   Alleva, Renata
   Borghi, Battista
   Pompili, Cecilia
   Sabbatini, Armando
   Rubini, Corrado
   Zuccatosta, Lina
   Bichisecchi, Elisabetta
   Valentino, Matteo
   Horwood, Keith
   Comar, Manola
   Bovenzi, Massimo
   Dong, Lan-Feng
   Neuzil, Jiri
   Amati, Monica
   Tomasetti, Marco
TI Combined circulating epigenetic markers to improve mesothelin
   performance in the diagnosis of malignant mesothelioma
SO LUNG CANCER
LA English
DT Article
DE Mesothelioma; Lung cancer; Mesothelin; Epigenetic biomarkers; Early
   diagnosis; Methylated gene thrombomodulin; miR-126
ID BREAST-CANCER METASTASIS; PLEURAL MESOTHELIOMA; LUNG-CANCER; SERUM
   MESOTHELIN; VASCULAR INTEGRITY; FOLLOW-UP; MIR-126; METHYLATION;
   ASBESTOS; GENE
AB Objectives: Malignant mesothelioma (MM) is a highly aggressive tumor with poor prognosis. A major challenge is the development and application of early and highly reliable diagnostic marker(s). Serum biomarkers, such as 'soluble mesothelin-related proteins' (SMRPs), is the most studied and frequently used in MM. However, the low sensitivity of SMRPs for early MM limits its value; therefore, additional biomarkers are required. In this study, two epigenetically regulated markers in MM (microRNA-126, miR126, and methylated thrombomodulin promoter, Met-TM) were combined with SMRPs and evaluated as a potential strategy to detect MM at an early stage.
   Materials and methods: A total of 188 subjects, including 45 MM patients, 99 asbestos-exposed subjects, and 44 healthy controls were prospectively enrolled, serum samples collected, and serum levels of SMRPs, miR-126 and Met-TM evaluated. Logistic regression analysis was performed to evaluate the diagnostic value of the three biomarkers. Using this approach, the performance of the '3-biomarker classifier' was tested by calculating the overall probability score of the MM and control samples, respectively, and the ROC curve was generated.
   Results and conclusion: The combination of the three biomarkers was the best predictor to differentiate MM patients from asbestos-exposed subjects and healthy controls. The accuracy and cancer specificity was confirmed in a second validation cohort and lung cancer population. We propose that the combination of the two epigenetic biomarkers with SMRPs as a diagnosis for early MM overcomes the limitations of using SMRPs alone. (c) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Santarelli, Lory; Staffolani, Sara; Strafella, Elisabetta; Nocchi, Linda; Manzella, Nicola; Grossi, Paola; Bracci, Massimo; Valentino, Matteo; Amati, Monica; Tomasetti, Marco] Polytech Univ Marche, Dept Clin & Mol Sci, I-60020 Ancona, Italy.
   [Pignotti, Elettra; Alleva, Renata; Borghi, Battista] IRCCS Orthopaed Inst Rizzoli, Dept Anesthesiol, Res Unit, Bologna, Italy.
   [Pompili, Cecilia; Sabbatini, Armando] United Hosp, Div Thorac Surg, I-60726 Ancona, Italy.
   [Rubini, Corrado] Polytech Univ Marche, Sect Anat Pathol, Dept Biomed Sci & Publ Hlth, I-60020 Ancona, Italy.
   [Zuccatosta, Lina] United Hosp, Dept Immunoallerg & Resp Dis, Pulm Dis Unit, Ancona, Italy.
   [Bichisecchi, Elisabetta] United Hosp, Div Radiol, Ancona, Italy.
   [Horwood, Keith] Greenslopes Private Hosp, Greenslopes, Qld, Australia.
   [Comar, Manola; Bovenzi, Massimo] Univ Trieste, Dept Med Sci, Trieste, Italy.
   [Dong, Lan-Feng; Neuzil, Jiri] Griffith Univ, Mitochondria Apoptosis & Canc Res Grp, Sch Med Sci, Southport, Qld 4215, Australia.
   [Dong, Lan-Feng; Neuzil, Jiri] Griffith Univ, Griffith Hlth Inst, Southport, Qld 4215, Australia.
   [Neuzil, Jiri] Acad Sci Czech Republic, Inst Biotechnol, Prague 4, Czech Republic.
C3 Marche Polytechnic University; Marche Polytechnic University;
   Greenslopes Private Hospital; University of Trieste; Griffith
   University; Griffith University - Gold Coast Campus; Menzies Health
   Institute Queensland; Griffith University; Griffith University - Gold
   Coast Campus; Czech Academy of Sciences; Institute of Biotechnology of
   the Czech Academy of Sciences
RP Tomasetti, M (通讯作者)，Polytech Univ Marche, Dept Clin & Mol Sci, I-60020 Ancona, Italy.
EM m.tomasetti@univpm.it
RI Bovenzi, Massimo/F-5530-2010; Pompili, Cecilia/AAI-1712-2020;
   Santarelli, Lory/AAU-4494-2020; Neuzil, Jiri/H-7204-2014; DONG,
   LANFENG/S-8805-2019; Pignotti, Elettra/IQW-7198-2023; COMAR,
   Manola/K-4613-2016; Bracci, Massimo/K-1192-2018; Comar,
   Manola/K-4613-2016
OI COMAR, Manola/0000-0002-9487-861X; Dong, Lanfeng/0000-0002-9857-6352;
   Bracci, Massimo/0000-0003-3901-5376; Comar, Manola/0000-0001-6310-3320;
   Alleva, Renata/0000-0001-7327-3833; santarelli,
   lory/0000-0003-1015-7098; Nocchi, Linda/0000-0002-2113-9031; Tomasetti,
   Marco/0000-0001-5036-7052; pompili, cecilia/0000-0001-6746-5441;
   BOVENZI, MASSIMO/0000-0002-6001-5218
FU National Institute against Occupational Injury Insurance (INAIL) of
   Italy [P998]; Cancer Council Queensland; National Health and Medical
   Research Council of Australia; Czech Science Foundation [P301/10/1937];
   Griffith University Senior Research Fellowship
FX This work was supported by a grant from National Institute against
   Occupational Injury Insurance (INAIL, P998) of Italy to LS and SS. JN
   was supported by grants from Cancer Council Queensland, National Health
   and Medical Research Council of Australia and the Czech Science
   FoundationP301/10/1937, and L.F.D. by the Griffith University Senior
   Research Fellowship. The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amati M, 2008, MUTAT RES-GEN TOX EN, V655, P52, DOI 10.1016/j.mrgentox.2008.06.011
   Amati M, 2008, CANCER EPIDEM BIOMAR, V17, P163, DOI 10.1158/1055-9965.EPI-07-0607
   Blanquart C, 2012, J THORAC ONCOL, V7, P883, DOI 10.1097/JTO.0b013e31824c9272
   Chan KCA, 2008, CLIN CHEM, V54, P1528, DOI 10.1373/clinchem.2008.104653
   Christensen BC, 2009, CANCER RES, V69, P227, DOI 10.1158/0008-5472.CAN-08-2586
   Corradi M, 2013, ANTICANCER RES, V33, P5517
   Cristaudo A, 2011, J THORAC ONCOL, V6, P1587, DOI 10.1097/JTO.0b013e31821e1c08
   Cristaudo A, 2010, OCCUP ENVIRON MED, V67, P233, DOI 10.1136/oem.2009.049205
   Destro A, 2008, LUNG CANCER, V59, P369, DOI 10.1016/j.lungcan.2007.08.035
   Dvorak HF, 2011, J SURG ONCOL, V103, P468, DOI 10.1002/jso.21709
   Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fukuoka K, 2013, MOL CLIN ONCOL, V1, P942, DOI 10.3892/mco.2013.175
   Goto Y, 2009, CANCER RES, V69, P9073, DOI 10.1158/0008-5472.CAN-09-1595
   Hollevoet K, 2012, J CLIN ONCOL, V30, P1541, DOI 10.1200/JCO.2011.39.6671
   Huang TH, 2014, ONCOGENE, V33, P3636, DOI 10.1038/onc.2013.335
   Jacobs DI, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-37
   Kobatake T, 2004, ONCOL REP, V12, P1087
   Ladou J, 2010, ENVIRON HEALTH PERSP, V118, P897, DOI 10.1289/ehp.1002285
   Li XH, 2012, ONCOL REP, V28, P77, DOI 10.3892/or.2012.1769
   Li Z, 2013, MOL CELL BIOCHEM, V381, P233, DOI 10.1007/s11010-013-1707-6
   Liu PL, 2010, MOL CARCINOGEN, V49, P874, DOI 10.1002/mc.20663
   Muley T, 2013, J THORAC ONCOL, V8, P947, DOI 10.1097/JTO.0b013e31828f696b
   Nelson HH, 2011, EPIGENETICS-US, V6, P1029, DOI 10.4161/epi.6.8.16074
   Nocchi L, 2011, J BIOL CHEM, V286, P19478, DOI 10.1074/jbc.M110.217331
   Ponomaryova AA, 2013, LUNG CANCER, V81, P397, DOI 10.1016/j.lungcan.2013.05.016
   Robinson BWS, 2003, LANCET, V362, P1612, DOI 10.1016/S0140-6736(03)14794-0
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Santarelli L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018232
   Scherpereel A, 2006, AM J RESP CRIT CARE, V173, P1155, DOI 10.1164/rccm.200511-1789OC
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tian FY, 2013, CANCER EPIDEMIOL, V37, P708, DOI 10.1016/j.canep.2013.05.012
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Tomasetti M, 2014, ANTIOXID REDOX SIGN, V21, P2109, DOI 10.1089/ars.2013.5215
   Tomasetti M, 2012, CLIN BIOCHEM, V45, P575, DOI 10.1016/j.clinbiochem.2012.02.009
   Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Weiler H, 2003, J THROMB HAEMOST, V1, P1515, DOI 10.1046/j.1538-7836.2003.00306.x
   Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089
   Zhang Y, 2013, ONCOL REP, V30, P1976, DOI 10.3892/or.2013.2633
   Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690
   Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7
   Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109
NR 44
TC 38
Z9 40
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD DEC
PY 2015
VL 90
IS 3
BP 457
EP 464
DI 10.1016/j.lungcan.2015.09.021
PG 8
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA CZ1NX
UT WOS:000366873700013
PM 26431916
DA 2025-01-12
ER

PT J
AU Xie, CR
   Li, Z
   Sun, HG
   Wang, FQ
   Sun, Y
   Zhao, WX
   Zhang, S
   Zhao, WX
   Wang, XM
   Yin, ZY
AF Xie, Cheng-Rong
   Li, Zhao
   Sun, Hong-Guang
   Wang, Fu-Qiang
   Sun, Yu
   Zhao, Wen-Xiu
   Zhang, Sheng
   Zhao, Wen-Xing
   Wang, Xiao-Min
   Yin, Zhen-Yu
TI Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma
SO ONCOTARGET
LA English
DT Article
DE EZH2; CHD5; hepatocellular carcinoma; prognosis; invasion
ID REMODELING FACTOR CHD5; GROUP PROTEIN EZH2; TUMOR-SUPPRESSOR;
   CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; DNA METHYLATION;
   PROSTATE-CANCER; BREAST-CANCER; EXPRESSION; GENE
AB Chromodomain helicase DNA binding protein 5 (CHD5) acts as a tumor suppressor in many cancers. In the present study, we demonstrated that reduced levels of CHD5 in hepatocellular carcinoma (HCC) tissues were significantly associated with metastasis and poor prognosis. Gain-of-function assays revealed that CHD5 suppressed motility and invasion of HCC cells. Subsequent investigations showed that CHD5 was epigenetically silenced by polycomb repressive complex 2 (PRC2)-mediated the trimethylation of histone H3 at lysine 27 (H3K27me3) in HCC cells. Furthermore, overexpression of CHD5 repressed enhancer of zeste homolog 2 (EZH2) and activated PRC2 target genes, such as p16 and p21. Chromatin immunoprecipitation and luciferase reporter assays also showed that CHD5 and EZH2 bind to each other's promoters and inhibit transcription. These findings uncovered, for the first time, a mutual suppression regulation between CHD5 and EZH2, which may provide new insights into their potential therapeutic significance for HCC.
C1 [Xie, Cheng-Rong; Li, Zhao; Sun, Hong-Guang; Wang, Fu-Qiang; Sun, Yu; Zhao, Wen-Xiu; Zhang, Sheng; Zhao, Wen-Xing; Wang, Xiao-Min; Yin, Zhen-Yu] Xiamen Univ, Dept Hepatobiliary Surg, Zhongshan Hosp, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Xiamen, Fujian, Peoples R China.
C3 Xiamen University
RP Yin, ZY (通讯作者)，Xiamen Univ, Dept Hepatobiliary Surg, Zhongshan Hosp, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Xiamen, Fujian, Peoples R China.
EM yinzy@xmu.edu.cn
RI Yin, Zhen-Yu/M-5479-2017; Yuhua, Xu/AFK-6705-2022; Sun,
   HongGuang/A-9385-2010
FU National Natural Science Foundation of China [81172286, 81372618]; '973'
   Program [2013CB910803]; National Key Sci-Tech Special Project of China
   [2012ZX10002011-005]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (no. 81172286 and no. 81372618), the '973'
   Program (no. 2013CB910803) and the National Key Sci-Tech Special Project
   of China (no. 2012ZX10002011-005). We appreciate the valuable comments
   from other members of our laboratories. The National Natural Science
   Foundation of China (no. 81172286 and no. 81372618), the '973' Program
   (no. 2013CB910803) and the National Key Sci-Tech Special Project of
   China (no. 2012ZX10002011-005).
CR [Anonymous], CA CANC J CLIN
   Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052
   Berezovska OP, 2006, CELL CYCLE, V5, P1886
   Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016
   Cai CX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029750
   Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Chen W, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-85
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223
   Climent J, 2010, J CLIN ONCOL, V28, P3770, DOI 10.1200/JCO.2009.27.0215
   Du XL, 2013, CLIN TRANSL ONCOL, V15, P198, DOI 10.1007/s12094-012-0903-2
   Egan CM, 2013, DEV CELL, V26, P223, DOI 10.1016/j.devcel.2013.07.008
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Fang QL, 2015, INT J ONCOL, V46, P782, DOI 10.3892/ijo.2014.2776
   Fatemi M, 2014, CANCER-AM CANCER SOC, V120, P172, DOI 10.1002/cncr.28316
   Gao SB, 2014, J HEPATOL, V61, P832, DOI 10.1016/j.jhep.2014.05.015
   Girard N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098176
   Kannike K, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.612424
   Kim H, 2000, LIVER, V20, P173, DOI 10.1034/j.1600-0676.2000.020002173.x
   Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Law ME, 2005, CANCER GENET CYTOGEN, V160, P1, DOI 10.1016/j.cancergencyto.2004.11.012
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033
   McCarthy N, 2010, NAT REV CANCER, V10, P666, DOI 10.1038/nrc2940
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mori N, 2003, BRIT J HAEMATOL, V122, P226, DOI 10.1046/j.1365-2141.2003.04434.x
   Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610
   Ning XH, 2015, CANCER LETT, V359, P198, DOI 10.1016/j.canlet.2015.01.005
   Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009
   Quan JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108066
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Sengupta K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000199
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Tang Qi-Bin, 2004, Hepatobiliary Pancreat Dis Int, V3, P124
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Vieira-Coimbra M, 2015, EUR J CLIN INVEST, V45, P16, DOI 10.1111/eci.12360
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306
   Wu X, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3182
   Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608
   Yamaguchi J, 2010, CANCER SCI, V101, P355, DOI 10.1111/j.1349-7006.2009.01387.x
   Yap KL, 2010, CRIT REV BIOCHEM MOL, V45, P488, DOI 10.3109/10409238.2010.512001
   Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017
   Yoshimura S, 2010, HYBRIDOMA, V29, P63, DOI 10.1089/hyb.2009.0069
   Zhao R, 2014, LIVER INT, V34, pE151, DOI 10.1111/liv.12503
   Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019
   Zhong J, 2013, TECHNOL CANCER RES T, V12, P269, DOI 10.7785/tcrt.2012.500315
   Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051
NR 53
TC 14
Z9 14
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 1
PY 2015
VL 6
IS 38
BP 40940
EP 40952
DI 10.18632/oncotarget.5724
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0SF
UT WOS:000366115500042
PM 26517514
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Carpentieri, A
   Cozzoli, E
   Scimeca, M
   Bonanno, E
   Sardanelli, AM
   Gambacurta, A
AF Carpentieri, A.
   Cozzoli, E.
   Scimeca, M.
   Bonanno, E.
   Sardanelli, A. M.
   Gambacurta, A.
TI Differentiation of human neuroblastoma cells toward the osteogenic
   lineage by mTOR inhibitor
SO CELL DEATH & DISEASE
LA English
DT Article
ID STEM-CELLS; CANCER-CELLS; HEXOKINASE 2; PYRUVATE-KINASE; BREAST-CANCER;
   IN-VITRO; METABOLISM; GROWTH; GLYCOLYSIS; WARBURG
AB Current hypothesis suggest that tumors can originate from adult cells after a process of 'reprogramming' driven by genetic and epigenetic alterations. These cancer cells, called cancer stem cells (CSCs), are responsible for the tumor growth and metastases. To date, the research effort has been directed to the identification, isolation and manipulation of this cell population. Independently of whether tumors were triggered by a reprogramming of gene expression or seeded by stem cells, their energetic metabolism is altered compared with a normal cell, resulting in a high aerobic glycolytic 'Warburg' phenotype and dysregulation of mitochondrial activity. This metabolic alteration is intricately linked to cancer progression. The aim of this work has been to demonstrate the possibility of differentiating a neoplastic cell toward different germ layer lineages, by evaluating the morphological, metabolic and functional changes occurring in this process. The cellular differentiation reported in this study brings to different conclusions from those present in the current literature. We demonstrate that 'in vitro' neuroblastoma cancer cells (chosen as experimental model) are able to differentiate directly into osteoblastic (by rapamycin, an mTOR inhibitor) and hepatic lineage without an intermediate 'stem' cell step. This process seems owing to a synergy among few master molecules, metabolic changes and scaffold presence acting in a concerted way to control the cell fate.
C1 [Carpentieri, A.; Cozzoli, E.; Gambacurta, A.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Biochem Lab, I-00133 Rome, Italy.
   [Scimeca, M.; Bonanno, E.] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy.
   [Sardanelli, A. M.] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy.
   [Sardanelli, A. M.] Univ Rome, Ctr Integrated Res, I-00128 Rome, Italy.
   [Gambacurta, A.] Univ Roma Tor Vergata, NAST Ctr Nanosci, I-00133 Rome, Italy.
C3 University of Rome Tor Vergata; University of Rome Tor Vergata;
   Universita degli Studi di Bari Aldo Moro; Sapienza University Rome;
   University of Rome Tor Vergata
RP Gambacurta, A (通讯作者)，Univ Roma Tor Vergata, Dept Expt Med & Surg, Biochem Lab, Via Montpellier 1, I-00133 Rome, Italy.
EM gambacurta@med.uniroma2.it
RI Bonanno, Elena/J-7609-2018; Sardanelli, Anna/AAD-4745-2021
OI Sardanelli, Anna Maria/0000-0002-8535-7601
FU Italian Ministry of Research ['2007KAWXCL_002']; : 'Progetto cellule
   staminali' NAST Centre
FX We thank Professor Alessandro Finazzi-Agro' for helpful discussion,
   technical criticisms and reading the manuscript and Graziano Bonelli for
   technical support. This work has been supported by the Italian Ministry
   of Research grant no. '2007KAWXCL_002'. We also thank the sources of
   private funding who have provided the basis for this study: 'Progetto
   cellule staminali' NAST Centre.
CR Alaimo G, 2013, J CELL PHYSIOL, V228, P1249, DOI 10.1002/jcp.24279
   BEEMER FA, 1984, EUR J CANCER CLIN ON, V20, P253, DOI 10.1016/0277-5379(84)90192-5
   Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200
   Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800
   Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845
   Chen Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.14
   Choi SM, 2011, BLOOD, V118, P1801, DOI 10.1182/blood-2011-03-340620
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   Diaz-Ruiz R, 2009, BBA-REV CANCER, V1796, P252, DOI 10.1016/j.bbcan.2009.07.003
   Escoté X, 2015, CANCER LETT, V356, P171, DOI 10.1016/j.canlet.2014.03.034
   Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025
   Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331
   Hu T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05810
   Hu YJ, 2013, MED HYPOTHESES, V80, P649, DOI 10.1016/j.mehy.2013.01.009
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938
   Jones Chris G, 2012, Methods Mol Biol, V915, P1, DOI 10.1007/978-1-61779-977-8_1
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Kim J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069030
   Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005
   Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234
   Lang JY, 2013, ONCOGENE, V32, P2247, DOI 10.1038/onc.2012.349
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lee MK, 2007, EXP MOL MED, V39, P376, DOI 10.1038/emm.2007.42
   Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001
   Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708
   Liu GJ, 2014, GENE DEV, V28, P1337, DOI 10.1101/gad.240416.114
   Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004
   Marfe G, 2012, LIFE SCI, V90, P825, DOI 10.1016/j.lfs.2012.03.004
   Marfe G, 2012, J CELL PHYSIOL, V227, P1250, DOI 10.1002/jcp.22953
   Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025
   Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776
   Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479
   Meseure D, 2014, J CANC PREV CURR RES, V1, DOI 10.15406/jcpcr.2014.01.00006.
   Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914
   Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107
   MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407
   MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262
   Marie SKN, 2011, CLINICS, V66, P33, DOI 10.1590/S1807-59322011001300005
   Neary CL, 2013, J CELL PHYSIOL, V228, P1943, DOI 10.1002/jcp.24361
   Panasyuk G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1667
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x
   Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097
   Ramos-Mejia V, 2012, TRENDS MOL MED, V18, P245, DOI 10.1016/j.molmed.2012.04.001
   Shulga N, 2010, J CELL SCI, V123, P894, DOI 10.1242/jcs.061846
   Smolková K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003
   Song IY, 2015, SEMIN CANCER BIOL, V32, P32, DOI 10.1016/j.semcancer.2014.03.006
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi K, 2013, DEVELOPMENT, V140, P2457, DOI 10.1242/dev.092551
   Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O., 1924, Biochem Z, V152, P319
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Wong Nicholas, 2013, Int J Cell Biol, V2013, P242513, DOI 10.1155/2013/242513
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x
   Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237
   2006, BIOWAVE, V8, P1
NR 70
TC 14
Z9 15
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV
PY 2015
VL 6
AR e1974
DI 10.1038/cddis.2015.244
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CZ5PU
UT WOS:000367155300012
PM 26561783
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kikuchi, M
   Yamashita, K
   Waraya, M
   Minatani, N
   Ushiku, H
   Kojo, K
   Ema, A
   Kosaka, Y
   Katoh, H
   Sengoku, N
   Enomoto, T
   Tanino, H
   Sawanobori, M
   Watanabe, M
AF Kikuchi, Mariko
   Yamashita, Keishi
   Waraya, Mina
   Minatani, Naoko
   Ushiku, Hideki
   Kojo, Ken
   Ema, Akira
   Kosaka, Yoshimasa
   Katoh, Hiroshi
   Sengoku, Norihiko
   Enomoto, Takumo
   Tanino, Hirokazu
   Sawanobori, Masakazu
   Watanabe, Masahiko
TI Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in
   phenylbutyrate treatment-resistant breast cancer
SO ONCOTARGET
LA English
DT Article
DE phenylbutyrate; breast cancer; epigenetic; histone deacetylase (HDAC);
   ZEB1
ID HISTONE DEACETYLASE INHIBITION; TO-MESENCHYMAL TRANSITION; SQUAMOUS-CELL
   CARCINOMA; I DOSE-ESCALATION; SODIUM PHENYLBUTYRATE; CISPLATIN
   SENSITIVITY; ESTROGEN-RECEPTOR; EPITHELIAL-CELLS; DOWN-REGULATION;
   EXPRESSION
AB Phenylbutyrate (PB) is a histone deacetylase antagonist that also exhibits antitumor activity. In this study, we used 7 breast cancer cell lines to identify biomarker candidates that predict PB sensitivity in breast cancer.
   Comprehensive gene expression profiles were compared using microarrays, and the importance of the identified genes to PB sensitivity was confirmed in gene transfection experiments. CRL and MDAMB453 cells were identified as PB-sensitive, while MDAMB231 cells were PB-resistant. RAB25 and ESRP1 were identified as key regulators of PB sensitivity, while ANKD1, ETS1, PTRF, IFI16 and KIAA1199 acted as PB resistance-related genes. Expression of these genes was dramatically altered by DNA demethylation treatments. RAB25 expression inhibited IFI16 and PTRF, while ESRP1 expression suppressed ANKRD1, ETS1, and KIAA1199. Both RAB25 and ESRP1 were suppressed by ZEB1, which was in turn regulated via epigenetic mechanisms. Thus, PB sensitivity is influenced by epigenetic expression alteration of ZEB1. The genes associated with PB sensitivity are downstream targets of ZEB1. Epigenetic regulation of ZEB1 may prove valuable as a critical biomarker for predicting resistance to breast cancer therapies.
C1 [Kikuchi, Mariko; Yamashita, Keishi; Waraya, Mina; Minatani, Naoko; Ushiku, Hideki; Kojo, Ken; Ema, Akira; Kosaka, Yoshimasa; Katoh, Hiroshi; Sengoku, Norihiko; Enomoto, Takumo; Tanino, Hirokazu; Watanabe, Masahiko] Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa, Japan.
C3 Kitasato University
RP Watanabe, M (通讯作者)，Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa, Japan.
EM gekaw@med.kitasato-u.ac.jp
RI Tanino, Hirokazu/AAN-4455-2021
OI Kojo, Ken/0000-0001-8744-8358
CR Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Camacho LH, 2007, INVEST NEW DRUG, V25, P131, DOI 10.1007/s10637-006-9017-4
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CATTORETTI G, 1988, BRIT J CANCER, V57, P353, DOI 10.1038/bjc.1988.81
   Cheng JM, 2010, INT J CANCER, V126, P2799, DOI 10.1002/ijc.24900
   Córdoba J, 2014, HEPATOLOGY, V59, P764, DOI 10.1002/hep.26789
   Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184
   Gilbert J, 2001, CLIN CANCER RES, V7, P2292
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Gore SD, 1997, CLIN CANCER RES, V3, P1755
   Goss Paul, 2002, Cancer Control, V9, P2
   Gruber AD, 1999, CANCER RES, V59, P5488
   Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432
   Kang HJ, 2014, CANCER RES, V74, P1484, DOI 10.1158/0008-5472.CAN-13-2020
   Kars MD, 2010, BIOMED PHARMACOTHER, V64, P458, DOI 10.1016/j.biopha.2010.01.008
   Khanna A, 2011, CELL MOL BIOL LETT, V16, P101, DOI 10.2478/s11658-010-0043-z
   Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921
   Kulp SK, 2006, CLIN CANCER RES, V12, P5199, DOI 10.1158/1078-0432.CCR-06-0429
   Kuscu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044661
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Linger RMA, 2013, ONCOGENE, V32, P3420, DOI 10.1038/onc.2012.355
   Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050
   McCleland ML, 2012, CANCER RES, V72, P5812, DOI 10.1158/0008-5472.CAN-12-1098
   Miller Elizabeth, 2014, F1000Res, V3, P198, DOI 10.12688/f1000research.4340.1
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Nakatani K, 2005, J CANCER RES CLIN, V131, P445, DOI 10.1007/s00432-004-0662-8
   O'Driscoll L, 2006, CURR CANCER DRUG TAR, V6, P365, DOI 10.2174/156800906777723958
   Pellatt AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080554
   RAVDIN PM, 1995, EUR J CANCER, V31A, pS11, DOI 10.1016/0959-8049(95)00307-5
   Roche Joelle, 2013, Cancers (Basel), V5, P334, DOI 10.3390/cancers5020334
   Scurr LL, 2008, CLIN CANCER RES, V14, P6924, DOI 10.1158/1078-0432.CCR-07-5189
   Seksenyan A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1018-2
   Spicer J, 2005, LANCET, V366, P634, DOI 10.1016/S0140-6736(05)67134-6
   Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
   Tahmasebi F, 2012, IMMUNOTHERAPY, V6, P43
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587
   Tong M, 2012, CANCER RES, V72, P6024, DOI 10.1158/0008-5472.CAN-12-1269
   Turner BC, 1998, CANCER RES, V58, P5466
   Uchida K, 2013, BREAST CANC, V22, P172
   Valladares-Ayerbes M, 2009, J CANCER RES CLIN, V135, P1185, DOI 10.1007/s00432-009-0559-7
   Vergara-Lluri ME, 2012, MODERN PATHOL, V25, P1326, DOI 10.1038/modpathol.2012.93
   Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392
   Walker V, 2014, ADV CLIN CHEM, V67, P73, DOI 10.1016/bs.acc.2014.09.002
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Witzig TE, 2000, CLIN CANCER RES, V6, P681
   Xu YL, 2014, GENE DEV, V28, P1191, DOI 10.1101/gad.241968.114
   Yamamoto H, 2011, BIOL PHARM BULL, V34, P324, DOI 10.1248/bpb.34.324
   Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699
   Yi JS, 2013, J PROTEOME RES, V12, P605, DOI 10.1021/pr300651m
   Yuan G, 2013, ONCOGENE, V32, P375, DOI 10.1038/onc.2012.40
   Zhou XL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0428-3
NR 52
TC 31
Z9 32
U1 1
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 12
PY 2016
VL 7
IS 2
BP 1741
EP 1753
DI 10.18632/oncotarget.6480
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GP
UT WOS:000369951100051
PM 26646320
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Mongre, R
   Sodhi, SS
   Sharma, N
   Ghosh, M
   Hyunkim, J
   Kim, N
   Park, YH
   Shin, YG
   Kim, SJ
   Jiao, ZJ
   Huynh, DL
   Jeong, DK
AF Mongre, Rajkumar
   Sodhi, Simrinder Singh
   Sharma, Neelesh
   Ghosh, Mrinmoy
   Hyunkim, Jeong
   Kim, Nameun
   Park, Yang Ho
   Shin, Young Gyu
   Kim, Sung Jin
   Jiao, Zhang Jiao
   Do Luong Huynh
   Jeong, Dong Kee
TI Epigenetic induction of epithelial to mesenchymal transition by
   <i>LCN2</i> mediates metastasis and tumorigenesis, which is abrogated by
   NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE naturaceutics; 2DG optical probe; tumor initiating cancer stem-like
   cells; karyorrhexis; Lipocalin-2; epithelial to mesenchymal transition
ID BREAST-CANCER PROGRESSION; LIPOCALIN 2; ORAL-CANCER; STEM-CELLS; NGAL;
   MATRIX-METALLOPROTEINASE-9; EXPRESSION; PLASTICITY; FEATURES
AB Tumor initiating cancer stem-like cells (TICSCs) have recently become the object of intensive study. HumanLipocalin- 2 (hLCN2) acts as a biomarker for cancers. The aim of the present study was to explore new insights regarding the potential role of LCN2 in inducing epithelial to mesenchymal transition (EMT) by transfecting LCN2 into CD133(+)-A549-TICSCs and its cross-talk with the NF-kappa B signaling pathway in adenocarcinoma of the lung. Furthermore, EMT was confirmed by transcriptomic analysis, immunoblotting and immunocyto/histochemical analyses. Tumorigenesis and metastasis were confirmed by molecular therapeutics tracer 2DG infrared optical probe in BALB/cSIc-nude mice. It was observed that the CD133(+)-expressing-LCN2-A549 TICSCs population increased in adenocarcinoma of the lung compared to the normal lung tissue. The expressions of genes involved in stemness, adhesion, motility and drug efflux was higher in these cells than in their non-LCN2 expressing counterparts. The present study revealed that elevated expression of LCN2 significantly induced metastasis via EMT. Overexpression of LCN2 significantly increased stemness and tumor metastasis by modulating NF-kappa B cellular signaling. BRM270, a novel inhibitor of NF-kappa B plays a significant role in the EMT reversal. BRM270, a naturaceutical induces cell shrinkage, karyorrhexis and programmed cell death (PCD) which were observed by Hoechst 33342 staining while flow cytometry analysis showed significant (P<0.05) decrease in cell population from G0-G1 phases. Also, 2DG guided in vivo model revealed that BRRM270 significantly (P<0.0003) reduced tumor metastasis and increased percent survival in real-time with complete resection. An elaborate study on the novel concept with respect to linking of naturaceutics as selective and potential anticancer agent that eliminates the elevated LCN2 induced EMT and tumor dissemination through cooperation with the NF-kappa B signaling as the baseline data for the planning of new therapeutic strategies was conducted for the first time. Our results also illustrate a molecular mechanistic approach for 2DG-guided molecular imaging-based cancer therapy using BRM270 as a novel cancer therapeutic drug to enhance the effect of doxorubicin (Dox)-resistant LCN2 induced metastasis of solid tumors in nude mice.
C1 [Mongre, Rajkumar; Ghosh, Mrinmoy; Hyunkim, Jeong; Kim, Nameun; Jiao, Zhang Jiao; Do Luong Huynh; Jeong, Dong Kee] Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Lab Anim Genet Engn & Stem Cell Biol, Jeju, South Korea.
   [Sodhi, Simrinder Singh] Guru Angad Dev Vet & Anim Sci Univ, Dept Vet & Anim Husb Extens Educ, Ludhiana, Punjab, India.
   [Sharma, Neelesh] Sher E Kashmir Univ Agr Sci & Technol, Fac Vet Sci & Anim Husb, Div Vet Med, Jammu, India.
   [Park, Yang Ho; Shin, Young Gyu] CHA Univ, BRM Inst, Seoul, South Korea.
   [Kim, Sung Jin] CHA Univ, CHA Canc Inst, Seoul, South Korea.
C3 Jeju National University; Guru Angad Dev Veterinary & Animal Sciences
   University (GADVASU); Sher-e-Kashmir University of Agricultural Sciences
   & Technology of Jammu (SKUAST Jammu); Pochon Cha University; Pochon Cha
   University
RP Jeong, DK (通讯作者)，Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Ara 1 Dong, Jeju City 690756, Jeju Do, South Korea.
EM dkjeong@jejunu.ac.kr
RI Huynh, Luong Do/GXZ-7121-2022; Zhang, Jiao Jiao/V-8705-2018; Ghosh,
   Mrinmoy/ABB-4479-2021; Sharma, Neelesh/G-9806-2013
OI huynh, Denish/0000-0002-4821-7271; Sharma, Neelesh/0000-0003-3932-4064;
   Ghosh, Mrinmoy/0000-0001-6817-622X
FU Next-Generation Bio Green 21 Program, Rural Development Administration,
   Republic of Korea [PJ01117401]
FX The authors thank Next-Generation Bio Green 21 Program organization.
   This study was supported by Next-Generation Bio Green 21 Program grant
   number PJ01117401, Rural Development Administration, Republic of Korea.
CR Akunuru S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.93
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Bolignano D, 2010, CANCER LETT, V288, P10, DOI 10.1016/j.canlet.2009.05.027
   Candido S, 2014, ONCOTARGET, V5, P1576, DOI 10.18632/oncotarget.1738
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Chen SS, 2012, DISCOV MED, V13, P7
   Choi M, 2015, CANCER LETT, V357, P591, DOI 10.1016/j.canlet.2014.12.023
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Kaur S, 2014, CLIN CANCER RES, V20, P688, DOI 10.1158/1078-0432.CCR-13-2174
   Kitamura H, 2009, LUNG CANCER, V66, P275, DOI 10.1016/j.lungcan.2009.07.019
   Kovar JL, 2009, ANAL BIOCHEM, V384, P254, DOI 10.1016/j.ab.2008.09.050
   Krysan K, 2013, AM J TRANSL RES, V5, P481
   Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105
   Leung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046677
   Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123
   Lin CW, 2012, ORAL DIS, V18, P734, DOI 10.1111/j.1601-0825.2012.01938.x
   Mannelqvist M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-169
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448
   Mongre RK, 2015, INT J ONCOL, V46, P2573, DOI 10.3892/ijo.2015.2961
   Nagai T, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3406
   Nakamura I, 2014, NAT SCI REP, V4, P1
   Rich JN, 2007, CELL STEM CELL, V1, P353, DOI 10.1016/j.stem.2007.09.011
   Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002
   Ruiz-Morales JM, 2015, TUMOR BIOL, V36, P3601, DOI 10.1007/s13277-014-2997-3
   Saeed AM, 2012, CANCER-AM CANCER SOC, V118, P4495, DOI 10.1002/cncr.26686
   Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83
   Shiiba M, 2013, INT J ONCOL, V42, P1197, DOI 10.3892/ijo.2013.1815
   Shrivastava S, 2015, SCI REP-UK, V5, DOI 10.1038/srep07819
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Tung MC, 2013, PROSTATE, V73, P1281, DOI 10.1002/pros.22670
   Wang PH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057020, 10.1371/journal.pone.0052088]
   Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224
   Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106
   Zhai LJ, 2012, ANAL CHEM, V84, P8763, DOI 10.1021/ac3020643
   Zhao P, 2014, J BIOL CHEM, V289, P5960, DOI 10.1074/jbc.M113.532234
NR 37
TC 27
Z9 27
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JAN
PY 2016
VL 48
IS 1
BP 84
EP 98
DI 10.3892/ijo.2015.3245
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ1WT
UT WOS:000366897300009
PM 26573874
OA Green Submitted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Hasegawa, S
   Nagano, H
   Konno, M
   Eguchi, H
   Tomokuni, A
   Tomimaru, Y
   Asaoka, T
   Wada, H
   Hama, N
   Kawamoto, K
   Marubashi, S
   Nishida, N
   Koseki, J
   Mori, M
   Doki, Y
   Ishii, H
AF Hasegawa, Shinichiro
   Nagano, Hiroaki
   Konno, Masamitsu
   Eguchi, Hidetoshi
   Tomokuni, Akira
   Tomimaru, Yoshito
   Asaoka, Tadafumi
   Wada, Hiroshi
   Hama, Naoki
   Kawamoto, Koichi
   Marubashi, Shigeru
   Nishida, Naohiro
   Koseki, Jun
   Mori, Masaki
   Doki, Yuichiro
   Ishii, Hideshi
TI A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis
   is closely related to the clinical outcome in pancreatic cancer patients
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Sox4; Ezh2; miR-335; pancreatic cancer; prognosis; biomarker;
   immunohistochemistry; laser captured microdissection
ID PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; DUCTAL ADENOCARCINOMA; TUMOR
   PROGRESSION; BREAST-CANCER; EXPRESSION; SOX4; CELLS; EZH2; METASTASIS
AB Pancreatic cancer has a poor prognosis because of its high invasiveness and recurrence, and these properties closely link to the phenomenon of epithelial-mesenchymal transition (EMT). Recently, it has been reported that Sox4 is indispensable for EMT in vitro and in vivo and regulates various master regulators of EMT including Zeb, Twist and Snail. Moreover, Sox4 induces the transcription of Ezh2 which is the histone methyltransferase, and reprograms the cancer epigenome to promote EMT and metastasis. Therefore, the present study evaluated the importance of Sox4, Ezh2 and miR-335, which regulate Sox4 expression epigenetically, in clinical samples with pancreatic cancer. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. We assessed the clinical significance of Sox4/Ezh2 axis and miR-335 expression, using immunohistochemistry and qRT-PCR with laser captured microdissection (LCM). The Sox4 positive patients had significantly worse prognosis as for disease-free survival (DFS) (P=0.0154) and the Ezh2-positive patients had significantly worse prognosis as for overall survival (OS) (P=0.0347). The miR-335 expression was inversely correlated with Sox4 expression in the identical clinical specimens, but it was not related to the prognosis. Sox4/Ezh2 axis was closely associated with the prognosis in pancreatic cancer patients.
C1 [Hasegawa, Shinichiro; Nagano, Hiroaki; Eguchi, Hidetoshi; Tomokuni, Akira; Tomimaru, Yoshito; Asaoka, Tadafumi; Wada, Hiroshi; Hama, Naoki; Kawamoto, Koichi; Marubashi, Shigeru; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka 5650871, Japan.
   [Hasegawa, Shinichiro; Konno, Masamitsu; Nishida, Naohiro; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka 5650871, Japan.
   [Koseki, Jun; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Canc Profiling Discovery, Suita, Osaka 5650871, Japan.
C3 Osaka University; Osaka University; Osaka University
RP Ishii, H (通讯作者)，Osaka Univ, Grad Sch Med, Dept Canc Profiling Discovery, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM mmori@gesurg.med.osaka-u.ac.jp; hishii@gesurg.med.osaka-u.ac.jp
RI Mori, Masaki/AGA-2440-2022; Koseki, Jun/ABH-7420-2020; Ishii,
   Hideshi/AAV-5317-2020; Tomimaru, Yoshito/IQS-7856-2023
OI Koseki, Jun/0000-0002-6473-4076
FU Platform for Drug Discovery, Informatics, and Structural Life Science,
   from the Ministry of Education, Culture, Sports, Science and Technology;
   Third Comprehensive 10-year Strategy for Cancer Control, Ministry of
   Health, Labor and Welfare; Kobayashi Cancer Research Foundation;
   Princess Takamatsu Cancer Research Fund, Japan; National Institute of
   Biomedical Innovation, Japan
FX We thank the members of our laboratories for their contribution. The
   present study was supported in part by a Grant-in-Aid for Scientific
   Research and a grant from the Platform for Drug Discovery, Informatics,
   and Structural Life Science, from the Ministry of Education, Culture,
   Sports, Science and Technology; a Grant-in-Aid from the Third
   Comprehensive 10-year Strategy for Cancer Control, Ministry of Health,
   Labor and Welfare; a grant from the Kobayashi Cancer Research
   Foundation; a grant from the Princess Takamatsu Cancer Research Fund,
   Japan; and a grant from the National Institute of Biomedical Innovation,
   Japan.
CR Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456
   Bilimoria KY, 2007, ANN SURG, V246, P173, DOI 10.1097/SLA.0b013e3180691579
   Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839
   Cano C, 2010, THESCIENTIFICWORLDJO, V10, P1947, DOI 10.1100/tsw.2010.183
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Grünert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175
   Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5
   Hay ED, 1995, ACTA ANAT, V154, P8
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Kondo M, 1999, CLIN CANCER RES, V5, P4005
   Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168
   Lioubinski O, 2003, DEV DYNAM, V227, P402, DOI 10.1002/dvdy.10311
   Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055
   Marchesi I, 2014, CELL CYCLE, V13, P516, DOI 10.4161/cc.27921
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078
   Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201
   Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Restivo A, 2006, ANAT REC PART A, V288A, P936, DOI 10.1002/ar.a.20367
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Satoh K, 2015, J GASTROENTEROL, V50, P140, DOI 10.1007/s00535-014-0997-0
   Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415
   Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040
   Shrikhande SV, 2007, ANN SURG ONCOL, V14, P118, DOI 10.1245/s10434-006-9131-8
   Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783
   Wang WS, 2014, BIOCHEM BIOPH RES CO, V452, P614, DOI 10.1016/j.bbrc.2014.08.124
NR 38
TC 29
Z9 32
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JAN
PY 2016
VL 48
IS 1
BP 145
EP 152
DI 10.3892/ijo.2015.3258
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ1WT
UT WOS:000366897300015
PM 26648239
OA Bronze
DA 2025-01-12
ER

PT J
AU Menschikowski, M
   Hagelgans, A
   Nacke, B
   Jandeck, C
   Sukocheva, O
   Siegert, G
AF Menschikowski, Mario
   Hagelgans, Albert
   Nacke, Brit
   Jandeck, Carsten
   Sukocheva, Olga
   Siegert, Gabriele
TI Epigenetic control of phospholipase A<sub>2</sub> receptor expression in
   mammary cancer cells
SO BMC CANCER
LA English
DT Article
ID IDIOPATHIC MEMBRANOUS NEPHROPATHY; MODULATES CISPLATIN SENSITIVITY;
   BREAST-CANCER; DNA METHYLATION; PROSTATE-CANCER; MOLECULAR SUBTYPES;
   COLORECTAL-CANCER; IN-VIVO; IDENTIFICATION; PLA2R1
AB Background: It has recently been proposed that the M-type phospholipase A(2) receptor (PLA2R1) acts as a tumour suppressor in certain malignancies including mammary cancer. Considering that DNA methylation is an important regulator of gene transcription during carcinogenesis, in the current study we analyzed the PLA2R1 expression, PLA2R1 promoter methylation, and selected micro RNA (miRNA) levels in normal human mammary epithelial cells (HMEC) and cancer cell lines.
   Methods: Levels of PLA2R1 and DNA methyltransferases (DNMT) specific mRNA were determined using real-time RT-PCR. Methylation specific-high resolution melting (MS-HRM) analysis was utilized to quantify the methylation degree of selected CpG sites localized in the promoter region of the PLA2R1 gene. Expression of miRNA was tested using miScript Primer Assay system.
   Results: Nearly complete methylation of the analyzed PLA2R1 promoter region along with PLA2R1 gene silencing was identified in MDA-MB-453 mammary cancer cells. In MCF-7 and BT-474 mammary cancer cell lines, a higher DNA methylation degree and reduced PLA2R1 expression were found in comparison with those in normal HMEC. Synergistic effects of demethylating agent (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) on PLA2R1 transcription in MDA-MB-453 cells confirmed the importance of DNA methylation and histone modification in the regulation of the PLA2R1 gene expression in mammary cells. Furthermore, significant positive correlation between the expression of DNMT1 and PLA2R1 gene methylation and negative correlation between the cellular levels of hsa-mir-141, -181b, and -181d-1 and the expression of PLA2R1 were identified in the analyzed cells. Analysis of combined z-score of miR-23b, -154 and -302d demonstrated a strong and significant positive correlation with PLA2R1 expression.
   Conclusions: Our data indicate that (i) PLA2R1 expression in breast cancer cells is controlled by DNA methylation and histone modifications, (ii) hypermethylation of the PLA2R1 promoter region is associated with up-regulation of DNMT1, and (iii) hsa-miR-23b, -154, and -302d, as well as hsa-miR-141, -181b, and -181d-1 are potential candidates for post-transcriptional regulation of PLA2R1 expression in mammary cancer cells.
C1 [Menschikowski, Mario; Hagelgans, Albert; Nacke, Brit; Jandeck, Carsten; Siegert, Gabriele] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, D-01307 Dresden, Germany.
   [Sukocheva, Olga] Flinders Univ South Australia, Sch Hlth Sci, Bedford Pk, SA 5042, Australia.
C3 Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Flinders University South Australia
RP Menschikowski, M (通讯作者)，Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
EM Mario.Menschikowski@uniklinikum-drersden.de
RI Sukocheva, Olga/V-9628-2017
OI Sukocheva, Olga/0000-0003-1041-3311
CR Aldred MA, 2003, CANCER RES, V63, P2864
   Amin R, 2011, LEUKEMIA LYMPHOMA, V52, P908, DOI 10.3109/10428194.2010.551160
   [Anonymous], TUMOUR BIOL
   Augert A, 2013, FREE RADICAL BIO MED, V65, P969, DOI 10.1016/j.freeradbiomed.2013.08.177
   Augert A, 2009, EMBO REP, V10, P271, DOI 10.1038/embor.2008.255
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bernard D, 2014, BBA-REV CANCER, V1846, P40, DOI 10.1016/j.bbcan.2014.03.003
   Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757
   Cuesta R, 2009, MOL CELL BIOL, V29, P2841, DOI 10.1128/MCB.01971-08
   Farazi TA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r9
   Glassock RJ, 2013, CONTRIB NEPHROL, V181, P131, DOI 10.1159/000348472
   Gorovetz M, 2006, GYNECOL ONCOL, V103, P831, DOI 10.1016/j.ygyno.2006.06.042
   Goto Y, 2015, INT J UROL, V22, P242, DOI 10.1111/iju.12700
   Hagelgans A, 2013, EXP MOL PATHOL, V94, P458, DOI 10.1016/j.yexmp.2013.03.006
   Hanasaki K, 2004, BIOL PHARM BULL, V27, P1165, DOI 10.1248/bpb.27.1165
   Hanasaki K, 2002, PROSTAG OTH LIPID M, V68-9, P71, DOI 10.1016/S0090-6980(02)00022-9
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Huang KT, 2011, BREAST CANCER RES TR, V130, P319, DOI 10.1007/s10549-011-1657-1
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Imanaka Y, 2011, J HUM GENET, V56, P270, DOI 10.1038/jhg.2011.1
   Ji JF, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-4
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kao LY, 2015, J AM SOC NEPHROL, V26, P291, DOI 10.1681/ASN.2013121315
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   LAMBEAU G, 1989, J BIOL CHEM, V264, P11503
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin XY, 2015, ONCOL REP, V33, P3053, DOI 10.3892/or.2015.3895
   Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6
   Mansueto Gelsomina, 2010, Genes Cancer, V1, P210, DOI 10.1177/1947601910366860
   Menschikowski M, 2008, NEOPLASIA, V10, P1195, DOI 10.1593/neo.08640
   Menschikowski M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-576
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Murakami M, 2010, BIOCHIMIE, V92, P561, DOI 10.1016/j.biochi.2010.03.015
   Pare R, 2013, J CLIN PATHOL, V66, P491, DOI 10.1136/jclinpath-2012-201081
   Quach ND, 2014, MOL PHARMACEUT, V11, P3443, DOI 10.1021/mp500174p
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Segal PE, 2012, ADV CHRONIC KIDNEY D, V19, P114, DOI 10.1053/j.ackd.2012.01.007
   Stefanska B, 2015, BRIT J PHARMACOL, V172, P2701, DOI 10.1111/bph.13136
   Su R, 2015, ONCOGENE, V34, P3226, DOI 10.1038/onc.2014.274
   Tamaru S, 2013, J IMMUNOL, V191, P1021, DOI 10.4049/jimmunol.1300738
   Taylor Molly A, 2014, Mol Cell Ther, V2, P1
   Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   van Jaarsveld MTM, 2013, ONCOGENE, V32, P4284, DOI 10.1038/onc.2012.433
   Vindrieux D, 2014, ONCOTARGET, V5, P1004, DOI 10.18632/oncotarget.1681
   Vindrieux D, 2013, CANCER RES, V73, P6334, DOI 10.1158/0008-5472.CAN-13-0318
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Xin CG, 2014, MOL CELL BIOCHEM, V387, P271, DOI 10.1007/s11010-013-1892-3
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zheng Y, 2015, J CANCER, V6, P671, DOI 10.7150/jca.11616
   Zhou XY, 2014, HELICOBACTER, V19, P174, DOI 10.1111/hel.12120
NR 55
TC 17
Z9 18
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 16
PY 2015
VL 15
AR 971
DI 10.1186/s12885-015-1937-y
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CY6VC
UT WOS:000366545900027
PM 26672991
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Brunelle, N
   Markovits, AN
   Rodrigue, S
   Lupien, M
   Jacques, PE
   Gévry, N
AF Brunelle, Nylene
   Markovits, Alexei Nordell
   Rodrigue, Sebastien
   Lupien, Mathieu
   Jacques, Pierre-Etienne
   Gevry, Nicolas
TI The histone variant H2A.Z is an important regulator of enhancer activity
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; GENOME-WIDE ANALYSIS; DNA
   METHYLATION; GENE-EXPRESSION; BINDING-SITES; CHROMATIN ACCESSIBILITY;
   GLUCOCORTICOID-RECEPTOR; EPIGENETIC SIGNATURES; NUCLEOSOME OCCUPANCY
AB Gene regulatory programs in different cell types are largely defined through cell-specific enhancers activity. The histone variant H2A.Z has been shown to play important roles in transcription mainly by controlling proximal promoters, but its effect on enhancer functions remains unclear. Here, we demonstrate by genome-wide approaches that H2A.Z is present at a subset of active enhancers bound by the estrogen receptor alpha (ER alpha). We also determine that H2A.Z does not influence the local nucleosome positioning around ER alpha enhancers using ChIP sequencing at nucleosomal resolution and unsupervised pattern discovery. We further highlight that H2A.Z-enriched enhancers are associated with chromatin accessibility, H3K122ac enrichment and hypomethylated DNA. Moreover, upon estrogen stimulation, the enhancers occupied by H2A.Z produce enhancer RNAs (eRNAs), and recruit RNA polymerase II as well as RAD21, a member of the cohesin complex involved in chromatin interactions between enhancers and promoters. Importantly, their recruitment and eRNAs production are abolished by H2A.Z depletion, thereby revealing a novel functional link between H2A.Z occupancy and enhancer activity. Taken together, our findings suggest that H2A.Z acts as an important player for enhancer functions by establishing and maintaining a chromatin environment required for RNA polymerase II recruitment, eRNAs transcription and enhancer-promoters interactions, all essential attributes of enhancer activity.
C1 [Brunelle, Nylene; Markovits, Alexei Nordell; Rodrigue, Sebastien; Jacques, Pierre-Etienne; Gevry, Nicolas] Univ Sherbrooke, Dept Biol, Fac Sci, Sherbrooke, PQ J1K 2R1, Canada.
   [Markovits, Alexei Nordell; Jacques, Pierre-Etienne] Univ Sherbrooke, Dept Informat, Fac Sci, Sherbrooke, PQ J1K 2R1, Canada.
   [Lupien, Mathieu] Univ Hlth Network, Princess Margaret Canc Centre, Ontario Canc Inst, Toronto, ON M5G 1L7, Canada.
   [Lupien, Mathieu] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada.
   [Jacques, Pierre-Etienne] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada.
C3 University of Sherbrooke; University of Sherbrooke; University of
   Toronto; University Health Network Toronto; Princess Margaret Cancer
   Centre; University of Toronto; University of Sherbrooke
RP Gévry, N (通讯作者)，Univ Sherbrooke, Dept Biol, Fac Sci, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.
EM pierre-etienne.jacques@usherbrooke.ca; nicolas.gevry@usherbrooke.ca
RI Lupien, Mathieu/KFB-6691-2024
OI Lupien, Mathieu/0000-0003-0929-9478; Rodrigue,
   Sebastien/0000-0002-5366-7234
FU Canadian Institute of Health Research (CIHR) [MOP-97802]; Fonds de
   recherche du Quebec - Sante (FRQS); Natural Sciences and Engineering
   Research Council of Canada (NSERC) [435710-2013]; FRQS, Chercheur
   boursier award; NSERC; Reseau Quebecois en reproduction (RQR-FONCER)
   doctoral fellowship; Universite de Sherbrooke doctoral fellowship;
   Calcul Quebec; Compute Canada; CIHR
FX Canadian Institute of Health Research (CIHR) [MOP-97802 to N.G.]; Fonds
   de recherche du Quebec - Sante (FRQS) (to N.G.); Natural Sciences and
   Engineering Research Council of Canada (NSERC) [435710-2013 to P.E'.J.];
   FRQS, Chercheur boursier award (to N.G., P.E'.J.); NSERC doctoral
   fellowship (to M.B.); Reseau Quebecois en reproduction (RQR-FONCER)
   doctoral fellowship (to M.B.); Universite de Sherbrooke doctoral
   fellowship (to M.B.); Calcul Quebec (in part); Compute Canada (in part).
   Funding for open access charge: CIHR [MOP-97802].
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   [Anonymous], PLOS BIOL
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Conerly ML, 2010, GENOME RES, V20, P1383, DOI 10.1101/gr.106542.110
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Dalvai M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003387
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037
   Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707
   Gévry N, 2009, GENE DEV, V23, P1522, DOI 10.1101/gad.1787109
   GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   Hardy S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000687
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Henikoff JG, 2011, P NATL ACAD SCI USA, V108, P18318, DOI 10.1073/pnas.1110731108
   Henikoff S, 2009, GENOME RES, V19, P460, DOI 10.1101/gr.087619.108
   Hoffman Michael M, 2013, Nucleic Acids Res, V41, P827, DOI 10.1093/nar/gks1284
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hu GQ, 2013, CELL STEM CELL, V12, P180, DOI 10.1016/j.stem.2012.11.003
   Hu GQ, 2011, GENOME RES, V21, P1650, DOI 10.1101/gr.121145.111
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707
   Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409
   John S, 2008, MOL CELL, V29, P611, DOI 10.1016/j.molcel.2008.02.010
   John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Kraushaar DC, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r121
   Kundaje A, 2012, GENOME RES, V22, P1735, DOI 10.1101/gr.136366.111
   Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884
   Li G, 2004, NAT STRUCT MOL BIOL, V11, P763, DOI 10.1038/nsmb801
   Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210
   Li ZY, 2012, CELL, V151, P1608, DOI 10.1016/j.cell.2012.11.018
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Mito Y, 2007, SCIENCE, V315, P1408, DOI 10.1126/science.1134004
   Mousavi K, 2013, MOL CELL, V51, P606, DOI 10.1016/j.molcel.2013.07.022
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027
   Nili EL, 2010, GENOME RES, V20, P1361, DOI 10.1101/gr.103945.109
   North JA, 2012, NUCLEIC ACIDS RES, V40, P10215, DOI 10.1093/nar/gks747
   Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295
   Poirier MG, 2008, J MOL BIOL, V379, P772, DOI 10.1016/j.jmb.2008.04.025
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Rodrigue S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011840
   Ruhl DD, 2006, BIOCHEMISTRY-US, V45, P5671, DOI 10.1021/bi060043d
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Sérandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110
   Shimko JC, 2011, J MOL BIOL, V408, P187, DOI 10.1016/j.jmb.2011.01.003
   Simon M, 2011, P NATL ACAD SCI USA, V108, P12711, DOI 10.1073/pnas.1106264108
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515
   Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465
   Svotelis A, 2009, METHODS MOL BIOL, V543, P243, DOI 10.1007/978-1-60327-015-1_16
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Tang QZ, 2011, CANCER RES, V71, P6940, DOI 10.1158/0008-5472.CAN-11-2091
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tillo D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009129
   Tolstorukov MY, 2009, GENOME RES, V19, P967, DOI 10.1101/gr.084830.108
   Tropberger P, 2013, CELL, V152, P859, DOI 10.1016/j.cell.2013.01.032
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006
   Watanabe S, 2013, SCIENCE, V340, P195, DOI 10.1126/science.1229758
   Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 92
TC 66
Z9 83
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV 16
PY 2015
VL 43
IS 20
BP 9742
EP 9756
DI 10.1093/nar/gkv825
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CY4WQ
UT WOS:000366410000023
PM 26319018
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Varadaraj, A
   Patel, P
   Serrao, A
   Bandyopadhay, T
   Lee, NY
   Jazaeri, AA
   Huang, ZQ
   Murphy, SK
   Mythreye, K
AF Varadaraj, Archana
   Patel, Pratik
   Serrao, Anne
   Bandyopadhay, Tirthankar
   Lee, Nam Y.
   Jazaeri, Amir A.
   Huang, Zhiqing
   Murphy, Susan K.
   Mythreye, Karthikeyan
TI Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast
   Epithelia
SO NEOPLASIA
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN-9; GROWTH-FACTOR-BETA; CANCER CELLS; I
   RECEPTORS; IDENTIFICATION; ACTIVIN; BMP9; ALK1; PROLIFERATION;
   INHIBITION
AB Anoikis, a cell death mechanism triggered upon cell-matrix detachment, is regarded as a physiological suppressor of metastasis that can be regulated by a diverse array of signals. The protein encoded by GDF2 is BMP9 and is a member of the bone morphogenetic protein family and the transforming growth factor (TGF) beta superfamily with emerging yet controversial roles in carcinogenesis. In an attempt to identify the function of growth and differentiation factor 2 (GDF2) in epithelial systems, we examined the signaling machinery that is involved and cell fate decisions in response to GDF2 in ovarian and breast epithelia. We find that GDF2 can robustly activate the SMAD1/5 signaling axis by increasing complex formation between the type I receptor serine threonine kinases activin receptor-like kinase (ALK) 3 and ALK6 and the type II receptor serine threonine kinase BMPRII. This activation is independent of cross talk with the SMAD2-transforming growth factor beta pathway. By activating SMAD1/5, epithelial cells regulate anchorage-independent growth by increasing anoikis sensitivity that is dependent on GDF2's ability to sustain the activation of SMAD1/5 via ALK3 and ALK6. Consistent with a role for GDF2 in promoting anoikis susceptibility, the analysis of cell lines and patient data suggests epigenetic silencing of GDF2 in cancer cell lines and increased promoter methylation in patients. These findings collectively indicate an antimetastatic role for GDF2 in ovarian and breast cancer. The work also implicates loss of GDF2 via promoter methylation-mediated downregulation in promotion of carcinogenesis with significant relevance for the use of epigenetic drugs currently in clinical trials.
C1 [Varadaraj, Archana; Patel, Pratik; Serrao, Anne; Bandyopadhay, Tirthankar; Mythreye, Karthikeyan] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
   Univ S Carolina, Coll Pharm, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.
   Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA.
   Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
   Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA.
   [Huang, Zhiqing; Murphy, Susan K.] Duke Univ, Dept Gynecol & Oncol, Durham, NC 29210 USA.
C3 University of South Carolina System; University of South Carolina
   Columbia; University of South Carolina System; University of South
   Carolina Columbia; University System of Ohio; Ohio State University;
   University System of Ohio; Ohio State University; University of Texas
   System; UTMD Anderson Cancer Center; Duke University
RP Mythreye, K (通讯作者)，Univ S Carolina, Dept Chem & Biochem, 631 Sumter St, Columbia, SC 29208 USA.
EM Mythreye@sc.edu
RI Jazaeri, Amir/I-3458-2015; Murphy, Susan/R-3903-2019; Lee,
   Nam/H-3073-2016; Karthikeyan, Mythreye/ABC-7345-2020
OI Mythreye, Karthikeyan/0000-0001-5478-0098; Bandyopadhyay,
   Tirthankar/0009-0000-7585-8800; Varadaraj, Archana/0000-0002-1868-1268;
   Murphy, Susan/0000-0001-8298-7272
FU Ovarian Cancer Research Fund [258785]; NIGMS/COBRE [5P20GM109091-02];
   Gail Parkins Ovarian Cancer Awareness fund; Office Of The Director;
   Office of Integrative Activities [1317771] Funding Source: National
   Science Foundation
FX This work was funded in part by the Ovarian Cancer Research Fund grant #
   258785, NIGMS/COBRE grant 5P20GM109091-02 to K. M., and the Gail Parkins
   Ovarian Cancer Awareness fund for S. K. M.
CR ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C
   Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107
   Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200
   Butler SJ, 2003, NEURON, V38, P389, DOI 10.1016/S0896-6273(03)00254-X
   Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264
   Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133
   Chen H, 2013, P NATL ACAD SCI USA, V110, P11887, DOI 10.1073/pnas.1306074110
   David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530
   David L, 2007, J CELL PHYSIOL, V213, P484, DOI 10.1002/jcp.21126
   David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Engers DW, 2013, BIOORG MED CHEM LETT, V23, P3248, DOI 10.1016/j.bmcl.2013.03.113
   Herhaus L, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140065
   Herrera B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069535
   Herrera B, 2009, CANCER RES, V69, P9254, DOI 10.1158/0008-5472.CAN-09-2912
   Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838
   Holtzhausen A, 2014, FASEB J, V28, P1248, DOI 10.1096/fj.13-239178
   Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Laux DW, 2013, DEVELOPMENT, V140, P3403, DOI 10.1242/dev.095307
   Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091
   LIU F, 1995, MOL CELL BIOL, V15, P3479
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   López-Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200
   Meng FL, 2013, INT J ONCOL, V43, P495, DOI 10.3892/ijo.2013.1960
   MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076
   Miller AF, 2000, J BIOL CHEM, V275, P17937, DOI 10.1074/jbc.275.24.17937
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Murphy SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040924
   Park JE, 2012, PLOS ONE, V8
   Préaudat M, 2002, J BIOMOL SCREEN, V7, P267, DOI 10.1089/108705702760047763
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Ren W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096816
   Ren W, 2014, MOL BIOL REP, V41, P1373, DOI 10.1007/s11033-013-2982-8
   Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Shankavaram UT, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-277
   Söderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947
   SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293
   Sun Y, 2008, INT J CANCER, V123, P1761, DOI 10.1002/ijc.23708
   Suzuki Y, 2010, J CELL SCI, V123, P1684, DOI 10.1242/jcs.061556
   TENDIJKE P, 1994, J BIOL CHEM, V269, P16985
   Wang K, 2011, J CANCER RES CLIN, V137, P1687, DOI 10.1007/s00432-011-1047-4
   Yamaguchi K, 2014, INT J CANCER, V135, P585, DOI 10.1002/ijc.28701
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104
NR 55
TC 19
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD NOV
PY 2015
VL 17
IS 11
BP 826
EP 838
DI 10.1016/j.neo.2015.11.003
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CY6YR
UT WOS:000366555200003
PM 26678910
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pellerito, C
   Morana, O
   Ferrante, F
   Calvaruso, G
   Notaro, A
   Sabella, S
   Fiore, T
AF Pellerito, C.
   Morana, O.
   Ferrante, F.
   Calvaruso, G.
   Notaro, A.
   Sabella, S.
   Fiore, T.
TI Synthesis, chemical characterization, computational studies and
   biological activity of new DNA methyltransferases (DNMTs) specific
   inhibitor. Epigenetic regulation as a new and potential approach to
   cancer therapy
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Organotin(IV); Caffeic acid; DNMT1; DNA methylation; Cancer
ID COUPLING-CONSTANTS; SOLID-STATE; NMR; COMPLEXES; DFT; ABSORPTION;
   SPECTRA
AB This work deals with the synthesis, the chemical characterization of dibutyltin(IV) complex of caffeic acid (Bu2Sn(IV)HCAF, caf1) and its cytotoxic action on tumor cells. The coordination environment at the tin center was investigated by FTIR, Sn-119{H-1} cross polarization magic angle spinning, electrospray ionization mass spectroscopy in the solid state and UV-vis, fluorescence and H-1, C-13 and Sn-119 NMR spectroscopy in solution phases. Density functional theory study confirmed the proposed structures in solution phase and indicated the most probably stable conformation. The effects on viability of breast cancer MDA-MB231, colorectal cancer HCT116, hepatocellular carcinoma HepG2 and Chang liver cells, an immortalized non-tumor hepatic cell line, have been investigated. The effect of a variation in structure of caf1 was found to lead to a change in the respective antiproliferative properties: caf1 induces loss of viability in HCT116, MDA-MB-231, and HepG2; the complex shows only moderate effects in non-tumor Chang liver cells. caf1 exerts lower cytotoxic activity than Bu2SnCl2, suggesting that the binding with H(3)CAF modulates the marked cytotoxic activity exerted by Bu2SnCl2; caf1 displays a considerably more pronounced antitumoural effect towards cell lines than caffeic acid. It is known that caffeic acid can modulate DNA (cytosine-5)-methyltransferases 1 (DNMT1) mediated DNA methylation. In this paper we demonstrate that caf1 treatment was able to induce a time-dependent reduction of global DNA methylated status. This effect was also confirmed by a concomitant reduction DNMT1 expression level. The effect induced by caf1 was more evident not only with respect to untreated cells but also compared to H(3)CAF treated cells. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Pellerito, C.; Morana, O.; Ferrante, F.; Fiore, T.] Univ Palermo, DiFC, I-90128 Palermo, Italy.
   [Calvaruso, G.; Notaro, A.; Sabella, S.] Policlin Univ, Dipartimento Sci & Tecnol Biol Chim & Farmaceut S, Biochim Lab, I-90127 Palermo, Italy.
   [Pellerito, C.; Fiore, T.] CIRCMSB, I-70121 Bari, Italy.
C3 University of Palermo; University of Palermo
RP Pellerito, C (通讯作者)，Dipartimento Fis & Chim, Viale Sci,Ed 17, I-90128 Palermo, Italy.
EM claudia.pellerito@unipa.it
RI Ferrante, Francesco/B-7526-2012
OI Notaro, Antonietta/0000-0002-9822-0823
FU Universita degli Studi di Palermo, Italy [2012-ATE-0475]; P.O.R.
   Sicilia, Misura 3.15 Quota Regionale [200-2006]
FX The AA gratefully acknowledges the financial support of the Universita
   degli Studi di Palermo, Italy (Grant 2012-ATE-0475). NMR experimental
   data were provided by Centro Grandi Apparecchiature-Uninetla-(Universita
   di Palermo) funded by P.O.R. Sicilia 200-2006, Misura 3.15 Quota
   Regionale.
CR [Anonymous], COORD CHEM REV
   [Anonymous], ADV APPL NMR ORGANOM
   [Anonymous], PERTANIKA J SCI TECH
   [Anonymous], POLYHEDRON
   [Anonymous], ORGANOMET CHEM
   [Anonymous], ORGANIC CHEM TIN
   Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc
   Bagno A, 2013, J ORGANOMET CHEM, V724, P139, DOI 10.1016/j.jorganchem.2012.10.041
   Baul TSB, 2005, J ORGANOMET CHEM, V690, P4232, DOI 10.1016/j.jorganchem.2005.06.030
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bertazzi N, 2007, DALTON T, P1440, DOI 10.1039/b616330k
   Boilet L, 2005, J PHYS CHEM A, V109, P1952, DOI 10.1021/jp047703d
   Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2
   BROWN DG, 1979, INORG CHEM, V18, P2039, DOI 10.1021/ic50197a068
   Carraher CE, 2012, J POLYM MATER, V29, P371
   Carraher CE, 2010, J INORG ORGANOMET P, V20, P570, DOI 10.1007/s10904-010-9336-y
   Casella G, 2008, INORG CHEM, V47, P4796, DOI 10.1021/ic8000976
   Casella G, 2010, ORG BIOMOL CHEM, V8, P2711, DOI 10.1039/c000679c
   Casella G, 2009, EUR J ORG CHEM, V2009, P3526, DOI 10.1002/ejoc.200900197
   Cornard JP, 2004, J PHYS CHEM A, V108, P4470, DOI 10.1021/jp0379188
   Fang MZ, 2003, CANCER RES, V63, P7563
   Frisch M. J., 2009, Gaussian 09
   Giuliano M, 2006, INT J MOL MED, V17, P811
   Giuliano M, 2009, BIOCHIMIE, V91, P457, DOI 10.1016/j.biochi.2008.11.003
   Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kutzelnigg W., 1990, NMR-BASIC PRINC PROG, V23, DOI DOI 10.1007/978-3-642-75932-13
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Matela G, 2012, CENT EUR J CHEM, V10, P1, DOI 10.2478/s11532-011-0107-6
   Monti Barbara, 2009, Curr Mol Pharmacol, V2, P95
   Nath M, 2001, COORDIN CHEM REV, V215, P99, DOI 10.1016/S0010-8545(00)00404-5
   NIELSON AJ, 1978, J CHEM SOC DALTON, P1501, DOI 10.1039/dt9780001501
   Osada S, 2005, TOXICOL LETT, V155, P329, DOI 10.1016/j.toxlet.2004.10.009
   Pellerito L, 2010, J INORG BIOCHEM, V104, P750, DOI 10.1016/j.jinorgbio.2010.03.008
   Pellerito O, 2013, J INORG BIOCHEM, V125, P16, DOI 10.1016/j.jinorgbio.2013.04.008
   Peterson KA, 2003, J CHEM PHYS, V119, P11099, DOI 10.1063/1.1622923
   PETROSYAN VS, 1977, PROG NUCL MAG RES SP, V11, P115, DOI 10.1016/0079-6565(77)80005-8
   Smith P.J., 1978, ANNREVNMR SPEC, V8, P291
   Song XQ, 2007, APPL ORGANOMET CHEM, V21, P545, DOI 10.1002/aoc.1241
   STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001
   Swislocka R, 2013, SPECTROCHIM ACTA A, V100, P21, DOI 10.1016/j.saa.2012.01.048
   Wang YQ, 2009, AQUAT TOXICOL, V95, P93, DOI 10.1016/j.aquatox.2009.06.008
   Wrackmeyer B, 1999, ANN R NMR S, V38, P203, DOI 10.1016/S0066-4103(08)60038-1
   Wrackmeyer B., 1985, ANNU REP NMR SPECTRO, V16, P73, DOI DOI 10.1016/S0066-4103(08)60226-4
NR 44
TC 15
Z9 15
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD SEP
PY 2015
VL 150
BP 18
EP 27
DI 10.1016/j.jinorgbio.2015.06.001
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CY3YC
UT WOS:000366344800003
PM 26072325
DA 2025-01-12
ER

PT J
AU Atrian, F
   Lelièvre, SA
AF Atrian, Farzaneh
   Lelievre, Sophie A.
TI Mining the epigenetic landscape of tissue polarity in search of new
   targets for cancer therapy
SO EPIGENOMICS
LA English
DT Article
DE basoapical polarity; cancer; DNA methylation; epigenetic drug;
   epithelial-to-mesenchymal transition; EZH2; histone modification; tissue
   architecture
ID EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS;
   POLYCOMB GROUP PROTEIN; HUMAN PROSTATE-CANCER; PHASE-II TRIAL;
   BREAST-CANCER; TUMOR-SUPPRESSOR; DNA METHYLATION; CELL POLARITY; MAMMARY
   EPITHELIUM
AB The epigenetic nature of cancer encourages the development of inhibitors of epigenetic pathways. Yet, the clinical use for solid tumors of approved epigenetic drugs is meager. We argue that this situation might improve upon understanding the coinfluence between epigenetic pathways and tissue architecture. We present emerging information on the epigenetic control of the polarity axis, a central feature of epithelial architecture created by the orderly distribution of multiprotein complexes at cell-cell and cell-extracellular matrix contacts and altered upon cancer onset (with apical polarity loss), invasive progression (with basolateral polarity loss) and metastatic development (with basoapical polarity imbalance). This information combined with the impact of polarity-related proteins on epigenetic mechanisms of cancer enables us to envision how to guide the choice of drugs specific for distinct epigenetic modifiers, in order to halt cancer development and counter the consequences of polarity alterations.
C1 [Atrian, Farzaneh; Lelievre, Sophie A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47906 USA.
   [Atrian, Farzaneh; Lelievre, Sophie A.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47906 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University
RP Lelièvre, SA (通讯作者)，Purdue Univ, Dept Basic Med Sci, 625 Harrison St,Lynn Hall, W Lafayette, IN 47906 USA.
EM lelievre@purdue.edu
OI LELIEVRE, Sophie/0000-0001-6606-2501
FU NIH [CA171704]; Keck Foundation
FX The authors acknowledge support from the NIH (CA171704 to SAL) and the
   Keck Foundation. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Abad PC, 2007, MOL BIOL CELL, V18, P348, DOI 10.1091/mbc.E06-06-0551
   Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Andersen A, 2013, ADV EXP MED BIOL, V754, P167, DOI 10.1007/978-1-4419-9967-2_8
   Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Barker CA, 2013, INT J RADIAT ONCOL, V86, P504, DOI 10.1016/j.ijrobp.2013.02.012
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bazzoun D, 2013, PHARMACOL THERAPEUT, V138, P418, DOI 10.1016/j.pharmthera.2013.02.004
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bunker BD, 2015, ELIFE, V4, DOI 10.7554/eLife.03189
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439
   Chang GM, 2010, CLIN CANCER RES, V16, P5390, DOI 10.1158/1078-0432.CCR-10-1461
   Chen CL, 2010, P NATL ACAD SCI USA, V107, P15810, DOI 10.1073/pnas.1004060107
   Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200
   Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121
   Feng X, 2012, CANCER BIOMARK, V11, P99, DOI 10.3233/CBM-2012-0264
   Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   Gregory GD, 2007, MOL CELL BIOL, V27, P8466, DOI 10.1128/MCB.00993-07
   Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Grzeschik NA, 2010, CELL CYCLE, V9, P3202, DOI 10.4161/cc.9.16.12633
   Hackanson B, 2014, RECENT RESULTS CANC, V201, P269, DOI 10.1007/978-3-642-54490-3_18
   Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44
   He W, 2013, BIOCHEM BIOPH RES CO, V435, P526, DOI 10.1016/j.bbrc.2013.04.074
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Kelly WK, 2015, CLIN CANCER RES, V21, P2198, DOI 10.1158/1078-0432.CCR-14-2556
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kirk JS, 2015, ONCOTARGET, V6, P3136, DOI 10.18632/oncotarget.3077
   Kishikawa Shotaro, 2002, Nucleic Acids Res Suppl, P209
   Klisovic RB, 2008, CLIN CANCER RES, V14, P2444, DOI 10.1158/1078-0432.CCR-07-1320
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Kornblith AB, 2002, J CLIN ONCOL, V20, P2441, DOI 10.1200/JCO.2002.04.044
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lelièvre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Lin XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067496
   Lin YW, 2014, CURR PHARM DESIGN, V20, P1698, DOI 10.2174/13816128113199990512
   Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107
   Liu ZL, 2014, TUMOR BIOL, V35, P9027, DOI 10.1007/s13277-014-2076-9
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Maryan N, 2015, MOL MED REP, V12, P728, DOI 10.3892/mmr.2015.3378
   Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109
   McCabe MT, 2014, EPIGENOMICS-UK, V6, P341, DOI [10.2217/epi.14.23, 10.2217/EPI.14.23]
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Medina-Franco JL, 2015, DRUG DISCOV TODAY, V20, P569, DOI 10.1016/j.drudis.2014.12.007
   Menendez L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-10
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244
   Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284
   Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567
   Oronsky B, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00134
   Ozawa M, 2015, BIOCHEM BIOPH RES CO, V458, P608, DOI 10.1016/j.bbrc.2015.02.012
   Ozturk N, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00005
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Paris L, 2008, BBA-BIOMEMBRANES, V1778, P646, DOI 10.1016/j.bbamem.2007.08.004
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Plummer R, 2009, CLIN CANCER RES, V15, P3177, DOI 10.1158/1078-0432.CCR-08-2859
   Prusevich P, 2014, ACS CHEM BIOL, V9, P1284, DOI 10.1021/cb500018s
   Ribeiro P, 2014, P NATL ACAD SCI USA, V111, pE1980, DOI 10.1073/pnas.1315508111
   Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019
   Sarkar S, 2013, INT J MOL SCI, V14, P21087, DOI 10.3390/ijms141021087
   Sarkar S, 2013, EPIGENOMICS-UK, V5, P87, DOI [10.2217/EPI.12.68, 10.2217/epi.12.68]
   Sarkar S, 2011, ANTICANCER RES, V31, P2723
   Schiller R, 2014, CHEMMEDCHEM, V9, P566, DOI 10.1002/cmdc.201300428
   Sehgal BU, 2006, J BIOL CHEM, V281, P35487, DOI 10.1074/jbc.M606317200
   Seidel C, 2012, BIOCHIMIE, V94, P2264, DOI 10.1016/j.biochi.2012.05.012
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Shi WY, 2014, J NEURO-ONCOL, V118, P313, DOI 10.1007/s11060-014-1433-2
   Smits KM, 2014, RADIOTHER ONCOL, V111, P168, DOI 10.1016/j.radonc.2014.05.001
   Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Tian HP, 2015, J BIOL CHEM
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   Vansteenkiste J, 2008, INVEST NEW DRUG, V26, P483, DOI 10.1007/s10637-008-9131-6
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wang SY, 2012, MOL MED, V18, P1402, DOI 10.2119/molmed.2012.00243
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Weth O, 2014, NUCLEIC ACIDS RES, V42, P11941, DOI 10.1093/nar/gku937
   Xu M, 2014, MOL CELL BIOL, V34, P3867, DOI 10.1128/MCB.00567-14
   Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148
   You JS, 2008, ONCOGENE, V27, P1376, DOI 10.1038/sj.onc.1210776
   Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
   Zhang JX, 2015, CANCER LETT, V356, P929, DOI 10.1016/j.canlet.2014.11.003
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
   Zibelman M., 2015, INVEST NEW DRUGS
NR 103
TC 4
Z9 4
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PY 2015
VL 7
IS 8
BP 1313
EP 1325
DI 10.2217/epi.15.83
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CY6YH
UT WOS:000366554200009
PM 26646365
DA 2025-01-12
ER

PT J
AU Tessitore, A
   Cicciarelli, G
   Del Vecchio, F
   Gaggiano, A
   Verzella, D
   Fischietti, M
   Mastroiaco, V
   Vetuschi, A
   Sferra, R
   Barnabei, R
   Capece, D
   Zazzeroni, F
   Alesse, E
AF Tessitore, Alessandra
   Cicciarelli, Germana
   Del Vecchio, Filippo
   Gaggiano, Agata
   Verzella, Daniela
   Fischietti, Mariafausta
   Mastroiaco, Valentina
   Vetuschi, Antonella
   Sferra, Roberta
   Barnabei, Remo
   Capece, Daria
   Zazzeroni, Francesca
   Alesse, Edoardo
TI MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC
   progression: study on C57BL/6J mice
SO BMC CANCER
LA English
DT Article
ID HUMAN HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; DOWN-REGULATION;
   BREAST-CANCER; CIRCULATING MICRORNAS; INSULIN-RESISTANCE; HEPATIC
   MICRORNAS; TUMOR-SUPPRESSOR; LIVER; SERUM
AB Background: Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Non-alcoholic fatty liver disease (NAFLD) is a frequent chronic liver disorder in developed countries. NAFLD can progress through the more severe non alcoholic steatohepatitis (NASH), cirrhosis and, lastly, HCC. Genetic and epigenetic alterations of coding genes as well as deregulation of microRNAs (miRNAs) activity play a role in HCC development. In this study, the C57BL/6J mouse model was long term high-fat (HF) or low-fat (LF) diet fed, in order to analyze molecular mechanisms responsible for the hepatic damage progression.
   Methods: Mice were HF or LF diet fed for different time points, then plasma and hepatic tissues were collected. Histological and clinical chemistry assays were performed to assess the progression of liver disease. MicroRNAs' differential expression was evaluated on pooled RNAs from tissues, and some miRNAs showing dysregulation were further analyzed at the individual level.
   Results: Cholesterol, low and high density lipoproteins, triglycerides and alanine aminotransferase increase was detected in HF mice. Gross anatomical examination revealed hepatomegaly in HF livers, and histological analysis highlighted different degrees and levels of steatosis, inflammatory infiltrate and fibrosis in HF and LF animals, demonstrating the progression from NAFLD through NASH. Macroscopic nodules, showing typical neoplastic features, were observed in 20 % of HF diet fed mice. Fifteen miRNAs differentially expressed in HF with respect to LF hepatic tissues during the progression of liver damage, and in tumors with respect to HF non tumor liver specimens were identified. Among them, miR-340-5p, miR-484, miR-574-3p, miR-720, whose expression was never described in NAFLD, NASH and HCC tissues, and miR-125a-5p and miR-182, which showed early and significant dysregulation in the sequential hepatic damage process.
   Conclusions: In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified. Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
C1 [Tessitore, Alessandra; Cicciarelli, Germana; Del Vecchio, Filippo; Gaggiano, Agata; Verzella, Daniela; Fischietti, Mariafausta; Mastroiaco, Valentina; Vetuschi, Antonella; Sferra, Roberta; Capece, Daria; Zazzeroni, Francesca; Alesse, Edoardo] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
   [Barnabei, Remo] S Salvatore Hosp, Unit Lab Med, Laquila, Italy.
C3 University of L'Aquila
RP Tessitore, A (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I-67100 Laquila, Italy.
EM alessandra.tessitore@univaq.it
RI Capece, Daria/AFR-1769-2022; Fischietti, Mariafausta/Y-6449-2019; Del
   Vecchio, Filippo/AAL-7354-2021
OI tessitore, alessandra/0000-0002-7663-2210; Capece,
   Daria/0000-0003-3126-2014; Del Vecchio, Filippo/0000-0003-1894-888X;
   Sferra, Roberta/0000-0003-3893-8320
FU MIUR-FIRB [RBAP10A9H9]
FX This work was supported by MIUR-FIRB grant n. RBAP10A9H9 to Edoardo
   Alesse. We thank Mauro Di Vito Nolfi for his support in artwork.
CR Aravalli RN, 2013, ARCH TOXICOL, V87, P227, DOI 10.1007/s00204-012-0931-2
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bertino G, 2012, SEMIN ONCOL, V39, P410, DOI 10.1053/j.seminoncol.2012.05.001
   Bhala N, 2013, CURR PHARM DESIGN, V19, P5169, DOI 10.2174/13816128113199990336
   Bosetti C, 2014, BEST PRACT RES CL GA, V28, P753, DOI 10.1016/j.bpg.2014.08.007
   Braconi C, 2010, CLIN CANCER RES, V16, P957, DOI 10.1158/1078-0432.CCR-09-2123
   Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595
   Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061
   Chen YH, 2009, ACTA PHARMACOL SIN, V30, P1138, DOI 10.1038/aps.2009.109
   Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265
   Cramp ME, 1999, GUT, V45, P168, DOI 10.1136/gut.45.2.168
   Csak T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129251
   Dekker MJ, 2010, AM J PHYSIOL-ENDOC M, V299, pE685, DOI 10.1152/ajpendo.00283.2010
   Dettmer MS, 2014, J MOL ENDOCRINOL, V52, P181, DOI 10.1530/JME-13-0266
   Dhayat SA, 2014, J SURG ONCOL, V110, P430, DOI 10.1002/jso.23668
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323
   Fan MQ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-21
   Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004
   Feng YY, 2014, CELL PHYSIOL BIOCHEM, V34, P1983, DOI 10.1159/000366394
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   Fraulob JC, 2010, J CLIN BIOCHEM NUTR, V46, P212, DOI 10.3164/jcbn.09-83
   Gori M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741465
   Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x
   Gui JH, 2011, CLIN SCI, V120, P183, DOI 10.1042/CS20100297
   Haj-Ahmad TA, 2014, J CANCER, V5, P103, DOI 10.7150/jca.6890
   He XX, 2015, MOL BIOSYST, V11, P532, DOI 10.1039/c4mb00563e
   Hill-Baskin AE, 2009, HUM MOL GENET, V18, P2975, DOI 10.1093/hmg/ddp236
   Hsieh TH, 2015, ONCOTARGET, V6, P494, DOI 10.18632/oncotarget.2674
   Hu JF, 2015, CLIN SCI, V129, P305, DOI 10.1042/CS20140012
   Hu ZG, 2012, MOL CELL BIOL, V32, P5035, DOI 10.1128/MCB.01002-12
   Huang SL, 2008, INT J CANCER, V123, P972, DOI 10.1002/ijc.23580
   Hung CH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/486407
   Ji JL, 2009, FEBS LETT, V583, P759, DOI 10.1016/j.febslet.2009.01.034
   Jiang LL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-318
   Karakatsanis A, 2013, MOL CARCINOGEN, V52, P297, DOI 10.1002/mc.21864
   Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101
   Kiran S, 2015, CELL SIGNAL, V27, P673, DOI 10.1016/j.cellsig.2014.11.026
   Lenarduzzi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053765
   Leti F, 2015, TRANSL RES, V166, P304, DOI 10.1016/j.trsl.2015.04.014
   Leung WKC, 2015, CANCER LETT, V362, P97, DOI 10.1016/j.canlet.2015.03.023
   Li LZ, 2014, CARCINOGENESIS, V35, P469, DOI 10.1093/carcin/bgt330
   Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245
   Liu H, 2010, WORLD J GASTROENTERO, V16, P4410, DOI 10.3748/wjg.v16.i35.4410
   Liu SG, 2013, ONCOL LETT, V5, P1639, DOI 10.3892/ol.2013.1251
   Longato L, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-14
   Lydatakis H, 2006, LIVER INT, V26, P864, DOI 10.1111/j.1478-3231.2006.01312.x
   McClain CJ, 2004, ALCOHOL, V34, P67, DOI 10.1016/j.alcohol.2004.07.007
   Michelotti GA, 2013, NAT REV GASTRO HEPAT, V10, P656, DOI 10.1038/nrgastro.2013.183
   Miller AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072324
   Nagoshi S, 2014, HEPATOL RES, V44, P22, DOI 10.1111/hepr.12166
   Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132
   Nomura K, 2012, J NUTR BIOCHEM, V23, P203, DOI 10.1016/j.jnutbio.2011.09.006
   Obika M, 2012, EXP DIABETES RES, DOI 10.1155/2012/145754
   Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085
   Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890
   Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107
   Pogribny IP, 2010, LAB INVEST, V90, P1437, DOI 10.1038/labinvest.2010.113
   Quan HY, 2013, BIOCHEM PHARMACOL, V85, P1330, DOI 10.1016/j.bcp.2013.02.007
   Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162
   Sand M, 2013, CELL TISSUE RES, V351, P85, DOI 10.1007/s00441-012-1514-5
   Sapp V, 2014, HEPATOLOGY, V60, P1581, DOI 10.1002/hep.27284
   Scarpati GDV, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/840921
   Schultz A, 2015, FOOD FUNCT, V6, P1684, DOI [10.1039/c5fo00251f, 10.1039/C5FO00251F]
   Shirasaki T, 2013, J VIROL, V87, P5270, DOI 10.1128/JVI.03022-12
   Sidhu K, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00068
   Simionescu N, 2014, MOL BIOL REP, V41, P5765, DOI 10.1007/s11033-014-3449-2
   Singhal A, 2012, CRIT REV ONCOL HEMAT, V82, P116, DOI 10.1016/j.critrevonc.2011.05.005
   Soini Y, 1996, CARCINOGENESIS, V17, P1007, DOI 10.1093/carcin/17.5.1007
   Strong AMP, 2014, ARCH BIOCHEM BIOPHYS, V563, P118, DOI 10.1016/j.abb.2014.07.012
   Summerer I, 2015, BRIT J CANCER, V113, P76, DOI 10.1038/bjc.2015.111
   Surwit RS, 2005, DIABETES RES CLIN PR, V69, P78, DOI 10.1016/j.diabres.2004.11.002
   Tahiri A, 2014, CARCINOGENESIS, V35, P76, DOI 10.1093/carcin/bgt333
   Tang QC, 2015, TUMOR BIOL, V36, P1701, DOI 10.1007/s13277-014-2771-6
   Tian Y, 2013, SEMIN CANCER BIOL, V23, P471, DOI 10.1016/j.semcancer.2013.08.010
   TSUKUMA H, 1990, INT J CANCER, V45, P231, DOI 10.1002/ijc.2910450205
   Waller-Evans H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082825
   Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100
   Wang CG, 2014, CHINESE J CANCER RES, V26, P17, DOI 10.3978/j.issn.1000-9604.2014.01.01
   Wang GF, 2009, FEBS J, V276, P5571, DOI 10.1111/j.1742-4658.2009.07238.x
   Wang J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-227
   Wang TH, 2015, MOL CARCINOG, V8
   Wang X, 2015, TUMOR BIOL, V36, P719, DOI 10.1007/s13277-014-2697-z
   Wei F, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-81
   Wu XJ, 2013, ASIAN PAC J CANCER P, V14, P885, DOI 10.7314/APJCP.2013.14.2.885
   Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860
   Xiao ZG, 2013, EUR J GASTROEN HEPAT, V25, P296, DOI 10.1097/MEG.0b013e32835c077a
   Xirouchakis E, 2009, ANN GASTROENTEROL, V22, P24
   Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127
   Yang JH, 2015, ONCOL REP, V34, P1415, DOI 10.3892/or.2015.4104
   Yang XW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-909
   Yang Y, 2010, CANCER GENET CYTOGEN, V200, P127, DOI 10.1016/j.cancergencyto.2010.03.014
   Yang YA, 2006, CANCER CELL, V9, P445, DOI 10.1016/j.ccr.2006.04.025
   Yang ZY, 2014, INT J CLIN EXP PATHO, V7, P7563
   Zearo S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-200
   Zhang MZ, 2013, J CONTROL RELEASE, V168, P251, DOI 10.1016/j.jconrel.2013.03.020
   Zheng JJ, 2015, MOL MED REP, V12, P1584, DOI 10.3892/mmr.2015.3546
   Zhong QS, 2014, J NEUROSCI RES, V92, P619, DOI 10.1002/jnr.23339
NR 98
TC 69
Z9 73
U1 1
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 5
PY 2016
VL 16
AR 3
DI 10.1186/s12885-015-2007-1
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DA0SO
UT WOS:000367507700002
PM 26728044
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Liu, CB
   Lin, JJ
AF Liu, Chibo
   Lin, Jianjun
TI Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by
   epigenetically activating ZEB1
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Long noncoding RNA; oncogene; osteosarcoma; epigenetics; ZEB1
ID SQUAMOUS-CELL CARCINOMA; HEPATOCELLULAR-CARCINOMA; PROGNOSTIC VALUE;
   BREAST-CANCER; MESSENGER-RNA; PROMOTES; EXPRESSION; PROLIFERATION;
   METASTASIS; PROGRESSION
AB Long noncoding RNAs (lncRNAs) have been demonstrated to be dysregulated in many disease states and have pivotal roles in various pathophysiological processes. However, the expression, roles and potential mechanism of lncRNA ZEB1-AS1 in osteosarcoma are still unknown. In this study, we measured ZEB1-AS1 expression and the results showed that ZEB1-AS1 was upregulated in osteosarcoma tissues and cells. Increased expression of ZEB1-AS1 is correlated with larger tumor size, progressed Enneking stage, tumor metastasis, worse recurrence-free and overall survival of osteosarcoma patients. Functional experiments showed that enhanced expression of ZEB1-AS1 promotes osteosarcoma cells proliferation and migration. By contrast, ZEB1-AS1 knockdown inhibits osteosarcoma cells proliferation and migration. Mechanistically, ZEB1-AS1 directly binds and recruits p300 to the ZEB1 promoter region, induces an open chromatin structure, and activates ZEB1 transcription. There is a significant correlation between the expression of ZEB1-AS1 and ZEB1 in osteosarcoma tissues. ZEB1 depletion abrogates the roles of ZEB1-AS1 on the proliferation and migration of osteosarcoma cells. Collectively, these findings demonstrated that ZEB1-AS1 functions as an oncogene in osteosarcoma via epigenetically activating ZEB1 and could be a potential target for osteosarcoma treatment.
C1 [Liu, Chibo] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
   [Lin, Jianjun] Fourth Hosp Ningbo, Dept Clin Lab, 291 Donggu Rd, Xiangshan 315700, Zhejiang, Peoples R China.
C3 Taizhou University
RP Lin, JJ (通讯作者)，Fourth Hosp Ningbo, Dept Clin Lab, 291 Donggu Rd, Xiangshan 315700, Zhejiang, Peoples R China.
EM linjianjunxs@yeah.net
RI liu, chibo/LKO-0895-2024
FU Zhejiang Medicine, Health, and Science [2013KYB295]
FX This work was supported by grant from Zhejiang Medicine, Health, and
   Science (2013KYB295).
CR Banerjee S, 2012, FEBS LETT, V586, P3793, DOI 10.1016/j.febslet.2012.09.012
   Bayram S, 2015, TUMOR BIOL, V36, P3863, DOI 10.1007/s13277-014-3028-0
   Boro A, 2015, AM J TRANSL RES, V7, P640
   Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003
   Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Geng ZH, 2016, AM J TRANSL RES, V8, P1886
   Guo XQ, 2014, TUMOR BIOL, V35, P10591, DOI 10.1007/s13277-014-2548-y
   He CB, 2016, APMIS, V124, P169, DOI 10.1111/apm.12480
   Jaffe Norman, 2013, Sarcoma, V2013, P203531, DOI 10.1155/2013/203531
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Li M, 2016, DNA CELL BIOL, V35, P235, DOI 10.1089/dna.2015.3171
   Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223
   Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295
   Liu X, 2008, NATURE, V451, P846, DOI 10.1038/nature06546
   Meng LY, 2012, HUM MOL GENET, V21, P3001, DOI 10.1093/hmg/dds130
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mir O, 2008, LANCET ONCOL, V9, P1198, DOI 10.1016/S1470-2045(08)70309-7
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Shen AD, 2012, J SURG ONCOL, V105, P830, DOI 10.1002/jso.23012
   Stazic D, 2011, NUCLEIC ACIDS RES, V39, P4890, DOI 10.1093/nar/gkr037
   Sun JB, 2016, MOL BIOL REP, V43, P427, DOI 10.1007/s11033-016-3975-1
   Wang A, 2004, BIOCHEM BIOPH RES CO, V325, P1509, DOI 10.1016/j.bbrc.2004.10.198
   Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239
   Wang YL, 2015, INT J CLIN EXP PATHO, V8, P11871
   Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006
   Yang F, 2014, FEBS J, V281, P802, DOI 10.1111/febs.12625
   Yoon AJ, 2014, AM J TRANSL RES, V6, P580
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010
   Yuan SX, 2014, CANCER LETT, V349, P87, DOI 10.1016/j.canlet.2014.03.029
NR 36
TC 122
Z9 126
U1 0
U2 13
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 10
BP 4095
EP 4105
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EB8OI
UT WOS:000387650100008
PM 27829995
DA 2025-01-12
ER

PT J
AU Brozek-Pluska, B
   Kopec, M
   Abramczyk, H
AF Brozek-Pluska, Beata
   Kopec, Monika
   Abramczyk, Halina
TI Development of a new diagnostic Raman method for monitoring epigenetic
   modifications in the cancer cells of human breast tissue
SO ANALYTICAL METHODS
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; DNA HYPERMETHYLATION; SPECTROSCOPY;
   SPECTRA; HYPOMETHYLATION; ACETYLATION; METHYLATION; EXPRESSION; COMMON;
   MICROSPECTROSCOPY
AB Cancer diagnosis requires better screening of early stages of pathology and monitoring patient responses to treatment. Current technologies in the clinical sector are expensive, sophisticated and time consuming. This paper develops a novel Raman based alternative for currently existing epigenetics research approaches. The proposed Raman approach can 'upgrade' cancer epigenetic tests and answer many questions by monitoring the biochemistry of cancer cells. We will show that Raman spectroscopy and Raman imaging can detect the relative amounts of acetylated and methylated lysine by monitoring the vibrations of the acetyl and methyl chemical functional groups. In comparison to existing tests and assays used to monitor molecular processes of acetylation and methylation of all proteins, Raman-based methods have the potential to be a powerful alternative for conventional methods of cell biology, because they allow non-invasive detection of cellular acetylation and methylation processes that are not limited to only those events that are sensitive to a specific antibody. Vibrational Raman signatures of acetylation and methylation processes in epithelial cells of human breast tissue (ductal and lobular carcinoma) have been used to identify and discriminate structures in normal and cancerous tissues. Our results demonstrate that the stretching vibration of the acetyl group observed at around 2938-2942 cm(-1) and the methyl group at 2970 cm(-1) by Raman spectroscopy is useful in monitoring these epigenetic molecular processes in cancer cells. The Raman vibrational marker is markedly blue-shifted from 2905 cm(-1) (non-acetylated C-H vibrations) for normal cells to 2942 cm(-1) (vibrations of the acetylated functional group) in cancer cells. The sensitivity and specificity obtained directly from PLSDA and cross-validation for a chosen model gives a sensitivity and specificity of 86.1% and 91.3% for calibration and 85.3% and 91.3% for cross-validation, respectively. The results presented in the paper provide strong evidence that the global acetylation level of histone and non-histone proteins increases in human breast cancer cells.
C1 [Brozek-Pluska, Beata; Kopec, Monika; Abramczyk, Halina] Lodz Univ Technol, Inst Appl Radiat Chem, Lab Laser Mol Spect, Wroblewskiego 15, PL-93590 Lodz, Poland.
C3 Lodz University of Technology
RP Abramczyk, H (通讯作者)，Lodz Univ Technol, Inst Appl Radiat Chem, Lab Laser Mol Spect, Wroblewskiego 15, PL-93590 Lodz, Poland.
EM abramczy@mitr.p.lodz.pl
OI Kopec, Monika/0000-0001-5412-0399; Brozek-Pluska,
   Beata/0000-0001-6924-2655; Abramczyk, Halina/0000-0002-7222-3583
FU National Science Centre Poland [UMO-2015/19/B/ST4/01878]
FX The project was funded through The National Science Centre Poland Grant
   UMO-2015/19/B/ST4/01878.
CR Abramczyk H, 2014, ANALYST, V139, P5547, DOI 10.1039/c4an00966e
   Abramczyk H, 2014, SPECTROCHIM ACTA A, V129, P609, DOI 10.1016/j.saa.2014.03.103
   Abramczyk H, 2013, CHEM REV, V113, P5766, DOI 10.1021/cr300147r
   Abramczyk H, 2011, J MOL LIQ, V164, P123, DOI 10.1016/j.molliq.2011.04.021
   Almond LM, 2014, GASTROINTEST ENDOSC, V79, P37, DOI 10.1016/j.gie.2013.05.028
   Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785
   BEDFORD MT, 1987, CANCER RES, V47, P5274
   Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011
   Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004
   Brozek-Pluska B, 2012, ANALYST, V137, P3773, DOI 10.1039/c2an16179f
   Brozek-Pluska B, 2011, J MED CHEM, V54, P3386, DOI 10.1021/jm200180f
   Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547
   Capoa A., 2003, ONCOL REP, V10, P545
   Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Chowdary MVP, 2006, BIOPOLYMERS, V83, P556, DOI 10.1002/bip.20586
   Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cuperlovic-Culf M., 2014, AM J CANC REV, V2, P1
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   Diem M, 2012, SPECTROSC-INT J, V27, P463, DOI 10.1155/2012/848360
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Ehlich M., 2009, EPIGENOMICS, V1, P239
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Feng S. Y., 2001, SCI CHINA SER C, V54, P828
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gniadecka M, 1998, J INVEST DERMATOL, V110, P393, DOI 10.1046/j.1523-1747.1998.00146.x
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Haka AS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3247154
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Henriksen P, 2012, MOL CELL PROTEOMICS, V11, P1510, DOI 10.1074/mcp.M112.017251
   Herranz Michel, 2007, Methods Mol Biol, V361, P25
   Hilvo M, 2011, CANCER RES, V71, P3236, DOI 10.1158/0008-5472.CAN-10-3894
   Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480
   Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c
   Huang NY, 2011, OPT EXPRESS, V19, P22892, DOI 10.1364/OE.19.022892
   Huang Y., 2011, BREAST CANCER RES, V13, P1
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jarvis RM, 2007, ANALYST, V132, P1053, DOI 10.1039/b702944f
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kline NJ, 1997, J RAMAN SPECTROSC, V28, P119, DOI 10.1002/(SICI)1097-4555(199702)28:2/3<119::AID-JRS73>3.0.CO;2-3
   Koljenovic S, 2005, ANAL CHEM, V77, P7958, DOI 10.1021/ac0512599
   Krafft C, 2005, SPECTROCHIM ACTA A, V61, P1529, DOI 10.1016/j.saa.2004.11.017
   Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297
   Lanouette S, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.134974
   Laska J, 2005, POLYMER, V46, P1485, DOI 10.1016/j.polymer.2004.12.008
   Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307
   Lin-Vien D., 1991, HDB INFRARED RAMAN C
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Matthews Q, 2010, APPL SPECTROSC, V64, P871, DOI 10.1366/000370210792080966
   Mau T, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00438
   Melki JR, 1999, CANCER RES, V59, P3730
   Miljkovic M, 2010, ANALYST, V135, P2002, DOI 10.1039/c0an00042f
   Nazlin KH, 1999, J AGR FOOD CHEM, V47, P924
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Ortiz C, 2006, ANAL BIOCHEM, V353, P157, DOI 10.1016/j.ab.2006.03.025
   Parker F. S., 1983, APPL RAMAN RESONANCE
   Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008
   Rehman IU, 2013, SER MED PHYS BIOMED, P1
   Rygula A, 2013, J RAMAN SPECTROSC, V44, P1061, DOI 10.1002/jrs.4335
   Seifert HH, 2007, EXP MOL PATHOL, V82, P292, DOI 10.1016/j.yexmp.2006.08.002
   Shetty G, 2006, BRIT J CANCER, V94, P1460, DOI 10.1038/sj.bjc.6603102
   SNYDER RG, 1978, SPECTROCHIM ACTA A, V34, P395, DOI 10.1016/0584-8539(78)80167-6
   Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x
   Spiker Jr C. R., 1975, BIOCHIM BIOPHYS ACTA, V88, P361
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Surmacki J, 2015, ANALYST, V140, P2121, DOI 10.1039/c4an01876a
   Talari ACS, 2015, APPL SPECTROSC REV, V50, P46, DOI 10.1080/05704928.2014.923902
   VERMA SP, 1977, BIOCHIM BIOPHYS ACTA, V486, P217, DOI 10.1016/0005-2760(77)90018-2
   Weinert N, 2011, FEMS MICROBIOL ECOL, V75, P497, DOI 10.1111/j.1574-6941.2010.01025.x
   Wise B.M., PLS TOOLBOX VERSION
   Xue-Gang L., 2007, HISTONE MODIFICATION, P321
   Yu YQ, 2007, J PHYS CHEM C, V111, P8971, DOI 10.1021/jp0675781
NR 82
TC 34
Z9 34
U1 0
U2 28
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PY 2016
VL 8
IS 48
BP 8542
EP 8553
DI 10.1039/c6ay02559e
PG 12
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Spectroscopy
GA EJ3GU
UT WOS:000393101400019
DA 2025-01-12
ER

PT J
AU Branham, MT
   Campoy, E
   Laurito, S
   Branham, R
   Urrutia, G
   Orozco, J
   Gago, F
   Urrutia, R
   Roqué, M
AF Branham, M. T.
   Campoy, E.
   Laurito, S.
   Branham, R.
   Urrutia, G.
   Orozco, J.
   Gago, F.
   Urrutia, R.
   Roque, M.
TI Epigenetic regulation of ID4 in the determination of the BRCAness
   phenotype in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast tumors; BRCAness; ID4; Aberrant DNA methylation
ID METHYLATION; EXPRESSION; BRCA1; HYPERMETHYLATION; IDENTIFICATION;
   SENSITIVITY; PROTEINS; MLPA
AB BRCAness breast tumors represent a group of sporadic tumors characterized by a reduction in BRCA1 gene expression. As BRCA1 is involved in double-strand breaks (DSBs) repair, dysfunctional BRCA pathway could make a tumor sensitive to DNA damaging drugs (e.g., platinum agents). Thus, accurately identifying BRCAness could contribute to therapeutic decision making in patients harboring these tumors. The purpose of this study was to identify if BRCAness tumors present a characteristic methylation profile and/or were related to specific clinicopathological features. BRCAness was measured by MLPA in 63 breast tumors; methylation status of 98 CpG sites within 84 cancer-related genes was analyzed by MSMLPA. Protein and mRNA expressions of the selected genes were measured by quantitative real-time PCR and Western Blot. BRCAness was associated with younger age, higher nuclear pleomorfism, and triple-negative (TN) status. Epigenetically, we found that the strongest predictors for BRCAness tumors were the methylations of MLH1 and PAX5 plus the unmethylations of CCND2 and ID4. We determined that ID4 unmethylation correlated with the expression levels of both its mRNA and protein. We observed an inverse relation between the expressions of ID4 and BRCA1. To the best of our knowledge, this is the first report suggesting an epigenetic regulation of ID4 in BRCAness tumors. Our findings give new information of BRCAness etiology and encourage future studies on potential drug targets for BRCAness breast tumors.
C1 [Branham, M. T.; Campoy, E.; Laurito, S.; Urrutia, G.; Roque, M.] IHEM CCT CONICET Mendoza, Mendoza, Argentina.
   [Branham, M. T.; Campoy, E.; Laurito, S.; Urrutia, G.; Roque, M.] Natl Univ Cuyo, Mendoza, Argentina.
   [Branham, R.] IANIGLA CCT CONICET Mendoza, Mendoza, Argentina.
   [Orozco, J.; Gago, F.] Gineco Mamario Inst Mendoza, Mendoza, Argentina.
   [Urrutia, R.] Mayo Clin, Ctr Individualized Med, Epigenom Translat Program, GI Res Unit,Div Gastroenterol & Hepatol, Rochester, NY USA.
C3 University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza;
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   Mayo Clinic
RP Branham, MT (通讯作者)，IHEM CCT CONICET Mendoza, Mendoza, Argentina.; Branham, MT (通讯作者)，Natl Univ Cuyo, Mendoza, Argentina.
EM mbranham@fcm.uncu.edu.ar
OI Roque, Maria/0000-0002-9564-1032; Campoy, Emanuel/0000-0003-0521-6073
FU National Institute of Cancer ("Instituto Nacional del Cancer"),
   Argentina; National Institutes of Health [DK52913]; Mayo Clinic SPORE in
   Pancreatic Cancer [P50 CA102701]; Mayo Clinic Center for Cell Signaling
   in Gastroenterology [P30DK084567]; National Institute of Diabetes and
   Digestive and Kidney Diseases [R01DK052913] Funding Source: NIH RePORTER
FX This study was supported in part by the National Institute of Cancer
   ("Instituto Nacional del Cancer"), Argentina. RU was supported by
   funding from the National Institutes of Health (grant DK52913), the Mayo
   Clinic SPORE in Pancreatic Cancer (P50 CA102701), and the Mayo Clinic
   Center for Cell Signaling in Gastroenterology (P30DK084567 to GL).
CR Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318
   Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Branham Jr R. L., 1990, SCI DATA ANAL
   Branham MT, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.17
   Branham RL, 2001, NEW ASTRON REV, V45, P649, DOI 10.1016/S1387-6473(01)00136-1
   Brekelmans CTM, 2006, ANN ONCOL, V17, P391, DOI 10.1093/annonc/mdj095
   Carey JP, 2013, ANTICANCER RES, V33, P4271
   Chalasani P, 2013, ONCOLOGIST, V18, P909, DOI 10.1634/theoncologist.2013-0039
   Chatagnon A, 2011, EPIGENETICS-US, V6, P1295, DOI 10.4161/epi.6.11.17875
   Crippa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087039
   Galatro TFD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061605
   de Candia P, 2004, ADV CANCER RES, V92, P81
   Dell'Orso S, 2010, ONCOTARGET, V1, P48, DOI 10.18632/oncotarget.108
   Domchek SM, 2015, J CLIN ONCOL, V33, P295, DOI 10.1200/JCO.2014.59.3178
   Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669
   Friedenson Bernard, 2005, MedGenMed, V7, P60
   Huffel S. V., 1991, Frontiers in Applied Mathematics
   Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z
   Larsen MJ, 2014, BREAST CANCER-BASIC, V8, P145, DOI 10.4137/BCBCR.S18715
   Lee JW, 2012, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2012-7
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Lips EH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3049
   Martini M, 2013, CANCER-AM CANCER SOC, V119, P1004, DOI 10.1002/cncr.27821
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Oonk AMM, 2012, ANN ONCOL, V23, P2301, DOI 10.1093/annonc/mdr621
   Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673
   Reinbolt RE, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00237
   Roldán G, 2006, CANCER BIOL THER, V5, P505, DOI 10.4161/cbt.5.5.2597
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Suh Dong Hoon, 2013, J Cancer Prev, V18, P227
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Urrutia G, 2015, CLIN EXP METASTAS, V32, P99, DOI 10.1007/s10585-015-9695-4
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
NR 39
TC 12
Z9 13
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2016
VL 155
IS 1
BP 13
EP 23
DI 10.1007/s10549-015-3648-0
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DC1VB
UT WOS:000369004200003
PM 26610810
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Shakeri, H
   Fakhrjou, A
   Nikanfar, A
   Mohaddes-Ardebili, SM
AF Shakeri, Halaleh
   Fakhrjou, Ashraf
   Nikanfar, Alireza
   Mohaddes-Ardebili, Seyyed M.
TI Methylation Analysis of BRCA1 and APC in Breast Cancer and It's
   Relationship to Clinicopathological Features
SO CLINICAL LABORATORY
LA English
DT Article
DE methylation; breast cancer; BRCA1; APC
ID CARCINOMA IN-SITU; PROMOTER HYPERMETHYLATION; DNA METHYLATION;
   BLOOD-CELLS; GENE; EXPRESSION; SIGNATURE
AB Background: Promoter methylation of tumor suppressor genes is an important epigenetic alteration that occurs in the primary stages of human tumors, including breast cancer. Identification of methylated genes and their relationship to clinical features can contribute to the prognosis and early detection of tumors. In this study, we explored the methylation status of APC and BRCA1 genes and their relationship to clinical factors in breast cancer patients.
   Methods: BRCA1 and APC promoter methylation was examined by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay in formalin-fixed paraffin embedded (FFPE) breast tissue from 75 patients.
   Results: APC promoter methylation was detected in 30.67% breast cancer tissues and BRCA1 was methylated in 9.33% of breast tumors. Methylation of APC was associated with low histological grade (p = 0.006) and methylation of BRCA1 was related with lymph node metastasis (p = 0.017).
   Conclusions: These findings suggest that the methylation status of APC and BRCA1 can be a predictive marker for early detection and better management of breast cancer patients.
C1 [Shakeri, Halaleh; Nikanfar, Alireza; Mohaddes-Ardebili, Seyyed M.] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Tabriz, Iran.
   [Shakeri, Halaleh; Mohaddes-Ardebili, Seyyed M.] Tabriz Univ Med Sci, Div Med Genet, Dept Biochem & Clin Labs, Fac Med, Tabriz, Iran.
   [Fakhrjou, Ashraf] Tabriz Univ Med Sci, Sch Med, Dept Pathol, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science
RP Mohaddes-Ardebili, SM (通讯作者)，Tabriz Univ Med Sci, Div Med Genet, Dept Biochem & Clin Labs, Fac Med, Tabriz, Iran.
EM mohaddesmo@yahoo.com
RI Nikanfar, Alireza/M-3906-2018
OI shakeri, halaleh/0009-0007-5526-175X
FU Hematology and Oncology Research Center, Tabriz University of Medical
   Sciences [92/2-1/4]
FX The authors would like to thank the Hematology and Oncology Research
   Center, Tabriz University of Medical Sciences for supporting this
   project which was a part of a MSc thesis (92/2-1/4).
CR Al-Moghrabi N, 2011, INT J ONCOL, V39, P129, DOI 10.3892/ijo.2011.1021
   Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Bagadi SAR, 2008, LIFE SCI, V82, P1288, DOI 10.1016/j.lfs.2008.04.020
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Esteller M, 2001, CANCER RES, V61, P3225
   Feng Jing, 2009, Ai Zheng, V28, P436
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Liu Zhen, 2007, Ai Zheng, V26, P586
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Montazeri Ali, 2008, Asia Pac Fam Med, V7, P6, DOI 10.1186/1447-056X-7-6
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Pang JMB, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3420
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Vo AT, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/602720
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
NR 23
TC 11
Z9 12
U1 0
U2 5
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2016
VL 62
IS 12
BP 2333
EP 2337
DI 10.7754/Clin.Lab.2016.160418
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA EG2AF
UT WOS:000390834800006
PM 28164568
DA 2025-01-12
ER

PT J
AU Kitagawa, K
   Kitagawa, M
AF Kitagawa, Kyoko
   Kitagawa, Masatoshi
TI The SCF-type E3 Ubiquitin Ligases as Cancer Targets
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE beta-TrCP; E3 ligase; F-box protein; FBXW7; human cancer; proteasome;
   SCF complex; SKP2; ubiquitin
ID F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT UBIQUITINATION; CYCLIN D1
   DEGRADATION; KAPPA-B-ALPHA; TUMOR-SUPPRESSOR; BREAST-CANCER; PROTEASOMAL
   DEGRADATION; MESENCHYMAL TRANSITION; TRANSCRIPTIONAL TARGET; MYELOGENOUS
   LEUKEMIA
AB The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-associated protein 2 (SKP2) (also known as FBXL1) is often overexpressed in human cancers, and functions as an oncogenic E3 ligase to degrade tumor suppressor gene products. Moreover, F-box/WD repeat-containing protein 7 (FBXW7) (also known as Fbw7) is often mutated in human cancers and functions as a tumor suppressive E3 ligase targeting oncogenic proteins for degradation. SKP2 is a potential drug target for cancer therapy and FBXW7 is useful in determining patient diagnosis, prognosis, and drug sensitivity. In this review, we also discuss other F-box proteins involved in cancer-associated cellular processes such as cell cycle control, epigenetic regulation, epithelial mesenchymal transition, apoptosis/survival, drug resistance, and DNA-damage responses.
C1 [Kitagawa, Kyoko; Kitagawa, Masatoshi] Hamamatsu Univ Sch Med, Dept Mol Biol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
C3 Hamamatsu University School of Medicine
RP Kitagawa, M (通讯作者)，Hamamatsu Univ Sch Med, Dept Mol Biol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
EM kitamasa@hama-med.ac.jp
FU Grants-in-Aid for Scientific Research [15K06994] Funding Source: KAKEN
CR Andreu EJ, 2005, CANCER RES, V65, P3264, DOI 10.1158/0008-5472.CAN-04-1357
   Appleman LJ, 2006, CELL CYCLE, V5, P2123, DOI 10.4161/cc.5.18.3139
   Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280
   Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017
   Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899
   Bhaskaran N, 2013, MOL CELL BIOL, V33, P85, DOI 10.1128/MCB.00288-12
   Bohgaki M, 2013, CELL DEATH DIFFER, V20, P812, DOI 10.1038/cdd.2013.7
   Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040
   Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200
   Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen BB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.271
   Chen BB, 2012, ONCOGENE, V31, P2566, DOI 10.1038/onc.2011.432
   Chen BB, 2013, NAT IMMUNOL, V14, P470, DOI 10.1038/ni.2565
   Chen JY, 2009, LEUKEMIA RES, V33, P1520, DOI 10.1016/j.leukres.2009.03.007
   Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108
   Chen ZW, 2014, NUCLEIC ACIDS RES, V42, P11560, DOI 10.1093/nar/gku876
   Chiaretti S, 2010, HAEMATOL-HEMATOL J, V95, P1114, DOI 10.3324/haematol.2009.015099
   Chiorazzi M, 2013, P NATL ACAD SCI USA, V110, P3943, DOI 10.1073/pnas.1217271110
   Chiurillo M. A., 2015, World J. Exp. Med., V5, P84, DOI DOI 10.5493/WJEM.V5.I2.84
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   Coon TA, 2012, CELL CYCLE, V11, P721, DOI 10.4161/cc.11.4.19171
   Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222
   Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013
   Diefenbacher ME, 2014, J CLIN INVEST, V124, P3407, DOI 10.1172/JCI73733
   Ding QQ, 2008, CANCER RES, V68, P6109, DOI 10.1158/0008-5472.CAN-08-0579
   Driscoll JJ, 2011, ANTI-CANCER AGENT ME, V11, P242
   Eyholzer M, 2010, LEUKEMIA RES, V34, P672, DOI 10.1016/j.leukres.2009.11.019
   Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   Fernández-Sáiz V, 2013, NAT CELL BIOL, V15, P72, DOI 10.1038/ncb2651
   Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847
   Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898
   Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859
   Hattori T, 2007, CANCER RES, V67, P10789, DOI 10.1158/0008-5472.CAN-07-2033
   Heride C, 2014, CURR BIOL, V24, pR215, DOI 10.1016/j.cub.2014.02.002
   Hershko A., 2012, ANNU REV BIOCHEM, V81, P203
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Huh J, 2013, MOL CELL BIOL, V33, P213, DOI 10.1128/MCB.00847-12
   Imaki H, 2003, CANCER RES, V63, P4607
   Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038
   Iwai K, 2014, BBA-MOL CELL RES, V1843, P129, DOI 10.1016/j.bbamcr.2013.03.011
   Janzer A, 2012, J BIOL CHEM, V287, P30984, DOI 10.1074/jbc.M112.341040
   Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304
   Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607
   Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194
   Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100
   Katayama H, 2010, BBA-GENE REGUL MECH, V1799, P829, DOI 10.1016/j.bbagrm.2010.09.004
   Katoh H, 2011, MOL CELL, V44, P770, DOI 10.1016/j.molcel.2011.10.012
   Kawakami E, 2015, MECH DEVELOP, V135, P31, DOI 10.1016/j.mod.2014.10.001
   Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x
   Kitagawa K, 2014, MOL CELL BIOL, V34, P2732, DOI 10.1128/MCB.01549-13
   Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401
   Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203
   Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328
   Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065
   Kurashige J, 2012, BRIT J CANCER, V106, P182, DOI 10.1038/bjc.2011.509
   Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35
   Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098
   Lau AW, 2012, FRONT BIOSCI-LANDMRK, V17, P2197, DOI 10.2741/4045
   le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4
   Lerner M, 2011, CELL CYCLE, V10, P2172, DOI 10.4161/cc.10.13.16248
   Li DN, 2015, BIOCHEM BIOPH RES CO, V458, P941, DOI 10.1016/j.bbrc.2015.02.089
   Li XR, 2010, ENDOCRINOLOGY, V151, P2462, DOI 10.1210/en.2009-1150
   Li Z, 2015, MOL CANCER RES, V13, P584, DOI 10.1158/1541-7786.MCR-14-0277-T
   Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007
   Liu Y, 2015, J BIOL CHEM, V290, P11843, DOI 10.1074/jbc.M114.629931
   Lozano T, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00294
   Lu YZ, 2012, J BIOL CHEM, V287, P41014, DOI 10.1074/jbc.M112.407106
   Luijsterburg MS, 2012, CURR OPIN CELL BIOL, V24, P439, DOI 10.1016/j.ceb.2012.03.008
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012
   Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004
   Nakajima T, 2015, J BIOL CHEM, V290, P10368, DOI 10.1074/jbc.M114.613018
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547
   Pierce NW, 2013, CELL, V153, P206, DOI 10.1016/j.cell.2013.02.024
   Qi FF, 2015, CLIN CANCER RES, V21, P3071, DOI 10.1158/1078-0432.CCR-14-2785
   Rodier G, 2008, EMBO J, V27, P679, DOI 10.1038/emboj.2008.6
   Sanchez N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065671
   Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011
   Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559
   Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259
   Schülein-Völk C, 2014, CELL REP, V9, P1099, DOI 10.1016/j.celrep.2014.09.057
   Shim EH, 2003, CANCER RES, V63, P1583
   Shimada M, 2009, CANCER SCI, V100, P866, DOI 10.1111/j.1349-7006.2009.01122.x
   Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432
   Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582
   Stamatopoulos B, 2009, BLOOD, V113, P5237, DOI 10.1182/blood-2008-11-189407
   Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076
   Sun W, 2010, CELL RES, V20, P1158, DOI 10.1038/cr.2010.134
   Suzuki S, 2007, AM J PATHOL, V171, P473, DOI 10.2353/ajpath.2007.070279
   Suzuki S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036249
   Suzuki S, 2011, GENES CELLS, V16, P1110, DOI 10.1111/j.1365-2443.2011.01553.x
   Takeyama H, 2014, MOL CANCER THER, V13, P976, DOI 10.1158/1535-7163.MCT-13-0571
   Tan MKM, 2011, MOL CELL BIOL, V31, P3687, DOI 10.1128/MCB.05746-11
   Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815
   Tsukada J, 2011, CYTOKINE, V54, P6, DOI 10.1016/j.cyto.2010.12.019
   Van Rechem C, 2011, J BIOL CHEM, V286, P30462, DOI 10.1074/jbc.M111.273508
   Vashisht AA, 2009, SCIENCE, V326, P718, DOI 10.1126/science.1176333
   Viñas-Castells R, 2014, NUCLEIC ACIDS RES, V42, P1079, DOI 10.1093/nar/gkt935
   Viñas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995
   Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129
   Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005
   Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017
   Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563
   Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200
   Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290
   Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7
   Welcker M, 2013, GENE DEV, V27, P2531, DOI 10.1101/gad.229195.113
   Welcker M, 2011, MOL CELL BIOL, V31, P1214, DOI 10.1128/MCB.01347-10
   Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003
   Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304
   Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459
   Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825
   Xu YF, 2010, J BIOL CHEM, V285, P34439, DOI 10.1074/jbc.M110.152306
   Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159
   Yumimoto K, 2015, J CLIN INVEST, V125, P621, DOI 10.1172/JCI78782
   Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286
   Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030
   Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470
   Zou CB, 2013, J BIOL CHEM, V288, P6306, DOI 10.1074/jbc.M112.426882
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 137
TC 31
Z9 36
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2016
VL 16
IS 2
BP 119
EP 129
DI 10.2174/1568009616666151112122231
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DG5GJ
UT WOS:000372104500004
PM 26560120
DA 2025-01-12
ER

PT J
AU Ashaie, MA
   Chowdhury, EH
AF Ashaie, Maeirah Afzal
   Chowdhury, Ezharul Hoque
TI Cadherins: The Superfamily Critically Involved in Breast Cancer
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Breast cancer; cell adhesion; cadherins; CDH1; CDH2; epigenetic
   silencing; EMT; tumor repressor; transcriptional factors; signaling
   pathways
ID EPITHELIAL-MESENCHYMAL TRANSITION; VASCULAR ENDOTHELIAL-CADHERIN;
   CANDIDATE TUMOR-SUPPRESSOR; INVASIVE DUCTAL CARCINOMA; CELL-ADHESION
   MOLECULES; LYMPH-NODE METASTASIS; REPRESSES E-CADHERIN; SEE VOL. 9;
   P-CADHERIN; TGF-BETA
AB Breast cancer, one of the leading causes of mortality and morbidity among females, is regulated in part by diverse classes of adhesion molecules one of which is known as cadherins. Located at adherens junctions, the members of this superfamily are responsible for upholding proper cell-cell adhesion. Cadherins possess diverse structures and functions and any alteration in their structures or functions causes impeding of normal mammary cells development and maintenance, thus leading to breast malignancy. E-, N-, P-, VE-, Proto-, desmosomal and FAT cadherins have been found to regulate breast cancer in positive as well as negative fashion, whereby both E-cadherin (CDH1) and N-cadherin (CDH2) contribute significantly towards transitioning from epithelial state to mesenchymal state (EMT) and enacting the abnormal cells to invade and metastasize nearby and distant tissues. Aberration in gene expression of cadherins can be either due to somatic or epigenetic silencing or via transcriptional factors. Besides other cadherins, E-cadherin which serves as hallmark of EMT is associated with several regulatory factors such as Snail, Slug, Twist, Zeb, KLF4, NFI, TBX2, SIX, b-Myb, COX-2, Arf6, FOXA2, GATA3 and SMAR1, which modulate E-cadherin gene transcription to promote or represses tumor invasion and colonization. Signaling molecules such as Notch, TGF-beta, estrogen receptors, EGF and Wnt initiate numerous signaling cascades via these vital factors of cell programming, controlling expression of E-cadherin at transcriptional (mRNA) and protein level. Thus, interactions of cadherins with their roles in tumor suppression and oncogenic transformation can be beneficial in providing valuable insights for breast cancer diagnosis and therapeutics development.
C1 [Ashaie, Maeirah Afzal; Chowdhury, Ezharul Hoque] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia.
C3 Monash University
RP Chowdhury, EH (通讯作者)，Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia.
EM md.ezharul.hoque@monash.edu
RI ashaie, maeirah/N-8539-2019; Chowdhury, Ezharul/Y-5249-2019
OI Chowdhury, Ezharul Hoque/0000-0002-5705-841X
FU Ministry of Higher Education (MOHE), Malaysia
   [FRGS/2/2013/SG05/MUSM/02/2]
FX The work was supported by a research grant (FRGS/2/2013/SG05/MUSM/02/2)
   of the Ministry of Higher Education (MOHE), Malaysia.
CR ElMoneim HMA, 2011, CLINICS, V66, P1765, DOI 10.1590/S1807-59322011001000015
   Adhikary A, 2014, J BIOL CHEM, V289, P25431, DOI 10.1074/jbc.M113.527267
   Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007
   Aithal MGS, 2013, J GENET, V92, P667, DOI 10.1007/s12041-013-0284-5
   Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151
   Albergaria A, 2011, INT J DEV BIOL, V55, P811, DOI 10.1387/ijdb.113382aa
   Albergaria A, 2010, HUM MOL GENET, V19, P2554, DOI 10.1093/hmg/ddq134
   Andrews JL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3065
   [Anonymous], 2005, HIPPOKRATIA
   Apostolopoulou M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033289
   Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064
   Bajpai S, 2009, J BIOL CHEM, V284, P18252, DOI 10.1074/jbc.M109.000661
   Baranwal S, 2009, BIOCH BIOPHYS RES CO, V384
   Bastid J, 2012, CANCER METAST REV, V31, P277, DOI 10.1007/s10555-011-9344-6
   Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1
   Ben Hamida A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-28
   Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731
   Bernardes N, 2014, INT J BIOCHEM CELL B, V50, P1, DOI 10.1016/j.biocel.2014.01.023
   Berx G, 2009, COLD SPRING HARBOR P, V1
   Bierie B, 2009, CELL CYCLE, V8, P3319, DOI 10.4161/cc.8.20.9727
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033
   Bocca C, 2014, EXPERT OPIN THER TAR, V18, P121, DOI 10.1517/14728222.2014.860447
   Bock C, 2014, J CANCER RES CLIN, V140, P1873, DOI 10.1007/s00432-014-1750-z
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Boscher C, 2012, J BIOL CHEM, V287, P32940, DOI 10.1074/jbc.M112.353334
   Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200
   Brambert PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117310
   Breier G, 2014, CELL TISSUE RES, V355, P523, DOI 10.1007/s00441-014-1851-7
   Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007
   Brouxhon SM, 2013, CLIN CANCER RES, V19, P3234, DOI 10.1158/1078-0432.CCR-12-2747
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cao YW, 2015, KAOHSIUNG J MED SCI, V31, P70, DOI 10.1016/j.kjms.2014.11.008
   Cardamone MD, 2009, P NATL ACAD SCI USA, V106, P7420, DOI 10.1073/pnas.0903033106
   Chen A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-552
   Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486
   Chen Y, 2013, BIOCHEM BIOPH RES CO, V430, P1083, DOI 10.1016/j.bbrc.2012.12.034
   Chiang KC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08686
   Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808
   Chitaev NA, 1997, J CELL BIOL, V138, P193, DOI 10.1083/jcb.138.1.193
   Christgen M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0517-z
   Chu IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061125
   Chung S, 2013, ONCOGENE, V32, P422, DOI 10.1038/onc.2012.65
   Clementz AG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2900
   Cleton-Jansen AM, 2002, BREAST CANCER RES, V4, P5, DOI 10.1186/bcr416
   Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141
   Coletta RD, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-4
   Côme C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478
   Connolly EC, 2011, CURR PHARM BIOTECHNO, V12, P2138
   Cool M, 1999, CANCER RES, V59, P2438
   Cristofanilli M, 2003, ONCOLOGIST, V8, P141, DOI 10.1634/theoncologist.8-2-141
   Cubillo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059948
   Davies EL, 1997, INT J ONCOL, V11, P415
   Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld
   Devemy E, 2009, PEPTIDES, V30, P1539, DOI 10.1016/j.peptides.2009.05.010
   Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293
   Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514
   Ding XM, 2013, J BIOL CHEM, V288, P10241, DOI 10.1074/jbc.M112.443655
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911-011-9217-1
   Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481
   Dubois-Marshall S, 2011, CLIN EXP METASTAS, V28, P811, DOI 10.1007/s10585-011-9412-x
   Fan XJ, 2013, HUM PATHOL, V44, P173, DOI 10.1016/j.humpath.2012.03.029
   Fang X, 2011, ONCOGENE, V30, P4707, DOI 10.1038/onc.2011.181
   Foster KW, 2000, CANCER RES, V60, P6488
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Fukagawa A, 2015, CANCER MED-US, V4, P125, DOI 10.1002/cam4.347
   de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8
   Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014
   Geng F, 2012, J CELL SCI, V125, P2615, DOI 10.1242/jcs.096735
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Ghiabi P, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0386-3
   Giampietro C, 2012, BLOOD, V119, P2159, DOI 10.1182/blood-2011-09-381012
   Globocan.iarc.fr, 2015, GLOBOCAN CANC FACT S
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Haidari M, 2013, LIFE SCI, V93, P994, DOI 10.1016/j.lfs.2013.10.027
   Haidari M, 2012, J BIOL CHEM, V287, P32981, DOI 10.1074/jbc.M112.395905
   Hajra KM, 2002, CANCER RES, V62, P1613
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2
   Harris PJ, 2012, EXPERT OPIN THER TAR, V16, P131, DOI 10.1517/14728222.2011.645808
   Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3
   Heimann R, 2000, CANCER RES, V60, P298
   Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029
   Hollestelle A, 2013, BREAST CANCER RES TR, V138, P47, DOI 10.1007/s10549-013-2415-3
   Hollnagel A, 2002, MOL CELL BIOL, V22, P4760, DOI 10.1128/MCB.22.13.4760-4770.2002
   Holthöfer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0
   Huang W, 2008, AM J PATHOL, V172, P893, DOI 10.2353/ajpath.2008.070899
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618
   Ito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118336
   Ivanov DB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1174, DOI 10.1023/A:1012445316415
   Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jeschke U, 2007, ANTICANCER RES, V27, P1969
   Jiang JA, 2011, CANCER BIOL THER, V11, P714, DOI 10.4161/cbt.11.8.15274
   Jiang WG, 2000, SURG ONCOL, V9, P151, DOI 10.1016/S0960-7404(01)00010-X
   Johansson EM, 2005, MOL ENDOCRINOL, V19, P992, DOI 10.1210/me.2004-0359
   Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735
   Katoh M, 2012, INT J ONCOLOGY  1017
   Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0
   Kaufmann U, 2000, J CELL SCI, V113, P4121
   Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x
   Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9
   Kim SA, 2011, P NATL ACAD SCI USA, V108, P9857, DOI 10.1073/pnas.1019003108
   Kim SY, 2011, CELL ADHES MIGR, V5, P97, DOI 10.4161/cam.5.2.14374
   Klus GT, 2001, INT J ONCOL, V19, P169
   Koopmansch B, 2013, BIOCHEM BIOPH RES CO, V431, P652, DOI 10.1016/j.bbrc.2013.01.070
   Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281
   Kuphal S, 2011, MELANOMA DEVELOPMENT: MOLECULAR BIOLOGY, GENETICS AND CLINICAL APPLICATION, P181, DOI 10.1007/978-3-7091-0371-5_9
   Labelle M, 2008, CANCER RES, V68, P1388, DOI 10.1158/0008-5472.CAN-07-2706
   Lagendijk AK, 2015, CURR TOP DEV BIOL, V112, P325, DOI 10.1016/bs.ctdb.2014.11.024
   Lee HK, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1118-z
   Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53
   Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082
   Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131
   Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x
   Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018
   Li X, 2014, ONCOGENE, V33, P4077, DOI 10.1038/onc.2013.370
   Li Y, 2015, ONCOTARGET, V6, P4345, DOI 10.18632/oncotarget.2999
   Li YQ, 2015, INT J ONCOL, V46, P1461, DOI 10.3892/ijo.2015.2878
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Liu RC, 2013, J BIOMOL STRUCT DYN, V31, P1137, DOI 10.1080/07391102.2012.726530
   Liu T, 2013, J SURG ONCOL, V107, P188, DOI 10.1002/jso.23240
   Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lopez D, 2009, ARCH BIOCHEM BIOPHYS, V482, P77, DOI 10.1016/j.abb.2008.11.016
   López-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741
   Lowndes M, 2014, J CELL SCI, V127, P2339, DOI 10.1242/jcs.146316
   Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147
   Lu SY, 2005, INT J CANCER, V116, P847, DOI 10.1002/ijc.21142
   Madhavan M, MOD PATHOL, V14, P423
   Maître JL, 2013, CURR BIOL, V23, pR626, DOI 10.1016/j.cub.2013.06.019
   Malhotra GK, 2010, CANCER BIOL THER, V10, P955, DOI 10.4161/cbt.10.10.13879
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Mansel R.E., 2007, METASTASIS BREAST CA
   Markiewicz A, 2014, AM J TRANSLATIONAL R, V6
   Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010
   Martinez I, 2011, CANCER RES, V71, P5370, DOI 10.1158/0008-5472.CAN-11-1044
   Masterson J, 2007, CELLS TISSUES ORGANS, V185, P175, DOI 10.1159/000101318
   McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691
   Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396
   Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354
   Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Morishige M, 2008, NAT CELL BIOL, V10, P85, DOI 10.1038/ncb1672
   Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006
   Mukherjee S, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt506
   Nakagawa M, 2011, ANTICANCER RES, V31, P2389
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nelson WJ, 2013, PROG MOL BIOL TRANSL, V116
   Niessen CM, 2011, PHYSL REV, V91
   Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677
   Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Oesterreich S, 2003, CANCER RES, V63, P5203
   Okegawa T, 2004, ACTA BIOCHIM POL, V51, P445
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005
   Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484
   Pang M.-F., 2015, ONCOGENE, P1
   Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Patel SD, 2006, CELL, V124, P1255, DOI 10.1016/j.cell.2005.12.046
   Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17
   Peinado H, 2005, CELL CYCLE, V4, P1749, DOI 10.4161/cc.4.12.2224
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Pérez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200
   Phillips S, 2014, CELL ADHES MIGR, V8, P578, DOI 10.4161/19336918.2014.972740
   PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Pötter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325
   Pultz BD, 2014, J CANCER, V5, P559, DOI 10.7150/jca.8925
   Qi C, 2009, INT J CANCER, V124, P793, DOI 10.1002/ijc.23775
   Qian X, 2014, ONCOGENE, V33, P3411, DOI 10.1038/onc.2013.310
   Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552
   Redies C, 2005, CELL MOL LIFE SCI, V62, P2840, DOI 10.1007/s00018-005-5320-z
   Reed AEM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0519-x
   Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286
   Rezaei M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3367
   Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338
   Ribeiro AS, 2013, J PATHOL, V229, P705, DOI 10.1002/path.4143
   Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408
   Ross JS, 2004, EXPERT REV MOL DIAGN, V4, P169, DOI 10.1586/14737159.4.2.169
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Roy SS, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/654698
   Sabe H, 2008, CELL ADHES MIGR, V2, P71, DOI 10.4161/cam.2.2.6191
   Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x
   Sanchez-Tilló E, 2011, AM J CANCER RES, V1, P897
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Schackmann RCJ, 2013, CANCER RES, V73, P4937, DOI 10.1158/0008-5472.CAN-13-0180
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229
   Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33
   Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3
   Shapiro L, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003053
   Shargh SA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0250-y
   Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249
   Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532
   Singh-Ranger G, 2002, EUR J SURG ONCOL, V28, P729, DOI 10.1053/ejso.2002.1329
   Singh-Ranger G, 2008, BREAST CANCER RES TR, V109, P189, DOI 10.1007/s10549-007-9641-5
   Singhai R, 2011, N AM J MED SCI, V3, P227, DOI 10.4297/najms.2011.3227
   Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11
   Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73
   Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245
   Sousa B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-734
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Sui XB, 2012, MOL BIOL REP, V39, P1105, DOI 10.1007/s11033-011-0837-8
   Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2
   Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161
   Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876
   Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1
   Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398
   Tao D, 2014, MED ONCOL, V32, P1
   Tao DY, 2014, INT J CLIN EXP PATHO, V7, P5819
   Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946
   Teng Y, 2014, CLIN EXP METASTAS, V31, P367, DOI 10.1007/s10585-013-9621-6
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Thomason HA, 2010, BIOCHEM J, V429, P419, DOI 10.1042/BJ20100567
   Tiwari N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057329
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Tong D, 2007, ONCOL RES, V16, P465, DOI 10.3727/096504007783338322
   Troyanovsky RB, 2007, MOL BIOL CELL, V18, P4343, DOI 10.1091/mbc.E07-01-0084
   Troyanovsky S, 2005, EUR J CELL BIOL, V84, P225, DOI 10.1016/j.ejcb.2004.12.009
   Tsang JYS, 2013, HUM PATHOL, V44, P2782, DOI 10.1016/j.humpath.2013.07.029
   Turashvili G, 2011, MODERN PATHOL, V24, P64, DOI 10.1038/modpathol.2010.189
   Valderrama F, 2008, NAT CELL BIOL, V10, P16, DOI 10.1038/ncb0108-16
   van Horssen R, 2012, BREAST CANCER RES TR, V136, P365, DOI 10.1007/s10549-012-2261-8
   van Nes JGH, 2012, BREAST CANCER RES TR, V133, P49, DOI 10.1007/s10549-011-1684-y
   van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647
   van Schooneveld E, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0526-y
   Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965
   Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151
   Vieira AF, 2014, ONCOTARGET, V5, P679, DOI 10.18632/oncotarget.1459
   Villarejo A, 2014, J BIOL CHEM, V289, P930, DOI 10.1074/jbc.M113.528026
   Vincent PA, 2004, AM J PHYSIOL-CELL PH, V286, pC987, DOI 10.1152/ajpcell.00522.2003
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   Visscher DW, 2008, J NATL CANCER I, V100, P421, DOI 10.1093/jnci/djn036
   Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041355
   Wang CA, 2014, CANCER RES, V74, P7357, DOI 10.1158/0008-5472.CAN-14-0666
   Weber GF, 2011, J CELL SCI, V124, P1183, DOI 10.1242/jcs.064618
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Xu R, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0159-3
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang SZ, 2001, INT J ONCOL, V18, P541
   Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260
   Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
   Zhang CC, 2010, CLIN CANCER RES, V16, P5177, DOI 10.1158/1078-0432.CCR-10-1343
   Zhang Z, 2015, CANCER LETT, V361, P240, DOI 10.1016/j.canlet.2015.03.008
   Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhou FH, 2014, INT J CLIN EXP PATHO, V7, P8692
   Zhou Y, 2015, BIOCHEM BIOPH RES CO, V457, P141, DOI 10.1016/j.bbrc.2014.12.038
   Zou L, 2009, CELL MOTIL CYTOSKEL, V66, P1048, DOI 10.1002/cm.20407
NR 284
TC 57
Z9 63
U1 0
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 5
BP 616
EP 638
DI 10.2174/138161282205160127095338
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DG4VM
UT WOS:000372071200013
PM 26825466
DA 2025-01-12
ER

PT J
AU Ghandadi, M
   Sahebkar, A
AF Ghandadi, Morteza
   Sahebkar, Amirhossein
TI MicroRNA-34a and its Target Genes: Key Factors in Cancer Multidrug
   Resistance
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Cancer; chemotherapy; MicroRNA; miR-34a; multidrug resistance
ID STEM-LIKE CELLS; PROSTATE-CANCER; BREAST-CANCER; ABC TRANSPORTERS;
   TUMOR-SUPPRESSOR; DRUG-RESISTANCE; CARCINOMA CELLS; P-GLYCOPROTEIN;
   SMALL-MOLECULE; PC3 CELLS
AB Following the first small non-coding RNA identification in 1993, accumulated knowledge on the biogenesis, homeostasis and functional roles of microRNAs in different physiological and pathophysiological conditions has been discovered. MicroRNAs act through epigenetic regulation of gene expression. MiR-34a is a member of the MiR-34 family that is involved in p53 pathways, and is implicated in cell death/survival signaling. MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity. Deregulation of MiR-34a has been reported in several types of cancers. MiR-34a downregulation has been correlated with cancer multidrug resistance (MDR), which is a major challenge for successful cancer chemotherapy. MiR-34a mimetic agents have been shown to attenuate drug resistance in different cancer cell lines. This review focuses on the in vitro, experimental and clinical findings dealing with the role of miR-34a downregulation in MDR, and potential therapeutic opportunities arising from this role of miR-34a.
C1 [Ghandadi, Morteza] Mashhad Univ Med Sci, Dept Pharmaceut Biotechnol, Mashhad, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran.
   [Sahebkar, Amirhossein] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Metab Res Ctr, Perth, WA 6009, Australia.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; East Metropolitan Health Service; Royal Perth Hospital;
   University of Western Australia
RP Sahebkar, A (通讯作者)，Mashhad Univ Med Sci, Sch Med, Dept Med Biotechnol, POB 91779-48564, Mashhad, Iran.
EM sahebkara@mums.ac.ir
RI Sahebkar, Amirhossein/B-5124-2018; Ghandadi, Morteza/L-1257-2018
CR Akao Y, 2014, INT J MOL SCI, V15, P1392, DOI 10.3390/ijms15011392
   Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   Alikanoglu AS, 2014, J BUON, V19, P430
   An Y, 2009, EXPERT OPIN DRUG MET, V5, P1529, DOI 10.1517/17425250903228834
   Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2
   Bauer C, 2015, J IMMUNOTHER, V38, P116, DOI 10.1097/CJI.0000000000000073
   Cao WG, 2014, TUMOR BIOL, V35, P1287, DOI 10.1007/s13277-013-1171-7
   Chakraborty S, 2014, FEBS LETT, V588, P549, DOI 10.1016/j.febslet.2013.11.040
   Chen CZ, 2013, IMMUNOL REV, V253, P112, DOI 10.1111/imr.12060
   Chen F, 2012, J BIOCHEM MOL TOXIC, V26, P79, DOI 10.1002/jbt.20412
   Chen HJ, 2015, MOL CELL BIOCHEM, V406, P21, DOI 10.1007/s11010-015-2420-4
   Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108
   Choi CH, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-30
   Corcoran C, 2014, PROSTATE, V74, P1320, DOI 10.1002/pros.22848
   Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070
   Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Duffy M., 2013, TUMOR BIOL, P1
   Fan YN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108514
   Ladelfa MF, 2012, CANCER LETT, V325, P11, DOI 10.1016/j.canlet.2012.05.031
   Fleischmann A, 2012, PROSTATE, V72, P991, DOI 10.1002/pros.21504
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Fujita Y, 2008, BIOCHEM BIOPH RES CO, V377, P114, DOI 10.1016/j.bbrc.2008.09.086
   Gao Xiaohua, 2014, J Exp Ther Oncol, V10, P275
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007
   Hammond SM, 2015, ADV DRUG DELIV REV
   Hull ML, 2013, REPROD BIOMED ONLINE, V27, P515, DOI 10.1016/j.rbmo.2013.07.012
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119
   Kang L, 2015, CANCER SCI, V106, P700, DOI 10.1111/cas.12656
   Karnak D, 2010, CURR DRUG TARGETS, V11, P699, DOI 10.2174/138945010791170888
   Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3
   Kim HB, 2015, INT J BIOL SCI, V11, P923, DOI 10.7150/ijbs.10896
   Kiss B, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2014.12.005
   Kojima K, 2010, PROSTATE, V70, P1501, DOI 10.1002/pros.21185
   Kontos CK, 2014, ANTI-CANCER AGENT ME, V14, P353, DOI 10.2174/18715206113139990091
   Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996
   Lai MG, 2015, MOL MED REP, V11, P3301, DOI 10.3892/mmr.2015.3182
   Li H, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-8
   Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5
   Li XJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.270
   Li XJ, 2012, ARCH MED RES, V43, P514, DOI 10.1016/j.arcmed.2012.09.007
   Li Y, 2010, CURR MED CHEM, V17, P786, DOI 10.2174/092986710790514507
   Li Y, 2014, ANTI-CANCER DRUG, V25, P423, DOI 10.1097/CAD.0000000000000074
   Lin XJ, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/258695
   Liu C, 2014, MOL CELL BIOCHEM, V393, P265, DOI 10.1007/s11010-014-2069-4
   Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Loebinger MR, 2008, BRIT J CANCER, V98, P380, DOI 10.1038/sj.bjc.6604185
   Ma W, 2015, ONCOTARGET, V6, P10432, DOI 10.18632/oncotarget.3394
   Mao SS, 2015, PROTEIN CELL, V6, P529, DOI 10.1007/s13238-015-0168-y
   Do MT, 2014, FREE RADICAL BIO MED, V74, P21, DOI [10.1016/j.freeradbiomed2014.06.010, 10.1016/j.freeradbiomed.2014.06.010]
   Misso G, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47
   Mortensen MM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-859
   Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007
   Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340
   Ogawa T, 2012, CANCER SCI, V103, P1737, DOI 10.1111/j.1349-7006.2012.02338.x
   Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Srivastava D, 2015, COLD SPRING HARB PER, P7
   Szulwach KE, 2010, J CELL BIOL, V189, P127, DOI 10.1083/jcb.200908151
   Tüfekci KU, 2014, METHODS MOL BIOL, V1107, P33, DOI 10.1007/978-1-62703-748-8_3
   Varadi Andras, 2002, Novartis Found Symp, V243, P54
   Vinall RL, 2012, INT J CANCER, V130, P2526, DOI 10.1002/ijc.26256
   Wang HX, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0130-x
   Wang X, 2013, CANCER BIOTHER RADIO, V28, P45, DOI 10.1089/cbr.2012.1218
   Weeraratne SD, 2011, NEURO-ONCOLOGY, V13, P165, DOI 10.1093/neuonc/noq179
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
   Yang F, 2014, TECHNOL CANCER RES T, V13, P77, DOI 10.7785/tcrt.2012.500364
   Zeng L, 2014, GENE THER, V21, P37, DOI 10.1038/gt.2013.55
   Zenz T, 2009, BLOOD, V113, P3801, DOI 10.1182/blood-2008-08-172254
   Zhou JY, 2014, CANCER LETT, V351, P265, DOI 10.1016/j.canlet.2014.06.010
NR 76
TC 34
Z9 38
U1 0
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 7
BP 933
EP 939
DI 10.2174/1381612822666151209153729
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DG4VQ
UT WOS:000372071600016
PM 26648462
DA 2025-01-12
ER

PT J
AU Lim, JA
   Juhnn, YS
AF Lim, Jeong Ah
   Juhnn, Yong-Sung
TI Isoproterenol increases histone deacetylase 6 expression and cell
   migration by inhibiting ERK signaling via PKA and Epac pathways in human
   lung cancer cells
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID PROTEIN-KINASE; BREAST-CANCER; STRESS RESILIENCE; REGULATED KINASE;
   PROSTATE-CANCER; HDAC6; CAMP; INFLAMMATION; INVASION; BINDING
AB Stress conditions are correlated with tumor growth, progression and metastasis. We hypothesized that stress signals might affect tumor progression via epigenetic control of gene expression and investigated the effects of stress signals on the expression levels of histone deacetylases (HDACs) and the underlying mechanisms of these effects in lung cancer cells. Treatment with isoproterenol (ISO), an analog of the stress signal epinephrine, increased the expression of HDAC6 protein and mRNA in H1299 lung cancer cells. ISO caused the deacetylation of alpha-tubulin and stimulated cell migration in an HDAC6-dependent manner. HDAC6 expression was increased by treatment with selective activators of cAMP-dependent protein kinase (PKA) or exchange protein activated by cAMP (Epac). ISO activated Rap1 via Epac, and constitutively active Rap1A increased the HDAC6 level; however, the knockdown of Rap1A decreased the 8-(4-cholorophenylthio)-2'-O-methyl-cAMP-induced increase in HDAC6 expression. Both PKA and Rap1A decreased c-Raf activation to inhibit extracellular signal-regulated kinase (ERK) signaling. Inhibition of ERK caused an increase in HDAC6 expression, and constitutively active MEK1 decreased the ISO-induced HDAC6 expression. We concluded that ISO increases HDAC6 expression via a PKA/Epac/ERK-dependent pathway that stimulates the migration of lung cancer cells. This study suggests that stress signals can stimulate the migration of cancer cells by inducing HDAC6 expression in lung cancer cells.
C1 [Juhnn, Yong-Sung] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 103 Daehak Ro, Seoul 110799, South Korea.
   [Juhnn, Yong-Sung] Seoul Natl Univ, Coll Med, Canc Res Inst, 103 Daehak Ro, Seoul 110799, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Juhnn, YS (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 103 Daehak Ro, Seoul 110799, South Korea.; Juhnn, YS (通讯作者)，Seoul Natl Univ, Coll Med, Canc Res Inst, 103 Daehak Ro, Seoul 110799, South Korea.
EM juhnn@snu.ac.kr
FU National R&D Program for Cancer Control, Ministry of Health and Welfare,
   Republic of Korea [0720540]; Basic Science Research Program through the
   National Research Foundation - Ministry of Education, Science, and
   Technology [2012R1A1A2044374]
FX This work was supported by a grant from the National R&D Program for
   Cancer Control, Ministry of Health and Welfare, Republic of Korea
   (0720540) and by the Basic Science Research Program through the National
   Research Foundation funded by the Ministry of Education, Science, and
   Technology (2012R1A1A2044374).
CR Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109
   Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4
   Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038
   Birdsey GM, 2012, BLOOD, V119, P894, DOI 10.1182/blood-2011-04-350025
   Bok J, 2003, J NEUROSCI, V23, P777
   Covington HE, 2009, J NEUROSCI, V29, P11451, DOI 10.1523/JNEUROSCI.1758-09.2009
   Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200
   Espallergues J, 2012, J NEUROSCI, V32, P4400, DOI 10.1523/JNEUROSCI.5634-11.2012
   Flaisher-Grinberg S, 2012, P NATL ACAD SCI USA, V109, P9167, DOI 10.1073/pnas.1205565109
   Gerits N, 2008, CELL SIGNAL, V20, P1592, DOI 10.1016/j.cellsig.2008.02.022
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gold PW, 2015, MOL PSYCHIATR, V20, P32, DOI 10.1038/mp.2014.163
   Hsieh TH, 2012, FASEB J, V26, P778, DOI 10.1096/fj.11-191742
   Jochems J, 2015, BIOL PSYCHIAT, V77, P345, DOI 10.1016/j.biopsych.2014.07.036
   Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898
   Kim EJ, 2015, J BIOL CHEM, V290, P9604, DOI 10.1074/jbc.M114.633198
   Kim SY, 2008, J BIOL CHEM, V283, P1350, DOI 10.1074/jbc.M702344200
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Lefkimmiatis K, 2014, PHARMACOL THERAPEUT, V143, P295, DOI 10.1016/j.pharmthera.2014.03.008
   Li YP, 2013, J BIOL CHEM, V288, P27646, DOI 10.1074/jbc.M113.463067
   Li Y, 2013, FEBS J, V280, P775, DOI 10.1111/febs.12079
   Lillberg K, 2003, AM J EPIDEMIOL, V157, P415, DOI 10.1093/aje/kwg002
   Luan B, 2014, CELL METAB, V19, P1058, DOI 10.1016/j.cmet.2014.03.024
   Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137
   Nikam VS, 2011, AM J RESP CELL MOL, V45, P692, DOI 10.1165/rcmb.2010-0240OC
   Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017
   Powell ND, 2013, BRAIN BEHAV IMMUN, V30, pS41, DOI 10.1016/j.bbi.2012.06.015
   Schuller HM, 2013, CANCER BIOMARK, V13, P133, DOI 10.3233/CBM-130323
   Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698
   Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2
   Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431
   Valenzuela-Fernández A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Wang LP, 2015, EUR REV MED PHARMACO, V19, P1170
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wittchen Erika S, 2011, Small GTPases, V2, P65
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033
NR 38
TC 24
Z9 26
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JAN
PY 2016
VL 48
AR e204
DI 10.1038/emm.2015.98
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA DC4AX
UT WOS:000369163200004
PM 27534532
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Eskander, RN
   Ali, S
   Dellinger, T
   Lankes, HA
   Randall, LM
   Ramirez, NC
   Monk, BJ
   Walker, JL
   Eisenhauer, E
   Hoang, BH
AF Eskander, Ramez N.
   Ali, Shamshad
   Dellinger, Thanh
   Lankes, Heather A.
   Randall, Leslie M.
   Ramirez, Nilsa C.
   Monk, Bradley J.
   Walker, Joan L.
   Eisenhauer, Eric
   Hoang, Bang H.
TI Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted
   Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid
   Adenocarcinoma <i>An NRG Oncology</i>/<i>Gynecologic Oncology Group
   Study</i>
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
DE Dkk3; SFRP1; SFRP4; Uterine cancer; Wnt pathway
ID BETA-CATENIN EXPRESSION; EPIGENETIC INACTIVATION; MUTATIONAL ANALYSIS;
   ANTAGONIST SFRP1; DOWN-REGULATION; BREAST-CANCER; PHASE-II; GENE; CELLS;
   REIC/DKK-3
AB Objective The aim of the study was to determine the differential expression patterns of the wingless-type (Wnt) pathway inhibitors Dkk3 (Dickkopf 3), SFRP1 (secreted frizzled-related protein 1), and SFRP4 in normal mullerian tissue and endometrial endometrioid adenocarcinoma specimens.
   Methods Messenger RNA (mRNA) and protein levels of the Wnt pathway inhibitors Dkk3, SFRP1, and SFRP4 were evaluated by real-time reverse transcription-polymerase chain reaction and Western blot analysis. A total of 87 human tissue specimens were obtained from 60 women who participated in Gynecologic Oncology Group protocol 210. Twenty-seven normal mullerian tissues, 32 early-stage, and 28 advanced-stage endometrial endometrioid cancer specimens were analyzed.
   Results Median age for this cohort was 60 years, with median body mass index of 32 kg/m(2). There was a difference in Dkk3 protein expression between normal mullerian tissues and primary endometrial endometrioid adenocarcinoma samples (P = 0.05). There was down-regulation of Dkk3, SFRP1, and SFRP4 mRNA expression in patients with high-grade disease (P = 0.08, 0.06, and 0.05, respectfully). Furthermore, a decrease in SFRP1 and SFPR4 mRNA expression was noted in patients with a diagnosis of locoregional and distant disease recurrence. Lastly, a trend toward decreased progression-free survival in patients with low Dkk3, SFRP1, and SFRP4 mRNA expression levels was noted.
   Conclusions Wnt pathway inhibitor (Dkk3, sFRP1, and/or sFRP4) expression was down-regulated in patients with high-grade disease and was associated with locoregional and distant disease recurrence. Despite sample size (power) limitations, these results support previous preclinical studies and may suggest a therapeutic role for Wnt signaling in endometrial cancer.
C1 [Eskander, Ramez N.; Randall, Leslie M.] Univ Calif Irvine, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Orange, CA 92868 USA.
   [Ali, Shamshad] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA.
   [Dellinger, Thanh; Lankes, Heather A.] City Hope Comprehens Canc Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol, Duarte, CA USA.
   [Ramirez, Nilsa C.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA.
   [Monk, Bradley J.] Creighton Univ, Univ Arizona, St Josephs Hosp & Med Ctr,Canc Ctr, Div Gynecol Oncol,Dept Obstet & Gynecol,Sch Med, Phoenix, AZ USA.
   [Walker, Joan L.] Univ Oklahoma, Dept Obstet & Gynecol, Div Gynecol Oncol, Oklahoma City, OK USA.
   [Eisenhauer, Eric] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Cincinnati, OH 45267 USA.
   [Hoang, Bang H.] Univ Calif Irvine, Dept Orthoped Surg, Orange, CA 92868 USA.
C3 University of California System; University of California Irvine;
   Roswell Park Comprehensive Cancer Center; City of Hope; University
   System of Ohio; Ohio State University; Nationwide Childrens Hospital;
   Research Institute at Nationwide Children's Hospital; Creighton
   University; University of Arizona; St. Joseph's Hospital and Medical
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University System of Ohio; University of Cincinnati;
   University of California System; University of California Irvine
RP Eskander, RN (通讯作者)，Univ Calif Irvine, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, 101 City Dr S,Bldg 56,Suite 260, Orange, CA 92868 USA.
EM Eskander@uci.edu
OI DELLINGER, THANH/0000-0003-1855-1989
FU National Cancer Institute Grants: NRG Oncology (NRG Oncology Operations
   Grant) [1 U10CA180822, U10CA180868]; GOG Statistical and Data Center
   [CA37517]; National Cancer Institute [P30CA062203] Funding Source: NIH
   RePORTER
FX The study was supported by National Cancer Institute Grants: NRG
   Oncology 1 U10CA180822, U10CA180868 (NRG Oncology Operations Grant),
   Gynecologic Oncology Group GOG) Administrative Office and the GOG Tissue
   Bank (CA27469), the GOG Statistical and Data Center (CA37517) as well as
   an institutional NIH-T32 training grant (Ruth L. Kirschenstein NRSA
   Institutional Research Grant, 2 T32 CA06039611).
CR Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2011, J CLIN ONCOL
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117
   Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505
   Boras-Granic Kata, 2008, Organogenesis, V4, P116
   Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039
   Chim CS, 2008, J CLIN PATHOL, V61, P1214, DOI 10.1136/jcp.2008.060152
   DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266
   Dellinger TH, 2012, GYNECOL ONCOL, V126, P259, DOI 10.1016/j.ygyno.2012.04.026
   Dihlmann S, 2001, ONCOGENE, V20, P645, DOI 10.1038/sj.onc.1204123
   Dunlap J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.6529
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Gatcliffe TA, 2008, INT J GYNECOL CANCER, V18, P954, DOI 10.1111/j.1525-1438.2007.01127.x
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hrzenjak A, 2004, J PATHOL, V204, P19, DOI 10.1002/path.1616
   Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138
   Ikeda T, 2000, ONCOL REP, V7, P323
   Jiang T, 2010, J OBSTET GYNAECOL RE, V36, P769, DOI 10.1111/j.1447-0756.2010.01234.x
   Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913
   Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723
   Mackay H, 2011, J CLIN ONCOL, V29
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924
   Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W
   Nozaki I, 2001, INT J ONCOL, V19, P117
   Obel Jennifer C, 2006, Clin Adv Hematol Oncol, V4, P459
   Oza AM, 2011, J CLIN ONCOL, V29, P3278, DOI 10.1200/JCO.2010.34.1578
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Pendás-Franco N, 2008, ANTICANCER RES, V28, P2613
   Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850
   Sakaguchi M, 2009, J BIOL CHEM, V284, P14236, DOI 10.1074/jbc.M808002200
   Schlosshauer PW, 2000, MODERN PATHOL, V13, P1066, DOI 10.1038/modpathol.3880196
   Scholten AN, 2003, J PATHOL, V201, P460, DOI 10.1002/path.1402
   Schwanhäusser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5
   Slomovitz BM, 2015, J CLIN ONCOL, V33, P930, DOI 10.1200/JCO.2014.58.3401
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943
   Tang YX, 2008, CANCER PREV RES, V1, P439, DOI 10.1158/1940-6207.CAPR-08-0165
   Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067
   Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   You A, 2011, J CANCER RES CLIN, V137, P621, DOI 10.1007/s00432-010-0916-6
NR 50
TC 15
Z9 17
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD JAN
PY 2016
VL 26
IS 1
BP 125
EP 132
DI 10.1097/IGC.0000000000000563
PG 8
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA DA1DU
UT WOS:000367537300017
PM 26397159
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Moisá, SJ
   Shike, DW
   Shoup, L
   Loor, JJ
AF Moisa, Sonia J.
   Shike, Daniel W.
   Shoup, Lindsay
   Loor, Juan J.
TI Maternal Plane of Nutrition During Late-Gestation and Weaning Age Alter
   Steer Calf Longissimus Muscle Adipogenic MicroRNA and Target Gene
   Expression
SO LIPIDS
LA English
DT Article
DE Nutrition; Epigenetics; Fetal programming; Marbling
ID 3T3-L1 ADIPOCYTE DIFFERENTIATION; SUBCUTANEOUS ADIPOSE DEPOTS; PREPARTUM
   SUPPLEMENT LEVEL; BREAST-CANCER CELLS; LIPID-METABOLISM;
   INSULIN-RESISTANCE; HOLSTEIN COWS; HUMAN OBESITY; ADIPONECTIN; TISSUE
AB The main objective was to evaluate if different planes of maternal nutrition during late gestation and weaning age alter microRNA (miRNA) and target gene expression in offspring longissimus muscle (LM). Early (EW) and normal weaned (NW) Angus x Simmental calves (n = 30) born to cows that were grazing endophyte-infected tall fescue and red clover pastures with no supplement [low plane of nutrition (LPN)], or supplemented with 2.3 and 9.1 kg of dried distiller's grains with solubles and soy hulls [medium and high plane of nutrition (MPN, HPN), respectively] during the last 105 +/- A 11 days of gestation were used. Biopsies of LM were harvested at 78 (early weaning), 187 (normal weaning) and 354 days of age. Results indicate a role of pro-adipogenic miRNA in the control of adipogenesis in LM of NW-MPN steers between 78 and 187 days of age through upregulation of (1) miR-103 which inhibits CAV1, a protein that destabilizes INSR and leads to insulin resistance; (2) miR-143 which inhibits DLK1, a protein that inhibits adipocyte differentiation; and (3) miR-21 which impairs TGFBR2-induced inhibition of adipocyte differentiation. Among the studied anti-adipogenic miRNA, cow plane of nutrition resulted in downregulation of miR-34a expression in MPN steers compared with HPN and LPN at 78 days of age. Data for miR-34a provided a potential sign of epigenetic regulation of LM in beef offspring due to the cow plane of nutrition during late gestation.
C1 [Moisa, Sonia J.; Loor, Juan J.] Univ Illinois, Dept Anim Sci, Mammalian NutriPhysioGenom, Urbana, IL 61801 USA.
   [Shike, Daniel W.; Shoup, Lindsay; Loor, Juan J.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA.
   [Loor, Juan J.] Univ Illinois, Div Nutr Sci, Illinois Informat Inst, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign;
   University of Illinois System; University of Illinois Urbana-Champaign;
   University of Illinois System; University of Illinois Urbana-Champaign
RP Loor, JJ (通讯作者)，Univ Illinois, Dept Anim Sci, Mammalian NutriPhysioGenom, 328 Mumford Hall, Urbana, IL 61801 USA.
EM jloor@uiuc.edu
RI Loor, Juan/H-3760-2012
OI Loor, Juan/0000-0003-1586-4365; MOISA, SONIA/0000-0003-1776-8721
FU "Division of Nutritional Sciences: Vision 20/20'' (University of
   Illinois, Urbana-Champaign) [ILLU-971-352]
FX We gratefully acknowledge the help from J. Segers, T. B. Wilson and L.
   Shoup at the time of collecting tissue samples, as well as the rest of
   the staff at the University of Illinois Beef and Sheep Field Laboratory
   for animal handling and care. Supported in part by a competitive grant
   from the "Division of Nutritional Sciences: Vision 20/20'' (University
   of Illinois, Urbana-Champaign) interdisciplinary nutrition-related
   research program. Project # ILLU-971-352 (National Institute of Food and
   Agriculture, USA).
CR Arita Y, 2012, BIOCHEM BIOPH RES CO, V425, P560, DOI 10.1016/j.bbrc.2012.08.024
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Basu U., 2012, Journal of Genomics, V1, P22
   Bohnert DW, 2013, J ANIM SCI, V91, P5485, DOI 10.2527/jas.2013-6301
   Bork S, 2011, J CELL PHYSIOL, V226, P2226, DOI 10.1002/jcp.22557
   Chen F, 2012, J BIOCHEM MOL TOXIC, V26, P79, DOI 10.1002/jbt.20412
   Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002
   Erhuma A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1702, DOI 10.1152/ajpendo.00605.2006
   Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Funston RN, 2010, J ANIM SCI, V88, pE205, DOI 10.2527/jas.2009-2351
   Ganesan J, 2013, CIRCULATION, V127, P2097, DOI 10.1161/CIRCULATIONAHA.112.000882
   Gerin I, 2010, AM J PHYSIOL-ENDOC M, V299, pE198, DOI 10.1152/ajpendo.00179.2010
   Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391
   Hoffstedt J, 2004, J CLIN ENDOCR METAB, V89, P1391, DOI 10.1210/jc.2003-031458
   Hulsmans M, 2011, FASEB J, V25, P2515, DOI 10.1096/fj.11-181149
   Ishida M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111537
   Ji P, 2014, J DAIRY SCI, V97, P3431, DOI 10.3168/jds.2013-7295
   Ji P, 2014, J DAIRY SCI, V97, P3441, DOI 10.3168/jds.2013-7296
   Jiang XY, 2014, CELL PHYSIOL BIOCHEM, V33, P1778, DOI 10.1159/000362957
   Jin WW, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-29
   Jin WW, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-90
   John E, 2012, NUCLEIC ACIDS RES, V40, P4446, DOI 10.1093/nar/gks025
   Kabara E, 2014, COMP IMMUNOL MICROB, V37, P49, DOI 10.1016/j.cimid.2013.10.007
   Kajimoto K, 2006, RNA, V12, P1626, DOI 10.1261/rna.7228806
   Kang M, 2013, GENET MOL RES, V12, P5267, DOI 10.4238/2013.November.7.1
   Kang M, 2013, MOL BIOL REP, V40, P5027, DOI 10.1007/s11033-013-2603-6
   Kavalkova P, 2013, HORM METAB RES, V45, P820, DOI 10.1055/s-0033-1353210
   Keller P, 2011, BMC ENDOCR DISORD, V11, DOI 10.1186/1472-6823-11-7
   Kim C, 2013, FEBS LETT, V587, P3853, DOI 10.1016/j.febslet.2013.10.018
   Kim YJ, 2012, J CELL PHYSIOL, V227, P183, DOI 10.1002/jcp.22716
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Kim YJ, 2015, MOL BIOL REP, V42, P617, DOI 10.1007/s11033-014-3807-0
   Kinoshita M, 2010, MOL ENDOCRINOL, V24, P1978, DOI 10.1210/me.2010-0054
   Lee J, 2010, AGING-US, V2, P527, DOI 10.18632/aging.100184
   Li HX, 2011, MOL BIOL REP, V38, P4273, DOI 10.1007/s11033-010-0550-z
   Lin Q, 2009, FEBS J, V276, P2348, DOI 10.1111/j.1742-4658.2009.06967.x
   Liu SY, 2015, CELL PHYSIOL BIOCHEM, V36, P1552, DOI 10.1159/000430318
   McFarlane C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087687
   McGregor RA, 2011, CURR MOL MED, V11, P304
   Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x
   Miretti S, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-194
   Moisá SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131478
   Moisá SJ, 2014, GENE REGUL SYST BIO, V8, P17, DOI 10.4137/GRSB.S11782
   Munshi A, 2009, J GENET GENOMICS, V36, P75, DOI 10.1016/S1673-8527(08)60094-6
   Ohtani Y, 2012, ANIM SCI J, V83, P788, DOI 10.1111/j.1740-0929.2012.01029.x
   Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005
   Ortega FJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009022
   Polster BJ, 2010, MOL GENET METAB, V101, P292, DOI 10.1016/j.ymgme.2010.07.016
   Pratt SL., 2010, Journal of Nucleic Acids Investigation, V1, P12
   Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-320
   Raddatz J, 2008, MEASUREMENT ADIPONEC, P79
   Ragaller V, 2011, J ANIM PHYSIOL AN N, V95, P6, DOI 10.1111/j.1439-0396.2010.01004.x
   Romao JM, 2011, EXP BIOL MED, V236, P997, DOI 10.1258/ebm.2011.011101
   Romao JM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-137
   Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313
   Sacco J, 2012, CURR OPIN LIPIDOL, V23, P220, DOI 10.1097/MOL.0b013e3283534c9f
   Shoup LM, 2015, J ANIM SCI, V93, P4926, DOI 10.2527/jas.2014-8564
   Shoup LM, 2015, J ANIM SCI, V93, P4936, DOI 10.2527/jas.2014-8565
   Smith J, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-18
   Subedi A, 2013, FEBS LETT, V587, P1556, DOI 10.1016/j.febslet.2013.03.040
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Wang HY, 2015, GENE, V559, P119, DOI 10.1016/j.gene.2015.01.021
   Wilfred BR, 2007, MOL GENET METAB, V91, P209, DOI 10.1016/j.ymgme.2007.03.011
   Wilkins JF, 2005, TRENDS GENET, V21, P356, DOI 10.1016/j.tig.2005.04.005
   Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08-1299
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Zhao JX, 2011, DOMEST ANIM ENDOCRIN, V40, P222, DOI 10.1016/j.domaniend.2011.01.004
   Zhu LL, 2013, MOL BIOL REP, V40, P5669, DOI 10.1007/s11033-013-2668-2
   Zhu YJ, 2014, ACTA BIOCH BIOPH SIN, V46, P590, DOI 10.1093/abbs/gmu036
NR 71
TC 15
Z9 18
U1 0
U2 42
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0024-4201
EI 1558-9307
J9 LIPIDS
JI Lipids
PD JAN
PY 2016
VL 51
IS 1
BP 123
EP 138
DI 10.1007/s11745-015-4092-y
PG 16
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA DA1FT
UT WOS:000367542400011
PM 26597919
DA 2025-01-12
ER

PT J
AU Teschendorff, AE
   Gao, Y
   Jones, A
   Ruebner, M
   Beckmann, MW
   Wachter, DL
   Fasching, PA
   Widschwendter, M
AF Teschendorff, Andrew E.
   Gao, Yang
   Jones, Allison
   Ruebner, Matthias
   Beckmann, Matthias W.
   Wachter, David L.
   Fasching, Peter A.
   Widschwendter, Martin
TI DNA methylation outliers in normal breast tissue identify field defects
   that are enriched in cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CLONAL DIVERSITY; CELLS; PROGRESSION; IDENTIFICATION; HETEROGENEITY;
   VARIABILITY; EVOLUTION; GENES; RISK
AB Identifying molecular alterations in normal tissue adjacent to cancer is important for understanding cancer aetiology and designing preventive measures. Here we analyse the DNA methylome of 569 breast tissue samples, including 50 from cancer-free women and 84 from matched normal cancer pairs. We use statistical algorithms for dissecting intra-and inter-sample cellular heterogeneity and demonstrate that normal tissue adjacent to breast cancer is characterized by tens to thousands of epigenetic alterations. We show that their genomic distribution is non-random, being strongly enriched for binding sites of transcription factors specifying chromatin architecture. We validate the field defects in an independent cohort and demonstrate that over 30% of the alterations exhibit increased enrichment within matched cancer samples. Breast cancers highly enriched for epigenetic field defects, exhibit adverse clinical outcome. Our data support a model where clonal epigenetic reprogramming towards reduced differentiation in normal tissue is an important step in breast carcinogenesis.
C1 [Teschendorff, Andrew E.; Jones, Allison; Widschwendter, Martin] UCL, Dept Womens Canc, Med Sch Bldg,Room 340,74 Huntley St, London WC1E 6AU, England.
   [Teschendorff, Andrew E.; Gao, Yang] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, CAS Key Lab Computat Biol, Shanghai 200031, Peoples R China.
   [Teschendorff, Andrew E.] UCL, UCL Canc Inst, Stat Canc Genom, Paul OGorman Bldg,72 Huntley St, London WC1E 6BT, England.
   [Ruebner, Matthias; Beckmann, Matthias W.; Fasching, Peter A.] Univ Erlangen Nurnberg, Univ Clin Erlangen, Dept Obstet & Gynaecol, D-91054 Erlangen, Germany.
   [Wachter, David L.] Univ Erlangen Nurnberg, Univ Clin Erlangen, Inst Pathol, Dept Surg Pathol, D-91054 Erlangen, Germany.
C3 University of London; University College London; Chinese Academy of
   Sciences; Max Planck Society; University of London; University College
   London; University of Erlangen Nuremberg; University of Erlangen
   Nuremberg
RP Teschendorff, AE; Widschwendter, M (通讯作者)，UCL, Dept Womens Canc, Med Sch Bldg,Room 340,74 Huntley St, London WC1E 6AU, England.; Teschendorff, AE (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, CAS Key Lab Computat Biol, Shanghai 200031, Peoples R China.; Teschendorff, AE (通讯作者)，UCL, UCL Canc Inst, Stat Canc Genom, Paul OGorman Bldg,72 Huntley St, London WC1E 6BT, England.
EM a.teschendorff@ucl.ac.uk; m.widschwendter@ucl.ac.uk
RI Fasching, Peter/ABH-9912-2020; GAO, Yang/HMO-8142-2023; Teschendorff,
   Andrew/AFP-1816-2022
OI Widschwendter, Martin/0000-0002-7778-8380
FU European Union [305428]; Eve Appeal; Department of Health NIHR
   Biomedical Research Centers funding scheme
FX The research leading to these results has received funding from the
   European Union's Seventh Framework Programme (FP7/2007-2013) under grant
   agreement number 305428 (Project EpiFemCare) and was strongly supported
   by funds from The Eve Appeal (http://www.eveappeal.org.uk/) and
   undertaken at UCLH/UCL, which received a proportion of its funding from
   the Department of Health NIHR Biomedical Research Centers funding
   scheme. A.E.T. thanks the Chinese Academy of Sciences, Shanghai
   Institute for Biological Sciences and Max-Planck Gesellschaft.
CR Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506
   Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bernstein C, 2013, WORLD J GASTRO ONCOL, V5, P43, DOI 10.4251/wjgo.v5.i3.43
   Boston RC, 2005, MAGN RESON IMAGING, V23, P591, DOI 10.1016/j.mri.2005.02.006
   Chai H, 2009, ANN CLIN LAB SCI, V39, P331
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Hair BY, 2015, BREAST CANCER RES TR, V151, P453, DOI 10.1007/s10549-015-3401-8
   Houseman EA, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0527-y
   Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Shibata D, 2006, NAT GENET, V38, P402, DOI 10.1038/ng0406-402
   Silva AL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-891
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Slieker RC, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-26
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Teschendorff AE, 2015, JAMA ONCOL, V1, P476, DOI 10.1001/jamaoncol.2015.1053
   Teschendorff AE, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003709
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Tsao JL, 2000, P NATL ACAD SCI USA, V97, P1236, DOI 10.1073/pnas.97.3.1236
   Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665
   West J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01630
   Yuan T, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004996
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 46
TC 157
Z9 180
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2016
VL 7
AR 10478
DI 10.1038/ncomms10478
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DC2AJ
UT WOS:000369019300006
PM 26823093
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, C
   Gu, YY
   Zhang, K
   Xie, KP
   Zhu, M
   Dai, NB
   Jiang, Y
   Guo, XJ
   Liu, MX
   Dai, JC
   Wu, LX
   Jin, GF
   Ma, HX
   Jiang, T
   Yin, R
   Xia, YK
   Liu, L
   Wang, SY
   Shen, B
   Huo, R
   Wang, QH
   Xu, L
   Yang, LQ
   Huang, XX
   Shen, HB
   Sha, JH
   Hu, ZB
AF Wang, Cheng
   Gu, Yayun
   Zhang, Kai
   Xie, Kaipeng
   Zhu, Meng
   Dai, Ningbin
   Jiang, Yue
   Guo, Xuejiang
   Liu, Mingxi
   Dai, Juncheng
   Wu, Linxiang
   Jin, Guangfu
   Ma, Hongxia
   Jiang, Tao
   Yin, Rong
   Xia, Yankai
   Liu, Li
   Wang, Shouyu
   Shen, Bin
   Huo, Ran
   Wang, Qianghu
   Xu, Lin
   Yang, Liuqing
   Huang, Xingxu
   Shen, Hongbing
   Sha, Jiahao
   Hu, Zhibin
TI Systematic identification of genes with a cancer-testis expression
   pattern in 19 cancer types
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CANCER/TESTIS ANTIGENS; RNA-SEQ; GENOME; LUNG; RECOMBINATION;
   IMMUNOTHERAPY; LANDSCAPE; DRIVER
AB Cancer-testis (CT) genes represent the similarity between the processes of spermatogenesis and tumorigenesis. It is possible that their selective expression pattern can help identify driver genes in cancer. In this study, we integrate transcriptomics data from multiple databases and systematically identify 876 new CT genes in 19 cancer types. We explore their relationship with testis-specific regulatory elements. We propose that extremely highly expressed CTgenes (EECTGs) are potential drivers activated through epigenetic mechanisms. We find mutually exclusive associations between EECTGs and somatic mutations in mutated genes, such as PIK3CA in breast cancer. We also provide evidence that promoter demethylation and close non-coding RNAs (namely, CT-ncRNAs) may be two mechanisms to reactivate EECTG gene expression. We show that the meiosis-related EECTG (MEIOB) and its nearby CT-ncRNA have a role in tumorigenesis in lung adenocarcinoma. Our findings provide methods for identifying epigenetic-driver genes of cancer, which could serve as targets of future cancer therapies.
C1 [Wang, Cheng; Gu, Yayun; Zhang, Kai; Xie, Kaipeng; Zhu, Meng; Dai, Ningbin; Jiang, Yue; Guo, Xuejiang; Liu, Mingxi; Dai, Juncheng; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Bin; Huo, Ran; Shen, Hongbing; Sha, Jiahao; Hu, Zhibin] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Cheng; Gu, Yayun; Zhang, Kai; Xie, Kaipeng; Zhu, Meng; Dai, Ningbin; Jiang, Yue; Dai, Juncheng; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Sch Publ Hlth,Dept Epidemol & Biostat, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 210029, Jiangsu, Peoples R China.
   [Wu, Linxiang; Wang, Qianghu] Nanjing Med Univ, Sch Basic Med Sci, Dept Bioinformat, Nanjing 210029, Jiangsu, Peoples R China.
   [Yin, Rong; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Mol & Translat Canc Res, Nanjing 210009, Jiangsu, Peoples R China.
   [Xia, Yankai; Wang, Shouyu] Nanjing Med Univ, Sch Publ Hlth,Dept Mol Cell Biol & Toxicol, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 210029, Jiangsu, Peoples R China.
   [Liu, Li] Nanjing Med Univ, Affiliated Hosp 1, Digest Endoscopy Ctr, Nanjing 210029, Jiangsu, Peoples R China.
   [Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Non Coding RNAs, Canc Biol Program, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Huang, Xingxu] Shanghai Tech Univ, Sch Life Sci & Technol, Pudong New Area, 100 Haike Rd, Shanghai 201210, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University; Nanjing Medical University;
   Nanjing Medical University; University of Texas System; UTMD Anderson
   Cancer Center; ShanghaiTech University
RP Shen, HB; Sha, JH; Hu, ZB (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.; Shen, HB; Hu, ZB (通讯作者)，Nanjing Med Univ, Sch Publ Hlth,Dept Epidemol & Biostat, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 210029, Jiangsu, Peoples R China.
EM hbshen@njmu.edu.cn; shajh@njmu.edu.cn; zhibin_hu@njmu.edu.cn
RI XU, Lin/HZL-5726-2023; Liu, Mingxi/C-1343-2017; shen,
   hong/HTQ-6147-2023; Wang, Qianghu/HJI-9741-2023; Yin,
   Rong/GOV-4425-2022; Chen, Wei/GZK-7348-2022; Jianwen, Zhao/A-1171-2014;
   Dai, Ningbin/AFS-0341-2022; Dai, Juncheng/HMO-9370-2023; Shen,
   Bin/ABD-5084-2021; Guo, Xuejiang/J-9600-2014
OI Xu, Lin/0000-0002-2153-4840; Liu, Mingxi/0000-0001-6499-7899; Ma,
   Hongxia/0000-0002-9821-6955; wang, qianghu/0000-0002-3488-1059; Shen,
   Hongbing/0000-0002-2581-5906; Yin, Rong/0000-0002-9744-4251; Shen,
   Bin/0000-0002-8946-8448; Dai, Juncheng/0000-0002-3909-5671; Guo,
   Xuejiang/0000-0002-0475-5705; huang, xingxu/0000-0001-8934-1247; Huo,
   Ran/0000-0001-5166-127X
FU National Key Basic Research Program [2013CB911400, 2015CB943003];
   National Natural Science Foundation of China [31530047, 81230067];
   Science Foundation for Distinguished Young Scholars of Jiangsu
   [BK2012042]; National Science Foundation for Distinguished Young
   Scholars of China [81225020]; Ten Thousand Talent Program and
   Distinguished Professor at Jiangsu
FX We thank The Genotype-Tissue Expression (GTEx) project for the use of
   expression abundance data from multiple normal tissues, The Encyclopedia
   of DNA Elements (ENCODE) project for use of methylation level data from
   multiple normal tissues, The Functional Annotation of The Mammalian
   Genome (FANTOM) project for use of promoter and enhancer activity data
   from multiple normal tissues and The Cancer Genome Atlas (TCGA) project
   for use of multiomics data from a large number of cancer samples. This
   research was supported by the National Key Basic Research Program Grant
   (2013CB911400, 2015CB943003), National Natural Science Foundation of
   China (31530047, 81230067), Science Foundation for Distinguished Young
   Scholars of Jiangsu (BK2012042), the National Science Foundation for
   Distinguished Young Scholars of China (81225020), and the Ten Thousand
   Talent Program and Distinguished Professor at Jiangsu. The funder
   agencies had no role in the study design, data collection and analysis,
   decision to publish or the preparation of the manuscript.
CR Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Baudat F, 2013, NAT REV GENET, V14, P794, DOI 10.1038/nrg3573
   BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0
   Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   COULIE PG, 1993, J IMMUNOTHER, V14, P104, DOI 10.1097/00002371-199308000-00004
   De Backer O, 1999, CANCER RES, V59, P3157
   Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Harada Y, 2010, CANCER RES, V70, P5829, DOI 10.1158/0008-5472.CAN-10-0255
   Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Luo MC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3788
   Madison BB, 2013, GENE DEV, V27, P2233, DOI 10.1101/gad.224659.113
   Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045
   Melé M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355
   Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436
   Ogi C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26012
   Orthwein A, 2014, SCIENCE, V344, P189, DOI 10.1126/science.1248024
   Park C, 2014, BIOINFORMATICS, V30, P2480, DOI 10.1093/bioinformatics/btu325
   Pe'er D, 2011, CELL, V144, P864, DOI 10.1016/j.cell.2011.03.001
   Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034
   Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039
   Rivas MA, 2015, SCIENCE, V348, P666, DOI 10.1126/science.1261877
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Stratton MR, 2013, EMBO MOL MED, V5, P169, DOI 10.1002/emmm.201202388
   Taguchi A, 2014, CANCER RES, V74, P4694, DOI 10.1158/0008-5472.CAN-13-3725
   Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112
   Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092
   Wawrzik M, 2009, EUR J HUM GENET, V17, P1463, DOI 10.1038/ejhg.2009.83
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Whitehurst AW, 2014, ANNU REV PHARMACOL, V54, P251, DOI 10.1146/annurev-pharmtox-011112-140326
   Zhou JB, 2013, INT J BIOCHEM CELL B, V45, P973, DOI 10.1016/j.biocel.2013.02.006
NR 50
TC 119
Z9 134
U1 3
U2 58
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2016
VL 7
AR 10499
DI 10.1038/ncomms10499
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DC2CF
UT WOS:000369024100001
PM 26813108
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Zhang, ML
   Li, HY
   Zou, D
   Gao, J
AF Zhang, Minglei
   Li, Hongyan
   Zou, Di
   Gao, Ji
TI Ruguo key genes and tumor driving factors identification of bladder
   cancer based on the RNA-seq profile
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE bladder cancer; differentially expressed genes; tumor driving factor;
   function analysis
ID TRANSCRIPTION FACTOR; BREAST-CANCER; II RECEPTOR; CELL-CYCLE;
   EXPRESSION; SIGNATURE; CHEMOTHERAPY; RADIOTHERAPY; PROGRESSION;
   INHIBITION
AB Aim: This study aimed to select several signature genes associated with bladder cancer, thus to investigate the possible mechanism in bladder cancer.
   Methods: The mRNA expression profile data of GSE31614, including ten bladder tissues and ten control samples, was downloaded from the Gene Expression Omnibus. The differentially expressed genes (DEGs) in bladder cancer samples compared with the control samples were screened using the Student's t-test method. Functional analysis for the DEGs was analyzed using the Database for Annotation, Visualization, and Integrated Discovery from the Gene Ontology database, followed by the transcription function annotation of DEGs from Tumor-Associated Gene database. Motifs of genes that had transcription functions in promoter region were analyzed using the Seqpos.
   Results: A total of 1,571 upregulated and 1,507 downregulated DEGs in the bladder cancer samples were screened. ELF3 and MYBL2 involved in cell cycle and DNA replication were tumor suppressors. MEG3, APEX1, and EZH2 were related with the cell epigenetic regulation in bladder cancer. Moreover, HOXB9 and EN1 that have their own motif were the transcription factors.
   Conclusion: Our study has identified several key genes involved in bladder cancer. ELF3 and MYBL2 are tumor suppressers, HOXB9 and EN1 are the main regulators, while MEG3, APEX1, and EZH2 are driving factors for bladder cancer progression.
C1 [Zhang, Minglei] Jilin Univ, Dept Orthoped, Div Tumor & Trauma Surg, Changchun 130033, Peoples R China.
   [Li, Hongyan; Gao, Ji] Jilin Univ, Dept Urol, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Peoples R China.
   [Zou, Di] Changchun Univ Chinese Med, Dept Nephrol, Affiliated Hosp 1, Changchun, Peoples R China.
C3 Jilin University; Jilin University; Changchun University of Chinese
   Medicine
RP Gao, J (通讯作者)，Jilin Univ, Dept Urol, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Peoples R China.
EM gsenior@163.com
RI Zhang, Minglei/U-8554-2019; Li, Hong/ABE-3959-2021
CR [Anonymous], MOL PHYLOGENET EVOL
   Bell D, 2012, CANCER-AM CANCER SOC, V118, P1288, DOI 10.1002/cncr.26412
   Böck M, 2014, DEV BIOL, V386, P321, DOI 10.1016/j.ydbio.2013.12.028
   Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252
   Chromecki TF, 2011, NAT REV UROL, V8, P440, DOI 10.1038/nrurol.2011.96
   Chung SD, 2012, NEW ENGL J MED, V367, P379, DOI 10.1056/NEJMc1206002
   Dancik GM, 2014, STEM CELLS, V32, P974, DOI 10.1002/stem.1625
   Dubos C, 2010, TRENDS PLANT SCI, V15, P573, DOI 10.1016/j.tplants.2010.06.005
   Dyrskjot L, 2012, BRIT J CANCER, V107, P1392, DOI 10.1038/bjc.2012.412
   GEISER AG, 1992, J BIOL CHEM, V267, P2588
   Gibson W, 2007, CANCER LETT, V248, P251, DOI 10.1016/j.canlet.2006.08.007
   Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511
   Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107
   Hiwasa K, 2012, ANTICANCER RES, V32, P3137
   Hollenhorst PC, 2011, ANNU REV BIOCHEM, V80, P437, DOI 10.1146/annurev.biochem.79.081507.103945
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   James ND, 2012, NEW ENGL J MED, V366, P1477, DOI 10.1056/NEJMoa1106106
   Kim MH, 2013, J CLIN INVEST, V123, P3211, DOI 10.1172/JCI65521
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Pfeffer PL, 2000, DEVELOPMENT, V127, P1017
   Rachakonda PS, 2013, P NATL ACAD SCI USA, V110, P17426, DOI 10.1073/pnas.1310522110
   Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271
   Ruxton GD, 2006, BEHAV ECOL, V17, P688, DOI 10.1093/beheco/ark016
   Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004
   Seki H, 2012, ANN SURG ONCOL, V19, P1831, DOI 10.1245/s10434-012-2295-5
   Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vitorino R, 2010, PROTEOMICS, V10, P3732, DOI 10.1002/pmic.201000261
   Wu XF, 2006, AM J HUM GENET, V78, P464, DOI 10.1086/500848
   Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516
   Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044
   Zhussupova A, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-P1-07-06
NR 36
TC 11
Z9 11
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2016
VL 9
BP 2717
EP 2723
DI 10.2147/OTT.S92529
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA DL3PA
UT WOS:000375544500001
PM 27217782
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Kamiya, T
   Goto, A
   Kurokawa, E
   Hara, H
   Adachi, T
AF Kamiya, Tetsuro
   Goto, Aki
   Kurokawa, Eri
   Hara, Hirokazu
   Adachi, Tetsuo
TI Cross Talk Mechanism among EMT, ROS, and Histone Acetylation in Phorbol
   Ester-Treated Human Breast Cancer MCF-7 Cells
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID EXTRACELLULAR-SUPEROXIDE DISMUTASE; MESENCHYMAL TRANSITION; DNA
   METHYLATION; UP-REGULATION; E-CADHERIN; EXPRESSION; SNAIL; PKC;
   FIBRONECTIN; PROGRESSION
AB Epithelial-mesenchymal transition (EMT) plays a pivotal role in the progression of cancer, and some transcription factors including Slug and Snail are known to be involved in EMT processes. It has been well established that the excess production of reactive oxygen species (ROS) and epigenetics such as DNA methylation and histone modifications participate in carcinogenesis; however, the cross talk mechanism among EMT, ROS, and epigenetics remains unclear. In the present study, we demonstrated that the treatment of human breast cancer MCF-7 cells with phorbol ester (TPA), a protein kinase C activator, significantly induced cell proliferation and migration, and these were accompanied by the significant induction of Slug expression. Moreover, the TPA-elicited induction of Slug expression was regulated by histone H3 acetylation and NADPH oxidase (NOX) 2-derived ROS signaling, indicating that ROS and histone acetylation are involved in TPA-elicited EMT processes. We herein determined the cross talk mechanism among EMT, ROS, and histone acetylation, and our results provide an insight into the progression of cancer metastasis.
C1 [Kamiya, Tetsuro; Goto, Aki; Kurokawa, Eri; Hara, Hirokazu; Adachi, Tetsuo] Gifu Pharmaceut Univ, Lab Clin Pharmaceut, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Kamiya, T (通讯作者)，Gifu Pharmaceut Univ, Lab Clin Pharmaceut, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM tekamiya@gifu-pu.ac.jp
RI Kamiya, Tetsuro/AAY-7093-2021
FU Japan Society for the Promotion for Science [26460070]; Gifu
   Pharmaceutical University; Grants-in-Aid for Scientific Research
   [26460070, 25460654] Funding Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Japan Society for the Promotion for Science (Tetsuro
   Kamiya, no. 26460070) and a grant for the encouragement of young
   scientists from Gifu Pharmaceutical University (Tetsuro Kamiya).
CR Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236
   Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023
   Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691
   Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ewart-Toland A, 2004, CANCER EPIDEM BIOMAR, V13, P759
   Fuchs IB, 2002, ANTICANCER RES, V22, P3415
   Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hajra KM, 2002, CANCER RES, V62, P1613
   HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P329, DOI 10.1098/rstb.1990.0015
   Huang L, 2008, J BIOL CHEM, V283, P7616, DOI 10.1074/jbc.M705839200
   Huang SY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029124
   Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517
   IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337
   Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamiya T, 2013, FREE RADICAL BIO MED, V61, P197, DOI 10.1016/j.freeradbiomed.2013.04.013
   Kamiya T, 2011, J CELL BIOCHEM, V112, P244, DOI 10.1002/jcb.22917
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Kume S, 2010, J CLIN INVEST, V120, P1043, DOI 10.1172/JCI41376
   Li L, 2010, AM J PATHOL, V176, P1767, DOI 10.2353/ajpath.2010.090345
   Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027
   Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200
   Makino J, 2012, FREE RADICAL RES, V46, P637, DOI 10.3109/10715762.2012.664841
   Naber HPH, 2013, BIOCHEM BIOPH RES CO, V435, P58, DOI 10.1016/j.bbrc.2013.04.037
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997
   Pal D, 2013, BBA-GEN SUBJECTS, V1830, P4040, DOI 10.1016/j.bbagen.2013.03.028
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Rada B, 2008, SEMIN IMMUNOPATHOL, V30, P237, DOI 10.1007/s00281-008-0126-3
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297
   Serrano MJ, 2014, ONCOTARGET, V5, P7486, DOI 10.18632/oncotarget.2217
   Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019
   Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361
   VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585
   Wright E, 2006, INT J CLIN PRACT, V60, P308, DOI 10.1111/j.1368-5031.2006.00825.x
   Zhang JD, 2005, J CELL BIOCHEM, V96, P522, DOI 10.1002/jcb.20535
   Zhang QH, 2015, GENET MOL RES, V14, P9200, DOI 10.4238/2015.August.7.30
   Zheng M, 2015, ONCOTARGET, V6, P6794
NR 47
TC 25
Z9 26
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 1284372
DI 10.1155/2016/1284372
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DM4HE
UT WOS:000376307200001
PM 27127545
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Mukherjee, N
   Islam, MS
   Roychowdhury, A
   Bhattacharya, R
   Chunder, N
   Bhattacharya, N
   Sinha, S
   Alam, N
   Roy, A
   Roychoudhury, S
   Panda, CK
AF Mukherjee, Nupur
   Islam, Md. Saimul
   Roychowdhury, Anirban
   Bhattacharya, Rittwika
   Chunder, Nilanjana
   Bhattacharya, Nilanjana
   Sinha, Satyabrata
   Alam, Neyaz
   Roy, Anup
   Roychoudhury, Susanta
   Panda, Chinmay Kumar
TI The stem cell renewal and DNA damage response pathways are frequently
   altered in fibroepithelial tumors of breast in Indian patients
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Fibroepithelial tumors; Genetic/epigenetic alterations; Stem cell
   renewal pathway; DNA damage response pathway; Cell cycle regulation
ID P16(INK4A) PROMOTER METHYLATION; MALIGNANT PHYLLODES TUMORS; MOLECULAR
   PATHOGENESIS; SIGNALING PATHWAY; MED12 MUTATIONS; CANCER; FIBROADENOMA;
   PROGRESSION; BENIGN; ONSET
AB Genetic and epigenetic alterations in genes associated with distinct cellular pathways were checked in fibroepithelial tumors, including fibroadenomas, benign and malignant phyllode and atypical ductal hyperplasia. A panel of 22 genes associated with different cellular pathways such as stem cell renewal (Wnt and Hedgehog), DNA damage response [homologous recombination (HR), mismatch repair (MMR) and nucleotide excision repair (NER)] and cell proliferation signaling pathway were tested. Alterations (genetic/epigenetic) of the genes associated with Wnt signaling pathway were detected in 100% (20/20) of the breast tumors for at least one out of the six Wnt antagonists tested. Frequent molecular alterations (57-64%) were detected in HR and MMR pathway and low frequency of alterations (8-25%) were seen in cell-proliferation and cell signaling pathways showing a differential pattern of alterations in different tumor types. The patterns of alterations, in particular the epigenetic alterations, differed little from that seen previously in breast carcinoma cells, suggesting epigenetic alterations to be an early event in the development of the tumors. In gene ontology analysis, it was evident that Wnt signaling pathway [GO: 0030111, Kegg: 04310], cell proliferation pathway [GO: 0008285] and pathways in cancer [Kegg: 05200] were significantly enriched by differentially altered genes in fibroadenoma and phyllode tumor types. All these results may provide a new breakthrough in early diagnosis, prognosis and treatment of these tumors. (C) 2015 Elsevier GmbH. All rights reserved.
C1 [Mukherjee, Nupur; Islam, Md. Saimul; Roychowdhury, Anirban; Bhattacharya, Rittwika; Chunder, Nilanjana; Bhattacharya, Nilanjana; Sinha, Satyabrata; Panda, Chinmay Kumar] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, W Bengal, India.
   [Sinha, Satyabrata] W Virginia Univ, Dept Ophthalmol, Morgantown, WV 26506 USA.
   [Alam, Neyaz] Chittaranjan Natl Canc Inst, Dept Surg Oncol, Kolkata 700026, W Bengal, India.
   [Roy, Anup] Dept Pathol, Darjeeling, W Bengal, India.
   [Roychoudhury, Susanta] Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, Kolkata, W Bengal, India.
C3 West Virginia University; Council of Scientific & Industrial Research
   (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)
RP Panda, CK (通讯作者)，Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, W Bengal, India.
EM nupurmukherjee10@gmail.com; saimulislam80@gmail.com;
   rittwikab@gmail.com; anirbanr91@gmail.com; bhattacharya.n@gmail.com;
   satyabratasinha@gmail.com; nalam@cnci.org.in; anuproy99@yahoo.com;
   susantarc@gmail.com; ckpanda.cnci@gmail.com
RI Islam/Y-5000-2019; Roychoudhury, Susanta/AAD-7946-2021; Sinha,
   Satyabrata/K-9095-2016; ROYCHOWDHURY, ANIRBAN/GOV-3409-2022
OI ROYCHOWDHURY, ANIRBAN/0000-0002-1571-9689; Sinha,
   Satyabrata/0000-0003-0514-8613
FU CSIR RA grant [09/030(0071)/2013-EMR-I]
FX We are thankful to the Director, Chittaranjan National Cancer Institute,
   Kolkata, India. Financial support for this work was provided by CSIR RA
   grant 09/030(0071)/2013-EMR-I (RA) to Dr. N. Mukherjee. We are also
   thankful to Mr. Chandraditya Chakrabarty for the technical help provided
   by him.
CR Balabanski L, 2014, MOL CLIN ONCOL, V2, P435, DOI 10.3892/mco.2014.251
   Bandyopadhyay R, 2010, J CYTOL, V27, P59, DOI 10.4103/0970-9371.70739
   Bhattacharya N, 2009, J ORAL PATHOL MED, V38, P759, DOI 10.1111/j.1600-0714.2009.00781.x
   Bhattacharya N, 2013, ANN SURG ONCOL, V20, pS424, DOI 10.1245/s10434-012-2715-6
   Bombonati A, 2011, J PATHOL, V223, P307, DOI 10.1002/path.2808
   Chen Kang Mei, 2011, Cancers (Basel), V3, P1580, DOI 10.3390/cancers3021580
   Chunder N, 2004, PATHOL RES PRACT, V200, P735, DOI 10.1016/j.prp.2004.09.001
   Chunder N, 2004, ANN SURG ONCOL, V11, P1045, DOI 10.1245/ASO.2004.02.022
   Cichon MA, 2010, J MAMMARY GLAND BIOL, V15, P389, DOI 10.1007/s10911-010-9195-8
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P2494, DOI 10.1016/j.humpath.2013.06.009
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   DIXON JM, 1991, BRIT MED BULL, V47, P258, DOI 10.1093/oxfordjournals.bmb.a072468
   DUPONT WD, 1994, NEW ENGL J MED, V331, P10, DOI 10.1056/NEJM199407073310103
   Gong G, 2001, CLIN CANCER RES, V7, P2410
   Guille A, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-66
   Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124
   Jara-Lazaro AR, 2009, AM J TRANSL RES, V1, P23
   Jardim DLF, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-112
   Karim RZ, 2009, J CLIN PATHOL, V62, P1016, DOI 10.1136/jcp.2009.066977
   Karim RZ, 2013, J CLIN PATHOL, V66, P496, DOI 10.1136/jclinpath-2012-201082
   Karim RZ, 2009, PATHOLOGY, V41, P105, DOI 10.1080/00313020802579342
   Kasami M, 1998, BREAST CANCER RES TR, V50, P185, DOI 10.1023/A:1006050208157
   Kersting C, 2006, LAB INVEST, V86, P54, DOI 10.1038/labinvest.3700358
   Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200
   Kleer CG, 2001, MODERN PATHOL, V14, P185, DOI 10.1038/modpathol.3880282
   Kuijper A, 2002, J PATHOL, V197, P575, DOI 10.1002/path.1161
   Lenhard MS, 2008, EUR J OBSTET GYN R B, V138, P217, DOI 10.1016/j.ejogrb.2007.08.002
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Liu GY, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-252
   Liu T, 2009, ANN ONCOL, V20, P441, DOI 10.1093/annonc/mdn651
   Marzese Diego M, 2011, J Med Case Rep, V5, P516, DOI 10.1186/1752-1947-5-516
   Mukherjee N, 2012, CANCER SCI, V103, P210, DOI 10.1111/j.1349-7006.2011.02131.x
   Muttarak M, 2006, Biomed Imaging Interv J, V2, pe33, DOI 10.2349/biij.2.2.e33
   NOGUCHI S, 1993, CANCER RES, V53, P4071
   Pfarr N, 2015, GENE CHROMOSOME CANC, V54, P444, DOI 10.1002/gcc.22256
   Sapino A, 2006, MODERN PATHOL, V19, P599, DOI 10.1038/modpathol.3800574
   Sawyer EJ, 2000, AM J PATHOL, V156, P1093, DOI 10.1016/S0002-9440(10)64977-2
   Senniappan S. N., 2012, WORLD J SURG RES, V4, pe1
   Sinha S, 2008, CANCER SCI, V99, P1984, DOI 10.1111/j.1349-7006.2008.00952.x
   Sinha S, 2008, ANN SURG ONCOL, V15, P1070, DOI 10.1245/s10434-007-9790-0
   Sinha S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-84
   Tse GMK, 2009, BREAST CANCER RES TR, V114, P441, DOI 10.1007/s10549-008-0030-5
   Wei J, 2014, CHIN J CANCER, V33, P492, DOI 10.5732/cjc.014.10048
   Yang XF, 2014, ARCH PATHOL LAB MED, V138, P25, DOI 10.5858/arpa.2012-0443-RA
   Yoshida M, 2015, BRIT J CANCER, V112, P1703, DOI 10.1038/bjc.2015.116
   Zhou HY, 2006, MOL CELL BIOL, V26, P8667, DOI 10.1128/MCB.00443-06
NR 48
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2016
VL 212
IS 3
BP 196
EP 203
DI 10.1016/j.prp.2015.12.008
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DG9FL
UT WOS:000372388100007
PM 26774289
DA 2025-01-12
ER

PT J
AU Gao, Y
   Jones, A
   Fasching, PA
   Ruebner, M
   Beckmann, MW
   Widschwendter, M
   Teschendorff, AE
AF Gao, Yang
   Jones, Allison
   Fasching, Peter A.
   Ruebner, Matthias
   Beckmann, Matthias W.
   Widschwendter, Martin
   Teschendorff, Andrew E.
TI The integrative epigenomic-transcriptomic landscape of ER positive
   breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
ID WIDE DNA METHYLATION; FACTOR-I WIF1; EPIGENETIC INACTIVATION; WNT
   PATHWAY; EXPRESSION; OVARIAN; GENES; CLASSIFICATION; PROLIFERATION;
   DELTA-EF1
AB Background: While recent integrative analyses of copy number and gene expression data in breast cancer have revealed a complex molecular landscape with multiple subtypes and many oncogenic/tumour suppressor driver events, much less is known about the role of DNA methylation in shaping breast cancer taxonomy and defining driver events.
   Results: Here, we applied a powerful integrative network algorithm to matched DNA methylation and RNA-Seq data for 724 estrogen receptor (ER)-positive (ER+) breast cancers and 111 normal adjacent tissue specimens from The Cancer Genome Atlas (TCGA) project, in order to identify putative epigenetic driver events and to explore the resulting molecular taxonomy. This revealed the existence of nine functionally deregulated epigenetic hotspots encompassing a total of 146 genes, which we were able to validate in independent data sets encompassing over 1000 ER+ breast cancers. Integrative clustering of the matched messenger RNA (mRNA) and DNA methylation data over these genes resulted in only two clusters, which correlated very strongly with the luminal-A and luminal B subtypes. Overall, luminal-A and luminal-B breast cancers shared the same epigenetically deregulated hotspots but with luminal-B cancers exhibiting increased aberrant DNA methylation patterns relative to normal tissue. We show that increased levels of DNA methylation and mRNA expression deviation from the normal state define a marker of poor prognosis. Our data further implicates epigenetic silencing of WNT signalling antagonists and bone morphogenetic proteins (BMP) as key events underlying both luminal subtypes but specially of luminal-B breast cancer. Finally, we show that DNA methylation changes within the identified epigenetic interactome hotspots do not exhibit mutually exclusive patterns within the same cancer sample, instead exhibiting coordinated changes within the sample.
   Conclusions: Our results indicate that the integrative DNA methylation and transcriptomic landscape of ER+ breast cancer is surprisingly homogeneous, defining two main subtypes which strongly correlate with luminalA/ B subtype status. In particular, we identify WNT and BMP signalling as key epigenetically deregulated tumour suppressor pathways in luminal ER+ breast cancer, with increased deregulation seen in luminal-B breast cancer.
C1 [Gao, Yang; Teschendorff, Andrew E.] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Key Lab Computat Biol, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
   [Jones, Allison; Widschwendter, Martin; Teschendorff, Andrew E.] UCL, Dept Womens Canc, London WC1E 6BT, England.
   [Fasching, Peter A.; Ruebner, Matthias; Beckmann, Matthias W.] Univ Erlangen Nurnberg, Univ Clin Erlangen, Dept Obstet & Gynaecol, D-91054 Erlangen, Germany.
   [Teschendorff, Andrew E.] UCL, Stat Genom Grp, UCL Canc Inst, London WC1E 6BT, England.
C3 Max Planck Society; Chinese Academy of Sciences; University of London;
   University College London; University of Erlangen Nuremberg; University
   of London; University College London
RP Teschendorff, AE (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Key Lab Computat Biol, CAS MPG Partner Inst Computat Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
EM a.teschendorff@ucl.ac.uk
RI Teschendorff, Andrew/AFP-1816-2022; Fasching, Peter/ABH-9912-2020
OI Widschwendter, Martin/0000-0002-7778-8380
FU Shanghai Institute for Biological Sciences, Chinese Academy of Sciences;
   Max-Planck Gesellschaft; European Union's Seventh Framework Programme
   (FP7) [305428]; Department of Health NIHR Biomedical Research Centres
FX AET and GY thank the Shanghai Institute for Biological Sciences, Chinese
   Academy of Sciences, and the Max-Planck Gesellschaft for the funding.
   Part of this work was also supported by the European Union's Seventh
   Framework Programme (FP7/2007-2013) under grant agreement number 305428
   (Project EpiFemCare) and done at UCLH/UCL, which received a proportion
   of its funding from the Department of Health NIHR Biomedical Research
   Centres funding scheme.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Ali HR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0431-1
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039
   Chan QKY, 2009, CARCINOGENESIS, V30, P114, DOI 10.1093/carcin/bgn215
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111
   Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34
   Du M, 2014, MOL MED REP, V10, P1051, DOI 10.3892/mmr.2014.2276
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073
   Hu F, 2013, BBA-MOL BASIS DIS, V1832, P2379, DOI 10.1016/j.bbadis.2013.08.011
   Palacios-Arreola MI, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/849720
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lal I, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3425
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Shen RL, 2009, BIOINFORMATICS, V25, P2906, DOI 10.1093/bioinformatics/btp543
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Wang C, 2011, J CANCER RES CLIN, V137, P985, DOI 10.1007/s00432-010-0963-z
   West J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01630
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Wiesmann F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2319
   Yang S, 2009, INT J BIOCHEM CELL B, V41, P853, DOI 10.1016/j.biocel.2008.08.030
   Yang S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-211
   Ying XX, 2015, CELL PHYSIOL BIOCHEM, V37, P1271, DOI 10.1159/000430249
   Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 45
TC 24
Z9 24
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD DEC 9
PY 2015
VL 7
AR 126
DI 10.1186/s13148-015-0159-0
PG 16
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CY2NK
UT WOS:000366245200001
PM 26664652
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Huang, ZJ
   Wu, TT
   Liu, AY
   Ouyang, GL
AF Huang, Zhengjie
   Wu, Tiantian
   Liu, Allan Yi
   Ouyang, Gaoliang
TI Differentiation and transdifferentiation potentials of cancer stem cells
SO ONCOTARGET
LA English
DT Article
DE cancer stem cell; differentiation; transdifferentiation; stromal cells;
   tumor microenvironment
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-ASSOCIATED MACROPHAGES; ACUTE
   MYELOID-LEUKEMIA; MARROW-DERIVED CELLS; HUMAN BREAST-CANCER;
   SUPPRESSOR-CELLS; INITIATING CELLS; PROSTATE-CANCER; SELF-RENEWAL;
   PROSPECTIVE IDENTIFICATION
AB Tumor cells actively contribute to constructing their own microenvironment during tumorigenesis and tumor progression. The tumor microenvironment contains multiple types of stromal cells that work together with the extracellular matrix and local and systemic factors to coordinately contribute to tumor initiation and progression. Tumor cells and their stromal compartments acquire many genetic and/or epigenetic alternations to facilitate tumor growth and metastasis. The cancer stem cell (CSC) concept has been widely applied to interpreting tumor initiation, growth, metastasis, dormancy and relapse. CSCs have differentiation abilities to generate the original lineage cells that are similar to their normal stem cell counterparts. Interestingly, recent evidence demonstrates that CSCs also have the potential to transdifferentiate into vascular endothelial cells and pericytes, indicating that CSCs can transdifferentiate into other lineage cells for promoting tumor growth and metastasis in some tissue contexts instead of only recruiting stromal cells from local or distant tissues. Although the transdifferentiation of CSCs into tumor stromal cells provides a new dimension that explains tumor heterogeneity, many aspects of CSC transdifferentiation remain elusive. In this review, we summarize the multi-lineage differentiation and transdifferentiation potentials of CSCs as well as discuss their potential contributions to tumor heterogeneity and tumor microenvironment in tumor progression.
C1 [Huang, Zhengjie] Xiamen Univ, Affiliated Hosp 1, Dept Surg Oncol, Xiamen, Peoples R China.
   [Huang, Zhengjie; Wu, Tiantian; Liu, Allan Yi; Ouyang, Gaoliang] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.
C3 Xiamen University; Xiamen University
RP Ouyang, GL (通讯作者)，Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.
EM allanyoyo@gmail.com; oygldz@xmu.edu.cn
RI Ouyang, Gaoliang/HOA-5229-2023
FU National Nature Science Foundation of China [81572598, 81372841,
   31171339, 31071302]; Fundamental Research Funds for the Central
   Universities [20720150060]; Program for New Century Excellent Talents in
   University [NCET-11-0296]
FX This work was supported by grants from the National Nature Science
   Foundation of China (No. 81572598, 81372841, 31171339, 31071302),
   Fundamental Research Funds for the Central Universities (20720150060)
   and Program for New Century Excellent Talents in University
   (NCET-11-0296).
CR Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191
   Amamoto R, 2014, SCIENCE, V343, P504, DOI 10.1126/science.1239882
   Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barcellos-de-Souza P, 2013, BBA-REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004
   Barth PJ, 2002, VIRCHOWS ARCH, V440, P298, DOI 10.1007/s004280100530
   Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Blagosklonny MV, 2007, CANCER BIOL THER, V6, P1684, DOI 10.4161/cbt.6.11.5167
   Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075
   Bonkhoff H, 2001, ANN ONCOL, V12, pS141, DOI 10.1093/annonc/12.suppl_2.S141
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590
   Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845
   Celià-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218
   Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472
   Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021
   Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024
   Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109
   Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848
   Emmink BL, 2011, GASTROENTEROLOGY, V141, P269, DOI 10.1053/j.gastro.2011.03.052
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513
   Hu HL, 2012, MOL VIS, V18, P2388
   Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015
   Ii M, 2009, CIRC RES, V105, P860, DOI 10.1161/CIRCRESAHA.109.199299
   Jain RK, 2012, CELL, V149, P1408, DOI 10.1016/j.cell.2012.05.025
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108
   Jotzu C, 2011, CELL ONCOL, V34, P55, DOI 10.1007/s13402-011-0012-1
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kim J, 2015, EMBO J, V34, P739, DOI 10.15252/embj.201490736
   Kim J, 2013, CELL REP, V3, P2088, DOI 10.1016/j.celrep.2013.05.036
   Koch U, 2011, ANNU REV CELL DEV BI, V27, P539, DOI 10.1146/annurev-cellbio-092910-154008
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101
   Li L, 2003, CANCER RES, V63, P2733
   Liu AY, 2013, CURR BIOL, V23, pR565, DOI 10.1016/j.cub.2013.05.023
   Liu H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.340
   Liu KC, 2013, ONCOTARGET, V4, P2366, DOI 10.18632/oncotarget.1424
   Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
   Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025
   Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004
   Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Menendez JA, 2014, CELL CYCLE, V13, P358, DOI 10.4161/cc.27770
   Mink SR, 2010, MOL CANCER RES, V8, P809, DOI 10.1158/1541-7786.MCR-09-0460
   Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107
   Mueller L, 2007, AM J PATHOL, V171, P1608, DOI 10.2353/ajpath.2007.060661
   Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452
   Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111
   Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371
   Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5
   Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012
   Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qiu H, 2015, CELL MOL LIFE SCI, V72, P3411, DOI 10.1007/s00018-015-1920-4
   Ramakrishnan M, 2013, CANCER RES, V73, P5360, DOI 10.1158/0008-5472.CAN-13-0896
   Rappa G, 2012, AM J PATHOL, V180, P2504, DOI 10.1016/j.ajpath.2012.02.020
   Ricci-Vitiani L, 2008, CELL DEATH DIFFER, V15, P1491, DOI 10.1038/cdd.2008.72
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Scaffidi P, 2011, NAT CELL BIOL, V13, P1051, DOI 10.1038/ncb2308
   Schäfer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944
   Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012
   Scully S, 2012, J NEUROSCI, V32, P12950, DOI 10.1523/JNEUROSCI.2017-12.2012
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108
   Stricker SH, 2013, GENE DEV, V27, P654, DOI 10.1101/gad.212662.112
   Suvà ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Wang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072962
   Wang Z, 2012, CELL STEM CELL, V10, P111, DOI 10.1016/j.stem.2012.01.002
   Wang ZM, 2013, ACTA PHARMACOL SIN, V34, P1374, DOI 10.1038/aps.2013.134
   Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537
   Wikström P, 2009, PROSTATE, V69, P799, DOI 10.1002/pros.20927
   Worthley DL, 2009, STEM CELLS, V27, P1463, DOI 10.1002/stem.63
   Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604
   Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113
   Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127
   Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237
   Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.152
   Zhau HYE, 2011, CLIN CANCER RES, V17, P2159, DOI 10.1158/1078-0432.CCR-10-2523
NR 120
TC 69
Z9 71
U1 1
U2 29
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 24
PY 2015
VL 6
IS 37
BP 39550
EP 39563
DI 10.18632/oncotarget.6098
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0RW
UT WOS:000366114400019
PM 26474460
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yang, LX
   Song, TJ
   Chen, LH
   Soliman, H
   Chen, JD
AF Yang, Leixiang
   Song, Tanjing
   Chen, Lihong
   Soliman, Hatem
   Chen, Jiandong
TI Nucleolar repression facilitates initiation and maintenance of
   senescence
SO CELL CYCLE
LA English
DT Article
DE chemotherapy; heterochromatin; nucleolus; NML; p53; rDNA; senescence
ID RNA-POLYMERASE-I; ACCELERATED CELLULAR SENESCENCE; HETEROCHROMATIN
   FORMATION; TUMOR-SUPPRESSOR; RIBOSOME BIOGENESIS; DNA-DAMAGE; KAPPA-B;
   TRANSCRIPTION; CELLS; P53
AB Tumor cells with defective apoptosis pathways often respond to chemotherapy by entering irreversible cell cycle arrest with features of senescence. However, rare cells can bypass entry to senescence, or re-enter cell cycle from a senescent state. Deficiency in senescence induction and maintenance may contribute to treatment resistance and early relapse after therapy. Senescence involves epigenetic silencing of cell cycle genes and reduced rRNA transcription. We found that senescence-inducing treatments such as DNA damage and RNA polymerase I inhibition stimulate the binding between the nucleolar protein NML (nucleomethylin) and SirT1. The NML complex promotes rDNA heterochromatin formation and represses rRNA transcription. Depletion of NML reduced the levels of H3K9Me3 and H3K27Me3 heterochromatin markers on rDNA and E2F1 target promoters in senescent cells, increased rRNA transcription, and increased the frequency of cell cycle re-entry. Depletion of the nucleolar transcription repressor factor TIP5 also promoted escape from senescence. Furthermore, tumor tissue staining showed that breast tumors without detectable nucleolar NML expression had poor survival. The results suggest that efficient regulation of nucleolar rDNA transcription facilitates the maintenance of irreversible cell cycle arrest in senescent cells. Deficiency in nucleolar transcription repression may accelerate tumor relapse after chemotherapy.
C1 [Yang, Leixiang; Song, Tanjing; Chen, Lihong; Chen, Jiandong] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA.
   [Soliman, Hatem] Univ S Florida, H Lee Moffitt Canc Ctr, Womens Oncol, Tampa, FL 33682 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; State University
   System of Florida; University of South Florida; State University System
   of Florida; University of South Florida; H Lee Moffitt Cancer Center &
   Research Institute
RP Chen, JD (通讯作者)，Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA.
EM Jiandong.chen@moffitt.org
RI Yang, Ye/GZM-4812-2022
FU National Institutes of Health [CA141244, CA109636]; Florida Department
   of Health [4BB14, 4KB12]; Miles For Moffitt award from the Moffitt
   Foundation; Tissue Core and Imaging Core at the H. Lee Moffitt Cancer
   Center & Research Institute, an NCI designated Comprehensive Cancer
   Center [P30-CA076292]
FX This work was supported by grants CA141244 and CA109636 from the
   National Institutes of Health, 4BB14, 4KB12 from the Florida Department
   of Health, and a Miles For Moffitt award from the Moffitt Foundation to
   J. Chen. This work was also supported in part by the Tissue Core and
   Imaging Core at the H. Lee Moffitt Cancer Center & Research Institute,
   an NCI designated Comprehensive Cancer Center (P30-CA076292).
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003
   Ayrault O, 2006, ONCOGENE, V25, P7577, DOI 10.1038/sj.onc.1209743
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184
   Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171
   Guetg C, 2010, EMBO J, V29, P2135, DOI 10.1038/emboj.2010.17
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027
   Keller C, 2012, MOL CELL, V47, P215, DOI 10.1016/j.molcel.2012.05.009
   Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883
   McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259
   Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Németh A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000889
   Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579
   Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005
   Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005
   te Poele RH, 2002, CANCER RES, V62, P1876
   van Koningsbruggen S, 2010, MOL BIOL CELL, V21, P3735, DOI 10.1091/mbc.E10-06-0508
   Vaughan S, 2011, AGING-US, V3, P913, DOI 10.18632/aging.100390
   Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230
   Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5
   Wu P. C., 2012, Experimental Oncology, V34, P298
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Yang LX, 2013, MOL CELL BIOL, V33, P3835, DOI 10.1128/MCB.00476-13
   Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000
   Zhang LF, 2007, CELL, V129, P693, DOI 10.1016/j.cell.2007.03.036
   Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024
NR 40
TC 35
Z9 37
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD NOV 17
PY 2015
VL 14
IS 22
BP 3613
EP 3623
DI 10.1080/15384101.2015.1100777
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CY3PV
UT WOS:000366322900018
PM 26505814
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Donzelli, S
   Mori, F
   Bellissimo, T
   Sacconi, A
   Casini, B
   Frixa, T
   Roscilli, G
   Aurisicchio, L
   Facciolo, F
   Pompili, A
   Carosi, MA
   Pescarmona, E
   Segatto, O
   Pond, G
   Muti, P
   Telera, S
   Strano, S
   Yarden, Y
   Blandino, G
AF Donzelli, Sara
   Mori, Federica
   Bellissimo, Teresa
   Sacconi, Andrea
   Casini, Beatrice
   Frixa, Tania
   Roscilli, Giuseppe
   Aurisicchio, Luigi
   Facciolo, Francesco
   Pompili, Alfredo
   Carosi, Maria Antonia
   Pescarmona, Edoardo
   Segatto, Oreste
   Pond, Greg
   Muti, Paola
   Telera, Stefano
   Strano, Sabrina
   Yarden, Yosef
   Blandino, Giovanni
TI Epigenetic silencing of miR-145-5p contributes to brain metastasis
SO ONCOTARGET
LA English
DT Article
DE brain metastases; lung cancer; mir-145-5p; epigenetic modifications;
   migration
ID CANCER-CELL-MIGRATION; HUMAN BREAST-TUMORS; LUNG ADENOCARCINOMA;
   MICRORNA; INVASION; EXPRESSION; PROLIFERATION; SUPPRESSES; CARCINOMA;
   MELANOMA
AB Brain metastasis is a major cause of morbidity and mortality of lung cancer patients. We assessed whether aberrant expression of specific microRNAs could contribute to brain metastasis. Comparison of primary lung tumors and their matched metastatic brain disseminations identified shared patterns of several microRNAs, including common down-regulation of miR-145-5p. Down-regulation was attributed to methylation of miR-145's promoter and affiliated elevation of several protein targets, such as EGFR, OCT-4, MUC-1, c-MYC and, interestingly, tumor protein D52 (TPD52). In line with these observations, restored expression of miR-145-5p and selective depletion of individual targets markedly reduced in vitro and in vivo cancer cell migration. In aggregate, our results attribute to miR-145-5p and its direct targets pivotal roles in malignancy progression and in metastasis.
C1 [Donzelli, Sara; Bellissimo, Teresa; Sacconi, Andrea; Frixa, Tania; Blandino, Giovanni] Italian Natl Canc Inst Regina Elena, Translat Oncogen Unit, Rome, Italy.
   [Mori, Federica; Strano, Sabrina] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Unit, Rome, Italy.
   [Casini, Beatrice; Carosi, Maria Antonia; Pescarmona, Edoardo] Italian Natl Canc Inst Regina Elena, Dept Pathol, Rome, Italy.
   [Roscilli, Giuseppe; Aurisicchio, Luigi] Takis Srl, Rome, Italy.
   [Facciolo, Francesco] Italian Natl Canc Inst Regina Elena, Unit Thorac Surg, Rome, Italy.
   [Pompili, Alfredo; Telera, Stefano] Italian Natl Canc Inst Regina Elena, Dept Neurosurg, Rome, Italy.
   [Segatto, Oreste] Italian Natl Canc Inst Regina Elena, Lab Cell Signaling, Rome, Italy.
   [Pond, Greg; Muti, Paola; Strano, Sabrina; Blandino, Giovanni] McMaster Univ, Fac Hlth Sci, Dept Oncol, Hamilton, ON, Canada.
   [Yarden, Yosef] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
C3 McMaster University; Weizmann Institute of Science
RP Blandino, G (通讯作者)，Italian Natl Canc Inst Regina Elena, Translat Oncogen Unit, Rome, Italy.
EM blandino@ifo.it
RI Strano, Sabrina/K-9654-2016; Donzelli, Sara/AAA-2557-2021; Roscilli,
   Giuseppe/KHC-6642-2024; Pond, Gregory/JOZ-2926-2023; Blandino,
   Giovanni/LLM-1397-2024; Muti, Paola/AAD-9108-2020; Donzelli,
   Sara/J-8182-2016; sacconi, andrea/J-3669-2018
OI strano, sabrina/0000-0002-6341-4230; Pond, Gregory/0000-0003-1033-0882;
   Pescarmona, Edoardo/0000-0002-0443-9331; BELLISSIMO,
   TERESA/0000-0002-8068-5841; Segatto, Oreste/0000-0003-2561-1142;
   Donzelli, Sara/0000-0002-8529-2895; /0000-0002-1239-7143; Aurisicchio,
   Luigi/0000-0003-3110-4534; Facciolo, Francesco/0000-0002-7137-8946;
   CASINI, BEATRICE/0000-0002-9038-0179; sacconi,
   andrea/0000-0002-8276-0438
FU AIRC [AIRC 14455]; EPIGEN [13/05/R/42]
FX This work was supported by AIRC to GB (AIRC 14455) and EPIGEN to GB
   (13/05/R/42).
CR Andl CD, 2004, AM J PHYSIOL-GASTR L, V287, pG1227, DOI 10.1152/ajpgi.00253.2004
   Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876
   Barnholtz-Sloan JS, 2004, J CLIN ONCOL, V22, P2865, DOI 10.1200/JCO.2004.12.149
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Biagioni F, 2012, EMBO MOL MED, V4, P1214, DOI 10.1002/emmm.201201483
   Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661
   Byrne JA, 2014, TUMOR BIOL, V35, P7369, DOI 10.1007/s13277-014-2006-x
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Cho WCS, 2011, RNA BIOL, V8, P125, DOI 10.4161/rna.8.1.14259
   Cioce M, 2014, ONCOGENE, V33, P5319, DOI 10.1038/onc.2013.476
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Dynoodt P, 2013, INT J ONCOL, V42, P1443, DOI 10.3892/ijo.2013.1823
   Eichler AF, 2007, ONCOLOGIST, V12, P884, DOI 10.1634/theoncologist.12-7-884
   Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58
   Ganci F, 2013, ANN ONCOL, V24, P3082, DOI 10.1093/annonc/mdt380
   Ganci F, 2014, LUNG CANCER, V85, P197, DOI 10.1016/j.lungcan.2014.04.008
   Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61
   Goto Y, 2014, FEBS LETT, V588, P1973, DOI 10.1016/j.febslet.2014.04.020
   Györffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329
   Hart M, 2014, MOL CANCER RES, V12, P250, DOI 10.1158/1541-7786.MCR-13-0230
   Horm TM, 2013, CELL ADHES MIGR, V7, P187, DOI 10.4161/cam.23131
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054652
   Lombardi G, 2014, CANCER TREAT REV, V40, P951, DOI 10.1016/j.ctrv.2014.05.007
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Melo SA, 2012, CLIN CANCER RES, V18, P4234, DOI 10.1158/1078-0432.CCR-11-2010
   Muti P, 2014, CANCER EPIDEM BIOMAR, V23, P2471, DOI 10.1158/1055-9965.EPI-14-0398
   Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y
   Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495
   Peng XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020341
   Sacconi A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.160
   Sachdeva M, 2010, AM J TRANSL RES, V2, P170
   Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021
   Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
   Schouten LJ, 2002, CANCER, V94, P2698, DOI 10.1002/cncr.10541
   Yan X, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-220
   Yin R, 2011, ONCOL REP, V25, P1747, DOI 10.3892/or.2011.1252
   Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28
   Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598
NR 47
TC 60
Z9 65
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 3
PY 2015
VL 6
IS 34
BP 35183
EP 35201
DI 10.18632/oncotarget.5930
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0QZ
UT WOS:000366111900017
PM 26440147
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Vrba, L
   Garbe, JC
   Stampfer, MR
   Futscher, BW
AF Vrba, Lukas
   Garbe, James C.
   Stampfer, Martha R.
   Futscher, Bernard W.
TI A lincRNA connected to cell mortality and epigenetically-silenced in
   most common human cancers
SO EPIGENETICS
LA English
DT Article
DE breast cancer; DNA methylation; epigenetics; immortality; HMEC; lncRNA;
   lincRNA; MORT; mammary epithelia; ncRNA; ZNF667-AS1
ID MAMMARY EPITHELIAL-CELLS; LONG NONCODING RNAS; X-CHROMOSOME; SENESCENCE
   BARRIERS; GENE; METHYLATION; INTEGRINS; EVOLUTION; DNA
AB Immortality is an essential characteristic of human carcinoma cells. We recently developed an efficient, reproducible method that immortalizes human mammary epithelial cells (HMEC) in the absence of gross genomic changes by targeting 2 critical senescence barriers. Consistent transcriptomic changes associated with immortality were identified using microarray analysis of isogenic normal finite pre-stasis, abnormal finite post-stasis, and immortal HMECs from 4 individuals. A total of 277 genes consistently changed in cells that transitioned from post-stasis to immortal. Gene ontology analysis of affected genes revealed biological processes significantly altered in the immortalization process. These immortalization-associated changes showed striking similarity to the gene expression changes seen in The Cancer Genome Atlas (TCGA) clinical breast cancer data. The most dramatic change in gene expression seen during the immortalization step was the downregulation of an unnamed, incompletely annotated transcript that we called MORT, for mortality, since its expression was closely associated with the mortal, finite lifespan phenotype. We show here that MORT (ZNF667-AS1) is expressed in all normal finite lifespan human cells examined to date and is lost in immortalized HMEC. MORT gene silencing at the mortal/immortal boundary was due to DNA hypermethylation of its CpG island promoter. This epigenetic silencing is also seen in human breast cancer cell lines and in a majority of human breast tumor tissues. The functional importance of DNA hypermethylation in MORT gene silencing is supported by the ability of 5-aza-2-deoxycytidine to reactivate MORT expression. Analysis of TCGA data revealed deregulation of MORT expression due to DNA hypermethylation in 15 out of the 17 most common human cancers. The epigenetic silencing of MORT in a large majority of the common human cancers suggests a potential fundamental role in cellular immortalization during human carcinogenesis.
C1 [Vrba, Lukas; Stampfer, Martha R.; Futscher, Bernard W.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
   [Garbe, James C.; Stampfer, Martha R.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Futscher, Bernard W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
C3 Arizona Center Cancer Care; University of Arizona; United States
   Department of Energy (DOE); Lawrence Berkeley National Laboratory;
   University of California System; University of California Berkeley;
   University of Arizona
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
EM bfutscher@uacc.arizona.edu
RI Vrba, Lukas/J-9268-2015
OI Vrba, Lukas/0000-0003-3042-6275
FU Margaret E. and Fenton L. Maynard Endowment for Breast Cancer Research
   and Center [ES006694, CA23074, CA65662, P42 ES04940]; LBNL DOE: the US.
   Department of Energy [DE-AC02-05CH11231]
FX This work was supported by the Margaret E. and Fenton L. Maynard
   Endowment for Breast Cancer Research and Center grants ES006694,
   CA23074, CA65662, P42 ES04940, LBNL DOE: the US. Department of Energy
   (DE-AC02-05CH11231).
CR [Anonymous], SCI
   [Anonymous], COLD SPRING HARB SYM
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28
   Carvalho B, 2007, BIOSTATISTICS, V8, P485, DOI 10.1093/biostatistics/kxl042
   Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dinger ME, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000176
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Gendrel AV, 2014, ANNU REV CELL DEV BI, V30, P561, DOI 10.1146/annurev-cellbio-101512-122415
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hezroni H, 2015, CELL REP, V11, P1110, DOI 10.1016/j.celrep.2015.04.023
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kapusta A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003470
   Keniry A, 2012, NAT CELL BIOL, V14, P659, DOI 10.1038/ncb2521
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016
   Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7
   Ling H, 2015, ONCOGENE, V34, P5003, DOI 10.1038/onc.2014.456
   Mitra Sheetal A., 2012, Frontiers in Genetics, V3, P17, DOI 10.3389/fgene.2012.00017
   Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0
   Pontier SM, 2009, J CELL SCI, V122, P207, DOI 10.1242/jcs.040394
   R_Development_Core_Team, 2015, R LANG ENV STAT COMP
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Society, 2015, CANC FACTS FIG 2015
   Stampfer M.R., 2013, Cell and Molecular Biology of Breast Cancer, P323
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Vincent-Salomon A, 2007, CANCER RES, V67, P5134, DOI 10.1158/0008-5472.CAN-07-0465
   Vrba L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-486
   Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006
NR 44
TC 26
Z9 31
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV 2
PY 2015
VL 10
IS 11
BP 1074
EP 1083
DI 10.1080/15592294.2015.1106673
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CY2NY
UT WOS:000366246600009
PM 26646903
OA Green Published, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Yang, M
   Liu, R
   Li, XJ
   Liao, J
   Pu, YP
   Pan, EC
   Wang, Y
   Yin, LH
AF Yang, Miao
   Liu, Ran
   Li, Xiajun
   Liao, Juan
   Pu, Yuepu
   Pan, Enchun
   Wang, Yi
   Yin, Lihong
TI Epigenetic Repression of miR-218 Promotes Esophageal Carcinogenesis by
   Targeting <i>ROBO1</i>
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE miR-218; CpG methylation; esophageal cancer; ROBO1
ID SQUAMOUS-CELL CARCINOMA; SUPPRESSOR GENES RASSF1A; TUMOR-SUPPRESSOR; DNA
   METHYLATION; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION;
   COLORECTAL-CANCER; BREAST-CANCER; HOST GENES; MICRORNA-218
AB miR-218, consisting of miR-218-1 at 4p15.31 and miR-218-2 at 5q35.1, was significantly decreased in esophageal squamous cell carcinoma (ESCC) in our previous study. The aim of this study was to determine whether aberrant methylation is associated with miR-218 repression. Bisulfite sequencing analysis (BSP), methylation specific PCR (MSP), and 5-aza-2-deoxycytidine treatment assay were applied to determine the methyaltion status of miR-218 in cells and clinical samples. In vitro assays were performed to explore the role of miR-218. Results showed that miR-218-1 was significantly CpG hypermethylated in tumor tissues (81%, 34/42) compared with paired non-tumor tissues (33%, 14/42) (p < 0.05). However, no statistical difference was found in miR-218-2. Accordingly, expression of miR-218 was negatively correlated with miR-218-1 methylation status (p < 0.05). After demethylation treatment by 5-aza-2-deoxycytidine, there was a 2.53- and 2.40-fold increase of miR-218 expression in EC109 and EC9706, respectively. miR-218 suppressed cell proliferation and arrested cells at G1 phase by targeting 3 untranslated region (3UTR) of roundabout guidance receptor 1 (ROBO1). A negative correlation was found between miR-218 and ROBO1 mRNA expression in clinical samples. In conclusion, our results support that aberrant CpG hypermethylation at least partly accounts for miR-218 silencing in ESCC, which impairs its tumor-suppressive function.
C1 [Yang, Miao; Liu, Ran; Li, Xiajun; Liao, Juan; Pu, Yuepu; Yin, Lihong] Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.
   [Pan, Enchun; Wang, Yi] Huaian Ctr Dis Control & Prevent, Huaian 223001, Peoples R China.
C3 Southeast University - China
RP Yin, LH (通讯作者)，Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.
EM 230129498@seu.edu.cn; ranliu@seu.edu.cn; 220122800@seu.edu.cn;
   230129495@seu.edu.cn; yppu@seu.edu.cn; hypec@163.com;
   wangyihuaian@163.com; lhyin@seu.edu.cn
FU National Natural Science Foundation of China [81111140396, 81072259,
   81573108, 81573191]; Fundamental Research Funds for the Central
   Universities; Innovative Research Project for Postgraduates in Colleges
   of Jiangsu Province [KYZZ_0078]; New Century Excellent Talents in
   University [NCET-13-0124]
FX This study is supported by the National Natural Science Foundation of
   China (Nos. 81111140396, 81072259, 81573108, 81573191), the Fundamental
   Research Funds for the Central Universities and Innovative Research
   Project for Postgraduates in Colleges of Jiangsu Province (KYZZ_0078),
   New Century Excellent Talents in University (NCET-13-0124), and the
   Fundamental Research Funds for the Central Universities.
CR Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Ao JY, 2015, TUMOR BIOL, V36, P8413, DOI 10.1007/s13277-015-3601-1
   Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Batliner J., 2013, CANCER RES, V73, P4186, DOI [10.1158/1538-7445.AM2013-4186, DOI 10.1158/1538-7445.AM2013-4186]
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171
   Coppedè F, 2014, CANCER LETT, V342, P238, DOI 10.1016/j.canlet.2011.12.030
   Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20
   Dallol A, 2002, CANCER RES, V62, P5874
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Dohi O, 2013, INT J ONCOL, V42, P411, DOI 10.3892/ijo.2012.1724
   Dong R, 2012, J INT MED RES, V40, P681, DOI 10.1177/147323001204000231
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Gröne J, 2006, ONCOL REP, V15, P1437
   Han GY, 2015, BIOCHEM BIOPH RES CO, V456, P804, DOI 10.1016/j.bbrc.2014.12.026
   He XQ, 2012, MOL MED, V18, P1491, DOI 10.2119/molmed.2012.00304
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Kinoshita T, 2012, ONCOTARGET, V3, P1386, DOI 10.18632/oncotarget.709
   Komatsu M, 2014, EPIGENOMICS-UK, V6, P567, DOI [10.2217/EPI.14.56, 10.2217/epi.14.56]
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Li QY, 2012, BIOCHEM BIOPH RES CO, V424, P28, DOI 10.1016/j.bbrc.2012.06.028
   Li XL, 2011, DIGEST DIS SCI, V56, P2849, DOI 10.1007/s10620-011-1711-1
   Mano Y, 2013, HUM PATHOL, V44, P2419, DOI 10.1016/j.humpath.2013.03.022
   Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Parray A, 2014, INT J CANCER, V135, P2493, DOI 10.1002/ijc.28919
   Qiu HF, 2011, ASIAN PAC J CANCER P, V12, P791
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Syrjänen KJ, 2002, J CLIN PATHOL, V55, P721, DOI 10.1136/jcp.55.10.721
   Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
   Uesugi A, 2011, CANCER RES, V71, P5765, DOI 10.1158/0008-5472.CAN-11-0368
   Yamamoto N, 2013, INT J ONCOL, V42, P1523, DOI 10.3892/ijo.2013.1851
   Yang M, 2013, ONCOL REP, V29, P169, DOI 10.3892/or.2012.2105
   Zhang C, 2015, ONCOL REP, V34, P952, DOI 10.3892/or.2015.4031
   Zhang QQ, 2015, ONCOTARGET, V6, P3123, DOI 10.18632/oncotarget.3060
NR 45
TC 14
Z9 17
U1 1
U2 35
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2015
VL 16
IS 11
BP 27781
EP 27795
DI 10.3390/ijms161126062
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CX4DI
UT WOS:000365648300127
PM 26610476
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Bicker, A
   Brahmer, AM
   Meller, S
   Kristiansen, G
   Gorr, TA
   Hankeln, T
AF Bicker, Anne
   Brahmer, Alexandra M.
   Meller, Sebastian
   Kristiansen, Glen
   Gorr, Thomas A.
   Hankeln, Thomas
TI The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast
   Cancer
SO PLOS ONE
LA English
DT Article
ID ENDOGENOUS MYOGLOBIN; RECEPTOR EXPRESSION; HYPOXIA; CELLS;
   DIFFERENTIATION; TRANSCRIPTION; NEUROGLOBIN; PREVENTION; MECHANISM; BETA
AB Myoglobin (MB) is not only strongly expressed in myocytes, but also at much lower levels in different cancer entities. 40% of breast tumors are MB-positive, with the globin being coexpressed with markers of tumor hypoxia in a proportion of cases. In breast cancer, MB expression is associated with a positive hormone receptor status and patient prognosis. In prostate cancer, another hormone-dependent cancer type, 53% of tumors were recently shown to express MB. Especially in more aggressive prostate cancer specimen MB expression also correlates with increased patient survival rates. Both findings might be due to tumor-suppressing properties of MB in cancer cells. In contrast to muscle, MB transcription in breast and prostate cancer mainly depends on a novel, alternative promoter site. We show here that its associated transcripts can be upregulated by hypoxia and downregulated by estrogens and androgens in MCF7 breast and LNCaP prostate cancer cells, respectively. Bioinformatic data mining of epigenetic histone marks and experimental verification reveal a hitherto uncharacterized transcriptional network that drives the regulation of the MB gene in cancer cells. We identified candidate hormone-receptor binding elements that may interact with the cancer-associated MB promoter to decrease its activity in breast and prostate cancer cells. Additionally, a regulatory element, 250 kb downstream of the promoter, acts as a hypoxia-inducible site within the transcriptional machinery. Understanding the distinct regulation of MB in tumors will improve unraveling the respiratory protein's function in the cancer context and may provide new starting points for developing therapeutic strategies.
C1 [Bicker, Anne; Brahmer, Alexandra M.; Hankeln, Thomas] Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55122 Mainz, Germany.
   [Meller, Sebastian; Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Bonn, Germany.
   [Gorr, Thomas A.] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland.
   [Gorr, Thomas A.] Univ Zurich, Regenerat Med Program, Zurich, Switzerland.
   [Gorr, Thomas A.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
C3 Johannes Gutenberg University of Mainz; University of Bonn; University
   of Zurich; University of Zurich; University of Zurich; University Zurich
   Hospital
RP Hankeln, T (通讯作者)，Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55122 Mainz, Germany.
EM hankeln@uni-mainz.de
RI Brahmer, Alexandra/ABI-6051-2020
OI Bicker, Dr. Anne/0000-0003-4364-9777; Gorr, Thomas/0000-0002-6023-4234
FU Center for Computational Sciences Mainz (CSM); Johannes Gutenberg
   University Mainz
FX This work was supported by the Center for Computational Sciences Mainz
   (CSM) 2013 and an intramural grant (Stufe 1) of Johannes Gutenberg
   University Mainz.
CR Behnes CL, 2013, EXP MOL PATHOL, V95, P307, DOI 10.1016/j.yexmp.2013.09.003
   Bicker A, 2014, HUM MOL GENET, V23, P479, DOI 10.1093/hmg/ddt438
   Burmester T, 2014, ACTA PHYSIOL, V211, P501, DOI 10.1111/apha.12312
   Chen RY, 2015, J IMMUNOL, V194, P4019, DOI 10.4049/jimmunol.1400806
   D'Aprile A, 2014, STEM CELLS, V32, P1267, DOI 10.1002/stem.1646
   Davis RW, 2014, J COMP PHYSIOL B, V184, P23, DOI 10.1007/s00360-013-0782-z
   Flögel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298
   Flögel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje
   Flonta SE, 2009, AM J PATHOL, V175, P201, DOI 10.2353/ajpath.2009.081124
   Fullwood Melissa J, 2010, Curr Protoc Mol Biol, VChapter 21, DOI 10.1002/0471142727.mb2115s89
   Galluzzo M, 2009, J CLIN INVEST, V119, P865, DOI 10.1172/JCI36579
   Glass CK, 2000, GENE DEV, V14, P121
   Gödecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495
   Guertin MJ, 2014, MOL ENDOCRINOL, V28, P1522, DOI 10.1210/me.2014-1130
   Guo MMWC, 2014, AM J CLIN EXP UROL, V2, P169
   Hendgen-Cotta UB, 2014, TRENDS CARDIOVAS MED, V24, P69, DOI 10.1016/j.tcm.2013.06.006
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151
   Kanatous SB, 2010, J EXP BIOL, V213, P2741, DOI 10.1242/jeb.041442
   Kristiansen G, 2010, BRIT J CANCER, V102, P1736, DOI 10.1038/sj.bjc.6605702
   Kristiansen G, 2011, J BIOL CHEM, V286, P43417, DOI 10.1074/jbc.M111.227553
   MacMunn CA., 1886, J PHYSL, V5, P24
   Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09
   Meller S, 2014, VIRCHOWS ARCH, V465, P419, DOI 10.1007/s00428-014-1646-y
   Merx Marc W., 2001, FASEB Journal, V15, P1077
   Oleksiewicz U, 2011, LUNG CANCER, V74, P411, DOI 10.1016/j.lungcan.2011.05.001
   Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426
   RUCK P, 1995, HEMATOL PATHOL, V9, P49
   Schlater AE, 2014, J APPL PHYSIOL, V117, P307, DOI 10.1152/japplphysiol.00973.2013
   Shiva S, 2007, CIRC RES, V100, P654, DOI 10.1161/01.RES.0000260171.52224.6b
   Steinmetz R, 1996, CANCER RES, V56, P5403
   WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.ph.51.030189.004233
   Wittenberg BA, 2009, AM J PHYSIOL-CELL PH, V296, pC390, DOI 10.1152/ajpcell.00002.2009
   Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243
   Zhang PJ, 2003, MODERN PATHOL, V16, P229, DOI 10.1097/01.MP.0000056630.76035.F3
NR 35
TC 26
Z9 28
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 11
PY 2015
VL 10
IS 11
AR e0142662
DI 10.1371/journal.pone.0142662
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV7DR
UT WOS:000364433100108
PM 26559958
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ben Dhiab, M
   Ziadi, S
   Mestiri, S
   Ben Gacem, R
   Ksiaa, F
   Trimeche, M
AF Ben Dhiab, Myriam
   Ziadi, Sonia
   Mestiri, Sarra
   Ben Gacem, Riadh
   Ksiaa, Feryel
   Trimeche, Mounir
TI DNA methylation patterns in EBV-positive and EBV-negative Hodgkin
   lymphomas
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Hodgkin lymphoma; Methylation; Epstein-Barr virus
ID EPSTEIN-BARR-VIRUS; ABERRANT PROMOTER HYPERMETHYLATION; LATENT
   MEMBRANE-PROTEIN; REED-STERNBERG CELLS; B-CELL; BREAST-CANCER;
   DAP-KINASE; CPG ISLAND; GENE; DISEASE
AB Purpose Hodgkin lymphoma (HL) is characterized by the presence of Hodgkin and Reed-Sternberg cells. Epstein-Barr virus (EBV) infection is thought to play an important role in the development of HL. Although epigenetic alterations, such as aberrant DNA methylation, are known to contribute to the pathogenesis of various malignancies, little is known about such alterations in HL and their putative relationships with EBV infection.
   Methods We investigated promoter methylation patterns of seven tumor-associated genes in 53 primary HL cases using methylation-specific PCR (MS-PCR). Concomitantly, the EBV infection status was assessed using PCR, in situ hybridization and immunohistochemistry.
   Results The gene promoter hypermethylation frequencies observed were 77.3 % for P16, 58.5 % for RASSF1A, 50.9 % for CDH1, 45.3 % for DAPK, 43.4 % for GSTP1, 37.7 % for SHP1 and 24.3 % for MGMT. SHP1 gene promoter hypermethylation was more frequently observed in patients at extreme ages (i.e., <= sign 15 and > 54 years) than in adult patients (p = 0.006) and in patients with B symptoms (p = 0.03). Interestingly, most of the analyzed gene promoters were more frequently hypermethylated in EBV-negative than in EBV-positive cases, in particular the DAPK gene promoter (58 % versus 27 %, p = 0.04). Furthermore, hypermethylation of multiple gene promoters (>= 3) was encountered more frequently in females than in males (86 % versus 57 %, p = 0.04), whereas EBV- positive cases were more common among males than females (55 % versus 30 %, p = 0.02).
   Conclusions Our results indicate that epigenetic changes frequently occur in both EBV-positive and EBV-negative HL. The rates of these changes were found to vary according to clinico-pathological parameters. These observations probably reflect the multitude of factors involved in HL development and the complexity of their interactions with genetic and/or hormonal factors.
C1 [Ben Dhiab, Myriam; Ziadi, Sonia; Mestiri, Sarra; Ben Gacem, Riadh; Ksiaa, Feryel; Trimeche, Mounir] CHU Farhat Hached, Dept Pathol, Sousse, Tunisia.
C3 Universite de Sousse; Hopital Farhat Hached
RP Trimeche, M (通讯作者)，CHU Farhat Hached, Dept Pathol, Sousse, Tunisia.
EM m_trimech@yahoo.fr
FU 'Ministre de l'Enseignement Superieur, de la Recherche Scientifique et
   de la Technologie'; 'Ministere de la Sante' of Tunisia
FX This work was supported by the 'Ministre de l'Enseignement Superieur, de
   la Recherche Scientifique et de la Technologie' and the 'Ministere de la
   Sante' of Tunisia.
CR Amara K, 2008, ANN ONCOL, V19, P1774, DOI 10.1093/annonc/mdn374
   Amara K, 2007, INT J CANCER, V121, P2693, DOI 10.1002/ijc.23038
   Ammerpohl O, 2012, LEUKEMIA, V26, P185, DOI 10.1038/leu.2011.194
   Armstrong AA, 1998, LEUKEMIA, V12, P1272, DOI 10.1038/sj.leu.2401097
   Armstrong AA, 1998, BRIT J CANCER, V77, P1045, DOI 10.1038/bjc.1998.174
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948
   Brousset P, 2004, INT J CANCER, V112, P533, DOI [10.1002/ijc.20397, 10.1002/IJC.20397]
   BROUSSET P, 1994, BLOOD, V84, P2447
   Challouf S, 2012, CLIN CHIM ACTA, V413, P795, DOI 10.1016/j.cca.2012.01.018
   Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   de Groot JS, 2014, CELL ONCOL, V37, P297, DOI 10.1007/s13402-014-0189-1
   Duijkers FAM, 2013, CELL ONCOL, V36, P351, DOI 10.1007/s13402-013-0140-x
   Esteller M, 2000, CANCER RES, V60, P129
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gallagher A, 2002, INT J CANCER, V101, P259, DOI 10.1002/ijc.10603
   García MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7
   Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T
   Glasser S.L., 1990, ROLE DIAGN ACCURACY, V66, P2196
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hernández-Losa J, 2005, CANCER-AM CANCER SOC, V103, P293, DOI 10.1002/cncr.20801
   Jaffe E.S., 2001, WHO CLASSIFICATION T, P237
   Jarrett RF, 2002, ANN ONCOL, V13, P23, DOI 10.1093/annonc/13.S1.23
   Jarrett RF, 1999, SEMIN HEMATOL, V36, P260
   Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502
   Ksiaa F, 2009, CLIN CHIM ACTA, V404, P128, DOI 10.1016/j.cca.2009.03.044
   Küppers R, 1999, J ACQ IMMUN DEF SYND, V21, pS74
   Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450
   MCKINNEY PA, 1989, BRIT J CANCER, V60, P942, DOI 10.1038/bjc.1989.395
   Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102
   Oka T, 2002, CANCER RES, V62, P6390
   Rawat A, 2014, CELL ONCOL, V37, P409, DOI 10.1007/s13402-014-0204-6
   Saito M, 2013, J MED VIROL, V85, P121, DOI 10.1002/jmv.23405
   Singal R, 2004, ONCOL REP, V12, P631
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Takeuchi S, 2011, LEUKEMIA RES, V35, P1345, DOI 10.1016/j.leukres.2011.04.015
   Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194
   Ushmorov A, 2006, BLOOD, V107, P2493, DOI 10.1182/blood-2005-09-3765
   Ushmorov A, 2004, BLOOD, V104, P3326, DOI 10.1182/blood-2003-04-1197
   Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1
   Yiannakopoulou E, 2014, CELL ONCOL, V37, P167, DOI 10.1007/s13402-014-0175-7
   Yousuf A, 2014, CELL ONCOL, V37, P245, DOI 10.1007/s13402-014-0179-3
NR 54
TC 26
Z9 28
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2015
VL 38
IS 6
BP 453
EP 462
DI 10.1007/s13402-015-0242-8
PG 10
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA CW9DK
UT WOS:000365298500005
PM 26350502
DA 2025-01-12
ER

PT J
AU Ozaki, Y
   Fujiwara, K
   Ikeda, M
   Ozaki, T
   Terui, T
   Soma, M
   Inazawa, J
   Nagase, H
AF Ozaki, Yumi
   Fujiwara, Kyoko
   Ikeda, Maki
   Ozaki, Toshinori
   Terui, Tadashi
   Soma, Masayoshi
   Inazawa, Johji
   Nagase, Hiroki
TI The oncogenic role of GASC1 in chemically induced mouse skin cancer
SO MAMMALIAN GENOME
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; HISTONE MODIFICATIONS; GENES;
   EPIGENETICS; FAMILY; AMPLIFICATION; DEMETHYLASES; METHYLATION;
   PROGRESSION
AB Gene amplified in squamous cell carcinoma (SCC) 1 (GASC1), also known as KDM4C/JMJD2C, encodes a histone demethylase that specifically demethylates lysine residues (H3K9, H3K36, and H1.4K26) and plays a crucial role in the regulation of gene expression as well as in heterochromatin formation. GASC1 is located at human chromosome 9p23-24, where frequent genomic amplification is observed in human esophageal cancer, and its aberrant expression is detected in a variety of human cancers, such as breast, colon, and prostate. Therefore, it is highly likely that GASC1 contributes to the genesis and/or development of cancer. However, there is a lack of direct evidence of GASC1 having an oncogenic function. In this study, we aimed to clarify the role of GASC1 in the skin SCC carcinogenesis. For this purpose, we generated Gasc1-heterozygous mice (Gasc1 (+/-)) with reduced expression of Gasc1. On the basis of our results, Gasc1 (+/-) mice displayed a significantly lower incidence and multiplicity of both benign and malignant tumors induced by the two-stage skin carcinogenesis protocol than wild-type mice. In addition, the volume of carcinoma was significantly lower in Gasc1 (+/-) mice. Consistent with these observations, knocking down of Gasc1 resulted in reduced cell viability of SCC cells in vitro. Our findings clearly demonstrated that GASC1 has an oncogenic role in skin carcinogenesis.
C1 [Ozaki, Yumi; Terui, Tadashi] Nihon Univ, Grad Sch Med, Dept Dermatol, Tokyo 1738610, Japan.
   [Fujiwara, Kyoko; Soma, Masayoshi] Nihon Univ, Sch Med, Dept Med, Div Gen Med,Itabashi Ku, Tokyo 1738610, Japan.
   [Fujiwara, Kyoko; Soma, Masayoshi] Nihon Univ, Sch Med, Res Inst Med Sci, Innovat Therapy Res Grp, Tokyo 1738610, Japan.
   [Ikeda, Maki] Nihon Univ, Sch Med, Dept Social Med, Div Publ Hlth, Tokyo 1738610, Japan.
   [Ozaki, Toshinori] Chiba Canc Ctr, Res Inst, Lab DNA Damage Signaling, Chiba 2608717, Japan.
   [Inazawa, Johji] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan.
   [Nagase, Hiroki] Chiba Canc Ctr, Res Inst, Canc Genet Lab, Chiba 2608717, Japan.
C3 Nihon University; Nihon University; Nihon University; Nihon University;
   Chiba Cancer Center; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Chiba Cancer Center
RP Fujiwara, K (通讯作者)，Nihon Univ, Sch Med, Dept Med, Div Gen Med,Itabashi Ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan.
EM fujiwara.kyoko@nihon-u.ac.jp; hnagase@chiba-cc.jp
OI Terui, Tadashi/0000-0002-0275-4311; Nagase, Hiroki/0000-0002-3992-5399
FU MEXT-Supported Program for the Strategic Research Foundation at Private
   Universities; JSPS KAKENHI [24591637, 15K09791]; Core Research for
   Evolutional Science and Technology (CREST) of Japan Science and
   Technology Corporation; New Energy and Industrial Technology Development
   Organization (NEDO); Grants-in-Aid for Scientific Research [15K09791,
   15H05908, 25250019, 24591637] Funding Source: KAKEN
FX We thank Mr. M. Kataba, Ms. A. Oguni, and Mr. J. Igarashi for their
   technical support and Ms. K. Takgata for her secretarial assistance.
   This work was supported in part by MEXT-Supported Program for the
   Strategic Research Foundation at Private Universities (2011-2015) to
   Kyoko Fujiwara, Tadashi Terui, Masayoshi Soma and Hiroki Nagase, by JSPS
   KAKENHI Grant Number 24591637, 15K09791 to Kyoko Fujiwara and Tadashi
   Terui, by the Core Research for Evolutional Science and Technology
   (CREST) of Japan Science and Technology Corporation to Johji Inazawa and
   the New Energy and Industrial Technology Development Organization (NEDO)
   to Johji Inazawa.
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Black JC, 2011, EPIGENETICS-US, V6, P13, DOI 10.4161/epi.6.1.13331
   BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925
   Fujiwara K, 2015, MOL CARCINOGEN, V54, P178, DOI 10.1002/mc.22085
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004
   Kang C, 2014, WORLD J GASTROENTERO, V20, P6433, DOI 10.3748/wjg.v20.i21.6433
   Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516
   Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013
   Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019
   Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147
   Sun LL, 2013, AM J CANCER RES, V3, P509
   Trojer P, 2009, J BIOL CHEM, V284, P8395, DOI 10.1074/jbc.M807818200
   Uimonen K, 2014, HISTOL HISTOPATHOL, V29, P797, DOI 10.14670/HH-29.797
   Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Yang ZQ, 2001, JPN J CANCER RES, V92, P423, DOI 10.1111/j.1349-7006.2001.tb01112.x
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
NR 30
TC 11
Z9 12
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-8990
EI 1432-1777
J9 MAMM GENOME
JI Mamm. Genome
PD DEC
PY 2015
VL 26
IS 11-12
BP 591
EP 597
DI 10.1007/s00335-015-9592-9
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA CX1FQ
UT WOS:000365442300001
PM 26248577
DA 2025-01-12
ER

PT J
AU Yang, L
   Ma, YM
   Han, WX
   Li, WW
   Cui, L
   Zhao, XH
   Tian, YT
   Zhou, ZX
   Wang, WG
   Wang, HY
AF Yang, Lan
   Ma, Yiming
   Han, Wenxiao
   Li, Weiwei
   Cui, Liang
   Zhao, Xinhua
   Tian, Yantao
   Zhou, Zhixiang
   Wang, Wengong
   Wang, Hongying
TI Proteinase-activated Receptor 2 Promotes Cancer Cell Migration through
   RNA Methylation-mediated Repression of miR-125b
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COLON-CANCER; BREAST-CANCER; MESSENGER-RNA; EXPRESSION; PROLIFERATION;
   METASTASIS; INVASION; TRYPSIN; TUMOR; PROTEASE-ACTIVATED-RECEPTOR-1
AB Proteinase activated-receptor 2 (PAR(2)) participates in cancer metastasis promoted by serine proteinases. The current study aimed to test the molecular mechanism by which PAR(2) promotes cancer cell migration. In different cancer cells, activation of PAR(2) by activating peptide (PAR(2)-AP) dramatically increased cell migration, whereas knock down of PAR(2) inhibited cellular motility. The PAR(2) activation also repressed miR-125b expression while miR-125b mimic successfully blocked PAR(2)-induced cell migration. Moreover, Grb associated-binding protein 2 (Gab2) was identified as a novel target gene of miR-125b and it mediated PAR(2)-induced cell migration. The correlation of PAR(2) with miR-125b and Gab2 was further supported by the findings obtained from human colorectal carcinoma specimens. Remarkably, knock down of NOP2/Sun domain family, member 2 (NSun2), a RNA methyltransferase, blocked the reduction in miR-125b induced by PAR(2). Furthermore, PAR(2) activation increased the level of N-6-methyladenosine (m(6)A)-containing pre-miR-125b in NSun2-dependent manner. Taken together, our results demonstrated that miR-125b mediates PAR(2)-induced cancer cell migration by targeting Gab2 and that NSun2-dependent RNA methylation contributes to the down-regulation of miR-125b by PAR(2) signaling. These findings suggest a novel epigenetic mechanism by which microenvironment regulates cancer cell migration by altering miRNA expression.
C1 [Yang, Lan; Ma, Yiming; Han, Wenxiao; Li, Weiwei; Zhao, Xinhua; Wang, Hongying] Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Canc Hosp,Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Cui, Liang; Tian, Yantao] Chinese Acad Med Sci, Dept Abdominal Surg Oncol, Inst Canc, Canc Hosp,Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Zhou, Zhixiang] Chinese Acad Med Sci, Dept Gastrointestinal Surg Oncol, Inst Canc, Canc Hosp,Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Wang, Wengong] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100191, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital - CAMS;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital - CAMS;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute & Hospital - CAMS; Peking Union Medical College; Peking
   University
RP Wang, HY (通讯作者)，Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Canc Hosp,Peking Union Med Coll, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.
EM hongyingwang@cicams.ac.cn
RI Ma, Yiming/AAG-3479-2019; zhang, xiaowei/GQH-5387-2022; Zhang,
   Xiaotong/HIR-6204-2022; liang, cui/KIE-2680-2024
OI Li, Weiwei/0000-0002-8298-2719; Wang, Hongying/0000-0001-8443-3839
FU 973 National Key Fundamental Research Program of China [2012CB967003];
   National Nature Science Foundation of China [81172034, 91129717]
FX This work was supported by funding from the 973 National Key Fundamental
   Research Program of China (2012CB967003) and the National Nature Science
   Foundation of China (81172034 and 91129717). The authors declare that
   they have no conflicts of interest with the contents of this article.
CR Amir S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061064
   Bera A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106343
   Black PC, 2007, PROSTATE, V67, P743, DOI 10.1002/pros.20503
   Blanco S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002403
   Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841
   Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200
   Dorn J, 2011, ANN ONCOL, V22, P877, DOI 10.1093/annonc/mdq462
   Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027
   Gieseler F, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-86
   Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3
   Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hu LC, 2013, TUMOR BIOL, V34, P2573, DOI 10.1007/s13277-013-0803-2
   Huang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033762
   Ji LJ, 2012, CELL RES, V22, P624, DOI 10.1038/cr.2012.36
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Li YY, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-33
   Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072383
   Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008
   Matsumura T, 2014, ANN SURG ONCOL, V21, pS743, DOI 10.1245/s10434-014-3889-x
   Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348
   Nishibori M, 2005, J PHARMACOL SCI, V97, P25, DOI 10.1254/jphs.FMJ04005X5
   Nishida N, 2011, INT J ONCOL, V38, P1437, DOI 10.3892/ijo.2011.969
   Ohta T, 2003, INT J ONCOL, V23, P61
   Sætrom P, 2009, CANCER RES, V69, P7459, DOI 10.1158/0008-5472.CAN-09-1201
   Sánchez-Hernández PE, 2008, GYNECOL ONCOL, V108, P19, DOI 10.1016/j.ygyno.2007.08.083
   Schaffner F, 2012, THROMB RES, V129, pS127, DOI 10.1016/S0049-3848(12)70032-4
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Soreide K, 2006, J PATHOL, V209, P147, DOI 10.1002/path.1999
   Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163
   Tsai KW, 2009, EPIGENETICS-US, V4, P587, DOI 10.4161/epi.4.8.10230
   Uusitalo-Jarvinen H, 2007, ARTERIOSCL THROM VAS, V27, P1456, DOI 10.1161/ATVBAHA.107.142539
   Versteeg HH, 2008, CANCER RES, V68, P7219, DOI 10.1158/0008-5472.CAN-08-0419
   Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048
   Wang H, 2008, J BIOL CHEM, V283, P809, DOI 10.1074/jbc.M703021200
   Wilson SR, 2004, PROSTATE, V60, P168, DOI 10.1002/pros.20047
   Wöhrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22
   Yada K, 2005, J SURG ONCOL, V89, P79, DOI 10.1002/jso.20197
   Yang RX, 2011, BREAST CANCER RES TR, V127, P549, DOI 10.1007/s10549-010-1244-x
   Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432
   Yuan S, 2014, MOL CELL BIOL, V34, P3630, DOI 10.1128/MCB.00243-14
   Zhang XT, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1692
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
   Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007
NR 46
TC 61
Z9 66
U1 1
U2 22
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 30
PY 2015
VL 290
IS 44
BP 26627
EP 26637
DI 10.1074/jbc.M115.667717
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CW2AO
UT WOS:000364793600028
PM 26354435
OA Green Published
DA 2025-01-12
ER

PT J
AU Wang, Y
   Chen, YJ
   Geng, H
   Qi, C
   Liu, YD
   Yue, D
AF Wang, Yong
   Chen, Yajing
   Geng, Hua
   Qi, Can
   Liu, Yunde
   Yue, Dan
TI Overexpression of YB1 and EZH2 are associated with cancer metastasis and
   poor prognosis in renal cell carcinomas
SO TUMOR BIOLOGY
LA English
DT Article
DE Enhancer of zeste homolog 2; Nuclear expression; Renal cell carcinoma;
   Y-Box-binding protein 1
ID BOX-BINDING PROTEIN-1; PROSTATE-CANCER; BREAST-CANCER; EXPRESSION;
   PROLIFERATION; YB-1; PROGRESSION; RESISTANCE; TARGET; GROWTH
AB Renal cell carcinoma (RCC) is the most common type of kidney cancers in adults, and metastasis represents the major cause of mortality of RCC patients. The Y-box binding protein 1 (YB1) is a multifunctional oncoprotein in various malignancies. Enhancer of zeste homolog 2 (EZH2), a polycomb histone methyltransferase, is a key epigenetic modifier implicated in various cancer metastasis. However, the expression patterns and clinical correlations of both YB1 and EZH2 in RCC remain largely unclear. In this study, the expression of YB1 and EZH2 were examined using immunohistochemistry staining in a study cohort including 165 RCC and 80 tumor adjacent normal tissues. RCC tissues showed a significant higher nuclear expression of YB1 (p < 0.001) and EZH2 (p < 0.001) as compared with the normal counterparts. In addition, YB1 and EZH2 nuclear overexpression were found to be positively associated with RCC stage (p < 0.001 and p = 0.005), Fuhrman tumor grade (p = 0.022 and p = 0.044), and metastasis (p < 0.001 and p = 0.009). Overall survival analysis indicated patients with YB1 (p = 0.004, HR 5.656 (2.006-10.944)) and/or EZH2 (p = 0.006, HR 4.551 (2.124-9.438)) nuclear overexpression correlated with poor survival. More interestingly, YB1 and EZH2 nuclear expression was correlated (p = 0.005). Further studies demonstrated that EZH2 expression was significantly downregulated in YB1 knockdown RCC cell lines. Functionally, YB1 knockdown inhibited RCC invasion in vitro. In conclusion, YB1 and EZH2 expression was correlated and associated with RCC incidence, tumor stage, grade, metastasis, and survival.
C1 [Wang, Yong] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.
   [Chen, Yajing; Liu, Yunde; Yue, Dan] Tianjin Med Univ, Sch Lab Med, Tianjin 300203, Peoples R China.
   [Geng, Hua] Tianjin Med Univ, Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China.
   [Qi, Can] Childrens Hosp Hebei Prov, Dept Urol, Shijiazhuang 050031, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Yue, D (通讯作者)，Tianjin Med Univ, Sch Lab Med, Tianjin 300203, Peoples R China.
EM danyue0705@sina.cn
FU National Natural Science Foundation of China [81202380, 81402094,
   81202100]; Ph.D. Programs Foundation of Ministry of Education of China
   [20111202120016]; Natural Science Foundation of Tianjin [12JCQNJC07800,
   12JCYBJC15600, 14JCQNJC11600]; China Postdoctoral Science Foundation
   [2013M541189]; Tianjin national undergraduate training programs for
   innovation and entrepreneurship [201310062002]
FX This work was supported by grants (81202380, 81402094, and 81202100)
   from the National Natural Science Foundation of China, grants
   (20111202120016) from Ph.D. Programs Foundation of Ministry of Education
   of China, grants (12JCQNJC07800, 12JCYBJC15600, and 14JCQNJC11600) from
   Natural Science Foundation of Tianjin, grant (2013M541189) from China
   Postdoctoral Science Foundation, and grant (201310062002) Tianjin
   national undergraduate training programs for innovation and
   entrepreneurship.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993
   Chattopadhyay R, 2008, MOL CELL BIOL, V28, P7066, DOI 10.1128/MCB.00244-08
   Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049
   Fujiwara-Okada Y, 2013, BRIT J CANCER, V108, P836, DOI 10.1038/bjc.2012.579
   Fushimi F, 2013, VIRCHOWS ARCH, V463, P553, DOI 10.1007/s00428-013-1460-y
   Hinz S, 2008, J CANCER RES CLIN, V134, P331, DOI 10.1007/s00432-007-0288-8
   Hinz S, 2009, J UROLOGY, V182, P2920, DOI 10.1016/j.juro.2009.08.014
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Lasham A, 2013, BIOCHEM J, V449, P11, DOI 10.1042/BJ20121323
   Maciejczyk A, 2012, ANTICANCER RES, V32, P3177
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Shiota M, 2011, ENDOCR-RELAT CANCER, V18, P505, DOI 10.1530/ERC-11-0017
   Singer EA, 2013, CURR OPIN ONCOL, V25, P273, DOI 10.1097/CCO.0b013e32835fc857
   Song YH, 2013, UROL ONCOL
   Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   WOLFFE AP, 1992, NEW BIOL, V4, P290
   Wu KM, 2014, CANCER RES, V74, P829, DOI 10.1158/0008-5472.CAN-13-2466
NR 22
TC 39
Z9 41
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 9
BP 7159
EP 7166
DI 10.1007/s13277-015-3417-z
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CW5KA
UT WOS:000365033100066
PM 25877750
DA 2025-01-12
ER

PT J
AU Eedunuri, VK
   Rajapakshe, K
   Fiskus, W
   Geng, CD
   Chew, SA
   Foley, C
   Shah, SS
   Shou, J
   Mohamed, JS
   Coarfa, C
   O'Malley, BW
   Mitsiades, N
AF Eedunuri, Vijay Kumar
   Rajapakshe, Kimal
   Fiskus, Warren
   Geng, Chuandong
   Chew, Sue Anne
   Foley, Christopher
   Shah, Shrijal S.
   Shou, John
   Mohamed, Junaith S.
   Coarfa, Cristian
   O'Malley, Bert W.
   Mitsiades, Nicholas
TI miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3
   and Inhibits Cell Proliferation
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ANDROGEN RECEPTOR; UVEAL MELANOMA; BREAST; EXPRESSION; AIB1; MICRORNAS;
   TRANSCRIPTION; ACTIVATION; GENOMICS; MICE
AB The p160 family of steroid receptor coactivators (SRCs) are pleiotropic transcription factor coactivators and "master regulators" of gene expression that promote cancer cell proliferation, survival, metabolism, migration, invasion, and metastasis. Cancers with high p160 SRC expression exhibit poor clinical outcomes and resistance to therapy, highlighting the SRCs as critical oncogenic drivers and, thus, therapeutic targets. microRNAs are important epigenetic regulators of protein expression. To examine the regulation of p160 SRCs by microRNAs, we used and combined 4 prediction algorithms to identify microRNAs that could target SRC1, SRC2, and SRC3 expression. For validation of these predictions, we assessed p160 SRC protein expression and cell viability after transfection of corresponding microRNA mimetics in breast cancer, uveal melanoma, and prostate cancer (PC) cell lines. Transfection of selected microRNA mimetics into breast cancer, uveal melanoma, and PC cells depleted SRC protein expression levels and exerted potent antiproliferative activity in these cell types. In particular, microRNA-137 (miR-137) depleted expression of SRC1, SRC2, and very potently, SRC3. The latter effect can be attributed to the presence of 3 miR-137 recognition sequences within the SRC3 3'-untranslated region. Using reverse phase protein array analysis, we identified a network of proteins, in addition to SRC3, that were modulated by miR-137 in PC cells. We also found that miR-137 and its host gene are epigenetically silenced in human cancer specimens and cell lines. These results support the development and testing of microRNA-based therapies (in particular based on restoring miR-137 levels) for targeting the oncogenic family of p160 SRCs in cancer.
C1 [Eedunuri, Vijay Kumar] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA 70130 USA.
   [Rajapakshe, Kimal; Fiskus, Warren; Geng, Chuandong; Chew, Sue Anne; Foley, Christopher; Shah, Shrijal S.; Shou, John; Mohamed, Junaith S.; Coarfa, Cristian; O'Malley, Bert W.; Mitsiades, Nicholas] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Fiskus, Warren; Geng, Chuandong; Chew, Sue Anne; Foley, Christopher; Shah, Shrijal S.; Shou, John; Mohamed, Junaith S.; Mitsiades, Nicholas] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Mitsiades, N (通讯作者)，Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407,Mail Stop BCM187, Houston, TX 77030 USA.
EM coarfa@bcm.edu; mitsiade@bcm.edu
RI Mohamed, Junaith/AAC-4050-2020; Rajapakshe, Kimal/P-1592-2015; Eedunuri,
   VIJAY/L-2213-2015
OI Mitsiades, Nicholas/0000-0002-4659-476X
FU American Cancer Society [RSG-14-218-01-TBG]; Prostate Cancer Foundation;
   Melanoma Research Alliance; Conquer Cancer Foundation of the American
   Society of Clinical Oncology; Translational Research in Breast Cancer
   Specialized Programs of Research Excellence Grant [P50CA186784]; Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   Grant [8818]; Department of Defense Breast Cancer Research Program
   Innovator Award; Pilot/Feasibility Program of the Diabetes and
   Endocrinology Research Center Grant at Baylor College of Medicine
   [P30-DK079638]; Alkek Foundation for Molecular Discovery Pilot grant;
   National Cancer Institute Cancer Center Support Grant [P30CA125123]; NCI
   Cancer Center Support Grant [P30CA125123]
FX This work was supported by the American Cancer Society Grant
   RSG-14-218-01-TBG (to N.M.), the Prostate Cancer Foundation (B.W.O. and
   N.M.), the Melanoma Research Alliance (N.M.), the Conquer Cancer
   Foundation of the American Society of Clinical Oncology Young
   Investigator and Career Development Awards (N.M.), the Translational
   Research in Breast Cancer Specialized Programs of Research Excellence
   Grant P50CA186784, The Eunice Kennedy Shriver National Institute of
   Child Health and Human Development Grant 8818 and Department of Defense
   Breast Cancer Research Program Innovator Award (B.W.O.), the
   Pilot/Feasibility Program of the Diabetes and Endocrinology Research
   Center Grant P30-DK079638 at Baylor College of Medicine (to N.M.), and
   an Alkek Foundation for Molecular Discovery Pilot grant (C.C.). N.M. is
   a Dan L. Duncan Scholar, a Caroline Wiess Law Scholar, and a member of
   the Dan L. Duncan Cancer Center (supported by the National Cancer
   Institute Cancer Center Support Grant P30CA125123) and the Center for
   Drug Discovery at Baylor College of Medicine. Assistance was also
   provided by the Shared Resources of the Dan L. Duncan Cancer Center
   (supported by the NCI Cancer Center Support Grant P30CA125123) and the
   Functional Proteomics RPPA Core Facility (The University of Texas M.D.
   Anderson Cancer Center, Houston, TX).
CR Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023
   Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541
   Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Byun B, 2007, BIOFACTORS, V31, P165, DOI 10.1002/biof.5520310303
   Cavarretta ITR, 2002, MOL ENDOCRINOL, V16, P253, DOI 10.1210/me.16.2.253
   Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910
   Chen LC, 2012, EUR J CANCER, V48, P3104, DOI 10.1016/j.ejca.2012.02.007
   Cheng CJ, 2013, CURR MED CHEM, V20, P3582
   Coarfa C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-572
   Dacic S, 2010, MODERN PATHOL, V23, P1577, DOI 10.1038/modpathol.2010.152
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115
   Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110
   Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179
   Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x
   Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gujral TS, 2013, ONCOGENE, V32, P3470, DOI 10.1038/onc.2012.378
   Han SJ, 2006, MOL ENDOCRINOL, V20, P45, DOI 10.1210/me.2005-0310
   He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111
   Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363
   Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476
   Kamburov A, 2009, NUCLEIC ACIDS RES, V37, pD623, DOI 10.1093/nar/gkn698
   Kashani-Sabet M, 2009, CLIN CANCER RES, V15, P6987, DOI 10.1158/1078-0432.CCR-09-1777
   Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704
   Komurov K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-282
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lanz RB, 2010, MOL ENDOCRINOL, V24, P859, DOI 10.1210/me.2009-0499
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li C, 2011, ONCOGENE, V30, P4350, DOI 10.1038/onc.2011.151
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li JV, 2013, MOL ENDOCRINOL, V27, P1113, DOI 10.1210/me.2012-1353
   Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968
   Lindholm EM, 2014, CLIN CANCER RES, V20, P404, DOI 10.1158/1078-0432.CCR-13-1865
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Lonard DM, 2012, NAT REV ENDOCRINOL, V8, P598, DOI 10.1038/nrendo.2012.100
   Lonard DM, 2010, MOL ENDOCRINOL, V24, P279, DOI 10.1210/me.2009-0276
   Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164
   Mitsiades N, 2011, INVEST OPHTH VIS SCI, V52, P7248, DOI 10.1167/iovs.11-7398
   Motamed M, 2014, MOL ENDOCRINOL, V28, P395, DOI 10.1210/me.2013-1404
   Nakka M, 2013, INT J BIOCHEM CELL B, V45, P763, DOI 10.1016/j.biocel.2012.12.012
   O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223
   Olivier BG, 2002, MOL BIOL REP, V29, P249, DOI 10.1023/A:1020346417223
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Poulaki V, 2012, ARVO M, V53
   Qin J, 2014, J CLIN INVEST, V124, P5013, DOI 10.1172/JCI76412
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rangel J, 2006, J CLIN ONCOL, V24, P4565, DOI 10.1200/JCO.2006.07.3833
   Reyes-Herrera Paula H., 2012, Genomics Proteomics & Bioinformatics, V10, P254, DOI 10.1016/j.gpb.2012.10.001
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rollins DA, 2015, MOL ENDOCRINOL, V29, P502, DOI 10.1210/me.2015-1005
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Slack FJ, 2013, CLIN CHEM, V59, P325, DOI 10.1373/clinchem.2011.181016
   Stahlhut C, 2013, GENOME MED, V5, DOI 10.1186/gm516
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thorsen SB, 2012, CANCER J, V18, P275, DOI 10.1097/PPO.0b013e318258b5d6
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Tien JCY, 2013, CANCER RES, V73, P3997, DOI 10.1158/0008-5472.CAN-12-3929
   Torres-Arzayus MI, 2006, CANCER RES, V66, P11381, DOI 10.1158/0008-5472.CAN-06-2316
   Torres-Arzayus MI, 2010, CANCER RES, V70, P4102, DOI 10.1158/0008-5472.CAN-09-4080
   Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027
   Troncale S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038686
   Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586
   Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018
   Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939
   Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222
   Winnay JN, 2006, ENDOCRINOLOGY, V147, P1322, DOI 10.1210/en.2005-0751
   Witkos TM, 2011, CURR MOL MED, V11, P93
   Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922
   Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955
   Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442
   Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030
   York B, 2013, MOL ENDOCRINOL, V27, P366, DOI 10.1210/me.2012-1324
   Yuan Y, 2014, BIORESOURCE TECHNOL, V174, P1, DOI 10.1016/j.biortech.2014.07.104
   Yue D, 2009, CURR GENOMICS, V10, P478, DOI 10.2174/138920209789208219
   Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003
   Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076
NR 94
TC 31
Z9 34
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD AUG
PY 2015
VL 29
IS 8
BP 1170
EP 1183
DI 10.1210/me.2015-1080
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA CW8TI
UT WOS:000365271800009
PM 26066330
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Vasudevan, D
   Hickok, JR
   Bovee, RC
   Pham, V
   Mantell, LL
   Bahroos, N
   Kanabar, P
   Cao, XJ
   Maienschein-Cline, M
   Garcia, BA
   Thomas, DD
AF Vasudevan, Divya
   Hickok, Jason R.
   Bovee, Rhea C.
   Vy Pham
   Mantell, Lin L.
   Bahroos, Neil
   Kanabar, Pinal
   Cao, Xing-Jun
   Maienschein-Cline, Mark
   Garcia, Benjamin A.
   Thomas, Douglas D.
TI Nitric Oxide Regulates Gene Expression in Cancers by Controlling Histone
   Posttranslational Modifications
SO CANCER RESEARCH
LA English
DT Article
ID NEGATIVE BREAST-CANCER; S-NITROSYLATION; TUMOR-GROWTH; NOS2;
   PROLIFERATION; METASTASIS; CONTRIBUTES; METHYLATION; PROGRESSION;
   INHIBITION
AB Altered nitric oxide (center dot NO) metabolism underlies cancer pathology, but mechanisms explaining many center dot NO-associated phenotypes remain unclear. We have found that cellular exposure to center dot NO changes histone posttranslational modifications (PTM) by directly inhibiting the catalytic activity of JmjC-domain containing histone demethylases. Herein, we describe how center dot NO exposure links modulation of histone PTMs to gene expression changes that promote oncogenesis. Through high-resolution mass spectrometry, we generated an extensive map of center dot NO-mediated histone PTM changes at 15 critical lysine residues on the core histones H3 and H4. Concomitant microarray analysis demonstrated that exposure to physiologic center dot NO resulted in the differential expression of over 6,500 genes in breast cancer cells. Measurements of the association of H3K9me2 and H3K9ac across genomic loci revealed that differential distribution of these particular PTMs correlated with changes in the level of expression of numerous oncogenes, consistent with epigenetic code. Our results establish that center dot NO functions as an epigenetic regulator of gene expression mediated by changes in histone PTMs. (C) 2015 AACR.
C1 [Vasudevan, Divya; Hickok, Jason R.; Bovee, Rhea C.; Vy Pham; Thomas, Douglas D.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
   [Mantell, Lin L.] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY USA.
   [Bahroos, Neil; Kanabar, Pinal; Maienschein-Cline, Mark] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY USA.
   [Cao, Xing-Jun; Garcia, Benjamin A.] Univ Penn, Dept Biochem & Biophys, Perelman Sch Med, Epigenet Program, Philadelphia, PA 19104 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Saint John's University; Saint
   John's University; University of Pennsylvania
RP Thomas, DD (通讯作者)，Univ Illinois, 833 S Wood St,MC 781, Chicago, IL 60612 USA.
EM ddthomas@uic.edu
OI Thomas, Douglas/0000-0003-1252-0786
FU National Institute of General Medical Sciences of the NIH [R01GM085232];
   National Center for Advancing Translational Sciences, NIH [UL1TR000050];
   NIH [DP2OD007447, R01GM110174]
FX This project was supported by the National Institute of General Medical
   Sciences of the NIH under award number R01GM085232. The project was also
   supported by the National Center for Advancing Translational Sciences,
   NIH, through grant UL1TR000050. B.A. Garcia acknowledges funding from
   the NIH through an Innovator Award (DP2OD007447) and grant R01GM110174.
   The authors also acknowledge ongoing support from the UIC Cancer Center.
CR Ampuja M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-429
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Boidot R, 2010, ONCOGENE, V29, P2577, DOI 10.1038/onc.2009.525
   Burke AJ, 2013, CARCINOGENESIS, V34, P503, DOI 10.1093/carcin/bgt034
   Chang ACM, 2015, CLIN EXP METASTAS, V32, P15, DOI 10.1007/s10585-014-9687-9
   Chang CF, 2015, FREE RADICAL BIO MED, V79, P324, DOI 10.1016/j.freeradbiomed.2014.11.012
   Cheng ZJ, 2014, GENE DEV, V28, P1758, DOI 10.1101/gad.246561.114
   Colussi C, 2008, P NATL ACAD SCI USA, V105, P19183, DOI 10.1073/pnas.0805514105
   Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299
   Garske AL, 2010, NAT CHEM BIOL, V6, P283, DOI [10.1038/NCHEMBIO.319, 10.1038/nchembio.319]
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gasparini G, 2000, Oncologist, V5 Suppl 1, P37
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Glynn SA, 2010, J CLIN INVEST, V120, P3843, DOI 10.1172/JCI42059
   Gross TJ, 2014, J IMMUNOL, V192, P2326, DOI 10.4049/jimmunol.1301758
   Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111
   Hickok JR, 2013, J BIOL CHEM, V288, P16004, DOI 10.1074/jbc.M112.432294
   Hickok JR, 2010, CURR PHARM DESIGN, V16, P381, DOI 10.2174/138161210790232149
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Ignarro LJ, 2002, J PHYSIOL PHARMACOL, V53, P503
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Li J, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-7
   Lin S, 2012, METHOD ENZYMOL, V512, P3, DOI 10.1016/B978-0-12-391940-3.00001-9
   Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200
   Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626
   Mukherjee D, 2013, AM J CANCER RES, V3, P46
   Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238
   Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241
   Okayama H, 2013, INT J CANCER, V132, P9, DOI 10.1002/ijc.27644
   Re A, 2011, MOL ENDOCRINOL, V25, P2003, DOI 10.1210/me.2011-1024
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Salhia B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085448
   Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747
   Sen N, 2011, P NATL ACAD SCI USA, V108, P20178, DOI 10.1073/pnas.1117820108
   Smith BC, 2012, CURR OPIN CHEM BIOL, V16, P498, DOI 10.1016/j.cbpa.2012.10.016
   Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Vasudevan D, 2014, VITAM HORM, V96, P265, DOI 10.1016/B978-0-12-800254-4.00011-8
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 50
TC 47
Z9 54
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2015
VL 75
IS 24
BP 5299
EP 5308
DI 10.1158/0008-5472.CAN-15-1582
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DA1JL
UT WOS:000367552000015
PM 26542213
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Yang, X
   Cheng, YD
   Lu, Q
   Wei, JF
   Yang, HW
   Gu, M
AF Yang, Xiao
   Cheng, Yidong
   Lu, Qiang
   Wei, Jifu
   Yang, Haiwei
   Gu, Min
TI Detection of stably expressed piRNAs in human blood
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE piRNA; serum; plasma; circulating; blood; biomarker
ID NOVO DNA METHYLATION; NONCODING RNAS; BREAST-CANCER; CELLS; MICRORNAS
AB Background: Circulating microRNAs are potential markers for disease detection. A novel class of small non-coding RNAs called Piwi-interacting RNAs (piRNAs) has been recently reported to participate in the epigenetic regulation of cancers and other diseases. This study aims to discover blood-based piRNAs which can be used as markers for disease detection and monitoring. Materials and methods: We selected five piRNAs for detection, namely, has-piR-651, has-piR-823, has-piR-36707, has-piR-36741 and has-piR-57125. Serum or plasma samples were used to isolate small RNAs, including the piRNAs. The extracted small RNAs were reverse-transcribed in the presence of a poly-A polymerase with an oligo-dT adaptor, and quantitative real-time PCR (qRT-PCR) was applied to measure the levels of piRNAs. Room-temperature incubation and repetitive freeze-thaw cycles were performed to measure the stability of the piRNAs. Results: Unlike the four other piRNAs, has-piR-57125 was present in both the serum and plasma samples. Regardless of the serum or plasma samples, qRT-PCR analysis indicated that the Ct values showed no remarkable variation with prolonged incubation time (P > 0.05). We also detected the Ct values of the samples with repetitive freeze-thaw cycles and observed a similar trend (P > 0.05) among the samples with diverse freeze-thaw cycles. Conclusion: This study is the first to report that piRNAs are stably expressed in human serum or plasma samples. Therefore, piRNAs can serve as valuable blood-based biomarkers for disease detection and monitoring.
C1 [Yang, Xiao; Cheng, Yidong; Lu, Qiang; Yang, Haiwei; Gu, Min] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China.
   [Wei, Jifu] Nanjing Med Univ, Affiliated Hosp 1, Clin Res Ctr, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Gu, M (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China.
EM hwyang2002@163.com; Lancetgu@aliyun.com
RI yang, xiao/HJI-7815-2023
OI Yang, Xiao/0000-0002-5429-9162; Lu, Qiang/0000-0003-3589-2507
CR Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003
   Cheng GF, 2015, ADV DRUG DELIVER REV, V81, P75, DOI 10.1016/j.addr.2014.09.001
   Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Law PTY, 2013, J HEPATOL, V58, P1165, DOI 10.1016/j.jhep.2013.01.032
   Mei YP, 2013, CANCER LETT, V336, P46, DOI 10.1016/j.canlet.2013.04.008
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135
   Zhang H, 2013, SURG ONCOL, V22, P217, DOI 10.1016/j.suronc.2013.07.001
   Zhou HH, 2010, BIOL CELL, V102, P645, DOI 10.1042/BC20100029
NR 17
TC 41
Z9 46
U1 0
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 8
BP 13353
EP 13358
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CW8TJ
UT WOS:000365271900167
PM 26550265
DA 2025-01-12
ER

PT J
AU Cohen, PA
   Donini, CF
   Nguyen, NT
   Lincet, H
   Vendrell, JA
AF Cohen, Pascale A.
   Donini, Caterina F.
   Nguyen, Nhan T.
   Lincet, Hubert
   Vendrell, Julie A.
TI The dark side of ZNF217, a key regulator of tumorigenesis with powerful
   biomarker value
SO ONCOTARGET
LA English
DT Article
DE ZNF217; oncogene; biomarker; hallmarks of cancer; carcinogenesis
ID BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; P15(INK4B)
   TUMOR-SUPPRESSOR; CANDIDATE ONCOGENE ZNF217; HUMAN TELOMERASE ACTIVITY;
   DNA COPY NUMBER; GENE-EXPRESSION; TGF-BETA; MICROARRAY ANALYSIS;
   AURORA-A
AB The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.
C1 [Cohen, Pascale A.; Donini, Caterina F.; Nguyen, Nhan T.; Lincet, Hubert; Vendrell, Julie A.] Fac Pharm Lyon, ISPB, Lyon, France.
   [Cohen, Pascale A.; Donini, Caterina F.; Nguyen, Nhan T.; Lincet, Hubert; Vendrell, Julie A.] Univ Lyon 1, F-69365 Lyon, France.
   [Cohen, Pascale A.; Donini, Caterina F.; Nguyen, Nhan T.; Lincet, Hubert; Vendrell, Julie A.] Ctr Rech Cancerol Lyon, INSERM, U1052, CNRS,UMR5286, Lyon, France.
C3 Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB)
RP Cohen, PA (通讯作者)，Fac Pharm Lyon, ISPB, Lyon, France.
EM pascale.cohen@univ-lyon1.fr
RI Vendrell, Julie/I-5867-2012; cohen, pascale/I-5875-2012
OI cohen, pascale/0000-0001-7016-9598; Donini, Caterina
   Francesca/0000-0001-8976-1524
FU PRES/Lyon Science Transfert [LST607]; Canceropole Lyon Auvergne
   Rhone-Alpes (CLARA) [2012/Oncostarter]; Department of the Rhone
   (Bernardin Award); Ligue Nationale Contre le Cancer (Comite 69); USTH
   PhD fellowship program; Rhone-Alpes region
FX This work was supported by PRES/Lyon Science Transfert (LST607,
   Universite Lyon 1), the Canceropole Lyon Auvergne Rhone-Alpes (CLARA,
   Grant 2012/Oncostarter), the Department of the Rhone (Bernardin Award),
   the Ligue Nationale Contre le Cancer (Comite 69), the USTH PhD
   fellowship program and the Rhone-Alpes region.
CR Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075
   Abdelzaher E, 2015, TUMOUR BIOL
   Aloraifi F, 2015, FEBS J
   Amiri A, 2007, ONCOGENE, V26, P3027, DOI 10.1038/sj.onc.1210101
   Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0
   Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782
   Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953
   Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124
   Berndt N, 2010, CELL DEATH DIFFER, V17, P1795, DOI 10.1038/cdd.2010.63
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Buttitta L, 2003, DEV BIOL, V258, P91, DOI 10.1016/S0012-1606(03)00116-7
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703
   Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R
   Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126
   de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   Etcheverry A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-701
   Fang ZY, 2010, ONCOL LETT, V1, P925, DOI 10.3892/ol_00000163
   Freier K, 2003, CANCER RES, V63, P1179
   Frietze S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-520
   Ghayad SE, 2010, INT J CANCER, V126, P545, DOI 10.1002/ijc.24750
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Ginzinger DG, 2000, CANCER RES, V60, P5405
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Györffy B, 2009, BREAST CANCER RES TR, V118, P433, DOI 10.1007/s10549-008-0242-8
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hoffman K, 1996, CANCER CHEMOTH PHARM, V37, P254
   Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352
   Huang HN, 2014, HUM PATHOL, V45, P2318, DOI 10.1016/j.humpath.2014.07.020
   Huang HN, 2014, MODERN PATHOL, V27, P983, DOI 10.1038/modpathol.2013.216
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085
   Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Krig SR, 2010, ONCOGENE, V29, P5500, DOI 10.1038/onc.2010.289
   Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200
   Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07
   Le Romancer M, 2010, STEROIDS, V75, P560, DOI 10.1016/j.steroids.2010.01.013
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li J, 2014, INT J CLIN EXP PATHO, V7, P3038
   Li PX, 2007, INT J CANCER, V120, P1863, DOI 10.1002/ijc.22300
   Li ZW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116170
   Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018
   Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159-8290.CD-12-0093
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mao XG, 2011, LAB INVEST, V91, P1068, DOI 10.1038/labinvest.2011.56
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010
   Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Nguyen NT, 2014, MOL ONCOL, V8, P1441, DOI 10.1016/j.molonc.2014.05.013
   Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482
   Niu NK, 2015, DRUG DES DEV THER, V9, P1555, DOI 10.2147/DDDT.S74197
   Nonet GH, 2001, CANCER RES, V61, P1250
   Opyrchal M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096995
   Peiró G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY
   Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548
   Plevova P, 2010, NEOPLASMA, V57, P325, DOI 10.4149/neo_2010_04_325
   Prestat E, 2013, COMPUT BIOL MED, V43, P334, DOI 10.1016/j.compbiomed.2012.12.002
   Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001
   Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06
   Rahman MT, 2012, ANTICANCER RES, V32, P3091
   Rahman MT, 2012, CANCER-AM CANCER SOC, V118, P2846, DOI 10.1002/cncr.26598
   Renner M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r137
   Rooney PH, 2004, J PATHOL, V204, P282, DOI 10.1002/path.1632
   Shi H, 2011, BREAST CANCER RES TR, V130, P905, DOI 10.1007/s10549-011-1600-5
   Shida A, 2014, ANTICANCER RES, V34, P4813
   Sillars-Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Sun G, 2008, INT J ONCOL, V32, P1065
   Sun GQ, 2009, MOL MED REP, V2, P851, DOI 10.3892/mmr_00000183
   Sun Y, 2008, INT J CANCER, V123, P1761, DOI 10.1002/ijc.23708
   Suzuki S, 2004, CLIN CANCER RES, V10, P3013, DOI 10.1158/1078-0432.CCR-03-0250
   Szczyrba J, 2013, INT J CANCER, V132, P775, DOI 10.1002/ijc.27731
   Tabach Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014632
   Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08
   Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027
   Thollet A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-291
   van Rooij E, 2014, EMBO MOL MED, V6, P851, DOI 10.15252/emmm.201100899
   Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899
   Vendrell JA, 2004, J MOL ENDOCRINOL, V32, P397, DOI 10.1677/jme.0.0320397
   Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095
   Vilquin P, 2013, INT J CANCER, V133, P1589, DOI 10.1002/ijc.28182
   Wang S, 2010, ONCOGENE, V29, P4225, DOI 10.1038/onc.2010.180
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044
   Xu Y, 2009, BRIT J CANCER, V100, P633, DOI 10.1038/sj.bjc.6604901
   Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343
   Yao JE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-95
   Yuen RKC, 2013, EPIGENETICS-US, V8, P192, DOI 10.4161/epi.23400
   Zhang Zi-Chao, 2015, Asian Pac J Cancer Prev, V16, P2459
   Zhu XQ, 2009, GYNECOL ONCOL, V112, P248, DOI 10.1016/j.ygyno.2008.09.045
NR 95
TC 47
Z9 55
U1 2
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 8
PY 2015
VL 6
IS 39
BP 41566
EP 41581
DI 10.18632/oncotarget.5893
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0TR
UT WOS:000366119600014
PM 26431164
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Vlahov, N
   Scrace, S
   Soto, MS
   Grawenda, AM
   Bradley, L
   Pankova, D
   Papaspyropoulos, A
   Yee, KS
   Buffa, F
   Goding, CR
   Timpson, P
   Sibson, N
   O'Neill, E
AF Vlahov, Nikola
   Scrace, Simon
   Soto, Manuel Sarmiento
   Grawenda, Anna M.
   Bradley, Leanne
   Pankova, Daniela
   Papaspyropoulos, Angelos
   Yee, Karen S.
   Buffa, Francesca
   Goding, Colin R.
   Timpson, Paul
   Sibson, Nicola
   O'Neill, Eric
TI Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts,
   and YAP-Mediated Invasion
SO CURRENT BIOLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR; HIPPO PATHWAY; BETA-CATENIN; CELL-MIGRATION; TYROSINE
   PHOSPHORYLATION; MESENCHYMAL TRANSITION; DNA METHYLATION; CANCER
   GENOMICS; EMERGING ROLES; ALPHA-CATENIN
AB Tumor progression to invasive carcinoma is associated with activation of SRC family kinase (SRC, YES, FYN) activity and loss of cellular cohesion. The hippo pathway-regulated cofactor YAP1 supports the tumorigenicity of RAS mutations but requires both inactivation of hippo signaling and YES-mediated phosphorylation of YAP1 for oncogenic activity. Exactly how SRC kinases are activated and hippo signaling is lost in sporadic human malignancies remains unknown. Here, we provide evidence that hippo-mediated inhibition of YAP1 is lost upon promoter methylation of theRASeffectorand hippo kinase scaffold RASSF1A. We find that RASSF1A promoter methylation reduces YAP phospho-S127, which derepresses YAP1, and actively supports YAP1 activation by switching RASSF1 transcription to the independently transcribed RASSF1C isoform that promotes Tyr kinase activity. Using affinity proteomics, proximity ligation, and real-time molecular visualization, we find that RASSF1C targets SRC/YES to epithelial cell-cell junctions and promotes tyrosine phosphorylation of E-cadherin, beta-catenin, and YAP1. RASSF1A restricts SRC activity, preventing motility, invasion, and tumorigenesis in vitro and in vivo, with epigenetic inactivation correlating with increased inhibitory pY527-SRC in breast tumors. These data imply that distinct RASSF1 isoforms have opposing functions, which provide a biomarker for YAP1 activation and explain correlations of RASSF1 methylation with advanced invasive disease in humans. The ablation of epithelial integrity together with subsequent YAP1 nuclear localization allows transcriptional activation of beta-catenin/TBX-YAP/TEAD target genes, including Myc, and an invasive phenotype. These findings define gene transcript switching as a tumor suppressor mechanism under epigenetic control.
C1 [Vlahov, Nikola; Scrace, Simon; Soto, Manuel Sarmiento; Grawenda, Anna M.; Bradley, Leanne; Pankova, Daniela; Papaspyropoulos, Angelos; Yee, Karen S.; Goding, Colin R.; Sibson, Nicola; O'Neill, Eric] Univ Oxford, Dept Oncol, CRUK MRC Oxford Inst, Oxford OX3 7DQ, England.
   [Buffa, Francesca] Univ Oxford, Dept Oncol, Appl Computat Genom Grp, Oxford OX3 7DQ, England.
   [Timpson, Paul] Univ New S Wales, Garvan Inst Med Res, Fac Med, Darlinghurst, NSW 2010, Australia.
   [Goding, Colin R.] Univ Oxford, Ludwig Inst Canc Res, Oxford OX3 7DQ, England.
C3 University of Oxford; University of Oxford; University of New South
   Wales Sydney; Garvan Institute of Medical Research; University of
   Oxford; Ludwig Institute for Cancer Research
RP O'Neill, E (通讯作者)，Univ Oxford, Dept Oncol, CRUK MRC Oxford Inst, Oxford OX3 7DQ, England.
EM eric.oneill@oncology.ox.ac.uk
RI Timpson, Paul/A-9429-2016; Soto, Manuel/L-7417-2016; Buffa, Francesca
   M./D-2574-2013
OI Buffa, Francesca M./0000-0003-0409-406X; SARMIENTO SOTO,
   MANUEL/0000-0003-0997-0153; Goding, Colin/0000-0002-1614-3909; Bradley,
   Leanne/0000-0002-3331-9689; Timpson, Paul/0000-0002-5514-7080
FU Cancer Research UK [A19277]; Medical Research Council; Oxford Cancer
   Research Centre development fund
FX We would like to thank A. Harris for advice and G. Brown for assistance
   with Imaris imaging. This work was supported by Cancer Research UK
   A19277, Cancer Research UK studentships (S.S. and N.V.), a Medical
   Research Council Studentship (A.P.), and an Oxford Cancer Research
   Centre development fund award to S.S. The authors apologize for any
   references omitted due to space constraints.
CR Ahn EY, 2013, MOL CANCER RES, V11, P748, DOI 10.1158/1541-7786.MCR-12-0665
   Allalou A, 2009, COMPUT METH PROG BIO, V94, P58, DOI 10.1016/j.cmpb.2008.08.006
   Anastassiou D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-529
   BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757
   Bidus MA, 2006, CLIN CANCER RES, V12, P83, DOI 10.1158/1078-0432.CCR-05-0835
   Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100
   Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756
   Canel M, 2010, CANCER RES, V70, P9413, DOI 10.1158/0008-5472.CAN-10-1454
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chamberlain CE, 2014, J CLIN INVEST, V124, P4093, DOI 10.1172/JCI69004
   Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Couzens AL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004712
   Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019
   Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Fukui H, 2014, DEV CELL, V31, P128, DOI 10.1016/j.devcel.2014.08.014
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gómez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246
   Grawenda AM, 2015, BRIT J CANCER, V113, P372, DOI 10.1038/bjc.2015.221
   Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055
   Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040
   Han CF, 2010, NAT IMMUNOL, V11, P734, DOI 10.1038/ni.1908
   Han JY, 2010, NATURE, V463, P1096, DOI 10.1038/nature08735
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010
   Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Kapoor A, 2014, CELL, V158, P185, DOI [10.1016/j.cell.2014.06.003, 10.1016/j.cell.2019.10.037]
   Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108
   Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027
   Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Malpeli G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-351
   Marzese DM, 2014, NEURO-ONCOLOGY, V16, P1499, DOI 10.1093/neuonc/nou107
   Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496
   Papaioannou VE, 2014, DEVELOPMENT, V141, P3819, DOI 10.1242/dev.104471
   Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035
   Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243
   Praskova M, 2008, CURR BIOL, V18, P311, DOI 10.1016/j.cub.2008.02.006
   Rapsomaniki MA, 2012, BIOINFORMATICS, V28, P1800, DOI 10.1093/bioinformatics/bts241
   Reeves ME, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-562
   Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026
   Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734
   Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031
   Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004
   Shen J, 2014, ONCOTARGET, V5, P11998, DOI 10.18632/oncotarget.2426
   Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228
   Tommasi S, 2011, ONCOGENE, V30, P690, DOI 10.1038/onc.2010.440
   van der Weyden L, 2008, ONCOGENE, V27, P4503, DOI 10.1038/onc.2008.94
   van der Weyden L, 2012, CANCER RES, V72, P3817, DOI 10.1158/0008-5472.CAN-11-3343
   Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776
   Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Yee KS, 2012, CANCER RES, V72, P2206, DOI 10.1158/0008-5472.CAN-11-2906
   Zhang H, 2014, J BIOL CHEM, V289, P18681, DOI 10.1074/jbc.M114.554584
NR 61
TC 63
Z9 66
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD DEC 7
PY 2015
VL 25
IS 23
BP 3019
EP 3034
DI 10.1016/j.cub.2015.09.072
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CY4OV
UT WOS:000366388600016
PM 26549256
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Aguilo, F
   Zhang, F
   Sancho, A
   Fidalgo, M
   Di Cecilia, S
   Vashisht, A
   Lee, DF
   Chen, CH
   Rengasamy, M
   Andino, B
   Jahouh, F
   Roman, A
   Krig, SR
   Wang, R
   Zhang, WJ
   Wohlschlegel, JA
   Wang, JL
   Walsh, MJ
AF Aguilo, Francesca
   Zhang, Fan
   Sancho, Ana
   Fidalgo, Miguel
   Di Cecilia, Serena
   Vashisht, Ajay
   Lee, Dung-Fang
   Chen, Chih-Hung
   Rengasamy, Madhumitha
   Andino, Blanca
   Jahouh, Farid
   Roman, Angel
   Krig, Sheryl R.
   Wang, Rong
   Zhang, Weijia
   Wohlschlegel, James A.
   Wang, Jianlong
   Walsh, Martin J.
TI Coordination of m<SUP>6</SUP>A mRNA Methylation and Gene Transcription
   by ZFP217 Regulates Pluripotency and Reprogramming
SO CELL STEM CELL
LA English
DT Article
ID BREAST-CANCER; ONCOGENE ZNF217; RECOGNITION; EXPRESSION;
   N-6-METHYLADENOSINE; IDENTIFICATION; TRANSITION; REPRESSION; PROTEINS;
   SUBUNIT
AB Epigenetic and epitranscriptomic networks have important functions in maintaining the pluripotency of embryonic stem cells (ESCs) and somatic cell reprogramming. However, the mechanisms integrating the actions of these distinct networks are only partially understood. Here we show that the chromatin-associated zinc finger protein 217 (ZFP217) coordinates epigenetic and epitranscriptomic regulation. ZFP217 interacts with several epigenetic regulators, activates the transcription of key pluripotency genes, and modulates N6-methyladenosine (m(6)A) deposition on their transcripts by sequestering the enzyme m(6)A methyltransferase-like 3 (METTL3). Consistently, Zfp217 depletion compromises ESC self-renewal and somatic cell reprogramming, globally increases m(6)A RNA levels, and enhances m(6)A modification of the Nanog, Sox2, Klf4, and c-Myc mRNAs, promoting their degradation. ZFP217 binds its own target gene mRNAs, which are also METTL3 associated, and is enriched at promoters of m(6)A-modified transcripts. Collectively, these findings shed light on how a transcription factor can tightly couple gene transcription to m(6)A RNA modification to ensure ESC identity.
C1 [Aguilo, Francesca; Sancho, Ana; Di Cecilia, Serena; Chen, Chih-Hung; Rengasamy, Madhumitha; Andino, Blanca; Wang, Rong; Walsh, Martin J.] Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, New York, NY 10029 USA.
   [Aguilo, Francesca; Sancho, Ana; Di Cecilia, Serena; Chen, Chih-Hung; Rengasamy, Madhumitha; Andino, Blanca; Walsh, Martin J.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
   [Zhang, Fan; Zhang, Weijia] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, Bioinformat Lab, New York, NY 10029 USA.
   [Fidalgo, Miguel; Lee, Dung-Fang; Wang, Jianlong] Icahn Sch Med Mt Sinai, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
   [Fidalgo, Miguel; Lee, Dung-Fang; Wang, Jianlong] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, New York, NY 10029 USA.
   [Vashisht, Ajay; Wohlschlegel, James A.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Vashisht, Ajay; Wohlschlegel, James A.] Univ Calif Los Angeles, Inst Genom & Prote, Los Angeles, CA 90095 USA.
   [Andino, Blanca; Jahouh, Farid; Wang, Rong; Walsh, Martin J.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Roman, Angel] CSIC, Inst Cajal, E-28002 Madrid, Spain.
   [Krig, Sheryl R.] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Icahn School of Medicine at Mount Sinai; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC);
   University of California System; University of California Davis
RP Aguilo, F (通讯作者)，Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, New York, NY 10029 USA.
EM francesca.aguilo@mssm.edu; martin.walsh@mssm.edu
RI Vashisht, Ajay/C-7368-2011; Andino, Blanca/HNJ-0026-2023; Aguilo,
   Francesca/ABF-2800-2020; Wang, Jianlong/AAG-9425-2020; Fidalgo,
   Miguel/I-7006-2019
OI Fidalgo, Miguel/0000-0003-1134-2674; Lee, Dung-Fang/0000-0003-2387-597X;
   Aguilo, Francesca/0000-0002-2374-2045; Wang,
   Jianlong/0000-0002-1317-6457; Jahouh, Farid/0000-0002-5379-994X
FU Catalan Agency for Administration of University and Research (AGAUR)
   under a Beatriu de Pinos postdoctoral fellowship; Senior Scholar Award
   in Aging [AG-SS-2482-10]; Ellison Medical Foundation; NIH [HL103967,
   DA028776, CA154903, GM089778, 1R01-GM095942, P30 NS061777]; Empire State
   Stem Cell Fund through the New York State Department of Health (NYSTEM)
   [C028103, C028121]; National Institute of General Medical Sciences
   [R01GM089778] Funding Source: NIH RePORTER
FX We thank Dr. A. Alonso of the Weill-Cornell College of Medicine's
   Epigenomic Sequencing Core for expert advice regarding sequencing and
   library preparation. We thank Dr. Carvajal-Gonzalez (University of
   Extremadura), Dr. Marrero (University of Barcelona), and Dr. Gacias
   (Icahn School of Medicine at Mount Sinai) for critically reading the
   manuscript and D. Munoz for graphical design. F.A. is supported by the
   Catalan Agency for Administration of University and Research (AGAUR)
   under a Beatriu de Pinos postdoctoral fellowship. This research was
   supported by the Senior Scholar Award in Aging AG-SS-2482-10 (to M.J.W.)
   from the Ellison Medical Foundation and awards HL103967, DA028776, and
   CA154903 from the NIH (to M.J.W.). J.A.W. was supported by award
   GM089778 from the NIH. J.W. was funded by a grant from the NIH
   (1R01-GM095942) and the Empire State Stem Cell Fund through the New York
   State Department of Health (NYSTEM C028103 and C028121). R.W. was funded
   by award P30 NS061777 from the NIH.
CR Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953
   Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   Bujnicki JM, 2002, J MOL EVOL, V55, P431, DOI 10.1007/s00239-002-2339-8
   Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703
   Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126
   Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112
   Fustin JM, 2013, CELL, V155, P793, DOI 10.1016/j.cell.2013.10.026
   Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417
   Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352
   Jia GF, 2013, TRENDS GENET, V29, P108, DOI 10.1016/j.tig.2012.11.003
   Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200
   Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li PX, 2007, INT J CANCER, V120, P1863, DOI 10.1002/ijc.22300
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159-8290.CD-12-0093
   Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432
   Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785
   Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003
   Nonet GH, 2001, CANCER RES, V61, P1250
   Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3
   Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001
   Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06
   Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027
   Thollet A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-291
   TUCK MT, 1992, INT J BIOCHEM, V24, P379, DOI 10.1016/0020-711X(92)90028-Y
   Vandevenne M, 2013, J BIOL CHEM, V288, P10616, DOI 10.1074/jbc.M112.441451
   Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902
   Welham MJ, 2011, BIOCHEM SOC T, V39, P674, DOI 10.1042/BST0390674
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454
   Yu HB, 2011, GENOME RES, V21, P1284, DOI 10.1101/gr.114488.110
   Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151
NR 41
TC 246
Z9 295
U1 3
U2 70
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 3
PY 2015
VL 17
IS 6
BP 689
EP 704
DI 10.1016/j.stem.2015.09.005
PG 16
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CY1AS
UT WOS:000366139100011
PM 26526723
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Flower, KJ
   Shenker, NS
   El-Bahrawy, M
   Goldgar, DE
   Parsons, MT
   Spurdle, AB
   Morris, JR
   Brown, R
   Flanagan, JM
AF Flower, Kirsty J.
   Shenker, Natalie S.
   El-Bahrawy, Mona
   Goldgar, David E.
   Parsons, Michael T.
   Spurdle, Amanda B.
   Morris, Joanna R.
   Brown, Robert
   Flanagan, James M.
CA KConFab Investigators
   Affect Study Grp
TI DNA methylation profiling to assess pathogenicity of <i>BRCA1</i>
   unclassified variants in breast cancer
SO EPIGENETICS
LA English
DT Article
DE BRCA1; breast cancer; epigenetic; methylation; variants
ID RECEPTOR IMMUNOCYTOCHEMISTRY; MISSENSE SUBSTITUTIONS;
   CLINICAL-SIGNIFICANCE; MOLECULAR SUBTYPES; SEQUENCE VARIANTS; MUTATION
   STATUS; RISK; ESTROGEN; GENES; CLASSIFICATION
AB Germline pathogenic mutations in BRCA1 increase risk of developing breast cancer. Screening for mutations in BRCA1 frequently identifies sequence variants of unknown pathogenicity and recent work has aimed to develop methods for determining pathogenicity. We previously observed that tumor DNA methylation can differentiate BRCA1-mutated from BRCA1-wild type tumors. We hypothesized that we could predict pathogenicity of variants based on DNA methylation profiles of tumors that had arisen in carriers of unclassified variants. We selected 150 FFPE breast tumor DNA samples [47 BRCA1 pathogenic mutation carriers, 65 BRCAx (BRCA1-wild type), 38 BRCA1 test variants] and analyzed a subset (n=54) using the Illumina 450K methylation platform, using the remaining samples for bisulphite pyrosequencing validation. Three validated markers (BACH2, C8orf31, and LOC654342) were combined with sequence bioinformatics in a model to predict pathogenicity of 27 variants (independent test set). Predictions were compared with standard multifactorial likelihood analysis. Prediction was consistent for c.5194-12G>A (IVS 19-12G>A) (P>0.99); 13 variants were considered not pathogenic or likely not pathogenic using both approaches. We conclude that tumor DNA methylation data alone has potential to be used in prediction of BRCA1 variant pathogenicity but is not independent of estrogen receptor status and grade, which are used in current multifactorial models to predict pathogenicity.
C1 [Flower, Kirsty J.; Shenker, Natalie S.; Brown, Robert; Flanagan, James M.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London SW7 2AZ, England.
   [El-Bahrawy, Mona] Univ London Imperial Coll Sci Technol & Med, Hamanoumachi Hosp, Dept Histopathol, London SW7 2AZ, England.
   [Goldgar, David E.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   [Parsons, Michael T.; Spurdle, Amanda B.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [KConFab Investigators] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Morris, Joanna R.; Affect Study Grp] Univ Birmingham, Sch Canc Sci, Genome Stabil Unit, Birmingham B15 2TT, W Midlands, England.
   [Brown, Robert] Inst Canc Res, Sect Mol Pathol, Sutton, Surrey, England.
C3 Imperial College London; Imperial College London; Utah System of Higher
   Education; University of Utah; Huntsman Cancer Institute; QIMR Berghofer
   Medical Research Institute; Peter Maccallum Cancer Center; University of
   Birmingham; University of London; Institute of Cancer Research - UK
RP Flanagan, JM (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London SW7 2AZ, England.
EM j.flanagan@imperial.ac.uk
RI Spurdle, Amanda/A-4978-2011; Shenker, Natalie/ABX-1855-2022; Morris,
   Joanna/AAK-3388-2021
OI Shenker, Natalie/0000-0002-8067-1079; Parsons,
   Michael/0000-0003-3242-8477; Morris, Joanna/0000-0001-9762-8133; Thorne,
   Heather/0000-0003-3610-2511; Flanagan, James/0000-0003-4955-1383; Brown,
   Robert/0000-0001-7960-5755
FU Breast Cancer Now Project [2010NovPR06]; Breast Cancer Now; NHMRC; NHMRC
   [1010719, 145684, 288704, 454508]; Cancer Research UK [A13086]; National
   Institute for Health Research (NIHR) Biomedical Research Center based at
   Imperial College Healthcare NHS Trust and Imperial College London;
   National Breast Cancer Foundation; National Health and Medical Research
   Council (NHMRC); Queensland Cancer Fund; Cancer Council of New South
   Wales; Cancer Council of Victoria; Cancer Council of Tasmania; Cancer
   Council of South Australia; Cancer Foundation of Western Australia;
   Guy's and St. Thomas' Charity
FX This study was funded by Breast Cancer Now Project 2010NovPR06. JMF and
   KJF were funded by Breast Cancer Now. ABS is supported by an NHMRC
   Senior Research Fellowship. MP was supported by funding from NHMRC
   project grant ID 1010719. The authors acknowledge funding from Cancer
   Research UK (A13086) and the National Institute for Health Research
   (NIHR) Biomedical Research Center based at Imperial College Healthcare
   NHS Trust and Imperial College London. We wish to thank Eveline
   Niedermayr, all the KConFab research nurses and staff, the heads and
   staff of the Family Cancer Clinics, and the Clinical Follow up Study
   (funded by NHMRC grants 145684, 288704 and 454508) for their
   contributions to this resource, and the many families who contribute to
   KConFab. KConFab is supported by grants from the National Breast Cancer
   Foundation, the National Health and Medical Research Council (NHMRC) and
   by the Queensland Cancer Fund, the Cancer Councils of New South Wales,
   Victoria, Tasmania and South Australia, and the Cancer Foundation of
   Western Australia. The AFFECT study is funded by Breast Cancer Now and
   Guy's and St. Thomas' Charity. AFFECT samples contributed by Louise
   Izatt (Guy's Hospital, London), Shirley Hodgson (St Georges Hospital,
   London), Sue Kenwrick (Addenbrooks Hospital, Cambridge) and Fiona
   Douglas (Freeman Hospital, Newcastle).
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bouwman P, 2013, CANCER DISCOV, V3, P1142, DOI 10.1158/2159-8290.CD-13-0094
   Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Easton DF, 2007, AM J HUM GENET, V81, P873, DOI 10.1086/521032
   Eggington JM, 2014, CLIN GENET, V86, P229, DOI 10.1111/cge.12315
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   García EBG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2223
   Goldgar DE, 2008, HUM MUTAT, V29, P1265, DOI 10.1002/humu.20897
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Killian JK, 2011, AM J PATHOL, V179, P55, DOI 10.1016/j.ajpath.2011.03.022
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lindor NM, 2013, ONCOLOGIST, V18, P518, DOI 10.1634/theoncologist.2012-0452
   Lovelock PK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1826
   Mann GJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1377
   Marinsek ZP, 2013, CYTOPATHOLOGY, V24, P7, DOI 10.1111/cyt.12024
   Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003
   Oyama Tetsunari, 2007, Breast Cancer, V14, P182
   Plon SE, 2008, HUM MUTAT, V29, P1282, DOI 10.1002/humu.20880
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244
   Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330
   Spurdle AB, 2008, HUM MUTAT, V29, P1304, DOI 10.1002/humu.20901
   Spurdle AB, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0474-y
   Spurdle AB, 2012, J MED GENET, V49, P525, DOI 10.1136/jmedgenet-2012-101037
   Tavtigian SV, 2008, HUM MUTAT, V29, P1342, DOI 10.1002/humu.20896
   Tavtigian SV, 2008, HUM MUTAT, V29, P1261, DOI 10.1002/humu.20903
   Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012
   Tung N, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2478
   van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Wells CA, 2004, VIRCHOWS ARCH, V445, P119, DOI 10.1007/s00428-004-1063-8
   Whiley PJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086836
   Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418
NR 39
TC 10
Z9 10
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC 2
PY 2015
VL 10
IS 12
BP 1121
EP 1132
DI 10.1080/15592294.2015.1111504
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DD4EG
UT WOS:000369874700004
PM 26727311
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Poli, E
   Zhang, J
   Nwachukwu, C
   Zheng, YL
   Adedokun, B
   Olopade, OI
   Han, YJ
AF Poli, Elizabeth
   Zhang, Jing
   Nwachukwu, Chika
   Zheng, Yonglan
   Adedokun, Babatunde
   Olopade, Olufunmilayo I.
   Han, Yoo-Jeong
TI Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer
   Is Associated with CpG Dinucleotide Methylation of the Promoter
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; TUMORS; MIR-29C; HYPERMETHYLATION; CARCINOMAS;
   PORTRAITS
AB Basal-like breast cancer is a molecularly distinct subtype of breast cancer that is highly aggressive and has a poor prognosis. MicroRNA-29c (miR-29c) has been shown to be significantly down-regulated in basal-like breast tumors and to be involved in cell invasion and sensitivity to chemotherapy. However, little is known about the genetic and regulatory factors contributing to the altered expression of miR-29c in basal-like breast cancer. We here report that epigenetic modifications at the miR-29c promoter, rather than copy number variation of the gene, may drive the lower expression of miR-29c in basal-like breast cancer. Bisulfite sequencing of CpG sites in the miR-29c promoter region showed higher methylation in basal-like breast cancer cell lines compared to luminal subtype cells with a significant inverse correlation between expression and methylation of miR-29c. Analysis of primary breast tumors using The Cancer Genome Atlas (TCGA) dataset confirmed significantly higher levels of methylation of the promoter in basal-like breast tumors compared to all other subtypes. Furthermore, inhibition of CpG methylation with 5-aza-CdR increases miR-29c expression in basal-like breast cancer cells. Flourescent In Situ Hybridization (FISH) revealed chromosomal abnormalities at miR-29c loci in breast cancer cell lines, but with no correlation between copy number variation and expression of miR-29c. Our data demonstrated that dysregulation of miR-29c in basal-like breast cancer cells may be in part driven by methylation at CpG sites. Epigenetic control of the miR-29c promoter by epigenetic modifiers may provide a potential therapeutic target to overcome the aggressive behavior of these cancers.
C1 [Poli, Elizabeth; Zhang, Jing; Nwachukwu, Chika; Zheng, Yonglan; Adedokun, Babatunde; Olopade, Olufunmilayo I.; Han, Yoo-Jeong] Univ Chicago, Dept Med, Ctr Clin Canc Genet & Global Hlth, Sect Hematol Oncol, Chicago, IL 60637 USA.
C3 University of Chicago
RP Han, YJ (通讯作者)，Univ Chicago, Dept Med, Ctr Clin Canc Genet & Global Hlth, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM yjhan@medicine.bsd.uchicago.edu
RI Zheng, Yonglan/O-4112-2019
OI Zheng, Yonglan/0000-0001-6597-7072
FU Howard Hughes Medical Fellows Program; Breast Cancer Research
   Foundation; Ralph and Marion Falk Medical Research Trust; National
   Institute of Health-Specialized Program of Research Excellence in Breast
   Cancer [(P50 CA125183]
FX This work was supported by funding to E. P. from Howard Hughes Medical
   Fellows Program, O. I. O. and Y.H from the Breast Cancer Research
   Foundation and the Ralph and Marion Falk Medical Research Trust. This
   research was also supported by the National Institute of
   Health-Specialized Program of Research Excellence in Breast Cancer (P50
   CA125183 to OIO). OIO is American Cancer Society Clinical Research
   Professor.
CR [Anonymous], 2013, Breast Cancer Facts Figures 2013-2014
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Baer C, 2012, CANCER RES, V72, P3775, DOI 10.1158/0008-5472.CAN-12-0803
   Barch M., 1997, AGT CYTOGENETICS LAB
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dawson K, 2013, CIRCULATION, V127, P1466, DOI 10.1161/CIRCULATIONAHA.112.001207
   Ding DP, 2011, CARCINOGENESIS, V32, P1025, DOI 10.1093/carcin/bgr078
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399-0004.2008.01076.x
   Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Hawkins SM, 2011, MOL ENDOCRINOL, V25, P821, DOI 10.1210/me.2010-0371
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072287
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Huang YW, 2014, GYNECOL ONCOL, V133, P340, DOI 10.1016/j.ygyno.2014.02.009
   Jia HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088057
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kogure T, 2012, J CELL MOL MED, V16, P2647, DOI 10.1111/j.1582-4934.2012.01578.x
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Matsuo M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-15
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Nygren MK, 2014, BRIT J CANCER, V110, P2072, DOI 10.1038/bjc.2014.113
   Pandi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058039
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Presneau N, 2013, BRIT J CANCER, V108, P964, DOI 10.1038/bjc.2012.518
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031
   Saito Y, 2013, INT J CANCER, V132, P1751, DOI 10.1002/ijc.27862
   Sandhu R, 2014, INT J ONCOL, V44, P563, DOI 10.3892/ijo.2013.2197
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
NR 40
TC 23
Z9 24
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 5
PY 2015
VL 10
IS 11
AR e0142224
DI 10.1371/journal.pone.0142224
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV5IS
UT WOS:000364303800070
PM 26539832
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Clocchiatti, A
   Di Giorgio, E
   Viviani, G
   Streuli, C
   Sgorbissa, A
   Picco, R
   Cutano, V
   Brancolini, C
AF Clocchiatti, Andrea
   Di Giorgio, Eros
   Viviani, Giulia
   Streuli, Charles
   Sgorbissa, Andrea
   Picco, Raffaella
   Cutano, Valentina
   Brancolini, Claudio
TI The MEF2-HDAC axis controls proliferation of mammary epithelial cells
   and acini formation <i>in vitro</i>
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE HDAC7; HDAC4; MEF2A; MEF2D; p21; CDKN1A; Cell cycle; Morphogenesis;
   Apoptosis; HDAC5; Breast cancer; HER2; ERBB2; Lapatinib; 3D culture;
   H3K27
ID BASEMENT-MEMBRANE CULTURES; TRANSCRIPTION FACTOR MEF2C; HISTONE
   DEACETYLASE 4; CLASS IIA HDACS; MUSCLE DIFFERENTIATION; BREAST-TUMORS;
   DEPENDENT REGULATION; GENE-EXPRESSION; LUMEN FORMATION; POOR-PROGNOSIS
AB The myocyte enhancer factor 2 and histone deacetylase (MEF2-HDAC) axis is a master regulator of different developmental programs and adaptive responses in adults. In this paper, we have investigated the contribution of the axis to the regulation of epithelial morphogenesis, using 3D organotypic cultures of MCF10A cells as a model. We have demonstrated that MEF2 transcriptional activity is upregulated during acini formation, which coincides with exit from the proliferative phase. Upregulation of the transcription of MEF2 proteins is coupled to downregulation of HDAC7, which occurs independently from changes in mRNA levels, and proteasome- or autophagy-mediated degradation. During acini formation, the MEF2-HDAC axis contributes to the promotion of cell cycle exit, through the engagement of the CDK inhibitor CDKN1A. Only in proliferating cells can HDAC7 bind to the first intron of the CDKN1A gene, a region characterized by epigenetic markers of active promoters and enhancers. In cells transformed by the oncogene HER2 (ERBB2), acini morphogenesis is altered, MEF2 transcription is repressed and HDAC7 is continuously expressed. Importantly, reactivation of MEF2 transcriptional activity in these cells, through the use of a HER2 inhibitor or by enhancing MEF2 function, corrected the proliferative defect and re-established normal acini morphogenesis.
C1 [Clocchiatti, Andrea; Di Giorgio, Eros; Viviani, Giulia; Sgorbissa, Andrea; Picco, Raffaella; Cutano, Valentina; Brancolini, Claudio] Univ Udine, Dipartiment Med & Biol Sci, I-33100 Udine, Italy.
   [Streuli, Charles] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
C3 University of Udine; University of Manchester
RP Brancolini, C (通讯作者)，Univ Udine, Dipartiment Med & Biol Sci, Ple Kolbe 4, I-33100 Udine, Italy.
EM claudio.brancolini@uniud.it
RI Clocchiatti, Andrea/AAA-1992-2021; Di Giorgio, Eros/AAF-4468-2020
OI BRANCOLINI, Claudio/0000-0002-6597-5373; Di Giorgio,
   Eros/0000-0003-0202-2222
FU Research Projects of National Interest (PRIN) [Progetto 2010W4J4RM_002];
   Associazione Italiana per la Ricerca sul Cancro (AIRC)
FX This work was supported by Research Projects of National Interest (PRIN)
   [grant number Progetto 2010W4J4RM_002] to C.B. A.C. received the 'Gemma
   del Como' fellowship from Associazione Italiana per la Ricerca sul
   Cancro (AIRC).
CR Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013
   Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10-07-0616
   Clocchiatti A, 2013, FASEB J, V27, P942, DOI 10.1096/fj.12-209346
   Clocchiatti A, 2013, CELL SIGNAL, V25, P269, DOI 10.1016/j.cellsig.2012.10.002
   Clocchiatti A, 2011, J CELL MOL MED, V15, P1833, DOI 10.1111/j.1582-4934.2011.01321.x
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Debnath I, 2013, INT IMMUNOL, V25, P99, DOI 10.1093/intimm/dxs088
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Demarchi F, 2006, J CELL BIOL, V175, P595, DOI 10.1083/jcb.200601024
   Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2
   Di Giorgio E, 2015, MOL CELL BIOL, V35, P1633, DOI 10.1128/MCB.01461-14
   Di Giorgio E, 2015, CELL MOL LIFE SCI, V72, P73, DOI 10.1007/s00018-014-1727-8
   Di Giorgio E, 2013, MOL CELL BIOL, V33, P4473, DOI 10.1128/MCB.01050-13
   Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511
   Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907
   Gjorevski N, 2011, NAT REV MOL CELL BIO, V12, P581, DOI 10.1038/nrm3168
   Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200
   Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06
   Ishikawa F, 2010, ONCOGENE, V29, P909, DOI 10.1038/onc.2009.387
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104
   Lee JL, 2014, J CELL SCI, V127, P3217, DOI 10.1242/jcs.146142
   Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826
   Lewandowski KT, 2014, J CELL SCI, V127, P315, DOI 10.1242/jcs.129148
   Lin Q, 1998, DEVELOPMENT, V125, P4565
   Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404
   Liu N, 2014, P NATL ACAD SCI USA, V111, P4109, DOI 10.1073/pnas.1401732111
   Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717
   Lo AT, 2012, J MAMMARY GLAND BIOL, V17, P103, DOI 10.1007/s10911-012-9251-7
   Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097
   Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171
   Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150
   McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371
   Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785
   Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789
   Nebbioso A, 2009, EMBO REP, V10, P776, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]
   Pallavi SK, 2012, EMBO J, V31, P2895, DOI 10.1038/emboj.2012.129
   Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624
   Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200
   Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623
   Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367
   Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960
   Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   Saramäki A, 2009, J BIOL CHEM, V284, P8073, DOI 10.1074/jbc.M808090200
   Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
   Sebastian S, 2013, GENE DEV, V27, P1247, DOI 10.1101/gad.215400.113
   Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z
   Simpson DR, 2011, CANCER RES, V71, P3822, DOI 10.1158/0008-5472.CAN-10-3782
   STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383
   Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Whyte J, 2010, J CELL SCI, V123, P3316, DOI 10.1242/jcs.065243
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12
NR 65
TC 25
Z9 32
U1 1
U2 10
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD NOV 1
PY 2015
VL 128
IS 21
BP 3961
EP 3976
DI 10.1242/jcs.170357
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CV8IK
UT WOS:000364526500013
PM 26403201
DA 2025-01-12
ER

PT J
AU Fenton, SE
   Birnbaum, LS
AF Fenton, Suzanne E.
   Birnbaum, Linda S.
TI Timing of Environmental Exposures as a Critical Element in Breast Cancer
   Risk
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID SEVESO WOMENS HEALTH; MAMMARY-GLAND; IN-UTERO; ENDOCRINE DISRUPTORS;
   DIOXIN EXPOSURE; FOLLOW-UP; DIETHYLSTILBESTROL; MORTALITY; LIFE; RAT
AB Objective: The role of the chemical environment in disease initiation or progression is becoming more evident. Endocrine disruption via environmental chemicals is now well documented in humans, rodent research models, and wildlife. Breast cancer is an endocrine-based disease whose risk may be modified by environmental exposures. Our purpose is to encourage more investigation into early life environmental exposures as they relate to breast cancer risk factors and disease over a lifetime.
   Evidence: The 2009 President's Cancer Panel, 2012 Institute of Medicine, 2013 Interagency Breast Cancer and the Environment Research Coordinating Committee reports, and research publications dated >2012 in PubMed were used to inform our perspective.
   Consensus Process: Literature was reviewed and evidence gathered on the effects of the environment on risk of breast cancer or mammary tumor development in animal research models as it pertained to the influence of timing of exposure on later-life outcomes.
   Conclusions: Evidence has accumulated for several chemicals that environmental factors have a stronger effect on breast cancer risk when exposure occurred early in life. The insecticide, dichlorodiphenyltrichloroethane, is an excellent example and is just one of several chemicals for which there seems to be both animal and human evidence for the developmental basis of adult disease. The developing breast undergoes many changes in early life, leaving it vulnerable to the effects of epigenetic marks, endocrine disruption, and carcinogens. More research is needed in the area of early beginnings of breast cancer, with prevention of the disease as the ultimate goal.
C1 [Fenton, Suzanne E.] NIEHS, Natl Toxicol Program NTP Lab, Div NTP, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
   [Birnbaum, Linda S.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS)
RP Fenton, SE (通讯作者)，NIEHS, 111 TW Alexander Dr,MDE1-08, Res Triangle Pk, NC 27709 USA.
EM fentonse@niehs.nih.gov
OI Birnbaum, Linda/0000-0001-5429-5658; Fenton, Suzanne/0000-0002-8956-398X
FU National Institutes of Health
FX This work was supported by the National Institutes of Health.
CR Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491
   American Public Health Association, BREAST CANC OCC NEED
   [Anonymous], 2012, JRSM SHORT REP, DOI DOI 10.1258/SHORTS.2012.012048
   [Anonymous], 2015, CANC FACTS FIG 2015
   Arrebola JP, 2015, SCI TOTAL ENVIRON, V520, P106, DOI 10.1016/j.scitotenv.2015.03.045
   BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171
   BARKER DJP, 1986, LANCET, V1, P1077
   Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686
   Biro FM, 2013, PEDIATRICS, V132, P1019, DOI 10.1542/peds.2012-3773
   Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623
   Centers for Disease Control and Prevention, OVERWEIGHT AND OBESI
   Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260
   Cohn BA, 2015, J CLIN ENDOCR METAB, V100, P2865, DOI 10.1210/jc.2015-1841
   Cresswell JL, 1997, LANCET, V350, P1131, DOI 10.1016/S0140-6736(97)06062-5
   Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771, DOI 10.1289/ehp.02110771
   [Department of Health and Human Services Interagency Breast Cancer and the Environment Research Coordinating Committee], BREAST CANC ENV PRIO
   Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002
   Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63
   Fenton SE, 2012, ANNU REV PHARMACOL, V52, P455, DOI 10.1146/annurev-pharmtox-010611-134659
   Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s
   GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201
   Hatakeyama M, 1999, J BIOCHEM MOL TOXIC, V13, P296, DOI 10.1002/(SICI)1099-0461(1999)13:6<296::AID-JBT2>3.0.CO;2-S
   Heindel JJ, 2013, OBESITY, V21, P1079, DOI 10.1002/oby.20222
   Hilakivi-Clarke L, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3649
   Ho ML, 2015, J OBSTET GYNAECOL, V35, P60, DOI 10.3109/01443615.2014.935717
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Ingber SZ, 2013, REGUL TOXICOL PHARM, V67, P421, DOI 10.1016/j.yrtph.2013.08.021
   Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013
   Jefferson WN, 2013, MOL ENDOCRINOL, V27, P1666, DOI 10.1210/me.2013-1211
   Johnson NA, 2012, ENVIRON HEALTH PERSP, V120, P1170, DOI 10.1289/ehp.1104327
   Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966
   La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047
   Laden F, 2001, INT J CANCER, V91, P568, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1081>3.0.CO;2-W
   Leijs MM, 2008, CHEMOSPHERE, V73, P999, DOI 10.1016/j.chemosphere.2008.05.053
   Lewis BC, 2001, TOXICOL SCI, V62, P46, DOI 10.1093/toxsci/62.1.46
   López-Cervantes M, 2004, ENVIRON HEALTH PERSP, V112, P207, DOI [10.1289/ehp.6492, 10.1289/ehp.112-1241830]
   Macon MB, 2013, J MAMMARY GLAND BIOL, V18, P43, DOI 10.1007/s10911-013-9275-7
   Manuwald U, 2012, OCCUP ENVIRON MED, V69, P636, DOI 10.1136/oemed-2012-100682
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Olaya-Contreras P, 1998, Cad Saude Publica, V14 Suppl 3, P125
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Park Jae-Hong, 2014, Osong Public Health Res Perspect, V5, P77, DOI 10.1016/j.phrp.2014.02.001
   Paulose T, 2015, REPROD TOXICOL, V54, P58, DOI 10.1016/j.reprotox.2014.09.012
   Reed CE, 2013, BIRTH DEFECTS RES C, V99, P134, DOI 10.1002/bdrc.21035
   Romieu I, 2000, AM J EPIDEMIOL, V152, P363, DOI 10.1093/aje/152.4.363
   Snedeker SM, 2001, ENVIRON HEALTH PERSP, V109, P35, DOI 10.2307/3434918
   Treviño LS, 2015, REPROD TOXICOL, V54, P136, DOI 10.1016/j.reprotox.2014.12.014
   Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625, DOI 10.1289/ehp.02110625
   Warner M, 2011, ENVIRON HEALTH PERSP, V119, P1700, DOI 10.1289/ehp.1103720
   White SS, 2011, ENVIRON HEALTH PERSP, V119, P1070, DOI 10.1289/ehp.1002741
NR 50
TC 34
Z9 40
U1 0
U2 13
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2015
VL 100
IS 9
BP 3245
EP 3250
DI 10.1210/jc.2015-2848
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA CW3BV
UT WOS:000364867800028
PM 26214118
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Lock, EF
   Dunson, DB
AF Lock, Eric F.
   Dunson, David B.
TI Shared kernel Bayesian screening
SO BIOMETRIKA
LA English
DT Article
DE Epigenetics; Independent screening; Methylation array; Misspecification;
   Multiple comparisons; Multiple testing; Nonparametric Bayes inference
ID MIXTURE MODEL; IDENTIFIABILITY
AB This article concerns testing for equality of distribution between groups. We focus on screening variables with shared distributional features such as common support, modes and patterns of skewness. We propose a Bayesian testing method using kernel mixtures, which improves performance by borrowing information across the different variables and groups through shared kernels and a common probability of group differences. The inclusion of shared kernels in a finite mixture, with Dirichlet priors on the weights, leads to a simple framework for testing that scales well for high-dimensional data. We provide closed asymptotic forms for the posterior probability of equivalence in two groups and prove consistency under model misspecification. The method is applied to DNA methylation array data from a breast cancer study, and compares favourably to competitors when Type I error is estimated via permutation.
C1 [Lock, Eric F.] Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA.
   [Dunson, David B.] Duke Univ, Dept Stat Sci, Durham, NC 27708 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   Duke University
RP Lock, EF (通讯作者)，Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA.
EM elock@umn.edu; dunson@duke.edu
RI Dunson, David/V-6323-2018
FU U.S. National Institutes of Health
FX This work was supported in part by the U.S. National Institutes of
   Health.
CR Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Albert JH, 1997, J AM STAT ASSOC, V92, P685, DOI 10.2307/2965716
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Chen MH, 2011, J AM STAT ASSOC, V106, P1259, DOI 10.1198/jasa.2011.ap10611
   Dunson DB, 2008, BIOMETRIKA, V95, P859, DOI 10.1093/biomet/asn043
   GOOD IJ, 1987, ANN STAT, V15, P670, DOI 10.1214/aos/1176350368
   Gopalan R, 1998, J AM STAT ASSOC, V93, P1130, DOI 10.2307/2669856
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Holmes CC, 2015, BAYESIAN ANAL, V10, P297, DOI 10.1214/14-BA914
   Johnson VE, 2010, J ROY STAT SOC B, V72, P143, DOI 10.1111/j.1467-9868.2009.00730.x
   KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572
   Khalili A, 2007, CANCER INFORM, V3, P43
   Kleun BJK, 2006, ANN STAT, V34, P837, DOI 10.1214/009053606000000029
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Ma L, 2011, J AM STAT ASSOC, V106, P1553, DOI 10.1198/jasa.2011.tm10003
   Mueller P., 2007, BAYESIAN STAT, V8, P349
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pennell ML, 2008, BIOMETRICS, V64, P413, DOI 10.1111/j.1541-0420.2007.00885.x
   Qiu P, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S13-S7
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Ronning G., 1989, J STAT COMPUT SIM, V32, P215, DOI DOI 10.1080/00949658908811178
   SCHOLZ FW, 1987, J AM STAT ASSOC, V82, P918, DOI 10.2307/2288805
   Scott JG, 2010, ANN STAT, V38, P2587, DOI 10.1214/10-AOS792
   Scott JG, 2006, J STAT PLAN INFER, V136, P2144, DOI 10.1016/j.jspi.2005.08.031
   TEICHER H, 1963, ANN MATH STAT, V34, P1265, DOI 10.1214/aoms/1177703862
   Walker SG, 2004, STAT SCI, V19, P111, DOI 10.1214/088342304000000134
   Xu L, 2010, J AGR BIOL ENVIR ST, V15, P308, DOI 10.1007/s13253-010-0020-z
   YAKOWITZ SJ, 1968, ANN MATH STAT, V39, P209, DOI 10.1214/aoms/1177698520
NR 29
TC 10
Z9 12
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-3444
EI 1464-3510
J9 BIOMETRIKA
JI Biometrika
PD DEC
PY 2015
VL 102
IS 4
BP 829
EP 842
DI 10.1093/biomet/asv032
PG 14
WC Biology; Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology; Mathematics
GA CY4LG
UT WOS:000366379000006
PM 27046939
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Hayashi-Takanaka, Y
   Maehara, K
   Harada, A
   Umehara, T
   Yokoyama, S
   Obuse, C
   Ohkawa, Y
   Nozaki, N
   Kimura, H
AF Hayashi-Takanaka, Yoko
   Maehara, Kazumitsu
   Harada, Akihito
   Umehara, Takashi
   Yokoyama, Shigeyuki
   Obuse, Chikashi
   Ohkawa, Yasuyuki
   Nozaki, Naohito
   Kimura, Hiroshi
TI Distribution of histone H4 modifications as revealed by a panel of
   specific monoclonal antibodies
SO CHROMOSOME RESEARCH
LA English
DT Article
DE Chromatin; Epigenetics; Histone modification; Monoclonal antibody
ID HUMAN GENOME; HUMAN-CELLS; DNA-DAMAGE; LYSINE 16; CHROMATIN SIGNATURES;
   20 MONOMETHYLATION; ACETYLATION SITES; BREAST-CANCER; LIVING CELLS;
   METHYLATION
AB Post-translational histone modifications play a critical role in genome functions such as epigenetic gene regulation and genome maintenance. The tail of the histone H4 N-terminus contains several amino acids that can be acetylated and methylated. Some of these modifications are known to undergo drastic changes during the cell cycle. In this study, we generated a panel of mouse monoclonal antibodies against histone H4 modifications, including acetylation at K5, K8, K12, and K16, and different levels of methylation at K20. Their specificity was evaluated by ELISA and immunoblotting using synthetic peptide and recombinant proteins that harbor specific modifications or amino acid substitutions. Immunofluorescence confirmed the characteristic distributions of target modifications. An H4K5 acetylation (H4K5ac)-specific antibody CMA405 reacted with K5ac only when the neighboring K8 was unacetylated. This unique feature allowed us to detect newly assembled H4, which is diacetylated at K5 and K12, and distinguish it from hyperacetylated H4, where K5 and K8 are both acetylated. Chromatin immunoprecipiation combined with deep sequencing (ChIP-seq) revealed that acetylation of both H4K8 and H4K16 were enriched around transcription start sites. These extensively characterized and highly specific antibodies will be useful for future epigenetics and epigenome studies.
C1 [Hayashi-Takanaka, Yoko; Kimura, Hiroshi] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan.
   [Hayashi-Takanaka, Yoko; Kimura, Hiroshi] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan.
   [Hayashi-Takanaka, Yoko; Ohkawa, Yasuyuki; Kimura, Hiroshi] JST, CREST, Kawaguchi, Saitama 3320012, Japan.
   [Maehara, Kazumitsu; Harada, Akihito; Ohkawa, Yasuyuki] Kyushu Univ, Fac Med, Dept Adv Med Initiat, Fukuoka 8128582, Japan.
   [Umehara, Takashi] RIKEN, Ctr Life Sci Technol, Yokohama, Kanagawa 2300045, Japan.
   [Yokoyama, Shigeyuki] RIKEN, Struct Biol Lab, Yokohama, Kanagawa 2300045, Japan.
   [Obuse, Chikashi] Hokkaido Univ, Sch Life Sci, Sapporo, Hokkaido 0010021, Japan.
   [Nozaki, Naohito] MAB Inst Inc, Sapporo, Hokkaido 0010021, Japan.
C3 Institute of Science Tokyo; Tokyo Institute of Technology; Osaka
   University; Japan Science & Technology Agency (JST); Kyushu University;
   RIKEN; RIKEN; Hokkaido University
RP Kimura, H (通讯作者)，Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.
EM hkimura@bio.titech.ac.jp
RI Ohkawa, Yasuyuki/ABG-1839-2021; Maehara, Kazumitsu/AFM-8560-2022;
   Hayashi, Yoko/GPT-4159-2022; Kimura, Hiroshi/B-9524-2015; Umehara,
   Takashi/N-5683-2015; Ohkawa, Yasuyuki/C-4087-2016; Yokoyama,
   Shigeyuki/N-6911-2015
OI Maehara, Kazumitsu/0000-0002-2933-5176; Kimura,
   Hiroshi/0000-0003-0854-083X; Umehara, Takashi/0000-0003-3464-2960;
   HAYASHI, Yoko/0000-0002-0556-6738; Ohkawa, Yasuyuki/0000-0001-6440-9954;
   Yokoyama, Shigeyuki/0000-0003-3133-7338
FU New Energy and Industrial Technology Development Organization of Japan;
   Japan Society for the Promotion of Science [25116005, 26291071];
   Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan Society for the Promotion of Science fellowship; Naito Foundation;
   Grants-in-Aid for Scientific Research [13J04024, 25116010, 26290064,
   25503002, 25116005, 26291071] Funding Source: KAKEN
FX We thank Hitoshi Niwa (RIKEN CDB) for ZHBTc4 mouse embryonic stem cells
   and Timothy Stasevich (Colorado State University) for proofreading the
   manuscript. This work was supported by the New Energy and Industrial
   Technology Development Organization of Japan, grants-in-aid from the
   Japan Society for the Promotion of Science (25116005 and 26291071), and
   the Platform for Drug Discovery, Informatics, and Structural Life
   Science from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan. Y.H.-T. was supported by a Japan Society for the
   Promotion of Science fellowship and by the Naito Foundation.
CR Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barman HK, 2006, BIOCHEM BIOPH RES CO, V345, P1547, DOI 10.1016/j.bbrc.2006.05.079
   Beck DB, 2012, GENE DEV, V26, P325, DOI 10.1101/gad.177444.111
   Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010
   Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i
   Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017
   Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085
   Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eberhart A, 2013, CHROMOSOME RES, V21, P535, DOI 10.1007/s10577-013-9375-7
   Eberhart A, 2012, CHROMOSOME RES, V20, P849, DOI 10.1007/s10577-012-9318-8
   Egelhofer TA, 2011, NAT STRUCT MOL BIOL, V18, P91, DOI 10.1038/nsmb.1972
   Ejlassi-Lassallette A, 2011, MOL BIOL CELL, V22, P245, DOI 10.1091/mbc.E10-07-0633
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Greeson NT, 2008, J BIOL CHEM, V283, P33168, DOI 10.1074/jbc.M806857200
   Hayashi-Takanaka Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106271
   Hayashi-Takanaka Y, 2011, NUCLEIC ACIDS RES, V39, P6475, DOI 10.1093/nar/gkr343
   Hayashi-Takanaka Y, 2009, J CELL BIOL, V187, P781, DOI 10.1083/jcb.200904137
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hori T, 2014, DEV CELL, V29, P740, DOI 10.1016/j.devcel.2014.05.001
   Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994
   Jorgensen S, 2013, NUCLEIC ACIDS RES, V41, P2797, DOI 10.1093/nar/gkt012
   Kapoor-Vazirani P, 2014, J BIOL CHEM, V289, P7425, DOI 10.1074/jbc.M113.520783
   Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341
   Kimura H, 1994, J BIOL CHEM, V269, P21439, DOI [10.1074/jbc.271.35.21439, DOI 10.1074/JBC.271.35.21439]
   Kimura H, 2008, CELL STRUCT FUNCT, V33, P61, DOI 10.1247/csf.07035
   Kimura H, 2006, J CELL BIOL, V175, P389, DOI 10.1083/jcb.200608001
   Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66
   Krishnan V, 2011, P NATL ACAD SCI USA, V108, P12325, DOI 10.1073/pnas.1102789108
   Lang DN, 2013, PROTEOMICS, V13, P2989, DOI 10.1002/pmic.201200568
   Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mukai T, 2011, BIOCHEM BIOPH RES CO, V411, P757, DOI 10.1016/j.bbrc.2011.07.020
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241
   Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rothbart SB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00489
   Sasaki K, 2009, P NATL ACAD SCI USA, V106, P16257, DOI 10.1073/pnas.0902150106
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09
   Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019
   Shinchi Y, 2015, EXP CELL RES, V334, P90, DOI 10.1016/j.yexcr.2015.03.010
   Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200
   Sinha D, 2010, J BIOL CHEM, V285, P16572, DOI 10.1074/jbc.M109.091298
   SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237
   Stasevich TJ, 2014, NATURE, V516, P272, DOI 10.1038/nature13714
   Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153
   Taylor GCA, 2013, GENOME RES, V23, P2053, DOI 10.1101/gr.155028.113
   TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B
   TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0
   TURNER BM, 1991, J CELL SCI, V99, P13
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wu SM, 2011, CELL CYCLE, V10, P68, DOI 10.4161/cc.10.1.14363
   Yokoyama Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3681
   Zheng YP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3203
NR 65
TC 42
Z9 45
U1 1
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0967-3849
EI 1573-6849
J9 CHROMOSOME RES
JI Chromosome Res.
PD DEC
PY 2015
VL 23
IS 4
BP 753
EP 766
DI 10.1007/s10577-015-9486-4
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CX5OI
UT WOS:000365751100008
PM 26343042
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Yamashita, N
   Tokunaga, E
   Kitao, H
   Hitchins, M
   Inoue, Y
   Tanaka, K
   Hisamatsu, Y
   Taketani, K
   Akiyoshi, S
   Okada, S
   Oda, Y
   Saeki, H
   Oki, E
   Maehara, Y
AF Yamashita, Nami
   Tokunaga, Eriko
   Kitao, Hiroyuki
   Hitchins, Megan
   Inoue, Yuka
   Tanaka, Kimihiro
   Hisamatsu, Yuichi
   Taketani, Kenji
   Akiyoshi, Sayuri
   Okada, Satoko
   Oda, Yoshinao
   Saeki, Hiroshi
   Oki, Eiji
   Maehara, Yoshihiko
TI Epigenetic Inactivation of <i>BRCA1</i> Through Promoter
   Hypermethylation and Its Clinical Importance in Triple-Negative Breast
   Cancer
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Basal-like breast cancer; BRCA1; Breast cancer; Promotor methylation;
   Triple-negative breast cancer
ID SPORADIC BREAST; DNA METHYLATION; POLY(ADP-RIBOSE) POLYMERASE; MUTATION
   CARRIERS; TUMOR SUPPRESSION; GENOME INTEGRITY; POOR-PROGNOSIS;
   OVARIAN-TUMORS; MESSENGER-RNA; EXPRESSION
AB Breast cancer susceptibility gene I (BRCA1) promoter methylation was detected in 16% of triple-negative breast cancer (TNBC) cases. BRCA1 promoter methylation was significantly associated with high nuclear grade, low BRCA1 mRNA levels, absent BRCA1 protein expression and poor prognosis. BRCA1 promoter methylation might contribute to the aggressive phenotype and depletion of BRCA1 expression in TNBC. Background: Triple-negative breast cancer (TNBC) has many similarities with basal-like breast cancer. Additionally, TNBCs are associated with Breast cancer susceptibility gene I (BRCA1) functional loss, which leads to impaired homologous recombination-mediated DNA repair. Although somatic mutations in BRCA1 rarely occur in sporadic breast cancer, lower than normal rates of expression of BRCA1 is reported to be an important factor that contributes to tumorigenesis in sporadic tumors. The epigenetic inactivation of BRCA1 expression might thus play an important role in sporadic breast cancer cases. Patients and Methods: Breast cancer specimens were obtained from 69 TNBC and 161 non-TNBC patients who underwent surgery without neoadjuvant systemic therapy. BRCA1 promoter methylation status was investigated using combined bisulfite and restriction analysis. BRCA1 mRNA expression was evaluated using quantitative reverse transcriptase polymerase chain reaction and BRCA1 protein expression was assessed using immunohistochemistry. Results: BRCA1 promoter methylation was found in 11 tumors and all of these were in TNBC cases (P < .0001). BRCA1 promoter methylation was significantly associated with lymphovessel invasion (P = .02), high nuclear grade (P = .05), low BRCA1 mRNA expression (P <. 0001), and loss of BRCA1 protein expression (P = .0015). BRCA1 promoter methylation was significantly associated with shorter overall survival (P = .038). Conclusion: BRCA1 promotor methylation was found only in TNBC cases and the methylated cases account for 16% of TNBC. BRCA1 promoter methylation was significantly associated with reduced BRCA1 expression, aggressive phenotype, and poor prognosis. BRCA1 promoter methylation is an important mechanism that leads to functional loss of BRCA1. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Yamashita, Nami; Inoue, Yuka; Tanaka, Kimihiro; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan.
   [Tokunaga, Eriko] Kyushu Univ, Grad Sch Med Sci, Dept Comprehens Clin Oncol, Fukuoka 8128582, Japan.
   [Kitao, Hiroyuki] Kyushu Univ, Grad Sch Med Sci, Dept Mol Oncol, Fukuoka 8128582, Japan.
   [Hitchins, Megan] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA.
   [Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Pathol Sci, Dept Anat Pathol, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Stanford
   University; Kyushu University
RP Tokunaga, E (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Comprehens Clin Oncol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM eriko@surg2.med.kyushu-u.ac.jp
RI Oki, Eiji/AFO-6423-2022; Hitchins, Megan/GXH-4566-2022; Maehara,
   Yoshihiko/A-4867-2010; Yamashita, Nami/LQK-4270-2024
OI Hitchins, Megan/0000-0002-3603-2309
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Ben Gacem R, 2012, CANCER EPIDEMIOL, V36, P190, DOI 10.1016/j.canep.2011.09.001
   CLAUS EB, 1991, AM J HUM GENET, V48, P232
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831
   Ignatov T, 2013, BREAST CANCER RES TR, V141, P205, DOI 10.1007/s10549-013-2693-9
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312
   Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   Miller BJ, 2003, AM J HUM GENET, V73, P748, DOI 10.1086/378522
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Oakman C, 2010, BREAST, V19, P312, DOI 10.1016/j.breast.2010.03.026
   Okada S, 2012, ANN SURG ONCOL, V19, P1499, DOI 10.1245/s10434-011-2166-5
   Pérez-Vallés A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Schubert EK, 1997, AM J HUM GENET, V60, P1031
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Sobin LH, 2011, TNM CLASSIFICATION M
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379
   Staff S, 2003, CANCER RES, V63, P4978
   Tan PH, 2005, MODERN PATHOL, V18, P374, DOI 10.1038/modpathol.3800254
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Tokunaga E, 2000, ONCOLOGY-BASEL, V59, P44, DOI 10.1159/000012136
   Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 44
TC 40
Z9 45
U1 1
U2 21
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD DEC
PY 2015
VL 15
IS 6
BP 498
EP 504
DI 10.1016/j.clbc.2015.06.009
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CW7PG
UT WOS:000365190800014
PM 26195437
DA 2025-01-12
ER

PT J
AU Nayak, SR
   Harrington, E
   Boone, D
   Hartmaier, R
   Chen, J
   Pathiraja, TN
   Cooper, KL
   Fine, JL
   Sanfilippo, J
   Davidson, NE
   Lee, AV
   Dabbs, D
   Oesterreich, S
AF Nayak, Shweta R.
   Harrington, Emily
   Boone, David
   Hartmaier, Ryan
   Chen, Jian
   Pathiraja, Thushangi N.
   Cooper, Kristine L.
   Fine, Jeffrey L.
   Sanfilippo, Joseph
   Davidson, Nancy E.
   Lee, Adrian V.
   Dabbs, David
   Oesterreich, Steffi
TI A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer
SO HORMONES & CANCER
LA English
DT Article
ID ESTROGEN-RECEPTOR; DNA METHYLATION; GENE; HYPERSENSITIVITY; EXPRESSION;
   CELLS; H2A.Z; DEPRIVATION; ESTRADIOL; TAMOXIFEN
AB Acquired resistance to aromatase inhibitors (AIs) remains a major clinical problem in the treatment of estrogen receptor-positive (ER+) breast cancer. We and others have previously reported widespread changes in DNA methylation using breast cancer cell line models of endocrine resistance. Here, we show that the histone variant HIST1H2BE is hypomethylated in estrogen deprivation-resistant C4-12 and long-term estrogen-deprived (LTED) cells compared with parental MCF-7 cells. As expected, this hypomethylation associates with increased expression of HIST1H2BE in C4-12 and LTED cells. Both overexpression and downregulation of HIST1H2BE caused decreased proliferation in breast cancer cell lines suggesting the need for tightly controlled expression of this histone variant. Gene expression analysis showed varied expression of HIST1H2BE in a large panel of breast cancer cell lines, without restriction to specific molecular subtypes. Analysis of HIST1H2BE messenger RNA (mRNA) expression in ER+ AI-treated breast tumors showed significantly higher expression in resistant (n = 19) compared with sensitive (n = 37) tumors (p = 0.01). Using nanostring analysis, we measured expression of all 61 histone variants in endocrine-resistant and endocrine-sensitive tumors. We found significant overexpression of 22 variant histone genes in tumors resistant to AI therapy. In silico The Cancer Genome Atlas (TCGA) analysis showed frequent amplification of the HIST1 locus. In summary, our studies show, for the first time, that overexpression of histone variants might be important in endocrine response in ER+ breast cancer, and that overexpression is at least in part mediated via epigenetic mechanisms and amplifications. Future studies addressing endocrine response should include a potential role of these currently understudied histone variants.
C1 [Nayak, Shweta R.; Sanfilippo, Joseph] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA.
   [Harrington, Emily; Boone, David; Hartmaier, Ryan; Chen, Jian; Lee, Adrian V.; Oesterreich, Steffi] Univ Pittsburgh, Inst Canc, Magee Womens Res Inst, Dept Pharmacol & Chem Biol,WCRC, Pittsburgh, PA 15213 USA.
   [Pathiraja, Thushangi N.] Genome Inst Singapore, Singapore, Singapore.
   [Cooper, Kristine L.] UPCI, Biostat Core Facil, Pittsburgh, PA USA.
   [Fine, Jeffrey L.; Dabbs, David] UPMC, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA USA.
   [Davidson, Nancy E.] UPMC, UPCI, Dept Med, Pittsburgh, PA USA.
   [Davidson, Nancy E.] UPMC, UPCI, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Magee-Womens Research Institute;
   Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Oesterreich, S (通讯作者)，Univ Pittsburgh, Inst Canc, Magee Womens Res Inst, Dept Pharmacol & Chem Biol,WCRC, 204 Craft Ave, Pittsburgh, PA 15213 USA.
EM oesterreichs@upmc.edu
RI Fine, Jeffrey/H-6175-2013
OI Fine, Jeffrey/0000-0002-2678-8014; Boone, David/0000-0002-1258-7473;
   Lee, Adrian/0000-0001-9917-514X
FU Magee-Womens Hospital of UPMC; Alexander von Humboldt Foundation; DOD
   predoctoral fellowship [DOD 5W81XWH-06-1-0713, R01CA097213]; Breast
   Cancer Research Foundation; Department of Pharmacology; Pennsylvania
   Department of Health; Cancer Center Support grant NIH [5P30 CA47904]
FX We would like to thank the Reproductive Endocrinology and Infertility
   fellowship program at the Magee-Womens Hospital of UPMC and specifically
   Drs. Anthony N Wakim, Tony Plant, and Kyle Orwig, who provided critical
   support throughout the studies. We would also like to thank Dr. Richard
   Santen at University of Virginia Health Sciences Center,
   Charlottesville, VA, for providing LTED cells, Dr. Gannon, whose group
   was instrumental in the generation of original screening data previously
   published (27), and Dr. Danny Hochbaum for outstanding guidance for
   cloning approaches. This project was in part funded through an Alexander
   von Humboldt Foundation fellowship (SO), a DOD predoctoral fellowship
   DOD 5W81XWH-06-1-0713 (T.N. Pathiraja), R01CA097213 (SO), Breast Cancer
   Research Foundation (ND, AVL, and SO), John Lazo Fellowship from the
   Department of Pharmacology (EAH), and a grant from the Pennsylvania
   Department of Health (SO, AVL). The Department specifically disclaims
   responsibility for any analyses, interpretations or conclusions.
   Lentivirus particles were provided by UPCI Core Facility, supported by
   Cancer Center Support grant NIH 5P30 CA47904.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Anderson H, 2007, J STEROID BIOCHEM, V106, P49, DOI 10.1016/j.jsbmb.2007.05.024
   Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020
   Baum M, 2002, EUR J CANCER, V38, P1984, DOI 10.1016/S0959-8049(02)00154-5
   Biermann K, 2007, ANTICANCER RES, V27, P3091
   Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2
   Churikov D, 2004, GENOMICS, V84, P745, DOI 10.1016/j.ygeno.2004.06.001
   Conerly ML, 2010, GENOME RES, V20, P1383, DOI 10.1101/gr.106542.110
   Dryhurst D, 2012, CANCER LETT, V315, P38, DOI 10.1016/j.canlet.2011.10.003
   Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431
   Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4
   Harbeck N, 2008, J CLIN ONCOL, V26, P5036, DOI 10.1200/JCO.2007.14.1697
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164
   Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martin LA, 2005, ENDOCR-RELAT CANCER, V12, P1017, DOI 10.1677/erc.1.00905
   MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918
   Miller WR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2931
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Oesterreich S, 2001, CANCER RES, V61, P5771
   Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831
   Pathiraja TN, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008326
   Rangasamy D, 2010, CURR MED CHEM, V17, P3155, DOI 10.2174/092986710792231941
   Santen R, 2001, J STEROID BIOCHEM, V79, P115, DOI 10.1016/S0960-0760(01)00151-0
   Santen RJ, 2008, ADV EXP MED BIOL, V630, P19
   Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465
   Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861
   Tanaka M, 2001, DEVELOPMENT, V128, P655
   Tomonaga T, 2003, CANCER RES, V63, P3511
   Valdés-Mora F, 2012, GENOME RES, V22, P307, DOI 10.1101/gr.118919.110
   Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186
NR 38
TC 29
Z9 35
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1868-8497
EI 1868-8500
J9 HORM CANCER-US
JI Horm. Cancer
PD DEC
PY 2015
VL 6
IS 5-6
BP 214
EP 224
DI 10.1007/s12672-015-0230-5
PG 11
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA CV6RJ
UT WOS:000364397600004
PM 26113056
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Zhuang, Y
   Nguyen, HT
   Burow, ME
   Zhuo, Y
   El-Dahr, SS
   Yao, X
   Cao, SB
   Flemington, EK
   Nephew, KP
   Fang, F
   Collins-Burow, B
   Rhodes, LV
   Yu, Q
   Jayawickramarajah, J
   Shan, B
AF Zhuang, Yan
   Nguyen, Hong T.
   Burow, Matthew E.
   Zhuo, Ying
   El-Dahr, Samir S.
   Yao, Xiao
   Cao, Subing
   Flemington, Erik K.
   Nephew, Kenneth P.
   Fang, Fang
   Collins-Burow, Bridgette
   Rhodes, Lyndsay V.
   Yu, Qiang
   Jayawickramarajah, Janarthanan
   Shan, Bin
TI Elevated expression of long intergenic non-coding RNA HOTAIR in a
   basal-like variant of MCF-7 breast cancer cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE HOTAIR; lincRNA; EZH2; breast cancer
ID ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION;
   NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; SIGNALING PATHWAY; HUMAN TUMORS;
   I COLLAGEN; CHROMATIN; INHIBITION; CHEMORESISTANCE
AB Epigenetic regulation of gene expression is critical to phenotypic maintenance and transition of human breast cancer cells. HOX antisense intergenic RNA (HOTAIR) is a long intergenic non-coding RNA that epigenetically represses gene expression via recruitment of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase. Elevated expression of HOTAIR promotes progression of breast cancer. In the current study we examined the expression and function of HOTAIR in MCF-7-TNR cells, a derivative of the luminal-like breast cancer cell line MCF-7 that acquired resistance to TNF--induced cell death. The expression of HOTAIR, markers of the luminal-like and basal-like subtypes, and growth were compared between MCF-7 and MCF-7-TNR cells. These variables were further assessed upon inhibition of HOTAIR, EZH2, p38 MAPK, and SRC kinase in MCF-7-TNR cells. When compared with MCF-7 cells, MCF-7-TNR cells exhibited an increase in the expression of HOTAIR, which correlated with characteristics of a luminal-like to basal-like transition as evidenced by dysregulated gene expression and accelerated growth. MCF-7-TNR cells exhibited reduced suppressive histone H3 lysine27 trimethylation on the HOTAIR promoter. Inhibition of HOTAIR and EZH2 attenuated the luminal-like to basal-like transition in terms of gene expression and growth in MCF-7-TNR cells. Inhibition of p38 and SRC diminished HOTAIR expression and the basal-like phenotype in MCF-7-TNR cells. HOTAIR was robustly expressed in the native basal-like breast cancer cells and inhibition of HOTAIR reduced the basal-like gene expression and growth. Our findings suggest HOTAIR-mediated regulation of gene expression and growth associated with the basal-like phenotype of breast cancer cells. (c) 2014 Wiley Periodicals, Inc.
C1 [Zhuang, Yan; Nguyen, Hong T.; Burow, Matthew E.; Collins-Burow, Bridgette; Rhodes, Lyndsay V.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
   [Zhuo, Ying; Yao, Xiao] Kadlec Reg Med Ctr, Richland, WA USA.
   [El-Dahr, Samir S.] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.
   [Cao, Subing; Flemington, Erik K.] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA.
   [Nephew, Kenneth P.; Fang, Fang] Indiana Univ Sch Med, Dept Med Sci, Bloomington, IN USA.
   [Yu, Qiang] Genome Inst Singapore, Singapore, Singapore.
   [Jayawickramarajah, Janarthanan] Tulane Univ, Dept Chem, New Orleans, LA 70118 USA.
   [Shan, Bin] Washington State Univ, Spokane, WA 99202 USA.
C3 Tulane University; Tulane University; Tulane University; Indiana
   University System; Indiana University Bloomington; Agency for Science
   Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore
   (GIS); Tulane University; Washington State University
RP Shan, B (通讯作者)，Washington State Univ, 412 E Spokane Falls Blvd, Spokane, WA 99202 USA.
RI Burow, Matthew/D-6351-2013; Rhodes, Lyndsay/AAC-4989-2020
OI Yu, Qiang/0000-0003-2132-8278; Shan, Bin/0000-0002-6869-2678; Rhodes,
   Lyndsay/0000-0001-7672-2059; Jayawickramarajah,
   Janarthanan/0000-0001-5271-1523
FU Washington State University Startup Fund; NIH [R01GM097571]
FX Grant sponsor: Washington State University Startup Fund; Grant sponsor:
   NIH; Grant number: R01GM097571
CR Antoon JW, 2012, AM J CANCER RES, V2, P446
   Antoon JW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00539
   Antoon JW, 2012, ONCOL REP, V27, P1779, DOI 10.3892/or.2012.1743
   Antoon JW, 2011, CANCER BIOL THER, V11, P678, DOI 10.4161/cbt.11.7.14903
   Antoon JW, 2011, J MOL ENDOCRINOL, V46, P205, DOI 10.1530/JME-10-0116
   Barancík M, 2001, EUR J PHARM SCI, V14, P29, DOI 10.1016/S0928-0987(01)00139-7
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Chisholm KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047998
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F
   Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Golas JM, 2003, CANCER RES, V63, P375
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Kant S, 2011, GENE DEV, V25, P2069, DOI 10.1101/gad.17224711
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Li C, 2011, MOL CARCINOGEN, V50, P563, DOI 10.1002/mc.20742
   Liu ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077293
   Marotta LLC, 2011, ONCOTARGET, V2, P588
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   McIlroy M, 2010, CANCER RES, V70, P1585, DOI 10.1158/0008-5472.CAN-09-3713
   Nguyen HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-16
   Page TH, 2009, CURR MOL MED, V9, P69, DOI 10.2174/156652409787314507
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9
   Pauler FM, 2012, CURR OPIN GENET DEV, V22, P283, DOI 10.1016/j.gde.2012.02.005
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947
   Saito S, 2011, BIOCHEM BIOPH RES CO, V408, P630, DOI 10.1016/j.bbrc.2011.04.075
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shan B, 2005, J BIOL CHEM, V280, P1103, DOI 10.1074/jbc.M406293200
   Shan B, 2005, EXP CELL RES, V305, P10, DOI 10.1016/j.yexcr.2004.09.033
   Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200
   Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200
   Shan B, 2007, J MOL CELL CARDIOL, V42, P517, DOI 10.1016/j.yjmcc.2006.08.004
   Shan B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011662
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Spitale RC, 2011, EPIGENETICS-US, V6, P539, DOI 10.4161/epi.6.5.15221
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169
   Weldon CB, 2004, INT J ONCOL, V24, P1473
   Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389
   Weldon CB, 2001, SURGERY, V130, P143, DOI 10.1067/msy.2001.115512
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48
   Yang H, 2006, ONCOGENE, V25, P4585, DOI 10.1038/sj.onc.1209481
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
   Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210
   Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35
   Zhuang Y, 2010, BIOCHEM BIOPH RES CO, V392, P608, DOI 10.1016/j.bbrc.2010.01.091
NR 65
TC 33
Z9 36
U1 0
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2015
VL 54
IS 12
BP 1656
EP 1667
DI 10.1002/mc.22237
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CU4EP
UT WOS:000363480000011
PM 25328122
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Labbozzetta, M
   Poma, P
   Vivona, N
   Gulino, A
   D'Alessandro, N
   Notarbartolo, M
AF Labbozzetta, Manuela
   Poma, Paola
   Vivona, Nicoletta
   Gulino, Alessandro
   D'Alessandro, Natale
   Notarbartolo, Monica
TI Epigenetic changes and nuclear factor-B activation, but not
   microRNA-224, downregulate Raf-1 kinase inhibitor protein in
   triple-negative breast cancer SUM 159 cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE triple-negative breast cancer; Raf-1 kinase inhibitor protein;
   epigenetic changes; microRNA-224; nuclear factor-kappa B
ID NF-KAPPA-B; METASTASIS; EXPRESSION; RKIP; SUPPRESSOR; INVASION;
   TRANSITION; REPRESSION; PATHWAYS; GENES
AB Raf-1 kinase inhibitor protein (RKIP) is a tumor suppressor and metastasis inhibitor, which enhances drug-induced apoptosis of cancer cells. Downregulation of RKIP may be significant in the biology of highly aggressive and drug-resistant tumors, for example triple-negative breast cancers (TNBCs). Potential causes for the low levels of RKIP expressed by SUM 159 TNBC cells were investigated in the present study. Bisulphite modification, methylation specific-polymerase chain reaction (PCR) and a TransAM NF-kappa B assay were performed and the results suggested that various mechanisms, including methylation of the gene promoter, histone deacetylation and nuclear factor-kappa B (NF-kappa B) activation, but not targeting by microRNA-224 (miR/miRNA-224), as determined by transfection of pre-miR-224 miRNA precursor or anti-miR-224 miRNA inhibitor, may downregulate RKIP in these cells. Furthermore, reverse transcription-quantitative PCR, western blotting, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium cell growth assay and flow cytometry revealed that in SUM 159 cells, the demethylating agent 5-aza-2-deoxycytidine (5-AZA), the histone deacetylase inhibitor trichostatin A (TSA) and the NF-kappa B inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) enhanced RKIP expression and resulted in significant cell growth inhibition and induction of apoptosis. 5-AZA and TSA mainly produced additive antitumor effects, while the combination of DHMEQ and TSA exhibited significant synergy in cell growth inhibition and induction of apoptosis assays. Increasing evidence that aberrant activation of NF-kappa B signaling is a frequent characteristic of TNBC highlights the fact that this transcription factor may be a useful target for treatment of such tumors. In addition to DHMEQ, proteasome inhibitors may also represent valuable therapeutic resources in this context. Notably, proteasome inhibitors, in addition to the inhibition of NF-kappa B activation, may also restore RKIP levels by inhibiting proteasome degradation of the ubiquitinated protein. The current results contribute to the understanding of the molecular mechanisms of RKIP downregulation in TNBC and suggest possible novel therapeutic approaches for the treatment of these types of cancer.
C1 [Labbozzetta, Manuela; Poma, Paola; Vivona, Nicoletta; D'Alessandro, Natale; Notarbartolo, Monica] Univ Palermo, Dept Hlth Sci & Mother & Child Care G DAlessandro, Pharmacol Unit, I-90127 Palermo, Italy.
   [Gulino, Alessandro] Univ Palermo, Dept Hlth Sci & Mother & Child Care G DAlessandro, Tumor Immunol Unit, I-90127 Palermo, Italy.
C3 University of Palermo; University of Palermo
RP Notarbartolo, M (通讯作者)，Univ Palermo, Dept Hlth Sci & Mother & Child Care G DAlessandro, Pharmacol Unit, 129 Via Vespro, I-90127 Palermo, Italy.
EM monica.notarbartolo@unipa.it
RI Notarbartolo di Villarosa, Monica/AAE-5324-2022; Poma,
   Paola/AAE-5325-2022; Labbozzetta, Manuela/AAE-5418-2022
FU Fund for Investment in Basic Research (FIRB) of Medical Research in
   Italy (MERIT) [RBNE08YYBM_004]; Finalized Research Fund (FFR)
   [2012-ATE-0509]
FX The present study was supported by the Fund for Investment in Basic
   Research (FIRB) of Medical Research in Italy (MERIT) (no.
   RBNE08YYBM_004) and the Finalized Research Fund (FFR; no. 2012/2013
   2012-ATE-0509).
CR Abramson VG, 2015, CANCER-AM CANCER SOC, V121, P8, DOI 10.1002/cncr.28914
   Al-Mulla F, 2008, J CLIN PATHOL, V61, P524, DOI 10.1136/jcp.2007.046987
   Al-Mulla F, 2013, AM J CANCER RES, V3, P446
   [Anonymous], FORUM IMMUN DIS THER
   Chen TC, 2014, J MOL MED, V92, P53, DOI 10.1007/s00109-013-1083-4
   CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015
   Fabbri M, 2010, ADV GENET, V70, P87, DOI [10.1016/S0065-2660(10)70004-3, 10.1016/B978-0-12-380866-0.60004-6]
   Florena AM, 2007, PATHOBIOLOGY, V74, P317, DOI 10.1159/000110024
   Hao CF, 2012, TUMOR BIOL, V33, P1159, DOI 10.1007/s13277-012-0358-7
   Hsu YL, 2012, J AGR FOOD CHEM, V60, P852, DOI 10.1021/jf2052515
   Huang L, 2012, BIOCHEM BIOPH RES CO, V425, P127, DOI 10.1016/j.bbrc.2012.07.025
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349
   Klysik J, 2008, CELL SIGNAL, V20, P1, DOI 10.1016/j.cellsig.2007.07.003
   Li DX, 2014, EXP THER MED, V8, P844, DOI 10.3892/etm.2014.1833
   Minn AJ, 2012, CELL CYCLE, V11, P2452, DOI 10.4161/cc.20624
   Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859
   Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Notarbartolo M, 2011, OMICS, V15, P267, DOI 10.1089/omi.2010.0096
   Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6
   Piao HL, 2014, NAT CELL BIOL, V16, P245, DOI 10.1038/ncb2909
   Poma P, 2006, INT J ONCOL, V28, P923
   Poma P, 2012, OMICS, V16, P579, DOI 10.1089/omi.2012.0048
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Schmadeka R, 2014, AM J CLIN PATHOL, V141, P462, DOI 10.1309/AJCPQN8GZ8SILKGN
   Schuierer MM, 2006, ONCOL REP, V16, P451
   Sethi S, 2011, TRANSL ONCOL, V4, P212, DOI 10.1593/tlo.10244
   Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051
   Umezawa K, 2011, BIOMED PHARMACOTHER, V65, P252, DOI 10.1016/j.biopha.2011.02.003
   Walker Evan J, 2011, For Immunopathol Dis Therap, V2, P195
   Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40
   Yang XW, 2001, CANCER RES, V61, P7025
   Yousuf S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092478
   Zhai FX, 2012, J CANCER RES CLIN, V138, P439, DOI 10.1007/s00432-011-1113-y
NR 37
TC 16
Z9 17
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2015
VL 10
IS 6
BP 3807
EP 3815
DI 10.3892/ol.2015.3787
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ6SZ
UT WOS:000367232600081
PM 26788213
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Mustafa, M
   Lee, JY
   Kim, MH
AF Mustafa, Muhammad
   Lee, Ji-Yeon
   Kim, Myoung Hee
TI CTCF negatively regulates HOXA10 expression in breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE CTCF; HOXA10; H3K27me3; Epigenetic silencing; Breast cancer
ID GENE-EXPRESSION; TRANSCRIPTION FACTORS; GENOME-WIDE; METHYLATION; TARGET
AB HOX genes not only play important roles in defining body patterning during embryonic development, but also control numerous cellular events in adult cells. Deregulated HOX gene expression in different cancers including breast cancer is now increasingly being reported. Given that human HOXA cluster is marked with several CTCF binding sites, we investigated whether the presence of CTCF is associated directly with expression of HOXA genes in breast cancer cells. Several HOX genes, such as HOXA4, HOXA5 and HOXA10, were deregulated by CTCF overexpression and knockdown in MCF-7 cells. Among these genes, HOXA10 is an emerging tumor suppressor for its role in activation of p53 and in countering tumorigenesis in breast cancer. Here we provided evidences that CTCF functions as a negative regulator of HOXA10 in breast cancer cells. The putative promoter region of HOXA10 lies between 5.3 and 6.1 kb upstream of its start codon and its promoter activity was negatively regulated by CTCF. Together with in-silico analysis and in vitro mutation assay we identified a 20 bp CTCF binding motif flanking with core ;promoter element of HOXA10. HOXA10 promoter region was kept inactivated by maintaining H3K27me3 inactivation marks in the presence of CTCF. Epigenetic silencing of HOXA10 by CTCF in breast cancer cells may contribute towards tumorigenesis by decreasing apoptosis and promoting metastasis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Kim, Myoung Hee] Yonsei Univ, Coll Med, Dept Anat, Embryol Lab, Seoul 03722, South Korea.
   Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kim, MH (通讯作者)，Yonsei Univ, Coll Med, Dept Anat, Embryol Lab, Seoul 03722, South Korea.
EM mhkim1@yuhs.ac
RI Mustafa, Muhammad/HKO-9687-2023; Kim, Tae-Hee/AAN-9079-2021
OI Lee, Ji-Yeon/0000-0002-0670-3095; Mustafa, Muhammad/0000-0002-8714-5311;
   Kim, Myoung Hee/0000-0001-5652-1452
FU Higher Education Commission of Pakistan; National Research Foundation
   (NRF) - Ministry of Education, Science and Technology
   [NRF-2013R1A1A2008399, NRF-2014R1A1A2056986]; Yonsei University College
   of Medicine, Korea [6-2014-0147]
FX M. Mustafa was supported by Higher Education Commission of Pakistan with
   a fully funded scholarship. This research was supported by the Basic
   Science Research Program through the National Research Foundation (NRF)
   funded by the Ministry of Education, Science and Technology
   (NRF-2013R1A1A2008399 and NRF-2014R1A1A2056986) and partly by a Faculty
   Research Grant (6-2014-0147) from Yonsei University College of Medicine,
   Korea.
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100
   Chen HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041374
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Chernukhin I, 2007, MOL CELL BIOL, V27, P1631, DOI 10.1128/MCB.01993-06
   Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Hur H, 2014, MOL BIOTECHNOL, V56, P64, DOI 10.1007/s12033-013-9682-4
   KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612
   Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N
   Méndez-Catalá CF, 2013, NEOPLASIA, V15, P898, DOI 10.1593/neo.121948
   Narendra V, 2015, SCIENCE, V347, P1017, DOI 10.1126/science.1262088
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Renaud J, 2005, J MED CHEM, V48, P364, DOI 10.1021/jm040858p
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847
   Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Xu M, 2014, MOL CELL BIOL, V34, P3867, DOI 10.1128/MCB.00567-14
   Zuin J, 2014, P NATL ACAD SCI USA, V111, P996, DOI 10.1073/pnas.1317788111
NR 25
TC 25
Z9 28
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 27
PY 2015
VL 467
IS 4
BP 828
EP 834
DI 10.1016/j.bbrc.2015.10.058
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW6YV
UT WOS:000365145300035
PM 26478432
DA 2025-01-12
ER

PT J
AU Tan, DY
   Zhang, J
   Nie, X
   Yu, C
   Li, ZZ
   Mamat, Z
   Jiang, H
   Yang, XM
   Zhang, J
   Yao, SH
   Tang, PZ
   Huang, JJ
AF Tan, Dunyong
   Zhang, Jie
   Nie, Xi
   Yu, Chao
   Li, Zhongzheng
   Mamat, Zulbnur
   Jiang, Huang
   Yang, Xiaomeng
   Zhang, Jiao
   Yao, Sihong
   Tang, Peizhi
   Huang, Jianjun
TI Histone 3 Trimethylation of IGFBP-7 Gene Promoter by Expression of D5
   Stat5a in Breast Epithelial Cells
SO CHINESE JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE breast cancer; chromatin immunoprecipitation assay (ChIP); D5 Stat5a;
   H3K27Me3; histone modification; IGFBP-7
ID MAMMARY-GLAND DEVELOPMENT; TRANSCRIPTION FACTORS; DNA METHYLATION;
   SIGNAL TRANSDUCER; CANCER; ACTIVATION; SURVIVAL; MARKER; ROLES; EZH2
AB As a very important transcription factor, signal transducer and activator of transcription 5a (Stat5a) has been reported to be involved in human reproductive cancers such as breast, prostate and ovarian cancer. However, up to date, the exact role of Stat5a in breast cancer is still not clear. The data reported are conflicting. D5 Stat5a is a variant of Stat5a we cloned recently. This newly cloned variant behave like its full length counterpart in terms of dimerization, being activated by prolactin and nuclear translocation, however it also behave differently in terms of effect on cell proliferation and interaction with other transcription factors. In the present study, we examined its effect on cell proliferation of cultured breast cancer cells (MCF-10A and MCF-7) by using adenovirus-mediated gene transfer and MTS technology. Also, quantitative real time polymerase chain reaction (qRT-PCR), chromatin immunoprecipitation assay (ChIP) and Western blot were used to probe the possible changes of insulin-like growth factor binding protein-7 (IGFBP-7) expression including mRNA and protein, and the epigenetic changes with overexpression of this newly cloned variant. The results clarified that D5 Stat5a (1) behaves as a promoting factor to the cell proliferation of MCF-10A and MCF-7, (2) induces enhancer of zeste homology 2 (EZH2) expression in breast epithelial cells, as well as histone 3 trimethylation of IGFBP-7 promoter region, and (3) lower IGFBP-7 expression was detected in breast cancer tissue. Taking together, we concluded that the mitogenic effect of D5 Stat5a on breast cells is, at least partly, through up-regulation of histone methyltransferase, EZH2, and therefore inhibiting IGFBP-7 expression by increasing H3K27Me3 of IGFBP-7 promoter region.
C1 [Tan, Dunyong; Zhang, Jie; Nie, Xi; Yu, Chao; Li, Zhongzheng; Mamat, Zulbnur; Jiang, Huang; Yang, Xiaomeng; Zhang, Jiao; Yao, Sihong] Jishou Univ, Sch Med, Inst Med Sci, Jishou 416000, Hunan, Peoples R China.
   [Tang, Peizhi; Huang, Jianjun] Jishou Univ, Affiliated Hosp 1, Dept Breast Surg, Jishou 416000, Hunan, Peoples R China.
C3 Jishou University; Jishou University
RP Tan, DY (通讯作者)，Jishou Univ, Sch Med, Inst Med Sci, Datianwan Campus, Jishou 416000, Hunan, Peoples R China.
EM naturet2002@yahoo.com
FU National Natural Science Foundation of China [81172497, 81260396];
   Jishou University Research Grant [jsdxkyzz101010, JGY201317]
FX This work was supported by National Natural Science Foundation of China
   (No. 81172497 and No. 81260396) and Jishou University Research Grant
   (No. jsdxkyzz101010 and JGY201317).
CR Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barros P, 2012, NUCLEIC ACIDS RES, V40, P7776, DOI 10.1093/nar/gks571
   Benatar T, 2012, BREAST CANCER RES TR, V133, P563, DOI 10.1007/s10549-011-1816-4
   Bradley HL, 2004, BLOOD, V103, P2965, DOI 10.1182/blood-2003-08-2963
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen D, 2013, MOL THER, V21, P758, DOI 10.1038/mt.2012.282
   Cheutin T, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002465
   Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7
   Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328
   Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926
   Hosui A, 2009, J EXP MED, V206, P819, DOI 10.1084/jem.20080003
   Ikeda K, 2005, INT ARCH ALLERGY IMM, V137, P45, DOI 10.1159/000085431
   Kalita A, 2013, IUBMB LIFE, V65, P462, DOI 10.1002/iub.1152
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Li HZ, 2004, CANCER RES, V64, P4774, DOI 10.1158/0008-5472.CAN-03-3499
   Lin YM, 2012, CHINESE J PHYSIOL, V55, P55, DOI 10.4077/CJP.2012.AMM118
   Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179
   Martini M, 2008, AM J CLIN PATHOL, V129, P472, DOI 10.1309/63H1A83HRTBQ07DB
   Nagy ZS, 2002, J LEUKOCYTE BIOL, V72, P819
   Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046
   Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105
   Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97
   Ostlund H., 2000, 2 INT S MOL BIOL BRE, P3
   Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484
   Song CX, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-2012
   Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tan D.Y., 2013, ADAPT MED, V5, P189
   Tan DY, 2014, CANCER LETT, V346, P148, DOI 10.1016/j.canlet.2013.12.030
   Tan DY, 2005, MOL ENDOCRINOL, V19, P1291, DOI 10.1210/me.2004-0304
   Thomas C, 2011, MOL CANCER THER, V10, P347, DOI 10.1158/1535-7163.MCT-10-0850
   Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z
   Walsh LA, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-10
   Wang JL, 2011, CHINESE J PHYSIOL, V54, P332, DOI 10.4077/CJP.2011.AMM087
   Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155
   Woelfle J, 2004, AM J PHYSIOL-ENDOC M, V286, pE393, DOI 10.1152/ajpendo.00389.2003
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yue CH, 2012, CHINESE J PHYSIOL, V55, P31, DOI 10.4077/CJP.2012.AMM109
NR 39
TC 1
Z9 1
U1 0
U2 14
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0304-4920
EI 2666-0059
J9 CHINESE J PHYSIOL
JI Chin. J. Physiol.
PD OCT 31
PY 2015
VL 58
IS 5
BP 275
EP 284
DI 10.4077/CJP.2015.BAD322
PG 10
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA CV2TX
UT WOS:000364111200001
PM 26387651
DA 2025-01-12
ER

PT J
AU Rauscher, GH
   Kresovich, JK
   Poulin, M
   Yan, LY
   Macias, V
   Mahmoud, AM
   Al-Alem, U
   Kajdacsy-Balla, A
   Wiley, EL
   Tonetti, D
   Ehrlich, M
AF Rauscher, Garth H.
   Kresovich, Jacob K.
   Poulin, Matthew
   Yan, Liying
   Macias, Virgilia
   Mahmoud, Abeer M.
   Al-Alem, Umaima
   Kajdacsy-Balla, Andre
   Wiley, Elizabeth L.
   Tonetti, Debra
   Ehrlich, Melanie
TI Exploring DNA methylation changes in promoter, intragenic, and
   intergenic regions as early and late events in breast cancer formation
SO BMC CANCER
LA English
DT Article
DE Breast cancer; DNA methylation; Hypomethylation; Hypermethylation;
   Pyrosequencing; Tumor suppressor genes; Field effect; TCGA database;
   Transcriptome; Histone modifications
ID CPG-ISLAND METHYLATION; SPORADIC BREAST; GENE-EXPRESSION;
   TUMOR-SUPPRESSOR; ADENOMATOUS POLYPOSIS; TREFOIL FACTOR-1;
   NORMAL-TISSUES; HYPERMETHYLATION; HYPOMETHYLATION; IDENTIFICATION
AB Background: Breast cancer formation is associated with frequent changes in DNA methylation but the extent of very early alterations in DNA methylation and the biological significance of cancer-associated epigenetic changes need further elucidation.
   Methods: Pyrosequencing was done on bisulfite-treated DNA from formalin-fixed, paraffin-embedded sections containing invasive tumor and paired samples of histologically normal tissue adjacent to the cancers as well as control reduction mammoplasty samples from unaffected women. The DNA regions studied were promoters (BRCA1, CD44, ESR1, GSTM2, GSTP1, MAGEA1, MSI1, NFE2L3, RASSF1A, RUNX3, SIX3 and TFF1), far-upstream regions (EN1, PAX3, PITX2, and SGK1), introns (APC, EGFR, LHX2, RFX1 and SOX9) and the LINE-1 and satellite 2 DNA repeats. These choices were based upon previous literature or publicly available DNA methylome profiles. The percent methylation was averaged across neighboring CpG sites.
   Results: Most of the assayed gene regions displayed hypermethylation in cancer vs. adjacent tissue but the TFF1 and MAGEA1 regions were significantly hypomethylated (p = 0.001). Importantly, six of the 16 regions examined in a large collection of patients (105 - 129) and in 15-18 reduction mammoplasty samples were already aberrantly methylated in adjacent, histologically normal tissue vs. non-cancerous mammoplasty samples (p <= 0.01). In addition, examination of transcriptome and DNA methylation databases indicated that methylation at three non-promoter regions (far-upstream EN1 and PITX2 and intronic LHX2) was associated with higher gene expression, unlike the inverse associations between cancer DNA hypermethylation and cancer-altered gene expression usually reported. These three non-promoter regions also exhibited normal tissue-specific hypermethylation positively associated with differentiation-related gene expression (in muscle progenitor cells vs. many other types of normal cells). The importance of considering the exact DNA region analyzed and the gene structure was further illustrated by bioinformatic analysis of an alternative promoter/intron gene region for APC.
   Conclusions: We confirmed the frequent DNA methylation changes in invasive breast cancer at a variety of genome locations and found evidence for an extensive field effect in breast cancer. In addition, we illustrate the power of combining publicly available whole-genome databases with a candidate gene approach to study cancer epigenetics.
C1 [Rauscher, Garth H.; Kresovich, Jacob K.; Al-Alem, Umaima] Univ Illinois, Div Epidemiol & Biostat, Sch Publ Hlth, Chicago, IL 60612 USA.
   [Poulin, Matthew; Yan, Liying] EpigenDx Inc, Hopkinton, MA USA.
   [Macias, Virgilia; Mahmoud, Abeer M.; Kajdacsy-Balla, Andre; Wiley, Elizabeth L.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
   [Tonetti, Debra] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA.
   [Ehrlich, Melanie] Tulane Univ, Human Genet Program, Tulane Canc Ctr, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Ehrlich, Melanie] Tulane Univ, Ctr Bioinformat & Genom, Hlth Sci Ctr, New Orleans, LA 70112 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Tulane University; Tulane
   University
RP Rauscher, GH (通讯作者)，Univ Illinois, Div Epidemiol & Biostat, Sch Publ Hlth, M-C 923, Chicago, IL 60612 USA.
EM garthr@uic.edu; ehrlich@tulane.edu
RI Al-alem, Umaima/AAW-2584-2021
OI Rauscher, Garth/0000-0003-0374-944X; Al-alem,
   Umaima/0000-0003-2984-076X; Kresovich, Jacob/0000-0002-9577-226X
FU NIH [2P50CA106743-06]; Louisiana Cancer Research Center grant
FX Financial support provided by a grant from NIH (2P50CA106743-06) to the
   University of Illinois at Chicago (GHR) and a Louisiana Cancer Research
   Center grant (ME). We would like to thank the Illinios Department of
   Public Health, Illinois State Cancer Registry for the case-finding for
   the parent study, and the patients who participated in the Breast Cancer
   Care in Chicago study. We would also like to thank the specimen donors
   of TCGA, Johns Hopkins University and University of Southern California
   for the DNA methylation data (Infinium HumanMethylation450) and the
   University of North Carolina for the gene expression data (Illumina
   HighSeq 2000 Total RNA Sequencing Version 2).
CR Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Buache E, 2011, ONCOGENE, V30, P3261, DOI 10.1038/onc.2011.41
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2001, CANCER RES, V61, P3105
   Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   Ehrlich M, 2014, EPIGENOMICS-UK, V6, P563, DOI [10.2217/EPI.14.48, 10.2217/epi.14.48]
   Ehrlich M, 2013, EPIGENOMICS-UK, V5, P553, DOI 10.2217/epi.13.43
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fleischer T, 2014, INT J CANCER, V134, P2615, DOI 10.1002/ijc.28606
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jung EJ, 2013, ANN LAB MED, V33, P431, DOI 10.3343/alm.2013.33.6.431
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Kanafi M, 2014, J CELL PHYSIOL, V229, P1369, DOI 10.1002/jcp.24570
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim MS, 2012, ONCOL REP, V27, P1681, DOI 10.3892/or.2012.1691
   Kreutzer JN, 2012, INT J ONCOL, V40, P914, DOI 10.3892/ijo.2011.1272
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lian ZQ, 2012, INT J ONCOL, V41, P629, DOI 10.3892/ijo.2012.1464
   Markicevic M, 2014, INT J MED SCI, V11, P663, DOI 10.7150/ijms.8194
   Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Montero AJ, 2006, CANCER BIOL THER, V5, P1494, DOI 10.4161/cbt.5.11.3299
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Ohashi Y, 2004, ONCOGENE, V23, P7772, DOI 10.1038/sj.onc.1208058
   Otte M, 2001, CANCER RES, V61, P6682
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Rohlin A, 2011, ONCOGENE, V30, P4977, DOI 10.1038/onc.2011.201
   Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Slater AA, 2013, EPIGENETICS-US, V8, P252, DOI 10.4161/epi.23817
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Sun XZ, 2012, BREAST CANCER RES TR, V131, P1003, DOI 10.1007/s10549-011-1789-3
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tsumagari K, 2013, EPIGENETICS-US, V8, P317, DOI 10.4161/epi.23989
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zheng SC, 2011, NEURO-ONCOLOGY, V13, P280, DOI 10.1093/neuonc/noq190
NR 65
TC 86
Z9 98
U1 0
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 29
PY 2015
VL 15
AR 816
DI 10.1186/s12885-015-1777-9
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CV2VS
UT WOS:000364115900001
PM 26510686
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Raghavan, V
   Vijayaraghavalu, S
   Peetla, C
   Yamada, M
   Morisada, M
   Labhasetwar, V
AF Raghavan, Vijay
   Vijayaraghavalu, Sivakumar
   Peetla, Chiranjeevi
   Yamada, Masayoshi
   Morisada, Megan
   Labhasetwar, Vinod
TI Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin
   Rafts from Resistant Breast Cancer Cells, Influencing Biophysical
   Characteristics of Membrane Lipids
SO LANGMUIR
LA English
DT Article
ID P-GLYCOPROTEIN ACTIVITY; MULTIDRUG-RESISTANCE; INTERFACIAL-TENSION;
   LEUKEMIA-CELLS; P388 CELLS; TRANSPORT; CERAMIDE; PLASMA; DEATH;
   POLYMORPHISM
AB Cell-membrane lipid composition can greatly influence biophysical properties of cell membranes, affecting various cellular functions. We previously showed that lipid synthesis becomes altered in the membranes of resistant breast cancer cells (MCF-7/ADR); they form a more rigid, hydrophobic lipid monolayer than do sensitive cell membranes (MCF-7). These changes in membrane lipids of resistant cells, attributed to epigenetic aberration, significantly affected drug transport and endocytic function, thus impacting the efficacy of anticancer drugs. The present study's objective was to determine the effects of the epigenetic drug, 5-aza-2'-deoxycytidine (DAC), delivered in sustained-release nanogels (DAC-NGs), on the composition and biophysical properties of membrane lipids of resistant cells. Resistant and sensitive cells were treated with DAC in solution (DAC-sol) or DAC-NGs, and cell-membrane lipids were isolated and analyzed for lipid composition and biophysical properties. In resistant cells, we found increased formation of cholesterol sphingomyelin (CHOL-SM) rafts with culturing time, whereas DAC treatment reduced their formation. In general, the effect of DAC-NGs was greater in changing the lipid composition than with DAC-sol. DAC treatment also caused a rise in levels of certain phospholipids and neutral lipids known to increase membrane fluidity, while reducing the levels of certain lipids known to increase membrane rigidity. Isotherm data showed increased lipid membrane fluidity following DAC treatment, attributed to decrease levels of CHOL-SM rafts (lamellar beta [L-beta] structures or ordered gel) and a corresponding increase in lipids that form lamellar alpha-structures (L-omega liquid crystalline phase). Sensitive cells showed marginal or insignificant changes in lipid profile following DAC-treatment, suggesting that epigenetic changes affecting lipid biosynthesis are more specific to resistant cells. Since membrane fluidity plays a major role in drug transport and endocytic function, treatment of resistant cells with epigenetic drugs with altered lipid profile could facilitate anticancer drug transport to overcome acquired drug resistance in a combination therapy.
C1 [Raghavan, Vijay; Vijayaraghavalu, Sivakumar; Peetla, Chiranjeevi; Yamada, Masayoshi; Morisada, Megan; Labhasetwar, Vinod] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
   [Labhasetwar, Vinod] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Labhasetwar, V (通讯作者)，Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
RI Raghavan, vijay/J-2063-2017; Labhasetwar, Vinod/J-9660-2016;
   Vijayaraghavalu, Sivakumar/IZE-6423-2023; Raghavan, vijay/D-2993-2009
OI Raghavan, vijay/0000-0002-2286-7719; Vijayaraghavalu,
   Sivakumar/0000-0002-6770-6716
FU National Cancer Institute of the National Institutes of Health [R01
   CA149359]
FX This study is funded by the National Cancer Institute of the National
   Institutes of Health (Grant No. R01 CA149359 to V.L.).
CR Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501
   BURDICK D, 1992, J BIOL CHEM, V267, P546
   Chandrasekar K, 2008, BIOMACROMOLECULES, V9, P1264, DOI 10.1021/bm701252y
   Clay AT, 2013, BIOCHEMISTRY-US, V52, P343, DOI 10.1021/bi301532c
   COVEY JM, 1984, CANCER TREAT REP, V68, P1475
   Crane JM, 2004, BIOPHYS J, V86, P2965, DOI 10.1016/S0006-3495(04)74347-7
   CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8
   CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Espinosa G, 2011, P NATL ACAD SCI USA, V108, P6008, DOI 10.1073/pnas.1018572108
   Ewers H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004721
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Frolov VA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004747
   Gayet L, 2005, BIOCHEMISTRY-US, V44, P4499, DOI 10.1021/bi048669w
   George KS, 2012, TOXICOL APPL PHARM, V259, P311, DOI 10.1016/j.taap.2012.01.007
   Ghetie MA, 2004, BLOOD, V104, P178, DOI 10.1182/blood-2003-12-4255
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gouazé V, 2001, MOL PHARMACOL, V60, P488
   Grösch S, 2012, PROG LIPID RES, V51, P50, DOI 10.1016/j.plipres.2011.11.001
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200
   Hendrich AB, 2003, CURR DRUG TARGETS, V4, P23, DOI 10.2174/1389450033347172
   HINDENBURG AA, 1987, CANCER RES, V47, P1421
   Kilkus J, 2003, J NEUROSCI RES, V72, P65, DOI 10.1002/jnr.10549
   Kopecka J, 2011, J CONTROL RELEASE, V149, P196, DOI 10.1016/j.jconrel.2010.10.003
   Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7
   Lavie Y, 2000, GLYCOCONJUGATE J, V17, P253, DOI 10.1023/A:1026553626537
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   MAY GL, 1988, INT J CANCER, V42, P728, DOI 10.1002/ijc.2910420517
   MESCHINI S, 1994, J MICROSC-OXFORD, V176, P204, DOI 10.1111/j.1365-2818.1994.tb03516.x
   Narváez-Rivas M, 2011, J CHROMATOGR A, V1218, P3453, DOI 10.1016/j.chroma.2011.03.067
   Pallarés-Trujillo J, 2000, INT J ONCOL, V16, P783
   Peetla C, 2014, LANGMUIR, V30, P7522, DOI 10.1021/la5015219
   Peetla C, 2013, ADV DRUG DELIVER REV, V65, P1686, DOI 10.1016/j.addr.2013.09.004
   Peetla C, 2010, MOL PHARMACEUT, V7, P2334, DOI 10.1021/mp100308n
   Pérez-Tomás R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Petelska AD, 2002, BBA-BIOMEMBRANES, V1561, P135, DOI 10.1016/S0005-2736(01)00463-1
   Petelska AD, 2000, BIOPHYS J, V78, P812, DOI 10.1016/S0006-3495(00)76638-0
   RAMU A, 1984, CANCER TREAT REP, V68, P637
   RAMU A, 1983, CANCER RES, V43, P5533
   Rauch C, 2000, BIOPHYS J, V78, P3036, DOI 10.1016/S0006-3495(00)76842-1
   Rauch C, 2009, EUR BIOPHYS J BIOPHY, V38, P829, DOI 10.1007/s00249-009-0429-x
   SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Todor I. N., 2012, Experimental Oncology, V34, P97
   Troost J, 2004, MOL PHARMACOL, V66, P1332, DOI 10.1124/mol.104.002329
   Vance D.E., 2002, BIOCH LIPIDS LIPOPRO
   Vijayaraghavalu S, 2013, CANCER LETT, V331, P122, DOI 10.1016/j.canlet.2012.12.009
   Vijayaraghavalu S, 2012, MOL PHARMACEUT, V9, P2730, DOI 10.1021/mp300281t
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   ZWAAL RFA, 1976, TRENDS BIOCHEM SCI, V1, P112, DOI 10.1016/0968-0004(76)90322-4
NR 51
TC 16
Z9 19
U1 2
U2 47
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD OCT 27
PY 2015
VL 31
IS 42
BP 11564
EP 11573
DI 10.1021/acs.langmuir.5b02601
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science
GA CV0CI
UT WOS:000363914600023
PM 26439800
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Maresca, L
   Spugnesi, L
   Lodovichi, S
   Cozzani, C
   Naccarato, AG
   Tancredi, M
   Collavoli, A
   Falaschi, E
   Rossetti, E
   Aretini, P
   Cervelli, T
   Galli, A
   Caligo, MA
AF Maresca, Luisa
   Spugnesi, Laura
   Lodovichi, Samuele
   Cozzani, Cristina
   Naccarato, Antonio Giuseppe
   Tancredi, Mariella
   Collavoli, Anita
   Falaschi, Elisabetta
   Rossetti, Elena
   Aretini, Paolo
   Cervelli, Tiziana
   Galli, Alvaro
   Caligo, Maria Adelaide
TI <i>MSH2</i> role in <i>BRCA1</i>-driven tumorigenesis: A preliminary
   study in yeast and in human tumors from <i>BRCA1</i>-VUS carriers
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE BRCA1; MSH2; Hereditary breast and ovarian cancer; Yeast functional
   assay; Mutational analysis
ID NONPOLYPOSIS-COLORECTAL-CANCER; DNA MISMATCH REPAIR; OVARIAN-CANCER;
   MISSENSE VARIANTS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; LYNCH
   SYNDROME; RECOMBINATION; MUTATIONS; GENE
AB BRCA1 interacts with several proteins implicated in homologous and non homologous recombination and in mismatch repair.
   The aim of this study is to determine if MSH2, a well known partner of BRCA1 involved in DNA repair, may contribute to breast and ovarian cancer development and progression.
   To better understand the functional interaction between BRCA1 and MSH2, we studied the effect of the deletion of MSH2 gene on BRCA1-induced genome instability in yeast. Preliminary results in yeast indicated that MSH2 and BRCA1 may interact to modulate homologous recombination (HR). We also carried out a genetic and epigenetic profiling of MSH2 gene by mutational analysis and promoter methylation evaluation in 9 breast and 2 ovarian tumors from carriers of BRCA1 unknown significance variants (VUS).
   2/2 ovarian and 2/9 breast tumors carried MSH2 somatic mutations possible pathogenics (4/11, 36%): a missense mutation in exon 3 (p.G162R), a duplication of exon 1 and a deletion of exon 2. In addition, two germline synonymous variants in exon 11 were identified. None of the tumors showed promoter methylation.
   In conclusion, a surprisingly high frequency of MSH2 gene mutations has been found in tumor tissues from BRCA1 VUS carrier patients. This result supports the indication deriving from the yeast model that BRCA1 driven tumorigenesis may be modulated by MSH2. (C) 2015 Published by Elsevier Masson SAS.
C1 [Maresca, Luisa; Spugnesi, Laura; Tancredi, Mariella; Collavoli, Anita; Falaschi, Elisabetta; Caligo, Maria Adelaide] Univ Pisa, Sect Genet Oncol, Pisa, Italy.
   [Lodovichi, Samuele; Cozzani, Cristina; Cervelli, Tiziana; Galli, Alvaro] CNR, Inst Clin Physiol, I-56100 Pisa, Italy.
   [Naccarato, Antonio Giuseppe] Univ Pisa, Div Surg Mol & Ultrastruct Pathol, Pisa, Italy.
   [Rossetti, Elena] Univ Pisa, Dept Senol, Pisa, Italy.
   [Aretini, Paolo] Fdn Pisana Sci Onlus, Pisa, Italy.
C3 University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Fisiologia Clinica (IFC-CNR); University of Pisa; University of Pisa
RP Caligo, MA (通讯作者)，Univ Pisa, Sect Genet Oncol, Pisa, Italy.
EM alvaro.galli@ifc.cnr.it; adelaide.caligo@do.unipi.it
RI Maresca, Luisa/IZP-5910-2023; Lodovichi, Samuele/JAC-4581-2023; Aretini,
   Paolo/AAF-1205-2020; Galli, Alvaro/AAL-7247-2020; Caligo,
   Maria/K-4289-2018; Galli, Alvaro/K-3146-2018
OI Lodovichi, Samuele/0000-0002-6780-7410; Caligo,
   Maria/0000-0003-0589-1829; Galli, Alvaro/0000-0002-9091-5639
FU Italian Association for Cancer Research (AIRC) [IG2013 N.14477]; Tuscany
   Tumor Institute (ITT) [BRCA1]
FX The authors wish to thank the Tuscany Tumor Institute (ITT) and the
   Italian Association for Cancer Research (AIRC) who founded this project
   [ITT grant: "BRCA1 role in repair of DNA damage: from the yeast
   Saccharomyces cerevisiae genetics to human breast carcinogenesis"
   (2009-2012); AIRC grant number: IG2013 N.14477 (2013-2015)]
CR Barrow E, 2009, CLIN GENET, V75, P141, DOI 10.1111/j.1399-0004.2008.01125.x
   Belvederesi L, 2008, HUM MUTAT, V29, pE296, DOI 10.1002/humu.20875
   Caligo MA, 2009, HUM MUTAT, V30, P123, DOI 10.1002/humu.20817
   Carvalho MA, 2007, CANCER RES, V67, P1494, DOI 10.1158/0008-5472.CAN-06-3297
   Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16
   Charbonnier FC, 2005, HUM MUTAT, V26, P255, DOI 10.1002/humu.20216
   Del Carratore R, 2004, MUTAGENESIS, V19, P333, DOI 10.1093/mutage/geh038
   Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215
   Ellsworth RE, 2010, CURR GENOMICS, V11, P146, DOI 10.2174/138920210791110951
   Engel C, 2012, J CLIN ONCOL, V30, P4409, DOI 10.1200/JCO.2012.43.2278
   Galli A, 1996, MUTAT RES-FUND MOL M, V354, P69, DOI 10.1016/0027-5107(96)00037-1
   GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Guidugli L, 2011, BREAST CANCER RES TR, V125, P265, DOI 10.1007/s10549-010-1112-8
   KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x
   Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243
   Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115
   Lovelock PK, 2006, J MED GENET, V43, P74, DOI 10.1136/jmg.2005.033258
   Malander S, 2006, GYNECOL ONCOL, V101, P238, DOI 10.1016/j.ygyno.2005.10.029
   Maxwell K.N., 2014, GENET MED
   Millot GA, 2012, HUM MUTAT, V33, P1526, DOI 10.1002/humu.22150
   Müller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Ollila S, 2008, HUM MUTAT, V29, P1355, DOI 10.1002/humu.20893
   Pal T, 2012, BRIT J CANCER, V107, P1783, DOI 10.1038/bjc.2012.452
   Pastrello C, 2011, GENET MED, V13, P115, DOI 10.1097/GIM.0b013e3182011489
   Peltomäki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060
   Peltomäki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2
   Rodriguez JA, 2004, EXP CELL RES, V293, P14, DOI 10.1016/j.yexcr.2003.09.027
   SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619
   SCHIESTL RH, 1988, GENETICS, V119, P237
   Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942
   Tavtigian SV, 2008, HUM MUTAT, V29, P1261, DOI 10.1002/humu.20903
   Thompson BA, 2013, HUM MUTAT, V34, P200, DOI 10.1002/humu.22213
   Tournier I, 2008, HUM MUTAT, V29, P1412, DOI 10.1002/humu.20796
   Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625
   Wang Y, 2000, GENE DEV, V14, P927
   Watson P, 2001, Fam Cancer, V1, P57, DOI 10.1023/A:1011590617833
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
NR 39
TC 15
Z9 16
U1 1
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 1878-0849
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD OCT
PY 2015
VL 58
IS 10
BP 531
EP 539
DI 10.1016/j.ejmg.2015.09.005
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CV3NY
UT WOS:000364167100004
PM 26381082
DA 2025-01-12
ER

PT J
AU Young, GM
   Radhakrishnan, VM
   Centuori, SM
   Gomes, CJ
   Martinez, JD
AF Young, Gavin M.
   Radhakrishnan, Vijayababu M.
   Centuori, Sara M.
   Gomes, Cecil J.
   Martinez, Jesse D.
TI Comparative analysis of 14-3-3 isoform expression and epigenetic
   alterations in colorectal cancer
SO BMC CANCER
LA English
DT Article
DE qRT-PCR; Colorectal cancer; 14-3-3; DNA methylation; Epigenetics
ID LUNG-CANCER; BREAST-CANCER; PROTEINS; METHYLATION; DIFFERENTIATION;
   PROGRESSION; CARCINOMA; CELLS; LEADS
AB Background: The 14-3-3 family is a group of intracellular proteins found in all eukaryotic organisms. Humans have seven isoforms that serve as scaffolds to promote interactions of regulatory phospho-proteins involved in many vital cellular processes and previous studies have shown that disturbances in native 14-3-3 levels can contribute significantly to the development of various cancers.
   Methods: DNA and RNA was extracted from frozen tissue samples collected by the Human Cooperative Tissue Network. RNA samples were reverse transcribed and subjected to qRT-PCR analysis using fluorescently labelled probes. Genomic DNA was treated with bisulfite and cloned into bacterial vectors for subsequent high-resolution sequencing. Mammalian NIH3T3 cells were transformed with 14-3-3 eta and Ras expression vectors synthesized from cDNA. Colonies were counted and transforming capability assessed after 21 days of growth. Cell lysates were analyzed by western blot to verify protein expression.
   Results: Here we examined normal and cancerous 14-3-3 expression levels of all seven isoforms in a cohort of sporadic colorectal adenocarcinomas and in a group of tumors and their matched normals using qRT-PCR analysis. We found a statistically significant decrease in the levels of 14-3-3 sigma, eta, and zeta observed among adenocarcinomas compared to normal tissue. A parallel analysis of microarray data from the TCGA dataset confirmed that expression of sigma and eta were down-regulated in colon tumors. To explore the mechanisms behind 14-3-3 expression changes, we examined the methylation status of the sigma, eta, and zeta gene promoters in selected samples. Our data identified novel CpG methylation sites in the eta promoter consistent with epigenetic silencing of both 14-3-3 sigma and eta isoforms during colon tumorigenesis. Because epigenetic silencing is the hallmark of a tumor suppressor we tested eta in focus formation assays and found that it is capable of suppressing ras-induced transformation of NIH3T3 cells.
   Conclusion: To our knowledge, this is the first study to identify the 14-3-3 eta gene as a tumor suppressor and that its expression is suppressed in colon tumors by DNA hypermethylation. These data suggest a link between 14-3-3 expression levels and the development of colon cancers.
C1 [Young, Gavin M.] Univ Arizona, Undergrad Biomed Res Program, Ctr Canc, Tucson, AZ 85724 USA.
   [Radhakrishnan, Vijayababu M.] Univ Arizona, Dept Pediat, Ctr Canc, Steele Childrens Res Ctr, Tucson, AZ 85724 USA.
   [Martinez, Jesse D.] Univ Arizona, Dept Cell & Mol Med, Ctr Canc, Tucson, AZ 85724 USA.
   [Centuori, Sara M.; Gomes, Cecil J.] Univ Arizona, Canc Biol Grad Interdisciplinary Program, Ctr Canc, Tucson, AZ 85724 USA.
   [Gomes, Cecil J.; Martinez, Jesse D.] Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA.
C3 University of Arizona; University of Arizona; University of Arizona;
   University of Arizona; University of Arizona
RP Martinez, JD (通讯作者)，Univ Arizona, Ctr Canc, Dept Cell & Mol Med, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM jmartinez@uacc.arizona.edu
FU National Institutes of Health [CA107510, CA023074]; Cooperative Human
   Tissue Network [5U01CA091664]
FX This work was funded, in whole or in part, by National Institutes of
   Health Grants CA107510 and CA023074 (to J.D.M.) and Cooperative Human
   Tissue Network grant number 5U01CA091664.
CR Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005
   Chen J, 2007, J NEUROSCI RES, V85, P1724, DOI 10.1002/jnr.21304
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007
   Gheibi A, 2012, Adv Biomed Res, V1, P80, DOI 10.4103/2277-9175.102990
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Kilani RT, 2008, MOL CELL BIOCHEM, V314, P161, DOI 10.1007/s11010-008-9777-6
   Leal MF, 2012, WORLD J GASTROENTERO, V18, P1531, DOI 10.3748/wjg.v18.i13.1531
   Li YY, 2011, METHODS MOL BIOL, V791, P11, DOI 10.1007/978-1-61779-316-5_2
   Li ZM, 2009, AM J TRANSL RES, V1, P326
   Lin MT, 2009, INT J CANCER, V125, P603, DOI 10.1002/ijc.24346
   Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007-0323
   Liu Y, 2010, BRAIN RES, V1336, P98, DOI 10.1016/j.brainres.2010.04.009
   Lodygin D, 2006, SEMIN CANCER BIOL, V16, P214, DOI 10.1016/j.semcancer.2006.03.008
   MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139
   Nakanishi Kozo, 1997, Human Antibodies, V8, P189
   Negraes PD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-238
   Perathoner A, 2005, CLIN CANCER RES, V11, P3274, DOI 10.1158/1078-0432.CCR-04-2207
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Qi WQ, 2007, MOL CARCINOGEN, V46, P847, DOI 10.1002/mc.20314
   Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492
   Radhakrishnan VM, 2011, GENE CHROMOSOME CANC, V50, P830, DOI 10.1002/gcc.20904
   Radhakrishnan VM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011433
   Schultz J, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-53
   Song YL, 2012, CANCER EPIDEMIOL, V36, P533, DOI 10.1016/j.canep.2012.05.003
   Wang ZH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-308
   Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015
   Yang XL, 2009, J NEUROL SCI, V276, P54, DOI 10.1016/j.jns.2008.08.040
   Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012
NR 31
TC 12
Z9 15
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 30
PY 2015
VL 15
AR 826
DI 10.1186/s12885-015-1856-y
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU9BD
UT WOS:000363836900007
PM 26518883
OA Green Published, Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Martin-Castillo, B
   Lopez-Bonet, E
   Cuyàs, E
   Viñas, G
   Pernas, S
   Dorca, J
   Menendez, JA
AF Martin-Castillo, Begona
   Lopez-Bonet, Eugeni
   Cuyas, Elisabet
   Vinas, Gemma
   Pernas, Sonia
   Dorca, Joan
   Menendez, Javier A.
TI Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a
   reclassification of clinically HER2-positive breast carcinomas
SO ONCOTARGET
LA English
DT Article
DE HER2; cancer stem cells; basal-like; cytokeratins; trastuzumab
ID EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; BASAL-LIKE
   PHENOTYPE; DE-NOVO RESISTANCE; ALDEHYDE DEHYDROGENASE; CD44(+)/CD24(-)
   PHENOTYPE; ADJUVANT TRASTUZUMAB; MAMMARY DEVELOPMENT; HER2
   AMPLIFICATION; PIK3CA MUTATIONS
AB Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a framework for predicting the response of cHER2+ to trastuzumab that integrates the molecular distinctions of intrinsic BC subtypes with recent knowledge on cancer stem cell (CSC) biology. First, we consider that two interchangeable populations of epithelial-like, aldehyde dehydrogenase (ALDH)-expressing and mesenchymallike, CD44+ CD24(-/low) CSCs can be found in significantly different proportions across all intrinsic BC subtypes. Second, we overlap all the intrinsic subtypes across cHER2+ BC to obtain a continuum of mixed phenotypes in which one extreme exhibits a high identity with ALDH+ CSCs and the other extreme exhibits a high preponderance of CD44+ CD24(-/low) CSCs. The differential enrichment of trastuzumab-responsive ALDH+ CSCs versus trastuzumab-refractory CD44+ CD24(-/low) CSCs can explain both the clinical behavior and the primary efficacy of trastuzumab in each molecular subtype of cHER2+ (i.e., HER2-enriched/cHER2+, luminal A/cHER2+, luminal B/cHER2+, basal/ cHER2+, and claudin-low/cHER2+). The intrinsic plasticity determining the epigenetic ability of cHER2+ tumors to switch between epithelial and mesenchymal CSC states will vary across the continuum of mixed phenotypes, thus dictating their intratumoral heterogeneity and, hence, their evolutionary response to trastuzumab. Because CD44+ CD24(-/low) mesenchymal-like CSCs distinctively possess a highly endocytic activity, the otherwise irrelevant HER2 can open the door to a type of "Trojan horse" approach by employing antibody-drug conjugates such as T-DM1, which will allow a rapid and CSC-targeted delivery of cytotoxic drugs to therapeutically manage trastuzumabunresponsive basal/cHER2+ BC. Contrary to the current dichotomous model used clinically, our model proposes that a reclassification of cHER2+ tumors based on the spectrum of molecular BC subtypes might inform on their CSC-determined sensitivity to trastuzumab, thus providing a better delineation of the predictive value of cHER2+ in BC by incorporating CSCs-driven intra-tumor heterogeneity into clinical decisions.
C1 [Martin-Castillo, Begona] Catalan Inst Oncol, Unit Clin Res, Girona, Catalonia, Spain.
   [Martin-Castillo, Begona; Cuyas, Elisabet; Vinas, Gemma; Dorca, Joan; Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Catalonia, Spain.
   [Martin-Castillo, Begona] Univ Complutense, Fac Pharm, Dept Biochem & Mol Biol 2, E-28040 Madrid, Spain.
   [Lopez-Bonet, Eugeni] Dr Josep Trueta Hosp Girona, Dept Anat Pathol, Girona, Catalonia, Spain.
   [Cuyas, Elisabet; Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, ProCURE Program Canc Therapeut Resistance, Girona, Catalonia, Spain.
   [Vinas, Gemma; Dorca, Joan] Catalan Inst Oncol, Dept Med Oncol, Girona, Catalonia, Spain.
   [Pernas, Sonia] Hosp Univ Bellvitge, Bellvitge Res Inst IDIBELL, Catalan Inst Oncol, Dept Med Oncol,Breast Unit, Barcelona, Catalonia, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI); Complutense University of Madrid; Universitat de Girona;
   Girona University Hospital Dr. Josep Trueta; Institut Catala
   d'Oncologia; Institut Catala d'Oncologia; Institut Catala d'Oncologia;
   University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital
RP Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Catalonia, Spain.
EM jmenendez@iconcologia.net
RI Cuyas, Elisabet/G-8582-2018; MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI Lopez-Bonet, Eugeni/0000-0002-9199-0702; MENENDEZ MENENDEZ, JAVIER
   ABEL/0000-0001-8733-4561; PERNAS SIMON, SONIA/0000-0002-1485-5080;
   Cuyas, Elisabet/0000-0001-5353-440X; Martin-Castillo,
   Begona/0000-0001-8344-8174
FU Ministerio de Ciencia e Innovacion [SAF2012-38914]; Plan Nacional de
   I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR), Departament d'Economia I Coneixement, Catalonia, Spain [2014
   SGR229]; Ministerio de Sanidad, Servicios Sociales e Igualdad (Ayudas a
   la Investigacion Independiente) [EC10-125]
FX This work was supported by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2012-38914), Plan Nacional de I+D+I, Spain and the
   Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014
   SGR229), Departament d'Economia I Coneixement, Catalonia, Spain to
   Javier A. Menendez. The authors would like to thank Dr. Kenneth McCreath
   for editorial support. This work was supported also by a grant from the
   Ministerio de Sanidad, Servicios Sociales e Igualdad (EC10-125, Ayudas a
   la Investigacion Independiente) to Begona Martin-Castillo.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alexe G, 2007, CANCER RES, V67, P10669, DOI 10.1158/0008-5472.CAN-07-0539
   Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915
   Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Bagaria SP, 2012, ANN SURG ONCOL, V19, P935, DOI 10.1245/s10434-011-2032-5
   Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782
   Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868
   Bedard PL, 2009, J MAMMARY GLAND BIOL, V14, P55, DOI 10.1007/s10911-009-9116-x
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Bhagirath D, 2015, ONCOTARGET, V6, P9018, DOI 10.18632/oncotarget.3379
   Bhatia S, 2012, NAT BIOTECHNOL, V30, P604, DOI 10.1038/nbt.2294
   Boulbes DR, 2015, BREAST CANCER RES TR, V151, P501, DOI 10.1007/s10549-015-3414-3
   Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Cescon DW, 2015, J CLIN ONCOL, V33, P1318, DOI 10.1200/JCO.2014.59.3160
   Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788
   Chakrabarty A, 2013, CANCER RES, V73, P1190, DOI 10.1158/0008-5472.CAN-12-2440
   Chekhun S. V., 2015, Experimental Oncology, V37, P58
   Chia S, 2008, J CLIN ONCOL, V26, P5697, DOI 10.1200/JCO.2007.15.8659
   Chung A, CLIN BREAST CANC
   Chung SS, 2014, INT J ONCOL, V44, P403, DOI 10.3892/ijo.2013.2195
   Cirenajwis H, 2010, ANTI-CANCER DRUG, V21, P897, DOI 10.1097/CAD.0b013e32833f2f77
   Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y
   Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x
   Cufí S, 2012, ONCOTARGET, V3, P1600
   Cufí S, 2012, ONCOTARGET, V3, P395, DOI 10.18632/oncotarget.488
   Del Barco S, 2011, ONCOTARGET, V2, P896, DOI 10.18632/oncotarget.387
   Dhillon J, 2010, ONCOGENE, V29, P6294, DOI 10.1038/onc.2010.365
   Diessner J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.115
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Ding KS, 2014, J BIOL CHEM, V289, P16057, DOI 10.1074/jbc.M113.529552
   Dontu G, 2005, STEM CELL REV, V1, P207, DOI 10.1385/SCR:1:3:207
   Douville J, 2009, STEM CELLS DEV, V18, P17, DOI 10.1089/scd.2008.0055
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216
   Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254
   Geyer FC, 2012, ADV ANAT PATHOL, V19, P39, DOI 10.1097/PAP.0b013e31823fafa0
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460
   Goding CR, 2014, NAT REV CANCER, V14, P568, DOI 10.1038/nrc3781
   Gray J, 2012, NATURE, V486, P328, DOI 10.1038/486328a
   Guarneri V, 2013, ANN ONCOL, V24, P2990, DOI 10.1093/annonc/mdt364
   Guiu S, 2012, ANN ONCOL, V23, P2997, DOI 10.1093/annonc/mds586
   Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110
   Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hurley J, 2006, J CLIN ONCOL, V24, P1831, DOI 10.1200/JCO.2005.02.8886
   Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005
   Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Kim HP, 2014, ONCOGENE, V33, P3334, DOI 10.1038/onc.2013.285
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669
   Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207
   Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260
   Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014
   Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087
   Koziel JE, 2015, BREAST CANCER RES TR, V149, P607, DOI 10.1007/s10549-015-3270-1
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Laakso M, 2006, CLIN CANCER RES, V12, P4185, DOI 10.1158/1078-0432.CCR-06-0353
   Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849
   Lesniak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071987
   Lesniak D, 2009, CANCER RES, V69, P8620, DOI 10.1158/0008-5472.CAN-09-1591
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-59
   Liu H, 2008, HUM PATHOL, V39, P167, DOI 10.1016/j.humpath.2007.06.012
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Loibl S, 2014, J CLIN ONCOL, V32, P3212, DOI 10.1200/JCO.2014.55.7876
   Lower EE, 2009, BREAST CANCER RES TR, V113, P301, DOI 10.1007/s10549-008-9931-6
   Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327
   Majewski IJ, 2015, J CLIN ONCOL, V33, P1334, DOI 10.1200/JCO.2014.55.2158
   Mao Y, 2015, MOL BIOSYST, V11, P1029, DOI 10.1039/c4mb00710g
   Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Marjanovic ND, 2013, CELL CYCLE, V12, P2713, DOI 10.4161/cc.26075
   Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655
   Martin-Castillo B, 2010, ANN ONCOL, V21, P187, DOI 10.1093/annonc/mdp494
   Martin-Castillo B, 2015, ONCOTARGET, V6, P7104, DOI 10.18632/oncotarget.3106
   Martin-Castillo B, 2013, CELL CYCLE, V12, P225, DOI 10.4161/cc.23274
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Mehta K, 2009, THESCIENTIFICWORLDJO, V9, P1438, DOI 10.1100/tsw.2009.166
   Menendez Javier A, 2014, Oncoscience, V1, P803
   Menendez JA, 2014, CELL CYCLE, V13, P358, DOI 10.4161/cc.27770
   Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735
   Mocanu MM, 2005, CANCER LETT, V227, P201, DOI 10.1016/j.canlet.2005.01.028
   Nakanishi T, 2010, BRIT J CANCER, V102, P815, DOI 10.1038/sj.bjc.6605553
   Nakshatri H, 2009, CURR STEM CELL RES T, V4, P50, DOI 10.2174/157488809787169110
   Ohnishi K, 2014, BIOCHEM BIOPH RES CO, V455, P10, DOI 10.1016/j.bbrc.2014.07.020
   Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225
   Oliveras-Ferraros C, 2011, BIOCHEM BIOPH RES CO, V407, P412, DOI 10.1016/j.bbrc.2011.03.039
   Oliveras-Ferraros C, 2010, INT J ONCOL, V37, P669, DOI 10.3892/ijo_00000716
   Oliveras-Ferraros C, 2010, BIOCHEM BIOPH RES CO, V397, P27, DOI 10.1016/j.bbrc.2010.05.041
   Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440
   Papadaki MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-651
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Perez EA, 2010, J CLIN ONCOL, V28, P4307, DOI 10.1200/JCO.2009.26.2154
   Perou C.M., 2011, COLD SPRING HARB PER, V3
   Phillips S, 2014, CELL ADHES MIGR, V8, P578, DOI 10.4161/19336918.2014.972740
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Prat A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju152
   Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842
   Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x
   Rakha EA, 2009, BREAST CANCER RES TR, V113, P411, DOI 10.1007/s10549-008-9952-1
   Reim F, 2009, CANCER RES, V69, P8058, DOI 10.1158/0008-5472.CAN-09-0834
   Rennstam K, 2010, BREAST CANCER RES TR, V122, P315, DOI 10.1007/s10549-009-0568-x
   Rexer BN, 2013, CANCER RES, V73, P3817, DOI 10.1158/0008-5472.CAN-13-0687
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Roesler R, 2010, LANCET ONCOL, V11, P225, DOI 10.1016/S1470-2045(09)70404-8
   Santinelli A, 2008, INT J CANCER, V122, P999, DOI 10.1002/ijc.23051
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457
   Sjostrom M, 2015, J CLIN PATHOL
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Swain SM, 2015, NEW ENGL J MED, V372, P1964
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1
   Tanner M, 2004, MOL CANCER THER, V3, P1585
   Tuma RS, 2012, J NATL CANCER I, V104, P968, DOI 10.1093/jnci/djs307
   Turner NC, 2013, CLIN CANCER RES, V19, P6380, DOI 10.1158/1078-0432.CCR-13-0915
   Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5
   Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665
   Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x
   Viale G, 2012, ANN ONCOL, V23, P207, DOI 10.1093/annonc/mds326
   Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125
   Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T
   Yang ZY, 2015, ONCOTARGET, V6, P5072, DOI 10.18632/oncotarget.3241
   Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004
NR 144
TC 28
Z9 32
U1 1
U2 26
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 20
PY 2015
VL 6
IS 32
BP 32317
EP 32338
DI 10.18632/oncotarget.6094
PG 22
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0DQ
UT WOS:000363186600020
PM 26474458
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Borbely, G
   Haldosen, LA
   Dahlman-Wright, K
   Zhao, CY
AF Borbely, Gabor
   Haldosen, Lars-Arne
   Dahlman-Wright, Karin
   Zhao, Chunyan
TI Induction of USP17 by combining BET and HDAC inhibitors in breast cancer
   cells
SO ONCOTARGET
LA English
DT Article
DE breast cancer; epigenetics; BET; HDAC; combined treatment
ID DUB/USP17 DEUBIQUITINATING ENZYMES; HISTONE DEACETYLASE INHIBITORS;
   FAMILY; MYC; IDENTIFICATION; TRANSCRIPTION; TARGET
AB Members of the bromodomain and extra-C terminal (BET) domain protein family and the histone deacetylase (HDAC) enzyme family regulate the expression of important oncogenes and tumor suppressor genes. Here we show that the BET inhibitor JQ1 inhibits proliferation and induces apoptosis of both triple negative and estrogen receptor positive breast cancer cells. Consistent with the critical role of histone acetylation in the regulation of gene expression, treatment with JQ1 or the HDAC inhibitor mocetinostat was associated with global changes in gene expression resulting in suppression of genes involved in cell-cycle regulation. Combining JQ1 with mocetinostat, further decreased cell viability. This synergistic effect was associated with increased suppression of genes essential for cell-cycle progression. Furthermore, we detected dramatic increase in the expression of several members of the ubiquitin-specific protease 17 (USP17) family of deubiquitinating enzymes in response to the combination treatment. Increased expression of USP17 enzymes were able to attenuate the Ras/MAPK pathway causing decrease in cell viability, while, siRNA mediated depletion of USP17 significantly decreased cytotoxicity after the combination treatment. In conclusion, our study demonstrates that co-treatment with BET inhibitors and HDAC inhibitors reduces breast cancer cell viability through induction of USP17.
C1 [Borbely, Gabor; Haldosen, Lars-Arne; Dahlman-Wright, Karin; Zhao, Chunyan] Karolinska Inst, Novum, Dept Biosci & Nutr, Huddinge, Sweden.
   [Dahlman-Wright, Karin] Karolinska Inst, SciLifeLab, Solna, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; SciLifeLab
RP Borbely, G (通讯作者)，Swetox, Sodertalje, Sweden.
EM gabor.borbely@swetox.se; chunyan.zhao@ki.se
FU Center for Biosciences
FX The authors would like to acknowledge the expert skills and advice of
   Dr. Indranil Sinha and Dr. Gergely Talaber, Department of Biosciences
   and Nutrition, Karolinska Institutet. We also thank the Bioinformatics
   and Expression Analysis core facility at the Karolinska Institutet (BEA:
   www.bea.ki.se) for performing the Affymetrix assays. The research was
   supported by the Center for Biosciences.
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Balijepalli MK, 2010, PHARMACOGN RES, V2, P113, DOI 10.4103/0974-8490.62949
   Bihani T, 2015, ONCOTARGET, V6, P2407, DOI 10.18632/oncotarget.2964
   Burrows JF, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-250
   Burrows JF, 2009, J BIOL CHEM, V284, P9587, DOI 10.1074/jbc.M807216200
   Burrows JF, 2005, GENOMICS, V85, P524, DOI 10.1016/j.ygeno.2004.11.013
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026
   Garnier JM, 2014, EXPERT OPIN THER PAT, V24, P185, DOI 10.1517/13543776.2014.859244
   Giltnane JM, 2014, DISCOV MED, V17, P275
   Gosmini R, 2014, J MED CHEM, V57, P8111, DOI 10.1021/jm5010539
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Joydeep B, 2014, PNAS, V111, P2721
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143
   Mataga MA, 2012, ANTICANCER RES, V32, P2523
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436
   Patel MC, 2013, MOL CELL BIOL, V33, P2497, DOI 10.1128/MCB.01180-12
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ramakrishna S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037772
   Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659
   Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041
   Sengupta S, 2015, BREAST CANCER RES TR, V150, P265, DOI 10.1007/s10549-015-3319-1
   Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691
NR 34
TC 73
Z9 76
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 20
PY 2015
VL 6
IS 32
BP 33623
EP 33635
DI 10.18632/oncotarget.5601
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0DQ
UT WOS:000363186600114
PM 26378038
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Lee, SH
   Lee, EH
   Lee, SH
   Lee, YM
   Kim, HD
   Kim, YZ
AF Lee, Sang Hyuk
   Lee, Eun Hee
   Lee, Sung-Hun
   Lee, Young Min
   Kim, Hyung Dong
   Kim, Young Zoon
TI Epigenetic Role of Histone 3 Lysine Methyltransferase and Demethylase in
   Regulating Apoptosis Predicting the Recurrence of Atypical Meningioma
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Atypical Meningioma; Apoptosis; Histone Modification; Recurrence;
   Epigenetics
ID INTRACRANIAL MENINGIOMAS; DIAGNOSTIC-CRITERIA; CELL-PROLIFERATION;
   CLINICAL ARTICLE; NERVOUS-SYSTEM; LABELING INDEX; BREAST-CANCER;
   EXPRESSION; SURVIVIN; RADIOTHERAPY
AB Alteration of apoptosis is related with progression and recurrence of atypical meningiomas (AMs). However, no comprehensive study has been conducted regarding histone modification regulating apoptosis in AMs. This study aimed to determine the prognostic values of certain apoptosis-associated factors, and examine the role of histone modification on apoptosis in AMs. The medical records of 67 patients with AMs, as diagnosed during recent 13 yr, were reviewed retrospectively. Immunohistochemical staining was performed on archived paraffin-embedded tissues for pro-apoptotic factors (CASP3, IGFBP, TRAIL-R1, BAX, and XAF1), anti-apoptotic factors (survivin, ERK, RAF1, MDM2, and BCL2), and the histone modifying enzymes (MLL2, RIZ, EZH1, NSD2, KDM5c, JMJD2a, UTX, and JMJD5). Twenty-six (38.8%) patients recurred during the follow-up period (mean duration 47.7 months). In terms of time-to-recurrence (TTR), overexpression of CASP3, TRAIL-R1, and BAX had a longer TTR than low expression, and overexpression of survivin, MDM2, and BCL2 had a shorter TTR than low expression (P<0.05). Additionally, overexpression of MLL2, UTX, and JMJ5 had shorter TTRs than low expression, and overexpression of KDM5c had a longer TTR than low expression. However, in the multivariate analysis of predicting factors for recurrence, low expression of CASP3 (P<0.001), and BAX (P<0.001), and overexpression of survivin (P=0.007), and MDM2 (P=0.037) were associated with recurrence independently, but any enzymes modifying histone were not associated with recurrence. Conclusively, this study suggests certain apoptosis-associated factors should be associated with recurrence of AMs, which may be regulated epigenetically by histone modifying enzymes.
C1 [Lee, Sang Hyuk; Lee, Young Min; Kim, Young Zoon] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Neurosurg, Chang Won 630723, South Korea.
   [Lee, Sang Hyuk; Lee, Young Min; Kim, Young Zoon] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Div Neurooncol, Chang Won 630723, South Korea.
   [Lee, Eun Hee] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Pathol, Chang Won 630723, South Korea.
   [Lee, Sung-Hun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Kim, Hyung Dong] Dong A Univ, Med Ctr, Coll Med, Dept Neurosurg, Busan, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center; University of Texas System; UTMD
   Anderson Cancer Center; Dong A University
RP Kim, YZ (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Neurosurg, 158 Paryong Ro, Chang Won 630723, South Korea.
EM yzkim@skku.edu
OI KIM, YOUNG ZOON/0000-0001-9724-3081; Lee, sang hyuk/0000-0003-4225-5485
FU research fund of Samsung Changwon Hospital
FX Laboratory experiment of this study was supported financially by the
   research fund of Samsung Changwon Hospital.
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4
   Alama A, 2007, J CLIN NEUROSCI, V14, P355, DOI 10.1016/j.jocn.2006.04.001
   Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177
   Angileri FF, 2008, CANCER-AM CANCER SOC, V112, P2258, DOI 10.1002/cncr.23407
   Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x
   Brat DJ, 2008, ARCH PATHOL LAB MED, V132, P993, DOI 10.1043/1543-2165(2008)132[993:SNUARO]2.0.CO;2
   Choy W, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1116
   Eng J, 2005, ACAD RADIOL, V12, P909, DOI 10.1016/j.acra.2005.04.005
   Ho DMT, 2002, CANCER, V94, P1538, DOI 10.1002/cncr.10351
   Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315
   Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284
   Kane AJ, 2011, CANCER-AM CANCER SOC, V117, P1272, DOI 10.1002/cncr.25591
   Kayaselçuk F, 2004, J NEURO-ONCOL, V67, P209, DOI 10.1023/B:NEON.0000021823.05163.2c
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kim MS, 2014, J NEUROSURG, V121, P1189, DOI 10.3171/2014.7.JNS132661
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Konstantinidou AE, 2007, APOPTOSIS, V12, P695, DOI 10.1007/s10495-006-0001-4
   Konstantinidou AE, 1998, J PATHOL, V186, P325
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026
   Maes L, 2005, CELL PROLIFERAT, V38, P3, DOI 10.1111/j.1365-2184.2005.00325.x
   Marosi C, 2008, CRIT REV ONCOL HEMAT, V67, P153, DOI 10.1016/j.critrevonc.2008.01.010
   Matsumori Y, 2006, STROKE, V37, P507, DOI 10.1161/01.STR.0000199057.00365.20
   Mellai M, 2008, ANTICANCER RES, V28, P109
   Moon HS, 2012, J KOREAN NEUROSURG S, V52, P14, DOI 10.3340/jkns.2012.52.1.14
   Murati A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-304
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058
   Pearson BE, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E3
   Perry A., 2007, WHO Classification of Tumors of the Central Nervous System, P164
   Rogers L, 2010, J NEURO-ONCOL, V99, P393, DOI 10.1007/s11060-010-0343-1
   Sabbatini M, 2011, PATHOL ONCOL RES, V17, P51, DOI 10.1007/s12253-010-9279-1
   Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x
   Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0
   Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544
   Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549
   Tanzler E, 2011, INT J RADIAT ONCOL, V79, P508, DOI 10.1016/j.ijrobp.2009.11.032
   Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x
   Xia MH, 2015, TUMOR BIOL, V36, P605, DOI 10.1007/s13277-014-2616-3
   Yamamoto H, 2014, WORLD J GASTROENTERO, V20, P3927, DOI 10.3748/wjg.v20.i14.3927
   Yamasaki F, 2000, CANCER-AM CANCER SOC, V89, P1102, DOI 10.1002/1097-0142(20000901)89:5<1102::AID-CNCR20>3.0.CO;2-L
NR 48
TC 8
Z9 8
U1 0
U2 1
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD AUG
PY 2015
VL 30
IS 8
BP 1157
EP 1166
DI 10.3346/jkms.2015.30.8.1157
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CV4AE
UT WOS:000364207000023
PM 26240495
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Zheng, XB
   Yue, SB
   Chen, HY
   Weber, B
   Jia, JL
   Zheng, YX
AF Zheng, Xiaobin
   Yue, Sibiao
   Chen, Haiyang
   Weber, Blake
   Jia, Junling
   Zheng, Yixian
TI Low-Cell-Number Epigenome Profiling Aids the Study of Lens Aging and
   Hematopoiesis
SO CELL REPORTS
LA English
DT Article
ID LINEAR DNA AMPLIFICATION; EMBRYONIC STEM-CELLS; CHIP-SEQ;
   GENE-EXPRESSION; SELF-RENEWAL; H3K4 METHYLATION; NUCLEAR CATARACT;
   LIMITED NUMBERS; CHROMATIN STATE; BREAST-CANCER
AB Understanding how chromatin modification regulates development and disease can be limited by available material. Despite recent progress, balancing high-quality and reliable mapping using chromatin-immunoprecipitation-based deep sequencing (ChIP-seq) remains a challenge. We report two techniques, recovery via protection (RP)-ChIP-seq and favored amplification RP-ChIP-seq (FARP-ChIP-seq), that provide reproducible mapping in as few as 500 cells. RP-ChIP-seq allows detection of age-associated epigenetic changes in a single mouse lens, whereas FARP-ChIP-seq accurately maps histone H3 lysine 4 trimethylation (H3K4me3) and H3K27me3 in long-term hematopoietic stem cells (LT-HSCs), short-term HSCs (ST-HSCs), and multi-potent progenitors (MPPs) from one mouse. These datasets not only highlight genes that may be involved in lens aging but also indicate a lack of H3K4me3/H3K27me3 bivalency on hematopoietic genes in HSCs.
C1 [Zheng, Xiaobin; Yue, Sibiao; Chen, Haiyang; Weber, Blake; Jia, Junling; Zheng, Yixian] Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21218 USA.
   [Jia, Junling] Zhejiang Univ, Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China.
   [Jia, Junling] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Carnegie Institution for Science; Zhejiang University; Zhejiang
   University
RP Jia, JL (通讯作者)，Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21218 USA.
EM junlingjia@zju.edu.cn; zheng@ciwemb.edu
RI Zheng, Xiaobin/AAD-7564-2019
FU Ellison Medical Foundation; NIH [GM056312, GM106023]
FX We thank Kang Zhang (UCSD) for advice on cataract, Allison Pinder, Nick
   Ingolia, and Frederick Tan for deep sequencing and advice on data
   analyses, Ona Martin for proofreading, and members of the Zheng lab for
   critical comments. This work was supported by the Ellison Medical
   Foundation and by NIH grants GM056312 and GM106023.
CR Adli M, 2011, NAT PROTOC, V6, P1656, DOI 10.1038/nprot.2011.402
   Adli M, 2010, NAT METHODS, V7, P615, DOI [10.1038/nmeth.1478, 10.1038/NMETH.1478]
   Aguilar CA, 2013, NAT NANOTECHNOL, V8, P709, DOI 10.1038/nnano.2013.195
   Benayoun BA, 2014, CELL, V158, P673, DOI 10.1016/j.cell.2014.06.027
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Brind'Amour J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7033
   Cabezas-Wallscheid N, 2014, CELL STEM CELL, V15, P507, DOI 10.1016/j.stem.2014.07.005
   Daley T, 2013, NAT METHODS, V10, P325, DOI 10.1038/nmeth.2375
   Hawse J, 2003, MOL VIS, V9, P515
   Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07
   Jia JL, 2012, CELL, V151, P576, DOI 10.1016/j.cell.2012.09.023
   Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020
   Kim J, 2009, NAT PROTOC, V4, P506, DOI 10.1038/nprot.2009.23
   Kircher M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr771
   Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lara-Astiaso D, 2014, SCIENCE, V345, P943, DOI 10.1126/science.1256271
   LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169
   Liao JM, 2014, HUM MOL GENET, V23, P6119, DOI 10.1093/hmg/ddu315
   MCCAFFREY R, 1975, NEW ENGL J MED, V292, P775, DOI 10.1056/NEJM197504102921504
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Ng JH, 2013, DEV CELL, V24, P324, DOI 10.1016/j.devcel.2012.12.011
   Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017
   Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8
   Puri D, 2015, FEBS J, V282, P1675, DOI 10.1111/febs.13165
   Reynaud D, 2008, NAT IMMUNOL, V9, P927, DOI 10.1038/ni.1626
   Ruotolo R, 2003, MOL VIS, V9, P538
   Rybak JN, 2005, NAT METHODS, V2, P291, DOI 10.1038/NMETH745
   Segev F, 2005, EYE, V19, P80, DOI 10.1038/sj.eye.6701423
   Shankaranarayanan P, 2012, NAT PROTOC, V7, P328, DOI 10.1038/nprot.2011.447
   Shankaranarayanan P, 2011, NAT METHODS, V8, P565, DOI [10.1038/nmeth.1626, 10.1038/NMETH.1626]
   Sun DQ, 2014, CELL STEM CELL, V14, P673, DOI 10.1016/j.stem.2014.03.002
   Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643
   Weishaupt H, 2010, BLOOD, V115, P247, DOI 10.1182/blood-2009-07-235176
   Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zwart W, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-232
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 41
TC 31
Z9 39
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD NOV 17
PY 2015
VL 13
IS 7
BP 1505
EP 1518
DI 10.1016/j.celrep.2015.10.004
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CW4UK
UT WOS:000364990700021
PM 26549448
OA gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Manville, CM
   Smith, K
   Sondka, Z
   Rance, H
   Cockell, S
   Cowell, IG
   Lee, KC
   Morris, NJ
   Padget, K
   Jackson, GH
   Austin, CA
AF Manville, Catriona M.
   Smith, Kayleigh
   Sondka, Zbyslaw
   Rance, Holly
   Cockell, Simon
   Cowell, Ian G.
   Lee, Ka Cheong
   Morris, Nicholas J.
   Padget, Kay
   Jackson, Graham H.
   Austin, Caroline A.
TI Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast
   cancer epithelial cells
SO BIOLOGY OPEN
LA English
DT Article
DE ChIP seq; TOP2B; Topoisomerase II
ID TOPOISOMERASE-II-BETA; ESTROGEN-RECEPTOR-ALPHA; RNA-POLYMERASE-II;
   GENE-EXPRESSION; BINDING-SITES; EMBRYONIC-DEVELOPMENT; CHROMATIN
   TEMPLATES; NEURONAL SURVIVAL; STRAND BREAKS; RIBOSOMAL-RNA
AB We report the whole genome ChIP seq for human TOP2B from MCF7 cells. Using three different peak calling methods, regions of binding were identified in the presence or absence of the nuclear hormone estradiol, as TOP2B has been reported to play a role in ligand-induced transcription. TOP2B peaks were found across the whole genome, 50% of the peaks fell either within a gene or within 5 kb of a transcription start site. TOP2B peaks coincident with gene promoters were less frequently associated with epigenetic features marking active promoters in estradiol treated than in untreated cells. Significantly enriched transcription factor motifs within the DNA sequences underlying the peaks were identified. These included SP1, KLF4, TFAP2A, MYF, REST, CTCF, ESR1 and ESR2. Gene ontology analysis of genes associated with TOP2B peaks found neuronal development terms including axonogenesis and axon guidance were significantly enriched. In the absence of functional TOP2B there are errors in axon guidance in the zebrafish eye. Specific heparin sulphate structures are involved in retinal axon targeting. The glycosaminoglycan biosynthesis-heparin sulphate/heparin pathway is significantly enriched in the TOP2B gene ontology analysis, suggesting changes in this pathway in the absence of TOP2B may cause the axon guidance faults.
C1 [Manville, Catriona M.; Smith, Kayleigh; Sondka, Zbyslaw; Rance, Holly; Cowell, Ian G.; Lee, Ka Cheong; Austin, Caroline A.] Newcastle Univ, Inst Cellular & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Cockell, Simon] Newcastle Univ, Fac Med Sci, Bioinformat Support Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Morris, Nicholas J.] Newcastle Univ, Sch Biomed Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Padget, Kay] Northumbria Univ, Dept Appl Biol, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
   [Jackson, Graham H.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Northumbria University; Newcastle University - UK
RP Austin, CA (通讯作者)，Newcastle Univ, Inst Cellular & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM caroline.austin@ncl.ac.uk; caroline.austin@ncl.ac.uk
RI Cockell, Simon/AFV-9495-2022; Jackson, Graham/GMW-7638-2022
OI Austin, Caroline/0000-0002-1921-5947; Cowell, Ian/0000-0002-8606-0447;
   Padget, Kay/0000-0002-3702-7114; Cockell, Simon/0000-0002-6831-9806;
   Morris, Nicholas/0000-0002-8389-7508
FU Leukaemia and Lymphoma Research specialist programme [12031]; Gordon
   Piller studentship; Biotechnology and Biological Science Research
   Council; Newcastle University
FX This work was supported by Leukaemia and Lymphoma Research specialist
   programme [12031] and a Gordon Piller studentship to K.S.; Biotechnology
   and Biological Science Research Council CASE studentships to C.M.M. and
   H.R. Funding for open access charges from Newcastle University.
CR Akimitsu N, 2003, BIOCHEM BIOPH RES CO, V307, P301, DOI 10.1016/S0006-291X(03)01169-0
   Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Basu SN, 2009, NUCLEIC ACIDS RES, V37, pD832, DOI 10.1093/nar/gkn835
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertelsen B, 2014, EUR J HUM GENET, V22, P1283, DOI 10.1038/ejhg.2014.24
   Bhat S, 2012, PROG NEUROBIOL, V99, P1, DOI 10.1016/j.pneurobio.2012.06.001
   BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0
   CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cowell IG, 2012, P NATL ACAD SCI USA, V109, P8989, DOI 10.1073/pnas.1204406109
   Cowell IG, 2011, NUCLEUS-PHILA, V2, P61, DOI 10.4161/nucl.2.1.14194
   Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772
   Dastidar SG, 2012, J BIOL CHEM, V287, P14749, DOI 10.1074/jbc.M111.328336
   De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772
   Dereuddre S, 1997, CANCER RES, V57, P4301
   Dovey M, 2009, MOL CELL BIOL, V29, P3746, DOI 10.1128/MCB.01684-08
   EGYHAZI E, 1987, MOL CELL BIOL, V7, P4308, DOI 10.1128/MCB.7.12.4308
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   French SL, 2011, MOL CELL BIOL, V31, P482, DOI 10.1128/MCB.00589-10
   Gimelli S, 2014, MOL CYTOGENET, V7, DOI 10.1186/s13039-014-0054-y
   Giusti-Rodríguez P, 2013, J CLIN INVEST, V123, P4557, DOI 10.1172/JCI66031
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013
   Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   Hao YW, 1997, BIOCHEM BIOPH RES CO, V234, P194, DOI 10.1006/bbrc.1997.6539
   Hedges VL, 2012, FRONT NEUROENDOCRIN, V33, P403, DOI 10.1016/j.yfrne.2012.08.005
   Heng X, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-4
   Irie A, 2002, DEVELOPMENT, V129, P61
   Johnson CA, 2001, J BIOL CHEM, V276, P4539, DOI 10.1074/jbc.C000824200
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Joshi RS, 2012, NUCLEIC ACIDS RES, V40, P7907, DOI 10.1093/nar/gks626
   Jothi R, 2008, NUCLEIC ACIDS RES, V36, P5221, DOI 10.1093/nar/gkn488
   Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017
   Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196
   King IF, 2013, NATURE, V501, P58, DOI 10.1038/nature12504
   Kouzine F, 2014, NUCLEUS-PHILA, V5, P195, DOI 10.4161/nucl.28909
   Kouzine F, 2013, NAT STRUCT MOL BIOL, V20, P396, DOI 10.1038/nsmb.2517
   LEE MP, 1989, J BIOL CHEM, V264, P21779
   LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200
   LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024
   Lyu YL, 2006, MOL CELL BIOL, V26, P7929, DOI 10.1128/MCB.00617-06
   Lyu YL, 2003, P NATL ACAD SCI USA, V100, P7123, DOI 10.1073/pnas.1232376100
   Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200
   Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997
   McNamara S, 2008, MOL CELL BIOL, V28, P2066, DOI 10.1128/MCB.01576-07
   Meitzen J, 2011, J CHEM NEUROANAT, V42, P236, DOI 10.1016/j.jchemneu.2011.02.002
   Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9
   Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590
   Mondal N, 2003, NUCLEIC ACIDS RES, V31, P5016, DOI 10.1093/nar/gkg705
   Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483
   Naughton C, 2013, NAT STRUCT MOL BIOL, V20, P387, DOI 10.1038/nsmb.2509
   Nevin LM, 2011, DEVELOPMENT, V138, P2457, DOI 10.1242/dev.060335
   Nur-E-Kamal A, 2007, BRAIN RES, V1154, P50, DOI 10.1016/j.brainres.2007.04.029
   Papantonis A, 2013, CHEM REV, V113, P8683, DOI 10.1021/cr300513p
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   Salceda J, 2006, EMBO J, V25, P2575, DOI 10.1038/sj.emboj.7601142
   Sano K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004103
   Sapetto-Rebow B, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-71
   SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332
   THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0
   Tiwari VK, 2012, P NATL ACAD SCI USA, V109, pE934, DOI 10.1073/pnas.1119798109
   Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671
   Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200
   TSUTSUI K, 1993, J BIOL CHEM, V268, P19076
   Wendorff TJ, 2012, J MOL BIOL, V424, P109, DOI 10.1016/j.jmb.2012.07.014
   West KL, 1999, NUCLEIC ACIDS RES, V27, P984, DOI 10.1093/nar/27.4.984
   Wong RHF, 2009, CELL, V136, P1056, DOI 10.1016/j.cell.2008.12.040
   Wu CC, 2011, SCIENCE, V333, P459, DOI 10.1126/science.1204117
   Xiao H, 2005, ONCOGENE, V24, P8105, DOI 10.1038/sj.onc.1208958
   Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001
   Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200
   Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x
   Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131
   Zandvliet DWJ, 1996, BBA-GENE STRUCT EXPR, V1307, P239, DOI 10.1016/0167-4781(96)00063-2
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 85
TC 39
Z9 43
U1 2
U2 15
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 2046-6390
J9 BIOL OPEN
JI Biol. Open
PD NOV 15
PY 2015
VL 4
IS 11
BP 1436
EP 1447
DI 10.1242/bio.014308
PG 12
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA CW6AF
UT WOS:000365078200011
PM 26459242
OA Green Accepted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Gyorffy, B
   Bottai, G
   Fleischer, T
   Munkácsy, G
   Budczies, J
   Paladini, L
   Borresen-Dale, AL
   Kristensen, VN
   Santarpia, L
AF Gyorffy, Balazs
   Bottai, Giulia
   Fleischer, Thomas
   Munkacsy, Gyongyi
   Budczies, Jan
   Paladini, Laura
   Borresen-Dale, Anne-Lise
   Kristensen, Vessela N.
   Santarpia, Libero
TI Aberrant DNA methylation impacts gene expression and prognosis in breast
   cancer subtypes
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer subtypes; DNA methylation biomarkers; gene expression;
   immune genes; prognosis
ID TUMOR-INFILTRATING LYMPHOCYTES; HORMONE-RECEPTOR STATUS; MOLECULAR
   SUBTYPES; PROFILES; REVEALS; SFRP1; CHEMOTHERAPY; RECURRENCE; PATHWAY;
   RISK
AB DNA methylation has a substantial impact on gene expression, affecting the prognosis of breast cancer (BC) patients dependent on molecular subtypes. In this study, we investigated the prognostic relevance of the expression of genes reported as aberrantly methylated, and the link between gene expression and DNA methylation in BC subtypes. The prognostic value of the expression of 144 aberrantly methylated genes was evaluated in ER+/HER2-, HER2+, and ER-/HER2- molecular BC subtypes, in a meta-analysis of two large transcriptomic cohorts of BC patients (n=1,938 and n=1,640). The correlation between gene expression and DNA methylation in distinct gene regions was also investigated in an independent dataset of 104 BCs. Survival and Pearson correlation analyses were computed for each gene separately. The expression of 48 genes was significantly associated with BC prognosis (p<0.05), and 32 of these prognostic genes exhibited a direct expression-methylation correlation. The expression of several immune-related genes, including CD3D and HLA-A, was associated with both relapse-free survival (HR=0.42, p=3.5E-06; HR=0.35, p=1.7E-08) and overall survival (HR=0.50, p=5.5E-04; HR=0.68, p=4.5E-02) in ER-/HER2- BCs. On the overall, the distribution of both positive and negative expression-methylation correlation in distinct gene regions have different effects on gene expression and prognosis in BC subtypes. This large-scale meta-analysis allowed the identification of several genes consistently associated with prognosis, whose DNA methylation could represent a promising biomarker for prognostication and clinical stratification of patients with distinct BC subtypes.
   What's new? DNA methylation profiles may play an important role in the development and progression of breast cancer (BC) subtypes, but the prognostic value of aberrantly methylated biomarkers in distinct subtypes and the role of DNA methylation in distinct gene regions remain controversial. This study assesses the prognostic impact of the expression of aberrantly methylated genes and expression-methylation correlations in BC subtypes. Key methylated prognostic genes were identified, including immune-related genes, particularly in ER-/HER2- tumors. DNA methylation in specific gene regions differentially affects gene expression, supporting the importance of epigenetic biomarkers for prognostication and clinical stratification of patients with distinct BC subtypes.
C1 [Gyorffy, Balazs; Munkacsy, Gyongyi] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, H-1085 Budapest, Hungary.
   [Gyorffy, Balazs] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary.
   [Bottai, Giulia; Paladini, Laura; Santarpia, Libero] IRCCS Clin & Res Inst Humanitas, Oncol Expt Therapeut Unit, I-20089 Rozzano Milan, Italy.
   [Fleischer, Thomas; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] OUS Radiumhosp, Inst Canc Res, Dept Genet, Oslo, Norway.
   [Fleischer, Thomas; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] Univ Oslo, Fac Med, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, N-0316 Oslo, Norway.
   [Budczies, Jan] Charite, Inst Pathol, Campus Charite Mitte, D-13353 Berlin, Germany.
   [Kristensen, Vessela N.] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol, Lorenskog, Norway.
   [Kristensen, Vessela N.] Akershus Univ Hosp, Lab Sci EpiGen, Div Med, Lorenskog, Norway.
C3 Hungarian Research Network; HUN-REN Research Centre for Natural
   Sciences; Semmelweis University; Semmelweis University; University of
   Oslo; Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Oslo; University of Oslo
RP Santarpia, L (通讯作者)，IRCCS Clin & Res Inst Humanitas, Oncol Expt Therapeut Unit, Via Manzoni 113, I-20089 Rozzano Milan, Italy.
EM v.n.kristensen@medisin.uio.no; libero.santarpia@humanitasresearch.it
RI Budczies, Jan/AAG-8122-2020; Paladini, Laura/LSJ-0930-2024; Gyorffy,
   Balazs/AAA-9135-2021; Fleischer, Thomas/T-8066-2017
OI Paladini, Laura/0009-0006-2614-5162; Budczies, Jan/0000-0002-6668-5327;
   Santarpia, Libero/0000-0001-6777-1449; Fleischer,
   Thomas/0000-0003-0985-8460; Gyorffy, Balazs/0000-0002-5772-3766
FU Associazione Italiana Ricerca sul Cancro [6251]; OTKA K [108655];
   Norwegian Research Council [193387/V50]; Norwegian Cancer Society
   [4196163832]; Academy of Finland (AKA) [108655] Funding Source: Academy
   of Finland (AKA)
FX Grant sponsor: Associazione Italiana Ricerca sul Cancro; Grant number:
   6251; Grant sponsor: OTKA K; Grant number: 108655; Grant sponsor:
   Norwegian Research Council; Grant number: 193387/V50; Grant sponsor:
   Norwegian Cancer Society; Grant number: 4196163832
CR Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491
   Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078-0432.CCR-11-2701
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bukur J, 2012, SEMIN CANCER BIOL, V22, P350, DOI 10.1016/j.semcancer.2012.03.003
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Fleischer T, 2014, INT J CANCER, V134, P2615, DOI 10.1002/ijc.28606
   Györffy B, 2009, BREAST CANCER RES TR, V118, P433, DOI 10.1007/s10549-008-0242-8
   Gyorffy B, 2012, BREAST CANCER RES TR, V132, P1025, DOI 10.1007/s10549-011-1676-y
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jeong YJ, 2013, ONCOL REP, V29, P1946, DOI 10.3892/or.2013.2335
   Jeschke J, 2015, FEBS J, V282, P1801, DOI 10.1111/febs.13125
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kaneko K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-454
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443
   Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Marchesi M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-247
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Santarpia L, 2013, ONCOLOGIST, V18, P1063, DOI 10.1634/theoncologist.2013-0163
   Santarpia L, 2012, BREAST CANCER RES TR, V134, P333, DOI 10.1007/s10549-012-2035-3
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stefansson O.A., 2014, Mol Oncol
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/EPI.12.21, 10.2217/epi.12.21]
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
NR 46
TC 122
Z9 134
U1 2
U2 87
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2016
VL 138
IS 1
BP 87
EP 97
DI 10.1002/ijc.29684
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU0JY
UT WOS:000363203600013
PM 26174627
DA 2025-01-12
ER

PT J
AU Lee, JY
   Lee, SH
   Heo, SH
   Kim, KS
   Kim, C
   Kim, DK
   Ko, JJ
   Park, KS
AF Lee, Jae-Young
   Lee, Se-Hwan
   Heo, Sun-Hee
   Kim, Kwang-Soo
   Kim, Changhoon
   Kim, Dae-Kwan
   Ko, Jeong-Jae
   Park, Kyung-Soon
TI Novel Function of Lysine Methyltransferase G9a in the Regulation of Sox2
   Protein Stability
SO PLOS ONE
LA English
DT Article
ID HISTONE H3 LYSINE-9; NEGATIVE REGULATION; DNA METHYLATION;
   BREAST-CANCER; CELLS; MAINTENANCE; DNMT1; TRANSCRIPTION; METASTASIS;
   EXPRESSION
AB G9a is a lysine methyltransferase (KMTase) for histone H3 lysine 9 that plays critical roles in a number of biological processes. Emerging evidence suggests that aberrant expression of G9a contributes to tumor metastasis and maintenance of a malignant phenotype in cancer by inducing epigenetic silencing of tumor suppressor genes. Here, we show that G9a regulates Sox2 protein stability in breast cancer cells. When G9a lysine methyltransferase activity was chemically inhibited in the ER(+) breast cancer cell line MCF7, Sox2 protein levels were decreased. In addition, ectopic overexpression of G9a induced accumulation of Sox2. Changes in cell migration, invasion, and mammosphere formation by MCF7 cells were correlated with the activity or expression level of G9a. Ectopic expression of G9a also increased Sox2 protein levels in another ER(+) breast cancer cell line, ZR-75-1, whereas it did not affect Sox2 expression in MDA-MB-231 cells, an ER(-) breast cancer cell line, or in glioblastoma cell lines. Furthermore, treatment of mouse embryonic stem cells with a KMT inhibitor, BIX-01294, resulted in a rapid reduction in Sox2 protein expression despite increased Sox2 transcript levels. This finding suggests that G9a has a novel function in the regulation of Sox2 protein stability in a cell type-dependent manner.
C1 [Lee, Jae-Young; Lee, Se-Hwan; Heo, Sun-Hee; Kim, Kwang-Soo; Kim, Dae-Kwan; Ko, Jeong-Jae; Park, Kyung-Soon] CHA Univ, Coll Life Sci, Dept Biomed Sci, Seoul, South Korea.
   [Kim, Changhoon] Hanyang Univ, Dept Biomed Sci, Grad Sch Biomed Sci & Engn, Seoul 133791, South Korea.
C3 Pochon Cha University; Hanyang University
RP Park, KS (通讯作者)，CHA Univ, Coll Life Sci, Dept Biomed Sci, Seoul, South Korea.
EM kspark@cha.ac.kr
RI Lee, Jae-Young/GWZ-2558-2022
OI Lee, Se-Hwan/0009-0008-3826-2125; Kim, Changhoon/0000-0001-5971-863X
FU Rural Development Administration, Republic of Korea [PJ010033]
FX This work was carried out with the support of "Cooperative Research
   Program for Agriculture Science & Technology Development (PJ010033)",
   Rural Development Administration, Republic of Korea.
CR Apostolou P, 2012, CURR STEM CELL RES T, V7, P415, DOI 10.2174/157488812804484639
   Bittencourt D, 2012, P NATL ACAD SCI USA, V109, P19673, DOI 10.1073/pnas.1211803109
   Brown SE, 2001, MAMM GENOME, V12, P916, DOI 10.1007/s00335-001-3029-3
   Chaturvedi CP, 2012, P NATL ACAD SCI USA, V109, P18845, DOI 10.1073/pnas.1213951109
   Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018
   Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Islam K, 2013, P NATL ACAD SCI USA, V110, P16778, DOI 10.1073/pnas.1216365110
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200
   Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88
   Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Wu H, 2011, CELL RES, V21, P365, DOI 10.1038/cr.2010.157
   Zhang JQ, 2011, CELL RES, V21, P1723, DOI 10.1038/cr.2011.176
NR 26
TC 11
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2015
VL 10
IS 10
AR e0141118
DI 10.1371/journal.pone.0141118
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CU0ZU
UT WOS:000363249300031
PM 26492085
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Singh, B
   Owens, KM
   Bajpai, P
   Desouki, MM
   Srinivasasainagendra, V
   Tiwari, HK
   Singh, KK
AF Singh, Bhupendra
   Owens, Kjerstin M.
   Bajpai, Prachi
   Desouki, Mohamed Mokhtar
   Srinivasasainagendra, Vinodh
   Tiwari, Hemant K.
   Singh, Keshav K.
TI Mitochondrial DNA Polymerase POLG1 Disease Mutations and Germline
   Variants Promote Tumorigenic Properties
SO PLOS ONE
LA English
DT Article
ID COPY-NUMBER; HUMAN CANCERS; SYNONYMOUS MUTATIONS; DRIVER MUTATIONS;
   MTDNA DEPLETION; ALPERS-SYNDROME; BREAST-CANCER; KINASE GENE;
   CROSS-TALK; GAMMA
AB Germline mutations in mitochondrial DNA polymerase gamma (POLG1) induce mitochondrial DNA (mtDNA) mutations, depletion, and decrease oxidative phosphorylation. Earlier, we identified somatic mutations in POLG1 and the contribution of these mutations in human cancer. However, a role for germline variations in POLG1 in human cancers is unknown. In this study, we examined a role for disease associated germline variants of POLG1, POLG1 gene expression, copy number variation and regulation in human cancers. We analyzed the mutations, expression and copy number variation in POLG1 in several cancer databases and validated the analyses in primary breast tumors and breast cancer cell lines. We discovered 5-aza-2'-deoxycytidine led epigenetic regulation of POLG1, mtDNA-encoded genes and increased mitochondrial respiration. We conducted comprehensive race based bioinformatics analyses of POLG1 gene in more than 33,000 European-Americans and 5,000 African-Americans. We identified a mitochondrial disease causing missense variation in polymerase domain of POLG1 protein at amino acid 1143 (E1143G) to be 25 times more prevalent in European-Americans (allele frequency 0.03777) when compared to African-American (allele frequency 0.00151) population. We identified T251I and P587L missense variations in exonuclease and linker region of POLG1 also to be more prevalent in European-Americans. Expression of these variants increased glucose consumption, decreased ATP production and increased matrigel invasion. Interestingly, conditional expression of these variants revealed that matrigel invasion properties conferred by these germline variants were reversible suggesting a role of epigenetic regulators. Indeed, we identified a set of miRNA whose expression was reversible after variant expression was turned off. Together, our studies demonstrate altered genetic and epigenetic regulation of POLG1 in human cancers and suggest a role for POLG1 germline variants in promoting tumorigenic properties.
C1 [Singh, Bhupendra; Bajpai, Prachi; Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
   [Owens, Kjerstin M.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
   [Desouki, Mohamed Mokhtar] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA.
   [Srinivasasainagendra, Vinodh; Tiwari, Hemant K.] Univ Alabama Birmingham, Dept Biostat, Sect Stat Genet, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Dept Environm Hlth, Birmingham, AL USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL USA.
   [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham; Roswell
   Park Comprehensive Cancer Center; Vanderbilt University; University of
   Alabama System; University of Alabama Birmingham; University of Alabama
   System; University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Veterans Affairs Medical Center -
   Birmingham
RP Singh, KK (通讯作者)，Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
EM kksingh@uab.edu
RI Bajpai, Prachi/U-7462-2018
OI Owens, Kjerstin/0000-0001-5210-319X
FU Veterans Administration [1I01BX001716]; NIH [R21 5R21CA176054]
FX This study was supported by grants from Veterans Administration
   1I01BX001716 and NIH R21 5R21CA176054. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abu-Amero KK, 2005, ARCH PATHOL LAB MED, V129, P1295
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chornokur G, 2011, PROSTATE, V71, P985, DOI 10.1002/pros.21314
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Copeland WC, 2010, SUBCELL BIOCHEM, V50, P211, DOI 10.1007/978-90-481-3471-7_11
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   DeSantis C, 2013, CA-CANCER J CLIN, V63, P151, DOI 10.3322/caac.21173
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Drummond DA, 2008, CELL, V134, P341, DOI 10.1016/j.cell.2008.05.042
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Goodman DB, 2013, SCIENCE, V342, P475, DOI 10.1126/science.1241934
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hosnijeh FS, 2014, BLOOD, V124, P530, DOI 10.1182/blood-2013-10-532085
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kelly RDW, 2012, NUCLEIC ACIDS RES, V40, P10124, DOI 10.1093/nar/gks770
   Koochekpour S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074688
   Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011
   Lee W, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.34
   Linkowska K, 2015, ANN HUM GENET
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mito T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055789
   Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Osella M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00345
   Owens KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023846
   Parmley JL, 2006, MOL BIOL EVOL, V23, P301, DOI 10.1093/molbev/msj035
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Posada IJ, 2010, MED CLIN-BARCELONA, V135, P452, DOI 10.1016/j.medcli.2010.03.031
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Selvanayagam P, 1996, LAB INVEST, V74, P592
   Singh KK, 2009, J HUM GENET, V54, P516, DOI 10.1038/jhg.2009.71
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381
   Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tewari S, 2012, INVEST OPHTH VIS SCI, V53, P4881, DOI 10.1167/iovs.12-9732
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tsao J, 2010, METHODS MOL BIOL, V632, P73, DOI 10.1007/978-1-60761-663-4_5
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   WARBURG O, 1956, SCIENCE, V124, P269
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Wu CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213
   Yin PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838
   Zhou M, 2013, NATURE, V495, P111, DOI 10.1038/nature11833
NR 67
TC 18
Z9 18
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2015
VL 10
IS 10
AR e0139846
DI 10.1371/journal.pone.0139846
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CU0CX
UT WOS:000363184600020
PM 26468652
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wang, JH
   Hua, W
   Huang, SK
   Fan, K
   Takeshima, L
   Mao, Y
   Hoon, DSB
AF Wang, Jinhua
   Hua, Wei
   Huang, Sharon K.
   Fan, Kun
   Takeshima, Ling
   Mao, Ying
   Hoon, Dave S. B.
TI RASSF8 regulates progression of cutaneous melanoma through nuclear
   factor-κb
SO ONCOTARGET
LA English
DT Article
DE RASSF8; P53; melanoma; methylation; P65
ID BREAST-CANCER CELLS; TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; FAMILY;
   DNA; HYPERMETHYLATION; IDENTIFICATION; APOPTOSIS; BIOMARKER; INVASION
AB Our group previously demonstrated that the RASSF1 gene has a significant tumor suppressor role in cutaneous melanoma. The RASSF8 gene is a member of the N-terminal RASSF gene family. Previously, we identified RASSF8 (HOJ1, NCBI Gene ID: 11228) expression in cutaneous melanoma; however the functional role of RASSF8 in melanoma is not known. RASSF8 expression was assessed in melanoma cell lines and tumors of different AJCC stages. Results indicated that RASSF8 expression was low in metastatic melanoma lines and decreased with melanoma progression. We then explored the mechanism of RASSF8 downregulation in melanoma by assessing methylation of RASSF8 and demonstrated that methylation of RASSF8 gene promoter was higher in advanced than in early stages melanomas. Functional activity of RASSF8 in melanoma lines by knockdown and overexpression of RASSF8 demonstrated that RASSF8 expression significantly inhibited cell growth, cell migration and invasion, whereas knockdown of RASSF8 expression significantly increased cell growth, cell migration and invasion of melanoma cells by increasing expression of P65 and its downstream target IL-6. Moreover RASSF8 was found to induce apoptosis in melanoma cells by activating the P53-P21 pathway, and also in vivo studies demonstrated that inhibiting RASSF8 increases the tumorigenic properties of human melanoma xenografts. These results suggest that RASSF8 plays a significant role in suppressing the progression of cutaneous melanoma.
C1 [Wang, Jinhua; Huang, Sharon K.; Takeshima, Ling; Hoon, Dave S. B.] John Wayne Canc Inst, Providence St Johns Hlth Ctr, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Hua, Wei; Fan, Kun; Mao, Ying] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China.
C3 John Wayne Cancer Institute; Fudan University
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Providence St Johns Hlth Ctr, Dept Mol Oncol, Santa Monica, CA 90404 USA.
EM hoond@jwci.org
RI Hoon, Dave/C-7146-2018
OI Mao, Ying/0000-0001-8055-115X
FU National Institute of Health, National Cancer Institute [PO1 CA029605,
   1R01CA167967-01A1]; Adelson Medical Research Foundation; China National
   Funds for Distinguished Young Scientists [81025013]; China National
   Natural Science Foundation [81001115]; International S&T Cooperation
   Program of China [2014DFA31470]
FX This work was supported by National Institute of Health, National Cancer
   Institute (grant number PO1 CA029605 Project II and Core C to [D. H.],
   grant number 1R01CA167967-01A1 [D. H.]); Adelson Medical Research
   Foundation [D. H.]; China National Funds for Distinguished Young
   Scientists (81025013); China National Natural Science Foundation
   (81001115); International S&T Cooperation Program of China
   (2014DFA31470).
CR Allen NPC, 2007, ONCOGENE, V26, P6203, DOI 10.1038/sj.onc.1210440
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567
   Falvella FS, 2006, ONCOGENE, V25, P3934, DOI 10.1038/sj.onc.1209422
   Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380
   Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42
   Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jüliger S, 2007, CANCER RES, V67, P10984, DOI 10.1158/0008-5472.CAN-07-0519
   Keats JJ, 2007, CANCER CELL, V12, P31
   Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8
   Lock FE, 2010, ONCOGENE, V29, P4307, DOI 10.1038/onc.2010.192
   Maruyama R, 2008, CARCINOGENESIS, V29, P1312, DOI 10.1093/carcin/bgn060
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Narita N, 2009, ONCOGENE, V28, P3058, DOI 10.1038/onc.2009.164
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120
   Richter AM, 2010, EUR J CANCER, V46, P2986, DOI 10.1016/j.ejca.2010.06.128
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Rushworth SA, 2010, CANCER RES, V70, P2973, DOI 10.1158/0008-5472.CAN-09-3407
   Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021
   Schagdarsurengin U, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-264
   Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Sunami E, 2008, ANN NY ACAD SCI, V1137, P171, DOI 10.1196/annals.1448.011
   Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Underhill-Day N, 2011, EPIGENETICS-US, V6, P284, DOI 10.4161/epi.6.3.14108
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V134, P1103, DOI 10.1007/s10549-012-2038-0
   Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635
   Wang JH, 2015, J INVEST DERMATOL, V135, P532, DOI 10.1038/jid.2014.418
   Wang J, 2013, J INVEST DERMATOL, V133, P2050, DOI 10.1038/jid.2013.114
   Wang JH, 2010, MOL CANCER RES, V8, P266, DOI 10.1158/1541-7786.MCR-09-0221
   Yi M, 2011, J CELL PHYSIOL, V226, P2360, DOI 10.1002/jcp.22568
NR 39
TC 16
Z9 18
U1 1
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 6
PY 2015
VL 6
IS 30
BP 30165
EP 30177
DI 10.18632/oncotarget.5030
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0CL
UT WOS:000363183200126
PM 26334503
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ren, XY
   Zhou, GQ
   Jiang, W
   Sun, Y
   Xu, YF
   Li, YQ
   Tang, XR
   Wen, X
   He, QM
   Yang, XJ
   Liu, N
   Ma, J
AF Ren, Xian-Yue
   Zhou, Guan-Qun
   Jiang, Wei
   Sun, Ying
   Xu, Ya-Fei
   Li, Ying-Qin
   Tang, Xin-Ran
   Wen, Xin
   He, Qing-Mei
   Yang, Xiao-Jing
   Liu, Na
   Ma, Jun
TI Low SFRP1 Expression Correlates with Poor Prognosis and Promotes Cell
   Invasion by Activating the Wnt/β-Catenin Signaling Pathway in NPC
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID FRIZZLED-RELATED PROTEIN-1; NEGATIVE BREAST-CANCER; NASOPHARYNGEAL
   CARCINOMA; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; REPORTING
   RECOMMENDATIONS; ABERRANT EXPRESSION; TUMOR-SUPPRESSOR; GASTRIC-CANCER;
   WNT PATHWAY
AB Distant metastasis remains the predominant mode of treatment failure in nasopharyngeal carcinoma (NPC). Unfortunately, the molecular events underlying NPC metastasis remain poorly understood. Secreted frizzled-related protein 1 (SFRP1) plays an important role in tumorigenesis and progression. However, little is known about the function and mechanism of SFRP1 in NPC. Immunohistochemistry was used to determine SFRP1 expression levels in patients with NPC. SFRP1 function was evaluated using MTT, colony formation, wound-healing, Transwell assays, and in vivo models. The methylation level of SFRP1 in NPC cells was examined using bisulfate pyrosequencing; the Wnt/beta-catenin signaling pathway genes were studied using Western blotting. Compared with patients with high SFRP1 expression, patients with low SFRP1 expression had worse overall survival [HR, 2.32; 95% confidence interval (CI), 1.36-3.94; P = 0.002], disease-free survival (HR, 1.98; 95% CI, 1.23-3.18; P = 0.005), and distant metastasis-free survival (HR, 2.07; 95% CI, 1.19-3.59; P = 0.009). Multivariate Cox regression analysis indicated that SFRP1 was an independent prognostic factor. Furthermore, SFRP1 was significantly downregulated in NPC cell lines. SFRP1 overexpression suppressed NPC cell proliferation, migration, and invasion in vitro and lung colonization in vivo. SFRP1 expression was restored after treatment with a demethylation agent, and the SFRP1 promoter region was hypermethylated in NPC cells. beta-Catenin, c-Myc, and cyclin D1 were downregulated after SFRP1 restoration, which suggested that SFRP1 suppressed growth and metastasis by inhibiting the Wnt/beta-catenin signaling pathway in NPC. SFRP1 provides further insight into NPC progression and may provide novel therapeutic targets for NPC treatment. (C) 2015 AACR.
C1 [Ren, Xian-Yue; Zhou, Guan-Qun; Sun, Ying; Xu, Ya-Fei; Li, Ying-Qin; Tang, Xin-Ran; Wen, Xin; He, Qing-Mei; Yang, Xiao-Jing; Liu, Na; Ma, Jun] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China.
   [Jiang, Wei] Guilin Med Univ, Affiliated Hosp, Dept Radiat Oncol, Guilin, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Guilin
   Medical University
RP Ma, J (通讯作者)，Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
EM liun1@sysucc.org.cn; majun2@mail.sysu.edu.cn
RI Li, Mengxuan/LBG-9819-2024; liu, xinyi/GWZ-8739-2022
OI Liu, Na/0000-0001-8654-3636; ren, xianyue/0000-0002-1845-0814
FU National Natural Science Foundation of China [81402532, 81372409];
   Natural Science Foundation of Guangdong Province [S2013010012220];
   Science and Technology Project of Guangzhou City, China [132000507,
   14570006]; Health & Medical Collaborative Innovation Project of
   Guangzhou City, China [201400000001]; National Science & Technology
   Pillar Program during the Twelfth Five-year Plan Period [2014BAI09B10]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81402532, G.-Q. Zhou; 81372409, Y. Sun); the
   Natural Science Foundation of Guangdong Province (No. S2013010012220, Y.
   Sun); the Science and Technology Project of Guangzhou City, China (No.
   132000507, Y. Sun); the Science and Technology Project of Guangzhou
   City, China (No. 14570006, J. Ma); the Health & Medical Collaborative
   Innovation Project of Guangzhou City, China (No. 201400000001, J. Ma);
   and the National Science & Technology Pillar Program during the Twelfth
   Five-year Plan Period (No. 2014BAI09B10, J. Ma).
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bernemann C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-174
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Cheng CK, 2011, BLOOD, V118, P6638, DOI 10.1182/blood-2011-05-354712
   Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833
   Cooper SJ, 2012, MOL CANCER THER, V11, P2105, DOI 10.1158/1535-7163.MCT-11-0873
   Dave K, 2012, CURR TOP MED CHEM, V12, P1834
   Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537
   Flanagan JM, 2013, ANN ONCOL, V24, P2813, DOI 10.1093/annonc/mdt370
   Gauger KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-59
   Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143
   Guo Y, 2011, NEOPLASMA, V58, P110, DOI 10.4149/neo_2011_02_110
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Herbst Andreas, 2007, Methods Mol Biol, V361, P63
   Jeong YJ, 2013, ONCOL REP, V29, P1946, DOI 10.3892/or.2013.2335
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x
   Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89
   Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024
   LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9
   Li LL, 2015, EPIGENOMICS-UK, V7, P155, DOI [10.2217/epi.14.79, 10.2217/EPI.14.79]
   Liu N, 2013, CANCER LETT, V329, P181, DOI 10.1016/j.canlet.2012.10.032
   Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237
   McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
   Mitsui Y, 2014, ONCOTARGET, V5, P2198, DOI 10.18632/oncotarget.1889
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860
   QingLing Zhang, 2011, J Pathol, V223, P574, DOI 10.1002/path.2820
   Qu Y, 2013, EUR J CANCER, V49, P3718, DOI 10.1016/j.ejca.2013.07.011
   Rawson JB, 2011, CARCINOGENESIS, V32, P741, DOI 10.1093/carcin/bgr020
   Shu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027346
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Wands JR, 2014, HEPATOLOGY, V60, P452, DOI 10.1002/hep.27081
   Xu L, 2013, HUM PATHOL, V44, P1357, DOI 10.1016/j.humpath.2012.10.025
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 44
TC 34
Z9 38
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD OCT
PY 2015
VL 8
IS 10
BP 968
EP 977
DI 10.1158/1940-6207.CAPR-14-0369
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU3BS
UT WOS:000363399200011
PM 26276746
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Katz, TA
   Liao, SG
   Palmieri, VJ
   Dearth, RK
   Pathiraja, TN
   Huo, ZG
   Shaw, P
   Small, S
   Davidson, NE
   Peters, DG
   Tseng, GC
   Oesterreich, S
   Lee, AV
AF Katz, Tiffany A.
   Liao, Serena G.
   Palmieri, Vincent J.
   Dearth, Robert K.
   Pathiraja, Thushangi N.
   Huo, Zhiguang
   Shaw, Patricia
   Small, Sarah
   Davidson, Nancy E.
   Peters, David G.
   Tseng, George C.
   Oesterreich, Steffi
   Lee, Adrian V.
TI Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a
   Parity-Induced Hypermethylation of <i>Igf1r</i> That Persists Long after
   Parturition
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-I; BREAST-CANCER CHEMOPREVENTION; SURGICAL ADJUVANT
   BREAST; END BUD FORMATION; GENE-EXPRESSION; DUCTAL MORPHOGENESIS; BOWEL
   PROJECT; TAMOXIFEN; PREVENTION; RISK
AB The most effective natural prevention against breast cancer is an early first full-term pregnancy. Understanding how the protective effect is elicited will inform the development of new prevention strategies. To better understand the role of epigenetics in long-term protection, we investigated parity-induced DNA methylation in the mammary gland. FVB mice were bred or remained nulliparous and mammary glands harvested immediately after involution (early) or 6.5 months following involution (late), allowing identification of both transient and persistent changes. Targeted DNA methylation (109 Mb of Ensemble regulatory features) analysis was performed using the Sure Select XT Mouse Methyl-seq assay and massively parallel sequencing. Two hundred sixty-nine genes were hyper-methylated and 128 hypomethylated persistently at both the early and late time points. Pathway analysis of the persistently differentially methylated genes revealed Igf1r to be central to one of the top identified signaling networks, and Igf1r itself was one of the most significantly hypermethylated genes. Hypermethylation of Igf1r in the parous mammary gland was associated with a reduction of Igf1r mRNA expression. These data suggest that the IGF pathway is regulated at multiple levels during pregnancy and that its modification might be critical in the protective role of pregnancy. This supports the approach of lowering IGF action for prevention of breast cancer, a concept that is currently being tested clinically. (C) 2015 AACR.
C1 [Katz, Tiffany A.; Palmieri, Vincent J.; Small, Sarah; Davidson, Nancy E.; Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Womens Canc Res Ctr, Inst Canc, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Liao, Serena G.; Huo, Zhiguang; Tseng, George C.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Dearth, Robert K.] Univ Texas Rio Grande Valley, Dept Biol, Edinburg, TX USA.
   [Pathiraja, Thushangi N.] Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Singapore, Singapore.
   [Shaw, Patricia; Peters, David G.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Texas System;
   University of Texas Rio Grande Valley; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Lee, AV (通讯作者)，Magee Womens Res Inst, Room A412,204 Craft Ave, Pittsburgh, PA 15213 USA.
EM oesterreichs@upmc.edu; leeav@upmc.edu
RI Peters, David/AAD-4629-2019
OI Peters, David/0000-0003-4354-1125; Lee, Adrian/0000-0001-9917-514X; Huo,
   Zhiguang/0000-0002-8032-4392
FU National Cancer Institute of the NIH [R01CA94118, T32CA186873];
   Scientific Advisory Council award from Susan G. Komen for the Cure;
   University of Pittsburgh Cancer Institute, UPMC;  [P30CA047904]
FX This project used the UPCI Tissue and Research Pathology Services shared
   facilities that are supported in part by award P30CA047904. This work
   was supported in part by the National Cancer Institute of the NIH under
   award number R01CA94118 (A. V. Lee) and T32CA186873 (T. A. Katz). A. V.
   Lee is a recipient of a Scientific Advisory Council award from Susan G.
   Komen for the Cure and a Hillman Foundation Fellow. The authors
   acknowledge support from the University of Pittsburgh Cancer Institute,
   UPMC, and by the University of Pittsburgh Center for Simulation and
   Modeling through the high performance computing resources provided.
CR Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   [Anonymous], AM J EPIDEMIOL
   Asztalos S, 2010, CANCER PREV RES, V3, P301, DOI 10.1158/1940-6207.CAPR-09-0069
   Avraham A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091805
   Barton M, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00213
   Bassett JK, 2013, CANCER CAUSE CONTROL, V24, P1555, DOI 10.1007/s10552-013-0232-y
   Blakely CM, 2006, CANCER RES, V66, P6421, DOI 10.1158/0008-5472.CAN-05-4235
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Dearth RK, 2010, CANCER PREV RES, V3, P312, DOI 10.1158/1940-6207.CAPR-09-0074
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Fisher BJ, 1998, INT J RADIAT ONCOL, V42, P117, DOI 10.1016/S0360-3016(98)00177-1
   Freedman AN, 2011, J CLIN ONCOL, V29, P2327, DOI 10.1200/JCO.2010.33.0258
   Ghosh S, 2014, BREAST CANCER RES TR, V147, P653, DOI 10.1007/s10549-014-3132-2
   Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522
   Gong ZH, 2014, INT J CANCER, V134, P1422, DOI 10.1002/ijc.28466
   Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520
   Holmes MD, 2002, CANCER EPIDEM BIOMAR, V11, P862
   Jerry DJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3482
   Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kleinberg DL, 2011, PITUITARY, V14, P44, DOI 10.1007/s11102-010-0257-0
   Kleinberg DL, 2000, J MAMMARY GLAND BIOL, V5, P7, DOI 10.1023/A:1009507030633
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li J, 2011, ANN APPL STAT, V5, P994, DOI 10.1214/10-AOAS393
   Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1512
   MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209
   Matthews T J, 2014, NCHS Data Brief, P1
   MUSTACCHI P, 1961, ARCH INTERN MED, V108, P639, DOI 10.1001/archinte.1961.03620100131018
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Peri S, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-46
   Pike MC, 2004, ONCOGENE, V23, P6379, DOI 10.1038/sj.onc.1207899
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Raafat A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043624
   Rajkumar L, 2001, P NATL ACAD SCI USA, V98, P11755, DOI 10.1073/pnas.201393798
   Rambaldi D, 2009, BIOINFORMATICS, V25, P2281, DOI 10.1093/bioinformatics/btp381
   Richards RG, 2004, ENDOCRINOLOGY, V145, P3106, DOI 10.1210/en.2003-1112
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Ruan WF, 2006, MOL ENDOCRINOL, V20, P426, DOI 10.1210/me.2005-0283
   Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360
   Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075
   Russo IH, 2011, J MAMMARY GLAND BIOL, V16, P221, DOI 10.1007/s10911-011-9228-y
   Russo J, 2008, CANCER EPIDEM BIOMAR, V17, P51, DOI 10.1158/1055-9965.EPI-07-0678
   Russo J, 2012, INT J CANCER, V131, P1059, DOI 10.1002/ijc.27323
   Schonfeld SJ, 2011, AM J EPIDEMIOL, V173, P509, DOI 10.1093/aje/kwq404
   Sikora MJ, 2014, CANCER RES, V74, P1463, DOI 10.1158/0008-5472.CAN-13-2779
   Singh B, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0463-1
   Sun ZY, 2011, ENDOCRINOLOGY, V152, P3233, DOI 10.1210/en.2010-1296
   Vogel VG, 2010, CANCER PREV RES, V3, P696, DOI 10.1158/1940-6207.CAPR-10-0076
   Wang HQ, 2011, BIOINFORMATICS, V27, P225, DOI 10.1093/bioinformatics/btq650
   Waters EA, 2012, BREAST CANCER RES TR, V134, P875, DOI 10.1007/s10549-012-2089-2
   Wu H, 2010, BIOSTATISTICS, V11, P499, DOI 10.1093/biostatistics/kxq005
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Yang D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076650
   Zhang B, 2013, GENOME RES, V23, P1522, DOI 10.1101/gr.156539.113
   ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147
NR 55
TC 17
Z9 23
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD OCT
PY 2015
VL 8
IS 10
BP 1000
EP 1009
DI 10.1158/1940-6207.CAPR-15-0178
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU3BS
UT WOS:000363399200014
PM 26290394
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Stolzenburg, S
   Beltran, AS
   Swift-Scanlan, T
   Rivenbark, AG
   Rashwan, R
   Blancafort, P
AF Stolzenburg, S.
   Beltran, A. S.
   Swift-Scanlan, T.
   Rivenbark, A. G.
   Rashwan, R.
   Blancafort, P.
TI Stable oncogenic silencing <i>in vivo</i> by programmable and targeted
   <i>de novo</i> DNA methylation in breast cancer
SO ONCOGENE
LA English
DT Article
ID TRANSCRIPTION FACTOR SOX2; STEM-CELLS; EXPRESSION; GENES;
   DIFFERENTIATION; REPRESSION; EFFECTORS; PROTEINS; MEMORY; TUMORS
AB With the recent comprehensive mapping of cancer genomes, there is now a need for functional approaches to edit the aberrant epigenetic state of key cancer drivers to reprogram the epi-pathology of the disease. In this study we utilized a programmable DNA-binding methyltransferase to induce targeted incorporation of DNA methylation (DNAme) in the SOX2 oncogene in breast cancer through a six zinc finger (ZF) protein linked to DNA methyltransferase 3A (ZF-DNMT3A). We demonstrated long-lasting oncogenic repression, which was maintained even after suppression of ZF-DNMT3A expression in tumor cells. The de novo DNAme was faithfully propagated and maintained through cell generations even after the suppression of the expression of the chimeric methyltransferase in the tumor cells. Xenograft studies in NUDE mice demonstrated stable SOX2 repression and long-term breast tumor growth inhibition, which lasted for >100 days post implantation of the tumor cells in mice. This was accompanied with a faithful maintenance of DNAme in the breast cancer implants. In contrast, downregulation of SOX2 by ZF domains engineered with the Krueppel-associated box repressor domain resulted in a transient and reversible suppression of oncogenic gene expression. Our results indicated that targeted de novo DNAme of the SOX2 oncogenic promoter was sufficient to induce long-lasting epigenetic silencing, which was not only maintained during cell division but also significantly delayed the tumorigenic phenotype of cancer cells in vivo, even in the absence of treatment. Here, we outline a genome-based targeting approach to long-lasting tumor growth inhibition with potential applicability to many other oncogenic drivers that are currently refractory to drug design.
C1 [Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia.
   [Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Univ Western Australia, Sch Anat Physiol & Human Biol, Nedlands, WA 6009, Australia.
   [Stolzenburg, S.; Beltran, A. S.; Blancafort, P.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC USA.
   [Swift-Scanlan, T.] Univ N Carolina, Sch Nursing, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
   [Rivenbark, A. G.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA.
C3 Harry Perkins Institute of Medical Research; University of Western
   Australia; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina School of Medicine
RP Blancafort, P (通讯作者)，Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia.
EM pilar.blancafort@uwa.edu.au
RI Blancafort, Pilar/K-9029-2012
OI Rashwan, Rabab/0000-0001-9557-0062; Blancafort,
   Pilar/0000-0002-3881-7396
FU Australian Research Council (ARC) Future Fellowship [FT130101767];
   Cancer Council of Western Australia Research Fellowship; National Health
   and Medical Research Council [APP1069308]; National Institutes of Health
   [R01CA170370, R01DA036906]; National Breast Cancer Foundation
   [NC-14-024]; Barbara Senich Genomics Innovation Award; Barbara Senich
   Genomics Innovation Endowment Fund; Susan G Komen Foundation [KG090180]
FX This research was supported by an Australian Research Council (ARC)
   Future Fellowship FT130101767, the Cancer Council of Western Australia
   Research Fellowship, National Health and Medical Research Council grant
   APP1069308, National Institutes of Health grants R01CA170370,
   R01DA036906, the National Breast Cancer Foundation NC-14-024 (PB) and
   the Barbara Senich Genomics Innovation Award, the Barbara Senich
   Genomics Innovation Endowment Fund and the Susan G Komen Foundation
   KG090180 (TSS).
CR Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740
   Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932
   Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019
   Blancafort P, 2013, MOL PHARMACOL, V83, P563, DOI 10.1124/mol.112.080697
   Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811
   Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x
   Chaikind B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096931
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Hathaway NA, 2012, CELL, V149, P1447, DOI 10.1016/j.cell.2012.03.052
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Konermann S., 2013, NATURE
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lange UC, 2010, BIOESSAYS, V32, P659, DOI 10.1002/bies.201000030
   Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768
   Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035
   Nunna S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087703
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696
   Siddique A, 2013, J MOL BIOL, V425, P479, DOI 10.1016/j.jmb.2012.11.038
   Sikorska M, 2008, J NEUROSCI RES, V86, P1680, DOI 10.1002/jnr.21635
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Stolzenburg S, 2010, METHODS MOL BIOL, V649, P117, DOI 10.1007/978-1-60761-753-2_7
   Sussman RT, 2013, J BIOL CHEM, V288, P24234, DOI 10.1074/jbc.M113.469783
   Wiedenheft B, 2012, NATURE, V482, P331, DOI 10.1038/nature10886
   Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94
NR 39
TC 65
Z9 67
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT
PY 2015
VL 34
IS 43
BP 5427
EP 5435
DI 10.1038/onc.2014.470
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CU4EM
UT WOS:000363479700003
PM 25684141
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Wu, MZ
   Chen, SF
   Nieh, S
   Benner, C
   Ger, LP
   Jan, CI
   Ma, L
   Chen, CH
   Hishida, T
   Chang, HT
   Lin, YS
   Montserrat, N
   Gascon, P
   Sancho-Martinez, I
   Belmonte, JCI
AF Wu, Min-Zu
   Chen, Su-Feng
   Nieh, Shin
   Benner, Christopher
   Ger, Luo-Ping
   Jan, Chia-Ing
   Ma, Li
   Chen, Chien-Hung
   Hishida, Tomoaki
   Chang, Hong-Tai
   Lin, Yaoh-Shiang
   Montserrat, Nuria
   Gascon, Pedro
   Sancho-Martinez, Ignacio
   Izpisua Belmonte, Juan Carlos
TI Hypoxia Drives Breast Tumor Malignancy through a TET-TNFα-p38-MAPK
   Signaling Axis
SO CANCER RESEARCH
LA English
DT Article
ID CANCER STEM-CELL; EPITHELIAL-MESENCHYMAL TRANSITION; ACTIVATED
   PROTEIN-KINASE; MOLECULAR HETEROGENEITY; IDENTIFICATION; EXPRESSION;
   5-METHYLCYTOSINE; HIF-1-ALPHA; MECHANISMS; CARCINOMAS
AB Hypoxia is a hallmark of solid tumors that drives malignant progression by altering epigenetic controls. In breast tumors, aberrant DNA methylation is a prevalent epigenetic feature associated with increased risk of metastasis and poor prognosis. However, the mechanism by which hypoxia alters DNA methylation or other epigenetic controls that promote breast malignancy remains poorly understood. We discovered that hypoxia deregulates TET1 and TET3, the enzymes that catalyze conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), thereby leading to breast tumor-initiating cell (BTIC) properties. TET1/3 and 5hmC levels were closely associated with tumor hypoxia, tumor malignancy, and poor prognosis in breast cancer patients. Mechanistic investigations showed that hypoxia leads to genome-wide changes in DNA hydroxymethylation associated with upregulation of TNFa expression and activation of its downstream p38-MAPK effector pathway. Coordinate functions of TET1 and TET3 were also required to activate TNFa-p38-MAPK signaling as a response to hypoxia. Our results reveal how signal transduction through the TET-TNFa-p38-MAPK signaling axis is required for the acquisition of BTIC characteristics and tumorigenicity in vitro and in vivo, with potential implications for how to eradicate BTIC as a therapeutic strategy. (C) 2015 AACR.
C1 [Wu, Min-Zu; Ma, Li; Chen, Chien-Hung; Hishida, Tomoaki; Sancho-Martinez, Ignacio; Izpisua Belmonte, Juan Carlos] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA.
   [Chen, Su-Feng] China Med Univ, Dept Dent Hyg, Taichung, Taiwan.
   [Chen, Su-Feng; Nieh, Shin] Natl Def Med Ctr, Dept Pathol, Taipei, Taiwan.
   [Chen, Su-Feng; Nieh, Shin; Lin, Yaoh-Shiang] Triserv Gen Hosp, Taipei, Taiwan.
   [Benner, Christopher] Salk Inst Biol Studies, Integrat Genom & Bioinformat Core, La Jolla, CA 92037 USA.
   [Ger, Luo-Ping] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan.
   [Jan, Chia-Ing] China Med Univ & Hosp, Dept Pathol, Taichung, Taiwan.
   [Chang, Hong-Tai] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung, Taiwan.
   [Lin, Yaoh-Shiang] Natl Def Med Ctr, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan.
   [Lin, Yaoh-Shiang] Kaohsiung Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg, Kaohsiung, Taiwan.
   [Montserrat, Nuria; Gascon, Pedro] Univ Barcelona, Dept Med Oncol, Hosp Clin Barcelona, Barcelona, Spain.
C3 Salk Institute; China Medical University Taiwan; National Defense
   Medical Center; Tri-Service General Hospital; Salk Institute; National
   Sun Yat Sen University; Kaohsiung Veterans General Hospital; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   Kaohsiung Veterans General Hospital; National Defense Medical Center;
   Kaohsiung Veterans General Hospital; University of Barcelona; Hospital
   Clinic de Barcelona
RP Belmonte, JCI (通讯作者)，Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM belmonte@salk.edu
RI Chung, Chi-Hsiang/AAY-3386-2021; Ma, Li/AAD-6532-2020; Chen,
   Chien-Hung/X-4596-2019; Chen, Wei-Yu/ABH-4523-2020; Chiang,
   Chi-Ling/O-3038-2016; Benner, Christopher/KMA-4093-2024; Montserrat,
   Nuria/F-3136-2016
OI Montserrat, Nuria/0000-0002-1603-1755; Benner,
   Christopher/0000-0002-4618-0719
FU G. Harold and Leila Y. Mathers Charitable Foundation; Leona M. and Harry
   B. Helmsley Charitable Trust [2012-PG-MED002]
FX This work was supported by grants from the G. Harold and Leila Y.
   Mathers Charitable Foundation and The Leona M. and Harry B. Helmsley
   Charitable Trust (2012-PG-MED002).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411
   Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220
   Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515
   Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234
   Esteva FJ, 2004, CANCER-AM CANCER SOC, V100, P499, DOI 10.1002/cncr.11940
   Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Lin YC, 2012, NAT IMMUNOL, V13, P1196, DOI 10.1038/ni.2432
   Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007
   Oeztuerk-Winder F, 2012, BIOCHEM J, V445, P1, DOI 10.1042/BJ20120401
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Semenza GL, 2012, TRENDS MOL MED, V18, P534, DOI 10.1016/j.molmed.2012.08.001
   Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480
   Shahrzad S, 2007, EPIGENETICS-US, V2, P119, DOI 10.4161/epi.2.2.4613
   Singh SK, 2003, CANCER RES, V63, P5821
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Taddei ML, 2013, CANCER LETT, V341, P80, DOI 10.1016/j.canlet.2013.01.042
   Takasaki T, 1998, PATHOL INT, V48, P800, DOI 10.1111/j.1440-1827.1998.tb03840.x
   Tsuchihara K, 2009, NUCLEIC ACIDS RES, V37, P2249, DOI 10.1093/nar/gkp066
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361
   Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zer C, 2007, PHYSIOL GENOMICS, V31, P343, DOI 10.1152/physiolgenomics.00080.2007
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
NR 53
TC 100
Z9 116
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 15
PY 2015
VL 75
IS 18
BP 3912
EP 3924
DI 10.1158/0008-5472.CAN-14-3208
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU2EJ
UT WOS:000363335800025
PM 26294212
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Zhuo, CH
   Li, QG
   Wu, YC
   Li, YW
   Nie, J
   Li, DW
   Peng, JJ
   Lian, P
   Li, B
   Cai, GX
   Li, XX
   Cai, SJ
AF Zhuo, Changhua
   Li, Qingguo
   Wu, Yuchen
   Li, Yiwei
   Nie, Jia
   Li, Dawei
   Peng, Junjie
   Lian, Peng
   Li, Bin
   Cai, Guoxiang
   Li, Xinxiang
   Cai, Sanjun
TI LINE-1 hypomethylation in normal colon mucosa is associated with poor
   survival in Chinese patients with sporadic colon cancer
SO ONCOTARGET
LA English
DT Article
DE colon cancer; LINE-1; microsatellite instability; epigenetic
   modification; survival analysis
ID ISLAND METHYLATOR PHENOTYPE; ELEMENT DNA METHYLATION; TUMOR-SUPPRESSOR
   GENES; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PREOPERATIVE
   RADIOTHERAPY; MOLECULAR-FEATURES; SERRATED PATHWAY; MOBILE ELEMENTS;
   BREAST-CANCER
AB Genetic and epigenetic pathways are not independent in colorectal cancer (CRC) carcinogenesis. We aimed to determine the influence of various molecular features on Chinese patients' colon cancer-specific survival (CCSS). Various genetic and epigenetic modifications were detected in paired tumor and normal mucosa tissue samples. The prognostic variables regarding patient CCSS were determined. Overall, 127 patients, including 83 males and 44 females, completed a median follow-up of 65 (3-85) months. A mean LINE-1 methylation rate of 64.62% (range, 9.45-86.93) was observed. Hypermethylation at the hMLH1 gene promoter was detected in 26 (20.47%) patients. KRAS was mutated in 52 (40.94%) patients. Sixteen (12.60%) patients were confirmed as microsatellite instability (MSI)High, and 76 (59.84%) were found to have loss of heterozygosity at 18q. The LINE-1 methylation level, MSI status, perineural invasion and distant metastases were confirmed as independent prognostic factors for patient CCSS. A stratified survival analysis further revealed that certain subgroups of patients with LINE-1 hypomethylation had significantly worse survival (all p < 0.05). Our data revealed that both genetic and epigenetic abnormalities can concurrently exist during colonic tumorigenesis. As a global epigenetic change, LINE-1 hypomethylation in normal colon mucosa might be associated with a worse outcome in certain Chinese patients with colon cancer.
C1 [Zhuo, Changhua; Li, Qingguo; Wu, Yuchen; Li, Yiwei; Li, Dawei; Peng, Junjie; Lian, Peng; Cai, Guoxiang; Li, Xinxiang; Cai, Sanjun] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Dept Colorectal Surg,Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Zhuo, Changhua] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Dept Surg Oncol, Fuzhou 350014, Peoples R China.
   [Nie, Jia; Li, Bin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol,Unit Mol Immunol, Shanghai 200031, Peoples R China.
C3 Fudan University; Fujian Medical University; Chinese Academy of
   Sciences; Shanghai Institute of Immunity and Infection, CAS; Pasteur
   Network
RP Cai, SJ (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Dept Colorectal Surg,Shanghai Med Coll, Shanghai 200032, Peoples R China.
EM lxx1149@163.com; caisanjun@gmail.com
RI Cai, Jun/GLS-4538-2022; CAI, GUOXIANG/LKK-9614-2024; Li,
   Bin/AAR-4966-2021; ZHUO, CHANGHUA/H-7592-2012
OI ZHUO, CHANGHUA/0000-0002-5900-9048; Cai, Guoxiang/0000-0002-7772-7078
FU National Natural Science Foundation of China [81372646, 81472222]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81372646 to Cai SJ, and No. 81472222 to Li DW).
CR Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94
   Alonso S, 2015, ONCOTARGET, V6, P3420, DOI 10.18632/oncotarget.2852
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Boland CR, 1998, CANCER RES, V58, P5248
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Cho KJ, 2012, CURR BIOL, V22, P945, DOI 10.1016/j.cub.2012.03.067
   Curtin Karen, 2011, Patholog Res Int, V2011, P902674, DOI 10.4061/2011/902674
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Eads CA, 2001, CANCER RES, V61, P3410
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Estécio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006
   Goel A, 2010, GASTROENTEROLOGY, V138, P1854, DOI 10.1053/j.gastro.2010.01.035
   Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hughes LAE, 2013, CANCER RES, V73, P5858, DOI 10.1158/0008-5472.CAN-12-4306
   Hughes LAE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018571
   Irahara N, 2010, DIAGN MOL PATHOL, V19, P157, DOI 10.1097/PDM.0b013e3181c93fd1
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamiyama H, 2012, ONCOGENE, V31, P5029, DOI 10.1038/onc.2011.652
   Kang GH, 2011, ARCH PATHOL LAB MED, V135, P698, DOI 10.1043/2010-0523-RA.1
   Kawakami K, 2006, BRIT J CANCER, V94, P593, DOI 10.1038/sj.bjc.6602940
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Lee S, 2008, PATHOL INT, V58, P104, DOI 10.1111/j.1440-1827.2007.02197.x
   Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066
   Leodolter A, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.14
   Li QG, 2014, TUMOR BIOL, V35, P6389, DOI 10.1007/s13277-014-1817-0
   Li QG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000395
   LU LJW, 1983, CANCER LETT, V19, P231, DOI 10.1016/0304-3835(83)90159-3
   Markowitz S, 2000, J CLIN ONCOL, V18, p75S
   Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859
   MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002
   Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698
   Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362
   Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Russo AL, 2014, CANCER-AM CANCER SOC, V120, P1482, DOI 10.1002/cncr.28599
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Rustgi AK, 2013, CANCER CELL, V24, P1, DOI 10.1016/j.ccr.2013.06.008
   Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Silviera ML, 2012, CANCER PREV RES, V5, P374, DOI 10.1158/1940-6207.CAPR-11-0336
   Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001
   Stein LD, 2004, NATURE, V431, P915, DOI 10.1038/431915a
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Tanaka N, 2010, AM J PATHOL, V177, P2731, DOI 10.2353/ajpath.2010.100361
   Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398
   Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wong JJL, 2011, MODERN PATHOL, V24, P396, DOI 10.1038/modpathol.2010.212
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Yamada A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098059
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zlobec I, 2011, J PATHOL, V225, P336, DOI 10.1002/path.2879
NR 84
TC 7
Z9 8
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 15
PY 2015
VL 6
IS 27
BP 23820
EP 23836
DI 10.18632/oncotarget.4450
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT9SU
UT WOS:000363157700057
PM 26172297
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Perez-Janices, N
   Blanco-Luquin, I
   Torrea, N
   Liechtenstein, T
   Escors, D
   Cordoba, A
   Vicente-Garcia, F
   Jauregui, I
   De La Cruz, S
   Illarramendi, JJ
   Coca, V
   Berdasco, M
   Kochan, G
   Ibañez, B
   Lera, JM
   Guerrero-Setas, D
AF Perez-Janices, Noemi
   Blanco-Luquin, Idoia
   Torrea, Natalia
   Liechtenstein, Therese
   Escors, David
   Cordoba, Alicia
   Vicente-Garcia, Francisco
   Jauregui, Isabel
   De La Cruz, Susana
   Illarramendi, Jose Juan
   Coca, Valle
   Berdasco, Maria
   Kochan, Grazyna
   Ibanez, Berta
   Lera, Jose Miguel
   Guerrero-Setas, David
TI Differential involvement of <i>RASSF2</i> hypermethylation in breast
   cancer subtypes and their prognosis
SO ONCOTARGET
LA English
DT Article
DE breast cancer; DNA methylation; prognosis; RASSF1; RASSF2
ID EPIGENETIC INACTIVATION; PROMOTER METHYLATION; GENE; EXPRESSION;
   ASSOCIATION; SUPPRESSOR; SUBCLASSES; MUTATIONS; EFFECTOR; SURVIVAL
AB Breast cancer is a heterogeneous disease that can be subdivided into clinical, histopathological and molecular subtypes (luminal A-like, luminal B-like/HER2-negative, luminal B-like/HER2-positive, HER2-positive, and triple-negative). The study of new molecular factors is essential to obtain further insights into the mechanisms involved in the tumorigenesis of each tumor subtype. RASSF2 is a gene that is hypermethylated in breast cancer and whose clinical value has not been previously studied. The hypermethylation of RASSF1 and RASSF2 genes was analyzed in 198 breast tumors of different subtypes. The effect of the demethylating agent 5-aza-2'-deoxycytidine in the re-expression of these genes was examined in triple-negative (BT-549), HER2 (SK-BR-3), and luminal cells (T-47D). Different patterns of RASSF2 expression for distinct tumor subtypes were detected by immunohistochemistry. RASSF2 hypermethylation was much more frequent in luminal subtypes than in non-luminal tumors (p = 0.001). The re-expression of this gene by lentiviral transduction contributed to the differential cell proliferation and response to antineoplastic drugs observed in luminal compared with triple-negative cell lines. RASSF2 hypermethylation is associated with better prognosis in multivariate statistical analysis (P = 0.039). In conclusion, RASSF2 gene is differently methylated in luminal and non-luminal tumors and is a promising suppressor gene with clinical involvement in breast cancer.
C1 [Perez-Janices, Noemi; Blanco-Luquin, Idoia; Guerrero-Setas, David] Inst Invest Sanitarias Navarra IdiSNA, Canc Epigenet Grp, Navarrabiomed Fdn Miguel Servet FMS, Navarra, Spain.
   [Perez-Janices, Noemi; Blanco-Luquin, Idoia; Liechtenstein, Therese; Escors, David] UCL, Rayne Inst, Div Infect & Immun, London, England.
   [Blanco-Luquin, Idoia] IdiSNA, Navarrabiomed Fdn Miguel Servet, Canc Immunomodulat Grp, Navarra, Spain.
   [Torrea, Natalia; Escors, David; Kochan, Grazyna] Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland.
   [Cordoba, Alicia; Jauregui, Isabel] Complejo Hosp Navarra, Navarra Hlth Serv, Dept Pathol, Navarra, Spain.
   [Vicente-Garcia, Francisco; Lera, Jose Miguel] Complejo Hosp Navarra, Navarra Hlth Serv, Dept Surg, Navarra, Spain.
   [De La Cruz, Susana; Illarramendi, Jose Juan] Complejo Hosp Navarra, Navarra Hlth Serv, Dept Med Oncol, Navarra, Spain.
   [Coca, Valle] IdiSNA, Navarrabiomed Fdn Miguel Servet, Biobank Unit, Navarra, Spain.
   [Berdasco, Maria] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Canc Epigenet Grp, Barcelona, Spain.
   [Ibanez, Berta] IdiSNA, Navarrabiomed Fdn Miguel Servet, Red Evaluac Serv Sanitarios & Enfermedades Cron R, Navarra, Spain.
C3 University of London; King's College London; University College London;
   Navarrabiomed; University of Edinburgh; Servicio Navarro de Salud -
   Osasunbidea; Servicio Navarro de Salud - Osasunbidea; Servicio Navarro
   de Salud - Osasunbidea; Navarrabiomed; Institut d'Investigacio Biomedica
   de Bellvitge (IDIBELL); Navarrabiomed
RP Guerrero-Setas, D (通讯作者)，Inst Invest Sanitarias Navarra IdiSNA, Canc Epigenet Grp, Navarrabiomed Fdn Miguel Servet FMS, Navarra, Spain.
EM dguerres@navarra.es
RI Kochan, Grazyna/A-1094-2009; Luquin, Idoia/AAA-9134-2019; Escors,
   David/C-1549-2008; Ibanez, Berta/A-6924-2017
OI Escors-Murugarren, David/0000-0003-2828-4458; Kochan,
   Grazyna/0000-0002-0534-9661; Ibanez, Berta/0000-0002-7797-4845; Blanco,
   Idoia/0000-0003-2917-586X
FU SARAY (Asociacion Navarra de Cancer de Mama); Department of Health from
   the Government of Navarra [66/08]; Basque Foundation for Health
   Innovation and Research (BIOEF) [BIO/CM/013]; RefBio Pyrenees Biomedical
   Network (ncRNAbc); APICS Predoctoral Fellowship from Department of
   Health of the Government of Navarra; APICS Postdoctoral grant from
   Department of Health of the Government of Navarra; Miguel Servet
   Fellowship from the ISCIII; European Union; Swedish National Space
   Agency (SNSA) [66/08] Funding Source: Swedish National Space Agency
   (SNSA)
FX We are grateful to all the patients who participated in the study. We
   also thank staff of the Hospital Complex of Navarra (Navarra Health
   Service, Pamplona, Spain) for their invaluable support: JM
   Martinez-Penuela, A Panizo, N Diaz and MJ Diaz De Cerio from the
   Department of Pathology Section A, R Vera and E Salgado from the
   Department of Medical Oncology and AI Iruin from the Department of
   Pharmacy. We also wish to thank M Esteller from Cancer Epigenetics and
   Biology Program (PEBC, Barcelona, Spain), D Megias from the Confocal
   Microscopy Core Unit, Spanish National Cancer Research Centre (Madrid,
   Spain), AF Fernandez from IUOPA (Oviedo, Spain), and A Aramendia, M
   Arraiza, E Gochi, S Maria and E Reta from Navarrabiomed (Pamplona,
   Spain) for their technical assistance. We also appreciate the recent
   support from SARAY (Asociacion Navarra de Cancer de Mama). This work was
   funded by research grants from the Department of Health from the
   Government of Navarra (66/08), from the Basque Foundation for Health
   Innovation and Research (BIOEF, BIO/CM/013), and from the RefBio
   Pyrenees Biomedical Network (ncRNAbc). NPJ and IBL were recipients of
   APICS Predoctoral Fellowship and a Postdoctoral grant, respectively,
   both from the Department of Health of the Government of Navarra; DE is
   funded by a Miguel Servet Fellowship from the ISCIII, and DGS is funded
   by the European Union.
CR Bertucci F, 2009, INT J CANCER, V124, P1338, DOI 10.1002/ijc.24055
   Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279
   BOS JL, 1989, CANCER RES, V49, P4682
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041
   Clark Jennifer, 2012, Mol Biol Int, V2012, P705948, DOI 10.1155/2012/705948
   Cooper WN, 2008, ONCOGENE, V27, P1805, DOI 10.1038/sj.onc.1210805
   Corcuera LA, 2012, FOOD CHEM TOXICOL, V50, P989, DOI 10.1016/j.fct.2011.11.052
   Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854
   Escors D, 2008, BLOOD, V111, P3050, DOI 10.1182/blood-2007-11-122408
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gharanei S, 2013, EPIGENETICS-US, V8, P893, DOI 10.4161/epi.25617
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Guerrero D, 2011, INT J CANCER, V128, P2853, DOI 10.1002/ijc.25629
   Guerrero-Setas D, 2013, HISTOPATHOLOGY, V63, P659, DOI 10.1111/his.12204
   Guerrero-Setas D, 2013, MODERN PATHOL, V26, P1111, DOI 10.1038/modpathol.2013.32
   Guiu S, 2012, ANN ONCOL, V23, P2997, DOI 10.1093/annonc/mds586
   Hill JJ, 2015, J PROTEOME RES, V14, P1376, DOI 10.1021/pr500987r
   Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263
   Horne HN, 2009, MOL CANCER RES, V7, P199, DOI 10.1158/1541-7786.MCR-08-0314
   Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201
   Kaira K, 2007, INT J ONCOL, V31, P169
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Lawrence RT, 2015, CELL REP IN PRESS
   Leidy J, 2014, ARCH PATHOL LAB MED, V138, P37, DOI 10.5858/arpa.2012-0439-RA
   Pereira CBL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060576
   Luo D, 2012, EXP THER MED, V3, P391, DOI 10.3892/etm.2011.440
   Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679
   Meng WHA, 2012, MOL BIOL INT
   Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001
   Oakman C, 2013, ANN ONCOL, V24, P1203, DOI 10.1093/annonc/mds627
   Park HW, 2007, INT J CANCER, V120, P7, DOI 10.1002/ijc.22276
   Perez-Janices N, 2015, ONCOTARGET, V6, P368, DOI 10.18632/oncotarget.2745
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Richter Antje M, 2013, Cancers (Basel), V5, P1566, DOI 10.3390/cancers5041566
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Schagdarsurengin U, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-264
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Thike AA, 2010, AM J SURG PATHOL, V34, P956, DOI 10.1097/PAS.0b013e3181e02f45
   To SQ, 2012, J STEROID BIOCHEM, V132, P331, DOI 10.1016/j.jsbmb.2012.07.007
   Tobin NP, 2015, ANN ONCOL, V26, P81, DOI 10.1093/annonc/mdu498
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200
   Wells M, 2003, WHO CLASSIFICATION T, P13
   Wu Y, 2014, ASIAN PAC J CANCER P, V15, P1171, DOI 10.7314/APJCP.2014.15.3.1171
   Xi Biao, 2008, Biotechnology Journal, V3, P484, DOI 10.1002/biot.200800020
   Zhang X, 2014, J OBSTET GYNAECOL RE, V40, P1375, DOI 10.1111/jog.12322
   Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185
NR 50
TC 19
Z9 20
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 15
PY 2015
VL 6
IS 27
BP 23944
EP 23958
DI 10.18632/oncotarget.4062
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT9SU
UT WOS:000363157700066
PM 26284587
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, QL
   Jin, J
   Ying, JM
   Cui, Y
   Sun, MK
   Zhang, L
   Fan, Y
   Xu, B
   Zhang, Q
AF Liu, Qianling
   Jin, Jie
   Ying, Jianming
   Cui, Yun
   Sun, Mengkui
   Zhang, Lian
   Fan, Yu
   Xu, Ben
   Zhang, Qian
TI Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1
   in human renal cell carcinoma and its role as a potential therapeutic
   target
SO ONCOTARGET
LA English
DT Article
DE ASC/TMS1; tumor suppressor; DNA methylation; renal cell carcinoma;
   chemosensitivity
ID CASPASE RECRUITMENT DOMAIN; BREAST-CANCER CELLS; NF-KAPPA-B;
   COLORECTAL-CANCER; DOWN-REGULATION; CLEAR-CELL; P53; APOPTOSIS; ASC;
   METHYLATION
AB This study investigated the epigenetic alteration and biological function of the pro-apoptotic gene ASC/TMS1 in renal cell carcinoma. ASC/TMS1 was downregulated in five out of six RCC cell lines. A significant downregulation was also detected in sixty-seven paired renal tumors compared with adjacent non-cancerous tissues. The downregulation of ASC/TMS1 was correlated with promoter hypermethylation and could be restored with demethylation treatment. Re-expression of ASC/TMS1 in silenced RCC cell lines inhibited cell viability, colony formation, arrested cell cycle, induced apoptosis, suppressed cell invasion and repressed tumorigenicity in SCID mice. The antitumorigenic function of ASC/TMS1 in renal cancer was partially regulated by activation of p53 and p21 signaling. In addition, restoration of ASC/TMS1 sensitizes RCC cells to DNA damaging agents. Knockdown of ASC/TMS1 reduced DNA damaging agents-induced p53 activation and cell apoptosis. Moreover, ASC/TMS1 hypermethylation was further detected in 41.1% (83/202) of RCC tumors, but only 12% in adjacent non-cancerous tissues. ASC/TMS1 methylation was significantly correlated with higher tumor nuclear grade. In conclusion, ASC/TMS1 is a novel functional tumor suppressor in renal carcinogenesis. ASC/TMS1 tumor specific methylation may be a useful biomarker for designing improved diagnostic and therapeutic strategies for RCC.
C1 [Liu, Qianling; Jin, Jie; Cui, Yun; Sun, Mengkui; Zhang, Lian; Fan, Yu; Xu, Ben; Zhang, Qian] Peking Univ, Dept Urol, Hosp 1, Beijing 100034, Peoples R China.
   [Liu, Qianling; Jin, Jie; Cui, Yun; Sun, Mengkui; Zhang, Lian; Fan, Yu; Xu, Ben; Zhang, Qian] Natl Res Ctr Genitourinary Oncol, Inst Urol, Beijing 100034, Peoples R China.
   [Ying, Jianming] Chinese Acad Med Sci, Dept Pathol, Inst Canc, Beijing 100021, Peoples R China.
   [Ying, Jianming] Chinese Acad Med Sci, Canc Hosp, Peking Union Med Coll PUMC, Beijing 100021, Peoples R China.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College; Cancer Institute &
   Hospital - CAMS
RP Zhang, Q (通讯作者)，Peking Univ, Dept Urol, Hosp 1, Beijing 100034, Peoples R China.
EM zhangqian@bjmu.edu.cn
RI Jin, Jie/GQH-8572-2022
FU National Natural Science Foundation [81272290]
FX This study was supported by grants from National Natural Science
   Foundation (No. 81272290).
CR Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   Bex A, 2010, EUR UROL, V58, P819, DOI 10.1016/j.eururo.2010.08.029
   Conway KE, 2000, CANCER RES, V60, P6236
   Das PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-28
   Drexler SK, 2012, P NATL ACAD SCI USA, V109, P18384, DOI 10.1073/pnas.1209171109
   Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Gopisetty G, 2006, MOL IMMUNOL, V43, P1729, DOI 10.1016/j.molimm.2005.11.010
   HALDAR S, 1994, CANCER RES, V54, P2095
   Hasegawa M, 2007, ONCOGENE, V26, P1748, DOI 10.1038/sj.onc.1209965
   He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Hong S, 2013, CANCER LETT, V331, P183, DOI 10.1016/j.canlet.2012.12.020
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   KISHIMOTO Y, 1992, CANCER RES, V52, P4799
   Levine A J, 1989, Princess Takamatsu Symp, V20, P221
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Machida EO, 2006, CANCER RES, V66, P6210, DOI 10.1158/0008-5472.CAN-05-4447
   MALKIN D, 1994, CANCER RES, V54, P2077
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7
   Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   McConnell BB, 2000, CANCER RES, V60, P6243
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   MIYASHITA T, 1995, CELL, V80, P293
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371
   Morrissey C, 2001, CANCER RES, V61, P7277
   MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022
   Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087
   Okuda H, 2006, ONCOGENE, V25, P1733, DOI 10.1038/sj.onc.1209200
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559
   Ramachandran K, 2009, CANCER RES, V69, P1527, DOI 10.1158/0008-5472.CAN-08-3609
   Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003
   Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027
NR 46
TC 27
Z9 28
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2015
VL 6
IS 26
BP 22706
EP 22723
DI 10.18632/oncotarget.4256
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT6WW
UT WOS:000362954800087
PM 26093088
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhou, SH
   Chen, L
   Mashrah, M
   Zhu, Y
   Liu, JN
   Yang, X
   He, ZJ
   Wang, LZ
   Xiang, TX
   Yao, ZG
   Guo, F
   Yang, WJ
   Zhang, CP
AF Zhou, Shanghui
   Chen, Ling
   Mashrah, Mubarak
   Zhu, Yun
   Liu, Jiannan
   Yang, Xi
   He, Zhijing
   Wang, Lizhen
   Xiang, Tingxiu
   Yao, Zhigang
   Guo, Feng
   Yang, Wenjun
   Zhang, Chenping
TI Deregulation of secreted frizzled-related proteins is associated with
   aberrant β-catenin activation in the carcinogenesis of oral submucous
   fibrosis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE Wnt antagonist; methylation; tumor suppressor gene; Wnt signaling; OSF;
   OSCC
ID CANDIDATE TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; BREAST-CANCER; WNT
   PATHWAY; E-CADHERIN; NASOPHARYNGEAL; EXPRESSION; CARCINOMA; GENES; SFRP1
AB Secreted frizzled-related proteins (SFRPs), the first identified Wnt antagonists, have been well recognized as tumor suppressors in multiple human cancers through suppressing the Wnt/beta-catenin pathway. To better elucidate the mechanisms of SFRPs involved in the carcinogenesis of oral submucous fibrosis (OSF), one of the precancerous lesions of oral squamous cell carcinoma (OSCC), we investigated expression and localization of SFRP1, SFRP5, and beta-catenin in normal oral epithelium, OSF, and OSCC tissues. We found that SFRP1 and SFRP5 were readily expressed in normal oral mucous tissues but gradually decreased in OSF early, moderately advanced, and advanced tissues and rarely expressed in OSCC tissues. We found the changes of SFRP1 localization and SFRP5 localization from nucleus to cytoplasm in the carcinogenesis of OSF. There is a significant association among reduced SFRP1, SFRP5, and cytoplasmic/nuclear beta-catenin expression, which is correlated with higher tumor grade and stage of OSCC. We further found that SFRP1 and SFRP5 were frequently methylated in OSCC cases with betel quid chewing habit but not in normal oral mucous and different stages of OSF tissues, suggesting that methylation of SFRP1 and SFRP5 is tumor specific in the carcinogenesis of OSF. Taken together, our data demonstrated that reduced SFRP1 and SFRP5 by promoter methylation could lead to cytoplasmic/nuclear accumulation of beta-catenin and tumor progression. The changes of SFRPs and beta-catenin localization, as well as SFRPs' methylation, could be useful predictors or biomarkers of OSF malignant progression and prognosis.
C1 [Zhou, Shanghui; Mashrah, Mubarak; Zhu, Yun; Liu, Jiannan; Yang, Xi; Yang, Wenjun; Zhang, Chenping] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai 200011, Peoples R China.
   [Chen, Ling; Xiang, Tingxiu] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
   [He, Zhijing] Cent S Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China.
   [Wang, Lizhen] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral Pathol, Shanghai 200011, Peoples R China.
   [Yao, Zhigang] Cent S Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha, Hunan, Peoples R China.
   [Guo, Feng] Cent S Univ, Xiangya Hosp, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China.
C3 Shanghai Jiao Tong University; Chongqing Medical University; Central
   South University; Shanghai Jiao Tong University; Central South
   University; Central South University
RP Zhang, CP (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM zhang.chenping@hotmail.com
RI GUO, FENG/JRX-3555-2023; Mashrah, Mubarak/N-8535-2019; 刘,
   剑楠/LLM-3627-2024; Xiang, Tingxiu/E-6157-2016; Wang, Lizhen/ABG-6917-2021
OI Mashrah, Mubarak/0000-0003-4372-0465; Zhou, Shanghui/0000-0003-0694-3010
FU National Natural Science Foundation of China [81202133]; Fifth
   Outstanding Youth Fund of Shanghai Ninth People's Hospital, Shanghai
   Jiao Tong University School of Medicine; Science and Technology
   Commission of Shanghai Municipality [15411950301]
FX This article was supported by the National Natural Science Foundation of
   China (number 81202133), the Fifth Outstanding Youth Fund of Shanghai
   Ninth People's Hospital, Shanghai Jiao Tong University School of
   Medicine, and research grant (number 15411950301) from Science and
   Technology Commission of Shanghai Municipality.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Alvarado CG, 2011, HISTOPATHOLOGY, V59, P283, DOI 10.1111/j.1365-2559.2011.03929.x
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bezdekova Michala, 2007, Biomedical Papers (Olomouc), V151, P251
   Braakhuis BJM, 2005, ANN ONCOL, V16, P249, DOI 10.1093/annonc/mdi713
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   González-Moles MA, 2014, ORAL ONCOL, V50, P818, DOI 10.1016/j.oraloncology.2014.06.005
   Gupta PC, 1998, NATL MED J INDIA, V11, P113
   Iwai S, 2005, J CANCER RES CLIN, V131, P773, DOI 10.1007/s00432-005-0027-y
   Kaur J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067361
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Laxmidevi Lankesh B, 2010, J Oral Sci, V52, P633, DOI 10.2334/josnusd.52.633
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Li LL, 2015, EPIGENOMICS-UK, V7, P155, DOI [10.2217/epi.14.79, 10.2217/EPI.14.79]
   Mahomed F, 2007, ORAL DIS, V13, P386, DOI 10.1111/j.1601-0825.2006.01295.x
   Pannone G, 2010, ONCOL REP, V24, P1035, DOI 10.3892/or_00000952
   PILLAI R, 1992, CANCER, V69, P2011, DOI 10.1002/1097-0142(19920415)69:8<2011::AID-CNCR2820690802>3.0.CO;2-B
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004
   Tilakaratne WM, 2006, ORAL ONCOL, V42, P561, DOI 10.1016/j.oraloncology.2005.08.005
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wollina U, 2015, CLIN COSMET INV DERM, V8, P193, DOI 10.2147/CCID.S80576
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Yeh KT, 2003, INT J ONCOL, V23, P1001
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Zhang XL, 2007, ORAL ONCOL, V43, P424, DOI 10.1016/j.oraloncology.2006.08.010
NR 33
TC 19
Z9 21
U1 1
U2 13
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 2923
EP 2931
DI 10.2147/OTT.S91460
PG 9
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CT9TV
UT WOS:000363160400001
PM 26508877
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Zhang, L
   Zhan, SY
   Yao, J
   Lowery, FJ
   Zhang, QL
   Huang, WC
   Li, P
   Li, M
   Wang, X
   Zhang, CY
   Wang, H
   Ellis, K
   Cheerathodi, M
   McCarty, JH
   Palmieri, D
   Saunus, J
   Lakhani, S
   Huang, SY
   Sahin, AA
   Aldape, KD
   Steeg, PS
   Yu, DH
AF Zhang, Lin
   Zhan, Siyuan
   Yao, Jun
   Lowery, Frank J.
   Zhang, Qingling
   Huang, Wen-Chien
   Li, Ping
   Li, Min
   Wang, Xiao
   Zhang, Chenyu
   Wang, Hai
   Ellis, Kenneth
   Cheerathodi, Mujeeburahiman
   McCarty, Joseph H.
   Palmieri, Diane
   Saunus, Jodi
   Lakhani, Sunil
   Huang, Suyun
   Sahin, Aysegul A.
   Aldape, Kenneth D.
   Steeg, Patricia S.
   Yu, Dihua
TI Microenvironment-induced PTEN loss by exosomal microRNA primes brain
   metastasis outgrowth
SO NATURE
LA English
DT Article
ID BREAST-CANCER; CELLS; MIR-17-92; PHOSPHATASE; FAMILY
AB The development of life-threatening cancer metastases at distant organs requires disseminated tumour cells' adaptation to, and co-evolution with, the drastically different microenvironments of metastatic sites(1). Cancer cells of common origin manifest distinct gene expression patterns after metastasizing to different organs(2). Clearly, the dynamic interaction between metastatic tumour cells and extrinsic signals at individual metastatic organ sites critically effects the subsequent metastatic outgrowth(3,4). Yet, it is unclear when and how disseminated tumour cells acquire the essential traits from the microenvironment of metastatic organs that prime their subsequent outgrowth. Here we show that both human and mouse tumour cells with normal expression of PTEN, an important tumour suppressor, lose PTEN expression after dissemination to the brain, but not to other organs. The PTEN level in PTEN-loss brain metastatic tumour cells is restored after leaving the brain microenvironment. This brain microenvironment-dependent, reversible PTEN messenger RNA and protein downregulation is epigenetically regulated by microRNAs from brain astrocytes. Mechanistically, astrocyte-derived exosomes mediate an intercellular transfer of PTEN-targeting microRNAs to metastatic tumour cells, while astrocyte-specific depletion of PTEN-targeting microRNAs or blockade of astrocyte exosome secretion rescues the PTEN loss and suppresses brain metastasis in vivo. Furthermore, this adaptive PTEN loss in brain metastatic tumour cells leads to an increased secretion of the chemokine CCL2, which recruits IBA1-expressing myeloid cells that reciprocally enhance the outgrowth of brain metastatic tumour cells via enhanced proliferation and reduced apoptosis. Our findings demonstrate a remarkable plasticity of PTEN expression in metastatic tumour cells in response to different organ microenvironments, underpinning an essential role of co-evolution between the metastatic cells and their microenvironment during the adaptive metastatic outgrowth. Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients.
C1 [Zhang, Lin; Zhan, Siyuan; Yao, Jun; Lowery, Frank J.; Zhang, Qingling; Huang, Wen-Chien; Li, Ping; Li, Min; Wang, Xiao; Zhang, Chenyu; Wang, Hai; Ellis, Kenneth; Yu, Dihua] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Zhang, Lin; Lowery, Frank J.; Yu, Dihua] Univ Texas Houston, Hlth Sci Ctr, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX 77030 USA.
   [Zhan, Siyuan] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.
   [Cheerathodi, Mujeeburahiman; McCarty, Joseph H.; Huang, Suyun] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
   [Palmieri, Diane; Steeg, Patricia S.] NCI, Womans Malignancies Branch, Bethesda, MD 20892 USA.
   [Saunus, Jodi; Lakhani, Sunil] Univ Queensland, Clin Res Ctr, Brisbane, Qld 4029, Australia.
   [Lakhani, Sunil] Sch Med & Pathol Queensland, Brisbane, Qld 4029, Australia.
   [Lakhani, Sunil] Royal Brisbane & Womens Hosp, Brisbane, Qld 4029, Australia.
   [Sahin, Aysegul A.; Aldape, Kenneth D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Yu, Dihua] China Med Univ, Ctr Mol Med, Taichung 40402, Taiwan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Notre Dame; University of Texas System; UTMD Anderson
   Cancer Center; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); University of Queensland; Royal Brisbane &
   Women's Hospital; University of Texas System; UTMD Anderson Cancer
   Center; China Medical University Taiwan
RP Yu, DH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
EM dyu@mdanderson.org
RI Huang, Youju/A-9477-2011; Huang, Yuqi/HNC-0466-2023; Richard,
   ZHANG/HSF-0276-2023; Cheng, Ann-Lii/ACM-0936-2022; Steeg,
   Patricia/KPB-7977-2024; ZHANG, XIAOGUANG/AEX-5387-2022; Aldape,
   Kenneth/ADV-7384-2022; Zhang, Siyuan/AAH-1157-2021; Saunus,
   Jodi/C-6657-2011; Lakhani, Sunil/I-1970-2018; Zhang, Siyuan/A-1276-2014
OI Saunus, Jodi/0000-0002-4604-4709; Lakhani, Sunil/0000-0003-4067-2760;
   Yu, Dihua/0000-0001-6231-9381; Lowery, Frank/0000-0002-4620-5293; Zhang,
   Siyuan/0000-0003-0910-3666
FU DOD Center of Excellence [W81XWH-06-2-0033]; NIH [5R00CA158066-05]; DOD
   [W81XWH-11-1-0003]; Isaiah Fidler Fellowship in Cancer [PO1-CA099031];
   Susan G. Komen Breast Cancer Foundation [KG091020]; METAvivor Research
   Grant; Breast and Ovarian Cancers Moon Shot program; China Medical
   University Research Fund; Sowell-Huggins Pre-doctoral Fellowship and
   Professorship in Cancer Research;  [RO1-CA112567-06];  [R01CA184836]
FX We thank M.-C. Hung, H.-K. Lin and Z. Lu for reading the manuscript, A.
   Yung for PTEN promoter constructs, MD Anderson Cancer Center (MDACC)
   shRNA and ORFome, FAGS, histology and high-resolution electron
   microscopy support, the animal core facilities (NIH CA16672) for
   technical support, and members of the Yu laboratory for helpful
   discussions. Thanks to A. Matsika for histological review and tissue
   microarray construction. This work was supported partially by DOD Center
   of Excellence grant (P.S.S.) subproject W81XWH-06-2-0033 (D.Y.), NIH
   Pathway to Independence Award 5R00CA158066-05 (S.Z.), DOD Postdoctoral
   Fellowship W81XWH-11-1-0003 (C.Z.), Isaiah Fidler Fellowship in Cancer
   Metastasis (F.J.L.), PO1-CA099031 project 4 (D.Y.), RO1-CA112567-06
   (D.Y.), R01CA184836 (D.Y.), Susan G. Komen Breast Cancer Foundation
   Promise Grant KG091020 (D.Y), METAvivor Research Grant (D.Y.), Breast
   and Ovarian Cancers Moon Shot program, China Medical University Research
   Fund, and Sowell-Huggins Pre-doctoral Fellowship (L.Z.) and
   Professorship (D.Y.) in Cancer Research. D.Y. is the Hubert L. & Olive
   Stringer Distinguished Chair in Basic Science at the MDACC.
CR Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862
   Conti I, 2004, SEMIN CANCER BIOL, V14, P149, DOI 10.1016/j.semcancer.2003.10.009
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Frühbeis C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00119
   Gonzalez-Angulo AM, 2011, MOL CANCER THER, V10, P1093, DOI 10.1158/1535-7163.MCT-10-1089
   Gray J, 2010, NATURE, V464, P989, DOI 10.1038/464989a
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131
   Liu SQ, 2014, J BIOL CHEM, V289, P12446, DOI 10.1074/jbc.M114.550723
   Mecha M., 2011, Protocol Exchange
   Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004
   Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409
   Park ES, 2011, P NATL ACAD SCI USA, V108, P17456, DOI 10.1073/pnas.1114210108
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Suetsugu A, 2013, ADV DRUG DELIVER REV, V65, P383, DOI 10.1016/j.addr.2012.08.007
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Wikman H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3150
   Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309
   Zhu HQ, 2014, AM J PATHOL, V184, P2828, DOI 10.1016/j.ajpath.2014.06.024
NR 26
TC 918
Z9 1022
U1 8
U2 376
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 5
PY 2015
VL 527
IS 7576
BP 100
EP 104
DI 10.1038/nature15376
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV4XV
UT WOS:000364270700051
PM 26479035
OA Green Accepted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Piccolo, SR
   Andrulis, IL
   Cohen, AL
   Conner, T
   Moos, PJ
   Spira, AE
   Buys, SS
   Johnson, WE
   Bild, AH
AF Piccolo, Stephen R.
   Andrulis, Irene L.
   Cohen, Adam L.
   Conner, Thomas
   Moos, Philip J.
   Spira, Avrum E.
   Buys, Saundra S.
   Johnson, W. Evan
   Bild, Andrea H.
TI Gene-expression patterns in peripheral blood classify familial breast
   cancer susceptibility
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Breast cancer; Disease risk; Biomarker
ID RISK PREDICTION; VALIDATION; SIGNATURE; VARIANTS; PATHWAYS; REVEALS;
   DISEASE; TUMORS; BRCA1; WOMEN
AB Background: Women with a family history of breast cancer face considerable uncertainty about whether to pursue standard screening, intensive screening, or prophylactic surgery. Accurate and individualized risk-estimation approaches may help these women make more informed decisions. Although highly penetrant genetic variants have been associated with familial breast cancer (FBC) risk, many individuals do not carry these variants, and many carriers never develop breast cancer. Common risk variants have a relatively modest effect on risk and show limited potential for predicting FBC development. As an alternative, we hypothesized that additional genomic data types, such as gene-expression levels, which can reflect genetic and epigenetic variation, could contribute to classifying a person's risk status. Specifically, we aimed to identify common patterns in gene-expression levels across individuals who develop FBC.
   Methods: We profiled peripheral blood mononuclear cells from women with a family history of breast cancer (with or without a germline BRCA1/2 variant) and from controls. We used the support vector machines algorithm to differentiate between patients who developed FBC and those who did not. Our study used two independent datasets, a training set of 124 women from Utah (USA) and an external validation (test) set from Ontario (Canada) of 73 women (197 total). We controlled for expression variation associated with clinical, demographic, and treatment variables as well as lymphocyte markers.
   Results: Our multigene biomarker provided accurate, individual-level estimates of FBC occurrence for the Utah cohort (AUC = 0.76 [0.67-84]). Even at their lower confidence bounds, these accuracy estimates meet or exceed estimates from alternative approaches. Our Ontario cohort resulted in similarly high levels of accuracy (AUC = 0.73 [0.59-0.86]), thus providing external validation of our findings. Individuals deemed to have "high" risk by our model would have an estimated 2.4 times greater odds of developing familial breast cancer than individuals deemed to have "low" risk.
   Conclusions: Together, these findings suggest that gene-expression levels in peripheral blood cells reflect genomic variation associated with breast cancer risk and that such data have potential to be used as a non-invasive biomarker for familial breast cancer risk.
C1 [Piccolo, Stephen R.; Moos, Philip J.; Bild, Andrea H.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT USA.
   [Piccolo, Stephen R.; Spira, Avrum E.; Johnson, W. Evan] Boston Univ, Sch Med, Div Computat Biomed, Boston, MA 02118 USA.
   [Piccolo, Stephen R.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA.
   [Andrulis, Irene L.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
   [Cohen, Adam L.; Conner, Thomas; Buys, Saundra S.] Huntsman Canc Inst, Salt Lake City, UT USA.
   [Cohen, Adam L.; Buys, Saundra S.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Johnson, W. Evan; Bild, Andrea H.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Boston University;
   Brigham Young University; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; Utah System of Higher
   Education; University of Utah; Huntsman Cancer Institute; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Johnson, WE (通讯作者)，Boston Univ, Sch Med, Div Computat Biomed, Boston, MA 02118 USA.
EM wej@bu.edu; andreab@genetics.utah.edu
RI Andrulis, Irene/E-7267-2013
OI Moos, Philip/0000-0002-8223-442X; Johnson, W. Evan/0000-0002-6247-6595
FU NIH [R01GM085601, 5T32CA093247]; National Institutes of Health
   [U01CA69446]; National Center for Research Resources; National Center
   for Advancing Translational Sciences, National Institutes of Health
   [UL1RR025764]; National Cancer Institute [P30CA042014, UM1 CA164920]; 
   [1R01HG005692]
FX A Bild was supported by R01GM085601 (NIH), institutional funds, and a
   private donor. S Piccolo received funding via 5T32CA093247 (NIH). W
   Johnson and S Piccolo received support from 1R01HG005692. The Utah
   Breast Cancer Family Registry was supported through cooperative
   agreement from the National Institutes of Health U01CA69446, the
   National Center for Research Resources, and the National Center for
   Advancing Translational Sciences, National Institutes of Health grant
   UL1RR025764, and by award number P30CA042014 from the National Cancer
   Institute. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NCI or the NIH.
   This work was also supported by grant UM1 CA164920 from the National
   Cancer Institute. The content of this manuscript does not necessarily
   reflect the views or policies of the National Cancer Institute or any of
   the collaborating centers in the Breast Cancer Family Registry (BCFR),
   nor does mention of trade names, commercial products, or organizations
   imply endorsement by the US Government or the BCFR.
CR Aaroe Jorgen, 2010, Breast Cancer Res, V12, pR7, DOI 10.1186/bcr2472
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Cuzick Jack, 2014, Lancet, V383, P1041, DOI 10.1016/S0140-6736(13)62292-8
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   Hall M., 2009, ACM SIGKDD EXPLOR NE, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu ZD, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r180
   MacInnis RJ, 2013, BRIT J CANCER, V109, P1296, DOI 10.1038/bjc.2013.382
   Meiser B, 2003, J WOMENS HEALTH, V12, P769, DOI 10.1089/154099903322447738
   Michael CM, 2012, EVOLUTION TRANSLATIO
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Mohr S, 2007, TRENDS MOL MED, V13, P422, DOI 10.1016/j.molmed.2007.08.003
   Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797
   Nurtdinov RN, 2010, NUCLEIC ACIDS RES, V38, pD726, DOI 10.1093/nar/gkp969
   Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676
   Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533
   Piccolo SR, 2012, GENOMICS, V100, P337, DOI 10.1016/j.ygeno.2012.08.003
   Piccolo SR, 2012, J MACH LEARN RES, V13, P555
   Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Rockhill B, 2001, J NATL CANCER I, V93, P358, DOI 10.1093/jnci/93.5.358
   Rossouw JE, 2002, RISKS BENEFITS ESTRO, V288
   Sawyer S, 2012, J CLIN ONCOL, V30, P4330, DOI 10.1200/JCO.2012.41.7469
   Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107
   Sharma P, 2005, BREAST CANCER RES, V7, pR634, DOI 10.1186/bcr1203
   Sing T., 2009, ROCR: Visualizing the performance of scoring classifiers
   Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022
   Smith RA, 2011, CA-CANCER J CLIN, V61, P8, DOI 10.3322/caac.20096
   Spira A, 2007, NAT MED, V13, P361, DOI 10.1038/nm1556
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vapnik V.N., 1998, Technometrics, V1, DOI DOI 10.1080/00401706.1999.10485951
   Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727
   Waddell N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000080
   Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 49
TC 11
Z9 11
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD NOV 4
PY 2015
VL 8
AR 72
DI 10.1186/s12920-015-0145-6
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CW8ZR
UT WOS:000365288600001
PM 26538066
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, ZY
   Wang, PW
   Shieh, DB
   Chiu, KY
   Liou, YM
AF Chen, Zhi-Yuan
   Wang, Pei-Wen
   Shieh, Dar-Bin
   Chiu, Kuan-Ying
   Liou, Ying-Ming
TI Involvement of gelsolin in TGF-beta 1 induced epithelial to mesenchymal
   transition in breast cancer cells
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE GSN; TGF-beta 1; EMT; Methylation specific PCR; DNA methyltransferases
ID GROWTH-FACTOR-BETA; ACTIN-BINDING PROTEINS; DOWN-REGULATION; STEM-CELLS;
   EXPRESSION; MOTILITY; CYTOSKELETON; CARCINOMA; INVASION; CARCINOGENESIS
AB Background: Increasing evidence suggests that transforming growth factor-beta 1 (TGF-beta 1) triggers epithelial to mesenchymal transition (EMT) and facilitates breast cancer stem cell differentiation. Gelsolin (GSN) is a ubiquitous actin filament-severing protein. However, the relationship between the expression level of GSN and the TGF-beta signaling for EMT progression in breast cancer cells is not clear.
   Results: TGF-beta 1 acted on MDA-MB231 breast cancer cells by decreasing cell proliferation, changing cell morphology to a fibroblast-like shape, increasing expressions for CD44 and GSN, and increasing EMT expression and cell migration/invasion. Study with GSN overexpression (GSN op) in both MDA-MB231 and MCF-7 cells demonstrated that increased GSN expression resulted in alterations of cell proliferation and cell cycle progression, modification of the actin filament assembly associated with altering cell surface elasticity and cell detachment in these breast cancer cells. In addition, increased cell migration was found in GSN op MDA-MB231 cells. Studies with GSN op and silencing by small interfering RNA verified that GSN could modulate the expression of vimentin. Sorted by flow cytometry, TGF-beta 1 increased subpopulation of CD44+/CD22- cells increasing their expressions for GSN, Nanog, Sox2, Oct4, N-cadherin, and vimentin but decreasing the E-cadherin expression. Methylation specific PCR analysis revealed that TGF-beta 1 decreased 50 % methylation but increased 3-fold unmethylation on the GSN promoter in CD44+/CD22- cells. Two DNA methyltransferases, DNMT1and DNMT3B were also inhibited by TGF-beta 1.
   Conclusions: TGF-beta 1 induced epigenetic modification of GSN could alter the EMT process in breast cancer cells.
C1 [Chen, Zhi-Yuan; Chiu, Kuan-Ying; Liou, Ying-Ming] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
   [Wang, Pei-Wen; Shieh, Dar-Bin] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan.
   [Shieh, Dar-Bin] Natl Cheng Kung Univ, Inst Oral Med, Tainan 701, Taiwan.
   [Liou, Ying-Ming] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung 40227, Taiwan.
C3 National Chung Hsing University; National Cheng Kung University;
   National Cheng Kung University; National Chung Hsing University
RP Liou, YM (通讯作者)，Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
EM ymlion@dragon.nchu.edu.tw
OI Liou, Ying-Ming/0000-0002-8190-7629; Wang, Pei-Wen/0000-0002-1863-3661
FU National Science Council of Taiwan government [NSC 102-2320-B-005-002]
FX This work was supported by the National Science Council of Taiwan
   government (to Y-M L., Grant: NSC 102-2320-B-005-002). The authors also
   wished to thank Ms Meng-Shiun Chang for performing the experiments on
   migration assay in GSN op MDA-MB231 cells.
CR Abedini MR, 2014, P NATL ACAD SCI USA, V111, P14442, DOI 10.1073/pnas.1401166111
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Asch HL, 1999, BREAST CANCER RES TR, V55, P179
   Asch HL, 1996, CANCER RES, V56, P4841
   Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353
   Bruna A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2039
   Bursac P, 2005, NAT MATER, V4, P557, DOI 10.1038/nmat1404
   Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110
   Deng RZ, 2015, ONCOL LETT, V9, P2129, DOI 10.3892/ol.2015.3002
   Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534
   Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398
   Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3
   Gupta C, 2014, EXP CELL RES, V324, P75, DOI 10.1016/j.yexcr.2014.03.019
   Haga K, 2004, INT J CANCER, V111, P873, DOI 10.1002/ijc.20348
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hsu YC, 2011, J CELL PHYSIOL, V226, P2721, DOI 10.1002/jcp.22623
   Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377
   Jacobs Keith M, 2012, Int J Cell Biol, V2012, P930710, DOI 10.1155/2012/930710
   Kiselar JG, 2003, P NATL ACAD SCI USA, V100, P3942, DOI 10.1073/pnas.0736004100
   Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X
   KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375
   Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024
   Li GH, 2012, MED RES REV, V32, P999, DOI 10.1002/med.20231
   Litwin M, 2012, LIFE SCI, V90, P851, DOI 10.1016/j.lfs.2012.03.039
   Liu Jingbo, 2007, Cancer Genomics & Proteomics, V4, P377
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604
   Marino N, 2013, CANCER RES, V73, P5949, DOI 10.1158/0008-5472.CAN-13-0368
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461
   Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2
   Peng KW, 2012, BBA-GEN SUBJECTS, V1820, P469, DOI 10.1016/j.bbagen.2012.01.014
   Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003
   Radwanska A, 2012, EXP CELL RES, V318, P2312, DOI 10.1016/j.yexcr.2012.07.005
   Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100
   Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297
   Shieh DB, 2006, ORAL ONCOL, V42, P599, DOI 10.1016/j.oraloncology.2005.10.021
   Shieh DB, 2010, J CELL PHYSIOL, V223, P423, DOI 10.1002/jcp.22051
   Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018
   Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1
   Thor AD, 2001, CLIN CANCER RES, V7, P2415
   Tian MZ, 2011, CELL SIGNAL, V23, P951, DOI 10.1016/j.cellsig.2010.10.015
   van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023
   Velasco-Velázquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005
   Wang PW, 2014, INT J CANCER, V135, P2760, DOI 10.1002/ijc.28928
   Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411
   YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0
   Yin SP, 2006, CANCER RES, V66, P4173, DOI 10.1158/0008-5472.CAN-05-3514
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
NR 49
TC 24
Z9 27
U1 0
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD OCT 20
PY 2015
VL 22
AR 90
DI 10.1186/s12929-015-0197-0
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CT6TQ
UT WOS:000362945700002
PM 26482896
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hervouet, E
   Claude-Taupin, A
   Gauthier, T
   Perez, V
   Fraichard, A
   Adami, P
   Despouy, G
   Monnien, F
   Algros, MP
   Jouvenot, M
   Delage-Mourroux, R
   Boyer-Guittaut, M
AF Hervouet, Eric
   Claude-Taupin, Aurore
   Gauthier, Thierry
   Perez, Valerie
   Fraichard, Annick
   Adami, Pascale
   Despouy, Gilles
   Monnien, Franck
   Algros, Marie-Paule
   Jouvenot, Michele
   Delage-Mourroux, Regis
   Boyer-Guittaut, Michael
TI The autophagy <i>GABARAPL1</i> gene is epigenetically regulated in
   breast cancer models
SO BMC CANCER
LA English
DT Article
DE Autophagy; GABARAP; GABARAPL1; GABARAPL2; Breast cancer; CREB-1; DNA
   methylation; Epigenetics
ID DNA METHYLATION; MICROSATELLITE INSTABILITY; TUMOR-SUPPRESSOR;
   PROSTATE-CANCER; HIGH EXPRESSION; CHROMOSOME 17Q; MESSENGER-RNA; CELLS;
   INHIBITION; PROTEIN
AB Background: The GABARAP family members (GABARAP, GABARAPL1/GEC1 and GABARAPL2 /GATE-16) are involved in the intracellular transport of receptors and the autophagy pathway. We previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer.
   Methods: In this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.
   Results: Our data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.
   Conclusions: Our work strongly suggests that epigenetic inhibitors and CREB-1 modulators may be used in the future to regulate autophagy in breast cancer cells.
C1 [Hervouet, Eric; Claude-Taupin, Aurore; Gauthier, Thierry; Perez, Valerie; Fraichard, Annick; Adami, Pascale; Despouy, Gilles; Jouvenot, Michele; Delage-Mourroux, Regis; Boyer-Guittaut, Michael] Univ Franche Comte, Estrogenes Express Genique & Pathol Syst Nerveux, SFR IBCT FED4234, Lab Biochim,UFR Sci & Tech, F-25030 Besancon, France.
   [Monnien, Franck; Algros, Marie-Paule] Univ Hosp Jean Minjoz, Dept Pathol, F-25030 Besancon, France.
C3 Universite de Franche-Comte; Universite de Franche-Comte; CHU Besancon
RP Hervouet, E (通讯作者)，Univ Franche Comte, Estrogenes Express Genique & Pathol Syst Nerveux, SFR IBCT FED4234, Lab Biochim,UFR Sci & Tech, 16 Route Gray, F-25030 Besancon, France.
EM eric.hervouet@univ-fcomte.fr
RI Despouy, Gilles/ABE-1702-2021; Gauthier, Thierry/GQZ-4264-2022;
   DELAGE-MOURROUX, Régis/ABE-1424-2021; fraichard, annick/ABE-1289-2021;
   Guittaut, Michael/ABE-4274-2021; Hervouet, Eric/U-5784-2019;
   Claude-Taupin, Aurore/GQW-6605-2022
OI Gilles, Despouy/0000-0001-9250-9821; Claude-Taupin,
   Aurore/0000-0002-0792-4295; Guittaut, Michael/0000-0001-9540-5593;
   DELAGE-MOURROUX, Regis/0000-0002-7145-5948; Hervouet,
   Eric/0000-0002-4841-7812; Monnien, Franck/0000-0002-2799-3730
FU Universite de Franche-Comte; Ministere de l'Enseignement Superieur de la
   Recherche (MESR); Region de Franche-Comte; Ligue Contre le Cancer [007.
   Y-2014]
FX We thank Dr. Vincent Coulon (Montpellier, France) for providing the
   pCDNA3.1-CREB-1 plasmid [60]. This work was supported by the Universite
   de Franche-Comte, and funding from "BQR Jeunes chercheurs" of Universite
   de Franche-Comte, Ministere de l'Enseignement Superieur de la Recherche
   (MESR), Region de Franche-Comte 2013 and Ligue Contre le Cancer (# 007.
   Y-2014). ACT was supported by a fellowship from Region de Franche-Comte.
CR Ali MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060185
   Arrigo AP, 2005, METHODS, V35, P126, DOI 10.1016/j.ymeth.2004.08.003
   Bai H, 2012, ONCOGENE, V31, P4397, DOI 10.1038/onc.2011.613
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Berthier A, 2010, BRIT J CANCER, V102, P1024, DOI 10.1038/sj.bjc.6605568
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261
   Cartron PF, 2013, MOL ONCOL, V7, P452, DOI 10.1016/j.molonc.2012.11.004
   Cheray M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-9
   Claude-Taupin A, 2015, METHODS MOL BIOL, V1238, P487, DOI 10.1007/978-1-4939-1804-1_25
   Cluzeau T, 2011, CELL CYCLE, V10, P2339, DOI 10.4161/cc.10.14.16308
   Cook JL, 2008, CIRC RES, V102, P1539, DOI 10.1161/CIRCRESAHA.108.176594
   Coulon V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011235
   Dunwell T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-44
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Füllgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   GAO X, 1995, CANCER RES, V55, P1002
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   He G, 2014, TUMOR BIOL, V35, P1003, DOI 10.1007/s13277-013-1134-z
   Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001
   Hervouet E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.7
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hervouet E, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-31
   Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333
   Hervouet E, 2009, CLIN CANCER RES, V15, P3519, DOI 10.1158/1078-0432.CCR-08-2062
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Klebig C, 2005, CANCER RES, V65, P394
   Le Grand JN, 2011, AUTOPHAGY, V7, P1098, DOI 10.4161/auto.7.10.15904
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu C, 2014, ONCOL REP, V31, P2043, DOI 10.3892/or.2014.3096
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mahmoud L, 2014, RNA BIOL, V11, P124, DOI 10.4161/rna.27863
   Mansuy V, 2004, BIOCHEM BIOPH RES CO, V325, P639, DOI 10.1016/j.bbrc.2004.10.072
   Nemos C, 2003, MOL BRAIN RES, V119, P216, DOI 10.1016/j.molbrainres.2003.09.011
   Oh M, 2008, BIOCHEM BIOPH RES CO, V369, P1179, DOI 10.1016/j.bbrc.2008.03.019
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Pernodet N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3341
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Rozen S, 2000, Methods Mol Biol, V132, P365
   RUSSELL SEH, 1990, ONCOGENE, V5, P1581
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   SAITO H, 1993, CANCER RES, V53, P3382
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Seguin-Py S, 2012, BIOCHIMIE, V94, P748, DOI 10.1016/j.biochi.2011.11.006
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032
   Swiderek E, 2013, BIOCHEM BIOPH RES CO, V441, P707, DOI 10.1016/j.bbrc.2013.10.098
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Wang Y, 2013, AUTOPHAGY, V9, P2069, DOI 10.4161/auto.26447
   Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076016
   Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020
   Zou CF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-22
NR 62
TC 43
Z9 44
U1 1
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 17
PY 2015
VL 15
AR 729
DI 10.1186/s12885-015-1761-4
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5QQ
UT WOS:000362865700002
PM 26474850
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Matkar, S
   Sharma, P
   Gao, SB
   Gurung, B
   Katona, BW
   Liao, J
   Muhammad, AB
   Kong, XC
   Wang, L
   Jin, GH
   Dang, CV
   Hua, XX
AF Matkar, Smita
   Sharma, Paras
   Gao, Shubin
   Gurung, Buddha
   Katona, Bryson W.
   Liao, Jennifer
   Muhammad, Abdul Bari
   Kong, Xiang-Cheng
   Wang, Lei
   Jin, Guanghui
   Dang, Chi V.
   Hua, Xianxin
TI An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to
   HER2 Inhibition via FOXO/c-Myc Axis
SO CANCER CELL
LA English
DT Article
ID TRANSCRIPTION FACTORS; TRASTUZUMAB HERCEPTIN; TYROSINE KINASE; C-MYC;
   ACTIVATION; RESISTANCE; MLL; LAPATINIB; THERAPY; GROWTH
AB Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers. However, the cancer cells often quickly develop an adaptive response to HER2 kinase inhibitors. We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, lapatinib. Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib. An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.
C1 [Matkar, Smita; Sharma, Paras; Gurung, Buddha; Katona, Bryson W.; Liao, Jennifer; Muhammad, Abdul Bari; Kong, Xiang-Cheng; Wang, Lei; Hua, Xianxin] Univ Penn, Abramson Canc Ctr, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.
   [Dang, Chi V.] Univ Penn, Abramson Canc Ctr, Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA.
   [Gao, Shubin; Jin, Guanghui] Xiamen Univ, Coll Med, Xiamen 361006, Peoples R China.
   [Wang, Lei] Wuhan Univ, Renmin Hosp, Dept Urol, Wuhan 430060, Peoples R China.
C3 University of Pennsylvania; University of Pennsylvania; Xiamen
   University; Wuhan University
RP Hua, XX (通讯作者)，Univ Penn, Abramson Canc Ctr, Abramson Family Canc Res Inst, Dept Canc Biol, 412 Curie Blvd, Philadelphia, PA 19104 USA.
EM huax@mail.med.upenn.edu
RI Dang, Chi/Y-3375-2019
OI Dang, Chi/0000-0002-4031-2522; Katona, Bryson/0000-0001-8186-9119
FU NIH [R01-DK085121, 1-R01-CA-178856, R01 DK097555]; Caring for Carcinoid
   Foundation-AACR Grant Care for Carcinoid Foundation [11-60-33]; ITMAT of
   the University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Breast Cancer Coalition's Refunds for Research; NIH/NIDDK Center for
   Molecular Studies in Digestive and Liver Diseases [P30DK050306]
FX We thank Drs. Peter Zhou and Yong Wan for critically reading the
   manuscript, Brian Bakke and Haoren Wang for technical assistance, and
   Ashley Banks for editing the manuscript. This work was supported in part
   by grants from the NIH (R01-DK085121, 1-R01-CA-178856, and R01
   DK097555), Caring for Carcinoid Foundation-AACR Grant Care for Carcinoid
   Foundation (11-60-33), a pilot grant from ITMAT of the University of
   Pennsylvania, as well as a sarcoma pilot grant from University of
   Pennsylvania, and a grant from Pennsylvania Breast Cancer Coalition's
   Refunds for Research. This work was also supported in part by the
   NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases
   (P30DK050306) and its core facilities (Molecular Biology/Gene Expression
   Core). We thank Austin Thiel for help in assembling the epigenetic shRNA
   library and John Tobias for statistical analysis.
CR Aksamitiene E, 2010, CELL SIGNAL, V22, P1369, DOI 10.1016/j.cellsig.2010.05.006
   [Anonymous], BREAST CANC RES
   Bellovin DI, 2013, ADV EXP MED BIOL, V734, P91, DOI 10.1007/978-1-4614-1445-2_6
   Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Choi NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037554
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740
   Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012
   Gan BY, 2010, CANCER CELL, V18, P472, DOI 10.1016/j.ccr.2010.10.019
   Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108
   Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A
   Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109
   Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253
   Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143
   Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852
   Makrythanasis P, 2013, CLIN GENET, V84, P539, DOI 10.1111/cge.12081
   Molina MA, 2001, CANCER RES, V61, P4744
   Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351
   Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024
   Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Peck B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00096
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Smith E, 2011, GENE DEV, V25, P661, DOI 10.1101/gad.2015411
   SPENCER CA, 1991, ADV CANCER RES, V56, P1
   Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034
   Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168
   Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101
   Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010
   Zhu JD, 2008, P NATL ACAD SCI USA, V105, P6584, DOI 10.1073/pnas.0802785105
NR 48
TC 69
Z9 85
U1 0
U2 37
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD OCT 12
PY 2015
VL 28
IS 4
BP 472
EP 485
DI 10.1016/j.ccell.2015.09.005
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT5KO
UT WOS:000362848800011
PM 26461093
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Fu, A
   Jacobs, DI
   Hoffman, AE
   Zheng, TZ
   Zhu, Y
AF Fu, Alan
   Jacobs, Daniel I.
   Hoffman, Aaron E.
   Zheng, Tongzhang
   Zhu, Yong
TI PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly
   by remodeling the cancer epigenome
SO CARCINOGENESIS
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION; HIWI GENE; PIRNAS; PROLIFERATION;
   CELLS; CARCINOMA; GERMLINE; RECEPTOR; RISK
AB Although PIWI-interacting RNAs (piRNAs) account for the largest class of the small non-coding RNA superfamily, virtually nothing is known of their function in human carcinogenesis. Once thought to be expressed solely in the germ line where they safeguard the genome against transposon-induced insertional mutations, piRNAs are now believed to play an active role in somatic gene regulation through sequence-specific histone modification and DNA methylation. In the current study, we investigate the role of piRNA-021285 (piR-021285) in the regulation of the breast cancer methylome. Genotypic screening of a panel of single-nucleotide polymorphism (SNP)-containing piRNAs revealed a significant association between SNP rs1326306 G> T in piR-021285 and increased likelihood for breast cancer in a Connecticut-based population (441 cases and 479 controls). Given nascent but compelling evidence of piRNA-mediated gene-specific methylation in the soma, a genome-wide methylation screen was then carried out using wild type (WT) and variant piR-021285 mimic-transfected MCF7 cells to explore whether the observed association could be attributed in part to piR-021285-induced methylation at cancer-relevant genes. We found significant methylation differences at a number of experimentally implicated breast cancer-related genes, including attenuated 5' untranslated region (UTR)/first exon methylation at the proinvasive ARHGAP11A gene in variant mimic-transfected cells. Follow-up functional analyses revealed both concurrent increased ARHGAP11A mRNA expression and enhanced invasiveness in variant versus WT piR-021285 mimic-transfected breast cancer cell lines. Taken together, our findings demonstrate the first evidence supporting a role of piRNAs, a novel group of non-coding RNA, in human tumorigenesis via a piRNA-mediated epigenetic mechanism, which warrants further confirmation and investigation.
C1 [Fu, Alan; Jacobs, Daniel I.; Zheng, Tongzhang; Zhu, Yong] Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
   [Hoffman, Aaron E.] Tulane Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA.
   [Hoffman, Aaron E.] Tulane Canc Ctr, New Orleans, LA 70112 USA.
C3 Yale University; Tulane University; Tulane University
RP Zhu, Y (通讯作者)，Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
FU Yale-National Cancer Institute (NCI) [T32 CA105666]
FX D.I.J. was supported by the Yale-National Cancer Institute (NCI)
   predoctoral training grant T32 CA105666. Yale University.
CR Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916
   Aravin AA, 2007, SCIENCE, V318, P761, DOI 10.1126/science.1146484
   Bamezai S, 2012, STEM CELLS, V30, P2603, DOI 10.1002/stem.1237
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Brennecke J, 2008, SCIENCE, V322, P1387, DOI 10.1126/science.1165171
   Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Choschzick M, 2010, HUM PATHOL, V41, P358, DOI 10.1016/j.humpath.2009.08.008
   Cichocki F, 2010, J IMMUNOL, V185, P2009, DOI 10.4049/jimmunol.1000855
   Fu A, 2014, RNA BIOL, V11, P1301, DOI 10.1080/15476286.2014.996091
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Grivna ST, 2006, GENE DEV, V20, P1709, DOI 10.1101/gad.1434406
   Grochola LF, 2008, BRIT J CANCER, V99, P1083, DOI 10.1038/sj.bjc.6604653
   He W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-426
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kagawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083629
   Kim VN, 2006, GENE DEV, V20, P1993, DOI 10.1101/gad.1456106
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Law PTY, 2013, J HEPATOL, V58, P1165, DOI 10.1016/j.jhep.2013.01.032
   Li DW, 2012, EXP BIOL MED, V237, P1231, DOI 10.1258/ebm.2012.011380
   Liu JJ, 2010, INT J CLIN EXP PATHO, V3, P328
   Luoh SW, 2004, ONCOGENE, V23, P1354, DOI 10.1038/sj.onc.1207251
   Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Rajasethupathy P, 2012, CELL, V149, P693, DOI 10.1016/j.cell.2012.02.057
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   Ross RJ, 2014, NATURE, V505, P353, DOI 10.1038/nature12987
   Santos EDS, 2008, INT J ONCOL, V33, P25
   Sawa Masaaki, 2009, Drug Des Devel Ther, V2, P255
   Sharma M, 2013, BIOTECHNOL LETT, V35, P1561, DOI 10.1007/s10529-013-1257-8
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Siomi MC, 2011, NAT REV MOL CELL BIO, V12, P246, DOI 10.1038/nrm3089
   Sun GA, 2011, BRAIN RES, V1373, P183, DOI 10.1016/j.brainres.2010.11.097
   Wang Y, 2013, EXP THER MED, V5, P315, DOI 10.3892/etm.2012.766
   Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706
   Xu J, 2013, CELL REP, V3, P1526, DOI 10.1016/j.celrep.2013.04.017
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zeng Y, 2011, CHINESE MED J-PEKING, V124, P2144, DOI 10.3760/cma.j.issn.0366-6999.2011.14.012
   Zhao YM, 2012, CANCER-AM CANCER SOC, V118, P2708, DOI 10.1002/cncr.26524
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
NR 43
TC 118
Z9 133
U1 2
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2015
VL 36
IS 10
BP 1094
EP 1102
DI 10.1093/carcin/bgv105
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5KZ
UT WOS:000362850200002
PM 26210741
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Rüger, N
   Roatsch, M
   Emmrich, T
   Franz, H
   Schüle, R
   Jung, M
   Link, A
AF Rueger, Nicole
   Roatsch, Martin
   Emmrich, Thomas
   Franz, Henriette
   Schuele, Roland
   Jung, Manfred
   Link, Andreas
TI Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the
   JumonjiC-Domain-Containing Histone Demethylase KDM4A
SO CHEMMEDCHEM
LA English
DT Article
DE acyl hydrazides; acyl hydrazones; epigenetics; histone demethylase;
   tetrazoles
ID HUMAN BREAST-CANCER; LYSINE DEMETHYLASES; JMJD2 FAMILY; IN-VITRO;
   2-OXOGLUTARATE; GROWTH; TRANSFORMATION; SPECIFICITY; DESIGN; CELLS
AB The JumonjiC-domain-containing histone demethylase2A (JMJD2A, KDM4A) is a key player in the epigenetic regulation of gene expression. Previous publications have shown that both elevated and lowered enzyme levels are associated with certain types of cancer, and therefore the definite role of KDM4A in oncogenesis remains elusive. To identify a novel molecular starting point with favorable physicochemical properties for the investigation of the physiological role of KDM4A, we screened a number of molecules bearing an iron-chelating moiety by using two independent assays. In this way, we were able to identify 2-(1H-tetrazol-5-yl)acetohydrazide as a novel fragment-like lead structure with low relative molecular mass (M-r=142Da), low complexity, and an IC50 value of 46.6m in a formaldehyde dehydrogenase (FDH)-coupled assay and 2.4m in an antibody-based assay. Despite its small size, relative selectivity against two other demethylases could be demonstrated for this compound. This is the first example of a tetrazole group as a warhead in JMJD demethylases.
C1 [Rueger, Nicole; Emmrich, Thomas; Link, Andreas] Ernst Moritz Arndt Univ Greifswald, Inst Pharm, D-17487 Greifswald, Germany.
   [Roatsch, Martin; Jung, Manfred] Univ Freiburg, Inst Pharmaceut Sci, D-79104 Freiburg, Germany.
   [Franz, Henriette; Schuele, Roland] Univ Freiburg, Med Ctr, Dept Urol, Womens Hosp, D-79106 Freiburg, Germany.
   [Franz, Henriette; Schuele, Roland] Univ Freiburg, Med Ctr, Clin Res Ctr, D-79106 Freiburg, Germany.
C3 Universitat Greifswald; University of Freiburg; University of Freiburg;
   University of Freiburg
RP Rüger, N (通讯作者)，Ernst Moritz Arndt Univ Greifswald, Inst Pharm, Friedrich Ludwig Jahn Str 17, D-17487 Greifswald, Germany.
EM Link@uni-greifswald.de
RI Schüle, Rebecca/B-5763-2019; Link, Andreas/H-5067-2013; Jung,
   Manfred/Q-8029-2016; Roatsch, Martin/I-3676-2012
OI Link, Andreas/0000-0003-1262-6636; Jung, Manfred/0000-0002-6361-7716;
   Roatsch, Martin/0000-0002-9274-1433; Franz,
   Henriette/0000-0001-9358-7442
FU Deutsche Forschungsgemeinschaft [SFB992]; Studienstiftung des deutschen
   Volkes
FX M.J. and R.S. thank the Deutsche Forschungsgemeinschaft for funding
   (SFB992 MEDEP-Medical Epigenetics). M.R. thanks the Studienstiftung des
   deutschen Volkes for support. Furthermore, we thank Johanna Senger
   (University of Freiburg) for performing the histone deacetylase assay.
CR Berry WL, 2012, INT J ONCOL, V41, P1701, DOI 10.3892/ijo.2012.1618
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Chang KH, 2011, CHEMMEDCHEM, V6, P759, DOI 10.1002/cmdc.201100026
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Chen ZZ, 2007, P NATL ACAD SCI USA, V104, P10818, DOI 10.1073/pnas.0704525104
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273
   Day JA, 2013, J MED CHEM, V56, P7997, DOI 10.1021/jm401053m
   FINNEGAN WG, 1958, J AM CHEM SOC, V80, P3908, DOI 10.1021/ja01548a028
   FRIEDMAN L, 1960, J ORG CHEM, V25, P877, DOI 10.1021/jo01076a001
   Guerra-Calderas L, 2015, CANCER GENET-NY, V208, P215, DOI 10.1016/j.cancergen.2014.11.001
   Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655
   Hansch C., 1995, EXPLORING QSAR FUNDA, V1
   Heinemann B, 2014, NATURE, V514, pE1, DOI 10.1038/nature13688
   Heltweg B, 2005, METHODS, V36, P332, DOI 10.1016/j.ymeth.2005.03.003
   Hoffmann I, 2012, MOL ONCOL, V6, P683, DOI 10.1016/j.molonc.2012.07.004
   Hopkinson RJ, 2013, CHEM SCI, V4, P3110, DOI [10.1039/C3SC51122G, 10.1039/c3sc51122g]
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758
   Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kogure M, 2013, CANCER LETT, V336, P76, DOI 10.1016/j.canlet.2013.04.009
   Krishnan S, 2012, ANAL BIOCHEM, V420, P48, DOI 10.1016/j.ab.2011.08.034
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Li BX, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-90
   Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152
   Luo FT, 1998, TETRAHEDRON LETT, V39, P9455, DOI 10.1016/S0040-4039(98)02143-1
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033
   Mantri M, 2010, J MOL BIOL, V401, P211, DOI 10.1016/j.jmb.2010.05.054
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Patani N, 2011, ANTICANCER RES, V31, P4115
   RABINI T, 1965, J ORG CHEM, V30, P2486, DOI 10.1021/jo01018a525
   Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s
   Rose NR, 2012, J MED CHEM, V55, P6639, DOI 10.1021/jm300677j
   Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b
   SCHULZE W, 1963, J PRAKT CHEM, V19, P91, DOI 10.1002/prac.19630190114
   Sekirnik R, 2009, CHEM COMMUN, P6376, DOI 10.1039/b916357c
   Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179
   Thinnes CC, 2014, BBA-GENE REGUL MECH, V1839, P1416, DOI 10.1016/j.bbagrm.2014.05.009
   ULRICH H, 1962, J ORG CHEM, V27, P2160, DOI 10.1021/jo01053a062
   Van Rechem C, 2015, CANCER DISCOV, V5, P245, DOI 10.1158/2159-8290.CD-14-1159
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wilde F, 2013, EXPERT OPIN DRUG DIS, V8, P597, DOI 10.1517/17460441.2013.780022
   Woon E. C. Y., 2012, ANGEW CHEM, V124, P1663
   Woon ECY, 2012, ANGEW CHEM INT EDIT, V51, P1631, DOI 10.1002/anie.201107833
   Xu WH, 2015, BIOL CHEM, V396, P929, DOI 10.1515/hsz-2014-0284
NR 48
TC 28
Z9 29
U1 0
U2 27
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD NOV
PY 2015
VL 10
IS 11
BP 1875
EP 1883
DI 10.1002/cmdc.201500335
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CU8FS
UT WOS:000363777500010
PM 26337137
DA 2025-01-12
ER

PT J
AU Nguyen, VTM
   Barozzi, I
   Faronato, M
   Lombardo, Y
   Steel, JH
   Patel, N
   Darbre, P
   Castellano, L
   Gyorffy, B
   Woodley, L
   Meira, A
   Patten, DK
   Vircillo, V
   Periyasamy, M
   Ali, S
   Frige, G
   Minucci, S
   Coombes, RC
   Magnani, L
AF Nguyen, Van T. M.
   Barozzi, Iros
   Faronato, Monica
   Lombardo, Ylenia
   Steel, Jennifer H.
   Patel, Naina
   Darbre, Philippa
   Castellano, Leandro
   Gyorffy, Balazs
   Woodley, Laura
   Meira, Alba
   Patten, Darren K.
   Vircillo, Valentina
   Periyasamy, Manikandan
   Ali, Simak
   Frige, Gianmaria
   Minucci, Saverio
   Coombes, R. Charles
   Magnani, Luca
TI Differential epigenetic reprogramming in response to specific endocrine
   therapies promotes cholesterol biosynthesis and cellular invasion
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; MEVALONATE PATHWAY;
   SUPER-ENHANCERS; PIONEER FACTORS; IN-VITRO; CHROMATIN; RESISTANCE;
   EXPRESSION; GROWTH
AB Endocrine therapies target the activation of the oestrogen receptor alpha (ER alpha) via distinct mechanisms, but it is not clear whether breast cancer cells can adapt to treatment using drug-specific mechanisms. Here we demonstrate that resistance emerges via drug-specific epigenetic reprogramming. Resistant cells display a spectrum of phenotypical changes with invasive phenotypes evolving in lines resistant to the aromatase inhibitor (AI). Orthogonal genomics analysis of reprogrammed regulatory regions identifies individual drug-induced epigenetic states involving large topologically associating domains (TADs) and the activation of super-enhancers. AI-resistant cells activate endogenous cholesterol biosynthesis (CB) through stable epigenetic activation in vitro and in vivo. Mechanistically, CB sparks the constitutive activation of oestrogen receptors alpha (ER alpha) in AI-resistant cells, partly via the biosynthesis of 27-hydroxycholesterol. By targeting CB using statins, ER alpha binding is reduced and cell invasion is prevented. Epigenomic-led stratification can predict resistance to AI in a subset of ER alpha-positive patients.
C1 [Nguyen, Van T. M.; Faronato, Monica; Lombardo, Ylenia; Steel, Jennifer H.; Patel, Naina; Castellano, Leandro; Meira, Alba; Patten, Darren K.; Periyasamy, Manikandan; Ali, Simak; Coombes, R. Charles; Magnani, Luca] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England.
   [Barozzi, Iros; Frige, Gianmaria; Minucci, Saverio] European Inst Oncol, I-20139 Milan, Italy.
   [Darbre, Philippa] Univ Reading, Sch Biol Sci, Reading RG6 6LA, Berks, England.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, MTA TTK Lendulet Canc Biomarker Res Grp, H-1117 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, MTA SE Pediat & Nephrol Res Grp, H-1117 Budapest, Hungary.
   [Woodley, Laura] Charing Cross Hosp, ECMC, London W12 0NN, England.
   [Vircillo, Valentina] Univ Calabria, Dept Pharm Hlth & Nutr Sci, I-87036 Arcavacata Di Rende, CS, Italy.
C3 Imperial College London; IRCCS European Institute of Oncology (IEO);
   University of Reading; Hungarian Research Network; HUN-REN Research
   Centre for Natural Sciences; Semmelweis University; Semmelweis
   University; Imperial College London; University of Calabria
RP Magnani, L (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England.
EM l.magnani@imperial.ac.uk
RI Castellano, Leandro/AAE-1366-2021; Ali, Simak/N-4740-2019; Minucci,
   Saverio/J-9669-2012; Barozzi, Iros/GLQ-8907-2022; periyasamy,
   manikandan/AAB-7924-2020; Rodriguez Meira, Alba/IQW-6288-2023; Gyorffy,
   Balazs/AAA-9135-2021; magnani, luca/N-1094-2015; Steel,
   Jennifer/B-4737-2013; Ali, Simak/M-6912-2018; Frige,
   Gianmaria/AAC-5782-2022
OI magnani, luca/0000-0002-7534-0785; Minucci, Saverio/0000-0001-5678-536X;
   Steel, Jennifer/0000-0003-4439-0090; Rodriguez Meira,
   Alba/0000-0001-9630-6968; Castellano, Leandro/0000-0002-3059-4829;
   Periyasamy, Manikandan/0000-0001-7626-2531; Gyorffy,
   Balazs/0000-0002-5772-3766; Barozzi, Iros/0000-0003-0690-3473; Ali,
   Simak/0000-0002-1320-0816; Frige, Gianmaria/0000-0003-3253-7091;
   Coombes, Raoul Charles/0000-0002-4811-1100
FU Imperial Junior Research Fellowship; Wellcome Trust [103034/Z/13/Z];
   OTKA [K108655]; National Institute for Health Research (NIHR) Biomedical
   Research Centre; Experimental Cancer Medicine Centre; Cancer Research UK
   Centre at Imperial College Healthcare NHS Trust, Imperial College,
   London; Wellcome Trust [103034/Z/13/Z] Funding Source: Wellcome Trust
FX This work was supported by an Imperial Junior Research Fellowship to
   L.M. and a Wellcome Trust grant (103034/Z/13/Z) to D.K.P. and the OTKA
   K108655 grant to B.G. We wish to thank Mrs Lorna Watson for her help
   with the manuscript. The Imperial College Healthcare NHS Trust Tissue
   Bank provided tissue samples. Other investigators may have received
   samples from these same tissues. The research was supported by the
   National Institute for Health Research (NIHR) Biomedical Research
   Centre, the Experimental Cancer Medicine Centre and the Cancer Research
   UK Centre at Imperial College Healthcare NHS Trust, Imperial College,
   London. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Ahern TP, 2014, LANCET ONCOL, V15, pE461, DOI 10.1016/S1470-2045(14)70119-6
   Ahern TP, 2011, JNCI-J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291
   Bao T, 2012, BREAST CANCER RES TR, V131, P709, DOI 10.1007/s10549-011-1859-6
   Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031
   BRIGGS MR, 1993, J BIOL CHEM, V268, P14490
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood-2009-07-230508
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Dowen JM, 2014, CELL, V159, P374, DOI 10.1016/j.cell.2014.09.030
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007
   Kobayashi Y, 2015, CLIN CANCER RES, V21, P4652, DOI 10.1158/1078-0432.CCR-14-3368
   Lin ML, 2015, ONCOTARGET, V6, P21685, DOI 10.18632/oncotarget.3942
   Lombardo Y, 2012, P NATL ACAD SCI USA, V109, P16558, DOI 10.1073/pnas.1206268109
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Magnani L, 2015, ONCOTARGET, V6, P21878, DOI 10.18632/oncotarget.4243
   Magnani L, 2014, MOL CELL ENDOCRINOL, V382, P633, DOI 10.1016/j.mce.2013.04.026
   Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   Malik AN, 2014, NAT NEUROSCI, V17, P1330, DOI 10.1038/nn.3808
   Martin LA, 2011, STEROIDS, V76, P772, DOI 10.1016/j.steroids.2011.02.035
   Miller WR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2611
   Miller WR, 2009, J CLIN ONCOL, V27, P1382, DOI 10.1200/JCO.2008.16.8849
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Pagani O, 2014, NEW ENGL J MED, V371, P107, DOI 10.1056/NEJMoa1404037
   Palmieri C, 2014, MOL CELL ENDOCRINOL, V382, P695, DOI 10.1016/j.mce.2013.08.001
   Parris TZ, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.8
   Pasquali L, 2014, NAT GENET, V46, P136, DOI 10.1038/ng.2870
   Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039
   Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833
   Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005
   Stasevich TJ, 2014, NATURE, V516, P272, DOI 10.1038/nature13714
   Suvà ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030
   Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081
   Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641
   Warita K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07593
   Warner M, 2014, NEW ENGL J MED, V370, P572, DOI 10.1056/NEJMcibr1315176
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006
   Xie W, 2013, CELL, V153, P1134, DOI 10.1016/j.cell.2013.04.022
   Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064
   YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 55
TC 101
Z9 105
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV
PY 2015
VL 6
AR 10044
DI 10.1038/ncomms10044
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CY4KD
UT WOS:000366376100001
PM 26610607
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Huang, L
   Holtzinger, A
   Jagan, I
   BeGora, M
   Lohse, I
   Ngai, N
   Nostro, C
   Wang, RN
   Muthuswamy, LB
   Crawford, HC
   Arrowsmith, C
   Kalloger, SE
   Renouf, DJ
   Connor, AA
   Cleary, S
   Schaeffer, DF
   Roehrl, M
   Tsao, MS
   Gallinger, S
   Keller, G
   Muthuswamy, SK
AF Huang, Ling
   Holtzinger, Audrey
   Jagan, Ishaan
   BeGora, Michael
   Lohse, Ines
   Ngai, Nicholas
   Nostro, Cristina
   Wang, Rennian
   Muthuswamy, Lakshmi B.
   Crawford, Howard C.
   Arrowsmith, Cheryl
   Kalloger, Steve E.
   Renouf, Daniel J.
   Connor, Ashton A.
   Cleary, Sean
   Schaeffer, David F.
   Roehrl, Michael
   Tsao, Ming-Sound
   Gallinger, Steven
   Keller, Gordon
   Muthuswamy, Senthil K.
TI Ductal pancreatic cancer modeling and drug screening using human
   pluripotent stem cell- and patient-derived tumor organoids
SO NATURE MEDICINE
LA English
DT Article
ID IN-VITRO; BREAST-CANCER; BETA-CELLS; TRANSCRIPTION; GENERATION;
   MANAGEMENT; CULTURE; SOX9
AB There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53(R175H) induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and fat drug screening to identify precision therapy strategies.
C1 [Huang, Ling; Holtzinger, Audrey; Jagan, Ishaan; BeGora, Michael; Lohse, Ines; Ngai, Nicholas; Nostro, Cristina; Muthuswamy, Lakshmi B.; Arrowsmith, Cheryl; Roehrl, Michael; Tsao, Ming-Sound; Keller, Gordon; Muthuswamy, Senthil K.] Univ Toronto, UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Holtzinger, Audrey; Nostro, Cristina; Keller, Gordon] UHN, McEwen Ctr Regenerat Med, Toronto, ON, Canada.
   [Wang, Rennian] Univ Western Ontario, Dept Physiol, London, ON, Canada.
   [Wang, Rennian] Univ Western Ontario, Dept Pharmacol, London, ON, Canada.
   [Crawford, Howard C.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Crawford, Howard C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Arrowsmith, Cheryl] Struct Genom Consortium, Toronto, ON, Canada.
   [Kalloger, Steve E.; Schaeffer, David F.] Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada.
   [Kalloger, Steve E.; Renouf, Daniel J.; Schaeffer, David F.] Univ British Columbia, Dept Med, Vancouver, BC, Canada.
   [Kalloger, Steve E.; Renouf, Daniel J.; Schaeffer, David F.] Pancreas Ctr British Columbia, Vancouver, BC, Canada.
   [Renouf, Daniel J.] British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada.
   [Connor, Ashton A.; Cleary, Sean; Gallinger, Steven] Univ Toronto, Div Gen Surg, Toronto, ON, Canada.
   [Tsao, Ming-Sound] UHN, Dept Pathol, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; University Health Network
   Toronto; Western University (University of Western Ontario); Western
   University (University of Western Ontario); University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan; University of Toronto; Structural Genomics
   Consortium; University of British Columbia; University of British
   Columbia; British Columbia Cancer Agency; University of Toronto;
   University of Toronto; University Health Network Toronto
RP Muthuswamy, SK (通讯作者)，Univ Toronto, UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada.
EM smuthusw@bidmc.harvard.edu
RI Muthuswamy, Senthil/AGY-2834-2022; Roehrl, Michael/AAU-8506-2020; huang,
   ling/ABB-1647-2020; Tsao, Ming/M-3503-2017; Begora,
   Michael/LXA-7341-2024; Gallinger, Steven/E-4575-2013
OI Nostro, Maria Cristina/0000-0003-1166-8252; Connor,
   Ashton/0000-0002-7596-3771; Muthuswamy, Senthil K/0000-0001-6564-9634;
   Keller, Gordon/0000-0001-9309-9297; Arrowsmith,
   Cheryl/0000-0002-4971-3250; Tsao, Ming/0000-0002-9160-5405; huang,
   ling/0000-0001-8855-788X
FU Ontario Institute for Cancer Research (OICR) PanCuRx program; Canadian
   Cancer Society; Lee K Margaret Lau Chair for Breast Cancer Research;
   AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for
   Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative
   Medicines Initiative (EU/EFPIA) (ULTRA-DD grant) [115766]; Janssen;
   Merck and Co.; Novartis Pharma AG; Ontario Ministry of Economic
   Development and Innovation; Pfizer; Sao Paulo Research Foundation
   (FAPESP); Takeda; Wellcome Trust; Ontario Ministry of Health and Long
   Term Care (OMOHLTC); Campbell Family Institute for Breast cancer
   research
FX We thank members of S.K.M.'s laboratory for helpful suggestions and
   discussions, D. Barsyte-Lovejoy for helping with epigenetic drug
   screening experiments and members of the PanCuRx team, including D.
   Hedley, for support and assistance. This work was supported by the
   Ontario Institute for Cancer Research (OICR) PanCuRx program; Canadian
   Cancer Society; Lee K Margaret Lau Chair for Breast Cancer Research and
   Campbell Family Institute for Breast cancer research to S.K.M. The
   Structural Genomics Consortium is a registered charity (number 1097737)
   that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim,
   Canada Foundation for Innovation, Eshelman Institute for Innovation,
   Genome Canada, Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD
   grant 115766), Janssen, Merck and Co., Novartis Pharma AG, Ontario
   Ministry of Economic Development and Innovation, Pfizer, Sao Paulo
   Research Foundation (FAPESP), Takeda, and the Wellcome Trust. This was
   also funded in part by the Ontario Ministry of Health and Long Term Care
   (OMOHLTC). The views expressed do not necessarily reflect those of the
   OMOHLTC.
CR Agbunag C, 2006, METHOD ENZYMOL, V407, P703, DOI 10.1016/S0076-6879(05)07055-2
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086
   Chakravarty G, 2011, CANCER BIOL THER, V11, P71, DOI 10.4161/cbt.11.1.13952
   Chang DK, 2014, CURR OPIN GENET DEV, V24, P74, DOI 10.1016/j.gde.2013.12.001
   Ghaneh P, 2008, POSTGRAD MED J, V84, P478, DOI 10.1136/gut.2006.103333
   Hick AC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-66
   Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204
   Jennings RE, 2013, DIABETES, V62, P3514, DOI 10.2337/db12-1479
   Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001
   Kanji ZS, 2013, CAN MED ASSOC J, V185, P1219, DOI 10.1503/cmaj.121368
   Kolodecik T, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00415
   LAITIO M, 1974, J ANAT, V117, P619
   Li XN, 2014, NAT MED, V20, P769, DOI 10.1038/nm.3585
   Lyttle BM, 2008, DIABETOLOGIA, V51, P1169, DOI 10.1007/s00125-008-1006-z
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   McCracken KW, 2012, SEMIN CELL DEV BIOL, V23, P656, DOI 10.1016/j.semcdb.2012.06.009
   Nielsen SK, 2008, DEV DYNAM, V237, P2039, DOI 10.1002/dvdy.21610
   OUTZEN HC, 1981, TRANSPLANTATION, V32, P101, DOI 10.1097/00007890-198108000-00004
   Pagliuca FW, 2014, CELL, V159, P428, DOI 10.1016/j.cell.2014.09.040
   Pan FC, 2011, DEV DYNAM, V240, P530, DOI 10.1002/dvdy.22584
   Rezania A, 2014, NAT BIOTECHNOL, V32, P1121, DOI 10.1038/nbt.3033
   Riedel MJ, 2012, DIABETOLOGIA, V55, P372, DOI 10.1007/s00125-011-2344-9
   Schiesser JV, 2014, ANN NY ACAD SCI, V1311, P124, DOI 10.1111/nyas.12369
   van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
NR 28
TC 549
Z9 625
U1 10
U2 162
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2015
VL 21
IS 11
BP 1364
EP 1371
DI 10.1038/nm.3973
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA CV9QH
UT WOS:000364621200023
PM 26501191
OA Green Accepted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Xiao, XM
   Xiao, YY
   Wen, RL
   Zhang, YH
   Li, XX
   Wang, HL
   Huang, JQ
   Liu, JH
   Long, TD
   Tang, J
AF Xiao, Xiaomin
   Xiao, Yingying
   Wen, Ruiling
   Zhang, Yuhua
   Li, Xiaoxia
   Wang, Haoli
   Huang, Jianqiong
   Liu, Jiahua
   Long, Tiandi
   Tang, Jun
TI Promoting roles of the secreted frizzled-related protein 2 as a Wnt
   agonist in lung cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE secreted frizzled-related protein 2; cell proliferation; cell invasion;
   lung cancer; Wnt pathway
ID FREQUENT EPIGENETIC INACTIVATION; MAMMARY-GLAND TUMORS; SIGNALING
   PATHWAY; BREAST-CANCER; SFRP GENES; ACTIVATION; CARCINOMA; MOTILITY;
   DISEASE; GROWTH
AB The secreted frizzled-related protein 2 (SFRP2) plays a pivotal role in the Wnt pathway, however, it functions as an agonist or an antagonist is still controversial. We profiled SFRP2 expression in several lung cancer cell lines, and found that A549 and 95-D exhibited the lowest and the highest level of SFRP2, respectively. Then we employed the SFRP2-overexpressing plasmid and siRNA to transfect A549 and 95-D cells, respectively. Through MTT assays, we found that SFRP2 knockdown inhibited cell proliferation, and halted the 95-D cells in G1 phase of the cell cycle by down-regulation of CCND1 and CDK4, indicating that SFRP2 has the ability of promoting lung cancer cell proliferation. We further checked the cell properties of migration and invasion, using wound scratch assay and Transwell assays. The data showed decreased migrated and invasive 95-D cells after SFRP2 knockdown, and the observations were the opposite in the overexpressing model, implying that SFRP2 promoted lung cancer cell invasion. Moreover, the canonical Wnt pathway was also studied through detection of beta-catenin by western blotting. In the SFRP2 overexpressing model, A549 cells presented stronger expression of P-catenin compared with controls, while it was the opposite in 95-D cells. These results suggested that SFRP2 serves as a Wnt agonist in lung cancer cells. Together, the findings of this study implied that SFRP2 is not only an agonist of Wnt pathway, but also a cancer promoting protein for lung cancer, indicating SFRP2 as a promising therapeutic target for lung cancer treatment.
C1 [Tang, Jun] Guangzhou Med Univ, KingMed Diagnost, Guangzhou 510330, Guangdong, Peoples R China.
   Guangzhou Med Univ, KingMed Sch Lab Med, Guangzhou 510330, Guangdong, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University
RP Tang, J (通讯作者)，Guangzhou Med Univ, KingMed Diagnost, 2429 XinGang Dong Rd, Guangzhou 510330, Guangdong, Peoples R China.
EM jtanguc@gmail.com
FU Guangzhou Medical University [B147048]; Science and Information
   Technology Bureau of Guangzhou [2011Y1-00022, [2012]224-8]; Science and
   Information Technology Bureau of Guangzhou Haizhu District [2012-ZD-02]
FX This study was supported by grants from Guangzhou Medical University
   (B147048, to J. Tang), the Science and Information Technology Bureau of
   Guangzhou (2011Y1-00022 and [2012]224-8, to J. Tang), and the Science
   and Information Technology Bureau of Guangzhou Haizhu District
   (2012-ZD-02, to J. Tang).
CR Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056
   Clevers H, 2006, CANCER RES, V66, P2, DOI 10.1158/0008-5472.CAN-05-3849
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008-5472.CAN-08-3402
   Fontenot E, 2013, MOL CANCER THER, V12, P685, DOI 10.1158/1535-7163.MCT-12-1066
   Gehmert S, 2008, BIOCHEM BIOPH RES CO, V371, P752, DOI 10.1016/j.bbrc.2008.04.151
   Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Lee JL, 2004, BREAST CANCER RES TR, V84, P139, DOI 10.1023/B:BREA.0000018412.83348.ff
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783
   Sathi GA, 2009, ORAL ONCOL, V45, P856, DOI 10.1016/j.oraloncology.2009.02.001
   Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100
   Shi Y, 2007, ACTA PHARMACOL SIN, V28, P1499, DOI 10.1111/j.1745-7254.2007.00692.x
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Tsuruta JK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086642
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Xiao C, 2014, MOL MED REP, V10, P2293, DOI 10.3892/mmr.2014.2542
NR 27
TC 16
Z9 17
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2015
VL 34
IS 5
BP 2259
EP 2266
DI 10.3892/or.2015.4221
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5NO
UT WOS:000362857300006
PM 26323494
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Narayanan, SP
   Singh, S
   Gupta, A
   Yadav, S
   Singh, SR
   Shukla, S
AF Narayanan, Sathiya Pandi
   Singh, Smriti
   Gupta, Amit
   Yadav, Sandhya
   Singh, Shree Ram
   Shukla, Sanjeev
TI Integrated genomic analyses identify <i>KDM1A</i>'s role in cell
   proliferation via modulating <i>E2F</i> signaling activity and associate
   with poor clinical outcome in oral cancer
SO CANCER LETTERS
LA English
DT Article
DE Oral cancer; Histone demethylase; KDM1A; E2F1 signaling; Cell
   proliferation
ID PROTEIN LYSINE METHYLATION; EPITHELIAL OVARIAN-CANCER; BREAST-CANCER;
   EPIGENETIC MODIFICATIONS; HISTONE DEMETHYLASES; GENE-EXPRESSION;
   PROSTATE-CANCER; STEM-CELLS; LSD1; TRANSCRIPTION
AB The histone demethylase KDM1A specifically demethylates lysine residues and its deregulation has been implicated in the initiation and progression of various cancers. However, KDM1A's molecular role and its pathological consequences, and prognostic significance in oral cancer remain less understood. In the present study, we sought to investigate the expression of KDM1A and its downstream role in oral cancer pathogenesis. By comparing mRNA expression profiles, we identified an elevated KDM1A expression in oral tumors when compared to normal oral tissues. In silica pathway prediction identified the association between KDM1A and E2F1 signaling in oral cancer. Pathway scanning, functional annotation analysis and In vitro assays showed the KDM1A's involvement in oral cancer cell proliferation and the cell cycle. Moreover, real time PCR and luciferase assays confirmed KDM1A's role in regulation of E2F1 signaling activity in oral cancer. Elevated KDM1A expression is associated with poor clinical outcome in oral cancer. Our data indicate that deregulated KDM1A expression is positively associated with proliferative phenotype of oral cancer and confers poor clinical outcome. These cumulative data suggest that KDM1A might be a potential diagnostic and therapeutic target for oral cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Narayanan, Sathiya Pandi; Singh, Smriti; Gupta, Amit; Yadav, Sandhya; Shukla, Sanjeev] IISERB, ERPL, Bhopal, Madhya Pradesh, India.
   [Singh, Shree Ram] NCI, Basic Res Lab, Ctr Canc Res, Frederick, MD 21702 USA.
C3 Indian Institute of Science Education & Research (IISER) - Bhopal;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Shukla, S (通讯作者)，IISERB, ERPL, Bhopal, Madhya Pradesh, India.
EM singhshr@mail.nih.gov; sanjeevs@iiserb.ac.in
RI Narayanan, Sathiya Pandi/AFS-0744-2022; Gupta, Amit/ABI-1617-2020;
   Shukla, Sanjeev/L-8391-2018; Singh, Smriti/LTF-1452-2024; Singh, Shree
   Ram/B-7614-2008
OI Shukla, Sanjeev/0000-0003-3361-0588; Yadav, Sandhya/0000-0002-0443-2439;
   Sathiya Pandi, Narayanan/0000-0001-6307-0493; Singh,
   Smriti/0000-0001-5731-7285; Singh, Shree Ram/0000-0001-6545-583X; Gupta,
   Amit/0000-0003-3752-5081
FU IISER Bhopal; Ministry of Human Resource Development; Council of
   Scientific & Industrial Research
FX We thank IISER Bhopal for Intramural research funds. We thank Ministry
   of Human Resource Development for fellowships to Dr. Sathiya Pandi, Ms.
   Smriti Singh and Mr. Amit Gupta. We thank Council of Scientific &
   Industrial Research for fellowship to Ms. Sandhya Yadav.
CR Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002
   Andruska N, 2015, ONCOGENE, V34, P3760, DOI 10.1038/onc.2014.292
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Baykul T, 2010, J INT MED RES, V38, P737, DOI 10.1177/147323001003800302
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Chen C, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0155-1
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Cho HS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2074
   Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176
   Crea F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-52
   Derr RS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-604
   Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ferlay J., GLOBOCAN 2012 V1 0
   Ford PJ, 2013, J Cancer Policy, V1, pE2, DOI 10.1016/j.jcpo.2013.04.002
   Gotea V, 2008, NUCLEIC ACIDS RES, V36, pW133, DOI 10.1093/nar/gkn300
   Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x
   Gupta B, 2013, INT DENT J, V63, P12, DOI 10.1111/j.1875-595x.2012.00131.x
   Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884
   He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109
   Hoffmann I, 2012, MOL ONCOL, V6, P683, DOI 10.1016/j.molonc.2012.07.004
   Hung JJ, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-18
   Kaimal V, 2010, NUCLEIC ACIDS RES, V38, pW96, DOI 10.1093/nar/gkq418
   Kampranis SC, 2009, ADV CANCER RES, V102, P103, DOI 10.1016/S0065-230X(09)02004-1
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lan WH, 2013, MED HYPOTHESES, V81, P823, DOI 10.1016/j.mehy.2013.09.005
   Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Messadi Diana V, 2009, J Calif Dent Assoc, V37, P789
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Nagasawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118002
   Pajtler KW, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-19
   Sciubba J J, 2001, Am J Clin Dermatol, V2, P239, DOI 10.2165/00128071-200102040-00005
   Shah FD, 2011, INDIAN J CLIN BIOCHE, V26, P326, DOI 10.1007/s12291-011-0149-8
   Shah JP, 2009, ORAL ONCOL, V45, P394, DOI 10.1016/j.oraloncology.2008.05.017
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shukla S, 2014, BBA-GEN SUBJECTS, V1840, P3494, DOI 10.1016/j.bbagen.2014.09.017
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09
   Theisen ER, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-752
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Venkatesh S, 2015, NAT REV MOL CELL BIO, V16, P178, DOI 10.1038/nrm3941
   Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221
   Wen N, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-134
   Worku D, 2008, ANTICANCER RES, V28, P2135
   Yuan CP, 2015, J ORAL PATHOL MED, V44, P159, DOI 10.1111/jop.12220
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 55
TC 15
Z9 16
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 28
PY 2015
VL 367
IS 2
BP 162
EP 172
DI 10.1016/j.canlet.2015.07.022
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CQ9QJ
UT WOS:000360949600011
PM 26225839
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Chen, CC
   Lee, KD
   Pai, MY
   Chu, PY
   Hsu, CC
   Chiu, CC
   Chen, LT
   Chang, JY
   Hsiao, SH
   Leu, YW
AF Chen, Chih-Cheng
   Lee, Kuan-Der
   Pai, Mei-Yu
   Chu, Pei-Yi
   Hsu, Chia-Chen
   Chiu, Chia-Chen
   Chen, Li-Tzong
   Chang, Jang-Yang
   Hsiao, Shu-Huei
   Leu, Yu-Wei
TI Changes in DNA methylation are associated with the development of drug
   resistance in cervical cancer cells
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE DNA methylation; DRUG; Cancer
ID EPIGENETIC GENE-REGULATION; MESENCHYMAL STEM-CELLS; BREAST-CANCER;
   PROMOTER METHYLATION; TARGETED METHYLATION; COLORECTAL-CANCER;
   GASTRIC-CANCER; TUMOR-GROWTH; KINASE GENE; IN-VIVO
AB Background and propose: Changes in DNA methylation are associated with changes in somatic cell fate without the alteration of coding sequences. In addition to its use as a traceable biomarker, reversible DNA methylation could also serve as a therapeutic target. In particular, if the development of drug resistance is associated with changes in DNA methylation, then demethylation might reverse the resistance phenotype. The reversion of the drug-resistance might then be feasible if the association between abnormal DNA methylation and the development of drug-resistance could be identified.
   Methods: Methylation differences between the drug-resistance cervical cancer cell, SiHa, and its derived oxaliplatin-resistant S3 cells were detected by methylation specific microarray. The drug-resistance cells were treated with demethylation agent to see if the resistance phenotype were reversed. Targeted methylation of one of the identified locus in normal cell is expected to recapitulate the development of resistance and a two-component reporter system is adopted to monitor the increase of DNA methylation in live cells.
   Results: In this report, we identified methylation changes, both genome-wide and within individual loci, in the oxaliplatin-resistant cervical cancer cell S3 compared with its parental cell line SiHa. Treatment of S3 with a demethylation agent reversed increases in methylation and allowed the expression of methylation-silenced genes. Treatment with the demethylation agent also restored the sensitivity of S3 to cisplatin, taxol, and oxaliplatin to the same level as that of SiHa. Finally, we found that methylation of the target gene Casp8AP2 is sufficient to increase drug resistance in different cells.
   Conclusions: These results suggest that global methylation is associated with the development of drug resistance and could serve as a biomarker and therapeutic target for drug resistance in cervical cancer.
C1 [Chen, Chih-Cheng; Lee, Kuan-Der; Chiu, Chia-Chen] Chang Gung Univ, Coll Med, Dept Hematol & Oncol, Chang Gung Mem Hosp, Taoyuan, Taiwan.
   [Chen, Chih-Cheng; Lee, Kuan-Der; Chiu, Chia-Chen] Chang Gung Inst Technol, Taoyuan, Taiwan.
   [Pai, Mei-Yu; Hsu, Chia-Chen; Chiu, Chia-Chen; Hsiao, Shu-Huei; Leu, Yu-Wei] Natl Chung Cheng Univ, Dept Life Sci, Human Epigen Ctr, Chiayi 621, Taiwan.
   [Pai, Mei-Yu; Hsu, Chia-Chen; Chiu, Chia-Chen; Hsiao, Shu-Huei; Leu, Yu-Wei] Natl Chung Cheng Univ, Inst Biomed Sci, Chiayi 621, Taiwan.
   [Chu, Pei-Yi] Show Chwan Mem Hosp, Dept Pathol, Changhua, Taiwan.
   [Chen, Li-Tzong] Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan 350, Miaoli County, Taiwan.
   [Chang, Jang-Yang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Div Hematol Oncol, Dept Internal Med,Coll Med, Tainan 704, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University of Science & Technology; National Chung Cheng University;
   National Chung Cheng University; Show Chwan Memorial Hospital; National
   Health Research Institutes - Taiwan; National Cheng Kung University;
   National Cheng Kung University Hospital
RP Leu, YW (通讯作者)，Natl Chung Cheng Univ, Dept Life Sci, Human Epigen Ctr, Chiayi 621, Taiwan.
EM bioywl@ccu.edu.tw
RI Chang, Jang-Yang/D-2099-2010
OI Chu, Pei-Yi/0000-0001-7336-2465
FU Chang Gung Memorial Hospital [CMR-PG6B0521, CMRPG6B0371]; MoST [MoST
   103-2314-B-182A-090, NSC 102-2320-B-194-003-MY3]; NHRI
   [NHRI-EX102-10259NI]
FX YWL and CCC are supported by Chang Gung Memorial Hospital (CMR-PG6B0521
   and CMRPG6B0371). YWL and KDL are supported by MoST (MoST
   103-2314-B-182A-090). YWL and SHH are supported by MoST (NSC
   102-2320-B-194-003-MY3) and NHRI (NHRI-EX102-10259NI).
CR Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Candelaria M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029181
   Chekhun V. F., 2006, Ukrainskii Biokhimicheskii Zhurnal, V78, P5
   Chen SJ, 2015, BIOCHEM PHARMACOL, V95, P28, DOI 10.1016/j.bcp.2015.03.006
   Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048
   De Carvalho DD, 2010, TRENDS CELL BIOL, V20, P609, DOI 10.1016/j.tcb.2010.08.003
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Farkas SA, 2013, EPIGENETICS-US, V8, P1213, DOI 10.4161/epi.26346
   Finnberg N, 2008, CELL CYCLE, V7, P1525, DOI 10.4161/cc.7.11.5975
   Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Hilakivi-Clarke L, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3649
   Hsiao SH, 2010, BIOCHEM BIOPH RES CO, V400, P305, DOI 10.1016/j.bbrc.2010.08.048
   Hsiao SH, 2009, SEMIN CANCER BIOL, V19, P198, DOI 10.1016/j.semcancer.2009.02.015
   Hsu CC, 2010, BIOCHEM BIOPH RES CO, V402, P228, DOI 10.1016/j.bbrc.2010.09.131
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeong DH, 2006, INT J GYNECOL CANCER, V16, P1234, DOI 10.1111/j.1525-1438.2006.00522.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Kim M, 2012, J ENVIRON SCI HEAL C, V30, P323, DOI 10.1080/10590501.2012.731959
   Koh KP, 2013, CURR OPIN CELL BIOL, V25, P152, DOI 10.1016/j.ceb.2013.02.014
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670
   Lehmann U, 2002, CANCER RES, V62, P6634
   Len YW, 2003, CANCER RES, V63, P6110
   Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133
   Lin YS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-3
   Liu G, 2014, ONCOL REP, V32, P581, DOI 10.3892/or.2014.3224
   Maeda O, 2014, ONCOL REP, V31, P1883, DOI 10.3892/or.2014.3014
   Messerschmidt DM, 2014, GENE DEV, V28, P812, DOI 10.1101/gad.234294.113
   Onda K, 2012, ANTICANCER RES, V32, P4439
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Radford EJ, 2014, SCIENCE, V345, P785, DOI 10.1126/science.1255903
   Si Xinxin, 2014, Yichuan, V36, P411, DOI 10.3724/SP.J.1005.2014.0411
   Siegel EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122495
   Siegmund KD, 2009, P NATL ACAD SCI USA, V106, P4828, DOI 10.1073/pnas.0810276106
   Smith ZD, 2014, NATURE, V511, P611, DOI 10.1038/nature13581
   Sun SY, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-13
   Tang XM, 2004, MOL CANCER RES, V2, P685
   Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Wermann H, 2010, J PATHOL, V221, P433, DOI 10.1002/path.2725
   Yamaguchi S, 2003, CANCER LETT, V194, P99, DOI 10.1016/S0304-3835(03)00055-7
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yan Pearlly S., 2009, V507, P89, DOI 10.1007/978-1-59745-522-0_8
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
NR 52
TC 38
Z9 46
U1 3
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD OCT 13
PY 2015
VL 15
AR 98
DI 10.1186/s12935-015-0248-3
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT3JP
UT WOS:000362703300001
PM 26464562
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Fang, C
   Jian, ZY
   Shen, XF
   Wei, XM
   Yu, GZ
   Zeng, XT
AF Fang, Cheng
   Jian, Zhi-Yuan
   Shen, Xian-Feng
   Wei, Xue-Mei
   Yu, Guo-Zheng
   Zeng, Xian-Tao
TI Promoter Methylation of the Retinoic Acid Receptor Beta2 (RARβ2) Is
   Associated with Increased Risk of Breast Cancer: A PRISMA Compliant
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID DNA HYPERMETHYLATION; CLINICAL-SIGNIFICANCE; ABERRANT METHYLATION;
   CIRCULATING DNA; TUMOR; GENES; ER; POLYMORPHISM; EXPRESSION; REPRESSION
AB Background
   Epigenetic studies demonstrate that an association may exist between methylation of the retinoic acid receptor beta2 (RAR beta 2) gene promoter and breast cancer onset risk, tumor stage, and histological grade, however the results of these studies are not consistent. Hence, we performed this meta-analysis to ascertain a more comprehensive and accurate association.
   Materials and Methods
   Relevant studies were retrieved from the PubMed, Embase and Chinese National Knowledge Infrastructure databases up to February 28, 2015. After two independent reviewers screened the studies and extracted the necessary data, meta-analysis was performed using Review Manager 5.2 software.
   Results
   Nineteen eligible articles, including 20 studies, were included in our analysis. Compared to non-cancerous controls, the frequency of RAR beta 2 methylation was 7.27 times higher in patients with breast cancer (odds ratio (OR) = 7.27, 95% confidence interval (CI) = 3.01-17.52). Compared to late-stage RAR beta 2 methylated patients, the pooled OR of early-stage ones was 0.81 (OR = 0.81, 95% CI = 0.55-1.17). The OR of low-grade RAR beta 2 methylated patients was 0.96 (OR = 0.96, 95% CI = 0.74-1.25) compared to high-grade RAR beta 2 methylated patients.
   Conclusion
   RAR beta 2 methylation is significantly increased in breast cancer samples when compared to non-cancerous controls. RAR beta 2 could serve as a potential epigenetic marker for breast cancer detection and management.
C1 [Fang, Cheng; Yu, Guo-Zheng; Zeng, Xian-Tao] Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based Med & Translat Med, Wuhan 430072, Peoples R China.
   [Jian, Zhi-Yuan; Shen, Xian-Feng] Hubei Univ Med, Taihe Hosp, Dept Gen Surg, Shiyan, Peoples R China.
   [Wei, Xue-Mei] North Sichuan Med Coll, Affiliated Hosp, Dept Nursing, Nanchong 637000, Peoples R China.
C3 Wuhan University; Hubei University of Medicine; North Sichuan Medical
   University
RP Zeng, XT (通讯作者)，Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based Med & Translat Med, Wuhan 430072, Peoples R China.
EM zengxiantao1128@163.com
RI Zhang, Jinwei/Q-7959-2019
OI Zeng, Xian-Tao/0000-0003-1262-725X
CR Bagadi SAR, 2008, LIFE SCI, V82, P1288, DOI 10.1016/j.lfs.2008.04.020
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   Bistulfi G, 2006, CANCER RES, V66, P10308, DOI 10.1158/0008-5472.CAN-06-1052
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Corlazzoli F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004305
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Donepudi MS, 2014, J CANCER RES THER, V10, P506, DOI 10.4103/0973-1482.137927
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng J, 2010, TUMOR BIOL, V31, P321, DOI 10.1007/s13277-010-0040-x
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Hayashi K, 2003, INT J ONCOL, V22, P623
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mirza S, 2012, ANN SURG ONCOL, V19, P3107, DOI 10.1245/s10434-012-2323-5
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Pappas JJ, 2008, GENE CHROMOSOME CANC, V47, P978, DOI 10.1002/gcc.20603
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pirouzpanah S, 2010, CANCER CAUSE CONTROL, V21, P2101, DOI 10.1007/s10552-010-9629-z
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Rykova EY, 2008, ANN NY ACAD SCI, V1137, P232, DOI 10.1196/annals.1448.021
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117
   Swellam M, 2015, IUBMB LIFE, V67, P61, DOI 10.1002/iub.1346
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Tsou HC, 1998, EXP CELL RES, V245, P221, DOI 10.1006/excr.1998.4268
   Van der Auwera I, 2009, CANCER BIOL THER, V8, P2252
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V131, P859, DOI 10.1007/s10549-011-1485-3
   Wang SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037928
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   XU XC, 1994, CANCER RES, V54, P3580
   Zeng XT, 2015, J PERIODONTOL, V86, P812, DOI 10.1902/jop.2015.140698
   Zeng XT, 2015, ORAL ONCOL, V51, P446, DOI 10.1016/j.oraloncology.2015.02.095
   Zeng XT, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-469
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   ZHANG XK, 1994, CANCER RES, V54, P5663
NR 49
TC 15
Z9 15
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2015
VL 10
IS 10
AR e0140329
DI 10.1371/journal.pone.0140329
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CT0TY
UT WOS:000362511200063
PM 26451736
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Smith, L
   Baxter, EW
   Chambers, PA
   Green, CA
   Hanby, AM
   Hughes, TA
   Nash, CE
   Millican-Slater, RA
   Stead, LF
   Verghese, ET
   Speirs, V
AF Smith, Laura
   Baxter, Euan W.
   Chambers, Philip A.
   Green, Caroline A.
   Hanby, Andrew M.
   Hughes, Thomas A.
   Nash, Claire E.
   Millican-Slater, Rebecca A.
   Stead, Lucy F.
   Verghese, Eldo T.
   Speirs, Valerie
TI Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but
   Not Tumour Fibroblasts Contributes to Breast Carcinogenesis
SO PLOS ONE
LA English
DT Article
ID RECEPTOR BETA ISOFORMS; GENE-EXPRESSION; EPIGENETIC REGULATION; STROMAL
   CELLS; TGF-BETA; CANCER; MICRORNAS; GROWTH; ER-BETA-2; SIGNATURE
AB Background
   MicroRNA (miR) expression is commonly dysregulated in many cancers, including breast. MiR-92 is one of six miRs encoded by the miR-17-92 cluster, one of the best-characterised oncogenic miR clusters. We examined expression of miR-92 in the breast epithelium and stroma during breast cancer progression. We also investigated the role of miR-92 in fibroblasts in vitro and showed that down-regulation in normal fibroblasts enhances the invasion of breast cancer epithelial cells.
   Methodology/Principal Findings
   We used laser microdissection (LMD) to isolate epithelial cells from matched normal, DCIS and invasive tissue from 9 breast cancer patients and analysed miR-92 expression by qRT-PCR. Expression of ER beta 1, a direct miR-92 target, was concurrently analysed for each case by immunohistochemistry. LMD was also used to isolate matched normal (NFs) and cancer-associated fibroblasts (CAFs) from 14 further cases. Effects of miR-92 inhibition in fibroblasts on epithelial cell invasion in vitro was examined using a Matrigel T assay. miR-92 levels decreased in microdissected epithelial cells during breast cancer progression with highest levels in normal breast epithelium, decreasing in DCIS (p<0.01) and being lowest in invasive breast tissue (p<0.01). This was accompanied by a shift in cell localisation of ER beta 1 from nuclear expression in normal breast epithelium to increased cytoplasmic expression during progression to DCIS (p = 0.0078) and invasive breast cancer (p = 0.031). ER beta 1 immunoreactivity was also seen in stromal fibroblasts in tissues. Where miR-92 expression was low in microdissected NFs this increased in matched CAFs; a trend also seen in cultured primary fibroblasts. Down-regulation of miR-92 levels in NFs but not CAFs enhanced invasion of both MCF-7 and MDA-MB-231 breast cancer epithelial cells.
   Conclusions
   miR-92 is gradually lost in breast epithelial cells during cancer progression correlating with a shift in ER beta 1 immunoreactivity from nuclei to the cytoplasm. Our data support a functional role in fibroblasts where modification of miR-92 expression can influence the invasive capacity of breast cancer epithelial cells. However in silico analysis suggests that ER beta 1 may not be the most important miR-92 target in breast cancer.
C1 [Smith, Laura; Baxter, Euan W.; Chambers, Philip A.; Green, Caroline A.; Hanby, Andrew M.; Nash, Claire E.; Stead, Lucy F.; Verghese, Eldo T.; Speirs, Valerie] Univ Leeds, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England.
   [Hughes, Thomas A.] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England.
   [Millican-Slater, Rebecca A.] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England.
C3 University of Leeds; University of Leeds; Saint James's University
   Hospital
RP Speirs, V (通讯作者)，Univ Leeds, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England.
EM v.speirs@leeds.ac.uk
RI Speirs, Valerie/ABE-7377-2021; Stead, Lucy/H-7378-2019; Hughes,
   Thomas/O-8031-2015
OI Hughes, Thomas/0000-0003-1169-3386; Chambers,
   Philip/0000-0002-0926-717X; Stead, Lucy/0000-0002-9550-4150; Speirs,
   Valerie/0000-0002-0602-4666; Millican-Slater,
   Rebecca/0000-0001-6280-4598
FU Breast Cancer [2010NovPR56, TB2009LEE]; Medical Research Council
   [G0902032]; Yorkshire Cancer Research Grant [L316]; MRC [G0902032]
   Funding Source: UKRI
FX Funded by Breast Cancer Now (formerly Breast Cancer Campaign) Grant
   numbers 2010NovPR56, TB2009LEE (http://breastcancernow.org/) to VS,
   Medical Research Council Grant number G0902032 (http://www.mrc.ac.uk/)
   to ETV, and Yorkshire Cancer Research Grant number L316
   (http://yorkshirecancerresearch.org.uk/) to VS. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Nakhle H, 2010, CANCER RES, V70, P4778, DOI 10.1158/0008-5472.CAN-09-4104
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237
   Busch S, 2015, ONCOGENE, V34, P27, DOI 10.1038/onc.2013.527
   Chan M, 2013, CLIN CANCER RES, V19, P4477, DOI 10.1158/1078-0432.CCR-12-3401
   Chen Beibei, 2012, Int J Cell Biol, V2012, P672462, DOI 10.1155/2012/672462
   Ciucci A, 2014, GYNECOL ONCOL, V132, P351, DOI 10.1016/j.ygyno.2013.12.027
   Cummings M, 2009, CELL ONCOL, V31, P467, DOI 10.3233/CLO-2009-0495
   Dakhlallah D, 2013, AM J RESP CRIT CARE, V187, P397, DOI 10.1164/rccm.201205-0888OC
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jones DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044294
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444
   Manni I, 2009, FASEB J, V23, P3957, DOI 10.1096/fj.09-131847
   Nilsson S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036051
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Owens P, 2012, P NATL ACAD SCI USA, V109, P2814, DOI 10.1073/pnas.1101139108
   Pardo I, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3627
   Pospisil V, 2011, EMBO J, V30, P4450, DOI 10.1038/emboj.2011.317
   Pouliot F, 2003, CANCER RES, V63, P277
   RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528
   Si HY, 2013, J CANCER RES CLIN, V139, P223, DOI 10.1007/s00432-012-1315-y
   Siletz A, 2013, CANCER MICROENVIRON, V6, P91, DOI 10.1007/s12307-012-0121-z
   Simpkins SA, 2012, J PATHOL, V227, P490, DOI 10.1002/path.4034
   Smith L, 2010, J CELL MOL MED, V14, P2172, DOI 10.1111/j.1582-4934.2009.00867.x
   Smith L, 2010, BIOCHEM J, V429, P283, DOI 10.1042/BJ20100373
   Tili E, 2010, NUCLEIC ACIDS RES, V38, P7673, DOI 10.1093/nar/gkq637
   Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Tripathi A, 2008, INT J CANCER, V122, P1557, DOI 10.1002/ijc.23267
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhao LY, 2012, INT J BIOCHEM CELL B, V44, P2051, DOI 10.1016/j.biocel.2012.08.005
NR 51
TC 18
Z9 20
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 5
PY 2015
VL 10
IS 10
AR e0139698
DI 10.1371/journal.pone.0139698
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CT0PR
UT WOS:000362499200051
PM 26437339
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Dötsch, MM
   Kloten, V
   Schlensog, M
   Heide, T
   Braunschweig, T
   Veeck, J
   Petersen, I
   Knüchel, R
   Dahl, E
AF Doetsch, Magnus Mathias
   Kloten, Vera
   Schlensog, Martin
   Heide, Timon
   Braunschweig, Till
   Veeck, Juergen
   Petersen, Iver
   Knuechel, Ruth
   Dahl, Edgar
TI Low expression of ITIH5 in adenocarcinoma of the lung is associated with
   unfavorable patients' outcome
SO EPIGENETICS
LA English
DT Article
DE biomarker; DNA-methylation; non-small-cell lung cancer (NSCLC); gene
   signature; ITIH5; intrinsic expression subtype
ID URINARY TRYPSIN-INHIBITOR; GENE-EXPRESSION; BREAST-CANCER; EPIGENETIC
   INACTIVATION; CLASSIFICATION; METHYLATION; SURVIVAL; MUTATION; RECEPTOR
AB Inter--trypsin inhibitor heavy chain 5 (ITIH5) is supposed to be involved in extracellular matrix stability and thus may play a key role in the inhibition of tumor progression. The current study is the first to analyze in depth ITIH5 expression and DNA methylation, as well as its potential clinical impact in non-small-cell lung carcinoma (NSCLC). We examined ITIH5 mRNA expression in tumor and adjacent normal lung tissue specimens of NSCLC patients. In addition, methylation frequency of the ITIH5 promoter was investigated using methylation-specific PCR and pyrosequencing. Significance of our data was validated by independent data sets from The Cancer Genome Atlas and the Kaplan-Meier Plotter platform. Furthermore, ITIH5 protein expression was evaluated by immunohistochemistry utilizing a tissue microarray with 385 distinct lung tissue samples. Based on our tissue collections, ITIH5 mRNA expression was significantly decreased in NSCLC compared to normal lung tissue in line with an increased methylation frequency in lung cancer tissue. Independent TCGA data confirmed significant expression loss of ITIH5 in lung cancer concordant with ITIH5 promoter hypermethylation in NSCLC. Of interest, low ITIH5 mRNA expression was particularly found in the magnoid and squamoid ADC expression subtype, concordant with an unfavorable patients' outcome in squamoid as well as tobacco smoking ADC patients. In conclusion, ITIH5 may be a novel putative tumor suppressor gene in NSCLC with a potential molecular significance in the squamoid ADC subtype and further clinical impact for risk stratification of adenocarcinoma patients. In addition, ITIH5 may serve as a novel biomarker for prognosis of tobacco smoking ADC patients.
C1 [Doetsch, Magnus Mathias; Kloten, Vera; Schlensog, Martin; Heide, Timon; Braunschweig, Till; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Aachen, Germany.
   [Veeck, Juergen; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, RWTH Cent Biomat Bank, Aachen, Germany.
   [Petersen, Iver] Univ Hosp Jena, Inst Pathol, Jena, Germany.
C3 RWTH Aachen University; RWTH Aachen University; Friedrich Schiller
   University of Jena
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Aachen, Germany.
EM edahl@ukaachen.de
RI Braunschweig, Till/AAO-5725-2020
OI Braunschweig, Till/0000-0001-9166-2912
CR Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Hayes DN, 2006, J CLIN ONCOL, V24, P5079, DOI 10.1200/JCO.2005.05.1748
   HUANG L, 1993, J BIOL CHEM, V268, P26725
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Kloten V, 2014, EPIGENETICS-US, V9, P1290, DOI 10.4161/epi.32089
   KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361
   KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326
   Kohler LH, 2012, VIRCHOWS ARCH, V461, P49, DOI 10.1007/s00428-012-1250-y
   Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282
   Noetzel E, 2010, ONCOGENE, V29, P4814, DOI 10.1038/onc.2010.229
   Oing C, 2011, CLIN EPIGENETICS, V2, P419, DOI 10.1007/s13148-011-0043-5
   Pao W, 2012, NAT MED, V18, P349, DOI 10.1038/nm.2697
   Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5
   Park YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044225
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Subramanian J, 2010, JNCI-J NATL CANCER I, V102, P464, DOI 10.1093/jnci/djq025
   Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224
   Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, Pathologe, V29 Suppl 2, P338, DOI 10.1007/s00292-008-1044-9
   Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185
   Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530
NR 31
TC 31
Z9 31
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD OCT 3
PY 2015
VL 10
IS 10
BP 903
EP 912
DI 10.1080/15592294.2015.1078049
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CT1KG
UT WOS:000362556600002
PM 26252352
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Watanabe, K
   Amano, Y
   Ishikawa, R
   Sunohara, M
   Kage, H
   Ichinose, J
   Sano, A
   Nakajima, J
   Fukayama, M
   Yatomi, Y
   Nagase, T
   Ohishi, N
   Takai, D
AF Watanabe, Kousuke
   Amano, Yosuke
   Ishikawa, Rie
   Sunohara, Mitsuhiro
   Kage, Hidenori
   Ichinose, Junji
   Sano, Atsushi
   Nakajima, Jun
   Fukayama, Masashi
   Yatomi, Yutaka
   Nagase, Takahide
   Ohishi, Nobuya
   Takai, Daiya
TI Histone methylation-mediated silencing of miR-139 enhances invasion of
   non-small-cell lung cancer
SO CANCER MEDICINE
LA English
DT Article
DE Epigenetic repression; histones; lung neoplasms; microRNAs; neoplasm
   metastasis
ID DOWN-REGULATION; MICRORNAS; DISRUPTION; EXPRESSION; GENES
AB MicroRNA expression is frequently altered in human cancers, and some microRNAs act as oncogenes or tumor suppressors. MiR-139-5p (denoted thereafter as miR-139) has recently been reported to function as a tumor suppressor in several types of human cancer (hepatocellular carcinoma, colorectal cancer, breast cancer, and gastric cancer), but its function in non-small-cell lung cancer (NSCLC) and the mechanism of its suppression have not been studied in detail. MiR-139 was suppressed frequently in primary NSCLCs. MiR-139 is located within the intron of PDE2A and its expression was significantly correlated with the expression of PDE2A. A chromatin immunoprecipitation assay revealed that miR-139 was epigenetically silenced by histone H3 lysine 27 trimethylation (H3K27me3) of its host gene PDE2A and this process was independent of promoter DNA methylation. Pharmacological inhibition of both histone methylation and deacetylation-induced miR-139 with its host gene PDE2A. Ectopic expression of miR-139 in lung cancer cell lines did not affect the proliferation nor the migration but significantly suppressed the invasion through the extracellular matrix. In primary NSCLCs, decreased expression of miR-139 was significantly associated with distant lymph node metastasis and histological invasiveness (lymphatic invasion and vascular invasion) on both univariate and multivariate analyses. Collectively, these results suggest that H3K27me3-mediated silencing of miR-139 enhances an invasive and metastatic phenotype of NSCLC.
C1 [Watanabe, Kousuke; Amano, Yosuke; Ishikawa, Rie; Sunohara, Mitsuhiro; Kage, Hidenori; Nagase, Takahide; Ohishi, Nobuya] Tokyo Univ Hosp, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Ichinose, Junji; Sano, Atsushi; Nakajima, Jun] Tokyo Univ Hosp, Dept Cardiothorac Surg, Bunkyo Ku, Tokyo 1138655, Japan.
   [Fukayama, Masashi] Tokyo Univ Hosp, Dept Pathol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Yatomi, Yutaka; Takai, Daiya] Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo;
   University of Tokyo
RP Takai, D (通讯作者)，Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM dtakai-ind@umin.ac.jp
RI Sano, Atsushi/E-5868-2013; Kage, Hidenori/LMM-9773-2024; Ichinose,
   Junji/K-9662-2019; Nagase, Takeshi/M-1189-2015
OI Yatomi, Yutaka/0000-0003-1719-4297; Nakajima, Jun/0000-0003-1174-0816;
   Nagase, Takeshi/0000-0003-4868-0773; Watanabe,
   Kousuke/0000-0003-4670-3679
FU Takeda Science Foundation; Japan Society for the Promotion of Science,
   KAKENHI [23390147, 24659267, 24501339, 24791455]; Grants-in-Aid for
   Scientific Research [24791455, 24501339, 15K20917] Funding Source: KAKEN
FX This work was supported by Takeda Science Foundation, Japan Society for
   the Promotion of Science, KAKENHI (Grant Numbers: 23390147, 24659267,
   24501339, 24791455).
CR [Anonymous], 2001, MOL CLONING
   Arora S, 2011, INT J CANCER, V129, P2621, DOI 10.1002/ijc.25939
   Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   Kitano K, 2011, CANCER SCI, V102, P2126, DOI 10.1111/j.1349-7006.2011.02101.x
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Krishnan K, 2013, RNA, V19, P1767, DOI 10.1261/rna.042143.113
   Kusakabe M, 2009, BIOCHEM BIOPH RES CO, V390, P1283, DOI 10.1016/j.bbrc.2009.10.137
   Liu R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077068
   Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108
   Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Shen K, 2012, BIOCHEM PHARMACOL, V84, P320, DOI 10.1016/j.bcp.2012.04.017
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Watanabe Kousuke, 2013, Frontiers in Genetics, V4, P275, DOI 10.3389/fgene.2013.00275
   Watanabe K, 2012, INT J CANCER, V130, P2580, DOI 10.1002/ijc.26254
   Weksberg R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-180
   Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124
NR 28
TC 39
Z9 43
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD OCT
PY 2015
VL 4
IS 10
BP 1573
EP 1582
DI 10.1002/cam4.505
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT4RI
UT WOS:000362794000011
PM 26256448
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Gentilini, D
   Garagnani, P
   Pisoni, S
   Bacalini, MG
   Calzari, L
   Mari, D
   Vitale, G
   Franceschi, C
   Di Blasio, AM
AF Gentilini, Davide
   Garagnani, Paolo
   Pisoni, Serena
   Bacalini, Maria Giulia
   Calzari, Luciano
   Mari, Daniela
   Vitale, Giovanni
   Franceschi, Claudio
   Di Blasio, Anna Maria
TI Stochastic epigenetic mutations (DNA methylation) increase exponentially
   in human aging and correlate with X chromosome inactivation skewing in
   females
SO AGING-US
LA English
DT Article
DE epimutations; DNA methylation; aging; X chromosome inactivation skewing;
   epigenetics
ID BREAST-CANCER; BLOOD-CELLS; AGE; WOMEN; HYPOMETHYLATION; CENTENARIANS;
   LONGEVITY; FREQUENCY; DIETS; RATES
AB In this study we applied a new analytical strategy to investigate the relations between stochastic epigenetic mutations (SEMs) and aging. We analysed methylation levels through the Infinium HumanMethylation27 and HumanMethylation450 BeadChips in a population of 178 subjects ranging from 3 to 106 years. For each CpG probe, epimutated subjects were identified as the extreme outliers with methylation level exceeding three times interquartile ranges the first quartile (Q1-(3 x IQR)) or the third quartile (Q3+(3 x IQR)). We demonstrated that the number of SEMs was low in childhood and increased exponentially during aging. Using the HUMARA method, skewing of X chromosome inactivation (XCI) was evaluated in heterozygotes women. Multivariate analysis indicated a significant correlation between log(SEMs) and degree of XCI skewing after adjustment for age (beta = 0.41; confidence interval: 0.14, 0.68; p-value = 0.0053). The PATH analysis tested the complete model containing the variables: skewing of XCI, age, log(SEMs) and overall CpG methylation. After adjusting for the number of epimutations we failed to confirm the well reported correlation between skewing of XCI and aging. This evidence might suggest that the known correlation between XCI skewing and aging could not be a direct association but mediated by the number of SEMs.
C1 [Gentilini, Davide; Pisoni, Serena; Calzari, Luciano; Vitale, Giovanni; Di Blasio, Anna Maria] IRCCS, Ist Auxol Italiano, I-20095 Milan, Italy.
   [Garagnani, Paolo; Bacalini, Maria Giulia; Franceschi, Claudio] Univ Bologna, Alma Mater Studiorum, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy.
   [Garagnani, Paolo; Bacalini, Maria Giulia; Franceschi, Claudio] Univ Bologna, Interdept Ctr L Galvani, I-40126 Bologna, Italy.
   [Mari, Daniela] Maggiore Policlin Hosp, IRCCS Ca Granda Fdn, Geriatr Unit, Milan, Italy.
   [Vitale, Giovanni] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
C3 IRCCS Istituto Auxologico Italiano; University of Bologna; University of
   Bologna; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of
   Milan
RP Franceschi, C (通讯作者)，Univ Bologna, Alma Mater Studiorum, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy.
EM claudio.franceschi@unibo.it
RI Gentilini, Davide/AAB-2567-2019; Franceschi, Claudio/L-4484-2017;
   BACALINI, MARIA GIULIA/K-4931-2016; Calzari, Luciano/AAA-5075-2020;
   VITALE, GIOVANNI/B-6548-2008; Mari, Daniela/K-5663-2016
OI BACALINI, MARIA GIULIA/0000-0003-1618-2673; Calzari,
   Luciano/0000-0003-4283-0988; Gentilini, Davide/0000-0002-8391-0725; Di
   Blasio, Anna Maria/0000-0001-6451-4156; VITALE,
   GIOVANNI/0000-0003-2478-683X; Mari, Daniela/0000-0002-6950-0789;
   Garagnani, Paolo/0000-0002-4161-3626
FU European Union [259679, 266486, 602757]
FX This work was supported by the European Union's Seventh Framework
   Programme (grant agreement no. 259679 "IDEAL", grant agreement no.
   266486 "NUAGE", grant agreement no. 602757 "HUMAN").
CR Abkowitz JL, 1998, P NATL ACAD SCI USA, V95, P3862, DOI 10.1073/pnas.95.7.3862
   [Anonymous], 2004, MULTIPLE IMPUTATION
   [Anonymous], 2015, R package version 2.14.0
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Bacalini MG, 2015, AGING-US, V7, P97, DOI 10.18632/aging.100718
   Bacalini MG, 2014, MECH AGEING DEV, V136, P101, DOI 10.1016/j.mad.2013.12.006
   Barfield R, 2015, CPGASSOC ASS METHVLA
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Brix TH, 2005, J CLIN ENDOCR METAB, V90, P5949, DOI 10.1210/jc.2005-1366
   Busque L, 2009, BLOOD, V113, P3472, DOI 10.1182/blood-2008-12-195677
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   COTTER PD, 1995, J CLIN INVEST, V96, P2090, DOI 10.1172/JCI118258
   Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Garagnani P, 2012, AGING CELL
   Gentilini D, 2013, AGE, V35, P1961, DOI 10.1007/s11357-012-9463-1
   Gentilini D, 2012, AGING CELL, V11, P277, DOI 10.1111/j.1474-9726.2012.00790.x
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Invernizzi P, 2004, LANCET, V363, P533, DOI 10.1016/S0140-6736(04)15541-4
   Kennedy SR, 2012, MECH AGEING DEV, V133, P118, DOI 10.1016/j.mad.2011.10.009
   Knudsen PS, 2007, CYTOGENET GENOME RES, V116, P24, DOI 10.1159/000097414
   Kristiansen M, 2005, J MED GENET, V42, P877, DOI 10.1136/jmg.2005.032433
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lechner M, 2010, ADV GENET, V70, P247, DOI [10.1016/B978-0-12-380866-0.60009-5, 10.1016/S0065-2660(10)70009-2]
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   Medema RH, 2007, CELL, V129, P1253, DOI 10.1016/j.cell.2007.06.008
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Ong ML, 2014, AGING CELL, V13, P142, DOI 10.1111/acel.12159
   Özbalkan Z, 2005, ARTHRITIS RHEUM-US, V52, P1564, DOI 10.1002/art.21026
   Piyathilake C, 2011, CANCER EPIDEM BIOMAR, V20, P719, DOI 10.1158/1055-9965.EPI-11-0094
   Rezwan FI, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0081-5
   Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x
   Sandovici I, 2004, HUM GENET, V115, P387, DOI 10.1007/s00439-004-1177-8
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932
   van Otterdijk SD, 2013, BIOCHEM SOC T, V41, P803, DOI 10.1042/BST20120358
   Wang D, 2012, BIOINFORMATICS, V28, P729, DOI 10.1093/bioinformatics/bts013
NR 43
TC 57
Z9 61
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2015
VL 7
IS 8
BP 568
EP 578
DI 10.18632/aging.100792
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA CS7JU
UT WOS:000362260700014
PM 26342808
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Bansal, N
   Petrie, K
   Christova, R
   Chung, CY
   Leibovitch, BA
   Howell, L
   Gil, V
   Sbirkov, Y
   Lee, E
   Wexler, J
   Ariztia, EV
   Sharma, R
   Zhu, J
   Bernstein, E
   Zhou, MM
   Zelent, A
   Farias, E
   Waxman, S
AF Bansal, Nidhi
   Petrie, Kevin
   Christova, Rossitza
   Chung, Chi-Yeh
   Leibovitch, Boris A.
   Howell, Louise
   Gil, Veronica
   Sbirkov, Yordan
   Lee, EunJee
   Wexler, Joanna
   Ariztia, Edgardo V.
   Sharma, Rajal
   Zhu, Jun
   Bernstein, Emily
   Zhou, Ming-Ming
   Zelent, Arthur
   Farias, Eduardo
   Waxman, Samuel
TI Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal
   transition and maintenance of a stem cell phenotype in triple negative
   breast cancer
SO ONCOTARGET
LA English
DT Article
DE epigenetics; SIN3; PF1; triple negative breast cancer; cancer stem cells
ID ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTION FACTOR SNAIL; INDUCIBLE EARLY
   GENE; SIN3 COREPRESSOR; MAMMARY-GLAND; SELF-RENEWAL; BASAL-LIKE;
   EXPRESSION; REPRESSION; COMPLEX
AB Triple negative breast cancer (TNBC) is characterized by a poorly differentiated phenotype and limited treatment options. Aberrant epigenetics in this subtype represent a potential therapeutic opportunity, but a better understanding of the mechanisms contributing to the TNBC pathogenesis is required. The SIN3 molecular scaffold performs a critical role in multiple cellular processes, including epigenetic regulation, and has been identified as a potential therapeutic target. Using a competitive peptide corresponding to the SIN3 interaction domain of MAD (Tat-SID), we investigated the functional consequences of selectively blocking the paired amphipathic alpha-helix (PAH2) domain of SIN3. Here, we report the identification of the SID-containing adaptor PF1 as a factor required for maintenance of the TNBC stem cell phenotype and epithelial-to-mesenchymal transition (EMT). Tat-SID peptide blocked the interaction between SIN3A and PF1, leading to epigenetic modulation and transcriptional downregulation of TNBC stem cell and EMT markers. Importantly, Tat-SID treatment also led to a reduction in primary tumor growth and disseminated metastatic disease in vivo. In support of these findings, knockdown of PF1 expression phenocopied treatment with Tat-SID both in vitro and in vivo. These results demonstrate a critical role for a complex containing SIN3A and PF1 in TNBC and provide a rational for its therapeutic targeting.
C1 [Bansal, Nidhi; Leibovitch, Boris A.; Wexler, Joanna; Ariztia, Edgardo V.; Sharma, Rajal; Zhou, Ming-Ming; Farias, Eduardo; Waxman, Samuel] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Oncol, New York, NY 10029 USA.
   [Petrie, Kevin; Christova, Rossitza; Howell, Louise; Gil, Veronica; Sbirkov, Yordan] Inst Canc Res, Div Clin Studies, Sutton, Surrey, England.
   [Chung, Chi-Yeh] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Dept Genet & Genom Sci, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Lee, EunJee; Zhu, Jun] Icahn Sch Med Mt Sinai, Genet & Genom Sci, New York, NY 10029 USA.
   [Bernstein, Emily] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, Dept Oncol Sci, New York, NY 10029 USA.
   [Zelent, Arthur] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Hematooncol,Dept Med, Coral Gables, FL 33124 USA.
C3 Icahn School of Medicine at Mount Sinai; University of London; Institute
   of Cancer Research - UK; Icahn School of Medicine at Mount Sinai; Icahn
   School of Medicine at Mount Sinai; Icahn School of Medicine at Mount
   Sinai; University of Miami
RP Waxman, S (通讯作者)，Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Oncol, New York, NY 10029 USA.
EM samuel.waxman@mssm.edu
RI Zelent, Arthur/B-3532-2009; Bansal, Nidhi/R-1462-2016; Sbirkov,
   Yordan/GSM-6746-2022; Petrie, Kevin/I-7115-2015
OI Zelent, Arthur/0000-0002-7968-9888; Sbirkov, Yordan/0000-0002-6554-3773;
   Leibovitch, Boris/0000-0001-6771-5906; Petrie,
   Kevin/0000-0002-9805-9152; Bansal, Nidhi/0000-0001-6502-3930
FU National Institute of Health-National Cancer Institute [R01CA158121];
   Samuel Waxman Cancer Research Foundation; Chemotherapy Foundation;
   Worldwide Cancer Research [11-0301]; Leukaemia and Lymphoma Research
   Fund [11046]
FX This study was supported by grants from the National Institute of
   Health-National Cancer Institute (R01CA158121), Samuel Waxman Cancer
   Research Foundation, the Chemotherapy Foundation, Worldwide Cancer
   Research (11-0301) and the Leukaemia and Lymphoma Research Fund (11046).
   We thank Prof. Liliana Ossowski (Professor Emeritus, Icahn School of
   Medicine at Mount Sinai) for critical reading of the manuscript.
CR Abramson VG, 2014, CURR BREAST CANCER R, V6, P154, DOI 10.1007/s12609-014-0152-1
   Arnedos M, 2012, THER ADV MED ONCOL, V4, P195, DOI 10.1177/1758834012444711
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0
   Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558
   Bansal N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026156
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Baymaz HI, 2015, BBA-GENE REGUL MECH, V1849, P1051, DOI 10.1016/j.bbagrm.2015.06.012
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bosch A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3247
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x
   Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293
   Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Enkhbaatar Z, 2013, CELL CYCLE, V12, P2100, DOI 10.4161/cc.25142
   Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107
   Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641
   Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hartkopf AD, 2014, BREAST CANCER RES TR, V147, P345, DOI 10.1007/s10549-014-3113-5
   Ho AS, 2013, ONCOTARGETS THER, V6, P223, DOI 10.2147/OTT.S34680
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Jelinic P, 2011, MOL CELL BIOL, V31, P54, DOI 10.1128/MCB.00840-10
   Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681
   Johnsen SA, 2002, J CELL BIOCHEM, V87, P233, DOI 10.1002/jcb.10299
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001
   Kidder BL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r32
   Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014
   Kumar GS, 2011, J MOL BIOL, V408, P987, DOI 10.1016/j.jmb.2011.03.043
   Kwon YJ, 2015, MOL CANCER THER, V14, P1824, DOI 10.1158/1535-7163.MCT-14-0980-T
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Le Guezennec X, 2006, NUCLEIC ACIDS RES, V34, P3929, DOI 10.1093/nar/gkl537
   Lee N, 2009, MOL CELL BIOL, V29, P1401, DOI 10.1128/MCB.01643-08
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006
   Valdespino-Gómez VM, 2012, CIR CIR, V80, P440
   Mendoza-Parra MA, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt829
   Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   Moshkin YM, 2009, MOL CELL, V35, P782, DOI 10.1016/j.molcel.2009.07.020
   Muenst S, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/902042
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Shiozawa Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.57
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5
   STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5
   Strobl-Mazzulla PH, 2012, J CELL BIOL, V198, P999, DOI 10.1083/jcb.201203098
   Swanson KA, 2004, NAT STRUCT MOL BIOL, V11, P738, DOI 10.1038/nsmb798
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155
   Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084
   Viré E, 2014, MOL CELL, V53, P806, DOI 10.1016/j.molcel.2014.01.029
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yochum GS, 2002, MOL CELL BIOL, V22, P7868, DOI 10.1128/MCB.22.22.7868-7876.2002
   Yochum GS, 2001, MOL CELL BIOL, V21, P4110, DOI 10.1128/MCB.21.13.4110-4118.2001
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zou MR, 2014, J BIOL CHEM, V289, P17620, DOI 10.1074/jbc.M114.570853
NR 71
TC 27
Z9 32
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 27
PY 2015
VL 6
IS 33
BP 34087
EP 34105
DI 10.18632/oncotarget.6048
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0PE
UT WOS:000366107200018
PM 26460951
OA Green Accepted, gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Wilson, LE
   Kim, S
   Xu, ZL
   Harlid, S
   Sandler, DP
   Taylor, JA
AF Wilson, Lauren E.
   Kim, Sangmi
   Xu, Zongli
   Harlid, Sophia
   Sandler, Dale P.
   Taylor, Jack A.
TI Non-Steroidal Anti-Inflammatory Drug Use and Genomic DNA Methylation in
   Blood
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; EXPRESSION; TISSUES; SISTER; GENES; CELLS
AB Background
   Non-steroidal anti-inflammatory drug (NSAID) use is associated with decreased risk of some cancers. NSAID use modulates the epigenetic profile of normal colonic epithelium and may reduce risk of colon cancer through this pathway; however, the effect of NSAID use on the DNA methylation profile of other tissues including whole blood has not yet been examined.
   Findings
   Using the Sister Study cohort, we examined the association between NSAID usage and whole genome methylation patterns in blood DNA. Blood DNA methylation status across 27,589 CpG sites was evaluated for 871 women using the Illumina Infinium HumanMethylation27 Beadchip, and in a non-overlapping replication sample of 187 women at 485,512 CpG sites using the Infinium HumanMethylation450 Beadchip. We identified a number of CpG sites that were differentially methylated in regular, long-term users of NSAIDs in the discovery group, but none of these sites were statistically significant in our replication group.
   Conclusions
   We found no replicable methylation differences in blood related to NSAID usage. If NSAID use does effect blood DNA methylation patterns, differences are likely small.
C1 [Wilson, Lauren E.; Xu, Zongli; Harlid, Sophia; Sandler, Dale P.; Taylor, Jack A.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
   [Kim, Sangmi] Georgia Regents Univ, Ctr Canc, Dept Med, Hematol Oncol Sect, Augusta, GA USA.
   [Kim, Sangmi] Med Coll Georgia, Augusta, GA 30912 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); University System of Georgia;
   Augusta University; University System of Georgia; Augusta University
RP Taylor, JA (通讯作者)，NIEHS, Epidemiol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM taylor@niehs.nih.gov
RI Harlid, Sophia/AAJ-5809-2021; Sandler, Dale/E-5110-2019; taylor,
   jack/C-7154-2019
OI taylor, jack/0000-0001-5303-6398; xu, zongli/0000-0002-9034-8902;
   Wilson, Lauren/0000-0002-5953-2293; Sandler, Dale/0000-0002-6776-0018
FU National Institute of Environmental Health Sciences, NIH [Z01 ES044005,
   Z01 ES044032, Z01 ES049033]
FX This research was supported by the Intramural Research Program of the
   National Institute of Environmental Health Sciences, NIH (Z01 ES044005,
   Z01 ES044032, and Z01 ES049033).
CR Accomando WP, 2012, CLIN CANCER RES, V18, P6147, DOI 10.1158/1078-0432.CCR-12-1008
   Brasky TM, 2010, CANCER CAUSE CONTROL, V21, P1503, DOI 10.1007/s10552-010-9579-5
   Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X
   Guay SP, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-14
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Harlid S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118757
   Harlid S, 2014, ENVIRON HEALTH PERSP, V122, P673, DOI 10.1289/ehp.1307480
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Huang SK, PROSTAGLANDIN E2 INC, P3703
   Huang SK, 2012, FASEB J, V26, P3703, DOI 10.1096/fj.11-203323
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Katsurano M, ONCOGENE, P342, DOI [10.1038/onc.2011.241, DOI 10.1038/0NC.2011.241]
   Noreen F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju161
   O'Hagan Heather A M, CANCER CELL, V20, P606, DOI [10.1016/j.ccr.2011.09.012, DOI 10.1016/J.CCR.2011.09.012]
   Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025
   Pan MR, 2008, EXP BIOL MED, V233, P456, DOI 10.3181/0709-RM-257
   Siegel EM, 2014, CANCER EPIDEM BIOMAR, V23, P2622, DOI 10.1158/1055-9965.EPI-14-0464
   Tahara T, 2009, CANCER SCI, V100, P1192, DOI 10.1111/j.1349-7006.2009.01175.x
   Takkouche B, 2008, JNCI-J NATL CANCER I, V100, P1439, DOI 10.1093/jnci/djn324
   Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608
   Xu ZL, 2014, CARCINOGENESIS, V35, P356, DOI 10.1093/carcin/bgt391
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zhao YS, 2009, BREAST CANCER RES TR, V117, P141, DOI 10.1007/s10549-008-0228-6
NR 23
TC 8
Z9 9
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2015
VL 10
IS 9
AR e0138920
DI 10.1371/journal.pone.0138920
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CS0ZW
UT WOS:000361792100115
PM 26393518
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Loriot, C
   Domingues, M
   Berger, A
   Menara, M
   Ruel, M
   Morin, A
   Castro-Vega, LJ
   Letouzé, É
   Martinelli, C
   Bemelmans, AP
   Larue, L
   Gimenez-Roqueplo, AP
   Favier, J
AF Loriot, Celine
   Domingues, Melanie
   Berger, Adeline
   Menara, Melanie
   Ruel, Maeva
   Morin, Aurelie
   Castro-Vega, Luis-Jaime
   Letouze, Eric
   Martinelli, Cosimo
   Bemelmans, Alexis-Pierre
   Larue, Lionel
   Gimenez-Roqueplo, Anne-Paule
   Favier, Judith
TI Deciphering the molecular basis of invasiveness in <i>Sdhb</i>-deficient
   cells
SO ONCOTARGET
LA English
DT Article
DE paraganglioma; SDHB; metastasis; EMT; keratin 19
ID EPITHELIAL-MESENCHYMAL TRANSITION; GENE-MUTATIONS; BREAST-CANCER;
   TUMOR-CELLS; PHEOCHROMOCYTOMAS; PARAGANGLIOMAS; SUCCINATE;
   NEUROBLASTOMA; EXPRESSION; CARCINOMA
AB Metastatic pheochromocytomas and paragangliomas (PPGL) are malignant neuroendocrine tumors frequently associated with germline mutations in the SDHB gene. SDHB-mutated PPGL display a hypermethylator phenotype associated with hallmarks of epithelial-to-mesenchymal transition (EMT). In the present study, we report the characterization of a unique model of Sdhb knockout in mouse chromaffin cells. Sdhb deficient cells exhibit a metastatic phenotype as highlighted by increased individual cell migration (characterized by faster motility and increased persistence) as well as high invasive and adhesion abilities. This phenotype is associated with the modulation of Twist1, Twist2, Tcf3, Snai1, N-cadherin or Krt19 expression, reflecting an EMT-like reprogramming of cells. Krt19 is epigenetically silenced in Sdhb-deficient cells and re-expressed after treatment by the demethylating agent decitabine. Krt19 rescue by lentiviral transduction in Sdhb-deficient cells and Krt19 inhibition by RNA interference in wild-type cells were performed. Both studies revealed the involvement of KRT19 in the invasive phenotype by modulating collective and individual migration and cell/extra-cellular matrix adhesion properties. These findings underline the role of hypermethylation and EMT in the in vitro acquisition of metastatic properties, following SDHB loss of function.
C1 [Loriot, Celine; Menara, Melanie; Ruel, Maeva; Morin, Aurelie; Castro-Vega, Luis-Jaime; Martinelli, Cosimo; Gimenez-Roqueplo, Anne-Paule; Favier, Judith] INSERM, Paris Cardiovasc Res Ctr, UMR970, F-75015 Paris, France.
   [Loriot, Celine; Domingues, Melanie; Menara, Melanie; Ruel, Maeva; Morin, Aurelie; Castro-Vega, Luis-Jaime; Martinelli, Cosimo; Gimenez-Roqueplo, Anne-Paule; Favier, Judith] Univ Paris 05, Sorbonne Paris Cite, Fac Med, F-75006 Paris, France.
   [Domingues, Melanie; Larue, Lionel] Inst Curie, CNRS, INSERM, U1021,UMR3347, F-91405 Orsay, France.
   [Berger, Adeline] INSERM, Inst Vis, U968, F-75012 Paris, France.
   [Berger, Adeline] Univ Paris 06, F-75005 Paris, France.
   [Letouze, Eric] Ligue Natl Canc, Programme Cartes Identite Tumeurs, F-75013 Paris, France.
   [Bemelmans, Alexis-Pierre] CEA, Mol Imaging Res Ctr MIRCen, DSV, I2BM, F-92265 Fontenay Aux Roses, France.
   [Bemelmans, Alexis-Pierre] CEA, CNRS, URA 2210, F-92265 Fontenay Aux Roses, France.
   [Gimenez-Roqueplo, Anne-Paule] Hop Europeen Georges Pompidou, Serv Genet, Assistance Publ Hop Paris, F-75015 Paris, France.
   [Gimenez-Roqueplo, Anne-Paule] Natl Canc Inst, Rare Adrenal Canc Network, Cort Medullosurrenale Tumeurs Endocrines, F-75014 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Universite Paris Cite; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Universite Paris Saclay; Universite PSL; UNICANCER; Institut
   Curie; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Sorbonne Universite; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Sorbonne Universite; Universite Paris
   Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CEA;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Saint-Louis - APHP; Hopital Universitaire Europeen
   Georges-Pompidou - APHP; Institut National du Cancer (INCA) France
RP Favier, J (通讯作者)，INSERM, Paris Cardiovasc Res Ctr, UMR970, F-75015 Paris, France.
EM judith.favier@inserm.fr
RI Castro-Vega, Luis/L-5587-2019; Bemelmans, Alexis-Pierre/H-4476-2019;
   Larue, Lionel/I-6532-2016; Letouzé, Eric/AAP-9924-2020; Berger,
   Adeline/Q-2372-2018; Gimenez-Roqueplo, Anne-Paule/T-6752-2018; Favier,
   Judith/M-7601-2017
OI Berger, Adeline/0000-0003-2986-4489; Bemelmans,
   Alexis/0000-0001-7605-5225; Letouze, Eric/0000-0002-6369-2839;
   Gimenez-Roqueplo, Anne-Paule/0000-0002-4816-670X; Favier,
   Judith/0000-0001-8190-5853
FU Programme Hospitalier de Recherche Clinique grant [COMETE 3 (AOM 06
   179)]; Agence Nationale de la Recherche [ANR-2011- JCJC-00701
   MODEOMAPP]; European Union [259735]; Plan Cancer: Appel a projets
   Epigenetique et Cancer [EPIG201303 METABEPIC]
FX This work was supported by the Programme Hospitalier de Recherche
   Clinique grant COMETE 3 (AOM 06 179) and the Agence Nationale de la
   Recherche (ANR-2011- JCJC-00701 MODEOMAPP). This project was also funded
   by the European Union Seventh Framework Programme (FP7/2007-2013) under
   grant agreement number 259735 and by the Plan Cancer: Appel a projets
   Epigenetique et Cancer 2013 (EPIG201303 METABEPIC).
CR Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709
   Androulakis N, 2012, BRIT J CANCER, V106, P1917, DOI 10.1038/bjc.2012.202
   Bemelmans AP, 2005, J GENE MED, V7, P1367, DOI 10.1002/jgm.788
   Carén H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-66
   Cascón A, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv053
   Castro-Vega LJ, 2015, ONCOGENE
   Castro-Vega LJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7044
   Crowel DL, 1999, J DENT RES, V78, P1256, DOI 10.1177/00220345990780061001
   Dahia PLM, 2014, NAT REV CANCER, V14, P108, DOI 10.1038/nrc3648
   Favier J, 2014, NATURE REV ENDOCRINO
   Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   Ju JH, 2013, CLIN CANCER RES, V19, P4335, DOI 10.1158/1078-0432.CCR-12-3295
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092
   Lepoutre-Lussey C., 2015, Molecular and cellular endocrinology
   Letouzé E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018
   Loriot C, 2012, J CLIN ENDOCR METAB, V97, pE954, DOI 10.1210/jc.2011-3437
   Morin A, 2014, INT J CANC
   Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180
   Nakajima Y, 2000, ANAT RECORD, V258, P119, DOI 10.1002/(SICI)1097-0185(20000201)258:2<119::AID-AR1>3.0.CO;2-U
   Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284
   Nozato M, 2013, INT J ONCOL, V42, P134, DOI 10.3892/ijo.2012.1684
   Paiva F, 2011, DNA CELL BIOL, V30, P85, DOI 10.1089/dna.2010.1108
   Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628
   Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161
   Seltmann K, 2013, J INVEST DERMATOL, V133, P181, DOI 10.1038/jid.2012.256
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V329, P508, DOI 10.1016/j.bbrc.2005.02.006
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112
NR 30
TC 57
Z9 59
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 20
PY 2015
VL 6
IS 32
BP 32955
EP 32965
DI 10.18632/oncotarget.5106
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0DQ
UT WOS:000363186600066
PM 26460615
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Barutcu, AR
   Lajoie, BR
   McCord, RP
   Tye, CE
   Hong, D
   Messier, TL
   Browne, G
   van Wijnen, AJ
   Lian, JB
   Stein, JL
   Dekker, J
   Imbalzano, AN
   Stein, GS
AF Barutcu, A. Rasim
   Lajoie, Bryan R.
   McCord, Rachel P.
   Tye, Coralee E.
   Hong, Deli
   Messier, Terri L.
   Browne, Gillian
   van Wijnen, Andre J.
   Lian, Jane B.
   Stein, Janet L.
   Dekker, Job
   Imbalzano, Anthony N.
   Stein, Gary S.
TI Chromatin interaction analysis reveals changes in small chromosome and
   telomere clustering between epithelial and breast cancer cells
SO GENOME BIOLOGY
LA English
DT Article
DE Hi-C; Chromosome Conformation Capture; Breast Cancer; Topologically
   Associating Domain; TAD; Telomere
ID HI-C; SPATIAL-ORGANIZATION; TOPOLOGICAL DOMAINS; GENE-EXPRESSION; DISTAL
   ENHANCER; GENOME; LANDSCAPE; CONFORMATION; SCALE; ARCHITECTURE
AB Background: Higher-order chromatin structure is often perturbed in cancer and other pathological states. Although several genetic and epigenetic differences have been charted between normal and breast cancer tissues, changes in higher-order chromatin organization during tumorigenesis have not been fully explored. To probe the differences in higher-order chromatin structure between mammary epithelial and breast cancer cells, we performed Hi-C analysis on MCF-10A mammary epithelial and MCF-7 breast cancer cell lines.
   Results: Our studies reveal that the small, gene-rich chromosomes chr16 through chr22 in the MCF-7 breast cancer genome display decreased interaction frequency with each other compared to the inter-chromosomal interaction frequency in the MCF-10A epithelial cells. Interestingly, this finding is associated with a higher occurrence of open compartments on chr16-22 in MCF-7 cells. Pathway analysis of the MCF-7 up-regulated genes located in altered compartment regions on chr16-22 reveals pathways related to repression of WNT signaling. There are also differences in intra-chromosomal interactions between the cell lines; telomeric and sub-telomeric regions in the MCF-10A cells display more frequent interactions than are observed in the MCF-7 cells.
   Conclusions: We show evidence of an intricate relationship between chromosomal organization and gene expression between epithelial and breast cancer cells. Importantly, this work provides a genome-wide view of higher-order chromatin dynamics and a resource for studying higher-order chromatin interactions in two cell lines commonly used to study the progression of breast cancer.
C1 [Barutcu, A. Rasim; Hong, Deli; van Wijnen, Andre J.; Imbalzano, Anthony N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA 01655 USA.
   [Lajoie, Bryan R.; McCord, Rachel P.; Dekker, Job] Univ Massachusetts, Sch Med, Program Syst Biol, Worcester, MA 01655 USA.
   [Dekker, Job] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA.
   [van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
   [Tye, Coralee E.; Hong, Deli; Messier, Terri L.; Browne, Gillian; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Tye, Coralee E.; Hong, Deli; Messier, Terri L.; Browne, Gillian; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.] Univ Vermont, Coll Med, Univ Vermont Canc Ctr, Burlington, VT 05405 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; Mayo Clinic; University of Vermont;
   University of Vermont
RP Stein, GS (通讯作者)，Univ Vermont, Coll Med, Dept Biochem, 89 Beaumont Ave, Burlington, VT 05405 USA.
EM gary.stein@uvm.edu
RI Hong, Deli/AAG-2565-2021; Lajoie, Bryan/ABP-4675-2022; van Wijnen,
   Andre/AAG-3578-2019; Barutcu, Rasim/O-5973-2019
OI Tye, Coralee/0000-0002-3349-1833; van Wijnen, Andre
   J./0000-0002-4458-0946; McCord, Rachel/0000-0003-0010-5323; Barutcu,
   Ahmet Rasim/0000-0002-4838-8695
FU National Cancer Institute [P01 CA082834]; Pfizer Investigator-Initiated
   Research Award - IIR [WS2049100]
FX We would like to thank Jeffrey A. Nickerson and Imbalzano and Stein lab
   members for critical discussion, Alper Kucukural for technical help with
   RNA-seq analysis, Seda Barutcu for critical reading of the manuscript
   and scientific input, Jonathan Gordon, Scott Tighe and Robert Devins for
   their help with deep sequencing. The next-generation sequencing was
   performed in the Advanced Genome Technologies Core Massively Parallel
   Sequencing Facility and was supported by the University of Vermont
   Cancer Center, Lake Champlain Cancer Research Organization, UVM College
   of Agriculture and Life Sciences, and the UVM College of Medicine. This
   work was supported by National Cancer Institute grant P01 CA082834 and
   Pfizer Investigator-Initiated Research Award - IIR Grant WS2049100.
CR Barbieri M, 2013, BIOCHEM SOC T, V41, P508, DOI 10.1042/BST20120238
   Barnett DH, 2008, CANCER RES, V68, P3505, DOI 10.1158/0008-5472.CAN-07-6151
   Belton JM, 2012, METHODS, V58, P268, DOI 10.1016/j.ymeth.2012.05.001
   Berriz GF, 2009, BIOINFORMATICS, V25, P3043, DOI 10.1093/bioinformatics/btp498
   Bickmore WA, 2013, ANNU REV GENOM HUM G, V14, P67, DOI 10.1146/annurev-genom-091212-153515
   Bolzer A, 2005, PLOS BIOL, V3, P826, DOI 10.1371/journal.pbio.0030157
   Bonora G, 2014, CURR OPIN GENET DEV, V27, P92, DOI 10.1016/j.gde.2014.05.002
   Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004
   Chuang CH, 2007, SEMIN CELL DEV BIOL, V18, P698, DOI 10.1016/j.semcdb.2007.08.012
   Cremer M, 2001, CHROMOSOME RES, V9, P541, DOI 10.1023/A:1012495201697
   Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007
   Cremer T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003889
   Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458
   de Laat W, 2013, NATURE, V502, P499, DOI 10.1038/nature12753
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dey P, 2010, DIAGN CYTOPATHOL, V38, P382, DOI 10.1002/dc.21234
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Draskovic I, 2009, P NATL ACAD SCI USA, V106, P15726, DOI 10.1073/pnas.0907689106
   Dryden NH, 2014, GENOME RES, V24, P1854, DOI 10.1101/gr.175034.114
   Duggal G, 2014, NUCLEIC ACIDS RES, V42, P87, DOI 10.1093/nar/gkt857
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gibcus JH, 2013, MOL CELL, V49, P773, DOI 10.1016/j.molcel.2013.02.011
   Giorgetti L, 2014, CELL, V157, P950, DOI 10.1016/j.cell.2014.03.025
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018
   Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007
   Hughes JR, 2014, NAT GENET, V46, P205, DOI 10.1038/ng.2871
   Imakaev M, 2012, NAT METHODS, V9, P999, DOI [10.1038/NMETH.2148, 10.1038/nmeth.2148]
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lajoie BR, 2015, METHODS, V72, P65, DOI 10.1016/j.ymeth.2014.10.031
   Le Dily F, 2014, GENE DEV, V28, P2151, DOI 10.1101/gad.241422.114
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marella NV, 2009, CANCER RES, V69, P5946, DOI 10.1158/0008-5472.CAN-09-0420
   Matilainen JM, 2010, J BIOL CHEM, V285, P24174, DOI 10.1074/jbc.M110.124073
   McCord RP, 2013, GENOME RES, V23, P260, DOI 10.1101/gr.138032.112
   Meaburn KJ, 2008, J CELL BIOL, V180, P39, DOI 10.1083/jcb.200708204
   Meaburn KJ, 2009, J CELL BIOL, V187, P801, DOI 10.1083/jcb.200909127
   Misteli T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000794
   Mourad R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113354
   Nora EP, 2013, BIOESSAYS, V35, P818, DOI 10.1002/bies.201300040
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002
   Osmanbeyoglu HU, 2013, NUCLEIC ACIDS RES, V41, P8061, DOI 10.1093/nar/gkt586
   Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1
   Pope BD, 2014, NATURE, V515, P402, DOI 10.1038/nature13986
   Quinlan AR, 2014, CURR PROTOC BIOINFOR, V47, p11 12
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rocha PP, 2012, MOL CELL, V47, P873, DOI 10.1016/j.molcel.2012.06.036
   Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177
   Rousseau M, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r60
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Saramäki A, 2009, J BIOL CHEM, V284, P8073, DOI 10.1074/jbc.M808090200
   Seitan VC, 2013, GENOME RES, V23, P2066, DOI 10.1101/gr.161620.113
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Song L, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0509-9
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Therizols P, 2014, SCIENCE, V346, P1238, DOI 10.1126/science.1259587
   Van Bortle K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r82
   Wang JB, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-70
   Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09
   Zeitz MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073974
   Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
NR 71
TC 154
Z9 194
U1 0
U2 36
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD SEP 28
PY 2015
VL 16
AR 214
DI 10.1186/s13059-015-0768-0
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CS1CU
UT WOS:000361801000003
PM 26415882
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Alnaes, GIG
   Ronneberg, JA
   Kristensen, VN
   Tost, J
AF Alnaes, Grethe I. Grenaker
   Ronneberg, Jo Anders
   Kristensen, Vessela N.
   Tost, Joerg
TI Heterogeneous DNA Methylation Patterns in the <i>GSTP1</i> Promoter Lead
   to Discordant Results between Assay Technologies and Impede Its
   Implementation as Epigenetic Biomarkers in Breast Cancer
SO GENES
LA English
DT Article
DE DNA methylation; breast cancer; GSTP1; biomarker; heterogeneity; method;
   MethyLight; MSP; pyrosequencing; mass spectrometry
ID GLUTATHIONE-S-TRANSFERASE; CPG ISLAND METHYLATION; TIME PCR ASSAY;
   COLORECTAL-CANCER; HYPERMETHYLATION PROFILE; ACCURATE QUANTIFICATION;
   PROSTATE-CANCER; TUMORS; PI; CARCINOGENESIS
AB Altered DNA methylation patterns are found in many diseases, particularly in cancer, where the analysis of DNA methylation holds the promise to provide diagnostic, prognostic and predictive information of great clinical value. Methylation of the promoter-associated CpG island of GSTP1 occurs in many hormone-sensitive cancers, has been shown to be a biomarker for the early detection of cancerous lesions and has been associated with important clinical parameters, such as survival and response to treatment. In the current manuscript, we assessed the performance of several widely-used sodium bisulfite conversion-dependent methods (methylation-specific PCR, MethyLight, pyrosequencing and MALDI mass-spectrometry) for the analysis of DNA methylation patterns in the GSTP1 promoter. We observed large discordances between the results obtained by the different technologies. Cloning and sequencing of the investigated region resolved single-molecule DNA methylation patterns and identified heterogeneous DNA methylation patterns as the underlying cause of the differences. Heterogeneous DNA methylation patterns in the GSTP1 promoter constitute a major obstacle to the implementation of DNA methylation-based analysis of GSTP1 and might explain some of the contradictory findings in the analysis of the significance of GSTP1 promoter methylation in breast cancer.
C1 [Alnaes, Grethe I. Grenaker; Ronneberg, Jo Anders; Kristensen, Vessela N.] Radiumhosp, Inst Canc Res, Dept Canc Genet, Oslo Univ Hosp, N-0310 Oslo, Norway.
   [Kristensen, Vessela N.] Univ Oslo, Inst Clin Med, N-0318 Oslo, Norway.
   [Kristensen, Vessela N.] Univ Oslo, Dept Clin Mol Biol EpiGen, N-1478 Ahus, Lorenskog, Norway.
   [Tost, Joerg] CEA, Ctr Natl Genotypage, Lab Epigenet & Environm, Inst Genom, F-91000 Evry, France.
C3 University of Oslo; University of Oslo; University of Oslo; CEA;
   Universite Paris Saclay
RP Tost, J (通讯作者)，CEA, Ctr Natl Genotypage, Lab Epigenet & Environm, Inst Genom, F-91000 Evry, France.
EM Grethe.I.Grenaker.Alnas@rr-research.no; Jo.Anders.Ronneberg@gmail.com;
   v.n.kristensen@medisin.uio.no; tost@cng.fr
RI Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817
FU Norwegian Cancer Society [D-03067]; Functional Genomics Program (FUGE)
   of the Norwegian Research Council [152004/150]; French-Norwegian
   cooperation program Aurora Grant [23486TE]
FX Jo Anders Ronneberg is a fellow of the Faculty Division the Norwegian
   Radium Hospital, University of Oslo. This work was supported by Grant
   D-03067 from The Norwegian Cancer Society (Vessela N. Kristensen), Grant
   152004/150 from The Functional Genomics Program (FUGE) of the Norwegian
   Research Council (Vessela N. Kristensen) (VNK) and the French-Norwegian
   cooperation program Aurora Grant 23486TE (Jorg Tost, VNK).
CR Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Ban N, 1996, CANCER RES, V56, P3577
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   CHOW NWI, 1988, J BIOL CHEM, V263, P12797
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]
   Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Everhard S, 2009, NEURO-ONCOLOGY, V11, P348, DOI 10.1215/15228517-2009-001
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014
   Klajic J, 2014, CLIN CANCER RES, V20, P6357, DOI 10.1158/1078-0432.CCR-14-0297
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lee WP, 1996, CANCER CHEMOTH PHARM, V38, P45, DOI 10.1007/s002800050446
   Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   MULDER TPJ, 1995, CANCER RES, V55, P2696
   Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573
   Parkinson JF, 2008, J NEURO-ONCOL, V87, P71, DOI 10.1007/s11060-007-9486-0
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Payne SR, 2010, EPIGENOMICS-UK, V2, P575, DOI 10.2217/EPI.10.35
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Schnekenburger M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00170
   Schüffler P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-r105
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Vinarskaja A, 2012, WORLD J UROL, V30, P319, DOI 10.1007/s00345-011-0750-8
   Wang ZP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09301
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 49
TC 16
Z9 18
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD SEP
PY 2015
VL 6
IS 3
BP 878
EP 900
DI 10.3390/genes6030878
PG 23
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CS0OS
UT WOS:000361761900025
PM 26393654
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Deckers, IAG
   Schouten, LJ
   Van Neste, L
   van Vlodrop, IJH
   Soetekouw, PMMB
   Baldewijns, MMLL
   Jeschke, J
   Ahuja, N
   Herman, JG
   van den Brandt, PA
   van Engeland, M
AF Deckers, Ivette A. G.
   Schouten, Leo J.
   Van Neste, Leander
   van Vlodrop, Iris J. H.
   Soetekouw, Patricia M. M. B.
   Baldewijns, Marcella M. L. L.
   Jeschke, Jana
   Ahuja, Nita
   Herman, James G.
   van den Brandt, Piet A.
   van Engeland, Manon
TI Promoter Methylation of <i>CDO1</i> Identifies Clear-Cell Renal Cell
   Cancer Patients with Poor Survival Outcome
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HIPPEL-LINDAU GENE; CYSTEINE DIOXYGENASE; DNA METHYLATION; CARCINOMA;
   NETHERLANDS; ACTIVATION; MUTATIONS; BIOMARKER; TAURINE; COHORT
AB Purpose: In this era of molecular diagnostics, prediction of clear-cell renal cell cancer (ccRCC) survival requires optimization, as current prognostic markers fail to determine individual patient outcome. Epigenetic events are promising molecular markers. Promoter CpG island methylation of cysteine dioxygenase type 1 (CDO1), which was identified as prognostic marker for breast cancer, is studied as a potential marker for ccRCC survival.
   Experimental Design: We collected primary tissues of 365 ccRCC cases identified within the prospective Netherlands Cohort Study (NLCS). In this population-based series, CDO1 promoter methylation was observed in 124 of 324 (38.3%) patients with successful methylation-specific PCR analysis. Kaplan-Meier curves and Wilcoxon tests were used to evaluate 10-year ccRCC-specific survival. Cox regression analysis was used to obtain crude and multivariate HRs and 95% confidence intervals (CI). The relative prognostic value of multivariate models with and without CDO1 promoter methylation was compared using likelihood-ratio tests.
   Results: Patients with CDO1 promoter methylation have a significantly poorer survival than those without (Wilcoxon P = 0.006). Differences in survival were independent of other prognostic factors, including age and sex (HR, 1.66; 95% CI, 1.12-2.45) and TNM stage, tumor size, and Fuhrman grade (HR, 1.89; 95% CI, 1.25-2.85). Multivariate models performed better with than without CDO1 promoter methylation status (likelihood-ratio P = 0.003). Survival curves were validated in an independent series of 280 ccRCC cases from The Cancer Genome Atlas (TCGA; Wilcoxon P < 0.001).
   Conclusions: CDO1 promoter methylation may not substitute common prognostic makers to predict ccRCC survival, but offers additional, relevant prognostic information, indicating that it might be a novel molecular marker to determine ccRCC prognosis. (C)2015 AACR.
C1 [Deckers, Ivette A. G.; Schouten, Leo J.; van den Brandt, Piet A.] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol GROW, Dept Epidemiol, NL-6202 AZ Maastricht, Netherlands.
   [Van Neste, Leander; van Vlodrop, Iris J. H.; Baldewijns, Marcella M. L. L.; van Engeland, Manon] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol GROW, Dept Pathol, NL-6202 AZ Maastricht, Netherlands.
   [Soetekouw, Patricia M. M. B.] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol GROW, Div Med Oncol,Dept Internal Med, NL-6202 AZ Maastricht, Netherlands.
   [Jeschke, Jana; Ahuja, Nita; Herman, James G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Jeschke, Jana] Univ Libre Bruxelles, Fac Med, Lab Canc Epigenet, Brussels, Belgium.
   [Ahuja, Nita] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
   [Ahuja, Nita] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA.
C3 Maastricht University; Maastricht University; Maastricht University;
   Johns Hopkins University; Universite Libre de Bruxelles; Johns Hopkins
   University; Johns Hopkins University
RP van Engeland, M (通讯作者)，Maastricht Univ, Med Ctr, POB 616,5800 MD, NL-6202 AZ Maastricht, Netherlands.
EM manon.van.engeland@mumc.nl
RI van Engeland, Manon/A-7479-2009; Schouten, Leo/AAB-2275-2019
OI Jeschke, Jana/0000-0002-6047-2558; Baldewijns,
   Marcella/0000-0002-0882-2944; van den Brandt, Piet/0000-0001-8781-8099;
   Schouten, Leo/0000-0003-3361-7560
FU Dutch Cancer Society [UM 2009-4536]
FX This study was supported by the Dutch Cancer Society (UM 2009-4536).
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Andresen K, 2012, EPIGENETICS-US, V7, P1249, DOI 10.4161/epi.22191
   BRADLEY H, 1994, J RHEUMATOL, V21, P1192
   Brait M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044951
   Casparie M, 2007, CELL ONCOL, V29, P19
   Chesney RW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S4
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   de Peralta-Venturina M, 2001, AM J SURG PATHOL, V25, P275, DOI 10.1097/00000478-200103000-00001
   Derks S, 2004, CELL ONCOL, V26, P291
   Dietrich D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-247
   Dominy JE, 2007, AM J PHYSIOL-ENDOC M, V293, pE62, DOI 10.1152/ajpendo.00053.2007
   Eble J., 2004, WHO CLASSIFICATION T
   FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007
   Fukushige S, 2013, TOHOKU J EXP MED, V229, P173, DOI 10.1620/tjem.229.173
   Goldbohm RA., 1994, TIJDSCHR SOC GEZONDH, V72, P80
   HEAFIELD MT, 1990, NEUROSCI LETT, V110, P216, DOI 10.1016/0304-3940(90)90814-P
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermanek P., 1987, TNM CLASSIFICATION M, V4th
   Jeschke J, 2013, CLIN CANCER RES, V19, P3201, DOI 10.1158/1078-0432.CCR-12-3751
   Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joseph CA, 2007, CHEM COMMUN, P3338, DOI 10.1039/b702158e
   Kwon YJ, 2012, J THORAC ONCOL, V7, P20, DOI 10.1097/JTO.0b013e3182307f62
   Ljungberg B, 2010, EUR UROL, V58, P398, DOI 10.1016/j.eururo.2010.06.032
   Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525
   Oya M, 2003, CARCINOGENESIS, V24, P377, DOI 10.1093/carcin/24.3.377
   Satsu H, 2003, BIOCHEM J, V375, P441, DOI 10.1042/BJ20030535
   Smits KM, 2008, CLIN CANCER RES, V14, P782, DOI 10.1158/1078-0432.CCR-07-1753
   Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762
   Stipanuk MH, 2009, AMINO ACIDS, V37, P55, DOI 10.1007/s00726-008-0202-y
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   van Houwelingen KP, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-57
   VANDENBRANDT PA, 1990, INT J EPIDEMIOL, V19, P553
   VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   YAGODA A, 1995, SEMIN ONCOL, V22, P42
NR 37
TC 52
Z9 54
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2015
VL 21
IS 15
BP 3492
EP 3500
DI 10.1158/1078-0432.CCR-14-2049
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CS2NK
UT WOS:000361907800018
PM 25904753
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Bao, L
   Cardiff, RD
   Steinbach, P
   Messer, KS
   Ellies, LG
AF Bao, Lei
   Cardiff, Robert D.
   Steinbach, Paul
   Messer, Karen S.
   Ellies, Lesley G.
TI Multipotent luminal mammary cancer stem cells model tumor heterogeneity
SO BREAST CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; MOLECULAR CHARACTERIZATION; EXPRESSION; MOUSE; PHENOTYPE;
   GLAND; IDENTIFICATION; PROGENITORS; TRANSITION; INDUCTION
AB Introduction: The diversity of human breast cancer subtypes has led to the hypothesis that breast cancer is actually a number of different diseases arising from cells at various stages of differentiation. The elusive nature of the cell(s) of origin thus hampers approaches to eradicate the disease.
   Methods: Clonal cell lines were isolated from primary transgenic polyomavirus middle T (PyVmT) luminal tumors. Mammary cancer stem cell (MaCSC) properties were examined by immunofluorescence, flow cytometry, differentiation assays and in vivo tumorigenesis.
   Results: Clonal cell lines isolated from primary PyVmT mouse mammary luminal tumors can differentiate into luminal, myoepithelial, alveolar and adipocyte lineages. Upon orthotopic injection, progeny of a single cell follow a pattern of progression from ductal carcinoma in situ, to adenoma, adenocarcinoma and epithelial metastasis that recapitulates the transgenic model. Tumors can evolve in vivo from hormone receptor-positive to hormone receptor-negative Her2-positive, or triple negative CD44hi basal-like and claudin-low tumors. Contrary to the current paradigm, we have defined a model in which multiple tumor subtypes can originate from a single multipotent cancer stem cell that undergoes genetic and/or epigenetic evolution during tumor progression. As in human tumors, the more aggressive tumor subtypes express nuclear p53. Tumor cell lines can also be derived from these more advanced tumor subtypes.
   Conclusions: Since the majority of human tumors are of the luminal subtype, understanding the cell of origin of these tumors and how they relate to other tumor subtypes will impact cancer therapy. Analysis of clonal cell lines derived from different tumor subtypes suggests a developmental hierarchy of MaCSCs, which may provide insights into the progression of human breast cancer.
C1 [Bao, Lei; Messer, Karen S.] Univ Calif San Diego, Moores UCSD Canc Ctr, Bioinformat & Biostat Shared Resource, La Jolla, CA 92093 USA.
   [Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA.
   [Steinbach, Paul] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Ellies, Lesley G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   [Messer, Karen S.] Univ Calif San Diego, Dept Family & Prevent Med, Divison Biostat & Bioinformat, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California Davis;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Ellies, LG (通讯作者)，Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM lellies@ucsd.edu
OI Messer, Karen/0000-0002-9298-2413
FU US National Cancer Institute's Mouse Models of Human Cancers Consortium
   [K22CA118182, R01CA158448, 5R01CA155293, U01 CA141541, U01 CA141582, U01
   CA105490]; UCSD microscopy core [NS047101]
FX This work was supported by K22CA118182 and R01CA158448 (LGE);
   5R01CA155293 (LB, KSM); U01 CA141541, U01 CA141582 and U01 CA105490 from
   the US National Cancer Institute's Mouse Models of Human Cancers
   Consortium (RDC); NS047101 (UCSD microscopy core). We thank Sarah Davie,
   Hang M. Ha, Carol Ou and Jeanine Kleeman for technical assistance. We
   thank Roger Y Tsien, Pamela L Mellon and David A Cheresh for helpful
   discussions.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Damonte P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2104
   Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9
   Diallo R, 2001, J PATHOL, V193, P27, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH747>3.0.CO;2-H
   Garcia-Closas M, 2008, CLIN CANCER RES, V14, P8000, DOI 10.1158/1078-0432.CCR-08-0975
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hollern DP, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3672
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4
   Meyer MJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2449
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Namba R, 2004, MOL CANCER RES, V2, P453
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   PICKETT PB, 1975, J CELL BIOL, V66, P316, DOI 10.1083/jcb.66.2.316
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Santagata S, 2014, J CLIN INVEST, V124, P859, DOI 10.1172/JCI70941
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Smith Brittni A, 2012, Genes Cancer, V3, P550, DOI 10.1177/1947601913475359
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan SB, 2005, EXPERT SYST APPL, V28, P667, DOI 10.1016/j.eswa.2004.12.023
   TENNENBAUM T, 1995, P NATL ACAD SCI USA, V92, P7041, DOI 10.1073/pnas.92.15.7041
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   WELLINGS SR, 1975, J NATL CANCER I, V55, P231
   Zucchi I, 2002, P NATL ACAD SCI USA, V99, P8660, DOI 10.1073/pnas.132259399
NR 39
TC 35
Z9 39
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD OCT 14
PY 2015
VL 17
AR 137
DI 10.1186/s13058-015-0615-y
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT7IC
UT WOS:000362987300001
PM 26467658
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kala, R
   Shah, HN
   Martin, SL
   Tollefsbol, TO
AF Kala, Rishabh
   Shah, Harsh N.
   Martin, Samantha L.
   Tollefsbol, Trygve O.
TI Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA
   damage response by affecting SIRT1 and DNMT enzyme expression, including
   SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative
   breast cancer
SO BMC CANCER
LA English
DT Article
DE Combination; Epigenetics; Apoptosis; Genomic stability; SIRT1;
   gamma-H2AX; DNMTs; Telomerase; Breast cancer cells
ID EPIGALLOCATECHIN GALLATE; INHIBITION; PROMOTER; METHYLATION; APOPTOSIS;
   HTERT; CELLS; GENE
AB Background: Nutrition is believed to be a primary contributor in regulating gene expression by affecting epigenetic pathways such as DNA methylation and histone modification. Resveratrol and pterostilbene are phytoalexins produced by plants as part of their defense system. These two bioactive compounds when used alone have been shown to alter genetic and epigenetic profiles of tumor cells, but the concentrations employed in various studies often far exceed physiologically achievable doses. Triple-negative breast cancer (TNBC) is an often fatal condition that may be prevented or treated through novel dietary-based approaches.
   Methods: HCC1806 and MDA-MB-157 breast cancer cells were used as TNBC cell lines in this study. MCF10A cells were used as control breast epithelial cells to determine the safety of this dietary regimen. CompuSyn software was used to determine the combination index (CI) for drug combinations.
   Results: Combinatorial resveratrol and pterostilbene administered at close to physiologically relevant doses resulted in synergistic (CI <1) growth inhibition of TNBCs. SIRT1, a type III histone deacetylase (HDAC), was down-regulated in response to this combinatorial treatment. We further explored the effects of this novel combinatorial approach on DNA damage response by monitoring gamma-H2AX and telomerase expression. With combination of these two compounds there was a significant decrease in these two proteins which might further resulted in significant growth inhibition, apoptosis and cell cycle arrest in HCC1806 and MDA-MB-157 breast cancer cells, while there was no significant effect on cellular viability, colony forming potential, morphology or apoptosis in control MCF10A breast epithelial cells. SIRT1 knockdown reproduced the effects of combinatorial resveratrol and pterostilbene-induced SIRT1 down-regulation through inhibition of both telomerase activity and gamma-H2AX expression in HCC1806 breast cancer cells. As a part of the repair mechanisms and role of SIRT1 in recruiting DNMTs, the effects of this combination treatment was also explored on DNA methyltransferases (DNMTs) expression. Interestingly, the compounds resulted in a significant down-regulation of DNMT enzymes with no significant effects on DNMT enzyme expression in MCF10A control cells.
   Conclusion: Collectively, these results provide new insights into the epigenetic mechanisms of a novel combinatorial nutrient control strategy that exhibits synergy and may contribute to future recalcitrant TNBC prevention and/or therapy.
C1 [Kala, Rishabh; Shah, Harsh N.; Martin, Samantha L.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI Kala, Rishabh/AAR-1625-2020
OI Shah, Harsh/0000-0002-4371-9205
FU NCI [ROI CA178441]; American Institute for Cancer Research [316184]
FX This work was supported in part by grants from the NCI (ROI CA178441)
   and the American Institute for Cancer Research (316184). We thank
   Michael Daniel for his critical reading of the manuscript.
CR Ahmed A, 2003, J ANTI-AGING MED, V6, P315, DOI 10.1089/109454503323028911
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Büchner FL, 2011, INT J CANCER, V128, P2971, DOI 10.1002/ijc.25636
   Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026
   Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147
   di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504
   Estrela JM, 2013, CRIT REV CL LAB SCI, V50, P65, DOI 10.3109/10408363.2013.805182
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   González CA, 2011, INT J CANCER, V129, P449, DOI 10.1002/ijc.25679
   Gracia A, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0411-9
   Holt SE, 1996, MOL CELL BIOL, V16, P2932
   Howells LM, 2007, ACTA PHARMACOL SIN, V28, P1274, DOI 10.1111/j.1745-7254.2007.00690.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kala R., 2012, J NUTR FOOD SCI
   Kala Rishabh, 2013, J Clin Bioinforma, V3, P6, DOI 10.1186/2043-9113-3-6
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Love WK, 2008, TRANSL ONCOL, V1, P148, DOI 10.1593/tlo.08142
   De Bonis ML, 2014, STEM CELL REP, V2, P690, DOI 10.1016/j.stemcr.2014.03.002
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mikstacka R, 2010, PLANT FOOD HUM NUTR, V65, P57, DOI 10.1007/s11130-010-0154-8
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Nakamura AJ, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-6
   O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155
   Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825
   Podhorecka M, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/920161
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rajendran P, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-4
   Saldanha SN, 2014, EXP CELL RES, V324, P40, DOI 10.1016/j.yexcr.2014.01.024
   Sim HG, 2005, EUR J CANCER, V41, P834, DOI 10.1016/j.ejca.2004.12.033
   Stünkel W, 2011, J BIOMOL SCREEN, V16, P1153, DOI 10.1177/1087057111422103
   Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200
   Wang YM, 2011, MOL CANCER RES, V9, P1100, DOI 10.1158/1541-7786.MCR-11-0007
   Yamashita S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101864
   Zhang B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084931
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 42
TC 118
Z9 127
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 12
PY 2015
VL 15
AR 672
DI 10.1186/s12885-015-1693-z
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT2LF
UT WOS:000362632600003
PM 26459286
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lin, CS
   Lin, YC
   Adebayo, BO
   Wu, A
   Chen, JH
   Peng, YJ
   Cheng, MF
   Lee, WH
   Hsiao, M
   Chao, TY
   Yeh, CT
AF Lin, Chun-Shu
   Lin, Ying-Chin
   Adebayo, Bamodu Oluwaseun
   Wu, Alexander
   Chen, Jia-Hong
   Peng, Yi-Jen
   Cheng, Ming-Fang
   Lee, Wei-Hwa
   Hsiao, Michael
   Chao, Tsu-Yi
   Yeh, Chi-Tai
TI Silencing JARID1B suppresses oncogenicity, sternness and increases
   radiation sensitivity in human oral carcinoma
SO CANCER LETTERS
LA English
DT Article
DE JARID1B; Oral cancer; Cancer stem cell; shJARID1B; Radiotherapy; Head
   and neck cancer
ID SQUAMOUS-CELL CARCINOMA; MESENCHYMAL TRANSITION; BREAST-CANCER;
   SELF-RENEWAL; EXPRESSION; KDM5B; HEAD; NECK; PROLIFERATION; NOMENCLATURE
AB Purpose: Oral squamous cell carcinoma (OSCC) is a major cause of human mortality globally and radiotherapy is one of the main treatment modalities, however its therapeutic effect is often limited by radioresistance. JARID1B is an epigenetic factor with reported oncogenic potential in various cancer types. We investigated the effect of JARID1B inhibition on migration and invasion of human OSCC cell lines, as well as on clinical patients' outcome.
   Materials and Methods: Wound healing, matrigel invasion, Sulforhodamine B, and spheroid formation assays were used to characterize the signaling pathways of shJARID1B in response to radiation treatment. We evaluated the prognostic relevance of Jarid1b expression in a cohort of 81 OSCC patients.
   Results: Human OSCC cell lines, including SAS, HSO, Cal27, TW2.6 and SCC4 cells, were used. shJARID1B cells significantly inhibited migration and invasion ability compared to their vector or wild type counterparts. Silencing shJARID1B significantly inhibited oral cancer stem cell activity and potentiated the tumor-inhibitory activity of radiation therapy in OSCC. Radiotherapy coupled with shJARID1B knockdown reduced mRNA levels of NQO1, KEAP1, NRF2, FOXO1, FOXO3, KLF4, OCT4, CD133, and Nanog in malignant OSCC cells. OSCC spheroid formation ability was markedly reduced in the shJARID1B cells. JARID1B overexpression is a dependent prognostic factor in OSCC patients.
   Conclusions: Silencing shJARID1B inhibits migration and invasion of human OSCC, reduces cancer stem cell activities and potentiates tumor-inhibiting radiotherapeutic effects. JARID1B knockdown prior to radiotherapy is a potential effective therapeutic strategy for the treatment of OSCC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Lin, Chun-Shu] Triserv Gen Hosp, Natl Def Med Ctr, Dept Radiat Oncol, Taipei, Taiwan.
   [Lin, Chun-Shu; Adebayo, Bamodu Oluwaseun; Chen, Jia-Hong; Chao, Tsu-Yi; Yeh, Chi-Tai] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Lin, Ying-Chin] Taipei Med Univ, Shuang Ho Hosp, Dept Family Med, New Taipei, Taiwan.
   [Lin, Ying-Chin] Taipei Med Univ, Shuang Ho Hosp, Dept Occupat Med, New Taipei, Taiwan.
   [Lin, Ying-Chin] Taipei Med Univ, Coll Med, Sch Med, Dept Family Med, Taipei, Taiwan.
   [Wu, Alexander] Taipei Med Univ, Coll Med, PhD Program Translat Med, Taipei, Taiwan.
   [Chen, Jia-Hong; Chao, Tsu-Yi] Natl Def Med Ctr, Triserv Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan.
   [Peng, Yi-Jen] Natl Def Med Ctr, Triserv Gen Hosp, Dept Pathol, Taipei, Taiwan.
   [Cheng, Ming-Fang] Hualien Armed Forced Gen Hosp, Div Histol & Clin Pathol, Hualien, Taiwan.
   [Lee, Wei-Hwa] Taipei Med Univ, Dept Pathol, Shuang Ho Hosp, Taipei, Taiwan.
   [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Yeh, Chi-Tai] Taipei Med Univ, Dept Med Res & Educ, Shuang Ho Hosp, Taipei, Taiwan.
C3 National Defense Medical Center; Tri-Service General Hospital; Taipei
   Medical University; Taipei Medical University; Shuang Ho Hospital;
   Taipei Medical University; Shuang Ho Hospital; Taipei Medical
   University; Taipei Medical University; National Defense Medical Center;
   Tri-Service General Hospital; Tri-Service General Hospital; National
   Defense Medical Center; Taipei Medical University; Shuang Ho Hospital;
   Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital
RP Chao, TY (通讯作者)，Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
EM j0607@ms6.hinet.net; ctyeh@s.tmu.edu.tw
RI Cheng, Ming-Fang/H-6004-2019; Huang, Chi-Chang/A-3280-2013; Peng,
   Yi-Jen/X-9124-2019; Hsiao, Michael/U-6238-2019; chen,
   yuling/JMQ-4121-2023; Lin, Chung-Ying/I-5434-2016; Bamodu, Oluwaseun
   Adebayo/B-9784-2018
OI Bamodu, Oluwaseun Adebayo/0000-0001-8229-0408; Peng,
   Yi-Jen/0000-0003-4630-2103; Hsiao, Michael/0000-0001-8529-9213
FU National Science Council Taiwan [MOST103-2325-B-038-002]; Tri-Service
   General Hospital [TSGH-C103-057]; Taipei Medical University-Shuang Ho
   Hospital [100TMU-SHH-07, 101TMU-SHH-04]
FX This work was supported by the National Science Council Taiwan grant to
   Tsu-Yi Chao (MOST103-2325-B-038-002), study project of Tri-Service
   General Hospital (TSGH-C103-057), and grants from Taipei Medical
   University-Shuang Ho Hospital (100TMU-SHH-07 and 101TMU-SHH-04) to
   Chi-Tai Yeh. The authors thank Fang-Ting Kuo (Flow Cytometry Core
   Facility Center, Department of Medical Research, and Taipei Medical
   University-Shuang Ho Hospital) for her assistance with the flow
   cytometry and molecular and cell-based assays, and the Cancer Registry
   Group of Tr-Service General Hospital for the clinical data support.
CR Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Chung CH, 2006, CANCER RES, V66, P8210, DOI 10.1158/0008-5472.CAN-06-1213
   Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Enkhbaatar Z, 2013, CELL CYCLE, V12, P2100, DOI 10.4161/cc.25142
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Huang S, 2012, BIOESSAYS, V34, P149, DOI 10.1002/bies.201100031
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Roesch A, 2008, INT J CANCER, V122, P1047, DOI 10.1002/ijc.23211
   Sanjiv K, 2012, INT J CANCER, V130, P1440, DOI 10.1002/ijc.26142
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Stewart MH, 2015, BLOOD, V125, P2075, DOI 10.1182/blood-2014-08-596734
   Tsai CJ, 2013, INT J RADIAT ONCOL, V85, P415, DOI 10.1016/j.ijrobp.2012.05.032
   Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yeh C.-T., 2011, EVID-BASED COMPL ALT, V2011, P13
   Yu Yang, 2012, Front Biosci (Elite Ed), V4, P1528
NR 23
TC 48
Z9 52
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD NOV 1
PY 2015
VL 368
IS 1
BP 36
EP 45
DI 10.1016/j.canlet.2015.07.003
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CR3XD
UT WOS:000361265500006
PM 26184998
DA 2025-01-12
ER

PT J
AU Kwon, MJ
   Han, J
   Seo, JH
   Song, K
   Jeong, HM
   Choi, JS
   Kim, YJ
   Lee, SH
   Choi, YL
   Shin, YK
AF Kwon, Mi Jeong
   Han, Jinil
   Seo, Ji Hyun
   Song, Kyoung
   Jeong, Hae Min
   Choi, Jong-Sun
   Kim, Yu Jin
   Lee, Seon-Heui
   Choi, Yoon-La
   Shin, Young Kee
TI CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and
   Triple-Negative Breast Cancer
SO PLOS ONE
LA English
DT Article
ID TUMOR-GROWTH; BASAL-LIKE; EXPRESSION; CELLS; METASTASIS; MECHANISMS;
   PHENOTYPE; CARCINOMA; SURVIVAL; DISEASE
AB CD24 is associated with unfavourable prognoses in various cancers, but the prevalence of CD24 expression and its influence on clinical outcome in subtypes of breast cancers remain unclear. CD24 expression was analyzed by immunohistochemistry in 747 breast cancer tissues, and DNA methylation and histone modification status in the promoter region of CD24 were assessed using bisulfite sequencing and chromatin immunoprecipitation assay. 213 (28.5%) samples exhibited high CD24 expression in the membrane and/or cytoplasm of breast cancer cells, and CD24 overexpression was significantly correlated with the presence of lymph node metastasis and more advanced pathological stage. Patients with CD24-high tumours had significantly shorter patient survival than those with CD24-low tumours. Importantly, multivariate analysis that included tumour size, lymph node metastasis and chemotherapy demonstrated that high CD24 expression is independently associated with poorer survival in luminal A and triple-negative breast cancer (TNBC) subtypes. Furthermore, CD24 gene expression was associated with histone acetylation independent of DNA methylation, suggesting its epigenetic regulation in breast cancer. Our results suggest that CD24 overexpression is an independent unfavourable prognostic factor in breast cancer, especially for luminal A and TNBC subtypes, and CD24 may be a promising therapeutic target for specific subtypes of breast cancer.
C1 [Kwon, Mi Jeong] Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.
   [Kwon, Mi Jeong] Kyungpook Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Daegu, South Korea.
   [Han, Jinil] Gencurix Inc, Seoul, South Korea.
   [Seo, Ji Hyun; Jeong, Hae Min; Shin, Young Kee] Seoul Natl Univ, Lab Mol Pathol & Canc Genom, Coll Pharm, Dept Pharm, Seoul, South Korea.
   [Song, Kyoung] ABION Inc, Seoul, South Korea.
   [Choi, Jong-Sun; Shin, Young Kee] Seoul Natl Univ, Ctr Anticanc Compan Diagnost, Sch Biol Sci, Inst Entrepreneurial BioConvergence, Seoul, South Korea.
   [Kim, Yu Jin; Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Lab Canc Genom & Mol Pathol,Samsung Biomed Res In, Seoul, South Korea.
   [Lee, Seon-Heui] Gachon Univ, Coll Nursing, Dept Nursing Sci, Inchon, South Korea.
   [Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea.
   [Choi, Yoon-La] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Seoul National University (SNU); Seoul National University (SNU);
   Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Gachon
   University; Sungkyunkwan University (SKKU); Samsung Medical Center;
   Sungkyunkwan University (SKKU)
RP Choi, YL (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Lab Canc Genom & Mol Pathol,Samsung Biomed Res In, Seoul, South Korea.
EM ylachoi@skku.edu; ykeeshin@snu.ac.kr
RI Shin, Young/C-8929-2011; Kim, Yu/L-8480-2017
OI Shin, Young Kee/0000-0003-0896-718X; Kwon, Mi Jeong/0000-0002-7599-878X
FU Kyungpook National University Research Fund from the Samsung Biomedical
   Research Institute [SMX1132711]; R&D program for Society of the National
   Research Foundation (NRF) [2013M3C8A1079312]; Basic Science Research
   Program through the NRF - Ministry of Science, ICT & Future Planning
   [NRF-2012R1A1A3014050]
FX This work was supported by the Kyungpook National University Research
   Fund, 2013 & 2014 (MJK), a grant (SMX1132711 [YLC]) from the Samsung
   Biomedical Research Institute, the R&D program for Society of the
   National Research Foundation (NRF) (2013M3C8A1079312 [YKS]) and Basic
   Science Research Program through the NRF (NRF-2012R1A1A3014050 [YLC])
   funded by the Ministry of Science, ICT & Future Planning. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. Two authors (JH and KS) are
   employed by a commercial company, Gencurix for JH and ABION for KS,
   respectively. These commercial affiliations provided support in the form
   of salaries for authors [JH and KS], but did not have any additional
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The specific roles of these
   authors are articulated in the 'author contributions' section.
CR Abraham BK, 2005, CLIN CANCER RES, V11, P1154
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216
   Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619
   Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Bretz N, 2012, CLIN EXP METASTAS, V29, P27, DOI 10.1007/s10585-011-9426-4
   Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988
   Choi YL, J PATHOL TRANSL MED, V40, P103
   Choi YL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-507
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Darwish Nevine S, 2004, Cancer Res Treat, V36, P298, DOI 10.4143/crt.2004.36.5.298
   Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hosonaga M, 2014, CANCER SCI, V105, P779, DOI 10.1111/cas.12427
   Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Kaipparettu BA, 2008, INT J CANCER, V123, P66, DOI 10.1002/ijc.23480
   Kim HJ, 2011, BREAST, V20, P78, DOI 10.1016/j.breast.2010.08.001
   Kristiansen G, 2004, J MOL HISTOL, V35, P255
   Kristiansen G, 2003, CLIN CANCER RES, V9, P4906
   Kristiansen G, 2010, LAB INVEST, V90, P1102, DOI 10.1038/labinvest.2010.70
   Kwon MJ, 2011, LAB INVEST, V91, P1652, DOI 10.1038/labinvest.2011.117
   Lee JH, 2009, ONCOL REP, V22, P1149, DOI 10.3892/or_00000548
   Lim J, 2014, ARCH BIOCHEM BIOPHYS, V558, P120, DOI 10.1016/j.abb.2014.06.022
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   Perou CM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003293
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Surowiak P, 2006, BRIT J CANCER, V95, P339, DOI 10.1038/sj.bjc.6603254
   Thomas S, 2012, CANCER RES, V72, P5600, DOI 10.1158/0008-5472.CAN-11-3666
   Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084
NR 36
TC 63
Z9 71
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2015
VL 10
IS 10
AR e0139112
DI 10.1371/journal.pone.0139112
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CT0TS
UT WOS:000362510600043
PM 26444008
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kang, J
   Lee, HJ
   Jun, SY
   Park, ES
   Maeng, LS
AF Kang, Jun
   Lee, Hee Jin
   Jun, Sun-Young
   Park, Eun Su
   Maeng, Lee-so
TI Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss
   of X Chromosome Inactivation
SO PLOS ONE
LA English
DT Article
ID GENOMIC CHARACTERIZATION; BREAST-CANCER; TUMOR-ANTIGEN; GENE;
   IMMUNOTHERAPY; MELANOMA; ABNORMALITIES; LYMPHOCYTES; ACTIVATION; RNA
AB Background
   Cancertestis antigens (CTAs) are potential targets for cancer immunotherapy. Many CTAs are located on the X chromosome and are epigenetically regulated. Loss of X chromosome inactivation (XCI) is observed in breast and ovarian cancers and is thought to be related to the overexpression of CTAs. We investigated the relation between expression of CTAs and loss of XCI in endometrial cancer.
   Materials and Methods
   We used data generated by The Cancer Genome Atlas Genome Data Analysis Centers and data for Xist knockout mice available at the Gene Expression Omnibus.
   Results
   The status of XCI was estimated by methylation status, and deletion or gain of the X chromosome. The endometrial cancers were classified into the following three groups: preserved inactivated X chromosome (Xi) (n = 281), partial reactivation of Xi (n = 52), and two copies of active X group (n = 38). Loss of XCI was more common in serous adenocarcinoma. Expression of CTAs increased in endometrial cancer with loss of XCI, which was accompanied by global hypomethylation. Expression of CTAs did not increase in Xist knockout mice.
   Conclusions
   Loss of XCI is common in serous adenocarcinoma. Global hypomethylation, and not loss of XCI, is the main mechanism of overexpression of CTAs.
C1 [Kang, Jun; Jun, Sun-Young; Park, Eun Su; Maeng, Lee-so] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Hosp Pathol, Inchon, South Korea.
   [Lee, Hee Jin] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea.
C3 Catholic University of Korea; University of Ulsan; Asan Medical Center
RP Kang, J (通讯作者)，Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Hosp Pathol, Inchon, South Korea.
EM jkang.alien@gmail.com
RI Kim, Jin/Q-6322-2018; Kim, Jong/M-5732-2019
OI Jun, Sun-Young/0000-0002-3007-2094
CR Ahn J.Y., 2008, NAT ED, V1, P24
   BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0
   C.G. Nature, 2012, NATURE, V489, P519
   Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   De Backer O, 1999, CANCER RES, V59, P3157
   DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677
   Ganesan S, 2005, COLD SH Q B, V70, P93, DOI 10.1101/sqb.2005.70.045
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Jacobsen A., 2013, cgdsr: R-Based API for accessing the MSKCC Cancer Genomics Data Server (CGDS)
   Kang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118927
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Lax S F, 1997, Verh Dtsch Ges Pathol, V81, P228
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200
   Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Tureci O, 1996, CANCER RES, V56, P4766
   Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103
   WEBER J, 1994, CANCER RES, V54, P1766
   Whitehurst AW, 2014, ANNU REV PHARMACOL, V54, P251, DOI 10.1146/annurev-pharmtox-011112-140326
   Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034
NR 27
TC 9
Z9 9
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2015
VL 10
IS 9
AR e0137476
DI 10.1371/journal.pone.0137476
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CR0WB
UT WOS:000361043100044
PM 26360551
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Sarma, P
   Bag, I
   Ramaiah, MJ
   Kamal, A
   Bhadra, U
   Bhadra, MP
AF Sarma, Pranjal
   Bag, Indira
   Ramaiah, M. Janaki
   Kamal, Ahmed
   Bhadra, Utpal
   Bhadra, Manika Pal
TI Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53
   axis
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE Akt; docking; histone acetylation; p53 dependent genes; p53 acetylation;
   SIRTs; tubulin acetylation
ID SIGNALING PATHWAY; P53 ACETYLATION; HISTONE H3; INHIBITORS; SIRT1;
   PHOSPHORYLATION; APOPTOSIS; ACTIVATION; RESISTANCE; MTOR
AB In a previous study we reported the role of potent bisindole-PBD conjugate as an inclusion in the arsenal of breast cancer therapeutics. In breast cancer cell proliferation, PI3K/AKT/mTOR pathway plays a crucial role by prosurvival mechanism that inhibits programmed cell death. Here, 2 breast cancer cells lines, MCF-7 and MDA-MB-231 were treated with Vorinostat (suberoylanilide hydroxamic acid / SAHA) and bisindole-PBD (5b). We have investigated the effect on PI3K/AKT/mTOR pathway and SIRT expression including epigenetic regulation. There was consistent decrease in the level of PI3K, AKT, mTOR proteins upon treatment of 5b in both MCF-7 and MDA-MB-231 cell lines compared to untreated controls. Treatment with caspase inhibitor (Q-VD-OPH) confirmed that the effect of 5b on PI3K signaling was ahead of apoptosis. Real time PCR and western blot analysis showed profound reduction in the mRNA and protein levels of SIRT1 and SIRT2. Molecular docking studies also supported the interaction of 5b with various amino acids of SIRT2 proteins. Treatment with 5b caused epigenetic changes that include increase of acetylated forms of p53, increase of histone acetylation at p21 promoter as well as decrease in methylation state of p21 gene. Compound 5b thus acts as SIRT inhibitor and cause p53 activation via inhibition of growth factor signaling and activation of p53 dependent apoptotic signaling. This present study focuses bisindole-PBD on epigenetic alteration putting 5b as a promising therapeutic tool in the realm of breast cancer research.
C1 [Sarma, Pranjal; Bag, Indira; Ramaiah, M. Janaki; Bhadra, Manika Pal] Indian Inst Chem Technol, CSIR, Ctr Chem Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Bag, Indira; Bhadra, Utpal] CSIR, Ctr Cellular & Mol Biol, Funct Genom & Gene Silencing Grp, Hyderabad, Andhra Pradesh, India.
   [Ramaiah, M. Janaki] SASTRA Univ, Sch Chem & Biotechnol, Tirumalaisamudram, Thanjavur, India.
   [Kamal, Ahmed] Indian Inst Chem Technol, CSIR, Med Chem & Pharmacol, Hyderabad 500007, Andhra Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Indian Institute of Chemical Technology (IICT); Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Centre for Cellular &
   Molecular Biology (CCMB); Shanmugha Arts, Science, Technology & Research
   Academy (SASTRA); Council of Scientific & Industrial Research (CSIR) -
   India; CSIR - Indian Institute of Chemical Technology (IICT)
RP Bhadra, MP (通讯作者)，Indian Inst Chem Technol, CSIR, Ctr Chem Biol, Hyderabad 500007, Andhra Pradesh, India.
EM manikapb@gmail.com
RI RAMAIAH, JANAKI/AAL-9074-2020; SARMA, PRANJAL/AAE-2582-2020
OI Ramaiah, Janaki/0000-0003-1814-2819; SARMA, PRANJAL/0000-0003-0207-1278
FU CSIR [CSC0111]
FX The authors acknowledge CSIR 12th FYP (CSC0111) for the financial
   support.
CR Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1
   Andreani A, 2008, J MED CHEM, V51, P4563, DOI 10.1021/jm800194k
   Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Botta G, 2012, CURR MED CHEM, V19, P5871, DOI 10.2174/092986712804143303
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Brünner-Kubath C, 2011, BREAST CANCER RES TR, V129, P387, DOI 10.1007/s10549-010-1232-1
   Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Chiang GG, 2009, J CLIN ONCOL, V27, P2278
   Choi G, 2013, INT J ONCOL, V43, P1205, DOI 10.3892/ijo.2013.2035
   Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861
   Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147
   FAN SJ, 1995, CANCER RES, V55, P1649
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fröjdö S, 2011, MOL CELL ENDOCRINOL, V335, P166, DOI 10.1016/j.mce.2011.01.008
   German S, 2013, HERED CANCER CLIN PR, V11, DOI 10.1186/1897-4287-11-5
   Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0
   Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamal A, 2012, BIOORG MED CHEM LETT, V22, P571, DOI 10.1016/j.bmcl.2011.10.080
   Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054
   Lain S, 2003, EUR J CANCER, V39, P1053, DOI 10.1016/S0959-8049(03)00063-7
   LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665
   Li Kai, 2011, N Am J Med Sci (Boston), V4, P104
   Lin Zhenghong, 2013, Genes Cancer, V4, P97, DOI 10.1177/1947601912475079
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101
   McAuliffe PF, 2010, CLIN BREAST CANCER, V10, pS59, DOI 10.3816/CBC.2010.s.013
   Minakshi N, 2014, CELL CYCLE, V13
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224
   Olmos Y, 2011, DRUG RESIST UPDATE, V14, P35, DOI 10.1016/j.drup.2010.12.001
   Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Plumb JA, 2000, CANCER RES, V60, P6039
   Rivera E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2573
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Saretzki G, 2010, CURR PHARM DESIGN, V16, P79, DOI 10.2174/138161210789941874
   Sarma P, 2014, CANCER BIOL THER, V15, P1320, DOI 10.4161/cbt.29705
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602
   Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Trapp J, 2006, J MED CHEM, V49, P7307, DOI 10.1021/jm060118b
   van Agthoven T, 2009, J CLIN ONCOL, V27, P542, DOI 10.1200/JCO.2008.17.1462
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96
   Yardley DA, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/137414
   Zhang Q, 2012, EMBO MOL MED, V4, P298, DOI 10.1002/emmm.201100211
NR 64
TC 17
Z9 19
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD OCT
PY 2015
VL 16
IS 10
BP 1486
EP 1501
DI 10.1080/15384047.2015.1071731
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT8KC
UT WOS:000363064000009
PM 26192233
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Cordero, F
   Ferrero, G
   Polidoro, S
   Fiorito, G
   Campanella, G
   Sacerdote, C
   Mattiello, A
   Masala, G
   Agnoli, C
   Frasca, G
   Panico, S
   Palli, D
   Krogh, V
   Tumino, R
   Vineis, P
   Naccarati, A
AF Cordero, Francesca
   Ferrero, Giulio
   Polidoro, Silvia
   Fiorito, Giovanni
   Campanella, Gianluca
   Sacerdote, Carlotta
   Mattiello, Amalia
   Masala, Giovanna
   Agnoli, Claudia
   Frasca, Graziella
   Panico, Salvatore
   Palli, Domenico
   Krogh, Vittorio
   Tumino, Rosario
   Vineis, Paolo
   Naccarati, Alessio
TI Differentially methylated microRNAs in prediagnostic samples of subjects
   who developed breast cancer in the European Prospective Investigation
   into Nutrition and Cancer (EPIC-Italy) cohort
SO CARCINOGENESIS
LA English
DT Article
ID EPIGENOME-WIDE ASSOCIATION; DNA-METHYLATION; EPIGENETIC EPIDEMIOLOGY;
   EXPRESSION; METASTASIS; BLOOD; RISK; PROFILE; GENES
AB The crosstalk between microRNAs (miRNAs) and other epigenetic factors may lead to novel hypotheses about carcinogenesis identifying new targets for research. Because a single miRNA can regulate multiple downstream target genes, its altered expression may potentially be a sensitive biomarker to detect early malignant transformation and improve diagnosis and prognosis. In the current study, we tested the hypothesis that altered methylation of miRNA encoding genes, associated with deregulated mature miRNA expression, may be related to dietary and lifestyle factors and may contribute to cancer development. In a case-control study nested in a prospective cohort (EPIC-Italy), we analysed DNA methylation levels of miRNA encoding genes (2191 CpG probes related to 517 genes) that are present in the Infinium Human Methylation450 BeadChip array in prediagnostic peripheral white blood cells of subjects who developed colorectal cancer (CRC, n = 159) or breast cancer (BC, n = 166) and matched subjects who remained clinically healthy. In the whole cohort, several differentially methylated miRNA genes were observed in association with age, sex, smoking habits and physical activity. Interestingly, in the case-control study, eight differentially methylated miRNAs were identified in subjects who went on to develop BC (miR-328, miR-675, miR-1307, miR-1286, miR-1275, miR-1910, miR-24-1 and miR-548a-1; all Bonferroni-adjusted P < 0.05). No significant associations were found with CRC. Assuming that altered methylation of miRNAs detectable in blood may be present before diagnosis, it may represent a biomarker for early detection or risk of cancer and may help to understand the cascade of events preceding tumour onset.
C1 [Cordero, Francesca; Ferrero, Giulio] Univ Turin, Dept Comp Sci, I-10149 Turin, Italy.
   [Ferrero, Giulio] Univ Turin, Dept Clin & Biol Sci, I-10043 Orbassano, Italy.
   [Polidoro, Silvia; Vineis, Paolo; Naccarati, Alessio] Human Genet Fdn, Mol & Genet Epidemiol Unit, I-10126 Turin, Italy.
   [Fiorito, Giovanni] Human Genet Fdn, Genom Variat Human Populat & Complex Dis Unit, I-10126 Turin, Italy.
   [Fiorito, Giovanni] Univ Turin, Dept Clin & Biol Sci, I-10126 Turin, Italy.
   [Campanella, Gianluca] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London W2 1PG, England.
   [Sacerdote, Carlotta] Univ Turin, AO Citta Salute & Sci, Unit Canc Epidemiol, I-10126 Turin, Italy.
   [Sacerdote, Carlotta] Ctr Canc Prevent CPO, I-10126 Turin, Italy.
   [Mattiello, Amalia; Panico, Salvatore] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy.
   [Masala, Giovanna; Palli, Domenico] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, I-50141 Florence, Italy.
   [Agnoli, Claudia; Frasca, Graziella; Krogh, Vittorio; Tumino, Rosario] Ist Nazl Tumori, Fdn IRCCS, Epidemiol & Prevent Unit, I-20133 Milan, Italy.
   [Vineis, Paolo] Univ London Imperial Coll Sci Technol & Med, MRC PHE Ctr Environm & Hlth, London W2 1PG, England.
C3 University of Turin; University of Turin; University of Turin; Imperial
   College London; University of Turin; A.O.U. Citta della Salute e della
   Scienza di Torino; University of Naples Federico II; ISPRO Istituto per
   lo studio, la prevenzione e la rete oncologica; Fondazione IRCCS
   Istituto Nazionale Tumori Milan; Imperial College London
RP Naccarati, A (通讯作者)，Human Genet Fdn Torino HuGeF, Via Nizza 52, Turin, Italy.
EM alessio.naccarati@hugef-torino.org
RI Sacerdote, Carlotta/K-3611-2018; Panico, Salvatore/K-6506-2016; Masala,
   Giovanna/AAC-5474-2022; Ferrero, Giulio/K-9508-2019; Cordero,
   Francesca/AAB-3655-2019; Krogh, Vittorio/AAA-9171-2019; Polidoro,
   Silvia/GYJ-3517-2022; Campanella, Gianluca/G-2617-2010; Krogh,
   Vittorio/K-2628-2016; Mattiello, Amalia/K-5112-2016; Fiorito,
   Giovanni/AFV-6938-2022; Ferrero, Giulio/B-9838-2014; Agnoli,
   Claudia/K-5916-2016
OI Campanella, Gianluca/0000-0002-5411-6338; Krogh,
   Vittorio/0000-0003-0122-8624; Mattiello, Amalia/0000-0003-3676-7353;
   Panico, Salvatore/0000-0002-5498-8312; tumino,
   rosario/0000-0003-2666-414X; Masala, Giovanna/0000-0002-5758-9069;
   Fiorito, Giovanni/0000-0002-7651-5452; Polidoro,
   Silvia/0000-0003-2968-0575; Ferrero, Giulio/0000-0002-4580-0680; PALLI,
   Domenico/0000-0002-5558-2437; Sacerdote, Carlotta/0000-0002-8008-5096;
   Agnoli, Claudia/0000-0003-4472-1179; Naccarati,
   Alessio/0000-0001-5774-0905; Cordero, Francesca/0000-0002-3143-3330
FU Compagnia di San Paolo, Torino, Italy; Associazione Italiana per la
   Ricerca sul Cancro (AIRC), Italy [13236]
FX Compagnia di San Paolo, Torino, Italy (to P.V.); Associazione Italiana
   per la Ricerca sul Cancro (AIRC, IG 2012, project no: 13236) Italy (to
   D.P.).
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Agnoli C, 2011, J NUTR, V141, P1552, DOI 10.3945/jn.111.140061
   Aure MR, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r126
   Barrow TM, 2014, BIOCHEM BIOPH RES CO, V455, P70, DOI 10.1016/j.bbrc.2014.08.002
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Campanella G., 2014, INT J EPIDEMIOL
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Du WW, 2013, J CELL SCI, V126, P1440, DOI 10.1242/jcs.118299
   Duttagupta R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020769
   Dweep H, 2014, METHODS MOL BIOL, V1182, P289, DOI 10.1007/978-1-4939-1062-5_25
   Ell B, 2014, J BIOL CHEM, V289, P21888, DOI 10.1074/jbc.M114.582866
   Fiorito G, 2014, NUTR METAB CARDIOVAS, V24, P483, DOI 10.1016/j.numecd.2013.10.026
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Guo L, 2014, MOL BIOL REP, V41, P201, DOI 10.1007/s11033-013-2852-4
   Hastie Trevor., 2014, impute: Imputation for microarray data R package version
   Heijmans BT, 2012, INT J EPIDEMIOL, V41, P74, DOI 10.1093/ije/dyr225
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kim WT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015260
   Kita Y, 2014, EXPERT REV MOL DIAGN, V14, P673, DOI 10.1586/14737159.2014.925399
   Koestler DC, 2013, STAT APPL GENET MOL, V12, P225, DOI 10.1515/sagmb-2012-0068
   Langevin SM, 2014, EPIGENETICS-US, V9, P884, DOI 10.4161/epi.28575
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913
   Liang TM, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/679563
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Noguer-Dance M, 2010, HUM MOL GENET, V19, P3566, DOI 10.1093/hmg/ddq272
   Peña-Chilet M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-529
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027355
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Riboli E, 2001, J NUTR, V131, p170S, DOI 10.1093/jn/131.1.170S
   Ross SA, 2011, ADV NUTR, V2, P472, DOI 10.3945/an.111.001206
   Saikumar J, 2012, TOXICOL SCI, V129, P256, DOI 10.1093/toxsci/kfs210
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Shen J, 2012, EPIGENETICS-US, V7, P1230, DOI 10.4161/epi.22140
   Shi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086295
   Steegenga Wilma T, 2014, Age (Dordr), V36, P9648, DOI 10.1007/s11357-014-9648-x
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Tarallo S, 2014, MUTAGENESIS, V29, P385, DOI 10.1093/mutage/geu028
   Volinia S, 2013, P NATL ACAD SCI USA, V110, P7413, DOI 10.1073/pnas.1304977110
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Wu Q, 2012, CLIN CHIM ACTA, V413, P1058, DOI 10.1016/j.cca.2012.02.016
   Xu ZL, 2014, CARCINOGENESIS, V35, P356, DOI 10.1093/carcin/bgt391
   Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239
NR 51
TC 30
Z9 32
U1 0
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2015
VL 36
IS 10
BP 1144
EP 1153
DI 10.1093/carcin/bgv102
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5KZ
UT WOS:000362850200008
PM 26168820
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Moelans, CB
   Vlug, EJ
   Ercan, C
   Bult, P
   Buerger, H
   Cserni, G
   van Diest, PJ
   Derksen, PWB
AF Moelans, Cathy B.
   Vlug, Eva J.
   Ercan, Cigdem
   Bult, Peter
   Buerger, Horst
   Cserni, Gabor
   van Diest, Paul J.
   Derksen, Patrick W. B.
TI Methylation biomarkers for pleomorphic lobular breast cancer - a short
   report
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Sporadic breast cancer; Lobular breast cancer; Pleomorphic lobular
   breast cancer; DNA hypermethylation; MS-MLPA; Epigenetics
ID PROMOTER HYPERMETHYLATION; SPORADIC BREAST; DNA METHYLATION; E-CADHERIN;
   MAMMARY-CARCINOMA; EXPRESSION; RASSF1A; TUMORS; BRCA1; DIFFERENTIATION
AB Background Pleomorphic invasive lobular cancer (pleomorphic ILC) is a rare variant of ILC that is characterized by a classic ILC-like growth pattern combined with an infiltrative ductal cancer (IDC)-like high nuclear atypicality. There is an ongoing discussion whether pleomorphic ILC is a dedifferentiated form of ILC or in origin an IDC with a secondary loss of cohesion. Since gene promoter hypermethylation is an early event in breast carcinogenesis and thus may provide information on tumor progression, we set out to compare the methylation patterns of pleomorphic ILC, classic ILC and IDC. In addition, we aimed at analyzing the methylation status of pleomorphic ILC.
   Methods We performed promoter methylation profiling of 24 established and putative tumor suppressor genes by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) analysis in 20 classical ILC, 16 pleomorphic ILC and 20 IDC cases.
   Results We found that pleomorphic ILC showed relatively low TP73 and MLH1 methylation levels and relatively high RASSF1A methylation levels compared to classic ILC. Compared to IDC, pleomorphic ILC showed relatively low MLH1 and BRCA1 methylation levels. Hierarchical cluster analysis revealed a similar methylation pattern for pleomorphic ILC and IDC, while the methylation pattern of classic ILC was different.
   Conclusion This is the first report to identify TP73, RASSF1A, MLH1 and BRCA1 as possible biomarkers to distinguish pleomorphic ILC from classic ILC and IDC.
C1 [Moelans, Cathy B.; Vlug, Eva J.; Ercan, Cigdem; van Diest, Paul J.; Derksen, Patrick W. B.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands.
   [Bult, Peter] Radboud Univ Nijmegen, Dept Pathol, NL-6525 ED Nijmegen, Netherlands.
   [Buerger, Horst] Inst Pathol, Paderborn, Germany.
   [Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Kecskemet, Hungary.
C3 Utrecht University; Utrecht University Medical Center; Radboud
   University Nijmegen
RP Moelans, CB (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM C.B.Moelans@umcutrecht.nl; pderksen@umcutrecht.nl
RI Cserni, Gabor/JCN-6784-2023; Bult, Peter/L-4236-2015; Derksen,
   Patrick/C-6643-2008
OI Moelans, Cathy/0000-0001-9992-8703; Bult, Peter/0000-0001-6427-9889;
   Cserni, Gabor/0000-0003-1344-7744; Derksen, Patrick/0000-0003-0732-7762
FU Netherlands Organization for Scientific Research [NWO-VIDI 917.96.318]
FX This work was supported by a grant from The Netherlands Organization for
   Scientific Research (NWO-VIDI 917.96.318). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adem C, 2003, CANCER, V97, P1, DOI 10.1002/cncr.11048
   [Anonymous], BREAST CANC RES
   Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Berx G, 1996, ONCOGENE, V13, P1919
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Buchanan CL, 2008, J SURG ONCOL, V98, P314, DOI 10.1002/jso.21121
   Chen Kang Mei, 2011, Cancers (Basel), V3, P1580, DOI 10.3390/cancers3021580
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   de Groot JS, 2014, CELL ONCOL, V37, P297, DOI 10.1007/s13402-014-0189-1
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395
   Dötsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Ercan C, 2012, CELL ONCOL, V35, P111, DOI 10.1007/s13402-012-0071-y
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   EUSEBI V, 1992, HUM PATHOL, V23, P655, DOI 10.1016/0046-8177(92)90321-S
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fadare O, 2008, HUM PATHOL, V39, P331, DOI 10.1016/j.humpath.2007.07.014
   Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001
   Gudlaugsson E, 2010, BREAST CANCER RES TR, V121, P35, DOI 10.1007/s10549-009-0442-x
   Hömig-Hölzel C, 2012, DIAGN MOL PATHOL, V21, P189, DOI 10.1097/PDM.0b013e3182595516
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001
   Middleton LP, 2000, AM J SURG PATHOL, V24, P1650, DOI 10.1097/00000478-200012000-00009
   Monhollen L, 2012, HISTOPATHOLOGY, V61, P365, DOI 10.1111/j.1365-2559.2012.04230.x
   Müller HM, 2003, CANCER RES, V63, P7641
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rawat A, 2014, CELL ONCOL, V37, P409, DOI 10.1007/s13402-014-0204-6
   Reis JS, 2005, J PATHOL, V207, P1, DOI 10.1002/path.1806
   Sardanelli F, 2004, AM J ROENTGENOL, V183, P1149, DOI 10.2214/ajr.183.4.1831149
   Sarrío D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Shao MM, 2012, VIRCHOWS ARCH, V461, P313, DOI 10.1007/s00428-012-1289-9
   Simpson PT, 2008, J PATHOL, V215, P231, DOI 10.1002/path.2358
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R
   Varga Zsuzsanna, 2008, Breast Dis, V30, P15, DOI 10.3233/BD-2009-0278
   Verschuur-Maes AHJ, 2012, BREAST CANCER RES TR, V136, P705, DOI 10.1007/s10549-012-2301-4
   Vlug E., 2013, ARCH IMMUNOL THER EX, P1
   WEIDNER N, 1992, HUM PATHOL, V23, P1167, DOI 10.1016/0046-8177(92)90035-2
NR 48
TC 11
Z9 11
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD OCT
PY 2015
VL 38
IS 5
BP 397
EP 405
DI 10.1007/s13402-015-0241-9
PG 9
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA CT5WK
UT WOS:000362881600007
PM 26392358
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Choi, HJ
   Park, JH
   Park, M
   Won, HY
   Joo, HS
   Lee, CH
   Lee, JY
   Kong, G
AF Choi, Hee-Joo
   Park, Ji-Hye
   Park, Mikyung
   Won, Hee-Young
   Joo, Hyeong-seok
   Lee, Chang Hoon
   Lee, Jeong-Yeon
   Kong, Gu
TI UTX inhibits EMT-induced breast CSC properties by epigenetic repression
   of EMT genes in cooperation with LSD1 and HDAC1
SO EMBO REPORTS
LA English
DT Article
DE breast CSC; EMT; UTX
ID EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HISTONE
   DEMETHYLASE UTX; STEM-CELLS; E-CADHERIN; LYSINE 27; CANCER; SNAIL;
   SUPPRESSOR; EXPRESSION
AB The histone H3K27 demethylase, UTX, is a known component of the H3K4 methyltransferase MLL complex, but its functional association with H3K4 methylation in human cancers remains largely unknown. Here we demonstrate that UTX loss induces epithelial-mesenchymal transition (EMT)-mediated breast cancer stem cell (CSC) properties by increasing the expression of the SNAIL, ZEB1 and ZEB2 EMT transcription factors (EMT-TFs) and of the transcriptional repressor CDH1. UTX facilitates the epigenetic silencing of EMT-TFs by inducing competition between MLL4 and the H3K4 demethylase LSD1. EMT-TF promoters are occupied by c-Myc and MLL4, and UTX recognizes these proteins, interrupting their transcriptional activation function. UTX decreases H3K4me2 and H3 acetylation at these promoters by forming a transcriptional repressive complex with LSD1, HDAC1 and DNMT1. Taken together, our findings indicate that UTX is a prominent tumour suppressor that functions as a negative regulator of EMT-induced CSC-like properties by epigenetically repressing EMT-TFs.
C1 [Choi, Hee-Joo; Won, Hee-Young; Joo, Hyeong-seok; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea.
   [Park, Ji-Hye; Lee, Jeong-Yeon; Kong, Gu] Hanyang Univ, IBBR, Seoul 133791, South Korea.
   [Park, Mikyung; Lee, Chang Hoon] Dongguk Univ, Coll Pharm, Seoul, South Korea.
C3 Hanyang University; Hanyang University; Dongguk University
RP Lee, JY (通讯作者)，Hanyang Univ, IBBR, Seoul 133791, South Korea.
EM jy2jy2@hanyang.ac.kr; gkong@hanyang.ac.kr
RI Choi, Hyuk/AAF-7713-2019
OI Choi, Hee-Joo/0000-0001-6432-8193
FU National Research Foundation of Korea (NRF) - Korean Government
   [2010-0020879]
FX This study was supported by the National Research Foundation of Korea
   (NRF), which is funded by the Korean Government (No. 2010-0020879).
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Herz HM, 2010, MOL CELL BIOL, V30, P2485, DOI 10.1128/MCB.01633-09
   Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lim S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066558
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Terashima M, 2010, BIOCHEM BIOPH RES CO, V399, P238, DOI 10.1016/j.bbrc.2010.07.061
   Tie F, 2012, MOL CELL BIOL, V32, P2323, DOI 10.1128/MCB.06392-11
   Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang CC, 2012, P NATL ACAD SCI USA, V109, P15324, DOI 10.1073/pnas.1204166109
   Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
NR 38
TC 91
Z9 98
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD OCT
PY 2015
VL 16
IS 10
BP 1288
EP 1298
DI 10.15252/embr.201540244
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CT1KV
UT WOS:000362558100010
PM 26303947
OA Green Published
DA 2025-01-12
ER

PT J
AU Sloane, MA
   Nunez, AC
   Packham, D
   Kwok, CT
   Suthers, G
   Hesson, LB
   Ward, RL
AF Sloane, Mathew A.
   Nunez, Andrea C.
   Packham, Deborah
   Kwok, Chau-To
   Suthers, Graeme
   Hesson, Luke B.
   Ward, Robyn L.
TI Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal
   Cancer
SO JAMA ONCOLOGY
LA English
DT Article
ID CONSTITUTIONAL PROMOTER METHYLATION; LYNCH SYNDROME; GENOMIC
   REARRANGEMENTS; GERMLINE EPIMUTATIONS; BREAST-CANCER; MLH1; EXPRESSION;
   DELETION; BRCA1; RISK
AB IMPORTANCE Constitutional hypermethylation of 1 allele throughout the soma (constitutional epimutation) is an accepted mechanism of cancer predisposition. Understanding the origin and inheritance of epimutations is important for assessing cancer risk in affected families.
   OBSERVATIONS We report a 29-year-old man with early-onset colorectal cancer who showed a constitutional MLH1 epimutation (approximately 50% of allelesmethylated and allele-specific loss of MLH1 expression) that was stable over a 16-year period. The epimutation was inherited without a genetic alteration from his asymptomatic mother. She showed methylation on the same allele but in less than 5% of her somatic cells.
   CONCLUSIONS AND RELEVANCE These findings indicate that low-level somatic mosaicism for an epimutation in an asymptomatic parent can produce a nonmosaic constitutional epimutation in a child. Asymptomatic low-level methylation in some individuals may be associated with substantial cancer risk to their offspring.
C1 [Ward, Robyn L.] Univ Queensland, Brian Wilson Chancellery, Level 3, Brisbane, Qld 4072, Australia.
   [Sloane, Mathew A.; Nunez, Andrea C.; Packham, Deborah; Kwok, Chau-To; Hesson, Luke B.; Ward, Robyn L.] Univ New South Wales, Lowy Canc Res Ctr, Adult Canc Program, Sydney, NSW, Australia.
   [Sloane, Mathew A.; Nunez, Andrea C.; Packham, Deborah; Kwok, Chau-To; Hesson, Luke B.; Ward, Robyn L.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia.
   [Suthers, Graeme] Univ Adelaide, Dept Paediat, Adelaide, SA 5005, Australia.
   [Suthers, Graeme] Sonic Healthcare, Macquarie Pk, NSW, Australia.
C3 University of Queensland; University of New South Wales Sydney;
   University of New South Wales Sydney; University of Adelaide
RP Ward, RL (通讯作者)，Univ Queensland, Brian Wilson Chancellery, Level 3, Brisbane, Qld 4072, Australia.
EM r.ward@uq.edu.au
RI Hesson, Luke/HDM-0311-2022; Ward, Robyn Lynne/I-2313-2013
OI Ward, Robyn Lynne/0000-0002-6877-8906
FU Cancer Council NSW [RG13-07]; Cancer Australia
FX This study was supported by Cancer Council NSW (RG13-07) and Cancer
   Australia.
CR Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   Goel A, 2011, INT J CANCER, V128, P869, DOI 10.1002/ijc.25422
   Gylling A, 2009, INT J CANCER, V124, P2333, DOI 10.1002/ijc.24230
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Hitchins MP, 2013, FAM CANCER, V12, P189, DOI 10.1007/s10689-013-9613-3
   Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003
   Hyland PL, 2014, EPIGENETICS-US, V9, P685, DOI 10.4161/epi.28151
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Lynch HT, 1999, J MED GENET, V36, P801
   Morak M, 2011, J MED GENET, V48, P513, DOI 10.1136/jmedgenet-2011-100050
   Tinat J, 2008, FAM CANCER, V7, P339, DOI 10.1007/s10689-008-9196-6
NR 14
TC 23
Z9 23
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD OCT
PY 2015
VL 1
IS 7
BP 953
EP 957
DI 10.1001/jamaoncol.2015.1484
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW5HX
UT WOS:000383675900015
PM 26181641
DA 2025-01-12
ER

PT J
AU Wiegmans, AP
   Yap, PY
   Ward, A
   Lim, YC
   Khanna, KK
AF Wiegmans, Adrian P.
   Yap, Pei-Yi
   Ward, Ambber
   Lim, Yi Chieh
   Khanna, Kum Kum
TI Differences in Expression of Key DNA Damage Repair Genes after
   Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1
   Inhibition
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; HOMOLOGOUS-RECOMBINATION; RAD51;
   THERAPY; PROTEIN; FANCD2; BRCA1; PHOSPHORYLATION; SENSITIVITY;
   DEFICIENCY
AB The triple-negative breast cancer (TNBC) subtype represents a cancer that is highly aggressive with poor patient outcome. Current preclinical success has been gained through synthetic lethality, targeting genome instability with PARP inhibition in breast cancer cells that harbor silencing of the homologous recombination (HR) pathway. Histone deacetylase inhibitors (HDACi) are a class of drugs that mediate epigenetic changes in expression of HR pathway genes. Here, we compare the activity of the pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA), the class I/IIa HDAC inhibitor valproic acid (VPA), and the HDAC1/2-specific inhibitor romidepsin (ROMI) for their capability to regulate DNA damage repair gene expression and in sensitizing TNBC to PARPi. We found that two of the HDACis tested, SAHA and ROMI, but not VPA, indeed inhibit HR repair and that RAD51, BARD1, and FANCD2 represent key proteins whose inhibition is required for HDACi-mediated therapy with PARP inhibition in TNBC. We also observed that restoration of BRCA1 function stabilizes the genome compared with mutant BRCA1 that results in enhanced polyploid population after combination treatment with HDACi and PARPi. Furthermore, we found that overexpression of the key HR protein RAD51 represents a mechanism for this resistance, promoting aberrant repair and the enhanced polyploidy observed. These findings highlight the key components of HR in guiding synthetic lethality with PARP inhibition and support the rationale for utilizing the novel combination of HDACi and PARPi against TNBC in the clinical setting. (C) 2015 AACR.
C1 [Wiegmans, Adrian P.; Yap, Pei-Yi; Ward, Ambber; Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Herston, Qld 4029, Australia.
   [Wiegmans, Adrian P.] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Herston, Qld 4029, Australia.
   [Lim, Yi Chieh] QIMR Berghofer Med Res Inst, Translat Brain Canc Lab, Herston, Qld, Australia.
C3 QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical
   Research Institute; QIMR Berghofer Medical Research Institute
RP Wiegmans, AP (通讯作者)，QIMR Berghofer Med Res Inst, Herston, Qld 4029, Australia.
EM adrian.wiegmans@qimrberghofer.edu.au
RI Wiegmans, Adrian/K-1609-2015; Khanna, Kum/I-1747-2013
OI Lim, Yi Chieh/0000-0003-1261-5419; Khanna, Kum Kum/0000-0001-8650-5381
FU National Breast Cancer Foundation Australia [PF-13-12]; Cancer Council
   Queensland [1061216]; National Health and Medical Research Council
   [1017028]
FX A.P. Wiegmans was funded by a fellowship from National Breast Cancer
   Foundation Australia (PF-13-12), P.-Y. Yap and Y.C. Lim are funded by a
   Cancer Council Queensland project grant (1061216) and K.K. Khanna is
   funded by a National Health and Medical Research Council Project Grant
   (1017028).
CR Adimoolam S, 2007, P NATL ACAD SCI USA, V104, P19482, DOI 10.1073/pnas.0707828104
   Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939
   Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184
   Certo MT, 2011, NAT METHODS, V8, P671, DOI [10.1038/NMETH.1648, 10.1038/nmeth.1648]
   Chen JJ, 1999, CANCER RES, V59, p1752S
   Chiu HW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076340
   Daboussi F, 2002, CELL SIGNAL, V14, P969, DOI 10.1016/S0898-6568(02)00052-9
   Daemen A, 2012, BREAST CANCER RES TR, V135, P505, DOI 10.1007/s10549-012-2188-0
   Dalgard CL, 2008, CLIN CANCER RES, V14, P3113, DOI 10.1158/1078-0432.CCR-07-4836
   Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200
   Fagerholm R, 2013, ANN ONCOL, V24, P2780, DOI 10.1093/annonc/mdt290
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Ha K, 2014, ONCOTARGET, V5, P5637, DOI 10.18632/oncotarget.2154
   Henning W, 2003, TOXICOLOGY, V193, P91, DOI 10.1016/S0300-483X(03)00291-9
   Huang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100993
   Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson N, 2013, P NATL ACAD SCI USA, V110, P17041, DOI 10.1073/pnas.1305170110
   Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208
   Kotian S, 2011, J BIOL CHEM, V286, P7722, DOI 10.1074/jbc.C110.194233
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104
   Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899
   Min A, 2015, BREAST CANCER RES, V17, P534
   Nakanishi K, 2011, METHODS MOL BIOL, V745, P283, DOI 10.1007/978-1-61779-129-1_16
   Orre LM, 2006, BIOCHEM BIOPH RES CO, V341, P334, DOI 10.1016/j.bbrc.2005.12.185
   Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Sharma S, 2008, TRANSL ONCOL, V1, P141, DOI 10.1593/tlo.08136
   Slingerland M, 2014, ANTI-CANCER DRUG, V25, P140, DOI 10.1097/CAD.0000000000000040
   Slupianek A, 2009, LEUKEMIA, V23, P2308, DOI 10.1038/leu.2009.164
   Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278
   van der Groep P, 2008, BREAST CANCER RES TR, V107, P41, DOI 10.1007/s10549-007-9534-7
   Venkitaraman AR, 2004, NAT REV CANCER, V4, P266, DOI 10.1038/nrc1321
   Wang YM, 2012, CANCER RES, V72, P4037, DOI 10.1158/0008-5472.CAN-12-0103
   Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092
   Wiegmans AP, 2014, ONCOTARGET, V5, P3261, DOI 10.18632/oncotarget.1923
   Woditschka S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju145
   Xie CZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079106
   Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018
   Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004
   Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566
NR 44
TC 38
Z9 46
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2015
VL 14
IS 10
BP 2321
EP 2331
DI 10.1158/1535-7163.MCT-15-0374
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CU3EA
UT WOS:000363405600016
PM 26294743
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Kang, HJ
   Kim, JM
   Kim, SY
   Kim, SW
   Shin, IS
   Kim, HR
   Park, MH
   Shin, MG
   Yoon, JH
   Yoon, JS
AF Kang, Hee-Ju
   Kim, Jae-Min
   Kim, Seon-Young
   Kim, Sung-Wan
   Shin, Il-Seon
   Kim, Hye-Ran
   Park, Min-Ho
   Shin, Myung-Geun
   Yoon, Jung-Han
   Yoon, Jin-Sang
TI A Longitudinal Study of <i>BDNF</i> Promoter Methylation and Depression
   in Breast Cancer
SO PSYCHIATRY INVESTIGATION
LA English
DT Article
DE Breast cancer; Depression; BDNF; DNA methylation; Epigenetics
ID QUALITY-OF-LIFE; SEROTONIN TRANSPORTER GENE; NEUROTROPHIC-FACTOR;
   VAL66MET POLYMORPHISM; MAJOR DEPRESSION; EPIGENETIC REGULATION; SLC6A4
   METHYLATION; DNA METHYLATION; BRAIN; WOMEN
AB Objective Brain-derived neurotrophic factor (BDNF) is investigated in depression related to medical disorders and its secretion is influenced by epigenetic factors. We investigated the association between BDNF promoter methylation and depression following mastectomy for breast cancer.
   Methods In total, 309 patients with breast cancer were evaluated 1 week after mastectomy, and 244 (79%) were followed up 1 year later. Depression was diagnosed (major or minor depressive disorder) according to DSM-IV criteria and depression severity was estimated by Montgomery-Asberg Depression Rating Scale (MADRS). We assessed BDNF promoter methylation using leukocyte DNA. The effects of BDNF methylation on depression diagnosis and severity were investigated using multivariate logistic and linear regression models, respectively. The two-way interaction between BDNF methylation and the val66met polymorphism on depression was also evaluated using multivariate logistic regression models.
   Results Higher BDNF methylation was independently associated with depression diagnosis and with more severe symptoms at both 1 week and 1 year after mastectomy. No significant methylation-genotype interactions were found.
   Conclusion A role for BDNF in depression related to breast cancer was supported. Indeed, the association between depression and BDNF methylation may be useful for identifying patients who are at high risk for depression and for suggesting directions for promising drug research.
C1 [Kang, Hee-Ju; Kim, Jae-Min; Kim, Seon-Young; Kim, Sung-Wan; Shin, Il-Seon; Yoon, Jin-Sang] Chonnam Natl Univ, Dept Psychiat, Sch Med, Gwangju 61469, South Korea.
   [Kim, Hye-Ran] Chonnam Natl Univ, Sch Med, Ctr Biomed Human Resources, Brain Korea Project 21, Gwangju 61469, South Korea.
   [Park, Min-Ho; Yoon, Jung-Han] Chonnam Natl Univ, Hwasun Hosp, Breast & Endocrine Tumor Clin, Hwasun, South Korea.
   [Shin, Myung-Geun] Chonnam Natl Univ, Sch Med, Dept Lab Med, Gwangju 61469, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Chonnam National University
RP Kim, JM (通讯作者)，Chonnam Natl Univ, Dept Psychiat, Sch Med, 160 Baekseo Ro, Gwangju 61469, South Korea.
EM jmkim@chonnam.ac.kr
RI Wan, Kim/AAI-8744-2020; shin, i/JCE-1227-2023; KIM, Jae-Min/S-7637-2019
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0003]; Chonnam National University Hospital
   Biomedical Research Institute [CRI 14032-1]; National R&D Program for
   Cancer Control, Ministry for Health and Welfare, Republic of Korea
   [2013-1320070]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0003) and
   was supported by a grant of Chonnam National University Hospital
   Biomedical Research Institute (CRI 14032-1). Prof. M-G Shin is
   part-funded by a grant from the National R&D Program for Cancer Control,
   Ministry for Health and Welfare, Republic of Korea (No. 2013-1320070).
   The Ministry of Health and Welfare of Korea and Chonnam National
   University Hospital Biomedical Research Institute had no further role in
   study design; in the collection, analysis and interpretation of data; in
   the writing of the report; or in the decision to submit the paper for
   publication.
CR [Anonymous], AJCC CANC STAG HDB A
   Bower JE, 2008, J CLIN ONCOL, V26, P768, DOI 10.1200/JCO.2007.14.3248
   Bozzini S, 2009, INT J MOL MED, V24, P813, DOI 10.3892/ijmm_00000297
   Burgess C, 2005, BRIT MED J, V330, P702, DOI 10.1136/bmj.38343.670868.D3
   Caspi A, 2010, AM J PSYCHIAT, V167, P509, DOI 10.1176/appi.ajp.2010.09101452
   Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43
   Devlin AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012201
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Ell K, 2005, J CLIN ONCOL, V23, P3052, DOI 10.1200/JCO.2005.08.041
   Fann JR, 2008, GEN HOSP PSYCHIAT, V30, P112, DOI 10.1016/j.genhosppsych.2007.10.008
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fingeret MC, 2013, CANCER TREAT REV, V39, P673, DOI 10.1016/j.ctrv.2012.12.010
   Fuchikami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023881
   Giese-Davis J, 2011, J CLIN ONCOL, V29, P413, DOI 10.1200/JCO.2010.28.4455
   Henningsson S, 2009, BIOL PSYCHIAT, V66, P477, DOI 10.1016/j.biopsych.2009.04.009
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kang HJ, 2013, PROG NEURO-PSYCHOPH, V44, P23, DOI 10.1016/j.pnpbp.2013.01.006
   Karege F, 2005, MOL BRAIN RES, V136, P29, DOI 10.1016/j.molbrainres.2004.12.020
   Kim JM, 2008, NEUROBIOL AGING, V29, P789, DOI 10.1016/j.neurobiolaging.2006.11.021
   Kim JM, 2013, J PSYCHIATR RES, V47, P1222, DOI 10.1016/j.jpsychires.2013.04.010
   Kim JM, 2013, J AFFECT DISORDERS, V149, P93, DOI 10.1016/j.jad.2013.01.008
   Kim JM, 2013, J AFFECT DISORDERS, V148, P57, DOI 10.1016/j.jad.2012.11.048
   Kim JM, 2012, PSYCHOSOM MED, V74, P8, DOI 10.1097/PSY.0b013e318241530c
   Kinnally EL, 2010, GENES BRAIN BEHAV, V9, P575, DOI 10.1111/j.1601-183X.2010.00588.x
   LINDESAY J, 1990, INT J GERIATR PSYCH, V5, P171, DOI 10.1002/gps.930050305
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Melas PA, 2012, INT J NEUROPSYCHOPH, V15, P669, DOI 10.1017/S1461145711000940
   Mill J, 2007, MOL PSYCHIATR, V12, P799, DOI 10.1038/sj.mp.4001992
   MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
   Niitsu T, 2013, PROG NEURO-PSYCHOPH, V45, P183, DOI 10.1016/j.pnpbp.2013.05.011
   Pei Y, 2012, AM J MED GENET B, V159B, P560, DOI 10.1002/ajmg.b.32062
   Philibert R, 2007, AM J MED GENET B, V144B, P101, DOI 10.1002/ajmg.b.30414
   Philibert RA, 2008, AM J MED GENET B, V147B, P543, DOI 10.1002/ajmg.b.30657
   Pidsley R, 2011, BIOL PSYCHIAT, V69, P146, DOI 10.1016/j.biopsych.2010.03.029
   Powell TR, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.73
   Reich M, 2008, BREAST CANCER RES TR, V110, P9, DOI 10.1007/s10549-007-9706-5
   Safarinejad MR, 2013, PSYCHO-ONCOLOGY, V22, P1242, DOI 10.1002/pon.3130
   Schroeder M, 2010, CURR OPIN PSYCHIATR, V23, P588, DOI 10.1097/YCO.0b013e32833d16c1
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09m05305whi
   Shim EJ, 2008, PSYCHO-ONCOLOGY, V17, P548, DOI 10.1002/pon.1275
   THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   Weinberger T, 2010, PSYCHIAT CLIN N AM, V33, P409, DOI 10.1016/j.psc.2010.01.005
   Xu J, 2013, LUPUS, V22, P1001, DOI 10.1177/0961203313498793
   Zhao JY, 2013, PSYCHOSOM MED, V75, P523, DOI 10.1097/PSY.0b013e3182924cf4
   Zhou JX, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-34
   Zill P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040479
NR 49
TC 28
Z9 32
U1 0
U2 15
PU KOREAN NEUROPSYCHIATRIC ASSOC
PI SEOUL
PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL,
   137-882, SOUTH KOREA
EI 1976-3026
J9 PSYCHIAT INVEST
JI Psychiatry Investig.
PD OCT
PY 2015
VL 12
IS 4
BP 523
EP 531
DI 10.4306/pi.2015.12.4.523
PG 9
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA CV1BR
UT WOS:000363988700014
PM 26508964
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Agodi, A
   Barchitta, M
   Quattrocchi, A
   Maugeri, A
   Canto, C
   Marchese, AE
   Vinciguerra, M
AF Agodi, Antonella
   Barchitta, Martina
   Quattrocchi, Annalisa
   Maugeri, Andrea
   Canto, Carolina
   Marchese, Anna Elisa
   Vinciguerra, Manlio
TI Low fruit consumption and folate deficiency are associated with LINE-1
   hypomethylation in women of a cancer-free population
SO GENES AND NUTRITION
LA English
DT Article
DE Mediterranean diet; Folate intake; Epigenetics; Global methylation
ID GLOBAL DNA METHYLATION; BIOACTIVE FOOD COMPONENTS; MEDITERRANEAN DIET;
   BREAST-CANCER; BLADDER-CANCER; FAMILY-HISTORY; LEUKOCYTE DNA;
   LIFE-STYLE; RISK; BLOOD
AB Several dietary agents, such as micronutrient and non-nutrient components, the so-called bioactive food components, have been shown to display anticancer properties and influence genetic processes. The most common epigenetic change is DNA methylation. Hypomethylation of long interspersed elements (LINE-1) has been associated with an increased risk of several cancers, although conflicting findings have also been observed. The aim of the present study was to test the hypothesis that a low adherence to the Mediterranean diet (MD) and folate deficiency may cause LINE-1 hypomethylation in blood leukocytes of healthy women, and thus genomic instability. One hundred and seventy-seven non-pregnant women were enrolled. Mediterranean diet score (MDS) and folate intake were calculated using a food frequency questionnaire. LINE-1 methylation level was measured by pyrosequencing analysis in three CpG sites of LINE-1 promoter. According to MDS, only 9.6 % of subjects achieved a high adherence to MD. Taking into account the use of supplements, there was a high prevalence of folate deficiency (73.4 %). Women whose consumption of fruit was below the median value (i.e.,<201 gr/day) were 3.7 times more likely to display LINE-1 hypomethylation than women whose consumption was above the median value (OR 3.7; 95 % CI 1.4-9.5). Similarly, women with folate deficiency were 3.6 times more likely to display LINE-1 hypomethylation than women with no folate deficiency (OR 3.6; 95 % CI 1.1-12.1). A dietary pattern characterized by low fruit consumption and folate deficiency is associated with LINE-1 hypomethylation and with cancer risk.
C1 [Agodi, Antonella; Barchitta, Martina; Quattrocchi, Annalisa; Maugeri, Andrea; Canto, Carolina] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, I-95121 Catania, Italy.
   [Agodi, Antonella; Barchitta, Martina] Univ Catania, LaPoSS, Lab Policies & Social Serv, I-95121 Catania, Italy.
   [Canto, Carolina] Oncopath Srl, Floridia, SR, Italy.
   [Marchese, Anna Elisa] UOC Lab Analisi 1 PO Vittorio Emanuele, Catania, Italy.
   [Vinciguerra, Manlio] UCL, Inst Liver & Digest Hlth, London, England.
   [Vinciguerra, Manlio] Nottingham Trent Univ, Interdisciplinary Biomed Res Ctr, Sch Sci & Technol, Nottingham, England.
C3 University of Catania; University of Catania; University of London;
   University College London; Nottingham Trent University
RP Agodi, A (通讯作者)，Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95121 Catania, Italy.
EM agodia@unict.it
RI Vinciguerra, Manlio/N-1309-2015; Quattrocchi, Annalisa/AAU-5458-2020;
   Maugeri, Andrea/K-1018-2017; Agodi, Antonella/B-3501-2011; Marchese,
   Anna Elisa/J-2204-2018; Barchitta, Martina/A-1362-2015
OI Maugeri, Andrea/0000-0003-2655-8574; Vinciguerra,
   Manlio/0000-0002-1768-3894; Quattrocchi, Annalisa/0000-0002-5764-6721;
   Marchese, Anna Elisa/0000-0002-9796-0758; Barchitta,
   Martina/0000-0002-0905-5003; Agodi, Antonella/0000-0002-4405-8162
FU Bench Srl, University of Catania
FX This work was supported in part by grants from Bench Srl, University of
   Catania. We are grateful to Fabrizio Italia (Oncopath s.r.l, Floridia,
   SR, Italy) for his technical support.
CR Agodi A, 2011, EUR J CLIN NUTR, V65, P1302, DOI 10.1038/ejcn.2011.125
   Agodi A, 2014, 2014 C INT SOC ENV E
   Agodi A, 2014, MUTAGENESIS, V29, P101, DOI 10.1093/mutage/get065
   Agodi A, 2013, ANN NUTR METAB, V63, P179, DOI 10.1159/000346962
   Martínez-González MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043134
   Barchitta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109478
   Barchitta M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/742620
   Buckland G, 2013, INT J CANCER, V132, P2918, DOI 10.1002/ijc.27958
   Castelló A, 2014, BRIT J CANCER, V111, P1454, DOI 10.1038/bjc.2014.434
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Couto E, 2011, BRIT J CANCER, V104, P1493, DOI 10.1038/bjc.2011.106
   Crider KS, 2012, ADV NUTR, V3, P21, DOI 10.3945/an.111.000992
   da Silva R, 2009, PUBLIC HEALTH NUTR, V12, P1676, DOI 10.1017/S1368980009990541
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Delgado-Cruzata L, 2015, J NUTR, V145, P783, DOI 10.3945/jn.114.202853
   Delgado-Cruzata L, 2014, EPIGENETICS-US, V9, P243, DOI 10.4161/epi.26880
   Deroo LA, 2014, CARCINOGENESIS, V35, P333, DOI 10.1093/carcin/bgt342
   Dos Santos Silva I, 1999, CANC EPIDEMIOLOGY PR
   Duthie SJ, 2011, J INHERIT METAB DIS, V34, P101, DOI 10.1007/s10545-010-9128-0
   Estécio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Filomeno M, 2015, BRIT J CANCER, V112, P1816, DOI 10.1038/bjc.2015.153
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Gallus S, 2013, EUR J NUTR, V52, P677, DOI 10.1007/s00394-012-0372-y
   Gomes MVM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052570
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Kim YI, 2007, MOL NUTR FOOD RES, V51, P267, DOI 10.1002/mnfr.200600191
   LaRowe TL, 2007, J AM DIET ASSOC, V107, P1124, DOI 10.1016/j.jada.2007.04.013
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Martín-Núñez GM, 2014, MOL NUTR FOOD RES, V58, P1528, DOI 10.1002/mnfr.201400079
   Milner JA, 2004, J NUTR, V134, p2492S, DOI 10.1093/jn/134.9.2492S
   Ministry of Health, 2003, LIN GUID SAN AL IT
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296
   Olmedo-Requena R, 2013, PUBLIC HEALTH NUTR, V17, P648
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Ono H, 2012, CANCER SCI, V103, P2159, DOI 10.1111/cas.12013
   Piyathilake CJ, 2012, CANCER PREV RES, V5, P385, DOI 10.1158/1940-6207.CAPR-11-0387
   Piyathilake CJ, 2011, NUTRITION, V27, P513, DOI 10.1016/j.nut.2010.08.018
   Pounis G, 2014, NUTRITION, V30, P822, DOI 10.1016/j.nut.2013.11.014
   Pufulete M, 2005, GUT, V54, P648, DOI 10.1136/gut.2004.054718
   Sheng W, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-20
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Su L. Joseph, 2012, Frontiers in Genetics, V2, P91, DOI 10.3389/fgene.2011.00091
   Tamura T, 2006, AM J CLIN NUTR, V83, P993, DOI 10.1093/ajcn/83.5.993
   Tollefsbol T., 2009, Cancer Epigenetics
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Wallace NA, 2008, GENE, V419, P75, DOI 10.1016/j.gene.2008.04.013
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012
   Wilcken B, 2003, J MED GENET, V40, P619, DOI 10.1136/jmg.40.8.619
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   Wilson AG, 2008, J PERIODONTOL, V79, P1514, DOI 10.1902/jop.2008.080172
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang QH, 2009, CANCER EPIDEM BIOMAR, V18, P1439, DOI 10.1158/1055-9965.EPI-08-0908
   Zhang FF, 2012, EPIGENETICS-US, V7, P606, DOI 10.4161/epi.20236
   Zhang FF, 2011, J NUTR, V141, P1165, DOI 10.3945/jn.110.134536
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 65
TC 66
Z9 69
U1 2
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1555-8932
EI 1865-3499
J9 GENES NUTR
JI Genes Nutr.
PD SEP
PY 2015
VL 10
IS 5
AR 30
DI 10.1007/s12263-015-0480-4
PG 10
WC Genetics & Heredity; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Nutrition & Dietetics
GA CQ7XO
UT WOS:000360820100004
PM 26183162
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Seven, D
   Dogan, S
   Kiliç, E
   Karaman, E
   Koseoglu, H
   Buyru, N
AF Seven, Didem
   Dogan, Soydan
   Kilic, Erkan
   Karaman, Emin
   Koseoglu, Hikmet
   Buyru, Nur
TI Downregulation of Rab25 activates Akt1 in head and neck squamous cell
   carcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE Ras-associated binding 25 protein; Akt1; head and neck squamous cell
   carcinoma; tumor suppression; gene expression
ID OVARIAN-CANCER CELLS; CANINE KIDNEY-CELLS; BREAST-CANCER; IN-VITRO;
   EXPRESSION; GTPASES; PROTEINS; IDENTIFICATION; TUMORS; GENE
AB Several studies have suggested that Ras-associated binding 25 protein (Rab25) is involved in the pathogenesis of human cancer. Although it has been demonstrated that the development of head and neck squamous cell carcinoma (HNSCC) is the result of an accumulation of multiple sequential genetic and epigenetic alterations in key genes with important functions in cell growth and the cell cycle, recent studies have indicated that HNSCC is a complex and heterogenous disease. To the best of our knowledge, there is no data regarding the regulation of the Rab25 gene at the mRNA or protein level in HNSCC. Furthermore, available data on Rab25 expression in other types of cancer are conflicting. The aim of the present study was to investigate whether Rab25 is involved in the development and/or progression of HNSCC, and to analyze the mechanisms underlying its effects in this type of cancer. The expression of Rab25 mRNA in HNSCC tissues and adjacent non-tumor tissue samples was measured using reverse transcription-quantitative polymerase chain reaction, while the level of the Rab25, Akt1 and phosphorylated-Akt1 proteins was measured using western blotting. Expression of Rab25 mRNA and protein was downregulated in 69.1% and 56.1% of tumor tissue samples, respectively. This downregulation was associated with an increase in p-Akt1 expression, in the absence of a change in total Akt1 protein levels, in tumor tissues compared with normal tissues. The current findings suggest that Rab25 acts as a tumor suppressor in HNSCC.
C1 [Seven, Didem; Dogan, Soydan; Koseoglu, Hikmet; Buyru, Nur] Istanbul Univ, Dept Med Biol, Cerrahpasa Med Fac, TR-34098 Kocamustafapasa, Fatih, Turkey.
   [Kilic, Erkan; Karaman, Emin] Istanbul Univ, Dept Otorhinolaryngol, Cerrahpasa Med Fac, TR-34098 Kocamustafapasa, Fatih, Turkey.
C3 Istanbul University; Istanbul University - Cerrahpasa; Istanbul
   University; Istanbul University - Cerrahpasa
RP Buyru, N (通讯作者)，Istanbul Univ, Dept Med Biol, Cerrahpasa Med Fac, 53 Kocamustafapasa St, TR-34098 Kocamustafapasa, Fatih, Turkey.
EM nbuyru@yahoo.com
RI Köseoğlu, Hikmet/A-8081-2008; Buyru, Nur/D-1810-2019; Seven,
   Didem/AAL-5780-2021
OI Buyru, Nur/0000-0002-6920-1455; Seven, Didem/0000-0003-3406-5905
FU Istanbul University [13732, 34503]
FX This study was supported by the Research Fund of Istanbul University
   (grant nos. 13732 and 34503).
CR Agarwal R, 2009, TRAFFIC, V10, P1561, DOI 10.1111/j.1600-0854.2009.00969.x
   Amornphimoltham P, 2013, CLIN CANCER RES, V19, P1375, DOI 10.1158/1078-0432.CCR-12-2858
   [Anonymous], SEER Cancer Statistics Review, 1975-2018
   Báez A, 2008, J ENVIRON SCI HEAL C, V26, P174, DOI 10.1080/10590500802129431
   Bigelow RLH, 2009, BREAST CANCER RES TR, V117, P31, DOI 10.1007/s10549-008-0170-7
   Calvo A, 2002, CANCER RES, V62, P5325
   Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47
   Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012
   Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739
   Cheng JM, 2010, INT J CANCER, V126, P2799, DOI 10.1002/ijc.24900
   Cheng KW, 2005, METHOD ENZYMOL, V403, P202, DOI 10.1016/S0076-6879(05)03017-X
   Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573
   Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125
   Cheng KW, 2012, EMBO MOL MED, V4, P125, DOI 10.1002/emmm.201100193
   Demokan S, 2006, ANN ONCOL, V17, P995, DOI 10.1093/annonc/mdl048
   Deneka M, 2003, CRIT REV BIOCHEM MOL, V38, P121, DOI 10.1080/713609214
   Fan Y, 2006, PATHOLOGY, V38, P561, DOI 10.1080/00313020601024037
   Gleich Lyon L, 2002, Cancer Control, V9, P369
   Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983
   GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419
   Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103
   Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347
   He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406
   Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x
   Lapierre LA, 2011, CYTOSKELETON, V68, P97, DOI 10.1002/cm.20497
   Liu YT, 2012, MOL MED REP, V6, P1006, DOI 10.3892/mmr.2012.1052
   Mitra S, 2012, BIOCHEM SOC T, V40, P1404, DOI 10.1042/BST20120249
   Mor O, 2003, ONCOGENE, V22, P7702, DOI 10.1038/sj.onc.1207039
   Natrajan R, 2006, J PATHOL, V210, P49, DOI 10.1002/path.2021
   Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072
   Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500
   Rodman JS, 2000, J CELL SCI, V113, P183
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwartz SL, 2007, J CELL SCI, V120, P3905, DOI 10.1242/jcs.015909
   Sheach LA, 2009, BRIT J CANCER, V101, P498, DOI 10.1038/sj.bjc.6605153
   Tang BL, 2010, TUMOR BIOL, V31, P359, DOI 10.1007/s13277-010-0030-z
   Tong M, 2012, CANCER RES, V72, P6024, DOI 10.1158/0008-5472.CAN-12-1269
   Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023
   Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136
   Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhang JX, 2013, CARCINOGENESIS, V34, P2401, DOI 10.1093/carcin/bgt187
NR 43
TC 8
Z9 9
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2015
VL 10
IS 3
BP 1927
EP 1931
DI 10.3892/ol.2015.3433
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CQ9GZ
UT WOS:000360923000123
PM 26622777
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhang, YY
   Zhang, JY
   Liu, ZW
   Liu, YJ
   Tuo, SH
AF Zhang, Yuanyuan
   Zhang, Junying
   Liu, Zhaowen
   Liu, Yajun
   Tuo, Shouheng
TI A network-based approach to identify disease-associated gene modules
   through integrating DNA methylation and gene expression
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DNA methylation; Gene expression; Gene network; Integrative analysis;
   Canonical correlation analysis
ID BREAST-CANCER; PROMOTER METHYLATION; CELL; GENOME; VALIDATION
AB Formation and progression of complex diseases are generally the joint effect of genetic and epigenetic disorders, thus an integrative analysis of epigenetic and genetic data is essential for understanding mechanism of the diseases. In this study, we integrate Illuminate 450k DNA methylation and gene expression data to calculate the weights of gene network using Principal Component Analysis (PCA) and Canonical Correlation Analysis (CCA). The approach considers all methylation values of CpG sites in a gene, rather than averaging them which was used in other studies ignoring the variability of the methylation sites. Through comparing topological features of control network with those of case network, including global and local features, candidate disease-associated genes and gene modules are identified. We apply the approach to real data, breast invasive carcinoma (BRCA). It successfully identifies susceptibility breast cancer-related genes, such as TP53, BRCA1, EP300, CDK2, MCM7 and so forth, within which most are previously known to breast cancer. Also, GO and pathway enrichment analysis indicate that these genes enrich in cell apoptosis and regulation of cell death which are cancer-related biological processes. Importantly, through analyzing the functions and comparing expression and methylation values of these genes between cases and controls, we find some genes, such as VASN, SNRPD3, and gene modules, targeted by POLR2C, CHMP1B and TAF9, which might be novel breast cancer-related biomarkers. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Zhang, Yuanyuan; Zhang, Junying; Liu, Zhaowen; Liu, Yajun; Tuo, Shouheng] Xidian Univ, Sch Comp Sci & Technol, Xian 710071, Peoples R China.
C3 Xidian University
RP Zhang, JY (通讯作者)，Xidian Univ, Sch Comp Sci & Technol, Xian 710071, Peoples R China.
EM jyzhang@mail.xidian.edu.cn
RI Yajun, Liu/R-2758-2016; Zhang, Junying/IYS-2873-2023; Yuanyuan,
   Zhang/KCK-1271-2024; Liu, Zhaowen/AAM-6710-2021
OI Zhang, Yuanyuan/0000-0003-3935-3201
FU Natural Science Foundation of China [61070137, 61201312, 61170183];
   Research Fund for the Doctoral Program of Higher Education of China
   [20130203110017]; Fundamental Research Funds for the Central
   Universities of China [BDY171416, JB140306]
FX This work was supported by the Natural Science Foundation of China under
   Grants 61070137, 61201312, 61170183, Research Fund for the Doctoral
   Program of Higher Education of China (No. 20130203110017), and the
   Fundamental Research Funds for the Central Universities of China (No.
   BDY171416, JB140306).
CR [Anonymous], JOURNAL OF GRAPH ALG
   Bai F, 2014, CANCER RES, V74, P6161, DOI 10.1158/0008-5472.CAN-14-1119
   Bartlett TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084573
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Cheng CP, 2014, BIOINFORMATICS, V30, P3054, DOI 10.1093/bioinformatics/btu433
   Danon L, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/09/P09008
   Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Keller MP, 2008, GENOME RES, V18, P706, DOI 10.1101/gr.074914.107
   Kim SJ, 2014, CANCER LETT, V355, P217, DOI 10.1016/j.canlet.2014.08.042
   Kristensen VN, 2014, NAT REV CANCER, V14, P299, DOI 10.1038/nrc3721
   Li YS, 2014, MOL BIOSYST, V10, P180, DOI 10.1039/c3mb70270g
   Liu H, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-158
   Mitra K, 2013, NAT REV GENET, V14, P719, DOI 10.1038/nrg3552
   Moran S, 2014, EPIGENETICS-US, V9, P829, DOI 10.4161/epi.28790
   Park HJ, 2014, ONCOTARGET, V5, P5087, DOI 10.18632/oncotarget.2086
   Pey J, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-134
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Renner M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r137
   Ritchie MD, 2015, NAT REV GENET, V16, P85, DOI 10.1038/nrg3868
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Sun H, 2013, STAT MED, V32, P2127, DOI 10.1002/sim.5694
   Wirtenberger M, 2006, CARCINOGENESIS, V27, P2201, DOI 10.1093/carcin/bgl067
   Zannetti A, 2005, BIOCHEM PHARMACOL, V70, P1277, DOI 10.1016/j.bcp.2005.07.024
   Zhang Qingyang, 2014, BMC Syst Biol, V8, P1338, DOI 10.1186/s12918-014-0136-9
   Zhang YY, 2015, MOL BIOSYST, V11, P1786, DOI 10.1039/c5mb00141b
NR 31
TC 11
Z9 11
U1 0
U2 24
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 25
PY 2015
VL 465
IS 3
BP 437
EP 442
DI 10.1016/j.bbrc.2015.08.033
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CR5XS
UT WOS:000361418300020
PM 26282201
DA 2025-01-12
ER

PT J
AU Rodríguez-Miguel, C
   Moral, R
   Escrich, R
   Vela, E
   Solanas, M
   Escrich, E
AF Rodriguez-Miguel, Cristina
   Moral, Raquel
   Escrich, Raquel
   Vela, Elena
   Solanas, Montserrat
   Escrich, Eduard
TI The Role of Dietary Extra Virgin Olive Oil and Corn Oil on the
   Alteration of Epigenetic Patterns in the Rat DMBA-Induced Breast Cancer
   Model
SO PLOS ONE
LA English
DT Article
ID INDUCED MAMMARY-CARCINOMA; TUMOR-SUPPRESSOR GENE; DNA
   METHYLTRANSFERASES; LIPID INFLUENCE; CPG ISLAND; METHYLATION;
   EXPRESSION; ESTROGEN; TRIMETHYLATION; INSTABILITY
AB Disruption of epigenetic patterns is a major change occurring in all types of cancers. Such alterations are characterized by global DNA hypomethylation, gene-promoter hypermethylation and aberrant histone modifications, and may be modified by environment. Nutritional factors, and especially dietary lipids, have a role in the etiology of breast cancer. Thus, we aimed to analyze the influence of different high fat diets on DNA methylation and histone modifications in the rat dimethylbenz(a) anthracene (DMBA)-induced breast cancer model. Female Sprague-Dawley rats were fed a low-fat, a high corn-oil or a high extra-virgin olive oil (EVOO) diet from weaning or from induction with DMBA. In mammary glands and tumors we analyzed global and gene specific (RASSF1A, TIMP3) DNA methylation by LUMA and bisulfite pyrosequencing assays, respectively. We also determined gene expression and enzymatic activity of DNA methyltransferases (DNMT1, DNMT3a and DNMT3b) and evaluated changes in histone modifications (H3K4me2, H3K27me3, H4K20me3 and H4K16ac) by western-blot. Our results showed variations along time in the global DNA methylation of the mammary gland displaying decreases at puberty and with aging. The olive oil-enriched diet, on the one hand, increased the levels of global DNA methylation in mammary gland and tumor, and on the other, changed histone modifications patterns. The corn oil-enriched diet increased DNA methyltransferase activity in both tissues, resulting in an increase in the promoter methylation of the tumor suppressor genes RASSF1A and TIMP3. These results suggest a differential effect of the high fat diets on epigenetic patterns with a relevant role in the neoplastic transformation, which could be one of the mechanisms of their differential promoter effect, clearly stimulating for the high corn-oil diet and with a weaker influence for the high EVOO diet, on breast cancer progression.
C1 [Rodriguez-Miguel, Cristina; Moral, Raquel; Escrich, Raquel; Vela, Elena; Solanas, Montserrat; Escrich, Eduard] Univ Autonoma Barcelona, Fac Med, Dept Cell Biol Physiol & Immunol, Physiol Unit,Grp Multidisciplinari Estudi Canc Ma, E-08193 Barcelona, Spain.
C3 University of Barcelona; Autonomous University of Barcelona
RP Moral, R (通讯作者)，Univ Autonoma Barcelona, Fac Med, Dept Cell Biol Physiol & Immunol, Physiol Unit,Grp Multidisciplinari Estudi Canc Ma, E-08193 Barcelona, Spain.
EM Raquel.Moral@uab.cat
RI Garcia, Montserrat/O-4684-2016; Moral, Raquel/H-2122-2015
OI Moral, Raquel/0000-0002-2738-6121; SOLANAS GARCIA,
   MONTSERRAT/0000-0003-2949-1344
FU Plan Nacional I+D+I [AGL2006-07691/ALI, AGL2011-24778]; Fundacion
   Patrimonio Comunal Olivarero [FPCO2008-165.396, FPCO2013-CF611.084];
   Agencia para el Aceite de Oliva del Ministerio de Agricultura,
   Alimentacion y Medio Ambiente [AAO2008-165.471]; Organizacion
   Interprofesional del Aceite de Oliva Espanol [OIP2009-165.646];
   Departament de Salut i d'Agricultura, Alimentacio i Accio Rural de la
   Generalitat de Catalunya [GC2010-165.000]
FX This work was supported by "Plan Nacional I+D+I 2004-2007 & 2008-2011"
   (AGL2006-07691/ALI & AGL2011-24778) to EE; "Fundacion Patrimonio Comunal
   Olivarero" (FPCO2008-165.396; FPCO2013-CF611.084) to EE; "Agencia para
   el Aceite de Oliva del Ministerio de Agricultura, Alimentacion y Medio
   Ambiente" (AAO2008-165.471) to EE; "Organizacion Interprofesional del
   Aceite de Oliva Espanol" (OIP2009-165.646) to EE; and Departament de
   Salut i d'Agricultura, Alimentacio i Accio Rural de la Generalitat de
   Catalunya" (GC2010-165.000) to EE. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003
   Bachman KE, 1999, CANCER RES, V59, P798
   Chodosh LA, 1998, J MAMMARY GLAND BIOL, V3, P389, DOI 10.1023/A:1018784031651
   Costa I, 2004, BREAST CANCER RES TR, V86, P225, DOI 10.1023/B:BREA.0000036896.75548.0c
   Costa I, 2002, ARCH PATHOL LAB MED, V126, P915
   Dammann R, 2001, CANCER RES, V61, P3105
   Di Francesco A, 2015, J NUTR BIOCHEM, V26, P250, DOI 10.1016/j.jnutbio.2014.10.013
   Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Escrich E, 2006, OLIVE OIL AND HEALTH, P317, DOI 10.1079/9781845930684.0317
   Escrich E, 2014, CANCER TREAT RES, V159, P289, DOI 10.1007/978-3-642-38007-5_17
   Escrich Eduard, 1994, In Vivo (Attiki), V8, P1107
   Escrich Eduard, 1994, In Vivo (Attiki), V8, P1099
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005
   Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Guthrie N, 1999, PROG LIPID RES, V38, P261, DOI 10.1016/S0163-7827(99)00006-5
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kutanzi K, 2013, CANCER BIOL THER, V14, P564, DOI 10.4161/cbt.24599
   Li JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106290
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Moral R, 2011, NUTR CANCER, V63, P410, DOI 10.1080/01635581.2011.535956
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Russo J, 1997, ENDOCR-RELAT CANCER, V4, P7, DOI 10.1677/erc.0.0040007
   Sant Karilyn E, 2012, Methods Mol Biol, V889, P385, DOI 10.1007/978-1-61779-867-2_24
   Schwingshackl L, 2014, INT J CANCER, V135, P1884, DOI 10.1002/ijc.28824
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Solanas M, 2002, INT J ONCOL, V21, P745
   Solanas M, 2010, CARCINOGENESIS, V31, P871, DOI 10.1093/carcin/bgp243
   Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   World Cancer Research Fund/American Institute for Cancer Research, 2007, FOOD NUTRITION PHYSI
   Yenbutr P, 1998, MECH AGEING DEV, V106, P93, DOI 10.1016/S0047-6374(98)00093-1
NR 44
TC 33
Z9 33
U1 0
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2015
VL 10
IS 9
AR e0138980
DI 10.1371/journal.pone.0138980
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CS1BS
UT WOS:000361798100047
PM 26401660
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Brisotto, G
   di Gennaro, A
   Damiano, V
   Armellin, M
   Perin, T
   Maestro, R
   Santarosa, M
AF Brisotto, Giulia
   di Gennaro, Alessandra
   Damiano, Valentina
   Armellin, Michela
   Perin, Tiziana
   Maestro, Roberta
   Santarosa, Manuela
TI An improved sequencing-based strategy to estimate locus-specific DNA
   methylation
SO BMC CANCER
LA English
DT Article
DE DNA-methylation; miR-200c/miR-141 locus; Method; Cancer; Bisulfite
   treatment; Sequencing; E-cadherin; CDH1; Promoter
ID QUALITY-OF-LIFE; ESOPHAGEAL CANCER; COLORECTAL-CANCER; CO-MORBIDITY;
   ELDERLY-PATIENTS; SURGERY; IMPACT; OUTCOMES; OLDER; MANAGEMENT
AB Background: DNA methylation is an important epigenetic mechanism of transcriptional control that plays an essential role in several cellular functions. Aberrant DNA methylation in cancer has been frequently associated with downregulation of microRNAs and protein coding genes, such as miR-200c/miR-141 cluster and E-cadherin. Current strategies to assess DNA methylation, including bisulfite treatment-based assays, tend to be time-consuming and may be quite expensive when a precise appraisal is required. The Sanger-sequencing of the amplified bisulfite-treated DNA (BSP) might represent a practical option to measure DNA methylation at single CpG resolution. However, this strategy often produces noisy data, which affects accurate quantification. Here we propose an improved, reliable and cost-effective BSP-based protocol that allows proper DNA methylation assessment.
   Methods: Our strategy, named normalized-BSP (NBSP), takes advantage of tailed C-balanced primers and a normalization procedure based on C/T ratio to overcome BSP-associated noise problems and nucleotide signal unbalance. NBSP was applied to estimate miR-200c/miR-141 locus methylation in serial dilution experiments and was compared to conventional methods. Besides, it was applied in the analysis of FFPE breast cancer samples and further validated in the context of the E-cadherin promoter.
   Results: NBSP strategy outperformed conventional BSP in the estimate of the fraction of methylated cytosine in serial dilution experiments, providing data in agreement with the widely used but cumbersome cloning-based protocol. This held true for both miR-200c/miR-141 locus and E-cadherin promoter analyses. Moreover, the miR-200c/miR-141 locus methylation reflected the decrease in miRNA expression both in breast cancer cell lines and in the FFPE samples.
   Conclusions: NBSP is a rapid and economical method to estimate the extent of methylation at each CpG of a given locus. Notably, NBSP works efficiently on FFPE samples, thus disclosing the perspective of its application also in the diagnostic setting.
C1 [Brisotto, Giulia; di Gennaro, Alessandra; Damiano, Valentina; Armellin, Michela; Maestro, Roberta; Santarosa, Manuela] CRO, Aviano Natl Canc Inst, Expt Oncol 1, I-33081 Aviano, PN, Italy.
   [Perin, Tiziana] CRO, Aviano Natl Canc Inst, Pathol, I-33081 Aviano, PN, Italy.
C3 IRCCS Aviano (CRO); IRCCS Aviano (CRO)
RP Maestro, R (通讯作者)，CRO, Aviano Natl Canc Inst, Expt Oncol 1, Via F Gallini 2, I-33081 Aviano, PN, Italy.
EM rmaestro@cro.it
RI Armellin, Michela/AAZ-1068-2020; Perin, Tiziana/AAC-2403-2020; BRISOTTO,
   GIULIA/AAC-2214-2020; Santarosa, Manuela/A-7300-2013; Damiano,
   Valentina/AAR-2240-2020; Maestro, Roberta/M-1846-2015
OI Armellin, Michela/0000-0002-0637-7023; Perin,
   Tiziana/0000-0002-9823-0167; BRISOTTO, GIULIA/0000-0001-5514-7032;
   Santarosa, Manuela/0000-0001-7682-2578; Damiano,
   Valentina/0000-0002-9137-3253; Maestro, Roberta/0000-0002-6642-5592
FU Current Research Fund from Italian Ministry of Health; Berlucchi
   Foundation (Brescia, Italy)
FX This study was supported by Current Research Fund from Italian Ministry
   of Health to Carlo Castoro and by a grant from Berlucchi Foundation
   (Brescia, Italy) to Carlo Castoro. The funding bodies had no role in the
   design of the study, in the collection, analysis, and interpretation of
   data, in the writing of the manuscript and in the decision to submit the
   manuscript for publication.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   [Anonymous], 2014, LANCET, V383, P383, DOI 10.1016/S0140-6736(14)60134-3
   Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124
   Berger Nathan A, 2006, Trans Am Clin Climatol Assoc, V117, P147
   Bezjak A, 2008, J CLIN ONCOL, V26, P5052, DOI 10.1200/JCO.2007.12.6094
   Blazeby JM, 2003, EUR J CANCER, V39, P1384, DOI 10.1016/S0959-8049(03)00270-3
   Brédart A, 2002, PATIENT EDUC COUNS, V46, P131, DOI 10.1016/S0738-3991(01)00152-5
   BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917
   Camerlo A, 2012, J VISC SURG, V149, pE203, DOI 10.1016/j.jviscsurg.2012.03.006
   Castoro C, 2011, ANN SURG ONCOL, V18, P3743, DOI 10.1245/s10434-011-1753-9
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Choung RS, 2013, J PUBLIC HEALTH-HEID, V21, P87, DOI 10.1007/s10389-012-0513-z
   Derogar M, 2012, J CLIN ONCOL, V30, P413, DOI 10.1200/JCO.2011.38.9791
   Djärv T, 2009, J CLIN ONCOL, V27, P1963, DOI 10.1200/JCO.2008.20.5864
   Djärv T, 2014, BRIT J SURG, V101, P495, DOI 10.1002/bjs.9417
   Donohoe CL, 2011, WORLD J SURG, V35, P1853, DOI 10.1007/s00268-011-1123-6
   Edge SB., 2009, AJCC cancer staging manual, V7th
   Extermann M, 2007, J CLIN ONCOL, V25, P1824, DOI 10.1200/JCO.2007.10.6559
   Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003
   Gutschow CA, 2013, LANGENBECK ARCH SURG, V398, P231, DOI 10.1007/s00423-012-0960-6
   Hölscher AH, 2003, CHIRURG, V74, P726, DOI 10.1007/s00104-003-0649-z
   Jacobs M, 2014, QUAL LIFE RES, V23, P1097, DOI 10.1007/s11136-013-0545-z
   Koppert LB, 2012, BRIT J SURG, V99, P1693, DOI 10.1002/bjs.8952
   Kouba E, 2007, BJU INT, V99, P72, DOI 10.1111/j.1464-410X.2007.06533.x
   Marventano S, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-S2-S15
   McLeod R S, 1999, Adv Surg, V33, P293
   Ney DM, 2009, NUTR CLIN PRACT, V24, P395, DOI 10.1177/0884533609332005
   Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001
   Orsini RG, 2013, EJSO-EUR J SURG ONC, V39, P164, DOI 10.1016/j.ejso.2012.10.005
   Orsini RG, 2015, DIS COLON RECTUM, V58, P179, DOI 10.1097/DCR.0000000000000292
   Parameswaran R, 2008, ANN SURG ONCOL, V15, P2372, DOI 10.1245/s10434-008-0042-8
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6
   Pisanu A, 2007, TUMORI J, V93, P478
   Prabhu Vinay, 2013, Rev Urol, V15, P161
   Pultrum BB, 2010, ANN SURG ONCOL, V17, P1572, DOI 10.1245/s10434-010-0966-7
   Rolstad S, 2011, VALUE HEALTH, V14, P1101, DOI 10.1016/j.jval.2011.06.003
   Ruol A, 2007, J THORAC CARDIOV SUR, V133, P1186, DOI 10.1016/j.jtcvs.2006.12.040
   Scarpa M, 2013, SURG ENDOSC, V27, P2911, DOI 10.1007/s00464-013-2854-2
   Scarpa M, 2013, J GASTROINTEST SURG, V17, P421, DOI 10.1007/s11605-012-2069-1
   Scarpa M, 2011, WORLD J GASTROENTERO, V17, P4660, DOI 10.3748/wjg.v17.i42.4660
   Schmidt CE, 2005, WORLD J SURG, V29, P190, DOI 10.1007/s00268-004-7556-4
   Schulte T, 2010, LUNG CANCER, V68, P115, DOI 10.1016/j.lungcan.2009.05.019
   Scott NW., 2008, EORTC QLQ-C30 Reference Values
   Singh Mabi L, 2014, Dent Clin North Am, V58, P783, DOI 10.1016/j.cden.2014.07.004
   Sivarajan G, 2014, EUR UROL, V65, P58, DOI 10.1016/j.eururo.2013.08.019
   Steyerberg EW, 2007, J CLIN ONCOL, V25, P2389, DOI 10.1200/JCO.2006.09.7931
   Tapias LF, 2013, ANN THORAC SURG, V95, P1741, DOI 10.1016/j.athoracsur.2013.01.084
   Tatematsu N, 2013, EUR J CANCER CARE, V22, P308, DOI 10.1111/ecc.12030
   Tougeron D, 2008, BRIT J CANCER, V99, P1586, DOI 10.1038/sj.bjc.6604749
   Ugolini G, 2014, WORLD J GASTROENTERO, V20, P3762, DOI 10.3748/wjg.v20.i14.3762
   Won E, 2014, ONCOLOGIST, V19, P367, DOI 10.1634/theoncologist.2013-0178
   Wu PC, 2003, LANCET ONCOL, V4, P481, DOI 10.1016/S1470-2045(03)01167-7
   Xu HY, 2014, ONCOL LETT, V7, P260, DOI 10.3892/ol.2013.1694
   Yang HX, 2012, BRIT J SURG, V97, P862
NR 55
TC 6
Z9 7
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD SEP 21
PY 2015
VL 15
AR 639
DI 10.1186/s12885-015-1646-6
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CR6AQ
UT WOS:000361425900001
PM 26391005
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mostafavi-Pour, Z
   Kianpour, S
   Dehghani, M
   Mokarram, P
   Torabinejad, S
   Monabati, A
AF Mostafavi-Pour, Z.
   Kianpour, S.
   Dehghani, M.
   Mokarram, P.
   Torabinejad, S.
   Monabati, A.
TI Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Integrin alpha(4); E-Cadherin; DU145; PC3; Prostate cancer; DNA
   methylation
ID CPG ISLAND METHYLATION; DNA METHYLATION; ADHESION RECEPTORS;
   TUMOR-SUPPRESSOR; BREAST-CANCER; EXPRESSION; CELLS; INVASION;
   HYPERMETHYLATION; RECURRENCE
AB Prostate cancer is the second most common malignancy in men worldwide. Abnormal epigenetic alterations such as DNA methylation and histone modification play an important role in tumor initiation, progression and regulation of cancer-related genes such as integrin alpha 4 and E-cadherin. Expression of these genes was determined by semi-quantitative reverse transcriptase-PCR in prostate cancer cell lines, DU145 and PC3, before and after treatment with 5-aza-2-deoxycytidine and trichostatin A. Laser capture microdissection microscopy was used to obtain exclusively affected epithelial cells from prostate gland biopsies of 30 patients with prostate cancer and 40 with benign prostate hyperplasia. DNA bisulfite modifications followed by methylation-specific PCR were used to evaluate the promoter methylation status of E-cadherin and alpha 4 integrin genes in extracted DNA from patients and aforementioned cell lines. The integrin alpha 4 promoter in DU145 was fully methylated, whereas in PC3 cells, partial methylation was detected. E-cadherin was expressed in both cell lines; trichostatin A and 5-aza-2-deoxycytidine treatment had no effect on E-cadherin expression, however the combined treatment of both drugs or 5-aza-2-deoxycytidine alone increased integrin alpha 4 expression. Integrin alpha 4 and E-cadherin were hypermethylated in 66.6 % and 6.6 % of prostate cancer cases, respectively; no hypermethylation was observed in patients with benign prostate hyperplasia. These results together suggest that aberrant DNA methylation is one of the mechanisms involved in integrin alpha 4 expression and may play an important role in human prostate carcinogenesis. In addition, the higher rate of integrin alpha 4 gene methylation in prostate cancer patients elects it as a potential molecular tumor marker.
C1 [Mostafavi-Pour, Z.; Kianpour, S.; Mokarram, P.] Shiraz Univ Med Sci, Recombinant Prot Lab, Dept Biochem, Shiraz, Iran.
   [Mostafavi-Pour, Z.] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Shiraz, Iran.
   [Dehghani, M.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Div Oncol, Houston, TX 77030 USA.
   [Torabinejad, S.] Shiraz Univ Med Sci, Shiraz Nephrourol Res Ctr, Shiraz, Iran.
   [Torabinejad, S.; Monabati, A.] Shiraz Univ Med Sci, Dept Pathol, Shiraz, Iran.
C3 Shiraz University of Medical Science; Shiraz University of Medical
   Science; University of Texas System; University of Texas Health Science
   Center Houston; Shiraz University of Medical Science; Shiraz University
   of Medical Science
RP Mostafavi-Pour, Z (通讯作者)，Shiraz Univ Med Sci, Recombinant Prot Lab, Dept Biochem, Shiraz, Iran.
EM zmostafavipour88@yahoo.co.uk
RI Torabinezhad, Simin/AAL-7651-2021; Monabati, Ahmad/I-3324-2016;
   Mokarram, Pooneh/E-1613-2012; Dehghani, Mehdi/D-1739-2019;
   mostafavi-pour, zohreh/T-5588-2018
OI Monabati, Ahmad/0000-0002-3378-1937; Dehghani,
   Mehdi/0000-0002-2979-0865; Torabinezhad, Simin/0000-0002-3637-048X;
   mostafavi-pour, zohreh/0000-0002-3779-177X; Mokarram,
   Pooneh/0000-0002-9717-0473
FU Office of the Vice-Chancellor for Research, Shiraz University of Medical
   Sciences [87- 4148]; Shiraz Nephrourology Research Center
FX This study was part of the dissertation of Sedighe Kianpour, submitted
   to Shiraz university of Medical Sciences in partial fulfillment of the
   requirements for the M.Sc. in clinical Biochemistry. This study was
   supported by grant no 87- 4148 from the Office of the Vice-Chancellor
   for Research, Shiraz University of Medical Sciences, and Shiraz
   Nephrourology Research Center.
CR Al-Rayyan N, 2014, CANCER LETT, V347, P139, DOI 10.1016/j.canlet.2014.02.001
   Cheng JC, 2011, ONCOGENE, V30, P3930, DOI 10.1038/onc.2011.117
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Dehghani M, 2009, IRAN J IMMUNOL, V6, P92, DOI IJIv6i2A5
   Engl T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-4
   Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355
   Goel HL, 2008, ENDOCR-RELAT CANCER, V15, P657, DOI 10.1677/ERC-08-0019
   Gosslar U, 1996, P NATL ACAD SCI USA, V93, P4821, DOI 10.1073/pnas.93.10.4821
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jia YF, 2004, CANCER RES, V64, P8674, DOI 10.1158/0008-5472.CAN-04-0069
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Katto J, 2011, CARCINOGENESIS, V32, P1414, DOI 10.1093/carcin/bgr120
   Keil KP, 2014, DEV BIOL, V387, P142, DOI 10.1016/j.ydbio.2014.01.020
   Kim H, 2005, CANCER RES, V65, P8118, DOI 10.1158/0008-5472.CAN-04-4562
   Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200
   Kong ANT, 2013, CANCER PREV RES, V6, P622, DOI 10.1158/1940-6207.CAPR-13-0202
   Lee EJ, 2008, INT J CANCER, V123, P2073, DOI 10.1002/ijc.23598
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8
   Liu AJ, 2009, INT J BIOL SCI, V5, P276
   Liu HH, 2014, BIOMEDICINE-TAIWAN, V4, P7, DOI 10.7603/s40681-014-0002-5
   Majumdar S, 2011, CURR GENOMICS, V12, P486, DOI 10.2174/138920211797904061
   Mostafavi-Pour Z, 2012, MOL BIOL REP, V39, P7339, DOI 10.1007/s11033-012-1565-4
   Naghibalhossaini F, 2012, MOL BIOL REP, V39, P6171, DOI 10.1007/s11033-011-1434-6
   Nam JS, 2004, CLIN EXP METASTAS, V21, P49, DOI 10.1023/B:CLIN.0000017180.19881.c1
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470
   Phé V, 2010, BJU INT, V105, P1364, DOI 10.1111/j.1464-410X.2009.09167.x
   Portela A, 2013, ONCOGENE, V32, P5421, DOI 10.1038/onc.2013.162
   QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X
   Ren Jian-Zhen, 2010, Chin J Cancer, V29, P38
   Schmid MC, 2011, CANCER RES, V71, P6965, DOI 10.1158/0008-5472.CAN-11-0588
   Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2
   Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176
   Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2
   Zhu Y, 2011, MOL BIOL REP, V38, P1603, DOI 10.1007/s11033-010-0269-x
NR 39
TC 17
Z9 18
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD SEP
PY 2015
VL 21
IS 4
BP 921
EP 927
DI 10.1007/s12253-015-9917-8
PG 7
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CQ1UM
UT WOS:000360385400009
PM 25743258
DA 2025-01-12
ER

PT J
AU Asiaf, A
   Ahmad, ST
   Malik, AA
   Aziz, SA
   Rasool, Z
   Masood, A
   Zargar, MA
AF Asiaf, Asia
   Ahmad, Shiekh Tanveer
   Malik, Ajaz Ahmad
   Aziz, Shiekh Aejaz
   Rasool, Zubaida
   Masood, Akbar
   Zargar, Mohammad Afzal
TI Protein expression and methylation of MGMT, a DNA repair gene and their
   correlation with clinicopathological parameters in invasive ductal
   carcinoma of the breast
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; Promoter methylation; MGMT; MSP; Kashmir
ID PROMOTER HYPERMETHYLATION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE;
   CANCER PATIENTS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE;
   AFRICAN-AMERICAN; CELL CARCINOMA; TUMOR; ESTROGEN; INACTIVATION;
   PROGRESSION
AB Epigenetic mechanisms such as DNA methylation are being increasingly recognized to play an important role in cancer and may serve as a cancer biomarker. The aim of this study was to evaluate the promoter methylation status of MGMT (O6-methylguanine-DNA methyltransferase) and a possible correlation with the expression of MGMT and standard clinicopathological parameters in invasive ductal breast carcinoma patients (IDC) of Kashmir. Methylation-specific PCR was carried out to investigate the promoter methylation status of MGMT in breast tumors paired with the corresponding normal tissue samples from 128 breast cancer patients. The effect of promoter methylation on protein expression in the primary breast cancer and adjacent normal tissues was evaluated by immunohistochemistry (n = 128) and western blotting (n = 30). The frequency of tumor hypermethylation was 39.8 % and a significant difference in methylation frequency among breast tumors were found (p < 0.001) when compared with the corresponding normal tissue. Immunohistochemical analysis showed no detectable expression of MGMT in 68/128 (53.1 %) tumors. MGMT promoter methylation mediated gene silencing was associated with loss of its protein expression (rs = -0.285, p = 0.001, OR = 3.38, 95 % CI = 1.59-7.17). A significant correlation was seen between loss of MGMT and lymph node involvement (p = 0.030), tumor grade (p < 0.0001), loss of estrogen receptors (ER; p = 0.021) and progesterone receptors (PR) (p = 0.016). Also, MGMT methylation was found to be associated with tumor grade (p = 0.011), tumor stage (p = 0.009), and loss of ER (p = 0.003) and PR receptors (p = 0.009). To our knowledge, our findings, for the first time, in Kashmiri population, indicate that MGMT is aberrantly methylated in breast cancer and promoter hypermethylation could be attributed to silencing of MGMT gene expression in breast cancer. Our data suggests that MGMT promoter hypermethylation could have a potential function as molecular biomarker of breast oncogenesis. Also, based on their predictive value of response to therapy, the immunohistochemical evaluation and interpretation of MGMT may also help in future to establish therapeutic strategies for patients with breast cancer.
C1 [Asiaf, Asia; Masood, Akbar; Zargar, Mohammad Afzal] Univ Kashmir, Dept Biochem, Fac Biol Sci, Srinagar 190006, Jammu & Kashmir, India.
   [Ahmad, Shiekh Tanveer] Univ Calgary, Clarke H Smith Brain Tumour Ctr, Calgary, AB T2N 2T9, Canada.
   [Malik, Ajaz Ahmad] Sherikashmir Inst Med Sci, Dept Gen Surg, Srinagar 190011, Kashmir, India.
   [Aziz, Shiekh Aejaz] Sherikashmir Inst Med Sci, Dept Med Oncol, Srinagar 190011, Kashmir, India.
   [Rasool, Zubaida] Sher Kashmir Inst Med Sci, Dept Pathol, Soura, Srinagar 190011, Kashmir, India.
C3 University of Kashmir; University of Calgary; Sher-i-Kashmir Institute
   of Medical Sciences; Sher-i-Kashmir Institute of Medical Sciences;
   Sher-i-Kashmir Institute of Medical Sciences
RP Zargar, MA (通讯作者)，Univ Kashmir, Dept Biochem, Fac Biol Sci, Srinagar 190006, Jammu & Kashmir, India.
EM asiaf29@gmail.com; tasheikh@ucalgary.ca; mazargar65@gmail.com
RI Ahmad, Shiekh/AAB-1948-2020; Rasool, Zubaida/M-3764-2017; Zargar,
   Mohammad Afzal/G-7393-2018
OI Ahmad, Shiekh Tanveer/0000-0002-9882-8636; Rasool,
   Zubaida/0000-0003-0463-1734; Zargar, Mohammad Afzal/0000-0002-2844-7141
FU University Grants Commission (UGC), New Delhi, India
FX The authors are thankful to the University Grants Commission (UGC), New
   Delhi, India, for providing the funds that allowed us to carry out this
   research.
CR Alkam Y, 2013, HISTOPATHOLOGY, V63, P713, DOI 10.1111/his.12220
   [Anonymous], 2013, GLOBOCAN 2012 ESTIMA
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Belanich M, 1996, CANCER CHEMOTH PHARM, V37, P547, DOI 10.1007/s002800050427
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.3.CO;2-3
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Enokida H, 2005, INT J CANCER, V116, P174, DOI 10.1002/ijc.21017
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2000, CANCER RES, V60, P2368
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Indian Council of Medical Research ND, 2013, NAT CANC REG PROGR C
   Isono S, 2014, ONCOL LETT, V7, P1778, DOI 10.3892/ol.2014.1985
   Jacinto FV, 2007, DNA REPAIR, V6, P1155, DOI 10.1016/j.dnarep.2007.03.013
   Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008
   Kang S, 2006, INT J CANCER, V118, P2168, DOI 10.1002/ijc.21609
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576
   Matsukura S, 2001, ANN SURG ONCOL, V8, P807, DOI 10.1007/s10434-001-0807-9
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Neto JC, 2012, EXP MOL PATHOL, V92, P20, DOI 10.1016/j.yexmp.2011.09.019
   Osanai T, 2005, JPN J CLIN ONCOL, V35, P121, DOI 10.1093/jjco/hyi036
   PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X
   PEGG AE, 1990, CANCER RES, V50, P6119
   PERTSCHUK LP, 1990, CANCER-AM CANCER SOC, V66, P1663, DOI 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C
   Rhodes A, 2002, AM J CLIN PATHOL, V118, P408
   Sabharwal A, 2006, CURR OPIN PHARMACOL, V6, P355, DOI 10.1016/j.coph.2006.03.011
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Sharma S, 2009, ANTICANCER RES, V29, P3759
   Silber JR, 1996, P NATL ACAD SCI USA, V93, P6941, DOI 10.1073/pnas.93.14.6941
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Soejima H, 2005, BIOCHEM CELL BIOL, V83, P429, DOI 10.1139/O05-140
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Visvanathan K, 2006, CLIN CANCER RES, V12, P6591, DOI 10.1158/1078-0432.CCR-06-2001
   Viswanathan M., 2006, Indian Journal of Experimental Biology, V44, P115
   Wani SQ, 2012, J CANCER RES THER, V8, P389, DOI 10.4103/0973-1482.103518
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
NR 46
TC 18
Z9 22
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2015
VL 36
IS 8
BP 6485
EP 6496
DI 10.1007/s13277-015-3339-9
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP9DL
UT WOS:000360193800088
PM 25820821
DA 2025-01-12
ER

PT J
AU Coradini, D
   Boracchi, P
   Oriana, S
   Biganzoli, E
   Ambrogi, F
AF Coradini, Danila
   Boracchi, Patrizia
   Oriana, Saro
   Biganzoli, Elia
   Ambrogi, Federico
TI Epithelial cell identity in hyperplastic precursors of breast cancer
SO CHINESE JOURNAL OF CANCER
LA English
DT Article
DE Mammary epithelial cell identity; Hyperplastic enlarged lobular unit;
   Atypical ductal hyperplasia; Ductal carcinoma in situ
ID ESTROGEN-RECEPTOR-ALPHA; EPIGENETIC REGULATION; GENE-EXPRESSION;
   MAMMARY; GROWTH; MORPHOGENESIS; PROLIFERATION; PROGESTERONE; FOXC1;
   LESIONS
AB Introduction: In the adult human breast, hyperplastic enlarged lobular unit (HELU) and atypical ductal hyperplasia (ADH) are two common abnormalities that frequently coexist with ductal carcinoma in situ (DCIS). For this reason, they have been proposed as the early steps in a biological continuum toward breast cancer.
   Methods: We investigated in silico the expression of 369 genes experimentally recognized as involved in establishing and maintaining epithelial cell identity and mammary gland remodeling, in HELUs or ADHs with respect to the corresponding patient-matched normal tissue.
   Results: Despite the common luminal origin, HELUs and ADHs proved to be characterized by distinct gene profiles that overlap for 5 genes only. While HELUs were associated with the overexpression of progesterone receptor (PGR), ADHs were characterized by the overexpression of estrogen receptor 1 (ESR1) coupled with the overexpression of some proliferation-associated genes.
   Conclusions: This unexpected finding contradicts the notion that in differentiated luminal cells the expression of estrogen receptor (ER) is dissociated from cell proliferation and suggests that the establishing of an ER-dependent signaling is able to sustain cell proliferation in an autocrine manner as an early event in tumor initiation. Although clinical evidence indicates that only a fraction of HELUs and ADHs evolve to invasive cancer, present findings warn that exposure to synthetic progestins, frequently administered as hormone-replacement therapy, and estrogens, when abnormally produced by adipose cells and persistently present in the stroma surrounding the mammary gland, may cause these hyperplastic lesions.
C1 [Coradini, Danila; Boracchi, Patrizia; Biganzoli, Elia; Ambrogi, Federico] Univ Milan, Dept Clin Sci & Community Hlth Med Stat Biometry, I-20133 Milan, Italy.
   [Oriana, Saro] Ambrosiana Clin, Senol Ctr, I-20090 Milan, Italy.
C3 University of Milan
RP Coradini, D (通讯作者)，Univ Milan, Dept Clin Sci & Community Hlth Med Stat Biometry, Via Vanzetti 5, I-20133 Milan, Italy.
EM danila.coradini@gmail.com
RI Biganzoli, Elia/J-1678-2012; Patrizia, Boracchi/AAB-8851-2019; Ambrogi,
   Federico/D-4294-2015
OI Biganzoli, Elia/0000-0003-1202-5873; boracchi,
   patrizia/0000-0001-8506-2005; Ambrogi, Federico/0000-0001-9358-011X
CR Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299
   Boimel PJ, 2011, GENOMICS, V98, P164, DOI 10.1016/j.ygeno.2011.05.011
   Booth BW, 2007, GROWTH FACTORS, V25, P227, DOI 10.1080/08977190701750698
   Brock HW, 2005, DEV DYNAM, V232, P633, DOI 10.1002/dvdy.20298
   Carrascosa C, 2012, ONCOGENE, V31, P1521, DOI 10.1038/onc.2011.356
   Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005
   Clarke RB, 1997, CANCER RES, V57, P4987
   Coradini D, 2014, CHIN J CANCER, V33, P501, DOI 10.5732/cjc.014.10066
   Csanaky K, 2014, J MOL NEUROSCI, V52, P28, DOI 10.1007/s12031-013-0193-3
   Dabbs DJ, 2006, MODERN PATHOL, V19, P344, DOI 10.1038/modpathol.3800538
   Damjanovich L, 1997, Acta Chir Hung, V36, P69
   Dave H, 2011, INDIAN J EXP BIOL, V49, P879
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Emery LA, 2009, AM J PATHOL, V175, P1292, DOI 10.2353/ajpath.2009.090115
   Ferrari F, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-446
   Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295
   Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Ivanov SV, 2013, BRIT J CANCER, V109, P444, DOI 10.1038/bjc.2013.326
   Jones JL, 2003, J PATHOL, V201, P562, DOI 10.1002/path.1483
   KENNY AJ, 1989, LANCET, V2, P785
   KOUKOULIS GK, 1991, AM J PATHOL, V139, P787
   Lain AR, 2013, MOL ENDOCRINOL, V27, P1743, DOI 10.1210/me.2013-1144
   Lakhani SR, 1996, LAB INVEST, V74, P129
   Lee HJ, 2013, DEVELOPMENT, V140, P1397, DOI 10.1242/dev.088948
   Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367
   Lee S, 2007, AM J PATHOL, V171, P252, DOI 10.2353/ajpath.2007.061010
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907
   Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Ng RK, 2008, NAT CELL BIOL, V10, P1280, DOI 10.1038/ncb1786
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608
   Oyama T, 2000, Breast Cancer, V7, P326, DOI 10.1007/BF02966399
   Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103
   Peluso JJ, 2007, SEMIN REPROD MED, V25, P198, DOI 10.1055/s-2007-973432
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120
   Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Schnitt SJ, 2003, ADV ANAT PATHOL, V10, P113, DOI 10.1097/00125480-200305000-00001
   Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003
   Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tan HN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-31
   Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531
   Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7
   Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570
   Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338
   Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122
   Yustein JT, 2010, P NATL ACAD SCI USA, V107, P3534, DOI 10.1073/pnas.0901230107
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 59
TC 3
Z9 3
U1 0
U2 5
PU SUN YAT SEN UNIV MED SCI WHO
PI GUANGZHOU
PA 651 DONGFENG RD E, GUANGZHOU, GUANGDONG 510060, PEOPLES R CHINA
SN 1000-467X
EI 1944-446X
J9 CHIN J CANCER
JI Chin. J. Cancer
PD MAR 5
PY 2015
VL 34
AR 3
DI 10.1186/s40880-015-0004-z
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP9OQ
UT WOS:000360224500003
PM 25962646
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Murria, R
   Palanca, S
   de Juan, I
   Alenda, C
   Egoavil, C
   Seguí, FJ
   García-Casado, Z
   Juan, MJ
   Sánchez, AB
   Segura, A
   Santaballa, A
   Chirivella, I
   Llop, M
   Pérez, G
   Barragán, E
   Salas, D
   Bolufer, P
AF Murria, Rosa
   Palanca, Sarai
   de Juan, Inmaculada
   Alenda, Cristina
   Egoavil, Cecilia
   Segui, Francisco J.
   Garcia-Casado, Zaida
   Juan, Maria J.
   Sanchez, Ana B.
   Segura, Angel
   Santaballa, Ana
   Chirivella, Isabel
   Llop, Marta
   Perez, Gema
   Barragan, Eva
   Salas, Dolores
   Bolufer, Pascual
TI Immunohistochemical, genetic and epigenetic profiles of hereditary and
   triple negative breast cancers. Relevance in personalized medicine
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Sporadic breast cancer; hereditary breast cancer; miR expression
   profile; BRCA1; BRCA2; mutations; molecular markers
ID DEPENDENT PROBE AMPLIFICATION; PROMOTER METHYLATION; ESTROGEN-RECEPTOR;
   EXPRESSION PROFILES; BRCA2 MUTATIONS; AURORA KINASE; C-MYC; TUMORS;
   PREVALENCE; HYPERMETHYLATION
AB This study aims to identify the profile of immunohistochemical (IHC) parameters, copy number aberrations (CNAs) and epigenetic alterations [ promoter methylation (PM) and miR expression] related to hereditary (H) and triple negative (TN) breast cancer (BC). This profile could be of relevance for guiding tumor response to treatment with targeting therapy. The study comprises 278 formalin fixed paraffin-embedded BCs divided into two groups: H group, including 88 hereditary BC (HBC) and 190 non hereditary (NHBC), and TN group, containing 79 TNBC and 187 non TNBC (NTNBC). We assessed IHC parameters (Ki67, ER, PR, HER2, CK5/6, CK18 and Cadherin-E), CNA of 20 BC related genes, and PM of 24 tumor suppressor genes employing MLPA/MS-MLPA (MRC Holland, Amsterdam). MiR-4417, miR-423-3p, miR-590-5p and miR-187-3p expression was assessed by quantitative RT-PCR (Applied Biosystems). Binary logistic regression was applied to select the parameters that better differentiate the HBC or TN groups. For HBC we found that, ER expression, ERBB2 CNA and PM in RASSF1 and TIMP3 were associated with NHBC whereas; MYC and AURKA CNA were linked to HBC. For TNBC, we found that CDC6 CNA, GSTP1 and RASSF1 PM and miR-423-3p hyperexpression were characteristic of NTNBC, while MYC aberrations, BRCA1 hypermethylation and miR-590-5p and miR-4417 hyperexpression were more indicative of TNBC. The selected markers allow establishing BC subtypes, which are characterized by showing similar etiopathogenetic mechanisms, some of them being molecular targets for known drugs or possible molecular targets. These results could be the basis to implement a personalized therapy.
C1 [Murria, Rosa; Palanca, Sarai; de Juan, Inmaculada; Llop, Marta; Perez, Gema; Barragan, Eva; Bolufer, Pascual] Univ Hosp La Fe, Mol Biol Lab, Serv Clin Anal, Valencia 46009, Spain.
   [Alenda, Cristina; Egoavil, Cecilia; Segui, Francisco J.] Univ Gen Hosp, Dept Pathol, Alicante, Spain.
   [Garcia-Casado, Zaida] IVO, Mol Biol Lab, Valencia, Spain.
   [Juan, Maria J.] IVO, Dept Oncol, Valencia, Spain.
   [Sanchez, Ana B.] Elche Hosp, Genet Counseling Unit, Alicante, Spain.
   [Segura, Angel] Univ Hosp La Fe, Genet Counseling Unit, Valencia 46009, Spain.
   [Santaballa, Ana] Univ Hosp La Fe, Dept Oncol, Valencia 46009, Spain.
   [Chirivella, Isabel] Clin Univ Hosp, Genet Counseling Unit, Valencia, Spain.
   [Salas, Dolores] Generalitat Valenciana, Conselleria Sanitat, Gen Dept Publ Hlth, Valencia, Spain.
C3 General University Hospital of Alicante; Instituto Valenciano De
   Oncologia; Instituto Valenciano De Oncologia
RP Bolufer, P (通讯作者)，Univ Hosp La Fe, Mol Biol Lab, Escuela Enfermeria 7a Planta,Avd Campanar 21, Valencia 46009, Spain.
EM bolufer_pas@gva.es
RI Llop, Marta/KTI-2524-2024; SalasTrejo, Dolores/S-1139-2017;
   Garcia-Casado, Zaida/Z-2125-2019; Alenda, Cristina/AAR-3433-2020; de
   Juan Jimenez, Inmaculada/B-8922-2015; Egoavil, Cecilia/X-5134-2018
OI Llop, Marta/0000-0002-0106-7296; Egoavil, Cecilia/0000-0003-0166-4901;
   Alenda, Cristina/0000-0002-0560-1759; GARCIA-CASADO,
   ZAIDA/0000-0001-6592-6099
FU Carlos III Health Institute [PI10/00347]
FX We would like to thank to the Carlos III Health Institute for having
   granted this project PI10/00347 and to the Health Research Institute La
   Fe for having granted Rosa Murria Estal which made possible her
   participation in the study. We should thank the effort to perform this
   work to the pathologist Ana Garcia Martinez (University Hospital La Fe).
   We also should thank to the molecular biologist Jose Antonio Lopez
   Guerrero (Valencia Institute of Oncology); to the laboratory technician
   Estefania Rojas Calvente (University Hospital of Alicante) and to Jacobo
   Martinez Santamaria and Mercedes Goicoechea Saez (General department of
   public health, Conselleria de Sanitat, Generalitat Valenciana). Finally
   we would like to acknowledge the patients enrolled in this study and the
   Biobank of the General University Hospital of Alicante and the biobank
   for the biomedical research and public health of the Comunidad
   Valenciana (IBSP-CV) as part of the Valenciana Biobank Network (RVB) and
   the National Biobank.
CR Ali HR, 2012, BRIT J CANCER, V106, P1798, DOI 10.1038/bjc.2012.167
   Ariazi EA, 2002, CANCER RES, V62, P6510
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098
   Bunyan DJ, 2004, BRIT J CANCER, V91, P1155, DOI 10.1038/sj.bjc.6602121
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   CLAUS EB, 1991, AM J HUM GENET, V48, P232
   Couch FJ, 2007, CANCER EPIDEM BIOMAR, V16, P1416, DOI 10.1158/1055-9965.EPI-07-0129
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Cardeñosa EE, 2008, MED CLIN-BARCELONA, V130, P121, DOI 10.1157/13115767
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325
   Gillett CE, 2001, J PATHOL, V193, P433, DOI 10.1002/path.831
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585
   Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560
   Guan ZY, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-110
   Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
   Hartman AR, 2012, CANCER-AM CANCER SOC, V118, P2787, DOI 10.1002/cncr.26576
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kajabova V, 2013, TRANSL ONCOL, V6, P297, DOI 10.1593/tlo.13244
   Kornegoor R, 2012, BREAST CANCER RES TR, V135, P49, DOI 10.1007/s10549-012-2051-3
   Lasabova Z, 2010, NEOPLASMA, V57, P35, DOI 10.4149/neo_2010_01_035
   Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280
   Li SG, 2013, BIOMED REP, V1, P499, DOI 10.3892/br.2013.95
   Li YT, 2014, EUR J MED RES, V19, DOI 10.1186/2047-783X-19-35
   Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Milanezi F, 2008, EXPERT REV MOL DIAGN, V8, P417, DOI 10.1586/14737159.8.4.417
   Moelans CB, 2010, MODERN PATHOL, V23, P1029, DOI 10.1038/modpathol.2010.84
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Murria R, 2015, AM J CANCER RES, V5, P375
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ponder BAJ, 2000, BRIT J CANCER, V83, P1301
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643
   Roa JC, 2004, REV MED CHILE, V132, P1069
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Rummukainen JK, 2001, MODERN PATHOL, V14, P1030, DOI 10.1038/modpathol.3880431
   Saxena A, 2012, EXP THER MED, V4, P1097, DOI 10.3892/etm.2012.710
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Seong MW, 2014, BREAST CANCER RES TR, V146, P63, DOI 10.1007/s10549-014-3006-7
   Sharma P, 2014, BREAST CANCER RES TR, V145, P707, DOI 10.1007/s10549-014-2980-0
   Siggelkow W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-562
   Singhi AD, 2012, MODERN PATHOL, V25, P378, DOI 10.1038/modpathol.2011.171
   Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tun NM, 2014, CLIN GENET, V85, P43, DOI 10.1111/cge.12270
   Turner NC, 2011, BREAST CANCER RES TR, V127, P283, DOI 10.1007/s10549-011-1375-8
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x
   Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691
   Yang Hongfei, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P804
   Yuan Peng, 2009, Zhonghua Zhongliu Zazhi, V31, P282, DOI 10.3760/cma.j.issn.0253-3766.2009.04.012
NR 68
TC 24
Z9 25
U1 0
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 7
BP 2330
EP 2343
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CQ0MY
UT WOS:000360291600023
PM 26328265
DA 2025-01-12
ER

PT J
AU Menendez, JA
AF Menendez, Javier A.
TI The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the
   Market Potential for New Metabostemness-Targeting Oncology Drugs
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Cancer stem cells; drugs; epigenetics; metabolism; metabostemness
ID BREAST-CANCER; ENERGY-METABOLISM; TUMOR HETEROGENEITY; SOMATIC-CELLS;
   METFORMIN; PLURIPOTENCY; LSD1; DEMETHYLASE; PLASTICITY; AUTOPHAGY
AB The current global portfolio of oncology drugs is unlikely to produce durable disease remission for millions of cancer patients worldwide. This is due, in part, to the existence of so-called cancer stem cells (CSCs), a particularly aggressive type of malignant cell that is capable of indefinite self-replication, is refractory to conventional treatments, and is skilled at spreading and colonizing distant organs. To date, no drugs from big-league Pharma companies are capable of killing CSCs. Why? Quite simply, a classic drug development approach based on mutated genes and pathological protein products cannot efficiently target the plastic, epigenetic proclivity of cancer tissues to generate CSCs. Recent studies have proposed that certain elite metabolites (oncometabolites) and other common metabolites can significantly influence the establishment and maintenance of epigenetic signatures of stemness and cancer. Consequently, cellular metabolism and the core epigenetic codes, DNA methylation and histone modification, can be better viewed as an integrated metaboloepigenetic dimension of CSCs, which we have recently termed cancer metabostemness. By targeting weaknesses in the bridge connecting metabolism and epigenetics, a new generation of metabostemness-specific drugs can be generated for potent and long-lasting elimination of life-threatening CSCs. Here I evaluate the market potential of re-modeling the oncology drug pipeline by discovering and developing new metabolic approaches able to target the apparently undruggable epigenetic programs that dynamically regulate the plasticity of non-CSC and CSC cellular states.
C1 [Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Catalan Inst Oncol, Translat Res Lab, Metab & Canc Grp, Girona, Catalonia, Spain.
   [Menendez, Javier A.] Metabostem, Girona, Catalonia, Spain.
C3 Universitat de Girona; Girona University Hospital Dr. Josep Trueta;
   Institut d'Investigacio Biomedica de Girona (IDIBGI); Institut Catala
   d'Oncologia
RP Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Catalan Inst Oncol ICO, Ave Francia S-N, E-17007 Girona, Spain.
EM jmenendez@iconcologia.net
RI MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561
FU Ministerio de Ciencia e Innovacion [SAF2012-38914]; Plan Nacional de
   I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) [2014 SGR229]; Departament d'Economia I Coneixement, Catalonia,
   Spain
FX This work was supported by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2012-38914), Plan Nacional de I+D+I, Spain and the
   Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014
   SGR229), Departament d'Economia I Coneixement, Catalonia, Spain to
   Javier A. Menendez. The author would like to thank Dr. Kenneth McCreath
   for editorial support.
CR Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793
   Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002
   [Anonymous], 2015, CANCER DISCOV, V5, P4, DOI 10.1158/2159-8290.CD-NB2014-178
   [Anonymous], ANN ONCOL S2
   Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083
   Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chaterjee M, 2011, BONE MARROW RES, DOI 10.1155/2011/362938
   Choi DS, 2014, STEM CELLS, V32, P2309, DOI 10.1002/stem.1746
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Cufí S, 2012, ONCOTARGET, V3, P395, DOI 10.18632/oncotarget.488
   Cufí S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Cuyàs E, 2015, ONCOTARGET, V6, P12279, DOI 10.18632/oncotarget.3733
   Cuyàs E, 2014, ONCOTARGET, V5, P3970, DOI 10.18632/oncotarget.2147
   DeLaBarre B, 2014, CHEM BIOL, V21, P1143, DOI 10.1016/j.chembiol.2014.08.007
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254
   Goding CR, 2014, NAT REV CANCER, V14, P568, DOI 10.1038/nrc3781
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Katada S, 2012, CELL, V148, P24, DOI 10.1016/j.cell.2012.01.001
   Knoepfler PS, 2015, ONCOGENE, DOI [10.1038/onc.2014.172, DOI 10.1038/0NC.2014.172]
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marjanovic ND, 2013, CELL CYCLE, V12, P2713, DOI 10.4161/cc.26075
   Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655
   Martinez-Pastor B, 2013, CANCER DISCOV, V3, P497, DOI 10.1158/2159-8290.CD-13-0059
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Menendez JA, 2015, CELL CYCLE
   Menendez Javier A, 2014, Oncoscience, V1, P803
   Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262
   Menendez JA, 2014, ADV EXP MED BIOL, V824, P117, DOI 10.1007/978-3-319-07320-0_10
   Menendez JA, 2014, CELL CYCLE, V13, P699, DOI 10.4161/cc.28079
   Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479
   Menendez JA, 2011, CELL CYCLE, V10, P3658, DOI 10.4161/cc.10.21.18128
   Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030
   Morin A, 2014, INT J CANCER, V135, P2237, DOI 10.1002/ijc.29080
   Mould DP, 2015, MED RES REV, V35, P586, DOI 10.1002/med.21334
   Muñoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Nam H, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003837
   Norton L, 2011, ONCOLOGY-NY, V25, P30
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Salehzadeh-Yazdi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111686
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Teslaa T, 2015, EMBO J, V34, P138, DOI 10.15252/embj.201490446
   Varga J, 2014, FEBS LETT, V588, P2422, DOI 10.1016/j.febslet.2014.06.019
   Vazquez-Martin A, 2010, CURR MOL MED, V10, P674, DOI 10.2174/156652410792630625
   Vazquez-Martin A, 2013, CELL CYCLE, V12, P207, DOI 10.4161/cc.23352
   Vazquez-Martin A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00964
   Vazquez-Martin A, 2012, AGING-US, V4, P393, DOI 10.18632/aging.100465
   Vazquez-Martin A, 2012, CELL CYCLE, V11, P974, DOI 10.4161/cc.11.5.19450
   Vazquez-Martin A, 2011, DRUG RESIST UPDATE, V14, P212, DOI 10.1016/j.drup.2011.04.003
   Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Yang M, 2013, J CLIN INVEST, V123, P3652, DOI 10.1172/JCI67228
   Yin F, 2014, MOL CELL BIOL, V34, P158, DOI 10.1128/MCB.00631-13
NR 73
TC 14
Z9 14
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 25
BP 3644
EP 3653
DI 10.2174/1381612821666150710150327
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CP8ZB
UT WOS:000360182400010
PM 26166605
DA 2025-01-12
ER

PT J
AU Spitzwieser, M
   Holzweber, E
   Pfeiler, G
   Hacker, S
   Cichna-Markl, M
AF Spitzwieser, Melanie
   Holzweber, Elisabeth
   Pfeiler, Georg
   Hacker, Stefan
   Cichna-Markl, Margit
TI Applicability of <i>HIN-1</i>, <i>MGMT</i> and <i>RASSF1A</i> promoter
   methylation as biomarkers for detecting field cancerization in breast
   cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID SPORADIC COLORECTAL-CANCER; TUMOR-RELATED GENES; DNA METHYLATION;
   EPIGENETIC BIOMARKERS; ESTROGEN-RECEPTOR; PROSTATE-CANCER;
   COLONIC-MUCOSA; CPG ISLAND; SERUM DNA; MS-HRM
AB Introduction: It has been shown in some articles that genetic and epigenetic abnormalities cannot only be found in tumor tissues but also in adjacent regions that appear histologically normal. This phenomenon is metaphorically called field cancerization or field defect. Field cancerization is regarded as clinically significant because it is assumed to be an important factor in local recurrence of cancer. As the field showing these molecular abnormalities may not be removed completely by surgery, these changes might lead to neoplasms and subsequent transformation to a tumor. We aimed to investigate the applicability of the methylation status of six tumor suppressor genes as biomarkers for detecting field cancerization in breast cancer.
   Methods: The promoter methylation status of CCND2, DAPK1, GSTP1, HIN-1, MGMT and RASSF1A was determined by methylation-sensitive high-resolution melting (MS-HRM) analysis. MS-HRM methods for CCND2, MGMT and RASSF1A were developed in-house, primer sequences for DAPK1, GSTP1 and HIN-1 have already been published. Biopsy samples were taken from tumor, tumor-adjacent and tumor-distant tissue from 17 breast cancer patients. Normal breast tissues of four healthy women served as controls.
   Results: All MS-HRM methods proved to be very sensitive. LODs were in the range from 0.1 to 1.5 %, LOQs ranged from 0.3 to 5.3 %. A total of 94 %, 82 % and 65 % of the tumors showed methylation of RASSF1A, HIN-1 and MGMT promoters, respectively. The methylation status of these promoters was significantly lower in tumor-distant tissues than in tumor tissues. Tumor-adjacent tissues showed higher methylation status of RASSF1A, HIN-1 and MGMT promoters than tumor-distant tissues, indicating field cancerization. The methylation status of the HIN-1 promoter in tumor-adjacent tissues was found to correlate strongly with that in the corresponding tumors (r = 0.785, p < 0.001), but not with that in the corresponding tumor-distant tissues (r = 0.312, p = 0.239).
   Conclusions: Among the gene promoters investigated, the methylation status of the HIN-1 promoter can be considered the best suitable biomarker for detecting field cancerization. Further investigation is needed to test whether it can be used for defining surgical margins in order to prevent future recurrence of breast cancer.
C1 [Spitzwieser, Melanie; Holzweber, Elisabeth; Cichna-Markl, Margit] Univ Vienna, Dept Analyt Chem, A-1090 Vienna, Austria.
   [Pfeiler, Georg] Med Univ Vienna, Div Gynecol & Gynecol Oncol, Dept Obstet & Gynecol, A-1090 Vienna, Austria.
   [Hacker, Stefan] Med Univ Vienna, Dept Plast & Reconstruct Surg, A-1090 Vienna, Austria.
C3 University of Vienna; Medical University of Vienna; Medical University
   of Vienna
RP Cichna-Markl, M (通讯作者)，Univ Vienna, Dept Analyt Chem, Wahringer Str 38, A-1090 Vienna, Austria.
EM margit.cichna@univie.ac.at
OI Cichna-Markl, Margit/0000-0001-8699-674X; Hacker,
   Stefan/0000-0002-6376-4687
CR Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Belshaw NJ, 2008, BRIT J CANCER, V99, P136, DOI 10.1038/sj.bjc.6604432
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Cai FF, 2011, INT J MOL SCI, V12, P4465, DOI 10.3390/ijms12074465
   Candiloro ILM, 2011, EPIGENETICS-US, V6, P501, DOI 10.4161/epi.6.4.14853
   Candiloro ILM, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-7
   Chai H, 2009, ANN CLIN LAB SCI, V39, P331
   Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323
   Dakubo GD, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-2
   Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Duffy MJ, 2013, MED PRIN PRACT, V22, P4, DOI 10.1159/000338393
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Farzanehfar M, 2013, DNA CELL BIOL, V32, P371, DOI 10.1089/dna.2012.1949
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   García-Giménez JL, 2012, CLIN CHIM ACTA, V413, P1576, DOI 10.1016/j.cca.2012.05.021
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kajabova V, 2013, TRANSL ONCOL, V6, P297, DOI 10.1593/tlo.13244
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Kristensen LS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02789
   Krop I, 2003, CANCER RES, V63, P2024
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Mehrotra J, 2008, PROSTATE, V68, P152, DOI 10.1002/pros.20675
   Migheli F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052501
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Simó-Riudalbas L, 2014, HUM GENET, V133, P713, DOI 10.1007/s00439-013-1373-5
   Subramaniam MM, 2014, MOL CARCINOGEN, V53, P98, DOI 10.1002/mc.21951
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Supic G, 2011, ORAL ONCOL, V47, P702, DOI 10.1016/j.oraloncology.2011.05.014
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   US Environmental Protection Agency, 2000, ASS VAL NOND NONQ PE, P20460
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz TK, 2010, EXPERT REV MOL DIAGN, V10, P575, DOI 10.1586/ERM.10.46
   Wojdacz TK, 2009, EPIGENETICS-US, V4, P231, DOI 10.4161/epi.9020
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yan PS, 2003, CANCER RES, V63, P6178
   Yang B, 2013, NEOPLASIA, V15, P399, DOI 10.1593/neo.13280
NR 46
TC 35
Z9 42
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD SEP 14
PY 2015
VL 17
AR 125
DI 10.1186/s13058-015-0637-5
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CR1PC
UT WOS:000361096300001
PM 26370119
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ho, JY
   Hsu, RJ
   Wu, CL
   Chen, SH
   Wu, MY
   Yu, JC
   Gao, HW
   Yen, AMF
   Chen, HH
   Yu, CP
AF Ho, Jar-Yi
   Hsu, Ren-Jun
   Wu, Chieh-Lin
   Chen, Sheng-Hsien
   Wu, Ming-Ye
   Yu, Jyh-Cherng
   Gao, Hong-Wei
   Yen, Amy Ming-Fang
   Chen, Hsiu-Hsi
   Yu, Cheng-Ping
TI BRCA1 mislocalization associated with breast carcinogenesis and poor
   prognosis in Taiwanese women
SO EUROPEAN JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE BRCA1; breast cancer; carcinogenesis; mislocalization; prognosis
ID NUCLEAR EXPORT SEQUENCE; SUBCELLULAR-LOCALIZATION; EARLY-ONSET; CANCER;
   MUTATIONS; PROTEINS; GENE; IDENTIFICATION; EXPRESSION; INTERACT
AB We aimed to elucidate whether and how BRCA1 mislocalization [including membranous nuclear (MN) forms and negative patterns] is associated with the occurrence and the prognosis of breast cancer in young Taiwanese women. A case-control study was carried out to enroll 84 patients with breast cancer and 81 patients with benign breast disease. The subcellular localization of BRCA1 was examined using immunofluorescent assays on fresh tissue touch-imprinting slides to classify staining results into diffuse nuclear (DN), MN, and negative staining. Genetic variations of BRCA1 nuclear localization/transportation-related sequences were analyzed by cDNA sequencing of both nuclear localization signals (NLS) and nuclear export signals (NES). The BRCA1 antibody was verified by two other published ones. Comparisons of immunofluorescent assay with immunohistochemical and H&E staining methods were also performed. BRCA1 mislocalization conferred a 3.13-fold [95% confidence interval (CI): 1.31-7.50] risk of developing breast cancer for the MN form and a 5.79-fold (95% CI:1.58-21.23) risk for BRCA1-negative cases compared with DN staining. However, no genetic variant was found in the NES or the NLS region of the BRCA1 gene. In terms of prognosis, BRCA1 mislocalization showed a 3.5-fold (95% CI: 1.20-10.09) increased risk of breast cancer death compared with DN staining after adjusting for tumor node metastasis stage. BRCA1 MN forms and BRCA1-negative patterns led to a higher risk of carcinogenesis and a poor prognosis of breast cancer. Such BRCA1 mislocalization may not be directly caused by the genetic effects of the NLS and NES domains, but stem from nongenetic modifications (such as epigenetic silencing).
C1 [Ho, Jar-Yi] Triserv Gen Hosp, Grad Inst Life Sci, Taipei 114, Taiwan.
   [Hsu, Ren-Jun; Wu, Chieh-Lin; Wu, Ming-Ye; Yu, Cheng-Ping] Triserv Gen Hosp, Dept Pathol, Taipei 114, Taiwan.
   [Hsu, Ren-Jun; Wu, Chieh-Lin; Wu, Ming-Ye; Yu, Cheng-Ping] Triserv Gen Hosp, Grad Inst Pathol & Parasitol, Natl Def Med Ctr, Taipei 114, Taiwan.
   [Yu, Jyh-Cherng] Tri Serv Gen Hosp, Dept Surg, Taipei 114, Taiwan.
   [Gao, Hong-Wei; Yu, Cheng-Ping] Triserv Gen Hosp, Dept Pathol, Taipei 114, Taiwan.
   [Yen, Amy Ming-Fang] Taipei Med Univ, Coll Oral Med, Sch Oral Hyg, Taipei, Taiwan.
   [Chen, Hsiu-Hsi] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan.
   [Chen, Sheng-Hsien] Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan.
C3 Tri-Service General Hospital; Tri-Service General Hospital; National
   Defense Medical Center; Tri-Service General Hospital; Tri-Service
   General Hospital; Tri-Service General Hospital; Taipei Medical
   University; National Taiwan University; Chi Mei Hospital
RP Yu, CP (通讯作者)，Triserv Gen Hosp, Dept Pathol, 114 161,Sect 6,Minquan E Rd, Taipei 114, Taiwan.
EM cpyupath@yahoo.com.tw
RI chen, yuying/JNS-9778-2023; Wu, Chieh-Lin/KDO-1764-2024; Zhu,
   Guan-Cheng/GXH-6945-2022; Hsu, Chien-Ning/GLS-4014-2022
OI Ho, Jar-Yi/0000-0001-6933-041X; Chen, Tony Hsiu-Hsi/0000-0002-5799-6705;
   Yu, Cheng-Ping/0000-0002-0693-5056; Wu, Chieh-Lin
   (Stanley)/0000-0002-7090-7172
FU National Science Council [NSC 88-2314-B-016-062]; National Defense
   Medical Center [DOD-90-72]; Armed Forces Tao-Yuan General Hospital
   [AFTYGH-93-09, AFTYGH-97-04]; Taichung Armed Forces General Hospital
   [TCAFGH-93-01]; Tri-Service General Hospital [TSGH-C96-1-S01]
FX This article was supported by the National Science Council (NSC
   88-2314-B-016-062), National Defense Medical Center (DOD-90-72), Armed
   Forces Tao-Yuan General Hospital (AFTYGH-93-09, AFTYGH-97-04), Taichung
   Armed Forces General Hospital (TCAFGH-93-01), and Tri-Service General
   Hospital (TSGH-C96-1-S01). All patient information was obtained
   according to TSGH institutional review board guidelines
   (TSGHIRB-093-05-00004; TSGHIRB-097-05-008).
CR Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633
   Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863
   Chen ST, 2003, BREAST CANCER RES TR, V77, P133, DOI 10.1023/A:1021386026051
   ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171
   Glover-Collins K, 2008, CELL SIGNAL, V20, P958, DOI 10.1016/j.cellsig.2008.01.007
   Henderson BR, 2005, BIOESSAYS, V27, P884, DOI 10.1002/bies.20277
   Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303
   Kuo WH, 2012, J HUM GENET, V57, P130, DOI 10.1038/jhg.2011.142
   Kuschel B, 2000, EUR J CANCER PREV, V9, P139, DOI 10.1097/00008469-200006000-00001
   Lee WY, 2002, APPL IMMUNOHISTO M M, V10, P310, DOI 10.1097/00022744-200212000-00004
   Li SSL, 1999, HUM GENET, V104, P201, DOI 10.1007/s004390050936
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200
   Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861
   Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011
   Rennert G, 2005, EUR J CANCER PREV, V14, P357, DOI 10.1097/00008469-200508000-00008
   Rodríguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200
   Rodriguez JA, 2004, EXP CELL RES, V293, P14, DOI 10.1016/j.yexcr.2003.09.027
   Singh AK, 2011, EUR J CANCER PREV, V20, P478, DOI 10.1097/CEJ.0b013e32834761a6
   Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W
   Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630
   Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924
   Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430
   Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123
   Zhang HT, 2008, BREAST, V17, P563, DOI 10.1016/j.breast.2008.08.003
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-8278
EI 1473-5709
J9 EUR J CANCER PREV
JI Eur. J. Cancer Prev.
PD SEP
PY 2015
VL 24
IS 5
BP 407
EP 415
DI 10.1097/CEJ.0000000000000114
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP4KQ
UT WOS:000359850800006
PM 25622084
DA 2025-01-12
ER

PT J
AU Hu, Z
   Xie, LL
AF Hu, Zhuang
   Xie, Lingling
TI LHX6 inhibits breast cancer cell proliferation and invasion via
   repression of the Wnt/β-catenin signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE LIM homeobox domain 6; breast cancer; proliferation; invasion;
   Wnt/beta-catenin signaling pathway
ID POTENTIAL TUMOR-SUPPRESSOR; LIM-HOMEOBOX GENE; BETA-CATENIN; EXPRESSION;
   STATISTICS; CARCINOMAS; METHYLATION; MIGRATION; SUBTYPES; PITX2
AB LIM homeobox domain 6 (LHX6), a member of the LHX family of proteins, has been implicated in cancer development. However, the involvement of LHX6 in the development of breast cancer remains unclear. In the present study, the epigenetic regulation, biological function and associated molecular mechanisms of LHX6 in breast cancer were analyzed. The expression levels of LHX6 were demonstrated to be markedly decreased in breast cancer tissues and cell lines. In addition, it was found that increased LHX6 expression in breast cancer cell lines inhibited cell proliferation and invasion. Furthermore, increased LHX6 expression significantly decreased the expression of beta-catenin in MDA-MB-231 breast cancer cells, and small interfering RNA-beta-catenin enhanced LHX6-induced inhibition of cell proliferation and invasion in MDA-MB-231 breast cancer cells. These results indicate that LHX6 inhibits breast cancer cell growth and invasion through suppression of the Wnt/beta-catenin signaling pathway. Thus, the present study provides a novel insight into the underlying mechanism of tumorigenesis in breast cancer, indicating the therapeutic potential of LHX6 in the treatment of breast cancer.
C1 [Hu, Zhuang] Henan Univ, Dept Breast & Thyroid Surg, Huaihe Hosp, Kaifeng 475000, Hanan, Peoples R China.
   [Xie, Lingling] Zhangqiu City Hosp Tradit Chinese Med, Zhangqiu 250200, Shandong, Peoples R China.
C3 Henan University
RP Hu, Z (通讯作者)，Henan Univ, Dept Breast & Thyroid Surg, Huaihe Hosp, 8 Baogonghu North Rd, Kaifeng 475000, Hanan, Peoples R China.
EM hu_zhuangkf@126.com
CR Alifragis P, 2004, J NEUROSCI, V24, P5643, DOI 10.1523/JNEUROSCI.1245-04.2004
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5
   Choi Y, 2008, BIOL REPROD, V79, P442, DOI 10.1095/biolreprod.108.069393
   Estécio MRH, 2006, ONCOGENE, V25, P5018, DOI 10.1038/sj.onc.1209509
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Grigoriou M, 1998, DEVELOPMENT, V125, P2063
   Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1
   Hung TM, 2011, CARCINOGENESIS, V32, P1815, DOI 10.1093/carcin/bgr219
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jung S, 2011, INT J ONCOL, V38, P859, DOI 10.3892/ijo.2011.904
   Kuzmanov A, 2014, MOL ONCOL, V8, P401, DOI 10.1016/j.molonc.2013.12.009
   Kwon SY, 2015, HISTOPATHOLOGY, V66, P755, DOI 10.1111/his.12606
   Liodis P, 2007, J NEUROSCI, V27, P3078, DOI 10.1523/JNEUROSCI.3055-06.2007
   Liu WB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.366
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Samowitz WS, 1999, CANCER RES, V59, P1442
   Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tang XL, 2014, NUCLEIC ACIDS RES, V42, P2988, DOI 10.1093/nar/gkt1275
   Vadlamudi U, 2005, J CELL SCI, V118, P1129, DOI 10.1242/jcs.01706
   Vladimirova V, 2009, NEOPLASIA, V11, P700, DOI 10.1593/neo.09406
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Winchell CJ, 2013, EVODEVO, V4, DOI 10.1186/2041-9139-4-4
   Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418
   Zhang ZC, 2013, J BIOL CHEM, V288, P2485, DOI 10.1074/jbc.M112.402933
NR 27
TC 30
Z9 30
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2015
VL 12
IS 3
BP 4634
EP 4639
DI 10.3892/mmr.2015.3997
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CP5OW
UT WOS:000359933900199
PM 26129710
DA 2025-01-12
ER

PT J
AU Nalabothula, N
   Al-Jumaily, T
   Eteleeb, AM
   Flight, RM
   Shao, XR
   Moseley, H
   Rouchka, EC
   Fondufe-Mittendorf, YN
AF Nalabothula, Narasimharao
   Al-Jumaily, Taha
   Eteleeb, Abdallah M.
   Flight, Robert M.
   Shao Xiaorong
   Moseley, Hunter
   Rouchka, Eric C.
   Fondufe-Mittendorf, Yvonne N.
TI Genome-Wide Profiling of PARP1 Reveals an Interplay with Gene Regulatory
   Regions and DNA Methylation
SO PLOS ONE
LA English
DT Article
ID CHROMATIN-STRUCTURE; HYPERSENSITIVE SITES; HISTONE H1; BINDING;
   POLY(ADP-RIBOSE); EXPRESSION; TRANSCRIPTION; ACTIVATION; DATABASE; CELLS
AB Poly (ADP-ribose) polymerase-1 (PARP1) is a nuclear enzyme involved in DNA repair, chromatin remodeling and gene expression. PARP1 interactions with chromatin architectural multi-protein complexes (i.e. nucleosomes) alter chromatin structure resulting in changes in gene expression. Chromatin structure impacts gene regulatory processes including transcription, splicing, DNA repair, replication and recombination. It is important to delineate whether PARP1 randomly associates with nucleosomes or is present at specific nucleosome regions throughout the cell genome. We performed genome-wide association studies in breast cancer cell lines to address these questions. Our studies show that PARP1 associates with epigenetic regulatory elements genome-wide, such as active histone marks, CTCF and DNase hypersensitive sites. Additionally, the binding of PARP1 to chromatin genome-wide is mutually exclusive with DNA methylation pattern suggesting a functional interplay between PARP1 and DNA methylation. Indeed, inhibition of PARylation results in genome-wide changes in DNA methylation patterns. Our results suggest that PARP1 controls the fidelity of gene transcription and marks actively transcribed gene regions by selectively binding to transcriptionally active chromatin. These studies provide a platform for developing our understanding of PARP1' s role in gene regulation.
C1 [Nalabothula, Narasimharao; Al-Jumaily, Taha; Flight, Robert M.; Moseley, Hunter; Fondufe-Mittendorf, Yvonne N.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Eteleeb, Abdallah M.; Rouchka, Eric C.] Univ Louisville, Dept Comp Engn & Comp Sci, Louisville, KY 40292 USA.
   [Eteleeb, Abdallah M.] Washington Univ, McDonnell Genome Inst, St Louis, MO USA.
   [Shao Xiaorong] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.
C3 University of Kentucky; University of Louisville; Washington University
   (WUSTL); University of California System; University of California
   Berkeley
RP Fondufe-Mittendorf, YN (通讯作者)，Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
EM y.fondufe-mittendorf@uky.edu
RI Flight, Robert/A-5671-2009; Rouchka, Eric/A-8545-2008
OI Moseley, Hunter/0000-0003-3995-5368; Eteleeb, Abdallah
   M./0000-0001-9045-250X; Flight, Robert/0000-0001-8141-7788
FU NIH from the National Center for Research Resources [P20GM103436, 2P20
   RR020171]; International Rett Syndrome Foundation grant; 
   [1R01ES024478];  [NSF1517986]; Direct For Biological Sciences [1517986,
   1419282] Funding Source: National Science Foundation; Div Of Biological
   Infrastructure [1419282] Funding Source: National Science Foundation;
   Div Of Molecular and Cellular Bioscience [1517986] Funding Source:
   National Science Foundation
FX This research was supported by NIH grants P20GM103436 (ECR); 2P20
   RR020171 (YNFM) (from the National Center for Research Resources),
   1R01ES024478, NSF1517986 and International Rett Syndrome Foundation
   grant (YNFM). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Althaus FR, 2005, ONCOGENE, V24, P11, DOI 10.1038/sj.onc.1208382
   Bai P, 2012, CELL METAB, V16, P290, DOI 10.1016/j.cmet.2012.06.016
   Bao L, 2008, NUCLEIC ACIDS RES, V36, pD83, DOI 10.1093/nar/gkm875
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Blahnik KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017121
   Breiling A., 2006, CSH Protoc
   Brogaard K, 2012, NATURE, V486, P496, DOI 10.1038/nature11142
   Bürkle A, 2005, INT J BIOCHEM CELL B, V37, P1043, DOI 10.1016/j.biocel.2004.10.006
   Caiafa P, 2009, FASEB J, V23, P672, DOI 10.1096/fj.08-123265
   Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147
   Ciccarone F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046927
   Clark NJ, 2012, J BIOL CHEM, V287, P32430, DOI 10.1074/jbc.M112.397067
   Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106
   Crawford GE, 2006, NAT METHODS, V3, P503, DOI 10.1038/NMETH888
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108
   D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249
   De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Farrar D, 2010, MOL CELL BIOL, V30, P1199, DOI 10.1128/MCB.00827-09
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   Field Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000216
   Flight R., 2015, FMDATABREASTCAPARP1
   Flight R., 2015, FM PARP1 CORRELATION
   Flight R., 2015, FMCORRELATIONBREASTC
   Flight RM, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00098
   Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576
   Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138
   Fuchs G, 2014, GENOME RES
   Geiger T, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014050
   Gholami AM, 2013, CELL REP, V4, P609, DOI 10.1016/j.celrep.2013.07.018
   Gits CMM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-429
   Gits CMM, 2014, INT J CANCER, V135, P348, DOI 10.1002/ijc.28694
   Acuña LIG, 2013, WIRES RNA, V4, P77, DOI 10.1002/wrna.1142
   Gottschalk AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI 10.1073/pnas.0906920106
   GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111
   Guastafierro T, 2008, J BIOL CHEM, V283, P21873, DOI 10.1074/jbc.M801170200
   Guerrero PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016401
   Hackenberg M, 2011, NUCLEIC ACIDS RES, V39, pD75, DOI 10.1093/nar/gkq942
   Haring M, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-11
   Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029
   Ji YBA, 2010, CURR OPIN GENET DEV, V20, P512, DOI 10.1016/j.gde.2010.06.001
   Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522
   Johansson HJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3175
   Johnson LM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000280
   Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017
   Kaplan N, 2010, NAT STRUCT MOL BIOL, V17, P918, DOI 10.1038/nsmb0810-918
   Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667
   Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112
   Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Melnikov AA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni092
   Nalabothula N, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-92
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Nusinow DA, 2007, J BIOL CHEM, V282, P12851, DOI 10.1074/jbc.M610502200
   O'Geen H, 2011, METHODS MOL BIOL, V791, P265, DOI 10.1007/978-1-61779-316-5_20
   Ogino H, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-41
   Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407
   Petesch SJ, 2008, CELL, V134, P74, DOI 10.1016/j.cell.2008.05.029
   Petesch SJ, 2012, TRENDS GENET, V28, P285, DOI 10.1016/j.tig.2012.02.005
   Petesch SJ, 2012, MOL CELL, V45, P64, DOI 10.1016/j.molcel.2011.11.015
   Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288
   Polach KJ, 2000, J MOL BIOL, V298, P211, DOI 10.1006/jmbi.2000.3644
   Ragab A, 2003, NUCLEIC ACIDS RES, V31, P7083, DOI 10.1093/nar/gkg923
   Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Schones DE, 2008, NAT REV GENET, V9, P179, DOI 10.1038/nrg2270
   Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979
   Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797
   Struhl K, 2013, NAT STRUCT MOL BIOL, V20, P267, DOI 10.1038/nsmb.2506
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Timinszky G, 2009, NAT STRUCT MOL BIOL, V16, P923, DOI 10.1038/nsmb.1664
   Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764
   Vahdati A, 2014, J MECH BEHAV BIOMED, V30, P244, DOI 10.1016/j.jmbbm.2013.11.015
   van de Garde MDB, 2014, J IMMUNOL, V192, P1196, DOI 10.4049/jimmunol.1302138
   Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3
   Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426
   Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Ziebarth JD, 2013, NUCLEIC ACIDS RES, V41, pD188, DOI 10.1093/nar/gks1165
NR 90
TC 54
Z9 67
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2015
VL 10
IS 8
AR e0135410
DI 10.1371/journal.pone.0135410
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CP6KK
UT WOS:000359995500021
PM 26305327
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Muyan, M
   Güpür, G
   Yasar, P
   Ayaz, G
   User, SD
   Kazan, HH
   Huang, YF
AF Muyan, Mesut
   Gupur, Gizem
   Yasar, Pelin
   Ayaz, Gamze
   User, Sirma Damla
   Kazan, Hasan Huseyin
   Huang, Yanfang
TI Modulation of Estrogen Response Element-Driven Gene Expressions and
   Cellular Proliferation with Polar Directions by Designer Transcription
   Regulators
SO PLOS ONE
LA English
DT Article
ID HUMAN-BREAST-CANCER; ZINC-FINGER PROTEINS; RECEPTOR-ALPHA; ER-ALPHA;
   ACTIVATION FUNCTIONS; REPRESSION; ESTRADIOL; BINDING; DOMAIN; CELLS
AB Estrogen receptor a (ER alpha), as a ligand-dependent transcription factor, mediates 17 beta-estradiol (E2) effects. ERa is a modular protein containing a DNA binding domain (DBD) and transcription activation domains (AD) located at the amino-and carboxyl-termini. The interaction of the E2-activated ERa dimer with estrogen response elements (EREs) of genes constitutes the initial step in the ERE-dependent signaling pathway necessary for alterations of cellular features. We previously constructed monomeric transcription activators, or monotransactivators, assembled from an engineered ERE-binding module (EBM) using the ER alpha-DBD and constitutively active ADs from other transcription factors. Monotransactivators modulated cell proliferation by activating and repressing ERE-driven gene expressions that simulate responses observed with E2-ER alpha. We reasoned here that integration of potent heterologous repression domains (RDs) into EBM could generate monotransrepressors that alter ERE-bearing gene expressions and cellular proliferation in directions opposite to those observed with E2-ER alpha or monotransactivators. Consistent with this, monotransrepressors suppressed reporter gene expressions that emulate the ERE-dependent signaling pathway. Moreover, a model monotransrepressor regulated DNA synthesis, cell cycle progression and proliferation of recombinant adenovirus infected ER-negative cells through decreasing as well as increasing gene expressions with polar directions compared with E2-ER alpha or monotransactivator. Our results indicate that an 'activator' or a 'repressor' possesses both transcription activating/enhancing and repressing/decreasing abilities within a chromatin context. Offering a protein engineering platform to alter signal pathway-specific gene expressions and cell growth, our approach could also be used for the development of tools for epigenetic modifications and for clinical interventions wherein multigenic de-regulations are an issue.
C1 [Muyan, Mesut; Gupur, Gizem; Yasar, Pelin; Ayaz, Gamze; User, Sirma Damla; Kazan, Hasan Huseyin] Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
   [Muyan, Mesut; Huang, Yanfang] Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14619 USA.
C3 Middle East Technical University; University of Rochester
RP Muyan, M (通讯作者)，Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
EM mmuyan@metu.edu.tr
RI Ayaz, Gamze/CAI-8918-2022; Gupur, Gizem/KZU-2327-2024; Kazan,
   Hasan/HSH-9265-2023; Muyan, Mesut/AAZ-4888-2020
OI Yasar, Pelin/0000-0003-3027-9842; Muyan, Mesut/0000-0003-3058-6228
FU Turkiye Bilimsel ve Teknolojik Arastirma Kurumu [TUBITAK-KBAG 212T031];
   Middle East Technical University [METU-BAP-08-11-2012-125]
FX This work was supported by Turkiye Bilimsel ve Teknolojik Arastirma
   Kurumu, TUBITAK-KBAG 212T031, and Middle East Technical University,
   METU-BAP-08-11-2012-125. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693
   Ayer DE, 1996, MOL CELL BIOL, V16, P5772
   AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0
   Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351
   BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543
   Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135
   BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218
   Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   ElAshry D, 1996, J STEROID BIOCHEM, V59, P261, DOI 10.1016/S0960-0760(96)00118-5
   Falahi F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00022
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082
   Gersbach CA, 2014, ACCOUNTS CHEM RES, V47, P2309, DOI 10.1021/ar500039w
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Huang J, 2005, MOL ENDOCRINOL, V19, P2696, DOI 10.1210/me.2005-0120
   Huang J, 2004, MOL CELL ENDOCRINOL, V218, P65, DOI 10.1016/j.mce.2003.12.005
   Huang Jing, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P379, DOI 10.2174/156800805774912944
   Huang YF, 2011, ENDOCRINE, V39, P48, DOI 10.1007/s12020-010-9411-8
   Inaoka T, 2003, J BIOL CHEM, V278, P2169, DOI 10.1074/jbc.M208722200
   Juárez-Moreno K, 2013, EPIGENETICS-US, V8, P164, DOI 10.4161/epi.23503
   Kasten MM, 1996, MOL CELL BIOL, V16, P4215
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Krishnamurthy M, 2011, ACS CHEM BIOL, V6, P1321, DOI 10.1021/cb200308e
   Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4
   Levenson AS, 1998, BRIT J CANCER, V78, P88, DOI 10.1038/bjc.1998.447
   Li XD, 2004, MOL CELL BIOL, V24, P7681, DOI 10.1128/MCB.24.17.7681-7694.2004
   Li XD, 2008, J MOL ENDOCRINOL, V40, P211, DOI 10.1677/JME-07-0156
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041
   McDonnell DP, 2010, CURR OPIN PHARMACOL, V10, P620, DOI 10.1016/j.coph.2010.09.007
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666
   Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859
   Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669
   Murakami Y, 2005, J REPROD DEVELOP, V51, P639, DOI 10.1262/jrd.17029
   Mussolino C, 2012, CURR OPIN BIOTECH, V23, P644, DOI 10.1016/j.copbio.2012.01.013
   Muyan M, 2001, MOL CELL ENDOCRINOL, V182, P249, DOI 10.1016/S0303-7207(01)00493-2
   Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270
   Nott SL, 2010, MOL MED, V16, P10, DOI 10.2119/molmed.2009.00107
   Nott SL, 2009, J BIOL CHEM, V284, P15277, DOI 10.1074/jbc.M900365200
   O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603
   Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313
   Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/NMETH.2600, 10.1038/nmeth.2600]
   Reynolds N, 2013, DEVELOPMENT, V140, P505, DOI 10.1242/dev.083105
   Sadowski I, 1988, NATURE, V335
   Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5
   Sathya G, 2002, MOL CELL ENDOCRINOL, V192, P171, DOI 10.1016/S0303-7207(01)00673-6
   SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C
   Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259
   THIESEN HJ, 1991, NUCLEIC ACIDS RES, V19, P3996, DOI 10.1093/nar/19.14.3996
   TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718
   Yi P, 2002, MOL ENDOCRINOL, V16, P674, DOI 10.1210/me.16.4.674
   Yi P, 2002, MOL ENDOCRINOL, V16, P1810, DOI 10.1210/me.2001-0323
   Zalatan JG, 2015, CELL, V160, P339, DOI 10.1016/j.cell.2014.11.052
NR 58
TC 12
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2015
VL 10
IS 8
AR e0136423
DI 10.1371/journal.pone.0136423
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CP5MR
UT WOS:000359926900108
PM 26295471
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Duan, ZH
   Wang, HC
   Zhao, DM
   Ji, XX
   Song, M
   Yang, XJ
   Cui, W
AF Duan, Zhao-Heng
   Wang, Hao-Chuan
   Zhao, Dong-Mei
   Ji, Xiao-Xin
   Song, Min
   Yang, Xiao-Jun
   Cui, Wei
TI Cooperatively transcriptional and epigenetic regulation of sonic
   hedgehog overexpression drives malignant potential of breast cancer
SO CANCER SCIENCE
LA English
DT Article
DE Breast cancer; hypomethylation; NF-B; Sonic hedgehog; transcriptional
   regulation
ID NF-KAPPA-B; PROMOTER HYPOMETHYLATION; SIGNALING PATHWAY; DNA
   METHYLATION; GENE; EXPRESSION; ACTIVATION; IDENTIFICATION; METASTASIS;
   CARCINOMA
AB Sonic hedgehog (Shh), a ligand of Hedgehog signaling pathway, is considered an important oncogene and an exciting potential therapeutic target in several cancers. Comprehensive understanding of the regulation mechanism of Shh in cancer cells is necessary to find an effective approach to selectively block its tumorigenic function. We and others previously demonstrated that nuclear factor-kappa B (NF-B) activation and promoter hypomethylation contributed to the overexpression of Shh. However, the relationship between transcriptional and epigenetic regulation of Shh, and their roles in the malignant phenotype of cancer cells are still not clearly elucidated. In the present study, our data showed that the level of Shh was higher in breast cancer tissues with positive NF-B nuclear staining and promoter hypomethylation. In addition, survival analysis revealed that Shh overexpression, but not hypomethylation and NF-B nuclear staining, was a poor prognosis indicator for breast cancers. Moreover, invitro data demonstrated that both NF-B activation and hypomethylation in promoter region were positively associated with the overexpression of Shh. Mechanistically, the hypomethylation in Shh promoter could facilitate NF-B binding to its site, and subsequently cooperate to induce transcription of Shh. Furthermore, the biological function data indicated that overexpressed Shh enhanced the self-renewal capacity and migration ability of breast cancer cells, which could be augmented by promoter demethylation and NF-B activation. Overall, our findings reveal multiple and cooperative mechanisms of Shh upregulation in cancer cells, and the roles of Shh in tumor malignant behavior, thus suggesting a new strategy for therapeutic interventions to reduce Shh in tumors and improve patients' prognosis.
C1 [Duan, Zhao-Heng; Wang, Hao-Chuan; Zhao, Dong-Mei; Ji, Xiao-Xin; Cui, Wei] Shenyang Pharmaceut Univ, Dept Pharmacol, Coll Life Sci & Biopharmaceut, Shenyang 110016, Peoples R China.
   [Song, Min] China Med Univ, Dept Pathol, Affiliated Hosp 1, Shenyang, Peoples R China.
   [Song, Min] China Med Univ, Coll Basic Med Sci, Shenyang, Peoples R China.
   [Yang, Xiao-Jun] Shantou Univ, Coll Med, Ctr Neurosci, Shantou, Peoples R China.
C3 Shenyang Pharmaceutical University; China Medical University; China
   Medical University; Shantou University
RP Cui, W (通讯作者)，Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
EM xiaojunyang.cn@gmail.com; cuiwei_syphu@126.com
RI 晓路, 许/IVH-4053-2023
FU National Natural Science Foundation of China [81102028]; Liaoning
   Science and Technology Program, China [20111137, 2012225109]; Scientific
   Research Fund of Liaoning Provincial Education Department, China
   [L2013389L]
FX National Natural Science Foundation of China (No. 81102028); Liaoning
   Science and Technology Program (No. 20111137 and No. 2012225109), China;
   Scientific Research Fund of Liaoning Provincial Education Department
   (No. L2013389L), China.
CR [Anonymous], NAT REV CANC
   Baba Y, 2014, CLIN CANCER RES, V20, P1114, DOI 10.1158/1078-0432.CCR-13-1645
   Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Bièche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306
   Casey B, 2000, CURR OPIN GENET DEV, V10, P257, DOI 10.1016/S0959-437X(00)00085-X
   Chari NS, 2007, ADV ANAT PATHOL, V14, P344, DOI 10.1097/PAP.0b013e3180ca8a1d
   Cui W, 2010, CANCER SCI, V101, P927, DOI 10.1111/j.1349-7006.2010.01495.x
   Fan HX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0041-5
   Giri PK, 2012, J BIOL CHEM, V287, P29417, DOI 10.1074/jbc.M112.379859
   Haller F, 2015, INT J CANCER, V136, P1013, DOI 10.1002/ijc.29088
   He HC, 2012, PATHOL ONCOL RES, V18, P349, DOI 10.1007/s12253-011-9451-2
   Hsu YT, 2013, CLIN CANCER RES, V19, P6272, DOI 10.1158/1078-0432.CCR-13-1734
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   James SR, 2013, EPIGENETICS-US, V8, P849, DOI 10.4161/epi.25500
   Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010
   Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096
   Kim TJ, 2011, J SURG ONCOL, V104, P472, DOI 10.1002/jso.21988
   Li JM, 2012, SURG TODAY, V42, P770, DOI 10.1007/s00595-012-0157-1
   Li QY, 2011, ANZ J SURG, V81, P440, DOI 10.1111/j.1445-2197.2010.05585.x
   Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008-5472.CAN-05-4588
   Ning H, 2013, ONCOTARGET, V4, P2237, DOI 10.18632/oncotarget.1357
   Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Saze Z, 2012, DIGEST SURG, V29, P115, DOI 10.1159/000336949
   Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Wang LH, 2006, MODERN PATHOL, V19, P675, DOI 10.1038/modpathol.3800573
   Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467
   Wang LH, 2015, ONCOTARGET, V6, P9740, DOI 10.18632/oncotarget.3149
   Wang TP, 2012, CARCINOGENESIS, V33, P1158, DOI 10.1093/carcin/bgs138
   Xu MH, 2012, MED ONCOL, V29, P1010, DOI 10.1007/s12032-011-9899-7
   Yamasaki A, 2010, CANCER IMMUNOL IMMUN, V59, P675, DOI 10.1007/s00262-009-0783-7
NR 33
TC 35
Z9 36
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2015
VL 106
IS 8
BP 1084
EP 1091
DI 10.1111/cas.12697
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP4QI
UT WOS:000359867000018
PM 25990213
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kutty, RV
   Tay, CY
   Lim, CS
   Feng, SS
   Leong, DT
AF Kutty, Rajaletchumy Veloo
   Tay, Chor Yong
   Lim, Chen Siew
   Feng, Si-Shen
   Leong, David Tai
TI Anti-migratory and increased cytotoxic effects of novel dual drug-loaded
   complex hybrid micelles in triple negative breast cancer cells
SO NANO RESEARCH
LA English
DT Article
DE nanomedicine; biomaterials; nanobiology; biodegradable polymers; drug
   targeting
ID VITAMIN-E TPGS; HISTONE DEACETYLASE INHIBITOR; POLYMERIC MICELLES;
   TARGETED DELIVERY; MIXED MICELLES; PACLITAXEL; NANOPARTICLES;
   NANOMEDICINE; MICROTUBULES; EPIGENETICS
AB A polymer-based nanocarrier was developed for the co-delivery of epigenetic and chemotherapeutic drugs. The sterically stabilized hybrid micelle system uses micelles composed of D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000). In this study, suberoylanilide hydroxamic acid (SAHA) and paclitaxel were used as model drugs for combination chemotherapy to enhance therapeutic efficiency in targeting mesenchyme-like triple negative breast cancer (TNBC) cells. Combination therapy of paclitaxel and SAHA in a dual drug micelle system, (P + S)(mic), exhibited an IC50 value of 0.52 mu g/mL, which is about 5.91-fold more cytotoxic than the mere combination of free drugs (P + S). Furthermore, the (P + S)(mic) formulation was far more effective at inhibiting cell migration by more than 3.4-fold than the control. Thus, our findings show that the co-delivery of these drugs using the micelle system greatly enhances their therapeutic effect at a lower dosage, thereby minimizing toxicity. In addition, this formulation is proved to be remarkably effective in preventing cell migration at low dosage.
C1 [Kutty, Rajaletchumy Veloo; Tay, Chor Yong; Lim, Chen Siew; Feng, Si-Shen; Leong, David Tai] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117585, Singapore.
   [Feng, Si-Shen] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China.
   [Leong, David Tai] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore.
C3 National University of Singapore; Naval Medical University; National
   University of Singapore
RP Feng, SS (通讯作者)，Natl Univ Singapore, Dept Chem & Biomol Engn, 4 Engn Dr, Singapore 117585, Singapore.
EM chefss@nus.edu.sg; cheltwd@nus.edu.sg
RI kutty, rajaletchumy/L-7536-2019; Tay, Chor/C-1999-2016; Leong,
   David/G-1056-2012
OI Leong, David/0000-0001-8539-9062; Tay, Chor Yong/0000-0001-6721-7106
FU Agency of Science, Technology and Research (A*STAR), Singapore
   [R-398-000-077-305]; Chinese Ministry of Science and Technology (MOST)
   [R-398-000-077-305]; National University of Singapore; FSF
   [R-397-000-136-731, R-397-000-136-112]; Ministry of Education Research
   [R-279-000-376-112]; Ministry of Higher Education (MOHE) of Malaysia;
   Lee Kuan Yew Postdoctoral Fellowship
FX This work was supported by the Singapore China Cooperative Research
   Project between the Agency of Science, Technology and Research (A*STAR),
   Singapore and Chinese Ministry of Science and Technology (MOST)
   (R-398-000-077-305 to DTL and SSF), National University of Singapore,
   FSF research grant (R-397-000-136-731, R-397-000-136-112 to DTL and
   SSF), and Ministry of Education Research grant (R-279-000-376-112 to
   CYT). C. S. L. and R. V. K. received research scholarships from National
   University of Singapore and the Ministry of Higher Education (MOHE) of
   Malaysia respectively. C. Y. T. was supported by the Lee Kuan Yew
   Postdoctoral Fellowship.
CR Alexis Frank, 2010, Handb Exp Pharmacol, P55, DOI 10.1007/978-3-642-00477-3_2
   An ZH, 2010, CANCER LETT, V292, P215, DOI 10.1016/j.canlet.2009.12.006
   Angelucci A, 2010, GYNECOL ONCOL, V119, P557, DOI 10.1016/j.ygyno.2010.07.036
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin SB, 2011, NAT MED, V17, P288, DOI 10.1038/nm0311-288
   Cai YY, 2010, J CLIN PHARM THER, V35, P521, DOI 10.1111/j.1365-2710.2009.01095.x
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Chen HW, 2010, NANO RES, V3, P852, DOI 10.1007/s12274-010-0056-y
   Chiao J, 2009, U. S. Patent, Patent No. 20090105329
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Chong W, 2012, J SURG RES, V178, P851, DOI 10.1016/j.jss.2012.07.023
   Cooper AL, 2007, GYNECOL ONCOL, V104, P596, DOI 10.1016/j.ygyno.2006.09.011
   Cortez CC, 2008, MUTAT RES-FUND MOL M, V647, P44, DOI 10.1016/j.mrfmmm.2008.07.006
   Devinoy E, 2010, J MAMMARY GLAND BIOL, V15, P1, DOI 10.1007/s10911-010-9171-3
   Dietrich CS, 2010, GYNECOL ONCOL, V116, P126, DOI 10.1016/j.ygyno.2009.09.039
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Feng SS, 2007, CHEM ENG SCI, V62, P6641, DOI 10.1016/j.ces.2007.08.006
   Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719
   Gill KK, 2012, EUR J PHARM SCI, V46, P64, DOI 10.1016/j.ejps.2012.02.010
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Hasan AS, 2007, INT J PHARMACEUT, V344, P53, DOI 10.1016/j.ijpharm.2007.05.066
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hu CMJ, 2010, THER DELIV, V1, P323, DOI 10.4155/TDE.10.13
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Koo CX, 2012, MOL BIOL REP, V39, P7695, DOI 10.1007/s11033-012-1605-0
   Kutty RV, 2014, NANOMEDICINE-UK, V9, P561, DOI [10.2217/NNM.14.19, 10.2217/nnm.14.19]
   Kutty RV, 2013, BIOMATERIALS, V34, P10160, DOI 10.1016/j.biomaterials.2013.09.043
   Leong DT, 2014, ADV DRUG DELIVER REV, V79-80, P95, DOI 10.1016/j.addr.2014.06.007
   Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762
   Li YY, 2014, BIOCONJUGATE CHEM, V25, P2055, DOI 10.1021/bc500414e
   Ma K, 2013, ADV FUNCT MATER, V23, P1172, DOI 10.1002/adfm.201102963
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Mi Y, 2012, BIOMATERIALS, V33, P7519, DOI 10.1016/j.biomaterials.2012.06.100
   Modesitt SC, 2010, GYNECOL ONCOL, V119, P351, DOI 10.1016/j.ygyno.2010.06.030
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Mu L, 2005, INT J PHARMACEUT, V306, P142, DOI 10.1016/j.ijpharm.2005.08.026
   Mu L, 2002, J CONTROL RELEASE, V80, P129, DOI 10.1016/S0168-3659(02)00025-1
   Muthu MS, 2015, BIOMATERIALS, V39, P234, DOI 10.1016/j.biomaterials.2014.11.008
   Muthu MS, 2014, THERANOSTICS, V4, P660, DOI 10.7150/thno.8698
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rodriguez Luis G., 2004, V294, P23
   Sarfstein R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024468
   Sawant RR, 2010, METHODS MOL BIOL, V624, P131, DOI 10.1007/978-1-60761-609-2_9
   Setyawati MI, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2655
   Setyawati MI, 2014, ACS APPL MATER INTER, V6, P21822, DOI 10.1021/am502591c
   Setyawati MI, 2014, NANOMEDICINE-UK, V9, P369, DOI [10.2217/NNM.14.6, 10.2217/nnm.14.6]
   Shan XQ, 2009, BIOMED MICRODEVICES, V11, P1187, DOI 10.1007/s10544-009-9336-2
   Sun Z, 2010, CELL RES, V20, P1170, DOI 10.1038/cr.2010.133
   Tan GR, 2014, BIOMATERIALS, V35, P3044, DOI 10.1016/j.biomaterials.2013.12.033
   Taurin S, 2012, J CONTROL RELEASE, V164, P265, DOI 10.1016/j.jconrel.2012.07.013
   Tay CY, 2014, ADV FUNCT MATER, V24, P5936, DOI 10.1002/adfm.201401664
   Tay CY, 2014, NANO RES, V7, P805, DOI 10.1007/s12274-014-0441-z
   Tay CY, 2014, ACS APPL MATER INTER, V6, P6248, DOI 10.1021/am501266a
   Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298
   Verma MS, 2012, NANO RES, V5, P49, DOI 10.1007/s12274-011-0184-z
   Westerlund A, 1997, CLIN EXP METASTAS, V15, P318, DOI 10.1023/A:1018481617275
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Xing RJ, 2013, NANO RES, V6, P1, DOI 10.1007/s12274-012-0275-5
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947
   Zhang ZP, 2012, BIOMATERIALS, V33, P4889, DOI 10.1016/j.biomaterials.2012.03.046
   Zhao B, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-47
NR 65
TC 32
Z9 35
U1 1
U2 73
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
SN 1998-0124
EI 1998-0000
J9 NANO RES
JI Nano Res.
PD AUG
PY 2015
VL 8
IS 8
BP 2533
EP 2547
DI 10.1007/s12274-015-0760-8
PG 15
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CP4PR
UT WOS:000359865100008
DA 2025-01-12
ER

PT J
AU Li, Q
   Hou, LJ
   Ding, GF
   Li, YL
   Wang, JP
   Qian, B
   Sun, JG
   Wang, QZ
AF Li, Qiang
   Hou, Liejun
   Ding, Guofu
   Li, Yinglong
   Wang, Jiangping
   Qian, Biao
   Sun, Jianguo
   Wang, Qinzhang
TI KDM6B induces epithelial-mesenchymal transition and enhances clear cell
   renal cell carcinoma metastasis through the activation of SLUG
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ccRCC; KDM6B; EMT; SLUG
ID DEMETHYLASE JMJD3 CONTRIBUTES; LYSINE 27 TRIMETHYLATION;
   GENE-EXPRESSION; H3K27 DEMETHYLASES; BREAST-CANCER; HISTONE; UTX;
   COMPLEXES; PROTEINS; EMT
AB Clear cell renal cell carcinoma (ccRCC) is one of the most common kidney cancers; epithelial-mesenchymal transition (EMT) is associated with carcinoma invasion and metastasis. There have been several studies about the molecular regulation of EMT, but the relationship between histone demethylase and EMT is little known. Here, we reported KDM6B has high expression level in ccRCC and is positively correlated with poor ccRCC prognosis. KDM6B, also known as JMJD3, is a histone demethylase, can remove repressive histone H3K27me3 marks from chromatin, thereby activating gene expression. We found that the knockdown of KDM6B could inhibit ccRCC tumorigenesis in vitro; furthermore, KDM6B could induce EMT in ccRCC cells by activating the expression of master transcription factor SLUG. ChIP assays revealed that KDM6B stimulated SLUG expression by demethylate histone H3K27me3. The knockdown of KDM6B strongly inhibited ccRCC cell invasion in vitro, while the overexpression of KDM6B shown the opposite trend. Meanwhile, our analysis of the ccRCC tissue found that KDM6B expression was significantly corresponded with lymph node metastasis. Together, our data provide a novel epigenetic mechanism regulating tumor cell invasion and EMT, and provide a biomolecule for ccRCC diagnosis and prognosis.
C1 [Li, Qiang; Ding, Guofu; Li, Yinglong; Wang, Jiangping; Qian, Biao; Wang, Qinzhang] Shihezi Univ, Coll Med, Affiliated Hosp 1, Dept Urol, Shihezi 832008, Peoples R China.
   [Hou, Liejun] Ningbo Univ, Coll Med, Affiliated Hosp, Dept Urol, Ningbo 315211, Zhejiang, Peoples R China.
   [Sun, Jianguo] Shanghai Jiao Tong Univ, Sch Basic Med Sci, Inst Physiol & Psychol, Shanghai 200030, Peoples R China.
C3 Shihezi University; Ningbo University; Shanghai Jiao Tong University
RP Wang, QZ (通讯作者)，Shihezi Univ, Coll Med, Affiliated Hosp 1, Dept Urol, Shihezi 832008, Peoples R China.
EM qinzhangwang1977@163.com
OI li, qiang/0000-0002-1854-8918
FU Xinjiang Reg-iment medical and health [2011BA049, 2011-04];  [2011CD002]
FX This work was supported by grants (2011CD002) from excellent young of
   Xinjiang and grants (2011BA049; 2011-04) from Xinjiang Reg-iment medical
   and health.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Brannon A Rose, 2010, Genes Cancer, V1, P152
   Campbell MJ, 2013, ADV EXP MED BIOL, V754, P81, DOI 10.1007/978-1-4419-9967-2_4
   Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Hübner MR, 2010, COLD SH Q B, V75, P43, DOI 10.1101/sqb.2010.75.020
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4
   Schuettengruber B, 2009, DEVELOPMENT, V136, P3531, DOI 10.1242/dev.033902
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Sivakumar R, 2009, INT J ONCOL, V34, P329, DOI 10.3892/ijo_00000155
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Wendt MK, 2012, CELL TISSUE RES, V347, P85, DOI 10.1007/s00441-011-1199-1
   Zhao HJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006039
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
NR 33
TC 35
Z9 38
U1 0
U2 11
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 6
BP 6334
EP 6344
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CO6PD
UT WOS:000359277700032
PM 26261509
DA 2025-01-12
ER

PT J
AU Magnani, L
   Patten, DK
   Nguyen, VTM
   Hong, SP
   Steel, JH
   Patel, N
   Lombardo, Y
   Faronato, M
   Gomes, AR
   Woodley, L
   Page, K
   Guttery, D
   Primrose, L
   Garcia, DF
   Shaw, J
   Viola, P
   Green, A
   Nolan, C
   Ellis, IO
   Rakha, EA
   Shousha, S
   Lam, EWF
   Gyorffy, B
   Lupien, M
   Coombes, RC
AF Magnani, Luca
   Patten, Darren K.
   Nguyen, Van T. M.
   Hong, Sung-Pil
   Steel, Jennifer H.
   Patel, Naina
   Lombardo, Ylenia
   Faronato, Monica
   Gomes, Ana R.
   Woodley, Laura
   Page, Karen
   Guttery, David
   Primrose, Lindsay
   Garcia, Daniel Fernandez
   Shaw, Jacqui
   Viola, Patrizia
   Green, Andrew
   Nolan, Christopher
   Ellis, Ian O.
   Rakha, Emad A.
   Shousha, Sami
   Lam, Eric W. -F.
   Gyorffy, Balazs
   Lupien, Mathieu
   Coombes, R. Charles
TI The pioneer factor PBX1 is a novel driver of metastatic progression in
   ER'-positive breast cancer
SO ONCOTARGET
LA English
DT Article
DE breast cancer; estrogen receptor; drug resistance; metastasis; pioneer
   factors
ID PATHOLOGICAL PROGNOSTIC FACTORS; ESTROGEN-RECEPTOR-ALPHA; TERM
   FOLLOW-UP; POSTMENOPAUSAL WOMEN; OVARIAN-CANCER; CROSS-TALK;
   27-HYDROXYCHOLESTEROL; FULVESTRANT; RESISTANCE; BINDING
AB Over 30% of ERa breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ERa binding. Here we demonstrate that PBX1 plays a central role in regulating the ERa transcriptional response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of EGF-ERa genes highly expressed in aggressive breast tumours. Retrospective stratification of luminal patients using PBX1 protein levels in primary cancer further demonstrates that elevated PBX1 protein levels correlate with earlier metastatic progression. In agreement, PBX1 protein levels are significantly upregulated during metastatic progression in ERa-positive breast cancer patients. Finally we reveal that PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification of the PBX1 locus. Correspondingly, ERa-positive breast cancer patients carrying PBX1 amplification are characterized by poor survival. Notably, we demonstrate that PBX1 amplification can be identified in tumor derived-circulating free DNA of ERa-positive metastatic patients. Metastatic patients with PBX1 amplification are also characterized by shorter relapse-free survival. Our data identifies PBX1 amplification as a functional hallmark of aggressive ERa-positive breast cancers. Mechanistically, PBX1 amplification impinges on several critical pathways associated with aggressive ERa-positive breast cancer.
C1 [Magnani, Luca; Patten, Darren K.; Nguyen, Van T. M.; Hong, Sung-Pil; Steel, Jennifer H.; Patel, Naina; Lombardo, Ylenia; Faronato, Monica; Gomes, Ana R.; Woodley, Laura; Shousha, Sami; Lam, Eric W. -F.; Coombes, R. Charles] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England.
   [Page, Karen; Guttery, David; Primrose, Lindsay; Garcia, Daniel Fernandez; Shaw, Jacqui] Univ Leicester, Dept Canc Studies, Leicester, Leics, England.
   [Viola, Patrizia] Royal Brampton Hosp, Dept Histopathol, Lab Med, London, England.
   [Green, Andrew; Nolan, Christopher; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, MTA TTK Lendulet Canc Biomarker Res Grp, H-1085 Budapest, Hungary.
   [Gyorffy, Balazs] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary.
   [Lupien, Mathieu] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Lupien, Mathieu] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
C3 Imperial College London; University of Leicester; Royal Brompton
   Hospital; Hungarian Research Network; HUN-REN Research Centre for
   Natural Sciences; Semmelweis University; Semmelweis University;
   University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto
RP Magnani, L (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England.
EM l.magnani@imperial.ac.uk
RI Garcia, Daniel/AAQ-4162-2020; Guttery, David/H-2011-2012; Ellis,
   Ian/JJF-5555-2023; Green, Andrew/AAF-1991-2020; Gyorffy,
   Balazs/AAA-9135-2021; Gomes, Ana/HMO-6669-2023; Lam, Eric/AAW-8566-2020;
   Rakha, Emad/Q-5554-2019; Steel, Jennifer/B-4737-2013; magnani,
   luca/N-1094-2015; Lupien, Mathieu/KFB-6691-2024
OI Gyorffy, Balazs/0000-0002-5772-3766; Page, Karen/0000-0003-0440-9244;
   Nguyen, Thuy Mai Van/0000-0002-5898-0043; Fernandez Garcia,
   Daniel/0000-0002-4438-9666; Coombes, Raoul Charles/0000-0002-4811-1100;
   Rakha, Emad/0000-0002-5009-5525; Green, Andrew/0000-0002-0488-5913;
   Shaw, Jacqui/0000-0003-4227-503X; Steel, Jennifer/0000-0003-4439-0090;
   Guttery, David/0000-0003-0418-580X; Ellis, Ian/0000-0001-5292-8474; Lam,
   Eric/0000-0003-1274-3576; magnani, luca/0000-0002-7534-0785; viola,
   patrizia/0000-0002-2869-3908; Lupien, Mathieu/0000-0003-0929-9478
FU Imperial Junior Research Fellowship; Breast Cancer Campaign Pilot Grant
   [P46869]; Wellcome Trust [103034/Z/13/Z]; OTKA [K108655]; National
   Institute for Health Research (NIHR) Biomedical Research Centre;
   Experimental Cancer Medicine Centre, Cancer Research UK Centre at
   Imperial College Healthcare NHS Trust Imperial College London; Ontario
   Institute for Cancer Research (OICR); Canadian Institute of Health
   Research (CIHR); Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD); Fundamental Research Funds for the
   Central Universities [YD2014SK0002]; 111 Project [111-2-07]; 333 high
   level project of Jiangsu Province [BRA2014245]; National 12th Five-year
   Plan "Major Scientific and Technological Special Project for Significant
   New Drugs Creation" project [2012ZX0950-1001-001]; Wellcome Trust
   [103034/Z/13/Z] Funding Source: Wellcome Trust
FX This work was supported by an Imperial Junior Research Fellowship and a
   Breast Cancer Campaign Pilot Grant (P46869) to LM, Wellcome Trust
   [103034/Z/13/Z] to DKP and the OTKA K108655 grant to BG, The Imperial
   College Healthcare NHS Trust Tissue Bank provided tissue samples. Other
   investigators may have received samples from these same tissues' The
   research [was funded / supported by] the National Institute for Health
   Research (NIHR) Biomedical Research Centre based and Experimental Cancer
   Medicine Centre, Cancer Research UK Centre at Imperial College
   Healthcare NHS Trust Imperial College London. M.L. holds a young
   investigator award from the Ontario Institute for Cancer Research (OICR)
   and a new investigator salary award from the Canadian Institute of
   Health Research (CIHR). The views expressed are those of the author(s)
   and not necessarily those of the NHS, the NIHR or the Department of
   Health.This study was partially supported by the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD), the
   Fundamental Research Funds for the Central Universities (YD2014SK0002).
   the 111 Project (111-2-07), 333 high level project of Jiangsu Province
   (BRA2014245), and the National 12th Five-year Plan "Major Scientific and
   Technological Special Project for Significant New Drugs Creation"
   project (NO.2012ZX0950-1001-001).
CR Barone I, 2010, ONCOGENE, V29, P2404, DOI 10.1038/onc.2009.520
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brunner AL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r71
   Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822
   Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Györffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Ling GY, 2010, MOL CELL BIOL, V30, P5531, DOI 10.1128/MCB.00601-10
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2007, MOL ENDOCRINOL, V21, P797, DOI 10.1210/me.2006-0074
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Magnani L, 2013, P NATL ACAD SCI US
   Magnani L, 2013, MOL CELL ENDOCRINOL
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   Martin LA, 2005, ENDOCR-RELAT CANCER, V12, pS75, DOI 10.1677/erc.1.01023
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908
   Nielsen CB, 2012, GENOME RES, V22, P2262, DOI 10.1101/gr.140665.112
   Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1
   Page K, 2011, BRIT J CANCER, V104, P1342, DOI 10.1038/bjc.2011.89
   Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517
   Perey L, 2007, ANN ONCOL, V18, P64, DOI 10.1093/annonc/mdl341
   Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Sarajlic A, 2014, BREAST CANCER RES TR, V143, P393, DOI 10.1007/s10549-013-2805-6
   Shaw JA, 2011, GENOMIC ANAL CIRCULA
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Theodorou V, 2012, GENOME RES
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081
   Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Whale AS, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks203
   Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 55
TC 44
Z9 49
U1 1
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2015
VL 6
IS 26
BP 21878
EP 21891
DI 10.18632/oncotarget.4243
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT6WW
UT WOS:000362954800027
PM 26215677
OA Green Published, gold, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Dong, Y
   Cao, BP
   Zhang, MY
   Han, WD
   Herman, JG
   Fuks, F
   Zhao, YL
   Guo, MZ
AF Dong, Yan
   Cao, Baoping
   Zhang, Meiying
   Han, Weidong
   Herman, James G.
   Fuks, Francois
   Zhao, Yali
   Guo, Mingzhou
TI Epigenetic silencing of NKD2, a major component of Wnt signaling,
   promotes breast cancer growth
SO ONCOTARGET
LA English
DT Article
DE NKD2; DNA methylation; Wnt signaling; epigenetics; breast cancer
ID PATHWAY; METHYLATION; PROGRESSION; CARCINOMA; NAKED2; GENES;
   HETEROZYGOSITY; INSTABILITY; ANTAGONIST; TARGET
AB Naked cuticle homolog 2 (NKD2) has been reported to antagonize Wnt signaling in zebrafish, mouse and mammals. The aim of this study is to investigate the epigenetic changes and mechanisms of NKD2 in human breast cancer development. Six breast cancer cell lines (MCF-7, ZR75-1, MDA-MB-468, MDA-MB-231, T47D and BT474) and 68 cases of primary human breast cancer were studied using methylation specific PCR, immunohistochemistry, western blot, flow cytometry techniques and a xenograft mouse model. The expression of NKD1 and NKD2 was regulated by promoter region methylation in breast cancer cells. No NKD1 methylation was found in primary human breast cancer. NKD2 was methylated in 51.4% (35/68) of human primary breast cancer samples. NKD2 methylation was significantly associated with reduction of NKD2 expression, and tumor stage (p < 0.05). NKD2 suppressed breast cancer cell proliferation both in vitro and in vivo. NKD2 induced G1/S arrest and inhibited Wnt signaling in breast cancer cells. In conclusion, NKD2 is frequently methylated in human breast cancer, and the expression of NKD2 is regulated by promoter region methylation. NKD2 suppresses breast cancer proliferation by inhibiting Wnt signaling.
C1 [Dong, Yan; Cao, Baoping; Zhang, Meiying; Guo, Mingzhou] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
   [Dong, Yan; Han, Weidong] Chinese Peoples Liberat Army Gen Hosp, Sch Life Sci, Inst Basic Med, Dept Mol Biol, Beijing 100853, Peoples R China.
   [Cao, Baoping; Zhang, Meiying] Nankai Univ, Coll Med, Tianjin 300071, Peoples R China.
   [Herman, James G.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA.
   [Fuks, Francois] Free Univ Brussels ULB, Lab Canc Epigenet, B-1070 Brussels, Belgium.
   [Zhao, Yali] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hainan Hosp, Cent Lab, Hai Tang Wan 572013, Sanya, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital; Nankai University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Universite Libre de Bruxelles; Chinese People's Liberation
   Army General Hospital
RP Guo, MZ (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
EM zhaoyl301@163.com; mzguo1@gmail.com
RI Wang, Haitao/GYV-1262-2022; Cao, Baoping/HDN-2120-2022; Fuks,
   Francois/HJY-8201-2023
FU National Basic Research Program of China (973 Program) [2012CB934002,
   2015cb553904]; National High-tech R&D Program of China (863 Program)
   [SS2012AA020314, SS2012AA020821, SS2012AA020303]; National Key
   Scientific instrument Special Programme of China [2011YQ03013405];
   National Science Foundation of China (NSFC) [81402345, 81121004,
   81490753]; Key Science and Technology Project in Hainan Province
   [ZD2X2013003]
FX This work was supported by the following grants: National Basic Research
   Program of China (973 Program No. 2012CB934002. 2015cb553904), National
   High-tech R&D Program of China (863 Program No. SS2012AA020314,
   SS2012AA020821, SS2012AA020303), National Key Scientific instrument
   Special Programme of China (Grant No. 2011YQ03013405), National Science
   Foundation of China (NSFC No 81402345, 81121004 and 81490753) and the
   Key Science and Technology Project in Hainan Province (ZD2X2013003).
CR Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001
   Azim HA, 2014, J THORAC DIS, V6, P864, DOI 10.3978/j.issn.2072-1439.2014.06.38
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Focken T, 2011, CYTOGENET GENOME RES, V135, P84, DOI 10.1159/000332005
   Friedrich K, 2008, CELL ONCOL, V30, P39
   Frye M, 2010, CANCER LETT, V289, P71, DOI 10.1016/j.canlet.2009.08.004
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Götze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981
   Guo JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007982
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   Guo MZ, 2008, EPIGENETICS-US, V3, P336, DOI 10.4161/epi.3.6.7158
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu TH, 2006, BIOCHEM BIOPH RES CO, V350, P911, DOI 10.1016/j.bbrc.2006.09.121
   Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2
   King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350
   Lee YN, 2008, CELL SIGNAL, V20, P443, DOI 10.1016/j.cellsig.2007.11.005
   Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101
   Oldenburg RA, 2007, CRIT REV ONCOL HEMAT, V63, P125, DOI 10.1016/j.critrevonc.2006.12.004
   Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201
   Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tsuda H, 2009, BREAST CANCER-TOKYO, V16, P186, DOI 10.1007/s12282-009-0124-x
   Usongo M, 2013, DEV DYNAM, V242, P291, DOI 10.1002/dvdy.23919
   Wang K, 2013, MOL HUM REPROD, V19, P57, DOI 10.1093/molehr/gas051
   Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898
   Yan WJ, 2013, EPIGENETICS-US, V8, P1373, DOI 10.4161/epi.26781
   Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615
   Zhao S, 2015, ONCOGENE
   Zob D, 2013, CHIRURGIA-BUCHAREST, V108, P557
NR 34
TC 28
Z9 31
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2015
VL 6
IS 26
BP 22126
EP 22138
DI 10.18632/oncotarget.4244
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT6WW
UT WOS:000362954800045
PM 26124080
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Brewer, TF
   Chang, CJ
AF Brewer, Thomas F.
   Chang, Christopher J.
TI An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde
   in Living Cells
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID HISTONE DEMETHYLATION; DNA METHYLATION; START SITES; URINE; BLOOD;
   CHROMATOGRAPHY; MECHANISM; HEADSPACE; MOLECULE; REVERSAL
AB Formaldehyde (FA) is a reactive carbonyl species (RCS) produced in living systems that has been implicated in epigenetics as well as in the pathologies of various cancers, diabetes, and heart, liver, and neuro-degenerative diseases. Traditional methods for biological FA detection rely on sample destruction and/or extensive processing, resulting in a loss of spatiotemporal information. To help address this technological gap, we present the design, synthesis, and biological evaluation of a fluorescent probe for live-cell FA imaging that relies on a FA-induced aza-Cope rearrangement. Formaldehyde probe-1 (FAP-1) is capable of detecting physiologically relevant concentrations of FA in aqueous buffer and in live cells with high selectivity over potentially competing biological analytes. Moreover, FAP-1 can visualize endogenous FA produced by lysine-specific demethylase 1 in a breast cancer cell model, presaging the potential utility of this chemical approach to probe RCS biology.
C1 [Brewer, Thomas F.; Chang, Christopher J.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   [Chang, Christopher J.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   [Chang, Christopher J.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley;
   University of California System; University of California Berkeley;
   Howard Hughes Medical Institute
RP Chang, CJ (通讯作者)，Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
EM chrischang@berkeley.edu
RI Chang, Chris/M-8030-2016
OI Brewer, Thomas/0000-0003-2978-0250
FU NIH [GM 79465, T32 GM066698]; National Institute of General Medical
   Sciences [T32GM066698, R01GM079465] Funding Source: NIH RePORTER
FX We thank the NIH (GM 79465) for support of this work. C.J.C. is an
   Investigator of the Howard Hughes Medical Institute. T.F.B. was
   partially supported by a Chemical Biology Training Grant from the NIH
   (T32 GM066698). We thank Ann Fischer (UC Berkeley Tissue Culture
   Facility) for expert technical assistance.
CR Andersen ME, 2010, TOXICOL SCI, V118, P716, DOI 10.1093/toxsci/kfq303
   Baan R, 2009, LANCET ONCOL, V10, P1143, DOI 10.1016/S1470-2045(09)70358-4
   Chan J, 2012, NAT CHEM, V4, P973, DOI [10.1038/NCHEM.1500, 10.1038/nchem.1500]
   Chaves-Ferreira M, 2015, ANGEW CHEM INT EDIT, V54, P1172, DOI 10.1002/anie.201409344
   Chen XQ, 2012, CHEM REV, V112, P1910, DOI 10.1021/cr200201z
   Chen XQ, 2011, CHEM SOC REV, V40, P4783, DOI 10.1039/c1cs15037e
   Cho DG, 2009, CHEM SOC REV, V38, P1647, DOI 10.1039/b804436h
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Ebeler SE, 1997, J CHROMATOGR B, V702, P211, DOI 10.1016/S0378-4347(97)00369-1
   Fitzpatrick PF, 2010, ARCH BIOCHEM BIOPHYS, V493, P13, DOI 10.1016/j.abb.2009.07.019
   Fu Y, 2015, CELL, V161, P879, DOI 10.1016/j.cell.2015.04.010
   Greer EL, 2015, CELL, V161, P868, DOI 10.1016/j.cell.2015.04.005
   Grimm JB, 2013, ACS CHEM BIOL, V8, P1303, DOI 10.1021/cb4000822
   He R, 2012, CHRONIC FORMALDEHYDE, P59
   HECK HD, 1985, AM IND HYG ASSOC J, V46, P1, DOI 10.1080/15298668591394275
   Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kalapos MP, 2013, DIABETES RES CLIN PR, V99, P260, DOI 10.1016/j.diabres.2012.11.003
   Kato S, 2001, ANAL CHEM, V73, P2992, DOI 10.1021/ac001498q
   Klinman JP, 2003, BBA-PROTEINS PROTEOM, V1647, P131, DOI 10.1016/S1570-9639(03)00077-3
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liteplo RG., 2002, Formaldehyde: Concise International Chemical Assessment Document 40
   Lukinavicius G, 2014, NAT CHEM, V6, P663, DOI 10.1038/nchem.2020
   Luo WH, 2001, J CHROMATOGR B, V753, P253, DOI 10.1016/S0378-4347(00)00552-1
   Michel BW, 2012, J AM CHEM SOC, V134, P15668, DOI 10.1021/ja307017b
   Munoz A.O, 2015, US Pat.,, Patent No. [2015/0025054, 20150025054, 20150025054 Al]
   Roth A, 2015, J AM CHEM SOC, DOI [10.1021/jacs.5b05339, DOI 10.1021/JACS.5B05339]
   Shen L, 2014, ANNU REV BIOCHEM, V83, P585, DOI 10.1146/annurev-biochem-060713-035513
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Song H, 2012, TETRAHEDRON LETT, V53, P4913, DOI 10.1016/j.tetlet.2012.06.117
   Spanel P, 1999, RAPID COMMUN MASS SP, V13, P1354, DOI 10.1002/(SICI)1097-0231(19990730)13:14<1354::AID-RCM641>3.3.CO;2-A
   SZARVAS T, 1986, J RADIOAN NUCL CH LE, V106, P357, DOI 10.1007/BF02163668
   Takeuchi A, 2007, B ENVIRON CONTAM TOX, V79, P1, DOI 10.1007/s00128-007-9172-0
   Teng S, 2001, CHEM-BIOL INTERACT, V130, P285, DOI 10.1016/S0009-2797(00)00272-6
   Tong ZQ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01807
   Tong ZQ, 2013, AGE, V35, P583, DOI 10.1007/s11357-012-9388-8
   Tong ZQ, 2011, NEUROBIOL AGING, V32, P31, DOI 10.1016/j.neurobiolaging.2009.07.013
   Tong ZQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010234
   Tsang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062322
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Tulpule K, 2013, J NEUROCHEM, V127, P7, DOI 10.1111/jnc.12356
   Uno SN, 2014, NAT CHEM, V6, P681, DOI [10.1038/nchem.2002, 10.1038/NCHEM.2002]
   Wang J., 2012, ANGEW CHEM, V124, P9790
   Wang TN, 2013, J AM CHEM SOC, V135, P12429, DOI 10.1021/ja406077j
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wilson JL, 2014, CHEM-EUR J, V20, P14698, DOI 10.1002/chem.201403901
   Yang YM, 2013, CHEM REV, V113, P192, DOI 10.1021/cr2004103
   Yu PH, 2003, BBA-PROTEINS PROTEOM, V1647, P193, DOI 10.1016/S1570-9639(03)00101-8
   Yu PH, 2003, ANAL BIOCHEM, V318, P285, DOI 10.1016/S0003-2697(03)00211-2
   Zhang GQ, 2015, CELL, V161, P893, DOI 10.1016/j.cell.2015.04.018
   Zheng KB, 2014, CHEM SCI, V5, P3439, DOI 10.1039/c4sc00283k
   Zhou W, 2015, SENSOR ACTUAT B-CHEM, V209, P664, DOI 10.1016/j.snb.2014.12.043
NR 56
TC 229
Z9 249
U1 4
U2 346
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 2
PY 2015
VL 137
IS 34
BP 10886
EP 10889
DI 10.1021/jacs.5b05340
PG 4
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA CQ8OF
UT WOS:000360867000007
PM 26306005
OA Green Published
DA 2025-01-12
ER

PT J
AU Yu, ZJ
   Xiao, QH
   Zhao, L
   Ren, J
   Bai, XF
   Sun, ML
   Wu, HZ
   Liu, XJ
   Song, ZG
   Yan, YY
   Mi, XY
   Wang, EH
   Jin, F
   Wei, MJ
AF Yu, Zhaojin
   Xiao, Qinghuan
   Zhao, Lin
   Ren, Jie
   Bai, Xuefeng
   Sun, Mingli
   Wu, Huizhe
   Liu, Xiaojian
   Song, Zhiguo
   Yan, Yuanyuan
   Mi, Xiaoyi
   Wang, Enhua
   Jin, Feng
   Wei, Minjie
TI DNA Methyltransferase 1/3a Overexpression in Sporadic Breast Cancer is
   Associated with Reduced Expression of Estrogen Receptor-Alpha/Breast
   Cancer Susceptibility Gene 1 and Poor Prognosis
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE epigenetics; immunohistochemistry; therapy
ID DE-NOVO METHYLATION; CYTOSINE-5 METHYLTRANSFERASES; MAINTENANCE
   METHYLATION; CLINICAL-SIGNIFICANCE; PROTEIN EXPRESSION; 3B
   OVEREXPRESSION; CHINESE WOMEN; ALPHA ER; DNMT1; BRCA1
AB DNA methyltransferases (DNMTs), including DNMT1, 3a, and 3b, play an important role in the progression of many malignant tumors. However, it remains unclear whether expression of DNMTs is associated with the development of breast cancer. This study aimed to explore the clinical significance of DNMT proteins in sporadic breast cancer. We investigated the expression of DNMT1, 3a, and 3b in 256 breast cancer and 36 breast fibroadenoma, using immunohistochemistry. The expression of DNMT1 and 3a was significantly higher in breast cancer than in fibroadenoma. In breast cancer, the expression of DNMT1 was significantly correlated with lymph node metastasis (P=0.020), and the expression of DNMT3a and 3b was significantly correlated with advanced clinical stages (P=0.046 and 0.012, respectively). Overexpression of DNMT1/3a was correlated with promoter hypermethylation and reduced expression of ER and BRCA1. The expression levels of DNMT1 or DNMT3a were associated with a significantly shorter DFS or OS in a subgroup of breast cancer patients (patients with the age 50 years old, ER-negative status, or HER2-postive status). The expression of DNMT1 or a combined expression of DNMT1 and 3a was associated with poor prognosis in patients who received chemotherapy and endocrine therapy, but not in patients who received chemotherapy alone. These findings suggest that DNMT1 and 3a may be involved in the progression and prognosis of sporadic breast cancer. (C) 2014 Wiley Periodicals, Inc.
C1 [Yu, Zhaojin; Xiao, Qinghuan; Zhao, Lin; Ren, Jie; Bai, Xuefeng; Sun, Mingli; Wu, Huizhe; Liu, Xiaojian; Song, Zhiguo; Yan, Yuanyuan; Wei, Minjie] China Med Univ, Sch Pharmaceut Sci, Dept Pharmacol, Shenyang, Peoples R China.
   [Liu, Xiaojian] Liaoning Med Univ, Basic Med Coll, Dept Pharmacol, Jinzhou, Peoples R China.
   [Mi, Xiaoyi; Wang, Enhua] China Med Univ, Coll Basic Med Sci, Dept Pathol, Shenyang, Peoples R China.
   [Mi, Xiaoyi; Wang, Enhua; Wei, Minjie] China Med Univ, Inst Pathol & Pathophysiol, Shenyang, Peoples R China.
   [Jin, Feng] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Shenyang, Peoples R China.
C3 China Medical University; Jinzhou Medical University; China Medical
   University; China Medical University; China Medical University
RP Wei, MJ (通讯作者)，92 Beier Rd, Shenyang 110001, Peoples R China.
RI Chen, Huanhuan/HTO-5007-2023; Xiao, Qinghuan/L-1114-2019
OI Yu, Zhaojin/0000-0002-0438-5601
FU National Natural Science Foundation of China [81173092]; Liaoning ST
   Projects [2011415052]; Shenyang Technology Projects [F12-148-9-00]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   number: 81173092; Grant sponsor: Liaoning S&T Projects; Grant number:
   2011415052; Grant sponsor: Shenyang Technology Projects; Grant number:
   F12-148-9-00
CR Amara K, 2010, CANCER SCI, V101, P1722, DOI 10.1111/j.1349-7006.2010.01569.x
   Bai XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040024
   Ben Gacem R, 2012, HUM PATHOL, V43, P1731, DOI 10.1016/j.humpath.2011.12.022
   BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848
   Daniel FI, 2010, ARCH ORAL BIOL, V55, P1024, DOI 10.1016/j.archoralbio.2010.08.009
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x
   Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Gravina GL, 2011, ENDOCRINOLOGY, V152, P4550, DOI 10.1210/en.2011-1056
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Kullmann K, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-7
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Liu WB, 2011, TOXICOL APPL PHARM, V251, P70, DOI 10.1016/j.taap.2010.12.002
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x
   Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002
   Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Walker RA, 1999, J PATHOL, V188, P229, DOI 10.1002/(SICI)1096-9896(199907)188:3<229::AID-PATH341>3.0.CO;2-F
   Wang YS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030635, 10.1371/journal.pone.0048669, 10.1371/journal.pone.0047302]
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 43
TC 46
Z9 50
U1 0
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD SEP
PY 2015
VL 54
IS 9
BP 707
EP 719
DI 10.1002/mc.22133
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CP2MG
UT WOS:000359710600005
PM 24464625
DA 2025-01-12
ER

PT J
AU Ullah, F
   Khan, T
   Ali, N
   Malik, FA
   Kayani, MA
   Shah, STA
   Saeed, M
AF Ullah, Farman
   Khan, Taimoor
   Ali, Nawab
   Malik, Faraz Arshad
   Kayani, Mahmood Akhtar
   Shah, Syed Tahir Abbas
   Saeed, Muhammad
TI Promoter Methylation Status Modulate the Expression of Tumor Suppressor
   (RbL2/p130) Gene in Breast Cancer
SO PLOS ONE
LA English
DT Article
ID RETINOBLASTOMA FAMILY; DIFFERENTIAL EXPRESSION; POCKET PROTEINS;
   DOWN-REGULATION; GASTRIC-CANCER; RB2/P130; PRB2/P130; P107; MEMBERS;
   IDENTIFICATION
AB Background
   Aberrant expression of tumor suppressor genes may correspond to the abnormal cell development and tumorigenesis. Rbl2/p130, a member of retinoblastoma family of proteins, has growth suppressive properties. Numerous studies reported de-regulation of Rbl2/p130 in various types of cancer as a consequence of a number of genetic alterations. However, role of epigenetic mechanisms like DNA methylation in Rbl2/p130 expression remains elusive.
   Methods
   In the current study, 76 breast cancer tumors along with normal tissues (n = 76), blood (n = 76) of respective individuals and control blood (n = 50) were analyzed. Rbl2/p130 expression was analyzed by quantitative real time PCR (syber green method). Promoter methylation status was studied through methylation specific PCR of bisulfite converted genomic DNA. Data was analyzed using various statistical tests.
   Results
   We report significantly reduced Rbl2/p130 expression (P = 0.001) in tumors tissues as compared to control samples. Similarly, Rbl2/p130 expression varies with age and disease stages (P = 0.022), which suggest its involvement in tumor progression. Aberrant promotermethylation (Delta meth) was found in almost all the diseased samples and that was significantly different (P<0.001) with control samples. Similarly, methylation status varies significantly with tumor progression stages (P = 0.022). Hyper-methylation was observed at -1, +3, +15 and +75 of Rbl2/p130 promoter flanking around the TSS. Statistical analysis revealed that Rbl2/p130 expression negatively correlates to its promoter methylation (r = -0.412) in tumor tissues. Our results reflect an epigenetic regulation of Rbl2/p130 expression in breast cancer. This highlights the importance of Rbl2/p130 promoter methylation in breast cancer pathogenesis.
C1 [Ullah, Farman; Khan, Taimoor; Malik, Faraz Arshad; Kayani, Mahmood Akhtar; Shah, Syed Tahir Abbas; Saeed, Muhammad] COMSATS Inst Informat Technol CIIT, Dept Biosci, Canc Genet & Epigenet Lab, Islamabad, Pakistan.
   [Ali, Nawab] Kohat Univ Sci & Technol KUST, Dept Biotechnol & Genet Engn, Kohat, Pakistan.
C3 COMSATS University Islamabad (CUI); Kohat University of Science &
   Technology
RP Saeed, M (通讯作者)，COMSATS Inst Informat Technol CIIT, Dept Biosci, Canc Genet & Epigenet Lab, Islamabad, Pakistan.
EM muhammad.saeed@comsats.edu.pk
RI /I-1343-2018; malik, Faraz./AFQ-1839-2022; Shah, Syed Tahir
   Abbas/K-4637-2015; Kayani, Mahmood/I-7760-2015
OI Kayani, Mahmood/0000-0001-9886-180X; Ali, Nawab/0000-0002-4651-9946
FU Higher Education Commission (HEC); COMSATS Research Grant Program
   (CRGP); CIIT
FX The author specially acknowledge the Higher Education Commission (HEC),
   COMSATS Research Grant Program (CRGP), and CIIT for their research grant
   for supporting this study.
CR [Anonymous], TURK J MED SCI
   [Anonymous], J BIOMATERIALS NANOB
   Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005
   Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629
   Baldi A, 1996, CLIN CANCER RES, V2, P1239
   Baldi A, 1997, CLIN CANCER RES, V3, P1691
   Baxter E, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-45
   Campioni M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-38
   Cenci M, 2005, ANTICANCER RES, V25, P2187
   Cherkasova E, 2011, ONCOGENE, V30, P4697, DOI 10.1038/onc.2011.179
   Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135
   Claudio P, 2002, GENOME BIOL, V3
   CLAUDIO PP, 1994, CANCER RES, V54, P5556
   Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619
   Colozza M, 2005, ANN ONCOL, V16, P1723, DOI 10.1093/annonc/mdi352
   D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524
   De Falco G, 2007, BLOOD, V110, P1301, DOI 10.1182/blood-2006-12-064865
   Dong SW, 2012, WORLD J GASTROENTERO, V18, P576, DOI 10.3748/wjg.v18.i6.576
   Feng L, 2011, BIOCHEM BIOPH RES CO, V406, P534, DOI 10.1016/j.bbrc.2011.02.081
   Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001
   Guo XB, 2011, BIOCHEM BIOPH RES CO, V404, P622, DOI 10.1016/j.bbrc.2010.12.026
   Hatzimichael E, 2009, CLIN LYMPHOMA MYELOM, V9, P239, DOI 10.3816/CLM.2009.n.047
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Khan ZN, 2013, ASIAN PAC J CANCER P, V14, P2255, DOI 10.7314/APJCP.2013.14.3.2255
   Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li QY, 2015, ONCOL LETT, V9, P1807, DOI 10.3892/ol.2015.2908
   Ling YQ, 2014, BIOCHEM BIOPH RES CO, V444, P147, DOI 10.1016/j.bbrc.2014.01.012
   Lu F, 2011, ANAT REC, V294, P1787, DOI 10.1002/ar.21471
   Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476
   Masciullo V, 2008, CLIN CANCER RES, V14, P4775, DOI 10.1158/1078-0432.CCR-07-4055
   McDonald ER, 2000, INT J ONCOL, V16, P871
   Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923
   Obata Y, 2015, IMMUNOL CELL BIOL, V93, P226, DOI 10.1038/icb.2014.114
   Paggi MG, 2001, CANCER RES, V61, P4651
   Rocha-Sanchez SMS, 2007, INT J DEV BIOL, V51, P585, DOI 10.1387/ijdb.072387sr
   Sabir M, 2014, CELL ONCOL, V37, P203, DOI 10.1007/s13402-014-0173-9
   Scambia G, 2006, ONCOGENE, V25, P5302, DOI 10.1038/sj.onc.1209620
   Smith EJ, 1996, MOL CELL BIOL, V16, P6965
   Smith L, 2008, BIOCHEM SOC T, V36, P708, DOI 10.1042/BST0360708
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Strauss WM., 2001, CURR PROTOC MOL BIOL
   Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514
   Suzuki M, 2010, SURG TODAY, V40, P602, DOI 10.1007/s00595-009-4094-6
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
NR 45
TC 13
Z9 13
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2015
VL 10
IS 8
AR e0134687
DI 10.1371/journal.pone.0134687
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO9JX
UT WOS:000359492800013
PM 26271034
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Shi, XW
   Liu, H
   Cao, J
   Liu, Q
   Tang, GJ
   Liu, WL
   Liu, HY
   Deng, DR
   Qiao, FY
   Wu, YY
AF Shi, Xinwei
   Liu, Hao
   Cao, Jing
   Liu, Qing
   Tang, Guiju
   Liu, Wanlu
   Liu, Haiyi
   Deng, Dongrui
   Qiao, Fuyuan
   Wu, Yuanyuan
TI Promoter Hypomethylation of Maspin Inhibits Migration and Invasion of
   Extravillous Trophoblast Cells during Placentation
SO PLOS ONE
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR;
   EPIGENETIC MODIFICATION; ABERRANT EXPRESSION; OVARIAN-CARCINOMA; GENE
   MASPIN; APOPTOSIS; TRANSCRIPTION; PREECLAMPSIA
AB Objective
   Extravillous trophoblast (EVT) cells invade the endometrium and the maternal spiral arterioles during the first trimester. Mammary Serine Protease Inhibitor (Maspin, SERPINB5) plays a putative role in regulating the invasive activity of cytotrophoblasts. The maspin gene is silenced in various cancers by an epigenetic mechanism that involves aberrant cytosine methylation. We investigated the effect of the methylation status of the maspin promoter on the maspin expression and the aggressiveness of EVT cells.
   Methods
   Western blotting was used to detect the maspin protein expression in EVT cells upon hypoxia. The proliferative ability, the apoptosis rate and the migration and invasiveness were measured with Cell Counting Kit-8 assay, Flow Cytometry technology and Transwell methods. Subsequently, we treated cells with recombinant maspin protein. The methylation degree of maspin promoter region upon hypoxia/decitabine was detected by bisulfite sequencing PCR and methylation-specific PCR. Finally, we explored the effects of decitabine on maspin protein expression and the aggressiveness of EVT cells.
   Results
   Hypoxia effectively increased maspin protein expression in EVT cells and significantly inhibited their aggressiveness. The addition of recombinant maspin protein inhibited this aggressiveness. Decitabine reduced the methylation in the maspin promoter region and effectively increased the maspin protein expression, which significantly weakened the migration and invasiveness of EVT cells.
   Discussion
   The methylation status of the maspin promoter is an important factor that affects the migration and invasion of EVT cells during early pregnancy. A decrease in the methylation status can inhibit the migration and invasion of EVT cells to affect placentation and can result in the ischemia and hypoxia of placenta.
C1 [Shi, Xinwei; Cao, Jing; Liu, Qing; Liu, Wanlu; Liu, Haiyi; Deng, Dongrui; Qiao, Fuyuan; Wu, Yuanyuan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan 430074, Hubei, Peoples R China.
   [Liu, Hao] Wuhan Third Hosp, Dept Urol, Wuhan, Hubei, Peoples R China.
   [Tang, Guiju] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Wu, YY (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan 430074, Hubei, Peoples R China.
EM qianmei98@163.com
RI Li, Qiuyang/HNP-5226-2023
FU National Natural Science Foundation of China [81200451]; National
   Science and Technology Support Plan of China [2014BA105B05]
FX This work was funded by the National Natural Science Foundation of China
   (No. 81200451) and the National Science and Technology Support Plan of
   China (2014BA105B05). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Beecken W.-D., 2000, J Cell Mol Med, V4, P262, DOI 10.1111/j.1582-4934.2000.tb00125.x
   Canning MT, 2001, EXP CELL RES, V267, P88, DOI 10.1006/excr.2001.5243
   Cella N, 2006, FASEB J, V20, P1510, DOI 10.1096/fj.05-5500fje
   Chen X, 2011, J HUAZHONG U SCI-MED, V31, P235, DOI 10.1007/s11596-011-0259-9
   Chen Y, 2013, BIOCHEM BIOPH RES CO, V430, P1083, DOI 10.1016/j.bbrc.2012.12.034
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Dokras A, 2002, PLACENTA, V23, P274, DOI 10.1053/plac.2001.0784
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Feng Hui Chen, 2005, J Soc Gynecol Investig, V12, pe21, DOI 10.1016/j.jsgi.2005.02.008
   Fisher Susan J, 2004, Reprod Biol Endocrinol, V2, P53, DOI 10.1186/1477-7827-2-53
   Fitzgerald M, 2003, NEOPLASIA, V5, P427, DOI 10.1016/S1476-5586(03)80045-3
   Fujisawa K, 2005, LAB INVEST, V85, P214, DOI 10.1038/labinvest.3700214
   Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669
   Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447
   Hong SN, 2009, ONCOL REP, V21, P425, DOI 10.3892/or_00000240
   Huppertz B, 2008, J CLIN PATHOL, V61, P1296, DOI 10.1136/jcp.2008.055277
   Khalkhali-Ellis Z, 2006, CLIN CANCER RES, V12, P7279, DOI 10.1158/1078-0432.CCR-06-1589
   Lee H, 2007, MOL MICROBIOL, V65, P1018, DOI 10.1111/j.1365-2958.2007.05844.x
   Li HWR, 2006, GYNECOL ONCOL, V101, P76, DOI 10.1016/j.ygyno.2005.09.037
   Li ZG, 2005, ONCOGENE, V24, P2008, DOI 10.1038/sj.onc.1208449
   LIANG P, 1992, CANCER RES, V52, P6966
   Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568
   Liu Q, 2014, PLACENTA, V35, P876, DOI 10.1016/j.placenta.2014.08.088
   Maass N, 2001, J PATHOL, V195, P321
   Maass Nicolai, 2002, Clin Breast Cancer, V3, P281, DOI 10.3816/CBC.2002.n.032
   Murai S, 2006, CANCER SCI, V97, P883, DOI 10.1111/j.1349-7006.2006.00266.x
   Naves T, 2013, BIOCHEM PHARMACOL, V85, P1153, DOI 10.1016/j.bcp.2013.01.022
   Neal CL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-336
   Pierson CR, 2002, PROSTATE, V53, P255, DOI 10.1002/pros.10107
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Shi HY, 2007, CELL MOTIL CYTOSKEL, V64, P338, DOI 10.1002/cm.20187
   Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201
   Shi XW, 2012, J HUAZHONG U SCI-MED, V32, P879, DOI 10.1007/s11596-012-1051-1
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Sugimoto S, 2004, CANCER LETT, V203, P209, DOI 10.1016/j.canlet.2003.09.010
   Wada K, 2004, J INVEST DERMATOL, V122, P805, DOI 10.1111/j.0022-202X.2004.22308.x
   Wolf N, 2010, ENDOCRINOLOGY, V151, P2835, DOI 10.1210/en.2009-1195
   Xu JJ, 2011, J OBSTET GYNAECOL RE, V37, P187, DOI 10.1111/j.1447-0756.2010.01334.x
   Yang ZM, 2014, REPROD SCI, V21, P72, DOI 10.1177/1933719113488448
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 41
TC 7
Z9 9
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2015
VL 10
IS 8
AR e0135359
DI 10.1371/journal.pone.0135359
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO7PP
UT WOS:000359353300076
PM 26263377
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Ding, W
   Fan, XL
   Xu, X
   Huang, JZ
   Xu, SH
   Geng, Q
   Li, R
   Chen, D
   Yan, GR
AF Ding, Wen
   Fan, Xiao-Lu
   Xu, Xuan
   Huang, Jin-Zhou
   Xu, Song-Hui
   Geng, Qian
   Li, Rong
   Chen, De
   Yan, Guang-Rong
TI Epigenetic Silencing of ITGA2 by MiR-373 Promotes Cell Migration in
   Breast Cancer
SO PLOS ONE
LA English
DT Article
ID SIGNALING PATHWAY; PROSTATE-CANCER; TUMOR INVASION; METASTASIS;
   EXPRESSION; INTEGRIN; SUPPRESSOR; ANGIOGENESIS; MICRORNAS; CARCINOMA
AB The loss of ITGA2 plays an important role in cancer metastasis in several solid cancers. However, the molecular mechanism of ITGA2 loss in primary cancers remains unclear. In this study, we found that a lower ITGA2 protein level was observed in breast cancers compared to adjacent non-cancerous breast tissues. Interestingly, the reduction degree of ITGA2 at the protein level was far more than that at the mRNA level. We further showed that the translation of ITGA2 mRNA was directly inhibited by miR-373 through binding to ITGA2-3'UTR. Silencing of ITGA2 detached cell-cell interactions, induced the deploymerization of stress fiber F-actin and stimulated cancer cell migration, similar to the effect of miR-373 over-expression. The co-expression of ITGA2, not ITGA2-3'UTR, could abrogate miR-373-induced cancer cell migration because that the expression of ITGA2-3'UTR was inhibited by co-transfected miR-373. ITGA2 protein level was inversely associated with miR-373 level in breast cancers (r = -0.663, P<0.001). 73.33% of breast cancer patients with high miR-373 and low ITGA2 expression exhibited the lymph node-positive metastases. Together, our results show that epigenetic silencing of ITGA2 by miR-373 stimulates breast cancer migration, and miR-373(high)/ITGA2(low) may be as a prognosis biomarker for breast cancer patients.
C1 [Ding, Wen; Fan, Xiao-Lu; Xu, Xuan; Huang, Jin-Zhou; Xu, Song-Hui; Yan, Guang-Rong] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China.
   [Ding, Wen; Fan, Xiao-Lu; Xu, Xuan; Huang, Jin-Zhou; Xu, Song-Hui; Chen, De; Yan, Guang-Rong] Guangzhou Med Univ, Affiliated Hosp 3, Biomed Res Ctr, Guangzhou, Guangdong, Peoples R China.
   [Ding, Wen; Fan, Xiao-Lu; Xu, Xuan; Huang, Jin-Zhou; Xu, Song-Hui; Chen, De; Yan, Guang-Rong] Guangzhou Med Univ, Affiliated Hosp 3, Dept Surg, Guangzhou, Guangdong, Peoples R China.
   [Geng, Qian; Li, Rong] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China.
   [Chen, De; Yan, Guang-Rong] Guangdong Higher Educ Inst, Key Lab Reprod & Genet, Key Lab Major Obstetr Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
C3 Jinan University; Guangzhou Medical University; Guangzhou Medical
   University; Southern Medical University - China
RP Yan, GR (通讯作者)，Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China.
EM ynlirong@vip.sina.com; drchende@gzhmu.edu.cn; jxygr007@yahoo.com
RI xu, songhui/L-6615-2019; Ding, Wen/JGD-3843-2023
OI Yan, Guang-Rong/0000-0003-4859-8710
FU National Natural Science Foundation of China [81071618, 81272285];
   Zhujiang Science & Technology New Star Projects of Guangzhou
   [2011J2200042]; Natural Science Foundation of Guangdong Province of
   China [S2012010008882]; R&D plan of Guangzhou and Panyu [2011B031800043,
   2011-Z03-29]
FX This work was supported by the National Natural Science Foundation of
   China (81071618, 81272285), Zhujiang Science & Technology New Star
   Projects of Guangzhou (2011J2200042) and the Natural Science Foundation
   of Guangdong Province of China (S2012010008882) and the R&D plan of
   Guangzhou and Panyu (2011B031800043, 2011-Z03-29). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Augoff K, 2011, MOL CANCER RES, V9, P1500, DOI 10.1158/1541-7786.MCR-11-0311
   Chen DL, 2013, CARCINOGENESIS, V34, P803, DOI 10.1093/carcin/bgs400
   Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5
   Chin SP, 2015, PROSTATE, V75, P723, DOI 10.1002/pros.22954
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577
   Ferraro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115276
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Kinose Y, 2015, ONCOTARGET, V6, P11342, DOI 10.18632/oncotarget.3604
   Kinouchi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115936
   Liu H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-80
   Liu JF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-43
   Liu P, 2012, J CELL PHYSIOL, V227, P867, DOI 10.1002/jcp.22993
   Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010
   Pan HJ, 2009, BREAST CANCER RES TR, V118, P197, DOI 10.1007/s10549-008-0179-y
   Pan X, 2011, NAT MED, V17, P708, DOI 10.1038/nm.2369
   Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328
   Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Robertson JH, 2009, CLIN EXP METASTAS, V26, P769, DOI 10.1007/s10585-009-9276-5
   Sawhney RS, 2006, J BIOL CHEM, V281, P8497, DOI 10.1074/jbc.M600787200
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200
   Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585-012-9561-6
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373
   Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080
   Xu SH, 2015, J PATHOL, V236, P175, DOI 10.1002/path.4515
   Yan GR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063656
   Yan GR, 2012, PROTEOMICS, V12, P2391, DOI 10.1002/pmic.201100652
   Yan GR, 2011, PROTEOMICS, V11, P912, DOI 10.1002/pmic.201000539
   Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315
   Yuan KF, 2013, GASTROENTEROLOGY, V145, P853, DOI 10.1053/j.gastro.2013.06.008
NR 35
TC 51
Z9 60
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2015
VL 10
IS 8
AR e0135128
DI 10.1371/journal.pone.0135128
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO7PJ
UT WOS:000359352600040
PM 26258411
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Mahalingaiah, PKS
   Ponnusamy, L
   Singh, KP
AF Mahalingaiah, Prathap Kumar S.
   Ponnusamy, Logeswari
   Singh, Kamaleshwar P.
TI Chronic oxidative stress causes estrogen-independent aggressive
   phenotype, and epigenetic inactivation of estrogen receptor alpha in
   MCF-7 breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Oxidative stress; Epigenetics; Breast cancer; MCF-7 cells; Estrogen
   receptor; Hydrogen peroxide; 5-Aza-2'-deoxycytidine
ID HISTONE DEACETYLASE INHIBITOR; GENE-EXPRESSION; HORMONAL-THERAPY; DNA
   METHYLATION; ER-ALPHA; TAMOXIFEN RESISTANCE; ENHANCED EXPRESSION;
   OXIDANT STRESS; POOR-PROGNOSIS; MECHANISMS
AB The role of chronic oxidative stress in the development and aggressive growth of estrogen receptor (ER)-positive breast cancer is well known; however, the mechanistic understanding is not clear. Estrogen-independent growth is one of the features of aggressive subtype of breast cancer. Therefore, the objective of this study was to evaluate the effect of oxidative stress on estrogen sensitivity and expression of nuclear estrogen receptors in ER-positive breast cancer cells. MCF-7 cells chronically exposed to hydrogen peroxide were used as a cell model in this study, and their growth in response to 17-beta estradiol was evaluated by cell viability, cell cycle, and cell migration analysis. Results were further confirmed at molecular level by analysis of gene expressions at transcript and protein levels. Histone H3 modifications, expression of epigenetic regulatory genes, and the effect of DNA demethylation were also analyzed. Loss of growth in response to estrogen with a decrease in ER alpha expression was observed in MCF-7 cells adapted to chronic oxidative stress. Increases in mtTFA and NRF1 in these cells further suggested the role of mitochondria-dependent redox-sensitive growth signaling as an alternative pathway to estrogen-dependent growth. Changes in expression of epigenetic regulatory genes, levels of histone H3 modifications as well as significant restorations of both ER alpha expression and estrogen response by 5-Aza-2'-deoxycytidine further confirmed the epigenetic basis for estrogen-independent growth in these cells. In conclusion, results of this study suggest that chronic oxidative stress can convert estrogen-dependent nonaggressive breast cancer cells into estrogen-independent aggressive form potentially by epigenetic mechanism.
C1 [Mahalingaiah, Prathap Kumar S.; Ponnusamy, Logeswari; Singh, Kamaleshwar P.] Texas Tech Univ, Dept Environm Toxicol, Inst Environm & Human Hlth TIEHH, Lubbock, TX 79409 USA.
C3 Texas Tech University System; Texas Tech University
RP Singh, KP (通讯作者)，Texas Tech Univ, Dept Environm Toxicol, Inst Environm & Human Hlth TIEHH, Lubbock, TX 79409 USA.
EM kamaleshwar.singh@ttu.edu
RI Ponnusamy, Logeswari/AAG-9823-2019; Singh, Kamaleshwar/AAE-9166-2020
CR Al Saleh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020610
   Bergqvist J, 2006, EUR J CANCER, V42, P1104, DOI 10.1016/j.ejca.2006.01.028
   Billam M, 2009, CANCER BIOL THER, V8, P485, DOI 10.4161/cbt.8.6.7582
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   Conway K, 2005, BREAST CANCER RES, V7, pR871, DOI 10.1186/bcr1315
   Cunha S, 2014, CELL REP, V6, P141, DOI 10.1016/j.celrep.2013.12.010
   Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351
   Felty Q, 2005, BIOCHEMISTRY-US, V44, P6900, DOI 10.1021/bi047629p
   Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Frasor J, 2015, MOL CELL ENDOCRINOL, V418, P235, DOI 10.1016/j.mce.2014.09.013
   Gago-Dominguez M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1628
   Ganie SA, 2011, EUR REV MED PHARMACO, V15, P906
   Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Girault I, 2003, CLIN CANCER RES, V9, P1259
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Hayashi S, 2015, INT J CLIN ONCOL, V20, P262, DOI 10.1007/s10147-015-0788-5
   Heirman I, 2006, FREE RADICAL BIO MED, V40, P285, DOI 10.1016/j.freeradbiomed.2005.08.033
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hewitt SC, 2000, BREAST CANCER RES, V2, P345, DOI 10.1186/bcr79
   Hwang SL, 2008, J AGR FOOD CHEM, V56, P859, DOI 10.1021/jf072826r
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jezierska-Drutel A, 2013, ADV CANCER RES, V119, P107, DOI 10.1016/B978-0-12-407190-2.00003-4
   Jordan VC, 2007, STEROIDS, V72, P7, DOI 10.1016/j.steroids.2006.10.009
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180
   Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x
   Kurokawa H, 2000, CANCER RES, V60, P5887
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016
   Li WG, 2005, LIFE SCI, V76, P1735, DOI 10.1016/j.lfs.2004.09.024
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luqmani YA, 2009, INT J ONCOL, V34, P231, DOI 10.3892/ijo_00000145
   Mahalingaiah PKS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087371
   Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Okada F, 2006, BRIT J CANCER, V94, P854, DOI 10.1038/sj.bjc.6603016
   Okoh VO, 2015, BRIT J CANCER, V112, P1687, DOI 10.1038/bjc.2014.586
   Okoh VO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054206
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pilat MJP, 1998, ANTICANCER RES, V18, P2575
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018
   Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020
   Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743
   Schacter JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100364
   Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030
   Sogon T, 2007, J STEROID BIOCHEM, V105, P106, DOI 10.1016/j.jsbmb.2006.12.104
   Stoner M, 2002, MOL ENDOCRINOL, V16, P2231, DOI 10.1210/me.2001-0347
   Toki N, 2010, VIRCHOWS ARCH, V456, P387, DOI 10.1007/s00428-010-0895-7
   Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200
   Viedma-Rodríguez R, 2014, ONCOL REP, V32, P3, DOI 10.3892/or.2014.3190
   Wani G, 1998, CANCER LETT, V125, P123, DOI 10.1016/S0304-3835(97)00507-7
   Wei J, 2012, TUMOR BIOL, V33, P413, DOI 10.1007/s13277-011-0234-x
   Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yau C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2120
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 73
TC 33
Z9 35
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2015
VL 153
IS 1
BP 41
EP 56
DI 10.1007/s10549-015-3514-0
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP3JL
UT WOS:000359775100006
PM 26208486
DA 2025-01-12
ER

PT J
AU Tsai, KW
   Li, GC
   Chen, CH
   Yeh, MH
   Huang, JS
   Tseng, HH
   Fu, TY
   Liou, HH
   Pan, HW
   Huang, SF
   Chen, CC
   Chang, HY
   Ger, LP
   Chang, HT
AF Tsai, Kuo-Wang
   Li, Guan-Cheng
   Chen, Chien-Hsun
   Yeh, Ming-Hsin
   Huang, Jer-Shyung
   Tseng, Hui-Hwa
   Fu, Ting-Ying
   Liou, Huei-Han
   Pan, Hung-Wei
   Huang, Sheng-Feng
   Chen, Chien-Chou
   Chang, Hui-Yu
   Ger, Luo-Ping
   Chang, Hong-Tai
TI Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor
   in breast cancer patients, especially for an ER/PR-negative subtype
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DNA methylation; 5-hydroxymethylcytosine (5hmC);
   Ten-eleven-translocation (TET); Breast cancer; Epigenetic regulation;
   Prognosis
ID POPULATION-BASED COHORT; DNA METHYLATION; GENE-EXPRESSION;
   DRUG-RESISTANCE; NUCLEAR EXPORT; TET PROTEINS; 5-METHYLCYTOSINE;
   HYPOMETHYLATION; HYDROXYLATION; LOCALIZATION
AB DNA methylation at the 5 position of cytosine (5mC) is an epigenetic hallmark in cancer. The 5mC can be converted to 5-hydroxymethylcytosine (5hmC) through a ten-eleven-translocation (TET). We investigated the impact of 5mC, 5hmC, TET1, and TET2 on tumorigenesis and prognosis of breast cancer. Immunohistochemistry was used to assess the levels of 5mC, 5hmC, TET1, and TET2 in the corresponding tumor adjacent normal (n = 309), ductal carcinoma in situ (DCIS, n = 120), and invasive ductal carcinoma (IDC, n = 309) tissues for 309 breast ductal carcinoma patients. 5mC, 5hmC, TET1-n, and TET2-n were significantly decreased during DCIS and IDC progression. In IDC, the decrease of 5hmC was correlated with the cytoplasmic mislocalization of TET1 (p < 0.001) as well as poor disease-specific survival (DSS) (adjusted hazard ratio [AHR] 1.95, p = 0.003) and disease-free survival (DFS) (AHR 1.91, p = 0.006). The combined decrease of 5mC and 5hmC was correlated with worse DSS (AHR 2.19, p = 0.008) and DFS (AHR 1.99, p = 0.036). Stratification analysis revealed that the low level of 5mC was associated with poor DSS (AHR 1.89, p = 0.044) and DFS (AHR 2.02, p = 0.035) for the ER/PR-positive subtype. Conversely, the low level of 5hmC was associated with worse DSS (AHR 2.77, p = 0.002) and DFS (AHR 2.69, p = 0.006) for the ER/PR-negative subtype. The decreases of 5mC, 5hmC, TET1-n, and TET2-n were biomarkers of tumor development. The global reduction of 5hmC was a poor prognostic factor for IDC, especially for ER/PR-negative subtype.
C1 [Tsai, Kuo-Wang; Li, Guan-Cheng; Liou, Huei-Han; Pan, Hung-Wei; Huang, Sheng-Feng; Chang, Hui-Yu; Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 81362, Taiwan.
   [Li, Guan-Cheng; Ger, Luo-Ping] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Chen, Chien-Hsun] Kaohsiung Vet Gen Hosp, Dept Radiat Oncol, Kaohsiung 81362, Taiwan.
   [Yeh, Ming-Hsin] St Josephs Hosp, Breast Canc Ctr, Yunlin, Taiwan.
   [Huang, Jer-Shyung] Kaohsiung Vet Gen Hosp, Dept Radiol, Kaohsiung 81362, Taiwan.
   [Tseng, Hui-Hwa; Fu, Ting-Ying] Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, Kaohsiung 81362, Taiwan.
   [Chen, Chien-Chou] Kaohsiung Armed Forces Gen Hosp, Zuoying Branch, Dept Family Med, Kaohsiung, Taiwan.
   [Chang, Hong-Tai] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 81362, Taiwan.
   [Chang, Hong-Tai] Kaohsiung Vet Gen Hosp, Ctr Geriatr & Gerontol, Kaohsiung 81362, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Sun Yat Sen University;
   Kaohsiung Veterans General Hospital; Kaohsiung Veterans General
   Hospital; Kaohsiung Veterans General Hospital; Kaohsiung Veterans
   General Hospital; Kaohsiung Veterans General Hospital
RP Ger, LP (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, 386 Ta Chung 1st Rd, Kaohsiung 81362, Taiwan.
EM lpger@vghks.gov.tw; htchang@vghks.gov.tw
RI wang, yichun/IXW-7812-2023; Chung, Chi-Hsiang/AAY-3386-2021; Tsai,
   Kuo-Wang/AFS-8885-2022
OI Tsai, Kuo-Wang/0000-0002-9028-9834
FU Kaohsiung Veterans General Hospital [VGHKS102-002, VGHKS103-106,
   VGHKS104-060, VGHKS104-117]; National Science Council
   [NSC100-2314-B-075B-008]
FX This work was supported by Grants from Kaohsiung Veterans General
   Hospital (VGHKS102-002, VGHKS103-106, VGHKS104-060, and VGHKS104-117)
   and from National Science Council (NSC100-2314-B-075B-008).
CR Alco G, 2015, ONCOL LETT, V9, P1046, DOI 10.3892/ol.2015.2852
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517
   Chung CJ, 2015, INT J MOL SCI, V16, P677, DOI 10.3390/ijms16010677
   Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007
   Compare D, 2011, J CLIN PATHOL, V64, P677, DOI 10.1136/jcp.2010.087858
   Dahl C, 2011, CLIN CHIM ACTA, V412, P831, DOI 10.1016/j.cca.2011.02.013
   Department of Health, 2011, CANC REG ANN REP
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Figueroa JD, 2015, BREAST CANCER RES TR, V150, P457, DOI 10.1007/s10549-015-3314-6
   Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443
   Guo JU, 2011, CELL CYCLE, V10, P2662, DOI 10.4161/cc.10.16.17093
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Haffner MC, 2011, ONCOTARGET, V2, P627
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Hung MC, 2011, J CELL SCI, V124, P3381, DOI 10.1242/jcs.089110
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jin SG, 2011, NUCLEIC ACIDS RES, V39, P5015, DOI 10.1093/nar/gkr120
   Kinney SRM, 2013, ADV EXP MED BIOL, V754, P57, DOI 10.1007/978-1-4419-9967-2_3
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Liu Chunhua, 2013, P 2013 IEEE INT S IN, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0062828
   Madzo J, 2013, SEMIN HEMATOL, V50, P61, DOI 10.1053/j.seminhematol.2013.01.004
   Müller T, 2012, AM J PATHOL, V181, P675, DOI 10.1016/j.ajpath.2012.04.017
   Orr BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041036
   Pastor WA, 2011, NATURE, V473, P394, DOI 10.1038/nature10102
   Pérez C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031605
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Sekimoto T, 2012, GENES CELLS, V17, P525, DOI 10.1111/j.1365-2443.2012.01609.x
   Shen RL, 2009, INT J CLIN EXP PATHO, V2, P21
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016
   Turner JG, 2008, CURR MED CHEM, V15, P2648, DOI 10.2174/092986708786242859
   Xiao P, 2013, BIOCHEM BIOPH RES CO, V439, P373, DOI 10.1016/j.bbrc.2013.08.075
   Xu YF, 2012, CELL, V151, P1200, DOI 10.1016/j.cell.2012.11.014
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yang B, 2013, UROL ONCOL-SEMIN ORI, V31, P628, DOI 10.1016/j.urolonc.2011.05.009
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yang Q, 2013, J BIOMED NANOTECHNOL, V9, P1607, DOI 10.1166/jbn.2013.1713
   Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791
   Zhang HK, 2010, CELL RES, V20, P1390, DOI 10.1038/cr.2010.156
NR 52
TC 48
Z9 55
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2015
VL 153
IS 1
BP 219
EP 234
DI 10.1007/s10549-015-3525-x
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP3JL
UT WOS:000359775100022
PM 26253945
DA 2025-01-12
ER

PT J
AU Zhang, B
   Zhang, H
   Shen, G
AF Zhang, Bin
   Zhang, Hao
   Shen, Gang
TI Metastasis-associated protein 2 (MTA2) promotes the metastasis of
   non-small-cell lung cancer through the inhibition of the cell adhesion
   molecule Ep-CAM and E-cadherin
SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE MTA2; metastasis; NSCLC; Ep-CAM; E-cadherin
ID HUMAN BREAST-CANCER; COLORECTAL-CANCER; EPCAM EXPRESSION;
   CARCINOMA-CELLS; PROSTATE-CANCER; BETA-CATENIN; MOUSE MODEL; INVASION;
   GROWTH; PROGRESSION
AB Objective: Metastasis-associated protein 2 is considered as an intrinsic subunit of the nucleosome remodelling and histone deacetylase complex, which contributes to the epigenetic silencing genes. More and more evidence suggests that metastasis-associated protein 2 is required to maintain the malignant phenotype, but the role of metastasis-associated protein 2 function in mediating tumour metastasis in non-small-cell lung cancer has not been explored.
   Methods: Bioinformatics was used to detect the GEO 3141 database, the online tool of Kmplot was used to confirm the high expression of metastasis-associated protein 2 in influencing 5-year overall survival. Wound-healing assay, Transwell invasion assay and Living imaging assay together showed that MTA2 shRNA inhibited cell migration and invasion in vitro and in vivo. Chromatin immunoprecipitation, quantitative chromatin immunoprecipitation and luciferase reporter assays showed metastasis-associated protein 2 binding on the promoter of the epithelial transmembrane glycoprotein (Ep-CAM) and cell adhesion molecule E-cadherin.
   Results: The patient samples collected in our hospital show that metastasis-associated protein 2 was expressed in aggressive lung cancer cells, and its higher expression is correlated with poor prognosis. Metastasis-associated protein 2 promoted cell migration and invasion in vitro and in vivo through binding on the promoter of Ep-CAM and E-cadherin. Luciferase reporter assays showed repressed or enhanced E-cadherin or Ep-CAM promoter-driven luciferase reporter under metastasis-associated protein 2 overexpression or depletion. The changes in the level of protein and RNA implied that suppression of downstream E-cadherin or Ep-CAM was an important mechanism by which metastasis-associated protein 2 triggered epithelial-mesenchymal transition and metastasis.
   Conclusions: Together, our experiments reveal the mechanism for metastasis-associated protein 2 in facilitating invasive potential of non-small-cell lung cancer cells, suggesting that metastasis-associated protein 2 might be a potential therapeutic target for treating the metastasis of non-small-cell lung cancer.
C1 [Zhang, Bin; Zhang, Hao] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Resp Diease, Hangzhou 310009, Zhejiang, Peoples R China.
   [Shen, Gang] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Thorac Surg, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Shen, G (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Thorac Surg, Hangzhou 310009, Zhejiang, Peoples R China.
EM binzhangzhejiang@163.com
RI Zhang, Bin/AAF-7758-2020
CR Adjei AA, 2002, SEMIN ONCOL, V29, P50, DOI 10.1053/sonc.2002.30758
   Balzar M, 1999, EXP CELL RES, V246, P108, DOI 10.1006/excr.1998.4263
   Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691
   Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029
   Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Gadalla SE, 2013, BIOCHEM BIOPH RES CO, V439, P203, DOI 10.1016/j.bbrc.2013.08.059
   Ganti AK, 2011, ONCOLOGY-NY, V25, P64
   Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733
   Hay ED, 1995, ACTA ANAT, V154, P8
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Lam WK, 2007, RESPIROLOGY, V12, P471, DOI 10.1111/j.1440-1843.2007.01105.x
   Li W, 2007, CELL TISSUE RES, V329, P351, DOI 10.1007/s00441-007-0412-8
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437
   Liu YP, 2012, EXP THER MED, V3, P745, DOI 10.3892/etm.2012.475
   Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997
   PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141
   Rao CG, 2005, INT J ONCOL, V27, P49
   Richardson F, 2012, ANTICANCER RES, V32, P537
   Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200
   de Cos JS, 2009, LUNG CANCER, V63, P140, DOI 10.1016/j.lungcan.2008.04.013
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Spizzo G, 2011, J CLIN PATHOL, V64, P415, DOI 10.1136/jcp.2011.090274
   Wang Shuhua, 2010, Zhongguo Fei Ai Za Zhi, V13, P777, DOI 10.3779/j.issn.1009-3419.2010.08.05
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
   Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200
   Yoshida GJ, 2014, BIOCHEM BIOPH RES CO, V443, P622, DOI 10.1016/j.bbrc.2013.12.016
   Yoshida GJ, 2014, BIOCHEM BIOPH RES CO, V443, P239, DOI 10.1016/j.bbrc.2013.11.093
   Zhang H, 2006, CLIN CANCER RES, V12, P1479, DOI 10.1158/1078-0432.CCR-05-1519
   Zhou CF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-102
   Zhou J, 2014, BIOCHEM BIOPH RES CO, V444, P387, DOI 10.1016/j.bbrc.2014.01.062
   Zhu CJ, 2014, BIOCHEM BIOPH RES CO, V445, P667, DOI 10.1016/j.bbrc.2014.02.082
NR 39
TC 26
Z9 32
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0368-2811
EI 1465-3621
J9 JPN J CLIN ONCOL
JI Jpn. J. Clin. Oncol.
PD AUG
PY 2015
VL 45
IS 8
BP 755
EP 766
DI 10.1093/jjco/hyv062
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP1ZJ
UT WOS:000359676300011
PM 25969565
OA Bronze
DA 2025-01-12
ER

PT J
AU Liu, C
   Li, S
   Dai, XY
   Ma, J
   Wan, JH
   Jiang, H
   Wang, P
   Liu, ZL
   Zhang, HQ
AF Liu, Chang
   Li, Shuai
   Dai, Xiaoyan
   Ma, Ji
   Wan, Junhu
   Jiang, Hao
   Wang, Peng
   Liu, Zhaoli
   Zhang, Hongquan
TI PRC2 regulates RNA polymerase III transcribed non-translated RNA gene
   transcription through EZH2 and SUZ12 interaction with TFIIIC complex
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE ACTIVITY; BREAST-CANCER;
   CELL-PROLIFERATION; TARGET GENE; POL II; POLYCOMB; METHYLATION;
   ENHANCER; REPRESSION
AB Polycomb repression complex 2 (PRC2) component EZH2 tri-methylates H3K27 and exerts epigenetic repression on target gene expression. EZH2-mediated epigenetic control of RNA polymerase II (Pol II) transcribed coding gene transcription has been well established. However, little is known about EZH2-mediated epigenetic regulation of RNA polymerase III (Pol III) transcription. Here we present a paradigm that EZH2 is involved in the repression of Pol III transcription via interaction with transcriptional factor complex IIIC (TFIIIC). EZH2 and H3K27me3 co-occupy the promoter of tRNA(Tyr), 5S rRNA and 7SL RNA genes. Depletion of EZH2 or inhibition of EZH2 methyltransferase activity led to upregulation of Pol III target gene transcription. EZH2-mediated repression of Pol III transcribed gene expression requires presence of SUZ12. SUZ12 was able to interact with TFIIIC complex and knockdown of SUZ12 decreased occupancy of EZH2 and H3K27me3 at the promoter of Pol III target genes. Our findings pointed out a previously unidentified role of PRC2 complex in suppressing transcription of Pol III transcribed non-translated RNA genes, putting Pol III on a new layer of epigenetic regulation.
C1 [Liu, Chang; Li, Shuai; Dai, Xiaoyan; Ma, Ji; Wan, Junhu; Jiang, Hao; Wang, Peng; Liu, Zhaoli; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100191, Peoples R China.
   [Liu, Chang; Li, Shuai; Dai, Xiaoyan; Ma, Ji; Wan, Junhu; Jiang, Hao; Wang, Peng; Liu, Zhaoli; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
   [Liu, Chang; Li, Shuai; Dai, Xiaoyan; Ma, Ji; Wan, Junhu; Jiang, Hao; Wang, Peng; Liu, Zhaoli; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Lab Mol Cell Biol & Tumor Biol,Dept Anat Histol &, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Zhang, HQ (通讯作者)，Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Carcinogenesis & Translat Res, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM Hongquan.Zhang@bjmu.edu.cn
RI Wang, Pengfei/AAN-8797-2020; Liu, ZHAOLI/HPF-4779-2023; Wan,
   Junhu/V-3895-2019; zhang, ying/HJB-1230-2022
FU Ministry of Science and Technology of China [2015CB553906, 2013CB910501,
   2013ZX09401-004-006]; National Natural Science Foundation of China
   [81230051, 30830048, 31170711, 81321003]; Beijing Natural Science
   Foundation [7120002]; 111 Project of the Ministry of Education, Peking
   University [BMU20120314, BMU20130364]; Leading Academic Discipline
   Project of Beijing Education Bureau
FX Ministry of Science and Technology of China [2015CB553906, 2013CB910501,
   2013ZX09401-004-006]; National Natural Science Foundation of China
   [81230051, 30830048, 31170711, 81321003]; Beijing Natural Science
   Foundation [7120002]; 111 Project of the Ministry of Education, Peking
   University [BMU20120314, BMU20130364]; Leading Academic Discipline
   Project of Beijing Education Bureau (to H.Z.).
CR Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Fairley JA, 2012, MOL CELL, V45, P541, DOI 10.1016/j.molcel.2011.11.030
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327
   Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005
   He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111
   Kanduri M, 2013, EPIGENETICS-US, V8, P1280, DOI 10.4161/epi.26546
   Kaneko S, 2014, MOL CELL, V53, P290, DOI 10.1016/j.molcel.2013.11.012
   Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107
   Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104
   Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Li H, 2012, CANCER PREV RES, V5, P484, DOI 10.1158/1940-6207.CAPR-11-0414
   Marshall L, 2008, CELL, V133, P78, DOI 10.1016/j.cell.2008.02.035
   Moir RD, 2006, P NATL ACAD SCI USA, V103, P15044, DOI 10.1073/pnas.0607129103
   Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794
   Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005
   Nuytten M, 2008, ONCOGENE, V27, P1449, DOI 10.1038/sj.onc.1210774
   O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001
   Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801
   Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021
   Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07
   Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wan JH, 2015, NUCLEIC ACIDS RES, V43, P3591, DOI 10.1093/nar/gkv238
   White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0
   Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097
   Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064
   Zhong Q, 2013, CARCINOGENESIS, V34, P2460, DOI 10.1093/carcin/bgt219
NR 49
TC 19
Z9 22
U1 1
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 27
PY 2015
VL 43
IS 13
BP 6270
EP 6284
DI 10.1093/nar/gkv574
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CP3JZ
UT WOS:000359776500013
PM 26038315
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Rushton, MD
   Young, DA
   Loughlin, J
   Reynard, LN
AF Rushton, Michael D.
   Young, David A.
   Loughlin, John
   Reynard, Louise N.
TI Differential DNA methylation and expression of inflammatory and zinc
   transporter genes defines subgroups of osteoarthritic hip patients
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID BREAST-TUMORS; CARTILAGE; CHONDROCYTES; REVEALS
AB Objectives We have previously shown that the cartilage DNA methylome delineates two clusters of osteoarthritic (OA) hip patients, characterised by differential methylation of inflammatory genes, while others have demonstrated a link between zinc homeostasis and inflammation in OA. We aimed to investigate these effects at the methylation and gene expression level.
   Methods We used our previously generated methylation data while quantitative PCR was used to measure gene expression using RNA from the hip cartilage of members of both clusters and from control individuals without hip OA.
   Results One of the OA clusters is characterised by the promoter hypomethylation and increased expression of inflammation-associated genes including IL1A and TNF. Furthermore, we show that the increase in expression of these genes is accompanied by increased expression of several zinc transporter genes. In addition, the zinc responsive transcription factor MTF1 is also upregulated, which is accompanied by an increase in the expression of its targets the metalloproteinases MMP13 and ADAMTS5.
   Conclusions We have identified a subgroup of OA hip patients that are epigenetically and transcriptiomically characterised by a cartilage inflammatory phenotype with concurrent differential regulation of zinc regulators. The identification of subgroups enhances stratified phenotyping of OA patients and has important implications for future therapeutic applications.
C1 [Rushton, Michael D.; Young, David A.; Loughlin, John; Reynard, Louise N.] Newcastle Univ, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Rushton, MD (通讯作者)，Newcastle Univ, Sch Med, Inst Cellular Med, Musculoskeletal Res Grp, 4th Floor Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM michael.rushton@ncl.ac.uk
RI Young, David/H-2023-2014
OI Loughlin, John/0000-0003-2018-3361; Young, David/0000-0002-7078-6745;
   Reynard, Louise/0000-0002-6613-1797
FU Arthritis Research UK [20028]; NIHR Newcastle Biomedical Research
   Centre; Medical Research Council; Arthritis Research UK as part of the
   MRC-Arthritis Research UK Centre for Integrated Research into
   Musculoskeletal Ageing (CIMA); European Union Seventh Framework Program
   (FP7) [305815 (D-BOARD)]; MRC [MR/K006312/1] Funding Source: UKRI
FX This research was funded by Arthritis Research UK (#20028), by the NIHR
   Newcastle Biomedical Research Centre, by the Medical Research Council
   and Arthritis Research UK as part of the MRC-Arthritis Research UK
   Centre for Integrated Research into Musculoskeletal Ageing (CIMA) and by
   the European Union Seventh Framework Program (FP7/2007-2013) under grant
   agreement number 305815 (D-BOARD).
CR Barter MJ, 2012, OSTEOARTHR CARTILAGE, V20, P339, DOI 10.1016/j.joca.2011.12.012
   Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2
   Egefjord L, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-7
   Fernández-Tajes J, 2014, ANN RHEUM DIS, V73, P668, DOI 10.1136/annrheumdis-2012-202783
   Foster M, 2013, J NUTR BIOCHEM, V24, P1655, DOI 10.1016/j.jnutbio.2013.02.006
   Jeffries MA, 2014, ARTHRITIS RHEUMATOL, V66, P2804, DOI 10.1002/art.38762
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kraus VB, 2014, NATURE, V507, P441, DOI 10.1038/507441a
   Kuettner KE, 2005, OSTEOARTHR CARTILAGE, V13, P93, DOI 10.1016/j.joca.2004.11.006
   Rushton MD, 2014, ARTHRITIS RHEUMATOL, V66, P2450, DOI 10.1002/art.38713
   Scanzello CR, 2008, CURR OPIN RHEUMATOL, V20, P565, DOI 10.1097/BOR.0b013e32830aba34
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Stessman HA, 2014, CELL, V156, P872, DOI 10.1016/j.cell.2014.02.002
   Zhang Q, 2008, ANN RHEUM DIS, V67, P1633, DOI 10.1136/ard.2007.079574
NR 17
TC 23
Z9 25
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD SEP
PY 2015
VL 74
IS 9
BP 1778
EP 1782
DI 10.1136/annrheumdis-2014-206752
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA CO7XY
UT WOS:000359378100029
PM 25854584
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Liang, YJ
   Hu, J
   Li, JT
   Liu, YJ
   Yu, JY
   Zhuang, XQ
   Mu, LL
   Kong, XY
   Hong, DL
   Yang, QF
   Hu, GH
AF Liang, Yajun
   Hu, Jing
   Li, Jiatao
   Liu, Yingjie
   Yu, Jingyi
   Zhuang, Xueqian
   Mu, Lili
   Kong, Xiangyin
   Hong, Dengli
   Yang, Qifeng
   Hu, Guohong
TI Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-like Cell
   Traits in Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID ASTROCYTE ELEVATED GENE-1; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR
   PROGRESSION; METADHERIN; METASTASIS; PROTEIN; IDENTIFICATION;
   EXPRESSION; CBP; CHEMORESISTANCE
AB Cancer stem-like cells (CSC) are a cell subpopulation that can reinitiate tumors, resist chemotherapy, and give rise to metastases. Metadherin (MTDH) contributes widely to tumor growth, drug resistance, relapse, and metastasis, but its molecular mechanisms of action are not well understood. Here, we report that MTDH drives CSC expansion by promoting the expression of TWIST1, a transcription factor critical for cancer cell stemness and metastasis. MTDH activates TWIST1 expression indirectly by facilitating histone H3 acetylation on the TWIST1 promoter, a process mediated by the histone acetyltransferase CBP. Mechanistic investigations showed that MTDH interacts with CBP and prevents its ubiquitin-mediated degradation, licensing its transcriptional activation of TWIST1. In clinical specimens of breast cancer, MTDH expression correlates positively with TWIST1 expression and CSC abundance. Overall, our work revealed that MTDH promotes CSC accumulation and breast tumorigenicity by regulating TWIST1, deepening the understanding of MTDH function in cancer. (C)2015 AACR.
C1 [Liang, Yajun; Hu, Jing; Li, Jiatao; Liu, Yingjie; Yu, Jingyi; Zhuang, Xueqian; Kong, Xiangyin; Hu, Guohong] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.
   [Liang, Yajun; Hu, Jing; Li, Jiatao; Liu, Yingjie; Yu, Jingyi; Zhuang, Xueqian; Kong, Xiangyin; Hu, Guohong] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
   [Liang, Yajun; Kong, Xiangyin; Hu, Guohong] Shanghai Jiao Tong Univ, Sch Med, China Collaborat Innovat Ctr Syst Biomed, Shanghai 200030, Peoples R China.
   [Mu, Lili; Hong, Dengli] Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis,Natl Minist, Shanghai 200030, Peoples R China.
   [Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250100, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Shandong University
RP Hu, GH (通讯作者)，Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.
EM ghhu@sibs.ac.cn
RI 胡, 国宏/HOH-6469-2023; Liu, Yingjie/K-4087-2019
OI Hong, Dengli/0000-0001-5251-0297; Yang, Qifeng/0000-0003-0576-8513; Hu,
   Guohong/0000-0002-2980-5166
FU National 973 programs [2011CB510105, 2013CB910904]; National Natural
   Science Foundation of China [81430070, 81222032, 31371409]; Ministry of
   Science and Technology of China [2012ZX09506-001-005]
FX This work was supported by National 973 programs (2011CB510105 and
   2013CB910904) and grants from the National Natural Science Foundation of
   China (81430070, 81222032, 31371409) and the Ministry of Science and
   Technology of China (2012ZX09506-001-005).
CR Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Blanco MA, 2011, J BIOL CHEM, V286, P19982, DOI 10.1074/jbc.M111.240077
   Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026
   Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0
   Casimiro S, 2014, CLIN EXP METASTAS, V31, P689, DOI 10.1007/s10585-014-9659-0
   Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11
   Cho KH, 2013, CANCER LETT, V336, P167, DOI 10.1016/j.canlet.2013.04.024
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Dong PX, 2014, CARCINOGENESIS, V35, P760, DOI 10.1093/carcin/bgt369
   Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029
   Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010
   Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297
   Fang F, 2014, STEM CELLS, V32, P1805, DOI 10.1002/stem.1705
   Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367
   Goodman RH, 2000, GENE DEV, V14, P1553
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Guo F, 2014, CELL REP, V8, P1704, DOI 10.1016/j.celrep.2014.08.033
   Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X
   Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962
   Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713
   Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93
   Liang YJ, 2011, THORAC CANCER, V2, P143, DOI 10.1111/j.1759-7714.2011.00064.x
   Liu LP, 2010, CANCER RES, V70, P3750, DOI 10.1158/0008-5472.CAN-09-3838
   Liu XW, 2014, CELL CYCLE, V13, DOI 10.4161/cc.28607
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164
   Suh SS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004652
   Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385
   Thirkettle HJ, 2009, ONCOGENE, V28, P3663, DOI 10.1038/onc.2009.223
   Tsukerman P, 2014, ONCOTARGET, V5, P12141, DOI 10.18632/oncotarget.2559
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Wan LL, 2014, CANCER RES, V74, P5336, DOI 10.1158/0008-5472.CAN-14-1349
   Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027
   Wang K, 2013, HEPATOLOGY, V58, P706, DOI 10.1002/hep.26402
   Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128
   Wei Y, 2009, CELL CYCLE, V8, P2132
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yoo BK, 2011, HEPATOLOGY, V53, P1538, DOI 10.1002/hep.24216
   Yoo BK, 2011, PHARMACOL THERAPEUT, V130, P1, DOI 10.1016/j.pharmthera.2011.01.008
   Yoo BK, 2010, CANCER RES, V70, P3249, DOI 10.1158/0008-5472.CAN-09-4009
   Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460
   Zhu K, 2011, CLIN CANCER RES, V17, P7294, DOI 10.1158/1078-0432.CCR-11-1327
NR 49
TC 77
Z9 82
U1 2
U2 42
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2015
VL 75
IS 17
BP 3672
EP 3680
DI 10.1158/0008-5472.CAN-15-0930
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CS2QV
UT WOS:000361917100022
PM 26141861
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Nagata, DED
   Ting, HA
   Cavassani, KA
   Schaller, MA
   Mukherjee, S
   Ptaschinski, C
   Kunkel, SL
   Lukacs, NW
AF Nagata, D. E. de Almeida
   Ting, H-A
   Cavassani, K. A.
   Schaller, M. A.
   Mukherjee, S.
   Ptaschinski, C.
   Kunkel, S. L.
   Lukacs, N. W.
TI Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase
   controls iTreg development and regulates pathogenic T-cell responses
   during pulmonary viral infection
SO MUCOSAL IMMUNOLOGY
LA English
DT Article
ID TANDEM REPEATS POLYMORPHISM; SYNCYTIAL VIRUS-INFECTION;
   IMMUNE-RESPONSES; VARIABLE NUMBER; BREAST-CANCER; CUTTING EDGE;
   DIFFERENTIATION; PLASTICITY; NFAT; SPECIFICATION
AB The generation of regulatory T (Treg) cells is driven by Foxp3 and is responsible for dampening inflammation and reducing autoimmunity. In this study, the epigenetic regulation of inducible Treg (iTreg) cells was examined and an H3K4 histone methyltransferase, SMYD3 (SET and MYND Domain 3), which regulates the expression of Foxp3 by a TGF beta 1/Smad3 (transforming growth factor-beta 1/Smad3)-dependent mechanism, was identified. Using chromatin immunoprecipitation assays, SMYD3 depletion led to a reduction in H3K4me3 in the promoter region and CNS1 (conserved noncoding DNA sequence) of the foxp3 locus. SMYD3 abrogation affected iTreg cell formation while allowing dysregulated interleukin-17 production. In a mouse model of respiratory syncytial virus (RSV) infection, a model in which iTreg cells have a critical role in regulating lung pathogenesis, SMYD3(-/-) mice demonstrated exacerbation of RSV-induced disease related to enhanced proinflammatory responses and worsened pathogenesis within the lung. Our data highlight a novel activation role for the TGF beta-inducible SMYD3 in regulating iTreg cell formation leading to increased severity of virus-related disease.
C1 [Nagata, D. E. de Almeida; Ting, H-A; Cavassani, K. A.; Schaller, M. A.; Mukherjee, S.; Ptaschinski, C.; Kunkel, S. L.; Lukacs, N. W.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48104 USA.
C3 University of Michigan System; University of Michigan
RP Lukacs, NW (通讯作者)，Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48104 USA.
EM nlukacs@umich.edu
RI Schaller, Matthew/AAL-7640-2020; Lukacs, Nicholas/ABH-5583-2020
OI Lukacs, Nicholas/0000-0003-2403-6481; Ting, Hung-An/0000-0001-9125-8944
FU NIH [AI073876, T32 AI007413]
FX We thank Susan Morris, Andrew Rasky, Ron Allen, Ana L. Coelho, Amrita D.
   Joshi, Lisa Riggs Johnson, and Pamela Lincoln for technical assistance;
   Robin Kunkel for art work; and Dr onnett for critical reading of the
   manuscript. This work was supported by the NIH grants: AI073876 (to
   N.W.L.) and T32 AI007413 (to D.D.A.N.).
CR Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010
   Durant LR, 2013, J VIROL, V87, P10946, DOI 10.1128/JVI.01295-13
   Ehrensberger AH, 2012, CRIT REV BIOCHEM MOL, V47, P464, DOI 10.3109/10409238.2012.697125
   Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Frank B, 2006, INT J CANCER, V118, P2917, DOI 10.1002/ijc.21696
   Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020
   Kanno Y, 2012, ANNU REV IMMUNOL, V30, P707, DOI 10.1146/annurev-immunol-020711-075058
   Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917
   Kittan NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078045
   Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200
   Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584
   Lee SM, 2008, BLOOD, V111, P3599, DOI 10.1182/blood-2007-09-115014
   Li QX, 2012, J IMMUNOL, V188, P4268, DOI 10.4049/jimmunol.1102376
   Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787
   Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442
   Loebbermann J, 2012, MUCOSAL IMMUNOL, V5, P161, DOI 10.1038/mi.2011.62
   Lotz MT, 2012, CURR ALLERGY ASTHM R, V12, P380, DOI 10.1007/s11882-012-0278-z
   Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209
   Mukherjee S, 2011, AM J PATHOL, V179, P248, DOI 10.1016/j.ajpath.2011.03.003
   Murai M, 2010, MUCOSAL IMMUNOL, V3, P443, DOI 10.1038/mi.2010.27
   Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010
   Ruden DM, 2008, CURR GENOMICS, V9, P500, DOI 10.2174/138920208786241207
   Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402
   Samstein RM, 2012, CELL, V151, P153, DOI 10.1016/j.cell.2012.06.053
   Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638
   van der Veeken J, 2013, COLD SH Q B, V78, P215, DOI 10.1101/sqb.2013.78.020289
   Wen HT, 2008, BLOOD, V111, P1797, DOI 10.1182/blood-2007-08-106443
   Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
   Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487
   Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042
   Yamashita M, 2006, IMMUNITY, V24, P611, DOI 10.1016/j.immuni.2006.03.017
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
   Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598
   Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547
   Ziegler Steven F, 2006, Expert Rev Clin Immunol, V2, P639, DOI 10.1586/1744666X.2.4.639
NR 46
TC 59
Z9 73
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1933-0219
EI 1935-3456
J9 MUCOSAL IMMUNOL
JI Mucosal Immunol.
PD SEP
PY 2015
VL 8
IS 5
BP 1131
EP 1143
DI 10.1038/mi.2015.4
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CP5WB
UT WOS:000359954600017
PM 25669152
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Kochan, DZ
   Kovalchuk, O
AF Kochan, David Z.
   Kovalchuk, Olga
TI Circadian disruption and breast cancer: An epigenetic link?
SO ONCOTARGET
LA English
DT Article
DE breast cancer; circadian disruption (CD); epigenetics; circadian
   rhythms; melatonin (MLT)
ID ESTROGEN-RECEPTOR-ALPHA; LONG-TERM SHIFTWORK; DNA METHYLATION;
   SUPRACHIASMATIC NUCLEUS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CELL-GROWTH;
   ER-ALPHA; MELATONIN; LIGHT
AB Breast cancer is already the most common malignancy affecting women worldwide, and evidence is mounting that breast cancer induced by circadian disruption ( CD) is a warranted concern. Numerous studies have investigated various aspects of the circadian clock in relation to breast cancer, and evidence from these studies indicates that melatonin and the core clock genes can play a crucial role in breast cancer development. Even though epigenetics has been increasingly recognized as a key player in the etiology of breast cancer and linked to circadian rhythms, and there is evidence of overlap between epigenetic deregulation and breast cancer induced by circadian disruption, only a handful of studies have directly investigated the role of epigenetics in CD-induced breast cancer. This review explores the circadian clock and breast cancer, and the growing role of epigenetics in breast cancer development and circadian rhythms. We also summarize the current knowledge and next steps for the investigation of the epigenetic link in CD-induced breast cancer.
C1 [Kochan, David Z.; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
FU Canadian Breast Cancer Foundation
FX Research in Dr. Kovalchuk's laboratory was supported by the Canadian
   Breast Cancer Foundation.
CR Abrahamson EE, 2001, BRAIN RES, V916, P172, DOI 10.1016/S0006-8993(01)02890-6
   Alvarez-Saavedra M, 2011, HUM MOL GENET, V20, P731, DOI 10.1093/hmg/ddq519
   Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9
   [Anonymous], SLEEP MED CLIN
   [Anonymous], ENCY NEUROSCIENCE
   [Anonymous], MICRORNAOME VASCULAR
   [Anonymous], PLOS ONE
   [Anonymous], BREAST CANC MEN
   [Anonymous], WORLD CANC FACTSH
   [Anonymous], SCI S HLTH EFF SHIFT
   [Anonymous], BRIT J CANCER
   Antle MC, 2005, TRENDS NEUROSCI, V28, P145, DOI 10.1016/j.tins.2005.01.003
   Arendt J, 2006, CHRONOBIOL INT, V23, P21, DOI 10.1080/07420520500464361
   Azzi A, 2014, NAT NEUROSCI, V17, P377, DOI 10.1038/nn.3651
   BENITEZKING G, 1993, LIFE SCI, V53, P201, DOI 10.1016/0024-3205(93)90670-X
   Blask DE, 2009, SLEEP MED REV, V13, P257, DOI 10.1016/j.smrv.2008.07.007
   Blask DE, 2003, BREAST CANCER RES TR, V79, P313, DOI 10.1023/A:1024030518065
   Blumenthal RD, 2001, CLIN CANCER RES, V7, P3178
   Brena RM, 2007, HUM MOL GENET, V16, pR96, DOI 10.1093/hmg/ddm073
   Britten A, 2013, EUR J PHARMACOL, V717, P67, DOI 10.1016/j.ejphar.2012.11.069
   Butler MP, 2009, J BIOL RHYTHM, V24, P340, DOI 10.1177/0748730409344800
   Cajochen C, 2011, J APPL PHYSIOL, V110, P1432, DOI 10.1152/japplphysiol.00165.2011
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004
   Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075
   Chen YJ, 2013, J BREAST CANCER, V16, P40
   Chen-Goodspeed M, 2007, J BIOL RHYTHM, V22, P291, DOI 10.1177/0748730407303387
   Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017
   Cos S, 2006, CANCER LETT, V235, P266, DOI 10.1016/j.canlet.2005.04.025
   Coticchia CM, 2009, BREAST CANCER RES TR, V115, P545, DOI 10.1007/s10549-008-0097-z
   Dauchy RT, 2014, CANCER RES, V74, P4099, DOI 10.1158/0008-5472.CAN-13-3156
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Depres-Brummer P, 1995, J Infus Chemother, V5, P144
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Filipski E, 2004, CANCER RES, V64, P7879, DOI 10.1158/0008-5472.CAN-04-0674
   Flynn-Evans EE, 2013, JNCI-J NATL CANCER I, V105, P1292, DOI 10.1093/jnci/djt169
   Folkard S, 2008, CHRONOBIOL INT, V25, P215, DOI 10.1080/07420520802106835
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3
   Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589
   Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492
   Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585
   Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038
   Giordano SH, 2004, CANCER, V101, P51, DOI 10.1002/cncr.20312
   Göke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887
   Gooley JJ, 2011, J CLIN ENDOCR METAB, V96, pE463, DOI 10.1210/jc.2010-2098
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Hansen J, 2012, EUR J CANCER, V48, P1722, DOI 10.1016/j.ejca.2011.07.005
   Hata K, 2002, DEVELOPMENT, V129, P1983
   Haus E, 2006, CANCER CAUSE CONTROL, V17, P489, DOI 10.1007/s10552-005-9015-4
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hormozdiari F, 2011, GENOME RES, V21, P840, DOI 10.1101/gr.115956.110
   Hutvágner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3
   Izadi P, 2012, CELL J, V14, P102
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jiang GC, 2013, J BIOL CHEM, V288, P8966, DOI 10.1074/jbc.M112.412650
   Joska Tammy M, 2014, Biology (Basel), V3, P560, DOI 10.3390/biology3030560
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Jung CH, 2013, ONCOL REP, V29, P2109, DOI 10.3892/or.2013.2381
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
   Kim IS, 2010, BIOCHEM BIOPH RES CO, V394, P443, DOI 10.1016/j.bbrc.2010.03.070
   Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Knutsson A, 2013, SCAND J WORK ENV HEA, V39, P170, DOI 10.5271/sjweh.3323
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Korkmaz A, 2009, REV ENDOCR METAB DIS, V10, P261, DOI 10.1007/s11154-009-9117-5
   Kothari A, 1997, CANCER LETT, V111, P59, DOI 10.1016/S0304-3835(96)04493-X
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P94, DOI 10.1016/j.mrgentox.2010.05.006
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Lévi F, 2006, CANCER CAUSE CONTROL, V17, P611, DOI 10.1007/s10552-005-9004-7
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Lieberman HB, 2011, J MOL CELL BIOL, V3, P39, DOI 10.1093/jmcb/mjq039
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu CG, 2008, NAT PROTOC, V3, P563, DOI 10.1038/nprot.2008.14
   Liu CG, 2008, METHODS, V44, P22, DOI 10.1016/j.ymeth.2007.10.010
   Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274
   Liu KH, 2012, J THEOR BIOL, V304, P103, DOI 10.1016/j.jtbi.2012.03.037
   Liu R, 2015, CANCER CAUSE CONTROL, V26, P171, DOI 10.1007/s10552-014-0494-z
   Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Mallis MM, 2005, AVIAT SPACE ENVIR MD, V76, pB94
   Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Monsees GM, 2012, INT J CANCER, V131, P2547, DOI 10.1002/ijc.27564
   MOORE RY, 1983, FED PROC, V42, P2783
   Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649
   Mourits MJE, 2001, OBSTET GYNECOL, V97, P855, DOI 10.1016/S0029-7844(00)01196-0
   Na YJ, 2009, EXP MOL MED, V41, P638, DOI 10.3858/emm.2009.41.9.070
   Nagel R, 2009, FEBS J, V276, P5447, DOI 10.1111/j.1742-4658.2009.07229.x
   Nakamura W, 2005, J NEUROSCI, V25, P5481, DOI 10.1523/JNEUROSCI.0889-05.2005
   Niederhuber J.E., 2020, Abeloff's clinical oncology
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Park SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100429
   PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126
   Parl FF, 2009, ANN NY ACAD SCI, V1155, P68, DOI 10.1111/j.1749-6632.2008.03676.x
   Rabstein S, 2013, SCAND J WORK ENV HEA, V39, P448, DOI 10.5271/sjweh.3360
   Reiter RJ, 2004, J PINEAL RES, V37, P213, DOI 10.1111/j.1600-079X.2004.00165.x
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Salminen A, 2014, CELL MOL LIFE SCI, V71, P1855, DOI 10.1007/s00018-013-1524-9
   Sauer LA, 2001, LIFE SCI, V68, P2835, DOI 10.1016/S0024-3205(01)01062-1
   Schwimmer H, 2014, CHRONOBIOL INT, V31, P144, DOI 10.3109/07420528.2013.842925
   Shackney SE, 2003, ADV ANAT PATHOL, V10, P278, DOI 10.1097/00125480-200309000-00003
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Shi FQ, 2013, ENVIRON MOL MUTAGEN, V54, P406, DOI 10.1002/em.21790
   Sigal A, 2000, CANCER RES, V60, P6788
   Sigurdardottir LG, 2013, CANCER EPIDEM BIOMAR, V22, P872, DOI 10.1158/1055-9965.EPI-12-1227-T
   Silver R, 1996, NEUROREPORT, V7, P1224, DOI 10.1097/00001756-199604260-00026
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Siré C, 2009, FEBS LETT, V583, P1039, DOI 10.1016/j.febslet.2009.02.024
   Soto-Vega E, 2004, J PINEAL RES, V37, P98, DOI 10.1111/j.1600-079X.2004.00141.x
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538
   Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744
   Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330
   Tsutsui S, 2002, J SURG ONCOL, V79, P216, DOI 10.1002/jso.10079
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Vinogradova IA, 2009, AGING-US, V1, P855, DOI 10.18632/aging.100092
   Vriend LEM, 2013, BBA-REV CANCER, V1836, P227, DOI 10.1016/j.bbcan.2013.05.002
   Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Welsh DK, 2010, ANNU REV PHYSIOL, V72, P551, DOI 10.1146/annurev-physiol-021909-135919
   Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599
   WILSON ST, 1992, J CLIN ENDOCR METAB, V75, P669, DOI 10.1210/jc.75.2.669
   Xiao LY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095878
   Yan LX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2803
   Yan X, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-220
   Yang XW, 2001, CANCER RES, V61, P7025
   Zelinski EL, 2014, NEUROSCI BIOBEHAV R, V40, P80, DOI 10.1016/j.neubiorev.2014.01.007
   Zeng ZL, 2010, J BIOCHEM, V148, P319, DOI 10.1093/jb/mvq069
   Zhang YS, 2012, J BIOL CHEM, V287, P41514, DOI 10.1074/jbc.M112.404871
   Zhang ZG, 2014, BIOCHEM BIOPH RES CO, V454, P109, DOI 10.1016/j.bbrc.2014.10.049
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 157
TC 26
Z9 31
U1 3
U2 31
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 10
PY 2015
VL 6
IS 19
BP 16866
EP 16882
DI 10.18632/oncotarget.4343
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO2VB
UT WOS:000359013600026
PM 26220712
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Liang, XM
   Zeng, JP
   Wang, LX
   Shen, L
   Ma, XP
   Li, SY
   Wu, YJ
   Ma, L
   Ci, XY
   Guo, Q
   Jia, MT
   Shen, HY
   Sun, YD
   Liu, ZF
   Liu, SL
   Li, WJ
   Yu, H
   Chen, CY
   Jia, JH
AF Liang, Xiuming
   Zeng, Jiping
   Wang, Lixiang
   Shen, Li
   Ma, Xueping
   Li, Shuyan
   Wu, Yujiao
   Ma, Lin
   Ci, Xinyu
   Guo, Qing
   Jia, Mutian
   Shen, Haiyu
   Sun, Yundong
   Liu, Zhifang
   Liu, Shili
   Li, Wenjuan
   Yu, Han
   Chen, Chunyan
   Jia, Jihui
TI Histone demethylase RBP2 promotes malignant progression of gastric
   cancer through TGF-β1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit
SO ONCOTARGET
LA English
DT Article
DE RBP2; TGF-beta 1; feedback circuit; metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; REPRESSOR COMPLEX; H3K4
   DEMETHYLASE; MASTER REGULATOR; BREAST-CANCER; CELLS; METASTASIS; GROWTH;
   EXPRESSION
AB Some feedback pathways are critical in the process of tumor development or malignant progression. However the mechanisms through which these pathways are epigenetically regulated have not been fully elucidated. Here, we demonstrated that the histone demethylase RBP2 was crucial for TGF-beta 1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit that was implicated in malignant progression of tumors and its knockdown significantly inhibited gastric cancer (GC) metastasis both in vitro and in vivo. Mechanistically, RBP2 can directly bind to E-cadherin promoter and suppress its expression, facilitating EMT and distant metastasis of GC. RBP2 can also be induced by TGF-beta 1, a key inducer of EMT, through phosphorylated Smad3 (p-Smad3) pathway in GC. The upregulated RBP2 can be recruited by p-smad3 to E-cadherin promoter and enhance its suppression, contributing to the promotion of metastasis of GC. In addition, the suppression of E-cadherin by RBP2 attenuated inhibition of Smad3 phosphorylation (exerted by E-cadherin), resulting further induction of RBP2 expression, and thus constituting positive feedback regulation during GC malignant progression. This TGF-beta 1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit may be a novel mechanism for GC malignant progression and suppression of RBP2 expression may serve as a new strategy for the prevention of tumor distant metastasis.
C1 [Liang, Xiuming; Shen, Li; Ma, Xueping; Li, Shuyan; Wu, Yujiao; Ma, Lin; Ci, Xinyu; Jia, Mutian; Sun, Yundong; Liu, Shili; Li, Wenjuan; Yu, Han; Jia, Jihui] Shandong Univ, Sch Med, Dept Microbiol, Key Lab Expt Teratol,Chinese Minist Educ, Jinan 250100, Peoples R China.
   [Zeng, Jiping; Liu, Zhifang] Shandong Univ, Sch Med, Dept Biochem, Jinan 250100, Peoples R China.
   [Wang, Lixiang] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250100, Peoples R China.
   [Chen, Chunyan] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250100, Shandong, Peoples R China.
   [Shen, Haiyu] Shandong Univ, Jinan Cent Hosp, Dept Gastrointestinal Surg, Jinan 250100, Shandong, Peoples R China.
   [Guo, Qing] Ningxia Peoples Hosp, Dept Nursing, Yinchuan, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Shandong
   University; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences
RP Jia, JH (通讯作者)，Shandong Univ, Sch Med, Dept Microbiol, Key Lab Expt Teratol,Chinese Minist Educ, Jinan 250100, Peoples R China.
EM jiajihui@sdu.edu.cn
RI Ci, Xin/HJA-3884-2022; Shen, Li/B-3562-2008; chen,
   chunyan/AAP-8995-2021; Guo, Qing/J-9661-2016; liu, zhifang/KIJ-0501-2024
OI Liang, Xiuming/0000-0003-0202-1211
FU National Basic Research Program of China (973 Program) [2012CB911202];
   National Natural Science Foundation of China [81371781, 81171536,
   81470318, 81170514]; Independent Innovation Foundation of Shandong
   University; Science and technology development plan project of Shandong
   province
FX This work was supported by the National Basic Research Program of China
   (973 Program, No. 2012CB911202), the National Natural Science Foundation
   of China (Nos. 81371781, 81171536, 81470318 and 81170514), Independent
   Innovation Foundation of Shandong University, Science and technology
   development plan project of Shandong province. JJ and XL designed the
   study; XL, JZ, LW, LS, XM, SL, YW, LM, XC, QG, HS and MJ performed the
   study; JJ, XL, YS, ZL, WL, SL, HY and CC analyzed data; JJ supervised
   the study; XL and JJ wrote the paper.
CR Ahn SM, 2012, ONCOGENE, V31, P3051, DOI 10.1038/onc.2011.484
   Chen G, 2012, J BIOL CHEM, V287, P23184, DOI 10.1074/jbc.M112.351411
   Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200
   Cho IJ, 2010, HEPATOLOGY, V52, P2053, DOI 10.1002/hep.23931
   Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998
   Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Enkhbaatar Z, 2013, CELL CYCLE, V12, P2100, DOI 10.4161/cc.25142
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Jung SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3562
   Kato M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003389
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299
   Liang XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069784
   Liep J, 2012, EPIGENETICS-US, V7, P315, DOI 10.4161/epi.19464
   Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030
   Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mise N, 2012, J BIOL CHEM, V287, P31393, DOI 10.1074/jbc.M112.357624
   Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Samantarrai D, 2013, MOL CANCER RES, V11, P315, DOI 10.1158/1541-7786.MCR-12-0649
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012
   Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020
   Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023
   Stergachis AB, 2013, CELL, V154, P888, DOI 10.1016/j.cell.2013.07.020
   Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200
   Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Xu WP, 2013, HEPATOLOGY, V58, P1977, DOI 10.1002/hep.26541
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yeh YC, 2010, AM J PATHOL, V177, P1743, DOI 10.2353/ajpath.2010.091183
   Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794
   Yuan H, 2013, CANCER RES, V73, P1581, DOI 10.1158/0008-5472.CAN-12-2377
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
   Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254
NR 46
TC 28
Z9 30
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 10
PY 2015
VL 6
IS 19
BP 17661
EP 17674
DI 10.18632/oncotarget.3756
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO2VB
UT WOS:000359013600084
PM 25974964
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Pan, YM
   Wang, LM
   Kang, SG
   Lu, YY
   Yang, ZX
   Huynh, T
   Chen, CY
   Zhou, RH
   Guo, MZ
   Zhao, YL
AF Pan, Yuanming
   Wang, Liming
   Kang, Seung-gu
   Lu, Youyong
   Yang, Zaixing
   Tien Huynh
   Chen, Chunying
   Zhou, Ruhong
   Guo, Mingzhou
   Zhao, Yuliang
TI Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer
   Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and
   Metastasis-Associated Protein 1
SO ACS NANO
LA English
DT Article
DE pancreatic cancer; Gd@C-82(OH)(22); metastasis; HDAC1; MTA1; HIF-1
   alpha; RECK
ID HDAC INHIBITORS; BREAST-CANCER; INDUCED ANGIOGENESIS; MTA1 PROMOTES;
   TUMOR-GROWTH; EXPRESSION; HYPOXIA; RECK; CELLS; NANOPARTICLES
AB The treatment of pancreatic cancer frequently fails due to local recurrence and hepatic metastasis. Our previous study found that Gd@C-82(OH)(22) can suppress pancreatic cancer by inhibiting MMP-2/9 expression. In this study, we further explored the epigenetic mechanism of Gd@C-82(OH)(22) in human pancreatic cancer metastasis. Gd@C-82(OH)(22) suppressed tumor metastasis through down-regulation of metastasis-associated protein 1 (MTA1), HDAC1, HIF-1 alpha, and MMP-2/9 and up-regulation of reversion-cysteine protein with the Kazal motif (RECK). The level of acetylation was increased in the promoter region of the RECK gene after Gd@C-82(OH)(22) treatment. The interaction of MTA1, HDAC1, and HIF-1 alpha was inhibited by Gd@C-82(OH)(22). Furthermore, large-scale molecular dynamics simulations revealed Gd@C-82(OH)(22) could serve as an effective HDAC inhibitor to the protein protein association between HDAC1 and MTA1, especially through MTA1's SANT and ELM2 dimerization domains. Our findings implicate Gd@C-82(OH)(22) as a novel HDAC inhibitor acting to increase RECK expression by suppressing the MTA1/HDAC1 co-repressor complex. Gd@C-82(OH)(22) may serve as a potential HDAC1 inhibitor to suppress pancreatic cancer cell invasion and metastasis both in vitro and in vivo. According to computer analysis and experimental validation, Gd@C-82(OH)(22) activates RECK expression by inhibiting the interaction of HDAC1 and MTA1.
C1 [Pan, Yuanming; Guo, Mingzhou] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
   [Wang, Liming; Chen, Chunying; Zhao, Yuliang] Chinese Acad Sci, Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Wang, Liming; Chen, Chunying; Zhao, Yuliang] Chinese Acad Sci, Inst High Energy Phys, Beijing 100190, Peoples R China.
   [Kang, Seung-gu; Tien Huynh; Zhou, Ruhong] IBM Corp, Thomas J Watson Res Ctr, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
   [Lu, Youyong] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Lab Mol Onc, Beijing 100142, Peoples R China.
   [Yang, Zaixing; Zhou, Ruhong] Soochow Univ, SRMP, Inst Quantitat Biol & Med, Suzhou 215123, Peoples R China.
   [Yang, Zaixing; Zhou, Ruhong] Soochow Univ, RAD X, Suzhou 215123, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese Academy of
   Sciences; National Center for Nanoscience & Technology, CAS; Chinese
   Academy of Sciences; Institute of High Energy Physics, CAS;
   International Business Machines (IBM); Peking University; Soochow
   University - China; Soochow University - China
RP Zhou, RH (通讯作者)，IBM Corp, Thomas J Watson Res Ctr, Computat Biol Ctr, 1101 Kitchawan Rd, Yorktown Hts, NY 10598 USA.
EM ruhongz@us.ibm.com; mzguo@hotmail.com; zhaoyuliang@ihep.ac.cn
RI Kang, Seung-gu/AAC-2047-2021; Wang, Liming/A-6924-2012; Yang,
   Zaixing/H-9334-2019; Wang, Haitao/GYV-1262-2022; Chen,
   Chunying/AAA-2891-2021; Pan, Yuanming/IAR-8437-2023
OI Wang, Liming/0000-0003-1382-9195; Yang, Zaixing/0000-0003-3521-6867;
   Pan, Yuanming/0000-0001-8050-8047; Zhou, Ruhong/0000-0001-8624-5591;
   Chen, Chunying/0000-0002-6027-0315
FU National Basic Research Program (973 Program) [2012CB934002,
   2010CB912802, 2011CB933400]; National Hightech R&D Program (863 Program)
   [SS2012AA02A209, SS2012AA020821, SS2012AA02A203]; National Key
   Scientific Instrument Special Program of China [2011YQ03013405]; Major
   Equipment Program [2011YQ030134]; National Science Foundation of China
   [81121004, 81071953, 81161120432, 1205166, 11435002, 21320102003]
FX This work was financially supported by grants from the National Basic
   Research Program (973 Program Nos. 2012CB934002, 2010CB912802, and
   2011CB933400), National Hightech R&D Program (863 Program Nos.
   SS2012AA02A209, SS2012AA020821, and SS2012AA02A203), National Key
   Scientific Instrument Special Program of China (Grant 2011YQ03013405),
   the Major Equipment Program (2011YQ030134), and the National Science
   Foundation of China (Grants 81121004, 81071953, 81161120432, 1205166,
   11435002, and 21320102003).
CR Afanas'ev I, 2011, AGING DIS, V2, P219
   Akakura N, 2001, CANCER RES, V61, P6548
   Akakura Nobuaki, 2001, Hokkaido Journal of Medical Science, V76, P375
   Balasenthil S, 2007, CANCER RES, V67, P7132, DOI 10.1158/0008-5472.CAN-07-0750
   Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38
   Bosetti C, 2012, MOL CARCINOGEN, V51, P3, DOI 10.1002/mc.20785
   Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Chen SY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/197946
   Damaskos C, 2015, ANTICANCER RES, V35, P3129
   De Souza C, 2015, RECENT PAT ANTI-CANC, V10, P145
   Du JF, 2015, J CELL PHYSIOL, V230, P1321, DOI 10.1002/jcp.24871
   Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hu HT, 2010, ACTA PHARMACOL SIN, V31, P102, DOI 10.1038/aps.2009.181
   Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146
   Iguchi H, 2000, INT J ONCOL, V16, P1211
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717
   Jeong SG, 2015, CELL BIOCHEM FUNCT, V33, P37, DOI 10.1002/cbf.3084
   Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852
   Kang SG, 2012, P NATL ACAD SCI USA, V109, P15431, DOI 10.1073/pnas.1204600109
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32
   Lee KJ, 2010, BBA-MOL CELL RES, V1803, P608, DOI 10.1016/j.bbamcr.2010.01.004
   Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0
   Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395
   Li YY, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-33
   Lin KT, 2012, CLIN CANCER RES, V18, P4691, DOI 10.1158/1078-0432.CCR-12-0633
   Liu LT, 2003, CANCER RES, V63, P3069
   Liu T, 2006, CANCER TREAT REV, V32, P157, DOI 10.1016/j.ctrv.2005.12.006
   Liu Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6988
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Masui T, 2003, CLIN CANCER RES, V9, P1779
   Meng J, 2013, INTEGR BIOL-UK, V5, P43, DOI 10.1039/c2ib20145c
   Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020
   Miyake S, 2013, INT J ONCOL, V43, P1431, DOI 10.3892/ijo.2013.2068
   Nagaraj SRM, 2015, MOL CARCINOGEN, V54, P333, DOI 10.1002/mc.22104
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
   Ouaissi M, 2012, PANCREATOLOGY, V12, P146, DOI 10.1016/j.pan.2012.02.013
   Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998
   Sankaran D, 2012, J BIOL CHEM, V287, P5483, DOI 10.1074/jbc.M111.324632
   Schneider G, 2012, GUT, V61, P329, DOI 10.1136/gutjnl-2011-301576
   Corrêa TCS, 2010, J CELL BIOCHEM, V110, P52, DOI 10.1002/jcb.22472
   Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008-5472.CAN-08-2635
   Toh Y, 2000, J EXP CLIN CANC RES, V19, P105
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Tsaur I, 2015, J CELL MOL MED, V19, P1795, DOI 10.1111/jcmm.12583
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783
   Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068
   Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324
   Yin JJ, 2008, MOL PHARMACOL, V74, P1132, DOI 10.1124/mol.108.048348
   Yin JJ, 2009, BIOMATERIALS, V30, P611, DOI 10.1016/j.biomaterials.2008.09.061
   Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000
   Zgouras D, 2003, BIOCHEM BIOPH RES CO, V300, P832, DOI 10.1016/S0006-291X(02)02916-9
   Zhang MY, 2010, J NANOSCI NANOTECHNO, V10, P8556, DOI 10.1166/jnn.2010.2490
   Zheng LN, 2015, ANAL BIOANAL CHEM, V407, P2383, DOI 10.1007/s00216-014-8422-3
   Zhou GQ, 2010, J NANOSCI NANOTECHNO, V10, P8597, DOI 10.1166/jnn.2010.2486
   Zuo G, 2011, J PHYS CHEM C, V115, P23323, DOI 10.1021/jp208967t
   Zuo GH, 2010, ACS NANO, V4, P7508, DOI 10.1021/nn101762b
NR 67
TC 58
Z9 59
U1 1
U2 107
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUL
PY 2015
VL 9
IS 7
BP 6826
EP 6836
DI 10.1021/nn506782f
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CO0EP
UT WOS:000358823200019
PM 26083726
DA 2025-01-12
ER

PT J
AU Wang, LH
   Chen, GL
   Chen, K
   Ren, Y
   Li, HH
   Jiang, XR
   Jia, L
   Fu, SY
   Li, Y
   Liu, XW
   Wang, S
   Yang, JY
   Wu, CF
AF Wang, Lihui
   Chen, Guoliang
   Chen, Kang
   Ren, Yong
   Li, Huahuan
   Jiang, Xiaorui
   Jia, Lina
   Fu, Shiyuan
   Li, Yi
   Liu, Xinwei
   Wang, Shuang
   Yang, Jingyu
   Wu, Chunfu
TI Dual targeting of retinoid X receptor and histone deacetylase with DW22
   as a novel antitumor approach
SO ONCOTARGET
LA English
DT Article
DE Retinoid X receptor; Histone deacetylase; DW22; anti-tumor
ID CELL LUNG-CANCER; PHASE-II; BEXAROTENE; GROWTH; EXPRESSION;
   ANGIOGENESIS; METASTASIS; VORINOSTAT; ACTIVATION; INHIBITORS
AB Retinoid X receptor (RXR) and Histone deacetylase (HDAC) are considered important targets for cancer therapy due to their crucial roles in genetic or epigenetic regulations of cancer development and progression. Here, we evaluated the potential of dual targeting of RXR and HDAC using DW22 as a novel therapeutic approach to cancer treatment. We found that the co-expression of RXR-alpha and HDAC1 was frequently appeared in lung cancer and breast cancer tissues and cell lines. RXR was activated by DW22 in RXR alpha and HDAC1 overexpressed A549 and MDA-MB-435 cell lines. Meanwhile, DW22 inhibited the activity of HDAC by decreasing its expression in A549 and MDA-MB-435 cell lines, but not in RXR alpha and HDAC1 deficient cell lines. Moreover, DW22 suppressed cell growth, induced cell differentiation, prompted cell apoptosis and arrested cell cycle in A549, MDA-MB-435 or HL60 cell lines. Treatment human umbilical vascular endothelial cells (HUVECs) with DW22 suppressed migration, invasion and tube formation through decreasing VEGF expression. The up-regulation of Ac-H3 and p21, and down-regulation of VEGF caused by DW22 was markedly attenuated by silencing of HDAC1. Furthermore, knockdown of RXR alpha by siRNA completely blocked DW22-induced cell differentiation, but partially attenuated DW22-caused inhibition of cell proliferation, induction of cell apoptosis, and suppression of cell migration, invasion and tube formation. Moreover, intravenous administration of DW22 significantly retarded tumor growth of A549 and MDA-MB-435 xenograft mice models, and induced no substantial weight loss and gross toxicity. In addition, DW22 also reduced cell proliferation, angiogenesis, and induced cell apoptosis in vivo. Collectively, our data demonstrates that dual targeting of RXR and HDAC using DW22 possesses pleiotropic antitumor activities both in vitro and in vivo, providing a novel therapeutic approach for cancer treatment.
C1 [Wang, Lihui; Chen, Kang; Li, Huahuan; Jiang, Xiaorui; Jia, Lina; Fu, Shiyuan; Li, Yi; Liu, Xinwei; Wang, Shuang; Yang, Jingyu; Wu, Chunfu] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang, Peoples R China.
   [Wang, Lihui; Chen, Kang; Li, Huahuan; Jiang, Xiaorui; Fu, Shiyuan; Li, Yi; Liu, Xinwei; Wang, Shuang; Yang, Jingyu; Wu, Chunfu] Shenyang Pharmaceut Univ, Benxi Inst Pharmaceut Res, Benxi, Peoples R China.
   [Chen, Guoliang] Shenyang Pharmaceut Univ, Key Lab Struct Based Drugs Design, Shenyang, Peoples R China.
   [Chen, Guoliang] Shenyang Pharmaceut Univ, Discovery Minist Educ, Shenyang, Peoples R China.
   [Ren, Yong] Wuhan Gen Hosp Guangzhou Command, Peoples Liberat Army, Dept Pathol, Wuhan, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   Shenyang Pharmaceutical University; Shenyang Pharmaceutical University
RP Yang, JY (通讯作者)，Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang, Peoples R China.
EM yangjingyu2006@gmail.com; wucf@syphu.edu.cn
RI xiaorui, jiang/AAV-7726-2021; liu, 轩/ISR-9283-2023; wang,
   xicheng/IXX-0974-2023
OI , Jingyu Yang/0000-0002-2791-5281
FU National High Technology Research and Development Program of China (863
   Program) [2012AA020305]; China Postdoctoral Science Foundation
   [20100481213, 2012T50474]; Liaoning Science and Technology Program
   [2011404012-1]; Shenyang Pharmaceutical University Science Foundation
   [ZCJJ2013401]
FX The authors gratefully acknowledge financial support from the National
   High Technology Research and Development Program of China (863 Program)
   (No. 2012AA020305), China Postdoctoral Science Foundation funded project
   (20100481213, 2012T50474), Liaoning Science and Technology Program (No.
   2011404012-1) and Shenyang Pharmaceutical University Science Foundation
   (No. ZCJJ2013401).
CR Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   [Anonymous], EVID BASED COMPLEMEN
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Blumenschein GR, 2008, J CLIN ONCOL, V26, P1879, DOI 10.1200/JCO.2007.12.2689
   Chen GL, 2013, BIOORG MED CHEM LETT, V23, P3891, DOI 10.1016/j.bmcl.2013.04.067
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   Dawood S, 2009, CANCER INVEST, V27, P482, DOI 10.1080/07357900802574660
   Dummer R, 2012, LEUKEMIA LYMPHOMA, V53, P1501, DOI 10.3109/10428194.2012.656625
   Esteva FJ, 2003, J CLIN ONCOL, V21, P999, DOI 10.1200/JCO.2003.05.068
   Friedrich M, 2002, HISTOCHEM J, V34, P35, DOI 10.1023/A:1021343825552
   Giannini G, 2012, FUTURE MED CHEM, V4, P1439, DOI [10.4155/fmc.12.80, 10.4155/FMC.12.80]
   Govindan R, 2006, J CLIN ONCOL, V24, P4848, DOI 10.1200/JCO.2006.07.7404
   Hainaut P, 2013, CURR OPIN ONCOL, V25, P50, DOI 10.1097/CCO.0b013e32835b651e
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang Yen-Hua, 2014, Biomed Res Int, V2014, P195162, DOI 10.1155/2014/195162
   Jin JS, 2012, PATHOL ONCOL RES, V18, P713, DOI 10.1007/s12253-012-9499-7
   Li YX, 2011, BREAST CANCER RES TR, V128, P667, DOI 10.1007/s10549-010-1083-9
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Murata M, 2000, JPN J CANCER RES, V91, P1154, DOI 10.1111/j.1349-7006.2000.tb00899.x
   Pal-Bhadra M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-180
   Pang XF, 2010, CANCER RES, V70, P1951, DOI 10.1158/0008-5472.CAN-09-3201
   Papi A, 2012, ANTICANCER RES, V32, P2855
   Patan S, 2004, CANC TREAT, V117, P3
   Ray A, 2013, J BIOL CHEM, V288, P27232, DOI 10.1074/jbc.M113.481184
   Shahbazian D, 2012, ADV PHARMACOL, V65, P1, DOI 10.1016/B978-0-12-397927-8.00001-4
   Simboeck E, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M110.184481
   Venugopal B, 2011, CURR MED CHEM, V18, P1658, DOI 10.2174/092986711795471284
   Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467
   Xiang ZL, 2011, CLIN CANCER RES, V17, P5463, DOI 10.1158/1078-0432.CCR-10-3096
   Yen WC, 2006, BRIT J CANCER, V94, P654, DOI 10.1038/sj.bjc.6602995
NR 31
TC 23
Z9 25
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 30
PY 2015
VL 6
IS 12
BP 9740
EP 9755
DI 10.18632/oncotarget.3149
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO0WO
UT WOS:000358874600011
PM 25762635
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, N
   Wang, ZY
   Wang, Y
   Xie, XM
   Shen, JG
   Peng, C
   You, JS
   Peng, F
   Tang, HL
   Guan, XY
   Chen, JP
AF Wang, Neng
   Wang, Zhiyu
   Wang, Yu
   Xie, Xiaoming
   Shen, Jiangang
   Peng, Cheng
   You, Jieshu
   Peng, Fu
   Tang, Hailin
   Guan, Xinyuan
   Chen, Jianping
TI Dietary compound isoliquiritigenin prevents mammary carcinogenesis by
   inhibiting breast cancer stem cells through WIF1 demethylation
SO ONCOTARGET
LA English
DT Article
DE mammary tumorigenesis; cancer stem cells; WIF1 demethylation; DNMT1;
   Isoliquiritigenin
ID FACTOR-I WIF1; DNA METHYLATION; PHASE-I; WNT; CHEMOPREVENTION;
   EXPRESSION; TUMORIGENESIS; 5-AZACYTIDINE; GROWTH; HYPERMETHYLATION
AB Breast cancer stem cells (CSCs) are considered as the root of mammary tumorigenesis. Previous studies have demonstrated that ISL efficiently limited the activities of breast CSCs. However, the cancer prevention activities of ISL and its precise molecular mechanisms remain largely unknown. Here, we report a novel function of ISL as a natural demethylation agent targeting WIF1 to prevent breast cancer. ISL administration suppressed in vivo breast cancer initiation and progression, accompanied by reduced CSC-like populations. A global gene expression profile assay further identified WIF1 as the main response gene of ISL treatment, accompanied by the simultaneous downregulation of beta-catenin signaling and G0/G1 phase arrest in breast CSCs. In addition, WIF1 inhibition significantly relieved the CSC-limiting effects of ISL and methylation analysis further revealed that ISL enhanced WIF1 gene expression via promoting the demethylation of its promoter, which was closely correlated with the inhibition of DNMT1 methyltransferase. Molecular docking analysis finally revealed that ISL could stably dock into the catalytic domain of DNMT1. Taken together, our findings not only provide preclinical evidence to demonstrate the use of ISL as a dietary supplement to inhibit mammary carcinogenesis but also shed novel light on WIF1 as an epigenetic target for breast cancer prevention.
C1 [Wang, Neng; Wang, Zhiyu; Shen, Jiangang; You, Jieshu; Peng, Fu; Chen, Jianping] Univ Hong Kong, Sch Chinese Med, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Zhiyu] Guangzhou Univ Chinese Med, Dept Mammary Dis, Guangdong Prov Hosp Chinese Med, Clin Med Coll 2, Guangzhou, Guangdong, Peoples R China.
   [Wang, Yu] Univ Hong Kong, Dept Pharmacol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Xie, Xiaoming] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol,Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
   [Peng, Cheng; Chen, Jianping] Chengdu Univ Tradit Chinese Med, Sch Pharmaceut Sci, Chengdu, Peoples R China.
   [Guan, Xinyuan] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; Guangzhou University of Chinese Medicine;
   University of Hong Kong; State Key Lab Oncology South China; Sun Yat Sen
   University; Chengdu University of Traditional Chinese Medicine;
   University of Hong Kong
RP Chen, JP (通讯作者)，Univ Hong Kong, Sch Chinese Med, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
EM jpjpchen@yahoo.com
RI wang, zhiyu/K-5255-2016; Wang, Yu/B-4534-2009; Tang,
   Hailin/AFJ-8662-2022; CHENG, PENG/HNP-4206-2023; PENG, Fu/KRQ-8632-2024;
   /A-3639-2009
OI wang, yu/0000-0001-8697-2940; Peng, Cheng/0000-0003-3303-906X; Tang,
   Hailin/0000-0002-3206-782X; PENG, Fu/0000-0003-0289-4426;
   /0000-0003-1874-9805
FU HMRF from the government of Hong Kong [11121951]; Chengdu University of
   Traditional Chinese medicine [319512]
FX This research was funded by HMRF 11121951 from the government of Hong
   Kong, and Project 319512 from Chengdu University of Traditional Chinese
   medicine. Confocal imaging and flow cytometry data were acquired using
   equipment maintained by the University of Hong Kong Li Ka Shing Faculty
   of Medicine Faculty Core Facility.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2013, TEXTILE APPAREL ED
   [Anonymous], CANC MANAGEMENT
   [Anonymous], J BIOMED BIOTECHNOL
   Baba M, 2002, BIOL PHARM BULL, V25, P247, DOI 10.1248/bpb.25.247
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Chang WC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-94
   Chen G, 2012, APOPTOSIS, V17, P90, DOI 10.1007/s10495-011-0658-1
   Cheng XD, 2008, STRUCTURE, V16, P341, DOI 10.1016/j.str.2008.01.004
   Chikan NA, 2013, APPL BIOCHEM BIOTECH, V170, P164, DOI 10.1007/s12010-013-0158-6
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Crowell JA, 2005, EUR J CANCER, V41, P1889, DOI 10.1016/j.ejca.2005.04.016
   Cuendet M, 2010, CANCER PREV RES, V3, P221, DOI 10.1158/1940-6207.CAPR-09-0049
   Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191
   den Hollander P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00250
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   ElBayoumy K, 1997, P SOC EXP BIOL MED, V216, P211, DOI 10.3181/00379727-216-44171
   Franci C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058183
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Joska Tammy M, 2014, Biology (Basel), V3, P560, DOI 10.3390/biology3030560
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kelloff GJ, 2000, ADV CANCER RES, V78, P199
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200
   Kwon GT, 2009, J NUTR BIOCHEM, V20, P663, DOI 10.1016/j.jnutbio.2008.06.005
   Landis-Piwowar KR, 2014, CANCER GROWTH METAST, V7, P19, DOI 10.4137/CGM.S11288
   Lau GTY, 2010, PLANTA MED, V76, P780, DOI 10.1055/s-0029-1240699
   Lee YM, 2010, TOXICOL IN VITRO, V24, P776, DOI 10.1016/j.tiv.2009.12.024
   Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Li YY, 2011, J NUTR BIOCHEM, V22, P799, DOI 10.1016/j.jnutbio.2010.11.001
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Liu J, 2008, CARCINOGENESIS, V29, P2195, DOI 10.1093/carcin/bgn194
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Lohberger B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043664
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Maor S, 2007, HORM METAB RES, V39, P179, DOI 10.1055/s-2007-970415
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Nagy T, 2007, J BIOL CHEM, V282, P31766, DOI 10.1074/jbc.M705403200
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Pan MH, 2015, MOL NUTR FOOD RES, V59, P21, DOI 10.1002/mnfr.201400515
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Park I, 2009, CANCER LETT, V277, P174, DOI 10.1016/j.canlet.2008.12.005
   Pogribny I. P., 2010, Experimental Oncology, V32, P132
   Polakis P, 2000, GENE DEV, V14, P1837
   Ramachandran I, 2012, ONCOGENE, V31, P2725, DOI 10.1038/onc.2011.455
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535-7163.MCT-09-0147
   Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006
   SAIKI JH, 1978, CANCER-AM CANCER SOC, V42, P2111, DOI 10.1002/1097-0142(197811)42:5<2111::AID-CNCR2820420505>3.0.CO;2-I
   Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023
   Subramaniam D, 2010, MINI-REV MED CHEM, V10, P359, DOI 10.2174/138955710791330954
   Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150
   Tu SM, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-40
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   VESELY J, 1977, VOP ONKOL+, V23, P65
   Wang CM, 2013, CANCER PREV RES, V6, P437, DOI 10.1158/1940-6207.CAPR-12-0345
   Wang N, 2014, CARCINOGENESIS, V35, P2544, DOI 10.1093/carcin/bgu187
   Wang Xiao-Bing, 2007, Ai Zheng, V26, P996
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   WEISS AJ, 1972, CANCER CHEMOTH REP 1, V56, P413
   WEISS AJ, 1977, CANCER TREAT REP, V61, P55
   YAMAMOTO S, 1991, CARCINOGENESIS, V12, P317, DOI 10.1093/carcin/12.2.317
   Yang CS, 2014, J BIOMED RES, V28, P447, DOI 10.7555/JBR.28.20140079
   Yang ZAY, 2010, ACTA BIOCH BIOPH SIN, V42, P418, DOI 10.1093/abbs/gmq037
   Yoo J, 2012, ADV PROTEIN CHEM STR, V87, P219, DOI 10.1016/B978-0-12-398312-1.00008-1
   Yu JH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055934, 10.1371/journal.pone.0057564]
   Zannetti A, 2005, BIOCHEM PHARMACOL, V70, P1277, DOI 10.1016/j.bcp.2005.07.024
NR 78
TC 62
Z9 67
U1 0
U2 26
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 30
PY 2015
VL 6
IS 12
BP 9854
EP 9876
DI 10.18632/oncotarget.3396
PG 23
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO0WO
UT WOS:000358874600019
PM 25918249
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, Q
   Wei, JM
   Su, P
   Gao, P
AF Wang, Qin
   Wei, Junmin
   Su, Peng
   Gao, Peng
TI Histone demethylase JARID1C promotes breast cancer metastasis cells via
   down regulating BRMS1 expression
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE JARID1C; Breast cancer; Metastasis; BRMS1
ID TUMOR-METASTASIS; GENE; SUPPRESSOR; MUTATIONS; PROTEIN; KDM5C
AB Metastasis is the leading cause of death in breast cancer patients. However, until now, the mechanisms of breast cancer metastasis remain elusive. Epigenetic switch, including histone methylation or demethylation, which can either activates or represses transcription. The JARID1C is a histone demethylase that promotes cancer cell growth and is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. But the pathogenic breadth and mechanistic aspects of this effect relative to breast cancer have not been defined. In this study, we aimed to investigate the role of JARID1C in breast cancer. In clinical breast cancer samples, we found that JARID1C expression was significantly upregulated in cancer lesions compared with paired normal breast tissues and its expression level is positively correlated with metastasis. Silencing JARID1C in breast cancer cells could inhibit cell migration and invasion. Moreover, we also found that the expression of BRMS1 was modulated by JARID1C. Silencing of JARID1C dramatically increased BRMS1 expression both at mRNA and protein level. Mechanistically, we found JARID1C exerts its function through modulation of H3K4me3 at the BRMS1 gene promoter, which was associated with inactive BRMS1 transcription. BRMS1 knockdown reversed shJARID1C-induced migration inhibition. Further, BRMS1 expression in human breast cancer is negatively correlated with JARID1C expression. Our results, for the first time, portray a pivotal role of JARID1C in regulating metastatic behaviors of breast cancer cells. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Wang, Qin] Shandong Univ, Qilu Hosp, Dept Anesthesiol, Jinan 250012, Shandong, Peoples R China.
   [Wei, Junmin] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Ctr Canc, Jinan 250012, Shandong, Peoples R China.
   [Su, Peng; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Wei, JM (通讯作者)，Shandong Univ, Qilu Hosp, Dept Chemotherapy, Ctr Canc, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM weijunmin2002@yahoo.com
FU National Natural Science Foundation of China [30672434]; Independent
   innovation fund of Shandong University [2012JC019]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 30672434) and Independent innovation fund
   of Shandong University (grant no. 2012JC019).
CR Albert M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003461
   Chicas A, 2012, P NATL ACAD SCI USA, V109, P8971, DOI 10.1073/pnas.1119836109
   Geng SQ, 2014, CANCER LETT, V349, P1, DOI 10.1016/j.canlet.2014.03.036
   Gossage L, 2014, GENE CHROMOSOME CANC, V53, P38, DOI 10.1002/gcc.22116
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Jensen Lars R, 2010, Pathogenetics, V3, P2, DOI 10.1186/1755-8417-3-2
   Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563
   Koehler C, 2008, BIOMOL NMR ASSIGM, V2, P9, DOI 10.1007/s12104-007-9071-7
   Liu Y, 2015, MOL CELL BIOL, V35, P303, DOI 10.1128/MCB.00869-14
   Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266
   Sheng XJ, 2014, EUR J GYNAECOL ONCOL, V35, P236
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Simensen RJ, 2012, GENET COUNSEL, V23, P31
   Smith J, 2009, PROTEIN EXPRES PURIF, V67, P70, DOI 10.1016/j.pep.2009.04.010
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Stein J, 2014, AM J PATHOL, V184, P2430, DOI 10.1016/j.ajpath.2014.05.022
   Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182
   Xu J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002553
NR 18
TC 30
Z9 35
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 21
PY 2015
VL 464
IS 2
BP 659
EP 666
DI 10.1016/j.bbrc.2015.07.049
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CO9RS
UT WOS:000359514000047
PM 26182878
DA 2025-01-12
ER

PT J
AU Vincent, KM
   Findlay, SD
   Postovit, LM
AF Vincent, Krista Marie
   Findlay, Scott D.
   Postovit, Lynne Marie
TI Assessing breast cancer cell lines as tumour models by comparison of
   mRNA expression profiles
SO BREAST CANCER RESEARCH
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; IN-VITRO; MOLECULAR PORTRAITS;
   EPITHELIAL-CELLS; STEM-CELLS; ESTABLISHMENT; PATTERNS; GENES;
   FIBROBLASTS; CULTIVATION
AB Introduction: Breast cancer researchers use cell lines to model myriad phenomena ranging from DNA repair to cancer stem cell phenotypes. Though appropriate, and even requisite, for many studies, the suitability of cell lines as tumour models has come into question owing to possibilities of tissue culture artefacts and clonal selection. These issues are compounded by the inability of cancer cells grown in isolation to fully model the in situ tumour environment, which also contains a plethora of non-tumour cell types. It is thus important to understand similarities and differences between cancer cell lines and the tumours that they represent so that the optimal tumour models can be chosen to answer specific research questions.
   Methods: In the present study, we compared the RNA-sequencing transcriptomes of a collection of breast cancer cell lines to transcriptomes obtained from hundreds of tumours using The Cancer Genome Atlas. Tumour purity was accounted for by analysis of stromal and immune scores using the ESTIMATE algorithm so that differences likely resulting from non-tumour cells could be accounted for.
   Results: We found the transcriptional characteristics of breast cancer cell lines to mirror those of the tumours. We identified basal and luminal cell lines that are most transcriptionally similar to their respective breast tumours. Our comparison of expression profiles revealed pronounced differences between breast cancer cell lines and tumours, which could largely be attributed to the absence of stromal and immune components in cell culture. A focus on the Wnt pathway revealed the transcriptional downregulation or absence of several secreted Wnt antagonists in culture. Gene set enrichment analysis suggests that cancer cell lines have enhanced proliferation and glycolysis independent of stromal and immune contributions compared with breast cancer cells in situ.
   Conclusions: This study demonstrates that many of the differences between breast cancer cell lines and tumours are due to the absence of stromal and immune components in vitro. Hence, extra precautions should be taken when modelling extracellular proteins in vitro. The specific differences discovered emphasize the importance of choosing an appropriate model for each research question.
C1 [Vincent, Krista Marie; Findlay, Scott D.; Postovit, Lynne Marie] Univ Alberta, Fac Med & Dent, Dept Oncol, Edmonton, AB T6G 2E1, Canada.
   [Vincent, Krista Marie; Findlay, Scott D.] Univ Western Ontario, Fac Med & Dent, Dept Anat & Cell Biol, London, ON N6A 3K7, Canada.
C3 University of Alberta; Western University (University of Western
   Ontario)
RP Postovit, LM (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Oncol, 114th St & 87th Ave, Edmonton, AB T6G 2E1, Canada.
EM postovit@ualberta.ca
RI Findlay, Scott/AAP-9554-2021
OI Findlay, Scott/0000-0002-0393-1623; Postovit,
   Lynne-Marie/0000-0002-8088-4197
FU Alberta Innovates - Health Solutions Translational Health Chair in
   cancer; Canadian Breast Cancer Foundation; Canadian Institutes of Health
   Research; Ontario Graduate Scholarship
FX This work was supported by an Alberta Innovates - Health Solutions
   Translational Health Chair in cancer and a Canadian Breast Cancer
   Foundation operating grant (to LMP). LMP was the recipient of the
   Peter-Lougheed Premier New Investigator Award from the Canadian
   Institutes of Health Research. SDF is a recipient of an Ontario Graduate
   Scholarship, and KMV is a Vanier Scholar.
CR AMADORI D, 1993, BREAST CANCER RES TR, V28, P251, DOI 10.1007/BF00666586
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Daemen A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0658-5
   Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   EBERT T, 1990, CANCER RES, V50, P5531
   ENGEL LW, 1978, CANCER RES, V38, P3352
   Ertel A, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-55
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Kabiri Z, 2014, DEVELOPMENT, V141, P2206, DOI 10.1242/dev.104976
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   LASFARGUES EY, 1958, JNCI-J NATL CANCER I, V21, P1131
   Lee J, 2008, GYNECOL ONCOL, V109, P270, DOI 10.1016/j.ygyno.2008.01.034
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Östman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045
   Pongracz J, 2003, EUR J IMMUNOL, V33, P1949, DOI 10.1002/eji.200323564
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Sandberg R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r65
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   van Staveren WCG, 2009, BBA-REV CANCER, V1795, P92, DOI 10.1016/j.bbcan.2008.12.004
   Winslow S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0530-2
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
NR 39
TC 56
Z9 63
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD AUG 20
PY 2015
VL 17
AR 114
DI 10.1186/s13058-015-0613-0
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP2EH
UT WOS:000359689800001
PM 26289960
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Roy, BC
   Subramaniam, D
   Ahmed, I
   Jala, VR
   Hester, CM
   Greiner, KA
   Haribabu, B
   Anant, S
   Umar, S
AF Roy, B. C.
   Subramaniam, D.
   Ahmed, I.
   Jala, V. R.
   Hester, C. M.
   Greiner, K. A.
   Haribabu, B.
   Anant, S.
   Umar, S.
TI Role of bacterial infection in the epigenetic regulation of Wnt
   antagonist WIF1 by PRC2 protein EZH2
SO ONCOGENE
LA English
DT Article
ID HISTONE METHYLTRANSFERASE; BREAST-CANCER; E-CADHERIN; IN-VIVO; CATENIN;
   PROLIFERATION; REPRESSION; PATHWAY; OVEREXPRESSION; TUMORIGENESIS
AB The enhancer of zeste homolog-2 (EZH2) represses gene transcription through histone H3 lysine-27-trimethylation (H3K27me3). Citrobacter rodentium (CR) promotes crypt hyperplasia and tumorigenesis by aberrantly regulating Wnt/beta-catenin signaling. We aimed at investigating EZH2's role in epigenetically regulating Wnt/beta-catenin signaling following bacterial infection. NIH: Swiss outbred and Apc(Min/+) mice were infected with CR (10(8) CFU); BLT1(-/)-Apc(Min/+) mice, azoxymethane (AOM)/dextran sodium sulfate (DSS)-treated mice and de-identified human adenocarcinoma samples were the models of colon cancer. Following infection with wild-type but not mutant CR, elevated EZH2 levels in the crypt at days 6 and 12 (peak hyperplasia) coincided with increases in H3K27me3 and beta-catenin levels, respectively. Chromatin immunoprecipitation revealed EZH2 and H3K27me3's occupancy on WIF1 (Wnt inhibitory factor 1) promoter resulting in reduced WIF1 mRNA and protein expression. Following EZH2 knockdown via small interfering RNA or EZH2-inhibitor deazaneplanocin A (Dznep) either alone or in combination with histone deacetylase inhibitor suberoylanilide hydroxamic acid, WIF1 promoter activity increased significantly while the overexpression of EZH2 attenuated WIF1 reporter activity. Ectopic overexpression of SET domain mutant (F681Y) almost completely rescued WIF1 reporter activity and partially rescued WIF1 protein levels, whereas H3K27me3 levels were significantly attenuated suggesting that an intact methyltransferases activity is required for EZH2-dependent effects. Interestingly, although beta-catenin levels were lower in EZH2-knocked down cells, F681Y mutants exhibited only partial reduction in beta-catenin levels. Besides EZH2, increases in miR-203 expression in the crypts at days 6 and 12 post infection correlated with reduced levels of its target WIF1; overexpression of miR-203 in primary colonocytes decreased WIF1 mRNA and protein levels. Elevated levels of EZH2 and beta-catenin with concomitant decrease in WIF1 expression in the polyps of CR-infected Apc(Min/+) mice paralleled changes recorded in BLT1(-/-) Apc(Min/+), AOM/DSS and human adenocarcinomas. Thus, EZH2-induced downregulation of WIF1 expression may partially regulate Wnt/beta-catenin-dependent crypt hyperplasia in response to CR infection.
C1 [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Mol Physiol, Kansas City, KS 66160 USA.
   [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Integrat Physiol, Kansas City, KS 66160 USA.
   [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Family Med Res Div, Kansas City, KS 66160 USA.
   [Jala, V. R.; Haribabu, B.] Univ Kansas, James Graham Brown Canc Ctr, Kansas City, KS 66160 USA.
   [Jala, V. R.; Haribabu, B.] Univ Kansas, Dept Microbiol & Immunol, Kansas City, KS 66160 USA.
   [Anant, S.; Umar, S.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA.
C3 University of Kansas; University of Kansas Medical Center; University of
   Kansas; University of Kansas Medical Center; University of Kansas;
   University of Kansas Medical Center; University of Kansas; University of
   Kansas; University of Kansas
RP Umar, S (通讯作者)，Univ Kansas, Med Ctr, Ctr Canc, 3901 Rainbow Blvd,4028 Wahl Hall East, Kansas City, KS 66160 USA.
EM sumar@kumc.edu
RI Anant, Shrikant/AAF-8020-2020; Jala, Venkatakrishna/K-7255-2018;
   Bodduluri, Haribabu/A-2584-2010
OI Bodduluri, Haribabu/0000-0002-8261-3294; Ahmed,
   Ishfaq/0009-0005-6632-7510
FU National Institutes of Health [R01 CA131413]; University of Kansas
   Medical Center, Kansas City, KS, USA
FX We thank Dr Philip R Hardwidge (Department of Diagnostic
   Medicine/Pathobiology, College of Veterinary Medicine, Kansas State
   University, Manhattan, KS, USA) for Citrobacter rodentium mutants. This
   work was partially supported by the National Institutes of Health Grant
   R01 CA131413 and start-up funds from the University of Kansas Medical
   Center, Kansas City, KS, USA.
CR Ahmed I, 2013, AM J PHYSIOL-GASTR L, V304, pG356, DOI 10.1152/ajpgi.00372.2012
   Ahmed I, 2012, INFECT IMMUN, V80, P3107, DOI 10.1128/IAI.00236-12
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   BOFFA LC, 1978, J BIOL CHEM, V253, P3364
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Chan DW, 2006, GASTROENTEROLOGY, V131, P1218, DOI 10.1053/j.gastro.2006.07.020
   Chandrakesan P, 2014, ONCOGENE, V33, P2639, DOI 10.1038/onc.2013.210
   Chandrakesan P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079432
   Chandrakesan P, 2010, J BIOL CHEM, V285, P33485, DOI 10.1074/jbc.M110.129353
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101
   Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009
   Hayashi Y, 2013, GUT, V62, P1536, DOI 10.1136/gutjnl-2011-301625
   Ihara A, 2007, J PHARMACOL SCI, V103, P24, DOI 10.1254/jphs.FP0060651
   Joshi P, 2008, J BIOL CHEM, V283, P27757, DOI 10.1074/jbc.M804442200
   Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Sellin JH, 2001, CANCER RES, V61, P2899
   Sellin JH, 2009, EXP CELL RES, V315, P97, DOI 10.1016/j.yexcr.2008.10.019
   Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Umar S, 2005, ONCOGENE, V24, P6709, DOI 10.1038/sj.onc.1208820
   Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x
   Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006
   Umar S, 2012, CURR COLORECT CANC R, V8, P298, DOI 10.1007/s11888-012-0143-4
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
NR 38
TC 25
Z9 26
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 20
PY 2015
VL 34
IS 34
BP 4519
EP 4530
DI 10.1038/onc.2014.386
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CP9BR
UT WOS:000360189200011
PM 25486432
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Isosaka, M
   Niinuma, T
   Nojima, M
   Kai, M
   Yamamoto, E
   Maruyama, R
   Nobuoka, T
   Nishida, T
   Kanda, T
   Taguchi, T
   Hasegawa, T
   Tokino, T
   Hirata, K
   Suzuki, H
   Shinomura, Y
AF Isosaka, Mai
   Niinuma, Takeshi
   Nojima, Masanori
   Kai, Masahiro
   Yamamoto, Eiichiro
   Maruyama, Reo
   Nobuoka, Takayuki
   Nishida, Toshirou
   Kanda, Tatsuo
   Taguchi, Takahiro
   Hasegawa, Tadashi
   Tokino, Takashi
   Hirata, Koichi
   Suzuki, Hiromu
   Shinomura, Yasuhisa
TI A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal
   Stromal Tumors
SO PLOS ONE
LA English
DT Article
ID TARGETING BCL-W; HEPATOCELLULAR-CARCINOMA; INHIBITS MIGRATION;
   COLORECTAL-CANCER; PANCREATIC-CANCER; DNA METHYLATION; GASTRIC-CANCER;
   OVARIAN-CANCER; ANATOMIC SITE; BREAST-CANCER
AB Background
   Dysregulation of microRNA (miRNA) has been implicated in gastrointestinal stromal tumors (GISTs) but the mechanism is not fully understood. In this study, we aimed to explore the involvement of epigenetic alteration of miRNA genes in GISTs.
   Methods
   GIST-T1 cells were treated with 5-aza-2'-deoxycytidine (5-aza-dC) and 4-phenylbutyric acid (PBA), after which miRNA expression profiles were analyzed using TaqMan miRNA arrays. DNA methylation was then analyzed using bisulfite pyrosequencing. The functions of miRNAs were examined using MTT assays, wound-healing assays, Boyden chamber assays and Matrigel invasion assays. Gene expression microarrays were analyzed to assess effect of ectopic miRNA expression in GIST-T1 cells.
   Results
   Of the 754 miRNAs analyzed, 61 were significantly upregulated in GIST-T1 cells treated with 5-aza-dC plus PBA. Among those, 21 miRNA genes were associated with an upstream CpG island (CGI), and the CGIs of miR-34a and miR-335 were frequently methylated in GIST-T1 cells and primary GIST specimens. Transfection of miR-34a or miR-335 mimic molecules into GIST-T1 cells suppressed cell proliferation, and miR-34a also inhibited migration and invasion by GIST-T1 cells. Moreover, miR-34a downregulated a number of predicted target genes, including PDGFRA. RNA interference-mediated knockdown of PDGFRA in GIST-T1 cells suppressed cell proliferation, suggesting the tumor suppressive effect of miR-34a is mediated, at least in part, through targeting PDGFRA.
   Conclusions
   Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs.
C1 [Isosaka, Mai; Yamamoto, Eiichiro; Maruyama, Reo; Shinomura, Yasuhisa] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan.
   [Niinuma, Takeshi; Kai, Masahiro; Yamamoto, Eiichiro; Suzuki, Hiromu] Sapporo Med Univ, Dept Mol Biol, Sapporo, Hokkaido, Japan.
   [Nojima, Masanori] Univ Tokyo, Inst Med Sci, Ctr Translat Res, Tokyo, Japan.
   [Nobuoka, Takayuki; Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido, Japan.
   [Nishida, Toshirou] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
   [Kanda, Tatsuo] Sanjo Gen Hosp, Dept Surg, Sanjo City, Niigata, Japan.
   [Taguchi, Takahiro] Kochi Univ, Grad Sch Kuroshio Sci, Div Human Hlth & Med Sci, Nankoku, Kochi, Japan.
   [Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido, Japan.
   [Tokino, Takashi] Sapporo Med Univ, Sch Med, Res Inst Frontier Med, Med Genome Sci, Sapporo, Hokkaido, Japan.
C3 Sapporo Medical University; Sapporo Medical University; University of
   Tokyo; Sapporo Medical University; National Cancer Center - Japan; Kochi
   University; Sapporo Medical University; Sapporo Medical University
RP Suzuki, H (通讯作者)，Sapporo Med Univ, Dept Mol Biol, Sapporo, Hokkaido, Japan.
EM hsuzuki@sapmed.ac.jp
RI Tokino, Takashi/AAI-9887-2021; Kanda, Tatsuo/KBB-3197-2024; Nojima,
   Masanori/ABE-2237-2020
OI Nojima, Masanori/0000-0002-8788-2522
FU Japan Society for Promotion of Science [25670371, 26860514]; Takeda
   Science Foundation [2011]; Project for Developing Innovative Research on
   Cancer Therapeutics (P-DIRECT) [11093014]; Grants-in-Aid for Scientific
   Research [25670371, 15K08973, 26860514, 25430115] Funding Source: KAKEN
FX This study was supported in part by Grant-in-Aid for Challenging
   Exploratory Research from the Japan Society for Promotion of Science (No
   25670371), Grant-in-Aid for Young Scientists (B) from the Japan Society
   for Promotion of Science (No 26860514), the Takeda Science Foundation
   (No 2011), and the Project for Developing Innovative Research on Cancer
   Therapeutics (P-DIRECT) (No 11093014). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825
   Assamaki R, 2007, GENE CHROMOSOME CANC, V46, P564, DOI 10.1002/gcc.20439
   Barrowman J, 2012, HUM MOL GENET, V21, P4084, DOI 10.1093/hmg/dds233
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Cao J, 2013, ONCOL REP, V30, P701, DOI 10.3892/or.2013.2482
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033
   Choi HJ, 2010, INT J CANCER, V126, P1640, DOI 10.1002/ijc.24897
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   de la Rosa J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3268
   Dohi O, 2013, INT J ONCOL, V42, P411, DOI 10.3892/ijo.2012.1724
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fan R, 2014, TUMOR BIOL, V35, P4209, DOI 10.1007/s13277-013-1551-z
   Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545
   Gao L, 2014, TUMOR BIOL, V35, P8309, DOI 10.1007/s13277-014-2092-9
   Gao Y, 2015, TUMOR BIOL, V36, P2875, DOI 10.1007/s13277-014-2917-6
   Garofalo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067581
   Gong M, 2014, MOL CANCER RES, V12, P101, DOI 10.1158/1541-7786.MCR-13-0136
   Guan XY, 2001, CANCER RES, V61, P3806
   Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He LR, 2011, INT J CANCER, V129, P143, DOI 10.1002/ijc.25669
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Heyn H, 2011, INT J CANCER, V129, P2797, DOI 10.1002/ijc.25962
   Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1
   Igarashi S, 2010, CLIN CANCER RES, V16, P5114, DOI 10.1158/1078-0432.CCR-10-0581
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Jiang J, 2012, MED ONCOL, V29, P3472, DOI 10.1007/s12032-012-0259-z
   Joensuu H, 2013, LANCET, V382, P973, DOI 10.1016/S0140-6736(13)60106-3
   Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111
   Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035
   Li Y, 2014, GASTROENTEROLOGY, V146, P1701, DOI 10.1053/j.gastro.2014.02.029
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu S, 2014, TUMOR BIOL, V35, P9131, DOI 10.1007/s13277-014-2177-5
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lynch J, 2012, CARCINOGENESIS, V33, P976, DOI 10.1093/carcin/bgs114
   Nakatani H, 2005, CANCER SCI, V96, P116, DOI 10.1111/j.1349-7006.2005.00018.x
   Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803
   Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034
   Peng H, 2013, HEPATOLOGY, V57, P2299, DOI 10.1002/hep.26258
   Peng Y, 2014, BIOSCIENCE REP, V34, P247, DOI 10.1042/BSR20140020
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Shimizu T, 2013, EUR UROL, V63, P1091, DOI 10.1016/j.eururo.2012.11.030
   Shu MF, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-59
   Silber J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033844
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461
   Tang DJ, 2010, HEPATOLOGY, V51, P1255, DOI 10.1002/hep.23451
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Wang HQ, 2013, TUMOR BIOL, V34, P3101, DOI 10.1007/s13277-013-0878-9
   Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655
   Wozniak A, 2007, GENE CHROMOSOME CANC, V46, P261, DOI 10.1002/gcc.20408
   Xu Y, 2012, ONCOGENE, V31, P1398, DOI 10.1038/onc.2011.340
   Yan Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040037
   Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207
NR 60
TC 17
Z9 21
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2015
VL 10
IS 7
AR e0133754
DI 10.1371/journal.pone.0133754
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN7DN
UT WOS:000358594300031
PM 26214687
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Luo, Y
   Yu, LT
   Yu, TT
   Jiang, FX
   Cai, XB
   Zhao, YL
   Pan, SY
   Luo, C
AF Luo, Ying
   Yu, Luting
   Yu, Tingting
   Jiang, Feixia
   Cai, Xubing
   Zhao, Yilun
   Pan, Shiyang
   Luo, Chen
TI The association of <i>DNA methyltransferase 1</i> gene polymorphisms
   with susceptibility to childhood acute lymphoblastic leukemia
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Acute lymphoblastic leukemia; DNA methyltransferase 1; Polymorphism;
   Susceptibility
ID DNA-METHYLTRANSFERASE ACTIVITY; BREAST-CANCER RISK; CYTOSINE-DNA;
   COLON-CANCER; LUNG-CANCER; EXPRESSION; CELLS; HYPERMETHYLATION;
   TUMORIGENESIS; PROGRESSION
AB Background: It has been suggested that aberrant DNA methylation is a common epigenetic alteration in malignancies. Genetic variations in DNA methyltransferase 1 gene (DNMT1), which encodes the maintenance methyltransferase, have been demonstrated to be involved in cancer susceptibility. In the present study, we investigated whether genetic polymorphisms in DNMT1 could be associated with risk of childhood acute lymphoblastic leukemia (ALL) in a Chinese population.
   Methods: We selected seven tagging single-nucleotide polymorphisms (tagSNPs, rs11880388, rs10423341, rs7253062, rs11085721, rs2228611, rs2228612 and rs16999593) in DNMT1 and genotyped these SNPs by using TaqMan method in a case-control study of 377 patients with ALL and 500 healthy controls. The logistic regression was used to assess the genetic associations with occurrence of ALL with adjustment for possible confounders.
   Results: We found that one (rs11085721) of the seven tagSNPs was significantly associated with the risk of ALL. Compared with individuals' with DNMT1 rs11085721 GG genotype, those subjects carrying the rs11085721 GT genotypes were associated with significantly increased risk for ALL (GT vs. GG: OR = 1.29, 95% CI = 1.10-1.51). Similar association was also observed when combined the individuals with rs11085721 GT and rs11085721 TT genotypes (GT/TT vs. TT: OR = 1.29, 95% CI = 1.10-1.50). No positive results were observed for the other tagSNPs.
   Conclusions: Our results suggest that the DNMT1 rs11085721 polymorphism may confer susceptibility to ALL in the Chinese population. The initial findings should be validated by large population-based prospective studies in the future. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Luo, Ying; Pan, Shiyang] Nanjing Med Univ, Dept Lab Med, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Luo, Ying; Cai, Xubing; Zhao, Yilun] Nanjing Red Cross Blood Ctr, Nanjing 210003, Jiangsu, Peoples R China.
   [Yu, Luting; Luo, Chen] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China.
   [Yu, Tingting] Nanjing Med Univ, Sch Basic Med Sci, Dept Dev Genet, Nanjing 210029, Jiangsu, Peoples R China.
   [Jiang, Feixia] Nanjing Med Univ, Nanjing Hosp 1, Dept Lab Med, Nanjing 210006, Jiangsu, Peoples R China.
C3 Nanjing Medical University; China Pharmaceutical University; Nanjing
   Medical University; Nanjing Medical University
RP Pan, SY (通讯作者)，Nanjing Med Univ, Dept Lab Med, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM sypan@njmu.edu.cn; chenluo@cpu.edu.cn
RI yu, tingting/HGA-4783-2022
OI Yu, Tingting/0000-0003-1694-7592; Pan, Shiyang/0000-0001-9320-6988
FU Nanjing Health Bureau Youth Starting program [QYK11150]; Nanjing Health
   Bureau General program [YKK12162]; Nanjing Health Bureau Youth Training
   program
FX This study was supported by Nanjing Health Bureau Youth Starting program
   (No. QYK11150), Nanjing Health Bureau General program (No. YKK12162),
   and Nanjing Health Bureau Youth Training program. And we also thanks for
   the technical help of Biolight Tec, Company in Nanjing.
CR Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Herman JG, 1996, CANCER RES, V56, P722
   Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaatsch P, 2010, CANCER TREAT REV, V36, P277, DOI 10.1016/j.ctrv.2010.02.003
   Krajinovic M, 2004, BLOOD, V103, P252, DOI 10.1182/blood-2003-06-1794
   Kullmann K, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-7
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li KK, 2013, SEMIN HEMATOL, V50, P48, DOI 10.1053/j.seminhematol.2013.01.005
   Liou JY, 2005, EXP CELL RES, V306, P75, DOI 10.1016/j.yexcr.2005.01.011
   Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   Mani S, 2010, ADV GENET, V70, P327, DOI [10.1016/B978-0-12-380866-0.60012-5, 10.1016/S0065-2660(10)70012-2]
   Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932
   Migliorini G, 2013, BLOOD, V122, P3298, DOI 10.1182/blood-2013-03-491316
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Pui CH, 2000, CURR OPIN ONCOL, V12, P3, DOI 10.1097/00001622-200001000-00002
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Treviño LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432
   Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016
   Wiemels J, 2012, CHEM-BIOL INTERACT, V196, P59, DOI 10.1016/j.cbi.2012.01.007
   Wu HZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092911
   Yang XX, 2012, INT J MOL SCI, V13, P8364, DOI 10.3390/ijms13078364
   Zhu J, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0399-4
NR 31
TC 7
Z9 7
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2015
VL 73
BP 35
EP 39
DI 10.1016/j.biopha.2015.05.001
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CN4YE
UT WOS:000358435700007
PM 26211580
DA 2025-01-12
ER

PT J
AU Song, FF
   Xia, LL
   Ji, P
   Tang, YB
   Huang, ZM
   Zhu, L
   Zhang, J
   Wang, JQ
   Zhao, GP
   Ge, HL
   Zhang, Y
   Wang, Y
AF Song, F-f
   Xia, L-l
   Ji, P.
   Tang, Y-b
   Huang, Z-m
   Zhu, L.
   Zhang, J.
   Wang, J-q
   Zhao, G-p
   Ge, H-l
   Zhang, Y.
   Wang, Y.
TI Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and
   stemness through the modulation on 5-methyl-dCTP metabolism and global
   hypomethylation
SO ONCOGENESIS
LA English
DT Article
ID DNA METHYLATION; DUTP PYROPHOSPHATASE; OXIDATIVE STRESS;
   MAMMALIAN-CELLS; POOR-PROGNOSIS; GENE; EXPRESSION; DAMAGE; REPAIR;
   PYROPHOSPHOHYDROLASE
AB Human DCTPP1 (dCTP pyrophosphatase 1), also known as XTP3-transactivated protein A, belongs to MazG-like nucleoside triphosphate pyrophosphatase (NTP-PPase) superfamily. Being a newly identified pyrophosphatase, its relevance to tumorigenesis and the mechanisms are not well investigated. In the present study, we have confirmed our previous study that DCTPP1 was significantly hyperexpressed in breast cancer and further demonstrated its strong association with tumor progression and poor prognosis in breast cancer. Knockdown of DCTPP1 in breast cancer cell line MCF-7 cells remarkably retarded proliferation and colony formation in vitro. The capacity of mammosphere formation of MCF-7 was suppressed with the silence of DCTPP1, which was consistent with the enhanced mammosphere-forming ability in DCTPP1-overexpressed MDA-MB-231 cells. To further dissect the mechanisms of DCTPP1 in promoting tumor cell growth and stemness maintenance, its biochemical properties and biological functions were investigated. DCTPP1 displayed bioactive form with tetrameric structure similar to other MazG domain-containing pyrophosphatases based on structure simulation. A substrate preference for dCTP and its methylated or halogen-modified derivatives over the other canonical (deoxy-) NTPs was demonstrated from enzymatic assay. This substrate preference was also proved in breast cancer cells that the intracellular 5-methyl-dCTP level increased in DCTPP1-deficient MCF-7 cells but decreased in DCTPP1-overexpressed MDA-MB-231 cells. Moreover, global methylation level was elevated in DCTPP1-knockdown MCF-7 cells or mammosphere-forming MCF-7 cells but decreased significantly in DCTPP1-overexpressed MDA-MB-231 cells and its mammospheres. Our results thus indicated that human DCTPP1 was capable of modulating the concentration of intracellular 5-methyl-dCTP. This in turn affected global methylation, contributing to a known phenomenon of hypomethylation related to the cancer cell growth and stemness maintenance. Our current investigations point to the pathological functions of DCTPP1 overexpression in breast cancer cells with aberrant dCTP metabolism and epigenetic modification.
C1 [Song, F-f; Ji, P.; Wang, J-q; Ge, H-l; Zhang, Y.; Wang, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China.
   [Xia, L-l; Zhao, G-p; Wang, Y.] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China.
   [Tang, Y-b; Huang, Z-m; Zhu, L.; Zhang, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol, Shanghai 200025, Peoples R China.
   [Xia, L-l; Zhao, G-p] Fudan Univ, Sch Life Sci, Dept Microbiol & Microbial Engn, Shanghai 200433, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Jiao Tong University; Fudan University
RP Wang, Y (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China.
EM zhangy@shsmu.edu.cn; ywang@sibs.ac.cn
RI Wang, Junqing/F-5793-2017; Zhang, Xiaohong/A-3060-2015; Zhang,
   Jian/GXA-1303-2022; Huang, Zhimin/ADW-5425-2022; Huang,
   Zhimin/R-4712-2018
OI Zhang, Jian/0000-0002-6558-791X; Zhao, Guo-Ping/0000-0002-7621-6620;
   Xia, Liliang/0000-0002-5877-336X; Huang, Zhimin/0000-0001-9230-6039
FU Shanghai Municipal Education Committee [13ZZ083]; Shanghai Natural
   Science Foundation [14ZR1436300]; Shanghai Municipal Health Bureau
   [20114195]; Undergraduate Innovation Programs of SJTUSM [2013016]
FX This work was supported by grants from the Shanghai Municipal Education
   Committee (13ZZ083), the Shanghai Natural Science Foundation
   (14ZR1436300), the Shanghai Municipal Health Bureau (20114195) and the
   Undergraduate Innovation Programs of SJTUSM (2013016).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848
   Badouard C, 2005, J CHROMATOGR B, V827, P26, DOI 10.1016/j.jchromb.2005.03.025
   Burgis NE, 2003, J BACTERIOL, V185, P3101, DOI 10.1128/JB.185.10.3101-3110.2003
   Chabardès-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100
   Corson TW, 2011, CHEMBIOCHEM, V12, P1767, DOI 10.1002/cbic.201100007
   Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x
   Galperin MY, 2006, MOL MICROBIOL, V59, P5, DOI 10.1111/j.1365-2958.2005.04950.x
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200
   Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998
   HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P329, DOI 10.1098/rstb.1990.0015
   HOLLIDAY R, 1991, SOMAT CELL MOLEC GEN, V17, P537, DOI 10.1007/BF01233618
   Holliday R, 1998, MUTAT RES-FUND MOL M, V400, P361, DOI 10.1016/S0027-5107(98)00034-7
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Kaito C, 2001, DEV GROWTH DIFFER, V43, P383
   KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446
   Kamiya H, 2003, NUCLEIC ACIDS RES, V31, P517, DOI 10.1093/nar/gkg137
   Kang JI, 2008, CHEM RES TOXICOL, V21, P1211, DOI 10.1021/tx800037h
   Kobow K, 2012, EPILEPSIA, V53, P11, DOI 10.1111/epi.12031
   Ladner RD, 2000, CANCER RES, V60, P3493
   Lao VV, 2009, CARCINOGENESIS, V30, P886, DOI 10.1093/carcin/bgp060
   LIAKOPOULOU A, 1964, BIOCHIM BIOPHYS ACTA, V89, P158, DOI 10.1016/0926-6569(64)90112-9
   Liao YP, 2014, HUM MOL GENET, V23, P1894, DOI 10.1093/hmg/ddt583
   Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127
   Lodish H BA, 2004, MOL CELL BIOL, P956
   Lu LD, 2010, J BIOL CHEM, V285, P28076, DOI 10.1074/jbc.M109.088872
   Lyu LD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003814
   MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0
   Martí-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev
   McLennan AG, 2006, CELL MOL LIFE SCI, V63, P123, DOI 10.1007/s00018-005-5386-7
   Mishima M, 2004, J BIOL CHEM, V279, P33806, DOI 10.1074/jbc.M402393200
   Morisaki T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110736
   Moroz OV, 2005, J MOL BIOL, V347, P243, DOI 10.1016/j.jmb.2005.01.030
   Nonaka M, 2009, FEBS J, V276, P1654, DOI 10.1111/j.1742-4658.2009.06898.x
   NYCE J, 1991, SOMAT CELL MOLEC GEN, V17, P543, DOI 10.1007/BF01233619
   Okamoto K, 1996, INT J CANCER, V65, P437, DOI 10.1002/(SICI)1097-0215(19960208)65:4<437::AID-IJC7>3.0.CO;2-Y
   Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485
   Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520
   Rai P, 2010, MUTAT RES-GEN TOX EN, V703, P71, DOI 10.1016/j.mrgentox.2010.07.010
   Requena CE, 2014, BIOCHEM J, V459, P171, DOI 10.1042/BJ20130894
   Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51
   Riggins GJ, 2001, HUM MOL GENET, V10, P663, DOI 10.1093/hmg/10.7.663
   Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200
   Takatori H, 2010, LIVER INT, V30, P438, DOI 10.1111/j.1478-3231.2009.02177.x
   Tian T, 2013, CHEM COMMUN, V49, P10085, DOI 10.1039/c3cc44017f
   Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798
   Valinluck V, 2006, CHEM RES TOXICOL, V19, P556, DOI 10.1021/tx050341w
   Valinluck V, 2005, NUCLEIC ACIDS RES, V33, P3057, DOI 10.1093/nar/gki612
   Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992
   Wani G, 1998, CANCER LETT, V125, P123, DOI 10.1016/S0304-3835(97)00507-7
   Wilson PM, 2012, MOL CANCER THER, V11, P616, DOI 10.1158/1535-7163.MCT-11-0781
   Wu BL, 2007, J MOL BIOL, V367, P1405, DOI 10.1016/j.jmb.2007.01.057
   Zhang Y, 2013, Eur J Histochem, V57, pe29, DOI 10.4081/ejh.2013.e29
NR 63
TC 33
Z9 38
U1 2
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD JUN
PY 2015
VL 4
AR e159
DI 10.1038/oncsis.2015.10
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CN8UF
UT WOS:000358718900010
PM 26075750
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Cheng, CT
   Chu, YY
   Yeh, CN
   Huang, SC
   Chen, MH
   Wang, SY
   Tsai, CY
   Chiang, KC
   Chen, YY
   Ma, MC
   Liu, CT
   Chen, TW
   Yeh, TS
AF Cheng, Chi-Tung
   Chu, Yin-Yi
   Yeh, Chun-Nan
   Huang, Shih-Chiang
   Chen, Ming Huang
   Wang, Shang-Yu
   Tsai, Chun-Yi
   Chiang, Kun-Chun
   Chen, Yen-Yang
   Ma, Ming-Chun
   Liu, Chien-Ting
   Chen, Tsung-Wen
   Yeh, Ta-Sen
TI Peritumoral SPARC expression and patient outcome with resectable
   intrahepatic cholangiocarcinoma
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE SPARC; mass-forming cholangiocarcinoma; prognosis; predicting factors
ID PANCREATIC ADENOCARCINOMA; HEPATOCELLULAR-CARCINOMA; HEPATIC RESECTION;
   BREAST-CANCER; PERIPHERAL CHOLANGIOCARCINOMA; MULTIVARIATE-ANALYSIS;
   PROGNOSTIC-FACTORS; ENDOTHELIAL-CELLS; ENHANCED GROWTH; ALBUMIN-BINDING
AB Background and objectives: Cholangiocarcinoma (CCA) affects thousands worldwide with increasing incidence. SPARC (secreted protein acidic and rich in cysteine) plays an important role in cellular matrix interactions, wound repair, and cellular migration, and has been reported to prevent malignancy from growth. SPARC undergoes epigenetic silencing in pancreatic malignancy, but is frequently expressed by stromal fibroblasts adjacent to infiltrating pancreatic adenocarcinomas. CCA is also a desmoplastic tumor, similar to pancreatic adenocarcinoma. SPARC's clinical influence on clinicopathological characteristics of mass-forming (MF)-CCA still remains unclear. In this study, we evaluate the expression of SPARC in tumor and stromal tissue to clarity its relation with prognosis.
   Methods: Seventy-eight MF-CCA patients who underwent hepatectomy with curative intent were enrolled for an immunohistochemical study of SPARC. The expression of immunostaining of SPARC was characterized for both tumor and stromal tissues. We conducted survival analysis with 16 clinicopathological variables. The overall survival (OS) was analyzed by Kaplan-Meier analysis and Cox proportional hazards regression modeling.
   Results: Thirty-three men and 45 women with MF-CCA were studied. Within total 78 subjects, 12 (15.4%) were classified as tumor negative/stroma negative, 37 (47.4%) as tumor positive/stroma negative, four (5.1%) as tumor negative/stroma positive, and 25 (32.1%) as tumor positive/stroma positive. With a median follow-up of 13.6 months, the 5-year OS was 14.9%. Cox proportional hazard analysis revealed that SPARC tumor positive and stromal negative immunostaining and curative hepatectomy predicted favorable OS in patients with MF-CCA after hepatectomy.
   Conclusion: MF-CCA patients with SPARC tumor positive and stromal negative expression may have favorable OS rates after curative hepatectomy.
C1 [Cheng, Chi-Tung; Yeh, Chun-Nan; Wang, Shang-Yu; Tsai, Chun-Yi; Chen, Tsung-Wen; Yeh, Ta-Sen] Chang Gung Univ, Dept Surg, Chang Gung Mem Hosp, Taoyuan, Taiwan.
   [Chu, Yin-Yi] Chang Gung Univ, Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan.
   [Huang, Shih-Chiang] Chang Gung Univ, Chang Gung Mem Hosp, Dept Pathol, Taoyuan, Taiwan.
   [Chen, Ming Huang] Taipei Vet Gen Hosp, Div Hematol & Oncol, Dept Med, Taipei, Taiwan.
   [Chiang, Kun-Chun] Chang Gung Univ, Chang Gung Mem Hosp, Dept Surg, Keelung, Taiwan.
   [Chen, Yen-Yang; Ma, Ming-Chun; Liu, Chien-Ting] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung, Taiwan.
   [Chen, Yen-Yang; Ma, Ming-Chun; Liu, Chien-Ting] Chang Gung Univ, Taoyuan, Taiwan.
C3 Chang Gung University; Chang Gung Memorial Hospital; Chang Gung
   University; Chang Gung Memorial Hospital; Chang Gung University; Chang
   Gung Memorial Hospital; Taipei Veterans General Hospital; Chang Gung
   Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital;
   Chang Gung University
RP Yeh, CN (通讯作者)，Chang Gung Univ, Dept Surg, Chang Gung Mem Hosp, 5 Fu Hsing St, Taoyuan, Taiwan.
EM yehchunnan@gmail.com
RI w, s/IUO-2655-2023; CHENG, CHI-TUNG/AAE-9437-2019; Hui,
   Rosaline/E-7287-2010; Huang, Shih-Chiang/G-3197-2013; CHENG,
   CHI-TUNG/G-7554-2011
OI Huang, Shih-Chiang/0000-0002-5092-4434; Wang, Shang
   Yu/0000-0003-1514-3015; CHENG, CHI-TUNG/0000-0002-2697-4642
FU Chang Gung Medical Research Program [3B0363, CMRPG3B0533]; National
   Science Council [NMRPG5D6031, MOST 103-2314-B-182A-081-MY2]
FX This work was supported by Chang Gung Medical Research Program grants
   3B0363 and CMRPG3B0533 to C-NY and by grants from the National Science
   Council (NMRPG5D6031 and MOST 103-2314-B-182A-081-MY2).
CR Bathe OF, 2001, HEPATO-GASTROENTEROL, V48, P1289
   Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI16804
   Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857
   Chen MF, 1999, J GASTROEN HEPATOL, V14, P1144, DOI 10.1046/j.1440-1746.1999.01983.x
   Chen MF, 2003, WORLD J SURG, V27, P443, DOI 10.1007/s00268-002-6708-7
   Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221
   de Groen PC, 1999, NEW ENGL J MED, V341, P1368, DOI 10.1056/NEJM199910283411807
   Faivre L, 2000, BLOOD, V96, P4064
   FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648
   Handrich SJ, 2005, AM J ROENTGENOL, V184, P20, DOI 10.2214/ajr.184.1.01840020
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824
   Jacob K, 1999, CANCER RES, V59, P4453
   Jarnagin WR, 2001, ANN SURG, V234, P507, DOI 10.1097/00000658-200110000-00010
   John TA, 2003, AM J PHYSIOL-LUNG C, V284, pL187, DOI 10.1152/ajplung.00152.2002
   Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7
   KLOMPJE J, 1987, EUR J SURG ONCOL, V13, P345
   Koukourakis MI, 2003, CANCER RES, V63, P5376
   Levy MJ, 2005, CLIN GASTROENTEROL H, V3, P974, DOI 10.1016/S1542-3565(05)00408-8
   Lindmark F, 2004, JNCI-J NATL CANCER I, V96, P1248, DOI 10.1093/jnci/djh227
   Liver Cancer Study Group of Japan, 1997, CLASS PRIM LIV CANC
   Mantoni TS, 2008, CANCER BIOL THER, V7, P1806, DOI 10.4161/cbt.7.11.6846
   Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Ohtsuka M, 2002, BRIT J SURG, V89, P1525, DOI 10.1046/j.1365-2168.2002.02268.x
   Okabayashi T, 2000, AM J GASTROENTEROL, V95, P204
   Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087
   Piao CQ, 2005, CARCINOGENESIS, V26, P725, DOI 10.1093/carcin/bgi016
   Puolakkainen PA, 2004, MOL CANCER RES, V2, P215
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0
   Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807
   SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872
   Seol MA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-78
   Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889
   Shirabe K, 2002, SURGERY, V131, pS159, DOI 10.1067/msy.2002.119498
   Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002
   Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250
   Uehara H, 1999, AM J GASTROENTEROL, V94, P2513
   Uenishi T, 2001, WORLD J SURG, V25, P865, DOI 10.1007/s00268-001-0042-3
   Ustundag Y, 2008, WORLD J GASTROENTERO, V14, P6458, DOI 10.3748/wjg.14.6458
   Utispan K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-13
   Wang CS, 2004, BRIT J CANCER, V91, P1924, DOI 10.1038/sj.bjc.6602213
   Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003
   Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P273, DOI 10.1016/j.plefa.2004.12.004
   Weber SM, 2001, J AM COLL SURGEONS, V193, P384, DOI 10.1016/S1072-7515(01)01016-X
   West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187
   Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6
   Yamashita K, 2003, CANCER, V97, P2412, DOI 10.1002/cncr.11368
   Yeh CN, 2004, ANN SURG ONCOL, V11, P606, DOI 10.1245/ASO.2004.04.028
   Yeh CN, 2003, ANN SURG ONCOL, V10, P1070, DOI 10.1245/ASO.2003.03.072
   Yeh CN, 2002, J SURG ONCOL, V81, P195, DOI 10.1002/jso.10178
NR 54
TC 8
Z9 8
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 1899
EP 1907
DI 10.2147/OTT.S78728
PG 9
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CN7XV
UT WOS:000358650200001
PM 26251613
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Khanal, T
   Kim, D
   Johnson, A
   Choubey, D
   Kim, K
AF Khanal, Tilak
   Kim, Dasom
   Johnson, Abby
   Choubey, Divaker
   Kim, Kyounghyun
TI Deregulation of NR2E3, an orphan nuclear receptor, by benzo(a)
   pyrene-induced oxidative stress is associated with histone modification
   status change of the estrogen receptor gene promoter
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Polycyclic aromatic hydrocarbon; An orphan nuclear receptor;
   Epigenetics; Histone demethylase; Antioxidant
ID POLYCYCLIC AROMATIC-HYDROCARBONS; BREAST-CANCER; CELL-PROLIFERATION;
   DIOL-EPOXIDE; EXPRESSION; ACTIVATION; INDUCTION; RISK; ROD;
   TRANSCRIPTION
AB We previously reported that NR2E3, an orphan nuclear receptor, plays an important role in maintaining the basal expression of estrogen receptor a (ER) and that the NR2E3 level is highly correlated with the relapse-free survival of breast cancer patients. Here, we investigated the role of NR2E3 in benzo(a) pyrene (BaP)-mediated cell injury. BaP treatment reduced NR2E3 homo-dimer formation and expression and subsequently decreased ER expression. The chromatin immunoprecipitation assay results showed that the treatment of MCF-7 breast cancer cells and the mouse liver with BaP released NR2E3 from the ER promoter to transform the transcriptionally active histone modification status into a repressive state. NR2E3 depletion in MCF-7 cells also induced a similar inactive epigenetic status in the ER promoter region, indicating that NR2E3 is an essential epigenetic player that maintains basal ER expression. Interestingly, these negative effects of BaP on the expression levels of NR2E3 and ER were rescued by antioxidant treatment. Collectively, our study provides novel evidence to show that BaP-induced oxidative stress decreases ER expression, in part by regulating NR2E3 function, which modulates the epigenetic status of the ER promoter. NR2E3 is likely an essential epigenetic player that maintains basal ER expression to protect cells from BaP-induced oxidative injury. Published by Elsevier Ireland Ltd.
C1 [Khanal, Tilak; Kim, Dasom; Johnson, Abby; Choubey, Divaker; Kim, Kyounghyun] Univ Cincinnati, Dept Environm Hlth, Coll Med, Cincinnati, OH 45267 USA.
C3 University System of Ohio; University of Cincinnati
RP Kim, K (通讯作者)，Univ Cincinnati, Dept Environm Hlth, Coll Med, Kettering Lab Complex,Rm 242,160 Panzeca Way, Cincinnati, OH 45267 USA.
EM kim2ku@ucmail.uc.edu
RI Choubey, Divaker/A-4771-2008
OI Kim, Kyounghyun/0000-0002-7240-2768
FU NIEHS Grant from Center Environmental Genetics [P30-ES006096]; CCTST
   (Center for Clinical & Translational Science & Training) Junior T1
   grant; College of Medicine in University of Cincinnati
FX This research was supported by NIEHS Grant (P30-ES006096) from Center
   Environmental Genetics, CCTST (Center for Clinical & Translational
   Science & Training) Junior T1 grant and starting fund from College of
   Medicine in University of Cincinnati.
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Androutsopoulos VP, 2014, TOXICOL LETT, V230, P304, DOI 10.1016/j.toxlet.2013.08.005
   Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029
   Burczynski ME, 1999, CANCER RES, V59, P607
   Burczynski ME, 2000, CANCER RES, V60, P908
   Burdick AD, 2003, CANCER RES, V63, P7825
   Chen JC, 2005, J NEUROSCI, V25, P118, DOI 10.1523/JNEUROSCI.3571-04.2005
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802
   GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107
   Gire AI, 2007, MOL VIS, V13, P1970
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071
   Huang ZQ, 1996, DRUG METAB DISPOS, V24, P899
   Kazerouni N, 2001, FOOD CHEM TOXICOL, V39, P423, DOI 10.1016/S0278-6915(00)00158-7
   Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Li DH, 1996, CANCER RES, V56, P287
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Milam AH, 2002, P NATL ACAD SCI USA, V99, P473, DOI 10.1073/pnas.022533099
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pachydaki SI, 2009, ARCH OPHTHALMOL-CHIC, V127, P71, DOI 10.1001/archophthalmol.2008.534
   PAHLMAN R, 1987, CARCINOGENESIS, V8, P773, DOI 10.1093/carcin/8.6.773
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   PELKONEN O, 1982, PHARMACOL REV, V34, P189
   Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070
   Petralia SA, 1999, SCAND J WORK ENV HEA, V25, P215, DOI 10.5271/sjweh.426
   Pluchino LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108698
   Qin Q, 2013, J OCUL PHARMACOL TH, V29, P298, DOI 10.1089/jop.2012.0135
   Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200
   SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B
   Schorderet DF, 2009, HUM MUTAT, V30, P1475, DOI 10.1002/humu.21096
   Sharon D, 2003, ARCH OPHTHALMOL-CHIC, V121, P1316, DOI 10.1001/archopht.121.9.1316
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Takemura H, 2010, TOXICOLOGY, V274, P42, DOI 10.1016/j.tox.2010.05.009
   Tan MHE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074359
   Teneng I, 2011, EPIGENETICS-US, V6, P355, DOI 10.4161/epi.6.3.14282
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006
   Wen Z, 2012, MOL CELL BIOL, V32, P26, DOI 10.1128/MCB.05513-11
   Xiong P, 2001, CANCER RES, V61, P8465
   Yoon JH, 2001, CANCER RES, V61, P7110
NR 47
TC 13
Z9 15
U1 0
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD SEP 17
PY 2015
VL 237
IS 3
BP 228
EP 236
DI 10.1016/j.toxlet.2015.06.1708
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA CN4YM
UT WOS:000358436500008
PM 26149760
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Mehdipour, P
   Karami, F
   Javan, F
   Mehrazin, M
AF Mehdipour, P.
   Karami, F.
   Javan, Firouzeh
   Mehrazin, M.
TI Linking ATM Promoter Methylation to Cell Cycle Protein Expression in
   Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM
   Territory
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE ATM; Methylation; Telomere length; Brain tumor; Protein expression
ID TELOMERE MAINTENANCE; BREAST-CANCER; GLIOMA-CELLS; DNA-DAMAGE; GENE;
   HYPERMETHYLATION; STABILITY; CARCINOMA; FAMILY; TARGET
AB Ataxia telangiectasia mutated (ATM) is a key gene in DNA double-strand break (DSB), and therefore, most of its disabling genetic alterations play an important initiative role in many types of cancer. However, the exact role of ATM gene and its epigenetic alterations, especially promoter methylation in different grades of brain tumors, remains elusive. The current study was conducted to query possible correlations among methylation statue of ATM gene, ATM/ retinoblastoma (RB) protein expression, D1853N ATM polymorphism, telomere length (TL), and clinicopathological characteristics of various types of brain tumors. Isolated DNA from 30 fresh tissues was extracted from different types of brain tumors and two brain tissues from deceased normal healthy individuals. DNAs were treated with bisulfate sodium using DNA modification kit (Qiagen). Methylation-specific polymerase chain reaction (MSP-PCR) was implicated to determine the methylation status of treated DNA templates confirmed by promoter sequencing. Besides, the ATM and RB protein levels were determined by immunofluorescence (IF) assay using monoclonal mouse antihuman against ATM, P53, and RB proteins. To achieve an interactive correlation, the methylation data were statistically analyzed by considering TL and D1853N ATM polymorphism. More than 73 % of the brain tumors were methylated in ATM gene promoter. There was strong correlation between ATM promoter methylation and its protein expression (p < 0.001). As a triangle, meaningful correlation was also found between methylated ATM promoter and ATM protein expression with D1853N ATM polymorphism (p = 0.01). ATM protein expression was not in line with RB protein expression while it was found to be significantly correlated with ATM promoter methylation (p = 0.01). There was significant correlation between TL neither with ATM promoter methylation nor with ATM protein expression nor with D1853N polymorphism. However, TL has shown strong correlation with patient's age and tumor grade (p = 0.01). Given the important role of cell cycle checkpoint proteins as well as RB and ATM in TL and cancer evolution, further assessment is warranted to shed more light on the pathway linking the telomere instability to tumor progression. High ATM methylation rate in brain tumor patients could open a new avenue toward early screening and cancer therapy.
C1 [Mehdipour, P.; Karami, F.; Javan, Firouzeh; Mehrazin, M.] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
   [Mehdipour, P.; Karami, F.; Javan, Firouzeh; Mehrazin, M.] Univ Tehran Med Sci, Shariati Hosp, Dept Surg, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences
RP Mehdipour, P (通讯作者)，Univ Tehran Med Sci, Sch Med, Dept Med Genet, Keshavarz Blvd,Sina St, Tehran, Iran.
EM mehdipor@tums.ac.ir
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   [Anonymous], ANN SURG ONCOLOGY
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268
   Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Chiu YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051108
   Flanagan JM, 2013, ANN ONCOL, V24, P2813, DOI 10.1093/annonc/mdt370
   García-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011
   Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235
   Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337
   Kanoh J, 2003, J MOL BIOL, V326, P1081, DOI 10.1016/S0022-2836(03)00030-5
   Kheirollahi M, 2011, MED ONCOL, V28, P864, DOI 10.1007/s12032-010-9506-3
   Kheirollahi M, 2011, MED ONCOL, V28, P7, DOI 10.1007/s12032-009-9412-8
   Kim JW, 2014, INT J CANCER, V134, P72, DOI 10.1002/ijc.28245
   Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040504
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020
   Lee S.Y., 2010, Proceedings of the acceleration poster session at the 2008 Wallace research symposium on talent development, P10
   Liang YL, 2009, WORLD J SURG, V33, P661, DOI 10.1007/s00268-008-9840-1
   Liberzon E, 2003, CANCER GENET CYTOGEN, V146, P167, DOI 10.1016/S0165-4608(03)00130-4
   Lin WC, 2001, GENE DEV, V15, P1833
   Mehdipour P, 2011, MED ONCOL, V28, P733, DOI 10.1007/s12032-010-9525-0
   Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3
   Muraki K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003386
   Oliver AW, 2007, TRENDS BIOCHEM SCI, V32, P351, DOI 10.1016/j.tibs.2007.06.004
   Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222
   Safar AM, 2007, ARCH PATHOL LAB MED, V131, P936
   Silva E, 2004, CURR BIOL, V14, P1341, DOI 10.1016/j.cub.2004.06.056
   Sinha S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.128
   Tapia T, 2008, BREAST CANCER RES TR, V107, P281, DOI 10.1007/s10549-007-9544-5
   Treilleux I, 2007, HISTOPATHOLOGY, V51, P63, DOI 10.1111/j.1365-2559.2007.02726.x
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Wu CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057036
   Ye CZ, 2007, CANCER-AM CANCER SOC, V109, P1729, DOI 10.1002/cncr.22592
   Ye JN, 2012, ENDOCRINE, V41, P479, DOI 10.1007/s12020-012-9593-3
NR 36
TC 17
Z9 20
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD AUG
PY 2015
VL 52
IS 1
BP 293
EP 302
DI 10.1007/s12035-014-8864-9
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CN3QO
UT WOS:000358341600027
PM 25159481
DA 2025-01-12
ER

PT J
AU Johnson, KC
   Koestler, DC
   Fleischer, T
   Chen, PP
   Jenson, EG
   Marotti, JD
   Onega, T
   Kristensen, VN
   Christensen, BC
AF Johnson, Kevin C.
   Koestler, Devin C.
   Fleischer, Thomas
   Chen, Panpan
   Jenson, Erik G.
   Marotti, Jonathan D.
   Onega, Tracy
   Kristensen, Vessela N.
   Christensen, Brock C.
TI DNA methylation in ductal carcinoma in situ related with future
   development of invasive breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Breast; Methylation; Array; DCIS; Cancer; TCGA
ID CLASS DISCOVERY; GENE; GENOME; EXPRESSION; RISK; FREQUENT;
   HYPERMETHYLATION; IDENTIFICATION; TRANSCRIPTION; PROGRESSION
AB Background: Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-invasive lesion associated with an increased risk for future invasive ductal carcinoma. However, accurate risk stratification for development of invasive disease and appropriate treatment decisions remain clinical challenges. DNA methylation alterations are early events in the progression of cancer and represent emerging molecular markers that may predict invasive recurrence more accurately than traditional measures of DCIS prognosis.
   Results: We measured DNA methylation using the Illumina HumanMethylation450K array of estrogen-receptor positive DCIS (n = 40) and adjacent-normal (n = 15) tissues from subjects in the New Hampshire Mammography Network longitudinal breast imaging registry. We identified locus-specific methylation differences between DCIS and matched adjacent-normal tissue (95,609 CpGs, Q < 0.05). Among 40 DCIS cases, 13 later developed invasive disease and we identified 641 CpG sites that exhibited differential DNA methylation (P < 0.01 and median \Delta beta\ > 0.1) in these cases compared with age-matched subjects without invasive disease. The set of differentially methylated CpG loci associated with disease progression was enriched in homeobox-containing genes (P = 1.3E-09) and genes involved with limb morphogenesis (P = 1.0E-05). In an independent cohort, a subset of genes with progression-related differential methylation between DCIS and invasive breast cancer were confirmed. Further, the functional relevance of these genes' regulation by methylation was demonstrated in early stage breast cancers from The Cancer Genome Atlas database.
   Conclusions: This work contributes to the understanding of epigenetic alterations that occur in DCIS and illustrates the potential of DNA methylation as markers of DCIS progression.
C1 [Johnson, Kevin C.; Chen, Panpan; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.
   [Johnson, Kevin C.; Chen, Panpan; Onega, Tracy; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Epidemiol, Hanover, NH 03755 USA.
   [Koestler, Devin C.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
   [Fleischer, Thomas; Kristensen, Vessela N.] Oslo Univ Hosp, Radiumhosp, Dept Genet, Inst Canc Res, Oslo, Norway.
   [Fleischer, Thomas; Kristensen, Vessela N.] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Breast Canc, Fac Med, Oslo, Norway.
   [Jenson, Erik G.; Marotti, Jonathan D.] Geisel Sch Med Dartmouth, Dept Pathol, Hanover, NH 03755 USA.
   [Onega, Tracy] Geisel Sch Med Dartmouth, Dept Data Sci, Hanover, NH 03755 USA.
   [Onega, Tracy] Geisel Sch Med Dartmouth, Dartmouth Inst, Lebanon, NH 03766 USA.
   [Kristensen, Vessela N.] Akershus Hosp, Div Med, Dept Clin Mol Biol EpiGen, Lorenskog, Norway.
   [Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH 03755 USA.
C3 Dartmouth College; Dartmouth College; University of Kansas; University
   of Kansas Medical Center; University of Oslo; University of Oslo;
   Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth
   College
RP Christensen, BC (通讯作者)，Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, HB 7650,Remsen 611, Hanover, NH 03755 USA.
EM Brock.Christensen@dartmouth.edu
RI Christensen, Brock/B-8460-2009; Fleischer, Thomas/T-8066-2017; Koestler,
   Devin/D-7902-2015
OI Fleischer, Thomas/0000-0003-0985-8460; Koestler,
   Devin/0000-0002-0598-0146
FU  [P20GM104416];  [ACS-IRG8200327];  [U01CA086082];  [HHSN261201100031C]
FX BCC received grants P20GM104416 and ACS-IRG8200327. TO received grants
   U01CA086082 and HHSN261201100031C.
CR [Anonymous], EPIGENETICS OFFICIAL
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422
   Bijker N, 2006, J CLIN ONCOL, V24, P3381, DOI 10.1200/JCO.2006.06.1366
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Duggal S, 2013, JNCI-J NATL CANCER I, V105, P681, DOI 10.1093/jnci/djt098
   Dumenil TD, 2014, GENE CHROMOSOME CANC, V53, P537, DOI 10.1002/gcc.22164
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones JL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1397
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koestler DC, 2014, MODERN PATHOL, V27, P145, DOI 10.1038/modpathol.2013.104
   Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108
   Kron K, 2012, CLIN CANCER RES, V18, P2896, DOI 10.1158/1078-0432.CCR-11-2901
   Lechner M, 2013, GENOME MED, V5, DOI 10.1186/gm419
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   MacKenzie TA, 2007, CANCER CAUSE CONTROL, V18, P939, DOI 10.1007/s10552-007-9035-3
   Marshall E, 2014, SCIENCE, V343, P1454, DOI 10.1126/science.343.6178.1454
   Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Pace LE, 2014, JAMA-J AM MED ASSOC, V311, P1327, DOI 10.1001/jama.2014.1398
   Pang JMB, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3420
   Polyak Kornelia, 2010, Journal of the National Cancer Institute Monographs, P210, DOI 10.1093/jncimonographs/lgq019
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Roessler Jessica, 2012, BMC Res Notes, V5, P210, DOI 10.1186/1756-0500-5-210
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shah N, 2013, CANCER RES, V73, P5449, DOI 10.1158/0008-5472.CAN-13-1178
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Tomida S, 2007, ONCOGENE, V26, P4600, DOI 10.1038/sj.onc.1210242
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang Y, 2012, HUM MOL GENET, V21, P569, DOI 10.1093/hmg/ddr491
   Warren JL, 2005, CANCER, V104, P1840, DOI 10.1002/cncr.21406
   Wickerham DL, 2013, JNCI-J NATL CANCER I, V105, P1521, DOI 10.1093/jnci/djt268
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
NR 56
TC 44
Z9 54
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JUL 25
PY 2015
VL 7
AR 75
DI 10.1186/s13148-015-0094-0
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CN4UY
UT WOS:000358427000001
PM 26213588
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Martinez-Ledesma, E
   Verhaak, RGW
   Treviño, V
AF Martinez-Ledesma, Emmanuel
   Verhaak, Roeland G. W.
   Trevino, Victor
TI Identification of a multi-cancer gene expression biomarker for cancer
   clinical outcomes using a network-based algorithm
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TISSUE-GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; HUMAN OVARIAN-CANCER;
   BREAST-CANCER; MESENCHYMAL TRANSITION; PROGNOSTIC SIGNATURE; VARIABLE
   SELECTION; DOWN-REGULATION; CELL CARCINOMA; METASTASIS
AB Cancer types are commonly classified by histopathology and more recently through molecular characteristics such as gene expression, mutations, copy number variations, and epigenetic alterations. These molecular characterizations have led to the proposal of prognostic biomarkers for many cancer types. Nevertheless, most of these biomarkers have been proposed for a specific cancer type or even specific subtypes. Although more challenging, it is useful to identify biomarkers that can be applied for multiple types of cancer. Here, we have used a network-based exploration approach to identify a multi-cancer gene expression biomarker highly connected by ESR1, PRKACA, LRP1, JUN and SMAD2 that can be predictive of clinical outcome in 12 types of cancer from The Cancer Genome Atlas (TCGA) repository. The gene signature of this biomarker is highly supported by cancer literature, biological terms, and prognostic power in other cancer types. Additionally, the signature does not seem to be highly associated with specific mutations or copy number alterations. Comparisons with cancer-type specific and other multi-cancer biomarkers in TCGA and other datasets showed that the performance of the proposed multi-cancer biomarker is superior, making the proposed approach and multi-cancer biomarker potentially useful in research and clinical settings.
C1 [Martinez-Ledesma, Emmanuel; Trevino, Victor] Escuela Nacl Med Tecnol Monterrey, Dept Invest & Innovac, Grp Enfoque & Invest Bioinformat, Monterrey 64849, Nuevo Leon, Mexico.
   [Martinez-Ledesma, Emmanuel; Verhaak, Roeland G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
   [Verhaak, Roeland G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
C3 Tecnologico de Monterrey; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Treviño, V (通讯作者)，Escuela Nacl Med Tecnol Monterrey, Dept Invest & Innovac, Grp Enfoque & Invest Bioinformat, Monterrey 64849, Nuevo Leon, Mexico.
RI Trevino, Victor/C-9219-2009
OI Martinez Ledesma, Juan Emmanuel/0000-0003-1191-7917
FU CONACyT; Tecnologico de Monterrey [CAT220]
FX We thank CONACyT and Tecnologico de Monterrey CAT220 for funds. We also
   thank Erica Goodoff, Guy Cardineau, Sean Scott, and Raquel Cuevas for
   writing editions. The results shown here are in whole or part based upon
   data generated by the TCGA Research Network:
   http://cancergenome.nih.gov/.
CR Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
   Ahmed D, 2012, CLIN TRANSL GASTROEN, V3, DOI 10.1038/ctg.2012.21
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], NUCLEIC ACIDS RES
   Arnold P, 2012, BIOINFORMATICS, V28, P487, DOI 10.1093/bioinformatics/btr695
   ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015
   Bae JA, 2014, CLIN CANCER RES, V20, P4115, DOI 10.1158/1078-0432.CCR-13-2863
   Baker M, 2012, NATURE, V487, P282, DOI 10.1038/487282a
   Bandini S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26137
   Bauer JA, 2010, CLIN CANCER RES, V16, P681, DOI 10.1158/1078-0432.CCR-09-1091
   Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bradburn MJ, 2003, BRIT J CANCER, V89, P431, DOI 10.1038/sj.bjc.6601119
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861
   Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059
   Chang CC, 2013, CANCER RES, V73, P4147, DOI 10.1158/0008-5472.CAN-12-4085
   Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375
   Chatr-aryamontri A, 2013, NUCLEIC ACIDS RES, V41, pD816, DOI 10.1093/nar/gks1158
   Chen R, 2014, CANCER RES, V74, P2892, DOI 10.1158/0008-5472.CAN-13-2775
   Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920
   Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174
   Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985
   Chin YR, 2014, CANCER DISCOV, V4, P942, DOI 10.1158/2159-8290.CD-13-0873
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Darb-Esfahani S, 2009, ENDOCR-RELAT CANCER, V16, P1229, DOI 10.1677/ERC-08-0338
   Daves MH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-56
   Davies S, 2011, ONCOL REP, V25, P855, DOI 10.3892/or.2011.1147
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Ein-Dor L, 2006, P NATL ACAD SCI USA, V103, P5923, DOI 10.1073/pnas.0601231103
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Grabowski P, 2004, ANN NY ACAD SCI, V1014, P270, DOI 10.1196/annals.1294.030
   Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/NMETH.2689, 10.1038/nmeth.2689]
   Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730
   Han L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4963
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Helpap B, 2009, HISTOL HISTOPATHOL, V24, P661, DOI 10.14670/HH-24.661
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Isaksson HS, 2014, ONCOTARGET, V5, P4040, DOI 10.18632/oncotarget.1938
   Ito R, 2004, BIOL PHARM BULL, V27, P315, DOI 10.1248/bpb.27.315
   Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568
   Karachaliou N, 2013, J THORAC ONCOL, V8, P295, DOI 10.1097/JTO.0b013e31827db621
   Kikuchi R, 2007, CANCER RES, V67, P7095, DOI 10.1158/0008-5472.CAN-06-4567
   Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Ladner RD, 2000, CANCER RES, V60, P3493
   Langer S, 2006, EUR J GYNAECOL ONCOL, V27, P345
   Lara R, 2011, ONCOGENE, V30, P3513, DOI 10.1038/onc.2011.61
   Li J, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1033
   Li J, 2012, NUCLEIC ACIDS RES, V40, pW123, DOI 10.1093/nar/gks386
   Li L, 2013, J BIOL CHEM, V288, P703, DOI 10.1074/jbc.C112.396903
   Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010
   Li ZJ, 2013, J CLIN ONCOL, V31, P1172, DOI 10.1200/JCO.2012.44.3184
   Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467
   Maak M, 2013, ANN SURG, V257, P1053, DOI 10.1097/SLA.0b013e31827c1180
   Maldonado V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-152
   Mangé A, 2012, CLIN CANCER RES, V18, P1992, DOI 10.1158/1078-0432.CCR-11-2527
   Martínez E, 2015, ONCOGENE, V34, P2732, DOI 10.1038/onc.2014.216
   Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116
   Meng H, 2011, CLIN CANCER RES, V17, P2426, DOI 10.1158/1078-0432.CCR-10-2385
   Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510
   Moody SE, 2015, ONCOGENE, V34, P2061, DOI 10.1038/onc.2014.153
   Moreau Y, 2012, NAT REV GENET, V13, P523, DOI 10.1038/nrg3253
   Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618
   Mutch DM, 2001, GENOME BIOL, V2
   Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392
   Natarajan TG, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-13
   Neyns B, 1996, ONCOGENE, V12, P1247
   Nicolasjilwan M, 2015, J NEURORADIOLOGY, V42, P212, DOI 10.1016/j.neurad.2014.02.006
   Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Pandey SN, 2006, J GASTROINTEST CANC, V37, P124, DOI 10.1007/s12029-007-9002-y
   Park YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044225
   Peng Z, 2014, PROSTATE CANCER P D, V17, P81, DOI 10.1038/pcan.2013.57
   Pénzváltó Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059503
   Pinto-Leite R, 2014, TUMOR BIOL, V35, P4599, DOI 10.1007/s13277-013-1604-3
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Pressinotti NC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-130
   Qiang L, 2009, CANCER LETT, V279, P13, DOI 10.1016/j.canlet.2009.01.016
   Rampias T, 2014, CLIN CANCER RES, V20, P2933, DOI 10.1158/1078-0432.CCR-13-2721
   Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d
   Rizki A, 2008, CANCER RES, V68, P1378, DOI 10.1158/0008-5472.CAN-07-2225
   Rolle CE, 2014, MOL CANCER THER, V13, P576, DOI 10.1158/1535-7163.MCT-13-0109
   Romao LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055605
   Rung J, 2013, NAT REV GENET, V14, P89, DOI 10.1038/nrg3394
   Russo A, 2012, ONCOGENE, V31, P4828, DOI 10.1038/onc.2011.643
   Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344
   Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621
   Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652
   Slattery ML, 2011, MUTAT RES-FUND MOL M, V706, P13, DOI 10.1016/j.mrfmmm.2010.10.005
   Slyskova J, 2012, CLIN CANCER RES, V18, P5878, DOI 10.1158/1078-0432.CCR-12-1380
   Spisak S, 2010, DIS MARKERS, V28, P1, DOI 10.3233/DMA-2010-0677
   Spitz MR, 2011, CANCER DISCOV, V1, P420, DOI 10.1158/2159-8290.CD-11-0080
   Starmans MHW, 2008, BRIT J CANCER, V99, P1884, DOI 10.1038/sj.bjc.6604746
   Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128
   Stratford JK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000307
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102
   Szymanowska-Narloch A, 2013, ADV MED SCI-POLAND, V58, P196, DOI 10.2478/ams-2013-0025
   Tan WQ, 2011, J UROLOGY, V186, P2071, DOI 10.1016/j.juro.2011.06.049
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
   Menéndez ST, 2012, J MOL MED, V90, P1173, DOI 10.1007/s00109-012-0893-0
   Turinsky AL, 2014, METHODS MOL BIOL, V1091, P315, DOI 10.1007/978-1-62703-691-7_22
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Venet D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002240
   Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wakefield A, 2013, CANCER RES, V73, P745, DOI 10.1158/0008-5472.CAN-12-1321
   Wan YW, 2010, ONCOL REP, V24, P489, DOI 10.3892/or_00000883
   Wang HX, 2014, HUM PATHOL, V45, P401, DOI 10.1016/j.humpath.2013.10.005
   Wang Y, 2014, J BIOL CHEM, V289, P14225, DOI 10.1074/jbc.M113.527671
   Weber RG, 2001, INT J CANCER, V91, P213, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1036>3.3.CO;2-D
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Winter C, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002511
   Wu GM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r112
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Yoshihara K, 2012, CLIN CANCER RES, V18, P1374, DOI 10.1158/1078-0432.CCR-11-2725
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129
   Yu XX, 2014, MOL BIOSYST, V10, P2270, DOI 10.1039/c4mb00258j
   Yuan Y, 2014, NAT BIOTECHNOL, V32, P644, DOI 10.1038/nbt.2940
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhang JT, 2013, BBA-MOL CELL RES, V1833, P2961, DOI 10.1016/j.bbamcr.2013.07.021
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 135
TC 61
Z9 64
U1 1
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 23
PY 2015
VL 5
AR 11966
DI 10.1038/srep11966
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN3VS
UT WOS:000358356700001
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Gong, LL
   Govan, JM
   Evans, EB
   Dai, H
   Wang, E
   Lee, SW
   Lin, HK
   Lazar, AJ
   Mills, GB
   Lin, SY
AF Gong, Lili
   Govan, Jeane M.
   Evans, Elizabeth B.
   Dai, Hui
   Wang, Edward
   Lee, Szu-Wei
   Lin, Hui-Kuan
   Lazar, Alexander J.
   Mills, Gordon B.
   Lin, Shiaw-Yih
TI Nuclear PTEN tumor-suppressor functions through maintaining
   heterochromatin structure
SO CELL CYCLE
LA English
DT Article
DE breast cancer; heterochromatin; HP1; PTEN; satellite DNA
ID HISTONE H3; EPIGENETIC CONTROL; MOLECULAR-CLONING; SATELLITE REPEATS;
   NONCODING RNAS; LYSINE 9; METHYLATION; CANCER; CELLS; GENE
AB The tumor suppressor, PTEN, is one of the most commonly mutated genes in cancer. Recently, PTEN has been shown to localize in the nucleus and is required to maintain genomic stability. Here, we show that nuclear PTEN, independent of its phosphatase activity, is essential for maintaining heterochromatin structure. Depletion of PTEN leads to loss of heterochromatic foci, decreased chromatin compaction, overexpression of heterochromatic genes, and reduced protein stability of heterochromatin protein 1 . We found that the C-terminus of PTEN is required to maintain heterochromatin structure. Additionally, cancer-associated PTEN mutants lost their tumor-suppressor function when their heterochromatin structure was compromised. We propose that this novel role of PTEN accounts for its function in guarding genomic stability and suppressing tumor development.
C1 [Gong, Lili; Govan, Jeane M.; Evans, Elizabeth B.; Dai, Hui; Wang, Edward; Mills, Gordon B.; Lin, Shiaw-Yih] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Lee, Szu-Wei; Lin, Hui-Kuan] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Lin, SY (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
EM sylin@mdanderson.org
RI Mills, Gordon/L-5416-2014; Lazar, Alexander/A-3416-2008; Gong,
   Lili/F-8452-2014; Govan, Jeane/B-6205-2015
OI Gong, Lili/0000-0002-3129-3868; Lazar, Alexander/0000-0002-6395-4499
FU Department of Defense [W81XWH-10-1-0558]; NCI [P50CA083639]
FX This work was supported by a Department of Defense Era of Hope Scholar
   Award (W81XWH-10-1-0558) to S.-Y.L, and NCI P50CA083639 to S.-Y.L and
   G.B.M.
CR Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009
   Andegeko Y, 2001, J BIOL CHEM, V276, P38224
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188
   BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819
   Bouzinba-Segard H, 2006, P NATL ACAD SCI USA, V103, P8709, DOI 10.1073/pnas.0508006103
   Bubien V, 2013, J MED GENET, V50, P255, DOI 10.1136/jmedgenet-2012-101339
   Carey M, 2007, CSH PROTOCOLS, V2007
   Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848
   Chen ZH, 2014, CELL REP, V8, P2003, DOI 10.1016/j.celrep.2014.08.008
   Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007
   Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219
   Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8
   Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887
   Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109
   Hall LE, 2012, CHROMOSOME RES, V20, P535, DOI 10.1007/s10577-012-9297-9
   Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110
   Li DM, 1997, CANCER RES, V57, P2124
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895
   SAUNDERS WS, 1993, J CELL SCI, V104, P573
   Schuster-Böckler B, 2012, NATURE, V488, P504, DOI 10.1038/nature11273
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Sun Z, 2014, CELL REP, V6, P844, DOI 10.1016/j.celrep.2014.01.030
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Valgardsdottir R, 2008, NUCLEIC ACIDS RES, V36, P423, DOI 10.1093/nar/gkm1056
   Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039
NR 33
TC 34
Z9 49
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD JUL 18
PY 2015
VL 14
IS 14
BP 2323
EP 2332
DI 10.1080/15384101.2015.1044174
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CN0TK
UT WOS:000358126400023
PM 25946202
OA Bronze, Green Published
DA 2025-01-12
ER

EF